PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Lau, T; Horschitz, S; Berger, S; Bartsch, D; Schloss, P				Lau, Thorsten; Horschitz, Sandra; Berger, Stefan; Bartsch, Dusan; Schloss, Patrick			Antidepressant-induced internalization of the serotonin transporter in serotonergic neurons	FASEB JOURNAL			English	Article						depression; citalopram; confocal microscopy	DOWN-REGULATION; NOREPINEPHRINE TRANSPORTER; DOPAMINE TRANSPORTER; PROTEIN-KINASE; MESSENGER-RNA; EXPRESSION; BINDING; TRAFFICKING; RECEPTORS; INCREASES	A deficiency of serotonergic signaling is thought to be involved in the etiology of depression. Thus, drugs blocking the reuptake of serotonin back into the neurons are widely used in treatment of this disease; however, their delayed effect in remission of patients suggests that the clinical response does not rely on simple serotonin uptake inhibition but may include further regulatory mechanisms. We have analyzed cellular serotonin transporter (SERT) expression on exposure to the selective serotonin reuptake inhibitor citalopram in serotonergic neurons expressing the native SERT allele in its natural surroundings. Biotinylation of SERT-expressing HEK293 cells, as well as confocal microscopy analysis in these cells and in serotonergic neurons, revealed that exposure to citalopram time dependently reduces the amount of cell surface-expressed SERT. Furthermore, in serotonergic neurons, longer exposure to citalopram not only caused an internalization of SERT proteins from the cell surface but also induced a redistribution of SERT from neurite extensions into the soma. This process was reversible on drug removal. Microarray analysis performed on citalopram-treated serotonergic neurons revealed that antidepressant treatment does not alter SERT mRNA expression, suggesting that SERT trafficking from and to the cell membrane is regulated on the posttranscriptional level.	[Lau, Thorsten; Horschitz, Sandra; Schloss, Patrick] Cent Inst Mental Hlth, Biochem Lab, D-68159 Mannheim, Germany; [Berger, Stefan; Bartsch, Dusan] Cent Inst Mental Hlth, Dept Mol Biol, D-68159 Mannheim, Germany	Central Institute of Mental Health; Central Institute of Mental Health	Schloss, P (corresponding author), Cent Inst Mental Hlth, Biochem Lab, J5, D-68159 Mannheim, Germany.	patrick.schloss@zi-mannheim.de						Adell A, 2002, BRAIN RES REV, V39, P154, DOI 10.1016/S0165-0173(02)00182-0; Benmansour S, 2002, J NEUROSCI, V22, P6766; Benmansour S, 1999, J NEUROSCI, V19, P10494; Bernstein EM, 1999, J BIOL CHEM, V274, P889, DOI 10.1074/jbc.274.2.889; BLAKELY RD, 1994, J EXP BIOL, V196, P263; Blakely RD, 2000, CURR OPIN NEUROBIOL, V10, P328, DOI 10.1016/S0959-4388(00)00088-X; Cannon DM, 2006, BIOL PSYCHIAT, V60, P207, DOI 10.1016/j.biopsych.2006.05.005; Chen NH, 2004, PFLUG ARCH EUR J PHY, V447, P519, DOI 10.1007/s00424-003-1064-5; Coyle JT, 2003, NEURON, V38, P157, DOI 10.1016/S0896-6273(03)00195-8; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Daws LC, 2002, BIOCHEM BIOPH RES CO, V290, P1545, DOI 10.1006/bbrc.2002.6384; De-Miguel FF, 2005, CELL MOL NEUROBIOL, V25, P297, DOI 10.1007/s10571-005-3061-z; Duman RS, 1997, ARCH GEN PSYCHIAT, V54, P597; Glatz K, 2003, J NEUROCHEM, V86, P1072, DOI 10.1046/j.1471-4159.2003.01944.x; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Horschitz S, 2003, J NEUROCHEM, V86, P958, DOI 10.1046/j.1471-4159.2003.01899.x; Horschitz S, 2001, NEUROREPORT, V12, P2181, DOI 10.1097/00001756-200107200-00027; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Jayanthi LD, 2005, AAPS J, V7, pE728, DOI 10.1208/aapsj070373; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lau T, 2006, NEUROREPORT, V17, P975, DOI 10.1097/01.wnr.0000223395.66951.01; Little KY, 2006, J PSYCHIATR NEUROSCI, V31, P333; Little KY, 2002, MOL PHARMACOL, V61, P436, DOI 10.1124/mol.61.2.436; Mamounas LA, 2000, J NEUROSCI, V20, P771, DOI 10.1523/JNEUROSCI.20-02-00771.2000; Mash DC, 2000, J CHEM NEUROANAT, V20, P271, DOI 10.1016/S0891-0618(00)00102-2; MELTZER H, 1989, BRIT J PSYCHIAT, V155, P25, DOI 10.1192/S0007125000291733; Millan MJ, 2006, PHARMACOL THERAPEUT, V110, P135, DOI 10.1016/j.pharmthera.2005.11.006; Miner LH, 2006, J NEUROSCI, V26, P1571, DOI 10.1523/JNEUROSCI.4450-05.2006; Mouillet-Richard S, 2000, J BIOL CHEM, V275, P9186, DOI 10.1074/jbc.275.13.9186; Muller HK, 2006, J BIOL CHEM, V281, P28901, DOI 10.1074/jbc.M602848200; Nemeroff CB, 1998, BIOL PSYCHIAT, V44, P517; Nibuya M, 1996, J NEUROSCI, V16, P2365; OVERO KF, 1982, PROG NEURO-PSYCHOPH, V6, P311, DOI 10.1016/S0278-5846(82)80181-4; PINEYRO G, 1994, J NEUROSCI, V14, P3036; Qian Y, 1997, J NEUROSCI, V17, P45, DOI 10.1523/JNEUROSCI.17-01-00045.1997; Ramamoorthy S, 1999, SCIENCE, V285, P763, DOI 10.1126/science.285.5428.763; Ressler KJ, 2000, DEPRESS ANXIETY, V12, P2, DOI 10.1002/1520-6394(2000)12:1+<2::AID-DA2>3.3.CO;2-W; Samuvel DJ, 2005, J NEUROSCI, V25, P29, DOI 10.1523/JNEUROSCI.3754-04.2005; Scanlon SM, 2001, BIOCHEMISTRY-US, V40, P10507, DOI 10.1021/bi010730z; Schloss P, 1998, J PSYCHOPHARMACOL, V12, P115, DOI 10.1177/026988119801200201; Schloss P, 2004, PHARMACOL THERAPEUT, V102, P47, DOI 10.1016/j.pharmthera.2004.02.001; SCHLOSS P, 1995, BIOCHEMISTRY-US, V34, P12590, DOI 10.1021/bi00039a014; Sur C, 1996, NEUROSCIENCE, V73, P217, DOI 10.1016/0306-4522(96)00030-9; Sur C, 1996, EUR J NEUROSCI, V8, P2753, DOI 10.1111/j.1460-9568.1996.tb01570.x; Thakker DR, 2005, MOL PSYCHIATR, V10, P782, DOI 10.1038/sj.mp.4001687; TROJANOWSKI JQ, 1982, BRAIN RES, V231, P33, DOI 10.1016/0006-8993(82)90005-1; WAN XCS, 1982, BRAIN RES, V243, P215, DOI 10.1016/0006-8993(82)90244-X; Willins DL, 1998, ANN NY ACAD SCI, V861, P121, DOI 10.1111/j.1749-6632.1998.tb10182.x; Zahniser NR, 2001, PHARMACOL THERAPEUT, V92, P21, DOI 10.1016/S0163-7258(01)00158-9; Zavosh A, 1999, BRAIN RES BULL, V49, P291, DOI 10.1016/S0361-9230(99)00063-5; Zhu MY, 1998, J NEUROCHEM, V70, P1547; Zhu MY, 1997, J NEUROCHEM, V68, P134	52	38	38	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1702	1714		10.1096/fj.07-095471	http://dx.doi.org/10.1096/fj.07-095471			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18216289				2022-12-25	WOS:000256352700011
J	Goda, AE; Yoshida, T; Horinaka, M; Yasuda, T; Shiraishi, T; Wakada, M; Sakai, T				Goda, A. E.; Yoshida, T.; Horinaka, M.; Yasuda, T.; Shiraishi, T.; Wakada, M.; Sakai, T.			Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole	ONCOGENE			English	Article						dipyridamole; TRAIL; DR5; survivin; D-type cyclins; cdk6	APOPTOSIS-INDUCING LIGAND; DEATH RECEPTOR 5/TRAIL-R2; METHOTREXATE CYTOTOXICITY; IN-VITRO; SURVIVIN; TUMOR; PROLIFERATION; ACTIVATION; INHIBITION; CASPASE-3	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has emerged as an attractive cytokine that selectively targets cancer cells, however its efficacy has been challenged by a number of resistance mechanisms. Therefore, the current study investigated the potential of dipyridamole to enhance TRAIL efficacy and the probable underlying mechanisms. Dipyridamole dramatically sensitized p53-mutant human cancer cell lines: SW480, MG63 and DU145, to the antitumor activity of TRAIL, as evidenced by enabling TRAIL to efficiently cleave initiator and executioner caspases. Although dipyridamole upregulated both DR4 and DR5 and increased their cell surface expression, RNA interference revealed a preferential dependence on DR5. Moreover, dipyridamole inhibited survivin expression and its important consequences were confirmed by small interfering RNA. Mechanistically, dipyridamole induced transcriptional shutdown of survivin expression accompanying G(1) arrest that was characterized by downregulation of D-type cyclins and cdk6. In addition, a transcriptional mechanism powered by CCAAT/enhancer-binding protein (C/EBP) homologous protein (CHOP) induction was responsible for DR5 upregulation by dipyridamole. Importantly, dipyridamole-induced enhancement of TRAIL efficacy and alterations of protein expression were independent of either protein kinase A or protein kinase G. In conclusion, findings of the present study described novel mechanisms of dipyridamole action and highlighted its promising use as a potential enhancer of TRAIL efficacy.	[Goda, A. E.; Yoshida, T.; Horinaka, M.; Yasuda, T.; Wakada, M.; Sakai, T.] Kyoto Prefectural Univ Med, Dept Mol Targeting Canc Prevent, Grad Sch Med Sci, Kamigyo Ku, Kyoto 6028566, Japan; [Goda, A. E.] Tanta Univ, Dept Pharmacol & Toxicol, Fac Pharm, Tanta, Egypt; [Yasuda, T.; Shiraishi, T.] Kyoto Prefectural Univ Med, Dept Urol, Grad Sch Med Sci, Kyoto 6028566, Japan	Kyoto Prefectural University of Medicine; Egyptian Knowledge Bank (EKB); Tanta University; Kyoto Prefectural University of Medicine	Sakai, T (corresponding author), Kyoto Prefectural Univ Med, Dept Mol Targeting Canc Prevent, Grad Sch Med Sci, Kamigyo Ku, Kyoto 6028566, Japan.	tsakai@koto.kpu-m.ac.jp	Goda, Ahmed/AAA-4688-2020	Goda, Ahmed/0000-0001-8200-6104				Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Aouad SM, 2004, J IMMUNOL, V172, P2316, DOI 10.4049/jimmunol.172.4.2316; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Azuhata T, 2006, J PEDIATR SURG, V41, P1431, DOI 10.1016/j.jpedsurg.2006.04.020; Carlo-Stella C, 2007, CLIN CANCER RES, V13, P2313, DOI 10.1158/1078-0432.CCR-06-2774; CLARKE WR, 1994, PULM PHARMACOL, V7, P81, DOI 10.1006/pulp.1994.1009; Fulda S, 2004, CANCER RES, V64, P337, DOI 10.1158/0008-5472.CAN-03-1656; Hung KY, 2001, KIDNEY INT, V60, P872, DOI 10.1046/j.1523-1755.2001.060003872.x; Kappler M, 2004, CANCER GENE THER, V11, P186, DOI 10.1038/sj.cgt.7700677; Kelley RF, 2005, J BIOL CHEM, V280, P2205, DOI 10.1074/jbc.M410660200; KENNEDY DG, 1986, BIOCHEM PHARMACOL, V35, P3053, DOI 10.1016/0006-2952(86)90385-0; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Lin J, 2001, ONCOGENE, V20, P2000, DOI 10.1038/sj.onc.1204375; Lu ML, 2005, J BIOL CHEM, V280, P6742, DOI 10.1074/jbc.M411519200; Nakata S, 2004, ONCOGENE, V23, P6261, DOI 10.1038/sj.onc.1207830; Pirnia F, 2002, CELL DEATH DIFFER, V9, P905, DOI 10.1038/sj.cdd.4401062; Ren YG, 2004, MOL BIOL CELL, V15, P5064, DOI 10.1091/mbc.e04-03-0184; Rodrigues M, 2004, BRAZ J MED BIOL RES, V37, P591, DOI 10.1590/S0100-879X2004000400017; Saito S, 2003, BIOCHEM BIOPH RES CO, V311, P17, DOI 10.1016/j.bbrc.2003.09.161; SALZMAN EW, 1972, ANN NY ACAD SCI, V201, P61, DOI 10.1111/j.1749-6632.1972.tb16287.x; SATO S, 1993, ANTI-CANCER DRUG DES, V8, P289; Shiraishi T, 2005, CANCER RES, V65, P6364, DOI 10.1158/0008-5472.CAN-05-0312; Thompson KL, 2003, TOXICOL SCI, V74, P260, DOI 10.1093/toxsci/kfg113; Van Geelen CMM, 2004, DRUG RESIST UPDATE, V7, P345, DOI 10.1016/j.drup.2004.11.002; VANMOUWERIK TJ, 1987, BIOCHEM PHARMACOL, V36, P809, DOI 10.1016/0006-2952(87)90168-7; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang SL, 2003, P NATL ACAD SCI USA, V100, P15095, DOI 10.1073/pnas.2435285100; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yamaguchi H, 2004, J BIOL CHEM, V279, P45495, DOI 10.1074/jbc.M406933200; Yoshida T, 2005, CANCER RES, V65, P5662, DOI 10.1158/0008-5472.CAN-05-0693; Yoshida T, 2001, FEBS LETT, V507, P381, DOI 10.1016/S0014-5793(01)02947-7; Yoshida T, 2007, MOL CANCER RES, V5, P615, DOI 10.1158/1541-7786.MCR-06-0045; Zhang M, 2006, J EXP CLIN CANC RES, V25, P391; Zhuplatov SB, 2006, BASIC CLIN PHARMACOL, V99, P431, DOI 10.1111/j.1742-7843.2006.pto_516.x	35	22	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	24					3435	3445		10.1038/sj.onc.1211008	http://dx.doi.org/10.1038/sj.onc.1211008			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18193086				2022-12-25	WOS:000256309900008
J	Guo, W; Flanagan, J; Jasuja, R; Kirkland, J; Jiang, L; Bhasin, S				Guo, Wen; Flanagan, John; Jasuja, Ravi; Kirkland, James; Jiang, Lan; Bhasin, Shalender			The effects of myostatin on adipogenic differentiation of human bone marrow-derived mesenchymal stem cells are mediated through cross-communication between Smad3 and Wnt/beta-catenin signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; GROSS MUSCLE HYPERTROPHY; SKELETAL-MUSCLE; TGF-BETA; ADIPOCYTE DIFFERENTIATION; WNT; MICE; GENE; PROLIFERATION; INHIBITION	The effects of myostatin on adipogenic differentiation are poorly understood, and the underlying mechanisms are unknown. We determined the effects of human recombinant myostatin protein on adipogenesis of bone marrow-derived human mesenchymal stem cells (hMSCs) and adipose tissue-derived preadipocytes. For both progenitor cell types, differentiation in the presence of myostatin caused a dose-dependent reduction of lipid accumulation and diminished incorporation of exogenous fatty acid into cellular lipids. Myostatin significantly down-regulated the expression of adipocyte markers PPAR gamma, C/EBP alpha, leptin, and aP2, but not C/EBP beta. Overexpression of PPAR gamma, but not C/EBP beta,blocked the inhibitory effects of myostatin on adipogenesis. Myostatin induced phosphorylation of Smad3 in hMSCs; knockdown of Smad3 by RNAi or inhibition of its upstream kinase by an Alk5 inhibitor blocked the inhibitory effect of myostatin on adipogenesis in hMSCs, implying an important role of Smad3 activation in this event. Furthermore, myostatin enhanced nuclear translocation of beta-catenin and formation of the Smad3-beta-catenin-TCF4 complex, together with the altered expression of a number of Wnt/beta-catenin pathway genes in hMSCs. The inhibitory effects of myostatin on adipogenesis were blocked by RNAi silencing of beta-catenin and diminished by overexpression of dominant-negative TCF4. The conclusion is that myostatin inhibited adipogenesis in human bone marrow-derived mesenchymal stem cells and preadipocytes. These effects were mediated, in part, by activation of Smad3 and cross-communication of the TGF beta/Smad signal to Wnt/beta-catenin/TCF4 pathway, leading to down-regulation of PPAR gamma.	[Guo, Wen; Flanagan, John; Jasuja, Ravi; Kirkland, James; Jiang, Lan; Bhasin, Shalender] Boston Univ, Sch Med, Boston Med Ctr, Endocrinol Sect, Boston, MA 02118 USA; [Guo, Wen; Flanagan, John; Jasuja, Ravi; Kirkland, James; Jiang, Lan; Bhasin, Shalender] Boston Univ, Sch Med, Boston Med Ctr, Sect Diabet, Boston, MA 02118 USA; [Guo, Wen; Flanagan, John; Jasuja, Ravi; Kirkland, James; Jiang, Lan; Bhasin, Shalender] Boston Univ, Sch Med, Boston Med Ctr, Sect Nutr & Geriatr, Boston, MA 02118 USA; [Flanagan, John] Karolinska Inst, SE-17177 Stockholm, Sweden	Boston Medical Center; Boston University; Boston Medical Center; Boston University; Boston Medical Center; Boston University; Karolinska Institutet	Guo, W (corresponding author), 670 Albany St, Boston, MA 02118 USA.	wguo@bu.edu	Flanagan, John/AAG-4857-2019	Flanagan, John/0000-0001-6957-756X; Guo, Wen/0000-0002-4474-2837	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059261, R01DK049296, R01DK078512] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK059261, R01 DK078512, R01 DK 49296, R01 DK 70431, DK 42600, R01 DK 59261] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akimoto T, 2005, BIOCHEM BIOPH RES CO, V329, P381, DOI 10.1016/j.bbrc.2005.01.136; Artaza JN, 2005, ENDOCRINOLOGY, V146, P3547, DOI 10.1210/en.2005-0362; Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200; Briata P, 2003, MOL CELL, V12, P1201, DOI 10.1016/S1097-2765(03)00407-6; Cai LH, 2007, CELL RES, V17, P62, DOI 10.1038/sj.cr.7310138; Clop A, 2006, NAT GENET, V38, P813, DOI 10.1038/ng1810; COWTHORN WP, 2007, IN PRESS CELL DEATH; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; Feldman BJ, 2006, P NATL ACAD SCI USA, V103, P15675, DOI 10.1073/pnas.0607501103; Fischer L, 2002, J BIOL CHEM, V277, P30870, DOI 10.1074/jbc.M109330200; Guo W, 2007, AM J PHYSIOL-ENDOC M, V293, pE576, DOI 10.1152/ajpendo.00523.2006; Guo W, 2007, AM J PHYSIOL-ENDOC M, V292, pE1041, DOI 10.1152/ajpendo.00557.2006; Hammarstedt A, 2007, BIOCHEM BIOPH RES CO, V357, P700, DOI 10.1016/j.bbrc.2007.03.202; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hill JJ, 2002, J BIOL CHEM, V277, P40735, DOI 10.1074/jbc.M206379200; Hirai S, 2007, DOMEST ANIM ENDOCRIN, V32, P1, DOI 10.1016/j.domaniend.2005.12.001; Jian HY, 2006, GENE DEV, V20, P666, DOI 10.1101/gad.1388806; Joulia D, 2003, EXP CELL RES, V286, P263, DOI 10.1016/S0014-4827(03)00074-0; Kennell JA, 2005, J BIOL CHEM, V280, P24004, DOI 10.1074/jbc.M501080200; Kioussi C, 2002, CELL, V111, P673, DOI 10.1016/S0092-8674(02)01084-X; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; Langley B, 2002, J BIOL CHEM, V277, P49831, DOI 10.1074/jbc.M204291200; Lee SJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000789; Liang YC, 2007, J EXP BIOL, V210, P477, DOI 10.1242/jeb.02665; Mackay DL, 2006, J CELL PHYSIOL, V207, P722, DOI 10.1002/jcp.20617; Marcell TJ, 2001, AM J PHYSIOL-ENDOC M, V281, pE1159, DOI 10.1152/ajpendo.2001.281.6.E1159; Martyn JK, 2004, ANAT REC PART A, V281A, P1363, DOI 10.1002/ar.a.20140; McMahon CD, 2003, AM J PHYSIOL-ENDOC M, V285, pE82, DOI 10.1152/ajpendo.00275.2002; McPherron AC, 2002, J CLIN INVEST, V109, P595, DOI 10.1172/JCI200213562; Moldes M, 2003, BIOCHEM J, V376, P607, DOI 10.1042/BJ20030426; Mosher DS, 2007, PLOS GENET, V3, P779, DOI 10.1371/journal.pgen.0030079; Mulholland DJ, 2005, ENDOCR REV, V26, P898, DOI 10.1210/er.2003-0034; Nakamura T, 2003, BIOCHEM BIOPH RES CO, V303, P306, DOI 10.1016/S0006-291X(03)00325-5; Nishi M, 2002, BIOCHEM BIOPH RES CO, V293, P247, DOI 10.1016/S0006-291X(02)00209-7; Pal R, 2006, STEM CELLS DEV, V15, P29, DOI 10.1089/scd.2006.15.29; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Rebbapragada A, 2003, MOL CELL BIOL, V23, P7230, DOI 10.1128/MCB.23.20.7230-7242.2003; Reisz-Porszasz S, 2003, AM J PHYSIOL-ENDOC M, V285, pE876, DOI 10.1152/ajpendo.00107.2003; Rodgers BD, 2001, ENDOCRINOLOGY, V142, P1412, DOI 10.1210/en.142.4.1412; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Sato M, 2006, ACTA DERM-VENEREOL, V86, P300, DOI 10.2340/00015555-0101; Schuelke M, 2004, NEW ENGL J MED, V350, P2682, DOI 10.1056/NEJMoa040933; Shelton GD, 2007, NEUROMUSCULAR DISORD, V17, P721, DOI 10.1016/j.nmd.2007.06.008; Steelman CA, 2006, FASEB J, V20, P580, DOI 10.1096/fj.05-5125fje; Takada I, 2007, NAT CELL BIOL, V9, P1273, DOI 10.1038/ncb1647; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tchkonia T, 2002, AM J PHYSIOL-REG I, V282, pR1286, DOI 10.1152/ajpregu.00653.2001; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Warner DR, 2005, FEBS LETT, V579, P3539, DOI 10.1016/j.febslet.2005.05.024; Wehling M, 2000, FASEB J, V14, P103, DOI 10.1096/fasebj.14.1.103; Wright WS, 2007, DIABETES, V56, P295, DOI 10.2337/db06-1339; Xie W, 2006, LIPIDS, V41, P267, DOI 10.1007/s11745-006-5096-4; Yang XL, 2004, BIOCHEM BIOPH RES CO, V317, P1045, DOI 10.1016/j.bbrc.2004.03.152; Zhou SH, 2005, J BIOL CHEM, V280, P22688, DOI 10.1074/jbc.M412953200; Zhou SH, 2004, J BONE MINER RES, V19, P463, DOI 10.1359/JBMR.0301239; Zhu XL, 2000, FEBS LETT, V474, P71, DOI 10.1016/S0014-5793(00)01570-2; Zimmers TA, 2002, SCIENCE, V296, P1486, DOI 10.1126/science.1069525	57	85	96	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9136	9145		10.1074/jbc.M708968200	http://dx.doi.org/10.1074/jbc.M708968200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18203713	Green Published, hybrid			2022-12-25	WOS:000254465800043
J	Liu, PF; Theruvathu, JA; Darwanto, A; Lao, VV; Pascal, T; Goddard, WA; Sowers, LC				Liu, Pingfang; Theruvathu, Jacob A.; Darwanto, Agus; Lao, Victoria Valinluck; Pascal, Tod; Goddard, William A., III; Sowers, Lawrence C.			Mechanisms of base selection by the Escherichia coli mispaired uracil glycosylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMINE-DNA GLYCOSYLASE; EXCISION-REPAIR; CATALYTIC MECHANISM; HYPOCHLOROUS ACID; RECOGNITION; MISMATCH; CELLS; SMUG1; STABILITY; DUPLEXES	The repair of the multitude of single-base lesions formed daily in cells of all living organisms is accomplished primarily by the base excision repair pathway that initiates repair through a series of lesion-selective glycosylases. In this article, singleturnover kinetics have been measured on a series of oligonucleotide substrates containing both uracil and purine analogs for the Escherichia coli mispaired uracil glycosylase ( MUG). The relative rates of glycosylase cleavage have been correlated with the free energy of helix formation and with the size and electronic inductive properties of a series of uracil 5-substituents. Data are presented that MUG can exploit the reduced thermodynamic stability of mispairs to distinguish U: A from U: G pairs. Discrimination against the removal of thymine results primarily from the electron-donating property of the thymine 5-methyl substituent, whereas the size of the methyl group relative to a hydrogen atom is a secondary factor. A series of parameters have been obtained that allow prediction of relative MUG cleavage rates that correlate well with observed relative rates that vary over 5 orders of magnitude for the series of base analogs examined. We propose that these parameters may be common among DNA glycosylases; however, specific glycosylases may focus more or less on each of the parameters identified. The presence of a series of glycosylases that focus on different lesion properties, all coexisting within the same cell, would provide a robust and partially redundant repair system necessary for the maintenance of the genome.	[Liu, Pingfang; Theruvathu, Jacob A.; Darwanto, Agus; Lao, Victoria Valinluck; Sowers, Lawrence C.] Loma Linda Univ, Sch Med, Dept Basic Sci, Loma Linda, CA 92354 USA; [Pascal, Tod; Goddard, William A., III; Sowers, Lawrence C.] CALTECH, Dept Chem, Pasadena, CA 91125 USA	Loma Linda University; California Institute of Technology	Sowers, LC (corresponding author), Alumni Hall Basic Sci, Rm 101,11021 Campus St, Loma Linda, CA 92354 USA.	lsowers@llu.edu			NATIONAL CANCER INSTITUTE [R01CA112293] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050351] Funding Source: NIH RePORTER; NCI NIH HHS [CA 112293] Funding Source: Medline; NIGMS NIH HHS [GM 50351] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allawi HT, 1997, BIOCHEMISTRY-US, V36, P10581, DOI 10.1021/bi962590c; Barrett TE, 1999, EMBO J, V18, P6599, DOI 10.1093/emboj/18.23.6599; Bennett MT, 2006, J AM CHEM SOC, V128, P12510, DOI 10.1021/ja0634829; Bianchet MA, 2003, BIOCHEMISTRY-US, V42, P12455, DOI 10.1021/bi035372+; Boorstein RJ, 2001, J BIOL CHEM, V276, P41991, DOI 10.1074/jbc.M106953200; CARADONNA SJ, 1980, J BIOL CHEM, V255, P2293; CHEONG C, 1988, NUCLEIC ACIDS RES, V16, P5115, DOI 10.1093/nar/16.11.5115; Dinner AR, 2001, NATURE, V413, P752, DOI 10.1038/35099587; ERITJA R, 1986, NUCLEIC ACIDS RES, V14, P8135, DOI 10.1093/nar/14.20.8135; Fujimoto J, 1996, NUCLEIC ACIDS RES, V24, P754, DOI 10.1093/nar/24.4.754; GAIT MJ, 1983, OLIGONUCLEOTIDES SYN; Hang B, 2002, BIOCHEMISTRY-US, V41, P2158, DOI 10.1021/bi011542b; HANSCH C, 1973, J MED CHEM, V16, P1207, DOI 10.1021/jm00269a003; Henderson JP, 2003, J BIOL CHEM, V278, P23522, DOI 10.1074/jbc.M303928200; Henderson JP, 2001, J BIOL CHEM, V276, P7867, DOI 10.1074/jbc.M005379200; Jang YH, 2001, J PHYS CHEM A, V105, P274, DOI 10.1021/jp994432b; Jiang Q, 2003, J BIOL CHEM, V278, P32834, DOI 10.1074/jbc.M304021200; Krokan HE, 2000, FEBS LETT, V476, P73, DOI 10.1016/S0014-5793(00)01674-4; Krosky DJ, 2004, BIOCHEMISTRY-US, V43, P4188, DOI 10.1021/bi036303y; Lari SU, 2006, DNA REPAIR, V5, P1407, DOI 10.1016/j.dnarep.2006.06.009; Law SM, 1996, BIOCHEMISTRY-US, V35, P12329, DOI 10.1021/bi9614545; Lindahl T, 2000, MUTAT RES-REV MUTAT, V462, P129, DOI 10.1016/S1383-5742(00)00024-7; Lindahl T, 1980, Methods Enzymol, V65, P284; Liu PF, 2003, DNA REPAIR, V2, P199, DOI 10.1016/S1568-7864(02)00198-2; Liu PF, 2002, CHEM RES TOXICOL, V15, P1001, DOI 10.1021/tx020030a; Matsubara M, 2004, NUCLEIC ACIDS RES, V32, P5291, DOI 10.1093/nar/gkh859; Minetti CASA, 2003, J MOL BIOL, V328, P1047, DOI 10.1016/S0022-2836(03)00365-6; MOSBAUGH DW, 1994, PROG NUCLEIC ACID RE, V48, P315, DOI 10.1016/S0079-6603(08)60859-4; MULLAART E, 1990, MUTAT RES, V237, P189, DOI 10.1016/0921-8734(90)90001-8; NEDDERMANN P, 1993, J BIOL CHEM, V268, P21218; Nilsen H, 1997, NUCLEIC ACIDS RES, V25, P750, DOI 10.1093/nar/25.4.750; Nilsen H, 2001, EMBO J, V20, P4278, DOI 10.1093/emboj/20.15.4278; O'Neill RJ, 2003, J BIOL CHEM, V278, P20526, DOI 10.1074/jbc.M210860200; Parker JB, 2007, NATURE, V449, P433, DOI 10.1038/nature06131; PARKER WB, 1990, PHARMACOL THERAPEUT, V48, P381, DOI 10.1016/0163-7258(90)90056-8; Pearl LH, 2000, MUTAT RES-DNA REPAIR, V460, P165, DOI 10.1016/S0921-8777(00)00025-2; PETRUSKA J, 1986, P NATL ACAD SCI USA, V83, P1559, DOI 10.1073/pnas.83.6.1559; RICHARD EG, 1975, CRC HDB BIOCH MOL BI, V1, P589; SAAVA R, 1995, NATURE, V373, P487; Sagi J, 1999, CHEM RES TOXICOL, V12, P917, DOI 10.1021/tx990088y; Saul R L, 1986, Basic Life Sci, V38, P529; Seiple L, 2006, NUCLEIC ACIDS RES, V34, P140, DOI 10.1093/nar/gkj430; SHAPIRO R, 1969, BIOCHEMISTRY-US, V8, P1806, DOI 10.1021/bi00833a004; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; SOBER HA, 1970, HDB BIOCH, pJ3; Sousa MML, 2007, MOL ASPECTS MED, V28, P276, DOI 10.1016/j.mam.2007.04.006; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; Sung JS, 2000, BIOCHEMISTRY-US, V39, P10224, DOI 10.1021/bi0007066; Sung JS, 2006, FEBS J, V273, P1620, DOI 10.1111/j.1742-4658.2006.05192.x; Valinluck V, 2006, CHEM RES TOXICOL, V19, P556, DOI 10.1021/tx050341w; Valinluck V, 2002, CHEM RES TOXICOL, V15, P1595, DOI 10.1021/tx020062y; Watkins NE, 2005, NUCLEIC ACIDS RES, V33, P6258, DOI 10.1093/nar/gki918; Whiteman M, 1997, CHEM RES TOXICOL, V10, P1240, DOI 10.1021/tx970086i; Wibley JEA, 2003, MOL CELL, V11, P1647, DOI 10.1016/S1097-2765(03)00235-1; Wilson DM, 2007, DNA REPAIR, V6, P544, DOI 10.1016/j.dnarep.2006.10.017; Wong I, 2002, J BIOL CHEM, V277, P19424, DOI 10.1074/jbc.M201198200	56	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					8829	8836		10.1074/jbc.M707174200	http://dx.doi.org/10.1074/jbc.M707174200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18208817	hybrid, Green Published			2022-12-25	WOS:000254465800009
J	Chiribau, CB; Cheng, LH; Cucoranu, IC; Yu, YS; Clempus, RE; Sorescu, D				Chiribau, Calin B.; Cheng, Lihong; Cucoranu, Ioan C.; Yu, Yong-Shen; Clempus, Roza E.; Sorescu, Dan			FOXO3A regulates peroxiredoxin III expression in human cardiac fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTOR; NECROSIS-FACTOR-ALPHA; MAMMALIAN PEROXIREDOXIN; REDUCE PEROXIDES; OXIDATIVE STRESS; PROTEINS; ISOFORMS; PHOSPHORYLATION; MITOCHONDRIA; THIOREDOXIN	Human cardiac fibroblasts are protected from oxidative stress triggered by inflammation after myocardial injury (Li, P. F., Dietz, R., and von Harsdorf, R. (1999) FEBS Lett. 448, 206 - 210) by expressing potent antioxidant defenses such as superoxide dismutases, catalases, glutathione-peroxidases, and peroxiredoxins. Recently the transcription factor FOXO3A has been shown to increase resistance to oxidative stress by up-regulation of mitochondrial superoxide dismutase and peroxisomal catalase (Kops, G. J., Dansen, T. B., Polderman, P. E., Saarloos, I., Wirtz, K. W., Coffer, P. J., Huang, T. T., Bos, J. L., Medema, R. H., and Burgering, B. M. (2002) Nature 419, 316 - 321; Nemoto, S., and Finkel, T. (2002) Science 295, 2450 - 2452). We hypothesized that FOXO3A also regulates the expression of Prx III, the mitochondrial peroxiredoxin, in human cardiac fibroblasts. We found that depletion of FOXO3A leads to a dramatic reduction of Prx III mRNA and protein in serum-deprived human cardiac fibroblasts. These data suggest that endogenous FOXO3A is necessary for base-line expression of Prx III. Next, we identified two putative FOXO3A DNA binding sites in Prx III promoter at -267 and -244 nucleotides relative to the start codon. We demonstrated that both sequences are required for binding of endogenous FOXO3A to the Prx III promoter by performing electromobility shift assays and chromatin immunoprecipitation assays. Inhibition of endogenous FOXO3A by insulin growth factor 1 prevented binding of FOXO3A to Prx III promoter. In contrast, overexpression of FOXO3A increased Prx III promoter activity. Furthermore, depletion of Prx III was associated with enhanced apoptosis and oxidative stress after serum deprivation. We conclude that FOXO3A mediates Prx III expression, and this may play a critical role in the resistance to oxidative stress in cardiac fibroblasts.	[Chiribau, Calin B.; Cheng, Lihong; Cucoranu, Ioan C.; Yu, Yong-Shen; Clempus, Roza E.; Sorescu, Dan] Emory Univ, Sch Med, Div Cardiol, Dept Med, Atlanta, GA 30322 USA	Emory University	Sorescu, D (corresponding author), Emory Univ, Sch Med, Div Cardiol, Dept Med, 1639 Pierce Dr,Woodruff Mem Bldg,Rm 319, Atlanta, GA 30322 USA.	dsoresc@emory.edu						Araki M, 1999, J BIOL CHEM, V274, P2271, DOI 10.1074/jbc.274.4.2271; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Burgering BMT, 2003, J LEUKOCYTE BIOL, V73, P689, DOI 10.1189/jlb.1202629; Chae HZ, 1999, DIABETES RES CLIN PR, V45, P101, DOI 10.1016/S0168-8227(99)00037-6; Chae HZ, 1999, METHOD ENZYMOL, V300, P219; Chang TS, 2002, J BIOL CHEM, V277, P25370, DOI 10.1074/jbc.M110432200; Chang TS, 2004, J BIOL CHEM, V279, P41975, DOI 10.1074/jbc.M407707200; Cucoranu I, 2005, CIRC RES, V97, P900, DOI 10.1161/01.RES.0000187457.24338.3D; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Hansen JM, 2006, TOXICOL SCI, V91, P643, DOI 10.1093/toxsci/kfj175; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Li PF, 1999, FEBS LETT, V448, P206, DOI 10.1016/S0014-5793(99)00370-1; Nemoto S, 2006, J BIOL CHEM, V281, P10555, DOI 10.1074/jbc.M511626200; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Neufeld KL, 1997, P NATL ACAD SCI USA, V94, P3034, DOI 10.1073/pnas.94.7.3034; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Rhee SG, 2005, FREE RADICAL BIO MED, V38, P1543, DOI 10.1016/j.freeradbiomed.2005.02.026; Sorescu D, 2002, CIRCULATION, V105, P1429, DOI 10.1161/01.CIR.0000012917.74432.66; Wonsey DR, 2002, P NATL ACAD SCI USA, V99, P6649, DOI 10.1073/pnas.102523299; Wood ZA, 2003, SCIENCE, V300, P650, DOI 10.1126/science.1080405; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Zhang H, 2007, ARCH BIOCHEM BIOPHYS, V465, P119, DOI 10.1016/j.abb.2007.05.001; Zheng WH, 2000, J BIOL CHEM, V275, P39152, DOI 10.1074/jbc.M002417200	26	104	107	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8211	8217		10.1074/jbc.M710610200	http://dx.doi.org/10.1074/jbc.M710610200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18195003	hybrid, Green Published			2022-12-25	WOS:000254288000018
J	Huang, WQ; Zhu, CL; Wang, H; Horvath, E; Eklund, EA				Huang, Weiqi; Zhu, Chunliu; Wang, Hao; Horvath, Elizabeth; Eklund, Elizabeth A.			The interferon consensus sequence-binding protein (ICSBP/IRF8) represses PTPN13 gene transcription in differentiating myeloid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE; GP91(PHOX) EXPRESSION; FAS LIGATION; LEUKEMIA; PU.1; FAP-1; APOPTOSIS; MACROPHAGES; DEATH; DNA	The interferon consensus sequence-binding protein (ICSBP/IRF8) is an interferon regulatory factor that is expressed in myeloid and B-cells. ICSBP-deficient mice develop a myeloproliferative disorder characterized by cytokine hypersensitivity and apoptosis resistance. To identify ICSBP target genes involved in these effects, we screened a CpG island microarray with chromatin that co-immunoprecipitated with ICSBP from myeloid cells. Using this technique, we identified PTPN13 as an ICSBP target gene. PTPN13 encodes Fas-associated phosphatase 1 (Fap-1), a ubiquitously expressed protein-tyrosine phosphatase. This was of interest because interaction of Fap-1 with Fas results in Fas dephosphorylation and inhibition of Fas-induced apoptosis. In this study, we found that ICSBP influenced Fas-induced apoptosis in a Fap-1-dependent manner. We also found that ICSBP interacted with a cis element in the proximal PTPN13 promoter and repressed transcription. This interaction increased during myeloid differentiation and was regulated by phosphorylation of conserved tyrosine residues in the interferon regulatory factor domain of ICSBP. ICSBP deficiency was present in human myeloid malignancies, including chronic myeloid leukemia. Therefore, these studies identified a mechanism for increased survival of mature myeloid cells in the ICSBP-deficient murine model and in human myeloid malignancies with decreased ICSBP expression.	[Huang, Weiqi; Zhu, Chunliu; Wang, Hao; Horvath, Elizabeth; Eklund, Elizabeth A.] Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA; [Huang, Weiqi; Zhu, Chunliu; Wang, Hao; Horvath, Elizabeth; Eklund, Elizabeth A.] Northwestern Univ, Robert H Lurie Comprahens Canc Ctr, Chicago, IL 60611 USA; [Horvath, Elizabeth; Eklund, Elizabeth A.] Jesse Brown Vet Hlth Adm Med Ctr, Chicago, IL 60612 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center	Eklund, EA (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Med, 710 N Fairbanks Ct,Olson 8524, Chicago, IL 60611 USA.	e-eklund@northwestern.edu	Huang, Weiqi/E-4341-2010	Wang, Hao/0000-0003-2131-0377	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL088747] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL088747] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dubchak I, 2000, GENOME RES, V10, P1304, DOI 10.1101/gr.142200; Eklund EA, 1999, J IMMUNOL, V163, P6095; Eklund EA, 1998, J BIOL CHEM, V273, P13957, DOI 10.1074/jbc.273.22.13957; Gabriele L, 1999, J EXP MED, V190, P411, DOI 10.1084/jem.190.3.411; GARRONE P, 1995, J EXP MED, V182, P1265, DOI 10.1084/jem.182.5.1265; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Huang WQ, 2007, J BIOL CHEM, V282, P6629, DOI 10.1074/jbc.M607760200; Huang WQ, 2006, MOL CELL BIOL, V26, P6311, DOI 10.1128/MCB.00036-06; Inazawa J, 1996, GENOMICS, V31, P240, DOI 10.1006/geno.1996.0039; Ivanov VN, 2003, MOL CELL BIOL, V23, P3623, DOI 10.1128/MCB.23.10.3623-3635.2003; Josefsen D, 1999, EXP HEMATOL, V27, P1451, DOI 10.1016/S0301-472X(99)00073-9; Kautz B, 2001, J BIOL CHEM, V276, P37868; Kim YM, 1999, J IMMUNOL, V163, P2000; Komada Y, 1997, BRIT J HAEMATOL, V99, P325, DOI 10.1046/j.1365-2141.1997.3903204.x; KONIECZNA I, 2008, INPRESS J CLIN INVES; Kuwata T, 2002, MOL CELL BIOL, V22, P7439, DOI 10.1128/MCB.22.21.7439-7448.2002; LARRICK JW, 1980, J IMMUNOL, V125, P6; Loots GG, 2002, GENOME RES, V12, P832, DOI 10.1101/gr.225502; Ma YY, 2004, NAT IMMUNOL, V5, P380, DOI 10.1038/ni1054; Mayor C, 2000, BIOINFORMATICS, V16, P1046, DOI 10.1093/bioinformatics/16.11.1046; Michor F, 2005, NATURE, V435, P1267, DOI 10.1038/nature03669; NELSON N, 1993, MOL CELL BIOL, V13, P588, DOI 10.1128/MCB.13.1.588; Oberley MJ, 2003, METHOD ENZYMOL, V371, P577; Otten HG, 2004, LEUKEMIA, V18, P1401, DOI 10.1038/sj.leu.2403414; Qian ZJ, 2002, P NATL ACAD SCI USA, V99, P14925, DOI 10.1073/pnas.222491799; Rehli M, 2000, J BIOL CHEM, V275, P9773, DOI 10.1074/jbc.275.13.9773; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Scheller M, 1999, BLOOD, V94, P3764, DOI 10.1182/blood.V94.11.3764.423k03_3764_3771; Schmidt M, 1998, BLOOD, V91, P22, DOI 10.1182/blood.V91.1.22.22_22_29; Schmidt M, 2001, BLOOD, V97, P3648, DOI 10.1182/blood.V97.11.3648; Sharf R, 1997, J BIOL CHEM, V272, P9785; Tamura T, 2005, BLOOD, V106, P1938, DOI 10.1182/blood-2005-01-0080; Wang IM, 2000, J IMMUNOL, V165, P271, DOI 10.4049/jimmunol.165.1.271; Yanagisawa J, 1997, J BIOL CHEM, V272, P8539, DOI 10.1074/jbc.272.13.8539; Yoshida S, 2002, J HUM GENET, V47, P614, DOI 10.1007/s100380200094; Zhang Y, 1998, P NATL ACAD SCI USA, V95, P2586, DOI 10.1073/pnas.95.5.2586; Zhu CL, 2004, J BIOL CHEM, V279, P50874, DOI 10.1074/jbc.M405736200	38	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7921	7935		10.1074/jbc.M706710200	http://dx.doi.org/10.1074/jbc.M706710200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18195016	hybrid			2022-12-25	WOS:000253997900068
J	Sparling, DP; Griesel, BA; Weems, J; Olson, AL				Sparling, David P.; Griesel, Beth A.; Weems, Juston; Olson, Ann Louise			GLUT4 enhancer factor (GEF) interacts with MEF2A and HDAC5 to regulate the GLUT4 promoter in adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSIVE GLUCOSE TRANSPORTER; II HISTONE DEACETYLASES; TRANSCRIPTION FACTOR; SKELETAL-MUSCLE; TRANSGENIC MICE; GENE PROMOTER; ADIPOSE-TISSUE; DB/DB MICE; EXPRESSION; ACTIVATION	The insulin-responsive glucose transporter, GLUT4, is regulated in various physiologic states at the transcriptional level. When expressed in transgenic mice, the human GLUT4 promoter is governed by two cis-acting sequences: an MEF2 binding domain and Domain I, that function both as positive and negative regulators depending on the physiologic state. MEF2 proteins and GLUT4 enhancer factor ( GEF) are known ligands for these cis-acting elements, but their mechanism of action is unclear. To begin to understand this important process, we have characterized GEF structural domains and its interactions with the MEF2A isoform. We find that the C terminus of GEF comprises its DNA-binding domain, but does not contribute to GEF homo-oligomerization. We also have found that GEF dimerizes with increased affinity to a hypophosphorylated form of MEF2A. Furthermore, we demonstrated that MEF2A binding to its cognate binding site can increase the DNA binding activity of GEF to Domain I, suggesting a novel mechanism for MEF2A transcriptional activation. Finally, we have demonstrated that the transcriptional co-repressor HDAC5 can interact with GEF in the absence of MEF2 proteins and specifically inhibit GLUT4 promoter activity. These findings lead to the hypothesis that GEF and the MEF2 proteins form a complex on the GLUT4 promoter that allows for recruitment of transcriptional co-regulators ( repressors and/ or activators) to control GLUT4 promoter activity.	[Sparling, David P.; Griesel, Beth A.; Weems, Juston; Olson, Ann Louise] Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Olson, AL (corresponding author), POB 26901,Rm 853, Oklahoma City, OK 73190 USA.	ann-olson@ouhsc.edu		Sparling, David/0000-0001-5940-1544	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062341] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK062341, R01 DK062341] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGER J, 1989, NATURE, V340, P70, DOI 10.1038/340070a0; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Black BL, 1998, MOL CELL BIOL, V18, P69, DOI 10.1128/MCB.18.1.69; Brozinick JT, 2001, DIABETES, V50, P593, DOI 10.2337/diabetes.50.3.593; Charron MJ, 1999, J BIOL CHEM, V274, P3253, DOI 10.1074/jbc.274.6.3253; Christ-Roberts CY, 2004, METABOLISM, V53, P1233, DOI 10.1016/j.metabol.2004.03.022; Czubryt MP, 2003, P NATL ACAD SCI USA, V100, P1711, DOI 10.1073/pnas.0337639100; Eyster CA, 2005, J BIOL CHEM, V280, P17978, DOI 10.1074/jbc.M409806200; GARVEY WT, 1989, SCIENCE, V245, P60, DOI 10.1126/science.2662408; GIBBS EM, 1995, J CLIN INVEST, V95, P1512, DOI 10.1172/JCI117823; Han AD, 2005, J MOL BIOL, V345, P91, DOI 10.1016/j.jmb.2004.10.033; Holmes BF, 2004, AM J PHYSIOL-ENDOC M, V287, pE739, DOI 10.1152/ajpendo.00080.2004; KAHN BB, 1988, J CLIN INVEST, V82, P691, DOI 10.1172/JCI113649; Knight JB, 2003, P NATL ACAD SCI USA, V100, P14725, DOI 10.1073/pnas.2432756100; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; MacLean PS, 2002, BIOCHEM BIOPH RES CO, V292, P409, DOI 10.1006/bbrc.2002.6654; McGee SL, 2004, DIABETES, V53, P1208, DOI 10.2337/diabetes.53.5.1208; Mora S, 2000, J BIOL CHEM, V275, P16323, DOI 10.1074/jbc.M910259199; Mora S, 2001, ENDOCRINOLOGY, V142, P1999, DOI 10.1210/en.142.5.1999; Morin S, 2005, J BIOL CHEM, V280, P32272, DOI 10.1074/jbc.M507640200; OLSON AL, 1995, J BIOL CHEM, V270, P23491, DOI 10.1074/jbc.270.40.23491; Oshel KM, 2000, J BIOL CHEM, V275, P23666, DOI 10.1074/jbc.M001452200; Potthoff MJ, 2007, J CLIN INVEST, V117, P2459, DOI 10.1172/JCI31960; SINHA MK, 1991, DIABETES, V40, P472, DOI 10.2337/diabetes.40.4.472; SIVITZ WI, 1989, NATURE, V340, P72, DOI 10.1038/340072a0; Sparling DP, 2007, AM J PHYSIOL-ENDOC M, V292, pE1149, DOI 10.1152/ajpendo.00521.2006; Thai MV, 1998, J BIOL CHEM, V273, P14285, DOI 10.1074/jbc.273.23.14285; ZIEL FH, 1988, DIABETES, V37, P885, DOI 10.2337/diabetes.37.7.885	30	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7429	7437		10.1074/jbc.M800481200	http://dx.doi.org/10.1074/jbc.M800481200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18216015	Green Published, hybrid			2022-12-25	WOS:000253997900017
J	Sohl, CD; Isin, EM; Eoff, RL; Marsch, GA; Stec, DF; Guengerich, FP				Sohl, Christal D.; Isin, Emre M.; Eoff, Robert L.; Marsch, Glenn A.; Stec, Donald F.; Guengerich, F. Peter			Cooperativity in oxidation reactions catalyzed by cytochrome P450 1A2 - Highly cooperative pyrene hydroxylation and multiphasic kinetics of ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYCLIC AROMATIC-HYDROCARBONS; PURIFIED CYTOCHROME-P-450; ESCHERICHIA-COLI; DRUG-METABOLISM; DIFFERENT FORMS; MULTIPLE FORMS; ACTIVE-SITE; RABBIT; ACTIVATION; 3A4	Rabbit liver cytochrome P450 ( P450) 1A2 was found to catalyze the 5,6-epoxidation of alpha-naphthoflavone (alpha NF), 1-hydroxylation of pyrene, and the subsequent 6-, 8-, and other hydroxylations of 1-hydroxy ( OH) pyrene. Plots of steady-state rates of product formation versus substrate concentration were hyperbolic for alpha NF epoxidation but highly cooperative ( Hill n coefficients of 2 - 4) for pyrene and 1-OH pyrene hydroxylation. When any of the three substrates (alpha NF, pyrene, 1-OH pyrene) were mixed with ferric P450 1A2 using stopped-flow methods, the changes in the heme Soret spectra were relatively slow and multiphasic. Changes in the fluorescence of all of the substrates were much faster, consistent with rapid initial binding to P450 1A2 in a manner that does not change the heme spectrum. For binding of pyrene to ferrous P450 1A2, the course of the spectra revealed sequential changes in opposite directions, consistent with P450 1A2 being involved in a series of transitions to explain the kinetic multiphasicity as opposed to multiple, slowly inter-converting populations of enzyme undergoing the same event at different rates. Models of rabbit P450 1A2 based on a published crystal structure of a human P450 1A2-alpha NF complex show active site space for only one alpha NF or for two pyrenes. The spectral changes observed for binding and hydroxylation of pyrene and 1-OH pyrene could be fit to a kinetic model in which hydroxylation occurs only when two substrates are bound. Elements of this mechanism may be relevant to other cases of P450 cooperativity.	[Sohl, Christal D.; Isin, Emre M.; Eoff, Robert L.; Guengerich, F. Peter] Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA; [Sohl, Christal D.; Isin, Emre M.; Eoff, Robert L.; Guengerich, F. Peter] Vanderbilt Univ, Ctr Mol Toxicol, Sch Med, Nashville, TN 37232 USA; [Marsch, Glenn A.] Grove City Coll, Dept Phys, Grove City, PA 16127 USA; [Stec, Donald F.] Vanderbilt Univ, Dept Chem, Nashville, TN 37235 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Guengerich, FP (corresponding author), Vanderbilt Univ, Dept Biochem, Sch Med, 638 Robinson Res Bldg,2200 Pierce Ave, Nashville, TN 37232 USA.	f.guengerich@vanderbilt.edu		Isin, Emre/0000-0003-3402-7685	NATIONAL CANCER INSTITUTE [F32CA119776, R37CA090426] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR019022] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NCI NIH HHS [F32 CA119776, R37 CA090426] Funding Source: Medline; NCRR NIH HHS [S10 RR019022] Funding Source: Medline; NIEHS NIH HHS [P30 ES000267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALTERMAN MA, 1990, BIOMED CHROMATOGR, V4, P221, DOI 10.1002/bmc.1130040510; Atkins WM, 2006, EXPERT OPIN DRUG MET, V2, P573, DOI 10.1517/17425255.2.4.573; Atkins WM, 2005, ANNU REV PHARMACOL, V45, P291, DOI 10.1146/annurev.pharmtox.45.120403.100004; BAUER E, 1995, CHEM RES TOXICOL, V8, P136, DOI 10.1021/tx00043a018; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUENING MK, 1978, BIOCHEM BIOPH RES CO, V82, P348, DOI 10.1016/0006-291X(78)90616-2; BURLEIGH BD, 1969, ANAL BIOCHEM, V27, P536, DOI 10.1016/0003-2697(69)90067-0; CAMBILLAU C, 1997, TURBO FRODO; Chetiyanukornkul T, 2002, J CHROMATOGR A, V961, P107, DOI 10.1016/S0021-9673(02)00363-1; Chun YJ, 2007, J BIOL CHEM, V282, P17486, DOI 10.1074/jbc.M700863200; CONNEY AH, 1982, CANCER RES, V42, P4875; Dabrowski MJ, 2002, J AM CHEM SOC, V124, P11866, DOI 10.1021/ja027552x; Ekroos M, 2006, P NATL ACAD SCI USA, V103, P13682, DOI 10.1073/pnas.0603236103; Fernando H, 2007, ARCH BIOCHEM BIOPHYS, V460, P129, DOI 10.1016/j.abb.2006.12.025; FERSHT A, 1999, STRUCTURE MECH PROTE, P158; FOUST GP, 1969, ANAL BIOCHEM, V27, P530, DOI 10.1016/0003-2697(69)90066-9; Girsch P, 1997, BBA-BIOENERGETICS, V1318, P202, DOI 10.1016/S0005-2728(96)00138-7; GOTOH O, 1992, J BIOL CHEM, V267, P83; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; GRIFFIN BW, 1972, BIOCHEMISTRY-US, V11, P4740, DOI 10.1021/bi00775a017; Guengerich F.P., 2005, CYTOCHROME P450 STRU, V3rd ed., P377, DOI [10.1007/0-387-27447-2_10, DOI 10.1007/0-387-27447-2_10]; Guengerich F. P., 2007, PRINCIPLES METHODS T, P1981; Guengerich FP, 2001, CHEM RES TOXICOL, V14, P611, DOI 10.1021/tx0002583; Guengerich FP, 2004, BIOCHEMISTRY-US, V43, P10775, DOI 10.1021/bi0491393; GUENGERICH FP, 1983, BIOCHEMISTRY-US, V22, P2811, DOI 10.1021/bi00281a007; GUENGERICH FP, 1977, J BIOL CHEM, V252, P3970; GUENGERICH FP, 1994, P 8 INT C CYT P450 B, P97; Hanna IH, 1998, ARCH BIOCHEM BIOPHYS, V350, P324, DOI 10.1006/abbi.1997.0534; Harlow GR, 1998, P NATL ACAD SCI USA, V95, P6636, DOI 10.1073/pnas.95.12.6636; HAUGEN DA, 1976, J BIOL CHEM, V251, P7929; Hosea NA, 2000, BIOCHEMISTRY-US, V39, P5929, DOI 10.1021/bi992765t; HUANG MT, 1981, J BIOL CHEM, V256, P6829; Hutzler JM, 2002, DRUG METAB DISPOS, V30, P355, DOI 10.1124/dmd.30.4.355; Isin EM, 2006, J BIOL CHEM, V281, P9127, DOI 10.1074/jbc.M511375200; Isin EM, 2007, J BIOL CHEM, V282, P6863, DOI 10.1074/jbc.M610346200; JOHNSON EF, 1983, J BIOL CHEM, V258, P2785; JOHNSON EF, 1977, J BIOL CHEM, V252, P2839; JOHNSON EF, 1979, MOL PHARMACOL, V15, P708; Johnson Kenneth A., 2003, P1; Jushchyshyn MI, 2005, ARCH BIOCHEM BIOPHYS, V438, P21, DOI 10.1016/j.abb.2005.02.027; KAPITULNIK J, 1977, CLIN PHARMACOL THER, V22, P475; Kelly SM, 2005, BBA-PROTEINS PROTEOM, V1751, P119, DOI 10.1016/j.bbapap.2005.06.005; Kim D, 2005, ANNU REV PHARMACOL, V45, P27, DOI 10.1146/annurev.pharmtox.45.120403.100010; Kim YD, 2004, ENVIRON RES, V94, P262, DOI 10.1016/S0013-9351(03)00134-8; Koley AP, 1997, J BIOL CHEM, V272, P3149, DOI 10.1074/jbc.272.6.3149; KUBY SA, 1991, STUDY ENZYMES, V1, P283; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LAKOWICZ JR, 1999, PRINCIPLES FLUORESCE, P9; LAMBERT M, 1994, APPL ENVIRON MICROB, V60, P3597, DOI 10.1128/AEM.60.10.3597-3601.1994; LASKER JM, 1982, SCIENCE, V216, P1419, DOI 10.1126/science.7089530; LAUNEN L, 1995, CAN J MICROBIOL, V41, P477, DOI 10.1139/m95-064; Lehrer SS, 1997, METHOD ENZYMOL, V278, P286; MCMANUS ME, 1984, CARCINOGENESIS, V5, P1717, DOI 10.1093/carcin/5.12.1717; Miller GP, 2001, BIOCHEMISTRY-US, V40, P7262, DOI 10.1021/bi010402z; NEBERT DW, 1968, J BIOL CHEM, V243, P6242; Ngui JS, 2000, DRUG METAB DISPOS, V28, P1043; OHAVER TC, 1976, ANAL CHEM, V48, P312, DOI 10.1021/ac60366a016; Ortiz de Montellano P. R., 2005, CYTOCHROME P450 STRU; PALMER G, 1992, J BIOL CHEM, V267, P665; Parikh A, 1997, NAT BIOTECHNOL, V15, P784, DOI 10.1038/nbt0897-784; Parikh A, 1999, BIOCHEMISTRY-US, V38, P5283, DOI 10.1021/bi990142+; QUATTROCHI LC, 1986, P NATL ACAD SCI USA, V83, P6731, DOI 10.1073/pnas.83.18.6731; RAHA CR, 1983, J CHROMATOGR, V264, P453, DOI 10.1016/S0021-9673(01)95052-6; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; Roberts AG, 2005, BIOCHEMISTRY-US, V44, P1353, DOI 10.1021/bi0481390; SANDHU P, 1994, ARCH BIOCHEM BIOPHYS, V309, P168, DOI 10.1006/abbi.1994.1099; Sansen S, 2007, J BIOL CHEM, V282, P14348, DOI 10.1074/jbc.M611692200; SCHENKMAN JB, 1967, MOL PHARMACOL, V3, P113; Schrag ML, 2000, DRUG METAB DISPOS, V28, P1198; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; SCHWAB GE, 1988, MOL PHARMACOL, V33, P493; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Segel I.H., 1975, ENZYME KINETICS; Shimada T, 1998, CHEM RES TOXICOL, V11, P1048, DOI 10.1021/tx980090+; Shiu WY, 2000, J PHYS CHEM REF DATA, V29, P41, DOI 10.1063/1.556055; SHOU M, 1994, BIOCHEMISTRY-US, V33, P6450, DOI 10.1021/bi00187a009; Tracy Timothy S, 2006, Drugs R D, V7, P349, DOI 10.2165/00126839-200607060-00004; Ueng YF, 1997, BIOCHEMISTRY-US, V36, P370, DOI 10.1021/bi962359z; WIEBEL FJ, 1971, ARCH BIOCHEM BIOPHYS, V144, P78, DOI 10.1016/0003-9861(71)90456-5; WIEBEL FJ, 1975, P NATL ACAD SCI USA, V72, P3917, DOI 10.1073/pnas.72.10.3917; Williams JA, 2004, DRUG METAB DISPOS, V32, P1201, DOI 10.1124/dmd.104.000794; Williams PA, 2003, NATURE, V424, P464, DOI 10.1038/nature01862; Williams PA, 2004, SCIENCE, V305, P683, DOI 10.1126/science.1099736; Witherow LE, 1999, J PHARMACOL EXP THER, V290, P58; YANG CS, 1985, CANCER RES, V45, P1140; Yano JK, 2004, J BIOL CHEM, V279, P38091, DOI 10.1074/jbc.C400293200; Yun CH, 2005, J BIOL CHEM, V280, P12279, DOI 10.1074/jbc.M411019200	87	51	51	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					7293	7308		10.1074/jbc.M709783200	http://dx.doi.org/10.1074/jbc.M709783200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18187423	hybrid			2022-12-25	WOS:000253779600074
J	Tran, S; Norstrom, E; Dahlback, B				Tran, Sinh; Norstrom, Eva; Dahlback, Bjorn			Effects of prothrombin on the individual activated protein C-mediated cleavages of coagulation factor Va	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-BOND CLEAVAGES; BLOOD-COAGULATION; FACTOR-XA; ANTICOAGULANT ACTIVITY; BINDING-SITE; HEAVY-CHAIN; GLA DOMAIN; FACTOR VA(R506Q); HONG-KONG; COMPLEX	The factor Va(FVa) inactivation by activated protein C( APC), mediated by cleavages at Arg(306) and Arg(506) in FVa, is inhibited by both factor Xa (FXa) and prothrombin. Although FXa is known to specifically inhibit the Arg506 cleavage, the effect of prothrombin has not been confined to one cleavage site. We used recombinant FV variants, FV: R506Q/R679Q and FV: R306Q/R679Q, to investigate the effect of prothrombin on the individual cleavage sites. The APC-mediated FVa inhibition was monitored by a prothrombinase-based FVa assay, and apparent first order rate constants were calculated for each of the cleavage sites both in the presence and absence of prothrombin. Prothrombin impaired cleavages at both Arg306 and Arg506 and the inhibition correlated with a delayed appearance of proteolytic products on Western blots. Almost complete inhibition was obtained at around 3 mu M prothrombin, whereas half-maximal inhibition was obtained at 0.7 mu M prothrombin. After cleavage of prothrombin by thrombin, the inhibitory activity was lost. The inhibitory effect of prothrombin on APC-mediated inhibition of FVa was seen both in the presence and absence of protein S, but in particular for the Arg306 sites, it was more pronounced in the presence of protein S. Thus, prothrombin inhibition of APC inactivation of FVa appears to be due to both impaired APC function and decreased APC cofactor function of protein S. In conclusion, FVa, being part of the prothrombinase complex, is protected from APC by both FXa and prothrombin. Release of products of prothrombin activation from the prothrombinase complex would alleviate the protection, allowing APC-mediated inactivation of FVa.	[Tran, Sinh; Norstrom, Eva; Dahlback, Bjorn] Lund Univ, Univ Hosp, Dept Lab Med, Wallenberg Lab, SE-20502 Malmo, Sweden	Lund University; Skane University Hospital	Dahlback, B (corresponding author), Lund Univ, Univ Hosp, Dept Lab Med, Wallenberg Lab, SE-20502 Malmo, Sweden.	bjorn.dahlback@med.lu.se		Dahlback, Bjorn/0000-0003-1546-0328				Anderson PJ, 2000, J BIOL CHEM, V275, P16435, DOI 10.1074/jbc.M001255200; Autin L, 2006, PROTEINS, V63, P440, DOI 10.1002/prot.20848; BAKKER HM, 1994, J BIOL CHEM, V269, P20662; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; Blostein MD, 2000, J BIOL CHEM, V275, P38120, DOI 10.1074/jbc.M007174200; Bock PE, 2007, J THROMB HAEMOST, V5, P81, DOI 10.1111/j.1538-7836.2007.02496.x; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; Bukys MA, 2006, J BIOL CHEM, V281, P39194, DOI 10.1074/jbc.M604482200; Butenas S, 2002, BIOCHEMISTRY-MOSCOW+, V67, P3; Chan WP, 1998, BLOOD, V91, P1135, DOI 10.1182/blood.V91.4.1135; Chen L, 2003, J BIOL CHEM, V278, P27564, DOI 10.1074/jbc.M302707200; DAHLBACK B, 1983, BIOCHEM J, V209, P837, DOI 10.1042/bj2090837; DAHLBACK B, 1992, BIOCHEMISTRY-US, V31, P12769, DOI 10.1021/bi00166a009; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; Dahlback B, 2005, J INTERN MED, V257, P209, DOI 10.1111/j.1365-2796.2004.01444.x; Deguchi H, 1997, BIOCHEM J, V321, P729, DOI 10.1042/bj3210729; Esmon CT, 2000, BBA-PROTEIN STRUCT M, V1477, P349, DOI 10.1016/S0167-4838(99)00266-6; Fiske CH, 1925, J BIOL CHEM, V66, P375; Gale AJ, 2002, PROTEIN SCI, V11, P2091, DOI 10.1110/ps.0210002; Gale AJ, 2007, J BIOL CHEM, V282, P21848, DOI 10.1074/jbc.M702192200; KALAFATIS M, 1994, BBA-MOL BASIS DIS, V1227, P113, DOI 10.1016/0925-4439(94)90086-8; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; KOTKOW KJ, 1995, J BIOL CHEM, V270, P4551, DOI 10.1074/jbc.270.9.4551; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; LUCKOW EA, 1989, BIOCHEMISTRY-US, V28, P2348, DOI 10.1021/bi00431a055; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; Mann KG, 1999, THROMB HAEMOSTASIS, V82, P165; Mann KG, 1997, J BIOL CHEM, V272, P20678, DOI 10.1074/jbc.272.33.20678; MITCHELL CA, 1988, J CLIN INVEST, V82, P2142, DOI 10.1172/JCI113836; NICOLAES GAF, 1995, J BIOL CHEM, V270, P21158, DOI 10.1074/jbc.270.36.21158; Norstrom E, 2002, BLOOD, V100, P524, DOI 10.1182/blood-2002-02-0343; Norstrom EA, 2003, J BIOL CHEM, V278, P24904, DOI 10.1074/jbc.M303829200; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; ROSING J, 1995, J BIOL CHEM, V270, P27852, DOI 10.1074/jbc.270.46.27852; ROSING J, 1980, J BIOL CHEM, V255, P274; Schenone M, 2004, CURR OPIN HEMATOL, V11, P272, DOI 10.1097/01.moh.0000130308.37353.d4; Segers K, 2007, THROMB HAEMOSTASIS, V98, P530, DOI 10.1160/TH07-02-0150; Shen L, 1997, BIOCHEMISTRY-US, V36, P16025, DOI 10.1021/bi971730v; Shen MC, 2001, THROMB HAEMOSTASIS, V85, P270; Smirnov MD, 1999, BLOOD, V94, P3839, DOI 10.1182/blood.V94.11.3839.423k07_3839_3846; Smirnov MD, 1998, J BIOL CHEM, V273, P9031, DOI 10.1074/jbc.273.15.9031; SOLYMOSS S, 1988, J BIOL CHEM, V263, P14884; Sun YH, 2004, J BIOL CHEM, V279, P47528, DOI 10.1074/jbc.M407366200; Tosetto A, 1998, BRIT J HAEMATOL, V103, P871, DOI 10.1046/j.1365-2141.1998.01028.x; VANRIJN JLML, 1984, BIOCHEMISTRY-US, V23, P4557, DOI 10.1021/bi00315a008; Williamson D, 1998, BLOOD, V91, P1140, DOI 10.1182/blood.V91.4.1140; Yegneswaran S, 2004, J BIOL CHEM, V279, P49019, DOI 10.1074/jbc.M406645200	47	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					6648	6655		10.1074/jbc.M708036200	http://dx.doi.org/10.1074/jbc.M708036200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18198180	hybrid			2022-12-25	WOS:000253779600006
J	Karam, F; Mbow, F; Fletcher, H; Senghor, CS; Coulibaly, KD; LeFevre, AM; Gueye, NFN; Dieye, T; Sow, PS; Mboup, S; Lienhardt, C				Karam, Farba; Mbow, Fatou; Fletcher, Helen; Senghor, Cheikh S.; Coulibaly, Koura D.; LeFevre, Andrea M.; Gueye, Ndeye F. Ngom; Dieye, Tandakha; Sow, Papa S.; Mboup, Souleymane; Lienhardt, Christian			Sensitivity of IFN-gamma Release Assay to Detect Latent Tuberculosis Infection Is Retained in HIV-Infected Patients but Dependent on HIV/AIDS Progression	PLOS ONE			English	Article							MYCOBACTERIUM-TUBERCULOSIS; SKIN-TEST; DIAGNOSIS; INDIVIDUALS; ENUMERATION; PREVALENCE; REACTIVITY; RESPONSES; CHILDREN; ANTIGENS	Background. Detection and treatment of latent TB infection (LTBI) in HIV infected individuals is strongly recommended to decrease morbidity and mortality in countries with high levels of HIV. Objective. To assess the validity of a newly developed in-house ELISPOT interferon-c release assay (IGRA) for the detection of LTBI amongst HIV infected individuals, in comparison with the Tuberculin Skin Test (TST). Methodology/Principal Findings. ESAT6/CFP10 (EC) ELISPOT assays were performed, together with a TST, in 285 HIV infected individuals recruited in HIV clinics in Dakar, Senegal, who had no signs of active TB at time of enrolment. Thirty eight of the subjects (13.3%) failed to respond to PHA stimulation and were excluded from the analysis. In the 247 remaining patients, response to PHA did not vary according to CD4 cell count categories (p = 0.51). EC ELISPOT was positive in 125 (50.6%) subjects, while 53 (21.5%) had a positive TST. Concordance between EC ELISPOT and TST was observed in 151 patients (61.1%) (kappa = 0.23). The proportion of subjects with a positive response to the EC ELISPOT assay decreased with declining CD4 counts (p trend = 0.001), but were consistently higher than the proportion of TST responders. In multivariate analysis, the risk of being EC-ELISPOT positive in HIV infected individuals was associated with age, CD4 count and HIV-1 strain. Conclusion. Our study indicates that IGRAs using M. tuberculosis specific antigens are likely to retain their validity for the diagnosis of LTBI among HIV positive individuals, but may be impaired by T-cell anergy in severely immuno-suppressed individuals.	[Mbow, Fatou; Lienhardt, Christian] Inst Rech Dev Programme TB, Dakar, Senegal; [Fletcher, Helen] Univ Oxford, Churchill Hosp, Ctr Clin Vaccinol Trop Med, Oxford, England; [Senghor, Cheikh S.; Coulibaly, Koura D.; Sow, Papa S.] Hosp Fann, Clin Maladies Infect, Dakar, Senegal; [LeFevre, Andrea M.] London Sch Hygiene & Trop Med, Infect Dis Epidemiol Unit, London, England; [Gueye, Ndeye F. Ngom] Hosp Fann, Ctr Trait Ambul, Dakar, Senegal; [Karam, Farba; Dieye, Tandakha; Mboup, Souleymane] Hosp Aristide Le Dantec, Lab Bacteriol, Dakar, Senegal; [Lienhardt, Christian] Int Union Against TB & Lung Dis, Clin Trial Div, Paris, France	Institut de Recherche pour le Developpement (IRD); University of Oxford; University of London; London School of Hygiene & Tropical Medicine	Lienhardt, C (corresponding author), Inst Rech Dev Programme TB, Dakar, Senegal.	clienhardt@iuatld.org	Fletcher, Helen/D-1470-2011; Rehman, Andrea/AAP-3172-2020; Lienhardt, Christian/AAU-4969-2021; Rehman, Andrea M/H-1351-2015	Rehman, Andrea/0000-0001-9967-5822; Lienhardt, Christian/0000-0003-0233-893X; Rehman, Andrea M/0000-0001-9967-5822; Fletcher, Helen/0000-0002-0435-1006	European Commission, Framework Programme 5 [QOL 2001-01613]; Medical Research Council [G0700837] Funding Source: researchfish; MRC [G0700837] Funding Source: UKRI	European Commission, Framework Programme 5(European CommissionEuropean Commission Joint Research Centre); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The study has been conducted under funding from the European Commission, Framework Programme 5, Project QOL 2001-01613.	Andersen P, 2000, LANCET, V356, P1099, DOI 10.1016/S0140-6736(00)02742-2; Arend SM, 2001, CLIN DIAGN LAB IMMUN, V8, P1089, DOI 10.1128/CDLI.8.6.1089-1096.2001; BLAND JM, 1995, LANCET, V346, P1085, DOI 10.1016/S0140-6736(95)91748-9; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Brock I, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-56; Chapman ALN, 2002, AIDS, V16, P2285, DOI 10.1097/00002030-200211220-00008; Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009; Dheda K, 2005, AIDS, V19, P2038, DOI 10.1097/01.aids.0000191923.08938.5b; Dieye TN, 2005, JAIDS-J ACQ IMM DEF, V39, P32, DOI 10.1097/01.qai.0000160515.20581.ad; Doherty TM, 2002, J CLIN MICROBIOL, V40, P704, DOI 10.1128/JCM.40.2.704-706.2002; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Elliott AM, 1999, INT J TUBERC LUNG D, V3, P239; Ewer K, 2003, LANCET, V361, P1168, DOI 10.1016/S0140-6736(03)12950-9; Garcia-Garcia MD, 2000, INT J EPIDEMIOL, V29, P369; Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362; Hoffmann M, 2007, AIDS, V21, P390, DOI 10.1097/QAD.0b013e328012164b; HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968, DOI 10.1093/clinids/17.6.968; KANKI PJ, 1994, LANCET, V343, P943, DOI 10.1016/S0140-6736(94)90065-5; Lalvani A, 2001, J INFECT DIS, V183, P469, DOI 10.1086/318081; Lalvani T, 1998, P NATL ACAD SCI USA, V95, P270, DOI 10.1073/pnas.95.1.270; Lienhardt C, 2003, AM J RESP CRIT CARE, V168, P448, DOI 10.1164/rccm.200212-1483OC; Madhi SA, 1999, PEDIATR INFECT DIS J, V18, P800, DOI 10.1097/00006454-199909000-00011; Menzies D, 2007, ANN INTERN MED, V146, P340, DOI 10.7326/0003-4819-146-5-200703060-00006; *MIN SANT PREV SEN, 2002, B EP MIN SANT PREV S, V9; PAI M, 2007, LANCET INFECT DIS; Palme IB, 2002, PEDIATR INFECT DIS J, V21, P1053, DOI 10.1097/00006454-200211000-00016; Shafer RW, 1996, CLIN INFECT DIS, V22, P683, DOI 10.1093/clinids/22.4.683; Sonnenberg P, 2005, J INFECT DIS, V191, P150, DOI 10.1086/426827; Sutherland R, 2006, AIDS, V20, P821, DOI 10.1097/01.aids.0000218545.31716.a4; Thiam S, 2005, Med Trop (Mars), V65, P43; Ulrichs T, 2000, INFECT IMMUN, V68, P6073, DOI 10.1128/IAI.68.10.6073-6076.2000; WHALEN C, 1995, AM J RESP CRIT CARE, V151, P129, DOI 10.1164/ajrccm.151.1.7812542; *WHO, 2000, WHOHTMTB2004330	33	67	71	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2008	3	1							e1441	10.1371/journal.pone.0001441	http://dx.doi.org/10.1371/journal.pone.0001441			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SN	18197251	Green Submitted, Green Published, Green Accepted, gold			2022-12-25	WOS:000260503800012
J	Cushing, MC; Mariner, PD; Liao, JT; Sims, EA; Anseth, KS				Cushing, Melinda C.; Mariner, Peter D.; Liao, Jo-Tsu; Sims, Evan A.; Anseth, Kristi S.			Fibroblast growth factor represses Smad-mediated myofibroblast activation in aortic valvular interstitial cells	FASEB JOURNAL			English	Article						transforming growth factor-beta 1; heart disease; alpha-smooth muscle actin; cell signaling	SMOOTH MUSCLE ACTIN; TGF-BETA; EXTRACELLULAR-MATRIX; SIGNALING PATHWAYS; TRANSFORMING GROWTH-FACTOR-BETA-1; VALVE STENOSIS; TISSUE-REPAIR; PHENOTYPE; EXPRESSION; INDUCTION	This study aimed to identify signaling pathways that oppose connective tissue fibrosis in the aortic valve. Using valvular interstitial cells (VICs) isolated from porcine aortic valve leaflets, we show that basic fibroblast growth factor (FGF-2) effectively blocks transforming growth factor-beta 1 (TGF-beta 1)-mediated myofibroblast activation. FGF-2 prevents the induction of alpha-smooth muscle actin (alpha SMA) expression and the exit of VICs from the cell cycle, both of which are hallmarks of myofibroblast activation. By blocking the activity of the Smad transcription factors that serve as the downstream nuclear effectors of TGF-beta 1, FGF-2 treatment inhibits fibrosis in VICs. Using an exogenous Smad-responsive transcriptional promoter reporter, we show that Smad activity is repressed by FGF-2, likely an effect of the fact that FGF-2 treatment prevents the nuclear localization of Smads in these cells. This appears to be a direct effect of FGF signaling through mitogen-activated protein kinase (MAPK) cascades as the treatment of VICs with the MAPK/ extracellular regulated kinase (MEK) inhibitor U0126 acted to induce fibrosis and blocked the ability of FGF-2 to inhibit TGF-beta 1 signaling. Furthermore, FGF-2 treatment of VICs blocks the development of pathological contractile and calcifying phenotypes, suggesting that these pathways may be utilized in the engineering of effective treatments for valvular disease.	[Cushing, Melinda C.; Mariner, Peter D.; Liao, Jo-Tsu; Sims, Evan A.; Anseth, Kristi S.] Univ Colorado, Dept Chem & Biol Engn, Boulder, CO 80309 USA; [Mariner, Peter D.; Anseth, Kristi S.] Univ Colorado, Howard Hughes Med Inst, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder	Anseth, KS (corresponding author), Univ Colorado, Dept Chem & Biol Engn, ECCH 111,UCB 424, Boulder, CO 80309 USA.	kristi.anseth@colorado.edu			Howard Hughes Medical Institute Funding Source: Medline; NHLBI NIH HHS [R01 HL089260-01A1, R01 HL089260, R01 HL089260-02] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL089260] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Badid C, 2000, HISTOL HISTOPATHOL, V15, P269, DOI 10.14670/HH-15.269; Cushing MC, 2005, MATRIX BIOL, V24, P428, DOI 10.1016/j.matbio.2005.06.007; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; DESMOULIERE A, 1995, AM J PATHOL, V146, P56; Doukas J, 2002, MOL THER, V5, P517, DOI 10.1006/mthe.2002.0579; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Greenberg RS, 2006, FASEB J, V20, P1006, DOI 10.1096/fj.05-4838fje; Hinz B, 2001, MOL BIOL CELL, V12, P2730, DOI 10.1091/mbc.12.9.2730; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; Javelaud D, 2005, ONCOGENE, V24, P5742, DOI 10.1038/sj.onc.1208928; Jian B, 2003, ANN THORAC SURG, V75, P457, DOI 10.1016/S0003-4975(02)04312-6; JOHNSON CM, 1987, J MOL CELL CARDIOL, V19, P1185, DOI 10.1016/S0022-2828(87)80529-1; Kaden JJ, 2005, INT J MOL MED, V16, P869; Kaden JJ, 2005, CARDIOVASC PATHOL, V14, P80, DOI 10.1016/j.carpath.2005.01.002; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Leask A, 2004, FASEB J, V18, P816, DOI 10.1096/fj.03-1273rev; Maltseva O, 2001, INVEST OPHTH VIS SCI, V42, P2490; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 2003, GENE DEV, V17, P2993, DOI 10.1101/gad.1167003; Matsuura I, 2005, BIOCHEMISTRY-US, V44, P12546, DOI 10.1021/bi050560g; Mattey DL, 1997, ANN RHEUM DIS, V56, P426, DOI 10.1136/ard.56.7.426; Merryman WD, 2006, J BIOMECH, V39, P88, DOI 10.1016/j.jbiomech.2004.11.008; Mohler ER, 1999, J HEART VALVE DIS, V8, P254; Papetti M, 2003, INVEST OPHTH VIS SCI, V44, P4994, DOI 10.1167/iovs.03-0291; Rabkin E, 2001, CIRCULATION, V104, P2525, DOI 10.1161/hc4601.099489; Rabkin-Aikawa E, 2004, J HEART VALVE DIS, V13, P841; RONNOVJESSEN L, 1993, LAB INVEST, V68, P696; Sato M, 2003, CELL STRUCT FUNCT, V28, P105; Schiller M, 2004, J DERMATOL SCI, V35, P83, DOI 10.1016/j.jdermsci.2003.12.006; SCOTTBURDEN T, 1989, J CELL PHYSIOL, V141, P267, DOI 10.1002/jcp.1041410206; Serini G, 1998, J CELL BIOL, V142, P873, DOI 10.1083/jcb.142.3.873; Tamaoki M, 2005, AM J PATHOL, V167, P71, DOI 10.1016/S0002-9440(10)62954-9; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Walker GA, 2004, CIRC RES, V95, P253, DOI 10.1161/01.RES.0000136520.07995.aa; Wells RG, 2000, AM J PHYSIOL-GASTR L, V279, pG845, DOI 10.1152/ajpgi.2000.279.5.G845; Yang JW, 2003, AM J PATHOL, V163, P621, DOI 10.1016/S0002-9440(10)63689-9; Yata Y, 2002, HEPATOLOGY, V35, P1022, DOI 10.1053/jhep.2002.32673; Yu L, 2002, CURR OPIN PHARMACOL, V2, P177, DOI 10.1016/S1471-4892(02)00144-3	40	101	111	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					1769	1777		10.1096/fj.07-087627	http://dx.doi.org/10.1096/fj.07-087627			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18218921	Green Published			2022-12-25	WOS:000256352700017
J	Xu, XR; Gammon, MD; Zeisel, SH; Lee, YL; Wetmur, JG; Teitelbaum, SL; Bradshaw, PT; Neugut, AI; Santella, RM; Chen, J				Xu, Xinran; Gammon, Marilie D.; Zeisel, Steven H.; Lee, Yin Leng; Wetmur, James G.; Teitelbaum, Susan L.; Bradshaw, Patrick T.; Neugut, Alfred I.; Santella, Regina M.; Chen, Jia			Choline metabolism and risk of breast cancer in a population-based study	FASEB JOURNAL			English	Article						methyl diet; methylation; genetic polymorphism; phosphatidylethanolamine N-methyltransferase; choline dehydrogenase; betaine-homocysteine methyltransferase	DIETARY REQUIREMENTS	Choline is an essential nutrient required for methyl group metabolism, but its role in carcinogenesis and tumor progression is not well understood. By utilizing a population-based study of 1508 cases and 1556 controls, we investigated the associations of dietary intake of choline and two related micronutrients, methionine and betaine, and risk of breast cancer. The highest quintile of choline consumption was associated with a lower risk of breast cancer [odds ratio (OR): 0.76; 95% confidence interval (CI): 0.58-1.00] compared with the lowest quintile. Two putatively functional single nucleotide polymorphisms of choline-metabolizing genes, PEMT -774G > C (rs12325817) and CHDH +432G > T (rs12676), were also found be related to breast cancer risk. Compared with the PEMT GG genotype, the variant CC genotype was associated with an increased risk of breast cancer (OR: 1.30; 95% CI: 1.01-1.67). The CHDH minor T allele was also associated with an increased risk (OR: 1.19; 95% CI: 1.00-1.41) compared with the major G allele. The BHMT rs3733890 polymorphism was also examined but was found not to be associated with breast cancer risk. We observed a significant interaction between dietary betaine intake and the PEMT rs7926 polymorphism (P-interaction = 0.04). Our findings suggest that choline metabolism may play an important role in breast cancer etiology.	[Xu, Xinran; Lee, Yin Leng; Teitelbaum, Susan L.; Chen, Jia] Mt Sinai Sch Med, Dept Community & Prevent Med, New York, NY 10029 USA; [Wetmur, James G.] Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA; [Wetmur, James G.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA; [Chen, Jia] Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; [Chen, Jia] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA; [Gammon, Marilie D.; Bradshaw, Patrick T.] Univ N Carolina, Dept Nutr, Chapel Hill, NC USA; [Zeisel, Steven H.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA; [Neugut, Alfred I.] Columbia Univ, Dept Epidemiol, New York, NY USA; [Neugut, Alfred I.] Columbia Univ, Dept Med, New York, NY USA; [Santella, Regina M.] Columbia Univ, Dept Environm Hlth Sci, New York, NY USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Columbia University; Columbia University; Columbia University	Chen, J (corresponding author), Mt Sinai Sch Med, Dept Community & Prevent Med, Box 1043,1 Gustave L Levy Pl, New York, NY 10029 USA.	jia.chen@mssm.edu	Bradshaw, Patrick/AAJ-7529-2021	Bradshaw, Patrick/0000-0001-7761-3129; Xu, Xinran/0000-0001-6435-8181	NCI NIH HHS [UO1CA/ES66572, U01 CA066572, CA109753, UO1CA66572, R01 CA109753] Funding Source: Medline; NCRR NIH HHS [M01 RR000046-461213, M01 RR000046] Funding Source: Medline; NIDDK NIH HHS [R01 DK055865, R01 DK055865-07, DK56350, P30 DK056350-08, DK55865, P30 DK056350] Funding Source: Medline; NIEHS NIH HHS [P30ES09089, P30 ES010126, P30 ES009089, P30ES10126, ES10126, P30 ES010126-089008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA109753, U01CA066572] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000046] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055865, P30DK056350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126, P30ES009089] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BLOCK G, 1986, AM J EPIDEMIOL, V124, P453, DOI 10.1093/oxfordjournals.aje.a114416; DALMEIJER GW, 2007, EUR J CLIN NUTR; Fischer LM, 2007, AM J CLIN NUTR, V85, P1275; Fischer LM, 2005, J NUTR, V135, P826, DOI 10.1093/jn/135.4.826; NEWBERNE PM, 1986, ANNU REV NUTR, V6, P407, DOI 10.1146/annurev.nu.06.070186.002203; Potischman N, 1997, CANCER CAUSE CONTROL, V8, P713, DOI 10.1023/A:1018475203820; Shaw GM, 2004, AM J EPIDEMIOL, V160, P102, DOI 10.1093/aje/kwh187; Tsujiuchi T, 1999, JPN J CANCER RES, V90, P909, DOI 10.1111/j.1349-7006.1999.tb00834.x; Yates AA, 1998, J AM DIET ASSOC, V98, P699, DOI 10.1016/S0002-8223(98)00160-6; ZEISEL SH, 1995, J NUTR, V125, P3049; Zeisel SH, 2006, ANNU REV NUTR, V26, P229, DOI 10.1146/annurev.nutr.26.061505.111156	11	92	95	1	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					2045	2052		10.1096/fj.07-101279	http://dx.doi.org/10.1096/fj.07-101279			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18230680	Green Submitted, Green Accepted			2022-12-25	WOS:000256352700043
J	Hiroi, YK; Guo, ZM; Li, YX; Beggs, AH; Liao, JK				Hiroi, Yukio; Guo, Zhongmin; Li, Yuxin; Beggs, Alan H.; Liao, James K.			Dynamic regulation of endothelial NOS mediated by competitive interaction with alpha-actinin-4 and calmodulin	FASEB JOURNAL			English	Article						endothelium; nitric oxide; ionophore	NITRIC-OXIDE SYNTHASE; PROTEIN-PROTEIN INTERACTIONS; ALPHA-ACTININ; S-NITROSYLATION; PLASMALEMMAL CAVEOLAE; BINDING; CELLS; PHOSPHORYLATION; ACTIVATION; RECEPTOR	Alpha-actinins are critical components of the actin cytoskeleton. Here we show that alpha-actinins serve an other important biological function by binding to and competitively inhibiting calcium-dependent activation of endothelial NOS (eNOS). alpha-actinin-2 was found to associate with eNOS in a yeast two-hybrid. screen. In vascular endothelial cells, which only express alpha-actinin-1 and 4, alpha-actinin-4 interacted and colocalized with eNOS. Addition of alpha-actinin-4 directly inhibited eNOS recombinant protein, and overexpression of alpha-actinin-4 inhibited eNOS activity in eNOS-transfected COS-7 cells and bovine aortic endothelial cells (BAECs). In contrast, knockdown of alpha-actinin-4 by siRNA increased eNOS activity in BAECs. The alpha-actinin-4-binding site on eNOS was mapped to a central region comprising the calmodulin-binding domain, and the eNOS-binding site on alpha-actinin-4 was mapped to the fourth spectrin-like rod domain, R4. Treatment of endothelial cells with a calcium ionophore, A23187, decreased alpha-actinin-4-eNOS interaction, leading to translocation of alpha-actinin-4 from plasma membrane to cytoplasm. Indeed, addition of calmodulin displaced alpha-actinin-4 binding to eNOS and increased eNOS activity. These findings indicate that eNOS activity in vascular endothelial cells is tonically and dynamically regulated by competitive interaction with alpha-actinin-4 and calmodulin.	[Hiroi, Yukio; Guo, Zhongmin; Li, Yuxin; Liao, James K.] Brigham & Womens Hosp, Boston, MA 02139 USA; [Beggs, Alan H.] Harvard Univ, Sch Med, Program Genom, Childrens Hosp Boston, Boston, MA USA; [Beggs, Alan H.] Harvard Univ, Sch Med, Div Genet, Childrens Hosp Boston, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Liao, JK (corresponding author), Brigham & Womens Hosp, 65 Landsdowne St,Room 275, Boston, MA 02139 USA.	jliao@rics.bwh.harvard.edu	Li, yuxin/GSD-1668-2022; li, yu/HGL-9518-2022; li, Yu/HCI-9086-2022	Beggs, Alan/0000-0001-8818-0568	NHLBI NIH HHS [R01 HL080187, R01 HL052233-10, R01 HL052233-12, R01 HL052233, R01 HL080187-03, R01 HL070274-05, R01 HL080187-01A1, R01 HL070274, R01 HL052233-11, R01 HL070274-03, HL052233, R01 HL080187-02, R01 HL070274-04] Funding Source: Medline; NIAMS NIH HHS [R01 AR044345-10, R01 AR044345-11, R01 AR044345, AR044345] Funding Source: Medline; NIDDK NIH HHS [R01 DK062729-04, R01 DK062729-05, R01 DK062729] Funding Source: Medline; NINDS NIH HHS [P50 NS010828, P50 NS010828-310036, P50 NS010828-320036, P50 NS010828-300036] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070274, R01HL080187, R01HL052233] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS010828] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Araki N, 2000, J CELL SCI, V113, P3329; Bauer PM, 2003, J BIOL CHEM, V278, P14841, DOI 10.1074/jbc.M211926200; BEGGS AH, 1992, J BIOL CHEM, V267, P9281; Blair A, 1999, J BIOL CHEM, V274, P32512, DOI 10.1074/jbc.274.45.32512; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BURRIDGE K, 1981, NATURE, V294, P565, DOI 10.1038/294565a0; Chakraborty S, 2006, J BIOL CHEM, V281, P35070, DOI 10.1074/jbc.M602474200; CHANDLER L, 1998, YOUNG EXCEPTIONAL CH, V1, P14; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Djinovic-Carugo K, 2002, FEBS LETT, V513, P119, DOI 10.1016/S0014-5793(01)03304-X; Dudzinski DM, 2006, ANNU REV PHARMACOL, V46, P235, DOI 10.1146/annurev.pharmtox.44.101802.121844; Erwin PA, 2005, J BIOL CHEM, V280, P19888, DOI 10.1074/jbc.M413058200; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Forstermann U, 2006, CIRCULATION, V113, P1708, DOI 10.1161/CIRCULATIONAHA.105.602532; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Gonzalez E, 2002, J BIOL CHEM, V277, P39554, DOI 10.1074/jbc.M207299200; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Iwakiri Y, 2006, P NATL ACAD SCI USA, V103, P19777, DOI 10.1073/pnas.0605907103; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; Laufs U, 1997, J BIOL CHEM, V272, P31725, DOI 10.1074/jbc.272.50.31725; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; MILLAKE DB, 1989, NUCLEIC ACIDS RES, V17, P6725, DOI 10.1093/nar/17.16.6725; Nedvetsky PI, 2002, P NATL ACAD SCI USA, V99, P16510, DOI 10.1073/pnas.262701999; Otey CA, 2004, CELL MOTIL CYTOSKEL, V58, P104, DOI 10.1002/cm.20007; Prabhakar P, 2000, J BIOL CHEM, V275, P19416, DOI 10.1074/jbc.M001952200; Ravi K, 2004, P NATL ACAD SCI USA, V101, P2619, DOI 10.1073/pnas.0300464101; Razani B, 2001, J BIOL CHEM, V276, P38121; Sessa WC, 2004, J CELL SCI, V117, P2427, DOI 10.1242/jcs.01165; Shaul PW, 2002, ANNU REV PHYSIOL, V64, P749, DOI 10.1146/annurev.physiol.64.081501.155952; Sonveaux P, 2004, CIRC RES, V95, P154, DOI 10.1161/01.RES.0000136344.27825.72; Sun JX, 2002, P NATL ACAD SCI USA, V99, P13108, DOI 10.1073/pnas.202260999; Takada F, 2001, P NATL ACAD SCI USA, V98, P1595, DOI 10.1073/pnas.041609698; Tang JH, 2001, J MOL BIOL, V310, P845, DOI 10.1006/jmbi.2001.4789; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; YOUSSOUFIAN H, 1990, AM J HUM GENET, V47, P62; Zhang Q, 2006, ARTERIOSCL THROM VAS, V26, P1015, DOI 10.1161/01.ATV.0000216044.49494.c4	39	6	6	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2008	22	5					1450	1457		10.1096/fj.07-9309com	http://dx.doi.org/10.1096/fj.07-9309com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301LW	18180332	Green Accepted			2022-12-25	WOS:000255898700017
J	Hsu, YH; Burke, JE; Stephens, DL; Deems, RA; Li, S; Asmus, KM; Woods, VL; Dennis, EA				Hsu, Yuan-Hao; Burke, John E.; Stephens, Daren L.; Deems, Raymond A.; Li, Sheng; Asmus, Kyle M.; Woods, Virgil L., Jr.; Dennis, Edward A.			Calcium binding rigidifies the C2 domain and the intradomain interaction of GIVA phospholipase A(2) as revealed by hydrogen/deuterium exchange mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-SPECIFIC ASSAYS; CYTOSOLIC PHOSPHOLIPASE; HYDROGEN-EXCHANGE; CRYSTAL-STRUCTURE; ARACHIDONIC-ACID; CATALYTIC DOMAIN; PROTEIN; MEMBRANE; MECHANISM; PHOSPHORYLATION	The GIVA phospholipase A(2) (PLA(2)) contains two domains: a calcium-binding domain (C2) and a catalytic domain. These domains are linked via a flexible tether. GIVA PLA(2) activity is Ca2+-dependent in that calcium binding promotes protein docking to the phospholipid membrane. In addition, the catalytic domain has a lid that covers the active site, presumably regulating GIVA PLA(2) activity. We now present studies that explore the dynamics and conformational changes of this enzyme in solution utilizing peptide amide hydrogen/deuterium (H/D) exchange coupled with liquid chromatography-mass spectrometry (DXMS) to probe the solvent accessibility and backbone flexibility of the C2 domain, the catalytic domain, and the intact GIVA PLA(2). We also analyzed the changes in H/D exchange of the intact GIVA PLA(2) upon Ca2+ binding. The DXMS results showed a fast H/D-exchanging lid and a slow exchanging central core. The C2 domain showed two distinct regions: a fast exchanging region facing away from the catalytic domain and a slow exchanging region present in the "cleft" region between the C2 and catalytic domains. The slow exchanging region of the C2 domain is in tight proximity to the catalytic domain. The effects of Ca2+ binding on GIVA PLA(2) are localized in the C2 domain and suggest that binding of two distinct Ca2+ ions causes tightening up of the regions that surround the anion hole at the tip of the C2 domain. This conformational change may be the initial step in GIVA PLA(2) activation.	[Li, Sheng; Asmus, Kyle M.; Woods, Virgil L., Jr.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Hsu, Yuan-Hao; Burke, John E.; Stephens, Daren L.; Dennis, Edward A.] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; [Hsu, Yuan-Hao; Burke, John E.; Stephens, Daren L.; Deems, Raymond A.; Dennis, Edward A.] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Woods, VL (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.	vwoods@ucsd.edu; edennis@ucsd.edu	Burke, John/H-3922-2019; Burke, John/A-5659-2013; hsu, yuan-hao/B-5744-2009; Dennis, Edward A./M-5554-2019	Burke, John/0000-0001-7904-9859; Burke, John/0000-0003-1668-2109; Dennis, Edward A./0000-0003-3738-3140	NATIONAL CANCER INSTITUTE [R33CA099835, R21CA099835, R21CA118595] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022160] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037684] Funding Source: NIH RePORTER; NCI NIH HHS [CA 118595, CA 099835] Funding Source: Medline; NIAID NIH HHS [AI 0220221, AI 022160] Funding Source: Medline; NIGMS NIH HHS [GM 20501, R01 GM020501, GM 037684] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO F, 1986, BIOCHIM BIOPHYS ACTA, V878, P273, DOI 10.1016/0005-2760(86)90156-6; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Brudler R, 2006, J MOL BIOL, V363, P148, DOI 10.1016/j.jmb.2006.07.078; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Corbin JA, 2007, BIOCHEMISTRY-US, V46, P4322, DOI 10.1021/bi062140c; Das S, 2003, J BIOL CHEM, V278, P41431, DOI 10.1074/jbc.M304897200; Das S, 2002, J BIOL CHEM, V277, P23838, DOI 10.1074/jbc.M202322200; Dessen A, 1999, CELL, V97, P349, DOI 10.1016/S0092-8674(00)80744-8; Engen JR, 2001, ANAL CHEM, V73, p256A, DOI 10.1021/ac012452f; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; GOETZL EJ, 1995, FASEB J, V9, P1051, DOI 10.1096/fasebj.9.11.7649404; Hamuro Y, 2004, J MOL BIOL, V340, P1185, DOI 10.1016/j.jmb.2004.05.042; Hochrein JM, 2006, PROTEIN SCI, V15, P65, DOI 10.1110/ps.051782206; Hoofnagle AN, 2001, P NATL ACAD SCI USA, V98, P956, DOI 10.1073/pnas.98.3.956; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KRAMER RM, 1995, AGENT ACTION SUPPL, V46, P65; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Lucas KK, 2005, BRIT J PHARMACOL, V144, P940, DOI 10.1038/sj.bjp.0706116; Lucas KK, 2005, PROSTAG OTH LIPID M, V77, P235, DOI 10.1016/j.prostaglandins.2005.02.004; Malkova S, 2005, BIOPHYS J, V89, P1861, DOI 10.1529/biophysj.105.061515; Mandell JG, 1998, P NATL ACAD SCI USA, V95, P14705, DOI 10.1073/pnas.95.25.14705; Mosior M, 1998, J BIOL CHEM, V273, P2184, DOI 10.1074/jbc.273.4.2184; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; Nalefski EA, 1997, BIOCHEMISTRY-US, V36, P12011, DOI 10.1021/bi9717340; Perisic O, 1999, J BIOL CHEM, V274, P14979, DOI 10.1074/jbc.274.21.14979; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Sapirstein A, 2000, BBA-MOL CELL BIOL L, V1488, P139, DOI 10.1016/S1388-1981(00)00116-5; Schaloske RH, 2006, BBA-MOL CELL BIOL L, V1761, P1246, DOI 10.1016/j.bbalip.2006.07.011; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Six DA, 2003, J BIOL CHEM, V278, P23842, DOI 10.1074/jbc.M301386200; Stahelin RV, 2007, J BIOL CHEM, V282, P20467, DOI 10.1074/jbc.M701396200; Subramanian P, 2005, J BIOL CHEM, V280, P17601, DOI 10.1074/jbc.M414173200; Xu GY, 1998, J MOL BIOL, V280, P485, DOI 10.1006/jmbi.1998.1874; Yang HC, 1999, ANAL BIOCHEM, V269, P278, DOI 10.1006/abio.1999.4053	40	36	39	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9820	9827		10.1074/jbc.M708143200	http://dx.doi.org/10.1074/jbc.M708143200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18211893	Green Published, hybrid			2022-12-25	WOS:000254671600037
J	Romeo, GR; Kazlauskas, A				Romeo, Giulio R.; Kazlauskas, Andrius			Oxysterol and diabetes activate STAT3 and control endothelial expression of profilin-1 via OSBP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; INSULIN-RESISTANCE; RECEPTOR; ATHEROSCLEROSIS; TRANSCRIPTION; INFLAMMATION; DYSFUNCTION; LDL; GENERATION; INHIBITION	Endothelial dysfunction plays a central role in diabetic vascular disease, but its molecular bases are not completely defined. We showed previously that the actin-binding protein proflin-1 was increased in the diabetic endothelium and that attenuated expression of profilin-1 protected against atherosclerosis. Also 7-ketocholesterol up-regulated profilin-1 in endothelial cells via transcriptional mechanisms. The present study addressed the pathways responsible for profilin-1 gene expression in 7-ketocholesterol-stimulated endothelial cells and in the diabetic aorta. In luciferase reporter assays, the response to 7-ketocholesterol within the 5'-flanking region of profilin-1 was dependent on a single STAT response element. In aortic endothelial cells, 7-ketocholesterol enhanced STAT3 activation, which required JAK2 and tyrosine 394 phosphorylation of oxysterol-binding protein-1. These changes were recapitulated in the aorta of diabetic rats. Also 7-ketocholesterol in cultured endothelial cells and diabetes in the aorta elicited the recruitment of STAT3 and relevant coregulatory factors to the oxysterol-responsive region of the profilin-1 promoter. These events were required for profilin-1 up-regulation. These studies identify a previously unrecognized oxysterol-binding protein-mediated mode of activation of STAT3 that controls the expression of the proatherogenic protein profilin-1 in response to 7-ketocholesterol and the diabetic milieu.	[Romeo, Giulio R.; Kazlauskas, Andrius] Harvard Univ, Sch Med, Eye Res Inst, Boston, MA 02114 USA	Harvard University; Harvard Medical School	Romeo, GR (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02115 USA.	giulio.romeo@joslin.harvard.edu						Agrawal S, 2002, MOL CELL BIOL, V22, P1981, DOI 10.1128/MCB.22.7.1981-1992.2002; Banes-Berceli AKL, 2007, AM J PHYSIOL-HEART C, V293, pH1291, DOI 10.1152/ajpheart.00181.2007; Brown AJ, 1997, J LIPID RES, V38, P1730; Chikani G, 2004, AM J PHYSIOL-ENDOC M, V287, pE386, DOI 10.1152/ajpendo.00106.2004; Collins JL, 2002, J MED CHEM, V45, P1963, DOI 10.1021/jm0255116; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; deKoning JP, 1996, BLOOD, V87, P1335, DOI 10.1182/blood.V87.4.1335.bloodjournal8741335; Didry D, 1998, J BIOL CHEM, V273, P25602, DOI 10.1074/jbc.273.40.25602; Eberharter A, 2004, J CELL SCI, V117, P3707, DOI 10.1242/jcs.01175; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Festa A, 2000, CIRCULATION, V102, P42, DOI 10.1161/01.CIR.102.1.42; Fledderus JO, 2007, BLOOD, V109, P4249, DOI 10.1182/blood-2006-07-036020; Giraud S, 2002, J BIOL CHEM, V277, P8004, DOI 10.1074/jbc.M111486200; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Ingber DE, 2002, CIRC RES, V91, P877, DOI 10.1161/01.RES.0000039537.73816.E5; JOHNSTONE MT, 1993, CIRCULATION, V88, P2510, DOI 10.1161/01.CIR.88.6.2510; Kang F, 1999, J BIOL CHEM, V274, P36963, DOI 10.1074/jbc.274.52.36963; Lamharzi N, 2004, DIABETES, V53, P3217, DOI 10.2337/diabetes.53.12.3217; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Massey JB, 2006, CURR OPIN LIPIDOL, V17, P296, DOI 10.1097/01.mol.0000226123.17629.ab; Olkkonen VM, 2004, BIOCHEM CELL BIOL, V82, P87, DOI 10.1139/o03-088; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Pennathur S, 2001, J CLIN INVEST, V107, P853, DOI 10.1172/JCI11194; RIDGWAY ND, 1992, J CELL BIOL, V116, P307, DOI 10.1083/jcb.116.2.307; Ridker PM, 1998, LANCET, V351, P88, DOI 10.1016/S0140-6736(97)09032-6; Romeo G, 2004, FASEB J, V18, P725, DOI 10.1096/fj.03-0841fje; Romeo GR, 2007, CIRC RES, V101, P357, DOI 10.1161/CIRCRESAHA.107.151399; Schachinger V, 2000, CIRCULATION, V101, P1899, DOI 10.1161/01.CIR.101.16.1899; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Shao H, 2004, J BIOL CHEM, V279, P18967, DOI 10.1074/jbc.M314037200; Sheppard HM, 2001, MOL CELL BIOL, V21, P39, DOI 10.1128/MCB.21.1.39-50.2001; Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Steinberg HO, 1997, CIRCULATION, V96, P3287; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; TAYLOR FR, 1984, J BIOL CHEM, V259, P2382; TESFAMARIAM B, 1990, J CLIN INVEST, V85, P929, DOI 10.1172/JCI114521; Wang PY, 2005, SCIENCE, V307, P1472, DOI 10.1126/science.1107710; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; Zelcer N, 2006, J CLIN INVEST, V116, P607, DOI 10.1172/JCI27883	43	47	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9595	9605		10.1074/jbc.M710092200	http://dx.doi.org/10.1074/jbc.M710092200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18230613	hybrid			2022-12-25	WOS:000254671600013
J	Gavira, JA; Camara-Artigas, A; De Jesus-Bonilla, W; Lopez-Garriga, J; Lewis, A; Pietri, R; Yeh, SR; Cadilla, CL; Garcia-Ruiz, JM				Gavira, Jose A.; Camara-Artigas, Ana; De Jesus-Bonilla, Walleska; Lopez-Garriga, Juan; Lewis, Ariel; Pietri, Ruth; Yeh, Syun-Ru; Cadilla, Carmen L.; Garcia-Ruiz, Juan Manuel			Structure and ligand selection of hemoglobin II from Lucina pectinata	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCAPHARCA DIMERIC HEMOGLOBIN; SULFIDE-REACTIVE HEMOGLOBIN; AMINO-ACID-SEQUENCE; TYROSINE B10; MYCOBACTERIUM-TUBERCULOSIS; BACTERIA SYMBIOSIS; CRYSTAL-STRUCTURE; HEME REACTIVITY; BINDING; MODEL	Lucina pectinata ctenidia harbor three heme proteins: sulfide-reactive hemoglobin I (HbI(Lp)) and the oxygen transporting hemoglobins II and III (HbII(Lp) and HbIII(Lp)) that remain unaffected by the presence of H2S. The mechanisms used by these three proteins for their function, including ligand control, remain unknown. The crystal structure of oxygen-bound HbII(Lp) shows a dimeric oxyHbII(Lp) where oxygen is tightly anchored to the heme through hydrogen bonds with Tyr(30)(B10) and Gln(65)(E7). The heme group is buried farther within HbII(Lp) than in HbI(Lp). The proximal His(97)(F8) is hydrogen bonded to a water molecule, which interacts electrostatically with a propionate group, resulting in a Fe-His vibration at 211 cm(-1). The combined effects of the HbIILp small heme pocket, the hydrogen bonding network, the His97 trans-effect, and the orientation of the oxygen molecule confer stability to the oxy-HbII(Lp) complex. Oxidation of HbI(Lp) Phe(B10) -> Tyr and HbII(Lp) only occurs when the pH is decreased from pH 7.5 to 5.0. Structural and resonance Raman spectroscopy studies suggest that HbII(Lp) oxygen binding and transport to the host bacteria may be regulated by the dynamic displacements of the Gln65(E7) and Tyr30(B10) pair toward the heme to protect it from changes in the heme oxidation state from Fe-II to Fe-III.	[De Jesus-Bonilla, Walleska; Lopez-Garriga, Juan; Lewis, Ariel; Pietri, Ruth] Univ Puerto Rico, Dept Chem, Mayaguez, PR 00681 USA; [Gavira, Jose A.; Garcia-Ruiz, Juan Manuel] PT Ciencias Salud, CSIC, Lab Estudios Cristalog, Granada 18100, Spain; [Camara-Artigas, Ana] Univ Almeria, Dept Quim Fis, Almeria 04120, Spain; [Yeh, Syun-Ru] Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; [Cadilla, Carmen L.] Univ Puerto Rico, Dept Biochem, San Juan, PR 00936 USA	University of Puerto Rico; University of Puerto Rico Mayaguez; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Almeria; Yeshiva University; Albert Einstein College of Medicine; University of Puerto Rico	Lopez-Garriga, J (corresponding author), Univ Puerto Rico, Dept Chem, POB 9019,Mayaguez Campus, Mayaguez, PR 00681 USA.	lopezj@uprm.edu	Gavira, Jose A./C-2491-2009; Garcia-Ruiz, Juan Manuel/C-4389-2015; García-Ruiz, Juan Manuel/U-1085-2019; Camara-Artigas, Ana/M-2252-2019	Gavira, Jose A./0000-0002-7386-6484; Garcia-Ruiz, Juan Manuel/0000-0002-4743-8718; García-Ruiz, Juan Manuel/0000-0002-4743-8718; Camara-Artigas, Ana/0000-0003-2197-726X; Yeh, Syun-Ru/0000-0002-9858-386X	NCRR NIH HHS [G12 RR003051, P20 RR 016470, G12 RR 03051] Funding Source: Medline; NHLBI NIH HHS [HL 65465] Funding Source: Medline; NIGMS NIH HHS [S06 GM 08103-34] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003051, P20RR016470] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM008103] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1997, NUCLEIC ACIDS RES, V25, P3402; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Binkowski TA, 2003, NUCLEIC ACIDS RES, V31, P3352, DOI 10.1093/nar/gkg512; BLAXTER ML, 1994, J BIOL CHEM, V269, P30181; Bolognesi M, 1999, BIOPHYS J, V77, P1093, DOI 10.1016/S0006-3495(99)76959-6; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Califano S., 1976, VIBRATIONAL STATES, P95; CARVER TE, 1992, J BIOL CHEM, V267, P14443; Cerda J, 1999, BIOSPECTROSCOPY, V5, P289; CONDON PJ, 1994, J BIOL CHEM, V269, P25259; COULSON CA, 1947, NATURE, V159, P794; Couture M, 1999, P NATL ACAD SCI USA, V96, P11223, DOI 10.1073/pnas.96.20.11223; Das TK, 1999, J BIOL CHEM, V274, P2916, DOI 10.1074/jbc.274.5.2916; De Jesus-Bonilla W, 2006, J BIOL INORG CHEM, V11, P334, DOI 10.1007/s00775-006-0082-0; De Jesus-Bonilla W, 2007, BIOCHEMISTRY-US, V46, P10451, DOI 10.1021/bi7003262; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fernandez-Alberti S, 2006, BIOPHYS J, V91, P1698, DOI 10.1529/biophysj.106.081646; Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412; Garcia-Ruiz JM, 2003, METHOD ENZYMOL, V368, P130, DOI 10.1016/S0076-6879(03)68008-0; Gavira JA, 2006, ACTA CRYSTALLOGR F, V62, P196, DOI 10.1107/S1744309106002648; Hirota S, 1996, J AM CHEM SOC, V118, P7845, DOI 10.1021/ja9608297; HOCKENHULLJOHNSON JD, 1991, J PROTEIN CHEM, V10, P609, DOI 10.1007/BF01025713; Hubbard SJ, 1993, NACCESS COMPUTER PRO; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KRAUS DW, 1990, J BIOL CHEM, V265, P16043; KRAUS DW, 1990, J BIOL CHEM, V265, P16054; Krissinel E, 2005, LECT NOTES COMPUT SC, V3695, P163; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leon RG, 2004, PROTEIN EXPRES PURIF, V38, P184, DOI 10.1016/j.pep.2004.08.014; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Lu CY, 2007, J BIOL CHEM, V282, P13627, DOI 10.1074/jbc.M609397200; Milani M, 2001, EMBO J, V20, P3902, DOI 10.1093/emboj/20.15.3902; Mukai M, 2001, J BIOL CHEM, V276, P7272, DOI 10.1074/jbc.M009280200; Navarro AM, 1996, INORG CHIM ACTA, V243, P161, DOI 10.1016/0020-1693(95)04903-7; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pardanani A, 1998, J MOL BIOL, V284, P729, DOI 10.1006/jmbi.1998.2195; Peterson ES, 1997, BIOCHEMISTRY-US, V36, P13110, DOI 10.1021/bi971156n; Pietri R, 2005, BBA-PROTEINS PROTEOM, V1747, P195, DOI 10.1016/j.bbapap.2004.11.005; Pietri R, 2006, BBA-PROTEINS PROTEOM, V1764, P758, DOI 10.1016/j.bbapap.2005.11.006; READ KRH, 1965, COMP BIOCHEM PHYSIOL, V15, P137; Rizzi M, 1996, J MOL BIOL, V258, P1, DOI 10.1006/jmbi.1996.0228; RIZZI M, 1994, J MOL BIOL, V244, P86, DOI 10.1006/jmbi.1994.1706; Royer WE, 1996, P NATL ACAD SCI USA, V93, P14526, DOI 10.1073/pnas.93.25.14526; ROYER WE, 1995, J MOL BIOL, V253, P168, DOI 10.1006/jmbi.1995.0543; Royer WE, 2001, TRENDS BIOCHEM SCI, V26, P297, DOI 10.1016/S0968-0004(01)01811-4; Saroff HA, 2004, J THEOR BIOL, V229, P113, DOI 10.1016/j.jtbi.2004.03.007; SMERDON SJ, 1993, BIOCHEMISTRY-US, V32, P5132, DOI 10.1021/bi00070a023; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Torres-Mercado E, 2003, J PROTEIN CHEM, V22, P683, DOI 10.1023/B:JOPC.0000008734.44356.b7; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; YANG J, 1995, P NATL ACAD SCI USA, V92, P4224, DOI 10.1073/pnas.92.10.4224; Zhou YQ, 2003, J MOL BIOL, V326, P593, DOI 10.1016/S0022-2836(02)01329-3	53	22	25	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9414	9423		10.1074/jbc.M705026200	http://dx.doi.org/10.1074/jbc.M705026200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18203714	Green Published, hybrid			2022-12-25	WOS:000254465800071
J	Zhao, Y; Chen, YQ; Bonacci, TM; Bredt, DS; Li, SY; Bensch, WR; Moller, DE; Kowala, M; Konrad, RJ; Cao, GQ				Zhao, Yang; Chen, Yan-Qun; Bonacci, Tabetha M.; Bredt, David S.; Li, Shuyu; Bensch, William R.; Moller, David E.; Kowala, Mark; Konrad, Robert J.; Cao, Guoqing			Identification and characterization of a major liver lysophosphatidylcholine acyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; ACYL-COA; SACCHAROMYCES-CEREVISIAE; TRIACYLGLYCEROL SYNTHESIS; ACID ACYLTRANSFERASE; O-ACYLTRANSFERASES; II CELLS; METABOLISM; CLONING; GLYCEROLIPIDS	Phosphatidylcholine (PC) is synthesized through the Kennedy pathway, but more than 50% of PC is remodeled through the Lands cycle, i.e. the deacylation and reacylation of PC to attain the final and proper fatty acids within PC. The reacylation step is catalyzed by lysophosphatidylcholine acyltransferase (LPCAT), and we report here the identification of a novel LPCAT, which we named LPCAT3. LPCAT3 belongs to the membrane-bound O-acyltransferase (MBOAT) family and encodes a protein of 487 amino acids with a calculated molecular mass of 56 kDa. Membranes from HEK293 cells overexpressing LPCAT3 showed significantly increased LPCAT activity as assessed by thin layer chromatography analysis with substrate preference toward unsaturated fatty acids. LPCAT3 is localized within the endoplasmic reticulum and is primarily expressed in metabolic tissues including liver, adipose, and pancreas. In a human hepatoma Huh7 cells, RNA interference-mediated knockdown of LPCAT3 resulted in virtually complete loss of membrane LPCAT activity, suggesting that LPCAT3 is primarily responsible for hepatic LPCAT activity. Furthermore, peroxisome proliferator-activated receptor alpha agonists dose-dependently regulated LPCAT3 in liver in a peroxisome proliferatoractivated receptor alpha-dependent fashion, implicating a role of LPCAT3 in lipid homeostasis. Our studies identify a long-sought enzyme that plays a critical role in PC remodeling in metabolic tissues and provide an invaluable tool for future investigations on how PC remodeling may potentially impact glucose and lipid homeostasis.	[Zhao, Yang; Chen, Yan-Qun; Bonacci, Tabetha M.; Bredt, David S.; Li, Shuyu; Bensch, William R.; Moller, David E.; Kowala, Mark; Konrad, Robert J.; Cao, Guoqing] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA	Eli Lilly	Cao, GQ (corresponding author), Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA.	guoqing_cao@lilly.com		Chen, Yan Q/0000-0001-9311-6077				Agarwal AK, 2007, J ENDOCRINOL, V193, P445, DOI 10.1677/JOe-07-0027; Aguado B, 1998, J BIOL CHEM, V273, P4096, DOI 10.1074/jbc.273.7.4096; Bao SZ, 2006, J BIOL CHEM, V281, P187, DOI 10.1074/jbc.M509105200; Beigneux AP, 2006, J LIPID RES, V47, P734, DOI 10.1194/jlr.M500556-JLR200; Benghezal M, 2007, J BIOL CHEM, V282, P30845, DOI 10.1074/jbc.M702719200; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Cao JS, 2004, J BIOL CHEM, V279, P31727, DOI 10.1074/jbc.M402930200; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Chen XN, 2006, P NATL ACAD SCI USA, V103, P11724, DOI 10.1073/pnas.0604946103; Choy PC, 1997, BBA-LIPID LIPID MET, V1348, P124, DOI 10.1016/S0005-2760(97)00114-8; Coleman RA, 2004, PROG LIPID RES, V43, P134, DOI 10.1016/S0163-7827(03)00051-1; Eberhardt C, 1997, J BIOL CHEM, V272, P20299, DOI 10.1074/jbc.272.32.20299; Hofmann K, 2000, TRENDS BIOCHEM SCI, V25, P111, DOI 10.1016/S0968-0004(99)01539-X; Jain S, 2007, J BIOL CHEM, V282, P30562, DOI 10.1074/jbc.M706326200; KENNEDY EP, 1989, PHOSPHATIDYLCHOLINE, P1; Lands W., 1976, ENZYMES BIOL MEMBRAN, V2, P3; LANDS WEM, 1960, J BIOL CHEM, V235, P2233; LANDS WEM, 1982, J BIOL CHEM, V257, P4968; LANDS WEM, 1963, J BIOL CHEM, V238, P898; MACDONALD JIS, 1991, BIOCHIM BIOPHYS ACTA, V1084, P105, DOI 10.1016/0005-2760(91)90209-Z; MERKL I, 1963, J BIOL CHEM, V238, P905; Nakanishi H, 2006, J BIOL CHEM, V281, P20140, DOI 10.1074/jbc.M600225200; Riekhof WR, 2007, J BIOL CHEM, V282, P36853, DOI 10.1074/jbc.M706718200; Riekhof WR, 2007, J BIOL CHEM, V282, P28344, DOI 10.1074/jbc.M705256200; Shindou H, 2007, J BIOL CHEM, V282, P6532, DOI 10.1074/jbc.M609641200; Staels B, 1998, CIRCULATION, V98, P2088, DOI 10.1161/01.CIR.98.19.2088; Tamaki H, 2007, J BIOL CHEM, V282, P34288, DOI 10.1074/jbc.M704509200; Tran K, 2006, BBA-MOL CELL BIOL L, V1761, P463, DOI 10.1016/j.bbalip.2006.03.018; Yang YZ, 2004, J BIOL CHEM, V279, P55866, DOI 10.1074/jbc.M406710200; Yao HB, 2008, J BIOL CHEM, V283, P849, DOI 10.1074/jbc.M706160200	30	120	126	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8258	8265		10.1074/jbc.M710422200	http://dx.doi.org/10.1074/jbc.M710422200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18195019	hybrid			2022-12-25	WOS:000254288000023
J	Harris, M; Garcia-Caballero, A; Stutts, MJ; Firsov, D; Rossier, BC				Harris, Michael; Garcia-Caballero, Agustin; Stutts, M. Jackson; Firsov, Dmitri; Rossier, Bernard C.			Preferential assembly of epithelial sodium channel (ENaC) subunits in Xenopus Oocytes - Role of furin-mediated endogenous proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SUBUNIT; ALPHA-SUBUNIT; NA+ CHANNEL; RAT-KIDNEY; EXPRESSION; MATURATION	The epithelial sodium channel ( ENaC) is preferentially assembled into heteromeric alpha beta gamma complexes. The alpha and gamma ( not beta) subunits undergo proteolytic cleavage by endogenous furin-like activity correlating with increased ENaC function. We identified full-length subunits and their fragments at the cell surface, as well as in the intracellular pool, for all homo- and heteromeric combinations (alpha, beta, gamma, alpha beta, alpha gamma, beta gamma, and alpha beta gamma). We assayed corresponding channel function as amiloride-sensitive sodium transport (I-Na). We varied furin-mediated proteolysis by mutating the P1 site in alpha and/ or gamma subunit furin consensus cleavage sites (alpha(mu)t and gamma(mut)). Our findings were as follows. (i) The beta subunit alone is not transported to the cell surface nor cleaved upon assembly with the alpha and/ or gamma subunits. ( ii) The alpha subunit alone ( or in combination with beta and/ or gamma) is efficiently transported to the cell surface; a surface-expressed 65-kDa alpha ENaC fragment is undetected in alpha(mut)beta gamma, and I-Na is decreased by 60%. ( iii) The gamma subunit alone does not appear at the cell surface; gamma co-expressed with alpha reaches the surface but is not detectably cleaved; and gamma in alpha beta gamma complexes appears mainly as a 76-kDa species in the surface pool. Although basal INa of alpha beta gamma(mut) was similar to alpha beta gamma, gamma(mut) was not detectably cleaved at the cell surface. Thus, furin-mediated cleavage is not essential for participation of alpha and gamma in alpha beta gamma heteromers. Basal I-Na is reduced by preventing furin-mediated cleavage of the alpha, but not gamma, subunits. Residual current in the absence of furin-mediated proteolysis may be due to non-furin endogenous proteases.	[Harris, Michael; Firsov, Dmitri; Rossier, Bernard C.] Univ Lausanne, Dept Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland; [Garcia-Caballero, Agustin; Stutts, M. Jackson] Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA	University of Lausanne; University of North Carolina; University of North Carolina Chapel Hill	Rossier, BC (corresponding author), Univ Lausanne, Dept Pharmacol & Toxicol, 27 Rue Bugnon, CH-1005 Lausanne, Switzerland.	Bernard.Rossier@unil.ch			NHLBI NIH HHS [HL034322] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034322] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abrami L, 2005, TRENDS MICROBIOL, V13, P72, DOI 10.1016/j.tim.2004.12.004; Bonny O, 1999, J CLIN INVEST, V104, P967, DOI 10.1172/JCI6821; Bruns JB, 2007, J BIOL CHEM, V282, P6153, DOI 10.1074/jbc.M610636200; Ergonul Z, 2006, AM J PHYSIOL-RENAL, V291, pF683, DOI 10.1152/ajprenal.00422.2005; Eskandari S, 1999, J BIOL CHEM, V274, P27281, DOI 10.1074/jbc.274.38.27281; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; FIRSOV D, 1997, NOVA ACTA LEOPOLDINA, V302, P13; Frindt G, 2002, AM J PHYSIOL-RENAL, V283, pF717, DOI 10.1152/ajprenal.00379.2001; Harris M, 2007, J BIOL CHEM, V282, P58, DOI 10.1074/jbc.M605125200; Hughey RP, 2004, J BIOL CHEM, V279, P18111, DOI 10.1074/jbc.C400080200; Hughey RP, 2003, J BIOL CHEM, V278, P37073, DOI 10.1074/jbc.M307003200; Jasti J, 2007, NATURE, V449, P316, DOI 10.1038/nature06163; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Loffing J, 2001, AM J PHYSIOL-RENAL, V280, pF675, DOI 10.1152/ajprenal.2001.280.4.F675; Masilamani S, 1999, J CLIN INVEST, V104, pR19, DOI 10.1172/JCI7840; Michlig S, 2005, J BIOL CHEM, V280, P38264, DOI 10.1074/jbc.M506308200; Rubera I, 2003, J CLIN INVEST, V112, P554, DOI 10.1172/JCI200316956; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681	19	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7455	7463		10.1074/jbc.M707399200	http://dx.doi.org/10.1074/jbc.M707399200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18195015	Green Published, hybrid			2022-12-25	WOS:000253997900020
J	Mahrour, N; Redwine, WB; Florens, L; Swanson, SK; Martin-Brown, S; Bradford, WD; Staehling-Hampton, K; Washburn, MP; Conaway, RC; Conaway, JW				Mahrour, Nawel; Redwine, William B.; Florens, Laurence; Swanson, Selene K.; Martin-Brown, Skylar; Bradford, William D.; Staehling-Hampton, Karen; Washburn, Michael P.; Conaway, Ronald C.; Conaway, Joan W.			Characterization of Cullin-box sequences that direct recruitment of Cul2-Rbx1 and Cul5-Rbx2 modules to elongin BC-based ubiquitin ligases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IDENTIFICATION TECHNOLOGY; TUMOR-SUPPRESSOR COMPLEX; SOCS-BOX; SHOTGUN PROTEOMICS; ADAPTER PROTEIN; BINDING; GENE; FAMILY; DEFINES; CLONING	The Elongin BC-box protein family includes the von Hippel-Lindau tumor suppressor and suppressor of cytokine signaling proteins, which are substrate recognition subunits of structurally related classes of E3 ubiquitin ligases composed of Elongin C-Elongin B-Cullin 2-Rbx1 (Cul2 ubiquitin ligases) or of Elongin C-Elongin B-Cullin 5-Rbx2 (Cul5 ubiquitin ligases). The Elongin BC complex acts as an adaptor that links a substrate recognition subunit to heterodimers of either Cullin 2 (Cul2) and RING finger protein Rbx1 or Cullin 5 (Cul5) and Rbx2. It has been shown (Kamura, T., Maenaka, K., Kotoshiba, S., Matsumoto, M., Kohda, D., Conaway, R. C., Conaway, J. W., and Nakayama, K. I. (2004) Genes Dev. 18, 3055 - 3065) that interaction of BC-box proteins with their cognate Cul-Rbx module is determined by specific regions, called Cul2- or Cul5-boxes, located immediately downstream of their BC-boxes. Here, we investigate further the mechanisms governing assembly of BC-box proteins with their specific Cul-Rbx modules. Through purification and characterization of a larger collection of BC-box proteins that serve as substrate recognition subunits of Cul2 and Cul5 ubiquitin ligases and through structure-function studies, we define Cul2- and Cul5-boxes in greater detail. Although it previously appeared that there was little sequence similarity between Cul5- and Cul2-box motifs, analyses of newly identified BC-box proteins reveal that residues conserved in the Cul2-box represent a subset of those conserved in the Cul5-box. The sequence motif LP phi P, which is conserved in most Cul5-boxes and has been suggested to specify assembly of Cul5 ligases, is compatible with Cul2 interaction. Finally, the spacing between BC- and Cullin- boxes is much more flexible than has been appreciated and can vary from as few as 3 and as many as similar to 80 amino acids. Taken together, our findings shed new light on the mechanisms by which BC- box proteins direct recruitment of Cullin-Rbx modules during reconstitution of ubiquitin ligases.	[Mahrour, Nawel; Redwine, William B.; Florens, Laurence; Swanson, Selene K.; Martin-Brown, Skylar; Bradford, William D.; Staehling-Hampton, Karen; Washburn, Michael P.; Conaway, Ronald C.; Conaway, Joan W.] Stowers Inst Med Res, Kansas City, MO 64110 USA; [Conaway, Ronald C.; Conaway, Joan W.] Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA	Stowers Institute for Medical Research; University of Kansas; University of Kansas Medical Center	Conaway, JW (corresponding author), Stowers Inst Med Res, 1000 E 50th St, Kansas City, MO 64110 USA.	jlc@stowers-institute.org		Florens, Laurence/0000-0002-9310-6650; Washburn, Michael/0000-0001-7568-2585; Conaway, Joan/0000-0002-2786-0663	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041628, R01GM041628] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41628] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bullock AN, 2006, P NATL ACAD SCI USA, V103, P7637, DOI 10.1073/pnas.0601638103; Elkins MB, 2006, DEV DYNAM, V235, P1845, DOI 10.1002/dvdy.20824; ENDO T, 2007, NATURE, V387, P921; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Florens Laurence, 2006, V328, P159; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Hooper JD, 2000, GENOMICS, V66, P113, DOI 10.1006/geno.2000.6167; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kamura T, 2004, GENE DEV, V18, P3055, DOI 10.1101/gad.1252404; Kamura T, 2001, J BIOL CHEM, V276, P29748, DOI 10.1074/jbc.M103093200; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Lim R, 2002, J BIOL CHEM, V277, P40997, DOI 10.1074/jbc.M206041200; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Luo K, 2007, FASEB J, V21, P1742, DOI 10.1096/fj.06-7241com; Makarova KS, 2002, TRENDS BIOCHEM SCI, V27, P384, DOI 10.1016/S0968-0004(02)02140-0; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McDonald WH, 2002, INT J MASS SPECTROM, V219, P245, DOI 10.1016/S1387-3806(02)00563-8; Mehle A, 2006, J BIOL CHEM, V281, P17259, DOI 10.1074/jbc.M602413200; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Tabb DL, 2002, J PROTEOME RES, V1, P21, DOI 10.1021/pr015504q; Vasudevan S, 2007, EMBO REP, V8, P279, DOI 10.1038/sj.embor.7400895; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Wolters DA, 2001, ANAL CHEM, V73, P5683, DOI 10.1021/ac010617e; Yu YK, 2004, GENE DEV, V18, P2867, DOI 10.1101/gad.1250204; Zheng PZ, 1998, P NATL ACAD SCI USA, V95, P14745, DOI 10.1073/pnas.95.25.14745; Zybailov B, 2006, J PROTEOME RES, V5, P2339, DOI 10.1021/pr060161n	32	120	126	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					8005	8013		10.1074/jbc.M706987200	http://dx.doi.org/10.1074/jbc.M706987200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18187417	hybrid			2022-12-25	WOS:000253997900075
J	Tchesnokova, V; Aprikian, P; Yakovenko, O; Larock, C; Kidd, B; Vogel, V; Thomas, W; Sokurenko, E				Tchesnokova, Veronika; Aprikian, Pavel; Yakovenko, Olga; Larock, Christopher; Kidd, Brian; Vogel, Viola; Thomas, Wendy; Sokurenko, Evgeni			Integrin-like allosteric properties of the catch bond-forming FimH adhesin of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL ADHESION; P-SELECTIN; MONOCLONAL-ANTIBODIES; STRUCTURAL BASIS; LIGAND-BINDING; ACTIVATION; DOMAIN; AFFINITY; SHEAR; FORCE	FimH is the adhesive subunit of type 1 fimbriae of the Escherichia coli that is composed of a mannose-binding lectin domain and a fimbria-incorporating pilin domain. FimH is able to interact with mannosylated surface via a shear-enhanced catch bond mechanism. We show that the FimH lectin domain possesses a ligand-induced binding site (LIBS), a type of allosterically regulated epitopes characterized in integrins. Analogous to integrins, in FimH the LIBS epitope becomes exposed in the presence of the ligand (or "activating" mutations) and is located far from the ligand-binding site, close to the interdomain interface. Also, the antibody binding to the LIBS shifts adhesin from the low to high affinity state. Binding of streptavidin to the biotinylated residue within the LIBS also locks FimH in the high affinity state, suggesting that the allosteric perturbations in FimH are sustained by the interdomain wedging. In the presence of antibodies, the strength of bacterial adhesion to mannose is increased similar to the increase observed under shear force, suggesting the same allosteric mechanism, a shift in the interdomain configuration. Thus, an integrin-like allosteric link between the binding pocket and the interdomain conformation can serve as the basis for the catch bond property of FimH and, possibly, other adhesive proteins.	[Yakovenko, Olga; Kidd, Brian; Thomas, Wendy] Univ Washington, Dept Bioengn, Seattle, WA 98105 USA; [Tchesnokova, Veronika; Aprikian, Pavel; Yakovenko, Olga; Larock, Christopher; Sokurenko, Evgeni] Univ Washington, Dept Microbiol, Seattle, WA 98105 USA; [Thomas, Wendy; Sokurenko, Evgeni] Univ Washington, Nanotechnol Ctr, Seattle, WA 98105 USA; [Vogel, Viola] ETH, Dept Mat, CH-8093 Zurich, Switzerland	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Swiss Federal Institutes of Technology Domain; ETH Zurich	Thomas, W (corresponding author), Univ Washington, Dept Bioengn, Seattle, WA 98105 USA.	wendyt@u.washington.edu; evs@u.washington.edu	LaRock, Christopher/E-1554-2013; Vogel, Viola/O-8025-2015	LaRock, Christopher/0000-0003-3035-5331; Vogel, Viola/0000-0003-2898-7671; Thomas, Wendy/0000-0001-8602-0819; Kidd, Brian/0000-0003-2110-1145				Aprikian P, 2007, J BIOL CHEM, V282, P23437, DOI 10.1074/jbc.M702037200; Arnaout MA, 2005, ANNU REV CELL DEV BI, V21, P381, DOI 10.1146/annurev.cellbio.21.090704.151217; Bazzoni G, 1998, TRENDS BIOCHEM SCI, V23, P30, DOI 10.1016/S0968-0004(97)01141-9; Chigaev A, 2003, BIOPHYS J, V85, P3951, DOI 10.1016/S0006-3495(03)74809-7; Choudhury D, 1999, SCIENCE, V285, P1061, DOI 10.1126/science.285.5430.1061; DEMBO M, 1988, PROC R SOC SER B-BIO, V234, P55, DOI 10.1098/rspb.1988.0038; Doggett TA, 2002, BIOPHYS J, V83, P194, DOI 10.1016/S0006-3495(02)75161-8; DU XP, 1993, J BIOL CHEM, V268, P23087; Dustin ML, 2006, P NATL ACAD SCI USA, V103, P4335, DOI 10.1073/pnas.0600899103; Evans E, 2004, P NATL ACAD SCI USA, V101, P11281, DOI 10.1073/pnas.0401870101; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; Guo B, 2006, P NATL ACAD SCI USA, V103, P9844, DOI 10.1073/pnas.0601255103; Hall DA, 2000, MOL PHARMACOL, V58, P1412, DOI 10.1124/mol.58.6.1412; Hammer DA, 2005, CURR BIOL, V15, pR96, DOI 10.1016/j.cub.2005.01.028; Humphries MJ, 2003, CURR OPIN STRUC BIOL, V13, P236, DOI 10.1016/S0959-440X(03)00035-6; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; Hung CS, 2002, MOL MICROBIOL, V44, P903, DOI 10.1046/j.1365-2958.2002.02915.x; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Isberg RR, 2002, CELL, V110, P1, DOI 10.1016/S0092-8674(02)00821-8; Jin M, 2004, STRUCTURE, V12, P2137, DOI 10.1016/j.str.2004.10.005; Khaspekova S G, 1996, Biokhimiia, V61, P412; KIMURA T, 1995, J BIOL CHEM, V270, P16056, DOI 10.1074/jbc.270.27.16056; Konstantopoulos K, 2003, CURR BIOL, V13, pR611, DOI 10.1016/S0960-9822(03)00529-3; Liddington RC, 2002, J CELL BIOL, V158, P833, DOI 10.1083/jcb.200206011; Luo BH, 2005, P NATL ACAD SCI USA, V102, P3679, DOI 10.1073/pnas.0409440102; Luo BH, 2004, J BIOL CHEM, V279, P27466, DOI 10.1074/jbc.M404354200; Marshall BT, 2003, NATURE, V423, P190, DOI 10.1038/nature01605; Mould AP, 2005, J BIOL CHEM, V280, P4238, DOI 10.1074/jbc.M412240200; Mould AP, 2002, J BIOL CHEM, V277, P19800, DOI 10.1074/jbc.M201571200; Nilsson LM, 2006, J BIOL CHEM, V281, P16656, DOI 10.1074/jbc.M511496200; Phan UT, 2006, NAT IMMUNOL, V7, P883, DOI 10.1038/ni1366; Puklin-Faucher E, 2006, J CELL BIOL, V175, P349, DOI 10.1083/jcb.200602071; Qi SY, 2006, P NATL ACAD SCI USA, V103, P4416, DOI 10.1073/pnas.0510991103; Sarangapani KK, 2004, J BIOL CHEM, V279, P2291, DOI 10.1074/jbc.M310396200; SATO M, 1992, J BIOCHEM-TOKYO, V111, P331, DOI 10.1093/oxfordjournals.jbchem.a123758; Schoolmeester A, 2004, BLOOD, V104, P390, DOI 10.1182/blood-2003-12-4224; Sokurenko EV, 2001, MOL MICROBIOL, V41, P675, DOI 10.1046/j.1365-2958.2001.02545.x; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Thomas W, 2006, BIOPHYS J, V90, P753, DOI 10.1529/biophysj.105.066548; Thomas WE, 2004, MOL MICROBIOL, V53, P1545, DOI 10.1111/j.1365-2958.2004.04226.x; Thomas WE, 2002, CELL, V109, P913, DOI 10.1016/S0092-8674(02)00796-1; Thomas W, 2006, J CELL BIOL, V174, P911, DOI 10.1083/jcb.200609029; TUCEK S, 1995, TRENDS PHARMACOL SCI, V16, P205, DOI 10.1016/S0165-6147(00)89023-9; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Xiao T, 2004, NATURE, V432, P59, DOI 10.1038/nature02976; Yago T, 2004, J CELL BIOL, V166, P913, DOI 10.1083/jcb.200403144; Zang Q, 2001, J BIOL CHEM, V276, P6922, DOI 10.1074/jbc.M005868200	48	55	60	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7823	7833		10.1074/jbc.M707804200	http://dx.doi.org/10.1074/jbc.M707804200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18174167	hybrid			2022-12-25	WOS:000253997900058
J	Zhang, J; Goodson, ML; Hong, Y; Sarge, KD				Zhang, Jie; Goodson, Michael L.; Hong, Yiling; Sarge, Kevin D.			MEL-18 interacts with HSF2 and the SUMO E2 UBC9 to inhibit HSF2 sumoylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; POLYCOMB; CONJUGATION; UBIQUITIN	In a previous study we found that sumoylation of the DNA-binding protein heat shock factor 2 ( HSF2) is up-regulated during mitosis, but the mechanism that mediates this regulation was unknown. Here we show that HSF2 interacts with the polycomb protein MEL-18, that this interaction decreases during mitosis, and that overexpression and RNA interference-mediated reduction of MEL-18 result in decreased and increased HSF2 sumoylation, respectively. Other results suggest that MEL-18 may also function to inhibit the sumoylation of other cellular proteins. The results also show that MEL-18 is able to interact with the small ubiquitin-like modifier ( SUMO) ubiquitin carrier protein ( E2) enzyme UBC9 and that MEL-18 inhibits the ability of UBC9 to transfer the SUMO protein to target proteins. Together, the results in this work suggest a mechanism in which MEL-18 bound to HSF2 inhibits its sumoylation by binding to and inhibiting the activity of UBC9 enzymes in the vicinity of HSF2. These results provide an explanation for how mitotic HSF2 sumoylation is regulated and suggest that MEL-18, in contrast to the sumoylation-stimulating activities of the polycomb protein PC2, actually functions like an anti-SUMO ubiquitin-protein isopeptide ligase ( E3), interacting both with HSF2 and the SUMO E2 UBC9 but acting to inhibit UBC9 activity to decrease sumoylation of a target protein, in this case that of HSF2.	[Zhang, Jie; Goodson, Michael L.; Hong, Yiling; Sarge, Kevin D.] Univ Kentucky, Albert B Chandler Med Ctr, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA	University of Kentucky	Sarge, KD (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.	kdsarge@uky.edu	Goodson, Michael L/G-4175-2010	Goodson, Michael/0000-0002-3464-490X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061053, R01GM064606] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM064606, R01 GM061053-01A1, R01 GM064606-04, R01 GM061053-04, R01 GM064606-01A2, R01 GM061053-03, GM64606, R01 GM061053, GM61053, R01 GM061053-02, R01 GM064606-02, R01 GM064606-03] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anckar J, 2006, MOL CELL BIOL, V26, P955, DOI 10.1128/MCB.26.3.955-964.2006; Bossis G, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-13; Breiling A, 2007, INT REV CYTOL, V258, P83, DOI 10.1016/S0074-7696(07)58002-2; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Dohmen RJ, 2004, BBA-MOL CELL RES, V1695, P113, DOI 10.1016/j.bbamcr.2004.09.021; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Goodson ML, 2001, J BIOL CHEM, V276, P18513, DOI 10.1074/jbc.M008066200; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hietakangas V, 2003, MOL CELL BIOL, V23, P2953, DOI 10.1128/MCB.23.8.2953-2968.2003; Hilgarth Roland S., 2005, V301, P329; Hong YL, 2001, J BIOL CHEM, V276, P40263, DOI 10.1074/jbc.M104714200; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kerscher O, 2006, ANNU REV CELL DEV BI, V22, P159, DOI 10.1146/annurev.cellbio.22.010605.093503; Li B, 2007, BIOCHEM J, V405, P369, DOI 10.1042/BJ20061873; Mukhopadhyay D, 2007, TRENDS BIOCHEM SCI, V32, P286, DOI 10.1016/j.tibs.2007.05.002; Ringrose L, 2007, DEVELOPMENT, V134, P223, DOI 10.1242/dev.02723; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Sarge KD, 2005, TRENDS BIOCHEM SCI, V30, P605, DOI 10.1016/j.tibs.2005.09.004; Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009; Schwartz YB, 2007, NAT REV GENET, V8, P9, DOI 10.1038/nrg1981; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Takahashi Y, 2001, GENE, V275, P223, DOI 10.1016/S0378-1119(01)00662-X; Xing HY, 2005, SCIENCE, V307, P421, DOI 10.1126/science.1106478	28	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7464	7469		10.1074/jbc.M707122200	http://dx.doi.org/10.1074/jbc.M707122200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18211895	Green Published, Green Accepted, hybrid			2022-12-25	WOS:000253997900021
J	D'hoedt, D; Owsianik, G; Prenen, J; Cuajungco, MP; Grimm, C; Heller, S; Voets, T; Nilius, B				D'hoedt, Dieter; Owsianik, Grzegorz; Prenen, Jean; Cuajungco, Math Pham; Grimm, Christian; Heller, Stefan; Voets, Thomas; Nilius, Bernd			Stimulus-specific modulation of the cation channel TRPV4 by PACSIN 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-EVOKED ACTIVATION; ANKYRIN REPEAT DOMAIN; MICE LACKING TRPV4; ENDOTHELIAL-CELLS; ION-CHANNEL; PROTEIN; CA2+; EXPRESSION; LOCALIZATION; SENSITIVITY	TRPV4, a member of the vanilloid subfamily of the transient receptor potential (TRP) channels, is activated by a variety of stimuli, including cell swelling, moderate heat, and chemical compounds such as synthetic 4 alpha-phorbol esters. TRPV4 displays a widespread expression in various cells and tissues and has been implicated in diverse physiological processes, including osmotic homeostasis, thermo- and mechanosensation, vasorelaxation, tuning of neuronal excitability, and bladder voiding. The mechanisms that regulate TRPV4 in these different physiological settings are currently poorly understood. We have recently shown that the relative amount of TRPV4 in the plasma membrane is enhanced by interaction with the SH3 domain of PACSIN 3, a member of the PACSIN family of proteins involved in synaptic vesicular membrane trafficking and endocytosis. Here we demonstrate that PACSIN 3 strongly inhibits the basal activity of TRPV4 and its activation by cell swelling and heat, while leaving channel gating induced by the synthetic ligand 4 alpha-phorbol 12,13-didecanoate unaffected. A single proline mutation in the SH3 domain of PACSIN 3 abolishes its inhibitory effect on TRPV4, indicating that PACSIN 3 must bind to the channel to modulate its function. In line herewith, mutations at specific proline residues in the N terminus of TRPV4 abolish binding of PACSIN 3 and render the channel insensitive to PACSIN 3-induced inhibition. Taken together, these data suggest that PACSIN 3 acts as an auxiliary protein of TRPV4 channel that not only affects the channel's subcellular localization but also modulates its function in a stimulus-specific manner.	[D'hoedt, Dieter; Owsianik, Grzegorz; Prenen, Jean; Voets, Thomas; Nilius, Bernd] Katholieke Univ Leuven, Dept Physiol, B-3000 Louvain, Belgium; [Cuajungco, Math Pham; Grimm, Christian; Heller, Stefan] Stanford Univ, Sch Med, Dept Otolaryngol Head & Neck Surg & Mol & Cellula, Stanford, CA 94305 USA; [Cuajungco, Math Pham] Calif State Univ Fullerton, Dept Biol Sci, Fullerton, CA 92831 USA	KU Leuven; Stanford University; California State University System; California State University Fullerton	D'hoedt, D (corresponding author), Katholieke Univ Leuven, Dept Physiol, Campus Gasthuisberg,O&N 1,Herestr 49 Bus 802, B-3000 Louvain, Belgium.	dieter.dhoedt@med.kuleuven.be	Grimm, Christian/ABF-9121-2020; Voets, Thomas/AAD-4389-2019; Voets, Thomas/E-2466-2012; Cuajungco, Math/B-2647-2008	Grimm, Christian/0000-0002-0177-5559; Voets, Thomas/0000-0001-5526-5821; Voets, Thomas/0000-0001-5526-5821; Cuajungco, Math/0000-0003-0749-9564	NIDCD NIH HHS [DC 004563] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC004563] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Andrade YN, 2005, J CELL BIOL, V168, P869, DOI 10.1083/jcb.200409070; Arikkath J, 2003, CURR OPIN NEUROBIOL, V13, P298, DOI 10.1016/S0959-4388(03)00066-7; Arniges M, 2004, J BIOL CHEM, V279, P54062, DOI 10.1074/jbc.M409708200; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Chivian D, 2003, PROTEINS, V53, P524, DOI 10.1002/prot.10529; Chivian D, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl480; Chung MK, 2003, J BIOL CHEM, V278, P32037, DOI 10.1074/jbc.M303251200; Cuajungco MP, 2006, J BIOL CHEM, V281, P18753, DOI 10.1074/jbc.M602452200; Delany NS, 2001, PHYSIOL GENOMICS, V4, P165, DOI 10.1152/physiolgenomics.2001.4.3.165; Fernandez-Fernandez JM, 2002, AM J PHYSIOL-CELL PH, V283, pC1705, DOI 10.1152/ajpcell.00245.2002; Fu Y, 2006, AM J PHYSIOL-RENAL, V290, pF1305, DOI 10.1152/ajprenal.00391.2005; Gao X, 2003, J BIOL CHEM, V278, P27129, DOI 10.1074/jbc.M302517200; Guler AD, 2002, J NEUROSCI, V22, P6408; Jin XS, 2006, J BIOL CHEM, V281, P25006, DOI 10.1074/jbc.C600153200; Kim DE, 2004, NUCLEIC ACIDS RES, V32, pW526, DOI 10.1093/nar/gkh468; Kim DE, 2005, PROTEINS, V61, P193, DOI 10.1002/prot.20737; Kohler R, 2006, ARTERIOSCL THROM VAS, V26, P1495, DOI 10.1161/01.ATV.0000225698.36212.6a; Lee HS, 2005, J NEUROSCI, V25, P1304, DOI 10.1523/JNEUROSCI.4745.04.2005; Liedtke W., 2007, V179, P473; Liedtke W, 2003, P NATL ACAD SCI USA, V100, P13698, DOI 10.1073/pnas.1735416100; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Liedtke W, 2007, EXP PHYSIOL, V92, P507, DOI 10.1113/expphysiol.2006.035642; Liu XB, 2006, J BIOL CHEM, V281, P15485, DOI 10.1074/jbc.M600549200; Mangos S, 2007, GENE EXPR PATTERNS, V7, P480, DOI 10.1016/j.modgep.2006.10.011; McCleverty CJ, 2006, PROTEIN SCI, V15, P2201, DOI 10.1110/ps.062357206; Mizuno A, 2003, AM J PHYSIOL-CELL PH, V285, pC96, DOI 10.1152/ajpcell.00559.2002; Modregger J, 2000, J CELL SCI, V113, P4511; Nilius B, 2004, AM J PHYSIOL-CELL PH, V286, pC195, DOI 10.1152/ajpcell.00365.2003; Nilius B, 2001, PFLUG ARCH EUR J PHY, V443, P227, DOI 10.1007/s004240100676; Owsianik G, 2006, REV PHYSIOL BIOCH P, V156, P61, DOI 10.1007/s10254-005-0006-3; Owsianik G, 2006, ANNU REV PHYSIOL, V68, P685, DOI 10.1146/annurev.physiol.68.040204.101406; PaltaufDoburzynska J, 1997, CELL CALCIUM, V21, P43, DOI 10.1016/S0143-4160(97)90095-6; Pedersen SF, 2005, CELL CALCIUM, V38, P233, DOI 10.1016/j.ceca.2005.06.028; Plomann M, 1998, EUR J BIOCHEM, V256, P201, DOI 10.1046/j.1432-1327.1998.2560201.x; Richards MW, 2004, TRENDS PHARMACOL SCI, V25, P626, DOI 10.1016/j.tips.2004.10.008; Ritter B, 1999, FEBS LETT, V454, P356, DOI 10.1016/S0014-5793(99)00830-3; Rohl CA, 2004, PROTEINS, V55, P656, DOI 10.1002/prot.10629; Sidhaye VK, 2006, P NATL ACAD SCI USA, V103, P4747, DOI 10.1073/pnas.0511211103; Simons KT, 1997, J MOL BIOL, V268, P209, DOI 10.1006/jmbi.1997.0959; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Strotmann R, 2003, J BIOL CHEM, V278, P26541, DOI 10.1074/jbc.M302590200; Sumoy L, 2001, GENE, V262, P199, DOI 10.1016/S0378-1119(00)00531-X; Suzuki M, 2003, J BIOL CHEM, V278, P22664, DOI 10.1074/jbc.M302561200; Voets T, 2005, NAT CHEM BIOL, V1, P85, DOI 10.1038/nchembio0705-85; Vriens J, 2005, CIRC RES, V97, P908, DOI 10.1161/01.RES.0000187474.47805.30; Vriens J, 2004, P NATL ACAD SCI USA, V101, P396, DOI 10.1073/pnas.0303329101; Vriens J, 2007, J BIOL CHEM, V282, P12796, DOI 10.1074/jbc.M610485200; Watanabe H, 2003, NATURE, V424, P434, DOI 10.1038/nature01807; Watanabe H, 2003, CELL CALCIUM, V33, P489, DOI 10.1016/S0143-4160(03)00064-2; Watanabe H, 2002, J BIOL CHEM, V277, P47044, DOI 10.1074/jbc.M208277200; Watanabe H, 2002, J BIOL CHEM, V277, P13569, DOI 10.1074/jbc.M200062200; Wegierski T, 2006, EMBO J, V25, P5659, DOI 10.1038/sj.emboj.7601429; Wissenbach U, 2000, FEBS LETT, V485, P127, DOI 10.1016/S0014-5793(00)02212-2; ZHOU ZA, 1993, J PHYSIOL-LONDON, V469, P245, DOI 10.1113/jphysiol.1993.sp019813	54	91	96	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2008	283	10					6272	6280		10.1074/jbc.M706386200	http://dx.doi.org/10.1074/jbc.M706386200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HM	18174177	Green Published, hybrid			2022-12-25	WOS:000253779500034
J	Walsh, H; Govind, AP; Mastro, R; Hoda, JC; Bertrand, D; Vallejo, Y; Green, WN				Walsh, Heather; Govind, Anitha P.; Mastro, Ryan; Hoda, J. C.; Bertrand, Daniel; Vallejo, Yolanda; Green, William N.			Up-regulation of nicotinic receptors by nicotine varies with receptor subtype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-BUNGAROTOXIN RECEPTORS; RAT STRIATAL SYNAPTOSOMES; SUBUNIT MESSENGER-RNA; ACETYLCHOLINE-RECEPTORS; BINDING-SITES; CONOTOXIN-MII; MOUSE-BRAIN; EXPRESSION; PROTEIN; AUTORADIOGRAPHY	Recent evidence suggests that in addition to alpha 4 beta 2 and alpha 3-containing nicotinic receptors, alpha 6-containing receptors are present in midbrain dopaminergic neurons and involved in the nicotine reward pathway. Using heterologous expression, we found that alpha 6 beta 2, like alpha 3 beta 2 and alpha 4 beta 2 receptors, formed high affinity epibatidine binding complexes that are pentameric, trafficked to the cell surface, and produced acetylcholine-evoked currents. Chronic nicotine exposure up-regulated alpha 6 beta 2 receptors with differences in up-regulation time course and concentration dependence compared with alpha 4 beta 2 receptors, the predominant high affinity nicotine binding site in brain. The alpha 6 beta 2 receptor up-regulation required higher nicotine concentrations than for alpha 4 beta 2 but lower than for alpha 3 beta 2 receptors. The alpha 6 beta 2 up-regulation occurred 10-fold faster than for alpha 4 beta 2 and slightly faster than for alpha 3 beta 2. Our data suggest that nicotinic receptor up-regulation is subtype-specific such that alpha 6-containing receptors up-regulate in response to transient, high nicotine exposures, whereas sustained, low nicotine exposures up-regulate alpha 4 beta 2 receptors.	[Walsh, Heather; Govind, Anitha P.; Mastro, Ryan; Vallejo, Yolanda; Green, William N.] Univ Chicago, Dept Neurobiol, Chicago, IL 60637 USA; [Hoda, J. C.; Bertrand, Daniel] Univ Geneva, Fac Med, Dept Neurosci, CH-1211 Geneva 4, Switzerland	University of Chicago; University of Geneva	Green, WN (corresponding author), 947 E 58th St, Chicago, IL 60637 USA.	wgreen@midway.uchicago.edu						Benowitz NL, 2006, CLIN PHARMACOL THER, V80, P703, DOI 10.1016/j.clpt.2006.09.007; BENOWITZ NL, 1988, CLIN PHARMACOL THER, V44, P23, DOI 10.1038/clpt.1988.107; BENOWITZ NL, 1983, NEW ENGL J MED, V309, P139, DOI 10.1056/NEJM198307213090303; BENOWITZ NL, 1990, CIBA F SYMP, V152, P186; Brody AL, 2006, ARCH GEN PSYCHIAT, V63, P907, DOI 10.1001/archpsyc.63.8.907; Buisson B, 1998, MOL PHARMACOL, V53, P555, DOI 10.1124/mol.53.3.555; Buisson B, 2001, J NEUROSCI, V21, P1819, DOI 10.1523/JNEUROSCI.21-06-01819.2001; Champtiaux N, 2003, J NEUROSCI, V23, P7820; Champtiaux N, 2002, J NEUROSCI, V22, P1208, DOI 10.1523/JNEUROSCI.22-04-01208.2002; Chen DN, 1997, J BIOL CHEM, V272, P24024, DOI 10.1074/jbc.272.38.24024; Chubet RG, 1996, BIOTECHNIQUES, V20, P136; Cooper ST, 1999, J BIOL CHEM, V274, P27145, DOI 10.1074/jbc.274.38.27145; Dani JA, 2003, MOL PSYCHIATR, V8, P255, DOI 10.1038/sj.mp.4001284; DEVREOTES PN, 1975, J CELL BIOL, V65, P335, DOI 10.1083/jcb.65.2.335; Drisdel RC, 2000, J NEUROSCI, V20, P133, DOI 10.1523/JNEUROSCI.20-01-00133.2000; Eertmoed AL, 1998, METHOD ENZYMOL, V293, P564; Evans NM, 2003, EUR J PHARMACOL, V466, P31, DOI 10.1016/S0014-2999(03)01540-1; FLORES CM, 1992, MOL PHARMACOL, V41, P31; Gerzanich V, 1997, MOL PHARMACOL, V51, P320, DOI 10.1124/mol.51.2.320; Ghosheh OA, 2001, DRUG METAB DISPOS, V29, P645; Gopalakrishnan M, 1996, J PHARMACOL EXP THER, V276, P289; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; Grinevich VP, 2005, J PHARMACOL EXP THER, V312, P619, DOI 10.1124/jpet.104.075069; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Kaiser SA, 1998, J NEUROCHEM, V70, P1069; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; Kishi M, 2006, MOL PHARMACOL, V70, P2037, DOI 10.1124/mol.106.029298; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kulak JM, 1997, J NEUROSCI, V17, P5263; Kuryatov A, 2000, NEUROPHARMACOLOGY, V39, P2570, DOI 10.1016/S0028-3908(00)00144-1; Lai A, 2005, MOL PHARMACOL, V67, P1639, DOI 10.1124/mol.104.006429; LeNovere N, 1996, EUR J NEUROSCI, V8, P2428; Lindstrom J, 1996, Ion Channels, V4, P377; MARGIOTTA JF, 1987, J NEUROSCI, V7, P3612; Marks MJ, 1998, J PHARMACOL EXP THER, V285, P377; MARKS MJ, 1992, J NEUROSCI, V12, P2765; McCallum SE, 2006, J NEUROCHEM, V96, P1028, DOI 10.1111/j.1471-4159.2005.03646.x; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; Mugnaini M, 2002, EUR J NEUROSCI, V16, P1633, DOI 10.1046/j.1460-9568.2002.02220.x; Nashmi R, 2007, BIOCHEM PHARMACOL, V74, P1145, DOI 10.1016/j.bcp.2007.06.040; Nelson ME, 2001, J GEN PHYSIOL, V118, P563, DOI 10.1085/jgp.118.5.563; Nguyen HN, 2003, J PHARMACOL EXP THER, V307, P1090, DOI 10.1124/jpet.103.056408; Nicke A, 2004, FEBS LETT, V575, P52, DOI 10.1016/j.febslet.2004.08.035; Parker SL, 2004, MOL PHARMACOL, V65, P611, DOI 10.1124/mol.65.3.611; PENG X, 1994, MOL PHARMACOL, V46, P523; Perry DC, 1999, J PHARMACOL EXP THER, V289, P1545; PERRY DC, 1995, J PHARMACOL EXP THER, V275, P1030; Quik M, 2006, J PHARMACOL EXP THER, V316, P481, DOI 10.1124/jpet.105.094375; Rakhilin S, 1999, J CELL BIOL, V146, P203; Rangwala F, 1997, J NEUROSCI, V17, P8201; Ruskin DN, 2007, EUR J PHARMACOL, V559, P161, DOI 10.1016/j.ejphar.2007.01.006; Sallette J, 2004, J BIOL CHEM, V279, P18767, DOI 10.1074/jbc.M308260200; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHWARTZ RD, 1985, J NEUROCHEM, V45, P427, DOI 10.1111/j.1471-4159.1985.tb04005.x; Tumkosit P, 2006, MOL PHARMACOL, V70, P1358, DOI 10.1124/mol.106.027326; Vallejo YF, 2005, J NEUROSCI, V25, P5563, DOI 10.1523/JNEUROSCI.5240-04.2005; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; WADA E, 1989, J COMP NEUROL, V284, P314, DOI 10.1002/cne.902840212; Wang F, 1998, J BIOL CHEM, V273, P28721, DOI 10.1074/jbc.273.44.28721; Webster JC, 1999, BRIT J PHARMACOL, V127, P1337, DOI 10.1038/sj.bjp.0702686; Whiteaker P, 2000, MOL PHARMACOL, V57, P913; Whiteaker P, 2002, J NEUROSCI, V22, P2522, DOI 10.1523/JNEUROSCI.22-07-02522.2002; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; Wonnacott S, 2005, CURR OPIN PHARMACOL, V5, P53, DOI 10.1016/j.coph.2004.12.002; Zoli M, 2002, J NEUROSCI, V22, P8785	65	73	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2008	283	10					6022	6032		10.1074/jbc.M703432200	http://dx.doi.org/10.1074/jbc.M703432200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HM	18174175	hybrid			2022-12-25	WOS:000253779500007
J	Rosenberg, M; Straussman, R; Ben-Ya'acov, A; Ronen, D; Ravid, S				Rosenberg, Michael; Straussman, Ravid; Ben-Ya'acov, Ami; Ronen, Daniel; Ravid, Shoshana			MHC-IIB Filament Assembly and Cellular Localization Are Governed by the Rod Net Charge	PLOS ONE			English	Article							NONMUSCLE MYOSIN-II; COILED-COIL ROD; STRESS FIBERS; SMOOTH-MUSCLE; PHOSPHORYLATION; REGIONS; TAIL; ORGANIZATION; MECHANISM; RESIDUES	Background. Actin-dependent myosin II molecular motors form an integral part of the cell cytoskeleton. Myosin II molecules contain a long coiled-coil rod that mediates filament assembly required for myosin II to exert its full activity. The exact mechanisms orchestrating filament assembly are not fully understood. Methodology/Principal Findings. Here we examine mechanisms controlling filament assembly of non-muscle myosin IIB heavy chain (MHC-IIB). We show that in vitro the entire C-terminus region of net positive charge, found in myosin II rods, is important for self-assembly of MHC-IIB fragments. In contrast, no particular sequences in the rod region with net negative charge were identified as important for self-assembly, yet a minimal area from this region is necessary. Proper paracrystal formation by MHC-IIB fragments requires the 196aa charge periodicity along the entire coiled-coil region. In vivo, in contrast to self-assembly in vitro, negatively-charged regions of the coiled-coil were found to play an important role by controlling the intracellular localization of native MHC-IIB. The entire positively-charged region is also important for intracellular localization of native MHC-IIB. Conclusions/Significance. A correct distribution of positive and negative charges along myosin II rod is a necessary component in proper filament assembly and intracellular localization of MHC-IIB.	[Rosenberg, Michael; Straussman, Ravid; Ben-Ya'acov, Ami; Ronen, Daniel; Ravid, Shoshana] Hebrew Univ Jerusalem, Fac Med, Dept Biochem, Jerusalem, Israel	Hebrew University of Jerusalem	Ravid, S (corresponding author), Hebrew Univ Jerusalem, Fac Med, Dept Biochem, Jerusalem, Israel.	ravid@cc.huji.ac.il			Israel Cancer Research Foundation; Israel Ministry of Health; Israel Cancer Association	Israel Cancer Research Foundation; Israel Ministry of Health; Israel Cancer Association	This work was supported by grants from Israel Cancer Research Foundation, Israel Ministry of Health, and Israel Cancer Association.	ATKINSON SJ, 1992, J MOL BIOL, V226, P7, DOI 10.1016/0022-2836(92)90118-4; ATKINSON SJ, 1991, J CELL SCI, V99, P823; BENNETT PM, 1981, J MOL BIOL, V146, P201, DOI 10.1016/0022-2836(81)90432-0; CHOWRASHI PK, 1977, J CELL BIOL, V74, P136, DOI 10.1083/jcb.74.1.136; Cohen C, 1998, J STRUCT BIOL, V122, P180, DOI 10.1006/jsbi.1998.3983; Craig R, 2006, CURR OPIN STRUC BIOL, V16, P204, DOI 10.1016/j.sbi.2006.03.006; EILERTSEN KJ, 1994, J CELL BIOL, V126, P1201, DOI 10.1083/jcb.126.5.1201; Even-Faitelson L, 2005, CELL SIGNAL, V17, P1137, DOI 10.1016/j.cellsig.2004.12.015; Geeves MA, 2005, ADV PROTEIN CHEM, V71, P161, DOI 10.1016/S0065-3233(04)71005-0; Hoppe PE, 1996, J CELL BIOL, V135, P371, DOI 10.1083/jcb.135.2.371; Hostetter D, 2004, PLOS BIOL, V2, P1880, DOI 10.1371/journal.pbio.0020356; Ikebe M, 2001, J BIOL CHEM, V276, P30293, DOI 10.1074/jbc.M101969200; Joo E, 2007, DEV CELL, V13, P677, DOI 10.1016/j.devcel.2007.09.001; Kolega J, 1999, CELL MOTIL CYTOSKEL, V43, P255, DOI 10.1002/(SICI)1097-0169(1999)43:3<255::AID-CM8>3.0.CO;2-T; Kolega J, 2003, MOL BIOL CELL, V14, P4745, DOI 10.1091/mbc.E03-04-0205; Kolega J, 2006, MOL BIOL CELL, V17, P4435, DOI 10.1091/mbc.E06-05-0431; LANGANGER G, 1986, J CELL BIOL, V102, P200, DOI 10.1083/jcb.102.1.200; Lo CM, 2004, MOL BIOL CELL, V15, P982, DOI 10.1091/mbc.E03-06-0359; MCLACHLAN AD, 1982, NATURE, V299, P226, DOI 10.1038/299226a0; Meshel AS, 2005, NAT CELL BIOL, V7, P157, DOI 10.1038/ncb1216; Nakasawa T, 2005, BIOCHEMISTRY-US, V44, P174, DOI 10.1021/bi048807h; Olney JJ, 1996, J BIOL CHEM, V271, P20375, DOI 10.1074/jbc.271.34.20375; Rosenberg M, 2006, MOL BIOL CELL, V17, P1364, DOI 10.1091/mbc.e05-07-0597; Sato MK, 2007, MOL BIOL CELL, V18, P1009, DOI 10.1091/mbc.E06-08-0706; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; Shoffner JD, 1996, BIOCHEM BIOPH RES CO, V218, P860, DOI 10.1006/bbrc.1996.0153; Sohn RL, 1997, J MOL BIOL, V266, P317, DOI 10.1006/jmbi.1996.0790; STRAND D, 1994, J CELL BIOL, V127, P1361, DOI 10.1083/jcb.127.5.1361; Straussman R, 2005, J MOL BIOL, V353, P613, DOI 10.1016/j.jmb.2005.08.010; Straussman R, 2007, J MOL BIOL, V366, P1232, DOI 10.1016/j.jmb.2006.11.083; SVITKINA TM, 1989, CELL MOTIL CYTOSKEL, V12, P150, DOI 10.1002/cm.970120304; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; Tang NY, 2001, CURR BIOL, V11, P1131, DOI 10.1016/S0960-9822(01)00320-7; Trybus KM, 1991, CURR OPIN CELL BIOL, V3, P105, DOI 10.1016/0955-0674(91)90172-U; Tsunashima Y, 2004, BIOPOLYMERS, V75, P264, DOI 10.1002/bip.20114; Tullio AN, 1997, P NATL ACAD SCI USA, V94, P12407, DOI 10.1073/pnas.94.23.12407; Verkhovsky AB, 1999, BIOCHEM SOC SYMP, V65, P207; VERKHOVSKY AB, 1995, J CELL BIOL, V131, P989, DOI 10.1083/jcb.131.4.989; VERKHOVSKY AB, 1993, J CELL BIOL, V123, P637, DOI 10.1083/jcb.123.3.637	39	22	22	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2008	3	1							e1496	10.1371/journal.pone.0001496	http://dx.doi.org/10.1371/journal.pone.0001496			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SR	18231583	Green Published, Green Submitted, gold			2022-12-25	WOS:000260504200009
J	Wiesner, M; Zentz, C; Mayr, C; Wimmer, R; Hammerschmidt, W; Zeidler, R; Moosmann, A				Wiesner, Martina; Zentz, Caroline; Mayr, Christine; Wimmer, Rainer; Hammerschmidt, Wolfgang; Zeidler, Reinhard; Moosmann, Andreas			Conditional Immortalization of Human B Cells by CD40 Ligation	PLOS ONE			English	Article								It is generally assumed that human differentiated cells have a limited life-span and proliferation capacity in vivo, and that genetic modifications are a prerequisite for their immortalization in vitro. Here we readdress this issue, studying the long-term proliferation potential of human B cells. It was shown earlier that human B cells from peripheral blood of healthy donors can be efficiently induced to proliferate for up to ten weeks in vitro by stimulating their receptor CD40 in the presence of interleukin-4. When we applied the same stimuli under conditions of modified cell number and culture size, we were surprised to find that our treatment induced B cells to proliferate throughout an observation period of presently up to 1650 days, representing more than 370 population doublings, which suggested that these B cells were immortalized in vitro. Long-term CD40-stimulated B cell cultures could be established from most healthy adult human donors. These B cells had a constant phenotype, were free from Epstein-Barr virus, and remained dependent on CD40 ligation. They had constitutive telomerase activity and stabilized telomere length. Moreover, they were susceptible to activation by Toll-like receptor 9 ligands, and could be used to expand antigen-specific cytotoxic T cells in vitro. Our results indicate that human somatic cells can evade senescence and be conditionally immortalized by external stimulation only, without a requirement for genetic manipulation or oncoviral infection. Conditionally immortalized human B cells are a new tool for immunotherapy and studies of B cell oncogenesis, activation, and function.	[Wiesner, Martina; Zentz, Caroline; Moosmann, Andreas] GSF, Natl Res Ctr, Clin Cooperat Grp Mol Oncol, Munich, Germany; [Mayr, Christine] Tech Univ, Inst Human Genet, Munich, Germany; [Wimmer, Rainer] Univ Munich, Inst Human Genet, Munich, Germany; [Hammerschmidt, Wolfgang] GSF, Natl Res Ctr Env & Hlth, Dept Gene Vectors, Munich, Germany; [Zeidler, Reinhard] Univ Munich, Dept Otorhinolaryn, Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	Moosmann, A (corresponding author), GSF, Natl Res Ctr, Clin Cooperat Grp Mol Oncol, Munich, Germany.	moosmann@gsf.de	Zeidler, Reinhard/M-9837-2014; Hammerschmidt, Wolfgang/ABG-3921-2021	Zeidler, Reinhard/0000-0002-3357-4954; Hammerschmidt, Wolfgang/0000-0002-4659-0427; Moosmann, Andreas/0000-0001-8044-5146	HW & J Hector-Stiftung; Wilhelm Sander-Stiftung; Deutsche Forschungsgemeinschaft;  [SFB 455];  [FB-Transregio 36]	HW & J Hector-Stiftung; Wilhelm Sander-Stiftung; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); ; 	This study was supported by HW & J Hector-Stiftung, Wilhelm Sander-Stiftung, and Deutsche Forschungsgemeinschaft (SFB 455 and SFB-Transregio 36).	ARPIN C, 1995, SCIENCE, V268, P720, DOI 10.1126/science.7537388; BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; Bartz H, 2004, VACCINE, V23, P148, DOI 10.1016/j.vaccine.2004.05.020; Berger R, 2004, CANCER GENET CYTOGEN, V153, P86, DOI 10.1016/j.cancergencyto.2003.12.015; Bergwelt-Baildon von M., 2004, CANCER RES, V64, P4056; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BURDIN N, 1995, J IMMUNOL, V154, P2533; Busson-Le Coniat M, 2002, ANN GENET-PARIS, V45, P193, DOI 10.1016/S0003-3995(02)01138-3; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; Forsyth NR, 2004, NEOPLASIA, V6, P258, DOI 10.1593/neo.04103; Galibert L, 1996, J EXP MED, V183, P77, DOI 10.1084/jem.183.1.77; GALIBERT L, 1995, EUR J IMMUNOL, V25, P733, DOI 10.1002/eji.1830250316; GARRONE P, 1995, J EXP MED, V182, P1265, DOI 10.1084/jem.182.5.1265; Gudgeon NH, 2005, J VIROL, V79, P5477, DOI 10.1128/JVI.79.9.5477-5488.2005; Hammer MH, 2005, EUR J IMMUNOL, V35, P2250, DOI 10.1002/eji.200526230; Hartmann G, 2000, J IMMUNOL, V164, P944, DOI 10.4049/jimmunol.164.2.944; Hathcock KS, 2005, IMMUNOL REV, V205, P104, DOI 10.1111/j.0105-2896.2005.00267.x; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Hooijberg E, 2000, J IMMUNOL, V165, P4239, DOI 10.4049/jimmunol.165.8.4239; Hu BT, 1997, J IMMUNOL, V159, P1068; Igarashi H, 1997, BLOOD, V89, P1299, DOI 10.1182/blood.V89.4.1299; Jung D, 2001, IMMUNOL INVEST, V30, P157, DOI 10.1081/IMM-100104023; Kansal R, 2005, MODERN PATHOL, V18, P235, DOI 10.1038/modpathol.3800299; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kondo E, 2002, J IMMUNOL, V169, P2164, DOI 10.4049/jimmunol.169.4.2164; Lapointe R, 2003, CANCER RES, V63, P2836; Martens UM, 2002, BRIT J HAEMATOL, V119, P810, DOI 10.1046/j.1365-2141.2002.03910.x; Mayr C, 2006, BLOOD, V107, P742, DOI 10.1182/blood-2005-05-2093; Mitalipova MM, 2005, NAT BIOTECHNOL, V23, P19, DOI 10.1038/nbt0105-19; Miura T, 2004, AGING CELL, V3, P333, DOI 10.1111/j.1474-9728.2004.00134.x; Moosmann A, 2002, BLOOD, V100, P1755, DOI 10.1182/blood.V100.5.1755.h81702001755_1755_1764; Norrback KF, 1996, BLOOD, V88, P222; O'Nions J, 2004, J GEN VIROL, V85, P881, DOI 10.1099/vir.0.19704-0; Okubo M, 2001, CANCER GENET CYTOGEN, V129, P30, DOI 10.1016/S0165-4608(01)00420-4; POPE JH, 1968, INT J CANCER, V3, P857, DOI 10.1002/ijc.2910030619; RIVOLTINI L, 1995, CANCER RES, V55, P3149; ROUSSET F, 1995, INT IMMUNOL, V7, P1243, DOI 10.1093/intimm/7.8.1243; Rufer N, 2001, BLOOD, V98, P597, DOI 10.1182/blood.V98.3.597; Schultze JL, 1997, J CLIN INVEST, V100, P2757, DOI 10.1172/JCI119822; Shay JW, 2005, CARCINOGENESIS, V26, P867, DOI 10.1093/carcin/bgh296; Siwicki JK, 2004, GENE CHROMOSOME CANC, V41, P133, DOI 10.1002/gcc.20059; Son NH, 2000, J IMMUNOL, V165, P1191, DOI 10.4049/jimmunol.165.3.1191; Stewart SA, 2006, ANNU REV CELL DEV BI, V22, P531, DOI 10.1146/annurev.cellbio.22.010305.104518; Sugimoto M, 2004, CANCER RES, V64, P3361, DOI 10.1158/0008-5472.CAN-04-0079; Vollmer J, 2004, IMMUNOLOGY, V113, P212, DOI 10.1111/j.1365-2567.2004.01962.x; von Bergwelt-Baildon M, 2004, CANCER RES, V64, P4055, DOI 10.1158/0008-5472.CAN-03-3606; von Bergwelt-Baildon MS, 2002, BLOOD, V99, P3319, DOI 10.1182/blood.V99.9.3319; VONBERGWELTBAIL.M, 2004, CANCER RES, V63, P2836; Wagner M, 2004, J IMMUNOL, V172, P954, DOI 10.4049/jimmunol.172.2.954; Weng NP, 1998, IMMUNITY, V9, P151, DOI 10.1016/S1074-7613(00)80597-X; Weng NP, 1997, P NATL ACAD SCI USA, V94, P10827, DOI 10.1073/pnas.94.20.10827; WENG NP, 1995, P NATL ACAD SCI USA, V92, P11091, DOI 10.1073/pnas.92.24.11091; Zentz C, 2007, HUM IMMUNOL, V68, P75, DOI 10.1016/j.humimm.2006.12.004; Zippelius A, 2002, J EXP MED, V195, P485, DOI 10.1084/jem.20011658	55	64	70	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2008	3	1							e1464	10.1371/journal.pone.0001464	http://dx.doi.org/10.1371/journal.pone.0001464			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SO	18213373	Green Submitted, Green Published, gold			2022-12-25	WOS:000260503900010
J	van Wassenhove, V; Buonomano, DV; Shimojo, S; Shams, L				van Wassenhove, Virginie; Buonomano, Dean V.; Shimojo, Shinsuke; Shams, Ladan			Distortions of Subjective Time Perception Within and Across Senses	PLOS ONE			English	Article							MULTISENSORY INTEGRATION; INTERVAL DISCRIMINATION; DURATION JUDGMENTS; AUDITORY SENSATION; VISUAL FLICKER; RHESUS-MONKEYS; INTERNAL CLOCK; MODEL; BRAIN; INFORMATION	Background. The ability to estimate the passage of time is of fundamental importance for perceptual and cognitive processes. One experience of time is the perception of duration, which is not isomorphic to physical duration and can be distorted by a number of factors. Yet, the critical features generating these perceptual shifts in subjective duration are not understood. Methodology/Findings. We used prospective duration judgments within and across sensory modalities to examine the effect of stimulus predictability and feature change on the perception of duration. First, we found robust distortions of perceived duration in auditory, visual and auditory-visual presentations despite the predictability of the feature changes in the stimuli. For example, a looming disc embedded in a series of steady discs led to time dilation, whereas a steady disc embedded in a series of looming discs led to time compression. Second, we addressed whether visual (auditory) inputs could alter the perception of duration of auditory (visual) inputs. When participants were presented with incongruent audio-visual stimuli, the perceived duration of auditory events could be shortened or lengthened by the presence of conflicting visual information; however, the perceived duration of visual events was seldom distorted by the presence of auditory information and was never perceived shorter than their actual durations. Conclusions/Significance. These results support the existence of multisensory interactions in the perception of duration and, importantly, suggest that vision can modify auditory temporal perception in a pure timing task. Insofar as distortions in subjective duration can neither be accounted for by the unpredictability of an auditory, visual or auditory-visual event, we propose that it is the intrinsic features of the stimulus that critically affect subjective time distortions.	[Shimojo, Shinsuke] CALTECH, Div Biol, Pasadena, CA 91125 USA; [Buonomano, Dean V.; Shams, Ladan] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA USA; [Buonomano, Dean V.] Univ Calif Los Angeles, Dept Neurobiol, Los Angeles, CA USA	California Institute of Technology; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	van Wassenhove, V (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.	vvw@caltech.edu	van Wassenhove, Virginie/F-4129-2010	van Wassenhove, Virginie/0000-0002-2569-5502	HFSP [RGP70/2003]; JST.ERATO Shimojo Implicit Brain Function Project	HFSP(Human Frontier Science Program); JST.ERATO Shimojo Implicit Brain Function Project(Japan Science & Technology Agency (JST))	HFSP grant (RGP70/2003) to LS and SS. JST.ERATO Shimojo Implicit Brain Function Project to WW.	Alais D, 2004, CURR BIOL, V14, P257, DOI 10.1016/j.cub.2004.01.029; ALLAN LG, 1979, PERCEPT PSYCHOPHYS, V26, P340, DOI 10.3758/BF03204158; BALL W, 1971, SCIENCE, V171, P818, DOI 10.1126/science.171.3973.818; Battelli L, 2007, TRENDS COGN SCI, V11, P204, DOI 10.1016/j.tics.2007.03.001; Bendixen A, 2005, NEUROSCI LETT, V383, P284, DOI 10.1016/j.neulet.2005.04.034; Block RA, 1997, PSYCHON B REV, V4, P184, DOI 10.3758/BF03209393; Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357; Bresciani JP, 2006, J VISION, V6, P554, DOI 10.1167/6.5.2; Buonomano DV, 2000, J NEUROSCI, V20, P1129, DOI 10.1523/JNEUROSCI.20-03-01129.2000; Burr D, 2007, NAT NEUROSCI, V10, P423, DOI 10.1038/nn1874; Coull JT, 1998, J NEUROSCI, V18, P7426; Coull JT, 2004, SCIENCE, V303, P1506, DOI 10.1126/science.1091573; Deneve S, 2004, J PHYSIOLOGY-PARIS, V98, P249, DOI 10.1016/j.jphysparis.2004.03.011; Dhamala M, 2007, NEUROIMAGE, V34, P764, DOI 10.1016/j.neuroimage.2006.07.044; Droit-Volet S, 2004, COGNITION EMOTION, V18, P849, DOI 10.1080/02699930341000194; DROITVOLET S, 2006, BEHAV PROCESSES; Eagleman DM, 2004, NATURE, V428, P854, DOI 10.1038/nature02467; EFRON R, 1970, NEUROPSYCHOLOGIA, V8, P57, DOI 10.1016/0028-3932(70)90025-4; Ernst MO, 2002, NATURE, V415, P429, DOI 10.1038/415429a; Ernst MO, 2004, TRENDS COGN SCI, V8, P162, DOI 10.1016/j.tics.2004.02.002; Franconeri SL, 2003, PERCEPT PSYCHOPHYS, V65, P999, DOI 10.3758/BF03194829; FRANCONERI SL, 2005, PSYCHOL RES, V16; GEBHARD JW, 1959, AM J PSYCHOL, V72, P521, DOI 10.2307/1419493; GOLDSTONE S, 1963, PERCEPT MOTOR SKILL, V17, P763, DOI 10.2466/pms.1963.17.3.763; Guttman SE, 2005, PSYCHOL SCI, V16, P228, DOI 10.1111/j.0956-7976.2005.00808.x; Hodinott-Hill I, 2002, CURR BIOL, V12, P1779, DOI 10.1016/S0960-9822(02)01219-8; Ivry RB, 2004, CURR OPIN NEUROBIOL, V14, P225, DOI 10.1016/j.conb.2004.03.013; James W., 1890, PRINCIPLES PSYCHOL; Johnston A, 2006, CURR BIOL, V16, P472, DOI 10.1016/j.cub.2006.01.032; Kanai R., 2006, J VISION, P1; Karmarkar UR, 2003, LEARN MEMORY, V10, P141, DOI 10.1101/lm.55503; Karmarkar UR, 2007, NEURON, V53, P427, DOI 10.1016/j.neuron.2007.01.006; KORDING KP, 2007, CAUSAL INFEREN UNPUB; Leon MI, 2003, NEURON, V38, P317, DOI 10.1016/S0896-6273(03)00185-5; Lewis PA, 2003, CURR OPIN NEUROBIOL, V13, P250, DOI 10.1016/S0959-4388(03)00036-9; Maier JX, 2004, NEURON, V43, P177, DOI 10.1016/j.neuron.2004.06.027; Massaro D.W., 1998, PERCEIVING TALKING F; Mauk MD, 2004, ANNU REV NEUROSCI, V27, P307, DOI 10.1146/annurev.neuro.27.070203.144247; Morrone MC, 2005, NAT NEUROSCI, V8, P950, DOI 10.1038/nn1488; N'Diaye K, 2004, COGNITIVE BRAIN RES, V21, P250, DOI 10.1016/j.cogbrainres.2004.04.006; Nagarajan SS, 1998, J NEUROSCI, V18, P1559; Oleron G, 1952, ANN PSYCHOL, V52, P383; Pariyadath V, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001264; Park J, 2003, EXP BRAIN RES, V149, P527, DOI 10.1007/s00221-003-1376-x; Pascual-Leone A, 2001, PROG BRAIN RES, V134, P427; Pelli DG, 1997, SPATIAL VISION, V10, P437, DOI 10.1163/156856897X00366; PENNER MJ, 1977, J ACOUST SOC AM, V61, P552, DOI 10.1121/1.381297; Penney T.B., 2005, PSYCHOL FRANCA, V50, P131, DOI [10.1016/j.psfr.2004.10.011, DOI 10.1016/J.PSFR.2004.10.011]; Penney TB, 2000, J EXP PSYCHOL HUMAN, V26, P1770, DOI 10.1037//0096-1523.26.6.1770; PLOMP R, 1964, J ACOUST SOC AM, V36, P277, DOI 10.1121/1.1918946; Poppel E, 1997, TRENDS COGN SCI, V1, P56, DOI 10.1016/S1364-6613(97)01008-5; POPPEL E, 1978, PERCEPTION; Recanzone GH, 2003, J NEUROPHYSIOL, V89, P1078, DOI 10.1152/jn.00706.2002; Roach NW, 2006, P ROY SOC B-BIOL SCI, V273, P2159, DOI 10.1098/rspb.2006.3578; ROSACLOT M, 2002, INT J THEOR APPL FIN, V5, P123, DOI DOI 10.1142/S0219024902001377; ROSE D, 1995, PERCEPTION, V24, P1177, DOI 10.1068/p241177; Ross J, 2001, TRENDS NEUROSCI, V24, P113, DOI 10.1016/S0166-2236(00)01685-4; SCHIFF W, 1962, SCIENCE, V136, P982, DOI 10.1126/science.136.3520.982; Shams L, 2005, NEUROREPORT, V16, P1923, DOI 10.1097/01.wnr.0000187634.68504.bb; SHIPLEY T, 1964, SCIENCE, V145, P1328, DOI 10.1126/science.145.3638.1328; TREISMAN M, 1963, PSYCHOL MONOGR, V77, P1, DOI 10.1037/h0093864; Tse PU, 2004, PERCEPT PSYCHOPHYS, V66, P1171, DOI 10.3758/BF03196844; van Beers RJ, 1999, J NEUROPHYSIOL, V81, P1355, DOI 10.1152/jn.1999.81.3.1355; van Wassenhove V, 2007, J NEUROSCI, V27, P2663, DOI 10.1523/JNEUROSCI.4844-06.2007; Watanabe K, 2001, PSYCHOL SCI, V12, P109, DOI 10.1111/1467-9280.00319; Wearden JH, 1998, Q J EXP PSYCHOL-B, V51, P97; WELCH RB, 1980, PSYCHOL BULL, V88, P638, DOI 10.1037/0033-2909.88.3.638; Westheimer G, 1999, EXP BRAIN RES, V129, P121, DOI 10.1007/s002210050942; Wittmann M, 1999, CHRONOBIOL INT, V16, P17, DOI 10.3109/07420529908998709; Wright BA, 1997, J NEUROSCI, V17, P3956; Yarrow K, 2003, CURR BIOL, V13, P1134, DOI 10.1016/S0960-9822(03)00413-5; YARROW K, 2001, ILLUSORY PERCEPTIONS, P302; Zakay D, 1997, CURR DIR PSYCHOL SCI, V6, P12, DOI 10.1111/1467-8721.ep11512604; [No title captured]	74	134	138	1	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2008	3	1							e1437	10.1371/journal.pone.0001437	http://dx.doi.org/10.1371/journal.pone.0001437			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	366SN	18197248	Green Published, Green Accepted, gold, Green Submitted			2022-12-25	WOS:000260503800009
J	Freed, WJ; Chen, J; Baeckman, CM; Schwartz, CM; Vazin, T; Cai, JL; Spivak, CE; Lupica, CR; Rao, MS; Zeng, XM				Freed, William J.; Chen, Jia; Baeckman, Cristina M.; Schwartz, Catherine M.; Vazin, Tandis; Cai, Jingli; Spivak, Charles E.; Lupica, Carl R.; Rao, Mahendra S.; Zeng, Xianmin			Gene Expression Profile of Neuronal Progenitor Cells Derived from hESCs: Activation of Chromosome 11p15.5 and Comparison to Human Dopaminergic Neurons	PLOS ONE			English	Article							EMBRYONIC STEM-CELLS; BECKWITH-WIEDEMANN-SYNDROME; SIGNATURE SEQUENCING MPSS; IN-VITRO; CONGENITAL HYPERINSULINISM; REGULATABLE LENTIVIRUS; BEHAVIORAL-CHANGES; IMPRINTED GENES; NONCODING RNA; H19 GENE	Background. We initiated differentiation of human embryonic stem cells (hESCs) into dopamine neurons, obtained a purified population of neuronal precursor cells by cell sorting, and determined patterns of gene transcription. Methodology. Dopaminergic differentiation of hESCs was initiated by culturing hESCs with a feeder layer of PA6 cells. Differentiating cells were then sorted to obtain a pure population of PSA-NCAM-expressing neuronal precursors, which were then analyzed for gene expression using Massive Parallel Signature Sequencing (MPSS). Individual genes as well as regions of the genome which were activated were determined. Principal Findings. A number of genes known to be involved in the specification of dopaminergic neurons, including MSX1, CDKN1C, Pitx1 and Pitx2, as well as several novel genes not previously associated with dopaminergic differentiation, were expressed. Notably, we found that a specific region of the genome located on chromosome 11p15.5 was highly activated. This region contains several genes which have previously been associated with the function of dopaminergic neurons, including the gene for tyrosine hydroxylase (TH), the rate-limiting enzyme in catecholamine biosynthesis, IGF2, and CDKN1C, which cooperates with Nurr1 in directing the differentiation of dopaminergic neurons. Other genes in this region not previously recognized as being involved in the functions of dopaminergic neurons were also activated, including H19, TSSC4, and HBG2. IGF2 and CDKN1C were also found to be highly expressed in mature human TH-positive dopamine neurons isolated from human brain samples by laser capture. Conclusions. The present data suggest that the H19-IGF2 imprinting region on chromosome 11p15.5 is involved in the process through which undifferentiated cells are specified to become neuronal precursors and/or dopaminergic neurons.	[Freed, William J.; Chen, Jia; Baeckman, Cristina M.; Vazin, Tandis; Spivak, Charles E.; Lupica, Carl R.; Zeng, Xianmin] NIDA, Cellular Neurobiol Res Branch, IRP, NIH,US Dept HHS, Baltimore, MD USA; [Schwartz, Catherine M.; Rao, Mahendra S.] NIH, Natl Inst Aging, Dept Hlth & Human Serv DHHS, Lab Neurosci, Intramural Res Prog, Baltimore, MD USA; [Cai, Jingli] Thomas Jefferson Univ, Farber Inst Neurosci, Philadelphia, PA USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Jefferson University	Freed, WJ (corresponding author), NIDA, Cellular Neurobiol Res Branch, IRP, NIH,US Dept HHS, Baltimore, MD USA.	wfreed@mail.nih.gov	Lupica, Carl/AAY-3193-2021; backman, cristina/C-1276-2013	Lupica, Carl/0000-0002-5375-3263; 	NIDA; NIA; DHHS; NATIONAL INSTITUTE ON DRUG ABUSE [ZIADA000472, Z01DA000472] Funding Source: NIH RePORTER	NIDA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); DHHS; NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	Research was supported by the IRPs of NIDA and NIA, NIDA, DHHS.	Alonso G, 2001, GLIA, V34, P253, DOI 10.1002/glia.1059; Andersson E, 2006, CELL, V124, P393, DOI [10.1016/j.cell.2005.10.037, 10.1016/J.CELL.2005.10.037]; Andersson E, 2006, DEVELOPMENT, V133, P507, DOI 10.1242/dev.02224; Baer K, 2007, EXP NEUROL, V204, P828, DOI 10.1016/j.expneurol.2006.12.008; Bahi A, 2004, EUR J NEUROSCI, V20, P3473, DOI 10.1111/j.1460-9568.2004.03771.x; Bahi A, 2004, EUR J NEUROSCI, V19, P1621, DOI 10.1111/j.1460-9568.2004.03260.x; Barrett T, 2001, NEUROBIOL DIS, V8, P822, DOI 10.1006/nbdi.2001.0423; Bendall SC, 2007, NATURE, V448, P1015, DOI 10.1038/nature06027; Bjorklund LM, 2002, P NATL ACAD SCI USA, V99, P2344, DOI 10.1073/pnas.022438099; BLASSKAMPMANN S, 1994, J NEUROSCI RES, V37, P359, DOI 10.1002/jnr.490370308; Brenner S, 2000, P NATL ACAD SCI USA, V97, P1665, DOI 10.1073/pnas.97.4.1665; Brenner S, 2000, NAT BIOTECHNOL, V18, P630, DOI 10.1038/76469; Brimble SN, 2004, STEM CELLS DEV, V13, P585, DOI 10.1089/scd.2004.13.585; Buytaert-Hoefen KA, 2004, STEM CELLS, V22, P669, DOI 10.1634/stemcells.22-5-669; Cai XZ, 2007, RNA, V13, P313, DOI 10.1261/rna.351707; Chung S, 2005, MOL CELL NEUROSCI, V28, P241, DOI 10.1016/j.mcn.2004.09.008; Cichon S, 1996, AM J MED GENET, V67, P229, DOI 10.1002/(SICI)1096-8628(19960409)67:2<229::AID-AJMG17>3.0.CO;2-L; Clark AT, 2004, HUM MOL GENET, V13, P727, DOI 10.1093/hmg/ddh088; Dentice M, 2005, NAT CELL BIOL, V7, P698, DOI 10.1038/ncb1272; Donarum EA, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-22; Fournet JC, 2000, HORM RES, V53, P2, DOI 10.1159/000053197; Fournet JC, 2001, AM J PATHOL, V158, P2177, DOI 10.1016/S0002-9440(10)64689-5; Gabory A, 2006, CYTOGENET GENOME RES, V113, P188, DOI 10.1159/000090831; Jaenisch R, 1997, TRENDS GENET, V13, P323, DOI 10.1016/S0168-9525(97)01180-3; Jongeneel CV, 2005, GENOME RES, V15, P1007, DOI 10.1101/gr.4041005; Jorgensen JR, 2006, EXP NEUROL, V198, P427, DOI 10.1016/j.expneurol.2005.12.023; Joseph B, 2003, P NATL ACAD SCI USA, V100, P15619, DOI 10.1073/pnas.2635658100; Kawasaki H, 2002, P NATL ACAD SCI USA, V99, P1580, DOI 10.1073/pnas.032662199; Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0; Kim JH, 2002, NATURE, V418, P50, DOI 10.1038/nature00900; Lee MP, 1999, HUM MOL GENET, V8, P683, DOI 10.1093/hmg/8.4.683; Lewis A, 2006, CYTOGENET GENOME RES, V113, P81, DOI 10.1159/000090818; Li H, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-103; Ling JQ, 2006, SCIENCE, V312, P269, DOI 10.1126/science.1123191; LUSTIG O, 1994, MOL REPROD DEV, V38, P239, DOI 10.1002/mrd.1080380302; Marinelli M., 2006, CNS & Neurological Disorders-Drug Targets, V5, P79, DOI 10.2174/187152706784111542; MayerProschel M, 1997, NEURON, V19, P773, DOI 10.1016/S0896-6273(00)80960-5; Micha AE, 1999, DIGESTION, V60, P477, DOI 10.1159/000007694; Michna L, 2001, MOL BRAIN RES, V90, P68, DOI 10.1016/S0169-328X(01)00092-4; Miura T, 2004, STEM CELLS DEV, V13, P694, DOI 10.1089/scd.2004.13.694; Nass R, 2003, ANNU REV PHARMACOL, V43, P521, DOI 10.1146/annurev.pharmtox.43.100901.135934; Odorico JS, 2001, STEM CELLS, V19, P193, DOI 10.1634/stemcells.19-3-193; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; Patton SJ, 1998, MOL BIOL EVOL, V15, P1373, DOI 10.1093/oxfordjournals.molbev.a025865; Paulsen M, 2000, HUM MOL GENET, V9, P1829, DOI 10.1093/hmg/9.12.1829; Perrier AL, 2004, P NATL ACAD SCI USA, V101, P12543, DOI 10.1073/pnas.0404700101; Prakash N, 2006, CELL MOL LIFE SCI, V63, P187, DOI 10.1007/s00018-005-5387-6; RACHMILEWITZ J, 1992, FEBS LETT, V309, P25, DOI 10.1016/0014-5793(92)80731-U; Redmond DE, 2003, DEV BRAIN RES, V146, P99, DOI 10.1016/j.devbrainres.2003.10.001; Reik W, 1997, TRENDS GENET, V13, P330, DOI 10.1016/S0168-9525(97)01200-6; Riddle R, 2003, DEV BRAIN RES, V147, P3, DOI 10.1016/j.devbrainres.2003.09.010; Schwartz CM, 2005, STEM CELLS DEV, V14, P517, DOI 10.1089/scd.2005.14.517; Scott RE, 2005, DIFFERENTIATION, V73, P294; Seutin V, 2005, BRIT J PHARMACOL, V146, P167, DOI 10.1038/sj.bjp.0706328; Sproul D, 2005, NAT REV GENET, V6, P775, DOI 10.1038/nrg1688; TAYLOR ER, 1991, J MOL ENDOCRINOL, V7, P145, DOI 10.1677/jme.0.0070145; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Vasiliauskas D, 1999, MECH DEVELOP, V82, P79, DOI 10.1016/S0925-4773(99)00014-3; Xu RH, 2002, NAT BIOTECHNOL, V20, P1261, DOI 10.1038/nbt761; Yan YP, 2005, STEM CELLS, V23, P781, DOI 10.1634/stemcells.2004-0365; Yokomine T, 2005, GENOME RES, V15, P154, DOI 10.1101/gr.2609605; Zeng XM, 2004, STEM CELLS, V22, P292, DOI 10.1634/stemcells.22-3-292; Zeng XM, 2004, STEM CELLS, V22, P925, DOI 10.1634/stemcells.22-6-925; Zeng XM, 2003, STEM CELLS, V21, P647, DOI 10.1634/stemcells.21-6-647; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0; Zhu Y, 2001, GENE DEV, V15, P859, DOI 10.1101/gad.862101	66	27	28	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2008	3	1							e1422	10.1371/journal.pone.0001422	http://dx.doi.org/10.1371/journal.pone.0001422			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366GT	18183302	Green Published, gold, Green Submitted			2022-12-25	WOS:000260469400018
J	van Vliet-Ostaptchouk, JV; Onland-Moret, NC; Shiri-Sverdlov, R; van Gorp, PJJ; Custers, A; Peeters, PHM; Wijmenga, C; Hofker, MH; van der Schouw, YT				van Vliet-Ostaptchouk, Jana V.; Onland-Moret, N. Charlotte; Shiri-Sverdlov, Ronit; van Gorp, Patrick J. J.; Custers, Anne; Peeters, Petra H. M.; Wijmenga, Cisca; Hofker, Marten H.; van der Schouw, Yvonne T.			Polymorphisms of the TUB Gene Are Associated with Body Composition and Eating Behavior in Middle-Aged Women	PLOS ONE			English	Article							GLYCEMIC LOAD; FOOD-INTAKE; MESSENGER-RNA; NORMAL-WEIGHT; OBESE; PROTEIN; FAT; EXPRESSION; MOUSE; IDENTIFICATION	Background. The TUB gene, encoding an evolutionary conserved protein, is highly expressed in the hypothalamus and might act as a transcription factor. Mutations in TUB cause late-onset obesity, insulin-resistance and neurosensory deficits in mice. An association of common variants in the TUB gene with body weight in humans has been reported. Methods/Findings. The aim was to investigate the relationship of single nucleotide polymorphisms (SNPs) of the TUB gene (rs2272382, rs2272383 and rs1528133) with both anthropometry and self-reported macronutrient intake from a validated food frequency questionnaire. These associations were studied in a population-based, cross-sectional study of 1680 middle-aged Dutch women, using linear regression analysis. The minor allele C of the rs1528133 SNP was significantly associated with increased weight (+1.88 kg, P=0.022) and BMI (+0.56 units, P=0.05). Compared with non-carriers, both AG heterozygotes and AA homozygotes of the rs2272382 SNP derived less energy from fat (AG: -0.55 +/- 0.28%, P=0.05, AA: -0.95 +/- 0.48%, P=0.047). However, both genotypes were associated with an increased energy intake from carbohydrates (0.69 +/- 0.33%, P=0.04 and 1.68 +/- 0.56%, P=0.003, respectively), mainly because of a higher consumption of mono- and disaccharides. Both these SNPs, rs2272382 and rs1528133, were also associated with a higher glycemic load in the diet. The glycemic load was higher among those with AG and AA genotypes for the variant rs2272382 than among the wild types (+1.49 (95% CI: -0.27-3.24) and +3.89 (95% CI: 0.94-6.85) units, respectively). Carriers of the minor allele C of rs1528133 were associated with an increased glycemic load of 1.85 units compared with non-carriers. Conclusions. Genetic variation of the TUB gene was associated with both body composition and macronutrient intake, suggesting that TUB might influence eating behavior.	[van Vliet-Ostaptchouk, Jana V.; Hofker, Marten H.] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Lab Med, Groningen, Netherlands; [van Vliet-Ostaptchouk, Jana V.; Shiri-Sverdlov, Ronit; van Gorp, Patrick J. J.; Custers, Anne; Hofker, Marten H.] Maastricht Univ, Dept Mol Genet, Maastricht, Netherlands; [Onland-Moret, N. Charlotte; Wijmenga, Cisca] Univ Med Ctr Utrecht, DBG Dept Med Genet, Utrecht, Netherlands; [Onland-Moret, N. Charlotte; Peeters, Petra H. M.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Wijmenga, Cisca] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands	University of Groningen; Maastricht University; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; University of Groningen	van der Schouw, YT (corresponding author), Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands.	Y.T.vanderSchouw@umcutrecht.nl	van Gorp, Patrick/S-3892-2019; Shiri-Sverdlov, Ronit/X-2642-2019; van Gorp, Patrick/L-9580-2018; van der Schouw, Yvonne T./F-8327-2014; Wijmenga, Cisca/D-2173-2009; Wijmenga, Cisca/AAE-7719-2019; Shiri-Sverdlov, Ronit/E-5571-2017; Onland-Moret, N. Charlotte/G-9185-2011	van Gorp, Patrick/0000-0002-0355-5349; Shiri-Sverdlov, Ronit/0000-0002-6736-7814; van Gorp, Patrick/0000-0002-0355-5349; van der Schouw, Yvonne T./0000-0002-4605-435X; Wijmenga, Cisca/0000-0002-5635-1614; Shiri-Sverdlov, Ronit/0000-0002-6736-7814; Onland-Moret, N. Charlotte/0000-0002-2360-913X; van Vliet-Ostaptchouk, Jana/0000-0002-7943-3153	Dutch Diabetes Foundation; European Vascular Genomics Network; SenterNovem; IOP Genomics [IGE05012]; European Commission-Europe Against Cancer [WHO AEP/90/05]; Dutch Ministry of Health; Dutch Prevention Fund; LK Research Fund; World Cancer Research Fund [98A04, 2000/30]	Dutch Diabetes Foundation; European Vascular Genomics Network; SenterNovem; IOP Genomics; European Commission-Europe Against Cancer; Dutch Ministry of Health; Dutch Prevention Fund; LK Research Fund; World Cancer Research Fund(World Cancer Research Fund International (WCRF))	We thank the Dutch Diabetes Foundation, the European Vascular Genomics Network, and SenterNovem (IOP Genomics IGE05012) for financial support. The Prospect-EPIC study was financed by the European Commission-Europe Against Cancer (WHO AEP/90/05), the Dutch Ministry of Health, the Dutch Prevention Fund, the LK Research Fund, and the World Cancer Research Fund (WCRF 98A04 and WCRF 2000/30).	Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279; Aubert R, 2000, INT J OBESITY, V24, P920, DOI 10.1038/sj.ijo.0801253; Backberg M, 2004, MOL BRAIN RES, V125, P129, DOI 10.1016/j.molbrainres.2004.03.012; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Berthoud HR, 2002, NEUROSCI BIOBEHAV R, V26, P393, DOI 10.1016/S0149-7634(02)00014-3; Boggon TJ, 1999, SCIENCE, V286, P2119, DOI 10.1126/science.286.5447.2119; Boker LK, 2001, EUR J EPIDEMIOL, V17, P1047, DOI 10.1023/A:1020009325797; BRAY GA, 1992, AM J CLIN NUTR, V55, P265; Castillo M, 2006, J MOL NEUROSCI, V30, P153, DOI 10.1385/JMN:30:1:153; COLEMAN DL, 1990, J HERED, V81, P424, DOI 10.1093/oxfordjournals.jhered.a111019; DECASTRO JM, 1993, PHYSIOL BEHAV, V53, P777, DOI 10.1016/0031-9384(93)90188-L; Giannaccini G, 2007, CLIN BIOCHEM, V40, P806, DOI 10.1016/j.clinbiochem.2007.03.020; Gorwood P, 2003, EUR J PHARMACOL, V480, P163, DOI 10.1016/j.ejphar.2003.08.103; Guan XM, 1998, MOL BRAIN RES, V59, P273, DOI 10.1016/S0169-328X(98)00150-8; Hagan MM, 2001, AM J PHYSIOL-REG I, V280, pR814, DOI 10.1152/ajpregu.2001.280.3.R814; HARE B, 2006, AM J CLIN NUTR, V84, P952; Hare-Bruun H, 2006, AM J CLIN NUTR, V84, P871, DOI 10.1093/ajcn/84.4.871; Ikeda A, 2002, J CELL SCI, V115, P9; Kapeller R, 1999, J BIOL CHEM, V274, P24980, DOI 10.1074/jbc.274.35.24980; Kleyn PW, 1996, CELL, V85, P281, DOI 10.1016/S0092-8674(00)81104-6; Koegler FH, 1999, PHYSIOL BEHAV, V67, P809, DOI 10.1016/S0031-9384(99)00104-3; Kretsch MJ, 1999, J AM DIET ASSOC, V99, P300, DOI 10.1016/S0002-8223(99)00078-4; Lau C, 2006, AM J CLIN NUTR, V84, P641, DOI 10.1093/ajcn/84.3.641; Leibowitz SF, 2004, PEPTIDES, V25, P473, DOI 10.1016/j.peptides.2004.02.006; LICHTMAN SW, 1992, NEW ENGL J MED, V327, P1893, DOI 10.1056/NEJM199212313272701; Liu SM, 2000, AM J CLIN NUTR, V71, P1455; Livesey G, 2005, P NUTR SOC, V64, P105, DOI 10.1079/PNS2004400; Loos RJF, 2005, AM J CLIN NUTR, V82, P1097, DOI 10.1093/ajcn/82.5.1097; Ma YS, 2005, AM J EPIDEMIOL, V161, P359, DOI 10.1093/aje/kwi051; Mak HY, 2006, NAT GENET, V38, P363, DOI 10.1038/ng1739; McMillan-Price J, 2006, ARCH INTERN MED, V166, P1466, DOI 10.1001/archinte.166.14.1466; MORTON GJ, 2006, CENTRAL NERVOUS SYST, V443, P289; Mukhopadhyay A, 2005, CELL METAB, V2, P35, DOI 10.1016/j.cmet.2005.06.004; Nishina PM, 1998, GENOMICS, V54, P215, DOI 10.1006/geno.1998.5567; Ocke MC, 1997, INT J EPIDEMIOL, V26, pS49, DOI 10.1093/ije/26.suppl_1.S49; PRENTICE AM, 1986, BRIT MED J, V292, P983, DOI 10.1136/bmj.292.6526.983; Rankinen T, 2006, ANNU REV NUTR, V26, P413, DOI 10.1146/annurev.nutr.26.061505.111218; Reed DR, 1997, BEHAV GENET, V27, P373, DOI 10.1023/A:1025692031673; Rodgers RJ, 2002, NEUROPEPTIDES, V36, P303, DOI 10.1016/S0143-4179(02)00085-9; Sahly I, 1998, HUM MOL GENET, V7, P1437, DOI 10.1093/hmg/7.9.1437; Santagata S, 2001, SCIENCE, V292, P2041, DOI 10.1126/science.1061233; Shiri-Sverdlov R, 2006, DIABETES, V55, P385, DOI 10.2337/diabetes.55.02.06.db05-0997; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Stubdal H, 2000, MOL CELL BIOL, V20, P878, DOI 10.1128/MCB.20.3.878-882.2000; Wang Y, 2006, PHYSL GENOMICS; Willett W, 2001, EAT DRINK BE HLTH HA; Williams G, 2000, P NUTR SOC, V59, P385, DOI 10.1017/S0029665100000434; Wynne K, 2005, J ENDOCRINOL, V184, P291, DOI 10.1677/joe.1.05866	48	19	20	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2008	3	1							e1405	10.1371/journal.pone.0001405	http://dx.doi.org/10.1371/journal.pone.0001405			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366GT	18183286	Green Submitted, Green Published, gold			2022-12-25	WOS:000260469400002
J	Chappell, AE; Bunz, M; Smoll, E; Dong, H; Lytle, C; Barrett, KE; McCole, DF				Chappell, Alfred E.; Bunz, Michael; Smoll, Eric; Dong, Hui; Lytle, Christian; Barrett, Kim E.; McCole, Declan F.			Hydrogen peroxide inhibits Ca2+-dependent chloride secretion across colonic epithelial cells via distinct kinase signaling pathways and ion transport proteins	FASEB JOURNAL			English	Article						reactive oxygen species; PI3-kinase; MAP kinases; NKCC1	EPIDERMAL-GROWTH-FACTOR; INFLAMMATORY-BOWEL-DISEASE; K-CL COTRANSPORTER; REACTIVE OXYGEN METABOLITES; FACTOR RECEPTOR; ELECTROLYTE TRANSPORT; FREE-RADICALS; TYROSINE PHOSPHORYLATION; INTESTINAL PERMEABILITY; ULCERATIVE-COLITIS	Reactive oxygen species (ROS) are key mediators in a number of inflammatory conditions, including inflammatory bowel disease (IBD). ROS, including hydrogen peroxide (H2O2), modulate intestinal epithelial ion transport and are believed to contribute to IBD-associated diarrhea. Intestinal crypt fluid secretion, driven by electrogenic Cl- secretion, hydrates and sterilizes the crypt, thus reducing bacterial adherence. Here, we show that pathophysiological concentrations of H2O2 inhibit Ca2+-dependent Cl- secretion across T-84 colonic epithelial cells by elevating cytosolic Ca2+, which contributes to activation of two distinct signaling pathways. One involves recruitment of the Ca2+-responsive kinases, Src and Pyk-2, as well as extracellular signal-regulated kinase (ERK). A separate pathway recruits p38 MAP kinase and phosphoinositide 3-kinase (PI3-K) signaling. The ion transport response to Ca2+-dependent stimuli is mediated in part by K+ efflux through basolateral K+ channels and Cl- uptake by the Na+-K+-2Cl(-) cotransporter, NKCC1. We demonstrate that H2O2 inhibits Ca2+-dependent basolateral K+ efflux and also inhibits NKCC1 activity independently of inhibitory effects on apical Cl- conductance. Thus, we have demonstrated that H2O2 inhibits Ca2+-dependent Cl- secretion through multiple negative regulatory signaling pathways and inhibition of specific ion transporters. These findings increase our understanding of mechanisms by which inflammation disturbs intestinal epithelial function and contributes to intestinal pathophysiology.	[Chappell, Alfred E.; Bunz, Michael; Smoll, Eric; Dong, Hui; Barrett, Kim E.; McCole, Declan F.] Univ Calif San Diego, Dept Med, Div Gastroenterol, Sch Med, La Jolla, CA 92093 USA; [Lytle, Christian] Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA	University of California System; University of California San Diego; University of California System; University of California Riverside	McCole, DF (corresponding author), Univ Calif San Diego, Dept Med, Div Gastroenterol, Sch Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	dmccole@ucsd.edu	McCole, Declan/AAL-2454-2020; Lytle, Christian/X-2836-2019; Barrett, Kim Elaine/AAE-7762-2019; Barrett, Kim/AAE-2794-2022	Lytle, Christian/0000-0001-5442-1546; Barrett, Kim Elaine/0000-0002-6704-998X; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028305, T32DK007202] Funding Source: NIH RePORTER; NIDDK NIH HHS [T32 DK007202, DK-28305, R01 DK028305] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUGERON C, 1984, CANCER RES, V44, P3961; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Banan A, 2000, FREE RADICAL BIO MED, V28, P727, DOI 10.1016/S0891-5849(00)00160-X; Barrett KE, 2000, ANNU REV PHYSIOL, V62, P535, DOI 10.1146/annurev.physiol.62.1.535; Basuroy S, 2006, BIOCHEM J, V393, P69, DOI 10.1042/BJ20050959; CARTWRIGHT CA, 1985, J CLIN INVEST, V76, P1837, DOI 10.1172/JCI112176; Choudhary S, 2001, DIGEST DIS SCI, V46, P2222, DOI 10.1023/A:1011975218006; Conner EM, 1996, NUTRITION, V12, P274, DOI 10.1016/S0899-9007(96)00000-8; Cooke HJ, 1998, NEWS PHYSIOL SCI, V13, P269; Darman RB, 2002, J BIOL CHEM, V277, P37542, DOI 10.1074/jbc.M206293200; Del Castillo IC, 2005, AM J PHYSIOL-CELL PH, V289, pC1332, DOI 10.1152/ajpcell.00580.2004; DHARMSATHAPHORN K, 1986, J CLIN INVEST, V77, P348, DOI 10.1172/JCI112311; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Dong H, 2005, AM J PHYSIOL-GASTR L, V288, pG457, DOI 10.1152/ajpgi.00381.2004; Dowd BFX, 2003, J BIOL CHEM, V278, P27347, DOI 10.1074/jbc.M301899200; Duvall MD, 1998, AM J PHYSIOL-CELL PH, V275, pC1313, DOI 10.1152/ajpcell.1998.275.5.C1313; Forsyth CB, 2007, J PHARMACOL EXP THER, V321, P84, DOI 10.1124/jpet.106.113019; GAGINELLA TS, 1995, GASTROENTEROLOGY, V109, P2019, DOI 10.1016/0016-5085(95)90772-6; Gassler N, 2001, AM J PHYSIOL-GASTR L, V281, pG216, DOI 10.1152/ajpgi.2001.281.1.G216; Gonzalez A, 2006, NEUROCHEM RES, V31, P741, DOI 10.1007/s11064-006-9078-y; Granados MP, 2006, BIOCHEM CELL BIOL, V84, P39, DOI 10.1139/O05-150; Greig E, 2000, ANN NY ACAD SCI, V915, P327; GRISHAM MB, 1994, LANCET, V344, P859, DOI 10.1016/S0140-6736(94)92831-2; GRISHAM MB, 1990, INFLAMMATION, V14, P531, DOI 10.1007/BF00914274; GRISHAM MB, 1992, ANN NY ACAD SCI, V664, P103, DOI 10.1111/j.1749-6632.1992.tb39753.x; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HARRIS ML, 1992, PHARMACOL THERAPEUT, V53, P375, DOI 10.1016/0163-7258(92)90057-7; Hirota CL, 2006, BRIT J PHARMACOL, V149, P463, DOI 10.1038/sj.bjp.0706889; Holmes EW, 1998, DIGEST DIS SCI, V43, P1088, DOI 10.1023/A:1018899222258; KACHUR JF, 1995, INFLAMMATION, V19, P245, DOI 10.1007/BF01534465; KACHUR JF, 1995, INFLAMMATION, V19, P717, DOI 10.1007/BF01534574; KARAYALCIN SS, 1990, J CLIN INVEST, V86, P60, DOI 10.1172/JCI114715; KEELY SJ, 1995, EUR J PHARMACOL, V279, P203, DOI 10.1016/0014-2999(95)00156-F; Keely SJ, 1998, J BIOL CHEM, V273, P27111, DOI 10.1074/jbc.273.42.27111; Keely SJ, 2003, AM J PHYSIOL-CELL PH, V284, pC339, DOI 10.1152/ajpcell.00144.2002; Keely SJ, 2000, J BIOL CHEM, V275, P12619, DOI 10.1074/jbc.275.17.12619; KESHAVARZIAN A, 1992, DIGEST DIS SCI, V37, P1866; Kim YM, 2007, J PROTEOME RES, V6, P593, DOI 10.1021/pr060326s; KLEBANOFF SJ, 1992, INFLAMMATION BASIC P, P541; Kruidenier L, 2003, J PATHOL, V201, P17, DOI 10.1002/path.1408; LihBrody L, 1996, DIGEST DIS SCI, V41, P2078, DOI 10.1007/BF02093613; Lytle C, 1996, AM J PHYSIOL-CELL PH, V270, pC437, DOI 10.1152/ajpcell.1996.270.2.C437; Lytle C, 1997, J BIOL CHEM, V272, P15069, DOI 10.1074/jbc.272.24.15069; MATTHEWS JB, 1992, J CLIN INVEST, V90, P1608, DOI 10.1172/JCI116030; McCole DF, 2007, J BIOL CHEM, V282, P13303, DOI 10.1074/jbc.M700424200; McCole DF, 1997, BIOCHEM PHARMACOL, V54, P1133, DOI 10.1016/S0006-2952(97)00266-9; McCole DF, 2005, GASTROENTEROLOGY, V129, P591, DOI 10.1053/j.gastro.2005.06.004; McCole DF, 2002, J BIOL CHEM, V277, P42603, DOI 10.1074/jbc.M206487200; NGUYEN TD, 1994, BIOCHEM PHARMACOL, V47, P403, DOI 10.1016/0006-2952(94)90032-9; Ohashi T, 2006, J PHARMACOL EXP THER, V318, P296, DOI 10.1124/jpet.106.102541; OWEN NE, 1985, J BIOL CHEM, V260, P1445; Oz HS, 2005, J NUTR BIOCHEM, V16, P297, DOI 10.1016/j.jnutbio.2004.09.007; Pavlick KP, 2002, FREE RADICAL BIO MED, V33, P311, DOI 10.1016/S0891-5849(02)00853-5; PAYNE JA, 1995, J BIOL CHEM, V270, P17977, DOI 10.1074/jbc.270.30.17977; Perez A, 2007, AM J PHYSIOL-LUNG C, V292, pL383, DOI 10.1152/ajplung.00403.2005; RADI R, 1991, J BIOL CHEM, V266, P4244; Rao R, 1999, BIOCHEM PHARMACOL, V57, P685, DOI 10.1016/S0006-2952(98)00333-5; Resta-Lenert S, 2002, GASTROENTEROLOGY, V122, P1070, DOI 10.1053/gast.2002.32372; REYNOLDS A, J PHYSL, V582, P507; SANDLE GI, 1990, GASTROENTEROLOGY, V99, P97, DOI 10.1016/0016-5085(90)91235-X; Schmitz H, 2000, ANN NY ACAD SCI, V915, P312; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Shiratsuchi H, 2005, AM J PHYSIOL-CELL PH, V288, pC1083, DOI 10.1152/ajpcell.00543.2004; Smith AJ, 2006, FASEB J, V20, P2486, DOI 10.1096/fj.06-6391com; Soderholm JD, 2002, GUT, V50, P307, DOI 10.1136/gut.50.3.307; TAMAI H, 1991, J PHARMACOL EXP THER, V257, P887; TAMAI H, 1992, J CLIN INVEST, V89, P301, DOI 10.1172/JCI115576; TEST ST, 1984, J BIOL CHEM, V259, P399; Uribe JM, 1996, AM J PHYSIOL-CELL PH, V271, pC914, DOI 10.1152/ajpcell.1996.271.3.C914; Uribe JM, 1996, J BIOL CHEM, V271, P26588, DOI 10.1074/jbc.271.43.26588; VENGLARIK CJ, 1990, AM J PHYSIOL, V259, pC358; Walker J, 2003, AM J PHYSIOL-GASTR L, V285, pG850, DOI 10.1152/ajpgi.00077.2003; WATSON AJM, 1994, GUT, V35, P1575, DOI 10.1136/gut.35.11.1575; WEYMER A, 1985, J CLIN INVEST, V76, P1828, DOI 10.1172/JCI112175; Zheng Y, 2005, REDOX REP, V10, P29, DOI 10.1179/135100005X21660	75	14	14	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					2023	2036		10.1096/fj.07-099697	http://dx.doi.org/10.1096/fj.07-099697			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18211955	Green Accepted			2022-12-25	WOS:000256352700041
J	Chew, EH; Lu, J; Bradshaw, TD; Holmgren, A				Chew, Eng-Hui; Lu, Jun; Bradshaw, Tracey D.; Holmgren, Arne			Thioredoxin reductase inhibition by antitumor quinols: a quinol pharmacophore effect correlating to antiproliferative activity	FASEB JOURNAL			English	Article						Michael acceptors; anticancer agents; antitumor mechanism of action; selenocysteine	EARLY EMBRYONIC LETHALITY; MAMMALIAN THIOREDOXIN; GLUTATHIONE-REDUCTASE; ANTICANCER ACTIVITY; THERAPEUTIC AGENTS; INDUCED APOPTOSIS; ESCHERICHIA-COLI; LUNG-CARCINOMA; CANCER-THERAPY; HUMAN PLACENTA	Novel heteroaromatic-substituted 4-hydroxycyclohexa2,5-dienones (quinols) demonstrate potent in vitro antiproliferative activity and in vivo antitumor activity in tumor xenografts. The mechanism of action of these promising novel anticancer agents, however, remains to be fully elucidated. The thioredoxin (Trx) system comprising Trx, thioredoxin reductase (TrxR), and NADPH participates in a broad range of cellular functions involved in cell survival and proliferation. Accumulating evidence has indicated that the selenocysteine-containing mammalian TrxR is a valid molecular target for development of novel cancer therapeutics. In this study, we demonstrate that structural analogs containing a quinol pharmacophore inhibited TrxR with potencies correlated with their antiproliferative and cytotoxic efficacies. Benzenesulfonyl-6F-indole-substituted quinol (compound 6) irreversibly inhibited TrxR most strongly with a half-maximal inhibitory concentration of 2.7 mu M after 1 h of incubation with recombinant rat TrxR. The inhibition was shown to be concentration-, time-, and NADPH-dependent and mediated through a direct quinol attack on the penultimate C-terminal selenocysteine residue. Moreover, TrxR activity in lysates of HCT 116 cells treated with apoptosis-inducing doses of quinols was significantly reduced. From the results obtained, we propose that TrxR inhibition is a critical cellular event that contributes to the proapoptotic effects of quinols.	[Chew, Eng-Hui; Lu, Jun; Holmgren, Arne] Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, SE-17177 Stockholm, Sweden; [Bradshaw, Tracey D.] Univ Nottingham, Sch Pharm, Ctr Biomol Sci, Nottingham NG7 2RD, England	Karolinska Institutet; University of Nottingham	Holmgren, A (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, SE-17177 Stockholm, Sweden.	arne.holmgren@ki.se	Chew, Eng Hui/D-8975-2016; Lu, Jun/E-9701-2017	Chew, Eng Hui/0000-0002-2615-8987; Lu, Jun/0000-0002-1699-8835				Anestal K, 2003, J BIOL CHEM, V278, P15966, DOI 10.1074/jbc.M210733200; Arner ESJ, 2006, SEMIN CANCER BIOL, V16, P420, DOI 10.1016/j.semcancer.2006.10.009; ARNER ES, 2000, CURRENT PROTOCOLS S, V5, DOI UNSP 7.4.1-7.4.14; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Arner ESJ, 1999, J MOL BIOL, V292, P1003, DOI 10.1006/jmbi.1999.3085; Arscott LD, 1997, P NATL ACAD SCI USA, V94, P3621, DOI 10.1073/pnas.94.8.3621; Becker K, 2001, J MED CHEM, V44, P2784, DOI 10.1021/jm001014i; Berggren M, 1996, ANTICANCER RES, V16, P3459; Berry JM, 2005, J MED CHEM, V48, P639, DOI 10.1021/jm040859h; Biterova EI, 2005, P NATL ACAD SCI USA, V102, P15018, DOI 10.1073/pnas.0504218102; BOYD MR, 1995, DRUG DEVELOP RES, V34, P91, DOI 10.1002/ddr.430340203; Bradshaw TD, 2005, CANCER RES, V65, P3911, DOI 10.1158/0008-5472.CAN-04-4141; Cassidy PB, 2006, CARCINOGENESIS, V27, P2538, DOI 10.1093/carcin/bgl111; Cenas N, 2004, J BIOL CHEM, V279, P2583, DOI 10.1074/jbc.M310292200; Chew EH, 2006, BIOCHEM BIOPH RES CO, V346, P242, DOI 10.1016/j.bbrc.2006.05.106; Conrad M, 2004, MOL CELL BIOL, V24, P9414, DOI 10.1128/MCB.24.21.9414-9423.2004; Davis W, 2001, J PHARMACOL EXP THER, V296, P1; Dinkova-Kostova AT, 2001, P NATL ACAD SCI USA, V98, P3404, DOI 10.1073/pnas.051632198; Fang JG, 2005, J BIOL CHEM, V280, P25284, DOI 10.1074/jbc.M414645200; Fritz-Wolf K, 2007, J MOL BIOL, V370, P116, DOI 10.1016/j.jmb.2007.04.044; GASDASKA PY, 1995, FEBS LETT, V373, P5, DOI 10.1016/0014-5793(95)01003-W; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Gorlatov SN, 1998, P NATL ACAD SCI USA, V95, P8520, DOI 10.1073/pnas.95.15.8520; Gromer S, 2004, MED RES REV, V24, P40, DOI 10.1002/med.10051; Gromer S, 1998, J BIOL CHEM, V273, P20096, DOI 10.1074/jbc.273.32.20096; Gromer S, 1998, BIOCHEM J, V332, P591, DOI 10.1042/bj3320591; Hashemy SI, 2006, J BIOL CHEM, V281, P10691, DOI 10.1074/jbc.M511373200; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; Jakupoglu C, 2005, MOL CELL BIOL, V25, P1980, DOI 10.1128/MCB.25.5.1980-1988.2005; Kahlos K, 2001, INT J CANCER, V95, P198, DOI 10.1002/1097-0215(20010520)95:3<198::AID-IJC1034>3.0.CO;2-F; Kim SJ, 2005, CLIN CANCER RES, V11, P8425, DOI 10.1158/1078-0432.CCR-05-0449; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Lee SR, 2000, P NATL ACAD SCI USA, V97, P2521, DOI 10.1073/pnas.050579797; Lillig CH, 2007, ANTIOXID REDOX SIGN, V9, P25, DOI 10.1089/ars.2007.9.25; Lion CJ, 2006, BIOORG MED CHEM LETT, V16, P5005, DOI 10.1016/j.bmcl.2006.07.072; Lu J, 2006, CANCER RES, V66, P4410, DOI 10.1158/0008-5472.CAN-05-3310; Lu J, 2007, P NATL ACAD SCI USA, V104, P12288, DOI 10.1073/pnas.0701549104; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; McCarroll AJ, 2007, J MED CHEM, V50, P1707, DOI 10.1021/jm061163m; Nonn L, 2003, MOL CELL BIOL, V23, P916, DOI 10.1128/MCB.23.3.916-922.2003; Novoselov SV, 2003, PROTEIN SCI, V12, P372, DOI 10.1110/ps.0226503; Raffel J, 2003, J LAB CLIN MED, V142, P46, DOI 10.1016/S0022-2143(03)00068-4; REN XL, 1993, BIOCHEMISTRY-US, V32, P9701, DOI 10.1021/bi00088a023; ROZELL B, 1985, EUR J CELL BIOL, V38, P79; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sandalova T, 2001, P NATL ACAD SCI USA, V98, P9533, DOI 10.1073/pnas.171178698; Soini Y, 2001, CLIN CANCER RES, V7, P1750; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Sun QA, 2001, P NATL ACAD SCI USA, V98, P3673, DOI 10.1073/pnas.051454398; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; Urig S, 2006, SEMIN CANCER BIOL, V16, P452, DOI 10.1016/j.semcancer.2006.09.004; Papp LV, 2007, ANTIOXID REDOX SIGN, V9, P775, DOI 10.1089/ars.2007.1528; Wang XF, 2007, TOXICOL APPL PHARM, V218, P88, DOI 10.1016/j.taap.2006.10.029; Wells G, 2003, J MED CHEM, V46, P532, DOI 10.1021/jm020984y; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; Witte AB, 2005, FREE RADICAL BIO MED, V39, P696, DOI 10.1016/j.freeradbiomed.2005.04.025; Yoo MH, 2006, J BIOL CHEM, V281, P13005, DOI 10.1074/jbc.C600012200; Zhon LW, 1998, J BIOL CHEM, V273, P8581, DOI 10.1074/jbc.273.15.8581; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897; Zhong LW, 2000, J BIOL CHEM, V275, P18121, DOI 10.1074/jbc.M000690200	61	48	51	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					2072	2083		10.1096/fj.07-101477	http://dx.doi.org/10.1096/fj.07-101477			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18180330				2022-12-25	WOS:000256352700046
J	Sanders, RJ; Ofman, R; Dacremont, G; Wanders, RJA; Kemp, S				Sanders, Robert-Jan; Ofman, Rob; Dacremont, Georges; Wanders, Ronald J. A.; Kemp, Stephan			Characterization of the human omega-oxidation pathway for omega-hydroxy-very-long-chain fatty acids	FASEB JOURNAL			English	Article						X-linked adrenoleukodystrophy; cytochrome P450; Sjogren-Larson syndrome; ALDH3A2	X-LINKED ADRENOLEUKODYSTROPHY; SJOGREN-LARSSON-SYNDROME; ALDEHYDE DEHYDROGENASE; RAT-LIVER; GENE; FAMILY; IDENTIFICATION; OXIDOREDUCTASE; LOCALIZATION; FIBROBLASTS	Very-long-chain fatty acids (VLCFAs) have long been known to be degraded exclusively in peroxisomes via beta-oxidation. A defect in peroxisomal beta-oxidation results in elevated levels of VLCFAs and is associated with the most frequent inherited disorder of the central nervous system white matter, X-linked adrenoleukodystrophy. Recently, we demonstrated that VLCFAs can also undergo omega-oxidation, which may provide an alternative route for the breakdown of VLCFAs. The omega-oxidation of VLCFA is initiated by CYP4F2 and CYP4F3B, which produce omega-hydroxy-VLCFAs. In this article, we characterized the enzymes involved in the formation of very-long-chain dicarboxylic acids from omega-hydroxy-VLCFAs. We demonstrate that very-long-chain dicarboxylic acids are produced via two independent pathways. The first is mediated by an as yet unidentified, microsomal NAD(+)-dependent alcohol dehydrogenase and fatty aldehyde dehydrogenase, which is encoded by the ALDH3A2 gene and is deficient in patients with Sjogren-Larsson syndrome. The second pathway involves the NADPH-dependent hydroxylation of omega-hydroxy-VLCFAs by CYP4F2, CYP4F3B, or CYP4F3A. Enzyme kinetic studies show that oxidation of omega-hydroxy-VLCFAs occurs predominantly via the NAD(+)-dependent route. Overall, our data demonstrate that in humans all enzymes are present for the complete conversion of VLCFAs to their corresponding very-long-chain dicarboxylic acids.	[Sanders, Robert-Jan; Ofman, Rob; Wanders, Ronald J. A.; Kemp, Stephan] Univ Amsterdam, Acad Med Ctr, Lab Genet Metab Dis, Dept Pediat,Emma Childrens Hosp & Clin Chem, NL-1105 AZ Amsterdam, Netherlands; [Dacremont, Georges] Univ Ghent, Dept Pediat, B-9000 Ghent, Belgium	Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Ghent University	Kemp, S (corresponding author), Univ Amsterdam, Acad Med Ctr, Lab Genet Metab Dis, Dept Pediat,Emma Childrens Hosp & Clin Chem, Room F0-224,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	s.kemp@amc.uva.nl	Kemp, Stephan/A-3935-2008	Kemp, Stephan/0000-0003-2023-064X				Bezman L, 2001, ANN NEUROL, V49, P512, DOI 10.1002/ana.101; DeLaurenzi V, 1996, NAT GENET, V12, P52; Doerflinger N, 1998, HUM GENE THER, V9, P1025, DOI 10.1089/hum.1998.9.7-1025; Dubois-Dalcq M, 1999, TRENDS NEUROSCI, V22, P4, DOI 10.1016/S0166-2236(98)01319-8; Ferdinandusse S, 2004, J LIPID RES, V45, P1104, DOI 10.1194/jlr.M300512-JLR200; Fouquet F, 1997, NEUROBIOL DIS, V3, P271, DOI 10.1006/nbdi.1997.0127; HO JK, 1995, J CLIN INVEST, V96, P1455, DOI 10.1172/JCI118182; HSU LC, 1994, GENE, V151, P285, DOI 10.1016/0378-1119(94)90672-6; HSU LC, 1995, ADV EXP MED BIOL, V372, P159; Hsu MH, 2007, J BIOL CHEM, V282, P5225, DOI 10.1074/jbc.M608176200; Jansen GA, 1999, BBA-MOL CELL BIOL L, V1440, P176, DOI 10.1016/S1388-1981(99)00126-2; Kelson TL, 1997, BBA-GEN SUBJECTS, V1335, P99, DOI 10.1016/S0304-4165(96)00126-2; Kemp S, 1998, NAT MED, V4, P1261, DOI 10.1038/3242; KUNDU RK, 1991, J CLIN INVEST, V88, P1865, DOI 10.1172/JCI115508; LEE T, 1979, J BIOL CHEM, V254, P2892; LINDAHL R, 1979, BIOCHEM J, V183, P55, DOI 10.1042/bj1830055; Moser H., 2001, METABOLIC MOL BASES, VII, P3257; MOSER HW, 1981, NEUROLOGY, V31, P1241, DOI 10.1212/WNL.31.10.1241; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; Nguyen X, 1999, AM J PHYSIOL-REG I, V276, pR1691; Peters C, 2004, BLOOD, V104, P881, DOI 10.1182/blood-2003-10-3402; RIZZO WB, 1991, J CLIN INVEST, V88, P1643, DOI 10.1172/JCI115478; RIZZO WB, 1989, NEUROLOGY, V39, P1415, DOI 10.1212/WNL.39.11.1415; ROBBINS KC, 1968, ARCH BIOCHEM BIOPHYS, V123, P531, DOI 10.1016/0003-9861(68)90174-4; ROCCHICCIOLI F, 1986, PEDIATR RES, V20, P62, DOI 10.1203/00006450-198601000-00018; Sanders RJ, 2006, J BIOL CHEM, V281, P13180, DOI 10.1074/jbc.M513481200; Sanders RJ, 2005, J LIPID RES, V46, P1001, DOI 10.1194/jlr.M400510-JLR200; SINGH I, 1984, PEDIATR RES, V18, P286, DOI 10.1203/00006450-198403000-00016; Singh I, 1998, NEW ENGL J MED, V339, P702, DOI 10.1056/NEJM199809033391012; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Valianpour F, 2003, MOL GENET METAB, V79, P189, DOI 10.1016/S1096-7192(03)00098-2; Vasiliou Vasilis, 2005, Human Genomics, V2, P138; WAKABAYASHI K, 1963, BIOCHIM BIOPHYS ACTA, V70, P132, DOI 10.1016/0006-3002(63)90733-9; Wanders RJA, 1998, MOL ASPECTS MED, V19, P71, DOI 10.1016/S0098-2997(98)00003-X; Wanders RJA, 2004, MOL GENET METAB, V83, P16, DOI 10.1016/j.ymgme.2004.08.016; Wanders RJA, 2007, PFLUG ARCH EUR J PHY, V453, P719, DOI 10.1007/s00424-006-0142-x; Willemsen MAAP, 2001, BRAIN, V124, P1426, DOI 10.1093/brain/124.7.1426; WOLVETANG EJ, 1990, BIOCHIM BIOPHYS ACTA, V1035, P6, DOI 10.1016/0304-4165(90)90166-T; Xu FY, 2004, J PHARMACOL EXP THER, V308, P887, DOI 10.1124/jpet.103.059626; ZORZANO A, 1990, GEN PHARMACOL, V21, P697, DOI 10.1016/0306-3623(90)91020-R	40	39	50	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					2064	2071		10.1096/fj.07-099150	http://dx.doi.org/10.1096/fj.07-099150			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18182499	Green Published			2022-12-25	WOS:000256352700045
J	Bogunovic, B; Stojakovic, M; Chen, L; Maric, M				Bogunovic, Branka; Stojakovic, Milica; Chen, Leonard; Maric, Maja			An unexpected functional link between lysosomal thiol reductase and mitochondrial manganese superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MNSOD GENE-EXPRESSION; NF-KAPPA-B; OXIDATIVE STRESS; DILATED CARDIOMYOPATHY; ANTIOXIDANT ENZYMES; HYDROGEN-PEROXIDE; REDOX REGULATION; DISULFIDE BONDS; DEFICIENT MICE; CELL-GROWTH	Gamma interferon-inducible thiol reductase ( GILT) is an enzyme involved in the initial steps of antigen processing and presentation. Recently we have shown that GILT is also expressed in mouse T cells, where it exerts an inhibitory role on T cell activation. In this study, we identified mitochondrial manganese superoxide dismutase (SOD2) as one of the key intermediaries affected by GILT expression in fibroblasts. Expression and activity of SOD2 is reduced in the absence of GILT because of reduced SOD2 protein stability. The forced increase in SOD2 expression in the absence of GILT restores fibroblast proliferation to wild-type levels. Thus, GILT appears to have a fundamental role in cellular proliferation mediated through its influence on SOD2 protein activity and expression.	[Bogunovic, Branka; Chen, Leonard; Maric, Maja] Georgetown Univ, Dept Microbiol & Immunol, Med Ctr, Washington, DC 20057 USA; [Stojakovic, Milica] Childrens Natl Med Ctr, Childrens Res Inst, Ctr Canc & Immunol Res, Washington, DC 20010 USA	Georgetown University; Children's National Health System	Maric, M (corresponding author), Georgetown Univ, Dept Microbiol & Immunol, Med Ctr, 3900 Reservoir Rd NW,Med Dent C301, Washington, DC 20057 USA.	mam254@georgetown.edu						ALLEN RG, 1991, P SOC EXP BIOL MED, V196, P117; Aquilano K, 2006, FASEB J, V20, P1683, DOI 10.1096/fj.05-5225fje; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Arunachalam B, 2000, P NATL ACAD SCI USA, V97, P745, DOI 10.1073/pnas.97.2.745; Arunachalam B, 1998, J IMMUNOL, V160, P5797; Barjaktarevic I, 2006, J IMMUNOL, V177, P4369, DOI 10.4049/jimmunol.177.7.4369; BASS DA, 1983, J IMMUNOL, V130, P1910; Bickerstaff AA, 2000, J IMMUNOL, V164, P5132, DOI 10.4049/jimmunol.164.10.5132; BIZE IB, 1980, CANCER RES, V40, P3686; Bravard A, 1999, FREE RADICAL BIO MED, V26, P1027, DOI 10.1016/S0891-5849(98)00299-8; Bravard A, 2002, CARCINOGENESIS, V23, P705, DOI 10.1093/carcin/23.5.705; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Cho HY, 2006, ANTIOXID REDOX SIGN, V8, P76, DOI 10.1089/ars.2006.8.76; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; DAS KC, 1995, MOL CELL BIOCHEM, V148, P45, DOI 10.1007/BF00929502; DAS KC, 1995, AM J PHYSIOL-LUNG C, V269, pL588, DOI 10.1152/ajplung.1995.269.5.L588; Dhar SK, 2004, J BIOL CHEM, V279, P28209, DOI 10.1074/jbc.M403553200; Duttaroy A, 2003, GENETICS, V165, P2295; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Friedman JS, 2001, J EXP MED, V193, P925, DOI 10.1084/jem.193.8.925; Gilbert DL, 1999, REACTIVE OXYGEN SPEC, P138; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Halliwell B., 2007, FREE RADICALS BIOL M; Hernandez-Saavedra D, 2003, CANCER RES, V63, P159; Huang TT, 2001, FREE RADICAL BIO MED, V31, P1101, DOI 10.1016/S0891-5849(01)00694-3; Huang TT, 1997, ARCH BIOCHEM BIOPHYS, V344, P424, DOI 10.1006/abbi.1997.0237; Jackson SH, 2004, NAT IMMUNOL, V5, P818, DOI 10.1038/ni1096; Keller T, 2003, NITRIC OXIDE-BIOL CH, V9, P183, DOI 10.1016/j.niox.2004.01.003; Laurent A, 2005, CANCER RES, V65, P948; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; Li SJ, 2000, CANCER RES, V60, P3927; Li W, 2004, AM J PHYSIOL-HEART C, V286, pH47, DOI 10.1152/ajpheart.00730.2003; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; LUNDSTROMLJUNG J, 1998, PROLYL HYDROXYLASE P, P297; LUSTER AD, 1988, J BIOL CHEM, V263, P12036; Maric M, 2001, SCIENCE, V294, P1361, DOI 10.1126/science.1065500; MEISLER AI, 1973, J CELL SCI, V12, P847; Mukhopadhyay S, 2004, J BIOMED BIOTECHNOL, P195, DOI 10.1155/S1110724304401016; OBERLEY LW, 1988, MOL CELL BIOCHEM, V84, P147, DOI 10.1007/BF00421049; Patenaude A, 2004, J BIOL CHEM, V279, P27302, DOI 10.1074/jbc.M402496200; Phan UT, 2000, J BIOL CHEM, V275, P25907, DOI 10.1074/jbc.M003459200; Rahimi F, 2005, FEBS J, V272, P2811, DOI 10.1111/j.1742-4658.2005.04703.x; Raina S, 1997, ANNU REV MICROBIOL, V51, P179, DOI 10.1146/annurev.micro.51.1.179; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; Roos G, 2007, J MOL BIOL, V368, P800, DOI 10.1016/j.jmb.2007.02.045; Samper E, 2003, AGING CELL, V2, P277, DOI 10.1046/j.1474-9728.2003.00062.x; Scarpulla RC, 2002, BBA-GENE STRUCT EXPR, V1576, P1, DOI 10.1016/S0167-4781(02)00343-3; Scorziello A, 2007, J NEUROCHEM, V103, P1472, DOI 10.1111/j.1471-4159.2007.04845.x; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; Tarpey MM, 2001, CIRC RES, V89, P224, DOI 10.1161/hh1501.094365; Van Remmen H, 2001, AM J PHYSIOL-HEART C, V281, pH1422, DOI 10.1152/ajpheart.2001.281.3.H1422; Zhao HT, 2003, FREE RADICAL BIO MED, V34, P1359, DOI 10.1016/S0891-5849(03)00142-4	55	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					8855	8862		10.1074/jbc.M708998200	http://dx.doi.org/10.1074/jbc.M708998200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18218638	hybrid			2022-12-25	WOS:000254465800012
J	Kaiserova, K; Tang, XL; Srivastava, S; Bhatnagar, A				Kaiserova, Karin; Tang, Xian-Liang; Srivastava, Sanjay; Bhatnagar, Aruni			Role of nitric oxide in regulating aldose reductase activation in the ischemic heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SULFENIC ACIDS; SMOOTH-MUSCLE-CELLS; REPERFUSION INJURY; MYOCARDIAL-CONTRACTILITY; S-NITROSYLATION; MOUSE HEART; LATE-PHASE; RAT-HEART; PEROXYNITRITE; AKT	Aldose reductase (AR) catalyzes the reduction of several aldehydes ranging from lipid peroxidation products to glucose. The activity of AR is increased in the ischemic heart due to oxidation of its cysteine residues, but the underlying mechanisms remain unclear. To examine signaling mechanisms regulating AR activation, we studied the role of nitric oxide ( NO). Treatment with the NO synthase ( NOS) inhibitor, N-nitro-L-arginine methyl ester prevented ischemia-induced AR activation and myocardial sorbitol accumulation in rat hearts subjected to global ischemia ex vivo or coronary ligation in situ, whereas inhibition of inducible NOS and neuronal NOS had no effect. Activation of AR in the ischemic heart was abolished by pretreatment with peroxynitrite scavengers hesperetin or 5, 10, 15, 20-tetrakis-[4-sulfonatophenyl]- porphyrinato-iron [III]. Site-directed mutagenesis and electrospray ionization mass spectrometry analyses showed that Cys-298 of AR was readily oxidized to sulfenic acid by peroxynitrite. Treatment with bradykinin and insulin led to a phosphatidylinositol 3-kinase ( PI3K)- dependent increase in the phosphorylation of endothelial NOS at Ser-1177 and, even in the absence of ischemia, was sufficient in activating AR. Activation of AR by bradykinin and insulin was reversed upon reduction with dithiothreitol or by inhibiting NOS or PI3K. Treatment with AR inhibitors sorbinil or tolrestat reduced post-ischemic recovery in the rat hearts subjected to global ischemia and increased the infarct size when given before ischemia or upon reperfusion. These results suggest that AR is a cardioprotective protein and that its activation in the ischemic heart is due to peroxynitrite-mediated oxidation of Cys-298 to sulfenic acid via the PI3K/Akt/endothelial NOS pathway.	[Kaiserova, Karin; Tang, Xian-Liang; Srivastava, Sanjay; Bhatnagar, Aruni] Univ Louisville, Inst Mol Cardiol, Louisville, KY 40202 USA	University of Louisville	Bhatnagar, A (corresponding author), Univ Louisville, Inst Mol Cardiol, Louisville, KY 40202 USA.	aruni@louisville.edu	Srivastava, Sanjay/D-3921-2012; Tang, Xian-Liang/L-5703-2015		NHLBI NIH HHS [HL 59378, HL 65618, HL 78825, HL 55477] Funding Source: Medline; NIEHS NIH HHS [ES 11860, ES 11594] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL078825, R01HL065618, R01HL055477, R01HL059378] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011594, P01ES011860] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adachi T, 2004, NAT MED, V10, P1200, DOI 10.1038/nm1119; Becker LB, 1999, AM J PHYSIOL-HEART C, V277, pH2240, DOI 10.1152/ajpheart.1999.277.6.H2240; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Bell RM, 2003, J MOL CELL CARDIOL, V35, P185, DOI 10.1016/S0022-2828(02)00310-3; Berges A, 2007, PHARMACOL RES, V55, P72, DOI 10.1016/j.phrs.2006.10.008; BHATNAGAR A, 1992, BIOCHEM MED METAB B, V48, P91, DOI 10.1016/0885-4505(92)90055-4; BHATNAGAR A, 1990, BIOCHEM PHARMACOL, V39, P1115, DOI 10.1016/0006-2952(90)90292-S; BHATNAGAR A, 1995, J CARDIOVASC PHARM, V26, P343, DOI 10.1097/00005344-199509000-00001; Bolli R, 2000, CIRC RES, V87, P972, DOI 10.1161/01.RES.87.11.972; Chandra A, 1997, BBA-PROTEIN STRUCT M, V1341, P217, DOI 10.1016/S0167-4838(97)00084-8; Chandra A, 1997, BIOCHEMISTRY-US, V36, P15801, DOI 10.1021/bi9714722; Chandra D, 2002, DIABETES, V51, P3095, DOI 10.2337/diabetes.51.10.3095; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; DEMASTER EG, 1995, BIOCHEMISTRY-US, V34, P11494, DOI 10.1021/bi00036a023; Dierks T, 2005, CELL, V121, P541, DOI 10.1016/j.cell.2005.03.001; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dixit BL, 2000, J BIOL CHEM, V275, P21587, DOI 10.1074/jbc.M909235199; DOWNEY JM, 1990, ANNU REV PHYSIOL, V52, P487, DOI 10.1146/annurev.ph.52.030190.002415; Ferdinandy P, 2000, CIRC RES, V87, P241, DOI 10.1161/01.RES.87.3.241; Flesch M, 1999, J AM COLL CARDIOL, V33, P1062, DOI 10.1016/S0735-1097(98)00660-3; Folmes CDL, 2006, CIRC RES, V99, P61, DOI 10.1161/01.RES.0000229656.05244.11; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Gao F, 2002, CIRCULATION, V105, P1497, DOI 10.1161/01.CIR.0000012529.00367.0F; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Hwang YC, 2001, FASEB J, V15, P243, DOI 10.1096/fj.01-0368fje; Hwang YYC, 2003, FASEB J, V17, P2331, DOI 10.1096/fj.03-0128fje; Ishii T, 1999, BIOCHEM PHARMACOL, V58, P133, DOI 10.1016/S0006-2952(99)00060-X; Iwata K, 2006, J PHARMACOL SCI, V102, P37, DOI 10.1254/jphs.FP0060218; JOHNSTON DL, 1991, CIRC RES, V68, P714, DOI 10.1161/01.RES.68.3.714; Kaiserova K, 2005, CIRCULATION, V112, pU337; Kaiserova K, 2006, J BIOL CHEM, V281, P15110, DOI 10.1074/jbc.M600837200; KLONER RA, 1989, CIRCULATION, V80, P1115, DOI 10.1161/01.CIR.80.5.1115; Kloner RA, 2001, CIRCULATION, V104, P3158, DOI 10.1161/hc5001.100039; Lancel S, 2004, J AM COLL CARDIOL, V43, P2348, DOI 10.1016/j.jacc.2004.01.047; Liu Q, 2002, J AM COLL CARDIOL, V39, P718, DOI 10.1016/S0735-1097(01)01803-4; Martinez-Ruiz A, 2004, CARDIOVASC RES, V62, P43, DOI 10.1016/j.cardiores.2004.01.013; Matsui T, 2001, CIRCULATION, V104, P330; Mungrue IN, 2002, J CLIN INVEST, V109, P735, DOI 10.1172/JCI200213265; Ng DTF, 1998, DIABETES, V47, P961, DOI 10.2337/diabetes.47.6.961; Node K, 1996, CIRCULATION, V93, P356, DOI 10.1161/01.CIR.93.2.356; Nossuli TO, 1997, CIRCULATION, V96, P2317; Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006; Percival MD, 1999, BIOCHEMISTRY-US, V38, P13574, DOI 10.1021/bi991028u; PETRASH JM, 1992, J BIOL CHEM, V267, P24833; Ping PP, 1999, AM J PHYSIOL-HEART C, V277, pH1771, DOI 10.1152/ajpheart.1999.277.5.H1771; Poole LB, 2004, ANNU REV PHARMACOL, V44, P325, DOI 10.1146/annurev.pharmtox.44.101802.121735; RADI R, 1991, J BIOL CHEM, V266, P4244; Ramana KV, 2000, BIOCHEMISTRY-US, V39, P12172, DOI 10.1021/bi000796e; Ramana KV, 2003, FASEB J, V17, P417, DOI 10.1096/fj.02-0722com; Ramasamy R, 1997, DIABETES, V46, P292, DOI 10.2337/diabetes.46.2.292; Ramasamy R, 1998, AM J PHYSIOL-HEART C, V275, pH195, DOI 10.1152/ajpheart.1998.275.1.H195; Rittner HL, 1999, J CLIN INVEST, V103, P1007, DOI 10.1172/JCI4711; ROCHETTE L, 1980, J CARDIOVASC PHARM, V2, P267, DOI 10.1097/00005344-198005000-00005; Sergeev P, 2004, ANESTHESIOLOGY, V100, P474, DOI 10.1097/00000542-200403000-00005; Shinmura K, 2002, CIRC RES, V91, P240, DOI 10.1161/01.RES.0000029970.97247.57; Spycher SE, 1997, FASEB J, V11, P181, DOI 10.1096/fasebj.11.2.9039961; Srivastava S, 1999, BIOCHEMISTRY-US, V38, P42, DOI 10.1021/bi981794l; Srivastava S, 2004, J BIOL CHEM, V279, P53395, DOI 10.1074/jbc.M403416200; Srivastava S, 2001, BIOCHEM J, V358, P111, DOI 10.1042/0264-6021:3580111; Srivastava S, 1998, J BIOL CHEM, V273, P10893, DOI 10.1074/jbc.273.18.10893; Srivastava SK, 2005, ENDOCR REV, V26, P380, DOI 10.1210/er.2004-0028; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Tracey WR, 2000, AM J PHYSIOL-HEART C, V279, pH1447, DOI 10.1152/ajpheart.2000.279.4.H1447; Ungvari Zoltan, 2005, Current Vascular Pharmacology, V3, P221, DOI 10.2174/1570161054368607; Vikramadithyan RK, 2005, J CLIN INVEST, V115, P2434, DOI 10.1172/JCI24819; Xie P, 2000, J BIOL CHEM, V275, P24907, DOI 10.1074/jbc.M001051200; Yang JC, 2000, CIRCULATION, V102, P3046	67	39	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9101	9112		10.1074/jbc.M709671200	http://dx.doi.org/10.1074/jbc.M709671200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18223294	Green Published, hybrid			2022-12-25	WOS:000254465800040
J	Chen, YD; Erickson, HP				Chen, Yaodong; Erickson, Harold P.			In vitro assembly studies of FtsZ/Tubulin-like proteins (TubZ) from Bacillus plasmids - Evidence for a capping mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THURINGIENSIS SUBSP ISRAELENSIS; DNA SEGREGATION; CELL-DIVISION; FTSZ; POLYMERIZATION; TUBULIN; PBTOXIS; CYTOSKELETON; REPLICATION; HYDROLYSIS	Proteins with a weak sequence similarity to tubulin and FtsZ are expressed from large plasmids of Bacillus anthracis and Bacillus thuringiensis and are probably involved in plasmid segregation. Previously designated RepX and TubZ, we designate them here as TubZ-Ba and TubZ-Bt. We have expressed and purified the proteins for in vitro studies. TubZ-Ba and TubZ-Bt share only 21% amino acid identity, but they have remarkably similar biochemical properties. They both assemble into two-stranded filaments and larger bundles above a critical concentration, and they hydrolyze GTP at a very high rate, similar to 20 GTP min(-1) TubZ(-1). Assembly is also supported by GTP gamma S. A tiny amount of GTP gamma S stabilizes polymers assembled in GTP and inhibits the GTPase by a mechanism involving cooperativity. The nucleotide in the polymers is almost 100% GDP, which is similar to microtubules but very different from the 20-30% GDP in FtsZ polymers. This suggests that the TubZ polymers have a capping mechanism that may be related to the GTP cap that produces dynamic instability of microtubules.	[Chen, Yaodong; Erickson, Harold P.] Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University	Erickson, HP (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA.	h.Erickson@cellbio.duke.edu	Chen, Yaodong/X-8923-2019; Chen, Yaodong/C-6138-2011	Chen, Yaodong/0000-0002-3751-0923	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066014] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM066014-06, R01 GM066014, GM 66014] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Becker E, 2006, EMBO J, V25, P5919, DOI 10.1038/sj.emboj.7601443; Berry C, 2002, APPL ENVIRON MICROB, V68, P5082, DOI 10.1128/AEM.68.10.5082-5095.2002; Bouet JY, 2007, MOL MICROBIOL, V63, P468, DOI 10.1111/j.1365-2958.2006.05537.x; Chen YD, 2005, J BIOL CHEM, V280, P22549, DOI 10.1074/jbc.M500895200; Chen YD, 2005, BIOPHYS J, V88, P505, DOI 10.1529/biophysj.104.044149; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Ebersbach G, 2006, MOL MICROBIOL, V61, P1428, DOI 10.1111/j.1365-2958.2006.05322.x; Erickson HP, 2007, BIOESSAYS, V29, P668, DOI 10.1002/bies.20601; ERICKSON HP, 1992, ANNU REV BIOPH BIOM, V21, P145, DOI 10.1146/annurev.bb.21.060192.001045; Garner EC, 2007, SCIENCE, V315, P1270, DOI 10.1126/science.1138527; Gerdes K, 2000, MOL MICROBIOL, V37, P455, DOI 10.1046/j.1365-2958.2000.01975.x; Gonzalez JM, 2003, J BIOL CHEM, V278, P37664, DOI 10.1074/jbc.M305230200; Ingerman E, 2005, METHOD ENZYMOL, V404, P611, DOI 10.1016/S0076-6879(05)04053-X; Larsen RA, 2007, GENE DEV, V21, P1340, DOI 10.1101/gad.1546107; Margolin W, 2007, CURR BIOL, V17, pR633, DOI 10.1016/j.cub.2007.06.020; Minton AP, 2005, J PHARM SCI-US, V94, P1668, DOI 10.1002/jps.20417; Minton AP, 2000, CURR OPIN STRUC BIOL, V10, P34, DOI 10.1016/S0959-440X(99)00045-7; Moller-Jensen J, 2003, MOL CELL, V12, P1477, DOI 10.1016/S1097-2765(03)00451-9; Romberg L, 2004, BIOCHEMISTRY-US, V43, P282, DOI 10.1021/bi035465r; Scheffers DJ, 2000, MOL MICROBIOL, V35, P1211, DOI 10.1046/j.1365-2958.2000.01791.x; Tang M, 2007, J BACTERIOL, V189, P8053, DOI 10.1128/JB.00908-07; Tang MJ, 2006, APPL ENVIRON MICROB, V72, P6948, DOI 10.1128/AEM.00976-06; Tinsley E, 2006, J BACTERIOL, V188, P2829, DOI 10.1128/JB.188.8.2829-2835.2006; Vaughan S, 2004, J MOL EVOL, V58, P19, DOI 10.1007/s00239-003-2523-5	24	44	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8102	8109		10.1074/jbc.M709163200	http://dx.doi.org/10.1074/jbc.M709163200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18198178	Green Published, hybrid			2022-12-25	WOS:000254288000006
J	Etheridge, KT; Compton, SA; Barrientos, KS; Ozgur, S; Griffith, JD; Counter, CM				Etheridge, Katherine T.; Compton, Sarah A.; Barrientos, Katharine S.; Ozgur, Sezgin; Griffith, Jack D.; Counter, Christopher M.			Tethering telomeric double- and single-stranded DNA-binding proteins inhibits telomere elongation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; COMPLEX; POT1; LENGTH; TRF1; END; INSTABILITY; MAINTAIN; YEAST	Mammalian telomeres are composed of G-rich repetitive double-stranded (ds) DNA with a 3 ' single-stranded (ss) overhang and associated proteins that together maintain chromosome end stability. Complete replication of telomeric DNA requires de novo elongation of the ssDNA by the enzyme telomerase, with telomeric proteins playing a key role in regulating telomerase-mediated telomere replication. In regards to the protein component of mammalian telomeres, TRF1 and TRF2 bind to the dsDNA of telomeres, whereas POT1 binds to the ssDNA portion. These three proteins are linked through either direct interactions or by the proteins TIN2 and TPP1. To determine the biological consequence of connecting telomeric dsDNA to ssDNA through a multiprotein assembly, we compared the effect of expressing TRF1 and POT1 in trans versus in cis in the form of a fusion of these two proteins, on telomere length in telomerase-positive cells. When expressed in trans these two proteins induced extensive telomere elongation. Fusing TRF1 to POT1 abrogated this effect, inducing mild telomere shortening, and generated looped DNA structures, as assessed by electron microscopy, consistent with the protein forming a complex with dsDNA and ssDNA. We speculate that such a protein bridge between dsDNA and ssDNA may inhibit telomerase access, promoting telomere shortening.	[Etheridge, Katherine T.; Barrientos, Katharine S.; Ozgur, Sezgin; Counter, Christopher M.] DUMC 3813, Dept Radiat Oncol, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; [Compton, Sarah A.; Ozgur, Sezgin; Griffith, Jack D.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Counter, CM (corresponding author), DUMC 3813, Dept Radiat Oncol, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.	count004@mc.duke.edu		Counter, Christopher M/0000-0003-0748-3079	NATIONAL CANCER INSTITUTE [R01CA082481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES013773] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819] Funding Source: NIH RePORTER; NCI NIH HHS [CA82481] Funding Source: Medline; NIEHS NIH HHS [ES13773] Funding Source: Medline; NIGMS NIH HHS [GM31819] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Armbruster BN, 2004, MOL CELL BIOL, V24, P3552, DOI 10.1128/MCB.24.8.3552-3561.2004; Armbruster BN, 2003, MOL CELL BIOL, V23, P3237, DOI 10.1128/MCB.23.9.3237-3246.2003; Armbruster BN, 2001, MOL CELL BIOL, V21, P7775, DOI 10.1128/MCB.21.22.7775-7786.2001; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Bianchi A, 1997, EMBO J, V16, P1785, DOI 10.1093/emboj/16.7.1785; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Chai WH, 2005, MOL CELL BIOL, V25, P2158, DOI 10.1128/MCB.25.6.2158-2168.2005; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Colgin LM, 2003, CURR BIOL, V13, P942, DOI 10.1016/S0960-9822(03)00339-7; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hockemeyer D, 2006, CELL, V126, P63, DOI 10.1016/j.cell.2006.04.044; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Karlseder J, 2003, MOL CELL BIOL, V23, P6533, DOI 10.1128/MCB.23.18.6533-6541.2003; Liu D, 2004, J BIOL CHEM, V279, P51338, DOI 10.1074/jbc.M409293200; Liu D, 2004, NAT CELL BIOL, V6, P673, DOI 10.1038/ncb1142; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; O'Connor MS, 2006, P NATL ACAD SCI USA, V103, P11874, DOI 10.1073/pnas.0605303103; O'Connor MS, 2004, J BIOL CHEM, V279, P28585, DOI 10.1074/jbc.M312913200; O'Hayer KM, 2006, METHOD ENZYMOL, V407, P637, DOI 10.1016/S0076-6879(05)07050-3; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Stansel RM, 2001, EMBO J, V20, P5532; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Vega LR, 2003, NAT REV MOL CELL BIO, V4, P948, DOI 10.1038/nrm1256; Veldman T, 2004, CURR BIOL, V14, P2264, DOI 10.1016/j.cub.2004.12.031; Wu L, 2006, CELL, V126, P49, DOI 10.1016/j.cell.2006.05.037; Yang Q, 2005, MOL CELL BIOL, V25, P1070, DOI 10.1128/MCB.25.3.1070-1080.2005; Ye JZS, 2004, J BIOL CHEM, V279, P47264, DOI 10.1074/jbc.M409047200; Ye JZS, 2004, GENE DEV, V18, P1649, DOI 10.1101/gad.1215404	33	9	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					6935	6941		10.1074/jbc.M708711200	http://dx.doi.org/10.1074/jbc.M708711200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18178559	hybrid, Green Published			2022-12-25	WOS:000253779600037
J	Hodges, AR; Krementsova, EB; Trybus, KM				Hodges, Alex R.; Krementsova, Elena B.; Trybus, Kathleen M.			She3p binds to the rod of yeast myosin V and prevents it from dimerizing, forming a single-headed motor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASH1 MESSENGER-RNA; MONOMERIC MYOSIN; SACCHAROMYCES-CEREVISIAE; STRUCTURAL ELEMENTS; LOCALIZATION; PROCESSIVITY; PROTEIN; MYO4P; ACTIN; COORDINATION	Vertebrate myosin Va is a dimeric processive motor that walks on actin filaments to deliver cargo. In contrast, the two class V myosins in budding yeast, Myo2p and Myo4p, are non-processive (Reck-Peterson, S. L., Tyska, M. J., Novick, P. J., and Mooseker, M. S. ( 2001) J. Cell Biol. 153, 1121-1126). We previously showed that a chimera with the motor domain of Myo4p on the backbone of vertebrate myosin Va was processive, demonstrating that the Myo4p motor domain has a high duty ratio. Here we examine the properties of a chimera containing the rod and globular tail of Myo4p joined to the motor domain and neck of mouse myosin Va. Surprisingly, the adaptor protein She3p binds to the rod region of Myo4p and forms a homogeneous single-headed myosin-She3p complex, based on sedimentation equilibrium and velocity data. We propose that She3p forms a heterocoiled-coil with Myo4p and is a subunit of the motor. She3p does not affect the maximal actin-activated ATPase in solution or the velocity of movement in an ensemble in vitro motility assay. At the single molecule level, the monomeric myosin-She3p complex showed no processivity. When this construct was dimerized with a leucine zipper, short processive runs were obtained. Robust continuous movement was observed when multiple monomeric myosin-She3p motors were bound to a quantum dot "cargo." We propose that continuous transport of mRNA by Myo4p-She3p in yeast is accomplished either by multiple high duty cycle monomers or by molecules that may be dimerized by She2p, the homodimeric downstream binding partner of She3p.	[Hodges, Alex R.; Krementsova, Elena B.; Trybus, Kathleen M.] Univ Vermont, Dept Mol Physiol & Biophys, Burlington, VT 05405 USA	University of Vermont	Trybus, KM (corresponding author), Univ Vermont, Dept Mol Physiol & Biophys, 149 Beaumont Ave, Burlington, VT 05405 USA.	kathleen.trybus@uvm.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078097] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM078097] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker JE, 2004, P NATL ACAD SCI USA, V101, P5542, DOI 10.1073/pnas.0307247101; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Bohl F, 2000, EMBO J, V19, P5514, DOI 10.1093/emboj/19.20.5514; Chartrand P, 1999, CURR BIOL, V9, P333, DOI 10.1016/S0960-9822(99)80144-4; Darzacq X, 2003, CURR OPIN MICROBIOL, V6, P614, DOI 10.1016/j.mib.2003.10.005; Diefenbach RJ, 1998, BIOCHEMISTRY-US, V37, P16663, DOI 10.1021/bi981163r; Dunn AR, 2007, NAT STRUCT MOL BIOL, V14, P246, DOI 10.1038/nsmb1206; Dunn BD, 2007, J CELL BIOL, V178, P1193, DOI 10.1083/jcb.200707080; Estrada P, 2003, J CELL BIOL, V163, P1255, DOI 10.1083/jcb.200304030; Gonsalvez GB, 2005, BIOL CELL, V97, P75; Gonzalez I, 1999, CURR BIOL, V9, P337, DOI 10.1016/S0960-9822(99)80145-6; Gross SP, 2002, J CELL BIOL, V156, P855, DOI 10.1083/jcb.200105055; Heuck A, 2007, P NATL ACAD SCI USA, V104, P19778, DOI 10.1073/pnas.0706780104; Hodges AR, 2007, J BIOL CHEM, V282, P27192, DOI 10.1074/jbc.M703968200; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Jambhekar A, 2005, P NATL ACAD SCI USA, V102, P18005, DOI 10.1073/pnas.0509229102; Jansen RP, 1996, CELL, V84, P687, DOI 10.1016/S0092-8674(00)81047-8; Krementsov DN, 2004, J CELL BIOL, V164, P877, DOI 10.1083/jcb.200310065; Krementsova EB, 2006, J BIOL CHEM, V281, P6079, DOI 10.1074/jbc.M510041200; Lister I, 2004, EMBO J, V23, P1729, DOI 10.1038/sj.emboj.7600180; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; Long RM, 2000, EMBO J, V19, P6592, DOI 10.1093/emboj/19.23.6592; Lu HL, 2006, J BIOL CHEM, V281, P31987, DOI 10.1074/jbc.M605181200; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Moore JR, 2001, J CELL BIOL, V155, P625, DOI 10.1083/jcb.200103128; Niessing D, 2004, CELL, V119, P491, DOI 10.1016/j.cell.2004.10.018; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; Park H, 2006, MOL CELL, V21, P331, DOI 10.1016/j.molcel.2005.12.015; Philo JS, 2000, ANAL BIOCHEM, V279, P151, DOI 10.1006/abio.2000.4480; Purcell TJ, 2005, P NATL ACAD SCI USA, V102, P13873, DOI 10.1073/pnas.0506441102; Reck-Peterson SL, 2001, J CELL BIOL, V153, P1121, DOI 10.1083/jcb.153.5.1121; Rosenfeld SS, 2004, J BIOL CHEM, V279, P40100, DOI 10.1074/jbc.M402583200; Schmid M, 2006, CURR BIOL, V16, P1538, DOI 10.1016/j.cub.2006.06.025; Sellers JR, 2006, CURR OPIN CELL BIOL, V18, P68, DOI 10.1016/j.ceb.2005.12.014; Shepard KA, 2003, P NATL ACAD SCI USA, V100, P11429, DOI 10.1073/pnas.2033246100; Tomishige M, 2002, SCIENCE, V297, P2263, DOI 10.1126/science.1073386; Toth J, 2005, J BIOL CHEM, V280, P30594, DOI 10.1074/jbc.M505209200; VATANABE S, 2007, J BIOL CHEM      DEC; Veigel C, 2005, NAT CELL BIOL, V7, P861, DOI 10.1038/ncb1287; Veigel C, 2002, NAT CELL BIOL, V4, P59, DOI 10.1038/ncb732; Vilfan A, 2005, BIOPHYS J, V88, P3792, DOI 10.1529/biophysj.104.046763; Weisman LS, 2006, NAT REV MOL CELL BIO, V7, P243, DOI 10.1038/nrm1892	42	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					6906	6914		10.1074/jbc.M708865200	http://dx.doi.org/10.1074/jbc.M708865200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18175803	hybrid			2022-12-25	WOS:000253779600034
J	Marden, JJ; Zhang, YL; Oakley, FD; Zhou, WH; Luo, MH; Jia, HP; McCray, PB; Yaniv, M; Weitzman, JB; Engelhard, JF				Marden, Jennifer J.; Zhang, Yulong; Oakley, Fredrick D.; Zhou, Weihong; Luo, Meihui; Jia, Hong Peng; McCray, Paul B., Jr.; Yaniv, Moshe; Weitzman, Jonathan B.; Engelhard, John F.			JunD protects the liver from ischemia/reperfusion injury by dampening AP-1 transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN D1 EXPRESSION; DNA-BINDING ACTIVITY; C-JUN; ISCHEMIA-REPERFUSION; HEPATIC-INJURY; MOUSE-LIVER; PROLIFERATION; SUPEROXIDE; KINASE; CELLS	The AP-1 transcription factor modulates a wide range of cellular processes, including cellular proliferation, programmed cell death, and survival. JunD is a major component of the AP-1 complex following liver ischemia/reperfusion (I/R) injury; however, its precise function in this setting remains unclear. We investigated the functional significance of JunD in regulating AP-1 transcription following partial lobar I/R injury to the liver, as well as the downstream consequences for hepatocellular remodeling. Our findings demonstrate that JunD plays a protective role, reducing I/R injury to the liver by suppressing acute transcriptional activation of AP-1. In the absence of JunD, c-Jun phosphorylation and AP-1 activation in response to I/R injury were elevated, and this correlated with increased caspase activation, injury, and alterations in hepatocyte proliferation. The expression of dominant negative JNK1 inhibited c-Jun phosphorylation, AP-1 activation, and hepatic injury following I/R in JunD-/- mice but, paradoxically, led to an enhancement of AP-1 activation and liver injury in JunD(+/-) littermates. Enhanced JunD/JNK1-dependent liver injury correlated with the acute induction of diphenylene iodonium-sensitive NADPH-dependent superoxide production by the liver following I/R. In this context, dominant negative JNK1 expression elevated both Nox2 and Nox4 mRNA levels in the liver in a JunD-dependent manner. These findings suggest that JunD counterbalances JNK1 activation and the downstream redox-dependent hepatic injury that results from I/R, and may do so by regulating NADPH oxidases.	[Zhang, Yulong; Oakley, Fredrick D.; Zhou, Weihong; Luo, Meihui; Engelhard, John F.] Univ Iowa, Coll Med, Dept Anat & Cell Biol, Iowa City, IA 52242 USA; [Jia, Hong Peng; McCray, Paul B., Jr.] Univ Iowa, Coll Med, Dept Pediat, Iowa City, IA 52242 USA; [McCray, Paul B., Jr.; Engelhard, John F.] Univ Iowa, Coll Med, Ctr Gene Therapy, Iowa City, IA 52242 USA; [Marden, Jennifer J.] Univ Iowa, Coll Med, Mol & Cell Biol Interdisciplinary Grad Program, Iowa City, IA 52242 USA; [Weitzman, Jonathan B.] Inst Pasteur, F-75724 Paris, France; [Weitzman, Jonathan B.] Univ Paris 07, INSERM Epigenet Pathol & Dev, U741, F-75724 Paris 15, France	University of Iowa; University of Iowa; University of Iowa; University of Iowa; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Engelhard, JF (corresponding author), Univ Iowa, Coll Med, Dept Anat & Cell Biol, 51 Newton Rd, Iowa City, IA 52242 USA.	john-engelhardt@uiowa.edu	jia, jhp@mm8899/AAH-6611-2020	Weitzman, Jonathan/0000-0001-8445-0102; McCray, Paul/0000-0002-4067-577X; Engelhardt, John/0000-0003-2389-9277	NIDDK NIH HHS [R01 DK067928, DK51315, P30 DK054759, R01 DK051315, DK067928, DK54759] Funding Source: Medline; NIGMS NIH HHS [T32 GM007337] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK054759, R01DK067928, R01DK051315] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007337] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Ameyar-Zazoua M, 2005, ONCOGENE, V24, P2298, DOI 10.1038/sj.onc.1208424; Anderson RD, 2000, GENE THER, V7, P1034, DOI 10.1038/sj.gt.3301197; ARTHUR MJP, 1985, GASTROENTEROLOGY, V89, P1114, DOI 10.1016/0016-5085(85)90218-5; ATALLA SL, 1985, TRANSPLANTATION, V40, P584, DOI 10.1097/00007890-198512000-00002; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Colletti LM, 1996, HEPATOLOGY, V23, P506; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; Dong C, 2000, NATURE, V405, P91, DOI 10.1038/35011091; Gerald D, 2004, CELL, V118, P781, DOI 10.1016/j.cell.2004.08.025; Harada H, 2004, ARCH BIOCHEM BIOPHYS, V423, P103, DOI 10.1016/j.abb.2003.08.035; Ishii M, 2004, J IMMUNOL, V172, P2569, DOI 10.4049/jimmunol.172.4.2569; Jaeschke A, 2006, MOL CELL, V23, P899, DOI 10.1016/j.molcel.2006.07.028; Kim Yang-Il, 2003, J Hepatobiliary Pancreat Surg, V10, P195; KOO A, 1992, HEPATOLOGY, V15, P507, DOI 10.1002/hep.1840150325; Kretzschmar M, 2003, EXP TOXICOL PATHOL, V54, P423, DOI 10.1078/0940-2993-00291; Kupiec-Weglinski JW, 2005, TRANSPL P, V37, P1653, DOI 10.1016/j.transproceed.2005.03.134; Li QA, 2006, MOL CELL BIOL, V26, P140, DOI 10.1128/MCB.26.1.140-154.2006; MATHEWS WR, 1994, FREE RADICAL BIO MED, V16, P763, DOI 10.1016/0891-5849(94)90191-0; Okaya T, 2003, J INVEST SURG, V16, P141, DOI 10.1080/08941930390205782; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Qiao L, 2003, MOL CELL BIOL, V23, P3052, DOI 10.1128/MCB.23.9.3052-3066.2003; Ronai Z, 2004, MOL CELL, V15, P843, DOI 10.1016/j.molcel.2004.09.011; Sabapathy K, 2004, CELL CYCLE, V3, P1520, DOI 10.4161/cc.3.12.1315; Sabapathy K, 2004, MOL CELL, V15, P713, DOI 10.1016/j.molcel.2004.08.028; Schlossberg H, 1996, HEPATOLOGY, V23, P1546, DOI 10.1053/jhep.1996.v23.pm0008675176; Schwabe RF, 2003, HEPATOLOGY, V37, P824, DOI 10.1053/jhep.2003.50135; Sheerin A, 2001, MECH AGEING DEV, V122, P1813, DOI 10.1016/S0047-6374(01)00319-0; Smyrniotis V, 2003, J AM COLL SURGEONS, V197, P949, DOI 10.1016/j.jamcollsurg.2003.07.009; Thepot D, 2000, DEVELOPMENT, V127, P143; Troen G, 2004, J MOL DIAGN, V6, P297, DOI 10.1016/S1525-1578(10)60525-9; Uehara T, 2005, J HEPATOL, V42, P850, DOI 10.1016/j.jhep.2005.01.030; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Xiao L, 2007, BIOCHEM J, V403, P573, DOI 10.1042/BJ20061436; Yazgan O, 2002, J BIOL CHEM, V277, P29710, DOI 10.1074/jbc.M204552200; Zhou WH, 2001, HEPATOLOGY, V33, P902, DOI 10.1053/jhep.2001.23073; Zwacka RM, 1998, NAT MED, V4, P698, DOI 10.1038/nm0698-698	38	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					6687	6695		10.1074/jbc.M705606200	http://dx.doi.org/10.1074/jbc.M705606200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18182393	Green Accepted, hybrid			2022-12-25	WOS:000253779600010
J	Zhou, DH; Palam, LR; Jiang, L; Narasimhan, J; Staschke, KA; Wek, RC				Zhou, Donghui; Palam, L. Reddy; Jiang, Li; Narasimhan, Jana; Staschke, Kirk A.; Wek, Ronald C.			Phosphorylation of eIF2 directs ATF5 translational control in response to diverse stress conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; MESSENGER-RNA TRANSLATION; UNFOLDED PROTEIN RESPONSE; NEURAL PROGENITOR CELLS; AMINO-ACID CONTROL; GENE-EXPRESSION; EUKARYOTIC INITIATION-FACTOR-2; BINDING; CHOP; GCN4	Phosphorylation of eukaryotic initiation factor 2 ( eIF2) is an important mechanism regulating global and gene-specific translation in response to different environmental stresses. Central to the eIF2 kinase response is the preferential translation of ATF4 mRNA, encoding a transcriptional activator of genes involved in stress remediation. In this report, we addressed whether there are additional transcription factors whose translational expression is regulated by eIF2 kinases. We show that the expression of the basic zipper transcriptional regulator ATF5 is induced in response to many different stresses, including endoplasmic reticulum stress, arsenite exposure, and proteasome inhibition, by a mechanism requiring eIF2 phosphorylation. ATF5 is subject to translational control as illustrated by the preferential association of ATF5 mRNA with large polyribosomes in response to stress. ATF5 translational control involves two upstream open reading frames ( uORFs) located in the 5'-leader of the ATF5 mRNA, a feature shared with ATF4. Mutational analyses of the 5'-leader of ATF5 mRNA fused to a luciferase reporter suggest that the 5'-proximal uORF1 is positive-acting, allowing scanning ribosomes to reinitiate translation of a downstream ORF. During non-stressed conditions, when eIF2 phosphorylation is low, ribosomes reinitiate translation at the next ORF, the inhibitory uORF2. Phosphorylation of eIF2 during stress delays translation reinitiation, allowing scanning ribosomes to bypass uORF2, and instead translate the ATF5 coding region. In addition to translational control, ATF5 mRNA levels are significantly reduced in ATF4(-/-) mouse embryo fibroblasts, suggesting that ATF4 contributes to basal ATF5 transcription. These results demonstrate that eIF2 kinases direct the translational expression of multiple transcription regulators by a mechanism involving delayed translation reinitiation.	[Zhou, Donghui; Palam, L. Reddy; Jiang, Li; Narasimhan, Jana; Staschke, Kirk A.; Wek, Ronald C.] Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Wek, RC (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.	rwek@iupui.edu	Staschke, Kirk/HGC-5664-2022; palam, lakshmi reddy/H-4902-2015	Staschke, Kirk/0000-0001-8722-9585; 	NIGMS NIH HHS [R01GM49164, R01GM64350] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064350, R01GM049164] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angelastro JM, 2003, J NEUROSCI, V23, P4590; Angelastro JM, 2006, ONCOGENE, V25, P907, DOI 10.1038/sj.onc.1209116; Angelastro JM, 2005, J NEUROSCI, V25, P3889, DOI 10.1523/JNEUROSCI.3447-04.2005; Averous J, 2004, J BIOL CHEM, V279, P5288, DOI 10.1074/jbc.M311862200; Chen C, 2004, J BIOL CHEM, V279, P27948, DOI 10.1074/jbc.M313920200; Chen H, 2004, J BIOL CHEM, V279, P50829, DOI 10.1074/jbc.M409173200; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; Dong SM, 2005, J NEUROPATH EXP NEUR, V64, P948, DOI 10.1097/01.jnen.0000186940.14779.90; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; Hansen MB, 2002, GENOMICS, V80, P344, DOI 10.1006/geno.2002.6838; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hinnebusch AG, 2005, ANNU REV MICROBIOL, V59, P407, DOI 10.1146/annurev.micro.59.031805.133833; Hinnebusch AG, 2002, EUKARYOT CELL, V1, P22, DOI 10.1128/EC.01.1.22-32.2002; Hoffmann B, 2001, MOL BIOL CELL, V12, P2846, DOI 10.1091/mbc.12.9.2846; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Jiang HY, 2005, J BIOL CHEM, V280, P14189, DOI 10.1074/jbc.M413660200; Jiang HY, 2004, MOL CELL BIOL, V24, P1365, DOI 10.1128/MCB.24.3.1365-1377.2004; Jiang HY, 2003, MOL CELL BIOL, V23, P5651, DOI 10.1128/MCB.23.16.5651-5663.2003; JOHANNES G, 1998, RNA N Y, V12, P1500; Kevil CG, 1997, BIOCHEM BIOPH RES CO, V238, P277, DOI 10.1006/bbrc.1997.7284; Kilberg MS, 2005, ANNU REV NUTR, V25, P59, DOI 10.1146/annurev.nutr.24.012003.132145; Lu PD, 2004, J CELL BIOL, V167, P27, DOI 10.1083/jcb.200408003; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; Marciniak SJ, 2006, PHYSIOL REV, V86, P1133, DOI 10.1152/physrev.00015.2006; Mason JL, 2005, MOL CELL NEUROSCI, V29, P372, DOI 10.1016/j.mcn.2005.03.004; Mathews M. B., 1996, TRANSLATIONAL CONTRO, P1; Narasimhan J, 2004, J BIOL CHEM, V279, P22820, DOI 10.1074/jbc.M402228200; PALUH JL, 1988, P NATL ACAD SCI USA, V85, P3728, DOI 10.1073/pnas.85.11.3728; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Tripathi G, 2002, EMBO J, V21, P5448, DOI 10.1093/emboj/cdf507; Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101; Vinson C, 2002, MOL CELL BIOL, V22, P6321, DOI 10.1128/MCB.22.18.6321-6335.2002; Watatani Y, 2008, J BIOL CHEM, V283, P2543, DOI 10.1074/jbc.M707781200; Wek RC, 2006, BIOCHEM SOC T, V34, P7, DOI 10.1042/BST0340007; Wek RC, 2004, TOP CURR GENET, V7, P171; Wek RC, 2007, ANTIOXID REDOX SIGN, V9, P2357, DOI 10.1089/ars.2007.1764; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	41	191	194	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					7064	7073		10.1074/jbc.M708530200	http://dx.doi.org/10.1074/jbc.M708530200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18195013	hybrid			2022-12-25	WOS:000253779600051
J	Xiao, H; Xu, LH; Yamada, Y; Liu, DX				Xiao, Han; Xu, Ling Hui; Yamada, Yoshiyuki; Liu, Ding Xiang			Coronavirus Spike Protein Inhibits Host Cell Translation by Interaction with eIF3f	PLOS ONE			English	Article								In response to viral infection, the expression of numerous host genes, including predominantly a number of proinflammatory cytokines and chemokines, is usually up-regulated at both transcriptional and translational levels. It was noted that in cells infected with coronavirus, transcription and translation of some of these genes were differentially induced. Drastic induction of their expression at the transcriptional level was observed in cells infected with coronavirus. However, induction of the same genes at the translational level was usually found to be minimal to moderate. To investigate the underlying mechanisms, yeast two-hybrid screen was carried out using SARS-CoV proteins as baits, revealing that a subunit of the eukaryotic initiation factor 3 (eIF3), eIF3f, may interact with the N-terminal region of the SARS-CoV spike ( S) protein. This interaction was subsequently confirmed by co-immunoprecipitation and immunofluorescent staining. Meanwhile, parallel experiments confirmed that eIF3f could also interact with the S protein of another coronavirus, the avian coronavirus infectious bronchitis virus (IBV). These interactions led to the inhibition of translation of a reporter gene in both in vitro expression system and intact cells. Interestingly, IBV-infected cells stably expressing a Flag-tagged eIF3f showed much higher translation of IL-6 and IL-8, suggesting that the interaction between coronavirus S protein and eIF3f plays a functional role in controlling the expression of host genes, especially genes that are induced during coronavirus infection cycles. This study reveals a novel mechanism exploited by coronavirus to regulate viral pathogenesis.	[Xiao, Han; Xu, Ling Hui; Yamada, Yoshiyuki; Liu, Ding Xiang] Inst Mol & Cell Biol, Proteos, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Liu, DX (corresponding author), Inst Mol & Cell Biol, Proteos, Singapore.	dxliu@imcb.a-star.edu.sg	Liu, Ding Xiang/A-2226-2011		Agency for Science, Technology and Research, Singapore; Biomedical Research Council [BMRC 03/1/22/17/220]	Agency for Science, Technology and Research, Singapore(Agency for Science Technology & Research (A*STAR)); Biomedical Research Council(Agency for Science Technology & Research (A*STAR))	This work was supported by the Agency for Science, Technology and Research, Singapore, and a grant from the Biomedical Research Council (BMRC 03/1/22/17/220), Agency for Science, Technology and Research, Singapore.	Ahmed M, 2003, J VIROL, V77, P4646, DOI 10.1128/JVI.77.8.4646-4657.2003; Alcami A, 2000, IMMUNOL TODAY, V21, P447, DOI 10.1016/S0167-5699(00)01699-6; Ali IK, 2001, EMBO J, V20, P4233, DOI 10.1093/emboj/20.15.4233; BLACK BL, 1992, J VIROL, V66, P4058, DOI 10.1128/JVI.66.7.4058-4064.1992; Bos ECW, 1995, VIROLOGY, V214, P453, DOI 10.1006/viro.1995.0056; Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003; Cebulla CM, 1999, INTERVIROLOGY, V42, P325, DOI 10.1159/000053968; Cheung CY, 2002, LANCET, V360, P1831, DOI 10.1016/S0140-6736(02)11772-7; de Haan CAM, 2004, J VIROL, V78, P6048, DOI 10.1128/JVI.78.11.6048-6054.2004; Ferran MC, 1997, J VIROL, V71, P371, DOI 10.1128/JVI.71.1.371-377.1997; Gale M, 2000, MICROBIOL MOL BIOL R, V64, P239, DOI 10.1128/MMBR.64.2.239-280.2000; Glass WG, 2004, J IMMUNOL, V173, P4030, DOI 10.4049/jimmunol.173.6.4030; Guidotti LG, 2000, VIROLOGY, V273, P221, DOI 10.1006/viro.2000.0442; Joachims M, 1999, J VIROL, V73, P718, DOI 10.1128/JVI.73.1.718-727.1999; Jones BM, 2004, CLIN EXP IMMUNOL, V135, P467, DOI 10.1111/j.1365-2249.2003.02391.x; KATSURA A, 1997, J BIOL CHEM, V272, P1101; KEITH RJ, 1997, J BIOL CHEM, V272, P7106; LAMPHEAR BJ, 1993, J BIOL CHEM, V268, P19200; Laurent AM, 1998, J GEN VIROL, V79, P2765, DOI 10.1099/0022-1317-79-11-2765; Law HKW, 2005, BLOOD, V106, P2366, DOI 10.1182/blood-2004-10-4166; Liu DX, 1997, J VIROL, V71, P1814, DOI 10.1128/JVI.71.3.1814-1820.1997; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; NATHALIE M, 1997, J BIOL CHEM, V272, P1110; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; Schneider RJ, 2003, TRENDS BIOCHEM SCI, V28, P130, DOI 10.1016/S0968-0004(03)00029-X; SCHNEIDER RJ, 2000, TRANSLATIONAL CONTRO, P901; Shi J, 2006, ONCOGENE, V25, P4923, DOI 10.1038/sj.onc.1209495; Shi JQ, 2003, J BIOL CHEM, V278, P5062, DOI 10.1074/jbc.M206427200; Silverman RH, 1999, NATURE, V397, P208, DOI 10.1038/16586; Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9; Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0; Tseng CTK, 2005, J IMMUNOL, V174, P7977, DOI 10.4049/jimmunol.174.12.7977; Wang L, 2006, ONCOGENE, V25, P4320, DOI 10.1038/sj.onc.1209458; Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x; Wong RSM, 2003, BRIT MED J, V326, P1358, DOI 10.1136/bmj.326.7403.1358; Yuan H, 1998, VIROLOGY, V251, P383, DOI 10.1006/viro.1998.9413; Zhang YC, 2004, INFECT IMMUN, V72, P4410, DOI 10.1128/IAI.72.8.4410-4415.2004; Ziegler T, 2005, J VIROL, V79, P13800, DOI 10.1128/JVI.79.21.13800-13805.2005	39	54	60	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2008	3	1							e1494	10.1371/journal.pone.0001494	http://dx.doi.org/10.1371/journal.pone.0001494			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SR	18231581	Green Published, Green Submitted, gold			2022-12-25	WOS:000260504200007
J	Charvin, G; Cross, FR; Siggia, ED				Charvin, Gilles; Cross, Frederick R.; Siggia, Eric D.			A Microfluidic Device for Temporally Controlled Gene Expression and Long-Term Fluorescent Imaging in Unperturbed Dividing Yeast Cells	PLOS ONE			English	Article								Background. Imaging single cells with fluorescent markers over multiple cell cycles is a powerful tool for unraveling the mechanism and dynamics of the cell cycle. Over the past ten years, microfluidic techniques in cell biology have emerged that allow for good control of growth environment. Yet the control and quantification of transient gene expression in unperturbed dividing cells has received less attention. Methodology/Principal Findings. Here, we describe a microfluidic flow cell to grow Saccharomyces Cerevisiae for more than 8 generations (approximate to 12 hrs) starting with single cells, with controlled flow of the growth medium. This setup provides two important features: first, cells are tightly confined and grow in a remarkably planar array. The pedigree can thus be determined and single-cell fluorescence measured with 3 minutes resolution for all cells, as a founder cell grows to a micro-colony of more than 200 cells. Second, we can trigger and calibrate rapid and transient gene expression using reversible administration of inducers that control the GAL1 or MET3 promoters. We then show that periodic 10-20 minutes gene induction pulses can drive many cell division cycles with complete coherence across the cell cluster, with either a G1/S trigger (cln1 cln2 cln3 MET3-CLN2) or a mitotic trigger (cdc20 GALL-CDC20). Conclusions/Significance. In addition to evident cell cycle applications, this device can be used to directly measure the amount and duration of any fluorescently scorable signal-transduction or gene-induction response over a long time period. The system allows direct correlation of cell history (e.g., hysteresis or epigenetics) or cell cycle position with the measured response.	[Charvin, Gilles; Siggia, Eric D.] Rockefeller Univ, Ctr Studies Phys & Biol, New York, NY 10021 USA; [Cross, Frederick R.] Rockefeller Univ, New York, NY USA	Rockefeller University; Rockefeller University	Charvin, G (corresponding author), Rockefeller Univ, Ctr Studies Phys & Biol, 1230 York Ave, New York, NY 10021 USA.	gilles.charvin@gmail.com		charvin, gilles/0000-0002-6852-6952	National Institute of Health; National Science Foundation [DMR-0517138]; Human Frontier Science Program Organization [cross-disciplinary fellowship]	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); Human Frontier Science Program Organization(Human Frontier Science Program)	This work was supported by the National Institute of Health (EDS, FRC), the National Science Foundation DMR-0517138 (EDS), and a long-term cross-disciplinary fellowship from the Human Frontier Science Program Organization (GC).	AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Balaban NQ, 2004, SCIENCE, V305, P1622, DOI 10.1126/science.1099390; Battogtokh D, 2006, PHYS REV E, V73, DOI 10.1103/PhysRevE.73.011910; Bean JM, 2006, MOL CELL, V21, P3, DOI 10.1016/j.molcel.2005.10.035; Burke D., 2000, METHODS YEAST GENETI; Cookson S, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100032; Costanzo M, 2004, CELL, V117, P899, DOI 10.1016/j.cell.2004.05.024; Cross FR, 2005, PHYS REV E, V72, DOI 10.1103/PhysRevE.72.021910; de Bruin RAM, 2004, CELL, V117, P887, DOI 10.1016/j.cell.2004.05.025; Di Talia S, 2007, NATURE, V448, P947, DOI 10.1038/nature06072; Gordon A, 2007, NAT METHODS, V4, P175, DOI 10.1038/nmeth1008; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; JOHNSTON GC, 1977, EXP CELL RES, V105, P79, DOI 10.1016/0014-4827(77)90154-9; KRON SJ, 1994, MOL BIOL CELL, V5, P1003, DOI 10.1091/mbc.5.9.1003; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; LORD PG, 1981, J CELL SCI, V50, P361; LOUVION JF, 1993, GENE, V131, P129, DOI 10.1016/0378-1119(93)90681-R; Mao XC, 2002, CURR MICROBIOL, V45, P37, DOI 10.1007/s00284-001-0046-0; Mateus C, 2000, YEAST, V16, P1313, DOI 10.1002/1097-0061(200010)16:14<1313::AID-YEA626>3.0.CO;2-O; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Paliwal S, 2007, NATURE, V446, P46, DOI 10.1038/nature05561; Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037; Sia SK, 2003, ELECTROPHORESIS, V24, P3563, DOI 10.1002/elps.200305584; Smith AE, 2000, P NATL ACAD SCI USA, V97, P9871, DOI 10.1073/pnas.97.18.9871; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Sveiczer A, 1996, J CELL SCI, V109, P2947; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509	28	100	102	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2008	3	1							e1468	10.1371/journal.pone.0001468	http://dx.doi.org/10.1371/journal.pone.0001468			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SO	18213377	Green Published, gold, Green Submitted			2022-12-25	WOS:000260503900014
J	Wrage, PC; Tran, T; To, K; Keefer, EW; Ruhn, KA; Hong, J; Hattangadi, S; Trevino, I; Tansey, MG				Wrage, Philip C.; Tran, Thi; To, Khai; Keefer, Edward W.; Ruhn, Kelly A.; Hong, John; Hattangadi, Supriya; Trevino, Isaac; Tansey, Malu G.			The Neuro-Glial Properties of Adipose-Derived Adult Stromal (ADAS) Cells Are Not Regulated by Notch 1 and Are Not Derived from Neural Crest Lineage	PLOS ONE			English	Article								We investigated whether adipose-derived adult stromal ( ADAS) are of neural crest origin and the extent to which Notch 1 regulates their growth and differentiation. Mouse ADAS cells cultured in media formulated for neural stem cells (NSC) displayed limited capacity for self-renewal, clonogenicity, and neurosphere formation compared to NSC from the subventricular zone in the hippocampus. Although ADAS cells expressed Nestin, GFAP, NSE and Tuj1 in vitro, exposure to NSC differentiation supplements did not induce mature neuronal marker expression. In contrast, in mesenchymal stem cell (MSC) media, ADAS cells retained their ability to proliferate and differentiate beyond 20 passages and expressed high levels of Nestin. In neuritizing cocktails, ADAS cells extended processes, downregulated Nestin expression, and displayed depolarization-induced Ca2+ transients but no spontaneous or evoked neural network activity on Multi-Electrode Arrays. Deletion of Notch 1 in ADAS cell cultures grown in NSC proliferation medium did not significantly alter their proliferative potential in vitro or the differentiation-induced downregulation of Nestin. Co-culture of ADAS cells with fibroblasts that stably expressed the Notch ligand Jagged 1 or overexpression of the Notch intracellular domain (NICD) did not alter ADAS cell growth, morphology, or cellular marker expression. ADAS cells did not display robust expression of neural crest transcription factors or genes (Sox, CRABP2, and TH); and lineage tracing analyses using Wnt1-Cre; Rosa26R-lacZ or -EYFP reporter mice confirmed that fewer than 2% of the ADAS cell population derived from a Wnt1-positive population during development. In summary, although media formulations optimized for MSCs or NSCs enable expansion of mouse ADAS cells in vitro, we find no evidence that these cells are of neural crest origin, that they can undergo robust terminal differentiation into functionally mature neurons, and that Notch 1 is likely to be a key regulator of their cellular and molecular characteristics.	[Keefer, Edward W.] Univ Texas SW Med Ctr, Dept Plastic Surg, Dallas, TX USA; [Wrage, Philip C.; Tran, Thi; To, Khai; Ruhn, Kelly A.; Hong, John; Hattangadi, Supriya; Trevino, Isaac] Univ Texas SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Tansey, MG (corresponding author), Univ Texas SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA.	malu.tansey@utsouthwestern.edu		Keefer, Edward/0000-0002-0470-9186	National Parkinson Foundation; National Institutes of Health (NIH) Neurological Disorders and Stroke (NINDS) [NS051526-02]; NIH [GM007062]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS051526] Funding Source: NIH RePORTER	National Parkinson Foundation; National Institutes of Health (NIH) Neurological Disorders and Stroke (NINDS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by a grant from the National Parkinson Foundation, an Exploratory/Developmental R21 grant NS051526-02 (MGT) from the National Institutes of Health (NIH) Neurological Disorders and Stroke (NINDS), and an NIH Predoctoral Training Grant GM007062 (PCW). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors have no financial, personal, or professional interests that could be construed to have influenced the paper.	Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Ashjian PH, 2003, PLAST RECONSTR SURG, V111, P1922, DOI 10.1097/01.PRS.0000055043.62589.05; Bossolasco P, 2005, EXP NEUROL, V193, P312, DOI 10.1016/j.expneurol.2004.12.013; Burstyn-Cohen T, 2004, DEVELOPMENT, V131, P5327, DOI 10.1242/dev.01424; Cornell RA, 2005, SEMIN CELL DEV BIOL, V16, P663, DOI 10.1016/j.semcdb.2005.06.009; Croft AP, 2004, STEM CELLS DEV, V13, P409, DOI 10.1089/scd.2004.13.409; De Calisto J, 2005, DEVELOPMENT, V132, P2587, DOI 10.1242/dev.01857; de Melker AA, 2004, DEV DYNAM, V230, P708, DOI 10.1002/dvdy.20091; Dezawa M, 2004, J CLIN INVEST, V113, P1701, DOI 10.1172/JCI200420935; Fernandes KJL, 2006, EXP NEUROL, V201, P32, DOI 10.1016/j.expneurol.2006.03.018; Fernandes KJL, 2004, NAT CELL BIOL, V6, P1082, DOI 10.1038/ncb1181; Fraser JK, 2006, TRENDS BIOTECHNOL, V24, P150, DOI 10.1016/j.tibtech.2006.01.010; Gaiano N, 2002, ANNU REV NEUROSCI, V25, P471, DOI 10.1146/annurev.neuro.25.030702.130823; Ge WH, 2002, J NEUROSCI RES, V69, P848, DOI 10.1002/jnr.10364; Hsieh J, 2004, P NATL ACAD SCI USA, V101, P16659, DOI 10.1073/pnas.0407643101; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Joseph NM, 2004, DEVELOPMENT, V131, P5599, DOI 10.1242/dev.01429; Kalcheim C, 2005, INT J DEV BIOL, V49, P105, DOI 10.1387/ijdb.041949ck; Kang SK, 2003, EXP NEUROL, V183, P355, DOI 10.1016/S0014-4886(03)00089-X; Kang SK, 2004, J CELL SCI, V117, P4289, DOI 10.1242/jcs.01264; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Kurrasch DM, 2004, METHOD ENZYMOL, V389, P3; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Lu P, 2004, J NEUROSCI RES, V77, P174, DOI 10.1002/jnr.20148; Morrison SJ, 2000, CELL, V101, P499, DOI 10.1016/S0092-8674(00)80860-0; Nakagami H, 2005, ARTERIOSCL THROM VAS, V25, P2542, DOI 10.1161/01.ATV.0000190701.92007.6d; Nichols AM, 2004, GENESIS, V40, P40, DOI 10.1002/gene.20061; Rehman J, 2004, CIRCULATION, V109, P1292, DOI 10.1161/01.CIR.0000121425.42966.F1; Safford KM, 2002, BIOCHEM BIOPH RES CO, V294, P371, DOI 10.1016/S0006-291X(02)00469-2; Safford KM, 2004, EXP NEUROL, V187, P319, DOI 10.1016/j.expneurol.2004.01.027; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Sauka-Spengler T, 2006, CURR OPIN GENET DEV, V16, P360, DOI 10.1016/j.gde.2006.06.006; Schaffler A, 2007, STEM CELLS, V25, P818, DOI 10.1634/stemcells.2006-0589; Schmidt C, 2005, ANAT EMBRYOL, V209, P349, DOI 10.1007/s00429-005-0459-9; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Taylor MK, 2007, DEVELOPMENT, V134, P2435, DOI 10.1242/dev.005520; Wakamatsu Y, 2000, DEVELOPMENT, V127, P2811; Weinmaster G, 2006, DEVELOPMENT, V133, P3277, DOI 10.1242/dev.02515; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02-02-0105; Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859	44	26	30	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2008	3	1							e1453	10.1371/journal.pone.0001453	http://dx.doi.org/10.1371/journal.pone.0001453			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SN	18197263	gold, Green Submitted, Green Published			2022-12-25	WOS:000260503800024
J	Jiemjit, A; Fandy, TE; Carraway, H; Bailey, KA; Baylin, S; Herman, JG; Gore, SD				Jiemjit, A.; Fandy, T. E.; Carraway, H.; Bailey, K. A.; Baylin, S.; Herman, J. G.; Gore, S. D.			p21(WAF1/CIP1) induction by 5-azacytosine nucleosides requires DNA damage	ONCOGENE			English	Article; Proceedings Paper	96th Annual Meeting of the American-Association-for-Cancer-Research	APR 16-20, 2005	Anaheim, CA	Amer Assoc Canc Res		decitabine; apoptosis; DNA methyltransferase inhibitors; histone deacetylase inhibitors; epigenetics; p21	HISTONE DEACETYLASE INHIBITION; ACUTE MYELOID-LEUKEMIA; 5-AZA-2'-DEOXYCYTIDINE DECITABINE; HEMATOPOIETIC MALIGNANCIES; FUNDAMENTAL ROLE; GENE-EXPRESSION; CANCER-CELLS; METHYLATION; DEMETHYLATION; APOPTOSIS	Decitabine (DAC) and 5-azacitidine have recently been approved for the treatment of myelodysplastic syndrome. The pharmacodynamic effects of DAC and 5-azacitidine outside their known activity as inhibitors of DNA methyltransferases (DNMTs) require further investigation. The purpose of this study was to investigate the effect of DAC on the expression of p21(WAF1/CIP1), a gene with a putative CpG island surrounding its promoter region. Promoter methylation analysis of p21(WAF1/CIP1) in leukemia cells revealed the absence of CpG methylation. However, DAC upregulated p21(WAF1/CIP1) expression in a dose-dependent manner (ED(50) = 103.34 nM) and induced G2/M cell cycle arrest in leukemia cells. Sequential application of DAC followed by different histone deacetylase inhibitors induced expression of p21(WAF1/CIP1) synergistically. Upregulation of p21(WAF1/CIP1) paralleled DAC-induced apoptosis (ED50 = 153 nM). Low doses of DAC induced gamma-H2AX expression (ED(50) =16.5 nM) and upregulated p21(WAF1/CIP1) in congenic HCT 116 colon cancer cells in a DNMT-independent and p53-dependent fashion. Inhibition of p53 transactivation by pifithrin-alpha or the kinase activity of ATM by either the specific ATM inhibitor KU-5593 or caffeine abrogated p21(WAF1/CIP1) upregulation, indicating that DAC upregulation of p21(WAF1/CIP1) was p53- and ATM-dependent in leukemia cells. In conclusion, DAC upregulates p21(WAF1/CIP1) in DNMT-independent manner via the DNA damage/ATM/p53 axis.	[Jiemjit, A.; Fandy, T. E.; Carraway, H.; Bailey, K. A.; Baylin, S.; Herman, J. G.; Gore, S. D.] Sidney Kimmel Comprehens Canc Ctr John Hopkins, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Gore, SD (corresponding author), Sidney Kimmel Comprehens Canc Ctr John Hopkins, 1650 Orleans St, Baltimore, MD 21231 USA.	gorest@jhmi.edu	Carraway, Hetty/AAR-4977-2020; Bailey, Kayleen/G-7716-2018	Carraway, Hetty/0000-0001-5241-3614; Bailey, Kayleen/0000-0002-8193-642X	NCI NIH HHS [R01 CA125635, L30 CA111124-01, P30 CA006973, K24CA111717, L30 CA111124, K24 CA111717, P30 CA06973] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006973, K24CA111717, R01CA125635] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Brakensiek K, 2005, LEUKEMIA RES, V29, P1357, DOI 10.1016/j.leukres.2005.04.012; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CHOU TC, 1977, J BIOL CHEM, V252, P6438; Galm O, 2006, BLOOD REV, V20, P1, DOI 10.1016/j.blre.2005.01.006; Galm O, 2004, LEUKEMIA, V18, P1687, DOI 10.1038/sj.leu.2403434; Gartel AL, 2005, LEUKEMIA RES, V29, P1237, DOI 10.1016/j.leukres.2005.04.023; Gartel AL, 2002, MOL CANCER THER, V1, P639; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Issa JPJ, 2004, BLOOD, V103, P1635, DOI 10.1182/blood-2003-03-0687; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Ju R, 2003, CANCER RES, V63, P2891; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Karpf AR, 2001, MOL PHARMACOL, V59, P751, DOI 10.1124/mol.59.4.751; KASTAN MB, 1991, CANCER RES, V51, P6304; Milutinovic S, 2004, J BIOL CHEM, V279, P27915, DOI 10.1074/jbc.M312823200; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Sarkaria JN, 1999, CANCER RES, V59, P4375; Schmelz K, 2005, LEUKEMIA, V19, P103, DOI 10.1038/sj.leu.2403552; Schmelz K, 2005, INT J CANCER, V114, P683, DOI 10.1002/ijc.20797; Scott SA, 2006, LEUKEMIA RES, V30, P69, DOI 10.1016/j.leukres.2005.05.010; Tamm I, 2005, ANN HEMATOL, V84, P47, DOI 10.1007/s00277-005-0013-0; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Vaute O, 2002, NUCLEIC ACIDS RES, V30, P475, DOI 10.1093/nar/30.2.475; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930; Zhu WG, 2004, J BIOL CHEM, V279, P15161, DOI 10.1074/jbc.M311703200; Zhu WG, 2001, ONCOGENE, V20, P7787, DOI 10.1038/sj.onc.1204970	33	76	80	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2008	27	25					3615	3623		10.1038/sj.onc.1211018	http://dx.doi.org/10.1038/sj.onc.1211018			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18223691	Green Accepted			2022-12-25	WOS:000256468500013
J	Ramsey, CS; Yeung, F; Stoddard, PB; Li, D; Creutz, CE; Mayo, MW				Ramsey, C. S.; Yeung, F.; Stoddard, P. B.; Li, D.; Creutz, C. E.; Mayo, M. W.			Copine-I represses NF-kappa B transcription by endoproteolysis of p65	ONCOGENE			English	Article						NF-kappa B; copine-I; endoproteolysis; p65; transcription; repressor	PHOSPHOLIPID-BINDING PROTEINS; DEPENDENT TRANSCRIPTION; KINASE ALPHA; SUBUNIT; FAMILY; DOMAIN; PHOSPHORYLATION; ACETYLATION; SURVIVAL; DNA	Nuclear factor-kappa B (NF-kappa B) is a dynamic transcription factor that regulates important biological processes involved in cancer initiation and progression. Identifying regulators that control the half-life of NF-kappa B is important to understanding molecular processes that control the duration of transcriptional responses. In this study we identify copine-I, a calcium phospholipid-binding protein, as a novel repressor that physically interacts with p65 to inhibit NF-kappa B transcription. Knockdown of copine-I by siRNA increases tumor necrosis factor alpha-stimulated NF-kappa B transcription, while copine-I expression blocks endogenous transcription. Copine-I abolishes NF-kappa B transcription by inducing endoprotease processing of the N-terminus of p65, a process antagonized by I kappa B alpha. Copine-I stimulates endoproteolysis of p65 within a conserved region that is required for base-specific contact with DNA. p65 proteins lacking the N-terminus fail to bind to DNA and act as dominant-negative molecules that inhibit NF-kappa B transcription. Our work provides evidence that copine-I regulates the half-life of NF-kappa B transcriptional responses through a novel mechanism that involves endoproteolysis of the p65 protein.	[Ramsey, C. S.; Yeung, F.; Stoddard, P. B.; Li, D.; Mayo, M. W.] Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; [Creutz, C. E.] Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Mayo, MW (corresponding author), Univ Virginia, Dept Biochem & Mol Genet, Box 800733, Charlottesville, VA 22908 USA.	mwm3y@virginia.edu			NCI NIH HHS [R01CA095644, R01CA104397] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095644, R01CA104397] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; BALDWIN AS, 1996, ANNU REV IMMUNOL, V14, P681; Burstein E, 2005, J BIOL CHEM, V280, P22222, DOI 10.1074/jbc.M501928200; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen LF, 2005, MOL CELL BIOL, V25, P7966, DOI 10.1128/MCB.25.18.7966-7975.2005; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; Creutz CE, 1998, J BIOL CHEM, V273, P1393, DOI 10.1074/jbc.273.3.1393; David A, 2003, J LEUKOCYTE BIOL, V74, P551, DOI 10.1189/jlb.1202624; Dickeson SK, 1998, CELL MOL LIFE SCI, V54, P556, DOI 10.1007/s000180050184; Fujikawa K, 2001, BLOOD, V98, P1662, DOI 10.1182/blood.V98.6.1662; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hoberg JE, 2006, MOL CELL BIOL, V26, P457, DOI 10.1128/MCB.26.2.457-471.2006; Hoberg JE, 2004, MOL CELL, V16, P245, DOI 10.1016/j.molcel.2004.10.010; Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Kang KH, 2001, J BIOL CHEM, V276, P24638, DOI 10.1074/jbc.M101291200; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kim TM, 2005, CLIN CANCER RES, V11, P79; Kurosawa S, 2000, J IMMUNOL, V165, P4697, DOI 10.4049/jimmunol.165.8.4697; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; Li SM, 2004, SCIENCE, V303, P540, DOI 10.1126/science.1091403; Lin L, 1996, MOL CELL BIOL, V16, P2248; Maine GN, 2007, EMBO J, V26, P436, DOI 10.1038/sj.emboj.7601489; Maitra R, 2003, BIOCHEM BIOPH RES CO, V303, P842, DOI 10.1016/S0006-291X(03)00445-5; Mayo MW, 2002, J BIOL CHEM, V277, P11116, DOI 10.1074/jbc.M108670200; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Phelps CB, 2000, J BIOL CHEM, V275, P24392, DOI 10.1074/jbc.M003784200; Preston GA, 2002, J AM SOC NEPHROL, V13, P2840, DOI 10.1097/01.ASN.0000034911.03334.C3; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; Saccani S, 2004, J EXP MED, V200, P107, DOI 10.1084/jem.20040196; Tomsig JL, 2004, BIOCHEM J, V378, P1089, DOI 10.1042/BJ20031654; Tomsig JL, 2003, J BIOL CHEM, V278, P10048, DOI 10.1074/jbc.M212632200; Tomsig JL, 2002, CELL MOL LIFE SCI, V59, P1467, DOI 10.1007/s00018-002-8522-7; Tomsig JL, 2000, BIOCHEMISTRY-US, V39, P16163, DOI 10.1021/bi0019949; Whittaker CA, 2002, MOL BIOL CELL, V13, P3369, DOI 10.1091/mbc.E02-05-0259; Wilson KS, 2002, AM J PATHOL, V161, P1171, DOI 10.1016/S0002-9440(10)64394-5; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	42	33	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2008	27	25					3516	3526		10.1038/sj.onc.1211030	http://dx.doi.org/10.1038/sj.onc.1211030			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18212740				2022-12-25	WOS:000256468500003
J	Lane, JR; Henderson, D; Powney, B; Wise, A; Rees, S; Daniels, D; Plumpton, C; Kinghorn, I; Milligan, G				Lane, J. Robert; Henderson, David; Powney, Ben; Wise, Alan; Rees, Stephen; Daniels, Dion; Plumpton, Chris; Kinghorn, Ian; Milligan, Graeme			Antibodies that identify only the active conformation of G(i) family G protein alpha subunits	FASEB JOURNAL			English	Article						G protein-coupled receptor; ligand screening	NUCLEOTIDE-BINDING PROTEIN-G0; HETEROTRIMERIC G-PROTEIN; MONOCLONAL-ANTIBODIES; COUPLED RECEPTORS; CRYSTAL-STRUCTURE; ADENYLATE-CYCLASE; GTPASE ACTIVITY; ACTIVATION; INHIBITION; ASSAY	Production of antisera able to recognize individual heterotrimeric G protein alpha subunits resulted in rapid expansion of information on their distribution and function. However, no antibodies that specifically recognize the active state have been available. Four-way primary screening of 763 hybridomas generated from mice immunized with guanosine 5'-O-(3-thio)triphosphate-loaded G alpha(i1) and isolated using an automated robotic colony picker identified three antibodies that interacted with the constitutively active, Q(204)L, mutant but neither the constitutively inactive, G(203)A, mutant nor wild-type G alpha(i1). This profile extended to other closely related G(i) family G proteins but not to the less closely related G alpha(s) and G alpha(q)/G alpha(11) families. Each antibody was, however, also able to identify wild-type, GDP-bound Gi family G proteins in the presence of fluoroaluminate, which mimics the presence of the terminal phosphate of GTP and hence generates an active/transition state conformation. Stimulation of cells coexpressing a wild-type G alpha(i) subunit and the dopamine D2 receptor with the agonist ligand norapomorphine also allowed these conformationally selective antibodies to bind the G protein. Such reagents allow the specific identification of activated G proteins in a native environment and may allow the development of label-free screening assays for G protein-coupled receptor-mediated activation of G(i) family G proteins.	[Lane, J. Robert; Henderson, David; Milligan, Graeme] Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Glasgow G12 8QQ, Lanark, Scotland; [Powney, Ben; Wise, Alan; Rees, Stephen; Daniels, Dion] GlaxoSmithKline Res & Dev Ltd, Screening & Compound Profiling, Harlow, Essex, England; [Plumpton, Chris; Kinghorn, Ian] GlaxoSmithKline Res & Dev Ltd, Biol Reagents & Assay Dev, Med Res Ctr, Stevenage, Herts, England	University of Glasgow; GlaxoSmithKline; GlaxoSmithKline	Milligan, G (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	g.milligan@bio.gla.ac.uk	Milligan, Graeme/F-9426-2011	Milligan, Graeme/0000-0002-6946-3519; Lane, J. Robert/0000-0002-7361-7875	Biotechnology and Biological Sciences Research Council Funding Source: Medline; Medical Research Council Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ADIE EJ, 1992, BIOCHEM J, V285, P529, DOI 10.1042/bj2850529; Bynum J, 1999, HYBRIDOMA, V18, P407, DOI 10.1089/hyb.1999.18.407; DAVIS JM, 1982, J IMMUNOL METHODS, V50, P161, DOI 10.1016/0022-1759(82)90222-8; Ferrer M, 2003, ASSAY DRUG DEV TECHN, V1, P261, DOI 10.1089/15406580360545071; Frang H, 2003, ASSAY DRUG DEV TECHN, V1, P275, DOI 10.1089/15406580360545080; Frank M, 2005, J BIOL CHEM, V280, P24584, DOI 10.1074/jbc.M414630200; Gales C, 2006, NAT STRUCT MOL BIOL, V13, P778, DOI 10.1038/nsmb1134; GIERSCHIK P, 1986, P NATL ACAD SCI USA, V83, P2258, DOI 10.1073/pnas.83.7.2258; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; Gupta A, 2007, J BIOL CHEM, V282, P5116, DOI 10.1074/jbc.M609254200; Harrison C, 2003, LIFE SCI, V74, P489, DOI 10.1016/j.lfs.2003.07.005; Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892; Jacoby E, 2006, CHEMMEDCHEM, V1, P760, DOI 10.1002/cmdc.200600134; Jameson EE, 2005, J BIOL CHEM, V280, P7712, DOI 10.1074/jbc.M413810200; Jameson EE, 2007, ANAL CHEM, V79, P1158, DOI 10.1021/ac061099g; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; Kilpatrick KE, 1997, HYBRIDOMA, V16, P381, DOI 10.1089/hyb.1997.16.381; Kostenis E, 2005, TRENDS PHARMACOL SCI, V26, P595, DOI 10.1016/j.tips.2005.09.007; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lane JR, 2007, MOL PHARMACOL, V71, P1349, DOI 10.1124/mol.106.032722; MAILLEUX P, 1992, NEUROSCIENCE, V51, P311, DOI 10.1016/0306-4522(92)90317-U; Mancia F, 2007, P NATL ACAD SCI USA, V104, P4303, DOI 10.1073/pnas.0700301104; MCCLUE SJ, 1992, BIOCHEM J, V284, P565, DOI 10.1042/bj2840565; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; Milligan G, 2006, BRIT J PHARMACOL, V147, pS46, DOI 10.1038/sj.bjp.0706405; Milligan G, 2003, TRENDS PHARMACOL SCI, V24, P87, DOI 10.1016/S0165-6147(02)00027-5; MILLIGAN G, 1988, BIOCHEM J, V255, P1; MITCHELL FM, 1993, BIOCHEM J, V293, P495, DOI 10.1042/bj2930495; MULLANEY I, 1990, J NEUROCHEM, V55, P1890, DOI 10.1111/j.1471-4159.1990.tb05773.x; Reiter E, 2006, TRENDS ENDOCRIN MET, V17, P159, DOI 10.1016/j.tem.2006.03.008; Rios C, 2006, BRIT J PHARMACOL, V148, P387, DOI 10.1038/sj.bjp.0706757; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943	36	13	13	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1924	1932		10.1096/fj.07-100388	http://dx.doi.org/10.1096/fj.07-100388			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18199696				2022-12-25	WOS:000256352700032
J	Roesli, C; Mumprecht, V; Neri, D; Detmar, M				Roesli, Christoph; Mumprecht, Viviane; Neri, Dario; Detmar, Michael			Identification of the surface-accessible, lineage-specific vascular proteome by two-dimensional peptide mapping	FASEB JOURNAL			English	Article						angiogenesis; lymphangiogenesis; endothelium; proteomics; membrane proteins	LYMPHATIC ENDOTHELIAL-CELLS; PROMOTES TUMOR-METASTASIS; MEMBRANE-PROTEINS; IN-VIVO; LYMPHANGIOGENESIS; DISEASE; GROWTH; INDUCTION; BIOTINYLATION; ANGIOGENESIS	The formation of blood vessels (angiogenesis) and of lymphatic vessels (lymphangiogenesis) actively contributes to cancer progression and inflammation. Thus, there has been a quest for identifying the molecular mechanisms that control lymphatic and blood vessel formation and function. Membrane and extracellular matrix proteins can serve as suitable targets for imaging and/or therapeutic targeting; however, conventional proteomic technologies often fail to identify them systematically due to insolubility in water and low abundance of membrane proteins. To circumvent this problem, we applied a gel-free proteomics methodology termed two-dimensional peptide mapping (2DPM) to cultured blood vascular (BECs) and lymphatic (LECs) endothelial cells. 2D-PM comprises biotinylation of surface-accessible proteins, their selective enrichment, separation by HPLC, and analysis by mass spectrometry. We identified 184 proteins that were specifically or predominantly expressed by LECs and 185 proteins specifically expressed by BECs, whereas 377 additional proteins were equally detected in both cell types. For representative proteins, the differential, lineage-specific expression was confirmed by Western analyses of cultured cells and by differential immunofluorescence analyses of tissue samples. Our results identify the surface-accessible, vascular lineage-specific proteome, and they also reveal 2D-PM as a powerful technology for the large-scale screening of lineage-specific protein expression.	[Roesli, Christoph; Mumprecht, Viviane; Neri, Dario; Detmar, Michael] ETH, Swiss Fed Inst Technol, Inst Pharmaceut Sci, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Detmar, M (corresponding author), ETH, Swiss Fed Inst Technol, Inst Pharmaceut Sci, Wolfgang Pauli Str 10,HCI H303, CH-8093 Zurich, Switzerland.	michael.detmar@pharma.ethz.ch	Neri, Dario/P-4368-2016; Roesli, Christoph/B-9527-2018	Neri, Dario/0000-0001-5234-7370; Roesli, Christoph/0000-0001-6182-5020	NCI NIH HHS [CA-69184, CA-92644] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA092644, R01CA069184] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alitalo K, 2005, NATURE, V438, P946, DOI 10.1038/nature04480; Alitalo K, 2002, CANCER CELL, V1, P219, DOI 10.1016/S1535-6108(02)00051-X; Bruneel A, 2003, PROTEOMICS, V3, P714, DOI 10.1002/pmic.200300409; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Christian S, 2003, J CELL BIOL, V163, P871, DOI 10.1083/jcb.200304132; Cueni LN, 2006, J INVEST DERMATOL, V126, P2167, DOI 10.1038/sj.jid.5700464; Durr E, 2004, NAT BIOTECHNOL, V22, P985, DOI 10.1038/nbt993; Hirakawa S, 2005, J EXP MED, V201, P1089, DOI 10.1084/jem.20041896; Hirakawa S, 2003, AM J PATHOL, V162, P575, DOI 10.1016/S0002-9440(10)63851-5; Hirakawa S, 2007, BLOOD, V109, P1010, DOI 10.1182/blood-2006-05-021758; Hong YK, 2004, NAT GENET, V36, P683, DOI 10.1038/ng1383; JOHNSON RS, 1987, ANAL CHEM, V59, P2621, DOI 10.1021/ac00148a019; Kajiya K, 2005, EMBO J, V24, P2885, DOI 10.1038/sj.emboj.7600763; Karsan A, 2005, MOL CELL PROTEOMICS, V4, P191, DOI 10.1074/mcp.M400152-MCP200; Kerjaschki D, 2006, NAT MED, V12, P230, DOI 10.1038/nm1340; Kriehuber E, 2001, J EXP MED, V194, P797, DOI 10.1084/jem.194.6.797; Kunstfeld R, 2004, BLOOD, V104, P1048, DOI 10.1182/blood-2003-08-2964; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Nasdala I, 2002, J BIOL CHEM, V277, P16294, DOI 10.1074/jbc.M111999200; Neri D, 2005, NAT REV CANCER, V5, P436, DOI 10.1038/nrc1627; Ogura Y, 2005, LIFE SCI, V77, P2804, DOI 10.1016/j.lfs.2005.05.028; Oliver G, 2002, GENE DEV, V16, P773, DOI 10.1101/gad.975002; Oliver G, 2004, NAT REV IMMUNOL, V4, P35, DOI 10.1038/nri1258; Olsen CL, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-43; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; Peitsch WK, 2005, J INVEST DERMATOL, V125, P761, DOI 10.1111/j.0022-202X.2005.23793.x; Petrova TV, 2002, EMBO J, V21, P4593, DOI 10.1093/emboj/cdf470; Podgrabinska S, 2002, P NATL ACAD SCI USA, V99, P16069, DOI 10.1073/pnas.242401399; Roesli C, 2006, CURR OPIN CHEM BIOL, V10, P35, DOI 10.1016/j.cbpa.2005.12.017; Rybak JN, 2005, NAT METHODS, V2, P291, DOI 10.1038/NMETH745; Sanchez J.-C, 2004, BIOMEDICAL APPL PROT; Scheurer SB, 2005, PROTEOMICS, V5, P2718, DOI 10.1002/pmic.200401163; Shin JW, 2006, MOL BIOL CELL, V17, P576, DOI 10.1091/mbc.E05-04-0368; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Stevens TJ, 2000, PROTEINS, V39, P417, DOI 10.1002/(SICI)1097-0134(20000601)39:4<417::AID-PROT140>3.0.CO;2-Y; Tobler NE, 2006, J LEUKOCYTE BIOL, V80, P691, DOI 10.1189/jlb.1105653	38	30	31	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					1933	1944		10.1096/fj.07-100529	http://dx.doi.org/10.1096/fj.07-100529			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18180333				2022-12-25	WOS:000256352700033
J	Newstead, SL; Potter, JA; Wilson, JC; Xu, GG; Chien, CH; Watts, AG; Withers, SG; Taylor, GL				Newstead, Simon L.; Potter, Jane A.; Wilson, Jennifer C.; Xu, Guogang; Chien, Chin-Hsiang; Watts, Andrew G.; Withers, Stephen G.; Taylor, Garry L.			The structure of Clostridium perfringens NanI sialidase and its catalytic intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; VIRUS NEURAMINIDASE; BACTERIAL SIALIDASE; BINDING; WATER; RECOGNITION; MECHANISM; HYDRATION; DOMAINS; COMPLEX	Clostridium perfringens is a Gram-positive bacterium responsible for bacteremia, gas gangrene, and occasionally food poisoning. Its genome encodes three sialidases, nanH, nanI, and nanJ, that are involved in the removal of sialic acids from a variety of glycoconjugates and that play a role in bacterial nutrition and pathogenesis. Recent studies on trypanosomal ( trans-) sialidases have suggested that catalysis in all sialidases may proceed via a covalent intermediate similar to that of other retaining glycosidases. Here we provide further evidence to support this suggestion by reporting the 0.97 angstrom resolution atomic structure of the catalytic domain of the C. perfringens NanI sialidase, and complexes with its substrate sialic acid ( N-acetylneuramic acid) also to 0.97 A resolution, with a transition-state analogue (2-deoxy2,3-dehydro-N-acetylneuraminic acid) to 1.5 A resolution, and with a covalent intermediate formed using a fluorinated sialic acid analogue to 1.2 angstrom resolution. Together, these structures provide high resolution snapshots along the catalytic pathway. The crystal structures suggested that NanI is able to hydrate 2-deoxy-2,3-dehydro-N-acetylneuraminic acid to N-acetylneuramic acid. This was confirmed by NMR, and a mechanism for this activity is suggested.	[Newstead, Simon L.; Potter, Jane A.; Xu, Guogang; Taylor, Garry L.] Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland; [Chien, Chin-Hsiang] Natl Yang Ming Univ, Sch Life Sci, Inst Biochem, Taipei 112, Taiwan; [Watts, Andrew G.; Withers, Stephen G.] Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada	University of St Andrews; National Yang Ming Chiao Tung University; University of British Columbia	Taylor, GL (corresponding author), Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland.	glt2@st-andrews.ac.uk	Taylor, Garry/G-3017-2014; Wilson, Jennifer/H-5297-2013; Xu, Guogang/AAN-9289-2020	Newstead, Simon/0000-0001-7432-2270; Taylor, Garry/0000-0001-9486-566X; /0000-0002-3056-9578; Xu, Guogang/0000-0002-6380-3500; Watts, Andrew/0000-0003-4299-2717	Biotechnology and Biological Sciences Research Council Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Amaya MF, 2004, STRUCTURE, V12, P775, DOI 10.1016/j.str.2004.02.036; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Boraston AB, 2004, BIOCHEM J, V382, P769, DOI 10.1042/BJ20040892; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURMEISTER WP, 1993, STRUCTURE, V1, P19, DOI 10.1016/0969-2126(93)90005-2; Buschiazzo A, 2000, EMBO J, V19, P16, DOI 10.1093/emboj/19.1.16; Buschiazzo A, 2002, MOL CELL, V10, P757, DOI 10.1016/S1097-2765(02)00680-9; Chavas LMG, 2005, J BIOL CHEM, V280, P469, DOI 10.1074/jbc.M411506200; CHONG AKJ, 1992, EUR J BIOCHEM, V207, P335, DOI 10.1111/j.1432-1033.1992.tb17055.x; Clarke C, 2001, J AM CHEM SOC, V123, P12238, DOI 10.1021/ja004315q; Crennell S, 2000, NAT STRUCT BIOL, V7, P1068; CRENNELL S, 1994, STRUCTURE, V2, P535, DOI 10.1016/S0969-2126(00)00053-8; CRENNELL SJ, 1993, P NATL ACAD SCI USA, V90, P9852, DOI 10.1073/pnas.90.21.9852; FLASHNER M, 1983, ARCH BIOCHEM BIOPHYS, V221, P188, DOI 10.1016/0003-9861(83)90135-2; GASKELL A, 1995, STRUCTURE, V3, P1197, DOI 10.1016/S0969-2126(01)00255-6; GLOSTER TM, 2004, J CHEM SOC CHEM COMM, V16, P1794; HEHRE EJ, 1977, BIOCHEMISTRY-US, V16, P1780, DOI 10.1021/bi00628a003; Holdgate GA, 1997, BIOCHEMISTRY-US, V36, P9663, DOI 10.1021/bi970294+; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kruse S, 1996, PROTEIN EXPRES PURIF, V7, P415, DOI 10.1006/prep.1996.0062; Ladbury JE, 1996, CHEM BIOL, V3, P973, DOI 10.1016/S1074-5521(96)90164-7; LAI ECK, 1994, BIOCHEMISTRY-US, V33, P14743, DOI 10.1021/bi00253a012; LEGLER G, 1990, ADV CARBOHYD CHEM BI, V48, P319, DOI 10.1016/S0065-2318(08)60034-7; LOU Y, 1998, J MOL BIOL, V285, P323; LOU Y, 1998, STRUCTURE CAMB, V6, P521; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Moustafa I, 2004, J BIOL CHEM, V279, P40819, DOI 10.1074/jbc.M404965200; Newstead S, 2004, ACTA CRYSTALLOGR D, V60, P2063, DOI 10.1107/S090744490402181X; Newstead SL, 2005, ACTA CRYSTALLOGR D, V61, P1483, DOI 10.1107/S0907444905026132; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; ROGGENTIN P, 1995, BIOL CHEM H-S, V376, P569; ROGGENTIN P, 1989, GLYCOCONJUGATE J, V6, P349, DOI 10.1007/BF01047853; Rood JI, 1998, ANNU REV MICROBIOL, V52, P333, DOI 10.1146/annurev.micro.52.1.333; Rye CS, 2000, CURR OPIN CHEM BIOL, V4, P573, DOI 10.1016/S1367-5931(00)00135-6; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Shimizu T, 2002, P NATL ACAD SCI USA, V99, P996, DOI 10.1073/pnas.022493799; Taylor G, 1996, CURR OPIN STRUC BIOL, V6, P830, DOI 10.1016/S0959-440X(96)80014-5; TAYLOR G, 1999, SIALOBIOLOGY OTHER N, P187; Thobhani S, 2003, J AM CHEM SOC, V125, P7154, DOI 10.1021/ja029759w; TRAVING C, 1994, GLYCOCONJUGATE J, V11, P141, DOI 10.1007/BF00731154; VARGHESE JN, 1992, PROTEINS, V14, P327, DOI 10.1002/prot.340140302; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0; Watson JN, 2003, BIOCHEMISTRY-US, V42, P12682, DOI 10.1021/bi035396g; Watts AG, 2006, J BIOL CHEM, V281, P4149, DOI 10.1074/jbc.M510677200; Watts AG, 2003, J AM CHEM SOC, V125, P7532, DOI 10.1021/ja0344967; WENTWORTH DF, 1974, BIOCHEMISTRY-US, V13, P4715, DOI 10.1021/bi00720a006	47	92	100	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9080	9088		10.1074/jbc.M710247200	http://dx.doi.org/10.1074/jbc.M710247200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18218621	Green Published, hybrid			2022-12-25	WOS:000254465800038
J	Pan, YP; Weng, J; Cao, Y; Bhosle, RC; Zhou, M				Pan, Yaping; Weng, Jun; Cao, Yu; Bhosle, Rahul C.; Zhou, Ming			Functional coupling between the Kv1.1 channel and aldoketoreductase Kv beta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED K+ CHANNELS; POTASSIUM CHANNEL; BETA-SUBUNIT; METHIONINE OXIDATION; MOLECULAR-BASIS; FAST INACTIVATION; ION CHANNELS; RAT-BRAIN; VOLTAGE; ALPHA	The Shaker family voltage-dependent potassium channels (Kv1) assemble with cytosolic beta-subunits (Kv beta) to form a stable complex. All Kv beta subunits have a conserved core domain, which in one of them (Kv beta 2) is an aldoketoreductase that utilizes NADPH as a cofactor. In addition to this core, Kv beta 1 has an N terminus that closes the channel by the N-type inactivation mechanism. Point mutations in the putative catalytic site of Kv beta 1 alter the on-rate of inactivation. Whether the core of Kv beta 1 functions as an enzyme and whether its enzymatic activity affects N-type inactivation had not been explored. Here, we show that Kv beta 1 is a functional aldoketoreductase and that oxidation of the Kv beta 1-bound cofactor, either enzymatically by a substrate or non-enzymatically by hydrogen peroxide or NADP(+), induces a large increase in open channel current. The modulation is not affected by deletion of the distal C terminus of the channel, which has been suggested in structural studies to interact with Kv beta. The rate of increase in current, which reflects NADPH oxidation, is similar to 2-fold faster at 0-mV membrane potential than at similar to 100 mV. Thus, cofactor oxidation by Kv beta 1 is regulated by membrane potential, presumably via voltage-dependent structural changes in Kv1.1 channels.	[Pan, Yaping; Weng, Jun; Cao, Yu; Bhosle, Rahul C.; Zhou, Ming] Columbia Univ Coll Phys & Surg, Dept Physiol & Cellular Biophys, New York, NY 10032 USA	Columbia University	Zhou, M (corresponding author), Columbia Univ Coll Phys & Surg, Dept Physiol & Cellular Biophys, 630 West 168th St, New York, NY 10032 USA.	mz2140@columbia.edu	Cao, Yu/GNP-6653-2022	Cao, Yu/0000-0003-1409-2068	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL086392] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 086392, R01 HL086392] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adelman JP, 1995, NEURON, V15, P1449, DOI 10.1016/0896-6273(95)90022-5; ALDRICH RW, 1979, J PHYSIOL-LONDON, V291, P531, DOI 10.1113/jphysiol.1979.sp012829; Bahring R, 2001, J BIOL CHEM, V276, P22923, DOI 10.1074/jbc.M100483200; Cahalan MD, 2001, J CLIN IMMUNOL, V21, P235, DOI 10.1023/A:1010958907271; Ciorba MA, 1999, FEBS LETT, V442, P48, DOI 10.1016/S0014-5793(98)01616-0; Ciorba MA, 1997, P NATL ACAD SCI USA, V94, P9932, DOI 10.1073/pnas.94.18.9932; CONNOR JA, 1971, J PHYSIOL-LONDON, V213, P31, DOI 10.1113/jphysiol.1971.sp009366; Gu C, 2003, SCIENCE, V301, P646, DOI 10.1126/science.1086998; Gulbis JM, 2000, SCIENCE, V289, P123, DOI 10.1126/science.289.5476.123; Heilstedt HA, 2001, EPILEPSIA, V42, P1103, DOI 10.1046/j.1528-1157.2001.08801.x; Heinemann SH, 1995, FEBS LETT, V377, P383, DOI 10.1016/0014-5793(95)01377-6; Hoshi T, 2001, J PHYSIOL-LONDON, V531, P1, DOI 10.1111/j.1469-7793.2001.0001j.x; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; Lee SH, 2000, CHEM RES TOXICOL, V13, P698, DOI 10.1021/tx000101a; Lee SY, 2003, AM J PHYSIOL-CELL PH, V284, pC1614, DOI 10.1152/ajpcell.00429.2002; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MCCORMACK T, 1994, CELL, V79, P1133, DOI 10.1016/0092-8674(94)90004-3; Murata Y, 2005, NATURE, V435, P1239, DOI 10.1038/nature03650; Nagaya N, 1997, J BIOL CHEM, V272, P3022, DOI 10.1074/jbc.272.5.3022; Nerbonne JM, 2000, J PHYSIOL-LONDON, V525, P285, DOI 10.1111/j.1469-7793.2000.t01-1-00285.x; Parcej DN, 2003, J MOL BIOL, V333, P103, DOI 10.1016/j.jmb.2003.07.009; Pongs O, 1999, ANN NY ACAD SCI, V868, P344, DOI 10.1111/j.1749-6632.1999.tb11296.x; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; RHODES KJ, 1995, J NEUROSCI, V15, P5360; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; Schlegel BP, 1998, BIOCHEMISTRY-US, V37, P3538, DOI 10.1021/bi9723055; SCOTT VES, 1994, P NATL ACAD SCI USA, V91, P1637, DOI 10.1073/pnas.91.5.1637; Sokolova O, 2003, P NATL ACAD SCI USA, V100, P12607, DOI 10.1073/pnas.2235650100; Tipparaju SM, 2005, AM J PHYSIOL-CELL PH, V288, pC366, DOI 10.1152/ajpcell.00354.2004; Trimmer JS, 2004, ANNU REV PHYSIOL, V66, P477, DOI 10.1146/annurev.physiol.66.032102.113328; Veal EA, 2007, MOL CELL, V26, P1, DOI 10.1016/j.molcel.2007.03.016; Wallner M, 1999, P NATL ACAD SCI USA, V96, P4137, DOI 10.1073/pnas.96.7.4137; Weng J, 2006, J BIOL CHEM, V281, P15194, DOI 10.1074/jbc.M513809200; Xia XM, 1999, J NEUROSCI, V19, P5255, DOI 10.1523/jneurosci.19-13-05255.1999; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	38	46	49	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8634	8642		10.1074/jbc.M709304200	http://dx.doi.org/10.1074/jbc.M709304200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18222921	Green Published, hybrid			2022-12-25	WOS:000254288000062
J	Seabold, GK; Wang, PY; Chang, K; Wang, CY; Wang, YX; Petralia, RS; Wenthold, RJ				Seabold, Gail K.; Wang, Philip Y.; Chang, Kai; Wang, Chang-Yu; Wang, Ya-Xian; Petralia, Ronald S.; Wenthold, Robert J.			The SALM family of adhesion-like molecules forms heteromeric and homomeric complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEAT; OLFACTORY-BULB AXONS; CELL-ADHESION; TRANSMEMBRANE PROTEINS; HIPPOCAMPAL-NEURONS; NEURITE OUTGROWTH; SYNAPSE FORMATION; NERVOUS-SYSTEM; SLIT PROTEINS; NMDA RECEPTOR	Synaptic adhesion-like molecules (SALMs) are a newly discovered family of adhesion molecules that play roles in synapse formation and neurite outgrowth. The SALM family is comprised of five homologous molecules that are expressed largely in the central nervous system. SALMs 1 - 3 contain PDZ-binding domains, whereas SALMs 4 and 5 do not. We are interested in characterizing the interactions of the SALMs both among the individual members and with other binding partners. In the present study, we focused on the interactions formed by the five SALM members in rat brain and heterologous cells. In brain, we found that SALMs 1 -3 strongly co-immunoprecipitated with each other, whereas SALMs 4 and 5 did not, suggesting that SALMs 4 and 5 mainly form homomeric complexes. In heterologous cells transfected with SALMs, co-immunoprecipitation studies showed that all five SALMs form heteromeric and homomeric complexes. We also determined if SALMs could form trans-cellular associations between transfected heterologous cells. Both SALMs 4 and 5 formed homophilic, but not heterophilic associations, whereas no trans associations were formed by the other SALMs. The ability of SALM4 to form trans interactions is due to its extracellular N terminus because chimeras of SALM4 N terminus and SALM2 C terminus can form trans interactions, whereas chimeras of SALM2 N terminus and SALM4 C terminus cannot. Co-culture experiments using HeLa cells and rat hippocampal neurons expressing the SALMs showed that SALM4 is recruited to points of contact between the cells. In neurons, these points of contact were seen in both axons and dendrites.	[Seabold, Gail K.; Wang, Philip Y.; Chang, Kai; Wang, Chang-Yu; Wang, Ya-Xian; Petralia, Ronald S.; Wenthold, Robert J.] NIDCD, NIH, Neurochem Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Wenthold, RJ (corresponding author), 50 S Dr,Bldg 50 Rm 4140, Bethesda, MD 20892 USA.	wenthold@nidcd.nih.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [ZIADC000003, Z01DC000003] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Abelson JF, 2005, SCIENCE, V310, P317, DOI 10.1126/science.1116502; Bando T, 2005, MOL CELL BIOL, V25, P4166, DOI 10.1128/MCB.25.10.4166-4175.2005; Barton WA, 2003, EMBO J, V22, P3291, DOI 10.1093/emboj/cdg325; Battye R, 2001, J NEUROSCI, V21, P4290, DOI 10.1523/JNEUROSCI.21-12-04290.2001; Benson DL, 2001, NAT REV NEUROSCI, V2, P899, DOI 10.1038/35104078; Biederer T, 2002, SCIENCE, V297, P1525, DOI 10.1126/science.1072356; Biederer T, 2007, NAT PROTOC, V2, P670, DOI 10.1038/nprot.2007.92; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; Brose K, 2000, CURR OPIN NEUROBIOL, V10, P95, DOI 10.1016/S0959-4388(99)00066-5; Buchstaller A, 1996, J CELL BIOL, V135, P1593, DOI 10.1083/jcb.135.6.1593; Carim-Todd L, 2003, EUR J NEUROSCI, V18, P3167, DOI 10.1111/j.1460-9568.2003.03003.x; Chen JH, 2001, J NEUROSCI, V21, P1548, DOI 10.1523/JNEUROSCI.21-05-01548.2001; Chen YN, 2006, BRAIN RES REV, V51, P265, DOI 10.1016/j.brainresrev.2005.11.005; Chih B, 2004, HUM MOL GENET, V13, P1471, DOI 10.1093/hmg/ddh158; Craig AM, 2006, TRENDS NEUROSCI, V29, P8, DOI 10.1016/j.tins.2005.11.002; Dalva MB, 2007, NAT REV NEUROSCI, V8, P206, DOI 10.1038/nrn2075; Dean C, 2003, NAT NEUROSCI, V6, P708, DOI 10.1038/nn1074; ESHHAR N, 1993, NEUROSCIENCE, V57, P943, DOI 10.1016/0306-4522(93)90040-M; Fogel AI, 2007, J NEUROSCI, V27, P12516, DOI 10.1523/JNEUROSCI.2739-07.2007; Fournier AE, 2002, J NEUROSCI, V22, P8876; Georgakopoulos A, 1999, MOL CELL, V4, P893, DOI 10.1016/S1097-2765(00)80219-1; Gerrow K, 2006, FRONT BIOSCI-LANDMRK, V11, P2400, DOI 10.2741/1978; Ginsberg MH, 2005, CURR OPIN CELL BIOL, V17, P509, DOI 10.1016/j.ceb.2005.08.010; Gomi F, 2000, J NEUROSCI, V20, P3206, DOI 10.1523/JNEUROSCI.20-09-03206.2000; Haines BP, 2005, DEV BIOL, V281, P145, DOI 10.1016/j.ydbio.2005.01.030; He XLL, 2003, NEURON, V38, P177, DOI 10.1016/S0896-6273(03)00232-0; HIRANO S, 1987, J CELL BIOL, V105, P2501, DOI 10.1083/jcb.105.6.2501; Hivert B, 2002, MOL CELL NEUROSCI, V21, P534, DOI 10.1006/mcne.2002.1193; Howitt JA, 2004, EMBO J, V23, P4406, DOI 10.1038/sj.emboj.7600446; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; Kaech S, 2006, NAT PROTOC, V1, P2406, DOI 10.1038/nprot.2006.356; Karaulanov EE, 2006, EMBO REP, V7, P283, DOI 10.1038/sj.embor.7400614; KINGSTON RE, 1997, CURRENT PROTOCOLS MO; Ko JW, 2006, NEURON, V50, P233, DOI 10.1016/j.neuron.2006.04.005; Kuja-Panula J, 2003, J CELL BIOL, V160, P963, DOI 10.1083/jcb.200209074; Kunz S, 1998, J CELL BIOL, V143, P1673, DOI 10.1083/jcb.143.6.1673; Lacy SE, 1999, GENOMICS, V62, P417, DOI 10.1006/geno.1999.6033; Li HS, 1999, CELL, V96, P807, DOI 10.1016/S0092-8674(00)80591-7; Li WW, 2004, J BIOL CHEM, V279, P43780, DOI 10.1074/jbc.M401803200; Lin JC, 2003, NAT NEUROSCI, V6, P1270, DOI 10.1038/nn1148; Liu Z, 2004, MOL CELL NEUROSCI, V26, P232, DOI 10.1016/j.mcn.2004.01.002; Maness PF, 2007, NAT NEUROSCI, V10, P19, DOI 10.1038/nn1827; Mi S, 2004, NAT NEUROSCI, V7, P221, DOI 10.1038/nn1188; Milligan ED, 2001, J NEUROSCI, V21, P2808, DOI 10.1523/JNEUROSCI.21-08-02808.2001; Morimura N, 2006, GENE, V380, P72, DOI 10.1016/j.gene.2006.05.014; Ono T, 2003, J NEUROSCI, V23, P5887; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; Petralia RS, 2005, MOL CELL NEUROSCI, V29, P436, DOI 10.1016/j.mcn.2005.03.013; Petralia RS, 1997, J COMP NEUROL, V385, P456, DOI 10.1002/(SICI)1096-9861(19970901)385:3<456::AID-CNE9>3.0.CO;2-2; Petralia RS, 1999, METH MOL B, V128, P73; Philibert RA, 2000, GENE, V246, P303, DOI 10.1016/S0378-1119(00)00049-4; Sans N, 2003, NAT CELL BIOL, V5, P520, DOI 10.1038/ncb990; Scheiffele P, 2000, CELL, V101, P657, DOI 10.1016/S0092-8674(00)80877-6; Shan WS, 2000, J CELL BIOL, V148, P579, DOI 10.1083/jcb.148.3.579; Sonderegger P, 1998, PROG BRAIN RES, V117, P93; Stoeckli ET, 1996, DEV BIOL, V177, P15, DOI 10.1006/dbio.1996.0141; STOECKLI ET, 1995, NEURON, V14, P1165, DOI 10.1016/0896-6273(95)90264-3; Taguchi A, 1996, MOL BRAIN RES, V35, P31, DOI 10.1016/0169-328X(95)00178-U; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; Taniguchi H, 2007, J NEUROSCI, V27, P2815, DOI 10.1523/JNEUROSCI.0032-07.2007; Tepass U, 2000, NAT REV MOL CELL BIO, V1, P91, DOI 10.1038/35040042; Wang CY, 2006, J NEUROSCI, V26, P2174, DOI 10.1523/JNEUROSCI.3799-05.2006; Washbourne P, 2004, J NEUROSCI, V24, P9244, DOI 10.1523/JNEUROSCI.3339-04.2004; Yamagata M, 2003, CURR OPIN CELL BIOL, V15, P621, DOI 10.1016/S0955-0674(03)00107-8	64	44	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8395	8405		10.1074/jbc.M709456200	http://dx.doi.org/10.1074/jbc.M709456200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18227064	hybrid, Green Published			2022-12-25	WOS:000254288000037
J	Holmstrom, TH; Mialon, A; Kallio, M; Nymalm, Y; Mannermaa, L; Holm, T; Johansson, H; Black, E; Gillespie, D; Salminen, TA; Langel, U; Valdez, BC; Westermarck, J				Holmstrom, Tim H.; Mialon, Antoine; Kallio, Marko; Nymalm, Yvonne; Mannermaa, Leni; Holm, Tina; Johansson, Henrik; Black, Elizabeth; Gillespie, David; Salminen, Tiina A.; Langel, Ulo; Valdez, Benigno C.; Westermarck, Jukka			c-Jun supports ribosomal RNA processing and nucleolar localization of RNA helicase DDX21	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE COMPLEMENTATION; CELL-PROLIFERATION; PROTEIN; II/GU; DIFFERENTIATION; TRANSFORMATION; TRANSCRIPTION; BIOGENESIS; APOPTOSIS; COFACTOR	The molecular mechanisms by which the AP-1 transcription factor c-Jun exerts its biological functions are not clearly understood. In addition to its well established role in transcriptional regulation of gene expression, several reports have suggested that c-Jun may also regulate cell behavior by non-transcriptional mechanisms. Here, we report that small interfering RNA-mediated depletion of c-Jun from mammalian cells results in inhibition of 28 S and 18 S rRNA accumulation. Moreover, we show that c-Jun depletion results in partial translocation of RNA helicase DDX21, implicated in rRNA processing, from the nucleolus to the nucleoplasm. We demonstrate that DDX21 translocation is rescued by exogenous c-Jun expression and that c-Jun depletion inhibits rRNA binding of DDX21. Furthermore, the direct interaction between c-Jun and DDX21 regulates nucleolar localization of DDX21. These results demonstrate that in addition to its transcriptional effects, c-Jun regulates rRNA processing and nucleolar compartmentalization of the rRNA processing protein DDX21. Thus, our results demonstrate a nucleolar mechanism through which c-Jun can regulate cell behavior. Moreover, these results suggest that the phenotypes observed previously in c-Jun-depleted mouse models and cell lines could be partly due to the effects of c-Jun on rRNA processing.	[Westermarck, Jukka] Univ Tampere, Inst Med Technol, Tampere 33520, Finland; [Westermarck, Jukka] Tampere Univ Hosp, Inst Med Technol, Tampere 33520, Finland; [Holmstrom, Tim H.; Mialon, Antoine; Kallio, Marko; Mannermaa, Leni; Westermarck, Jukka] Univ Turku, Ctr Biotechnol, FIN-20520 Turku, Finland; [Holmstrom, Tim H.; Mialon, Antoine; Kallio, Marko; Mannermaa, Leni; Westermarck, Jukka] Abo Akad Univ, Ctr Biotechnol, FIN-20520 Turku, Finland; [Valdez, Benigno C.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Houston, TX 77030 USA; [Gillespie, David] Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; [Black, Elizabeth; Gillespie, David] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; [Holm, Tina; Johansson, Henrik; Langel, Ulo] Univ Stockholm, Dept Neurochem, S-10691 Stockholm, Sweden; [Nymalm, Yvonne; Salminen, Tiina A.] Abo Akad Univ, Dept Biochem & Pharm, FIN-20520 Turku, Finland; [Holmstrom, Tim H.; Kallio, Marko] State Tech Res Ctr Finland, Turku 20521, Finland	Tampere University; Tampere University; Tampere University Hospital; University of Turku; Abo Akademi University; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; University of Glasgow; Beatson Institute; Stockholm University; Abo Akademi University	Westermarck, J (corresponding author), Univ Tampere, Inst Med Technol, Teiskontie 35, Tampere 33520, Finland.	ltjuwe@uta.fi	Johansson, Henrik J/O-3363-2014; Salminen, Tiina A./AAM-5443-2021; Salminen, Tiina A/G-7492-2019; Westermarck, Jukka/AAL-6464-2020	Johansson, Henrik J/0000-0003-4729-4205; Salminen, Tiina A./0000-0002-4135-8020; Salminen, Tiina A/0000-0002-4135-8020; Westermarck, Jukka/0000-0001-7478-3018; Langel, Ulo/0000-0001-6107-0844; Kallio, Marko/0000-0002-6345-1680; Gillespie, David/0000-0002-6338-0544				Behrens A, 2002, EMBO J, V21, P1782, DOI 10.1093/emboj/21.7.1782; Black EJ, 2004, ONCOGENE, V23, P2357, DOI 10.1038/sj.onc.1207377; Chudakov DM, 2004, NAT BIOTECHNOL, V22, P1435, DOI 10.1038/nbt1025; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Fang DY, 2004, P NATL ACAD SCI USA, V101, P14782, DOI 10.1073/pnas.0404445101; Henning D, 2003, J BIOL CHEM, V278, P52307, DOI 10.1074/jbc.M310846200; Hu CD, 2002, MOL CELL, V9, P789, DOI 10.1016/S1097-2765(02)00496-3; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Koch HB, 2007, CELL CYCLE, V6, P205, DOI 10.4161/cc.6.2.3742; Lapik YR, 2004, MOL CELL, V15, P17, DOI 10.1016/j.molcel.2004.05.020; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Leppa S, 2001, MOL CELL BIOL, V21, P4369, DOI 10.1128/MCB.21.13.4369-4378.2001; MacLaren A, 2004, MOL CELL BIOL, V24, P9006, DOI 10.1128/MCB.24.20.9006-9018.2004; Mariani O, 2007, CANCER CELL, V11, P361, DOI 10.1016/j.ccr.2007.02.007; Mialon A, 2005, MOL CELL BIOL, V25, P5040, DOI 10.1128/MCB.25.12.5040-5051.2005; Narayan K, 2007, NAT IMMUNOL, V8, P92, DOI 10.1038/ni1414; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Valdez BC, 2000, EUR J BIOCHEM, V267, P6395, DOI 10.1046/j.1432-1327.2000.01727.x; Valdez BC, 1998, BIOTECHNIQUES, V24, P1032, DOI 10.2144/98246cr03; Valdez BC, 1996, NUCLEIC ACIDS RES, V24, P1220, DOI 10.1093/nar/24.7.1220; Valdez BC, 1997, EUR J BIOCHEM, V250, P800, DOI 10.1111/j.1432-1033.1997.00800.x; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045; Westermarck J, 2002, EMBO J, V21, P451, DOI 10.1093/emboj/21.3.451; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Yang CS, 2005, MOL CELL BIOL, V25, P1298, DOI 10.1128/MCB.25.4.1298-1308.2005; Yang HS, 2003, J BIOL CHEM, V278, P38847, DOI 10.1074/jbc.M302258200	27	41	43	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					7046	7053		10.1074/jbc.M709613200	http://dx.doi.org/10.1074/jbc.M709613200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18180292	hybrid			2022-12-25	WOS:000253779600049
J	Kang, JA; Zhou, Y; Weis, TL; Liu, H; Ulaszek, J; Satgurunathan, N; Zhou, L; van Besien, K; Crispino, J; Verma, A; Low, PS; Wickrema, A				Kang, Jeong-Ah; Zhou, Ying; Weis, Tahlia L.; Liu, Hui; Ulaszek, Jodie; Satgurunathan, Nilesh; Zhou, Li; van Besien, Koen; Crispino, John; Verma, Amit; Low, Philip S.; Wickrema, Amittha			Osteopontin regulates actin cytoskeleton and contributes to cell proliferation in primary erythroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID PROGENITOR CELLS; PROTEIN-KINASE; SIGNALING PATHWAY; GENE-EXPRESSION; DEFICIENT MICE; ERYTHROPOIETIN; PHOSPHORYLATION; ACTIVATION; SURVIVAL; DIFFERENTIATION	Erythropoietin and stem cell factor are the key cytokines that regulate early stages of erythroid differentiation. However, it remains undetermined whether additional cytokines also play a role in the differentiation program. Here, we report that osteopontin (OPN) is highly expressed and secreted by erythroblasts during differentiation. We also demonstrate that OPN-deficient human and mouse erythroblasts exhibit defects in F-actin filaments, and addition of exogenous OPN to OPN-deficient erythroblasts restored the F-actin filaments in these cells. Furthermore, our studies demonstrate that OPN contributes to erythroblast proliferation. OPN knock-out male mice exhibit lower hematocrit and hemoglobin levels compared with their wild-type counterparts. We also show that OPN mediates phosphorylation or activation of multiple proteins including Rac-1 GTPase and the actin-binding protein, adducin, in human erythroblasts. In addition, we show that the OPN effects include regulation of intracellular calcium in human erythroblasts. Finally, we demonstrate that human erythroblasts express CD44 and integrins beta(1) and alpha(4), three known receptors for OPN, and that the integrin beta(1) receptor is involved in transmitting the proliferative signal. Together these results provide evidence for signal transduction by OPN and contribution to multiple functions during the erythroid differentiation program in human and mouse.	[Kang, Jeong-Ah; Zhou, Ying; Liu, Hui; Ulaszek, Jodie; Satgurunathan, Nilesh; van Besien, Koen; Crispino, John; Wickrema, Amittha] Univ Chicago, Hematol Oncol Sect, MC2115, Dept Med, Chicago, IL 60637 USA; [Weis, Tahlia L.; Low, Philip S.] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA; [Zhou, Li; Verma, Amit] Albert Einstein Univ, Dept Med, New York, NY 10461 USA	University of Chicago; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Yeshiva University	Wickrema, A (corresponding author), Univ Chicago, Hematol Oncol Sect, MC2115, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA.	Awickrem@medicine.bsd.uchicago.edu	van Besien, Koen W./G-4221-2012	van Besien, Koen W./0000-0002-8164-6211; Low, Philip/0000-0001-9042-5528; Crispino, John/0000-0002-8182-8306	NCI NIH HHS [R01 CA098550] Funding Source: Medline; NHLBI NIH HHS [R01 HL082946-02, HL082946, R01 HL082946-01, R01 HL082946] Funding Source: Medline; NIGMS NIH HHS [T32-GM008296-17, R01 GM024417, T32 GM008296] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098550] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082946] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024417, T32GM008296] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arai A, 2002, ONCOGENE, V21, P2641, DOI 10.1038/sj.onc.1205346; Ashkar S, 2000, SCIENCE, V287, P860, DOI 10.1126/science.287.5454.860; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; DENHARDT DT, 1995, ANN NY ACAD SCI, V760, P127, DOI 10.1111/j.1749-6632.1995.tb44625.x; Denhardt DT, 2001, ANNU REV PHARMACOL, V41, P723, DOI 10.1146/annurev.pharmtox.41.1.723; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; Duvall CL, 2007, J BONE MINER RES, V22, P286, DOI 10.1359/JBMR.061103; Fukata Y, 1999, J CELL BIOL, V145, P347, DOI 10.1083/jcb.145.2.347; Iwata M, 2004, BLOOD, V103, P4496, DOI 10.1182/blood-2004-01-0256; JacobsHelber SM, 1997, J BIOL CHEM, V272, P6850, DOI 10.1074/jbc.272.11.6850; KALTA TA, 2006, BLOOD, V108, P3637; Katagiri YU, 1999, CANCER RES, V59, P219; KELLEY LL, 1993, BLOOD, V82, P2340; Koury MJ, 2002, CURR OPIN HEMATOL, V9, P93, DOI 10.1097/00062752-200203000-00002; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KOURY ST, 1989, J CELL BIOL, V109, P3005, DOI 10.1083/jcb.109.6.3005; Lin YH, 2000, MOL CELL BIOL, V20, P2734, DOI 10.1128/MCB.20.8.2734-2742.2000; Lin YH, 2001, J BIOL CHEM, V276, P46024, DOI 10.1074/jbc.M105132200; Manno S, 2005, J BIOL CHEM, V280, P7581, DOI 10.1074/jbc.M410650200; Matsuoka Y, 1996, J BIOL CHEM, V271, P25157, DOI 10.1074/jbc.271.41.25157; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; MUTA K, 1994, J CLIN INVEST, V94, P34, DOI 10.1172/JCI117327; MUTA K, 1995, BLOOD, V86, P572, DOI 10.1182/blood.V86.2.572.bloodjournal862572; Razzouk S, 2002, BONE, V30, P40, DOI 10.1016/S8756-3282(01)00637-8; Rittling SR, 1999, EXP NEPHROL, V7, P103; Stamnes M, 2002, CURR OPIN CELL BIOL, V14, P428, DOI 10.1016/S0955-0674(02)00349-6; Uddin S, 2004, P NATL ACAD SCI USA, V101, P147, DOI 10.1073/pnas.0307075101; WASEEM A, 1988, EUR J BIOCHEM, V178, P563, DOI 10.1111/j.1432-1033.1988.tb14483.x; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; WICKREMA A, 1992, BLOOD, V80, P1940, DOI 10.1182/blood.V80.8.1940.1940; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; WICKREMA A, 1994, J CELL PHYSIOL, V160, P417, DOI 10.1002/jcp.1041600304	33	33	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					6997	7006		10.1074/jbc.M706712200	http://dx.doi.org/10.1074/jbc.M706712200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18174176	hybrid, Green Accepted			2022-12-25	WOS:000253779600044
J	Krol, HA; Krawczyk, PM; Bosch, KS; Aten, JA; Hol, EM; Reits, EA				Krol, Hilde A.; Krawczyk, Przemek M.; Bosch, Klazien S.; Aten, Jacob A.; Hol, Elly M.; Reits, Eric A.			Polyglutamine Expansion Accelerates the Dynamics of Ataxin-1 and Does Not Result in Aggregate Formation	PLOS ONE			English	Article								Background. Polyglutamine expansion disorders are caused by an expansion of the polyglutamine (polyQ) tract in the disease related protein, leading to severe neurodegeneration. All polyQ disorders are hallmarked by the presence of intracellular aggregates containing the expanded protein in affected neurons. The polyQ disorder SpinoCerebellar Ataxia 1 (SCA1) is caused by a polyQ-expansion in the ataxin-1 protein, which is thought to lead to nuclear aggregates. Methodology/Principal Findings. Using advanced live cell fluorescence microscopy and a filter retardation assay we show that nuclear accumulations formed by polyQ-expanded ataxin-1 do not resemble aggregates of other polyQ-expanded proteins. Instead of being static, insoluble aggregates, nuclear accumulations formed by the polyQ-expanded ataxin-1 showed enhanced intracellular kinetics as compared to wild-type ataxin-1. During mitosis, ataxin-1 accumulations redistributed equally among daughter cells, in contrast to polyQ aggregates. Interestingly, polyQ expansion did not affect the nuclear-cytoplasmic shuttling of ataxin-1 as proposed before. Conclusions/Significance. These results indicate that polyQ expansion does not necessarily lead to aggregate formation, and that the enhanced kinetics may affect the nuclear function of ataxin-1. The unexpected findings for a polyQ-expanded protein and their consequences for ongoing SCA1 research are discussed.	[Krol, Hilde A.; Krawczyk, Przemek M.; Bosch, Klazien S.; Aten, Jacob A.; Reits, Eric A.] Univ Amsterdam, Acad Med Ctr, Dept Cell Biol & Histol, NL-1105 AZ Amsterdam, Netherlands; [Hol, Elly M.] Royal Netherlands Acad Arts & Sci, Netherlands Inst Neurosci, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW)	Reits, EA (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Cell Biol & Histol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	e.a.reits@amc.uva.nl	Hol, Elly/J-2025-2019; Hol, Elly M/F-1891-2013	Hol, Elly/0000-0001-5604-2603; Hol, Elly M/0000-0001-5604-2603	NWO [Veni Grant]	NWO(Netherlands Organization for Scientific Research (NWO))	Supported by NWO-Veni grant	BEENA T, 1998, CLUES PATHOGENESIS S, P241; Burright EN, 1997, HUM MOL GENET, V6, P513, DOI 10.1093/hmg/6.4.513; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Cummings CJ, 2000, ANNU REV GENOM HUM G, V1, P281, DOI 10.1146/annurev.genom.1.1.281; de Chiara C, 2005, J MOL BIOL, V354, P883, DOI 10.1016/j.jmb.2005.09.083; Gold DA, 2003, NEURON, V40, P1119, DOI 10.1016/S0896-6273(03)00769-4; Hobdy-Henderson KC, 2003, TRAFFIC, V4, P681, DOI 10.1034/j.1600-0854.2003.00124.x; Irwin S, 2005, J CELL SCI, V118, P233, DOI 10.1242/jcs.01611; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Lam YC, 2006, CELL, V127, P1335, DOI 10.1016/j.cell.2006.11.038; Llorian M, 2005, J BIOL CHEM, V280, P38862, DOI 10.1074/jbc.M509185200; Matilla A, 1997, NATURE, V389, P974, DOI 10.1038/40159; MATILLADUENAS A, 2007, CLIN GENETIC MOL PAT, P1; Mizutani A, 2005, EMBO J, V24, P3339, DOI 10.1038/sj.emboj.7600785; Okazawa H, 2002, NEURON, V34, P701, DOI 10.1016/S0896-6273(02)00697-9; Ordway JM, 1997, CELL, V91, P753, DOI 10.1016/S0092-8674(00)80464-X; ROBITAILLE Y, 1995, ACTA NEUROPATHOL, V90, P572; Rujano MA, 2006, PLOS BIOL, V4, P2325, DOI 10.1371/journal.pbio.0040417; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Serra HG, 2006, CELL, V127, P697, DOI 10.1016/j.cell.2006.09.036; Serra HG, 2004, HUM MOL GENET, V13, P2535, DOI 10.1093/hmg/ddh268; SERVADIO A, 1995, NAT GENET, V10, P94, DOI 10.1038/ng0595-94; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; Slow EJ, 2005, P NATL ACAD SCI USA, V102, P11402, DOI 10.1073/pnas.0503634102; Stenoien DL, 2002, NAT CELL BIOL, V4, P806, DOI 10.1038/ncb859; Tsai CC, 2004, P NATL ACAD SCI USA, V101, P4047, DOI 10.1073/pnas.0400615101; Tsuda H, 2005, CELL, V122, P633, DOI 10.1016/j.cell.2005.06.012; Wanker EE, 1999, METHOD ENZYMOL, V309, P375; Yue S, 2001, HUM MOL GENET, V10, P25, DOI 10.1093/hmg/10.1.25	30	12	14	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2008	3	1							e1503	10.1371/journal.pone.0001503	http://dx.doi.org/10.1371/journal.pone.0001503			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SR	18231590	Green Published, Green Submitted, gold			2022-12-25	WOS:000260504200016
J	Lohse, MB; Johnson, AD				Lohse, Matthew B.; Johnson, Alexander D.			Differential Phagocytosis of White versus Opaque Candida albicans by Drosophila and Mouse Phagocytes	PLOS ONE			English	Article								The human fungal pathogen Candida albicans resides asymptomatically in the gut of most healthy people but causes serious invasive diseases in immunocompromised patients. Many C. albicans strains have the ability to stochastically switch between distinct white and opaque cell types, but it is not known with certainty what role this switching plays in the physiology of the organism. Here, we report a previously undescribed difference between white and opaque cells, namely their interaction with host phagocytic cells. We show that both Drosophila hemocyte- derived S2 cells and mouse macrophage-derived RAW264.7 cells preferentially phagocytose white cells over opaque cells. This difference is seen both in the overall percentage of cultured cells that phagocytose white versus opaque C. albicans and in the average number of C. albicans taken up by each phagocytic cell. We conclude that susceptibility to phagocytosis by cells of the innate immune system is an important distinction between white and opaque C. albicans, and propose that one role of switching from the prevalent white form into the rarer opaque form may be to allow C. albicans to escape phagocytosis.	[Lohse, Matthew B.; Johnson, Alexander D.] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; [Johnson, Alexander D.] Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Johnson, AD (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.	ajohnson@cgl.ucsf.edu			Ellison Medical Foundation [ID-SS-0628-04]; National Institutes of Health [A149187]; NSF [graduate research fellowship]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049187] Funding Source: NIH RePORTER	Ellison Medical Foundation(Lawrence Ellison Foundation); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF(National Science Foundation (NSF)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was funded by Ellison Medical Foundation grant ID-SS-0628-04 and National Institutes of Health RO1 grant A149187. MBL was supported by a NSF graduate research fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agaisse H, 2005, SCIENCE, V309, P1248, DOI 10.1126/science.1116008; Behnsen J, 2007, PLOS PATHOG, V3, P138, DOI 10.1371/journal.ppat.0030013; Bennett RJ, 2005, ANNU REV MICROBIOL, V59, P233, DOI 10.1146/annurev.micro.59.030804.121310; Cheng LW, 2003, CELL MICROBIOL, V5, P875, DOI 10.1046/j.1462-5822.2003.00327.x; Elrod-Erickson M, 2000, CURR BIOL, V10, P781, DOI 10.1016/S0960-9822(00)00569-8; Geiger J, 2004, INFECT IMMUN, V72, P667, DOI 10.1128/IAI.72.2.667-677.2004; Huang GH, 2006, P NATL ACAD SCI USA, V103, P12813, DOI 10.1073/pnas.0605270103; Johnson A, 2003, NAT REV MICROBIOL, V1, P106, DOI 10.1038/nrmicro752; KOLOTILA MP, 1990, INFECT IMMUN, V58, P1174, DOI 10.1128/IAI.58.5.1174-1179.1990; Kvaal C, 1999, INFECT IMMUN, V67, P6652; Kvaal CA, 1997, INFECT IMMUN, V65, P4468, DOI 10.1128/IAI.65.11.4468-4475.1997; Lachke SA, 2003, INFECT IMMUN, V71, P4970, DOI 10.1128/IAI.71.9.4970-4976.2003; Lan CY, 2002, P NATL ACAD SCI USA, V99, P14907, DOI 10.1073/pnas.232566499; Lockhart SR, 2003, EUKARYOT CELL, V2, P49, DOI 10.1128/EC.2.1.49-61.2003; Marcil A, 2002, INFECT IMMUN, V70, P6319, DOI 10.1128/IAI.70.11.6319-6329.2002; Miller MG, 2002, CELL, V110, P293, DOI 10.1016/S0092-8674(02)00837-1; Pearson AM, 2003, MICROBES INFECT, V5, P815, DOI 10.1016/S1286-4579(03)00157-6; Philips JA, 2005, SCIENCE, V309, P1251, DOI 10.1126/science.1116006; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; RIKKERINK EHA, 1988, J BACTERIOL, V170, P895, DOI 10.1128/jb.170.2.895-899.1988; SLUTSKY B, 1987, J BACTERIOL, V169, P189, DOI 10.1128/JB.169.1.189-197.1987; SOLL DR, 1993, TRENDS GENET, V9, P61, DOI 10.1016/0168-9525(93)90189-O; Soll DR, 2004, BIOESSAYS, V26, P10, DOI 10.1002/bies.10379; Srikantha T, 2006, EUKARYOT CELL, V5, P1674, DOI 10.1128/EC.00252-06; Stroschein-Stevenson SL, 2006, PLOS BIOL, V4, P87, DOI 10.1371/journal.pbio.0040004; Tsong AE, 2003, CELL, V115, P389, DOI 10.1016/S0092-8674(03)00885-7; Zordan RE, 2006, P NATL ACAD SCI USA, V103, P12807, DOI 10.1073/pnas.0605138103	27	99	102	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2008	3	1							e1473	10.1371/journal.pone.0001473	http://dx.doi.org/10.1371/journal.pone.0001473			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SO	18213381	Green Published, Green Submitted, gold			2022-12-25	WOS:000260503900018
J	Wang, Y; Werz, C; Xu, DB; Chen, ZH; Li, Y; Hafen, E; Bergmann, A				Wang, Yuan; Werz, Christian; Xu, Dongbin; Chen, Zhihong; Li, Ying; Hafen, Ernst; Bergmann, Andreas			Drosophila cbl Is Essential for Control of Cell Death and Cell Differentiation during Eye Development	PLOS ONE			English	Article								Background. Activation of cell surface receptors transduces extracellular signals into cellular responses such as proliferation, differentiation and survival. However, as important as the activation of these receptors is their appropriate spatial and temporal down-regulation for normal development and tissue homeostasis. The Cbl family of E3-ubiquitin ligases plays a major role for the ligand-dependent inactivation of receptor tyrosine kinases (RTKs), most notably the Epidermal Growth Factor Receptor (EGFR) through ubiquitin-mediated endocytosis and lysosomal degradation. Methodology/Principal Findings. Here, we report the mutant phenotypes of Drosophila cbl (D-cbl) during eye development. D-cbl mutants display overgrowth, inhibition of apoptosis, differentiation defects and increased ommatidial spacing. Using genetic interaction and molecular markers, we show that most of these phenotypes are caused by increased activity of the Drosophila EGFR. Our genetic data also indicate a critical role of ubiquitination for D-cbl function, consistent with biochemical models. Conclusions/Significance. These data may provide a mechanistic model for the understanding of the oncogenic activity of mammalian cbl genes.	[Werz, Christian; Hafen, Ernst] Eidgenoss Tech Hochschule Zurich, Inst Mol Syst Biol, Zurich, Switzerland; [Wang, Yuan; Xu, Dongbin; Chen, Zhihong; Li, Ying] Univ Texas MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Bergmann, A (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA.	abergman@mdanderson.org	Xu, Dongbin/C-1469-2012		National Institutes of Health (NIH) [GM068016]; MD Anderson DNA Analysis Core Facility [CA16672]; NIH Cancer Center; Robert A. Welch Foundation [G-1496]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068016] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MD Anderson DNA Analysis Core Facility; NIH Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Robert A. Welch Foundation(The Welch Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by National Institutes of Health (NIH) grant GM068016 to AB. Sequencing by the MD Anderson DNA Analysis Core Facility was supported by the NIH Cancer Center support grant CA16672. We gratefully acknowledge support by the Robert A. Welch Foundation (G-1496).	Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; BASLER K, 1989, SCIENCE, V243, P931, DOI 10.1126/science.2493159; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; CAGAN RL, 1989, DEV BIOL, V136, P346, DOI 10.1016/0012-1606(89)90261-3; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; Cordero J, 2004, MECH DEVELOP, V121, P1523, DOI 10.1016/j.mod.2004.07.004; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; FREEMAN M, 1994, MECH DEVELOP, V48, P25, DOI 10.1016/0925-4773(94)90003-5; FREEMAN M, 1992, CELL, V69, P963, DOI 10.1016/0092-8674(92)90615-J; Gabay L, 1997, SCIENCE, V277, P1103, DOI 10.1126/science.277.5329.1103; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Griffiths EK, 2003, MOL CELL BIOL, V23, P7708, DOI 10.1128/MCB.23.21.7708-7718.2003; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Herz HM, 2006, DEVELOPMENT, V133, P1871, DOI 10.1242/dev.02356; Hime GR, 1997, ONCOGENE, V14, P2709, DOI 10.1038/sj.onc.1201223; Jekely G, 2005, DEV CELL, V9, P197, DOI 10.1016/j.devcel.2005.06.004; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Karim FD, 1996, GENETICS, V143, P315; Kramer S, 1999, DEVELOPMENT, V126, P2515; KRETZSCHMAR D, 1992, EMBO J, V11, P2531, DOI 10.1002/j.1460-2075.1992.tb05318.x; Krieser RJ, 2007, DEVELOPMENT, V134, P2407, DOI 10.1242/dev.02860; Kumar JP, 1998, DEVELOPMENT, V125, P3875; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; Kwak EL, 2006, CLIN CANCER RES, V12, P4283, DOI 10.1158/1078-0432.CCR-06-0189; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LEBOVITZ RM, 1986, DEV BIOL, V117, P663, DOI 10.1016/0012-1606(86)90335-0; Lesokhin AM, 1999, DEV BIOL, V205, P129, DOI 10.1006/dbio.1998.9121; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Newsome TP, 2000, DEVELOPMENT, V127, P851; OKANO H, 1992, DIFFERENTIATION, V52, P1, DOI 10.1111/j.1432-0436.1992.tb00494.x; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pai LM, 2000, CELL, V103, P51, DOI 10.1016/S0092-8674(00)00104-5; Peschard P, 2003, CANCER CELL, V3, P519, DOI 10.1016/S1535-6108(03)00136-3; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; Robertson H, 2000, ONCOGENE, V19, P3299, DOI 10.1038/sj.onc.1203624; Rohrbaugh M, 2002, CURR BIOL, V12, P576, DOI 10.1016/S0960-9822(02)00743-1; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; Schmidt MHH, 2005, NAT REV MOL CELL BIO, V6, P907, DOI 10.1038/nrm1762; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; Srivastava M, 2007, CELL DEATH DIFFER, V14, P92, DOI 10.1038/sj.cdd.4401931; Thien CBF, 2005, GROWTH FACTORS, V23, P161, DOI 10.1080/08977190500153763; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Tio M, 1997, DEVELOPMENT, V124, P343; Tsygankov AY, 2001, ONCOGENE, V20, P6382, DOI 10.1038/sj.onc.1204781; Voas MG, 2004, DEV DYNAM, V229, P162, DOI 10.1002/dvdy.10449; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Werz C, 2005, DEVELOPMENT, V132, P5343, DOI 10.1242/dev.02150; Xu D, 2006, CELL DEATH DIFFER, V13, P1697, DOI 10.1038/sj.cdd.4401920; Xu DB, 2005, DEVELOPMENT, V132, P2125, DOI 10.1242/dev.01790; XU T, 1993, DEVELOPMENT, V117, P1223; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Yu SY, 2002, DEVELOPMENT, V129, P3269	65	15	15	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2008	3	1							e1447	10.1371/journal.pone.0001447	http://dx.doi.org/10.1371/journal.pone.0001447			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SN	18197257	Green Submitted, gold, Green Published			2022-12-25	WOS:000260503800018
J	Zhu, QJ; Liu, C; Ge, Z; Fang, XL; Zhang, X; Straat, K; Bjorkholm, M; Xu, DW				Zhu, Qingjun; Liu, Cheng; Ge, Zheng; Fang, Xiaolei; Zhang, Xi; Straat, Klas; Bjorkholm, Magnus; Xu, Dawei			Lysine-Specific Demethylase 1 (LSD1) Is Required for the Transcriptional Repression of the Telomerase Reverse Transcriptase (hTERT) Gene	PLOS ONE			English	Article								Background. Lysine-specific demethylase 1 (LSD1), catalysing demethylation of mono- and di-methylated histone H3-K4 or K9, exhibits diverse transcriptional activities by mediating chromatin reconfiguration. The telomerase reverse transcriptase (hTERT) gene, encoding an essential component for telomerase activity that is involved in cellular immortalization and transformation, is silent in most normal human cells while activated in up to 90% of human cancers. It remains to be defined how exactly the transcriptional activation of the hTERT gene occurs during the oncogenic process. Methodology/Principal Findings. In the present study, we determined the effect of LSD1 on hTERT transcription. In normal human fibroblasts with a tight hTERT repression, a pharmacological inhibition of LSD1 led to a weak hTERT expression, and a robust induction of hTERT mRNA was observed when LSD1 and histone deacetylases (HDACs) were both inhibited. Small interference RNA-mediated depletion of both LSD1 and CoREST, a co-repressor in HDAC-containing complexes, synergistically activated hTERT transcription. In cancer cells, inhibition of LSD1 activity or knocking-down of its expression led to significant increases in levels of hTERT mRNA and telomerase activity. Chromatin immunoprecipitation assay showed that LSD1 occupied the hTERT proximal promoter, and its depletion resulted in elevated di-methylation of histone H3-K4 accompanied by increased H3 acetylation locally in cancer cells. Moreover, during the differentiation of leukemic HL60 cells, the decreased hTERT expression was accompanied by the LSD1 recruitment to the hTERT promoter. Conclusions/Significance. LSD1 represses hTERT transcription via demethylating H3-K4 in normal and cancerous cells, and together with HDACs, participates in the establishment of a stable repression state of the hTERT gene in normal or differentiated malignant cells. The findings contribute to better understandings of hTERT/telomerase regulation, which may be implicated in the development of therapeutic strategies for telomerase dysregulation-associated human diseases including cancers.	[Zhu, Qingjun] Shandong Univ Traditional Chinese Med, Coll Basic Med Sci, Jinan, Peoples R China; [Fang, Xiaolei] Shandong Univ, Second Hosp, Inst Urol, Jinan, Peoples R China; [Zhang, Xi] Shandong Univ, Qilu Hosp, Dept Obstet & Gynecol, Jinan, Peoples R China; [Zhu, Qingjun; Liu, Cheng; Ge, Zheng; Straat, Klas; Bjorkholm, Magnus; Xu, Dawei] Karolinska Univ, Hosp Solna, Karolinska Inst, Dept Med,Div Hematol, Stockholm, Sweden	Shandong University of Traditional Chinese Medicine; Shandong University; Shandong University; Karolinska Institutet; Karolinska University Hospital	Xu, DW (corresponding author), Karolinska Univ, Hosp Solna, Karolinska Inst, Dept Med,Div Hematol, Stockholm, Sweden.	Dawei.Xu@ki.se		Xu, Dawei/0000-0003-3141-4524	Swedish Cancer Society; Cancer Society in Stockholm; Swedish Research Council; Swedish Society of Medicine; Stockholm County Council; Karolinsks Institute Foundation	Swedish Cancer Society(Swedish Cancer Society); Cancer Society in Stockholm; Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Society of Medicine; Stockholm County Council(Stockholm County Council); Karolinsks Institute Foundation	This study was supported by grants from The Swedish Cancer Society, the Cancer Society in Stockholm, the Swedish Research Council, Swedish Society of Medicine, Stockholm County Council and the Karolinsks Institute Foundation (D Xu). The funders played no part in the work related to this manuscript.	Albanell J, 1996, CANCER RES, V56, P1503; Atkinson SP, 2005, CANCER RES, V65, P7585, DOI 10.1158/0008-5472.CAN-05-1715; Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Blasco MA, 2005, NAT REV GENET, V6, P611, DOI 10.1038/nrg1656; Christensen J, 2007, CELL, V128, P1063, DOI 10.1016/j.cell.2007.02.003; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200; Flores I, 2005, SCIENCE, V309, P1253, DOI 10.1126/science.1115025; Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038; Ge Z, 2006, MOL CELL BIOL, V26, P230, DOI 10.1128/MCB.26.1.230-237.2006; Guccione E, 2006, NAT CELL BIOL, V8, P764, DOI 10.1038/ncb1434; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Horikawa I, 2003, CARCINOGENESIS, V24, P1167, DOI 10.1093/carcin/bgg085; Horikawa I, 1999, CANCER RES, V59, P826; Hou M, 2002, EXP CELL RES, V274, P25, DOI 10.1006/excr.2001.5462; Huang Y, 2007, P NATL ACAD SCI USA, V104, P8023, DOI 10.1073/pnas.0700720104; Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570; Klose RJ, 2007, CELL, V128, P889, DOI 10.1016/j.cell.2007.02.013; Kumakura S, 2005, CANCER RES, V65, P2778, DOI 10.1158/0008-5472.CAN-04-1819; Kyo S, 2002, ONCOGENE, V21, P688, DOI 10.1038/sj.onc.1205163; Lan F, 2007, MOL CELL, V26, P89, DOI 10.1016/j.molcel.2007.02.023; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Lee MG, 2006, MOL CELL BIOL, V26, P6395, DOI 10.1128/MCB.00723-06; Lee MG, 2006, CHEM BIOL, V13, P563, DOI 10.1016/j.chembiol.2006.05.004; Lin SY, 2003, CELL, V113, P881, DOI 10.1016/S0092-8674(03)00430-6; Liu C, 2007, CANCER RES, V67, P2626, DOI 10.1158/0008-5472.CAN-06-4126; Liu JP, 1999, FASEB J, V13, P2091, DOI 10.1096/fasebj.13.15.2091; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Rudolph T, 2007, MOL CELL, V26, P103, DOI 10.1016/j.molcel.2007.02.025; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Sarin KY, 2005, NATURE, V436, P1048, DOI 10.1038/nature03836; Sharma HW, 1995, P NATL ACAD SCI USA, V92, P12343, DOI 10.1073/pnas.92.26.12343; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shi Y, 2007, MOL CELL, V25, P1, DOI 10.1016/j.molcel.2006.12.010; Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Takakura M, 1999, CANCER RES, V59, P551; Takakura M, 2001, NUCLEIC ACIDS RES, V29, P3006, DOI 10.1093/nar/29.14.3006; Wang JX, 2007, NATURE, V446, P882, DOI 10.1038/nature05671; Wang SW, 2004, J BIOL CHEM, V279, P55401, DOI 10.1074/jbc.M411352200; Wang SW, 2003, J BIOL CHEM, V278, P18842, DOI 10.1074/jbc.M209544200; Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546; Xu D, 1996, LEUKEMIA, V10, P1354; Xu DW, 1998, BRIT J HAEMATOL, V102, P1367, DOI 10.1046/j.1365-2141.1998.00969.x; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; Zhang W, 1996, CLIN CANCER RES, V2, P799	46	24	28	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2008	3	1							e1446	10.1371/journal.pone.0001446	http://dx.doi.org/10.1371/journal.pone.0001446			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SN	18197256	gold, Green Published, Green Submitted			2022-12-25	WOS:000260503800017
J	Chen, GL; Zhou, XY; Nicolaou, P; Rodriguez, P; Song, GJ; Mitton, B; Pathak, A; Zachariah, A; Fan, GC; Dorn, GW; Kranias, EG				Chen, Guoli; Zhou, Xiaoyang; Nicolaou, Persoulla; Rodriguez, Patricia; Song, Guojie; Mitton, Bryan; Pathak, Anand; Zachariah, Amit; Fan, Guo-Chang; Dorn, Gerald W., II; Kranias, Evangelia G.			A human polymorphism of protein phosphatase-1 inhibitor-1 is associated with attenuated contractile response of cardiomyocytes to beta-adrenergic stimulation	FASEB JOURNAL			English	Article						cardiac function; phospholamban; heart failure	PROTEIN PHOSPHATASE INHIBITOR-1; HEART-FAILURE; TROPONIN-I; SIGNAL-TRANSDUCTION; HORMONAL-REGULATION; CARDIAC MYOCYTES; BINDING PROTEIN; RABBIT HEART; PHOSPHORYLATION; RECEPTORS	Aberrant beta-adrenergic signaling and depressed calcium homeostasis, associated with an imbalance of protein kinase A and phosphatase-1 activities, are hallmarks of heart failure. Phosphatase-1 is restrained by its endogenous inhibitor, protein phosphatase inhibitor-1 (PPI-1). We assessed 352 normal subjects, along with 959 patients with heart failure and identified a polymorphism in PPI-1 (G147D) exclusively in black subjects. To determine whether the G147D variant could affect cardiac function, we infected adult cardiomyocytes with adenoviruses expressing D147 or wild-type (G147) PPI-1. Under basal conditions, there were no significant differences in fractional shortening or contraction or relaxation rates. However, the enhancement of contractile parameters after isoproterenol stimulation was significantly blunted in D147 compared with G147 and control myocytes. Similar findings were observed in calcium kinetics. The attenuated beta-agonist response was associated with decreased (50%) phosphorylation of phospholamban (PLN) at serine 16, whereas phosphorylation of troponin I and ryanodine receptor was unaltered. These findings suggest that the human G147D PPI-1 can attenuate responses of cardiomyocytes to beta-adrenergic agonists by decreasing PLN phosphorylation and therefore may contribute to deteriorated function in heart failure.	[Chen, Guoli; Zhou, Xiaoyang; Nicolaou, Persoulla; Rodriguez, Patricia; Song, Guojie; Mitton, Bryan; Pathak, Anand; Zachariah, Amit; Fan, Guo-Chang; Kranias, Evangelia G.] Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA; [Dorn, Gerald W., II] Univ Cincinnati, Coll Med, Dept Med, Cincinnati, OH 45267 USA; [Song, Guojie] Jiaxing Univ Coll Med, Jiaxing, Peoples R China; [Kranias, Evangelia G.] Acad Athens, Fdn Biomed Res, Ctr Basic Res, Div Mol Biol, Athens, Greece	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Jiaxing University; Academy of Athens	Kranias, EG (corresponding author), Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	litsa.kranias@uc.edu	Fan, Guo-Chang/E-1153-2012	Fan, Guo-Chang/0000-0002-0439-8277	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL087861, P50HL077101, R01HL064018] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-26507, P50 HL077101, R01 HL064018, HL-77101, HL-64018, R01 HL087861] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD Z, 1989, J BIOL CHEM, V264, P3859; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Carr AN, 2002, MOL CELL BIOL, V22, P4124, DOI 10.1128/MCB.22.12.4124-4135.2002; Chu GX, 2000, J BIOL CHEM, V275, P38938, DOI 10.1074/jbc.M004079200; DEPAOLIROACH AA, 2003, HDB CELL SIGNALING, P613; El-Armouche A, 2004, CARDIOVASC RES, V61, P87, DOI 10.1016/j.cardiores.2003.11.005; Endo S, 1996, BIOCHEMISTRY-US, V35, P5220, DOI 10.1021/bi952940f; Fan GC, 2004, AM J PHYSIOL-HEART C, V287, pH1705, DOI 10.1152/ajpheart.01211.2003; Fan GC, 2004, CIRC RES, V94, P1474, DOI 10.1161/01.RES.0000129179.66631.00; Feldman DS, 2005, NAT CLIN PRACT CARD, V2, P475, DOI 10.1038/ncpcardio0309; GAUTEL M, 1995, EMBO J, V14, P1952, DOI 10.1002/j.1460-2075.1995.tb07187.x; Gupta RC, 1996, AM J PHYSIOL-HEART C, V270, pH1159, DOI 10.1152/ajpheart.1996.270.4.H1159; Gupta RC, 2003, AM J PHYSIOL-HEART C, V285, pH2373, DOI 10.1152/ajpheart.00442.2003; HAASE H, 1993, FEBS LETT, V335, P217, DOI 10.1016/0014-5793(93)80733-B; HARTZELL HC, 1988, PROG BIOPHYS MOL BIO, V52, P165, DOI 10.1016/0079-6107(88)90014-4; HOFMANN PA, 1994, CIRC RES, V74, P718, DOI 10.1161/01.RES.74.4.718; KRANIAS EG, 1982, NATURE, V298, P182, DOI 10.1038/298182a0; KRANIAS EG, 1985, BIOCHIM BIOPHYS ACTA, V844, P193, DOI 10.1016/0167-4889(85)90090-4; Marian AJ, 2006, J MOL CELL CARDIOL, V41, P11, DOI 10.1016/j.yjmcc.2006.04.001; Neumann J, 1997, J MOL CELL CARDIOL, V29, P265, DOI 10.1006/jmcc.1996.0271; Pathak A, 2005, CIRC RES, V96, P756, DOI 10.1161/01.RES.0000161256.85833.fa; Rodriguez P, 2007, AM J PHYSIOL-HEART C, V293, pH762, DOI 10.1152/ajpheart.00104.2007; SOLARO RJ, 1976, NATURE, V262, P615, DOI 10.1038/262615a0; VALDIVIA HH, 1995, SCIENCE, V267, P1997, DOI 10.1126/science.7701323; Weiser DC, 2004, J BIOL CHEM, V279, P48904, DOI 10.1074/jbc.M404416200	25	14	14	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					1790	1796		10.1096/fj.07-097428	http://dx.doi.org/10.1096/fj.07-097428			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18192322	Green Accepted			2022-12-25	WOS:000256352700019
J	Grumolato, L; Ghzili, H; Montero-Hadjadje, M; Gasman, S; Lesage, J; Tanguy, Y; Galas, L; Ait-Ali, D; Leprince, J; Guerineau, NC; Elkahloun, AG; Fournier, A; Vieau, D; Vaudry, H; Anouar, Y				Grumolato, Luca; Ghzili, Hafida; Montero-Hadjadje, Maite; Gasman, Stephane; Lesage, Jean; Tanguy, Yannick; Galas, Ludovic; Ait-Ali, Djida; Leprince, Jerome; Guerineau, Nathalie C.; Elkahloun, Abdel G.; Fournier, Alain; Vieau, Didier; Vaudry, Hubert; Anouar, Youssef			Selenoprotein T is a PACAP-regulated gene involved in intracellular Ca2+ mobilization and neuroendocrine secretion	FASEB JOURNAL			English	Article						cell differentiation; pituitary adenylate cyclase-activating polypeptide; cAMP; PC12 cells	CYCLASE-ACTIVATING POLYPEPTIDE; PHEOCHROMOCYTOMA CELLS; ENDOPLASMIC-RETICULUM; MUSCULAR-DYSTROPHY; SIGNALING PATHWAYS; NEUROPEPTIDE-Y; NEURAL CREST; PC12 CELLS; CYCLIC-AMP; G-PROTEIN	Selenoproteins contain the essential trace element selenium, the deficiency of which is associated with cancer or accelerated aging. Although selenoproteins are thought to be instrumental for the effects of selenium, the biological function of many of these proteins remains unknown. Here, we studied the role of selenoprotein T (SelT), a selenocysteine (Sec)-containing protein with no known function, which we have identified as a novel target gene of the neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) during PC12 cell differentiation. SelT was found to be ubiquitously expressed throughout embryonic development and in adulthood in rat. Immunocytochemical analysis revealed that SelT is mainly localized to the endoplasmic reticulum through a hydrophobic domain. PACAP and cAMP induced a rapid and long-lasting increase in SelT gene expression in PC12 cells, in a Ca2+-dependent manner. These results suggested a possible role of SelT in PACAP signaling during PC12 cell differentiation. Indeed, overexpression of SelT in PC12 cells provoked an increase in the concentration of intracellular Ca2+ ([Ca2+](i)) that was dependent on the Sec residue. Conversely, SelT gene knockdown inhibited the PACAP-induced increase in [Ca2+] i and reduced hormone secretion. These findings demonstrate the implication of a selenoprotein in the regulation of Ca2+ homeostasis and neuroendocrine secretion in response to a cAMP-stimulating trophic factor.	[Grumolato, Luca; Ghzili, Hafida; Montero-Hadjadje, Maite; Tanguy, Yannick; Galas, Ludovic; Ait-Ali, Djida; Leprince, Jerome; Vaudry, Hubert; Anouar, Youssef] Univ Rouen, INSERM, Lab Cellular & Mol Neuroendocrinol, CNRS,European Inst Peptide Res,IFRMP 23,UA,U413, F-76821 Mont St Aignan, France; [Gasman, Stephane] Univ Strasbourg, CNRS, Inst Neurosci Cellulaires & Integrat,LC2, Dept Neurotransmiss & Neuroendocrine Secret,UMR 7, Strasbourg, France; [Lesage, Jean] Univ Lille 1, Perinatal Stress Unit, Dept Adaptat Neurosci & Physiol, F-59655 Villeneuve Dascq, France; [Guerineau, Nathalie C.] Univ Montpellier I, CNRS, INSERM, Funct Genom Inst,Dept Endocrinol,UMR5203,U661, Montpellier, France; [Guerineau, Nathalie C.] Univ Montpellier 2, Montpellier, France; [Elkahloun, Abdel G.] NHGRI, Genome Technol Branch, NIH, Bethesda, MD 20892 USA; [Fournier, Alain] Univ Quebec, Inst Natl Rech Sci, Inst Armand Frappier, Montreal, PQ H3C 3P8, Canada	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rouen Normandie; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Quebec; Institut national de la recherche scientifique (INRS); University of Quebec Montreal	Anouar, Y (corresponding author), Univ Rouen, INSERM, Lab Cellular & Mol Neuroendocrinol, CNRS,European Inst Peptide Res,IFRMP 23,UA,U413, F-76821 Mont St Aignan, France.	youssef.anouar@univ-rouen.fr	lesage, jean/R-5019-2018; stéphane, gasman/Q-1145-2019; Grumolato, Luca/A-1697-2015; Leprince, Jerome/N-9083-2017; Montero-Hadjadje, Maite/AAC-5692-2019; Anouar, Youssef/F-9683-2017; Gasman, Stephane/D-5113-2017; galas, ludovic/A-2500-2014	lesage, jean/0000-0002-6329-1613; stéphane, gasman/0000-0001-8415-1276; Grumolato, Luca/0000-0001-8231-3032; Montero-Hadjadje, Maite/0000-0001-8859-893X; Gasman, Stephane/0000-0001-8415-1276; vieau, didier/0000-0002-3254-3662; Leprince, Jerome/0000-0002-7814-9927; Guerineau, Nathalie/0000-0003-2517-4210	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZICHG200346, Z01HG200346] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ANDERSON DJ, 1993, ANNU REV NEUROSCI, V16, P129, DOI 10.1146/annurev.ne.16.030193.001021; Apostolou S, 2004, ONCOGENE, V23, P5032, DOI 10.1038/sj.onc.1207683; Baqui MMA, 2000, ENDOCRINOLOGY, V141, P4309, DOI 10.1210/en.141.11.4309; Bilodeau ML, 2000, MOL CELL BIOL, V20, P3004, DOI 10.1128/MCB.20.9.3004-3014.2000; Bosl MR, 1997, P NATL ACAD SCI USA, V94, P5531, DOI 10.1073/pnas.94.11.5531; Carlson BA, 2004, J BIOL CHEM, V279, P8011, DOI 10.1074/jbc.M310470200; Clark HF, 2003, GENOME RES, V13, P2265, DOI 10.1101/gr.1293003; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; DiCicco-Bloom E, 2000, DEV BIOL, V219, P197, DOI 10.1006/dbio.2000.9604; Diwadkar-Navsariwala V, 2006, P NATL ACAD SCI USA, V103, P8179, DOI 10.1073/pnas.0508218103; Ferguson AD, 2006, J BIOL CHEM, V281, P3536, DOI 10.1074/jbc.M511386200; Ferreiro A, 2002, AM J HUM GENET, V71, P739, DOI 10.1086/342719; Galas L, 2002, ENDOCRINOLOGY, V143, P1686, DOI 10.1210/en.143.5.1686; Gasman S, 2004, MOL BIOL CELL, V15, P520, DOI 10.1091/mbc.E03-06-0402; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Grumolato L, 2003, ENDOCRINOLOGY, V144, P2368, DOI 10.1210/en.2002-0106; Grumolato L, 2003, EUR J NEUROSCI, V17, P71, DOI 10.1046/j.1460-9568.2003.02426.x; Guirland C, 2003, J NEUROSCI, V23, P2274; Hamelink C, 2002, J NEUROSCI, V22, P5310; Hatfield DL, 2002, MOL CELL BIOL, V22, P3565, DOI 10.1128/MCB.22.11.3565-3576.2002; Higo T, 2005, CELL, V120, P85, DOI 10.1016/j.cell.2004.11.048; Hu YJ, 2003, CANCER RES, V63, P3347; Hu YJ, 2001, CANCER RES, V61, P2307; Kim HY, 2004, MOL BIOL CELL, V15, P1055, DOI 10.1091/mbc.E03-08-0629; Korotkov KV, 2001, J BIOL CHEM, V276, P15330, DOI 10.1074/jbc.M009861200; Kryukov GV, 1999, J BIOL CHEM, V274, P33888, DOI 10.1074/jbc.274.48.33888; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Kumaraswamy E, 2003, MOL CELL BIOL, V23, P1477, DOI 10.1128/MCB.23.5.1477-1488.2003; Lamouche S, 1999, AM J PHYSIOL-REG I, V276, pR162, DOI 10.1152/ajpregu.1999.276.1.R162; Lazarovici P, 1998, MOL PHARMACOL, V54, P547, DOI 10.1124/mol.54.3.547; Lesage J, 2001, ENDOCRINOLOGY, V142, P1692, DOI 10.1210/en.142.5.1692; Li Y, 2004, J CELL BIOL, V164, P35, DOI 10.1083/jcb.200307010; Mabuchi T, 2004, J NEUROSCI, V24, P7283, DOI 10.1523/JNEUROSCI.0983-04.2004; MAY V, 1995, J NEUROCHEM, V65, P978; Moghadaszadeh B, 2001, NAT GENET, V29, P17, DOI 10.1038/ng713; Nakagawa S, 2002, J NEUROSCI, V22, P3673; Osipenko ON, 2000, J BIOL CHEM, V275, P16626, DOI 10.1074/jbc.M909636199; Petit N, 2003, HUM MOL GENET, V12, P1045, DOI 10.1093/hmg/ddg115; Rayman MP, 2000, LANCET, V356, P233, DOI 10.1016/S0140-6736(00)02490-9; Sakai Y, 2002, REGUL PEPTIDES, V109, P149, DOI 10.1016/S0167-0115(02)00198-2; Tanaka J, 1997, REGUL PEPTIDES, V72, P1, DOI 10.1016/S0167-0115(97)01038-0; Tanaka K, 1996, ENDOCRINOLOGY, V137, P956, DOI 10.1210/en.137.3.956; Taupenot L, 2003, NEW ENGL J MED, V348, P1134, DOI 10.1056/NEJMra021405; Taupenot L, 1999, HYPERTENSION, V34, P1152, DOI 10.1161/01.HYP.34.5.1152; Thisse C, 2003, GENE EXPR PATTERNS, V3, P525, DOI 10.1016/S1567-133X(03)00054-1; Turquier V, 2001, MOL PHARMACOL, V60, P42, DOI 10.1124/mol.60.1.42; Vaudry D, 2000, PHARMACOL REV, V52, P269; Vaudry D, 2002, J NEUROCHEM, V83, P1272, DOI 10.1046/j.1471-4159.2002.01242.x; Waschek JA, 1998, P NATL ACAD SCI USA, V95, P9602, DOI 10.1073/pnas.95.16.9602; Zheng Y, 2005, J CELL PHYSIOL, V205, P97, DOI 10.1002/jcp.20378	50	110	121	3	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1756	1768		10.1096/fj.06-075820	http://dx.doi.org/10.1096/fj.06-075820			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18198219				2022-12-25	WOS:000256352700016
J	Hartl, B; Zeller, T; Blanchette, P; Kremmer, E; Dobner, T				Haertl, B.; Zeller, T.; Blanchette, P.; Kremmer, E.; Dobner, T.			Adenovirus type 5 early region 1B 55-kDa oncoprotein can promote cell transformation by a mechanism independent from blocking p53-activated transcription	ONCOGENE			English	Article						E1B-55K; Mre11; PML-NBs; cytoplasmic perinuclear body; CRM1	P53 TUMOR-SUPPRESSOR; E1B 55-KILODALTON ONCOPROTEIN; GENE-EXPRESSION; NUCLEAR EXPORT; MESSENGER-RNAS; PROTEIN; E4ORF6; 1B; PHOSPHORYLATION; REPRESSION	Inhibition of p53-activated transcription is an integral part of the mechanism by which early region 1B 55K oncoprotein (E1B-55K) from adenovirus type 5 (Ad5) contributes to complete cell transformation in combination with Ad E1A. In addition, more recent data suggest that the mode of action of the Ad protein during transformation may involve additional functions and other protein interactions. In the present study, we performed a comprehensive mutational analysis to assign further transforming functions of Ad5 E1B-55K to distinct domains within the viral polypeptide. Results from these studies show that the functions required for transformation are encoded within several patches of the 55K primary sequence, including several clustered cysteine and histidine residues, some of which match the consensus for zinc fingers. In addition, two amino-acid substitutions (C454S/C456S) created a 55K mutant protein, which had substantially reduced transforming activity. Interestingly, the same mutations neither affected binding to p53 nor inhibition of p53-mediated transactivation. Therefore, an activity necessary for efficient transformation of primary rat cells can be separated from functions required for inhibition of p53-stimulated transcription. Our data indicate that this activity is linked to the ability of the Ad5 protein to bind to components of the Mre11/Rad50/NBS1 DNA double-strand break repair complex, and/or its ability to assemble multiprotein aggregates in the cytoplasm and nucleus of transformed rat cells. These results introduce a new function for Ad5 E1B-55K and suggest that the viral protein contributes to cell transformation through p53 transcription-dependent and-independent pathways.	[Haertl, B.; Dobner, T.] Heinrich Pette Inst Expt Virol & Immunol, Dept Mol Virol, D-20251 Hamburg, Germany; [Zeller, T.] Geneart Biopk, Regensburg, Germany; [Blanchette, P.] McGill Univ, Dept Biochem, Montreal, PQ, Canada; [Kremmer, E.] GSF Inst Mol Immunol, Munich, Germany	Heinrich Pette Institute; McGill University; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Dobner, T (corresponding author), Heinrich Pette Inst Expt Virol & Immunol, Dept Mol Virol, Martinistr 52, D-20251 Hamburg, Germany.	thomas.dobner@hpi.uni-hamburg.de						ANDERSON CW, 1984, J VIROL, V50, P387, DOI 10.1128/JVI.50.2.387-396.1984; Barral PM, 2005, FEBS LETT, V579, P2752, DOI 10.1016/j.febslet.2005.03.095; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; Blanchette P, 2004, MOL CELL BIOL, V24, P9619, DOI 10.1128/MCB.24.21.9619-9629.2004; Boivin D, 1999, J VIROL, V73, P1245, DOI 10.1128/JVI.73.2.1245-1253.1999; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; Budhu AS, 2005, CELL CYCLE, V4, P1510, DOI 10.4161/cc.4.11.2187; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Carter CC, 2003, VIROLOGY, V315, P224, DOI 10.1016/S0042-6822(03)00526-9; Dellaire G, 2004, BIOESSAYS, V26, P963, DOI 10.1002/bies.20089; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Endter C, 2005, ONCOGENE, V24, P55, DOI 10.1038/sj.onc.1208170; Endter C, 2004, CURR TOP MICROBIOL, V273, P163; Endter C, 2001, P NATL ACAD SCI USA, V98, P11312, DOI 10.1073/pnas.191361798; Flint SJ, 2005, VIROLOGY, V337, P7, DOI 10.1016/j.virol.2005.04.007; Flint SJ, 2003, CURR TOP MICROBIOL, V272, P287; Florin L, 2004, J VIROL, V78, P5546, DOI 10.1128/JVI.78.11.5546-5553.2004; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Gabler S, 1998, J VIROL, V72, P7960, DOI 10.1128/JVI.72.10.7960-7971.1998; Gallimore PH, 1997, J VIROL, V71, P6629, DOI 10.1128/JVI.71.9.6629-6640.1997; Garcia-Mata R, 2002, TRAFFIC, V3, P388, DOI 10.1034/j.1600-0854.2002.30602.x; Grand RJA, 1999, ONCOGENE, V18, P955, DOI 10.1038/sj.onc.1202358; Greenberg RA, 2005, CURR MOL MED, V5, P213, DOI 10.2174/1566524053586590; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; Hobom U, 2004, J VIROL, V78, P7685, DOI 10.1128/JVI.78.14.7685-7697.2004; Hutton FG, 2000, ONCOGENE, V19, P452, DOI 10.1038/sj.onc.1203316; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kindsmuller K, 2007, P NATL ACAD SCI USA, V104, P6684, DOI 10.1073/pnas.0702158104; Koch P, 2001, CANCER RES, V61, P5941; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kratzer F, 2000, ONCOGENE, V19, P850, DOI 10.1038/sj.onc.1203395; Lee HJ, 2002, J BIOL CHEM, V277, P5411, DOI 10.1074/jbc.M105326200; Liao DQ, 1999, VIROLOGY, V254, P11, DOI 10.1006/viro.1998.9512; Liu Y, 2005, J VIROL, V79, P14004, DOI 10.1128/JVI.79.22.14004-14016.2005; Lober C, 2002, J GEN VIROL, V83, P2047, DOI 10.1099/0022-1317-83-8-2047; Maheswaran S, 1998, ONCOGENE, V16, P2041, DOI 10.1038/sj.onc.1201741; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Moll UM, 2005, CURR OPIN CELL BIOL, V17, P631, DOI 10.1016/j.ceb.2005.09.007; Nevels M, 1997, P NATL ACAD SCI USA, V94, P1206, DOI 10.1073/pnas.94.4.1206; NEVELS M, 2007, ADENOVIRUS METHODS P, P187; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; Sieber T, 2007, J VIROL, V81, P95, DOI 10.1128/JVI.01608-06; Teodoro JG, 1997, J VIROL, V71, P3620, DOI 10.1128/JVI.71.5.3620-3627.1997; TEODORO JG, 1994, J VIROL, V68, P776, DOI 10.1128/JVI.68.2.776-786.1994; Wan YP, 2004, CHINESE MED J-PEKING, V117, P753; Wendt J, 2006, ONCOGENE, V25, P972, DOI 10.1038/sj.onc.1209031; YEW PR, 1990, VIROLOGY, V179, P795, DOI 10.1016/0042-6822(90)90147-J; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; Zhao LY, 2003, J VIROL, V77, P13171, DOI 10.1128/JVI.77.24.13171-13181.2003; Zhao LY, 2003, J VIROL, V77, P11809, DOI 10.1128/JVI.77.21.11809-11821.2003	51	27	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2008	27	26					3673	3684		10.1038/sj.onc.1211039	http://dx.doi.org/10.1038/sj.onc.1211039			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18212738				2022-12-25	WOS:000256659300004
J	Khan, AA; Mao, XO; Banwait, S; DerMardirossian, CM; Bokoch, GM; Jin, KL; Greenberg, DA				Khan, Adil A.; Mao, Xiao Ou; Banwait, Surita; DerMardirossian, Celine M.; Bokoch, Gary M.; Jin, Kunlin; Greenberg, David A.			Regulation of hypoxic neuronal death signaling by neuroglobin	FASEB JOURNAL			English	Article						soma; polarity; DISC; death-inducing signaling complex	CELL-DEATH; APOPTOSIS; RECEPTOR; RAFTS; ACTIVATION; MEDIATION; CHANNELS	The signal transduction pathways involved in neuronal death are not well understood. Neuroglobin (Ngb), a recently discovered vertebrate globin expressed predominantly in the brain, shows increased expression in neurons in response to oxygen deprivation and protects neurons from ischemic and hypoxic death. The mechanism of this neuroprotection is unclear. We examined the surface distribution of raft membrane microdomains in cortical neuron cultures during hypoxia using the raft marker cholera toxin B (CTx-B) subunit. Mechanistically, we demonstrate that hypoxia induces rapid polarization of somal membranes and aggregation of microdomains with the subjacent mitochondrial network. This signaling complex is formed well before neurons commit to die, consistent with an early role in death signal transduction. Neurons from Ngb-overexpressing transgenic (Ngb-Tg) mice do not undergo microdomain polarization or mitochondrial aggregation in response to, and are resistant to death from hypoxia. We link the protective actions of Ngb to inhibition of Pak1 kinase activity and Rac1-GDP-dissociation inhibitor disassociation, and inhibition of actin assembly and death-signaling module polarization.	[Khan, Adil A.; Mao, Xiao Ou; Banwait, Surita; Jin, Kunlin; Greenberg, David A.] Buck Inst Age Res, Novato, CA 94945 USA; [DerMardirossian, Celine M.; Bokoch, Gary M.] Scripps Res Inst, Dept Cell Biol, La Jolla, CA USA	Buck Institute for Research on Aging; Scripps Research Institute	Khan, AA (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.	akhan@buckinstitute.org	DerMardirossian, Celine/P-1020-2015		NINDS NIH HHS [P01 NS035965-080002, NS35965, P01 NS035965] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS035965] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Acuto O, 2000, ANNU REV IMMUNOL, V18, P165, DOI 10.1146/annurev.immunol.18.1.165; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; Conforti L, 2000, J PHYSIOL-LONDON, V524, P783, DOI 10.1111/j.1469-7793.2000.00783.x; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571; Delmas D, 2004, ONCOGENE, V23, P8979, DOI 10.1038/sj.onc.1208086; DerMardirossian C, 2004, MOL CELL, V15, P117, DOI 10.1016/j.molcel.2004.05.019; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Friedman JE, 1998, NEUROSCIENCE, V82, P421; Furne C, 2006, P NATL ACAD SCI USA, V103, P4128, DOI 10.1073/pnas.0507864103; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Haga N, 2003, ONCOGENE, V22, P5579, DOI 10.1038/sj.onc.1206576; Hueber AO, 2003, CELL DEATH DIFFER, V10, P7, DOI 10.1038/sj.cdd.4401155; Hueber AO, 2002, EMBO REP, V3, P190, DOI 10.1093/embo-reports/kvf022; Khan AA, 2007, P NATL ACAD SCI USA, V104, P19114, DOI 10.1073/pnas.0706167104; Khan AA, 2006, P NATL ACAD SCI USA, V103, P17944, DOI 10.1073/pnas.0607497103; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Li Z, 2003, CELL, V114, P215, DOI 10.1016/S0092-8674(03)00559-2; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Martens JR, 2000, J BIOL CHEM, V275, P7443, DOI 10.1074/jbc.275.11.7443; Muppidi JR, 2004, IMMUNITY, V21, P461, DOI 10.1016/j.immuni.2004.10.001; Namura S, 1998, J NEUROSCI, V18, P3659; Pal S, 2003, J NEUROSCI, V23, P4798; Raman N, 1999, AM J PHYSIOL-CELL PH, V276, pC1312, DOI 10.1152/ajpcell.1999.276.6.C1312; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; SCHON A, 1989, BIOCHEMISTRY-US, V28, P5019, DOI 10.1021/bi00438a017; Subauste MC, 2000, J BIOL CHEM, V275, P9725, DOI 10.1074/jbc.275.13.9725; Sun YJ, 2001, P NATL ACAD SCI USA, V98, P15306, DOI 10.1073/pnas.251466698; Vallone B, 2004, P NATL ACAD SCI USA, V101, P17351, DOI 10.1073/pnas.0407633101; VAN AL, 1997, GENE DEV, V11, P2295; Villalba M, 2001, J CELL BIOL, V155, P331, DOI 10.1083/jcb.200107080; Wakasugi K, 2003, J BIOL CHEM, V278, P36505, DOI 10.1074/jbc.M305519200; Yu SP, 1997, SCIENCE, V278, P114, DOI 10.1126/science.278.5335.114; Zhu LP, 2000, CELL CALCIUM, V28, P107, DOI 10.1054/ceca.2000.0138	35	73	80	1	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1737	1747		10.1096/fj.07-100784	http://dx.doi.org/10.1096/fj.07-100784			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18198211	Green Accepted			2022-12-25	WOS:000256352700014
J	Hastie, C; Masters, JR; Moss, SE; Naaby-Hansen, S				Hastie, Claire; Masters, John R.; Moss, Stephen E.; Naaby-Hansen, Soren			Interferon-gamma reduces cell surface expression of annexin 2 and suppresses the invasive capacity of prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASSETTE TRANSPORTER A1; PROTEIN-KINASE-C; IFN-GAMMA; DOWN-REGULATION; PLASMINOGEN-ACTIVATOR; MALIGNANT PROGRESSION; RECYCLING ENDOSOMES; CHOLESTEROL EFFLUX; ANTIGEN EXPRESSION; ABCA1 TRANSPORTER	The effect of interferon-gamma (IFN gamma) treatment on cell surface protein expression was studied in the human prostate cancer cell line 1542CP3TX. IFN gamma increased both the number and abundance of proteins in membrane fractions. In contrast, the expression of annexin 2 and its binding partner p11 decreased by 4-fold after 24 h of exposure, with the remaining anx2(t) complexes localized to lipid rafts. Within the same time scale, IFN gamma reduced the abundance of the peripherally attached, anx2(t)-associated proteases procathepsin B and plasminogen. The invasive capacity of the cancer cells was reduced by treatment with IFN gamma or antibody to annexin 2 in 1542CP3TX cells, but not in LNCaP, an annexin 2-negative prostate cancer cell line. Expression of annexin 2 in LNCaP cells increased their invasiveness. IFN gamma induced calpain expression and activation and increased the phosphorylation and degradation of the calpain substrate ABCA1 in 1542CP3TX cancer cells. Surface expression of annexin 2 was reduced in cells treated with glyburide, an ABCA1 inhibitor, whereas inhibition of calpain abrogated IFN gamma-induced annexin 2 down-regulation and suppression of Matrigel invasion. The findings suggest annexin 2 externalization is coupled to lipid efflux in prostate epithelium and that IFN gamma induces down-regulation of the protease-binding anx2t scaffold at the cell surface and consequently acts to suppress invasiveness through calpain-mediated degradation of the lipid transporter ABCA1.	[Naaby-Hansen, Soren] Arhus Univ Hosp, Dept Clin Immunol, Aalborg Sygehus, DK-9100 Aalborg, Denmark; [Hastie, Claire] Univ Portsmouth, Sch Pharm & Biomed Sci, Portsmouth PO1 2UP, Hants, England; [Masters, John R.] Royal Free & UCL Med Sch, Prostate Canc Res Ctr, London W1W 7EJ, England; [Moss, Stephen E.] UCL, Div Cell Biol, Inst Ophthalmol, London WC1E 6BT, England	Aalborg University; Aarhus University; University of Portsmouth; University of London; University College London; University of London; University College London	Naaby-Hansen, S (corresponding author), Aalborg Sygehus Nord, Klin Immunol Afdeling, DK-9100 Aalborg, Denmark.	sonh@rn.dk	aukim-hastie, claire/A-7485-2011; Masters, John R/C-5694-2011		NATIONAL INSTITUTE ON AGING [R01AG014960] Funding Source: NIH RePORTER; Medical Research Council [G0100116] Funding Source: Medline; NIA NIH HHS [R01 AG14960] Funding Source: Medline; MRC [G0100116] Funding Source: UKRI	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Aas V, 1999, CELL SIGNAL, V11, P101, DOI 10.1016/S0898-6568(98)00040-0; Amrani Y, 2001, AM J RESP CRIT CARE, V164, P2098, DOI 10.1164/ajrccm.164.11.2108005; Anderson F, 2002, CLIN IMMUNOL, V102, P200, DOI 10.1006/clim.2001.5161; Brichory FM, 2001, P NATL ACAD SCI USA, V98, P9824, DOI 10.1073/pnas.171320598; Bright RK, 1997, CANCER RES, V57, P995; Brownstein C, 2001, ANN NY ACAD SCI, V947, P143; Chapman LP, 2003, ENDOCRINOLOGY, V144, P1062, DOI 10.1210/en.2002-220650; Chen W, 2001, J BIOL CHEM, V276, P43564, DOI 10.1074/jbc.M107938200; Chetcuti A, 2001, CANCER RES, V61, P6331; Choi S, 2000, CLIN EXP METASTAS, V18, P45, DOI 10.1023/A:1026507713080; CHUNG CY, 1994, J CELL BIOL, V126, P539, DOI 10.1083/jcb.126.2.539; Diaz VM, 2004, GUT, V53, P993, DOI 10.1136/gut.2003.026831; Dieu-Nosjean MC, 2001, J IMMUNOL, V167, P5594, DOI 10.4049/jimmunol.167.10.5594; DiPaolo RS, 1999, J CLIN ONCOL, V17, P2213, DOI 10.1200/JCO.1999.17.7.2213; Emoto K, 2001, CANCER, V92, P1419, DOI 10.1002/1097-0142(20010915)92:6<1419::AID-CNCR1465>3.0.CO;2-J; Falcone DJ, 2001, BLOOD, V97, P777, DOI 10.1182/blood.V97.3.777; Fitzpatrick SL, 2000, BIOCHEMISTRY-US, V39, P1021, DOI 10.1021/bi991411z; Flieger D, 2001, CLIN EXP IMMUNOL, V123, P9, DOI 10.1046/j.1365-2249.2001.01435.x; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; GLENNEY JR, 1989, J CELL BIOL, V108, P569, DOI 10.1083/jcb.108.2.569; GROVES A, 1992, THESIS U COLL LONDON; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; Hastie C, 2005, ONCOGENE, V24, P5905, DOI 10.1038/sj.onc.1208747; Heinzel S, 2001, CANCER IMMUNOL IMMUN, V49, P671, DOI 10.1007/s002620000163; Hobeika AC, 1998, INT J CANCER, V77, P138, DOI 10.1002/(SICI)1097-0215(19980703)77:1<138::AID-IJC21>3.0.CO;2-9; Hobeika AC, 1997, ONCOGENE, V14, P1165, DOI 10.1038/sj.onc.1200939; Hu XY, 2002, NAT IMMUNOL, V3, P859, DOI 10.1038/ni828; Ibrahim EC, 2001, CANCER RES, V61, P6838; Jacovina AT, 2001, J BIOL CHEM, V276, P49350, DOI 10.1074/jbc.M106289200; Kaul M, 2001, FEBS LETT, V500, P91, DOI 10.1016/S0014-5793(01)02592-3; Kominsky SL, 2000, CANCER RES, V60, P3904; Kramer G, 2001, J INTERF CYTOK RES, V21, P475, DOI 10.1089/10799900152434349; Kwon MJ, 2005, FRONT BIOSCI-LANDMRK, V10, P300, DOI 10.2741/1529; Loftus IM, 2002, BRIT J SURG, V89, P680, DOI 10.1046/j.1365-2168.2002.02099.x; Ma JX, 2000, J BIOL CHEM, V275, P12806, DOI 10.1074/jbc.275.17.12806; Ma KY, 2000, J BIOL CHEM, V275, P15541, DOI 10.1074/jbc.275.20.15541; Mai JX, 2000, BBA-PROTEIN STRUCT M, V1477, P215, DOI 10.1016/S0167-4838(99)00274-5; Menell JS, 1999, NEW ENGL J MED, V340, P994, DOI 10.1056/NEJM199904013401303; Merrifield CJ, 2001, CURR BIOL, V11, P1136, DOI 10.1016/S0960-9822(01)00321-9; Miller A, 2000, THYROID, V10, P945, DOI 10.1089/thy.2000.10.945; Mita Y, 2001, IMMUNOL LETT, V78, P97, DOI 10.1016/S0165-2478(01)00241-3; Naaby-Hansen Soren, 2003, Methods Mol Med, V81, P277; Nagano K, 2004, ONCOGENE, V23, P1693, DOI 10.1038/sj.onc.1207297; Neufeld EB, 2004, J BIOL CHEM, V279, P15571, DOI 10.1074/jbc.M314160200; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Rand JH, 2000, BBA-MOL CELL RES, V1498, P169, DOI 10.1016/S0167-4889(00)00093-8; Raynor CM, 1999, BIOCHEMISTRY-US, V38, P5089, DOI 10.1021/bi982095b; Roshy S, 2003, CANCER METAST REV, V22, P271, DOI 10.1023/A:1023007717757; Ryu SY, 2000, ANTICANCER RES, V20, P3331; Satish L, 2005, MOL CELL BIOL, V25, P1922, DOI 10.1128/MCB.25.5.1922-1941.2005; Sharma MR, 2006, EXP MOL PATHOL, V81, P146, DOI 10.1016/j.yexmp.2006.03.003; Shinohara N, 1998, PROSTATE, V35, P56, DOI 10.1002/(SICI)1097-0045(19980401)35:1<56::AID-PROS8>3.0.CO;2-F; SINGH RK, 1995, P NATL ACAD SCI USA, V92, P4562, DOI 10.1073/pnas.92.10.4562; Slovin SF, 1998, CLIN CANCER RES, V4, P643; So EY, 2000, J IMMUNOL, V165, P5472, DOI 10.4049/jimmunol.165.10.5472; Solito E, 2003, ENDOCRINOLOGY, V144, P1164, DOI 10.1210/en.2002-220592; Street SEA, 2001, BLOOD, V97, P192, DOI 10.1182/blood.V97.1.192; Wang N, 2003, J CLIN INVEST, V111, P99, DOI 10.1172/JCI200316808; Wang XQ, 2002, BIOCHEM BIOPH RES CO, V290, P891, DOI 10.1006/bbrc.2001.6293; Wang XQ, 2002, ARTERIOSCL THROM VAS, V22, pE5, DOI 10.1161/01.ATV.0000018287.03856.DD; WRIGHT JF, 1994, BIOCHEM BIOPH RES CO, V198, P983, DOI 10.1006/bbrc.1994.1140; Yamauchi Y, 2003, J BIOL CHEM, V278, P47890, DOI 10.1074/jbc.M306258200; Yan DH, 1999, ONCOGENE, V18, P807, DOI 10.1038/sj.onc.1202369; Zeuschner D, 2001, EUR J CELL BIOL, V80, P499, DOI 10.1078/0171-9335-00184; Zobiack N, 2003, MOL BIOL CELL, V14, P4896, DOI 10.1091/mbc.E03-06-0387	66	20	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2008	283	18					12595	12603		10.1074/jbc.M800189200	http://dx.doi.org/10.1074/jbc.M800189200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	293MS	18211896	Green Published, hybrid			2022-12-25	WOS:000255340000076
J	Carreno, R; Li, D; Sen, M; Nira, I; Yamakawa, T; Ma, Q; Legge, GB				Carreno, Roberto; Li, Dan; Sen, Mehmet; Nira, Iris; Yamakawa, Tatsuo; Ma, Qing; Legge, Glen B.			A mechanism for antibody-mediated outside-in activation of LFA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; INTERCELLULAR-ADHESION MOLECULE-3; LEUKOCYTE BETA(2) INTEGRINS; BINDING-SITES; HIGH-AFFINITY; CR3-DEPENDENT ADHESION; IMMUNOLOGICAL SYNAPSE; MONOCLONAL-ANTIBODY; STRUCTURAL BASIS; CELL-ACTIVATION	MEM83 is an inserted domain (I-domain)-specific antibody that up-regulates the interaction of LFA-1 with ICAM-1 through an outside-in activation mechanism. We demonstrate here that there is no change in the affinity of the MEM83 antibody for the I-domain in either its low (wild-type) or high affinity form and that MEM83 does not enhance the binding of the wild-type I-domain to ICAM-1. Furthermore, we show that the antibody acts as an activating agent to induce LFA-1/ICAM-1-dependent homotypic cell aggregation only as an IgG, but not as a Fab fragment. On the basis of these data, we propose an avidity-based mechanism that requires no direct activation of the LFA-1 I-domain by the binding of the antibody; rather, activation is enhanced when there is an interaction with both arms of the IgG. A molecular model of the antibody interaction with LFA-1 illustrates the symmetry and accessibility of the two MEM83 epitopes across the LFA-1/ICAM-1 heterotetramer. We hypothesize that MEM83 stabilizes adjacent LFA-1 molecules in their active form by the free energy that is gained from the binding of the I-domains to each arm of the IgG. This leads to stabilization of the open state of the integrin and outside-in signaling. Our model supports a mechanism in which both affinity and avidity regulation are required in the activation of LFA-1.	[Carreno, Roberto; Sen, Mehmet; Nira, Iris; Yamakawa, Tatsuo; Legge, Glen B.] Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA; [Li, Dan; Ma, Qing] Univ Texas Houston, MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA	University of Houston System; University of Houston; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center	Legge, GB (corresponding author), Univ Houston, Dept Biol & Biochem, 4800 Calhoun Rd, Houston, TX 77204 USA.	glegge@uh.edu	Smith, Iris/AAK-2032-2020	Smith, Iris/0000-0001-5560-8871				Adler AJ, 2007, CURR CANCER DRUG TAR, V7, P3, DOI 10.2174/156800907780006931; Alonso JL, 2002, CURR BIOL, V12, pR340, DOI 10.1016/S0960-9822(02)00852-7; ANDREW D, 1993, EUR J IMMUNOL, V23, P2217, DOI 10.1002/eji.1830230925; Astrof NS, 2006, BIOCHEMISTRY-US, V45, P15020, DOI 10.1021/bi061566o; BAILLY P, 1994, P NATL ACAD SCI USA, V91, P5306, DOI 10.1073/pnas.91.12.5306; BAZIL V, 1990, FOLIA BIOL-PRAGUE, V36, P41; Binnerts ME, 1996, J BIOL CHEM, V271, P9962, DOI 10.1074/jbc.271.17.9962; BINNERTS ME, 1994, EUR J IMMUNOL, V24, P2155, DOI 10.1002/eji.1830240933; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Carrasco YR, 2004, IMMUNITY, V20, P589, DOI 10.1016/S1074-7613(04)00105-0; DEFOUGEROLLES AR, 1992, J EXP MED, V175, P185, DOI 10.1084/jem.175.1.185; Dorfleutner A, 2004, MOL BIOL CELL, V15, P4416, DOI 10.1091/mbc.E03-09-0640; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DUSTIN ML, 1989, COLD SPRING HARB SYM, V54, P753; Eargle J, 2006, BIOINFORMATICS, V22, P504, DOI 10.1093/bioinformatics/bti825; Eniola AO, 2005, BIOPHYS J, V89, P3577, DOI 10.1529/biophysj.104.057729; Gamberg JC, 1999, AIDS, V13, P2043, DOI 10.1097/00002030-199910220-00006; Giblin PA, 2006, CURR PHARM DESIGN, V12, P2771, DOI 10.2174/138161206777947731; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Hermand P, 2000, J BIOL CHEM, V275, P26002, DOI 10.1074/jbc.M002823200; HOGG N, 1993, AM REV RESPIR DIS, V148, pS55, DOI 10.1164/ajrccm/148.6_Pt_2.S55; Huang LL, 2006, J LEUKOCYTE BIOL, V80, P905, DOI 10.1189/jlb.1105649; Ihanus E, 2003, EUR J BIOCHEM, V270, P1710, DOI 10.1046/j.1432-1033.2003.03528.x; Ihanus E, 2007, BLOOD, V109, P802, DOI 10.1182/blood-2006-04-014878; Jin M, 2006, P NATL ACAD SCI USA, V103, P5758, DOI 10.1073/pnas.0601164103; JOHNSTON SC, 1990, J IMMUNOL, V145, P1181; Kallen J, 1999, J MOL BIOL, V292, P1, DOI 10.1006/jmbi.1999.3047; Kaplan MJ, 2000, IMMUNOL INVEST, V29, P427; KEIZER GD, 1988, J IMMUNOL, V140, P1393; KELLEHER D, 1995, J LEUKOCYTE BIOL, V58, P539, DOI 10.1002/jlb.58.5.539; Kelly TA, 1999, J IMMUNOL, V163, P5173; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; Knorr R, 1997, J EXP MED, V186, P719, DOI 10.1084/jem.186.5.719; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LANDIS RC, 1994, J CELL BIOL, V126, P529, DOI 10.1083/jcb.126.2.529; LANDIS RC, 1993, J CELL BIOL, V120, P1519, DOI 10.1083/jcb.120.6.1519; Last-Barney K, 2001, J AM CHEM SOC, V123, P5643, DOI 10.1021/ja0104249; Laudanna C, 2006, THROMB HAEMOSTASIS, V95, P5, DOI 10.1160/TH05-07-0482; Lebedeva T, 2005, CURR OPIN IMMUNOL, V17, P251, DOI 10.1016/j.coi.2005.04.008; Legge GB, 2000, J MOL BIOL, V295, P1251, DOI 10.1006/jmbi.1999.3409; Legge GB, 2002, PROTEINS, V48, P151, DOI 10.1002/prot.10134; Lu CF, 2004, J IMMUNOL, V173, P3972, DOI 10.4049/jimmunol.173.6.3972; Lu CF, 2001, J IMMUNOL, V166, P5629, DOI 10.4049/jimmunol.166.9.5629; LUB M, 1995, IMMUNOL TODAY, V16, P479, DOI 10.1016/0167-5699(95)80031-X; Luo BH, 2006, CURR OPIN CELL BIOL, V18, P579, DOI 10.1016/j.ceb.2006.08.005; Ma Q, 2002, J BIOL CHEM, V277, P10638, DOI 10.1074/jbc.M112417200; Malissen B, 1999, SCIENCE, V285, P207, DOI 10.1126/science.285.5425.207; Nishida N, 2006, IMMUNITY, V25, P583, DOI 10.1016/j.immuni.2006.07.016; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; Perez OD, 2007, BMC IMMUNOL, V8, DOI 10.1186/1471-2172-8-2; ROBINSON MK, 1992, J IMMUNOL, V148, P1080; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; Salas A, 2002, J BIOL CHEM, V277, P50255, DOI 10.1074/jbc.M209822200; Shi C, 2006, TRENDS CARDIOVAS MED, V16, P146, DOI 10.1016/j.tcm.2006.03.002; Shi CW, 1996, P NATL ACAD SCI USA, V93, P4051, DOI 10.1073/pnas.93.9.4051; Shimaoka M, 2004, CURR TOP MED CHEM, V4, P1485, DOI 10.2174/1568026043387575; Shimaoka M, 2001, P NATL ACAD SCI USA, V98, P6009, DOI 10.1073/pnas.101130498; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; Shimaoka M, 2000, NAT STRUCT BIOL, V7, P674, DOI 10.1038/77978; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Sumen C, 2004, J CELL BIOL, V166, P579, DOI 10.1083/jcb.200404059; Tanaka Y, 2000, HISTOL HISTOPATHOL, V15, P1169, DOI 10.14670/HH-15.1169; Tian L, 2000, EUR J IMMUNOL, V30, P810, DOI 10.1002/1521-4141(200003)30:3<810::AID-IMMU810>3.3.CO;2-O; Watanabe T, 1998, INT J CARDIOL, V66, pS45, DOI 10.1016/S0167-5273(98)00147-8; Weitz-Schmidt G, 2003, ENDOTHELIUM-J ENDOTH, V10, P43, DOI 10.1080/10623320303360; Weitz-Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058; Yang W, 2004, P NATL ACAD SCI USA, V101, P2333, DOI 10.1073/pnas.0307291101; Yang YT, 2004, MOL CELL, V14, P269, DOI 10.1016/S1097-2765(04)00204-7; Yung Raymond L., 2003, Biol Proced Online, V5, P211, DOI 10.1251/bpo64	69	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10642	10648		10.1074/jbc.M704699200	http://dx.doi.org/10.1074/jbc.M704699200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18199751	hybrid			2022-12-25	WOS:000254894700046
J	Dierssen, U; Beraza, N; Lutz, HH; Liedtke, C; Ernst, M; Wasmuth, HE; Trautwein, C				Dierssen, Uta; Beraza, Naiara; Lutz, Holger H.; Liedtke, Christian; Ernst, Matthias; Wasmuth, Hermann E.; Trautwein, Christian			Molecular dissection of gp 130-dependent pathways in hepatocytes during liver regeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOKINE RECEPTOR GP130; GROWTH-FACTOR RECEPTOR; SIGNAL TRANSDUCER; KERATINOCYTE MIGRATION; STAT ACTIVATION; IN-VIVO; PROLIFERATION; INTERLEUKIN-6; SOCS3; TRANSCRIPTION	Interleukin-6 (IL-6) via its signal transducer gp130 is an important mediator of liver regeneration involved in protecting from lipopolysaccharide (LPS)-induced liver injury after partial hepatectomy (PH). Here we generated mice either defective (Delta) in hepatocyte- specific gp130-dependent Ras or STAT activation to define their role during liver regeneration. Deletion of gp130-dependent signaling had major impact on acute phase gene (APG) regulation after PH. APG expression was blocked in gp130-Delta STAT animals, whereas gp130-Delta Ras mice showed an enhanced APG response and stronger SOCS3 regulation correlating with delayed hepatocyte proliferation. To define the role of SOCS3 during hepatocyte proliferation, primary hepatocytes were co-stimulated with IL-6 and hepatocyte growth factor. Higher SOCS3 expression in gp130-Delta Ras hepatocytes correlated with delayed hepatocyte proliferation. Next, we tested the impact of LPS, mimicking bacterial infection, on liver regeneration. LPS and PH induced SOCS3 and APG in all animal strains and delayed cell cycle progression. Additionally, IL-6/gp130 dependent STAT3 activation in hepatocytes was essential in mediating protection and thus required for maximal proliferation. Unexpectedly, oncostatin M was most strongly induced in gp130-Delta STAT animals after PH/LPS-induced stress and was associated with hepatocyte proliferation in this strain. In summary, gp130-dependent STAT3 activation and concomitant SOCS3 during liver regeneration is involved in timing of DNA synthesis and protects hepatocyte proliferation during stress conditions.	[Dierssen, Uta; Beraza, Naiara; Lutz, Holger H.; Liedtke, Christian; Wasmuth, Hermann E.; Trautwein, Christian] Rhein Westfal TH Aachen, Univ Hosp, Med Klin 3, D-52074 Aachen, Germany; [Ernst, Matthias] Ludwig Inst Canc Res, Colon Mol & Cell Biol Lab, Melbourne, Vic 3050, Australia	RWTH Aachen University; RWTH Aachen University Hospital; Ludwig Institute for Cancer Research	Trautwein, C (corresponding author), Rhein Westfal TH Aachen, Univ Hosp, Med Klin 3, Pauwelsstr 30, D-52074 Aachen, Germany.	ctrautwein@ukaachen.de	Ernst, Matthias/D-5111-2012; Liedtke, Christian/DTV-1874-2022	Ernst, Matthias/0000-0002-6399-1177; Liedtke, Christian/0000-0003-4681-7887; Beraza, Naiara/0000-0003-0718-0940				Beraza N, 2005, HEPATOLOGY, V41, P460, DOI 10.1002/hep.20590; Blindenbacher A, 2003, HEPATOLOGY, V38, P674, DOI 10.1053/jhep.2003.50378; Cacalano NA, 2001, NAT CELL BIOL, V3, P460, DOI 10.1038/35074525; Coutant A, 2002, HEPATOLOGY, V36, P1079, DOI 10.1053/jhep.2002.36160; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; Croker BA, 2004, IMMUNITY, V20, P153, DOI 10.1016/S1074-7613(04)00022-6; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Deshpande RR, 2002, ANN SURG, V236, P248, DOI 10.1097/00000658-200208000-00014; Ernst M, 2004, TRENDS GENET, V20, P23, DOI 10.1016/j.tig.2003.11.003; Ernst M, 2001, J EXP MED, V194, P189, DOI 10.1084/jem.194.2.189; Evans MK, 2007, ONCOGENE, V26, P1941, DOI 10.1038/sj.onc.1209993; Fausto N, 1995, FASEB J, V9, P1527, DOI 10.1096/fasebj.9.15.8529831; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; Goren I, 2006, J INVEST DERMATOL, V126, P477, DOI 10.1038/sj.jid.5700063; Hirano T, 1998, Int Rev Immunol, V16, P249; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Kadry Z, 2004, LIVER TRANSPLANT, V10, P1078, DOI 10.1002/lt.20200; Kim JS, 2005, TRANSPLANTATION, V79, P1206, DOI 10.1097/01.TP.0000160758.13505.D2; Klein C, 2005, J CLIN INVEST, V115, P860, DOI 10.1172/JCI200523640; Ledda-Columbano GM, 1998, ONCOGENE, V17, P1039, DOI 10.1038/sj.onc.1202018; Leu JI, 2001, MOL CELL BIOL, V21, P414, DOI 10.1128/MCB.21.2.414-424.2001; Li W, 2002, J BIOL CHEM, V277, P28411, DOI 10.1074/jbc.M202807200; Luedde T, 2001, HEPATOLOGY, V34, p384A, DOI 10.1053/jhep.2001.0341254; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Nakamura K, 2004, HEPATOLOGY, V39, P635, DOI 10.1002/hep.20086; Pietrangelo A, 2007, GASTROENTEROLOGY, V132, P294, DOI 10.1053/j.gastro.2006.10.018; PINES J, 1995, ADV CANCER RES, V66, P181, DOI 10.1016/S0065-230X(08)60254-7; Sommer U, 2005, J BIOL CHEM, V280, P31478, DOI 10.1074/jbc.M506008200; Streetz KL, 2000, GUT, V47, P309, DOI 10.1136/gut.47.2.309; Stross C, 2006, J BIOL CHEM, V281, P8458, DOI 10.1074/jbc.M511212200; Suda T, 2002, CYTOKINE, V17, P335, DOI 10.1006/cyto.2002.1023; Sun R, 2005, BIOCHEM BIOPH RES CO, V338, P1943, DOI 10.1016/j.bbrc.2005.10.171; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Talarmin H, 1999, MOL CELL BIOL, V19, P6003; Thoresen GH, 2003, CELL PHYSIOL BIOCHEM, V13, P229; Tokumaru S, 2005, J IMMUNOL, V175, P4662, DOI 10.4049/jimmunol.175.7.4662; Tokumaru S, 2005, BIOCHEM BIOPH RES CO, V327, P100, DOI 10.1016/j.bbrc.2004.11.145; Trautwein C, 1996, GASTROENTEROLOGY, V110, P1854, DOI 10.1053/gast.1996.v110.pm8964411; Wuestefeld T, 2003, J BIOL CHEM, V278, P11281, DOI 10.1074/jbc.M208470200; Xia L, 2002, J BIOL CHEM, V277, P30716, DOI 10.1074/jbc.M202823200	41	37	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9886	9895		10.1074/jbc.M705483200	http://dx.doi.org/10.1074/jbc.M705483200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18216023	hybrid			2022-12-25	WOS:000254671600045
J	Charalambous, C; Gsandtner, I; Keuerleber, S; Milan-Lobo, L; Kudlacek, O; Freissmuth, M; Zezula, J				Charalambous, Christoforos; Gsandtner, Ingrid; Keuerleber, Simon; Milan-Lobo, Laura; Kudlacek, Oliver; Freissmuth, Michael; Zezula, Juergen			Restricted collision coupling of the A(2A) receptor revisited - Evidence for physical separation of two signaling cascades	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISRUPT MICROFILAMENT ORGANIZATION; HUMAN SEROTONIN TRANSPORTER; ACTIVATED PROTEIN-KINASE; A2 ADENOSINE RECEPTORS; A(2A)-ADENOSINE RECEPTOR; ADENYLATE-CYCLASE; LIPID RAFTS; MEMBRANE MICRODOMAINS; ALPHA-SUBUNITS; CELL-MEMBRANES	The A(2A)-adenosine receptor is a prototypical G(s) protein-coupled receptor but stimulates MAPK/ERK in a G(s)-independent way. The A(2A) receptor has long been known to undergo restricted collision coupling with Gs; the mechanistic basis for this mode of coupling has remained elusive. Here we visualized agonist-induced changes in mobility of the yellow fluorescent protein-tagged receptor by fluorescence recovery after photo-bleaching microscopy. Stimulation with a specific A(2A) receptor agonist did not affect receptor mobility. In contrast, stimulation with dopamine decreased the mobility of the D-2 receptor. When coexpressed in the same cell, the A(2A) receptor precluded the agonist-induced change in D-2 receptor mobility. Thus, the A(2A) receptor did not only undergo restricted collision coupling, but it also restricted the mobility of the D-2 receptor. Restricted mobility was not due to tethering to the actin cytoskeleton but was, in part, related to the cholesterol content of the membrane. Depletion of cholesterol increased receptor mobility but blunted activation of adenylyl cyclase, which was accounted for by impaired formation of the ternary complex of agonist, receptor, and G protein. These observations support the conclusion that the A(2A) receptor engages G(s) and thus signals to adenylyl cyclase in cholesterol-rich domains of the membrane. In contrast, stimulation of MAPK by the A(2A) receptor was not impaired. These findings are consistent with a model where the recruitment of these two pathways occurs in physically segregated membrane microdomains. Thus, the A(2A) receptor is the first example of a G protein-coupled receptor documented to select signaling pathways in a manner dependent on the lipid microenvironment of the membrane.	[Charalambous, Christoforos; Gsandtner, Ingrid; Keuerleber, Simon; Milan-Lobo, Laura; Kudlacek, Oliver; Freissmuth, Michael; Zezula, Juergen] Med Univ Vienna, Ctr Biomol Med & Pharmacol, Inst Pharmacol, A-1090 Vienna, Austria	Medical University of Vienna	Freissmuth, M (corresponding author), Med Univ Vienna, Ctr Biomol Med & Pharmacol, Inst Pharmacol, Wahringer Str 13A, A-1090 Vienna, Austria.	michael.freissmuth@meduniwien.ac.at		Kudlacek, Oliver/0000-0002-3086-8551; Freissmuth, Michael/0000-0001-9398-1765				Babiychuk EB, 2006, BIOCHEM J, V397, P407, DOI 10.1042/BJ20060056; Bockaert J, 2004, PHARMACOL THERAPEUT, V103, P203, DOI 10.1016/j.pharmthera.2004.06.004; BRAUN S, 1979, BIOCHEMISTRY-US, V18, P2134, DOI 10.1021/bi00577a045; BRAUN S, 1979, MOL PHARMACOL, V16, P737; Burgueno J, 2003, J BIOL CHEM, V278, P37545, DOI 10.1074/jbc.M302809200; Chini B, 2004, J MOL ENDOCRINOL, V32, P325, DOI 10.1677/jme.0.0320325; FERRE S, 1991, P NATL ACAD SCI USA, V88, P7238, DOI 10.1073/pnas.88.16.7238; Fuxe K, 2005, J MOL NEUROSCI, V26, P209, DOI 10.1385/JMN:26:2-3:209; Gimpl G, 2000, EUR J BIOCHEM, V267, P2483, DOI 10.1046/j.1432-1327.2000.01280.x; GROSS W, 1991, MOL PHARMACOL, V39, P524; Gsandtner I, 2005, J BIOL CHEM, V280, P31898, DOI 10.1074/jbc.M506515200; Gsandtner I, 2006, MOL PHARMACOL, V70, P447, DOI 10.1124/mol.106.026757; Hein P, 2006, J BIOL CHEM, V281, P33345, DOI 10.1074/jbc.M606713200; Hering H, 2003, J NEUROSCI, V23, P3262; Hernandez-Deviez DJ, 2002, NAT NEUROSCI, V5, P623, DOI 10.1038/nn865; INOKUCHI JI, 1987, J LIPID RES, V28, P565; Just H, 2004, J BIOL CHEM, V279, P6650, DOI 10.1074/jbc.M306092200; Kleuss C, 2003, EMBO J, V22, P826, DOI 10.1093/emboj/cdg095; Klinger M, 2002, J BIOL CHEM, V277, P32490, DOI 10.1074/jbc.M200556200; Klinger M, 2002, N-S ARCH PHARMACOL, V366, P287, DOI 10.1007/s00210-002-0617-z; Korkhov VM, 2006, J BIOL CHEM, V281, P13439, DOI 10.1074/jbc.M511382200; Kudlacek O, 2003, NEUROPSYCHOPHARMACOL, V28, P1317, DOI 10.1038/sj.npp.1300181; Kudlacek O, 2001, J BIOL CHEM, V276, P3010, DOI 10.1074/jbc.M007910200; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; Lissandron V, 2005, J MOL BIOL, V354, P546, DOI 10.1016/j.jmb.2005.09.089; LOHSE MJ, 1991, MOL PHARMACOL, V39, P517; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; Milojevic T, 2006, MOL PHARMACOL, V69, P1083, DOI 10.1124/mol.105.015818; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; NANOFF C, 1993, J RECEPTOR RES, V13, P961, DOI 10.3109/10799899309073703; NANOFF C, 1991, MOL PHARMACOL, V39, P130; Navratil AM, 2003, J BIOL CHEM, V278, P31593, DOI 10.1074/jbc.M304273200; Pfrieger FW, 2003, CELL MOL LIFE SCI, V60, P1158, DOI 10.1007/s00018-003-3018-7; ROSENWALD AG, 1992, BIOCHEMISTRY-US, V31, P3581, DOI 10.1021/bi00129a005; Schmid JA, 2001, J BIOL CHEM, V276, P3805, DOI 10.1074/jbc.M007357200; Seidel MG, 1999, J BIOL CHEM, V274, P25833, DOI 10.1074/jbc.274.36.25833; Sexl V, 1997, J BIOL CHEM, V272, P5792, DOI 10.1074/jbc.272.9.5792; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; SPECTOR I, 1983, SCIENCE, V219, P493, DOI 10.1126/science.6681676; TOLKOVSKY AM, 1978, BIOCHEMISTRY-US, V17, P3811, DOI 10.1021/bi00611a021; Waldhoer M, 1999, J BIOL CHEM, V274, P30571, DOI 10.1074/jbc.274.43.30571; Willmann R, 2006, EMBO J, V25, P4050, DOI 10.1038/sj.emboj.7601288; Youvan D. C., 1997, BIOTECHNOLOGY, V3, P1; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	47	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9276	9288		10.1074/jbc.M706275200	http://dx.doi.org/10.1074/jbc.M706275200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18218631	hybrid			2022-12-25	WOS:000254465800058
J	Okuda, H; Sakuhana, C; Yamamoto, R; Mizukami, Y; Kawai, R; Sumita, Y; Koga, M; Shirai, M; Matsuda, K				Okuda, Hiroshi; Sakuhana, Chihaya; Yamamoto, Risa; Mizukami, Yuko; Kawai, Rika; Sumita, Yusuke; Koga, Motoki; Shirai, Mutsunori; Matsuda, Kazuhiko			The intermediate domain defines broad nucleotide selectivity for protein folding in Chlamydophila GroEL1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONIN GROEL; ALLOSTERIC TRANSITIONS; CHLAMYDIA-PNEUMONIAE; ESCHERICHIA-COLI; IN-VITRO; ATP; RELEASE; ADP; ATHEROSCLEROSIS; RECONSTITUTION	The chaperonin GroEL assists protein folding in the presence of ATP and magnesium through substrate protein capsulation in combination with the cofactor GroES. Recent studies have revealed the details of folding cycles of GroEL from Escherichia coli, yet little is known about the GroEL-assisted protein folding mechanisms in other bacterial species. Using three model enzyme assays, we have found that GroEL1 from Chlamydophila pneumoniae, an obligate human pathogen, has a broader selectivity for nucleotides in the refolding reaction. To elucidate structural factors involved in such nucleotide selectivity, GroEL chimeras were constructed by exchanging apical, intermediate, and equatorial domains between E. coli GroEL and C. pneumoniae GroEL1. In vitro folding assays using chimeras revealed that the intermediate domain is the major contributor to the nucleotide selectivity of C. pneumoniae GroEL1. Additional site-directed mutation experiments led to the identification of Gln(400) and Ile(404) in the intermediate domain of C. pneumoniae GroEL1 as residues that play a key role in defining the nucleotide selectivity of the protein refolding reaction.	[Okuda, Hiroshi; Sakuhana, Chihaya; Yamamoto, Risa; Mizukami, Yuko; Kawai, Rika; Sumita, Yusuke; Koga, Motoki; Matsuda, Kazuhiko] Kinki Univ, Sch Agr, Dept Appl Biol Chem, Nara 6318505, Japan; [Shirai, Mutsunori] Yamaguchi Univ, Sch Med, Dept Microbiol, Ube, Yamaguchi 7558505, Japan	Kindai University (Kinki University); Yamaguchi University	Matsuda, K (corresponding author), Kinki Univ, Sch Agr, Dept Appl Biol Chem, 3327-204 Nakamachi, Nara 6318505, Japan.	kmatsuda@nara.kindai.ac.jp	Matsuda, Kazuhiko/AAX-4926-2020	Okuda, Hiroshi/0000-0002-5747-8086				BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BRAIG K, 1995, NAT STRUCT BIOL, V2, P1083, DOI 10.1038/nsb1295-1083; Bulut Y, 2002, J IMMUNOL, V168, P1435, DOI 10.4049/jimmunol.168.3.1435; Campbell LA, 2004, NAT REV MICROBIOL, V2, P23, DOI 10.1038/nrmicro796; Chapman E, 2006, P NATL ACAD SCI USA, V103, P15800, DOI 10.1073/pnas.0607534103; Chaudhuri TK, 2001, CELL, V107, P235, DOI 10.1016/S0092-8674(01)00523-2; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; Goyal K, 2006, J MOL EVOL, V63, P781, DOI 10.1007/s00239-006-0037-7; GRAYSTON JT, 1989, INT J SYST BACTERIOL, V39, P88, DOI 10.1099/00207713-39-1-88; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HOLLNEUGEBAUER B, 1991, BIOCHEMISTRY-US, V30, P11609; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Horwich AL, 2006, CHEM REV, V106, P1917, DOI 10.1021/cr040435v; Houry WA, 1999, NATURE, V402, P147, DOI 10.1038/45977; Huang YS, 1999, J BIOL CHEM, V274, P10405, DOI 10.1074/jbc.274.15.10405; Hyeon C, 2006, P NATL ACAD SCI USA, V103, P18939, DOI 10.1073/pnas.0608759103; Karunakaran KP, 2003, J BACTERIOL, V185, P1958, DOI 10.1128/JB.185.6.1958-1966.2003; KAWATA Y, 1994, FEBS LETT, V345, P229, DOI 10.1016/0014-5793(94)00456-0; Kerner MJ, 2005, CELL, V122, P209, DOI 10.1016/j.cell.2005.05.028; Kipnis Y, 2007, P NATL ACAD SCI USA, V104, P3119, DOI 10.1073/pnas.0700070104; KUBO T, 1993, J BIOL CHEM, V268, P19346; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; MIZOBATA T, 1992, J BIOL CHEM, V267, P17773; Motojima F, 2003, J BIOL CHEM, V278, P26648, DOI 10.1074/jbc.M300806200; Okuda H, 2007, BIOMETALS, V20, P903, DOI 10.1007/s10534-006-9078-z; Ranson NA, 2001, CELL, V107, P869, DOI 10.1016/S0092-8674(01)00617-1; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; Sasu S, 2001, CIRC RES, V89, P244, DOI 10.1161/hh1501.094184; Stan G, 2007, P NATL ACAD SCI USA, V104, P8803, DOI 10.1073/pnas.0700607104; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Zheng WJ, 2006, P NATL ACAD SCI USA, V103, P7664, DOI 10.1073/pnas.0510426103	33	4	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9300	9307		10.1074/jbc.M710057200	http://dx.doi.org/10.1074/jbc.M710057200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18230606	hybrid			2022-12-25	WOS:000254465800060
J	Wang, YH; Srinivasan, K; Siddiqui, MR; George, SP; Tomar, A; Khurana, S				Wang, Yaohong; Srinivasan, Kamalakkannan; Siddiqui, Mohammad Rizwan; George, Sudeep P.; Tomar, Alok; Khurana, Seema			A novel role for villin in intestinal epithelial cell survival and homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ULCERATIVE-COLITIS; CYTOCHROME-C; PHOSPHOLIPASE C-GAMMA(1); MITOCHONDRIAL FISSION; ISCHEMIA-REPERFUSION; ACTIN CYTOSKELETON; AXONAL-TRANSPORT; BRUSH-BORDERS; F-ACTIN; APOPTOSIS	Apoptosis is a key regulator for the normal turnover of the intestinal mucosa, and abnormalities associated with this function have been linked to inflammatory bowel disease and colorectal cancer. Despite this, little is known about the mechanism (s) mediating intestinal epithelial cell apoptosis. Villin is an actin regulatory protein that is expressed in every cell of the intestinal epithelium as well as in exocrine glands associated with the gastrointestinal tract. In this study we demonstrate for the first time that villin is an epithelial cell-specific anti-apoptotic protein. Absence of villin predisposes mice to dextran sodium sulfate-induced colitis by promoting apoptosis. To better understand the cellular and molecular mechanisms of the anti-apoptotic function of villin, we overexpressed villin in the Madin-Darby canine kidney Tet-Off epithelial cell line to demonstrate that expression of villin protects cells from apoptosis by maintaining mitochondrial integrity thus inhibiting the activation of caspase-9 and caspase-3. Furthermore, we report that the anti-apoptotic response of villin depends on activation of the pro-survival proteins, phosphatidylinositol 3-kinase and phosphorylated Akt. The results of our studies shed new light on the previously unrecognized function of villin in the regulation of apoptosis in the gastrointestinal epithelium.	[Wang, Yaohong; Srinivasan, Kamalakkannan; Siddiqui, Mohammad Rizwan; George, Sudeep P.; Tomar, Alok; Khurana, Seema] Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Khurana, S (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Nash 402,894 Union Ave, Memphis, TN 38163 USA.	skhurana@utmem.edu		Khurana, Seema/0000-0002-6884-810X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054755, R01DK065006] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 65006, DK 54755] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Athman R, 2005, CELL MICROBIOL, V7, P1109, DOI 10.1111/j.1462-5822.2005.00535.x; Baines CP, 2007, NAT CELL BIOL, V9, P550, DOI 10.1038/ncb1575; BEDI A, 1995, CANCER RES, V55, P1811; Budd SL, 2000, P NATL ACAD SCI USA, V97, P6161, DOI 10.1073/pnas.100121097; Bullen TF, 2006, LAB INVEST, V86, P1052, DOI 10.1038/labinvest.3700464; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; De Vos KJ, 2005, CURR BIOL, V15, P678, DOI 10.1016/j.cub.2005.02.064; DEBEAUREGARD MAC, 1995, EMBO J, V14, P409, DOI 10.1002/j.1460-2075.1995.tb07017.x; Dignass AU, 2001, INFLAMM BOWEL DIS, V7, P68, DOI 10.1097/00054725-200102000-00014; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ELSASSER HP, 1991, HISTOCHEMISTRY, V95, P383, DOI 10.1007/BF00266966; Erichsen K, 2005, INFLAMM BOWEL DIS, V11, P744, DOI 10.1097/01.MIB.0000174374.83601.86; Ferrary E, 1999, J CELL BIOL, V146, P819, DOI 10.1083/jcb.146.4.819; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Gauthier R, 2001, AM J PHYSIOL-CELL PH, V280, pC1540, DOI 10.1152/ajpcell.2001.280.6.C1540; George SP, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M703617200; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Gourlay CW, 2004, J CELL BIOL, V164, P803, DOI 10.1083/jcb.200310148; Hagiwara C, 2002, J GASTROEN HEPATOL, V17, P758, DOI 10.1046/j.1440-1746.2002.02791.x; HALL PA, 1994, J CELL SCI, V107, P3569; Hill MM, 2002, PHARMACOL THERAPEUT, V93, P243, DOI 10.1016/S0163-7258(02)00193-6; Hollenbeck PJ, 2005, J CELL SCI, V118, P5411, DOI 10.1242/jcs.053850; Imoto M, 1998, J CELL SCI, V111, P1341; Iwamoto M, 1996, J PATHOL, V180, P152; Kersting S, 2004, AM J PATHOL, V165, P425, DOI 10.1016/S0002-9440(10)63308-1; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Koon HW, 2007, P NATL ACAD SCI USA, V104, P2013, DOI 10.1073/pnas.0610664104; Koya RC, 2000, J BIOL CHEM, V275, P15343, DOI 10.1074/jbc.275.20.15343; Kruidenier L, 2003, J PATHOL, V201, P28, DOI 10.1002/path.1409; Kumar N, 2004, J BIOL CHEM, V279, P3096, DOI 10.1074/jbc.M308878200; Kusano H, 2000, ONCOGENE, V19, P4807, DOI 10.1038/sj.onc.1203868; Louvard RAD, 2003, MOL BIOL CELL, V14, P4641, DOI 10.1091/mbc.E03-02-0091; Mahajan NP, 1998, NAT BIOTECHNOL, V16, P547, DOI 10.1038/nbt0698-547; Martinez JA, 2006, GASTROENTEROLOGY, V131, P579, DOI 10.1053/j.gastro.2006.06.009; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Mashimo H, 1996, SCIENCE, V274, P262, DOI 10.1126/science.274.5285.262; MERRITT AJ, 1995, J CELL SCI, V108, P2261; MORRIS RL, 1995, J CELL BIOL, V131, P1315, DOI 10.1083/jcb.131.5.1315; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Noda T, 1998, AM J PHYSIOL-GASTR L, V274, pG270, DOI 10.1152/ajpgi.1998.274.2.G270; Ohkawara T, 2006, IMMUNOL LETT, V107, P148, DOI 10.1016/j.imlet.2006.09.002; OKAYASU I, 1990, GASTROENTEROLOGY, V98, P694, DOI 10.1016/0016-5085(90)90290-H; Panebra A, 2001, AM J PHYSIOL-CELL PH, V281, pC1046, DOI 10.1152/ajpcell.2001.281.3.C1046; PASRICHA PJ, 1995, GASTROENTEROLOGY, V109, P994, DOI 10.1016/0016-5085(95)90411-5; Paul G, 2005, CLIN EXP IMMUNOL, V140, P547, DOI 10.1111/j.1365-2249.2005.02775.x; Phillips MJ, 2003, LANCET, V362, P1112, DOI 10.1016/S0140-6736(03)14467-4; Pinson KI, 1998, DEV DYNAM, V211, P109, DOI 10.1002/(SICI)1097-0177(199801)211:1<109::AID-AJA10>3.0.CO;2-7; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; RIMM DL, 1995, DIGEST DIS SCI, V40, P389, DOI 10.1007/BF02065426; Seidelin JB, 2006, APMIS, V114, P508, DOI 10.1111/j.1600-0463.2006.apm_116.x; Tomar A, 2004, MOL BIOL CELL, V15, P4807, DOI 10.1091/mbc.E04-05-0431; Tomar A, 2006, J BIOL CHEM, V281, P31972, DOI 10.1074/jbc.M604323200; Vachon PH, 2002, GASTROENTEROLOGY, V123, P1980, DOI 10.1053/gast.2002.37072; Vetuschi A, 2002, DIGEST DIS SCI, V47, P1447, DOI 10.1023/A:1015931128583; Wang YH, 2007, AM J PHYSIOL-CELL PH, V292, pC1775, DOI 10.1152/ajpcell.00420.2006; Waterhouse NJ, 2001, J CELL BIOL, V153, P319, DOI 10.1083/jcb.153.2.319; Wu B, 2003, FASEB J, V17, P1156, DOI 10.1096/fj.02-0499fje; Yu YM, 2004, IMMUNOL RES, V29, P55, DOI 10.1385/IR:29:1-3:055; Yukawa M, 2002, INT J COLORECTAL DIS, V17, P70, DOI 10.1007/s003840100340	60	61	65	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9454	9464		10.1074/jbc.M707962200	http://dx.doi.org/10.1074/jbc.M707962200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18198174	hybrid			2022-12-25	WOS:000254465800075
J	Chessa, D; Dorsey, CW; Winter, M; Baumler, AJ				Chessa, Daniela; Dorsey, Caleb W.; Winter, Maria; Baumler, Andreas J.			Binding specificity of Salmonella plasmid-encoded fimbriae assessed by glycomics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 FIMBRIAE; KLEBSIELLA-PNEUMONIAE; TISSUE DISTRIBUTION; ESCHERICHIA-COLI; TYPHIMURIUM; EXPRESSION; GENES; CONSTRUCTION; INFECTION; PATHOLOGY	The Salmonella enterica serotype Typhimurium (S. Typhimurium) genome encodes 12 intestinal colonization factors of the chaperone/usher fimbrial assembly class; however, the binding specificity is known for only one of these adhesins, known as type 1 fimbriae. Here we explored the utility of glycomics to determine the carbohydrate binding specificity of plasmid-encoded fimbriae from S. Typhimurium. A cosmid carrying the pef operon was introduced into Escherichia coli and expression of fimbrial filaments composed of PefA confirmed by flow cytometry and immune-electron microscopy. Plasmid-encoded fimbriae were purified from the surface of E. coli, and the resulting preparation was shown to contain PefA as the sole major protein component. The binding of purified plasmid-encoded fimbriae to a glycanarray suggested that this adhesin specifically binds the trisaccharide Gal beta 1-4(Fuc alpha 1-3)GlcNAc, also known as the Lewis X (Le(x)) blood group antigen. Results from the glycanarray were validated by enzyme-linked immunosorbent assay (ELISA) in which plasmid-encoded fimbriae bound Lex-coated wells in a concentration-dependent manner. The binding of plasmid-encoded fimbriae to Le(x)-coated wells could be inhibited by co-incubation with soluble Le(x) antigen. Our results establish glycomic analysis as a promising new approach for determining the carbohydrate binding specificity of bacterial adhesins.	[Chessa, Daniela; Winter, Maria; Baumler, Andreas J.] Univ Calif Davis, Sch Med, Dept Med Microbiol & Immunol, Davis, CA 95616 USA; [Dorsey, Caleb W.; Baumler, Andreas J.] Texas A&M Univ, Hlth Sci Ctr, Coll Med, Dept Med Microbiol & Immunol, College Stn, TX 77843 USA	University of California System; University of California Davis; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Baumler, AJ (corresponding author), Univ Calif Davis, Sch Med, Dept Med Microbiol & Immunol, 1 Shields Ave, Davis, CA 95616 USA.	ajbaumler@ucdavis.edu	Baumler, Andreas J/H-2301-2011	Baumler, Andreas J/0000-0001-9152-7809; Chessa, Daniela/0000-0002-1260-2805	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI065534, R29AI040124, R01AI044170, R01AI040124] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062116] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI040124, AI 065534, AI 044170, AI 040124] Funding Source: Medline; NIGMS NIH HHS [GM 62116] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baumler AJ, 1996, INFECT IMMUN, V64, P61; BOYD JF, 1985, GUT, V26, P935, DOI 10.1136/gut.26.9.935; CLEGG S, 1987, INFECT IMMUN, V55, P281, DOI 10.1128/IAI.55.2.281-287.1987; CLEGG S, 1985, INFECT IMMUN, V48, P275, DOI 10.1128/IAI.48.2.275-279.1985; DUGUID JP, 1966, J PATHOL BACTERIOL, V92, P107, DOI 10.1002/path.1700920113; Duncan MJ, 2005, J BIOL CHEM, V280, P37707, DOI 10.1074/jbc.M501249200; Emanuelsson O, 2007, NAT PROTOC, V2, P953, DOI 10.1038/nprot.2007.131; FRIEDRICH MJ, 1993, MOL MICROBIOL, V8, P543, DOI 10.1111/j.1365-2958.1993.tb01599.x; GRUBER A, 1995, BIOTECHNIQUES, V19, P28; Hancox LS, 1997, FEMS IMMUNOL MED MIC, V19, P289, DOI 10.1016/S0928-8244(97)00095-3; Humphries A, 2005, INFECT IMMUN, V73, P5329, DOI 10.1128/IAI.73.9.5329-5338.2005; Humphries AD, 2003, MOL MICROBIOL, V48, P1357, DOI 10.1046/j.1365-2958.2003.03507.x; Kisiela D, 2005, INFECT IMMUN, V73, P6187, DOI 10.1128/IAI.73.9.6187-6190.2005; Kisiela D, 2006, MICROBIOL-SGM, V152, P1337, DOI 10.1099/mic.0.28588-0; KOSCIELAK J, 1986, GLYCOCONJUGATE J, V3, P95, DOI 10.1007/BF01108615; McClelland M, 2001, NATURE, V413, P852, DOI 10.1038/35101614; MCGOVERN VJ, 1979, AM J SURG PATHOL, V3, P483, DOI 10.1097/00000478-197912000-00001; Newburg DS, 2005, ANNU REV NUTR, V25, P37, DOI 10.1146/annurev.nutr.25.050304.092553; Nicholson B, 2000, MOL MICROBIOL, V35, P728, DOI 10.1046/j.1365-2958.2000.01743.x; Nuccio SP, 2007, MICROBIOL MOL BIOL R, V71, P551, DOI 10.1128/MMBR.00014-07; PURCELL BK, 1987, J BACTERIOL, V169, P5831, DOI 10.1128/jb.169.12.5831-5834.1987; Ravn V, 2000, APMIS, V108, P1, DOI 10.1034/j.1600-0463.2000.d01-1.x; Reis BP, 2003, VET MICROBIOL, V97, P269, DOI 10.1016/j.vetmic.2003.09.019; Santos RL, 2002, VET PATHOL, V39, P200, DOI 10.1354/vp.39-2-200; Santos RL, 2001, INFECT IMMUN, V69, P4610, DOI 10.1128/IAI.69.7.4610-4617.2001; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Thankavel K, 1999, J BIOL CHEM, V274, P5797, DOI 10.1074/jbc.274.9.5797; Weening EH, 2005, INFECT IMMUN, V73, P3358, DOI 10.1128/IAI.73.6.3358-3366.2005; WOODALL LD, 1993, J BACTERIOL, V175, P2770, DOI 10.1128/JB.175.9.2770-2778.1993	29	39	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8118	8124		10.1074/jbc.M710095200	http://dx.doi.org/10.1074/jbc.M710095200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18211897	hybrid			2022-12-25	WOS:000254288000008
J	LaRochelle, O; Labbe, S; Harrisson, JF; Simard, C; Tremblay, V; St-Gelais, G; Govindan, MV; Seguin, C				LaRochelle, Olivier; Labbe, Simon; Harrisson, Jean-Francois; Simard, Carl; Tremblay, Veronique; St-Gelais, Genevieve; Govindan, Manjapra V.; Seguin, Carl			Nuclear factor-1 and metal transcription factor-1 synergistically activate the mouse metallothionein-1 gene in response to metal ions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT-HOMOLOGOUS SEQUENCES; REGULATORY ELEMENTS; FACTOR MTF-1; ENCODING METALLOTHIONEIN; BINDING PROTEINS; PROMOTER; EXPRESSION; ZINC; FAMILY; VIVO	Metal activation of metallothionein (MT) gene transcription is dependent on the presence of metal regulatory elements (MREs), which are present in five non-identical copies (MREa through MREe) in the promoter of the mouse MT-1 gene and on the capacity of metal transcription factor-1 (MTF-1) to bind to the MREs in the presence of zinc. We detected a protein, distinct from MTF-1, specifically binding to the MREc region. DNA binding competition experiments using synthetic oligonucleotides and specific anti-NF1 antibodies showed that this protein binds to an NF1 site overlapping the MREc element as well as to a second site upstream of the Sp1a site and corresponds to NF1 or a related protein. Transfection experiments showed that loss of the two NF1 sites decreased metal-induced MT promoter activity by 55-70% in transiently transfected cells and almost completely abrogated metal and tert-butylhydroquinone (tBHQ) induction in stably transfected cells. Similarly, expression of an inactive NF1 protein strongly inhibited MT-1 promoter activity. Using synthetic promoters containing NF1 and MRE sites fused to a minimal MT promoter, we showed that these NF1 sites did not confer metal induction but enhanced metal-induced promoter activity. Chromatin immunoprecipitation assays confirmed that NF1 binds to the mouse MT-1 promoter in vivo and showed that NF1 binding is zinc- inducible. In addition, zinc- induced NF1 DNA binding was MTF-1-dependent. Taken together, these studies show that NF1 acts synergistically with MTF-1 to activate the mouse MT-1 promoter in response to metal ions and tert-butylhydroquinone and contributes to maximal activation of the gene.	[Seguin, Carl] Univ Laval, CHUQ, Hotel Dieu Quebec, Ctr Rech Cancerol, Quebec City, PQ G1R 2J6, Canada; Univ Laval, Fac Med, Dept Anat & Physiol, Ste Foy, PQ G1K 7P4, Canada	Laval University; Laval University	Seguin, C (corresponding author), Univ Laval, CHUQ, Hotel Dieu Quebec, Ctr Rech Cancerol, 11 Cote Palais, Quebec City, PQ G1R 2J6, Canada.	carl.seguin@crhdq.ulaval.ca		Labbe, Simon/0000-0002-4947-523X				Adilakshmi T, 2002, J BIOL CHEM, V277, P4147, DOI 10.1074/jbc.M109785200; Andrews GK, 2001, EMBO J, V20, P1114, DOI 10.1093/emboj/20.5.1114; Aniskovitch LP, 1997, ARCH BIOCHEM BIOPHYS, V341, P337, DOI 10.1006/abbi.1997.9976; Aniskovitch LP, 1998, ONCOGENE, V16, P1475, DOI 10.1038/sj.onc.1201659; APARICIO O, 2005, CURRENT PROTOCOLS MO; Bi YY, 2004, BIOCHEM J, V380, P695, DOI 10.1042/BJ20031677; Blomquist P, 1996, J BIOL CHEM, V271, P153, DOI 10.1074/jbc.271.1.153; Candeliere GA, 1996, MOL CELL BIOL, V16, P584; CARTER AD, 1984, P NATL ACAD SCI-BIOL, V81, P7392, DOI 10.1073/pnas.81.23.7392; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; Chen XH, 1999, BIOCHEMISTRY-US, V38, P12915, DOI 10.1021/bi9913000; Coyle P, 2002, CELL MOL LIFE SCI, V59, P627, DOI 10.1007/s00018-002-8454-2; CULOTTA VC, 1989, MOL CELL BIOL, V9, P1376, DOI 10.1128/MCB.9.3.1376; Dalton TP, 1996, J BIOL CHEM, V271, P26233, DOI 10.1074/jbc.271.42.26233; Daniels PJ, 2003, NUCLEIC ACIDS RES, V31, P6710, DOI 10.1093/nar/gkg913; Datta PK, 1997, BIOCHEM BIOPH RES CO, V230, P159, DOI 10.1006/bbrc.1996.5655; De la Serna IL, 2000, MOL CELL BIOL, V20, P2839, DOI 10.1128/MCB.20.8.2839-2851.2000; Faraonio R, 2000, EUR J BIOCHEM, V267, P1743, DOI 10.1046/j.1432-1327.2000.01167.x; Ghoshal K, 2002, MOL CELL BIOL, V22, P8302, DOI 10.1128/MCB.22.23.8302-8319.2002; Giedroc DP, 2001, ANTIOXID REDOX SIGN, V3, P577, DOI 10.1089/15230860152542943; Gronostajski RM, 2000, GENE, V249, P31, DOI 10.1016/S0378-1119(00)00140-2; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; Hung CF, 1999, MOL ENDOCRINOL, V13, P1704, DOI 10.1210/me.13.10.1704; Jacob ST, 2002, ENVIRON HEALTH PERSP, V110, P827, DOI 10.1289/ehp.02110s5827; LABBE S, 1993, NUCLEIC ACIDS RES, V21, P1549, DOI 10.1093/nar/21.7.1549; LABBE S, 1991, NUCLEIC ACIDS RES, V19, P4225, DOI 10.1093/nar/19.15.4225; Laity JH, 2007, ARCH BIOCHEM BIOPHYS, V463, P201, DOI 10.1016/j.abb.2007.03.019; LaRochelle O, 2001, J BIOL CHEM, V276, P41879, DOI 10.1074/jbc.M108313200; LaRochelle O, 2001, BIOCHEM J, V353, P591, DOI 10.1042/0264-6021:3530591; Li QW, 1998, NUCLEIC ACIDS RES, V26, P5182, DOI 10.1093/nar/26.22.5182; MACARTHUR CA, 1987, J BIOL CHEM, V262, P2161; Majumder S, 2001, GENE EXPRESSION, V9, P203, DOI 10.3727/000000001783992588; Marr MT, 2006, GENE DEV, V20, P1458, DOI 10.1101/gad.1418806; MARTINEZ E, 1991, MOL CELL BIOL, V11, P2937, DOI 10.1128/MCB.11.6.2937; Mellor J, 2005, MOL CELL, V19, P147, DOI 10.1016/j.molcel.2005.06.023; Moffatt P, 1998, DNA CELL BIOL, V17, P501, DOI 10.1089/dna.1998.17.501; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; Murphy BJ, 1999, CANCER RES, V59, P1315; OIKARINEN J, 1987, J BIOL CHEM, V262, P11064; Palmiter RD, 1998, P NATL ACAD SCI USA, V95, P8428, DOI 10.1073/pnas.95.15.8428; PALMITER RD, 1992, P NATL ACAD SCI USA, V89, P6333, DOI 10.1073/pnas.89.14.6333; Park JS, 2000, MOL BIOL CELL, V11, P2915, DOI 10.1091/mbc.11.9.2915; POUYSSEGUR J, 1999, METHODS MOL MED VASC, P315; QUAIFE CJ, 1994, BIOCHEMISTRY-US, V33, P7250, DOI 10.1021/bi00189a029; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; RADTKE F, 1995, NUCLEIC ACIDS RES, V23, P2277, DOI 10.1093/nar/23.12.2277; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SEARLE PF, 1985, MOL CELL BIOL, V5, P1480, DOI 10.1128/MCB.5.6.1480; SEGUIN C, 1988, NUCLEIC ACIDS RES, V16, P10547, DOI 10.1093/nar/16.22.10547; SENEAR AW, 1982, COLD SPRING HARB SYM, V47, P539; Smirnova IV, 2000, J BIOL CHEM, V275, P9377, DOI 10.1074/jbc.275.13.9377; Smith CL, 1997, J BIOL CHEM, V272, P27493, DOI 10.1074/jbc.272.44.27493; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; STUART GW, 1985, NATURE, V317, P828, DOI 10.1038/317828a0; Sutter NB, 2003, P NATL ACAD SCI USA, V100, P1105, DOI 10.1073/pnas.242732999; THOMASSIN H, 1992, NUCLEIC ACIDS RES, V20, P3091, DOI 10.1093/nar/20.12.3091; Wang Y, 2004, BIOL CHEM, V385, P623, DOI 10.1515/BC.2004.077; WESTIN G, 1988, EMBO J, V7, P3763, DOI 10.1002/j.1460-2075.1988.tb03260.x; WU L, 1992, P NATL ACAD SCI USA, V89, P4811, DOI 10.1073/pnas.89.11.4811; Yin H, 2005, PROSTATE, V62, P209, DOI 10.1002/pros.20136	61	24	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8190	8201		10.1074/jbc.M800640200	http://dx.doi.org/10.1074/jbc.M800640200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18230604	hybrid			2022-12-25	WOS:000254288000016
J	Yang, PH; Cheung, WKC; Peng, Y; He, ML; Wu, GQ; Xie, D; Jiang, BH; Huang, QH; Chen, Z; Lin, MCM; Kung, HF				Yang, Pai-Hao; Cheung, William K. C.; Peng, Ying; He, Ming-Liang; Wu, Guo-Qing; Xie, Dan; Jiang, Bing-Hua; Huang, Qiu-Hua; Chen, Zhu; Lin, Marie C. M.; Kung, Hsiang-Fu			Makorin-2 is a neurogenesis inhibitor downstream of phosphatidylinositol 3-kinase/Akt (PI3K/Akt) signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY XENOPUS EMBRYO; PROTEIN-KINASE-B; NEURAL INDUCTION; FINGER PROTEINS; MESSENGER-RNA; GROWTH-FACTOR; PI 3-KINASE; EXPRESSION; CELLS; GENE	Makorin-2 belongs to the makorin RING zinc finger gene family, which encodes putative ribonucleoproteins. Here we cloned the Xenopus makorin-2 (mkrn2) and characterized its function in Xenopus neurogenesis. Forced overexpression of mkrn2 produced tadpoles with dorso-posterior deficiencies and small-head/short-tail phenotype, whereas knockdown of mkrn2 by morpholino antisense oligonucleotides induced double axis in tadpoles. In Xenopus animal cap explant assay, mkrn2 inhibited activin, and retinoic acid induced animal cap neuralization, as evident from the suppression of a pan neural marker, neural cell adhesion molecule. Surprisingly, the anti-neurogenic activity of mkrn2 is independent of the two major neurogenesis signaling cascades, BMP-4 and Wnt8 pathways. Instead, mkrn2 works specifically through the phosphatidylinositol 3-kinase( PI3K) and Akt-mediated neurogenes is pathway. Overexpression of mkrn2 completely abrogated constitutively active PI3K-and Akt-induced, but not dominant negative glycogen synthase kinase-3 beta(GSK-3 beta)-induced, neural cell adhesion molecule expression, indicating that mkrn2 acts downstream of PI3K and Akt and upstream of GSK-3 beta. Moreover, mkrn2 up-regulated them RNA and protein levels of GSK-3 beta. These results revealed for the first time the important role of mkrn2 as a new player in PI3K/Akt-mediated neurogenesis during Xenopus embryonic development.	[Yang, Pai-Hao; Cheung, William K. C.; Wu, Guo-Qing; Lin, Marie C. M.] Univ Hong Kong, Dept Chem, Inst Mol Technol, Open Lab Chem Biol, Pokfulam, Hong Kong, Peoples R China; [Yang, Pai-Hao; He, Ming-Liang; Wu, Guo-Qing; Xie, Dan; Kung, Hsiang-Fu] Sun Yat Sen Univ, Joiny State Key Lab Oncol S China, Guangzhou 510120, Peoples R China; [Yang, Pai-Hao; He, Ming-Liang; Wu, Guo-Qing; Xie, Dan; Kung, Hsiang-Fu] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China; [Peng, Ying] Sun Yat Sen Univ, Affiliated Hosp 2, Dept Neurol, Guangzhou 510120, Peoples R China; [Jiang, Bing-Hua] Nanjing Med Univ, Dept Pathol, Ctr Canc, Nanjing 210029, Jiangsu, Peoples R China; [Huang, Qiu-Hua; Chen, Zhu] Shanghai Med Univ 2, Rui Jin Hosp, Shanghai Inst Hematol, Shanghai 200025, Peoples R China	University of Hong Kong; Sun Yat Sen University; Chinese University of Hong Kong; Sun Yat Sen University; Nanjing Medical University; Shanghai Jiao Tong University	Lin, MCM (corresponding author), Univ Hong Kong, Dept Chem, Inst Mol Technol, Open Lab Chem Biol, Pokfulam, Hong Kong, Peoples R China.	mcllin@hkusua.hku.hk; hkung@cuhk.edu.hk	HE, Ming-Liang/AFK-4738-2022; HE, Ming-Liang/AAG-3397-2022	He, Ming-Liang/0000-0002-4317-2836; Jiang, Bing-Hua/0000-0003-4526-2031; HE, Mingliang/0000-0002-9942-9151				Baker JC, 1999, GENE DEV, V13, P3149, DOI 10.1101/gad.13.23.3149; Blom N, 2004, PROTEOMICS, V4, P1633, DOI 10.1002/pmic.200300771; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; De J, 1999, GENE, V228, P133, DOI 10.1016/S0378-1119(98)00617-9; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; Gray TA, 2000, GENOMICS, V66, P76, DOI 10.1006/geno.2000.6199; Gray TA, 2001, GENOMICS, V77, P119, DOI 10.1006/geno.2001.6627; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; Hudson BP, 2004, NAT STRUCT MOL BIOL, V11, P257, DOI 10.1038/nsmb738; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Jiang BH, 1998, P NATL ACAD SCI USA, V95, P14179, DOI 10.1073/pnas.95.24.14179; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kim JH, 2005, GENE DEV, V19, P776, DOI 10.1101/gad.1289405; KINTNER CR, 1987, DEVELOPMENT, V99, P311; Lai WS, 1999, MOL CELL BIOL, V19, P4311; MAENO M, 1994, P NATL ACAD SCI USA, V91, P10260, DOI 10.1073/pnas.91.22.10260; Nieuwkoop P. D., 1994, NORMAL TABLE XENOPUS, P162; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Omwancha J, 2006, ENDOCRINE, V29, P363, DOI 10.1385/ENDO:29:2:363; Peng Y, 2004, J BIOL CHEM, V279, P28509, DOI 10.1074/jbc.M402294200; Stern CD, 2005, DEVELOPMENT, V132, P2007, DOI 10.1242/dev.01794; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; Umbhauer M, 2000, J CELL SCI, V113, P2865; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Vogt PK, 2001, TRENDS MOL MED, V7, P482, DOI 10.1016/S1471-4914(01)02161-X; Wymann MP, 2005, CURR OPIN CELL BIOL, V17, P141, DOI 10.1016/j.ceb.2005.02.011; XU RH, 1995, BIOCHEM BIOPH RES CO, V212, P212, DOI 10.1006/bbrc.1995.1958; Zhang QH, 2000, GENOME RES, V10, P1546, DOI 10.1101/gr.140200	31	24	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8486	8495		10.1074/jbc.M704768200	http://dx.doi.org/10.1074/jbc.M704768200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18198183	Green Published, hybrid			2022-12-25	WOS:000254288000047
J	Badarau, A; Shi, Q; Chow, JW; Zajicek, J; Mobashery, S; Vakulenko, S				Badarau, Adriana; Shi, Qicun; Chow, Joseph W.; Zajicek, Jaroslav; Mobashery, Shahriar; Vakulenko, Sergei			Aminoglycoside 2 ''-phosphotransferase type IIIa from Enterococcus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIBIOTIC KINASE APH(3')-IIIA; THEORELL-CHANCE MECHANISM; KINETIC MECHANISM; STAPHYLOCOCCUS-AUREUS; CATALYTIC MECHANISM; ESCHERICHIA-COLI; RESISTANCE; PHOSPHOTRANSFERASE; ACETYLTRANSFERASE; ENZYME	Aminoglycoside 2 ''-phosphotransferases mediate high level resistance to aminoglycoside antibiotics in Gram-positive microorganisms, thus posing a serious threat to the treatment of serious enterococcal infections. This work reports on cloning, purification, and detailed mechanistic characterization of aminoglycoside 2 ''-phosphotransferase, known as type Ic enzyme. In an unexpected finding, the enzyme exhibits strong preference for guanosine triphosphate over adenosine triphosphate as the phosphate donor, a unique observation among all characterized aminoglycoside phosphotransferases. The enzyme phosphorylates only certain 4,6-disubstituted aminoglycosides exclusively at the 2 ''-hydroxyl with k(cat) values of 0.5-1.0 s(-1) and K-m values in the nanomolar range for all substrates but kanamycin A. Based on this unique substrate profile, the enzyme is renamed aminoglycoside 2 ''-phosphotransferase type IIIa. Product and deadend inhibition patterns indicated a random sequential Bi Bi mechanism. Both the solvent viscosity effect and determination of the rate constant for dissociation of guanosine triphosphate indicated that at pH 7.5 the release of guanosine triphosphate is rate-limiting. A computational model for the enzyme is presented that sheds light on the structural aspects of interest in this family of enzymes.	[Badarau, Adriana; Shi, Qicun; Zajicek, Jaroslav; Mobashery, Shahriar; Vakulenko, Sergei] Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; [Chow, Joseph W.] Merck Res Labs, Dept Infect Dis Clin Res, N Wales, PA 19454 USA	University of Notre Dame; Merck & Company	Vakulenko, S (corresponding author), Univ Notre Dame, Dept Chem & Biochem, 417 Nieuwland Sci Hall, Notre Dame, IN 46556 USA.	svakulen@nd.edu	Chow, Joseph W/W-4164-2017	Chow, Joseph W/0000-0002-5934-5877	NIAID NIH HHS [R01 AI057393, R01 AI057393-03, AI 057393] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI057393] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams JA, 2001, CHEM REV, V101, P2271, DOI 10.1021/cr000230w; ALTSCHUL SF, 1997, NUCLEIC ACIDS RES, V25, P3402; Azucena E, 1997, J AM CHEM SOC, V119, P2317, DOI 10.1021/ja964278w; BLACKLOW SC, 1988, BIOCHEMISTRY-US, V27, P1158, DOI 10.1021/bi00404a013; Boehr DD, 2001, J BIOL CHEM, V276, P23929, DOI 10.1074/jbc.M100540200; CASE DA, 2004, AMBER, V8; Chen-Goodspeed M, 1999, BIOORG CHEM, V27, P395, DOI 10.1006/bioo.1999.1144; Cleland WW, 2006, CHEM REV, V106, P3252, DOI 10.1021/cr050287o; COLE PA, 1994, J BIOL CHEM, V269, P30880; Draker KA, 2003, BIOCHEMISTRY-US, V42, P6565, DOI 10.1021/bi034148h; Fromm H J, 1979, Methods Enzymol, V63, P467; Gaal T, 1997, SCIENCE, V278, P2092, DOI 10.1126/science.278.5346.2092; Jana S, 2005, BIOTECHNOL LETT, V27, P519, DOI 10.1007/s10529-005-2544-9; Kim C, 2005, BIOORG CHEM, V33, P149, DOI 10.1016/j.bioorg.2004.11.001; Kim C, 2004, BIOCHEMISTRY-US, V43, P2373, DOI 10.1021/bi036095+; Lee HK, 2002, ANTIMICROB AGENTS CH, V46, P3253, DOI 10.1128/AAC.46.10.3253-3256.2002; Leskovac V., 2003, COMPREHENSIVE ENZYME, P111; LIDE DR, 2004, HDB CHEM PHYS, P58; Magnet S, 2003, ANTIMICROB AGENTS CH, V47, P1577, DOI 10.1128/AAC.47.5.1577-1583.2003; Magnet S, 2001, BIOCHEMISTRY-US, V40, P3700, DOI 10.1021/bi002736e; Magnet S, 2005, CHEM REV, V105, P477, DOI 10.1021/cr0301088; MARTEL A, 1983, EUR J BIOCHEM, V133, P515, DOI 10.1111/j.1432-1033.1983.tb07494.x; MCKAY GA, 1994, BIOCHEMISTRY-US, V33, P6936, DOI 10.1021/bi00188a024; MCKAY GA, 1995, J BIOL CHEM, V270, P24686, DOI 10.1074/jbc.270.42.24686; McKay GA, 1996, BIOCHEMISTRY-US, V35, P8680, DOI 10.1021/bi9603884; MENARD R, 1993, ANTIMICROB AGENTS CH, V37, P78, DOI 10.1128/AAC.37.1.78; Morrison J. F., 2001, ENCY LIFE SCI, P1; Nurizzo D, 2003, J MOL BIOL, V327, P491, DOI 10.1016/S0022-2836(03)00121-9; SCHOWEN KB, 1982, METHOD ENZYMOL, V87, P551; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SIREGAR JJ, 1995, BIOCHEMISTRY-US, V34, P12681, DOI 10.1021/bi00039a026; SIREGAR JJ, 1994, ANTIMICROB AGENTS CH, V38, P641, DOI 10.1128/AAC.38.4.641; Thompson PR, 2002, BIOCHEMISTRY-US, V41, P7001, DOI 10.1021/bi0256680; Toth M, 2007, BIOCHEMISTRY-US, V46, P5570, DOI 10.1021/bi6024512; Vakulenko SB, 2003, CLIN MICROBIOL REV, V16, P430, DOI 10.1128/CMR.16.3.430-450.2003	35	12	12	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7638	7647		10.1074/jbc.M709645200	http://dx.doi.org/10.1074/jbc.M709645200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18199745	hybrid			2022-12-25	WOS:000253997900039
J	Hagemann, IS; Miller, DL; Klco, JM; Nikiforovich, GV; Baranski, TJ				Hagemann, Ian S.; Miller, Daniel L.; Klco, Jeffery M.; Nikiforovich, Gregory V.; Baranski, Thomas J.			Structure of the complement factor 5a receptor-ligand complex studied by disulfide trapping and molecular modeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; HUMAN C5A RECEPTOR; SITE-DIRECTED MUTAGENESIS; CRITICAL RESIDUES; DRUG DISCOVERY; BINDING SITE; ACTIVATION; IDENTIFICATION; ANAPHYLATOXIN; REGION	Complement factor 5a (C5a) is an anaphylatoxin that acts by binding to a G protein-coupled receptor, the C5aR. The relative orientation of this ligand-receptor pair is investigated here using the novel technique of disulfide trapping by random mutagenesis (DTRM) and molecular modeling. In the DTRM technique, an unpaired cysteine is introduced in the ligand, and a library of randomly mutagenized receptors is screened to identify mutants that introduce a cysteine at a position in the receptor that allows functional interactions with the ligand. By repeating this analysis at six positions of C5a, we identify six unique sets of intermolecular interactions for the C5a-C5aR complex, which are then compared with an independently developed computational three-dimensional model of the complex. This analysis reveals that the interface of the receptor N terminus with the cysteine-containing ligand molecules is selected from a variety of possible receptor conformations that exist in dynamic equilibrium. In contrast, DTRM identifies a single position in the second extracellular loop of the receptor that interacts specifically with a cysteine probe placed in the C-terminal tail of the C5a ligand.	[Hagemann, Ian S.; Miller, Daniel L.; Klco, Jeffery M.; Baranski, Thomas J.] Washington Univ, Dept Med, St Louis, MO 63110 USA; [Hagemann, Ian S.; Miller, Daniel L.; Klco, Jeffery M.; Baranski, Thomas J.] Washington Univ, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; [Nikiforovich, Gregory V.] Washington Univ, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Baranski, TJ (corresponding author), 660 S Euclid Ave,Campus Box 8127, St Louis, MO 63110 USA.	baranski@wustl.edu	Hagemann, Ian/ABB-2854-2021; Klco, Jeffery/M-9717-2018	Hagemann, Ian/0000-0002-3855-9745; Klco, Jeffery/0000-0003-2961-6960	NIGMS NIH HHS [GM22086, GM63720, GM71634] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071634, R01GM022086, R56GM022086, R01GM063720] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allegretti M, 2005, CURR MED CHEM, V12, P217, DOI 10.2174/0929867053363379; Baranski TJ, 1999, J BIOL CHEM, V274, P15757, DOI 10.1074/jbc.274.22.15757; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Brown AJ, 2000, YEAST, V16, P11, DOI 10.1002/(SICI)1097-0061(20000115)16:1<11::AID-YEA502>3.0.CO;2-K; BUBECK P, 1994, EUR J BIOCHEM, V219, P897, DOI 10.1111/j.1432-1033.1994.tb18571.x; Cain SA, 2003, BIOCHEM PHARMACOL, V66, P1833, DOI 10.1016/S0006-2952(03)00473-8; Cain SA, 2001, BIOCHEMISTRY-US, V40, P14047, DOI 10.1021/bi011055w; Chen ZG, 1998, J BIOL CHEM, V273, P10411, DOI 10.1074/jbc.273.17.10411; Cherezov V, 2007, SCIENCE, V318, P1258, DOI 10.1126/science.1150577; DEMARTINO JA, 1995, J BIOL CHEM, V270, P15966, DOI 10.1074/jbc.270.27.15966; DEMARTINO JA, 1994, J BIOL CHEM, V269, P14446; Dohlman HG, 2001, ANNU REV BIOCHEM, V70, P703, DOI 10.1146/annurev.biochem.70.1.703; Drews J, 2000, SCIENCE, V287, P1960, DOI 10.1126/science.287.5460.1960; Fan QR, 2005, NATURE, V433, P269, DOI 10.1038/nature03206; Finch AM, 1997, J MED CHEM, V40, P877, DOI 10.1021/jm960727r; Fredriksson R, 2005, MOL PHARMACOL, V67, P1414, DOI 10.1124/mol.104.009001; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; Gerber BO, 2001, J BIOL CHEM, V276, P3394, DOI 10.1074/jbc.M007748200; Geva A, 2000, J BIOL CHEM, V275, P35393, DOI 10.1074/jbc.M005602200; Hagemann IS, 2006, J BIOL CHEM, V281, P36783, DOI 10.1074/jbc.M607686200; Higginbottom A, 2005, J BIOL CHEM, V280, P17831, DOI 10.1074/jbc.M410797200; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; KAWAI M, 1992, J MED CHEM, V35, P220, DOI 10.1021/jm00080a004; Klco JM, 2006, J BIOL CHEM, V281, P12010, DOI 10.1074/jbc.M600548200; Klco JM, 2005, NAT STRUCT MOL BIOL, V12, P320, DOI 10.1038/nsmb913; KOLAKOWSKI LF, 1995, J BIOL CHEM, V270, P18077, DOI 10.1074/jbc.270.30.18077; Matsumoto ML, 2007, J BIOL CHEM, V282, P3105, DOI 10.1074/jbc.M607679200; MERY L, 1994, J BIOL CHEM, V269, P3457; MERY L, 1993, EUR J HAEMATOL, V51, P282; MOLLISON KW, 1989, P NATL ACAD SCI USA, V86, P292, DOI 10.1073/pnas.86.1.292; Nikiforovich GV, 2005, BIOPHYS J, V89, P3780, DOI 10.1529/biophysj.105.070722; Nikiforovich GV, 2003, BIOCHEMISTRY-US, V42, P9110, DOI 10.1021/bi034586o; Raffetseder U, 1996, EUR J BIOCHEM, V235, P82, DOI 10.1111/j.1432-1033.1996.00082.x; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; TOTH MJ, 1994, PROTEIN SCI, V3, P1159, DOI 10.1002/pro.5560030802; Vogen SM, 1999, J PEPT RES, V53, P8, DOI 10.1111/j.1399-3011.1999.tb01612.x; Zhang XL, 1997, PROTEIN SCI, V6, P65; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P172, DOI 10.1021/bi00427a025	38	21	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7763	7775		10.1074/jbc.M709467200	http://dx.doi.org/10.1074/jbc.M709467200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18195008	hybrid			2022-12-25	WOS:000253997900053
J	Heller, WP; Hayes, ML; Hanson, MR				Heller, Wade P.; Hayes, Michael L.; Hanson, Maureen R.			Cross-competition in editing of chloroplast RNA transcripts in vitro implicates sharing of trans-factors between different C targets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENTATRICOPEPTIDE REPEAT PROTEIN; PSBL MESSENGER-RNA; ARABIDOPSIS-THALIANA; MITOCHONDRIAL GENOME; PEA-CHLOROPLASTS; INITIATION CODON; TOBACCO; SEQUENCE; SITES; ELEMENTS	C -> U plant organellar RNA editing is required for the translation of evolutionarily conserved and functional proteins. 28 different C targets of RNA editing have been identified in maize chloroplasts, and hundreds of Cs are edited in mitochondria. Mutant analysis in Arabidopsis has indicated that absence of a single site-specific recognition protein can result in loss of editing of a single C target, raising the possibility that each C target requires a recognition protein. Here we show that transcripts encompassing two editing sites, ZMrpoB C467 and ZMrps14 C80, can compete editing activity from each other in vitro despite limited sequence similarity. The signal causing competition overlaps a 5'-cis element required for editing efficiency. A single five-nucleotide mutation spanning the region from -20 to -16 relative to the edited C of rpoB C467 is sufficient to eliminate its substrate editing as well as its ability to compete editing activity from rps14 C80 substrates. A corresponding mutation in an rps14 C80 competitor likewise eliminated its ability to compete editing activity from rpoB C467 substrates. Taken together, our results indicate that the RNA sequences mediating both editing efficiency and cross-competition are highly similar and that a common protein is involved in their editing. Sharing of trans-factors can facilitate editing of the large number of different C targets in plant organelles so that a different protein factor would not be required for every editing site.	[Heller, Wade P.; Hayes, Michael L.; Hanson, Maureen R.] Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	Cornell University	Hanson, MR (corresponding author), Cornell Univ, Dept Mol Biol & Genet, Biotech Bldg, Ithaca, NY 14853 USA.	mrh5@cornell.edu	Hanson, Maureen R/D-3879-2009	Hanson, Maureen R/0000-0001-8141-3058; Heller, Wade/0000-0002-5964-9715				BARKAN A, 1994, EMBO J, V13, P3170, DOI 10.1002/j.1460-2075.1994.tb06616.x; BOCK R, 1994, EMBO J, V13, P4623, DOI 10.1002/j.1460-2075.1994.tb06784.x; Chateigner-Boutin AL, 2002, MOL CELL BIOL, V22, P8448, DOI 10.1128/MCB.22.24.8448-8456.2002; CHAUDHURI S, 1995, EMBO J, V14, P2951, DOI 10.1002/j.1460-2075.1995.tb07295.x; Corneille S, 2000, MOL GEN GENET, V264, P419, DOI 10.1007/s004380000295; Giege P, 1999, P NATL ACAD SCI USA, V96, P15324, DOI 10.1073/pnas.96.26.15324; Handa H, 2003, NUCLEIC ACIDS RES, V31, P5907, DOI 10.1093/nar/gkg795; Hashimoto M, 2003, PLANT J, V36, P541, DOI 10.1046/j.1365-313X.2003.01900.x; Hayes ML, 2007, RNA, V13, P281, DOI 10.1261/rna.295607; Hayes ML, 2006, NUCLEIC ACIDS RES, V34, P3742, DOI 10.1093/nar/gkl490; Hegeman CE, 2005, PLANT J, V42, P124, DOI 10.1111/j.1365-313X.2005.02360.x; Hirose T, 2001, EMBO J, V20, P1144, DOI 10.1093/emboj/20.5.1144; HOCH B, 1991, NATURE, V353, P178, DOI 10.1038/353178a0; Inada M, 2004, PLANT CELL PHYSIOL, V45, P1615, DOI 10.1093/pcp/pch191; Kotera E, 2005, NATURE, V433, P326, DOI 10.1038/nature03229; KUDLA J, 1992, EMBO J, V11, P1099, DOI 10.1002/j.1460-2075.1992.tb05149.x; Lurin C, 2004, PLANT CELL, V16, P2089, DOI 10.1105/tpc.104.022236; Meierhoff K, 2003, PLANT CELL, V15, P1480, DOI 10.1105/tpc.010397; Miyamoto T, 2004, P NATL ACAD SCI USA, V101, P48, DOI 10.1073/pnas.0307163101; Miyamoto T, 2002, MOL CELL BIOL, V22, P6726, DOI 10.1128/MCB.22.19.6726-6734.2002; Notsu Y, 2002, MOL GENET GENOMICS, V268, P434, DOI 10.1007/s00438-002-0767-1; Okuda K, 2007, P NATL ACAD SCI USA, V104, P8178, DOI 10.1073/pnas.0700865104; Reed ML, 2001, GENE, V272, P165, DOI 10.1016/S0378-1119(01)00545-5; Reed ML, 2001, NUCLEIC ACIDS RES, V29, P1507, DOI 10.1093/nar/29.7.1507; Sasaki Y, 2001, J BIOL CHEM, V276, P3937, DOI 10.1074/jbc.M008166200; Shikanai T, 2006, CELL MOL LIFE SCI, V63, P698, DOI 10.1007/s00018-005-5449-9; Tillich M, 2005, PLANT J, V43, P708, DOI 10.1111/j.1365-313X.2005.02484.x; Tillich M, 2001, MAIZE GENET COOP NEW, V75, P42; Tsudzuki T, 2001, J MOL EVOL, V53, P327, DOI 10.1007/s002390010222; Zito F, 1997, PLANT MOL BIOL, V33, P79, DOI 10.1023/A:1005734809834	30	21	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7314	7319		10.1074/jbc.M709595200	http://dx.doi.org/10.1074/jbc.M709595200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18192271	hybrid, Green Published			2022-12-25	WOS:000253997900004
J	Shen, G; Schluchter, WM; Bryant, DA				Shen, Gaozhong; Schluchter, Wendy M.; Bryant, Donald A.			Biogenesis of phycobiliproteins - I. cpcS-I and cpcU mutants of the cyanobacterium Synechococcus sp PCC 7002 define a heterodimeric phyococyanobilin lyase specific for beta-phycocyanin and allophycocyanin subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE ANALYSIS; LIGHT-HARVESTING PROTEINS; GAMMA-N-METHYLASPARAGINE; SP STRAIN PCC-7002; C-PHYCOCYANIN; ENERGY-TRANSFER; LINKER-POLYPEPTIDE; AGMENELLUM-QUADRUPLICATUM; MASTIGOCLADUS-LAMINOSUS; FREMYELLA-DIPLOSIPHON	Phycobilin lyases covalently attach phycobilin chromophores to apo-phycobiliproteins ( PBPs). Genome analyses of the unicellular, marine cyanobacterium Synechococcus sp. PCC 7002 identified three genes, denoted cpcS-I, cpcU, and cpcV, that were possible candidates to encode phycocyanobilin ( PCB) lyases. Single and double mutant strains for cpcS-I and cpcU exhibited slower growth rates, reduced PBP levels, and impaired assembly of phycobilisomes, but a cpcV mutant had no discernable phenotype. A cpcS-I cpcU cpcT triple mutant was nearly devoid of PBP. SDS-PAGE and mass spectrometry demonstrated that the cpcS-I and cpcU mutants produced an altered form of the phycocyanin ( PC) beta subunit, which had a mass similar to 588 Da smaller than the wild-type protein. Some free PCB ( mass = 588 Da) was tentatively detected in the phycobilisome fraction purified from the mutants. The modified PC from the cpcS-I, cpcU, and cpcS-I cpcU mutant strains was purified, and biochemical analyses showed that Cys-153 of CpcB carried a PCB chromophore but Cys-82 did not. These results show that both CpcS-I and CpcU are required for covalent attachment of PCB to Cys-82 of the PC beta subunit in this cyanobacterium. Suggesting that CpcS-I and CpcU are also required for attachment of PCB to allophycocyanin subunits in vivo, allophycocyanin levels were significantly reduced in all but the CpcV-less strain. These conclusions have been validated by in vitro experiments described in the accompanying report ( Saunee, N. A., Williams, S. R., Bryant, D. A., and Schluchter, W. M. ( 2008) J. Biol. Chem. 283, 7513- 7522). We conclude that the maturation of PBP in vivo depends on three PCB lyases: CpcE-CpcF, CpcS-I-CpcU, and CpcT.	[Shen, Gaozhong; Bryant, Donald A.] Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; [Schluchter, Wendy M.] Univ New Orleans, Dept Biol Sci, New Orleans, LA 70148 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Louisiana System; University of New Orleans	Bryant, DA (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, S-235 Frear Bldg,Univ Pk, University Pk, PA 16802 USA.	dab14@psu.edu	Schluchter, Wendy/G-9662-2013		NIGMS NIH HHS [GM-31625] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031625] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BREJC K, 1995, J MOL BIOL, V249, P424, DOI 10.1006/jmbi.1995.0307; Bryant D.A., 1991, CELL CULTURE SOMATIC, V1st ed., P255; BRYANT DA, 1990, ARCH MICROBIOL, V153, P550, DOI 10.1007/BF00245264; COBLEY J, 2000, 10 INT S PHOT PROK B, P81; Cobley JG, 2002, MOL MICROBIOL, V44, P1517, DOI 10.1046/j.1365-2958.2002.02966.x; DEBRECZENY MP, 1993, J PHYS CHEM-US, V97, P9852, DOI 10.1021/j100140a050; DEBRECZENY MP, 1995, J PHYS CHEM-US, V99, P8412, DOI 10.1021/j100020a080; DELORIMIER R, 1990, BIOCHIM BIOPHYS ACTA, V1019, P29, DOI 10.1016/0005-2728(90)90121-J; DELORIMIER R, 1990, ARCH MICROBIOL, V153, P541, DOI 10.1007/BF00245263; DELORIMIER R, 1984, P NATL ACAD SCI-BIOL, V81, P7946; DUERRING M, 1991, J MOL BIOL, V217, P577, DOI 10.1016/0022-2836(91)90759-Y; FAIRCHILD CD, 1994, J BIOL CHEM, V269, P8686; FAIRCHILD CD, 1992, P NATL ACAD SCI USA, V89, P7017, DOI 10.1073/pnas.89.15.7017; Frigaard NU, 2004, METH MOL B, V274, P325; GINDT YM, 1992, J PHOTOCH PHOTOBIO B, V15, P75, DOI 10.1016/1011-1344(92)87007-V; GINDT YM, 1994, BBA-BIOENERGETICS, V1186, P153, DOI 10.1016/0005-2728(94)90174-0; GLAZER AN, 1989, J BIOL CHEM, V264, P1; Glockner G, 2000, J MOL EVOL, V51, P382; Gomez-Lojero C, 2003, BIOCHEMISTRY-US, V42, P13800, DOI 10.1021/bi0346998; Hirschberg J., 1994, MOL BIOL CYANOBACTER, DOI [10.1007/978-94-011-0227-8_18, DOI 10.1007/978-94-011-0227-8_18]; KLOTZ AV, 1987, J BIOL CHEM, V262, P17350; KLOTZ AV, 1986, J BIOL CHEM, V261, P5891; Lecomte JTJ, 1996, PROTEINS, V25, P267, DOI 10.1002/(SICI)1097-0134(199607)25:3<267::AID-PROT1>3.3.CO;2-8; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; MacKinney G, 1941, J BIOL CHEM, V140, P315; MAXSON P, 1989, BIOCHIM BIOPHYS ACTA, V977, P40, DOI 10.1016/S0005-2728(89)80007-6; Miller CA, 2007, THESIS U NEW ORLEANS; ONG LJ, 1988, LIGHT ENERGY TRANSDU, P102; PLANK T, 1995, J BACTERIOL, V177, P6798, DOI 10.1128/jb.177.23.6798-6803.1995; PLANK T, 1995, J BACTERIOL, V177, P6804, DOI 10.1128/jb.177.23.6804-6809.1995; RAPS S, 1990, PLANT PHYSIOL, V92, P358, DOI 10.1104/pp.92.2.358; Reuter W, 1999, P NATL ACAD SCI USA, V96, P1363, DOI 10.1073/pnas.96.4.1363; Sakamoto T, 1998, ARCH MICROBIOL, V169, P10; SAUNEE NA, 2006, THESIS U NEW ORLEANS; Saunee NA, 2008, J BIOL CHEM, V283, P7513, DOI 10.1074/jbc.M708165200; SCHIRMER T, 1985, J MOL BIOL, V184, P257, DOI 10.1016/0022-2836(85)90379-1; SCHIRMER T, 1986, J MOL BIOL, V188, P651, DOI 10.1016/S0022-2836(86)80013-4; SCHIRMER T, 1987, J MOL BIOL, V196, P677, DOI 10.1016/0022-2836(87)90040-4; Shen G., 2004, PS 2004 LIGHT HARV S, P14; Shen G, 2006, J BIOL CHEM, V281, P17768, DOI 10.1074/jbc.M602563200; SHEN GZ, 1995, PHOTOSYNTH RES, V44, P41, DOI 10.1007/BF00018295; Shen GZ, 2002, J BIOL CHEM, V277, P20343, DOI 10.1074/jbc.M201103200; Sidler W. A., 1994, MOL BIOL CYANOBACTER, P139, DOI [10.1007/978-94-011-0227-8_7, DOI 10.1007/978-94-011-0227-8_7]; STEVENS SE, 1980, P NATL ACAD SCI-BIOL, V77, P6052, DOI 10.1073/pnas.77.10.6052; SWANSON RV, 1992, J BIOL CHEM, V267, P16146; SWANSON RV, 1990, J MOL BIOL, V214, P787, DOI 10.1016/0022-2836(90)90293-U; Toole CM, 1998, MOL MICROBIOL, V30, P475, DOI 10.1046/j.1365-2958.1998.01082.x; ZHAO JD, 1989, ARCH MICROBIOL, V152, P447, DOI 10.1007/BF00446927; Zhao JD, 2001, BBA-BIOENERGETICS, V1505, P248, DOI 10.1016/S0005-2728(01)00175-X; Zhao KH, 2007, P NATL ACAD SCI USA, V104, P14300, DOI 10.1073/pnas.0706209104; Zhao KH, 2006, J BIOL CHEM, V281, P8573, DOI 10.1074/jbc.M513796200; ZHOU J, 1992, THESIS PENNSYLVANIA; ZHOU JH, 1992, J BIOL CHEM, V267, P16138	53	72	83	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7503	7512		10.1074/jbc.M708164200	http://dx.doi.org/10.1074/jbc.M708164200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18199754	hybrid			2022-12-25	WOS:000253997900025
J	Spohr, TCDSE; Choi, JW; Gardell, SE; Herr, DR; Rehen, SK; Gomes, FCA; Chun, J				Spohr, Tania Cristina de Sampaio E.; Choi, Ji Woong; Gardell, Shannon E.; Herr, Deron R.; Rehen, Stevens Kastrup; Gomes, Flavia Carvalho Alcantara; Chun, Jerold			Lysophosphatidic acid receptor-dependent secondary effects via astrocytes promote neuronal differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE; RADIAL GLIA; LYSOPHOSPHOLIPID RECEPTORS; SIGNALING DEFICITS; CORTICAL-NEURONS; CEREBRAL-CORTEX; SOLUBLE FACTORS; RAT ASTROCYTES; PROTEIN KINASE; GENE PROMOTER	Lysophosphatidic acid ( LPA) is a simple phospholipid derived from cell membranes that has extracellular signaling properties mediated by at least five G protein-coupled receptors referred to as LPA(1)-LPA(5). In the nervous system, receptor-mediated LPA signaling has been demonstrated to influence a range of cellular processes; however, an unaddressed aspect of LPA signaling is its potential to produce specific secondary effects, whereby LPA receptor-expressing cells exposed to, or "primed," by LPA may then act on other cells via distinct, yet LPA-initiated, mechanisms. In the present study, we examined cerebral cortical astrocytes as possible indirect mediators of the effects of LPA on developing cortical neurons. Cultured astrocytes express at least four LPA receptor subtypes, known as LPA1-LPA4. Cerebral cortical astrocytes primed by LPA exposure were found to increase neuronal differentiation of cortical progenitor cells. Treatment of unprimed astrocyte-progenitor cocultures with conditioned medium derived from LPA-primed astrocytes yielded similar results, suggesting the involvement of an astrocyte-derived soluble factor induced by LPA. At least two LPA receptor subtypes are involved in LPA priming, since the priming effect was lost in astrocytes derived from LPA receptor double-null mice( LPA(1)((-/-))/ LPA(2)((-/-))). Moreover, the loss of LPA-dependent differentiation in receptor double-null astrocytes could be rescued by retrovirally transduced expression of a single deleted receptor. These data demonstrate that receptor-mediated LPA signaling in astrocytes can induce LPA-dependent, indirect effects on neuronal differentiation.	[Choi, Ji Woong; Gardell, Shannon E.; Herr, Deron R.; Chun, Jerold] Scripps Res Inst, Dept Mol Biol, Helen L Dorris Child Adolescent Neuropsuchiat Dis, La Jolla, CA 92037 USA; [Spohr, Tania Cristina de Sampaio E.; Rehen, Stevens Kastrup; Gomes, Flavia Carvalho Alcantara] Univ Fed Rio de Janeiro, Dept Anat, Inst Ciencias Biomed, BR-21949590 Rio De Janeiro, RJ, Brazil	Scripps Research Institute; Universidade Federal do Rio de Janeiro	Chun, J (corresponding author), Scripps Res Inst, Dept Mol Biol, Helen L Dorris Child Adolescent Neuropsuchiat Dis, ICND 118,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	fgomes@anato.ufrj.br; jchun@scripps.edu	Rehen, Stevens/J-5874-2012; Spohr, Tania/I-4299-2015; Herr, Deron/AAB-7380-2020; Neurociencia, Inct/I-1011-2013; Chun, Jerold/Y-4670-2019; Gomes, Flavia/AAX-6354-2021; Gomes, Flavia/C-5383-2013	Rehen, Stevens/0000-0003-4216-9501; Spohr, Tania/0000-0001-8691-5962; Herr, Deron/0000-0001-5755-0896; Gomes, Flavia/0000-0003-2966-0638	NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH051699, R01MH051699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048478] Funding Source: NIH RePORTER; NIMH NIH HHS [MH051699] Funding Source: Medline; NINDS NIH HHS [NS048478] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Barnabe-Heider F, 2005, NEURON, V48, P253, DOI 10.1016/j.neuron.2005.08.037; Campbell DS, 2001, NEURON, V32, P1013, DOI 10.1016/S0896-6273(01)00551-7; Chen S, 2006, J NEUROSCI, V26, P3079, DOI 10.1523/JNEUROSCI.3785-05.2006; Christopherson KS, 2005, CELL, V120, P421, DOI 10.1016/j.cell.2004.12.020; Chun J, 2006, CURR PHARM DESIGN, V12, P161, DOI 10.2174/138161206775193109; Chun J, 1996, MOL CELL NEUROSCI, V7, P304, DOI 10.1006/mcne.1996.0023; Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384; Contos JJA, 2002, MOL CELL BIOL, V22, P6921, DOI 10.1128/MCB.22.19.6921-6929.2002; De Sampaio E., 2002, EUR J NEUROSCI, V16, P2059, DOI [10.1046/j.1460-9568.2002.02283.x, DOI 10.1046/J.1460-9568.2002.02283.X]; ESTIVILLTORRUS G, 2008, IN PRESS CEREBRAL CO; Freire E, 2004, J CELL SCI, V117, P4067, DOI 10.1242/jcs.01276; Fukushima N, 2000, DEV BIOL, V228, P6, DOI 10.1006/dbio.2000.9930; Fukushima N, 2002, MOL CELL NEUROSCI, V20, P271, DOI 10.1006/mcne.2002.1123; Fukushima N, 1998, P NATL ACAD SCI USA, V95, P6151, DOI 10.1073/pnas.95.11.6151; Fukushima N, 2007, NEUROCHEM INT, V50, P302, DOI 10.1016/j.neuint.2006.09.008; Garcia-Segura LM, 1999, J NEUROBIOL, V40, P574, DOI 10.1002/(SICI)1097-4695(19990915)40:4<574::AID-NEU12>3.0.CO;2-8; GARCIAABREU J, 1995, J NEUROSCI RES, V40, P471, DOI 10.1002/jnr.490400406; Gardell SE, 2006, TRENDS MOL MED, V12, P65, DOI 10.1016/j.molmed.2005.12.001; Gomes FCA, 1999, GLIA, V26, P97; Gomes FCA, 2001, BRAZ J MED BIOL RES, V34, P611, DOI 10.1590/S0100-879X2001000500008; Gomes FCA, 1999, GLIA, V25, P247, DOI 10.1002/(SICI)1098-1136(19990201)25:3<247::AID-GLIA5>3.0.CO;2-2; Harrison SM, 2003, MOL CELL NEUROSCI, V24, P1170, DOI 10.1016/j.mcn.2003.09.001; Hatten ME, 2002, SCIENCE, V297, P1660, DOI 10.1126/science.1074572; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Ishii I, 2000, MOL PHARMACOL, V58, P895, DOI 10.1124/mol.58.5.895; Ishii I, 2004, ANNU REV BIOCHEM, V73, P321, DOI 10.1146/annurev.biochem.73.011303.073731; Ishii I, 2002, J BIOL CHEM, V277, P25152, DOI 10.1074/jbc.M200137200; Johnson MA, 2007, J NEUROSCI, V27, P3069, DOI 10.1523/JNEUROSCI.4562-06.2007; Keller JN, 1997, J NEUROCHEM, V69, P1073; Kingsbury MA, 2003, NAT NEUROSCI, V6, P1292, DOI 10.1038/nn1157; Kornyei Z, 2007, FASEB J, V21, P2496, DOI 10.1096/fj.06-7756com; Lee CW, 2006, J BIOL CHEM, V281, P23589, DOI 10.1074/jbc.M603670200; Lie DC, 2005, NATURE, V437, P1370, DOI 10.1038/nature04108; Lim DA, 1999, P NATL ACAD SCI USA, V96, P7526, DOI 10.1073/pnas.96.13.7526; Ma DK, 2005, CURR OPIN NEUROBIOL, V15, P514, DOI 10.1016/j.conb.2005.08.003; Martinez R, 2005, J NEUROSCI RES, V80, P341, DOI 10.1002/jnr.20463; Martinez R, 2002, J BIOL CHEM, V277, P49311, DOI 10.1074/jbc.M209284200; Moller T, 2001, J BIOL CHEM, V276, P25946, DOI 10.1074/jbc.M102691200; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; Patten BA, 2006, J NEUROSCI, V26, P3102, DOI 10.1523/JNEUROSCI.4829-05.2006; Rao TS, 2003, BRAIN RES, V990, P182, DOI 10.1016/S0006-8993(03)03527-3; Rouach N, 2006, EUR J NEUROSCI, V23, P1453, DOI 10.1111/j.1460-9568.2006.04671.x; Sato K, 2005, J NEUROCHEM, V92, P904, DOI 10.1111/j.1471-4159.2004.02933.x; Sayas CL, 1999, J BIOL CHEM, V274, P37046, DOI 10.1074/jbc.274.52.37046; Schmid RS, 2003, P NATL ACAD SCI USA, V100, P4251, DOI 10.1073/pnas.0630496100; SILVER J, 1982, J COMP NEUROL, V210, P10, DOI 10.1002/cne.902100103; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; Sorensen SD, 2003, MOL PHARMACOL, V64, P1199, DOI 10.1124/mol.64.5.1199; Sousa VD, 2004, EUR J NEUROSCI, V19, P1721, DOI 10.1111/j.1460.9568.2004.03249.x; Steiner MR, 2002, BBA-MOL CELL BIOL L, V1582, P154, DOI 10.1016/S1388-1981(02)00150-6; Stipursky J, 2007, GLIA, V55, P1023, DOI 10.1002/glia.20522; Svetlov SI, 2004, STEM CELLS DEV, V13, P685, DOI 10.1089/scd.2004.13.685; Tabuchi S, 2000, NEUROCHEM RES, V25, P573, DOI 10.1023/A:1007542532395; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Tomas M, 2003, J NEUROCHEM, V87, P220, DOI 10.1046/j.1471-4159.2003.01993.x; Weiner JA, 2001, J NEUROSCI, V21, P7069, DOI 10.1523/JNEUROSCI.21-18-07069.2001; Weiner JA, 1998, J COMP NEUROL, V398, P587; Weiner JA, 1999, P NATL ACAD SCI USA, V96, P5233, DOI 10.1073/pnas.96.9.5233; Ye XQ, 2002, NEUROREPORT, V13, P2169, DOI 10.1097/00001756-200212030-00002; Yuan XB, 2003, NAT CELL BIOL, V5, P38, DOI 10.1038/ncb895	61	65	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7470	7479		10.1074/jbc.M707758200	http://dx.doi.org/10.1074/jbc.M707758200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18198181	Green Published, hybrid			2022-12-25	WOS:000253997900022
J	Stork, R; Zettlitz, KA; Muller, D; Rether, M; Hanisch, FG; Kontermann, RE				Stork, Roland; Zettlitz, Kirstin A.; Mueller, Dafne; Rether, Miriam; Hanisch, Franz-Georg; Kontermann, Roland E.			N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICLE-STIMULATING-HORMONE; ALBUMIN-BINDING FAB; HUMAN SERUM-ALBUMIN; THERAPEUTIC PROTEINS; STRUCTURAL-CHARACTERIZATION; ANTIBODY MOLECULES; HUMAN RECOMBINANT; FUSION PROTEIN; HEPATITIS-C; CELL-LINE	The therapeutic efficacy of recombinant antibodies such as single-chain Fv fragments and small bispecific or bifunctional molecules is often limited by rapid elimination from the circulation because of their small size. Here, we have investigated the effects of N-glycosylation on the activity and pharmacokinetics of a small bispecific single-chain diabody (scDb CEACD3) developed for the retargeting of cytotoxic T cells to CEA-expressing tumor cells. We could show that the introduction of N-glycosylation sequons into the flanking linker and a C-terminal extension results in the production of N-glycosylated molecules after expression in transfected HEK293 cells. N-Glycosylated scDb variants possessing 3, 6, or 9 N-glycosylation sites, respectively, retained antigen binding activity and bispecificity for target and effector cells as shown in a target cell-dependent IL-2 release assay, although activity was reduced similar to 3-5-fold compared with the unmodified scDb. All N-glycosylated scDb variants exhibited a prolonged circulation time compared with scDb, leading to a 2-3-fold increase of the area under curve (AUC). In comparison, conjugation of a branched 40-kDa PEG chain increased AUC by a factor of 10.6, while a chimeric anti-CEA IgG1 molecule had the longest circulation time with a 17-fold increase in AUC. Thus, N-glycosylation complements the repertoire of strategies to modulate pharmacokinetics of small recombinant antibody molecules by an approach that moderately prolongs circulation time.	[Stork, Roland; Zettlitz, Kirstin A.; Mueller, Dafne; Rether, Miriam; Kontermann, Roland E.] Univ Stuttgart, Inst Zellbiol & Immunol, D-70569 Stuttgart, Germany; [Hanisch, Franz-Georg] Univ Cologne, Zentrum Mol Med Koln, Fak Med, Inst Biochem 2, D-50931 Cologne, Germany	University of Stuttgart; University of Cologne	Stork, R (corresponding author), Univ Stuttgart, Inst Zellbiol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.	roland.kontermann@izi.uni-stuttgart.de	Kontermann, Roland E./F-9263-2014; Zettlitz, Kirstin/AAC-1015-2022	Zettlitz, Kirstin/0000-0003-4870-6603; Mueller, Dafne/0000-0002-1544-3475				Bailon P, 2001, BIOCONJUGATE CHEM, V12, P195, DOI 10.1021/bc000082g; Bain VG, 2006, J HEPATOL, V44, P671, DOI 10.1016/j.jhep.2005.12.011; Baker KN, 2001, BIOTECHNOL BIOENG, V73, P188, DOI 10.1002/bit.1051; Bragonzi A, 2000, BBA-GEN SUBJECTS, V1474, P273, DOI 10.1016/S0304-4165(00)00023-4; Chapman AP, 2002, ADV DRUG DELIVER REV, V54, P531, DOI 10.1016/S0169-409X(02)00026-1; Chaudhury C, 2003, J EXP MED, V197, P315, DOI 10.1084/jem.20021829; CHESTER KA, 1994, LANCET, V343, P455, DOI 10.1016/S0140-6736(94)92695-6; Chuang VTG, 2002, PHARMACEUT RES, V19, P569; Cohen O, 2004, BIOCHEM J, V378, P117, DOI 10.1042/BJ20031305; Dennis MS, 2007, CANCER RES, V67, P254, DOI 10.1158/0008-5472.CAN-06-2531; Dumont JA, 2006, BIODRUGS, V20, P151, DOI 10.2165/00063030-200620030-00002; Duncan R, 2006, NAT REV CANCER, V6, P688, DOI 10.1038/nrc1958; Elliott S, 2003, NAT BIOTECHNOL, V21, P414, DOI 10.1038/nbt799; Engelmann K, 2005, GLYCOBIOLOGY, V15, P1111, DOI 10.1093/glycob/cwi099; Fitch JCK, 1999, CIRCULATION, V100, P2499, DOI 10.1161/01.CIR.100.25.2499; Groulet A, 2002, INT J CANCER, V100, P367, DOI 10.1002/ijc.10477; Hambrock HO, 2004, J BIOL CHEM, V279, P11727, DOI 10.1074/jbc.M309318200; Harris JM, 2003, NAT REV DRUG DISCOV, V2, P214, DOI 10.1038/nrd1033; HOVGAARD D, 1993, EUR J HAEMATOL, V50, P32; Jefferis R, 2005, BIOTECHNOL PROGR, V21, P11, DOI 10.1021/bp040016j; Jefferis R, 2005, ADV EXP MED BIOL, V564, P143; Kaufmann B, 2004, GLYCOBIOLOGY, V14, P609, DOI 10.1093/glycob/cwh063; KAWATSU M, 1990, J PHARMACOBIO-DYNAM, V13, P549, DOI 10.1248/bpb1978.13.549; Kubetzko S, 2005, MOL PHARMACOL, V68, P1439, DOI 10.1124/mol.105.014910; Kubetzko S, 2006, J BIOL CHEM, V281, P35186, DOI 10.1074/jbc.M604127200; Lencer WI, 2005, TRENDS CELL BIOL, V15, P5, DOI 10.1016/j.tcb.2004.11.004; Lobo ED, 2004, J PHARM SCI-US, V93, P2645, DOI 10.1002/jps.20178; Mahmood I, 2005, CLIN PHARMACOKINET, V44, P331, DOI 10.2165/00003088-200544040-00001; Muller D, 2007, J BIOL CHEM, V282, P12650, DOI 10.1074/jbc.M700820200; Natarajan A, 2005, BIOCONJUGATE CHEM, V16, P113, DOI 10.1021/bc0498121; Nguyen A, 2006, PROTEIN ENG DES SEL, V19, P291, DOI 10.1093/protein/gzl011; Ni HY, 2000, THROMB RES, V99, P407, DOI 10.1016/S0049-3848(00)00263-2; Packer NH, 1998, GLYCOCONJUGATE J, V15, P737, DOI 10.1023/A:1006983125913; Perlman S, 2003, J CLIN ENDOCR METAB, V88, P3227, DOI 10.1210/jc.2002-021201; SARENEVA T, 1993, J INTERFERON RES, V13, P267, DOI 10.1089/jir.1993.13.267; Schlereth B, 2005, CANCER RES, V65, P2882, DOI 10.1158/0008-5472.CAN-04-2637; Sinclair AM, 2005, J PHARM SCI-US, V94, P1626, DOI 10.1002/jps.20319; Stork R, 2007, PROTEIN ENG DES SEL, V20, P569, DOI 10.1093/protein/gzm061; TERNANT D, 2005, EXP OPIN BIOL THE S1, V5, P537; Wang ML, 1998, PROTEIN ENG, V11, P1277, DOI 10.1093/protein/11.12.1277; Weenen C, 2004, J CLIN ENDOCR METAB, V89, P5204, DOI 10.1210/jc.2004-0425; Werner RG, 2007, ACTA PAEDIATR, V96, P17, DOI 10.1111/j.1651-2227.2007.00199.x; Wuttke M, 2001, J BIOL CHEM, V276, P36839, DOI 10.1074/jbc.M105689200	43	69	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7804	7812		10.1074/jbc.M709179200	http://dx.doi.org/10.1074/jbc.M709179200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18211902	hybrid			2022-12-25	WOS:000253997900056
J	Truscott, SM; Wang, X; Lybarger, L; Biddison, WE; McBerry, C; Martinko, JM; Connolly, JM; Linette, GP; Fremont, DH; Hansen, TH; Carreno, BM				Truscott, Steven M.; Wang, Xiaoli; Lybarger, Lonnie; Biddison, William E.; McBerry, Cortez; Martinko, John M.; Connolly, Janet M.; Linette, Gerald P.; Fremont, Daved H.; Hansen, Ted H.; Carreno, Beatriz M.			Human major histocompatibility complex (MHC) class I molecules with disulfide traps secure disease-related antigenic peptides and exclude competitor peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOTOXIC T-LYMPHOCYTES; SINGLE-CHAIN TRIMERS; CELL-RECEPTOR; MONOCLONAL-ANTIBODIES; DENDRITIC CELLS; DNA VACCINES; EPITOPE; HLA-A2; RECOGNITION; HLA-B27	The ongoing discovery of disease-associated epitopes detected by CD8 T cells greatly facilitates peptide-based vaccine approaches and the construction of multimeric soluble recombinant proteins ( e. g. tetramers) for isolation and enumeration of antigen-specific CD8 T cells. Related to these outcomes of epitope discovery is the recent demonstration that MHC class I/peptide complexes can be expressed as single chain trimers ( SCTs) with peptide, beta(2)m and heavy chain connected by linkers to form a single polypeptide chain. Studies using clinically relevant mouse models of human disease have shown that SCTs expressed by DNA vaccination are potent stimulators of cytotoxic T lymphocytes. Their vaccine efficacy has been attributed to the fact that SCTs contain a preprocessed and preloaded peptide that is stably displayed on the cell surface. Although SCTs of HLA class I/ peptide complexes have been previously reported, they have not been characterized for biochemical stability or susceptibility to exogenous peptide binding. Here we demonstrate that human SCTs remain almost exclusively intact when expressed in cells and can incorporate a disulfide trap that dramatically excludes the binding of exogenous peptides. The mechanistic and practical applications of these findings for vaccine development and T cell isolation/ enumeration are discussed.	[Truscott, Steven M.; Wang, Xiaoli; Connolly, Janet M.; Fremont, Daved H.; Hansen, Ted H.] Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; [Truscott, Steven M.; Wang, Xiaoli; Connolly, Janet M.; Fremont, Daved H.; Hansen, Ted H.] Washington Univ, Sch Med, Dept Immunol, St Louis, MO 63110 USA; [Linette, Gerald P.; Carreno, Beatriz M.] Washington Univ, Sch Med, Dept Internal Med, Div Oncol, St Louis, MO 63110 USA; [Biddison, William E.] Natl Inst Hlth, NINDS, Mol Immunol Sect, Neuroimmunol Branch, Bethesda, MD 20892 USA; [Lybarger, Lonnie] Univ Arizona, Arizona Hlth Sci Ctr, Dept Cell Biol & Anat, Tucson, AZ 85724 USA; [McBerry, Cortez; Martinko, John M.] So Illinois Univ, Dept Microbiol, Carbondale, IL 62901 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Arizona; University of Arizona Health Sciences; Southern Illinois University System; Southern Illinois University	Hansen, TH (corresponding author), Washington Univ, Sch Med, Dept Pathol, Box 8118,660 S Euclid Ave, St Louis, MO 63110 USA.	hansen@pathology.wustl.edu		Fremont, Daved/0000-0002-8544-2689	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI055849, R56AI055849, U54AI057160, R01AI027568] Funding Source: NIH RePORTER; NIAID NIH HHS [AI055849, AI027568, U54-AI057160] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altman JD, 2004, METHOD CELL BIOL, V75, P433; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Biddison WE, 2003, J IMMUNOL, V171, P3064, DOI 10.4049/jimmunol.171.6.3064; BRODSKY FM, 1979, IMMUNOL REV, V47, P3, DOI 10.1111/j.1600-065X.1979.tb00288.x; CARRENO BM, 1992, J IMMUNOL, V148, P894; CARRENO BM, 1990, P NATL ACAD SCI USA, V87, P3420, DOI 10.1073/pnas.87.9.3420; Choudhuri K, 2005, NATURE, V436, P578, DOI 10.1038/nature03843; Crew MD, 2005, MOL IMMUNOL, V42, P1205, DOI 10.1016/j.molimm.2004.11.013; Donnelly JJ, 2005, J IMMUNOL, V175, P633, DOI 10.4049/jimmunol.175.2.633; ELLIS SA, 1982, HUM IMMUNOL, V5, P49, DOI 10.1016/0198-8859(82)90030-1; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Ge Q, 2002, P NATL ACAD SCI USA, V99, P13729, DOI 10.1073/pnas.212515299; Granfors Kaisa, 2002, Arthritis Rheum, V46, P606, DOI 10.1002/art.10041; Greten TF, 2002, J IMMUNOL METHODS, V271, P125, DOI 10.1016/S0022-1759(02)00346-0; Hansen TH, 2006, CANCER IMMUNOL IMMUN, V55, P235, DOI 10.1007/s00262-005-0091-9; Harris MR, 2001, INT IMMUNOL, V13, P1275, DOI 10.1093/intimm/13.10.1275; Huang CH, 2005, GENE THER, V12, P1180, DOI 10.1038/sj.gt.3302519; HUET S, 1990, INT IMMUNOL, V2, P311, DOI 10.1093/intimm/2.4.311; Hung CF, 2007, VACCINE, V25, P127, DOI 10.1016/j.vaccine.2006.06.087; Jaramillo A, 2004, BREAST CANCER RES TR, V88, P29, DOI 10.1007/s10549-004-8918-1; KANNAGI M, 1992, J VIROL, V66, P2928, DOI 10.1128/JVI.66.5.2928-2933.1992; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P6458, DOI 10.1073/pnas.91.14.6458; KAWAKAMI Y, 1995, J IMMUNOL, V154, P3961; Kim S, 2005, NATURE, V436, P709, DOI 10.1038/nature03847; Lauterbach H, 2006, J IMMUNOL, V176, P4600, DOI 10.4049/jimmunol.176.8.4600; Lazarski CA, 2005, IMMUNITY, V23, P29, DOI 10.1016/j.immuni.2005.05.009; LIE WR, 1991, J EXP MED, V173, P449, DOI 10.1084/jem.173.2.449; Linette GP, 2005, CLIN CANCER RES, V11, P7692, DOI 10.1158/1078-0432.CCR-05-1198; LURQUIN C, 1989, CELL, V58, P293, DOI 10.1016/0092-8674(89)90844-1; Lybarger L, 2003, J BIOL CHEM, V278, P27105, DOI 10.1074/jbc.M303716200; Mitaksov V, 2007, CHEM BIOL, V14, P909, DOI 10.1016/j.chembiol.2007.07.010; MORRISON J, 1992, EUR J IMMUNOL, V22, P903, DOI 10.1002/eji.1830220404; Myers NB, 2000, J IMMUNOL, V165, P5656, DOI 10.4049/jimmunol.165.10.5656; Oved K, 2005, CANCER IMMUNOL IMMUN, V54, P867, DOI 10.1007/s00262-005-0666-5; PARKER KC, 1994, J IMMUNOL, V152, P163; Parkhurst MR, 1996, J IMMUNOL, V157, P2539; Peters B, 2005, PLOS BIOL, V3, P379, DOI 10.1371/journal.pbio.0030091; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Primeau T, 2005, IMMUNOL RES, V32, P109, DOI 10.1385/IR:32:1-3:109; Princiotta MF, 2003, IMMUNITY, V18, P343, DOI 10.1016/S1074-7613(03)00051-7; Purcell AW, 2007, NAT REV DRUG DISCOV, V6, P404, DOI 10.1038/nrd2224; REDDEHASE MJ, 1989, NATURE, V337, P651, DOI 10.1038/337651a0; Schott E, 2002, P NATL ACAD SCI USA, V99, P13735, DOI 10.1073/pnas.212515399; SMITH JD, 1993, J EXP MED, V178, P2035, DOI 10.1084/jem.178.6.2035; STAM NJ, 1990, INT IMMUNOL, V2, P113, DOI 10.1093/intimm/2.2.113; Stevenson FK, 2004, P NATL ACAD SCI USA, V101, P14646, DOI 10.1073/pnas.0404896101; TRUSCOTT SM, 2007, THESIS WASHINGTON U; Truscott SM, 2007, J IMMUNOL, V178, P6280, DOI 10.4049/jimmunol.178.10.6280; Utz U, 1996, J VIROL, V70, P843, DOI 10.1128/JVI.70.2.843-851.1996; Wang ZC, 2002, J IMMUNOL, V169, P3146, DOI 10.4049/jimmunol.169.6.3146; Yachi PP, 2005, NAT IMMUNOL, V6, P785, DOI 10.1038/ni1220; Yewdell JTW, 1999, ANNU REV IMMUNOL, V17, P51, DOI 10.1146/annurev.immunol.17.1.51; Yewdell JW, 2003, NAT REV IMMUNOL, V3, P952, DOI 10.1038/nri1250; Yu YYL, 1999, INT IMMUNOL, V11, P1897, DOI 10.1093/intimm/11.12.1897; Yu YYL, 2002, J IMMUNOL, V168, P3145, DOI 10.4049/jimmunol.168.7.3145; Zhang YX, 2007, IMMUNOLOGY, V121, P105, DOI 10.1111/j.1365-2567.2007.02543.x	56	16	18	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7480	7490		10.1074/jbc.M709935200	http://dx.doi.org/10.1074/jbc.M709935200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18195006	Green Published, hybrid			2022-12-25	WOS:000253997900023
J	Vogl, C; Klein, CM; Batke, AF; Schweingruber, ME; Stolz, J				Vogl, Christian; Klein, Cornelia M.; Batke, Angelika F.; Schweingruber, M. Ernst; Stolz, Juergen			Characterization of Thi9, a novel thiamine (vitamin B-1) transporter from Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPRESSIBLE EXPRESSION VECTORS; YEAST SACCHAROMYCES-CEREVISIAE; FISSION YEAST; GENETIC-REGULATION; BIOSYNTHETIC GENE; THIAZOLE BIOSYNTHESIS; HETEROLOGOUS MODULES; SHUTTLE VECTORS; NMT1 PROMOTER; FAMILY	Thiamine is an essential component of the human diet and thiamine diphosphate-dependent enzymes play an important role in carbohydrate metabolism in all living cells. Although the yeasts Saccharomyces cerevisiae and Schizosaccharomyces pombe can derive thiamine from biosynthesis, both are also able to take up thiamine from external sources, leading to the down-regulation of the enzymes involved in its formation. We have isolated the S. pombe thiamine transporter Thi9 by genetic complementation of mutants defective in thiamine biosynthesis and transport. Thi9 localizes to the S. pombe cell surface and works as a high-affinity proton/ thiamine symporter. The uptake of thiamine was reduced in the presence of pyrithiamine, oxythiamine, amprolium, and the thiazole part of thiamine, indicating that these compounds are substrates of Thi9. In pyrithiamine-resistant mutants, a conserved glutamate residue close to the first of the 12 transmembrane domains is exchanged by a lysine and this causes aberrant localization of the protein. Thiamine uptake is significantly increased in thiamine-deficient medium and this is associated with an increase in thi9(+) mRNA and protein levels. Upon addition of thiamine, the thi9(+) mRNA becomes undetectable within minutes, whereas the Thi9 protein appears to be stable. The protein is distantly related to transporters for amino acids, gamma-aminobutyric acid and polyamines, and not to any of the known thiamine transporters. We also found that the pyridoxine transporter Bsu1 has a marked contribution to the thiamine uptake activity of S. pombe cells.	[Vogl, Christian; Klein, Cornelia M.; Batke, Angelika F.; Stolz, Juergen] Univ Regensburg, Lehrstuhl Zellbiol & Plfazenphysiol, D-93040 Regensburg, Germany; [Schweingruber, M. Ernst] Univ Bern, Inst Cell Biol, CH-3012 Bern, Switzerland	University of Regensburg; University of Bern	Stolz, J (corresponding author), Tech Univ Munich, Lehrstuhl Ernahrungsphysiol, Am Forum 5, D-85350 Freising Weihenstephan, Germany.	stolz@wzw.tum.de						Andoh T, 2004, BIOCHEM BIOPH RES CO, V317, P1138, DOI 10.1016/j.bbrc.2004.03.171; Ashokkumar B, 2006, AM J PHYSIOL-RENAL, V291, pF796, DOI 10.1152/ajprenal.00078.2006; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; BARBET N, 1992, GENE, V114, P59, DOI 10.1016/0378-1119(92)90707-V; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; Bassler K., 2002, VITAMIN LEXIKON; Begley TP, 1999, ARCH MICROBIOL, V171, P293, DOI 10.1007/s002030050713; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; Brachmann CB, 1998, YEAST, V14, P115; Chatterjee A, 2007, J AM CHEM SOC, V129, P2914, DOI 10.1021/ja067606t; Chatterjee A, 2006, J AM CHEM SOC, V128, P7158, DOI 10.1021/ja061413o; CROTT MT, 2006, EUKARYOT CELL, V5, P1175; Diaz GA, 1999, NAT GENET, V22, P309, DOI 10.1038/10385; Dutta B, 1999, J BIOL CHEM, V274, P31925, DOI 10.1074/jbc.274.45.31925; Enjo F, 1997, J BIOL CHEM, V272, P19165, DOI 10.1074/jbc.272.31.19165; Eudy JD, 2000, MOL GENET METAB, V71, P581, DOI 10.1006/mgme.2000.3112; FANKHAUSER H, 1994, GENE, V147, P141, DOI 10.1016/0378-1119(94)90054-X; Fleming JC, 1999, NAT GENET, V22, P305, DOI 10.1038/10379; FORSBURG SL, 1993, NUCLEIC ACIDS RES, V21, P2955, DOI 10.1093/nar/21.12.2955; Ganapathy V, 2004, PFLUG ARCH EUR J PHY, V447, P641, DOI 10.1007/s00424-003-1068-1; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Goffeau A, 1997, YEAST, V13, P43, DOI 10.1002/(SICI)1097-0061(199701)13:1<43::AID-YEA56>3.0.CO;2-J; Grossmann G, 2006, EUKARYOT CELL, V5, P945, DOI 10.1128/EC.00206-05; Hohmann S, 1998, BBA-PROTEIN STRUCT M, V1385, P201, DOI 10.1016/S0167-4838(98)00069-7; IWASHIMA A, 1990, BIOCHIM BIOPHYS ACTA, V1022, P211, DOI 10.1016/0005-2736(90)90116-6; IWASHIMA A, 1973, BIOCHIM BIOPHYS ACTA, V330, P222, DOI 10.1016/0005-2736(73)90227-7; Jack DL, 2000, MICROBIOL-SGM, V146, P1797, DOI 10.1099/00221287-146-8-1797; Kall L, 2004, J MOL BIOL, V338, P1027, DOI 10.1016/j.jmb.2004.03.016; Koser S.A., 1968, VITAMIN REQUIREMENTS; Labay V, 1999, NAT GENET, V22, P300, DOI 10.1038/10372; Liang DT, 1999, J CELL SCI, V112, P559; MANETTI AGO, 1994, YEAST, V10, P1075, DOI 10.1002/yea.320100809; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; McQuire TA, 2006, CURR GENET, V50, P269, DOI 10.1007/s00294-006-0086-x; Miranda-Rios J, 2001, P NATL ACAD SCI USA, V98, P9736, DOI 10.1073/pnas.161168098; Mitchison JM, 1970, METHOD CELL PHYSIOL, V4, P131; Mojzita D, 2006, MOL GENET GENOMICS, V276, P147, DOI 10.1007/s00438-006-0130-z; Moreno MB, 2000, YEAST, V16, P861; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; NAGY M, 1992, P NATL ACAD SCI USA, V89, P8966, DOI 10.1073/pnas.89.19.8966; Niederberger C, 1996, GENE, V171, P119, DOI 10.1016/0378-1119(96)00101-1; Nosaka K, 2005, MOL MICROBIOL, V58, P467, DOI 10.1111/j.1365-2958.2005.04835.x; Nosaka K, 2006, APPL MICROBIOL BIOT, V72, P30, DOI 10.1007/s00253-006-0464-9; Paulsen IT, 1998, FEBS LETT, V430, P116, DOI 10.1016/S0014-5793(98)00629-2; PRAEKELT UM, 1994, YEAST, V10, P481, DOI 10.1002/yea.320100407; Rodionov DA, 2002, J BIOL CHEM, V277, P48949, DOI 10.1074/jbc.M208965200; ROSE AB, 1990, METHOD ENZYMOL, V185, P234; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHWEINGRUBER AM, 1991, CURR GENET, V19, P249, DOI 10.1007/BF00355050; SCHWEINGRUBER ME, 1990, CURR GENET, V17, P191, DOI 10.1007/BF00312609; SCHWEINGRUBER ME, 1986, J BIOL CHEM, V261, P5877; SERRANO R, 1983, FEBS LETT, V156, P11, DOI 10.1016/0014-5793(83)80237-3; Settembre E, 2003, CURR OPIN STRUC BIOL, V13, P739, DOI 10.1016/j.sbi.2003.10.006; Siam R, 2004, METHODS, V33, P189, DOI 10.1016/j.ymeth.2003.11.013; Singleton CK, 1997, GENE, V199, P111, DOI 10.1016/S0378-1119(97)00354-5; Sipiczki M, 2000, GENOME BIOL, V1, DOI [10.1186/gb-2000-1-2-reviews1011, DOI 10.1186/GB-2000-1-2-REVIEWS1011]; Stolz J, 2005, EUKARYOT CELL, V4, P319, DOI 10.1128/EC.4.2.319-326.2005; Stolz J, 2003, J BIOL CHEM, V278, P18990, DOI 10.1074/jbc.M300949200; Subramanian VS, 2007, J PHYSIOL-LONDON, V582, P73, DOI 10.1113/jphysiol.2007.128843; TANG CSL, 1994, J BIOL CHEM, V269, P11921; TOMMASINO M, 1991, CURR GENET, V20, P63, DOI 10.1007/BF00312766; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Webb E, 1997, J BACTERIOL, V179, P4399, DOI 10.1128/jb.179.13.4399-4402.1997; Wightman R, 2003, MICROBIOL-SGM, V149, P1447, DOI 10.1099/mic.0.26194-0; Williams RJ, 1930, J BIOL CHEM, V87, P581; Winkler W, 2002, NATURE, V419, P952, DOI 10.1038/nature01145; Zhao RB, 2002, AM J PHYSIOL-CELL PH, V282, pC1512, DOI 10.1152/ajpcell.00547.2001; ZURLINDEN A, 1994, J BACTERIOL, V176, P6631, DOI 10.1128/JB.176.21.6631-6635.1994; ZURLINDEN A, 1992, GENE, V117, P141, DOI 10.1016/0378-1119(92)90503-H; Zurlinden A, 1997, J BACTERIOL, V179, P5956, DOI 10.1128/jb.179.18.5956-5958.1997	73	18	19	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7379	7389		10.1074/jbc.M708275200	http://dx.doi.org/10.1074/jbc.M708275200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18201975	hybrid			2022-12-25	WOS:000253997900012
J	Wang, QY; Li, LY; Ye, YH				Wang, Qiuyan; Li, Lianyun; Ye, Yihong			Inhibition of p97-dependent protein degradation by Eeyarestatin I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ER-ASSOCIATED DEGRADATION; TRANSMEMBRANE CONDUCTANCE REGULATOR; RETICULUM-ASSOCIATED DEGRADATION; UBIQUITIN-PROTEASOME SYSTEM; CELL ANTIGEN RECEPTOR; ENDOPLASMIC-RETICULUM; QUALITY-CONTROL; MEMBRANE-PROTEIN; MISFOLDED GLYCOPROTEINS; AAA-ATPASE	Elimination of misfolded proteins from the endoplasmic reticulum ( ER) by ER-associated degradation involves substrate retro-translocation from the ER lumen into the cytosol for degradation by the proteasome. For many substrates, retrotranslocation requires the action of ubiquitinating enzymes, which polyubiquitinate substrates emerging from the ER lumen, and of the p97-Ufd1-Npl4 ATPase complex, which hydrolyzes ATP to dislocate polyubiquitinated substrates into the cytosol. Polypeptides extracted by p97 are eventually transferred to the proteasome for destruction. In mammalian cells, ERAD can be blocked by a chemical inhibitor termed Eeyarestatin I, but the mechanism of EerI action is unclear. Here we report that EerI can associate with a p97 complex to inhibit ERAD. The interaction of EerI with the p97 complex appears to negatively influence a deubiquitinating process that is mediated by p97-associated deubiquitinating enzymes. We further show that ataxin-3, a p97-associated deubiquitinating enzyme previously implicated in ER-associated degradation, is among those affected. Interestingly, p97-associated deubiquitination is also involved in degradation of a soluble substrate. Our analyses establish a role for a novel deubiquitinating process in proteasome-dependent protein turnover.	[Wang, Qiuyan; Li, Lianyun; Ye, Yihong] NIDDK, Mol Biol Lab, Natl Inst Hlth, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Ye, YH (corresponding author), NIDDK, Mol Biol Lab, Natl Inst Hlth, 5 Ctr Dr, Bethesda, MD 20892 USA.	yihongy@mail.nih.gov		Li, Lianyun/0000-0003-4194-3059	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK036136, Z01DK036136] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams J, 2004, CANCER CELL, V5, P417, DOI 10.1016/S1535-6108(04)00120-5; Bays NW, 2001, MOL BIOL CELL, V12, P4114, DOI 10.1091/mbc.12.12.4114; Bays NW, 2002, CURR BIOL, V12, pR366, DOI 10.1016/S0960-9822(02)00862-X; Bence NF, 2005, METHOD ENZYMOL, V399, P481, DOI 10.1016/S0076-6879(05)99033-2; Bhamidipati A, 2005, MOL CELL, V19, P741, DOI 10.1016/j.molcel.2005.07.027; Blom D, 2004, EMBO J, V23, P650, DOI 10.1038/sj.emboj.7600090; Braun S, 2002, EMBO J, V21, P615, DOI 10.1093/emboj/21.4.615; Burnett B, 2003, HUM MOL GENET, V12, P3195, DOI 10.1093/hmg/ddg344; Buschhorn BA, 2004, FEBS LETT, V577, P422, DOI 10.1016/j.febslet.2004.10.039; Caldwell SR, 2001, J BIOL CHEM, V276, P23296, DOI 10.1074/jbc.M102962200; Carvalho P, 2006, CELL, V126, P361, DOI 10.1016/j.cell.2006.05.043; DeLaBarre B, 2006, MOL CELL, V22, P451, DOI 10.1016/j.molcel.2006.03.036; Denic V, 2006, CELL, V126, P349, DOI 10.1016/j.cell.2006.05.045; Fiebiger E, 2004, MOL BIOL CELL, V15, P1635, DOI 10.1091/mbc.E03-07-0506; Friedlander R, 2000, NAT CELL BIOL, V2, P379, DOI 10.1038/35017001; Gauss R, 2006, NAT CELL BIOL, V8, P849, DOI 10.1038/ncb1445; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Hirsch C, 2003, EMBO J, V22, P1036, DOI 10.1093/emboj/cdg107; Hitchcock AL, 2001, MOL BIOL CELL, V12, P3226, DOI 10.1091/mbc.12.10.3226; Huppa JB, 1997, IMMUNITY, V7, P113, DOI 10.1016/S1074-7613(00)80514-2; Kikkert M, 2001, BIOCHEM J, V358, P369, DOI 10.1042/0264-6021:3580369; Kim W, 2005, MOL CELL, V19, P753, DOI 10.1016/j.molcel.2005.08.010; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Lilley BN, 2005, P NATL ACAD SCI USA, V102, P14296, DOI 10.1073/pnas.0505014102; Lilley BN, 2005, IMMUNOL REV, V207, P126, DOI 10.1111/j.0105-2896.2005.00318.x; Lilley BN, 2004, NATURE, V429, P834, DOI 10.1038/nature02592; Lybarger L, 2003, IMMUNITY, V18, P121, DOI 10.1016/S1074-7613(02)00509-5; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Neuber O, 2005, NAT CELL BIOL, V7, P993, DOI 10.1038/ncb1298; Ng DTW, 2000, J CELL BIOL, V150, P77, DOI 10.1083/jcb.150.1.77; Oda Y, 2006, J CELL BIOL, V172, P383, DOI 10.1083/jcb.200507057; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; Richly H, 2005, CELL, V120, P73, DOI 10.1016/j.cell.2004.11.013; Romisch K, 2005, ANNU REV CELL DEV BI, V21, P435, DOI 10.1146/annurev.cellbio.21.012704.133250; Schuberth C, 2005, NAT CELL BIOL, V7, P999, DOI 10.1038/ncb1299; Shamu CE, 1999, J CELL BIOL, V147, P45, DOI 10.1083/jcb.147.1.45; Shamu CE, 2001, MOL BIOL CELL, V12, P2546, DOI 10.1091/mbc.12.8.2546; Sun F, 2006, J BIOL CHEM, V281, P36856, DOI 10.1074/jbc.M607085200; Swanson R, 2001, GENE DEV, V15, P2660, DOI 10.1101/gad.933301; Szathmary R, 2005, MOL CELL, V19, P765, DOI 10.1016/j.molcel.2005.08.015; Taxis C, 2003, J BIOL CHEM, V278, P35903, DOI 10.1074/jbc.M301080200; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Vashist S, 2001, J CELL BIOL, V155, P355, DOI 10.1083/jcb.200106123; Vashist S, 2004, J CELL BIOL, V165, P41, DOI 10.1083/jcb.200309132; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Wang QY, 2006, J CELL BIOL, V174, P963, DOI 10.1083/jcb.200605100; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071; Ye YH, 2003, J CELL BIOL, V162, P71, DOI 10.1083/jcb.200302169; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Ye YH, 2005, ESSAYS BIOCHEM, V41, P99, DOI 10.1042/EB0410099; Ye YH, 2005, P NATL ACAD SCI USA, V102, P14132, DOI 10.1073/pnas.0505006102; Ye YH, 2004, NATURE, V429, P841, DOI 10.1038/nature02656; Ye YH, 2006, J STRUCT BIOL, V156, P29, DOI 10.1016/j.jsb.2006.01.005; Younger JM, 2006, CELL, V126, P571, DOI 10.1016/j.cell.2006.06.041; Yu H, 1999, J BIOL CHEM, V274, P36852, DOI 10.1074/jbc.274.52.36852; Zhong XY, 2006, HUM MOL GENET, V15, P2409, DOI 10.1093/hmg/ddl164; Zhong XY, 2004, J BIOL CHEM, V279, P45676, DOI 10.1074/jbc.M409034200	60	149	157	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7445	7454		10.1074/jbc.M708347200	http://dx.doi.org/10.1074/jbc.M708347200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18199748	hybrid, Green Published			2022-12-25	WOS:000253997900019
J	Zubieta, C; Arkus, KAJ; Cahoon, RE; Jez, JM				Zubieta, Chloe; Arkus, Kiani A. J.; Cahoon, Rebecca E.; Jez, Joseph M.			A single amino acid change is responsible for evolution of acyltransferase specificity in bacterial methionine biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME-CATALYZED ACYLATION; HOMOSERINE TRANSACETYLASE; ESCHERICHIA-COLI; BACILLUS-CEREUS; MECHANISTIC CHARACTERIZATION; S-ADENOSYLMETHIONINE; CRYSTAL-STRUCTURE; TRANSSUCCINYLASE; CYSTATHIONINE; SUBSTRATE	Bacteria and yeast rely on either homoserine transsuccinylase (HTS, metA) or homoserine transacetylase (HTA; met2) for the biosynthesis of methionine. Although HTS and HTA catalyze similar chemical reactions, these proteins are typically unrelated in both sequence and three-dimensional structure. Here we present the 2.0 angstrom resolution x-ray crystal structure of the Bacillus cereus metA protein in complex with homoserine, which provides the first view of a ligand bound to either HTA or HTS. Surprisingly, functional analysis of the B. cereus metA protein shows that it does not use succinyl-CoA as a substrate. Instead, the protein catalyzes the transacetylation of homoserine using acetyl-CoA. Therefore, the B. cereus metA protein functions as an HTA despite greater than 50% sequence identity with bona fide HTS proteins. This result emphasizes the need for functional confirmation of annotations of enzyme function based on either sequence or structural comparisons. Kinetic analysis of site-directed mutants reveals that the B. cereus metA protein and the E. coli HTS share a common catalytic mechanism. Structural and functional examination of the B. cereus metA protein reveals that a single amino acid in the active site determines acetyl-CoA (Glu-111) versus succinyl-CoA (Gly-111) specificity in the metA-like of acyltransferases. Switching of this residue provides a mechanism for evolving substrate specificity in bacterial methionine biosynthesis. Within this enzyme family, HTS and HTA activity likely arises from divergent evolution in a common structural scaffold with conserved catalytic machinery and homoserine binding sites.	[Zubieta, Chloe; Arkus, Kiani A. J.; Cahoon, Rebecca E.; Jez, Joseph M.] Donald Danforth Plant Sci Ctr, St Louis, MO 63132 USA	Donald Danforth Plant Science Center	Jez, JM (corresponding author), Donald Danforth Plant Sci Ctr, 975 N Warson Rd, St Louis, MO 63132 USA.	jjez@danforthcenter.org		Zubieta, Chloe/0000-0003-4558-9333				AGUILAR A, 1982, ANTIMICROB AGENTS CH, V21, P381, DOI 10.1128/AAC.21.3.381; Auger S, 2002, MICROBIOL-SGM, V148, P507, DOI 10.1099/00221287-148-2-507; Bareich DC, 2003, CHEM BIOL, V10, P967, DOI 10.1016/j.chembiol.2003.09.016; Born TL, 1999, BIOCHEMISTRY-US, V38, P14416, DOI 10.1021/bi991710o; Born TL, 2000, BIOCHEMISTRY-US, V39, P8556, DOI 10.1021/bi000462p; Bourhy P, 1997, J BACTERIOL, V179, P4396, DOI 10.1128/jb.179.13.4396-4398.1997; BRUSH A, 1971, BIOCHEM BIOPH RES CO, V45, P735, DOI 10.1016/0006-291X(71)90478-5; Coe DM, 2007, ARCH BIOCHEM BIOPHYS, V461, P211, DOI 10.1016/j.abb.2007.03.004; DATKO AH, 1974, J BIOL CHEM, V249, P1139; Ejim L, 2004, BIOORGAN MED CHEM, V12, P3825, DOI 10.1016/j.bmc.2004.05.009; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Goudarzi M, 2006, EXTREMOPHILES, V10, P469, DOI 10.1007/s00792-006-0522-3; Hanzelka BL, 1996, J BACTERIOL, V178, P5291, DOI 10.1128/jb.178.17.5291-5294.1996; Ivanova N, 2003, NATURE, V423, P87, DOI 10.1038/nature01582; Jacques SL, 2003, CHEM BIOL, V10, P989, DOI 10.1016/j.chembiol.2003.09.015; JENSEN RA, 1976, ANNU REV MICROBIOL, V30, P409, DOI 10.1146/annurev.mi.30.100176.002205; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KAPLAN MM, 1966, J BIOL CHEM, V241, P4463; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Mirza IA, 2005, BIOCHEMISTRY-US, V44, P15768, DOI 10.1021/bi051951y; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nazi I, 2005, BIOCHEMISTRY-US, V44, P13560, DOI 10.1021/bi0514764; Park SD, 1998, MOL CELLS, V8, P286; Penning TM, 2001, CHEM REV, V101, P3027, DOI 10.1021/cr000049n; ROHL F, 1987, ARCH MICROBIOL, V147, P315, DOI 10.1007/BF00406126; Rosen R, 2004, FEBS LETT, V577, P386, DOI 10.1016/j.febslet.2004.10.037; ROWBURY RJ, 1964, J GEN MICROBIOL, V36, P341, DOI 10.1099/00221287-36-3-341; UMBARGER HE, 1978, ANNU REV BIOCHEM, V47, P533, DOI 10.1146/annurev.bi.47.070178.002533; Val DL, 1998, J BACTERIOL, V180, P2644, DOI 10.1128/JB.180.10.2644-2651.1998; Viola RE, 2001, ACCOUNTS CHEM RES, V34, P339, DOI 10.1021/ar000057q; WYMAN A, 1975, J BIOL CHEM, V250, P3897; Ziegler K, 2007, BIOCHEM BIOPH RES CO, V361, P510, DOI 10.1016/j.bbrc.2007.07.044; Ziegler K, 2007, BIOCHEMISTRY-US, V46, P2674, DOI 10.1021/bi0620252; Zubieta C, 2007, PROTEINS, V68, P999, DOI 10.1002/prot.21208	34	15	17	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7561	7567		10.1074/jbc.M709283200	http://dx.doi.org/10.1074/jbc.M709283200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18216013	hybrid			2022-12-25	WOS:000253997900031
J	Kiryu-Seo, S; Kato, R; Ogawa, T; Nakagomi, S; Nagata, K; Kiyama, H				Kiryu-Seo, Sumiko; Kato, Ryuichi; Ogawa, Tokiko; Nakagomi, Saya; Nagata, Kenichi; Kiyama, Hiroshi			Neuronal injury-inducible gene is synergistically regulated by ATF3, c-Jun, and STAT3 through the interaction with Sp1 in damaged neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING TRANSCRIPTION FACTOR-3; NERVE GROWTH-FACTOR; AXOTOMIZED FACIAL MOTONEURONS; AXONAL REGENERATION; ENDOPEPTIDASE DINE; PERIPHERIN GENE; TRANSGENIC MICE; IN-VIVO; EXPRESSION; PROMOTER	Nerve injury requires the expression of large ensembles of genes. The key molecular mechanism for this gene transcription regulation in injured neurons is poorly understood. Among many nerve injury-inducible genes, the gene encoding damage-induced neuronal endopeptidase (DINE) showed most marked expression response to various kinds of nerve injuries in central and peripheral nervous system neurons. This unique feature led us to examine the promoter region of the DINE gene and clarify both the injury-responsive element within the promoter and its related transcriptional machinery. This study showed that DINE promoter was activated by leukemia inhibitory factor and nerve growth factor withdrawal, which were pivotal for the up-regulation of DINE mRNA after nerve injury. The injury-inducible transcription factors such as activating transcription factor 3 (ATF3), c-Jun, and STAT3, which were located at the downstream of leukemia inhibitory factor and nerve growth factor withdrawal, seemed to be involved in the activation of the DINE promoter. Surprisingly, these transcription factors did not bind to the DINE promoter directly. Instead, the general transcription factor, Sp1, bound to a GC box within the promoter. ATF3, c-Jun, and STAT3 interacted with Sp1 and are associated with the GC box region of the DINE gene in injured neurons. These findings suggested that Sp1 recruit ATF3, c-Jun, and STAT3 to obtain the requisite synergistic effect. Of these transcription factors, ATF3 may be the most critical, because ATF3 is specifically expressed after nerve injury.	[Kiryu-Seo, Sumiko; Kato, Ryuichi; Ogawa, Tokiko; Nakagomi, Saya; Nagata, Kenichi; Kiyama, Hiroshi] Osaka City Univ, Grad Sch Med, Dept Anat & Neurobiol, Abeno Ku, Osaka 5458585, Japan	Osaka Metropolitan University	Kiyama, H (corresponding author), Osaka City Univ, Grad Sch Med, Dept Anat & Neurobiol, Abeno Ku, 1-4-3 Asahimachi, Osaka 5458585, Japan.	kiyama@med.osaka-cu.ac.jp	Kiyama, Hiroshi/M-8867-2014; Nakagomi, Saya/ABE-4676-2020; Kiryu-Seo, Sumiko/M-8865-2014	Kiyama, Hiroshi/0000-0001-5963-046X; Nakagomi, Saya/0000-0002-8272-6192; Kiryu-Seo, Sumiko/0000-0001-6213-1258				Bacon A, 2007, J NEUROSCI, V27, P6573, DOI 10.1523/JNEUROSCI.1596-07.2007; BELECKYADAMS T, 1993, J NEUROSCI, V13, P5056, DOI 10.1523/JNEUROSCI.13-12-05056.1993; Boeshore KL, 2004, J NEUROBIOL, V59, P216, DOI 10.1002/neu.10308; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; Dunah AW, 2002, SCIENCE, V296, P2238, DOI 10.1126/science.1072613; Gao Y, 2004, NEURON, V44, P609, DOI 10.1016/j.neuron.2004.10.030; GLOSTER A, 1994, J NEUROSCI, V14, P7319; Haas CA, 1999, J NEUROBIOL, V41, P559, DOI 10.1002/(SICI)1097-4695(199912)41:4<559::AID-NEU11>3.0.CO;2-A; Hai T, 1999, GENE EXPRESSION, V7, P321; Hirota H, 1996, J EXP MED, V183, P2627, DOI 10.1084/jem.183.6.2627; Hung JJ, 2006, MOL CELL BIOL, V26, P1770, DOI 10.1128/MCB.26.5.1770-1785.2006; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Kato R, 2002, J NEUROSCI, V22, P9410; Kirsch M, 2003, MOL CELL NEUROSCI, V24, P130, DOI 10.1016/S1044-7431(03)00130-1; Kiryu S, 1995, J NEUROSCI, V15, P7872; Kiryu-Seo S, 2000, P NATL ACAD SCI USA, V97, P4345, DOI 10.1073/pnas.070509897; KISSELEVA T, 2002, GENE, V281, P1; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Lin SB, 2006, MOL ENDOCRINOL, V20, P3376, DOI 10.1210/me.2006-0177; Liu L, 2005, P NATL ACAD SCI USA, V102, P8150, DOI 10.1073/pnas.0501643102; Loeffler S, 2005, INT J CANCER, V115, P202, DOI 10.1002/ijc.20871; Maehara K, 2002, BIOCHEM BIOPH RES CO, V295, P187, DOI 10.1016/S0006-291X(02)00646-0; Makwana M, 2005, FEBS J, V272, P2628, DOI 10.1111/j.1742-4658.2005.04699.x; Nakagomi S, 2003, J NEUROSCI, V23, P5187; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Namikawa K, 2000, J NEUROSCI, V20, P2875; Ohba N, 2004, J NEUROCHEM, V91, P956, DOI 10.1111/j.1471-4159.2004.02784.x; Okuyama N, 2007, BRAIN RES, V1132, P36, DOI 10.1016/j.brainres.2006.11.019; Pearson AG, 2003, MOL BRAIN RES, V120, P38, DOI 10.1016/j.molbrainres.2003.09.014; Qiu J, 2005, J NEUROSCI, V25, P1645, DOI 10.1523/JNEUROSCI.3269-04.2005; Raivich G, 2004, NEURON, V43, P57, DOI 10.1016/j.neuron.2004.06.005; Ryu H, 2003, J NEUROSCI, V23, P3597; Ryu H, 2003, P NATL ACAD SCI USA, V100, P4281, DOI 10.1073/pnas.0737363100; Safe S, 2005, EUR J CANCER, V41, P2438, DOI 10.1016/j.ejca.2005.08.006; Schweizer U, 2002, J CELL BIOL, V156, P287, DOI 10.1083/jcb.200107009; Seijffers R, 2007, J NEUROSCI, V27, P7911, DOI 10.1523/JNEUROSCI.5313-06.2007; Shadiack AM, 2001, J NEUROSCI, V21, P363, DOI 10.1523/JNEUROSCI.21-02-00363.2001; Shadiack AM, 1998, P NATL ACAD SCI USA, V95, P7727, DOI 10.1073/pnas.95.13.7727; Takeda M, 2000, INVEST OPHTH VIS SCI, V41, P2412; Tsujino H, 2000, MOL CELL NEUROSCI, V15, P170, DOI 10.1006/mcne.1999.0814; Uveges TE, 2002, J NEUROSCI, V22, P7959; Valdenaire O, 1999, MOL BRAIN RES, V64, P211, DOI 10.1016/S0169-328X(98)00321-0; VANSELOW J, 1994, J NEUROSCI, V14, P499; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Yang J, 2005, CANCER RES, V65, P939; Yao GL, 1997, EUR J NEUROSCI, V9, P1047, DOI 10.1111/j.1460-9568.1997.tb01455.x	48	61	61	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					6988	6996		10.1074/jbc.M707514200	http://dx.doi.org/10.1074/jbc.M707514200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18192274	hybrid			2022-12-25	WOS:000253779600043
J	Konitsiotis, AD; Raynal, N; Bihan, D; Hohenester, E; Farndale, RW; Leitinger, B				Konitsiotis, Antonios D.; Raynal, Nicolas; Bihan, Dominique; Hohenester, Erhard; Farndale, Richard W.; Leitinger, Birgit			Characterization of high affinity binding motifs for the discoidin domain receptor DDR2 in collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; STRUCTURAL BASIS; INTEGRINS ALPHA(1)BETA(1); EXTRACELLULAR-MATRIX; CELL INVASION; ACTIVATION; SITE; PROLIFERATION; PEPTIDES; IDENTIFICATION	The discoidin domain receptors, DDR1 and DDR2, are receptor tyrosine kinases that are activated by native triple-helical collagen. Here we have located three specific DDR2 binding sites by screening the entire triple-helical domain of collagen II, using the Collagen II Toolkit, a set of overlapping triple-helical peptides. The peptide sequence that bound DDR2 with highest affinity interestingly contained the sequence for the high affinity binding site for von Willebrand factor in collagen III. Focusing on this sequence, we used a set of truncated and alanine-substituted peptides to characterize the sequence GVMGFO (O is hydroxyproline) as the minimal collagen sequence required for DDR2 binding. Based on a recent NMR analysis of the DDR2 collagen binding domain, we generated a model of the DDR2-collagen interaction that explains why a triple-helical conformation is required for binding. Triple-helical peptides comprising the DDR2 binding motif not only inhibited DDR2 binding to collagen II but also activated DDR2 transmembrane signaling. Thus, DDR2 activation may be effected by single triple-helices rather than fibrillar collagen.	[Raynal, Nicolas; Bihan, Dominique; Farndale, Richard W.] Univ Cambridge, Cambridge CB2 1QW, England; [Hohenester, Erhard] Univ London Imperial Coll Sci Technol & Med, Div Cell & Mol Biol, London SW7 2AZ, England; [Konitsiotis, Antonios D.; Leitinger, Birgit] Univ London Imperial Coll Sci Technol & Med, Div Natl Heart & Lung Inst NHLI, Mol Med Sect, London SW7 2AZ, England	University of Cambridge; Imperial College London; Imperial College London	Farndale, RW (corresponding author), Univ Cambridge, Cambridge CB2 1QW, England.	rwf10@mole.bio.cam.ac.uk; b.leitinger@imperial.ac.uk			Medical Research Council [G0400701] Funding Source: Medline; Wellcome Trust [054334] Funding Source: Medline; MRC [G0400701] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Ferri N, 2004, AM J PATHOL, V164, P1575, DOI 10.1016/S0002-9440(10)63716-9; Flamant M, 2006, J AM SOC NEPHROL, V17, P3374, DOI 10.1681/ASN.2006060677; Hou GP, 2001, J CLIN INVEST, V107, P727, DOI 10.1172/JCI10720; Ichikawa O, 2007, EMBO J, V26, P4168, DOI 10.1038/sj.emboj.7601833; Kadler KE, 2007, J CELL SCI, V120, P1955, DOI 10.1242/jcs.03453; Kim JK, 2005, J BIOL CHEM, V280, P32512, DOI 10.1074/jbc.M502431200; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Knight CG, 1998, J BIOL CHEM, V273, P33287, DOI 10.1074/jbc.273.50.33287; Labrador JP, 2001, EMBO REP, V2, P446, DOI 10.1093/embo-reports/kve094; Lebbink RJ, 2007, INT IMMUNOL, V19, P1011, DOI 10.1093/intimm/dxm071; Leitinger B, 2004, J MOL BIOL, V344, P993, DOI 10.1016/j.jmb.2004.09.089; Leitinger B, 2003, J BIOL CHEM, V278, P16761, DOI 10.1074/jbc.M301370200; Leitinger B, 2007, MATRIX BIOL, V26, P146, DOI 10.1016/j.matbio.2006.10.007; Leitinger B, 2006, MATRIX BIOL, V25, P355, DOI 10.1016/j.matbio.2006.05.006; Lisman T, 2006, BLOOD, V108, P3753, DOI 10.1182/blood-2006-03-011965; Matsuyama W, 2005, J IMMUNOL, V174, P6490, DOI 10.4049/jimmunol.174.10.6490; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; Noordeen NA, 2006, J BIOL CHEM, V281, P22744, DOI 10.1074/jbc.M603233200; Olaso E, 2002, J BIOL CHEM, V277, P3606, DOI 10.1074/jbc.M107571200; Olaso E, 2001, J CLIN INVEST, V108, P1369, DOI 10.1172/JCI12373; ONLEY DJ, 2001, THESIS U CAMBRIDGE; Ram R, 2006, J NEURO-ONCOL, V76, P239, DOI 10.1007/s11060-005-6874-1; Raynal N, 2006, J BIOL CHEM, V281, P3821, DOI 10.1074/jbc.M509818200; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shah NK, 1996, BIOCHEMISTRY-US, V35, P10262, DOI 10.1021/bi960046y; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; Siljander PRM, 2004, J BIOL CHEM, V279, P47763, DOI 10.1074/jbc.M404685200; Smethurst PA, 2007, J BIOL CHEM, V282, P1296, DOI 10.1074/jbc.M606479200; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Vogel WF, 2001, MOL CELL BIOL, V21, P2906, DOI 10.1128/MCB.21.8.2906-2917.2001; Vogel WF, 2006, CELL SIGNAL, V18, P1108, DOI 10.1016/j.cellsig.2006.02.012; Xu Y, 2000, J BIOL CHEM, V275, P38981, DOI 10.1074/jbc.M007668200; Yoshida D, 2007, J NEURO-ONCOL, V82, P29, DOI 10.1007/s11060-006-9246-6; Zhang WM, 2003, J BIOL CHEM, V278, P7270, DOI 10.1074/jbc.M210313200	35	152	156	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					6861	6868		10.1074/jbc.M709290200	http://dx.doi.org/10.1074/jbc.M709290200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18201965	Green Submitted, hybrid			2022-12-25	WOS:000253779600029
J	Kabra, R; Knight, KK; Zhou, R; Snyder, PM				Kabra, Rajesh; Knight, Kristin K.; Zhou, Ruifeng; Snyder, Peter M.			Nedd4-2 induces endocytosis and degradation of proteolytically cleaved epithelial Na+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CHANNEL; PY MOTIF; SURFACE EXPRESSION; LIDDLE-SYNDROME; GAMMA-SUBUNIT; WW DOMAIN; A6 CELLS; ENAC; MUTATIONS; ACTIVATION	As a pathway for Na+ reabsorption, the epithelial Na+ channel ENaC is critical for Na+ homeostasis and blood pressure control. Na+ transport is regulated by Nedd4-2, an E3 ubiquitin ligase that decreases ENaC expression at the cell surface. To investigate the underlying mechanisms, we proteolytically cleaved/activated ENaC at the cell surface and then quantitated the rate of disappearance of cleaved channels using electro-physiological and biochemical assays. We found that cleaved ENaC channels were rapidly removed from the cell surface. Deletion or mutation of the Nedd4-2 binding motifs in alpha,beta, and gamma ENaC dramatically reduced endocytosis, whereas a mutation that disrupts a YXXempty set endocytosis motif had no effect. ENaC endocytosis was also decreased by silencing of Nedd4-2 and by expression of a dominant negative Nedd4-2 construct. Conversely, Nedd4-2 overexpression increased ENaC endocytosis in human embryonic kidney 293 cells but had no effect in Fischer rat thyroid epithelia. In addition to its effect on endocytosis, Nedd4-2 also increased the rate of degradation of the cell surface pool of cleaved alpha ENaC. Together the data indicate that Nedd4-2 reduces ENaC surface expression by altering its trafficking at two distinct sites in the endocytic pathway, inducing endocytosis of cleaved channels and targeting them for degradation.	[Snyder, Peter M.] Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Mol Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Snyder, PM (corresponding author), Univ Iowa, Coll Med, Dept Internal Med, 371 EMRB, Iowa City, IA 52242 USA.	peter-snyder@uiowa.edu						BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; Bruns JB, 2007, J BIOL CHEM, V282, P6153, DOI 10.1074/jbc.M610636200; Butterworth MB, 2005, J GEN PHYSIOL, V125, P81, DOI 10.1085/jgp.2004.09124; Caldwell RA, 2004, AM J PHYSIOL-CELL PH, V286, pC190, DOI 10.1152/ajpcell.00342.2003; Carattino MD, 2006, J BIOL CHEM, V281, P18901, DOI 10.1074/jbc.M604109200; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Chraibi A, 1998, J GEN PHYSIOL, V111, P127, DOI 10.1085/jgp.111.1.127; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Goulet CC, 1998, J BIOL CHEM, V273, P30012, DOI 10.1074/jbc.273.45.30012; Hanwell D, 2002, J BIOL CHEM, V277, P9772, DOI 10.1074/jbc.M110904200; Henry PC, 2003, J BIOL CHEM, V278, P20019, DOI 10.1074/jbc.M211153200; Hughey RP, 2007, CURR OPIN NEPHROL HY, V16, P444, DOI 10.1097/MNH.0b013e32821f6072; Hughey RP, 2004, J BIOL CHEM, V279, P18111, DOI 10.1074/jbc.C400080200; Hughey RP, 2003, J BIOL CHEM, V278, P37073, DOI 10.1074/jbc.M307003200; Itani OA, 2005, AM J PHYSIOL-RENAL, V289, pF334, DOI 10.1152/ajprenal.00394.2004; Kamynina E, 2001, FASEB J, V15, P204, DOI 10.1096/fj.00-0191com; Kanelis V, 2001, NAT STRUCT BIOL, V8, P407, DOI 10.1038/87562; Kleyman TR, 2006, KIDNEY INT, V70, P1391, DOI 10.1038/sj.ki.5001860; Knight KK, 2006, P NATL ACAD SCI USA, V103, P2805, DOI 10.1073/pnas.0511184103; Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676; Lu C, 2007, TRAFFIC, V8, P1246, DOI 10.1111/j.1600-0854.2007.00602.x; Malik B, 2005, AM J PHYSIOL-RENAL, V289, pF107, DOI 10.1152/ajprenal.00179.2002; Malik B, 2001, J BIOL CHEM, V276, P12903, DOI 10.1074/jbc.M010626200; MCDONALD FJ, 1994, AM J PHYSIOL, V266, pL728, DOI 10.1152/ajplung.1994.266.6.L728; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; Mohan S, 2004, J BIOL CHEM, V279, P32071, DOI 10.1074/jbc.M405091200; Russo CJ, 2005, HYPERTENSION, V46, P488, DOI 10.1161/01.HYP.0000178594.63193.c0; Schild L, 2004, REV PHYSIOL BIOCH P, V151, P93, DOI 10.1007/s10254-004-0023-7; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Snyder PM, 2005, ENDOCRINOLOGY, V146, P5079, DOI 10.1210/en.2005-0894; Snyder PM, 2004, J BIOL CHEM, V279, P45753, DOI 10.1074/jbc.M407858200; Snyder PM, 2004, J BIOL CHEM, V279, P5042, DOI 10.1074/jbc.M312477200; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; Snyder PM, 2000, J CLIN INVEST, V105, P45, DOI 10.1172/JCI7869; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Staruschenko A, 2005, J BIOL CHEM, V280, P39161, DOI 10.1074/jbc.M509608200; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Volk KA, 2005, J BIOL CHEM, V280, P18348, DOI 10.1074/jbc.M413689200; Wang H, 2006, J BIOL CHEM, V281, P14129, DOI 10.1074/jbc.M512511200; Wiemuth D, 2007, BIOCHEM J, V405, P147, DOI 10.1042/BJ20060747; Zhou RF, 2007, J BIOL CHEM, V282, P20207, DOI 10.1074/jbc.M611329200	44	74	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2008	283	10					6033	6039		10.1074/jbc.M708555200	http://dx.doi.org/10.1074/jbc.M708555200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HM	18174164	hybrid			2022-12-25	WOS:000253779500008
J	Sato, Y; Shibata, H; Nakano, H; Matsuzono, Y; Kashiwayama, Y; Kobayashi, Y; Fujiki, Y; Imanaka, T; Kato, H				Sato, Yasuhiko; Shibata, Hiroyuki; Nakano, Hiroaki; Matsuzono, Yuji; Kashiwayama, Yoshinori; Kobayashi, Yuji; Fujiki, Yukio; Imanaka, Tsuneo; Kato, Hiroaki			Characterization of the interaction between recombinant human peroxin Pex3p and Pex19p - Identification of Trp-104 in Pex3p as a critical residue for the interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEINS; TARGETING SIGNAL RECEPTOR; ZELLWEGER-SYNDROME; FUNCTIONAL COMPLEMENTATION; BIOGENESIS DISORDERS; IMPORT; BINDS; MUTATIONS; CHAPERONE; MULTIPLE	Proteins required for peroxisome biogenesis are termed peroxins. The peroxin Pex3p is a peroxisomal membrane protein (PMP), involved in peroxisomal membrane biogenesis. It acts as a docking receptor for another peroxin Pex19p, which is a specific carrier protein for newly synthesized PMPs. Here we have determined the physicochemical properties and binding manners of Pex3p-Pex19p interaction, in terms of the affinity, the stoichiometry, and the binding site in Pex3p. The cytosolic domain of human Pex3p was overproduced, using an Escherichia coli expression system and was highly purified by two chromatography steps. Gel filtration chromatography analyses and intrinsic tryptophan fluorescence titrations revealed that a one-to-one complex is formed between monomeric Pex3p and monomeric Pex19p. The tryptophan fluorescence spectrum of Pex3p showed a large 18-nm blue shift of the maximum emission wavelength by the binding of Pex19p. This result indicates that either one or two tryptophan residues of Pex3p (Trp-104 and Trp-224) are directly involved in binding to Pex19p. We investigated the binding activities of the wild-type and tryptophan mutants of Pex3p by pull-down assays and surface plasmon resonance analyses. As a result, the wild-type and the W104A and W104F mutants showed K-D values of 3.4 nM, 1080 nM, and 66.2 nM, respectively. The affinity differences with mutation affected their peroxisome restoring activities in pex3 ZPG208 cells. These findings suggest that the indole ring of Trp-104 directly interacts with Pex19p to facilitate the specific peroxisomal translocation of the Pex19p-PMP complexes.	[Sato, Yasuhiko; Nakano, Hiroaki; Kato, Hiroaki] Kyoto Univ, Sch Pharmaceut Sci, Dept Biol Struct, Sakyo Ku, Kyoto 6068501, Japan; [Shibata, Hiroyuki] Natl Cardiovasc Ctr, Res Inst, Dept Cardiac Physiol, Osaka 5658565, Japan; [Matsuzono, Yuji; Fujiki, Yukio] Kyushu Univ, Grad Sch, Fac Sci, JST,CREST,Dept Biol,Higashi Ku, Fukuoka 8128581, Japan; [Kashiwayama, Yoshinori; Imanaka, Tsuneo] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Biol Chem, Toyama 9300194, Japan; [Kobayashi, Yuji] Osaka Univ Pharmaceut Sci, Takatsuki, Osaka 5691094, Japan	Kyoto University; National Cerebral & Cardiovascular Center - Japan; Japan Science & Technology Agency (JST); Kyushu University; University of Toyama; Osaka University of Pharmaceutical Sciences	Kato, H (corresponding author), Kyoto Univ, Sch Pharmaceut Sci, Dept Biol Struct, Sakyo Ku, 46-29 Yoshida Shimoadachi Cho, Kyoto 6068501, Japan.	katohiro@pharm.kyoto-u.ac.jp		Kato, Hiroaki/0000-0002-5993-4532; Imanaka, Tsuneo/0000-0003-4677-1356				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Fang Y, 2004, J CELL BIOL, V164, P863, DOI 10.1083/jcb.200311131; Fransen M, 2005, J MOL BIOL, V346, P1275, DOI 10.1016/j.jmb.2005.01.013; Fransen M, 2001, MOL CELL BIOL, V21, P4413, DOI 10.1128/MCB.21.13.4413-4424.2001; Fujiki Y, 2000, FEBS LETT, V476, P42, DOI 10.1016/S0014-5793(00)01667-7; Ghaedi K, 2000, MOL BIOL CELL, V11, P2085, DOI 10.1091/mbc.11.6.2085; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gloeckner CJ, 2000, BIOCHEM BIOPH RES CO, V271, P144, DOI 10.1006/bbrc.2000.2572; Gould SJ, 2000, TRENDS GENET, V16, P340, DOI 10.1016/S0168-9525(00)02056-4; Hoepfner D, 2005, CELL, V122, P85, DOI 10.1016/j.cell.2005.04.025; Honsho M, 2002, J BIOL CHEM, V277, P44513, DOI 10.1074/jbc.M206139200; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; Jones JM, 2004, J CELL BIOL, V164, P57, DOI 10.1083/jcb.200304111; Kammerer S, 1998, FEBS LETT, V429, P53, DOI 10.1016/S0014-5793(98)00557-2; Kashiwayama Y, 2005, BBA-MOL CELL RES, V1746, P116, DOI 10.1016/j.bbamcr.2005.10.006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Matsuzono Y, 2006, J BIOL CHEM, V281, P36, DOI 10.1074/jbc.M509819200; Matsuzono Y, 1999, P NATL ACAD SCI USA, V96, P2116, DOI 10.1073/pnas.96.5.2116; Matsuzono Y, 2006, J CELL SCI, V119, P3539, DOI 10.1242/jcs.03100; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; Muntau AC, 2000, AM J HUM GENET, V67, P967, DOI 10.1086/303071; Muntau AC, 2003, EUR J CELL BIOL, V82, P333, DOI 10.1078/0171-9335-00325; Pinto MP, 2006, J BIOL CHEM, V281, P34492, DOI 10.1074/jbc.M607183200; Purdue PE, 2001, ANNU REV CELL DEV BI, V17, P701, DOI 10.1146/annurev.cellbio.17.1.701; Sacksteder KA, 2000, J CELL BIOL, V148, P931, DOI 10.1083/jcb.148.5.931; Schliebs W, 1999, J BIOL CHEM, V274, P5666, DOI 10.1074/jbc.274.9.5666; Shibata H, 2004, J BIOL CHEM, V279, P38486, DOI 10.1074/jbc.M402204200; Shimozawa N, 2000, HUM MOL GENET, V9, P1995, DOI 10.1093/hmg/9.13.1995; Snyder WB, 2000, J CELL BIOL, V149, P1171, DOI 10.1083/jcb.149.6.1171; Tamura S, 1998, P NATL ACAD SCI USA, V95, P4350, DOI 10.1073/pnas.95.8.4350; TERLECKY SR, 1995, EMBO J, V14, P3627, DOI 10.1002/j.1460-2075.1995.tb00032.x; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; Urquhart AJ, 2000, J BIOL CHEM, V275, P4127, DOI 10.1074/jbc.275.6.4127; Wanders RJA, 1998, MOL ASPECTS MED, V19, P71, DOI 10.1016/S0098-2997(98)00003-X	34	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2008	283	10					6136	6144		10.1074/jbc.M706139200	http://dx.doi.org/10.1074/jbc.M706139200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HM	18174172	hybrid			2022-12-25	WOS:000253779500020
J	Rustad, TR; Harrell, MI; Liao, RL; Sherman, DR				Rustad, Tige R.; Harrell, Maria I.; Liao, Reiling; Sherman, David R.			The Enduring Hypoxic Response of Mycobacterium tuberculosis	PLOS ONE			English	Article							STATIONARY-PHASE; GENE-EXPRESSION; LUNG GRANULOMAS; PERSISTENCE; MECHANISMS; PROTEIN; LATENCY; MODEL; DEVR; ACR	Background. A significant body of evidence accumulated over the last century suggests a link between hypoxic microenvironments within the infected host and the latent phase of tuberculosis. Studies to test this correlation have identified the M. tuberculosis initial hypoxic response, controlled by the two-component response regulator DosR. The initial hypoxic response is completely blocked in a dosR deletion mutant. Methodology/Principal Findings. We show here that a dosR deletion mutant enters bacteriostasis in response to in vitro hypoxia with only a relatively mild decrease in viability. In the murine infection model, the phenotype of the mutant was indistinguishable from that of the parent strain. These results suggested that additional genes may be essential for entry into and maintenance of bacteriostasis. Detailed microarray analysis of oxygen starved cultures revealed that DosR regulon induction is transient, with induction of nearly half the genes returning to baseline within 24 hours. In addition, a larger, sustained wave of gene expression follows the DosR-mediated initial hypoxic response. This Enduring Hypoxic Response (EHR) consists of 230 genes significantly induced at four and seven days of hypoxia but not at initial time points. These genes include a surprising number of transcriptional regulators that could control the program of bacteriostasis. We found that the EHR is independent of the DosR-mediated initial hypoxic response, as EHR expression is virtually unaltered in the dosR mutant. Conclusions/Significance. Our results suggest a reassessment of the role of DosR and the initial hypoxic response in MTB physiology. Instead of a primary role in survival of hypoxia induced bacteriostasis, DosR may regulate a response that is largely optional in vitro and in mouse infections. Analysis of the EHR should help elucidate the key regulatory factors and enzymatic machinery exploited by M. tuberculosis for long-term bacteriostasis in the face of oxygen deprivation.	[Rustad, Tige R.; Liao, Reiling; Sherman, David R.] Seattle Biomed Res Inst, Seattle, WA 98109 USA; [Rustad, Tige R.; Harrell, Maria I.; Sherman, David R.] Univ Washington, Dept Pathobiol, Seattle, WA USA; [Harrell, Maria I.] Fred Hutchinson Canc Res Ctr, Seattle, WA USA	Center for Infectious Disease Research; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Sherman, DR (corresponding author), Seattle Biomed Res Inst, 4 Nickerson St, Seattle, WA 98109 USA.	david.sherman@sbri.org			Akibene Foundation TIGR/NIAID [N01-AI-15447 DRS R01]; NIH [AI 47704 TRR F32, AI 638772]	Akibene Foundation TIGR/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Pilot work: Akibene Foundation TIGR/NIAID grant providing arrays: N01-AI-15447 DRS R01 grant: NIH AI 47704 TRR F32 fellowship: NIH AI 638772	Aly S, 2007, J PATHOL, V212, P295, DOI 10.1002/path.2185; Aly S, 2006, J PATHOL, V210, P298, DOI 10.1002/path.2055; Betts JC, 2002, MOL MICROBIOL, V43, P717, DOI 10.1046/j.1365-2958.2002.02779.x; Boon C, 2002, J BACTERIOL, V184, P6760, DOI 10.1128/JB.184.24.6760-6767.2002; Boshoff HIM, 2004, J BIOL CHEM, V279, P40174, DOI 10.1074/jbc.M406796200; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009; CORPER H. J., 1933, AMER REV TUBERC, V28, P856; Cosma CL, 2003, ANNU REV MICROBIOL, V57, P641, DOI 10.1146/annurev.micro.57.030502.091033; DANNENBERG AM, 1993, HOSP PRACT, V28, P51, DOI 10.1080/21548331.1993.11442738; Dye C, 2006, LANCET, V367, P938, DOI 10.1016/S0140-6736(06)68384-0; Fenhalls G, 2002, INFECT IMMUN, V70, P6330, DOI 10.1128/IAI.70.11.6330-6338.2002; Florczyk MA, 2003, INFECT IMMUN, V71, P5332, DOI 10.1128/IAI.71.9.5332-5343.2003; Flynn JL, 2001, INFECT IMMUN, V69, P4195, DOI 10.1128/IAI.69.7.4195-4201.2001; Gomez JE, 2004, TUBERCULOSIS, V84, P29, DOI 10.1016/j.tube.2003.08.003; Hampshire T, 2004, TUBERCULOSIS, V84, P228, DOI 10.1016/j.tube.2003.12.010; Hegde P, 2000, BIOTECHNIQUES, V29, P548, DOI 10.2144/00293bi01; Herbert D, 1996, ANTIMICROB AGENTS CH, V40, P2296, DOI 10.1128/AAC.40.10.2296; KINGER AK, 1993, GENE, V131, P113, DOI 10.1016/0378-1119(93)90678-V; Lewis KN, 2003, J INFECT DIS, V187, P117, DOI 10.1086/345862; Lillebaek T, 2002, J INFECT DIS, V185, P401, DOI 10.1086/338342; Malhotra V, 2004, FEMS MICROBIOL LETT, V231, P237, DOI 10.1016/S0378-1097(04)00002-3; Manabe YC, 2000, NAT MED, V6, P1327, DOI 10.1038/82139; McKinney JD, 2000, NATURE, V406, P735, DOI 10.1038/35021074; MEDLAR EM, 1952, AM REV TUBERC PULM, V66, P36; Parish T, 2003, INFECT IMMUN, V71, P1134, DOI 10.1128/IAI.71.3.1134-1140.2003; Park HD, 2003, MOL MICROBIOL, V48, P833, DOI 10.1046/j.1365-2958.2003.03474.x; Parrish NM, 1998, TRENDS MICROBIOL, V6, P107, DOI 10.1016/S0966-842X(98)01216-5; Peh HL, 2001, ANTIMICROB AGENTS CH, V45, P2403, DOI 10.1128/AAC.45.8.2403-2404.2001; Primm TP, 2000, J BACTERIOL, V182, P4889, DOI 10.1128/JB.182.17.4889-4898.2000; Raviglione MC, 2001, ANN NY ACAD SCI, V953, P88, DOI 10.1111/j.1749-6632.2001.tb11364.x; Roberts DM, 2004, J BIOL CHEM, V279, P23082, DOI 10.1074/jbc.M401230200; SCHNAPPINGER DES, 2003, J EXP MED, V198; SCHOOLNIK GK, 2001, METHODS ENZ IN PRESS; Sharma D, 2006, FEMS IMMUNOL MED MIC, V48, P329, DOI 10.1111/j.1574-695X.2006.00160.x; Sherman DR, 2001, P NATL ACAD SCI USA, V98, P7534, DOI 10.1073/pnas.121172498; Shi LB, 2003, P NATL ACAD SCI USA, V100, P241, DOI 10.1073/pnas.0136863100; Sirakova TD, 2006, MICROBIOL-SGM, V152, P2717, DOI 10.1099/mic.0.28993-0; Stover CK, 2000, NATURE, V405, P962, DOI 10.1038/35016103; Sweany HC, 1931, AM REV TUBERC, V24, P558; Timm J, 2003, P NATL ACAD SCI USA, V100, P14321, DOI 10.1073/pnas.2436197100; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Voskuil MI, 2004, TUBERCULOSIS, V84, P218, DOI 10.1016/j.tube.2004.02.003; Voskuil MI, 2003, J EXP MED, V198, P705, DOI 10.1084/jem.20030205; WAYNE LG, 1994, ANTIMICROB AGENTS CH, V38, P2054, DOI 10.1128/AAC.38.9.2054; WAYNE LG, 1977, INFECT IMMUN, V17, P528, DOI 10.1128/IAI.17.3.528-530.1977; Wayne LG, 1996, INFECT IMMUN, V64, P2062, DOI 10.1128/IAI.64.6.2062-2069.1996; WAYNE LG, 1982, INFECT IMMUN, V37, P1042, DOI 10.1128/IAI.37.3.1042-1049.1982; Wayne LG, 2001, ANNU REV MICROBIOL, V55, P139, DOI 10.1146/annurev.micro.55.1.139; Yuan Y, 1998, P NATL ACAD SCI USA, V95, P9578, DOI 10.1073/pnas.95.16.9578	50	353	369	1	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2008	3	1							e1502	10.1371/journal.pone.0001502	http://dx.doi.org/10.1371/journal.pone.0001502			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SR	18231589	gold, Green Published, Green Submitted			2022-12-25	WOS:000260504200015
J	Somel, M; Creely, H; Franz, H; Mueller, U; Lachmann, M; Khaitovich, P; Paabo, S				Somel, Mehmet; Creely, Hilliary; Franz, Henriette; Mueller, Uwe; Lachmann, Michael; Khaitovich, Philipp; Paeaebo, Svante			Human and Chimpanzee Gene Expression Differences Replicated in Mice Fed Different Diets	PLOS ONE			English	Article							POSITIVE SELECTION; EVOLUTION; BRAIN; NUTRITION; SIZE; HOMO	Although the human diet is markedly different from the diets of closely related primate species, the influence of diet on phenotypic and genetic differences between humans and other primates is unknown. In this study, we analyzed gene expression in laboratory mice fed diets typical of humans and of chimpanzees. The effects of human diets were found to be significantly different from that of a chimpanzee diet in the mouse liver, but not in the brain. Importantly, 10% of the genes that differ in their expression between humans and chimpanzee livers differed also between the livers of mice fed the human and chimpanzee diets. Furthermore, both the promoter sequences and the amino acid sequences of these diet-related genes carry more differences between humans and chimpanzees than random genes. Our results suggest that the mouse can be used to study at least some aspects of human-specific traits.	[Somel, Mehmet; Khaitovich, Philipp] Chinese Acad Sci, Shanghai Inst Biol Sci, Partner Inst Computat Biol, Shanghai, Peoples R China; [Somel, Mehmet; Creely, Hilliary; Franz, Henriette; Lachmann, Michael; Khaitovich, Philipp; Paeaebo, Svante] Max Planck Inst Evol Anthropol, Leipzig, Germany; [Mueller, Uwe] Univ Leipzig, Ctr Biotechnol & Biomed, Leipzig, Germany	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Max Planck Society; Leipzig University	Somel, M (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Partner Inst Computat Biol, Shanghai, Peoples R China.	somel@eva.mpg.de; khaitovich@eva.mpg.de	Khaitovich, Philipp/HGC-8520-2022; Somel, Mehmet/B-1471-2016	Somel, Mehmet/0000-0002-3138-1307; Muller, Uwe/0000-0003-1502-9271; Franz, Henriette/0000-0001-9358-7442	Chinese Academy of Sciences; Max Planck Society; Bundesministerium fur Bildung und Forschung of Germany; German-American Fullbright Commission [fellowship]	Chinese Academy of Sciences(Chinese Academy of Sciences); Max Planck Society(Max Planck SocietyFoundation CELLEX); Bundesministerium fur Bildung und Forschung of Germany(Federal Ministry of Education & Research (BMBF)); German-American Fullbright Commission	The study was financially supported by the Chinese Academy of Sciences, the Max Planck Society and the Bundesministerium fur Bildung und Forschung of Germany. Author HC was supported by a German-American Fullbright Commission fellowship. None of these institutions played any direct or indirect role in in the design and conduct of the study, in the collection, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript.	AIELLO LC, 1995, CURR ANTHROPOL, V36, P199, DOI 10.1086/204350; ANDREWS P, 1991, PHILOS T R SOC B, V334, P199, DOI 10.1098/rstb.1991.0109; ANDREWS P, 1991, PHILOS T R SOC LON B, V334, P209; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bakewell MA, 2007, P NATL ACAD SCI USA, V104, P7489, DOI 10.1073/pnas.0701705104; Bersaglieri T, 2004, AM J HUM GENET, V74, P1111, DOI 10.1086/421051; BRACE CL, 1987, EVOLUTION, V41, P705, DOI 10.1111/j.1558-5646.1987.tb05847.x; Caceres M, 2003, P NATL ACAD SCI USA, V100, P13030, DOI 10.1073/pnas.2135499100; *CHIMP SEQ AN CONS, 2005, NATURE, V0437; Enard W, 2002, SCIENCE, V296, P340, DOI 10.1126/science.1068996; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Gilad Y, 2006, NATURE, V440, P242, DOI 10.1038/nature04559; Haygood R, 2007, NAT GENET, V39, P1140, DOI 10.1038/ng2104; Khaitovich P, 2005, SCIENCE, V309, P1850, DOI 10.1126/science.1108296; Khaitovich P, 2006, CURR BIOL, V16, pR356, DOI 10.1016/j.cub.2006.03.082; Kitajka K, 2004, P NATL ACAD SCI USA, V101, P10931, DOI 10.1073/pnas.0402342101; LEONARD WR, 1994, AM J HUM BIOL, V6, P77, DOI 10.1002/ajhb.1310060111; Milton K, 2003, J NUTR, V133, p3886S, DOI 10.1093/jn/133.11.3886S; Molteni R, 2002, NEUROSCIENCE, V112, P803, DOI 10.1016/S0306-4522(02)00123-9; Muller MM, 2006, P NATL ACAD SCI USA, V103, P14250, DOI 10.1073/pnas.0606668103; Perry GH, 2007, NAT GENET, V39, P1256, DOI 10.1038/ng2123; Prufer K, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-41; Ulijaszek SJ, 2002, P NUTR SOC, V61, P517, DOI 10.1079/PNS2002180; Ungar PS, 2006, ANNU REV ANTHROPOL, V35, P209, DOI 10.1146/annurev.anthro.35.081705.123153; Wrangham R, 2003, COMP BIOCHEM PHYS A, V136, P35, DOI 10.1016/S1095-6433(03)00020-5	25	35	36	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2008	3	1							e1504	10.1371/journal.pone.0001504	http://dx.doi.org/10.1371/journal.pone.0001504			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SR	18231591	Green Published, gold			2022-12-25	WOS:000260504200017
J	Cui, J; Chen, C; Lu, HZ; Sun, TZ; Shen, PP				Cui, Jun; Chen, Chun; Lu, Haizhu; Sun, Tingzhe; Shen, Pingping			Two Independent Positive Feedbacks and Bistability in the Bcl-2 Apoptotic Switch	PLOS ONE			English	Article							MITOCHONDRIAL APOPTOSIS; PHARMACOLOGICAL MANIPULATION; CELL-DEATH; BAX; ACTIVATION; PROTEINS; MODEL; MCL-1; PERMEABILITY; DEGRADATION	Background. The complex interplay between B-cell lymphoma 2 (Bcl-2) family proteins constitutes a crucial checkpoint in apoptosis. Its detailed molecular mechanism remains controversial. Our former modeling studies have selected the 'Direct Activation Model' as a better explanation for experimental observations. In this paper, we continue to extend this model by adding interactions according to updating experimental findings. Methodology/Principal Findings. Through mathematical simulation we found bistability, a kind of switch, can arise from a positive (double negative) feedback in the Bcl-2 interaction network established by anti-apoptotic group of Bcl-2 family proteins. Moreover, Bax/Bak auto-activation as an independent positive feedback can enforce the bistability, and make it more robust to parameter variations. By ensemble stochastic modeling, we also elucidated how intrinsic noise can change ultrasensitive switches into gradual responses. Our modeling result agrees well with recent experimental data where bimodal Bax activation distributions in cell population were found. Conclusions/Significance. Along with the growing experimental evidences, our studies successfully elucidate the switch mechanism embedded in the Bcl-2 interaction network and provide insights into pharmacological manipulation of Bcl-2 apoptotic switch as further cancer therapies.	[Cui, Jun; Chen, Chun; Lu, Haizhu; Sun, Tingzhe; Shen, Pingping] Nanjing Univ, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, Nanjing 210008, Peoples R China	Nanjing University	Shen, PP (corresponding author), Nanjing Univ, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, Nanjing 210008, Peoples R China.	ppshen@nju.edu.cn	Chen, Chun/D-7835-2013	Chen, Chun/0000-0002-3608-6972; Sun, Tingzhe/0000-0002-9575-4993	National Natural Science Foundation of China [30571538]; Program for New Century Excellent Talents in University [NCET-06-0445]; Key Project of Chinese Ministry of Education [NO107049]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET)); Key Project of Chinese Ministry of Education(Ministry of Education, China)	This work was supported by the National Natural Science Foundation of China (Project No. 30571538), the Program for New Century Excellent Talents in University (NCET-06-0445) and the Key Project of Chinese Ministry of Education (NO107049).	Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Bagci EZ, 2006, BIOPHYS J, V90, P1546, DOI 10.1529/biophysj.105.068122; Bhalla US, 2004, BIOPHYS J, V87, P745, DOI 10.1529/biophysj.104.040501; Bouchier-Hayes L, 2005, J CLIN INVEST, V115, P2640, DOI 10.1172/JCI26274; Chen C, 2007, FEBS LETT, V581, P5143, DOI 10.1016/j.febslet.2007.09.063; Chen C, 2007, BIOPHYS J, V92, P4304, DOI 10.1529/biophysj.106.099606; Chipuk JE, 2006, CELL DEATH DIFFER, V13, P1396, DOI 10.1038/sj.cdd.4401963; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Dejean LM, 2005, MOL BIOL CELL, V16, P2424, DOI 10.1091/mbc.E04-12-1111; Dlugosz PJ, 2006, EMBO J, V25, P2287, DOI 10.1038/sj.emboj.7601126; Eissing T, 2005, IEE P SYST BIOL, V152, P221, DOI 10.1049/ip-syb:20050046; Eissing T, 2004, J BIOL CHEM, V279, P36892, DOI 10.1074/jbc.M404893200; Eissing T, 2007, BIOPHYS J, V92, P3332, DOI 10.1529/biophysj.106.100362; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Ferrell JE, 2001, CHAOS, V11, P227, DOI 10.1063/1.1349894; Fischer SE, 2004, J EXP MED, V200, P905, DOI 10.1084/jem.20040402; Galonek HL, 2006, NAT CELL BIOL, V8, P1317, DOI 10.1038/ncb1206-1317; Gomez-Benito M, 2005, MOL PHARMACOL, V67, P1991, DOI 10.1124/mol.104.007021; Green DR, 2005, J CLIN INVEST, V115, P2610, DOI 10.1172/JCI26321; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hua F, 2005, J IMMUNOL, V175, P985, DOI 10.4049/jimmunol.175.2.985; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Kuwana T, 2003, CURR OPIN CELL BIOL, V15, P691, DOI 10.1016/j.ceb.2003.10.004; Legewie S, 2006, PLOS COMPUT BIOL, V2, P1061, DOI 10.1371/journal.pcbi.0020120; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Nair VD, 2004, J BIOL CHEM, V279, P27494, DOI 10.1074/jbc.M312135200; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Peng J, 2006, J BIOL CHEM, V281, P35802, DOI 10.1074/jbc.M608303200; Ruffolo SC, 2003, J BIOL CHEM, V278, P25039, DOI 10.1074/jbc.M302930200; Saikumar P, 1999, AM J MED, V107, P489, DOI 10.1016/S0002-9343(99)00259-4; Tan CB, 2006, J BIOL CHEM, V281, P14764, DOI 10.1074/jbc.M602374200; Valentijn AJ, 2003, J CELL BIOL, V162, P599, DOI 10.1083/jcb.200302154; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Youle RJ, 2007, SCIENCE, V315, P776, DOI 10.1126/science.1138870; Zi ZK, 2005, FEBS LETT, V579, P1101, DOI 10.1016/j.febslet.2005.01.009	40	39	40	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2008	3	1							e1469	10.1371/journal.pone.0001469	http://dx.doi.org/10.1371/journal.pone.0001469			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SO	18213378	Green Submitted, gold, Green Published			2022-12-25	WOS:000260503900015
J	Saar, S; Mitra, PP				Saar, Sigal; Mitra, Partha P.			A Technique for Characterizing the Development of Rhythms in Bird Song	PLOS ONE			English	Article								The developmental trajectory of nervous system dynamics shows hierarchical structure on time scales spanning ten orders of magnitude from milliseconds to years. Analyzing and characterizing this structure poses significant signal processing challenges. In the context of birdsong development, we have previously proposed that an effective way to do this is to use the dynamic spectrum or spectrogram, a classical signal processing tool, computed at multiple time scales in a nested fashion. Temporal structure on the millisecond timescale is normally captured using a short time Fourier analysis, and structure on the second timescale using song spectrograms. Here we use the dynamic spectrum on time series of song features to study the development of rhythm in juvenile zebra finch. The method is able to detect rhythmic structure in juvenile song in contrast to previous characterizations of such song as unstructured. We show that the method can be used to examine song development, the accuracy with which rhythm is imitated, and the variability of rhythms across different renditions of a song. We hope that this technique will provide a standard, automated method for measuring and characterizing song rhythm.	[Saar, Sigal] CUNY City Coll, Dept Biol, New York, NY 10031 USA; [Saar, Sigal; Mitra, Partha P.] Cold Spring Harbor Lab, Cold Spring Harbor, NY USA	City University of New York (CUNY) System; City College of New York (CUNY); Cold Spring Harbor Laboratory	Saar, S (corresponding author), CUNY City Coll, Dept Biol, New York, NY 10031 USA.	plosone@sigalsaar.com		Mitra, Partha/0000-0001-8818-6804	NIH [5R01MH071744-03]; US Public Health Services (PHS) [DC04722-07, NS050436]; NIH RCMI [G12RR-03060]; NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003060] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH071744] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS050436] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC004722] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Public Health Services (PHS)(United States Department of Health & Human ServicesUnited States Public Health Service); NIH RCMI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	This research was supported by Crick-Clay professorship, NIH grant 5R01MH071744-03, US Public Health Services (PHS) grants DC04722-07, NS050436 and by a NIH RCMI grant G12RR-03060 to CCNY. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Deregnaucourt S, 2005, NATURE, V433, P710, DOI 10.1038/nature03275; Deregnaucourt S, 2004, ANN NY ACAD SCI, V1016, P364, DOI 10.1196/annals.1298.036; Goller F, 2004, ANN NY ACAD SCI, V1016, P130, DOI 10.1196/annals.1298.009; Percival Donald B., 1993, SPECTRAL ANAL PHYS A; PRICE PH, 1979, J COMP PHYSIOL PSYCH, V93, P260, DOI 10.1037/h0077553; SAAR S, 2005, DEV RHYTHM SYNTAX ZE; Tchernichovski O, 2001, SCIENCE, V291, P2564, DOI 10.1126/science.1058522; Tchernichovski O, 2004, ANN NY ACAD SCI, V1016, P348, DOI 10.1196/annals.1298.031; THERNICHOVSKI O, 2000, ANIM BEHAV, V59, P1167; THOMSON DJ, 1982, P IEEE, V70, P1055, DOI 10.1109/PROC.1982.12433; Wild JM, 1998, J NEUROBIOL, V36, P441, DOI 10.1002/(SICI)1097-4695(19980905)36:3<441::AID-NEU11>3.0.CO;2-E	11	47	47	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2008	3	1							e1461	10.1371/journal.pone.0001461	http://dx.doi.org/10.1371/journal.pone.0001461			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SO	18213370	Green Accepted, gold, Green Published			2022-12-25	WOS:000260503900007
J	Gladieux, P; Zhang, XG; Afoufa-Bastien, D; Sanhueza, RMV; Sbaghi, M; Le Cam, B				Gladieux, Pierre; Zhang, Xiu-Guo; Afoufa-Bastien, Damien; Sanhueza, Rosa-Maria Valdebenito; Sbaghi, Mohamed; Le Cam, Bruno			On the Origin and Spread of the Scab Disease of Apple: Out of Central Asia	PLOS ONE			English	Article							PATHOGEN MYCOSPHAERELLA-GRAMINICOLA; POPULATION-STRUCTURE; VENTURIA-INAEQUALIS; GENETIC-STRUCTURE; FUNGAL PATHOGEN; MICROSATELLITE MARKERS; MULTILOCUS STRUCTURE; MIGRATION PATTERNS; ASSIGNMENT METHODS; ALLELIC RICHNESS	Venturia inaequalis is an ascomycete fungus responsible for apple scab, a disease that has invaded almost all apple growing regions worldwide, with the corresponding adverse effects on apple production. Monitoring and predicting the effectiveness of intervention strategies require knowledge of the origin, introduction pathways, and population biology of pathogen populations. Analysis of the variation of genetic markers using the inferential framework of population genetics offers the potential to retrieve this information. Methodology/Principal Findings. Here, we present a population genetic analysis of microsatellite variation in 1,273 strains of V. inaequalis representing 28 orchard samples from seven regions in five continents. Analysis of molecular variance revealed that most of the variation (88%) was distributed within localities, which is consistent with extensive historical migrations of the fungus among and within regions. Despite this shallow population structure, clustering analyses partitioned the data set into separate groups corresponding roughly to geography, indicating that each region hosts a distinct population of the fungus. Comparison of the levels of variability among populations, along with coalescent analyses of migration models and estimates of genetic distances, was consistent with a scenario in which the fungus emerged in Central Asia, where apple was domesticated, before its introduction into Europe and, more recently, into other continents with the expansion of apple growing. Across the novel range, levels of variability pointed to multiple introductions and all populations displayed signatures of significant post-introduction increases in population size. Most populations exhibited high genotypic diversity and random association of alleles across loci, indicating recombination both in native and introduced areas. Conclusions/Significance. Venturia inaequalis is a model of invasive phytopathogenic fungus that has now reached the ultimate stage of the invasion process with a broad geographic distribution and well-established populations displaying high genetic variability, regular sexual reproduction, and demographic expansion.	[Gladieux, Pierre; Afoufa-Bastien, Damien; Le Cam, Bruno] INRA, UMR077 1, Angers, France; [Zhang, Xiu-Guo] Shandong Agr Univ, Dept Plant Pathol, Tai An, Shandong, Peoples R China; [Sanhueza, Rosa-Maria Valdebenito] Natl Res Ctr Grap & Wine, Bento Goncalves, Brazil; [Sbaghi, Mohamed] INRA, Ctr Region Rech Agronom Kenitra, Kenitra, Morocco	INRAE; Shandong Agricultural University	Zhang, XG (corresponding author), Shandong Agr Univ, Dept Plant Pathol, Tai An, Shandong, Peoples R China.	zhxg@sdau.edu.cn; lecam@angers.inra.fr	Gladieux, Pierre/D-1014-2014	Gladieux, Pierre/0000-0003-1929-1576	Microsoft Corporation	Microsoft Corporation(Microsoft)	Part of this work was carried out by using the resources of the Computational Biology Service Unit from Cornell University which is partially funded by Microsoft Corporation.	Agapow PM, 2001, MOL ECOL NOTES, V1, P101, DOI 10.1046/j.1471-8278.2000.00014.x; ANAGNOSTAKIS SL, 1987, MYCOLOGIA, V79, P23, DOI 10.2307/3807741; Anderson PK, 2004, TRENDS ECOL EVOL, V19, P535, DOI 10.1016/j.tree.2004.07.021; Ardlie KG, 2002, NAT REV GENET, V3, P299, DOI 10.1038/nrg777; Bandyopadhyay R, 1998, PLANT DIS, V82, P356, DOI 10.1094/PDIS.1998.82.4.356; Banke S, 2005, MOL ECOL, V14, P1881, DOI 10.1111/j.1365-294X.2005.02536.x; Barton NH, 2000, PHILOS T R SOC B, V355, P1553, DOI 10.1098/rstb.2000.0716; Beerli P, 2001, P NATL ACAD SCI USA, V98, P4563, DOI 10.1073/pnas.081068098; Berry O, 2004, MOL ECOL, V13, P551, DOI 10.1046/j.1365-294X.2004.2081.x; Boehm EWA, 2003, PHYTOPARASITICA, V31, P236, DOI 10.1007/BF02980833; BROWN AHD, 1980, GENETICS, V96, P523; Brown JKM, 2002, SCIENCE, V297, P537, DOI 10.1126/science.1072678; Brown James K. M., 1994, Trends in Microbiology, V2, P470, DOI 10.1016/0966-842X(94)90124-4; BRUNNER PC, 2007, J EVOLUTION BIOL, V20, P1; Burgess T, 2001, MYCOL RES, V105, P1331, DOI 10.1017/S0953756201005056; Campbell FT, 2001, BIOSCIENCE, V51, P148, DOI 10.1641/0006-3568(2001)051[0148:TSORAF]2.0.CO;2; CAVALLISFORZA LL, 1967, AM J HUM GENET, V19, P233, DOI 10.2307/2406616; Chen RS, 1996, GENETICS, V142, P1119; Corander J, 2003, GENETICS, V163, P367; Cornuet JM, 1996, GENETICS, V144, P2001; Couch BC, 2005, GENETICS, V170, P613, DOI 10.1534/genetics.105.041780; Cui LW, 2003, TRENDS PARASITOL, V19, P220, DOI 10.1016/S1471-4922(03)00085-0; Dieringer D, 2003, MOL ECOL NOTES, V3, P167, DOI 10.1046/j.1471-8286.2003.00351.x; Donnelly MJ, 2002, TRENDS PARASITOL, V18, P75, DOI 10.1016/S1471-4922(01)02198-5; Donnelly MJ, 2001, MOL BIOL EVOL, V18, P1353, DOI 10.1093/oxfordjournals.molbev.a003919; ElMousadik A, 1996, THEOR APPL GENET, V92, P832, DOI 10.1007/BF00221895; Engelbrecht CJB, 2004, MOL ECOL, V13, P2995, DOI 10.1111/j.1365-294X.2004.02312.x; EXCOFFIER L, 1992, GENETICS, V131, P479; Excoffier L, 2005, EVOL BIOINFORM, V1, P47, DOI 10.1177/117693430500100003; Facon B, 2006, TRENDS ECOL EVOL, V21, P130, DOI 10.1016/j.tree.2005.10.012; Falush D, 2003, GENETICS, V164, P1567; Fisher MC, 2002, P NATL ACAD SCI USA, V99, P9067, DOI 10.1073/pnas.132178099; Fisher MC, 2001, P NATL ACAD SCI USA, V98, P4558, DOI 10.1073/pnas.071406098; Fry WE, 1997, BIOSCIENCE, V47, P363, DOI 10.2307/1313151; Garrison VH, 2003, BIOSCIENCE, V53, P469, DOI 10.1641/0006-3568(2003)053[0469:AAADFD]2.0.CO;2; Gomez-Alpizar L, 2007, P NATL ACAD SCI USA, V104, P3306, DOI 10.1073/pnas.0611479104; GOODWIN SB, 1994, P NATL ACAD SCI USA, V91, P11591, DOI 10.1073/pnas.91.24.11591; Guerin F, 2004, MOL ECOL NOTES, V4, P268, DOI 10.1111/j.1471-8286.2004.00637.x; Guerin F, 2004, PHYTOPATHOLOGY, V94, P364, DOI 10.1094/PHYTO.2004.94.4.364; Guerin F, 2007, FUNGAL GENET BIOL, V44, P284, DOI 10.1016/j.fgb.2006.10.005; Hancock J.F., 2004, PLANT EVOLUTION ORIG; Harris SA, 2002, TRENDS GENET, V18, P426, DOI 10.1016/S0168-9525(02)02689-6; Hume JCC, 2003, TRENDS PARASITOL, V19, P144, DOI 10.1016/S1471-4922(03)00008-4; Ivors K, 2006, MOL ECOL, V15, P1493, DOI 10.1111/j.1365-294X.2006.02864.x; JIN L, 1995, HEREDITY, V74, P274, DOI 10.1038/hdy.1995.41; JOBLING M, 2004, HUMAN EVOLUTIONARY G, P15253; Jorde LB, 1998, BIOESSAYS, V20, P126, DOI 10.1002/(SICI)1521-1878(199802)20:2<126::AID-BIES5>3.0.CO;2-R; Joy DA, 2003, SCIENCE, V300, P318, DOI 10.1126/science.1081449; Kareiva P, 2007, SCIENCE, V316, P1866, DOI 10.1126/science.1140170; Kauer M, 2003, MOL BIOL EVOL, V20, P1329, DOI 10.1093/molbev/msg148; Kimmel M, 1998, GENETICS, V148, P1921; King JP, 2000, MOL BIOL EVOL, V17, P1859, DOI 10.1093/oxfordjournals.molbev.a026287; Leberg PL, 2002, MOL ECOL, V11, P2445, DOI 10.1046/j.1365-294X.2002.01612.x; Mabberley, 2006, STORY APPLE; Malvarez G, 2007, PHYTOPATHOLOGY, V97, P470, DOI 10.1094/PHYTO-97-4-0470; Manel S, 2005, TRENDS ECOL EVOL, V20, P136, DOI 10.1016/j.tree.2004.12.004; MCHARDY W, 1996, APPL SCAB BIOL EPIDE; Milgroom MG, 1996, ANNU REV PHYTOPATHOL, V34, P457, DOI 10.1146/annurev.phyto.34.1.457; MORGAN J, 1993, BOOK APPLES; NEI M, 1975, EVOLUTION, V29, P1, DOI 10.2307/2407137; NEI M, 1973, P NATL ACAD SCI USA, V70, P3321, DOI 10.1073/pnas.70.12.3321; Paetkau D, 2004, MOL ECOL, V13, P55, DOI 10.1046/j.1365-294X.2004.02008.x; Palm ME, 2001, BIOSCIENCE, V51, P141, DOI 10.1641/0006-3568(2001)051[0141:SATIOI]2.0.CO;2; Parker IM, 2004, ANNU REV ECOL EVOL S, V35, P675, DOI 10.1146/annurev.ecolsys.34.011802.132339; Peakall R, 2006, MOL ECOL NOTES, V6, P288, DOI 10.1111/j.1471-8286.2005.01155.x; Perrings C, 2002, CONSERV ECOL, V6; Pfaff CL, 2001, AM J HUM GENET, V68, P198, DOI 10.1086/316935; Pimentel D, 2000, BIOSCIENCE, V50, P53, DOI 10.1641/0006-3568(2000)050[0053:EAECON]2.3.CO;2; Piry S, 2004, J HERED, V95, P536, DOI 10.1093/jhered/esh074; Piry S, 1999, J HERED, V90, P502, DOI 10.1093/jhered/90.4.502; Pritchard JK, 2000, GENETICS, V155, P945; Raboin LM, 2007, FUNGAL GENET BIOL, V44, P64, DOI 10.1016/j.fgb.2006.07.004; Rannala B, 1997, P NATL ACAD SCI USA, V94, P9197, DOI 10.1073/pnas.94.17.9197; Reich DE, 1998, P NATL ACAD SCI USA, V95, P8119, DOI 10.1073/pnas.95.14.8119; Reich DE, 1999, MOL BIOL EVOL, V16, P453, DOI 10.1093/oxfordjournals.molbev.a026127; Rivas GG, 2004, MOL ECOL, V13, P471, DOI 10.1046/j.1365-294X.2003.02043.x; RIZZO DM, 2005, FUNGAL COMMUNITY, P857; Sakai AK, 2001, ANNU REV ECOL SYST, V32, P305, DOI 10.1146/annurev.ecolsys.32.081501.114037; Schofl G, 2006, MOL ECOL, V15, P3895, DOI 10.1111/j.1365-294X.2006.03065.x; Smart C. D., 2001, Biological Invasions, V3, P235, DOI 10.1023/A:1015200920772; Stukenbrock EH, 2007, MOL BIOL EVOL, V24, P398; Stukenbrock EH, 2006, MOL ECOL, V15, P2895, DOI 10.1111/j.1365-294X.2006.02986.x; Taylor JW, 1999, ANNU REV PHYTOPATHOL, V37, P197, DOI 10.1146/annurev.phyto.37.1.197; Taylor JW, 2003, CURR OPIN MICROBIOL, V6, P351, DOI 10.1016/S1369-5274(03)00088-2; Tenzer I, 1999, PHYTOPATHOLOGY, V89, P748, DOI 10.1094/PHYTO.1999.89.9.748; Tenzer I, 1997, EUR J PLANT PATHOL, V103, P565, DOI 10.1023/A:1008636913211; Tenzer I, 1999, EUR J PLANT PATHOL, V105, P545, DOI 10.1023/A:1008775900736; Wikler K, 2000, CAN J BOT, V78, P709, DOI 10.1139/cjb-78-6-709; Wilson EE, 1928, PHYTOPATHOLOGY, V18, P375; Wingfield MJ, 2001, BIOSCIENCE, V51, P134, DOI 10.1641/0006-3568(2001)051[0134:WMOEFF]2.0.CO;2; Wirth T, 2005, MOL ECOL, V14, P3289, DOI 10.1111/j.1365-294X.2005.02687.x; WOOD F, 2003, SILK ROAD; YARWOOD CE, 1970, SCIENCE, V168, P218, DOI 10.1126/science.168.3928.218; Zaffarano PL, 2006, PHYTOPATHOLOGY, V96, P941, DOI 10.1094/PHYTO-96-0941; Zeigler RS, 1998, ANNU REV PHYTOPATHOL, V36, P249, DOI 10.1146/annurev.phyto.36.1.249; Zhan J, 2003, FUNGAL GENET BIOL, V38, P286, DOI 10.1016/S1087-1845(02)00538-8	96	96	100	0	43	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2008	3	1							e1455	10.1371/journal.pone.0001455	http://dx.doi.org/10.1371/journal.pone.0001455			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SN	18197265	Green Published, gold, Green Submitted			2022-12-25	WOS:000260503800026
J	Wiggins, P				Wiggins, Philippa			Life Depends upon Two Kinds of Water	PLOS ONE			English	Article							LOW-DENSITY WATER; POSSIBLE MECHANISM; LIQUID; GELS	Background. Many well-documented biochemical processes lack a molecular mechanism. Examples are: how ATP hydrolysis and an enzyme contrive to perform work, such as active transport; how peptides are formed from amino acids and DNA from nucleotides; how proteases cleave peptide bonds, how bone mineralises; how enzymes distinguish between sodium and potassium; how chirality of biopolymers was established prebiotically. Methodology/Principal Findings. It is shown that involvement of water in all these processes is mandatory, but the water must be of the simplified configuration in which there are only two strengths of water-water hydrogen bonds, and in which these two types of water coexist as microdomains throughout the liquid temperature range. Since they have different strengths of hydrogen bonds, the microdomains differ in all their physical and chemical properties. Solutes partition asymmetrically, generating osmotic pressure gradients which must be compensated for or abolished. Displacement of the equilibrium between high and low density waters incurs a thermodynamic cost which limits solubility, depresses ionisation of water, drives protein folding and prevents high density water from boiling at its intrinsic boiling point which appears to be below 0 degrees C. Active processes in biochemistry take place in sequential partial reactions, most of which release small amounts of free energy as heat. This ensures that the system is never far from equilibrium so that efficiency is extremely high. Energy transduction is neither possible and nor necessary. Chirality was probably established in prebiotic clays which must have carried stable populations of high density and low density water domains. Bioactive enantiomorphs partition into low density water in which they polymerise spontaneously. Conclusions/Significance. The simplified model of water has great explanatory power.			Wiggins, P (corresponding author), Mairangi Bay, Auckland, New Zealand.	p.wiggins@paradise.net.nz						[Anonymous], 1973, WATER COMPREHENSIVE; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Cacace MG, 1997, Q REV BIOPHYS, V30, P241, DOI 10.1017/S0033583597003363; Chaplin MF, 2000, BIOPHYS CHEM, V83, P211, DOI 10.1016/S0301-4622(99)00142-8; Cho CH, 1997, J CHEM PHYS, V107, P7979, DOI 10.1063/1.475060; Drost-Hansen W, 2001, CELL MOL BIOL, V47, P865; EISENBERG D, 1969, W STRUCTURE PROPERTI; GEORGE P, 1970, BIOCHIM BIOPHYS ACTA, V223, P1, DOI 10.1016/0005-2728(70)90126-X; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HASSELBACH W, 1982, ANN NY ACAD SCI, V402, P459, DOI 10.1111/j.1749-6632.1982.tb25768.x; HENDERSON LJ, 1913, FITNESS ENV, P111; HOFFMAN M, 1992, SCIENCE, V256, P1758, DOI 10.1126/science.1615319; Holt JK, 2006, SCIENCE, V312, P1034, DOI 10.1126/science.1126298; Ling G.N., 1962, PHYS THEORY LIVING S; Mathews C.K., 1990, BIOCHEMISTRY-US, V3d; Mishima O, 1998, NATURE, V396, P329, DOI 10.1038/24540; Mishima O, 1998, NATURE, V392, P164, DOI 10.1038/32386; Rees Martin., 1999, JUST 6 NUMBERS; Robinson GW, 1999, BIOPHYS J, V77, P3311, DOI 10.1016/S0006-3495(99)77162-6; ROBINSON JD, 1979, BIOCHIM BIOPHYS ACTA, V549, P145, DOI 10.1016/0304-4173(79)90013-2; Scala A, 2000, NATURE, V406, P166, DOI 10.1038/35018034; STANLEY HE, 1994, PHYSICA A, V205, P122, DOI 10.1016/0378-4371(94)90495-2; VEDAMUTHU M, 1994, J PHYS CHEM-US, V98, P2222, DOI 10.1021/j100060a002; WIGGINS P, 2001, WATER SCI FOOD HLTH, V8; Wiggins Philippa M., 2002, Journal of Biological Physics and Chemistry, V2, P25, DOI 10.4024/12020205.jbpc.02.01; WIGGINS PM, 1990, MICROBIOL REV, V54, P432, DOI 10.1128/MMBR.54.4.432-449.1990; WIGGINS PM, 1982, J THEOR BIOL, V99, P665, DOI 10.1016/0022-5193(82)90193-X; WIGGINS PM, 1982, J THEOR BIOL, V99, P645, DOI 10.1016/0022-5193(82)90192-8; Wiggins PM, 1999, AM J PHYSIOL-CELL PH, V276, pC291, DOI 10.1152/ajpcell.1999.276.2.C291; Wiggins PM, 2002, PHYSICA A, V314, P485, DOI 10.1016/S0378-4371(02)01086-5; WIGGINS PM, 1990, BIOPHYS J, V58, P585, DOI 10.1016/S0006-3495(90)82402-4; WIGGINS PM, 1995, LANGMUIR, V11, P1984, DOI 10.1021/la00006a026; WIGGINS PM, 1995, CELL BIOCHEM FUNCT, V13, P165, DOI 10.1002/cbf.290130305; Wiggins PM, 2001, CELL MOL BIOL, V47, P735; WIGGINS PM, 1991, BIOPHYS J, V60, P8, DOI 10.1016/S0006-3495(91)82026-4; WIGGINS PM, 1995, PROG POLYM SCI, V20, P1121, DOI 10.1016/0079-6700(95)00015-8; Wiggins PM, 1996, CELL BIOL INT, V20, P429, DOI 10.1006/cbir.1996.0054; WIGGINS PM, 1987, INT REV CYTOL, V108, P249, DOI 10.1016/S0074-7696(08)61440-0	38	49	53	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2008	3	1							e1406	10.1371/journal.pone.0001406	http://dx.doi.org/10.1371/journal.pone.0001406			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366GT	18183287	Green Published, gold, Green Submitted			2022-12-25	WOS:000260469400003
J	Kwei, KA; Kim, YH; Girard, L; Kao, J; Pacyna-Gengelbach, M; Salari, K; Lee, J; Choi, YL; Sato, M; Wang, P; Hernandez-Boussard, T; Gazdar, AF; Petersen, I; Minna, JD; Pollack, JR				Kwei, K. A.; Kim, Y. H.; Girard, L.; Kao, J.; Pacyna-Gengelbach, M.; Salari, K.; Lee, J.; Choi, Y-L; Sato, M.; Wang, P.; Hernandez-Boussard, T.; Gazdar, A. F.; Petersen, I.; Minna, J. D.; Pollack, J. R.			Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer	ONCOGENE			English	Article						TITF1; lineage-specific oncogene; genomic profiling; lung cancer; TTF-1; NKX2-1	TRANSCRIPTION FACTOR-I; COPY NUMBER ALTERATION; GENE-EXPRESSION; BREAST-CANCER; PROSTATE-CANCER; REVEALS; ADENOCARCINOMAS; AMPLIFICATION; DEPENDENCY; MICROARRAY	Lung cancer is a leading cause of cancer death, where the amplification of oncogenes contributes to tumorigenesis. Genomic pro. ling of 128 lung cancer cell lines and tumors revealed frequent focal DNA amplification at cytoband 14q13.3, a locus not amplified in other tumor types. The smallest region of recurrent amplification spanned the homeobox transcription factor TITF1 (thyroid transcription factor 1; also called NKX2-1), previously linked to normal lung development and function. When amplified, TITF1 exhibited increased expression at both the RNA and protein levels. Small interfering RNA (siRNA)mediated knockdown of TITF1 in lung cancer cell lines with amplification led to reduced cell proliferation, manifested by both decreased cell-cycle progression and increased apoptosis. Our findings indicate that TITF1 amplification and overexpression contribute to lung cancer cell proliferation rates and survival and implicate TITF1 as a lineage-specific oncogene in lung cancer.	[Pollack, J. R.] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; [Girard, L.; Sato, M.; Gazdar, A. F.; Minna, J. D.] Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; [Pacyna-Gengelbach, M.; Petersen, I.] Univ Hosp Charite, Inst Pathol, Berlin, Germany; [Salari, K.; Hernandez-Boussard, T.] Stanford Univ, Dept Genet, Stanford, CA 94305 USA; [Choi, Y-L] Sungkyunkwan Univ, Samsung Med Ctr, Dept Pathol, Seoul, South Korea; [Wang, P.] Univ Washington, Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98195 USA	Stanford University; University of Texas System; University of Texas Southwestern Medical Center Dallas; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Stanford University; Sungkyunkwan University (SKKU); Samsung Medical Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Pollack, JR (corresponding author), Stanford Univ, Sch Med, Dept Pathol, CCSR-3245A,269 Campus Dr, Stanford, CA 94305 USA.	pollack1@stanford.edu	Sato, MITSUO/I-7280-2014	Sato, MITSUO/0000-0001-5458-9576	NATIONAL CANCER INSTITUTE [R01CA097139, P50CA070907, T32CA009151] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA070907-11, R01 CA097139-02, T32 CA009151-31, T32 CA009151, P50 CA070907-10, R01 CA97139, T32 CA09151, R01 CA097139, P50CA70907, P50 CA070907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bashyam MD, 2005, NEOPLASIA, V7, P556, DOI 10.1593/neo.04586; Bergamaschi A, 2006, GENE CHROMOSOME CANC, V45, P1033, DOI 10.1002/gcc.20366; Birmingham A, 2006, NAT METHODS, V3, P199, DOI 10.1038/NMETH854; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Garraway LA, 2006, NAT REV CANCER, V6, P593, DOI 10.1038/nrc1947; Holst F, 2007, NAT GENET, V39, P655, DOI 10.1038/ng2006; Jackson AL, 2006, RNA, V12, P1197, DOI 10.1261/rna.30706; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kao J, 2006, GENE CHROMOSOME CANC, V45, P761, DOI 10.1002/gcc.20339; Kendall J, 2007, P NATL ACAD SCI USA, V104, P16663, DOI 10.1073/pnas.0708286104; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Lapointe J, 2007, CANCER RES, V67, P8504, DOI 10.1158/0008-5472.CAN-07-0673; Lechner JF, 2001, RADIAT RES, V155, P235, DOI 10.1667/0033-7587(2001)155[0235:PCDTMA]2.0.CO;2; Miccadei S, 2002, MOL ENDOCRINOL, V16, P837, DOI 10.1210/me.16.4.837; Minoo P, 1999, DEV BIOL, V209, P60, DOI 10.1006/dbio.1999.9234; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Puglisi F, 1999, MODERN PATHOL, V12, P318; Ramirez RD, 2004, CANCER RES, V64, P9027, DOI 10.1158/0008-5472.CAN-04-3703; Sato M, 2007, J THORAC ONCOL, V2, P327, DOI 10.1097/01.JTO.0000263718.69320.4c; Tan DF, 2003, HUM PATHOL, V34, P597, DOI 10.1016/S0046-8177(03)00180-1; Tanaka H, 2007, CANCER RES, V67, P6007, DOI 10.1158/0008-5472.CAN-06-4774; Tian JM, 2006, CANCER RES, V66, P10399, DOI 10.1158/0008-5472.CAN-06-1564; Tibshirani R, 2008, BIOSTATISTICS, V9, P18, DOI 10.1093/biostatistics/kxm013; Travis WD., 2004, TRAVIS WB WHO CLASSI; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Yatabe Y, 2002, AM J SURG PATHOL, V26, P767, DOI 10.1097/00000478-200206000-00010	31	154	160	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2008	27	25					3635	3640		10.1038/sj.onc.1211012	http://dx.doi.org/10.1038/sj.onc.1211012			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18212743	Green Accepted			2022-12-25	WOS:000256468500015
J	Bhavsar, PK; Sukkar, MB; Khorasani, N; Lee, KY; Chung, KF				Bhavsar, Pankaj K.; Sukkar, Maria B.; Khorasani, Nadia; Lee, Kang-Yun; Chung, Kian Fan			Glucocorticoid suppression of CX(3)CL1 (fractalkine) by reduced gene promoter recruitment of NF-kappa B	FASEB JOURNAL			English	Article						epithelial cells; transcription factor; displacement; chromatin	TUMOR-NECROSIS-FACTOR; SMOOTH-MUSCLE-CELLS; INTERFERON-GAMMA; TNF-ALPHA; EPITHELIAL-CELLS; IFN-GAMMA; TRANSCRIPTION FACTORS; ENDOTHELIAL-CELLS; RESPONSE ELEMENT; IMMUNE-SYSTEM	Glucocorticoids are an important anti-inflammatory treatment of many inflammatory diseases including asthma. However, the mechanisms by which they mediate their suppressive effects are not fully understood. Respiratory epithelial cells are a source of CX(3)CL1 (fractalkine), which mediates cell adhesion and acts as a chemoattractant for monocytes, T cells, and mast cells. We show, in lung A549 epithelial cells, that the tumor necrosis factor-alpha (TNF-alpha) and IFN gamma synergistically induced protein release and mRNA expression of CX(3)CL1 is inhibited by dexamethasone, without interfering with cytokine-induced nuclear translocation of NF-kappa B, and by an inhibitor of I kappa B kinase 2, AS602868. DNA binding assays confirmed the ability of NF-kappa B to bind to the proximal CX(3)CL1 promoter. Chromatin immunoprecipitation assays showed a 5-fold increase in the recruitment of NF-kappa B to the CX(3)CL1 gene promoter in response to IFN gamma/TNF-alpha; this too was reversed by dexamethasone. In contrast, dexamethasone did not displace NF-kappa B from the granulocytemacrophage colony-stimulating factor gene promoter. We conclude that CX(3)CL1 expression is regulated through the NF-kappa B pathway and that dexamethasone inhibits CX(3)CL1 expression through a glucocorticoid receptor-dependent (RU486 sensitive) mechanism. This study also provides support for the action of glucocorticoids mediating their suppressive effects on expression by interfering with the binding of transcriptional activators at native gene promoters.	[Bhavsar, Pankaj K.; Sukkar, Maria B.; Khorasani, Nadia; Lee, Kang-Yun; Chung, Kian Fan] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Airway Dis Sect, London SW3 6LY, England	Imperial College London	Bhavsar, PK (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Airway Dis Sect, Guy Scadding Bldg,Dovehouse St, London SW3 6LY, England.	p.bhavsar@imperial.ac.uk	Chung, Kian Fan/B-1872-2012; Sukkar, Maria B/L-6917-2013; Chung, Kian Fan/I-8456-2019	Chung, Kian Fan/0000-0001-7101-1426; Chung, Kian Fan/0000-0001-7101-1426; Sukkar, Maria/0000-0003-4591-2399	Medical Research Council [G0400503B] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		ABBINANTENISSEN JM, 1995, AM J PHYSIOL-LUNG C, V268, pL601, DOI 10.1152/ajplung.1995.268.4.L601; Adcock IM, 2001, PULM PHARMACOL THER, V14, P211, DOI 10.1006/pupt.2001.0283; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BARKER JNWN, 1990, J CLIN INVEST, V85, P605, DOI 10.1172/JCI114481; Brostjan C, 1996, J BIOL CHEM, V271, P19612, DOI 10.1074/jbc.271.32.19612; Catley MC, 2005, BRIT J PHARMACOL, V145, P114, DOI 10.1038/sj.bjp.0706170; Chen YM, 2003, BRIT J PHARMACOL, V138, P950, DOI 10.1038/sj.bjp.0705088; De Bosscher K, 2000, P NATL ACAD SCI USA, V97, P3919, DOI 10.1073/pnas.97.8.3919; El-Shazly A, 2006, J IMMUNOL, V176, P1860, DOI 10.4049/jimmunol.176.3.1860; Fahy OL, 2003, LAB INVEST, V83, P721, DOI 10.1097/01.LAB.0000069518.49544.B8; Frelin C, 2003, ONCOGENE, V22, P8187, DOI 10.1038/sj.onc.1206963; Garside H, 2004, J BIOL CHEM, V279, P50050, DOI 10.1074/jbc.M407309200; Garton KJ, 2001, J BIOL CHEM, V276, P37993; Imaizumi T, 2000, TOHOKU J EXP MED, V192, P127, DOI 10.1620/tjem.192.127; Imanishi D, 2000, J IMMUNOL, V165, P3907, DOI 10.4049/jimmunol.165.7.3907; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Ito K, 2006, J EXP MED, V203, P7, DOI 10.1084/jem.20050466; JAHNKE A, 1994, FEBS LETT, V354, P220, DOI 10.1016/0014-5793(94)01130-3; JOHNSON DR, 1994, MOL CELL BIOL, V14, P1322, DOI 10.1128/MCB.14.2.1322; Kochetkova M, 1996, J BIOL CHEM, V271, P14438, DOI 10.1074/jbc.271.24.14438; Lasa M, 2002, MOL CELL BIOL, V22, P7802, DOI 10.1128/MCB.22.22.7802-7811.2002; Lee AH, 2000, BIOCHEM J, V350, P131, DOI 10.1042/0264-6021:3500131; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Menetski JP, 2000, J BIOL CHEM, V275, P7619, DOI 10.1074/jbc.275.11.7619; Murphy PM, 2000, PHARMACOL REV, V52, P145; Newton R, 1998, EUR J BIOCHEM, V254, P81, DOI 10.1046/j.1432-1327.1998.2540081.x; Ning W, 2004, P NATL ACAD SCI USA, V101, P14895, DOI 10.1073/pnas.0401168101; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Novac N, 2006, FASEB J, V20, P1074, DOI 10.1096/fj.05-5457com; OHMORI Y, 1995, J IMMUNOL, V154, P5235; Polito AJ, 1998, J ALLERGY CLIN IMMUN, V102, P714, DOI 10.1016/S0091-6749(98)70008-9; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; Rimaniol AC, 2003, J ALLERGY CLIN IMMUN, V112, P1139, DOI 10.1016/j.jaci.2003.09.041; SCHEINMAN RI, 1995, SCIENCE, V270, P286; Sukkar MB, 2004, AM J PHYSIOL-LUNG C, V287, pL1230, DOI 10.1152/ajplung.00014.2004; Yoshida H, 2001, NEUROSCI LETT, V303, P132, DOI 10.1016/S0304-3940(01)01699-8	39	42	45	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					1807	1816		10.1096/fj.07-094235	http://dx.doi.org/10.1096/fj.07-094235			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18230685				2022-12-25	WOS:000256352700021
J	Clark, PA; Moioli, EK; Sumner, DR; Mao, JJ				Clark, Paul A.; Moioli, Eduardo K.; Sumner, D. Rick; Mao, Jeremy J.			Porous implants as drug delivery vehicles to augment host tissue integration	FASEB JOURNAL			English	Article						stem cells; transforming growth factor-beta; bone morphogenetic proteins; osteoblasts; wound healing; controlled release	MESENCHYMAL STEM-CELLS; GROWTH-FACTOR BETA-1; TITANIUM IMPLANTS; OSTEOGENIC DIFFERENTIATION; BONE REGENERATION; RHTGF-BETA-2; SCAFFOLDS; SURFACES; INGROWTH; RELEASE	The common premise of synthetic implants in the restoration of diseased tissues and organs is to use inert and solid materials. Here, a porous titanium implant was fabricated for the delivery of microencapsulated bioactive cues. Control- released transforming growth factor-beta 1 (TGF-beta 1) promoted the proliferation and migration of human mesenchymal stem cells into porous implants in vitro. At 4 wk of implantation in the rabbit humerus, control- released TGF-beta 1 from porous implants significantly increased bone- to- implant contact (BIC) by 96% and bone ingrowth by 50% over placebos. Control- released 100 ng TGF-beta 1 induced equivalent BIC and bone ingrowth to adsorbed 1 mu g TGF-beta 1, suggesting that controlled release is effective at 10- fold less drug dose than adsorption. Histomorphometry, scanning electron microscopy, and microcomputed tomography showed that control- released TGF-beta 1 enhanced bone ingrowth in the implant's pores and surface. These findings suggest that solid prostheses can be transformed into porous implants to serve as drug delivery carriers, from which control- released bioactive cues augment host tissue integration.	[Moioli, Eduardo K.; Mao, Jeremy J.] Columbia Univ, Med Ctr, Coll Dent Med, Fu Fdn Sch Engn & Appl Sci,Dept Biomed Engn, New York, NY 10032 USA; [Clark, Paul A.] Univ Wisconsin, Dept Neurol Surg, Madison, WI USA; [Sumner, D. Rick] Rush Univ, Dept Anat & Cell Biol, Chicago, IL 60612 USA	Columbia University; University of Wisconsin System; University of Wisconsin Madison; Rush University	Mao, JJ (corresponding author), Columbia Univ, Med Ctr, Coll Dent Med, Fu Fdn Sch Engn & Appl Sci,Dept Biomed Engn, 630 W 168 St,PH7E-CDM, New York, NY 10032 USA.	jmao@columbia.edu		Sumner, Dale/0000-0001-9575-3862	NIBIB NIH HHS [EB02332] Funding Source: Medline; NIDCR NIH HHS [RC2 DE020767, DE015391] Funding Source: Medline; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB002332] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [RC2DE020767, R01DE015391] Funding Source: NIH RePORTER	NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALBREKTSSON T, 1981, ACTA ORTHOP SCAND, V52, P155, DOI 10.3109/17453678108991776; Alhadlaq A, 2004, STEM CELLS DEV, V13, P436, DOI 10.1089/1547328041797552; Alhadlaq A, 2004, ANN BIOMED ENG, V32, P911, DOI 10.1023/B:ABME.0000032454.53116.ee; Alliston Tamara N., 2000, P233; An Y. H., 2000, MECH TESTING BONE BO, P41; Clark PA, 2005, J APPL PHYSIOL, V98, P1922, DOI 10.1152/japplphysiol.01080.2004; COHEN S, 1991, PHARMACEUT RES, V8, P713, DOI 10.1023/A:1015841715384; CORY AH, 1991, CANCER COMMUN, V3, P207, DOI 10.3727/095535491820873191; De Ranieri A, 2005, BONE, V37, P55, DOI 10.1016/j.bone.2005.03.011; Dimitriou R, 2005, INJURY, V36, P1392, DOI 10.1016/j.injury.2005.07.019; Doll B, 2001, CRIT REV EUKAR GENE, V11, P173; Holland TA, 2007, OSTEOARTHR CARTILAGE, V15, P187, DOI 10.1016/j.joca.2006.07.006; Hong L, 2005, ANN BIOMED ENG, V33, P511, DOI 10.1007/s10439-005-2510-7; Hunziker EB, 1996, J BONE JOINT SURG AM, V78A, P721, DOI 10.2106/00004623-199605000-00012; Ingham E, 2000, P I MECH ENG H, V214, P21, DOI 10.1243/0954411001535219; Leach JK, 2004, EXPERT OPIN BIOL TH, V4, P1015, DOI 10.1517/14712598.4.7.1015; Lind M, 1998, ACTA ORTHOP SCAND, V69, P2; Linkhart TA, 1996, BONE, V19, pS1, DOI 10.1016/S8756-3282(96)00138-X; Liu Y, 2007, BIOMATERIALS, V28, P2677, DOI 10.1016/j.biomaterials.2007.02.003; Lossdorfer S, 2004, J BIOMED MATER RES A, V70A, P361, DOI 10.1002/jbm.a.30025; Lu L, 2000, J BIOMED MATER RES, V50, P440, DOI 10.1002/(SICI)1097-4636(20000605)50:3<440::AID-JBM19>3.0.CO;2-G; Marion NW, 2006, METHOD ENZYMOL, V420, P339, DOI 10.1016/S0079-6879(06)20016-8; MCKOY BE, 2000, MECH TESTING BONE BO, P439; Meredith DO, 2007, J MATER SCI-MATER M, V18, P405, DOI 10.1007/s10856-006-0706-5; Misch CE., 1993, CONT IMPLANT DENT, V1st; Moioli EK, 2007, ADV DRUG DELIVER REV, V59, P308, DOI 10.1016/j.addr.2007.03.019; Moioli EK, 2007, WOUND REPAIR REGEN, V15, P413, DOI 10.1111/j.1524-475X.2007.00244.x; Moioli EK, 2006, TISSUE ENG, V12, P537, DOI 10.1089/ten.2006.12.537; Nebe JGB, 2007, MACROMOL BIOSCI, V7, P567, DOI 10.1002/mabi.200600293; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; PRIME KL, 1991, SCIENCE, V252, P1164, DOI 10.1126/science.252.5009.1164; ROBERTS AB, 2000, SKELETAL GROWTH FACT, P233; Schliephake H, 2005, J BIOMED MATER RES B, V73B, P88, DOI 10.1002/jbm.b.30183; Sumner D. R., 2001, Journal of Musculoskeletal & Neuronal Interactions, V1, P333; Sumner DR, 2006, J BONE JOINT SURG AM, V88A, P806, DOI 10.2106/JBJS.E.00846; Sumner DR, 2001, J ORTHOP RES, V19, P85; Yamamoto M, 2000, J CONTROL RELEASE, V64, P133, DOI 10.1016/S0168-3659(99)00129-7; Zhang H, 2005, J BIOMED MATER RES A, V75A, P98, DOI 10.1002/jbm.a.30400; Zhang R, 2004, J BIOMED MATER RES B, V71B, P408, DOI 10.1002/jbm.b.30110; [No title captured]	40	22	25	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1684	1693		10.1096/fj.07-094789	http://dx.doi.org/10.1096/fj.07-094789			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18198217				2022-12-25	WOS:000256352700009
J	Rytinki, MM; Palvimo, JJ				Rytinki, Miia M.; Palvimo, Jorma J.			SUMOylation modulates the transcription repressor function of RIP140	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-INTERACTING PROTEIN-140; SUBNUCLEAR LOCALIZATION; COREPRESSOR RIP140; ESTROGEN-RECEPTOR; ANDROGEN RECEPTOR; SUMO MODIFICATION; PIAS PROTEINS; ACTIVATION; UBIQUITIN; DOMAINS	RIP140/NRIP1 (receptor-interacting protein 140) functions as a corepressor of nuclear receptors. It plays an important role in the transcriptional control of energy metabolism and female fertility. RIP140 contains four distinct repression domains (RD1-RD4), and the repressive activity of RIP140 involves complex mechanisms. The function of both RD1 and RD2 is linked to recruitment of histone deacetylases and C-terminal binding protein, respectively, but the mechanism of repression for RD3 and RD4 has remained elusive. Because covalent modification by small ubiquitin-like modifiers (SUMO-1, -2, and -3; SUMOylation) is often associated with transcriptional repression, we studied whether SUMOylation is involved in the repressive activity of RIP140. We show that two conserved lysines, Lys(756) and Lys(1154), located in RD3 and RD4, respectively, are subject to reversible SUMOylation, with SUMO-1 being more efficiently conjugated than SUMO-2. Interestingly, mutations of the RIP140 SUMOylation sites compromised the transcription repressor function of RIP140 and blunted its capacity to repress estrogen receptor alpha-dependent transcription. Conjugation of SUMO-1 also influenced the subnuclear distribution pattern of RIP140. In sum, our demonstration that the function of RIP140 repression domains 3 and 4 can be modulated by reversible SUMO modification thus adds a novel level to the regulation of RIP140 activity, which may have ramifications in the control of gene networks exerted by RIP140.	[Rytinki, Miia M.; Palvimo, Jorma J.] Univ Kuopio, Inst Biomed Med Biochem, FI-70211 Kuopio, Finland	University of Eastern Finland	Palvimo, JJ (corresponding author), Univ Kuopio, Inst Biomed Med Biochem, POB 1627, FI-70211 Kuopio, Finland.	jorma.palvimo@uku.fi		Palvimo, Jorma/0000-0003-2373-0578				Augereau P, 2006, J STEROID BIOCHEM, V102, P51, DOI 10.1016/j.jsbmb.2006.09.005; Bailey D, 2004, J BIOL CHEM, V279, P692, DOI 10.1074/jbc.M306195200; Bossis G, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-13; Castet A, 2004, NUCLEIC ACIDS RES, V32, P1957, DOI 10.1093/nar/gkh524; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Christian M, 2004, J BIOL CHEM, V279, P15645, DOI 10.1074/jbc.M313906200; Christian M, 2006, TRENDS ENDOCRIN MET, V17, P243, DOI 10.1016/j.tem.2006.06.008; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Hay RT, 2007, TRENDS CELL BIOL, V17, P370, DOI 10.1016/j.tcb.2007.08.002; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hecker CM, 2006, J BIOL CHEM, V281, P16117, DOI 10.1074/jbc.M512757200; Heldring N, 2004, MOL CELL BIOL, V24, P3445, DOI 10.1128/MCB.24.8.3445-3459.2004; Heun P, 2007, CURR OPIN CELL BIOL, V19, P350, DOI 10.1016/j.ceb.2007.04.014; Huq MDM, 2006, EMBO J, V25, P5094, DOI 10.1038/sj.emboj.7601389; Huq MDM, 2005, MOL CELL PROTEOMICS, V4, P975, DOI 10.1074/mcp.M500015-MCP200; Huq MDM, 2005, PROTEOMICS, V5, P2157, DOI 10.1002/pmic.200401090; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kerscher O, 2007, EMBO REP, V8, P550, DOI 10.1038/sj.embor.7400980; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Kotaja N, 2002, J BIOL CHEM, V277, P30283, DOI 10.1074/jbc.M204768200; Leonardsson G, 2004, P NATL ACAD SCI USA, V101, P8437, DOI 10.1073/pnas.0401013101; Mellgren G, 2003, MOL CELL ENDOCRINOL, V203, P91, DOI 10.1016/S0303-7207(03)00097-2; Mukhopadhyay D, 2007, SCIENCE, V315, P201, DOI 10.1126/science.1127085; Nathan D, 2006, GENE DEV, V20, P966, DOI 10.1101/gad.1404206; Palvimo JJ, 2007, BIOCHEM SOC T, V35, P1405, DOI 10.1042/BST0351405; Perdomo J, 2005, MOL CELL BIOL, V25, P1549, DOI 10.1128/MCB.25.4.1549-1559.2005; Peters GA, 1999, MOL ENDOCRINOL, V13, P286, DOI 10.1210/me.13.2.286; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Spengler ML, 2005, CELL SIGNAL, V17, P153, DOI 10.1016/j.cellsig.2004.06.007; Steel JH, 2005, J ENDOCRINOL, V185, P1, DOI 10.1677/joe.1.05896; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Tazawa H, 2003, MOL CELL BIOL, V23, P4187, DOI 10.1128/MCB.23.12.4187-4198.2003; Tiefenbach J, 2006, MOL BIOL CELL, V17, P1643, DOI 10.1091/mbc.E05-07-0610; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; Vo N, 2001, MOL CELL BIOL, V21, P6181, DOI 10.1128/MCB.21.18.6181-6188.2001; Wei LN, 2004, MOL CELL ENDOCRINOL, V218, P39, DOI 10.1016/j.mce.2003.12.010; Wei LN, 2000, J BIOL CHEM, V275, P40782, DOI 10.1074/jbc.M004821200; White R, 2000, NAT MED, V6, P1368, DOI 10.1038/82183; Windahl SH, 1999, J STEROID BIOCHEM, V71, P93, DOI 10.1016/S0960-0760(99)00128-4; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7	43	40	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11586	11595		10.1074/jbc.M709359200	http://dx.doi.org/10.1074/jbc.M709359200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18211901	hybrid			2022-12-25	WOS:000255067400059
J	Moss, BL; Gross, S; Gammon, ST; Vinjamoori, A; Piwnica-Worms, D				Moss, Britney L.; Gross, Shimon; Gammon, Seth T.; Vinjamoori, Anant; Piwnica-Worms, David			Identification of a ligand-induced transient refractory period in nuclear factor-kappa B signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; CANCER DEVELOPMENT; TEMPORAL CONTROL; GENE-EXPRESSION; KINASE-ACTIVITY; IKK-BETA; ALPHA; CELLS; ACTIVATION; DYNAMICS	In response to a variety of extracellular ligands, nuclear factor-kappa B (NF-kappa B) signaling regulates inflammation, cell proliferation, and apoptosis. It is likely that cells are not continuously exposed to stimulating ligands in vivo but rather experience transient pulses. To study the temporal regulation of NF-kappa B and its major regulator, inhibitor of NF-kappa B alpha(I kappa B alpha), in real time, we utilized a novel transcriptionally coupled I kappa B alpha-firefly luciferase fusion reporter and characterized the dynamics and responsiveness of I kappa B alpha processing upon a short 30-s pulse of tumor necrosis factor alpha( TNF alpha) or a continuous challenge of TNF alpha following a 30-s preconditioning pulse. Strikingly, a 30-s pulse of TNF alpha robustly activated inhibitor of NF-kappa B kinase (IKK), leading to I kappa B alpha degradation, NF-kappa B nuclear translocation, and strong transcriptional up-regulation of I kappa B alpha. Furthermore, we identified a transient refractory period (lasting up to 120 min) following preconditioning, during which the cells were not able to fully degrade I kappa B alpha upon a second TNF alpha challenge. Kinase assays of IKK activity revealed that regulation of IKK activity correlated in part with this transient refractory period. In contrast, experiments involving sequential exposure to TNF alpha and interleukin-1 alpha indicated that receptor dynamics could not explain this phenomenon. Utilizing a well accepted computational model of NF-kappa B dynamics, we further identified an additional layer of regulation, downstream of IKK, that may govern the temporal capacity of cells to respond to a second proinflammatory insult. Overall, the data suggested that nuclear export of NF-kappa B.I kappa B alpha complexes represented another rate-limiting step that may impact this refractory period, thereby providing an additional regulatory mechanism.	[Moss, Britney L.; Gross, Shimon; Gammon, Seth T.; Vinjamoori, Anant; Piwnica-Worms, David] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, Mol Imaging Ctr, St Louis, MO 63110 USA; [Piwnica-Worms, David] Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Piwnica-Worms, D (corresponding author), Washington Univ, Sch Med, Mallinckrodt Inst Radiol, Mol Imaging Ctr, 510 S Kingshighway Blvd,Box 8225, St Louis, MO 63110 USA.	piwnica-wormsd@mir.wustl.edu	Gammon, Seth/C-8778-2014	Gammon, Seth/0000-0001-8647-0975; Moss, Britney/0000-0002-1037-5717	NCI NIH HHS [P50 CA 94056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA094056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTS B, 1994, MOL BIOL CELL, P771; Barken D, 2005, SCIENCE, V308, DOI 10.1126/science.1107904; Blanque R, 1998, GEN PHARMACOL, V31, P301, DOI 10.1016/S0306-3623(97)00434-5; Bunting K, 2007, J IMMUNOL, V178, P7097, DOI 10.4049/jimmunol.178.11.7097; Cheong R, 2006, J BIOL CHEM, V281, P2945, DOI 10.1074/jbc.M510085200; Covert MW, 2005, SCIENCE, V309, P1854, DOI 10.1126/science.1112304; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Dri P, 2000, J IMMUNOL, V165, P2165, DOI 10.4049/jimmunol.165.4.2165; Gloire G, 2006, BIOCHEM PHARMACOL, V72, P1493, DOI 10.1016/j.bcp.2006.04.011; Gross S, 2005, NAT METHODS, V2, P607, DOI 10.1038/NMETH779; Han JH, 2005, NAT IMMUNOL, V6, P1198, DOI 10.1038/ni1274; Hastie CJ, 2006, NAT PROTOC, V1, P968, DOI 10.1038/nprot.2006.149; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; HIGUCHI M, 1994, J IMMUNOL, V152, P3550; Hoffmann A, 2006, IMMUNOL REV, V210, P171, DOI 10.1111/j.0105-2896.2006.00375.x; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; HOLTMANN H, 1987, J IMMUNOL, V139, P1161; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Karmann K, 1996, J EXP MED, V184, P173, DOI 10.1084/jem.184.1.173; Kearns JD, 2006, J CELL BIOL, V173, P659, DOI 10.1083/jcb.200510155; Kim HJ, 2006, CELL DEATH DIFFER, V13, P738, DOI 10.1038/sj.cdd.4401877; Liu YC, 2005, NAT REV IMMUNOL, V5, P941, DOI 10.1038/nri1731; Naamane N, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-55; Nejjari M, 1999, INT J CANCER, V83, P518, DOI 10.1002/(SICI)1097-0215(19991112)83:4<518::AID-IJC14>3.3.CO;2-H; Nelson DE, 2004, SCIENCE, V306, P704, DOI 10.1126/science.1099962; O'Dea EL, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100148; Pando MP, 2000, J BIOL CHEM, V275, P21278, DOI 10.1074/jbc.M002532200; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Place RF, 2003, J CELL PHYSIOL, V195, P470, DOI 10.1002/jcp.10262; Prajapati S, 2004, J BIOL CHEM, V279, P1739, DOI 10.1074/jbc.M306273200; Sniegowski JA, 2005, J BIOL CHEM, V280, P26248, DOI 10.1074/jbc.M412327200; Trinchieri G, 2007, NAT REV IMMUNOL, V7, P179, DOI 10.1038/nri2038; Werner SL, 2005, SCIENCE, V309, P1857, DOI 10.1126/science.1113319; Winsauer G, 2007, THROMB HAEMOSTASIS, V97, P364, DOI 10.1160/TH06-08-0473; Wullaert A, 2007, ENDOCR REV, V28, P365, DOI 10.1210/er.2006-0031; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zhang LP, 2006, J AM CHEM SOC, V128, P4766, DOI 10.1021/ja0580439	40	16	17	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8687	8698		10.1074/jbc.M706831200	http://dx.doi.org/10.1074/jbc.M706831200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18203717	hybrid, Green Published			2022-12-25	WOS:000254288000067
J	Lin, DH; Kamsteeg, EJ; Zhang, Y; Jin, Y; Sterling, H; Yue, P; Roos, M; Duffield, A; Spencer, J; Caplan, M; Wang, WH				Lin, Daohong; Kamsteeg, Erik-Jan; Zhang, Yan; Jin, Yan; Sterling, Hyacinth; Yue, Peng; Roos, Marcel; Duffield, Amy; Spencer, Joanna; Caplan, Michael; Wang, Wen-Hui			Expression of tetraspan protein CD63 activates protein-tyrosine kinase (PTK) and enhances the PTK-induced inhibition of ROMK channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIETARY K-INTAKE; POTASSIUM-TRANSPORT; DISTAL NEPHRON; RPTP-ALPHA; PHOSPHORYLATION; INTERNALIZATION; ENDOCYTOSIS; SECRETION; MEMBRANE; PKC	In the present study, we tested the role of CD63 in regulating ROMK1 channels by protein-tyrosine kinase (PTK). Immunocytochemical staining shows that CD63 and receptor-linked tyrosine phosphatase alpha(RPTP alpha) are expressed in the cortical collecting duct and outer medulla collecting duct. Immunoprecipitation of tissue lysates from renal cortex and outer medulla or 293T cells transfected with CD63 reveals that CD63 was associated with RPTP alpha both in situ and in transfected cells. Expression of CD63 in 293T cells stimulated the phosphorylation of tyrosine residue 416 of c-Src but decreased the phosphorylation of tyrosine residue 527, indicating that expression of CD63 stimulates the activity of c-Src. Furthermore, c-Src was coimmunoprecipitated with RPTP alpha and CD63 both in 293T cells transfected with CD63 and in lysates prepared from native rat kidney. Potassium restriction had no effect on the expression of RPTP alpha, but it increased the association between c-Src and RPTP alpha in the renal cortex and outer medulla. We also used two-electrode voltage clamp to study the effect of CD63 on ROMK channels in Xenopus oocytes. Expression of CD63 had no significant effect on potassium currents in oocytes injected with ROMK1; however, it significantly enhanced the c-Src-induced inhibition of ROMK channels in oocytes injected with ROMK1 + c-Src. The effect of CD63 on the c-Src-induced inhibition was not due to a decreased expression of ROMK1 channels, because blocking PTK with herbimycin A abolished the inhibitory effect of c-Src on ROMK channels in oocytes injected with ROMK1 + cSrc + CD63. Furthermore, coexpression of CD63 enhanced tyrosine phosphorylation of ROMK1. We conclude that CD63 plays a role in the regulation of ROMK channels through its association with RPTP alpha, which in turn interacts with and activates Src family PTK, thus reducing ROMK activity.	[Lin, Daohong; Zhang, Yan; Jin, Yan; Sterling, Hyacinth; Yue, Peng; Wang, Wen-Hui] New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA; [Kamsteeg, Erik-Jan; Roos, Marcel; Duffield, Amy; Spencer, Joanna; Caplan, Michael] Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	New York Medical College; Yale University	Wang, WH (corresponding author), New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA.	wenhui_wang@nymc.edu		Duffield, Amy/0000-0003-2018-1964	NHLBI NIH HHS [P01 HL034300] Funding Source: Medline; NIDDK NIH HHS [R01 DK054983, DK54983, DK17433] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034300] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054983, P01DK017433] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Babilonia E, 2005, J BIOL CHEM, V280, P10790, DOI 10.1074/jbc.M414610200; Bhandari V, 1998, J BIOL CHEM, V273, P8691, DOI 10.1074/jbc.273.15.8691; Brandt DT, 2003, J BIOL CHEM, V278, P34073, DOI 10.1074/jbc.M211650200; CARMO AM, 1995, EUR J IMMUNOL, V25, P2090, DOI 10.1002/eji.1830250743; Chu PY, 2003, AM J PHYSIOL-RENAL, V285, pF1179, DOI 10.1152/ajprenal.00150.2003; Claas C, 2001, J BIOL CHEM, V276, P7974, DOI 10.1074/jbc.M008650200; DAUM G, 1994, J BIOL CHEM, V269, P10524; Duffield A, 2003, P NATL ACAD SCI USA, V100, P15560, DOI 10.1073/pnas.2536699100; Flagg TP, 1999, J GEN PHYSIOL, V114, P685, DOI 10.1085/jgp.114.5.685; Giebisch G, 1998, AM J PHYSIOL-RENAL, V274, pF817, DOI 10.1152/ajprenal.1998.274.5.F817; Harrison SC, 2003, CELL, V112, P737, DOI 10.1016/S0092-8674(03)00196-X; Hebert SC, 2005, PHYSIOL REV, V85, P319, DOI 10.1152/physrev.00051.2003; HEIJNEN HF, 2003, J THROMB HAEMOST, V6, P1173; Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609; Israels SJ, 2005, THROMB HAEMOSTASIS, V93, P311, DOI 10.1160/TH04-08-0503; KANEKO T, 1995, AM J PHYSIOL-RENAL, V268, pF1102, DOI 10.1152/ajprenal.1995.268.6.F1102; Kohda Y, 1998, KIDNEY INT, V54, P1214, DOI 10.1046/j.1523-1755.1998.00120.x; Lin DH, 2004, AM J PHYSIOL-RENAL, V286, pF881, DOI 10.1152/ajprenal.00301.2003; Lin DH, 2002, AM J PHYSIOL-RENAL, V283, pF671, DOI 10.1152/ajprenal.00160.2002; Macica CM, 1996, AM J PHYSIOL-RENAL, V271, pF588, DOI 10.1152/ajprenal.1996.271.3.F588; Moral Z, 2001, J BIOL CHEM, V276, P7156, DOI 10.1074/jbc.M008671200; Odintsova E, 2003, J CELL SCI, V116, P4557, DOI 10.1242/jcs.00793; Okochi H, 1999, J CLIN GASTROENTEROL, V29, P63, DOI 10.1097/00004836-199907000-00016; Ostman A, 2006, NAT REV CANCER, V6, P307, DOI 10.1038/nrc1837; Palmer LG, 1997, AM J PHYSIOL-RENAL, V273, pF404, DOI 10.1152/ajprenal.1997.273.3.F404; Palmer LG, 1999, AM J PHYSIOL-RENAL, V277, pF821, DOI 10.1152/ajprenal.1999.277.6.F821; Rous BA, 2002, MOL BIOL CELL, V13, P1071, DOI 10.1091/mbc.01-08-0409; Sackin H, 2004, BIOPHYS J, V86, P2145, DOI 10.1016/S0006-3495(04)74274-5; Satlin LM, 1999, SEMIN NEPHROL, V19, P155; Skubitz KM, 1996, J IMMUNOL, V157, P3617; Sterling H, 2004, AM J PHYSIOL-RENAL, V286, pF1072, DOI 10.1152/ajprenal.00425.2003; Sterling H, 2002, J BIOL CHEM, V277, P4317, DOI 10.1074/jbc.M109739200; von Wichert G, 2003, J CELL BIOL, V161, P143, DOI 10.1083/jcb.200211061; Wang WH, 2000, AM J PHYSIOL-RENAL, V278, pF165, DOI 10.1152/ajprenal.2000.278.1.F165; Wei Y, 2001, AM J PHYSIOL-RENAL, V281, pF206, DOI 10.1152/ajprenal.2001.281.2.F206; Zeng L, 2003, J CELL BIOL, V160, P137, DOI 10.1083/jcb.200206049; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200	37	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7674	7681		10.1074/jbc.M705574200	http://dx.doi.org/10.1074/jbc.M705574200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18211905	Green Published, hybrid			2022-12-25	WOS:000253997900043
J	Mishra, A; Dikshit, P; Purkayastha, S; Sharma, J; Nukina, N; Jana, NR				Mishra, Amit; Dikshit, Priyanka; Purkayastha, Sudarshana; Sharma, Jaiprakash; Nukina, Nobuyuki; Jana, Nihar Ranjan			E6-AP promotes misfolded polyglutamine proteins for proteasomal degradation and suppresses polyglutamine protein aggregation and toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BULBAR MUSCULAR-ATROPHY; ANDROGEN RECEPTOR PROTEIN; TRANSGENIC MOUSE MODEL; N-TERMINAL HUNTINGTIN; WILD-TYPE HUNTINGTIN; CO-CHAPERONE CHIP; UBIQUITIN LIGASE; EXPANDED POLYGLUTAMINE; E6-ASSOCIATED PROTEIN; AMELIORATES PHENOTYPES	The accumulation of intracellular protein deposits as inclusion bodies is the common pathological hallmark of most age-related neurodegenerative disorders including polyglutamine diseases. Appearance of aggregates of the misfolded mutant disease proteins suggest that cells are unable to efficiently degrade them, and failure of clearance leads to the severe disturbances of the cellular quality control system. Recently, the quality control ubiquitin ligase CHIP has been shown to suppress the polyglutamine protein aggregation and toxicity. Here we have identified another ubiquitin ligase, called E6-AP, which is able to promote the proteasomal degradation of misfolded polyglutamine proteins and suppress the polyglutamine protein aggregation and polyglutamine protein-induced cell death. E6-AP interacts with the soluble misfolded polyglutamine protein and associates with their aggregates in both cellular and transgenic mouse models. Partial knockdown of E6-AP enhances the rate of aggregate formation and cell death mediated by the polyglutamine protein. Finally, we have demonstrated the up-regulation of E6-AP in the expanded polyglutamine protein-expressing cells as well as cells exposed to proteasomal stress. These findings suggest that E6-AP is a critical mediator of the neuronal response to misfolded polyglutamine proteins and represents a potential therapeutic target in the polyglutamine diseases.	[Mishra, Amit; Dikshit, Priyanka; Purkayastha, Sudarshana; Sharma, Jaiprakash; Jana, Nihar Ranjan] Natl Brain Res Ctr, Mol & Cellular Neurosci Lab, Manesar 122050, Gurgaon, India; [Nukina, Nobuyuki] RIKEN, Brain Sci Inst, Lab Struct Neuropathol, Wako, Saitama 3510198, Japan	Department of Biotechnology (DBT) India; National Brain Research Centre (NBRC); RIKEN	Jana, NR (corresponding author), Natl Brain Res Ctr, Mol & Cellular Neurosci Lab, Manesar 122050, Gurgaon, India.	nihar@nbrc.ac.in	Nukina, Nobuyuki/GPP-6265-2022	Mishra, Amit/0000-0001-9401-4400; Jana, Nihar/0000-0002-6549-4211				Adachi H, 2003, J NEUROSCI, V23, P2203; Adachi H, 2007, J NEUROSCI, V27, P5115, DOI 10.1523/JNEUROSCI.1242-07.2007; Al-Ramahi I, 2006, J BIOL CHEM, V281, P26714, DOI 10.1074/jbc.M601603200; Bae BI, 2005, NEURON, V47, P29, DOI 10.1016/j.neuron.2005.06.005; Bailey CK, 2002, HUM MOL GENET, V11, P515, DOI 10.1093/hmg/11.5.515; Bates GP, 2005, NAT REV GENET, V6, P766, DOI 10.1038/nrg1686; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Cattaneo E, 2003, NEWS PHYSIOL SCI, V18, P34, DOI 10.1152/nips.01410.2002; Cha JHJ, 2000, TRENDS NEUROSCI, V23, P387, DOI 10.1016/S0166-2236(00)01609-X; Chai YH, 1999, HUM MOL GENET, V8, P673, DOI 10.1093/hmg/8.4.673; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Cummings CJ, 2001, HUM MOL GENET, V10, P1511, DOI 10.1093/hmg/10.14.1511; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Di Prospero NA, 2005, NAT REV GENET, V6, P756, DOI 10.1038/nrg1690; Dickey CA, 2007, J CLIN INVEST, V117, P648, DOI 10.1172/JCI29715; Dikshit P, 2007, BIOCHEM BIOPH RES CO, V357, P761, DOI 10.1016/j.bbrc.2007.04.018; Gatchel JR, 2005, NAT REV GENET, V6, P743, DOI 10.1038/nrg1691; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Jana NR, 2000, HUM MOL GENET, V9, P2009, DOI 10.1093/hmg/9.13.2009; Jana NR, 2005, J BIOL CHEM, V280, P11635, DOI 10.1074/jbc.M412042200; Jana NR, 2003, J CHEM NEUROANAT, V26, P95, DOI 10.1016/S0891-0618(03)00029-2; Jana NR, 2001, HUM MOL GENET, V10, P1049, DOI 10.1093/hmg/10.10.1049; Jiang YH, 1998, NEURON, V21, P799, DOI 10.1016/S0896-6273(00)80596-6; Khan OY, 2006, MOL ENDOCRINOL, V20, P544, DOI 10.1210/me.2005-0110; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Kumar P, 2007, HUM MOL GENET, V16, P848, DOI 10.1093/hmg/ddm030; Kumar S, 1999, J BIOL CHEM, V274, P18785, DOI 10.1074/jbc.274.26.18785; Martin-Aparicio E, 2001, J NEUROSCI, V21, P8772, DOI 10.1523/JNEUROSCI.21-22-08772.2001; Miller VM, 2005, J NEUROSCI, V25, P9152, DOI 10.1523/JNEUROSCI.3001-05.2005; Nuber U, 1998, EUR J BIOCHEM, V254, P643, DOI 10.1046/j.1432-1327.1998.2540643.x; Oda H, 1999, P NATL ACAD SCI USA, V96, P9557, DOI 10.1073/pnas.96.17.9557; Petrucelli L, 2004, HUM MOL GENET, V13, P703, DOI 10.1093/hmg/ddh083; Reiner A, 2003, MOL NEUROBIOL, V28, P259, DOI 10.1385/MN:28:3:259; Reiter LT, 2006, HUM MOL GENET, V15, P2825, DOI 10.1093/hmg/ddl225; Ross CA, 2003, P NATL ACAD SCI USA, V100, P1, DOI 10.1073/pnas.0237018100; Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291; Sahara N, 2005, J NEUROCHEM, V94, P1254, DOI 10.1111/j.1471-4159.2005.03272.x; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Shin YG, 2005, J BIOL CHEM, V280, P23727, DOI 10.1074/jbc.M503326200; Tobin AJ, 2000, TRENDS CELL BIOL, V10, P531, DOI 10.1016/S0962-8924(00)01853-5; Urushitani M, 2004, J NEUROCHEM, V90, P231, DOI 10.1111/j.1471-4159.2004.02486.x; Venkatraman P, 2004, MOL CELL, V14, P95, DOI 10.1016/S1097-2765(04)00151-0; Wang GH, 2000, HUM MOL GENET, V9, P1795, DOI 10.1093/hmg/9.12.1795; Wang GH, 1999, NEUROREPORT, V10, P2435, DOI 10.1097/00001756-199908200-00001; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6; Yewdell JW, 2001, TRENDS CELL BIOL, V11, P294, DOI 10.1016/S0962-8924(01)02030-X; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	49	64	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7648	7656		10.1074/jbc.M706620200	http://dx.doi.org/10.1074/jbc.M706620200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18201976	hybrid			2022-12-25	WOS:000253997900040
J	Enesa, K; Zakkar, M; Chaudhury, H; Luong, LA; Rawlinson, L; Mason, JC; Haskard, DO; Dean, JLE; Evans, PC				Enesa, Karine; Zakkar, Mustafa; Chaudhury, Hera; Luong, Le A.; Rawlinson, Lesley; Mason, Justin C.; Haskard, Dorian O.; Dean, Jonathan L. E.; Evans, Paul C.			NF-kappa B suppression by the deubiquitinating enzyme Cezanne - A novel negative feedback loop in pro-inflammatory signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FINGER PROTEIN A20; UBIQUITIN-DEPENDENT KINASE; SHEAR-STRESS; GENE-EXPRESSION; ACTIVATION; CYLD; IDENTIFICATION; OSCILLATIONS; INTERACTS; RESPONSES	Transcription factors belonging to the NF-kappa B family regulate inflammation by inducing pro-inflammatory molecules (e. g. interleukin (IL)-8) in response to cytokines (e. g. tumor necrosis factor (TNF) alpha, IL-1) or other stimuli. Several negative regulators of NF-kappa B, including the ubiquitin-editing enzyme A20, participate in the resolution of inflammatory responses. We report that Cezanne, a member of the A20 family of the deubiquitinating cysteine proteases, can be induced by TNF alpha in cultured cells. Silencing of endogenous Cezanne using small interfering RNA led to elevated NF-kappa B luciferase reporter gene activity and enhanced expression of IL-8 transcripts in TNF alpha-treated cells. Thus we conclude that endogenous Cezanne can attenuate NF-kappa B activation and the induction of pro-inflammatory transcripts in response to TNF receptor (TNFR) signaling. Overexpression studies revealed that Cezanne suppressed NF-kappa B nuclear translocation and transcriptional activity by targeting the TNFR signaling pathway at the level of the I kappa B kinase complex or upstream from it. These effects were not observed in a form of Cezanne that was mutated at the catalytic cysteine residue (Cys(209)), indicating that the deubiquitinating activity of Cezanne is essential for NF-kappa B regulation. Finally, we demonstrate that Cezanne can be recruited to activated TNFRs where it suppresses the build-up of polyubiquitinated RIP1 signal adapter proteins. Thus we conclude that Cezanne forms a novel negative feedback loop in pro-inflammatory signaling and that it suppresses NF-kappa B activation by targeting RIP1 signaling intermediaries for deubiquitination.	[Enesa, Karine; Zakkar, Mustafa; Chaudhury, Hera; Luong, Le A.; Mason, Justin C.; Haskard, Dorian O.; Evans, Paul C.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, BHF Cardiocvasc Sci Unit, London W12 0NN, England; [Rawlinson, Lesley; Dean, Jonathan L. E.] Univ London Imperial Coll Sci Technol & Med, Kennedy Inst, Div Rheumatol, London W12 0NN, England	Imperial College London; Imperial College London; University of Oxford	Evans, PC (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, BHF Cardiocvasc Sci Unit, Hammersmith Campus,Du Cane Rd, London W12 0NN, England.	paul.evans@imperial.ac.uk		Mason, Justin/0000-0001-7783-1660	British Heart Foundation Funding Source: Medline	British Heart Foundation(British Heart Foundation)		Alford KA, 2007, J BIOL CHEM, V282, P6232, DOI 10.1074/jbc.M610987200; Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Bignell GR, 2000, NAT GENET, V25, P160, DOI 10.1038/76006; Boone DL, 2004, NAT IMMUNOL, V5, P1052, DOI 10.1038/ni1110; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Chen X, 2002, GENE DEV, V16, P289, DOI 10.1101/gad.961502; Cummins JM, 2004, CELL CYCLE, V3, P689, DOI 10.4161/cc.3.6.924; Cunningham KS, 2005, LAB INVEST, V85, P9, DOI 10.1038/labinvest.3700215; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Evans Paul C., 2005, Expert Reviews in Molecular Medicine, V7, P1, DOI 10.1017/S1462399405009415; Evans PC, 2001, BIOCHEM J, V357, P617, DOI 10.1042/0264-6021:3570617; Evans PC, 2003, J BIOL CHEM, V278, P23180, DOI 10.1074/jbc.M301863200; Evans PC, 2004, BIOCHEM J, V378, P727, DOI 10.1042/BJ20031377; Ganguli A, 2005, CIRC RES, V96, P626, DOI 10.1161/01.RES.0000160435.83210.95; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Heyninck K, 1999, J CELL BIOL, V145, P1471, DOI 10.1083/jcb.145.7.1471; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Nelson DE, 2004, SCIENCE, V306, P704, DOI 10.1126/science.1099962; Partridge J, 2007, FASEB J, V21, P3553, DOI 10.1096/fj.06-8059com; Passerini AG, 2004, P NATL ACAD SCI USA, V101, P2482, DOI 10.1073/pnas.0305938101; Reiley WW, 2007, J EXP MED, V204, P1475, DOI 10.1084/jem.20062694; Soares L, 2004, NAT IMMUNOL, V5, P45, DOI 10.1038/ni1017; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; Stegmeier F, 2007, NATURE, V446, P876, DOI 10.1038/nature05694; Sun LJ, 2004, CURR OPIN CELL BIOL, V16, P119, DOI 10.1016/j.ceb.2004.02.005; Tang ED, 2003, J BIOL CHEM, V278, P37297, DOI 10.1074/jbc.M303389200; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang YZ, 2004, J CELL BIOL, V164, P973, DOI 10.1083/jcb.200401010; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Wu CJ, 2006, NAT CELL BIOL, V8, P398, DOI 10.1038/ncb1384; Yamawaki H, 2003, CIRCULATION, V108, P1619, DOI 10.1161/01.CIR.0000089373.49941.C4; Zetoune FS, 2001, CYTOKINE, V15, P282, DOI 10.1006/cyto.2001.0921; Zhang J, 2006, J CLIN INVEST, V116, P3042, DOI 10.1172/JCI28746; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	37	162	169	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					7036	7045		10.1074/jbc.M708690200	http://dx.doi.org/10.1074/jbc.M708690200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18178551	hybrid			2022-12-25	WOS:000253779600048
J	Garapaty, S; Mahajan, MA; Samuels, HH				Garapaty, Shivani; Mahajan, Muktar A.; Samuels, Herbert H.			Components of the CCR4-NOT complex function as nuclear hormone receptor coactivators via association with the NRC-interacting factor NIF-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TERMINAL A/B DOMAIN; THYROID-HORMONE; IN-VIVO; TRANSCRIPTIONAL COACTIVATOR; GENE-EXPRESSION; BINDING PROTEIN; MEDIATED TRANSCRIPTION; YEAST; ACTIVATION	CCR4-NOT is an evolutionarily conserved, multicomponent complex known to be involved in transcription as well as mRNA degradation. Various subunits (e.g. CNOT1 and CNOT7/CAF1) have been reported to be involved in influencing nuclear hormone receptor activities. Here, we show that CCR4/CNOT6 and RCD1/CNOT9, members of the CCR4-NOT complex, potentiate nuclear receptor activity. RCD1 interacts in vivo and in vitro with NIF-1 (NRC-interacting factor), a previously characterized nuclear receptor cotransducer that activates nuclear receptors via its interaction with NRC. As with NIF-1, RCD1 and CCR4 do not directly associate with nuclear receptors; however, they enhance ligand-dependent transcriptional activation by nuclear hormone receptors. CCR4 mediates its effect through the ligand binding domain of nuclear receptors and small interference RNA-mediated silencing of endogenous CCR4 results in a marked decrease in nuclear receptor activation. Furthermore, knockdown of CCR4 results in an attenuated stimulation of RAR alpha target genes ( e. g. Sox9 and HoxA1) as shown by quantitative PCR assays. The silencing of endogenous NIF-1 also resulted in a comparable decrease in the RAR-mediated induction of both Sox9 and HoxA1. Furthermore, CCR4 associates in vivo with NIF-1. In addition, the CCR4-enhanced transcriptional activation by nuclear receptors is dependent on NIF-1. The small interference RNA-mediated knockdown of NIF-1 blocks the ligand-dependent potentiating effect of CCR4. Our results suggest that CCR4 plays a role in the regulation of certain endogenous RAR alpha target genes and that RCD1 and CCR4 might mediate their function through their interaction with NIF-1.	[Garapaty, Shivani; Mahajan, Muktar A.; Samuels, Herbert H.] NYU, Sch Med, Dept Med & Pharmacol, New York, NY 10016 USA	New York University	Samuels, HH (corresponding author), NYU, Sch Med, Dept Pharmacol, 550 First Ave,MSB 424, New York, NY 10016 USA.	samuels@med.nyu.edu		Mahajan, Muktar/0000-0003-1024-6808	NIDDK NIH HHS [DK 16636] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK016636, R37DK016636, R01DK016636] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acconcia F, 2006, CANCER LETT, V238, P1, DOI 10.1016/j.canlet.2005.06.018; Afonja O, 2002, ONCOGENE, V21, P7850, DOI 10.1038/sj.onc.1205985; Albert TK, 2000, NUCLEIC ACIDS RES, V28, P809, DOI 10.1093/nar/28.3.809; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Aoyagi S, 2005, VITAM HORM, V70, P281, DOI 10.1016/S0083-6729(05)70009-1; Badarinarayana V, 2000, GENETICS, V155, P1045; Belakavadi M, 2006, REV PHYSIOL BIOCH P, V156, P23, DOI 10.1007/s10254-005-0002-7; Berthet C, 2004, MOL CELL BIOL, V24, P5808, DOI 10.1128/MCB.24.13.5808-5820.2004; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Blazek E, 2005, CHROMOSOMA, V113, P399, DOI 10.1007/s00412-005-0329-5; Caira F, 2000, J BIOL CHEM, V275, P5308, DOI 10.1074/jbc.275.8.5308; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chang TC, 2004, GENE DEV, V18, P2010, DOI 10.1101/gad.1219104; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen JJ, 2001, J MOL BIOL, V314, P683, DOI 10.1006/jmbi.2001.5162; Chen JJ, 2002, EMBO J, V21, P1414, DOI 10.1093/emboj/21.6.1414; Chen YH, 2006, CANCER RES, V66, P8749, DOI 10.1158/0008-5472.CAN-06-0581; Collart MA, 2004, PROG NUCLEIC ACID RE, V77, P289, DOI 10.1016/S0079-6603(04)77008-7; COLLART MA, 1994, GENE DEV, V8, P525, DOI 10.1101/gad.8.5.525; DENIS CL, 1984, GENETICS, V108, P833; Dupressoir A, 2001, BMC Genomics, V2, P9, DOI 10.1186/1471-2164-2-9; Flamant F, 2007, MOL ENDOCRINOL, V21, P321, DOI 10.1210/me.2006-0035; Fu MF, 2004, BIOCHEM PHARMACOL, V68, P1199, DOI 10.1016/j.bcp.2004.05.037; Garces RG, 2007, PROTEIN SCI, V16, P176, DOI 10.1110/ps.062600507; Ge K, 2002, NATURE, V417, P563, DOI 10.1038/417563a; Goodson Michael, 2005, Nucl Recept Signal, V3, pe003; Hadzic E, 1998, J BIOL CHEM, V273, P10270, DOI 10.1074/jbc.273.17.10270; Hager GL, 2004, BBA-GENE STRUCT EXPR, V1677, P46, DOI 10.1016/j.bbaexp.2003.09.016; Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037; Herdick M, 2000, J MOL BIOL, V304, P793, DOI 10.1006/jmbi.2000.4267; Hiroi N, 2002, EMBO J, V21, P5235, DOI 10.1093/emboj/cdf521; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hu X, 2000, TRENDS ENDOCRIN MET, V11, P6, DOI 10.1016/S1043-2760(99)00215-5; Inoue A, 2002, J MOL ENDOCRINOL, V29, P175, DOI 10.1677/jme.0.0290175; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Ito M, 2001, TRENDS ENDOCRIN MET, V12, P127, DOI 10.1016/S1043-2760(00)00355-6; Jayne S, 2006, BIOCHEM J, V398, P461, DOI 10.1042/BJ20060406; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kang YK, 2002, P NATL ACAD SCI USA, V99, P2642, DOI 10.1073/pnas.261715899; Kim H, 2005, ONCOGENE, V24, P5629, DOI 10.1038/sj.onc.1208718; Ko L, 2000, P NATL ACAD SCI USA, V97, P6212, DOI 10.1073/pnas.97.11.6212; Kuang SQ, 2002, J BIOL CHEM, V277, P45356, DOI 10.1074/jbc.C200509200; Lee SK, 1999, J BIOL CHEM, V274, P34283, DOI 10.1074/jbc.274.48.34283; Li DS, 2004, MOL CELL BIOL, V24, P3838, DOI 10.1128/MCB.24.9.3838-3848.2004; Li DS, 1999, MOL CELL BIOL, V19, P7191; Liu HY, 2001, J BIOL CHEM, V276, P7541, DOI 10.1074/jbc.M009112200; Liu HY, 1998, EMBO J, V17, P1096, DOI 10.1093/emboj/17.4.1096; Lonard DM, 2006, CELL, V125, P411, DOI 10.1016/j.cell.2006.04.021; Lonard DM, 2005, TRENDS BIOCHEM SCI, V30, P126, DOI 10.1016/j.tibs.2005.01.001; Mahajan MA, 2005, ENDOCR REV, V26, P583, DOI 10.1210/er.2004-0012; Mahajan MA, 2002, MOL CELL BIOL, V22, P6883, DOI 10.1128/MCB.22.19.6883-6894.2002; Mahajan MA, 2000, MOL CELL BIOL, V20, P5048, DOI 10.1128/MCB.20.14.5048-5063.2000; Mahajan MA, 2007, MOL ENDOCRINOL, V21, P1822, DOI 10.1210/me.2005-0529; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Morel AP, 2003, J CELL SCI, V116, P2929, DOI 10.1242/jcs.00480; Morita M, 2007, MOL CELL BIOL, V27, P4980, DOI 10.1128/MCB.02304-06; Nakamura T, 2004, NAT GENET, V36, P528, DOI 10.1038/ng1344; Okazaki N, 1998, MOL CELL BIOL, V18, P887, DOI 10.1128/MCB.18.2.887; ONATE SA, 1995, SCIENCE, V270, P1354; Prevot D, 2001, J BIOL CHEM, V276, P9640, DOI 10.1074/jbc.M008201200; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; Sharma D, 2002, P NATL ACAD SCI USA, V99, P7934, DOI 10.1073/pnas.122004799; Stallcup MR, 2003, J STEROID BIOCHEM, V85, P139, DOI 10.1016/S0960-0760(03)00222-X; Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; Tian HH, 2006, MOL ENDOCRINOL, V20, P2036, DOI 10.1210/me.2005-0437; Tucker M, 2001, CELL, V104, P377, DOI 10.1016/S0092-8674(01)00225-2; Ugai H, 1999, J MOL MED, V77, P481, DOI 10.1007/s001099900021; Urahama N, 2005, GENES CELLS, V10, P1127, DOI 10.1111/j.1365-2443.2005.00906.x; Warnmark A, 2003, MOL ENDOCRINOL, V17, P1901, DOI 10.1210/me.2002-0384; Winkler GS, 2006, EMBO J, V25, P3089, DOI 10.1038/sj.emboj.7601194; Xu JM, 2003, MOL ENDOCRINOL, V17, P1681, DOI 10.1210/me.2003-0116; Xu W, 2005, BIOCHEM CELL BIOL, V83, P418, DOI 10.1139/O05-057; Yoon HG, 2003, EMBO J, V22, P1336, DOI 10.1093/emboj/cdg120; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhang XT, 2005, MOL CELL, V19, P89, DOI 10.1016/j.molcel.2005.05.015; Zhu YJ, 2000, J BIOL CHEM, V275, P13510, DOI 10.1074/jbc.275.18.13510; Zwartjes CGM, 2004, J BIOL CHEM, V279, P10848, DOI 10.1074/jbc.M311747200	83	33	38	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					6806	6816		10.1074/jbc.M706986200	http://dx.doi.org/10.1074/jbc.M706986200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18180299	hybrid			2022-12-25	WOS:000253779600023
J	Hwang, SK; Nagai, Y; Kim, D; Okita, TW				Hwang, Seon-Kap; Nagai, Yasuko; Kim, Dongwook; Okita, Thomas W.			Direct appraisal of the potato tuber ADP-glucose pyrophosphorylase large subunit in enzyme function by study of a novel mutant form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTTRANSLATIONAL REDOX-MODIFICATION; ADPGLUCOSE PYROPHOSPHORYLASE; ESCHERICHIA-COLI; STARCH SYNTHESIS; CRYSTAL-STRUCTURE; MUTAGENESIS; ACTIVATION; SITE; MECHANISM; ACID	The higher plant ADP-glucose pyrophosphorylase is a heterotetramer consisting of two subunit types, which have evolved at different rates from a common ancestral gene. The potato tuber small subunit ( SS) displays both catalytic and regulatory properties, whereas the exact role of the large subunit (LS), which contains substrate and effector binding sites, remains unresolved. We identified a mutation, S302N, which increased the solubility of the recombinant potato tuber LS and, in turn, enabling it to form a homotetrameric structure. The LS302N homotetramer possesses very little enzyme activity at a level 100-fold less than that seen for the unactivated SS homotetramer. Unlike the SS enzyme, however, the LS302N homotetramer enzyme is neither activated by the effector 3-phosphoglycerate nor inhibited by Pi. When combined with the catalytically silenced SS, S-D143N, however, the LS302N-containing enzyme shows significantly enhanced catalytic activity and restored 3-PGA activation. This unmasking of catalytic and regulatory potential of the LS is conspicuously evident when the activities of the resurrected L-K41R.T51K.S302N homotetramer are compared with its heterotetrameric form assembled with S-D143N. Overall, these results indicate that the LS possesses catalytic and regulatory properties only when assembled with SS and that the net properties of the heterotetrameric enzyme is a product of subunit synergy.	[Hwang, Seon-Kap; Nagai, Yasuko; Kim, Dongwook; Okita, Thomas W.] Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA	Washington State University	Okita, TW (corresponding author), Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA.	okita@wsu.edu		Okita, Tom/0000-0002-2246-0599; Hwang, Paul/0000-0001-9552-5341				BALL K, 1994, J BIOL CHEM, V269, P24706; Ballicora MA, 2005, J BIOL CHEM, V280, P10189, DOI 10.1074/jbc.M413540200; Ballicora MA, 1998, PLANT PHYSIOL, V118, P265, DOI 10.1104/pp.118.1.265; Ballicora MA, 2004, PHOTOSYNTH RES, V79, P1, DOI 10.1023/B:PRES.0000011916.67519.58; Ballicora MA, 2000, J BIOL CHEM, V275, P1315, DOI 10.1074/jbc.275.2.1315; Blankenfeldt W, 2000, EMBO J, V19, P6652, DOI 10.1093/emboj/19.24.6652; Brown K, 1999, EMBO J, V18, P4096, DOI 10.1093/emboj/18.15.4096; Burger BT, 2003, PLANTA, V217, P449, DOI 10.1007/s00425-003-1000-0; Cross JM, 2004, PLANT PHYSIOL, V135, P137, DOI 10.1104/pp.103.036699; Doan DNP, 1999, PLANT PHYSIOL, V121, P965, DOI 10.1104/pp.121.3.965; Frueauf JB, 2003, PLANT J, V33, P503, DOI 10.1046/j.1365-313X.2003.01643.x; Frueauf JB, 2001, J BIOL CHEM, V276, P46319, DOI 10.1074/jbc.M107408200; Fu YB, 1998, PLANT PHYSIOL, V117, P989, DOI 10.1104/pp.117.3.989; Fu YB, 1998, J BIOL CHEM, V273, P25045, DOI 10.1074/jbc.273.39.25045; Geigenberger P, 2005, J EXP BOT, V56, P1469, DOI 10.1093/jxb/eri178; Georgelis N, 2007, PLANT CELL, V19, P1458, DOI 10.1105/tpc.106.049676; Gomez-Casati DF, 2000, ARCH BIOCHEM BIOPHYS, V384, P319, DOI 10.1006/abbi.2000.2101; Greene TW, 1998, P NATL ACAD SCI USA, V95, P10322, DOI 10.1073/pnas.95.17.10322; Greene TW, 1996, P NATL ACAD SCI USA, V93, P1509, DOI 10.1073/pnas.93.4.1509; Hendriks JHM, 2003, PLANT PHYSIOL, V133, P838, DOI 10.1104/pp.103.024513; Hwang SK, 2007, PHYTOCHEMISTRY, V68, P464, DOI 10.1016/j.phytochem.2006.11.027; Hwang SK, 2006, FEBS LETT, V580, P6741, DOI 10.1016/j.febslet.2006.11.029; Hwang SK, 2005, FEBS LETT, V579, P983, DOI 10.1016/j.febslet.2004.12.067; Hwang SK, 2004, PROTEIN EXPRES PURIF, V38, P99, DOI 10.1016/j.pep.2004.07.018; IGLESIAS AA, 1993, J BIOL CHEM, V268, P1081; Jin XS, 2005, EMBO J, V24, P694, DOI 10.1038/sj.emboj.7600551; Kolbe A, 2005, P NATL ACAD SCI USA, V102, P11118, DOI 10.1073/pnas.0503410102; LACOGNATA U, 1995, MOL GEN GENET, V246, P538, DOI 10.1007/BF00298960; OKITA TW, 1990, PLANT PHYSIOL, V93, P785, DOI 10.1104/pp.93.2.785; Salamone PR, 2000, FEBS LETT, V482, P113, DOI 10.1016/S0014-5793(00)01985-2; Salamone PR, 2002, P NATL ACAD SCI USA, V99, P1070, DOI 10.1073/pnas.012603799; Slattery CJ, 2000, TRENDS PLANT SCI, V5, P291, DOI 10.1016/S1360-1385(00)01657-5; Tiessen A, 2002, PLANT CELL, V14, P2191, DOI 10.1105/tpc.003640	33	25	26	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					6640	6647		10.1074/jbc.M707447200	http://dx.doi.org/10.1074/jbc.M707447200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18199755	hybrid			2022-12-25	WOS:000253779600005
J	Lyons, PJ; Callaway, MB; Fricker, LD				Lyons, Peter J.; Callaway, Myrasol B.; Fricker, Lloyd D.			Characterization of carboxypeptidase A6, an extracellular matrix peptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAST-CELL CARBOXYPEPTIDASE; DUANE-SYNDROME; RAT-BRAIN; NEUROTENSIN; GENE; ENKEPHALIN; INHIBITOR; REGION; IDENTIFICATION; DEGENERATION	Carboxypeptidase A6 (CPA6) is a member of the M14 metallocarboxypeptidase family that is highly expressed in the adult mouse olfactory bulb and broadly expressed in embryonic brain and other tissues. A disruption in the human CPA6 gene is linked to Duane syndrome, a defect in the abducens nerve/lateral rectus muscle connection. In this study the cellular distribution, processing, and substrate specificity of human CPA6 were investigated. The 50-kDa pro-CPA6 is routed through the constitutive secretory pathway, processed by furin or a furin-like enzyme into the 37-kDa active form, and secreted into the extracellular matrix. CPA6 cleaves the C-terminal residue from a range of substrates, including small synthetic substrates, larger peptides, and proteins. CPA6 has a preference for large hydrophobic C-terminal amino acids as well as histidine. Peptides with a penultimate glycine or proline are very poorly cleaved. Several neuropeptides were found to be processed by CPA6, including Met- and Leu-enkephalin, angiotensin I, and neurotensin. Whereas CPA6 converts enkephalin and neurotensin into forms known to be inactive toward their receptors, CPA6 converts inactive angiotensin I into the biologically active angiotensin II. Taken together, these data suggest a role for CPA6 in the regulation of neuropeptides in the extracellular environment within the olfactory bulb and other parts of the brain.	[Lyons, Peter J.; Callaway, Myrasol B.; Fricker, Lloyd D.] Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Fricker, LD (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	fricker@aecom.yu.edu		Lyons, Peter/0000-0001-5214-5445	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051271] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004494] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-04494] Funding Source: Medline; NIDDK NIH HHS [DK-51271] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arolas JL, 2007, CURR PHARM DESIGN, V13, P349, DOI 10.2174/138161207780162980; AVILES FX, 1993, EUR J BIOCHEM, V211, P381, DOI 10.1111/j.1432-1033.1993.tb17561.x; Bennett GW, 1998, DEV BRAIN RES, V111, P189, DOI 10.1016/S0165-3806(98)00137-0; BOGAN N, 1982, NEUROSCIENCE, V7, P895, DOI 10.1016/0306-4522(82)90050-1; Bouma BN, 2006, ANN MED, V38, P378, DOI 10.1080/07853890600852898; Calabrese G, 2000, EUR J HUM GENET, V8, P319, DOI 10.1038/sj.ejhg.5200461; Calabrese G, 1998, EUR J HUM GENET, V6, P187, DOI 10.1038/sj.ejhg.5200173; Ciccotosto GD, 1999, J CELL BIOL, V144, P459, DOI 10.1083/jcb.144.3.459; COLE KR, 1991, BIOCHEMISTRY-US, V30, P648, DOI 10.1021/bi00217a009; Davila-Garcia M I, 1990, Adv Exp Med Biol, V265, P75; de la Vega MR, 2007, FASEB J, V21, P851, DOI 10.1096/fj.06-7330com; Doobay MF, 2007, AM J PHYSIOL-REG I, V292, pR373, DOI 10.1152/ajpregu.00292.2006; Escobar ML, 1997, BRAIN RES, V751, P330, DOI 10.1016/S0006-8993(96)01373-X; Fernandez-Gonzalez A, 2002, SCIENCE, V295, P1904, DOI 10.1126/science.1068912; Fontenele-Neto JD, 2005, MOL BRAIN RES, V137, P132, DOI 10.1016/j.molbrainres.2005.02.026; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; FRICKER LD, 2004, HDB PROTEOLYTIC ENZY, V1, P848; FRICKER LD, 2004, HDB PROTEOLYTIC ENZY, V1, P840; Fricker LD, 2007, ENDOCRINOLOGY, V148, P4185, DOI 10.1210/en.2007-0123; Garcia KC, 1997, P NATL ACAD SCI USA, V94, P13838, DOI 10.1073/pnas.94.25.13838; Geisler S, 2006, PEPTIDES, V27, P2364, DOI 10.1016/j.peptides.2006.03.037; GENAIN CP, 1985, J CLIN INVEST, V76, P1939, DOI 10.1172/JCI112191; Goodman R.R., 1983, P827; Gutowski NJ, 2000, EUR J NEUROL, V7, P145, DOI 10.1046/j.1468-1331.2000.00029.x; HAMBROOK JM, 1976, NATURE, V262, P782, DOI 10.1038/262782a0; Huang HJ, 1999, CANCER RES, V59, P2981; Kalinina E, 2007, FASEB J, V21, P836, DOI 10.1096/fj.06-7329com; Karamyan VT, 2007, REGUL PEPTIDES, V143, P15, DOI 10.1016/j.regpep.2007.03.006; Kitabgi P, 2006, PEPTIDES, V27, P2515, DOI 10.1016/j.peptides.2005.12.017; Lee M, 1999, BIOORGAN MED CHEM, V7, P1755, DOI 10.1016/S0968-0896(99)00110-8; Lundequist A, 2004, J BIOL CHEM, V279, P32339, DOI 10.1074/jbc.M405576200; MAZELLA J, 1988, J BIOL CHEM, V263, P144; MEEK JL, 1977, NEUROPHARMACOLOGY, V16, P151, DOI 10.1016/0028-3908(77)90064-8; MOLINA MA, 1994, J BIOL CHEM, V269, P21467; MOYSE E, 1987, NEUROSCIENCE, V22, P525, DOI 10.1016/0306-4522(87)90350-2; MULLEN RJ, 1976, P NATL ACAD SCI USA, V73, P208, DOI 10.1073/pnas.73.1.208; OLIANAS MC, 1992, MOL PHARMACOL, V42, P109; Pizzuti A, 2002, INVEST OPHTH VIS SCI, V43, P3609; Saavedra JM, 2005, CELL MOL NEUROBIOL, V25, P485, DOI 10.1007/s10571-005-4011-5; Seidah NG, 2002, ESSAYS BIOCHEM, V38, P79, DOI 10.1042/bse0380079; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; Thomas AG, 2006, ADV EXP MED BIOL, V576, P327; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Varlamov O, 1996, J BIOL CHEM, V271, P6077, DOI 10.1074/jbc.271.11.6077; VINCENT C, 1994, HUM MOL GENET, V3, P1859, DOI 10.1093/hmg/3.10.1859; VOGEL Z, 1977, FEBS LETT, V80, P332, DOI 10.1016/0014-5793(77)80469-9; Wei SW, 2002, J BIOL CHEM, V277, P14954, DOI 10.1074/jbc.M112254200	47	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					7054	7063		10.1074/jbc.M707680200	http://dx.doi.org/10.1074/jbc.M707680200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18178555	hybrid			2022-12-25	WOS:000253779600050
J	Machida, K; Kono-Okada, A; Hongo, K; Mizobata, T; Kawata, Y				Machida, Kodai; Kono-Okada, Akane; Hongo, Kunihiro; Mizobata, Tomohiro; Kawata, Yasushi			Hydrophilic residues (526)KNDAAD(531) in the flexible C-terminal region of the chaperonin GroEL are critical for substrate protein folding within the central cavity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI GROEL; MOLECULAR CHAPERONES; CRYSTAL-STRUCTURE; CRYOELECTRON MICROSCOPY; MALATE-DEHYDROGENASE; COMPLEX; INTERMEDIATE; ATP; POLYPEPTIDE; CIS	The final 23 residues in the C-terminal region of Escherichia coli GroEL are invisible in crystallographic analyses due to high flexibility. To probe the functional role of these residues in the chaperonin mechanism, we generated and characterized C-terminal truncated, double ring, and single ring mutants of GroEL. The ability to assist the refolding of substrate proteins rhodanese and malate dehydrogenase decreased suddenly when 23 amino acids were truncated, indicating that a sudden change in the environment within the central cavity had occurred. From further experiments and analyses of the hydropathy of the C-terminal region, we focused on the hydrophilicity of the sequence region (526)KNDAAD(531) and generated two GroEL mutants where these residues were changed to a neutral hydropathy sequence ((526)GGGAAG(531)) and a hydrophobic sequence ((526)IGIAAI(531)), respectively. Very interestingly, the two mutants were found to be defective in function both in vitro and in vivo. Deterioration of function was not observed in mutants where this region was replaced by a scrambled ((526)NKADDA(531)) or homologous ((526)RQEGGE(531)) sequence, indicating that the hydrophilicity of this sequence was important. These results highlight the importance of the hydrophilic nature of (526)KNDAAD(531) residues in the flexible C-terminal region for proper protein folding within the central cavity of GroEL.	Tottori Univ, Grad Sch Med Sci, Fac Engn, Dept Biotechnol, Tottori 6808552, Japan; Tottori Univ, Grad Sch Med Sci, Inst Regenerat Med & Biofunct, Dept Biomed Sci, Tottori 6808552, Japan	Tottori University; Tottori University	Kawata, Y (corresponding author), Tottori Univ, Grad Sch Med Sci, Fac Engn, Dept Biotechnol, Tottori 6808552, Japan.	kawata@bio.tottori-u.ac.jp	Kawata, Yasushi/ABA-9608-2021; Mizobata, Tomohiro/V-6672-2019	Mizobata, Tomohiro/0000-0002-7808-2099; Kawata, Yasushi/0000-0002-2744-1506				BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BURNETT BP, 1994, J BACTERIOL, V176, P6980, DOI 10.1128/JB.176.22.6980-6985.1994; Chaudhuri TK, 2001, CELL, V107, P235, DOI 10.1016/S0092-8674(01)00523-2; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; ELLIS RJ, 1994, CURR BIOL, V4, P633; Fairclough R H, 1978, Methods Enzymol, V48, P347; Falke S, 2005, J MOL BIOL, V348, P219, DOI 10.1016/j.jmb.2005.02.027; Fang YC, 2002, J BIOMED SCI, V9, P223; Farr GW, 2007, P NATL ACAD SCI USA, V104, P5342, DOI 10.1073/pnas.0700820104; Farr GW, 2003, EMBO J, V22, P3220, DOI 10.1093/emboj/cdg313; Fenton WA, 1997, PROTEIN SCI, V6, P743; GETHING MJ, 1992, NATURE, V355, P3; Getz EB, 1999, ANAL BIOCHEM, V273, P73, DOI 10.1006/abio.1999.4203; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hayer-Hartl M, 2000, METH MOL B, V140, P127; HOLLNEUGEBAUER B, 1991, BIOCHEMISTRY-US, V30, P11609; Horwich AL, 2006, CHEM REV, V106, P1917, DOI 10.1021/cr040435v; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; Inobe T, 2001, BBA-PROTEIN STRUCT M, V1545, P160, DOI 10.1016/S0167-4838(00)00274-0; Kawata Y, 1999, BIOCHEMISTRY-US, V38, P15731, DOI 10.1021/bi9909750; Koradi R, 1996, J MOL GRAPHICS, V14, P29; KUBO T, 1993, J BIOL CHEM, V268, P19346; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MCLENNAN NF, 1994, MOL MICROBIOL, V14, P309, DOI 10.1111/j.1365-2958.1994.tb01292.x; MCLENNAN NF, 1993, MOL MICROBIOL, V7, P49, DOI 10.1111/j.1365-2958.1993.tb01096.x; MILLER AD, 1993, BIOCHEM J, V291, P139, DOI 10.1042/bj2910139; Miyazaki T, 2002, J BIOL CHEM, V277, P50621, DOI 10.1074/jbc.M209183200; Motojima F, 2004, P NATL ACAD SCI USA, V101, P15005, DOI 10.1073/pnas.0406132101; Motojima F, 2003, J BIOL CHEM, V278, P26648, DOI 10.1074/jbc.M300806200; Ranson NA, 2006, NAT STRUCT MOL BIOL, V13, P147, DOI 10.1038/nsmb1046; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; Sakikawa C, 1999, J BIOL CHEM, V274, P21251, DOI 10.1074/jbc.274.30.21251; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; Taguchi H, 2004, J BIOL CHEM, V279, P45737, DOI 10.1074/jbc.M406795200; Tang YC, 2006, CELL, V125, P903, DOI 10.1016/j.cell.2006.04.027; Thiyagarajan P, 1996, STRUCTURE, V4, P79, DOI 10.1016/S0969-2126(96)00011-1; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; Wang JD, 1998, P NATL ACAD SCI USA, V95, P12163, DOI 10.1073/pnas.95.21.12163; Wang JD, 2002, CELL, V111, P1027, DOI 10.1016/S0092-8674(02)01198-4; Weber F, 1998, NAT STRUCT BIOL, V5, P977, DOI 10.1038/2952; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Yoshimi T, 2006, J BIOCHEM, V139, P407, DOI 10.1093/jb/mvj043	49	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					6886	6896		10.1074/jbc.M708002200	http://dx.doi.org/10.1074/jbc.M708002200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18184659	hybrid, Green Submitted			2022-12-25	WOS:000253779600032
J	Taylor, K; Clarke, DJ; McCullough, B; Chin, W; Seo, E; Yang, D; Oppenheim, J; Uhrin, D; Govan, JRW; Campopiano, DJ; MacMillan, D; Barran, P; Dorin, JR				Taylor, Karen; Clarke, David J.; McCullough, Bryan; Chin, Wutharath; Seo, Emily; Yang, De; Oppenheim, Joost; Uhrin, Dusan; Govan, John R. W.; Campopiano, Dominic J.; MacMillan, Derek; Barran, Perdita; Dorin, Julia R.			Analysis and separation of residues important for the chemoattractant and antimicrobial activities of beta-defensin 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-DEFENSINS; IMMATURE DENDRITIC CELLS; INDUCIBLE PEPTIDE; HOST-DEFENSE; CHEMOKINE; CCR6; IDENTIFICATION; RECEPTOR; INNATE; IMMUNITY	beta-Defensins are important in mammalian immunity displaying both antimicrobial and chemoattractant activities. Three canonical disulfide intramolecular bonds are believed to be dispensable for antimicrobial activity but essential for chemoattractant ability. However, here we show that HBD3 ( human beta-defensin 3) alkylated with iodoactemide and devoid of any disulfide bonds is still a potent chemoattractant. Furthermore, when the canonical six cysteine residues are replaced with alanine, the peptide is no longer active as a chemoattractant. These findings are replicated by the murine ortholog Defb14. We restore the chemoattractant activity of Defb14 and HBD3 by introduction of a single cysteine in the fifth position (Cys(V)) of the beta-defensin six cysteine motif. In contrast, a peptide with a single cysteine at the first position (Cys(I)) is inactive. Moreover, a range of overlapping linear fragments of Defb14 do not act as chemoattractants, suggesting that the chemotactic activity of this peptide is not dependent solely on an epitope surrounding Cys(V). Full-length peptides either with alkylated cysteine residues or with cysteine residues replaced with alanine are still strongly antimicrobial. Defb14 peptide fragments were also tested for antimicrobial activity, and peptides derived from the N-terminal region display potent antimicrobial activity. Thus, the chemoattractant and antimicrobial activities of beta-defensins can be separated, and both of these functions are independent of intramolecular disulfide bonds. These findings are important for further understanding of the mechanism of action of defensins and for therapeutic design.	[Taylor, Karen; Dorin, Julia R.] Western Gen Hosp, MRC, Human Res Unit, Edinburgh EH4 2XU, Midlothian, Scotland; [Clarke, David J.; McCullough, Bryan; Chin, Wutharath; Seo, Emily; Uhrin, Dusan; Campopiano, Dominic J.; Barran, Perdita] Univ Edinburgh, Sch Chem, Edinburgh EH9 3JJ, Midlothian, Scotland; [Yang, De; Oppenheim, Joost] NCI Frederick, NIH, Sci Applicat & Int Cooperat Inc, Ctr Canc Res,Lab Mol Immunoregulat, Frederick, MD 21702 USA; [Govan, John R. W.] Univ Edinburgh, Cyst Fibrosis Lab, Edinburgh EH16 4SB, Midlothian, Scotland; [MacMillan, Derek] UCL, Christopher Ingold Labs, Dept Chem, London WC1H 0AJ, England	University of Edinburgh; University of Edinburgh; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); University of Edinburgh; University of London; University College London	Dorin, JR (corresponding author), Western Gen Hosp, MRC, Human Res Unit, Edinburgh EH4 2XU, Midlothian, Scotland.	julia.dorin@hgu.mrc.ac.uk	Barran, Perdita/AAY-6303-2021	Clarke, David/0000-0002-3741-2952; Campopiano, Dominic/0000-0001-8573-6735; Barran, Perdita/0000-0002-7720-586X	MRC [MC_U127527201] Funding Source: UKRI; Engineering and Physical Sciences Research Council [GR/S77639/01, EP/C541561/1] Funding Source: researchfish; Medical Research Council [MC_U127527201] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ali MF, 2001, BBA-PROTEIN STRUCT M, V1550, P81, DOI 10.1016/S0167-4838(01)00272-2; Baba M, 1997, J BIOL CHEM, V272, P14893, DOI 10.1074/jbc.272.23.14893; Bauer F, 2001, PROTEIN SCI, V10, P2470, DOI 10.1110/ps.ps.24401; Biragyn A, 2001, J IMMUNOL, V167, P6644, DOI 10.4049/jimmunol.167.11.6644; Bohling A, 2006, BIOCHEMISTRY-US, V45, P5663, DOI 10.1021/bi052026e; Boniotto M, 2003, BIOCHEM J, V374, P707, DOI 10.1042/BJ20030528; Campopiano DJ, 2004, J BIOL CHEM, V279, P48671, DOI 10.1074/jbc.M404690200; Conejo-Garcia JR, 2004, NAT MED, V10, P950, DOI 10.1038/nm1097; Garcia JRC, 2001, FASEB J, V15, P1819, DOI 10.1096/fj.00-0865fje; Garcia JRC, 2001, CELL TISSUE RES, V306, P257, DOI 10.1007/s004410100433; Harder J, 2001, J BIOL CHEM, V276, P5707, DOI 10.1074/jbc.M008557200; Hoover DM, 2000, J BIOL CHEM, V275, P32911, DOI 10.1074/jbc.M006098200; Hoover DM, 2001, J BIOL CHEM, V276, P39021, DOI 10.1074/jbc.M103830200; Hoover DM, 2003, ANTIMICROB AGENTS CH, V47, P2804, DOI 10.1128/AAC.47.9.2804-2809.2003; HOOVER DM, 2002, J BIOL CHEM; HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047; Jacoby E, 2006, CHEMMEDCHEM, V1, P760, DOI 10.1002/cmdc.200600134; Jia HP, 2001, GENE, V263, P211; Kluver E, 2005, BIOCHEMISTRY-US, V44, P9804, DOI 10.1021/bi050272k; Lehrer RI, 2004, NAT REV MICROBIOL, V2, P727, DOI 10.1038/nrmicro976; Maemoto A, 2004, J BIOL CHEM, V279, P44188, DOI 10.1074/jbc.M406154200; Malik ZA, 2006, ACTA CRYSTALLOGR F, V62, P631, DOI 10.1107/S1744309106006890; Morrison G, 2002, INFECT IMMUN, V70, P3053, DOI 10.1128/IAI.70.6.3053-3060.2002; Morrison GM, 2002, MAMM GENOME, V13, P445, DOI 10.1007/s00335-002-3014-5; Pazgier M, 2006, CELL MOL LIFE SCI, V63, P1294, DOI 10.1007/s00018-005-5540-2; PAZGIER M, 2006, J BIOL CHEM; Salzman NH, 2003, NATURE, V422, P522, DOI 10.1038/nature01520; Sawai MV, 2001, BIOCHEMISTRY-US, V40, P3810, DOI 10.1021/bi002519d; Schibli DJ, 2002, J BIOL CHEM, V277, P8279, DOI 10.1074/jbc.M108830200; Schutyser E, 2003, CYTOKINE GROWTH F R, V14, P409, DOI 10.1016/S1359-6101(03)00049-2; Semple CAM, 2005, BMC EVOL BIOL, V5, DOI 10.1186/1471-2148-5-32; Semple CA, 2006, MOL DIVERS, V10, P575, DOI 10.1007/s11030-006-9031-7; Sorensen OE, 2005, J IMMUNOL, V174, P4870, DOI 10.4049/jimmunol.174.8.4870; Soruri A, 2007, EUR J IMMUNOL, V37, P2474, DOI 10.1002/eji.200737292; Taylor K, 2007, ANTIMICROB AGENTS CH, V51, P1719, DOI 10.1128/AAC.01531-06; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; Wu ZB, 2003, P NATL ACAD SCI USA, V100, P8880, DOI 10.1073/pnas.1533186100; Yang D, 2000, J LEUKOCYTE BIOL, V68, P9; Yang D, 1999, J IMMUNOL, V163, P1737; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525	41	78	81	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					6631	6639		10.1074/jbc.M709238200	http://dx.doi.org/10.1074/jbc.M709238200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18180295	hybrid			2022-12-25	WOS:000253779600004
J	Oxmann, D; Held-Feindt, J; Stark, AM; Hattermann, K; Yoneda, T; Mentlein, R				Oxmann, D.; Held-Feindt, J.; Stark, A. M.; Hattermann, K.; Yoneda, T.; Mentlein, R.			Endoglin expression in metastatic breast cancer cells enhances their invasive phenotype	ONCOGENE			English	Article						breast cancer; metastasis; brain; tumor invasion; growth factor receptor	DIFFERENTIAL EXPRESSION; BRAIN-SEEKING; TGF-BETA; COMPLEX; CD105	Endoglin is a cell-surface adhesion protein as well as a coreceptor for transforming growth factor-beta (TGF-beta). It is located on endothelial and few other cells, but also found on certain tumor cells. Brain metastatic breast tumor cells derived from the MDA-MB-231 cell line heavily express endoglin in contrast to the corresponding parental ones. To clarify whether this determines their invasive phenotype, we compared their biological properties with endoglin-silenced brain-metastatic cells, low-expressing parental cells and these transfected with L- and S-endoglins, isoforms transducing or lacking TGF-beta signals. All L-endoglin-overexpressing cells were characterized by numerous invadopodia where endoglin was preferentially localized. Endoglin-expression resulted in elevated levels of the matrix metalloproteinases (MMP-1 and MMP-19) and downregulation of the plasminogen activator inhibitor-1. In Boyden-chamber and wound-healing assays, endoglin-overexpressing cells showed a considerably higher migration and chemotaxis to TGF-beta. In 3D spheroid confrontation assays between breast tumor cells and TGF-beta-secreting glioma cells, high L-endoglin-expressing cells invaded into the glioma-spheroids whereas low-endoglin-expressing cells dissociated in the culture; invasion was blocked by TGF-beta antibodies. In contrast to parental cells, endoglin-overexpressing cells invaded deeply into mouse brain slices. Thus, endoglin expression on tumor cells enhances their invasive character by formation of invadopodia, extracellular proteolysis, chemotaxis and migration.	[Oxmann, D.; Hattermann, K.; Mentlein, R.] Univ Kiel, Dept Anat, D-24098 Kiel, Germany; [Held-Feindt, J.; Stark, A. M.] Univ Klinikum Schleswig Holstein, Dept Neurosurg, Kiel, Germany; [Yoneda, T.] Univ Texas Hlth Sci Ctr San Antonio, Div Endocrinol & Metab, San Antonio, TX 78229 USA	University of Kiel; University of Kiel; Schleswig Holstein University Hospital; University of Texas System; University of Texas Health San Antonio	Mentlein, R (corresponding author), Univ Kiel, Dept Anat, Olshausenstr 40, D-24098 Kiel, Germany.	rment@anat.uni-kiel.de	Mentlein, Rolf/B-1613-2010; Hattermann, Kirsten/E-8043-2010; Held-Feindt, Janka/E-4690-2010	Mentlein, Rolf/0000-0002-6350-3911; 				Andre F, 2006, ANN ONCOL, V17, P945, DOI 10.1093/annonc/mdl053; Beck IM, 2007, J INVEST DERMATOL, V127, P1107, DOI 10.1038/sj.jid.5700674; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Djonov V, 2001, J PATHOL, V195, P147, DOI 10.1002/path.927; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Fonsatti E, 2003, ONCOGENE, V22, P6557, DOI 10.1038/sj.onc.1206813; Fonsatti E, 2001, J CELL PHYSIOL, V188, P1, DOI 10.1002/jcp.1095; Forstreuter F, 2002, J NEUROIMMUNOL, V132, P93, DOI 10.1016/S0165-5728(02)00315-6; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; Held-Feindt J, 2003, J NEURO-ONCOL, V63, P117, DOI 10.1023/A:1023943405292; Kousidou OC, 2004, ANTICANCER RES, V24, P4025; LASTRES P, 1994, BIOCHEM J, V301, P765, DOI 10.1042/bj3010765; Ludwig A, 2005, J NEUROCHEM, V93, P1293, DOI 10.1111/j.1471-4159.2005.03123.x; Mazar A P, 1999, Angiogenesis, V3, P15, DOI 10.1023/A:1009095825561; Mentlein R, 2004, J NEURO-ONCOL, V67, P9, DOI 10.1023/B:NEON.0000021737.89357.cc; Munoz-Najar UM, 2006, ONCOGENE, V25, P2379, DOI 10.1038/sj.onc.1209273; Palmieri D, 2007, CANCER RES, V67, P4190, DOI 10.1158/0008-5472.CAN-06-3316; Postiglione L, 2005, INT J ONCOL, V26, P1193; Stark AM, 2005, NEUROSURG REV, V28, P115, DOI 10.1007/s10143-004-0364-3; Stark AM, 2007, J NEURO-ONCOL, V81, P39, DOI 10.1007/s11060-006-9207-0; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Weaver AM, 2006, CLIN EXP METASTAS, V23, P97, DOI 10.1007/s10585-006-9014-1; Weil RJ, 2005, AM J PATHOL, V167, P913, DOI 10.1016/S0002-9440(10)61180-7; Yoneda T, 2001, J BONE MINER RES, V16, P1486, DOI 10.1359/jbmr.2001.16.8.1486	26	60	69	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2008	27	25					3567	3575		10.1038/sj.onc.1211025	http://dx.doi.org/10.1038/sj.onc.1211025			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18223685				2022-12-25	WOS:000256468500008
J	Gao, L; Hanson, MN; Balakrishnan, M; Boyer, PL; Roques, BP; Hughes, SH; Kim, B; Bambara, RA				Gao, Lu; Hanson, Mark Nils; Balakrishnan, Mini; Boyer, Paul L.; Roques, Bernard P.; Hughes, Stephen H.; Kim, Baek; Bambara, Robert A.			Apparent defects in processive DNA synthesis, strand transfer, and primer elongation of met-184 mutants of HIV-1 reverse transcriptase derive solely from a dNTP utilization defect	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MURINE LEUKEMIA-VIRUS; HIGH-LEVEL RESISTANCE; IN-VITRO; RNASE-H; GENETIC-RECOMBINATION; STERIC HINDRANCE; DRUG-RESISTANCE; 3TC RESISTANCE; WILD-TYPE	The 2', 3'-dideoxy-3'-thiacytidine drug-resistant M184I HIV-1 reverse transcriptase (RT) has been shown to synthesize DNA with decreased processivity compared with the wild-type RT. M184A displays an even more severe processivity defect. However, the basis of this decreased processivity has been unclear, and both primer-template binding and dNTP interaction defects have been proposed to account for it. In this study, we show that the altered properties of the M184I and M184A RT mutants that we have measured, including decreased processivity, a slower rate of primer extension, and increased strand transfer activity, can all be explained by a defect in dNTP utilization. These alterations are observed only at low dNTP concentration and vanish as the dNTP concentration is raised. The mutant RTs exhibit a normal dissociation rate from a DNA primer-RNA template while paused during synthesis. Slower than normal synthesis at physiological dNTP concentration, coupled with normal dissociation from the primer-template, results in the lowered processivity. The mutant RTs exhibit normal DNA 3'-end-directed and RNA 5'-end-directed ribonuclease H activity. The reduced rate of DNA synthesis causes an increase in the ratio of ribonuclease H to polymerase activity thereby promoting increased strand transfer. These latter results are consistent with an observed higher rate of recombination by HIV-1 strains with Met-184 mutations.	[Gao, Lu; Hanson, Mark Nils; Balakrishnan, Mini; Bambara, Robert A.] Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA; [Kim, Baek] Univ Rochester, Med Ctr, Dept Microbiol & Immunol, Rochester, NY 14642 USA; [Boyer, Paul L.; Hughes, Stephen H.] NCI, NIH, HIV Drug Resistance Program, Frederick, MD 21702 USA; Univ Paris 05, CNRS, UFR Sci Pharmaceut & Biol,UMR 8600, Unite Pharmacochim Mol & Struct,INSERM U266, F-75270 Paris 06, France	University of Rochester; University of Rochester; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Bambara, RA (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Box 712,601 Elmwood Ave, Rochester, NY 14642 USA.	Robert_Bambara@urmc.rochester.edu			NATIONAL CANCER INSTITUTE [ZIABC010481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049573] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NIGMS NIH HHS [GM 49573] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Back NKT, 1997, ANTIMICROB AGENTS CH, V41, P2484, DOI 10.1128/AAC.41.11.2484; Back NKT, 1996, EMBO J, V15, P4040, DOI 10.1002/j.1460-2075.1996.tb00777.x; Balakrishnan M, 2001, J BIOL CHEM, V276, P36482, DOI 10.1074/jbc.M102860200; BAMBARA RA, 1978, J BIOL CHEM, V253, P413; BOUCHER CAB, 1993, ANTIMICROB AGENTS CH, V37, P2231, DOI 10.1128/AAC.37.10.2231; Boyer PL, 2001, J VIROL, V75, P6321, DOI 10.1128/JVI.75.14.6321-6328.2001; BOYER PL, 1995, ANTIMICROB AGENTS CH, V39, P1624, DOI 10.1128/AAC.39.7.1624; CLAVEL F, 1989, J VIROL, V63, P1455, DOI 10.1128/JVI.63.3.1455-1459.1989; DEROCQUIGNY H, 1991, BIOCHEM BIOPH RES CO, V180, P1010, DOI 10.1016/S0006-291X(05)81166-0; DESTEFANO JJ, 1993, BIOCHEMISTRY-US, V32, P6908, DOI 10.1021/bi00078a014; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; Diamond TL, 2004, J BIOL CHEM, V279, P51545, DOI 10.1074/jbc.M408573200; Feng JY, 1999, BIOCHEMISTRY-US, V38, P9440, DOI 10.1021/bi990709m; Fuentes GM, 1996, J BIOL CHEM, V271, P1966, DOI 10.1074/jbc.271.4.2063; Gao HQ, 1998, J MOL BIOL, V277, P559, DOI 10.1006/jmbi.1998.1624; Gao HQ, 2000, J MOL BIOL, V300, P403, DOI 10.1006/jmbi.2000.3823; GAO Q, 1993, ANTIMICROB AGENTS CH, V37, P1390, DOI 10.1128/AAC.37.6.1390; Halvas EK, 2000, J VIROL, V74, P6669, DOI 10.1128/JVI.74.14.6669-6674.2000; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Jamburuthugoda VK, 2008, J BIOL CHEM, V283, P9206, DOI 10.1074/jbc.M710149200; Julias JG, 2004, VIROLOGY, V322, P13, DOI 10.1016/j.virol.2004.01.004; Kew Y, 1998, J BIOL CHEM, V273, P7529, DOI 10.1074/jbc.273.13.7529; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; Nikolenko GN, 2004, J VIROL, V78, P8761, DOI 10.1128/JVI.78.16.8761-8770.2004; Operario DJ, 2006, J BIOL CHEM, V281, P32113, DOI 10.1074/jbc.M604665200; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; Ray AS, 2002, ANTIVIR RES, V56, P189, DOI 10.1016/S0166-3542(02)00102-X; Sarafianos SG, 1999, P NATL ACAD SCI USA, V96, P10027, DOI 10.1073/pnas.96.18.10027; Sharma PL, 1999, J VIROL, V73, P8448, DOI 10.1128/JVI.73.10.8448-8456.1999; Skasko M, 2005, J BIOL CHEM, V280, P12190, DOI 10.1074/jbc.M412859200; Song M, 2006, J BIOL CHEM, V281, P24227, DOI 10.1074/jbc.M603097200; Svarovskaia ES, 2000, J VIROL, V74, P7171, DOI 10.1128/JVI.74.15.7171-7178.2000; TANESE N, 1991, J VIROL, V65, P4387, DOI 10.1128/JVI.65.8.4387-4397.1991; Telesnitsky A., 1997, P121; TELESNITSKY A, 1990, P NATL ACAD SCI USA, V87, P2052; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; Wilson JE, 1996, J BIOL CHEM, V271, P13656, DOI 10.1074/jbc.271.23.13656; Wisniewski M, 2000, P NATL ACAD SCI USA, V97, P11978, DOI 10.1073/pnas.210392297	40	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9196	9205		10.1074/jbc.M710148200	http://dx.doi.org/10.1074/jbc.M710148200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18218634	Green Published, hybrid			2022-12-25	WOS:000254465800049
J	McAndrew, RP; Wang, YD; Mohsen, AW; He, M; Vockley, J; Kim, JJP				McAndrew, Ryan P.; Wang, Yudong; Mohsen, Al-Walid; He, Miao; Vockley, Jerry; Kim, Jung-Ja P.			Structural basis for substrate fatty acyl chain specificity - Crystal structure of human very-long-chain acyl-CoA dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; COENZYME-A DEHYDROGENASE; BETA-OXIDATION; 3-DIMENSIONAL STRUCTURE; CATALYTIC BASE; WILD-TYPE; ACID; PURIFICATION; DEFICIENCY; COMPLEX	Very-long-chain acyl-CoA dehydrogenase (VLCAD) is a member of the family of acyl-CoA dehydrogenases (ACADs). Unlike the other ACADs, which are soluble homotetramers, VLCAD is a homodimer associated with the mitochondrial membrane. VLCAD also possesses an additional 180 residues in the C terminus that are not present in the other ACADs. We have determined the crystal structure of VLCAD complexed with myristoyl-CoA, obtained by co-crystallization, to 1.91-A resolution. The overall fold of the N-terminal similar to 400 residues of VLCAD is similar to that of the soluble ACADs including medium-chain acyl-CoA dehydrogenase (MCAD). The novel C-terminal domain forms an alpha-helical bundle that is positioned perpendicular to the two N-terminal helical domains. The fatty acyl moiety of the bound substrate/product is deeply imbedded inside the protein; however, the adenosine pyrophosphate portion of the C14-CoA ligand is disordered because of partial hydrolysis of the thioester bond and high mobility of the CoA moiety. The location of Glu-422 with respect to the C2-C3 of the bound ligand and FAD confirms Glu-422 to be the catalytic base. In MCAD, Gln-95 and Glu-99 form the base of the substrate binding cavity. In VLCAD, these residues are glycines (Gly-175 and Gly-178), allowing the binding channel to extend for an additional 12 angstrom and permitting substrate acyl chain lengths as long as 24 carbons to bind. VLCAD deficiency is among the more common defects of mitochondrial beta-oxidation and, if left undiagnosed, can be fatal. This structure allows us to gain insight into how a variant VLCAD genotype results in a clinical phenotype.	[McAndrew, Ryan P.; Kim, Jung-Ja P.] Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; [Wang, Yudong; Mohsen, Al-Walid; He, Miao; Vockley, Jerry] Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Dept Pediat, Pittsburgh, PA 15213 USA	Medical College of Wisconsin; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kim, JJP (corresponding author), Med Coll Wisconsin, Dept Biochem, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	jjkim@mcw.edu	Vockley, Jerry/B-5210-2016; Mohsen, Al-Walid/D-6577-2018; Wang, Yudong/ABG-1086-2021; Vockley, Jerry/AAF-8523-2020	Vockley, Jerry/0000-0002-8180-6457; Mohsen, Al-Walid/0000-0002-0096-5959; Wang, Yudong/0000-0003-3224-4555; Vockley, Jerry/0000-0002-8180-6457	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029076] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 29076] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andresen BS, 1999, AM J HUM GENET, V64, P479, DOI 10.1086/302261; AOYAMA T, 1995, J CLIN INVEST, V95, P2465, DOI 10.1172/JCI117947; AOYAMA T, 1993, BIOCHEM BIOPH RES CO, V191, P1369, DOI 10.1006/bbrc.1993.1368; Battaile KP, 2004, J BIOL CHEM, V279, P16526, DOI 10.1074/jbc.M400034200; Battaile KP, 2002, J BIOL CHEM, V277, P12200, DOI 10.1074/jbc.M111296200; Beinert H., 1963, ENZYMES, P447; BROSS P, 1990, J BIOL CHEM, V265, P7116; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; CRANE FL, 1956, J BIOL CHEM, V218, P717; DeLano WL, 2002, PYMOL USERS MANUAL; DJORDJEVIC S, 1994, BIOCHEMISTRY-US, V33, P4258, DOI 10.1021/bi00180a021; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Ensenauer R, 2005, J BIOL CHEM, V280, P32309, DOI 10.1074/jbc.M504460200; FRERMAN FE, 1985, BIOCHEM MED METAB B, V33, P38, DOI 10.1016/0006-2944(85)90124-3; Fu ZJ, 2004, BIOCHEMISTRY-US, V43, P9674, DOI 10.1021/bi049290c; GARLAND PB, 1965, BIOCHEM J, V97, P587, DOI 10.1042/bj0970587; GHISLA S, 1984, BIOCHEMISTRY-US, V23, P3154, DOI 10.1021/bi00309a008; Goetzman ES, 2007, MOL GENET METAB, V91, P138, DOI 10.1016/j.ymgme.2007.01.013; Gregersen N, 2001, HUM MUTAT, V18, P169, DOI 10.1002/humu.1174.abs; Greville G D, 1968, Essays Biochem, V4, P155; Hanley PJ, 2003, J PHYSIOL-LONDON, V547, P387, DOI 10.1113/jphysiol.2002.037044; HOWARD AJ, 2000, CRYSTALLOGRAPHIC COM, V7; IKEDA Y, 1985, J BIOL CHEM, V260, P1311; IZAI K, 1992, J BIOL CHEM, V267, P1027; Kim JJP, 2004, EUR J BIOCHEM, V271, P483, DOI 10.1046/j.1432-1033.2003.03948.x; KIM JJP, 1993, P NATL ACAD SCI USA, V90, P7523, DOI 10.1073/pnas.90.16.7523; KUMAR NR, 1996, FLAVIN FLAVOPROTEINS, P633; Le WP, 2000, BBA-MOL CELL BIOL L, V1485, P121, DOI 10.1016/S1388-1981(00)00034-2; Lee HJ, 1996, BIOCHEMISTRY-US, V35, P12412, DOI 10.1021/bi9607867; Malkowski MG, 2000, SCIENCE, V289, P1933, DOI 10.1126/science.289.5486.1933; MATSUBARA Y, 1989, J BIOL CHEM, V264, P16321; MCANDREW RP, 2007, FASEB J, V649, P649; McPherson A., 1999, CRYSTALLIZATION BIOL; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nakajima Y, 2002, J BIOCHEM, V131, P365, DOI 10.1093/oxfordjournals.jbchem.a003111; Nina M, 2000, EUR BIOPHYS J BIOPHY, V29, P439, DOI 10.1007/PL00006649; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; RUZICKA FJ, 1977, J BIOL CHEM, V252, P8440; Satoh A, 2003, J BIOCHEM, V134, P297, DOI 10.1093/jb/mvg143; Souri M, 1998, EUR J BIOCHEM, V257, P592, DOI 10.1046/j.1432-1327.1998.2570592.x; Souri M, 1998, J BIOL CHEM, V273, P4227, DOI 10.1074/jbc.273.7.4227; Souri M, 1998, FEBS LETT, V426, P187, DOI 10.1016/S0014-5793(98)00343-3; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tiffany KA, 1997, BIOCHEMISTRY-US, V36, P8455, DOI 10.1021/bi970422u; Tokuoka K, 2006, J BIOCHEM, V139, P789, DOI 10.1093/jb/mvj088; TRIEVEL RC, 1995, BIOCHEMISTRY-US, V34, P8597, DOI 10.1021/bi00027a009; Wendt KU, 1997, SCIENCE, V277, P1811, DOI 10.1126/science.277.5333.1811; Zhang J, 2002, BIOCHEM BIOPH RES CO, V297, P1033, DOI 10.1016/S0006-291X(02)02336-7	51	75	92	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9435	9443		10.1074/jbc.M709135200	http://dx.doi.org/10.1074/jbc.M709135200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18227065	hybrid, Green Published			2022-12-25	WOS:000254465800073
J	Suzuki, N; Bajad, S; Shuman, J; Shulaev, V; Mittler, R				Suzuki, Nobuhiro; Bajad, Sunil; Shuman, Joel; Shulaev, Vladimir; Mittler, Ron			The transcriptional co-activator MBF1c is a key regulator of thermotolerance in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC ASCORBATE PEROXIDASE-1; FINGER PROTEIN ZAT12; SALICYLIC-ACID; TEMPERATURE-STRESS; REACTIVE OXYGEN; ABSCISIC-ACID; CELL-DEATH; HEAT; EXPRESSION; DEFENSE	The ability of an organism to acclimate to its environment is a key determinant in its global distribution and capacity to compete with other organisms. The heat stress response, a highly conserved environmental and developmental program in eukaryotic and prokaryotic organisms, is an important component of the acclimation response of plants. Previous studies have shown that heat shock transcription factors play an important role in thermotolerance in plants and other organisms, controlling the expression of different heat shock proteins and detoxifying enzymes. In contrast, although several other pathways, involving ethylene, salicylic acid ( SA), and trehalose, were recently shown to play a central role in thermotolerance in plants, a key regulator of these responses was not identified. Here we report that the highly conserved transcriptional coactivator, MBF1c ( multiprotein bridging factor 1c), is a key regulator of thermotolerance in Arabidopsis thaliana. MBF1c protein accumulates rapidly and is localized to nuclei during heat stress. MBF1c is required for thermotolerance and functions upstream to SA, trehalose, ethylene, and pathogenesis-related protein 1 during heat stress. In contrast, MBF1c is not required for the expression of transcripts encoding HSFA2 and different heat shock proteins. Interestingly, MBF1c interacts with TPS5 ( trehalose phosphate synthase 5), which is also heat-inducible, and mutants deficient in TPS5 are thermosensitive. Our results provide evidence for the existence of a tightly coordinated heat stress-response network, involving trehalose- ,SA-, and ethylene-signaling pathways, that is under the control of MBF1c.	[Suzuki, Nobuhiro; Mittler, Ron] Univ Nevada, Dept Biochem & Mol Biol, Reno, NV 89557 USA; [Bajad, Sunil; Shuman, Joel; Shulaev, Vladimir] Virginia Tech, Virginia Bioinformat Inst, Blacksburg, VA 24061 USA; [Mittler, Ron] Hebrew Univ Jerusalem, Dept Plant Sci, IL-91904 Jerusalem, Israel	Nevada System of Higher Education (NSHE); University of Nevada Reno; Virginia Polytechnic Institute & State University; Hebrew University of Jerusalem	Mittler, R (corresponding author), Univ Nevada, Dept Biochem & Mol Biol, MS200, Reno, NV 89557 USA.	ronm@unr.edu	Suzuki, Nobuhiro/Y-2851-2019; Mittler, Ron/ABE-6496-2020	Suzuki, Nobuhiro/0000-0002-0225-1597	NCRR NIH HHS [P20 RR 016464] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016464] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Avonce N, 2004, PLANT PHYSIOL, V136, P3649, DOI 10.1104/pp.104.052084; Avonce N, 2006, BMC EVOL BIOL, V6, DOI 10.1186/1471-2148-6-109; Baniwal SK, 2004, J BIOSCIENCES, V29, P471, DOI 10.1007/BF02712120; Brendel C, 2002, MOL ENDOCRINOL, V16, P1367, DOI 10.1210/me.16.6.1367; Busk PK, 2003, EXP CELL RES, V286, P102, DOI 10.1016/S0014-4827(03)00091-0; Cancel JD, 2002, PLANT PHYSIOL, V129, P1557, DOI 10.1104/pp.003780; Ciftci-Yilmaz S, 2007, J BIOL CHEM, V282, P9260, DOI 10.1074/jbc.M611093200; Clarke SM, 2004, PLANT J, V38, P432, DOI 10.1111/j.1365-313X.2004.02054.x; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; Davletova S, 2005, PLANT CELL, V17, P268, DOI 10.1105/tpc.104.026971; Davletova S, 2005, PLANT PHYSIOL, V139, P847, DOI 10.1104/pp.105.068254; Eastmond PJ, 2003, CURR OPIN PLANT BIOL, V6, P231, DOI 10.1016/S1369-5266(03)00037-2; Elbein AD, 2003, GLYCOBIOLOGY, V13, p17R, DOI 10.1093/glycob/cwg047; Gancedo C, 2004, FEMS YEAST RES, V4, P351, DOI 10.1016/S1567-1356(03)00222-8; Grennan AK, 2007, PLANT PHYSIOL, V144, P3, DOI 10.1104/pp.104.900223; Iba K, 2002, ANNU REV PLANT BIOL, V53, P225, DOI 10.1146/annurev.arplant.53.100201.160729; Kaminaka H, 2006, EMBO J, V25, P4400, DOI 10.1038/sj.emboj.7601312; Kaplan F, 2004, PLANT PHYSIOL, V136, P4159, DOI 10.1104/pp.104.052142; Kotak S, 2007, PLANT CELL, V19, P182, DOI 10.1105/tpc.106.048165; Larkindale J, 2005, PLANT PHYSIOL, V138, P882, DOI 10.1104/pp.105.062257; Larkindale J, 2002, PLANT PHYSIOL, V128, P682, DOI 10.1104/pp.010320; Leyman B, 2001, TRENDS PLANT SCI, V6, P510, DOI 10.1016/S1360-1385(01)02125-2; Lindquist S, 1992, CURR OPIN GENET DEV, V2, P748, DOI 10.1016/S0959-437X(05)80135-2; Liu QX, 2003, DEVELOPMENT, V130, P719, DOI 10.1242/dev.00297; Miller G, 2006, ANN BOT-LONDON, V98, P279, DOI 10.1093/aob/mcl107; Mishra SK, 2002, GENE DEV, V16, P1555, DOI 10.1101/gad.228802; MITTLER R, 1995, PLANT CELL, V7, P29, DOI 10.1105/tpc.7.1.29; Myouga F, 2006, PLANT J, V48, P249, DOI 10.1111/j.1365-313X.2006.02873.x; Nawrath C, 1999, PLANT CELL, V11, P1393, DOI 10.1105/tpc.11.8.1393; Panchuk II, 2002, PLANT PHYSIOL, V129, P838, DOI 10.1104/pp.001362; Rizhsky L, 2004, J BIOL CHEM, V279, P11736, DOI 10.1074/jbc.M313350200; Rizhsky L, 2004, PLANT PHYSIOL, V134, P1683, DOI 10.1104/pp.103.033431; Rizhsky L, 2003, J BIOL CHEM, V278, P38921, DOI 10.1074/jbc.M304987200; Rolland F, 2002, PLANT CELL, V14, pS185, DOI 10.1105/tpc.010455; SHULAEV V, 1995, PLANT CELL, V7, P1691, DOI 10.1105/tpc.7.10.1691; Sijwali PS, 2001, PROTEIN EXPRES PURIF, V22, P128, DOI 10.1006/prep.2001.1416; Suzuki N, 2005, PLANT PHYSIOL, V139, P1313, DOI 10.1104/pp.105.070110; Takemaru K, 1997, P NATL ACAD SCI USA, V94, P7251, DOI 10.1073/pnas.94.14.7251; Takemaru K, 1998, MOL CELL BIOL, V18, P4971, DOI 10.1128/MCB.18.9.4971; Tsuda K, 2004, BBA-GENE STRUCT EXPR, V1680, P1, DOI 10.1016/j.bbaexp.2004.08.004; Tsuda K, 2004, PLANT CELL PHYSIOL, V45, P225, DOI 10.1093/pcp/pch017; VAN DER STRAETEN D, 1993, PLANT PHYSIOL, V102, P401, DOI 10.1104/pp.102.2.401; VIERLING E, 1991, ANNU REV PLANT PHYS, V42, P579, DOI 10.1146/annurev.pp.42.060191.003051; von Koskull-Doring P, 2007, TRENDS PLANT SCI, V12, P452, DOI 10.1016/j.tplants.2007.08.014; Wingler A, 2000, PLANT PHYSIOL, V124, P105, DOI 10.1104/pp.124.1.105; Zimmermann P, 2004, PLANT PHYSIOL, V136, P2621, DOI 10.1104/pp.104.046367	46	189	209	6	56	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9269	9275		10.1074/jbc.M709187200	http://dx.doi.org/10.1074/jbc.M709187200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18201973	hybrid, Green Published			2022-12-25	WOS:000254465800057
J	Adam, SA; Sengupta, K; Goldman, RD				Adam, Stephen A.; Sengupta, Kaushik; Goldman, Robert D.			Regulation of nuclear lamin polymerization by importin alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION SITES; ENVELOPE; PROTEIN; RAN; RECOGNITION; EXPRESSION; PATHWAY; BINDING; DOMAIN; CELLS	Nuclear lamins are integral components of the nuclear envelope and are important for the regulation of many aspects of nuclear function, including gene transcription and DNA replication. During interphase, the lamins form an intranuclear intermediate filament network that must be disassembled and reassembled when cells divide. Little is known about factors regulating this assembly/disassembly cycle. Using in vitro nuclear assembly and lamin assembly assays, we have identified a role for the nuclear transport factor importin alpha in the regulation of lamin assembly. Exogenous importin alpha inhibited nuclear lamin assembly in Xenopus interphase egg nuclear assembly assays. Fractionation of the egg extract used for nuclear assembly identified a high molecular weight complex containing the major egg lamin, XLB3, importin alpha, and importin beta. This complex could be dissociated by RanGTP or a competing nuclear localization sequence, indicating that lamin assembly is Ran-and importin alpha-dependent in the egg extract. We show that the addition of importin alpha to purified lamin B3 prevents the assembly of lamins in solution. Lamin assembly assays show that importin alpha prevents the self-association of lamins required to assemble lamin filaments into the typical paracrystals formed in vitro. These results suggest a role for importin alpha in regulating lamin assembly and possibly modulating the interactions of lamins with lamin-binding proteins.	[Adam, Stephen A.; Sengupta, Kaushik; Goldman, Robert D.] Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Adam, SA (corresponding author), W129 303 E Chicago Ave, Chicago, IL 60611 USA.	s-adam@northwestern.edu		Adam, Stephen/0000-0003-3444-7655	NATIONAL CANCER INSTITUTE [R01CA031760] Funding Source: NIH RePORTER; NCI NIH HHS [5 R01 CA 031760-25] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; Askjaer P, 2002, MOL BIOL CELL, V13, P4355, DOI 10.1091/mbc.E02-06-0346; Burke B, 1990, CURR OPIN CELL BIOL, V2, P514, DOI 10.1016/0955-0674(90)90136-3; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; CLARKE PR, 2004, S SOC EXP BIOL, V56, P193; DESSEV G, 1991, J CELL BIOL, V112, P523, DOI 10.1083/jcb.112.4.523; Dhe-Paganon S, 2002, J BIOL CHEM, V277, P17381, DOI 10.1074/jbc.C200038200; Dickmanns A, 1996, J CELL SCI, V109, P1449; Dorner D, 2007, FEBS J, V274, P1362, DOI 10.1111/j.1742-4658.2007.05695.x; EGGERT M, 1993, EUR J BIOCHEM, V213, P659, DOI 10.1111/j.1432-1033.1993.tb17806.x; Ellenberg J, 1999, METHODS, V19, P362, DOI 10.1006/meth.1999.0872; Foisner Roland, 2003, ScientificWorldJournal, V3, P1; Fontes MRM, 2003, BIOCHEM J, V375, P339, DOI 10.1042/BJ20030510; Geles KG, 2002, MOL BIOL CELL, V13, P3138, DOI 10.1091/mbc.E02-02-0069; GERACE L, 1980, CELL, V19, P277, DOI 10.1016/0092-8674(80)90409-2; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; HAAS M, 1993, EUR J CELL BIOL, V62, P237; Hachet V, 2004, EMBO J, V23, P1526, DOI 10.1038/sj.emboj.7600154; Harel A, 2004, MOL CELL, V16, P319, DOI 10.1016/S1097-2765(04)00647-1; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; JENKINS H, 1993, J CELL SCI, V106, P275; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; Krimm I, 2002, STRUCTURE, V10, P811, DOI 10.1016/S0969-2126(02)00777-3; LEUKEL M, 1995, EUR J CELL BIOL, V68, P133; Liu J, 2000, MOL BIOL CELL, V11, P3937, DOI 10.1091/mbc.11.11.3937; LOEWINGER L, 1988, EMBO J, V7, P2301, DOI 10.1002/j.1460-2075.1988.tb03073.x; Lopez-Soler RI, 2001, J CELL BIOL, V154, P61, DOI 10.1083/jcb.200101025; Lourim D, 1998, J CELL SCI, V111, P3675; Mattout A, 2006, CURR OPIN CELL BIOL, V18, P335, DOI 10.1016/j.ceb.2006.03.007; MOIR RD, 1991, J CELL SCI, V99, P363; Moir RD, 2000, J CELL BIOL, V151, P1155, DOI 10.1083/jcb.151.6.1155; NAKAJIMA N, 1995, FEBS LETT, V365, P108, DOI 10.1016/0014-5793(95)00453-G; NEWPORT JW, 1990, J CELL BIOL, V111, P2247, DOI 10.1083/jcb.111.6.2247; Nigg E A, 1992, Semin Cell Biol, V3, P245, DOI 10.1016/1043-4682(92)90026-R; Pemberton LF, 1999, J CELL BIOL, V145, P1407, DOI 10.1083/jcb.145.7.1407; Quimby BB, 2003, CURR OPIN CELL BIOL, V15, P338, DOI 10.1016/S0955-0674(03)00046-2; ROBER RA, 1989, DEVELOPMENT, V105, P365; Shumaker DK, 2005, P NATL ACAD SCI USA, V102, P15494, DOI 10.1073/pnas.0507612102; Shumaker DK, 2003, CURR OPIN CELL BIOL, V15, P358, DOI 10.1016/S0955-0674(03)00050-4; SINENSKY M, 1994, J CELL SCI, V107, P61; STICK R, 1988, EMBO J, V7, P3189, DOI 10.1002/j.1460-2075.1988.tb03186.x; Tsai MY, 2006, SCIENCE, V311, P1887, DOI 10.1126/science.1122771; Zastrow MS, 2004, J CELL SCI, V117, P979, DOI 10.1242/jcs.01102	43	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8462	8468		10.1074/jbc.M709572200	http://dx.doi.org/10.1074/jbc.M709572200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18227062	Green Published, hybrid			2022-12-25	WOS:000254288000044
J	Liu, QYP; Yuan, HP; Bennett, EP; Levery, SB; Nudelman, E; Spence, J; Pietz, G; Saunders, K; White, T; Olsson, ML; Henrissat, B; Sulzenbacher, G; Clausen, H				Liu, Qiyong P.; Yuan, Huaiping; Bennett, Eric P.; Levery, Steven B.; Nudelman, Edward; Spence, Jean; Pietz, Greg; Saunders, Kristen; White, Thayer; Olsson, Martin L.; Henrissat, Bernard; Sulzenbacher, Gerlind; Clausen, Henrik			Identification of a GH110 subfamily of alpha 1,3-galactosidases - Novel enzymes for removal of the alpha 3Gal xenotransplantation antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDASE-C; MOLECULAR-CLONING; EXPRESSION; SEQUENCE; PURIFICATION; GLYCOSIDASES; CDNA; EVOLUTIONARY; XENOANTIGEN; GENE	In search of alpha-galactosidases with improved kinetic properties for removal of the immunodominant alpha 1,3-linked galactose residues of blood group B antigens, we recently identified a novel prokaryotic family of alpha-galactosidases (CAZy GH110) with highly restricted substrate specificity and neutral pH optimum (Liu, Q. P., Sulzenbacher, G., Yuan, H., Bennett, E. P., Pietz, G., Saunders, K., Spence, J., Nudelman, E., Levery, S. B., White, T., Neveu, J. M., Lane, W. S., Bourne, Y., Olsson, M. L., Henrissat, B., and Clausen, H. (2007) Nat. Biotechnol. 25, 454-464). One member of this family from Bacteroides fragilis had exquisite substrate specificity for the branched blood group B structure Gal alpha 1-3(Fuc alpha 1-2) Gal, whereas linear oligosaccharides terminated by alpha 1,3-linked galactose such as the immunodominant xenotransplantation epitope Gal alpha 1-3Gal beta 1-4GlcNAc did not serve as substrates. Here we demonstrate the existence of two distinct subfamilies of GH110 in B. fragilis and thetaiotaomicron strains. Members of one subfamily have exclusive specificity for the branched blood group B structures, whereas members of a newly identified subfamily represent linkage specific alpha 1,3-galactosidases that act equally well on both branched blood group B and linear alpha 1,3Gal structures. We determined by one-dimensional H-1 NMR spectroscopy that GH110 enzymes function with an inverting mechanism, which is in striking contrast to all other known alpha-galactosidases that use a retaining mechanism. The novel GH110 subfamily offers enzymes with highly improved performance in enzymatic removal of the immunodominant alpha 3Gal xenotransplantation epitope.	[Liu, Qiyong P.; Yuan, Huaiping; Nudelman, Edward; Spence, Jean; Pietz, Greg; Saunders, Kristen; White, Thayer; Clausen, Henrik] ZymeQuest Inc, Beverly, MA 01915 USA; [Bennett, Eric P.; Pietz, Greg; Clausen, Henrik] Univ Copenhagen, Dept Cellular & Mol Med, DK-2200 Copenhagen, Denmark; [Bennett, Eric P.; Pietz, Greg; Clausen, Henrik] Univ Copenhagen, Dept Odontol, DK-2200 Copenhagen, Denmark; [Levery, Steven B.] Univ New Hampshire, Dept Chem, Durham, NH 03824 USA; [Olsson, Martin L.] Lund Univ, Div Hematol & Transfus Med, SE-22185 Lund, Sweden; [Olsson, Martin L.] Lund Univ, Dept Lab Med, SE-22185 Lund, Sweden; [Olsson, Martin L.] Univ Lund Hosp, Ctr Blood, SE-22185 Lund, Sweden; [Olsson, Martin L.] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; [Olsson, Martin L.] Harvard Univ, Sch Med, Boston, MA 02215 USA; [Henrissat, Bernard; Sulzenbacher, Gerlind] Univ Aix Marseille 1, Architecture & Fonct Macromol Biol, CNRS, UMR6098, F-13288 Marseille 9, France; [Henrissat, Bernard; Sulzenbacher, Gerlind] Univ Aix Marseille 2, Architecture & Fonct Macromol Biol, CNRS, UMR6098, F-13288 Marseille 9, France	University of Copenhagen; University of Copenhagen; University System Of New Hampshire; University of New Hampshire; Lund University; Lund University; Lund University; Skane University Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Liu, QYP (corresponding author), ZymeQuest Inc, 100 Cummings Ctr,Suite 436H, Beverly, MA 01915 USA.	pliu@zymequest.com	clausen, henrik/AAD-8016-2021; Sulzenbacher, Gerlind/A-6801-2018; Henrissat, Bernard/J-2475-2012; Bennett, Eric/AAG-6120-2020	Sulzenbacher, Gerlind/0000-0003-4844-2820; Henrissat, Bernard/0000-0002-3434-8588; Bennett, Eric/0000-0002-4976-0647; Olsson, Martin L/0000-0003-1647-9610; Clausen, Henrik/0000-0002-0915-5055				Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; BOCK K, 1982, ANNU REP NMR SPECTRO, V13, P1; BRECHER ME, 2005, TECHNICAL MANUAL, P732; Brouns SJJ, 2006, J BACTERIOL, V188, P2392, DOI 10.1128/JB.188.7.2392-2399.2006; Calcutt MJ, 2002, FEMS MICROBIOL LETT, V214, P77, DOI 10.1111/j.1574-6968.2002.tb11327.x; CLAUSEN H, 1985, BIOCHEMISTRY-US, V24, P3578, DOI 10.1021/bi00335a028; Comfort DA, 2007, BIOCHEMISTRY-US, V46, P3319, DOI 10.1021/bi061521n; Coutinho PM, 1999, ROY SOC CH, P3; DABROWSKI J, 1988, BIOCHEMISTRY-US, V27, P5149, DOI 10.1021/bi00414a030; Davis MO, 1997, BIOCHEM MOL BIOL INT, V42, P453; Davis MO, 1996, BIOCHEM MOL BIOL INT, V39, P471; Desnick RJ, 2004, J INHERIT METAB DIS, V27, P385, DOI 10.1023/B:BOLI.0000031101.12838.c6; DISTLER JJ, 1973, J BIOL CHEM, V248, P6772; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Ezzelarab M, 2005, XENOTRANSPLANTATION, V12, P278, DOI 10.1111/j.1399-3089.2005.00236.x; Galili U, 2006, TRANSFUS APHER SCI, V35, P45, DOI 10.1016/j.transci.2006.05.007; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; GOLDSTEIN J, 1982, SCIENCE, V215, P168, DOI 10.1126/science.6274021; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; Henrissat B, 1998, BIOCHEM SOC T, V26, P153, DOI 10.1042/bst0260153; Katayama T, 2004, J BACTERIOL, V186, P4885, DOI 10.1128/JB.186.15.4885-4893.2004; Keusch JJ, 2000, J BIOL CHEM, V275, P25308, DOI 10.1074/jbc.M002629200; KOBATA A, 1979, ANAL BIOCHEM, V100, P1, DOI 10.1016/0003-2697(79)90102-7; Liu DG, 2002, XENOTRANSPLANTATION, V9, P228, DOI 10.1034/j.1399-3089.2002.01068.x; Liu QYP, 2007, NAT BIOTECHNOL, V25, P454, DOI 10.1038/nbt1298; Luo Y, 1999, XENOTRANSPLANTATION, V6, P238, DOI 10.1034/j.1399-3089.1999.00035.x; Milland J, 2006, J IMMUNOL, V176, P2448, DOI 10.4049/jimmunol.176.4.2448; Ogawa H, 2002, XENOTRANSPLANTATION, V9, P290, DOI 10.1034/j.1399-3089.2002.01098.x; Ogawa H, 2000, J BIOL CHEM, V275, P19368, DOI 10.1074/jbc.M001888200; Omura S, 2001, P NATL ACAD SCI USA, V98, P12215, DOI 10.1073/pnas.211433198; Rajan SS, 2004, STRUCTURE, V12, P1619, DOI 10.1016/j.str.2004.06.020; Rigden DJ, 2002, FEBS LETT, V523, P17, DOI 10.1016/S0014-5793(02)02879-X; Royle Louise, 2006, V347, P125; Rye CS, 2000, CURR OPIN CHEM BIOL, V4, P573, DOI 10.1016/S1367-5931(00)00135-6; Sharma A, 2003, TRANSPLANTATION, V75, P430, DOI 10.1097/01.TP.0000053615.98201.77; Stam MR, 2006, PROTEIN ENG DES SEL, V19, P555, DOI 10.1093/protein/gzl044; Stam MR, 2005, CARBOHYD RES, V340, P2728, DOI 10.1016/j.carres.2005.09.018; Stone KR, 2007, ARTHROSCOPY, V23, P411, DOI 10.1016/j.arthro.2006.12.024; WANG AM, 1990, J BIOL CHEM, V265, P21859; Watanabe S, 2008, GLYCOBIOLOGY, V18, P9, DOI 10.1093/glycob/cwm114; Xu J, 2007, PLOS BIOL, V5, P1574, DOI 10.1371/journal.pbio.0050156; Zeleny R, 1997, ANAL BIOCHEM, V246, P96, DOI 10.1006/abio.1996.9973; ZHU A, 1993, GENE, V137, P309, DOI 10.1016/0378-1119(93)90026-Y; Zhu A, 1995, ARCH BIOCHEM BIOPHYS, V324, P65, DOI 10.1006/abbi.1995.9928; ZHU A, 1994, GENE, V140, P227, DOI 10.1016/0378-1119(94)90548-7	45	40	51	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8545	8554		10.1074/jbc.M709020200	http://dx.doi.org/10.1074/jbc.M709020200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18227066	Green Published, hybrid			2022-12-25	WOS:000254288000053
J	Chao, KC; Chao, KF; Fu, YS; Liu, SH				Chao, Kuo Ching; Chao, Kuo Fang; Fu, Yu Show; Liu, Shing Hwa			Islet-Like Clusters Derived from Mesenchymal Stem Cells in Wharton's Jelly of the Human Umbilical Cord for Transplantation to Control Type 1 Diabetes	PLOS ONE			English	Article							CENTRAL-NERVOUS-SYSTEM; BONE-MARROW; IN-VITRO; GLUCOSE-METABOLISM; ENDOCRINE-CELLS; BLOOD-CELLS; NEURONS; DIFFERENTIATION; EXPRESSION; FUSION	Background. There is a widespread interest in developing renewable sources of islet-replacement tissue for type I diabetes mellitus. Human mesenchymal cells isolated from the Wharton's jelly of the umbilical cord (HUMSCs), which can be easily obtained and processed compared with embryonic and bone marrow stem cells, possess stem cell properties. HUMSCs may be a valuable source for the generation of islets. Methodology and Principal Findings. HUMSCs were induced to transform into islet-like cell clusters in vitro through stepwise culturing in neuron-conditioned medium. To assess the functional stability of the islet-like cell clusters in vivo, these cell clusters were transplanted into the liver of streptozotocin-induced diabetic rats via laparotomy. Glucose tolerance was measured on week 12 after transplantation accompanied with immunohistochemistry and electron microscopy analysis. These islet-like cell clusters were shown to contain human C-peptide and release human insulin in response to physiological glucose levels. Real-time RT-PCR detected the expressions of insulin and other pancreatic beta-cell-related genes (Pdx1, Hlxb9, Nkx2.2, Nkx6.1, and Glut-2) in these islet-like cell clusters. The hyperglycemia and glucose intolerance in streptozotocin-induced diabetic rats was significantly alleviated after xenotransplantation of islet-like cell clusters, without the use of immunosuppressants. In addition to the existence of islet-like cell clusters in the liver, some special fused liver cells were also found, which characterized by human insulin and nuclei-positive staining and possessing secretory granules. Conclusions and Significance. In this study, we successfully differentiate HUMSCs into mature islet-like cell clusters, and these islet-like cell clusters possess insulin-producing ability in vitro and in vivo. HUMSCs in Wharton's Jelly of the umbilical cord seem to be the preferential source of stem cells to convert into insulin-producing cells, because of the large potential donor pool, its rapid availability, no risk of discomfort for the donor, and low risk of rejection.	[Fu, Yu Show] Natl Yang Ming Univ, Sch Med, Dept Anat, Taipei, Taiwan; [Chao, Kuo Ching; Chao, Kuo Fang] Natl Taiwan Univ, Coll Med, Inst Toxicol, Taipei, Taiwan	National Yang Ming Chiao Tung University; National Taiwan University	Liu, SH (corresponding author), Natl Taiwan Univ, Coll Med, Inst Toxicol, Taipei, Taiwan.	shliu@ha.mc.ntu.edu.tw		LIU, SHING-HWA/0000-0002-9976-1197	National Science Council of Taiwan [NSC95-2323-B-0002-007]	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan)	This study was supported by grants from the National Science Council of Taiwan (NSC95-2323-B-0002-007). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Bonner-Weir S, 2000, P NATL ACAD SCI USA, V97, P7999, DOI 10.1073/pnas.97.14.7999; DAHLSTRAND J, 1995, DEV BRAIN RES, V84, P109, DOI 10.1016/0165-3806(94)00162-S; Daneman D, 2006, LANCET, V367, P847, DOI 10.1016/S0140-6736(06)68341-4; Delacour A, 2004, MECH DEVELOP, V121, P3, DOI 10.1016/j.mod.2003.11.004; DELTOUR L, 1993, P NATL ACAD SCI USA, V90, P527, DOI 10.1073/pnas.90.2.527; Devendra D, 2004, BMJ-BRIT MED J, V328, P750, DOI 10.1136/bmj.328.7442.750; Donath MY, 1999, DIABETES, V48, P738, DOI 10.2337/diabetes.48.4.738; Edlund H, 2002, NAT REV GENET, V3, P524, DOI 10.1038/nrg841; Ende N, 2004, BIOCHEM BIOPH RES CO, V325, P665, DOI 10.1016/j.bbrc.2004.10.091; Ende N, 2004, BIOCHEM BIOPH RES CO, V321, P168, DOI 10.1016/j.bbrc.2004.06.121; Fu YS, 2006, STEM CELLS, V24, P115, DOI 10.1634/stemcells.2005-0053; Fu YS, 2004, J BIOMED SCI, V11, P652, DOI 10.1159/000079678; GUNNARSSON R, 1983, LANCET, V2, P571; Hori Y, 2002, P NATL ACAD SCI USA, V99, P16105, DOI 10.1073/pnas.252618999; Hori Y, 2005, PLOS MED, V2, P347, DOI 10.1371/journal.pmed.0020103; Ianus A, 2003, J CLIN INVEST, V111, P843, DOI 10.1172/JCI200316502; Ikeya T, 2002, CURR BIOL, V12, P1293, DOI 10.1016/S0960-9822(02)01043-6; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Lumelsky N, 2001, SCIENCE, V292, P1389, DOI 10.1126/science.1058866; Medvinsky A, 2003, NATURE, V422, P823, DOI 10.1038/422823a; Mfopou JK, 2007, STEM CELLS, V25, P1156, DOI 10.1634/stemcells.2006-0720; Mitchell KE, 2003, STEM CELLS, V21, P50, DOI 10.1634/stemcells.21-1-50; Naftanel MA, 2004, PLOS MED, V1, P198, DOI 10.1371/journal.pmed.0010058; Nanji SA, 2006, DIABETES OBES METAB, V8, P15, DOI 10.1111/j.1463-1326.2005.00476.x; Oh SH, 2004, LAB INVEST, V84, P607, DOI 10.1038/labinvest.3700074; OHGAWARA H, 1993, TOHOKU J EXP MED, V169, P159, DOI 10.1620/tjem.169.159; OTONKOSKI T, 1993, J CLIN INVEST, V92, P1459, DOI 10.1172/JCI116723; Pileggi A, 2006, CURR OPIN ORGAN TRAN, V11, P7, DOI 10.1097/01.mot.0000203878.00901.26; Ramiya VK, 2000, NAT MED, V6, P278; Robertson RP, 2004, NEW ENGL J MED, V350, P694, DOI 10.1056/NEJMra032425; ROBERTSON RP, 1992, J CLIN INVEST, V90, P320, DOI 10.1172/JCI115865; Rulifson EJ, 2002, SCIENCE, V296, P1118, DOI 10.1126/science.1070058; Seaberg RM, 2004, NAT BIOTECHNOL, V22, P1115, DOI 10.1038/nbt1004; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; Treutelaar MK, 2003, DIABETES, V52, P2503, DOI 10.2337/diabetes.52.10.2503; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Waki A, 2001, BRAIN RES, V894, P88, DOI 10.1016/S0006-8993(01)01983-7; Wang HS, 2004, STEM CELLS, V22, P1330, DOI 10.1634/stemcells.2004-0013; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Weiss ML, 2006, STEM CELLS, V24, P781, DOI 10.1634/stemcells.2005-0330; Yang LJ, 2002, P NATL ACAD SCI USA, V99, P8078, DOI 10.1073/pnas.122210699	44	242	287	1	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2008	3	1							e1451	10.1371/journal.pone.0001451	http://dx.doi.org/10.1371/journal.pone.0001451			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SN	18197261	Green Published, Green Submitted, gold			2022-12-25	WOS:000260503800023
J	Mangal, TD; Paterson, S; Fenton, A				Mangal, Tara D.; Paterson, Steve; Fenton, Andrew			Predicting the Impact of Long-Term Temperature Changes on the Epidemiology and Control of Schistosomiasis: A Mechanistic Model	PLOS ONE			English	Article								Background. Many parasites of medical and veterinary importance are transmitted by cold-blooded intermediate hosts or vectors, the abundance of which will vary with ambient temperatures, potentially altering disease prevalence. In particular, if global climate change will increase mean ambient temperature in a region endemic with a human pathogen then it is possible that the incidence of disease will similarly increase. Here we examine this possibility by using a mathematical model to explore the effects of increasing long-term mean ambient temperature on the prevalence and abundance of the parasite Schistosoma mansoni, the causative agent of schistosomiasis in humans. Principal Findings. The model showed that the impact of temperature on disease prevalence and abundance is not straightforward; the mean infection burden in humans increases up to 30 degrees C, but then crashes at 35 degrees C, primarily due to increased mortalities of the snail intermediate host. In addition, increased temperatures changed the dynamics of disease from stable, endemic infection to unstable, epidemic cycles at 35 degrees C. However, the prevalence of infection was largely unchanged by increasing temperatures. Temperature increases also affected the response of the model to changes in each parameter, indicating certain control strategies may become less effective with local temperature changes. At lower temperatures, the most effective single control strategy is to target the adult parasites through chemotherapy. However, as temperatures increase, targeting the snail intermediate hosts, for example through molluscicide use, becomes more effective. Conclusions. These results show that S. mansoni will not respond to increased temperatures in a linear fashion, and the optimal control strategy is likely to change as temperatures change. It is only through a mechanistic approach, incorporating the combined effects of temperature on all stages of the life-cycle, that we can begin to predict the consequences of climate change on the incidence and severity of such diseases.	[Paterson, Steve; Fenton, Andrew] Univ Liverpool, Sch Biol Sci, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Mangal, TD (corresponding author), Univ Liverpool, Sch Biol Sci, Liverpool L69 3BX, Merseyside, England.	d.mangal@liverpool.ac.uk	Paterson, Steve/D-2154-2009; Fenton, Andy/B-5972-2009	Paterson, Steve/0000-0002-1307-2981; Fenton, Andy/0000-0002-7676-917X	University of Liverpool studentship	University of Liverpool studentship	TM was funded by a University of Liverpool studentship.	Allen EJ, 2003, ACTA TROP, V87, P251, DOI 10.1016/S0001-706X(03)00065-2; ANDERSON RM, 1979, PARASITOLOGY, V79, P63, DOI 10.1017/S0031182000051982; CHEEVER AW, 1968, AM J TROP MED HYG, V17, P38, DOI 10.4269/ajtmh.1968.17.38; Chitsulo L, 2000, ACTA TROP, V77, P41, DOI 10.1016/S0001-706X(00)00122-4; COHEN JE, 1977, ANNU REV ECOL SYST, V8, P209, DOI 10.1146/annurev.es.08.110177.001233; Feng ZL, 2002, MATH BIOSCI, V177, P271, DOI 10.1016/S0025-5564(01)00115-8; Gryseels B, 1996, PARASITOL TODAY, V12, P115, DOI 10.1016/0169-4758(96)80671-5; Hales S, 2002, LANCET, V360, P830, DOI 10.1016/S0140-6736(02)09964-6; MACDONAL.G, 1965, T ROY SOC TROP MED H, V59, P489, DOI 10.1016/0035-9203(65)90152-5; Malone JB, 2001, ACTA TROP, V79, P59, DOI 10.1016/S0001-706X(01)00103-6; Malone JB, 2001, ACTA TROP, V79, P7, DOI [10.1016/S0001-706X(01)00098-5, 10.1016/S0001-706X(01)00133-4]; Malone JB, 1997, PARASITOL TODAY, V13, P112, DOI 10.1016/S0169-4758(97)01009-0; Martens WJM, 1997, CLIMATIC CHANGE, V35, P145, DOI 10.1023/A:1005365413932; MARTENS WJM, 1995, GLOBAL ENVIRON CHANG, V5, P195, DOI 10.1016/0959-3780(95)00051-O; MAY RM, 1979, NATURE, V280, P455, DOI 10.1038/280455a0; Ottersen G, 2001, OECOLOGIA, V128, P1, DOI 10.1007/s004420100655; Patz JA, 2000, INT J PARASITOL, V30, P1395, DOI 10.1016/S0020-7519(00)00141-7; Patz JA, 2005, NATURE, V438, P310, DOI 10.1038/nature04188; Poulin R, 2006, PARASITOLOGY, V132, P143, DOI 10.1017/S0031182005008693; Stenseth NC, 2002, SCIENCE, V297, P1292, DOI 10.1126/science.1071281; STURROCK RF, 1994, PARASITOLOGY, V109, P443, DOI 10.1017/S0031182000080690; WHO, 2003, CLIM CHANG HUM HLTH; Williams GM, 2002, ACTA TROP, V82, P253, DOI 10.1016/S0001-706X(02)00017-7; WOOLHOUSE MEJ, 1991, ACTA TROP, V49, P241, DOI 10.1016/0001-706X(91)90077-W; WOOLHOUSE MEJ, 1992, ACTA TROP, V50, P189, DOI 10.1016/0001-706X(92)90076-A; WOOLHOUSE MEJ, 1994, EPIDEMIOLOGY HUMAN S, P197; Yang HM, 1998, MEM I OSWALDO CRUZ, V93, P63	27	78	79	1	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2008	3	1							e1438	10.1371/journal.pone.0001438	http://dx.doi.org/10.1371/journal.pone.0001438			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SN	18197249	Green Submitted, gold, Green Published			2022-12-25	WOS:000260503800010
J	Nakayama, T; Ishii, T; Hotta, T; Mizuno, K				Nakayama, Takateru; Ishii, Takeharu; Hotta, Takashi; Mizuno, Koichi			Radial microtubule organization by histone H1 on nuclei of cultured tobacco BY-2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER-PLANT CELLS; 49 KDA PROTEIN; GAMMA-TUBULIN; ORGANIZING CENTERS; NUCLEATION; SITES; SPINDLE; LOCALIZATION; CYTOSKELETON; CENTROSOMES	In acentriolar higher plant cells, the surface of the nucleus acts as a microtubule-organizing center, substituting for the centrosome. However, the protein factors responsible for this microtubule organization are unknown. The nuclear surfaces of cultured tobacco BY-2 cells possess particles that generate microtubules. We attempted to isolate the proteins in these particles to determine their role in microtubule organization. When incubated with plant or mammalian tubulin, some, but not all, of the isolated nuclei generated abundant microtubules radially from their surfaces. The substance to induce the formation of radial microtubules was confirmed by SDS-PAGE to be a protein with apparent molecular mass of 38 kDa. Partial analysis of the amino acid sequences of the peptide fragments suggested it was a histone H1-related protein. Cloning and cDNA sequence analysis confirmed this and revealed that when the recombinant protein was incubated with tubulin, it could organize microtubules as well as the 38-kDa protein. Histone H1 and tubulin formed complexes immediately, even on ice, and then clusters of these structures were formed. These clusters generated radial microtubules. This microtubule-organizing property was confined to histone H1; all other core histones failed to act as organizers. On immunoblot analysis, rabbit antibodies raised against the 38-kDa protein cross-reacted with histone H1 proteins from tobacco BY-2 cells. These antibodies virtually abolished the ability of the nucleus to organize radial microtubules. Indirect immunofluorescence showed that the antigen was distributed at the nuclear plasm and particularly at nuclear periphery independently from DNA.	[Nakayama, Takateru; Ishii, Takeharu; Hotta, Takashi; Mizuno, Koichi] Osaka Univ, Grad Sch Sci, Dept Biol Sci, Osaka 5600043, Japan	Osaka University	Mizuno, K (corresponding author), Osaka Univ, Grad Sch Sci, Dept Biol Sci, 1-1 Machikaneyama Cho, Osaka 5600043, Japan.	kmizuno@bio.sci.osaka-u.ac.jp						Baluska F, 1997, INT REV CYTOL, V175, P91, DOI 10.1016/S0074-7696(08)62126-9; BASKIN TI, 1990, ANNU REV PLANT PHYS, V41, P277, DOI 10.1146/annurev.pp.41.060190.001425; CLAYTON L, 1985, J CELL BIOL, V101, P319, DOI 10.1083/jcb.101.1.319; Erhardt M, 2002, J CELL SCI, V115, P2423; FALCONER MM, 1988, PROTOPLASMA, V144, P46, DOI 10.1007/BF01320279; FLANDERS DJ, 1990, DEVELOPMENT, V110, P897; GIDDINGS TH, 1991, CYTOSKELETAL BASIS P, P229; GUNNING BES, 1985, J CELL SCI, P157, DOI 10.1242/jcs.1985.Supplement_2.9; HASEZAWA S, 1993, PROTOPLASMA, V176, P64, DOI 10.1007/BF01378940; HASEZAWA S, 1991, BOT ACTA, V104, P206, DOI 10.1111/j.1438-8677.1991.tb00218.x; HORIO T, 1991, J CELL SCI, V99, P693; Hotta T, 2007, CELL STRUCT FUNCT, V32, P79, DOI 10.1247/csf.07031; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; Iwamatsu A, 1991, Seikagaku, V63, P139; Kaczanowski S, 2001, J MOL EVOL, V53, P19, DOI 10.1007/s002390000000; Kumagai F, 1999, EUR J CELL BIOL, V78, P109, DOI 10.1016/S0171-9335(99)80012-0; Kumagai F, 2001, PLANT CELL PHYSIOL, V42, P723, DOI 10.1093/pcp/pce091; KUMAGAI F, 1995, BOT ACTA, V108, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT AM, 1980, CHROMOSOMA, V76, P295, DOI 10.1007/BF00327268; Lambert AM, 1993, CURR OPIN CELL BIOL, V5, P116, DOI 10.1016/S0955-0674(05)80016-X; LEDBETTER MC, 1963, J CELL BIOL, V19, P239, DOI 10.1083/jcb.19.1.239; LIU B, 1993, J CELL SCI, V104, P1217; LIU B, 1994, PLANT CELL, V6, P303, DOI 10.1105/tpc.6.2.303; MITHIEUX G, 1984, J BIOL CHEM, V259, P5523; MIZUNO K, 1993, PROTOPLASMA, V173, P77, DOI 10.1007/BF01378864; MIZUNO K, 1981, J BIOCHEM-TOKYO, V89, P329, DOI 10.1093/oxfordjournals.jbchem.a133199; MULTIGNER L, 1992, NATURE, V360, P33, DOI 10.1038/360033a0; Murata T, 2005, NAT CELL BIOL, V7, P961, DOI 10.1038/ncb1306; OAKLEY BR, 1990, CELL, V61, P1289, DOI 10.1016/0092-8674(90)90693-9; PICKETTHEAPS JD, 1966, J CELL SCI, V1, P109; Schmit AC, 2002, INT REV CYTOL, V220, P257; Schmit AC, 1996, CHROMOSOMA, V104, P405, DOI 10.1007/BF00352264; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SHIBAOKA H, 1994, CURR OPIN CELL BIOL, V6, P10, DOI 10.1016/0955-0674(94)90110-4; Shimamura M, 2004, PLANT CELL, V16, P45, DOI 10.1105/tpc.016501; Staiger CJ, 1991, CURR OPIN CELL BIOL, V3, P33, DOI 10.1016/0955-0674(91)90163-S; STEARNS T, 1991, CELL, V32, P577; Stoppin V, 1996, EUR J CELL BIOL, V69, P11; STOPPIN V, 1994, PLANT CELL, V6, P1099, DOI 10.1105/tpc.6.8.1099; SZEKERES M, 1995, PLANT MOL BIOL, V27, P597, DOI 10.1007/BF00019325; Wasteneys GO, 2004, PLANT PHYSIOL, V136, P3884, DOI 10.1104/pp.104.900133; ZHENG YX, 1991, CELL, V65, P817, DOI 10.1016/0092-8674(91)90389-G	43	24	24	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16632	16640		10.1074/jbc.M705764200	http://dx.doi.org/10.1074/jbc.M705764200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18184653	hybrid			2022-12-25	WOS:000256497100040
J	Bonnomet, A; Polette, M; Strumane, K; Gilles, C; Dalstein, V; Kileztky, C; Berx, G; van Roy, F; Birembaut, P; Nawrocki-Raby, B				Bonnomet, A.; Polette, M.; Strumane, K.; Gilles, C.; Dalstein, V.; Kileztky, C.; Berx, G.; van Roy, F.; Birembaut, P.; Nawrocki-Raby, B.			The E-cadherin-repressed hNanos1 gene induces tumor cell invasion by upregulating MT1-MMP expression	ONCOGENE			English	Article						hNanos1; E-cadherin; MT1-MMP; cancer; cell invasion	MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; GERMLINE STEM-CELLS; MESSENGER-RNA; POSTERIOR DETERMINANT; DROSOPHILA GERMLINE; NANOS; PUMILIO; COMPLEX; CANCER; ADHESION	In this study, we examined the role of the E-cadherin-repressed gene human Nanos1 (hNanos1) in tumor invasion process. First, our in vivo study revealed that hNanos1 mRNAs were overexpressed in invasive lung carcinomas. Moreover, hNanos1 was co-localized with MT1-MMP (membrane type 1-matrix metalloproteinase) in E-cadherin-negative invasive lung tumor clusters. Using an inducible Tet-on system, we showed that induction of hNanos1 expression in DLD1 cells increased their migratory and invasive abilities in a three-dimensional migration and in a modified Boyden chamber assay. Accordingly, we demonstrated that hNanos1 upregulated MT1-MMP expression at the mRNA and protein levels. Inversely, using an RNA interference strategy to inhibit hNanos1 expression in invasive Hs578T, BT549 and BZR cancer cells, we observed a downregulation of MT1-MMP mRNA and protein and concomitantly a decrease of the invasive capacities of tumor cells in a modified Boyden chamber assay. Taken together, our results demonstrate that hNanos1, by regulating MT1-MMP expression, plays an important role in the acquisition of invasive properties by epithelial tumor cells.	[Bonnomet, A.; Polette, M.; Dalstein, V.; Kileztky, C.; Birembaut, P.; Nawrocki-Raby, B.] Univ Reims, Histol Lab, CHU Maison Blanche, IFR 53,INSERM UMRS 514, F-51100 Reims, France; [Bonnomet, A.; Gilles, C.] Univ Liege, CHU Sart Tilman, Lab Dev & Tumor Biol, Liege, Belgium; [Strumane, K.; Berx, G.; van Roy, F.] Univ Ghent VIB, Dept Mol Biomed Res, B-9052 Ghent, Belgium; [Strumane, K.] Leiden Univ, Med Ctr, Dept IHB, Leiden, Netherlands	CHU de Reims; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Reims Champagne-Ardenne; University of Liege; Flanders Institute for Biotechnology (VIB); Ghent University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Nawrocki-Raby, B (corresponding author), Univ Reims, Histol Lab, CHU Maison Blanche, IFR 53,INSERM UMRS 514, 45 Rue Cognacq Jay, F-51100 Reims, France.	beatrice.raby@univ-reims.fr	POLETTE, Myriam/P-5147-2016; van Roy, Frans M/C-6123-2009; BIREMBAUT, Philippe/P-5210-2016; DALSTEIN, Véronique/P-5250-2016; Raby, Beatrice/P-5666-2016	van Roy, Frans M/0000-0003-4358-1039; Raby, Beatrice/0000-0002-3163-8619; BONNOMET, Arnaud/0000-0002-4933-3338; Berx, Geert/0000-0001-5770-2458; POLETTE, Myriam/0000-0001-8173-3246				Ara T, 2000, CANCER LETT, V157, P115, DOI 10.1016/S0304-3835(00)00494-8; Asaoka-Taguchi M, 1999, NAT CELL BIOL, V1, P431, DOI 10.1038/15666; Bartolome RA, 2006, CANCER RES, V66, P248, DOI 10.1158/0008-5472.CAN-05-2489; Behrens J, 2005, BIOCHEM SOC T, V33, P672, DOI 10.1042/BST0330672; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Bhat KM, 1999, GENETICS, V151, P1479; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; Deshpande G, 1999, CELL, V99, P271, DOI 10.1016/S0092-8674(00)81658-X; Edwards TA, 2001, CELL, V105, P281, DOI 10.1016/S0092-8674(01)00318-X; Forbes A, 1998, DEVELOPMENT, V125, P679; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GILLES C, 2004, RISE FALL EPITHELIAL, P1; Hatzfeld M, 2005, EUR J CELL BIOL, V84, P205, DOI 10.1016/j.ejcb.2004.12.016; Hazgui S, 2005, AM J PHYSIOL-CELL PH, V289, pC1547, DOI 10.1152/ajpcell.00319.2005; Hlubek F, 2004, INT J CANCER, V108, P321, DOI 10.1002/ijc.11522; Jaruzelska J, 2003, DEV GENES EVOL, V213, P120, DOI 10.1007/s00427-003-0303-2; Kitadai Y, 1996, AM J PATHOL, V149, P1541; Kobayashi S, 1996, NATURE, V380, P708, DOI 10.1038/380708a0; Luo J, 1999, CANCER RES, V59, P3552; Mareel M, 1996, J CELL BIOCHEM, V61, P524; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; MURATA Y, 1995, CELL, V80, P747, DOI 10.1016/0092-8674(95)90353-4; Nawrocki-Raby B, 2003, AM J PATHOL, V163, P653, DOI 10.1016/S0002-9440(10)63692-9; Polette M, 2005, CANCER RES, V65, P7691, DOI 10.1158/0008-5472.CAN-04-4230; Polette M, 1998, CLIN EXP METASTAS, V16, P105; Polette M, 2004, CRIT REV ONCOL HEMAT, V49, P179, DOI 10.1016/j.critrevonc.2003.10.008; Reynolds AB, 2004, ONCOGENE, V23, P7947, DOI 10.1038/sj.onc.1208161; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Sonoda J, 2001, GENE DEV, V15, P762, DOI 10.1101/gad.870801; Strumane K, 2006, CANCER RES, V66, P10007, DOI 10.1158/0008-5472.CAN-05-3096; Takahashi M, 2002, ONCOGENE, V21, P5861, DOI 10.1038/sj.onc.1205755; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WANG C, 1994, DEV DYNAM, V199, P103, DOI 10.1002/aja.1001990204	34	26	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	26					3692	3699		10.1038/sj.onc.1211035	http://dx.doi.org/10.1038/sj.onc.1211035			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18223680				2022-12-25	WOS:000256659300006
J	Coric, T; Passamaneck, YJ; Zhang, P; Di Gregorio, A; Canessa, CM				Coric, Tatjana; Passamaneck, Yale J.; Zhang, Ping; Di Gregorio, Anna; Canessa, Cecilia M.			Simple chordates exhibit a proton-independent function of acid-sensing ion channels	FASEB JOURNAL			English	Article						ascidian; degenerin/epithelial sodium channel (ENaC) family; proton gating; Ciona; knockdown expression	CENTRAL-NERVOUS-SYSTEM; CIONA-INTESTINALIS; CONTRIBUTES; EXPRESSION; GENOME; LOCOMOTION; INSIGHTS; NEURONS; TOUCH; GENE	Acid-sensing ion channels (ASICs) constitute a family of neuron-specific voltage-insensitive sodium channels gated by extracellular protons. Functions of ASICs in mammals include nociception, mechano-sensation, and modulation of synaptic transmission. However, the role protons play in mediating the effects of ASICs remains elusive. We have examined ASICs from the ascidian Ciona intestinalis, a simple chordate organism whose nervous system in the larval stage exhibits high similarity to that of higher vertebrates. We found that the ascidian genome contains a single ASIC gene that gives rise to two splice forms analogous to the mammalian ASIC1 and ASIC2. CiASIC is expressed in most neurons of the larva but is absent in the adult. Despite high sequence similarity with mammalian counterparts, CiASIC is proton-insensitive when examined in heterologous systems or in larval neurons; the latter rules out the possibility that proton sensitivity is conferred by accessory proteins or particular factors present only in Ciona neurons. Down-regulation of the CiASIC transcript by double-stranded RNA disrupted the regular pattern of larval swimming, implying that proton-independent mechanisms mediate the effects of ASIC in vivo. Together the data identify ASIC as a highly conserved channel distinctive of chordate nervous systems and show that protons are not essential for ASIC function.	[Coric, Tatjana; Zhang, Ping; Canessa, Cecilia M.] Yale Univ, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; [Passamaneck, Yale J.; Di Gregorio, Anna] Cornell Univ, Weill Med Coll, Dept Cell & Dev Biol, New York, NY 10021 USA	Yale University; Cornell University	Canessa, CM (corresponding author), Yale Univ, Dept Cellular & Mol Physiol, 333 Cedar St, New Haven, CT 06520 USA.	cecilia.canessa@yale.edu	Di Gregorio, Anna/C-4766-2008		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD050704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054062] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ainsley JA, 2003, CURR BIOL, V13, P1557, DOI 10.1016/S0960-9822(03)00596-7; BONE Q, 1992, J MAR BIOL ASSOC UK, V72, P161, DOI 10.1017/S0025315400048864; Brown ER, 2005, EUR J NEUROSCI, V22, P2541, DOI 10.1111/j.1460-9568.2005.04420.x; CLONEY RA, 1982, AM ZOOL, V22, P817; Corbo JC, 1997, DEVELOPMENT, V124, P589; Coric T, 2005, J PHYSIOL-LONDON, V568, P725, DOI 10.1113/jphysiol.2005.087734; Coric T, 2003, J BIOL CHEM, V278, P45240, DOI 10.1074/jbc.M304441200; Dehal P, 2005, PLOS BIOL, V3, P1700, DOI 10.1371/journal.pbio.0030314; Dehal P, 2002, SCIENCE, V298, P2157, DOI 10.1126/science.1080049; Delsuc F, 2006, NATURE, V439, P965, DOI 10.1038/nature04336; Garcia-Anoveros J, 2001, J NEUROSCI, V21, P2678, DOI 10.1523/JNEUROSCI.21-08-02678.2001; Imai JH, 2007, J COMP NEUROL, V501, P316, DOI 10.1002/cne.21246; Imai JH, 2007, J COMP NEUROL, V501, P335, DOI 10.1002/cne.21247; Jasti J, 2007, NATURE, V449, P316, DOI 10.1038/nature06163; NICOL D, 1991, J COMP NEUROL, V309, P415, DOI 10.1002/cne.903090402; Oda-Ishii I, 2007, DEV DYNAM, V236, P1806, DOI 10.1002/dvdy.21213; Ohno S., 1970, P1; OKAMURA Y, 1994, NEURON, V13, P937, DOI 10.1016/0896-6273(94)90259-3; Okamura Y, 2005, PHYSIOL GENOMICS, V22, P269, DOI 10.1152/physiolgenomics.00229.2004; Passamaneck YJ, 2005, DEV DYNAM, V233, P1, DOI 10.1002/dvdy.20300; Paukert M, 2004, J BIOL CHEM, V279, P18783, DOI 10.1074/jbc.M401477200; Price MP, 2000, NATURE, V407, P1007, DOI 10.1038/35039512; Price MP, 2001, NEURON, V32, P1071, DOI 10.1016/S0896-6273(01)00547-5; Roza C, 2004, J PHYSIOL-LONDON, V558, P659, DOI 10.1113/jphysiol.2004.066001; Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X; Wemmie JA, 2003, J NEUROSCI, V23, P5496; Wemmie JA, 2006, TRENDS NEUROSCI, V29, P578, DOI 10.1016/j.tins.2006.06.014; Zega G, 2006, J EXP BIOL, V209, P3405, DOI 10.1242/jeb.02421	29	19	19	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1914	1923		10.1096/fj.07-100313	http://dx.doi.org/10.1096/fj.07-100313			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18211956				2022-12-25	WOS:000256352700031
J	Hsieh, SH; Ying, NW; Wu, MH; Chiang, WF; Hsu, CL; Wong, TY; Jin, YT; Hong, TM; Chen, YL				Hsieh, S. H.; Ying, N. W.; Wu, M. H.; Chiang, W. F.; Hsu, C. L.; Wong, T. Y.; Jin, Y. T.; Hong, T. M.; Chen, Y. L.			Galectin-1, a novel ligand of neuropilin-1, activates VEGFR-2 signaling and modulates the migration of vascular endothelial cells	ONCOGENE			English	Article						galectin-1; neuropilin-1; endothelial cells; oral cancer	BREAST-CANCER; GROWTH-FACTOR; EXPRESSION; RECEPTORS; FIBRONECTIN; DIFFERENTIATION; SUSCEPTIBILITY; GLYCOSYLATION; ANGIOGENESIS; PROGRESSION	Galectin-1 (Gal-1), a homodimeric prototype of the galectins with a single carbohydrate-recognition domain, was recently identified as being overexpressed in tumor-associated capillary endothelial cells. The role of Gal-1 in endothelial cellular functions and the mechanism of action of Gal-1 remain unknown. Neuropilin-1 (NRP1) is a neuronal receptor that mediates repulsive growth cone guidance, and NRP1 functions in endothelial cells as a coreceptor (with vascular endothelial growth factor receptors (VEGFRs)) for VEGF(165). In this study, we found that Gal-1 was overexpressed in the tumor-associated endothelial cells of oral squamous cell carcinomas (P<0.001). Gal-1 increased the proliferation and adhesion of endothelial cells, and enhanced cell migration in combination with VEGF165. Surprisingly, Gal-1 selectively bound NRP1 via the carbohydrate-recognition domain, but did not bind VEGFR-1, VEGFR-2 or VEGFR-3. The Gal-1-NRP1 interaction mediated the migration and adhesion of endothelial cells. The binding of Gal-1 to NRP1 enhanced VEGFR-2 phosphorylation and stimulated the activation of the mitogen activated protein (MAP) kinases SAPK1/JNK (stress activated protein kinase-1/c-Jun NH2-terminal kinase). These findings show, for the first time, that Gal-1 can directly bind to NRP1 on endothelial cells, and can promote the NRP1/VEGFR-2-mediated signaling pathway as well as NRP1-mediated biological activities.	[Hsieh, S. H.; Ying, N. W.; Wong, T. Y.; Jin, Y. T.; Chen, Y. L.] Natl Cheng Kung Univ, Coll Med, Inst Oral Med, Tainan 70101, Taiwan; [Wu, M. H.; Chen, Y. L.] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 70101, Taiwan; [Chiang, W. F.] Chi Mei Med Ctr, Oral Maxillofacial Sect, Tainan, Taiwan; [Hsu, C. L.] Chang Gung Mem Hosp, Dept Internal Med, Div Hematol Oncol, Taipei 10591, Taiwan; [Wong, T. Y.] Natl Taiwan Univ, Coll Med, NTU Ctr Gen Med, Taipei 10764, Taiwan	National Cheng Kung University; National Cheng Kung University; Chi Mei Hospital; Chang Gung Memorial Hospital; National Taiwan University	Chen, YL (corresponding author), Natl Cheng Kung Univ, Coll Med, Inst Oral Med, 1 Univ Rd, Tainan 70101, Taiwan.	htm@gate.sinica.edu.tw; yuhling@mail.ncku.edu.tw	Chiang, Wei-Fan/L-6537-2019; Chen, Yuh-Ling/AAS-7957-2021	Chiang, Wei-Fan/0000-0002-9240-1404; 				Camby I, 2006, GLYCOBIOLOGY, V16, p137R, DOI 10.1093/glycob/cwl025; Castro-Rivera E, 2004, P NATL ACAD SCI USA, V101, P11432, DOI 10.1073/pnas.0403969101; CHIANG WF, 2007, ORAL ONCOL IN PRESS; Clausse N, 1999, Angiogenesis, V3, P317, DOI 10.1023/A:1026584523789; Elola MT, 2005, J BIOMED SCI, V12, P13, DOI 10.1007/s11373-004-8169-5; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Fischer C, 2005, J BIOL CHEM, V280, P37266, DOI 10.1074/jbc.M411580200; Fons P, 2004, J CELL PHYSIOL, V200, P351, DOI 10.1002/jcp.20076; Gaudet AD, 2005, CURR DRUG TARGETS, V6, P419, DOI 10.2174/1389450054021864; Glinsky VV, 2000, CANCER RES, V60, P2584; GU MJ, 1994, J CELL SCI, V107, P175; He J, 2006, LAB INVEST, V86, P578, DOI 10.1038/labinvest.3700420; Hong TM, 2007, CLIN CANCER RES, V13, P4759, DOI 10.1158/1078-0432.CCR-07-0001; Hu B, 2007, ONCOGENE, V26, P5577, DOI 10.1038/sj.onc.1210348; Jung EJ, 2007, INT J CANCER, V120, P2331, DOI 10.1002/ijc.22434; Kadri T, 2005, STEM CELLS DEV, V14, P204, DOI 10.1089/scd.2005.14.204; Konigsberg W, 2001, THROMB HAEMOSTASIS, V86, P757, DOI 10.1055/s-0037-1616129; Murga M, 2005, BLOOD, V105, P1992, DOI 10.1182/blood-2004-07-2598; Neufeld G, 2002, TRENDS CARDIOVAS MED, V12, P13, DOI 10.1016/S1050-1738(01)00140-2; OZEKI Y, 1995, GLYCOBIOLOGY, V5, P255, DOI 10.1093/glycob/5.2.255; Parsons-Wingerter P, 2005, AM J PATHOL, V167, P193, DOI 10.1016/S0002-9440(10)62965-3; QUN Z, 1993, ARCH BIOCHEM BIOPHYS, V300, P6, DOI 10.1006/abbi.1993.1002; Rabinovich GA, 2005, BRIT J CANCER, V92, P1188, DOI 10.1038/sj.bjc.6602493; Rorive S, 2001, GLIA, V33, P241, DOI 10.1002/1098-1136(200103)33:3<241::AID-GLIA1023>3.0.CO;2-1; Shintani Y, 2006, EMBO J, V25, P3045, DOI 10.1038/sj.emboj.7601188; Thijssen VLJL, 2006, P NATL ACAD SCI USA, V103, P15975, DOI 10.1073/pnas.0603883103; Toscano MA, 2007, NAT IMMUNOL, V8, P825, DOI 10.1038/ni1482; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; Valenzuela HF, 2007, CANCER RES, V67, P6155, DOI 10.1158/0008-5472.CAN-05-4431; van den Brule FA, 2001, J PATHOL, V193, P80, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH730>3.0.CO;2-2	30	163	170	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	26					3746	3753		10.1038/sj.onc.1211029	http://dx.doi.org/10.1038/sj.onc.1211029			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18223683				2022-12-25	WOS:000256659300012
J	Wagner, S; Carpentier, I; Rogov, V; Kreike, M; Ikeda, F; Lohr, F; Wu, CJ; Ashwell, JD; Dotsch, V; Dikic, I; Beyaert, R				Wagner, S.; Carpentier, I.; Rogov, V.; Kreike, M.; Ikeda, F.; Loehr, F.; Wu, C-J; Ashwell, J. D.; Doetsch, V.; Dikic, I.; Beyaert, R.			Ubiquitin binding mediates the NF-kappa B inhibitory potential of ABIN proteins	ONCOGENE			English	Article						ABIN; NF-kappa B; ubiquitin; TNF; protein-protein interaction	ADENOVIRAL GENE-TRANSFER; A20-BINDING INHIBITOR; NEMO/IKK-GAMMA; KINASE COMPLEX; ACTIVATION; ALPHA; A20; IKK; RIP	Deregulated nuclear factor kappa B (NF-kappa B) activation plays an important role in inflammation and tumorigenesis. ABIN proteins have been characterized as negative regulators of NF-kappa B signaling. However, their mechanism of NF-kappa B inhibition remained unclear. With the help of a yeast two-hybrid screen, we identified ABIN proteins as novel ubiquitin-interacting proteins. The minimal ubiquitin-binding domain (UBD) corresponds to the ABIN homology domain 2 (AHD2) and is highly conserved in ABIN-1, ABIN-2 and ABIN-3. Moreover, this region is also present in NF-kappa B essential modulator/I kappa B kinase gamma (NEMO/IKK gamma) and the NEMO-like protein optineurin, and is therefore termed UBD in ABIN proteins and NEMO (UBAN). Nuclear magnetic resonance studies of the UBAN domain identify it as a novel type of UBD, with the binding surface on ubiquitin being significantly different from the binding surface of other UBDs. ABIN-1 specifically binds ubiquitinated NEMO via a bipartite interaction involving its UBAN and NEMO-binding domain. Mutations in the UBAN domain led to a loss of ubiquitin binding and impaired the NF-kappa B inhibitory potential of ABINs. Taken together, these data illustrate an important role for ubiquitin binding in the negative regulation of NF-kappa B signaling by ABINs and identify UBAN as a novel UBD.	[Carpentier, I.; Kreike, M.; Beyaert, R.] Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signal Transduct Inflammat, B-9052 Ghent, Belgium; [Carpentier, I.; Kreike, M.; Beyaert, R.] Univ Ghent, Dept Mol Biol, Zwijnaarde, Belgium; [Wagner, S.; Ikeda, F.; Dikic, I.] Univ Frankfurt, Sch Med, Inst Biochem 2, Frankfurt, Germany; [Rogov, V.; Loehr, F.; Doetsch, V.] Univ Frankfurt, Inst Biophys Chem, Frankfurt, Germany; [Rogov, V.] Russian Acad Sci, Inst Prot Res, Pushchino 142292, Russia; [Wu, C-J; Ashwell, J. D.] NCI, Lab Immune Cell Biol, NIH, Bethesda, MD 20892 USA	Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University; Goethe University Frankfurt; Goethe University Frankfurt; Russian Academy of Sciences; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Beyaert, R (corresponding author), Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signal Transduct Inflammat, Technologiepk 927, B-9052 Ghent, Belgium.	ivan.dikic@biochem2.de; rudi.beyaert@dmbr.ugent.be	Doetsch, Volker/D-5697-2011; Ikeda, Fumiyo/AAD-3770-2020; Dikic, Ivan/O-4650-2015; Beyaert, Rudi/B-2589-2009; Wagner, Sebastian/B-9056-2012	Ikeda, Fumiyo/0000-0003-0407-2768; Dikic, Ivan/0000-0001-8156-9511; Dotsch, Volker/0000-0001-5720-212X; Beyaert, Rudi/0000-0002-5704-582X	NATIONAL CANCER INSTITUTE [ZIABC010779, Z01BC010779] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agou F, 2004, J BIOL CHEM, V279, P54248, DOI 10.1074/jbc.M406423200; Calzado MA, 2007, CURR MED CHEM, V14, P367, DOI 10.2174/092986707779941113; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; El Bakkouri K, 2005, J BIOL CHEM, V280, P17938, DOI 10.1074/jbc.M413588200; Heyninck K, 1999, J CELL BIOL, V145, P1471, DOI 10.1083/jcb.145.7.1471; Heyninck K, 2003, FEBS LETT, V536, P135, DOI 10.1016/S0014-5793(03)00041-3; Hicke L, 2005, NAT REV MOL CELL BIO, V6, P610, DOI 10.1038/nrm1701; Liu WK, 2004, BIOCHEM J, V378, P867, DOI 10.1042/BJ20031736; Mauro C, 2006, J BIOL CHEM, V281, P18482, DOI 10.1074/jbc.M601502200; Shambharkar PB, 2007, EMBO J, V26, P1794, DOI 10.1038/sj.emboj.7601622; Shembade N, 2007, EMBO J, V26, P3910, DOI 10.1038/sj.emboj.7601823; Tang ED, 2003, J BIOL CHEM, V278, P37297, DOI 10.1074/jbc.M303389200; Van Huffel S, 2001, J BIOL CHEM, V276, P30216, DOI 10.1074/jbc.M100048200; Weaver BK, 2007, MOL CELL BIOL, V27, P4603, DOI 10.1128/MCB.00223-07; Wu CJ, 2006, NAT CELL BIOL, V8, P398, DOI 10.1038/ncb1384; Wullaert A, 2005, HEPATOLOGY, V42, P381, DOI 10.1002/hep.20785; Wullaert A, 2007, J BIOL CHEM, V282, P81, DOI 10.1074/jbc.M607481200; Wullaert A, 2006, TRENDS IMMUNOL, V27, P533, DOI 10.1016/j.it.2006.09.003; Zhou HL, 2005, CANCER CELL, V7, P425, DOI 10.1016/j.ccr.2005.04.012; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273; Zhu G, 2007, CURR BIOL, V17, P1438, DOI 10.1016/j.cub.2007.07.041	21	176	186	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2008	27	26					3739	3745		10.1038/sj.onc.1211042	http://dx.doi.org/10.1038/sj.onc.1211042			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18212736				2022-12-25	WOS:000256659300011
J	Cuende, J; Moreno, S; Bolanos, JP; Almeida, A				Cuende, J.; Moreno, S.; Bolanos, J. P.; Almeida, A.			Retinoic acid downregulates Rae1 leading to APC(Cdh1) activation and neuroblastoma SH-SY5Y differentiation	ONCOGENE			English	Article						retinoic acid; Rae1; Cdh1; Skp2; p27; neuroblastoma	ANAPHASE-PROMOTING COMPLEX; CDK INHIBITOR P27; CELL-CYCLE EXIT; POSTMITOTIC NEURONS; AXONAL GROWTH; S-PHASE; DEGRADATION; P27(KIP1); SKP2; PHOSPHORYLATION	In neuroblastoma cells, retinoic acid induces cell cycle arrest and differentiation through degradation of the F-box protein, Skp2, and stabilization of cyclin-dependent kinase inhibitor, p27. However, the mechanism responsible for retinoic acid-mediated Skp2 destabilization is unknown. Since Skp2 is degraded by anaphase-promoting complex (APC)(Cdh1), here we studied whether retinoic acid promotes differentiation of human SH-SY5Y neuroblastoma cells by modulating Cdh1. We found that retinoic acid induced the nuclear accumulation of Cdh1 that paralleled Skp2 destabilization and p27 accumulation. The mRNA and protein abundance of Rae1-a nuclear export factor that limits APC(Cdh1) activity in mitosis decreased upon retinoic acid-induced inhibition of neuroblastoma cell proliferation. Furthermore, either Rae1 overexpression or Cdh1 inhibition promoted Skp2 accumulation, p27 destabilization and prevented retinoic acid-induced cell cycle arrest and differentiation. Conversely, inhibition of Rae1 accelerated retinoic acid-induced differentiation. Thus, retinoic acid downregulates Rae1, hence facilitating APC(Cdh1)-mediated Skp2 degradation leading to the arrest of cell cycle progression and neuroblastoma differentiation.	[Cuende, J.; Almeida, A.] Hosp Univ Salamanca, Unidad Invest, Inst Estudios Ciencias Salud Castilla & Leon, Salamanca 37007, Spain; [Cuende, J.; Bolanos, J. P.; Almeida, A.] Univ Salamanca, Inst Neurociencias Castilla & Leon, Dept Bioquim & Biol Mol, E-37008 Salamanca, Spain; [Moreno, S.] Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, E-37008 Salamanca, Spain	University of Salamanca; University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Almeida, A (corresponding author), Hosp Univ Salamanca, Unidad Invest, Inst Estudios Ciencias Salud Castilla & Leon, Paseo San Vicente 58-182, Salamanca 37007, Spain.	aaparra@usal.es	ALMEIDA, ANGELES/B-4727-2017; Bolaños, Juan Pedro/M-9518-2019; 2008, Ibsal/A-1268-2012; Moreno, Sergio/K-3671-2014	ALMEIDA, ANGELES/0000-0003-0485-8904; Bolaños, Juan Pedro/0000-0002-3949-6862; Moreno, Sergio/0000-0002-8039-1413				Almeida A, 2005, J NEUROSCI, V25, P8115, DOI 10.1523/JNEUROSCI.1143-05.2005; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Binne UK, 2007, NAT CELL BIOL, V9, P225, DOI 10.1038/ncb1532; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Blower MD, 2005, CELL, V121, P223, DOI 10.1016/j.cell.2005.02.016; Borriello A, 2006, CANCER RES, V66, P4240, DOI 10.1158/0008-5472.CAN-05-2759; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Clagett-Dame M, 2006, J NEUROBIOL, V66, P739, DOI 10.1002/neu.20241; Dow R, 2001, J BIOL CHEM, V276, P45945, DOI 10.1074/jbc.M103593200; Encinas M, 2000, J NEUROCHEM, V75, P991, DOI 10.1046/j.1471-4159.2000.0750991.x; Gieffers C, 1999, P NATL ACAD SCI USA, V96, P11317, DOI 10.1073/pnas.96.20.11317; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Jeganathan KB, 2005, NATURE, V438, P1036, DOI 10.1038/nature04221; Konishi Y, 2004, SCIENCE, V303, P1026, DOI 10.1126/science.1093712; Lasorella A, 2006, NATURE, V442, P471, DOI 10.1038/nature04895; Maden M, 2002, NAT REV NEUROSCI, V3, P843, DOI 10.1038/nrn963; Matthay M A, 1999, Chest, V116, p119S; Nakamura M, 2003, CELL DEATH DIFFER, V10, P230, DOI 10.1038/sj.cdd.4401125; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Ohtsuka T, 2004, NAT CELL BIOL, V6, P121, DOI 10.1038/ncb1087; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; Reynolds CP, 2003, CANCER LETT, V197, P185, DOI 10.1016/S0304-3835(03)00108-3; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Zancai P, 2005, ONCOGENE, V24, P2483, DOI 10.1038/sj.onc.1208458	27	49	50	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	23					3339	3344		10.1038/sj.onc.1210987	http://dx.doi.org/10.1038/sj.onc.1210987			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	304LQ	18212744				2022-12-25	WOS:000256111400012
J	Sirvent, A; Leroy, C; Boureux, A; Simon, V; Roche, S				Sirvent, A.; Leroy, C.; Boureux, A.; Simon, V.; Roche, S.			The Src-like adaptor protein regulates PDGF-induced actin dorsal ruffles in a c-Cbl-dependent manner	ONCOGENE			English	Article						SLAP; Src; PDGF; Cbl; DNA synthesis; F-actin assembly	RECEPTOR TYROSINE KINASES; DNA-SYNTHESIS; NEGATIVE REGULATION; FIBROBLASTS; MITOGENESIS; EXPRESSION; THYMOCYTES; MIGRATION; BINDING; SLAP	The Src-like adaptor protein (SLAP) belongs to the subfamily of adapter proteins that negatively regulate cellular signalling initiated by tyrosine kinases. SLAP has a unique, myristylated N-terminus, followed by SH3 and SH2 domains with high homology to Src family tyrosine kinases (SFK) and a unique C-terminal tail, which is important for c-Cbl binding. We have previously shown that SLAP negatively regulates platelet-derived growth factor (PDGF)-induced mitogenesis in fibroblasts and we now report that it regulates F-actin assembly for dorsal ruffles formation. c-Cbl mediated SLAP inhibition towards actin remodelling. Moreover, SLAP enhanced PDGF-induced c-Cbl phosphorylation by SFK. In contrast, SLAP mitogenic inhibition was not mediated by c-Cbl, but it rather involved a competitive mechanism with SFK for PDGF-receptor (PDGFR) association and mitogenic signalling. Accordingly, phosphorylation of the Src mitogenic substrates Stat3 and Shc were reduced by SLAP. Thus, we concluded that SLAP regulates PDGFR signalling by two independent mechanisms: a competitive mechanism for PDGF-induced Src mitogenic signalling and a non-competitive mechanism for dorsal ruffles formation mediated by c-Cbl.	[Roche, S.] Univ Montpellier 1, CNRS, CRBM, UMR5237, F-34293 Montpellier 05, France; Univ Montpellier 2, Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Universite de Montpellier	Roche, S (corresponding author), Univ Montpellier 1, CNRS, CRBM, UMR5237, 1919 Route Mende, F-34293 Montpellier 05, France.	serge.roche@crbm.cnrs.fr		roche, serge/0000-0003-3413-3859				Boureux A, 2005, J CELL SCI, V118, P3717, DOI 10.1242/jcs.02491; Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079; Broome MA, 1999, ONCOGENE, V18, P2908, DOI 10.1038/sj.onc.1202873; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Lanzetti L, 2004, NATURE, V429, P309, DOI 10.1038/nature02542; Manes G, 2000, MOL CELL BIOL, V20, P3396, DOI 10.1128/MCB.20.10.3396-3406.2000; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Myers MD, 2006, NAT IMMUNOL, V7, P57, DOI 10.1038/ni1291; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; Reddi AL, 2007, J BIOL CHEM, V282, P29336, DOI 10.1074/jbc.M701797200; Roche S, 1998, CURR BIOL, V8, P975, DOI 10.1016/S0960-9822(98)70400-2; Roche S, 1998, MOL CELL BIOL, V18, P7119, DOI 10.1128/MCB.18.12.7119; Scaife RM, 2003, J CELL SCI, V116, P463, DOI 10.1242/jcs.00244; Schmidt MHH, 2005, NAT REV MOL CELL BIO, V6, P907, DOI 10.1038/nrm1762; Sosinowski T, 2001, IMMUNITY, V15, P457, DOI 10.1016/S1074-7613(01)00195-9; Suetsugu S, 2003, DEV CELL, V5, P595, DOI 10.1016/S1534-5807(03)00297-1; Swaminathan G, 2007, ONCOGENE, V26, P4095, DOI 10.1038/sj.onc.1210184; Teckchandani AM, 2005, EXP CELL RES, V307, P247, DOI 10.1016/j.yexcr.2005.03.010; Veracini L, 2006, J CELL SCI, V119, P2921, DOI 10.1242/jcs.03015	19	17	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	24					3494	3500		10.1038/sj.onc.1211011	http://dx.doi.org/10.1038/sj.onc.1211011			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18193084	Green Submitted, Bronze			2022-12-25	WOS:000256309900015
J	Ushmorov, A; Hogarty, MD; Liu, X; Knauss, H; Debatin, KM; Beltinger, C				Ushmorov, A.; Hogarty, M. D.; Liu, X.; Knauss, H.; Debatin, K. M.; Beltinger, C.			N-myc augments death and attenuates protective effects of Bcl-2 in trophically stressed neuroblastoma cells	ONCOGENE			English	Article						N-myc; bcl-2; survivin; FLIP(L); neuroblastoma	ADVANCED-STAGE NEUROBLASTOMA; NEURO-BLASTOMA CELLS; ANTI-APOPTOSIS GENE; C-MYC; CASPASE-8 EXPRESSION; MEDIATED APOPTOSIS; ONCOLOGY GROUP; AMPLIFICATION; SURVIVIN; ACTIVATION	N-myc has proapoptotic functions, yet it acts as an oncogene in neuroblastoma. Thus, antiapoptotic mechanisms have to be operative in neuroblastoma cells that antagonize the proapoptotic effects of N-myc. We conditionally activated N-myc in SH-EP neuroblastoma cells subjected to the trophic stress of serum or nutrient deprivation while changing the expression of Bcl-2, survivin and FLIPL, antiapoptotic molecules often over-expressed in poor prognosis neuroblastomas. Bcl-2 protected SH-EP cells from death during nutritional deprivation by activating energetically advantageous oxidative phosphorylation. N-myc overrode the metabolic protection provided by Bcl-2-induced oxidative phosphorylation by reestablishing the glycolytic phenotype and attenuated the antiapoptotic effect of Bcl-2during metabolic stress. Survivin partially antagonized the growth suppressive function of N-myc in SH-EP neuroblastoma cells during serum deprivation whereas FLIPL did not. These findings advance our understanding of the functions of N-myc in neuroblastoma cells.	[Ushmorov, A.; Knauss, H.; Debatin, K. M.; Beltinger, C.] Univ Childrens Hosp, D-89075 Ulm, Germany; [Hogarty, M. D.] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA	Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Beltinger, C (corresponding author), Univ Childrens Hosp, Eythstr 24, D-89075 Ulm, Germany.	christian.beltinger@uniklinik-ulm.de	Ushmorov, Alexey/AAI-6445-2020; Debatin, Klaus-Michael/J-9704-2014	Debatin, Klaus-Michael/0000-0002-8397-1886; Ushmorov, Alexey/0000-0003-3724-7253				Adida C, 1998, LANCET, V351, P882, DOI 10.1016/S0140-6736(05)70294-4; Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Boatright KM, 2004, BIOCHEM J, V382, P651, DOI 10.1042/BJ20040809; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; BREIT S, 1989, J NEUROSCI RES, V24, P21, DOI 10.1002/jnr.490240105; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CASTLE VP, 1993, AM J PATHOL, V143, P1543; Chan HSL, 1997, CLIN CANCER RES, V3, P1699; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Cohn SL, 2000, J CLIN ONCOL, V18, P3604, DOI 10.1200/JCO.2000.18.21.3604; Dohi T, 2004, J CLIN INVEST, V114, P1117, DOI 10.1172/JCI200422222; Eggert A, 2001, CANCER RES, V61, P1314; Fantin VR, 2006, CANCER CELL, V9, P425, DOI 10.1016/j.ccr.2006.04.023; Fischer M, 2005, J MOL DIAGN, V7, P89, DOI 10.1016/S1525-1578(10)60013-X; Fulda S, 1999, ONCOGENE, V18, P1479, DOI 10.1038/sj.onc.1202435; Fulda S, 2006, CANCER RES, V66, P10016, DOI 10.1158/0008-5472.CAN-05-4079; Ganten TM, 2004, CELL DEATH DIFFER, V11, pS86, DOI 10.1038/sj.cdd.4401437; Goldsmith KC, 2005, CANCER LETT, V228, P133, DOI 10.1016/j.canlet.2005.01.048; Hogarty MD, 2003, CANCER LETT, V197, P173, DOI 10.1016/S0304-3835(03)00103-4; Hopkins-Donaldson S, 2000, CANCER RES, V60, P4315; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Islam A, 2000, ONCOGENE, V19, P617, DOI 10.1038/sj.onc.1203358; Jasty R, 2001, NEOPLASIA, V3, P304, DOI 10.1038/sj.neo.7900171; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kim YH, 2003, MOL CELLS, V16, P67; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; LIU X, 2007, ONCOGENE, V27; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; Matthay KK, 2000, J CLIN ONCOL, V18, P3591, DOI 10.1200/JCO.2000.18.21.3591; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Miller MA, 2006, J PEDIAT HEMATOL ONC, V28, P412, DOI 10.1097/01.mph.0000212937.00287.e5; NAKAGAWARA A, 1990, CANCER RES, V50, P3043; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261; NISEN PD, 1988, J NATL CANCER I, V80, P1633, DOI 10.1093/jnci/80.20.1633; Papas KK, 1999, FEBS LETT, V446, P338, DOI 10.1016/S0014-5793(99)00240-9; Poulaki V, 2001, CANCER RES, V61, P4864; Ricci-Vitiani L, 2004, J EXP MED, V200, P1257, DOI 10.1084/jem.20040921; ROSS RA, 1983, J NATL CANCER I, V71, P741; Roth W, 2004, VITAM HORM, V67, P189; SCHWEIGERER L, 1990, CANCER RES, V50, P4411; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Sharp DA, 2005, J BIOL CHEM, V280, P19401, DOI 10.1074/jbc.M413962200; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; SLAVC I, 1990, CANCER RES, V50, P1459; Song JX, 2005, IMMUNITY, V22, P621, DOI 10.1016/j.immuni.2005.03.012; Stupack DG, 2006, NATURE, V439, P95, DOI 10.1038/nature04323; Tang XX, 2006, CANCER RES, V66, P2826, DOI 10.1158/0008-5472.CAN-05-0854; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Ueda K, 1996, J VIROL, V70, P1375, DOI 10.1128/JVI.70.3.1375-1383.1996; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Vaupel P, 2004, SEMIN RADIAT ONCOL, V14, P198, DOI 10.1016/j.semradonc.2004.04.008; WADA RK, 1993, CANCER, V72, P3346, DOI 10.1002/1097-0142(19931201)72:11<3346::AID-CNCR2820721134>3.0.CO;2-E	58	27	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	24					3424	3434		10.1038/sj.onc.1211017	http://dx.doi.org/10.1038/sj.onc.1211017			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18193081				2022-12-25	WOS:000256309900007
J	Hayes, VH; Devlin, G; Quinlan, RA				Hayes, Victoria H.; Devlin, Glyn; Quinlan, Roy A.			Truncation of alpha B-crystallin by the myopathy-causing Q151X mutation significantly destabilizes the protein leading to aggregate formation in transfected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; CHAPERONE-LIKE ACTIVITY; DESMIN-RELATED MYOPATHY; A-CRYSTALLIN; METHANOCOCCUS-JANNASCHII; FILAMENT INTERACTIONS; IMMUNOREACTIVE ALPHA; QUATERNARY STRUCTURE; LENS; ASSEMBLIES	Here we investigate the effects of a myopathy-causing mutation in alpha B-crystallin, Q151X, upon its structure and function. This mutation removes the C-terminal domain of alpha B-crystallin, which is expected to compromise both its oligomerization and chaperone activity. We compared this to two other alpha B-crystallin mutants (450delA, 464delCT) and also to a series of C-terminal truncations (E164X, E165X, K174X, and A171X). We find that the effects of the Q151X mutation were not always as predicted. Specifically, we have found that although the Q151X mutation decreased oligomerization of alpha B-crystallin and even increased some chaperone activities, it also significantly destabilized alpha B-crystallin causing it to self-aggregate. This conclusion was supported by our analyses of both the other disease-causing mutants and the series of C-terminal truncation constructs of alpha B-crystallin. The 450delA and 464delCT mutants could only be refolded and assayed as a complex with wild type alpha B-crystallin, which was not the case for Q151X alpha B-crystallin. From these studies, we conclude that all three disease-causing mutations (450delA, 464delCT, and Q151X) in the C-terminal extension destabilize alpha B-crystallin and increase its tendency to self-aggregate. We propose that it is this, rather than a catastrophic loss of chaperone activity, which is a major factor in the development of the reported diseases for the three disease-causing mutations studied here. In support of this hypothesis, we show that Q151X alpha B-crystallin is found mainly in the insoluble fraction of cell extracts from transient transfected cells, due to the formation of cytoplasmic aggregates.	[Hayes, Victoria H.; Quinlan, Roy A.] Univ Durham, Sch Biol & Biomed Sci, Durham DH1 3LE, England; [Devlin, Glyn] Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England	Durham University; University of Cambridge	Quinlan, RA (corresponding author), Univ Durham, Sch Biol & Biomed Sci, Durham DH1 3LE, England.	r.a.quinlan@durham.ac.uk	Quinlan, Roy/A-1348-2012	Quinlan, Roy/0000-0003-0644-4123	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS042803] Funding Source: NIH RePORTER; Biotechnology and Biological Sciences Research Council Funding Source: Medline; NINDS NIH HHS [P01NS42803, P01 NS042803, P01 NS042803-010004] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andley UP, 1996, J BIOL CHEM, V271, P31973, DOI 10.1074/jbc.271.50.31973; Aquilina JA, 2004, J BIOL CHEM, V279, P28675, DOI 10.1074/jbc.M403348200; Berry V, 2001, AM J HUM GENET, V69, P1141, DOI 10.1086/324158; BLOEMENDAL H, 1991, PROG NUCLEIC ACID RE, V41, P259; Bousquet O, 2001, J CELL BIOL, V155, P747, DOI 10.1083/jcb.200104063; Bova MP, 1999, P NATL ACAD SCI USA, V96, P6137, DOI 10.1073/pnas.96.11.6137; Colvis CM, 2000, ELECTROPHORESIS, V21, P2219, DOI 10.1002/1522-2683(20000601)21:11<2219::AID-ELPS2219>3.0.CO;2-R; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; Der Perng M, 1999, J BIOL CHEM, V274, P33235, DOI 10.1074/jbc.274.47.33235; Doss-Pepe EW, 1998, EXP EYE RES, V67, P657, DOI 10.1006/exer.1998.0561; Feil IK, 2001, J BIOL CHEM, V276, P12024, DOI 10.1074/jbc.M010856200; Ghosh JG, 2005, PROTEIN SCI, V14, P684, DOI 10.1110/ps.041152805; Ghosh JG, 2005, BIOCHEMISTRY-US, V44, P14854, DOI 10.1021/bi0503910; Ghosh JG, 2008, INT J BIOCHEM CELL B, V40, P954, DOI 10.1016/j.biocel.2007.10.035; Ghosh JG, 2006, BIOCHEMISTRY-US, V45, P9878, DOI 10.1021/bi060970k; Goldfarb LG, 1998, NAT GENET, V19, P402, DOI 10.1038/1300; Haley DA, 1998, J MOL BIOL, V277, P27, DOI 10.1006/jmbi.1997.1611; Haley DA, 2000, J MOL BIOL, V298, P261, DOI 10.1006/jmbi.2000.3657; HE SM, 1995, J MASS SPECTROM, V30, P424, DOI 10.1002/jms.1190300305; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Horwitz J, 2004, EXP EYE RES, V79, P817, DOI 10.1016/j.exer.2004.05.007; Horwitz J, 1998, METHOD ENZYMOL, V290, P365, DOI 10.1016/S0076-6879(98)90032-5; Inagaki N, 2006, BIOCHEM BIOPH RES CO, V342, P379, DOI 10.1016/j.bbrc.2006.01.154; IWAKI T, 1991, KIDNEY INT, V40, P52, DOI 10.1038/ki.1991.178; Jimenez-Asensio J, 1999, J BIOL CHEM, V274, P32287, DOI 10.1074/jbc.274.45.32287; Kappe G, 2001, BBA-GENE STRUCT EXPR, V1520, P1, DOI 10.1016/S0167-4781(01)00237-8; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1074, P201, DOI 10.1016/0304-4165(91)90062-L; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P173, DOI 10.1016/0167-4838(91)90146-Q; Kennaway CK, 2005, J BIOL CHEM, V280, P33419, DOI 10.1074/jbc.M504263200; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kim R, 1998, P NATL ACAD SCI USA, V95, P9129, DOI 10.1073/pnas.95.16.9129; Kim R, 2003, P NATL ACAD SCI USA, V100, P8151, DOI 10.1073/pnas.1032940100; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu YZ, 2006, INVEST OPHTH VIS SCI, V47, P1069, DOI 10.1167/iovs.05-1004; Meehan S, 2007, J MOL BIOL, V372, P470, DOI 10.1016/j.jmb.2007.06.060; Morner C., 1894, HOPPE SEYL, V18, P61; Munoz-Marmol AM, 1998, P NATL ACAD SCI USA, V95, P11312, DOI 10.1073/pnas.95.19.11312; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; Pasta SY, 2004, MOL VIS, V10, P655; Pasta SY, 2003, J BIOL CHEM, V278, P51159, DOI 10.1074/jbc.M307523200; Perng MD, 2004, MOL BIOL CELL, V15, P2335, DOI 10.1091/mbc.E03-12-0893; Perng MD, 1999, J CELL SCI, V112, P2099; Plater ML, 1996, J BIOL CHEM, V271, P28558, DOI 10.1074/jbc.271.45.28558; QUINLAN RA, 1989, J CELL SCI, V93, P71; Rajan S, 2006, BIOCHEMISTRY-US, V45, P15684, DOI 10.1021/bi060705z; Schroder R, 2007, J CELL MOL MED, V11, P416, DOI 10.1111/j.1582-4934.2007.00057.x; Selcen D, 2003, ANN NEUROL, V54, P804, DOI 10.1002/ana.10767; Simon S, 2007, J BIOL CHEM, V282, P34276, DOI 10.1074/jbc.M703267200; SMITH JB, 1995, J PROTEIN CHEM, V14, P179, DOI 10.1007/BF01980330; Sreelakshmi Y, 2006, MOL VIS, V12, P581; Stamler R, 2005, J MOL BIOL, V353, P68, DOI 10.1016/j.jmb.2005.08.025; Thampi P, 2003, BIOCHEMISTRY-US, V42, P11857, DOI 10.1021/bi030129w; Thampi P, 2002, INVEST OPHTH VIS SCI, V43, P3265; Treweek TM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001046; Ueda Y, 2002, MOL CELL PROTEOMICS, V1, P357, DOI 10.1074/mcp.M200007-MCP200; Ueda Y, 2002, INVEST OPHTH VIS SCI, V43, P205; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; VANKLEEF FSM, 1976, EUR J BIOCHEM, V66, P477; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; White HE, 2006, STRUCTURE, V14, P1197, DOI 10.1016/j.str.2006.05.021; ZANTEMA A, 1992, J BIOL CHEM, V267, P12936	62	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10500	10512		10.1074/jbc.M706453200	http://dx.doi.org/10.1074/jbc.M706453200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18230612	hybrid, Green Accepted, Green Published			2022-12-25	WOS:000254894700032
J	Stowell, SR; Arthur, CM; Mehta, P; Slanina, KA; Blixt, O; Leffler, H; Smith, DF; Cummings, RD				Stowell, Sean R.; Arthur, Connie M.; Mehta, Padmaja; Slanina, Kristen A.; Blixt, Ola; Leffler, Hakon; Smith, David F.; Cummings, Richard D.			Galectin-1,-2, and-3 exhibit differential recognition of sialylated glycans and blood group antigens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; CARBOHYDRATE-BINDING PROTEIN-35; N-ACETYLLACTOSAMINE UNITS; HAMSTER OVARY CELLS; HIGH-AFFINITY; STRUCTURAL DETERMINANTS; INFLAMMATORY RESPONSES; ACETYL LACTOSAMINE; GANGLIOSIDE GM(1); ENDOGENOUS LECTIN	Human galectins have functionally divergent roles, although most of the members of the galectin family bind weakly to the simple disaccharide lactose (Gal beta 1-4Glc). To assess the specificity of galectin-glycan interactions in more detail, we explored the binding of several important galectins (Gal-1, Gal-2, and Gal-3) using a dose-response approach toward a glycan microarray containing hundreds of structurally diverse glycans, and we compared these results to binding determinants on cells. All three galectins exhibited differences in glycan binding characteristics. On both the microarray and on cells, Gal-2 and Gal-3 exhibited higher binding than Gal-1 to fucose-containing A and B blood group antigens. Gal-2 exhibited significantly reduced binding to all sialylated glycans, whereas Gal-1 bound alpha 2-3-but not alpha 2-6-sialylated glycans, and Gal-3 bound to some glycans terminating in either alpha 2-3- or alpha 2-6-sialic acid. The effects of sialylation on Gal-1, Gal-2, and Gal-3 binding to cells also reflected differences in cellular sensitivity to Gal-1-, Gal-2-, and Gal-3-induced phosphatidylserine exposure. Each galectin exhibited higher binding for glycans with poly-N-acetyllactosamine (poly(LacNAc)) sequences (Gal beta 1-4GlcNAc)(n) when compared with N-acetyllactosamine (LacNAc) glycans (Gal beta 1-4GlcNAc). However, only Gal-3 bound internal LacNAc within poly(LacNAc). These results demonstrate that each of these galectins mechanistically differ in their binding to glycans on the microarrays and that these differences are reflected in the determinants required for cell binding and signaling. The specific glycan recognition by each galectin underscores the basis for differences in their biological activities.	[Stowell, Sean R.; Arthur, Connie M.; Slanina, Kristen A.; Smith, David F.; Cummings, Richard D.] Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; [Mehta, Padmaja] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA; [Blixt, Ola] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; [Leffler, Hakon] Lund Univ, Sect Microbiol Immunol & Glycobiol, S-22362 Lund, Sweden	Emory University; Oklahoma Medical Research Foundation; Scripps Research Institute; Lund University	Cummings, RD (corresponding author), Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.	rdcummi@emory.edu	Leffler, Hakon/A-2416-2019	Blixt, Ola/0000-0003-4143-6276; Leffler, Hakon/0000-0003-4482-8945	NHLBI NIH HHS [HL 085607, P01 HL085607] Funding Source: Medline; NIGMS NIH HHS [T32 GM008169, GM 62116] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL085607] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008169, U54GM062116] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad N, 2004, J BIOL CHEM, V279, P10841, DOI 10.1074/jbc.M312834200; Ahmad N, 2004, GLYCOBIOLOGY, V14, P817, DOI 10.1093/glycob/cwh095; Allen HJ, 1998, GLYCOCONJUGATE J, V15, P691, DOI 10.1023/A:1006988515346; Almkvist J, 2002, J IMMUNOL, V168, P4034, DOI 10.4049/jimmunol.168.8.4034; Almkvist J, 2001, INFECT IMMUN, V69, P832, DOI 10.1128/IAI.69.2.832-837.2001; Appukuttan PS, 2002, J MOL RECOGNIT, V15, P180, DOI 10.1002/jmr.573; BAENZIGER JU, 1979, J BIOL CHEM, V254, P9795; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; Blixt O, 2004, P NATL ACAD SCI USA, V101, P17033, DOI 10.1073/pnas.0407902101; Bochner BS, 2005, J BIOL CHEM, V280, P4307, DOI 10.1074/jbc.M412378200; Breuilh L, 2007, INFECT IMMUN, V75, P5148, DOI 10.1128/IAI.02006-06; Brewer CF, 2002, GLYCOCONJUGATE J, V19, P459, DOI 10.1023/B:GLYC.0000014075.62724.d0; Camby I, 2006, GLYCOBIOLOGY, V16, p137R, DOI 10.1093/glycob/cwl025; Carlsson S, 2007, GLYCOBIOLOGY, V17, P663, DOI 10.1093/glycob/cwm026; COOPER DNW, 1991, J CELL BIOL, V115, P1437, DOI 10.1083/jcb.115.5.1437; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1230; Dias-Baruffi M, 2003, J BIOL CHEM, V278, P41282, DOI 10.1074/jbc.M306624200; Dumic J, 2006, BBA-GEN SUBJECTS, V1760, P616, DOI 10.1016/j.bbagen.2005.12.020; FEIZI T, 1994, BIOCHEMISTRY-US, V33, P6342, DOI 10.1021/bi00186a038; FRIGERI LG, 1993, BIOCHEMISTRY-US, V32, P7644, DOI 10.1021/bi00081a007; Fukumori T, 2003, CANCER RES, V63, P8302; Glinsky VV, 2001, CANCER RES, V61, P4851; Glinsky VV, 2003, CANCER RES, V63, P3805; Hahn HP, 2004, CELL DEATH DIFFER, V11, P1277, DOI 10.1038/sj.cdd.4401485; Hatch NE, 2006, J BIOL CHEM, V281, P27292, DOI 10.1074/jbc.M600448200; Hirabayashi J, 2002, BBA-GEN SUBJECTS, V1572, P232, DOI 10.1016/S0304-4165(02)00311-2; HOKKE CH, 1995, EUR J BIOCHEM, V228, P981, DOI 10.1111/j.1432-1033.1995.tb20350.x; Hsu DK, 2000, AM J PATHOL, V156, P1073, DOI 10.1016/S0002-9440(10)64975-9; Ilarregui JM, 2005, ANN RHEUM DIS, V64, P96, DOI 10.1136/ard.2005.044347; JENG KCG, 1994, IMMUNOL LETT, V42, P113, DOI 10.1016/0165-2478(94)90072-8; Jiang JX, 2006, NEUROSIGNALS, V15, P266, DOI 10.1159/000105517; Karmakar S, 2005, J BIOL CHEM, V280, P28623, DOI 10.1074/jbc.M414140200; KNIBBS RN, 1993, J BIOL CHEM, V268, P14940; Kohatsu L, 2006, J IMMUNOL, V177, P4718, DOI 10.4049/jimmunol.177.7.4718; Kopitz J, 1998, J BIOL CHEM, V273, P11205, DOI 10.1074/jbc.273.18.11205; Kopitz J, 2001, J BIOL CHEM, V276, P35917, DOI 10.1074/jbc.M105135200; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; La M, 2003, AM J PATHOL, V163, P1505, DOI 10.1016/S0002-9440(10)63507-9; LEFFLER H, 1986, J BIOL CHEM, V261, P119; Leffler H, 2002, GLYCOCONJUGATE J, V19, P433, DOI 10.1023/B:GLYC.0000014072.34840.04; Leppanen A, 2005, J BIOL CHEM, V280, P5549, DOI 10.1074/jbc.m412019200; LOTAN R, 1975, J BIOL CHEM, V250, P8518; MASSA SM, 1993, BIOCHEMISTRY-US, V32, P260, DOI 10.1021/bi00052a033; MERKLE RK, 1987, J BIOL CHEM, V262, P8179; Moiseeva EP, 2003, BBA-GEN SUBJECTS, V1619, P125, DOI 10.1016/S0304-4165(02)00447-6; Nam HJ, 2006, J BIOL CHEM, V281, P25670, DOI 10.1074/jbc.M604421200; Nieminen J, 2007, J BIOL CHEM, V282, P1374, DOI 10.1074/jbc.M604506200; NOVOGRODSKY A, 1975, J IMMUNOL, V115, P1243; Oliveira FL, 2007, J LEUKOCYTE BIOL, V82, P300, DOI 10.1189/jlb.1206747; ORIOL R, 1986, VOX SANG, V51, P161, DOI 10.1111/j.1423-0410.1986.tb01946.x; Ozaki K, 2004, NATURE, V429, P72, DOI 10.1038/nature02502; Patnaik SK, 2006, GLYCOBIOLOGY, V16, P305, DOI 10.1093/glycob/cwj063; Pelletier I, 2003, J BIOL CHEM, V278, P22223, DOI 10.1074/jbc.M302693200; Pelletier I, 2002, J BIOL CHEM, V277, P17663, DOI 10.1074/jbc.M201562200; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Rabinovich GA, 2000, EUR J IMMUNOL, V30, P1331, DOI 10.1002/(SICI)1521-4141(200005)30:5<1331::AID-IMMU1331>3.3.CO;2-8; REED RA, 1987, BIOCHEMISTRY-US, V26, P824, DOI 10.1021/bi00377a025; Rubinstein N, 2004, TISSUE ANTIGENS, V64, P1, DOI 10.1111/j.0001-2815.2004.00278.x; Sangeetha SR, 2005, INT J BIOL MACROMOL, V35, P269, DOI 10.1016/j.ijbiomac.2005.03.004; Sano H, 2000, J IMMUNOL, V165, P2156, DOI 10.4049/jimmunol.165.4.2156; Sato S, 2002, GLYCOCONJUGATE J, V19, P583, DOI 10.1023/B:GLYC.0000014089.17121.cc; SATO S, 1992, J BIOL CHEM, V267, P6983; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; Siebert HC, 2003, BIOCHEMISTRY-US, V42, P14762, DOI 10.1021/bi035477c; SOLOMON JC, 1991, CARBOHYD RES, V213, P293, DOI 10.1016/S0008-6215(00)90616-5; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; SPRINGER GF, 1969, J CLIN INVEST, V48, P1280, DOI 10.1172/JCI106094; Stillman BN, 2006, J IMMUNOL, V176, P778, DOI 10.4049/jimmunol.176.2.778; Stowell SR, 2007, BLOOD, V109, P219, DOI 10.1182/blood-2006-03-007153; Stowell SR, 2004, GLYCOBIOLOGY, V14, P157, DOI 10.1093/glycob/cwh018; Sturm A, 2004, J IMMUNOL, V173, P3825, DOI 10.4049/jimmunol.173.6.3825; Toscano MA, 2007, NAT IMMUNOL, V8, P825, DOI 10.1038/ni1482; van Liempt E, 2006, FEBS LETT, V580, P6123, DOI 10.1016/j.febslet.2006.10.009; VIITALA J, 1984, EUR J BIOCHEM, V138, P393, DOI 10.1111/j.1432-1033.1984.tb07928.x; WOO HJ, 1990, J BIOL CHEM, V265, P7097; YAMAOKA A, 1995, J IMMUNOL, V154, P3479; Yi W, 2005, J AM CHEM SOC, V127, P2040, DOI 10.1021/ja045021y; Zhang PJ, 2005, MOL PHARMACOL, V67, P1334, DOI 10.1124/mol.104.004481; ZHOU Q, 1990, ARCH BIOCHEM BIOPHYS, V281, P27, DOI 10.1016/0003-9861(90)90408-Q	79	312	316	3	45	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					10109	10123		10.1074/jbc.M709545200	http://dx.doi.org/10.1074/jbc.M709545200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18216021	Green Published, hybrid			2022-12-25	WOS:000254671600065
J	Andreasson, C; Fiaux, J; Rampelt, H; Mayer, MP; Bukau, B				Andreasson, Claes; Fiaux, Jocelyne; Rampelt, Heike; Mayer, Matthias P.; Bukau, Bernd			Hsp110 is a nucleotide-activated exchange factor for Hsp70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMIDE HYDROGEN-EXCHANGE; MOLECULAR CHAPERONE SSE1; CONFORMATIONAL-CHANGES; MASS-SPECTROMETRY; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; PROTEIN DYNAMICS; ATPASE ACTIVITY; BINDING; FAMILY	Hsp110 proteins constitute a subfamily of the Hsp70 chaperones and are potent nucleotide exchange factors ( NEFs) for canonical Hsp70s of the eukaryotic cytosol. Here, we show that the NEF activity of the yeast Hsp110 homologue Sse1 itself is controlled by nucleotide. Nucleotide binding results in formation of a stabilized conformation of Sse1 that is required for association with the yeast Hsp70 Ssa1. The interaction triggers release of bound ADP from Ssa1, but nucleotide persists bound to Sse1 in the complex. Surprisingly, removal of this nucleotide does not affect the integrity of the complex. Instead, rebinding of ATP to the Hsp70 prompts the dissociation of the complex. Our data demonstrate that in contrast to previously characterized NEFs for Hsp70 chaperones, the NEF activity of Sse1 requires nucleotide binding and let us propose a new model for Hsp110 function.	[Andreasson, Claes; Fiaux, Jocelyne; Rampelt, Heike; Mayer, Matthias P.; Bukau, Bernd] Univ Heidelberg, DKFZ ZBH Alliance, Zentrum Mol Biol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Bukau, B (corresponding author), Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	bukau@zmbh.uni-heidelberg.de	Mayer, Matthias P./B-9340-2013	Mayer, Matthias P./0000-0002-7859-3112; Bukau, Bernd/0000-0003-0521-7199; Rampelt, Heike/0000-0002-5458-5652; Andreasson, Claes/0000-0001-8948-0685				BUCHBERGER A, 1994, EMBO J, V13, P1687, DOI 10.1002/j.1460-2075.1994.tb06433.x; CRAI EA, 2005, PROTEIN FOLDING HDB, V2, P490; Dragovic Z, 2006, EMBO J, V25, P2519, DOI 10.1038/sj.emboj.7601138; Easton DP, 2000, CELL STRESS CHAPERON, V5, P276, DOI 10.1379/1466-1268(2000)005<0276:THAGSP>2.0.CO;2; HA JH, 1999, MOL CHAPERONES FOLDI, V1, P573; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; Liu QL, 2007, CELL, V131, P106, DOI 10.1016/j.cell.2007.08.039; Mayer MP, 2005, CELL MOL LIFE SCI, V62, P670, DOI 10.1007/s00018-004-4464-6; Raviol H, 2006, FEBS LETT, V580, P168, DOI 10.1016/j.febslet.2005.11.069; Raviol H, 2006, EMBO J, V25, P2510, DOI 10.1038/sj.emboj.7601139; Rist W, 2005, PROTEIN SCI, V14, P626, DOI 10.1110/ps.041098305; Rist W, 2003, J BIOL CHEM, V278, P51415, DOI 10.1074/jbc.M307160200; Rist W, 2006, J BIOL CHEM, V281, P16493, DOI 10.1074/jbc.M600847200; Shaner L, 2004, J BIOL CHEM, V279, P21992, DOI 10.1074/jbc.M313739200; Shaner L, 2005, J BIOL CHEM, V280, P41262, DOI 10.1074/jbc.M503614200; Shaner L, 2007, CELL STRESS CHAPERON, V12, P1, DOI 10.1379/CSC-245R.1; Shaner L, 2006, BIOCHEMISTRY-US, V45, P15075, DOI 10.1021/bi061279k; Shomura Y, 2005, MOL CELL, V17, P367, DOI 10.1016/j.molcel.2004.12.023; Sondermann H, 2001, SCIENCE, V291, P1553, DOI 10.1126/science.1057268; Steel GJ, 2004, SCIENCE, V303, P98, DOI 10.1126/science.1092287; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; Trott A, 2005, GENETICS, V170, P1009, DOI 10.1534/genetics.105.043109; Wales TE, 2006, MASS SPECTROM REV, V25, P158, DOI 10.1002/mas.20064; WEI JY, 1995, J BIOL CHEM, V270, P26677, DOI 10.1074/jbc.270.44.26677; Yam AYW, 2005, J BIOL CHEM, V280, P41252, DOI 10.1074/jbc.M503615200; Yamagishi N, 2004, J BIOL CHEM, V279, P41727, DOI 10.1074/jbc.M407947200; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437	27	112	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					8877	8884		10.1074/jbc.M710063200	http://dx.doi.org/10.1074/jbc.M710063200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18218635	hybrid			2022-12-25	WOS:000254465800015
J	Ohta, T; Imagawa, T; Ito, S				Ohta, Toshio; Imagawa, Toshiaki; Ito, Shigeo			Novel gating and sensitizing mechanism of capsaicin receptor (TRPV1) - Tonic inhibitory regulation of extracellular sodium through the external protonation sites on TRPV1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTENTIAL V1 PTRPV1; VANILLOID RECEPTOR-1; SENSORY NEURONS; ANTAGONIST CAPSAZEPINE; NEUROPATHIC PAIN; IN-VIVO; ACTIVATION; CHANNELS; SENSITIVITY; DETERMINANTS	Transient receptor potential V1 (TRPV1) is a nonselective cation channel expressed in nociceptors and activated by capsaicin. TRPV1 detects diverse stimuli, including acid, heat, and endogenous vanilloids, and functions as a molecular integrator of pain perception. Herein we demonstrate a novel regulatory role of extracellular Na+ ([Na+](o)) on TRPV1 function. In human embryonic kidney 293 cells expressing porcine TRPV1, low [ Na+](o) evoked increases of [Ca2+](i) that were suppressed by TRPV1 antagonists and facilitated responses to capsaicin, protons, heat, and an endovanilloid. [Na+](o) removal simultaneously elicited a [Ca2+](i) increase and outward-rectified current with a reversal potential similar to those of capsaicin. Neutralization of the two acidic residues which confer the proton sensitivity to TRPV1 resulted in a reduction of low [Na+](o)-induced responses. In primary culture of porcine sensory neurons, the removal of [Na+](o) produced a [Ca2+](i) increase and current responses only in the cells responding to capsaicin. Low [Na+](o) evoked a [Ca2+](i) increase in sensory neurons of wild type mice, but not TRPV1-null mice, and in human embryonic kidney 293 cells expressing human TRPV1. The present results suggest that [Na+](o) negatively regulates the gating and polymodal sensitization of the TRPV1 channel. [Na+](o) surrounding several proton-sensitive sites on the extracellular side of the pore-forming loop of the TRPV1 channel may play an important role as a brake to suppress the excessive activity of this channel under physiological conditions.	[Ohta, Toshio; Ito, Shigeo] Hokkaido Univ, Grad Sch Vet Med, Dept Biomed Sci, Pharmacol Lab, Sapporo, Hokkaido 0600818, Japan; [Imagawa, Toshiaki] Hokkaido Univ, Grad Sch Sci, Div Chem, Sapporo, Hokkaido 0600810, Japan	Hokkaido University; Hokkaido University	Ohta, T (corresponding author), Hokkaido Univ, Grad Sch Vet Med, Dept Biomed Sci, Pharmacol Lab, N18W9, Sapporo, Hokkaido 0600818, Japan.	tohta@vetmed.hokudai.ac.jp	Imagawa, Toshiaki/A-4255-2012					Ahern GP, 2006, J BIOL CHEM, V281, P8991, DOI 10.1074/jbc.M513429200; Ahern GP, 2005, J NEUROSCI, V25, P5109, DOI 10.1523/JNEUROSCI.0237-05.2005; Caterina MJ, 2001, ANNU REV NEUROSCI, V24, P487, DOI 10.1146/annurev.neuro.24.1.487; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chuang HH, 2001, NATURE, V411, P957, DOI 10.1038/35082088; Correll CC, 2004, NEUROSCI LETT, V370, P55, DOI 10.1016/j.neulet.2004.07.058; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; Dingledine R, 1999, PHARMACOL REV, V51, P7; Gavva NR, 2005, J PHARMACOL EXP THER, V313, P474, DOI 10.1124/jpet.104.079855; Gavva NR, 2004, J BIOL CHEM, V279, P20283, DOI 10.1074/jbc.M312577200; Goswami C, 2006, J NEUROCHEM, V96, P254, DOI 10.1111/j.1471-4159.2005.03551.x; HOLZER P, 1991, PHARMACOL REV, V43, P143; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; Jerman JC, 2000, BRIT J PHARMACOL, V130, P916, DOI 10.1038/sj.bjp.0703390; Jordt SE, 2000, P NATL ACAD SCI USA, V97, P8134, DOI 10.1073/pnas.100129497; Jordt SE, 2002, CELL, V108, P421, DOI 10.1016/S0092-8674(02)00637-2; Kim SR, 2005, J NEUROSCI, V25, P662, DOI 10.1523/JNEUROSCI.4166-04.2005; Liu LJ, 2007, J NEUROPHYSIOL, V97, P2001, DOI 10.1152/jn.00887.2006; Lukacz ES, 2001, OBSTET GYNECOL, V98, P974, DOI 10.1016/S0029-7844(01)01490-9; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; McIntyre P, 2001, BRIT J PHARMACOL, V132, P1084, DOI 10.1038/sj.bjp.0703918; Meier SD, 2006, J NEUROSCI METH, V155, P251, DOI 10.1016/j.jneumeth.2006.01.009; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Offenstadt G, 2006, MINERVA ANESTESIOL, V72, P353; Ohta T, 2005, BIOCHEM PHARMACOL, V71, P173, DOI 10.1016/j.bcp.2005.09.028; Ohta T, 2007, BIOCHEM PHARMACOL, V73, P1646, DOI 10.1016/j.bcp.2007.01.029; Ohta T, 2006, J PHYSIOL-LONDON, V576, P809, DOI 10.1113/jphysiol.2006.112250; Phillips E, 2004, J BIOL CHEM, V279, P17165, DOI 10.1074/jbc.M313328200; Pomonis JD, 2003, J PHARMACOL EXP THER, V306, P387, DOI 10.1124/jpet.102.046268; Prescott ED, 2003, SCIENCE, V300, P1284, DOI 10.1126/science.1083646; Rosenbaum T, 2004, J GEN PHYSIOL, V123, P53, DOI 10.1085/jgp.200308906; Schroder UH, 1999, NEUROPHARMACOLOGY, V38, P319, DOI 10.1016/S0028-3908(98)00198-1; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Tousova K, 2005, MOL CELL NEUROSCI, V30, P207, DOI 10.1016/j.mcn.2005.07.004; Trevisani M, 2002, NAT NEUROSCI, V5, P546, DOI 10.1038/nn852; van der Stelt M, 2004, EUR J BIOCHEM, V271, P1827, DOI 10.1111/j.1432-1033.2004.04081.x; Walker KM, 2003, J PHARMACOL EXP THER, V304, P56, DOI 10.1124/jpet.102.042010	38	44	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9377	9387		10.1074/jbc.M709377200	http://dx.doi.org/10.1074/jbc.M709377200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18230619	hybrid			2022-12-25	WOS:000254465800068
J	Patrakitkomjorn, S; Kobayashi, D; Morikawa, T; Wilson, MM; Tsubota, N; Irie, A; Ozawa, T; Aoki, M; Arimura, N; Kaibuchi, K; Saya, H; Araki, N				Patrakitkomjorn, Siriporn; Kobayashi, Daiki; Morikawa, Takashi; Wilson, Masayo Morifuji; Tsubota, Nobuyuki; Irie, Atsushi; Ozawa, Tatsuya; Aoki, Masashi; Arimura, Nariko; Kaibuchi, Kozo; Saya, Hideyuki; Araki, Norie			Neurofibromatosis type 1 (NF1) tumor suppressor, neurofibromin, regulates the neuronal differentiation of PC12 cells via its associating protein, CRMP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAENORHABDITIS-ELEGANS; GENE-PRODUCT; ALZHEIMERS-DISEASE; SENSORY NEURONS; NERVOUS-SYSTEM; PHOSPHORYLATION; KINASE; PATHWAY; FAMILY; RHO	Neurofibromatosis type 1 (NF1) tumor suppressor gene product, neurofibromin, functions in part as a Ras-GAP, a negative regulator of Ras. Neurofibromin is implicated in the neuronal abnormality of NF1 patients; however, the precise cellular function of neurofibromin has yet to be clarified. Using proteomic strategies, we identified a set of neurofibromin-associating cellular proteins, including axon regulator CRMP-2 (Collapsin response mediator protein-2). CRMP-2 directly bound to the C-terminal domain of neurofibromin, and this association was regulated by the manner of CRMP-2 phosphorylation. In nerve growth factor-stimulated PC12 cells, neurofibromin and CRMP-2 co-localized particularly on the distal tips and branches of extended neurites. Suppression of neurofibromin using NF1 small interfering RNA significantly inhibited this neurite outgrowth and up-regulated a series of CRMP-2 phosphorylations by kinases identified as CDK5, GSK-3b, and Rho kinase. Overexpression of the NF1-RAS-GAP-related domain rescued these NF1 small interfering RNA-induced events. Our results suggest that neurofibromin regulates neuronal differentiation by performing one or more complementary roles. First, neurofibromin directly regulates CRMP-2 phosphorylation accessibility through the complex formation. Also, neurofibromin appears to indirectly regulate CRMP-2 activity by suppressing CRMP-2-phosphorylating kinase cascades via its Ras-GAP function. Our study demonstrates that the functional association of neurofibromin and CRMP-2 is essential for neuronal cell differentiation and that lack of expression or abnormal regulation of neurofibromin can result in impaired function of neuronal cells, which is likely a factor in NF1-related pathogenesis.	[Patrakitkomjorn, Siriporn; Kobayashi, Daiki; Morikawa, Takashi; Wilson, Masayo Morifuji; Tsubota, Nobuyuki; Ozawa, Tatsuya; Aoki, Masashi; Saya, Hideyuki; Araki, Norie] Kumamoto Univ, Sch Med, Grad Sch Med Sci, Dept Tumor Genet & Biol, Kumamoto 8608556, Japan; [Irie, Atsushi] Kumamoto Univ, Sch Med, Grad Sch Med Sci, Dept Immunogenet, Kumamoto 8608556, Japan; [Arimura, Nariko; Kaibuchi, Kozo] Nagoya Univ, Grad Sch Med, Dept Cell Pharmacol, Nagoya, Aichi 4668550, Japan	Kumamoto University; Kumamoto University; Nagoya University	Araki, N (corresponding author), Kumamoto Univ, Sch Med, Grad Sch Med Sci, Dept Tumor Genet & Biol, Kumamoto 8608556, Japan.	nori@gpo.kumamoto-u.ac.jp	Saya, Hideyuki/J-4325-2013	Kobayashi, Daiki/0000-0003-4131-5220				Bito H, 2000, NEURON, V26, P431, DOI 10.1016/S0896-6273(00)81175-7; BOLLAG G, 1993, EMBO J, V12, P1923, DOI 10.1002/j.1460-2075.1993.tb05841.x; Byk T, 1998, EUR J BIOCHEM, V254, P14, DOI 10.1046/j.1432-1327.1998.2540014.x; Byk T, 1996, J NEUROSCI, V16, P688; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Cole A, 2004, BIOCHEM J, V377, P249, DOI 10.1042/BJ20031259; Cole AR, 2006, J BIOL CHEM, V281, P16591, DOI 10.1074/jbc.M513344200; Costa RM, 2002, NATURE, V415, P526, DOI 10.1038/nature711; Dasgupta B, 2003, CURR OPIN GENET DEV, V13, P20, DOI 10.1016/S0959-437X(02)00015-1; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; Fahsold R, 2000, AM J HUM GENET, V66, P790, DOI 10.1086/302809; Feng LP, 2004, FEBS LETT, V557, P275, DOI 10.1016/S0014-5793(03)01507-2; Fukata Y, 2002, NAT CELL BIOL, V4, P583, DOI 10.1038/ncb825; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; GREGORY PE, 1993, SOMAT CELL MOLEC GEN, V19, P265, DOI 10.1007/BF01233074; Guo HF, 2000, NATURE, V403, P895, DOI 10.1038/35002593; Hamajima N, 1996, GENE, V180, P157, DOI 10.1016/S0378-1119(96)00445-3; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Kimura T, 2005, J NEUROCHEM, V93, P1371, DOI 10.1111/j.1471-4159.2005.03063.x; Lee S, 2002, J BIOL CHEM, V277, P6542, DOI 10.1074/jbc.M108047200; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Li CJ, 2001, DEV BRAIN RES, V130, P231, DOI 10.1016/S0165-3806(01)00190-0; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; MINTURN JE, 1995, J COMP NEUROL, V355, P369, DOI 10.1002/cne.903550304; Nakayama AY, 2000, J NEUROSCI, V20, P5329, DOI 10.1523/JNEUROSCI.20-14-05329.2000; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; Owen R, 2003, MOL CELL NEUROSCI, V23, P626, DOI 10.1016/S1044-7431(03)00095-2; Ozawa T, 2005, J BIOL CHEM, V280, P39524, DOI 10.1074/jbc.M503707200; Ozon S, 1998, J NEUROCHEM, V70, P2386; Sayas CL, 1999, J BIOL CHEM, V274, P37046, DOI 10.1074/jbc.274.52.37046; STEPHENS K, 1987, Genomics, V1, P353, DOI 10.1016/0888-7543(87)90037-1; Tokuo H, 2001, FEBS LETT, V494, P48, DOI 10.1016/S0014-5793(01)02309-2; Uchida Y, 2005, GENES CELLS, V10, P165, DOI 10.1111/j.1365-2443.2005.00827.x; Wang LH, 1996, J NEUROSCI, V16, P6197; Xu HM, 1997, BRAIN RES, V759, P149, DOI 10.1016/S0006-8993(97)00328-4; Yoshimura T, 2006, BIOCHEM BIOPH RES CO, V340, P62, DOI 10.1016/j.bbrc.2005.11.147; Yoshimura T, 2005, CELL, V120, P137, DOI 10.1016/j.cell.2004.11.012; Yunoue S, 2003, J BIOL CHEM, V278, P26958, DOI 10.1074/jbc.M209413200	42	67	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9399	9413		10.1074/jbc.M708206200	http://dx.doi.org/10.1074/jbc.M708206200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18218617	hybrid			2022-12-25	WOS:000254465800070
J	Kienlen-Campard, P; Tasiaux, B; Van Hees, J; Li, M; Huysseune, S; Sato, T; Fei, JZ; Aimoto, S; Courtoy, PJ; Smith, SO; Constantinescu, SN; Octave, JN				Kienlen-Campard, Pascal; Tasiaux, Bernadette; Van Hees, Joanne; Li, Mingli; Huysseune, Sandra; Sato, Takeshi; Fei, Jeffrey Z.; Aimoto, Saburo; Courtoy, Pierre J.; Smith, Steven O.; Constantinescu, Stefan N.; Octave, Jean-Noel			Amyloidogenic processing but not amyloid precursor protein (APP) intracellular C-terminal domain production requires a precisely oriented APP dimer assembled by transmembrane GXXXG motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE ACTIVITY; CELL-SURFACE-RECEPTOR; ALZHEIMERS-DISEASE; BETA-SECRETASE; A-BETA; SIGNAL-TRANSDUCTION; HELIX ASSOCIATION; MEMBRANE-PROTEINS; GLYCOPHORIN-A; ALPHA-HELICES	The beta-amyloid peptide (A beta) is the major constituent of the amyloid core of senile plaques found in the brain of patients with Alzheimer disease. A beta is produced by the sequential cleavage of the amyloid precursor protein (APP) by beta-and gamma-secretases. Cleavage of APP by gamma-secretase also generates the APP intracellular C-terminal domain (AICD) peptide, which might be involved in regulation of gene transcription. APP contains three Gly-XXX-Gly (GXXXG) motifs in its jux-tamembrane and transmembrane (TM) regions. Such motifs are known to promote dimerization via close apposition of TM sequences. We demonstrate that pairwise replacement of glycines by leucines or isoleucines, but not alanines, in a GXXXG motif led to a drastic reduction of A beta 40 and A beta 42 secretion. beta-Cleavage of mutant APP was not inhibited, and reduction of A beta secretion resulted from inhibition of gamma-cleavage. It was anticipated that decreased gamma-cleavage of mutant APP would result from inhibition of its dimerization. Surprisingly, mutations of the GXXXG motif actually enhanced dimerization of the APP C-terminal fragments, possibly via a different TM alpha-helical interface. Increased dimerization of the TM APP C-terminal domain did not affect AICD production.	[Van Hees, Joanne; Li, Mingli; Constantinescu, Stefan N.] Univ Catholique Louvain, Christian de Duve Inst, B-1200 Brussels, Belgium; [Van Hees, Joanne; Li, Mingli; Constantinescu, Stefan N.] Univ Catholique Louvain, Ludwig Inst Canc Res, B-1200 Brussels, Belgium; [Courtoy, Pierre J.] Univ Catholique Louvain, Christian de Duve Inst Cellular Pathol, Cell Unit, B-1200 Brussels, Belgium; [Kienlen-Campard, Pascal; Tasiaux, Bernadette; Huysseune, Sandra; Octave, Jean-Noel] Univ Catholique Louvain, Ctr Neurosci, Expt Pharmacol Unit, B-1200 Brussels, Belgium; [Fei, Jeffrey Z.; Smith, Steven O.] SUNY Stony Brook, Dept Biochem & Cell Biol, Struct Biol Ctr, Stony Brook, NY 11794 USA; [Sato, Takeshi; Aimoto, Saburo] Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan	Universite Catholique Louvain; Ludwig Institute for Cancer Research; Universite Catholique Louvain; Universite Catholique Louvain; Universite Catholique Louvain; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Osaka University	Constantinescu, SN (corresponding author), Univ Catholique Louvain, Christian de Duve Inst, Av Hippocrate 74, B-1200 Brussels, Belgium.	stefan.constantinescu@bru.licr.org; octave@nchm.ucl.ac.be	Constantinescu, Stefan N/E-5277-2012; Smith, Steven/HDM-9496-2022	Kienlen-Campard, Pascal/0000-0003-1086-2942; Constantinescu, Stefan N./0000-0002-8599-2699	NATIONAL INSTITUTE ON AGING [RF1AG027317, R01AG027317] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG027317, R01 AG027317-01, R01 AG027317-02, AG027317, RF1 AG027317, R01 AG027317-03] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adams PD, 1996, PROTEINS, V26, P257, DOI 10.1002/(SICI)1097-0134(199611)26:3<257::AID-PROT2>3.0.CO;2-B; ALVES DC, 2006, J NEUROSCI, V26, P6377; Annaert W, 1999, TRENDS NEUROSCI, V22, P439, DOI 10.1016/S0166-2236(99)01455-1; BORMANN BJ, 1989, J BIOL CHEM, V264, P4033; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Cao XW, 2004, J BIOL CHEM, V279, P24601, DOI 10.1074/jbc.M402248200; Chen FS, 2006, NATURE, V440, P1208, DOI 10.1038/nature04667; Chen FS, 2002, J BIOL CHEM, V277, P36521, DOI 10.1074/jbc.M205093200; Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; De Strooper B, 2007, EMBO REP, V8, P141, DOI 10.1038/sj.embor.7400897; Ebinu JO, 2002, NEURON, V34, P499, DOI 10.1016/S0896-6273(02)00704-3; Edbauer D, 2002, J BIOL CHEM, V277, P13389, DOI 10.1074/jbc.M111571200; Eilers M, 2002, BIOPHYS J, V82, P2720, DOI 10.1016/S0006-3495(02)75613-0; Fortini ME, 2002, NAT REV MOL CELL BIO, V3, P673, DOI 10.1038/nrm910; Hebert SS, 2006, EMBO REP, V7, P739, DOI 10.1038/sj.embor.7400704; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Huysseune S, 2007, BIOCHEM BIOPH RES CO, V361, P317, DOI 10.1016/j.bbrc.2007.06.186; Javadpour MM, 1999, BIOPHYS J, V77, P1609, DOI 10.1016/S0006-3495(99)77009-8; Kakuda N, 2006, J BIOL CHEM, V281, P14776, DOI 10.1074/jbc.M513453200; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kienlen-Campard P, 2002, J BIOL CHEM, V277, P15666, DOI 10.1074/jbc.M200887200; Kleiger G, 2002, BIOCHEMISTRY-US, V41, P5990, DOI 10.1021/bi0200763; Lee SF, 2004, J BIOL CHEM, V279, P4144, DOI 10.1074/jbc.M309745200; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; Leissring MA, 2002, P NATL ACAD SCI USA, V99, P4697, DOI 10.1073/pnas.072033799; LEMMON MA, 1994, NAT STRUCT BIOL, V1, P157, DOI 10.1038/nsb0394-157; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Liu W, 2005, BIOCHEMISTRY-US, V44, P3591, DOI 10.1021/bi047827g; Macq AF, 1998, J BIOL CHEM, V273, P28931, DOI 10.1074/jbc.273.44.28931; Marchesi VT, 2005, P NATL ACAD SCI USA, V102, P9093, DOI 10.1073/pnas.0503181102; Munter LM, 2007, EMBO J, V26, P1702, DOI 10.1038/sj.emboj.7601616; Muresan Z, 2004, HUM MOL GENET, V13, P475, DOI 10.1093/hmg/ddh054; Niimura M, 2005, J BIOL CHEM, V280, P12967, DOI 10.1074/jbc.M409829200; Octave JN, 2000, J BIOL CHEM, V275, P1525, DOI 10.1074/jbc.275.3.1525; Pardossi-Piquard R, 2005, NEURON, V46, P541, DOI 10.1016/j.neuron.2005.04.008; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Pierrot N, 2004, J NEUROCHEM, V88, P1140, DOI 10.1046/j.1471-4159.2003.02227.x; Pitsi D, 2004, J BIOL CHEM, V279, P25333, DOI 10.1074/jbc.M312710200; Pitsi D, 2002, J NEUROCHEM, V83, P390, DOI 10.1046/j.1471-4159.2002.01138.x; Ren Z, 2007, J BIOL CHEM, V282, P35350, DOI 10.1074/jbc.M702739200; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Sato T, 2006, BIOCHEMISTRY-US, V45, P5503, DOI 10.1021/bi052485f; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Scheuermann S, 2001, J BIOL CHEM, V276, P33923, DOI 10.1074/jbc.M105410200; Senes A, 2004, CURR OPIN STRUC BIOL, V14, P465, DOI 10.1016/j.sbi.2004.07.007; Sergeant N, 2002, J NEUROCHEM, V81, P663, DOI 10.1046/j.1471-4159.2002.00901.x; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Smith SO, 2001, BIOCHEMISTRY-US, V40, P6553, DOI 10.1021/bi010357v; Soba P, 2005, EMBO J, V24, P3624, DOI 10.1038/sj.emboj.7600824; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vooijs M, 2004, J BIOL CHEM, V279, P50864, DOI 10.1074/jbc.M409430200; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107	59	115	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7733	7744		10.1074/jbc.M707142200	http://dx.doi.org/10.1074/jbc.M707142200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18201969	Green Accepted, hybrid			2022-12-25	WOS:000253997900050
J	Pearson, JL; Robinson, TJ; Munoz, MJ; Kornblihtt, AR; Garcia-Blanco, MA				Pearson, James L.; Robinson, Timothy J.; Munoz, Manuel J.; Kornblihtt, Alberto R.; Garcia-Blanco, Mariano A.			Identification of the cellular targets of the transcription factor TCERG1 reveals a prevalent role in mRNA processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLICING IN-VIVO; POLYMERASE-II; HUNTINGTONS-DISEASE; TERMINAL DOMAIN; BINDING-PROTEIN; CA150 INTERACTS; EXPRESSION DATA; FF DOMAINS; ELONGATION; GENE	The transcription factor TCERG1 (also known as CA150) associates with RNA polymerase II holoenzyme and alters the elongation efficiency of reporter transcripts. TCERG1 is also found as a component of highly purified spliceosomes and has been implicated in splicing. To elucidate the function of TCERG1, we used short interfering RNA-mediated knockdown followed by en masse gene expression analysis to identify its cellular targets. Analysis of data from HEK293 and HeLa cells identified high confidence targets of TCERG1. We found that targets of TCERG1 were enriched in microRNA-binding sites, suggesting the possibility of post-transcriptional regulation. Consistently, reverse transcription-PCR analysis revealed that many of the changes observed upon TCERG1 knockdown were because of differences in alternative mRNA processing of the 3'-untranslated regions. Furthermore, a novel computational approach, which can identify alternatively processed events from conventional microarray data, showed that TCERG1 led to widespread alterations in mRNA processing. These findings provide the strongest support to date for a role of TCERG1 in mRNA processing and are consistent with proposals that TCERG1 couples transcription and processing.	[Pearson, James L.; Garcia-Blanco, Mariano A.] Duke Univ, Med Ctr, Dept Mol Genet & Mirobiol, Durham, NC 27710 USA; [Robinson, Timothy J.] Duke Univ, Med Ctr, Dept Mol Canc Biol, Durham, NC 27710 USA; [Robinson, Timothy J.] Duke Univ, Med Ctr, Med Sci Training Program, Durham, NC 27710 USA; [Garcia-Blanco, Mariano A.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; [Pearson, James L.; Garcia-Blanco, Mariano A.] Duke Univ, Med Ctr, Ctr RNA Biol, Durham, NC 27710 USA; [Munoz, Manuel J.; Kornblihtt, Alberto R.] Univ Buenos Aires, Fac Ciencias Exactas & Nat, IFIBYNE CONICET, Dept Fisiol Biol Mol & Celular,Lab Fisiol & Biol, Buenos Aires, DF, Argentina	Duke University; Duke University; Duke University; Duke University; Duke University; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires	Garcia-Blanco, MA (corresponding author), Duke Univ, Med Ctr, Dept Mol Genet & Mirobiol, Durham, NC 27710 USA.	garci001@mc.duke.edu		Munoz, Manuel J./0000-0002-1152-5449; Kornblihtt, Alberto/0000-0003-4322-0831	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071037] Funding Source: NIH RePORTER; NIGMS NIH HHS [1R01 GM071037] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andresen JM, 2007, J MED GENET, V44, P44, DOI 10.1136/jmg.2006.045153; Arango M, 2006, J NEUROSCI, V26, P4649, DOI 10.1523/JNEUROSCI.5409-05.2006; Bird G, 2004, MOL CELL BIOL, V24, P8963, DOI 10.1128/MCB.24.20.8963-8969.2004; Carty SM, 2000, P NATL ACAD SCI USA, V97, P9015, DOI 10.1073/pnas.160266597; Chattopadhyay B, 2003, NEUROSCI LETT, V345, P93, DOI 10.1016/S0304-3940(03)00436-1; Cheng DH, 2007, MOL CELL, V25, P71, DOI 10.1016/j.molcel.2006.11.019; Cope LM, 2004, BIOINFORMATICS, V20, P323, DOI 10.1093/bioinformatics/btg410; Cramer P, 1999, MOL CELL, V4, P251, DOI 10.1016/S1097-2765(00)80372-X; de la Mata M, 2003, MOL CELL, V12, P525, DOI 10.1016/j.molcel.2003.08.001; de la Mata M, 2006, NAT STRUCT MOL BIOL, V13, P973, DOI 10.1038/nsmb1155; Deckert J, 2006, MOL CELL BIOL, V26, P5528, DOI 10.1128/MCB.00582-06; Dresios J, 2005, P NATL ACAD SCI USA, V102, P1865, DOI 10.1073/pnas.0409764102; Fan WH, 2006, THEOR BIOL MED MODEL, V3, DOI 10.1186/1742-4682-3-19; Florez PM, 2005, J VIROL, V79, P6172, DOI 10.1128/JVI.79.10.6172-6179.2005; Fong YW, 2001, NATURE, V414, P929, DOI 10.1038/414929a; Furger A, 2002, GENE DEV, V16, P2792, DOI 10.1101/gad.983602; Goldstrohm AC, 2001, MOL CELL BIOL, V21, P7617, DOI 10.1128/MCB.21.22.7617-7628.2001; Goldstrohm AC, 2001, GENE, V277, P31, DOI 10.1016/S0378-1119(01)00695-3; GOLDSTROHM AC, 2001, THESIS DUKE U DURHAM; Holbert S, 2001, P NATL ACAD SCI USA, V98, P1811, DOI 10.1073/pnas.041566798; Hu GK, 2001, GENOME RES, V11, P1237, DOI 10.1101/gr.165501; Kadener S, 2001, EMBO J, V20, P5759, DOI 10.1093/emboj/20.20.5759; Kita H, 2002, HUM MOL GENET, V11, P2279, DOI 10.1093/hmg/11.19.2279; Kornblihtt AR, 2005, CURR OPIN CELL BIOL, V17, P262, DOI 10.1016/j.ceb.2005.04.014; Kornblihtt AR, 2004, RNA, V10, P1489, DOI 10.1261/rna.7100104; Lin KT, 2004, MOL CELL BIOL, V24, P9176, DOI 10.1128/MCB.24.20.9176-9185.2004; Makarov EM, 2002, SCIENCE, V298, P2205, DOI 10.1126/science.1077783; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Neubauer G, 1998, NAT GENET, V20, P46, DOI 10.1038/1700; Newman JC, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-9-r81; Rappsilber J, 2002, GENOME RES, V12, P1231, DOI 10.1101/gr.473902; Reed R, 2003, CURR OPIN CELL BIOL, V15, P326, DOI 10.1016/S0955-0674(03)00048-6; Sanchez-Alvarez M, 2006, MOL CELL BIOL, V26, P4998, DOI 10.1128/MCB.01991-05; Smart F, 2007, J NEUROCHEM, V101, P1367, DOI 10.1111/j.1471-4159.2007.04521.x; Smith MJ, 2004, MOL CELL BIOL, V24, P9274, DOI 10.1128/MCB.24.21.9274-9285.2004; Stalteri MA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-13; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun X, 2004, CHROMOSOMA, V113, P244, DOI 10.1007/s00412-004-0314-4; SUNE C, 1995, J VIROL, V69, P3098; Sune C, 1999, MOL CELL BIOL, V19, P4719; Sune C, 1997, MOL CELL BIOL, V17, P6029, DOI 10.1128/MCB.17.10.6029; Wagner EJ, 2002, MOL CELL, V10, P943, DOI 10.1016/S1097-2765(02)00645-7	43	37	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7949	7961		10.1074/jbc.M709402200	http://dx.doi.org/10.1074/jbc.M709402200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18187414	hybrid, Green Published			2022-12-25	WOS:000253997900070
J	Graille, M; Chaillet, M; van Tilbeurgh, H				Graille, Marc; Chaillet, Maxime; van Tilbeurgh, Herman			Structure of yeast Dom34 - A protein related to translation termination factor eRF1 and involved in No-Go decay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DECAY; RELEASE FACTOR ERF1; STOP CODON RECOGNITION; SM-LIKE PROTEINS; MOLECULAR-BIOLOGY; CRYSTAL-STRUCTURE; NONSENSE; DEGRADATION; RIBOSOME; COMPLEX	The yeast protein Dom34 has been described to play a critical role in a newly identified mRNA decay pathway called No-Go decay. This pathway clears cells from mRNAs inducing translational stalls through endonucleolytic cleavage. Dom34 is related to the translation termination factor eRF1 and physically interacts with Hbs1, which is itself related to eRF3. We have solved the 2.5-angstrom resolution crystal structure of Saccharomyces cerevisiae Dom34. This protein is organized in three domains with the central and C-terminal domains structurally homologous to those from eRF1. The N-terminal domain of Dom34 is different from eRF1. It adopts a Sm-fold that is often involved in the recognition of mRNA stem loops or in the recruitment of mRNA degradation machinery. The comparison of eRF1 and Dom34 domains proposed to interact directly with eRF3 and Hbs1, respectively, highlights striking structural similarities with eRF1 motifs identified to be crucial for the binding to eRF3. In addition, as observed for eRF1 that enhances eRF3 binding to GTP, the interaction of Dom34 with Hbs1 results in an increase in the affinity constant of Hbs1 for GTP but not GDP. Taken together, these results emphasize that eukaryotic cells have evolved two structurally related complexes able to interact with ribosomes either paused at a stop codon or stalled in translation by the presence of a stable stem loop and to trigger ribosome release by catalyzing chemical bond hydrolysis.	[Graille, Marc; Chaillet, Maxime; van Tilbeurgh, Herman] Univ Paris 11, CNRS, Inst Biochim & Biophys Mol & Cellulaire, UMR 8619,IFR 115, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Graille, M (corresponding author), Univ Paris 11, CNRS, Inst Biochim & Biophys Mol & Cellulaire, UMR 8619,IFR 115, F-91405 Orsay, France.	marc.graille@u-psud.fr	GRAILLE, Marc/D-3242-2014	GRAILLE, Marc/0000-0002-7853-5852; Chaillet, Maxime/0000-0001-6812-4147				Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; Adham IM, 2003, MOL CELL BIOL, V23, P1470, DOI 10.1128/MCB.23.4.1470-1476.2003; Alkalaeva EZ, 2006, CELL, V125, P1125, DOI 10.1016/j.cell.2006.04.035; Amrani N, 2004, NATURE, V432, P112, DOI 10.1038/nature03060; Amrani N, 2006, NAT REV MOL CELL BIO, V7, P415, DOI 10.1038/nrm1942; Araki Y, 2001, EMBO J, V20, P4684, DOI 10.1093/emboj/20.17.4684; ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; Behm-Ansmant I, 2007, EMBO J, V26, P1591, DOI 10.1038/sj.emboj.7601588; Bertram G, 2000, RNA, V6, P1236, DOI 10.1017/S1355838200000777; Bouveret E, 2000, EMBO J, V19, P1661, DOI 10.1093/emboj/19.7.1661; Buhler M, 2006, NAT STRUCT MOL BIOL, V13, P462, DOI 10.1038/nsmb1081; Carr-Schmid A, 2002, MOL CELL BIOL, V22, P2564, DOI 10.1128/MCB.22.8.2564-2574.2002; Chang YF, 2007, ANNU REV BIOCHEM, V76, P51, DOI 10.1146/annurev.biochem.76.050106.093909; Chavatte L, 2002, EMBO J, V21, P5302, DOI 10.1093/emboj/cdf484; Clement SL, 2006, NAT STRUCT MOL BIOL, V13, P299, DOI 10.1038/nsmb0406-299; Conti E, 2005, CURR OPIN CELL BIOL, V17, P316, DOI 10.1016/j.ceb.2005.04.005; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; Davis L, 1998, GENETICS, V149, P45; Doma MK, 2006, NATURE, V440, P561, DOI 10.1038/nature04530; EBERHART CG, 1995, DEVELOPMENT, V121, P3477; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; Eurwilaichitr L, 1999, MOL MICROBIOL, V32, P485, DOI 10.1046/j.1365-2958.1999.01346.x; Frischmeyer PA, 2002, SCIENCE, V295, P2258, DOI 10.1126/science.1067338; Frolova L, 1996, RNA, V2, P334; Frolova LY, 1999, RNA, V5, P1014, DOI 10.1017/S135583829999043X; Fromont-Racine M, 2000, YEAST, V17, P95, DOI 10.1002/1097-0061(20000630)17:2<95::AID-YEA16>3.0.CO;2-H; Garneau NL, 2007, NAT REV MOL CELL BIO, V8, P113, DOI 10.1038/nrm2104; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; Heurgue-Hamard V, 2006, J BIOL CHEM, V281, P36140, DOI 10.1074/jbc.M608571200; Holbrook JA, 2004, NAT GENET, V36, P801, DOI 10.1038/ng1403; Ibba M, 1999, SCIENCE, V286, P1893, DOI 10.1126/science.286.5446.1893; Inagaki Y, 2003, NUCLEIC ACIDS RES, V31, P4227, DOI 10.1093/nar/gkg440; Ito K, 1998, RNA, V4, P958, DOI 10.1017/S1355838298971874; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kambach C, 1999, CELL, V96, P375, DOI 10.1016/S0092-8674(00)80550-4; Karzai AW, 2000, NAT STRUCT BIOL, V7, P449; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; Kisselev LL, 2000, TRENDS BIOCHEM SCI, V25, P561, DOI 10.1016/S0968-0004(00)01669-8; Kobayashi T, 2004, J BIOL CHEM, V279, P45693, DOI 10.1074/jbc.M405163200; KOONIN EV, 1994, NUCLEIC ACIDS RES, V22, P2166, DOI 10.1093/nar/22.11.2166; Kuzmiak HA, 2006, TRENDS MOL MED, V12, P306, DOI 10.1016/j.molmed.2006.05.005; Le Hir H, 2000, GENE DEV, V14, P1098; Le Hir H, 2001, EMBO J, V20, P4987, DOI 10.1093/emboj/20.17.4987; Lee HH, 2007, MOL CELL, V27, P938, DOI 10.1016/j.molcel.2007.07.019; Lehner B, 2004, GENOME RES, V14, P1315, DOI 10.1101/gr.2122004; LIBBY RT, 1991, MOL MICROBIOL, V5, P999, DOI 10.1111/j.1365-2958.1991.tb01872.x; Maquat LE, 2002, SCIENCE, V295, P2221, DOI 10.1126/science.1071285; MARQUAT LE, 2004, NAT REV MOL CELL BIO, V5, P89; Merkulova TI, 1999, FEBS LETT, V443, P41, DOI 10.1016/S0014-5793(98)01669-X; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Negrutskii BS, 1998, PROG NUCLEIC ACID RE, V60, P47, DOI 10.1016/S0079-6603(08)60889-2; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; Ogle JM, 2005, ANNU REV BIOCHEM, V74, P129, DOI 10.1146/annurev.biochem.74.061903.155440; Pillai RS, 2001, EMBO J, V20, P5470, DOI 10.1093/emboj/20.19.5470; Pisareva VP, 2006, J BIOL CHEM, V281, P40224, DOI 10.1074/jbc.M607461200; Rehwinkel J, 2006, TRENDS BIOCHEM SCI, V31, P639, DOI 10.1016/j.tibs.2006.09.005; Roth M, 2002, ACTA CRYSTALLOGR D, V58, P805, DOI 10.1107/S0907444902003943; Salas-Marco J, 2004, MOL CELL BIOL, V24, P7769, DOI 10.1128/MCB.24.17.7769-7778.2004; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Schumacher MA, 2002, EMBO J, V21, P3546, DOI 10.1093/emboj/cdf322; Song HW, 2000, CELL, V100, P311, DOI 10.1016/S0092-8674(00)80667-4; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P1863, DOI 10.1107/S0907444999010033; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tharun S, 2000, NATURE, V404, P515, DOI 10.1038/35006676; Tollervey D, 2006, NATURE, V440, P425, DOI 10.1038/440425a; van Hoof A, 2002, SCIENCE, V295, P2262, DOI 10.1126/science.1067272; Wallrapp C, 1998, FEBS LETT, V440, P387, DOI 10.1016/S0014-5793(98)01492-6; Wilusz CJ, 2005, NAT STRUCT MOL BIOL, V12, P1031, DOI 10.1038/nsmb1037; Xi RW, 2005, DEVELOPMENT, V132, P5365, DOI 10.1242/dev.02151; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; YANG W, 1995, STRUCTURE, V3, P131, DOI 10.1016/S0969-2126(01)00142-3; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x	72	67	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					7145	7154		10.1074/jbc.M708224200	http://dx.doi.org/10.1074/jbc.M708224200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18180287	hybrid, Green Published			2022-12-25	WOS:000253779600060
J	Gillen, CM; Courtney, HS; Schulze, K; Rohde, M; Wilson, MR; Timmer, AM; Guzman, CA; Nizet, V; Chhatwal, GS; Walker, MJ				Gillen, Christine M.; Courtney, Harry S.; Schulze, Kai; Rohde, Manfred; Wilson, Mark R.; Timmer, Anjuli M.; Guzman, Carlos A.; Nizet, Victor; Chhatwal, G. S.; Walker, Mark J.			Opacity factor activity and epithelial cell binding by the serum opacity factor protein of Streptococcus pyogenes are functionally discrete	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCI; HIGH-DENSITY-LIPOPROTEIN; FIBRONECTIN-BINDING; SURFACE PROTEIN; M1 PROTEIN; INTRANASAL IMMUNIZATION; INTRACELLULAR INVASION; CONFORMATIONAL EPITOPE; NORTHERN-TERRITORY; LIPOTEICHOIC ACID	Serum opacity factor (SOF) is a unique multifunctional virulence determinant expressed at the surface of Streptococcus pyogenes and has been shown to elicit protective immunity against GAS infection in a murine challenge model. SOF consists of two distinct domains with different binding capacities: an N-terminal domain that binds apolipoprotein AI and a C-terminal repeat domain that binds fibronectin and fibrinogen. The capacity of SOF to opacify serum by disrupting the structure of high density lipoproteins may preclude its use as a vaccine antigen in humans. This study generated mutant forms of recombinant SOF with reduced (100-fold) or abrogated opacity factor (OF) activity, for use as vaccine antigens. However, alterations introduced into the N-terminal SOF peptide (SOF Delta Fn) by mutagenesis to abrogate OF activity, abolish the capacity of SOF to protect against lethal systemic S. pyogenes challenge in a murine model. Mutant forms of purified SOF Delta Fn peptide were also used to assess the contribution of OF activity to the pathogenic processes of cell adhesion and cell invasion. Using latex beads coated with full-length SOF, SOF Delta Fn peptide, or a peptide encompassing the C-terminal repeats (FnBD), we demonstrate that adhesion to HEp-2 cells is mediated by both SOF Delta Fn and FnBD. The HEp-2 cell binding displayed by the N-terminal SOF Delta Fn peptide is independent of OF activity. We demonstrate that while the N terminus of SOF does not directly mediate intracellular uptake by epithelial cells, this domain enhances epithelial cell uptake mediated by full-length SOF, in comparison to the FnBD alone.	[Gillen, Christine M.; Wilson, Mark R.; Walker, Mark J.] Univ Wollongong, Sch Biol Sci, Wollongong, NSW 2522, Australia; [Courtney, Harry S.] Univ Tennessee, Ctr Hlth Sci, Dept Med, Memphis, TN 38104 USA; [Courtney, Harry S.] Univ Tennessee, Ctr Hlth Sci, Vet Affairs Med Ctr, Memphis, TN 38104 USA; [Schulze, Kai; Guzman, Carlos A.] Helmholtz Ctr Infect Res, Dept Vaccinol, Braunschweig, Germany; [Rohde, Manfred; Chhatwal, G. S.] Helmholtz Ctr Infect Res, Dept Microbiol Pathogen, D-38124 Braunschweig, Germany; [Timmer, Anjuli M.; Nizet, Victor] Univ Calif San Diego, Dept Pediat, Div Pharmacol & Drug Discovery, La Jolla, CA 92093 USA	University of Wollongong; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; Helmholtz Association; Helmholtz-Center for Infection Research; Helmholtz Association; Helmholtz-Center for Infection Research; University of California System; University of California San Diego	Walker, MJ (corresponding author), Univ Wollongong, Sch Biol Sci, Wollongong, NSW 2522, Australia.	mwalker@uow.edu.au	Wilson, Mark R/B-3254-2018; Nizet, Victor/AAF-3190-2019; Walker, Mark J./F-6940-2011; Gillen, Christine M/A-2717-2014	Wilson, Mark R/0000-0002-9551-7445; Duplancic, Christine/0000-0002-1775-3055; Walker, Mark/0000-0001-7423-2769; Nizet, Victor/0000-0003-3847-0422				[Anonymous], 1982, PHYS BIOCH APPL BIOC; [Anonymous], 1996, CIRCULAR DICHROISM C; Beall B, 2000, MICROBIOL-SGM, V146, P1195, DOI 10.1099/00221287-146-5-1195; BESSEN D, 1988, INFECT IMMUN, V56, P2666, DOI 10.1128/IAI.56.10.2666-2672.1988; BISNO AL, 1995, PRINCIPLES PRACTICE, V2, P1786; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Courtney HS, 2006, J BIOL CHEM, V281, P5515, DOI 10.1074/jbc.M512538200; Courtney HS, 2006, MOL MICROBIOL, V59, P936, DOI 10.1111/j.1365-2958.2005.04977.x; Courtney HS, 1999, MOL MICROBIOL, V32, P89, DOI 10.1046/j.1365-2958.1999.01328.x; Courtney HS, 2003, INFECT IMMUN, V71, P5097, DOI 10.1128/IAI.71.9.5097-5103.2003; Courtney HS, 2002, CURR MICROBIOL, V44, P236, DOI 10.1007/s00284-001-0037-1; Cue D, 2001, MICROB PATHOGENESIS, V31, P231, DOI 10.1006/mpat.2001.0467; Cue D, 1998, INFECT IMMUN, V66, P4593, DOI 10.1128/IAI.66.10.4593-4601.1998; Cue D, 2000, P NATL ACAD SCI USA, V97, P2858, DOI 10.1073/pnas.050587897; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; Currie B J, 2000, Australas J Dermatol, V41, P139, DOI 10.1046/j.1440-0960.2000.00417.x; Dombek PE, 1999, MOL MICROBIOL, V31, P859, DOI 10.1046/j.1365-2958.1999.01223.x; EMANCIPATOR K, 1992, INFECT IMMUN, V60, P596, DOI 10.1128/IAI.60.2.596-601.1992; Finger Florian, 2004, N Z Med J, V117, pU847; Gillard BK, 2007, BIOCHEMISTRY-US, V46, P12968, DOI 10.1021/bi701525w; Gillen CM, 2002, MICROBIOL-SGM, V148, P169, DOI 10.1099/00221287-148-1-169; Goodfellow AM, 2000, J CLIN MICROBIOL, V38, P389; Gravekamp C, 1996, INFECT IMMUN, V64, P3576, DOI 10.1128/IAI.64.9.3576-3583.1996; Grunfeld C, 1999, J LIPID RES, V40, P245; Hyka N, 2001, BLOOD, V97, P2381, DOI 10.1182/blood.V97.8.2381; Ionescu RM, 1999, NAT STRUCT BIOL, V6, P304; Jadoun J, 1998, J INFECT DIS, V178, P147, DOI 10.1086/515589; Jeng A, 2003, J BACTERIOL, V185, P1208, DOI 10.1128/JB.185.4.1208-1217.2003; Katerov V, 2000, CURR MICROBIOL, V40, P149, DOI 10.1007/s002849910031; Kawabata S, 2001, INFECT IMMUN, V69, P924, DOI 10.1128/IAI.69.2.924-930.2001; Kreikemeyer B, 2004, J BIOL CHEM, V279, P15850, DOI 10.1074/jbc.M313613200; KREIKEMEYER B, 1995, MOL MICROBIOL, V17, P137, DOI 10.1111/j.1365-2958.1995.mmi_17010137.x; Kreikemeyer B, 1999, FEMS MICROBIOL LETT, V178, P305, DOI 10.1016/S0378-1097(99)00373-0; Levels JHM, 2003, INFECT IMMUN, V71, P3280, DOI 10.1128/IAI.71.6.3280-3284.2003; LEVINE DM, 1993, P NATL ACAD SCI USA, V90, P12040, DOI 10.1073/pnas.90.24.12040; McArthur J, 2004, INFECT IMMUN, V72, P7342, DOI 10.1128/IAI.72.12.7342-7345.2004; McArthur JD, 2006, MOL MICROBIOL, V59, P1, DOI 10.1111/j.1365-2958.2005.04967.x; Medina E, 1999, J IMMUNOL, V163, P3396; Molinari G, 2000, CELL MICROBIOL, V2, P145, DOI 10.1046/j.1462-5822.2000.00040.x; Molinari G, 1997, INFECT IMMUN, V65, P1357, DOI 10.1128/IAI.65.4.1357-1363.1997; Oehmcke S, 2004, INFECT IMMUN, V72, P4302, DOI 10.1128/IAI.72.7.4302-4308.2004; Okada N, 1998, MICROBIOL-SGM, V144, P3079, DOI 10.1099/00221287-144-11-3079; OWENS RJ, 1990, J CLIN INVEST, V86, P1142, DOI 10.1172/JCI114819; Ozeri V, 1998, MOL MICROBIOL, V30, P625, DOI 10.1046/j.1365-2958.1998.01097.x; PANCHOLI V, 1992, J EXP MED, V176, P415, DOI 10.1084/jem.176.2.415; Podbielski A, 1999, MOL MICROBIOL, V31, P1051, DOI 10.1046/j.1365-2958.1999.01241.x; Purushothaman SS, 2003, INFECT IMMUN, V71, P5823, DOI 10.1128/IAI.71.10.5823-5830.2003; RAKONJAC JV, 1995, INFECT IMMUN, V63, P622, DOI 10.1128/IAI.63.2.622-631.1995; Relf WA, 1996, PEPTIDE RES, V9, P12; Reymond MT, 1997, PROTEIN SCI, V6, P706; Rezcallah MS, 2005, CELL MICROBIOL, V7, P645, DOI 10.1111/j.1462-5822.2004.00497.x; Rohde M, 2003, CELL MICROBIOL, V5, P323, DOI 10.1046/j.1462-5822.2003.00279.x; Sanderson-Smith ML, 2006, J BIOL CHEM, V281, P25965, DOI 10.1074/jbc.M603846200; SARAVANI GA, 1990, FEMS MICROBIOL LETT, V68, P35; Schmid FX., 1989, SPECTRAL METHODS CHA, P251; Schrager HM, 1998, J CLIN INVEST, V101, P1708, DOI 10.1172/JCI2121; Schulze K, 2006, VACCINE, V24, P1446, DOI 10.1016/j.vaccine.2005.06.039; SRINIVAS RV, 1991, J CELL BIOCHEM, V45, P224, DOI 10.1002/jcb.240450214; Svartman M, 1980, STREPTOCOCCAL DIS IM, P669; TADA N, 1993, MOL CELL BIOCHEM, V119, P171, DOI 10.1007/BF00926868; Tart AH, 2007, TRENDS MICROBIOL, V15, P318, DOI 10.1016/j.tim.2007.05.001; Terao Y, 2002, J BIOL CHEM, V277, P47428, DOI 10.1074/jbc.M209133200; Terao Y, 2001, MOL MICROBIOL, V42, P75, DOI 10.1046/j.1365-2958.2001.02579.x; Timmer AM, 2006, MOL MICROBIOL, V62, P15, DOI 10.1111/j.1365-2958.2006.05337.x; Walker MJ, 2005, TRENDS MICROBIOL, V13, P308, DOI 10.1016/j.tim.2005.05.006; WESSELS MR, 1994, INFECT IMMUN, V62, P433, DOI 10.1128/IAI.62.2.433-441.1994; Winram SB, 1996, MICROBIOL-SGM, V142, P2311, DOI 10.1099/13500872-142-8-2311; Zou W, 1999, J IMMUNOL, V163, P820	68	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2008	283	10					6359	6366		10.1074/jbc.M706739200	http://dx.doi.org/10.1074/jbc.M706739200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HM	18180300	Green Submitted, hybrid			2022-12-25	WOS:000253779500043
J	Amisten, S; Braun, OO; Johansson, L; Ridderstrale, M; Melander, O; Erlinge, D				Amisten, Stefan; Braun, Oscar Oe.; Johansson, Lovisa; Ridderstrale, Martin; Melander, Olle; Erlinge, David			The P2Y(13) Met-158-Thr Polymorphism, Which Is in Linkage Disequilibrium with the P2Y(12) Locus, Is Not Associated with Acute Myocardial Infarction	PLOS ONE			English	Article								Background and Aims. The aims of this study were to investigate (1) if P2Y(12) polymorphisms defining the P2Y(12) H2 allele are associated with any other SNPs that may explain the previously reported association with increased ADP induced platelet activation and association with peripheral arterial disease and coronary artery disease and (2) if such variants are associated with acute myocardial infarction (AMI) or classical risk factors for AMI. Methods and Results. The P2Y(13) Met-158-Thr polymorphism was found to be in linkage disequilibrium (LD) with the P2Y(12) H2 haplotype (all examined SNPs: D' = 1.0, r(2) = 0.936-1.0), defining a novel P2Y(12) H2/P2Y(13) Thr-158 haplotype. Genotyping of an AMI case control population (n = 1244 cases, 2488 controls) revealed no association of the P2Y(13) Thr-158 allele with AMI (OR = 0.96, 95% C.I. 0.82-1.12, P = 0.63). Also, no differences between the genotype frequencies of P2Y(13) Met-158-Met and Met-158-Thr/Thr-158-Thr were seen in AMI case-control subpopulations (early onset AMI OR = 1.06, 95% C.I. 0.85-1.31, P = 0.62); family history of AMI (OR = 0.98, 95% C.I. 0.78-1.22, P = 0.83) nor in early onset AMIs with family history of AMI (OR = 1.0, 95% C.I. 0.74-1.36, P = 1.0). Genotyping of the P2Y(13) Met-158-Thr polymorphism in a population based sample (n = 6055) revealed no association with cardiovascular risk factors. In addition, the P2Y(13) Met-158-Thr polymorphism was genotyped in a diabetes case-control population, and associations were found neither with DM nor with any examined DM risk factors. Conclusion Genotyping. The P2Y(13) Met-158-Thr polymorphism is in tight LD with the P2Y(12) locus but is not associated with AMI or classical cardiovascular risk factors.	[Amisten, Stefan; Braun, Oscar Oe.; Erlinge, David] Univ Lund Hosp, Dept Cardiol, S-22185 Lund, Sweden; [Johansson, Lovisa; Ridderstrale, Martin; Melander, Olle] Lund Univ, Dept Clin Sci, Malmo, Sweden	Lund University; Skane University Hospital; Lund University	Erlinge, D (corresponding author), Univ Lund Hosp, Dept Cardiol, S-22185 Lund, Sweden.	david.erlinge@med.lu.se	Ridderstråle, Martin/F-7678-2012; Reinius, Lovisa/C-4555-2014	Reinius, Lovisa/0000-0001-5029-0120; O. Braun, Oscar/0000-0003-3263-2718; Melander, Olle/0000-0002-2581-484X	Swedish Scientific Research Council; Swedish Heart and Lung Foundation Lund University Hospital; Vascular Wall program (Lund Medical faculty)	Swedish Scientific Research Council(Swedish Research Council); Swedish Heart and Lung Foundation Lund University Hospital; Vascular Wall program (Lund Medical faculty)	The study has been supported by the Swedish Scientific Research Council, the Swedish Heart and Lung Foundation Lund University Hospital funds and the Vascular Wall program (Lund Medical faculty).	AMISTEN S, 2006, EUR HEART J; Angiolillo DJ, 2005, THROMB RES, V116, P491, DOI 10.1016/j.thromres.2005.03.001; Ayyanathan K, 1996, BIOCHEM BIOPH RES CO, V218, P783, DOI 10.1006/bbrc.1996.0139; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; BERGFELD GR, 1992, CARDIOVASC RES, V26, P40, DOI 10.1093/cvr/26.1.40; Bertrand ME, 2002, EUR HEART J, V23, P1809, DOI 10.1053/euhj.2002.3385; Cattaneo M, 2003, P NATL ACAD SCI USA, V100, P1978, DOI 10.1073/pnas.0437879100; Cavallari U, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-59; COADE SB, 1989, CIRC RES, V65, P531, DOI 10.1161/01.RES.65.3.531; Communi D, 2001, J BIOL CHEM, V276, P41479, DOI 10.1074/jbc.M105912200; CRIQUI MH, 1992, NEW ENGL J MED, V326, P381, DOI 10.1056/NEJM199202063260605; CUISSET T, 2007, THROMB RES; Fontana P, 2003, CIRCULATION, V108, P2971, DOI 10.1161/01.CIR.0000106904.80795.35; Fontana P, 2003, CIRCULATION, V108, P989, DOI 10.1161/01.CIR.0000085073.69189.88; Hetherington SL, 2005, ARTERIOSCL THROM VAS, V25, P252, DOI 10.1161/01.ATV.0000148708.44691.27; Hollopeter G, 2001, NATURE, V409, P202, DOI 10.1038/35051599; Lee DK, 2001, GENE, V275, P83, DOI 10.1016/S0378-1119(01)00651-5; Leng GC, 1996, INT J EPIDEMIOL, V25, P1172, DOI 10.1093/ije/25.6.1172; Manjer J, 2001, EUR J CANCER PREV, V10, P489, DOI 10.1097/00008469-200112000-00003; McCullough PA, 2007, CLIN J AM SOC NEPHRO, V2, P611, DOI 10.2215/CJN.03871106; Murugappan S, 2006, FRONT BIOSCI-LANDMRK, V11, P1977, DOI 10.2741/1939; Orho-Melander M, 2002, DIABETES, V51, P2658, DOI 10.2337/diabetes.51.8.2658; Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493; Remijn JA, 2007, CLIN CHEM LAB MED, V45, P187, DOI 10.1515/CCLM.2007.036; Schettert IT, 2006, THROMB RES, V118, P679, DOI 10.1016/j.thromres.2005.11.009; Skol AD, 2006, NAT GENET, V38, P209, DOI 10.1038/ng1706; von Beckerath N, 2005, BLOOD COAGUL FIBRIN, V16, P199, DOI 10.1097/01.mbc.0000164429.21040.0a; Wang LW, 2005, CIRC RES, V96, P189, DOI 10.1161/01.RES.0000153670.07559.E4; Wiviott SD, 2007, N ENGL J MED; Zhang FL, 2001, J BIOL CHEM, V276, P8608, DOI 10.1074/jbc.M009718200; Ziegler S, 2005, STROKE, V36, P1394, DOI 10.1161/01.STR.0000169922.79281.a5	31	9	9	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2008	3	1							e1462	10.1371/journal.pone.0001462	http://dx.doi.org/10.1371/journal.pone.0001462			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SO	18213371	gold, Green Submitted, Green Published			2022-12-25	WOS:000260503900008
J	Boucrot, E; Kirchhausen, T				Boucrot, Emmanuel; Kirchhausen, Tomas			Mammalian Cells Change Volume during Mitosis	PLOS ONE			English	Article								Using single cell-imaging methods we have found that the volume of adherent cells grown in culture decreases as the cells rounds when it enters mitosis. A minimal volume is reached at metaphase. Rapid volume recovery initiates before abscission as cells make the transition from metaphase to cytokinesis. These volume changes are simultaneous with the rapid surface area decrease and recovery observed in mitotic cells [1].	[Boucrot, Emmanuel; Kirchhausen, Tomas] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Kirchhausen, T (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.	kirchhausen@crystal.harvard.edu			NIH [GM075252, GM62566]; International Human Frontier Science Program Organization (HFSPO) [fellowship]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM075252, P01GM062566] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); International Human Frontier Science Program Organization (HFSPO)(Human Frontier Science Program); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by NIH GM075252 and GM62566 (TK). EB was supported by a fellowship from the International Human Frontier Science Program Organization (HFSPO).	Boucrot E, 2007, P NATL ACAD SCI USA, V104, P7939, DOI 10.1073/pnas.0702511104; Chen LX, 2007, CELL PROLIFERAT, V40, P253, DOI 10.1111/j.1365-2184.2007.00432.x; Coupin GT, 1999, J CELL SCI, V112, P2431; Habela CW, 2007, CELL CYCLE, V6, P1613, DOI 10.4161/cc.6.13.4357; Rouzaire-Dubois B, 1998, J PHYSIOL-LONDON, V510, P93, DOI 10.1111/j.1469-7793.1998.093bz.x; SCHNEIDER EL, 1976, EXP CELL RES, V98, P298, DOI 10.1016/0014-4827(76)90441-9; Wondergem N, 2001, J PHYSIOL-LONDON, V532, P661, DOI 10.1111/j.1469-7793.2001.0661e.x; Wright LP, 2006, J LIPID RES, V47, P883, DOI 10.1194/jlr.R600004-JLR200	8	67	67	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2008	3	1							e1477	10.1371/journal.pone.0001477	http://dx.doi.org/10.1371/journal.pone.0001477			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SO	18213385	Green Published, gold, Green Submitted			2022-12-25	WOS:000260503900022
J	Biddick, RK; Law, GL; Young, ET				Biddick, Rhiannon K.; Law, G. Lynn; Young, Elton T.			Adr1 and Cat8 Mediate Coactivator Recruitment and Chromatin Remodeling at Glucose-Regulated Genes	PLOS ONE			English	Article								Background. Adr1 and Cat8 co-regulate numerous glucose-repressed genes in S. cerevisiae, presenting a unique opportunity to explore their individual roles in coactivator recruitment, chromatin remodeling, and transcription. Methodology/Principal Findings. We determined the individual contributions of Cat8 and Adr1 on the expression of a cohort of glucose-repressed genes and found three broad categories: genes that need both activators for full derepression, genes that rely mostly on Cat8 and genes that require only Adr1. Through combined expression and recruitment data, along with analysis of chromatin remodeling at two of these genes, ADH2 and FBP1, we clarified how these activators achieve this wide range of co-regulation. We find that Adr1 and Cat8 are not intrinsically different in their abilities to recruit coactivators but rather, promoter context appears to dictate which activator is responsible for recruitment to specific genes. These promoter-specific contributions are also apparent in the chromatin remodeling that accompanies derepression: ADH2 requires both Adr1 and Cat8, whereas, at FBP1, significant remodeling occurs with Cat8 alone. Although over-expression of Adr1 can compensate for loss of Cat8 at many genes in terms of both activation and chromatin remodeling, this over-expression cannot complement all of the cat8D phenotypes. Conclusions/Significance. Thus, at many of the glucose-repressed genes, Cat8 and Adr1 appear to have interchangeable roles and promoter architecture may dictate the roles of these activators.	[Biddick, Rhiannon K.; Law, G. Lynn] Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Young, ET (corresponding author), Univ Washington, Dept Biochem, Seattle, WA 98195 USA.	ety@u.washington.edu			NIGMS [PHS MRSA T32 GM07270]; National Institutes of Health [GM26079]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026079, T32GM007270] Funding Source: NIH RePORTER	NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	R. Biddick was supported in part by PHS MRSA T32 GM07270 from NIGMS. The research was supported by a grant from the National Institutes of Health GM26079 to ETY.	Agricola E, 2004, BIOCHEMISTRY-US, V43, P8878, DOI 10.1021/bi049577+; Agricola E, 2006, MOL MICROBIOL, V62, P1433, DOI 10.1111/j.1365-2958.2006.05451.x; Andrau JC, 2006, MOL CELL, V22, P179, DOI 10.1016/j.molcel.2006.03.023; Bhoite LT, 2001, GENE DEV, V15, P2457, DOI 10.1101/gad.921601; COLLART MAO, 2005, CURRENT PROTOCOLS MO; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Di Mauro E, 2002, J BIOL CHEM, V277, P7002, DOI 10.1074/jbc.M106719200; Di Mauro E, 2000, J BIOL CHEM, V275, P7612, DOI 10.1074/jbc.275.11.7612; Dombek KM, 1997, MOL CELL BIOL, V17, P1450, DOI 10.1128/MCB.17.3.1450; DONOVIEL MS, 1995, MOL CELL BIOL, V15, P3442; Doyon Y, 2004, CURR OPIN GENET DEV, V14, P147, DOI 10.1016/j.gde.2004.02.009; DRYSDALE CM, 1995, MOL CELL BIOL, V15, P1220, DOI 10.1128/MCB.15.3.1220; Dudley AM, 1999, GENE DEV, V13, P2940, DOI 10.1101/gad.13.22.2940; ESTRUCH F, 1993, MOL CELL BIOL, V13, P3872, DOI 10.1128/MCB.13.7.3872; Fan XC, 2006, NAT STRUCT MOL BIOL, V13, P117, DOI 10.1038/nsmb1049; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Haurie V, 2001, J BIOL CHEM, V276, P76, DOI 10.1074/jbc.M008752200; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Karpichev IV, 1998, MOL CELL BIOL, V18, P6560, DOI 10.1128/MCB.18.11.6560; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Komarnitsky PB, 1998, MOL CELL BIOL, V18, P5861, DOI 10.1128/MCB.18.10.5861; Kratzer S, 1997, MOL MICROBIOL, V26, P631, DOI 10.1046/j.1365-2958.1997.5611937.x; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; Li XY, 2000, SCIENCE, V288, P1242, DOI 10.1126/science.288.5469.1242; Liu CL, 2005, PLOS BIOL, V3, P1753, DOI 10.1371/journal.pbio.0030328; Pray-Grant MG, 2002, MOL CELL BIOL, V22, P8774, DOI 10.1128/MCB.22.24.8774-8786.2002; Roth S, 2004, CURR GENET, V45, P121, DOI 10.1007/s00294-003-0476-2; Schuller HJ, 2003, CURR GENET, V43, P139, DOI 10.1007/s00294-003-0381-8; Steinmetz EJ, 2006, MOL CELL, V24, P735, DOI 10.1016/j.molcel.2006.10.023; Tachibana C, 2005, MOL CELL BIOL, V25, P2138, DOI 10.1128/MCB.25.6.2138-2146.2005; Tachibana C, 2007, J BIOL CHEM, V282, P37308, DOI 10.1074/jbc.M707363200; TAGUCHI AKW, 1987, GENETICS, V116, P531; Takagi Y, 2006, J BIOL CHEM, V281, P80, DOI 10.1074/jbc.M508253200; Young ET, 2003, J BIOL CHEM, V278, P26146, DOI 10.1074/jbc.M301981200; Yuan GC, 2005, SCIENCE, V309, P626, DOI 10.1126/science.1112178; Zanton SJ, 2006, GENE DEV, V20, P2250, DOI 10.1101/gad.1437506	39	41	41	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2008	3	1							e1436	10.1371/journal.pone.0001436	http://dx.doi.org/10.1371/journal.pone.0001436			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SN	18197247	Green Published, gold, Green Submitted			2022-12-25	WOS:000260503800008
J	Maisey, HC; Quach, D; Hensler, ME; Liu, GY; Gallo, RL; Nizet, V; Doran, KS				Maisey, Heather C.; Quach, Darin; Hensler, Mary E.; Liu, George Y.; Gallo, Richard L.; Nizet, Victor; Doran, Kelly S.			A group B streptococcal pilus protein promotes phagocyte resistance and systemic virulence	FASEB JOURNAL			English	Article						Streptococcus agalactiae; pili; GBS; macrophage; neutrophil; antimicrobial peptides	ESCHERICHIA-COLI STRAINS; LACTOCOCCUS-LACTIS; ANTIMICROBIAL PEPTIDES; TYPE-1 FIMBRIAE; MECHANISMS; EXPRESSION; ANTIGENS; BACTERIA; ADHESION; MUTANTS	Group B Streptococcus (GBS) is a major cause of invasive bacterial infections in newborns and certain adult populations. Surface filamentous appendages known as pili have been recently identified in GBS. However, little is known about the role of these structures in disease pathogenesis. In this study we sought to probe potential functional role(s) of PilB, the major GBS pilus protein subunit, by coupling analysis of an isogenic GBS pilB knockout strain with heterologous expression of the pilB gene in the nonpathogenic bacterium Lactococcus lactis. We found the knockout GBS strain that lacked PilB was more susceptible than wild-type (WT) GBS to killing by isolated macrophages and neutrophils. Survival was linked to the ability of PilB to mediate GBS resistance to cathelicidin antimicrobial peptides. Furthermore, the PilB-deficient GBS mutant was more readily cleared from the mouse bloodstream and less-virulent in vivo compared to the WT parent strain. Strikingly, overexpression of the pilB gene alone in L. lactis enhanced resistance to phagocyte killing, increased bloodstream survival, and conferred virulence in a mouse challenge model. Together these data demonstrate that the pilus backbone subunit, PilB, plays an integral role in GBS virulence and suggests a novel role for gram-positive pili in thwarting the innate defenses of phagocyte killing.	[Quach, Darin; Doran, Kelly S.] San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; [Quach, Darin; Doran, Kelly S.] San Diego State Univ, Ctr Microbial Sci, San Diego, CA 92182 USA; [Maisey, Heather C.; Hensler, Mary E.; Nizet, Victor; Doran, Kelly S.] Univ Calif San Diego, Sch Med, Dept Pediat, Div Pharmacol & Drug Discovery, La Jolla, CA 92093 USA; [Gallo, Richard L.] Univ Calif San Diego, Sch Med, Dept Med, Div Dermatol, La Jolla, CA 92093 USA; [Nizet, Victor] Univ Calif San Diego, Sch Med, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA; [Liu, George Y.] Cedars Sinai Med Ctr, Div Pediat Infect Dis, Los Angeles, CA 90048 USA; [Liu, George Y.] Cedars Sinai Med Ctr, Immunobiol Res Inst, Los Angeles, CA 90048 USA	California State University System; San Diego State University; California State University System; San Diego State University; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Cedars Sinai Medical Center; Cedars Sinai Medical Center	Doran, KS (corresponding author), San Diego State Univ, Dept Biol, Rm 317,5500 Campanile Dr, San Diego, CA 92182 USA.	kdoran@sciences.sdsu.edu	Nizet, Victor/AAF-3190-2019; Gallo, Richard L/A-8931-2009	Gallo, Richard L/0000-0002-1401-7861; Nizet, Victor/0000-0003-3847-0422; Quach, Darin/0000-0002-3244-5376	NIAID NIH HHS [R01 AI052453-07, R01 AI052453, R37 AI052453] Funding Source: Medline; NIAMS NIH HHS [R01 AR052728, R01 AR052728-04] Funding Source: Medline; NINDS NIH HHS [R01 NS051247, R01NS051247] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052453, R37AI052453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR052728] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS051247] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Althouse C, 2003, INFECT IMMUN, V71, P6446, DOI 10.1128/IAI.71.11.6446-6452.2003; Andres E, 2004, J INTERN MED, V255, P519, DOI 10.1046/j.1365-2796.2003.01278.x; Barocchi MA, 2006, P NATL ACAD SCI USA, V103, P2857, DOI 10.1073/pnas.0511017103; BLUMENSTOCK E, 1982, INFECT IMMUN, V35, P264, DOI 10.1128/IAI.35.1.264-269.1982; Braff MH, 2007, J INFECT DIS, V195, P1365, DOI 10.1086/513277; Buccato S, 2006, J INFECT DIS, V194, P331, DOI 10.1086/505433; Chromek M, 2006, NAT MED, V12, P636, DOI 10.1038/nm1407; CISAR JO, 1988, INFECT IMMUN, V56, P2984, DOI 10.1128/IAI.56.11.2984-2989.1988; Doran KS, 2004, MOL MICROBIOL, V54, P23, DOI 10.1111/j.1365-2958.2004.04266.x; Dramsi S, 2006, MOL MICROBIOL, V60, P1401, DOI 10.1111/j.1365-2958.2006.05190.x; DUGUID JP, 1969, J MED MICROBIOL, V2, P535, DOI 10.1099/00222615-2-4-535; FIVESTAYLOR PM, 1985, INFECT IMMUN, V47, P752, DOI 10.1128/IAI.47.3.752-759.1985; Framson PE, 1997, APPL ENVIRON MICROB, V63, P3539, DOI 10.1128/AEM.63.9.3539-3547.1997; FREITAG NE, 1995, MOL MICROBIOL, V16, P575, DOI 10.1111/j.1365-2958.1995.tb02420.x; Frick IM, 2003, J BIOL CHEM, V278, P16561, DOI 10.1074/jbc.M301995200; GBARAH A, 1993, INFECT IMMUN, V61, P1687, DOI 10.1128/IAI.61.5.1687-1693.1993; GIBBONS RJ, 1988, INFECT IMMUN, V56, P439, DOI 10.1128/IAI.56.2.439-445.1988; GOETZ MB, 1987, J INFECT DIS, V156, P229, DOI 10.1093/infdis/156.1.229; Gutekunst H, 2003, INFECT IMMUN, V71, P5056, DOI 10.1128/IAI.71.9.5056-5064.2003; Hamilton A, 2006, INFECT IMMUN, V74, P6179, DOI 10.1128/IAI.00895-06; HOLO H, 1989, APPL ENVIRON MICROB, V55, P3119, DOI 10.1128/AEM.55.12.3119-3123.1989; Jin T, 2004, J IMMUNOL, V172, P1169, DOI 10.4049/jimmunol.172.2.1169; KEITH BR, 1990, INFECT IMMUN, V58, P3448, DOI 10.1128/IAI.58.10.3448-3454.1990; KOGA T, 1993, INFECT IMMUN, V61, P1371, DOI 10.1128/IAI.61.4.1371-1377.1993; KUIPERS OP, 1993, EUR J BIOCHEM, V216, P281, DOI 10.1111/j.1432-1033.1993.tb18143.x; Lauer P, 2005, SCIENCE, V309, P105, DOI 10.1126/science.1111563; Liu GY, 2004, P NATL ACAD SCI USA, V101, P14491, DOI 10.1073/pnas.0406143101; LOCK R, 1990, INFECT IMMUN, V58, P37, DOI 10.1128/IAI.58.1.37-42.1990; Maione D, 2005, SCIENCE, V309, P148, DOI 10.1126/science.1109869; Maisey HC, 2007, J BACTERIOL, V189, P1464, DOI 10.1128/JB.01153-06; Mellata M, 2003, INFECT IMMUN, V71, P494, DOI 10.1128/IAI.71.1.494-503.2003; Mora M, 2005, P NATL ACAD SCI USA, V102, P15641, DOI 10.1073/pnas.0507808102; Mygind PH, 2005, NATURE, V437, P975, DOI 10.1038/nature04051; Nizet V, 2006, CURR ISSUES MOL BIOL, V8, P11; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; OLSEN A, 1989, NATURE, V338, P652, DOI 10.1038/338652a0; Peschel A, 2002, TRENDS MICROBIOL, V10, P179, DOI 10.1016/S0966-842X(02)02333-8; Poyart C, 2003, MOL MICROBIOL, V49, P1615, DOI 10.1046/j.1365-2958.2003.03655.x; Pritzlaff CA, 2001, MOL MICROBIOL, V39, P236, DOI 10.1046/j.1365-2958.2001.02211.x; Rosini R, 2006, MOL MICROBIOL, V61, P126, DOI 10.1111/j.1365-2958.2006.05225.x; Saito T, 1997, ARCH ORAL BIOL, V42, P539, DOI 10.1016/S0003-9969(97)00054-X; Sauer FG, 2000, CURR OPIN MICROBIOL, V3, P65, DOI 10.1016/S1369-5274(99)00053-3; Scott JR, 2006, MOL MICROBIOL, V62, P320, DOI 10.1111/j.1365-2958.2006.05279.x; Telford JL, 2006, NAT REV MICROBIOL, V4, P509, DOI 10.1038/nrmicro1443; Timmer AM, 2006, MOL MICROBIOL, V62, P15, DOI 10.1111/j.1365-2958.2006.05337.x; Ton-That H, 2004, TRENDS MICROBIOL, V12, P228, DOI 10.1016/j.tim.2004.03.004; WEERKAMP AH, 1986, J BACTERIOL, V165, P746, DOI 10.1128/jb.165.3.746-755.1986; Whittaker CJ, 1996, ANNU REV MICROBIOL, V50, P513, DOI 10.1146/annurev.micro.50.1.513; WILKINSON HW, 1977, J CLIN MICROBIOL, V6, P183; Wilson WW, 2001, J MICROBIOL METH, V43, P153, DOI 10.1016/S0167-7012(00)00224-4; YANAGAWA R, 1968, JPN J VET RES, V16, P31	51	85	93	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1715	1724		10.1096/fj.07-093963	http://dx.doi.org/10.1096/fj.07-093963			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18198218	Green Accepted			2022-12-25	WOS:000256352700012
J	Gey, U; Czupalla, C; Hoflack, B; Rodel, G; Krause-Buchholz, U				Gey, Uta; Czupalla, Cornelia; Hoflack, Bernard; Roedel, Gerhard; Krause-Buchholz, Udo			Yeast pyruvate dehydrogenase complex is regulated by a concerted activity of two kinases and two phosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN PHOSPHATASE; MAMMALIAN PYRUVATE; PHOSPHORYLATION-DEPHOSPHORYLATION; PHOSPHOPROTEOME ANALYSIS; MITOCHONDRIAL PROTEOME; MASS-SPECTROMETRY; LACTIC-ACIDOSIS; ELECTROPHORESIS; DISSOCIATION	The activity of yeast pyruvate dehydrogenase complex is regulated by reversible phosphorylation. Recently we identified two enzymes that are involved in the phosphorylation (Pkp1p) and dephosphorylation (Ppp1p) of Pda1p, the alpha-subunit of the pyruvate dehydrogenase complex. Here we provide evidence that two additional mitochondrial proteins, Pkp2p (Yg1059wp) and Ppp2p (Ycr079wp), are engaged in the regulation of this complex by affecting the phosphorylation state of Pda1p. Our data indicate complementary activities of the kinases and a redundant function for the phosphatases. Both proteins are associated with the complex. We propose a model for the role of the regulatory enzymes and the phosphorylation state of Pda1p in the assembly process of the pyruvate dehydrogenase complex.	[Gey, Uta; Roedel, Gerhard; Krause-Buchholz, Udo] Tech Univ Dresden, Inst Genet, D-01062 Dresden, Germany; [Czupalla, Cornelia; Hoflack, Bernard] Tech Univ Dresden, Ctr Biotechnol, D-01307 Dresden, Germany	Technische Universitat Dresden; Technische Universitat Dresden	Krause-Buchholz, U (corresponding author), Tech Univ Dresden, Inst Genet, D-01062 Dresden, Germany.	Udo.Krause-Buchholz@tu-dresden.de	Roedel, Gerhard/AAH-3762-2022; Roedel, Gerhard/AFQ-8997-2022; Krause, Udo/N-8167-2014; HOFLACK, Bernard/AAZ-6668-2020	Krause, Udo/0000-0001-9493-4522; 				Agrawal GK, 2005, PROTEOMICS, V5, P4684, DOI 10.1002/pmic.200500021; Bao HY, 2004, BIOCHEMISTRY-US, V43, P13442, DOI 10.1021/bi0494875; Bao HY, 2004, BIOCHEMISTRY-US, V43, P13432, DOI 10.1021/bi049488x; Boubekeur S, 1999, J BIOL CHEM, V274, P21044, DOI 10.1074/jbc.274.30.21044; Boubekeur S, 2001, EUR J BIOCHEM, V268, P5057, DOI 10.1046/j.1432-1327.2001.02418.x; Chi A, 2007, P NATL ACAD SCI USA, V104, P2193, DOI 10.1073/pnas.0607084104; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Czupalla C, 2006, MOL CELL PROTEOMICS, V5, P134, DOI 10.1074/mcp.M500291-MCP200; Czupalla C, 2005, PROTEOMICS, V5, P3868, DOI 10.1002/pmic.200402059; DAUM G, 1982, J BIOL CHEM, V257, P3028; Ficarro SB, 2002, NAT BIOTECHNOL, V20, P301, DOI 10.1038/nbt0302-301; Gonzalez A, 2006, J BIOL CHEM, V281, P35057, DOI 10.1074/jbc.M607919200; Gorg A, 2000, ELECTROPHORESIS, V21, P1037, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1037::AID-ELPS1037>3.0.CO;2-V; GUDI R, 1995, J BIOL CHEM, V270, P28989, DOI 10.1074/jbc.270.48.28989; Henderson NS, 2000, ELECTROPHORESIS, V21, P2925, DOI 10.1002/1522-2683(20000801)21:14<2925::AID-ELPS2925>3.0.CO;2-2; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; JAMES AG, 1995, FEBS LETT, V373, P111, DOI 10.1016/0014-5793(95)01020-F; Kaiser C. S., 1994, METHODS YEAST GENETI, P207; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Kolobova E, 2001, BIOCHEM J, V358, P69, DOI 10.1042/0264-6021:3580069; Korotchkina LG, 2001, J BIOL CHEM, V276, P37223, DOI 10.1074/jbc.M103069200; Krause-Buchholz U, 2006, FEBS LETT, V580, P2553, DOI 10.1016/j.febslet.2006.04.002; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; LINN TC, 1969, P NATL ACAD SCI USA, V62, P234, DOI 10.1073/pnas.62.1.234; Machius M, 2001, P NATL ACAD SCI USA, V98, P11218, DOI 10.1073/pnas.201220098; Maj MC, 2005, J CLIN ENDOCR METAB, V90, P4101, DOI 10.1210/jc.2005-0123; Meisinger C, 2000, ANAL BIOCHEM, V287, P339, DOI 10.1006/abio.2000.4868; Murray J, 2004, ELECTROPHORESIS, V25, P2520, DOI 10.1002/elps.200406006; Ohlmeier S, 2004, J BIOL CHEM, V279, P3956, DOI 10.1074/jbc.M310160200; Patel MS, 2006, BIOCHEM SOC T, V34, P217, DOI 10.1042/BST0340217; Patel MS, 2003, BIOCHEM MOL BIOL EDU, V31, P5, DOI 10.1002/bmb.2003.494031010156; POPOV KM, 1992, J BIOL CHEM, V267, P13127; Ray R, 2003, METHOD ENZYMOL, V366, P95; Reed L J, 1981, Curr Top Cell Regul, V18, P95; Reed LJ, 2001, J BIOL CHEM, V276, P38329, DOI 10.1074/jbc.R100026200; REED LJ, 1985, CURR TOP CELL REGUL, V27, P41; Reinders J, 2007, MOL CELL PROTEOMICS, V6, P1896, DOI 10.1074/mcp.M700098-MCP200; Reinders J, 2006, J PROTEOME RES, V5, P1543, DOI 10.1021/pr050477f; ROBINSON BH, 1975, PEDIATR RES, V9, P935, DOI 10.1203/00006450-197512000-00015; Roche TE, 2001, PROG NUCLEIC ACID RE, V70, P33, DOI 10.1016/S0079-6603(01)70013-X; Ruan HH, 2007, FEMS YEAST RES, V7, P209, DOI 10.1111/j.1567-1364.2006.00160.x; RUBENSTEIN EM, 2007, CELL, V6, P571; Saito H, 2004, J BIOCHEM, V136, P267, DOI 10.1093/jb/mvh135; Sakumoto N, 2002, YEAST, V19, P587, DOI 10.1002/yea.860; Schagger H, 2001, METHOD CELL BIOL, V65, P231, DOI 10.1016/S0091-679X(01)65014-3; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Seyda A, 2001, J INHERIT METAB DIS, V24, P551, DOI 10.1023/A:1012463726810; Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100; Stoops JK, 1997, J BIOL CHEM, V272, P5757, DOI 10.1074/jbc.272.9.5757; Strumilo S, 2005, ACTA BIOCHIM POL, V52, P759; Sugden Mary C., 2006, Archives of Physiology and Biochemistry, V112, P139, DOI 10.1080/13813450600935263; SUGDEN PH, 1978, BIOCHEM J, V169, P433, DOI 10.1042/bj1690433; Tal R, 2007, J BIOL CHEM, V282, P5617, DOI 10.1074/jbc.M605940200; UHLINGER DJ, 1986, BIOCHEMISTRY-US, V25, P5673, DOI 10.1021/bi00367a049; WENZEL TJ, 1992, EUR J BIOCHEM, V209, P697, DOI 10.1111/j.1432-1033.1992.tb17338.x; WENZEL TJ, 1993, EUR J BIOCHEM, V218, P405, DOI 10.1111/j.1432-1033.1993.tb18390.x; WIELAND O, 1969, FEBS LETT, V3, P271, DOI 10.1016/0014-5793(69)80156-0; WIELAND OH, 1982, REV PHYSIOL BIOCH P, V96, P123, DOI 10.1007/BFb0031008; YEAMAN SJ, 1989, BIOCHEM J, V257, P625, DOI 10.1042/bj2570625; Zhu H, 2000, NAT GENET, V26, P283, DOI 10.1038/81576	61	66	73	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9759	9767		10.1074/jbc.M708779200	http://dx.doi.org/10.1074/jbc.M708779200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18180296	hybrid			2022-12-25	WOS:000254671600030
J	Bae, GU; Gaio, U; Yang, YJ; Lee, HJ; Kang, JS; Krauss, RS				Bae, Gyu-Un; Gaio, Ursula; Yang, Youn-Joo; Lee, Hye-Jin; Kang, Jong-Sun; Krauss, Robert S.			Regulation of myoblast motility and fusion by the CXCR4-associated sialomucin, CD164	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL MEMBRANE-PROTEINS; CHEMOKINE RECEPTOR CXCR4; MUSCLE PROGENITOR CELLS; SKELETAL-MUSCLE; MYOGENIC DIFFERENTIATION; NEGATIVE REGULATOR; SATELLITE CELLS; ENDOLYN CD164; BONE-MARROW; MIGRATION	Myoblast fusion is fundamental to the development and regeneration of skeletal muscle. To fuse, myoblasts undergo cell-cell recognition and adhesion and merger of membranes between apposing cells. Cell migration must occur in advance of these events to bring myoblasts into proximity, but the factors that regulate myoblast motility are not fully understood. CD164 is a cell surface sialomucin that is targeted to endosomes and lysosomes via its intracellular region. In hematopoietic progenitor cells, CD164 forms complexes with the motility-stimulating chemokine receptor, CXCR4, in response to the CXCR4 ligand, CXCL12/SDF-1 (Forde, S., Tye, B. J., Newey, S. E., Roubelakis, M., Smythe, J., McGuckin, C. P., Pettengell, R., and Watt, S. M. (2007) Blood 109, 1825-1833). We have previously shown that CD164 stimulates myotube formation in vitro. We report here that CD164 is associated with CXCR4 in C2C12 myoblasts. Cells in which CD164 levels are increased or decreased via overexpression or RNA interference-mediated knockdown, respectively, show enhanced or reduced myotube formation and cell migration, the latter both basally and in response to CXCL12/SDF-1. Furthermore, expression of CD164 cytoplasmic tail mutants that alter the endosome/lysosome targeting sequence and, consequently, the subcellular localization in myoblasts, reveals a similar correlation between cell motility and myotube formation. Finally, Cd164 mRNA is expressed in the dorsal somite (the early myogenic compartment of the mouse embryo) and in premuscle masses. Taken together, these results suggest that CD164 is a regulator of myoblast motility and that this property contributes to its ability to promote myoblast fusion into myotubes.	[Bae, Gyu-Un; Gaio, Ursula; Yang, Youn-Joo; Krauss, Robert S.] Mt Sinai Sch Med, Dept Dev & Regenerat Biol, New York, NY 10029 USA; [Lee, Hye-Jin; Kang, Jong-Sun] Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst, Suwon 440746, South Korea	Icahn School of Medicine at Mount Sinai; Sungkyunkwan University (SKKU)	Krauss, RS (corresponding author), Mt Sinai Sch Med, Dept Dev & Regenerat Biol, Box 1020, New York, NY 10029 USA.	Robert.Krauss@mssm.edu			NIAMS NIH HHS [AR 050403] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050403] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAE GU, UNPUB; Becciolini L, 2006, BBA-MOL CELL BIOL L, V1761, P43, DOI 10.1016/j.bbalip.2006.01.006; Bischoff R, 1997, DEV DYNAM, V208, P505, DOI 10.1002/(SICI)1097-0177(199704)208:4<505::AID-AJA6>3.0.CO;2-M; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; Bondesen BA, 2007, FASEB J, V21, P3338, DOI 10.1096/fj.06-7070com; Chan JYH, 2001, J BIOL CHEM, V276, P2139, DOI 10.1074/jbc.M007965200; Donati C, 2004, FASEB J, V18, P449, DOI 10.1096/fj.04-1780fje; Fernando RN, 2007, J NEUROCHEM, V102, P967, DOI 10.1111/j.1471-4159.2007.04659.x; Forde S, 2007, BLOOD, V109, P1825, DOI 10.1182/blood-2006-05-023028; Galvez BG, 2006, J CELL BIOL, V174, P231, DOI 10.1083/jcb.200512085; Gogos JA, 1996, J CELL BIOL, V134, P837, DOI 10.1083/jcb.134.4.837; Han JW, 2001, J BIOL CHEM, V276, P42084, DOI 10.1074/jbc.M106688200; Horsley V, 2004, CELLS TISSUES ORGANS, V176, P67, DOI 10.1159/000075028; Hunziker W, 1996, BIOESSAYS, V18, P379, DOI 10.1002/bies.950180508; Ihrke G, 2004, TRAFFIC, V5, P946, DOI 10.1111/j.1600-0854.2004.00236.x; Ihrke G, 2000, BIOCHEM J, V345, P287, DOI 10.1042/0264-6021:3450287; Ihrke G, 2001, EMBO J, V20, P6256, DOI 10.1093/emboj/20.22.6256; Jansen KM, 2006, J CELL BIOL, V174, P403, DOI 10.1083/jcb.200601102; Jorgensen-Tye B, 2005, TISSUE ANTIGENS, V65, P220, DOI 10.1111/j.1399-0039.2005.00358.x; Kang JS, 2002, EMBO J, V21, P114, DOI 10.1093/emboj/21.1.114; Kang JS, 2004, J CELL BIOL, V167, P493, DOI 10.1083/jcb.200405039; Krauss RS, 2005, J CELL SCI, V118, P2355, DOI 10.1242/jcs.02397; Lee YN, 2001, MOL CELL BIOL, V21, P7696, DOI 10.1128/MCB.21.22.7696-7706.2001; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; Makarova O, 2000, BIOTECHNIQUES, V29, P970, DOI 10.2144/00295bm08; Mulieri PJ, 2000, DEV DYNAM, V219, P40, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1032>3.0.CO;2-M; Mylona E, 2006, J CELL PHYSIOL, V209, P314, DOI 10.1002/jcp.20724; Odemis V, 2005, MOL CELL NEUROSCI, V30, P494, DOI 10.1016/j.mcn.2005.07.019; Perry RLS, 2000, FRONT BIOSCI, V5, pD750, DOI 10.2741/Perry; Potter BA, 2006, TRAFFIC, V7, P146, DOI 10.1111/j.1600-0854.2005.00371.x; Ratajczak MZ, 2003, STEM CELLS, V21, P363, DOI 10.1634/stemcells.21-3-363; Schwander M, 2003, DEV CELL, V4, P673, DOI 10.1016/S1534-5807(03)00118-7; Suzuki J, 2000, MOL CELL BIOL, V20, P4658, DOI 10.1128/MCB.20.13.4658-4665.2000; Tajbakhsh S, 2000, CURR TOP DEV BIOL, V48, P225; Takaesu G, 2006, J CELL BIOL, V175, P383, DOI 10.1083/jcb.200608031; Tapscott SJ, 2005, DEVELOPMENT, V132, P2685, DOI 10.1242/dev.01874; Vasyutina E, 2005, GENE DEV, V19, P2187, DOI 10.1101/gad.346205; Vasyutina E, 2006, ANAT EMBRYOL, V211, pS37, DOI 10.1007/s00429-006-0118-9; Visel A, 2004, NUCLEIC ACIDS RES, V32, pD552, DOI 10.1093/nar/gkh029; Watt SM, 2000, LEUKEMIA LYMPHOMA, V37, P1, DOI 10.3109/10428190009057625; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Zannettino ACW, 1998, BLOOD, V92, P2613, DOI 10.1182/blood.V92.8.2613.420k15_2613_2628; Zhu W, 2007, J BIOL CHEM, V282, P18676, DOI 10.1074/jbc.M610232200; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	44	55	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8301	8309		10.1074/jbc.M706730200	http://dx.doi.org/10.1074/jbc.M706730200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18227060	Green Published, hybrid			2022-12-25	WOS:000254288000028
J	Miao, Q; Sun, Y; Wei, TT; Zhao, XY; Zhao, K; Yan, L; Zhang, XJ; Shu, HJ; Yang, FY				Miao, Qi; Sun, Yang; Wei, Taotao; Zhao, Xingyu; Zhao, Kai; Yan, Ling; Zhang, Xujia; Shu, Hongjun; Yang, Fuyu			Chymotrypsin B cached in rat liver lysosomes and involved in apoptotic regulation through a mitochondrial pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; CELL-DEATH; SERINE PROTEASES; CASPASES; CLEAVAGE; ACTIVATION; PERMEABILIZATION; MEMBRANE; STEP	Lysosomes can trigger the mitochondrial apoptotic pathway by releasing proteases. Here we report that a 25-kDa protein purified from rat liver lysosomes possesses a long standing potent Bid cleavage activity at neutral pH, and the truncated Bid can in turn induce rapid mitochondrial release of cytochrome c. This protease was revealed as chymotrypsin B by biochemical and mass spectrometric analysis. Although it was long recognized as a digestive protease exclusively secreted by the exocrine pancreas, our data support that it also expresses and intracellularly resides in rat liver lysosomes. Translocation of lysosomal chymotrypsin B into cytosol was triggered by apoptotic stimuli such as tumor necrosis factor-alpha, and intracellular delivery of chymotrypsin B protein induced apoptotic cell death with a potency comparable with cathepsin B, suggestive of a lysosomal-mitochondrial pathway to apoptosis regulated by chymotrypsin B following its release. Noteworthily, either knockdown of chymotrypsin B expression by RNA interference or pretreatment with chymotrypsin B inhibitor N-p-tosyl- L-phenylalanine chloromethyl ketone significantly reduced tumor necrosis factor-alpha-induce apoptosis. These results demonstrate for the first time that chymotrypsin B is not only restricted to the pancreas but can function intracellularly as a pro-apoptotic protease.	[Miao, Qi; Sun, Yang; Wei, Taotao; Zhao, Xingyu; Zhao, Kai; Yan, Ling; Zhang, Xujia; Yang, Fuyu] Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; [Shu, Hongjun] Univ N Texas, Hlth Sci Ctr, Adv Mass Spectrometry Lab, Ft Worth, TX 76107 USA; [Sun, Yang; Zhao, Xingyu; Zhao, Kai] Grad Univ Chinese Acad Sci, Beijing 100049, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; University of North Texas System; University of North Texas Health Science Center; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Yang, FY (corresponding author), Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, 15 Datun Rd, Beijing 100101, Peoples R China.	yangfy@sun5.ibp.ac.cn						Abraham MC, 2004, TRENDS CELL BIOL, V14, P184, DOI 10.1016/j.tcb.2004.03.002; Alimonti JB, 2001, J BIOL CHEM, V276, P6974, DOI 10.1074/jbc.M008444200; BELL GI, 1984, J BIOL CHEM, V259, P4265; Boya P, 2003, ONCOGENE, V22, P3927, DOI 10.1038/sj.onc.1206622; Cirman T, 2004, J BIOL CHEM, V279, P3578, DOI 10.1074/jbc.M308347200; Egger L, 2003, CELL DEATH DIFFER, V10, P1188, DOI 10.1038/sj.cdd.4401288; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Grabarek J, 2002, INT J ONCOL, V20, P225; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Guicciardi ME, 2000, J CLIN INVEST, V106, P1127, DOI 10.1172/JCI9914; Hirsch T, 1998, J IMMUNOL, V161, P35; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mathiasen IS, 2002, TRENDS MOL MED, V8, P212, DOI 10.1016/S1471-4914(02)02328-6; Murn J, 2004, GENES CELLS, V9, P1103, DOI 10.1111/j.1365-2443.2004.00794.x; Pillay CS, 2002, BIOCHEM J, V363, P417, DOI 10.1042/0264-6021:3630417; Salvesen GS, 2001, J CLIN INVEST, V107, P21, DOI 10.1172/JCI11829; Stenson-Cox C, 2003, BIOCHEM PHARMACOL, V66, P1469, DOI 10.1016/S0006-2952(03)00499-4; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Turk B, 2002, BIOL CHEM, V383, P1035, DOI 10.1515/BC.2002.112; Venekei I, 1996, FEBS LETT, V379, P143, DOI 10.1016/0014-5793(95)01484-5; Werneburg NW, 2002, AM J PHYSIOL-GASTR L, V283, pG947, DOI 10.1152/ajpgi.00151.2002; Yan L, 2003, FEBS LETT, V555, P545, DOI 10.1016/s0014-5793(03)01346-2; Yuan XM, 2002, P NATL ACAD SCI USA, V99, P6286, DOI 10.1073/pnas.092135599; Zelphati O, 2001, J BIOL CHEM, V276, P35103, DOI 10.1074/jbc.M104920200; Zhai DY, 2001, EUR J BIOCHEM, V268, P48, DOI 10.1046/j.1432-1327.2001.01841.x	27	21	22	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8218	8228		10.1074/jbc.M709789200	http://dx.doi.org/10.1074/jbc.M709789200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18211899	hybrid			2022-12-25	WOS:000254288000019
J	Seravalli, J; Ragsdale, SW				Seravalli, Javier; Ragsdale, Stephen W.			Pulse-chase studies of the synthesis of acetyl-CoA by carbon monoxide dehydrogenase/acetyl-CoA synthase - Evidence for a random mechanism of methyl and carbonyl addition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A SYNTHASE; IRON-SULFUR PROTEIN; WOOD-LJUNGDAHL PATHWAY; CLOSTRIDIUM-THERMOACETICUM; KINETIC CHARACTERIZATION; ALPHA-SUBUNIT; ACTIVE-SITE; DECARBONYLASE/SYNTHASE COMPLEX; MOORELLA-THERMOACETICA; REDUCTIVE ACTIVATION	Carbon monoxide dehydrogenase/acetyl-CoA synthase catalyzes acetyl-CoA synthesis from CO, CoA, and a methylated corrinoid iron-sulfur protein, which acts as a methyl donor. This reaction is the last step in the Wood-Ljungdahl pathway of anaerobic carbon fixation. The binding sequence for the three substrates has been debated for over a decade. Different binding orders imply different mechanisms (i.e. paramagnetic versus diamagnetic mechanisms). Ambiguity arises because CO and CoA can each undergo isotopic exchange with acetyl-CoA, suggesting that either of these two substrates could be the last to bind to the acetyl-CoA synthase active site. Furthermore, carbonylation, CoA binding, and methyl transfer can all occur in the absence of the other two substrates. Here, we report pulse-chase studies, which unambiguously establish the order in which the three substrates bind. Although a CoA pulse is substantially diluted by excess CoA in the chase, isotope recovery of a pulse of labeled CO or methyl group is unaffected by the presence of excess unlabeled CO or methyl group in the chase. These results demonstrate that CoA is the last substrate to bind and that CO and the methyl group bind randomly as the first substrate in acetyl-CoA synthesis. Up to 100% of the methyl groups and CoA and up to 60 - 70% of the CO employed in the pulse phase can be trapped in the product acetyl-CoA.	[Seravalli, Javier; Ragsdale, Stephen W.] Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Ragsdale, SW (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, 1150 W Med Ctr Dr,5301 MSRB 3, Ann Arbor, MI 48109 USA.	sragsdal@umich.edu			NIGMS NIH HHS [R01 GM039451] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039451] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andi B, 2004, BIOCHEMISTRY-US, V43, P11790, DOI 10.1021/bi048766p; ANDREESE.JR, 1973, J BACTERIOL, V114, P743, DOI 10.1128/JB.114.2.743-751.1973; Banerjee R, 2003, ANNU REV BIOCHEM, V72, P209, DOI 10.1146/annurev.biochem.72.121801.161828; Barondeau DP, 1997, J AM CHEM SOC, V119, P3959, DOI 10.1021/ja963597k; Bhaskar B, 1998, BIOCHEMISTRY-US, V37, P14491, DOI 10.1021/bi9812423; Bramlett MR, 2006, BIOCHEMISTRY-US, V45, P8674, DOI 10.1021/bi060003+; Darnault C, 2003, NAT STRUCT BIOL, V10, P271, DOI 10.1038/nsb912; Dobbek H, 2001, SCIENCE, V293, P1281, DOI 10.1126/science.1061500; Doukov T, 2000, STRUCTURE, V8, P817, DOI 10.1016/S0969-2126(00)00172-6; Doukov TI, 2007, J BIOL CHEM, V282, P6609, DOI 10.1074/jbc.M609828200; Drennan CL, 2001, P NATL ACAD SCI USA, V98, P11973, DOI 10.1073/pnas.211429998; Errey JC, 2006, BIOCHEMISTRY-US, V45, P3033, DOI 10.1021/bi052297p; George SJ, 2005, J AM CHEM SOC, V127, P13500, DOI 10.1021/ja0528329; GORST CM, 1991, J BIOL CHEM, V266, P20687; Grahame DA, 1996, BIOCHEMISTRY-US, V35, P593, DOI 10.1021/bi9511494; Gu WW, 2003, J AM CHEM SOC, V125, P15343, DOI 10.1021/ja036602a; KUMAR M, 1993, J AM CHEM SOC, V115, P11646, DOI 10.1021/ja00077a093; KUMAR M, 1992, J AM CHEM SOC, V114, P8713, DOI 10.1021/ja00048a062; LEBERTZ H, 1987, J AM CHEM SOC, V109, P3173, DOI 10.1021/ja00244a066; Lindahl PA, 2004, J BIOL INORG CHEM, V9, P516, DOI 10.1007/s00775-004-0564-x; Lindahl PA, 2002, BIOCHEMISTRY-US, V41, P2097, DOI 10.1021/bi015932+; Loke HK, 2002, J AM CHEM SOC, V124, P8667, DOI 10.1021/ja025924w; LU WP, 1991, J BIOL CHEM, V266, P3554; LU WP, 1990, J BIOL CHEM, V265, P3124; LU Z, 1995, J AM CHEM SOC, V117, P3994, DOI 10.1021/ja00119a014; LUNDIE LL, 1984, J BACTERIOL, V159, P700, DOI 10.1128/JB.159.2.700-703.1984; Maynard EL, 1999, J AM CHEM SOC, V121, P9221, DOI 10.1021/ja992120g; Maynard EL, 2001, BIOCHEMISTRY-US, V40, P13262, DOI 10.1021/bi015604+; Maynard EL, 2001, J AM CHEM SOC, V123, P4697, DOI 10.1021/ja004017t; Menon S, 1996, BIOCHEMISTRY-US, V35, P12119, DOI 10.1021/bi961014d; Menon S, 1998, BIOCHEMISTRY-US, V37, P5689, DOI 10.1021/bi9727996; PEZACKA E, 1984, P NATL ACAD SCI-BIOL, V81, P6261, DOI 10.1073/pnas.81.20.6261; PEZACKA E, 1988, J BIOL CHEM, V263, P16000; Ragsdale SW, 2006, CHEM REV, V106, P3317, DOI 10.1021/cr0503153; RAGSDALE SW, 1987, J BIOL CHEM, V262, P14289; Ragsdale SW, 2004, CRIT REV BIOCHEM MOL, V39, P165, DOI 10.1080/10409230490496577; RAGSDALE SW, 1985, J BIOL CHEM, V260, P3970; RAGSDALE SW, 1985, P NATL ACAD SCI USA, V82, P6811, DOI 10.1073/pnas.82.20.6811; RAGSDALE SW, 1983, J BIOL CHEM, V258, P2364; RAM MS, 1995, J AM CHEM SOC, V117, P2365, DOI 10.1021/ja00113a032; Ram MS, 1997, J AM CHEM SOC, V119, P1648, DOI 10.1021/ja963061z; RAMER SE, 1989, BIOCHEMISTRY-US, V28, P4675, DOI 10.1021/bi00437a025; RAYBUCK SA, 1988, BIOCHEMISTRY-US, V27, P7698, DOI 10.1021/bi00420a019; ROBERTS DL, 1989, P NATL ACAD SCI USA, V86, P32, DOI 10.1073/pnas.86.1.32; Rose I A, 1980, Methods Enzymol, V64, P47; Russell WK, 1998, BIOCHEMISTRY-US, V37, P10016, DOI 10.1021/bi980149b; Schenker RP, 2003, J AM CHEM SOC, V125, P13962, DOI 10.1021/ja037893q; Seravalli J, 2004, BIOCHEMISTRY-US, V43, P3944, DOI 10.1021/bi036194n; Seravalli J, 2000, BIOCHEMISTRY-US, V39, P1274, DOI 10.1021/bi991812e; Seravalli J, 2002, BIOCHEMISTRY-US, V41, P1807, DOI 10.1021/bi011687i; Seravalli J, 2001, J AM CHEM SOC, V123, P1786, DOI 10.1021/ja005709k; Seravalli J, 1999, BIOCHEMISTRY-US, V38, P5728, DOI 10.1021/bi982473c; SHIN W, 1992, BIOCHEMISTRY-US, V31, P6003, DOI 10.1021/bi00141a007; SHIN WS, 1992, BIOCHEMISTRY-US, V31, P12870, DOI 10.1021/bi00166a023; SIEGEL IH, 1975, ENZYME KINETICS BEHA; Svetlitchnyi V, 2004, P NATL ACAD SCI USA, V101, P446, DOI 10.1073/pnas.0304262101; Tan XS, 2006, J AM CHEM SOC, V128, P12331, DOI 10.1021/ja0627702; Tan XS, 2003, J AM CHEM SOC, V125, P318, DOI 10.1021/ja028442t; Tan XS, 2002, J AM CHEM SOC, V124, P6277, DOI 10.1021/ja016676r; Volbeda A, 2004, J BIOL INORG CHEM, V9, P525, DOI 10.1007/s00775-004-0565-9; Webster CE, 2004, J AM CHEM SOC, V126, P3410, DOI 10.1021/ja038083h; WILKINSON KD, 1979, J BIOL CHEM, V254, P2567; Xia JQ, 1997, J AM CHEM SOC, V119, P8301, DOI 10.1021/ja971025+; XIA JQ, 1995, J AM CHEM SOC, V117, P7065, DOI 10.1021/ja00132a004; Xia JQ, 1996, J AM CHEM SOC, V118, P483, DOI 10.1021/ja952845u; Yu M, 2006, BIOCHEMISTRY-US, V45, P14788, DOI 10.1021/bi061621t; ZEHNDER AJB, 1976, SCIENCE, V194, P1165, DOI 10.1126/science.793008	67	43	46	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8384	8394		10.1074/jbc.M709470200	http://dx.doi.org/10.1074/jbc.M709470200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18203715	hybrid, Green Published			2022-12-25	WOS:000254288000036
J	Li, K; Li, YC; Wu, WJ; Gordon, WR; Chang, DW; Lu, M; Scoggin, S; Fu, TH; Vien, L; Histen, G; Zheng, J; Martin-Hollister, R; Duensing, T; Singh, S; Blacklow, SC; Yao, ZB; Aster, JC; Zhou, BBS				Li, Kang; Li, Yucheng; Wu, Wenjuan; Gordon, Wendy R.; Chang, David W.; Lu, Mason; Scoggin, Shane; Fu, Tihui; Vien, Long; Histen, Gavin; Zheng, Ji; Martin-Hollister, Rachel; Duensing, Thomas; Singh, Sanjaya; Blacklow, Stephen C.; Yao, Zhengbin; Aster, Jon C.; Zhou, Bin-Bing S.			Modulation of Notch signaling by antibodies specific for the extracellular negative regulatory region of NOTCH3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALAGILLE-SYNDROME; GAMMA-SECRETASE; PROTEOLYTIC ACTIVATION; INTRACELLULAR DOMAIN; HUMAN JAGGED1; STEM-CELLS; MUTATIONS; LIGAND; MICE; CLEAVAGE	The Notch pathway regulates the development of many tissues and cell types and is involved in a variety of human diseases, making it an attractive potential therapeutic target. This promise has been limited by the absence of potent inhibitors or agonists that are specific for individual human Notch receptors (NOTCH1-4). Using an unbiased functional screening, we identified monoclonal antibodies that specifically inhibit or induce activating proteolytic cleavages in NOTCH3. Remarkably, the most potent inhibitory and activating antibodies bind to overlapping epitopes within a juxtamembrane negative regulatory region that protects NOTCH3 from proteolysis and activation in its resting autoinhibited state. The inhibitory antibodies revert phenotypes conveyed on 293T cells by NOTCH3 signaling, such as increased cellular proliferation, survival, and motility, whereas the activating antibody mimics some of the effects of ligand-induced Notch activation. These findings provide insights into the mechanisms of Notch autoinhibition and activation and pave the way for the further development of specific antibody-based modulators of the Notch receptors, which are likely to be of utility in a wide range of experimental and therapeutic settings.	[Li, Kang; Li, Yucheng; Wu, Wenjuan; Chang, David W.; Lu, Mason; Scoggin, Shane; Fu, Tihui; Vien, Long; Zheng, Ji; Martin-Hollister, Rachel; Duensing, Thomas; Singh, Sanjaya; Yao, Zhengbin; Zhou, Bin-Bing S.] Tanox Inc, Houston, TX 77025 USA; [Gordon, Wendy R.; Histen, Gavin; Blacklow, Stephen C.; Aster, Jon C.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Li, K (corresponding author), Pfizer La Jolla, 10628 Sci Ctr Dr, San Diego, CA 92121 USA.	kyfli@yahoo.com; binbing_s_zhou@yahoo.com	Wu, wenjuan/GPX-6968-2022	Gordon, Wendy/0000-0001-7696-5560; Scoggin, Shane/0000-0003-2510-2823	NCI NIH HHS [P01 CA119070-03, P01 CA119070] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA119070] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Bellavia D, 2002, P NATL ACAD SCI USA, V99, P3788, DOI 10.1073/pnas.062050599; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Dallman MJ, 2005, CURR OPIN IMMUNOL, V17, P259, DOI 10.1016/j.coi.2005.04.002; de Pooter Renee F., 2006, V330, P113; Domenga V, 2004, GENE DEV, V18, P2730, DOI 10.1101/gad.308904; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fre S, 2005, NATURE, V435, P964, DOI 10.1038/nature03589; Fung M, 2003, CLIN EXP IMMUNOL, V133, P160, DOI 10.1046/j.1365-2249.2003.02213.x; Garg V, 2005, NATURE, V437, P270, DOI 10.1038/nature03940; Gordon WR, 2007, NAT STRUCT MOL BIOL, V14, P295, DOI 10.1038/nsmb1227; Haruki N, 2005, CANCER RES, V65, P3555, DOI 10.1158/0008-5472.CAN-04-3132; Hicks C, 2002, J NEUROSCI RES, V68, P655, DOI 10.1002/jnr.10263; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Krebs LT, 2000, GENE DEV, V14, P1343; Kumano K, 2003, IMMUNITY, V18, P699, DOI 10.1016/S1074-7613(03)00117-1; Li LH, 1997, NAT GENET, V16, P243, DOI 10.1038/ng0797-243; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Lu CF, 2001, J IMMUNOL, V166, P5629, DOI 10.4049/jimmunol.166.9.5629; McCright B, 2001, DEVELOPMENT, V128, P491; McDaniell R, 2006, AM J HUM GENET, V79, P169, DOI 10.1086/505332; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Nam YS, 2007, P NATL ACAD SCI USA, V104, P2103, DOI 10.1073/pnas.0611092104; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; Ong CT, 2006, J BIOL CHEM, V281, P5106, DOI 10.1074/jbc.M506108200; Park JT, 2006, CANCER RES, V66, P6312, DOI 10.1158/0008-5472.CAN-05-3610; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Petcherski AG, 2000, NATURE, V405, P364, DOI 10.1038/35012645; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Saito T, 2003, IMMUNITY, V18, P675, DOI 10.1016/S1074-7613(03)00111-0; Sanchez-Irizarry C, 2004, MOL CELL BIOL, V24, P9265, DOI 10.1128/MCB.24.21.9265-9273.2004; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shimizu K, 2002, EMBO J, V21, P294, DOI 10.1093/emboj/21.3.294; Singec I, 2006, NAT METHODS, V3, P801, DOI 10.1038/nmeth926; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Sun X, 1997, DEVELOPMENT, V124, P3439; Varnum-Finney B, 2000, J CELL SCI, V113, P4313; Vas V, 2004, J LEUKOCYTE BIOL, V75, P714, DOI 10.1189/jlb.1003462; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wong GT, 2004, J BIOL CHEM, V279, P12876, DOI 10.1074/jbc.M311652200; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644	46	158	198	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					8046	8054		10.1074/jbc.M800170200	http://dx.doi.org/10.1074/jbc.M800170200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18182388	hybrid			2022-12-25	WOS:000253997900079
J	Bai, Y; Ahmad, U; Wang, Y; Li, JH; Choy, JC; Kim, RW; Kirkiles-Smith, N; Maher, SE; Karras, JG; Bennett, CF; Bothwell, ALM; Pober, JS; Tellides, G				Bai, Yalai; Ahmad, Usman; Wang, Yinong; Li, Jie H.; Choy, Jonathan C.; Kim, Richard W.; Kirkiles-Smith, Nancy; Maher, Stephen E.; Karras, James G.; Bennett, C. Frank; Bothwell, Alfred L. M.; Pober, Jordan S.; Tellides, George			Interferon-gamma induces X-linked inhibitor of apoptosis-associated factor-1 and noxa expression and potentiates human vascular smooth muscle cell apoptosis by STAT3 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE RESPONSE FACTOR; IFN-GAMMA; GENE-EXPRESSION; TRANSCRIPTION FACTOR; SIGNAL TRANSDUCERS; HUMAN NEUTROPHILS; STIMULATED GENE; ONCOSTATIN-M; INDUCTION; ALPHA	Interferon (IFN)-gamma actions on the vessel wall play an important role in the pathogenesis of arteriosclerosis, yet the contribution of different IFN-gamma signaling pathways to the phenotypic modulation of vascular smooth muscle cells (VSMCs) are poorly understood. We investigated the effects of IFN-gamma on VSMCs and arteries through interactions involving signal transducer and activator of transcription (STAT) proteins. In addition to STAT1 activation, IFN-gamma consistently phosphorylated STAT3 in human VSMCs but weakly or not at all in human endothelial cells or mouse VSMCs. STAT3 activation resulted in nuclear translocation of this transcription factor. By selectively inhibiting STAT3 and not STAT1 signaling, we identified a number of candidate IFN-gamma-inducible, STAT3-dependent gene products by microarray analysis. Results for selected genes, including the pro-apoptotic molecules X-linked inhibitor of apoptosis associated factor-1 (XAF1) and Noxa, were verified by real time quantitative reverse transcription-PCR and immunoblot analyses. IFN-gamma-induced STAT3 and STAT1 signaling in VSMCs demonstrated reciprocal inhibition. STAT3 activation by IFN-gamma sensitized VSMCs to apoptosis triggered by both death receptor- and mitochondrial-mediated pathways. Knock down of XAF1 and Noxa expression inhibited the priming of VSMCs to apoptotic stimuli by IFN-gamma. Finally, we confirmed the in vivo relevance of our observations using a chimeric animal model of immunodeficient mice bearing human coronary artery grafts in which the expression of XAF1 and Noxa as well as the pro-apoptotic effects induced by IFN-gamma were dependent on STAT3. The data suggest STAT1-independent signaling by IFN-gamma via STAT3 that promotes the death of human VSMCs.	[Bai, Yalai; Ahmad, Usman; Wang, Yinong; Kim, Richard W.; Kirkiles-Smith, Nancy; Tellides, George] Yale Univ, Sch Med, Dept Surg, New Haven, CT 06510 USA; [Li, Jie H.; Choy, Jonathan C.; Pober, Jordan S.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; [Maher, Stephen E.; Bothwell, Alfred L. M.; Pober, Jordan S.] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Interdept Program Vasc Biol & Transplantat, New Haven, CT 06510 USA; [Karras, James G.; Bennett, C. Frank] ISIS Pharmaceut, Carlsbad, CA 92008 USA	Yale University; Yale University; Yale University; Yale University; Isis Pharmaceuticals Inc	Tellides, G (corresponding author), Yale Univ, Sch Med, Dept Surg, 295 Congress Ave 454, New Haven, CT 06510 USA.	george.tellides@yale.edu		Choy, Jonathan/0000-0003-1837-8514	NHLBI NIH HHS [P01 HL70295] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070295] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abell K, 2005, NAT CELL BIOL, V7, P392, DOI 10.1038/ncb1242; Alsayed Y, 2000, J IMMUNOL, V164, P1800, DOI 10.4049/jimmunol.164.4.1800; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Burns WR, 2005, AM J TRANSPLANT, V5, P1226, DOI 10.1111/j.1600-6143.2005.00892.x; Butler M, 1997, LAB INVEST, V77, P379; Caldenhoven E, 1999, J LEUKOCYTE BIOL, V65, P391, DOI 10.1002/jlb.65.3.391; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040; Costa-Pereira AP, 2002, P NATL ACAD SCI USA, V99, P8043, DOI 10.1073/pnas.122236099; Cowburn AS, 2006, J BIOL CHEM, V281, P12458, DOI 10.1074/jbc.M511277200; Deb DK, 2003, J IMMUNOL, V171, P267, DOI 10.4049/jimmunol.171.1.267; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; El-Hashemite N, 2004, CANCER RES, V64, P3436, DOI 10.1158/0008-5472.CAN-03-3609; Fang P, 2006, EXP CELL RES, V312, P1229, DOI 10.1016/j.yexcr.2005.12.011; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; Gamero AM, 2006, J BIOL CHEM, V281, P16238, DOI 10.1074/jbc.M509516200; Gil MP, 2001, P NATL ACAD SCI USA, V98, P6680, DOI 10.1073/pnas.111163898; Ho HH, 2006, J BIOL CHEM, V281, P14111, DOI 10.1074/jbc.M511797200; Hong F, 2002, J CLIN INVEST, V110, P1503, DOI 10.1172/JCI200215841; Kaur N, 2003, J NEUROCHEM, V87, P437, DOI 10.1046/j.1471-4159.2003.02012.x; KORDULA T, 1995, BIOCHEM BIOPH RES CO, V216, P999, DOI 10.1006/bbrc.1995.2719; Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263; Leaman DW, 2002, J BIOL CHEM, V277, P28504, DOI 10.1074/jbc.M204851200; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Lu Y, 2006, J BIOL CHEM, V281, P36683, DOI 10.1074/jbc.M607374200; Mahboubi K, 2002, J BIOL CHEM, V277, P8012, DOI 10.1074/jbc.M107542200; Nguyen H, 2001, J BIOL CHEM, V276, P33361, DOI 10.1074/jbc.M105070200; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Peilot H, 2000, J BIOL CHEM, V275, P22895, DOI 10.1074/jbc.M002783200; Qing YL, 2004, J BIOL CHEM, V279, P41679, DOI 10.1074/jbc.M406413200; Radaeva S, 2002, GASTROENTEROLOGY, V122, P1020, DOI 10.1053/gast.2002.32388; Radaeva S, 2004, BIOCHEM J, V379, P199, DOI 10.1042/BJ20031495; Ramana CV, 2005, BIOCHEM BIOPH RES CO, V327, P727, DOI 10.1016/j.bbrc.2004.12.074; Ramana CV, 2000, EMBO J, V19, P263, DOI 10.1093/emboj/19.2.263; Ramana CV, 2001, P NATL ACAD SCI USA, V98, P6674, DOI 10.1073/pnas.111164198; RAZ R, 1994, J BIOL CHEM, V269, P24391; Rosner D, 2006, AM J PATHOL, V168, P2054, DOI 10.2353/ajpath.2006.050473; Sakamoto E, 2005, J LEUKOCYTE BIOL, V78, P301, DOI 10.1189/jlb.1104690; Sato T, 1997, BLOOD, V90, P4749, DOI 10.1182/blood.V90.12.4749.4749_4749_4758; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stephanou A, 2005, GROWTH FACTORS, V23, P177, DOI 10.1080/08977190500178745; Stephens JM, 1998, J BIOL CHEM, V273, P31408, DOI 10.1074/jbc.273.47.31408; Sun YP, 2005, J BIOL CHEM, V280, P15561, DOI 10.1074/jbc.m412630200; Tamai M, 2006, J LAB CLIN MED, V147, P182, DOI 10.1016/j.lab.2005.12.001; Tellides G, 2000, NATURE, V403, P207, DOI 10.1038/35003221; Tellides G, 2007, CIRC RES, V100, P622, DOI 10.1161/01.RES.0000258861.72279.29; Wang YN, 2004, FASEB J, V18, P606, DOI 10.1096/fj.03-0840fje; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	52	31	35	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					6832	6842		10.1074/jbc.M706021200	http://dx.doi.org/10.1074/jbc.M706021200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18192275	hybrid			2022-12-25	WOS:000253779600026
J	Kaden, D; Munter, LM; Joshi, M; Treiber, C; Weise, C; Bethge, T; Voigt, P; Schaefer, M; Beyermann, M; Reif, B; Multhaup, G				Kaden, Daniela; Munter, Lisa-Marie; Joshi, Mangesh; Treiber, Carina; Weise, Christoph; Bethge, Tobias; Voigt, Philipp; Schaefer, Michael; Beyermann, Michael; Reif, Bernd; Multhaup, Gerd			Homophilic interactions of the amyloid precursor protein (APP) ectodomain are regulated by the loop region and affect beta-secretase cleavage of APP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; CRYSTAL-STRUCTURE; EXTRACELLULAR DOMAIN; BINDING DOMAIN; RECEPTOR; PATHWAY; HETERODIMERIZATION; HOMODIMERIZATION; DIMERIZATION; MECHANISMS	We found previously by fluorescence resonance energy transfer experiments that amyloid precursor protein( APP) homodimerizes in living cells. APP homodimerization is likely to be mediated by two sites of the ectodomain and a third site within the transmembrane sequence of APP. We have now investigated the role of the N-terminal growth factor-like domain in APP dimerization by NMR, biochemical, and cell biological approaches. Under nonreducing conditions, the N-terminal domain of APP formed SDS-labile and SDS-stable complexes. The presence of SDS was sufficient to convert native APP dimers entirely into monomers. Addition of an excess of a synthetic peptide ( APP residues 91 - 116) containing the disulfide bridge-stabilized loop inhibited cross linking of preexisting SDS-labile APP ectodomain dimers. Surface plasmon resonance analysis revealed that this peptide specifically bound to the N-terminal domain of APP and that binding was entirely dependent on the oxidation of the thiol groups. By solution-state NMR we detected small chemical shift changes indicating that the loop peptide interacted with a large protein surface rather than binding to a defined pocket. Finally, we studied the effect of the loop peptide added to the medium of living cells. Whereas the levels of alpha-secretory APP increased, soluble beta-cleaved APP levels decreased. Because A beta 40 and A beta 42 decreased to similar levels as soluble beta-cleaved APP, we conclude either that beta-secretase binding to APP was impaired or that the peptide allosterically affected APP processing. We suggest that APP acquires a loop-mediated homodimeric state that is further stabilized by interactions of hydrophobic residues of neighboring domains.	[Kaden, Daniela; Munter, Lisa-Marie; Treiber, Carina; Bethge, Tobias; Voigt, Philipp; Multhaup, Gerd] Free Univ Berlin, Inst Chem & Biochem, D-14195 Berlin, Germany; [Joshi, Mangesh; Beyermann, Michael; Reif, Bernd] Leibniz Inst Mol Pharmacol, D-13125 Berlin, Germany; [Voigt, Philipp; Schaefer, Michael] Charite, Neurowissensch Forsch Zentrum, D-14195 Berlin, Germany	Free University of Berlin; Leibniz Forschungsinstitut furr Molekulare Pharmakologie (FMP); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Multhaup, G (corresponding author), Free Univ Berlin, Inst Chem & Biochem, Thielallee 63, D-14195 Berlin, Germany.	multhaup@chemie.fu-berlin.de	Horstmann, Britta/C-2154-2008	Reif, Bernd/0000-0001-7368-7198; Munter, Lisa/0000-0001-5736-1462; Voigt, Philipp/0000-0003-4366-0490				Barnham KJ, 2003, J BIOL CHEM, V278, P17401, DOI 10.1074/jbc.M300629200; Beher D, 1996, J BIOL CHEM, V271, P1613, DOI 10.1074/jbc.271.3.1613; CHANAT E, 1993, EMBO J, V12, P2159, DOI 10.1002/j.1460-2075.1993.tb05864.x; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; DAIGLE I, 1993, P NATL ACAD SCI USA, V90, P12045, DOI 10.1073/pnas.90.24.12045; Dulubova I, 2004, BIOCHEMISTRY-US, V43, P9583, DOI 10.1021/bi049041o; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Ferguson KM, 2000, EMBO J, V19, P4632, DOI 10.1093/emboj/19.17.4632; Gralle M, 2006, J MOL BIOL, V357, P493, DOI 10.1016/j.jmb.2005.12.053; GREENBERG SM, 1995, NEUROSCI LETT, V198, P52, DOI 10.1016/0304-3940(95)11944-R; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; HILBICH C, 1993, J BIOL CHEM, V268, P26571; HYNES TR, 1990, BIOCHEMISTRY-US, V29, P10018, DOI 10.1021/bi00495a002; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; KITAGUCHI N, 1990, BIOCHIM BIOPHYS ACTA, V1038, P105, DOI 10.1016/0167-4838(90)90017-A; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Morimoto T, 1998, J NEUROSCI RES, V51, P185, DOI 10.1002/(SICI)1097-4547(19980115)51:2<185::AID-JNR7>3.0.CO;2-9; MULTHAUP G, 1994, BIOCHIMIE, V76, P304, DOI 10.1016/0300-9084(94)90163-5; Munter LM, 2007, EMBO J, V26, P1702, DOI 10.1038/sj.emboj.7601616; OKAMOTO T, 1995, J BIOL CHEM, V270, P4205, DOI 10.1074/jbc.270.9.4205; Reinhard C, 2005, EMBO J, V24, P3996, DOI 10.1038/sj.emboj.7600860; Rossjohn J, 1999, NAT STRUCT BIOL, V6, P327; Salzmann M, 1998, P NATL ACAD SCI USA, V95, P13585, DOI 10.1073/pnas.95.23.13585; Scheuermann S, 2001, J BIOL CHEM, V276, P33923, DOI 10.1074/jbc.M105410200; Schmechel A, 2004, J BIOL CHEM, V279, P39710, DOI 10.1074/jbc.M402785200; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Sinha S, 1999, P NATL ACAD SCI USA, V96, P11049, DOI 10.1073/pnas.96.20.11049; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SMALL DH, 1994, J NEUROSCI, V14, P2117; SMALL DH, 1992, J NEUROSCI, V12, P4143; Soba P, 2005, EMBO J, V24, P3624, DOI 10.1038/sj.emboj.7600824; Stiegler AL, 2006, J MOL BIOL, V364, P424, DOI 10.1016/j.jmb.2006.09.019; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wang YC, 2004, MOL CELL, V15, P343, DOI 10.1016/j.molcel.2004.06.037; Westmeyer GG, 2004, J BIOL CHEM, V279, P53205, DOI 10.1074/jbc.M410378200; Wilson IA, 1999, CURR OPIN STRUC BIOL, V9, P696, DOI 10.1016/S0959-440X(99)00032-9; Yu CJ, 2001, J BIOL CHEM, V276, P43756, DOI 10.1074/jbc.C100410200	37	81	84	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					7271	7279		10.1074/jbc.M708046200	http://dx.doi.org/10.1074/jbc.M708046200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18182389	hybrid, Green Published			2022-12-25	WOS:000253779600072
J	Arany, I; Faisal, A; Nagamine, Y; Safirstein, RL				Arany, Istvan; Faisal, Amir; Nagamine, Yoshikuni; Safirstein, Robert L.			p66(shc) inhibits pro-survival epidermal growth factor receptor/ERK signaling during severe oxidative stress in mouse renal proximal tubule cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF-RECEPTOR; ACTIVATION; EXPRESSION; PROTEIN; KINASE; SHC; INJURY; ERK; PATHWAY; PHOSPHORYLATION	The fully executed epidermal growth factor receptor (EGFR)/Ras/MEK/ERK pathway serves a pro-survival role in renal epithelia under moderate oxidative stress. We and others have demonstrated that during severe oxidative stress, however, the activated EGFR is disconnected from ERK activation in cultured renal proximal tubule cells and also in renal proximal tubules after ischemia/reperfusion injury, resulting in necrotic death. Studies have shown that the tyrosine-phosphorylated p46/52 isoforms of the ShcA family of adaptor proteins connect the activated EGFR to activation of Ras and ERK, whereas the p66(shc) isoform can inhibit this p46/52(shc) function. Here, we determined that severe oxidative stress ( after a brief period of activation) terminates activation of the Ras/MEK/ERK pathway, which coincides with ERK/JNK-dependent Ser(36) phosphorylation of p66(shc). Isoform-specific knockdown of p66(shc) or mutation of Ser(36) to Ala, but not to Asp, attenuated severe oxidative stress-mediated ERK inhibition and cell death in vitro. Also, severe oxidative stress ( unlike ligand stimulation and moderate oxidative stress, both of which support survival) increased binding of p66(shc) to the activated EGFR and Grb2. This binding dissociated the SOS1 adaptor protein from the EGFR-recruited signaling complex, leading to termination of Ras/MEK/ERK activation. Notably, Ser(36) phosphorylation of p66(shc) and its increased binding to the EGFR also occurred in the kidney after ischemia/reperfusion injury in vivo. At the same time, SOS1 binding to the EGFR declined, similar to the in vitro findings. Thus, the mechanism we propose in vitro offers a means to ameliorate oxidative stress-induced cell injury by either inhibiting Ser(36) phosphorylation of p66(shc) or knocking down p66(sh)c expression in vivo.	[Arany, Istvan] Univ Mississippi, Med Ctr, Dept Pediat, Div Pediat Nephrol, Jackson, MS 39126 USA; [Arany, Istvan; Safirstein, Robert L.] Univ Arkansas Med Sci, Dept Internal Med, Little Rock, AR 72205 USA; [Arany, Istvan; Safirstein, Robert L.] Cent Arkansas Vet Healthcare Syst, Little Rock, AR 72205 USA; [Faisal, Amir] Lincolns Inn Fields Labs, Canc Res UK London Res Inst, Prot Phosphorylat Lab, London WC2A 3PX, England; [Nagamine, Yoshikuni] Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland	University of Mississippi; University of Mississippi Medical Center; University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System; Cancer Research UK; Friedrich Miescher Institute for Biomedical Research	Arany, I (corresponding author), Univ Mississippi, Med Ctr, Dept Pediat, Div Pediat Nephrol, 2500 N State St, Jackson, MS 39126 USA.	iarany@ped.umsmed.edu	Faisal, Amir/AAE-8992-2020	Faisal, Amir/0000-0002-7376-8286	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK058324] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01 DK 58324-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andreucci M, 2003, KIDNEY INT, V64, P1189, DOI 10.1046/j.1523-1755.2003.00204.x; Arany I, 2008, KIDNEY INT, V73, P5, DOI 10.1038/sj.ki.5002583; Arany I, 2005, KIDNEY INT, V68, P1573, DOI 10.1111/j.1523-1755.2005.00569.x; Arany I, 2004, KIDNEY INT, V65, P1231, DOI 10.1111/j.1523-1755.2004.00500.x; Arany I, 2002, ANTIVIR RES, V55, P331, DOI 10.1016/S0166-3542(02)00070-0; BREYER MD, 1990, AM J PHYSIOL, V259, pF553, DOI 10.1152/ajprenal.1990.259.4.F553; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Di Mari JF, 1999, AM J PHYSIOL-RENAL, V277, pF195, DOI 10.1152/ajprenal.1999.277.2.F195; Dong J, 2004, AM J PHYSIOL-RENAL, V287, pF1049, DOI 10.1152/ajprenal.00132.2004; Faisal A, 2004, J BIOL CHEM, V279, P3202, DOI 10.1074/jbc.M310010200; GAMOU S, 1995, FEBS LETT, V357, P161, DOI 10.1016/0014-5793(94)01335-X; Goldkorn T, 1998, AM J RESP CELL MOL, V19, P786, DOI 10.1165/ajrcmb.19.5.3249; HARRIS RC, 1991, AM J KIDNEY DIS, V17, P627, DOI 10.1016/S0272-6386(12)80336-2; Hu YY, 2005, MOL BIOL CELL, V16, P3705, DOI 10.1091/mbc.E05-04-0301; Hung CC, 2003, J BIOL CHEM, V278, P29317, DOI 10.1074/jbc.M302368200; Ichiki T, 2003, HYPERTENSION, V42, P177, DOI 10.1161/01.HYP.0000079791.26014.04; Iordanov MS, 2002, MOL CELL BIOL, V22, P5380, DOI 10.1128/MCB.22.15.5380-5394.2002; Khanday FA, 2006, J CELL BIOL, V172, P817, DOI 10.1083/jcb.200506001; Kisielow M, 2002, BIOCHEM J, V363, P1, DOI 10.1042/0264-6021:3630001; Kleiner S, 2007, FEBS J, V274, P227, DOI 10.1111/j.1742-4658.2006.05578.x; Le S, 2001, J BIOL CHEM, V276, P48332, DOI 10.1074/jbc.M106612200; Luzi L, 2000, CURR OPIN GENET DEV, V10, P668, DOI 10.1016/S0959-437X(00)00146-5; Meves A, 2001, TOXICOL LETT, V122, P205, DOI 10.1016/S0378-4274(01)00359-9; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Migliaccio E, 2006, ANTIOXID REDOX SIGN, V8, P600, DOI 10.1089/ars.2006.8.600; NORMAN J, 1990, CLIN SCI, V78, P445, DOI 10.1042/cs0780445; Okada S, 1997, J BIOL CHEM, V272, P28042, DOI 10.1074/jbc.272.44.28042; Pellegrini M, 2005, APOPTOSIS, V10, P13, DOI 10.1007/s10495-005-6057-8; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Purdom S, 2003, BIOGERONTOLOGY, V4, P181, DOI 10.1023/A:1025123413403; Purdom S, 2003, TRENDS MOL MED, V9, P206, DOI 10.1016/S1471-4914(03)00048-0; Rao GN, 1996, ONCOGENE, V13, P713; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; Safirstein RL, 1999, RENAL FAILURE, V21, P359, DOI 10.3109/08860229909085099; Skulachev VP, 2000, IUBMB LIFE, V49, P177; Sorenson CM, 2002, AM J PHYSIOL-RENAL, V283, pF1085, DOI 10.1152/ajprenal.00380.2001; Taira T, 1996, VIRCHOWS ARCH, V427, P583; Terzi F, 2000, J CLIN INVEST, V106, P225, DOI 10.1172/JCI8315; TOUBEAU GN, 1994, EXP NEPHROL, V2, P229; Wang ZF, 2003, J AM SOC NEPHROL, V14, P3147, DOI 10.1097/01.ASN.0000098681.56240.1A; Yamakawa T, 2000, HYPERTENSION, V35, P313, DOI 10.1161/01.HYP.35.1.313; Yano T, 1999, NEPHRON, V81, P230, DOI 10.1159/000045281; Zaccagnini G, 2004, CIRCULATION, V109, P2917, DOI 10.1161/01.CIR.0000129309.58874.0F; Zhougang SG, 2004, AM J PHYSIOL-RENAL, V286, pF858, DOI 10.1152/ajprenal.00282.2003	45	73	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2008	283	10					6110	6117		10.1074/jbc.M708799200	http://dx.doi.org/10.1074/jbc.M708799200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HM	18174162	hybrid			2022-12-25	WOS:000253779500017
J	Jeppesen, B; Smith, C; Gibson, DF; Tait, JF				Jeppesen, Brian; Smith, Christina; Gibson, Donald F.; Tait, Jonathan F.			Entropic and enthalpic contributions to annexin V-membrane binding - A comprehensive quantitative model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL ANTICOAGULANT PROTEIN; CALCIUM-DEPENDENT BINDING; X-RAY CRYSTALLOGRAPHY; PHOSPHOLIPID-BINDING; KINASE-C; PHOSPHATIDYLSERINE EXPOSURE; CELL-DEATH; IN-VIVO; VESICLES; DYNAMICS	Annexin V binds to membranes with very high affinity, but the factors responsible remain to be quantitatively elucidated. Analysis by isothermal microcalorimetry and calcium titration under conditions of low membrane occupancy showed that there was a strongly positive entropy change upon binding. For vesicles containing 25% phosphatidylserine at 0.15 M ionic strength, the free energy of binding was -53 kcal/mol protein, whereas the enthalpy of binding was -38 kcal/mol. Addition of 4 M urea decreased the free energy of binding by about 30% without denaturing the protein, suggesting that hydrophobic forces make a significant contribution to binding affinity. This was confirmed by mutagenesis studies that showed that binding affinity was modulated by the hydrophobicity of surface residues that are likely to enter the interfacial region upon protein-membrane binding. The change in free energy was quantitatively consistent with predictions from the Wimley-White scale of interfacial hydrophobicity. In contrast, binding affinity was not increased by making the protein surface more positively charged, nor decreased by making it more negatively charged, ruling out general ionic interactions as major contributors to binding affinity. The affinity of annexin V was the same regardless of the head group present on the anionic phospholipids tested (phosphatidylserine, phosphatidylglycerol, phosphatidylmethanol, and cardiolipin), ruling out specific interactions between the protein and non-phosphate moieties of the head group as a significant contributor to binding affinity. Analysis by fluorescence resonance energy transfer showed that multimers did not form on phosphatidylserine membranes at low occupancy, indicating that annexin-annexin interactions did not contribute to binding affinity. In summary, binding of annexin V to membranes is driven by both enthalpic and entropic forces. Dehydration of hydrophobic regions of the protein surface as they enter the interfacial region makes an important contribution to overall binding affinity, supplementing the role of protein-calcium-phosphate chelates.	[Jeppesen, Brian; Smith, Christina; Gibson, Donald F.; Tait, Jonathan F.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; [Tait, Jonathan F.] Univ Washington, Dept Med Med Genet, Seattle, WA 98195 USA; [Tait, Jonathan F.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Tait, JF (corresponding author), Univ Washington, Dept Lab Med, Box 357110, Seattle, WA 98195 USA.	tait@u.washington.edu	Smith, Christina/GXG-6941-2022		NCI NIH HHS [CA 102348] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102348] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREE HAM, 1990, J BIOL CHEM, V265, P4923; BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P7970, DOI 10.1021/bi00246a014; BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P7961, DOI 10.1021/bi00246a013; BAZZI MD, 1993, CELL SIGNAL, V5, P357, DOI 10.1016/0898-6568(93)90075-W; BLACKWOOD RA, 1990, BIOCHEM J, V266, P195, DOI 10.1042/bj2660195; Blankenberg FG, 1998, P NATL ACAD SCI USA, V95, P6349, DOI 10.1073/pnas.95.11.6349; Budisa N, 1998, EUR J BIOCHEM, V253, P1, DOI 10.1046/j.1432-1327.1998.2530001.x; Campos B, 1998, BIOCHEMISTRY-US, V37, P8004, DOI 10.1021/bi973142n; Cesarman-Maus G, 2006, BLOOD, V107, P4375, DOI 10.1182/blood-2005-07-2636; Cezanne L, 1999, BIOCHEMISTRY-US, V38, P2779, DOI 10.1021/bi9818568; CONCHA NO, 1992, FEBS LETT, V314, P159, DOI 10.1016/0014-5793(92)80964-I; CONCHA NO, 1993, SCIENCE, V261, P1321, DOI 10.1126/science.8362244; EVANS TC, 1994, BIOCHEMISTRY-US, V33, P13231, DOI 10.1021/bi00249a009; FUNAKOSHI T, 1987, BIOCHEMISTRY-US, V26, P5572, DOI 10.1021/bi00391a053; Gerke V, 2005, NAT REV MOL CELL BIO, V6, P449, DOI 10.1038/nrm1661; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; GILMANSHIN R, 1994, BIOCHEMISTRY-US, V33, P8225, DOI 10.1021/bi00193a008; HAVERSTICK DM, 1987, P NATL ACAD SCI USA, V84, P4475, DOI 10.1073/pnas.84.13.4475; HUBER R, 1992, J MOL BIOL, V223, P683, DOI 10.1016/0022-2836(92)90984-R; Isas JM, 2005, BIOCHEMISTRY-US, V44, P16435, DOI 10.1021/bi051751m; Isas JM, 2004, J BIOL CHEM, V279, P32492, DOI 10.1074/jbc.M402568200; Jin M, 2004, J BIOL CHEM, V279, P40351, DOI 10.1074/jbc.M405846200; JUNKER M, 1993, BIOCHEMISTRY-US, V32, P9968, DOI 10.1021/bi00089a012; Kastl K, 2006, CHEMBIOCHEM, V7, P106, DOI 10.1002/cbic.200500265; Kohler G, 1997, BIOCHEMISTRY-US, V36, P8189, DOI 10.1021/bi9703960; Ladokhin AS, 2005, BIOCHEMISTRY-US, V44, P3402, DOI 10.1021/bi047805u; Lahorte CMM, 2004, EUR J NUCL MED MOL I, V31, P887, DOI 10.1007/s00259-004-1555-4; Langen R, 1998, J BIOL CHEM, V273, P22453, DOI 10.1074/jbc.273.35.22453; Lee ME, 2006, J AM CHEM SOC, V128, P4948, DOI 10.1021/ja058600r; MEERS P, 1994, BIOCHEMISTRY-US, V33, P5829, DOI 10.1021/bi00185a022; MEERS P, 1993, BIOCHEMISTRY-US, V32, P5411, DOI 10.1021/bi00071a016; Megli FM, 1998, BIOCHEMISTRY-US, V37, P10540, DOI 10.1021/bi9801255; Menke M, 2005, BIOCHEMISTRY-US, V44, P15296, DOI 10.1021/bi051585i; Mo Y, 2003, J BIOL CHEM, V278, P2437, DOI 10.1074/jbc.M210286200; MOORE PB, 1982, J BIOL CHEM, V257, P9663; Moss SE, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-4-219; Oling F, 2000, J MOL BIOL, V304, P561, DOI 10.1006/jmbi.2000.4183; Patel DR, 2005, BIOCHEMISTRY-US, V44, P2833, DOI 10.1021/bi047642+; Patel DR, 2001, BIOCHEMISTRY-US, V40, P7054, DOI 10.1021/bi010345+; PLAGER DA, 1994, BIOCHEMISTRY-US, V33, P13239, DOI 10.1021/bi00249a010; Rand JH, 2004, THROMB RES, V114, P383, DOI 10.1016/j.thromres.2004.07.021; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; Rezus YLA, 2006, P NATL ACAD SCI USA, V103, P18417, DOI 10.1073/pnas.0606538103; REZUS YL, 2007, PHYS REV LETT, V99; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; SWAIRJO MA, 1995, NAT STRUCT BIOL, V2, P968, DOI 10.1038/nsb1195-968; TAIT JF, 1989, J BIOL CHEM, V264, P7944; TAIT JF, 1992, ARCH BIOCHEM BIOPHYS, V298, P187, DOI 10.1016/0003-9861(92)90111-9; Tait JF, 1999, J BIOL CHEM, V274, P3048, DOI 10.1074/jbc.274.5.3048; Tait JF, 2004, ANAL BIOCHEM, V329, P112, DOI 10.1016/j.ab.2004.02.043; Tait JF, 2006, J NUCL MED, V47, P1546; THIAGARAJAN P, 1990, J BIOL CHEM, V265, P17420; VOGES D, 1994, J MOL BIOL, V238, P199, DOI 10.1006/jmbi.1994.1281; White SH, 2001, J BIOL CHEM, V276, P32395, DOI 10.1074/jbc.R100008200; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; Wood BL, 1996, BLOOD, V88, P1873	56	24	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2008	283	10					6126	6135		10.1074/jbc.M707637200	http://dx.doi.org/10.1074/jbc.M707637200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HM	18174168	hybrid			2022-12-25	WOS:000253779500019
J	Gaidelyte, A; Vaara, M; Bamford, DH				Gaidelyte, Ausra; Vaara, Martti; Bamford, Dennis H.			Bacteria, Phages and Septicemia	PLOS ONE			English	Article								The use of phages is an attractive option to battle antibiotic resistant bacteria in certain bacterial infections, but the role of phage ecology in bacterial infections is obscure. Here we surveyed the phage ecology in septicemia, the most severe type of bacterial infection. We observed that the majority of the bacterial isolates from septicemia patients spontaneously secreted phages active against other isolates of the same bacterial strain, but not to the strain causing the disease. Such phages were also detected in the initial blood cultures, indicating that phages are circulating in the blood at the onset of sepsis. The fact that most of the septicemic bacterial isolates carry functional prophages suggests an active role of phages in bacterial infections. Apparently, prophages present in sepsis-causing bacterial clones play a role in clonal selection during bacterial invasion.	[Gaidelyte, Ausra; Bamford, Dennis H.] Univ Helsinki, Inst Biotechnol, Dept Biol & Environm Sci, Helsinki, Finland; [Vaara, Martti] Helsinki Univ Hosp, Dept Clin Microbiol, Helsinki, Finland	University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Bamford, DH (corresponding author), Univ Helsinki, Inst Biotechnol, Dept Biol & Environm Sci, Helsinki, Finland.	dennis.bamford@helsinki.fi	Domanska, Ausra/H-5206-2013; Domanska, Ausra/W-8927-2019; Vaara, Martti S/D-1698-2013	Domanska, Ausra/0000-0002-3772-6003; Bamford, Dennis/0000-0002-6438-8118	Finland Finnish Centre of Excellence Programme [1210253, 1213992, 1213467]	Finland Finnish Centre of Excellence Programme	This work was supported by the Academy of Finland Finnish Centre of Excellence Programme 2006-2011 (grants 1210253, 1213992, 1213467 to DHB).	Alekshun MN, 2007, CELL, V128, P1037, DOI 10.1016/j.cell.2007.03.004; Alisky J, 1998, J INFECTION, V36, P5, DOI 10.1016/S0163-4453(98)92874-2; BAMFORD JKH, 1991, VIROLOGY, V181, P348, DOI 10.1016/0042-6822(91)90501-2; Biswas B, 2002, INFECT IMMUN, V70, P204, DOI 10.1128/IAI.70.1.204-210.2002; Boyd EF, 2005, BACTERIOPHAGE: BIOLOGY AND APPLICATIONS, P223; Boyd EF, 2002, TRENDS MICROBIOL, V10, P521, DOI 10.1016/S0966-842X(02)02459-9; Canchaya C, 2004, MOL MICROBIOL, V53, P9, DOI 10.1111/j.1365-2958.2004.04113.x; Casjens S, 2003, MOL MICROBIOL, V49, P277, DOI 10.1046/j.1365-2958.2003.03580.x; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; Goerke C, 2006, ANTIMICROB AGENTS CH, V50, P171, DOI 10.1128/AAC.50.1.171-177.2006; Heymann DL, 2006, CELL, V124, P671, DOI 10.1016/j.cell.2006.02.009; Jikia D, 2005, CLIN EXP DERMATOL, V30, P23, DOI 10.1111/j.1365-2230.2004.01600.x; Loeffler JM, 2001, SCIENCE, V294, P2170, DOI 10.1126/science.1066869; Loeffler JM, 2006, INFECT IMMUN, V74, P4486, DOI 10.1128/IAI.00020-06; Matsushiro A, 1999, J BACTERIOL, V181, P2257, DOI 10.1128/JB.181.7.2257-2260.1999; OLKKONEN VM, 1989, VIROLOGY, V171, P229, DOI 10.1016/0042-6822(89)90530-8; Schuch R, 2002, NATURE, V418, P884, DOI 10.1038/nature01026; Sulakvelidze A, 2005, BACTERIOPHAGE: BIOLOGY AND APPLICATIONS, P381; Sulakvelidze A, 2005, DRUG DISCOV TODAY, V10, P807, DOI 10.1016/S1359-6446(05)03441-0; Teel LD, 2002, INFECT IMMUN, V70, P4282, DOI 10.1128/IAI.70.8.4282-4291.2002; *US FDA, FDA APPR LIST SPEC B; Wong CS, 2000, NEW ENGL J MED, V342, P1930, DOI 10.1056/NEJM200006293422601; Zhang XP, 2000, J INFECT DIS, V181, P664, DOI 10.1086/315239	23	18	18	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 7	2007	2	11							e1145	10.1371/journal.pone.0001145	http://dx.doi.org/10.1371/journal.pone.0001145			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10IZ	18188406	gold, Green Published, Green Submitted			2022-12-25	WOS:000207459000028
J	Ramachandran, B; Yu, GS; Gulick, T				Ramachandran, Bindu; Yu, Gengsheng; Gulick, Tod			Nuclear respiratory factor 1 controls myocyte enhancer factor 2A transcription to provide a mechanism for coordinate expression of respiratory chain subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; CONTROLLING MITOCHONDRIAL BIOGENESIS; ACTIVATED PROTEIN-KINASE; GLUT4 GENE-EXPRESSION; SKELETAL-MUSCLE; DNA-BINDING; GLUCOSE-TRANSPORTER; HEART/MUSCLE ISOFORM; MOUSE EMBRYOGENESIS; COACTIVATOR PGC-1	Nuclear respiratory factors NRF1 and NRF2 regulate the expression of nuclear genes encoding heme biosynthetic enzymes, proteins required for mitochondrial genome transcription and protein import, and numerous respiratory chain subunits. NRFs thereby coordinate the expression of nuclear and mitochondrial genes relevant to mitochondrial biogenesis and respiration. Only two of the nuclear-encoded respiratory chain subunits have evolutionarily conserved tissue-specific forms: the cytochrome c oxidase (COX) subunits VIa and VIIa heart/muscle (H) and ubiquitous (L) isoforms. We used genome comparisons to conclude that the promoter regions of COX6A(H) and COX7A(H) lack NRF sites but have conserved myocyte enhancer factor 2 (MEF2) elements. We show that MEF2A mRNA is induced with forced expression of NRF1 and that the MEF2A 5'-regulatory region contains an evolutionarily conserved canonical element that binds endogenous NRF1 in chromatin immunoprecipitation (ChIP) assays. NRF1 regulates MEF2A promoter-reporters according to overexpression, RNA interference underexpression, and promoter element mutation studies. As there are four mammalian MEF2 isotypes, we used an isoform-specific antibody in ChIP to confirm MEF2A binding to the COX6A(H) promoter. These findings support a role for MEF2A as an intermediary in coordinating respiratory chain subunit expression in heart and muscle through a NRF1 -> MEF2A -> COXH transcriptional cascade. MEF2A also bound the MEF2A and PPARGC1A promoters in ChIP, placing it within a feedback loop with PGC1 alpha in controlling NRF1 activity. Interruption of this cascade and loop may account for striated muscle mitochondrial defects in mef2a null mice. Our findings also account for the previously described indirect regulation by NRF1 of other MEF2 targets in muscle such as GLUT4.	[Ramachandran, Bindu; Yu, Gengsheng; Gulick, Tod] Massachusetts Gen Hosp, Diabet Res Lab, Dept Med, Charlestown, MA 02129 USA; [Yu, Gengsheng; Gulick, Tod] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Gulick, T (corresponding author), Massachusetts Gen Hosp, Diabet Res Lab, Dept Med, CNY 149 8219, Charlestown, MA 02129 USA.	gulick@helix.mgh.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK040561, K02DK002461, R01DK055875] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL72713] Funding Source: Medline; NIDDK NIH HHS [DK02461, P30-DK40561, DK55875] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTHONY G, 1993, P NATL ACAD SCI USA, V90, P1652, DOI 10.1073/pnas.90.5.1652; Ausubel FM, 1998, CURRENT PROTOCOLS MO; Baar K, 2003, FASEB J, V17, P1666, DOI 10.1096/fj.03-0049com; Bachman NJ, 1997, GENOMICS, V42, P146, DOI 10.1006/geno.1997.4687; Berdeaux R, 2007, NAT MED, V13, P597, DOI 10.1038/nm1573; Bergeron R, 2001, AM J PHYSIOL-ENDOC M, V281, pE1340, DOI 10.1152/ajpendo.2001.281.6.E1340; Bergstrom DA, 2002, MOL CELL, V9, P587, DOI 10.1016/S1097-2765(02)00481-1; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; CALZONE FJ, 1991, DEVELOPMENT, V112, P335; Cam H, 2004, MOL CELL, V16, P399, DOI 10.1016/j.molcel.2004.09.037; CHAU CMA, 1992, J BIOL CHEM, V267, P6999; Cripps RM, 2004, DEV BIOL, V267, P536, DOI 10.1016/j.ydbio.2003.12.004; Cuthbertson DJ, 2007, DIABETES, V56, P2078, DOI 10.2337/db06-1716; Czubryt MP, 2003, P NATL ACAD SCI USA, V100, P1711, DOI 10.1073/pnas.0337639100; DeSimone S, 1996, DEVELOPMENT, V122, P31; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; Fazio IK, 2001, J BIOL CHEM, V276, P18710, DOI 10.1074/jbc.M100080200; Finck BN, 2005, CELL METAB, V1, P133, DOI 10.1016/j.cmet.2005.01.006; Gleyzer N, 2005, MOL CELL BIOL, V25, P1354, DOI 10.1128/MCB.25.4.1354-1366.2005; GOPALAKRISHNAN L, 1995, J BIOL CHEM, V270, P18019, DOI 10.1074/jbc.270.30.18019; GUGNEJA S, 1995, MOL CELL BIOL, V15, P102, DOI 10.1128/MCB.15.1.102; Gugneja S, 1997, J BIOL CHEM, V272, P18732, DOI 10.1074/jbc.272.30.18732; Handschin C, 2003, P NATL ACAD SCI USA, V100, P7111, DOI 10.1073/pnas.1232352100; Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037; Herzig RP, 2000, J BIOL CHEM, V275, P13134, DOI 10.1074/jbc.275.17.13134; Holmes BF, 2005, AM J PHYSIOL-ENDOC M, V289, pE1071, DOI 10.1152/ajpendo.00606.2004; Huo L, 1999, GENE, V233, P213, DOI 10.1016/S0378-1119(99)00135-3; Huo L, 2001, MOL CELL BIOL, V21, P644, DOI 10.1128/MCB.21.2.644-654.2001; Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604; Lenka N, 1998, PROG NUCLEIC ACID RE, V61, P309, DOI 10.1016/S0079-6603(08)60830-2; Li B, 1999, J BIOL CHEM, V274, P17534, DOI 10.1074/jbc.274.25.17534; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; LIU ML, 1994, J BIOL CHEM, V269, P28514; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; Mora S, 2000, J BIOL CHEM, V275, P16323, DOI 10.1074/jbc.M910259199; Naya FJ, 2002, NAT MED, V8, P1303, DOI 10.1038/nm789; Nguyen HT, 1998, DEV BIOL, V204, P550, DOI 10.1006/dbio.1998.9081; Parsons WJ, 1996, AM J PHYSIOL-HEART C, V270, pH567, DOI 10.1152/ajpheart.1996.270.2.H567; Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100; Piantadosi CA, 2006, J BIOL CHEM, V281, P324, DOI 10.1074/jbc.M508805200; Ramachandran B, 2008, J BIOL CHEM, V283, P10318, DOI 10.1074/jbc.M707623200; Scarpulla RC, 2006, J CELL BIOCHEM, V97, P673, DOI 10.1002/jcb.20743; Schaff er I. E., 1999, MITOCHONDRIA, P141; Shalizi AK, 2005, CURR TOP DEV BIOL, V69, P239, DOI 10.1016/S0070-2153(05)69009-6; Subramanian SV, 1996, MECH DEVELOP, V57, P103, DOI 10.1016/0925-4773(96)00542-4; TAANMAN JW, 1993, BIOCHIM BIOPHYS ACTA, V1225, P95, DOI 10.1016/0925-4439(93)90128-N; Thai MV, 1998, J BIOL CHEM, V273, P14285, DOI 10.1074/jbc.273.23.14285; Towler MC, 2007, CIRC RES, V100, P328, DOI 10.1161/01.RES.0000256090.42690.05; Tripoli G, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-2-r11; van der Linden AM, 2007, EMBO J, V26, P358, DOI 10.1038/sj.emboj.7601479; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; WAN B, 1995, J BIOL CHEM, V270, P26433, DOI 10.1074/jbc.270.44.26433; Wang CG, 2006, P NATL ACAD SCI USA, V103, P11567, DOI 10.1073/pnas.0603363103; Watanabe T, 1998, MOL CELL BIOL, V18, P442, DOI 10.1128/MCB.18.1.442; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yu M, 2002, BBA-GENE STRUCT EXPR, V1574, P345, DOI 10.1016/S0167-4781(02)00228-2; Zhao M, 1999, MOL CELL BIOL, V19, P21; Zhu BM, 2005, J BIOL CHEM, V280, P28749, DOI 10.1074/jbc.M502491200; Zhu BM, 2004, MOL CELL BIOL, V24, P8264, DOI 10.1128/MCB.24.18.8264-8275.2004; Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599	66	72	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2008	283	18					11935	11946		10.1074/jbc.M707389200	http://dx.doi.org/10.1074/jbc.M707389200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	293MS	18222924	hybrid, Green Published			2022-12-25	WOS:000255340000009
J	Inforzato, A; Rivieccio, V; Morreale, AP; Bastone, A; Salustri, A; Scarchilli, L; Verdoliva, A; Vincenti, S; Gallo, G; Chiapparino, C; Pacello, L; Nucera, E; Serlupi-Crescenzi, O; Day, AJ; Bottazzi, B; Mantovani, A; De Santis, R; Salvatori, G				Inforzato, Antonio; Rivieccio, Vincenzo; Morreale, Antonio P.; Bastone, Antonio; Salustri, Antonietta; Scarchilli, Laura; Verdoliva, Antonio; Vincenti, Silvia; Gallo, Grazia; Chiapparino, Caterina; Pacello, Lucrezia; Nucera, Eleonora; Serlupi-Crescenzi, Ottaviano; Day, Anthony J.; Bottazzi, Barbara; Mantovani, Alberto; De Santis, Rita; Salvatori, Giovanni			Structural characterization of PTX3 disulfide bond network and its multimeric status in cumulus matrix organization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-REACTIVE PROTEIN; LONG PENTRAXIN PTX3; SERUM AMYLOID-P; RECOGNITION RECEPTOR PTX3; ACUTE PHASE PROTEINS; DENDRITIC CELLS; CHROMOSOMAL LOCALIZATION; COMPLEMENT ACTIVATION; GEL ELECTROPHORESIS; GENOMIC STRUCTURE	PTX3 is an acute phase glycoprotein that plays keyroles in resistance to certain pathogens and in female fertility. PTX3 exerts its functions by interacting with a number of structurally unrelated molecules, a capacity that is likely to rely on its complex multimeric structure stabilized by interchain disulfide bonds. In this study, PAGE analyses performed under both native and denaturing conditions indicated that human recombinant PTX3 is mainly composed of covalently linked octamers. The network of disulfide bonds supporting this octameric assembly was resolved by mass spectrometry and Cys to Ser site-directed mutagenesis. Here we report that cysteine residues at positions 47, 49, and 103 in the N-terminal domain form three symmetric interchain disulfide bonds stabilizing four protein subunits in a tetrameric arrangement. Additional interchain disulfide bonds formed by the C-terminal domain cysteines Cys(317) and Cys(318) are responsible for linking the PTX3 tetramers into octamers. We also identified three intrachain disulfide bonds within the C-terminal domain that we used as structural constraints to build a new three-dimensional model for this domain. Previously it has been shown that PTX3 is a key component of the cumulus oophorus extracellular matrix, which forms around the oocyte prior to ovulation, because cumuli from PTX3(-/-) mice show defective matrix organization. Recombinant PTX3 is able to restore the normal phenotype ex vivo in cumuli from PTX3(-/-) mice. Here we demonstrate that PTX3 Cys to Ser mutants, mainly assembled into tetramers, exhibited wild type rescue activity, whereas a mutant, predominantly composed of dimers, had impaired functionality. These findings indicate that protein oligomerization is essential forPTX3activity within the cumulus matrix and implicate PTX3 tetramers as the functional molecular units required for cumulus matrix organization and stabilization.	[Inforzato, Antonio; Morreale, Antonio P.; Vincenti, Silvia; Gallo, Grazia; Chiapparino, Caterina; Pacello, Lucrezia; Nucera, Eleonora; Serlupi-Crescenzi, Ottaviano; De Santis, Rita; Salvatori, Giovanni] Sigma Tau Res & Dev, I-00040 Pomezia, Italy; [Inforzato, Antonio; Day, Anthony J.] Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; [Rivieccio, Vincenzo; Verdoliva, Antonio] Tecnogen SpA, I-81015 Piana Di Monte Verna, Italy; [Bastone, Antonio] Ist Ric Farmacol Mario Negri, I-20157 Milan, Italy; [Salustri, Antonietta; Scarchilli, Laura] Univ Roma Tor Vergata, Dept Publ Hlth & Cell Biol, I-00133 Rome, Italy; [Bottazzi, Barbara; Mantovani, Alberto] Ist Clin Humanitas ICH, I-20089 Rozzano, Italy	University of Manchester; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Rome Tor Vergata; IRCCS Humanitas Research Hospital	Salvatori, G (corresponding author), Sigma Tau Ind Farmaceut Riunite SpA, Immunol Area, R&D Dept, Via Pontina Km 30-400, I-00040 Rome, Italy.	giovanni.salvatori@sigma-tau.it	bottazzi, barbara/ABH-9274-2020; Mantovani, Alberto/HCI-7449-2022; Day, Anthony/O-1658-2015; Inforzato, Antonio/ABG-4513-2020; Inforzato, Antonio/K-6954-2012	bottazzi, barbara/0000-0002-1930-9257; Mantovani, Alberto/0000-0001-5578-236X; Day, Anthony/0000-0002-1415-3134; Inforzato, Antonio/0000-0001-8110-0027; SALUSTRI, ANTONIETTA/0000-0002-8731-1041; DE SANTIS, Rita/0000-0002-5037-0611	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom; Wellcome Trust Funding Source: Medline	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); Wellcome Trust(Wellcome TrustEuropean Commission)		Agrawal A, 2001, J IMMUNOL, V166, P3998, DOI 10.4049/jimmunol.166.6.3998; ALLES VV, 1994, BLOOD, V84, P3483; ANDREWS P, 1970, METHOD BIOCHEM ANAL, P113; Baruah P, 2006, BLOOD, V107, P151, DOI 10.1182/blood-2005-03-1112; Baruah P, 2006, J LEUKOCYTE BIOL, V80, P87, DOI 10.1189/jlb.0805445; Bottazzi B, 1997, J BIOL CHEM, V272, P32817, DOI 10.1074/jbc.272.52.32817; BREVIARIO F, 1992, J BIOL CHEM, V267, P22190; BRISTOW CL, 1986, MOL IMMUNOL, V23, P1045, DOI 10.1016/0161-5890(86)90003-9; BUTTERMAN M, 1988, ELECTROPHORESIS, V9, P293, DOI 10.1002/elps.1150090702; Camozzi M, 2005, ARTERIOSCL THROM VAS, V25, P1837, DOI 10.1161/01.ATV.0000177807.54959.7d; Camozzi M, 2006, J BIOL CHEM, V281, P22605, DOI 10.1074/jbc.M601023200; Day AJ, 2005, TRENDS IMMUNOL, V26, P637, DOI 10.1016/j.it.2005.09.009; Doni A, 2006, J LEUKOCYTE BIOL, V79, P797, DOI 10.1189/jlb.0905493; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; EMSLEY J, 1994, NATURE, V367, P338, DOI 10.1038/367338a0; Garlanda C, 2002, NATURE, V420, P182, DOI 10.1038/nature01195; Gaziano R, 2004, ANTIMICROB AGENTS CH, V48, P4414, DOI 10.1128/AAC.48.11.4414-4421.2004; Goodman Adam R., 1996, Cytokine and Growth Factor Reviews, V7, P191, DOI 10.1016/1359-6101(96)00019-6; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HSU YC, 1995, GENOMICS, V28, P220, DOI 10.1006/geno.1995.1134; Inforzato A, 2006, BIOCHEMISTRY-US, V45, P11540, DOI 10.1021/bi0607453; Introna M, 1996, BLOOD, V87, P1862; KAPLAN MH, 1974, J IMMUNOL, V112, P2135; Khreiss T, 2004, CIRCULATION, V110, P2713, DOI 10.1161/01.CIR.0000146846.00816.DD; Kishore U, 2001, Results Probl Cell Differ, V33, P225; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE GW, 1993, J IMMUNOL, V150, P1804; Lupas AN, 2005, ADV PROTEIN CHEM, V70, P37, DOI 10.1016/S0065-3233(04)70003-0; McCormack FX, 2002, J CLIN INVEST, V109, P707, DOI 10.1172/JCI200215293; Milner CM, 2003, J CELL SCI, V116, P1863, DOI 10.1242/jcs.00407; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; Nauta AJ, 2003, EUR J IMMUNOL, V33, P465, DOI 10.1002/immu.200310022; Omeis IA, 1996, GENOMICS, V36, P543, DOI 10.1006/geno.1996.0503; PEPYS MB, 1983, ADV IMMUNOL, V34, P141, DOI 10.1016/S0065-2776(08)60379-X; Presta M, 2007, J CELL MOL MED, V11, P723, DOI 10.1111/j.1582-4934.2007.00061.x; RASSOULI M, 1992, J BIOL CHEM, V267, P2947; Rivieccio V, 2007, PROTEIN EXPRES PURIF, V51, P49, DOI 10.1016/j.pep.2006.07.009; RO A, 2007, IMMUNOLOGY, V121, P40; ROBYT JF, 1971, ARCH BIOCHEM BIOPHYS, V147, P262, DOI 10.1016/0003-9861(71)90334-1; RODBARD D, 1970, P NATL ACAD SCI USA, V65, P970, DOI 10.1073/pnas.65.4.970; Roumenina LT, 2006, BIOCHEMISTRY-US, V45, P4093, DOI 10.1021/bi052646f; Rovere P, 2000, BLOOD, V96, P4300; Rusnati M, 2004, BLOOD, V104, P92, DOI 10.1182/blood-2003-10-3433; Salustri A, 2004, DEVELOPMENT, V131, P1577, DOI 10.1242/dev.01056; Scarchilli L, 2007, J BIOL CHEM, V282, P30161, DOI 10.1074/jbc.M703738200; Shrive AK, 1999, J MOL BIOL, V290, P997, DOI 10.1006/jmbi.1999.2956; Thompson D, 1999, STRUCTURE, V7, P169, DOI 10.1016/S0969-2126(99)80023-9; van Rossum AP, 2004, ARTHRITIS RHEUM-US, V50, P2667, DOI 10.1002/art.20370; Varani S, 2002, MOL ENDOCRINOL, V16, P1154, DOI 10.1210/me.16.6.1154; VouretCraviari V, 1997, INFECT IMMUN, V65, P1345, DOI 10.1128/IAI.65.4.1345-1350.1997; Xu DS, 2003, NEURON, V39, P513, DOI 10.1016/S0896-6273(03)00463-X; YING SC, 1993, J IMMUNOL, V150, P169; Zouki C, 2001, J IMMUNOL, V167, P5355, DOI 10.4049/jimmunol.167.9.5355	53	104	109	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					10147	10161		10.1074/jbc.M708535200	http://dx.doi.org/10.1074/jbc.M708535200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18223257	hybrid			2022-12-25	WOS:000254671600068
J	Jamburuthugoda, VK; Santos-Velazquez, JM; Skasko, M; Operario, DJ; Purohit, V; Chugh, P; Szymanski, EA; Wedekind, JE; Bambara, RA; Kim, B				Jamburuthugoda, Varuni K.; Santos-Velazquez, Jose M.; Skasko, Mark; Operario, Darwin J.; Purohit, Vandana; Chugh, Pauline; Szymanski, Erika A.; Wedekind, Joseph E.; Bambara, Robert A.; Kim, Baek			Reduced dNTP binding affinity of 3TC-resistant M184I HIV-1 reverse transcriptase variants responsible for viral infection failure in macrophage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; HIGH-LEVEL RESISTANCE; DNA-SYNTHESIS; 3TC RESISTANCE; IN-VITRO; POLYMERASE FIDELITY; PROCESSIVITY DEFECT; NUCLEOSIDE ANALOG; ESCHERICHIA-COLI; STERIC HINDRANCE	We characterized HIV-1 reverse transcriptase (RT) variants either with or without the (-)-2',3'-deoxy-3'-thiacytidine-resistant M184I mutation isolated from a single HIV-1 infected patient. First, unlike variants with wild-type M184, M184I RT variants displayed significantly reduced DNA polymerase activity at low dNTP concentrations, which is indicative of reduced dNTP binding affinity. Second, the M184I variant displayed a similar to 10- to 13-fold reduction in dNTP binding affinity, compared with the Met-184 variant. However, the k(pol) values of these two RTs were similar. Third, unlike HIV-1 vectors with wild-type RT, the HIV-1 vector harboring M184I RT failed to transduce cell types containing low dNTP concentrations, such as human macrophage, likely due to the reduced DNA polymerization activity of the M184IRT under low cellular dNTP concentration conditions. Finally, we compared the binary complex structures of wild-type and M184I RTs. The Ile mutation at position 184 with a longer and more rigid beta-branched side chain, which was previously known to alter the RT-template interaction, also appears to deform the shape of the dNTP binding pocket. This can restrict ground state dNTP binding and lead to inefficient DNA synthesis particularly at low dNTP concentrations, ultimately contributing to viral replication failure in macrophage and instability in vivo of the M184I mutation.	[Jamburuthugoda, Varuni K.; Skasko, Mark; Operario, Darwin J.; Chugh, Pauline; Szymanski, Erika A.; Kim, Baek] Univ Rochester, Med Ctr, Dept Microbiol & Immunol, Rochester, NY 14642 USA; [Santos-Velazquez, Jose M.; Purohit, Vandana; Wedekind, Joseph E.; Bambara, Robert A.] Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Kim, B (corresponding author), Univ Rochester, Med Ctr, Dept Microbiol & Immunol, 601 Elmwood Ave,Box 672, Rochester, NY 14642 USA.	baek_kim@urmc.rochester.edu			NIAID NIH HHS [AI 49781, T32 AI049815] Funding Source: Medline; NIGMS NIH HHS [R25 GM 64133] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI049815, R01AI049781] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM064133] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aquaro S, 2005, J ANTIMICROB CHEMOTH, V55, P872, DOI 10.1093/jac/dki104; Avidan O, 2002, EUR J BIOCHEM, V269, P859, DOI 10.1046/j.0014-2956.2001.02719.x; Back NKT, 1997, ANTIMICROB AGENTS CH, V41, P2484, DOI 10.1128/AAC.41.11.2484; Back NKT, 1996, EMBO J, V15, P4040, DOI 10.1002/j.1460-2075.1996.tb00777.x; BAKHANASHVILI M, 1993, BIOCHEMISTRY-US, V32, P7559, DOI 10.1021/bi00080a030; BAMBARA RA, 1978, J BIOL CHEM, V253, P413; BOUCHER CAB, 1993, ANTIMICROB AGENTS CH, V37, P2231, DOI 10.1128/AAC.37.10.2231; Cherry E, 1997, ANTIMICROB AGENTS CH, V41, P2763, DOI 10.1128/AAC.41.12.2763; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; Deval J, 2004, J BIOL CHEM, V279, P509, DOI 10.1074/jbc.M308806200; Diamond TL, 2004, J BIOL CHEM, V279, P51545, DOI 10.1074/jbc.M408573200; Diamond TL, 2003, J BIOL CHEM, V278, P29913, DOI 10.1074/jbc.M211754200; Ding JP, 1998, J MOL BIOL, V284, P1095, DOI 10.1006/jmbi.1998.2208; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; Essink BBO, 1997, NUCLEIC ACIDS RES, V25, P3212, DOI 10.1093/nar/25.16.3212; Feng JY, 1999, BIOCHEMISTRY-US, V38, P9440, DOI 10.1021/bi990709m; Feng JY, 1999, BIOCHEMISTRY-US, V38, P55, DOI 10.1021/bi982340r; Frost SDW, 2000, J VIROL, V74, P6262, DOI 10.1128/JVI.74.14.6262-6268.2000; Gao HQ, 2000, J MOL BIOL, V300, P403, DOI 10.1006/jmbi.2000.3823; Gao L, 2008, J BIOL CHEM, V283, P9196, DOI 10.1074/jbc.M710148200; GAO Q, 1993, ANTIMICROB AGENTS CH, V37, P1390, DOI 10.1128/AAC.37.6.1390; Gulick R, 1998, AIDS, V12, pS17; Hsu ML, 1997, NUCLEIC ACIDS RES, V25, P4532, DOI 10.1093/nar/25.22.4532; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Jamburuthugoda VK, 2006, J BIOL CHEM, V281, P13388, DOI 10.1074/jbc.M600291200; JAMBURUTHUGODA VK, UNPUB; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; JOHNSON KA, 1995, METHOD ENZYMOL, V249, P38; Julias JG, 2004, VIROLOGY, V322, P13, DOI 10.1016/j.virol.2004.01.004; Kim B, 1997, METHODS, V12, P318, DOI 10.1006/meth.1997.0485; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; Mathe C, 2006, ANTIVIR RES, V71, P276, DOI 10.1016/j.antiviral.2006.04.017; Operario DJ, 2005, VIROLOGY, V335, P106, DOI 10.1016/j.virol.2005.02.010; Perez-Bercoff D, 2007, J VIROL, V81, P4540, DOI 10.1128/JVI.01620-06; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; Rezende LF, 1998, NUCLEIC ACIDS RES, V26, P3066, DOI 10.1093/nar/26.12.3066; ROBERTS JD, 1989, MOL CELL BIOL, V9, P469, DOI 10.1128/MCB.9.2.469; Sarafianos SG, 1999, P NATL ACAD SCI USA, V96, P10027, DOI 10.1073/pnas.96.18.10027; SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P875, DOI 10.1128/AAC.37.4.875; Selmi B, 2001, J BIOL CHEM, V276, P48466, DOI 10.1074/jbc.M107003200; Skasko M, 2005, J BIOL CHEM, V280, P12190, DOI 10.1074/jbc.M412859200; SUO Z, 1998, J BIOL CHEM, V273, P27257; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; Vaccaro JA, 2000, ANTIMICROB AGENTS CH, V44, P217, DOI 10.1128/AAC.44.1.217-221.2000; Van Rompay KKA, 2002, J VIROL, V76, P6083, DOI 10.1128/JVI.76.12.6083-6092.2002; Weiss KK, 2000, BIOCHEMISTRY-US, V39, P10684, DOI 10.1021/bi000788y; Weiss KK, 2004, BIOCHEMISTRY-US, V43, P4490, DOI 10.1021/bi035258r; Weiss KK, 2002, J BIOL CHEM, V277, P22662, DOI 10.1074/jbc.M200202200	49	23	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9206	9216		10.1074/jbc.M710149200	http://dx.doi.org/10.1074/jbc.M710149200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18218633	Green Published, hybrid			2022-12-25	WOS:000254465800050
J	Belova, GI; Postnikov, YV; Furusawa, T; Birger, Y; Bustin, M				Belova, Galina I.; Postnikov, Yuri V.; Furusawa, Takashi; Birger, Yehudit; Bustin, Michael			Chromosomal protein HMGN1 enhances the heat shock-induced remodeling of Hsp70 chromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOBILITY-GROUP PROTEINS; LINKER HISTONE H1; RNA-POLYMERASE-II; IN-VIVO; TRANSCRIPTION FACTOR; GENE-REGULATION; PHOSPHORYLATION; BINDING; EXPRESSION; ELONGATION	The nucleosome-binding protein HMGN1 affects the structure and function of chromatin; however, its role in regulating specific gene expression in living cells is not fully understood. Here we use embryonic fibroblasts from Hmgn1(+/+) and Hmgn1(-/-) mice to examine the effect of HMGN1 on the heat shock-induced transcriptional activation of Hsp70, a well characterized gene known to undergo a rapid chromatin re-structuring during transcriptional activation. We find that loss of HMGN1 decreases the levels of Hsp70 transcripts at the early stages of heat shock. HMGN1 enhances the rate of heat shock-induced changes in the Hsp70 chromatin but does not affect the chromatin structure before induction, an indication that it does not predispose the gene to rapid activation. Heat shock elevates the levels of H3K14 acetylation in the Hsp70 chromatin of wild type cells more efficiently than in the chromatin of Hmgn1(+/+) cells, whereas treatment with histone deacetylase inhibitors abrogates the effects of HMGN1 on the heat shock response. We suggest that HMGN1 enhances the rate of heat shock-induced H3K14 acetylation in the Hsp70 promoter, thereby enhancing the rate of chromatin remodeling and the subsequent transcription during the early rounds of Hsp70 activation when the gene is still associated with histones in a nucleosomal conformation.	[Belova, Galina I.; Postnikov, Yuri V.; Furusawa, Takashi; Birger, Yehudit; Bustin, Michael] NCI, Prot Sect, Lab Metab, NIH, Bethesda, MD 20892 USA; [Birger, Yehudit] Chaim Sheba Med Ctr, Canc Res Ctr, IL-52621 Tel Hashomer, Israel	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Chaim Sheba Medical Center	Bustin, M (corresponding author), NCI, Prot Sect, Lab Metab, NIH, 37 Convent Dr,Rm 3122, Bethesda, MD 20892 USA.	bustinm@mail.nih.gov	Bustin, Michael/G-6155-2015	Bustin, Michael/0000-0002-5147-7242	NATIONAL CANCER INSTITUTE [ZIABC011154, ZIABC004496] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 BC004496-30] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Ausio J, 2000, BIOESSAYS, V22, P873, DOI 10.1002/1521-1878(200010)22:10<873::AID-BIES1>3.3.CO;2-I; BARRATT A, 1994, AM J PUBLIC HEALTH, V84, P779, DOI 10.2105/AJPH.84.5.779; Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Bianchi ME, 2005, CURR OPIN GENET DEV, V15, P496, DOI 10.1016/j.gde.2005.08.007; Birger Y, 2005, CANCER RES, V65, P6711, DOI 10.1158/0008-5472.CAN-05-0310; Birger Y, 2003, EMBO J, V22, P1665, DOI 10.1093/emboj/cdg142; Bustin M, 2005, MOL CELL, V17, P617, DOI 10.1016/j.molcel.2005.02.019; BUSTIN M, 1989, METHOD ENZYMOL, V170, P214; Bustin M, 2001, TRENDS BIOCHEM SCI, V26, P431, DOI 10.1016/S0968-0004(01)01855-2; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Catez F, 2004, MOL CELL BIOL, V24, P4321, DOI 10.1128/MCB.24.10.4321-4328.2004; Catez F, 2003, BIOCHEM CELL BIOL, V81, P113, DOI 10.1139/o03-040; Catez F, 2002, EMBO REP, V3, P760, DOI 10.1093/embo-reports/kvf156; Chakrabarti SK, 2002, J BIOL CHEM, V277, P13286, DOI 10.1074/jbc.M111857200; Corey LL, 2003, GENE DEV, V17, P1392, DOI 10.1101/gad.1071803; Dai C, 2007, CELL, V130, P1005, DOI 10.1016/j.cell.2007.07.020; DING HF, 1994, SCIENCE, V265, P796, DOI 10.1126/science.8047885; Dyson MH, 2005, CELL CYCLE, V4, P13, DOI 10.4161/cc.4.1.1362; Fan YH, 2005, CELL, V123, P1199, DOI 10.1016/j.cell.2005.10.028; Fan YH, 2003, MOL CELL BIOL, V23, P4559, DOI 10.1128/MCB.23.13.4559-4572.2003; Hill DA, 2000, BIOCHEMISTRY-US, V39, P11649, DOI 10.1021/bi001330z; Hock R, 2007, TRENDS CELL BIOL, V17, P72, DOI 10.1016/j.tcb.2006.12.001; Horn PJ, 2002, NAT STRUCT BIOL, V9, P263, DOI 10.1038/nsb776; HUNT CR, 1993, GENOMICS, V16, P193, DOI 10.1006/geno.1993.1158; KARPOV VL, 1984, CELL, V36, P423, DOI 10.1016/0092-8674(84)90235-6; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; Lee JS, 2002, EXP MOL MED, V34, P131, DOI 10.1038/emm.2002.19; Lever MA, 2000, NATURE, V408, P873, DOI 10.1038/35048603; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Lim JH, 2005, EMBO J, V24, P3038, DOI 10.1038/sj.emboj.7600768; Lim JH, 2004, MOL CELL, V15, P573, DOI 10.1016/j.molcel.2004.08.006; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; Murga M, 2007, J CELL BIOL, V178, P1101, DOI 10.1083/jcb.200704140; Ni ZY, 2004, MOL CELL, V13, P55, DOI 10.1016/S1097-2765(03)00526-4; Ozsolak F, 2007, NAT BIOTECHNOL, V25, P244, DOI 10.1038/nbt1279; PARANJAPE SM, 1995, GENE DEV, V9, P1978, DOI 10.1101/gad.9.16.1978; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Postnikov YV, 2006, BIOCHEMISTRY-US, V45, P15092, DOI 10.1021/bi0613271; POSTNIKOV YV, 1991, NUCLEIC ACIDS RES, V19, P717, DOI 10.1093/nar/19.4.717; Reeves R, 2001, GENE, V277, P63, DOI 10.1016/S0378-1119(01)00689-8; Rubinstein YR, 2005, FEBS J, V272, P5853, DOI 10.1111/j.1742-4658.2005.04980.x; Sgarra R, 2004, FEBS LETT, V574, P1, DOI 10.1016/j.febslet.2004.08.013; SHEN XT, 1995, CELL, V82, P47, DOI 10.1016/0092-8674(95)90051-9; Shen XT, 1996, CELL, V86, P475, DOI 10.1016/S0092-8674(00)80120-8; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Thomson S, 2004, MOL CELL, V15, P585, DOI 10.1016/j.molcel.2004.08.002; TRIESCHMANN L, 1995, EMBO J, V14, P1478, DOI 10.1002/j.1460-2075.1995.tb07134.x; Ueda T, 2006, J BIOL CHEM, V281, P10182, DOI 10.1074/jbc.M600821200; VAN H, 1989, CHROMATIN, P16; WEINTRAUB H, 1984, CELL, V38, P17, DOI 10.1016/0092-8674(84)90522-1; Woodcock CL, 2006, CHROMOSOME RES, V14, P17, DOI 10.1007/s10577-005-1024-3; Young JC, 2004, NAT REV MOL CELL BIO, V5, P781, DOI 10.1038/nrm1492; Zlatanova J, 2000, FASEB J, V14, P1697, DOI 10.1096/fj.99-0869rev	54	23	23	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8080	8088		10.1074/jbc.M709782200	http://dx.doi.org/10.1074/jbc.M709782200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18218636	Green Accepted, hybrid			2022-12-25	WOS:000254288000004
J	Chatterjee, N; Stegmuller, J; Schatzle, P; Karram, K; Koroll, M; Werner, HB; Nave, KA; Trotter, J				Chatterjee, Nivedita; Stegmueller, Judith; Schaetzle, Philipp; Karram, Khalad; Koroll, Michael; Werner, Hauke B.; Nave, Klaus-Armin; Trotter, Jacqueline			Interaction of syntenin-1 and the NG2 proteoglycan in migratory oligodendrocyte precursor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; PDZ DOMAINS; PROTEIN; MEMBRANE; EXPRESSION; RECEPTORS; COMPLEXES; MOLECULE; SURFACE; MYELIN	Migration of oligodendrocyte precursors along axons is a necessary prerequisite for myelination, but little is known about underlying mechanisms. NG2 is a large membrane proteoglycan implicated in oligodendrocyte migration. Here we show that a PDZ domain protein termed syntenin-1 interacts with NG2 and that syntenin-1 is necessary for normal rates of migration. The association of syntenin-1 with NG2, identified in a yeast two-hybrid screen, was confirmed by colocalization of both proteins within processes of oligodendroglial precursor cells and by coimmunoprecipitation from cell extracts. Syntenin-1 also colocalizes with NG2 in "co-capping" assays, demonstrating a lateral association of both proteins in live oligodendrocytes. RNA interference-mediated down-regulation of syntenin-1 in glial cells results in a significant reduction of migration in vitro, as does the presence of polyclonal antibody against NG2. Thus syntenin plays a role in the migration of oligodendroglial precursors, and we suggest that NG2-syntenin-1 interactions contribute to this.	[Chatterjee, Nivedita; Stegmueller, Judith; Schaetzle, Philipp; Karram, Khalad; Trotter, Jacqueline] Johannes Gutenberg Univ Mainz, Dept Biol, D-55128 Mainz, Germany; [Koroll, Michael] Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; [Werner, Hauke B.; Nave, Klaus-Armin] Max Planck Inst Expt Med, Dept Neurogenet, D-37075 Gottingen, Germany	Johannes Gutenberg University of Mainz; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Max Planck Society	Trotter, J (corresponding author), Johannes Gutenberg Univ Mainz, Dept Biol, Bentzelweg 3, D-55128 Mainz, Germany.	trotter@uni-mainz.de	Nave, Klaus-Armin/C-8883-2011; Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763; Werner, Hauke/0000-0002-7710-5738				Barritt DS, 2000, J CELL BIOCHEM, V79, P213, DOI 10.1002/1097-4644(20001101)79:2<213::AID-JCB50>3.0.CO;2-G; Bergles DE, 2000, NATURE, V405, P187, DOI 10.1038/35012083; Butt AM, 2002, J NEUROCYTOL, V31, P551, DOI 10.1023/A:1025751900356; Eisenmann KM, 1999, NAT CELL BIOL, V1, P507, DOI 10.1038/70302; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; Fialka I, 1999, J BIOL CHEM, V274, P26233, DOI 10.1074/jbc.274.37.26233; Gimferrer I, 2005, J IMMUNOL, V175, P1406, DOI 10.4049/jimmunol.175.3.1406; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; Hirbec H, 2005, MOL CELL NEUROSCI, V28, P737, DOI 10.1016/j.mcn.2004.12.005; Hirbec H, 2002, J BIOL CHEM, V277, P15221, DOI 10.1074/jbc.C200112200; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; Jannatipour M, 2001, J BIOL CHEM, V276, P33093, DOI 10.1074/jbc.M105792200; JUNG M, 1995, EUR J NEUROSCI, V7, P1245, DOI 10.1111/j.1460-9568.1995.tb01115.x; Karram K, 2005, J ANAT, V207, P735, DOI 10.1111/j.1469-7580.2005.00461.x; Koroll M, 2001, J BIOL CHEM, V276, P10646, DOI 10.1074/jbc.M010647200; Kramer EM, 1997, J BIOL CHEM, V272, P8937; Lin D, 1999, J BIOL CHEM, V274, P3726, DOI 10.1074/jbc.274.6.3726; Majumdar M, 2003, CELL SIGNAL, V15, P79, DOI 10.1016/S0898-6568(02)00045-1; Makagiansar IT, 2004, J BIOL CHEM, V279, P55262, DOI 10.1074/jbc.M411045200; MAYER B, 1990, J NEUROIMMUNOL, V29, P193, DOI 10.1016/0165-5728(90)90162-G; Niehaus A, 1999, J NEUROSCI, V19, P4948; Nishiyama A, 2007, NEUROSCIENTIST, V13, P62, DOI 10.1177/1073858406295586; Ohno K, 2004, MOL CELL NEUROSCI, V26, P518, DOI 10.1016/j.mcn.2004.04.007; Pluschke G, 1996, P NATL ACAD SCI USA, V93, P9710, DOI 10.1073/pnas.93.18.9710; Sarkar D, 2004, PHARMACOL THERAPEUT, V104, P101, DOI 10.1016/j.pharmthera.2004.08.004; Schneider S, 2001, J NEUROSCI, V21, P920, DOI 10.1523/JNEUROSCI.21-03-00920.2001; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Simons M, 2007, CURR OPIN NEUROBIOL, V17, P533, DOI 10.1016/j.conb.2007.08.003; Srivastava S, 1998, NEURON, V21, P581, DOI 10.1016/S0896-6273(00)80568-1; Stegmuller J, 2003, J BIOL CHEM, V278, P3590, DOI 10.1074/jbc.M210010200; Tomoda T, 2004, GENE DEV, V18, P541, DOI 10.1101/gad.1151204; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; TROTTER J, 1989, J NEUROSCI RES, V22, P369, DOI 10.1002/jnr.490220402; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545; Zimmermann P, 2005, DEV CELL, V9, P377, DOI 10.1016/j.devcel.2005.07.011; Zimmermann P, 2002, MOL CELL, V9, P1215, DOI 10.1016/S1097-2765(02)00549-X; Zimmermann P, 2001, MOL BIOL CELL, V12, P339, DOI 10.1091/mbc.12.2.339	37	47	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8310	8317		10.1074/jbc.M706074200	http://dx.doi.org/10.1074/jbc.M706074200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18218632	hybrid			2022-12-25	WOS:000254288000029
J	Ren, H; Salous, AK; Paul, JM; Lamb, KA; Dwyer, DS; Peoples, RW				Ren, Hong; Salous, Abdelghaffar K.; Paul, Jaclyn M.; Lamb, Kaitlin A.; Dwyer, Donard S.; Peoples, Robert W.			Functional interactions of alcohol-sensitive sites in the N-methyl-D-aspartate receptor M3 and M4 domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRIC-ACID; MEMBRANE-ASSOCIATED DOMAIN; ACTIVATED ION CURRENT; ETHANOL INHIBITION; HIPPOCAMPAL-NEURONS; GLYCINE RECEPTORS; NMDA RECEPTORS; SINGLE-CHANNEL; SUBUNIT; GABA(A)	The N-methyl-D-aspartate receptor is an important mediator of the behavioral effects of ethanol in the central nervous system. Previous studies have demonstrated sites in the third and fourth membrane- associated (M) domains of the N-methyl-D-aspartate receptor NR2A subunit that influence alcohol sensitivity and ion channel gating. We investigated whether two of these sites, Phe-637 in M3 and Met-823 in M4, interactively regulate the ethanol sensitivity of the receptor by testing dual substitution mutants at these positions. A majority of the mutations decreased steady-state glutamate EC50 values and maximal steady-state to peak current ratios (I-ss/I-p), whereas only two mutations altered peak glutamate EC50 values. Steady-state glutamate IC50 values were correlated with maximal glutamate Iss/Ip values, suggesting that changes in glutamate potency were attributable to changes in desensitization. In addition, there was a significant interaction between the substituents at positions 637 and 823 with respect to glutamate potency and desensitization. IC50 values for ethanol among the mutants varied over the approximate range 100-325mM. The sites in M3 and M4 significantly interacted in regulating ethanol sensitivity, although this was apparently dependent upon the presence of methionine in position 823. Molecular dynamics simulations of the NR2A subunit revealed possible binding sites for ethanol near both positions in the M domains. Consistent with this finding, the sum of the molecular volumes of the substituents at the two positions was not correlated with ethanol IC50 values. Thus, there is a functional interaction between Phe-637 and Met-823 with respect to glutamate potency, desensitization, and ethanol sensitivity, but the two positions do not appear to form a unitary site of alcohol action.	[Ren, Hong; Salous, Abdelghaffar K.; Paul, Jaclyn M.; Lamb, Kaitlin A.; Peoples, Robert W.] Marquette Univ, Dept Biomed Sci, Milwaukee, WI 53201 USA; [Dwyer, Donard S.] Louisiana State Univ, Hlth Sci Ctr, Dept Psychiat, Shreveport, LA 71130 USA	Marquette University; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Peoples, RW (corresponding author), Marquette Univ, Dept Biomed Sci, SC 446,POB 1881, Milwaukee, WI 53201 USA.	robert.peoples@marquette.edu			NIAAA NIH HHS [AA 015203-01A1] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA015203] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Alvestad RM, 2003, J BIOL CHEM, V278, P11020, DOI 10.1074/jbc.M210167200; Beck C, 1999, NEURON, V22, P559, DOI 10.1016/S0896-6273(00)80710-2; CHU B, 1995, J NEUROCHEM, V65, P140; Clark M, 2006, J CHEM INF MODEL, V46, P231, DOI 10.1021/ci050268f; DILDY JE, 1989, BRAIN RES, V499, P383, DOI 10.1016/0006-8993(89)90789-0; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; GONZALES RA, 1990, J PHARMACOL EXP THER, V253, P1138; GOTHERT M, 1989, N-S ARCH PHARMACOL, V340, P516; HOFFMAN PL, 1989, J NEUROCHEM, V52, P1937, DOI 10.1111/j.1471-4159.1989.tb07280.x; Jenkins A, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-06-j0002.2001; Jung SW, 2005, J BIOL CHEM, V280, P308, DOI 10.1074/jbc.M409871200; Koltchine VV, 1999, MOL PHARMACOL, V56, P1087, DOI 10.1124/mol.56.5.1087; Krasowski MD, 2000, BRIT J PHARMACOL, V129, P731, DOI 10.1038/sj.bjp.0703087; Krupp JJ, 1999, J NEUROSCI, V19, P1165; Kuner T, 1996, NEURON, V17, P343, DOI 10.1016/S0896-6273(00)80165-8; LIMALANDMAN MTR, 1989, FEBS LETT, V247, P61, DOI 10.1016/0014-5793(89)81241-4; Lin Y, 2004, J NEUROSCI, V24, P10138, DOI 10.1523/JNEUROSCI.3159-04.2004; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; LOVINGER DM, 1990, J NEUROSCI, V10, P1372; Low CM, 2000, P NATL ACAD SCI USA, V97, P11062, DOI 10.1073/pnas.180307497; Mascia MP, 2000, P NATL ACAD SCI USA, V97, P9305, DOI 10.1073/pnas.160128797; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; MIRSHAHI T, 1995, NEUROPHARMACOLOGY, V34, P347, DOI 10.1016/0028-3908(94)00155-L; Mohrmann R, 2002, J NEUROSCI RES, V68, P265, DOI 10.1002/jnr.10219; Moykkynen T, 2003, J PHARMACOL EXP THER, V306, P546, DOI 10.1124/jpet.103.050666; Peoples RW, 2000, NEUROPHARMACOLOGY, V39, P1681, DOI 10.1016/S0028-3908(00)00067-8; Peoples RW, 1996, ANNU REV PHARMACOL, V36, P185, DOI 10.1146/annurev.pa.36.040196.001153; PEOPLES RW, 1992, BRAIN RES, V571, P342, DOI 10.1016/0006-8993(92)90674-X; Peoples RW, 1997, BRIT J PHARMACOL, V122, P1035, DOI 10.1038/sj.bjp.0701483; Ren H, 2007, BRIT J PHARMACOL, V151, P749, DOI 10.1038/sj.bjp.0707254; Ren H, 2003, J BIOL CHEM, V278, P48815, DOI 10.1074/jbc.M302097200; Ren H, 2003, J BIOL CHEM, V278, P276, DOI 10.1074/jbc.M209486200; Ronald KM, 2001, J BIOL CHEM, V276, P44729, DOI 10.1074/jbc.M102800200; Rutter AR, 2002, J NEUROCHEM, V81, P1298, DOI 10.1046/j.1471-4159.2002.00923.x; Sobolevsky AI, 2007, J GEN PHYSIOL, V129, P509, DOI 10.1085/jgp.200609718; Topf N, 2003, ANESTHESIOLOGY, V98, P306, DOI 10.1097/00000542-200302000-00007; Ueno S, 1999, BRIT J PHARMACOL, V127, P377, DOI 10.1038/sj.bjp.0702563; Wick MJ, 1998, P NATL ACAD SCI USA, V95, P6504, DOI 10.1073/pnas.95.11.6504; Williams DB, 1999, BIOPHYS J, V77, P2563, DOI 10.1016/S0006-3495(99)77091-8; Wright JM, 1996, BRAIN RES, V738, P249, DOI 10.1016/S0006-8993(96)00780-9; Yamakura T, 1999, J BIOL CHEM, V274, P23006, DOI 10.1074/jbc.274.33.23006	41	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8250	8257		10.1074/jbc.M705933200	http://dx.doi.org/10.1074/jbc.M705933200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18208816	Green Published, Green Submitted, hybrid			2022-12-25	WOS:000254288000022
J	Lopez, JJ; Lorch, M				Lopez, Jakob J.; Lorch, Mark			Location and orientation of serotonin receptor 1a agonists in model and complex lipid membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTRON-DIFFRACTION; SPINNING NMR; MAS NMR; CHOLESTEROL; BILAYERS; SPHINGOLIPIDS; LOCALIZATION; SPECTROSCOPY; TRYPTOPHAN; DOMAINS	Magic angle spinning (MAS) NMR has been used to investigate the location and orientation of five serotonin receptor 1a agonists (serotonin, buspirone, quipazine, 8-OH-DPAT, and LY-163,165) in single component model lipid and brain lipid membranes. The agonist locations are probed by monitoring changes in the lipid proton chemical shifts and by MAS-assisted nuclear Overhauser enhancement spectroscopy, which indicates the orientation of the agonists with respect to the 1,2-dioleoyl-sn-glycero-3-phosphocholine lipids. In the single component bilayer, the membrane agonists are found predominantly in the top of the hydrophobic chain or in the glycerol region of the membrane. Most of the agonists orient approximately parallel to the membrane plane, with the exception of quipazine, whose piperazine ring is found in the glycerol region, whereas its benzene ring is located within the lipid hydrophobic chain. The location of the agonist in brain lipid membranes is similar to the 1,2-dioleoyl-sn-glycero-3-phosphocholine lipid bilayers; however, many of the agonists appear to locate close to the cholesterol in the membrane in preference to the phospholipids.	[Lorch, Mark] Univ Hull, Dept Chem, Kingston Upon Hull HU6 7RX, N Humberside, England; [Lopez, Jakob J.] JW Goethe Univ Frankfurt, Inst Biophys Chem, D-60438 Frankfurt, Germany	University of Hull; Goethe University Frankfurt	Lorch, M (corresponding author), Univ Hull, Dept Chem, Kingston Upon Hull HU6 7RX, N Humberside, England.	M.Lorch@hull.ac.uk			Engineering and Physical Sciences Research Council [EP/C508912/1] Funding Source: researchfish	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Allen JA, 2007, NAT REV NEUROSCI, V8, P128, DOI 10.1038/nrn2059; Castanho MARB, 2006, EUR BIOPHYS J BIOPHY, V35, P92, DOI 10.1007/s00249-005-0007-9; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; FORBES J, 1988, J AM CHEM SOC, V110, P1059, DOI 10.1021/ja00212a010; Gaede HC, 2005, J PHYS CHEM B, V109, P13014, DOI 10.1021/jp0511000; Goni FM, 2006, BBA-BIOMEMBRANES, V1758, P1902, DOI 10.1016/j.bbamem.2006.09.011; Gross JD, 1997, J AM CHEM SOC, V119, P796, DOI 10.1021/ja962951b; Holland GP, 2006, J MAGN RESON, V181, P316, DOI 10.1016/j.jmr.2006.05.017; Huster D, 1999, J PHYS CHEM B, V103, P243, DOI 10.1021/jp983428h; Keller R., 2004, COMPUTER AIDED RESON, V1; Leonard A, 2001, LANGMUIR, V17, P2019, DOI 10.1021/la001382p; Lucero HA, 2004, ARCH BIOCHEM BIOPHYS, V426, P208, DOI 10.1016/j.abb.2004.03.020; McIntosh TJ, 2003, BIOPHYS J, V85, P1656, DOI 10.1016/S0006-3495(03)74595-0; MILLAN MJ, 1995, J PHARMACOL EXP THER, V273, P1418; OBRIEN JS, 1965, J LIPID RES, V6, P537; Ollila F, 2002, ARCH BIOCHEM BIOPHYS, V399, P103, DOI 10.1006/abbi.2001.2759; PEROUTKA SJ, 1986, J NEUROCHEM, V47, P529; Pinkus A. G., 1970, Journal of Physical Chemistry, V74, P1042, DOI 10.1021/j100700a013; Polozov IV, 2004, BIOPHYS J, V87, P1741, DOI 10.1529/biophysj.104.040725; Pucadyil TJ, 2005, CELL MOL NEUROBIOL, V25, P553, DOI 10.1007/s10571-005-3969-3; Ramstedt B, 2006, BBA-BIOMEMBRANES, V1758, P1945, DOI 10.1016/j.bbamem.2006.05.020; Scheidt HA, 2004, BBA-BIOMEMBRANES, V1663, P97, DOI 10.1016/j.bbamem.2004.02.004; SCHIFFER M, 1992, PROTEIN ENG, V5, P213, DOI 10.1093/protein/5.3.213; Siarheyeva A, 2006, BIOCHEMISTRY-US, V45, P6203, DOI 10.1021/bi0524870; STAMM H, 1989, J AM CHEM SOC, V111, P6544, DOI 10.1021/ja00199a010; SUBCZYNSKI WK, 1994, BIOCHEMISTRY-US, V33, P7670, DOI 10.1021/bi00190a022; Villalain J, 1996, EUR J BIOCHEM, V241, P586, DOI 10.1111/j.1432-1033.1996.00586.x; Warschawski DE, 2005, EUR BIOPHYS J BIOPHY, V34, P987, DOI 10.1007/s00249-005-0482-z; WIENER MC, 1992, BIOPHYS J, V61, P434, DOI 10.1016/S0006-3495(92)81849-0; WIMLEY WC, 1993, BIOCHEMISTRY-US, V32, P6307, DOI 10.1021/bi00076a001; Yau WM, 1998, BIOCHEMISTRY-US, V37, P14713, DOI 10.1021/bi980809c	31	4	4	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7813	7822		10.1074/jbc.M707480200	http://dx.doi.org/10.1074/jbc.M707480200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18187421	Green Published, hybrid			2022-12-25	WOS:000253997900057
J	Perroy, J; Raynaud, F; Homburger, V; Rousset, MC; Telley, L; Bockaert, J; Fagni, L				Perroy, Julie; Raynaud, Fabrice; Homburger, Vincent; Rousset, Marie-Claude; Telley, Ludovic; Bockaert, Joel; Fagni, Laurent			Direct interaction enables cross-talk between ionotropic and group I metabotropic glutamate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-ASPARTATE RECEPTORS; LONG-TERM DEPRESSION; RESONANCE ENERGY-TRANSFER; NMDA RESPONSES; IP3 RECEPTORS; HOMER BINDS; NEURONS; POTENTIATION; HIPPOCAMPUS; ACTIVATION	Functional interplay between ionotropic and metabotropic receptors frequently involves complex intracellular signaling cascades. The group I metabotropic glutamate receptor mGlu5a co-clusters with the ionotropic N-methyl-D-aspartate (NMDA) receptor in hippocampal neurons. In this study, we report that a more direct cross-talk can exist between these types of receptors. Using bioluminescence resonance energy transfer in living HEK293 cells, we demonstrate that mGlu5a and NMDA receptor clustering reflects the existence of direct physical interactions. Consequently, the mGlu5a receptor decreased NMDA receptor current, and reciprocally, the NMDA receptor strongly reduced the ability of the mGlu5a receptor to release intracellular calcium. We show that deletion of the C terminus of the mGlu5a receptor abolished both its interaction with the NMDA receptor and reciprocal inhibition of the receptors. This direct functional interaction implies a higher degree of target-effector specificity, timing, and subcellular localization of signaling than could ever be predicted with complex signaling pathways.	[Perroy, Julie; Raynaud, Fabrice; Homburger, Vincent; Rousset, Marie-Claude; Telley, Ludovic; Bockaert, Joel; Fagni, Laurent] Univ Montpellier 1 & 2, CNRS UMR 5203, INSERM,U661, Inst Genom Font, F-34094 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Perroy, J (corresponding author), Univ Montpellier 1 & 2, CNRS UMR 5203, INSERM,U661, Inst Genom Font, 141 Rue Cardonille, F-34094 Montpellier, France.	julie.perroy@igf.cnrs.fr		Raynaud, Fabrice/0000-0003-3055-0524; perroy, julie/0000-0001-6199-0448; Telley, Ludovic/0000-0002-5041-1997				Ango F, 1999, NEUROPHARMACOLOGY, V38, P793, DOI 10.1016/S0028-3908(99)00005-2; ANIKSZTEJN L, 1992, EUR J NEUROSCI, V4, P500, DOI 10.1111/j.1460-9568.1992.tb00900.x; Anwyl R, 1999, BRAIN RES REV, V29, P83, DOI 10.1016/S0165-0173(98)00050-2; Attucci S, 2001, BRIT J PHARMACOL, V132, P799, DOI 10.1038/sj.bjp.0703904; Awad H, 2000, J NEUROSCI, V20, P7871; Balasubramanian S, 2004, J BIOL CHEM, V279, P18840, DOI 10.1074/jbc.M313470200; BASHIR ZI, 1993, EUR J PHARMACOL, V239, P265, DOI 10.1016/0014-2999(93)91009-C; BASHIR ZI, 1993, NATURE, V363, P347, DOI 10.1038/363347a0; BOLSHAKOV VY, 1994, SCIENCE, V264, P1148, DOI 10.1126/science.7909958; Bortolotto ZA, 1999, CURR OPIN NEUROBIOL, V9, P299, DOI 10.1016/S0959-4388(99)80044-0; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P19, DOI 10.1113/jphysiol.1983.sp014477; Doherty AJ, 1997, NEUROPHARMACOLOGY, V36, P265, DOI 10.1016/S0028-3908(97)00001-4; Ehrengruber MU, 2004, MOL NEUROBIOL, V29, P213, DOI 10.1385/MN:29:3:213; Fagni L, 2000, TRENDS NEUROSCI, V23, P80, DOI 10.1016/S0166-2236(99)01492-7; Fagni L, 2004, SEMIN CELL DEV BIOL, V15, P289, DOI 10.1016/j.semcdb.2003.12.018; Fiorentini C, 2003, J BIOL CHEM, V278, P20196, DOI 10.1074/jbc.M213140200; FORSYTHE ID, 1988, J PHYSIOL-LONDON, V396, P515, DOI 10.1113/jphysiol.1988.sp016975; Hannan AJ, 2001, NAT NEUROSCI, V4, P282, DOI 10.1038/85132; HARVEY J, 1993, BRIT J PHARMACOL, V109, P1085, DOI 10.1111/j.1476-5381.1993.tb13733.x; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Kotecha SA, 2003, J BIOL CHEM, V278, P27742, DOI 10.1074/jbc.M301946200; Liu F, 2000, NATURE, V403, P274, DOI 10.1038/35002014; Mannaioni G, 2001, J NEUROSCI, V21, P5925, DOI 10.1523/JNEUROSCI.21-16-05925.2001; McIlhinney RAJ, 1998, NEUROPHARMACOLOGY, V37, P1355, DOI 10.1016/S0028-3908(98)00121-X; MELLON P, 1981, CELL, V27, P279, DOI 10.1016/0092-8674(81)90411-6; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Oliet SHR, 1997, NEURON, V18, P969, DOI 10.1016/S0896-6273(00)80336-0; Pisani A, 2001, NEUROSCIENCE, V106, P579, DOI 10.1016/S0306-4522(01)00297-4; Pisani A, 1997, BRIT J PHARMACOL, V120, P1007, DOI 10.1038/sj.bjp.0700999; Tsien Roger Y., 1993, Trends in Cell Biology, V3, P242, DOI 10.1016/0962-8924(93)90124-J; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; Ugolini A, 1997, NEUROPHARMACOLOGY, V36, P1047, DOI 10.1016/S0028-3908(97)00103-2; WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134; Xiao B, 2000, CURR OPIN NEUROBIOL, V10, P370, DOI 10.1016/S0959-4388(00)00087-8; Xu W, 2007, NEURON, V53, P399, DOI 10.1016/j.neuron.2006.12.020; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5	37	92	92	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					6799	6805		10.1074/jbc.M705661200	http://dx.doi.org/10.1074/jbc.M705661200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18182392	hybrid			2022-12-25	WOS:000253779600022
J	Mariappan, M; Radhakrishnan, K; Dierks, T; Schmidt, B; von Figura, K				Mariappan, Malaiyalam; Radhakrishnan, Karthikeyan; Dierks, Thomas; Schmidt, Bernhard; von Figura, Kurt			ERp44 mediates a thiol-independent retention of formylglycine-generating enzyme in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SULFATASE DEFICIENCY; PROTEIN MODIFICATION; CRYSTAL-STRUCTURE; HUMAN ARYLSULFATASE; MECHANISM; CYSTEINE; CONVERSION; MUTATIONS; CATALYSIS; PARALOG	Inside the endoplasmic reticulum (ER) formylglycine-generating enzyme (FGE) catalyzes in newly synthesized sulfatases the post-translational oxidation of a specific cysteine. Thereby formylglycine is generated, which is essential for sulfatase activity. Here we show that ERp44 interacts with FGE forming heterodimeric and, to a lesser extent, also heterotetrameric and octameric complexes, which are stabilized through disulfide bonding between cysteine 29 of ERp44 and cysteines 50 and 52 in the N-terminal region of FGE. ERp44 mediates FGE retrieval to the ER via its C-terminal RDEL signal. Increasing ERp44 levels by overexpression enhances and decreasing ERp44 levels by silencing reduces ER retention of FGE. Suppressing disulfide bonding by mutating the critical cysteines neither abrogates ERp44.FGE complex formation nor interferes with ERp44-mediated retention of FGE, indicating that noncovalent interactions between ERp44 and FGE are sufficient to mediate ER retention. The N-terminal region of FGE harboring Cys(50) and Cys(52) is dispensible for catalytic activity in vitro but required for FGE-mediated activation of sulfatases in vivo. This in vivo activity is affected neither by overexpression nor by silencing of ERp44, indicating that a further ER component interacting with the N-terminal extension of FGE is critical for sulfatase activation.	[Radhakrishnan, Karthikeyan; Dierks, Thomas] Univ Bielefeld, Fak Chem Biochem 1, D-33615 Bielefeld, Germany; [Mariappan, Malaiyalam; Schmidt, Bernhard; von Figura, Kurt] Univ Gottingen, Zentrum Biochem & Mol Zellbiol, Biochem Abt 2, D-37073 Gottingen, Germany	University of Bielefeld; University of Gottingen	Dierks, T (corresponding author), Univ Bielefeld, Fak Chem Biochem 1, Univ Str 25, D-33615 Bielefeld, Germany.	thomas.dierks@uni-bielefeld.de	Dierks, Thomas/A-3596-2012; mariappan, malaiyalam/K-9024-2012	Dierks, Thomas/0000-0001-6426-1339; Radhakrishnan, Karthikeyan/0000-0003-1731-7410				Anelli T, 2002, EMBO J, V21, P835, DOI 10.1093/emboj/21.4.835; Anelli T, 2003, EMBO J, V22, P5015, DOI 10.1093/emboj/cdg491; Anelli T, 2007, EMBO J, V26, P4177, DOI 10.1038/sj.emboj.7601844; Annunziata Ida, 2007, Hum Mutat, V28, P928, DOI 10.1002/humu.9504; Boltes I, 2001, STRUCTURE, V9, P483, DOI 10.1016/S0969-2126(01)00609-8; CONARY J, 1986, EUR J BIOCHEM, V158, P71, DOI 10.1111/j.1432-1033.1986.tb09722.x; Cosma MP, 2004, HUM MUTAT, V23, P576, DOI 10.1002/humu.20040; Cosma MP, 2003, CELL, V113, P445, DOI 10.1016/S0092-8674(03)00348-9; Dickmanns A, 2005, J BIOL CHEM, V280, P15180, DOI 10.1074/jbc.M414317200; Dierks T, 1997, P NATL ACAD SCI USA, V94, P11963, DOI 10.1073/pnas.94.22.11963; Dierks T, 2005, CELL, V121, P541, DOI 10.1016/j.cell.2005.03.001; Dierks T, 1998, J BIOL CHEM, V273, P25560, DOI 10.1074/jbc.273.40.25560; Dierks T, 1999, EMBO J, V18, P2084, DOI 10.1093/emboj/18.8.2084; Dierks T, 2003, CELL, V113, P435, DOI 10.1016/S0092-8674(03)00347-7; DIERKS T, 2001, ENCY MOL MED, P3042; Diez-Roux G, 2005, ANNU REV GENOM HUM G, V6, P355, DOI 10.1146/annurev.genom.6.080604.162334; Higo T, 2005, CELL, V120, P85, DOI 10.1016/j.cell.2004.11.048; Hopwood JJ, 2001, METABOLIC MOL BASES, P3725; Lukatela G, 1998, BIOCHEMISTRY-US, V37, P3654, DOI 10.1021/bi9714924; Mariappan M, 2005, J BIOL CHEM, V280, P15173, DOI 10.1074/jbc.M413698200; Miech C, 1998, J BIOL CHEM, V273, P4835, DOI 10.1074/jbc.273.9.4835; Otsu M, 2006, ANTIOXID REDOX SIGN, V8, P274, DOI 10.1089/ars.2006.8.274; Preusser-Kunze A, 2005, J BIOL CHEM, V280, P14900, DOI 10.1074/jbc.M413383200; Roeser D, 2006, P NATL ACAD SCI USA, V103, P81, DOI 10.1073/pnas.0507592102; Sardiello M, 2005, HUM MOL GENET, V14, P3203, DOI 10.1093/hmg/ddi351; Schlotawa Lars, 2008, Hum Mutat, V29, P205, DOI 10.1002/humu.9515; SCHMIDT B, 1995, CELL, V82, P271, DOI 10.1016/0092-8674(95)90314-3; Selmer T, 1996, EUR J BIOCHEM, V238, P341, DOI 10.1111/j.1432-1033.1996.0341z.x; von Bulow R, 2001, J MOL BIOL, V305, P269, DOI 10.1006/jmbi.2000.4297; von Figura K, 1998, BIOESSAYS, V20, P505, DOI 10.1002/(SICI)1521-1878(199806)20:6<505::AID-BIES9>3.0.CO;2-K; Wang ZV, 2007, MOL CELL BIOL, V27, P3716, DOI 10.1128/MCB.00931-06	31	41	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2008	283	10					6375	6383		10.1074/jbc.M709171200	http://dx.doi.org/10.1074/jbc.M709171200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HM	18178549	hybrid			2022-12-25	WOS:000253779500045
J	Sun, XJ; Xu, PF; Zhou, T; Hu, M; Fu, CT; Zhang, Y; Jin, Y; Chen, Y; Chen, SJ; Huang, QH; Liu, TX; Chen, Z				Sun, Xiao-Jian; Xu, Peng-Fei; Zhou, Ting; Hu, Ming; Fu, Chun-Tang; Zhang, Yong; Jin, Yi; Chen, Yi; Chen, Sai-Juan; Huang, Qiu-Hua; Liu, Ting Xi; Chen, Zhu			Genome-Wide Survey and Developmental Expression Mapping of Zebrafish SET Domain-Containing Genes	PLOS ONE			English	Article							HISTONE H3; CHROMATIN MODIFICATIONS; METHYLTRANSFERASE; PROTEIN; METHYLATION; IDENTIFICATION; REPRESSION; GENETICS; BLIMP-1; SMYD3	SET domain-containing proteins represent an evolutionarily conserved family of epigenetic regulators, which are responsible for most histone lysine methylation. Since some of these genes have been revealed to be essential for embryonic development, we propose that the zebrafish, a vertebrate model organism possessing many advantages for developmental studies, can be utilized to study the biological functions of these genes and the related epigenetic mechanisms during early development. To this end, we have performed a genome-wide survey of zebrafish SET domain genes. 58 genes total have been identified. Although gene duplication events give rise to several lineage-specific paralogs, clear reciprocal orthologous relationship reveals high conservation between zebrafish and human SET domain genes. These data were further subject to an evolutionary analysis ranging from yeast to human, leading to the identification of putative clusters of orthologous groups (COGs) of this gene family. By means of whole-mount mRNA in situ hybridization strategy, we have also carried out a developmental expression mapping of these genes. A group of maternal SET domain genes, which are implicated in the programming of histone modification states in early development, have been identified and predicted to be responsible for all known sites of SET domain-mediated histone methylation. Furthermore, some genes show specific expression patterns in certain tissues at certain stages, suggesting the involvement of epigenetic mechanisms in the development of these systems. These results provide a global view of zebrafish SET domain histone methyltransferases in evolutionary and developmental dimensions and pave the way for using zebrafish to systematically study the roles of these genes during development.	[Sun, Xiao-Jian; Xu, Peng-Fei; Hu, Ming; Zhang, Yong; Jin, Yi; Chen, Yi; Chen, Sai-Juan; Huang, Qiu-Hua; Liu, Ting Xi; Chen, Zhu] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Shanghai Inst Hematol,State Key Lab Med Genom, Shanghai 200030, Peoples R China; [Sun, Xiao-Jian; Zhou, Ting; Fu, Chun-Tang; Chen, Sai-Juan; Liu, Ting Xi; Chen, Zhu] Shanghai Jiao Tong Univ, Sch Med, Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Shanghai, Peoples R China; [Sun, Xiao-Jian; Chen, Zhu] Shanghai Jiao Tong Univ, Shanghai Ctr Syst Biomed, Shanghai, Peoples R China; [Liu, Ting Xi] E Inst Shanghai Univ, Model Organ Div, Shanghai, Peoples R China	Chinese Academy of Sciences; Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Liu, TX (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Shanghai Inst Hematol,State Key Lab Med Genom, Shanghai 200030, Peoples R China.	txliu@sibs.ac.cn; zchen@stn.sh.cn	Xu, Pengfei/AAA-3809-2022; Sun, Xiao-Jian/D-1560-2011	Xu, Pengfei/0000-0002-7318-8548; Sun, Xiao-Jian/0000-0001-8826-4614; Zhou, Ting/0000-0002-1880-5371	National Natural Science Foundation of China [30370334, 30525019]; Hundred Talents Program of Chinese Academy of Sciences; Chinese National Key Basic Research Project (973); Samuel Waxman Cancer Research Foundation, New York [co-principal investigator]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Hundred Talents Program of Chinese Academy of Sciences(Chinese Academy of Sciences); Chinese National Key Basic Research Project (973)(National Basic Research Program of China); Samuel Waxman Cancer Research Foundation, New York	This work was in part supported by the National Natural Science Foundation of China Grant 30370334 (to QHH), Grant 30525019, Hundred Talents Program of Chinese Academy of Sciences (to TXL), and the Chinese National Key Basic Research Project (973) (to ZC). XJS is a co-principal investigator supported by the Samuel Waxman Cancer Research Foundation, New York.	Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Amores A, 1998, SCIENCE, V282, P1711, DOI 10.1126/science.282.5394.1711; Aravind L, 2003, CELL CYCLE, V2, P369, DOI 10.4161/cc.2.4.419; Ayyanathan K, 2003, GENE DEV, V17, P1855, DOI 10.1101/gad.1102803; Baxendale S, 2004, NAT GENET, V36, P88, DOI 10.1038/ng1280; Biron VL, 2004, DEV BIOL, V276, P337, DOI 10.1016/j.ydbio.2004.08.038; Bradbury J, 2004, PLOS BIOL, V2, P568, DOI 10.1371/journal.pbio.0020148; Brown MA, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-26; Buonamici S, 2003, BLOOD CELL MOL DIS, V31, P206, DOI 10.1016/S1079-9796(03)00159-1; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Caretti G, 2004, GENE DEV, V18, P2627, DOI 10.1101/gad.1241904; Cheng XD, 2005, ANNU REV BIOPH BIOM, V34, P267, DOI 10.1146/annurev.biophys.34.040204.144452; Chou A, 1999, BIOINFORMATICS, V15, P376, DOI 10.1093/bioinformatics/15.5.376; Dodge JE, 2004, MOL CELL BIOL, V24, P2478, DOI 10.1128/MCB.24.6.2478-2486.2004; Dosch R, 2004, DEV CELL, V6, P771, DOI 10.1016/j.devcel.2004.05.002; Finn RD, 2006, NUCLEIC ACIDS RES, V34, pD247, DOI 10.1093/nar/gkj149; Garcia BA, 2007, J BIOL CHEM, V282, P7641, DOI 10.1074/jbc.M607900200; Giraldez AJ, 2006, SCIENCE, V312, P75, DOI 10.1126/science.1122689; Gottlieb PD, 2002, NAT GENET, V31, P25, DOI 10.1038/ng866; Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151; Hamamoto R, 2006, CANCER SCI, V97, P113, DOI 10.1111/j.1349-7006.2006.00146.x; Hayashi K, 2005, NATURE, V438, P374, DOI 10.1038/nature04112; Heasman J, 2002, DEV BIOL, V243, P209, DOI 10.1006/dbio.2001.0565; Hedges SB, 2002, NAT REV GENET, V3, P838, DOI 10.1038/nrg929; Hernandez-Lagunas L, 2005, DEV BIOL, V278, P347, DOI 10.1016/j.ydbio.2004.11.014; Horsley V, 2006, CELL, V126, P597, DOI 10.1016/j.cell.2006.06.048; Huang J, 2006, NATURE, V444, P629, DOI 10.1038/nature05287; Huang S, 2002, NAT REV CANCER, V2, P469, DOI 10.1038/nrc819; Hulo N, 2006, NUCLEIC ACIDS RES, V34, pD227, DOI 10.1093/nar/gkj063; HWANG I, 1995, IMMUNOGENETICS, V42, P353, DOI 10.1007/BF00179396; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; Katan-Khaykovich Y, 2005, EMBO J, V24, P2138, DOI 10.1038/sj.emboj.7600692; Kim SM, 2006, BIOCHEM BIOPH RES CO, V345, P318, DOI 10.1016/j.bbrc.2006.04.095; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Klose RJ, 2006, NAT REV GENET, V7, P715, DOI 10.1038/nrg1945; Koonin EV, 2005, ANNU REV GENET, V39, P309, DOI 10.1146/annurev.genet.39.073003.114725; KORNBERG RD, 1992, ANNU REV CELL BIOL, V8, P563, DOI 10.1146/annurev.cellbio.8.1.563; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kudoh T, 2001, GENOME RES, V11, P1979, DOI 10.1101/gr.209601; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; Kustikova O, 2005, SCIENCE, V308, P1171, DOI 10.1126/science.1105063; Lin WC, 2006, CURR OPIN GENET DEV, V16, P137, DOI 10.1016/j.gde.2006.02.002; Lin Y, 1997, SCIENCE, V276, P596, DOI 10.1126/science.276.5312.596; Liu TX, 2002, P NATL ACAD SCI USA, V99, P6136, DOI 10.1073/pnas.072560099; Marino-Ramirez L, 2006, PROTEINS, V62, P838, DOI 10.1002/prot.20814; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; Messika EJ, 1998, J EXP MED, V188, P515, DOI 10.1084/jem.188.3.515; Mochizuki N, 2000, BLOOD, V96, P3209, DOI 10.1182/blood.V96.9.3209.h8003209_3209_3214; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Nishio H, 2004, P NATL ACAD SCI USA, V101, P11257, DOI 10.1073/pnas.0401343101; O'Carroll D, 2000, MOL CELL BIOL, V20, P9423, DOI 10.1128/MCB.20.24.9423-9433.2000; O'Carroll D, 2001, MOL CELL BIOL, V21, P4330, DOI 10.1128/MCB.21.13.4330-4336.2001; Ohinata Y, 2005, NATURE, V436, P207, DOI 10.1038/nature03813; Pearson W R, 2000, Methods Mol Biol, V132, P185; Pelegri F, 2003, DEV DYNAM, V228, P535, DOI 10.1002/dvdy.10390; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Postlethwait JH, 1998, NAT GENET, V18, P345, DOI 10.1038/ng0498-345; Prince VE, 2002, NAT REV GENET, V3, P827, DOI 10.1038/nrg928; Rayasam GV, 2003, EMBO J, V22, P3153, DOI 10.1093/emboj/cdg288; Sandman K, 2006, CURR OPIN MICROBIOL, V9, P520, DOI 10.1016/j.mib.2006.08.003; Santos F, 2005, DEV BIOL, V280, P225, DOI 10.1016/j.ydbio.2005.01.025; Schier AF, 2005, ANNU REV GENET, V39, P561, DOI 10.1146/annurev.genet.37.110801.143752; Schneider R, 2002, TRENDS BIOCHEM SCI, V27, P396, DOI 10.1016/S0968-0004(02)02141-2; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Song HD, 2004, P NATL ACAD SCI USA, V101, P16240, DOI 10.1073/pnas.0407241101; Stern HM, 2003, NAT REV CANCER, V3, P533, DOI 10.1038/nrc1126; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sun XJ, 2005, J BIOL CHEM, V280, P35261, DOI 10.1074/jbc.M504012200; Tachibana M, 2005, GENE DEV, V19, P815, DOI 10.1101/gad.1284005; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Tan XG, 2006, P NATL ACAD SCI USA, V103, P2713, DOI 10.1073/pnas.0509503103; THATCHER TH, 1994, NUCLEIC ACIDS RES, V22, P174, DOI 10.1093/nar/22.2.174; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Torres-Padilla ME, 2007, NATURE, V445, P214, DOI 10.1038/nature05458; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; Tsuge M, 2005, NAT GENET, V37, P1104, DOI 10.1038/ng1638; Woods IG, 2005, GENOME RES, V15, P1307, DOI 10.1101/gr.4134305; Xie M, 1997, J BIOL CHEM, V272, P26360, DOI 10.1074/jbc.272.42.26360; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	83	93	100	3	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2008	3	1							e1499	10.1371/journal.pone.0001499	http://dx.doi.org/10.1371/journal.pone.0001499			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SR	18231586	gold, Green Published			2022-12-25	WOS:000260504200012
J	Caviedes-Vidal, E; Karasov, WH; Chediack, JG; Fasulo, V; Cruz-Neto, AP; Otani, L				Caviedes-Vidal, Enrique; Karasov, William H.; Chediack, Juan Gabriel; Fasulo, Veronica; Cruz-Neto, Ariovaldo P.; Otani, Lye			Paracellular Absorption: A Bat Breaks the Mammal Paradigm	PLOS ONE			English	Article							SPARROW PASSER-DOMESTICUS; SMALL-INTESTINE; PASSIVE ABSORPTION; ROUSETTUS-AEGYPTIACUS; LIQUID-CHROMATOGRAPHY; GLUCOSE-ABSORPTION; AMINO-ACIDS; IN-VIVO; RAT; TRANSPORT	Bats tend to have less intestinal tissue than comparably sized nonflying mammals. The corresponding reduction in intestinal volume and hence mass of digesta carried is advantageous because the costs of flight increase with load carried and because take-off and maneuverability are diminished at heavier masses. Water soluble compounds, such as glucose and amino acids, are absorbed in the small intestine mainly via two pathways, the transporter-mediated transcellular and the passive, paracellular pathways. Using the microchiropteran bat Artibeus literatus (mean mass 80.6 +/- 3.7 g), we tested the predictions that absorption of water-soluble compounds that are not actively transported would be extensive as a compensatory mechanism for relatively less intestinal tissue, and would decline with increasing molecular mass in accord with sieve-like paracellular absorption. Using a standard pharmacokinetic technique, we fed, or injected intraperitonealy the metabolically inert carbohydrates L-rhamnose (molecular mass = 164 Da) and cellobiose (molecular mass = 342 Da) which are absorbed only by paracellular transport, and 3-O-methyl-D-glucose (3OMD-glucose) which is absorbed via both mediated (active) and paracellular transport. As predicted, the bioavailability of paracellular probes declined with increasing molecular mass (rhamnose, 90 +/- 11%; cellobiose, 10 +/- 3%, n = 8) and was significantly higher in bats than has been reported for laboratory rats and other mammals. In addition, absorption of 3OMD-glucose was high (96 +/- 11%). We estimated that the bats rely on passive, paracellular absorption for more than 70% of their total glucose absorption, much more than in non-flying mammals. Although possibly compensating for less intestinal tissue, a high intestinal permeability that permits passive absorption might be less selective than a carrier-mediated system for nutrient absorption and might permit toxins to be absorbed from plant and animal material in the intestinal lumen.	[Caviedes-Vidal, Enrique; Chediack, Juan Gabriel; Fasulo, Veronica] Univ Nacl San Luis, CONICET, Fac Ciencias Humanas, Lab Biol Prof E Caviedes Codelia, San Luis, Argentina; [Caviedes-Vidal, Enrique; Chediack, Juan Gabriel] Univ Nacl San Luis, Dept Bioquim & Ciencias Biol, San Luis, Argentina; [Karasov, William H.] Univ Wisconsin Madison, Dept Wildlife Ecol, Madison, WI USA; [Fasulo, Veronica] Univ Nacl San Luis, Fac Ciencias Human, Area Psicobiol, San Luis, Argentina; [Cruz-Neto, Ariovaldo P.; Otani, Lye] Univ Estadual Paulista, Inst Biocien, Dept Zool, Sao Paulo, Brazil	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Universidad Nacional de San Luis; Universidad Nacional de San Luis; University of Wisconsin System; University of Wisconsin Madison; Universidad Nacional de San Luis; Universidade Estadual Paulista	Caviedes-Vidal, E (corresponding author), Univ Nacl San Luis, CONICET, Fac Ciencias Humanas, Lab Biol Prof E Caviedes Codelia, San Luis, Argentina.	enrique.caviedes@gmail.com	cruz-neto, ariovaldo/Y-7225-2019; Vazquez-Dominguez, Guillermo GVD/L-7818-2014; Chediack, Juan Gabriel/ABB-6521-2021; Cruz-Neto, Ariovaldo P/B-2958-2013; Caviedes-Vidal, Enrique/J-9204-2013	cruz-neto, ariovaldo/0000-0001-5270-7276; Cruz-Neto, Ariovaldo P/0000-0001-5270-7276; Caviedes-Vidal, Enrique/0000-0003-4526-4969; Chediack, Juan Gabriel/0000-0002-5049-5860	National Science Foundation (USA) [IBN-0216709, IOS-0615678]; Agencia Nacional de Promocion Cientifica y Tecnologica (Argentina); Universidad Nacional de San Luis (Argentina) [25561, 22Q751]; Max McGraw Wildlife Foundation	National Science Foundation (USA)(National Science Foundation (NSF)); Agencia Nacional de Promocion Cientifica y Tecnologica (Argentina)(ANPCyT); Universidad Nacional de San Luis (Argentina); Max McGraw Wildlife Foundation	Funding was provided by the National Science Foundation (USA) (IBN-0216709 and IOS-0615678 to WHK), the Agencia Nacional de Promocion Cientifica y Tecnologica (Argentina) and the Universidad Nacional de San Luis (Argentina) (FONCYT 25561 and 22Q751 respectively, to EC-V) and, the Max McGraw Wildlife Foundation.	Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Afik D, 1997, PHYSIOL ZOOL, V70, P370, DOI 10.1086/639618; ANDERSON JH, 1973, J MORPHOL, V141, P281, DOI 10.1002/jmor.1051410304; ANUMULA KR, 1994, ANAL BIOCHEM, V220, P275, DOI 10.1006/abio.1994.1338; BARRY RE, 1976, J MAMMAL, V57, P273, DOI 10.2307/1379688; BIJLSMA PB, 1995, GASTROENTEROLOGY, V108, P687, DOI 10.1016/0016-5085(95)90440-9; BUDDINGTON RK, 1992, AM J PHYSIOL, V263, pG605, DOI 10.1152/ajpgi.1992.263.5.G605; CaviedesVidal E, 1996, AM J PHYSIOL-REG I, V271, pR561, DOI 10.1152/ajpregu.1996.271.3.R561; Chang MH, 2004, J EXP BIOL, V207, P3109, DOI 10.1242/jeb.01154; Chang MH, 2004, J COMP PHYSIOL B, V174, P181, DOI 10.1007/s00360-003-0403-3; CHANG RLS, 1975, BIOPHYS J, V15, P861, DOI 10.1016/S0006-3495(75)85862-0; Chediack JG, 2003, J COMP PHYSIOL B, V173, P187, DOI 10.1007/s00360-002-0314-8; Chediack JG, 2001, J EXP BIOL, V204, P723; CHIVERS DJ, 1980, J MORPHOL, V166, P337, DOI 10.1002/jmor.1051660306; DELAHUNTY T, 1987, COMP BIOCHEM PHYS A, V86, P565, DOI 10.1016/0300-9629(87)90542-1; Diamond J, 1999, IBIS, V141, P181, DOI 10.1111/j.1474-919X.1999.tb07540.x; DIAMOND J, 1991, NEWS PHYSIOL SCI, V6, P92, DOI 10.1152/physiologyonline.1991.6.2.92; DIAMOND JM, 1984, J PHYSIOL-LONDON, V349, P419, DOI 10.1113/jphysiol.1984.sp015165; Du P., 1998, J BIOMOL TECH, V9, P31; FASULO V, 2004, BIOCELL, V28, P58; FINE KD, 1993, GASTROENTEROLOGY, V105, P1117, DOI 10.1016/0016-5085(93)90957-E; FORMAN GL, 1972, KANS U SCI B, V49, P591; Gibaldi M., 1982, PHARMACOKINETICS, P494; GUILLEMETTE M, 1994, AUK, V111, P900, DOI 10.2307/4088822; IKEDA TS, 1989, J MEMBRANE BIOL, V110, P87, DOI 10.1007/BF01870995; KARASOV WH, 1988, BIOSCIENCE, V38, P602, DOI 10.2307/1310825; KARASOV WH, 1994, AM J PHYSIOL, V267, pG18, DOI 10.1152/ajpgi.1994.267.1.G18; KARASOV WH, 1985, AM J PHYSIOL, V249, pG271, DOI 10.1152/ajpgi.1985.249.2.G271; KEEGAN DJ, 1979, S AFR J ZOOL, V14, P220; Kisielinski K, 2002, CLIN EXP MED, V2, P131, DOI 10.1007/s102380200018; KLITE PD, 1965, J BACTERIOL, V90, P375, DOI 10.1128/JB.90.2.375-379.1965; Lane JS, 1999, AM J PHYSIOL-GASTR L, V276, pG789, DOI 10.1152/ajpgi.1999.276.3.G789; Lavin SR, 2004, INTEGR COMP BIOL, V44, P717; Levey DJ, 1996, COMP BIOCHEM PHYS A, V113, P225, DOI 10.1016/0300-9629(95)02046-2; LOO JCK, 1968, J PHARM SCI, V57, P918, DOI 10.1002/jps.2600570602; MADARA JL, 1988, AM J PHYSIOL, V254, pG416, DOI 10.1152/ajpgi.1988.254.3.G416; MADARA JL, 1988, CELL, V53, P497, DOI 10.1016/0092-8674(88)90562-4; MADARA JL, 1986, J CELL BIOL, V102, P2125, DOI 10.1083/jcb.102.6.2125; MADARA JL, 1987, J MEMBRANE BIOL, V100, P149, DOI 10.1007/BF02209147; Maina JN, 2000, J EXP BIOL, V203, P3045; Makanya AN, 1997, J EXP BIOL, V200, P2415; Makanya AN, 2001, ACTA BIOL HUNG, V52, P75, DOI 10.1556/ABiol.52.2001.1.8; MAYHEW TM, 1985, J ANAT, V141, P1; MOTULSKY HJ, 1987, FASEB J, V1, P365, DOI 10.1096/fasebj.1.5.3315805; Nagy KA, 1999, ANNU REV NUTR, V19, P247, DOI 10.1146/annurev.nutr.19.1.247; NORBERG UM, 1995, FUNCT ECOL, V9, P48, DOI 10.2307/2390089; Nudds RL, 2002, AM J PHYSIOL-REG I, V283, pR249, DOI 10.1152/ajpregu.00409.2001; PAPPENHEIMER IR, 1987, J MEMBRANE BIOL, V100, P137, DOI 10.1007/BF02209146; PAPPENHEIMER JR, 1993, AM J PHYSIOL, V265, pG409, DOI 10.1152/ajpgi.1993.265.3.G409; PAPPENHEIMER JR, 1990, AM J PHYSIOL, V259, pG290, DOI 10.1152/ajpgi.1990.259.2.G290; PAPPENHEIMER JR, 1987, J MEMBRANE BIOL, V100, P123, DOI 10.1007/BF02209145; Pencek RR, 2002, J NUTR, V132, P1929, DOI 10.1093/jn/132.7.1929; Polson C, 2003, J CHROMATOGR B, V785, P263, DOI 10.1016/S1570-0232(02)00914-5; Riviere JE, 1999, COMP PHARMACOKINETIC; SCHWARTZ RM, 1995, GASTROENTEROLOGY, V109, P1206, DOI 10.1016/0016-5085(95)90580-4; Sigalet DL, 1996, J SURG RES, V61, P379, DOI 10.1006/jsre.1996.0133; Sigalet DL, 2000, J PEDIATR SURG, V35, P661, DOI 10.1053/jpsu.2000.5937; SMULDERS AP, 1971, J MEMBRANE BIOL, V5, P297, DOI 10.1007/BF01957348; Snipes RL, 1997, ADV ANAT EMBRYOL CEL, V138, P1; SNIPES RL, 1994, DIGESTIVE SYSTEM IN MAMMALS: FOOD, FORM, AND FUNCTION, P234, DOI 10.1017/CBO9780511661716.016; Tedman R.A., 1985, Australian Mammalogy, V8, P271; Tracy CR, 2007, J EXP BIOL, V210, P1726, DOI 10.1242/jeb.02766; UHING MR, 1995, J CLIN INVEST, V95, P2799, DOI 10.1172/JCI117984; Verzar F., 1936, ABSORPTION INTESTINE; WAGNER JG, 1974, J PHARMACOKINET BIOP, V2, P469, DOI 10.1007/BF01070942; WILKINSON L, 1992, SYSTAT WINDOWS STAT, P750; Wood HO, 1944, J ANAT, V78, P103	67	52	55	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2008	3	1							e1425	10.1371/journal.pone.0001425	http://dx.doi.org/10.1371/journal.pone.0001425			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366GT	18183305	Green Submitted, gold, Green Published			2022-12-25	WOS:000260469400021
J	Binda, O; Nassif, C; Branton, PE				Binda, O.; Nassif, C.; Branton, P. E.			SIRT1 negatively regulates HDAC1-dependent transcriptional repression by the RBP1 family of proteins	ONCOGENE			English	Article						transcription; RBP1; BCAA; SIRT1; HDAC1; mSIN3A	CANDIDATE TUMOR-SUPPRESSOR; HISTONE DEACETYLASE COMPLEX; N-COR; COREPRESSOR COMPLEX; DNA-BINDING; LIFE-SPAN; SACCHAROMYCES-CEREVISIAE; CALORIE RESTRICTION; GROWTH ARREST; CANCER-CELLS	Both RBP1 and the highly related protein BCAA play a role in the induction of growth arrest and cellular senescence via mechanisms involving transcriptional repression. While investigating the transcriptional repression activities of RBP1, we observed a genetic link between RBP1 and SIR2. Further work uncovered an interaction between RBP1 family proteins and the mammalian homologue of SIR2, SIRT1. Interestingly, the HDAC-dependent transcriptional repression domain of RBP1 proteins, termed R2, is necessary and sufficient for the interaction with SIRT1. In vitro and in vivo binding studies indicated that the p33(ING1b) and p33(ING2) subunits of the mSIN3A/HDAC1 complex are responsible for the recruitment of SIRT1 to the R2 domain. To investigate the biological relevance of this interaction, we used the sirtuin activator resveratrol and the sirtuin inhibitor sirtinol in transcriptional repression assays and demonstrated that SIRT1 activity negatively regulates R2-mediated transcriptional repression activity. We therefore propose a novel mechanism of class I HDAC regulation by a class III HDAC. Explicitly, SIRT1 is recruited by ING proteins and inhibits R2-associated mSIN3A/HDAC1 transcriptional repression activity.	[Binda, O.; Nassif, C.; Branton, P. E.] McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; [Branton, P. E.] McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada; [Branton, P. E.] McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University; McGill University	Branton, PE (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Bldg,Room 702,3655 Promenader Sir Wi, Montreal, PQ H3G 1Y6, Canada.	philip.branton@mcgill.ca	Binda, Olivier/A-5941-2009	Binda, Olivier/0000-0002-1539-0828				Bae NS, 2004, J BIOCHEM, V135, P695, DOI 10.1093/jb/mvh084; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Binda O, 2006, MOL CELL BIOL, V26, P1917, DOI 10.1128/MCB.26.5.1917-1931.2006; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Bordone L, 2006, PLOS BIOL, V4, P210, DOI 10.1371/journal.pbio.0040031; Bouras T, 2005, J BIOL CHEM, V280, P10264, DOI 10.1074/jbc.M408748200; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Dannenberg JH, 2005, GENE DEV, V19, P1581, DOI 10.1101/gad.1286905; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; Fleischer TC, 2003, MOL CELL BIOL, V23, P3456, DOI 10.1128/MCB.23.10.3456-3467.2003; Garkavtsev I, 1997, MOL CELL BIOL, V17, P2014, DOI 10.1128/MCB.17.4.2014; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; Grozinger CM, 2001, J BIOL CHEM, V276, P38837, DOI 10.1074/jbc.M106779200; Guarente L, 2005, MECH AGEING DEV, V126, P923, DOI 10.1016/j.mad.2005.03.013; Guarente L, 2005, CELL, V120, P473, DOI 10.1016/j.cell.2005.01.029; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Herrscher RF, 1995, GENE DEV, V9, P3067, DOI 10.1101/gad.9.24.3067; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Huang EY, 2000, GENE DEV, V14, P45; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kataoka H, 2003, CANCER RES, V63, P5785; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kim S, 1999, MOL BIOL CELL, V10, P3125, DOI 10.1091/mbc.10.10.3125; Kortschak RD, 2000, TRENDS BIOCHEM SCI, V25, P294, DOI 10.1016/S0968-0004(00)01597-8; Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Laherty CD, 1998, MOL CELL, V2, P33, DOI 10.1016/S1097-2765(00)80111-2; Lai A, 2001, MOL CELL BIOL, V21, P2918, DOI 10.1128/MCB.21.8.2918-2932.2001; Lai A, 1999, ONCOGENE, V18, P2091, DOI 10.1038/sj.onc.1202520; Laj A, 1999, MOL CELL BIOL, V19, P6632; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Longo VD, 2006, CELL, V126, P257, DOI 10.1016/j.cell.2006.07.002; Lu RQ, 1999, J CELL PHYSIOL, V179, P297, DOI 10.1002/(SICI)1097-4652(199906)179:3<297::AID-JCP7>3.0.CO;2-P; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Meehan WJ, 2004, J BIOL CHEM, V279, P1562, DOI 10.1074/jbc.M307969200; Michan S, 2007, BIOCHEM J, V404, P1, DOI 10.1042/BJ20070140; Michishita E, 2005, MOL BIOL CELL, V16, P4623, DOI 10.1091/mbc.E05-01-0033; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nikolaev AY, 2004, BIOCHEM BIOPH RES CO, V323, P1216, DOI 10.1016/j.bbrc.2004.08.227; North BJ, 2005, METHODS, V36, P338, DOI 10.1016/j.ymeth.2005.03.004; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Ota H, 2006, ONCOGENE, V25, P176, DOI 10.1038/sj.onc.1209049; Ota H, 2007, J MOL CELL CARDIOL, V43, P571, DOI 10.1016/j.yjmcc.2007.08.008; Parsons XH, 2003, P NATL ACAD SCI USA, V100, P1609, DOI 10.1073/pnas.0434064100; Patsialou A, 2005, NUCLEIC ACIDS RES, V33, P66, DOI 10.1093/nar/gki145; Pedeux R, 2005, MOL CELL BIOL, V25, P6639, DOI 10.1128/MCB.25.15.6639-6648.2005; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Qiu Y, 2006, MOL CELL, V22, P669, DOI 10.1016/j.molcel.2006.04.019; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Rogina B, 2002, SCIENCE, V298, P1745, DOI 10.1126/science.1078986; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Sasaki T, 2006, AGING CELL, V5, P413, DOI 10.1111/j.1474-9726.2006.00235.x; Sgambato A, 2001, MUTAT RES-GEN TOX EN, V496, P171, DOI 10.1016/S1383-5718(01)00232-7; SHORE D, 1984, EMBO J, V3, P2817, DOI 10.1002/j.1460-2075.1984.tb02214.x; Skowyra D, 2001, J BIOL CHEM, V276, P8734, DOI 10.1074/jbc.M007664200; Takata T, 2003, BIOCHEM BIOPH RES CO, V301, P250, DOI 10.1016/S0006-291X(02)03020-6; Thiagalingam S, 2003, ANN NY ACAD SCI, V983, P84, DOI 10.1111/j.1749-6632.2003.tb05964.x; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Underhill C, 2000, J BIOL CHEM, V275, P40463, DOI 10.1074/jbc.M007864200; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Vieyra D, 2002, J BIOL CHEM, V277, P29832, DOI 10.1074/jbc.M200197200; Wilsker D, 2005, GENOMICS, V86, P242, DOI 10.1016/j.ygeno.2005.03.013; Wilson JM, 2006, EMBO REP, V7, P1247, DOI 10.1038/sj.embor.7400829; Yoon HG, 2003, EMBO J, V22, P1336, DOI 10.1093/emboj/cdg120; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1	73	55	55	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	24					3384	3392		10.1038/sj.onc.1211014	http://dx.doi.org/10.1038/sj.onc.1211014			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18193082				2022-12-25	WOS:000256309900003
J	Menendez, A; Calarese, DA; Stanfield, RL; Chow, KC; Scanlan, CN; Kunert, R; Katinger, H; Burton, DR; Wilson, IA; Scott, JK				Menendez, Alfredo; Calarese, Daniel A.; Stanfield, Robyn L.; Chow, Keith C.; Scanlan, Chris N.; Kunert, Renate; Katinger, Herman; Burton, Dennis R.; Wilson, Ian A.; Scott, Jamie K.			A peptide inhibitor of HIV-1 neutralizing antibody 2G12 is not a structural mimic of the natural carbohydrate epitope on gp120	FASEB JOURNAL			English	Article						peptide mimics; HIV-1 envelope proteins; crystal structure; phage-displayed peptide libraries	IMMUNODEFICIENCY-VIRUS TYPE-1; CROSS-CLADE NEUTRALIZATION; HIGH-AFFINITY MIMOTOPE; CAPSULAR POLYSACCHARIDE; CRYPTOCOCCUS-NEOFORMANS; FILAMENTOUS PHAGE; MONOCLONAL-ANTIBODIES; ANTICARBOHYDRATE ANTIBODIES; ANTI-HIV-1 ANTIBODY; SEROGROUP-C	MAb 2G12 neutralizes HIV-1 by binding with high affinity to a cluster of high-mannose oligosaccharides on the envelope glycoprotein, gp120. Screening of phage-displayed peptide libraries with 2G12 identified peptides that bind specifically, with Kds ranging from 0.4 to 200 mu M. The crystal structure of a 21-mer peptide ligand in complex with 2G12 Fab was determined at 2.8 angstrom resolution. Comparison of this structure with previous structures of 2G12-carbohydrate complexes revealed striking differences in the mechanism of 2G12 binding to peptide vs. carbohydrate. The peptide occupies a site different from, but adjacent to, the primary carbohydrate-binding site on 2G12, and makes only slightly fewer contacts to the Fab than Man(9)GlcNAC(2) (51 vs. 56, respectively). However, only two antibody contacts with the peptide are hydrogen bonds in contrast to six with Man(9)GlcNAC(2), and only three of the antibody residues that interact with Man(9)GlcNAC(2) also contact the peptide. Thus, this mechanism of peptide binding to 2G12 does not support structural mimicry of the native carbohydrate epitope on gp120, since it neither replicates the oligosaccharide footprint on the antibody nor most of the contact residues. Moreover, 2G12.1 peptide is not an immunogenic mimic of the 2G12 epitope, since antisera produced against it did not bind gp120.	[Menendez, Alfredo; Chow, Keith C.; Scott, Jamie K.] Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada; [Wilson, Ian A.] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; [Scott, Jamie K.] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC V5A 1S6, Canada; [Calarese, Daniel A.; Stanfield, Robyn L.; Burton, Dennis R.; Wilson, Ian A.] Scripps Res Inst, Dept Mol Biol, La Jolla, CA USA; [Scanlan, Chris N.; Burton, Dennis R.] Scripps Res Inst, Dept Immunol, La Jolla, CA USA; [Kunert, Renate; Katinger, Herman] Univ Nat Resources & Appl Life Sci, Inst Appl Microbiol, Vienna, Austria	Simon Fraser University; Scripps Research Institute; Simon Fraser University; Scripps Research Institute; Scripps Research Institute; University of Natural Resources & Life Sciences, Vienna	Wilson, IA (corresponding author), Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada.	wilson@scripps.edu; jkscott@sfu.ca	Stanfield, Robyn/AAH-3190-2019; Kunert, Renate E/B-9185-2018	Kunert, Renate E/0000-0002-3397-3621	NIAID NIH HHS [R21 AI049808-01, AI33292, R01 AI049111-03, R01 AI049111, AI49808, R01 AI049111-01A1, R01 AI049111-02, R37 AI033292, AI49111, R01 AI033292, R21 AI049808-02] Funding Source: Medline; NIGMS NIH HHS [GM46192, R01 GM046192] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033292, R37AI033292, R21AI049808, R01AI049111] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046192] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams EW, 2004, CHEM BIOL, V11, P875, DOI 10.1016/j.chembiol.2004.04.010; Barbas C. F., 2001, PHAGE DISPLAY LAB MA; Beenhouwer DO, 2002, J IMMUNOL, V169, P6992, DOI 10.4049/jimmunol.169.12.6992; Binley JA, 2004, J VIROL, V78, P13232, DOI 10.1128/JVI.78.23.13232-13252.2004; Bonnycastle LLC, 1996, J MOL BIOL, V258, P747, DOI 10.1006/jmbi.1996.0284; Brett PJ, 2002, J BIOL CHEM, V277, P20468, DOI 10.1074/jbc.M200387200; Buchwald UK, 2005, INFECT IMMUN, V73, P325, DOI 10.1128/IAI.73.1.325-333.2005; Calarese DA, 2003, SCIENCE, V300, P2065, DOI 10.1126/science.1083182; Calarese DA, 2005, P NATL ACAD SCI USA, V102, P13372, DOI 10.1073/pnas.0505763102; Clement MJ, 2003, J BIOL CHEM, V278, P47928, DOI 10.1074/jbc.M308259200; Craig L, 1998, J MOL BIOL, V281, P183, DOI 10.1006/jmbi.1998.1907; DSouza MP, 1997, J INFECT DIS, V175, P1056, DOI 10.1086/516443; Dudkin VY, 2004, J AM CHEM SOC, V126, P9560, DOI 10.1021/ja047720g; Geng XD, 2004, ANGEW CHEM INT EDIT, V43, P2562, DOI 10.1002/anie.200353626; Haaparanta T, 1995, MOL DIVERS, V1, P39, DOI 10.1007/BF01715808; Johnson MA, 2003, J BIOL CHEM, V278, P24740, DOI 10.1074/jbc.M301846200; KARLSSON R, 1994, ANAL BIOCHEM, V221, P142, DOI 10.1006/abio.1994.1390; Krauss IJ, 2007, J AM CHEM SOC, V129, P11042, DOI 10.1021/ja074804r; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; Lee HK, 2004, ANGEW CHEM INT EDIT, V43, P1000, DOI 10.1002/anie.200353105; Lesinski GB, 2001, VACCINE, V19, P1717, DOI 10.1016/S0264-410X(00)00397-2; Li HG, 2004, ORG BIOMOL CHEM, V2, P483, DOI 10.1039/b314565d; Lou Q, 1999, J PEPT RES, V53, P252, DOI 10.1034/j.1399-3011.1999.00025.x; Luo P, 2000, J BIOL CHEM, V275, P16146, DOI 10.1074/jbc.M909121199; Maitta RW, 2004, INFECT IMMUN, V72, P196, DOI 10.1128/IAI.72.1.196-208.2004; Mandal M, 2004, ANGEW CHEM INT EDIT, V43, P2557, DOI 10.1002/anie.200353625; Manoutcharian K, 1999, CLIN IMMUNOL, V91, P117, DOI 10.1006/clim.1998.4669; Mascola JR, 1999, J VIROL, V73, P4009, DOI 10.1128/JVI.73.5.4009-4018.1999; Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; Menendez A, 2005, ANAL BIOCHEM, V336, P145, DOI 10.1016/j.ab.2004.09.048; Menendez A, 2004, J MOL BIOL, V338, P311, DOI 10.1016/j.jmb.2004.02.051; Ni JH, 2006, BIOCONJUGATE CHEM, V17, P493, DOI 10.1021/bc0502816; Nieba L, 1996, ANAL BIOCHEM, V234, P155, DOI 10.1006/abio.1996.0067; Parren PWHI, 2001, J VIROL, V75, P8340, DOI 10.1128/JVI.75.17.8340-8347.2001; Phalipon A, 1997, EUR J IMMUNOL, V27, P2620, DOI 10.1002/eji.1830271022; Pincus S H, 2001, Int Rev Immunol, V20, P221, DOI 10.3109/08830180109043035; Pincus SH, 1998, J IMMUNOL, V160, P293; Prinz DM, 2004, J IMMUNOL METHODS, V285, P1, DOI 10.1016/j.jim.2003.08.005; Prinz DM, 2003, IMMUNOLOGY, V110, P242, DOI 10.1046/j.1365-2567.2003.01732.x; Roux KH, 2004, MOL IMMUNOL, V41, P1001, DOI 10.1016/j.molimm.2004.05.008; Sanders RW, 2002, J VIROL, V76, P7293, DOI 10.1128/JVI.76.14.7293-7305.2002; Saphire EO, 2007, J MOL BIOL, V369, P696, DOI 10.1016/j.jmb.2007.01.060; Scanlan CN, 2003, ADV EXP MED BIOL, V535, P205; Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; TRKOLA A, 1995, J VIROL, V69, P6609, DOI 10.1128/JVI.69.11.6609-6617.1995; Trkola A, 1996, J VIROL, V70, P1100, DOI 10.1128/JVI.70.2.1100-1108.1996; Tumanova O. Yu., 2002, Molekulyarnaya Biologiya (Moscow), V36, P657; Valadon P, 1998, J IMMUNOL, V161, P1829; Valadon P, 1996, J MOL BIOL, V261, P11, DOI 10.1006/jmbi.1996.0438; van Houten NE, 2006, VACCINE, V24, P4188, DOI 10.1016/j.vaccine.2006.01.001; Vyas NK, 2003, P NATL ACAD SCI USA, V100, P15023, DOI 10.1073/pnas.2431286100; Wang JS, 2007, ORG BIOMOL CHEM, V5, P1529, DOI 10.1039/b702961f; Wang LX, 2004, CHEM BIOL, V11, P127, DOI 10.1016/j.chembiol.2003.12.020; Young ACM, 1997, J MOL BIOL, V274, P622, DOI 10.1006/jmbi.1997.1407; ZHONG GM, 1994, J BIOL CHEM, V269, P24183; Zwick MB, 1998, ANAL BIOCHEM, V264, P87, DOI 10.1006/abio.1998.2793; Zwick MB, 2001, J VIROL, V75, P6692, DOI 10.1128/JVI.75.14.6692-6699.2001	59	25	31	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2008	22	5					1380	1392		10.1096/fj.07-8983com	http://dx.doi.org/10.1096/fj.07-8983com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301LW	18198210	Green Accepted			2022-12-25	WOS:000255898700011
J	Harrison, B; Kraus, M; Burch, L; Stevens, C; Craig, A; Gordon-Weeks, P; Hupp, TR				Harrison, Ben; Kraus, Michaela; Burch, Lindsay; Stevens, Craig; Craig, Ashley; Gordon-Weeks, Phillip; Hupp, Ted R.			DAPK-1 binding to a linear peptide motif in MAP1B stimulates autophagy and membrane blebbing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; CELL-DEATH; INTERACTION NETWORKS; INDUCED APOPTOSIS; P53 CONTAINS; DOCKING SITE; KINASE; DOMAIN; MDM2; CHECKPOINT	DAPK-1 (death-activated protein kinase) has wide ranging functions in cell growth control; however, DAPK-1 interacting proteins that mediate these effects are not well defined. Protein-protein interactions are driven in part by linear interaction motifs, and combinatorial peptide libraries were used to identify peptide interfaces for the kinase domain of DAPK-1. Peptides bound to DAPK-1 core kinase domain fragments had homology to the N-terminal domain of the microtubule-associated protein MAP1B. Immunobinding assays demonstrated that DAPK-1 can bind to the full-length human MAP1B, a smaller N-terminal miniprotein containing amino acids 1-126 and the 12-amino acid polypeptides acquired by peptide selection. Amino acid starvation of cells induced a stable immune complex between MAP1B and DAPK-1, identifying a signal that forms the endogenous complex in cells. DAPK-1 and MAP1B co-expression form a synthetic lethal interaction as they cooperate to induce growth inhibition in a clonogenic assay. In cells, two co-localizing populations of DAPK-1 and MAP1B were observed using confocal microscopy; one pool co-localized with MAP1B plus tubulin, and a second pool co-localized with MAP1B plus cortical F-actin. Reduction of MAP1B protein using short interfering RNA attenuated DAPK-1-stimulated autophagy. Transfected MAP1B can synergize with DAPK-1 to stimulate membrane blebbing, whereas reduction of MAP1B using short interfering RNA attenuates DAPK-1 membrane blebbing activity. The autophagy inhibitor 3-methyladenine inhibits the DAPK-1 plus MAP1B-mediated membrane blebbing. These data highlight the utility of peptide aptamers to identify novel binding interfaces and highlight a role for MAP1B in DAPK-1-dependent signaling in autophagy and membrane blebbing.	[Harrison, Ben; Burch, Lindsay; Stevens, Craig; Craig, Ashley; Hupp, Ted R.] Univ Edinburgh, Ctr Canc, Cell Signaling Unit, Edinburgh EH4 2XR, Midlothian, Scotland; [Kraus, Michaela; Gordon-Weeks, Phillip] Kings Coll London, MRC Ctr Dev Neurobiol, London SE1 1UL, England	University of Edinburgh; University of London; King's College London	Hupp, TR (corresponding author), Univ Edinburgh, Ctr Canc, Cell Signaling Unit, S Crewe Rd, Edinburgh EH4 2XR, Midlothian, Scotland.	ted.hupp@ed.ac.uk	Gordon-Weeks, Phillip R./C-5328-2009	Gordon-Weeks, Phillip R./0000-0002-4738-4246; Harrison, Benjamin/0000-0002-6078-5060	MRC [G9900989, G0400034] Funding Source: UKRI; Cancer Research UK Funding Source: Medline; Medical Research Council [G9900989, G0400034] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Anjum R, 2005, CURR BIOL, V15, P1762, DOI 10.1016/j.cub.2005.08.050; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bialik S, 2006, ANNU REV BIOCHEM, V75, P189, DOI 10.1146/annurev.biochem.75.103004.142615; Bonnet C, 2001, J BIOL CHEM, V276, P12839, DOI 10.1074/jbc.M011380200; Burch L, 2004, J MOL BIOL, V337, P129, DOI 10.1016/j.jmb.2004.01.017; Caenepeel S, 2004, P NATL ACAD SCI USA, V101, P11707, DOI 10.1073/pnas.0306880101; Chen CH, 2005, EMBO J, V24, P294, DOI 10.1038/sj.emboj.7600510; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Craig AL, 2004, ONCOGENE, V23, P8411, DOI 10.1038/sj.onc.1208035; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; Craig AL, 2007, MOL CELL BIOL, V27, P3542, DOI 10.1128/MCB.01595-06; Davies H, 2005, CANCER RES, V65, P7591, DOI 10.1158/0008-5472.CAN-05-1855; Del Rio JA, 2004, CURR BIOL, V14, P840, DOI 10.1016/j.cub.2004.04.046; Dornan D, 2003, MOL CELL BIOL, V23, P8846, DOI 10.1128/MCB.23.23.8846-8861.2003; Finlan L, 2004, J BIOL CHEM, V279, P49395, DOI 10.1074/jbc.M405974200; Gonzalez-Billault C, 2001, MOL BIOL CELL, V12, P2087, DOI 10.1091/mbc.12.7.2087; Goold RG, 2005, MOL CELL NEUROSCI, V28, P524, DOI 10.1016/j.mcn.2004.11.005; Gordon-Weeks PR, 2004, J NEUROBIOL, V58, P70, DOI 10.1002/neu.10266; Gordon-Weeks PR, 2000, MICROSC RES TECHNIQ, V48, P63, DOI 10.1002/(SICI)1097-0029(20000115)48:2<63::AID-JEMT2>3.0.CO;2-1; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Halpain S, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-6-224; Hardie DG, 2005, CURR OPIN CELL BIOL, V17, P167, DOI 10.1016/j.ceb.2005.01.006; Hunter T, 2005, CELL, V123, P765, DOI 10.1016/j.cell.2005.11.017; Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094; Jimenez-Mateos EM, 2006, BIOCHEM J, V397, P53, DOI 10.1042/BJ20060205; Jin YJ, 2003, J BIOL CHEM, V278, P51587, DOI 10.1074/jbc.M309165200; Jin YJ, 2002, J BIOL CHEM, V277, P46980, DOI 10.1074/jbc.M208585200; Jin YJ, 2001, J BIOL CHEM, V276, P39667, DOI 10.1074/jbc.M101886200; Johnson SA, 2005, NAT METHODS, V2, P17, DOI 10.1038/NMETH731; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kastan MB, 2001, ACTA ONCOL, V40, P686; Kawai T, 2003, MOL CELL BIOL, V23, P6174, DOI 10.1128/MCB.23.17.6174-6186.2003; Kochl R, 2006, TRAFFIC, V7, P129, DOI 10.1111/j.1600-0854.2005.00368.x; Lin Y, 2007, J BIOL CHEM, V282, P16792, DOI 10.1074/jbc.M611559200; Luciani MG, 2000, J MOL BIOL, V300, P503, DOI 10.1006/jmbi.2000.3830; McEntyre JR, 2004, TRENDS BIOCHEM SCI, V29, P627, DOI 10.1016/j.tibs.2004.10.006; Neduva V, 2005, PLOS BIOL, V3, P2090, DOI 10.1371/journal.pbio.0030405; Neduva V, 2006, CURR OPIN BIOTECH, V17, P465, DOI 10.1016/j.copbio.2006.08.002; Puntervoll P, 2003, NUCLEIC ACIDS RES, V31, P3625, DOI 10.1093/nar/gkg545; Raval A, 2007, CELL, V129, P879, DOI 10.1016/j.cell.2007.03.043; Raveh T, 2000, P NATL ACAD SCI USA, V97, P1572, DOI 10.1073/pnas.020519497; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; RIEDERER B, 1986, J NEUROCYTOL, V15, P763, DOI 10.1007/BF01625193; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; Shimizu H, 2002, J BIOL CHEM, V277, P28446, DOI 10.1074/jbc.M202296200; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Stevens C, 2007, J BIOL CHEM, V282, P13791, DOI 10.1074/jbc.M605649200; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697; Trivedi N, 2005, J CELL SCI, V118, P993, DOI 10.1242/jcs.01697; Uchida Y, 2003, J BIOL CHEM, V278, P366, DOI 10.1074/jbc.M210091200; Wallace M, 2006, MOL CELL, V23, P251, DOI 10.1016/j.molcel.2006.05.029; Wang WJ, 2002, J CELL BIOL, V159, P169, DOI 10.1083/jcb.200204050; Xu ZX, 2007, CELL DEATH DIFFER, V14, P1948, DOI 10.1038/sj.cdd.4402207; York JD, 2004, SCIENCE, V306, P2053, DOI 10.1126/science.1107225	56	111	119	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9999	10014		10.1074/jbc.M706040200	http://dx.doi.org/10.1074/jbc.M706040200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18195017	hybrid			2022-12-25	WOS:000254671600056
J	Ito, H; Yokono, M; Tanaka, R; Tanaka, A				Ito, Hisashi; Yokono, Makio; Tanaka, Ryouichi; Tanaka, Ayumi			Identification of a novel vinyl reductase gene essential for the biosynthesis of monovinyl chlorophyll in Synechocystis sp PCC6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHANOBACTERIUM-THERMOAUTOTROPHICUM; PCC 6803; ARABIDOPSIS-THALIANA; DIVINYL-CHLOROPHYLLS; EUGLENA-GRACILIS; PHOTOSYSTEM-II; CYANOBACTERIUM; OXYGENASE; LIGHT; MUTANTS	The vast majority of oxygenic photosynthetic organisms use monovinyl chlorophyll for their photosynthetic reactions. For the biosynthesis of this type of chlorophyll, the reduction of the 8-vinyl group that is located on the B-ring of the macrocycle is essential. Previously, we identified the gene encoding 8-vinyl reductase responsible for this reaction in higher plants and termed it DVR. Among the sequenced genomes of cyanobacteria, only several Synechococcus species contain DVR homologues. Therefore, it has been hypothesized that many other cyanobacteria producing monovinyl chlorophyll should contain a vinyl reductase that is unrelated to the higher plant DVR. To identify the cyanobacterial gene that is responsible for monovinyl chlorophyll synthesis, we developed a bioinformatics tool, correlation coefficient calculation tool, which calculates the correlation coefficient between the distributions of a certain phenotype and genes among a group of organisms. The program indicated that the distribution of a gene encoding a putative dehydrogenase protein is best correlated with the distribution of the DVR-less cyanobacteria. We subsequently knocked out the corresponding gene ( Slr1923) in Synechocystis sp. PCC6803 and characterized the mutant. The knock-out mutant lost its ability to synthesize monovinyl chlorophyll and accumulated 3,8-divinyl chlorophyll instead. We concluded that Slr1923 encodes the vinyl reductase or a subunit essential for monovinyl chlorophyll synthesis. The function and evolution of 8-vinyl reductase genes are discussed.	[Ito, Hisashi; Yokono, Makio; Tanaka, Ryouichi; Tanaka, Ayumi] Hokkaido Univ, Inst Low Temp Sci, Sapporo, Hokkaido 0600819, Japan	Hokkaido University	Ito, H (corresponding author), Hokkaido Univ, Inst Low Temp Sci, Sapporo, Hokkaido 0600819, Japan.	ito98@lowtem.hokudai.ac.jp	Tanaka, Ayumi/D-9003-2012; Tanaka, Ryouichi/A-4030-2012; Ito, Hisashi/A-4211-2012; Yokono, Makio/N-8425-2015	Tanaka, Ryouichi/0000-0002-5858-5326; Ito, Hisashi/0000-0002-2482-5870; Yokono, Makio/0000-0002-4813-2120				Ahmadinejad N, 2007, GENE, V402, P35, DOI 10.1016/j.gene.2007.07.023; Akimoto S, 2005, CHEM PHYS LETT, V409, P167, DOI 10.1016/j.cplett.2005.05.006; ALEX LA, 1990, BIOCHEMISTRY-US, V29, P7237, DOI 10.1021/bi00483a011; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BRAKS IJ, 1994, J BACTERIOL, V176, P7677, DOI 10.1128/JB.176.24.7677-7687.1994; Chew AGM, 2007, J BIOL CHEM, V282, P2967, DOI 10.1074/jbc.M609730200; CHISHOLM SW, 1988, NATURE, V334, P340, DOI 10.1038/334340a0; Fromme P, 2003, FEBS LETT, V555, P40, DOI 10.1016/S0014-5793(03)01124-4; Giorgi LB, 1996, J BIOL CHEM, V271, P2093, DOI 10.1074/jbc.271.4.2093; Hihara Y, 1998, PLANT PHYSIOL, V117, P1205, DOI 10.1104/pp.117.4.1205; Jen CH, 2006, PLANT J, V46, P336, DOI 10.1111/j.1365-313X.2006.02681.x; Lee S, 2000, CURR MICROBIOL, V40, P283, DOI 10.1007/s002849910056; LIVINGSTON DJ, 1987, BIOCHEMISTRY-US, V26, P4228, DOI 10.1021/bi00388a008; Manning WM, 1943, J BIOL CHEM, V151, P1; Maqueo Chew AG, 2007, ANNU REV MICROBIOL, V61, P113, DOI 10.1146/annurev.micro.61.080706.093242; Maresca JA, 2004, J BACTERIOL, V186, P2558, DOI 10.1128/JB.186.9.2558-2566.2004; Nagata N, 2005, PLANT CELL, V17, P233, DOI 10.1105/tpc.104.027276; Nakanishi H, 2005, PLANT CELL PHYSIOL, V46, P467, DOI 10.1093/pcp/pci053; Obornik M, 2005, MOL BIOL EVOL, V22, P2343, DOI 10.1093/molbev/msi230; Ouchane S, 2004, J BIOL CHEM, V279, P6385, DOI 10.1074/jbc.M309851200; Pruzinska A, 2003, P NATL ACAD SCI USA, V100, P15259, DOI 10.1073/pnas.2036571100; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Satoh S, 2001, J BIOL CHEM, V276, P4293, DOI 10.1074/jbc.M008238200; Satoh S, 2006, PLANT CELL PHYSIOL, V47, P1622, DOI 10.1093/pcp/pcl026; Schafer L, 2006, PLANT CELL ENVIRON, V29, P1349, DOI 10.1111/j.1365-3040.2006.01515.x; Schafer L, 2005, J PHOTOCH PHOTOBIO B, V78, P195, DOI 10.1016/j.jphotobiol.2004.11.007; Stanier G., 1988, METHOD ENZYMOL, V167, P157, DOI DOI 10.1016/0076-6879(88)67017-0; SUZUKI JY, 1995, J BIOL CHEM, V270, P3732, DOI 10.1074/jbc.270.8.3732; Tanaka A, 1998, P NATL ACAD SCI USA, V95, P12719, DOI 10.1073/pnas.95.21.12719; Tanaka R, 2003, PLANT CELL PHYSIOL, V44, P1266, DOI 10.1093/pcp/pcg172; Tanaka R, 2007, ANNU REV PLANT BIOL, V58, P321, DOI 10.1146/annurev.arplant.57.032905.105448; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tomo T, 2007, P NATL ACAD SCI USA, V104, P7283, DOI 10.1073/pnas.0701847104; WEINSTEIN JD, 1983, J BIOL CHEM, V258, P6799	34	73	75	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9002	9011		10.1074/jbc.M708369200	http://dx.doi.org/10.1074/jbc.M708369200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18230620	Green Published, hybrid			2022-12-25	WOS:000254465800030
J	Dorwart, MR; Shcheynikov, N; Baker, JMR; Forman-Kay, JD; Muallem, S; Thomas, PJ				Dorwart, Michael R.; Shcheynikov, Nikolay; Baker, Jennifer M. R.; Forman-Kay, Julie D.; Muallem, Shmuel; Thomas, Philip J.			Congenital chloride-losing diarrhea causing mutations in the STAS domain result in misfolding and mistrafficking of SLC26A3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSPLASIA SULFATE TRANSPORTER; ANTI-SIGMA FACTOR; TRANSCRIPTION FACTOR SIGMA(F); HIGH ENDOTHELIAL VENULES; ADENOMA DRA GENE; BACILLUS-SUBTILIS; PENDRED-SYNDROME; ANION-EXCHANGER; FUNCTIONAL-ANALYSIS; FACTOR SPOIIAB	Congenital chloride-losing diarrhea (CLD) is a genetic disorder causing watery stool and dehydration. Mutations in SLC26A3 ( solute carrier 26 family member 3), which functions as a coupled Cl-/HCO3- exchanger, cause CLD. SLC26A3 is a membrane protein predicted to contain 12 transmembrane-spanning alpha-helices and a C-terminal STAS (sulfate transporters and anti-sigma-factor) domain homologous to the bacterial anti-sigma-factor antagonists. The STAS domain is required for SLC26A3 Cl-/HCO3- exchange function and for the activation of cystic fibrosis transmembrane conductance regulator by SLC26A3. Here we investigate the molecular mechanism(s) by which four CLD-causing mutations (Delta Y526/ 7, I544N, I675/6ins, and G702Tins) in the STAS domain lead to disease. In a heterologous mammalian expression system biochemical, immunohistochemical, and ion transport experiments suggest that the four CLD mutations cause SLC26A3 transporter misfolding and/or mistrafficking. Expression studies with the isolated STAS domain suggest that the I675/6ins and G702Tins mutations disrupt the STAS domain directly, whereas limited proteolysis experiments suggest that the Delta Y526/ 7 and I544N mutations affect a later step in the folding and/ or trafficking pathway. The data suggest that these CLD-causing mutations cause disease by at least two distinct molecular mechanisms, both ultimately leading to loss of functional protein at the plasma membrane.	[Dorwart, Michael R.; Shcheynikov, Nikolay; Muallem, Shmuel; Thomas, Philip J.] Univ Texas SW Med Ctr Dallas, Dept Physiol, Dallas, TX 75390 USA; [Dorwart, Michael R.] Univ Texas SW Med Ctr Dallas, Mol Biophys Program, Dallas, TX 75390 USA; [Baker, Jennifer M. R.; Forman-Kay, Julie D.] Hosp Sick Children, Program Mol Struct & Funct, Toronto, ON M5G 1X8, Canada; [Baker, Jennifer M. R.; Forman-Kay, Julie D.] Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Thomas, PJ (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Physiol, Dallas, TX 75390 USA.	Philip.Thomas@utsouthwestern.edu	Thomas, Philip J/F-7115-2012	Forman-Kay, Julie/0000-0001-8265-972X	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK049835, R01DK038938, R01DK049835] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE 12309] Funding Source: Medline; NIDDK NIH HHS [DK 38938, DK 49835] Funding Source: Medline; NIGMS NIH HHS [GM 08203] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alvarez BV, 2005, EMBO J, V24, P2499, DOI 10.1038/sj.emboj.7600736; Aravind L, 2000, CURR BIOL, V10, pR53, DOI 10.1016/S0960-9822(00)00335-3; Byeon MK, 1998, PROTEIN EXPRES PURIF, V12, P67, DOI 10.1006/prep.1997.0809; Byeon MK, 1996, ONCOGENE, V12, P387; Campbell C, 2001, HUM MUTAT, V17, P403, DOI 10.1002/humu.1116; Canani RB, 2004, GASTROENTEROLOGY, V127, P630, DOI 10.1053/j.gastro.2004.03.071; Chapman JM, 2002, CANCER RES, V62, P5083; Chernova MN, 2003, J PHYSIOL-LONDON, V549, P3, DOI 10.1113/jphysiol.2003.039818; Clarkson J, 2003, BIOCHEM J, V372, P113, DOI 10.1042/BJ20021748; Dawson PA, 2005, CURR MED CHEM, V12, P385, DOI 10.2174/0929867053363144; Deak L, 2005, J PHYSIOL-LONDON, V563, P483, DOI 10.1113/jphysiol.2004.078857; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DUNCAN L, 1993, P NATL ACAD SCI USA, V90, P2325, DOI 10.1073/pnas.90.6.2325; Duncan L, 1996, J MOL BIOL, V260, P147, DOI 10.1006/jmbi.1996.0389; Everett LA, 1997, NAT GENET, V17, P411, DOI 10.1038/ng1297-411; Garsin DA, 1998, J MOL BIOL, V284, P557, DOI 10.1006/jmbi.1998.2201; Girard JP, 1999, P NATL ACAD SCI USA, V96, P12772, DOI 10.1073/pnas.96.22.12772; Hemminki A, 1998, ONCOGENE, V16, P681, DOI 10.1038/sj.onc.1201538; Hihnala S, 2006, J PEDIATR GASTR NUTR, V42, P369, DOI 10.1097/01.mpg.0000214161.37574.9a; Hoglund P, 1996, NAT GENET, V14, P316, DOI 10.1038/ng1196-316; Hoglund P, 1998, AM J HUM GENET, V63, P760, DOI 10.1086/301998; HOLMBERG C, 1986, CLIN GASTROENTEROL, V15, P583; Jacob P, 2002, GASTROENTEROLOGY, V122, P709, DOI 10.1053/gast.2002.31875; Jiang Z, 2002, J BIOL CHEM, V277, P33963, DOI 10.1074/jbc.M202660200; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Karniski LP, 2004, HUM MOL GENET, V13, P2165, DOI 10.1093/hmg/ddh242; Karniski LP, 1998, AM J PHYSIOL-RENAL, V275, pF79, DOI 10.1152/ajprenal.1998.275.1.F79; Karniski LP, 2001, HUM MOL GENET, V10, P1485, DOI 10.1093/hmg/10.14.1485; Kere J, 1999, AM J PHYSIOL-GASTR L, V276, pG7, DOI 10.1152/ajpgi.1999.276.1.G7; Kim KH, 2005, J BIOL CHEM, V280, P6463, DOI 10.1074/jbc.M409162200; Knauf F, 2001, P NATL ACAD SCI USA, V98, P9425, DOI 10.1073/pnas.141241098; Ko SBH, 2004, NAT CELL BIOL, V6, P343, DOI 10.1038/ncb1115; Ko SBH, 2002, EMBO J, V21, P5662, DOI 10.1093/emboj/cdf580; Kovacs H, 1998, P NATL ACAD SCI USA, V95, P5067, DOI 10.1073/pnas.95.9.5067; Liu XZ, 2003, HUM MOL GENET, V12, P1155, DOI 10.1093/hmg/ddg127; Lohi H, 2003, AM J PHYSIOL-CELL PH, V284, pC769, DOI 10.1152/ajpcell.00270.2002; Lohi H, 2002, J BIOL CHEM, V277, P14246, DOI 10.1074/jbc.M111802200; Lohi H, 2002, AM J PHYSIOL-GASTR L, V283, pG567, DOI 10.1152/ajpgi.00356.2001; Lohi H, 2000, GENOMICS, V70, P102, DOI 10.1006/geno.2000.6355; Ludwig J, 2001, P NATL ACAD SCI USA, V98, P4178, DOI 10.1073/pnas.071613498; Magnin T, 1996, MOL MICROBIOL, V19, P901, DOI 10.1046/j.1365-2958.1996.434964.x; Makela S, 2002, HUM MUTAT, V20, P425, DOI 10.1002/humu.10139; Masuda S, 2004, J MOL BIOL, V340, P941, DOI 10.1016/j.jmb.2004.05.040; Moseley RH, 1999, AM J PHYSIOL-GASTR L, V276, pG185, DOI 10.1152/ajpgi.1999.276.1.G185; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Mount DB, 2004, PFLUG ARCH EUR J PHY, V447, P710, DOI 10.1007/s00424-003-1090-3; NAJAFI SMA, 1995, J BACTERIOL, V177, P2912, DOI 10.1128/jb.177.10.2912-2913.1995; Navaratnam D, 2005, BIOPHYS J, V89, P3345, DOI 10.1529/biophysj.105.068759; Park HJ, 2003, J MED GENET, V40, P242, DOI 10.1136/jmg.40.4.242; Park M, 2002, J BIOL CHEM, V277, P50503, DOI 10.1074/jbc.M201862200; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; Rossi A, 2001, HUM MUTAT, V17, P159, DOI 10.1002/humu.1; Rotman-Pikielny P, 2002, HUM MOL GENET, V11, P2625, DOI 10.1093/hmg/11.21.2625; Rouached H, 2005, J BIOL CHEM, V280, P15976, DOI 10.1074/jbc.M501635200; Royaux IE, 2000, ENDOCRINOLOGY, V141, P839, DOI 10.1210/en.141.2.839; Satoh H, 1998, J BIOL CHEM, V273, P12307, DOI 10.1074/jbc.273.20.12307; Scott DA, 2000, AM J PHYSIOL-CELL PH, V278, pC207, DOI 10.1152/ajpcell.2000.278.1.C207; Seavers PR, 2001, STRUCTURE, V9, P605, DOI 10.1016/S0969-2126(01)00623-2; Shcheynikov N, 2006, J GEN PHYSIOL, V127, P511, DOI 10.1085/jgp.200509392; Shibagaki N, 2004, J BIOL CHEM, V279, P30791, DOI 10.1074/jbc.M403248200; Shibagaki N, 2006, J BIOL CHEM, V281, P22964, DOI 10.1074/jbc.M603462200; Soleimani M, 2001, AM J PHYSIOL-RENAL, V280, pF356, DOI 10.1152/ajprenal.2001.280.2.F356; Taylor JP, 2002, J CLIN ENDOCR METAB, V87, P1778, DOI 10.1210/jc.87.4.1778; Toure A, 2001, J BIOL CHEM, V276, P20309, DOI 10.1074/jbc.M011740200; Vincourt JB, 2003, FASEB J, V17, P890, DOI 10.1096/fj.02-0787fje; Vincourt JB, 2002, GENOMICS, V79, P249, DOI 10.1006/geno.2002.6689; Waldegger S, 2001, GENOMICS, V72, P43, DOI 10.1006/geno.2000.6445; Wilkinson DJ, 1997, AM J PHYSIOL-LUNG C, V273, pL127, DOI 10.1152/ajplung.1997.273.1.L127; Xie QH, 2002, AM J PHYSIOL-RENAL, V283, pF826, DOI 10.1152/ajprenal.00079.2002; Zheng J, 2001, NEUROREPORT, V12, P1929, DOI 10.1097/00001756-200107030-00032	70	48	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8711	8722		10.1074/jbc.M704328200	http://dx.doi.org/10.1074/jbc.M704328200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18216024	Green Published, hybrid			2022-12-25	WOS:000254288000069
J	Slugoski, MD; Ng, AML; Yao, SYM; Smith, KM; Lin, CC; Zhang, J; Karpinski, E; Cass, CE; Baldwin, SA; Young, JD				Slugoski, Melissa D.; Ng, Amy M. L.; Yao, Sylvia Y. M.; Smith, Kyla M.; Lin, Colin C.; Zhang, Jing; Karpinski, Edward; Cass, Carol E.; Baldwin, Stephen A.; Young, James D.			A proton-mediated conformational shift identifies a mobile pore-lining cysteine residue (Cys-561) in human concentrative nucleoside transporter 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; ELECTROPHYSIOLOGICAL CHARACTERIZATION; MOLECULAR-CLONING; COTRANSPORTER; CHANNEL; PURINE; FAMILY; HCNT1; ACCESSIBILITY; MUTAGENESIS	The concentrative nucleoside transporter (CNT) protein family in humans is represented by three members, hCNT1, hCNT2, and hCNT3. Belonging to a CNT subfamily phylogenetically distinct from hCNT1/2, hCNT3 mediates transport of a broad range of purine and pyrimidine nucleosides and nucleoside drugs, whereas hCNT1 and hCNT2 are pyrimidine and purine nucleoside-selective, respectively. All three hCNTs are Na+-coupled. Unlike hCNT1/2, however, hCNT3 is also capable of H+-mediated nucleoside cotransport. Using site-directed mutagenesis in combination with heterologous expression in Xenopus oocytes, we have identified a C-terminal intramembranous cysteine residue of hCNT3 (Cys-561) that reversibly binds the hydrophilic thiol-reactive reagent p-chloromercuribenzene sulfonate (PCMBS). Access of this membrane-impermeant probe to Cys-561, as determined by inhibition of hCNT3 transport activity, required H+, but not Na+, and was blocked by extracellular uridine. Although this cysteine residue is also present in hCNT1 and hCNT2, neither transporter was affected by PCMBS. We conclude that Cys-561 is located in the translocation pore in a mobile region within or closely adjacent to the nucleoside binding pocket and that access of PCMBS to this residue reports a specific H+-induced conformational state of the protein.	[Slugoski, Melissa D.; Ng, Amy M. L.; Yao, Sylvia Y. M.; Smith, Kyla M.; Lin, Colin C.; Karpinski, Edward; Young, James D.] Univ Alberta, Dept Physiol, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada; [Zhang, Jing; Cass, Carol E.] Univ Alberta, Dept Oncol, Edmonton, AB T6G 2H7, Canada; [Zhang, Jing; Cass, Carol E.] Cross Canc Inst, Edmonton, AB T6G 2H7, Canada; [Baldwin, Stephen A.] Univ Leeds, Inst Membrane & Syst Biol, Astbury Ctr Struct Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Alberta; University of Alberta; University of Alberta; University of Leeds	Young, JD (corresponding author), Univ Alberta, Dept Physiol, Membrane Prot Res Grp, 7-55 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	james.young@ualberta.ca	Cass, Carol E/F-5861-2010					AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Baldwin SA, 2004, PFLUG ARCH EUR J PHY, V447, P735, DOI 10.1007/s00424-003-1103-2; Berezin C, 2004, BIOINFORMATICS, V20, P1322, DOI 10.1093/bioinformatics/bth070; Boudker O, 2007, NATURE, V445, P387, DOI 10.1038/nature05455; CASS CE, 1995, DRUG TRANSPORT ANTIM, P403; Damaraju VL, 2003, ONCOGENE, V22, P7524, DOI 10.1038/sj.onc.1206952; Gray JH, 2004, PFLUG ARCH EUR J PHY, V447, P728, DOI 10.1007/s00424-003-1107-y; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Hamilton SR, 2001, J BIOL CHEM, V276, P27981, DOI 10.1074/jbc.M100518200; Hu HK, 2006, MOL PHARMACOL, V69, P1542, DOI 10.1124/mol.105.018945; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; King AE, 2006, TRENDS PHARMACOL SCI, V27, P416, DOI 10.1016/j.tips.2006.06.004; Kirsch RD, 1998, NUCLEIC ACIDS RES, V26, P1848, DOI 10.1093/nar/26.7.1848; KRUPKA RM, 1994, BBA-BIOMEMBRANES, V1193, P165, DOI 10.1016/0005-2736(94)90346-8; Latini S, 2001, J NEUROCHEM, V79, P463, DOI 10.1046/j.1471-4159.2001.00607.x; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Loewen SK, 1999, J BIOL CHEM, V274, P24475, DOI 10.1074/jbc.274.35.24475; Loewen SK, 2004, MOL MEMBR BIOL, V21, P1, DOI 10.1080/0968768031000140836; Loewen SK, 2003, YEAST, V20, P661, DOI 10.1002/yea.1000; Ritzel MWL, 1998, MOL MEMBR BIOL, V15, P203; Ritzel MWL, 1997, AM J PHYSIOL-CELL PH, V272, pC707, DOI 10.1152/ajpcell.1997.272.2.C707; Ritzel MWL, 2001, J BIOL CHEM, V276, P2914, DOI 10.1074/jbc.M007746200; ROTHSTEIN A, 1970, CURRENT TOPICS MEMBR, V1, P135; Slugoski MD, 2007, BIOCHEMISTRY-US, V46, P1684, DOI 10.1021/bi061692s; Smith FM, 2007, MOL MEMBR BIOL, V24, P53, DOI 10.1080/09687860600942534; Smith KM, 2005, J BIOL CHEM, V280, P25436, DOI 10.1074/jbc.M409454200; Smith KM, 2004, J PHYSIOL-LONDON, V558, P807, DOI 10.1113/jphysiol.2004.068189; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; Williams DB, 1999, BIOPHYS J, V77, P2563, DOI 10.1016/S0006-3495(99)77091-8; Xiao GQ, 2001, MOL PHARMACOL, V59, P339, DOI 10.1124/mol.59.2.339; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; YAN RT, 1993, CELL, V75, P37, DOI 10.1016/S0092-8674(05)80082-0; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973; Yao SY, 2002, AM J PHYSIOL-CELL PH, V283, pC155, DOI 10.1152/ajpcell.00587.2001; Yao SYM, 2007, J BIOL CHEM, V282, P30607, DOI 10.1074/jbc.M703285200; Yao SYM, 2000, PRACT APPROACH SER, P47; Yao SYM, 2001, BIOCHEM J, V353, P387, DOI 10.1042/0264-6021:3530387; Young JD, 2001, CURR TOP MEMBR, V50, P329; Zhang J, 2006, BIOCHEM J, V394, P389, DOI 10.1042/BJ20051476	39	16	16	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8496	8507		10.1074/jbc.M710433200	http://dx.doi.org/10.1074/jbc.M710433200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18199742	Green Published, hybrid			2022-12-25	WOS:000254288000048
J	Vicente, R; Villalonga, N; Calvo, M; Escalada, A; Solsona, C; Soler, C; Tamkun, MM; Felipe, A				Vicente, Ruben; Villalonga, Nuria; Calvo, Maria; Escalada, Artur; Solsona, Carles; Soler, Concepcio; Tamkun, Michael M.; Felipe, Antonio			Kv1.5 association modifies Kv1.3 traffic and membrane localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; CHANNEL SURFACE EXPRESSION; LYMPHOCYTE K+ CHANNEL; JURKAT T-LYMPHOCYTES; POTASSIUM CHANNEL; CELL-SURFACE; LIPID RAFTS; SUBUNIT COMPOSITION; ION CHANNELS; MACROPHAGES	Kv1.3 activity is determined by raft association. In addition to Kv1.3, leukocytes also express Kv1.5, and both channels control physiological responses. Because the oligomeric composition may modify the channel targeting to the membrane, we investigated heterotetrameric Kv1.3/Kv1.5 channel traffic and targeting in HEK cells. Kv1.3 and Kv1.5 generate multiple heterotetramers with differential surface expression according to the subunit composition. FRET analysis and pharmacology confirm the presence of functional hybrid channels. Raft association was evaluated by cholesterol depletion, caveolae colocalization, and lateral diffusion at the cell surface. Immunoprecipitation showed that both Kv1.3 and heteromeric channels associate with caveolar raft domains. However, homomeric Kv1.3 channels showed higher association with caveolin traffic. Moreover, FRAP analysis revealed higher mobility for hybrid Kv1.3/Kv1.5 than Kv1.3 homotetramers, suggesting that heteromers target to distinct surface microdomains. Studies with lipopolysaccharide-activated macrophages further supported that different physiological mechanisms govern Kv1.3 and Kv1.5 targeting to rafts. Our results implicate the traffic and localization of Kv1.3/Kv1.5 heteromers in the complex regulation of immune system cells.	[Vicente, Ruben; Villalonga, Nuria; Felipe, Antonio] Univ Barcelona, Mol Physiol Lab, Dept Bioquim & Biol Mol, Inst Biomed, E-08028 Barcelona, Spain; [Calvo, Maria] Univ Barcelona, Dept Biol Cellular, Inst Invest Biomed August Pi & Sunyer, E-08036 Barcelona, Spain; [Escalada, Artur; Solsona, Carles; Soler, Concepcio] Univ Barcelona, Dept Patol & Terapeut Expt, Hosp Llobregat, E-08907 Barcelona, Spain; [Tamkun, Michael M.] Colorado State Univ, Dept Biomed Sci, Ft Collins, CO 80523 USA	University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Colorado State University	Felipe, A (corresponding author), Univ Barcelona, Mol Physiol Lab, Dept Bioquim & Biol Mol, Inst Biomed, Avda Diagonal 645, E-08028 Barcelona, Spain.	afelipe@ub.edu	Felipe, Antonio/M-8297-2015; García, Rubén Vicente/L-1097-2014; Calvo, Maria/I-1872-2015; Soler, Concepció/L-1185-2014	Felipe, Antonio/0000-0002-7294-6431; García, Rubén Vicente/0000-0003-0401-4808; Calvo, Maria/0000-0002-7473-0474; Soler, Concepció/0000-0001-6502-5012	NHLBI NIH HHS [HL 49330] Funding Source: Medline; NINDS NIH HHS [NS 41542] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041542] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Beeton C, 2005, NEUROSCIENTIST, V11, P550, DOI 10.1177/1073858405278016; Bock J, 2003, BIOCHEM BIOPH RES CO, V305, P890, DOI 10.1016/S0006-291X(03)00763-0; Cogolludo A, 2006, CIRC RES, V98, P931, DOI 10.1161/01.RES.0000216858.04599.e1; Coleman SK, 1999, J NEUROCHEM, V73, P849, DOI 10.1046/j.1471-4159.1999.0730849.x; Colley BS, 2007, NEUROSCIENCE, V144, P531, DOI 10.1016/j.neuroscience.2006.09.055; El-Yazbi AF, 2006, AM J PHYSIOL-GASTR L, V291, pG1020, DOI 10.1152/ajpgi.00159.2006; Eldstrom J, 2002, FEBS LETT, V531, P529, DOI 10.1016/S0014-5793(02)03572-X; Eldstrom J, 2006, FEBS LETT, V580, P6039, DOI 10.1016/j.febslet.2006.09.069; Folco EJ, 2004, AM J PHYSIOL-HEART C, V287, pH681, DOI 10.1152/ajpheart.00152.2004; Hajdu P, 2003, PFLUG ARCH EUR J PHY, V445, P674, DOI 10.1007/s00424-002-0974-y; Holmes TC, 1996, J NEUROSCI, V16, P1581; Huang FT, 2004, J BIOL CHEM, V279, P16657, DOI 10.1074/jbc.C400046200; Isshiki M, 1999, CELL CALCIUM, V26, P201, DOI 10.1054/ceca.1999.0073; Koch RO, 1997, J BIOL CHEM, V272, P27577, DOI 10.1074/jbc.272.44.27577; Kwak YG, 1999, J BIOL CHEM, V274, P13928, DOI 10.1074/jbc.274.20.13928; LEE TE, 1994, BIOPHYS J, V66, P667, DOI 10.1016/S0006-3495(94)80840-9; Li HL, 2005, J MOL CELL CARDIOL, V39, P121, DOI 10.1016/j.yjmcc.2005.03.013; Liu YT, 2007, J CELL PHYSIOL, V211, P205, DOI 10.1002/jcp.20924; Manganas LN, 2004, BIOCHEM BIOPH RES CO, V322, P577, DOI 10.1016/j.bbrc.2004.06.182; Manganas LN, 2001, P NATL ACAD SCI USA, V98, P14055, DOI 10.1073/pnas.241403898; Manganas LN, 2000, J BIOL CHEM, V275, P29685, DOI 10.1074/jbc.M005010200; Martel J, 1998, J MEMBRANE BIOL, V161, P183, DOI 10.1007/s002329900325; Martens JR, 2000, J BIOL CHEM, V275, P7443, DOI 10.1074/jbc.275.11.7443; Martens JR, 2004, TRENDS PHARMACOL SCI, V25, P16, DOI 10.1016/j.tips.2003.11.007; Martens JR, 2001, J BIOL CHEM, V276, P8409, DOI 10.1074/jbc.M009948200; McCormack T, 1999, J BIOL CHEM, V274, P20123, DOI 10.1074/jbc.274.29.20123; MCEWEN DP, 2007, MOL PHARM; Misonou H, 2004, CRIT REV BIOCHEM MOL, V39, P125, DOI 10.1080/10409230490475417; Mullen KM, 2006, ANN NEUROL, V60, P118, DOI 10.1002/ana.20884; O'Connell KMS, 2005, J CELL SCI, V118, P2155, DOI 10.1242/jcs.02348; O'Connell KMS, 2006, J NEUROSCI, V26, P9609, DOI 10.1523/JNEUROSCI.1825-06.2006; Pannasch U, 2006, MOL CELL NEUROSCI, V33, P401, DOI 10.1016/j.mcn.2006.08.009; Panyi G, 2004, P NATL ACAD SCI USA, V101, P1285, DOI 10.1073/pnas.0307421100; Park SA, 2006, BIOCHEM BIOPH RES CO, V346, P567, DOI 10.1016/j.bbrc.2006.05.149; PAYET MD, 1992, J BIOL CHEM, V267, P18270; PHILIPSON LH, 1993, BIOCHIM BIOPHYS ACTA, V1153, P111, DOI 10.1016/0005-2736(93)90282-5; Pottosin II, 2007, PFLUG ARCH EUR J PHY, V454, P235, DOI 10.1007/s00424-007-0208-4; Prevostel C, 2000, J CELL SCI, V113, P2575; Rapacciuolo A, 2003, J BIOL CHEM, V278, P35403, DOI 10.1074/jbc.M305675200; Rybin VO, 1999, CIRC RES, V84, P980, DOI 10.1161/01.RES.84.9.980; Schilling T, 2003, PFLUG ARCH EUR J PHY, V447, P312, DOI 10.1007/s00424-003-1155-3; Schlegel A, 1998, CELL SIGNAL, V10, P457, DOI 10.1016/S0898-6568(98)00007-2; Szabo I, 2004, PFLUG ARCH EUR J PHY, V448, P304, DOI 10.1007/s00424-004-1259-4; Vicente R, 2005, J IMMUNOL, V174, P4736, DOI 10.4049/jimmunol.174.8.4736; Vicente R, 2003, J BIOL CHEM, V278, P46307, DOI 10.1074/jbc.M304388200; Vicente R, 2006, J BIOL CHEM, V281, P37675, DOI 10.1074/jbc.M605617200; Villalonga N, 2007, BIOCHEM BIOPH RES CO, V352, P913, DOI 10.1016/j.bbrc.2006.11.120; Wong W, 2004, J BIOL CHEM, V279, P444, DOI 10.1074/jbc.M304675200; Wulff H, 2003, CURR OPIN DRUG DI DE, V6, P640; Zhu J, 2003, J BIOL CHEM, V278, P25558, DOI 10.1074/jbc.M207984200	50	59	60	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8756	8764		10.1074/jbc.M708223200	http://dx.doi.org/10.1074/jbc.M708223200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18218624	Green Published, hybrid			2022-12-25	WOS:000254288000073
J	Bradley, EW; Ruan, MM; Oursler, MJ				Bradley, Elizabeth W.; Ruan, Ming M.; Oursler, Merry J.			Novel pro-survival functions of the Kruppel-like transcription factor Egr2 in promotion of macrophage colony-stimulating factor-mediated osteoclast survival downstream of the MEK/ERK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; KAPPA-B PATHWAYS; BCL-2 FAMILY; CELL-DIFFERENTIATION; DEPENDENT DEGRADATION; ACTIVATES APOPTOSIS; SIGNALING PATHWAY; BH3 DOMAIN; IN-VITRO; C-CBL	Determining the underlying mechanisms of macrophage colony-stimulating factor (M-CSF)-mediated osteoclast survival may be important in identifying novel approaches for treating excessive bone loss. This study investigates M-CSF-mediated MEK/ERK activation and identifies a downstream effector of this pathway. M-CSF activates MEK/ERK and induces MEK-dependent expression of the immediate early gene Egr2. Inhibition of either MEK1/2 or inhibition of Egr2 increases osteoclast apoptosis. In contrast, wild-type Egr2 or an Egr2 point mutant unable to bind the endogenous repressors Nab1/2 (caEgr2) suppresses basal osteoclast apoptosis and rescues osteoclasts from apoptosis induced by MEK1/2 or Egr2 inhibition. Mechanistically, Egr2 induces pro-survival Blc2 family member Mcl1 while stimulating proteasome-mediated degradation of pro-apoptotic Bim. In addition, Egr2 increased the expression of c-Cbl, the E3 ubiquitin ligase that catalyzes Bim ubiquitination. M-CSF, therefore, promotes osteoclast survival through MEK/ ERK-dependent induction of Egr2 to control the Mcl1/Bim ratio, documenting a novel function of Egr2 in promoting survival.	[Ruan, Ming M.; Oursler, Merry J.] Mayo Clin, Endocrine Res Unit, Rochester, MN 55905 USA; [Bradley, Elizabeth W.; Oursler, Merry J.] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Oursler, MJ (corresponding author), Mayo Clin, Endocrine Res Unit, 200,1st St SW, Rochester, MN 55905 USA.	oursler.merryjo@mayo.edu		Bradley, Elizabeth/0000-0002-8814-5524	NIDCR NIH HHS [R01 DE14680] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014680] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adams KW, 2007, J BIOL CHEM, V282, P6192, DOI 10.1074/jbc.M610643200; Akiyama T, 2005, BIOL PROCED ONLINE, V7, P48, DOI 10.1251/bpo105; Akiyama T, 2003, EMBO J, V22, P6653, DOI 10.1093/emboj/cdg635; Baron V, 2003, ONCOGENE, V22, P4194, DOI 10.1038/sj.onc.1206560; Bouyer P, 2007, ENDOCRINOLOGY, V148, P831, DOI 10.1210/en.2006-0547; BOYD JM, 1995, ONCOGENE, V11, P1921; Carter JH, 2007, J IMMUNOL, V178, P6796, DOI 10.4049/jimmunol.178.11.6796; Carter JH, 2007, J IMMUNOL, V178, P3038, DOI 10.4049/jimmunol.178.5.3038; Chen JR, 2005, J BIOL CHEM, V280, P4632, DOI 10.1074/jbc.M411530200; Clohessy JG, 2006, J BIOL CHEM, V281, P5750, DOI 10.1074/jbc.M505688200; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Droin NM, 2003, MOL CELL BIOL, V23, P7638, DOI 10.1128/MCB.23.21.7638-7647.2003; Ehrengruber MU, 2000, GENE, V258, P63, DOI 10.1016/S0378-1119(00)00445-5; Faccio R, 2003, J CELL BIOL, V162, P499, DOI 10.1083/jcb.200212082; FULLER K, 1993, J EXP MED, V178, P1733, DOI 10.1084/jem.178.5.1733; Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503; Glantschnig H, 2003, CELL DEATH DIFFER, V10, P1165, DOI 10.1038/sj.cdd.4401285; Hegde R, 1998, J BIOL CHEM, V273, P7783, DOI 10.1074/jbc.273.14.7783; Hsu SY, 1997, P NATL ACAD SCI USA, V94, P12401, DOI 10.1073/pnas.94.23.12401; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Inohara N, 1998, J BIOL CHEM, V273, P8705, DOI 10.1074/jbc.273.15.8705; Jaworowski A, 1996, BIOCHEM J, V320, P1011, DOI 10.1042/bj3201011; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Karst M, 2004, J CELL PHYSIOL, V200, P99, DOI 10.1002/jcp.20036; Ke JY, 2006, J BIOL CHEM, V281, P39806, DOI 10.1074/jbc.M604671200; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Laslo P, 2006, CELL, V126, P755, DOI 10.1016/j.cell.2006.06.052; Levi G, 1996, DEVELOPMENT, V122, P113; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105; Lim JH, 2007, APOPTOSIS, V12, P411, DOI 10.1007/s10495-006-0576-9; Lucerna M, 2006, CANCER RES, V66, P6708, DOI 10.1158/0008-5472.CAN-05-2732; Minn AJ, 1996, J BIOL CHEM, V271, P6306, DOI 10.1074/jbc.271.11.6306; Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333; Nakamura H, 2003, J BONE MINER RES, V18, P1198, DOI 10.1359/jbmr.2003.18.7.1198; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; O'Donovan KJ, 1999, TRENDS NEUROSCI, V22, P167, DOI 10.1016/S0166-2236(98)01343-5; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Opferman JT, 2005, SCIENCE, V307, P1101, DOI 10.1126/science.1106114; OPTERMAN JT, 2006, CELL DEATH DIFFER, V13, P1260; Oursler MJ, 2005, AM J PHYSIOL-CELL PH, V288, pC156, DOI 10.1152/ajpcell.00092.2004; Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508; RUSSO MW, 1995, P NATL ACAD SCI USA, V92, P6873, DOI 10.1073/pnas.92.15.6873; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Sato S, 2004, J BIOL CHEM, V279, P33759, DOI 10.1074/jbc.M402055200; Svaren J, 1996, MOL CELL BIOL, V16, P3545; Swaminathan G, 2006, J CELL PHYSIOL, V209, P21, DOI 10.1002/jcp.20694; TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1373, DOI 10.1210/endo-122-4-1373; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; UDAGAWA N, 1989, ENDOCRINOLOGY, V125, P1805, DOI 10.1210/endo-125-4-1805; Unoki M, 2003, ONCOGENE, V22, P2172, DOI 10.1038/sj.onc.1206222; Unoki M, 2001, ONCOGENE, V20, P4457, DOI 10.1038/sj.onc.1204608; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Weng CJ, 2005, J BIOL CHEM, V280, P10491, DOI 10.1074/jbc.M412819200; Xiao DM, 2005, CANCER RES, V65, P9934, DOI 10.1158/0008-5472.CAN-05-1830; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang T, 1996, J CELL PHYSIOL, V166, P523, DOI 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zhan QM, 1997, ONCOGENE, V14, P1031, DOI 10.1038/sj.onc.1200927; Zhuang J, 2006, CELL DEATH DIFFER, V13, P1263, DOI 10.1038/sj.cdd.4401952	65	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					8055	8064		10.1074/jbc.M709500200	http://dx.doi.org/10.1074/jbc.M709500200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18198176	hybrid			2022-12-25	WOS:000253997900080
J	Kavurma, MM; Schoppet, M; Bobryshev, YV; Khachigian, LM; Bennett, MR				Kavurma, Mary M.; Schoppet, Michael; Bobryshev, Yuri V.; Khachigian, Levon M.; Bennett, Martin R.			TRAIL stimulates proliferation of vascular smooth muscle cells via activation of NF-kappa B and induction of insulin-like growth factor-1 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS-INDUCING LIGAND; ATHEROSCLEROTIC PLAQUE; DEATH DOMAIN; LIPID RAFTS; EXPRESSION; SURVIVAL; OSTEOPROTEGERIN; GENE; SP1; IDENTIFICATION	TRAIL/Apo2L (tumor necrosis factor-related apoptosis-inducing ligand) is a multifunctional protein regulating homeostasis of the immune system, infection, autoimmune diseases, and apoptosis. However, its function in normal, nontransformed tissues is not clear. Here we show that TRAIL increases vascular smooth muscle cell (VSMC) proliferation in vitro, effects that can be blocked with neutralizing antibodies to TRAIL receptors DR4 and DcR1. In aortocoronary saphenous vein bypass grafts in vivo, TRAIL co-localizes with VSMC, proliferating cell nuclear antigen, and insulin-like growth factor type 1 receptor (IGF1R) expression but not active caspase-3. TRAIL is required for serum-inducible IGF1R expression, and antisense IGF1R inhibits TRAIL-induced VSMC proliferation. At 1 ng/ml, TRAIL stimulates IGF1R mRNA expression greater than insulin-like growth factor-1 and also activates the IGF1R promoter 7-fold. TRAIL-inducible IGF1R expression requires NF-kappa B activation. Consistent with this, ammonium pyrrolidine dithiocarbamate, a pharmacological inhibitor of NF-kappa B, blocks TRAIL-induced IGF1R expression, and p65 overexpression increases IGF1R protein levels. In addition, NF-kappa B binds a novel TRAIL-responsive element on the IGF1R promoter. Our findings suggest that the biological functions of TRAIL in VSMC extend beyond its role in promoting apoptosis. Thus, TRAIL may play an important role in atherosclerosis by regulating IGF1R expression in VSMC in an NF-kappa B-dependent manner.	[Kavurma, Mary M.; Khachigian, Levon M.] Univ New S Wales, Ctr Vasc Res, Sydney, NSW 2052, Australia; [Kavurma, Mary M.; Schoppet, Michael; Bennett, Martin R.] Univ Cambridge, Addenbrookes Hosp, Div Cardiovasc Med, Cambridge CB2 2QQ, England; [Bobryshev, Yuri V.] Univ New S Wales, Fac Med, Kensington, NSW 2052, Australia	University of New South Wales Sydney; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of New South Wales Sydney	Kavurma, MM (corresponding author), Univ New S Wales, Ctr Vasc Res, Sydney, NSW 2052, Australia.	m.kavurma@unsw.edu.au	Bobryshev, Yuri/J-2838-2013; Khachigian, Levon/AAZ-7458-2020	Khachigian, Levon/0000-0003-3446-0323; Kavurma, Mary/0000-0001-7353-0932; Bennett, Martin/0000-0002-2565-1825	British Heart Foundation [RG/04/001, PG/04/005/16497] Funding Source: Medline	British Heart Foundation(British Heart Foundation)		Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; BEITNERJOHNSON D, 1995, MOL ENDOCRINOL, V9, P1147, DOI 10.1210/me.9.9.1147; BENNETT MR, 1995, J CLIN INVEST, V95, P2266, DOI 10.1172/JCI117917; Clarke MCH, 2006, NAT MED, V12, P1075, DOI 10.1038/nm1459; Corallini F, 2007, J CELL PHYSIOL, V212, P89, DOI 10.1002/jcp.21006; DU J, 1995, CIRC RES, V76, P963, DOI 10.1161/01.RES.76.6.963; Ehrhardt H, 2003, ONCOGENE, V22, P3842, DOI 10.1038/sj.onc.1206520; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Gochuico BR, 2000, AM J PHYSIOL-LUNG C, V278, pL1045, DOI 10.1152/ajplung.2000.278.5.L1045; Griffith TS, 1998, J IMMUNOL, V161, P2833; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Idelman G, 2003, J BIOL CHEM, V278, P3474, DOI 10.1074/jbc.M211606200; Kavurma MM, 2007, BIOCHEM J, V407, P79, DOI 10.1042/BJ20070380; Kavurma MM, 2001, J BIOL CHEM, V276, P4964, DOI 10.1074/jbc.M009251200; LI SW, 1994, J BIOL CHEM, V269, P32558; Lim HJ, 2004, BIOCHEM BIOPH RES CO, V325, P1106, DOI 10.1016/j.bbrc.2004.10.175; Ma YW, 2006, ENDOCRINOLOGY, V147, P1256, DOI 10.1210/en.2005-0888; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Michowitz Y, 2005, J AM COLL CARDIOL, V45, P1018, DOI 10.1016/j.jacc.2004.12.065; Morel J, 2005, J BIOL CHEM, V280, P15709, DOI 10.1074/jbc.M414469200; Muppidi JR, 2004, NAT IMMUNOL, V5, P182, DOI 10.1038/ni1024; Niessner A, 2006, CIRCULATION, V114, P2482, DOI 10.1161/CIRCULATIONAHA.106.642801; Okura Y, 2001, J MOL CELL CARDIOL, V33, P1777, DOI 10.1006/jmcc.2001.1441; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Patel VA, 2001, CIRC RES, V88, P895, DOI 10.1161/hh0901.090305; Petersohn D, 1996, EUR J BIOCHEM, V239, P827, DOI 10.1111/j.1432-1033.1996.0827u.x; Robertson NM, 2002, J IMMUNOL, V169, P5986, DOI 10.4049/jimmunol.169.10.5986; Sato K, 2006, J EXP MED, V203, P239, DOI 10.1084/jem.20051062; Schoppet M, 2006, ATHEROSCLEROSIS, V184, P446, DOI 10.1016/j.atherosclerosis.2005.10.028; Schoppet M, 2004, J CLIN ENDOCR METAB, V89, P4104, DOI 10.1210/jc.2003-031432; Secchiero P, 2003, CIRCULATION, V107, P2250, DOI 10.1161/01.CIR.0000062702.60708.C4; Secchiero P, 2004, CELL MOL LIFE SCI, V61, P1965, DOI 10.1007/s00018-004-4197-6; Secchiero P, 2004, NEOPLASIA, V6, P364, DOI 10.1593/neo.03421; Secchiero P, 2006, CIRCULATION, V114, P1522, DOI 10.1161/CIRCULATIONAHA.106.643841; Song JH, 2007, CANCER RES, V67, P6946, DOI 10.1158/0008-5472.CAN-06-3896; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Zhang J, 2001, J BIOL CHEM, V276, P29815, DOI 10.1074/jbc.M103838200; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681	42	75	77	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7754	7762		10.1074/jbc.M706927200	http://dx.doi.org/10.1074/jbc.M706927200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18178561	hybrid			2022-12-25	WOS:000253997900052
J	Noguchi, T; Ishii, K; Fukutomi, H; Naguro, I; Matsuzawa, A; Takeda, K; Ichijo, H				Noguchi, Takuya; Ishii, Ken; Fukutomi, Hisashi; Naguro, Isao; Matsuzawa, Atsushi; Takeda, Kohsuke; Ichijo, Hidenori			Requirement of reactive oxygen species-dependent activation of ASK1-p38 MAPK pathway for extracellular ATP-induced apoptosis in macrophage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATING KINASE-1; TUMOR-NECROSIS-FACTOR; INDUCED CELL-DEATH; P2X(7) RECEPTOR; NADPH OXIDASE; NUCLEOTIDE RECEPTOR; DENDRITIC CELLS; STRESS; INDUCTION; MYCOBACTERIA	Extracellular ATP, an autocrine or paracrine intercellular transmitter, is known to induce apoptosis in macrophages. However, the precise signaling mechanisms of ATP-induced apoptosis remain to be elucidated. Here we showed that activation of p38 mitogen-activated protein kinase (MAPK) plays a critical role in ATP-induced apoptosis. p38 activation and apoptosis in macrophages were induced by ATP. ATP-induced apoptosis was mediated in part by production of reactive oxygen species (ROS) derived from NOX2/gp91(phox), a component of the NADPH oxidase complex expressed in macrophages and neutrophils. Furthermore, ATP-induced ROS generation, p38 activation, and apoptosis were almost completely inhibited by selective P2X(7) receptor antagonists. We also found that ATP-induced apoptosis were diminished in ASK1-deficient macrophages accompanied by the lack of p38 activation. These results demonstrate that ROS-mediated activation of the ASK1-p38 MAPK pathway downstream of P2X(7) receptor is required for ATP-induced apoptosis in macrophages.	[Ichijo, Hidenori] Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Cell Signaling, Ctr Excellence Program,Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Japan Sci & Technol Corp, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; Japan Science & Technology Agency (JST); University of Tokyo	Ichijo, H (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Cell Signaling, Ctr Excellence Program,Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	ichijo@mol.f.u-tokyo.ac.jp	Noguchi, Takuya/T-6767-2019; Naguro, Isao/P-1337-2019; Matsuzawa, Atsushi/GLU-1387-2022	Noguchi, Takuya/0000-0001-6187-6645; Naguro, Isao/0000-0002-0338-8026; Ichijo, Hidenori/0000-0002-5005-6438; Matsuzawa, Atsushi/0000-0001-8303-3905; Takeda, Kohsuke/0000-0002-8359-8399				Andreyev AI, 2005, BIOCHEMISTRY-MOSCOW+, V70, P200, DOI 10.1007/s10541-005-0102-7; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; BOKOCH GM, 1994, CURR OPIN CELL BIOL, V6, P212, DOI 10.1016/0955-0674(94)90138-4; Chandel NS, 2001, J BIOL CHEM, V276, P42728, DOI 10.1074/jbc.M103074200; Cheewatrakoolpong B, 2005, BIOCHEM BIOPH RES CO, V332, P17, DOI 10.1016/j.bbrc.2005.04.087; Coutinho-Silva R, 1999, AM J PHYSIOL-CELL PH, V276, pC1139, DOI 10.1152/ajpcell.1999.276.5.C1139; Cruz CM, 2007, J BIOL CHEM, V282, P2871, DOI 10.1074/jbc.M608083200; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Donnelly-Roberts DL, 2004, J PHARMACOL EXP THER, V308, P1053, DOI 10.1124/jpet.103.059600; Fernando SL, 2005, J INFECT DIS, V192, P149, DOI 10.1086/430622; Ferrari D, 1997, J IMMUNOL, V159, P1451; Ferrari D, 1999, FEBS LETT, V447, P71, DOI 10.1016/S0014-5793(99)00270-7; Hentze H, 2003, CELL DEATH DIFFER, V10, P956, DOI 10.1038/sj.cdd.4401264; Hibell AD, 2001, J PHARMACOL EXP THER, V296, P947; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; Humphreys BD, 2000, J BIOL CHEM, V275, P26792; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kim YS, 2007, MOL CELL, V26, P675, DOI 10.1016/j.molcel.2007.04.021; Kornfeld H, 1999, CELL DEATH DIFFER, V6, P71, DOI 10.1038/sj.cdd.4400454; Kusner DJ, 2000, J IMMUNOL, V164, P379, DOI 10.4049/jimmunol.164.1.379; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lammas DA, 1997, IMMUNITY, V7, P433, DOI 10.1016/S1074-7613(00)80364-7; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; Nihei OK, 2000, BLOOD, V96, P996, DOI 10.1182/blood.V96.3.996.015k02_996_1005; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Noguchi T, 2005, J BIOL CHEM, V280, P37033, DOI 10.1074/jbc.M506771200; North RA, 1997, CURR OPIN NEUROBIOL, V7, P346, DOI 10.1016/S0959-4388(97)80062-1; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Pfeiffer ZA, 2004, J LEUKOCYTE BIOL, V75, P1173, DOI 10.1189/jlb.1203648; Pfeiffer ZA, 2007, FREE RADICAL BIO MED, V42, P1506, DOI 10.1016/j.freeradbiomed.2007.02.010; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Saunders BM, 2003, J IMMUNOL, V171, P5442, DOI 10.4049/jimmunol.171.10.5442; Setsukinai K, 2003, J BIOL CHEM, V278, P3170, DOI 10.1074/jbc.M209264200; STOLK J, 1994, AM J RESP CELL MOL, V11, P95, DOI 10.1165/ajrcmb.11.1.8018341; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Suzuki T, 2004, J NEUROSCI, V24, P1, DOI 10.1523/JNEUROSCI.3792-03.2004; Takeda K, 2003, CELL STRUCT FUNCT, V28, P23; Takeda K, 2008, ANNU REV PHARMACOL, V48, P199, DOI 10.1146/annurev.pharmtox.48.113006.094606; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Virginio C, 1999, J PHYSIOL-LONDON, V519, P335, DOI 10.1111/j.1469-7793.1999.0335m.x; ZANOVELLO P, 1990, J IMMUNOL, V145, P1545; Zorov DB, 2006, BBA-BIOENERGETICS, V1757, P509, DOI 10.1016/j.bbabio.2006.04.029	44	150	154	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7657	7665		10.1074/jbc.M708402200	http://dx.doi.org/10.1074/jbc.M708402200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18211888	hybrid			2022-12-25	WOS:000253997900041
J	Saunee, NA; Williams, SR; Bryan, DA; Schluchter, WM				Saunee, Nicolle A.; Williams, Shervonda R.; Bryan, Donald A.; Schluchter, Wendy M.			Biogenesis of phycobiliproteins - II. CpcS-I and CpcU comprise the heterodimeric bilin lyase that attaches phycocyanobilin to Cys-82 of beta-phycocyanin and Cys-81 of allophycocyanin subunits in synechococcus sp PCC 7002	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE ANALYSIS; C-PHYCOCYANIN; ENERGY-TRANSFER; MASTIGOCLADUS-LAMINOSUS; LINKER-POLYPEPTIDE; ALPHA-SUBUNITS; CYANOBACTERIAL PHYCOBILISOMES; MOLECULAR CHARACTERIZATION; AGMENELLUM-QUADRUPLICATUM; CHROMOPHORE ATTACHMENT	The Synechococcus sp. PCC 7002 genome encodes three genes, denoted cpcS-I, cpcU, cpcV, with sequence similarity to cpeS. CpcS-I copurified with His(6)-tagged (HT) CpcU as a heterodimer, CpcSU. When CpcSU was assayed for bilin lyase activity in vitro with phycocyanobilin (PCB) and apophycocyanin, the reaction product had an absorbance maximum of 622 nm and was highly fluorescent (lambda(max) = 643 nm). In control reactions with PCB and apophycocyanin, the products had absorption maxima at 635 nm and very low fluorescence yields, indicating they contained the more oxidized mesobiliverdin (Arciero, D. M., Bryant, D. A., and Glazer, A. N. (1988) J. Biol. Chem. 263, 18343-18349). Tryptic peptide mapping showed that the CpcSU-dependent reaction product had one major PCB-containing peptide that contained the PCB binding site Cys-82. The CpcSU lyase was also tested with recombinant apoHT-allophycocyanin (aporHT-AP) and PCB in vitro. AporHT-AP formed an ApcA/ ApcB heterodimer with an apparent mass of similar to 27 kDa. When aporHT-AP was incubated with PCB and CpcSU, the product had an absorbance maximum of 614 nm and a fluorescence emission maximum at 636 nm, the expected maxima for monomeric holo-AP. When no enzyme or CpcS-I or CpcU was added alone, the products had absorbance maxima between 645 and 647 nm and were not fluorescent. When these reaction products were analyzed by gel electrophoresis and zinc-enhanced fluorescence emission, only the reaction products from CpcSU had PCB attached to both AP subunits. Therefore, CpcSU is the bilin lyase-responsible for attachment of PCB to Cys-82 of CpcB and Cys-81 of ApcA and ApcB.	[Saunee, Nicolle A.; Williams, Shervonda R.; Schluchter, Wendy M.] Univ New Orleans, Dept Biol Sci, New Orleans, LA 70148 USA; [Bryan, Donald A.] Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	University of Louisiana System; University of New Orleans; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Schluchter, WM (corresponding author), Univ New Orleans, Dept Biol Sci, New Orleans, LA 70148 USA.	wschluch@uno.edu	Schluchter, Wendy/G-9662-2013		NIGMS NIH HHS [GM-31625] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031625] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCIERO DM, 1988, J BIOL CHEM, V263, P18343; BECK WF, 1992, J PHYS CHEM-US, V96, P4658, DOI 10.1021/j100190a094; BREJC K, 1995, J MOL BIOL, V249, P424, DOI 10.1006/jmbi.1995.0307; Bryant D.A., 1988, LIGHT ENERGY TRANSDU, P62; BRYANT DA, 1990, ARCH MICROBIOL, V153, P550, DOI 10.1007/BF00245264; BRYANT DA, 1991, PHOTOSYNTHETIC APPAR, P255; CAPUANO V, 1991, J BIOL CHEM, V266, P7239; Cobley JG, 2002, MOL MICROBIOL, V44, P1517, DOI 10.1046/j.1365-2958.2002.02966.x; DEBRECZENY MP, 1993, J PHYS CHEM-US, V97, P9852, DOI 10.1021/j100140a050; DELORIMIER R, 1990, BIOCHIM BIOPHYS ACTA, V1019, P29, DOI 10.1016/0005-2728(90)90121-J; DELORIMIER R, 1990, ARCH MICROBIOL, V153, P541, DOI 10.1007/BF00245263; DELORIMIER R, 1984, P NATL ACAD SCI-BIOL, V81, P7946; Dolganov N, 1999, J BACTERIOL, V181, P610, DOI 10.1128/JB.181.2.610-617.1999; FAIRCHILD CD, 1994, J BIOL CHEM, V269, P8686; FAIRCHILD CD, 1992, P NATL ACAD SCI USA, V89, P7017, DOI 10.1073/pnas.89.15.7017; Frankenberg N, 2003, J BIOL CHEM, V278, P9219, DOI 10.1074/jbc.M211643200; Frankenberg N, 2001, PLANT CELL, V13, P965, DOI 10.1105/tpc.13.4.965; GINDT YM, 1992, J PHOTOCH PHOTOBIO B, V15, P75, DOI 10.1016/1011-1344(92)87007-V; GINDT YM, 1994, BBA-BIOENERGETICS, V1186, P153, DOI 10.1016/0005-2728(94)90174-0; GLAZER AN, 1989, J BIOL CHEM, V264, P1; GLAZER AN, 1973, J BIOL CHEM, V248, P659; Gomez-Lojero C, 2003, BIOCHEMISTRY-US, V42, P13800, DOI 10.1021/bi0346998; GYSI JR, 1979, BIOCHEM J, V181, P577, DOI 10.1042/bj1810577; Hu IC, 2006, BIOCHEMISTRY-US, V45, P7092, DOI 10.1021/bi052067a; JUNG LJ, 1995, J BIOL CHEM, V270, P12877, DOI 10.1074/jbc.270.21.12877; Kahn K, 1997, J BACTERIOL, V179, P998, DOI 10.1128/jb.179.4.998-1006.1997; Kohchi T, 2001, PLANT CELL, V13, P425, DOI 10.1105/tpc.13.2.425; Li H, 2002, ARCH MICROBIOL, V178, P256, DOI 10.1007/s00203-002-0446-y; MAXSON P, 1989, BIOCHIM BIOPHYS ACTA, V977, P40, DOI 10.1016/S0005-2728(89)80007-6; Miller CA, 2007, THESIS U NEW ORLEANS; MIMURO M, 1986, BIOCHIM BIOPHYS ACTA, V848, P155, DOI 10.1016/0005-2728(86)90037-X; Reuter W, 1999, P NATL ACAD SCI USA, V96, P1363, DOI 10.1073/pnas.96.4.1363; SAUER K, 1987, PHOTOCHEM PHOTOBIOL, V46, P427, DOI 10.1111/j.1751-1097.1987.tb04790.x; SCHIRMER T, 1986, J MOL BIOL, V188, P651, DOI 10.1016/S0022-2836(86)80013-4; SCHIRMER T, 1987, J MOL BIOL, V196, P677, DOI 10.1016/0022-2836(87)90040-4; SCHIRMER T, 1987, BIOCHIM BIOPHYS ACTA, V893, P379, DOI 10.1016/0005-2728(87)90090-9; SCHLUCHTER WM, 1992, BIOCHEMISTRY-US, V31, P3092, DOI 10.1021/bi00127a009; SCHLUCHTER WM, 1994, THESIS PENNSYLVANIA; Shen G, 2008, J BIOL CHEM, V283, P7503, DOI 10.1074/jbc.M708164200; Shen G, 2006, J BIOL CHEM, V281, P17768, DOI 10.1074/jbc.M602563200; Sidler W. A., 1994, MOL BIOL CYANOBACTER, P139, DOI [10.1007/978-94-011-0227-8_7, DOI 10.1007/978-94-011-0227-8_7]; SWANSON RV, 1992, J BIOL CHEM, V267, P16146; Zhao KH, 2007, P NATL ACAD SCI USA, V104, P14300, DOI 10.1073/pnas.0706209104; Zhao KH, 2006, J BIOL CHEM, V281, P8573, DOI 10.1074/jbc.M513796200; Zhao KH, 2005, BIOCHEMISTRY-US, V44, P8126, DOI 10.1021/bi0500168; Zhao KH, 2005, BBA-BIOENERGETICS, V1706, P81, DOI 10.1016/j.bbabio.2004.09.008; Zhao KH, 2004, BBA-BIOENERGETICS, V1657, P131, DOI 10.1016/j.bbabio.2004.04.010; Zhao KH, 2000, FEBS LETT, V469, P9, DOI 10.1016/S0014-5793(00)01245-X; ZHOU J, 1992, THESIS PENNSYLVANIA; ZHOU JH, 1992, J BIOL CHEM, V267, P16138	50	54	57	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7513	7522		10.1074/jbc.M708165200	http://dx.doi.org/10.1074/jbc.M708165200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18199753	Green Published, hybrid			2022-12-25	WOS:000253997900026
J	Blount, AL; Vaughan, JM; Vale, WW; Bilezikjian, LM				Blount, Amy L.; Vaughan, Joan M.; Vale, Wylie W.; Bilezikjian, Louise M.			A smad-binding element in intron 1 participates in activin-dependent regulation of the follistatin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICLE-STIMULATING-HORMONE; GONADOTROPIN-RELEASING-HORMONE; RIBONUCLEIC-ACID LEVELS; GNRH RECEPTOR GENE; RAT ESTROUS-CYCLE; BETA-SUBUNIT GENE; TGF-BETA; PITUITARY FOLLISTATIN; TRANSCRIPTION ACTIVATION; SIGNAL-TRANSDUCTION	Follistatins exert critical autocrine or paracrine control in many tissues by binding and bio-neutralizing activin and several other transforming growth factor-beta ligands. In the pituitary, activin acts locally to induce follistatin expression and thus modulate its own actions. This local feedback loop safeguards against excessive activin signaling and maintains the necessary balance of activin and follistatin tone. To better understand the mechanisms underlying the activation of follistatin by activin A, follistatin transcription was evaluated in gonadotrope-derived alpha T3-1 cells. Transient transfection experiments established that follistatin-luciferase plasmids that incorporate up to 2.86 kb of the upstream region of the rat follistatin gene are not induced by activin A in alpha T3-1 cells. On the other hand, plasmids that incorporate intron 1 are responsive to activin A and induced by a constitutively active form of ALK4. These experiments ultimately identified a conserved Smad-binding element (SBE1) in intron 1, between +1791 and +1795. In alpha T3-1 cells treated with activin A, SBE1 preferentially recruits Smad3, but not Smad2, and mediates Smad3-dependent activation of follistatin transcription. shRNA knockdown of endogenous Smad3 in these cells compromises SBE1-mediated transcription in response to activin A and interferes with its ability to positively regulate follistatin mRNA levels. The findings of the current work illustrate the critical role of intron 1 of the follistatin gene in mediating Smad-dependent effects of activin and regulating the expression level of this gene in some cell types, such as pituitary cells of gonadotrope lineage.	[Blount, Amy L.; Vaughan, Joan M.; Vale, Wylie W.; Bilezikjian, Louise M.] Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA	Salk Institute	Bilezikjian, LM (corresponding author), Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	bilezikjian@salk.edu			NICHD NIH HHS [HD46941, HD13527, R01 HD046941] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD046941] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD013527] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Asahara H, 2001, MOL CELL BIOL, V21, P7892, DOI 10.1128/MCB.21.23.7892-7900.2001; Attisano L, 1996, MOL CELL BIOL, V16, P1066; Bailey JS, 2004, MOL ENDOCRINOL, V18, P1158, DOI 10.1210/me.2003-0442; Bartholin L, 2002, ONCOGENE, V21, P2227, DOI 10.1038/sj.onc.1205294; Bartholin L, 2001, ONCOGENE, V20, P5409, DOI 10.1038/sj.onc.1204720; Bernard DJ, 2004, MOL ENDOCRINOL, V18, P606, DOI 10.1210/me.2003-0264; Besecke LM, 1997, ENDOCRINOLOGY, V138, P2841, DOI 10.1210/en.138.7.2841; Bilezikjian LM, 1996, ENDOCRINOLOGY, V137, P4277, DOI 10.1210/en.137.10.4277; Bilezikjian LM, 2003, ENDOCRINOLOGY, V144, P732, DOI 10.1210/en.2002-220703; BILEZIKJIAN LM, 1993, ENDOCRINOLOGY, V133, P2554, DOI 10.1210/en.133.6.2554; Bilezikjian LM, 2006, REPRODUCTION, V132, P207, DOI 10.1530/rep.1.01073; Burger LL, 2004, J MOL ENDOCRINOL, V33, P559, DOI 10.1677/jme.1.01600; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Chang H, 2002, ENDOCR REV, V23, P787, DOI 10.1210/er.2002-0003; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Danila DC, 2000, J CLIN ENDOCR METAB, V85, P1009, DOI 10.1210/jc.85.3.1009; de Groot E, 2000, MOL BIOL REP, V27, P129, DOI 10.1023/A:1007159031000; DePaolo LV, 1997, P SOC EXP BIOL MED, V214, P328; DEPAOLO LV, 1993, ENDOCRINOLOGY, V132, P2221, DOI 10.1210/en.132.5.2221; Ding Y, 2005, RNA, V11, P1157, DOI 10.1261/rna.2500605; Ding Y, 2004, NUCLEIC ACIDS RES, V32, pW135, DOI 10.1093/nar/gkh449; ESCH FS, 1987, MOL ENDOCRINOL, V1, P849, DOI 10.1210/mend-1-11-849; Ethier JF, 2001, REPRODUCTION, V121, P667, DOI 10.1530/rep.0.1210667; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Guo QX, 1998, MOL ENDOCRINOL, V12, P96, DOI 10.1210/mend.12.1.0053; HALVORSON LM, 1994, ENDOCRINOLOGY, V134, P1247, DOI 10.1210/en.134.3.1247; Harrington AE, 2006, EMBO J, V25, P1035, DOI 10.1038/sj.emboj.7601000; Harrison CA, 2005, TRENDS ENDOCRIN MET, V16, P73, DOI 10.1016/j.tem.2005.01.003; HORN F, 1991, MOL ENDOCRINOL, V5, P347, DOI 10.1210/mend-5-3-347; Jeong KH, 2004, MOL CELL BIOL, V24, P6127, DOI 10.1128/MCB.24.14.6127-6139.2004; KAISER UB, 1992, ENDOCRINOLOGY, V130, P3048, DOI 10.1210/en.130.5.3048; KAISER UB, 1993, CLIN INVESTIG, V91, P25223; LEBRUN JJ, 1997, INHIBIN ACTIVIN FOLL, P1; Liu B, 1999, MOL CELL BIOL, V19, P424; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; MATZUK MM, 1995, NATURE, V374, P360, DOI 10.1038/374360a0; McGillivray SM, 2005, ENDOCRINOLOGY, V146, P2180, DOI 10.1210/en.2004-1566; MICHEL U, 1993, MOL CELL ENDOCRINOL, V91, P1, DOI 10.1016/0303-7207(93)90248-I; MICHEL U, 1990, BIOCHEM BIOPH RES CO, V173, P401, DOI 10.1016/S0006-291X(05)81072-1; MIYANAGA K, 1993, MOL CELL ENDOCRINOL, V92, P99, DOI 10.1016/0303-7207(93)90080-4; Muttukrishna S, 2004, MOL CELL ENDOCRINOL, V225, P45, DOI 10.1016/j.mce.2004.02.012; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; Norris DP, 2002, DEVELOPMENT, V129, P3455; Norwitz ER, 2002, J BIOL CHEM, V277, P37469, DOI 10.1074/jbc.M206571200; Osada SI, 2000, DEVELOPMENT, V127, P2503; Penabad JL, 1996, J CLIN ENDOCR METAB, V81, P3397, DOI 10.1210/jc.81.9.3397; Phillips DJ, 1998, FRONT NEUROENDOCRIN, V19, P287, DOI 10.1006/frne.1998.0169; Schmierer B, 2007, NAT REV MOL CELL BIO, V8, P970, DOI 10.1038/nrm2297; Schneyer A, 2004, MOL CELL ENDOCRINOL, V225, P25, DOI 10.1016/j.mce.2004.02.009; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; SHIMASAKI S, 1989, MOL ENDOCRINOL, V3, P651, DOI 10.1210/mend-3-4-651; SHIMASAKI S, 1988, P NATL ACAD SCI USA, V85, P4218, DOI 10.1073/pnas.85.12.4218; SHIMONAKA M, 1991, ENDOCRINOLOGY, V128, P3313, DOI 10.1210/endo-128-6-3313; Sidis Y, 2006, ENDOCRINOLOGY, V147, P3586, DOI 10.1210/en.2006-0089; SUGINO K, 1993, J BIOL CHEM, V268, P15579; Suszko MI, 2005, MOL ENDOCRINOL, V19, P1849, DOI 10.1210/me.2004-0475; Thompson TB, 2005, DEV CELL, V9, P535, DOI 10.1016/j.devcel.2005.09.008; Tiscornia G, 2006, NAT PROTOC, V1, P234, DOI 10.1038/nprot.2006.36; Tiscornia G, 2006, NAT PROTOC, V1, P241, DOI 10.1038/nprot.2006.37; VALE WW, 1990, PEPTIDE GROWTH FACTO, V95, P211; Watanabe M, 2002, DEV DYNAM, V225, P448, DOI 10.1002/dvdy.10176; Welt C, 2002, EXP BIOL MED, V227, P724, DOI 10.1177/153537020222700905; West BE, 2004, ENDOCRINOLOGY, V145, P4866, DOI 10.1210/en.2004-0598; Winters SJ, 1997, ENDOCRINOLOGY, V138, P4324, DOI 10.1210/en.138.10.4324; Winters SJ, 2007, MOL CELL ENDOCRINOL, V271, P45, DOI 10.1016/j.mce.2007.03.006; Zakaria MM, 2002, MOL ENDOCRINOL, V16, P1840, DOI 10.1210/me.2002-0088; Zhang H, 2006, MOL ENDOCRINOL, V20, P2909, DOI 10.1210/me.2006-0109; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	70	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					7016	7026		10.1074/jbc.M709502200	http://dx.doi.org/10.1074/jbc.M709502200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18184649	hybrid			2022-12-25	WOS:000253779600046
J	Kroth, PG; Chiovitti, A; Gruber, A; Martin-Jezequel, V; Mock, T; Parker, MS; Stanley, MS; Kaplan, A; Caron, L; Weber, T; Maheswari, U; Armbrust, EV; Bowler, C				Kroth, Peter G.; Chiovitti, Anthony; Gruber, Ansgar; Martin-Jezequel, Veronique; Mock, Thomas; Parker, Micaela Schnitzler; Stanley, Michele S.; Kaplan, Aaron; Caron, Lise; Weber, Till; Maheswari, Uma; Armbrust, E. Virginia; Bowler, Chris			A Model for Carbohydrate Metabolism in the Diatom Phaeodactylum tricornutum Deduced from Comparative Whole Genome Analysis	PLOS ONE			English	Article							CO2 CONCENTRATING MECHANISMS; BETA-CARBONIC ANHYDRASE; SKELETONEMA-COSTATUM; MARINE DIATOMS; THALASSIOSIRA-PSEUDONANA; INORGANIC CARBON; FUNCTIONAL-CHARACTERIZATION; MOLECULAR CHARACTERIZATION; MYOINOSITOL DEHYDROGENASE; CYANIDIOSCHYZON-MEROLAE	Background. Diatoms are unicellular algae responsible for approximately 20% of global carbon fixation. Their evolution by secondary endocytobiosis resulted in a complex cellular structure and metabolism compared to algae with primary plastids. Methodology/Principal Findings. The whole genome sequence of the diatom Phaeodactylum tricornutum has recently been completed. We identified and annotated genes for enzymes involved in carbohydrate pathways based on extensive EST support and comparison to the whole genome sequence of a second diatom, Thalassiosira pseudonana. Protein localization to mitochondria was predicted based on identified similarities to mitochondrial localization motifs in other eukaryotes, whereas protein localization to plastids was based on the presence of signal peptide motifs in combination with plastid localization motifs previously shown to be required in diatoms. We identified genes potentially involved in a C4-like photosynthesis in P. tricornutum and, on the basis of sequence-based putative localization of relevant proteins, discuss possible differences in carbon concentrating mechanisms and CO2 fixation between the two diatoms. We also identified genes encoding enzymes involved in photorespiration with one interesting exception: glycerate kinase was not found in either P. tricornutum or T. pseudonana. Various Calvin cycle enzymes were found in up to five different isoforms, distributed between plastids, mitochondria and the cytosol. Diatoms store energy either as lipids or as chrysolaminaran (a beta-1,3-glucan) outside of the plastids. We identified various beta-glucanases and large membrane-bound glucan synthases. Interestingly most of the glucanases appear to contain C-terminal anchor domains that may attach the enzymes to membranes. Conclusions/Significance. Here we present a detailed synthesis of carbohydrate metabolism in diatoms based on the genome sequences of Thalassiosira pseudonana and Phaeodactylum tricornutum. This model provides novel insights into acquisition of dissolved inorganic carbon and primary metabolic pathways of carbon in two different diatoms, which is of significance for an improved understanding of global carbon cycles.	[Kroth, Peter G.; Gruber, Ansgar; Weber, Till] Univ Konstanz, Fachbereich Biol, Constance, Germany; [Chiovitti, Anthony] Univ Melbourne, Sch Botany, Melbourne, Vic, Australia; [Martin-Jezequel, Veronique] Univ Nantes, Fac Sci, EA 2663, Nantes, France; [Mock, Thomas; Parker, Micaela Schnitzler; Armbrust, E. Virginia] Univ Washington, Sch Oceanogr, Seattle, WA USA; [Stanley, Michele S.] Dunstaffnage Marine Lab, Scottish Assoc Marine Sci, Oban, Argyll, Scotland; [Kaplan, Aaron] Hebrew Univ Jerusalem, Dept Plants & Env Sci, Jerusalem, Israel; [Caron, Lise] Univ Nantes, INSERM, Fac Med, U533, Nantes, France; [Maheswari, Uma; Bowler, Chris] Ecole Normale Super, CNRS, UMR8186, Paris, France; [Maheswari, Uma; Bowler, Chris] Villa Comun, Stazione Zool, Cell Signal Lab, Naples, Italy	University of Konstanz; University of Melbourne; Nantes Universite; University of Washington; University of Washington Seattle; UHI Millennium Institute; Hebrew University of Jerusalem; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Stazione Zoologica Anton Dohrn di Napoli	Kroth, PG (corresponding author), Univ Konstanz, Fachbereich Biol, Constance, Germany.	Peter.Kroth@unikonstanz.de	Gruber, Ansgar/B-9587-2008; Stanley, Michele S/D-5859-2013; Bowler, Chris/AAC-6256-2019; Kaplan, Aaron/GLN-5655-2022; Mock, Thomas/A-3127-2008; Kroth, Peter G/A-9728-2008	Gruber, Ansgar/0000-0002-5876-4391; Mock, Thomas/0000-0001-9604-0362; Kroth, Peter G/0000-0003-4734-8955; Parker, Micaela/0000-0003-1007-4612; Bowler, Chris/0000-0003-3835-6187; Shunmugam, Uma/0000-0001-7007-9234; martin-jezequel, veronique/0000-0002-6633-1334; Kaplan, Aaron/0000-0002-0815-5731; Stanley, Michele/0000-0002-2348-3231	Deutsche Forschungsgemeinschaft [1661/3-2, 1661/4-1]; University of Konstanz; Australian Research Council [LP0454982]; Defence Science and Technology Organization of the Australian Department of Defence; University of Melbourne; EU Sixth Framework Programme "Diatomics" [LSHG-CT-2004-512035]; University of Nantes; CNRS; German Academic Exchange Service (DAAD). [fellowship]; PNW Center for Human Health and Ocean Studies; NIH/National Institute of Environmental Health [P50 ES012762]; National Science Foundation [OCE-0434087]; Gordon and Betty Moore Foundation; Pacific Northwest Center for Human Health and Ocean Sciences; Marine Microbiology Investigator Award; US Department of Energy; Genoscope; Agence Nationale de la Recherche (ANR France); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P50ES012762] Funding Source: NIH RePORTER	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); University of Konstanz; Australian Research Council(Australian Research Council); Defence Science and Technology Organization of the Australian Department of Defence; University of Melbourne(University of Melbourne); EU Sixth Framework Programme "Diatomics"; University of Nantes; CNRS(Centre National de la Recherche Scientifique (CNRS)); German Academic Exchange Service (DAAD).(Deutscher Akademischer Austausch Dienst (DAAD)); PNW Center for Human Health and Ocean Studies; NIH/National Institute of Environmental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); Gordon and Betty Moore Foundation(Gordon and Betty Moore Foundation); Pacific Northwest Center for Human Health and Ocean Sciences; Marine Microbiology Investigator Award; US Department of Energy(United States Department of Energy (DOE)); Genoscope; Agence Nationale de la Recherche (ANR France)(French National Research Agency (ANR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	PGK is supported by the Deutsche Forschungsgemeinschaft (DFG, projects 1661/3-2, 1661/4-1) and the University of Konstanz. AC acknowledges funding from the Australian Research Council and industry partner, Akzo Nobel, Gateshead, UK (Industry Linkage Grant #LP0454982), as well as financial assistance from the Defence Science and Technology Organization of the Australian Department of Defence and the University of Melbourne (MRGS scheme). VMJ was supported by EU Sixth Framework Programme "Diatomics" (LSHG-CT-2004-512035), the University of Nantes and CNRS. TM was supported by a fellowship within the Postdoc program of the German Academic Exchange Service (DAAD). MSP is supported in part by the PNW Center for Human Health and Ocean Studies (NIH/National Institute of Environmental Health: P50 ES012762 and National Science Foundation: OCE-0434087) and by the Gordon and Betty Moore Foundation. MS was supported by the EC Sixth Framework Programme "Diatomics" (LSHG-CT-2004-512035). LC was supported by CNRS. EVA is supported by the Pacific Northwest Center for Human Health and Ocean Sciences (National Institute of Environmental Health: P50 ES012762 and National Science Foundation: OCE-0434087) and a Gordon and Betty Moore Foundation Marine Microbiology Investigator Award. Diatom whole genome sequencing was funded by the US Department of Energy and was performed at the Joint Genome Institute (Walnut Creek, CA, USA).The generation and sequencing of P. tricornutum ESTs was coordinated by CB and was performed at Genoscope (Evry, France) as a part of projects funded by Genoscope, the EU Sixth Framework Programme (Diatomics; LSHG-CT-2004-512035), and the Agence Nationale de la Recherche (ANR; France).	Alekseeva SA, 2005, APPL BIOCHEM MICRO+, V41, P185, DOI 10.1007/s10438-005-0033-5; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Armbrust EV, 2004, SCIENCE, V306, P79, DOI 10.1126/science.1101156; Badger MR, 2006, J EXP BOT, V57, P249, DOI 10.1093/jxb/eri286; Badger MR, 1998, CAN J BOT, V76, P1052, DOI 10.1139/b98-074; Ball SG, 2003, ANNU REV PLANT BIOL, V54, P207, DOI 10.1146/annurev.arplant.54.031902.134927; Barbier G, 2005, PLANT PHYSIOL, V137, P460, DOI 10.1104/pp.104.051169; BEARDALL J, 1990, Marine Microbial Food Webs, V4, P7; BEARDALL J, 1989, AQUAT BOT, V34, P105, DOI 10.1016/0304-3770(89)90052-1; Behrenfeld MJ, 1996, NATURE, V383, P508, DOI 10.1038/383508a0; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Brett CT, 2000, INT REV CYTOL, V199, P161, DOI 10.1016/S0074-7696(00)99004-1; Brzezinski MA, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014349; BURNELL JN, 1988, ARCH BIOCHEM BIOPHYS, V260, P187, DOI 10.1016/0003-9861(88)90440-7; Cabello-Pasini A, 2001, BOT MAR, V44, P199, DOI 10.1515/BOT.2001.026; CARDENAS ML, 1998, BIOCHIM BIOPHYS ACTA, V140, P242; Chiovitti A, 2004, EUR J PHYCOL, V39, P117, DOI 10.1080/0967026042000201885; COLMAN B, 1988, J EXP BOT, V39, P1025, DOI 10.1093/jxb/39.8.1025; DRECHSLER Z, 1993, PLANTA, V191, P34; DREW ED, 1984, STORAGE CARBOHYDRATE, P133; Edwards GE, 2004, ANNU REV PLANT BIOL, V55, P173, DOI 10.1146/annurev.arplant.55.031903.141725; Eisenhut M, 2006, PLANT PHYSIOL, V142, P333, DOI 10.1104/pp.106.082982; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; Emanuelsson O, 2007, NAT PROTOC, V2, P953, DOI 10.1038/nprot.2007.131; Falkowski PG, 1998, SCIENCE, V281, P200, DOI 10.1126/science.281.5374.200; Fey V, 2005, J EXP BOT, V56, P1491, DOI 10.1093/jxb/eri180; Fischer H, 1999, J PHYCOL, V35, P113, DOI 10.1046/j.1529-8817.1999.3510113.x; FOGG GE, 1983, BOT MAR, V26, P3, DOI 10.1515/botm.1983.26.1.3; FORD CW, 1965, J CHEM SOC, P7035, DOI 10.1039/jr9650007035; Geigenberger P, 2005, J EXP BOT, V56, P1469, DOI 10.1093/jxb/eri178; Gervais F, 2002, LIMNOL OCEANOGR, V47, P1324, DOI 10.4319/lo.2002.47.5.1324; GIBBS SP, 1981, INT REV CYTOL, V72, P49, DOI DOI 10.1016/S0074-7696(08)61194-8; Giordano M, 2005, ANNU REV PLANT BIOL, V56, P99, DOI 10.1146/annurev.arplant.56.032604.144052; Graciet E, 2002, J BIOL CHEM, V277, P12697, DOI 10.1074/jbc.M111121200; Granum E, 2005, CAN J BOT, V83, P898, DOI 10.1139/B05-077; Granum E, 2002, MAR ECOL PROG SER, V242, P83, DOI 10.3354/meps242083; Grauvogel C, 2007, MOL BIOL EVOL, V24, P1611, DOI 10.1093/molbev/msm075; Gross W, 2003, EUR J PHYCOL, V38, P191, DOI 10.1080/1364253031000121705; Gruber A, 2007, PLANT MOL BIOL, V64, P519, DOI 10.1007/s11103-007-9171-x; HAMA J, 1992, J EXP MAR BIOL ECOL, V162, P159, DOI 10.1016/0022-0981(92)90199-K; HANDA N, 1969, MAR BIOL, V4, P208, DOI 10.1007/BF00393894; Harada H, 2005, CAN J BOT, V83, P909, DOI 10.1139/B05-078; Harada H, 2005, PLANT PHYSIOL, V139, P1041, DOI 10.1104/pp.105.065185; Harada H, 2006, PLANT PHYSIOL, V142, P1318, DOI 10.1104/pp.106.086561; Harper JT, 2003, MOL BIOL EVOL, V20, P1730, DOI 10.1093/molbev/msg195; HIPPS PP, 1976, BIOCHEM BIOPH RES CO, V68, P1133, DOI 10.1016/0006-291X(76)90314-4; HUPPE HC, 1994, ANNU REV PLANT PHYS, V45, P577, DOI 10.1146/annurev.pp.45.060194.003045; HUSIC DW, 1987, CRIT REV PLANT SCI, V5, P45, DOI 10.1080/07352688709382234; Igamberdiev AU, 2001, PHYSIOL PLANTARUM, V111, P427, DOI 10.1034/j.1399-3054.2001.1110402.x; Jacquot JP, 1997, NEW PHYTOL, V136, P543, DOI 10.1046/j.1469-8137.1997.00784.x; Kanai R., 1999, C4 PLANT BIOL, P49, DOI [10.5860/choice.36-6275, DOI 10.5860/CHOICE.36-6275, DOI 10.1016/B978-012614440-6/50004-5]; Kaplan A, 1999, ANNU REV PLANT PHYS, V50, P539, DOI 10.1146/annurev.arplant.50.1.539; KAPLAN A, 1981, PLANT PHYSIOL, V67, P229, DOI 10.1104/pp.67.2.229; Kilian O, 2005, PLANT J, V41, P175, DOI 10.1111/j.1365-313X.2004.02294.x; Kozaki A, 1996, NATURE, V384, P557, DOI 10.1038/384557a0; Kroth PG, 2005, CURR GENET, V48, P389, DOI 10.1007/s00294-005-0033-2; Lavaud J, 2007, FUNCT PLANT SCI BIOT, V1, P267; Leboulanger C, 1998, J PHYCOL, V34, P651, DOI 10.1046/j.1529-8817.1998.340651.x; Leboulanger C, 1997, DEEP-SEA RES PT I, V44, P2131, DOI 10.1016/S0967-0637(97)00090-3; Lee RE, 1998, PROTIST, V149, P341, DOI 10.1016/S1434-4610(98)70040-9; Lesage G, 2006, MICROBIOL MOL BIOL R, V70, P317, DOI 10.1128/MMBR.00038-05; Liaud MF, 2000, MOL BIOL EVOL, V17, P213, DOI 10.1093/oxfordjournals.molbev.a026301; LOEWUS FA, 1983, ANNU REV PLANT PHYS, V34, P137, DOI 10.1146/annurev.pp.34.060183.001033; LONG JJ, 1994, J BIOL CHEM, V269, P2827; Maheswari U, 2005, NUCLEIC ACIDS RES, V33, pD344, DOI 10.1093/nar/gki121; Marchler-Bauer A, 2005, NUCLEIC ACIDS RES, V33, pD192, DOI 10.1093/nar/gki069; Martin William, 2000, VVolume 9, P9; Matsuzaki M, 2004, NATURE, V428, P653, DOI 10.1038/nature02398; MCCONVILLE MJ, 1986, CARBOHYD RES, V153, P330, DOI 10.1016/S0008-6215(00)90276-3; Merchant SS, 2007, SCIENCE, V318, P245, DOI 10.1126/science.1143609; MERRETT MJ, 1973, NEW PHYTOL, V72, P751, DOI 10.1111/j.1469-8137.1973.tb02051.x; Michelet L, 2005, P NATL ACAD SCI USA, V102, P16478, DOI 10.1073/pnas.0507498102; Michels AK, 2005, PLANT PHYSIOL, V137, P911, DOI 10.1104/pp.104.055285; Mitra M, 2004, PLANT PHYSIOL, V135, P173, DOI 10.1104/pp.103.037283; Montijn RC, 1999, J BACTERIOL, V181, P7414, DOI 10.1128/JB.181.24.7414-7420.1999; Nielsen H, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P122; Nielsen H, 1997, Int J Neural Syst, V8, P581, DOI 10.1142/S0129065797000537; Noctor G, 1998, ANNU REV PLANT PHYS, V49, P249, DOI 10.1146/annurev.arplant.49.1.249; NORMAN EG, 1991, PLANT PHYSIOL, V95, P693, DOI 10.1104/pp.95.3.693; Ogawa T, 2003, PHOTOSYNTH RES, V77, P105, DOI 10.1023/A:1025865500026; Oudot-Le Secq MP, 2007, MOL GENET GENOMICS, V277, P427, DOI 10.1007/s00438-006-0199-4; Park H, 2007, ENVIRON MICROBIOL, V9, P403, DOI 10.1111/j.1462-2920.2006.01151.x; Park YI, 1996, PHOTOSYNTH RES, V50, P23, DOI 10.1007/BF00018218; Parker MS, 2005, J PHYCOL, V41, P1142, DOI 10.1111/j.1529-8817.2005.00139.x; Parker MS, 2004, J PHYCOL, V40, P557, DOI 10.1111/j.1529-8817.2004.03184.x; Patron NJ, 2004, EUKARYOT CELL, V3, P1169, DOI 10.1128/EC.3.5.1169-1175.2004; PAUL JS, 1976, ARCH MICROBIOL, V110, P247, DOI 10.1007/BF00690234; PAULSEN BS, 1978, CARBOHYD RES, V62, P386, DOI 10.1016/S0008-6215(00)80888-5; PILKIS SJ, 1994, J BIOL CHEM, V269, P21925; Poulsen N, 2005, FEBS J, V272, P3413, DOI 10.1111/j.1742-4658.2005.04760.x; RAVEN JA, 1981, CAN B FISH AQUAT SCI, P55; Rayner JC, 1997, EMBO J, V16, P1832, DOI 10.1093/emboj/16.8.1832; Reinfelder JR, 2000, NATURE, V407, P996, DOI 10.1038/35039612; Reinfelder JR, 2004, PLANT PHYSIOL, V135, P2106, DOI 10.1104/pp.104.041319; RIEBESELL U, 1993, NATURE, V361, P249, DOI 10.1038/361249a0; Roach Peter J., 2002, Current Molecular Medicine (Hilversum), V2, P101, DOI 10.2174/1566524024605761; Roberts K, 2007, PLANT PHYSIOL, V145, P230, DOI 10.1104/pp.107.102616; ROESSLER PG, 1987, J PHYCOL, V23, P494, DOI 10.1111/j.1529-8817.1987.tb02536.x; Ruelland E, 1999, TRENDS PLANT SCI, V4, P136, DOI 10.1016/S1360-1385(99)01391-6; Satoh D, 2001, PLANT PHYSIOL, V126, P1459, DOI 10.1104/pp.126.4.1459; Scheibe R, 2005, J EXP BOT, V56, P1481, DOI 10.1093/jxb/eri181; Stein R, 1997, PHYTOCHEMISTRY, V46, P17, DOI 10.1016/S0031-9422(96)00830-8; Storseth TR, 2005, CARBOHYD RES, V340, P1159, DOI 10.1016/j.carres.2004.12.036; Storseth TR, 2006, CARBOHYD RES, V341, P2108, DOI 10.1016/j.carres.2006.05.005; Sugiyama J, 1999, J MOL BIOL, V286, P247, DOI 10.1006/jmbi.1998.2458; Sun N, 2003, PLANT MOL BIOL, V53, P467, DOI 10.1023/B:PLAN.0000019071.12878.9e; SUZUKI K, 1991, J PHYCOL, V27, P492, DOI 10.1111/j.0022-3646.1991.00492.x; Szabo E, 2007, PHYSIOL PLANTARUM, V129, P484, DOI 10.1111/j.1399-3054.2006.00849.x; Tamoi M, 1996, ARCH BIOCHEM BIOPHYS, V334, P27, DOI 10.1006/abbi.1996.0425; Tanaka Y, 2005, PLANT PHYSIOL, V138, P207, DOI 10.1104/pp.104.058982; Tolbert NE, 1997, ANNU REV PLANT PHYS, V48, P1, DOI 10.1146/annurev.arplant.48.1.1; TOLBERT NE, 1980, BIOCH PLANTS, P2; Tortell PD, 2000, LIMNOL OCEANOGR, V45, P744, DOI 10.4319/lo.2000.45.3.0744; Tortell PD, 1997, NATURE, V390, P243, DOI 10.1038/36765; Tsekos I, 1999, J PHYCOL, V35, P635, DOI 10.1046/j.1529-8817.1999.3540635.x; Van Oijen T, 2004, EUR J PHYCOL, V39, P161, DOI 10.1080/0967026042000202127; VARUM KM, 1984, J EXP MAR BIOL ECOL, V83, P13, DOI 10.1016/0022-0981(84)90114-X; VARUM KM, 1986, J EXP MAR BIOL ECOL, V102, P249, DOI 10.1016/0022-0981(86)90180-2; von Caemmerer S, 2003, PHOTOSYNTH RES, V77, P191, DOI 10.1023/A:1025830019591; Waterkeyn L., 1987, CELLULE, V74, P198; Weber APM, 2004, PLANT MOL BIOL, V55, P17, DOI 10.1007/s11103-004-0376-y; Weber APM, 2004, J EXP BOT, V55, P1231, DOI 10.1093/jxb/erh091; Wedel N, 1998, P NATL ACAD SCI USA, V95, P9699, DOI 10.1073/pnas.95.16.9699; Wiese A, 1999, FEBS LETT, V461, P13, DOI 10.1016/S0014-5793(99)01417-9; Wilhelm C, 2006, PROTIST, V157, P91, DOI 10.1016/j.protis.2006.02.003; Wingler A, 2000, PHILOS T R SOC B, V355, P1517, DOI 10.1098/rstb.2000.0712; WINKLER U, 1995, PLANTA, V195, P403; Wittpoth C, 1998, PLANTA, V206, P79, DOI 10.1007/s004250050376; WU J, 1991, BOT ACTA, V104, P283, DOI 10.1111/j.1438-8677.1991.tb00231.x; Yamaguchi K, 2000, PLANT CELL PHYSIOL, V41, P1397, DOI 10.1093/pcp/pcd074; Yoshida KI, 1997, J BACTERIOL, V179, P4591, DOI 10.1128/jb.179.14.4591-4598.1997; Zaslavskaia LA, 2000, J PHYCOL, V36, P379, DOI 10.1046/j.1529-8817.2000.99164.x; Zhang N, 1999, P NATL ACAD SCI USA, V96, P9438, DOI 10.1073/pnas.96.16.9438	134	324	340	10	136	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2008	3	1							e1426	10.1371/journal.pone.0001426	http://dx.doi.org/10.1371/journal.pone.0001426			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366GT	18183306	gold, Green Published, Green Submitted			2022-12-25	WOS:000260469400022
J	Connon, CJ; Nakamura, T; Hopkinson, A; Quantock, A; Yagi, N; Doutch, J; Meek, KM				Connon, Che J.; Nakamura, Takahiro; Hopkinson, Andy; Quantock, Andrew; Yagi, Naoto; Doutch, James; Meek, Keith M.			The Biomechanics of Amnion Rupture: An X-Ray Diffraction Study	PLOS ONE			English	Article								Pre-term birth is the leading cause of perinatal and neonatal mortality, 40% of which are attributed to the pre-term premature rupture of amnion. Rupture of amnion is thought to be associated with a corresponding decrease in the extracellular collagen content and/or increase in collagenase activity. However, there is very little information concerning the detailed organisation of fibrillar collagen in amnion and how this might influence rupture. Here we identify a loss of lattice like arrangement in collagen organisation from areas near to the rupture site, and present a 9% increase in fibril spacing and a 50% decrease in fibrillar organisation using quantitative measurements gained by transmission electron microscopy and the novel application of synchrotron X-ray diffraction. These data provide an accurate insight into the biomechanical process of amnion rupture and highlight X-ray diffraction as a new and powerful tool in our understanding of this process.	[Connon, Che J.] Univ Reading, Sch Pharm, Reading, Berks, England; [Nakamura, Takahiro] Kyoto Prefectural Univ Med, Dept Ophthalmol, Kyoto, Japan; [Hopkinson, Andy] Univ Nottingham, Dept Ophthalmol, Nottingham NG7 2RD, England; [Quantock, Andrew; Doutch, James; Meek, Keith M.] Cardiff Univ, Sch Optometry & Vis Sci, Cardiff, S Glam, Wales; [Yagi, Naoto] Japan Synchrotron Radiat Res Inst, Kobe, Hyogo, Japan	University of Reading; Kyoto Prefectural University of Medicine; University of Nottingham; Cardiff University; Japan Synchrotron Radiation Research Institute	Connon, CJ (corresponding author), Univ Reading, Sch Pharm, Reading, Berks, England.	c.j.connon@reading.ac.uk	Connon, Che/B-3128-2012; Hopkinson, Andrew/A-2287-2011	Connon, Che/0000-0001-8264-6531; Doutch, James/0000-0003-0747-8368	Royal Society; RCUK Fellowship; CCLRC Direct Access [46242]; Spring-8 [2006A1012]; MRC [G0600755] Funding Source: UKRI; Medical Research Council [G0600755] Funding Source: researchfish	Royal Society(Royal Society of London); RCUK Fellowship(UK Research & Innovation (UKRI)); CCLRC Direct Access; Spring-8(SPring-8); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by The Royal Society (CJC), RCUK Fellowship (CJC), CCLRC Direct Access Grant 46242 ( KM, CJC) and Spring-8 Grant 2006A1012 (AJQ). KM is a Royal Society-Wolfson Research Merit Award holder.	ALZAID NS, 1980, J REPROD FERTIL, V59, P383; APLIN JD, 1985, J CELL SCI, V79, P119; ASPDEN RM, 1981, PROC R SOC SER B-BIO, V212, P299, DOI 10.1098/rspb.1981.0040; BOURESLI MN, 1981, CELL TISSUE RES, V220, P263; BOURNE GL, 1960, AM J OBSTET GYNECOL, V79, P1070, DOI 10.1016/0002-9378(60)90512-3; Clark GL, 1934, AM J PHYSIOL, V108, P74, DOI 10.1152/ajplegacy.1934.108.1.74; Connon CJ, 2000, J REFRACT SURG, V16, P448; FARRELL RA, 1969, B MATH BIOPHYS, V31, P727, DOI 10.1007/BF02477784; Goldenberg RL, 1998, NEW ENGL J MED, V339, P313, DOI 10.1056/NEJM199807303390506; GOODFELLOW JM, 1978, J MOL BIOL, V119, P237, DOI 10.1016/0022-2836(78)90436-9; HALABURT JT, 1989, EUR J OBSTET GYN R B, V31, P75, DOI 10.1016/0028-2243(89)90028-2; HUKINS DWL, 1985, TRENDS BIOCHEM SCI, V10, P260, DOI 10.1016/0968-0004(85)90077-5; KEIRSE MJNC, 1989, AM J PERINAT, V6, P226, DOI 10.1055/s-2007-999582; Krenchel H., 1964, FIBRE REINFORCEMENT; Lei HQ, 1996, J CLIN INVEST, V98, P1971, DOI 10.1172/JCI119001; Lewis RA, 2000, J SYNCHROTRON RADIAT, V7, P348, DOI 10.1107/S0909049500009973; MALAK TM, 1993, PLACENTA, V14, P385, DOI 10.1016/S0143-4004(05)80460-6; Meek KM, 2003, MATRIX BIOL, V22, P467, DOI 10.1016/S0945-053X(03)00081-7; Moore RM, 2006, PLACENTA, V27, P1037, DOI 10.1016/j.placenta.2006.01.002; PAAVOLA LG, 1995, BIOL REPROD, V53, P321, DOI 10.1095/biolreprod53.2.321; Parry S, 1998, NEW ENGL J MED, V338, P663, DOI 10.1056/NEJM199803053381006; Stuart EL, 2005, BIOL REPROD, V72, P230, DOI 10.1095/biolreprod.104.033381; VENABLE JH, 1965, J CELL BIOL, V25, P407, DOI 10.1083/jcb.25.2.407; WATSON ML, 1958, J BIOPHYS BIOCHEM CY, V4, P475, DOI 10.1083/jcb.4.4.475; WORTHINGTON CR, 1984, INT J BIOL MACROMOL, V7, P2	25	31	31	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 7	2007	2	11							e1147	10.1371/journal.pone.0001147	http://dx.doi.org/10.1371/journal.pone.0001147			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10IZ	18188405	Green Submitted, Green Accepted, Green Published, gold			2022-12-25	WOS:000207459000030
J	Baldwin, RM; Parolin, DAE; Lorimer, IAJ				Baldwin, R. M.; Parolin, D. A. E.; Lorimer, I. A. J.			Regulation of glioblastoma cell invasion by PKC iota and RhoB	ONCOGENE			English	Article						atypical PKC; RhoB; PI 3-kinase; PTEN; glioblastoma	PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 3-KINASE; ACTIN CYTOSKELETON; LUNG-CANCER; GROWTH; LAMBDA; PHOSPHORYLATION; SUPPRESSOR; EXPRESSION; MIGRATION	Glioblastoma multiforme is the most aggressive form of primary brain tumor and remains largely incurable, in large part, due to its highly invasive nature. The phosphoinositide (PI) 3-kinase pathway is often constitutively active in these tumors due to activating mutations in the epidermal growth factor receptor, or deletion/loss of function of the tumor suppressor PTEN. Protein kinase C type iota (PKC iota), a member of the atypical protein kinase C family, is activated by the PI 3-kinase pathway and is an important downstream mediator. Here, we have assessed the role of PKC iota in glioblastoma cell invasion. Depletion of PKC iota with RNA interference caused an increase in actin stress fibers and a decrease in cell motility and invasion. Gene expression microarray analysis of U87MG cells showed that PKC iota repressed expression of mRNA for RhoB, which has previously been shown to have a role in actin stress fiber formation. Western blot analysis showed that both PKC iota depletion and pharmacological inhibition of PKC iota caused an increase in the protein levels of RhoB, as did inhibition of PI 3-kinase. Expression of RhoB from a constitutive promoter caused changes in actin stress fibers and cell invasion that were similar to those seen with PKC iota depletion. These data show that PKC iota, activated as a consequence of aberrant upstream PI 3-kinase signaling, mediates glioblastoma cell motility and invasion, and that repression of RhoB is key downstream event in PKC iota signaling leading to enhanced cell motility. In addition, constitutive expression of RhoB repressed PKC iota activity, as assessed by its phosphorylation status on Thr555. PKC iota and RhoB are, therefore, mutually antagonistic, potentially creating a sensitive switch between invasive and non-invasive phenotypes.	[Baldwin, R. M.; Parolin, D. A. E.; Lorimer, I. A. J.] Ottawa Hlth Res Inst, Ottawa, ON, Canada; [Baldwin, R. M.; Lorimer, I. A. J.] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada; [Lorimer, I. A. J.] Univ Ottawa, Dept Med, Ottawa, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa	Lorimer, IAJ (corresponding author), Ottawa Hosp, Reg Canc Ctr, Ctr Canc Therapeut, 501 Smyth Rd,3rd Floor, Ottawa, ON K1H 8L6, Canada.	ilorimer@ohri.ca						Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Baldwin RM, 2006, ONCOGENE, V25, P2909, DOI 10.1038/sj.onc.1209312; Bellail AC, 2004, INT J BIOCHEM CELL B, V36, P1046, DOI 10.1016/j.biocel.2004.01.013; Cai XM, 2005, INT J CANCER, V117, P905, DOI 10.1002/ijc.21251; Coghlan MP, 2000, MOL CELL BIOL, V20, P2880, DOI 10.1128/MCB.20.8.2880-2889.2000; Eder AM, 2005, P NATL ACAD SCI USA, V102, P12519, DOI 10.1073/pnas.0505641102; Etienne-Manneville S, 2005, J CELL BIOL, V170, P895, DOI 10.1083/jcb.200412172; Flynn P, 2000, J BIOL CHEM, V275, P11064, DOI 10.1074/jbc.275.15.11064; Forget MA, 2002, CLIN EXP METASTAS, V19, P9, DOI 10.1023/A:1013884426692; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; Gampel A, 1999, CURR BIOL, V9, P955, DOI 10.1016/S0960-9822(99)80422-9; Gardner TS, 2000, NATURE, V403, P339, DOI 10.1038/35002131; Gerhard R, 2005, J BIOL CHEM, V280, P1499, DOI 10.1074/jbc.M406014200; Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063; Gustafson WC, 2004, J BIOL CHEM, V279, P9400, DOI 10.1074/jbc.M312840200; Huang M, 2006, HISTOL HISTOPATHOL, V21, P213, DOI 10.14670/HH-21.213; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; Jiang K, 2004, MOL CELL BIOL, V24, P5565, DOI 10.1128/MCB.24.12.5565-5576.2004; Jin ZJ, 2005, J BIOL CHEM, V280, P16045, DOI 10.1074/jbc.M413488200; Kanzaki M, 2004, J CELL BIOL, V164, P279, DOI 10.1083/jcb.200306152; Lambrechts A, 2004, INT J BIOCHEM CELL B, V36, P1890, DOI 10.1016/j.biocel.2004.01.024; Lavictoire SJ, 2003, J BIOL CHEM, V278, P5292, DOI 10.1074/jbc.M209494200; Liu AX, 2000, FEBS LETT, V481, P205, DOI 10.1016/S0014-5793(00)02003-2; Losa JH, 2003, ONCOGENE, V22, P3998, DOI 10.1038/sj.onc.1206608; Messerschmidt A, 2005, J MOL BIOL, V352, P918, DOI 10.1016/j.jmb.2005.07.060; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Ohgaki H, 2007, AM J PATHOL, V170, P1445, DOI 10.2353/ajpath.2007.070011; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Regala RP, 2005, J BIOL CHEM, V280, P31109, DOI 10.1074/jbc.M505402200; Sang RL, 2007, CHEM BIOL DRUG DES, V69, P240, DOI 10.1111/j.1747-0285.2007.00502.x; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; Soloff RS, 2004, J IMMUNOL, V173, P3250, DOI 10.4049/jimmunol.173.5.3250; Tamura M, 1999, CANCER RES, V59, P442; Uberall F, 1999, J CELL BIOL, V144, P413, DOI 10.1083/jcb.144.3.413; Wheeler AP, 2004, EXP CELL RES, V301, P43, DOI 10.1016/j.yexcr.2004.08.012; Xu LJ, 2006, J BIOL CHEM, V281, P4457, DOI 10.1074/jbc.M510721200; Zhang L, 2006, CANCER RES, V66, P4627, DOI 10.1158/0008-5472.CAN-05-4527	37	45	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2008	27	25					3587	3595		10.1038/sj.onc.1211027	http://dx.doi.org/10.1038/sj.onc.1211027			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18212741				2022-12-25	WOS:000256468500010
J	Kim, S; Park, SY; Yong, H; Famulski, JK; Chae, S; Lee, JH; Kang, CM; Saya, H; Chan, GK; Cho, H				Kim, S.; Park, S-Y; Yong, H.; Famulski, J. K.; Chae, S.; Lee, J-H; Kang, C-M; Saya, H.; Chan, G. K.; Cho, H.			HBV X protein targets hBubR1, which induces dysregulation of the mitotic checkpoint	ONCOGENE			English	Article						HBV X; BubR1; chromosome instability; mitotic checkpoint	ANAPHASE-PROMOTING COMPLEX; CENTROSOME AMPLIFICATION; CHROMOSOMAL INSTABILITY; TUMOR-DEVELOPMENT; BUBR1; CELLS; ONCOPROTEIN; INHIBITION; REGULATOR; MAD2	Accurate chromosomal segregation is monitored by the mitotic checkpoint, and an increased rate of chromosomal missegregation leads to chromosomal instability (CIN). Here, we demonstrate that the HBV X protein (HBx) binds BubR1, a component of the mitotic checkpoint complex and co-localizes with BubR1 at the kinetochores. HBx binding to BubR1 attenuates the association between BubR1 and CDC20, an activator of the anaphase-promoting complex/cyclosome (APC/C) and induces slippage of mitotic arrest in the presence of microtubule poisons. In addition, HBx binding to BubR1 results in the accumulation of lagging chromosomes and chromosome bridges. In contrast, a C-terminally truncated HBx mutant (HBx(1-100)) fails to bind BubR1 and does not cause aberrant chromosomal segregation. This provides a novel mechanism for dysregulation of the mitotic checkpoint by a viral pathogen linking it to the accumulation of chromosomal instability in HBV-associated hepa tocarcinogenesis.	[Kim, S.; Park, S-Y; Yong, H.; Chae, S.; Lee, J-H; Cho, H.] Ajou Univ, Dept Biochem, Sch Med, Suwon 443721, Kyunggi Do, South Korea; [Famulski, J. K.; Chan, G. K.] Univ Alberta, Dept Oncol, Cross Canc Inst, Edmonton, AB, Canada; [Kang, C-M] Korea Inst Radiol & Med Sci, Seoul, South Korea; [Saya, H.] Keio Univ, Sch Med, Div Gene Regulat, Inst Adv Med Res, Tokyo, Japan	Ajou University; University of Alberta; Korea Institute of Radiological & Medical Sciences; Keio University	Cho, H (corresponding author), Ajou Univ, Dept Biochem, Sch Med, 5 Wonchon Dong, Suwon 443721, Kyunggi Do, South Korea.	gkc@ualberta.ca; hscho@ajou.ac.kr	Chan, Gordon/AAN-7784-2020; Saya, Hideyuki/J-4325-2013	Chan, Gordon/0000-0003-0497-9407; Cho, Hyeseong/0000-0002-4672-8887				Chan GKT, 1998, J CELL BIOL, V143, P49, DOI 10.1083/jcb.143.1.49; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; Cotsiki M, 2004, P NATL ACAD SCI USA, V101, P947, DOI 10.1073/pnas.0308006100; Dai W, 2004, CANCER RES, V64, P440, DOI 10.1158/0008-5472.CAN-03-3119; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Forgues M, 2003, MOL CELL BIOL, V23, P5282, DOI 10.1128/MCB.23.15.5282-5292.2003; Fujii R, 2006, CANCER RES, V66, P9099, DOI 10.1158/0008-5472.CAN-06-1886; Gollin SM, 2004, CURR OPIN ONCOL, V16, P25, DOI 10.1097/00001622-200401000-00006; HENDERSON AS, 1988, CANCER GENET CYTOGEN, V30, P269, DOI 10.1016/0165-4608(88)90194-X; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Kim S, 2007, J VIROL, V81, P1714, DOI 10.1128/JVI.01863-06; Kops GJPL, 2004, P NATL ACAD SCI USA, V101, P8699, DOI 10.1073/pnas.0401142101; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Lee S, 2002, J BIOL CHEM, V277, P8730, DOI 10.1074/jbc.M108025200; Lin Y, 1997, CANCER RES, V57, P5137; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Liu BY, 2005, P NATL ACAD SCI USA, V102, P63, DOI 10.1073/pnas.0406424101; Madden CR, 2001, DIS MARKERS, V17, P153, DOI 10.1155/2001/571254; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; MOROI Y, 1980, P NATL ACAD SCI-BIOL, V77, P1627, DOI 10.1073/pnas.77.3.1627; Murakami S, 2001, J GASTROENTEROL, V36, P651, DOI 10.1007/s005350170027; Sen S, 2000, CURR OPIN ONCOL, V12, P82, DOI 10.1097/00001622-200001000-00014; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Wang Q, 2004, BLOOD, V103, P1278, DOI 10.1182/blood-2003-06-2158; Weaver BAA, 2007, CANCER CELL, V11, P25, DOI 10.1016/j.ccr.2006.12.003; Yun C, 2004, MOL CANCER RES, V2, P159	28	57	60	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	24					3457	3464		10.1038/sj.onc.1210998	http://dx.doi.org/10.1038/sj.onc.1210998			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18193091				2022-12-25	WOS:000256309900010
J	Gackiere, F; Bidaux, G; Delcourt, P; Van Coppenolle, F; Katsogiannou, M; Dewailly, E; Bavencoffe, A; Van Chuoi-Mariot, MT; Mauroy, B; Prevarskaya, N; Mariot, P				Gackiere, Florian; Bidaux, Gabriel; Delcourt, Philippe; Van Coppenolle, Fabien; Katsogiannou, Maria; Dewailly, Etienne; Bavencoffe, Alexis; Van Chuoi-Mariot, Myriam Tran; Mauroy, Brigitte; Prevarskaya, Natalia; Mariot, Pascal			CaV3.2 T-type calcium channels are involved in calcium-dependent secretion of neuroendocrine prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-THRESHOLD EXOCYTOSIS; PROTEIN-KINASE-C; ACID-PHOSPHATASE; CA2+ CHANNELS; EPITHELIAL-CELLS; TUMOR-CELLS; DIFFERENTIATION; EXPRESSION; PROLIFERATION; FLUORESCENCE	Because prostate cancer is, in its early stages, an androgen-dependent pathology, treatments aiming at decreasing testosterone plasma concentration have been developed for many years now. However, a significant proportion of patients suffer a relapse after a few years of hormone therapy. The androgen-independent stage of prostate cancer has been shown to be associated with the development of neuroendocrine differentiation. We previously demonstrated that neuroendocrine prostate cancer cells derived from LNCaP cells overexpress CaV3.2 T-type voltage-dependent calcium channels. We demonstrate here using prostatic acid phosphatase as a marker of prostate secretion and FM1-43 fluorescence imaging of membrane trafficking that neuroendocrine differentiation is associated with an increase in calcium-dependent secretion which critically relies on CaV3.2 T-type calcium channel activity. In addition, we show that these channels are expressed by neuroendocrine cells in prostate cancer tissues obtained from patients after surgery. We propose that CaV3.2 T-type calcium channel up-regulation may account for the alteration of secretion during prostate cancer development and that these channels, by promoting the secretion of potential mitogenic factors, could participate in the progression of the disease toward an androgen-independent stage.	[Gackiere, Florian; Bidaux, Gabriel; Delcourt, Philippe; Van Coppenolle, Fabien; Katsogiannou, Maria; Dewailly, Etienne; Bavencoffe, Alexis; Van Chuoi-Mariot, Myriam Tran; Mauroy, Brigitte; Prevarskaya, Natalia; Mariot, Pascal] INSERM, Lab Physiol Cellulaire, Equipe Labellisee Ligue Contre Canc, U800, F-59650 Villeneuve Dascq, France; [Gackiere, Florian; Bidaux, Gabriel; Delcourt, Philippe; Van Coppenolle, Fabien; Katsogiannou, Maria; Dewailly, Etienne; Bavencoffe, Alexis; Van Chuoi-Mariot, Myriam Tran; Mauroy, Brigitte; Prevarskaya, Natalia; Mariot, Pascal] Univ Sci & Tech Lille, F-59650 Villeneuve Dascq, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille	Mariot, P (corresponding author), Univ Sci & Tech Lille, INSERM, U800, Lab Physiol Cellulaire, Batiment SN3, F-59655 Villeneuve Dascq, France.	Pascal.Mariot@univ-lille1.fr	; Bidaux, Gabriel/F-1294-2016	Mariot, Pascal/0000-0001-7226-9162; Prevarskaya, natacha/0000-0003-0316-197X; Bidaux, Gabriel/0000-0002-6162-3223; Bavencoffe, Alexis Guillaume/0000-0001-5659-5988				Asaga S, 2006, ANTICANCER RES, V26, P35; Aumuller G, 1999, UROLOGY, V53, P1041, DOI 10.1016/S0090-4295(98)00631-1; BANG YJ, 1994, P NATL ACAD SCI USA, V91, P5330, DOI 10.1073/pnas.91.12.5330; Bidaux G, 2005, ENDOCR-RELAT CANCER, V12, P367, DOI 10.1677/erc.1.00969; Bonkhoff H, 1998, PROSTATE, P18; BONKHOFF H, 1991, PROSTATE, V19, P91, DOI 10.1002/pros.2990190202; Brumback AC, 2004, METHODS, V33, P287, DOI 10.1016/j.ymeth.2004.01.002; Carbone E, 2006, PFLUG ARCH EUR J PHY, V453, P373, DOI 10.1007/s00424-006-0100-7; Carbone E, 2006, CELL CALCIUM, V40, P147, DOI 10.1016/j.ceca.2006.04.019; Chemin J, 2004, NEUROREPORT, V15, P671, DOI 10.1097/00001756-200403220-00019; Cochilla AJ, 1999, ANNU REV NEUROSCI, V22, P1, DOI 10.1146/annurev.neuro.22.1.1; COHEN RJ, 1991, BRIT J UROL, V68, P258, DOI 10.1111/j.1464-410X.1991.tb15318.x; COHEN RJ, 1990, BRIT J UROL, V66, P405, DOI 10.1111/j.1464-410X.1990.tb14963.x; COHEN RJ, 1992, ARCH PATHOL LAB MED, V116, P65; Cox ME, 1999, CANCER RES, V59, P3821; Cox ME, 2000, J BIOL CHEM, V275, P13812, DOI 10.1074/jbc.275.18.13812; Darszon A, 2006, CELL CALCIUM, V40, P241, DOI 10.1016/j.ceca.2006.04.028; Dizeyi N, 2004, PROSTATE, V59, P328, DOI 10.1002/pros.10374; Exintaris B, 2006, AUTON NEUROSCI-BASIC, V126, P371, DOI 10.1016/j.autneu.2006.02.019; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Gackiere F, 2006, CELL CALCIUM, V39, P357, DOI 10.1016/j.ceca.2005.12.003; Gee KR, 1999, ANAL BIOCHEM, V273, P41, DOI 10.1006/abio.1999.4202; Giancippoli A, 2006, BIOPHYS J, V90, P1830, DOI 10.1529/biophysj.105.071647; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Huang JT, 2006, PROSTATE, V66, P1399, DOI 10.1002/pros.20434; ISHIBE M, 1991, J CLIN ENDOCR METAB, V73, P785, DOI 10.1210/jcem-73-4-785; Johnson JL, 2005, BIOCHEM J, V391, P699, DOI 10.1042/BJ20050380; Kim JH, 2003, PFLUG ARCH EUR J PHY, V446, P88, DOI 10.1007/s00424-002-0995-6; Lee JH, 1999, BIOPHYS J, V77, P3034, DOI 10.1016/S0006-3495(99)77134-1; Lehen'kyi V, 2007, ONCOGENE, V26, P7380, DOI 10.1038/sj.onc.1210545; Lin MF, 2001, CELL BIOL INT, V25, P1139, DOI 10.1006/cbir.2001.0794; Lu FM, 2008, CELL CALCIUM, V43, P49, DOI 10.1016/j.ceca.2007.03.006; Mansvelder HD, 2000, J PHYSIOL-LONDON, V526, P327, DOI 10.1111/j.1469-7793.2000.t01-1-00327.x; Mariot P, 2002, J BIOL CHEM, V277, P10824, DOI 10.1074/jbc.M108754200; MASUMOTO N, 1995, CELL CALCIUM, V18, P223, DOI 10.1016/0143-4160(95)90067-5; Meng TC, 1998, J BIOL CHEM, V273, P22096, DOI 10.1074/jbc.273.34.22096; Nunez L, 2000, ENDOCRINOLOGY, V141, P2012, DOI 10.1210/en.141.6.2012; Pan ZH, 2001, NEURON, V32, P89, DOI 10.1016/S0896-6273(01)00454-8; Panner A, 2005, CELL CALCIUM, V37, P105, DOI 10.1016/j.ceca.2004.07.002; Park JY, 2003, FEBS LETT, V547, P37, DOI 10.1016/S0014-5793(03)00665-3; SHORTE SL, 1993, J PHYSIOL-LONDON, V470, P191, DOI 10.1113/jphysiol.1993.sp019854; Taira AL, 2007, ONCOLOGY-NY, V21, P1003; Thebault S, 2003, J CLIN INVEST, V111, P1691, DOI 10.1172/JCI200316293; Theodoropoulos VE, 2005, UROLOGY, V66, P897, DOI 10.1016/j.urology.2005.04.064; Toyota M, 1999, CANCER RES, V59, P4535; Veeramani S, 2005, ENDOCR-RELAT CANCER, V12, P805, DOI 10.1677/erc.1.00950; Weinstein MH, 1996, HUM PATHOL, V27, P683, DOI 10.1016/S0046-8177(96)90398-6; Yuan TC, 2006, ENDOCR-RELAT CANCER, V13, P151, DOI 10.1677/erc.1.01043; Zelivianski S, 2001, BBA-MOL CELL RES, V1539, P28, DOI 10.1016/S0167-4889(01)00087-8	50	66	74	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					10162	10173		10.1074/jbc.M707159200	http://dx.doi.org/10.1074/jbc.M707159200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18230611	hybrid, Green Published			2022-12-25	WOS:000254671600069
J	Golczak, M; Maeda, A; Bereta, G; Maeda, T; Kiser, PD; Hunzelmann, S; von Lintig, J; Blaner, WS; Palczewski, K				Golczak, Marcin; Maeda, Akiko; Bereta, Grzegorz; Maeda, Tadao; Kiser, Philip D.; Hunzelmann, Silke; von Lintig, Johannes; Blaner, William S.; Palczewski, Krzysztof			Metabolic basis of visual cycle inhibition by retinoid and nonretinoid compounds in the vertebrate retina	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STARGARDTS MACULAR DEGENERATION; LEBER CONGENITAL AMAUROSIS; PIGMENT EPITHELIAL-CELLS; MEDIATED GENE-TRANSFER; BINDING-PROTEIN; VITAMIN-A; MOUSE MODEL; CHILDHOOD BLINDNESS; SUBSTRATE SPECIFICITIES; LIPOFUSCIN FLUOROPHORE	In vertebrate retinal photoreceptors, the absorption of light by rhodopsin leads to photoisomerization of 11-cis-retinal to its all-trans isomer. To sustain vision, a metabolic system evolved that recycles all-trans-retinal back to 11-cis-retinal. The importance of this visual (retinoid) cycle is underscored by the fact that mutations in genes encoding visual cycle components induce a wide spectrum of diseases characterized by abnormal levels of specific retinoid cycle intermediates. In addition, intense illumination can produce retinoid cycle by-products that are toxic to the retina. Thus, inhibition of the retinoid cycle has therapeutic potential in physiological and pathological states. Four classes of inhibitors that include retinoid and nonretinoid compounds have been identified. We investigated the modes of action of these inhibitors by using purified visual cycle components and in vivo systems. We report that retinylamine was the most potent and specific inhibitor of the retinoid cycle among the tested compounds and that it targets the retinoid isomerase, RPE65. Hydrophobic primary amines like farnesylamine also showed inhibitory potency but a short duration of action, probably due to rapid metabolism. These compounds also are reactive nucleophiles with potentially high cellular toxicity. We also evaluated the role of a specific protein-mediated mechanism on retinoid cycle inhibitor uptake by the eye. Our results show that retinylamine is transported to and taken up by the eye by retinol-binding protein-independent and retinoic acid-responsive gene product 6-independent mechanisms. Finally, we provide evidence for a crucial role of lecithin: retinol acyltransferase activity in mediating tissue specific absorption and long lasting therapeutic effects of retinoid-based visual cycle inhibitors.	[Golczak, Marcin; Maeda, Akiko; Bereta, Grzegorz; Maeda, Tadao; Kiser, Philip D.; Hunzelmann, Silke; Palczewski, Krzysztof] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; [Hunzelmann, Silke; von Lintig, Johannes] Univ Freiburg, Inst Biol 1, D-79104 Freiburg, Germany; [Blaner, William S.] Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA	Case Western Reserve University; University of Freiburg; Columbia University	Palczewski, K (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, Wood Bldg 10900 Euclid Ave, Cleveland, OH 44106 USA.	kxp65@case.edu		von Lintig, Johannes/0000-0002-2079-2143	NATIONAL EYE INSTITUTE [R01EY009339, T32EY007157, P30EY011373] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY009339-19S1, P30 EY 11373, EY 09339, 2T32 EY 007157, P30 EY011373-129005, R01 EY009339, P30 EY011373, T32 EY007157, R01 EY009339-19] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Acland GM, 2005, MOL THER, V12, P1072, DOI 10.1016/j.ymthe.2005.08.008; Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/88327; Aleman TS, 2004, INVEST OPHTH VIS SCI, V45, P1259, DOI 10.1167/iovs.03-1230; Batten ML, 2005, PLOS MED, V2, P1177, DOI 10.1371/journal.pmed.0020333; Batten ML, 2004, J BIOL CHEM, V279, P10422, DOI 10.1074/jbc.M312410200; Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje; BERNI R, 1992, FEBS LETT, V308, P43, DOI 10.1016/0014-5793(92)81046-O; BLANER WS, 1985, J LIPID RES, V26, P1241; Caffery B E, 1988, J Am Optom Assoc, V59, P221; CANADA FJ, 1990, BIOCHEMISTRY-US, V29, P9690, DOI 10.1021/bi00493a026; Caruso RC, 1998, ARCH OPHTHALMOL-CHIC, V116, P759, DOI 10.1001/archopht.116.6.759; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; Conley B, 2000, J CLIN ONCOL, V18, P275, DOI 10.1200/JCO.2000.18.2.275; Coxon FP, 2001, J BIOL CHEM, V276, P48213, DOI 10.1074/jbc.M106473200; De S, 2002, J GEN PHYSIOL, V120, P147, DOI 10.1085/jgp.20028566; DELAEY JJ, 1995, RETINA-J RET VIT DIS, V15, P399, DOI 10.1097/00006982-199515050-00005; DOLENCE JM, 1995, P NATL ACAD SCI USA, V92, P5008, DOI 10.1073/pnas.92.11.5008; Edmondson DE, 2007, ARCH BIOCHEM BIOPHYS, V464, P269, DOI 10.1016/j.abb.2007.05.006; ELDRED GE, 1993, NATURE, V364, P396; Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899; Fujii H, 1997, EMBO J, V16, P4163, DOI 10.1093/emboj/16.14.4163; Gamble MV, 2000, BBA-PROTEIN STRUCT M, V1476, P3, DOI 10.1016/S0167-4838(99)00232-0; Golczak M, 2005, J BIOL CHEM, V280, P42263, DOI 10.1074/jbc.M509351200; Golczak M, 2005, P NATL ACAD SCI USA, V102, P8162, DOI 10.1073/pnas.0503318102; Gollapalli DR, 2004, P NATL ACAD SCI USA, V101, P10030, DOI 10.1073/pnas.0401936101; Huang CC, 2000, BIOCHEMISTRY-US, V39, P2593, DOI 10.1021/bi992356x; Imanishi Y, 2004, J CELL BIOL, V166, P447, DOI 10.1083/jcb.200405110; Imanishi Y, 2004, J CELL BIOL, V164, P373, DOI 10.1083/jcb.200311079; Isken A, 2007, J BIOL CHEM, V282, P1144, DOI 10.1074/jbc.M609109200; Jacobson SG, 2007, P NATL ACAD SCI USA, V104, P15123, DOI 10.1073/pnas.0706367104; Jacobson SG, 2006, MOL THER, V13, P1074, DOI 10.1016/j.ymthe.2006.03.005; Jin MH, 2005, CELL, V122, P449, DOI 10.1016/j.cell.2005.06.042; Jones TH, 2003, J NAT PROD, V66, P325, DOI 10.1021/np020558f; Kapust RB, 2001, PROTEIN ENG, V14, P993, DOI 10.1093/protein/14.12.993; Kawaguchi R, 2007, SCIENCE, V315, P820, DOI 10.1126/science.1136244; Khalil AA, 2000, CHEM RES TOXICOL, V13, P31, DOI 10.1021/tx990146f; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; KOTHAPALLI R, 1993, LIPIDS, V28, P969, DOI 10.1007/BF02537116; Kuksa V, 2003, VISION RES, V43, P2959, DOI 10.1016/S0042-6989(03)00482-6; Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001; LAW WC, 1989, BIOCHEM BIOPH RES CO, V161, P825, DOI 10.1016/0006-291X(89)92674-0; Maeda A, 2005, J BIOL CHEM, V280, P18822, DOI 10.1074/jbc.M501757200; Maeda A, 2006, MOL PHARMACOL, V70, P1220, DOI 10.1124/mol.106.026823; Maeda A, 2006, J BIOL CHEM, V281, P37697, DOI 10.1074/jbc.M608375200; Maiti P, 2006, BIOCHEMISTRY-US, V45, P852, DOI 10.1021/bi0518545; Maiti P, 2005, BIOCHEMISTRY-US, V44, P14463, DOI 10.1021/bi0510779; Maiti P, 2007, BIOCHEMISTRY-US, V46, P8700, DOI 10.1021/bi701061k; Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497; McBee JK, 2001, J BIOL CHEM, V276, P48483, DOI 10.1074/jbc.M105840200; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; Moiseyev G, 2005, P NATL ACAD SCI USA, V102, P12413, DOI 10.1073/pnas.0503460102; Molnar G, 2001, BIOCHEMISTRY-US, V40, P10542, DOI 10.1021/bi011158e; MUINDI JR, 1994, LEUKEMIA, V8, P16; NOY N, 1990, BIOCHEMISTRY-US, V29, P3888, DOI 10.1021/bi00468a014; PALCZEWSKI K, 1994, BIOCHEMISTRY-US, V33, P13741, DOI 10.1021/bi00250a027; Palczewski K, 2006, ANNU REV BIOCHEM, V75, P743, DOI 10.1146/annurev.biochem.75.103004.142743; Quadro L, 2005, ENDOCRINOLOGY, V146, P4479, DOI 10.1210/en.2005-0158; Quadro L, 1999, EMBO J, V18, P4633, DOI 10.1093/emboj/18.17.4633; Radu RA, 2004, P NATL ACAD SCI USA, V101, P5928, DOI 10.1073/pnas.0308302101; Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820; Radu RA, 2003, P NATL ACAD SCI USA, V100, P4742, DOI 10.1073/pnas.0737855100; Radu Roxana A, 2004, Novartis Found Symp, V255, P51; Redmond TM, 2005, P NATL ACAD SCI USA, V102, P13658, DOI 10.1073/pnas.0504167102; Rohrer B, 2003, INVEST OPHTH VIS SCI, V44, P310, DOI 10.1167/iovs.02-0567; SAARI JC, 1990, METHOD ENZYMOL, V190, P156; SAGAMI H, 1992, ARCH BIOCHEM BIOPHYS, V297, P314, DOI 10.1016/0003-9861(92)90678-P; Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303; Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981; Stecher H, 2000, METHOD ENZYMOL, V316, P330; Stecher H, 1999, J BIOL CHEM, V274, P8577, DOI 10.1074/jbc.274.13.8577; STEINBERG RH, 1985, DOC OPHTHALMOL, V60, P327, DOI 10.1007/BF00158922; Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200; Travis GH, 2007, ANNU REV PHARMACOL, V47, P469, DOI 10.1146/annurev.pharmtox.47.120505.105225; Ura H, 1998, MOL CARCINOGEN, V21, P93, DOI 10.1002/(SICI)1098-2744(199802)21:2<93::AID-MC3>3.0.CO;2-P; Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297; Van Hooser JP, 2002, J BIOL CHEM, V277, P19173, DOI 10.1074/jbc.M112384200; Vogel S, 2002, BIOCHEMISTRY-US, V41, P15360, DOI 10.1021/bi0268551; Wabbels B, 2006, GRAEF ARCH CLIN EXP, V244, P36, DOI 10.1007/s00417-005-0043-2; Xie YS, 1998, PROTEIN EXPRES PURIF, V14, P31, DOI 10.1006/prep.1998.0944	79	80	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9543	9554		10.1074/jbc.M708982200	http://dx.doi.org/10.1074/jbc.M708982200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18195010	hybrid, Green Accepted, Green Published			2022-12-25	WOS:000254671600007
J	Brandt, W; Khandekar, M; Suzuki, N; Yamamoto, M; Lim, KC; Engel, JD				Brandt, William; Khandekar, Melin; Suzuki, Norio; Yamamoto, Masayuki; Lim, Kim-Chew; Engel, James Douglas			Defining the functional boundaries of the Gata2 locus by rescue with a linked bacterial artificial chromosome transgene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-2; IN-VIVO; HEMATOPOIETIC DEFECT; RECOMBINATION; EXPRESSION; DIFFERENTIATION; SYSTEM; CELLS; SELECTION; MULTIPLE	Transcription factor GATA-2 is vital for both hematopoietic progenitor cell function and urogenital patterning. Transgenic mapping studies have shown that the hematopoietic and urogenital enhancers are located hundreds of kbp 5' and 3' to the Gata2 structural gene, and both are vital for embryonic development. Because the size of mammalian genes, including all of their associated regulatory elements, can exceed a megabase, transgenic complementation in mice has, in specific instances, proven to be a formidable hurdle. After incorporating the Gata2 structural gene as well as the distant hematopoietic and urogenital enhancers into a single, contiguous piece of DNA by fusing two bacterial artificial chromosomes ( BACs) into one, we formally tested the hypothesis that the functional boundaries of this locus are contained within this contiguous genomic span. We show that two independent lines of transgenic mice bearing a multicopy 413-kbp-linked Gata2 BAC transgene ( bearing sequences from -187 to +226 kbp of the locus) are able to fully rescue Gata2 null mutant embryonic lethality and that the rescued animals behave and reproduce normally. Surprisingly, the linked BAC confers expression in the ureteric epithelium, whereas sequences within any of the overlapping parental BACs and a yeast artificial chromosome that were originally tested do not, and thus these experiments also define a novel synthetic enhancer activity that has not been previously described. These genetic complementation studies define the required outer limits of the Gata2 locus and formally demonstrate that enhancers lying beyond those boundaries are not necessary for Gata2-regulated viability or fecundity.	[Brandt, William; Khandekar, Melin; Lim, Kim-Chew; Engel, James Douglas] Univ Michigan, Sch Med, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA; [Suzuki, Norio; Yamamoto, Masayuki] Tohoku Univ, Grad Sch Med, Dept Med Biochem, Sendai, Miyagi 9808575, Japan	University of Michigan System; University of Michigan; Tohoku University	Engel, JD (corresponding author), Univ Michigan, Sch Med, Dept Cell & Dev Biol, 3071 BSRB,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	engel@umich.edu	Suzuki, Norio/F-3456-2010; Suzuki, Norio/AAZ-9458-2021; Yamamoto, Masayuki/A-4873-2010	Suzuki, Norio/0000-0001-6100-3350; Yamamoto, Masayuki/0000-0002-9073-9436	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028896, T32GM008152, T32GM007315] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM007315, GM 28896, GM 07315, GM 08152] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blanton J, 2003, GENE DEV, V17, P664, DOI 10.1101/gad.1052003; BRIEGEL K, 1993, GENE DEV, V7, P1097, DOI 10.1101/gad.7.6.1097; Cleard F, 2006, NAT GENET, V38, P931, DOI 10.1038/ng1833; Dasen JS, 1999, CELL, V97, P587, DOI 10.1016/S0092-8674(00)80770-9; Frengen E, 1999, GENOMICS, V58, P250, DOI 10.1006/geno.1998.5693; HOESS RH, 1986, NUCLEIC ACIDS RES, V14, P2287, DOI 10.1093/nar/14.5.2287; Khandekar M, 2004, MOL CELL BIOL, V24, P10263, DOI 10.1128/MCB.24.23.10263-10276.2004; Khandekar M, 2007, DEVELOPMENT, V134, P1703, DOI 10.1242/dev.001297; Kitajima K, 2002, EMBO J, V21, P3060, DOI 10.1093/emboj/cdf301; Kotzamanis G, 2004, BMC BIOTECHNOL, V4, DOI 10.1186/1472-6750-4-1; Kouprina N, 1999, GENOMICS, V56, P262, DOI 10.1006/geno.1998.5727; LARIONOV V, 1994, NUCLEIC ACIDS RES, V22, P4154, DOI 10.1093/nar/22.20.4154; Lee EC, 2001, GENOMICS, V73, P56, DOI 10.1006/geno.2000.6451; Liu PT, 2003, GENOME RES, V13, P476, DOI 10.1101/gr.749203; Ma GT, 1997, DEVELOPMENT, V124, P907; Marra MA, 1997, GENOME RES, V7, P1072, DOI 10.1101/gr.7.11.1072; Minegishi N, 1998, J BIOL CHEM, V273, P3625, DOI 10.1074/jbc.273.6.3625; Osoegawa K, 2000, GENOME RES, V10, P116; Podolsky T, 1996, PLASMID, V36, P112, DOI 10.1006/plas.1996.0038; Saitoh N, 2000, EMBO J, V19, P2315, DOI 10.1093/emboj/19.10.2315; Siegel RW, 2001, FEBS LETT, V499, P147, DOI 10.1016/S0014-5793(01)02541-8; Sopher BL, 2006, GENE, V371, P136, DOI 10.1016/j.gene.2005.11.034; Suzuki N, 2006, P NATL ACAD SCI USA, V103, P2202, DOI 10.1073/pnas.0508928103; Tong Q, 2000, SCIENCE, V290, P134, DOI 10.1126/science.290.5489.134; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Tsai FY, 1997, BLOOD, V89, P3636, DOI 10.1182/blood.V89.10.3636.3636_3636_3643; West AG, 2004, MOL CELL, V16, P453, DOI 10.1016/j.molcel.2004.10.005; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; Zhang XM, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng081; Zhou YH, 2000, DEVELOPMENT, V127, P3829; Zhou YH, 1998, EMBO J, V17, P6689, DOI 10.1093/emboj/17.22.6689	31	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					8976	8983		10.1074/jbc.M709364200	http://dx.doi.org/10.1074/jbc.M709364200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18211891	Green Published, hybrid			2022-12-25	WOS:000254465800027
J	Gao, YJ; Chotoo, CK; Balut, CM; Sun, F; Bailey, MA; Devor, DC				Gao, Yajuan; Chotoo, Cavita K.; Balut, Corina M.; Sun, Fei; Bailey, Mark A.; Devor, Daniel C.			Role of s3 and s4 transmembrane domain charged amino acids in channel biogenesis and Gating of KCa2.3 and KCa3.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHAKER K+ CHANNEL; ACTIVATED POTASSIUM CHANNELS; VOLTAGE SENSOR; INTERMEDIATE CONDUCTANCE; ELECTROSTATIC INTERACTIONS; DEPENDENT ACTIVATION; CYSTIC-FIBROSIS; AAA ATPASE; RESIDUES; SEGMENTS	The role of positively charged arginines in the fourth transmembrane domain ( S4) and a single negatively charged amino acid in the third transmembrane domain ( S3) on channel biogenesis and gating of voltage-gated K+ channels (Kv) has been well established. Both intermediate ( KCa3.1) and small ( KCa2.x) conductance, Ca2+-activated K+ channels have two conserved arginines in S4 and a single conserved glutamic acid in S3, although these channels are voltage- independent. We demonstrate that mutation of any of these charged amino acids in KCa3.1 or KCa2.3 to alanine, glutamine, or charge reversal mutations results in a rapid degradation (< 30 min) of total protein, confirming the critical role of these amino acids in channel biogenesis. Mutation of the S4 arginine closest to the cytosolic side of KCa3.1 to histidine resulted in expression at the cell surface. Excised patch clamp experiments revealed that this Arg/ His mutation had a dramatically reduced open probability (P-o), relative to wild type channels. Additionally, we demonstrate, using a combination of short hairpin RNA, dominant negative, and co-immunoprecipitation studies, that both KCa3.1 and KCa2.3 are translocated out of the endoplasmic reticulum associated with Derlin-1. These misfolded channels are poly-ubiquitylated, recognized by p97, and targeted for proteasomal degradation. Our results suggest that S3 and S4 charged amino acids play an evolutionarily conserved role in the biogenesis and gating of KCa channels. Furthermore, these improperly folded K+ channels are translocated out of the endoplasmic reticulum in a Derlin-1- and p97-dependent fashion, poly-ubiquitylated, and targeted for proteasomal degradation.	[Gao, Yajuan; Chotoo, Cavita K.; Balut, Corina M.; Sun, Fei; Bailey, Mark A.; Devor, Daniel C.] Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Devor, DC (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, S331 BST,3500 Terrace St, Pittsburgh, PA 15261 USA.	dd2@pitt.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL083060] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 083060] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; Alvarez O, 2002, ADV PHYSIOL EDUC, V26, P327, DOI 10.1152/advan.00006.2002; Anderson PAV, 2001, COMP BIOCHEM PHYS B, V129, P17, DOI 10.1016/S1096-4959(01)00376-1; Bildl W, 2004, NEURON, V43, P847, DOI 10.1016/j.neuron.2004.08.033; Gerlach AC, 2000, J BIOL CHEM, V275, P585, DOI 10.1074/jbc.275.1.585; Gerlach AC, 2001, J BIOL CHEM, V276, P10963, DOI 10.1074/jbc.M007716200; Jentsch S, 2007, TRENDS BIOCHEM SCI, V32, P6, DOI 10.1016/j.tibs.2006.11.005; Jones HM, 2007, CHANNELS, V1, P80, DOI 10.4161/chan.3999; Jones HM, 2005, J BIOL CHEM, V280, P37257, DOI 10.1074/jbc.M508601200; Jones HM, 2004, J BIOL CHEM, V279, P15531, DOI 10.1074/jbc.M400069200; Keen JE, 1999, J NEUROSCI, V19, P8830, DOI 10.1523/JNEUROSCI.19-20-08830.1999; Lee SY, 2005, P NATL ACAD SCI USA, V102, P15441, DOI 10.1073/pnas.0507651102; Lu Z, 2001, NATURE, V413, P809, DOI 10.1038/35101535; Ma ZM, 2006, J GEN PHYSIOL, V127, P309, DOI 10.1085/jgp.200509421; Myers MP, 2004, FEBS LETT, V568, P110, DOI 10.1016/j.febslet.2004.05.023; PAPAZIAN DM, 1995, NEURON, V14, P1293, DOI 10.1016/0896-6273(95)90276-7; Sato Y, 2003, J BIOL CHEM, V278, P13227, DOI 10.1074/jbc.M300431200; Sato Y, 2002, P NATL ACAD SCI USA, V99, P60, DOI 10.1073/pnas.012399799; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; Seoh SA, 1996, NEURON, V16, P1159, DOI 10.1016/S0896-6273(00)80142-7; SIGWORTH FJ, 1977, NATURE, V270, P265, DOI 10.1038/270265a0; SIGWORTH FJ, 1980, J PHYSIOL-LONDON, V307, P97, DOI 10.1113/jphysiol.1980.sp013426; Silverman WR, 2003, P NATL ACAD SCI USA, V100, P2935, DOI 10.1073/pnas.0636603100; Singh S, 2001, J PHARMACOL EXP THER, V296, P600; Srivastava S, 2006, MOL CELL, V24, P665, DOI 10.1016/j.molcel.2006.11.012; Sun F, 2006, J BIOL CHEM, V281, P36856, DOI 10.1074/jbc.M607085200; Syme CA, 2003, J BIOL CHEM, V278, P8476, DOI 10.1074/jbc.M210072200; Tiwari-Woodruff SK, 2000, J GEN PHYSIOL, V115, P123, DOI 10.1085/jgp.115.2.123; TiwariWoodruff SK, 1997, BIOPHYS J, V72, P1489, DOI 10.1016/S0006-3495(97)78797-6; Traynelis SF, 1998, TRENDS NEUROSCI, V21, P137, DOI 10.1016/S0166-2236(98)01238-7; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Ye YH, 2006, J STRUCT BIOL, V156, P29, DOI 10.1016/j.jsb.2006.01.005; Zhang M, 2005, J MEMBRANE BIOL, V207, P169, DOI 10.1007/s00232-005-0812-1	34	28	28	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9049	9059		10.1074/jbc.M708022200	http://dx.doi.org/10.1074/jbc.M708022200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18227067	hybrid, Green Published			2022-12-25	WOS:000254465800035
J	Javed, A; Bae, JS; Afzal, F; Gutierrez, S; Pratap, J; Zaidi, SK; Lou, Y; van Wijnen, AJ; Stein, JL; Stein, GS; Lian, JB				Javed, Amjad; Bae, Jong-Sup; Afzal, Faiza; Gutierrez, Soraya; Pratap, Jitesh; Zaidi, Sayyed K.; Lou, Yang; van Wijnen, Andre J.; Stein, Janet L.; Stein, Gary S.; Lian, Jane B.			Structural coupling of smad and Runx2 for execution of the BMP2 osteogenic signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN; OSTEOBLAST DIFFERENTIATION; TRANSCRIPTION FACTORS; GENE-EXPRESSION; CLEIDOCRANIAL DYSPLASIA; RUNX/CBFA/AML FACTORS; NUCLEAR-MATRIX; STEM-CELLS; ACTIVATION; DOMAIN	Two regulatory pathways, bone morphogenetic protein (BMP)/transforming growth factor-beta(TGF beta) and the transcription factor RUNX2, are required for bone formation in vivo. Here we show the interdependent requirement of these pathways to induce an osteogenic program. A panel of Runx2 deletion and point mutants was used to examine RUNX2-SMAD protein-protein interaction and the biological consequences on BMP2-induced osteogenic signaling determined in Runx2 null cells. These cells do not respond to BMP2 signal in the absence of Runx2. We established that a triple mutation in the C-terminal domain of RUNX2, HTY (426 - 428), disrupts the RUNX2-SMAD interaction, is deficient in its ability to integrate the BMP2/TGF beta signal on promoter reporter assays, and is only marginally functional in promoting early stages of osteoblast differentiation. Furthermore, the HTY mutation overlaps the unique nuclear matrix targeting signal of Runx factors and exhibits reduced subnuclear targeting. Thus, formation of a RUNX2-SMAD osteogenic complex and subnuclear targeting are structurally and functionally inseparable. Our results establish the critical residues of RUNX2 for execution and completion of BMP2 signaling for osteoblastogenesis through a mechanism that requires RUNX2-SMAD transcriptional activity.	[Pratap, Jitesh; Zaidi, Sayyed K.; Lou, Yang; van Wijnen, Andre J.; Stein, Janet L.; Stein, Gary S.; Lian, Jane B.] Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; [Pratap, Jitesh; Zaidi, Sayyed K.; Lou, Yang; van Wijnen, Andre J.; Stein, Janet L.; Stein, Gary S.; Lian, Jane B.] Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Lian, JB (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, 55 Lake Ave N, Worcester, MA 01655 USA.	jane.lian@umassmed.edu	Zaidi, Sayyed Kaleem/I-5596-2019; Bae, Jong-Sup/AAU-9724-2020; van Wijnen, Andre J./AAG-3578-2019	Zaidi, Sayyed Kaleem/0000-0001-6664-5168; van Wijnen, Andre J./0000-0002-4458-0946; Javed, Amjad/0000-0002-0847-8266	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR048818, R01AR049069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R37DE012528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012528] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR049069, P01 AR 48818] Funding Source: Medline; NIDCR NIH HHS [DE 012528] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Afzal F, 2005, J CELL PHYSIOL, V204, P63, DOI 10.1002/jcp.20258; Bae JS, 2007, J CELL BIOCHEM, V100, P434, DOI 10.1002/jcb.21039; Bandyopadhyay A, 2006, PLOS GENET, V2, P2116, DOI 10.1371/journal.pgen.0020216; Choi JY, 2001, P NATL ACAD SCI USA, V98, P8650, DOI 10.1073/pnas.151236498; Dobreva G, 2006, CELL, V125, P971, DOI 10.1016/j.cell.2006.05.012; Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369; Fukuda S, 2007, MOL CELL BIOL, V27, P4931, DOI 10.1128/MCB.02435-06; Haag J, 2006, ARTHRITIS RHEUM, V54, P3878, DOI 10.1002/art.22261; Hassan MQ, 2007, MOL CELL BIOL, V27, P3337, DOI 10.1128/MCB.01544-06; Hassan MQ, 2006, J BIOL CHEM, V281, P40515, DOI 10.1074/jbc.M604508200; Hendy GN, 2005, HORM METAB RES, V37, P375, DOI 10.1055/s-2005-870152; Holleville N, 2007, DEV BIOL, V304, P860, DOI 10.1016/j.ydbio.2007.01.003; Itoh S, 2007, CURR OPIN CELL BIOL, V19, P176, DOI 10.1016/j.ceb.2007.02.015; Javed A, 2001, MOL CELL BIOL, V21, P2891, DOI 10.1128/MCB.21.8.2891-2905.2001; Javed A, 2000, J CELL SCI, V113, P2221; Kanzler B, 2000, DEVELOPMENT, V127, P1095; Knockaert M, 2006, P NATL ACAD SCI USA, V103, P11940, DOI 10.1073/pnas.0605133103; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Leboy PS, 2001, J BONE JOINT SURG AM, V83A, pS15; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Lee KS, 2002, ONCOGENE, V21, P7156, DOI 10.1038/sj.onc.1205937; Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200; Li XL, 2006, EXP CELL RES, V312, P854, DOI 10.1016/j.yexcr.2005.12.002; Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Liu TJ, 2007, J CELL PHYSIOL, V211, P728, DOI 10.1002/jcp.20988; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague Joan, 2003, Clin Adv Hematol Oncol, V1, P576; Miyazono K, 2005, CYTOKINE GROWTH F R, V16, P251, DOI 10.1016/j.cytogfr.2005.01.009; Otto F, 2002, HUM MUTAT, V19, P209, DOI 10.1002/humu.10043; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109; Schroeder Tania M., 2005, Birth Defects Research, V75, P213, DOI 10.1002/bdrc.20043; Suzuki A, 2006, P NATL ACAD SCI USA, V103, P10294, DOI 10.1073/pnas.0506945103; Tang L, 1999, J BIOL CHEM, V274, P33580, DOI 10.1074/jbc.274.47.33580; Xia Y, 2007, J BIOL CHEM, V282, P18129, DOI 10.1074/jbc.M701679200; Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101; Yang XL, 2002, TRENDS MOL MED, V8, P340, DOI 10.1016/S1471-4914(02)02340-7; Young DW, 2007, NATURE, V445, P442, DOI 10.1038/nature05473; Young DW, 2005, J CELL BIOCHEM, V94, P720, DOI 10.1002/jcb.20332; Zaidi SK, 2006, J CELL PHYSIOL, V209, P935, DOI 10.1002/jcp.20791; Zaidi SK, 2002, P NATL ACAD SCI USA, V99, P8048, DOI 10.1073/pnas.112664499; Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597; Zhao GQ, 2003, GENESIS, V35, P43, DOI 10.1002/gene.10167; Zhu W, 2004, J BONE MINER RES, V19, P2021, DOI 10.1359/JBMR.040821	45	178	188	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8412	8422		10.1074/jbc.M705578200	http://dx.doi.org/10.1074/jbc.M705578200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18204048	Green Published, hybrid			2022-12-25	WOS:000254288000039
J	Lanza, A; Cirillo, N; Rossiello, R; Rienzo, M; Cutillo, L; Casamassimi, A; de Nigris, F; Schiano, C; Rossiello, L; Femiano, F; Gombos, F; Napoli, C				Lanza, Alessandro; Cirillo, Nicola; Rossiello, Raffaele; Rienzo, Monica; Cutillo, Luisa; Casamassimi, Amelia; de Nigris, Filomena; Schiano, Concetta; Rossiello, Luigi; Femiano, Felice; Gombos, Fernando; Napoli, Claudio			Evidence of key role of Cdk2 overexpression in pemphigus vulgaris	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATERNAL-HYPERCHOLESTEROLEMIA; INTERMEDIATE-FILAMENTS; KERATINOCYTE ADHESION; SIGNALING PATHWAYS; CELL-SURFACE; CYCLIN-E; C-MYC; DISEASE; SKIN; DESMOGLEIN-3	The pathogenesis of pemphigus vulgaris (PV) is still poorly understood. Autoantibodies present in PV patients can promote detrimental effects by triggering altered transduction of signals, which results in a final acantholysis. To investigate mechanisms involved in PV, cultured keratinocytes were treated with PV serum. PV sera were able to promote the cell cycle progression, inducing the accumulation of cyclin-dependent kinase 2 (Cdk2). Microarray analysis on keratinocytes detected that PV serum induced important changes in genes coding for one and the same proteins with known biological functions involved in PV disease (560 differentially expressed genes were identified). Then, we used two different approaches to investigate the role of Cdk2. First, small interfering RNA depletion of Cdk2 prevented cell-cell detachment induced by PV sera. Second, pharmacological inhibition of Cdk2 activity through roscovitine prevented blister formation and acantholysis in the mouse model of the disease. In vivo PV serum was found to alter multiple different pathways by microarray analysis (1463 differentially expressed genes were identified). Major changes in gene expression induced by roscovitine were studied through comparison of effects of PV serum alone and in association with roscovitine. The most significantly enriched pathways were cell communication, gap junction, focal adhesion, adherens junction, and tight junction. Our data indicate that major Cdk2-dependent multiple gene regulatory events are present in PV. This alteration may influence the evolution of PV and its therapy.	[Rienzo, Monica; Casamassimi, Amelia; de Nigris, Filomena; Schiano, Concetta; Napoli, Claudio] Univ Naples 2, Dept Gen Pathol, Sch Med & Surg 1, I-80138 Naples, Italy; [Lanza, Alessandro; Cirillo, Nicola; Femiano, Felice; Gombos, Fernando; Napoli, Claudio] Univ Naples 2, Sch Med & Surg 1, Reg Ctr Craniofacial Malformat, I-80134 Naples, Italy; [Rossiello, Luigi] Univ Naples 2, Div Dermatol, Sch Med & Surg 1, I-80138 Naples, Italy; [Cutillo, Luisa] Theleton Inst Genet & Med Naples, I-80131 Naples, Italy	Universita della Campania Vanvitelli; Universita della Campania Vanvitelli; Universita della Campania Vanvitelli	Napoli, C (corresponding author), Univ Naples 2, Dept Gen Pathol, Sch Med & Surg 1, Complesso S Andrea Dame,Via L Crecchio 7, I-80138 Naples, Italy.	claudio.napoli@unina2.it	Casamassimi, Amelia/AAD-2816-2020; Schiano, Concetta/GOE-4310-2022; Femiano, Felice/AAQ-3711-2021; Schiano, Concetta/K-6431-2016	Casamassimi, Amelia/0000-0002-6010-4261; Cutillo, Luisa/0000-0002-2205-0338; Rienzo, Monica/0000-0002-4496-4894; Schiano, Concetta/0000-0002-2570-6910; Cirillo, NIcola/0000-0003-1429-1323; Lanza, Alessandro/0000-0002-5762-5613; FEMIANO, Felice/0000-0001-9341-2490; Napoli, Claudio/0000-0002-5455-555X; de nigris, filomena/0000-0002-2322-1557				AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B; Amagai M, 2006, EXP DERMATOL, V15, P815, DOI 10.1111/j.1600-0625.2006.00499.x; Amagai M, 2000, J CLIN INVEST, V105, P625, DOI 10.1172/JCI8748; ANHALT GJ, 1982, NEW ENGL J MED, V306, P1189, DOI 10.1056/NEJM198205203062001; Arredondo J, 2005, AM J PATHOL, V167, P1531, DOI 10.1016/S0002-9440(10)61239-4; Berkowitz P, 2006, P NATL ACAD SCI USA, V103, P12855, DOI 10.1073/pnas.0602973103; Bhol KC, 2000, CYTOKINE, V12, P1076, DOI 10.1006/cyto.1999.0642; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Bystryn JC, 2005, LANCET, V366, P61, DOI 10.1016/S0140-6736(05)66829-8; Caldelari R, 2001, J CELL BIOL, V153, P823, DOI 10.1083/jcb.153.4.823; Chernyavsky AI, 2007, J BIOL CHEM, V282, P13804, DOI 10.1074/jbc.M611365200; Cirillo N, 2007, IMMUNOLOGY, V121, P377, DOI 10.1111/j.1365-2567.2007.02585.x; Cirillo N, 2007, J CELL PHYSIOL, V210, P411, DOI 10.1002/jcp.20856; Cirlllo N, 2006, FEBS LETT, V580, P3276, DOI 10.1016/j.febslet.2006.04.089; Coulombe PA, 2002, CURR OPIN CELL BIOL, V14, P110, DOI 10.1016/S0955-0674(01)00301-5; de Nigris F, 2006, CELL CYCLE, V5, P1621, DOI 10.4161/cc.5.15.3138; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; FARB RM, 1978, P NATL ACAD SCI USA, V75, P459, DOI 10.1073/pnas.75.1.459; Feliciani C, 2000, J INVEST DERMATOL, V114, P71, DOI 10.1046/j.1523-1747.2000.00835.x; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; Garcia JF, 2003, BLOOD, V101, P681, DOI 10.1182/blood-2002-04-1128; Gombos F, 1974, Arch Stomatol (Napoli), V15, P69; Gombos F, 1978, Arch Stomatol (Napoli), V19, P239; Grando SA, 2006, J INVEST DERMATOL, V126, P1948, DOI 10.1038/sj.jid.5700151; Gu LH, 2007, CURR OPIN CELL BIOL, V19, P13, DOI 10.1016/j.ceb.2006.12.007; Harwell RM, 2004, J BIOL CHEM, V279, P12695, DOI 10.1074/jbc.M313407200; Huber O, 2003, CELL MOL LIFE SCI, V60, P1872, DOI 10.1007/s00018-003-3050-7; Kaldis P, 2005, CELL CYCLE, V4, P1491, DOI 10.4161/cc.4.11.2124; Lanza A, 2006, INT J IMMUNOPATH PH, V19, P399, DOI 10.1177/039463200601900216; LAVKER RM, 1991, AM J PATHOL, V138, P687; Li N, 2005, J CLIN INVEST, V115, P3440, DOI 10.1172/JCI24394; Mahoney MG, 1999, J CLIN INVEST, V103, P461, DOI 10.1172/JCI5252; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Napoli C, 2000, FASEB J, V14, P1996, DOI 10.1096/fj.99-0986com; Napoli C, 2005, METH MOLEC MED, V108, P215; Napoli C, 2002, CIRCULATION, V105, P1360, DOI 10.1161/01.CIR.0000013090.96919.FA; Napoli C, 1999, LANCET, V354, P1234, DOI 10.1016/S0140-6736(99)02131-5; Nguyen VT, 2000, AM J PATHOL, V157, P1377, DOI 10.1016/S0002-9440(10)64651-2; Nguyen VT, 2000, J CLIN INVEST, V106, P1467, DOI 10.1172/JCI10305; Nguyen VT, 2004, EXP CELL RES, V294, P534, DOI 10.1016/j.yexcr.2003.12.010; Nguyen VT, 2004, J BIOL CHEM, V279, P2135, DOI 10.1074/jbc.M309000200; Olvera M, 2001, MODERN PATHOL, V14, P1036, DOI 10.1038/modpathol.3880432; Osada K, 1997, J INVEST DERMATOL, V108, P482, DOI 10.1111/1523-1747.ep12289726; Pascale RM, 2002, HEPATOLOGY, V35, P1341, DOI 10.1053/jhep.2002.33682; Puviani M, 2003, J INVEST DERMATOL, V120, P164, DOI 10.1046/j.1523-1747.2003.12014.x; Schang LM, 2004, BBA-PROTEINS PROTEOM, V1697, P197, DOI 10.1016/j.bbapap.2003.11.024; Schmidt E, 2007, BRIT J DERMATOL, V156, P352, DOI 10.1111/j.1365-2133.2006.07646.x; Stanley JR, 2006, NEW ENGL J MED, V355, P1800, DOI 10.1056/NEJMra061111; SWANSON DL, 1983, J INVEST DERMATOL, V81, P258, DOI 10.1111/1523-1747.ep12518278; Tsunoda K, 2003, J IMMUNOL, V170, P2170, DOI 10.4049/jimmunol.170.4.2170; Williamson L, 2006, EMBO J, V25, P3298, DOI 10.1038/sj.emboj.7601224	51	41	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8736	8745		10.1074/jbc.M702186200	http://dx.doi.org/10.1074/jbc.M702186200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18199752	hybrid			2022-12-25	WOS:000254288000071
J	Wan, KF; Chan, SL; Sukumaran, SK; Lee, MC; Yu, VC				Wan, Kah Fei; Chan, Shing-Leng; Sukumaran, Sunil Kumar; Lee, Mei-Chin; Yu, Victor C.			Chelerythrine induces apoptosis through a Bax/Bak-independent mitochondrial mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY PROTEINS; CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION PORE; PROGRAMMED CELL-DEATH; BH3-ONLY PROTEINS; TRANSMEMBRANE DEPOLARIZATION; CANCER-CELLS; BH3 DOMAINS; BAX; INHIBITOR	Although murine embryonic fibroblasts (MEFs) with Bax or Bak deleted displayed no defect in apoptosis signaling, MEFs with Bax and Bak double knock-out (DKO) showed dramatic resistance to diverse apoptotic stimuli, suggesting that Bax and Bak are redundant but essential regulators for apoptosis signaling. Chelerythrine has recently been identified as a Bcl-xL inhibitor that is capable of triggering apoptosis via direct action on mitochondria. Here we report that in contrast to classic apoptotic stimuli, chelerythrine is fully competent in inducing apoptosis in the DKO MEFs. Wild-type and DKO MEFs are equally sensitive to chelerythrine-induced morphological and biochemical changes associated with apoptosis phenotype. Interestingly, chelerythrine-mediated release of cytochrome c is rapid and precedes Bax translocation and integration. Although the BH3 peptide of Bim is totally inactive in releasing cytochrome c from isolated mitochondria of DKO MEFs, chelerythrine maintains its potency and efficacy in inducing direct release of cytochrome c from these mitochondria. Furthermore, chelerythrine-mediated mitochondrial swelling and loss in mitochondrial membrane potential (Delta Psi(m)) are inhibited by cyclosporine A, suggesting that mitochondrial permeability transition pore is involved in chelerythrine-induced apoptosis. Although certain apoptotic stimuli have been shown to elicit cytotoxic effect in the DKO MEFs through alternate death mechanisms, chelerythrine does not appear to engage necrotic or autophagic death mechanism to trigger cell death in the DKO MEFs. These results, thus, argue for the existence of an alternative Bax/Bak-independent apoptotic mechanism that involves cyclosporine A-sensitive mitochondrial membrane permeability.	ASTAR, Inst Mol & Cell Biol, Singapore 138673, Singapore; [Chan, Shing-Leng] Natl Univ Singapore, Oncol Res Inst, Ctr Life Sci, Canc Program, Singapore 117456, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Lee, MC (corresponding author), ASTAR, Inst Mol & Cell Biol, 61 Biopolis Dr Proteos, Singapore 138673, Singapore.	mcbyuck@imcb.a-star.edu.sg	Chan, S.L./X-4154-2018; Yu, Victor/A-7899-2015	Chan, S.L./0000-0002-3270-0525; Yu, Victor/0000-0003-3270-4734; Lee, Mei Chin/0000-0001-7689-6446				Armstrong JS, 2001, EXP CELL RES, V262, P170, DOI 10.1006/excr.2000.5091; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Bouillet P, 2002, J CELL SCI, V115, P1567; Chan SL, 2004, CLIN EXP PHARMACOL P, V31, P119, DOI 10.1111/j.1440-1681.2004.03975.x; Chan SL, 2003, J BIOL CHEM, V278, P20453, DOI 10.1074/jbc.C300138200; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chmura SJ, 2000, CLIN CANCER RES, V6, P737; Crompton M, 1999, BIOCHEM SOC SYMP, V66, P167, DOI 10.1042/bss0660167; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Degenhardt K, 2002, CANCER CELL, V2, P193, DOI 10.1016/S1535-6108(02)00126-5; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Galindo MF, 2003, BRIT J PHARMACOL, V139, P797, DOI 10.1038/sj.bjp.0705309; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Kitada S, 2003, J MED CHEM, V46, P4259, DOI 10.1021/jm030190z; Kroll SL, 1998, AM J PHYSIOL-CELL PH, V274, pC167, DOI 10.1152/ajpcell.1998.274.1.C167; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Lei XB, 2006, FASEB J, V20, P2147, DOI 10.1096/fj.05-5665fje; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Lickliter JD, 2003, LEUKEMIA, V17, P2074, DOI 10.1038/sj.leu.2403102; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Malikova J, 2006, CELL BIOL TOXICOL, V22, P439, DOI 10.1007/s10565-006-0109-x; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Milanesi E, 2006, J BIOL CHEM, V281, P10066, DOI 10.1074/jbc.M513708200; Mizuta T, 2007, J BIOL CHEM, V282, P16623, DOI 10.1074/jbc.M611060200; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Oliver CL, 2005, MOL CANCER THER, V4, P23; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Real PJ, 2004, CANCER RES, V64, P7947, DOI 10.1158/0008-5472.CAN-04-0945; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Rovere-Querini P, 2004, EMBO REP, V5, P825, DOI 10.1038/sj.embor.7400205; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Tan KO, 2005, P NATL ACAD SCI USA, V102, P14623, DOI 10.1073/pnas.0503524102; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Wang JZ, 2004, J BIOL CHEM, V279, P19948, DOI 10.1074/jbc.M313629200; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Wilson-Annan J, 2003, J CELL BIOL, V162, P877, DOI 10.1083/jcb.200302144; Zhai D, 2006, CELL DEATH DIFFER, V13, P1419, DOI 10.1038/sj.cdd.4401937; Zhang YH, 2006, J MOL BIOL, V364, P536, DOI 10.1016/j.jmb.2006.09.023; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	51	50	52	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8423	8433		10.1074/jbc.M707687200	http://dx.doi.org/10.1074/jbc.M707687200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18230621	Green Published, hybrid			2022-12-25	WOS:000254288000040
J	Chu, WK; Dai, PM; Li, HL; Chen, JK				Chu, Wing-Keung; Dai, Pei-Min; Li, Hsin-Lun; Chen, Jan-Kan			Transcriptional activity of the Delta Np63 promoter is regulated by STAT3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53 HOMOLOG; EXPRESSION; P63; APOPTOSIS; CELLS; ACTIVATION; PATHWAY; CLONING; TUMORS	The N terminus-truncated splicing variant of TAp63 is known as Delta Np63.Delta Np63 lacks transactivation function and is thought to antagonize the transcriptional regulation of the p53 and TAp63 target genes. Overexpression of Delta Np63 has been observed in a number of human cancers, suggesting a role in carcinogenesis. In the present study we present data showing that the Delta Np63 gene promoter activity is positively regulated by Delta Np63 alpha, and such positive autoregulation is mediated via activation of STAT3 activity. We show that expression of Delta Np63 alpha in Hep3B cells induces Stat3 phosphorylation on Tyr-705 and Ser-727. A putative STAT3-responsive element ( STAT3-RE) is identified in the Delta Np63 promoter region. Electrophoretic mobility shift and avidin biotin-Conjugated DNA assays show direct binding of STAT3 to STAT3-RE of the Delta Np63 promoter, and such binding is stimulated by Delta Np63 alpha. Binding of the endogenous STAT3 to the Delta Np63 promoter in Hep3B cells was demonstrated by a chromatin immunoprecipitation assay. The stimulation of the Delta Np63 transcriptional activity by Delta Np63 alpha is abolished by Janus kinase 2 ( JAK2)/ STAT3 inhibitor AG490, dominant-negative STAT3, STAT3 small interfering RNA, and deletion of the STAT3-RE sequence from Delta Np63 promoter. Taken together these observations clearly indicated that autoregulation of Delta Np63 gene transcription is mediated through activation of STAT3 and its subsequent binding to the STAT3-RE. Because the activation of STAT3 by interleukin-6 also leads to Delta Np63 up-regulation and the blockade of Delta Np63 or STAT3 expression by siRNA leads to repression of the cell growth, the identified regulatory pathway is presumably of cell physiological significance.	[Chu, Wing-Keung; Dai, Pei-Min; Li, Hsin-Lun; Chen, Jan-Kan] Chang Gung Univ, Dept Physiol, Coll Med, Tao Yuan 333, Taiwan	Chang Gung University	Chen, JK (corresponding author), Chang Gung Univ, Dept Physiol, Coll Med, Tao Yuan 333, Taiwan.	jkc508@mail.cgu.edu.tw						Barbieri CE, 2003, J BIOL CHEM, V278, P51408, DOI 10.1074/jbc.M309943200; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Buettner R, 2002, CLIN CANCER RES, V8, P945; Chu WK, 2006, BIOCHEM BIOPH RES CO, V342, P1356, DOI 10.1016/j.bbrc.2006.02.111; COFFER P, 1995, ONCOGENE, V10, P985; Crook T, 2000, ONCOGENE, V19, P3439, DOI 10.1038/sj.onc.1203656; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Harmes DC, 2003, ONCOGENE, V22, P7607, DOI 10.1038/sj.onc.1207129; He B, 2003, BIOCHEM BIOPH RES CO, V301, P386, DOI 10.1016/S0006-291X(02)03071-1; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Ishida S, 2000, JPN J CANCER RES, V91, P174, DOI 10.1111/j.1349-7006.2000.tb00929.x; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; Lee H, 2006, BIOCHEM BIOPH RES CO, V344, P166, DOI 10.1016/j.bbrc.2006.03.128; Massion PP, 2003, CANCER RES, V63, P7113; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Mora LB, 2002, CANCER RES, V62, P6659; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Nylander K, 2000, INT J CANCER, V87, P368, DOI 10.1002/1097-0215(20000801)87:3<368::AID-IJC9>3.3.CO;2-A; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Park BJ, 2000, CANCER RES, V60, P3370; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; Silver DL, 2004, CANCER RES, V64, P3550, DOI 10.1158/0008-5472.CAN-03-3959; Trompeter HI, 2005, J IMMUNOL, V174, P4135, DOI 10.4049/jimmunol.174.7.4135; Wang DY, 2003, INVEST OPHTH VIS SCI, V44, P4698, DOI 10.1167/iovs.03-0272; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Westfall MD, 2004, CARCINOGENESIS, V25, P857, DOI 10.1093/carcin/bgh148; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zamo A, 2002, ONCOGENE, V21, P1038, DOI 10.1038/sj.onc.1205152; Zhang F, 2003, ONCOGENE, V22, P894, DOI 10.1038/sj.onc.1206158	32	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7328	7337		10.1074/jbc.M800183200	http://dx.doi.org/10.1074/jbc.M800183200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18198175	hybrid			2022-12-25	WOS:000253997900006
J	Malik, S; Bagla, S; Chaurasia, P; Duan, Z; Bhaumik, SR				Malik, Shivani; Bagla, Shruti; Chaurasia, Priyasri; Duan, Zhen; Bhaumik, Sukesh R.			Elongating RNA polymerase II is disassembled through specific degradation of its largest but not other Subunits in response to DNA damage in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION-COUPLED REPAIR; INDUCED UBIQUITINATION; MOLECULAR-MECHANISMS; GENOME MAINTENANCE; PYRIMIDINE DIMERS; EXCISION-REPAIR; CELL-CYCLE; DHFR GENE; STRAND; YEAST	Although previous biochemical studies have demonstrated global degradation of the largest subunit, Rpb1p, of RNA polymerase II in response to DNA damage, it is still not clear whether the initiating or elongating form of Rpb1p is targeted for degradation in vivo. Further, whether other components of RNA polymerase II are degraded in response to DNA damage remains unknown. Here, we show that the Rpb1p subunit of the elongating, but not initiating, form of RNA polymerase II is degraded at the active genes in response to 4-nitroquinoline-1-oxide-induced DNA damage in Saccharomyces cerevisiae. However, other subunits of RNA polymerase II are not degraded in response to DNA damage. Further, we show that Rpb1p is essential for RNA polymerase II assembly at the active gene, and thus, the degradation of Rpb1p following DNA damage disassembles elongating RNA polymerase II. Taken together, our data demonstrate that Rpb1p but not other subunits of elongating RNA polymerase II is specifically degraded in response to DNA damage, and such a degradation of Rpb1p is critical for the disassembly of elongating RNA polymerase II at the DNA lesion in vivo.	[Malik, Shivani; Bagla, Shruti; Chaurasia, Priyasri; Duan, Zhen; Bhaumik, Sukesh R.] So Illinois Univ, Sch Med, Dept Biochem & Mol Biol, Carbondale, IL 62901 USA	Southern Illinois University System; Southern Illinois University	Bhaumik, SR (corresponding author), So Illinois Univ, Sch Med, Dept Biochem & Mol Biol, Carbondale, IL 62901 USA.	sbhaumik@siumed.edu						Bhaumik SR, 2003, METHOD ENZYMOL, V370, P445; Bhaumik SR, 2002, MOL CELL BIOL, V22, P7365, DOI 10.1128/MCB.22.21.7365-7371.2002; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOOTSMA D, 2002, GENETIC BASIS HUMAN, P221; Bregman DB, 1996, P NATL ACAD SCI USA, V93, P11586, DOI 10.1073/pnas.93.21.11586; Buratowski S, 2005, CURR OPIN CELL BIOL, V17, P257, DOI 10.1016/j.ceb.2005.04.003; Buratowski S, 2003, NAT STRUCT BIOL, V10, P679, DOI 10.1038/nsb0903-679; Chen XF, 2007, MOL CELL BIOL, V27, P4617, DOI 10.1128/MCB.00404-07; CHRISTIANS FC, 1992, MUTAT RES, V274, P93, DOI 10.1016/0921-8777(92)90056-9; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; Cromie GA, 2001, MOL CELL, V8, P1163, DOI 10.1016/S1097-2765(01)00419-1; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Hanawalt PC, 2001, MUTAT RES-DNA REPAIR, V485, P3, DOI 10.1016/S0921-8777(00)00071-9; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1992, CANCER-AM CANCER SOC, V69, P2615, DOI 10.1002/1097-0142(19920515)69:10<2615::AID-CNCR2820691036>3.0.CO;2-1; Hasty P, 2003, SCIENCE, V299, P1355, DOI 10.1126/science.1079161; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Kalogeraki VS, 2003, J BIOL CHEM, V278, P19558, DOI 10.1074/jbc.M301060200; Kanaar R, 1998, TRENDS CELL BIOL, V8, P483, DOI 10.1016/S0962-8924(98)01383-X; Leadon SA, 2000, COLD SPRING HARB SYM, V65, P561, DOI 10.1101/sqb.2000.65.561; Lee KB, 2002, P NATL ACAD SCI USA, V99, P4239, DOI 10.1073/pnas.072068399; Ljungman M, 1996, ONCOGENE, V13, P823; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Luo ZH, 2001, MUTAT RES-DNA REPAIR, V486, P259, DOI 10.1016/S0921-8777(01)00097-0; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Ratner JN, 1998, J BIOL CHEM, V273, P5184, DOI 10.1074/jbc.273.9.5184; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; SANDS AT, 1995, NATURE, V377, P162, DOI 10.1038/377162a0; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; Sims RJ, 2004, CURR OPIN CELL BIOL, V16, P263, DOI 10.1016/j.ceb.2004.04.004; SMERDON MJ, 1990, CELL, V61, P675, DOI 10.1016/0092-8674(90)90479-X; Somesh BP, 2005, CELL, V121, P913, DOI 10.1016/j.cell.2005.04.010; Svejstrup JQ, 2003, J CELL SCI, V116, P447, DOI 10.1242/jcs.00271; SWEDER KS, 1993, SCIENCE, V262, P439, DOI 10.1126/science.8211165; SWEDER KS, 1992, P NATL ACAD SCI USA, V89, P10696, DOI 10.1073/pnas.89.22.10696; Tornaletti S, 1999, J BIOL CHEM, V274, P24124, DOI 10.1074/jbc.274.34.24124; van den Boom V, 2002, BIOESSAYS, V24, P780, DOI 10.1002/bies.10150; Woudstra EC, 2002, NATURE, V415, P929, DOI 10.1038/415929a; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; Yu SL, 2003, MOL CELL BIOL, V23, P382, DOI 10.1128/MCB.23.1.382-388.2003	42	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					6897	6905		10.1074/jbc.M707649200	http://dx.doi.org/10.1074/jbc.M707649200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18195014	hybrid			2022-12-25	WOS:000253779600033
J	Foss, M; Wilcox, BWL; Alsop, GB; Zhang, DH				Foss, Margit; Wilcox, Buck W. L.; Alsop, G. Bradley; Zhang, Dahong			Taxol Crystals Can Masquerade as Stabilized Microtubules	PLOS ONE			English	Article								Taxol is a potent anti-mitotic drug used in chemotherapy, angioplastic stents, and cell biology research. By binding and stabilizing microtubules, Taxol inhibits their dynamics, crucial for cell division, motility, and survival. The drug has also been reported to induce formation of asters and bundles composed of stabilized microtubules. Surprisingly, at commonly used concentrations, Taxol forms crystals that rapidly bind fluorescent tubulin subunits, generating structures with an uncanny resemblance to microtubule asters and bundles. Kinetic and topological considerations suggest that tubulin subunits, rather than microtubules, bind the crystals. This sequestration of tubulin from the subunit pool would be expected to shift the equilibrium of free to polymerized tubulin to disfavor assembly. Our results imply that some previously reported Taxol-induced asters or bundles could include or be composed of tubulin-decorated Taxol crystals. Thus, reevaluation of certain morphological, chemical, and physical properties of Taxol-treated microtubules may be necessary. Moreover, our findings suggest a novel mechanism for chemotherapy-induced cytotoxicity in non-dividing cells, with far-reaching medical implications.	[Foss, Margit; Zhang, Dahong] Oregon State Univ, Dept Zool, Corvallis, OR 97331 USA; [Wilcox, Buck W. L.; Alsop, G. Bradley] Oregon State Univ, Mol & Cell Biol Prog, Corvallis, OR USA; [Zhang, Dahong] Oregon State Univ, Ctr Genome Res & Biocomp, Corvallis, OR USA	Oregon State University; Oregon State University; Oregon State University	Zhang, DH (corresponding author), Oregon State Univ, Dept Zool, Corvallis, OR 97331 USA.	zhangd@science.oregonstate.edu			B.W.L. Wilcox [HHMI summer research fellowship]; NSF [MCB-0090725, 0424897]	B.W.L. Wilcox; NSF(National Science Foundation (NSF))	This work was supported by an HHMI summer research fellowship to B.W.L. Wilcox, and NSF Grant MCB-0090725, 0424897 to D. Zhang. The funders had no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript.	Antoine JC, 2007, LANCET NEUROL, V6, P75, DOI 10.1016/S1474-4422(06)70679-2; Cross RA, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P317; DEBRABANDER M, 1981, P NATL ACAD SCI-BIOL, V78, P5608; DERRY WB, 1995, BIOCHEMISTRY-US, V34, P2203, DOI 10.1021/bi00007a014; GAGLIO T, 1995, J CELL BIOL, V131, P693, DOI 10.1083/jcb.131.3.693; GLOUSHANKOVA NA, 1994, P NATL ACAD SCI USA, V91, P8597, DOI 10.1073/pnas.91.18.8597; GREEN KJ, 1983, CELL MOTIL CYTOSKEL, V3, P283, DOI 10.1002/cm.970030402; HAMMALVAREZ SF, 1994, P NATL ACAD SCI USA, V91, P7812, DOI 10.1073/pnas.91.16.7812; HARRIS PJ, 1992, J CELL SCI, V102, P557; Honore S, 2004, CANCER RES, V64, P4957, DOI 10.1158/0008-5472.CAN-04-0693; Jiko M, 2007, INT J CLIN ONCOL, V12, P284, DOI 10.1007/s10147-007-0681-y; Jordan MA, 1996, CANCER RES, V56, P816; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Jordan MA, 1999, METHOD CELL BIOL, V61, P267; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Lazareva EM, 2003, CELL BIOL INT, V27, P633, DOI 10.1016/S1065-6995(03)00120-3; Liggins RT, 1997, J PHARM SCI, V86, P1458, DOI 10.1021/js9605226; MATHEW AE, 1992, J MED CHEM, V35, P145, DOI 10.1021/jm00079a019; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; Pryor DE, 2002, BIOCHEMISTRY-US, V41, P9109, DOI 10.1021/bi020211b; ROBERTS JR, 1989, J HISTOCHEM CYTOCHEM, V37, P1659, DOI 10.1177/37.11.2572626; ROWINSKY EK, 1993, SEMIN ONCOL, V20, P1; SANDOVAL IV, 1984, J CELL BIOL, V99, pS113, DOI 10.1083/jcb.99.1.113s; SCHATTEN G, 1982, J CELL BIOL, V94, P455, DOI 10.1083/jcb.94.2.455; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; TURNER PF, 1984, J CELL BIOL, V99, P940, DOI 10.1083/jcb.99.3.940; URRUTIA R, 1991, P NATL ACAD SCI USA, V88, P6701, DOI 10.1073/pnas.88.15.6701; VERDE F, 1991, J CELL BIOL, V112, P1177, DOI 10.1083/jcb.112.6.1177; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; WHITE JG, 1982, AM J PATHOL, V108, P184; Xiao H, 2006, P NATL ACAD SCI USA, V103, P10166, DOI 10.1073/pnas.0603704103; Yang CM, 2006, ADV DRUG DELIVER REV, V58, P402, DOI 10.1016/j.addr.2006.01.017; Yvon AMC, 1999, MOL BIOL CELL, V10, P947, DOI 10.1091/mbc.10.4.947	33	23	24	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2008	3	1							e1476	10.1371/journal.pone.0001476	http://dx.doi.org/10.1371/journal.pone.0001476			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SO	18213384	Green Submitted, Green Published, gold			2022-12-25	WOS:000260503900021
J	Lesnick, TG; Sorenson, EJ; Ahlskog, JE; Henley, JR; Shehadeh, L; Papapetropoulos, S; Maraganore, DM				Lesnick, Timothy G.; Sorenson, Eric J.; Ahlskog, J. Eric; Henley, John R.; Shehadeh, Lina; Papapetropoulos, Spiridon; Maraganore, Demetrius M.			Beyond Parkinson Disease: Amyotrophic Lateral Sclerosis and the Axon Guidance Pathway	PLOS ONE			English	Article							CYCLIN-DEPENDENT KINASE-5; CENTRAL-NERVOUS-SYSTEM; ANTERIOR HORN CELLS; MOTOR-NEURONS; EXPRESSION; SEMAPHORIN; ALS; DROSOPHILA; MIGRATION; PROTEIN	Background. We recently described a genomic pathway approach to study complex diseases. We demonstrated that models constructed using single nucleotide polymorphisms (SNPs) within axon guidance pathway genes were highly predictive of Parkinson disease (PD) susceptibility, survival free of PD, and age at onset of PD within two independent whole-genome association datasets. We also demonstrated that several axon guidance pathway genes represented by SNPs within our final models were differentially expressed in PD. Methodology/ Principal Findings. Here we employed our genomic pathway approach to analyze data from a whole-genome association dataset of amyotrophic lateral sclerosis (ALS); and demonstrated that models constructed using SNPs within axon guidance pathway genes were highly predictive of ALS susceptibility (odds ratio = 1739.73, p= 2.92x10(-60)), survival free of ALS (hazards ratio = 149.80, p= 1.25x10(-74)), and age at onset of ALS (R-2= 0.86, p= 5.96x10(-66)). We also extended our analyses of a whole-genome association dataset of PD, which shared 320,202 genomic SNPs in common with the whole-genome association dataset of ALS. We compared for ALS and PD the genes represented by SNPs in the final models for susceptibility, survival free of disease, and age at onset of disease and noted that 52.2%, 37.8%, and 34.9% of the genes were shared respectively. Conclusions/Significance. Our findings for the axon guidance pathway and ALS have prior biological plausibility, overlap partially with PD, and may provide important insight into the causes of these and related neurodegenerative disorders.	[Lesnick, Timothy G.] Mayo Clin, Dept Hlth Sci Res, Div Biostat, Rochester, MN USA; [Henley, John R.] Mayo Clin, Dept Physiol & Biomed Engn, Rochester, MN USA; [Shehadeh, Lina] Univ Miami, Miller Sch Med, Mol & Cell Pharmacol, Miami, FL USA; [Papapetropoulos, Spiridon] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL USA; [Sorenson, Eric J.; Ahlskog, J. Eric] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; University of Miami; University of Miami; Mayo Clinic	Maraganore, DM (corresponding author), Mayo Clin, Dept Neurol, Rochester, MN 55905 USA.	dmaraganore@mayo.edu	Resource Center, NINDS Human Genetics/AGF-2474-2022; Sander-Effron, Samuel/AAX-2231-2020; Henley, John/D-7171-2011	Henley, John/0000-0003-1846-5941	National Institutes of Health [R01 ES10751]; Michael J. Fox Foundation; Linked Efforts to Accelerate Parkinson Solutions award; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL083673] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010751] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Michael J. Fox Foundation; Linked Efforts to Accelerate Parkinson Solutions award; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported in part by grants from the National Institutes of Health (R01 ES10751 to DMM), and the Michael J. Fox Foundation (Linked Efforts to Accelerate Parkinson Solutions award to DMM). The funders had no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript.	ABDULLA EM, 1993, ANN NY ACAD SCI, V679, P276, DOI 10.1111/j.1749-6632.1993.tb18308.x; Allan DW, 1998, J COMP NEUROL, V391, P275, DOI 10.1002/(SICI)1096-9861(19980216)391:3<275::AID-CNE1>3.0.CO;2-Z; Bajaj NPS, 1998, NEUROSCI LETT, V245, P45, DOI 10.1016/S0304-3940(98)00176-1; Bajaj NPS, 1999, PROG NEURO-PSYCHOPH, V23, P833, DOI 10.1016/S0278-5846(99)00044-5; Bajaj NPS, 2000, AMYOTROPH LATERAL SC, V1, P319, DOI 10.1080/146608200300079563; Barrett C, 2001, MECH DEVELOP, V106, P163, DOI 10.1016/S0925-4773(01)00415-4; Boulin T, 2006, CURR BIOL, V16, P1871, DOI 10.1016/j.cub.2006.08.056; Braak H, 2004, CELL TISSUE RES, V318, P121, DOI 10.1007/s00441-004-0956-9; Breslow NE, 1980, IARC SCI PUBL, P5; Brown RC, 2005, ENVIRON HEALTH PERSP, V113, P1250, DOI 10.1289/ehp.7567; Burgess RW, 2006, J NEUROSCI, V26, P5756, DOI 10.1523/JNEUROSCI.0736-06.2006; Chilton JK, 2006, DEV BIOL, V292, P13, DOI 10.1016/j.ydbio.2005.12.048; Chung YH, 2005, BRAIN RES, V1050, P203, DOI 10.1016/j.brainres.2005.05.060; Cohen S, 2005, EUR J NEUROSCI, V21, P1767, DOI 10.1111/j.1460-9568.2005.04021.x; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; Corti S, 2007, BRAIN, V130, P1289, DOI 10.1093/brain/awm043; COX DR, 1972, J R STAT SOC B, V34, P187; De Winter F, 2006, MOL CELL NEUROSCI, V32, P102, DOI 10.1016/j.mcn.2006.03.002; Draper N.R., 1998, APPL REGRESSION ANAL, P79; Dunckley T, 2007, NEW ENGL J MED, V357, P775, DOI 10.1056/NEJMoa070174; Eberhart J, 2002, DEV BIOL, V247, P89, DOI 10.1006/dbio.2002.0695; Feldner J, 2007, J NEUROSCI, V27, P4978, DOI 10.1523/JNEUROSCI.1132-07.2007; Fischer LR, 2004, EXP NEUROL, V185, P232, DOI 10.1016/j.expneurol.2003.10.004; Franz CK, 2005, J NEUROSCI, V25, P2081, DOI 10.1523/JNEUROSCI.4880-04.2005; Fung HC, 2006, LANCET NEUROL, V5, P911, DOI 10.1016/S1474-4422(06)70578-6; Garruto Ralph M., 2006, Current Alzheimer Research, V3, P397, DOI 10.2174/156720506778249425; Gomez TM, 2006, NAT REV NEUROSCI, V7, P115, DOI 10.1038/nrn1844; Hammond R, 2005, DEVELOPMENT, V132, P4483, DOI 10.1242/dev.02038; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Hu JH, 2003, J NEUROCHEM, V85, P422, DOI 10.1046/j.1471-4159.2003.01669.x; Huang X, 2003, DEVELOPMENT, V130, P3147, DOI 10.1242/dev.00518; Huber AB, 2005, NEURON, V48, P949, DOI 10.1016/j.neuron.2005.12.003; Ignacio S, 2005, ANN NY ACAD SCI, V1053, P121, DOI 10.1196/annals.1344.010; Jacquier A, 2006, ANN NEUROL, V60, P105, DOI 10.1002/ana.20886; Kanehisa M, 1997, TRENDS GENET, V13, P375, DOI 10.1016/S0168-9525(97)01223-7; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kanehisa M, 2006, NUCLEIC ACIDS RES, V34, pD354, DOI 10.1093/nar/gkj102; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kasperaviciute D, 2007, BRAIN, V130, P2292, DOI 10.1093/brain/awm055; Kato S, 2003, ACTA NEUROPATHOL, V106, P112, DOI 10.1007/s00401-003-0708-z; Kaufmann N, 1998, DEVELOPMENT, V125, P453; Kramer ER, 2006, NEURON, V50, P35, DOI 10.1016/j.neuron.2006.02.020; Lederer CW, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-26; Lesnick TG, 2007, PLOS GENET, V3, P984, DOI 10.1371/journal.pgen.0030098; Lim YS, 1999, J NEUROSCI, V19, P7048, DOI 10.1523/JNEUROSCI.19-16-07048.1999; Lindholm T, 2004, NEUROREPORT, V15, P649, DOI 10.1097/00001756-200403220-00015; Lucanic M, 2006, DEVELOPMENT, V133, P4549, DOI 10.1242/dev.02648; Maraganore DM, 2005, AM J HUM GENET, V77, P685, DOI 10.1086/496902; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; Nakamura S, 1997, NEUROLOGY, V48, P267, DOI 10.1212/WNL.48.1.267; Nguyen MD, 2001, NEURON, V30, P135, DOI 10.1016/S0896-6273(01)00268-9; Nguyen MD, 2003, J NEUROSCI, V23, P2131; Parent M, 2006, J NEURAL TRANSM-SUPP, P85; Patel K, 2001, DEVELOPMENT, V128, P5031; Patzke H, 2002, TRENDS NEUROSCI, V25, P8, DOI 10.1016/S0166-2236(00)02000-2; Sato-Maeda M, 2006, DEVELOPMENT, V133, P937, DOI 10.1242/dev.02268; Schneider VA, 2003, DEV BIOL, V263, P1, DOI 10.1016/S0012-1606(03)00329-4; Schymick JC, 2007, HUM MOL GENET, V16, pR233, DOI 10.1093/hmg/ddm215; Schymick JC, 2007, LANCET NEUROL, V6, P322, DOI 10.1016/S1474-4422(07)70037-6; Tudor EL, 2005, J BIOL CHEM, V280, P34735, DOI 10.1074/jbc.M506216200; van Es MA, 2008, NAT GENET, V40, P29, DOI 10.1038/ng.2007.52; VANES MA, 2007, LANCET NEUROL; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; Xiao T, 2003, J NEUROSCI, V23, P4190; Yu HH, 1998, NEURON, V20, P207, DOI 10.1016/S0896-6273(00)80450-X	65	46	47	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2008	3	1							e1449	10.1371/journal.pone.0001449	http://dx.doi.org/10.1371/journal.pone.0001449			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SN	18197259	Green Published, gold, Green Submitted			2022-12-25	WOS:000260503800020
J	Contu, D; Morelli, L; Santoni, F; Foster, JW; Francalacci, P; Cucca, F				Contu, Daniela; Morelli, Laura; Santoni, Federico; Foster, Jamie W.; Francalacci, Paolo; Cucca, Francesco			Y-Chromosome Based Evidence for Pre-Neolithic Origin of the Genetically Homogeneous but Diverse Sardinian Population: Inference for Association Scans	PLOS ONE			English	Article							MOLECULAR CHARACTERIZATION; LINKAGE DISEQUILIBRIUM; MULTIPLE-SCLEROSIS; MAXIMUM-LIKELIHOOD; IBERIAN PENINSULA; GENE FLOW; EUROPE; PERSPECTIVE; DEMOGRAPHY; HAPLOTYPE	The island of Sardinia shows a unique high incidence of several autoimmune diseases with multifactorial inheritance, particularly type 1 diabetes and multiple sclerosis. The prior knowledge of the genetic structure of this population is fundamental to establish the optimal design for association studies in these diseases. Previous work suggested that the Sardinians are a relatively homogenous population, but some reports were contradictory and data were largely based on variants subject to selection. For an unbiased assessment of genetic structure, we studied a combination of neutral Y-chromosome variants, 21 biallelic and 8 short tandem repeats (STRs) in 930 Sardinian males. We found a high degree of interindividual variation but a homogenous distribution of the detected variability in samples from three separate regions of the island. One haplogroup, I-M26, is rare or absent outside Sardinia and is very common (0.37 frequency) throughout the island, consistent with a founder effect. A Bayesian full likelihood analysis (BATWING) indicated that the time from the most recent common ancestor (TMRCA) of I-M26, was 21.0 (16.0-25.5) thousand years ago (KYA) and that the population began to expand 14.0 (7.8-22.0) KYA. These results suggest a largely pre-Neolithic settlement of the island with little subsequent gene flow from outside populations. Consequently, Sardinia is an especially attractive venue for case-control genome wide association scans in common multifactorial diseases. Concomitantly, the high degree of interindividual variation in the current population facilitates fine mapping efforts to pinpoint the aetiologic polymorphisms.	[Morelli, Laura; Foster, Jamie W.; Cucca, Francesco] Univ Sassari, Dipartimento Sci Biomed, I-07100 Sassari, Italy; [Contu, Daniela] Ospedale Microcitemico, Lab Immunogenet, Cagliari, Italy; [Santoni, Federico] Ctr Adv Stud Res & Dev Sardinia, CRS4, Pula, Italy; [Francalacci, Paolo] Univ Sassari, Dept Zool & Genet Evol, Sassari, Italy	University of Sassari; University of Sassari	Cucca, F (corresponding author), Univ Sassari, Dipartimento Sci Biomed, I-07100 Sassari, Italy.	fcucca@uniss.it		CUCCA, Francesco/0000-0002-7414-1995; FRANCALACCI, Paolo/0000-0001-7912-162X; Santoni, Federico/0000-0002-3258-4747	Telethon-JDRF [GJT030477]; Interreg III	Telethon-JDRF(Juvenile Diabetes Research Foundation); Interreg III(European Commission)	This work was supported by funds from Telethon-JDRF (GJT030477) to FC and Interreg III to PF.	Achilli A, 2004, AM J HUM GENET, V75, P910, DOI 10.1086/425590; Angius A, 2002, HUM GENET, V111, P9, DOI 10.1007/s00439-002-0753-z; Bickel DR, 2002, COMPUT STAT DATA AN, V39, P153, DOI 10.1016/S0167-9473(01)00057-3; Bosch E, 2006, ANN HUM GENET, V70, P459, DOI 10.1111/j.1469-1809.2005.00251.x; Bosch E, 2003, HUM GENET, V112, P353, DOI 10.1007/s00439-003-0913-9; Bosch E, 2001, AM J HUM GENET, V68, P1019, DOI 10.1086/319521; Capelli C, 2003, CURR BIOL, V13, P979, DOI 10.1016/S0960-9822(03)00373-7; Cappello N, 1996, ANN HUM GENET, V60, P125, DOI 10.1111/j.1469-1809.1996.tb01183.x; Cavalli-Sforza L. L., 1994, HIST GEOGRAPHY HUMAN; Cinnioglu C, 2004, HUM GENET, V114, P127, DOI 10.1007/s00439-003-1031-4; Contu D, 2002, DIABETES, V51, P3573, DOI 10.2337/diabetes.51.12.3573; CONTU L, 1992, TISSUE ANTIGENS, V40, P165, DOI 10.1111/j.1399-0039.1992.tb02041.x; CUCCA F, 1995, HUM IMMUNOL, V43, P301, DOI 10.1016/0198-8859(95)00042-3; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; Ellis N, 2002, GENOME RES, V12, P339; EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; Excoffier L, 2005, EVOL BIOINFORM, V1, P47, DOI 10.1177/117693430500100003; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Flores C, 2004, EUR J HUM GENET, V12, P855, DOI 10.1038/sj.ejhg.5201225; Francalacci P, 2003, AM J PHYS ANTHROPOL, V121, P270, DOI 10.1002/ajpa.10265; Fraumene C, 2003, HUM GENET, V114, P1, DOI 10.1007/s00439-003-1008-3; Hedges SB, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-31; Helgason A, 2005, NAT GENET, V37, P90, DOI 10.1038/ng1492; Jobling MA, 2003, NAT REV GENET, V4, P598, DOI 10.1038/nrg1124; KARVONEN M, 1993, DIABETOLOGIA, V36, P883, DOI 10.1007/BF02374468; Lampis R, 2000, HUM MOL GENET, V9, P2959, DOI 10.1093/hmg/9.20.2959; Lange K., 1997, MATH STAT METHODS GE; Lappalainen T, 2006, GENE, V376, P207, DOI 10.1016/j.gene.2006.03.004; LILLIU G, 1982, CIVILTA NURAGICA; Loudianos G, 1999, HUM MUTAT, V14, P294, DOI 10.1002/(SICI)1098-1004(199910)14:4<294::AID-HUMU4>3.0.CO;2-9; Marrosu MG, 2007, BMC GENET, V8, DOI 10.1186/1471-2156-8-25; Martinez L, 2007, EUR J HUM GENET, V15, P485, DOI 10.1038/sj.ejhg.5201769; Nei M, 1987, MOL EVOLUTIONARY GEN; Pugliatti M, 2006, EUR J NEUROL, V13, P700, DOI 10.1111/j.1468-1331.2006.01342.x; Rootsi S, 2004, AM J HUM GENET, V75, P128, DOI 10.1086/422196; Rootsi S, 2007, EUR J HUM GENET, V15, P204, DOI 10.1038/sj.ejhg.5201748; Rosatelli MC, 1998, HUM GENET, V103, P428, DOI 10.1007/s004390050846; ROSATELLI MC, 1992, AM J HUM GENET, V50, P422; Scozzari R, 2001, HUM IMMUNOL, V62, P871, DOI 10.1016/S0198-8859(01)00286-5; Semino O, 2000, SCIENCE, V290, P1155, DOI 10.1126/science.290.5494.1155; SINISCALCO M, 1961, NATURE, V190, P1179, DOI 10.1038/1901179a0; SLATKIN M, 1995, GENETICS, V139, P457; SONDAAR P, 1995, CR ACAD SCI II, V320, P145; SONDAAR PY, 1998, SARDINIAN AEGEAN CHR, P45; Thomson R, 2000, P NATL ACAD SCI USA, V97, P7360, DOI 10.1073/pnas.97.13.7360; Torroni A, 2001, AM J HUM GENET, V69, P844, DOI 10.1086/323485; Underhill PA, 1997, GENOME RES, V7, P996, DOI 10.1101/gr.7.10.996; Underhill PA, 2000, NAT GENET, V26, P358, DOI 10.1038/81685; WALSH PS, 1991, BIOTECHNIQUES, V10, P506, DOI 10.2144/000114018; Weale ME, 2002, MOL BIOL EVOL, V19, P1008, DOI 10.1093/oxfordjournals.molbev.a004160; Wells RS, 2001, P NATL ACAD SCI USA, V98, P10244, DOI 10.1073/pnas.171305098; Wilson IJ, 2003, J R STAT SOC A STAT, V166, P155, DOI 10.1111/1467-985X.00264; Xue YL, 2006, GENETICS, V172, P2431, DOI 10.1534/genetics.105.054270; Zavattari P, 2000, HUM MOL GENET, V9, P2947, DOI 10.1093/hmg/9.20.2947; Zei G, 2003, EUR J HUM GENET, V11, P802, DOI 10.1038/sj.ejhg.5201040; Zhivotovsky LA, 2004, AM J HUM GENET, V74, P50, DOI 10.1086/380911; ZOLEDZIEWSKA M, 2007, DIABETES IN PRESS	57	53	53	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2008	3	1							e1430	10.1371/journal.pone.0001430	http://dx.doi.org/10.1371/journal.pone.0001430			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366GT	18183308	Green Published, Green Submitted, gold			2022-12-25	WOS:000260469400024
J	Scharlemann, JPW; Benz, D; Hay, SI; Purse, BV; Tatem, AJ; Wint, GRW; Rogers, DJ				Scharlemann, Joern P. W.; Benz, David; Hay, Simon I.; Purse, Bethan V.; Tatem, Andrew J.; Wint, G. R. William; Rogers, David J.			Global Data for Ecology and Epidemiology: A Novel Algorithm for Temporal Fourier Processing MODIS Data	PLOS ONE			English	Article							TIME-SERIES; BOVINE TUBERCULOSIS; BORNE DISEASE; EAST-AFRICA; SATELLITE; NDVI; BLUETONGUE; PREDICTION; ACCURACY; EUROPE	Background. Remotely-sensed environmental data from earth-orbiting satellites are increasingly used to model the distribution and abundance of both plant and animal species, especially those of economic or conservation importance. Time series of data from the MODerate-resolution Imaging Spectroradiometer (MODIS) sensors on-board NASA's Terra and Aqua satellites offer the potential to capture environmental thermal and vegetation seasonality, through temporal Fourier analysis, more accurately than was previously possible using the NOAA Advanced Very High Resolution Radiometer (AVHRR) sensor data. MODIS data are composited over 8- or 16-day time intervals that pose unique problems for temporal Fourier analysis. Applying standard techniques to MODIS data can introduce errors of up to 30% in the estimation of the amplitudes and phases of the Fourier harmonics. Methodology/Principal Findings. We present a novel spline-based algorithm that overcomes the processing problems of composited MODIS data. The algorithm is tested on artificial data generated using randomly selected values of both amplitudes and phases, and provides an accurate estimate of the input variables under all conditions. The algorithm was then applied to produce layers that capture the seasonality in MODIS data for the period from 2001 to 2005. Conclusions/Significance. Global temporal Fourier processed images of 1 km MODIS data for Middle Infrared Reflectance, day- and night-time Land Surface Temperature (LST), Normalised Difference Vegetation Index (NDVI), and Enhanced Vegetation Index (EVI) are presented for ecological and epidemiological applications. The finer spatial and temporal resolution, combined with the greater geolocational and spectral accuracy of the MODIS instruments, compared with previous multi-temporal data sets, mean that these data may be used with greater confidence in species' distribution modelling.	[Hay, Simon I.; Tatem, Andrew J.] Univ Oxford, Dept Zool, Spatial Ecol & Epidemiol Grp, Oxford OX1 3PS, England; [Scharlemann, Joern P. W.; Benz, David; Hay, Simon I.; Purse, Bethan V.; Tatem, Andrew J.; Wint, G. R. William] Univ Oxford, Wellcome Trust Collaborative Progr, Kenya Med Res Inst, Ctr Geogr Med, Malaria Publ Hlth Epidemiol Grp, Nairobi, Kenya	University of Oxford; Kenya Medical Research Institute	Rogers, DJ (corresponding author), Univ Oxford, Dept Zool, Spatial Ecol & Epidemiol Grp, S Parks Rd, Oxford OX1 3PS, England.	david.rogers@zoo.ox.ac.uk	Purse, Bethan V/I-6640-2012; Hay, Simon Iain/F-8967-2015; Scharlemann, Jorn/A-4737-2008	Purse, Bethan V/0000-0001-5140-2710; Hay, Simon Iain/0000-0002-0611-7272; Scharlemann, Jorn/0000-0002-2834-6367; Wint, William/0000-0003-0916-0847; Tatem, Andrew/0000-0002-7270-941X	DEFRA [SE3229, SE4105]; Wellcome Trust [079091]; Pro-Poor Livestock Policy Initiative and Environmental Animal Health Management Initiative of the Food and Agriculture Organisation of the United Nations [TF/IGAD/CPA 183295-2006/AGAL, GCP/PHI/050/ITA]; BBSRC/DEFRA [BBS/B/00603, SE4104]; European Union [GOCE-2003-010284]; Biotechnology and Biological Sciences Research Council [BBS/B/00646, BBS/B/00603] Funding Source: researchfish	DEFRA(Department for Environment, Food & Rural Affairs (DEFRA)); Wellcome Trust(Wellcome TrustEuropean Commission); Pro-Poor Livestock Policy Initiative and Environmental Animal Health Management Initiative of the Food and Agriculture Organisation of the United Nations; BBSRC/DEFRA(Department for Environment, Food & Rural Affairs (DEFRA)UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); European Union(European Commission); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	The research was funded by grants from DEFRA (SE3229 to GRWW, SE4105 to Sarah Randolph supporting JPWS), Wellcome Trust (Senior Research Fellowship #079091 to SIH), Pro-Poor Livestock Policy Initiative and Environmental Animal Health Management Initiative of the Food and Agriculture Organisation of the United Nations (TF/IGAD/CPA 183295-2006/AGAL and GCP/PHI/050/ITA to GRWW), BBSRC/DEFRA (BBS/B/00603 to BVP and SE4104 to DJR), European Union (GOCE-2003-010284 EDEN supporting DB, GRWW and DJR). This work forms part of the output of the Malaria Atlas Project (MAP, http://www.map.ox.ac.uk) principally funded by the Wellcome Trust, UK. This publication is catalogued by the EDEN Steering Committee as EDEN 0047 (http://www.eden-fp6project.net/). The contents of this publication are the sole responsibility of the authors and do not necessarily reflect the views of the European Commission. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANDRES L, 1994, INT J REMOTE SENS, V15, P1115, DOI 10.1080/01431169408954145; ANDREWARTHA HG, 1954, DISTRIBUTION ABUNDAN; Baylis M, 2001, VET REC, V149, P639, DOI 10.1136/vr.149.21.639; Boyd D. S., 1998, REMOTE SENSING REV, V16, P293, DOI DOI 10.1080/02757259809532357; Chatfield C, 1980, ANAL TIME SERIES INT; EASTMAN JR, 1993, PHOTOGRAMM ENG REM S, V59, P991; FAO, 2007, GRIDD LIV WORLD; Friedl MA, 2002, REMOTE SENS ENVIRON, V83, P287, DOI 10.1016/S0034-4257(02)00078-0; Gilbert M, 2005, NATURE, V435, P491, DOI 10.1038/nature03548; Hay SI, 2006, ADV PARASIT, V62, P37, DOI 10.1016/S0065-308X(05)62002-7; Hay SI, 1999, TROP MED INT HEALTH, V4, P58, DOI 10.1046/j.1365-3156.1999.00355.x; Hendrickx G, 2000, PARASITOLOGY, V120, P121, DOI 10.1017/S0031182099005338; Hendrickx G, 2001, B ENTOMOL RES, V91, P333, DOI 10.1079/BER2001103; Huete A, 2002, REMOTE SENS ENVIRON, V83, P195, DOI 10.1016/S0034-4257(02)00096-2; Johnson DDP, 1998, P ROY SOC B-BIOL SCI, V265, P951, DOI 10.1098/rspb.1998.0383; Jonsson P, 2004, COMPUT GEOSCI-UK, V30, P833, DOI 10.1016/j.cageo.2004.05.006; Jonsson P, 2002, IEEE T GEOSCI REMOTE, V40, P1824, DOI 10.1109/TGRS.2002.802519; Julien Y, 2006, REMOTE SENS ENVIRON, V103, P43, DOI 10.1016/j.rse.2006.03.011; Justice CO, 1998, IEEE T GEOSCI REMOTE, V36, P1228, DOI 10.1109/36.701075; McPherson JM, 2007, ECOGRAPHY, V30, P135, DOI 10.1111/j.2006.0906-7590.04823.x; MENENTI M, 1993, ADV SPACE RES-SERIES, V13, P233, DOI 10.1016/0273-1177(93)90550-U; Myneni RB, 1998, J GEOPHYS RES-ATMOS, V103, P6145, DOI 10.1029/97JD03603; Myneni RB, 1997, NATURE, V386, P698, DOI 10.1038/386698a0; Nemani RR, 2003, SCIENCE, V300, P1560, DOI 10.1126/science.1082750; Omumbo JA, 2005, TROP MED INT HEALTH, V10, P557, DOI 10.1111/j.1365-3156.2005.01424.x; Omumbo JA, 2002, PHOTOGRAMM ENG REM S, V68, P161; Pettorelli N, 2005, TRENDS ECOL EVOL, V20, P503, DOI 10.1016/j.tree.2005.05.011; Press W.H, 1996, FORTRAN NUMERICAL RE, V1; Purse BV, 2004, MED VET ENTOMOL, V18, P90, DOI 10.1111/j.0269-283X.2004.00492.x; Randolph SE, 2006, ADV PARASIT, V62, P263, DOI 10.1016/S0065-308X(05)62008-8; Randolph SE, 2000, PARASITOLOGY, V121, P15, DOI 10.1017/S0031182099006083; Robinson T, 1997, MED VET ENTOMOL, V11, P235, DOI 10.1111/j.1365-2915.1997.tb00401.x; Roerink GJ, 2000, INT J REMOTE SENS, V21, P1911, DOI 10.1080/014311600209814; Rogers DJ, 2006, ADV PARASIT, V62, P181, DOI 10.1016/S0065-308X(05)62006-4; Rogers David J., 1994, P247; Rogers DJ, 2003, NAT REV MICROBIOL, V1, P231, DOI 10.1038/nrmicro776; Rogers DJ, 2002, PHOTOGRAMM ENG REM S, V68, P112; Rogers DJ, 1996, ANN TROP MED PARASIT, V90, P225, DOI 10.1080/00034983.1996.11813049; Rogers DJ, 2002, NATURE, V415, P710, DOI 10.1038/415710a; Rogers DJ, 2000, ADV PARASIT, V47, P129, DOI 10.1016/S0065-308X(00)47008-9; ROGERS DJ, 2004, TRYPANOSOMIASES, P129; ROGERS DJ, 2006, 36 PPLPI FAO UN; Salomon, 2004, GEOSC REM SENS S 200, V1, P241, DOI DOI 10.1109/IGARSS.2004.1369005; Schaaf CB, 2002, REMOTE SENS ENVIRON, V83, P135, DOI 10.1016/S0034-4257(02)00091-3; Tan B, 2006, REMOTE SENS ENVIRON, V105, P98, DOI 10.1016/j.rse.2006.06.008; Tatem AJ, 2003, VET MICROBIOL, V97, P13, DOI 10.1016/j.vetmic.2003.08.009; Verhoef W, 1996, INT J REMOTE SENS, V17, P231, DOI 10.1080/01431169608949001; Wan ZM, 1997, IEEE T GEOSCI REMOTE, V35, P980, DOI 10.1109/36.602541; Wen J, 2004, MT RES DEV, V24, P348, DOI 10.1659/0276-4741(2004)024[0348:ROACVI]2.0.CO;2; Wint GRW, 2002, TRENDS MICROBIOL, V10, P441, DOI 10.1016/S0966-842X(02)02444-7; Wolfe RE, 2002, REMOTE SENS ENVIRON, V83, P31, DOI 10.1016/S0034-4257(02)00085-8	51	196	197	0	44	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2008	3	1							e1408	10.1371/journal.pone.0001408	http://dx.doi.org/10.1371/journal.pone.0001408			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366GT	18183289	gold, Green Published, Green Accepted, Green Submitted			2022-12-25	WOS:000260469400005
J	Bermudez, O; Marchetti, S; Pages, G; Gimond, C				Bermudez, O.; Marchetti, S.; Pages, G.; Gimond, C.			Post-translational regulation of the ERK phosphatase DUSP6/MKP3 by the mTOR pathway	ONCOGENE			English	Article						ERK phosphatase DUSP6/MKP-3; mTOR; phosphorylation; degradation	ACTIVATED PROTEIN-KINASE; SPECIFICITY; MKP3; TRANSLATION; CANCER; MOTIF	MAP kinases phosphatases (MKPs) belong to the dual-specificity phosphatase family (DUSP) and dephosphorylate phosphothreonine and phosphotyrosine within MAP kinases. We had previously shown that DUSP6/MKP-3 was phosphorylated and degraded upon growth factor stimulation, in a MEK-dependent manner. Here we show that another pathway involved in growth factor signaling, the PI3K/mTOR signaling pathway, accounts for a part of the phosphorylation and degradation of DUSP6 induced by serum growth factors, as evidenced by experiments using pharmacological inhibitors of PI3 kinase and mammalian target of rapamycin (mTOR). Moreover, specific agonists of the mTOR pathway, such as amino acids or insulin/IGF-1, which do not activate extracellular signal regulated kinases (ERKs) in our cellular model, were also able to induce the phosphorylation and degradation of DUSP6. However, a basal activity of MEK was required for the mTOR pathway-mediated phosphorylation to occur. Mutagenesis studies identified serine 159 within DUSP6 as the target of the mTOR pathway. The ERK phosphatase DUSP6 may thus constitute a novel branch-point of the crosstalk between two major signaling pathways induced by growth factors, the MEK/ERK pathway and the PI3K/mTOR pathway.	[Bermudez, O.; Marchetti, S.; Pages, G.; Gimond, C.] Univ Nice Sophia Antipolis, CNRS, Ctr Antoine Lacassagne, Inst Signaling Dev Biol & Canc Res,UMR 6543, F-06189 Nice, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne	Gimond, C (corresponding author), Univ Nice Sophia Antipolis, CNRS, Ctr Antoine Lacassagne, Inst Signaling Dev Biol & Canc Res,UMR 6543, 33 Ave Valombrose, F-06189 Nice, France.	gimond@unice.fr	Pages, Gilles/N-7135-2017; Marchetti, Sandrine/P-6479-2016	Marchetti, Sandrine/0000-0001-8326-5730; Gimond, Clotilde/0000-0003-1708-4629				Averous J, 2006, ONCOGENE, V25, P6423, DOI 10.1038/sj.onc.1209887; Avruch J, 2006, ONCOGENE, V25, P6361, DOI 10.1038/sj.onc.1209882; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Chambard JC, 2007, BBA-MOL CELL RES, V1773, P1299, DOI 10.1016/j.bbamcr.2006.11.010; Echevarria D, 2005, DEV BIOL, V277, P114, DOI 10.1016/j.ydbio.2004.09.011; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Jeffrey KL, 2007, NAT REV DRUG DISCOV, V6, P391, DOI 10.1038/nrd2289; Kawakami Y, 2003, NAT CELL BIOL, V5, P513, DOI 10.1038/ncb989; Kim M, 2004, MOL CELL BIOL, V24, P573, DOI 10.1128/MCB.24.2.573-583.2004; Land SC, 2007, J BIOL CHEM, V282, P20534, DOI 10.1074/jbc.M611782200; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; Li CY, 2007, DEVELOPMENT, V134, P167, DOI 10.1242/dev.02701; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Mamane Y, 2006, ONCOGENE, V25, P6416, DOI 10.1038/sj.onc.1209888; Marchetti S, 2005, MOL CELL BIOL, V25, P854, DOI 10.1128/MCB.25.2.854-864.2005; Marchetti S, 2004, J CELL PHYSIOL, V199, P441, DOI 10.1002/jcp.10465; McKay MM, 2007, ONCOGENE, V26, P3113, DOI 10.1038/sj.onc.1210394; Murphy LO, 2006, TRENDS BIOCHEM SCI, V31, P268, DOI 10.1016/j.tibs.2006.03.009; Owens DM, 2007, ONCOGENE, V26, P3203, DOI 10.1038/sj.onc.1210412; Pouyssegur J, 2003, EUR J BIOCHEM, V270, P3291, DOI 10.1046/j.1432-1033.2003.03707.x; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Smith TG, 2006, FEBS LETT, V580, P4242, DOI 10.1016/j.febslet.2006.06.081	22	60	63	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2008	27	26					3685	3691		10.1038/sj.onc.1211040	http://dx.doi.org/10.1038/sj.onc.1211040			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18223677				2022-12-25	WOS:000256659300005
J	Luque-Ortega, JR; van't Hof, W; Veerman, ECI; Saugar, JM; Rivas, L				Roman Luque-Ortega, Juan; van't Hof, Wim; Veerman, Enno C. I.; Saugar, Jose M.; Rivas, Luis			Human antimicrobial peptide histatin 5 is a cell-penetrating peptide targeting mitochondrial ATP synthesis in Leishmania	FASEB JOURNAL			English	Article						bioenergetics; ATP synthase; Trypanosomatidae; histidine-rich peptide	CANDIDA-ALBICANS; DONOVANI PROMASTIGOTES; INTRACELLULAR DELIVERY; CONTAINING MOUTHRINSE; MICROBIAL EVALUATION; ANTIFUNGAL ACTIVITY; MEMBRANE; MELITTIN; PROTEINS; MECHANISM	Histatin 5 (Hst5) is a human salivary antimicrobial peptide that targets fungal mitochondria. In the human parasitic protozoa Leishmania, the mitochondrial ATP production is essential, as it lacks the bioenergetic switch between glycolysis and oxidative phosphorylation described in some yeasts. On these premises, Hst5 activity was assayed on both stages of its life cycle, promastigotes and amastigotes (LC50 = 7.3 and 14.4 mu M, respectively). In a further step, its lethal mechanism was studied. The main conclusions drawn were as follows: 1) Hst5 causes limited and temporary damage to the plasma membrane of the parasites, as assessed by electron microscopy, depolarization, and entrance of the vital dye SYTOX Green; 2) Hst5 translocates into the cytoplasm of Leishmania in an achiral receptor-independent manner with accumulation into the mitochondrion, as shown by confocal microscopy; and 3) Hst5 produces a bioenergetic collapse of the parasite, caused essentially by the decrease of mitochondrial ATP synthesis through inhibition of F1F0-ATPase, with subsequent fast ATP exhaustion. By using the Hst5 enantiomer, it was found that the key steps of its lethal mechanism involved no chiral recognition. Hst5 thus constitutes the first leishmanicidal peptide with a defined nonstereospecific intracellular target. The prospects of its development, by its own or as a carrier molecule for other leishmanicidal molecules, into a novel anti-Leishmania drug with a preferential subcellular accumulation are discussed.	[van't Hof, Wim; Veerman, Enno C. I.] Acad Ctr Dent Amsterdam, Dept Oral Biochem, NL-1066 EA Amsterdam, Netherlands; [Roman Luque-Ortega, Juan; Saugar, Jose M.; Rivas, Luis] CSIC, Ctr Invest Biol, Madrid 28040, Spain	Academic Center for Dentistry Amsterdam; Vrije Universiteit Amsterdam; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Rivas, L (corresponding author), CSIC, Ctr Invest Biol, Ramiro Maeztu 9, Madrid 28040, Spain.	luis.rivas@cib.csic.es	Rivas, Luis/O-8657-2017; Saugar, Jose M./C-7047-2008; Ortega, Juan Roman Luque/M-7583-2019	Rivas, Luis/0000-0002-2958-3233; Saugar, Jose M./0000-0001-8950-5766; 				Alberio SO, 2004, PARASITOL RES, V92, P246, DOI 10.1007/s00436-003-1027-y; Alvar J, 2006, TRENDS PARASITOL, V22, P552, DOI 10.1016/j.pt.2006.09.004; Alvarez-Fortes E, 1998, MOL BIOCHEM PARASIT, V93, P191, DOI 10.1016/S0166-6851(98)00029-2; Baev D, 2004, J BIOL CHEM, V279, P55060, DOI 10.1074/jbc.M411031200; Baev D, 2002, INFECT IMMUN, V70, P4777, DOI 10.1128/IAI.70.9.4777-4784.2002; Basu MK, 2004, CURR MOL MED, V4, P681, DOI 10.2174/1566524043360186; Bera A, 2003, MOL BIOCHEM PARASIT, V127, P23, DOI 10.1016/S0166-6851(02)00300-6; CASTEELS P, 1994, BIOCHEM BIOPH RES CO, V199, P339, DOI 10.1006/bbrc.1994.1234; Chicharro C, 2001, ANTIMICROB AGENTS CH, V45, P2441, DOI 10.1128/AAC.45.9.2441-2449.2001; Corradin S, 2002, BIOCHEM J, V367, P761, DOI 10.1042/BJ20020386; DAS A, 1993, MOL BIOCHEM PARASIT, V60, P293, DOI 10.1016/0166-6851(93)90140-S; den Hertog AL, 2004, BIOCHEM J, V379, P665, DOI 10.1042/BJ20031785; Diaz-Achirica P, 1998, BIOCHEM J, V330, P453, DOI 10.1042/bj3300453; DIAZACHIRICA P, 1994, EUR J BIOCHEM, V224, P257, DOI 10.1111/j.1432-1033.1994.tb20019.x; Fehlbaum P, 1996, P NATL ACAD SCI USA, V93, P1221, DOI 10.1073/pnas.93.3.1221; FISHER PJ, 1994, NATURE, V368, P651, DOI 10.1038/368651a0; Fitzgerald-Hughes DH, 2007, ANTIMICROB AGENTS CH, V51, P2793, DOI 10.1128/AAC.00094-07; Ghosh S, 2003, BIOCHEM J, V369, P447, DOI 10.1042/BJ20021684; Gledhill JR, 2005, BIOCHEM J, V386, P591, DOI 10.1042/BJ20041513; Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007; Gyurko C, 2000, ANTIMICROB AGENTS CH, V44, P348, DOI 10.1128/AAC.44.2.348-354.2000; Handman E, 2000, ADV PARASIT, V44, P1; Hannaert Veronique, 2003, Kinetoplastid Biology and Disease, V2, pUnpaginated; Haukland HH, 2001, FEBS LETT, V508, P389, DOI 10.1016/S0014-5793(01)03100-3; Helmerhorst EJ, 1999, J BIOL CHEM, V274, P7286, DOI 10.1074/jbc.274.11.7286; Helmerhorst EJ, 2001, J BIOL CHEM, V276, P5643, DOI 10.1074/jbc.M008229200; Helmerhorst EJ, 2001, P NATL ACAD SCI USA, V98, P14637, DOI 10.1073/pnas.141366998; Huang HW, 2006, BBA-BIOMEMBRANES, V1758, P1292, DOI 10.1016/j.bbamem.2006.02.001; Kavanagh K, 2004, J PHARM PHARMACOL, V56, P285, DOI 10.1211/0022357022971; Koczan G, 2002, BIOCONJUGATE CHEM, V13, P518, DOI 10.1021/bc015530e; Koshlukova SE, 1999, J BIOL CHEM, V274, P18872, DOI 10.1074/jbc.274.27.18872; Kragol G, 2001, BIOCHEMISTRY-US, V40, P3016, DOI 10.1021/bi002656a; Li XWS, 2006, J BIOL CHEM, V281, P22453, DOI 10.1074/jbc.M604064200; Li XWS, 2003, J BIOL CHEM, V278, P28553, DOI 10.1074/jbc.M300680200; Luque-Ortega JR, 2004, ANTIMICROB AGENTS CH, V48, P1534, DOI 10.1128/AAC.48.5.1534-1540.2004; Luque-Ortega JR, 2003, BIOCHEM J, V375, P221, DOI 10.1042/BJ20030544; Luque-Ortega JR, 2001, ANTIMICROB AGENTS CH, V45, P1121, DOI 10.1128/AAC.45.4.1121-1125.2001; Mangoni ML, 2005, J BIOL CHEM, V280, P984, DOI 10.1074/jbc.M410795200; Mickels N, 2001, J CLIN PERIODONTOL, V28, P404, DOI 10.1034/j.1600-051x.2001.028005404.x; MUKKADA AJ, 1985, SCIENCE, V229, P1099, DOI 10.1126/science.4035350; Opperdoes FR, 2007, TRENDS PARASITOL, V23, P149, DOI 10.1016/j.pt.2007.02.004; Oren Z, 1997, BIOCHEMISTRY-US, V36, P1826, DOI 10.1021/bi962507l; Otvos L, 2005, J PEPT SCI, V11, P697, DOI 10.1002/psc.698; Paris C, 2004, ANTIMICROB AGENTS CH, V48, P852, DOI 10.1128/AAC.48.3.852-859.2004; Podda E, 2006, BBA-GEN SUBJECTS, V1760, P1732, DOI 10.1016/j.bbagen.2006.09.006; Selsted ME, 2005, NAT IMMUNOL, V6, P551, DOI 10.1038/ni1206; Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260; Sharon M, 1999, BIOCHEMISTRY-US, V38, P15305, DOI 10.1021/bi991225t; Thevissen K, 2005, PEPTIDES, V26, P1113, DOI 10.1016/j.peptides.2005.01.008; Tielens AGM, 2002, TRENDS BIOCHEM SCI, V27, P564, DOI 10.1016/S0968-0004(02)02193-X; Torchilin VP, 2006, ANNU REV BIOMED ENG, V8, P343, DOI 10.1146/annurev.bioeng.8.061505.095735; Van Dyke T, 2002, J CLIN PERIODONTOL, V29, P168, DOI 10.1034/j.1600-051x.2002.290212.x; van Zandbergen G, 2004, J IMMUNOL, V173, P6521, DOI 10.4049/jimmunol.173.11.6521; VanHellemond JJ, 1997, MOL BIOCHEM PARASIT, V85, P135, DOI 10.1016/S0166-6851(97)02828-4; Veerman ECI, 2007, J BIOL CHEM, V282, P18831, DOI 10.1074/jbc.M610555200; VERCESI AE, 1991, J BIOL CHEM, V266, P14431; Vylkova S, 2006, ANTIMICROB AGENTS CH, V50, P324, DOI 10.1128/AAC.50.1.324-331.2006; Vylkova S, 2007, EUKARYOT CELL, V6, P1876, DOI 10.1128/EC.00039-07; WADE D, 1990, P NATL ACAD SCI USA, V87, P4761, DOI 10.1073/pnas.87.12.4761; XU T, 1991, INFECT IMMUN, V59, P2549, DOI 10.1128/IAI.59.8.2549-2554.1991; ZILBERSTEIN D, 1985, P NATL ACAD SCI USA, V82, P1716, DOI 10.1073/pnas.82.6.1716	61	90	95	2	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1817	1828		10.1096/fj.07-096081	http://dx.doi.org/10.1096/fj.07-096081			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18230684	Green Submitted			2022-12-25	WOS:000256352700022
J	Alfaro, JA; Zheng, RB; Persson, M; Letts, JA; Polakowski, R; Bai, Y; Borisova, SN; Seto, NOL; Lowary, TL; Palcic, MM; Evans, SV				Alfaro, Javier A.; Zheng, Ruixiang Blake; Persson, Mattias; Letts, James A.; Polakowski, Robert; Bai, Yu; Borisova, Svetlana N.; Seto, Nina O. L.; Lowary, Todd L.; Palcic, Monica M.; Evans, Stephen V.			ABO(H) blood group A and B glycosyltransferases recognize substrate via specific conformational changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; STRUCTURAL BASIS; HUMAN GLUCURONOSYLTRANSFERASE; DIFFERENTIAL RECOGNITION; ENZYMATIC-SYNTHESIS; DONOR SPECIFICITY; ACCEPTOR; GALACTOSYLTRANSFERASE; BIOSYNTHESIS; ANALOGS	The final step in the enzymatic synthesis of the ABO(H) blood group A and B antigens is catalyzed by two closely related glycosyltransferases, an alpha-(1 -> 3)-N-acetylgalactosaminyltransferase (GTA) and an alpha-(1 -> 3)-galactosyltransferase (GTB). Of their 354 amino acid residues, GTA and GTB differ by only four "critical" residues. High resolution structures for GTB and the GTA/GTB chimeric enzymes GTB/G176R and GTB/G176R/G235S bound to a panel of donor and acceptor analog substrates reveal "open," " semi-closed," and "closed" conformations as the enzymes go from the unliganded to the liganded states. In the open form the internal polypeptide loop (amino acid residues 177-195) adjacent to the active site in the unliganded or H-antigen-bound enzymes is composed of two alpha-helices spanning Arg(180) - Met(186) and Arg(188) - Asp(194), respectively. The semi-closed and closed forms of the enzymes are generated by binding of UDP or of UDP and Hantigen analogs, respectively, and show that these helices merge to form a single distorted helical structure with alternating alpha-3(10)-alpha character that partially occludes the active site. The closed form is distinguished from the semi-closed form by the ordering of the final nine C-terminal residues through the formation of hydrogen bonds to both UDP and H antigen analogs. The semi-closed forms for various mutants generally show significantly more disorder than the open forms, whereas the closed forms display little or no disorder depending strongly on the identity of residue 176. Finally, the use of synthetic analogs reveals how H antigen acceptor binding can be critical in stabilizing the closed conformation. These structures demonstrate a delicately balanced substrate recognition mechanism and give insight on critical aspects of donor and acceptor specificity, on the order of substrate binding, and on the requirements for catalysis.	[Alfaro, Javier A.; Letts, James A.; Borisova, Svetlana N.; Seto, Nina O. L.; Evans, Stephen V.] Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada; [Zheng, Ruixiang Blake; Polakowski, Robert; Bai, Yu; Palcic, Monica M.] Univ Alberta, Alberta Ingenuity Ctr Carbohydrate Sci, Edmonton, AB T6G 2G2, Canada; [Zheng, Ruixiang Blake; Polakowski, Robert; Bai, Yu; Palcic, Monica M.] Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada; [Persson, Mattias; Palcic, Monica M.] Carlsberg Lab, DK-2500 Copenhagen, Denmark; [Seto, Nina O. L.] Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	University of Victoria; University of Alberta; University of Alberta; National Research Council Canada	Evans, SV (corresponding author), Univ Victoria, Dept Biochem & Microbiol, POB 3055, Victoria, BC V8W 3P6, Canada.	svevans@uvic.ca	Lowary, Todd L/F-9608-2019; Letts, James Anthony/AAN-6632-2020; Alfaro, Javier/ABA-5639-2020	Lowary, Todd L/0000-0002-8331-8211; Letts, James Anthony/0000-0002-9864-3586; Alfaro, Javier/0000-0002-5553-6991; Evans, Stephen/0000-0002-0366-4027				Angulo J, 2006, J AM CHEM SOC, V128, P13529, DOI 10.1021/ja063550r; Bai Y, 2006, CARBOHYD RES, V341, P1702, DOI 10.1016/j.carres.2006.03.018; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BLANKEN WM, 1985, J BIOL CHEM, V260, P2927; Boix E, 2002, J BIOL CHEM, V277, P28310, DOI 10.1074/jbc.M202631200; Bourne Y, 2001, CURR OPIN STRUC BIOL, V11, P593, DOI 10.1016/S0959-440X(00)00253-0; Breton C, 2006, GLYCOBIOLOGY, V16, p29R, DOI 10.1093/glycob/cwj016; Charnock SJ, 1999, BIOCHEMISTRY-US, V38, P6380, DOI 10.1021/bi990270y; Chiu CPC, 2004, NAT STRUCT MOL BIOL, V11, P163, DOI 10.1038/nsmb720; Davies GJ, 2005, CURR OPIN STRUC BIOL, V15, P637, DOI 10.1016/j.sbi.2005.10.008; EVANS SV, 2003, J MOL GRAPHICS, V11, P134; Greenwell P, 1997, GLYCOCONJUGATE J, V14, P159, DOI 10.1023/A:1018581503164; HEARN VM, 1968, BIOCHEM J, V109, P315, DOI 10.1042/bj1090315; Heissigerova H, 2003, GLYCOBIOLOGY, V13, P377, DOI 10.1093/glycob/cwg042; Hu Y, 2004, CHEM BIOL, V11, P703, DOI 10.1016/j.chembiol.2004.02.024; Hu YN, 2002, CHEM BIOL, V9, P1287, DOI 10.1016/S1074-5521(02)00295-8; Jamaluddin H, 2007, J MOL BIOL, V369, P1270, DOI 10.1016/j.jmb.2007.04.012; KABAT EA, 1956, BLOOD GROUP SUBSTANC, P135; Kakuda S, 2004, J BIOL CHEM, V279, P22693, DOI 10.1074/jbc.M400622200; Kamath VP, 1999, GLYCOCONJUGATE J, V16, P599; KOBATA A, 1968, BIOCHEM BIOPH RES CO, V32, P272, DOI 10.1016/0006-291X(68)90380-X; Laferte S, 2000, EUR J BIOCHEM, V267, P4840, DOI 10.1046/j.1432-1327.2000.01544.x; Lee HJ, 2005, J BIOL CHEM, V280, P525, DOI 10.1074/jbc.M410245200; Letts JA, 2006, J BIOL CHEM, V281, P3625, DOI 10.1074/jbc.M507620200; Letts JA, 2007, ACTA CRYSTALLOGR D, V63, P860, DOI 10.1107/S0907444907026479; LOWARY TL, 1993, CARBOHYD RES, V249, P163, DOI 10.1016/0008-6215(93)84068-H; LOWARY TL, 1994, CARBOHYD RES, V251, P33, DOI 10.1016/0008-6215(94)84275-2; Marcus SL, 2003, J BIOL CHEM, V278, P12403, DOI 10.1074/jbc.M212002200; Nakahara T, 2006, PROTEIN ENG DES SEL, V19, P571, DOI 10.1093/protein/gzl046; Nguyen HP, 2003, J BIOL CHEM, V278, P49191, DOI 10.1074/jbc.M308770200; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; Patenaude SI, 2002, NAT STRUCT BIOL, V9, P685, DOI 10.1038/nsb832; Pedersen LC, 2000, J BIOL CHEM, V275, P34580, DOI 10.1074/jbc.M007399200; Pedersen LC, 2003, J BIOL CHEM, V278, P14420, DOI 10.1074/jbc.M210532200; Persson K, 2001, NAT STRUCT BIOL, V8, P166, DOI 10.1038/84168; Persson M, 2007, J BIOL CHEM, V282, P9564, DOI 10.1074/jbc.M610998200; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Qasba PK, 2005, TRENDS BIOCHEM SCI, V30, P53, DOI 10.1016/j.tibs.2004.11.005; Ramakrishnan B, 2002, J MOL BIOL, V318, P491, DOI 10.1016/S0022-2836(02)00020-7; SCHWYZER M, 1977, J BIOL CHEM, V252, P2346; Seto NOL, 1999, EUR J BIOCHEM, V259, P770, DOI 10.1046/j.1432-1327.1999.00086.x; Seto NOL, 2000, CARBOHYD RES, V324, P161, DOI 10.1016/S0008-6215(99)00297-9; Seto NOL, 1997, J BIOL CHEM, V272, P14133, DOI 10.1074/jbc.272.22.14133; Somsak L, 2003, CURR PHARM DESIGN, V9, P1177, DOI 10.2174/1381612033454919; Sujino K, 2000, J AM CHEM SOC, V122, P1261, DOI 10.1021/ja990964u; Unligil UM, 2000, EMBO J, V19, P5269, DOI 10.1093/emboj/19.20.5269; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; Vagin AA, 2001, ACTA CRYSTALLOGR D, V57, P1451, DOI 10.1107/S0907444901012409; WATKINS W M, 1959, Vox Sang, V4, P97; YAMAMOTO F, 1990, J BIOL CHEM, V265, P19257; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0	51	71	78	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					10097	10108		10.1074/jbc.M708669200	http://dx.doi.org/10.1074/jbc.M708669200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18192272	hybrid			2022-12-25	WOS:000254671600064
J	Courville, P; Urbankova, E; Rensing, C; Chaloupka, R; Quick, M; Cellier, MFM				Courville, Pascal; Urbankova, Eva; Rensing, Christopher; Chaloupka, Roman; Quick, Matthias; Cellier, Mathieu F. M.			Solute carrier 11 cation symport requires distinct residues in transmembrane helices 1 and 6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-ION TRANSPORTERS; ESCHERICHIA-COLI; MEMBRANE-PROTEINS; FUNCTIONAL DIVERGENCE; ACTIVE-TRANSPORT; ANION CHANNEL; NRAMP FAMILY; IDENTIFICATION; SELECTIVITY; TOPOLOGY	Ubiquitous solute carriers 11 (SLC11) contribute to metal-ion homeostasis by importing Me2+ and H+ into the cytoplasm. To identify residues mediating cation symport, Escherichia coli proton-dependent manganese transporter (MntH) was mutated at five SLC11-specific transmembrane (TM) sites; each mutant activity was compared with wild-type MntH, and the biochemical results were tested by homology threading. Cd2+ and H+ uptake kinetics were analyzed in whole cells as a function of pH and temperature, and right-side out membrane vesicles were used to detail energy requirements and to probe site accessibility by Cys replacement and thiol modification. This approach revealed that TM segment 1 (TMS1) residue Asp(34) couples H+ and Me2+ symport and contributes to MntH forward transport electrogenicity, whereas the TMS6 His(211) residue mediates pH-dependent Me2+ uptake; MntH Asn(37), Asn(250), and Asn(401) in TMS1, TMS7, and TMS11 participate in transporter cycling and/or helix packing interactions. These biochemical results fit the LeuT/SLC6 structural fold, which suggests that conserved peptide motifs Asp(34)-Pro-Gly (TMS1) and Met-Pro-His(211) (TMS6) form antiparallel "TM helix/extended peptide" boundaries, lining a "pore" cavity and enabling H+-dependent Me2+ import.	[Courville, Pascal; Cellier, Mathieu F. M.] INRS Inst Armand Frappier, Laval, PQ H7V 1B7, Canada; [Quick, Matthias] Columbia Univ Coll Phys & Surg, Ctr Mol Recognit, New York, NY 10032 USA; [Rensing, Christopher] Univ Arizona, Dept Soil Water & Environm Sci, Tucson, AZ 85721 USA; [Urbankova, Eva; Chaloupka, Roman] Charles Univ Prague, Inst Phys, Fac Math & Phys, CR-12116 Prague 2, Czech Republic	University of Quebec; Institut national de la recherche scientifique (INRS); Columbia University; University of Arizona; Charles University Prague	Cellier, MFM (corresponding author), INRS Inst Armand Frappier, 531 Bd Prairies, Laval, PQ H7V 1B7, Canada.	mathieu.cellier@iaf.inrs.ca	courville, pascal/A-5170-2009; Rensing, Christopher/D-3947-2011	Rensing, Christopher/0000-0002-5012-7953				Arguello JM, 2003, J MEMBRANE BIOL, V195, P93, DOI 10.1007/s00232-003-2048-2; BHATTACHARYYA P, 1970, J BACTERIOL, V104, P1307, DOI 10.1128/JB.104.3.1307-1311.1970; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; CELLIER M, 1995, P NATL ACAD SCI USA, V92, P10089, DOI 10.1073/pnas.92.22.10089; Cellier MF, 2007, MICROBES INFECT, V9, P1662, DOI 10.1016/j.micinf.2007.09.006; Chaloupka R, 2005, BIOCHEMISTRY-US, V44, P726, DOI 10.1021/bi048014v; Cheah JH, 2006, NEURON, V51, P431, DOI 10.1016/j.neuron.2006.07.011; Chen XZ, 1999, J BIOL CHEM, V274, P35089, DOI 10.1074/jbc.274.49.35089; Cheng HC, 2001, J PHARMACOL TOX MET, V46, P61, DOI 10.1016/S1056-8719(02)00166-1; Cohen A, 2003, P NATL ACAD SCI USA, V100, P10694, DOI 10.1073/pnas.1934572100; Courville P, 2006, BIOCHEM CELL BIOL, V84, P960, DOI 10.1139/O06-193; Courville P, 2004, J BIOL CHEM, V279, P3318, DOI 10.1074/jbc.M309913200; Daley DO, 2005, SCIENCE, V308, P1321, DOI 10.1126/science.1109730; DeLano WL, 2005, DRUG DISCOV TODAY, V10, P213, DOI 10.1016/S1359-6446(04)03363-X; Dutta SJ, 2007, BIOCHEMISTRY-US, V46, P3692, DOI 10.1021/bi0616394; Fortier A, 2005, J LEUKOCYTE BIOL, V77, P868, DOI 10.1189/jlb.1004616; Gaucher EA, 2002, TRENDS BIOCHEM SCI, V27, P315, DOI 10.1016/S0968-0004(02)02094-7; Granseth E, 2007, MOL MEMBR BIOL, V24, P329, DOI 10.1080/09687680701413882; Grass G, 2005, J BACTERIOL, V187, P1604, DOI 10.1128/JB.187.5.1604-1611.2005; Gu X, 2006, MOL BIOL EVOL, V23, P1937, DOI 10.1093/molbev/msl056; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Haemig HAH, 2004, J MEMBRANE BIOL, V201, P97, DOI 10.1007/s00232-004-0711-x; Holm L, 2000, BIOINFORMATICS, V16, P566, DOI 10.1093/bioinformatics/16.6.566; Hu J, 2006, P NATL ACAD SCI USA, V103, P6865, DOI 10.1073/pnas.0601944103; Jones DT, 2005, PROTEINS, V61, P143, DOI 10.1002/prot.20731; Kaback HR, 2007, P NATL ACAD SCI USA, V104, P491, DOI 10.1073/pnas.0609968104; Kawabata T, 2003, NUCLEIC ACIDS RES, V31, P3367, DOI 10.1093/nar/gkg581; Kehres DG, 2000, MOL MICROBIOL, V36, P1085, DOI 10.1046/j.1365-2958.2000.01922.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lam-Yuk-Tseung S, 2003, BLOOD, V101, P3699, DOI 10.1182/blood-2002-07-2108; Larsen RA, 2007, J BACTERIOL, V189, P2825, DOI 10.1128/JB.01925-06; Lemieux MJ, 2007, MOL MEMBR BIOL, V24, P333, DOI 10.1080/09687680701496507; Likitvivatanavong S, 2006, ARCH BIOCHEM BIOPHYS, V445, P46, DOI 10.1016/j.abb.2005.11.007; Liu GY, 1996, J BIOL CHEM, V271, P19717, DOI 10.1074/jbc.271.33.19717; Liu K, 2005, P NATL ACAD SCI USA, V102, P2192, DOI 10.1073/pnas.0409232102; Mackenzie B, 2004, PFLUG ARCH EUR J PHY, V447, P571, DOI 10.1007/s00424-003-1141-9; Mackenzie B, 2006, PFLUG ARCH EUR J PHY, V451, P544, DOI 10.1007/s00424-005-1494-3; Madabushi S, 2004, J BIOL CHEM, V279, P8126, DOI 10.1074/jbc.M312671200; Makui H, 2000, MOL MICROBIOL, V35, P1065, DOI 10.1046/j.1365-2958.2000.01774.x; Martin-Orozco N, 2006, MOL BIOL CELL, V17, P498, DOI 10.1091/mbc.E04-12-1096; Matsushita K, 2005, J BACTERIOL, V187, P4346, DOI 10.1128/JB.187.13.4346-4352.2005; Nevo Y, 2006, BBA-MOL CELL RES, V1763, P609, DOI 10.1016/j.bbamcr.2006.05.007; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Pieper U, 2006, NUCLEIC ACIDS RES, V34, pD291, DOI 10.1093/nar/gkj059; Pornillos O, 2006, FEBS LETT, V580, P358, DOI 10.1016/j.febslet.2005.12.054; Quick M, 2003, BIOCHEMISTRY-US, V42, P9147, DOI 10.1021/bi034842x; Rahman M, 2007, MOL MEMBR BIOL, V24, P407, DOI 10.1080/09687860701243998; Rensing C, 2000, P NATL ACAD SCI USA, V97, P652, DOI 10.1073/pnas.97.2.652; Richer E, 2003, J MOL EVOL, V57, P363, DOI 10.1007/s00239-003-2472-z; ROBERTSON DE, 1980, BIOCHEMISTRY-US, V19, P5692, DOI 10.1021/bi00566a005; Sacher A, 2001, J EXP BIOL, V204, P1053; Screpanti E, 2007, J STRUCT BIOL, V159, P261, DOI 10.1016/j.jsb.2007.01.011; Shindyalov IN, 1998, PROTEIN ENG, V11, P739, DOI 10.1093/protein/11.9.739; Singh SK, 2007, NATURE, V448, P952, DOI 10.1038/nature06038; Su CC, 2006, J BACTERIOL, V188, P7290, DOI 10.1128/JB.00684-06; Thwaites DT, 2007, EXP PHYSIOL, V92, P603, DOI 10.1113/expphysiol.2005.029959; Wu ST, 2007, NUCLEIC ACIDS RES, V35, P3375, DOI 10.1093/nar/gkm251; Zhang W, 2000, BIOCHEMISTRY-US, V39, P14538, DOI 10.1021/bi001947g; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154	60	37	37	2	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9651	9658		10.1074/jbc.M709906200	http://dx.doi.org/10.1074/jbc.M709906200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18227061	hybrid			2022-12-25	WOS:000254671600019
J	Mochizuki, K; Nishiyama, A; Jang, MK; Dey, A; Ghosh, A; Tamura, T; Natsume, H; Yao, HJ; Ozato, K				Mochizuki, Kazuki; Nishiyama, Akira; Jang, Moon Kyoo; Dey, Anup; Ghosh, Anu; Tamura, Tomohiko; Natsume, Hiroko; Yao, Hongjie; Ozato, Keiko			The bromodomain protein Brd4 stimulates G(1) gene transcription and promotes progression to S phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAPILLOMAVIRUS E2 PROTEIN; NF-KAPPA-B; P-TEFB; CHROMOSOMAL-PROTEIN; DNA-REPLICATION; CHROMATIN; EXPRESSION; RECOGNITION; ELONGATION; BLOCKS	Brd4 is a bromodomain protein that binds to acetylated chromatin. It regulates cell growth, although the underlying mechanism has remained elusive. Brd4 has also been shown to control transcription of viral genes, whereas its role in transcription of cellular genes has not been fully elucidated. Here we addressed the role of Brd4 in cell growth and transcription using a small hairpin ( sh) RNA approach. The Brd4 shRNA vector stably knocked down Brd4 protein expression by similar to 90% in NIH3T3 cells and mouse embryonic fibroblasts. Brd4 knockdown cells were growth impaired and grew more slowly than control cells. When synchronized by serum starvation and released, Brd4 knockdown cells were arrested at G(1), whereas control cells progressed to S phase. In microarray analysis, although numerous genes were up-regulated during G(1) in control cells, many of these G(1) genes were not up-regulated in Brd4 knockdown cells. Reintroduction of Brd4 rescued expression of these G(1) genes in Brd4 knockdown cells, allowing cells to progress toward S phase. Chromatin immunoprecipitation analysis showed that Brd4 was recruited to the promoters of these G(1) genes during G(0)-G(1) progression. Furthermore, Brd4 recruitment coincided with increased binding of Cdk9, a component of P-TEFb and RNA polymerase II to these genes. Brd4 recruitment was low to absent at genes not affected by Brd4 shRNA. The results indicate that Brd4 stimulates G(1) gene expression by binding to multiple G(1) gene promoters in a cell cycle-dependent manner.	[Mochizuki, Kazuki; Nishiyama, Akira; Jang, Moon Kyoo; Dey, Anup; Ghosh, Anu; Tamura, Tomohiko; Natsume, Hiroko; Yao, Hongjie; Ozato, Keiko] NICHD, NIH, Lab Mol Growth Regulat, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Ozato, K (corresponding author), NICHD, NIH, Lab Mol Growth Regulat, Bldg 6,Rm 2A01,6 Ctr Dr, Bethesda, MD 20892 USA.	ozatok@nih.go	Ghosh, Anu/ABF-4180-2020	Jang, Moon Kyoo/0000-0002-1657-2877; Ghosh, Anu/0000-0003-4528-8602	Intramural NIH HHS Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008815] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD008815] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Barboric M, 2001, MOL CELL, V8, P327, DOI 10.1016/S1097-2765(01)00314-8; Baxter MK, 2005, J VIROL, V79, P4806, DOI 10.1128/JVI.79.8.4806-4818.2005; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; Crowley TE, 2002, MOL ENDOCRINOL, V16, P1727, DOI 10.1210/me.2001-0353; Dahl JA, 2007, FRONT BIOSCI-LANDMRK, V12, P4925, DOI 10.2741/2438; Denis GV, 2000, CELL GROWTH DIFFER, V11, P417; DePamphilis ML, 2005, CELL CYCLE, V4, P70, DOI 10.4161/cc.4.1.1333; Dey A, 2000, MOL CELL BIOL, V20, P6537, DOI 10.1128/MCB.20.17.6537-6549.2000; Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Farina A, 2004, MOL CELL BIOL, V24, P9059, DOI 10.1128/MCB.24.20.9059-9069.2004; French CA, 2004, J CLIN ONCOL, V22, P4135, DOI 10.1200/JCO.2004.02.107; Gomes NP, 2006, GENE DEV, V20, P601, DOI 10.1101/gad.1398206; Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Haruki N, 2005, J MED GENET, V42, P558, DOI 10.1136/jmg.2004.029686; Hoek M, 2003, P NATL ACAD SCI USA, V100, P12183, DOI 10.1073/pnas.1635158100; Houzelstein D, 2002, MOL CELL BIOL, V22, P3794, DOI 10.1128/MCB.22.11.3794-3802.2002; Jang MK, 2005, MOL CELL, V19, P523, DOI 10.1016/j.molcel.2005.06.027; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; Kadota K, 2001, PHYSIOL GENOMICS, V4, P183, DOI 10.1152/physiolgenomics.2001.4.3.183; Kanazawa S, 2003, ONCOGENE, V22, P5707, DOI 10.1038/sj.onc.1206800; Kanazawa S, 2000, IMMUNITY, V12, P61, DOI 10.1016/S1074-7613(00)80159-4; Kanno T, 2004, MOL CELL, V13, P33, DOI 10.1016/S1097-2765(03)00482-9; Ladurner AG, 2003, MOL CELL, V11, P365, DOI 10.1016/S1097-2765(03)00035-2; Landgrebe J, 2002, GENOME BIOL, V3; Luecke HF, 2005, GENE DEV, V19, P1116, DOI 10.1101/gad.1297105; Maruyama T, 2002, MOL CELL BIOL, V22, P6509, DOI 10.1128/MCB.22.18.6509-6520.2002; Massague J, 2004, NATURE, V432, P298, DOI 10.1038/nature03094; Matangkasombut O, 2003, MOL CELL, V11, P353, DOI 10.1016/S1097-2765(03)00033-9; Nagashima T, 2007, MOL HUM REPROD, V13, P141, DOI 10.1093/molehr/gal115; Nakamura Y, 2007, J BIOL CHEM, V282, P4193, DOI 10.1074/jbc.M605971200; Nishiyama A, 2006, MOL BIOL CELL, V17, P814, DOI 10.1091/mbc.E05-08-0729; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tanaka TS, 2000, P NATL ACAD SCI USA, V97, P9127, DOI 10.1073/pnas.97.16.9127; van der Meijden CMJ, 2002, CANCER RES, V62, P3233; Wu SY, 2006, GENE DEV, V20, P2383, DOI 10.1101/gad.1448206; Wu SY, 2007, J BIOL CHEM, V282, P13141, DOI 10.1074/jbc.R700001200; Yang ZY, 2008, MOL CELL BIOL, V28, P967, DOI 10.1128/MCB.01020-07; Yang ZY, 2005, MOL CELL, V19, P535, DOI 10.1016/j.molcel.2005.06.029; You J, 2004, CELL, V117, P349, DOI 10.1016/S0092-8674(04)00402-7	44	164	208	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9040	9048		10.1074/jbc.M707603200	http://dx.doi.org/10.1074/jbc.M707603200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18223296	hybrid, Green Published			2022-12-25	WOS:000254465800034
J	Little, JT; Jurica, MS				Little, John T.; Jurica, Melissa S.			Splicing factor SPF30 bridges an interaction between the prespliceosome protein U2AF35 and tri-small nuclear ribonucleoprotein protein hPrp3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEX-LETHAL; SM PROTEIN; COMPLEX; RECOGNITION; GENE; SITE; NETWORK; CLONING; DOMAIN	Spliceosome assembly is a dynamic process involving the sequential recruitment and rearrangement of small nuclear ribonucleoproteins (snRNPs) on a pre-mRNA substrate. Here we identify several spliceosome protein interactions with different domains of human splicing factor SPF30 that have the potential to mediate the addition of the tri-snRNP to the pre-spliceosome. In particular, we show that the C-terminal tails of SmD1, SmD3, and the protein Lsm4 interact with the central Tudor domain of SPF30. We identify a novel interaction between the N-terminal domain of SPF30 and U2AF35, a pre-spliceosome protein that has a role in recognizing the 3' splice site and recruiting U2 snRNP. We also show that the C terminus of SPF30 interacts with a middle domain of hPrp3, a component of U4/U6 di-snRNP and the tri-snRNP. Importantly, we show that the U2AF35 and hPrp3 interactions with SPF30 can occur simultaneously, thereby potentially linking 3' splice site recognition with tri-snRNP addition. Finally, we note that SPF30 and its partner-interacting domains are not conserved in yeast, suggesting this interaction network may play an important role in the complex splicing observed in higher eukaryotes.	Univ Calif Santa Cruz, Dept Cell Mol & Dev Biol, Santa Cruz, CA 95064 USA; Univ Calif Santa Cruz, Ctr Mol Biol RNA, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz	Jurica, MS (corresponding author), MCD Bio, 1156 High St, Santa Cruz, CA 95064 USA.	jurica@biology.ucsc.edu			NIGMS NIH HHS [R01 GM072649] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM072649] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Behzadnia N, 2007, EMBO J, V26, P1737, DOI 10.1038/sj.emboj.7601631; Boehringer D, 2004, NAT STRUCT MOL BIOL, V11, P463, DOI 10.1038/nsmb761; Brahms H, 2001, RNA, V7, P1531, DOI 10.1017/S135583820101442X; Brow DA, 2002, ANNU REV GENET, V36, P333, DOI 10.1146/annurev.genet.36.043002.091635; Burge CB, 1999, RNA WORLD, P525; Campbell L, 1997, AM J HUM GENET, V61, P40, DOI 10.1086/513886; Cass DM, 2006, BIOCHEMISTRY-US, V45, P10092, DOI 10.1021/bi060429o; Cote J, 2005, J BIOL CHEM, V280, P28476, DOI 10.1074/jbc.M414328200; Deckert J, 2006, MOL CELL BIOL, V26, P5528, DOI 10.1128/MCB.00582-06; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; Friesen WJ, 2001, MOL CELL, V7, P1111, DOI 10.1016/S1097-2765(01)00244-1; Gonzalez-Santos JM, 2002, J BIOL CHEM, V277, P23764, DOI 10.1074/jbc.M111461200; Hartmuth K, 2002, P NATL ACAD SCI USA, V99, P16719, DOI 10.1073/pnas.262483899; Jady BE, 2003, EMBO J, V22, P1878, DOI 10.1093/emboj/cdg187; Jurica MS, 2003, MOL CELL, V12, P5, DOI 10.1016/S1097-2765(03)00270-3; Jurica MS, 2002, RNA, V8, P426, DOI 10.1017/S1355838202021088; Kambach C, 1999, CELL, V96, P375, DOI 10.1016/S0092-8674(00)80550-4; Kielkopf CL, 2001, CELL, V106, P595, DOI 10.1016/S0092-8674(01)00480-9; Kiss T, 2004, J CELL SCI, V117, P5949, DOI 10.1242/jcs.01487; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; Lallena MJ, 2002, CELL, V109, P285, DOI 10.1016/S0092-8674(02)00730-4; Liu SB, 2006, RNA, V12, P1418, DOI 10.1261/rna.55406; Lutzelberger M, 2005, J BIOL CHEM, V280, P25478, DOI 10.1074/jbc.M413737200; Makarov EM, 2002, SCIENCE, V298, P2205, DOI 10.1126/science.1077783; Meister G, 2001, EMBO J, V20, P2304, DOI 10.1093/emboj/20.9.2304; Merendino L, 1999, NATURE, V402, P838, DOI 10.1038/45602; MOORE MJ, 1993, RNA WORLD, P333; Neubauer G, 1998, NAT GENET, V20, P46, DOI 10.1038/1700; Pellizzoni L, 2002, SCIENCE, V298, P1775, DOI 10.1126/science.1074962; Rappsilber J, 2001, J BIOL CHEM, V276, P31142, DOI 10.1074/jbc.M103620200; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; Schaffert N, 2004, EMBO J, V23, P3000, DOI 10.1038/sj.emboj.7600296; Spadaccini R, 2006, RNA, V12, P410, DOI 10.1261/rna.2271406; Talbot K, 1998, HUM MOL GENET, V7, P2149, DOI 10.1093/hmg/7.13.2149; UTANS U, 1992, GENE DEV, V6, P631, DOI 10.1101/gad.6.4.631; Wu SP, 1999, NATURE, V402, P832, DOI 10.1038/45590; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZHANG M, 1992, P NATL ACAD SCI USA, V89, P8769, DOI 10.1073/pnas.89.18.8769; Zorio DAR, 1999, NATURE, V402, P835, DOI 10.1038/45597	40	12	13	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8145	8152		10.1074/jbc.M707984200	http://dx.doi.org/10.1074/jbc.M707984200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18211889	hybrid			2022-12-25	WOS:000254288000011
J	Liu, BY; Li, Z; Mahesh, SP; Pantanelli, S; Hwang, FS; Siu, WO; Nussenblatt, RB				Liu, Baoying; Li, Zhuqing; Mahesh, Sankaranarayana P.; Pantanelli, Seth; Hwang, Frank S.; Siu, Willie O.; Nussenblatt, Robert B.			Glucocorticoid-induced tumor necrosis factor receptor negatively regulates activation of human primary natural killer (NK) cells by blocking proliferative signals and increasing NK cell apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED TNF RECEPTOR; VERSUS-HOST-DISEASE; T-CELLS; CUTTING EDGE; ANTITUMOR IMMUNITY; SELF-TOLERANCE; PROTEIN GITR; FAMILY; LIGAND; SUPERFAMILY	Glucocorticoid-induced tumor necrosis factor receptor (GITR), found constitutively expressed on human primary natural killer (NK) cells at low levels was up-regulated upon stimulation by either Toll-like receptor ligand or NK cell growth factor, interleukin (IL)-15. cDNA microarray analysis showed that engagement of GITR primarily suppressed the activation of NF-KB pathway of NK cells and up-regulated anti-inflammatory genes heme oxygenase- 1 and IL-10. Further analysis revealed that GITR activation suppressed NK cell proliferation in response to IL-15. GITR activation also suppressed proinflammatory cytokine secretion and increased NK cell apoptosis. GITR activation resulted in blocked phosphorylation of Stat5 and Akt, which may have contributed to the observed antiproliferative effect of GITR on NK cells. Increased apoptosis was independent of the Fas-FasL pathway, but Bcl-XL and phospho-Bad protein expressions were diminished, suggesting involvement of the mitochondrial apoptosis pathway. The results suggest that although GITR is an activation marker for NK cells similar to that for T cells, GITR serves as a negative regulator for NK cell activation. Our studies demonstrate a novel physiological role of GITR on NK cells.	[Liu, Baoying; Li, Zhuqing; Mahesh, Sankaranarayana P.; Pantanelli, Seth; Hwang, Frank S.; Siu, Willie O.; Nussenblatt, Robert B.] NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Nussenblatt, RB (corresponding author), NEI, Immunol Lab, NIH, Bldg 10,Room 10N112,10 Ctr Dr, Bethesda, MD 20892 USA.	drbob@nei.nih.gov	Pantanelli, Seth/GRR-5413-2022	Pantanelli, Seth/0000-0003-4992-9606; Hwang, Frank/0000-0002-9462-9648	Intramural NIH HHS Funding Source: Medline; NATIONAL EYE INSTITUTE [Z01EY000376, Z01EY000464, ZIAEY000376, ZIAEY000464] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Baltz KM, 2007, FASEB J, V21, P2442, DOI 10.1096/fj.06-7724com; BANCROFT GJ, 1994, IMMUNOBIOLOGY, V191, P424, DOI 10.1016/S0171-2985(11)80448-1; Bushell A, 2007, AM J TRANSPLANT, V7, P759, DOI 10.1111/j.1600-6143.2006.01716.x; Carson WE, 1997, J CLIN INVEST, V99, P937, DOI 10.1172/JCI119258; Chalifour A, 2004, BLOOD, V104, P1778, DOI 10.1182/blood-2003-08-2820; Chan PH, 2004, NEUROCHEM RES, V29, P1943, DOI 10.1007/s11064-004-6869-x; CHAN SH, 1991, J EXP MED, V173, P869, DOI 10.1084/jem.173.4.869; Cohen AD, 2006, CANCER RES, V66, P4904, DOI 10.1158/0008-5472.CAN-05-2813; Esparza EM, 2005, J IMMUNOL, V174, P7869, DOI 10.4049/jimmunol.174.12.7869; Esparza EM, 2004, CELL MOL LIFE SCI, V61, P3087, DOI 10.1007/s00018-004-4417-0; Goodsell DS, 2004, ONCOLOGIST, V9, P226, DOI 10.1634/theoncologist.9-2-226; Green DR, 2003, IMMUNOL REV, V193, P70, DOI 10.1034/j.1600-065X.2003.00051.x; Grohmann U, 2007, NAT MED, V13, P579, DOI 10.1038/nm1563; Gurney AL, 1999, CURR BIOL, V9, P215, DOI 10.1016/S0960-9822(99)80093-1; Hail N, 2005, APOPTOSIS, V10, P687, DOI 10.1007/s10495-005-0792-8; Hanabuchi S, 2006, BLOOD, V107, P3617, DOI 10.1182/blood-2005-08-3419; Ji HB, 2004, J IMMUNOL, V172, P5823, DOI 10.4049/jimmunol.172.10.5823; Kanamaru F, 2004, J IMMUNOL, V172, P7306, DOI 10.4049/jimmunol.172.12.7306; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; Kim J, 2006, EXP MOL MED, V38, P94, DOI 10.1038/emm.2006.11; Ko HJ, 2007, CANCER RES, V67, P7477, DOI 10.1158/0008-5472.CAN-06-4639; Kohm AP, 2004, J IMMUNOL, V172, P4686, DOI 10.4049/jimmunol.172.8.4686; Kwon BS, 1999, J BIOL CHEM, V274, P6056, DOI 10.1074/jbc.274.10.6056; La S, 2005, EXP MOL MED, V37, P193, DOI 10.1038/emm.2005.26; Lanier LL, 2003, CURR OPIN IMMUNOL, V15, P308, DOI 10.1016/S0952-7915(03)00039-6; Lecoeur H, 1997, J IMMUNOL METHODS, V209, P111, DOI 10.1016/S0022-1759(97)00138-5; Lenardo MJ, 1996, J EXP MED, V183, P721, DOI 10.1084/jem.183.3.721; Li ZQ, 2005, J IMMUNOL, V174, P5187, DOI 10.4049/jimmunol.174.9.5187; Li ZQ, 2003, J AUTOIMMUN, V21, P83, DOI 10.1016/S0896-8411(03)00085-4; Mackay F, 2002, CURR OPIN IMMUNOL, V14, P783, DOI 10.1016/S0952-7915(02)00407-7; Marcenaro E, 2005, AUTOIMMUN REV, V4, P520, DOI 10.1016/j.autrev.2005.04.015; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Muriglan SJ, 2004, J EXP MED, V200, P149, DOI 10.1084/jem.20040116; Nocentini G, 1997, P NATL ACAD SCI USA, V94, P6216, DOI 10.1073/pnas.94.12.6216; Nocentini G, 2005, EUR J IMMUNOL, V35, P1016, DOI 10.1002/eji.200425818; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Parry RV, 2007, TRENDS IMMUNOL, V28, P161, DOI 10.1016/j.it.2007.02.004; Patel M, 2005, EUR J IMMUNOL, V35, P3581, DOI 10.1002/eji.200535421; Ramirez-Montagut T, 2006, J IMMUNOL, V176, P6434, DOI 10.4049/jimmunol.176.11.6434; Ronchetti S, 2002, BLOOD, V100, P350, DOI 10.1182/blood-2001-12-0276; Ronchetti S, 2004, EUR J IMMUNOL, V34, P613, DOI 10.1002/eji.200324804; Schmidt KN, 2004, J IMMUNOL, V172, P138, DOI 10.4049/jimmunol.172.1.138; Schwarz M, 2007, APOPTOSIS, V12, P869, DOI 10.1007/s10495-007-0748-2; Shi FD, 2006, NAT REV IMMUNOL, V6, P751, DOI 10.1038/nri1935; Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759; Shin HH, 2002, FEBS LETT, V514, P275, DOI 10.1016/S0014-5793(02)02379-7; Suvas S, 2005, J VIROL, V79, P11935, DOI 10.1128/JVI.79.18.11935-11942.2005; Tuyaerts S, 2007, J LEUKOCYTE BIOL, V82, P93, DOI 10.1189/jlb.0906568; Watts TH, 2005, ANNU REV IMMUNOL, V23, P23, DOI 10.1146/annurev.immunol.23.021704.115839; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5	50	55	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8202	8210		10.1074/jbc.M708944200	http://dx.doi.org/10.1074/jbc.M708944200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18230609	hybrid, Green Published			2022-12-25	WOS:000254288000017
J	McCulloch, CV; Morrow, V; Milasta, S; Comerford, I; Milligan, G; Graham, GJ; Isaacs, NW; Nibbs, RJB				McCulloch, Clare V.; Morrow, Valerie; Milasta, Sandra; Comerford, Iain; Milligan, Graeme; Graham, Gerard J.; Isaacs, Neil W.; Nibbs, Robert J. B.			Multiple roles for the C-terminal tail of the chemokine scavenger D6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-DEPENDENT CHANGES; BETA-ARRESTIN; RECEPTOR D6; CRYSTAL-STRUCTURE; CYTOPLASMIC END; INFLAMMATION; RHODOPSIN; HELIX-8; PHOSPHORYLATION; INTERNALIZATION	D6 is a heptahelical receptor that suppresses inflammation and tumorigenesis by scavenging extracellular pro-inflammatory CC chemokines. Previous studies suggested this is dependent on constitutive trafficking of stable D6 protein to and from the cell surface via recycling endosomes. By internalizing chemokine each time it transits the cell surface, D6 can, over time, remove large quantities of these inflammatory mediators. We have investigated the role of the conserved 58-amino acid C terminus of human D6, which, unlike the rest of the protein, shows no clear homology to other heptahelical receptors. We show that, in human HEK293 cells, a serine cluster in this region controls the constitutive phosphorylation, high stability, and intracellular trafficking itinerary of the receptor and drives green fluorescent protein-tagged beta-arrestins to membranes at, and near, the cell surface. Unexpectedly, however, these properties, and the last 44 amino acids of the C terminus, are dispensable for D6 internalization and effective scavenging of the chemokine CCL3. Even in the absence of the last 58 amino acids, D6 still initially internalizes CCL3 but, surprisingly, exposure to ligand inhibits subsequent CCL3 uptake by this mutant. Progressive scavenging is therefore abrogated. We conclude that the heptahelical body of D6 on its own can engage the endocytotic machinery of HEK293 cells but that the C terminus is indispensable for scavenging because it prevents initial chemokine engagement of D6 from inhibiting subsequent chemokine uptake.	[McCulloch, Clare V.; Morrow, Valerie; Comerford, Iain; Graham, Gerard J.; Nibbs, Robert J. B.] Univ Glasgow, Glasgow Biomed Res Ctr, Div Immunol Infect & Inflammat, Glasgow G12 8TA, Lanark, Scotland; [Milasta, Sandra; Milligan, Graeme] Univ Glasgow, Fac Biomed & Life Sci, Glasgow G12 8TA, Lanark, Scotland; [Isaacs, Neil W.] Univ Glasgow, Dept Chem, Glasgow G12 8TA, Lanark, Scotland	University of Glasgow; University of Glasgow; University of Glasgow	Nibbs, RJB (corresponding author), Univ Glasgow, Glasgow Biomed Res Ctr, Div Immunol Infect & Inflammat, 120 Univ Pl, Glasgow G12 8TA, Lanark, Scotland.	r.nibbs@clinmed.gla.ac.uk	Milligan, Graeme/F-9426-2011; Graham, Gerard/D-1240-2009	Milligan, Graeme/0000-0002-6946-3519; Graham, Gerard/0000-0002-7801-204X; Nibbs, Robert/0000-0002-8150-0044; Comerford, Iain/0000-0001-8753-4774	Biotechnology and Biological Sciences Research Council Funding Source: Medline; Cancer Research UK Funding Source: Medline; Wellcome Trust Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK); Wellcome Trust(Wellcome TrustEuropean Commission)		Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15493, DOI 10.1021/bi011545o; Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15483, DOI 10.1021/bi011546g; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Barlic J, 2000, NAT IMMUNOL, V1, P227, DOI 10.1038/79767; Bhandari D, 2007, J BIOL CHEM, V282, P36971, DOI 10.1074/jbc.M705085200; Blackburn PE, 2004, BIOCHEM J, V379, P263, DOI 10.1042/BJ20031266; Cheng ZJ, 2000, J BIOL CHEM, V275, P2479, DOI 10.1074/jbc.275.4.2479; Cherezov V, 2007, SCIENCE, V318, P1258, DOI 10.1126/science.1150577; Comerford I, 2006, EUR J IMMUNOL, V36, P1904, DOI 10.1002/eji.200535716; de la Torre YM, 2007, P NATL ACAD SCI USA, V104, P2319, DOI 10.1073/pnas.0607514104; de la Torre YM, 2005, EUR J IMMUNOL, V35, P1342, DOI 10.1002/eji.200526114; DeWire SM, 2007, ANNU REV PHYSIOL, V69, P483, DOI 10.1146/annurev.physiol.69.022405.154749; Feng GJ, 2003, J BIOL CHEM, V278, P33400, DOI 10.1074/jbc.M305866200; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; Fra AM, 2003, J IMMUNOL, V170, P2279, DOI 10.4049/jimmunol.170.5.2279; Galliera E, 2004, J BIOL CHEM, V279, P25590, DOI 10.1074/jbc.M400363200; GRAHAM GJ, 1994, J BIOL CHEM, V269, P4974; GRAHAM GJ, 1993, CELL GROWTH DIFFER, V4, P137; Hansell CAH, 2006, BIOCHEM SOC T, V34, P1009, DOI 10.1042/BST0341009; Hoare S, 1999, J BIOL CHEM, V274, P28682, DOI 10.1074/jbc.274.40.28682; Huttenrach F, 2005, J BIOL CHEM, V280, P37503, DOI 10.1074/jbc.M500535200; Huttenrauch F, 2002, J BIOL CHEM, V277, P30769, DOI 10.1074/jbc.M204033200; Jamieson T, 2005, NAT IMMUNOL, V6, P403, DOI 10.1038/ni1182; Kang DS, 2002, MOL PHARMACOL, V62, P281, DOI 10.1124/mol.62.2.281; Katragadda M, 2004, BBA-BIOMEMBRANES, V1663, P74, DOI 10.1016/j.bbamem.2004.01.012; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Kohout TA, 2004, J BIOL CHEM, V279, P23214, DOI 10.1074/jbc.M402125200; Lefkowitz RJ, 2006, MOL CELL, V24, P643, DOI 10.1016/j.molcel.2006.11.007; Mantovani A, 2006, NAT REV IMMUNOL, V6, P907, DOI 10.1038/nri1964; Marchese A, 2003, DEV CELL, V5, P709, DOI 10.1016/S1534-5807(03)00321-6; Milasta S, 2005, BIOCHEM J, V387, P573, DOI 10.1042/BJ20041745; Munoz V, 1997, BIOPOLYMERS, V41, P495, DOI 10.1002/(SICI)1097-0282(19970415)41:5<495::AID-BIP2>3.3.CO;2-6; Nibbs RJB, 1997, J BIOL CHEM, V272, P32078, DOI 10.1074/jbc.272.51.32078; Nibbs RJB, 2001, AM J PATHOL, V158, P867, DOI 10.1016/S0002-9440(10)64035-7; Nibbs RJB, 2007, J CLIN INVEST, V117, P1884, DOI 10.1172/JCI30068; Okuno T, 2003, J BIOL CHEM, V278, P41500, DOI 10.1074/jbc.M307335200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Rasmussen SGF, 2007, NATURE, V450, P383, DOI 10.1038/nature06325; Ridge KD, 2007, J BIOL CHEM, V282, P9297, DOI 10.1074/jbc.R600032200; Rosenbaum DM, 2007, SCIENCE, V318, P1266, DOI 10.1126/science.1150609; Rot A, 2004, ANNU REV IMMUNOL, V22, P891, DOI 10.1146/annurev.immunol.22.012703.104543; Sano T, 1997, J BIOL CHEM, V272, P23631, DOI 10.1074/jbc.272.38.23631; SANTOS DNM, 2006, J BIOL CHEM, V281, P12896; Serhan CN, 2007, ANNU REV IMMUNOL, V25, P101, DOI 10.1146/annurev.immunol.25.022106.141647; Shenoy SK, 2007, CIRC RES, V100, P1142, DOI 10.1161/01.RES.0000261939.88744.5a; Sun Y, 2002, J BIOL CHEM, V277, P49212, DOI 10.1074/jbc.M207294200; Swift S, 2006, J BIOL CHEM, V281, P4109, DOI 10.1074/jbc.M509525200; Verzijl D, 2006, J BIOL CHEM, V281, P35327, DOI 10.1074/jbc.M606877200; Weber M, 2004, MOL BIOL CELL, V15, P2492, DOI 10.1091/mbc.E03-09-0634; Whitehead GS, 2007, AM J RESP CRIT CARE, V175, P243, DOI 10.1164/rccm.200606-839OC	50	56	57	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7972	7982		10.1074/jbc.M710128200	http://dx.doi.org/10.1074/jbc.M710128200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18201974	Green Published, hybrid			2022-12-25	WOS:000253997900072
J	Zamyatkin, DF; Parra, F; Alonso, JMM; Harki, DA; Peterson, BR; Grochulski, P; Ng, KKS				Zamyatkin, Dmitry F.; Parra, Francisco; Martin Alonso, Jose M.; Harki, Daniel A.; Peterson, Blake R.; Grochulski, Pawel; Ng, Kenneth K. -S.			Structural insights into mechanisms of catalysis and inhibition in Norwalk virus polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT RNA-POLYMERASE; CRYSTAL-STRUCTURES; DIFFRACTION DATA; REPLICATION; COMPLEX; RNA-POLYMERASE-(3D(POL)); CONFORMATIONS; INITIATION; FIDELITY; BINDING	Crystal structures of Norwalk virus polymerase bound to an RNA primer-template duplex and either the natural substrate CTP or the inhibitor 5-nitrocytidine triphosphate have been determined to 1.8 A resolution. These structures reveal a closed conformation of the polymerase that differs significantly from previously determined open structures of calicivirus and picornavirus polymerases. These closed complexes are trapped immediately prior to the nucleotidyl transfer reaction, with the triphosphate group of the nucleotide bound to two manganese ions at the active site, poised for reaction to the 3'-hydroxyl group of the RNA primer. The positioning of the 5-nitrocytidine triphosphate nitro group between the alpha-phosphate and the 3'-hydroxyl group of the primer suggests a novel, general approach for the design of antiviral compounds mimicking natural nucleosides and nucleotides.	[Zamyatkin, Dmitry F.; Ng, Kenneth K. -S.] Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada; [Zamyatkin, Dmitry F.; Ng, Kenneth K. -S.] Univ Calgary, Alberta Ingenu Ctr Carbohydrate Sci, Calgary, AB T2N 1N4, Canada; [Parra, Francisco; Martin Alonso, Jose M.] Univ Oviedo, Inst Univ Biotecnol Asturias, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain; [Harki, Daniel A.; Peterson, Blake R.] Penn State Univ, Dept Chem, University Pk, PA 16802 USA; [Grochulski, Pawel] Univ Saskatchewan, Canadian Light Source Inc, Saskatoon, SK S7N 0X4, Canada	University of Calgary; University of Calgary; University of Oviedo; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Saskatchewan	Ng, KKS (corresponding author), Univ Calgary, Dept Biol Sci, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	ngk@ucalgary.ca	Martin Alonso, Jose Manuel/C-7763-2013; Parra, Francisco/D-5401-2009; Peterson, Blake Robert/AAG-8793-2020; Peterson, Blake/O-2497-2016	Martin Alonso, Jose Manuel/0000-0003-1725-6216; Parra, Francisco/0000-0002-1885-9521; Peterson, Blake/0000-0001-8251-3579; Ng, Kenneth K.S./0000-0001-7280-8445	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI054776] Funding Source: NIH RePORTER; NIAID NIH HHS [AI054776] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alberts IL, 2007, J AM CHEM SOC, V129, P11100, DOI 10.1021/ja071533b; Arnold JJ, 2004, BIOCHEMISTRY-US, V43, P5126, DOI 10.1021/bi035212y; Batra VK, 2006, STRUCTURE, V14, P757, DOI 10.1016/j.str.2006.01.011; Beard WA, 2006, CHEM REV, V106, P361, DOI 10.1021/cr0404904; Biswal BK, 2005, J BIOL CHEM, V280, P18202, DOI 10.1074/jbc.M413410200; Blanton LH, 2006, J INFECT DIS, V193, P413, DOI 10.1086/499315; Bruenn JA, 2003, NUCLEIC ACIDS RES, V31, P1821, DOI 10.1093/nar/gkg277; Cameron Craig E., 2002, P255; Castro C, 2007, P NATL ACAD SCI USA, V104, P4267, DOI 10.1073/pnas.0608952104; Choi KH, 2004, P NATL ACAD SCI USA, V101, P4425, DOI 10.1073/pnas.0400660101; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Ferrer-Orta C, 2006, CURR OPIN STRUC BIOL, V16, P27, DOI 10.1016/j.sbi.2005.12.002; Ferrer-Orta C, 2007, P NATL ACAD SCI USA, V104, P9463, DOI 10.1073/pnas.0700518104; Fullerton SWB, 2007, J VIROL, V81, P1858, DOI 10.1128/JVI.01462-06; Gohara DW, 2000, J BIOL CHEM, V275, P25523, DOI 10.1074/jbc.M002671200; Gohara DW, 2004, BIOCHEMISTRY-US, V43, P5149, DOI 10.1021/bi035429s; Harki DA, 2006, J MED CHEM, V49, P6166, DOI 10.1021/jm060872x; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Johnson SJ, 2003, P NATL ACAD SCI USA, V100, P3895, DOI 10.1073/pnas.0630532100; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Korneeva VS, 2007, J BIOL CHEM, V282, P16135, DOI 10.1074/jbc.M610090200; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Ng KKS, 2004, J BIOL CHEM, V279, P16638, DOI 10.1074/jbc.M400584200; Ng KKS, 2002, J BIOL CHEM, V277, P1381, DOI 10.1074/jbc.M109261200; Ortin J, 2006, ANNU REV MICROBIOL, V60, P305, DOI 10.1146/annurev.micro.60.080805.142248; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Rothwell PJ, 2005, ADV PROTEIN CHEM, V71, P401, DOI 10.1016/S0065-3233(04)71011-6; Steitz TA, 1998, NATURE, V391, P231, DOI 10.1038/34542; Tao YZ, 2002, CELL, V111, P733, DOI 10.1016/S0092-8674(02)01110-8; Thompson AA, 2007, J MOL BIOL, V366, P1459, DOI 10.1016/j.jmb.2006.11.070; Vazquez AL, 2000, J VIROL, V74, P3888, DOI 10.1128/JVI.74.8.3888-3891.2000	38	121	124	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7705	7712		10.1074/jbc.M709563200	http://dx.doi.org/10.1074/jbc.M709563200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18184655	hybrid			2022-12-25	WOS:000253997900047
J	Mason, AK; Jacobs, BE; Welling, PA				Mason, Amanda K.; Jacobs, Brandiese E.; Welling, Paul A.			AP-2-dependent internalization of potassium channel Kir2.3 is driven by a novel di-hydrophobic signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; ADAPTER PROTEIN COMPLEXES; COATED VESICLE FORMATION; BASOLATERAL MEMBRANE EXPRESSION; EPITHELIAL SODIUM-CHANNEL; CORTICAL COLLECTING DUCT; SELECTIVE GOLGI EXPORT; RECTIFIER K+ CHANNELS; VIRUS TYPE-1 NEF; SORTING SIGNALS	The localization and density of Kir2.3 channels are influenced by the balance between PDZ protein interaction at the cell surface and routing into the endocytic pathway. Here, we explore mechanisms by which the Kir2.3 channel is directed into the endocytic pathway. We found that Kir2.3 channels are constitutively internalized from the cell surface in a dynamin- dependent manner, indicative of vesicle-mediated endocytosis. The rate of Kir2.3 endocytosis was dramatically attenuated following RNA interference-mediated knockdown of either alpha adaptin (AP-2 clathrin adaptor) or clathrin heavy chain, revealing that Kir2.3 is internalized by an AP-2 clathrin-dependent mechanism. Structure-rationalized mutagenesis studies of a number of different potential AP-2 interaction motifs indicate that internalization of Kir2.3 is largely dependent on a non-canonical di-isoleucine motif (II413) embedded within the C terminus. Internalization assays using CD4-Kir2.3 chimeras demonstrate that the di-isoleucine signal acts in an autonomous and transplantable manner. Kir2.3 co-immunoprecipitates with alpha adaptin, and disruption of the di-isoleucine motif decreased interaction of the channel with AP-2. Replacement of the di-isoleucine motif with a canonical di-leucine internalization signal actually blocked Kir2.3 endocytosis. Moreover, in yeast three-hybrid studies, the Kir2.3 di-isoleucine motif does not bind the AP-2 alpha C-sigma 2 hemi-complex in the way that has been recently observed for canonical di-leucine signals. Altogether, the results indicate that Kir2.3 channels are marked for clathrin-dependent internalization from the plasma membrane by a novel AP-2-dependent signal.	[Mason, Amanda K.; Jacobs, Brandiese E.; Welling, Paul A.] Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Welling, PA (corresponding author), 655 W Baltimore St,BRB 5-029, Baltimore, MD 21201 USA.	pwelling@umaryland.edu			NIDDK NIH HHS [DK 063049] Funding Source: Medline; NIGMS NIH HHS [T32 GM 08181] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063049] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008181] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aguilar RC, 2001, J BIOL CHEM, V276, P13145, DOI 10.1074/jbc.M010591200; Alewine C, 2007, AM J PHYSIOL-CELL PH, V293, pC1733, DOI 10.1152/ajpcell.00323.2007; Alewine C, 2006, MOL BIOL CELL, V17, P4200, DOI 10.1091/mbc.E06-02-0129; Baba T, 1995, COLD SPRING HARB SYM, V60, P235, DOI 10.1101/SQB.1995.060.01.027; Bichet D, 2003, NAT REV NEUROSCI, V4, P957, DOI 10.1038/nrn1244; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Bremnes T, 1998, J BIOL CHEM, V273, P8638, DOI 10.1074/jbc.273.15.8638; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Chalfant ML, 1999, J BIOL CHEM, V274, P32889, DOI 10.1074/jbc.274.46.32889; Chaudhuri R, 2007, J VIROL, V81, P3877, DOI 10.1128/JVI.02725-06; Chu PY, 2003, AM J PHYSIOL-RENAL, V285, pF1179, DOI 10.1152/ajprenal.00150.2003; Coleman SH, 2005, J VIROL, V79, P2066, DOI 10.1128/JVI.79.4.2066-2078.2005; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Craig HM, 2000, VIROLOGY, V271, P9, DOI 10.1006/viro.2000.0277; Cremona O, 2001, J CELL SCI, V114, P1041; Damke H, 2001, MOL BIOL CELL, V12, P2578, DOI 10.1091/mbc.12.9.2578; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; De Matteis MA, 2004, BBA-BIOMEMBRANES, V1666, P264, DOI 10.1016/j.bbamem.2004.07.002; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; Doray B, 2007, MOL BIOL CELL, V18, P1887, DOI 10.1091/mbc.E07-01-0012; Edeling MA, 2006, NAT REV MOL CELL BIO, V7, P32, DOI 10.1038/nrm1786; Flagg TP, 1999, J GEN PHYSIOL, V114, P685, DOI 10.1085/jgp.114.5.685; Geisler C, 1998, J BIOL CHEM, V273, P21316, DOI 10.1074/jbc.273.33.21316; Greenberg M, 1998, CURR BIOL, V8, P1239, DOI 10.1016/S0960-9822(07)00518-0; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; Haucke V, 2005, BIOCHEM SOC T, V33, P1285, DOI 10.1042/BST0331285; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; Hofherr A, 2005, J CELL SCI, V118, P1935, DOI 10.1242/jcs.02322; Hofmann MW, 1999, J BIOL CHEM, V274, P36153, DOI 10.1074/jbc.274.51.36153; Ihrke G, 2004, TRAFFIC, V5, P946, DOI 10.1111/j.1600-0854.2004.00236.x; Kamsteeg EJ, 2001, BIOCHEM BIOPH RES CO, V282, P683, DOI 10.1006/bbrc.2001.4629; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Le Maout S, 2001, P NATL ACAD SCI USA, V98, P10475, DOI 10.1073/pnas.181481098; Ma D, 2002, CURR OPIN NEUROBIOL, V12, P287, DOI 10.1016/S0959-4388(02)00319-7; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Millar ID, 2006, J MEMBRANE BIOL, V211, P173, DOI 10.1007/s00232-006-0036-z; Motley A, 2003, J CELL BIOL, V162, P909, DOI 10.1083/jcb.200305145; Nakatsu F, 2003, CELL STRUCT FUNCT, V28, P419, DOI 10.1247/csf.28.419; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; O'Connell AD, 2005, P NATL ACAD SCI USA, V102, P9954, DOI 10.1073/pnas.0504332102; Ohno H, 1998, J BIOL CHEM, V273, P25915, DOI 10.1074/jbc.273.40.25915; Olsen O, 2002, AM J PHYSIOL-CELL PH, V282, pC183, DOI 10.1152/ajpcell.00249.2001; PALMER LG, 1994, J GEN PHYSIOL, V104, P693, DOI 10.1085/jgp.104.4.693; Peden AA, 2004, J CELL BIOL, V164, P1065, DOI 10.1083/jcb.200311064; Pegan S, 2005, NAT NEUROSCI, V8, P279, DOI 10.1038/nn1411; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Rappoport JZ, 2006, AM J PHYSIOL-CELL PH, V291, pC1072, DOI 10.1152/ajpcell.00160.2006; Rappoport JZ, 2005, TRAFFIC, V6, P539, DOI 10.1111/j.1600-0854.2005.00280.x; Rodionov DG, 1998, J BIOL CHEM, V273, P6005, DOI 10.1074/jbc.273.11.6005; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; SCHMID SL, 1991, J CELL BIOL, V114, P869, DOI 10.1083/jcb.114.5.869; Schmidt U, 2006, J CELL SCI, V119, P2321, DOI 10.1242/jcs.02943; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Simmen T, 2002, NAT CELL BIOL, V4, P154, DOI 10.1038/ncb745; Sorkin A, 2004, CURR OPIN CELL BIOL, V16, P392, DOI 10.1016/j.ceb.2004.06.001; Stockklausner C, 2003, J BIOL CHEM, V278, P17000, DOI 10.1074/jbc.M212243200; Stockklausner C, 2001, FEBS LETT, V493, P129, DOI 10.1016/S0014-5793(01)02286-4; Tong YH, 2001, J GEN PHYSIOL, V117, P103, DOI 10.1085/jgp.117.2.103; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Wang WH, 2006, AM J PHYSIOL-RENAL, V290, pF14, DOI 10.1152/ajprenal.00093.2005; Welling PA, 1997, AM J PHYSIOL-RENAL, V273, pF825, DOI 10.1152/ajprenal.1997.273.5.F825; Wenk MR, 2004, P NATL ACAD SCI USA, V101, P8262, DOI 10.1073/pnas.0401874101; Yoo D, 2005, J BIOL CHEM, V280, P35281, DOI 10.1074/jbc.M504836200; Yoo D, 2003, J BIOL CHEM, V278, P23066, DOI 10.1074/jbc.M212301200; Zeng WZ, 2002, AM J PHYSIOL-RENAL, V283, pF630, DOI 10.1152/ajprenal.00378.2001; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	68	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2008	283	10					5973	5984		10.1074/jbc.M709756200	http://dx.doi.org/10.1074/jbc.M709756200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HM	18180291	hybrid			2022-12-25	WOS:000253779500002
J	Naffar-Abu-Amara, S; Shay, T; Galun, M; Cohen, N; Isakoff, SJ; Kam, Z; Geiger, B				Naffar-Abu-Amara, Suha; Shay, Tal; Galun, Meirav; Cohen, Naomi; Isakoff, Steven J.; Kam, Zvi; Geiger, Benjamin			Identification of Novel Pro-Migratory, Cancer-Associated Genes Using Quantitative, Microscopy-Based Screening	PLOS ONE			English	Article								Background. Cell migration is a highly complex process, regulated by multiple genes, signaling pathways and external stimuli. To discover genes or pharmacological agents that can modulate the migratory activity of cells, screening strategies that enable the monitoring of diverse migratory parameters in a large number of samples are necessary. Methodology. In the present study, we describe the development of a quantitative, high-throughput cell migration assay, based on a modified phagokinetic tracks (PKT) procedure, and apply it for identifying novel pro-migratory genes in a cancer-related gene library. In brief, cells are seeded on fibronectin-coated 96-well plates, covered with a monolayer of carboxylated latex beads. Motile cells clear the beads, located along their migratory paths, forming tracks that are visualized using an automated, transmitted-light screening microscope. The tracks are then segmented and characterized by multi-parametric, morphometric analysis, resolving a variety of morphological and kinetic features. Conclusions. In this screen we identified 4 novel genes derived from breast carcinoma related cDNA library, whose over-expression induces major alteration in the migration of the stationary MCF7 cells. This approach can serve for high throughput screening for novel ways to modulate cellular migration in pathological states such as tumor metastasis and invasion.	[Naffar-Abu-Amara, Suha; Cohen, Naomi; Kam, Zvi; Geiger, Benjamin] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; [Shay, Tal] Weizmann Inst Sci, Dept Phys Complex Syst, Rehovot, Israel; [Galun, Meirav] Weizmann Inst Sci, Dept Comp Sci & Appl Math, Rehovot, Israel; [Isakoff, Steven J.] Mass Gen Hosp Canc Ctr, Boston, MA USA; [Isakoff, Steven J.] Harvard Med Sch, Dept Cell Biol, Boston, MA USA	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science; Harvard University; Harvard Medical School	Geiger, B (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	benny.geiger@weizmann.ac.il	Isakoff, Steven/ABE-3566-2020; Shay, Tal/J-4028-2016	Shay, Tal/0000-0003-0755-1350	Israel Science Foundation; NIGMS; NIH [U54GM64346]; Weizmann Institute; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM064346] Funding Source: NIH RePORTER	Israel Science Foundation(Israel Science Foundation); NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Weizmann Institute; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This study was supported by grants from the Israel Science Foundation and an NIGMS grant for the Cell Migration Consortium (NIH Grant U54GM64346), and by the Kahn fund for systems biology at the Weizmann Institute.	ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; Ayaki M, 2000, BBA-MOL CELL RES, V1495, P40, DOI 10.1016/S0167-4889(99)00153-6; Baudoux B, 2000, EUR J CELL BIOL, V79, P41, DOI 10.1078/S0171-9335(04)70006-0; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; COOMBER BL, 1990, ARTERIOSCLEROSIS, V10, P215, DOI 10.1161/01.ATV.10.2.215; Isakoff SJ, 2005, CANCER RES, V65, P10992, DOI 10.1158/0008-5472.CAN-05-2612; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; IWASAKI T, 1995, INT J CANCER, V63, P282, DOI 10.1002/ijc.2910630223; Kawa S, 1997, FEBS LETT, V420, P196, DOI 10.1016/S0014-5793(97)01516-0; Libotte T, 2001, EXP CELL RES, V270, P129, DOI 10.1006/excr.2001.5339; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Liron Y, 2006, J MICROSC-OXFORD, V221, P145, DOI 10.1111/j.1365-2818.2006.01550.x; Mastyugin V, 2004, J BIOMOL SCREEN, V9, P712, DOI 10.1177/1087057104269495; Mukai M, 2003, INT J ONCOL, V22, P1247; Ogata Riko, 1998, Kurume Medical Journal, V45, P11; Ohmori T, 2001, J BIOL CHEM, V276, P5274, DOI 10.1074/jbc.M005405200; Onishi Y, 2003, CLIN EXP METASTAS, V20, P51, DOI 10.1023/A:1022594503657; Pankov R, 2005, J CELL BIOL, V170, P793, DOI 10.1083/jcb.200503152; Paran Y, 2007, J STRUCT BIOL, V158, P233, DOI 10.1016/j.jsb.2006.12.013; Patan S, 2000, J NEURO-ONCOL, V50, P1, DOI 10.1023/A:1006493130855; Price LS, 2001, SEMIN CANCER BIOL, V11, P167, DOI 10.1006/scbi.2000.0367; SHARON E, 2001, SEGMENTATION BOUNDAR, P469; Takanami I, 2002, ONCOL REP, V9, P125; Witt AE, 2006, J PROTEOME RES, V5, P599, DOI 10.1021/pr050395r; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; WONG MKK, 1988, J CELL BIOL, V107, P1777, DOI 10.1083/jcb.107.5.1777; Zahm JM, 1997, CELL MOTIL CYTOSKEL, V37, P33, DOI 10.1002/(SICI)1097-0169(1997)37:1<33::AID-CM4>3.0.CO;2-I	28	19	19	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2008	3	1							e1457	10.1371/journal.pone.0001457	http://dx.doi.org/10.1371/journal.pone.0001457			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SO	18213366	Green Published, gold, Green Submitted			2022-12-25	WOS:000260503900003
J	Rintamaki, R; Grimaldi, S; Englund, A; Haukka, J; Partonen, T; Reunanen, A; Aromaa, A; Lonnqvist, J				Rintamaki, Reeta; Grimaldi, Sharon; Englund, Ani; Haukka, Jari; Partonen, Timo; Reunanen, Antti; Aromaa, Arpo; Lonnqvist, Jouko			Seasonal Changes in Mood and Behavior Are Linked to Metabolic Syndrome	PLOS ONE			English	Article							SERUM URIC-ACID; PATTERN ASSESSMENT QUESTIONNAIRE; CIRCADIAN CLOCK; LIGHT; EXPRESSION; TRANSCRIPTION; DOPAMINE; DISEASE; TIME; TEMPERATURE	Background. Obesity is a major public health problem worldwide. Metabolic syndrome is a risk factor to the cardiovascular diseases. It has been reported that disruptions of the circadian clockwork are associated with and may predispose to metabolic syndrome. Methodology and Principal Findings. 8028 individuals attended a nationwide health examination survey in Finland. Data were collected with a face-to-face interview at home and during an individual health status examination. The waist circumference, height, weight and blood pressure were measured and samples were taken for laboratory tests. Participants were assessed using the ATP-III criteria for metabolic syndrome and with the Seasonal Pattern Assessment Questionnaire for their seasonal changes in mood and behavior. Seasonal changes in weight in particular were a risk factor of metabolic syndrome, after controlling for a number of known risk and potential confounding factors. Conclusions and Significance. Metabolic syndrome is associated with high global scores on the seasonal changes in mood and behavior, and with those in weight in particular. Assessment of these changes may serve as a useful indicator of metabolic syndrome, because of easy assessment. Abnormalities in the circadian clockwork which links seasonal fluctuations to metabolic cycles may predispose to seasonal changes in weight and to metabolic syndrome.	[Rintamaki, Reeta; Grimaldi, Sharon; Englund, Ani; Haukka, Jari; Partonen, Timo; Lonnqvist, Jouko] Natl Publ Hlth Inst, Dept Mental Hlth & Alcohol Res, Helsinki, Finland; [Reunanen, Antti; Aromaa, Arpo] Natl Publ Hlth Inst, Dept Hlth & Funct Capacity, Helsinki, Finland; [Lonnqvist, Jouko] Helsinki Univ Hosp, Dept Psych, Helsinki, Finland	Finland National Institute for Health & Welfare; Finland National Institute for Health & Welfare; University of Helsinki; Helsinki University Central Hospital	Partonen, T (corresponding author), Natl Publ Hlth Inst, Dept Mental Hlth & Alcohol Res, Helsinki, Finland.	timo.partonen@ktl.fi	Haukka, Jari/G-1484-2014; Partonen, Timo/G-1105-2012	Haukka, Jari/0000-0003-1450-6208; Partonen, Timo/0000-0003-1951-2455; Rintamaki, Reeta/0000-0003-4678-5555	Academy of Finland [201097, 210262]; The Finnish Medical Foundation	Academy of Finland(Academy of Finland); The Finnish Medical Foundation	The study was supported in part by grants from the Academy of Finland (#201097 and #210262), and a grant from The Finnish Medical Foundation (to Dr. Partonen). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Asher G, 2006, TRENDS CELL BIOL, V16, P547, DOI 10.1016/j.tcb.2006.09.005; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Boothroyd CE, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030054; BRAINARD GC, 1987, BRAIN RES, V424, P199, DOI 10.1016/0006-8993(87)91211-X; Chen Z, 2007, SCIENCE, V316, P1916, DOI 10.1126/science.1140958; CHURCH WH, 1994, BRAIN RES BULL, V33, P419, DOI 10.1016/0361-9230(94)90285-2; Coutinho TD, 2007, AM J HYPERTENS, V20, P83, DOI 10.1016/j.amjhyper.2006.06.015; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; de Lau LML, 2005, ANN NEUROL, V58, P797, DOI 10.1002/ana.20663; Duan W, 2002, J NEUROCHEM, V80, P101, DOI 10.1046/j.0022-3042.2001.00676.x; Foulkes NS, 1996, P NATL ACAD SCI USA, V93, P14140, DOI 10.1073/pnas.93.24.14140; Foulkes NS, 1996, NATURE, V381, P83, DOI 10.1038/381083a0; Gottlieb DJ, 2005, ARCH INTERN MED, V165, P863, DOI 10.1001/archinte.165.8.863; Green CB, 2007, P NATL ACAD SCI USA, V104, P9888, DOI 10.1073/pnas.0702448104; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Hastings M, 2007, J ENDOCRINOL, V195, P187, DOI 10.1677/JOE-07-0378; Holmback U, 2003, EUR J NUTR, V42, P75, DOI 10.1007/s00394-003-0386-6; Joreskog KG., 1977, MATH METHODS DIGITAL, P125; KASPER S, 1989, ARCH GEN PSYCHIAT, V46, P823; Kaushik R, 2007, PLOS BIOL, V5, P1257, DOI 10.1371/journal.pbio.0050146; Kawamoto R, 2006, INTERNAL MED, V45, P605, DOI 10.2169/internalmedicine.45.1661; KAWATO M, 1982, J THEOR BIOL, V98, P369, DOI 10.1016/0022-5193(82)90125-4; Kornmann B, 2007, PLOS BIOL, V5, P179, DOI 10.1371/journal.pbio.0050034; Koskinen S, 2004, HLTH FUNCTIONAL CAPA; LAM RW, 1994, AM J PSYCHIAT, V151, P744; LAPOSKY AD, 2007, FEBS LETT IN PRESS, DOI DOI 10.1016/J.FEBSLET.2007.06.079]; Lincoln GA, 2006, SCIENCE, V314, P1941, DOI 10.1126/science.1132009; Liu C, 2007, NATURE, V447, P477, DOI 10.1038/nature05767; Louet JF, 2006, P NATL ACAD SCI USA, V103, P17868, DOI 10.1073/pnas.0608711103; Madden PAF, 1996, ARCH GEN PSYCHIAT, V53, P47; Magnusson A, 1996, J AFFECT DISORDERS, V40, P121, DOI 10.1016/0165-0327(96)00036-5; Magnusson A, 1997, J AFFECT DISORDERS, V42, P113, DOI 10.1016/S0165-0327(96)00104-8; Maldonado R, 1999, P NATL ACAD SCI USA, V96, P14094, DOI 10.1073/pnas.96.24.14094; Malik S, 2004, CIRCULATION, V110, P1245, DOI 10.1161/01.CIR.0000140677.20606.0E; Massy ZA, 2005, J AM SOC NEPHROL, V16, P109, DOI 10.1681/ASN.2004060495; Meijer JH, 2007, GEN COMP ENDOCR, V152, P159, DOI 10.1016/j.ygcen.2007.01.018; Onat A, 2006, AM J HYPERTENS, V19, P1055, DOI 10.1016/j.amjhyper.2006.02.014; Onat A, 2006, PREV MED, V43, P136, DOI 10.1016/j.ypmed.2006.04.005; Partonen T, 2004, ACTA PSYCHIAT SCAND, V109, P110, DOI 10.1046/j.0001-690X.2003.00226.x; Partonen T, 1998, LANCET, V352, P1369, DOI 10.1016/S0140-6736(98)01015-0; Partonen T, 2007, ANN MED, V39, P229, DOI 10.1080/07853890701278795; Pei LM, 2006, NAT MED, V12, P1048, DOI 10.1038/nm1471; Penfield S, 2005, CURR BIOL, V15, P1998, DOI 10.1016/j.cub.2005.11.010; Ptitsyn AA, 2007, PLOS COMPUT BIOL, V3, P1108, DOI 10.1371/journal.pcbi.0030120; Revel FG, 2007, P NATL ACAD SCI USA, V104, P13816, DOI 10.1073/pnas.0704699104; Roybal K, 2007, P NATL ACAD SCI USA, V104, P6406, DOI 10.1073/pnas.0609625104; Rudic RD, 2004, PLOS BIOL, V2, P1893, DOI 10.1371/journal.pbio.0020377; Sakamoto K, 2005, EUR J NEUROSCI, V22, P3129, DOI 10.1111/j.1460-9568.2005.04512.x; Stoleru D, 2007, CELL, V129, P207, DOI 10.1016/j.cell.2007.02.038; Storch KF, 2007, CELL, V130, P730, DOI 10.1016/j.cell.2007.06.045; Tarkkonen L., 1987, STAT STUDIES, V7; Thompson C, 2004, J AFFECT DISORDERS, V78, P219, DOI 10.1016/S0165-0327(02)00314-2; Thompson C, 1997, BRIT J PSYCHIAT, V170, P431, DOI 10.1192/bjp.170.5.431; Tu BP, 2006, NAT REV MOL CELL BIO, V7, P696, DOI 10.1038/nrm1980; Turek FW, 2005, SCIENCE, V308, P1043, DOI 10.1126/science.1108750; Ueda HR, 2004, P NATL ACAD SCI USA, V101, P11227, DOI 10.1073/pnas.0401882101; van Oort BEH, 2007, NATURWISSENSCHAFTEN, V94, P183, DOI 10.1007/s00114-006-0174-2; Vehkalahti K, 2000, STAT RES REPORTS, V17; Wehr T., 1984, SEASONAL PATTERN ASS; WHO, 2003, DIET NUTR PREVENTION, V916; Woon PY, 2007, P NATL ACAD SCI USA, V104, P14412, DOI 10.1073/pnas.0703247104; Yang XY, 2006, CELL, V126, P801, DOI 10.1016/j.cell.2006.06.050; Yanovski JA, 2000, NEW ENGL J MED, V342, P861, DOI 10.1056/NEJM200003233421206; Young MA, 2003, PSYCHIAT RES, V117, P75, DOI 10.1016/S0165-1781(02)00299-8; Zhang JF, 2006, NATURE, V439, P340, DOI 10.1038/nature04368	65	47	48	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2008	3	1							e1482	10.1371/journal.pone.0001482	http://dx.doi.org/10.1371/journal.pone.0001482			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	366SO	18213390	Green Published, Green Submitted, gold			2022-12-25	WOS:000260503900027
J	Schneider, A; Garlick, JA; Egles, C				Schneider, Aurore; Garlick, Jonathan A.; Egles, Christophe			Self-Assembling Peptide Nanofiber Scaffolds Accelerate Wound Healing	PLOS ONE			English	Article							EPIDERMAL-GROWTH-FACTOR; KERATINOCYTES IN-VITRO; INDUCED MOTILITY; FACTOR RECEPTOR; FACTOR-ALPHA; TISSUE; MIGRATION; REPAIR; MODEL; REEPITHILIALIZATION	Cutaneous wound repair regenerates skin integrity, but a chronic failure to heal results in compromised tissue function and increased morbidity. To address this, we have used an integrated approach, using nanobiotechnology to augment the rate of wound reepithelialization by combining self-assembling peptide (SAP) nanofiber scaffold and Epidermal Growth Factor (EGF). This SAP bioscaffold was tested in a bioengineered Human Skin Equivalent (HSE) tissue model that enabled wound reepithelialization to be monitored in a tissue that recapitulates molecular and cellular mechanisms of repair known to occur in human skin. We found that SAP underwent molecular self-assembly to form unique 3D structures that stably covered the surface of the wound, suggesting that this scaffold may serve as a viable wound dressing. We measured the rates of release of EGF from the SAP scaffold and determined that EGF was only released when the scaffold was in direct contact with the HSE. By measuring the length of the epithelial tongue during wound reepithelialization, we found that SAP scaffolds containing EGF accelerated the rate of wound coverage by 5 fold when compared to controls without scaffolds and by 3.5 fold when compared to the scaffold without EGF. In conclusion, our experiments demonstrated that biomaterials composed of a biofunctionalized peptidic scaffold have many properties that are well-suited for the treatment of cutaneous wounds including wound coverage, functionalization with bioactive molecules, localized growth factor release and activation of wound repair.	[Garlick, Jonathan A.; Egles, Christophe] Tufts Univ, Dept Biomed Engn, Medford, MA USA; [Schneider, Aurore] MIT, Ctr Biomed Engn, Cambridge, MA USA; [Schneider, Aurore; Garlick, Jonathan A.] Tufts Univ, Sch Dent Med, Dept Oral & Maxillofacial Pathol, Div Canc Biol & Tissue Engn, Boston, MA 02111 USA	Tufts University; Massachusetts Institute of Technology (MIT); Tufts University	Egles, C (corresponding author), Tufts Univ, Sch Dent Med, Dept Oral & Maxillofacial Pathol, Div Canc Biol & Tissue Engn, Boston, MA 02111 USA.	Christophe.egles@tufts.edu	Taylor, Graham/A-4027-2012	EGLES, Christophe/0000-0003-0982-7752	Center for Integrated Tissue Engineering at School of Dental Medicine at Tufts University; NIH/NIBIB; Fondation pour la Recherche Medicale	Center for Integrated Tissue Engineering at School of Dental Medicine at Tufts University; NIH/NIBIB(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale)	This study was supported by the Center for Integrated Tissue Engineering at School of Dental Medicine at Tufts University and NIH/NIBIB funds via the P41 Tissue Engineering Resource Center. AS is indebted to the Fondation pour la Recherche Medicale for financial support.	BARRANDON Y, 1987, CELL, V50, P1131, DOI 10.1016/0092-8674(87)90179-6; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; BROWN C, 1991, J INVEST DERMATOL, V96, P724, DOI 10.1111/1523-1747.ep12470960; BUCKLEY A, 1985, P NATL ACAD SCI USA, V82, P7340, DOI 10.1073/pnas.82.21.7340; BUCKLEY A, 1987, J SURG RES, V43, P322, DOI 10.1016/0022-4804(87)90088-6; Cha D, 1996, J INVEST DERMATOL, V106, P590, DOI 10.1111/1523-1747.ep12345083; FRANKLIN JD, 1979, PLAST RECONSTR SURG, V64, P766, DOI 10.1097/00006534-197912000-00003; Garlick JA, 1996, J DENT RES, V75, P912, DOI 10.1177/00220345960750030801; GARLICK JA, 1994, LAB INVEST, V70, P916; GARLICK JA, 1994, J INVEST DERMATOL, V103, P554, DOI 10.1111/1523-1747.ep12396847; Garlick Jonathan A., 1992, Journal of Dermatology (Tokyo), V19, P797; Garlick JA, 2007, ADV BIOCHEM ENG BIOT, V103, P207; Gelain F, 2007, MACROMOL BIOSCI, V7, P544, DOI 10.1002/mabi.200700033; Gottrup F, 2000, WOUND REPAIR REGEN, V8, P83, DOI 10.1046/j.1524-475x.2000.00083.x; Holmes TC, 2000, P NATL ACAD SCI USA, V97, P6728, DOI 10.1073/pnas.97.12.6728; Kisiday J, 2002, P NATL ACAD SCI USA, V99, P9996, DOI 10.1073/pnas.142309999; KNAUER DJ, 1984, J BIOL CHEM, V259, P5623; Kurten RC, 2005, AM J PHYSIOL-CELL PH, V288, pC109, DOI 10.1152/ajpcell.00024.2003; LAATO M, 1986, ANN SURG, V203, P379; Law B, 2006, BIOMACROMOLECULES, V7, P1261, DOI 10.1021/bm050920f; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; MATSUI C, 1995, J INVEST DERMATOL, V105, P648, DOI 10.1111/1523-1747.ep12324108; Mustoe T, 2004, AM J SURG, V187, p65S, DOI 10.1016/S0002-9610(03)00306-4; Nagai Y, 2006, J CONTROL RELEASE, V115, P18, DOI 10.1016/j.jconrel.2006.06.031; Niklason LE, 2001, J VASC SURG, V33, P628, DOI 10.1067/mva.2001.111747; NOGUCHI S, 1991, AM J PHYSIOL, V260, pE620, DOI 10.1152/ajpendo.1991.260.4.E620; OKEEFE E, 1982, J INVEST DERMATOL, V78, P482, DOI 10.1111/1523-1747.ep12510246; ONO I, 1995, J DERMATOL SCI, V10, P241, DOI 10.1016/0923-1811(95)00454-Z; RHEINWALD JG, 1975, CELL, V6, P317, DOI 10.1016/0092-8674(75)90183-X; Rovee D.T., 1972, EPIDERMAL WOUND HEAL, P71; ROVEE DT, 2003, EPIDERMIS WOUND HEAL; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SARRET Y, 1992, J INVEST DERMATOL, V98, P12, DOI 10.1111/1523-1747.ep12493517; SARRET Y, 1992, J INVEST DERMATOL, V99, P656, DOI 10.1111/1523-1747.ep12668151; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Tamariz-Dominguez E, 2002, CELL TISSUE RES, V307, P79, DOI 10.1007/s004410100450; Werner S, 2007, J INVEST DERMATOL, V127, P998, DOI 10.1038/sj.jid.5700786; WOODLEY DT, 1988, J CELL PHYSIOL, V136, P140, DOI 10.1002/jcp.1041360118; WU YJ, 1982, CELL, V31, P693, DOI 10.1016/0092-8674(82)90324-5; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; ZHANG SG, 1995, BIOMATERIALS, V16, P1385, DOI 10.1016/0142-9612(95)96874-Y; Zhang SG, 2003, NAT BIOTECHNOL, V21, P1171, DOI 10.1038/nbt874; Zhang SG, 2002, BIOTECHNOL ADV, V20, P321, DOI 10.1016/S0734-9750(02)00026-5	44	165	171	1	66	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2008	3	1							e1410	10.1371/journal.pone.0001410	http://dx.doi.org/10.1371/journal.pone.0001410			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366GT	18183291	Green Published, gold			2022-12-25	WOS:000260469400007
J	Tisserant, A; Konig, H				Tisserant, Anne; Koenig, Harald			Signal-Regulated Pre-mRNA Occupancy by the General Splicing Factor U2AF	PLOS ONE			English	Article							MAP-KINASE; TRANSDUCTION	Alternative splicing of transcripts in a signal-dependent manner has emerged as an important concept to ensure appropriate expression of splice variants under different conditions. Binding of the general splicing factor U2AF to splice sites preceding alternatively spliced exons has been suggested to be an important step for splice site recognition. For splicing to proceed, U2AF has to be replaced by other factors. We show here that U2AF interacts with the signal-dependent splice regulator Sam68 and that forced expression of Sam68 results in enhanced binding of the U2AF65 subunit to an alternatively spliced pre-mRNA sequence in vivo. Conversely, the rapid signal-induced and phosphorylation-dependent interference with Sam68 binding to RNA was accompanied by reduced pre-mRNA occupancy of U2AF in vivo. Our data suggest that Sam68 can affect splice site occupancy by U2AF in signal-dependent splicing. We propose that the induced release of U2AF from pre-mRNA provides a regulatory step to control alternative splicing.	[Tisserant, Anne; Koenig, Harald] Forschungszentrum Karlsruhe, Inst Genet & Toxikol, Karlsruhe, Germany	Helmholtz Association; Karlsruhe Institute of Technology	Konig, H (corresponding author), Forschungszentrum Karlsruhe, Inst Genet & Toxikol, Karlsruhe, Germany.	harald.koenig@itg.fzk.de		Konig, Harald/0000-0002-0117-0939	Deutsche Forschungsgemeinschaft [KO2046]; Forschungszentrum Karlsruhe GmbH [PhD student scholarship]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Forschungszentrum Karlsruhe GmbH	The work was funded by a Research grant from the Deutsche Forschungsgemeinschaft (DFG), grant# KO2046. Anne Tisserant was supported by a PhD student scholarship from the Forschungszentrum Karlsruhe GmbH.	Audibert A, 2002, MOL CELL BIOL, V22, P6706, DOI 10.1128/MCB.22.19.6706-6718.2002; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; Blencowe BJ, 2006, CELL, V126, P37, DOI 10.1016/j.cell.2006.06.023; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chiara MD, 1997, EMBO J, V16, P4746, DOI 10.1093/emboj/16.15.4746; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; Graveley BR, 2001, RNA, V7, P806, DOI 10.1017/S1355838201010317; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Kim E, 2007, NUCLEIC ACIDS RES, V35, P125, DOI 10.1093/nar/gkl924; Kim H, 2004, NAT GENET, V36, P915, DOI 10.1038/ng0904-915; Konig H, 1998, EMBO J, V17, P2904, DOI 10.1093/emboj/17.10.2904; Lin Q, 1997, J BIOL CHEM, V272, P27274, DOI 10.1074/jbc.272.43.27274; Maniatis T, 2002, NATURE, V418, P236, DOI 10.1038/418236a; Matlin AJ, 2005, NAT REV MOL CELL BIO, V6, P386, DOI 10.1038/nrm1645; Matter N, 2002, NATURE, V420, P691, DOI 10.1038/nature01153; MULLEN MP, 1991, GENE DEV, V5, P642, DOI 10.1101/gad.5.4.642; Niranjanakumari S, 2002, METHODS, V26, P182, DOI 10.1016/S1046-2023(02)00021-X; Pacheco TR, 2006, MOL CELL BIOL, V26, P8183, DOI 10.1128/MCB.00350-06; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; Reed R, 2000, CURR OPIN CELL BIOL, V12, P340, DOI 10.1016/S0955-0674(00)00097-1; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; Shin C, 2004, NAT REV MOL CELL BIO, V5, P727, DOI 10.1038/nrm1467; Stamm S, 2002, HUM MOL GENET, V11, P2409, DOI 10.1093/hmg/11.20.2409; Weg-Remers S, 2001, EMBO J, V20, P4194, DOI 10.1093/emboj/20.15.4194; ZAHALKA MA, 1995, J IMMUNOL, V154, P5345; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0	28	32	32	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2008	3	1							e1418	10.1371/journal.pone.0001418	http://dx.doi.org/10.1371/journal.pone.0001418			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366GT	18183298	gold, Green Submitted, Green Published			2022-12-25	WOS:000260469400014
J	Beamer, CA; Holian, A				Beamer, Celine A.; Holian, Andrij			Silica suppresses Toll-like receptor ligand-induced dendritic cell activation	FASEB JOURNAL			English	Article						pattern recognition receptor; costimulatory molecule; TLR4; MARCO	SCAVENGER RECEPTOR; CRYSTALLINE SILICA; T-CELL; PULMONARY CLEARANCE; TH2 RESPONSES; UNITED-STATES; NITRIC-OXIDE; MACROPHAGES; EXPOSURE; ANTIGEN	Inhalation of silica, without evidence of silicosis, is believed to predispose individuals to bacterial infections and impair respiratory immune functions. Silica may alter the sensitivity of antigen-presenting cells (APCs), such as macrophages and dendritic cells (DCs), to other types of infection; however, the exact nature of these exchanges remains uncertain. The purpose of the present study is to characterize the effect of silica exposure on innate pulmonary defense mechanisms following Toll-like receptor (TLR) ligand-induced activation using DCs as a model APC and determine whether these signals act in synergy or opposition to one another. Using C57B1/6 mice, pattern recognition receptor expression on DCs was examined in vitro and in vivo using flow cytometry, and the activation state of pulmonary and granulocyte-macrophage colony-stimulating factor-derived DCs was assessed in response to silica in combination with TLR ligands (lipopolysaccharide, cytosine-phosphate-guanine, or polyinosinic: polycytidylic acid) using flow cytometry and measurement of cytokine production. In this study, silica attenuated TLR ligand-dependent DC activation with regards to accessory molecule expression as well as nitric oxide and inflammatory cytokine production. Furthermore, silica's ability to modulate TLR ligand-dependent DC activation did not appear to be dependent on the class A scavenger receptors. Taken together, silica's ability to alter susceptibility to infection may be due to impaired inflammatory responses and reduced antibacterial activity.	[Beamer, Celine A.; Holian, Andrij] Univ Montana, Ctr Environm Hlth Sci, Sch Pharm & Allied Hlth Sci, Dept Biomed & Pharmaceut Sci, Missoula, MT 59812 USA	University of Montana System; University of Montana	Beamer, CA (corresponding author), Univ Montana, Ctr Environm Hlth Sci, Sch Pharm & Allied Hlth Sci, Dept Biomed & Pharmaceut Sci, 32 Campus Dr,Skaggs Bldg,Rm 285A, Missoula, MT 59812 USA.	celine.beamer@umontana.edu		Holian, Andrij/0000-0003-0072-4538; Beamer, Celine/0000-0003-4995-6145	NCRR NIH HHS [P20 RR17670, P20 RR017670] Funding Source: Medline; NIEHS NIH HHS [ES-015294, ES-013044, F32 ES013044, R01 ES015294] Funding Source: Medline; NIGMS NIH HHS [P30 GM103338] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017670] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES015294, F32ES013044] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Antonini JM, 2000, INHAL TOXICOL, V12, P1017; Antonini JM, 2000, LUNG, V178, P341, DOI 10.1007/s004080000038; Bang KM, 2005, INT J TUBERC LUNG D, V9, P437; Beamer CA, 2005, AM J PHYSIOL-LUNG C, V289, pL186, DOI 10.1152/ajplung.00474.2004; Beamer CA, 2007, AM J RESP CELL MOL, V37, P729, DOI 10.1165/rcmb.2007-0099OC; Becker M, 2006, EUR J IMMUNOL, V36, P950, DOI 10.1002/eji.200535660; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Chieppa M, 2003, J IMMUNOL, V171, P4552, DOI 10.4049/jimmunol.171.9.4552; Choi JK, 2005, J ENVIRON PATHOL TOX, V24, P163, DOI 10.1615/JEnvPathToxOncol.v24.i3.30; Coleman JW, 2002, CLIN EXP IMMUNOL, V129, P4, DOI 10.1046/j.1365-2249.2002.01918.x; COWIE RL, 1994, AM J RESP CRIT CARE, V150, P1460, DOI 10.1164/ajrccm.150.5.7952577; Dahl M, 2007, J CLIN INVEST, V117, P757, DOI 10.1172/JCI29968; del Hoyo GM, 2002, BLOOD, V99, P999, DOI 10.1182/blood.V99.3.999; Delclaux C, 2003, EUR RESPIR J, V22, p10S, DOI 10.1183/09031936.03.00420203; Demedts IK, 2005, AM J RESP CELL MOL, V32, P177, DOI 10.1165/rcmb.2004-0279OC; Diebold SS, 2003, NATURE, V424, P324, DOI 10.1038/nature01783; Ding M, 2006, AM J PHYSIOL-LUNG C, V290, pL291, DOI 10.1152/ajplung.00053.2005; Ding M, 2002, INT IMMUNOPHARMACOL, V2, P173, DOI 10.1016/S1567-5769(01)00170-9; Granucci F, 2003, BLOOD, V102, P2940, DOI 10.1182/blood-2002-12-3651; Hamilton RF, 2006, J BIOL CHEM, V281, P34218, DOI 10.1074/jbc.M605229200; HANNA PC, 1993, P NATL ACAD SCI USA, V90, P10198, DOI 10.1073/pnas.90.21.10198; Hwang M, 2007, J BIOMED MATER RES A, V80A, P513, DOI 10.1002/jbm.a.31106; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Jefferies CA, 2003, J BIOL CHEM, V278, P26258, DOI 10.1074/jbc.M301484200; Kaisho T, 2004, MICROBES INFECT, V6, P1388, DOI 10.1016/j.micinf.2004.08.019; Kaisho T, 2002, BBA-MOL CELL RES, V1589, P1, DOI 10.1016/S0167-4889(01)00182-3; Kaisho T, 2006, J ALLERGY CLIN IMMUN, V117, P979, DOI 10.1016/j.jaci.2006.02.023; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 2001, EUR RESPIR J, V18, P692; Lee MS, 2007, ANNU REV BIOCHEM, V76, P447, DOI 10.1146/annurev.biochem.76.060605.122847; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; Macagno A, 2007, TRENDS IMMUNOL, V28, P227, DOI 10.1016/j.it.2007.03.008; McWilliam AS, 1996, J EXP MED, V184, P2429, DOI 10.1084/jem.184.6.2429; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Migliaccio CT, 2005, TOXICOL APPL PHARM, V205, P168, DOI 10.1016/j.taap.2004.11.005; Ovrevik J, 2004, TOXICOL SCI, V81, P480, DOI 10.1093/toxsci/kfh214; Palacios EH, 2004, ONCOGENE, V23, P7990, DOI 10.1038/sj.onc.1208074; Parks CG, 2002, ARTHRITIS RHEUM-US, V46, P1840, DOI 10.1002/art.10368; Piercy J, 2006, IMMUNOLOGY, V118, P250, DOI 10.1111/j.1365-2567.2006.02363.x; Rao TD, 1998, IMMUNOL INVEST, V27, P181, DOI 10.3109/08820139809089455; Rees D, 2007, INT J TUBERC LUNG D, V11, P474; Robbins CS, 2004, AM J RESP CELL MOL, V30, P202, DOI 10.1165/rcmb.2003-0259OC; Saalmuller A, 2006, VET MICROBIOL, V117, P32, DOI 10.1016/j.vetmic.2006.04.007; Saeki H, 1996, VET PARASITOL, V61, P201, DOI 10.1016/0304-4017(95)00823-3; Samarasinghe R, 2006, J INTERF CYTOK RES, V26, P893, DOI 10.1089/jir.2006.26.893; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; Stumbles PA, 1999, IMMUNOL CELL BIOL, V77, P428, DOI 10.1046/j.1440-1711.1999.00850.x; Swanson KA, 2004, J IMMUNOL, V173, P4875, DOI 10.4049/jimmunol.173.8.4875; Swanson KA, 2004, AM J RESP CELL MOL, V30, P311, DOI 10.1165/rcmb.2003-0268OC; Trinchieri G, 2007, NAT REV IMMUNOL, V7, P179, DOI 10.1038/nri2038; Tsoumakidou M, 2006, IMMUNOL CELL BIOL, V84, P267, DOI 10.1111/j.1440-1711.2006.01428.x; VOGEL SN, 1982, INFECT IMMUN, V38, P681, DOI 10.1128/IAI.38.2.681-685.1982; Wan H, 2005, CELL MOL IMMUNOL, V2, P28; Wang SD, 2004, MICROBES INFECT, V6, P759, DOI 10.1016/j.micinf.2004.03.007; ZIMMERMAN BT, 1986, IMMUNOLOGY, V59, P521	55	21	21	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					2053	2063		10.1096/fj.07-095299	http://dx.doi.org/10.1096/fj.07-095299			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18180331				2022-12-25	WOS:000256352700044
J	Voisin, T; El Firar, A; Rouyer-Fessard, C; Gratio, V; Laburthe, M				Voisin, Thierry; El Firar, Aadil; Rouyer-Fessard, Christiane; Gratio, Valerie; Laburthe, Marc			A hallmark of immunoreceptor, the tyrosine-based inhibitory motif ITIM, is present in the G protein-coupled receptor OX1R for orexins and drives apoptosis: a novel mechanism	FASEB JOURNAL			English	Article						hypocretin; cancer cell death; colon cancer; tyrosine phosphatase; SHP-2	CANCER CELL-PROLIFERATION; COLON-CANCER; NEUROBLASTOMA-CELLS; EPIDERMAL-GROWTH; TYPE-2 RECEPTOR; LEUKEMIA-CELLS; CA2+ ENTRY; T-CELLS; ACTIVATION; PHOSPHATASE	Orexins acting at the G protein-coupled receptor (GPCR) OX1R have recently been shown to promote dramatic apoptosis in cancer cells. We report here that orexin-induced apoptosis is driven by an immunoreceptor tyrosine-based inhibitory motif (ITIM) ((IIYNFL)-N-358) present in the OX1R. This effect is mediated by SHP-2 phosphatase recruitment via a mechanism that requires Gq protein but is independent of phospholipase C activation. This is based on the following observations: 1) mutation of Y-358 into F abolished orexin-induced tyrosine phosphorylation in ITIM, orexin-induced apoptosis, and uncoupled OX1R from Gq protein in transfected Chinese hamster ovary (CHO) cells; 2) orexin-induced apoptosis in CHO cells expressing recombinant OX1R and in colon cancer cells expressing the native receptor was abolished by treatment with the tyrosine phosphatase inhibitor PAO and by transfection with a dominant-negative mutant of SHP-2; 3) orexins were unable to promote apoptosis in fibroblast cells invalidated for the G alpha q subunit and transfected with OX1R cDNA, whereas they promoted apoptosis in cells equipped with G alpha q and OX1R; and 4) the phospholipase C inhibitor U-73122 blocked orexin-stimulated inositol phosphate formation, whereas it had no effect on orexin-induced apoptosis in CHO cells expressing OX1R. These data unravel a novel mechanism, whereby ITIM-expressing GPCRs may trigger apoptosis.	INSERM, U773, Ctr Rech Biomed Bichat Beaujon CRB3, F-75018 Paris, France; Univ Paris Diderot, UMR 773, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Voisin, T (corresponding author), INSERM, U773, Ctr Rech Biomed Bichat Beaujon CRB3, F-75018 Paris, France.	tvoisin@bichat.inserm.fr	voisin, thierry/R-1241-2017; LABURTHE, Marc/C-1875-2012	voisin, thierry/0000-0002-4320-5183; 				Akl H, 2007, LEUKEMIA, V21, P788, DOI 10.1038/sj.leu.2404585; Barrow AD, 2006, EUR J IMMUNOL, V36, P1646, DOI 10.1002/eji.200636195; Cai T, 2002, J CELL BIOL, V159, P103, DOI 10.1083/jcb.200205017; Caravatta L, 2008, J CELL PHYSIOL, V214, P192, DOI 10.1002/jcp.21186; Cetin S, 2007, AM J PHYSIOL-GASTR L, V292, pG1347, DOI 10.1152/ajpgi.00375.2006; Chen J, 2004, ONCOGENE, V23, P3659, DOI 10.1038/sj.onc.1207471; Darmoul D, 2004, MOL CANCER RES, V2, P514; Date Y, 1999, P NATL ACAD SCI USA, V96, P748, DOI 10.1073/pnas.96.2.748; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; Duchesne C, 2003, J BIOL CHEM, V278, P14274, DOI 10.1074/jbc.M300425200; Edmunds C, 1999, EUR J IMMUNOL, V29, P3507, DOI 10.1002/(SICI)1521-4141(199911)29:11<3507::AID-IMMU3507>3.0.CO;2-9; Ferjoux G, 2003, MOL BIOL CELL, V14, P3911, DOI 10.1091/mbc.E03-02-0069; Ferrand A, 2005, J BIOL CHEM, V280, P10710, DOI 10.1074/jbc.M413309200; Frucht H, 1999, CLIN CANCER RES, V5, P2532; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; Gardella TJ, 1996, J BIOL CHEM, V271, P19888, DOI 10.1074/jbc.271.33.19888; Gaudin P, 1998, J BIOL CHEM, V273, P4990, DOI 10.1074/jbc.273.9.4990; Gentili C, 2006, J ENDOCRINOL, V188, P69, DOI 10.1677/joe.1.06397; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Hoff H, 2007, EUR J IMMUNOL, V37, P1072, DOI 10.1002/eji.200636240; Hubbard KB, 2006, CELL SIGNAL, V18, P135, DOI 10.1016/j.cellsig.2005.08.004; Johansson L, 2007, BRIT J PHARMACOL, V150, P97, DOI 10.1038/sj.bjp.0706959; Larsson KP, 2005, J BIOL CHEM, V280, P1771, DOI 10.1074/jbc.M406073200; Lawson AE, 2000, BLOOD, V96, P2084, DOI 10.1182/blood.V96.6.2084.h8002084_2084_2092; Magga J, 2006, BIOCHEM PHARMACOL, V71, P827, DOI 10.1016/j.bcp.2005.12.021; MAORET JJ, 1994, BIOCHEM BIOPH RES CO, V203, P465, DOI 10.1006/bbrc.1994.2205; Miura SI, 2000, EMBO J, V19, P4026, DOI 10.1093/emboj/19.15.4026; Nakamura K, 2000, J IMMUNOL, V164, P631, DOI 10.4049/jimmunol.164.2.631; Nasman J, 2006, J NEUROSCI, V26, P10658, DOI 10.1523/JNEUROSCI.2609-06.2006; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; Ravetch JV, 2000, SCIENCE, V290, P84, DOI 10.1126/science.290.5489.84; Rizzuto R, 2003, ONCOGENE, V22, P8619, DOI 10.1038/sj.onc.1207105; Rouet-Benzineb P, 2004, J BIOL CHEM, V279, P45875, DOI 10.1074/jbc.M404136200; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Sakurai T, 2007, NAT REV NEUROSCI, V8, P171, DOI 10.1038/nrn2092; Sly LM, 2003, EXP HEMATOL, V31, P1170, DOI 10.1016/j.exphem.2003.09.011; Smart D, 2000, BRIT J PHARMACOL, V129, P1289, DOI 10.1038/sj.bjp.0703257; Soderstrom TS, 2002, J IMMUNOL, V169, P2851, DOI 10.4049/jimmunol.169.6.2851; Teijeiro R, 2002, CELL PHYSIOL BIOCHEM, V12, P31, DOI 10.1159/000047824; Turner PR, 2000, MOL ENDOCRINOL, V14, P241, DOI 10.1210/me.14.2.241; Vazquez G, 2004, BBA-MOL CELL RES, V1742, P21, DOI 10.1016/j.bbamcr.2004.08.015; Voisin T, 2003, CELL MOL LIFE SCI, V60, P72, DOI 10.1007/s000180300005; Voisin T, 2006, ENDOCRINOLOGY, V147, P4977, DOI 10.1210/en.2006-0201; Wang N, 2006, J BIOL CHEM, V281, P21878, DOI 10.1074/jbc.M605018200; Wojciechowski W, 2005, J IMMUNOL, V174, P7859, DOI 10.4049/jimmunol.174.12.7859; Yuan LP, 2005, J BIOL CHEM, V280, P42701, DOI 10.1074/jbc.M506768200; Zocchi MR, 2001, EUR J IMMUNOL, V31, P3667, DOI 10.1002/1521-4141(200112)31:12<3667::AID-IMMU3667>3.0.CO;2-G	48	41	50	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1993	2002		10.1096/fj.07-098723	http://dx.doi.org/10.1096/fj.07-098723			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18198212				2022-12-25	WOS:000256352700038
J	Wilson, JB; Yamamoto, K; Marriott, AS; Hussain, S; Sung, P; Hoatlin, ME; Mathew, CG; Takata, M; Thompson, LH; Kupfer, GM; Jones, NJ				Wilson, J. B.; Yamamoto, K.; Marriott, A. S.; Hussain, S.; Sung, P.; Hoatlin, M. E.; Mathew, C. G.; Takata, M.; Thompson, L. H.; Kupfer, G. M.; Jones, N. J.			FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3	ONCOGENE			English	Article						fanconi anemia; ATR; interstrand crosslinks; DNA repair; RAD51 paralog; replication restart; epistasis	DOUBLE-STRAND BREAKS; HAMSTER CELL MUTANTS; ANEMIA PATHWAY; HOMOLOGOUS RECOMBINATION; COMPLEMENTATION GROUP; ATAXIA-TELANGIECTASIA; MONOUBIQUITINATED FANCD2; CROSS-LINKS; REPAIR; GENE	Fanconi anemia (FA) is a human disorder characterized by cancer susceptibility and cellular sensitivity to DNA crosslinks and other damages. Thirteen complementation groups and genes are identified, including BRCA2, which is defective in the FA-D1 group. Eight of the FA proteins, including FANCG, participate in a nuclear core complex that is required for the monoubiquitylation of FANCD2 and FANCI. FANCD2, like FANCD1/BRCA2, is not part of the core complex, and we previously showed direct BRCA2-FANCD2 interaction using yeast two-hybrid analysis. We now show in human and hamster cells that expression of FANCG protein, but not the other core complex proteins, is required for co-precipitation of BRCA2 and FANCD2. We also show that phosphorylation of FANCG serine 7 is required for its co-precipitation with BRCA2, XRCC3 and FANCD2, as well as the direct interaction of BRCA2-FANCD2. These results argue that FANCG has a role independent of the FA core complex, and we propose that phosphorylation of serine 7 is the signalling event required for forming a discrete complex comprising FANCD1/BRCA2-FANCD2-FANCG- XRCC3 (D1-D2-G-X3). Cells that fail to express either phospho-Ser7-FANCG, or full length BRCA2 protein, lack the interactions amongst the four component proteins. A role for D1-D2-G-X3 in homologous recombination repair (HRR) is supported by our finding that FANCG and the RAD51-paralog XRCC3 are epistatic for sensitivity to DNA crosslinking compounds in DT40 chicken cells. Our findings further define the intricate interface between FANC and HRR proteins in maintaining chromosome stability.	[Wilson, J. B.; Marriott, A. S.; Jones, N. J.] Univ Liverpool, Sch Biol Sci, Mol Oncol & Stem Cell Res Grp, Liverpool L69 7ZB, Merseyside, England; [Yamamoto, K.; Takata, M.] Kawasaki Med Sch, Dept Immunol & Med Genet, Okayama, Japan; [Hussain, S.] Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; [Sung, P.] Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA; [Hoatlin, M. E.] Oregon Hlth & Sci Univ, Div Biochem & Mol Biol, Portland, OR USA; [Mathew, C. G.] Oregon Hlth & Sci Univ, Div Biochem & Mol Biol, Portland, OR USA; [Thompson, L. H.] Lawrence Livermore Natl Lab, Biosci & Biotechnol Div, Livermore, CA USA; [Kupfer, G. M.] Yale Univ, Sch Med, Div Hematol Oncol, Dept Pediat, New Haven, CT USA	University of Liverpool; Kawasaki Medical School; University of Cambridge; Yale University; Oregon Health & Science University; Oregon Health & Science University; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; Yale University	Jones, NJ (corresponding author), Univ Liverpool, Sch Biol Sci, Mol Oncol & Stem Cell Res Grp, Biosci Bldg,Crown St, Liverpool L69 7ZB, Merseyside, England.	njjones@liv.ac.uk	Mathew, Christopher G/G-3434-2015; Jones, Nigel J/D-1997-2010	Mathew, Christopher G/0000-0003-4178-1838; Takata, Minoru/0000-0002-4926-3675				Alderton GK, 2004, HUM MOL GENET, V13, P3127, DOI 10.1093/hmg/ddh335; Alter BP, 1996, AM J HEMATOL, V53, P99, DOI 10.1002/(SICI)1096-8652(199610)53:2<99::AID-AJH7>3.3.CO;2-M; Blom E, 2004, DNA REPAIR, V3, P77, DOI 10.1016/j.dnarep.2003.09.007; Bogliolo M, 2007, EMBO J, V26, P1340, DOI 10.1038/sj.emboj.7601574; Bridge WL, 2005, NAT GENET, V37, P953, DOI 10.1038/ng1627; Busch DB, 1996, MUTAT RES-DNA REPAIR, V363, P209, DOI 10.1016/0921-8777(96)00014-6; Carreau M, 1999, MUTAT RES-DNA REPAIR, V435, P103, DOI 10.1016/S0921-8777(99)00041-5; Ciccia A, 2007, MOL CELL, V25, P331, DOI 10.1016/j.molcel.2007.01.003; Collins N, 2005, INT J HEMATOL, V82, P176, DOI 10.1532/IJH97.05108; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; de Winter JP, 1998, NAT GENET, V20, P281, DOI 10.1038/3093; de Winter JP, 2000, HUM MOL GENET, V9, P2665, DOI 10.1093/hmg/9.18.2665; Dronkert MLG, 2001, MUTAT RES-DNA REPAIR, V486, P217, DOI 10.1016/S0921-8777(01)00092-1; Esashi F, 2005, NATURE, V434, P598, DOI 10.1038/nature03404; Garcia-Higuera I, 1999, MOL CELL BIOL, V19, P4866; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Goggins M, 1996, CANCER RES, V56, P5360; Gordon SM, 2003, BLOOD, V102, P136, DOI 10.1182/blood-2002-11-3517; Gregory RC, 2003, SEMIN CANCER BIOL, V13, P77, DOI 10.1016/S1044-579X(02)00102-5; Groves MR, 1999, CURR OPIN STRUC BIOL, V9, P383, DOI 10.1016/S0959-440X(99)80052-9; Gudmundsdottir K, 2006, ONCOGENE, V25, P5864, DOI 10.1038/sj.onc.1209874; Henry-Mowatt J, 2003, MOL CELL, V11, P1109, DOI 10.1016/S1097-2765(03)00132-1; Hinz JM, 2007, NUCLEIC ACIDS RES, V35, P3733, DOI 10.1093/nar/gkm315; Hinz JM, 2006, DNA REPAIR, V5, P875, DOI 10.1016/j.dnarep.2006.05.039; Hirano S, 2005, EMBO J, V24, P418, DOI 10.1038/sj.emboj.7600534; Ho GPH, 2006, MOL CELL BIOL, V26, P7005, DOI 10.1128/MCB.02018-05; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Hussain S, 2004, HUM MOL GENET, V13, P1241, DOI 10.1093/hmg/ddh135; Hussain S, 2003, HUM MOL GENET, V12, P2503, DOI 10.1093/hmg/ddg266; Hussain S, 2006, DNA REPAIR, V5, P629, DOI 10.1016/j.dnarep.2006.02.007; Johnson MA, 2000, MUTAGENESIS, V15, P367, DOI 10.1093/mutage/15.4.367; Johnson MA, 1999, MUTAT RES-DNA REPAIR, V435, P271, DOI 10.1016/S0921-8777(99)00055-5; Kennedy RD, 2005, GENE DEV, V19, P2925, DOI 10.1101/gad.1370505; Kupfer GM, 1997, NAT GENET, V17, P487, DOI 10.1038/ng1297-487; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; Lamerdin JE, 2004, MUTAGENESIS, V19, P237, DOI 10.1093/mutage/geh019; Levitus M, 2006, CELL ONCOL, V28, P3; Ling C, 2007, EMBO J, V26, P2104, DOI 10.1038/sj.emboj.7601666; Liu N, 2002, NUCLEIC ACIDS RES, V30, P1009, DOI 10.1093/nar/30.4.1009; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Lyakhovich A, 2007, CELL CYCLE, V6, P1019, DOI 10.4161/cc.6.9.4223; Masson JY, 2001, GENE DEV, V15, P3296, DOI 10.1101/gad.947001; Mathew CG, 2006, ONCOGENE, V25, P5875, DOI 10.1038/sj.onc.1209878; Meetei AR, 2005, NAT GENET, V37, P958, DOI 10.1038/ng1626; Mi J, 2004, MOL CELL BIOL, V24, P8576, DOI 10.1128/MCB.24.19.8576-8585.2004; Mirchandani KD, 2006, EXP CELL RES, V312, P2647, DOI 10.1016/j.yexcr.2006.06.014; Nakanishi K, 2005, P NATL ACAD SCI USA, V102, P1110, DOI 10.1073/pnas.0407796102; Niedernhofer LJ, 2007, MOL CELL, V25, P487, DOI 10.1016/j.molcel.2007.02.002; Niedzwiedz W, 2004, MOL CELL, V15, P607, DOI 10.1016/j.molcel.2004.08.009; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; Ohashi A, 2005, J BIOL CHEM, V280, P14877, DOI 10.1074/jbc.M414669200; Pace P, 2002, EMBO J, V21, P3414, DOI 10.1093/emboj/cdf355; Patel KJ, 2007, DNA REPAIR, V6, P885, DOI 10.1016/j.dnarep.2007.02.002; Qiao FY, 2004, J BIOL CHEM, V279, P46035, DOI 10.1074/jbc.M408323200; Reid S, 2007, NAT GENET, V39, P162, DOI 10.1038/ng1947; Sarkaria JN, 1998, CANCER RES, V58, P4375; Smogorzewska A, 2007, CELL, V129, P289, DOI 10.1016/j.cell.2007.03.009; Takata M, 2001, MOL CELL BIOL, V21, P2858, DOI 10.1128/MCB.21.8.2858-2866.2001; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; Taniguchi T, 2006, BLOOD, V107, P4223, DOI 10.1182/blood-2005-10-4240; Tebbs RS, 2005, DNA REPAIR, V4, P11, DOI 10.1016/j.dnarep.2004.06.013; Thacker J, 2005, CANCER LETT, V219, P125, DOI 10.1016/j.canlet.2004.08.018; Thompson LH, 2005, NAT GENET, V37, P921, DOI 10.1038/ng0905-921; Thompson LH, 2005, ENVIRON MOL MUTAGEN, V45, P128, DOI 10.1002/em.20109; Waisfisz Q, 1999, P NATL ACAD SCI USA, V96, P10320, DOI 10.1073/pnas.96.18.10320; Wang WD, 2007, NAT REV GENET, V8, P735, DOI 10.1038/nrg2159; Wang XZ, 2004, MOL CELL BIOL, V24, P5850, DOI 10.1128/MCB.24.13.5850-5862.2004; WHITNEY M, 1995, NAT GENET, V11, P341, DOI 10.1038/ng1195-341; Wiegant WW, 2006, MUTAT RES-FUND MOL M, V600, P79, DOI 10.1016/j.mrfmmm.2006.03.001; Wilson JB, 2001, CARCINOGENESIS, V22, P1939, DOI 10.1093/carcin/22.12.1939; Xia B, 2007, NAT GENET, V39, P159, DOI 10.1038/ng1942; Xia B, 2006, MOL CELL, V22, P719, DOI 10.1016/j.molcel.2006.05.022; Yamada NA, 2004, J BIOL CHEM, V279, P23250, DOI 10.1074/jbc.M402247200; Yamamoto K, 2003, MOL CELL BIOL, V23, P5421, DOI 10.1128/MCB.23.15.5421-5430.2003; Yamashita T, 1998, P NATL ACAD SCI USA, V95, P13085, DOI 10.1073/pnas.95.22.13085; Yamashita YM, 2002, EMBO J, V21, P5558, DOI 10.1093/emboj/cdf534; Yang YG, 2005, CARCINOGENESIS, V26, P1731, DOI 10.1093/carcin/bgi134; Zhang NX, 2007, DNA REPAIR, V6, P1670, DOI 10.1016/j.dnarep.2007.06.002; Zhang Y, 1998, EMBO J, V17, P7304, DOI 10.1093/emboj/17.24.7304	80	69	75	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	26					3641	3652		10.1038/sj.onc.1211034	http://dx.doi.org/10.1038/sj.onc.1211034			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18212739				2022-12-25	WOS:000256659300001
J	Ho, LH; Read, SH; Dorstyn, L; Lambrusco, L; Kumar, S				Ho, L. H.; Read, S. H.; Dorstyn, L.; Lambrusco, L.; Kumar, S.			Caspase-2 is required for cell death induced by cytoskeletal disruption	ONCOGENE			English	Article						apoptosis; caspase-2 activation; Bid; Bax; initiator caspase; cytoskeleton	CYTOCHROME-C RELEASE; INDUCED APOPTOSIS; MITOCHONDRIAL PERMEABILIZATION; CANCER-CELLS; DNA-DAMAGE; GENE CED-3; ACTIVATION; ENCODES; COMPLEX; STRESS	Caspase-2 is one of the most conserved caspases, yet its biological function remains a matter of controversy. In the present article we analysed mouse embryonic fibroblasts (MEFs) from caspase-2 knockout mice for their sensitivity to various apoptosis inducing agents. We found that cell death induced by drugs that disrupt cytoskeleton is significantly inhibited in Casp2(-/-) MEFs. These drugs included zoledronic acid, vincristine, cytochalasin D and paclitaxel. We demonstrate that MEFs lacking Casp2 show clonogenic survival following drug treatment, whereas all Casp2(-/-) MEFs die, indicating that caspase-2 is required for apoptosis induced by cytoskeletal disruption. We further found that caspase-2 mediates apoptosis via Piddosome, Bid and Bax activation, and cytochrome c release. In the absence of caspase-2, Bid and Bax activation, and cytochrome c release are significantly delayed following drug treatment. Our data provide strong support for a context-dependent function of caspase-2 in apoptosis.	[Ho, L. H.; Read, S. H.; Dorstyn, L.; Lambrusco, L.; Kumar, S.] Inst Med & Vet Sci, Div Haematol, Hanson Inst, Adelaide, SA 5000, Australia; [Kumar, S.] Univ Adelaide, Dept Med, Adelaide, SA 5001, Australia	Hanson Institute; Institute Medical & Veterinary Science Australia; University of Adelaide	Kumar, S (corresponding author), Inst Med & Vet Sci, Div Haematol, Hanson Inst, POB 14,Rundle Mall, Adelaide, SA 5000, Australia.	sharad.kumar@imvs.sa.gov.au	Kumar, Sharad/AAX-7787-2020; Dorstyn, Loretta/F-3673-2013	Kumar, Sharad/0000-0001-7126-9814; Dorstyn, Loretta/0000-0001-9886-0989				Antignani A, 2006, CURR OPIN CELL BIOL, V18, P685, DOI 10.1016/j.ceb.2006.10.004; Baliga BC, 2004, CELL DEATH DIFFER, V11, P1234, DOI 10.1038/sj.cdd.4401492; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Bhalla KN, 2003, ONCOGENE, V22, P9075, DOI 10.1038/sj.onc.1207233; Bonzon C, 2006, MOL BIOL CELL, V17, P2150, DOI 10.1091/mbc.E05-12-1107; Butt AJ, 1998, J BIOL CHEM, V273, P6763, DOI 10.1074/jbc.273.12.6763; Colussi PA, 1998, J BIOL CHEM, V273, P26566, DOI 10.1074/jbc.273.41.26566; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Ekert PG, 2004, J CELL BIOL, V165, P835, DOI 10.1083/jcb.200312031; Gourlay CW, 2005, NAT REV MOL CELL BIO, V6, P583, DOI 10.1038/nrm1682; Green JR, 2004, ONCOLOGIST, V9, P3, DOI 10.1634/theoncologist.9-90004-3; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Handrick R, 2006, RADIOTHER ONCOL, V80, P199, DOI 10.1016/j.radonc.2006.07.021; Harvey NL, 1997, J BIOL CHEM, V272, P13134, DOI 10.1074/jbc.272.20.13134; Holleman A, 2005, BLOOD, V106, P1817, DOI 10.1182/blood-2004-11-4296; Kepp O, 2007, EMBO J, V26, P825, DOI 10.1038/sj.emboj.7601533; Kong JY, 2005, BIOCHEM CELL BIOL, V83, P608, DOI 10.1139/o05-066; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Kumar S, 2007, CELL DEATH DIFFER, V14, P32, DOI 10.1038/sj.cdd.4402060; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; Kumar S, 2000, CELL DEATH DIFFER, V7, P1039, DOI 10.1038/sj.cdd.4400756; Kumar S, 2002, SCIENCE, V297, P1290, DOI 10.1126/science.1076118; KUMAR S, 1995, FEBS LETT, V368, P69, DOI 10.1016/0014-5793(95)00602-6; Lamkanfi M, 2002, CELL DEATH DIFFER, V9, P358, DOI 10.1038/sj.cdd.4400989; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lavrik IN, 2006, BLOOD, V108, P559, DOI 10.1182/blood-2005-07-007096; Marsden VS, 2004, J CELL BIOL, V165, P775, DOI 10.1083/jcb.200312030; Martin SS, 2004, BBA-MOL CELL RES, V1692, P145, DOI 10.1016/j.bbamcr.2004.02.008; Mhaidat NM, 2007, MOL CANCER THER, V6, P752, DOI 10.1158/1535-7163.MCT-06-0564; Milleron RS, 2006, J BIOL CHEM, V281, P16991, DOI 10.1074/jbc.M512754200; O'Reilly LA, 2002, CELL DEATH DIFFER, V9, P832, DOI 10.1038/sj.cdd.4401033; Panaretakis T, 2005, MOL BIOL CELL, V16, P3821, DOI 10.1091/mbc.E04-10-0862; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Shearwin-Whyatt L, 2001, BIOCHEM BIOPH RES CO, V282, P1114, DOI 10.1006/bbrc.2001.4699; Shearwin-Whyatt LM, 2000, CELL DEATH DIFFER, V7, P155, DOI 10.1038/sj.cdd.4400632; Shih YL, 2006, MICROBIOL MOL BIOL R, V70, P729, DOI 10.1128/MMBR.00017-06; Shin S, 2005, EMBO J, V24, P3532, DOI 10.1038/sj.emboj.7600827; THEIRAULT RL, 2003, EXPERT REV ANTICANC, V3, P157; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Troy CM, 2001, J NEUROSCI, V21, P5007, DOI 10.1523/JNEUROSCI.21-14-05007.2001; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wang YF, 2004, CANCER CHEMOTH PHARM, V54, P322, DOI 10.1007/s00280-004-0831-0; Waterhouse NJ, 2003, CELL DEATH DIFFER, V10, P853, DOI 10.1038/sj.cdd.4401263; Wennerberg K, 2005, J CELL SCI, V118, P843, DOI 10.1242/jcs.01660; Yeung BHY, 2006, J BIOL CHEM, V281, P11923, DOI 10.1074/jbc.M508533200; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zhivotovsky B, 2005, BIOCHEM BIOPH RES CO, V331, P859, DOI 10.1016/j.bbrc.2005.03.191	49	99	100	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	24					3393	3404		10.1038/sj.onc.1211005	http://dx.doi.org/10.1038/sj.onc.1211005			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18193089				2022-12-25	WOS:000256309900004
J	Syriani, E; Gomez-Cabrero, A; Bosch, M; Moya, A; Abad, E; Gual, A; Gasull, X; Morales, M				Syriani, Enrique; Gomez-Cabrero, Azucena; Bosch, Marta; Moya, Alicia; Abad, Elena; Gual, Arcadi; Gasull, Xavier; Morales, Miguel			Profilin induces lamellipodia by growth factor-independent mechanism	FASEB JOURNAL			English	Article						actin cytoskeleton; cell spreading; lamella; protein transduction	TRABECULAR MESHWORK CELLS; IN-VIVO; INTRAOCULAR-PRESSURE; PROTEIN TRANSDUCTION; FUSION PROTEINS; CULTURED-CELLS; STRESS FIBERS; ACTIN; RAC; MOTILITY	Profilin has been implicated in cell motility and in a variety of cellular processes, such as membrane extension, endocytosis, and formation of focal complexes. In vivo, profilin replenish the pool of ATP-actin monomers by increasing the rate of nucleotide exchange of ADP-actin for ATP-actin, promoting the incorporation of new actin monomers at the barbed end of actin filaments. For this report, we generated a membrane-permeable version of profilin I (PTD4-PfnI) for the alteration of intracellular profilin levels taking advantage of the protein transduction technique. We show that profilin I induces lamellipodia formation independently of growth factor presence in primary bovine trabecular meshwork (BTM) cells. The effects are time- and concentration-dependent and specific to the profilin I isoform. Profilin II, the neuronal isoform, failed to extend lamellipodia in the same degree as profilin I. H133S, a mutation in the polyproline binding domain, showed a reduced ability to induce lamellipodia. H199E, mutation in the actin binding domain failed to induce membrane spreading and inhibit fetal bovine serum (FBS)-induced lamellipodia extension. Incubation with a synthetic polyproline domain peptide (GP5)3, fused to a transduction domain, abolished lamellipodia. induction by profilin or FBS. Time-lapse microscopy confirmed the effects of profilin on lamellipodia extension with a higher spreading velocity than FBS. PTD4-Pfn I was found in the inner lamellipodia domain, at the membrane leading edge where it colocalizes with endogenous profilin. While FBS-induced lamellipodia formation activates Rac1, PTD4-Pfn I stimulation did not induce Rac1 activation. We propose a role of profilin I favoring lamellipodia. formation by a mechanism downstream of growth factor.	[Syriani, Enrique; Gomez-Cabrero, Azucena; Moya, Alicia; Abad, Elena; Gual, Arcadi; Gasull, Xavier; Morales, Miguel] Univ Barcelona, Fac Med, Dept Physiol Sci 1, IDIBAPS, Barcelona 7, Spain; [Bosch, Marta] Univ Barcelona, Fac Med, Dept Cellular Biol, Barcelona 7, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona	Morales, M (corresponding author), Univ Barcelona, Fac Med, Dept Physiol Sci 1, IDIBAPS, Barcelona 7, Spain.	miguelmorales@ub.cdu	Gual, Arcadi/U-8272-2017; Morales, Miguel/G-8995-2014; Gasull, Xavier/T-9630-2017; Bosch, Marta/AAU-9099-2020	Gual, Arcadi/0000-0002-8604-3903; Morales, Miguel/0000-0002-8885-2333; Gasull, Xavier/0000-0002-6154-8323; Bosch, Marta/0000-0003-3934-6781				Ackermann M, 2003, NAT NEUROSCI, V6, P1194, DOI 10.1038/nn1135; Bear JE, 2002, CELL, V109, P509, DOI 10.1016/S0092-8674(02)00731-6; BjorkegrenSjogren C, 1997, FEBS LETT, V418, P258, DOI 10.1016/S0014-5793(97)01376-8; Bompard G, 2004, J CELL BIOL, V166, P957, DOI 10.1083/jcb.200403127; Braun A, 2002, GENE, V283, P219, DOI 10.1016/S0378-1119(01)00855-1; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Canela N, 2003, J BIOL CHEM, V278, P1158, DOI 10.1074/jbc.M207497200; CARLSSON L, 1977, J MOL BIOL, V115, P465, DOI 10.1016/0022-2836(77)90166-8; Cramer LP, 1999, CURR BIOL, V9, P1095, DOI 10.1016/S0960-9822(99)80478-3; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Devineni N, 1999, BRAIN RES, V823, P129, DOI 10.1016/S0006-8993(99)01147-6; Dong JX, 2000, BBA-MOL CELL RES, V1497, P253, DOI 10.1016/S0167-4889(00)00056-2; Dubin-Thaler BJ, 2004, BIOPHYS J, V86, P1794, DOI 10.1016/S0006-3495(04)74246-0; Evans NJ, 2006, EXP BIOL MED, V231, P882; FINKEL T, 1994, P NATL ACAD SCI USA, V91, P1510, DOI 10.1073/pnas.91.4.1510; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Giannone G, 2004, CELL, V116, P431, DOI 10.1016/S0092-8674(04)00058-3; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; Gomez-Cabrero A, 2005, MOL VIS, V11, P1071; Grenklo S, 2004, EUR J CELL BIOL, V83, P413, DOI 10.1078/0171-9335-00400; Hinz B, 1999, EXP CELL RES, V251, P234, DOI 10.1006/excr.1999.4541; Ho A, 2001, CANCER RES, V61, P474; Holt MR, 2001, TRENDS CELL BIOL, V11, P38, DOI 10.1016/S0962-8924(00)01876-6; Kang F, 1997, BIOCHEMISTRY-US, V36, P8384, DOI 10.1021/bi970065n; Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kovacs M, 2004, J BIOL CHEM, V279, P35557, DOI 10.1074/jbc.M405319200; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Kurokawa K, 2005, MOL BIOL CELL, V16, P4294, DOI 10.1091/mbc.E04-12-1076; Lambrechts A, 2006, J CELL SCI, V119, P1570, DOI 10.1242/jcs.02884; Lambrechts A, 1997, EMBO J, V16, P484, DOI 10.1093/emboj/16.3.484; Llobet A, 2003, NEWS PHYSIOL SCI, V18, P205, DOI 10.1152/nips.01443.2003; Llobet A, 1999, INVEST OPHTH VIS SCI, V40, P113; Mayboroda O, 1997, CELL MOTIL CYTOSKEL, V37, P166, DOI 10.1002/(SICI)1097-0169(1997)37:2<166::AID-CM9>3.0.CO;2-6; Meier O, 2002, J CELL BIOL, V158, P1119, DOI 10.1083/jcb.200112067; Mimuro H, 2000, J BIOL CHEM, V275, P28893, DOI 10.1074/jbc.M003882200; Moens PDJ, 2007, BBA-BIOMEMBRANES, V1768, P439, DOI 10.1016/j.bbamem.2006.12.012; Moissoglu K, 2006, MOL BIOL CELL, V17, P2770, DOI 10.1091/mbc.E06-01-0005; Moldovan NI, 1997, CURR BIOL, V7, P24, DOI 10.1016/S0960-9822(06)00024-8; Morales M, 2007, EUR J PHARMACOL, V567, P145, DOI 10.1016/j.ejphar.2007.04.020; Nakase I, 2007, BIOCHEMISTRY-US, V46, P492, DOI 10.1021/bi0612824; Obermann H, 2005, MOL HUM REPROD, V11, P53, DOI 10.1093/molehr/gah132; Posern G, 2000, J CELL PHYSIOL, V183, P416, DOI 10.1002/(SICI)1097-4652(200006)183:3<416::AID-JCP15>3.0.CO;2-R; Pring M, 2003, BIOCHEMISTRY-US, V42, P486, DOI 10.1021/bi026520j; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rothkegel M, 1996, J CELL SCI, V109, P83; Sathish K, 2004, CELL SIGNAL, V16, P589, DOI 10.1016/j.cellsig.2003.10.001; Schlunck G, 2004, MOL BIOL CELL, V15, P256, DOI 10.1091/mbc.E03-01-0019; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Singh SS, 1996, BIOCHEMISTRY-US, V35, P16544, DOI 10.1021/bi9609634; STAMER WD, 1995, CURR EYE RES, V14, P611, DOI 10.3109/02713689508998409; Stradal TEB, 2004, TRENDS CELL BIOL, V14, P303, DOI 10.1016/j.tcb.2004.04.007; Stuven T, 2003, EMBO J, V22, P5928, DOI 10.1093/emboj/cdg565; Suetsugu S, 1999, FEBS LETT, V457, P470, DOI 10.1016/S0014-5793(99)01086-8; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996; Wang F, 2002, NAT CELL BIOL, V4, P513, DOI 10.1038/ncb810; Witke W, 2004, TRENDS CELL BIOL, V14, P461, DOI 10.1016/j.tcb.2004.07.003; Witke W, 2001, P NATL ACAD SCI USA, V98, P3832, DOI 10.1073/pnas.051515498; Wittenmayer N, 2000, EUR J BIOCHEM, V267, P5247, DOI 10.1046/j.1432-1327.2000.01600.x; Wolven AK, 2000, J CELL BIOL, V150, P895, DOI 10.1083/jcb.150.4.895; Yamazaki D, 2005, CANCER SCI, V96, P379, DOI 10.1111/j.1349-7006.2005.00062.x; Yamazaki D, 2005, GENES CELLS, V10, P381, DOI 10.1111/j.1365-2443.2005.00845.x	64	13	13	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2008	22	5					1581	1596		10.1096/fj.06-7654com	http://dx.doi.org/10.1096/fj.06-7654com			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301LW	18184720				2022-12-25	WOS:000255898700030
J	Bolourani, P; Spiegelman, GB; Weeks, G				Bolourani, Parvin; Spiegelman, George B.; Weeks, Gerald			Rap1 activation in response to cAMP occurs downstream of Ras activation during Dictyostelium aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; CELL-MOVEMENT; MOLECULAR-GENETICS; SMALL GTPASES; LEADING-EDGE; CHEMOTAXIS; DISCOIDEUM; PROTEIN; MOTILITY; RECEPTOR	We have used a doubly disrupted rasC(-)/rasG(-) strain of Dictyostelium discoideum, which ectopically expresses the carA gene, to explore the relationship between the activation of RasC and RasG, the two proteins that are necessary for optimum cAMP signaling, and the activation of Rap1, a Ras subfamily protein, that is also activated by cAMP. The ectopic expression of carA restored early developmental gene expression to the rasC(-)/rasG(-) strain, rendering it suitable for an analysis of cAMP signal transduction. Because there was negligible signaling through both the cAMP chemotactic pathway and the adenylyl cyclase activation pathway in the rasC(-)/rasG(-)/[act15]:carA strain, it is clear that RasG and RasC are the only two Ras subfamily proteins that directly control these pathways. The position of Rap1 in the signal transduction cascade was clarified by the finding that Rap1 activation was totally abolished in rasC(-)/rasG(-)/[act15]: carA and rasG(-) cells but only slightly reduced in rasC(-) cells. Rap1 activation, therefore, occurs downstream of the Ras proteins and predominantly, if not exclusively, downstream of RasG. The finding that in vitro guanylyl cyclase activation is also abolished in the rasC(-)/rasG(-)/[act15]: carA strain identifies RasGRasC as the presumptive monomeric GTPases required for this activation.	[Bolourani, Parvin; Spiegelman, George B.; Weeks, Gerald] Univ British Columbia, Life Sci Ctr, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Weeks, G (corresponding author), Univ British Columbia, Life Sci Ctr, Dept Microbiol & Immunol, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	gerwee@interchange.ubc.ca						Alibaud L, 2003, BIOTECHNIQUES, V35, P78, DOI 10.2144/03351st03; Bolourani P, 2006, MOL BIOL CELL, V17, P4543, DOI 10.1091/mbc.E05-11-1019; Bosgraaf L, 2002, J MUSCLE RES CELL M, V23, P781, DOI 10.1023/A:1024431813040; Bosgraaf L, 2002, EMBO J, V21, P4560, DOI 10.1093/emboj/cdf438; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Chubb JR, 2000, J CELL SCI, V113, P709; Firtel RA, 2000, BIOESSAYS, V22, P603, DOI 10.1002/1521-1878(200007)22:7<603::AID-BIES3>3.0.CO;2-#; Funamoto S, 2001, J CELL BIOL, V153, P795, DOI 10.1083/jcb.153.4.795; Funamoto S, 2002, CELL, V109, P611, DOI 10.1016/S0092-8674(02)00755-9; Hoeller O, 2007, CURR BIOL, V17, P813, DOI 10.1016/j.cub.2007.04.004; Huang YE, 2003, MOL BIOL CELL, V14, P1913, DOI 10.1091/mbc.E02-10-0703; Iijima M, 2002, DEV CELL, V3, P469, DOI 10.1016/S1534-5807(02)00292-7; Jeon TJ, 2007, J CELL BIOL, V176, P1021, DOI 10.1083/jcb.200607072; JOHNSON RL, 1991, BIOCHEMISTRY-US, V30, P6982, DOI 10.1021/bi00242a025; Kae H, 2004, EMBO REP, V5, P602, DOI 10.1038/sj.embor.7400151; Kae H, 2007, EMBO REP, V8, P477, DOI 10.1038/sj.embor.7400936; Kang RJ, 2002, J CELL SCI, V115, P3675, DOI 10.1242/jcs.00039; Kessin RH., 2001, DICTYOSTELIUM EVOLUT, P1; Kimmel AR, 2003, SCIENCE, V300, P1525, DOI 10.1126/science.1085439; Kortholt A, 2006, J BIOL CHEM, V281, P23367, DOI 10.1074/jbc.M600804200; Lee S, 2005, MOL BIOL CELL, V16, P4572, DOI 10.1091/mbc.E05-04-0342; Lee S, 1999, MOL BIOL CELL, V10, P2829, DOI 10.1091/mbc.10.9.2829; Lim CJ, 2005, EXP CELL RES, V306, P47, DOI 10.1016/j.yexcr.2005.02.002; Lim CJ, 2001, EMBO J, V20, P4490, DOI 10.1093/emboj/20.16.4490; Loovers HM, 2006, MOL BIOL CELL, V17, P1503, DOI 10.1091/mbc.E05-09-0825; Manahan CL, 2004, ANNU REV CELL DEV BI, V20, P223, DOI 10.1146/annurev.cellbio.20.011303.132633; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; Mitin N, 2005, CURR BIOL, V15, pR563, DOI 10.1016/j.cub.2005.07.010; Parent CA, 1996, ANNU REV BIOCHEM, V65, P411; Postma M, 2004, EMBO REP, V5, P35, DOI 10.1038/sj.embor.7400051; REBSTEIN PJ, 1993, DEV GENET, V14, P347, DOI 10.1002/dvg.1020140504; Rebstein PJ, 1997, EXP CELL RES, V231, P276, DOI 10.1006/excr.1996.3466; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; ROBBINS SM, 1989, P NATL ACAD SCI USA, V86, P938, DOI 10.1073/pnas.86.3.938; Rodriguez-Viciana P, 2004, MOL CELL BIOL, V24, P4943, DOI 10.1128/MCB.24.11.4943-4954.2004; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sasaki AT, 2004, J CELL BIOL, V167, P505, DOI 10.1083/jcb.200406177; SNAARJAGALSKA BE, 1994, METHOD ENZYMOL, V237, P387; Takeda K, 2007, J BIOL CHEM, V282, P11874, DOI 10.1074/jbc.M610984200; THEIBERT A, 1986, J BIOL CHEM, V261, P5121; Tuxworth RI, 1997, J CELL BIOL, V138, P605, DOI 10.1083/jcb.138.3.605; vanHaastert PJM, 1997, FEBS LETT, V410, P25, DOI 10.1016/S0014-5793(97)00416-X; VANHAASTERT PJM, 1983, J BIOL CHEM, V258, P9636; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; Weeks G., 2005, DICTYOSTELIUM GENOMI, P211; Wessels D, 2004, EUKARYOT CELL, V3, P646, DOI 10.1128/EC.3.3.646-662.2004; Wilkins A, 2000, GENE DEV, V14, P1407; Wilkins A, 2001, TRENDS GENET, V17, P41, DOI 10.1016/S0168-9525(00)02181-8; WU LJ, 1995, J CELL BIOL, V129, P1667, DOI 10.1083/jcb.129.6.1667	51	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10232	10240		10.1074/jbc.M707459200	http://dx.doi.org/10.1074/jbc.M707459200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18180289	hybrid			2022-12-25	WOS:000254894700004
J	Park, SY; Kang, KB; Thapa, N; Kim, SY; Lee, SJ; Kim, IS				Park, Seung-Yoon; Kang, Kae-Bok; Thapa, Narendra; Kim, Sang-Yeob; Lee, Sung-Jin; Kim, In-San			Requirement of adaptor protein GULP during stabilin-2-mediated cell corpse engulfment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ELEGANS; APOPTOTIC CELLS; CAENORHABDITIS-ELEGANS; HYALURONAN RECEPTOR; CRKII/DOCK180/RAC PATHWAY; ENDOTHELIAL-CELLS; PTB-DOMAIN; CED-6; PHAGOCYTOSIS; IDENTIFICATION	The prompt clearance of cells undergoing apoptosis is critical during embryonic development and normal tissue turnover, as well as during inflammation and autoimmune responses. We recently demonstrated that stabilin-2 is a phosphatidylserine receptor that mediates the clearance of apoptotic cells, thereby releasing the anti-inflammatory cytokine, transforming growth factor-beta. However, the downstream signaling components of stabilin-2-mediated phagocytosis are not known. Here, we provide evidence that the adaptor protein, GULP, physically and functionally interacts with the stabilin-2 cytoplasmic tail. Using fluorescent resonance energy transfer analysis and biochemical approaches, we show that GULP directly binds to the cytoplasmic tail of stabilin-2. Knockdown of endogenous GULP expression significantly decreased stabilin-2-mediated phagocytosis. Conversely, overexpression of GULP caused an increase in aged cell engulfment. The phosphotyrosine binding (PTB) domain of GULP was sufficient for the interaction with stabilin-2; therefore, transduction of TAT fusion PTB domain acts as a dominant negative, resulting in impaired engulfment of aged red blood cells in stabilin-2 expressing cells. In addition, the PTB domain of GULP was able to specifically interact with the NPXY motif of the stabilin-2 cytoplasmic tail. Taken together, these results indicate that GULP is a likely downstream molecule in the stabilin-2-mediated signaling pathway and plays an important role in stabilin-2-mediated phagocytosis.	[Kang, Kae-Bok; Thapa, Narendra; Kim, Sang-Yeob; Lee, Sung-Jin; Kim, In-San] Kyungpook Natl Univ, Sch Med, Cell & Matrix Res Inst, Dept Biochem & Cell Biol, Jung 700422, Daegu, South Korea; [Park, Seung-Yoon] Dongguk Univ, Sch Med, Dept Biochem, Kyungju 780714, South Korea	Kyungpook National University; Dongguk University	Kim, IS (corresponding author), Kyungpook Natl Univ, Sch Med, Cell & Matrix Res Inst, Dept Biochem & Cell Biol, 101 Dongin Dong, Jung 700422, Daegu, South Korea.	iskim@knu.ac.kr	김, 인산/I-8988-2014; Kim, In-San/D-3956-2017					Adachi H, 2002, J BIOL CHEM, V277, P34264, DOI 10.1074/jbc.M204277200; Awasaki T, 2006, NEURON, V50, P855, DOI 10.1016/j.neuron.2006.04.027; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Calderwood DA, 2003, P NATL ACAD SCI USA, V100, P2272, DOI 10.1073/pnas.262791999; ELLIS RE, 1991, GENETICS, V129, P79; GIGLI I, 1968, EXP CELL RES, V51, P45, DOI 10.1016/0014-4827(68)90158-4; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Hamon Y, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000120; Kim JE, 2000, J BIOL CHEM, V275, P30907, DOI 10.1074/jbc.M002752200; Kinchen JM, 2007, J CELL SCI, V120, P2143, DOI 10.1242/jcs.03463; Kinchen JM, 2005, NATURE, V434, P93, DOI 10.1038/nature03263; Liu QA, 1999, CURR BIOL, V9, P1347, DOI 10.1016/S0960-9822(00)80061-5; Liu QA, 1998, CELL, V93, P961, DOI 10.1016/S0092-8674(00)81202-7; Ma Z, 2007, CURR BIOL, V17, P722, DOI 10.1016/j.cub.2007.03.014; McCourt PAG, 1999, HEPATOLOGY, V30, P1276, DOI 10.1002/hep.510300521; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Oka K, 1998, P NATL ACAD SCI USA, V95, P9535, DOI 10.1073/pnas.95.16.9535; Park SY, 2008, CELL DEATH DIFFER, V15, P192, DOI 10.1038/sj.cdd.4402242; Politz O, 2002, BIOCHEM J, V362, P155, DOI 10.1042/0264-6021:3620155; Reddien PW, 2004, ANNU REV CELL DEV BI, V20, P193, DOI 10.1146/annurev.cellbio.20.022003.114619; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Siegal G, 1999, NAT STRUCT BIOL, V6, P7, DOI 10.1038/4873; Smits E, 1999, CURR BIOL, V9, P1351, DOI 10.1016/S0960-9822(00)80062-7; Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5; Su HP, 2000, J BIOL CHEM, V275, P9542, DOI 10.1074/jbc.275.13.9542; Su HP, 2002, J BIOL CHEM, V277, P11772, DOI 10.1074/jbc.M109336200; Suzuki E, 2007, EXP CELL RES, V313, P3729, DOI 10.1016/j.yexcr.2007.06.015; Tamura Y, 2003, J BIOL CHEM, V278, P12613, DOI 10.1074/jbc.M210211200; Wu YC, 2001, DEV CELL, V1, P491, DOI 10.1016/S1534-5807(01)00056-9; Wu YC, 1998, CELL, V93, P951, DOI 10.1016/S0092-8674(00)81201-5; Zhou B, 2000, J BIOL CHEM, V275, P37733, DOI 10.1074/jbc.M003030200; Zhou Z, 2001, DEV CELL, V1, P477, DOI 10.1016/S1534-5807(01)00058-2; Zhou Z, 2001, CELL, V104, P43, DOI 10.1016/S0092-8674(01)00190-8	34	65	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10593	10600		10.1074/jbc.M709105200	http://dx.doi.org/10.1074/jbc.M709105200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18230608	hybrid			2022-12-25	WOS:000254894700041
J	Hausmann, A; Samans, B; Lill, R; Muehlenhoff, U				Hausmann, Anja; Samans, Birgit; Lill, Roland; Muehlenhoff, Ulrich			Cellular and mitochondrial remodeling upon defects in iron-sulfur protein biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; CYTOSOLIC FE/S PROTEINS; HEME-SYNTHESIS; CANDIDA-ALBICANS; GENE-EXPRESSION; TRANSCRIPTIONAL CONTROL; CLUSTER BIOSYNTHESIS; HOMEOSTASIS; FRATAXIN; MATURATION	Biogenesis of iron-sulfur (Fe/S) proteins in eukaryotes is an essential process involving the mitochondrial iron-sulfur cluster (ISC) assembly and export machineries and the cytosolic iron/sulfur protein assembly (CIA) apparatus. To define the integration of Fe/S protein biogenesis into cellular homeostasis, we compared the global transcriptional responses to defects in the three biogenesis systems in Saccharomyces cerevisiae using DNA microarrays. Depletion of a member of the CIA machinery elicited only weak (up to 2-fold) alterations in gene expression with no clear preference for any specific cellular process. In contrast, depletion of components of the mitochondrial ISC assembly and export systems induced strong and largely overlapping transcriptional responses of more than 200 genes (2-100-fold changes). These alterations were strikingly similar, yet not identical, to the transcriptional profiles developed upon iron starvation. Hence, mitochondria and their ISC systems serve as primary physiological regulators exerting a global control of numerous iron-dependent processes. First, ISC depletion activates the iron-responsive transcription factors Aft1/2p leading to increased cellular iron acquisition. Second, respiration and heme metabolism are repressed ensuring the balanced utilization of iron by the two major iron-consuming processes, iron-sulfur protein and heme biosynthesis. Third, the decreased respiratory activity is compensated by induction of genes involved in glucose acquisition. Finally, transcriptional remodeling of the citric acid cycle and the biosyntheses of ergosterol and biotin reflect the iron dependence of these pathways. Together, our data suggest a model in which mitochondria perform a global regulatory role in numerous cellular processes linked to iron homeostasis.	[Hausmann, Anja; Lill, Roland; Muehlenhoff, Ulrich] Univ Marburg, Inst Zytobiol & Zytopathol, D-35032 Marburg, Germany; [Samans, Birgit] Univ Marburg, Inst Mol Biol & Tumorforsch, D-35032 Marburg, Germany	Philipps University Marburg; Philipps University Marburg	Muehlenhoff, U (corresponding author), Univ Marburg, Inst Zytobiol & Zytopathol, Robert Koch Str 6, D-35032 Marburg, Germany.	muehlenh@staff.uni-marburg.de		Lill, Roland/0000-0002-8345-6518				Balk J, 2005, MOL CELL BIOL, V25, P10833, DOI 10.1128/MCB.25.24.10833-10841.2005; Balk J, 2004, EMBO J, V23, P2105, DOI 10.1038/sj.emboj.7600216; Barros MH, 2002, J BIOL CHEM, V277, P9997, DOI 10.1074/jbc.M112025200; Beinert H, 2000, J BIOL INORG CHEM, V5, P2, DOI 10.1007/s007750050002; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Belli G, 2004, J BIOL CHEM, V279, P12386, DOI 10.1074/jbc.M311879200; Biederbick A, 2006, MOL CELL BIOL, V26, P5675, DOI 10.1128/MCB.00112-06; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; CAMADRO JM, 1988, J BIOL CHEM, V263, P11675; Chen OS, 2004, J BIOL CHEM, V279, P29513, DOI 10.1074/jbc.M403209200; Chen OS, 2002, P NATL ACAD SCI USA, V99, P12321, DOI 10.1073/pnas.192449599; Craig EA, 2002, CELL MOL LIFE SCI, V59, P1658, DOI 10.1007/PL00012493; Crisp RJ, 2006, EMBO J, V25, P512, DOI 10.1038/sj.emboj.7600961; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Diekert K, 2001, METHOD CELL BIOL, V65, P37, DOI 10.1016/S0091-679X(01)65003-9; Dubacq C, 2006, MOL GENET GENOMICS, V275, P114, DOI 10.1007/s00438-005-0077-5; Epstein CB, 2001, MOL BIOL CELL, V12, P297, DOI 10.1091/mbc.12.2.297; Foury F, 2001, J BIOL CHEM, V276, P7762, DOI 10.1074/jbc.M005804200; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Harlow E., 1988, ANTIBODIES LAB MANUA; Hausmann A, 2005, P NATL ACAD SCI USA, V102, P3266, DOI 10.1073/pnas.0406447102; Hinnebusch AG, 2005, ANNU REV MICROBIOL, V59, P407, DOI 10.1146/annurev.micro.59.031805.133833; Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518; Kaplan J, 2006, BBA-MOL CELL RES, V1763, P646, DOI 10.1016/j.bbamcr.2006.03.008; Kim D, 2006, BIOCHEMISTRY-US, V45, P14772, DOI 10.1021/bi061429r; Kispal G, 1997, FEBS LETT, V418, P346, DOI 10.1016/S0014-5793(97)01414-2; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Knight SAB, 1998, J BIOL CHEM, V273, P18389, DOI 10.1074/jbc.273.29.18389; Kwast KE, 1999, P NATL ACAD SCI USA, V96, P5446, DOI 10.1073/pnas.96.10.5446; KWOK E, 2005, TOPICS CURRENT GENET, P59; Lan CY, 2004, MOL MICROBIOL, V53, P1451, DOI 10.1111/j.1365-2958.2004.04214.x; Lange H, 1999, J BIOL CHEM, V274, P18989, DOI 10.1074/jbc.274.27.18989; Lange H, 2000, P NATL ACAD SCI USA, V97, P1050, DOI 10.1073/pnas.97.3.1050; Lange H, 2004, J BIOL CHEM, V279, P29101, DOI 10.1074/jbc.M403721200; Lange H, 2001, EMBO REP, V2, P715, DOI 10.1093/embo-reports/kve161; Lesuisse E, 2003, HUM MOL GENET, V12, P879, DOI 10.1093/hmg/ddg096; Lesur I, 2004, MOL BIOL CELL, V15, P1297, DOI 10.1091/mbc.E03-10-0742; Lill R, 2005, TRENDS BIOCHEM SCI, V30, P133, DOI 10.1016/j.tibs.2005.01.006; Lill R, 2006, ANNU REV CELL DEV BI, V22, P457, DOI 10.1146/annurev.cellbio.22.010305.104538; Liu ZC, 2006, ANNU REV GENET, V40, P159, DOI 10.1146/annurev.genet.40.110405.090613; Masse E, 2005, TRENDS BIOCHEM SCI, V30, P462, DOI 10.1016/j.tibs.2005.06.005; McCammon MT, 2003, MOL BIOL CELL, V14, P958, DOI 10.1091/mbc.E02-07-0422; Mnaimneh S, 2004, CELL, V118, P31, DOI 10.1016/j.cell.2004.06.013; Muhlenhoff U, 2004, J BIOL CHEM, V279, P36906, DOI 10.1074/jbc.M406516200; Pennaneach V, 2006, MOL MICROBIOL, V59, P1357, DOI 10.1111/j.1365-2958.2006.05026.x; Pondarre C, 2006, HUM MOL GENET, V15, P953, DOI 10.1093/hmg/ddl012; Popescu BFG, 2007, J INORG BIOCHEM, V101, P957, DOI 10.1016/j.jinorgbio.2007.03.004; Protchenko O, 2003, J BIOL CHEM, V278, P36582, DOI 10.1074/jbc.M306584200; Puig S, 2005, CELL, V120, P99, DOI 10.1016/j.cell.2004.11.032; Rosenfeld E, 2003, YEAST, V20, P1115, DOI 10.1002/yea.1026; Rouault TA, 2005, NAT REV MOL CELL BIO, V6, P345, DOI 10.1038/nrm1620; Roy A, 2003, EMBO J, V22, P4826, DOI 10.1093/emboj/cdg455; Rutherford JC, 2005, J BIOL CHEM, V280, P10135, DOI 10.1074/jbc.M413731200; Rutherford JC, 2004, EUKARYOT CELL, V3, P1, DOI 10.1128/EC.3.1.1-13.2004; Rutherford JC, 2003, J BIOL CHEM, V278, P27636, DOI 10.1074/jbc.M300076200; Sambrook J, 2001, MOL CLONING LAB MANU; Santos R, 2004, MOL MICROBIOL, V54, P507, DOI 10.1111/j.1365-2958.2004.04281.x; Santos R, 2003, MICROBIOL-SGM, V149, P579, DOI 10.1099/mic.0.26108-0; Schuller HJ, 2003, CURR GENET, V43, P139, DOI 10.1007/s00294-003-0381-8; Shakoury-Elizeh M, 2004, MOL BIOL CELL, V15, P1233, DOI 10.1091/mbc.E03-09-0642; Sherman F, 2002, METHOD ENZYMOL, V350, P3, DOI 10.1016/S0076-6879(02)50954-X; Sipos K, 2002, J BIOL CHEM, V277, P26944, DOI 10.1074/jbc.M200677200; Taura T, 1998, P NATL ACAD SCI USA, V95, P7427, DOI 10.1073/pnas.95.13.7427; Wingert RA, 2005, NATURE, V436, P1035, DOI 10.1038/nature03887; Yamaguchi-Iwai Y, 2002, J BIOL CHEM, V277, P18914, DOI 10.1074/jbc.M200949200; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Zhang L, 1999, CELL MOL LIFE SCI, V56, P415, DOI 10.1007/s000180050442; Zhang Y, 2005, J BIOL CHEM, V280, P19794, DOI 10.1074/jbc.M500397200	71	95	97	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8318	8330		10.1074/jbc.M705570200	http://dx.doi.org/10.1074/jbc.M705570200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18227070	hybrid			2022-12-25	WOS:000254288000030
J	Higashi, T; Ikeda, T; Shirakawa, R; Kondo, H; Kawato, M; Horiguchi, M; Okuda, T; Okawa, K; Fukai, S; Nureki, O; Kita, T; Horiuchi, H				Higashi, Tomohito; Ikeda, Tomoyuki; Shirakawa, Ryutaro; Kondo, Hirokazu; Kawato, Mitsunori; Horiguchi, Masahito; Okuda, Tomohiko; Okawa, Katsuya; Fukai, Shuya; Nureki, Osamu; Kita, Toru; Horiuchi, Hisanori			Biochemical characterization of the Rho GTPase-regulated actin assembly by diaphanous-related formins, mDia1 and daam1, in platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN-RHO; SERINE-THREONINE KINASE; INTEGRIN ALPHA(IIB)BETA(3); VERTEBRATE GASTRULATION; AUTOREGULATORY DOMAIN; HOMOLOGY-2 DOMAIN; PUTATIVE TARGET; CAPPING PROTEIN; FISSION YEAST; MOUSE FORMIN	The diaphanous-related formins are actin nucleating and elongating factors. They are kept in an inactive state by an intramolecular interaction between the diaphanous inhibitory domain (DID) and the diaphanous-autoregulatory domain (DAD). It is considered that the dissociation of this autoinhibitory interaction upon binding of GTP-bound Rho to the GTPase binding domain next to DID induces exposure of the FH1-FH2 domains, which assemble actin filaments. Here, we isolated two diaphanous-related formins, mDia1 and Daam1, in platelet extracts by GTP-RhoA affinity column chromatography. We characterized them by a novel assay, where beads coated with the FH1-FH2-DAD domains of either mDia1 or Daam1 were incubated with platelet cytosol, and the assembled actin filaments were observed after staining with rhodamine-phalloidin. Both formins generated fluorescent filamentous structures on the beads. Quantification of the fluorescence intensity of the beads revealed that the initial velocity in the presence of mDia1 was more than 10 times faster than in the presence of Daam1. The actin assembly activities of both FH1-FH2-DADs were inhibited by adding cognate DID domains. GTP-RhoA, -RhoB, and -RhoC, but not GTP-Rac1 or -Cdc42, bound to both mDia1 and Daam1 and efficiently neutralized the inhibition by the DID domains. The association between RhoA and Daam1 was induced by thrombin stimulation in platelets, and RhoA-bound endogenous formins induced actin assembly, which was inhibited by the DID domains of Daam1 and mDia1. Thus, mDia1 and Daam1 are platelet actin assembly factors having distinct efficiencies, and they are directly regulated by Rho GTPases.	[Higashi, Tomohito; Ikeda, Tomoyuki; Shirakawa, Ryutaro; Kondo, Hirokazu; Kawato, Mitsunori; Horiguchi, Masahito; Kita, Toru; Horiuchi, Hisanori] Kyoto Univ, Dept Cardiovasc Med, Sakyo Ku, Kyoto 6068507, Japan; [Okuda, Tomohiko] Kyoto Univ, COE Format Genom Anal Dis Model Anim Multiple Gen, Kyoto 6068507, Japan; [Okawa, Katsuya] Kyoto Univ, Frontier Technol Ctr, Grad Sch Med, Kyoto 6068507, Japan; [Fukai, Shuya] Univ Tokyo, Div Life Sci, Synchrotron Radiat Res Org, Tokyo 1130032, Japan; [Fukai, Shuya; Nureki, Osamu] Tokyo Inst Technol, Dept Biol Informat, Grad Sch Biosci & Biotechnol, Yokohama, Kanagawa 2268501, Japan; [Fukai, Shuya] Tokyo Inst Technol, Ctr Biol Resources & Informat, Yokohama, Kanagawa 2268501, Japan; [Nureki, Osamu] RIKEN, Genom Sci Ctr, Yokohama, Kanagawa 2300045, Japan	Kyoto University; Kyoto University; Kyoto University; University of Tokyo; Tokyo Institute of Technology; Tokyo Institute of Technology; RIKEN	Horiuchi, H (corresponding author), Kyoto Univ, Dept Cardiovasc Med, Sakyo Ku, 54 shogoinkawaharacho, Kyoto 6068507, Japan.	horiuchi@kuhp.kyoto-u.ac.jp	NUREKI, OSAMU/G-4960-2014; Higashi, Tomohito/AHE-7942-2022; Fukai, Shuya/X-4838-2018	Fukai, Shuya/0000-0002-1241-1443; Higashi, Tomohito/0000-0001-5616-1477				Alberts AS, 2001, J BIOL CHEM, V276, P2824, DOI 10.1074/jbc.M006205200; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Aspenstrom P, 2006, EXP CELL RES, V312, P2180, DOI 10.1016/j.yexcr.2006.03.013; Chang F, 1997, J CELL BIOL, V137, P169, DOI 10.1083/jcb.137.1.169; Chardin P, 2006, NAT REV MOL CELL BIO, V7, P54, DOI 10.1038/nrm1788; Choi W, 2006, BLOOD, V107, P3145, DOI 10.1182/blood-2005-09-3563; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Copeland JW, 2002, MOL BIOL CELL, V13, P4088, DOI 10.1091/mbc.02-06-0092; Copeland SJ, 2007, J BIOL CHEM, V282, P30120, DOI 10.1074/jbc.M703834200; Eisenmann KM, 2007, J BIOL CHEM, V282, P25152, DOI 10.1074/jbc.M703243200; Goode BL, 2007, ANNU REV BIOCHEM, V76, P593, DOI 10.1146/annurev.biochem.75.103004.142647; Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6; Harris ES, 2004, J BIOL CHEM, V279, P20076, DOI 10.1074/jbc.M312718200; Higgs HN, 2005, TRENDS BIOCHEM SCI, V30, P342, DOI 10.1016/j.tibs.2005.04.014; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Kovar DR, 2003, J CELL BIOL, V161, P875, DOI 10.1083/jcb.200211078; Krebs A, 2001, J CELL SCI, V114, P3663; Lammers M, 2005, EMBO J, V24, P4176, DOI 10.1038/sj.emboj.7600879; Leng LJ, 1998, BLOOD, V91, P4206, DOI 10.1182/blood.V91.11.4206.411k30_4206_4215; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Li F, 2005, J BIOL CHEM, V280, P6986, DOI 10.1074/jbc.M411605200; Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2; Lu J, 2007, J MOL BIOL, V369, P1258, DOI 10.1016/j.jmb.2007.04.002; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Matusek T, 2006, DEVELOPMENT, V133, P957, DOI 10.1242/dev.02266; MORII N, 1992, J BIOL CHEM, V267, P20921; Moseley JB, 2004, MOL BIOL CELL, V15, P896, DOI 10.1091/mbc.E03-08-0621; Nezami AG, 2006, STRUCTURE, V14, P257, DOI 10.1016/j.str.2005.12.003; Nishioka H, 2001, BIOCHEM BIOPH RES CO, V280, P970, DOI 10.1006/bbrc.2001.4237; Otomo T, 2005, MOL CELL, V18, P273, DOI 10.1016/j.molcel.2005.04.002; Peng J, 2007, CANCER RES, V67, P7565, DOI 10.1158/0008-5472.CAN-07-1467; Pruyne D, 2002, SCIENCE, V297, P612, DOI 10.1126/science.1072309; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Romero S, 2004, CELL, V119, P419, DOI 10.1016/j.cell.2004.09.039; Rose R, 2005, NATURE, V435, P513, DOI 10.1038/nature03604; Sagot I, 2002, NAT CELL BIOL, V4, P626, DOI 10.1038/ncb834; Sato A, 2006, DEVELOPMENT, V133, P4219, DOI 10.1242/dev.02590; Schoenwaelder SM, 2002, J BIOL CHEM, V277, P14738, DOI 10.1074/jbc.M200661200; Seth A, 2006, J CELL BIOL, V174, P701, DOI 10.1083/jcb.200605006; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Xu YW, 2004, CELL, V116, P711, DOI 10.1016/S0092-8674(04)00210-7; Yamashita M, 2007, GENES CELLS, V12, P1255, DOI 10.1111/j.1365-2443.2007.01132.x; Zigmond SH, 2003, CURR BIOL, V13, P1820, DOI 10.1016/j.cub.2003.09.057	48	41	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8746	8755		10.1074/jbc.M707839200	http://dx.doi.org/10.1074/jbc.M707839200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18218625	Green Submitted, hybrid			2022-12-25	WOS:000254288000072
J	Perez-Berna, AJ; Guillen, J; Moreno, MR; Bernabeu, A; Pabst, G; Laggner, P; Villalain, J				Perez-Berna, Ana J.; Guillen, Jaime; Moreno, Miguel R.; Bernabeu, Angela; Pabst, Georg; Laggner, Peter; Villalain, Jose			Identification of the membrane-active regions of hepatitis C virus p7 protein - Biophysical characterization of the loop region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL PEPTIDE PEPTIDASE; MAJOR EPITOPE REGION; ION-CHANNEL; SECONDARY STRUCTURE; HEPTAD REPEAT; MODEL SYSTEMS; CORE PROTEIN; HIV-1 GP41; BINDING; DOMAIN	We have identified the membrane-active regions of the hepatitis C virus p7 protein by performing an exhaustive study of membrane rupture, hemifusion, and fusion induced by a p7-derived peptide library on model membranes having different phospholipid compositions. We report the identification in p7 of a highly membranotropic region located at the loop domain of the protein. Here, we have investigated the interaction of a peptide patterned after the p7 loop (peptide p7(L)), studying its binding and interaction with the lipid bilayer, and evaluated the binding-induced structural changes of the peptide and the phospholipids. We show that positively rich p7(L) strongly binds to negatively charged phospholipids and it is localized in a shallow position in the bilayer. Furthermore, peptide p7(L) exhibits a high tendency to oligomerize in the presence of phospholipids, which could be the driving force for the formation of the active ion channel. Therefore, our findings suggest that the p7 loop could be an attractive candidate for antiviral drug development, because it could be a target for antiviral compounds that may lead to new vaccine strategies.	[Perez-Berna, Ana J.; Guillen, Jaime; Moreno, Miguel R.; Bernabeu, Angela; Laggner, Peter; Villalain, Jose] Univ Miguel Hernandez, Inst Biol Mol & Celular, E-03202 Alicante, Spain; [Pabst, Georg] Austrian Acad Sci, Inst Biophys & Nanosyst Res, A-8042 Graz, Austria	Universidad Miguel Hernandez de Elche; Austrian Academy of Sciences	Laggner, P (corresponding author), Univ Miguel Hernandez, Inst Biol Mol & Celular, E-03202 Alicante, Spain.	jvillalain@umh.es	Perez-Berna, Ana/G-2789-2016; Pabst, Georg/I-6919-2015; Pabst, Georg/O-1452-2019; Guillen, Jaime/K-2892-2014; Guillen, Jaime/K-6175-2019; Bernabeu-Sanz, Angela/B-3111-2009	Pabst, Georg/0000-0003-1967-1536; Pabst, Georg/0000-0003-1967-1536; Guillen, Jaime/0000-0001-7415-1512; Guillen, Jaime/0000-0001-7415-1512; Bernabeu-Sanz, Angela/0000-0003-2506-7626; Villalain, Jose/0000-0002-5148-141X; Moreno Raja, Miguel/0000-0002-6758-3998; Perez-Berna, Ana/0000-0003-4145-532X				Ahn A, 2002, J VIROL, V76, P3267, DOI 10.1128/JVI.76.7.3267-3275.2002; Ait-Goughoulte M, 2006, J GEN VIROL, V87, P855, DOI 10.1099/vir.0.81664-0; Arrondo JLR, 1999, PROG BIOPHYS MOL BIO, V72, P367, DOI 10.1016/S0079-6107(99)00007-3; Berg T, 2003, HEPATOLOGY, V37, P1359, DOI 10.1053/jhep.2003.50219; Bernabeu A, 2007, BBA-BIOMEMBRANES, V1768, P1659, DOI 10.1016/j.bbamem.2007.02.023; Bottcher C. S. F., 1961, ANAL CHIM ACTA, V1061, P203; BRETSCHER MS, 1985, SCI AM, V253, P100, DOI 10.1038/scientificamerican1085-100; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; Carrere-Kremer S, 2002, J VIROL, V76, P3720, DOI 10.1128/JVI.76.8.3720-3730.2002; Chen Stephen L, 2006, Int J Med Sci, V3, P47; Cladera J, 1998, BIOPHYS J, V74, P2434, DOI 10.1016/S0006-3495(98)77951-2; Cladera J, 2001, EMBO J, V20, P19, DOI 10.1093/emboj/20.1.19; Contreras LM, 2001, BIOCHEMISTRY-US, V40, P3196, DOI 10.1021/bi002613u; DAVENPORT L, 1985, BIOCHEMISTRY-US, V24, P4097, DOI 10.1021/bi00336a044; Delboy MG, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-105; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; EFTINK MR, 1977, BIOCHEMISTRY-US, V16, P5546, DOI 10.1021/bi00644a024; Fisher DB, 2000, PLANT PHYSIOL, V123, P125, DOI 10.1104/pp.123.1.125; Golding C, 1996, BIOCHEMISTRY-US, V35, P10931, DOI 10.1021/bi960905i; Gonzalez ME, 2003, FEBS LETT, V552, P28, DOI 10.1016/S0014-5793(03)00780-4; Griffin SDC, 2004, J GEN VIROL, V85, P451, DOI 10.1099/vir.0.19634-0; Griffin SDC, 2003, FEBS LETT, V535, P34, DOI 10.1016/S0014-5793(02)03851-6; GROSS E, 1994, BIOPHYS J, V67, P208, DOI 10.1016/S0006-3495(94)80471-0; Guillen J, 2005, J VIROL, V79, P1743, DOI 10.1128/JVI.79.3.1743-1752.2005; Korazim O, 2006, J MOL BIOL, V364, P1103, DOI 10.1016/j.jmb.2006.08.091; Laggner P, 1994, Subcell Biochem, V23, P451; LAURENT TC, 1967, BIOCHIM BIOPHYS ACTA, V136, P191, DOI 10.1016/0304-4165(67)90063-3; LENTZ BR, 1993, CHEM PHYS LIPIDS, V64, P99, DOI 10.1016/0009-3084(93)90060-G; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Li H, 2001, P NATL ACAD SCI USA, V98, P1267, DOI 10.1073/pnas.031461598; LIN C, 1994, J VIROL, V68, P5063, DOI 10.1128/JVI.68.8.5063-5073.1994; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; Meers P, 2000, BBA-BIOMEMBRANES, V1467, P227, DOI 10.1016/S0005-2736(00)00224-8; MIZUSHIMA H, 1994, J VIROL, V68, P6215, DOI 10.1128/JVI.68.10.6215-6222.1994; Moreno MR, 2007, BIOCHEMISTRY-US, V46, P10572, DOI 10.1021/bi700911g; Moreno MR, 2006, BBA-BIOMEMBRANES, V1758, P111, DOI 10.1016/j.bbamem.2006.01.007; O'Shea P, 2003, BIOCHEM SOC T, V31, P990; Pabst Georg, 2006, Biophysical Reviews and Letters, V1, P57, DOI 10.1142/S1793048006000069; Pascual R, 2005, BIOCHEMISTRY-US, V44, P14275, DOI 10.1021/bi050928+; Pascual R, 2005, J VIROL, V79, P5142, DOI 10.1128/JVI.79.8.5142-5152.2005; Patargias G, 2006, J MED CHEM, V49, P648, DOI 10.1021/jm050721e; Pavlovic D, 2003, P NATL ACAD SCI USA, V100, P6104, DOI 10.1073/pnas.1031527100; PEBAYPEYROULA E, 1994, BIOPHYS CHEM, V53, P45, DOI 10.1016/0301-4622(94)00075-1; Penin F, 2004, HEPATOLOGY, V39, P5, DOI 10.1002/hep.20032; Perez-Berna AJ, 2006, BIOCHEMISTRY-US, V45, P3755, DOI 10.1021/bi0523963; Pozzetto B, 1996, NEPHROL DIAL TRANSPL, V11, P2; Qureshi SA, 2007, MED RES REV, V27, P353, DOI 10.1002/med.20063; RABENSTEIN M, 1995, BIOCHEMISTRY-US, V34, P13390, DOI 10.1021/bi00041a016; Sakai A, 2003, P NATL ACAD SCI USA, V100, P11646, DOI 10.1073/pnas.1834545100; Santos NC, 1998, BIOCHEMISTRY-US, V37, P8674, DOI 10.1021/bi9803933; Steinmann E, 2007, PLOS PATHOG, V3, P962, DOI 10.1371/journal.ppat.0030103; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; SUREWICZ WK, 1993, BIOCHEMISTRY-US, V32, P389, DOI 10.1021/bi00053a001; Tan SL, 2002, NAT REV DRUG DISCOV, V1, P867, DOI 10.1038/nrd937; Tokita H, 2000, J CLIN MICROBIOL, V38, P3450, DOI 10.1128/JCM.38.9.3450-3452.2000; Vauloup-Fellous C, 2006, J BIOL CHEM, V281, P27679, DOI 10.1074/jbc.M602587200; Veiga AS, 2007, FEBS J, V274, P5096, DOI 10.1111/j.1742-4658.2007.06029.x; WALL J, 1995, MOL MEMBR BIOL, V12, P183, DOI 10.3109/09687689509027506; WALL J, 1995, J CELL SCI, V108, P2673; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; ZHANG YP, 1992, BIOCHEMISTRY-US, V31, P11572, DOI 10.1021/bi00161a041	63	30	31	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8089	8101		10.1074/jbc.M709413200	http://dx.doi.org/10.1074/jbc.M709413200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18198177	hybrid			2022-12-25	WOS:000254288000005
J	Dadlani, H; Ballinger, ML; Osman, N; Getachew, R; Little, PJ				Dadlani, Harsha; Ballinger, Mandy L.; Osman, Narin; Getachew, Robel; Little, Peter J.			Smad and p38 MAP kinase-mediated signaling of proteoglycan synthesis in vascular smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA RECEPTOR; GROWTH-FACTOR; TRANSFORMING GROWTH-FACTOR-BETA-1; EXTRACELLULAR-MATRIX; CELL-MEMBRANE; IN-VITRO; EXPRESSION; SUPERFAMILY; ACTIVATION; ATHEROSCLEROSIS	Atherosclerosis is the underlying pathological process of most cardiovascular disease. A critical component of the "response to retention" hypothesis of atherogenesis is proteo-glycan/low density lipoprotein (LDL) binding. Transforming growth factor beta (TGF-beta) is present in atherosclerotic lesions, regulates vascular smooth muscle cell (VSMC) proteoglycan synthesis via an unknown signaling pathway, and increases proteoglycan/ LDL binding. This pathway was investigated using the activin receptor-like kinase 5 (ALK5) inhibitor SB431542 and inhibitors of p38 MAP kinase as a possible downstream or alternative mediator. TGF-beta stimulated and SB431542 inhibited the phosphorylation of Smad2/ 3. In human VSMC, TGF-beta increased [S-35] sulfate incorporation into proteoglycans associated with a 19% increase in glycosaminoglycan (GAG) chain size by size exclusion chromatography. SB431542 caused a concentration-dependent decrease in TGF-beta-mediated [S-35] sulfate incorporation with 92% inhibition at 3 mu M. Two different p38 MAP kinase inhibitors, SB203580 and SB202190, but not the inactive analogue SB202474, concentration-dependently blocked TGF-beta-mediated [S-35] sulfate incorporation. TGF-beta increased [H-3] glucosamine incorporation into glycosaminoglycans by 180% and [S-35] Met/Cys incorporation into proteoglycan core proteins by 35% with both effects completely inhibited by SB431542. Blocking both Smad2/3 and p38 MAP kinase pathways prevented the effect of TGF-beta to increase proteoglycan to LDL binding. TGF-beta mediates its effects on proteoglycan synthesis in VSMCs via the ALK5/Smad2/3 phosphorylation pathway as well as via the p38 MAP kinase signaling cascade. Further studies of downstream pathways controlling proteoglycan synthesis may identify potential therapeutic targets for the prevention of atherosclerosis and cardiovascular disease.	[Dadlani, Harsha; Ballinger, Mandy L.; Osman, Narin; Getachew, Robel; Little, Peter J.] Baker Heart Res Inst, Cell Biol Diabet Lab, Melbourne, Vic 3004, Australia; [Osman, Narin; Little, Peter J.] Monash Univ, Alfred Hosp, Cent Eastern Clin Sch, Dept Med & Immunol, Melbourne, Vic 3004, Australia; [Dadlani, Harsha] Univ Melbourne, Dept Mol Biol & Biochem, Parkville, Vic 3010, Australia	Baker Heart and Diabetes Institute; Florey Institute of Neuroscience & Mental Health; Monash University; University of Melbourne	Little, PJ (corresponding author), Baker Heart Res Inst, Cell Biol Diabet Lab, Melbourne, Vic 3004, Australia.	peter.little@baker.edu.au	Little, Peter J./F-9865-2015	Little, Peter J./0000-0002-0335-3835; Ballinger, Mandy/0000-0002-9706-0514				AGROTIS A, 1994, HYPERTENSION, V23, P593, DOI 10.1161/01.HYP.23.5.593; Agrotis Alex, 2005, Current Vascular Pharmacology, V3, P55, DOI 10.2174/1570161052773951; Ballinger ML, 2004, CELL MOL LIFE SCI, V61, P1296, DOI 10.1007/s00018-004-3389-4; Beckman JA, 2002, JAMA-J AM MED ASSOC, V287, P2570, DOI 10.1001/jama.287.19.2570; Bobik A, 1999, CIRCULATION, V99, P2883, DOI 10.1161/01.CIR.99.22.2883; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; BYTIELD DS, 2004, MOL PHARM, V65, P744; Deaton RA, 2005, J BIOL CHEM, V280, P31172, DOI 10.1074/jbc.M504774200; Gaedeke J, 2004, KIDNEY INT, V66, P112, DOI 10.1111/j.1523-1755.2004.00713.x; HEINECKE JW, 1986, J CLIN INVEST, V77, P757, DOI 10.1172/JCI112371; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Kawakami S, 2002, J CELL PHYSIOL, V191, P310, DOI 10.1002/jcp.10099; Laping NJ, 2002, MOL PHARMACOL, V62, P58, DOI 10.1124/mol.62.1.58; Little PJ, 2002, ARTERIOSCL THROM VAS, V22, P55, DOI 10.1161/hq0102.101100; Little PJ, 2003, DIABETES RES CLIN PR, V59, P93, DOI 10.1016/S0168-8227(02)00201-2; Lopez AD, 1998, NAT MED, V4, P1241, DOI 10.1038/3218; Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; McGillicuddy FC, 2006, VASC PHARMACOL, V44, P469, DOI 10.1016/j.vph.2006.03.002; Mori Y, 2004, ARTHRITIS RHEUM-US, V50, P4008, DOI 10.1002/art.20658; Nakashima Y, 2007, ARTERIOSCL THROM VAS, V27, P1159, DOI 10.1161/ATVBAHA.106.134080; Nigro J, 2004, DIABETOLOGIA, V47, P2105, DOI 10.1007/s00125-004-1588-z; Nigro J, 2002, ATHEROSCLEROSIS, V162, P119, DOI 10.1016/S0021-9150(01)00704-3; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Pignone M, 2000, BRIT MED J, V321, P983, DOI 10.1136/bmj.321.7267.983; Prante C, 2007, J BIOL CHEM, V282, P26441, DOI 10.1074/jbc.M702299200; Runyan CE, 2006, CELL SIGNAL, V18, P2077, DOI 10.1016/j.cellsig.2006.05.009; Schmidt A, 2006, EUR J CLIN INVEST, V36, P473, DOI 10.1111/j.1365-2362.2006.01658.x; SCHONHERR E, 1991, J BIOL CHEM, V266, P17640; Schonherr E, 1997, ARCH BIOCHEM BIOPHYS, V339, P353, DOI 10.1006/abbi.1996.9854; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Tanabe K, 2006, J CELL BIOCHEM, V99, P187, DOI 10.1002/jcb.20896; Ungefroren H, 2005, J BIOL CHEM, V280, P2644, DOI 10.1074/jbc.M411925200; Ungefroren H, 2003, J BIOL CHEM, V278, P11041, DOI 10.1074/jbc.M300035200; Vilar JMG, 2006, PLOS COMPUT BIOL, V2, P36, DOI 10.1371/journal.pcbi.0020003; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	38	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7844	7852		10.1074/jbc.M703125200	http://dx.doi.org/10.1074/jbc.M703125200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18223258	hybrid			2022-12-25	WOS:000253997900060
J	Li, K; Casta, A; Wang, R; Lozada, E; Fan, W; Kane, S; Ge, QY; Gu, W; Orren, D; Luo, JY				Li, Kai; Casta, Alex; Wang, Rui; Lozada, Enerlyn; Fan, Wei; Kane, Susan; Ge, Qingyuan; Gu, Wei; Orren, David; Luo, Jianyuan			Regulation of WRN protein cellular localization and enzymatic activities by SIRT1-mediated deacetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WERNER-SYNDROME PROTEIN; HOLLIDAY JUNCTIONS; P53; HELICASE; SIR2; DAMAGE; RPA; COLOCALIZES; INSTABILITY; METABOLISM	Werner syndrome is an autosomal recessive disorder associated with premature aging and cancer predisposition caused by mutations of the WRN gene. WRN is a member of the RecQ DNA helicase family with functions in maintaining genome stability. Sir2, an NAD-dependent histone deacetylase, has been proven to extend life span in yeast and Caenorhabditis elegans. Mammalian Sir2 (SIRT1) has also been found to regulate premature cellular senescence induced by the tumor suppressors PML and p53. SIRT1 plays an important role in cell survival promoted by calorie restriction. Here we show that SIRT1 interacts with WRN both in vitro and in vivo; this interaction is enhanced after DNA damage. WRN can be acetylated by acetyltransferase CBP/p300, and SIRT1 can deacetylate WRN both in vitro and in vivo. WRN acetylation decreases its helicase and exonuclease activities, and SIRT1 can reverse this effect. WRN acetylation alters its nuclear distribution. Down-regulation of SIRT1 reduces WRN translocation from nucleoplasm to nucleoli after DNA damage. These results suggest that SIRT1 regulates WRN-mediated cellular responses to DNA damage through deacetylation of WRN.	[Li, Kai; Wang, Rui; Fan, Wei; Luo, Jianyuan] Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA; [Li, Kai; Wang, Rui; Fan, Wei; Luo, Jianyuan] Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA 01605 USA; [Casta, Alex; Gu, Wei] Columbia Univ, Inst Canc Genet, New York, NY 10032 USA; [Lozada, Enerlyn; Orren, David] Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; [Kane, Susan; Ge, Qingyuan] Cell Signaling Technol, Danvers, MA 01923 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Columbia University; University of Kentucky	Luo, JY (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, 422 LRB,364 Plantat St, Worcester, MA 01605 USA.	Jianyuan.luo@umassmed.edu	Luo, Jianyuan/ABI-7585-2020	Luo, Jianyuan/0000-0001-6057-2914	NATIONAL CANCER INSTITUTE [R01CA113371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG026534] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA113371] Funding Source: Medline; NIA NIH HHS [R01 AG026534] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Avalos JL, 2002, MOL CELL, V10, P523, DOI 10.1016/S1097-2765(02)00628-7; Bachrati CZ, 2003, BIOCHEM J, V374, P577, DOI 10.1042/BJ20030491; Blander G, 1999, J BIOL CHEM, V274, P29463, DOI 10.1074/jbc.274.41.29463; Blander G, 2002, J BIOL CHEM, V277, P50934, DOI 10.1074/jbc.M210479200; Brosh RM, 2001, J BIOL CHEM, V276, P35093, DOI 10.1074/jbc.M103332200; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; Gray MD, 1998, EXP CELL RES, V242, P487, DOI 10.1006/excr.1998.4124; Guarente L, 2000, GENE DEV, V14, P1021; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Karmakar P, 2005, MECH AGEING DEV, V126, P1146, DOI 10.1016/j.mad.2005.06.004; Karmakar P, 2002, J BIOL CHEM, V277, P18291, DOI 10.1074/jbc.M111523200; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lebel M, 1998, P NATL ACAD SCI USA, V95, P13097, DOI 10.1073/pnas.95.22.13097; Leung AKL, 2003, BIOCHEM J, V376, P553, DOI 10.1042/BJ20031169; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25; MARTIN GM, 1970, LAB INVEST, V23, P86; McBurney MW, 2003, MOL CELL BIOL, V23, P38, DOI 10.1128/MCB.23.1.38-54.2003; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Nguyen DT, 2002, FEBS LETT, V521, P170, DOI 10.1016/S0014-5793(02)02868-5; Ogburn CE, 1997, HUM GENET, V101, P121, DOI 10.1007/s004390050599; Opresko PL, 2003, CARCINOGENESIS, V24, P791, DOI 10.1093/carcin/bgg034; Orren DK, 2006, FRONT BIOSCI-LANDMRK, V11, P2657, DOI 10.2741/1999; Ozgenc A, 2005, MUTAT RES-FUND MOL M, V577, P237, DOI 10.1016/j.mrfmmm.2005.03.020; Poot M, 2001, FASEB J, V15, P1224, DOI 10.1096/fj.00-0611fje; Sakamoto S, 2001, GENES CELLS, V6, P421, DOI 10.1046/j.1365-2443.2001.00433.x; Sommers JA, 2005, CANCER RES, V65, P1223, DOI 10.1158/0008-5472.CAN-03-0231; STEFANINI M, 1989, MUTAT RES, V219, P179, DOI 10.1016/0921-8734(89)90013-1; Vaitiekunaite R, 2007, MECH AGEING DEV, V128, P650, DOI 10.1016/j.mad.2007.09.004; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Yang Q, 2002, J BIOL CHEM, V277, P31980, DOI 10.1074/jbc.M204111200; Yannone SM, 2001, J BIOL CHEM, V276, P38242; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	41	130	136	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7590	7598		10.1074/jbc.M709707200	http://dx.doi.org/10.1074/jbc.M709707200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18203716	hybrid			2022-12-25	WOS:000253997900034
J	Loyer, P; Trembley, JH; Grenet, JA; Busson, A; Corlu, A; Zhao, W; Kocak, M; Kidd, VJ; Lahti, JM				Loyer, Pascal; Trembley, Janeen H.; Grenet, Jose A.; Busson, Adeline; Corlu, Anne; Zhao, Wei; Kocak, Mehmet; Kidd, Vincent J.; Lahti, Jill M.			Characterization of cyclin L1 and L2 interactions with CDK11 and splicing factors - Influence of cyclin L isoforms on splice site selection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; RS DOMAIN; PROTEIN; KINASE; TRANSCRIPTION; COMPLEXES; EXPRESSION; APOPTOSIS; RNPS1; CELLS	Although it has been reported that cyclin L1 alpha and L2 alpha proteins interact with CDK11(p110), the nature of the cyclin L transcripts, the formation of complexes between the five cyclin L and the three CDK11 protein isoforms, and the influence of these complexes on splicing have not been thoroughly investigated. Here we report that cyclin L1 and L2 genes generate 14 mRNA variants encoding six cyclin L proteins, one of which has not been described previously. Using cyclin L gene-specific antibodies, we demonstrate expression of multiple endogenous cyclin L proteins in human cell lines and mouse tissues. Moreover, we characterize interactions between CDK11(p110), mitosis-specific CDK11(p58), and apoptosis-specific CDK11(p46) with both cyclin L alpha and -beta proteins and the co-elution of these proteins following size exclusion chromatography. We further establish that CDK11(p110) and associated cyclin L alpha/beta proteins localize to splicing factor compartments and nucleoplasm and interact with serine/arginine-rich proteins. Importantly, we also determine the effect of CDK11-cyclin L complexes on pre-mRNA splicing. Pre-incubation of nuclear extracts with purified cyclin L alpha and -beta isoforms depletes the extract of in vitro splicing activity. Ectopic expression of cyclin L1 alpha, L1 beta, L2 alpha, or L2 beta or active CDK11(p110) individually enhances intracellular intron splicing activity, whereas expression of CDK11(p58/p46) or kinase-dead CDK11(p110) represses splicing activity. Finally, we demonstrate that expression of cyclins L alpha and -beta and CDK11(p110) strongly and differentially affects alternative splicing in vivo. Together, these data establish that CDK11(p110) interacts physically and functionally with cyclin L alpha and -beta isoforms and SR proteins to regulate splicing.	[Trembley, Janeen H.; Grenet, Jose A.; Kidd, Vincent J.; Lahti, Jill M.] St Jude Childrens Res Hosp, Dept Genet & Tumor Cell Biol, Memphis, TN 38105 USA; [Loyer, Pascal; Busson, Adeline; Corlu, Anne] Univ Rennes 1, INSERM, U Regulat Equilibres Fonct Foie Normal & Pathol 5, IFR140,Hop Pontchaillou, F-35033 Rennes, France; [Zhao, Wei; Kocak, Mehmet] St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN 38105 USA	St Jude Children's Research Hospital; CHU Rennes; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes; St Jude Children's Research Hospital	Lahti, JM (corresponding author), St Jude Childrens Res Hosp, Dept Genet & Tumor Cell Biol, 332 N Lauderdale, Memphis, TN 38105 USA.	Jill.Lahti@stjude.org	Corlu, Anne/U-8030-2018; LOYER, Pascal/K-1838-2019	Corlu, Anne/0000-0002-7370-0564; Kocak, Mehmet/0000-0002-3386-1734; LOYER, PASCAL/0000-0002-5656-2673; Trembley, Janeen/0000-0003-3597-2611	NCI NIH HHS [P30CA021765] Funding Source: Medline; NIGMS NIH HHS [R01GM044088] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044088] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berke JD, 2001, NEURON, V32, P277, DOI 10.1016/S0896-6273(01)00465-2; Beyaert R, 1997, J BIOL CHEM, V272, P11694, DOI 10.1074/jbc.272.18.11694; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; Chen HH, 2006, MOL CELL BIOL, V26, P2736, DOI 10.1128/MCB.26.7.2736-2745.2006; Chen HH, 2007, BIOCHEM BIOPH RES CO, V354, P735, DOI 10.1016/j.bbrc.2007.01.049; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; de Graaf K, 2004, J BIOL CHEM, V279, P4612, DOI 10.1074/jbc.M310794200; Dickinson LA, 2002, J BIOL CHEM, V277, P25465, DOI 10.1074/jbc.M202266200; Even Y, 2006, J CELL BIOCHEM, V99, P890, DOI 10.1002/jcb.20986; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Gururajan R, 1998, GENOME RES, V8, P929, DOI 10.1101/gr.8.9.929; Herrmann A, 2007, FASEB J, V21, P3142, DOI 10.1096/fj.07-8377com; Hu DL, 2003, J BIOL CHEM, V278, P8623, DOI 10.1074/jbc.M210057200; Hu DL, 2007, J CELL SCI, V120, P2424, DOI 10.1242/jcs.007963; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; Lai MC, 2003, EMBO J, V22, P1359, DOI 10.1093/emboj/cdg126; Li TY, 2004, MOL CELL BIOL, V24, P3188, DOI 10.1128/MCB.24.8.3188-3197.2004; Loyer P, 2005, CELL SIGNAL, V17, P1033, DOI 10.1016/j.cellsig.2005.02.005; Loyer P, 1998, J CELL SCI, V111, P1495; Mayeda A, 1999, METH MOL B, V118, P315; Nasim MT, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf108; Neugebauer KM, 1997, GENE DEV, V11, P1148, DOI 10.1101/gad.11.9.1148; Nybakken K, 2005, NAT GENET, V37, P1323, DOI 10.1038/ng1682; Petretti C, 2006, EMBO REP, V7, P418, DOI 10.1038/sj.embor.7400639; Shin C, 2004, NAT REV MOL CELL BIO, V5, P727, DOI 10.1038/nrm1467; STEPHENS C, 1987, EMBO J, V6, P2027, DOI 10.1002/j.1460-2075.1987.tb02467.x; Trembley JH, 2005, MOL CELL BIOL, V25, P1446, DOI 10.1128/MCB.25.4.1446-1457.2005; Trembley JH, 2004, PROG NUCLEIC ACID RE, V77, P263, DOI 10.1016/S0079-6603(04)77007-5; Trembley JH, 2003, J BIOL CHEM, V278, P2265, DOI 10.1074/jbc.M207518200; Trembley JH, 2002, J BIOL CHEM, V277, P2589, DOI 10.1074/jbc.M109755200; XIANG JL, 1994, J BIOL CHEM, V269, P15786; Yang LJ, 2004, J BIOL CHEM, V279, P11639, DOI 10.1074/jbc.M312895200; Zong HL, 2007, MOL CELL BIOL, V27, P7125, DOI 10.1128/MCB.01753-06	33	86	97	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7721	7732		10.1074/jbc.M708188200	http://dx.doi.org/10.1074/jbc.M708188200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18216018	hybrid			2022-12-25	WOS:000253997900049
J	Shi, Y; Chen, XF; Wu, ZY; Shi, WW; Yang, Y; Cui, N; Jiang, C; Harrison, RW				Shi, Yun; Chen, Xianfeng; Wu, Zhongying; Shi, Weiwei; Yang, Yang; Cui, Ningren; Jiang, Chun; Harrison, Robert W.			cAMP-dependent protein kinase phosphorylation produces interdomain movement in SUR2B leading to activation of the vascular K-ATP channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING DOMAINS; MOLECULAR-DYNAMICS SIMULATIONS; ARTERIAL SMOOTH-MUSCLE; ABC TRANSPORTER; SULFONYLUREA RECEPTOR; POTASSIUM CHANNELS; COMPLEX; MECHANISM; ROLES; CONFORMATION	Vascular ATP-sensitive K+ channels are activated by multiple vasodilating hormones and neurotransmitters via PKA. A critical PKA phosphorylation site (Ser-1387) is found in the second nucleotide-binding domain (NBD2) of the SUR2B subunit. To understand how phosphorylation at Ser-1387 leads to changes in channel activity, we modeled the SUR2B using a newly crystallized ABC protein SAV1866. The model showed that Ser-1387 was located on the interface of NBD2 with TMD1 and physically interacted with Tyr-506 in TMD1. A positively charged residue (Arg-1462) in NBD2 was revealed in the close vicinity of Ser-1387. Mutation of either of these three residues abolished PKA-dependent channel activation. Molecular dynamics simulations suggested that Ser-1387, Tyr-506, and Arg-1462 formed a compact triad upon Ser-1387 phosphorylation, leading to reshaping of the NBD2 interface and movements of NBD2 and TMD1. Restriction of the interdomain movements by engineering a disulfide bond between TMD1 and NBD2 prevented the channel activation in a redox-dependent manner. Thus, a channel-gating mechanism is suggested through enhancing the NBD-TMD coupling efficiency following Ser-1387 phosphorylation, which is shared by multiple vasodilators.	[Shi, Yun; Chen, Xianfeng; Wu, Zhongying; Shi, Weiwei; Yang, Yang; Cui, Ningren; Jiang, Chun] Georgia State Univ, Dept Biol, Atlanta, GA 30302 USA; [Chen, Xianfeng; Harrison, Robert W.] Georgia State Univ, Dept Comp Sci, Atlanta, GA 30302 USA	University System of Georgia; Georgia State University; University System of Georgia; Georgia State University	Jiang, C (corresponding author), Georgia State Univ, Dept Biol, POB 4010, Atlanta, GA 30302 USA.	cjiang@gsu.edu; rharrison@cs.gsu.edu	Shi, Yun S/T-8845-2018; Yang, Yang/B-3440-2008; SHI, WEIWEI/B-3477-2008; Shi, Yun/B-5623-2009; Chen, Xianfeng/ABG-8256-2021	Yang, Yang/0000-0003-4275-0515; SHI, WEIWEI/0000-0001-6216-712X; Shi, Yun/0000-0002-8842-9818; Yang, Yang/0000-0001-6417-3654; Harrison, Robert/0000-0003-2449-1214	NHLBI NIH HHS [R01 HL067890, HL067890] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067890] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Babenko AP, 2003, J BIOL CHEM, V278, P41577, DOI 10.1074/jbc.C300363200; Bienengraeber M, 2000, FASEB J, V14, P1943, DOI 10.1096/fj.00-0027com; Campbell JD, 2004, DIABETES, V53, pS123, DOI 10.2337/diabetes.53.suppl_3.S123; Campbell JD, 2003, EMBO REP, V4, P1038, DOI 10.1038/sj.embor.7400003; Chan KW, 2003, EMBO J, V22, P3833, DOI 10.1093/emboj/cdg376; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; Chen XF, 2004, J MOL MODEL, V10, P373, DOI 10.1007/s00894-004-0205-x; Cole WC, 2003, J CARDIOVASC ELECTR, V14, P94, DOI 10.1046/j.1540-8167.2003.02376.x; Cui Y, 2002, AM J RESP CELL MOL, V26, P135, DOI 10.1165/ajrcmb.26.1.4622; Dawson RJP, 2006, NATURE, V443, P180, DOI 10.1038/nature05155; Gaudet R, 2001, EMBO J, V20, P4964, DOI 10.1093/emboj/20.17.4964; Gribble FM, 1997, EMBO J, V16, P1145, DOI 10.1093/emboj/16.6.1145; HARRISON RW, 1994, PROTEIN ENG, V7, P1353, DOI 10.1093/protein/7.11.1353; HARRISON RW, 2003, P INT C COMP SCI ITS, P71; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hollenstein K, 2007, NATURE, V446, P213, DOI 10.1038/nature05626; Huopio H, 2000, J CLIN INVEST, V106, P897, DOI 10.1172/JCI9804; Jackson WF, 2005, MICROCIRCULATION, V12, P113, DOI 10.1080/10739680590896072; Li L, 2003, J MEMBRANE BIOL, V196, P61, DOI 10.1007/s00232-003-0625-z; Light PE, 2002, MOL ENDOCRINOL, V16, P2135, DOI 10.1210/me.2002-0084; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Lu T, 2001, J PHYSIOL-LONDON, V537, P811; Matsuo M, 2005, J MOL CELL CARDIOL, V38, P907, DOI 10.1016/j.yjmcc.2004.11.021; Matsuo M, 2002, EMBO J, V21, P4250, DOI 10.1093/emboj/cdf419; Mikhailov MV, 2005, EMBO J, V24, P4166, DOI 10.1038/sj.emboj.7600877; Moreau C, 2005, J MOL CELL CARDIOL, V38, P951, DOI 10.1016/j.yjmcc.2004.11.030; NELSON MT, 1995, AM J PHYSIOL-CELL PH, V268, pC799, DOI 10.1152/ajpcell.1995.268.4.C799; Pinkett HW, 2007, SCIENCE, V315, P373, DOI 10.1126/science.1133488; Quayle JM, 1997, PHYSIOL REV, V77, P1165, DOI 10.1152/physrev.1997.77.4.1165; Quinn KV, 2004, CIRC RES, V94, P1359, DOI 10.1161/01.RES.0000128513.34817.c4; Schwappach B, 2000, NEURON, V26, P155, DOI 10.1016/S0896-6273(00)81146-0; Seino S, 2003, PROG BIOPHYS MOL BIO, V81, P133, DOI 10.1016/S0079-6107(02)00053-6; Shi Y, 2007, AM J PHYSIOL-REG I, V293, pR1205, DOI 10.1152/ajpregu.00337.2007; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Verdon G, 2003, J MOL BIOL, V330, P343, DOI 10.1016/S0022-2836(03)00575-8; Wang XR, 2003, CIRC RES, V92, P1225, DOI 10.1161/01.RES.0000075601.95738.6D; Wellman GC, 1998, J PHYSIOL-LONDON, V507, P117, DOI 10.1111/j.1469-7793.1998.117bu.x; Yamada M, 1997, J PHYSIOL-LONDON, V499, P715, DOI 10.1113/jphysiol.1997.sp021963; Yamada M, 2004, MOL PHARMACOL, V66, P807, DOI 10.1124/mol.104.002717; Yamada M, 2004, MOL PHARMACOL, V65, P1198, DOI 10.1124/mol.65.5.1198; Yang Y, 2008, BBA-BIOMEMBRANES, V1778, P88, DOI 10.1016/j.bbamem.2007.08.030; Zaitseva J, 2005, EMBO J, V24, P1901, DOI 10.1038/sj.emboj.7600657; Zolnerciks JK, 2007, FASEB J, V21, P3937, DOI 10.1096/fj.07-8610com	45	26	29	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7523	7530		10.1074/jbc.M709941200	http://dx.doi.org/10.1074/jbc.M709941200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18198173	hybrid, Green Published			2022-12-25	WOS:000253997900027
J	Splan, KE; Ignatov, ME; Musier-Forsyth, K				Splan, Kathryn E.; Ignatov, Michael E.; Musier-Forsyth, Karin			Transfer RNA modulates the editing mechanism used by class II prolyl-tRNA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECIES-SPECIFIC DIFFERENCES; HAEMOPHILUS-INFLUENZAE YBAK; ESCHERICHIA-COLI; AMINO-ACIDS; INSERTION DOMAIN; ACTIVE-SITE; PROTEIN; DISCRIMINATION; AMINOACYLATION; CYS-TRNA(PRO)	Aminoacyl-tRNA synthetases catalyze the attachment of amino acids to their cognate tRNAs. To prevent errors in protein synthesis, many synthetases have evolved editing pathways by which misactivated amino acids ( pre-transfer editing) and misacylated tRNAs ( post-transfer editing) are hydrolyzed. Previous studies have shown that class II prolyl-tRNA synthetase ( ProRS) possesses both pre- and post-transfer editing functions against noncognate alanine. To assess the relative contributions of pre- and post-transfer editing, presented herein are kinetic studies of an Escherichia coli ProRS mutant in which post-transfer editing is selectively inactivated, effectively isolating the pre-transfer editing pathway. When post-transfer editing is abolished, substantial levels of alanine mischarging are observed under saturating amino acid conditions, indicating that pre-transfer editing alone cannot prevent the formation of Ala-tRNAPro. Steady-state kinetic parameters for aminoacylation measured under these conditions reveal that the preference for proline over alanine is 2000-fold, which is well within the regime where editing is required. Simultaneous measurement of AMP and Ala-tRNAPro formation in the presence of tRNAPro suggested that misactivated alanine is efficiently transferred to tRNA to form the mischarged product. In the absence of tRNA, enzyme-catalyzed Ala-AMP hydrolysis is the dominant form of editing, with "selective release" of noncognate adenylate from the active site constituting a minor pathway. Studies with human and Methanococcus jannaschii ProRS, which lack a post-transfer editing domain, suggest that enzymatic pre- transfer editing occurs within the aminoacylation active site. Taken together, the results reported herein illustrate how both pre- and post-transfer editing pathways work in concert to ensure accurate aminoacylation by ProRS.	[Ignatov, Michael E.; Musier-Forsyth, Karin] Ohio State Univ, Dept Chem, Columbus, OH 43210 USA; [Musier-Forsyth, Karin] Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA; [Splan, Kathryn E.] Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Minnesota System; University of Minnesota Twin Cities	Musier-Forsyth, K (corresponding author), 100 W 18th Ave, Columbus, OH 43210 USA.	musier@chemistry.ohio-state.edu	Ignatov, Michael/GLN-6479-2022		NIGMS NIH HHS [GM049928] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM049928, R29GM049928, R01GM049928] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahel I, 2003, P NATL ACAD SCI USA, V100, P15422, DOI 10.1073/pnas.2136934100; An S, 2005, J BIOL CHEM, V280, P34465, DOI 10.1074/jbc.M507550200; An SG, 2004, J BIOL CHEM, V279, P42359, DOI 10.1074/jbc.C400304200; Beebe K, 2003, EMBO J, V22, P668, DOI 10.1093/emboj/cdg065; Beuning PJ, 2000, P NATL ACAD SCI USA, V97, P8916, DOI 10.1073/pnas.97.16.8916; Beuning PJ, 2001, J BIOL CHEM, V276, P30779, DOI 10.1074/jbc.M104761200; Burke B, 2001, J BIOL CHEM, V276, P20286, DOI 10.1074/jbc.M100456200; Dock-Bregeon AC, 2000, CELL, V103, P877, DOI 10.1016/S0092-8674(00)00191-4; Dock-Bregeon AC, 2004, MOL CELL, V16, P375, DOI 10.1016/S1097-2765(04)00591-X; ENGLISCH S, 1986, NUCLEIC ACIDS RES, V14, P7529, DOI 10.1093/nar/14.19.7529; FERSHT AR, 1981, PROC R SOC SER B-BIO, V212, P351, DOI 10.1098/rspb.1981.0044; FERSHT AR, 1975, BIOCHEMISTRY-US, V14, P1, DOI 10.1021/bi00672a001; FERSHT AR, 1976, BIOCHEMISTRY-US, V15, P3342, DOI 10.1021/bi00660a026; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P1250, DOI 10.1021/bi00574a021; FREIST W, 1989, BIOCHEMISTRY-US, V28, P6787, DOI 10.1021/bi00443a001; Giege R, 1998, NUCLEIC ACIDS RES, V26, P5017, DOI 10.1093/nar/26.22.5017; Gruic-Sovulj I, 2007, FEBS LETT, V581, P5110, DOI 10.1016/j.febslet.2007.09.058; Guth EC, 2007, MOL CELL, V25, P531, DOI 10.1016/j.molcel.2007.01.015; Hati S, 2006, J BIOL CHEM, V281, P27862, DOI 10.1074/jbc.M605856200; Heacock D, 1996, BIOORG CHEM, V24, P273, DOI 10.1006/bioo.1996.0025; Hendrickson TL, 2003, MOL B INT U, P34; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; Ibba M, 2000, TRENDS BIOCHEM SCI, V25, P311, DOI 10.1016/S0968-0004(00)01600-5; Ibba M., 2005, AMINOACYL TRNA SYNTH; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; JAKUBOWSKI H, 1981, NUCLEIC ACIDS RES, V9, P3105, DOI 10.1093/nar/9.13.3105; Lee JW, 2006, NATURE, V443, P50, DOI 10.1038/nature05096; LEWINSOHN R, 1967, BIOCHIM BIOPHYS ACTA, V140, P24, DOI 10.1016/0005-2795(67)90378-9; LIN SX, 1984, BIOCHEMISTRY-US, V23, P4109, DOI 10.1021/bi00313a015; LIN SX, 1983, BIOCHEMISTRY-US, V22, P681, DOI 10.1021/bi00272a024; LIU HJ, 1995, NUCLEIC ACIDS RES, V23, P165, DOI 10.1093/nar/23.1.165; MASCARENHAS A, 2008, IN PRESS PROTEIN ENG; MUSIERFORSYTH K, 1991, P NATL ACAD SCI USA, V88, P209, DOI 10.1073/pnas.88.1.209; RAUNIO R, 1970, ACTA CHEM SCAND, V24, P2737, DOI 10.3891/acta.chem.scand.24-2737; Roy H, 2004, EMBO J, V23, P4639, DOI 10.1038/sj.emboj.7600474; Ruan BF, 2005, J BIOL CHEM, V280, P25887, DOI 10.1074/jbc.M502174200; SCHIMMEL P, 1995, TRENDS BIOCHEM SCI, V20, P1, DOI 10.1016/S0968-0004(00)88937-9; Stehlin C, 1997, BIOCHEMISTRY-US, V36, P2932, DOI 10.1021/bi962295s; Stehlin C, 1998, BIOCHEMISTRY-US, V37, P8605, DOI 10.1021/bi980364s; TSUI WC, 1981, NUCLEIC ACIDS RES, V9, P4627, DOI 10.1093/nar/9.18.4627; Wolfson AD, 2002, P NATL ACAD SCI USA, V99, P5965, DOI 10.1073/pnas.092152799; Wong FC, 2003, J BIOL CHEM, V278, P52857, DOI 10.1074/jbc.M309627200; Wong FC, 2002, BIOCHEMISTRY-US, V41, P7108, DOI 10.1021/bi012178j; Zhang H, 2000, PROTEINS, V40, P86, DOI 10.1002/(SICI)1097-0134(20000701)40:1<86::AID-PROT100>3.0.CO;2-Y	44	53	57	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					7128	7134		10.1074/jbc.M709902200	http://dx.doi.org/10.1074/jbc.M709902200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18180290	hybrid			2022-12-25	WOS:000253779600058
J	Stengel, A; Benz, P; Balsera, M; Soll, J; Bolter, B				Stengel, Anna; Benz, Philipp; Balsera, Monica; Soll, Juergen; Boelter, Bettina			TIC62 redox-regulated translocon composition and dynamics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPLAST PROTEIN IMPORT; CIRCULAR-DICHROISM; CALCIUM REGULATION; ARABIDOPSIS; EXPRESSION; LIGHT; MACHINERY; MEMBRANES; SIGNALS; COMPLEX	The preprotein translocon at the inner envelope of chloroplasts (Tic complex) facilitates the import of nuclear-encoded preproteins into the organelle. Seven distinct subunits have been identified so far. For each of those, specific functions have been proposed based on structural prediction or experimental evidence. Three of those subunits possess modules that could act as redox-active regulatory components in the import process. To date, however, the mode of redox regulation of the import process remains enigmatic. To investigate how the chloroplast redox state influences translocon behavior and composition, we studied the Tic component and the putative redox sensor Tic62 in more detail. The experimental results provide evidence that Tic62 can act as a bona fide dehydrogenase in vitro, and that it changes its localization in the chloroplast dependent on the NADP(+)/NADPH ratio in the stroma. Moreover, the redox state influences the interactions of Tic62 with the translocon and the flavoenzyme ferredoxin-NADP(+) oxidoreductase. Additionally, we give initial experimental insights into the Tic62 structure using circular dichroism measurements and demonstrate that the protein consists of two structurally different domains. Our results indicate that Tic62 possesses redox-dependent properties that would allow it to fulfill a role as redox sensor protein in the chloroplast.	[Stengel, Anna; Benz, Philipp; Balsera, Monica; Soll, Juergen; Boelter, Bettina] Univ Munich, Munich Ctr Integrated Prot Sci CiPSM, D-81377 Munich, Germany; [Stengel, Anna; Benz, Philipp; Balsera, Monica; Soll, Juergen; Boelter, Bettina] Univ Munich, Dept Biol 1, D-80638 Munich, Germany	University of Munich; University of Munich	Bolter, B (corresponding author), Univ Munich, Dept Biol 1, Menzinger Str 67, D-80638 Munich, Germany.	boelter@lrz.uni-muenchen.de	Balsera, Monica/K-2877-2014; Benz, J. Philipp/ABG-5009-2020	Balsera, Monica/0000-0002-5586-6050; Benz, J. Philipp/0000-0001-5361-4514				Balsera M, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-43; Becker T, 2004, EMBO J, V23, P520, DOI 10.1038/sj.emboj.7600089; Buchanan BB, 2005, ANNU REV PLANT BIOL, V56, P187, DOI 10.1146/annurev.arplant.56.032604.144246; Caliebe A, 1997, EMBO J, V16, P7342, DOI 10.1093/emboj/16.24.7342; Chigri F, 2005, PLANT J, V42, P821, DOI 10.1111/j.1365-313X.2005.02414.x; Chigri F, 2006, P NATL ACAD SCI USA, V103, P16051, DOI 10.1073/pnas.0607150103; Donahue JL, 1997, PLANT PHYSIOL, V113, P249, DOI 10.1104/pp.113.1.249; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; Fey V, 2005, J BIOL CHEM, V280, P5318, DOI 10.1074/jbc.M406358200; Gray JC, 2005, ANNU PLANT REV, V13, P237; Heddad M, 2006, PLANT PHYSIOL, V142, P75, DOI 10.1104/pp.106.081489; Hirohashi T, 2001, PLANT PHYSIOL, V125, P2154, DOI 10.1104/pp.125.4.2154; Hormann F, 2004, J BIOL CHEM, V279, P34756, DOI 10.1074/jbc.M402817200; Jarvis P, 2004, CURR BIOL, V14, pR1064, DOI 10.1016/j.cub.2004.11.049; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; Kelly SM, 2005, BBA-PROTEINS PROTEOM, V1751, P119, DOI 10.1016/j.bbapap.2005.06.005; Kessler F, 2006, TRAFFIC, V7, P248, DOI 10.1111/j.1600-0854.2005.00382.x; Kuchler M, 2002, EMBO J, V21, P6136, DOI 10.1093/emboj/cdf621; Lintala M, 2007, PLANT J, V49, P1041, DOI 10.1111/j.1365-313X.2006.03014.x; Mano J, 2001, BBA-BIOENERGETICS, V1504, P275, DOI 10.1016/S0005-2728(00)00256-5; Palatnik JF, 1997, PLANT PHYSIOL, V115, P1721, DOI 10.1104/pp.115.4.1721; Stengel A, 2007, BIOL CHEM, V388, P765, DOI 10.1515/BC.2007.099; Trebitsh T, 2000, MOL CELL BIOL, V20, P1116, DOI 10.1128/MCB.20.4.1116-1123.2000; Waegemann K, 1995, METHOD CELL BIOL, V50, P255, DOI 10.1016/S0091-679X(08)61035-3; Whitmore L, 2004, NUCLEIC ACIDS RES, V32, pW668, DOI 10.1093/nar/gkh371; Zickermann V, 2000, BBA-BIOENERGETICS, V1459, P61, DOI 10.1016/S0005-2728(00)00113-4	26	66	71	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					6656	6667		10.1074/jbc.M706719200	http://dx.doi.org/10.1074/jbc.M706719200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18180301	hybrid			2022-12-25	WOS:000253779600007
J	Zhang, M; Swanson, PC				Zhang, Ming; Swanson, Patrick C.			V(D)J recombinase binding and cleavage of cryptic recombination signal sequences identified from lymphoid malignancies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL RECEPTOR; CHROMOSOME-TRANSLOCATION; GENOMIC INSTABILITY; TAL-1 GENE; B-CELL; RAG; TRANSPOSITION; LEUKEMIA; LOCUS; REARRANGEMENT	V(D)J recombination is a process integral to lymphocyte development. However, this process is not always benign, since certain lymphoid malignancies exhibit recurrent chromosomal abnormalities, such as translocations and deletions, that harbor molecular signatures suggesting an origin from aberrant V( D) J recombination. Translocations involving LMO2, TAL1, Ttg- 1, and Hox11, as well as a recurrent interstitial deletion at 1p32 involving SIL/SCL, are cited examples of illegitimate V( D) J recombination. Previous studies using extrachromosomal substrates reveal that cryptic recombination signal sequences (cRSSs) identified near the translocation breakpoint in these examples support V( D) J recombination with efficiencies ranging from about 30- to 20,000-fold less than bona fide V( D) J recombination signals. To understand the molecular basis for these large differences, we investigated the binding and cleavage of these cRSSs by the RAG1/2 proteins that initiate V( D) J recombination. We find that the RAG proteins comparably bind all cRSSs tested, albeit more poorly than a consensus RSS. We show that four cRSSs that support levels of V( D) J recombination above background levels in cell culture ( LMO2, TAL1, Ttg- 1, and SIL) are also cleaved by the RAG proteins in vitro with efficiencies ranging from 18 to 70% of a consensus RSS. Cleavage of LMO2 and Ttg- 1 by the RAG proteins can also be detected in cell culture using ligation-mediated PCR. In contrast, Hox11 and SCL are nicked but not cleaved efficiently in vitro, and cleavage at other adventitious sites in plasmid substrates may also limit the ability to detect recombination activity at these cRSSs in cell culture.	[Zhang, Ming; Swanson, Patrick C.] Creighton Univ, Med Ctr, Dept Med Microbiol & Immunol, Omaha, NE 68178 USA	Creighton University	Swanson, PC (corresponding author), Creighton Univ, Med Ctr, Dept Med Microbiol & Immunol, 2500 Calif Plaza, Omaha, NE 68178 USA.	pswanson@creighton.edu			NCRR NIH HHS [C06 RR17417-01] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR017417] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; Bergeron S, 2006, METHOD ENZYMOL, V408, P511, DOI 10.1016/S0076-6879(06)08032-3; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; Cayuela JM, 1997, BLOOD, V90, P3720, DOI 10.1182/blood.V90.9.3720; Chatterji M, 2006, MOL CELL BIOL, V26, P1558, DOI 10.1128/MCB.26.4.1558-1568.2006; CHEN Q, 1990, J EXP MED, V172, P1403, DOI 10.1084/jem.172.5.1403; CHENG JT, 1990, J EXP MED, V171, P489, DOI 10.1084/jem.171.2.489; Cowell LG, 2003, J EXP MED, V197, P207, DOI 10.1084/jem.20020250; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; KAGAN J, 1989, P NATL ACAD SCI USA, V86, P4161, DOI 10.1073/pnas.86.11.4161; Kitagawa Y, 2002, J BIOL CHEM, V277, P46289, DOI 10.1074/jbc.M208353200; Kriatchko AN, 2006, MOL CELL BIOL, V26, P4712, DOI 10.1128/MCB.02487-05; Kuppers R, 2001, ONCOGENE, V20, P5580, DOI 10.1038/sj.onc.1204640; Lee AI, 2003, PLOS BIOL, V1, P56, DOI 10.1371/journal.pbio.0000001; Lewis SM, 1997, MOL CELL BIOL, V17, P3125, DOI 10.1128/MCB.17.6.3125; Liang HE, 2002, IMMUNITY, V17, P639, DOI 10.1016/S1074-7613(02)00448-X; Lieber MR, 2006, DNA REPAIR, V5, P1234, DOI 10.1016/j.dnarep.2006.05.013; Marculescu R, 2002, J EXP MED, V195, P85, DOI 10.1084/jem.20011578; Marculescu R, 2006, DNA REPAIR, V5, P1246, DOI 10.1016/j.dnarep.2006.05.015; Messier TL, 2003, EMBO J, V22, P1381, DOI 10.1093/emboj/cdg137; Nadel B, 1998, J IMMUNOL, V161, P6068; Neiditch MB, 2002, MOL CELL, V9, P871, DOI 10.1016/S1097-2765(02)00494-X; Raghavan SC, 2004, NATURE, V428, P88, DOI 10.1038/nature02355; Raghavan SC, 2001, J BIOL CHEM, V276, P29126, DOI 10.1074/jbc.M103797200; Rahman NS, 2006, J BIOL CHEM, V281, P12370, DOI 10.1074/jbc.M507906200; Reddy YVR, 2006, GENE DEV, V20, P1575, DOI 10.1101/gad.1432706; Swanson PC, 2004, J BIOL CHEM, V279, P4034, DOI 10.1074/jbc.M311100200; Swanson PC, 2002, MOL CELL BIOL, V22, P7790, DOI 10.1128/MCB.22.22.7790-7801.2002; Vanura K, 2007, PLOS BIOL, V5, P515, DOI 10.1371/journal.pbio.0050043; YOFFE G, 1989, BLOOD, V74, P374; ZUTTER M, 1990, P NATL ACAD SCI USA, V87, P3161, DOI 10.1073/pnas.87.8.3161	34	43	45	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					6717	6727		10.1074/jbc.M710301200	http://dx.doi.org/10.1074/jbc.M710301200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18187418	hybrid			2022-12-25	WOS:000253779600013
J	Cao, J; Chiarelli, C; Richman, O; Zarrabi, K; Kozarekar, P; Zucker, S				Cao, Jian; Chiarelli, Christian; Richman, Omer; Zarrabi, Kevin; Kozarekar, Pallavi; Zucker, Stanley			Membrane type 1 matrix metalloproteinase induces epithelial-to-mesenchymal transition in prostate cancer.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-CELL MIGRATION; 1-MATRIX METALLOPROTEINASE; CARCINOMA-CELLS; EXTRACELLULAR-MATRIX; TISSUE INHIBITOR; PRO-GELATINASE; INVASION; METASTASIS; EXPRESSION; GROWTH	By mining DNA microarray data bases at GenBankTM, we identified up-regulation of membrane type 1 matrix metalloproteinase (MT1-MMP) in human primary and metastatic prostate cancer specimens as compared with nonmalignant prostate tissues. To explore the role of up-regulated MT1-MMP in early stage cancer progression, we have employed a three-dimensional cell culture model. Minimally invasive human prostate cancer cells (LNCaP) were transfected with MT1-green fluorescent protein (GFP) chimeric cDNA as compared with GFP cDNA, and morphologic and phenotypic changes were characterized. GFP-expressing LNCaP cells formed multicellular spheroids with cuboidal-like epithelial morphology, whereas MT1-GFP-expressing cells displayed a fibroblast-like morphology and a scattered growth pattern in type I collagen gels. Cell morphologic changes were accompanied by decreased epithelial markers and enhanced mesenchymal markers, consistent with epithelial-to-mesenchymal transition. MT1-MMP-induced morphologic change and cell scattering were abrogated by target inhibition of either the catalytic domain or the hemopexin domain. We further demonstrated that MT1-MMP-induced phenotypic changes were dependent upon up-regulation of Wnt5a, which has been implicated in epithelial-to-mesenchymal transition. We conclude that MT1-MMP plays an important role in early cancer dissemination by converting epithelial cells to migratory mesenchymal-like cells.	[Cao, Jian; Richman, Omer; Zarrabi, Kevin; Kozarekar, Pallavi; Zucker, Stanley] SUNY Stony Brook, Dept Med, Sch Med, Stony Brook, NY 11794 USA; [Chiarelli, Christian; Zucker, Stanley] Vet Adm Med Ctr, Dept Res, Northport, NY 11768 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Cao, J (corresponding author), SUNY Stony Brook, Dept Med, Sch Med, Life Sci Bldg,Rm 004, Stony Brook, NY 11794 USA.	jian.cao@sunysb.edu			NCI NIH HHS [R01 CA 113553-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA113553] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barrett T, 2007, NUCLEIC ACIDS RES, V35, pD760, DOI 10.1093/nar/gkl887; Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5; Cao J, 2005, THROMB HAEMOSTASIS, V93, P770, DOI 10.1160/TH04-08-0555; Cao J, 1998, J BIOL CHEM, V273, P34745, DOI 10.1074/jbc.273.52.34745; Cao J, 2004, J BIOL CHEM, V279, P14129, DOI 10.1074/jbc.M312120200; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Cheng SF, 2003, AM J PATHOL, V162, P1937, DOI 10.1016/S0002-9440(10)64327-1; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Civenni G, 2003, EMBO REP, V4, P166, DOI 10.1038/sj.embor.embor735; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Dhanasekaran SM, 2004, FASEB J, V18, P243, DOI 10.1096/fj.04-2415fje; Dissanayake SK, 2007, J BIOL CHEM, V282, P17259, DOI 10.1074/jbc.M700075200; Dwivedi DJ, 2006, AM J PATHOL, V168, P69, DOI 10.2353/ajpath.2006.041089; Enmon RM, 2002, BIOTECHNOL BIOENG, V80, P580, DOI 10.1002/bit.10394; Even-Ram S, 2005, CURR OPIN CELL BIOL, V17, P524, DOI 10.1016/j.ceb.2005.08.015; Galvez BG, 2002, J CELL BIOL, V159, P509, DOI 10.1083/jcb.200205026; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Hess AR, 2003, CANCER RES, V63, P4757; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Illman SA, 2006, J CELL SCI, V119, P3856, DOI 10.1242/jcs.03157; IOZZO RV, 1995, CANCER RES, V55, P3495; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Klingelhofer J, 2003, ONCOGENE, V22, P1181, DOI 10.1038/sj.onc.1206245; Kurayoshi M, 2006, CANCER RES, V66, P10439, DOI 10.1158/0008-5472.CAN-06-2359; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; McGuire JK, 2003, AM J PATHOL, V162, P1831, DOI 10.1016/S0002-9440(10)64318-0; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Munshi HG, 2004, J BIOL CHEM, V279, P39042, DOI 10.1074/jbc.M404958200; Nie J, 2007, J BIOL CHEM, V282, P6438, DOI 10.1074/jbc.M607337200; Niggemann B, 2004, EXP CELL RES, V298, P178, DOI 10.1016/j.yexcr.2004.04.001; Nishita M, 2006, J CELL BIOL, V175, P555, DOI 10.1083/jcb.200607127; Nusse R, 2005, NATURE, V438, P747, DOI 10.1038/438747a; Pukrop T, 2006, P NATL ACAD SCI USA, V103, P5454, DOI 10.1073/pnas.0509703103; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Ripka S, 2007, CARCINOGENESIS, V28, P1178, DOI 10.1093/carcin/bgl255; Rozanov DV, 2004, EXP CELL RES, V293, P81, DOI 10.1016/j.yexcr.2003.10.006; Sabeh F, 2004, J CELL BIOL, V167, P769, DOI 10.1083/jcb.200408028; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Symowicz J, 2007, CANCER RES, V67, P2030, DOI 10.1158/0008-5472.CAN-06-2808; Taki M, 2003, CANCER SCI, V94, P593, DOI 10.1111/j.1349-7006.2003.tb01488.x; Tester AM, 2001, CLIN EXP METASTAS, V18, P553, DOI 10.1023/A:1011953118186; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tsatas D, 2002, J CLIN NEUROSCI, V9, P282, DOI 10.1054/jocn.2001.1063; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang J, 2006, CANCER RES, V66, P4549, DOI 10.1158/0008-5472.CAN-05-3850; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158; Zucker S, 2000, ONCOGENE, V19, P6642, DOI 10.1038/sj.onc.1204097	58	86	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2008	283	10					6232	6240		10.1074/jbc.M705759200	http://dx.doi.org/10.1074/jbc.M705759200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HM	18174174	hybrid			2022-12-25	WOS:000253779500030
J	Taylor, RP; Parker, GJ; Hazel, MW; Soesanto, Y; Fuller, W; Yazzie, MJ; McClain, DA				Taylor, Rodrick P.; Parker, Glendon J.; Hazel, Mark W.; Soesanto, Yudi; Fuller, William; Yazzie, Marla J.; McClain, Donald A.			Glucose deprivation stimulates O-GlcNAc modification of proteins through up-regulation of O-linked N-acetylglucosaminyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RESISTANCE; GLYCOGEN-SYNTHASE; SKELETAL-MUSCLE; TETRATRICOPEPTIDE REPEATS; HEXOSAMINE BIOSYNTHESIS; SUBSTRATE-SPECIFICITY; TRANSFERASE; STRESS; GLYCOSYLATION; PATHWAY	O-Linked N-acetylglucosamine (O-GlcNAc) is a post-translational modification of proteins that functions as a nutrient sensing mechanism. Here we report on regulation of O-GlcNAcylation over a broad range of glucose concentrations. We have discovered a significant induction of O-GlcNAc modification of a limited number of proteins under conditions of glucose deprivation. Beginning 12 h after treatment, glucose-deprived human hepatocellular carcinoma (HepG2) cells demonstrate a 7.8-fold increase in total O-GlcNAc modification compared with cells cultured in normal glucose (5 mM; p = 0.008). Some of the targets of glucose deprivation-induced O-GlcNAcylation are distinct from those modified in response to high glucose (20 mM) or glucosamine (10 mM) treatment, suggesting differential targeting with glucose deprivation and glucose excess. O-GlcNAcylation of glycogen synthase is significantly increased with glucose deprivation, and this O-GlcNAc increase contributes to a 60% decrease (p = 0.004) in glycogen synthase activity. Increased O-GlcNAc modification is not mediated by increased UDP-GlcNAc, the rate-limiting substrate for O-GlcNAcylation. Rather, the mRNA for nucleocytoplasmic O-linked N-acetylglucosaminyltransferase (OGT) increases 3.4-fold within 6 h of glucose deprivation (p = 0.006). Within 12 h, OGT protein increases 1.7-fold (p = 0.01) compared with normal glucose-treated cells. In addition, 12-h glucose deprivation leads to a 49% decrease in O-GlcNAcase protein levels (p = 0.03). We conclude that increased O-GlcNAc modification stimulated by glucose deprivation results from increased OGT and decreased O-GlcNAcase levels and that these changes affect cell metabolism, thus inactivating glycogen synthase.	[Taylor, Rodrick P.; Soesanto, Yudi; McClain, Donald A.] Univ Utah, Sch Med, Dept Biochem, Div Endocrinol, Salt Lake City, UT 84132 USA; [Taylor, Rodrick P.; Parker, Glendon J.; Hazel, Mark W.; Soesanto, Yudi; Fuller, William; Yazzie, Marla J.; McClain, Donald A.] Univ Utah, Sch Med, Dept Med, Salt Lake City, UT 84132 USA; [McClain, Donald A.] Vet Affairs Med Ctr, Res Serv, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Veterans Health Administration (VHA)	McClain, DA (corresponding author), Univ Utah, Sch Med, Dept Biochem, Div Endocrinol, 30 N 2030 E, Salt Lake City, UT 84132 USA.	donald.mcclain@hsc.utah.edu		McClain, Don/0000-0002-3310-2359; Fuller, William/0000-0002-5883-4433	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043526] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 43526] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Buse MG, 2006, AM J PHYSIOL-ENDOC M, V290, pE1, DOI 10.1152/ajpendo.00329.2005; Cheng XG, 2000, J STEROID BIOCHEM, V75, P147, DOI 10.1016/S0960-0760(00)00167-9; Cooksey RC, 1999, ENDOCRINOLOGY, V140, P1151, DOI 10.1210/en.140.3.1151; Crosson SM, 2003, J CLIN INVEST, V111, P1423, DOI 10.1172/JCI200317975; Gazdag AC, 2000, AM J PHYSIOL-REG I, V278, pR504, DOI 10.1152/ajpregu.2000.278.2.R504; Guinez C, 2006, GLYCOBIOLOGY, V16, P22, DOI 10.1093/glycob/cwj041; Guinez C, 2004, BIOCHEM BIOPH RES CO, V319, P21, DOI 10.1016/j.bbrc.2004.04.144; Guinez C, 2007, BIOCHEM BIOPH RES CO, V361, P414, DOI 10.1016/j.bbrc.2007.07.020; Hanover JA, 2003, ARCH BIOCHEM BIOPHYS, V409, P287, DOI 10.1016/S0003-9861(02)00578-7; Hardie DG, 2003, ENDOCRINOLOGY, V144, P5179, DOI 10.1210/en.2003-0982; Hebert LF, 1996, J CLIN INVEST, V98, P930, DOI 10.1172/JCI118876; Iyer SPN, 2003, J BIOL CHEM, V278, P24608, DOI 10.1074/jbc.M300036200; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; Lefebvre T, 2001, BIOCHEM J, V360, P179, DOI 10.1042/0264-6021:3600179; Love DC, 2003, J CELL SCI, V116, P647, DOI 10.1242/jcs.00246; Lubas WA, 2000, J BIOL CHEM, V275, P10983, DOI 10.1074/jbc.275.15.10983; Lubas WA, 1997, J BIOL CHEM, V272, P9316; Luo B, 2007, J BIOL CHEM, V282, P7172, DOI 10.1074/jbc.M607362200; Marshall S, 2004, J BIOL CHEM, V279, P35313, DOI 10.1074/jbc.M404133200; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; McClain DA, 1996, DIABETES, V45, P1003, DOI 10.2337/diabetes.45.8.1003; Nelson BA, 1997, AM J PHYSIOL-ENDOC M, V272, pE848, DOI 10.1152/ajpendo.1997.272.5.E848; Nolte D, 2002, MAMM GENOME, V13, P62, DOI 10.1007/s00335-001-2108-9; Park KS, 2000, METABOLISM, V49, P962, DOI 10.1053/meta.2000.7717; Parker G, 2004, J BIOL CHEM, V279, P20636, DOI 10.1074/jbc.M312139200; Parker GJ, 2003, J BIOL CHEM, V278, P10022, DOI 10.1074/jbc.M207787200; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROBINSON KA, 1995, DIABETES, V44, P1438, DOI 10.2337/diabetes.44.12.1438; Skurat AV, 2000, DIABETES, V49, P1096, DOI 10.2337/diabetes.49.7.1096; Sohn KC, 2004, BIOCHEM BIOPH RES CO, V322, P1045, DOI 10.1016/j.bbrc.2004.08.023; Walgren JLE, 2003, AM J PHYSIOL-ENDOC M, V284, pE424, DOI 10.1152/ajpendo.00382.2002; Wells L, 2004, J BIOL CHEM, V279, P38466, DOI 10.1074/jbc.M406481200; Yki-Jarvinen H, 1998, METABOLISM, V47, P449, DOI 10.1016/S0026-0495(98)90058-0; Zachara NE, 2004, J BIOL CHEM, V279, P30133, DOI 10.1074/jbc.M403773200; Zachara NE, 2004, BBA-GEN SUBJECTS, V1673, P13, DOI 10.1016/j.bbagen.2004.03.016; Zhang FX, 2003, CELL, V115, P715, DOI 10.1016/S0092-8674(03)00974-7	37	108	113	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2008	283	10					6050	6057		10.1074/jbc.M707328200	http://dx.doi.org/10.1074/jbc.M707328200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HM	18174169	hybrid			2022-12-25	WOS:000253779500010
J	Trape, S				Trape, Sebastien			Shark Attacks in Dakar and the Cap Vert Peninsula, Senegal: Low Incidence despite High Occurrence of Potentially Dangerous Species	PLOS ONE			English	Article								Background. The International Shark Attack File mentions only four unprovoked shark attacks on the coast of West Africa during the period 1828-2004, an area where high concentrations of sharks and 17 species potentially dangerous to man have been observed. To investigate if the frequency of shark attacks could be really low and not just under-reported and whether there are potentially sharks that might attack in the area, a study was carried out in Dakar and the Cap Vert peninsula, Senegal. Methodology/Principal Findings. Personnel of health facilities, administrative services, traditional authorities and groups of fishermen from the region of Dakar were interviewed about the occurrence of shark attacks, and visual censuses were conducted along the coastline to investigate shark communities associated with the coasts of Dakar and the Cap Vert peninsula. Six attacks were documented for the period 1947-2005, including two fatal ones attributed to the tiger shark Galeocerdo cuvieri. All attacks concerned fishermen and only one occurred after 1970. Sharks were observed year round along the coastline in waters 3-15 m depth. Two species potentially dangerous for man, the nurse shark Ginglymostoma cirratum and the blacktip shark Carcharhinus limbatus, represented together 94% of 1,071 sharks enumerated during 1,459 hours of observations. Threatening behaviour from sharks was noted in 12 encounters (1.1%), including 8 encounters with C. limbatus, one with Galeocerdo cuvieri and 3 with unidentified sharks. Conclusions/Significance. These findings suggest that the frequency of shark attacks on the coast of West Africa is underestimated. However, they also indicate that the risk is very low despite the abundance of sharks. In Dakar area, most encounters along the coastline with potentially dangerous species do not result in an attack. Compared to other causes of water related deaths, the incidence of shark attack appears negligible, at least one thousand fold lower.	[Trape, Sebastien] IRD, Unite Rech 070, Dakar, Senegal; [Trape, Sebastien] Univ Montpellier, Lab ECOLAG, Unit Mixte Rech 5119, Montpellier, France	Institut de Recherche pour le Developpement (IRD); Universite de Montpellier	Trape, S (corresponding author), IRD, Unite Rech 070, Dakar, Senegal.	sebastien_trape@yahoo.fr						BALDRIDGE HD, 1988, CALIF FISH GAME, V74, P208; BALDRIDGE HD, 1974, SHARK ATTACK; BLACHE J, 1970, CLES DETERMINATION P; BURGESS GH, 1990, DISCOVERING SHARKS, P101; Cadenat J., 1950, Bull Inst franc Afr noire, V12, P944; Cadenat J., 1957, Bull Inst franY Afr N, V19B, P274; CADENAT J, 1981, REQUINS MEDITERRANEE; Cadenat J, 1950, POISSONS MER SENEGAL; Caldicott DGE, 2001, INJURY, V32, P445, DOI 10.1016/S0020-1383(01)00041-9; Chauveau JP., 1989, CAHIERS SCI HUMAINES, V25, P237; CHAVANCE P, 2006, COMMISSION EUROPEENN, V1; Compagno L. J. V., 2001, ANNOTATED ILLUSTRATE, V2; COMPAGNO LJV, 1984, FAO FISHERIES SYNO 2, V125; COMPAGNO LJV, 1984, FAO FISHERIES SYNO 1, V125; DEJOU D, 1948, B MED AOF, V5, P23; MANIGUET X, 1991, DENTS MORT; *MIN EC FIN, 2006, DIR PREV STAT; REBERT JP, 1977, ATLAS NATL SENEGAL, P36; Seret B., 1990, POISSONS MER OUEST A; STEVENS JD, 1987, SHARKS	20	7	8	0	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2008	3	1							e1495	10.1371/journal.pone.0001495	http://dx.doi.org/10.1371/journal.pone.0001495			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SR	18231582	Green Published, gold, Green Submitted			2022-12-25	WOS:000260504200008
J	Valles, Y; Halanych, KM; Boore, JL				Valles, Yvonne; Halanych, Kenneth M.; Boore, Jeffrey L.			Group II Introns Break New Boundaries: Presence in a Bilaterian's Genome	PLOS ONE			English	Article								Group II introns are ribozymes, removing themselves from their primary transcripts, as well as mobile genetic elements, transposing via an RNA intermediate, and are thought to be the ancestors of spliceosomal introns. Although common in bacteria and most eukaryotic organelles, they have never been reported in any bilaterian animal genome, organellar or nuclear. Here we report the first group II intron found in the mitochondrial genome of a bilaterian worm. This location is especially surprising, since animal mitochondrial genomes are generally distinct from those of plants, fungi, and protists by being small and compact, and so are viewed as being highly streamlined, perhaps as a result of strong selective pressures for fast replication while establishing germ plasm during early development. This intron is found in the mtDNA of an annelid worm, (an undescribed species of Nephtys), where the complete sequence revealed a 1819 bp group II intron inside the cox1 gene. We infer that this intron is the result of a recent horizontal gene transfer event from a viral or bacterial vector into the mitochondrial genome of Nephtys sp. Our findings hold implications for understanding mechanisms, constraints, and selective pressures that account for patterns of animal mitochondrial genome evolution	[Valles, Yvonne; Boore, Jeffrey L.] Joint Genome Inst, Dept Energy DOE, Walnut Creek, CA USA; [Valles, Yvonne; Boore, Jeffrey L.] Univ Calif Berkley, Dept Integrat Biol, Berkeley, CA USA; [Halanych, Kenneth M.] Auburn Univ, Life Sci Dept, Auburn, AL USA; [Boore, Jeffrey L.] Genome Proj Solution, Hercules, CA USA	United States Department of Energy (DOE); Joint BioEnergy Institute - JBEI; Joint Genome Institute - JGI; University of California System; University of California Berkeley; Auburn University System; Auburn University	Boore, JL (corresponding author), Joint Genome Inst, Dept Energy DOE, Walnut Creek, CA USA.	JLBoore@Genome-ProjectSolutions.com	Halanych, Ken M/A-9480-2009; Valles, Yvonne/AAC-9380-2019	Halanych, Ken M/0000-0002-8658-9674; Valles, Yvonne/0000-0002-5435-4504	U.S. National Science Foundation [EAR-0120646]; U. S. Department of Energy's Office of Science, Biological and Environmental Research Program; University of California, Lawrence Berkeley National Laboratory [DE-AC02-05CH11231]	U.S. National Science Foundation(National Science Foundation (NSF)); U. S. Department of Energy's Office of Science, Biological and Environmental Research Program; University of California, Lawrence Berkeley National Laboratory(University of California System)	This study was supported by a grant from the U.S. National Science Foundation EAR-0120646 (to KMH and JLB). Part of this work was performed under the auspices of the U. S. Department of Energy's Office of Science, Biological and Environmental Research Program, and by the University of California, Lawrence Berkeley National Laboratory under Contract No. DE-AC02-05CH11231.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANDRE C, 1992, TRENDS GENET, V8, P128, DOI 10.1016/0168-9525(92)90370-J; Beagley CT, 1998, GENETICS, V148, P1091; Belfort M, 2002, MOBILE DNA; Bonen L, 2001, TRENDS GENET, V17, P322, DOI 10.1016/S0168-9525(01)02324-1; Boore JL, 1999, NUCLEIC ACIDS RES, V27, P1767, DOI 10.1093/nar/27.8.1767; Castresana J, 2000, MOL BIOL EVOL, V17, P540, DOI 10.1093/oxfordjournals.molbev.a026334; Clark M. E., 1962, Zoologische Jahrbuecher (Allgemeine Zoologie), V70, P24; CLARK ME, 1968, J MORPHOL, V124, P483, DOI 10.1002/jmor.1051240406; Dai LX, 2003, NUCLEIC ACIDS RES, V31, P424, DOI 10.1093/nar/gkg049; Dellaporta SL, 2006, P NATL ACAD SCI USA, V103, P8751, DOI 10.1073/pnas.0602076103; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Foley S, 2000, J VIROL, V74, P611, DOI 10.1128/JVI.74.2.611-618.2000; Folmer O., 1994, Molecular Marine Biology and Biotechnology, V3, P294; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Gray MW, 1999, SCIENCE, V283, P1476, DOI 10.1126/science.283.5407.1476; Haugen P, 2005, TRENDS GENET, V21, P111, DOI 10.1016/j.tig.2004.12.007; KNOOP V, 1994, J MOL BIOL, V242, P389, DOI 10.1006/jmbi.1994.1589; Kondo N, 2002, P NATL ACAD SCI USA, V99, P14280, DOI 10.1073/pnas.222228199; Lambowitz AM, 2004, ANNU REV GENET, V38, P1, DOI 10.1146/annurev.genet.38.072902.091600; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; Lehmann K, 2003, CRIT REV BIOCHEM MOL, V38, P249, DOI 10.1080/713609236; Lynch M, 2003, SCIENCE, V302, P1401, DOI 10.1126/science.1089370; Lynch M, 2006, SCIENCE, V311, P1727, DOI 10.1126/science.1118884; Medina M, 2006, P NATL ACAD SCI USA, V103, P9096, DOI 10.1073/pnas.0602444103; Morgenstern B, 1999, BIOINFORMATICS, V15, P211, DOI 10.1093/bioinformatics/15.3.211; Palmer JD, 2000, P NATL ACAD SCI USA, V97, P6960, DOI 10.1073/pnas.97.13.6960; Palmer JD, 1991, CURR OPIN GENET DEV, V1, P470, DOI 10.1016/S0959-437X(05)80194-7; Pontes MH, 2006, TRENDS MICROBIOL, V14, P406, DOI 10.1016/j.tim.2006.07.004; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; Robart AR, 2005, CYTOGENET GENOME RES, V110, P589, DOI 10.1159/000084992; Rot C, 2006, BMC EVOL BIOL, V6, DOI 10.1186/1471-2148-6-71; Shearer TL, 2002, MOL ECOL, V11, P2475, DOI 10.1046/j.1365-294X.2002.01652.x; Stamatakis A, 2005, BIOINFORMATICS, V21, P456, DOI 10.1093/bioinformatics/bti191; Swofford D. L., 2011, PAUP PHYLOGENETIC AN; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; van Oppen MJH, 1999, P ROY SOC B-BIOL SCI, V266, P179, DOI 10.1098/rspb.1999.0619; Wyman SK, 2004, BIOINFORMATICS, V20, P3252, DOI 10.1093/bioinformatics/bth352; YAMADA T, 1994, NUCLEIC ACIDS RES, V22, P2532, DOI 10.1093/nar/22.13.2532; Zimmerly S, 2001, NUCLEIC ACIDS RES, V29, P1238, DOI 10.1093/nar/29.5.1238; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	41	63	64	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2008	3	1							e1488	10.1371/journal.pone.0001488	http://dx.doi.org/10.1371/journal.pone.0001488			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SO	18213396	gold, Green Published, Green Submitted			2022-12-25	WOS:000260503900033
J	Kubica, M; Guzik, K; Koziel, J; Zarebski, M; Richter, W; Gajkowska, B; Golda, A; Maciag-Gudowska, A; Brix, K; Shaw, L; Foster, T; Potempa, J				Kubica, Malgorzata; Guzik, Krzysztof; Koziel, Joanna; Zarebski, Miroslaw; Richter, Walter; Gajkowska, Barbara; Golda, Anna; Maciag-Gudowska, Agnieszka; Brix, Klaudia; Shaw, Les; Foster, Timothy; Potempa, Jan			A Potential New Pathway for Staphylococcus aureus Dissemination: The Silent Survival of S. aureus Phagocytosed by Human Monocyte-Derived Macrophages	PLOS ONE			English	Article							FIBRONECTIN-BINDING PROTEINS; TOXIN INDUCES APOPTOSIS; ALPHA-TOXIN; IN-VITRO; LISTERIA-MONOCYTOGENES; ALVEOLAR MACROPHAGES; HUMAN KERATINOCYTES; CELLULAR INVASION; VIRULENCE FACTORS; AGR	Although considered to be an extracellular pathogen, Staphylococcus aureus is able to invade a variety of mammalian, nonprofessional phagocytes and can also survive engulfment by professional phagocytes such as neutrophils and monocytes. In both of these cell types S. aureus promptly escapes from the endosomes/phagosomes and proliferates within the cytoplasm, which quickly leads to host cell death. In this report we show that S. aureus interacted with human monocyte-derived macrophages in a very different way to those of other mammalian cells. Upon phagocytosis by macrophages, S. aureus persisted intracellularly in vacuoles for 3-4 days before escaping into the cytoplasm and causing host cell lysis. Until the point of host cell lysis the infected macrophages showed no signs of apoptosis or necrosis and were functional. They were able to eliminate intracellular staphylococci if prestimulated with interferon-gamma at concentrations equivalent to human therapeutic doses. S. aureus survival was dependent on the alternative sigma factor B as well as the global regulator agr, but not SarA. Furthermore, isogenic mutants deficient in alpha-toxin, the metalloprotease aureolysin, protein A, and sortase A were efficiently killed by macrophages upon phagocytosis, although with different kinetics. In particular alpha-toxin was a key effector molecule that was essential for S. aureus intracellular survival in macrophages. Together, our data indicate that the ability of S. aureus to survive phagocytosis by macrophages is determined by multiple virulence factors in a way that differs considerably from its interactions with other cell types. S. aureus persists inside macrophages for several days without affecting the viability of these mobile cells which may serve as vehicles for the dissemination of infection.	[Guzik, Krzysztof] Jagiellonian Univ, Fac Biochem, Dept Immunol, Krakow, Poland; [Zarebski, Miroslaw] Jagiellonian Univ, Fac Biochem Biophys Biotechnol, Dept Cell Biophys, Krakow, Poland; [Richter, Walter] Friedrich Schiller Univ Jena, Med Fac, Ctr Electron Microscopy, Jena, Germany; [Gajkowska, Barbara] Polish Acad Sci, Med Res Ctr, Dept Cell Ultrastructure, Warsaw, Poland; [Brix, Klaudia] Jacobs Univ Bremen, Sch Engn & Sci, Bremen, Germany; [Shaw, Les] Univ South Forida, Dept Biol, Tampa, FL USA; [Foster, Timothy] Trinity Coll Dublin, Moyne Inst Prevent Med, Dept Microbiol, Dublin, Ireland; [Koziel, Joanna; Golda, Anna; Maciag-Gudowska, Agnieszka; Potempa, Jan] Jagiellonian Univ, Fac Biochem Biophys & Biotechnol, Dept Microbiol, Krakow, Poland	Jagiellonian University; Jagiellonian University; Friedrich Schiller University of Jena; Polish Academy of Sciences; Jacobs University; State University System of Florida; University of South Florida; Trinity College Dublin; Jagiellonian University	Kubica, M (corresponding author), Jagiellonian Univ, Fac Biochem Biophys & Biotechnol, Dept Microbiol, Krakow, Poland.	staphaureus@gmail.com; kaniajoanna@gmail.com	Shaw, Lindsey/AAI-1741-2020; Potempa, Jan/AAA-6850-2021; Brix, Klaudia/F-5072-2013	Shaw, Lindsey/0000-0002-0629-8990; Brix, Klaudia/0000-0002-4476-0357	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABDELNOUR A, 1993, INFECT IMMUN, V61, P3879, DOI 10.1128/IAI.61.9.3879-3885.1993; Agerer F, 2005, J CELL SCI, V118, P2189, DOI 10.1242/jcs.02328; Alexander EH, 2003, BMC MICROBIOL, V3, DOI 10.1186/1471-2180-3-5; Ali F, 2003, J INFECT DIS, V188, P1119, DOI 10.1086/378675; Amer AO, 2002, CURR OPIN MICROBIOL, V5, P56, DOI 10.1016/S1369-5274(02)00286-2; Archer GL, 1998, CLIN INFECT DIS, V26, P1179, DOI 10.1086/520289; Bantel H, 2001, J CELL BIOL, V155, P637, DOI 10.1083/jcb.200105081; Baran J, 2001, INFECT IMMUN, V69, P1287, DOI 10.1128/IAI.69.3.1287-1297.2001; BAUGHN RE, 1975, INFECT IMMUN, V12, P346, DOI 10.1128/IAI.12.2.346-352.1975; Bayles KW, 1998, INFECT IMMUN, V66, P336, DOI 10.1128/IAI.66.1.336-342.1998; Bellingan GJ, 1996, J IMMUNOL, V157, P2577; Bischoff M, 2004, J BACTERIOL, V186, P4085, DOI 10.1128/JB.186.13.4085-4099.2004; Bischoff M, 2001, J BACTERIOL, V183, P5171, DOI 10.1128/JB.183.17.5171-5179.2001; Booth MC, 1997, INFECT IMMUN, V65, P1550, DOI 10.1128/IAI.65.4.1550-1556.1997; Bronner S, 2004, FEMS MICROBIOL REV, V28, P183, DOI 10.1016/j.femsre.2003.09.003; Burlak C, 2007, CELL MICROBIOL, V9, P1172, DOI 10.1111/j.1462-5822.2006.00858.x; Cheung AL, 2004, FEMS IMMUNOL MED MIC, V40, P1, DOI 10.1016/S0928-8244(03)00309-2; CHEUNG AL, 1994, J CLIN INVEST, V94, P1815, DOI 10.1172/JCI117530; Clement S, 2005, J INFECT DIS, V192, P1023, DOI 10.1086/432735; da Silva MCA, 2004, AM J PHYSIOL-LUNG C, V287, pL543, DOI 10.1152/ajplung.00256.2003; Decker T, 2005, NAT REV IMMUNOL, V5, P675, DOI 10.1038/nri1684; Drevets DA, 1999, INFECT IMMUN, V67, P3512, DOI 10.1128/IAI.67.7.3512-3517.1999; Dunman PM, 2001, J BACTERIOL, V183, P7341, DOI 10.1128/JB.183.24.7341-7353.2001; Dziewanowska K, 1999, INFECT IMMUN, V67, P4673, DOI 10.1128/IAI.67.9.4673-4678.1999; ELLIOTT GR, 1982, ANTIMICROB AGENTS CH, V22, P781, DOI 10.1128/AAC.22.5.781; Esen M, 2001, APOPTOSIS, V6, P431, DOI 10.1023/A:1012445925628; Foster TJ, 2005, NAT REV MICROBIOL, V3, P948, DOI 10.1038/nrmicro1289; Foster TJ, 1998, TRENDS MICROBIOL, V6, P484, DOI 10.1016/S0966-842X(98)01400-0; Fowler T, 2003, CELL MICROBIOL, V5, P417, DOI 10.1046/j.1462-5822.2003.00290.x; Fowler T, 2000, EUR J CELL BIOL, V79, P672, DOI 10.1078/0171-9335-00104; Giachino P, 2001, J BACTERIOL, V183, P1843, DOI 10.1128/JB.183.6.1843-1852.2001; Gomez MI, 2004, NAT MED, V10, P842, DOI 10.1038/nm1079; Gresham HD, 2000, J IMMUNOL, V164, P3713, DOI 10.4049/jimmunol.164.7.3713; Gruenberg J, 2006, NAT REV MOL CELL BIO, V7, P495, DOI 10.1038/nrm1959; Grundmeier M, 2004, INFECT IMMUN, V72, P7155, DOI 10.1128/IAI.72.12.7155-7163.2004; Guzik K, 2007, CELL DEATH DIFFER, V14, P171, DOI 10.1038/sj.cdd.4401927; HARMSEN AG, 1985, SCIENCE, V230, P1277, DOI 10.1126/science.4071052; Haslinger B, 2003, CELL MICROBIOL, V5, P729, DOI 10.1046/j.1462-5822.2003.00317.x; Haslinger-Loffler B, 2006, KIDNEY INT, V70, P1089, DOI 10.1038/sj.ki.5001710; Haslinger-Loffler B, 2005, CELL MICROBIOL, V7, P1087, DOI 10.1111/j.1462-5822.2005.00533.x; Hebert A, 2000, FEMS MICROBIOL LETT, V193, P57, DOI 10.1016/S0378-1097(00)00455-9; Henry-Stanley MJ, 2003, J SURG RES, V113, P42, DOI 10.1016/S0022-4804(03)00156-2; Horsburgh MJ, 2002, J BACTERIOL, V184, P5457, DOI 10.1128/JB.184.19.5457-5467.2002; JAKAB GJ, 1976, J CLIN INVEST, V57, P1533, DOI 10.1172/JCI108423; Join-Lambert OF, 2005, CELL MICROBIOL, V7, P167, DOI 10.1111/j.1462-5822.2004.00444.x; JONAS D, 1994, INFECT IMMUN, V62, P1304, DOI 10.1128/IAI.62.4.1304-1312.1994; KAPRAL FA, 1959, J EXP MED, V110, P123, DOI 10.1084/jem.110.1.123; KARNOVSKY MJ, 1965, J CELL BIOL, V27, pA137; Koterski JF, 2005, INFECT IMMUN, V73, P504, DOI 10.1128/IAI.73.1.504-513.2005; Lindsay JA, 2004, TRENDS MICROBIOL, V12, P378, DOI 10.1016/j.tim.2004.06.004; Liu GY, 2005, J EXP MED, V202, P209, DOI 10.1084/jem.20050846; LOWY FD, 1988, J ULTRA MOL STRUCT R, V98, P137, DOI 10.1016/S0889-1605(88)80906-6; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; MELLY MA, 1960, J EXP MED, V112, P1121, DOI 10.1084/jem.112.6.1121; Mempel M, 2002, BRIT J DERMATOL, V146, P943, DOI 10.1046/j.1365-2133.2002.04752.x; Menzies BE, 1998, INFECT IMMUN, V66, P5994, DOI 10.1128/IAI.66.12.5994-5998.1998; Menzies BE, 2000, FEMS IMMUNOL MED MIC, V29, P39, DOI 10.1016/S0928-8244(00)00185-1; Michailova L, 2000, INT J MED MICROBIOL, V290, P259; Monack DM, 1997, P NATL ACAD SCI USA, V94, P10385, DOI 10.1073/pnas.94.19.10385; Monack DM, 1996, P NATL ACAD SCI USA, V93, P9833, DOI 10.1073/pnas.93.18.9833; Nair SP, 2003, INFECT IMMUN, V71, P4167, DOI 10.1128/IAI.71.7.4167-4170.2003; Novick RP, 2003, MOL MICROBIOL, V48, P1429, DOI 10.1046/j.1365-2958.2003.03526.x; Nuzzo I, 2000, FEMS IMMUNOL MED MIC, V27, P235, DOI 10.1111/j.1574-695X.2000.tb01435.x; Peacock SJ, 1999, MICROBIOL-SGM, V145, P3477, DOI 10.1099/00221287-145-12-3477; Petti Cathy A., 2003, Cardiology Clinics, V21, P219, DOI 10.1016/S0733-8651(03)00030-4; Proctor RA, 2006, NAT REV MICROBIOL, V4, P295, DOI 10.1038/nrmicro1384; Qazi SNA, 2001, INFECT IMMUN, V69, P7074, DOI 10.1128/IAI.69.11.7074-7082.2001; ROGERS DE, 1952, J EXP MED, V95, P209, DOI 10.1084/jem.95.2.209; Rosenberger CM, 2003, NAT REV MOL CELL BIO, V4, P385, DOI 10.1038/nrm1104; Russell DG, 2007, NAT REV MICROBIOL, V5, P39, DOI 10.1038/nrmicro1538; Sabat A, 2003, J CLIN MICROBIOL, V41, P1801, DOI 10.1128/JCM.41.4.1801-1804.2003; SAVILL J, 1994, IMMUNOPHARMACOLOGY N, P295; Schnaith A, 2007, J BIOL CHEM, V282, P2695, DOI 10.1074/jbc.M609784200; Shaw L, 2004, MICROBIOL-SGM, V150, P217, DOI 10.1099/mic.0.26634-0; Shaw LN, 2006, J BACTERIOL, V188, P6070, DOI 10.1128/JB.00551-06; Shompole S, 2003, MOL MICROBIOL, V49, P919, DOI 10.1046/j.1365-2958.2003.03618.x; Sinha B, 1999, CELL MICROBIOL, V1, P101, DOI 10.1046/j.1462-5822.1999.00011.x; Staali L, 2006, CELL MICROBIOL, V8, P690, DOI 10.1111/j.1462-5822.2005.00662.x; Stuart LM, 2005, IMMUNITY, V22, P539, DOI 10.1016/j.immuni.2005.05.002; Stuart LM, 2005, J CELL BIOL, V170, P477, DOI 10.1083/jcb.200501113; Sun GW, 2005, CELL MICROBIOL, V7, P1447, DOI 10.1111/j.1462-5822.2005.00569.x; Underhill DM, 2002, ANNU REV IMMUNOL, V20, P825, DOI 10.1146/annurev.immunol.20.103001.114744; Voyich JA, 2005, J IMMUNOL, V175, P3907, DOI 10.4049/jimmunol.175.6.3907; Weglarczyk K, 2004, INFECT IMMUN, V72, P2590, DOI 10.1128/IAI.72.5.2590-2597.2004; Wesson CA, 1998, INFECT IMMUN, V66, P5238, DOI 10.1128/IAI.66.11.5238-5243.1998; Zetola N, 2005, LANCET INFECT DIS, V5, P275, DOI 10.1016/S1473-3099(05)70112-2; ZYCHLINSKY A, 1992, NATURE, V358, P167, DOI 10.1038/358167a0	87	305	317	2	58	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2008	3	1							e1409	10.1371/journal.pone.0001409	http://dx.doi.org/10.1371/journal.pone.0001409			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366GT	18183290	gold, Green Submitted, Green Published			2022-12-25	WOS:000260469400006
J	Schaefer, M; Steringer, JP; Lyko, F				Schaefer, Matthias; Steringer, Julia P.; Lyko, Frank			The Drosophila Cytosine-5 Methyltransferase Dnmt2 Is Associated with the Nuclear Matrix and Can Access DNA during Mitosis	PLOS ONE			English	Article							ENTAMOEBA-HISTOLYTICA; SPINDLE MATRIX; GAMMA-TUBULIN; NUMB PROTEIN; RNA; METHYLATION; LOCALIZATION; CELLS; EXPRESSION; SKELETOR	Cytosine-5 methyltransferases of the Dnmt2 family are highly conserved in evolution and their biological function is being studied in several organisms. Although all structural DNA methyltransferase motifs are present in Dnmt2, these enzymes show a strong tRNA methyltransferase activity. In line with an enzymatic activity towards substrates other than DNA, Dnmt2 has been described to localize to the cytoplasm. Using molecular and biochemical approaches we show here that Dnmt2 is both a cytoplasmic and a nuclear protein. Sub-cellular fractionation shows that a significant amount of Dnmt2 is bound to the nuclear matrix. Sub-cellular localization analysis reveals that Dnmt2 proteins are enriched in actively dividing cells. Dnmt2 localization is highly dynamic during the cell cycle. Using live imaging we observed that Dnmt2-EGFP enters prophase nuclei and shows a spindle-like localization pattern during mitotic divisions. Additional experiments suggest that this localization is microtubule dependent and that Dnmt2 can access DNA during mitotic cell divisions. Our results represent the first comprehensive characterization of Dnmt2 proteins on the cellular level and have important implications for our understanding of the molecular activities of Dnmt2.	[Schaefer, Matthias; Steringer, Julia P.; Lyko, Frank] Deutsch Krebsforschungszentrum, Div Epigenet, D-6900 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Lyko, F (corresponding author), Deutsch Krebsforschungszentrum, Div Epigenet, D-6900 Heidelberg, Germany.	f.lyko@dkfz.de	Matthias, Schaefer Ronald/E-9157-2015	Matthias, Schaefer Ronald/0000-0003-1952-8115	Deutsche Forschungsgemeinschaft [SCHA 1267/2-1]; Priority Programme Epigenetics	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Priority Programme Epigenetics	This work was supported by grants from the Deutsche Forschungsgemeinschaft (SCHA 1267/2-1 and Priority Programme Epigenetics).	Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; Banerjee S, 2005, MOL BIOCHEM PARASIT, V139, P91, DOI 10.1016/j.molbiopara.2004.10.003; Banerjee S, 2003, MOL BIOCHEM PARASIT, V126, P35, DOI 10.1016/S0166-6851(02)00244-X; Belmont AS, 2002, P NATL ACAD SCI USA, V99, P15855, DOI 10.1073/pnas.262672799; Bertrand E, 1998, GENE DEV, V12, P2463, DOI 10.1101/gad.12.16.2463; BRAND AH, 1993, DEVELOPMENT, V118, P401; Cotter L, 2007, J MOL BIOL, V369, P683, DOI 10.1016/j.jmb.2007.03.051; Dong AP, 2001, NUCLEIC ACIDS RES, V29, P439, DOI 10.1093/nar/29.2.439; Fisher O, 2004, NUCLEIC ACIDS RES, V32, P287, DOI 10.1093/nar/gkh161; Frye M, 2006, CURR BIOL, V16, P971, DOI 10.1016/j.cub.2006.04.027; Goll MG, 2006, SCIENCE, V311, P395, DOI 10.1126/science.1120976; Hermann A, 2003, J BIOL CHEM, V278, P31717, DOI 10.1074/jbc.M305448200; Huang JY, 1999, EMBO J, V18, P2184, DOI 10.1093/emboj/18.8.2184; Hung MS, 1999, P NATL ACAD SCI USA, V96, P11940, DOI 10.1073/pnas.96.21.11940; Inano K, 2000, J BIOCHEM-TOKYO, V128, P315, DOI 10.1093/oxfordjournals.jbchem.a022755; Jeltsch A, 2006, TRENDS BIOCHEM SCI, V31, P306, DOI 10.1016/j.tibs.2006.04.005; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008; Knoblich JA, 1997, P NATL ACAD SCI USA, V94, P13005, DOI 10.1073/pnas.94.24.13005; Kuhlmann M, 2005, NUCLEIC ACIDS RES, V33, P6405, DOI 10.1093/nar/gki952; Kunert N, 2003, DEVELOPMENT, V130, P5083, DOI 10.1242/dev.00716; LAM YW, 2006, CELL BIOL LAB HDB, P103; LIAU MC, 1975, BIOCHEMISTRY-US, V14, P127, DOI 10.1021/bi00672a022; Lyko F, 2000, MECH DEVELOP, V95, P215, DOI 10.1016/S0925-4773(00)00325-7; Moritz M, 1998, J CELL BIOL, V142, P775, DOI 10.1083/jcb.142.3.775; Okano M, 1998, NUCLEIC ACIDS RES, V26, P2536, DOI 10.1093/nar/26.11.2536; PATRIOTIS C, 1990, J CELL SCI, V95, P667; RAFF JW, 1993, J CELL BIOL, V121, P823, DOI 10.1083/jcb.121.4.823; Rai K, 2007, GENE DEV, V21, P261, DOI 10.1101/gad.1472907; Rath U, 2004, J CELL BIOCHEM, V93, P1033, DOI 10.1002/jcb.20243; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; RIEMER D, 1995, J CELL SCI, V108, P3189; Rozenski J, 1999, NUCLEIC ACIDS RES, V27, P196, DOI 10.1093/nar/27.1.196; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SAITOH Y, 1994, CELL, V76, P609, DOI 10.1016/0092-8674(94)90502-9; Sakita-Suto S, 2007, MOL BIOL CELL, V18, P1107, DOI 10.1091/mbc.E06-11-1021; Schuh M, 2007, CURR BIOL, V17, P237, DOI 10.1016/j.cub.2006.11.051; SHAFFER CD, 1994, METHOD CELL BIOL, V44, P185, DOI 10.1016/S0091-679X(08)60913-9; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Thompson M, 2003, SCIENCE, V302, P1399, DOI 10.1126/science.1089814; Walker DL, 2000, J CELL BIOL, V151, P1401, DOI 10.1083/jcb.151.7.1401; Wasser M, 2000, NAT CELL BIOL, V2, P268, DOI 10.1038/35010535; Webb C, 1999, COLD SPRING HARB SYM, V64, P109, DOI 10.1101/sqb.1999.64.109; Yoder JA, 1998, HUM MOL GENET, V7, P279, DOI 10.1093/hmg/7.2.279	44	29	31	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2008	3	1							e1414	10.1371/journal.pone.0001414	http://dx.doi.org/10.1371/journal.pone.0001414			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366GT	18183295	gold, Green Published, Green Submitted			2022-12-25	WOS:000260469400011
J	Abubaker, J; Bavi, P; Al-Harbi, S; Ibrahim, M; Siraj, AK; Al-Sanea, N; Abduljabbar, A; Ashari, LH; Alhomoud, S; Al-Dayel, F; Uddin, S; Al-Kuraya, KS				Abubaker, J.; Bavi, P.; Al-Harbi, S.; Ibrahim, M.; Siraj, A. K.; Al-Sanea, N.; Abduljabbar, A.; Ashari, L. H.; Alhomoud, S.; Al-Dayel, F.; Uddin, S.; Al-Kuraya, K. S.			Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population	ONCOGENE			English	Article						PIK3CA; MSI; PTEN; colorectal cancer	B-CELL LYMPHOMA; BREAST-CANCER; PHOSPHOINOSITIDE 3-KINASE; PTEN MUTATIONS; SAUDI-ARABIA; PATHWAY; GENE; EXPRESSION; PREVALENCE; CARCINOMAS	Activation of the phosphatidylinositol 3'-kinase (PI3K)/AKT pathway results in an increase in cell proliferation and survival. Somatic mutations within the PI3K catalytic subunit, PIK3CA are common cause of increasing PI3K activity and are believed to be oncogenic in many cancer types. Few reports addressed the association between PIK3CA mutations and tumor progression specifically in microsatellite instable (MSI) colorectal cancer (CRC). In the present study, we have evaluated PIK3CA mutational status in a series of 410 Middle Eastern CRC and 13 colon cell lines to study the prevalence of PIK3CA mutations in MSI cases, PTEN expression in CRC and possibility of therapeutic targeting of this set of patients. PIK3CA mutations were found in four of the cell lines tested and 51 colorectal carcinomas (12.2%). Three of these four mutated cell lines were MSI. PTEN was inactivated in 66.1% of the CRC. Furthermore, we observed a strong association between PIK3CA mutations and MSI status (P = 0.0046) while PTEN loss was more frequent in microsatellite stable (MSS) CRC (P = 0.043). A high prevalence of genetic alterations in PI3K/AKT pathway in Saudi cohort of CRC, predominance of PIK3CA mutations in the MSI subgroup and their possible involvement in development/progression of this subset of CRC are some of the significant findings of our study.	[Abubaker, J.; Bavi, P.; Al-Harbi, S.; Ibrahim, M.; Siraj, A. K.; Uddin, S.; Al-Kuraya, K. S.] King Faisal Specialist Hosp & Res Ctr, Dept Human Canc Genom Res, King Fahad Natl Ctr Childrens Canc & Res, Riyadh 11211, Saudi Arabia; [Al-Sanea, N.; Abduljabbar, A.; Ashari, L. H.; Alhomoud, S.] King Faisal Specialist Hosp & Res Ctr, Dept Colorectal Surg, Riyadh 11211, Saudi Arabia; [Al-Dayel, F.] King Faisal Specialist Hosp & Res Ctr, Dept Pathol, Riyadh 11211, Saudi Arabia	King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center	Al-Kuraya, KS (corresponding author), King Faisal Specialist Hosp & Res Ctr, Dept Human Canc Genom Res, King Fahad Natl Ctr Childrens Canc & Res, MBC 98-16,POB 3354, Riyadh 11211, Saudi Arabia.	kkuraya@kfshrc.edu.sa	Bavi, Prashant/B-2123-2009; Al-Sanea, Nasser AN/J-1565-2016	Bavi, Prashant/0000-0002-7711-2911; Al-Sanea, Nasser AN/0000-0002-6336-5942; Uddin, Shahab/0000-0003-1886-6710; Abubaker, Jehad/0000-0003-0681-7305				Abbott RT, 2003, MODERN PATHOL, V16, P607, DOI 10.1097/01.MP.0000067423.83712.74; Abubaker J, 2007, LEUKEMIA, V21, P2368, DOI 10.1038/sj.leu.2404873; Bader AG, 2005, NAT REV CANCER, V5, P921, DOI 10.1038/nrc1753; Bavi P, 2006, CANCER EPIDEM BIOMAR, V15, P1708, DOI 10.1158/1055-9965.EPI-05-0972; Boland CR, 1998, CANCER RES, V58, P5248; Bose S, 2006, MODERN PATHOL, V19, P238, DOI 10.1038/modpathol.3800525; Bose S, 2002, HUM PATHOL, V33, P405, DOI 10.1053/hupa.2002.124721; Bray F, 2002, EUR J CANCER, V38, P99, DOI 10.1016/S0959-8049(01)00350-1; Broderick DK, 2004, CANCER RES, V64, P5048, DOI 10.1158/0008-5472.CAN-04-1170; Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; ELHAZMI MAF, 1995, J MED GENET, V32, P623, DOI 10.1136/jmg.32.8.623; Frattini M, 2005, CANCER RES, V65, P11227, DOI 10.1158/0008-5472.CAN-05-2780; Garcia Z, 2006, EMBO J, V25, P655, DOI 10.1038/sj.emboj.7600967; Isbister WH, 2000, AUST NZ J SURG, V70, P269, DOI 10.1046/j.1440-1622.2000.01805.x; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Lee JW, 2005, ONCOGENE, V24, P1477, DOI 10.1038/sj.onc.1208304; Levine DA, 2005, CLIN CANCER RES, V11, P2875, DOI 10.1158/1078-0432.CCR-04-2142; Li VSW, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-29; Maruyama N, 2007, CLIN CANCER RES, V13, P408, DOI 10.1158/1078-0432.CCR-06-0267; Nassif NT, 2004, ONCOGENE, V23, P617, DOI 10.1038/sj.onc.1207059; Ollikainen M, 2007, INT J CANCER, V121, P915, DOI 10.1002/ijc.22768; Philp A J, 2000, Int J Surg Investig, V2, P267; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Singh B, 2002, GENE DEV, V16, P984, DOI 10.1101/gad.973602; Toyota M, 2000, J GASTROENTEROL, V35, P727, DOI 10.1007/s005350070030; Uddin S, 2006, BLOOD, V108, P4178, DOI 10.1182/blood-2006-04-016907; Velho S, 2005, EUR J CANCER, V41, P1649, DOI 10.1016/j.ejca.2005.04.022; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wymann MP, 2005, CURR OPIN CELL BIOL, V17, P141, DOI 10.1016/j.ceb.2005.02.011	32	74	77	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2008	27	25					3539	3545		10.1038/sj.onc.1211013	http://dx.doi.org/10.1038/sj.onc.1211013			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18193083				2022-12-25	WOS:000256468500005
J	Miyamoto, D; Miyamoto, M; Takahashi, A; Yomogita, Y; Higashi, H; Kondo, S; Hatakeyama, M				Miyamoto, D.; Miyamoto, M.; Takahashi, A.; Yomogita, Y.; Higashi, H.; Kondo, S.; Hatakeyama, M.			Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors	ONCOGENE			English	Article						SHP-2; gain-of-function mutation; NIH3T3; solid tumor; oncogenic RAS	PROTEIN-TYROSINE-PHOSPHATASE; HELICOBACTER-PYLORI CAGA; CAUSE NOONAN-SYNDROME; JUVENILE MYELOMONOCYTIC LEUKEMIA; SOMATIC PTPN11 MUTATIONS; FACIO-CUTANEOUS SYNDROME; GROWTH-FACTOR RECEPTOR; GERMLINE MUTATIONS; LEUKEMOGENESIS; ACTIVATION	SHP-2 protein tyrosine phosphatase plays an important role in activation of the RAS-dependent signaling. Gain-of-function mutations in the PTPN11 gene, which encodes SHP-2, have been found in the leukemia-prone developmental disorder Noonan syndrome as well as sporadic childhood leukemias, indicating that SHP-2 is a bona. de human oncoprotein. However, the role of SHP-2 mutations in non-hematological malignancies remains obscure. Here, we screened for PTPN11 mutations in primary solid tumors and identified a 1520C > A mutation that causes threonine-507 to lysine (T507K) substitution in the phosphatase domain of SHP-2 in a case of hepatocellular carcinoma. T507K SHP-2 exhibited altered substrate specificity with slightly elevated basal phosphatase activity. Upon expression in NIH3T3 cells, T507K SHP-2 induced transformed foci, which was not observed with wild type, Noonan-specific or leukemia-specific SHP-2. Furthermore, NIH3T3 cells transformed by T507K SHP-2 showed anchorage-independent growth and developed tumors in nude mice. These results indicate that quantitative and/or qualitative alteration in phosphatase activity determines the transforming potential as well as target cell/tissue spectrum of individual SHP-2 mutants as oncoproteins. Although rare in solid tumors, the identified T507K SHP-2 represents a distinct class of SHP-2 mutants with oncogenic RAS-like transforming activity, which could contribute to the development of solid tumors.	[Hatakeyama, M.] Hokkaido Univ, Div Mol Oncol, Inst Med Genet, Kita Ku, Sapporo, Hokkaido 0600815, Japan; [Miyamoto, D.; Miyamoto, M.; Kondo, S.] Hokkaido Univ, Grad Sch Med, Div Surg Oncol, Sapporo, Hokkaido 0600815, Japan	Hokkaido University; Hokkaido University	Hatakeyama, M (corresponding author), Hokkaido Univ, Div Mol Oncol, Inst Med Genet, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0600815, Japan.	mhata@igm.hokudai.ac.jp	Higashi, Hideaki/F-6872-2012	Kanemitsu, Atsushi/0000-0002-4156-9522				Agazie YM, 2003, J BIOL CHEM, V278, P13952, DOI 10.1074/jbc.M210670200; Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; Aoki Y, 2005, NAT GENET, V37, P1038, DOI 10.1038/ng1641; Bentires-Alj M, 2006, NAT MED, V12, P114, DOI 10.1038/nm1341; Bentires-Alj M, 2004, CANCER RES, V64, P8816, DOI 10.1158/0008-5472.CAN-04-1923; Chen YY, 2006, GENE CHROMOSOME CANC, V45, P583, DOI 10.1002/gcc.20322; Choong K, 1999, J PEDIAT HEMATOL ONC, V21, P523, DOI 10.1097/00043426-199911000-00014; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Digilio MC, 2002, AM J HUM GENET, V71, P389, DOI 10.1086/341528; Gelb BD, 2006, HUM MOL GENET, V15, pR220, DOI 10.1093/hmg/ddl197; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hatakeyama M, 2004, NAT REV CANCER, V4, P688, DOI 10.1038/nrc1433; Higashi H, 2004, J BIOL CHEM, V279, P17205, DOI 10.1074/jbc.M309964200; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Keilhack H, 2005, J BIOL CHEM, V280, P30984, DOI 10.1074/jbc.M504699200; Keilhack H, 1998, J BIOL CHEM, V273, P24839, DOI 10.1074/jbc.273.38.24839; Kosaki K, 2002, J CLIN ENDOCR METAB, V87, P3529, DOI 10.1210/jc.87.8.3529; Lauchle JO, 2006, PEDIATR BLOOD CANCER, V46, P579, DOI 10.1002/pbc.20644; Loh ML, 2004, BLOOD, V103, P2325, DOI 10.1182/blood-2003-09-3287; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Martinelli S, 2006, CANCER GENET CYTOGEN, V166, P124, DOI 10.1016/j.cancergencyto.2005.10.003; Mohi MG, 2007, CURR OPIN GENET DEV, V17, P23, DOI 10.1016/j.gde.2006.12.011; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Niihori T, 2006, NAT GENET, V38, P294, DOI 10.1038/ng1749; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; Roberts AE, 2007, NAT GENET, V39, P70, DOI 10.1038/ng1926; Rodriguez-Viciana P, 2006, SCIENCE, V311, P1287, DOI 10.1126/science.1124642; Schubbert S, 2006, NAT GENET, V38, P331, DOI 10.1038/ng1748; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; Tartaglia M, 2006, AM J HUM GENET, V78, P279, DOI 10.1086/499925; Tartaglia M, 2004, BLOOD, V104, P307, DOI 10.1182/blood-2003-11-3876; Tartaglia M, 2001, NAT GENET, V29, P465, DOI 10.1038/ng772; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Tartaglia M, 2007, NAT GENET, V39, P75, DOI 10.1038/ng1939; Tsutsumi R, 2006, MOL CELL BIOL, V26, P261, DOI 10.1128/MCB.26.1.261-276.2006	37	76	80	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2008	27	25					3508	3515		10.1038/sj.onc.1211019	http://dx.doi.org/10.1038/sj.onc.1211019			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18223690				2022-12-25	WOS:000256468500002
J	Ozaki, S; Kawakami, H; Nakamura, K; Fujikawa, N; Kagawa, W; Park, SY; Yokoyama, S; Kurumizaka, H; Katayama, T				Ozaki, Shogo; Kawakami, Hironori; Nakamura, Kenta; Fujikawa, Norie; Kagawa, Wataru; Park, Sam-Yong; Yokoyama, Shigeyuki; Kurumizaka, Hitoshi; Katayama, Tsutomu			A common mechanism for the ATP-DnaA-dependent formation of open complexes at the replication origin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; SINGLE-STRANDED-DNA; IN-VITRO; THERMOTOGA-MARITIMA; INITIATOR PROTEIN; STRUCTURAL BASIS; ABC-PRIMOSOME; E. COLI; MOTIF; BOX	Initiation of chromosomal replication and its cell cycle-coordinated regulation bear crucial and fundamental mechanisms in most cellular organisms. Escherichia coli DnaA protein forms a homomultimeric complex with the replication origin (oriC). ATP-DnaA multimers unwind the duplex within the oriC unwinding element (DUE). In this study, structural analyses suggested that several residues exposed in the central pore of the putative structure of DnaA multimers could be important for unwinding. Using mutation analyses, we found that, of these candidate residues, DnaA Val-211 and Arg-245 are prerequisites for initiation in vivo and in vitro. Whereas DnaA V211A and R245A proteins retained normal affinities for ATP/ADP and DNA and activity for the ATP-specific conformational change of the initiation complex in vitro, oriC complexes of these mutant proteins were inactive in DUE unwinding and in binding to the single-stranded DUE. Unlike oriC complexes including ADP-DnaA or the mutant DnaA, ATP-DnaA-oriC complexes specifically bound the upper strand of single-stranded DUE. Specific T-rich sequences within the strand were required for binding. The corresponding conserved residues of the DnaA ortholog in Thermotoga maritima, an ancient eubacterium, were also required for DUE unwinding, consistent with the idea that the mechanism and regulation for DUE unwinding can be evolutionarily conserved. These findings provide novel insights into mechanisms for pore-mediated origin unwinding, ATP/ADP-dependent regulation, and helicase loading of the initiation complex.	[Ozaki, Shogo; Kawakami, Hironori; Nakamura, Kenta; Katayama, Tsutomu] Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Mol Biol, Fukuoka 8128582, Japan; [Fujikawa, Norie; Kagawa, Wataru; Yokoyama, Shigeyuki; Kurumizaka, Hitoshi] RIKEN, Genom Res Ctr, Yokohama, Kanagawa 2300045, Japan; [Yokoyama, Shigeyuki] Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Tokyo 1130033, Japan; [Kurumizaka, Hitoshi] Waseda Univ, Grad Sch Adv Sci & Engn, Tokyo 1698555, Japan	Kyushu University; RIKEN; University of Tokyo; Waseda University	Katayama, T (corresponding author), Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Mol Biol, Fukuoka 8128582, Japan.	katayama@phar.kyushu-u.ac.jp	Kawakami, Hironori/H-6792-2017; Yokoyama, Shigeyuki/N-6911-2015	Kawakami, Hironori/0000-0001-8971-1914; Yokoyama, Shigeyuki/0000-0003-3133-7338; Kurumizaka, Hitoshi/0000-0001-7412-3722; Ozaki, Shogo/0000-0002-4384-1366; Kagawa, Wataru/0000-0002-8801-6589; Katayama, Tsutomu/0000-0001-9994-1684				Abe Y, 2007, J BIOL CHEM, V282, P17816, DOI 10.1074/jbc.M701841200; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; Camara JE, 2005, EMBO REP, V6, P736, DOI 10.1038/sj.embor.7400467; CROOKE E, 1993, J MOL BIOL, V233, P16, DOI 10.1006/jmbi.1993.1481; Enemark EJ, 2006, NATURE, V442, P270, DOI 10.1038/nature04943; Erzberger JP, 2006, NAT STRUCT MOL BIOL, V13, P676, DOI 10.1038/nsmb1115; Erzberger JP, 2002, EMBO J, V21, P4763, DOI 10.1093/emboj/cdf496; Felczak MM, 2005, J BIOL CHEM, V280, P24627, DOI 10.1074/jbc.M503684200; Felczak MM, 2004, J BIOL CHEM, V279, P51156, DOI 10.1074/jbc.M409695200; Fujikawa N, 2003, NUCLEIC ACIDS RES, V31, P2077, DOI 10.1093/nar/gkg309; Goedken ER, 2005, NAT STRUCT MOL BIOL, V12, P183, DOI 10.1038/nsmb889; Hanson PI, 2005, NAT REV MOL CELL BIO, V6, P519, DOI 10.1038/nrm1684; HWANG DS, 1992, J BIOL CHEM, V267, P23087; HWANG DS, 1988, J BIOL CHEM, V263, P10625; Ishida T, 2004, J BIOL CHEM, V279, P45546, DOI 10.1074/jbc.M402762200; Iyer LM, 2004, J STRUCT BIOL, V146, P11, DOI 10.1016/j.jsb.2003.10.010; Kaguni JM, 2006, ANNU REV MICROBIOL, V60, P351, DOI 10.1146/annurev.micro.60.080805.142111; Katayama T, 1998, CELL, V94, P61, DOI 10.1016/S0092-8674(00)81222-2; Kato J, 2001, EMBO J, V20, P4253, DOI 10.1093/emboj/20.15.4253; Kawakami H, 2005, J BIOL CHEM, V280, P27420, DOI 10.1074/jbc.M502764200; Kawakami H, 2006, MOL MICROBIOL, V62, P1310, DOI 10.1111/j.1365-2958.2006.05450.x; Keyamura K, 2007, GENE DEV, V21, P2083, DOI 10.1101/gad.1561207; Kogoma T, 1997, MICROBIOL MOL BIOL R, V61, P212, DOI 10.1128/.61.2.212-238.1997; Kumar A, 2007, J VIROL, V81, P4808, DOI 10.1128/JVI.02451-06; MASAI H, 1995, EUR J BIOCHEM, V230, P384; MASAI H, 1990, J BIOL CHEM, V265, P15134; McGarry KC, 2004, P NATL ACAD SCI USA, V101, P2811, DOI 10.1073/pnas.0400340101; Messer W, 2002, FEMS MICROBIOL REV, V26, P355, DOI 10.1016/S0168-6445(02)00127-4; Mott ML, 2007, NAT REV MICROBIOL, V5, P343, DOI 10.1038/nrmicro1640; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; Neuwald AF, 1999, GENOME RES, V9, P27; Nishida S, 2002, J BIOL CHEM, V277, P14986, DOI 10.1074/jbc.M108303200; O'Donnell M, 2006, J BIOL CHEM, V281, P10653, DOI 10.1074/jbc.R500028200; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Okuno T, 2006, J STRUCT BIOL, V156, P109, DOI 10.1016/j.jsb.2006.02.003; Ozaki S, 2006, GENES CELLS, V11, P425, DOI 10.1111/j.1365-2443.2006.00950.x; Pei HD, 2007, NUCLEIC ACIDS RES, V35, P3087, DOI 10.1093/nar/gkm137; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; Shimuta T, 2004, GENES CELLS, V9, P1151, DOI 10.1111/j.1365-2443.2004.00800.x; Speck C, 2001, EMBO J, V20, P1469, DOI 10.1093/emboj/20.6.1469; Su'etsugu M, 2005, J BIOL CHEM, V280, P6528, DOI 10.1074/jbc.M412060200; Su'etsugu M, 2001, MOL MICROBIOL, V40, P376, DOI 10.1046/j.1365-2958.2001.02378.x; Weigel C, 1999, MOL MICROBIOL, V34, P53, DOI 10.1046/j.1365-2958.1999.01568.x; Weigel C, 2002, MOL MICROBIOL, V46, P1149, DOI 10.1046/j.1365-2958.2002.03232.x; YUNG BYM, 1990, J BIOL CHEM, V265, P1282; Zakrzewska-Czerwinska J, 2007, FEMS MICROBIOL REV, V31, P378, DOI 10.1111/j.1574-6976.2007.00070.x	46	97	97	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8351	8362		10.1074/jbc.M708684200	http://dx.doi.org/10.1074/jbc.M708684200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18216012	hybrid			2022-12-25	WOS:000254288000033
J	Rhee, JE; Sheng, WY; Morgan, LK; Nolet, R; Liao, XB; Kenney, LJ				Rhee, Jee Eun; Sheng, Wanyun; Morgan, Leslie K.; Nolet, Ryan; Liao, Xiubei; Kenney, Linda J.			Amino acids important for DNA recognition by the response regulator OmpR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; NUCLEAR-MAGNETIC-RESONANCE; PATHOGENICITY ISLAND 2; POSITIVE REGULATOR; OUTER-MEMBRANE; SALMONELLA-TYPHIMURIUM; PHOSPHORYLATION SITE; TRANSCRIPTION FACTOR; SHIGELLA-FLEXNERI; RNA-POLYMERASE	Response regulators undergo regulated phosphorylation and dephosphorylation at conserved aspartic acid residues in bacterial signal transduction systems. OmpR is a winged helix-turn-helix DNA-binding protein that functions as a global regulator in bacteria and is also important in pathogenesis. A detailed mechanistic picture of how OmpR binds to DNA and activates transcription is lacking. We used NMR spectroscopy to solve the solution structure of the C-terminal domain of OmpR (OmpR(C)) and to analyze the chemical shift changes that occur upon DNA binding. There is little overlap in the interaction surface with residues of PhoB that were reportedly involved in protein/protein interactions in its head-to-tail dimer. Multiple factors account for the lack of overlap. One is that the spacing between the OmpR half-sites is shorter than observed with PhoB, requiring the arrangement of the two OmpR molecules to be different from that of the PhoB dimer on DNA. A second is the demonstration herein that OmpR can bind to its high affinity site as a monomer. As a result, OmpR(C) appears to be capable of adopting alternative orientations depending on the precise base composition of the binding site, which also contributes to the lack of overlap. In the presence of DNA, chemical shift changes occur in OmpR in the recognition alpha-helix3, the loop between beta-strand 4 and alpha-helix 1, and the loop between beta-strands 5 and 6. DNA contact residues are Val(203) (T), Arg(207) (G), and Arg(209) (phosphate backbone). Our results suggest that OmpR binds to DNA as a monomer and then forms a symmetric or asymmetric dimer, depending on the binding site. We propose that during activation OmpR binds to DNA and undergoes a conformational change that promotes phosphorylation of the N-terminal receiver domain, the receiver domains dimerize, and then the second monomer binds to DNA. The flexible linker of OmpR enables the second monomer to bind in multiple orientations (head-to-tail and head-to-head), depending on the specific DNA contacts.	[Sheng, Wanyun; Nolet, Ryan; Liao, Xiubei] Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60612 USA; [Rhee, Jee Eun; Morgan, Leslie K.; Kenney, Linda J.] Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Liao, XB (corresponding author), Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60612 USA.	xiubei@uic.edu; kenneyl@uic.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058746] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 058746] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIBA H, 1989, J BIOCHEM-TOKYO, V106, P5, DOI 10.1093/oxfordjournals.jbchem.a122817; Ames SK, 1999, P NATL ACAD SCI USA, V96, P11792, DOI 10.1073/pnas.96.21.11792; Basle A, 2006, J MOL BIOL, V362, P933, DOI 10.1016/j.jmb.2006.08.002; BERNARDINI ML, 1993, INFECT IMMUN, V61, P3625, DOI 10.1128/IAI.61.9.3625-3635.1993; BERNARDINI ML, 1990, J BACTERIOL, V172, P6274, DOI 10.1128/jb.172.11.6274-6281.1990; Blanco JB, 2003, CHEM BIOL, V10, P713, DOI 10.1016/S1074-5521(03)00172-8; Brzostek K, 2003, FEMS MICROBIOL LETT, V228, P265, DOI 10.1016/S0378-1097(03)00779-1; Cai SJ, 2002, J BIOL CHEM, V277, P24155, DOI 10.1074/jbc.M110715200; Clore GM, 1998, TRENDS BIOTECHNOL, V16, P22, DOI 10.1016/S0167-7799(97)01135-9; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DELGADO J, 1993, MOL MICROBIOL, V10, P1037, DOI 10.1111/j.1365-2958.1993.tb00974.x; Doreleijers JF, 1998, J MOL BIOL, V281, P149, DOI 10.1006/jmbi.1998.1808; DORMAN CJ, 1989, INFECT IMMUN, V57, P2136, DOI 10.1128/IAI.57.7.2136-2140.1989; Dorrell N, 1998, FEMS MICROBIOL LETT, V165, P145, DOI 10.1016/S0378-1097(98)00267-5; Feng XH, 2004, MOL MICROBIOL, V54, P823, DOI 10.1111/j.1365-2958.2004.04317.x; Feng XH, 2003, MOL MICROBIOL, V48, P1131, DOI 10.1046/j.1365-2958.2003.03502.x; Guillier M, 2006, MOL MICROBIOL, V59, P231, DOI 10.1111/j.1365-2958.2005.04929.x; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Haldimann A, 2001, J BACTERIOL, V183, P6384, DOI 10.1128/JB.183.21.6384-6393.2001; HALL MN, 1981, J MOL BIOL, V151, P1, DOI 10.1016/0022-2836(81)90218-7; HALL MN, 1981, J MOL BIOL, V146, P23, DOI 10.1016/0022-2836(81)90364-8; HARLOCKER SL, 1995, J BIOL CHEM, V270, P26849, DOI 10.1074/jbc.270.45.26849; Head CG, 1998, J MOL BIOL, V281, P857, DOI 10.1006/jmbi.1998.1985; Hoch JA, 1995, 2 COMPONENT SIGNAL T; Hong E, 2007, J BIOL CHEM, V282, P20667, DOI 10.1074/jbc.M609104200; Huang KJ, 1996, J MOL BIOL, V262, P615, DOI 10.1006/jmbi.1996.0540; IGO MM, 1988, J BACTERIOL, V170, P5971, DOI 10.1128/jb.170.12.5971-5973.1988; Kanelis V, 2001, IUBMB LIFE, V52, P291, DOI 10.1080/152165401317291147; KATO M, 1989, FEBS LETT, V249, P168, DOI 10.1016/0014-5793(89)80617-9; KENNEY LJ, 1995, P NATL ACAD SCI USA, V92, P8866, DOI 10.1073/pnas.92.19.8866; King-Scott J, 2007, J BIOL CHEM, V282, P37717, DOI 10.1074/jbc.M705081200; Kondo H, 1997, NAT STRUCT BIOL, V4, P28, DOI 10.1038/nsb0197-28; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lee AK, 2000, J BACTERIOL, V182, P771, DOI 10.1128/JB.182.3.771-781.2000; Lindgren SW, 1996, P NATL ACAD SCI USA, V93, P4197, DOI 10.1073/pnas.93.9.4197; Makino K, 1996, J MOL BIOL, V259, P15, DOI 10.1006/jmbi.1996.0298; Maris AE, 2005, J MOL BIOL, V350, P843, DOI 10.1016/j.jmb.2005.05.057; MartinezHackert E, 1997, STRUCTURE, V5, P109, DOI 10.1016/S0969-2126(97)00170-6; Mattison K, 2002, J MOL BIOL, V315, P497, DOI 10.1006/jmbi.2001.5222; Mattison K, 2002, J BIOL CHEM, V277, P32714, DOI 10.1074/jbc.M204122200; NARA F, 1986, MOL GEN GENET, V202, P194, DOI 10.1007/BF00331636; NIKAIDO H, 1983, J BACTERIOL, V153, P232, DOI 10.1128/JB.153.1.232-240.1983; Oshima T, 2002, MOL MICROBIOL, V46, P281, DOI 10.1046/j.1365-2958.2002.03170.x; PICKARD D, 1994, INFECT IMMUN, V62, P3984, DOI 10.1128/IAI.62.9.3984-3993.1994; PRATT LA, 1995, MOL MICROBIOL, V17, P565, DOI 10.1111/j.1365-2958.1995.mmi_17030565.x; RACZKOWSKA A, 2004, ACTA MICROBIOL POL, V53, P11; RAMPERSAUD A, 1994, J BIOL CHEM, V269, P12559; Romling U, 1998, MOL MICROBIOL, V28, P249, DOI 10.1046/j.1365-2958.1998.00791.x; RUSSO FD, 1991, J MOL BIOL, V222, P567, DOI 10.1016/0022-2836(91)90497-T; SLAUCH JM, 1989, J MOL BIOL, V210, P281, DOI 10.1016/0022-2836(89)90330-6; TATE S, 1988, FEBS LETT, V242, P27, DOI 10.1016/0014-5793(88)80978-5; Toro-Roman A, 2005, J MOL BIOL, V349, P11, DOI 10.1016/j.jmb.2005.03.059; Tran VK, 2000, J MOL BIOL, V299, P1257, DOI 10.1006/jmbi.2000.3809; TSUZUKI M, 1994, J MOL BIOL, V242, P607, DOI 10.1006/jmbi.1994.1610; VANALPHEN W, 1977, J BACTERIOL, V131, P623; Walthers D, 2003, J BACTERIOL, V185, P317, DOI 10.1128/JB.185.1.317-324.2003; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; Wishart DS, 2001, METHOD ENZYMOL, V338, P3; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Yoshida T, 2006, J BIOL CHEM, V281, P17114, DOI 10.1074/jbc.M602112200	62	64	65	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8664	8677		10.1074/jbc.M705550200	http://dx.doi.org/10.1074/jbc.M705550200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18195018	hybrid, Green Published			2022-12-25	WOS:000254288000065
J	Buttner, S; Bitto, A; Ring, J; Augsten, M; Zabrocki, P; Eisenberg, T; Jungwirth, H; Hutter, S; Carmona-Gutierrez, D; Kroemer, G; Winderickx, J; Madeo, F				Buettner, Sabrina; Bitto, Alessandro; Ring, Julia; Augsten, Manuela; Zabrocki, Piotr; Eisenberg, Tobias; Jungwirth, Helmut; Hutter, Sylvia; Carmona-Gutierrez, Didac; Kroemer, Guido; Winderickx, Joris; Madeo, Frank			Functional mitochondria are required for alpha-synuclein toxicity in aging yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROBLASTOMA SH-SY5Y CELLS; PARKINSONS-DISEASE; SACCHAROMYCES-CEREVISIAE; REGULATES APOPTOSIS; OXIDATIVE STRESS; DEATH; MUTATION; 6-HYDROXYDOPAMINE; NEURODEGENERATION; INVOLVEMENT	alpha-Synuclein is one of the principal toxic triggers of Parkinson disease, an age-associated neurodegeneration. Using old yeast as a model of alpha-synuclein expression in post-mitotic cells, we show that alpha-synuclein toxicity depends on chronological aging and results in apoptosis as well as necrosis. Neither disruption of key components of the unfolded protein response nor deletion of proapoptotic key players (including the yeast caspase YCA1, the apoptosis-inducing factor AIF1, or the serine protease OMI) did prevent alpha-synuclein-induced cell killing. However, abrogation of mitochondrial DNA (rho(0)) inhibited alpha-synuclein-induced reactive oxygen species formation and subsequent apoptotic cell death. Thus, introducing an aging yeast model of alpha-synuclein toxicity, we demonstrate a strict requirement of functional mitochondria.	[Buettner, Sabrina; Ring, Julia; Augsten, Manuela; Eisenberg, Tobias; Jungwirth, Helmut; Hutter, Sylvia; Carmona-Gutierrez, Didac; Madeo, Frank] Graz Univ, Inst Mol Biosci, A-8010 Graz, Austria; [Bitto, Alessandro; Zabrocki, Piotr; Winderickx, Joris] Catholic Univ Louvain, B-3000 Louvain, Belgium; [Kroemer, Guido] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France; [Kroemer, Guido] Univ Paris 11, F-94805 Villejuif, France	University of Graz; Universite Catholique Louvain; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay	Madeo, F (corresponding author), Graz Univ, Inst Mol Biosci, Humboldtstr 50, A-8010 Graz, Austria.	frank.madeo@uni-graz.at	KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020; Eisenberg, Tobias/AAV-7806-2021	KROEMER, Guido/0000-0002-9334-4405; Buttner, Sabrina/0000-0002-2786-8542; Madeo, Frank/0000-0002-5070-1329; Carmona-Gutierrez, Didac/0000-0001-7548-7771; Eisenberg, Tobias/0000-0003-3559-1130; Ring, Julia/0000-0003-4991-9328; Jungwirth, Helmut/0000-0003-4868-4571				Abou-Sleiman PM, 2006, NAT REV NEUROSCI, V7, P207, DOI 10.1038/nrn1868; Ahn SH, 2005, CELL, V120, P25, DOI 10.1016/j.cell.2004.11.016; Buttner S, 2007, MOL CELL, V25, P233, DOI 10.1016/j.molcel.2006.12.021; Chandra S, 2005, CELL, V123, P383, DOI 10.1016/j.cell.2005.09.028; Cooper AA, 2006, SCIENCE, V313, P324, DOI 10.1126/science.1129462; da Costa CA, 2002, J BIOL CHEM, V277, P50980, DOI 10.1074/jbc.M207825200; Eisenberg T, 2007, APOPTOSIS, V12, P1011, DOI 10.1007/s10495-007-0758-0; Ellis CE, 2005, MOL CELL BIOL, V25, P10190, DOI 10.1128/MCB.25.22.10190-10201.2005; Fabrizio P, 2004, J CELL BIOL, V166, P1055, DOI 10.1083/jcb.200404002; Fahrenkrog B, 2004, J CELL SCI, V117, P115, DOI 10.1242/jcs.00848; Fannjiang Y, 2004, GENE DEV, V18, P2785, DOI 10.1101/gad.1247904; Flower TR, 2005, J MOL BIOL, V351, P1081, DOI 10.1016/j.jmb.2005.06.060; Gomez-Santos C, 2003, J NEUROSCI RES, V73, P341, DOI 10.1002/jnr.10663; Gourlay CW, 2005, J CELL SCI, V118, P2119, DOI 10.1242/jcs.02337; Hardy J, 2006, ANN NEUROL, V60, P389, DOI 10.1002/ana.21022; Haynes CM, 2004, MOL CELL, V15, P767, DOI 10.1016/j.molcel.2004.08.025; Herker E, 2004, J CELL BIOL, V164, P501, DOI 10.1083/jcb.200310014; Kroemer G, 2007, PLOS BIOL, V5, P1409, DOI 10.1371/journal.pbio.0050206; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Laun P, 2001, MOL MICROBIOL, V39, P1166, DOI 10.1046/j.1365-2958.2001.02317.x; Liss B, 2001, NEWS PHYSIOL SCI, V16, P214; Ludovico P, 2002, MOL BIOL CELL, V13, P2598, DOI 10.1091/mbc.E01-12-0161; Madeo F, 2002, MOL CELL, V9, P911, DOI 10.1016/S1097-2765(02)00501-4; Madeo F, 1997, J CELL BIOL, V139, P729, DOI 10.1083/jcb.139.3.729; Madeo F, 1999, J CELL BIOL, V145, P757, DOI 10.1083/jcb.145.4.757; Moore DJ, 2005, ANNU REV NEUROSCI, V28, P57, DOI 10.1146/annurev.neuro.28.061604.135718; Outeiro TF, 2003, SCIENCE, V302, P1772, DOI 10.1126/science.1090439; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Sidrauski C, 1997, CELL, V90, P1031, DOI 10.1016/S0092-8674(00)80369-4; Strauss KM, 2005, HUM MOL GENET, V14, P2099, DOI 10.1093/hmg/ddi215; Sulzer D, 2000, P NATL ACAD SCI USA, V97, P11869, DOI 10.1073/pnas.97.22.11869; Tofaris GK, 2005, MOVEMENT DISORD, V20, pS37, DOI 10.1002/mds.20538; Wissing S, 2004, J CELL BIOL, V166, P969, DOI 10.1083/jcb.200404138; Wood-Kaczmar A, 2006, TRENDS MOL MED, V12, P521, DOI 10.1016/j.molmed.2006.09.007; Xu J, 2002, NAT MED, V8, P600, DOI 10.1038/nm0602-600; Yamamuro A, 2006, NEUROCHEM RES, V31, P657, DOI 10.1007/s11064-006-9062-6; Zabrocki P, 2005, FEBS J, V272, P1386, DOI 10.1111/j.1742-4658.2005.04571.x; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795	39	115	118	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7554	7560		10.1074/jbc.M708477200	http://dx.doi.org/10.1074/jbc.M708477200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18192273	hybrid			2022-12-25	WOS:000253997900030
J	Perez, JM; Arenas, FA; Pradenas, GA; Sandoval, JM; Vasquez, CC				Perez, Jose Manuel; Arenas, Felipe A.; Pradenas, Gonzalo A.; Sandoval, Juan M.; Vasquez, Claudio C.			Escherichia coli YqhD exhibits aldehyde reductase activity and protects from the harmful effect of lipid peroxidation-derived aldehydes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALCOHOL-DEHYDROGENASE; OXIDATIVE STRESS; GENE-EXPRESSION; MECHANISM; PRODUCTS; PROTEINS; ACROLEIN; IDENTIFICATION; INACTIVATION; GLUTATHIONE	Evidence that Escherichia coli YqhD is involved in bacterial response to compounds that generate membrane lipid peroxidation is presented. Overexpression of yqhD results in increased resistance to the reactive oxygen species-generating compounds hydrogen peroxide, paraquat, chromate, and potassium tellurite. Increased tolerance was also observed for the lipid peroxidation-derived aldehydes butanaldehyde, propanaldehyde, acrolein, and malondialdehyde and the membrane-peroxidizing compound tert-butylhydroperoxide. Expression of yqhD was also associated with changes in the concentration of intracellular peroxides and cytoplasmic protein carbonyl content and with a reduction in intracellular acrolein levels. When compared with the wild type strain, an yqhD mutant exhibited a sensitive phenotype to all these compounds and also augmented levels of thiobarbituric acid-reactive substances, which may indicate an increased level of lipid peroxidation. Purified YqhD catalyzes the in vitro reduction of acetaldehyde, malondialdehyde, propanaldehyde, butanaldehyde, and acrolein in a NADPH-dependent reaction. Finally, yqhD transcription was induced in cells that had been exposed to conditions favoring lipid peroxidation. Taken together these results indicate that this enzyme may have a physiological function by protecting the cell against the toxic effect of aldehydes derived from lipid oxidation. We speculate that in Escherichia coli YqhD is part of a glutathione-independent, NADPH-dependent response mechanism to lipid peroxidation.	[Perez, Jose Manuel; Arenas, Felipe A.; Pradenas, Gonzalo A.; Sandoval, Juan M.; Vasquez, Claudio C.] Univ Santiago Chile, Mol Microbiol Lab, Dept Biol, Fac Quim & Biol, Santiago, Chile	Universidad de Santiago de Chile	Vasquez, CC (corresponding author), Univ Santiago Chile, Mol Microbiol Lab, Dept Biol, Fac Quim & Biol, Casilla 40,Correo 33, Santiago, Chile.	cvasquez@usach.cl	Pérez-Donoso, José M./G-3668-2013	Pérez-Donoso, José M./0000-0002-9506-1716				Ackerley DF, 2006, J BACTERIOL, V188, P3371, DOI 10.1128/JB.188.9.3371-3381.2006; Burczynski ME, 2001, J BIOL CHEM, V276, P2890, DOI 10.1074/jbc.M006655200; Calderon IL, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000070; Cha MK, 1996, J BACTERIOL, V178, P5610, DOI 10.1128/jb.178.19.5610-5614.1996; Chen JJ, 1998, BBA-GEN SUBJECTS, V1380, P336, DOI 10.1016/S0304-4165(98)00002-6; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Denich TJ, 2003, J MICROBIOL METH, V52, P149, DOI 10.1016/S0167-7012(02)00155-0; Echave P, 2003, J BIOL CHEM, V278, P30193, DOI 10.1074/jbc.M304351200; ESTERBAUER H, 1975, Z NATURFORSCH C, V30, P466; Esterbauer H., 1982, FREE RADICAL LIPID P, P101; ESTERBAUER H, 1990, MEMBRANE LIPID OXIDA, V1, P239; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Girotti AW, 1998, J LIPID RES, V39, P1529; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; Hansen EH, 2004, APPL ENVIRON MICROB, V70, P1749, DOI 10.1128/AEM.70.3.1749-1757.2004; HARTLEY DP, 1995, ARCH BIOCHEM BIOPHYS, V316, P197, DOI 10.1006/abbi.1995.1028; Ho KK, 2005, J BACTERIOL, V187, P1067, DOI 10.1128/JB.187.3.1067-1073.2005; Hua Q, 2004, APPL ENVIRON MICROB, V70, P2354, DOI 10.1128/AEM.70.4.2354-2366.2004; Imlay JA, 2003, ANNU REV MICROBIOL, V57, P395, DOI 10.1146/annurev.micro.57.030502.090938; ITOH M, 1995, J BIOCHEM, V117, P780, DOI 10.1093/oxfordjournals.jbchem.a124776; Kitagawa M, 2000, FEMS MICROBIOL LETT, V184, P165, DOI 10.1111/j.1574-6968.2000.tb09009.x; Maness PC, 1999, APPL ENVIRON MICROB, V65, P4094; Mano J, 2002, PLANT CELL PHYSIOL, V43, P1445, DOI 10.1093/pcp/pcf187; Mates JM, 2000, TOXICOLOGY, V153, P83, DOI 10.1016/S0300-483X(00)00306-1; NEUDECKER T, 1991, MUTAT RES, V264, P193, DOI 10.1016/0165-7992(91)90077-H; Perez JM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000211; Picklo MJ, 2001, J NEUROPATH EXP NEUR, V60, P686, DOI 10.1093/jnen/60.7.686; PORTER NA, 1984, METHOD ENZYMOL, V105, P273; Refsgaard HHF, 2000, P NATL ACAD SCI USA, V97, P611, DOI 10.1073/pnas.97.2.611; Rice-Evans C, 1991, LAB TECHNIQUES BIOCH, V22, P147; Rittner HL, 1999, J CLIN INVEST, V103, P1007, DOI 10.1172/JCI4711; Semchyshyn H, 2005, CELL BIOL INT, V29, P898, DOI 10.1016/j.cellbi.2005.08.002; Shapiro E, 2002, ANTIMICROB AGENTS CH, V46, P2490, DOI 10.1128/AAC.46.8.2490-2497.2002; SLININGER PJ, 1985, APPL ENVIRON MICROB, V50, P1444, DOI 10.1128/AEM.50.6.1444-1450.1985; Srivastava S, 1998, BIOCHEM J, V329, P469, DOI 10.1042/bj3290469; Sulzenbacher G, 2004, J MOL BIOL, V342, P489, DOI 10.1016/j.jmb.2004.07.034; SZWEDA LI, 1993, J BIOL CHEM, V268, P3342; Turner RJ, 1999, MICROBIOL-UK, V145, P2549, DOI 10.1099/00221287-145-9-2549; Uchida K, 1998, P NATL ACAD SCI USA, V95, P4882, DOI 10.1073/pnas.95.9.4882; UCHIDA K, 1993, J BIOL CHEM, V268, P6288; Wang AY, 2005, J BACTERIOL, V187, P3259, DOI 10.1128/JB.187.9.3259-3266.2005; Yang IY, 2001, J BIOL CHEM, V276, P9071, DOI 10.1074/jbc.M008918200; Yoon SJ, 2002, J BIOCHEM MOL BIOL, V35, P297; Zhang Xiao-Mei, 2005, Sheng Wu Gong Cheng Xue Bao, V21, P743; Zu XY, 2007, TOXICOL SCI, V97, P562, DOI 10.1093/toxsci/kfm033	45	134	186	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7346	7353		10.1074/jbc.M708846200	http://dx.doi.org/10.1074/jbc.M708846200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18211903	hybrid			2022-12-25	WOS:000253997900008
J	Froquet, R; Cherix, N; Birke, R; Benghezal, M; Cameroni, E; Letourneur, F; Mosch, HU; De Virgilio, C; Cosson, P				Froquet, Romain; Cherix, Nathalie; Birke, Raphael; Benghezal, Mohammed; Cameroni, Elisabetta; Letourneur, Francois; Moesch, Hans-Ulrich; De Virgilio, Claudio; Cosson, Pierre			Control of cellular physiology by TM9 proteins in yeast and Dictyostelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; FILAMENTOUS GROWTH; LYSOSOMAL-ENZYMES; GENE DISRUPTION; PSEUDOHYPHAE FORMATION; SIGNALING PATHWAYS; INVASIVE GROWTH; MAP KINASE; FLO11 GENE; SLIME-MOLD	TM9 proteins constitute a well defined family, characterized by the presence of a large variable extracellular domain and nine putative transmembrane domains. This family is highly conserved throughout evolution and comprises three members in Dictyostelium discoideum and Saccharomyces cerevisiae and four in humans and mice. In Dictyostelium, previous analysis demonstrated that TM9 proteins are implicated in cellular adhesion. In this study, we generated TM9 mutants in S. cerevisiae and analyzed their phenotype with particular attention to cellular adhesion. S. cerevisiae strains lacking any one of the three TM9 proteins were severely suppressed for adhesive growth and filamentous growth under conditions of nitrogen starvation. In these mutants, expression of the FLO11-lacZ reporter gene was strongly reduced, whereas expression of FRE(Ty1)-lacZ was not, suggesting that TM9 proteins are implicated at a late stage of nutrient-controlled signaling pathways. We also reexamined the phenotype of Dictyostelium TM9 mutant cells, focusing on nutrient-controlled cellular functions. Although the initiation of multicellular development and autophagy was unaltered in Dictyostelium TM9 mutants, nutrient-controlled secretion of lysosomal enzymes was dysregulated in these cells. These results suggest that in both yeast and amoebae, TM9 proteins participate in the control of specific cellular functions in response to changing nutrient conditions.	[Froquet, Romain; Cherix, Nathalie; Benghezal, Mohammed; Cosson, Pierre] Univ Geneva, Ctr Med Univ, Dept Physiol & Metab Cellulaire, CH-1211 Geneva 4, Switzerland; [Birke, Raphael; Moesch, Hans-Ulrich] Univ Marburg, Dept Genet, D-35043 Marburg, Germany; [Cameroni, Elisabetta; De Virgilio, Claudio] Univ Fribourg, Dept Med, Div Biochem, CH-1700 Fribourg, Switzerland; [Letourneur, Francois] Univ Lyon 1, CNRS, UMR 5086, Inst Biol & Chim Prot,IFR128 Biosci Lyon Gerland, F-69367 Lyon 07, France	University of Geneva; Philipps University Marburg; University of Fribourg; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Cosson, P (corresponding author), Univ Geneva, Ctr Med Univ, Dept Physiol & Metab Cellulaire, Rue Michel Servet 1, CH-1211 Geneva 4, Switzerland.	Pierre.Cosson@medecine.unige.ch	De Virgilio, Claudio/B-4707-2012	Benghezal, Mohammed/0000-0002-4207-0192; De Virgilio, Claudio/0000-0001-8826-4323; Letourneur, Francois/0000-0003-2232-6127				Benghezal M, 2003, MOL BIOL CELL, V14, P2890, DOI 10.1091/mbc.E02-11-0724; BERTHOLDT G, 1985, CELL DIFFER DEV, V16, P187, DOI 10.1016/0045-6039(85)90516-0; Braus GH, 2003, MOL BIOL CELL, V14, P4272, DOI 10.1091/mbc.e03-01-0042; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; CATERINA MJ, 1994, J BIOL CHEM, V269, P1523; Cherix N, 2006, MOL BIOL CELL, V17, P4982, DOI 10.1091/mbc.E06-07-0619; Chluba-de Tapia J, 1997, GENE, V197, P195, DOI 10.1016/S0378-1119(97)00263-1; Cornillon S, 2000, J BIOL CHEM, V275, P34287, DOI 10.1074/jbc.M006725200; Cutler NS, 2001, MOL BIOL CELL, V12, P4103, DOI 10.1091/mbc.12.12.4103; DIMOND RL, 1983, METHOD ENZYMOL, V96, P815; DIMOND RL, 1981, J BIOL CHEM, V256, P6565; Gancedo JM, 2001, FEMS MICROBIOL REV, V25, P107, DOI 10.1016/S0168-6445(00)00056-5; Gebbie L, 2004, MOL BIOL CELL, V15, P3915, DOI 10.1091/mbc.E03-12-0908; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; Guo B, 2000, P NATL ACAD SCI USA, V97, P12158, DOI 10.1073/pnas.220420397; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; Journet A, 1999, J CELL SCI, V112, P3833; Kosta A, 2004, J BIOL CHEM, V279, P48404, DOI 10.1074/jbc.M408924200; Lefkir Y, 2003, MOL BIOL CELL, V14, P1835, DOI 10.1091/mbc.E02-10-0627; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; Lo WS, 1998, MOL BIOL CELL, V9, P161, DOI 10.1091/mbc.9.1.161; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; Mosch HU, 1997, GENETICS, V145, P671; Mosch HU, 1996, P NATL ACAD SCI USA, V93, P5352, DOI 10.1073/pnas.93.11.5352; Otto GP, 2004, J BIOL CHEM, V279, P15621, DOI 10.1074/jbc.M311139200; Otto GP, 2004, MOL MICROBIOL, V51, P63, DOI 10.1046/j.1365-2958.2003.03826.x; Otto GP, 2003, J BIOL CHEM, V278, P17636, DOI 10.1074/jbc.M212467200; Pan XW, 2000, CURR OPIN MICROBIOL, V3, P567, DOI 10.1016/S1369-5274(00)00142-9; Ravanel K, 2001, EUR J CELL BIOL, V80, P754, DOI 10.1078/0171-9335-00215; RICHARDSON JM, 1988, J CELL BIOL, V107, P2097, DOI 10.1083/jcb.107.6.2097; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; ROSE M, 1983, METHOD ENZYMOL, V101, P167; Rupp S, 1999, EMBO J, V18, P1257, DOI 10.1093/emboj/18.5.1257; SCHIESTL RH, 1991, P NATL ACAD SCI USA, V88, P7585, DOI 10.1073/pnas.88.17.7585; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGERKRUGER B, 1993, J BIOL CHEM, V268, P14376; Sugasawa T, 2001, GENE, V273, P227, DOI 10.1016/S0378-1119(01)00587-X; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Verstrepen KJ, 2006, MOL MICROBIOL, V60, P5, DOI 10.1111/j.1365-2958.2006.05072.x; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310	41	25	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					6764	6772		10.1074/jbc.M704484200	http://dx.doi.org/10.1074/jbc.M704484200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18178563	Green Submitted, Green Accepted, hybrid			2022-12-25	WOS:000253779600018
J	Kawahara, K; Hashimoto, M; Bar-On, P; Ho, GJ; Crews, L; Mizuno, H; Rockenstein, E; Imam, SZ; Masliah, E				Kawahara, Kohichi; Hashimoto, Makoto; Bar-On, Pazit; Ho, Gilbert J.; Crews, Leslie; Mizuno, Hideya; Rockenstein, Edward; Imam, Syed Z.; Masliah, Eliezer			alpha-Synuclein aggregates interfere with parkin solubility and distribution - Role in the pathogenesis of Parkinson disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEWY BODY DISEASE; UBIQUITIN-PROTEIN LIGASE; CENTRAL-NERVOUS-SYSTEM; NEUROBLASTOMA-CELLS; NEURODEGENERATIVE DISORDERS; NACP/ALPHA-SYNUCLEIN; ALZHEIMERS-DISEASE; IN-VITRO; PROTEASOMAL ACTIVITY; S-NITROSYLATION	Parkinson disease (PD) belongs to a heterogeneous group of neurodegenerative disorders with movement alterations, cognitive impairment, and alpha-synuclein accumulation in cortical and subcortical regions. Jointly, these disorders are denominated Lewy body disease. Mutations in the parkin gene are the most common cause of familial parkinsonism, and a growing number of studies have shown that stress factors associated with sporadic PD promote parkin accumulation in the insoluble fraction. alpha-Synuclein and parkin accumulation and mutations in these genes have been associated with familial PD. To investigate whether alpha-synuclein accumulation might be involved in the pathogenesis of these disorders by interfering with parkin solubility, synuclein-transfected neuronal cells were transduced with lentiviral vectors expressing parkin. Challenging neurons with proteasome inhibitors or amyloid-beta resulted in accumulation of insoluble parkin and, to a lesser extent, alpha-tubulin. Similarly to neurons in the brains of patients with Lewy body disease, in co-transduced cells alpha-synuclein and parkin colocalized and co-immunoprecipitated. These effects resulted in decreased parkin and alpha-tubulin ubiquitination, accumulation of insoluble parkin, and cytoskeletal alterations with reduced neurite outgrowth. Taken together, accumulation of alpha-synuclein might contribute to the pathogenesis of PD and other Lewy body diseases by promoting alterations in parkin and tubulin solubility, which in turn might compromise neural function by damaging the neuronal cytoskeleton. These studies provide a new perspective on the potential nature of pathogenic alpha-synuclein and parkin interactions in Parkinson disease.	[Imam, Syed Z.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA; [Imam, Syed Z.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA; [Imam, Syed Z.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Aging & Longev Studies, San Antonio, TX 78229 USA; [Kawahara, Kohichi; Hashimoto, Makoto; Bar-On, Pazit; Ho, Gilbert J.; Mizuno, Hideya; Rockenstein, Edward; Masliah, Eliezer] Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92039 USA; [Crews, Leslie; Masliah, Eliezer] Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92039 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of California System; University of California San Diego; University of California System; University of California San Diego	Masliah, E (corresponding author), Univ Calif San Diego, Dept Neurosci, 9500 Gilman Dr, La Jolla, CA 92093 USA.	emasliah@ucsd.edu	Kawahara, Kohichi/AAQ-5381-2021; Crews, Leslie/B-7584-2014	Crews, Leslie/0000-0003-0704-0067	NATIONAL INSTITUTE ON AGING [R37AG018440, R01AG018440, P01AG022074, P01AG010435] Funding Source: NIH RePORTER; NIA NIH HHS [AG10435, AG22074, AG18440] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ardley HC, 2003, MOL BIOL CELL, V14, P4541, DOI 10.1091/mbc.E03-02-0078; Betarbet R, 2005, EXP NEUROL, V191, pS17, DOI 10.1016/j.expneurol.2004.08.021; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Chandra S, 2005, CELL, V123, P383, DOI 10.1016/j.cell.2005.09.028; Choi P, 2000, NEUROREPORT, V11, P2635, DOI 10.1097/00001756-200008210-00006; Choi P, 2001, NEUROREPORT, V12, P2839, DOI 10.1097/00001756-200109170-00017; Chung KKK, 2005, METHOD ENZYMOL, V396, P139, DOI 10.1016/S0076-6879(05)96014-X; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; De Girolamo LA, 2000, J NEUROCHEM, V75, P133, DOI 10.1046/j.1471-4159.2000.0750133.x; Dickson DW, 2001, CURR OPIN NEUROL, V14, P423, DOI 10.1097/00019052-200108000-00001; Dickson DW, 1996, J NEURAL TRANSM-SUPP, P31; Drolet RE, 2004, NEUROTOXICOLOGY, V25, P761, DOI 10.1016/j.neuro.2004.05.002; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Golbe LI, 2004, ANN NEUROL, V55, P153, DOI 10.1002/ana.20036; GREGORI L, 1995, J BIOL CHEM, V270, P19702, DOI 10.1074/jbc.270.34.19702; Hampe C, 2006, HUM MOL GENET, V15, P2059, DOI 10.1093/hmg/ddl131; Hashimoto M, 2004, GENE THER, V11, P1713, DOI 10.1038/sj.gt.3302349; Hashimoto M, 2003, NEUROCHEM RES, V28, P1743, DOI 10.1023/A:1026073324672; Hashimoto M, 1999, NEUROREPORT, V10, P717, DOI 10.1097/00001756-199903170-00011; Hashimoto M, 1998, BRAIN RES, V799, P301, DOI 10.1016/S0006-8993(98)00514-9; Hashimoto M, 2003, J NEUROCHEM, V85, P1468, DOI 10.1046/j.1471-4159.2003.01791.x; Hashimoto M, 2001, NEURON, V32, P213, DOI 10.1016/S0896-6273(01)00462-7; Hattori N, 2003, J NEUROL, V250, P2, DOI 10.1007/s00415-003-1302-y; Haywood AFM, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-14; Hyun DH, 2005, J NEUROSCI RES, V82, P232, DOI 10.1002/jnr.20638; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Irizarry MC, 1998, J NEUROPATH EXP NEUR, V57, P334, DOI 10.1097/00005072-199804000-00005; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; Iwai A, 1996, BRAIN RES, V720, P230, DOI 10.1016/0006-8993(96)00014-5; Jensen LD, 2006, NEUROREPORT, V17, P1205, DOI 10.1097/01.wnr.0000230511.63220.e3; Jiang HB, 2004, HUM MOL GENET, V13, P1745, DOI 10.1093/hmg/ddh180; Jin KL, 2004, P NATL ACAD SCI USA, V101, P13363, DOI 10.1073/pnas.0403678101; Junn E, 2002, J BIOL CHEM, V277, P47870, DOI 10.1074/jbc.M203159200; Kahle PJ, 2004, EMBO REP, V5, P681, DOI 10.1038/sj.embor.7400188; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Ko HS, 2005, J NEUROSCI, V25, P7968, DOI 10.1523/JNEUROSCI.2172-05.2005; KOSAKA K, 1984, CLIN NEUROPATHOL, V3, P183; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Kyratzi E, 2007, J NEUROCHEM, V102, P1292, DOI 10.1111/j.1471-4159.2007.04620.x; Lashuel HA, 2002, J MOL BIOL, V322, P1089, DOI 10.1016/S0022-2836(02)00735-0; Lee HJ, 2006, EUR J NEUROSCI, V24, P3153, DOI 10.1111/j.1460-9568.2006.05210.x; Lo Bianco C, 2004, P NATL ACAD SCI USA, V101, P17510, DOI 10.1073/pnas.0405313101; Marr RA, 2003, J NEUROSCI, V23, P1992; MARSHALL LE, 1978, BIOCHIM BIOPHYS ACTA, V543, P590, DOI 10.1016/0304-4165(78)90315-X; MASLIAH E, 1993, BRAIN PATHOL, V3, P77, DOI 10.1111/j.1750-3639.1993.tb00728.x; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; McInerney-Leo A, 2005, MOVEMENT DISORD, V20, P1, DOI 10.1002/mds.20316; McKeith IG, 2005, NEUROLOGY, V65, P1863, DOI 10.1212/01.wnl.0000187889.17253.b1; McNaught KS, 2003, EXP NEUROL, V179, P38, DOI 10.1006/exnr.2002.8050; Moore DJ, 2005, ANNU REV NEUROSCI, V28, P57, DOI 10.1146/annurev.neuro.28.061604.135718; Mouradian MM, 2002, NEUROLOGY, V58, P179, DOI 10.1212/WNL.58.2.179; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; Ren Y, 2003, J NEUROSCI, V23, P3316; Safadi SS, 2007, BIOCHEMISTRY-US, V46, P14162, DOI 10.1021/bi7016969; Schlossmacher MG, 2002, AM J PATHOL, V160, P1655, DOI 10.1016/S0002-9440(10)61113-3; Shastry BS, 2001, NEUROSCI RES, V41, P5, DOI 10.1016/S0168-0102(01)00254-1; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Snyder H, 2004, J MOL NEUROSCI, V24, P425, DOI 10.1385/JMN:24:3:425; Souza JM, 2000, FEBS LETT, V474, P116, DOI 10.1016/S0014-5793(00)01563-5; Springer W, 2005, HUM MOL GENET, V14, P3407, DOI 10.1093/hmg/ddi371; Sriram SR, 2005, HUM MOL GENET, V14, P2571, DOI 10.1093/hmg/ddi292; Takeda A, 1998, AM J PATHOL, V152, P367; Takenouchi T, 2001, MOL CELL NEUROSCI, V17, P141, DOI 10.1006/mcne.2000.0923; Tang BS, 2006, HUM MOL GENET, V15, P1816, DOI 10.1093/hmg/ddl104; Trojanowski JQ, 1998, CELL DEATH DIFFER, V5, P832, DOI 10.1038/sj.cdd.4400432; Uversky VN, 2001, J BIOL CHEM, V276, P43495, DOI 10.1074/jbc.C100551200; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; Vila M, 2004, NAT MED, V10, pS58, DOI 10.1038/nm1068; Volles MJ, 2003, BIOCHEMISTRY-US, V42, P7871, DOI 10.1021/bi030086j; Wakabayashi K, 1998, ACTA NEUROPATHOL, V96, P445, DOI 10.1007/s004010050918; Wang C, 2005, HUM MOL GENET, V14, P3885, DOI 10.1093/hmg/ddi413; Wang C, 2005, J NEUROCHEM, V93, P422, DOI 10.1111/j.1471-4159.2005.03023.x; Wong ESP, 2007, J BIOL CHEM, V282, P12310, DOI 10.1074/jbc.M609466200; Yamada M, 2005, HUM GENE THER, V16, P262, DOI 10.1089/hum.2005.16.262; Yao DD, 2004, P NATL ACAD SCI USA, V101, P10810, DOI 10.1073/pnas.0404161101; Zeng BY, 2005, MECH AGEING DEV, V126, P760, DOI 10.1016/j.mad.2005.01.008; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	80	43	45	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					6979	6987		10.1074/jbc.M710418200	http://dx.doi.org/10.1074/jbc.M710418200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18195004	hybrid			2022-12-25	WOS:000253779600042
J	Liu, MY; Tanaka, WN; Zhu, H; Xie, G; Dooley, DM; Lei, BF				Liu, Mengyao; Tanaka, Wesley N.; Zhu, Hui; Xie, Gang; Dooley, David M.; Lei, Benfang			Direct hemin transfer from IsdA to IsdC in the iron-regulated surface determinant (Isd) heme acquisition system of Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOCOCCUS-PYOGENES; PROTEIN SHP; HTSABC TRANSPORTER; BINDING; IDENTIFICATION; HEMOGLOBIN; DISSOCIATION; HEMOPHORE; ENVELOPE	The iron-regulated surface determinants (Isd) of Staphylococcus aureus, including surface proteins IsdA, IsdB, IsdC, and IsdH and ATP-binding cassette transporter IsdDEF, constitute the machinery for acquiring heme as a preferred iron source. Here we report hemin transfer from hemin-containing IsdA (holo-IsdA) to hemin-free IsdC (apo-IsdC). The reaction has an equilibrium constant of 10 +/- 5 at 22 degrees C in favor of holo-IsdC formation. During the reaction, holo-IsdA binds to apo-IsdC and then transfers the cofactor to apo-IsdC with a rate constant of 54.3 +/- 1.8 s(-1) at 25 degrees C. The transfer rate is > 70,000 times greater than the rate of simple hemin dissociation from holo-IsdA into solvent (k(transfer) = 54.3 s(-1) versus k_(hemin) = 0.00076 s(-1)). The standard free energy change, Delta G(0), is - 27 kJ/mol for the formation of the holo-IsdA-apo-IsdC complex. IsdC has a higher affinity for hemin than IsdA. These results indicate that the IsdA-to-IsdC hemin transfer is through the activated holo-IsdA-apo-IsdC complex and is driven by the higher affinity of apo-IsdC for the cofactor. These findings demonstrate for the first time in the Isd system that heme transfer is rapid, direct, and affinity-driven from IsdA to IsdC. These results also provide the first example of heme transfer from one surface protein to another surface protein in Gram-positive bacteria and, perhaps most importantly, indicate that the mechanism of activated heme transfer, which we previously demonstrated between the streptococcal proteins Shp and HtsA, may apply in general to all bacterial heme transport systems.	[Liu, Mengyao; Tanaka, Wesley N.; Zhu, Hui; Xie, Gang; Lei, Benfang] Montana State Univ, Dept Vet Mol Biol, Bozeman, MT 59718 USA; [Dooley, David M.] Montana State Univ, Dept Chem & Biochem, Bozeman, MT 59718 USA	Montana State University System; Montana State University Bozeman; Montana State University System; Montana State University Bozeman	Lei, BF (corresponding author), Montana State Univ, Dept Vet Mol Biol, POB 173610, Bozeman, MT 59717 USA.	blei@montana.edu		Lei, Benfang Lei/0000-0001-8133-6021	NCRR NIH HHS [P20 RR020185, P20 RR-020185] Funding Source: Medline; NIGMS NIH HHS [R01 GM027659, GM27] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR020185] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Andrade MA, 2002, GENOME BIOL, V3; ANDRADE R, 2007, J MOL BIOL, V374, P374; Ascoli F, 1981, Methods Enzymol, V76, P72; Bates CS, 2003, INFECT IMMUN, V71, P1042, DOI 10.1128/IAI.71.3.1042-1055.2003; Burkhard KA, 2007, J BIOL CHEM, V282, P15126, DOI 10.1074/jbc.M611121200; de Villiers KA, 2007, J BIOL INORG CHEM, V12, P101, DOI 10.1007/s00775-006-0170-1; Deniau C, 2003, BIOCHEMISTRY-US, V42, P10627, DOI 10.1021/bi030015k; Drazek ES, 2000, MOL MICROBIOL, V36, P68, DOI 10.1046/j.1365-2958.2000.01818.x; Dryla A, 2003, MOL MICROBIOL, V49, P37, DOI 10.1046/j.1365-2958.2003.03542.x; Fuhrhop J. H., 1975, PORPHYRINS METALLOPO, P804; Grigg JC, 2007, MOL MICROBIOL, V63, P139, DOI 10.1111/j.1365-2958.2006.05502.x; GRITTITHS E, 1999, IRON INFECTION MOL P, P87; HARGROVE MS, 1994, J BIOL CHEM, V269, P4207; Hargrove MS, 1996, BIOCHEMISTRY-US, V35, P11293, DOI 10.1021/bi960371l; Hargrove MS, 1997, J BIOL CHEM, V272, P17385, DOI 10.1074/jbc.272.28.17385; Izadi-Pruneyre N, 2006, J BIOL CHEM, V281, P25541, DOI 10.1074/jbc.M603698200; KLEBBA PE, 1993, J BIOENERG BIOMEMBR, V25, P603; Lei BF, 2003, INFECT IMMUN, V71, P5962, DOI 10.1128/IAI.71.10.5962-5969.2003; Lei BF, 2002, INFECT IMMUN, V70, P4494, DOI 10.1128/IAI.70.8.4494-4500.2002; Liu MY, 2005, INFECT IMMUN, V73, P5086, DOI 10.1128/IAI.73.8.5086-5092.2005; Mack J, 2004, BIOCHEM BIOPH RES CO, V320, P781, DOI 10.1016/j.bbrc.2004.06.025; Maresso AW, 2006, BIOMETALS, V19, P193, DOI 10.1007/s10534-005-4863-7; Maresso AW, 2006, J BACTERIOL, V188, P8145, DOI 10.1128/JB.01011-06; Mazmanian SK, 2003, SCIENCE, V299, P906, DOI 10.1126/science.1081147; Nygaard TK, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-82; Nygaard TK, 2006, J BIOL CHEM, V281, P20761, DOI 10.1074/jbc.M601832200; Ran YC, 2007, J BIOL CHEM, V282, P31380, DOI 10.1074/jbc.M705967200; Reniere ML, 2007, BIOMETALS, V20, P333, DOI 10.1007/s10534-006-9032-0; Sharp KH, 2007, J BIOL CHEM, V282, P10625, DOI 10.1074/jbc.M700234200; Skaar EP, 2004, SCIENCE, V305, P1626, DOI 10.1126/science.1099930; Torres VJ, 2006, J BACTERIOL, V188, P8421, DOI 10.1128/JB.01335-06; Vermeiren CL, 2006, BIOCHEMISTRY-US, V45, P12867, DOI 10.1021/bi0607711; Zhu H, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-15	33	103	110	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					6668	6676		10.1074/jbc.M708372200	http://dx.doi.org/10.1074/jbc.M708372200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18184657	Green Accepted, hybrid			2022-12-25	WOS:000253779600008
J	Zhu, HS; Casselman, A; Reppert, SM				Zhu, Haisun; Casselman, Amy; Reppert, Steven M.			Chasing Migration Genes: A Brain Expressed Sequence Tag Resource for Summer and Migratory Monarch Butterflies (Danaus plexippus)	PLOS ONE			English	Article							OUABAIN BINDING-SITE; ENDOCRINE REGULATION; SUN COMPASS; GENOME; CLOCK; TIME; INSENSITIVITY; LEPIDOPTERA; MUTAGENESIS; RESIDUES	North American monarch butterflies (Danaus plexippus) undergo a spectacular fall migration. In contrast to summer butterflies, migrants are juvenile hormone (JH) deficient, which leads to reproductive diapause and increased longevity. Migrants also utilize time-compensated sun compass orientation to help them navigate to their overwintering grounds. Here, we describe a brain expressed sequence tag (EST) resource to identify genes involved in migratory behaviors. A brain EST library was constructed from summer and migrating butterflies. Of 9,484 unique sequences, 6068 had positive hits with the non-redundant protein database; the EST database likely represents similar to 52% of the gene-encoding potential of the monarch genome. The brain transcriptome was cataloged using Gene Ontology and compared to Drosophila. Monarch genes were well represented, including those implicated in behavior. Three genes involved in increased JH activity (allatotropin, juvenile hormone acid methyltransfersase, and takeout) were upregulated in summer butterflies, compared to migrants. The locomotion-relevant turtle gene was marginally upregulated in migrants, while the foraging and single-minded genes were not differentially regulated. Many of the genes important for the monarch circadian clock mechanism (involved in sun compass orientation) were in the EST resource, including the newly identified cryptochrome 2. The EST database also revealed a novel Na+/K+ ATPase allele predicted to be more resistant to the toxic effects of milkweed than that reported previously. Potential genetic markers were identified from 3,486 EST contigs and included 1599 double-hit single nucleotide polymorphisms (SNPs) and 98 microsatellite polymorphisms. These data provide a template of the brain transcriptome for the monarch butterfly. Our "snap-shot'' analysis of the differential regulation of candidate genes between summer and migratory butterflies suggests that unbiased, comprehensive transcriptional profiling will inform the molecular basis of migration. The identified SNPs and microsatellite polymorphisms can be used as genetic markers to address questions of population and subspecies structure.	[Zhu, Haisun; Casselman, Amy] Univ Massachusetts, Sch Med, Dept Neurobiol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Reppert, SM (corresponding author), Univ Massachusetts, Sch Med, Dept Neurobiol, Worcester, MA 01605 USA.	steven.reppert@umassmed.edu			NIH [R01 NS047141]; University of Massachusetts Medical School; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047141] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Massachusetts Medical School; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This research was supported by NIH R01 NS047141 and funds from the University of Massachusetts Medical School.	ACKERY PR, 1984, MILKWEED BUTTERFLIES, V7; Beldade P, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-130; Ben-Shahar Y, 2002, SCIENCE, V296, P741, DOI 10.1126/science.1069911; Bodily KD, 2001, J NEUROSCI, V21, P3113, DOI 10.1523/JNEUROSCI.21-09-03113.2001; Bonaldo MDF, 1996, GENOME RES, V6, P791, DOI 10.1101/gr.6.9.791; Brower AVZ, 2004, ANN ENTOMOL SOC AM, V97, P519, DOI 10.1603/0013-8746(2004)097[0519:GPASON]2.0.CO;2; BROWER AVZ, 1991, EVOLUTION, V45, P1281, DOI 10.1111/j.1558-5646.1991.tb04393.x; Brower Lincoln P., 1995, Journal of the Lepidopterists' Society, V49, P304; Brower LP, 1996, J EXP BIOL, V199, P93; Collins B, 2007, PFLUG ARCH EUR J PHY, V454, P857, DOI 10.1007/s00424-006-0188-9; Crosby MA, 2007, NUCLEIC ACIDS RES, V35, pD486, DOI 10.1093/nar/gkl827; Croyle ML, 1997, EUR J BIOCHEM, V248, P488, DOI 10.1111/j.1432-1033.1997.00488.x; EANES WF, 1978, EVOLUTION, V32, P784, DOI 10.1111/j.1558-5646.1978.tb04633.x; Froy O, 2003, SCIENCE, V300, P1303, DOI 10.1126/science.1084874; Goehring L, 2002, ECOL ENTOMOL, V27, P674, DOI 10.1046/j.1365-2311.2002.00454.x; Gregory TR, 2007, NUCLEIC ACIDS RES, V35, pD332, DOI 10.1093/nar/gkl828; Heinze S, 2007, SCIENCE, V315, P995, DOI 10.1126/science.1135531; Herman WS, 2001, P ROY SOC B-BIOL SCI, V268, P2509, DOI 10.1098/rspb.2001.1765; HERMAN WS, 1975, GEN COMP ENDOCR, V26, P534, DOI 10.1016/0016-6480(75)90176-8; HERMAN WS, 1985, MIGRATION MECH ADA S, V27, P799; Holt RA, 2002, SCIENCE, V298, P129, DOI 10.1126/science.1076181; HOLZINGER F, 1992, FEBS LETT, V314, P477, DOI 10.1016/0014-5793(92)81530-Y; Holzinger F, 1996, J CHEM ECOL, V22, P1921, DOI 10.1007/BF02028512; Huntley D, 2006, BIOINFORMATICS, V22, P495, DOI 10.1093/bioinformatics/btk006; Johny S, 2006, PARASITOLOGY, V132, P803, DOI 10.1017/S0031182006009863; LESSMAN CA, 1981, EXPERIENTIA, V37, P599, DOI 10.1007/BF01990072; Li S, 2005, PEPTIDES, V26, P63, DOI 10.1016/j.peptides.2004.08.023; Liu G, 2006, NATURE, V439, P551, DOI 10.1038/nature04381; MALCOLM SB, 1989, EXPERIENTIA, V45, P284, DOI 10.1007/BF01951814; Mebs D, 2000, CHEMOECOLOGY, V10, P201, DOI 10.1007/PL00001823; Min XJ, 2005, NUCLEIC ACIDS RES, V33, pW677, DOI 10.1093/nar/gki394; Mouritsen H, 2002, P NATL ACAD SCI USA, V99, P10162, DOI 10.1073/pnas.152137299; Newman JW, 2005, PROG LIPID RES, V44, P1, DOI 10.1016/j.plipres.2004.10.001; OBERHAUSER KS, 2004, MONARCH BUTTERFLY BI, V8; Papanicolaou A, 2008, NUCLEIC ACIDS RES, V36, pD582, DOI 10.1093/nar/gkm853; PARSONS JA, 1965, J PHYSIOL-LONDON, V178, P290, DOI 10.1113/jphysiol.1965.sp007628; Perez SM, 1997, NATURE, V387, P29, DOI 10.1038/387029a0; Pielage J, 2002, DEV BIOL, V249, P283, DOI 10.1006/dbio.2002.0770; PRICE EM, 1990, J BIOL CHEM, V265, P6638; Reppert SM, 2006, CELL, V124, P233, DOI 10.1016/j.cell.2006.01.009; Sarov-Blat L, 2000, CELL, V101, P647, DOI 10.1016/S0092-8674(00)80876-4; Sauman I, 2005, NEURON, V46, P457, DOI 10.1016/j.neuron.2005.03.014; Shinoda T, 2003, P NATL ACAD SCI USA, V100, P11986, DOI 10.1073/pnas.2134232100; SMITH DS, 1994, BUTTERFLIES W INDIES, V8; Tatar M, 2003, SCIENCE, V299, P1346, DOI 10.1126/science.1081447; THOMAS JB, 1988, CELL, V52, P133, DOI 10.1016/0092-8674(88)90537-5; Urquhart FA., 1960, MONARCH BUTTERFLY; Weinstock GM, 2006, NATURE, V443, P931, DOI 10.1038/nature05260; Wheat CW, 2006, MOL BIOL EVOL, V23, P499, DOI 10.1093/molbev/msj062; Whitfield CW, 2002, GENOME RES, V12, P555, DOI 10.1101/gr.5302; Xia QY, 2004, SCIENCE, V306, P1937, DOI 10.1126/science.1102210; Yuan Q, 2007, MOL BIOL EVOL, V24, P948, DOI 10.1093/molbev/msm011; Zhu HS, 2008, PLOS BIOL, V6, P138, DOI 10.1371/journal.pbio.0060004; Zhu HS, 2005, CURR BIOL, V15, pR953, DOI 10.1016/j.cub.2005.11.030	54	40	43	5	43	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2008	3	1							e1345	10.1371/journal.pone.0001345	http://dx.doi.org/10.1371/journal.pone.0001345			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366GT	18183285	Green Submitted, Green Published, gold			2022-12-25	WOS:000260469400001
J	Asim, M; Siddiqui, IA; Hafeez, BB; Baniahmad, A; Mukhtar, H				Asim, M.; Siddiqui, I. A.; Hafeez, B. B.; Baniahmad, A.; Mukhtar, H.			Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells	ONCOGENE			English	Article						androgen receptor; casodex; invasion; prostate cancer; PP2; Src kinase	GROWTH-FACTOR-I; MOUSE MODEL; INHIBITION; ACTIVATION; RNA; PHOSPHORYLATION; COACTIVATOR-1; PROGRESSION; METASTASIS; EXPRESSION	Prostate cancer is one of the most prominent malignancies of elderly men in many Western countries including Europe and the United States with increasing trend worldwide. The growth of normal prostate as well as of prostate carcinoma cells depends on functional androgen receptor (AR) signaling. AR manifests the biological actions of androgens and its transcriptional activity is known to be influenced by signal transduction pathways. Here we show that Src, a nonreceptor tyrosine kinase, is overexpressed in androgen-independent prostate carcinoma C4-2 cells. Interestingly, the expression of Src was found to progressively increase (up to threefold) in transgenic adenocarcinoma of mouse prostate mice as a function of age and cancer progression. Blocking Src kinase function by a specific inhibitor, PP2, resulted in decreased AR transactivation function on two different reporters, mouse mammary tumor virus (MMTV) and prostate-specific antigen (PSA). Consistent with this, overexpression of a functional Src mutant also led to a dramatic decrease in AR transactivation potential in a hormone-dependent manner. Interference with Src function in C4-2 cells led to decreased recruitment of AR on the target gene PSA enhancer and also resulted in the abrogation of hormone-dependent PSA transcript induction. Src inhibition also led to a dramatic decrease in the cell invasion in addition to decreasing the cellular growth. We suggest that targeting Src kinase could be an effective strategy to inhibit prostate cancer growth and metastasis.	[Mukhtar, H.] Univ Wisconsin, Dept Dermatol, Med Sci Ctr, Madison, WI 53706 USA; [Asim, M.; Baniahmad, A.] Univ Jena, Fac Med, Inst Human Genet & Anthropol, Jena, Germany; [Baniahmad, A.] Univ Kuopio, Dept Biosci, FIN-70211 Kuopio, Finland	University of Wisconsin System; University of Wisconsin Madison; Friedrich Schiller University of Jena; University of Eastern Finland	Mukhtar, H (corresponding author), Univ Wisconsin, Dept Dermatol, Med Sci Ctr, 1300 Univ Ave,Med Sci Ctr 25B, Madison, WI 53706 USA.	aban@mti.uni-jena.de; hmukhtar@wisc.edu	Siddiqui, Imtiaz/B-6587-2009		NCI NIH HHS [R01 CA101039, R01CA101039, R01 CA120451, R01CA78809, R01 CA078809, R01CA120451] Funding Source: Medline; NIDDK NIH HHS [P50 DK065303, P50DK065303-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA120451, R01CA078809, R01CA101039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK065303] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abreu-Martin MT, 1999, MOL CELL BIOL, V19, P5143; Adhami VM, 2004, CANCER RES, V64, P8715, DOI 10.1158/0008-5472.CAN-04-2840; Baniahmad A, 2005, J STEROID BIOCHEM, V93, P89, DOI 10.1016/j.jsbmb.2004.12.012; BRINKMANN AO, 1992, J STEROID BIOCHEM, V41, P361, DOI 10.1016/0960-0760(92)90362-M; Castoria G, 2003, J CELL BIOL, V161, P547, DOI 10.1083/jcb.200211099; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Chen S, 1998, MOL ENDOCRINOL, V12, P1558, DOI 10.1210/me.12.10.1558; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; CULIG Z, 1994, CANCER RES, V54, P5474; Dehm SM, 2007, MOL ENDOCRINOL, V21, P2855, DOI 10.1210/me.2007-0223; Dotzlaw H, 2002, MOL ENDOCRINOL, V16, P661, DOI 10.1210/me.16.4.661; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Guo ZY, 2006, CANCER CELL, V10, P309, DOI 10.1016/j.ccr.2006.08.021; Haag P, 2005, J STEROID BIOCHEM, V96, P251, DOI 10.1016/j.jsbmb.2005.04.029; Isaacs JT, 2000, JNCI-J NATL CANCER I, V92, P1367, DOI 10.1093/jnci/92.17.1367; Jenster G, 2000, J PATHOL, V191, P227; Jia L, 2005, CANCER RES, V65, P8003, DOI 10.1158/0008-5472.CAN-04-3679; Liao XB, 2005, MOL CANCER THER, V4, P505, DOI 10.1158/1535-7163.MCT-04-0313; Moehren U, 2007, MOL ENDOCRINOL, V21, P1039, DOI 10.1210/me.2006-0468; Notini AJ, 2005, J MOL ENDOCRINOL, V35, P547, DOI 10.1677/jme.1.01884; Perry JE, 1996, PROSTATE, P79; Peterziel H, 1999, ONCOGENE, V18, P6322, DOI 10.1038/sj.onc.1203032; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; Shah YM, 2005, MOL ENDOCRINOL, V19, P732, DOI 10.1210/me.2004-0298; Siddiqui IA, 2006, CARCINOGENESIS, V27, P833, DOI 10.1093/carcin/bgi323; THALMANN GN, 1994, CANCER RES, V54, P2577; Thalmann GN, 2000, PROSTATE, V44, P91; Ueda T, 2002, J BIOL CHEM, V277, P38087, DOI 10.1074/jbc.M203313200; Wang L, 2004, MOL CELL BIOL, V24, P2202, DOI 10.1128/MCB.24.5.2202-2213.2004; YOUNG CYF, 1992, BIOCHEMISTRY-US, V31, P818, DOI 10.1021/bi00118a026	30	65	67	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2008	27	25					3596	3604		10.1038/sj.onc.1211016	http://dx.doi.org/10.1038/sj.onc.1211016			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18223692	Green Accepted			2022-12-25	WOS:000256468500011
J	Ben Sahra, I; Laurent, K; Loubat, A; Giorgetti-Peraldi, S; Colosetti, P; Auberger, P; Tanti, JF; Le Marchand-Brustel, Y; Bost, F				Ben Sahra, I.; Laurent, K.; Loubat, A.; Giorgetti-Peraldi, S.; Colosetti, P.; Auberger, P.; Tanti, J. F.; Le Marchand-Brustel, Y.; Bost, F.			The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level	ONCOGENE			English	Article						prostate cancer; type II diabetes; AMPK; cell cycle; cyclin D1; apoptosis	ACTIVATED PROTEIN-KINASE; PROSTATE-CANCER CELLS; DEPENDENT GROWTH; HIGH-GLUCOSE; APOPTOSIS; DEATH; AMPK; TUMORIGENICITY; OVEREXPRESSION; TRANSFORMATION	Metformin is a widely used antidiabetic agent, which regulates glucose homeostasis through inhibition of liver glucose production and an increase in muscle glucose uptake. Recent studies suggest that metformin may reduce the risk of cancer, but its mode of action in cancer remains not elucidated. We investigated the effect of metformin on human prostate cancer cell proliferation in vitro and in vivo. Metformin inhibited the proliferation of DU145, PC-3 and LNCaP cancer cells with a 50% decrease of cell viability and had a modest effect on normal prostate epithelial cell line P69. Metformin did not induce apoptosis but blocked cell cycle in G(0)/G(1). This blockade was accompanied by a strong decrease of cyclin D1 protein level, pRb phosphorylation and an increase in p27(kip) protein expression. Metformin activated the AMP kinase pathway, a fuel sensor signaling pathway. However, inhibition of the AMPK pathway using siRNA against the two catalytic subunits of AMPK did not prevent the antiproliferative effect of metformin in prostate cancer cells. Importantly, oral and intraperitoneal treatment with metformin led to a 50 and 35% reduction of tumor growth, respectively, in mice bearing xenografts of LNCaP. Similar, to the in vitro study, metformin led to a strong reduction of cyclin D1 protein level in tumors providing evidence for a mechanism that may contribute to the antineoplastic effects of metformin suggested by recent epidemiological studies.	[Ben Sahra, I.; Laurent, K.; Giorgetti-Peraldi, S.; Tanti, J. F.; Le Marchand-Brustel, Y.; Bost, F.] Univ Nice Sophia Antipolis, INSERM, U568, F-06204 Nice 03, France; [Ben Sahra, I.; Laurent, K.; Loubat, A.; Giorgetti-Peraldi, S.; Colosetti, P.; Auberger, P.; Tanti, J. F.; Le Marchand-Brustel, Y.; Bost, F.] Univ Nice Sophia Antipolis, IFR50, F-06204 Nice 03, France; [Loubat, A.] Fac Med Nice, INSERM, U638, F-06034 Nice, France; [Colosetti, P.; Auberger, P.] Fac Med Nice, INSERM, U526, F-06034 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Bost, F (corresponding author), Univ Nice Sophia Antipolis, INSERM, U568, Batiment ARCHIMED,151 Route St Antoine Ginestiere, F-06204 Nice 03, France.	bost@unice.fr	Colosetti, Pascal/ABH-4585-2020; AUBERGER, Patrick/G-1491-2013; BOST, Frederic/AAN-4691-2020	AUBERGER, Patrick/0000-0002-2481-8275; BOST, Frederic/0000-0003-4509-4701; Tanti, Jean-Francois/0000-0003-1782-1318; Colosetti, Pascal/0000-0002-5848-6053; Giorgetti-Peraldi, Sophie/0000-0002-2751-2618				Alao JP, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-24; An D, 2006, DIABETOLOGIA, V49, P2174, DOI 10.1007/s00125-006-0338-9; Aouadi M, 2006, DIABETES, V55, P281, DOI 10.2337/diabetes.55.02.06.db05-0963; Bost F, 1999, MOL CELL BIOL, V19, P1938; Bost F, 2000, METHOD ENZYMOL, V314, P342; CAMPBELL IW, 1985, HORM METAB RES, V15, P105; Chen Y, 1998, ONCOGENE, V16, P1913, DOI 10.1038/sj.onc.1201719; Collins SP, 2000, BIOCHEM J, V345, P673, DOI 10.1042/0264-6021:3450673; Dagon Y, 2006, BIOCHEM BIOPH RES CO, V340, P43, DOI 10.1016/j.bbrc.2005.11.159; Davis JN, 2006, CANCER RES, V66, P11897, DOI 10.1158/0008-5472.CAN-06-2497; Denmeade SR, 2004, PROSTATE, V58, P211, DOI 10.1002/pros.10360; Detaille D, 2005, DIABETES, V54, P2179, DOI 10.2337/diabetes.54.7.2179; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Drobnjak M, 2000, CLIN CANCER RES, V6, P1891; El-Mir MY, 2000, J BIOL CHEM, V275, P223, DOI 10.1074/jbc.275.1.223; Erlich S, 2006, BIOCHEM PHARMACOL, V72, P427, DOI 10.1016/j.bcp.2006.05.007; Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7; Guigas B, 2006, DIABETES, V55, P865, DOI 10.2337/diabetes.55.04.06.db05-1178; Han EKH, 1998, PROSTATE, V35, P95, DOI 10.1002/(SICI)1097-0045(19980501)35:2<95::AID-PROS2>3.0.CO;2-F; Hardie DG, 2003, ENDOCRINOLOGY, V144, P5179, DOI 10.1210/en.2003-0982; Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420; Herrant M, 2004, ONCOGENE, V23, P7863, DOI 10.1038/sj.onc.1208069; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Ibanez L, 2006, J CLIN ENDOCR METAB, V91, P2888, DOI 10.1210/jc.2006-0336; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kim WH, 2007, CELL SIGNAL, V19, P791, DOI 10.1016/j.cellsig.2006.10.004; Libertini SJ, 2006, PROSTATE, V66, P70, DOI 10.1002/pros.20314; Lord JM, 2003, BRIT MED J, V327, P951, DOI 10.1136/bmj.327.7421.951; Loubat A, 1999, ONCOGENE, V18, P3324, DOI 10.1038/sj.onc.1202668; Marchesini G, 2001, LANCET, V358, P893, DOI 10.1016/S0140-6736(01)06042-1; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Park C, 2006, MOL CANCER THER, V5, P3191, DOI 10.1158/1535-7163.MCT-06-0570; Perry JE, 1998, PROSTATE, V35, P117; Plymate SR, 1996, J CLIN ENDOCR METAB, V81, P3709, DOI 10.1210/jc.81.10.3709; Ruderman NB, 2003, ACTA PHYSIOL SCAND, V178, P435, DOI 10.1046/j.1365-201X.2003.01164.x; Schneider MB, 2001, GASTROENTEROLOGY, V120, P1263, DOI 10.1053/gast.2001.23258; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zakikhani M, 2006, CANCER RES, V66, P10269, DOI 10.1158/0008-5472.CAN-06-1500; Zhang Y, 2007, FRONT BIOSCI, V12, P4855, DOI 10.2741/2433; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505	42	682	704	1	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2008	27	25					3576	3586		10.1038/sj.onc.1211024	http://dx.doi.org/10.1038/sj.onc.1211024			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18212742				2022-12-25	WOS:000256468500009
J	Lopez-Serra, L; Ballestar, E; Ropero, S; Setien, F; Billard, LM; Fraga, MF; Lopez-Nieva, P; Alaminos, M; Guerrero, D; Dante, R; Esteller, M				Lopez-Serra, L.; Ballestar, E.; Ropero, S.; Setien, F.; Billard, L-M; Fraga, M. F.; Lopez-Nieva, P.; Alaminos, M.; Guerrero, D.; Dante, R.; Esteller, M.			Unmasking of epigenetically silenced candidate tumor suppressor genes by removal of methyl-CpG-binding domain proteins	ONCOGENE			English	Article						DNA methylation; epigenetics; methyl-CpG-binding domain proteins; tumor suppressor genes; RNA interference	HISTONE DEACETYLASE COMPLEX; DNA METHYLATION; RETT-SYNDROME; TRANSCRIPTIONAL REPRESSION; CHROMOSOMAL-PROTEIN; CANCER-CELLS; MECP2; MBD2; IDENTIFICATION; ASSOCIATION	Methyl-cytosine-phosphate-guanine (CpG)-binding domain (MBD) proteins are bound to hypermethylated promoter CpG islands of tumor suppressor genes in human cancer cells, although a direct causal relationship at the genome-wide level between MBD presence and gene silencing remains to be demonstrated. To this end, we have inhibited the expression of MBD proteins in HeLa cells by short hairpin RNAs; and studied the functional consequences of MBD depletion using microarray-based expression analysis in conjunction with extensive bisulfite genomic sequencing and chromatin immunoprecipitation. The removal of MBDs results in a release of gene silencing associated witha loss of MBD occupancy in 5'-CpG islands without any change in the DNA methylation pattern. Our results unveil new targets for epigenetic inactivation mediated by MBDs in transformed cells, such as the cell adhesion protein gamma-parvin and the fibroblast growth factor 19, where we also demonstrate their bona. de tumor suppressor features. Our data support a fundamental role for MBD proteins in the direct maintenance of transcriptional repression of tumor suppressors and identify new candidate genes for epigenetic disruption in cancer cells.	[Esteller, M.] Spanish Natl Canc Res Ctr CNIO, Canc Epigenet Lab, Mol Pathol Program, Madrid, Spain; [Billard, L-M; Dante, R.] Ctr Leon Berard, INSERM, U590, Oncol Mol Lab, F-69373 Lyon, France; [Alaminos, M.] Univ Granada, Dept Histol, Granada, Spain; [Alaminos, M.] Fdn Hosp Clin, Granada, Spain; [Guerrero, D.] Ctr Invest Biomed, Serv Navarro Salud, Navarra, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; University of Granada; Servicio Navarro de Salud - Osasunbidea	Esteller, M (corresponding author), Spanish Natl Canc Res Ctr CNIO, Canc Epigenet Lab, Mol Pathol Program, C Melchor Fernandez Almagro 3, Madrid, Spain.	mesteller@cnio.es	Nieva, Pilar López/R-9516-2019; ALAMINOS, MIGUEL/N-9960-2016; Esteller, Manel/L-5956-2014; Ballestar, Esteban/ABG-8561-2020; Fraga, Mario F/H-7824-2017	Nieva, Pilar López/0000-0001-6369-2444; ALAMINOS, MIGUEL/0000-0003-4876-2672; Esteller, Manel/0000-0003-4490-6093; Fraga, Mario F/0000-0001-8450-2603; Ballestar, Esteban/0000-0002-1400-2440				Bakker J, 2002, J BIOL CHEM, V277, P22573, DOI 10.1074/jbc.M203009200; Ballestar E, 2005, BIOCHEM CELL BIOL, V83, P374, DOI 10.1139/o05-035; Ballestar E, 2005, HUM GENET, V116, P91, DOI 10.1007/s00439-004-1200-0; Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604; Bernard D, 2006, ONCOGENE, V25, P1358, DOI 10.1038/sj.onc.1209179; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Fatemi M, 2006, J CELL SCI, V119, P3033, DOI 10.1242/jcs.03099; Fournier C, 2002, EMBO J, V21, P6560, DOI 10.1093/emboj/cdf655; Fraga MF, 2003, NUCLEIC ACIDS RES, V31, P1765, DOI 10.1093/nar/gkg249; Fujita N, 2003, J BIOL CHEM, V278, P24132, DOI 10.1074/jbc.M302283200; Fujita N, 1999, MOL CELL BIOL, V19, P6415; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Guy J, 2001, NAT GENET, V27, P322, DOI 10.1038/85899; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hutchins AS, 2002, MOL CELL, V10, P81, DOI 10.1016/S1097-2765(02)00564-6; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Jordan C, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-36; Klose RJ, 2005, MOL CELL, V19, P667, DOI 10.1016/j.molcel.2005.07.021; Koizume S, 2002, NUCLEIC ACIDS RES, V30, P4770, DOI 10.1093/nar/gkf593; LAN MS, 1994, DNA CELL BIOL, V13, P505, DOI 10.1089/dna.1994.13.505; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; Lopez-Serra L, 2006, CANCER RES, V66, P8342, DOI 10.1158/0008-5472.CAN-06-1932; Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; Olski TM, 2001, J CELL SCI, V114, P525; Saito M, 2002, J BIOL CHEM, V277, P35434, DOI 10.1074/jbc.M203455200; Sansom OJ, 2003, NAT GENET, V34, P145, DOI 10.1038/ng1155; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; YIN WS, 1995, J BIOL CHEM, V270, P10147, DOI 10.1074/jbc.270.17.10147; Zhao XY, 2003, P NATL ACAD SCI USA, V100, P6777, DOI 10.1073/pnas.1131928100	39	47	47	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2008	27	25					3556	3566		10.1038/sj.onc.1211022	http://dx.doi.org/10.1038/sj.onc.1211022			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18223687				2022-12-25	WOS:000256468500007
J	Quinzii, CM; Lopez, LC; Von-Moltke, J; Naini, A; Krishna, S; Schuelke, M; Salviati, L; Navas, P; DiMauro, S; Hirano, M				Quinzii, Catarina M.; Lopez, Luis C.; Von-Moltke, Jakob; Naini, Ali; Krishna, Sindu; Schuelke, Markus; Salviati, Leonardo; Navas, Placido; DiMauro, Salvatore; Hirano, Michio			Respiratory chain dysfunction and oxidative stress correlate with severity of primary CoQ(10) deficiency	FASEB JOURNAL			English	Article						mitochondria; reactive oxygen species; COQ2; PDSS2	COENZYME Q(10) DEFICIENCY; MITOCHONDRIAL ELECTRON-TRANSPORT; CEREBELLAR-ATAXIA; MUTATIONS; ENCEPHALOMYOPATHY; SUPEROXIDE; GENE; NEPHROPATHY; METABOLISM; CELLS	Coenzyme Q(10) (CoQ(10)) is essential for electron transport in the mitochondrial respiratory chain and antioxidant defense. Last year, we reported the first mutations in CoQ(10) biosynthetic genes, COQ2, which encodes 4-parahydroxybenzoate: polyprenyl transferase; and PDSS2, which encodes subunit 2 of decaprenyl diphosphate synthase. However, the pathogenic mechanisms of primary CoQ(10) deficiency have not been well characterized. In this study, we investigated the consequence of severe CoQ(10) deficiency on bioenergetics, oxidative stress, and antioxidant defenses in cultured skin fibroblasts harboring COQ2 and PDSS2 mutations. Defects in the first two committed steps of the CoQ(10) biosynthetic pathway produce different biochemical alterations. PDSS2 mutant fibroblasts have 12% CoQ(10) relative to control cells and markedly reduced ATP synthesis, but do not show increased reactive oxygen species (ROS) production, signs of oxidative stress, or increased antioxidant defense markers. In contrast, COQ2 mutant fibroblasts have 30% CoQ(10) with partial defect in ATP synthesis, as well as significantly increased ROS production and oxidation of lipids and proteins. On the basis of a small number of cell lines, our results suggest that primary CoQ(10) deficiencies cause variable defects of ATP synthesis and oxidative stress, which may explain the different clinical features and may lead to more rational therapeutic strategies.	[Quinzii, Catarina M.; Lopez, Luis C.; Von-Moltke, Jakob; Naini, Ali; Krishna, Sindu; DiMauro, Salvatore; Hirano, Michio] Columbia Univ, Med Ctr, Dept Neurol, New York, NY 10032 USA; [Schuelke, Markus] Charite Virchow Univ Hosp, Dept Neuropediat, Berlin, Germany; [Salviati, Leonardo] Univ Padua, Dept Pediat, Serv Genet Clin Epidemiol, Padua, Italy; [Navas, Placido] Univ Pablo Olavide, CSIC, Inst Salud Carlos III, Ctr Andaluz Biol Desarrollo, Seville, Spain; [Navas, Placido] Univ Pablo Olavide, CSIC, Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Raras, Seville, Spain	Columbia University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Padua; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Pablo de Olavide; CSIC - Andalusian Center for Developmental Biology (CABD); Instituto de Salud Carlos III; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Consejo Superior de Investigaciones Cientificas (CSIC); Instituto de Salud Carlos III; Universidad Pablo de Olavide	Hirano, M (corresponding author), Columbia Univ, Med Ctr, Dept Neurol, 1150 St Nicholas Ave,Russ Berrie Med Sci Pavil,Rm, New York, NY 10032 USA.	mh29@columbia.edu	Lopez, Luis Carlos/AAP-9411-2020; NAVAS, PLACIDO/R-5943-2019; Lopez, Luis Carlos/L-5129-2014	Lopez, Luis Carlos/0000-0003-3355-0298; NAVAS, PLACIDO/0000-0002-4115-7966; Lopez, Luis Carlos/0000-0003-3355-0298; Schuelke, Markus/0000-0003-2824-3891	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD057543, P01HD032062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS011766, P50NS011766] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD057543-02, R01 HD057543-01, HD-32062, R01 HD057543, P01 HD032062] Funding Source: Medline; NINDS NIH HHS [NS-11766, P01 NS011766] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Artuch R, 2006, J NEUROL SCI, V246, P153, DOI 10.1016/j.jns.2006.01.021; Aure K, 2004, NEUROLOGY, V63, P727, DOI 10.1212/01.WNL.0000134607.76780.B2; Baracca A, 2007, BBA-BIOENERGETICS, V1767, P913, DOI 10.1016/j.bbabio.2007.05.005; Bentinger M, 2007, MITOCHONDRION, V7, pS41, DOI 10.1016/j.mito.2007.02.006; Boitier E, 1998, J NEUROL SCI, V156, P41, DOI 10.1016/S0022-510X(98)00006-9; Brand MD, 2004, FREE RADICAL BIO MED, V37, P755, DOI 10.1016/j.freeradbiomed.2004.05.034; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Di Giovanni S, 2001, NEUROLOGY, V57, P515, DOI 10.1212/WNL.57.3.515; DiMauro S, 2007, J CLIN INVEST, V117, P587, DOI 10.1172/JCI31423; Diomedi-Camassei F, 2007, J AM SOC NEPHROL, V18, P2773, DOI 10.1681/ASN.2006080833; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; Ferraro P, 2006, P NATL ACAD SCI USA, V103, P18586, DOI 10.1073/pnas.0609020103; Floreani M, 2005, FEBS J, V272, P1124, DOI 10.1111/j.1742-4658.2004.04542.x; Geromel V, 2001, FREE RADICAL RES, V35, P11, DOI 10.1080/10715760100300551; Gironi M, 2004, NEUROLOGY, V62, P818, DOI 10.1212/01.WNL.0000113719.67643.B7; Gonzalez-Aragon D, 2005, BIOFACTORS, V25, P31, DOI 10.1002/biof.5520250105; Heddi A, 1999, J BIOL CHEM, V274, P22968, DOI 10.1074/jbc.274.33.22968; Hirano M, 2006, MITOCHONDRIAL MED, P27; Horvath R, 2006, NEUROLOGY, V66, P253, DOI 10.1212/01.wnl.0000194241.35115.7c; Iuso A, 2006, J BIOL CHEM, V281, P10374, DOI 10.1074/jbc.M513387200; Lalani SR, 2005, ARCH NEUROL-CHICAGO, V62, P317, DOI 10.1001/archneur.62.2.317; Lamperti C, 2003, NEUROLOGY, V60, P1206, DOI 10.1212/01.WNL.0000055089.39373.FC; Le Ber I, 2007, NEUROLOGY, V68, P295, DOI 10.1212/01.wnl.0000252366.10731.43; Lenaz G, 2007, MITOCHONDRION, V7, pS8, DOI 10.1016/j.mito.2007.03.009; Lopez LC, 2006, AM J HUM GENET, V79, P1125, DOI 10.1086/510023; Lopez-Martin JM, 2007, HUM MOL GENET, V16, P1091, DOI 10.1093/hmg/ddm058; Manfredi G, 2002, METHODS, V26, P317, DOI 10.1016/S1046-2023(02)00037-3; Mattiazzi M, 2004, HUM MOL GENET, V13, P869, DOI 10.1093/hmg/ddh103; Miwa S, 2003, FREE RADICAL BIO MED, V35, P938, DOI 10.1016/S0891-5849(03)00464-7; Mollet J, 2007, J CLIN INVEST, V117, P765, DOI 10.1172/JCI29089; Musumeci O, 2001, NEUROLOGY, V56, P849, DOI 10.1212/WNL.56.7.849; Navas P, 2007, MITOCHONDRION, V7, pS34, DOI 10.1016/j.mito.2007.02.010; Nohl H, 2005, REDOX REP, V10, P199, DOI 10.1179/135100005X70170; OGASAHARA S, 1989, P NATL ACAD SCI USA, V86, P2379, DOI 10.1073/pnas.86.7.2379; Pallotti F, 2004, BIOCHEM J, V384, P287, DOI 10.1042/BJ20040561; PASQUALI P, 1981, J BIOENERG BIOMEMBR, V13, P141, DOI 10.1007/BF00763836; Quinzii C, 2006, AM J HUM GENET, V78, P345, DOI 10.1086/500092; Quinzii CM, 2005, NEUROLOGY, V64, P539, DOI 10.1212/01.WNL.0000150588.75281.58; Rahman S, 2001, J PEDIATR-US, V139, P456, DOI 10.1067/mpd.2001.117575; ROBINSON BH, 1992, BIOCHEM MED METAB B, V48, P122, DOI 10.1016/0885-4505(92)90056-5; Rotig A, 2000, LANCET, V356, P391, DOI 10.1016/S0140-6736(00)02531-9; Salviati L, 2005, NEUROLOGY, V65, P606, DOI 10.1212/01.wnl.0000172859.55579.a7; Smith CV, 1996, TOXICOL APPL PHARM, V140, P1, DOI 10.1006/taap.1996.0191; Sobreira C, 1997, NEUROLOGY, V48, P1238, DOI 10.1212/WNL.48.5.1238; SODERBERG K, 1980, J CELL PHYSIOL, V103, P169, DOI 10.1002/jcp.1041030121; Solans A, 2006, HUM MOL GENET, V15, P3063, DOI 10.1093/hmg/ddl248; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; Turunen M, 2004, BBA-BIOMEMBRANES, V1660, P171, DOI 10.1016/j.bbamem.2003.11.012; Uchida N, 2000, J BACTERIOL, V182, P6933, DOI 10.1128/JB.182.24.6933-6939.2000	51	114	120	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1874	1885		10.1096/fj.07-100149	http://dx.doi.org/10.1096/fj.07-100149			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18230681	Green Accepted, Green Submitted			2022-12-25	WOS:000256352700027
J	Stephan, A; Mateos, JM; Kozlov, SV; Cinelli, P; Kistler, AD; Hettwer, S; Rulicke, T; Streit, P; Kunz, B; Sonderegger, P				Stephan, Alexander; Mateos, Jose Maria; Kozlov, Serguei V.; Cinelli, Paolo; Kistler, Andreas David; Hettwer, Stefan; Ruelicke, Thomas; Streit, Peter; Kunz, Beat; Sonderegger, Peter			Neurotrypsin cleaves agrin locally at the synapse	FASEB JOURNAL			English	Article						extracellular proteolysis; mental retardation; cognitive function; synaptic plasticity; synaptosomes	NEURONS; BINDING; GROWTH; EXPRESSION; FILOPODIA; ROLES; LOCALIZATION; DYSTROGLYCAN; MODULATION; MATURATION	The synaptic serine protease neurotrypsin is considered to be essential for the establishment and maintenance of cognitive brain functions, because humans lacking functional neurotrypsin suffer from severe mental retardation. Neurotrypsin cleaves agrin at two homologous sites, liberating a 90-kDa and a C-terminal 22-kDa fragment from the N-terminal moiety of agrin. Morphological analyses indicate that neurotrypsin is contained in presynaptic terminals and externalized in association with synaptic activity, while agrin is localized to the extracellular space at or in the vicinity of the synapse. Here, we present a detailed biochemical analysis of neurotrypsin-mediated agrin cleavage in the murine brain. In brain homogenates, we found that neurotrypsin exclusively cleaves glycanated variants of agrin. Studies with isolated synaptosomes obtained by subcellular fractionation from brains of wild-type and neurotrypsin-overexpressing mice revealed that neurotrypsin-dependent cleavage of agrin was concentrated at synapses, where the most heavily glycanated variants of agrin predominate. Because agrin has been shown to play an important role in the formation and the maintenance of excitatory synapses in the central nervous system, its local cleavage at the synapse implicates the neurotrypsin/agrin system in the regulation of adaptive reorganizations of the synaptic circuitry in the context of cognitive functions, such as learning and memory.	[Stephan, Alexander; Kozlov, Serguei V.; Cinelli, Paolo; Kistler, Andreas David; Kunz, Beat; Sonderegger, Peter] Univ Zurich, Dept Biochem, CH-8057 Zurich, Switzerland; [Ruelicke, Thomas] Univ Zurich, Inst Lab Anim Sci, CH-8057 Zurich, Switzerland; [Mateos, Jose Maria; Streit, Peter] Univ Zurich, Brain Res Inst, CH-8057 Zurich, Switzerland; [Mateos, Jose Maria] Neurotune AG, Schlieren, Switzerland	University of Zurich; University of Zurich; University of Zurich	Sonderegger, P (corresponding author), Univ Zurich, Dept Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	peter.sonderegger@bioc.uzh.ch		Mateos, Jose Maria/0000-0002-3675-6198; Cinelli, Paolo/0000-0002-0163-9055; Kistler, Andreas/0000-0002-4114-9560				Annies M, 2006, MOL CELL NEUROSCI, V31, P515, DOI 10.1016/j.mcn.2005.11.005; Baker KA, 2006, CURR OPIN NEUROBIOL, V16, P529, DOI 10.1016/j.conb.2006.08.002; Barber AJ, 1997, DEV DYNAM, V208, P62, DOI 10.1002/(SICI)1097-0177(199701)208:1<62::AID-AJA6>3.0.CO;2-#; Bezakova G, 2003, NAT REV MOL CELL BIO, V4, P295, DOI 10.1038/nrm1074; Burgess RW, 2002, J NEUROCHEM, V83, P271, DOI 10.1046/j.1471-4159.2002.01102.x; Caroni P, 1997, J NEUROSCI METH, V71, P3, DOI 10.1016/S0165-0270(96)00121-5; Clegg DO, 2003, FRONT BIOSCI-LANDMRK, V8, pD723, DOI 10.2741/1020; Cohen NA, 1997, NEUROSCIENCE, V76, P581, DOI 10.1016/S0306-4522(96)00345-4; FRISCHKNECHT R, 2007, J NEUROSCI IN PRESS; Gesemann M, 1998, J BIOL CHEM, V273, P600, DOI 10.1074/jbc.273.1.600; Gesemann M, 1996, NEURON, V16, P755, DOI 10.1016/S0896-6273(00)80096-3; Gschwend TP, 1997, MOL CELL NEUROSCI, V9, P207, DOI 10.1006/mcne.1997.0616; Halfter W, 1997, J COMP NEUROL, V383, P1; Hilgenberg LGW, 2006, CELL, V125, P359, DOI 10.1016/j.cell.2006.01.052; HOCH W, 1993, NEURON, V11, P479, DOI 10.1016/0896-6273(93)90152-H; Hoover CL, 2003, J CELL BIOL, V161, P923, DOI 10.1083/jcb.200301013; Jontes JD, 2000, NEURON, V27, P11, DOI 10.1016/S0896-6273(00)00003-9; Kappler J, 2000, BIOCHEM BIOPH RES CO, V271, P287, DOI 10.1006/bbrc.2000.2583; Kim JH, 2007, NAT NEUROSCI, V10, P196, DOI 10.1038/nn1839; Knott GW, 2006, NAT NEUROSCI, V9, P1117, DOI 10.1038/nn1747; Koulen P, 1999, EUR J NEUROSCI, V11, P4188, DOI 10.1046/j.1460-9568.1999.00848.x; Kroger S, 2002, NEWS PHYSIOL SCI, V17, P207, DOI 10.1152/01390.2002; Ksiazek I, 2007, J NEUROSCI, V27, P7183, DOI 10.1523/JNEUROSCI.1609-07.2007; Kummer TT, 2006, CURR OPIN NEUROBIOL, V16, P74, DOI 10.1016/j.conb.2005.12.003; Li Z, 1997, NEUROSCIENCE, V79, P191, DOI 10.1016/S0306-4522(96)00654-9; Matus A, 2005, CURR OPIN NEUROBIOL, V15, P67, DOI 10.1016/j.conb.2005.01.015; McCroskery S, 2006, MOL CELL NEUROSCI, V33, P15, DOI 10.1016/j.mcn.2006.06.004; Molinari F, 2002, SCIENCE, V298, P1779, DOI 10.1126/science.1076521; Neuhuber B, 2003, MOL CELL NEUROSCI, V24, P1180, DOI 10.1016/j.mcn.2003.08.008; PHELAN P, 1997, ISOLATION SYNAPTOSOM; Proba K, 1998, BBA-GENE STRUCT EXPR, V1396, P143, DOI 10.1016/S0167-4781(97)00205-4; Reif R, 2007, FASEB J, V21, P3468, DOI 10.1096/fj.07-8800com; Ruegg MA, 1998, TRENDS NEUROSCI, V21, P22, DOI 10.1016/S0166-2236(97)01154-5; Rulicke T, 2004, METH MOL B, V254, P165; Sanes JR, 2001, NAT REV NEUROSCI, V2, P791, DOI 10.1038/35097557; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; Taguchi K, 2007, NEUROSCI LETT, V413, P42, DOI 10.1016/j.neulet.2006.11.061; Toni N, 2007, NAT NEUROSCI, V10, P727, DOI 10.1038/nn1908; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Winder SJ, 2001, TRENDS BIOCHEM SCI, V26, P118, DOI 10.1016/S0968-0004(00)01731-X; Xia B, 2002, MOL CELL NEUROSCI, V19, P539, DOI 10.1006/mcne.2001.1095; Yamaguchi Y, 2002, BBA-GEN SUBJECTS, V1573, P369, DOI 10.1016/S0304-4165(02)00405-1	43	92	98	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1861	1873		10.1096/fj.07-100008	http://dx.doi.org/10.1096/fj.07-100008			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18230682				2022-12-25	WOS:000256352700026
J	Marshall-Batty, KR; Nakai, H				Marshall-Batty, Kimberly R.; Nakai, Hiroshi			Activation of a dormant ClpX recognition motif of bacteriophage mu repressor by inducing high local flexibility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPERATURE-SENSITIVE MUTATIONS; ATP-DEPENDENT PROTEASES; DNA-BINDING; CONFORMATIONAL-CHANGES; IN-VITRO; PROTEIN; DEGRADATION; TRANSPOSITION; SUBSTRATE; OPERATOR	The C-terminal domain (CTD) of bacteriophage Mu immunity repressor ( Rep) regulates DNA binding by the N-terminal domain and degradation by ClpXP protease. Five residues at the Rep C terminus (CTD5) can serve as a ClpX recognition motif, but it is dormant unless activated, a state that can be induced by the presence of dominant-negative mutant repressors ( Vir). Conversion of Rep to ClpXP-sensitive form was associated with not only increased exposure of CTD5 to solvent but also increased CTD motion or flexibility as measured by fluorescence anisotropy. CTD mutations (V183S, K193S, and V196S) promoting ClpXP resistance without destroying the recognition motif prevented increased CTD motion induced by Vir. Suppression of ClpXP protease resistance conferred by the V196S mutation also correlated with restoration of CTD motion. The temperature-sensitive R47Q mutation present in cis within the DNA-binding domain restored ClpXP protease sensitivity to the V196S mutant, and anisotropy analysis indicated that R47Q allows the V196S CTD to gain increased flexibility when Vir was present. The results indicate that the CTD functions to turn the recognition motif on and off, most likely by modulating flexibility of the domain that harbors the ClpX recognition motif, suggesting a general mechanism by which proteins can regulate their own degradation.	[Marshall-Batty, Kimberly R.; Nakai, Hiroshi] Georgetown Univ, Med Ctr, Dept Biochem & Mol & Cellular Biol, Washington, DC 20057 USA	Georgetown University	Nakai, H (corresponding author), Georgetown Univ, Med Ctr, Dept Biochem & Mol & Cellular Biol, Box 571455,3900 Reservoir Rd NW, Washington, DC 20057 USA.	nakaih@georgetown.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058265] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 58265, GM 070441] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alazard R, 1998, EUR J BIOCHEM, V252, P408, DOI 10.1046/j.1432-1327.1998.2520408.x; Bolon DN, 2004, MOL CELL, V13, P443, DOI 10.1016/S1097-2765(04)00027-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cantor C. R., 1980, BIOPHYSICAL CHEM TEC; Defenbaugh DA, 2003, J BIOL CHEM, V278, P52333, DOI 10.1074/jbc.M308724200; Dougan DA, 2003, MOL CELL, V12, P373, DOI 10.1016/j.molcel.2003.08.012; Flynn JM, 2003, MOL CELL, V11, P671, DOI 10.1016/S1097-2765(03)00060-1; Flynn JM, 2001, P NATL ACAD SCI USA, V98, P10584, DOI 10.1073/pnas.191375298; GEUSKENS V, 1992, EMBO J, V11, P5121, DOI 10.1002/j.1460-2075.1992.tb05619.x; Gonciarz-Swiatek M, 1999, J BIOL CHEM, V274, P13999, DOI 10.1074/jbc.274.20.13999; Grimaud R, 1998, J BIOL CHEM, V273, P12476, DOI 10.1074/jbc.273.20.12476; Hauer JA, 1999, BIOCHEMISTRY-US, V38, P6774, DOI 10.1021/bi983074k; Haugland R.P., 2002, HDB FLUORESCENT PROB; Hoskins JR, 2002, P NATL ACAD SCI USA, V99, P11037, DOI 10.1073/pnas.172378899; Jones JM, 1998, J BIOL CHEM, V273, P459, DOI 10.1074/jbc.273.1.459; Jorgensen CI, 1998, MOL MICROBIOL, V27, P41, DOI 10.1046/j.1365-2958.1998.00655.x; Kenniston JA, 2003, CELL, V114, P511, DOI 10.1016/S0092-8674(03)00612-3; Kenniston JA, 2004, J STRUCT BIOL, V146, P130, DOI 10.1016/j.jsb.2003.10.023; Kim YI, 2000, MOL CELL, V5, P639, DOI 10.1016/S1097-2765(00)80243-9; KRAUSE HM, 1986, J BIOL CHEM, V261, P3744; Kriwacki RW, 1996, P NATL ACAD SCI USA, V93, P11504, DOI 10.1073/pnas.93.21.11504; Kruklitis R, 1996, EMBO J, V15, P935, DOI 10.1002/j.1460-2075.1996.tb00428.x; Laachouch JE, 1996, EMBO J, V15, P437, DOI 10.1002/j.1460-2075.1996.tb00374.x; Lackowicz J., 1999, PRINCIPLES FLUORESCE; Lamrani S, 1999, MOL MICROBIOL, V32, P327, DOI 10.1046/j.1365-2958.1999.01352.x; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; Levchenko I, 1997, GENE DEV, V11, P1561, DOI 10.1101/gad.11.12.1561; Marshall-Batty KR, 2008, MOL MICROBIOL, V67, P920, DOI 10.1111/j.1365-2958.2007.06099.x; Marshall-Batty KR, 2003, J BIOL CHEM, V278, P1612, DOI 10.1074/jbc.M209352200; Matouschek A, 2003, CURR OPIN STRUC BIOL, V13, P98, DOI 10.1016/S0959-440X(03)00010-1; MHAMMEDIALAOUI A, 1994, MOL MICROBIOL, V11, P1109, DOI 10.1111/j.1365-2958.1994.tb00387.x; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; Mukhopadhyay B, 2003, MOL MICROBIOL, V47, P171, DOI 10.1046/j.1365-2958.2003.03286.x; Neher SB, 2003, P NATL ACAD SCI USA, V100, P13219, DOI 10.1073/pnas.2235804100; Neuwald AF, 1999, GENOME RES, V9, P27; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Plafker K, 2002, J BIOL CHEM, V277, P30121, DOI 10.1074/jbc.M203006200; Rai SS, 2001, J MOL BIOL, V312, P311, DOI 10.1006/jmbi.2001.4957; Ranquet C, 2001, P NATL ACAD SCI USA, V98, P10220, DOI 10.1073/pnas.171620598; Rousseau P, 1996, J BIOL CHEM, V271, P9739, DOI 10.1074/jbc.271.16.9739; SHAPIRO JA, 1989, J BACTERIOL, V171, P5975, DOI 10.1128/jb.171.11.5975-5986.1989; SHAPIRO JA, 1989, J BACTERIOL, V171, P5963, DOI 10.1128/jb.171.11.5963-5974.1989; Stapelfeldt H, 1999, J AGR FOOD CHEM, V47, P3986, DOI 10.1021/jf9812026; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; Tcherkasskaya O, 2000, BIOCHEMISTRY-US, V39, P1879, DOI 10.1021/bi992117+; VAJDA S, 1994, BIOCHEMISTRY-US, V33, P13977, DOI 10.1021/bi00251a004; VOGEL JL, 1991, J BACTERIOL, V173, P6568, DOI 10.1128/jb.173.20.6568-6577.1991; Vogel JL, 1996, GENETICS, V142, P661; VONHOLDE KE, 1971, PHYS BIOCH; Wah DA, 2002, CHEM BIOL, V9, P1237, DOI 10.1016/S1074-5521(02)00268-5; Weast R.C., 1985, CRC HDB CHEM PHYS; Welty DJ, 1997, J MOL BIOL, V272, P31, DOI 10.1006/jmbi.1997.1193; Wojtyra UA, 2003, J BIOL CHEM, V278, P48981, DOI 10.1074/jbc.M307825200; Zhou YN, 2001, GENE DEV, V15, P627, DOI 10.1101/gad.864401	56	2	3	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9060	9070		10.1074/jbc.M705508200	http://dx.doi.org/10.1074/jbc.M705508200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18230617	Green Published, hybrid			2022-12-25	WOS:000254465800036
J	Arad, G; Hendel, A; Urbanke, C; Curth, U; Livneh, Z				Arad, Gali; Hendel, Ayal; Urbanke, Claus; Curth, Ute; Livneh, Zvi			Single-stranded DNA-binding protein recruits DNA polymerase V to primer termini on RecA-coated DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTAGENIC TRANSLESION REPLICATION; ESCHERICHIA-COLI-SSB; III HOLOENZYME; POL-V; EXONUCLEASE I; LESION BYPASS; GENE-PRODUCT; BETA-SUBUNIT; CHI SUBUNIT; MUTATIONS	Translesion DNA synthesis (TLS) by DNA polymerase V (polV) in Escherichia coli involves accessory proteins, including RecA and single-stranded DNA-binding protein (SSB). To elucidate the role of SSB in TLS we used an in vitro exonuclease protection assay and found that SSB increases the accessibility of 3' primer termini located at abasic sites in RecA-coated gapped DNA. The mutant SSB-113 protein, which is defective in protein-protein interactions, but not in DNA binding, was as effective as wild-type SSB in increasing primer termini accessibility, but deficient in supporting polV-catalyzed TLS. Consistently, the heterologous SSB proteins gp32, encoded by phage T4, and ICP8, encoded by herpes simplex virus 1, could replace E. coli SSB in the TLS reaction, albeit with lower efficiency. Immunoprecipitation experiments indicated that polV directly interacts with SSB and that this interaction is disrupted by the SSB-113 mutation. Taken together our results suggest that SSB functions to recruit polV to primer termini on RecA-coated DNA, operating by two mechanisms: 1) increasing the accessibility of 3' primer termini caused by binding of SSB to DNA and 2) a direct SSB-polV interaction mediated by the C terminus of SSB.	[Arad, Gali; Hendel, Ayal; Livneh, Zvi] Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; [Urbanke, Claus; Curth, Ute] Hannover Med Sch, Inst Biophys Chem, D-30625 Hannover, Germany	Weizmann Institute of Science; Hannover Medical School	Livneh, Z (corresponding author), Weizmann Inst Sci, Dept Biol Chem, Hertzl St, IL-76100 Rehovot, Israel.	zvi.livneh@weizmann.ac.il	Hendel, Ayal/GMW-7991-2022	Hendel, Ayal/0000-0002-3388-6202				Avkin S, 2002, P NATL ACAD SCI USA, V99, P3764, DOI 10.1073/pnas.062038699; Berdichevsky A, 2002, MOL CELL, V10, P917, DOI 10.1016/S1097-2765(02)00679-2; Cadman CJ, 2004, NUCLEIC ACIDS RES, V32, P6378, DOI 10.1093/nar/gkh980; CHASE JW, 1984, J BIOL CHEM, V259, P805; CLENDENNING JB, 1994, BIOPHYS CHEM, V52, P227, DOI 10.1016/0301-4622(94)00036-J; COX MM, 1981, J BIOL CHEM, V256, P4676; CURTH U, 1991, EUR J BIOCHEM, V196, P87, DOI 10.1111/j.1432-1033.1991.tb15789.x; Fedorov R, 2006, NUCLEIC ACIDS RES, V34, P6708, DOI 10.1093/nar/gkl1002; FRANK EG, 1993, P NATL ACAD SCI USA, V90, P8169, DOI 10.1073/pnas.90.17.8169; FRIEDBERG EC, 2006, DNA REPAIR MUTAGENES, P463; Fujii S, 2004, J MOL BIOL, V341, P405, DOI 10.1016/j.jmb.2004.06.017; Fujii S, 2006, EMBO J, V25, P5754, DOI 10.1038/sj.emboj.7601474; Genschel J, 2000, BIOL CHEM, V381, P183, DOI 10.1515/BC.2000.025; GLASSBERG J, 1979, J BACTERIOL, V140, P14, DOI 10.1128/JB.140.1.14-19.1979; Goodwin BK, 2000, J AGR RESOUR ECON, V25, P195; Handa P, 2001, J BIOL CHEM, V276, P16992, DOI 10.1074/jbc.M100393200; Jarosz DF, 2007, TRENDS MICROBIOL, V15, P70, DOI 10.1016/j.tim.2006.12.004; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; Kelman Z, 1998, EMBO J, V17, P2436, DOI 10.1093/emboj/17.8.2436; Kornberg A., 1991, DNA REPLICATION; LIEBERMAN HB, 1981, MOL GEN GENET, V183, P348, DOI 10.1007/BF00270639; LIEBERMAN HB, 1983, MOL GEN GENET, V190, P92, DOI 10.1007/BF00330329; Liu YH, 1998, J BACTERIOL, V180, P1766, DOI 10.1128/JB.180.7.1766-1770.1998; Livneh Z, 2001, J BIOL CHEM, V276, P25639, DOI 10.1074/jbc.R100019200; LOHMAN TM, 1988, TRENDS BIOCHEM SCI, V13, P250; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; Maor-Shoshani A, 2002, BIOCHEMISTRY-US, V41, P14438, DOI 10.1021/bi0262909; MEYER RR, 1990, MICROBIOL REV, V54, P342, DOI 10.1128/MMBR.54.4.342-380.1990; Pham P, 2001, NATURE, V409, P366, DOI 10.1038/35053116; Prakash S, 2005, ANNU REV BIOCHEM, V74, P317, DOI 10.1146/annurev.biochem.74.082803.133250; Reuven NB, 2001, J BIOL CHEM, V276, P5511, DOI 10.1074/jbc.M006828200; Reuven NB, 1999, J BIOL CHEM, V274, P31763, DOI 10.1074/jbc.274.45.31763; Reuven NB, 1998, MOL CELL, V2, P191, DOI 10.1016/S1097-2765(00)80129-X; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; SALLES B, 1983, P NATL ACAD SCI-BIOL, V80, P65, DOI 10.1073/pnas.80.1.65; Sandigursky M, 1996, RADIAT RES, V145, P619, DOI 10.2307/3579281; Sarov-Blat L, 1998, J BIOL CHEM, V273, P5520, DOI 10.1074/jbc.273.10.5520; Savvides SN, 2004, PROTEIN SCI, V13, P1942, DOI 10.1110/ps.04661904; SCHAAPER RM, 1982, MUTAT RES, V106, P1, DOI 10.1016/0027-5107(82)90186-5; Schlacher K, 2005, MOL CELL, V17, P561, DOI 10.1016/j.molcel.2005.01.006; Schlacher K, 2006, NATURE, V442, P883, DOI 10.1038/nature05042; Tang MJ, 2000, NATURE, V404, P1014, DOI 10.1038/35010020; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; Tang MJ, 1998, P NATL ACAD SCI USA, V95, P9755, DOI 10.1073/pnas.95.17.9755; Tomer G, 1999, BIOCHEMISTRY-US, V38, P5948, DOI 10.1021/bi982599+; Tomer G, 1998, P NATL ACAD SCI USA, V95, P14106, DOI 10.1073/pnas.95.24.14106; UMEZU K, 1994, J BIOL CHEM, V269, P30005; Wagner J, 2002, DNA REPAIR, V1, P159, DOI 10.1016/S1568-7864(01)00012-X; WANG TCV, 1982, J BACTERIOL, V151, P186, DOI 10.1128/JB.151.1.186-192.1982; WHITTIER RF, 1981, MOL GEN GENET, V183, P341, DOI 10.1007/BF00270638; WILLIAMS KR, 1984, J BIOL CHEM, V259, P1804; Witte G, 2005, NUCLEIC ACIDS RES, V33, P1662, DOI 10.1093/nar/gki310; Witte G, 2003, NUCLEIC ACIDS RES, V31, P4434, DOI 10.1093/nar/gkg498; WOOD RD, 1986, MOL GEN GENET, V204, P82, DOI 10.1007/BF00330191	56	27	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8274	8282		10.1074/jbc.M710290200	http://dx.doi.org/10.1074/jbc.M710290200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18223256	hybrid			2022-12-25	WOS:000254288000025
J	Levi, S; Rawet, M; Kliouchnikov, L; Parnis, A; Cassel, D				Levi, Sharon; Rawet, Moran; Kliouchnikov, Lena; Parnis, Anna; Cassel, Dan			Topology of amphipathic motifs mediating Golgi localization in ArfGAP1 and its splice isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING-PROTEIN; ADP-RIBOSYLATION FACTOR; COPI VESICLE FORMATION; MEMBRANE CURVATURE; ARF-GAP; DEPENDENT BINDING; ALPHA-SYNUCLEIN; FACTOR-I; COATOMER; HYDROLYSIS	The interaction of the Arf1-directed GTPase-activating protein ArfGAP1 with the Golgi apparatus depends on motifs in its noncatalytic part that are unstructured in solution but are capable of folding into amphipathic helices in vitro upon interaction with poorly packed lipids. In previous studies a few hydrophobic residues that are critical for lipid binding and Golgi localization were identified, but the precise topology of the amphipathic motifs has not been determined. Here we present a detailed analysis of the Golgi targeting and in vitro folding features of the region encompassing the amphipathic motifs (residues 199 294). Point mutation analysis revealed that most hydrophobic residues within this region contribute to Golgi localization, whereas analysis by proline replacements and alanine insertions revealed that Golgi interaction depends on folding into two amphipathic helices with a short interrupting sequence. Analysis of splice isoforms containing 10-residue in-frame insertions within their first amphipathic motifs revealed that the insertion causes a truncation of the amphipathic helix that does not extend beyond the insertion sequence. Lastly, a lysine replacement mutant recently reported to bind to negatively charged liposomes in a curvature-independent manner showed normal cellular distribution, suggesting that Golgi targeting of ArfGAP1 may involve factors other than sensing lipid packing.	[Levi, Sharon; Rawet, Moran; Kliouchnikov, Lena; Parnis, Anna; Cassel, Dan] Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel	Technion Israel Institute of Technology	Cassel, D (corresponding author), Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel.	danc@tx.technion.ac.il						Antonny B, 1997, J BIOL CHEM, V272, P30848, DOI 10.1074/jbc.272.49.30848; Antonny B, 2005, BIOCHEM SOC T, V33, P619, DOI 10.1042/BST0330619; Aoe T, 1997, EMBO J, V16, P7305, DOI 10.1093/emboj/16.24.7305; Bigay J, 2005, EMBO J, V24, P2244, DOI 10.1038/sj.emboj.7600714; Bigay J, 2003, NATURE, V426, P563, DOI 10.1038/nature02108; Chandra S, 2003, J BIOL CHEM, V278, P15313, DOI 10.1074/jbc.M213128200; Chevalier SA, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-70; Cornell RB, 2006, CURR PROTEIN PEPT SC, V7, P539, DOI 10.2174/138920306779025675; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; D'Souza-Schorey C, 2006, NAT REV MOL CELL BIO, V7, P347, DOI 10.1038/nrm1910; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; Drin G, 2007, NAT STRUCT MOL BIOL, V14, P138, DOI 10.1038/nsmb1194; Eugster A, 2000, EMBO J, V19, P3905, DOI 10.1093/emboj/19.15.3905; Fernandez-Ulibarri I, 2007, MOL BIOL CELL, V18, P3250, DOI 10.1091/mbc.E07-04-0334; FRANCO M, 1993, J BIOL CHEM, V268, P24531; Gillingham AK, 2007, ANNU REV CELL DEV BI, V23, P579, DOI 10.1146/annurev.cellbio.23.090506.123209; Goldberg J, 1999, CELL, V96, P893, DOI 10.1016/S0092-8674(00)80598-X; Honda A, 2005, J CELL BIOL, V168, P1039, DOI 10.1083/jcb.200409138; Huber I, 1998, J BIOL CHEM, V273, P24786, DOI 10.1074/jbc.273.38.24786; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Jao CC, 2004, P NATL ACAD SCI USA, V101, P8331, DOI 10.1073/pnas.0400553101; KRUSKAL WH, 1952, J AM STAT ASSOC, V47, P583, DOI 10.1080/01621459.1952.10483441; Lanoix J, 2001, J CELL BIOL, V155, P1199, DOI 10.1083/jcb.200108017; Lee SY, 2005, J CELL BIOL, V168, P281, DOI 10.1083/jcb.200404008; Liu W, 2005, J CELL BIOL, V168, P1053, DOI 10.1083/jcb.200410142; Mesmin B, 2007, BIOCHEMISTRY-US, V46, P1779, DOI 10.1021/bi062288w; MISHRA VK, 1994, J BIOL CHEM, V269, P7185; Nie ZZ, 2006, J CELL SCI, V119, P1203, DOI 10.1242/jcs.02924; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; Parnis A, 2006, J BIOL CHEM, V281, P3785, DOI 10.1074/jbc.M508959200; Randazzo PA, 2004, CELL SIGNAL, V16, P401, DOI 10.1016/j.cellsig.2003.09.012; Rein U, 2002, J CELL BIOL, V157, P395, DOI 10.1083/jcb.200112092; Robinson M, 2006, MOL BIOL CELL, V17, P1845, DOI 10.1091/mbc.E05-09-0832; Sabe H, 2006, CURR OPIN CELL BIOL, V18, P558, DOI 10.1016/j.ceb.2006.08.002; Seelig J, 2004, BBA-BIOMEMBRANES, V1666, P40, DOI 10.1016/j.bbamem.2004.08.004; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Szafer E, 2000, J BIOL CHEM, V275, P23615, DOI 10.1074/jbc.M003171200; Szafer E, 2001, J BIOL CHEM, V276, P47834, DOI 10.1074/jbc.M106000200; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TEAL SB, 1994, J BIOL CHEM, V269, P3135; Wong TA, 2005, P NATL ACAD SCI USA, V102, P12777, DOI 10.1073/pnas.0506156102; Yanagisawa LL, 2002, MOL BIOL CELL, V13, P2193, DOI 10.1091/mbc.01-11-0563; Yang JS, 2006, NAT CELL BIOL, V8, P1376, DOI 10.1038/ncb1503; Yang JS, 2005, EMBO J, V24, P4133, DOI 10.1038/sj.emboj.7600873; Yu S, 2002, MOL BIOL CELL, V13, P2559, DOI 10.1091/mbc.E02-04-0189; Zhao LY, 1999, J BIOL CHEM, V274, P14198, DOI 10.1074/jbc.274.20.14198; Zhao LY, 1997, P NATL ACAD SCI USA, V94, P4418, DOI 10.1073/pnas.94.9.4418	47	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8564	8572		10.1074/jbc.M709738200	http://dx.doi.org/10.1074/jbc.M709738200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18195007	hybrid			2022-12-25	WOS:000254288000055
J	Truong, DM; Kaler, G; Khandelwal, A; Swaan, PW; Nigam, SK				Truong, David M.; Kaler, Gregory; Khandelwal, Akash; Swaan, Peter W.; Nigam, Sanjay K.			Multi-level analysis of organic anion transporters 1, 3, and 6 reveals major differences in structural determinants of antiviral discrimination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSE-TRANSCRIPTASE INHIBITORS; PROXIMAL TUBULE CELLS; SLC22A FAMILY-MEMBERS; CATION TRANSPORTER; MULTIDRUG-RESISTANCE; NUCLEOTIDE ANALOGS; MOLECULAR-CLONING; OLFACTORY MUCOSA; CHOROID-PLEXUS; RAT-KIDNEY	Long-term exposure to antivirals is associated with serious cellular toxicity to the kidney and other tissues. Organic anion transporters (OATs) are believed to mediate the cellular uptake, and hence cytotoxicity, of many antivirals. However, a systematic in vitro and ex vivo analysis of interactions between these compounds with various OAT isoforms has been lacking. To characterize substrate interactions with mOat1, mOat3, and mOat6, a fluorescence-based competition assay in Xenopus oocytes as well as wild-type and knock-out whole embryonic kidney (WEK) organ culture systems was developed using 6-carboxyfluorescein, 5-carboxyfluorescein, and fluorescein. Of nine common antiviral drugs assessed in oocytes, many manifested higher affinity for SLC22a6 (mOat1), originally identified as NKT (e. g. adefovir and cidofovir), two (ddC and ddI) manifested significantly higher affinity for mOat3, while mOat6 had comparatively low but measurable affinity for certain antivirals. A live organ staining approach combined with fluorescent uptake in WEK cultures allowed the visualization of OAT-mediated uptake ex vivo into developing proximal tubule-like structures, as well as quantification of substrate interactions of individual OAT isoforms. In general, antiviral specificity of SLC22a6 (Oat1) (in Oat3(-/-) WEK culture) and SLC22a8 (Oat3) (in Oat1(-/-) WEK culture) was consistent with the Xenopus oocyte data. The combined observations suggest SLC22a8 (Oat3) is the major transporter interacting with ddC and ddI. Finally, quantitative structure-activity relationship analysis of the nine antivirals' physicochemical descriptors with their OAT affinity indicates that antiviral preferences of mOat1 are explained by high polar surface areas (e. g. phosphate groups), whereas mOat3 prefers hydrogen bond acceptors (e. g. amines, ketones) and low rotatable bond numbers. In contrast, hydrogen bond donors (e. g. amides, alcohols) diminish binding to mOat6. This suggests that, despite sharing close overall sequence homology, Oat1, Oat3, and Oat6 have signficantly different binding pockets. Taken together, the data provide a basis for understanding potential drug interactions in combination antiviral therapy, as well as suggesting structural mdifications for drug design, especially in the context of targeting toward or away from specific tissues.	[Truong, David M.; Kaler, Gregory; Nigam, Sanjay K.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Nigam, Sanjay K.] Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; [Nigam, Sanjay K.] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; [Khandelwal, Akash; Swaan, Peter W.] Univ Maryland, Dept Pharmaceut Sci, Baltimore, MD 21201 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University System of Maryland; University of Maryland Baltimore	Nigam, SK (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	snigam@ucsd.edu		Truong, David/0000-0002-5121-5111; Swaan, Peter/0000-0003-1767-1487; Khandelwal, Akash/0000-0002-0472-7173	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD040011] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI057695] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061425] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 057695] Funding Source: Medline; NICHD NIH HHS [HD 40011] Funding Source: Medline; NIDDK NIH HHS [DK 61425] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson PL, 2004, CLIN INFECT DIS, V38, P743, DOI 10.1086/381678; Antonelli A, 1997, BBA-MOL CELL RES, V1358, P39, DOI 10.1016/S0167-4889(97)00027-X; Anzai N, 2005, CURR OPIN NEPHROL HY, V14, P472, DOI 10.1097/01.mnh.0000170751.56527.7e; Bednarczyk D, 2000, PFLUG ARCH EUR J PHY, V440, P184, DOI 10.1007/s004240051038; Bongiovanni M, 2006, CURR MED CHEM, V13, P2789, DOI 10.2174/092986706778521931; BONVENTRE JV, 1988, ANNU REV MED, V39, P531, DOI 10.1146/annurev.med.39.1.531; Brady KP, 1999, GENOMICS, V56, P254, DOI 10.1006/geno.1998.5722; Burckhardt BC, 2003, REV PHYSIOL BIOCH P, V146, P95, DOI 10.1007/s10254-002-0003-8; Cha SH, 2000, J BIOL CHEM, V275, P4507, DOI 10.1074/jbc.275.6.4507; Cha SH, 2001, MOL PHARMACOL, V59, P1277, DOI 10.1124/mol.59.5.1277; Cihlar T, 2000, ANAL BIOCHEM, V283, P49, DOI 10.1006/abio.2000.4633; Cihlar T, 1999, MOL PHARMACOL, V56, P570, DOI 10.1124/mol.56.3.570; Cihlar T, 2001, NUCLEOS NUCLEOT NUCL, V20, P641, DOI 10.1081/NCN-100002341; De Clercq E, 2004, J CLIN VIROL, V30, P115, DOI 10.1016/j.jcv.2004.02.009; DECLERCK LS, 1994, J IMMUNOL METHODS, V172, P115, DOI 10.1016/0022-1759(94)90384-0; Dresser MJ, 2001, J PHARM SCI, V90, P397, DOI 10.1002/1520-6017(200104)90:4<397::AID-JPS1000>3.3.CO;2-4; EPSTEIN FH, 1994, ANN NY ACAD SCI, V718, P72; Epstein FH, 1997, KIDNEY INT, V51, P381, DOI 10.1038/ki.1997.50; Eraly SA, 2006, J BIOL CHEM, V281, P5072, DOI 10.1074/jbc.M508050200; Eraly SA, 2004, MOL PHARMACOL, V65, P479, DOI 10.1124/mol.65.3.479; Eraly SA, 2003, CURR OPIN NEPHROL HY, V12, P551, DOI 10.1097/00041552-200309000-00011; HITCHCOCK MJM, 1993, CLIN INFECT DIS, V16, pS16, DOI 10.1093/clinids/16.Supplement_1.S16; Jacqz-Aigrain E, 2005, SEMIN FETAL NEONAT M, V10, P139, DOI 10.1016/j.siny.2004.09.015; Kaler G, 2007, J BIOL CHEM, V282, P23841, DOI 10.1074/jbc.M703467200; Kaler G, 2006, BIOCHEM BIOPH RES CO, V351, P872, DOI 10.1016/j.bbrc.2006.10.136; Kojima R, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134848; Laitinen L, 1987, J HISTOCHEM CYTOCHEM, V35, P55, DOI 10.1177/35.1.3794309; Lewis W, 2003, PROG CARDIOVASC DIS, V45, P305, DOI 10.1053/pcad.2003.3b; Ljubojevic M, 2004, AM J PHYSIOL-RENAL, V287, pF124, DOI 10.1152/ajprenal.00029.2004; Lopez-Nieto C. E., 1996, Journal of the American Society of Nephrology, V7, P1301; LopezNieto CE, 1997, J BIOL CHEM, V272, P6471, DOI 10.1074/jbc.272.10.6471; Miller DS, 2004, ADV DRUG DELIVER REV, V56, P1811, DOI 10.1016/j.addr.2004.07.010; Monte JC, 2004, BIOCHEM BIOPH RES CO, V323, P429, DOI 10.1016/j.bbrc.2004.08.112; Pacifici GM, 2005, EARLY HUM DEV, V81, P647, DOI 10.1016/j.earlhumdev.2005.02.002; Pietruck F, 2006, DRUG METAB DISPOS, V34, P339, DOI 10.1124/dmd.105.006403; ROSS BD, 1986, KIDNEY INT, V29, P54, DOI 10.1038/ki.1986.8; Sweet DH, 2005, TOXICOL APPL PHARM, V204, P198, DOI 10.1016/j.taap.2004.10.016; Sweet DH, 2006, KIDNEY INT, V69, P837, DOI 10.1038/sj.ki.5000170; Sweet DH, 2002, J BIOL CHEM, V277, P26934, DOI 10.1074/jbc.M203803200; Sweet DH, 1997, J BIOL CHEM, V272, P30088, DOI 10.1074/jbc.272.48.30088; Takeda M, 2002, J PHARMACOL EXP THER, V300, P918, DOI 10.1124/jpet.300.3.918; TWENTYMAN PR, 1994, EUR J CANCER, V30A, P1360, DOI 10.1016/0959-8049(94)90187-2; Uwai Y, 2007, PHARM RES, V24, P811, DOI 10.1007/s11095-006-9196-x; Vidal F, 2006, ANTIMICROB AGENTS CH, V50, P3824, DOI 10.1128/AAC.00437-06; Wada S, 2000, J PHARMACOL EXP THER, V294, P844; Young B, 2005, AIDS PATIENT CARE ST, V19, P286, DOI 10.1089/apc.2005.19.286; Zubercova O, 1998, NEOPLASMA, V45, P53	47	78	81	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8654	8663		10.1074/jbc.M708615200	http://dx.doi.org/10.1074/jbc.M708615200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18174163	hybrid, Green Published			2022-12-25	WOS:000254288000064
J	Gao, N; Asamitsu, K; Hibi, Y; Ueno, T; Okamoto, T				Gao, Nan; Asamitsu, Kaori; Hibi, Yurina; Ueno, Takaharu; Okamoto, Takashi			AKIP1 enhances NF-kappa B-dependent gene expression by promoting the nuclear retention and phosphorylation of p65	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; IMMUNODEFICIENCY-VIRUS TYPE-1; PROTEIN-KINASE; TRANSCRIPTIONAL ACTIVITY; MEDIATED TRANSCRIPTION; SIGNAL-TRANSDUCTION; CATALYTIC SUBUNIT; SERINE KINASE; CAMP; INHIBITOR	In this study, we have identified protein kinase A-interacting protein 1 (AKIP1) as a binding partner of NF-kappa B p65 subunit, and AKIP1 enhances the NF-kappa B-mediated gene expression. AKIP1 is a nuclear protein and known to interact with the catalytic subunit of PKA (PKAc). We identified AKIP1 by a yeast two-hybrid screen using the N terminus region of p65 as bait. The interaction between AKIP1 and p65 was confirmed by glutathione S-transferase pull-down assay in vitro and immunoprecipitation-Western blotting assay in vivo. We found that the PKAc was present in the AKIP1 center dot p65 complex and enhanced the transcriptional activity of NF-kappa B by phosphorylating p65. In a transient luciferase assay, AKIP1 cotransfection efficiently increased the transcriptional activity of NF-kappa B induced by phorbol 12-myristate 13-acetate (PMA). When AKIP1 was knocked down by RNA interference, the PMA-mediated NF-kappa B-dependent gene expression was abolished, indicating a physiological role of AKIP1. We found that PKAc, which is maintained in an inactive form by binding to I kappa B alpha and NF-kappa B in resting cells, was activated by PMA-induced signaling and could phosphorylate p65. Overexpression of AKIP1 increased the PKAc binding to p65 and enhanced the PKAc-mediated phosphorylation of p65 at Ser-276. Interestingly, this p65 phosphorylation promoted nuclear translocation of p65 and enhanced NF-kappa B transcription. In fact, we observed that AKIP1 colocalized with p65 within the cells and appeared to retain p65 in nucleus. These findings indicate a positive role of AKIP1 in NF-kappa B signaling and suggest a novel mechanism by which AKIP1 augments the transcriptional competence of NF-kappa B.	[Gao, Nan; Asamitsu, Kaori; Hibi, Yurina; Ueno, Takaharu; Okamoto, Takashi] Nagoya City Univ, Grad Sch Med Sci, Dept Mol & Cellular Biol, Mizuho Ku, Nagoya, Aichi 4678601, Japan	Nagoya City University	Okamoto, T (corresponding author), Nagoya City Univ, Grad Sch Med Sci, Dept Mol & Cellular Biol, Mizuho Ku, 1 Kawasumi, Nagoya, Aichi 4678601, Japan.	tokamoto@med.nagoya-cu.ac.jp		Asamitsu, Kaori/0000-0001-5333-8011				Asamitsu K, 2003, J BIOL CHEM, V278, P26879, DOI 10.1074/jbc.M211831200; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; Carnegie GK, 2003, GENE DEV, V17, P1557, DOI 10.1101/gad.1095803; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; COBB CE, 1988, METHOD ENZYMOL, V159, P202; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; FANTOZZI DA, 1992, J BIOL CHEM, V267, P16824; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; Gao F, 2006, NAT CELL BIOL, V8, P1171, DOI 10.1038/ncb1483; HAYASHI T, 1993, J BIOL CHEM, V268, P26790; Hoberg JE, 2006, MOL CELL BIOL, V26, P457, DOI 10.1128/MCB.26.2.457-471.2006; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Kim YS, 2006, J BIOL CHEM, V281, P39051, DOI 10.1074/jbc.M604659200; Kitching R, 2003, BBA-GENE STRUCT EXPR, V1625, P116, DOI 10.1016/S0167-4781(02)00562-6; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Majumdar S, 2003, ONCOGENE, V22, P1206, DOI 10.1038/sj.onc.1206184; Minguet S, 2005, EUR J IMMUNOL, V35, P31, DOI 10.1002/eji.200425524; Moynagh P. N., 2005, J CELL SCI, V118, P4389; NEUMANN M, 1995, EMBO J, V14, P1991, DOI 10.1002/j.1460-2075.1995.tb07191.x; Okamoto T, 1997, CURR TOP CELL REGUL, V35, P149, DOI 10.1016/S0070-2137(97)80006-4; Okamoto T, 2007, CURR PHARM DESIGN, V13, P447, DOI 10.2174/138161207780162944; Sakurai H, 2003, J BIOL CHEM, V278, P36916, DOI 10.1074/jbc.M301598200; Sastri M, 2005, P NATL ACAD SCI USA, V102, P349, DOI 10.1073/pnas.0408608102; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; Takada N, 2002, J VIROL, V76, P8019, DOI 10.1128/JVI.76.16.8019-8030.2002; Takahashi N, 2002, EUR J BIOCHEM, V269, P4559, DOI 10.1046/j.1432-1033.2002.03157.x; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; Tetsuka T, 2004, EUR J BIOCHEM, V271, P3741, DOI 10.1111/j.1432-1033.2004.04314.x; Tetsuka T, 2000, J BIOL CHEM, V275, P4383, DOI 10.1074/jbc.275.6.4383; Uranishi H, 2001, J BIOL CHEM, V276, P13395, DOI 10.1074/jbc.M011176200; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Victoriano AFB, 2006, ANTIMICROB AGENTS CH, V50, P547, DOI 10.1128/AAC.50.2.547-555.2006; WALSH DA, 1994, FASEB J, V8, P1227, DOI 10.1096/fasebj.8.15.8001734; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; WEN W, 1994, J BIOL CHEM, V269, P32214; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wiley JC, 1999, J BIOL CHEM, V274, P6381, DOI 10.1074/jbc.274.10.6381; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yang JP, 1999, ONCOGENE, V18, P5177, DOI 10.1038/sj.onc.1202904; Yang JP, 1999, J BIOL CHEM, V274, P15662, DOI 10.1074/jbc.274.22.15662; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	48	61	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7834	7843		10.1074/jbc.M710285200	http://dx.doi.org/10.1074/jbc.M710285200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18178962	hybrid			2022-12-25	WOS:000253997900059
J	Huang, L; Cheng, HC; Isom, R; Chen, CS; Levine, RA; Pauli, BU				Huang, Lynn; Cheng, Hung-Chi; Isom, Richard; Chen, Chia-Sui; Levine, Roy A.; Pauli, Bendicht U.			Protein kinase C-epsilon mediates polymeric fibronectin assembly on the surface of blood-borne rat breast cancer cells to promote pulmonary metastasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL PEPTIDASE-IV; GENE-EXPRESSION PROFILES; PKC-EPSILON; CDNA MICROARRAY; TUMOR-CELLS; DELTA; ACTIVATION; INHIBITION; CARCINOMA; ADHESION	Malignant breast cancer cells that have entered the blood circulation from primary mammary fat pad tumors or are grown in end-over-end suspension culture assemble a characteristic, multi-globular polymeric fibronectin (polyFn) coat on their surfaces. Surface polyFn is critical for pulmonary metastasis, presumably by facilitating lung vascular arrest via endothelial dipeptidylpeptidase IV (CD26). Here, we show that cell-surface polyFn assembly is initiated by the state of suspension, is dependent upon the synthesis and secretion of cellular Fn, and is augmented in a dose-and time-dependent manner by plasma Fn. PolyFn assembly is regulated by protein kinase C-epsilon (PKC epsilon), which translocates rapidly and in increasing amounts from the cytosol to the plasma membrane and is phosphorylated. PolyFn assembly is impeded by select inhibitors of this kinase, i.e. bisindolylmaleimide I, Ro-32-0432, Go6983, and Rottlerin, by the phorbol 12-myristate 13-acetate-mediated and time-dependent loss of PKC epsilon protein and decreased plasma membrane translocation, and more specifically, by stable transfection of lung-metastatic MTF7L breast cancer cells with small interfering RNA-PKC epsilon and dominant-negative PKC epsilon constructs (e.g. RD-PKC epsilon). The inability to assemble a cell surface-associated polyFn coat by knockdown of endogenous Fn or PKC epsilon impedes cancer cells from metastasis to the lungs. The present studies identify a novel regulatory mechanism for polyFn assembly on blood-borne breast cancer cells and depict its effect on pulmonary metastasis.	[Huang, Lynn; Isom, Richard; Chen, Chia-Sui; Levine, Roy A.; Pauli, Bendicht U.] Cornell Univ, Dept Mol Med, Canc Cell Biol Labs, Ithaca, NY 14853 USA; [Cheng, Hung-Chi] Natl Cheng Kung Univ, Coll Med, Dept Biochem & Mol Biol, Tainan 701, Taiwan	Cornell University; National Cheng Kung University	Pauli, BU (corresponding author), Cornell Univ, Dept Mol Med, Canc Cell Biol Labs, VMC4 151, Ithaca, NY 14853 USA.	bup1@cornell.edu						Abdel-Ghany M, 1998, INVAS METAST, V18, P35, DOI 10.1159/000024497; Abdel-Ghany M, 2001, J BIOL CHEM, V276, P25438, DOI 10.1074/jbc.M100478200; Al Moustafa AE, 2002, ONCOGENE, V21, P2634, DOI 10.1038/sj.onc.1205351; Amatschek S, 2004, CANCER RES, V64, P844, DOI 10.1158/0008-5472.CAN-03-2361; Bandyopadhyay A, 2005, CANCER BIOL THER, V4, P168; Barr RK, 2001, INT J BIOCHEM CELL B, V33, P1047, DOI 10.1016/S1357-2725(01)00093-0; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Bogatkevich GS, 2003, AM J PHYSIOL-LUNG C, V285, pL334, DOI 10.1152/ajplung.00417.2002; Chen L, 2001, P NATL ACAD SCI USA, V98, P11114, DOI 10.1073/pnas.191369098; Cheng HC, 1999, CLIN EXP METASTAS, V17, P609, DOI 10.1023/A:1006757525190; Cheng HC, 2003, J BIOL CHEM, V278, P24600, DOI 10.1074/jbc.M303424200; Cheng HC, 1998, J BIOL CHEM, V273, P24207, DOI 10.1074/jbc.273.37.24207; Cheng JJ, 2001, J BIOL CHEM, V276, P31368, DOI 10.1074/jbc.M011317200; Chun J, 1997, J CELL PHYSIOL, V173, P361, DOI 10.1002/(SICI)1097-4652(199712)173:3<361::AID-JCP8>3.0.CO;2-L; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; De Servi B, 2005, ONCOGENE, V24, P4946, DOI 10.1038/sj.onc.1208676; Di-Capua N, 2003, J NEUROCHEM, V84, P409, DOI 10.1046/j.1471-4159.2003.01563.x; Dinter A, 1998, HISTOCHEM CELL BIOL, V109, P571, DOI 10.1007/s004180050256; FUJIHARA M, 1994, J IMMUNOL, V152, P1898; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gloyna W, 2005, REGUL PEPTIDES, V125, P179, DOI 10.1016/j.regpep.2004.08.023; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Hall A, 2005, BIOCHEM SOC T, V33, P891, DOI 10.1042/BST0330891; Hao XS, 2004, CANCER-AM CANCER SOC, V100, P1110, DOI 10.1002/cncr.20095; HAYMAN EG, 1979, J CELL BIOL, V83, P255, DOI 10.1083/jcb.83.1.255; Hoy M, 2003, J BIOL CHEM, V278, P35168, DOI 10.1074/jbc.M303927200; HUMPHRIES MJ, 1989, CANCER INVEST, V7, P373, DOI 10.3109/07357908909039866; HYNES RO, 1982, J CELL BIOL, V95, P369, DOI 10.1083/jcb.95.2.369; Imamdi R, 2004, J PHARMACOL EXP THER, V311, P892, DOI 10.1124/jpet.104.072678; Ivaska J, 2005, EMBO J, V24, P3834, DOI 10.1038/sj.emboj.7600847; Ivaska J, 2002, EMBO J, V21, P3608, DOI 10.1093/emboj/cdf371; Jerdeva GV, 2005, AM J PHYSIOL-CELL PH, V289, pC1052, DOI 10.1152/ajpcell.00546.2004; Jiang YQ, 2002, ONCOGENE, V21, P2270, DOI 10.1038/sj.onc.1205278; JOHNSON RC, 1991, CANCER RES, V51, P394; JOHNSON RC, 1993, J CELL BIOL, V121, P1423, DOI 10.1083/jcb.121.6.1423; Kiley SC, 1999, ONCOGENE, V18, P6748, DOI 10.1038/sj.onc.1203101; Kiley SC, 1999, CANCER RES, V59, P3230; KORACH S, 1986, CANCER RES, V46, P3624; Labat-Robert J, 2002, SEMIN CANCER BIOL, V12, P187, DOI 10.1016/S1044-579X(02)00022-6; Lee HB, 2004, KIDNEY INT, V65, P1170, DOI 10.1111/j.1523-1755.2004.00491.x; Levenson AS, 2005, CANCER RES, V65, P10651, DOI 10.1158/0008-5472.CAN-05-0845; Lopez-Andreo MJ, 2003, MOL BIOL CELL, V14, P4885, DOI 10.1091/mbc.E03-05-0295; Mackay A, 2003, ONCOGENE, V22, P2680, DOI 10.1038/sj.onc.1206349; Masso-Welch PA, 2001, BREAST CANCER RES TR, V68, P211, DOI 10.1023/A:1012265703669; Mendez CF, 2003, J BIOL CHEM, V278, P44753, DOI 10.1074/jbc.M308664200; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Munakata M, 2002, ANN THORAC SURG, V73, P1236, DOI 10.1016/S0003-4975(01)03594-9; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; Nebenfuhr A, 2002, PLANT PHYSIOL, V130, P1102, DOI 10.1104/pp.011569; Pan Q, 2005, CANCER RES, V65, P8366, DOI 10.1158/0008-5472.CAN-05-0553; Park YS, 2006, J NEUROSCI, V26, P8999, DOI 10.1523/JNEUROSCI.2828-06.2006; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Rinehart-Kim J, 2000, INT J CANCER, V88, P180, DOI 10.1002/1097-0215(20001015)88:2<180::AID-IJC6>3.0.CO;2-H; Rosenberg R, 2002, CYTOMETRY, V49, P150, DOI 10.1002/cyto.10161; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; Sakai T, 2003, NATURE, V423, P876, DOI 10.1038/nature01712; Schreckenberg R, 2004, CARDIOVASC RES, V63, P553, DOI 10.1016/j.cardiores.2004.04.032; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; Stahelin RV, 2005, J BIOL CHEM, V280, P19784, DOI 10.1074/jbc.M411285200; Stawowy P, 2005, CARDIOVASC RES, V67, P50, DOI 10.1016/j.cardiores.2005.03.002; Tachado SD, 2002, J CELL BIOCHEM, V85, P785, DOI 10.1002/jcb.10164; Tapia JA, 2006, BBA-MOL CELL RES, V1763, P25, DOI 10.1016/j.bbamcr.2005.10.007; Urtreger A, 1998, INT J CANCER, V78, P233, DOI 10.1002/(SICI)1097-0215(19981005)78:2<233::AID-IJC18>3.0.CO;2-B; Valledor AF, 2000, J IMMUNOL, V164, P29, DOI 10.4049/jimmunol.164.1.29; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; WAYS DK, 1992, CANCER RES, V52, P5604; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; Zeidman R, 1999, J CELL BIOL, V145, P713, DOI 10.1083/jcb.145.4.713; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Zhao H, 2004, INT J CANCER, V109, P65, DOI 10.1002/ijc.11676; Zucchi I, 2004, P NATL ACAD SCI USA, V101, P18147, DOI 10.1073/pnas.0408260101	72	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7616	7627		10.1074/jbc.M705839200	http://dx.doi.org/10.1074/jbc.M705839200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18184652	hybrid			2022-12-25	WOS:000253997900037
J	Zhu, ED; Demay, MB; Gori, F				Zhu, Eric D.; Demay, Marie B.; Gori, Francesca			Wdr5 is essential for osteoblast differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; CHONDROCYTE DIFFERENTIATION; H3K4 METHYLATION; BONE-DEVELOPMENT; GENE-EXPRESSION; WNT; PROTEIN; LRP5; APOPTOSIS; CELLS	Wdr5 is developmentally expressed in osteoblasts and accelerates osteoblast differentiation in vitro and in vivo. To address whether Wdr5 is essential for osteoblast differentiation, plasmid-based small interfering RNAs were used to stably suppress endogenous Wdr5 protein levels in MC3T3-E1 cells. Reduction of endogenous Wdr5 levels markedly inhibited osteoblast differentiation, evidenced by a significant decrease in alkaline phosphatase activity, Runx-2 and osteocalcin mRNAs, and absence of mineralized matrix formation. Wdr5 suppression also resulted in a reduction of histone H3 lysine 4 trimethylation, confirming its critical role in this modification. Because Wdr5 overexpression enhances canonical Wnt signaling in osteoblasts in vivo, the effects of Wdr5 silencing on this pathway were examined. The expression of the canonical Wnt target gene, c-myc, was decreased, whereas that of sfrp2, which is repressed by Wnt signaling, was increased with Wdr5 knockdown. Although only a minimal increase in apoptosis was observed, the antiapoptotic effect of Wnt signaling was also impaired with Wdr5 silencing. The expression of canonical Wnts was significantly decreased with Wdr5 knockdown, resulting in a decrease in nuclear beta-catenin protein levels. Activation of the canonical Wnt signaling pathway did not overcome the effects of Wdr5 knockdown on the expression of Wnt target genes. Chromatin immunoprecipitation demonstrated that Wdr5 is present on the Wnt1 promoter and on canonical Wnt response elements of the c-myc and Runx-2 promoters. These studies demonstrate that Wdr5 suppression interferes with the canonical Wnt signaling pathway at multiple stages and that optimal Wdr5 levels are required for induction of the osteoblast phenotype.	[Zhu, Eric D.; Demay, Marie B.; Gori, Francesca] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Endocrine Unit, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Gori, F (corresponding author), 50 Blossom St, Boston, MA 02114 USA.	gori@helix.mgh.harvard.edu			NIDDK NIH HHS [DK36597] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036597] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdelmagid SM, 2007, J CELL PHYSIOL, V210, P26, DOI 10.1002/jcp.20841; Akiyama H, 2004, GENE DEV, V18, P1072, DOI 10.1101/gad.1171104; Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200; Anderson PH, 2007, J STEROID BIOCHEM, V103, P601, DOI 10.1016/j.jsbmb.2006.12.084; Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960; Bain G, 2003, BIOCHEM BIOPH RES CO, V301, P84, DOI 10.1016/S0006-291X(02)02951-0; Canalis E, 2005, J Endocrinol Invest, V28, P3; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016; Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031; GAUR T, 2005, J BIOL CHEM; Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Gori F, 2001, J BIOL CHEM, V276, P46515, DOI 10.1074/jbc.M105757200; Gori F, 2006, DEV BIOL, V295, P498, DOI 10.1016/j.ydbio.2006.02.031; Hartmann C, 2006, TRENDS CELL BIOL, V16, P151, DOI 10.1016/j.tcb.2006.01.001; Hassan MQ, 2006, J BIOL CHEM, V281, P40515, DOI 10.1074/jbc.M604508200; Hens JR, 2005, J BONE MINER RES, V20, P1103, DOI 10.1359/JBMR.050210; Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013; Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200; Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564; Hwang SG, 2005, J BIOL CHEM, V280, P12758, DOI 10.1074/jbc.M413367200; Johnson ML, 2004, J BONE MINER RES, V19, P1749, DOI 10.1359/JBMR.040816; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551; Lee MK, 2006, J CELL BIOCHEM, V99, P986, DOI 10.1002/jcb.20990; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Longo KA, 2002, J BIOL CHEM, V277, P38239, DOI 10.1074/jbc.M206402200; Nobta M, 2005, J BIOL CHEM, V280, P15842, DOI 10.1074/jbc.M412891200; Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842; Reinhold MI, 2007, J BIOL CHEM, V282, P3653, DOI 10.1074/jbc.M608995200; Sierra J, 2006, GENE DEV, V20, P586, DOI 10.1101/gad.1385806; Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044; Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036; Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101	36	47	49	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7361	7367		10.1074/jbc.M703304200	http://dx.doi.org/10.1074/jbc.M703304200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18201971	hybrid			2022-12-25	WOS:000253997900010
J	Fujii, T; Takahashi, Y; Itomi, Y; Fujita, K; Morii, M; Tabuchi, Y; Asano, S; Tsukada, K; Takeguchi, N; Sakai, H				Fujii, Takuto; Takahashi, Yuji; Itomi, Yasuo; Fujita, Kyosuke; Morii, Magotoshi; Tabuchi, Yoshiaki; Asano, Shinji; Tsukada, Kazuhiro; Takeguchi, Noriaki; Sakai, Hideki			K+-Cl- cotransporter-3a up-regulates Na+,K+-ATPase in lipid rafts of gastric luminal parietal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+/K+-ATPASE; NA-K-2CL COTRANSPORTER; NA/K-ATPASE; MICE; SECRETION; EXCHANGER; BINDING; KCC3; RAT; HETEROGENEITY	Gastric parietal cells migrate from the luminal to the basal region of the gland, and they gradually lose acid secretory activity. So far, distribution and function of K+-C- cotransporters (KCCs) in gastric parietal cells have not been reported. We found that KCC3a but not KCC3b mRNA was highly expressed, and KCC3a protein was predominantly expressed in the basolateral membrane of rat gastric parietal cells located in the luminal region of the glands. KCC3a and the Na+, K+-ATPase alpha 1-subunit (alpha 1NaK) were coimmunoprecipitated, and both of them were highly localized in a lipid raft fraction. The ouabain-sensitive K+-dependent ATP-hydrolyzing activity (Na+,K+-ATPase activity) was significantly inhibited by a KCC inhibitor (R-(+)-[(2-n-butyl-6,7-dichloro-2-cyclopentyl-2,3-dihydro-1-oxo-1H-inden-5-yl)oxy]acetic acid (DIOA)). The stable exogenous expression of KCC3a in LLC-PK1 cells resulted in association of KCC3a with endogenous alpha 1NaK, and it recruited alpha 1NaK in lipid rafts, accompanying increases of Na+,K+-ATPase activity and ouabain-sensitive Na+ transport activity that were suppressed by DIOA, whereas the total expression level of alpha 1NaK in the cells was not significantly altered. On the other hand, the expression of KCC4 induced no association with alpha 1NaK. In conclusion, KCC3a forms a functional complex with alpha 1NaK in the basolateral membrane of luminal parietal cells, and it up-regulates alpha 1NaK in lipid rafts, whereas KCC3a is absent in basal parietal cells.	[Fujii, Takuto; Takahashi, Yuji; Itomi, Yasuo; Fujita, Kyosuke; Morii, Magotoshi; Takeguchi, Noriaki; Sakai, Hideki] Toyama Univ, Dept Pharmaceut Physiol, Toyama 9300194, Japan; [Tabuchi, Yoshiaki] Toyama Univ, Life Sci Res Ctr, Toyama 9300194, Japan; [Tsukada, Kazuhiro] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Surg 2, Toyama 9300194, Japan; [Asano, Shinji] Ritsumeikan Univ, Coll Informat Sci & Engn, Dept Mol Physiol, Shiga 5258577, Japan	University of Toyama; University of Toyama; University of Toyama; Ritsumeikan University	Sakai, H (corresponding author), Toyama Univ, Dept Pharmaceut Physiol, 2630 Sugitani, Toyama 9300194, Japan.	sakaih@pha.u-toyama.ac.jp		Asano, Shinji/0000-0003-1443-8970; Tabuchi, Yoshiaki/0000-0002-6007-6176				Adragna NC, 2004, J MEMBRANE BIOL, V201, P109, DOI 10.1007/s00232-004-0695-6; Balut C, 2006, AM J PHYSIOL-CELL PH, V290, pC87, DOI 10.1152/ajpcell.00184.2005; BAMBERG K, 1994, BBA-BIOMEMBRANES, V1190, P355, DOI 10.1016/0005-2736(94)90094-9; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Blanco G, 1998, AM J PHYSIOL-RENAL, V275, pF633, DOI 10.1152/ajprenal.1998.275.5.F633; Carmosino M, 2001, J CELL BIOL, V154, P1235, DOI 10.1083/jcb.200103010; Flagella M, 1999, J BIOL CHEM, V274, P26946, DOI 10.1074/jbc.274.38.26946; Fujii T, 2007, EUR J PHARMACOL, V560, P123, DOI 10.1016/j.ejphar.2006.12.031; Gamba G, 2005, PHYSIOL REV, V85, P423, DOI 10.1152/physrev.00011.2004; GARAY RP, 1988, MOL PHARMACOL, V33, P696; Gawenis LR, 2004, J BIOL CHEM, V279, P30531, DOI 10.1074/jbc.M403779200; HELANDER HF, 1984, GASTROENTEROLOGY, V87, P1064; Ikeda K, 2004, J NEUROSCI, V24, P10693, DOI 10.1523/JNEUROSCI.2909-04.2004; Imagawa T, 2005, J BIOL CHEM, V280, P18736, DOI 10.1074/jbc.M500137200; Karam SM, 1997, AM J PHYSIOL-GASTR L, V272, pG161, DOI 10.1152/ajpgi.1997.272.1.G161; Kimura T, 2002, J BIOL CHEM, V277, P20671, DOI 10.1074/jbc.M200523200; Kometiani P, 2005, MOL PHARMACOL, V67, P929, DOI 10.1124/mol.104.007302; Li XH, 2001, J PHYSIOL-LONDON, V537, P537, DOI 10.1111/j.1469-7793.2001.00537.x; Liang M, 2007, J BIOL CHEM, V282, P10585, DOI 10.1074/jbc.M609181200; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Lingwood D, 2005, J BIOL CHEM, V280, P36545, DOI 10.1074/jbc.M506670200; McDaniel N, 2005, AM J PHYSIOL-GASTR L, V289, pG550, DOI 10.1152/ajpgi.00095.2005; McDaniel N, 1999, AM J PHYSIOL-GASTR L, V276, pG1273, DOI 10.1152/ajpgi.1999.276.5.G1273; Mercado A, 2005, AM J PHYSIOL-RENAL, V289, pF1246, DOI 10.1152/ajprenal.00464.2004; Mount DB, 1999, J BIOL CHEM, V274, P16355, DOI 10.1074/jbc.274.23.16355; Murtazina R, 2006, J BIOL CHEM, V281, P17845, DOI 10.1074/jbc.M601740200; Pearson MM, 2001, NEUROSCIENCE, V103, P481, DOI 10.1016/S0306-4522(00)00567-4; Polishchuk R, 2004, NAT CELL BIOL, V6, P297, DOI 10.1038/ncb1109; Race JE, 1999, AM J PHYSIOL-CELL PH, V277, pC1210, DOI 10.1152/ajpcell.1999.277.6.C1210; Rossmann H, 2001, J PHYSIOL-LONDON, V534, P837, DOI 10.1111/j.1469-7793.2001.00837.x; Sachs G, 2001, EUR J GASTROEN HEPAT, V13, pS35; Sakai H, 2003, J PHYSIOL-LONDON, V551, P207, DOI 10.1113/jphysiol.2003.041921; Simons K, 2004, ANNU REV BIOPH BIOM, V33, P269, DOI 10.1146/annurev.biophys.32.110601.141803; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Teramachi S, 2002, J BIOL CHEM, V277, P37394, DOI 10.1074/jbc.M204772200; Tian J, 2006, MOL BIOL CELL, V17, P317, DOI 10.1091/mbc.E05-08-0735; Volonte D, 1999, J BIOL CHEM, V274, P12702, DOI 10.1074/jbc.274.18.12702; Wang HJ, 2004, J BIOL CHEM, V279, P17250, DOI 10.1074/jbc.M313239200; Wang KS, 2000, AM J PHYSIOL-GASTR L, V279, pG448, DOI 10.1152/ajpgi.2000.279.2.G448; Welker P, 2007, AM J PHYSIOL-REG I, V292, pR1328, DOI 10.1152/ajpregu.00166.2006; YODA A, 1970, BIOCHEM BIOPH RES CO, V40, P880, DOI 10.1016/0006-291X(70)90985-X	41	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					6869	6877		10.1074/jbc.M708429200	http://dx.doi.org/10.1074/jbc.M708429200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18178552	hybrid, Green Submitted			2022-12-25	WOS:000253779600030
J	Komazin-Meredith, G; Santos, WL; Filman, DJ; Hogle, JM; Verdine, GL; Coen, DM				Komazin-Meredith, Gloria; Santos, Webster L.; Filman, David J.; Hogle, James M.; Verdine, Gregory L.; Coen, Donald M.			The positively charged surface of herpes simplex virus UL42 mediates DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE PROCESSIVITY FACTOR; ACCESSORY PROTEIN UL44; CELL NUCLEAR ANTIGEN; CRYSTAL-STRUCTURE; C-TERMINUS; CATALYTIC SUBUNIT; LAC REPRESSOR; REPLICATION FACTOR; VIRAL REPLICATION; PRIMER-TEMPLATE	Herpes simplex virus DNA polymerase is a heterodimer composed of UL30, a catalytic subunit, and UL42, a processivity subunit. Mutations that decrease DNA binding by UL42 decrease long chain DNA synthesis by the polymerase. The crystal structure of UL42 bound to the C terminus of UL30 revealed an extensive positively charged surface ("back face"). We tested two hypotheses, 1) the C terminus of UL30 affects DNA binding and 2) the positively charged back face mediates DNA binding. Addressing the first hypothesis, we found that the presence of a peptide corresponding to the UL30 C terminus did not result in altered binding of UL42 to DNA. Addressing the second hypothesis, previous work showed that substitution of four conserved arginine residues on the basic face with alanines resulted in decreased DNA affinity. We tested the affinities for DNA and the stimulation of long chain DNA synthesis of mutants in which the four conserved arginine residues were substituted individually or together with lysines and also a mutant in which a conserved glutamine residue was substituted with an arginine to increase positive charge on the back face. We also engineered cysteines onto this surface to permit disulfide cross-linking studies. Last, we assayed the effects of ionic strength on DNA binding by UL42 to estimate the number of ions released upon binding. Our results taken together strongly suggest that the basic back face of UL42 contacts DNA and that positive charge on this surface is important for this interaction.	[Komazin-Meredith, Gloria; Filman, David J.; Hogle, James M.; Coen, Donald M.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; [Santos, Webster L.; Verdine, Gregory L.] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA	Harvard University; Harvard Medical School; Harvard University	Coen, DM (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 250 Longwood Ave, Boston, MA 02115 USA.	Don_Coen@hms.harvard.edu	Hogle, James/HIG-9121-2022	Santos, Webster/0000-0002-4731-8548; filman, david/0000-0002-8714-1644; Hogle, James/0000-0002-3655-1504	NIAID NIH HHS [AI 26077, R56 AI026077, R01 AI 19838, R01 AI026077] Funding Source: Medline; NIGMS NIH HHS [R01 GM044853, F32 GM 067380, R01 GM044853-15, F32 GM067380, F32 GM067380-03, GM 044853] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI026077, R01AI019838, R01AI026077] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM067380, R01GM044853] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Appleton BA, 2006, J BIOL CHEM, V281, P5224, DOI 10.1074/jbc.M506900200; Appleton BA, 2004, MOL CELL, V15, P233, DOI 10.1016/j.molcel.2004.06.018; Banerjee A, 2006, SCIENCE, V311, P1153, DOI 10.1126/science.1120288; Bridges KG, 2001, J VIROL, V75, P4990, DOI 10.1128/JVI.75.11.4990-4998.2001; Chaudhuri M, 2002, J VIROL, V76, P10270, DOI 10.1128/JVI.76.20.10270-10281.2002; CHOW CS, 1995, J VIROL, V69, P6965, DOI 10.1128/JVI.69.11.6965-6971.1995; DEHASETH PL, 1977, BIOCHEMISTRY-US, V16, P4783, DOI 10.1021/bi00641a004; DIGARD P, 1993, J VIROL, V67, P1159, DOI 10.1128/JVI.67.3.1159-1168.1993; DIGARD P, 1993, J VIROL, V67, P398, DOI 10.1128/JVI.67.1.398-406.1993; FUKUDA K, 1995, J BIOL CHEM, V270, P22527, DOI 10.1074/jbc.270.38.22527; GOTTLIEB J, 1994, J VIROL, V68, P4937, DOI 10.1128/JVI.68.8.4937-4945.1994; GOTTLIEB J, 1990, J VIROL, V64, P5976, DOI 10.1128/JVI.64.12.5976-5987.1990; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Jeruzalmi D, 2002, CURR OPIN STRUC BIOL, V12, P217, DOI 10.1016/S0959-440X(02)00313-5; Kalodimos CG, 2004, SCIENCE, V305, P386, DOI 10.1126/science.1097064; Kalodimos CG, 2002, EMBO J, V21, P2866, DOI 10.1093/emboj/cdf318; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Loregian A, 2004, J VIROL, V78, P9084, DOI 10.1128/JVI.78.17.9084-9092.2004; Loregian A, 2004, J VIROL, V78, P158, DOI 10.1128/JVI.78.1.158-167.2004; Loregian A, 2007, NUCLEIC ACIDS RES, V35, P4779, DOI 10.1093/nar/gkm506; Maga G, 2000, J MOL BIOL, V295, P791, DOI 10.1006/jmbi.1999.3394; MARSDEN HS, 1994, J GEN VIROL, V75, P3127, DOI 10.1099/0022-1317-75-11-3127; Matsumiya S, 2001, PROTEIN SCI, V10, P17, DOI 10.1110/ps.36401; Moarefi I, 2000, J MOL BIOL, V296, P1215, DOI 10.1006/jmbi.1999.3511; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; PARRIS DS, 1988, J VIROL, V62, P818, DOI 10.1128/JVI.62.3.818-825.1988; Pilger BD, 2004, CHEM BIOL, V11, P647, DOI 10.1016/j.chembiol.2004.01.018; PURIFOY DJM, 1977, NATURE, V269, P621, DOI 10.1038/269621a0; Randell JC, 2001, MOL CELL, V8, P911, DOI 10.1016/S1097-2765(01)00355-0; Randell JCW, 2005, J VIROL, V79, P12025, DOI 10.1128/JVI.79.18.12025-12034.2005; Randell JCW, 2004, J MOL BIOL, V335, P409, DOI 10.1016/j.jmb.2003.10.064; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; Shamoo Y, 1999, CELL, V99, P155, DOI 10.1016/S0092-8674(00)81647-5; STOW ND, 1993, NUCLEIC ACIDS RES, V21, P87, DOI 10.1093/nar/21.1.87; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TENNEY DJ, 1993, J VIROL, V67, P543, DOI 10.1128/JVI.67.1.543-547.1993; Weisshart K, 1999, J VIROL, V73, P55, DOI 10.1128/JVI.73.1.55-66.1999; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6961, DOI 10.1021/bi00527a030; Zuccola HJ, 2000, MOL CELL, V5, P267, DOI 10.1016/S1097-2765(00)80422-0	41	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2008	283	10					6154	6161		10.1074/jbc.M708691200	http://dx.doi.org/10.1074/jbc.M708691200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HM	18178550	hybrid, Green Accepted			2022-12-25	WOS:000253779500022
J	Hegde, A; Qiu, NC; Qiu, XH; Ho, SHK; Tay, KQY; George, J; Ng, FSL; Govindarajan, KR; Gong, ZY; Mathavan, S; Jiang, YJ				Hegde, Ashok; Qiu, Nick Chuanxin; Qiu, Xuehui; Ho, Steven Hao-Kee; Tay, Kenny Qi-Ye; George, Joshy; Ng, Felicia Soo Lee; Govindarajan, Kunde Ramamoorthy; Gong, Zhiyuan; Mathavan, Sinnakaruppan; Jiang, Yun-Jin			Genomewide Expression Analysis in Zebrafish mind bomb Alleles with Pancreas Defects of Different Severity Identifies Putative Notch Responsive Genes	PLOS ONE			English	Article								Background. Notch signaling is an evolutionarily conserved developmental pathway. Zebrafish mind bomb(mib) mutants carry mutations on mib gene, which encodes a RING E3 ligase required for Notch activation via Delta/Jagged ubiquitylation and internalization. Methodology/Principal Findings. We examined the mib mutants for defects in pancreas development using in situ hybridization and GFP expression analysis of pancreas-specific GFP lines, carried out the global gene expression profile analysis of three different mib mutant alleles and validated the microarray data using real-time PCR and fluorescent double in situ hybridization. Our study showed that the mib mutants have diminished exocrine pancreas and this defect was most severe in mib(ta52b) followed by mib(m132) and then mib(tfi91), which is consistent with the compromised Notch activity found in corresponding mib mutant alleles. Global expression profile analysis of mib mutants showed that there is a significant difference in gene expression profile of wt and three mib mutant alleles. There are 91 differentially expressed genes that are common to all three mib alleles. Through detailed analysis of microarray data, we have identified several previously characterized genes and some putative Notch-responsive genes involved in pancreas development. Moreover, results from real-time PCR and fluorescent double in situ hybridization were largely consistent with microarray data. Conclusions/Significance. This study provides, for the first time, a global gene expression profile in mib mutants generating useful genomic resources and providing an opportunity to identify the function of novel genes involved in Notch signaling and Notch-regulated developmental processes.	[Hegde, Ashok; Qiu, Nick Chuanxin; Qiu, Xuehui; Ho, Steven Hao-Kee; Tay, Kenny Qi-Ye; Jiang, Yun-Jin] Agcy Sci Technol & Res, Inst Mol & Cell Biol, Lab Dev Signalling & Patterning, Singapore, Singapore; [George, Joshy; Govindarajan, Kunde Ramamoorthy; Mathavan, Sinnakaruppan] Genome Inst Singapore, Agency Sci Technol & Res, Singapore, Singapore; [Ng, Felicia Soo Lee] Bioinform Inst, Agency Sci Technol & Res, Singapore, Singapore; [Gong, Zhiyuan] Natl Univ Singapore, Dept Biol Sci, Singapore, Singapore; [Jiang, Yun-Jin] Natl Univ Singapore, Dept Biochem, Singapore, Singapore; [Jiang, Yun-Jin] Nanyang Technol Univ, Sch Biol Sci, Singapore, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); Agency for Science Technology & Research (A*STAR); A*STAR - Bioinformatics Institute (BII); National University of Singapore; National University of Singapore; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Jiang, YJ (corresponding author), Agcy Sci Technol & Res, Inst Mol & Cell Biol, Lab Dev Signalling & Patterning, Singapore, Singapore.	yjjiang@imcb.a-star.edu.sg	George, Joshy/K-4841-2019; Jiang, Yun-Jin/E-3995-2010; Gong, Zhiyuan/H-8794-2012	Jiang, Yun-Jin/0000-0003-0499-7306; Gong, Zhiyuan/0000-0002-9660-5260; George, Joshy/0000-0001-8510-8229	Biomedical Research Council of Singapore [04/1/50/22/295]; Juvenile Diabetes Research Foundation International [04/1/50/22/295]	Biomedical Research Council of Singapore(Agency for Science Technology & Research (A*STAR)); Juvenile Diabetes Research Foundation International(Juvenile Diabetes Research Foundation)	This work was supported by a joint grant from the Biomedical Research Council of Singapore and Juvenile Diabetes Research Foundation International (BMRC-JDRF, 04/1/50/22/295) and the Biomedical Research Council of A*STAR (Agency for Science, Technology and Research), Singapore.	Amoyel M, 2005, DEVELOPMENT, V132, P775, DOI 10.1242/dev.01616; Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; Appel B, 1998, DEVELOPMENT, V125, P371; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bae YK, 2005, DEVELOPMENT, V132, P1375, DOI 10.1242/dev.01710; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; Bessho Y, 2001, GENES CELLS, V6, P175, DOI 10.1046/j.1365-2443.2001.00409.x; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Bulman MP, 2000, NAT GENET, V24, P438, DOI 10.1038/74307; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Chiang MK, 2003, DEV CELL, V4, P383, DOI 10.1016/S1534-5807(03)00035-2; Chong SW, 2005, TRENDS CELL BIOL, V15, P453, DOI 10.1016/j.tcb.2005.07.008; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Esni F, 2004, DEVELOPMENT, V131, P4213, DOI 10.1242/dev.01280; Fortini ME, 2001, CURR OPIN CELL BIOL, V13, P627, DOI 10.1016/S0955-0674(00)00261-1; Gradwohl G, 2000, P NATL ACAD SCI USA, V97, P1607, DOI 10.1073/pnas.97.4.1607; Gu GQ, 2004, DEVELOPMENT, V131, P165, DOI 10.1242/dev.00921; Gu GQ, 2002, DEVELOPMENT, V129, P2447; Habener JF, 2005, ENDOCRINOLOGY, V146, P1025, DOI 10.1210/en.2004-1576; Hans S, 2004, DEVELOPMENT, V131, P2957, DOI 10.1242/dev.01167; Hill DJ, 1999, J ENDOCRINOL, V160, P305, DOI 10.1677/joe.0.1600305; Hirata H, 2002, SCIENCE, V298, P840, DOI 10.1126/science.1074560; Holley SA, 2000, GENE DEV, V14, P1678; Holley SA, 2002, DEVELOPMENT, V129, P1175; Huang HG, 2001, GENESIS, V30, P134, DOI 10.1002/gene.1048; Hutchinson SA, 2006, DEVELOPMENT, V133, P2137, DOI 10.1242/dev.02355; INOUE A, 1994, DEV DYNAM, V199, P1, DOI 10.1002/aja.1001990102; Irvin DK, 2003, DEV NEUROSCI-BASEL, V25, P162, DOI 10.1159/000072265; Itoh M, 2003, DEV CELL, V4, P67, DOI 10.1016/S1534-5807(02)00409-4; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jensen J, 2000, NAT GENET, V24, P36, DOI 10.1038/71657; Jensen J, 2004, DEV DYNAM, V229, P176, DOI 10.1002/dvdy.10460; Jensen J, 2000, DIABETES, V49, P163, DOI 10.2337/diabetes.49.2.163; Jiang YJ, 1996, DEVELOPMENT, V123, P205; Jin YJ, 2002, J BIOL CHEM, V277, P46980, DOI 10.1074/jbc.M208585200; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Julich D, 2005, DEV BIOL, V286, P391, DOI 10.1016/j.ydbio.2005.06.040; Julich D, 2005, DEV CELL, V8, P575, DOI 10.1016/j.devcel.2005.01.016; Kidd S, 1998, GENE DEV, V12, P3728, DOI 10.1101/gad.12.23.3728; Kim HJ, 2005, BMC BIOL, V3, DOI 10.1186/1741-7007-3-23; Kohyama J, 2005, DEV BIOL, V286, P311, DOI 10.1016/j.ydbio.2005.08.003; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Kopan R, 2000, GENE DEV, V14, P2799, DOI 10.1101/gad.836900; Lai EC, 2002, CURR BIOL, V12, pR74, DOI 10.1016/S0960-9822(01)00679-0; Lam SH, 2006, PHYSIOL GENOMICS, V27, P351, DOI 10.1152/physiolgenomics.00201.2005; Leake D, 1999, DIFFERENTIATION, V65, P181, DOI 10.1046/j.1432-0436.1999.6540181.x; Lecourtois M, 1998, CURR BIOL, V8, P771, DOI 10.1016/S0960-9822(98)70300-8; Li LH, 1997, NAT GENET, V16, P243, DOI 10.1038/ng0797-243; Lowe AW, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000323; Lu FM, 1996, P NATL ACAD SCI USA, V93, P5663, DOI 10.1073/pnas.93.11.5663; Ma M, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030018; Mally MI, 1996, DIABETOLOGIA, V39, P474, DOI 10.1007/s001250050468; Matesic LE, 2006, HUM MOL GENET, V15, P3485, DOI 10.1093/hmg/ddl425; Mathavan S, 2005, PLOS GENET, V1, P260, DOI 10.1371/journal.pgen.0010029; McDaniell R, 2006, AM J HUM GENET, V79, P169, DOI 10.1086/505332; Mellitzer G, 2006, EMBO J, V25, P1344, DOI 10.1038/sj.emboj.7601011; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Oates AC, 2002, DEVELOPMENT, V129, P2929; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Olbrot M, 2002, P NATL ACAD SCI USA, V99, P6737, DOI 10.1073/pnas.102168499; Park HC, 2003, DEVELOPMENT, V130, P3747, DOI 10.1242/dev.00576; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; Pleau JM, 1997, BIOCHEM BIOPH RES CO, V233, P227, DOI 10.1006/bbrc.1997.6432; Pourquie O, 2003, SCIENCE, V301, P328, DOI 10.1126/science.1085887; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; Qiu XH, 2004, DEV DYNAM, V231, P621, DOI 10.1002/dvdy.20155; Rida PCG, 2004, DEV BIOL, V265, P2, DOI 10.1016/j.ydbio.2003.07.003; Riley BB, 2004, DEV DYNAM, V231, P278, DOI 10.1002/dvdy.20133; Schafer M, 2007, DEV BIOL, V301, P117, DOI 10.1016/j.ydbio.2006.09.018; Schena M, 1998, TRENDS BIOTECHNOL, V16, P301, DOI 10.1016/S0167-7799(98)01219-0; Shankaran SS, 2007, DEV BIOL, V304, P615, DOI 10.1016/j.ydbio.2007.01.004; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Takamiya M, 2006, DEV DYNAM, V235, P978, DOI 10.1002/dvdy.20720; Takke C, 1999, DEVELOPMENT, V126, P1811; THISSE B, 2001, NIH ZFIN DIRECT DATA; Thisse C., 2005, ZFIN DIRECT DATA SUB; Thompson BJ, 2007, J EXP MED, V204, P1825, DOI 10.1084/jem.20070872; Tsutsumi M, 2007, GENE EXPR PATTERNS, V7, P227, DOI 10.1016/j.modgep.2006.10.002; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van Haeften TW, 2004, EUR J CLIN INVEST, V34, P249, DOI 10.1111/j.1365-2362.2004.01337.x; vanEeden FJM, 1996, DEVELOPMENT, V123, P153; Wan HY, 2006, EXP CELL RES, V312, P1526, DOI 10.1016/j.yexcr.2006.01.016; Wang YL, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-59; Willer GB, 2005, GENETICS, V170, P1827, DOI 10.1534/genetics.105.041608; Xu J, 2006, GENETICS, V174, P735, DOI 10.1534/genetics.106.061523; Yan XQ, 2001, BLOOD, V98, P3793, DOI 10.1182/blood.V98.13.3793; Yang H, 2003, P NATL ACAD SCI USA, V100, P1122, DOI 10.1073/pnas.0237337100; Yee NS, 2005, DEV BIOL, V284, P84, DOI 10.1016/j.ydbio.2005.04.035; Yoo KW, 2006, FEBS LETT, V580, P4409, DOI 10.1016/j.febslet.2006.07.009; Zecchin E, 2007, DEV BIOL, V301, P192, DOI 10.1016/j.ydbio.2006.09.041; Zecchin E, 2004, DEV BIOL, V268, P174, DOI 10.1016/j.ydbio.2003.12.016; Zhang CJ, 2007, J MOL BIOL, V366, P1115, DOI 10.1016/j.jmb.2006.11.096; Zhang CJ, 2007, DEV BIOL, V305, P14, DOI 10.1016/j.ydbio.2007.01.034	98	13	14	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2008	3	1							e1479	10.1371/journal.pone.0001479	http://dx.doi.org/10.1371/journal.pone.0001479			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SO	18213387	Green Submitted, Green Published, gold			2022-12-25	WOS:000260503900024
J	Nakagawa, H; Tategu, M; Yamauchi, R; Sasaki, K; Sekimachi, S; Yoshida, K				Nakagawa, Hiroki; Tategu, Moe; Yamauchi, Rieko; Sasaki, Kaori; Sekimachi, Sota; Yoshida, Kenichi			Transcriptional Regulation of an Evolutionary Conserved Intergenic Region of CDT2-INTS7	PLOS ONE			English	Article							BIDIRECTIONAL PROMOTER; NUCLEAR; PROTEIN; E2F; L2DTL/CDT2; COMPLEX; FAMILY; PCNA	Background. In the mammalian genome, a substantial number of gene pairs (approximately 10%) are arranged head-to-head on opposite strands within 1,000 base pairs, and separated by a bidirectional promoter(s) that generally drives the co-expression of both genes and results in functional coupling. The significance of unique genomic configuration remains elusive. Methodology/Principal Findings. Here we report on the identification of an intergenic region of non-homologous genes, CDT2, a regulator of DNA replication, and an integrator complex subunit 7 (INTS7), an interactor of the largest subunit of RNA polymerase II. The CDT2-INTS7 intergenic region is 246 and 245 base pairs long in human and mouse respectively and is evolutionary well-conserved among several mammalian species. By measuring the luciferase activity in A549 cells, the intergenic human sequence was shown to be able to drive the reporter gene expression in either direction and notably, among transcription factors E2F, E2F1 similar to E2F4, but not E2F5 and E2F6, this sequence clearly up-regulated the reporter gene expression exclusively in the direction of the CDT2 gene. In contrast, B-Myb, c-Myb, and p53 down-regulated the reporter gene expression in the transcriptional direction of the INTS7 gene. Overexpression of E2F1 by adenoviral-mediated gene transfer resulted in an increased CDT2, but not INTS7, mRNA level. Real-time polymerase transcription (RT-PCR) analyses of the expression pattern for CDT2 and INTS7 mRNA in human adult and fetal tissues and cell lines revealed that transcription of these two genes are asymmetrically regulated. Moreover, the abundance of mRNA between mouse and rat tissues was similar, but these patterns were quite different from the results obtained from human tissues. Conclusions/Significance. These findings add a unique example and help to understand the mechanistic insights into the regulation of gene expression through an evolutionary conserved intergenic region of the mammalian genome.	[Nakagawa, Hiroki; Tategu, Moe; Yamauchi, Rieko; Sasaki, Kaori; Sekimachi, Sota; Yoshida, Kenichi] Meiji Univ, Sch Agr, Dept Life Sci, Kanagawa, Japan	Meiji University	Yoshida, K (corresponding author), Meiji Univ, Sch Agr, Dept Life Sci, Kanagawa, Japan.	yoshida@isc.meiji.ac.jp			JSPS	JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was partly supported by JSPS.	Baillat D, 2005, CELL, V123, P265, DOI 10.1016/j.cell.2005.08.019; Banks D, 2006, CELL CYCLE, V5, P1719, DOI 10.4161/cc.5.15.3150; Bellizzi D, 2007, GENOMICS, V89, P143, DOI 10.1016/j.ygeno.2006.09.004; Chen PY, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-2; GAVALAS A, 1995, J BIOL CHEM, V270, P2403, DOI 10.1074/jbc.270.5.2403; Goto Y, 2006, J CELL PHYSIOL, V209, P923, DOI 10.1002/jcp.20802; Goto Y, 2006, BBA-GENE STRUCT EXPR, V1759, P60, DOI 10.1016/j.bbaexp.2006.02.004; Hayashi R, 2007, DNA CELL BIOL, V26, P91, DOI 10.1089/dna.2006.0515; Hayashi R, 2006, J BIOL CHEM, V281, P35633, DOI 10.1074/jbc.M603800200; Higa LA, 2006, CELL CYCLE, V5, P1675, DOI 10.4161/cc.5.15.3149; Jin JP, 2006, MOL CELL, V23, P709, DOI 10.1016/j.molcel.2006.08.010; Johnson DG, 2006, CURR MOL MED, V6, P731; LI YY, 2006, PLOS COMPUT BIOL, V2; Liu C, 2005, EMBO J, V24, P3940, DOI 10.1038/sj.emboj.7600854; Pan HW, 2006, CELL CYCLE, V5, P2676, DOI 10.4161/cc.5.22.3500; Sansam CL, 2006, GENE DEV, V20, P3117, DOI 10.1101/gad.1482106; Segal Y, 2001, J BIOL CHEM, V276, P11791, DOI 10.1074/jbc.M007477200; Trinklein ND, 2004, GENOME RES, V14, P62, DOI 10.1101/gr.1982804; Yoshida K, 2004, ONCOGENE, V23, P3802, DOI 10.1038/sj.onc.1207488; Yoshida SH, 2003, GENETICS, V164, P881	20	11	13	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2008	3	1							e1484	10.1371/journal.pone.0001484	http://dx.doi.org/10.1371/journal.pone.0001484			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SO	18213392	gold, Green Published, Green Submitted			2022-12-25	WOS:000260503900029
J	Company, JB; Puig, P; Sarda, F; Palanques, A; Latasa, M; Scharek, R				Company, Joan B.; Puig, Pere; Sarda, Francesc; Palanques, Albert; Latasa, Mikel; Scharek, Renate			Climate Influence on Deep Sea Populations	PLOS ONE			English	Article							SHRIMP ARISTEUS-ANTENNATUS; ECOLOGICAL ASPECTS; 20-1ST CENTURY; DENSE WATER; FISHERIES; WESTERN; RISSO; MANAGEMENT; SIMULATION; CASCADES	Dynamics of biological processes on the deep-sea floor are traditionally thought to be controlled by vertical sinking of particles from the euphotic zone at a seasonal scale. However, little is known about the influence of lateral particle transport from continental margins to deep-sea ecosystems. To address this question, we report here how the formation of dense shelf waters and their subsequent downslope cascade, a climate induced phenomenon, affects the population of the deep-sea shrimp Aristeus antennatus. We found evidence that strong currents associated with intense cascading events correlates with the disappearance of this species from its fishing grounds, producing a temporary fishery collapse. Despite this initial negative effect, landings increase between 3 and 5 years after these major events, preceded by an increase of juveniles. The transport of particulate organic matter associated with cascading appears to enhance the recruitment of this deep-sea living resource, apparently mitigating the general trend of overexploitation. Because cascade of dense water from continental shelves is a global phenomenon, we anticipate that its influence on deep-sea ecosystems and fisheries worldwide should be larger than previously thought.	[Puig, Pere; Sarda, Francesc; Palanques, Albert; Latasa, Mikel] ICM CSIC, Barcelona, Spain; [Scharek, Renate] Inst Espanol Oceanogr (IEO), Ctr Oceanogr Gijon, Gijon, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Mediterraneo de Investigaciones Marinas y Ambientales (CMIMA); CSIC - Instituto de Ciencias del Mar (ICM)	Company, JB (corresponding author), ICM CSIC, Barcelona, Spain.	batista@icm.csic.es	Company, Joan B./K-7274-2014; Latasa, Mikel/D-2202-2011; Scharek, Renate/M-4530-2018; Sarda, Francisco/L-6229-2014; Palanques, Albert/C-2661-2013; Puig, Pere/E-5422-2013	Company, Joan B./0000-0002-5878-7155; Latasa, Mikel/0000-0002-8202-0923; Scharek, Renate/0000-0001-9306-9047; Sarda, Francisco/0000-0001-7905-4148; Puig, Pere/0000-0001-6189-5504; Palanques, Albert/0000-0003-2544-2342	US Office of Naval Research [N00014-1-0379]; Spanish Ministerio de Educacion y Ciencia [REN 2002-04151-C02-01]	US Office of Naval Research(Office of Naval Research); Spanish Ministerio de Educacion y Ciencia(Spanish Government)	Supported by the US Office of Naval Research grant N00014-1-0379 (PP; current meter data) and the Spanish Ministerio de Educacion y Ciencia grant REN 2002-04151-C02-01	Alegret J. L., 2004, HIST CONFRARIA PESCA, P295; Bethoux JP, 2002, J MARINE SYST, V33, P117, DOI 10.1016/S0924-7963(02)00055-6; BILLETT DSM, 1983, NATURE, V302, P520, DOI 10.1038/302520a0; Billett DSM, 2001, PROG OCEANOGR, V50, P13, DOI 10.1016/S0079-6611(01)00046-5; Caddy JF, 1999, REV FISH BIOL FISHER, V9, P1, DOI 10.1023/A:1008829909601; Canals M, 2006, NATURE, V444, P354, DOI 10.1038/nature05271; Carbonell A, 2003, FISH RES, V65, P323, DOI 10.1016/j.fishres.2003.09.023; D'Onghia G, 2005, FISH RES, V76, P22, DOI 10.1016/j.fishres.2005.05.007; D'Onghia G, 2004, SCI MAR, V68, P87, DOI 10.3989/scimar.2004.68s387; de Madron XD, 2005, PROG OCEANOGR, V64, P83, DOI 10.1016/j.pocean.2004.08.004; DEMESTRE M, 1990, THESIS U BARCELONA, P443; Demestre M, 1993, SCI MAR, V57, P183; Devine JA, 2006, NATURE, V439, P29, DOI 10.1038/439029a; FAO Nations F.a.A.O.o.t.U., 2004, STAT WORLD FISH AQ; Fieux M., 1974, C INTERNAT CNRS FORM, V215, P165; Font J, 2007, SCI MAR, V71, P339, DOI 10.3989/scimar.2007.71n2339; Gage JD, 2003, ECOSY WORLD, V28, P313; Gordon JDM, 2001, CONT SHELF RES, V21, P987, DOI 10.1016/S0278-4343(00)00121-7; Gregory JM, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL023209; Guillen J, 2000, SCI MAR, V64, P427, DOI 10.3989/scimar.2000.64n4427; Herring P., 2002, BIOL DEEP OCEAN, P314; Ivanov VV, 2004, PROG OCEANOGR, V60, P47, DOI 10.1016/j.pocean.2003.12.002; Lampitt RS, 2001, PROG OCEANOGR, V50, P27, DOI 10.1016/S0079-6611(01)00047-7; Lopez-Jurado JL, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL024430; Maynou F, 2006, AQUAT LIVING RESOUR, V19, P161, DOI 10.1051/alr:2006014; MEDOC Group, 1970, NATURE, V227, P1037, DOI [10.1038/2271037a0, DOI 10.1038/2271037A0]; Merino G, 2007, SCI MAR, V71, P537, DOI 10.3989/scimar.2007.71n3537; Merrett N.R., 1997, DEEP SEA DEMERSAL FI, P282; Morato T, 2006, FISH FISH, V7, P24, DOI 10.1111/j.1467-2979.2006.00205.x; Myers RA, 2003, NATURE, V423, P280, DOI 10.1038/nature01610; Pauly D, 2003, SCIENCE, V302, P1359, DOI 10.1126/science.1088667; Roberts CM, 2002, TRENDS ECOL EVOL, V17, P242, DOI 10.1016/S0169-5347(02)02492-8; SALAT J, 2006, UNUSUAL EXTENSION W; SARDA F, 1987, Investigacion Pesquera (Barcelona), V51, P213; Sarda F, 2004, SCI MAR, V68, P117, DOI 10.3989/scimar.2004.68s3117; SARDA F, 1994, FISH B-NOAA, V92, P599; Sarda F, 1997, MAR FRESHWATER RES, V48, P73, DOI 10.1071/MF95043; Sarda Francesc, 2003, Journal of Northwest Atlantic Fishery Science, V31, P127; Schroder K, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL027121; Smith CR, 2006, DEEP-SEA RES PT II, V53, P875, DOI 10.1016/j.dsr2.2006.02.001; Somot S, 2006, CLIM DYNAM, V27, P851, DOI 10.1007/s00382-006-0167-z; Worm B, 2006, SCIENCE, V314, P787, DOI 10.1126/science.1132294	42	174	176	0	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2008	3	1							e1431	10.1371/journal.pone.0001431	http://dx.doi.org/10.1371/journal.pone.0001431			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SN	18197243	Green Published, gold, Green Submitted			2022-12-25	WOS:000260503800004
J	Tabor, R; Friedrich, RW				Tabor, Rico; Friedrich, Rainer W.			Pharmacological Analysis of Ionotropic Glutamate Receptor Function in Neuronal Circuits of the Zebrafish Olfactory Bulb	PLOS ONE			English	Article							GRANULE CELLS; MITRAL CELLS; NMDA RECEPTORS; GABA RELEASE; DENDRODENDRITIC INHIBITION; PRESYNAPTIC INHIBITION; RECIPROCAL SYNAPSES; GAMMA-OSCILLATIONS; ODOR STIMULATION; ANTENNAL LOBE	Although synaptic functions of ionotropic glutamate receptors in the olfactory bulb have been studied in vitro, their roles in pattern processing in the intact system remain controversial. We therefore examined the functions of ionotropic glutamate receptors during odor processing in the intact olfactory bulb of zebrafish using pharmacological manipulations. Odor responses of mitral cells and interneurons were recorded by electrophysiology and 2-photon Ca(2+) imaging. The combined blockade of AMPA/kainate and NMDA receptors abolished odor-evoked excitation of mitral cells. The blockade of AMPA/kainate receptors alone, in contrast, increased the mean response of mitral cells and decreased the mean response of interneurons. The blockade of NMDA receptors caused little or no change in the mean responses of mitral cells and interneurons. However, antagonists of both receptor types had diverse effects on the magnitude and time course of individual mitral cell and interneuron responses and, thus, changed spatio-temporal activity patterns across neuronal populations. Oscillatory synchronization was abolished or reduced by AMPA/kainate and NMDA receptor antagonists, respectively. These results indicate that (1) interneuron responses depend mainly on AMPA/kainate receptor input during an odor response, (2) interactions among mitral cells and interneurons regulate the total olfactory bulb output activity, (3) AMPA/kainate receptors participate in the synchronization of odor-dependent neuronal ensembles, and (4) ionotropic glutamate receptor-containing synaptic circuits shape odor-specific patterns of olfactory bulb output activity. These mechanisms are likely to be important for the processing of odor-encoding activity patterns in the olfactory bulb.	[Tabor, Rico; Friedrich, Rainer W.] Max Planck Inst Med Res, Dept Biomed Opt, Heidelberg, Germany; [Friedrich, Rainer W.] Friedrich Miescher Inst, Basel, Switzerland	Max Planck Society; Friedrich Miescher Institute for Biomedical Research	Friedrich, RW (corresponding author), Max Planck Inst Med Res, Dept Biomed Opt, Heidelberg, Germany.	Rainer.Friedrich@fmi.ch		Friedrich, Rainer/0000-0001-9107-0482	Max-Planck-Society; Novartis Research Foundation; Deutsche Forschungsgemeinschaft [FOR 643]	Max-Planck-Society(Max Planck Society); Novartis Research Foundation; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was supported by the Max-Planck-Society, the Novartis Research Foundation and the Deutsche Forschungsgemeinschaft (FOR 643).	ALLISON AC, 1953, BIOL REV, V28, P195, DOI 10.1111/j.1469-185X.1953.tb01376.x; Andres K.H., 1970, CIBA FDN S TASTE SME, P177; Aroniadou-Anderjaska V, 1999, J NEUROPHYSIOL, V82, P489, DOI 10.1152/jn.1999.82.1.489; Aroniadou-Anderjaska V, 1999, J NEUROPHYSIOL, V81, P15, DOI 10.1152/jn.1999.81.1.15; Aroniadou-Anderjaska V, 2000, J NEUROPHYSIOL, V84, P1194, DOI 10.1152/jn.2000.84.3.1194; Aungst JL, 2003, NATURE, V426, P623, DOI 10.1038/nature02185; BERKOWICZ DA, 1994, J NEUROPHYSIOL, V71, P2557, DOI 10.1152/jn.1994.71.6.2557; CHAPUT MA, 1985, PHYSIOL BEHAV, V34, P249, DOI 10.1016/0031-9384(85)90113-1; Chen WR, 2000, NEURON, V25, P625, DOI 10.1016/S0896-6273(00)81065-X; Christie JM, 2005, NEURON, V46, P761, DOI 10.1016/j.neuron.2005.04.030; Didier A, 2001, P NATL ACAD SCI USA, V98, P6441, DOI 10.1073/pnas.101126398; DuchampViret P, 1997, PROG NEUROBIOL, V53, P561, DOI 10.1016/S0301-0082(97)00049-X; Edwards JG, 2002, J COMP NEUROL, V454, P294, DOI 10.1002/cne.10445; Egger V, 2005, J NEUROSCI, V25, P3521, DOI 10.1523/JNEUROSCI.4746-04.2005; Ennis M, 1996, NEUROREPORT, V7, P989, DOI 10.1097/00001756-199604100-00007; Friedrich RW, 2004, NAT NEUROSCI, V7, P862, DOI 10.1038/nn1292; Friedrich RW, 2004, J NEUROPHYSIOL, V91, P2658, DOI 10.1152/jn.01143.2003; Friedrich RW, 1997, NEURON, V18, P737, DOI 10.1016/S0896-6273(00)80314-1; Friedrich RW, 2001, SCIENCE, V291, P889, DOI 10.1126/science.291.5505.889; FULLER CL, 2006, J COMP NEUR IN PRESS; GRAY CM, 1988, EXP BRAIN RES, V69, P378; Halabisky B, 2000, J NEUROSCI, V20, P5124; HAMILTON KA, 1989, J NEUROPHYSIOL, V62, P609, DOI 10.1152/jn.1989.62.3.609; HASSELMO ME, 1990, COLD SPRING HARB SYM, V55, P599; Higashijima S, 2003, J NEUROPHYSIOL, V90, P3986, DOI 10.1152/jn.00576.2003; Hsia AY, 1999, J NEUROPHYSIOL, V82, P1082, DOI 10.1152/jn.1999.82.2.1082; Isaacson JS, 1999, NEURON, V23, P377, DOI 10.1016/S0896-6273(00)80787-4; Isaacson JS, 2001, P NATL ACAD SCI USA, V98, P337, DOI 10.1073/pnas.021445798; Isaacson JS, 1998, NEURON, V20, P749, DOI 10.1016/S0896-6273(00)81013-2; JAHR CE, 1982, J PHYSIOL-LONDON, V326, P213, DOI 10.1113/jphysiol.1982.sp014187; Kashiwadani H, 1999, J NEUROPHYSIOL, V82, P1786, DOI 10.1152/jn.1999.82.4.1786; Lagier S, 2004, J NEUROSCI, V24, P4382, DOI 10.1523/JNEUROSCI.5570-03.2004; Lagier S, 2007, P NATL ACAD SCI USA, V104, P7259, DOI 10.1073/pnas.0701846104; Laurent G, 2002, NAT REV NEUROSCI, V3, P884, DOI 10.1038/nrn964; Li J, 2005, J NEUROSCI, V25, P5784, DOI 10.1523/JNEUROSCI.0922-05.2005; MATHIESON WB, 1988, J COMP PHYSIOL A, V163, P489, DOI 10.1007/BF00604903; Murphy GJ, 2005, NAT NEUROSCI, V8, P354, DOI 10.1038/nn1403; NICKELL WT, 1994, BRAIN RES BULL, V35, P119, DOI 10.1016/0361-9230(94)90091-4; Olsen SR, 2007, NEURON, V54, P89, DOI 10.1016/j.neuron.2007.03.010; Pressler RT, 2006, NEURON, V49, P889, DOI 10.1016/j.neuron.2006.02.019; Rinberg D, 2006, NEURON, V51, P351, DOI 10.1016/j.neuron.2006.07.013; Root CM, 2007, P NATL ACAD SCI USA, V104, P11826, DOI 10.1073/pnas.0704523104; Sassoe-Pognetto M, 2000, J NEUROSCI, V20, P2192; Schoppa NE, 2006, J NEUROSCI, V26, P12996, DOI 10.1523/JNEUROSCI.3503-06.2006; Schoppa NE, 2006, NEURON, V49, P271, DOI 10.1016/j.neuron.2005.11.038; Schoppa NE, 2002, NAT NEUROSCI, V5, P1194, DOI 10.1038/nn953; Schoppa NE, 1998, J NEUROSCI, V18, P6790; Shang YH, 2007, CELL, V128, P601, DOI 10.1016/j.cell.2006.12.034; Shepherd G.M., 2004, SYNAPTIC ORG BRAIN, DOI [DOI 10.1093/ACPROF:OSO/9780195159561.001.1, 10.1093/acprof:oso/9780195159561.001.1]; Stopfer M, 1997, NATURE, V390, P70, DOI 10.1038/36335; Tabor R, 2004, J NEUROSCI, V24, P6611, DOI 10.1523/JNEUROSCI.1834-04.2004; TROMBLEY PQ, 1990, J NEUROPHYSIOL, V64, P598, DOI 10.1152/jn.1990.64.2.598; Urban NN, 2002, J PHYSIOL-LONDON, V542, P355, DOI 10.1113/jphysiol.2001.013491; Wachowiak M, 1999, J NEUROSCI, V19, P8808, DOI 10.1523/JNEUROSCI.19-20-08808.1999; Wachowiak M, 2004, P NATL ACAD SCI USA, V101, P9097, DOI 10.1073/pnas.0400438101; WACHOWIAK M, 2005, J NEUROPHYSIOL; Wachowiak M, 2006, SEMIN CELL DEV BIOL, V17, P411, DOI 10.1016/j.semcdb.2006.04.007; Yaksi E, 2006, NAT METHODS, V3, P377, DOI 10.1038/NMETH874; Yaksi E, 2007, PLOS BIOL, V5, P1453, DOI 10.1371/journal.pbio.0050178; Zelles T, 2006, J NEUROSCI, V26, P30, DOI 10.1523/JNEUROSCI.1419-05.2006	60	19	19	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2008	3	1							e1416	10.1371/journal.pone.0001416	http://dx.doi.org/10.1371/journal.pone.0001416			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366GT	18183297	Green Published, Green Submitted, gold			2022-12-25	WOS:000260469400013
J	Feng, HT; Cheng, TS; Pavlos, NJ; Yip, KHM; Carrello, A; Seeber, R; Eidne, K; Zheng, MH; Xu, JK				Feng, Haotian; Cheng, Taksum; Pavlos, Nathan J.; Yip, Kirk H. M.; Carrello, Amerigo; Seeber, Ruth; Eidne, Karin; Zheng, Ming H.; Xu, Jiake			Cytoplasmic terminus of vacuolar type proton pump accessory subunit ac45 is required for proper interaction with V-0 domain Subunits and efficient osteoclastic bone resorption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFANTILE MALIGNANT OSTEOPETROSIS; MEDIATED EXTRACELLULAR ACIDIFICATION; KAPPA-B LIGAND; H+-ATPASE; V-ATPASE; TRANSLOCATING ATPASE; A3 SUBUNIT; TARGETED DISRUPTION; ELECTRON-MICROSCOPY; RECEPTOR ACTIVATOR	Solubilization of mineralized bone by osteoclasts is largely dependent on the acidification of the extracellular resorption lacuna driven by the vacuolar (H+)-ATPases (V-ATPases) polarized within the ruffled border membranes. V-ATPases consist of two functionally and structurally distinct domains, V-1 and V-0. The peripheral cytoplasmically oriented V-1 domain drives ATP hydrolysis, which necessitates the translocation of protons across the integral membrane bound V-0 domain. Here, we demonstrate that an accessory subunit, Ac45, interacts with the V-0 domain and contributes to the vacuolar type proton pump-mediated function in osteoclasts. Consistent with its role in intracellular acidification, Ac45 was found to be localized to the ruffled border region of polarized resorbing osteoclasts and enriched in pH-dependent endosomal compartments that polarized to the ruffled border region of actively resorbing osteoclasts. Interestingly, truncation of the 26-amino acid residue cytoplasmic tail of Ac45, which encodes an autonomous internalization signal, was found to impair bone resorption in vitro. Furthermore, biochemical analysis revealed that although both wild type Ac45 and mutant were capable of associating with subunits a3, c, c '', and d, deletion of the cytoplasmic tail altered its binding proximity with a3, c '', and d. In all, our data suggest that the cytoplasmic terminus of Ac45 contains elements necessary for its proper interaction with V-0 domain and efficient osteoclastic bone resorption.	[Feng, Haotian; Cheng, Taksum; Pavlos, Nathan J.; Yip, Kirk H. M.; Carrello, Amerigo; Zheng, Ming H.; Xu, Jiake] Univ Western Australia, Sch Surg & Pathol, Ctr Orthopaed Res, Mol Orthopaed Lab, Nedlands, WA 6009, Australia; [Seeber, Ruth; Eidne, Karin] Univ Western Australia, Western Australia Inst Med Res, Nedlands, WA 6009, Australia	University of Western Australia; University of Western Australia	Xu, JK (corresponding author), Univ Western Australia, Sch Surg & Pathol, Ctr Orthopaed Res, Mol Orthopaed Lab, QE2 Med Ctr,2nd Floor M Block, Nedlands, WA 6009, Australia.	jiake.xu@uwa.edu.au	Seeber, Ruth/AAS-9411-2021	Seeber, Ruth/0000-0003-3265-7931; Xu, Jiake/0000-0003-2021-8309; /0000-0002-2151-3433; Pavlos, Nathan/0000-0001-7003-188X; Zheng, Minghao/0000-0003-1185-4768				ADACHI I, 1990, J BIOL CHEM, V265, P967; ARAI H, 1988, J BIOL CHEM, V263, P8796; BARON R, 1989, ANAT RECORD, V224, P317, DOI 10.1002/ar.1092240220; BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; CHATTERJEE D, 1992, P NATL ACAD SCI USA, V89, P6257, DOI 10.1073/pnas.89.14.6257; Dettmer J, 2006, PLANT CELL, V18, P715, DOI 10.1105/tpc.105.037978; Dow JAT, 1997, J EXP BIOL, V200, P237; Du J, 2006, J CELL SCI, V119, P2542, DOI 10.1242/jcs.02983; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Forgac M, 2007, NAT REV MOL CELL BIO, V8, P917, DOI 10.1038/nrm2272; Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131; GRINSTEIN S, 1992, J EXP BIOL, V172, P179; Holliday LS, 2000, J BIOL CHEM, V275, P32331, DOI 10.1074/jbc.M004795200; Holthuis JCM, 1999, EUR J BIOCHEM, V262, P484, DOI 10.1046/j.1432-1327.1999.00396.x; Hung HC, 2000, MOL BRAIN RES, V75, P330, DOI 10.1016/S0169-328X(99)00325-3; Hurtado-Lorenzo A, 2006, NAT CELL BIOL, V8, P124, DOI 10.1038/ncb1348; Inoue H, 1999, BBA-BIOENERGETICS, V1413, P130, DOI 10.1016/S0005-2728(99)00096-1; Jansen EJR, 1998, J CELL SCI, V111, P2999; Kornak U, 2000, HUM MOL GENET, V9, P2059, DOI 10.1093/hmg/9.13.2059; Kroeger KM, 2001, J BIOL CHEM, V276, P12736, DOI 10.1074/jbc.M011311200; Laitala-Leinonen T, 1999, ANTISENSE NUCLEIC A, V9, P155, DOI 10.1089/oli.1.1999.9.155; Lange PF, 2006, NATURE, V440, P220, DOI 10.1038/nature04535; Lee BS, 1999, J BIOL CHEM, V274, P29164, DOI 10.1074/jbc.274.41.29164; Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514; Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563; Michigami T, 2002, BONE, V30, P436, DOI 10.1016/S8756-3282(01)00684-6; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Nakamura I, 1997, FEBS LETT, V401, P207, DOI 10.1016/S0014-5793(96)01454-8; NELSON N, 1992, J BIOENERG BIOMEMBR, V24, P407, DOI 10.1007/BF00762533; NELSON N, 1992, J EXP BIOL, V172, P149; Nishi T, 2000, J BIOL CHEM, V275, P6824, DOI 10.1074/jbc.275.10.6824; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Norgett EE, 2007, J BIOL CHEM, V282, P14421, DOI 10.1074/jbc.M701226200; Ohira M, 2006, J BIOL CHEM, V281, P22752, DOI 10.1074/jbc.M601441200; Oka T, 2000, J BIOL CHEM, V275, P29556, DOI 10.1074/jbc.M002756200; Oka T, 2001, J BIOL CHEM, V276, P40050, DOI 10.1074/jbc.M106488200; Pavlos NJ, 2005, MOL CELL BIOL, V25, P5253, DOI 10.1128/MCB.25.12.5253-5269.2005; PERIN MS, 1991, J BIOL CHEM, V266, P3877; Sambade M, 2004, J BIOL CHEM, V279, P17361, DOI 10.1074/jbc.M314104200; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schoonderwoert VTG, 2002, MOL MEMBR BIOL, V19, P67, DOI 10.1080/09687680110112910; Scimeca JC, 2003, HUM MUTAT, V21, P151, DOI 10.1002/humu.10165; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Sun-Wada GH, 2003, GENE, V302, P147, DOI 10.1016/S0378-1119(02)01099-5; Sun-Wada GH, 2000, DEV BIOL, V228, P315, DOI 10.1006/dbio.2000.9963; SUNDQUIST KT, 1994, J BONE MINER RES, V9, P1575; SUPEK F, 1994, J BIOL CHEM, V269, P24102; SWALLOW CJ, 1993, J CELL PHYSIOL, V157, P453, DOI 10.1002/jcp.1041570304; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760; Toyomura T, 2003, J BIOL CHEM, V278, P22023, DOI 10.1074/jbc.M302436200; Vaananen HK, 2000, J CELL SCI, V113, P377; Vitavska O, 2003, J BIOL CHEM, V278, P18499, DOI 10.1074/jbc.M212844200; Wassmer T, 2006, MOL BIOL CELL, V17, P917, DOI 10.1091/mbc.E05-06-0511; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; Wilkens S, 2001, J BIOL CHEM, V276, P44064, DOI 10.1074/jbc.M106579200; Xu J, 2007, HISTOL HISTOPATHOL, V22, P443, DOI 10.14670/HH-22.443; Xu J, 2003, J CELL BIOCHEM, V88, P1256, DOI 10.1002/jcb.10477; Xu JK, 2000, J BONE MINER RES, V15, P2178, DOI 10.1359/jbmr.2000.15.11.2178; Yip KHM, 2006, AM J PATHOL, V169, P503, DOI 10.2353/ajpath.2006.050960; Zhao HB, 2001, J BIOL CHEM, V276, P39295, DOI 10.1074/jbc.M010999200	62	37	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2008	283	19					13194	13204		10.1074/jbc.M709712200	http://dx.doi.org/10.1074/jbc.M709712200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295UQ	18227071	Green Published, hybrid			2022-12-25	WOS:000255499800059
J	Yang, L; Clinton, JM; Blackburn, ML; Zhang, Q; Zou, JH; Zielinska-Kwiatkowska, A; Tang, BL; Chansky, HA				Yang, Liu; Clinton, Jeremiah M.; Blackburn, Michael L.; Zhang, Qi; Zou, Junhui; Zielinska-Kwiatkowska, Anna; Tang, Bor Luen; Chansky, Howard A.			Rab23 regulates differentiation of ATDC5 chondroprogenitor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOSOMAL SEX REVERSAL; SRY-RELATED GENE; CAMPOMELIC DYSPLASIA; NEGATIVE REGULATOR; GROWTH-PLATE; NEURAL-TUBE; OPEN BRAIN; MOUSE; SOX9; MUTATIONS	Insulin treatment of mouse ATDC5 chondroprogenitors induces these cells to differentiate into mature chondrocytes. To identify novel factors that are involved in this process, we carried out mutagenesis of ATDC5 cells through retroviral insertion and isolated two mutant clones incapable of differentiation. Inverse PCR analysis of these clones revealed that the retroviral DNA was inserted into the promoter region of the Rab23 gene, resulting in increased Rab23 expression. To investigate whether an elevated level of Rab23 protein led to inhibition of chondrogenic differentiation, we characterized ATDC5 cells that either overexpress endogenous Rab23 or stably express ectopic Rab23. Our results revealed that up-regulation of Rab23 can indeed inhibit chondrogenic differentiation with a concomitant down-regulation of matrix genes such as type II collagen and aggrecan. In addition, stable small interfering RNA knockdown of Rab23 also resulted in inhibition of chondrogenic differentiation as well as down-regulation of Sox9, a master regulator of chondrogenesis. Interestingly, Sox9 expression has recently been linked to Gli1, and we found that Rab23 knockdown decreased Gli1 expression in chondrocytes. Because the phenotypes of Rab23 mutations in mice and humans include defects in cartilage and bone development, our study suggests that Rab23 is involved in the control of Sox9 expression via Gli1 protein.	[Yang, Liu; Clinton, Jeremiah M.; Zhang, Qi; Zou, Junhui; Zielinska-Kwiatkowska, Anna; Chansky, Howard A.] Univ Washington, Dept Orthoped & Sports Med, Seattle, WA 98195 USA; [Yang, Liu; Blackburn, Michael L.; Chansky, Howard A.] Vet Affairs Puget Sound Hlth Care Syst, Med Res Serv, Seattle, WA 98108 USA; [Tang, Bor Luen] Natl Univ Singapore, Dept Biochem, Singapore 117597, Singapore	University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; National University of Singapore	Yang, L (corresponding author), Univ Washington, Dept Orthoped, 1660 S Columbian Way,GMR 151, Seattle, WA 98108 USA.	lyang@u.washington.edu	Tang, Bor Luen/E-4548-2012	Tang, Bor Luen/0000-0002-1925-636X	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR051455] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR051455] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Altaba AR, 2003, CURR OPIN GENET DEV, V13, P513, DOI 10.1016/j.gde.2003.08.005; ATSUMI T, 1990, CELL DIFFER DEV, V30, P109, DOI 10.1016/0922-3371(90)90079-C; Bi WM, 2001, P NATL ACAD SCI USA, V98, P6698, DOI 10.1073/pnas.111092198; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; Bien-Willner GA, 2007, HUM MOL GENET, V16, P1143, DOI 10.1093/hmg/ddm061; Caceres JF, 1997, J CELL BIOL, V138, P225, DOI 10.1083/jcb.138.2.225; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; Eggenschwiler JT, 2006, DEV BIOL, V290, P1, DOI 10.1016/j.ydbio.2005.09.022; Eggenschwiler JT, 2001, NATURE, V412, P194, DOI 10.1038/35084089; Evans TM, 2003, TRAFFIC, V4, P869, DOI 10.1046/j.1600-0854.2003.00141.x; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; GUNTHER T, 1994, DEVELOPMENT, V120, P3119; Guo AC, 2006, J NEUROSCI RES, V83, P1118, DOI 10.1002/jnr.20788; Jenkins D, 2007, AM J HUM GENET, V80, P1162, DOI 10.1086/518047; Kasarskis A, 1998, P NATL ACAD SCI USA, V95, P7485, DOI 10.1073/pnas.95.13.7485; Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657; Lefebvre Veronique, 2005, Birth Defects Research, V75, P200, DOI 10.1002/bdrc.20048; OLKKONEN VM, 1994, GENE, V138, P207, DOI 10.1016/0378-1119(94)90809-5; Rubio CA, 2003, EUR J CLIN INVEST, V33, P406, DOI 10.1046/j.1365-2362.2003.01151.x; Schwartz NB, 1999, PROG NUCLEIC ACID RE, V62, P177; Sekiya I, 2000, J BIOL CHEM, V275, P10738, DOI 10.1074/jbc.275.15.10738; Shea CM, 2003, J CELL BIOCHEM, V90, P1112, DOI 10.1002/jcb.10734; Smits P, 2004, J CELL BIOL, V164, P747, DOI 10.1083/jcb.200312045; St-Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; Wang Y, 2006, TRAFFIC, V7, P746, DOI 10.1111/j.1600-0854.2006.00416.x	27	22	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10649	10657		10.1074/jbc.M706795200	http://dx.doi.org/10.1074/jbc.M706795200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18218620	hybrid, Green Published			2022-12-25	WOS:000254894700047
J	Coffinier, C; Hudon, SE; Lee, R; Farber, EA; Nobumori, C; Miner, JH; Andres, DA; Spielmann, HP; Hrycyna, CA; Fong, LG; Young, SG				Coffinier, Catherine; Hudon, Sarah E.; Lee, Roger; Farber, Emily A.; Nobumori, Chika; Miner, Jeffrey H.; Andres, Douglas A.; Spielmann, H. Peter; Hrycyna, Christine A.; Fong, Loren G.; Young, Stephen G.			A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTANT LAMIN-A; ZMPSTE24-DEFICIENT MICE; RESTRICTIVE DERMOPATHY; ZINC METALLOPROTEINASE; PROGERIA; DISEASE; LIPODYSTROPHY; INFECTION; THERAPY; VIRUS	HIV protease inhibitors ( HIV-PIs) are key components of highly active antiretroviral therapy, but they have been associated with adverse side effects, including partial lipodystrophy and metabolic syndrome. We recently demonstrated that a commonly used HIV- PI, lopinavir, inhibits ZMPSTE24, thereby blocking lamin A biogenesis and leading to an accumulation of prelamin A. ZMPSTE24 deficiency in humans causes an accumulation of prelamin A and leads to lipodystrophy and other disease phenotypes. Thus, an accumulation of prelamin A in the setting of HIV- PIs represents a plausible mechanism for some drug side effects. Here we show, with metabolic labeling studies, that lopinavir leads to the accumulation of the farnesylated form of prelamin A. We also tested whether a new and chemically distinct HIV- PI, darunavir, inhibits ZMPSTE24. We found that darunavir does not inhibit the biochemical activity of ZMPSTE24, nor does it lead to an accumulation of farnesyl-prelamin A in cells. This property of darunavir is potentially attractive. However, all HIV- PIs, including darunavir, are generally administered with ritonavir, an HIV- PI that is used to block the metabolism of other HIV- PIs. Ritonavir, like lopinavir, inhibits ZMPSTE24 and leads to an accumulation of prelamin A.	[Coffinier, Catherine; Lee, Roger; Farber, Emily A.; Nobumori, Chika; Fong, Loren G.; Young, Stephen G.] Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Young, Stephen G.] Univ Calif Los Angeles, Dept Human Genet, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Hudon, Sarah E.; Hrycyna, Christine A.] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA; [Miner, Jeffrey H.] Washington Univ, Sch Med, Dept Internal Med, Div Renal, St Louis, MO 63110 USA; [Andres, Douglas A.; Spielmann, H. Peter] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Washington University (WUSTL); University of Kentucky	Coffinier, C (corresponding author), 695 Charles E Young Dr S, Los Angeles, CA 90095 USA.	coffinie@ucla.edu	lewchavaroj, runglawan/B-5191-2009	Young, Stephen/0000-0001-7270-3176	NCI NIH HHS [CA 099506] Funding Source: Medline; NHLBI NIH HHS [HL 86683, HL 76839] Funding Source: Medline; NIAMS NIH HHS [AR 050200, AR 049469] Funding Source: Medline; NIGMS NIH HHS [GM 66152] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA099506] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076839, R01HL086683] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066152] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal AK, 2003, HUM MOL GENET, V12, P1995, DOI 10.1093/hmg/ddg213; Alsina M, 2004, BLOOD, V103, P3271, DOI 10.1182/blood-2003-08-2764; Anderson JL, 2005, J BIOL CHEM, V280, P29454, DOI 10.1074/jbc.M504982200; Bergo MO, 2002, P NATL ACAD SCI USA, V99, P13049, DOI 10.1073/pnas.192460799; Burke B, 2002, NAT REV MOL CELL BIO, V3, P575, DOI 10.1038/nrm879; Cahn Pedro E, 2004, J Int Assoc Physicians AIDS Care (Chic), V3, P92, DOI 10.1177/154510970400300304; Caron M, 2007, CELL DEATH DIFFER, V14, P1759, DOI 10.1038/sj.cdd.4402197; Caron M, 2003, AIDS, V17, P2437, DOI 10.1097/00002030-200311210-00005; Carr A, 2003, AIDS, V17, pS141, DOI 10.1097/00002030-200304001-00017; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; Clarke SG, 2007, P NATL ACAD SCI USA, V104, P13857, DOI 10.1073/pnas.0706529104; Coffinier C, 2007, P NATL ACAD SCI USA, V104, P13432, DOI 10.1073/pnas.0704212104; COX AD, 1995, METHOD ENZYMOL, V255, P195; Dechat T, 2007, P NATL ACAD SCI USA, V104, P4955, DOI 10.1073/pnas.0700854104; Dierynck I, 2007, J VIROL, V81, P13845, DOI 10.1128/JVI.01184-07; Eder J, 2007, CURR PHARM DESIGN, V13, P271, DOI 10.2174/138161207779313560; Feng L, 2007, SCIENCE, V318, P1608, DOI 10.1126/science.1150755; Fenton C, 2007, DRUGS, V67, P2791, DOI 10.2165/00003495-200767180-00010; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; Fong LG, 2006, SCIENCE, V311, P1621, DOI 10.1126/science.1124875; Fong LG, 2004, P NATL ACAD SCI USA, V101, P18111, DOI 10.1073/pnas.0408558102; Glynn MW, 2005, HUM MOL GENET, V14, P2959, DOI 10.1093/hmg/ddi326; Green ML, 2002, J GEN INTERN MED, V17, P797, DOI 10.1046/j.1525-1497.2002.20201.x; Hammer SM, 2006, JAMA-J AM MED ASSOC, V296, P827, DOI 10.1001/jama.296.7.827; Hegele RA, 2000, MOL GENET METAB, V71, P539, DOI 10.1006/mgme.2000.3092; HENNEKES H, 1994, J CELL SCI, V107, P1019; Koh Y, 2003, ANTIMICROB AGENTS CH, V47, P3123, DOI 10.1128/AAC.47.10.3123-3129.2003; Leon A, 2007, J ANTIMICROB CHEMOTH, V60, P824, DOI 10.1093/jac/dkm285; Leung GK, 2001, J BIOL CHEM, V276, P29051, DOI 10.1074/jbc.M102908200; LUTZ RJ, 1992, P NATL ACAD SCI USA, V89, P3000, DOI 10.1073/pnas.89.7.3000; Mallampalli MP, 2005, P NATL ACAD SCI USA, V102, P14416, DOI 10.1073/pnas.0503712102; Mccoy C, 2007, CLIN THER, V29, P1559, DOI 10.1016/j.clinthera.2007.08.016; Moulson CL, 2005, J INVEST DERMATOL, V125, P913, DOI 10.1111/j.0022-202X.2005.23846.x; Navarro CL, 2005, HUM MOL GENET, V14, P1503, DOI 10.1093/hmg/ddi159; Nolan D, 2001, ANTIVIR THER, V6, P145; Schmidt WK, 2000, J BIOL CHEM, V275, P6227, DOI 10.1074/jbc.275.9.6227; Surleraux DLNG, 2005, J MED CHEM, V48, P1965, DOI 10.1021/jm049454n; Surleraux DLNG, 2005, J MED CHEM, V48, P1813, DOI 10.1021/jm049560p; Takahashi M, 2007, BIOL PHARM BULL, V30, P1947, DOI 10.1248/bpb.30.1947; Toth JI, 2005, P NATL ACAD SCI USA, V102, P12873, DOI 10.1073/pnas.0505767102; Troutman JM, 2005, BIOCONJUGATE CHEM, V16, P1209, DOI 10.1021/bc050068+; Vigouroux C, 1999, DIABETES METAB, V25, P383; Worman HJ, 2007, EXP CELL RES, V313, P2121, DOI 10.1016/j.yexcr.2007.03.028; Youle M, 2007, J ANTIMICROB CHEMOTH, V60, P1195, DOI 10.1093/jac/dkm364; Young SG, 2005, J LIPID RES, V46, P2531, DOI 10.1194/jlr.R500011-JLR200	46	49	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9797	9804		10.1074/jbc.M709629200	http://dx.doi.org/10.1074/jbc.M709629200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18230615	Green Published, hybrid			2022-12-25	WOS:000254671600034
J	Sekine, K; Takubo, K; Kikuchi, R; Nishimoto, M; Kitagawa, M; Abe, F; Nishikawa, K; Tsuruo, T; Naito, M				Sekine, Keiko; Takubo, Kohei; Kikuchi, Ryo; Nishimoto, Michie; Kitagawa, Masayuki; Abe, Fuminori; Nishikawa, Kiyohiro; Tsuruo, Takashi; Naito, Mikihiko			Small molecules destabilize cIAP1 by activating auto-ubiquitylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LIGASE ACTIVITY; X-LINKED INHIBITOR; CELL-DEATH; APOPTOSIS PROTEINS; IAP PROTEINS; CANCER-CELLS; BESTATIN; XIAP; IDENTIFICATION; MITOCHONDRIA	Overexpression of an anti-apoptotic protein cIAP1 caused by its genetic amplification was reported in certain cancers, such as hepatocellular carcinoma, esophageal squamous cell carcinoma, cervical cancer, and lung cancer, which confers resistance to chemotherapy and radiotherapy. Here we report cIAP1 to be selectively down-regulated by a class of small molecules ((-)-N-[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butyryl]-L-leucine methyl ester (ME-BS)), resulting in a sensitization of cancer cells to apoptosis. ME-BS directly interacts with the BIR3 domain of cIAP1, promotes auto-ubiquitylation dependent on its RING domain, and facilitates proteasomal degradation of cIAP1. Other IAPs such as XIAP and cIAP2 were not affected by ME-BS. These results suggest targeted destabilization of cIAP1 by small molecules as a novel method to treat cancers expressing cIAP1, which interferes with treatment. Manipulation of the intrinsic ubiquitin-ligase activity could be a novel strategy to develop small molecules for therapeutic purposes.	[Sekine, Keiko; Takubo, Kohei; Kikuchi, Ryo; Nishimoto, Michie; Tsuruo, Takashi; Naito, Mikihiko] Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; [Sekine, Keiko; Kitagawa, Masayuki; Abe, Fuminori; Nishikawa, Kiyohiro] Nippon Kayaku Co Ltd, Res & Dev Grp, Pharmaceut Res Labs, Kita Ku, Tokyo 1158588, Japan; [Tsuruo, Takashi] Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 1358550, Japan	University of Tokyo; Nippon Kayaku Co., Ltd.; Japanese Foundation for Cancer Research	Naito, M (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	mnaito@iam.u-tokyo.ac.jp		Kikuchi, Ryota/0000-0002-8839-2891				ABE F, 1990, CANCER IMMUNOL IMMUN, V32, P75, DOI 10.1007/BF01754202; Bartke T, 2004, MOL CELL, V14, P801, DOI 10.1016/j.molcel.2004.05.018; Chen ZH, 1999, BIOCHEM BIOPH RES CO, V264, P847, DOI 10.1006/bbrc.1999.1585; Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; Conze DB, 2005, MOL CELL BIOL, V25, P3348, DOI 10.1128/MCB.25.8.3348-3356.2005; Dai ZY, 2003, HUM MOL GENET, V12, P791, DOI 10.1093/hmg/ddg083; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eckelman BP, 2006, J BIOL CHEM, V281, P3254, DOI 10.1074/jbc.M510863200; Ferreira CG, 2001, ANN ONCOL, V12, P799, DOI 10.1023/A:1011167113067; Hao YY, 2004, NAT CELL BIOL, V6, P849, DOI 10.1038/ncb1159; Hunter AM, 2003, J BIOL CHEM, V278, P7494, DOI 10.1074/jbc.C200695200; Ichinose Y, 2003, JNCI-J NATL CANCER I, V95, P605, DOI 10.1093/jnci/95.8.605; Imoto I, 2002, CANCER RES, V62, P4860; Imoto I, 2001, CANCER RES, V61, P6629; Kasof GM, 2001, J BIOL CHEM, V276, P3238, DOI 10.1074/jbc.M003670200; Krajewska M, 2003, CLIN CANCER RES, V9, P4914; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li L, 2004, SCIENCE, V305, P1471, DOI 10.1126/science.1098231; NISHIZAWA R, 1977, J MED CHEM, V20, P510, DOI 10.1021/jm00214a010; Oost TK, 2004, J MED CHEM, V47, P4417, DOI 10.1021/jm040037k; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sasaki S, 1998, CLIN EXP IMMUNOL, V111, P30; Schimmer AD, 2004, CANCER CELL, V5, P25, DOI 10.1016/S1535-6108(03)00332-5; Sekine K, 1999, LEUKEMIA, V13, P729, DOI 10.1038/sj.leu.2401388; Sekine K, 2001, INT J CANCER, V94, P485, DOI 10.1002/ijc.1492; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Sun HY, 2004, J MED CHEM, V47, P4147, DOI 10.1021/jm0499108; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; TALMADGE JE, 1986, CANCER RES, V46, P4505; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Vaux DL, 2005, NAT REV MOL CELL BIO, V6, P287, DOI 10.1038/nrm1621; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vucic D, 2000, CURR BIOL, V10, P1359, DOI 10.1016/S0960-9822(00)00781-8; Wang XD, 2001, GENE DEV, V15, P2922; Yang QH, 2004, J BIOL CHEM, V279, P16963, DOI 10.1074/jbc.M401253200; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zobel K, 2006, ACS CHEM BIOL, V1, P525, DOI 10.1021/cb600276q	41	107	112	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					8961	8968		10.1074/jbc.M709525200	http://dx.doi.org/10.1074/jbc.M709525200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18230607	hybrid			2022-12-25	WOS:000254465800025
J	Gelsthorpe, ME; Baumann, N; Millard, E; Gale, SE; Langmade, SJ; Schaffer, JE; Ory, DS				Gelsthorpe, Mark E.; Baumann, Nikola; Millard, Elizabeth; Gale, Sarah E.; Langmade, S. Joshua; Schaffer, Jean E.; Ory, Daniel S.			Niemann-Pick type C1I1061T mutant encodes a functional protein that is selected for endoplasmic reticulum-associated degradation due to protein misfolding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; STEROL-SENSING DOMAIN; CELLULAR CHOLESTEROL HOMEOSTASIS; DENSITY-LIPOPROTEIN CHOLESTEROL; CYSTIC-FIBROSIS MUTATION; DISEASE TYPE-C; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; INTRACELLULAR-TRANSPORT; NPC1 PROTEIN; TRAFFICKING	Over 200 disease-causing mutations have been identified in the NPC1 gene. The most prevalent mutation, NPC1(I1061T), is predicted to lie within the cysteine-rich luminal domain and is associated with the classic juvenile-onset phenotype of Niemann-Pick type C disease. To gain insight into the molecular mechanism by which the NPC1(I1061T) mutation causes disease, we examined expression of the mutant protein in human fibroblasts homozygous for the NPC1(I1061T) mutation. Despite similar NPC1 mRNA levels between wild type and NPC1(I1061T) fibroblasts, NPC1 protein levels are decreased by 85% in NPC1(I1061)T cells. Metabolic labeling studies demonstrate that unlike wild type protein, which undergoes a glycosylation pattern shift from Endo H-sensitive to Endo H-resistant species, NPC1(I1061T) protein remains almost exclusively Endo H-sensitive and exhibits a reduced half-life (t(1/2) 6.5 h) versus wild type Endo H-resistant species (t(1/2) 42 h). Treatment with chemical chaperones, growth at permissive temperature, or inhibition of proteasomal degradation increases NPC1(I1061T) protein levels, indicating that the mutant protein is likely targeted for endoplasmic reticulum-associated degradation (ERAD) due to protein misfolding. Overexpression of NPC1(I1061T) in NPC1-deficient cells results in late endosomal localization of the mutant protein and complementation of the NPC mutant phenotype, likely due to a small proportion of the nascent NPC1(I1061T) protein that is able to fold correctly and escape the endoplasmic reticulum quality control checkpoints. Our findings provide the first description of an endoplasmic reticulum trafficking defect as a mechanism for human NPC disease, shedding light on the mechanism by which the NPC1(I1061T) mutation causes disease and suggesting novel approaches to treat NPC disease caused by the NPC1(I1061T) mutation.	[Gelsthorpe, Mark E.; Baumann, Nikola; Millard, Elizabeth; Gale, Sarah E.; Langmade, S. Joshua; Schaffer, Jean E.; Ory, Daniel S.] Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Internal Med, St Louis, MO 63110 USA; [Schaffer, Jean E.] Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; [Ory, Daniel S.] Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Ory, DS (corresponding author), Box 8086,660 S Euclid Ave, St Louis, MO 63110 USA.	dory@wustl.edu			NHLBI NIH HHS [HL 67773, HL 04482, 5 T32 HL 007275-29] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K02HL004482, R01HL067773, T32HL007275] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aridor M, 2002, TRAFFIC, V3, P781, DOI 10.1034/j.1600-0854.2002.31103.x; Aridor M, 2000, TRAFFIC, V1, P836, DOI 10.1034/j.1600-0854.2000.011104.x; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Chen W, 2001, J BIOL CHEM, V276, P43564, DOI 10.1074/jbc.M107938200; Choi HY, 2003, J BIOL CHEM, V278, P32569, DOI 10.1074/jbc.M304553200; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; Davies JP, 2000, J BIOL CHEM, V275, P24367, DOI 10.1074/jbc.M002184200; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Fernandez-Valero EM, 2005, CLIN GENET, V68, P245, DOI 10.1111/j.1399-0004.2005.00490.x; Frolov A, 2003, J BIOL CHEM, V278, P25517, DOI 10.1074/jbc.M302588200; Frolov A, 2001, J BIOL CHEM, V276, P46414, DOI 10.1074/jbc.M108099200; Gale SE, 2006, J BIOL CHEM, V281, P11082, DOI 10.1074/jbc.M509612200; Gelman MS, 2002, J CLIN INVEST, V110, P1591, DOI 10.1172/JCI200216786; Kopito Ron R., 1999, Physiological Reviews, V79, pS167; LISCUM L, 1987, J BIOL CHEM, V262, P17002; Millard EE, 2000, J BIOL CHEM, V275, P38445, DOI 10.1074/jbc.M003180200; Millard EE, 2005, J BIOL CHEM, V280, P28581, DOI 10.1074/jbc.M414024200; Millat G, 1999, AM J HUM GENET, V65, P1321, DOI 10.1086/302626; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; Ory DS, 2000, BBA-MOL CELL BIOL L, V1529, P331, DOI 10.1016/S1388-1981(00)00158-X; Park WD, 2003, HUM MUTAT, V22, P313, DOI 10.1002/humu.10255; PENTCHEV PG, 1985, P NATL ACAD SCI USA, V82, P8247, DOI 10.1073/pnas.82.23.8247; Rubenstein RC, 1997, J CLIN INVEST, V100, P2457, DOI 10.1172/JCI119788; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Schueler UH, 2004, J INHERIT METAB DIS, V27, P649, DOI 10.1023/B:BOLI.0000042959.44318.7c; SCHWEIZER A, 1995, J CELL SCI, V108, P2477; Scott C, 2004, BBA-MOL CELL BIOL L, V1685, P8, DOI 10.1016/j.bbalip.2004.08.006; Sharma M, 2001, J BIOL CHEM, V276, P8942, DOI 10.1074/jbc.M009172200; Shearer AG, 2004, J BIOL CHEM, V279, P188, DOI 10.1074/jbc.M307734200; Sifers RN, 2003, SCIENCE, V299, P1330, DOI 10.1126/science.1082718; Sitia R, 2003, NATURE, V426, P891, DOI 10.1038/nature02262; Spear ED, 2003, MOL BIOL CELL, V14, P2756, DOI 10.1091/mbc.E02-11-0717; WARD CL, 1994, J BIOL CHEM, V269, P25710; Watari H, 2000, EXP CELL RES, V259, P247, DOI 10.1006/excr.2000.4976; Watari H, 1999, J BIOL CHEM, V274, P21861, DOI 10.1074/jbc.274.31.21861; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Wojtanik KM, 2003, J BIOL CHEM, V278, P14850, DOI 10.1074/jbc.M300488200; Zhang M, 2001, J BIOL CHEM, V276, P3417, DOI 10.1074/jbc.M005393200	39	116	119	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8229	8236		10.1074/jbc.M708735200	http://dx.doi.org/10.1074/jbc.M708735200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18216017	Green Published, hybrid			2022-12-25	WOS:000254288000020
J	Kotake, T; Hojo, S; Tajima, N; Matsuoka, K; Koyama, T; Tsumuraya, Y				Kotake, Toshihisa; Hojo, Sachiko; Tajima, Noriaki; Matsuoka, Koji; Koyama, Tetsuo; Tsumuraya, Yoichi			A bifunctional enzyme with L-fucokinase and GDP-L-fucose pyrophosphorylase activities salvages free L-fucose in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-SUGAR PYROPHOSPHORYLASE; BETA-L-FUCOSE; CELL-WALL; SUBSTRATE-SPECIFICITY; XYLOGLUCAN; PURIFICATION; EXPRESSION; CLONING; KINASE; GENE	Monomeric sugars generated during the metabolism of polysaccharides, glycoproteins, and glycolipids are imported to the cytoplasm and converted to respective nucleotide sugars via monosaccharide 1-phosphates, to be reutilized as activated sugars. Because L-fucose (L-Fuc) is activated mainly in the form of GDP derivatives in seed plants, the salvage reactions for L-Fuc are expected to be independent from those for Glc, Gal, L-arabinose, and glucuronic acid, which are activated as UDP-sugars. For this study we have identified, in the genomic data base of Arabidopsis, the gene (designated AtFKGP) of a bifunctional enzyme with similarity to both L-fucokinase and GDP-L-Fuc pyrophosphorylase. Recombinant AtFKGP (rAt-FKGP) expressed in Escherichia coli showed both L-fucokinase and GDP-L-Fuc pyrophosphorylase activities, generating GDP-L-Fuc from L-Fuc, ATP, and GTPas the starting substrates. Point mutations in rAtFKGPs at either Gly(133) or Gly(830) caused loss of GDP-L-Fuc pyrophosphorylase and L-fucokinase activity, respectively. The apparent Km values of L-fucokinase activity of rAtFKGP for L-Fuc and ATP were 1.0 and 0.45mM, respectively, and those of GDP-L-Fuc pyrophosphorylase activity for L-Fuc 1-phosphate and GTP were 0.052 and 0.17mM, respectively. The expression of AtFKGP was detected in most cell types of Arabidopsis, indicating that salvage reactions for free L-Fuc catalyzed by AtFKGP occur ubiquitously in Arabidopsis. Loss-of-function mutants with tDNA insertion in AtFKGP exhibited higher accumulation of free L-Fuc in the soluble fraction than the wild-type plant. These results indicate that AtFKGP is a bifunctional enzyme with L-fucokinase and GDP-L-Fuc pyrophosphorylase activities, which salvages free L-Fuc in Arabidopsis.	[Kotake, Toshihisa; Hojo, Sachiko; Tsumuraya, Yoichi] Saitama Univ, Grad Sch Sci & Engn, Div Life Sci, Sakura Ku, Saitama City 3388570, Japan; [Tajima, Noriaki] Saitama Univ, Fac Sci, Dept Biochem & Mol Biol, Sakura Ku, Saitama City 3388570, Japan; [Matsuoka, Koji; Koyama, Tetsuo] Saitama Univ, Grad Sch Sci & Engn, Div Mat Sci, Sakura Ku, Saitama City 3388570, Japan	Saitama University; Saitama University; Saitama University	Kotake, T (corresponding author), Saitama Univ, Grad Sch Sci & Engn, Div Life Sci, Sakura Ku, 255 Shimo Okubo, Saitama City 3388570, Japan.	kotake@molbiol.saitama-u.ac.jp	KOTAKE, TOSHIHISA/F-1117-2011; Matsuoka, Koji/A-9463-2008; Tsumuraya, Yoichi/C-7903-2012	KOTAKE, TOSHIHISA/0000-0002-1110-5006; Matsuoka, Koji/0000-0002-8987-2715; 				Albermann C, 2000, GLYCOBIOLOGY, V10, P875, DOI 10.1093/glycob/10.9.875; ASPINALL GO, 1972, CAN J BIOCHEM CELL B, V50, P574, DOI 10.1139/o72-079; Bonin CP, 2000, PLANT J, V21, P445, DOI 10.1046/j.1365-313x.2000.00698.x; Bonin CP, 2003, PLANT PHYSIOL, V132, P883, DOI 10.1104/pp.103.022368; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown K, 1999, EMBO J, V18, P4096, DOI 10.1093/emboj/18.15.4096; Coyne MJ, 2005, SCIENCE, V307, P1778, DOI 10.1126/science.1106469; Hartley A, 2004, J MOL BIOL, V337, P387, DOI 10.1016/j.jmb.2004.01.043; HAYASHI T, 1989, ANNU REV PLANT PHYS, V40, P139, DOI 10.1146/annurev.pp.40.060189.001035; Iglesias N, 2006, PLANT CELL PHYSIOL, V47, P55, DOI 10.1093/pcp/pci223; ISHIHARA H, 1968, J BIOL CHEM, V243, P1103; Ishikawa M, 2000, PLANTA, V210, P782, DOI 10.1007/s004250050680; Kaplan CP, 1997, PLANT MOL BIOL, V34, P497, DOI 10.1023/A:1005816104743; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kotake T, 2004, J BIOL CHEM, V279, P45728, DOI 10.1074/jbc.M408716200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lange BM, 1999, P NATL ACAD SCI USA, V96, P13714, DOI 10.1073/pnas.96.24.13714; LEVY S, 1991, PLANT J, V1, P195; Levy S, 1997, PLANT J, V11, P373, DOI 10.1046/j.1365-313X.1997.11030373.x; MACDONALD DK, 1962, J ORG CHEM, V27, P1107, DOI 10.1021/jo01050a552; Mio T, 1998, J BIOL CHEM, V273, P14392, DOI 10.1074/jbc.273.23.14392; Niittymaki J, 2004, EUR J BIOCHEM, V271, P78, DOI 10.1046/j.1432-1033.2003.03904.x; Nothnagel EA, 1997, INT REV CYTOL, V174, P195, DOI 10.1016/S0074-7696(08)62118-X; O'Neill M., 1990, METHODS PLANT BIOCH, V2, P415, DOI DOI 10.1016/B978-0-12-461012-5.50018-5; O'Neill MA, 2001, SCIENCE, V294, P846, DOI 10.1126/science.1062319; Ohashi T, 2006, ANAL BIOCHEM, V352, P182, DOI 10.1016/j.ab.2006.02.026; Park SH, 1998, J BIOL CHEM, V273, P5685, DOI 10.1074/jbc.273.10.5685; Pastuszak I, 1998, J BIOL CHEM, V273, P30165, DOI 10.1074/jbc.273.46.30165; Pauly M, 2000, ANAL BIOCHEM, V278, P69, DOI 10.1006/abio.1999.4411; Perrin RM, 1999, SCIENCE, V284, P1976, DOI 10.1126/science.284.5422.1976; Reiter WD, 2001, PLANT MOL BIOL, V47, P95, DOI 10.1023/A:1010671129803; REITER WD, 1993, SCIENCE, V261, P1032, DOI 10.1126/science.261.5124.1032; RUDICK VL, 1974, J BIOL CHEM, V249, P7832; Sarria R, 2001, PLANT PHYSIOL, V127, P1595, DOI 10.1104/pp.010596; SCHMIDT RR, 1991, LIEBIGS ANN CHEM, P121; Sherson S, 1999, PLANT MOL BIOL, V39, P1003, DOI 10.1023/A:1006181908753; Thoden JB, 2003, J BIOL CHEM, V278, P33305, DOI 10.1074/jbc.M304789200; TSAY YH, 1991, MOL CELL BIOL, V11, P620, DOI 10.1128/MCB.11.2.620; van Ree R, 2000, J BIOL CHEM, V275, P11451, DOI 10.1074/jbc.275.15.11451	39	43	51	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8125	8135		10.1074/jbc.M710078200	http://dx.doi.org/10.1074/jbc.M710078200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18199744	hybrid			2022-12-25	WOS:000254288000009
J	Liu, ZY; Habener, JF				Liu, Zhengyu; Habener, Joel F.			Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION-FACTOR-7-LIKE-2 TCF7L2 GENE; DEPENDENT PROTEIN-KINASE; INSULIN-PRODUCING CELLS; EMBRYONIC STEM-CELLS; CYCLIN D1; REGULATES PROLIFERATION; INDEPENDENT ACTIVATION; RECEPTOR AGONISTS; SELF-RENEWAL; CATENIN	The insulinotropic hormone GLP-1 (glucagon-like peptide-1) is a new therapeutic agent that preserves or restores pancreatic beta cell mass. We report that GLP-1 and its agonist, exendin-4 (Exd4), induce Wnt signaling in pancreatic beta cells, both isolated islets, and in INS-1 cells. Basal and GLP-1 agonist-induced proliferation of beta cells requires active Wnt signaling. Cyclin D1 and c-Myc, determinants of cell proliferation, are up-regulated by Exd4. Basal endogenous Wnt signaling activity depends on Wnt frizzled receptors and the protein kinases Akt and GSK3 beta but not cAMP-dependent protein kinase. In contrast, GLP-1 agonists enhance Wnt signaling via GLP-1 receptor-mediated activation of Akt and beta cell independent of GSK3 beta. Inhibition of Wnt signaling by small interfering RNAs to beta-catenin or a dominant-negative TCF7L2 decreases both basal and Exd4-induced beta cell proliferation. Wnt signaling appears to mediate GLP-1-induced beta cell proliferation raising possibilities for novel treatments of diabetes.	[Habener, Joel F.] Massachusetts Gen Hosp, Mol Endocrinol Lab, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Habener, JF (corresponding author), Massachusetts Gen Hosp, Mol Endocrinol Lab, 55 Fruit St,Thier 306, Boston, MA 02114 USA.	jhabener@partners.org			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK057521, R01DK030834, R01DK055365, P30DK040561] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 30834, P30 DK040561, P30 DK040561-12, P30 DK 57521, DK 55365] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham EJ, 2002, ENDOCRINOLOGY, V143, P3152, DOI 10.1210/en.143.8.3152; Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200; Bai L, 2005, J ENDOCRINOL, V186, P343, DOI 10.1677/joe.1.06078; Briaud I, 2003, DIABETES, V52, P974, DOI 10.2337/diabetes.52.4.974; Burwinkel B, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-268; Buteau J, 1999, DIABETOLOGIA, V42, P856, DOI 10.1007/s001250051238; Buteau J, 2003, DIABETES, V52, P124, DOI 10.2337/diabetes.52.1.124; Buteau J, 2001, DIABETES, V50, P2237, DOI 10.2337/diabetes.50.10.2237; Cabrera O, 2006, P NATL ACAD SCI USA, V103, P2334, DOI 10.1073/pnas.0510790103; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Cauchi S, 2006, DIABETES, V55, P3189, DOI 10.2337/db06-0692; Cauchi S, 2006, DIABETES, V55, P2903, DOI 10.2337/db06-0474; Chen AE, 2005, NATURE, V433, P317, DOI 10.1038/nature03126; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; D'Amour KA, 2006, NAT BIOTECHNOL, V24, P1392, DOI 10.1038/nbt1259; Damcott CM, 2006, DIABETES, V55, P2654, DOI 10.2337/db06-0338; DasGupta R, 1999, DEVELOPMENT, V126, P4557; Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; Dessimoz J, 2005, CURR BIOL, V15, P1677, DOI 10.1016/j.cub.2005.08.037; Drucker DJ, 2006, LANCET, V368, P1696, DOI 10.1016/S0140-6736(06)69705-5; Egan JM, 2003, DIABETES-METAB RES, V19, P115, DOI 10.1002/dmrr.357; Feng ZL, 2004, BIOCHEM BIOPH RES CO, V324, P1333, DOI 10.1016/j.bbrc.2004.09.206; Filippa N, 1999, MOL CELL BIOL, V19, P4989; Florez JC, 2006, NEW ENGL J MED, V355, P241, DOI 10.1056/NEJMoa062418; Friedrichsen BN, 2006, J ENDOCRINOL, V188, P481, DOI 10.1677/joe.1.06160; Fukumoto S, 2001, J BIOL CHEM, V276, P17479, DOI 10.1074/jbc.C000880200; Gomez E, 2002, J BIOL CHEM, V277, P48146, DOI 10.1074/jbc.M209165200; Gordon MD, 2006, J BIOL CHEM, V281, P22429, DOI 10.1074/jbc.R600015200; Grant SFA, 2006, NAT GENET, V38, P320, DOI 10.1038/ng1732; Haraguchi K, 2004, BIOCHEM BIOPH RES CO, V313, P841, DOI 10.1016/j.bbrc.2003.12.021; Hardikar AA, 2002, ENDOCRINOLOGY, V143, P3505, DOI 10.1210/en.2001-211344; Heiser PW, 2006, DEVELOPMENT, V133, P2023, DOI 10.1242/dev.02366; Heller RS, 2003, GENE EXPRESSION, V11, P141, DOI 10.3727/000000003108749035; Heller RS, 2002, DEV DYNAM, V225, P260, DOI 10.1002/dvdy.10157; Heller RS, 1997, DIABETES, V46, P785, DOI 10.2337/diabetes.46.5.785; Hino S, 2005, MOL CELL BIOL, V25, P9063, DOI 10.1128/MCB.25.20.9063-9072.2005; Hisatomi Y, 2004, HEPATOLOGY, V39, P667, DOI 10.1002/hep.20063; Holst Jens Juul, 2004, Expert Opin Emerg Drugs, V9, P155, DOI 10.1517/14728214.9.1.155; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Hui HX, 2005, DIABETES-METAB RES, V21, P313, DOI 10.1002/dmrr.553; Katanaev VL, 2005, CELL, V120, P111, DOI 10.1016/j.cell.2004.11.014; Kieffer TJ, 1999, ENDOCR REV, V20, P876, DOI 10.1210/er.20.6.876; Kikuchi A, 2006, EXP MOL MED, V38, P1, DOI 10.1038/emm.2006.1; Kim MJ, 2006, J ENDOCRINOL, V188, P623, DOI 10.1677/joe.1.06480; Kleber M, 2005, J CELL BIOL, V169, P309, DOI 10.1083/jcb.200411095; Ku HT, 2004, STEM CELLS, V22, P1205, DOI 10.1634/stemcells.2004-0027; Kulkarni NH, 2005, J CELL BIOCHEM, V95, P1178, DOI 10.1002/jcb.20506; LACY PE, 1994, MT SINAI J MED, V61, P23; Lester LB, 1997, P NATL ACAD SCI USA, V94, P14942, DOI 10.1073/pnas.94.26.14942; Li LX, 2006, ENDOCRINOLOGY, V147, P3318, DOI 10.1210/en.2006-0155; Li YZ, 2003, J BIOL CHEM, V278, P471, DOI 10.1074/jbc.M209423200; List JF, 2004, AM J PHYSIOL-ENDOC M, V286, pE875, DOI 10.1152/ajpendo.00007.2004; Liu XX, 2005, CURR BIOL, V15, P1989, DOI 10.1016/j.cub.2005.10.050; Luo YQ, 2006, NEUROSCI LETT, V398, P291, DOI 10.1016/j.neulet.2006.01.024; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; MOJSOV S, 1987, J CLIN INVEST, V79, P616, DOI 10.1172/JCI112855; Moon Randall T, 2005, Sci STKE, V2005, pcm1; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Murtaugh LC, 2005, DEVELOPMENT, V132, P4663, DOI 10.1242/dev.02063; Naito AT, 2005, CIRC RES, V97, P144, DOI 10.1161/01.RES.0000175241.92285.f8; Paling NRD, 2004, J BIOL CHEM, V279, P48063, DOI 10.1074/jbc.M406467200; Papadopoulou S, 2005, DIABETES, V54, P2844, DOI 10.2337/diabetes.54.10.2844; Pradeep A, 2004, ONCOGENE, V23, P3689, DOI 10.1038/sj.onc.1207454; Quaiser T, 2006, BIOESSAYS, V28, P339, DOI 10.1002/bies.20386; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Rukstalis JM, 2006, ENDOCRINOLOGY, V147, P2997, DOI 10.1210/en.2005-1396; Rulifson IC, 2007, P NATL ACAD SCI USA, V104, P6247, DOI 10.1073/pnas.0701509104; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Schinner S, 2008, DIABETOLOGIA, V51, P147, DOI 10.1007/s00125-007-0848-0; SHU L, 2008, IN PRESS DIABETES; Skoglund G, 2000, DIABETES, V49, P1156, DOI 10.2337/diabetes.49.7.1156; Stadeli R, 2006, CURR BIOL, V16, pR378, DOI 10.1016/j.cub.2006.04.019; Suzuki Y, 2006, J BIOL CHEM, V281, P28499, DOI 10.1074/jbc.M604291200; Taurin S, 2006, J BIOL CHEM, V281, P9971, DOI 10.1074/jbc.M508778200; Teo R, 2006, DEV BIOL, V289, P91, DOI 10.1016/j.ydbio.2005.10.009; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tian Q, 2005, CELL CYCLE, V4, P215; Tian Q, 2004, P NATL ACAD SCI USA, V101, P15370, DOI 10.1073/pnas.0406499101; Trumper J, 2005, DIABETOLOGIA, V48, P1534, DOI 10.1007/s00125-005-1820-5; Trumper K, 2000, ANN NY ACAD SCI, V921, P242; Wang H, 2006, CIRC RES, V98, P1331, DOI 10.1161/01.RES.0000220650.26555.1d; Wang Q, 2004, DIABETOLOGIA, V47, P478, DOI 10.1007/s00125-004-1327-5; Wang Q, 2002, DIABETOLOGIA, V45, P1263, DOI 10.1007/s00125-002-0828-3; Wang XH, 2004, AM J PHYSIOL-HEART C, V287, pH2376, DOI 10.1152/ajpheart.01173.2003; Wells JM, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-4; Willert K, 2006, GENE DEV, V20, P1394, DOI 10.1101/gad.1424006; Xu G, 1999, DIABETES, V48, P2270, DOI 10.2337/diabetes.48.12.2270; Xu LF, 2000, GENE DEV, V14, P585; Yi FH, 2005, J BIOL CHEM, V280, P1457, DOI 10.1074/jbc.M411487200; Yue ZC, 2006, P NATL ACAD SCI USA, V103, P951, DOI 10.1073/pnas.0506894103; Zalzman M, 2005, DIABETES, V54, P2568, DOI 10.2337/diabetes.54.9.2568	95	232	251	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8723	8735		10.1074/jbc.M706105200	http://dx.doi.org/10.1074/jbc.M706105200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18216022	hybrid, Green Published			2022-12-25	WOS:000254288000070
J	Dries, DR; Newton, AC				Dries, Daniel R.; Newton, Alexandra C.			Kinetic analysis of the interaction of the C1 domain of protein kinase C with lipid membranes by stopped-flow spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER BINDING; ACTIVATION; PHOSPHATIDYLSERINE; DIACYLGLYCEROL; SPECIFICITY; COOPERATIVITY; MECHANISM; ISOFORMS; DELTA; PHOSPHORYLATION	The diacylglycerol DG)/phorbol ester-dependent translocation of conventional protein kinase C PKC) isozymes is mediated by the C1 domain, a membrane-targeting module that also selectively binds phosphatidylserine PS). Using stopped-flow spectroscopy, we dissect the contribution of DG/phorbol esters C1 ligand) and PS in driving the association and dissociation of the C1 domain from membranes. Specifically, we examine the binding to membranes of the C1B domain of PKC beta with a substituted Trp Y123W) whose fluorescence is quenched upon binding to membranes. Binding of this construct C1B beta-Y123W) to phospholipid vesicles is cooperative with respect to PS content and dependent on C1 ligand, as previously characterized. Stopped-flow analysis reveals that the apparent association rate k(on)(app)), but not the apparent dissociation rate k(off)(app)), is highly sensitive to PS content: the 60-fold increase in membrane affinity for vesicles containing no PS compared with 40 mol% PS results primarily from a robust 30-fold) increase in k(on)(app) with little effect 2-fold) on k(off)(app). Membrane affinity is also controlled by the content and structure of the C1 ligand. In contrast to PS, these ligands markedly alter k(off)(app) with smaller effects on k(on)(app). We also show that the affinity for phorbol ester-containing membranes is 2 orders of magnitude higher than that for DG-containing membranes primarily resulting from differences in k(off)(app). Our data are consistent with a model in which the C1 domain is recruited to the membrane via an initial weak electrostatic interaction with PS, followed by a rapid two-dimensional search for ligand, the binding of which retains the domain at the membrane. Thus, PS drives the initial encounter, and DG/phorbol esters retain the domain on membranes. The decreased effectiveness of DG compared with phorbol esters in retaining the C1 domain on membranes contributes to the molecular dichotomy of the rapid, transient nature of DG-dependent PKC signaling versus the chronic hyperactivity of phorbol ester-activated PKC.	[Newton, Alexandra C.] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Dries, Daniel R.] Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Newton, AC (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr,0721, La Jolla, CA 92093 USA.	anewton@ucsd.edu		DRIES, DANIEL/0000-0002-0530-5212	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008326, R37GM043154, R01GM043154, T32GM007752] Funding Source: NIH RePORTER; NIGMS NIH HHS [2T32 GM-08326, 2T32 GM-07752, GM-43154] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ananthanarayanan B, 2003, J BIOL CHEM, V278, P46886, DOI 10.1074/jbc.M307853200; BARTLETT GR, 1959, J BIOL CHEM, V234, P468; Bittova L, 2001, J BIOL CHEM, V276, P4218, DOI 10.1074/jbc.M008491200; Cho WH, 2005, ANNU REV BIOPH BIOM, V34, P119, DOI 10.1146/annurev.biophys.33.110502.133337; Codazzi F, 2001, CURR BIOL, V11, P1089, DOI 10.1016/S0960-9822(01)00326-8; Colon-Gonzalez F, 2006, BBA-MOL CELL BIOL L, V1761, P827, DOI 10.1016/j.bbalip.2006.05.001; Corbalan-Garcia S, 2006, BBA-MOL CELL BIOL L, V1761, P633, DOI 10.1016/j.bbalip.2006.04.015; Dibble ARG, 1996, BIOPHYS J, V71, P1877, DOI 10.1016/S0006-3495(96)79387-6; Dries DR, 2007, J BIOL CHEM, V282, P826, DOI 10.1074/jbc.C600268200; Gallegos LL, 2006, J BIOL CHEM, V281, P30947, DOI 10.1074/jbc.M603741200; Giorgione J, 2003, BIOCHEMISTRY-US, V42, P11194, DOI 10.1021/bi0350046; Giorgione JR, 2006, J BIOL CHEM, V281, P1660, DOI 10.1074/jbc.M510251200; Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110; Hurley JH, 2000, ANNU REV BIOPH BIOM, V29, P49, DOI 10.1146/annurev.biophys.29.1.49; Johnson JE, 2000, BIOCHEMISTRY-US, V39, P11360, DOI 10.1021/bi000902c; Johnson JE, 1998, BIOCHEMISTRY-US, V37, P12020, DOI 10.1021/bi981107q; KAZANIETZ MG, 1992, J BIOL CHEM, V267, P20878; KHANDWALA AS, 1971, BIOCHIM BIOPHYS ACTA, V233, P348, DOI 10.1016/0005-2736(71)90332-4; Killian JA, 2000, TRENDS BIOCHEM SCI, V25, P429, DOI 10.1016/S0968-0004(00)01626-1; Koivunen J, 2006, CANCER LETT, V235, P1, DOI 10.1016/j.canlet.2005.03.033; LEE MH, 1989, J BIOL CHEM, V264, P14797; LEE MH, 1992, BIOCHEMISTRY-US, V31, P5176, DOI 10.1021/bi00137a013; Medkova M, 1999, J BIOL CHEM, V274, P19852, DOI 10.1074/jbc.274.28.19852; Mosior M, 1998, BIOCHEMISTRY-US, V37, P17271, DOI 10.1021/bi981344t; MOSIOR M, 1995, J BIOL CHEM, V270, P25526, DOI 10.1074/jbc.270.43.25526; Nalefski EA, 2001, BIOCHEMISTRY-US, V40, P13216, DOI 10.1021/bi010761u; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; Pu YM, 2006, J BIOL CHEM, V281, P33773, DOI 10.1074/jbc.M606560200; Radic Z, 1997, J BIOL CHEM, V272, P23265, DOI 10.1074/jbc.272.37.23265; SHARKEY NA, 1984, P NATL ACAD SCI-BIOL, V81, P607, DOI 10.1073/pnas.81.2.607; Stahelin RV, 2004, J BIOL CHEM, V279, P29501, DOI 10.1074/jbc.M403191200; Tang C, 2006, NATURE, V444, P383, DOI 10.1038/nature05201; Violin JD, 2003, J CELL BIOL, V161, P899, DOI 10.1083/jcb.200302125; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	39	27	27	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7885	7893		10.1074/jbc.M709943200	http://dx.doi.org/10.1074/jbc.M709943200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18187412	hybrid			2022-12-25	WOS:000253997900064
J	Giganti, A; Rodriguez, M; Fould, B; Moulharat, N; Coge, F; Chomarat, P; Galizzi, JP; Valet, P; Saulnier-Blache, JS; Boutin, JA; Ferry, G				Giganti, Adeline; Rodriguez, Marianne; Fould, Benjamin; Moulharat, Natacha; Coge, Francis; Chomarat, Pascale; Galizzi, Jean-Pierre; Valet, Philippe; Saulnier-Blache, Jean-Sebastien; Boutin, Jean A.; Ferry, Gilles			Murine and human autotaxin alpha, beta, and gamma isoforms - Gene organization, tissue distribution, and biochemical characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOPHOSPHOLIPASE-D ACTIVITY; LYSOPHOSPHATIDIC ACID SYNTHESIS; MOTILITY-STIMULATING PROTEIN; PHOSPHODIESTERASE-I; NUCLEOTIDE PYROPHOSPHATASES/PHOSPHODIESTERASES; PREADIPOCYTE PROLIFERATION; ADIPOCYTE DIFFERENTIATION; MOLECULAR-CLONING; DIVALENT-CATIONS; BREAST-CANCER	Autotaxin is a type II ectonucleotide pyrophosphate phosphodiesterase enzyme. It has been recently discovered that it also has a lysophospholipase D activity. This enzyme probably provides most of the extracellular lysophosphatidic acid from lysophosphatidylcholine. The cloning and tissue distribution of the three isoforms (imaginatively called alpha, beta, and gamma) from human and mouse are reported in this study, as well as their tissue distribution by PCR in the human and mouse. The fate of the alpha isoform from human was also studied after purification and using mass spectrometry. Indeed, this particular isoform expresses the intron 12 in which a cleavage site is present, leading to a rapid catabolism of the isoform. For the human isoform gamma and the total autotaxin mRNA expression, quantitative PCR is presented in 21 tissues. The isoforms were expressed in two different hosts, insect cells and Chinese hamster ovary cells, and were highly purified. The characteristics of the six purified isoforms (pH and temperature dependence, K-m and V-max values, and their dependence on metal ions) are presented in this study. Their sensitivity to a small molecule inhibitor, hypericin, is also shown. Finally, the specificity of the isoforms toward a large family of lysophosphatidylcholines is reported. This study is the first complete description of the reported autotaxin isoforms.	[Giganti, Adeline; Rodriguez, Marianne; Fould, Benjamin; Moulharat, Natacha; Coge, Francis; Chomarat, Pascale; Galizzi, Jean-Pierre; Boutin, Jean A.; Ferry, Gilles] Inst Rech Servier, F-78290 Croissy sur Seine, France; [Valet, Philippe; Saulnier-Blache, Jean-Sebastien] INSERM, U 858 12MR, Dept Metab & Obes, F-31432 Toulouse, France	Servier; Institut de Recherches Internationales Servier; Institut National de la Sante et de la Recherche Medicale (Inserm)	Boutin, JA (corresponding author), Inst Rech Servier, 125,chemin Ronde, F-78290 Croissy sur Seine, France.	jean.boutin@fr.netgrs.com	Valet, Philippe/N-7472-2017; Boutin, Jean Albert/W-9103-2019; Saulnier-Blache, Jean Sebastien/X-7729-2018	Valet, Philippe/0000-0001-6520-7393; Boutin, Jean Albert/0000-0003-0068-7204; Saulnier-Blache, Jean Sebastien/0000-0002-8971-7723				Aoki J, 2004, SEMIN CELL DEV BIOL, V15, P477, DOI 10.1016/j.semcdb.2004.05.001; Bachner D, 1999, MECH DEVELOP, V84, P121, DOI 10.1016/S0925-4773(99)00048-9; Baker DL, 2006, J BIOL CHEM, V281, P22786, DOI 10.1074/jbc.M512486200; BELLI SI, 1994, BIOCHEM J, V304, P75, DOI 10.1042/bj3040075; Bollen M, 2000, CRIT REV BIOCHEM MOL, V35, P393, DOI 10.1080/10409230091169249; Boucharaba A, 2004, J CLIN INVEST, V114, P1714, DOI 10.1172/JCI200422123; Boucher J, 2005, DIABETOLOGIA, V48, P569, DOI 10.1007/s00125-004-1660-8; Brindley DN, 2004, J CELL BIOCHEM, V92, P900, DOI 10.1002/jcb.20126; Cimpean A, 2004, BIOCHEM J, V381, P71, DOI 10.1042/BJ20040465; Clair T, 1997, J BIOL CHEM, V272, P996, DOI 10.1074/jbc.272.2.996; Cui P, 2007, BIOORG MED CHEM LETT, V17, P1634, DOI 10.1016/j.bmcl.2006.12.114; Dennis J, 2005, J NEUROSCI RES, V82, P737, DOI 10.1002/jnr.20686; Durgam GG, 2005, J MED CHEM, V48, P4919, DOI 10.1021/jm049609r; Ferguson CG, 2006, ORG LETT, V8, P2023, DOI 10.1021/ol060414i; Ferry G, 2003, J BIOL CHEM, V278, P18162, DOI 10.1074/jbc.M301158200; Ferry G, 2007, FEBS LETT, V581, P3572, DOI 10.1016/j.febslet.2007.06.064; Gesta S, 2002, J LIPID RES, V43, P904; Gijsbers R, 2003, FEBS LETT, V538, P60, DOI 10.1016/S0014-5793(03)00133-9; Goding JW, 2003, BBA-MOL BASIS DIS, V1638, P1, DOI 10.1016/S0925-4439(03)00058-9; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; Gududuru V, 2006, BIOORG MED CHEM LETT, V16, P451, DOI 10.1016/j.bmcl.2005.08.096; Hausman D B, 2001, Obes Rev, V2, P239, DOI 10.1046/j.1467-789X.2001.00042.x; HERINGDORT DMZ, 2006, BIOCHIM BIOPHYS ACTA, V1758, P923; Jansen S, 2005, J CELL SCI, V118, P3081, DOI 10.1242/jcs.02438; Jiang GW, 2007, CHEMMEDCHEM, V2, P679, DOI 10.1002/cmdc.200600280; KAWAGOE H, 1995, GENOMICS, V30, P380, DOI 10.1006/geno.1995.0036; KAWASAKI T, 1987, BIOCHIM BIOPHYS ACTA, V920, P85, DOI 10.1016/0005-2760(87)90314-6; Koh E, 2003, CANCER RES, V63, P2042; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee HY, 1996, BIOCHEM BIOPH RES CO, V218, P714, DOI 10.1006/bbrc.1996.0127; Lee J, 2001, BIOCHEM PHARMACOL, V62, P219, DOI 10.1016/S0006-2952(01)00658-X; Luquain C, 2003, J LIPID RES, V44, P1963, DOI 10.1194/jlr.M300188-JLR200; Morishige J, 2007, BBA-MOL CELL BIOL L, V1771, P491, DOI 10.1016/j.bbalip.2007.01.005; MOULHARAT N, 2008, IN PRESS CHEM BIOL I; MURATA J, 1994, J BIOL CHEM, V269, P30479; NARITA M, 1994, J BIOL CHEM, V269, P28235; Pages C, 2001, J BIOL CHEM, V276, P11599, DOI 10.1074/jbc.M010111200; Piao JH, 1999, CYTOGENET CELL GENET, V87, P172, DOI 10.1159/000015459; Pradere JP, 2007, BBA-MOL CELL BIOL L, V1771, P93, DOI 10.1016/j.bbalip.2006.11.010; RAZZELL WE, 1959, J BIOL CHEM, V234, P2105; SCOTT WG, 1995, J MOL BIOL, V250, P327, DOI 10.1006/jmbi.1995.0380; Simon MF, 2005, J BIOL CHEM, V280, P14656, DOI 10.1074/jbc.M412585200; Stracke ML, 1997, ADV ENZYME REGUL, V37, P135, DOI 10.1016/S0065-2571(96)00017-9; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; Sugimoto S, 2006, BBA-MOL CELL BIOL L, V1761, P1410, DOI 10.1016/j.bbalip.2006.09.013; Tanaka M, 2006, J BIOL CHEM, V281, P25822, DOI 10.1074/jbc.M605142200; Tigyi G, 2001, PROSTAG OTH LIPID M, V64, P47, DOI 10.1016/S0090-6980(01)00107-1; Tokumura A, 1998, LIPIDS, V33, P1009, DOI 10.1007/s11745-998-0299-2; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; Tokumura A, 2007, LIFE SCI, V80, P1641, DOI 10.1016/j.lfs.2006.12.041; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; Valet P, 1998, J CLIN INVEST, V101, P1431, DOI 10.1172/JCI806; van Meeteren LA, 2005, J BIOL CHEM, V280, P21155, DOI 10.1074/jbc.M413183200; van Meeteren LA, 2007, PROG LIPID RES, V46, P145, DOI 10.1016/j.plipres.2007.02.001; van Meeteren LA, 2006, MOL CELL BIOL, V26, P5015, DOI 10.1128/MCB.02419-05; WYKLE RL, 1974, J BIOL CHEM, V249, P1742; WYKLE RL, 1977, ARCH BIOCHEM BIOPHYS, V184, P149, DOI 10.1016/0003-9861(77)90336-8; Yang SY, 2002, CLIN EXP METASTAS, V19, P603, DOI 10.1023/A:1020950420196; Zhou M.J., 2000, P SPIE INT SOC OPT E, V3926, P166	59	94	106	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7776	7789		10.1074/jbc.M708705200	http://dx.doi.org/10.1074/jbc.M708705200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18175805	hybrid			2022-12-25	WOS:000253997900054
J	Kim, CH; Kim, SJ; Kan, H; Kwon, HM; Roh, KB; Jiang, R; Yang, Y; Park, JW; Lee, HH; Ha, NC; Kang, HJ; Nonaka, M; Soderhall, K; Lee, BL				Kim, Chan-Hee; Kim, Su-Jin; Kan, Hongnan; Kwon, Hyun-Mi; Roh, Kyung-Baeg; Jiang, Rui; Yang, Yu; Park, Ji-Won; Lee, Hyeon-Hwa; Ha, Nam-Chul; Kang, Hee Jung; Nonaka, Masaru; Soderhall, Kenneth; Lee, Bok Luel			A three-step proteolytic cascade mediates the activation of the peptidoglycan-induced Toll pathway in an insect	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOLOTRICHIA-DIOMPHALIA LARVAE; PRO-PHENOL-OXIDASE; SERINE-PROTEASE; INNATE IMMUNITY; PROPHENOLOXIDASE ACTIVATION; MELANIZATION CASCADE; RECOGNITION PROTEIN; MOLECULAR-CLONING; TENEBRIO-MOLITOR; DROSOPHILA	The recognition of lysine-type peptidoglycans (PG) by the PG recognition complex has been suggested to cause activation of the serine protease cascade leading to the processing of Spatzle and subsequent activation of the Toll signaling pathway. So far, two serine proteases involved in the lysine-type PG Toll signaling pathway have been identified. One is a modular serine protease functioning as an initial enzyme to be recruited into the lysine-type PG recognition complex. The other is the Drosophila Spatzle processing enzyme (SPE), a terminal enzyme that converts Spatzle proprotein to its processed form capable of binding to the Toll receptor. However, it remains unclear how the initial PG recognition signal is transferred to Spatzle resulting in Toll pathway activation. Also, the biochemical characteristics and mechanism of action of a serine protease linking the modular serine protease and SPE have not been investigated. Here, we purified and cloned a novel upstream serine protease of SPE that we named SAE, SPE-activating enzyme, from the hemolymph of a large beetle, Tenebrio molitor larvae. This enzyme was activated by Tenebrio modular serine protease and in turn activated the Tenebrio SPE. The biochemical ordered functions of these three serine proteases were determined in vitro, suggesting that the activation of a three-step proteolytic cascade is necessary and sufficient for lysine-type PG recognition signaling. The processed Spatzle by this cascade induced antibacterial activity in vivo. These results demonstrate that the three-step proteolytic cascade linking the PG recognition complex and Spatzle processing is essential for the PG-dependent Toll signaling pathway.	[Kim, Chan-Hee; Kim, Su-Jin; Kan, Hongnan; Kwon, Hyun-Mi; Roh, Kyung-Baeg; Jiang, Rui; Yang, Yu; Park, Ji-Won; Lee, Hyeon-Hwa; Ha, Nam-Chul; Lee, Bok Luel] Pusan Natl Univ, Coll Pharm, Natl Res Lab Def Prot, Pusan 609735, South Korea; [Kang, Hee Jung] Hallym Univ, Coll Med, Dept Lab Med, Anyang 431070, South Korea; [Nonaka, Masaru] Univ Tokyo, Dept Biol Sci, Tokyo 1130033, Japan; [Soderhall, Kenneth] Uppsala Univ, Dept Comparat Physiol, S-75236 Uppsala, Sweden	Pusan National University; Hallym University; University of Tokyo; Uppsala University	Lee, BL (corresponding author), Pusan Natl Univ, Coll Pharm, Natl Res Lab Def Prot, Pusan 609735, South Korea.	brlee@pusan.ac.kr	Kim, Chan-Hee/C-6849-2016; Jiang, Rui/F-9248-2011; NONAKA, MASARU/G-4929-2014	Kim, Chan-Hee/0000-0002-5315-4981; Jiang, Rui/0000-0002-5580-9822				Anderson A F, 2000, Am J Knee Surg, V13, P19; Cherry S, 2006, NAT IMMUNOL, V7, P911, DOI 10.1038/ni1388; DeLotto Y, 1998, MECH DEVELOP, V72, P141, DOI 10.1016/S0925-4773(98)00024-0; Dissing M, 2001, EMBO J, V20, P2387, DOI 10.1093/emboj/20.10.2387; Ferrandon D, 2007, NAT REV IMMUNOL, V7, P862, DOI 10.1038/nri2194; Fujita T, 2002, NAT REV IMMUNOL, V2, P346, DOI 10.1038/nri800; Gottar M, 2006, CELL, V127, P1425, DOI 10.1016/j.cell.2006.10.046; Jang IH, 2006, DEV CELL, V10, P45, DOI 10.1016/j.devcel.2005.11.013; Ji CY, 2004, J BIOL CHEM, V279, P34101, DOI 10.1074/jbc.M404584200; Kambris Z, 2006, CURR BIOL, V16, P808, DOI 10.1016/j.cub.2006.03.020; Kawabata S, 1996, FEBS LETT, V398, P146, DOI 10.1016/S0014-5793(96)01224-0; Lee SY, 1998, EUR J BIOCHEM, V254, P50, DOI 10.1046/j.1432-1327.1998.2540050.x; Lee SY, 1998, EUR J BIOCHEM, V257, P615, DOI 10.1046/j.1432-1327.1998.2570615.x; LEMAITRE B, 2007, IMMUNOLOGY, V25, P697; LeMosy EK, 2001, P NATL ACAD SCI USA, V98, P5055, DOI 10.1073/pnas.081026598; Leulier F, 2003, NAT IMMUNOL, V4, P478, DOI 10.1038/ni922; Levashina EA, 1999, SCIENCE, V285, P1917, DOI 10.1126/science.285.5435.1917; Ligoxygakis P, 2002, SCIENCE, V297, P114, DOI 10.1126/science.1072391; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; MOON HJ, 1994, J BIOCHEM-TOKYO, V116, P53, DOI 10.1093/oxfordjournals.jbchem.a124502; Park JW, 2007, P NATL ACAD SCI USA, V104, P6602, DOI 10.1073/pnas.0610924104; Park JW, 2006, J BIOL CHEM, V281, P7747, DOI 10.1074/jbc.M510058200; Piao S, 2005, EMBO J, V24, P4404, DOI 10.1038/sj.emboj.7600891; Royet J, 2005, CURR OPIN IMMUNOL, V17, P11, DOI 10.1016/j.coi.2004.12.002; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; Tang HP, 2006, J BIOL CHEM, V281, P28097, DOI 10.1074/jbc.M601642200; Weber ANR, 2003, NAT IMMUNOL, V4, P794, DOI 10.1038/ni955; YOSHIDA H, 1986, BIOCHEM BIOPH RES CO, V141, P1177, DOI 10.1016/S0006-291X(86)80168-1; Zhang R, 2003, J BIOL CHEM, V278, P42072, DOI 10.1074/jbc.M307475200	30	118	131	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7599	7607		10.1074/jbc.M710216200	http://dx.doi.org/10.1074/jbc.M710216200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18195005	hybrid			2022-12-25	WOS:000253997900035
J	Bocharov, EV; Mineev, KS; Volynsky, PE; Ermolyuk, YS; Tkach, EN; Sobol, AG; Chupin, VV; Kirpichnikov, MP; Efremov, RG; Arseniev, AS				Bocharov, Eduard V.; Mineev, Konstantin S.; Volynsky, Pavel E.; Ermolyuk, Yaroslav S.; Tkach, Elena N.; Sobol, Alexander G.; Chupin, Vladimir V.; Kirpichnikov, Michail P.; Efremov, Roman G.; Arseniev, Alexander S.			Spatial structure of the dimeric transmembrane domain of the growth factor receptor ErbB2 presumably corresponding to the receptor active state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; ACTIVATION; PEPTIDES; SEQUENCE; DIMERIZATION; DYNAMICS	Proper lateral dimerization of the transmembrane domains of receptor tyrosine kinases is required for biochemical signal transduction across the plasma membrane. The spatial structure of the dimeric transmembrane domain of the growth factor receptor ErbB2 embedded into lipid bicelles was obtained by solution NMR, followed by molecular dynamics relaxation in an explicit lipid bilayer. ErbB2 transmembrane segments associate in a right-handed alpha-helical bundle through the N-terminal tandem GG4-like motif Thr(652)-X(3)Ser(656)-X-3-Gly(660), providing an explanation for the pathogenic power of some oncogenic mutations.	[Bocharov, Eduard V.; Mineev, Konstantin S.; Volynsky, Pavel E.; Sobol, Alexander G.; Chupin, Vladimir V.; Efremov, Roman G.; Arseniev, Alexander S.] Russian Acad Sci, MM Shemyakin Bioorgan Chem Inst, Div Struct Biol, Moscow 117997, Russia; [Ermolyuk, Yaroslav S.; Tkach, Elena N.; Kirpichnikov, Michail P.] Russian Acad Sci, MM Shemyakin Bioorgan Chem Inst, Lab Prot Engn, Moscow 117997, Russia	Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences	Bocharov, EV (corresponding author), Russian Acad Sci, MM Shemyakin Bioorgan Chem Inst, Div Struct Biol, Ulitsa Miklukho Maklaya 16-10, Moscow 117997, Russia.	bon@nmr.ru; aars@nmr.ru	Mineev, Konstantin S/Q-3948-2018; Volynsky, Pavel/A-8360-2014; Roman, Efremov/A-7460-2014; Mineev, Konstantin/AAC-6662-2019; Mineev, Konstantin/E-4151-2010; chupin, vladimir/J-8986-2015	Mineev, Konstantin S/0000-0002-2418-9421; Volynsky, Pavel/0000-0002-0471-4188; Roman, Efremov/0000-0002-5474-4721; Mineev, Konstantin/0000-0002-2418-9421; Mineev, Konstantin/0000-0002-2418-9421; 				BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; Beevers AJ, 2006, J MOL BIOL, V361, P945, DOI 10.1016/j.jmb.2006.07.004; Bennasroune A, 2004, MOL BIOL CELL, V15, P3464, DOI 10.1091/mbc.E03-10-0753; Bocharov EV, 2004, J BIOL CHEM, V279, P17697, DOI 10.1074/jbc.M313384200; Cavanagh J, 2007, PROTEIN NMR SPECTROSCOPY: PRINCIPLES AND PRACTICE, 2ND EDITION, P1; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Curran AR, 2003, CURR OPIN STRUC BIOL, V13, P412, DOI 10.1016/S0959-440X(03)00102-7; Daragan VA, 1997, PROG NUCL MAG RES SP, V31, P63, DOI 10.1016/S0079-6565(97)00006-X; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Duneau JP, 2007, BIOCHEMISTRY-US, V46, P2010, DOI 10.1021/bi061436f; EFREMOV RG, 1995, J PHYS CHEM-US, V99, P10658, DOI 10.1021/j100026a033; Enosh A, 2007, BIOINFORMATICS, V23, pE212, DOI 10.1093/bioinformatics/btl325; Fleishman SJ, 2002, P NATL ACAD SCI USA, V99, P15937, DOI 10.1073/pnas.252640799; Guntert P, 2003, PROG NUCL MAG RES SP, V43, P105, DOI 10.1016/S0079-6565(03)00021-9; Jiang GQ, 1999, CURR BIOL, V9, pR568, DOI 10.1016/S0960-9822(99)80357-1; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Langosch D, 1998, PROTEINS, V31, P150, DOI 10.1002/(SICI)1097-0134(19980501)31:2<150::AID-PROT5>3.0.CO;2-Q; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; MacKenzie KR, 2006, CHEM REV, V106, P1931, DOI 10.1021/cr0404388; Mendrola JM, 2002, J BIOL CHEM, V277, P4704, DOI 10.1074/jbc.M108681200; Moriki T, 2001, J MOL BIOL, V311, P1011, DOI 10.1006/jmbi.2001.4923; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Orekhov VY, 1995, APPL MAGN RESON, V9, P581, DOI 10.1007/BF03162365; Partridge AW, 2002, BIOPOLYMERS, V66, P350, DOI 10.1002/bip.10313; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Smith SO, 2002, BIOCHEMISTRY-US, V41, P9321, DOI 10.1021/bi012117l; Smith SO, 1996, NAT STRUCT BIOL, V3, P252, DOI 10.1038/nsb0396-252; Tanner KG, 1999, J BIOL CHEM, V274, P35985, DOI 10.1074/jbc.274.50.35985; Xie DW, 2000, J NATL CANCER I, V92, P412, DOI 10.1093/jnci/92.5.412; Yin H, 2007, SCIENCE, V315, P1817, DOI 10.1126/science.1136782; Zwahlen C, 1997, J AM CHEM SOC, V119, P6711, DOI 10.1021/ja970224q	35	169	172	1	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					6950	6956		10.1074/jbc.M709202200	http://dx.doi.org/10.1074/jbc.M709202200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18178548	hybrid			2022-12-25	WOS:000253779600039
J	Li, Z; Wang, C; Jiao, X; Katiyar, S; Casimiro, MC; Prendergast, GC; Powell, MJ; Pestell, RG				Li, Zhiping; Wang, Chenguang; Jiao, Xuanmao; Katiyar, Sanjay; Casimiro, Mathew C.; Prendergast, George C.; Powell, Michael J.; Pestell, Richard G.			Alternate cyclin d1 mRNA splicing modulates p27(KIP1) binding and cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA PROTEIN; ANDROGEN RECEPTOR; BREAST-CANCER; MICE LACKING; GERANYLGERANYLATED RHOB; INHIBITOR P27(KIP1); PROSTATE-CANCER; TUMOR-GROWTH; EXPRESSION; REPRESSION	Cyclin D1 is an important cell cycle regulator, but in cancer its overexpression also increases cellular migration mediated by p27(KIP1) stabilization and RhoA inhibition. Recently, a common polymorphism at the exon 4-intron 4 boundary of the human cyclin D1 gene within a splice donor region was associated with an altered risk of developing cancer. Altered RNA splicing caused by this polymorphism gives rise to a variant cyclin D1 isoform termed cyclin D1b, which has the same N terminus as the canonical cyclin D1a isoform but a distinct C terminus. In this study we show that these different isoforms have unique properties with regard to the cellular migration function of cyclin D1. Although they displayed little difference in transcriptional co-repression assays on idealized reporter genes, microarray cDNA expression analysis revealed differential regulation of genes, including those that influence cellular migration. Additionally, whereas cyclin D1a stabilized p27(KIP1) and inhibited RhoA-induced ROCK kinase activity, promoting cellular migration, cyclin D1b failed to stabilize p27(KIP1) or inhibit ROCK kinase activity and had no effect on migration. Our findings argue that alternate splicing is an important determinant of the function of cyclin D1 in cellular migration.	[Li, Zhiping; Wang, Chenguang; Jiao, Xuanmao; Katiyar, Sanjay; Casimiro, Mathew C.; Powell, Michael J.; Pestell, Richard G.] Thomas Jefferson Univ, Dept Canc Biol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Li, Zhiping; Wang, Chenguang; Jiao, Xuanmao; Katiyar, Sanjay; Casimiro, Mathew C.; Powell, Michael J.; Pestell, Richard G.] Thomas Jefferson Univ, Dept Med Oncol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Prendergast, George C.] Lankenau Inst Med Res, Wynnewood, PA 19096 USA	Jefferson University; Jefferson University; Lankenau Medical Center; Lankenau Institute for Medical Research	Wang, C (corresponding author), Thomas Jefferson Univ, Dept Canc Biol, Kimmel Canc Ctr, 233 S 10th St,Bluemle Life Sci Bldg,Rm 1050, Philadelphia, PA 19107 USA.	chenguang.wang@jefferson.edu; Richard.Pestell@jefferson.edu		Katiyar, Sanjay/0000-0003-1622-5661	NATIONAL CANCER INSTITUTE [R01CA070896, R01CA075503, P30CA056036, R01CA086072] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA86072, P30CA56036, R01CA75503, R01CA70896] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; Baldassarre G, 2005, CANCER CELL, V7, P51, DOI 10.1016/j.ccr.2004.11.025; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; BETTICHER DC, 1995, ONCOGENE, V11, P1005; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Burd CJ, 2006, P NATL ACAD SCI USA, V103, P2190, DOI 10.1073/pnas.0506281103; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chen Z, 2000, J BIOL CHEM, V275, P17974, DOI 10.1074/jbc.C000145200; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Drobnjak M, 2000, CLIN CANCER RES, V6, P1891; Du W, 1999, MOL CELL BIOL, V19, P1831; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Fu MF, 2005, J BIOL CHEM, V280, P16934, DOI 10.1074/jbc.M500403200; Fu MF, 2005, J BIOL CHEM, V280, P29728, DOI 10.1074/jbc.M503188200; Grimmler M, 2007, CELL, V128, P269, DOI 10.1016/j.cell.2006.11.047; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Holley SL, 2001, AM J PATHOL, V159, P1917, DOI 10.1016/S0002-9440(10)63038-6; Holnthoner W, 2002, J BIOL CHEM, V277, P45847, DOI 10.1074/jbc.M209354200; Hosokawa Y, 1998, GENE CHROMOSOME CANC, V22, P66, DOI 10.1002/(SICI)1098-2264(199805)22:1<66::AID-GCC9>3.0.CO;2-5; Howe D, 2001, HAEMATOLOGICA, V86, P563; Hulit J, 2006, CANCER RES, V66, P8529, DOI 10.1158/0008-5472.CAN-06-0149; Jiang K, 2004, MOL CELL BIOL, V24, P5565, DOI 10.1128/MCB.24.12.5565-5576.2004; Jin KL, 2004, FASEB J, V18, P287, DOI 10.1096/fj.03-0973com; Katiyar S, 2007, MOL CELL BIOL, V27, P1356, DOI 10.1128/MCB.01061-06; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Knudsen KE, 1999, CANCER RES, V59, P2297; Kong SM, 2000, CANCER RES, V60, P249; Leveque C, 2007, EXP CELL RES, V313, P2719, DOI 10.1016/j.yexcr.2007.04.018; Li ZP, 2006, CANCER RES, V66, P9986, DOI 10.1158/0008-5472.CAN-06-1596; Li ZP, 2006, MOL CELL BIOL, V26, P4240, DOI 10.1128/MCB.02124-05; Liu AX, 2001, P NATL ACAD SCI USA, V98, P6192, DOI 10.1073/pnas.111137198; Lu FM, 2003, CANCER RES, V63, P7056; McAllister SS, 2003, MOL CELL BIOL, V23, P216, DOI 10.1128/MCB.23.1.216-228.2003; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Neumeister P, 2003, MOL BIOL CELL, V14, P2005, DOI 10.1091/mbc.02-07-0102; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Reutens AT, 2001, MOL ENDOCRINOL, V15, P797, DOI 10.1210/me.15.5.797; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Sawa H, 1998, ONCOGENE, V16, P1701, DOI 10.1038/sj.onc.1201691; Sgambato A, 1997, CLIN CANCER RES, V3, P1879; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Solomon DA, 2003, J BIOL CHEM, V278, P30339, DOI 10.1074/jbc.M303969200; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Volpert OV, 2002, CANCER CELL, V2, P473, DOI 10.1016/S1535-6108(02)00209-X; Wang CG, 2003, MOL CELL BIOL, V23, P6159, DOI 10.1128/MCB.23.17.6159-6173.2003; Wang CG, 2005, CANCER RES, V65, P6557, DOI 10.1158/0008-5472.CAN-05-0486; Wang CG, 2006, P NATL ACAD SCI USA, V103, P11567, DOI 10.1073/pnas.0603363103; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wilby MJ, 1999, MOL CELL NEUROSCI, V14, P66, DOI 10.1006/mcne.1999.0766; Zhang B, 2005, NUCLEIC ACIDS RES, V33, pW741, DOI 10.1093/nar/gki475; Zwicker J, 1999, ONCOGENE, V18, P19, DOI 10.1038/sj.onc.1202286	62	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					7007	7015		10.1074/jbc.M706992200	http://dx.doi.org/10.1074/jbc.M706992200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18180298	hybrid			2022-12-25	WOS:000253779600045
J	Qin, SF; De Vries, GW				Qin, Suofu; De Vries, Gerald W.			alpha 2 but not alpha 1 AMP-activated protein kinase mediates oxidative stress-induced inhibition of retinal pigment epithelium cell phagocytosis of photoreceptor outer segments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; RAT-LIVER; STIMULATION; GLUCOSE; ENERGY; EXPRESSION; APOPTOSIS; RPE	Oxidative stress causes retinal pigment epithelium (RPE) cell dysfunction and is a major risk factor leading to the development of dry-type age- related macular degeneration. Taking pharmacological and genetic approaches, we address the mechanisms by which sublethal oxidative stress inhibits RPE cell phagocytosis. Sublethal oxidative stress dose-dependently inhibited RPE cell phagocytosis of photoreceptor outer segments (POS) and activated AMP-activated protein kinase ( AMPK) as determined by increased Thr(172) and Ser(79) phosphorylation of AMPK alpha and its substrate acetyl-CoA carboxylase, respectively. Similar to oxidative stress, 5-aminoimidazole-4-carboxamide riboside ( AICAR), a pharmacological activator of AMPK, inhibited RPE cell phagocytosis of POS in a dose-dependent manner. Inhibition of RPE cell phagocytosis by AICAR was fully reversed by blockade of AICAR translocation into cells by dipyridamole or inhibition of AICAR conversion to ZMP by adenosine kinase inhibitor 5-iodotubercidin. In agreement, AICAR-induced activation of AMPK was abolished by preincubation with dipyridamole or 5-iodotubercidin. Knock-out experiments further revealed that alpha 2 but not alpha 1 AMPK was involved in RPE cell phagocytosis and that activation of alpha 2 AMPK contributed to the inhibition of RPE cell phagocytosis by oxidative stress. Inhibition of RPE cell phagocytosis by activation of alpha 2 AMPK was associated with a dramatic increase in acetyl-CoA carboxylase phosphorylation. In comparison, AMPK had no role in oxidative stress-induced breakdown of RPE barrier function. Taken together, reduction in POS load under oxidative stress might direct RPE cells to a self-protected status. Thus, activating AMPK could have therapeutic potential in treating dry macular degeneration.	[Qin, Suofu; De Vries, Gerald W.] Allergan Pharmaceut Inc, Dept Biol Sci, Irvine, CA 92612 USA	AbbVie; Allergan	Qin, SF (corresponding author), Allergan Pharmaceut Inc, Dept Biol Sci, RD3-2D,2525 Dupont Dr, Irvine, CA 92612 USA.	qin_suofu@allergan.com		Qin, Suofu/0000-0002-3323-8846				ALDER VA, 1985, CURR EYE RES, V4, P121, DOI 10.3109/02713688508999977; Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5; Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; CARLING D, 2004, J CELL SCI, V117, P5479; Chen J, 2006, DEV BIOL, V291, P227, DOI 10.1016/j.ydbio.2005.11.039; DOREY CK, 1990, CURR EYE RES, V9, P549, DOI 10.3109/02713689008999595; DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1047; Du LN, 2003, J BIOL CHEM, V278, P18426, DOI 10.1074/jbc.M301295200; Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9; Finneman SC, 2001, J EXP MED, V194, P1289, DOI 10.1084/jem.194.9.1289; Fryer LGD, 2000, DIABETES, V49, P1978, DOI 10.2337/diabetes.49.12.1978; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; Hardie DG, 2003, FEBS LETT, V546, P113, DOI 10.1016/S0014-5793(03)00560-X; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Henin N, 1996, BBA-GEN SUBJECTS, V1290, P197, DOI 10.1016/0304-4165(96)00021-9; Honda S, 2001, MOL VIS, V7, P63; Kefas BA, 2003, J MOL ENDOCRINOL, V30, P151, DOI 10.1677/jme.0.0300151; Kindzelskii AL, 2004, J GEN PHYSIOL, V124, P139, DOI 10.1085/jgp.200409062; Kuramoto N, 2007, NEURON, V53, P233, DOI 10.1016/j.neuron.2006.12.015; Landree LE, 2004, J BIOL CHEM, V279, P3817, DOI 10.1074/jbc.M310991200; Marmorstein AD, 2001, TRAFFIC, V2, P867, DOI 10.1034/j.1600-0854.2001.21202.x; Marsin AS, 2000, CURR BIOL, V10, P1247, DOI 10.1016/S0960-9822(00)00742-9; MCLAREN MJ, 1993, INVEST OPHTH VIS SCI, V34, P317; MOLDAY RS, 1987, INVEST OPHTH VIS SCI, V28, P50; Rattan R, 2005, J BIOL CHEM, V280, P39582, DOI 10.1074/jbc.M507443200; Russell RR, 2004, J CLIN INVEST, V114, P495, DOI 10.1172/JCI200419297; Salt I, 1998, BIOCHEM J, V334, P177, DOI 10.1042/bj3340177; STEINBERG RH, 1985, DOC OPHTHALMOL, V60, P327, DOI 10.1007/BF00158922; Strauss O, 1998, ACTA ANAT, V162, P101; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271; Thompson DA, 2003, DEV OPHTHALMOL, V37, P141; Turnley AM, 1999, J NEUROCHEM, V72, P1707, DOI 10.1046/j.1471-4159.1999.721707.x; Winkler BS, 1999, MOL VIS, V5; Xavier GD, 2000, P NATL ACAD SCI USA, V97, P4023, DOI 10.1073/pnas.97.8.4023; YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1145/1165387.275645; Zheng B, 2007, P NATL ACAD SCI USA, V104, P819, DOI 10.1073/pnas.0610157104; Zou MH, 2003, J BIOL CHEM, V278, P34003, DOI 10.1074/jbc.M300215200	38	31	32	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					6744	6751		10.1074/jbc.M708848200	http://dx.doi.org/10.1074/jbc.M708848200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18195011	hybrid			2022-12-25	WOS:000253779600016
J	Sierra, AY; Gratacos, E; Carrasco, P; Clotet, J; Urena, J; Serra, D; Asins, G; Hegardt, FG; Casals, N				Sierra, Adriana Y.; Gratacos, Esther; Carrasco, Patricia; Clotet, Josep; Urena, Jesus; Serra, Dolors; Asins, Guillermina; Hegardt, Fausto G.; Casals, Nuria			CPT1c is localized in endoplasmic reticulum of neurons and has carnitine palmitoyltransferase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; EXPRESSION; TRIACYLGLYCEROL; SPHINGOLIPIDS; ACYLCARNITINE; INHIBITION; CONTAINS; PROTEINS; RESIDUES; MUTATION	CPT1c is a carnitine palmitoyltransferase 1 (CPT1) isoform that is expressed only in the brain. The enzyme has recently been localized in neuron mitochondria. Although it has high sequence identity with the other two CPT1 isoenzymes (a and b), no CPT activity has been detected to date. Our results indicate that CPT1c is expressed in neurons but not in astrocytes of mouse brain sections. Overexpression of CPT1c fused to the green fluorescent protein in cultured cells demonstrates that CPT1c is localized in the endoplasmic reticulum rather than mitochondria and that the N-terminal region of CPT1c is responsible for endoplasmic reticulum protein localization. Western blot experiments with cell fractions from adult mouse brain corroborate these results. In addition, overexpression studies demonstrate that CPT1c does not participate in mitochondrial fatty acid oxidation, as would be expected from its subcellular localization. To identify the substrate of CPT1c enzyme, rat cDNA was overexpressed in neuronal PC-12 cells, and the levels of acylcarnitines were measured by high-performance liquid chromatography-mass spectrometry. Palmitoylcarnitine was the only acylcarnitine to increase in transfected cells, which indicates that palmitoyl-CoA is the enzyme substrate and that CPT1c has CPT1 activity. Microsomal fractions of PC-12 and HEK293T cells overexpressing CPT1c protein showed a significant increase in CPT1 activity of 0.57 and 0.13 nmol.mg(-1).min(-1), respectively, which is similar to 50% higher than endogenous CPT1 activity. Kinetic studies demonstrate that CPT1c has similar affinity to CPT1a for both substrates but 20-300 times lower catalytic efficiency.	[Sierra, Adriana Y.; Gratacos, Esther; Carrasco, Patricia; Clotet, Josep; Casals, Nuria] Univ Int Catalunya, Sch Hlth Sci, Mol & Cellular Unit, Barcelona 08195, Spain; [Urena, Jesus] Univ Barcelona, Fac Biol, Dept Cell Biol, E-08028 Barcelona, Spain; [Urena, Jesus] Inst Rec Biomed Barcelona, Barcelona 08028, Spain; [Serra, Dolors; Asins, Guillermina; Hegardt, Fausto G.] Univ Barcelona, Sch Pharm, Dept Biochem & Mol Biol, E-08028 Barcelona, Spain; [Serra, Dolors; Asins, Guillermina; Hegardt, Fausto G.; Casals, Nuria] Inst Salud Carlos III, Inst Fisiopatol Obesidad & Nutr CB06 03, Ctr Invest Biomed Red CIBER, Madrid 28029, Spain	Universitat Internacional de Catalunya (UIC); University of Barcelona; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; University of Barcelona; CIBER - Centro de Investigacion Biomedica en Red; Instituto de Salud Carlos III	Casals, N (corresponding author), Univ Int Catalunya, Sch Hlth Sci, Mol & Cellular Unit, Josep Trueta S-N,Sant Cugat Valles, Barcelona 08195, Spain.	ncasals@csc.uic.es	Urena, Jesus/R-5385-2017; Gratacòs-Batlle, Esther/L-8740-2014; Casals, Nuria/L-3378-2014; Serra, Dolors/L-3657-2014; Clotet, Josep/AAF-2618-2019; Clotet, Josep/ABC-8727-2020	Urena, Jesus/0000-0003-1408-6039; Gratacòs-Batlle, Esther/0000-0001-8093-3713; Casals, Nuria/0000-0002-6719-4300; Serra, Dolors/0000-0002-4936-4206; Clotet, Josep/0000-0001-5462-8598				Abo-Hashema KAH, 1999, J BIOL CHEM, V274, P35577, DOI 10.1074/jbc.274.50.35577; ARDUINI A, 1994, J NEUROCHEM, V62, P1530; Broadway NM, 2003, BIOCHEM J, V370, P223, DOI 10.1042/BJ20021269; Buccoliero R, 2003, PHARMACOL RES, V47, P409, DOI 10.1016/S1043-6618(03)00049-5; Cohen I, 2001, J BIOL CHEM, V276, P5403, DOI 10.1074/jbc.M009555200; Dai Y, 2007, BIOCHEM BIOPH RES CO, V359, P469, DOI 10.1016/j.bbrc.2007.05.161; ESSER V, 1993, J BIOL CHEM, V268, P5817; Gooding JM, 2004, EUR J BIOCHEM, V271, P954, DOI 10.1111/j.1432-1033.2004.03997.x; Herrero L, 2005, DIABETES, V54, P462, DOI 10.2337/diabetes.54.2.462; Horie C, 2002, MOL BIOL CELL, V13, P1615, DOI 10.1091/mbc.01-12-0570; Jauregui O, 2007, ANAL CHIM ACTA, V599, P1, DOI 10.1016/j.aca.2007.07.066; Lopez-Vinas E, 2007, J BIOL CHEM, V282, P18212, DOI 10.1074/jbc.M700885200; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; Morillas M, 2003, J BIOL CHEM, V278, P9058, DOI 10.1074/jbc.M209999200; Morillas M, 2001, J BIOL CHEM, V276, P45001, DOI 10.1074/jbc.M106920200; Ohanian J, 2001, CELL MOL LIFE SCI, V58, P2053, DOI 10.1007/PL00000836; Price NT, 2002, GENOMICS, V80, P433, DOI 10.1006/geno.2002.6845; Prip-Buus C, 1998, FEBS LETT, V429, P173, DOI 10.1016/S0014-5793(98)00584-5; RUSINOL AE, 1994, J BIOL CHEM, V269, P27494; Sorensen Annette, 2002, Brain Res Gene Expr Patterns, V1, P167; van Echten-Deckert G, 2006, BBA-BIOMEMBRANES, V1758, P1978, DOI 10.1016/j.bbamem.2006.06.009; van Vlies N, 2007, MOL GENET METAB, V90, P24, DOI 10.1016/j.ymgme.2006.07.006; Washington L, 2003, J LIPID RES, V44, P1395, DOI 10.1194/jlr.M300123-JLR200; Wolfgang MJ, 2006, P NATL ACAD SCI USA, V103, P7282, DOI 10.1073/pnas.0602205103; YAMAZAKI N, 1995, FEBS LETT, V363, P41, DOI 10.1016/0014-5793(95)00277-G	25	121	123	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					6878	6885		10.1074/jbc.M707965200	http://dx.doi.org/10.1074/jbc.M707965200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18192268	Green Accepted, hybrid			2022-12-25	WOS:000253779600031
J	Gerber, HB; Pikman, Y; Fisher, RP				Gerber, Hilary B.; Pikman, Yana; Fisher, Robert P.			The CDK-Activating Kinase (CAK) Csk1 Is Required for Normal Levels of Homologous Recombination and Resistance to DNA Damage in Fission Yeast	PLOS ONE			English	Article								Background. Cyclin-dependent kinases (CDKs) perform essential roles in cell division and gene expression in all eukaryotes. The requirement for an upstream CDK-activating kinase (CAK) is also universally conserved, but the fission yeast Schizosaccharomyces pombe appears to be unique in having two CAKs with both overlapping and specialized functions that can be dissected genetically. The Mcs6 complex-orthologous to metazoan Cdk7/cyclin H/Mat1-activates the cell-cycle CDK, Cdk1, but its non-redundant essential function appears to be in regulation of gene expression, as part of transcription factor TFIIH. The other CAK is Csk1, an ortholog of budding yeast Cak1, which activates all three essential CDKs in S. pombe Cdk1, Mcs6 and Cdk9, the catalytic subunit of positive transcription elongation factor b (P-TEFb)-but is not itself essential. Methodology/Principal Findings. Cells lacking csk1(+) are viable but hypersensitive to agents that damage DNA or block replication. Csk1 is required for normal levels of homologous recombination (HR), and interacts genetically with components of the HR pathway. Tests of damage sensitivity in csk1, mcs6 and cdk9 mutants indicate that Csk1 acts pleiotropically, through Cdk9 and at least one other target ( but not through Mcs6) to preserve genomic integrity. Conclusions/Significance. The two CAKs in fission yeast, which differ with respect to their substrate range and preferences for monomeric CDKs versus CDK/cyclin complexes as substrates, also support different functions of the CDK network in vivo. Csk1 plays a non-redundant role in safeguarding genomic integrity. We propose that specialized activation pathways dependent on different CAKs might insulate CDK functions important in DNA damage responses from those capable of triggering mitosis.	[Gerber, Hilary B.; Pikman, Yana; Fisher, Robert P.] Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; [Gerber, Hilary B.] Cornell Univ, Grad Sch Med Sci, Prog Biochem Cell & Mol Biol, New York, NY USA	Memorial Sloan Kettering Cancer Center; Cornell University	Fisher, RP (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA.	r-fisher@ski.mskcc.org		Pikman, Yana/0000-0002-5336-0216	American Cancer Society [RSG-99-043-044-CCG]	American Cancer Society(American Cancer Society)	Work supported in part by American Cancer Society grant RSG-99-043-044-CCG to RPF.	Akamatsu Y, 2003, P NATL ACAD SCI USA, V100, P15770, DOI 10.1073/pnas.2632890100; Akamatsu Y, 2007, EMBO J, V26, P1352, DOI 10.1038/sj.emboj.7601582; Aylon Y, 2004, EMBO J, V23, P4868, DOI 10.1038/sj.emboj.7600469; Bamps S, 2004, BIOCHEM BIOPH RES CO, V325, P1424, DOI 10.1016/j.bbrc.2004.10.190; Bimbo A, 2005, EUKARYOT CELL, V4, P799, DOI 10.1128/EC.4.4.799-813.2005; Buck V, 1995, EMBO J, V14, P6173, DOI 10.1002/j.1460-2075.1995.tb00308.x; Caspari T, 2002, GENE DEV, V16, P1195, DOI 10.1101/gad.221402; Chen J, 2003, NATURE, V424, P228, DOI 10.1038/nature01746; Chiolo I, 2005, MOL CELL BIOL, V25, P5738, DOI 10.1128/MCB.25.13.5738-5751.2005; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; Damagnez V, 1995, EMBO J, V14, P6164, DOI 10.1002/j.1460-2075.1995.tb00307.x; DARBON JM, 1994, ONCOGENE, V9, P3127; Doe CL, 2004, NUCLEIC ACIDS RES, V32, P1480, DOI 10.1093/nar/gkh317; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; Esashi F, 1999, MOL CELL, V4, P167, DOI 10.1016/S1097-2765(00)80364-0; Espinoza FH, 1996, SCIENCE, V273, P1714, DOI 10.1126/science.273.5282.1714; Ferreira MG, 2004, GENE DEV, V18, P2249, DOI 10.1101/gad.315804; Fisher RP, 2005, J CELL SCI, V118, P5171, DOI 10.1242/jcs.02718; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Haruta N, 2006, NAT STRUCT MOL BIOL, V13, P823, DOI 10.1038/nsmb1136; Hermand D, 1998, EMBO J, V17, P7230, DOI 10.1093/emboj/17.24.7230; Hermand D, 2001, EMBO J, V20, P82, DOI 10.1093/emboj/20.1.82; Ira G, 2003, CELL, V115, P401, DOI 10.1016/S0092-8674(03)00886-9; Ira G, 2004, NATURE, V431, P1011, DOI 10.1038/nature02964; Kaldis P, 1996, CELL, V86, P553, DOI 10.1016/S0092-8674(00)80129-4; Kaldis P, 1998, J CELL SCI, V111, P3585; Kaldis P, 1998, MOL BIOL CELL, V9, P2545, DOI 10.1091/mbc.9.9.2545; Karagiannis J, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000433; Krejci L, 2003, NATURE, V423, P305, DOI 10.1038/nature01577; Krogh BO, 2004, ANNU REV GENET, V38, P233, DOI 10.1146/annurev.genet.38.072902.091500; Lee KM, 1999, CURR BIOL, V9, P441, DOI 10.1016/S0960-9822(99)80194-8; Lee KM, 2005, MOL BIOL CELL, V16, P2734, DOI 10.1091/mbc.E04-11-0982; Lehmann AR, 1996, MUTAT RES-DNA REPAIR, V363, P147, DOI 10.1016/0921-8777(96)00017-1; Liberi G, 2000, EMBO J, V19, P5027, DOI 10.1093/emboj/19.18.5027; Liu J, 2000, MOL BIOL EVOL, V17, P1061, DOI 10.1093/oxfordjournals.molbev.a026387; Maftahi M, 2002, NUCLEIC ACIDS RES, V30, P4781, DOI 10.1093/nar/gkf581; MOLZ L, 1989, GENETICS, V122, P773; MOLZ L, 1993, EMBO J, V12, P1723, DOI 10.1002/j.1460-2075.1993.tb05817.x; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Morgan D. O., 2007, CELL CYCLE PRINCIPLE; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Osman F, 2000, CURR GENET, V38, P113, DOI 10.1007/s002940000145; Ostapenko D, 2005, MOL CELL BIOL, V25, P3906, DOI 10.1128/MCB.25.10.3906-3913.2005; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; Pei Y, 2006, MOL CELL BIOL, V26, P777, DOI 10.1128/MCB.26.3.777-788.2006; Peterson CL, 2004, GENE DEV, V18, P602, DOI 10.1101/gad.1182704; Ross KE, 2000, MOL BIOL CELL, V11, P1597, DOI 10.1091/mbc.11.5.1597; Saiz JE, 2002, CURR BIOL, V12, P1100, DOI 10.1016/S0960-9822(02)00903-X; Sugawara N, 2003, MOL CELL, V12, P209, DOI 10.1016/S1097-2765(03)00269-7; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; Thuret JY, 1996, CELL, V86, P565, DOI 10.1016/S0092-8674(00)80130-0; Tsakraklides V, 2002, J BIOL CHEM, V277, P33482, DOI 10.1074/jbc.M205537200; VALAY JG, 1995, J MOL BIOL, V249, P535, DOI 10.1006/jmbi.1995.0316; Vaze MB, 2002, MOL CELL, V10, P373, DOI 10.1016/S1097-2765(02)00593-2; Veaute X, 2003, NATURE, V423, P309, DOI 10.1038/nature01585; Walworth NC, 2000, CURR OPIN CELL BIOL, V12, P697, DOI 10.1016/S0955-0674(00)00154-X; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0	61	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2008	3	1							e1492	10.1371/journal.pone.0001492	http://dx.doi.org/10.1371/journal.pone.0001492			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SR	18231579	Green Published, Green Submitted, gold			2022-12-25	WOS:000260504200005
J	Tcherepanova, I; Harris, J; Starr, A; Cleveland, J; Ketteringham, H; Calderhead, D; Horvatinovich, J; Healey, D; Nicolette, CA				Tcherepanova, Irina; Harris, Jason; Starr, Aijing; Cleveland, Jaclyn; Ketteringham, Helen; Calderhead, David; Horvatinovich, Joe; Healey, Don; Nicolette, Charles A.			Multiplex RT-PCR Amplification of HIV Genes to Create a Completely Autologous DC-Based Immunotherapy for the Treatment of HIV Infection	PLOS ONE			English	Article								Background. Effective therapy for HIV-infected individuals remains an unmet medical need. Promising clinical trials with dendritic cell (DC)-based immunotherapy consisting of autologous DC loaded with autologous virus have been reported, however, these approaches depend on large numbers of HIV virions to generate sufficient doses for even limited treatment regimens. Methodology/Principal Findings. The present study describes a novel approach for RT-PCR amplification of HIV antigens. Previously, RT-PCR amplification of autologous viral sequences has been confounded by the high mutation rate of the virus which results in unreliable primer-template binding. To resolve this problem we developed a multiplex RT-PCR strategy that allows reliable strain-independent amplification of highly polymorphic target antigens from any patient and requires neither viral sequence data nor custom-designed PCR primers for each individual. We demonstrate the application of our RT-PCR process to amplify translationally-competent RNA encoding regions of Gag, Vpr, Rev and Nef. The products amplified using this method represent a complex mixture of autologous antigens encoded by viral quasispecies. We further demonstrate that DCs electroporated with in vitro-transcribed HIV RNAs are capable of stimulating poly-antigen-specific CD8+ T cell responses in vitro. Conclusion/Significance. This study describes a strategy to overcome patient to patient viral diversity enabling strain-independent RT-PCR amplification of RNAs encoding sequence divergent quasispecies of Gag, Vpr, Rev and Nef from small volumes of infectious plasma. The approach allows creation of a completely autologous therapy that does not require advance knowledge of the HIV genomic sequences, does not have yield limitations and has no intact virus in the final product. The simultaneous use of autologous viral antigens and DCs may provoke broad patient-specific immune responses that could potentially induce effective control of viral loads in the absence of conventional antiretroviral drug therapy.	[Tcherepanova, Irina; Harris, Jason; Starr, Aijing; Cleveland, Jaclyn; Ketteringham, Helen; Calderhead, David; Horvatinovich, Joe; Healey, Don; Nicolette, Charles A.] Argos Therapeut Inc, Dept Res & Dev, Durham, NC USA		Tcherepanova, I (corresponding author), Argos Therapeut Inc, Dept Res & Dev, Durham, NC USA.	itcherepanova@argostherapeutics.com			Argos Therapeutics	Argos Therapeutics	All funding was provided by Argos Therapeutics.	Addo MM, 2002, DNA CELL BIOL, V21, P671, DOI 10.1089/104454902760330219; Allen TM, 2000, J IMMUNOL, V164, P4968, DOI 10.4049/jimmunol.164.9.4968; Altfeld M, 2001, J IMMUNOL, V167, P2743, DOI 10.4049/jimmunol.167.5.2743; Altfeld M, 2001, J EXP MED, V193, P169, DOI 10.1084/jem.193.2.169; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Barouch DH, 2002, NATURE, V415, P335, DOI 10.1038/415335a; Candotti D, 2004, J VIROL METHODS, V118, P39, DOI 10.1016/j.jviromet.2004.01.017; CHANG PS, 1990, CLIN BIOTECHNOL, V2, P23; Christopherson C, 1997, NUCLEIC ACIDS RES, V25, P654, DOI 10.1093/nar/25.3.654; Cohen WM, 2002, J VIROL, V76, P10219, DOI 10.1128/JVI.76.20.10219-10225.2002; Draenert R, 2006, J EXP MED, V203, P529, DOI 10.1084/jem.20052116; Erali M, 1999, J CLIN MICROBIOL, V37, P792, DOI 10.1128/JCM.37.3.792-795.1999; Evans DT, 1999, NAT MED, V5, P1270, DOI 10.1038/15224; Fang GW, 2004, AIDS, V18, P153, DOI 10.1097/00002030-200401230-00003; Friedrich TC, 2004, NAT MED, V10, P275, DOI 10.1038/nm998; Gamberg J, 2004, IMMUNOL CELL BIOL, V82, P38, DOI 10.1111/j.1440-1711.2004.01204.x; Gao F, 1996, J VIROL, V70, P7013, DOI 10.1128/JVI.70.10.7013-7029.1996; Garber DA, 2004, LANCET INFECT DIS, V4, P397, DOI 10.1016/S1473-3099(04)01056-4; Garcia F, 2005, J INFECT DIS, V191, P1680, DOI 10.1086/429340; Goulder PJR, 2004, NAT REV IMMUNOL, V4, P630, DOI 10.1038/nri1417; Goulder PJR, 1999, NAT MED, V5, P1233, DOI 10.1038/15184; Harrer T, 1996, J IMMUNOL, V156, P2616; Hel Z, 2006, J IMMUNOL, V176, P85, DOI 10.4049/jimmunol.176.1.85; Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991; Lu W, 2004, NAT MED, V10, P1359, DOI 10.1038/nm1147; McMichael AJ, 2006, ANNU REV IMMUNOL, V24, P227, DOI 10.1146/annurev.immunol.24.021605.090605; Nabel GJ, 2001, NATURE, V410, P1002, DOI 10.1038/35073500; Novitsky V, 2002, J VIROL, V76, P10155, DOI 10.1128/JVI.76.20.10155-10168.2002; Ogg GS, 1999, J VIROL, V73, P9153, DOI 10.1128/JVI.73.11.9153-9160.1999; Palmer S, 2003, J CLIN MICROBIOL, V41, P4531, DOI 10.1128/JCM.41.10.4531-4536.2003; Scriba TJ, 2005, VACCINE, V23, P1158, DOI 10.1016/j.vaccine.2004.08.026; Singh RAK, 2004, J IMMUNOL, V173, P4387, DOI 10.4049/jimmunol.173.7.4387; Su Z, 2002, CANCER RES, V62, P5041; Weissman D, 2000, J IMMUNOL, V165, P4710, DOI 10.4049/jimmunol.165.8.4710; Zanussi S, 1996, CLIN EXP IMMUNOL, V105, P220, DOI 10.1046/j.1365-2249.1996.d01-746.x	36	24	25	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2008	3	1							e1489	10.1371/journal.pone.0001489	http://dx.doi.org/10.1371/journal.pone.0001489			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SR	18231576	Green Published, Green Submitted, gold			2022-12-25	WOS:000260504200002
J	Hussain, MA; Naveed, SA; Sechi, LA; Ranjan, S; Alvi, A; Ahmed, I; Ranjan, A; Mukhopadhyay, S; Ahmed, N				Hussain, M. Abid; Naveed, Shaik A.; Sechi, Leonardo A.; Ranjan, Sarita; Alvi, Ayesha; Ahmed, Irshad; Ranjan, Akash; Mukhopadhyay, Sangita; Ahmed, Niyaz			Isocitrate Dehydrogenase of Helicobacter pylori Potentially Induces Humoral Immune Response in Subjects with Peptic Ulcer Disease and Gastritis	PLOS ONE			English	Article								Background. H. pylori causes gastritis and peptic ulcers and is a risk factor for the development of gastric carcinoma. Many of the proteins such as urease, porins, flagellins and toxins such as lipo-polysaccharides have been identified as potential virulence factors which induce proinflammatory reaction. We report immunogenic potentials of isocitrate dehydrogenase (ICD), an important house keeping protein of H. pylori. Methodology/Principal Findings. Amino acid sequences of H. pylori ICD were subjected to in silico analysis for regions with predictably high antigenic indexes. Also, computational modelling of the H. pylori ICD as juxtaposed to the E. coli ICD was carried out to determine levels of structure similarity and the availability of surface exposed motifs, if any. The icd gene was cloned, expressed and purified to a very high homogeneity. Humoral response directed against H. pylori ICD was detected through an enzyme linked immunosorbent assay ( ELISA) in 82 human subjects comprising of 58 patients with H. pylori associated gastritis or ulcer disease and 24 asymptomatic healthy controls. The H. pylori ICD elicited potentially high humoral immune response and revealed high antibody titers in sera corresponding to endoscopically-confirmed gastritis and ulcer disease subjects. However, urea-breath-test negative healthy control samples and asymptomatic control samples did not reveal any detectable immune responses. The ELISA for proinflammatory cytokine IL-8 did not exhibit any significant proinflammatory activity of ICD. Conclusions/Significance. ICD of H. pylori is an immunogen which interacts with the host immune system subsequent to a possible autolytic-release and thereby significantly elicits humoral responses in individuals with invasive H. pylori infection. However, ICD could not significantly stimulate IL8 induction in a cultured macrophage cell line (THP1) and therefore, may not be a notable proinflammatory agent.	[Hussain, M. Abid; Alvi, Ayesha; Ahmed, Niyaz] Ctr DNA Fingerprinting & Diagnost CDFD, Pathogen Evolut Lab, Hyderabad, Andhra Pradesh, India; [Naveed, Shaik A.; Ahmed, Irshad] Deccan Coll Med Sci & Allied Hosp, Ctr Liver Res & Diagnost, Hyderabad, Andhra Pradesh, India; [Sechi, Leonardo A.] Univ Degli Studi Sassari, Fac Med, Sezione Microbiol Speriment Clin, Dipart Sci Biomed, Sassari, Italy; [Ranjan, Sarita; Ranjan, Akash] CDFD, Comp Funct Genom Grp, Hyderabad, Andhra Pradesh, India; [Mukhopadhyay, Sangita] CDFD, Lab Mol Cell Biol, Hyderabad, Andhra Pradesh, India	Department of Biotechnology (DBT) India; Centre for DNA Fingerprinting & Diagnostics (CDFD); University of Sassari; Department of Biotechnology (DBT) India; Centre for DNA Fingerprinting & Diagnostics (CDFD); Department of Biotechnology (DBT) India; Centre for DNA Fingerprinting & Diagnostics (CDFD)	Ahmed, N (corresponding author), Ctr DNA Fingerprinting & Diagnost CDFD, Pathogen Evolut Lab, Hyderabad, Andhra Pradesh, India.	niyaz@cdfd.org.in	Shaik, Abdul Naveed/I-1018-2019; Ahmed, Niyaz/D-2589-2010; Sechi, Leonardo Antonio/Y-3109-2018	Shaik, Abdul Naveed/0000-0002-3672-2246; Ahmed, Niyaz/0000-0001-6425-7583; Ranjan, Akash/0000-0002-4582-1553; Mukhopadhyay, Sangita/0000-0002-5511-3315; sechi, leonardo antonio/0000-0003-0566-2049	Dept. of Biotechnology, Government of India [CDFD Core]	Dept. of Biotechnology, Government of India	Funding from CDFD Core Grants (Dept. of Biotechnology, Government of India)	AHMED KS, 2004, SINGAP MED J, V47, P291; Akhter Yusuf, 2007, Infect Agent Cancer, V2, P2, DOI 10.1186/1750-9378-2-2; ANDERSEN P, 1991, INFECT IMMUN, V59, P1905, DOI 10.1128/IAI.59.6.1905-1910.1991; Banerjee S, 2004, P NATL ACAD SCI USA, V101, P12652, DOI 10.1073/pnas.0404347101; Cao P, 1998, INFECT IMMUN, V66, P2984, DOI 10.1128/IAI.66.6.2984-2986.1998; Carroll IM, 2003, J CLIN MICROBIOL, V41, P5755, DOI 10.1128/JCM.41.12.5755-5759.2003; Choudhary RK, 2003, INFECT IMMUN, V71, P6338, DOI 10.1128/IAI.71.11.6338-6343.2003; COVER TL, 1995, J CLIN MICROBIOL, V33, P1496, DOI 10.1128/JCM.33.6.1496-1500.1995; COVER TL, 1994, J BIOL CHEM, V269, P10566; Dunn BE, 1997, CLIN MICROBIOL REV, V10, P720, DOI 10.1128/CMR.10.4.720; Falush D, 2003, SCIENCE, V299, P1582, DOI 10.1126/science.1080857; Glupczynski Y, 1998, BRIT MED BULL, V54, P175; GOOSSENS H, 1992, J CLIN MICROBIOL, V30, P176, DOI 10.1128/JCM.30.1.176-180.1992; Hussain MA, 2004, J CLIN MICROBIOL, V42, P2372, DOI 10.1128/JCM.42.6.2372-2378.2004; JOHANSEN HK, 1995, CLIN DIAGN LAB IMMUN, V2, P149, DOI 10.1128/CDLI.2.2.149-155.1995; Kauser F, 2005, J CLIN MICROBIOL, V43, P1538, DOI 10.1128/JCM.43.4.1538-1545.2005; Kauser F, 2004, J CLIN MICROBIOL, V42, P5302, DOI 10.1128/JCM.42.11.5302-5308.2004; Kimmel B, 2000, INFECT IMMUN, V68, P915, DOI 10.1128/IAI.68.2.915-920.2000; Linz B, 2007, NATURE, V445, P915, DOI 10.1038/nature05562; Megraud F, 1996, SCAND J GASTROENTERO, V31, P57, DOI 10.3109/00365529609094536; MITCHELL HM, 1988, MED J AUSTRALIA, V149, P604, DOI 10.5694/j.1326-5377.1988.tb120800.x; NEWELL DG, 1987, J GEN MICROBIOL, V133, P163; Phadnis SH, 1996, INFECT IMMUN, V64, P905, DOI 10.1128/IAI.64.3.905-912.1996; Pitson SM, 1999, EUR J BIOCHEM, V260, P258, DOI 10.1046/j.1432-1327.1999.00153.x; Prouzet-Mauleon V, 2005, J CLIN MICROBIOL, V43, P4237, DOI 10.1128/JCM.43.8.4237-4241.2005; Rizwan M, 2008, J BACTERIOL, V190, P1146, DOI 10.1128/JB.01309-07; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Suerbaum S, 2007, NAT REV MICROBIOL, V5, P441, DOI 10.1038/nrmicro1658; van der Ende A, 1998, INFECT IMMUN, V66, P1822, DOI 10.1128/IAI.66.5.1822-1826.1998; Yamaoka Y, 1998, J CLIN MICROBIOL, V36, P2258, DOI 10.1128/JCM.36.8.2258-2263.1998	30	10	11	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2008	3	1							e1481	10.1371/journal.pone.0001481	http://dx.doi.org/10.1371/journal.pone.0001481			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SO	18213389	Green Published, gold, Green Submitted			2022-12-25	WOS:000260503900026
J	Palmer, HG; Anjos-Afonso, F; Carmeliet, G; Takeda, H; Watt, FM				Palmer, Hector G.; Anjos-Afonso, Fernando; Carmeliet, Geert; Takeda, Hikaru; Watt, Fiona M.			The Vitamin D Receptor Is a Wnt Effector that Controls Hair Follicle Differentiation and Specifies Tumor Type in Adult Epidermis	PLOS ONE			English	Article							BETA-CATENIN; STEM-CELLS; MOUSE EPIDERMIS; E-CADHERIN; EXPRESSION; GROWTH; MICE; MORPHOGENESIS; ANALOGS; CANCER	We have investigated how Wnt and vitamin D receptor signals regulate epidermal differentiation. Many epidermal genes induced by beta-catenin, including the stem cell marker keratin 15, contain vitamin D response elements (VDREs) and several are induced independently of TCF/Lef. The VDR is required for beta-catenin induced hair follicle formation in adult epidermis, and the vitamin D analog EB1089 synergises with beta-catenin to stimulate hair differentiation. Human trichofolliculomas (hair follicle tumours) are characterized by high nuclear beta-catenin and VDR, whereas infiltrative basal cell carcinomas (BCCs) have high beta-catenin and low VDR levels. In mice, EB1089 prevents beta-catenin induced trichofolliculomas, while in the absence of VDR beta-catenin induces tumours resembling BCCs. We conclude that VDR is a TCF/Lef-independent transcriptional effector of the Wnt pathway and that vitamin D analogues have therapeutic potential in tumors with inappropriate activation of Wnt signalling.	[Palmer, Hector G.; Watt, Fiona M.] Li Ka Shing Ctr, Canc Res UK Cambridge Res Inst, Cambridge, England; [Anjos-Afonso, Fernando] Canc Res UK London Res Inst, London, England; [Carmeliet, Geert] Katholieke Univ Leuven, Lab Expt Med & Endocrinol, Leuven, Belgium; [Takeda, Hikaru] Yamagata Univ, Sch Med, Dept Dermatol, Yamagata, Japan	Cancer Research UK; CRUK Cambridge Institute; Cancer Research UK; KU Leuven; Yamagata University	Watt, FM (corresponding author), Li Ka Shing Ctr, Canc Res UK Cambridge Res Inst, Cambridge, England.	fiona.watt@cancer.org.uk	Palmer, Héctor G./AAG-8332-2019; Watt, Fiona/AHB-0226-2022; Seoane, Joan/AAG-9173-2019	Watt, Fiona/0000-0001-9151-5154; Seoane, Joan/0000-0002-6541-5974; Palmer, Hector/0000-0002-9823-5638; Anjos-Afonso, Fernando/0000-0003-4392-488X	European Union Marie Curie [Fellowship]; CR-UK	European Union Marie Curie(European Commission); CR-UK(Cancer Research UK)	HGP is the recipient of a European Union Marie Curie Fellowship. This work was supported by CR-UK.	Andl T, 2002, DEV CELL, V2, P643, DOI 10.1016/S1534-5807(02)00167-3; Benitah SA, 2005, SCIENCE, V309, P933, DOI 10.1126/science.1113579; Bikle DD, 2004, J NUTR, V134, p3472S, DOI 10.1093/jn/134.12.3472S; Blanpain C, 2006, ANNU REV CELL DEV BI, V22, P339, DOI 10.1146/annurev.cellbio.22.010305.104357; Braun KM, 2003, DEVELOPMENT, V130, P5241, DOI 10.1242/dev.00703; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Cianferotti L, 2007, P NATL ACAD SCI USA, V104, P9428, DOI 10.1073/pnas.0702884104; DasGupta R, 1999, DEVELOPMENT, V126, P4557; Deeb KK, 2007, NAT REV CANCER, V7, P684, DOI 10.1038/nrc2196; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; HUGHES MR, 1991, J RECEPTOR RES, V11, P699, DOI 10.3109/10799899109066437; Jaaskelainen T, 2000, J CELL BIOCHEM, V76, P548; Jih DM, 1999, J CUTAN PATHOL, V26, P113, DOI 10.1111/j.1600-0560.1999.tb01814.x; Karolchik D, 2003, NUCLEIC ACIDS RES, V31, P51, DOI 10.1093/nar/gkg129; Lo Celso C, 2004, DEVELOPMENT, V131, P1787, DOI 10.1242/dev.01052; Lowry WE, 2005, GENE DEV, V19, P1596, DOI 10.1101/gad.1324905; Mulholland DJ, 2005, ENDOCR REV, V26, P898, DOI 10.1210/er.2003-0034; Niemann C, 2002, DEVELOPMENT, V129, P95; Olson LE, 2006, CELL, V125, P593, DOI 10.1016/j.cell.2006.02.046; Owens DM, 2003, NAT REV CANCER, V3, P444, DOI 10.1038/nrc1096; Palmer HG, 2004, NAT MED, V10, P917, DOI 10.1038/nm1095; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Pena C, 2005, HUM MOL GENET, V14, P3361, DOI 10.1093/hmg/ddi366; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; Sakai Y, 2001, J CLIN INVEST, V107, P961, DOI 10.1172/JCI11676; Shah S, 2006, MOL CELL, V21, P799, DOI 10.1016/j.molcel.2006.01.037; Silva-Vargas V, 2005, DEV CELL, V9, P121, DOI 10.1016/j.devcel.2005.04.013; Skorija K, 2005, MOL ENDOCRINOL, V19, P855, DOI 10.1210/me.2004-0415; Van Cromphaut SJ, 2001, P NATL ACAD SCI USA, V98, P13324, DOI 10.1073/pnas.231474698; Vegesna V, 2002, ENDOCRINOLOGY, V143, P4389, DOI 10.1210/en.2002-220118; Watt FM, 2006, CURR OPIN GENET DEV, V16, P518, DOI 10.1016/j.gde.2006.08.006; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391	34	105	107	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2008	3	1							e1483	10.1371/journal.pone.0001483	http://dx.doi.org/10.1371/journal.pone.0001483			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SO	18213391	gold, Green Published, Green Submitted, Green Accepted			2022-12-25	WOS:000260503900028
J	Chapelsky, S; Batty, S; Frost, M; Mogridge, J				Chapelsky, Sarah; Batty, Sarah; Frost, Mia; Mogridge, Jeremy			Inhibition of Anthrax Lethal Toxin-Induced Cytolysis of RAW264.7 Cells by Celastrol	PLOS ONE			English	Article							UBIQUITIN-PROTEASOME SYSTEM; BACILLUS-ANTHRACIS; PROTECTIVE ANTIGEN; DEPENDENT PROCESS; DENDRITIC CELLS; KINASE-KINASE; MACROPHAGES; RECEPTOR; SUSCEPTIBILITY; ACTIVATION	Background. Bacillus anthracis is the bacterium responsible for causing anthrax. The ability of B. anthracis to cause disease is dependent on a secreted virulence factor, lethal toxin, that promotes survival of the bacteria in the host by impairing the immune response. A well-studied effect of lethal toxin is the killing of macrophages, although the molecular mechanisms involved have not been fully characterized. Methodology/Principal Findings. Here, we demonstrate that celastrol, a quinone methide triterpene derived from a plant extract used in herbal medicine, inhibits lethal toxin-induced death of RAW264.7 murine macrophages. Celastrol did not prevent cleavage of mitogen activated protein kinase kinase 1, a cytosolic target of the toxin, indicating that it did not inhibit the uptake or catalytic activity of lethal toxin. Surprisingly, celastrol conferred almost complete protection when it was added up to 1.5 h after intoxication, indicating that it could rescue cells in the late stages of intoxication. Since the activity of the proteasome has been implicated in intoxication using other pharmacological agents, we tested whether celastrol blocked proteasome activity. We found that celastrol inhibited the proteasome-dependent degradation of proteins in RAW264.7 cells, but only slightly inhibited proteasome-mediated cleavage of fluorogenic substrates in vitro. Furthermore, celastrol blocked stimulation of IL-18 processing, indicating that celastrol acted upstream of inflammasome activation. Conclusions/Significance. This work identifies celastrol as an inhibitor of lethal toxin-mediated macrophage lysis and suggests an inhibitory mechanism involving inhibition of the proteasome pathway.	[Chapelsky, Sarah; Batty, Sarah; Frost, Mia; Mogridge, Jeremy] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	University of Toronto	Mogridge, J (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.	jeremy.mogridge@utoronto.ca			NIH [RO1 AI067683]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI067683] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This research was supported by NIH grant RO1 AI067683. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abi-Habib RJ, 2005, MOL CANCER THER, V4, P1303, DOI 10.1158/1535-7163.MCT-05-0145; Abrami L, 2003, J CELL BIOL, V160, P321, DOI 10.1083/jcb.200211018; Agrawal A, 2003, NATURE, V424, P329, DOI 10.1038/nature01794; Alileche A, 2006, CELL CYCLE, V5, P100, DOI 10.4161/cc.5.1.2283; Alileche A, 2005, PLOS PATHOG, V1, P150, DOI 10.1371/journal.ppat.0010019; Banks David J., 2006, Expert Reviews in Molecular Medicine, V8, P1, DOI 10.1017/S1462399406010714; Banks DJ, 2005, CELL MICROBIOL, V7, P1173, DOI 10.1111/j.1462-5822.2005.00545.x; Batty S, 2006, CELL MICROBIOL, V8, P130, DOI 10.1111/j.1462-5822.2005.00606.x; Boyden ED, 2006, NAT GENET, V38, P240, DOI 10.1038/ng1724; Cleren C, 2005, J NEUROCHEM, V94, P995, DOI 10.1111/j.1471-4159.2005.03253.x; Collier RJ, 2003, ANNU REV CELL DEV BI, V19, P45, DOI 10.1146/annurev.cellbio.19.111301.140655; Cote CK, 2006, INFECT IMMUN, V74, P469, DOI 10.1128/IAI.74.1.469-480.2006; Crawford MA, 2006, J IMMUNOL, V176, P7557, DOI 10.4049/jimmunol.176.12.7557; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; During RL, 2005, J INFECT DIS, V192, P837, DOI 10.1086/432516; Fang H, 2005, J IMMUNOL, V174, P4966, DOI 10.4049/jimmunol.174.8.4966; Fang H, 2006, J IMMUNOL, V176, P6155, DOI 10.4049/jimmunol.176.10.6155; FRIEDLANDER AM, 1986, J BIOL CHEM, V261, P7123; Gimenez AP, 2004, J IMMUNOL, V173, P521, DOI 10.4049/jimmunol.173.1.521; Guidi-Rontani C, 1999, MOL MICROBIOL, V31, P9, DOI 10.1046/j.1365-2958.1999.01137.x; Ha SD, 2007, J BIOL CHEM, V282, P26275, DOI 10.1074/jbc.M703668200; Hieronymus H, 2006, CANCER CELL, V10, P321, DOI 10.1016/j.ccr.2006.09.005; Kassam A, 2005, CELL MICROBIOL, V7, P281, DOI 10.1111/j.1462-5822.2004.00458.x; Kisselev AF, 2005, METHOD ENZYMOL, V398, P364, DOI 10.1016/S0076-6879(05)98030-0; MILNE JC, 1994, J BIOL CHEM, V269, P20607; Mogridge J, 2002, P NATL ACAD SCI USA, V99, P7045, DOI 10.1073/pnas.052160199; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Nalepa G, 2006, NAT REV DRUG DISCOV, V5, P596, DOI 10.1038/nrd2056; Nandi D, 2006, J BIOSCIENCES, V31, P137, DOI 10.1007/BF02705243; Paccani SR, 2005, J EXP MED, V201, P325, DOI 10.1084/jem.20041557; Pellizzari R, 1999, FEBS LETT, V462, P199, DOI 10.1016/S0014-5793(99)01502-1; Salles II, 2003, P NATL ACAD SCI USA, V100, P12426, DOI 10.1073/pnas.2134042100; Squires RC, 2007, J BIOL CHEM, V282, P34260, DOI 10.1074/jbc.M705687200; Tang GQ, 1999, INFECT IMMUN, V67, P3055, DOI 10.1128/IAI.67.6.3055-3060.1999; Tschopp J, 2003, NAT REV MOL CELL BIO, V4, P95, DOI 10.1038/nrm1019; Verma R, 2004, SCIENCE, V306, P117, DOI 10.1126/science.1100946; Westerheide SD, 2004, J BIOL CHEM, V279, P56053, DOI 10.1074/jbc.M409267200; Wickliffe KE, 2008, CELL MICROBIOL, V10, P332, DOI 10.1111/j.1462-5822.2007.01044.x; Yang HJ, 2006, CANCER RES, V66, P4758, DOI 10.1158/0008-5472.CAN-05-4529; Zhang S, 2004, P NATL ACAD SCI USA, V101, P16756, DOI 10.1073/pnas.0405754101	40	17	17	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2008	3	1							e1421	10.1371/journal.pone.0001421	http://dx.doi.org/10.1371/journal.pone.0001421			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366GT	18183301	Green Published, Green Submitted, gold			2022-12-25	WOS:000260469400017
J	Falvella, FS; Colombo, F; Spinola, M; Campiglio, M; Pastorino, U; Dragani, TA				Falvella, F. S.; Colombo, F.; Spinola, M.; Campiglio, M.; Pastorino, U.; Dragani, T. A.			BHLHB3: a candidate tumor suppressor in lung cancer	ONCOGENE			English	Article						BHLHB2; DEC1; DEC2; SHARP-1; STRA13; lung cancer	E-BOX; DEC2; DIFFERENTIATION; EXPRESSION	BHLHB3 is a basic helix-loop-helix (bHLH) domain-containing protein that acts as a transcriptional repressor. We found that BHLHB3 transcript levels were low in three human lung cancer cell lines and downregulated in human lung adenocarcinomas as compared to normal lung tissue. BHLHB3 gene overexpression inhibited colony formation of A549, NCI-H520 and NCI-H596 lung cancer cells. The reduced colony growth was likely due to inhibition of cell proliferation as suggested by the downregulation of cyclin D1 (CCND1) expression in NCI-H520 cells transfected to overexpress the BHLHB3 gene; no evidence of apoptosis was observed. These results point to the potential role of the BHLHB3 protein as a tumor suppressor for lung cancer.	[Falvella, F. S.; Colombo, F.; Spinola, M.; Campiglio, M.; Dragani, T. A.] Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol & Labs, I-20133 Milan, Italy; [Pastorino, U.] Fdn IRCCS Ist Nazl Tumori, Unit Thorac Surg, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Dragani, TA (corresponding author), Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol & Labs, Via G Venezian 1, I-20133 Milan, Italy.	tommaso.dragani@istitutotumori.mi.it	Colombo, Francesca/B-4617-2013; Dragani, Tommaso A./K-4493-2016; Colombo, Francesca/Q-5292-2019; Pastorino, Ugo/C-2712-2017	Colombo, Francesca/0000-0003-2015-4317; Dragani, Tommaso A./0000-0001-5915-4598; Colombo, Francesca/0000-0003-2015-4317; Pastorino, Ugo/0000-0001-9974-7902	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Allenspach EJ, 2002, CANCER BIOL THER, V1, P466, DOI 10.4161/cbt.1.5.159; Azmi S, 2004, J BIOL CHEM, V279, P52643, DOI 10.1074/jbc.M409188200; Azmi S, 2003, J BIOL CHEM, V278, P20098, DOI 10.1074/jbc.M210427200; Berthet C, 2007, ONCOGENE, V26, P4469, DOI 10.1038/sj.onc.1210243; Davis RL, 2001, ONCOGENE, V20, P8342, DOI 10.1038/sj.onc.1205094; Falvella FS, 2007, LUNG CANCER, V56, P1, DOI 10.1016/j.lungcan.2006.11.008; Fujimoto K, 2001, BIOCHEM BIOPH RES CO, V280, P164, DOI 10.1006/bbrc.2000.4133; Honma S, 2002, NATURE, V419, P841, DOI 10.1038/nature01123; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Li YX, 2003, J BIOL CHEM, V278, P16899, DOI 10.1074/jbc.M300596200; Noshiro M, 2004, GENES CELLS, V9, P317, DOI 10.1111/j.1356-9597.2004.00722.x; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949	12	15	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	26					3761	3764		10.1038/sj.onc.1211038	http://dx.doi.org/10.1038/sj.onc.1211038			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18223678				2022-12-25	WOS:000256659300014
J	Lavigne, MD; Yates, L; Coxhead, P; Gorecki, DC				Lavigne, Matthieu D.; Yates, Laura; Coxhead, Peter; Gorecki, Dariusz C.			Nuclear-targeted chimeric vector enhancing nonviral gene transfer into skeletal muscle of Fabry mice in vivo	FASEB JOURNAL			English	Article						cell penetration peptides; gene therapy; TAT; pluronic	ALPHA-GALACTOSIDASE-A; PROTEIN TRANSDUCTION DOMAIN; INTRACELLULAR DELIVERY; ENZYME REPLACEMENT; HIV TAT; DNA; EXPRESSION; PEPTIDE; TRANSPORT; POLYMERS	Poor nuclear entry, especially into nondividing cells, is a limiting factor in nonviral gene delivery. We have engineered a novel chimeric vector relying on the controlled assembly of a TAT-tagged multisubunit DNA binding protein (EcoR124I) with expression plasmids containing the EcoR124I recognition site. Molecular interactions of this molecular assembly were studied by electrophoretic mobility shift assay and atomic force microscopy. Maintenance of nanocomplexes in an appropriate stoichiometric ratio was both necessary and sufficient to produce a significant (> 8-fold) increase in the activity of the therapeutic alpha-galactosidase A enzyme after intramuscular administration in the mouse model of Fabry disease. To our knowledge, this is the first molecular targeting system significantly enhancing plasmid-based expression in skeletal muscle. Coinjection with pluronic SP1017 produced further enhancement of gene expression, demonstrating cumulative effects of the increased nuclear delivery by TAT chimeras and transcription activation by the pluronic. Cell penetration peptides (CPP), such as TAT, have been shown to improve delivery of macromolecules, when linked directly. However, in our system TAT-enhanced targeting took place even though it was linked to the plasmid DNA molecule indirectly via two noncovalent bonds. Therefore, this proof-of principle result indicates that TAT (and potentially other CPP) can be used for targeting modular chimeric vectors and therapeutic nanodevices.	[Lavigne, Matthieu D.; Yates, Laura; Gorecki, Dariusz C.] Univ Portsmouth, Inst Biomed & Biomol Sci, Sch Pharm & Biomed Sci, Portsmouth PO1 2DT, Hants, England; [Coxhead, Peter] Univ Portsmouth, Inst Biomed & Biomol Sci, Sch Biol Sci, Portsmouth PO1 2DT, Hants, England	University of Portsmouth; University of Portsmouth	Gorecki, DC (corresponding author), Univ Portsmouth, Inst Biomed & Biomol Sci, Sch Pharm & Biomed Sci, St Michaels Bldg,White Swan Rd, Portsmouth PO1 2DT, Hants, England.	darek.gorecki@port.ac.uk		Coxhead, Peter/0000-0001-7550-0235; Yates, Laura/0000-0002-1620-1603; Gorecki, Dariusz/0000-0003-3584-1654; Lavigne, Matthieu/0000-0003-1543-8745	Wellcome Trust [067484] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Beck M, 2007, HUM GENET, V121, P1, DOI 10.1007/s00439-006-0280-4; Benenson Y, 2004, NATURE, V429, P423, DOI 10.1038/nature02551; Cardarelli F, 2007, MOL THER, V15, P1313, DOI 10.1038/sj.mt.6300172; Caron NJ, 2001, MOL THER, V3, P310, DOI 10.1006/mthe.2001.0279; Cartier R, 2002, GENE THER, V9, P157, DOI 10.1038/sj.gt.3301635; Chan CK, 1999, HUM GENE THER, V10, P1695, DOI 10.1089/10430349950017699; Chang CW, 2007, J CONTROL RELEASE, V118, P245, DOI 10.1016/j.jconrel.2006.11.025; Chauhan A, 2007, J CONTROL RELEASE, V117, P148, DOI 10.1016/j.jconrel.2006.10.031; Chen L, 2007, BIOCHEM SOC T, V35, P821, DOI 10.1042/BST0350821; Dean DA, 2005, GENE THER, V12, P881, DOI 10.1038/sj.gt.3302534; Desnick RJ, 2003, ANN INTERN MED, V138, P338, DOI 10.7326/0003-4819-138-4-200302180-00014; Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200; El-Andaloussi S, 2006, J GENE MED, V8, P1262, DOI 10.1002/jgm.950; Eng CM, 2001, NEW ENGL J MED, V345, P9, DOI 10.1056/NEJM200107053450102; Gorecki Dariusz C, 2006, Discov Med, V6, P191; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Ioannou YA, 2001, AM J HUM GENET, V68, P14, DOI 10.1086/316953; Janscak P, 1996, J MOL BIOL, V257, P977, DOI 10.1006/jmbi.1996.0217; Lavigne MD, 2007, J GENE MED, V9, P44, DOI 10.1002/jgm.992; Lavigne MD, 2005, MOL THER, V12, P985, DOI 10.1016/j.ymthe.2005.02.032; Leifert JA, 2002, GENE THER, V9, P1422, DOI 10.1038/sj.gt.3301819; Lundberg M, 2003, MOL THER, V8, P143, DOI 10.1016/S1525-0016(03)00135-7; Mernagh DR, 1998, BIOL CHEM, V379, P497, DOI 10.1515/bchm.1998.379.4-5.497; Nori A, 2003, BIOCONJUGATE CHEM, V14, P44, DOI 10.1021/bc0255900; Novo FJ, 1997, GENE THER, V4, P488, DOI 10.1038/sj.gt.3300410; Ohshima T, 1997, P NATL ACAD SCI USA, V94, P2540, DOI 10.1073/pnas.94.6.2540; PATEL J, 1992, GENE, V112, P21, DOI 10.1016/0378-1119(92)90298-4; Pennadam SS, 2007, LANGMUIR, V23, P41, DOI 10.1021/la061992a; Pennadam Sivanand S, 2004, J Nanobiotechnology, V2, P8, DOI 10.1186/1477-3155-2-8; Pennadam SS, 2004, J AM CHEM SOC, V126, P13208, DOI 10.1021/ja045275j; Pollard H, 1998, J BIOL CHEM, V273, P7507, DOI 10.1074/jbc.273.13.7507; Rajagopalan R, 2007, J GENE MED, V9, P275, DOI 10.1002/jgm.1014; Ramaswami U, 2007, ACTA PAEDIATR, V96, P122, DOI 10.1111/j.1651-2227.2007.00029.x; Ratanamart J, 2006, CURR GENE THER, V6, P93, DOI 10.2174/156652306775515583; Renigunta A, 2006, BIOCONJUGATE CHEM, V17, P327, DOI 10.1021/bc050263o; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Seelig G, 2006, SCIENCE, V314, P1585, DOI 10.1126/science.1132493; Seidel R, 2004, NAT STRUCT MOL BIOL, V11, P838, DOI 10.1038/nsmb816; Seidel R, 2007, CURR OPIN STRUC BIOL, V17, P80, DOI 10.1016/j.sbi.2006.12.003; Sloots A, 2005, FEBS J, V272, P4221, DOI 10.1111/j.1742-4658.2005.04834.x; Sriadibhatla S, 2006, MOL THER, V13, P804, DOI 10.1016/j.ymthe.2005.07.701; Suk JS, 2006, BIOMATERIALS, V27, P5143, DOI 10.1016/j.biomaterials.2006.05.013; TAYLOR I, 1992, NUCLEIC ACIDS RES, V20, P179, DOI 10.1093/nar/20.2.179; Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498; Torchinsky A, 2006, AM J REPROD IMMUNOL, V55, P36, DOI 10.1111/j.1600-0897.2005.00321.x; Torchinsky Arkady, 2002, BMC Dev Biol, V2, P2, DOI 10.1186/1471-213X-2-2; Toro A, 2006, J CLIN INVEST, V116, P2717, DOI 10.1172/JCI25052; Trollet C, 2006, CURR GENE THER, V6, P561, DOI 10.2174/156652306778520656; Tunnemann G, 2006, FASEB J, V20, P1775, DOI 10.1096/fj.05-5523com; Tung CH, 2002, BIOORGAN MED CHEM, V10, P3609, DOI 10.1016/S0968-0896(02)00248-1; Twaites BR, 2005, J CONTROL RELEASE, V108, P472, DOI 10.1016/j.jconrel.2005.08.009; Twaites BR, 2004, J CONTROL RELEASE, V97, P551, DOI 10.1016/j.jconrel.2004.03.032; Utvik JK, 1999, HUM GENE THER, V10, P291, DOI 10.1089/10430349950019075; Vaysse L, 2006, J GENE MED, V8, P754, DOI 10.1002/jgm.883; Volcke C, 2006, J BIOTECHNOL, V125, P11, DOI 10.1016/j.jbiotec.2006.02.010; Wagstaff KM, 2007, MOL THER, V15, P721, DOI 10.1038/sj.mt.6300093; Yoshimitsu M, 2006, CIRC J, V70, P1503, DOI 10.1253/circj.70.1503; Zanta MA, 1999, P NATL ACAD SCI USA, V96, P91, DOI 10.1073/pnas.96.1.91; Ziegler RJ, 2004, MOL THER, V9, P231, DOI 10.1016/j.ymthe.2003.11.015; Zinkevich V, 1997, NUCLEIC ACIDS RES, V25, P503, DOI 10.1093/nar/25.3.503	60	17	20	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					2097	2107		10.1096/fj.07-093765	http://dx.doi.org/10.1096/fj.07-093765			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18202142				2022-12-25	WOS:000256352700049
J	Lee, J; Sung, YH; Cheong, C; Choi, YS; Jeon, HK; Sun, W; Hahn, WC; Ishikawa, F; Lee, HW				Lee, J.; Sung, Y. H.; Cheong, C.; Choi, Y. S.; Jeon, H. K.; Sun, W.; Hahn, W. C.; Ishikawa, F.; Lee, H-W			TERT promotes cellular and organismal survival independently of telomerase activity	ONCOGENE			English	Article						telomerase; telomerase activity; TERT; cell death; cellular protection	REVERSE-TRANSCRIPTASE; CATALYTIC SUBUNIT; MOUSE TELOMERASE; INDUCED-APOPTOSIS; NEURONAL DEATH; CANCER-CELLS; IN-VITRO; HTERT; MICE; INHIBITION	The expression level of the telomerase catalytic subunit (telomerase reverse transcriptase, TERT) positively correlates with cell survival after exposure to several lethal stresses. However, whether the protective role of TERT is independent of telomerase activity has not yet been clearly explored. Here, we genetically evaluated the protective roles of both TERT and telomerase activity against cell death induced by staurosporine (STS) and N-methyl-D-aspartic acid (NMDA). First generation (G1) TERT-deficient mouse embryonic fibroblasts (MEFs) displayed an increased sensitivity to STS, while TERT transgenic MEFs were more resistant to STS-induced apoptosis than wildtype. Deletion of the telomerase RNA component (TERC) failed to alter the sensitivity of TERT transgenic MEFs to STS treatment. Similarly, NMDA-induced excitotoxic cell death of primary neurons was suppressed by TERT, but not by TERC both in vitro and in vivo. Specifically, NMDA accelerated death of TERT-deficient mice, while TERT transgenic mice showed enhanced survival when compared with wild-type littermates after administration of NMDA. In addition, the transgenic expression of TERT protected motor neurons from apoptosis induced by sciatic nerve axotomy. These results indicate that telomerase activity is not essential for the protective function of TERT. This telomerase activity-independent TERT function may contribute to cancer development and aging independently of telomere lengthening.	[Sung, Y. H.; Choi, Y. S.; Jeon, H. K.; Lee, H-W] Yonsei Univ, Dept Biochem, Brain Korea Program 21, Seoul 120749, South Korea; [Lee, J.; Cheong, C.] Sungkyunkwan Univ, Sch Med, Dept Mol Cell Biol, Suwon, South Korea; [Sun, W.] Korea Univ, Coll Med, Brain Korea Program 21, Dept Anat, Seoul 136705, South Korea; [Hahn, W. C.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Hahn, W. C.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Hahn, W. C.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Ishikawa, F.] Kyoto Univ, Dept Gene Mech, Kyoto, Japan	Yonsei University; Sungkyunkwan University (SKKU); Korea University; Korea University Medicine (KU Medicine); Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Kyoto University	Lee, HW (corresponding author), Yonsei Univ, Dept Biochem, Brain Korea Program 21, 134 Sinchon Dong, Seoul 120749, South Korea.	hwl@yonsei.ac.kr	Ishikawa, Fuyuki/AAU-4056-2021	Ishikawa, Fuyuki/0000-0002-5580-2305; sun, woong/0000-0003-1792-4894	NATIONAL INSTITUTE ON AGING [R01AG023145] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG23145] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Artandi SE, 2002, P NATL ACAD SCI USA, V99, P8191, DOI 10.1073/pnas.112515399; Autexier C, 1996, EMBO J, V15, P5928, DOI 10.1002/j.1460-2075.1996.tb00979.x; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Boklan J, 2002, CANCER RES, V62, P2104; Cao Y, 2002, ONCOGENE, V21, P3130, DOI 10.1038/sj.onc.1205419; Cerezo A, 2002, J CELL SCI, V115, P1305; Chen JL, 2003, GENE DEV, V17, P2747, DOI 10.1101/gad.1140303; Chung HK, 2005, CURR MOL MED, V5, P233, DOI 10.2174/1566524053586635; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Djebaili M, 2000, NEUROREPORT, V11, P2973, DOI 10.1097/00001756-200009110-00029; DUBOISDAUPHIN M, 1994, P NATL ACAD SCI USA, V91, P3309, DOI 10.1073/pnas.91.8.3309; Erdmann N, 2004, P NATL ACAD SCI USA, V101, P6080, DOI 10.1073/pnas.0401580101; Finkel T, 2007, NATURE, V448, P767, DOI 10.1038/nature05985; Folini M, 2005, EUR J CANCER, V41, P624, DOI 10.1016/j.ejca.2004.12.002; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Kang HJ, 2004, J NEUROSCI, V24, P1280, DOI 10.1523/JNEUROSCI.4082-03.2004; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Massard C, 2006, ONCOGENE, V25, P4505, DOI 10.1038/sj.onc.1209487; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Middleman EJ, 2006, MOL CELL BIOL, V26, P2146, DOI 10.1128/MCB.26.6.2146-2159.2006; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Perez-Navarro E, 2005, J NEUROCHEM, V92, P678, DOI 10.1111/j.1471-4159.2004.02904.x; Rahman R, 2005, ONCOGENE, V24, P1320, DOI 10.1038/sj.onc.1208232; Sarin KY, 2005, NATURE, V436, P1048, DOI 10.1038/nature03836; Seleznev K, 2006, J BIOL CHEM, V281, P22275, DOI 10.1074/jbc.M604330200; Shay JW, 2001, HUM MOL GENET, V10, P677, DOI 10.1093/hmg/10.7.677; Siegl-Cachedenier I, 2007, J CELL BIOL, V179, P277, DOI 10.1083/jcb.200704141; SOFIA RD, 1994, PHARMACOL RES, V29, P139, DOI 10.1016/1043-6618(94)80037-5; Sun W, 2003, J NEUROSCI, V23, P7298, DOI 10.1523/jneurosci.23-19-07298.2003; Sung YH, 2005, MOL CELLS, V19, P303; Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wong KK, 2000, NAT GENET, V26, P85, DOI 10.1038/79232; Wu YL, 2006, J CELL SCI, V119, P2797, DOI 10.1242/jcs.03001; Yi XM, 2000, NEOPLASIA, V2, P433, DOI 10.1038/sj.neo.7900113; Yuan XM, 1999, GENES CELLS, V4, P563, DOI 10.1046/j.1365-2443.1999.00284.x; Zhang PS, 2003, FASEB J, V17, P767, DOI 10.1096/fj.02-0603fje	49	114	119	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	26					3754	3760		10.1038/sj.onc.1211037	http://dx.doi.org/10.1038/sj.onc.1211037			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18223679				2022-12-25	WOS:000256659300013
J	Li, Y; Ozaki, T; Kikuchi, H; Yamamoto, H; Ohira, M; Nakagawara, A				Li, Y.; Ozaki, T.; Kikuchi, H.; Yamamoto, H.; Ohira, M.; Nakagawara, A.			A novel HECT-type E3 ubiquitin protein ligase NEDL1 enhances the p53-mediated apoptotic cell death in its catalytic activity-independent manner	ONCOGENE			English	Article						apoptosis; cisplatin; DNA damage; HECT-type E3 ubiquitin ligase; NEDL1; p53	GLYCOGEN-SYNTHASE KINASE-3-BETA; AMYOTROPHIC-LATERAL-SCLEROSIS; KINASE-I-EPSILON; TRANSCRIPTIONAL ACTIVATION; SIGNALING PATHWAY; DNA-BINDING; P53; NEUROBLASTOMA; DEGRADATION; NEURONS	NEDL1 (NEDD4-like ubiquitin protein ligase-1) is a newly identified HECT-type E3 ubiquitin protein ligase highly expressed in favorable neuroblastomas as compared with unfavorable ones. In this study, we found that NEDL1 cooperates with p53 to induce apoptosis. During cisplatin (CDDP)-mediated apoptosis in neuroblastoma SH-SY5Y cells, p53 was induced to accumulate in association with an increase in expression levels of NEDL1. Enforced expression of NEDL1 resulted in a decrease in number of G418-resistant colonies in SH-SY5Y and U2OS cells bearing wild-type p53, whereas NEDL1 had undetectable effect on p53-deficient H1299 and SAOS-2 cells. Similarly, enforced expression of NEDL1 increased number of U2OS cells with sub-G1 DNA content. Co-immunoprecipitation and in vitro binding assays revealed that NEDL1 binds to the COOH-terminal region of p53. Luciferase reporter assay showed that NEDL1 has an ability to enhance the transcriptional activity of p53. Small interfering RNA-mediated knockdown of the endogenous NEDL1 conferred the resistance of U2OS cells to adriamycin. It is noteworthy that NEDL1 enhanced pro-apoptotic activity of p53 in its catalytic activity-independent manner. Taken together, our present findings suggest that functional interaction of NEDL1 with p53 might contribute to the induction of apoptosis in cancerous cells bearing wild-type p53.	[Li, Y.; Ozaki, T.; Kikuchi, H.; Yamamoto, H.; Ohira, M.; Nakagawara, A.] Chiba Canc Ctr, Res Inst, Div Biochem, Chuo Ku, Chiba 2608717, Japan; [Li, Y.] Furukawa Elect Corp Ltd, Prod Technol Dev Ctr, Ichihara, Chiba, Japan	Chiba Cancer Center; Furukawa Electric	Nakagawara, A (corresponding author), Chiba Canc Ctr, Res Inst, Div Biochem, Chuo Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-cc.jp						Adhikary S, 2005, CELL, V123, P409, DOI 10.1016/j.cell.2005.08.016; Bijur GN, 2000, J BIOL CHEM, V275, P7583, DOI 10.1074/jbc.275.11.7583; Cluskey S, 2001, J CLIN PATHOL-MOL PA, V54, P386; Cross DAE, 2001, J NEUROCHEM, V77, P94, DOI 10.1046/j.1471-4159.2001.00251.x; de Aguilar JLG, 2000, NEUROBIOL DIS, V7, P406, DOI 10.1006/nbdi.2000.0295; Di Lello P, 2006, MOL CELL, V22, P731, DOI 10.1016/j.molcel.2006.05.007; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Ekegren T, 1999, ACTA NEUROL SCAND, V100, P317; Hetman M, 2000, J NEUROSCI, V20, P2567; Hino S, 2003, J BIOL CHEM, V278, P14066, DOI 10.1074/jbc.M213265200; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; Kiryu-Seo S, 2005, J NEUROSCI, V25, P1442, DOI 10.1523/JNEUROSCI.4041-04.2005; Kishida M, 2001, J BIOL CHEM, V276, P33147, DOI 10.1074/jbc.M103555200; Kitanaka C, 2002, J NATL CANCER I, V94, P358; Lee E, 2001, J CELL BIOL, V154, P983, DOI 10.1083/jcb.200102074; LEVINE AJ, 1994, J LAB CLIN MED, V123, P817; Martin LJ, 2002, J NEUROBIOL, V50, P181, DOI 10.1002/neu.10026; Martin LJ, 2000, NEUROBIOL DIS, V7, P613, DOI 10.1006/nbdi.2000.0314; Miyazaki K, 2004, J BIOL CHEM, V279, P11327, DOI 10.1074/jbc.M312389200; Miyazaki K, 2003, BIOCHEM BIOPH RES CO, V308, P106, DOI 10.1016/S0006-291X(03)01347-0; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Nakagawara A, 2004, CANCER LETT, V204, P213, DOI 10.1016/S0304-3835(03)00457-9; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Roos WP, 2006, TRENDS MOL MED, V12, P440, DOI 10.1016/j.molmed.2006.07.007; Shaw P, 1996, ONCOGENE, V12, P921; Thomas MC, 2005, MOL CELL, V17, P251, DOI 10.1016/j.molcel.2004.12.016; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299	29	40	45	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	26					3700	3709		10.1038/sj.onc.1211032	http://dx.doi.org/10.1038/sj.onc.1211032			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18223681				2022-12-25	WOS:000256659300007
J	Macias-Perez, IM; Zent, R; Carmosino, M; Breyer, MD; Breyer, RM; Pozzi, A				Macias-Perez, Ines M.; Zent, Roy; Carmosino, Monica; Breyer, Matthew D.; Breyer, Richard M.; Pozzi, Ambra			Mouse EP3 alpha, beta, and gamma receptor variants reduce tumor cell proliferation and tumorigenesis in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN COLON-CANCER; C-TERMINAL TAIL; NEURITE RETRACTION; PROSTAGLANDIN E(2); LIGAND-BINDING; 2 ISOFORMS; CONSTITUTIVE ACTIVITY; ERK ACTIVATION; ASPIRIN USE; SUBTYPE	Prostaglandin E-2, which exerts its functions by binding to four G protein-coupled receptors (EP1-4), is implicated in tumorigenesis. Among the four E-prostanoid (EP) receptors, EP3 is unique in that it exists as alternatively spliced variants, characterized by differences in the cytoplasmic C-terminal tail. Although three EP3 variants, alpha,beta,and gamma, have been described in mice, their functional significance in regulating tumorigenesis is unknown. In this study we provide evidence that expressing murine EP3 alpha, beta, and gamma receptor variants in tumor cells reduces to the same degree their tumorigenic potential in vivo. In addition, activation of each of the three mEP3 variants induces enhanced cell-cell contact and reduces cell proliferation in vitro in a Rho-dependent manner. Finally, we demonstrate that EP3-mediated RhoA activation requires the engagement of the heterotrimeric G protein G(12). Thus, our study provides strong evidence that selective activation of each of the three variants of the EP3 receptor suppresses tumor cell function by activating aG(12)-RhoA pathway.	[Macias-Perez, Ines M.; Zent, Roy; Carmosino, Monica; Breyer, Matthew D.; Breyer, Richard M.; Pozzi, Ambra] Vanderbilt Univ, Dept Med, Div Nephrol, Med Ctr N, Nashville, TN 37232 USA; [Macias-Perez, Ines M.; Zent, Roy; Pozzi, Ambra] Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA; [Zent, Roy] Vanderbilt Univ, Dept Cell & Dev Biol, Nashville, TN 37232 USA; [Zent, Roy; Pozzi, Ambra] Vet Affairs Hosp, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Pozzi, A (corresponding author), Vanderbilt Univ, Dept Med, Div Nephrol, Med Ctr N, B3109, Nashville, TN 37232 USA.	ambra.pozzi@vanderbilt.edu	Carmosino, Monica/O-2594-2014	Carmosino, Monica/0000-0001-7600-8816; Breyer, Matthew/0000-0003-1880-371X	NATIONAL CANCER INSTITUTE [R01CA094849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK074359, R01DK037097, R01DK069921] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA94849] Funding Source: Medline; NIDDK NIH HHS [R01-DK69921, R01-DK074359, DK37097] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bilson HA, 2004, FEBS LETT, V572, P271, DOI 10.1016/j.febslet.2004.06.089; Boie Y, 1997, EUR J PHARMACOL, V340, P227, DOI 10.1016/S0014-2999(97)01383-6; BREYER RM, 1994, J BIOL CHEM, V269, P6163; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Chang SH, 2004, P NATL ACAD SCI USA, V101, P591, DOI 10.1073/pnas.2535911100; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Falcetti E, 2007, BIOCHEM BIOPH RES CO, V360, P821, DOI 10.1016/j.bbrc.2007.06.135; Fukui K, 2006, J CANCER RES CLIN, V132, P627, DOI 10.1007/s00432-006-0107-7; Hasegawa H, 1996, J BIOL CHEM, V271, P1857, DOI 10.1074/jbc.271.4.1857; Hasegawa H, 2000, FEBS LETT, V473, P76, DOI 10.1016/S0014-5793(00)01508-8; Hasegawa H, 1997, BIOCHEM BIOPH RES CO, V234, P631, DOI 10.1006/bbrc.1997.6655; Hata AN, 2005, J BIOL CHEM, V280, P32442, DOI 10.1074/jbc.M502563200; Hata AN, 2005, MOL PHARMACOL, V67, P640, DOI 10.1124/mol.104.007971; Hata AN, 2004, PHARMACOL THERAPEUT, V103, P147, DOI 10.1016/j.pharmthera.2004.06.003; IRIE A, 1993, EUR J BIOCHEM, V217, P313, DOI 10.1111/j.1432-1033.1993.tb18248.x; IRIE A, 1994, BIOCHEM BIOPH RES CO, V204, P303, DOI 10.1006/bbrc.1994.2460; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kanda N, 2005, J PHARMACOL EXP THER, V315, P796, DOI 10.1124/jpet.105.091645; KARGMAN SL, 1995, CANCER RES, V55, P2556; Katoh H, 1996, J BIOL CHEM, V271, P29780, DOI 10.1074/jbc.271.47.29780; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Katoh H, 1998, J BIOL CHEM, V273, P2489, DOI 10.1074/jbc.273.5.2489; Kotani T, 2000, J CLIN ENDOCR METAB, V85, P4315; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; Negishi M, 1996, FEBS LETT, V386, P165, DOI 10.1016/0014-5793(96)00354-7; NEGISHI M, 1993, BIOCHIM BIOPHYS ACTA, V1175, P343, DOI 10.1016/0167-4889(93)90227-G; Nelson PJ, 2002, KIDNEY INT S1, V61, P99, DOI DOI 10.1046/J.1523-1755.2002.0610S1099.X; OKA M, 1994, AM J SURG, V167, P264, DOI 10.1016/0002-9610(94)90089-2; Pozzi A, 2004, J BIOL CHEM, V279, P29797, DOI 10.1074/jbc.M313989200; PUGH S, 1994, GUT, V35, P675, DOI 10.1136/gut.35.5.675; Rao R, 2007, J BIOL CHEM, V282, P16959, DOI 10.1074/jbc.M701214200; Riobo NA, 2005, TRENDS PHARMACOL SCI, V26, P146, DOI 10.1016/j.tips.2005.01.007; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; SANO H, 1995, CANCER RES, V55, P3785; Sasaki M, 2007, PROSTAG OTH LIPID M, V83, P237, DOI 10.1016/j.prostaglandins.2006.12.001; Scherpereel A, 2003, CANCER RES, V63, P6084; Shoji Y, 2004, GUT, V53, P1151, DOI 10.1136/gut.2003.028787; SUGIMOTO Y, 1993, J BIOL CHEM, V268, P2712; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; THUN MJ, 1993, CANCER RES, V53, P1322; Wilson RJ, 2005, BRIT J PHARMACOL, V144, P405, DOI 10.1038/sj.bjp.0706088; Yamada S, 2007, J CELL BIOL, V178, P517, DOI 10.1083/jcb.200701058	43	24	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2008	283	18					12538	12545		10.1074/jbc.M800105200	http://dx.doi.org/10.1074/jbc.M800105200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	293MS	18230618	Green Published, hybrid			2022-12-25	WOS:000255340000070
J	Wagner, JR; Zhang, JR; von Stetten, D; Guenther, M; Murgida, DH; Mroginski, MA; Walker, JM; Forest, KT; Hildebrandt, P; Vierstra, RD				Wagner, Jeremiah R.; Zhang, Junrui; von Stetten, David; Guenther, Mina; Murgida, Daniel H.; Mroginski, Maria Andrea; Walker, Joseph M.; Forest, Katrina T.; Hildebrandt, Peter; Vierstra, Richard D.			Mutational analysis of Deinococcus radiodurans bacteriophytochrome reveals key amino acids necessary for the photochromicity and proton exchange cycle of phytochromes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOPHORE-BINDING DOMAIN; RESONANCE RAMAN; TETRAPYRROLE CHROMOPHORE; BILIVERDIN CHROMOPHORE; BIOLOGICAL-ACTIVITY; STRUCTURAL-CHANGES; CPH1 PHYTOCHROME; PHOTOTRANSFORMATION; AGP1; PHOTORECEPTORS	The ability of phytochromes (Phy) to act as photointerconvertible light switches in plants and microorganisms depends on key interactions between the bilin chromophore and the apoprotein that promote bilin attachment and photointerconversion between the spectrally distinct red light-absorbing Pr conformer and far red light-absorbing Pfr conformer. Using structurally guided site-directed mutagenesis combined with several spectroscopic methods, we examined the roles of conserved amino acids within the bilin-binding domain of Deinococcus radiodurans bacteriophytochrome with respect to chromophore ligation and Pr/Pfr photoconversion. Incorporation of biliverdin IX alpha(BV), its structure in the Pr state, and its ability to photoisomerize to the first photocycle intermediate are insensitive to most single mutations, implying that these properties are robust with respect to small structural/electrostatic alterations in the binding pocket. In contrast, photoconversion to Pfr is highly sensitive to the chromophore environment. Many of the variants form spectrally bleached Meta-type intermediates in red light that do not relax to Pfr. Particularly important are Asp-207 and His-260, which are invariant within the Phy superfamily and participate in a unique hydrogen bond matrix involving the A, B, and C pyrrole ring nitrogens of BV and their associated pyrrole water. Resonance Raman spectroscopy demonstrates that substitutions of these residues disrupt the Pr to Pfr protonation cycle of BV with the chromophore locked in a deprotonated Meta-R-c-like photoconversion intermediate after red light irradiation. Collectively, the data show that a number of contacts contribute to the unique photochromicity of Phy-type photoreceptors. These include residues that fix the bilin in the pocket, coordinate the pyrrole water, and possibly promote the proton exchange cycle during photoconversion.	[Wagner, Jeremiah R.; Zhang, Junrui; Walker, Joseph M.; Vierstra, Richard D.] Univ Wisconsin, Dept Genet, Madison, WI 53706 USA; [Forest, Katrina T.] Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA; [von Stetten, David; Guenther, Mina; Murgida, Daniel H.; Mroginski, Maria Andrea; Hildebrandt, Peter] Tech Univ Berlin, D-10623 Berlin, Germany	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Technical University of Berlin	Vierstra, RD (corresponding author), Univ Wisconsin, Dept Genet, 425-G Henry Mall, Madison, WI 53706 USA.	vierstra@wisc.edu	Hildebrandt, Peter/J-5658-2014; Zhang, Junrui/J-2684-2012; Murgida, Daniel H./F-2350-2018	Hildebrandt, Peter/0000-0003-1030-5900; Murgida, Daniel H./0000-0001-5173-0183; von Stetten, David/0000-0001-7906-9788				Andel F, 1996, BIOCHEMISTRY-US, V35, P15997, DOI 10.1021/bi962175k; Andel F, 2000, BIOCHEMISTRY-US, V39, P2667, DOI 10.1021/bi991688z; Andel F, 1997, BIOSPECTROSCOPY, V3, P421, DOI 10.1002/(SICI)1520-6343(1997)3:6<421::AID-BSPY1>3.0.CO;2-3; Bhoo SH, 2001, NATURE, V414, P776, DOI 10.1038/414776a; Bhoo SH, 1997, J AM CHEM SOC, V119, P11717, DOI 10.1021/ja972875s; Bischoff M, 2001, BIOCHEMISTRY-US, V40, P181, DOI 10.1021/bi0011734; Borucki B, 2005, J BIOL CHEM, V280, P34358, DOI 10.1074/jbc.M505493200; Borucki B, 2003, BIOCHEMISTRY-US, V42, P13684, DOI 10.1021/bi035511n; Braslavsky SE, 2003, PHOTOCHROMISM: MOLECULES AND SYSTEMS, P738, DOI 10.1016/B978-044451322-9/50023-3; CHERRY JR, 1993, PLANT CELL, V5, P565, DOI 10.1105/tpc.5.5.565; Davis SJ, 1999, SCIENCE, V286, P2517, DOI 10.1126/science.286.5449.2517; Fischer AJ, 2005, BIOCHEMISTRY-US, V44, P15203, DOI 10.1021/bi051633z; Fischer AJ, 2004, P NATL ACAD SCI USA, V101, P17334, DOI 10.1073/pnas.0407645101; Foerstendorf H, 2001, BIOCHEMISTRY-US, V40, P14952, DOI 10.1021/bi0156916; Froehlich AC, 2005, EUKARYOT CELL, V4, P2140, DOI 10.1128/EC.4.12.2140-2152.2005; Hahn J, 2006, FEBS J, V273, P1415, DOI 10.1111/j.1742-4658.2006.05164.x; Hanzawa H, 2001, P NATL ACAD SCI USA, V98, P3612, DOI 10.1073/pnas.051629698; Inomata K, 2006, J BIOL CHEM, V281, P28162, DOI 10.1074/jbc.M603983200; Karniol B, 2005, BIOCHEM J, V392, P103, DOI 10.1042/BJ20050826; Kneip C, 1999, BIOCHEMISTRY-US, V38, P15185, DOI 10.1021/bi990688w; Kneip C, 2000, FEBS LETT, V482, P252, DOI 10.1016/S0014-5793(00)02069-X; LAGARIAS JC, 1980, J AM CHEM SOC, V102, P4821, DOI 10.1021/ja00534a042; Lamparter T, 2004, BIOCHEMISTRY-US, V43, P3659, DOI 10.1021/bi035693l; Lamparter T, 2001, EUR J BIOCHEM, V268, P4720, DOI 10.1046/j.1432-1327.2001.02395.x; MIZUTANI Y, 1994, BIOCHEMISTRY-US, V33, P153, DOI 10.1021/bi00167a020; Mroginski MA, 2004, J AM CHEM SOC, V126, P16734, DOI 10.1021/ja043959l; Mroginski MA, 2007, ACCOUNTS CHEM RES, V40, P258, DOI 10.1021/ar6000523; Quail PH, 2002, NAT REV MOL CELL BIO, V3, P85, DOI 10.1038/nrm728; Rockwell NC, 2006, ANNU REV PLANT BIOL, V57, P837, DOI 10.1146/annurev.arplant.56.032604.144208; RUDIGER W, 1983, P NATL ACAD SCI-BIOL, V80, P6244, DOI 10.1073/pnas.80.20.6244; Stevens JM, 2004, ACCOUNTS CHEM RES, V37, P999, DOI 10.1021/ar030266l; STOCKHAUS J, 1992, GENE DEV, V6, P2364, DOI 10.1101/gad.6.12a.2364; Tu SL, 2005, HANDBOOK OF PHOTOSENSORY RECEPTORS, P121, DOI 10.1002/352760510X.ch6; Vierstra RD, 2005, HANDBOOK OF PHOTOSENSORY RECEPTORS, P171, DOI 10.1002/352760510X.ch8; von Stetten D, 2007, J BIOL CHEM, V282, P2116, DOI 10.1074/jbc.M608878200; Wagner JR, 2007, J BIOL CHEM, V282, P12298, DOI 10.1074/jbc.M611824200; Wagner JR, 2005, NATURE, V438, P325, DOI 10.1038/nature04118; Yang X, 2007, P NATL ACAD SCI USA, V104, P12571, DOI 10.1073/pnas.0701737104; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976; Zhao KH, 2004, BIOCHEMISTRY-US, V43, P11576, DOI 10.1021/bi0491548	40	163	166	0	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2008	283	18					12212	12226		10.1074/jbc.M709355200	http://dx.doi.org/10.1074/jbc.M709355200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	293MS	18192276	Green Published, hybrid			2022-12-25	WOS:000255340000037
J	Carlucci, A; Gedressi, C; Lignitto, L; Nezi, L; Villa-Moruzzi, E; Avvedimento, EV; Gottesman, M; Garbi, C; Feliciello, A				Carlucci, Annalisa; Gedressi, Chiara; Lignitto, Luca; Nezi, Luigi; Villa-Moruzzi, Emma; Avvedimento, Enrico V.; Gottesman, Max; Garbi, Corrado; Feliciello, Antonio			Protein-tyrosine phosphatase PTPD1 regulates focal adhesion kinase autophosphorylation and cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; ACTIVATION; COMPLEX; DOMAIN; FAK; RHO; PAXILLIN; MOTILITY; SIGNALS; BETA	PTPD1 is a cytosolic nonreceptor tyrosine phosphatase and a positive regulator of the Src-epidermal growth factor transduction pathway. We show that PTPD1 localizes along actin filaments and at adhesion plaques. PTPD1 forms a stable complex via distinct molecular modules with actin, Src tyrosine kinase, and focal adhesion kinase (FAK), a scaffold protein kinase enriched at adhesion plaques. Overexpression of PTPD1 promoted cell scattering and migration, short hairpin RNA-mediated silencing of endogenous PTPD1, or expression of PTPD1 mutants lacking either catalytic activity (PTPD1(C1108S)) or the FERM domain (PTPD1(Delta 1-325)) significantly reduced cell motility. PTPD1 and Src catalytic activities were both required for epidermal growth factor-induced FAK autophosphorylation at its active site and for downstream propagation of ERK1/2 signaling. Our findings demonstrate that PTPD1 is a component of a multivalent scaffold complex nucleated by FAK at specific intracellular sites. By modulating Src-FAK signaling at adhesion sites, PTPD1 promotes the cytoskeleton events that induce cell adhesion and migration.	[Carlucci, Annalisa; Gedressi, Chiara; Lignitto, Luca; Nezi, Luigi; Avvedimento, Enrico V.; Garbi, Corrado; Feliciello, Antonio] Univ Naples Federico II, Fac Med, Ist Endocrinol & Oncol Sperimentale, CNR,Dipartimento Biol & Patol Mol & Cellulare, I-80131 Naples, Italy; [Villa-Moruzzi, Emma] Univ Pisa, Dipartimento Patol Sperimentale, I-56126 Pisa, Italy; [Gottesman, Max] Columbia Univ, Inst Canc Res, New York, NY 10032 USA	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; University of Pisa; Columbia University	Feliciello, A (corresponding author), Univ Naples Federico II, Fac Med, Ist Endocrinol & Oncol Sperimentale, CNR,Dipartimento Biol & Patol Mol & Cellulare, Via S Pansini, I-80131 Naples, Italy.	feliciel@unina.it	Nezi, Luigi/AAB-1957-2019	Nezi, Luigi/0000-0002-4670-7656; Feliciello, Antonio/0000-0002-7932-2170	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Andersen JN, 2004, FASEB J, V18, P8, DOI 10.1096/fj.02-1212rev; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Bianchi M, 2005, MOL CELL BIOCHEM, V272, P85, DOI 10.1007/s11010-005-7639-z; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Bogdan S, 2001, CURR BIOL, V11, pR292, DOI 10.1016/S0960-9822(01)00167-1; Cardone L, 2004, MOL CELL BIOL, V24, P4613, DOI 10.1128/MCB.24.11.4613-4626.2004; Carragher NO, 2004, TRENDS CELL BIOL, V14, P241, DOI 10.1016/j.tcb.2004.03.011; Chen RY, 2001, NAT CELL BIOL, V3, P439, DOI 10.1038/35074500; Cooper LA, 2003, MOL CELL BIOL, V23, P8030, DOI 10.1128/MCB.23.22.8030-8041.2003; DeMali KA, 2003, CURR OPIN CELL BIOL, V15, P572, DOI 10.1016/S0955-0674(03)00109-1; Dorner C, 1998, J BIOL CHEM, V273, P20267, DOI 10.1074/jbc.273.32.20267; Dunican DS, 2002, ONCOGENE, V21, P3253, DOI 10.1038/sj.onc.1205431; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Feliciello A, 2005, CELL SIGNAL, V17, P279, DOI 10.1016/j.cellsig.2004.09.009; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Hermiston ML, 2003, ANNU REV IMMUNOL, V21, P107, DOI 10.1146/annurev.immunol.21.120601.140946; ILLC D, 1995, NATURE, V377, P539; Iwahara T, 2004, P NATL ACAD SCI USA, V101, P17693, DOI 10.1073/pnas.0408413102; Jui HY, 2000, J BIOL CHEM, V275, P41124, DOI 10.1074/jbc.M007772200; Liang FB, 2005, J BIOL CHEM, V280, P24857, DOI 10.1074/jbc.M502780200; Livigni A, 2006, MOL BIOL CELL, V17, P263, DOI 10.1091/mbc.e05-09-0827; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; Manes S, 1999, MOL CELL BIOL, V19, P3125; MOLLER NPH, 1994, P NATL ACAD SCI USA, V91, P7477, DOI 10.1073/pnas.91.16.7477; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; NOBES CD, 1995, J CELL SCI, V108, P225; Ostman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Ren XD, 2000, J CELL SCI, V113, P3673; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Sallee JL, 2006, J BIOL CHEM, V281, P16189, DOI 10.1074/jbc.R600003200; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Seet BT, 2006, NAT REV MOL CELL BIO, V7, P473, DOI 10.1038/nrm1960; SEMICH R, 1990, J HISTOCHEM CYTOCHEM, V38, P59, DOI 10.1177/38.1.1688450; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Vuori K, 1996, MOL CELL BIOL, V16, P2606; WEISPOKUTTA S, 2002, CURR OPIN STRUC BIOL, V12, P255; Yamada KM, 2001, J CELL SCI, V114, P2375; Zeng L, 2003, J CELL BIOL, V160, P137, DOI 10.1083/jcb.200206049; Zhang ZY, 2006, J BIOL CHEM, V281, P1746, DOI 10.1074/jbc.M509590200	49	50	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10919	10929		10.1074/jbc.M707248200	http://dx.doi.org/10.1074/jbc.M707248200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18223254	hybrid			2022-12-25	WOS:000254894700073
J	Lopez-Alcala, C; Alvarez-Moya, B; Villalonga, P; Calvo, M; Bachs, O; Agell, N				Lopez-Alcala, Cristina; Alvarez-Moya, Blanca; Villalonga, Priam; Calvo, Maria; Bachs, Oriol; Agell, Neus			Identification of essential interacting elements in K-Ras/calmodulin binding and its role in K-Ras localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; CALMODULIN-BINDING; H-RAS; N-RAS; PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; TERMINAL DOMAIN; GTP-BINDING; PROTEIN; CA2+/CALMODULIN	We previously showed that K-Ras is a calmodulin-binding protein. Involvement of this interaction in anterograde and retrograde transport of K-Ras was then suggested. To test this we have analyzed here the domains of K-Ras essential for the interaction with calmodulin. At least three different regions in the K-Ras molecule were important; they are the hypervariable region, the alpha-helix between amino acids 151 and 166, and the Switch II. Within the hypervariable region, both the hydrophobic farnesyl group and the positive-charged amino acids were essential for the interaction between K-Ras and calmodulin in cellular extracts. Consistently, K-Ras S181D, which mimics phosphorylation of Ser-181 of K-Ras, also completely abolished binding to calmodulin. K-Ras mutants correctly farnesylated that did not bind calmodulin were all located at plasma membrane, showing that calmodulin interaction was not required for the transport of K-Ras to plasma membrane. In NIH3T3 cells, K-Ras and calmodulin colocalized mainly in the plasma membrane even after the addition of Ca2+ ionophore, indicating that interaction did not directly lead to K-Ras internalization. Furthermore, using a K-Ras with impaired binding to calmodulin but with membrane localization, we could demonstrate in striatal neurones that interaction between K-Ras and calmodulin was not required for Golgi K-Ras translocation induced by Ca2+ influx.	[Lopez-Alcala, Cristina; Alvarez-Moya, Blanca; Bachs, Oriol; Agell, Neus] Univ Barcelona, Dept Cellular Biol, Fac Med, Inst Invest Biomed August Pi i Sunyer, E-08036 Barcelona, Spain; [Villalonga, Priam] Inst Univ Invest Ciencies Salut, Grp Biol Cellular Del Canc Oncol Translac, Palma De Mallorca 07122, Spain; [Villalonga, Priam] Univ Illes Balears, Dept Biol Fonamental, Palma De Mallorca 07122, Spain; [Calvo, Maria] Univ Barcelona, Inst Invest Biomed, Unitat Microscopia, Serv Cientif Tecn, E-08036 Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Universitat de les Illes Balears; University of Barcelona	Agell, N (corresponding author), Univ Barcelona, Dept Cellular Biol, Fac Med, Inst Invest Biomed August Pi i Sunyer, C Casanova 143, E-08036 Barcelona, Spain.	agell@medicina.ub.es	Villalonga, Priam/K-4350-2014; Agell, Neus/E-9640-2016; Calvo, Maria/I-1872-2015; Moya, Blanca Alvarez/ABG-4314-2020	Villalonga, Priam/0000-0002-7190-6884; Agell, Neus/0000-0002-1205-6074; Calvo, Maria/0000-0002-7473-0474; Moya, Blanca Alvarez/0000-0003-2573-7909				Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; BALLESTER R, 1987, J BIOL CHEM, V262, P2688; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bivona TG, 2006, MOL CELL, V21, P481, DOI 10.1016/j.molcel.2006.01.012; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BOS JL, 1989, CANCER RES, V49, P4682; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; DYKES DC, 1992, J BIOMOL STRUCT DYN, V9, P1025, DOI 10.1080/07391102.1992.10507977; Elad-Sfadia G, 2002, J BIOL CHEM, V277, P37169, DOI 10.1074/jbc.M205698200; Fischer R, 1996, J BIOL CHEM, V271, P25067, DOI 10.1074/jbc.271.41.25067; Fivaz M, 2005, J CELL BIOL, V170, P429, DOI 10.1083/jcb.200409157; Goodwin JS, 2005, J CELL BIOL, V170, P261, DOI 10.1083/jcb.200502063; Hancock JF, 2005, BIOCHEM J, V389, P1, DOI 10.1042/BJ20050231; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Hayashi N, 2002, PROTEIN SCI, V11, P529, DOI 10.1110/ps.23702; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; Kloog Y, 2004, SEMIN CANCER BIOL, V14, P253, DOI 10.1016/j.semcancer.2004.04.004; Lee CHJ, 1996, J NEUROSCI, V16, P6784; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Magee T, 1999, CELL, V98, P9, DOI 10.1016/S0092-8674(00)80601-7; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Matsubara M, 2004, EMBO J, V23, P712, DOI 10.1038/sj.emboj.7600093; Matsubara M, 2003, J BIOL CHEM, V278, P48898, DOI 10.1074/jbc.M305488200; Olson MF, 2000, SEMIN IMMUNOL, V12, P63, DOI 10.1006/smim.2000.0208; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; Park JB, 1997, J BIOL CHEM, V272, P20857, DOI 10.1074/jbc.272.33.20857; Parton RG, 2004, TRENDS CELL BIOL, V14, P141, DOI 10.1016/j.tcb.2004.02.001; Paz A, 2001, ONCOGENE, V20, P7486, DOI 10.1038/sj.onc.1204950; Plowman SJ, 2005, BBA-MOL CELL RES, V1746, P274, DOI 10.1016/j.bbamcr.2005.06.004; Plowman SJ, 2005, P NATL ACAD SCI USA, V102, P15500, DOI 10.1073/pnas.0504114102; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; Rebollo A, 1999, BLOOD, V94, P2971, DOI 10.1182/blood.V94.9.2971.421k43_2971_2980; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Rotblat B, 2004, CANCER RES, V64, P3112, DOI 10.1158/0008-5472.CAN-04-0026; Sidhu RS, 2005, BIOCHEM BIOPH RES CO, V336, P105, DOI 10.1016/j.bbrc.2005.08.053; Sidhu RS, 2003, BIOCHEM BIOPH RES CO, V304, P655, DOI 10.1016/S0006-291X(03)00635-1; Swindells MB, 1996, NAT STRUCT BIOL, V3, P501, DOI 10.1038/nsb0696-501; Ulrich A, 2000, P NATL ACAD SCI USA, V97, P5191, DOI 10.1073/pnas.090500397; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; Vergeres G, 1998, BIOCHEM J, V330, P5, DOI 10.1042/bj3300005; Villalonga P, 2002, J BIOL CHEM, V277, P37929, DOI 10.1074/jbc.M202245200; Villalonga P, 2001, MOL CELL BIOL, V21, P7345, DOI 10.1128/MCB.21.21.7345-7354.2001; Wang KL, 1997, J BIOL CHEM, V272, P16002, DOI 10.1074/jbc.272.25.16002; WEINSTEIN H, 1994, ANNU REV PHYSIOL, V56, P213, DOI 10.1146/annurev.ph.56.030194.001241; Wes PD, 1996, EMBO J, V15, P5839, DOI 10.1002/j.1460-2075.1996.tb00971.x; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052	52	63	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10621	10631		10.1074/jbc.M706238200	http://dx.doi.org/10.1074/jbc.M706238200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18182391	hybrid			2022-12-25	WOS:000254894700044
J	Arias-Olguin, II; Vitko, I; Fortuna, M; Baumgart, JP; Sokolova, S; Shumilin, IA; Van Deusen, A; Soriano-Garcia, M; Gomora, JC; Perez-Reyes, E				Arias-Olguin, Imilla I.; Vitko, Iuliia; Fortuna, Michal; Baumgart, Joel P.; Sokolova, Svetlana; Shumilin, Igor A.; Van Deusen, Amy; Soriano-Garcia, Manuel; Gomora, Juan C.; Perez-Reyes, Edward			Characterization of the gating brake in the I-II loop of Ca(v)3.2 T-type Ca2+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHILDHOOD ABSENCE EPILEPSY; CALCIUM-CHANNELS; VOLTAGE SENSOR; DETERMINANTS; INACTIVATION; CACNA1H; CELLS	Mutations in the I-II loop of Ca(v)3.2 channels were discovered in patients with childhood absence epilepsy. All of these mutations increased the surface expression of the channel, whereas some mutations, and in particular C456S, altered the biophysical properties of channels. Deletions around C456S were found to produce channels that opened at even more negative potentials than control, suggesting the presence of a gating brake that normally prevents channel opening. The goal of the present study was to identify the minimal sequence of this brake and to provide insights into its structure. A peptide fragment of the I-II loop was purified from bacteria, and its structure was analyzed by circular dichroism. These results indicated that the peptide had a high alpha-helical content, as predicted from secondary structure algorithms. Based on homology modeling, we hypothesized that the proximal region of the I-II loop may form a helix-loop-helix structure. This model was tested by mutagenesis followed by electrophysiological measurement of channel gating. Mutations that disrupted the helices, or the loop region, had profound effects on channel gating, shifting both steady state activation and inactivation curves, as well as accelerating channel kinetics. Mutations designed to preserve the helical structure had more modest effects. Taken together, these studies showed that any mutations in the brake, including C456S, disrupted the structural integrity of the brake and its function to maintain these low voltage-activated channels closed at resting membrane potentials.	[Arias-Olguin, Imilla I.; Gomora, Juan C.] Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Mexico City 04510, DF, Mexico; [Arias-Olguin, Imilla I.; Vitko, Iuliia; Fortuna, Michal; Sokolova, Svetlana; Van Deusen, Amy; Perez-Reyes, Edward] Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA; [Shumilin, Igor A.] Univ Virginia, Dept Mol Phys & Biol Phys, Charlottesville, VA 22908 USA; [Baumgart, Joel P.; Perez-Reyes, Edward] Univ Virginia, Grad Program Neurosci, Charlottesville, VA 22908 USA; [Soriano-Garcia, Manuel] Univ Nacl Autonoma Mexico, Inst Chem, Mexico City 04510, DF, Mexico	Universidad Nacional Autonoma de Mexico; University of Virginia; University of Virginia; University of Virginia; Universidad Nacional Autonoma de Mexico	Gomora, JC (corresponding author), Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Mexico City 04510, DF, Mexico.	jgomora@ifc.unam.mx	Baumgart, Joel/K-3139-2014	Baumgart, Joel/0000-0002-1109-2567; Gomora, Juan Carlos/0000-0002-9871-1307; Van Deusen, Amy/0000-0003-2578-7332	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038691] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 038691] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arias JM, 2005, FEBS LETT, V579, P3907, DOI 10.1016/j.febslet.2005.06.008; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; CARBONE E, 1984, NATURE, V310, P501, DOI 10.1038/310501a0; Cataldi M, 2002, J BIOL CHEM, V277, P45969, DOI 10.1074/jbc.M203922200; Catterall WA, 2005, PHARMACOL REV, V57, P411, DOI 10.1124/pr.57.4.5; Chen YC, 2003, ANN NEUROL, V54, P239, DOI 10.1002/ana.10607; Frazier CJ, 2001, J GEN PHYSIOL, V118, P457, DOI 10.1085/jgp.118.5.457; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; Ginalski K, 2003, BIOINFORMATICS, V19, P1015, DOI 10.1093/bioinformatics/btg124; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; Kelly SM, 2000, CURR PROTEIN PEPT SC, V1, P349, DOI 10.2174/1389203003381315; Lacinova L, 2002, FEBS LETT, V531, P235, DOI 10.1016/S0014-5793(02)03509-3; Lam AD, 2005, PFLUG ARCH EUR J PHY, V451, P349, DOI 10.1007/s00424-005-1407-5; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Long SB, 2005, SCIENCE, V309, P903, DOI 10.1126/science.1116270; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; Marksteiner R, 2001, J PHYSIOL-LONDON, V537, P27, DOI 10.1111/j.1469-7793.2001.0027k.x; MATTESON DR, 1986, J GEN PHYSIOL, V87, P161, DOI 10.1085/jgp.87.1.161; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; Randall AD, 1997, NEUROPHARMACOLOGY, V36, P879, DOI 10.1016/S0028-3908(97)00086-5; Splawski I, 2004, CELL, V119, P19, DOI 10.1016/j.cell.2004.09.011; Talavera K, 2003, J GEN PHYSIOL, V121, P529, DOI 10.1085/jgp.200308794; Talavera K, 2006, PFLUG ARCH EUR J PHY, V453, P189, DOI 10.1007/s00424-006-0129-7; Tombola F, 2006, ANNU REV CELL DEV BI, V22, P23, DOI 10.1146/annurev.cellbio.21.020404.145837; Vitko I, 2005, J NEUROSCI, V25, P4844, DOI 10.1523/JNEUROSCI.0847-05.2005; Vitko I, 2007, J NEUROSCI, V27, P322, DOI 10.1523/JNEUROSCI.1817-06.2007; Yarov-Yarovoy V, 2006, P NATL ACAD SCI USA, V103, P7292, DOI 10.1073/pnas.0602350103	27	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8136	8144		10.1074/jbc.M708761200	http://dx.doi.org/10.1074/jbc.M708761200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18218623	Green Published, hybrid			2022-12-25	WOS:000254288000010
J	Shaw, BF; Lelie, HL; Durazo, A; Nersissian, AM; Xu, G; Chan, PK; Gralla, EB; Tiwari, A; Hayward, LJ; Borchelt, DR; Valentine, JS; Whitelegge, JP				Shaw, Bryan F.; Lelie, Herman L.; Durazo, Armando; Nersissian, Aram M.; Xu, Guillan; Chan, Pik K.; Gralla, Edith B.; Tiwari, Ashutosh; Hayward, Lawrence J.; Borchelt, David R.; Valentine, Joan S.; Whitelegge, Julian P.			Detergent-insoluble aggregates associated with amyotrophic lateral sclerosis in transgenic mice contain primarily full-length, unmodified superoxide dismutase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPPER-BINDING-SITE; ALS-LINKED SOD1; INTRACYTOPLASMIC HYALINE INCLUSIONS; IONIZATION MASS-SPECTROMETRY; MOLECULAR-WEIGHT COMPLEXES; EXPRESSING HUMAN SOD1; FAMILIAL ALS; MUTANT SOD1; CU,ZN-SUPEROXIDE DISMUTASE; PROTEIN AGGREGATION	Determining the composition of aggregated superoxide dismutase 1 (SOD1) species associated with amyotrophic lateral sclerosis (ALS), especially with respect to co-aggregated proteins and post-translational modifications, could identify cellular or biochemical factors involved in the formation of these aggregates and explain their apparent neurotoxicity. The results of mass spectrometric and shotgun-proteomic analyses of SOD1-containing aggregates isolated from spinal cords of symptomatic transgenic ALS mice using two different isolation strategies are presented, including 1) resistance to detergent extraction and 2) size exclusion-coupled anti-SOD1 immunoaffinity chromatography. Forty-eight spinal cords from three different ALS-SOD1 mutant mice were analyzed, namely G93A, G37R, and the unnatural double mutant H46R/H48Q. The analysis consistently revealed that the most abundant proteins recovered from aggregate species were full-length unmodified SOD1 polypeptides. Although aggregates from some spinal cord samples contained trace levels of highly abundant proteins, such as vimentin and neurofilament-3, no proteins were consistently found to co-purify with mutant SOD1 in stoichiometric quantities. The results demonstrate that the principal protein in the high molecular mass aggregates whose appearance correlates with symptoms of the disease is the unmodified, full-length SOD1 polypeptide.	[Whitelegge, Julian P.] Univ Calif Los Angeles, David Geffen Sch Med, NPI Semel Inst, Los Angeles, CA 90095 USA; [Shaw, Bryan F.; Lelie, Herman L.; Durazo, Armando; Chan, Pik K.; Gralla, Edith B.; Valentine, Joan S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Chem, Los Angeles, CA 90095 USA; [Shaw, Bryan F.; Lelie, Herman L.; Durazo, Armando; Chan, Pik K.; Gralla, Edith B.; Valentine, Joan S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biochem, Los Angeles, CA 90095 USA; [Nersissian, Aram M.] Occidental Coll, Dept Chem, Los Angeles, CA 90041 USA; [Xu, Guillan; Borchelt, David R.] Univ Florida, McKnight Brain Inst, Santa Fe Hlth Alzheimers Dis Res Ctr, Dept Neurosci, Gainesville, FL 32611 USA; [Tiwari, Ashutosh; Hayward, Lawrence J.] Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA 01605 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Occidental College; State University System of Florida; University of Florida; University of Massachusetts System; University of Massachusetts Worcester	Whitelegge, JP (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, NPI Semel Inst, 405 Hilgard Ave, Los Angeles, CA 90095 USA.	jpw@chem.ucla.edu	Valentine, Joan S/B-6665-2008; Shaw, Bryan/A-7001-2008; Tiwari, Ashutosh/A-7458-2008	Valentine, Joan S/0000-0002-7174-925X; Tiwari, Ashutosh/0000-0001-7373-349X; Hayward, Lawrence/0000-0003-0579-0358	NINDS NIH HHS [R01 NS 44170, P01 NS 049134-01, R01 NS044170, P01 NS049134] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044170, P01NS049134] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Banci L, 2007, P NATL ACAD SCI USA, V104, P11263, DOI 10.1073/pnas.0704307104; Basso M, 2006, J BIOL CHEM, V281, P33325, DOI 10.1074/jbc.M603489200; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Cheroni C, 2005, NEUROBIOL DIS, V18, P509, DOI 10.1016/j.nbd.2004.12.007; Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901; Choi JS, 2004, BIOCHEM BIOPH RES CO, V321, P574, DOI 10.1016/j.bbrc.2004.07.010; DE Beus MD, 2004, PROTEIN SCI, V13, P1347, DOI 10.1110/ps.03576904; DiDonato M, 2003, J MOL BIOL, V332, P601, DOI 10.1016/S0022-2836(03)00889-1; Elam JS, 2003, J BIOL CHEM, V278, P21032, DOI 10.1074/jbc.M300484200; Elam JS, 2003, NAT STRUCT BIOL, V10, P461, DOI 10.1038/nsb935; Gruzman A, 2007, P NATL ACAD SCI USA, V104, P12524, DOI 10.1073/pnas.0705044104; Hart PJ, 2006, CURR OPIN CHEM BIOL, V10, P131, DOI 10.1016/j.cbpa.2006.02.034; Hough MA, 2004, P NATL ACAD SCI USA, V101, P5976, DOI 10.1073/pnas.0305143101; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Jonsson PA, 2004, BRAIN, V127, P73, DOI 10.1093/brain/awh005; Kabashi E, 2006, BBA-MOL BASIS DIS, V1762, P1038, DOI 10.1016/j.bbadis.2006.06.006; Kato S, 1996, J NEUROPATH EXP NEUR, V55, P1089, DOI 10.1097/00005072-199655100-00009; Kato S, 2001, NEUROPATHOLOGY, V21, P67, DOI 10.1046/j.1440-1789.2001.00359.x; Kato S, 1997, AM J PATHOL, V151, P611; Kato S, 2000, ACTA NEUROPATHOL, V100, P490, DOI 10.1007/s004010000226; Kazmirski SL, 2002, NAT STRUCT BIOL, V9, P112, DOI 10.1038/nsb745; Kurahashi T, 2001, J AM CHEM SOC, V123, P9268, DOI 10.1021/ja015953r; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Maatkamp A, 2004, EUR J NEUROSCI, V20, P14, DOI 10.1111/j.1460-9568.2004.03430.x; Matsumoto G, 2005, J CELL BIOL, V171, P75, DOI 10.1083/jcb.200504050; Miyazaki K, 2004, J BIOL CHEM, V279, P11327, DOI 10.1074/jbc.M312389200; Niwa J, 2002, J BIOL CHEM, V277, P36793, DOI 10.1074/jbc.M206559200; Okado-Matsumoto A, 2002, P NATL ACAD SCI USA, V99, P9010, DOI 10.1073/pnas.132260399; Pasinelli P, 2004, NEURON, V43, P19, DOI 10.1016/j.neuron.2004.06.021; Pieri L, 2006, J BIOL CHEM, V281, P15337, DOI 10.1074/jbc.M511647200; Plakoutsi G, 2005, J MOL BIOL, V351, P910, DOI 10.1016/j.jmb.2005.06.043; Rakhit R, 2002, J BIOL CHEM, V277, P47551, DOI 10.1074/jbc.M207356200; Rodriguez JA, 2002, J BIOL CHEM, V277, P15932, DOI 10.1074/jbc.M112088200; Rodriguez JA, 2005, P NATL ACAD SCI USA, V102, P10516, DOI 10.1073/pnas.0502515102; Shaw BF, 2007, TRENDS BIOCHEM SCI, V32, P78, DOI 10.1016/j.tibs.2006.12.005; Shaw BF, 2006, J BIOL CHEM, V281, P18167, DOI 10.1074/jbc.M600623200; Shibata N, 1996, J NEUROPATH EXP NEUR, V55, P481, DOI 10.1097/00005072-199604000-00011; Shinder GA, 2001, J BIOL CHEM, V276, P12791, DOI 10.1074/jbc.M010759200; Sorgjerd K, 2006, J MOL BIOL, V356, P469, DOI 10.1016/j.jmb.2005.11.051; Stieber A, 2000, J NEUROL SCI, V173, P53, DOI 10.1016/S0022-510X(99)00300-7; Stokin GB, 2005, SCIENCE, V307, P1282, DOI 10.1126/science.1105681; Taylor DM, 2007, J BIOL CHEM, V282, P16329, DOI 10.1074/jbc.M610119200; Tiwari A, 2003, J BIOL CHEM, V278, P5984, DOI 10.1074/jbc.M210419200; Tortarolo M, 2006, J NEUROSCI RES, V83, P134, DOI 10.1002/jnr.20715; Urushitani M, 2002, J NEUROCHEM, V83, P1030, DOI 10.1046/j.1471-4159.2002.01211.x; Urushitani M, 2004, J NEUROCHEM, V90, P231, DOI 10.1111/j.1471-4159.2004.02486.x; Valentine JS, 2002, FREE RADICAL BIO MED, V33, P1314, DOI 10.1016/S0891-5849(02)01080-8; Valentine JS, 2005, ANNU REV BIOCHEM, V74, P563, DOI 10.1146/annurev.biochem.72.121801.161647; Vermeiren C, 2006, J NEUROCHEM, V96, P719, DOI 10.1111/j.1471-4159.2005.03577.x; Wang J, 2003, HUM MOL GENET, V12, P2753, DOI 10.1093/hmg/ddg312; Wang J, 2005, HUM MOL GENET, V14, P2335, DOI 10.1093/hmg/ddi236; Wang J, 2002, NEUROBIOL DIS, V10, P128, DOI 10.1006/nbdi.2002.0498; Wang J, 2005, NEUROBIOL DIS, V20, P943, DOI 10.1016/j.nbd.2005.06.005; Wang J, 2002, NEUROBIOL DIS, V9, P139, DOI 10.1006/nbdi.2001.0471; Watanabe M, 2001, NEUROBIOL DIS, V8, P933, DOI 10.1006/nbdi.2001.0443; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Whitelegge JP, 2004, PHYTOCHEMISTRY, V65, P1507, DOI 10.1016/j.phytochem.2004.05.018; Whitelegge JP, 2002, MOL CELL PROTEOMICS, V1, P816, DOI 10.1074/mcp.M200045-MCP200; Whitelegge JP, 1998, PROTEIN SCI, V7, P1423, DOI 10.1002/pro.5560070619; Whitelegge JP, 2000, PROTEIN SCI, V9, P1618, DOI 10.1110/ps.9.9.1618; Zhang H, 2004, FREE RADICAL BIO MED, V37, P2018, DOI 10.1016/j.freeradbiomed.2004.08.026	62	71	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8340	8350		10.1074/jbc.M707751200	http://dx.doi.org/10.1074/jbc.M707751200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18192269	hybrid, Green Published			2022-12-25	WOS:000254288000032
J	Montanuy, I; Torremocha, R; Hernandez-Munain, C; Sune, C				Montanuy, Immaculada; Torremocha, Rosana; Hernandez-Munain, Cristina; Sune, Carlos			Promoter influences transcription elongation - TATA-box element mediates the assembly of processive transcription complexes responsive to cyclin-dependent kinase 9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; LONG TERMINAL REPEAT; VIRUS TYPE-1 TRANSCRIPTION; C-MYC GENE; P-TEFB; MESSENGER-RNA; IN-VITRO; INDUCED EXPRESSION; INITIATOR ELEMENT; TRANS-ACTIVATION	Pausing of RNA polymerase II ( RNAPII) during transcript elongation is an important mechanism for regulating gene expression at many genes. In this study we investigated the mechanism of regulated elongation of c-myc and human immunodeficiency virus-1 ( HIV-1) using an in vitro elongation assay that reproduces the conditional block to elongation. We found that HIV-1 Tat can activate the RNAPII transcription complexes paused on c-myc by enhancing their elongation efficiency. We determined that cyclin-dependent kinase 9 ( CDK9), the kinase subunit of positive transcription elongation factor b ( P-TEFb) complex, regulates transcriptional elongation of c-myc and is present in transcription pre-initiation complexes formed on the c-myc promoter, which emphasizes a common mechanism of elongation control between HIV-1 and c-myc genes. We also investigated the roles of upstream elements of the HIV-1 and c-myc promoters in CDK9-activated transcriptional elongation. We found that the TATA-box element mediates the assembly of processive transcription complexes responsive to CDK9 and that specific combinations of upstream activation binding sites contribute to the recruitment of these complexes. We propose a common mechanism for elongation control at the c-myc and HIV-1 genes with an essential role for the TATA-box and specific modulatory contribution of upstream regulatory sequences, derived from the unique structure of the promoters, to form a composite surface for efficient recruitment of elongation-competent transcription complexes.	[Montanuy, Immaculada; Torremocha, Rosana; Sune, Carlos] CSIC, Inst Parasitol & Biomed Lopez Neyra, Parque Tecnol Ciencias Salud, Granada 18100, Spain; [Montanuy, Immaculada; Torremocha, Rosana; Sune, Carlos] CSIC, Dept Mol Biol, Granada 18100, Spain; [Hernandez-Munain, Cristina] CSIC, Dept Cell Biol & Immunol, Granada 18100, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); Consejo Superior de Investigaciones Cientificas (CSIC); Consejo Superior de Investigaciones Cientificas (CSIC)	Sune, C (corresponding author), CSIC, Inst Parasitol & Biomed Lopez Neyra, Parque Tecnol Ciencias Salud, Avenida Conocimiento S-N, Granada 18100, Spain.	csune@ipb.csic.es	Suñé, Carlos/AAA-8198-2019; de Munain, Cristina Hernandez Lopez/S-4389-2018	Suñé, Carlos/0000-0002-7991-0458; de Munain, Cristina Hernandez Lopez/0000-0002-6058-2458; Montanuy Sellart, Inmaculada/0000-0001-9743-112X				Barboric M, 2001, MOL CELL, V8, P327, DOI 10.1016/S1097-2765(01)00314-8; Batsche E, 2006, NAT STRUCT MOL BIOL, V13, P22, DOI 10.1038/nsmb1030; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BERKHOUT B, 1992, J VIROL, V66, P139, DOI 10.1128/JVI.66.1.139-149.1992; BIELINSKA A, 1989, J VIROL, V63, P4097, DOI 10.1128/JVI.63.9.4097-4100.1989; BIRAGYN A, 1995, J IMMUNOL, V155, P674; Campanero MR, 1999, MOL CELL BIOL, V19, P8442; CHINSKY JM, 1989, J BIOL CHEM, V264, P14561; CULLEN BR, 1993, CELL, V73, P417, DOI 10.1016/0092-8674(93)90126-B; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; GarciaMartinez LF, 1997, J BIOL CHEM, V272, P6951, DOI 10.1074/jbc.272.11.6951; HARLOW E, 1999, USING ANTIBODIES LAB, P521; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Kornblihtt AR, 2005, CURR OPIN CELL BIOL, V17, P262, DOI 10.1016/j.ceb.2005.04.014; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; KRUMM A, 1993, BIOESSAYS, V15, P659, DOI 10.1002/bies.950151005; Lee JM, 1997, J BIOL CHEM, V272, P10990; LONDON L, 1991, MOL CELL BIOL, V11, P4599, DOI 10.1128/MCB.11.9.4599; MAJELLO B, 1995, ONCOGENE, V10, P1841; Majello B, 1999, ONCOGENE, V18, P4598, DOI 10.1038/sj.onc.1202822; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; MCGEADY ML, 1986, DNA-J MOLEC CELL BIO, V5, P289, DOI 10.1089/dna.1986.5.289; Nogues G, 2002, J BIOL CHEM, V277, P43110, DOI 10.1074/jbc.M208418200; OLSEN HS, 1992, J VIROL, V66, P5594, DOI 10.1128/JVI.66.9.5594-5597.1992; Peterlin BM, 2006, MOL CELL, V23, P297, DOI 10.1016/j.molcel.2006.06.014; Pinaud S, 1998, J MOL BIOL, V280, P785, DOI 10.1006/jmbi.1998.1905; Ping YH, 1999, J BIOL CHEM, V274, P7399, DOI 10.1074/jbc.274.11.7399; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Raha T, 2005, PLOS BIOL, V3, P221, DOI 10.1371/journal.pbio.0030044; Ranish JA, 1999, GENE DEV, V13, P49, DOI 10.1101/gad.13.1.49; Raschke EE, 1999, J IMMUNOL, V163, P4375; RATNASABAPATHY R, 1990, GENE DEV, V4, P2061, DOI 10.1101/gad.4.12a.2061; RITTNER K, 1995, J MOL BIOL, V248, P562, DOI 10.1006/jmbi.1995.0243; Rosonina E, 2003, J BIOL CHEM, V278, P43034, DOI 10.1074/jbc.M307289200; Sanchez-Alvarez M, 2006, MOL CELL BIOL, V26, P4998, DOI 10.1128/MCB.01991-05; Sim RJ, 2004, GENE DEV, V18, P2437, DOI 10.1101/gad.1235904; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SPENCER CA, 1990, ONCOGENE, V5, P777; SUNE C, 1995, J VIROL, V69, P3098; Sune C, 1999, MOL CELL BIOL, V19, P4719; Sune C, 1997, MOL CELL BIOL, V17, P6029, DOI 10.1128/MCB.17.10.6029; Sune C, 2000, VIROLOGY, V274, P356, DOI 10.1006/viro.2000.0480; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; WRIGHT S, 1994, J MOL BIOL, V243, P568, DOI 10.1016/0022-2836(94)90031-0; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Yedavalli VSRK, 2003, J BIOL CHEM, V278, P6404, DOI 10.1074/jbc.M209162200; ZEICHNER SL, 1991, J VIROL, V65, P2436, DOI 10.1128/JVI.65.5.2436-2444.1991; ZENZIEGREGORY B, 1993, J BIOL CHEM, V268, P15823; Zhang ZQ, 2007, J BIOL CHEM, V282, P16981, DOI 10.1074/jbc.M610688200; Zhou MS, 2000, MOL CELL BIOL, V20, P5077, DOI 10.1128/MCB.20.14.5077-5086.2000; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	57	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7368	7378		10.1074/jbc.M706243200	http://dx.doi.org/10.1074/jbc.M706243200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18218627	hybrid			2022-12-25	WOS:000253997900011
J	Bortner, CD; Sifre, MI; Cidlowski, JA				Bortner, Carl D.; Sifre, Maria I.; Cidlowski, John A.			Cationic gradient reversal and cytoskeleton-independent volume regulatory pathways define an early stage of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE DEPOLARIZATION; FAS-INDUCED APOPTOSIS; CELL-VOLUME; ACTIN CYTOSKELETON; MEDIATED APOPTOSIS; ACTIVATION; SHRINKAGE; DEATH; K+; MECHANISMS	Cell shrinkage, or apoptotic volume decrease ( AVD), is a ubiquitous characteristic of programmed cell death that is independent of the death stimulus and occurs in all examples of apoptosis. Here we distinguished two specific stages of AVD based on cell size and a unique early reversal of intracellular ions that occurs in response to activation of both intrinsic and extrinsic cell death signal pathways. The primary stage of AVD is characterized by an early exchange of the normal intracellular ion distribution for sodium from 12 to 113.6 mM and potassium from 139.5 to 30 mM. This early ionic reversal is associated with a 20 - 40% decrease in cell volume, externalization of phosphatidylserine, loss of mitochondrial membrane potential, and caspase activation and activity along with nuclear condensation that occurs independent of actin cytoskeleton disruption. Disruption of the actin cytoskeleton, however, prevents a secondary stage of AVD in apoptotic cells, characterized by a loss of both potassium and sodium that results in an 80 - 85% loss in cell volume, DNA degradation, and apoptotic body formation. Together these studies demonstrate that AVD occurs in two distinct stages with the earliest stage reflecting a cellular cationic gradient reversal.	[Bortner, Carl D.; Sifre, Maria I.; Cidlowski, John A.] NIEHS, NIH, Dept Hlth & Human Serv, Lab Signal Transduct, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Bortner, CD (corresponding author), 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	bortner@niehs.nih.gov	Cidlowski, John A/G-2548-2019	Cidlowski, John A/0000-0003-1420-0516	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZICES102486, ZIAES090079] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 ES090079-12] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		BARBIERO G, 1995, EXP CELL RES, V217, P410, DOI 10.1006/excr.1995.1104; Barros LF, 2002, BIOL RES, V35, P209; Benson RSP, 1996, AM J PHYSIOL-CELL PH, V270, pC1190, DOI 10.1152/ajpcell.1996.270.4.C1190; Bortner CD, 1998, BIOCHEM PHARMACOL, V56, P1549, DOI 10.1016/S0006-2952(98)00225-1; Bortner CD, 2004, PFLUG ARCH EUR J PHY, V448, P313, DOI 10.1007/s00424-004-1266-5; Bortner CD, 2003, J BIOL CHEM, V278, P39176, DOI 10.1074/jbc.M303516200; Bortner CD, 2002, ANNU REV PHARMACOL, V42, P259, DOI 10.1146/annurev.pharmtox.42.083101.143836; Bortner CD, 2001, J BIOL CHEM, V276, P4304, DOI 10.1074/jbc.M005171200; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; Cain K, 2001, J BIOL CHEM, V276, P41985, DOI 10.1074/jbc.M107419200; COTTER TG, 1992, CANCER RES, V52, P997; Domnina LV, 2004, CELL BIOL INT, V28, P471, DOI 10.1016/j.cellbi.2004.03.017; Gomez-Angelats M, 2000, CELL TISSUE RES, V301, P33, DOI 10.1007/s004410000216; Grzanka A, 2003, BIOCHEM PHARMACOL, V66, P1611, DOI 10.1016/S0006-2952(03)00532-X; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hoffmann EK, 1995, INT REV CYTOL, V161, P173; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Lang F, 2000, CELL PHYSIOL BIOCHEM, V10, P417, DOI 10.1159/000016367; Lauber K, 2004, MOL CELL, V14, P277, DOI 10.1016/S1097-2765(04)00237-0; Levee MG, 1996, AM J PHYSIOL-CELL PH, V271, pC1981, DOI 10.1152/ajpcell.1996.271.6.C1981; Maeno E, 2000, P NATL ACAD SCI USA, V97, P9487, DOI 10.1073/pnas.140216197; Mann CL, 2001, ENDOCRINOLOGY, V142, P5059, DOI 10.1210/en.142.12.5059; Maruyama W, 2000, HISTOCHEM J, V32, P495, DOI 10.1023/A:1004104619154; Morley SC, 2003, J CELL BIOCHEM, V88, P1066, DOI 10.1002/jcb.10449; Nobel CSI, 2000, APOPTOSIS, V5, P153, DOI 10.1023/A:1009684713784; Papakonstanti EA, 2000, CELL PHYSIOL BIOCHEM, V10, P257, DOI 10.1159/000016366; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; SHENG M, 2000, ANNU REV PHYSIOL, V62, P79; Thompson GJ, 2001, BIOCHEM J, V357, P137, DOI 10.1042/0264-6021:3570137; Yamazaki Y, 2000, EXP CELL RES, V259, P64, DOI 10.1006/excr.2000.4970; Yu SP, 2000, P NATL ACAD SCI USA, V97, P9360, DOI 10.1073/pnas.97.17.9360	33	53	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					7219	7229		10.1074/jbc.M707809200	http://dx.doi.org/10.1074/jbc.M707809200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18187415	Green Accepted, hybrid			2022-12-25	WOS:000253779600067
J	Saddar, S; Dienhart, MK; Stuart, RA				Saddar, Sonika; Dienhart, Mary K.; Stuart, Rosemary A.			The F1F0-ATP synthase complex influences the assembly state of the cytochrome bc(1)-cytochrome oxidase supercomplex and its association with the TIM23 machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-CHAIN SUPERCOMPLEXES; MITOCHONDRIAL ATP SYNTHASE; TRANSLOCATION CONTACT SITES; C-OXIDASE; OXIDATIVE-PHOSPHORYLATION; SUBUNIT-E; SACCHAROMYCES-CEREVISIAE; CRISTAE MORPHOLOGY; YEAST MITOCHONDRIA; INNER MEMBRANE	The enzyme complexes involved in mitochondrial oxidative phosphorylation are organized into higher ordered assemblies termed supercomplexes. Subunits e and g (Su e and Su g, respectively) are catalytically nonessential subunits of the F1F0-ATP synthase whose presence is required to directly support the stable dimerization of the ATP synthase complex. We report here that Su g and Su e are also important for securing the correct organizational state of the cytochrome bc(1)-cytochrome oxidase ( COX) supercomplex. Mitochondria isolated from the Delta su e and Delta su g null mutant strains exhibit decreased levels of COX enzyme activity but appear to have normalCOXsubunit protein levels. An altered stoichiometry of the cytochrome bc(1)-COX supercomplex was observed in mitochondria deficient in Su e and/or Su g, and a perturbation in the association of Cox4, a catalytically important subunit of the COX complex, was also detected. In addition, an increase in the level of the TIM23 translocase associated with the cytochrome bc(1)-COX supercomplex is observed in the absence of Delta Su e and Su g. Together, our data highlight that a further level of complexity exists between the oxidative phosphorylation supercomplexes, whereby the organizational state of one complex, i.e. the ATP synthase, may influence that of another supercomplex, namely the cytochrome bc(1)-COX complex.	[Saddar, Sonika; Dienhart, Mary K.; Stuart, Rosemary A.] Marquette Univ, Dept Biol Sci, Milwaukee, WI 53233 USA	Marquette University	Stuart, RA (corresponding author), Marquette Univ, Dept Biol Sci, 530 N 15th St, Milwaukee, WI 53233 USA.	rosemary.stuart@marquette.edu			NIGMS NIH HHS [R01GM61573] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061573] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackerman SH, 2005, PROG NUCLEIC ACID RE, V80, P95, DOI 10.1016/S0079-6603(05)80003-0; ALLEN RD, 1995, PROTOPLASMA, V189, P1, DOI 10.1007/BF01280286; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Arnold I, 1997, FEBS LETT, V411, P195, DOI 10.1016/S0014-5793(97)00691-1; Arselin G, 2004, J BIOL CHEM, V279, P40392, DOI 10.1074/jbc.M404316200; Arselin G, 2003, EUR J BIOCHEM, V270, P1875, DOI 10.1046/j.1432-1033.2003.03557.x; Bernard DG, 2003, J BIOL CHEM, V278, P49732, DOI 10.1074/jbc.M308881200; Boekema EJ, 2007, J BIOL CHEM, V282, P1, DOI 10.1074/jbc.R600031200; Bornhovd C, 2006, J BIOL CHEM, V281, P13990, DOI 10.1074/jbc.M512334200; Boumans H, 1998, J BIOL CHEM, V273, P4872, DOI 10.1074/jbc.273.9.4872; Boumans H, 1998, BIOCHEM J, V331, P877, DOI 10.1042/bj3310877; Boyle GM, 1999, EUR J BIOCHEM, V262, P315, DOI 10.1046/j.1432-1327.1999.00345.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunner S, 2002, J BIOL CHEM, V277, P48484, DOI 10.1074/jbc.M209382200; Chacinska A, 2003, EMBO J, V22, P5370, DOI 10.1093/emboj/cdg532; Chacinska A, 2005, CELL, V120, P817, DOI 10.1016/j.cell.2005.01.011; Cruciat CM, 2000, J BIOL CHEM, V275, P18093, DOI 10.1074/jbc.M001901200; Devenish RJ, 2000, BBA-BIOENERGETICS, V1458, P428, DOI 10.1016/S0005-2728(00)00092-X; Dienhart M, 2002, J BIOL CHEM, V277, P39289, DOI 10.1074/jbc.M205720200; Donzeau M, 2000, CELL, V101, P401, DOI 10.1016/S0092-8674(00)80850-8; Dudkina NV, 2006, TRENDS PLANT SCI, V11, P232, DOI 10.1016/j.tplants.2006.03.007; Dudkina NV, 2005, P NATL ACAD SCI USA, V102, P3225, DOI 10.1073/pnas.0408870102; Everard-Gigot V, 2005, EUKARYOT CELL, V4, P346, DOI 10.1128/EC.4.2.346-355.2005; Gavin PD, 2004, J CELL SCI, V117, P2333, DOI 10.1242/jcs.01074; Gavin PD, 2003, BBA-BIOENERGETICS, V1607, P167, DOI 10.1016/j.bbabio.2003.09.013; Gilkerson RW, 2003, FEBS LETT, V546, P355, DOI 10.1016/S0014-5793(03)00633-1; Giraud MF, 2002, BBA-BIOENERGETICS, V1555, P174, DOI 10.1016/S0005-2728(02)00274-8; Heinemeyer J, 2007, J BIOL CHEM, V282, P12240, DOI 10.1074/jbc.M610545200; Herrmann J. M., 1994, CELL BIOL LAB HDB, VI, P538; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lemire BD, 2002, BBA-BIOENERGETICS, V1553, P102, DOI 10.1016/S0005-2728(01)00229-8; McKenzie M, 2006, J MOL BIOL, V361, P462, DOI 10.1016/j.jmb.2006.06.057; Mick DU, 2007, EMBO J, V26, P4347, DOI 10.1038/sj.emboj.7601862; Mokranjac D, 2005, J BIOL CHEM, V280, P23437, DOI 10.1074/jbc.C500135200; PAUL MF, 1989, EUR J BIOCHEM, V185, P163, DOI 10.1111/j.1432-1033.1989.tb15098.x; Paumard P, 2002, EMBO J, V21, P221, DOI 10.1093/emboj/21.3.221; Pfeiffer K, 2003, J BIOL CHEM, V278, P52873, DOI 10.1074/jbc.M308366200; Rak M, 2007, J BIOL CHEM, V282, P34039, DOI 10.1074/jbc.M703053200; Rak M, 2007, J BIOL CHEM, V282, P10853, DOI 10.1074/jbc.M608692200; Saddar S, 2005, J BIOL CHEM, V280, P24435, DOI 10.1074/jbc.M502804200; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; Schagger H, 2002, BBA-BIOENERGETICS, V1555, P154, DOI 10.1016/S0005-2728(02)00271-2; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; Schagger H, 2001, IUBMB LIFE, V52, P119, DOI 10.1080/15216540152845911; SHERMAN F, 1964, BIOCHIM BIOPHYS ACTA, V90, P1, DOI 10.1016/0304-4165(64)90113-8; Smeitink JA, 2006, CELL METAB, V3, P9, DOI 10.1016/j.cmet.2005.12.001; Soubannier V, 2002, J BIOL CHEM, V277, P10739, DOI 10.1074/jbc.M111882200; Spannagel C, 1998, BBA-BIOMEMBRANES, V1414, P260, DOI 10.1016/S0005-2736(98)00174-6; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; van der Laan M, 2006, CURR BIOL, V16, P2271, DOI 10.1016/j.cub.2006.10.025; Vogel F, 2006, J CELL BIOL, V175, P237, DOI 10.1083/jcb.200605138; Wurm CA, 2006, FEBS LETT, V580, P5628, DOI 10.1016/j.febslet.2006.09.012; Zhang M, 2002, J BIOL CHEM, V277, P43553, DOI 10.1074/jbc.C200551200	53	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					6677	6686		10.1074/jbc.M708440200	http://dx.doi.org/10.1074/jbc.M708440200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18187422	hybrid			2022-12-25	WOS:000253779600009
J	Metz, S; Naeth, G; Heinrich, PC; Muller-Newen, G				Metz, Silke; Naeth, Gudrun; Heinrich, Peter C.; Mueller-Newen, Gerhard			Novel inhibitors for murine and human leukemia inhibitory factor based on fused soluble receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOKINE BINDING DOMAIN; HUMAN INTERLEUKIN-6 RECEPTOR; IMMUNOGLOBULIN-LIKE DOMAIN; RHEUMATOID-ARTHRITIS; FACTOR LIF; IN-VITRO; LIGAND-BINDING; SYNOVIAL-FLUID; IL-6 RECEPTOR; ONCOSTATIN-M	Fusion proteins of the extracellular parts of cytokine receptors, also known as cytokine traps, turned out to be promising cytokine inhibitors useful in anti-cytokine therapies. Here we present newly designed cytokine traps for murine and human leukemia inhibitory factor (LIF) as prototypes for inhibitors targeting cytokines that signal through a heterodimer of two signaling receptors of the glycoprotein 130 (gp130) family. LIF signals through a receptor heterodimer of LIF receptor (LIFR) and gp130 and induces the tyrosine phosphorylation of STAT3 leading to target gene expression. The analysis of various receptor fusion and deletion constructs revealed that a truncated form of the murine LIF receptor consisting of the first five extracellular domains was a potent inhibitor for human LIF. For the efficient inhibition of murine LIF, the cytokine-binding module of murine gp130 had to be fused to the first five domains of murine LIFR generating mLIF-RFP (murine LIFR fusion protein). The tyrosine phosphorylation of STAT3 and subsequent gene induction induced by human or murine LIF are completely blocked by the respective inhibitor. Furthermore, both inhibitors are specific and do not alter the bioactivities of the closely related cytokines interleukin (IL)-6 and oncostatin M. The gained knowledge on the construction of LIF inhibitors can be transferred to the design of inhibitors for related cytokines such as IL-31, IL-27, and oncostatin M for the treatment of inflammatory and malignant diseases.	[Metz, Silke; Naeth, Gudrun; Heinrich, Peter C.; Mueller-Newen, Gerhard] Univ Klinikum RWTH Aachen, Inst Biochem, D-52074 Aachen, Germany	RWTH Aachen University; RWTH Aachen University Hospital	Muller-Newen, G (corresponding author), Univ Klinikum RWTH Aachen, Inst Biochem, Pauwelsstr 30, D-52074 Aachen, Germany.	mueller-newen@rwth-aachen.de						AARDEN LA, 1987, EUR J IMMUNOL, V17, P1411, DOI 10.1002/eji.1830171004; Aasland D, 2002, J MOL BIOL, V315, P637, DOI 10.1006/jmbi.2001.5282; Ancey C, 2003, J BIOL CHEM, V278, P16968, DOI 10.1074/jbc.C300081200; ARCONE R, 1991, EUR J BIOCHEM, V198, P541, DOI 10.1111/j.1432-1033.1991.tb16048.x; Bitard J, 2003, J BIOL CHEM, V278, P16253, DOI 10.1074/jbc.M207193200; Boulanger MJ, 2003, MOL CELL, V12, P577, DOI 10.1016/S1097-2765(03)00365-4; Boulay JL, 2003, IMMUNITY, V19, P159, DOI 10.1016/S1074-7613(03)00211-5; DELAGE G, 1995, HUM REPROD, V10, P2483; Diveu C, 2006, J BIOL CHEM, V281, P36673, DOI 10.1074/jbc.M607005200; Economides AN, 2003, NAT MED, V9, P47, DOI 10.1038/nm811; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; Giese B, 2003, J BIOL CHEM, V278, P39205, DOI 10.1074/jbc.M303347200; Goldenberg MM, 1999, CLIN THER, V21, P75, DOI 10.1016/S0149-2918(00)88269-7; Grotzinger J, 1997, PROTEINS, V27, P96; Hambartsoumian E, 1998, AM J REPROD IMMUNOL, V39, P137; He W, 2005, FEBS LETT, V579, P4317, DOI 10.1016/j.febslet.2005.06.061; He W, 2002, FEBS LETT, V514, P214, DOI 10.1016/S0014-5793(02)02367-0; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hermanns HM, 1999, J IMMUNOL, V163, P6651; HORSTEN U, 1995, FEBS LETT, V360, P43, DOI 10.1016/0014-5793(95)00053-C; Huyton T, 2007, P NATL ACAD SCI USA, V104, P12737, DOI 10.1073/pnas.0705577104; Ichihara M, 1997, BLOOD, V90, P165; Jazayeri JA, 2007, J INTERF CYTOK RES, V27, P281, DOI 10.1089/jir.2006.0138; Laird SM, 1997, HUM REPROD, V12, P569; LAYTON MJ, 1992, P NATL ACAD SCI USA, V89, P8616, DOI 10.1073/pnas.89.18.8616; LAYTON MJ, 1994, J BIOL CHEM, V269, P17048; LOTZ M, 1992, J CLIN INVEST, V90, P888, DOI 10.1172/JCI115964; Metz S, 2007, J BIOL CHEM, V282, P1238, DOI 10.1074/jbc.M606885200; MODRELL B, 1994, GROWTH FACTORS, V11, P81, DOI 10.3109/08977199409001050; Nishimoto N, 2004, ARTHRITIS RHEUM-US, V50, P1761, DOI 10.1002/art.20303; Ogata H, 2006, GASTROENTEROLOGY, V131, P179, DOI 10.1053/j.gastro.2006.04.025; Owczarek CM, 1997, J BIOL CHEM, V272, P23976, DOI 10.1074/jbc.272.38.23976; Piccinni MP, 1998, NAT MED, V4, P1020, DOI 10.1038/2006; Schlaak JF, 1996, CLIN EXP RHEUMATOL, V14, P155; Sharkey AM, 1999, BIOL REPROD, V60, P355, DOI 10.1095/biolreprod60.2.355; Simpson RJ, 1997, PROTEIN SCI, V6, P929, DOI 10.1002/pro.5560060501; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; VANDAM M, 1993, J BIOL CHEM, V268, P15285; Varghese JN, 2002, P NATL ACAD SCI USA, V99, P15959, DOI 10.1073/pnas.232432399; Voisin MB, 2002, J BIOL CHEM, V277, P13682, DOI 10.1074/jbc.M111624200; WARING PM, 1993, ARTHRITIS RHEUM, V36, P911, DOI 10.1002/art.1780360707; WEIERGRABER O, 1995, EUR J BIOCHEM, V234, P661, DOI 10.1111/j.1432-1033.1995.661_b.x	45	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2008	283	10					5985	5995		10.1074/jbc.M706610200	http://dx.doi.org/10.1074/jbc.M706610200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HM	18174171	hybrid			2022-12-25	WOS:000253779500003
J	Xiao, R; Tang, JS; Wang, CB; Colton, CK; Tian, JB; Zhu, MX				Xiao, Rui; Tang, Jisen; Wang, Chunbo; Colton, Craig K.; Tian, Jinbin; Zhu, Michael X.			Calcium plays a central role in the sensitization of TRPV3 channel to repetitive stimulations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; GATED ION-CHANNEL; CATION CHANNEL; 2-AMINOETHOXYDIPHENYL BORATE; VANILLOID RECEPTOR; HEAT; TEMPERATURE; CALMODULIN; ACTIVATION; DESENSITIZATION	Transient receptor potential channels are involved in sensing chemical and physical changes inside and outside of cells. TRPV3 is highly expressed in skin keratinocytes, where it forms a nonselective cation channel activated by hot temperatures in the innocuous and noxious range. The channel has also been implicated in flavor sensation in oral and nasal cavities as well as being a molecular target of some allergens and skin sensitizers. TRPV3 is unique in that its activity is sensitized upon repetitive stimulations. Here we investigated the role of calcium ions in the sensitization of TRPV3 to repetitive stimulations. We show that the sensitization is accompanied by a decrease of Ca2+-dependent channel inhibition mediated by calmodulin acting at an N-terminal site ( amino acids 108-130) and by an acidic residue (Asp(641)) at the pore loop of TRPV3. These sites also contribute to the voltage dependence of TRPV3. During sensitization, the channel displayed a gradual shift of the voltage dependence to more negative potentials as well as uncoupling from voltage sensing. The initial response to ligand stimulation was increased and sensitization to repetitive stimulations was decreased by increasing the intracellular Ca2+-buffering strength, inhibiting calmodulin, or disrupting the calmodulin-binding site. Mutation of Asp(641) to Asn abolished the high affinity extracellular Ca2+-mediated inhibition and greatly facilitated the activation of TRPV3. We conclude that Ca2+ inhibits TRPV3 from both the extracellular and intracellular sides. The inhibition is sequentially reduced, appearing as sensitization to repetitive stimulations.	[Xiao, Rui; Tang, Jisen; Wang, Chunbo; Colton, Craig K.; Tian, Jinbin; Zhu, Michael X.] Ohio State Univ, Ctr Mol Neurobiol, Columbus, OH 43210 USA; [Xiao, Rui; Tang, Jisen; Wang, Chunbo; Colton, Craig K.; Tian, Jinbin; Zhu, Michael X.] Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; [Xiao, Rui; Zhu, Michael X.] Ohio State Univ, Biophys Grad Program, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Zhu, MX (corresponding author), Ohio State Univ, Ctr Mol Neurobiol, 168 Rightmire Hall,1060 Carmack Rd, Columbus, OH 43210 USA.	zhu.55@osu.edu	tian, jinbin/L-6006-2019; Xiao, Rui/G-1193-2011; Tian, JinBin/B-7001-2019	Tian, JinBin/0000-0002-5516-7778; Xiao, Rui/0000-0001-5541-6685	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS056942, P30NS045758, R01NS042183] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS042183-03, P30 NS045758-039003, R01 NS042183-04, R01 NS 042183, P30 NS045758, P30 NS 045758, P30 NS045758-049003, R21 NS 056942, R21 NS056942-01, R21 NS056942, R01 NS042183, R21 NS056942-01S1] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Asakawa M, 2006, J INVEST DERMATOL, V126, P2664, DOI 10.1038/sj.jid.5700468; Bautista DM, 2006, CELL, V124, P1269, DOI 10.1016/j.cell.2006.02.023; Bhave G, 2002, NEURON, V35, P721, DOI 10.1016/S0896-6273(02)00802-4; Calixto JB, 2005, PHARMACOL THERAPEUT, V106, P179, DOI 10.1016/j.pharmthera.2004.11.008; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Chung MK, 2005, J BIOL CHEM, V280, P15928, DOI 10.1074/jbc.M500596200; Chung MK, 2004, J BIOL CHEM, V279, P21569, DOI 10.1074/jbc.M401872200; Chung MK, 2004, J NEUROSCI, V24, P5177, DOI 10.1523/JNEUROSCI.0934-04.2004; Chung MK, 2003, J BIOL CHEM, V278, P32037, DOI 10.1074/jbc.M303251200; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Dalton P, 2002, NAT NEUROSCI, V5, P199, DOI 10.1038/nn803; Delwiche J, 2004, FOOD QUAL PREFER, V15, P137, DOI 10.1016/S0950-3293(03)00041-7; Garcia-Martinez C, 2000, J BIOL CHEM, V275, P32552, DOI 10.1074/jbc.M002391200; Hu HZ, 2006, J CELL PHYSIOL, V208, P201, DOI 10.1002/jcp.20648; Hu HZ, 2004, J BIOL CHEM, V279, P35741, DOI 10.1074/jbc.M404164200; Jordt SE, 2003, CURR OPIN NEUROBIOL, V13, P487, DOI 10.1016/S0959-4388(03)00101-6; Liu M, 2003, J BIOL CHEM, V278, P5462, DOI 10.1074/jbc.M209111200; Matta JA, 2007, J PHYSIOL-LONDON, V585, P469, DOI 10.1113/jphysiol.2007.144287; Moqrich A, 2005, SCIENCE, V307, P1468, DOI 10.1126/science.1108609; Naraghi M, 1997, J NEUROSCI, V17, P6961; Nilius B, 2004, AM J PHYSIOL-CELL PH, V286, pC195, DOI 10.1152/ajpcell.00365.2003; Nilius B, 2005, J PHYSIOL-LONDON, V567, P35, DOI 10.1113/jphysiol.2005.088377; Nilius B, 2003, J BIOL CHEM, V278, P30813, DOI 10.1074/jbc.M305127200; Numazaki M, 2003, P NATL ACAD SCI USA, V100, P8002, DOI 10.1073/pnas.1337252100; Owsianik G, 2006, ANNU REV PHYSIOL, V68, P685, DOI 10.1146/annurev.physiol.68.040204.101406; Patapoutian A, 2003, NAT REV NEUROSCI, V4, P529, DOI 10.1038/nrn1141; Peier AM, 2002, SCIENCE, V296, P2046, DOI 10.1126/science.1073140; STERN MD, 1992, CELL CALCIUM, V13, P183, DOI 10.1016/0143-4160(92)90046-U; Talavera K, 2005, NATURE, V438, P1022, DOI 10.1038/nature04248; Tang J, 2001, J BIOL CHEM, V276, P21303, DOI 10.1074/jbc.M102316200; Togashi K, 2006, EMBO J, V25, P1804, DOI 10.1038/sj.emboj.7601083; Turner H, 2003, BIOCHEM J, V371, P341, DOI 10.1042/BJ20021381; Voets T, 2004, J BIOL CHEM, V279, P19, DOI 10.1074/jbc.M311201200; Voets T, 2003, J GEN PHYSIOL, V121, P245, DOI 10.1085/jgp.20028752; Voets T, 2002, J BIOL CHEM, V277, P33704, DOI 10.1074/jbc.M204828200; Voets T, 2004, NATURE, V430, P748, DOI 10.1038/nature02732; Wang CB, 2004, J BIOL CHEM, V279, P37423, DOI 10.1074/jbc.M407205200; XIAO R, 2008, CELL CALCIUM; Xu HX, 2006, NAT NEUROSCI, V9, P628, DOI 10.1038/nn1692; Xu HX, 2002, NATURE, V418, P181, DOI 10.1038/nature00882; Zhang Z, 2005, J BIOL CHEM, V280, P39185, DOI 10.1074/jbc.M506965200; Zhang ZM, 2001, P NATL ACAD SCI USA, V98, P3168, DOI 10.1073/pnas.051632698; Zhu MX, 2005, PFLUG ARCH EUR J PHY, V451, P105, DOI 10.1007/s00424-005-1427-1	43	75	77	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2008	283	10					6162	6174		10.1074/jbc.M706535200	http://dx.doi.org/10.1074/jbc.M706535200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HM	18178557	Green Accepted, hybrid			2022-12-25	WOS:000253779500023
J	Goto, E; Mito-Yoshida, M; Uematsu, M; Aoki, M; Matsuki, Y; Ohmura-Hoshino, M; Hotta, H; Miyagishi, M; Ishido, S				Goto, Eiji; Mito-Yoshida, Mari; Uematsu, Mika; Aoki, Masami; Matsuki, Yohei; Ohmura-Hoshino, Mari; Hotta, Hak; Miyagishi, Makoto; Ishido, Satoshi			An Excellent Monitoring System for Surface Ubiquitination-Induced Internalization in Mammals	PLOS ONE			English	Article								Background. At present, it is difficult to visualize the internalization of surface receptors induced by ubiquitination that is taken place at the plasma membrane in mammals. This problem makes it difficult to reveal molecular basis for ubiquitination-mediated internalization in mammals. Methodology/Principle Findings. In order to overcome it, we have generated T-REx-c-MIR, a novel mammalian Tet-on B cell line using a constitutively active E3 ubiquitin ligase, c-MIR, and its artificial target molecule. By applying the surface biotinylation method to T-REx-c-MIR, we succeeded to monitor the fate of surface target molecules after initiation of ubiquitination process by doxycycline (Dox)-induced c-MIR expression. Target molecules that preexisted at the plasma membrane before induction of c-MIR expression were oligo-ubiquitinated and degraded by Dox-induced c-MIR expression. Dox-induced c-MIR expression initiated rapid internalization of surface target molecules, and blockage of the internalization induced the accumulation of the surface target molecules that were newly ubiquitinated by c-MIR. Inhibition of the surface ubiquitination by down-regulating ubiquitin conjugating enzyme E2 impaired the internalization of target molecules. Finally, a complex of c-MIR and target molecule was detected at the plasma membrane. Conclusions/Significances. These results demonstrate that in T-REx-c-MIR, surface target molecule is ubiquitinated at the plasma membrane and followed by being internalized from the plasma membrane. Thus, T-REx-c-MIR is a useful experimental tool to analyze how surface ubiquitination regulates internalization in mammals.	[Goto, Eiji; Mito-Yoshida, Mari; Uematsu, Mika; Aoki, Masami; Matsuki, Yohei; Ohmura-Hoshino, Mari; Ishido, Satoshi] RIKEN, Res Ctr Allergy & Immunol, Lab Infect Immun, Yokohama, Kanagawa, Japan; [Hotta, Hak] Kobe Univ, Grad Sch Med, Dept Pathol & Microbiol, Kobe, Hyogo, Japan; [Miyagishi, Makoto] Univ Tokyo, Sch Med, Century 21 COE Prog, Tokyo, Japan	RIKEN; Kobe University; University of Tokyo	Ishido, S (corresponding author), RIKEN, Res Ctr Allergy & Immunol, Lab Infect Immun, Yokohama, Kanagawa, Japan.	ishido@rcai.riken.jp	Miyagishi, Makoto/L-8174-2016	Miyagishi, Makoto/0000-0001-7654-3616	Ministry of Education, Science, Sports, and Culture (MEXT) of Japan [Grant-in-Aid for Scientific Research]; Japan Society for the Promotion of Science (JSPS)	Ministry of Education, Science, Sports, and Culture (MEXT) of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports, and Culture (MEXT) of Japan and by the Japan Society for the Promotion of Science (JSPS).	BAKER A, 1995, LEUKEMIA RES, V19, P309, DOI 10.1016/0145-2126(94)00128-W; Barriere H, 2006, TRAFFIC, V7, P282, DOI 10.1111/j.1600-0854.2006.00384.x; Bartee E, 2004, J VIROL, V78, P1109, DOI 10.1128/JVI.78.3.1109-1120.2004; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Coscoy L, 2000, P NATL ACAD SCI USA, V97, P8051, DOI 10.1073/pnas.140129797; Duncan LM, 2006, EMBO J, V25, P1635, DOI 10.1038/sj.emboj.7601056; Dupre S, 2004, BBA-MOL CELL RES, V1695, P89, DOI 10.1016/j.bbamcr.2004.09.024; Goto E, 2003, J BIOL CHEM, V278, P14657, DOI 10.1074/jbc.M211285200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hewitt EW, 2002, EMBO J, V21, P2418, DOI 10.1093/emboj/21.10.2418; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Ishido S, 2000, J VIROL, V74, P5300, DOI 10.1128/JVI.74.11.5300-5309.2000; Kamsteeg EJ, 2006, P NATL ACAD SCI USA, V103, P18344, DOI 10.1073/pnas.0604073103; Lehner PJ, 2005, IMMUNOL REV, V207, P112, DOI 10.1111/j.0105-2896.2005.00314.x; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Matsuki Y, 2007, EMBO J, V26, P846, DOI 10.1038/sj.emboj.7601556; Matsumoto Sahohime, 2007, Methods Mol Biol, V360, P131; Mukhopadhyay D, 2007, SCIENCE, V315, P201, DOI 10.1126/science.1127085; Ohmura-Hoshino M, 2006, J BIOCHEM, V140, P147, DOI 10.1093/jb/mvj160; Ohmura-Hoshino M, 2006, J IMMUNOL, V177, P341, DOI 10.4049/jimmunol.177.1.341; RIDGE SA, 1990, P NATL ACAD SCI USA, V87, P1377, DOI 10.1073/pnas.87.4.1377; Ryan PE, 2006, TRENDS BIOCHEM SCI, V31, P79, DOI 10.1016/j.tibs.2005.12.004; Sanchez DJ, 2002, J BIOL CHEM, V277, P6124, DOI 10.1074/jbc.M110265200; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Stevenson PG, 2000, P NATL ACAD SCI USA, V97, P8455, DOI 10.1073/pnas.150240097; Thien CBF, 2005, BIOCHEM J, V391, P153, DOI 10.1042/BJ20050892; Zhou RF, 2007, J BIOL CHEM, V282, P20207, DOI 10.1074/jbc.M611329200	29	12	12	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2008	3	1							e1490	10.1371/journal.pone.0001490	http://dx.doi.org/10.1371/journal.pone.0001490			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SR	18231577	Green Submitted, gold, Green Published			2022-12-25	WOS:000260504200003
J	Le Mee, G; Ezzeddine, N; Capri, M; Ait-Ahmed, O				Le Mee, Gwenn; Ezzeddine, Nader; Capri, Michele; Ait-Ahmed, Ounissa			Repeat Length and RNA Expression Level Are Not Primary Determinants in CUG Expansion Toxicity in Drosophila Models	PLOS ONE			English	Article								Evidence for an RNA gain-of-function toxicity has now been provided for an increasing number of human pathologies. Myotonic dystrophies (DM) belong to a class of RNA-dominant diseases that result from RNA repeat expansion toxicity. Specifically, DM of type 1 (DM1), is caused by an expansion of CUG repeats in the 39UTR of the DMPK protein kinase mRNA, while DM of type 2 (DM2) is linked to an expansion of CCUG repeats in an intron of the ZNF9 transcript (ZNF9 encodes a zinc finger protein). In both pathologies the mutant RNA forms nuclear foci. The mechanisms that underlie the RNA pathogenicity seem to be rather complex and not yet completely understood. Here, we describe Drosophila models that might help unravelling the molecular mechanisms of DM1-associated CUG expansion toxicity. We generated transgenic flies that express inducible repeats of different type (CUG or CAG) and length (16, 240, 480 repeats) and then analyzed transgene localization, RNA expression and toxicity as assessed by induced lethality and eye neurodegeneration. The only line that expressed a toxic RNA has a (CTG) 240 insertion. Moreover our analysis shows that its level of expression cannot account for its toxicity. In this line, (CTG) 240.4, the expansion inserted in the first intron of CG9650, a zinc finger protein encoding gene. Interestingly, CG9650 and (CUG) 240.4 expansion RNAs were found in the same nuclear foci. In conclusion, we suggest that the insertion context is the primary determinant for expansion toxicity in Drosophila models. This finding should contribute to the still open debate on the role of the expansions per se in Drosophila and in human pathogenesis of RNA-dominant diseases.	[Le Mee, Gwenn; Ezzeddine, Nader; Capri, Michele; Ait-Ahmed, Ounissa] CNRS, Inst Genet Humaine, Unite Propre Rech 1142, Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Ait-Ahmed, O (corresponding author), CNRS, Inst Genet Humaine, Unite Propre Rech 1142, Montpellier, France.	Ounissa.Ait-ahmed@igh.cnrs.fr			CNRS; AFM; MRT;  [French national PhD programme];  [AFM fellowship]	CNRS(Centre National de la Recherche Scientifique (CNRS)); AFM(Association Francaise contre les Myopathies); MRT; ; 	This work was supported by the CNRS (Centre National de la Recherche Scientifique) and an AFM (Association Francaise contre les Myopathies) grant to OA. GLM was supported by a 3 year fellowship of the French national PhD programme (MRT) and a 1 year AFM fellowship. NE was supported by a 2 year AFM fellowship.	Amack JD, 1999, HUM MOL GENET, V8, P1975, DOI 10.1093/hmg/8.11.1975; Amack JD, 2001, HUM MOL GENET, V10, P1879, DOI 10.1093/hmg/10.18.1879; Begemann G, 1997, DEVELOPMENT, V124, P4321; Bilen J, 2005, ANNU REV GENET, V39, P153, DOI 10.1146/annurev.genet.39.110304.095804; BRAND AH, 1993, DEVELOPMENT, V118, P401; BROOK, 1992, CELL, V69, P385; Budnik V, 1996, CURR OPIN NEUROBIOL, V6, P858, DOI 10.1016/S0959-4388(96)80038-9; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; Capri M, 1997, MECH DEVELOP, V68, P91, DOI 10.1016/S0925-4773(97)00130-5; de Haro M, 2006, HUM MOL GENET, V15, P2138, DOI 10.1093/hmg/ddl137; Delaunay J, 2004, NUCLEIC ACIDS RES, V32, P3070, DOI 10.1093/nar/gkh627; Ezzeddine N, 2002, P NATL ACAD SCI USA, V99, P257, DOI 10.1073/pnas.012555499; FOUTS D, 1988, GENE, V63, P261, DOI 10.1016/0378-1119(88)90530-6; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; Ho TH, 2005, J CELL SCI, V118, P2923, DOI 10.1242/jcs.02404; Houseley JM, 2005, HUM MOL GENET, V14, P873, DOI 10.1093/hmg/ddi080; Kalifa Y, 2006, DEV CELL, V10, P291, DOI 10.1016/j.devcel.2006.01.001; Kim DH, 2005, NUCLEIC ACIDS RES, V33, P3866, DOI 10.1093/nar/gki698; Koob MD, 1999, NAT GENET, V21, P379, DOI 10.1038/7710; Liquori CL, 2001, SCIENCE, V293, P864, DOI 10.1126/science.1062125; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; Mahadevan MS, 2006, NAT GENET, V38, P1066, DOI 10.1038/ng1857; Mankodi A, 2000, SCIENCE, V289, P1769, DOI 10.1126/science.289.5485.1769; Margolis JM, 2006, HUM MOL GENET, V15, P1808, DOI 10.1093/hmg/ddl103; McGovern VL, 2003, MECH DEVELOP, V120, P1193, DOI 10.1016/s0925-4773(03)00159-X; Michalowski S, 1999, NUCLEIC ACIDS RES, V27, P3534, DOI 10.1093/nar/27.17.3534; Miller JW, 2000, EMBO J, V19, P4439, DOI 10.1093/emboj/19.17.4439; MOSES K, 1989, NATURE, V340, P531, DOI 10.1038/340531a0; Mutsuddi M, 2004, CURR BIOL, V14, P302, DOI 10.1016/j.cub.2004.01.034; O'Kane CJ, 2003, SEMIN CELL DEV BIOL, V14, P3, DOI 10.1016/S1084-9521(02)00162-3; Paul S, 2006, EMBO J, V25, P4271, DOI 10.1038/sj.emboj.7601296; Philips AV, 1998, SCIENCE, V280, P737, DOI 10.1126/science.280.5364.737; Ranum L.P., 2006, ANN REV NEUROSCI; Ranum LPW, 1998, NAT GENET, V19, P196, DOI 10.1038/570; Roberts R, 1997, P NATL ACAD SCI USA, V94, P13221, DOI 10.1073/pnas.94.24.13221; Rorth P, 1998, MECH DEVELOP, V78, P113, DOI 10.1016/S0925-4773(98)00157-9; Seznec H, 2001, HUM MOL GENET, V10, P2717, DOI 10.1093/hmg/10.23.2717; SHAW DJ, 1989, BRIT MED BULL, V45, P745, DOI 10.1093/oxfordjournals.bmb.a072355; Timchenko LT, 1996, NUCLEIC ACIDS RES, V24, P4407, DOI 10.1093/nar/24.22.4407; Tseng ASK, 2002, GENETICS, V162, P229; VAESSIN H, 1994, DEVELOPMENT, V120, P935; Wansink DG, 2003, CYTOGENET GENOME RES, V100, P230, DOI 10.1159/000072859; Worth PF, 2000, NAT GENET, V24, P214, DOI 10.1038/73411; Zhang YQ, 2002, GENESIS, V34, P142, DOI 10.1002/gene.10144	45	12	12	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2008	3	1							e1466	10.1371/journal.pone.0001466	http://dx.doi.org/10.1371/journal.pone.0001466			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SO	18213375	Green Published, Green Submitted, gold			2022-12-25	WOS:000260503900012
J	Allhorn, M; Olin, AI; Nimmerjahn, F; Collin, M				Allhorn, Maria; Olin, Anders I.; Nimmerjahn, Falk; Collin, Mattias			Human IgG/Fc gamma R Interactions Are Modulated by Streptococcal IgG Glycan Hydrolysis	PLOS ONE			English	Article							IMMUNOGLOBULIN-G; SERUM IGG; RHEUMATOID-ARTHRITIS; INTERACTION SITES; FC; RECEPTOR; PROTEIN; GLYCOSYLATION; PYOGENES; ENDOGLYCOSIDASE	Background. The human pathogen Streptococcus pyogenes produces an endoglycosidase, EndoS that hydrolyzes the chitobiose core of the asparagine-linked glycan on the heavy chain of human IgG. IgG-binding to Fc gamma receptors (Fc gamma R) on leukocytes triggers effector functions including phagocytosis, oxidative burst and the release of inflammatory mediators. The interactions between Fc gamma R and the Fc domain of IgG depend on the IgG glycosylation state. Methodology/Principal Findings. Here we show for the first time that EndoS hydrolyzes the heavy chain glycan of all four human IgG subclasses (IgG1-4), in purified form and in a plasma environment. An inactive form of EndoS, obtained by site-directed mutagenesis, binds IgG with high affinity, in contrast to wild type EndoS that only transiently interacts with IgG, as shown by Slot-blotting and surface plasmon resonance technology. Furthermore, EndoS hydrolysis of the IgG glycan influences the binding of IgG to immobilized soluble Fc gamma R and to an erythroleukemic cell line, K562, expressing Fc gamma RIIa. Incubation of whole blood with EndoS results in a dramatic decrease of IgG binding to activated monocytes as analyzed by flow cytometry. Moreover, the IgG bound to K562 cells dissociates when cells are treated with EndoS. Likewise, IgG bound to immobilized Fc gamma RIIa and subsequently treated with EndoS, dissociates from the receptor as analyzed by surface plasmon resonance and Western blot. Conclusions/Significance. We provide novel information about bacterial enzymatic modulation of the IgG/FccR interaction that emphasizes the importance of glycosylation for antibody effector functions. Moreover, EndoS could be used as a biochemical tool for specific IgG N-glycan hydrolysis and IgG purification/detection, or as a potential immunosuppressing agent for treatment of antibody-mediated pathological processes.	[Allhorn, Maria; Olin, Anders I.; Collin, Mattias] Lund Univ, Dept Clin Sci, Div Infect Med, Lund, Sweden; [Nimmerjahn, Falk] Nikolaus Fiebiger Ctr for Mol Med, Expt Immunol & Immunother, Erlangen, Germany	Lund University	Allhorn, M (corresponding author), Lund Univ, Dept Clin Sci, Div Infect Med, Lund, Sweden.	maria.allhorn@med.lu.se	Nimmerjahn, Falk/J-4986-2013; Collin, Mattias/C-6398-2009	Collin, Mattias/0000-0002-6166-7410; Nimmerjahn, Falk/0000-0002-5418-316X	Swedish Research Council [2005-4791, Assistant Professorship]; Foundations of Kock, Jeansson, Zoegas, Bergvall, Osterlund, Groschinsky; Swedish Society for Medical Research; Royal Physiografic Society; Medical Faculty at Lund University	Swedish Research Council(Swedish Research CouncilEuropean Commission); Foundations of Kock, Jeansson, Zoegas, Bergvall, Osterlund, Groschinsky; Swedish Society for Medical Research; Royal Physiografic Society(Royal Society of London); Medical Faculty at Lund University	This work was supported by the Swedish Research Council (projects 2005-4791), the Foundations of Kock, Jeansson, Zoegas, Bergvall, Osterlund, Groschinsky, the Swedish Society for Medical Research, the Royal Physiografic Society, and the Medical Faculty at Lund University. MC is the recipient of an Assistant Professorship from Swedish Research Council. The funders had no influence of the design and conduct of the study, in the collection, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript.	Allhorn M, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-3; Arnold JN, 2007, ANNU REV IMMUNOL, V25, P21, DOI 10.1146/annurev.immunol.25.022106.141702; Bisno AL, 1996, NEW ENGL J MED, V334, P240, DOI 10.1056/NEJM199601253340407; BURTON DR, 1992, ADV IMMUNOL, V51, P1, DOI 10.1016/S0065-2776(08)60486-1; Collin M, 2004, J BIOL CHEM, V279, P22558, DOI 10.1074/jbc.M402156200; Collin M, 2003, INFECT IMMUN, V71, P2983, DOI 10.1128/IAI.71.6.2983-2992.2003; Collin M, 2002, INFECT IMMUN, V70, P6646, DOI 10.1128/IAI.70.12.6646-6651.2002; Collin M, 2001, EMBO J, V20, P3046, DOI 10.1093/emboj/20.12.3046; Collin M, 2001, INFECT IMMUN, V69, P7187, DOI 10.1128/IAI.69.11.7187-7189.2001; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; DUBE R, 1990, GUT, V31, P431, DOI 10.1136/gut.31.4.431; FISCHETTI VA, 1989, CLIN MICROBIOL REV, V2, P285, DOI 10.1128/CMR.2.3.285-314.1989; FORSGREN A, 1966, J IMMUNOL, V97, P822; Holland M, 2002, CLIN EXP IMMUNOL, V129, P183, DOI 10.1046/j.1365-2249.2002.01864.x; HULETT MD, 1994, J BIOL CHEM, V269, P15287; HULETT MD, 1994, ADV IMMUNOL, V57, P1, DOI 10.1016/S0065-2776(08)60671-9; Jefferis R, 2002, IMMUNOL LETT, V82, P57, DOI 10.1016/S0165-2478(02)00019-6; Jefferis R, 1998, IMMUNOL REV, V163, P59, DOI 10.1111/j.1600-065X.1998.tb01188.x; Kaneko Y, 2006, SCIENCE, V313, P670, DOI 10.1126/science.1129594; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITTAUA R, 1990, J IMMUNOL, V144, P3183; Matsumoto A, 2000, J BIOCHEM-TOKYO, V128, P621, DOI 10.1093/oxfordjournals.jbchem.a022794; Nandakumar KS, 2007, EUR J IMMUNOL, V37, P2973, DOI 10.1002/eji.200737581; Nimmerjahn F, 2006, IMMUNITY, V24, P19, DOI 10.1016/j.immuni.2005.11.010; Nimmerjahn F, 2005, SCIENCE, V310, P1510, DOI 10.1126/science.1118948; Nimmerjahn F, 2005, IMMUNITY, V23, P41, DOI 10.1016/j.immuni.2005.05.010; Nimmerjahn F, 2006, SPRINGER SEMIN IMMUN, V28, P305, DOI 10.1007/s00281-006-0052-1; PAREKH R, 1989, J AUTOIMMUN, V2, P101, DOI 10.1016/0896-8411(89)90148-0; PAREKH RB, 1985, NATURE, V316, P452, DOI 10.1038/316452a0; RADEMACHER TW, 1994, P NATL ACAD SCI USA, V91, P6123, DOI 10.1073/pnas.91.13.6123; Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275; SJOBRING U, 1991, J BIOL CHEM, V266, P399; TARENTINO AL, 1994, METHOD ENZYMOL, V230, P44; VANZEBEN D, 1994, BRIT J RHEUMATOL, V33, P36; Woof JM, 2004, NAT REV IMMUNOL, V4, P89, DOI 10.1038/nri1266	35	81	88	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2008	3	1							e1413	10.1371/journal.pone.0001413	http://dx.doi.org/10.1371/journal.pone.0001413			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366GT	18183294	Green Published, gold, Green Submitted			2022-12-25	WOS:000260469400010
J	Carmody, LC; Baucum, AJ; Bass, MA; Colbran, RJ				Carmody, Leigh C.; Baucum, Anthony J., II; Bass, Martha A.; Colbran, Roger J.			Selective targeting of the gamma 1 isoform of protein phosphatase 1 to F-actin in intact cells requires multiple domains in spinophilin and neurabin	FASEB JOURNAL			English	Article						subcellular targeting; cytoskeleton; dendritic spine; synaptic plasticity	PROTEIN PHOSPHATASE 1; PRIMATE PREFRONTAL CORTEX; FILAMENT-BINDING PROTEIN; P70 S6 KINASE; DENDRITIC SPINES; CATALYTIC SUBUNIT; SUBCELLULAR-DISTRIBUTION; STRUCTURAL BASIS; PHOSPHORYLATION; LOCALIZATION	Protein phosphatase 1 (PP1) catalytic subunits dephosphorylate specific substrates in discrete subcellular compartments to modulate many cellular processes. Canonical PP1-binding motifs (R/K-V/I-X-F) in a family of proteins mediate subcellular targeting, and the amino acids that form the binding pocket for the canonical motif are identical in all PP1 isoforms. However, PP1 gamma 1 but not PP1 beta is selectively localized to F-actin-rich dendritic spines in neurons. Although the F-actin-binding proteins neurabin I and spinophilin (neurabin II) also bind PP1, their role in PP1 isoform selective targeting in intact cells is poorly understood. We show here that spinophilin selectively targets PP1 gamma 1, but not PP1 beta, to F-actin-rich cortical regions of intact cells. Mutation of a PP1 gamma 1 selectivity determinant (N(464)EDYDRR (470) in spinophilin: conserved as residues 473 -479 in neurabin) to VKDYDTW severely attenuated PP1 gamma 1 interactions with neurabins in vitro and in cells and disrupted PP1 gamma 1 targeting to F-actin. This domain is not involved in the weaker interactions of neurabins with PP1 beta. In contrast, mutation of the canonical PP1-binding motif attenuated interactions of neurabins with both isoforms. Thus, selective targeting of PP1 gamma 1 to F-actin by neurabins in intact cells requires both the canonical PP1-binding motif and an auxiliary PP1 gamma 1-selectivity determinant.	[Carmody, Leigh C.; Baucum, Anthony J., II; Bass, Martha A.; Colbran, Roger J.] Vanderbilt Univ, Med Ctr, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; [Baucum, Anthony J., II; Colbran, Roger J.] Vanderbilt Univ, Sch Med, Ctr Mol Neurosci, Nashville, TN 37232 USA; [Baucum, Anthony J., II; Colbran, Roger J.] Vanderbilt Univ, Sch Med, Vanderbilt Kennedy Ctr Res Human Dev, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Colbran, RJ (corresponding author), Vanderbilt Univ, Med Ctr, Sch Med, Dept Mol Physiol & Biophys, Robinson Res Bldg,Room 724, Nashville, TN 37232 USA.	roger.colbran@vanderbilt.edu	Colbran, Roger/AAU-7708-2021; Baucum, Anthony/I-5109-2013	Colbran, Roger/0000-0001-7401-8244; Baucum, Anthony/0000-0002-4756-9865; Carmody, Leigh/0000-0001-7941-2961	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD015052] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY008126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U2CDK059637, P60DK020593, U24DK059637, P30DK058404, P30DK020593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH065215] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS044282] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA068485, CA68485] Funding Source: Medline; NEI NIH HHS [EY08126, P30 EY008126] Funding Source: Medline; NICHD NIH HHS [P30 HD015052, HD15052] Funding Source: Medline; NIDDK NIH HHS [DK58404, P60 DK020593, P30 DK020593, DK59637, P30 DK058404, U24 DK059637, DK20593] Funding Source: Medline; NIMH NIH HHS [T32-MH65215, T32 MH065215] Funding Source: Medline; NINDS NIH HHS [P01 NS044282, P01-NS44282, P01 NS044282-010002] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALESSI DR, 1993, EUR J BIOCHEM, V213, P1055, DOI 10.1111/j.1432-1033.1993.tb17853.x; Allen PB, 2006, NEUROSCIENCE, V140, P897, DOI 10.1016/j.neuroscience.2006.02.067; Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; Bollen M, 2001, TRENDS BIOCHEM SCI, V26, P426, DOI 10.1016/S0968-0004(01)01836-9; Bordelon JR, 2005, CEREB CORTEX, V15, P1928, DOI 10.1093/cercor/bhi070; Buchanan FG, 2000, J BIOL CHEM, V275, P9742, DOI 10.1074/jbc.275.13.9742; Buchsbaum RJ, 2003, J BIOL CHEM, V278, P18833, DOI 10.1074/jbc.M207876200; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P8351, DOI 10.1073/pnas.95.14.8351; Carmody LC, 2004, J BIOL CHEM, V279, P21714, DOI 10.1074/jbc.M402261200; Ceulemans H, 2004, PHYSIOL REV, V84, P1, DOI 10.1152/physrev.00013.2003; Cohen PTW, 2002, J CELL SCI, V115, P241; Colbran RJ, 2003, METHOD ENZYMOL, V366, P156; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Endo S, 1996, BIOCHEMISTRY-US, V35, P5220, DOI 10.1021/bi952940f; Feng J, 2000, P NATL ACAD SCI USA, V97, P9287, DOI 10.1073/pnas.97.16.9287; Fleming IN, 1999, J BIOL CHEM, V274, P12753, DOI 10.1074/jbc.274.18.12753; Grossman SD, 2004, J NEUROCHEM, V90, P317, DOI 10.1111/j.1471-4159.2004.02491.x; Haneji T, 1998, BIOCHEM BIOPH RES CO, V248, P39, DOI 10.1006/bbrc.1998.8913; HEMMINGS HC, 1990, J BIOL CHEM, V265, P20369; Hsieh-Wilson LC, 1999, BIOCHEMISTRY-US, V38, P4365, DOI 10.1021/bi982900m; Hsieh-Wilson LC, 2003, J BIOL CHEM, V278, P1186, DOI 10.1074/jbc.M205754200; Hu XD, 2006, J NEUROCHEM, V98, P1841, DOI 10.1111/j.1471-4159.2006.04070.x; Huang HS, 2005, ARCH BIOCHEM BIOPHYS, V443, P33, DOI 10.1016/j.abb.2005.08.021; Lanner C, 2001, ARCH BIOCHEM BIOPHYS, V388, P135, DOI 10.1006/abbi.2001.2283; Lesage B, 2004, J BIOL CHEM, V279, P55978, DOI 10.1074/jbc.M411911200; MacMillan LB, 1999, J BIOL CHEM, V274, P35845, DOI 10.1074/jbc.274.50.35845; McAvoy T, 1999, BIOCHEMISTRY-US, V38, P12943, DOI 10.1021/bi991227d; Meiselbach H, 2006, CHEM BIOL, V13, P49, DOI 10.1016/j.chembiol.2005.10.009; Morishita W, 2001, NEURON, V32, P1133, DOI 10.1016/S0896-6273(01)00554-2; Muly EC, 2004, J COMP NEUROL, V469, P185, DOI 10.1002/cne.11001; Muly EC, 2004, CEREB CORTEX, V14, P1398, DOI 10.1093/cercor/bhh101; Nakanishi H, 1997, J CELL BIOL, V139, P951, DOI 10.1083/jcb.139.4.951; Oliver CJ, 2002, MOL CELL BIOL, V22, P4690, DOI 10.1128/MCB.22.13.4690-4701.2002; OUIMET CC, 1995, P NATL ACAD SCI USA, V92, P3396, DOI 10.1073/pnas.92.8.3396; Ouimet CC, 2004, J COMP NEUROL, V479, P374, DOI 10.1002/cne.20313; Richman JG, 2001, J BIOL CHEM, V276, P15003, DOI 10.1074/jbc.M011679200; Ryan XZP, 2005, NEURON, V47, P85, DOI 10.1016/j.neuron.2005.05.013; Sarrouilhe D, 2006, BIOCHIMIE, V88, P1099, DOI 10.1016/j.biochi.2006.04.010; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; SHIMA H, 1993, BIOCHEM BIOPH RES CO, V192, P1289, DOI 10.1006/bbrc.1993.1556; Smith FD, 1999, J BIOL CHEM, V274, P19894, DOI 10.1074/jbc.274.28.19894; Strack S, 1999, J COMP NEUROL, V413, P373; Terrak M, 2004, NATURE, V429, P780, DOI 10.1038/nature02582; Terry-Lorenzo RT, 2005, MOL BIOL CELL, V16, P2349, DOI 10.1091/mbc.E04-12-1054; Terry-Lorenzo RT, 2002, J BIOL CHEM, V277, P27716, DOI 10.1074/jbc.M203365200; Tolias KF, 2005, NEURON, V45, P525, DOI 10.1016/j.neuron.2005.01.024; Trinkle-Mulcahy L, 2001, J CELL SCI, V114, P4219; Tsukada M, 2005, J BIOL CHEM, V280, P11361, DOI 10.1074/jbc.M405525200; Wakula P, 2003, J BIOL CHEM, V278, P18817, DOI 10.1074/jbc.M300175200; Wang XH, 2005, NAT CELL BIOL, V7, P405, DOI 10.1038/ncb1237; Yan Z, 1999, NAT NEUROSCI, V2, P13, DOI 10.1038/4516; Yang J, 2000, J BIOL CHEM, V275, P22635, DOI 10.1074/jbc.M003082200; Zheng L, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh110; Zito K, 2004, NEURON, V44, P321, DOI 10.1016/j.neuron.2004.09.022	54	25	26	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					1660	1671		10.1096/fj.07-092841	http://dx.doi.org/10.1096/fj.07-092841			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18216290	Green Accepted			2022-12-25	WOS:000256352700007
J	Gong, ZD; Niklason, LE				Gong, Zhaodi; Niklason, Laura E.			Small-diameter human vessel wall engineered from bone marrow-derived mesenchymal stem cells (hMSCs)	FASEB JOURNAL			English	Article						smooth muscle cell; bioreactor; cyclic strain; extracellular matrix; soluble factors	SMOOTH-MUSCLE-CELL; GROWTH FACTOR-BB; PROGENITOR CELLS; BLOOD-VESSELS; ENDOTHELIAL-CELLS; STROMAL CELLS; TGF-BETA; DIFFERENTIATION; TISSUE; EXPRESSION	Using biodegradable scaffold and a biomimetic perfusion system, our lab has successfully engineered small-diameter vessel grafts using endothelial cells ( ECs) and smooth muscle cells (SMCs) obtained from vessels in various species. However, translating this technique into humans has presented tremendous obstacles due to species and age differences. SMCs from elderly persons have limited proliferative capacity and a reduction in collagen production, which impair the mechanical strength of engineered vessels. As an alternative cell source, adult human bone marrow-derived mesenchymal stem cells (hMSCs) were studied for their ability to differentiate into SMCs in culture plates as well as in a bioreactor system. In the former setting, immunofluorescence staining showed that MSCs, after induction for 14 days, expressed smooth muscle alpha-actin (SMA) and calponin, early and mid-SMC phenotypic markers, respectively. In the latter setting, vessel walls were constructed with MSC-derived SMCs. Various factors (i. e., matrix proteins, soluble factors, and cyclic strain) in the engineering system were further investigated for their effects on hMSC cell proliferation and differentiation into SMCs. Based on a screening of multiple factors, the engineering system was optimized by dividing the vessel culture into proliferation and differentiation phases. The vessel walls engineered under the optimized conditions were examined histologically and molecularly, and found to be substantially similar to native vessels. In conclusion, bone marrow-derived hMSCs can serve as a new cell source of SMCs in vessel engineering. Optimization of the culture conditions to drive SMC differentiation and matrix production significantly improved the quality of the hMSC-derived engineered vessel wall.	[Gong, Zhaodi; Niklason, Laura E.] Yale Univ, Sch Med, Med Ctr, Dept Anesthesiol, New Haven, CT 06520 USA	Yale University	Niklason, LE (corresponding author), Yale Univ, Sch Med, Med Ctr, Dept Anesthesiol, POB 208089, New Haven, CT 06520 USA.	laura.niklason@yale.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL083895, R01HL063766] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL063766-05, R01 HL083895-03, R01 HL063766, HL063766, R01HL083895, R01 HL083895] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARCINIEGAS E, 1992, J CELL SCI, V103, P521; Aubin JE, 1999, J CELL BIOCHEM, V72, P396, DOI 10.1002/(SICI)1097-4644(19990301)72:3<396::AID-JCB9>3.3.CO;2-Y; Ball SG, 2004, INT J BIOCHEM CELL B, V36, P714, DOI 10.1016/j.biocel.2003.10.015; Berk BC, 2001, PHYSIOL REV, V81, P999, DOI 10.1152/physrev.2001.81.3.999; Betsholtz C, 2004, CYTOKINE GROWTH F R, V15, P215, DOI 10.1016/j.cytogfr.2004.03.005; BIRUKOV KG, 1995, MOL CELL BIOCHEM, V144, P131, DOI 10.1007/BF00944392; BJORKERUD S, 1991, ARTERIOSCLER THROMB, V11, P892, DOI 10.1161/01.ATV.11.4.892; CAREY DJ, 1991, ANNU REV PHYSIOL, V53, P161, DOI 10.1146/annurev.physiol.53.1.161; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; CHAMLEYCAMPBELL JH, 1981, ATHEROSCLEROSIS, V40, P347, DOI 10.1016/0021-9150(81)90145-3; Chapman GB, 2000, AM J PHYSIOL-HEART C, V278, pH748, DOI 10.1152/ajpheart.2000.278.3.H748; CHARD RB, 1987, J THORAC CARDIOV SUR, V94, P132; Cho SW, 2005, ANN SURG, V241, P506, DOI 10.1097/01.sla.0000154268.12239.ed; CINTORINO M, 1991, INT J CANCER, V47, P843, DOI 10.1002/ijc.2910470609; CLYMAN RI, 1990, CIRC RES, V67, P175, DOI 10.1161/01.RES.67.1.175; Dandre F, 2004, AM J PHYSIOL-HEART C, V286, pH2042, DOI 10.1152/ajpheart.00625.2003; DARBY I, 1990, LAB INVEST, V63, P21; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; FRIEDENSTEIN AJ, 1976, EXP HEMATOL, V4, P267; GALMICHE MC, 1993, BLOOD, V82, P66, DOI 10.1182/blood.V82.1.66.bloodjournal82166; Gong ZD, 2004, ALCOHOL CLIN EXP RES, V28, P468, DOI 10.1097/01.ALC.0000118315.58404.C1; Hautmann MB, 1997, J BIOL CHEM, V272, P10948; HAYNESWORTH SE, 1992, BONE, V13, P69, DOI 10.1016/8756-3282(92)90363-2; HEDIN U, 1989, DEV BIOL, V133, P489, DOI 10.1016/0012-1606(89)90052-3; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805; Hirst SJ, 2000, AM J RESP CELL MOL, V23, P335, DOI 10.1165/ajrcmb.23.3.3990; Hoerstrup SP, 2002, CIRCULATION, V106, pI143, DOI 10.1161/01.cir.0000032872.55215.05; INGBER DE, 1994, INT REV CYTOL, V150, P173; Jiang YH, 2002, EXP HEMATOL, V30, P896, DOI 10.1016/S0301-472X(02)00869-X; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kadner A, 2002, EUR J CARDIO-THORAC, V21, P1055, DOI 10.1016/S1010-7940(02)00079-9; Kaushal S, 2001, NAT MED, V7, P1035, DOI 10.1038/nm0901-1035; Kim BS, 1999, NAT BIOTECHNOL, V17, P979, DOI 10.1038/13671; Kinner B, 2002, EXP CELL RES, V278, P72, DOI 10.1006/excr.2002.5561; Kurpinski Kyle, 2006, Molecular & Cellular Biomechanics, V3, P21; LI J, 1995, EXP HEMATOL, V23, P133; Li Q, 1997, Hypertens Res, V20, P217, DOI 10.1291/hypres.20.217; Li XR, 2005, J CLIN INVEST, V115, P118, DOI 10.1172/JCI200519189; Liu JY, 2007, CARDIOVASC RES, V75, P618, DOI 10.1016/j.cardiores.2007.04.018; MAJACK RA, 1987, J CELL BIOL, V105, P465, DOI 10.1083/jcb.105.1.465; MAROTTI KR, 1993, NATURE, V364, P73, DOI 10.1038/364073a0; Matsumura G, 2003, CIRCULATION, V108, P1729, DOI 10.1161/01.CIR.0000092165.32213.61; McKee JA, 2003, EMBO REP, V4, P633, DOI 10.1038/sj.embor.embor847; Mills I, 1997, J CELL PHYSIOL, V170, P228, DOI 10.1002/(SICI)1097-4652(199703)170:3<228::AID-JCP2>3.0.CO;2-Q; Niklason LE, 1999, SCIENCE, V284, P489, DOI 10.1126/science.284.5413.489; Niklason LE, 2001, J VASC SURG, V33, P628, DOI 10.1067/mva.2001.111747; Niklason LE, 1999, SCIENCE, V286, P1493, DOI 10.1126/science.286.5444.1493; NIKLASON LE, 2002, METHODS TISSUE ENG, P905; Noth U, 2002, J ORTHOP RES, V20, P1060, DOI 10.1016/S0736-0266(02)00018-9; O'Callaghan CJ, 2000, HYPERTENSION, V36, P319, DOI 10.1161/01.HYP.36.3.319; OWENS GK, 1995, PHYSIOL REV, V75, P487; Park JS, 2004, BIOTECHNOL BIOENG, V88, P359, DOI 10.1002/bit.20250; PAULY RR, 1992, CIRCULATION, V86, P68; Perry TE, 2003, ANN THORAC SURG, V75, P761, DOI 10.1016/S0003-4975(02)03776-1; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Poh M, 2005, LANCET, V365, P2122, DOI 10.1016/S0140-6736(05)66735-9; Raines EW, 2004, CYTOKINE GROWTH F R, V15, P237, DOI 10.1016/j.cytogfr.2004.03.004; Ross JJ, 2006, J CLIN INVEST, V116, P3139, DOI 10.1172/JCI28184; RUZICKA DL, 1988, J CELL BIOL, V107, P2575, DOI 10.1083/jcb.107.6.2575; SAPSFORD RN, 1981, J THORAC CARDIOV SUR, V81, P860; SAWTELL NM, 1989, J CELL BIOL, V109, P2929, DOI 10.1083/jcb.109.6.2929; Seliktar D, 2001, ANN BIOMED ENG, V29, P923, DOI 10.1114/1.1415522; Seruya M, 2004, CELL TRANSPLANT, V13, P93, DOI 10.3727/000000004773301762; Steinthorsson G, 1999, ACTA CHIR BELG, V99, P282; vanderLoop FTL, 1996, J CELL BIOL, V134, P401, DOI 10.1083/jcb.134.2.401; VEITH FJ, 1986, J VASC SURG, V3, P104; WEINBERG CB, 1986, SCIENCE, V231, P397, DOI 10.1126/science.2934816; WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003-9861(61)90291-0; Wu X, 2004, AM J PHYSIOL-HEART C, V287, pH480, DOI 10.1152/ajpheart.01232.2003; Yoshida T, 2007, AM J PHYSIOL-CELL PH, V292, pC886, DOI 10.1152/ajpcell.00449.2006; Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853; Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02-02-0105	73	249	268	1	57	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1635	1648		10.1096/fj.07-087924	http://dx.doi.org/10.1096/fj.07-087924			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18199698	Green Accepted			2022-12-25	WOS:000256352700005
J	Mattioli, B; Straface, E; Matarrese, P; Quaranta, MG; Giordani, L; Malorni, W; Viora, M				Mattioli, Benedetta; Straface, Elisabetta; Matarrese, Paola; Quaranta, Maria Giovanna; Giordani, Luciana; Malorni, Walter; Viora, Marina			Leptin as an immunological adjuvant: enhanced migratory and CD8(+) T cell stimulatory capacity of human dendritic cells exposed to leptin	FASEB JOURNAL			English	Article						chemotaxis; vaccination; cytoskeleton; CTL	CHEMOKINE RECEPTOR CCR7; UP-REGULATION; IMMUNE-RESPONSE; SERUM LEPTIN; LYMPH-NODES; RHO GTPASES; ACTIVATION; EXPRESSION; DIFFERENTIATION; MATURATION	Leptin is an adipocyte-derived hormone/cytokine that links nutrition, metabolism, and immune homeostasis and is endowed to modulate several immune responses. We previously demonstrated that both immature and mature human dendritic cells (DCs) express a functional leptin receptor, and we found that leptin activates DCs, licenses them for Th1 priming, and promotes DC survival. Moreover, we found that leptin induces rearrangement of actin microfilaments, leading to uropod and ruffle formation. Here we monitor the effects of leptin on DC migratory capacities, focusing on the intracellular signaling driving cytoskeleton rearrangement. We found that leptin increases immature DC migratory performance both by favoring cytoskeleton dynamics and by up-regulating CCR7 surface expression, thus favoring chemotactic responsiveness. We found that in immature DCs, leptin activates cofilin, favoring the turnover of actin microfilaments, and, by triggering Vav phosphorylation, promotes Rac1 activation. Finally, we found that in immature DCs, leptin up-regulates interleukin-12p70 production on CD40 stimulation and, more importantly, increases their capacity to stimulate activation of autologous CD8(+) T cells. Taken altogether, the findings herein highlight the potential use of leptin as an adjuvant tool in vaccination protocols employing ex vivo-generated autologous DCs.	[Mattioli, Benedetta; Straface, Elisabetta; Matarrese, Paola; Quaranta, Maria Giovanna; Giordani, Luciana; Malorni, Walter; Viora, Marina] Ist Super Sanita, Dept Drug Res & Evaluat, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS)	Viora, M (corresponding author), Ist Super Sanita, Dept Drug Res & Evaluat, 299 Viale Regina Elena, I-00161 Rome, Italy.	viora@iss.it	Malorni, Walter/G-5874-2016; Matarrese, Paola/A-4369-2014	Quaranta, Maria Giovanna/0000-0002-1077-1488; matarrese, paola/0000-0001-5477-3752; malorni, walter/0000-0002-1223-7000				Adema GJ, 2005, CURR OPIN IMMUNOL, V17, P170, DOI 10.1016/j.coi.2005.01.004; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Banchereau J, 2005, NAT REV IMMUNOL, V5, P296, DOI 10.1038/nri1592; Benvenuti F, 2004, SCIENCE, V305, P1150, DOI 10.1126/science.1099159; Berard F, 2000, J EXP MED, V192, P1535, DOI 10.1084/jem.192.11.1535; Boden G, 1996, J CLIN ENDOCR METAB, V81, P3419, DOI 10.1210/jc.81.9.3419; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; Chen H, 2000, TRENDS BIOCHEM SCI, V25, P19, DOI 10.1016/S0968-0004(99)01511-X; Cioffi JA, 1996, NAT MED, V2, P585, DOI 10.1038/nm0596-585; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; de Vries IJM, 2003, CANCER RES, V63, P12; de Vries IJM, 2003, CLIN CANCER RES, V9, P5091; Dhodapkar MV, 2001, J EXP MED, V193, P233, DOI 10.1084/jem.193.2.233; Fei H, 1997, P NATL ACAD SCI USA, V94, P7001, DOI 10.1073/pnas.94.13.7001; FLIER JS, 1995, CELL, V80, P15, DOI 10.1016/0092-8674(95)90445-X; Friedman JM, 1998, NUTR REV, V56, pS38; Fruhbeck G, 2006, BIOCHEM J, V393, P7, DOI 10.1042/BJ20051578; Gainsford T, 1999, MOL BIOTECHNOL, V11, P149, DOI 10.1007/BF02915808; Gao YF, 2005, J IMMUNOL, V175, P5783, DOI 10.4049/jimmunol.175.9.5783; Giammarioli AM, 2006, FEBS LETT, V580, P3335, DOI 10.1016/j.febslet.2006.04.095; Granucci F, 2001, NAT IMMUNOL, V2, P882, DOI 10.1038/ni0901-882; Granucci F, 2001, EUR J IMMUNOL, V31, P2539, DOI 10.1002/1521-4141(200109)31:9<2539::AID-IMMU2539>3.0.CO;2-9; Grunfeld C, 1996, J CLIN INVEST, V97, P2152, DOI 10.1172/JCI118653; Gutzmer R, 2003, J IMMUNOL, V171, P6363, DOI 10.4049/jimmunol.171.12.6363; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Holt MR, 2001, TRENDS CELL BIOL, V11, P38, DOI 10.1016/S0962-8924(00)01876-6; Hopken UE, 2002, BLOOD, V99, P1109, DOI 10.1182/blood.V99.4.1109; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Janik JE, 1997, J CLIN ENDOCR METAB, V82, P3084, DOI 10.1210/jc.82.9.3084; JONULEIT H, INT J CANC, V93, P243; Koch F, 1996, J EXP MED, V184, P741, DOI 10.1084/jem.184.2.741; La Cava A, 2004, J MOL MED, V82, P4, DOI 10.1007/s00109-003-0492-1; Lam QLK, 2007, J BIOL CHEM, V282, P27587, DOI 10.1074/jbc.M704579200; Lam QLK, 2006, EUR J IMMUNOL, V36, P3118, DOI 10.1002/eji.200636602; LANE P, 1995, EUR J IMMUNOL, V25, P1788, DOI 10.1002/eji.1830250646; Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; Luft T, 2004, BLOOD, V104, P1066, DOI 10.1182/blood-2003-12-4146; Macia L, 2006, J IMMUNOL, V177, P5997, DOI 10.4049/jimmunol.177.9.5997; MADEJ T, 1995, FEBS LETT, V373, P13, DOI 10.1016/0014-5793(95)00977-H; MAFFEI M, 1995, P NATL ACAD SCI USA, V92, P6957, DOI 10.1073/pnas.92.15.6957; Malorni W, 2004, THROMB HAEMOSTASIS, V92, P1159, DOI 10.1055/s-0037-1614296; Martin-Romero C, 2000, CELL IMMUNOL, V199, P15, DOI 10.1006/cimm.1999.1594; Mattioli B, 2005, J IMMUNOL, V174, P6820, DOI 10.4049/jimmunol.174.11.6820; McIlroy D, 2003, CANCER IMMUNOL IMMUN, V52, P583, DOI 10.1007/s00262-003-0414-7; O'Malley D, 2005, FASEB J, V19, P1917, DOI 10.1096/fj.05-4166fje; Ouaaz F, 2002, IMMUNITY, V16, P257, DOI 10.1016/S1074-7613(02)00272-8; Quaranta MG, 2003, FASEB J, V17, P2025, DOI 10.1096/fj.03-0272com; Randolph GJ, 2005, NAT REV IMMUNOL, V5, P617, DOI 10.1038/nri1670; Ridley AJ, 2001, J CELL SCI, V114, P2713; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Riol-Blanco L, 2005, J IMMUNOL, V174, P4070, DOI 10.4049/jimmunol.174.7.4070; Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; Sallusto F, 1999, EUR J IMMUNOL, V29, P1617, DOI 10.1002/(SICI)1521-4141(199905)29:05<1617::AID-IMMU1617>3.0.CO;2-3; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Sanchez-Margalet V, 2003, CLIN EXP IMMUNOL, V133, P11, DOI 10.1046/j.1365-2249.2003.02190.x; Sanchez-Sanchez N, 2006, J IMMUNOL, V176, P5153, DOI 10.4049/jimmunol.176.9.5153; Santos-Alvarez J, 1999, CELL IMMUNOL, V194, P6, DOI 10.1006/cimm.1999.1490; Saxena NK, 2007, CANCER RES, V67, P2497, DOI 10.1158/0008-5472.CAN-06-3075; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Shutt DC, 2000, CELL MOTIL CYTOSKEL, V46, P200, DOI 10.1002/1097-0169(200007)46:3<200::AID-CM5>3.0.CO;2-M; Steinman R. M, 1999, FUNDAMENTAL IMMUNOLO, P547; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093; Turtle CJ, 2004, CURR DRUG TARGETS, V5, P17, DOI 10.2174/1389450043490640; Verdijk P, 2004, EUR J IMMUNOL, V34, P156, DOI 10.1002/eji.200324241; Weber A, 1999, MOL CELL BIOCHEM, V190, P67, DOI 10.1023/A:1006984010267; White David W., 1996, Cytokine and Growth Factor Reviews, V7, P303, DOI 10.1016/S1359-6101(96)00040-8; Zarkesh-Esfahani H, 2004, J IMMUNOL, V172, P1809, DOI 10.4049/jimmunol.172.3.1809; Zhang FM, 1997, NATURE, V387, P206, DOI 10.1038/387206a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhao YR, 2003, BIOCHEM BIOPH RES CO, V300, P247, DOI 10.1016/S0006-291X(02)02838-3	74	42	46	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					2012	2022		10.1096/fj.07-098095	http://dx.doi.org/10.1096/fj.07-098095			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18218920				2022-12-25	WOS:000256352700040
J	Xia, N; Thodeti, CK; Hunt, TP; Xu, QB; Ho, M; Whitesides, GM; Westervelt, R; Ingber, DE				Xia, Nan; Thodeti, Charles K.; Hunt, Tom P.; Xu, Qiaobing; Ho, Madelyn; Whitesides, George M.; Westervelt, Robert; Ingber, Donald E.			Directional control of cell motility through focal adhesion positioning and spatial control of Rac activation	FASEB JOURNAL			English	Article						migration; extracellular matrix; microcontact printing; cytoskeleton; mechanical; traction	COUPLING MEMBRANE PROTRUSION; ARP2/3 COMPLEX; REGULATES ADHESION; ACTIN; CDC42; LAMELLIPODIA; CHEMOTAXIS; MIGRATION; RIGIDITY; PAXILLIN	Local physical interactions between cells and extracellular matrix (ECM) influence directional cell motility that is critical for tissue development, wound repair, and cancer metastasis. Here we test the possibility that the precise spatial positioning of focal adhesions governs the direction in which cells spread and move. NIH 3T3 cells were cultured on circular or linear ECM islands, which were created using a microcontact printing technique and were 1 mu m wide and of various lengths (1 to 8 mu m) and separated by 1 to 4.5 mu m wide nonadhesive barrier regions. Cells could be driven proactively to spread and move in particular directions by altering either the interisland spacing or the shape of similar-sized ECM islands. Immunofluorescence microscopy confirmed that focal adhesions assembled preferentially above the ECM islands, with the greatest staining intensity being observed at adhesion sites along the cell periphery. Rac-FRET analysis of living cells revealed that Rac became activated within 2 min after peripheral membrane extensions adhered to new ECM islands, and this activation wave propagated outward in an oriented manner as the cells spread from island to island. A computational model, which incorporates that cells preferentially protrude membrane processes from regions near newly formed focal adhesion contacts, could predict with high accuracy the effects of six different arrangements of micropatterned ECM islands on directional cell spreading. Taken together, these results suggest that physical properties of the ECM may influence directional cell movement by dictating where cells will form new focal adhesions and activate Rac and, hence, govern where new membrane protrusions will form.	[Xia, Nan; Thodeti, Charles K.; Ho, Madelyn; Ingber, Donald E.] Childrens Hosp, Dept Pathol, Vasc Biol Program, Boston, MA 02115 USA; [Xia, Nan; Thodeti, Charles K.; Ho, Madelyn; Ingber, Donald E.] Childrens Hosp, Dept Surg, Boston, MA 02115 USA; [Xia, Nan; Thodeti, Charles K.; Ho, Madelyn; Ingber, Donald E.] Harvard Univ, Sch Med, Boston, MA USA; [Hunt, Tom P.; Westervelt, Robert] Harvard Univ, Dept Phys, Boston, MA 02115 USA; [Hunt, Tom P.; Westervelt, Robert] Harvard Univ, Div Engn & Appl Sci, Boston, MA 02115 USA; [Xu, Qiaobing; Whitesides, George M.] Harvard Univ, Dept Chem & Chem Biol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard University; Harvard University	Ingber, DE (corresponding author), Childrens Hosp, Dept Pathol, Vasc Biol Program, KFRL 11-127, Boston, MA 02115 USA.	donald.ingber@childrens.harvard.edu	Ingber, Donald E/AAC-5894-2019; Xia, Nan/ABG-4600-2021		NCI NIH HHS [CA45548, P01 CA045548] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA045548] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beningo KA, 2001, J CELL BIOL, V153, P881, DOI 10.1083/jcb.153.4.881; Brock A, 2003, LANGMUIR, V19, P1611, DOI 10.1021/la026394k; Chen CS, 2003, BIOCHEM BIOPH RES CO, V307, P355, DOI 10.1016/S0006-291X(03)01165-3; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; CONDEELIS J, 1993, ANNU REV CELL BIOL, V9, P411, DOI 10.1146/annurev.cb.09.110193.002211; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; DeMali KA, 2003, J CELL SCI, V116, P2389, DOI 10.1242/jcs.00605; DeMali KA, 2002, J CELL BIOL, V159, P881, DOI 10.1083/jcb.200206043; Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995; Dubin-Thaler BJ, 2004, BIOPHYS J, V86, P1794, DOI 10.1016/S0006-3495(04)74246-0; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Goldmann WH, 2002, BIOCHEM BIOPH RES CO, V290, P749, DOI 10.1006/bbrc.2001.6243; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; Itoh RE, 2002, MOL CELL BIOL, V22, P6582, DOI 10.1128/MCB.22.18.6582-6591.2002; Jiang XY, 2005, P NATL ACAD SCI USA, V102, P975, DOI 10.1073/pnas.0408954102; Lo CM, 2000, BIOPHYS J, V79, P144, DOI 10.1016/S0006-3495(00)76279-5; MACHESKY LM, 1994, J CELL BIOL, V127, P107, DOI 10.1083/jcb.127.1.107; MOONEY DJ, 1995, J CELL SCI, V108, P2311; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; NAKATSUJI N, 1984, NATURE, V307, P453, DOI 10.1038/307453a0; Nayal A, 2006, J CELL BIOL, V173, P587, DOI 10.1083/jcb.200509075; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Parker KK, 2002, FASEB J, V16, DOI 10.1096/fj.02-0038com; Pelham RJ, 1997, P NATL ACAD SCI USA, V94, P13661, DOI 10.1073/pnas.94.25.13661; Peyton SR, 2005, J CELL PHYSIOL, V204, P198, DOI 10.1002/jcp.20274; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Riveline D, 2001, J CELL BIOL, V153, P1175, DOI 10.1083/jcb.153.6.1175; Roberts C, 1998, J AM CHEM SOC, V120, P6548, DOI 10.1021/ja972467o; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; Tan JL, 2004, TISSUE ENG, V10, P865, DOI 10.1089/1076327041348365; Ueda M, 2001, SCIENCE, V294, P864, DOI 10.1126/science.1063951; Van Haastert PJM, 2004, NAT REV MOL CELL BIO, V5, P626, DOI 10.1038/nrm1435; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Xiao Z, 1997, J CELL BIOL, V139, P365, DOI 10.1083/jcb.139.2.365	38	120	126	1	35	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1649	1659		10.1096/fj.07-090571	http://dx.doi.org/10.1096/fj.07-090571			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18180334				2022-12-25	WOS:000256352700006
J	Barbero, S; Barila, D; Mielgo, A; Stagni, V; Clair, K; Stupack, D				Barbero, Simone; Barila, Daniela; Mielgo, Ainhoa; Stagni, Venturina; Clair, Kiran; Stupack, Dwayne			Identification of a critical tyrosine residue in caspase 8 that promotes cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS; ACTIVATION; KINASE; REQUIREMENT; MOTILITY; INTEGRIN; RECEPTOR	Caspase 8 is a critical upstream initiator of programmed cell death but, paradoxically, has also been shown to promote cell migration. Here, we show that tyrosine 380 in the linker loop of human caspase 8 is a critical switch determining caspase 8 function. Our studies show that, in addition to its cytosolic distribution, caspase 8 is recruited to lamella of migrating cells. Although the catalytic domain of caspase 8 is sufficient for recruitment and promotion of cell migration, catalytic activity per se is not required. Instead, we find that integrin-mediated adhesion promotes caspase 8 phosphorylation on tyrosine 380. Accordingly, mutation of this site compromises localization to the periphery and the potentiation of cell migration. Mechanistically, this linker region of caspase 8 acts as a Src homology 2 binding site. In particular, tyrosine 380 is critical for interaction with Src homology 2 domains. The results identify a novel mechanism by which caspase 8 is recruited to the lamella of a migrating cell, promoting cell migration independent of its protease activity.	[Barbero, Simone; Mielgo, Ainhoa; Clair, Kiran; Stupack, Dwayne] Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA; [Barbero, Simone; Mielgo, Ainhoa; Clair, Kiran; Stupack, Dwayne] UCSD Moores Canc Ctr, La Jolla, CA 92093 USA; [Barbero, Simone; Mielgo, Ainhoa; Clair, Kiran; Stupack, Dwayne] Carattere Sci Fdn Santa Lucia, Ist Ricovero & Cura, I-00179 Rome, Italy; [Barila, Daniela; Stagni, Venturina] Univ Roma Tor Vergata, I-00133 Rome, Italy	University of California System; University of California San Diego; IRCCS Santa Lucia; University of Rome Tor Vergata	Stupack, D (corresponding author), Univ Calif San Diego, Ctr Canc, 3855 Hlth Sci Dr,MC0803, La Jolla, CA 92093 USA.	dstupack@ucsd.edu	Barilà, Daniela/K-8506-2016	Barilà, Daniela/0000-0002-6192-1562; stagni, venturina/0000-0002-3971-0398	NATIONAL CANCER INSTITUTE [R01CA107263] Funding Source: NIH RePORTER; NCI NIH HHS [CA107263] Funding Source: Medline; Worldwide Cancer Research [07-0461] Funding Source: Medline; Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Worldwide Cancer Research; Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Arechiga AF, 2007, J IMMUNOL, V179, P5291, DOI 10.4049/jimmunol.179.8.5291; Barnhart BC, 2004, EMBO J, V23, P3175, DOI 10.1038/sj.emboj.7600325; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; Cursi S, 2006, EMBO J, V25, P1895, DOI 10.1038/sj.emboj.7601085; Eliceiri BP, 2001, CIRC RES, V89, P1104, DOI 10.1161/hh2401.101084; Helfer B, 2006, CANCER RES, V66, P4273, DOI 10.1158/0008-5472.CAN-05-4183; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kang TB, 2004, J IMMUNOL, V173, P2976, DOI 10.4049/jimmunol.173.5.2976; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Pop C, 2007, BIOCHEMISTRY-US, V46, P4398, DOI 10.1021/bi602623b; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Stupack DG, 2006, NATURE, V439, P95, DOI 10.1038/nature04323; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Su H, 2005, SCIENCE, V307, P1465, DOI 10.1126/science.1104765; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3	16	64	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2008	283	19					13031	13034		10.1074/jbc.M800549200	http://dx.doi.org/10.1074/jbc.M800549200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295UQ	18216014	Green Published, hybrid			2022-12-25	WOS:000255499800040
J	Muller, P; Hrstka, R; Coomber, D; Lane, DP; Vojtesek, B				Muller, P.; Hrstka, R.; Coomber, D.; Lane, D. P.; Vojtesek, B.			Chaperone-dependent stabilization and degradation of p53 mutants	ONCOGENE			English	Article						chaperones; p53 mutant; stabilization; degradation; CHIP	HISTONE DEACETYLASE INHIBITORS; LI-FRAUMENI-SYNDROME; HEAT-SHOCK PROTEINS; PROTEASOMAL DEGRADATION; MONOCLONAL-ANTIBODIES; WILD-TYPE; HSP90; CELLS; TUMOR; LIGASE	p53 missense mutant proteins commonly show increased stability compared to wild-type p53, which is thought to depend largely on the inability of mutant p53 to induce the ubiquitin ligase MDM2. However, recent work using mouse models has shown that the accumulation of mutant p53 occurs only in tumour cells, indicating that stabilization requires additional factors. To clarify the stabilization of p53 mutants in tumours, we analysed factors that affect their folding and degradation. Although all missense mutants that we studied are more stable than wild-type p53, the levels correlate with individual structural characteristics, which may be reflected in different gain-of-function properties. In the absence of Hsp90 activity, the less stable unfolded p53 mutants preferentially associate in a complex with Hsp70 and CHIP (carboxy terminus of Hsp70-interacting protein), and we show that CHIP is responsible for ubiquitination and degradation of these mutants. The demonstration of a complex interplay between Hsp90, Hsp70 and CHIP that regulate the stability of different p53 mutant proteins improves our understanding of the pro-tumorigenic effects of increased Hsp90 activity during multi-stage carcinogenesis. Understanding the roles of Hsp90, Hsp70 and CHIP in cancers may also provide an important avenue through which to target p53 to enhance treatment of human cancers.	[Muller, P.; Hrstka, R.; Vojtesek, B.] Masaryk Mem Canc Inst, Dept Clin & Expt Pathol, Brno 65653, Czech Republic; [Muller, P.; Coomber, D.; Lane, D. P.] Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117548, Singapore	Masaryk Memorial Cancer Institute; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Vojtesek, B (corresponding author), Masaryk Mem Canc Inst, Dept Clin & Expt Pathol, Zluty Kopec 7, Brno 65653, Czech Republic.	vojtesek@mou.cz	Lane, David P/C-4920-2008; Hrstka, Roman/AAM-4430-2020; Muller, Petr/AAK-5014-2021; 高, 雨莉/HGU-8187-2022; Muller, Petr/F-7762-2015	Hrstka, Roman/0000-0002-6139-2664; Muller, Petr/0000-0002-8404-4494; Muller, Petr/0000-0002-8404-4494; Lane, David/0000-0003-0551-3545				Bali P, 2005, J BIOL CHEM, V280, P26729, DOI 10.1074/jbc.C500186200; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Barrette RW, 2006, CLIN VACCINE IMMUNOL, V13, P802, DOI 10.1128/CVI.00422-05; BARTEK J, 1993, J PATHOL, V169, P27, DOI 10.1002/path.1711690106; Blagosklonny MV, 2005, CANCER RES, V65, P7386, DOI 10.1158/0008-5472.CAN-04-3433; Blagosklonny MV, 2004, CELL CYCLE, V3, P1537, DOI 10.4161/cc.3.12.1278; Blagosklonny MV, 1997, ONCOGENE, V15, P1889, DOI 10.1038/sj.onc.1201374; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Esser C, 2005, J BIOL CHEM, V280, P27443, DOI 10.1074/jbc.M501574200; Esser C, 2004, BBA-MOL CELL RES, V1695, P171, DOI 10.1016/j.bbamcr.2004.09.020; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; George P, 2005, BLOOD, V105, P1768, DOI 10.1182/blood-2004-09-3413; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; King FW, 2001, EMBO J, V20, P6297, DOI 10.1093/emboj/20.22.6297; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Milner J, 1997, PATHOL BIOL, V45, P797; Nagata Y, 1999, ONCOGENE, V18, P6037, DOI 10.1038/sj.onc.1202978; Nenutil R, 2005, J PATHOL, V207, P251, DOI 10.1002/path.1838; Nimmanapalli R, 2003, CANCER RES, V63, P5126; O'Shea CC, 2005, CANCER CELL, V8, P61, DOI 10.1016/j.ccr.2005.06.009; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Peng YH, 2001, J BIOL CHEM, V276, P40583, DOI 10.1074/jbc.M102817200; Peng YH, 2001, J BIOL CHEM, V276, P6874, DOI 10.1074/jbc.C000781200; Selkirk James K., 1994, Applied and Theoretical Electrophoresis, V4, P11; Soussi T, 2005, BIOCHEM BIOPH RES CO, V331, P834, DOI 10.1016/j.bbrc.2005.03.190; VOJTESEK B, 1993, BRIT J CANCER, V67, P1254, DOI 10.1038/bjc.1993.234; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; Wang PL, 2001, ONCOGENE, V20, P2318, DOI 10.1038/sj.onc.1204316; Wang Y, 2007, BIOCHEM BIOPH RES CO, V356, P998, DOI 10.1016/j.bbrc.2007.03.076; Workman P, 2004, TRENDS MOL MED, V10, P47, DOI 10.1016/j.molmed.2003.12.005; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang Y, 2004, J BIOL CHEM, V279, P42545, DOI 10.1074/jbc.M314213200; Zylicz M, 2001, EMBO J, V20, P4634, DOI 10.1093/emboj/20.17.4634	41	133	138	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	24					3371	3383		10.1038/sj.onc.1211010	http://dx.doi.org/10.1038/sj.onc.1211010			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18223694				2022-12-25	WOS:000256309900002
J	Aiken, KJ; Bickford, JS; Kilberg, MS; Nick, HS				Aiken, Kimberly J.; Bickford, Justin S.; Kilberg, Michael S.; Nick, Harry S.			Metabolic regulation of manganese superoxide dismutase expression via essential amino acid deprivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MESSENGER-RNA; GENE-EXPRESSION; OXIDATIVE STRESS; INTERFERON-GAMMA; LIFE-SPAN; HISTONE DEACETYLASE; DOWN-REGULATION; S6 KINASE; INDUCTION	Organisms respond to available nutrient levels by rapidly adjusting metabolic flux, in part through changes in gene expression. A consequence of adaptations in metabolic rate is the production of mitochondria-derived reactive oxygen species. Therefore, we hypothesized that nutrient sensing could regulate the synthesis of the primary defense of the cell against superoxide radicals, manganese superoxide dismutase. Our data establish a novel nutrient-sensing pathway for manganese superoxide dismutase expression mediated through essential amino acid depletion concurrent with an increase in cellular viability. Most relevantly, our results are divergent from current mechanisms governing amino acid-dependent gene regulation. This pathway requires the presence of glutamine, signaling via the tricarboxylic acid cycle/electron transport chain, an intact mitochondrial membrane potential, and the activity of both the MEK/ERK and mammalian target of rapamycin kinases. Our results provide evidence for convergence of metabolic cues with nutrient control of antioxidant gene regulation, revealing a potential signaling strategy that impacts free radical-mediated mutations with implications in cancer and aging.	[Nick, Harry S.] Univ Florida, Coll Med, Dept Neurosci, Gainesville, FL 32610 USA; [Aiken, Kimberly J.; Bickford, Justin S.; Nick, Harry S.] Univ Florida, McKnight Brain Inst, Gainesville, FL 32610 USA; [Aiken, Kimberly J.; Bickford, Justin S.; Kilberg, Michael S.; Nick, Harry S.] Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Nick, HS (corresponding author), Univ Florida, Coll Med, Dept Neurosci, POB 100244, Gainesville, FL 32610 USA.	hnick@ufl.edu			NHLBI NIH HHS [HL06745, HL39593] Funding Source: Medline; NIDDK NIH HHS [R01 DK070647, R01 DK052064, DK52064, DK70647] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052064, R01DK070647] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; BAQUET A, 1993, EUR J BIOCHEM, V217, P1083, DOI 10.1111/j.1432-1033.1993.tb18340.x; Bruce-Keller AJ, 1999, J NEUROIMMUNOL, V93, P53, DOI 10.1016/S0165-5728(98)00190-8; Bruhat A, 1999, P NUTR SOC, V58, P625, DOI 10.1017/S0029665199000828; Brunet A, 2004, M S-MED SCI, V20, P856, DOI 10.1051/medsci/20042010856; Chang SH, 2003, BIOCHEM J, V371, P877, DOI 10.1042/BJ20021731; Chen C, 2005, BIOCHEM J, V391, P649, DOI 10.1042/BJ20050882; Chen H, 2004, J BIOL CHEM, V279, P50829, DOI 10.1074/jbc.M409173200; COX G, 1994, AM J RESP CELL MOL, V10, P493, DOI 10.1165/ajrcmb.10.5.7514009; DELVECCHIO PJ, 1991, CURR EYE RES, V10, P919, DOI 10.3109/02713689109020327; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; DOUGALL WC, 1991, ENDOCRINOLOGY, V129, P2376, DOI 10.1210/endo-129-5-2376; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Fernandez J, 2002, J BIOL CHEM, V277, P11780, DOI 10.1074/jbc.M110778200; Fonnum F, 1997, GLIA, V21, P106; Franchi-Gazzola R, 1999, J BIOL CHEM, V274, P28922, DOI 10.1074/jbc.274.41.28922; FRANK L, 1980, AM J MED, V69, P117, DOI 10.1016/0002-9343(80)90509-4; Gao N, 2006, BLOOD, V107, P241, DOI 10.1182/blood-2005-06-2409; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; Golab J, 2003, J BIOL CHEM, V278, P407, DOI 10.1074/jbc.M209125200; Goncharov NV, 2006, J APPL TOXICOL, V26, P148, DOI 10.1002/jat.1118; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Harris N, 2003, FREE RADICAL BIO MED, V34, P1599, DOI 10.1016/S0891-5849(03)00210-7; HATEFI Y, 1975, FED PROC, V34, P1699; Hinnebusch Alan G., 1994, Seminars in Cell Biology, V5, P417, DOI 10.1006/scel.1994.1049; Honda Y, 2002, ANN NY ACAD SCI, V959, P466, DOI 10.1111/j.1749-6632.2002.tb02117.x; Huang HM, 2003, J NEUROSCI RES, V74, P309, DOI 10.1002/jnr.10756; HURT J, 1992, NUCLEIC ACIDS RES, V20, P2985, DOI 10.1093/nar/20.12.2985; Kang HT, 2003, J BIOL CHEM, V278, P51223, DOI 10.1074/jbc.M307332200; Keller JN, 1998, J NEUROSCI, V18, P687; Kilberg MS, 2005, ANNU REV NUTR, V25, P59, DOI 10.1146/annurev.nutr.24.012003.132145; Kim DH, 2003, CURR TOP MICROBIOL, V279, P259; Kim YS, 2002, J BIOCHEM MOL BIOL, V35, P443; Kokoszka JE, 2001, P NATL ACAD SCI USA, V98, P2278, DOI 10.1073/pnas.051627098; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; Lee AS, 2005, METHODS, V35, P373, DOI 10.1016/j.ymeth.2004.10.010; Leung-Pineda V, 2004, BIOCHEM J, V379, P79, DOI 10.1042/BJ20031383; Lievremont JP, 1997, J BIOL CHEM, V272, P30873, DOI 10.1074/jbc.272.49.30873; Lindsley JE, 2004, COMP BIOCHEM PHYS B, V139, P543, DOI 10.1016/j.cbpc.2004.06.014; LIPSON KE, 1989, P NATL ACAD SCI USA, V86, P9774, DOI 10.1073/pnas.86.24.9774; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Martin DE, 2005, CURR OPIN CELL BIOL, V17, P158, DOI 10.1016/j.ceb.2005.02.008; Meijer AJ, 2003, J NUTR, V133, p2057S, DOI 10.1093/jn/133.6.2057S; MELENDEZ JA, 1993, FREE RADICAL BIO MED, V14, P601, DOI 10.1016/0891-5849(93)90141-G; Muller FL, 2008, BIOCHEM J, V409, P491, DOI 10.1042/BJ20071162; Neuhaus P, 2001, LIVER TRANSPLANT, V7, P473, DOI 10.1053/jlts.2001.24645; Pan YX, 2003, J BIOL CHEM, V278, P38402, DOI 10.1074/jbc.M304574200; Petroulakis E, 2006, BRIT J CANCER, V94, P195, DOI 10.1038/sj.bjc.6602902; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Raineri I, 1996, J INTERF CYTOK RES, V16, P61, DOI 10.1089/jir.1996.16.61; Rogers RJ, 2000, BIOCHEM J, V347, P233, DOI 10.1042/0264-6021:3470233; Rogers RJ, 2001, J BIOL CHEM, V276, P20419, DOI 10.1074/jbc.M008915200; Roth GS, 2005, J AM GERIATR SOC, V53, pS280, DOI 10.1111/j.1532-5415.2005.53489.x; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Sarbassov DD, 2005, J BIOL CHEM, V280, P39505, DOI 10.1074/jbc.M506096200; Scallet AC, 2003, ANN NY ACAD SCI, V993, P305, DOI 10.1111/j.1749-6632.2003.tb07538.x; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; Sun JT, 2002, GENETICS, V161, P661; Tee AR, 2005, SEMIN CELL DEV BIOL, V16, P29, DOI 10.1016/j.semcdb.2004.11.005; Tower J, 2000, MECH AGEING DEV, V118, P1, DOI 10.1016/S0047-6374(00)00152-4; Valko M, 2006, CHEM-BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009; VARGA J, 1995, J CLIN INVEST, V96, P475, DOI 10.1172/JCI118058; Varga J, 1996, ADV EXP MED BIOL, V398, P143; VARGA J, 1994, LAB INVEST, V70, P183; VISNER GA, 1990, J BIOL CHEM, V265, P2856; VISNER GA, 1992, BIOCHEM BIOPH RES CO, V188, P453; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Zwacka RM, 1998, HUM GENE THER, V9, P1381, DOI 10.1089/hum.1998.9.9-1381	73	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10252	10263		10.1074/jbc.M709944200	http://dx.doi.org/10.1074/jbc.M709944200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18187411	Green Published, hybrid			2022-12-25	WOS:000254894700006
J	Kawachi, M; Kobae, Y; Mimura, T; Maeshima, M				Kawachi, Miki; Kobae, Yoshihiro; Mimura, Tetsuro; Maeshima, Masayoshi			Deletion of a histidine-rich loop of AtMTP1, a vacuolar Zn2+/H+ antiporter of Arabidopsis thaliana, stimulates the transport activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-TRANSPORTER; CONFERS RESISTANCE; METAL TRANSPORT; PLASMA-MEMBRANE; H+-ATPASE; FAMILY; GENE; TOLERANCE; PROTEIN; YEAST	Arabidopsis thaliana AtMTP1 belongs to the cation diffusion facilitator family and is localized on the vacuolar membrane. We investigated the enzymatic kinetics of AtMTP1 by a heterologous expression system in the yeast Saccharomyces cerevisiae, which lacked genes for vacuolar membrane zinc transporters ZRC1 and COT1. The yeast mutant expressing AtMTP1 heterologously was tolerant to 10mM ZnCl2. Active transport of zinc into vacuoles of living yeast cells expressing AtMTP1 was confirmed by the fluorescent zinc indicator FuraZin-1. Zinc transport was quantitatively analyzed by using vacuolar membrane vesicles prepared from AtMTP1-expressing yeast cells and radioisotope Zn-65(2+). Active zinc uptake depended on a pH gradient generated by endogenous vacuolar H+-ATPase. The activity was inhibited by bafilomycin A(1), an inhibitor of the H+-ATPase. The K-m for Zn2+ and Vmax of AtMTP1 were determined to be 0.30 mu M and 1.22 nmol/min/mg, respectively. We prepared a mutant AtMTP1 that lacked the major part (32 residues from 185 to 216) of a long histidine-rich hydrophilic loop in the central part of AtMTP1. Yeast cells expressing the mutant became hyperresistant to high concentrations of Zn2+ and resistant to Co2+. The Km and Vmax values were increased 2 -11-fold. These results indicate that AtMTP1 functions as a Zn2+/H+ antiporter in vacuoles and that a histidine-rich region is not essential for zinc transport. We propose that a histidine-rich loop functions as a buffering pocket of Zn2+ and a sensor of the zinc level at the cytoplasmic surface. This loop may be involved in the maintenance of the level of cytoplasmic Zn2+.	[Kawachi, Miki; Kobae, Yoshihiro; Maeshima, Masayoshi] Nagoya Univ, Grad Sch Bioagr Sci, Lab Cell Dynam, Nagoya, Aichi 4648601, Japan; [Mimura, Tetsuro] Kobe Univ, Grad Sch Sci, Dept Biol, Kobe, Hyogo 6578501, Japan	Nagoya University; Kobe University	Maeshima, M (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Lab Cell Dynam, Nagoya, Aichi 4648601, Japan.	maeshima@agr.nagoya-u.ac.jp	Maeshima, Masayoshi/D-3073-2013	Maeshima, Masayoshi/0000-0002-1611-5481; Kobae, Yoshihiro/0000-0002-9997-490X				Anton A, 2004, J BACTERIOL, V186, P7499, DOI 10.1128/JB.186.22.7499-7507.2004; Arrivault S, 2006, PLANT J, V46, P861, DOI 10.1111/j.1365-313X.2006.02746.x; Becher M, 2004, PLANT J, V37, P251, DOI 10.1046/j.1365-313X.2003.01959.x; Blaudez D, 2003, PLANT CELL, V15, P2911, DOI 10.1105/tpc.017541; Bloss T, 2002, PLANTA, V214, P783, DOI 10.1007/s00425-001-0677-1; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; CONKLIN DS, 1994, MOL GEN GENET, V244, P303, DOI 10.1007/BF00285458; Delhaize E, 2003, PLANT CELL, V15, P1131, DOI 10.1105/tpc.009134; Desbrosses-Fonrouge AG, 2005, FEBS LETT, V579, P4165, DOI 10.1016/j.febslet.2005.06.046; Drager DB, 2004, PLANT J, V39, P425, DOI 10.1111/j.1365-313X.2004.02143.x; Gamsjaeger R, 2007, TRENDS BIOCHEM SCI, V32, P63, DOI 10.1016/j.tibs.2006.12.007; Gaxiola RA, 2007, FEBS LETT, V581, P2204, DOI 10.1016/j.febslet.2007.03.050; Guerinot ML, 2000, BBA-BIOMEMBRANES, V1465, P190, DOI 10.1016/S0005-2736(00)00138-3; Hara M, 2005, J EXP BOT, V56, P2695, DOI 10.1093/jxb/eri262; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KAMIZONO A, 1989, MOL GEN GENET, V219, P161, DOI 10.1007/BF00261172; Kim D, 2004, PLANT J, V39, P237, DOI 10.1111/j.1365-313X.2004.02126.x; Kobae Y, 2004, PLANT CELL PHYSIOL, V45, P1749, DOI 10.1093/pcp/pci015; Kramer U, 2005, CURR OPIN BIOTECH, V16, P133, DOI 10.1016/j.copbio.2005.02.006; Kramer U, 2005, TRENDS PLANT SCI, V10, P313, DOI 10.1016/j.tplants.2005.05.008; Lippard S. J., 1994, PRINCIPLES BIOINORGA; Lu M, 2007, SCIENCE, V317, P1746, DOI 10.1126/science.1143748; MacDiarmid CW, 2003, J BIOL CHEM, V278, P15065, DOI 10.1074/jbc.M300568200; MacDiarmid CW, 2002, J BIOL CHEM, V277, P39187, DOI 10.1074/jbc.M205052200; MAESHIMA M, 2000, BIOCHIM BIOPHYS ACTA, V1456, P37; Mao XQ, 2007, J BIOL CHEM, V282, P6992, DOI 10.1074/jbc.M610552200; Marschner H, 1995, MINERAL NUTR HIGHER, p[347, 362]; MATSUURAENDO C, 1990, EUR J BIOCHEM, V187, P745, DOI 10.1111/j.1432-1033.1990.tb15362.x; MATSUURAENDO C, 1992, PLANT PHYSIOL, V100, P718, DOI 10.1104/pp.100.2.718; Milon B, 2006, BBA-BIOMEMBRANES, V1758, P1696, DOI 10.1016/j.bbamem.2006.06.005; Nakanishi Y, 1998, PLANT PHYSIOL, V116, P589, DOI 10.1104/pp.116.2.589; Nakanishi Y, 2001, J BIOL CHEM, V276, P7654, DOI 10.1074/jbc.M009743200; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Paulsen IT, 1997, J MEMBRANE BIOL, V156, P99, DOI 10.1007/s002329900192; Persans MW, 2001, P NATL ACAD SCI USA, V98, P9995, DOI 10.1073/pnas.171039798; SHANNON RD, 1970, J INORG NUCL CHEM, V32, P1427, DOI 10.1016/0022-1902(70)80629-7; Shigaki T, 2001, ANAL BIOCHEM, V298, P118, DOI 10.1006/abio.2001.5341; Sze H, 1999, PLANT CELL, V11, P677, DOI 10.1105/tpc.11.4.677; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; Ueoka-Nakanishi H, 2000, EUR J BIOCHEM, V267, P3090, DOI 10.1046/j.1432-1033.2000.01343.x; van der Zaal BJ, 1999, PLANT PHYSIOL, V119, P1047, DOI 10.1104/pp.119.3.1047; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; Wei BX, 2007, BIOCHEMISTRY-US, V46, P8734, DOI 10.1021/bi700763w; Williams LE, 2000, BBA-BIOMEMBRANES, V1465, P104, DOI 10.1016/S0005-2736(00)00133-4; Williams LE, 2005, TRENDS PLANT SCI, V10, P491, DOI 10.1016/j.tplants.2005.08.008	46	111	118	2	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8374	8383		10.1074/jbc.M707646200	http://dx.doi.org/10.1074/jbc.M707646200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18203721	Green Published, hybrid			2022-12-25	WOS:000254288000035
J	Yang, W; Qiu, C; Biswas, N; Jin, J; Watkins, SC; Montelaro, RC; Coyne, CB; Wang, TY				Yang, Wei; Qiu, Chao; Biswas, Nabanita; Jin, Jing; Watkins, Simon C.; Montelaro, Ronald C.; Coyne, Carolyn B.; Wang, Tianyi			Correlation of the tight junction-like distribution of Claudin-1 to the cellular tropism of hepatitis C virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; TRANSMEMBRANE DOMAIN; MEMBRANE-PROTEINS; ENTRY; REPLICATION; ENDOCYTOSIS; RECEPTOR; BINDING; CELLS; CD81	Claudin-1 (CLDN1), a tight junction (TJ) protein, has recently been identified as an entry co-receptor for hepatitis C virus (HCV). Ectopic expression of CLDN1 rendered several non-hepatic cell lines permissive to HCV infection. However, little is known about the mechanism by which CLDN1 mediates HCV entry. It is believed that an additional entry receptor(s) is required because ectopic expression of CLDN1 in both HeLa and NIH3T3 cells failed to confer susceptibility to viral infection. Here we found that CLDN1 was co-immunoprecipitated with both HCV envelope proteins when expressed in 293T cells. Results from biomolecular fluorescence complementation assay showed that overexpressed CLDN1 also formed complexes with CD81 and low density lipoprotein receptor. Subsequent imaging analysis revealed that CLDN1 was highly enriched at sites of cell-cell contact in permissive cell lines, co-localizing with the TJ marker, ZO-1. However, in both HeLa and NIH3T3 cells the ectopically expressed CLDN1 appeared to reside predominantly in intracellular vesicles. The CLDN1-CD81 complex formed in HeLa cells was also exclusively distributed intracellularly, co-localizing with EEA1, an early endosomal marker. Correspondingly, transepithelial electric resistance, obtained from the naturally susceptible human liver cell line, Huh7, was much higher than that of the HeLa-CLDN1 cell line, suggesting that Huh7 is likely to form functional tight junctions. Finally, the disruption of TJ-enriched CLDN1 by tumor necrosis factor-alpha treatment markedly reduced the susceptibility of Huh7.5.1 cells to HCV infection. Our results suggest that the specific localization pattern of CLDN1 may be crucial in the regulation of HCV cellular tropism.	[Yang, Wei; Qiu, Chao; Biswas, Nabanita; Jin, Jing; Montelaro, Ronald C.; Wang, Tianyi] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Infect Dis & Microbiol, Pittsburgh, PA 15261 USA; [Jin, Jing; Montelaro, Ronald C.] Univ Pittsburgh, Dept Microbiol & Mol Genet, Pittsburgh, PA 15261 USA; [Watkins, Simon C.; Coyne, Carolyn B.] Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wang, TY (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Infect Dis & Microbiol, 130 DeSoto St, Pittsburgh, PA 15261 USA.	tywang@pitt.edu	Watkins, Simon/ABG-2590-2021; Qiu, Chao/M-6702-2014	Watkins, Simon/0000-0003-4092-1552; Qiu, Chao/0000-0001-9401-5219; Yang, Wei/0000-0003-0162-4221; Jin, Jing/0000-0003-3994-8600	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI068784] Funding Source: NIH RePORTER; NIAID NIH HHS [1 R21 AI 068784-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bartosch B, 2006, VIROLOGY, V348, P1, DOI 10.1016/j.virol.2005.12.027; Bartosch B, 2003, J EXP MED, V197, P633, DOI 10.1084/jem.20021756; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Blanchard E, 2006, J VIROL, V80, P6964, DOI 10.1128/JVI.00024-06; Bruewer M, 2005, FASEB J, V19, P923, DOI 10.1096/fj.04-3260com; Cai ZH, 2005, J VIROL, V79, P13963, DOI 10.1128/JVI.79.22.13963-13973.2005; CAROLYN B, 2007, CELL HOST MICROBE, V2, P181; Cocquerel L, 2000, J VIROL, V74, P3623, DOI 10.1128/JVI.74.8.3623-3633.2000; Cocquerel L, 2006, J GEN VIROL, V87, P1075, DOI 10.1099/vir.0.81646-0; Cocquerel L, 1998, J VIROL, V72, P2183, DOI 10.1128/JVI.72.3.2183-2191.1998; Cocquerel L, 2003, J VIROL, V77, P10677, DOI 10.1128/JVI.77.19.10677-10683.2003; Cocquerel L, 1999, J VIROL, V73, P2641, DOI 10.1128/JVI.73.4.2641-2649.1999; Codran A, 2006, J GEN VIROL, V87, P2583, DOI 10.1099/vir.0.81710-0; Cormier EG, 2004, P NATL ACAD SCI USA, V101, P7270, DOI 10.1073/pnas.0402253101; Coyne CB, 2006, CELL, V124, P119, DOI 10.1016/j.cell.2005.10.035; De Beeck AO, 2000, J BIOL CHEM, V275, P31428, DOI 10.1074/jbc.M003003200; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; Diedrich G, 2006, FEBS J, V273, P3871, DOI 10.1111/j.1742-4658.2006.05379.x; Evans MJ, 2007, NATURE, V446, P801, DOI 10.1038/nature05654; Frese M, 2003, J GEN VIROL, V84, P1253, DOI 10.1099/vir.0.18997-0; Fujita K, 2000, FEBS LETT, V476, P258, DOI 10.1016/S0014-5793(00)01744-0; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; Gregory M, 2001, ENDOCRINOLOGY, V142, P854, DOI 10.1210/en.142.2.854; Hrzenjak A, 2004, CELL MOL LIFE SCI, V61, P1520, DOI 10.1007/s00018-004-4101-4; Hsu M, 2003, P NATL ACAD SCI USA, V100, P7271, DOI 10.1073/pnas.0832180100; Ivanov AI, 2004, MOL BIOL CELL, V15, P176, DOI 10.1091/mbc.E03-05-0319; Jin J, 2007, J VIROL, V81, P11226, DOI 10.1128/JVI.00431-07; Kato T, 2005, J VIROL, V79, P592, DOI 10.1128/JVI.79.1.592-596.2005; Kovalenko OV, 2007, MOL CELL PROTEOMICS, V6, P1855, DOI 10.1074/mcp.M700183-MCP200; Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016; Mee CJ, 2008, J VIROL, V82, P461, DOI 10.1128/JVI.01894-07; Meertens L, 2006, J VIROL, V80, P11571, DOI 10.1128/JVI.01717-06; Petracca R, 2000, J VIROL, V74, P4824, DOI 10.1128/JVI.74.10.4824-4830.2000; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; Scarselli E, 2002, EMBO J, V21, P5017, DOI 10.1093/emboj/cdf529; Schneeberger EE, 2004, AM J PHYSIOL-CELL PH, V286, pC1213, DOI 10.1152/ajpcell.00558.2003; Shyu YJ, 2006, BIOTECHNIQUES, V40, P61, DOI 10.2144/000112036; Silver DL, 2001, J BIOL CHEM, V276, P25287, DOI 10.1074/jbc.M101726200; Van Itallie CM, 2004, PHYSIOLOGY, V19, P331, DOI 10.1152/physiol.00027.2004; Walters RW, 2002, CELL, V110, P789, DOI 10.1016/S0092-8674(02)00912-1; Yamamoto Y, 2003, BIOCHEM BIOPH RES CO, V308, P270, DOI 10.1016/S0006-291X(03)01358-5; ZAHRAOUI A, 1994, J CELL BIOL, V124, P101, DOI 10.1083/jcb.124.1.101; Zhang J, 2004, J VIROL, V78, P1448, DOI 10.1128/JVI.78.3.1448-1455.2004; Zhong J, 2005, P NATL ACAD SCI USA, V102, P9294, DOI 10.1073/pnas.0503596102	44	86	90	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8643	8653		10.1074/jbc.M709824200	http://dx.doi.org/10.1074/jbc.M709824200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18211898	Green Published, hybrid			2022-12-25	WOS:000254288000063
J	Zemach, A; Gaspan, O; Grafi, G				Zemach, Assaf; Gaspan, Ofer; Grafi, Gideon			The three methyl-CpG-binding domains of AtMBD7 control its subnuclear localization and mobility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLATION; HISTONE H1; MBD PROTEINS; LIVING CELLS; CHROMATIN; ARABIDOPSIS; FAMILY; PLANTS; MECP2	Three methyl-CpG-binding domain (MBD) proteins in Arabidopsis, AtMBD5, AtMBD6, and AtMBD7, are functional in binding methylated CpG dinucleotides in vitro and localize to the highly CpG-methylated chromocenters in vivo. These proteins differ, however, in their subnuclear localization pattern; AtMBD5 and AtMBD6, each containing a single MBD motif, show preference for two perinucleolar chromocenters, whereas AtMBD7, a naturally occurring poly-MBD protein containing three MBD motifs, localizes to all chromocenters. Here we studied the significance of multiple MBD motifs for subnuclear localization and mobility in living cells. We found that the number of MBD motifs determines the subnuclear localization of the MBD protein. Furthermore, live kinetic experiments showed that AtMBD7-green fluorescent protein (GFP) has lower mobility than AtMBD5-GFP and AtMBD6-GFP, which is conferred by cooperative activity of its three MBD motifs. Thus, the number of MBD motifs appears to affect not only binding affinity and mobility within the nucleus, but also the subnuclear localization of the protein. Our results suggest that poly-MBD proteins can directly affect chromatin structure by inducing intra-and inter-chromatin compaction via bridging over multiple methylated CpG sites.	[Zemach, Assaf; Gaspan, Ofer] Weizmann Inst Sci, Dept Plant Sci, IL-76100 Rehovot, Israel; [Grafi, Gideon] Ben Gurion Univ Negev, Jacob Blaustein Inst Desert Res, Albert Katz Dept Dryland Biotechnol, IL-84990 Sede Boqer, Israel	Weizmann Institute of Science; Ben Gurion University	Zemach, A (corresponding author), Weizmann Inst Sci, Dept Plant Sci, IL-76100 Rehovot, Israel.	assaf.zemach@weizmann.ac.il		Zemach, Assaf/0000-0003-3282-4445				Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Catez F, 2006, NAT STRUCT MOL BIOL, V13, P305, DOI 10.1038/nsmb1077; Fatemi M, 2006, J CELL SCI, V119, P3033, DOI 10.1242/jcs.03099; Georgel PT, 2003, J BIOL CHEM, V278, P32181, DOI 10.1074/jbc.M305308200; Grafi G, 1996, P NATL ACAD SCI USA, V93, P8962, DOI 10.1073/pnas.93.17.8962; Grafi G, 2007, BBA-GENE STRUCT EXPR, V1769, P287, DOI 10.1016/j.bbaexp.2007.02.004; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Jorgensen HF, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl527; Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008; Lever MA, 2000, NATURE, V408, P873, DOI 10.1038/35048603; McBryant SJ, 2006, CHROMOSOME RES, V14, P39, DOI 10.1007/s10577-006-1025-x; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; Nikitina T, 2007, MOL CELL BIOL, V27, P864, DOI 10.1128/MCB.01593-06; Phair RD, 2004, MOL CELL BIOL, V24, P6393, DOI 10.1128/MCB.24.14.6393-6402.2004; Roque A, 2004, NUCLEIC ACIDS RES, V32, P6111, DOI 10.1093/nar/gkh945; Springer NM, 2005, PLANT PHYSIOL, V138, P92, DOI 10.1104/pp.105.060566; Yoo SD, 2007, NAT PROTOC, V2, P1565, DOI 10.1038/nprot.2007.199; Zemach A, 2006, PLANT CELL, V18, P133, DOI 10.1105/tpc.105.036855; Zemach A, 2005, PLANT CELL, V17, P1549, DOI 10.1105/tpc.105.031567; Zemach A, 2003, PLANT J, V34, P565, DOI 10.1046/j.1365-313X.2003.01756.x; Zemach A, 2007, TRENDS PLANT SCI, V12, P80, DOI 10.1016/j.tplants.2006.12.004; Zhang XY, 2006, CELL, V126, P1189, DOI 10.1016/j.cell.2006.08.003; Zilberman D, 2007, NAT GENET, V39, P61, DOI 10.1038/ng1929	23	9	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8406	8411		10.1074/jbc.M706221200	http://dx.doi.org/10.1074/jbc.M706221200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18211904	Green Published, hybrid			2022-12-25	WOS:000254288000038
J	Barua, D; Faeder, JR; Haugh, JM				Barua, Dipak; Faeder, James R.; Haugh, Jason M.			Computational models of tandem Src homology 2 domain interactions and application to phosphoinositide 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P85-ALPHA REGULATORY SUBUNIT; RECEPTOR TYROSINE KINASES; SH2 DOMAINS; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; PI 3-KINASE; BINDING; PHOSPHORYLATION; SPECIFICITY; MOTIFS	Intracellular signal transduction proteins typically utilize multiple interaction domains for proper targeting, and thus a broad diversity of distinct signaling complexes may be assembled. Considering the coordination of only two such domains, as in tandem Src homology 2 ( SH2) domain constructs, gives rise to a kinetic scheme that is not adequately described by simple models used routinely to interpret in vitro binding measurements. To analyze the interactions between tandem SH2 domains and bisphosphorylated peptides, we formulated detailed kinetic models and applied them to the phosphoinositide 3-kinase p85 regulatory subunit/platelet-derived growth factor beta-receptor system. Data for this system from different in vitro assay platforms, including surface plasmon resonance, competition binding, and isothermal titration calorimetry, were reconciled to estimate the magnitude of the cooperativity characterizing the sequential binding of the high and low affinity SH2 domains ( C-SH2 and N-SH2, respectively). Compared with values based on an effective volume approximation, the estimated cooperativity is 3 orders of magnitude lower, indicative of significant structural constraints. Homodimerization of full-length p85 was found to be an alternative mechanism for high avidity binding to phosphorylated platelet-derived growth factor receptors, which would render the N-SH2 domain dispensable for receptor binding.	[Barua, Dipak; Haugh, Jason M.] N Carolina State Univ, Dept Chem & Biomol Engn, Raleigh, NC 27695 USA; [Faeder, James R.] Univ Pittsburgh, Sch Med, Dept Computat Biol, Pittsburgh, PA 15260 USA	University of North Carolina; North Carolina State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Haugh, JM (corresponding author), Box 7905,911 Partners Way, Raleigh, NC 27695 USA.	jason_haugh@ncsu.edu		Faeder, James/0000-0001-8127-609X; Haugh, Jason/0000-0002-2476-4027; Barua, Dipak/0000-0001-8394-1233	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035556, U54GM064346, R01GM067739, R01GM076570] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM067739-04, R01-GM076570, U54-GM064346, R01 GM067739, R01-GM067739, R37-GM35556] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barua D, 2007, BIOPHYS J, V92, P2290, DOI 10.1529/biophysj.106.093484; Bhattacharyya RP, 2006, ANNU REV BIOCHEM, V75, P655, DOI 10.1146/annurev.biochem.75.103004.142710; Blinov ML, 2004, BIOINFORMATICS, V20, P3289, DOI 10.1093/bioinformatics/bth378; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; Eungdamrong NJ, 2004, TRENDS CELL BIOL, V14, P661, DOI 10.1016/j.tcb.2004.10.007; Harpur AG, 1999, J BIOL CHEM, V274, P12323, DOI 10.1074/jbc.274.18.12323; Haugh JM, 2004, J THEOR BIOL, V230, P119, DOI 10.1016/j.jtbi.2004.04.023; HAUGH JM, 2007, CHEM BIOL SMALL MOL, V3, P1061; HERBST JJ, 1994, BIOCHEMISTRY-US, V33, P9376, DOI 10.1021/bi00198a002; Hlavacek William S, 2006, Sci STKE, V2006, pre6, DOI 10.1126/stke.3442006re6; Hlavacek WS, 2003, BIOTECHNOL BIOENG, V84, P783, DOI 10.1002/bit.10842; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; Kaur H, 2006, BIOCHEM J, V393, P235, DOI 10.1042/BJ20051022; KAVANAUGH WM, 1992, MOL CELL BIOL, V12, P3415, DOI 10.1128/MCB.12.8.3415; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; Kholodenko BN, 2006, NAT REV MOL CELL BIO, V7, P165, DOI 10.1038/nrm1838; Ladbury JE, 1996, CHEM BIOL, V3, P791, DOI 10.1016/S1074-5521(96)90063-0; LAUFFENBURGER DA, 1993, RECEPTORS MODELS BIN, P19; Layton MJ, 1998, J BIOL CHEM, V273, P33379, DOI 10.1074/jbc.273.50.33379; Lenz P, 2006, CURR BIOL, V16, P2150, DOI 10.1016/j.cub.2006.09.013; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; O'Brien R, 2000, PROTEIN SCI, V9, P570; Ottinger EA, 1998, J BIOL CHEM, V273, P729, DOI 10.1074/jbc.273.2.729; PANAYOTOU G, 1992, EMBO J, V11, P4261, DOI 10.1002/j.1460-2075.1992.tb05524.x; Park CS, 2003, J BIOL CHEM, V278, P37064, DOI 10.1074/jbc.M304968200; Pawson T, 2004, CELL, V116, P191, DOI 10.1016/S0092-8674(03)01077-8; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; Siegal G, 1998, J MOL BIOL, V276, P461, DOI 10.1006/jmbi.1997.1562; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; von Willebrand M, 1998, J BIOL CHEM, V273, P3994, DOI 10.1074/jbc.273.7.3994; Zhou HX, 2003, J MOL BIOL, V329, P1, DOI 10.1016/S0022-2836(03)00372-3; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	40	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7338	7345		10.1074/jbc.M708359200	http://dx.doi.org/10.1074/jbc.M708359200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18204097	hybrid, Green Published			2022-12-25	WOS:000253997900007
J	Inoue, H; Akita, M				Inoue, Hitoshi; Akita, Mitsuru			Three sets of translocation intermediates are formed during the early stage of protein import into chloroplasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR PROTEINS; ENVELOPE MEMBRANES; TRANSIT SEQUENCE; IDENTIFICATION; BINDING; OUTER; RECOGNITION; COMPONENTS; TRANSPORT; APPARATUS	During the early stage of protein import into chloroplasts, precursor proteins synthesized in the cytosol irreversibly bind to chloroplasts to form the early translocation intermediate under stringent energy conditions. Many efforts have been made to identify the components involved in protein import by analyzing the early intermediate. However, the state of the precursor within the intermediate has not been well investigated so far. In this study, an attempt was made to evaluate the extent of translocation of the precursor by determining the state of the precursor in the early intermediate under various conditions and analyzing the fragments generated by limited proteolysis of the precursors docked to chloroplasts. Our results indicate that three different sets of early intermediate are formed based on temperature and the hydrolysis of GTP/ ATP. These have been identified based on the size of proteolytic fragments of the precursor as "energy-dependent association," "insertion," and "penetration" states. These findings suggest two individual ATP-hydrolyzing steps during the early stage of protein import, one of which is temperature-sensitive. Our results also demonstrate that translocation through the outer envelope membrane is mainly dependent on internal ATP.	[Inoue, Hitoshi; Akita, Mitsuru] Ehime Univ, United Grad Agr Sci, Matsuyama, Ehime 7908566, Japan; [Inoue, Hitoshi; Akita, Mitsuru] Ehime Univ, Fac Agr, Matsuyama, Ehime 7908566, Japan	Ehime University; Ehime University	Akita, M (corresponding author), Ehime Univ, United Grad Agr Sci, Matsuyama, Ehime 7908566, Japan.	akita@agr.ehime-u.ac.jp		INOUE, Hitoshi/0000-0003-4988-337X				Akita M, 1997, J CELL BIOL, V136, P983, DOI 10.1083/jcb.136.5.983; Becker T, 2004, MOL BIOL CELL, V15, P5130, DOI 10.1091/mbc.E04-05-0405; Becker T, 2004, EMBO J, V23, P520, DOI 10.1038/sj.emboj.7600089; Bedard J, 2005, J EXP BOT, V56, P2287, DOI 10.1093/jxb/eri243; Bruce BD, 1994, PLANT MOL BIOL MAN J, VJ1, P1; Chen KY, 2007, PLANT J, V49, P149, DOI 10.1111/j.1365-313X.2006.02944.x; CHUA NH, 1978, P NATL ACAD SCI USA, V75, P6110, DOI 10.1073/pnas.75.12.6110; CLINE K, 1984, PLANT PHYSIOL, V75, P675, DOI 10.1104/pp.75.3.675; Hasunuma K, 2003, J BIOENERG BIOMEMBR, V35, P57, DOI 10.1023/A:1023493823368; Jelic M, 2002, BIOL CHEM, V383, P1875, DOI 10.1515/BC.2002.211; Kessler F, 2006, TRAFFIC, V7, P248, DOI 10.1111/j.1600-0854.2005.00382.x; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; Kouranov A, 1997, J CELL BIOL, V139, P1677, DOI 10.1083/jcb.139.7.1677; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHENY EA, 1994, PLANT CELL, V6, P427, DOI 10.2307/3869762; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ma YK, 1996, J CELL BIOL, V134, P315, DOI 10.1083/jcb.134.2.315; May T, 2000, PLANT CELL, V12, P53, DOI 10.1105/tpc.12.1.53; Nielsen E, 1997, EMBO J, V16, P935, DOI 10.1093/emboj/16.5.935; OBLONG JE, 1992, EMBO J, V11, P4401, DOI 10.1002/j.1460-2075.1992.tb05540.x; OLSEN LJ, 1992, J BIOL CHEM, V267, P433; OLSEN LJ, 1989, J BIOL CHEM, V264, P6724; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; Rensink WA, 2000, J BIOL CHEM, V275, P10265, DOI 10.1074/jbc.275.14.10265; Schleiff E, 2003, P NATL ACAD SCI USA, V100, P4604, DOI 10.1073/pnas.0730860100; SCHNELL DJ, 1993, J CELL BIOL, V120, P103, DOI 10.1083/jcb.120.1.103; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; Scott SV, 1996, J CELL BIOL, V132, P63, DOI 10.1083/jcb.132.1.63; THEG SM, 1989, J BIOL CHEM, V264, P6730; WAEGEMANN K, 1991, PLANT J, V1, P149, DOI 10.1111/j.1365-313X.1991.00149.x; Young ME, 1999, PLANT PHYSIOL, V121, P237, DOI 10.1104/pp.121.1.237	31	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7491	7502		10.1074/jbc.M709571200	http://dx.doi.org/10.1074/jbc.M709571200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18199746	hybrid			2022-12-25	WOS:000253997900024
J	Terrones, O; Etxebarria, A; Landajuela, A; Landeta, O; Antonsson, B; Basanez, G				Terrones, Oihana; Etxebarria, Aitor; Landajuela, Ane; Landeta, Olatz; Antonsson, Bruno; Basanez, Gorka			BIM and tBID are not mechanistically equivalent when assisting BAX to permeabilize bilayer membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; BCL-2 FAMILY; CONFORMATIONAL-CHANGE; ANTIMICROBIAL PEPTIDES; PROAPOPTOTIC MOLECULES; PORE FORMATION; BH3 DOMAINS; CARDIOLIPIN; APOPTOSIS; MITOCHONDRIA	BIM and tBID are two BCL-2 homology 3 (BH3)-only proteins with a particularly strong capacity to trigger BAX-driven mitochondrial outer membrane permeabilization, a crucial event in mammalian apoptosis. However, the means whereby BIM and tBID fulfill this task is controversial. Here, we used a reconstituted liposomal system bearing physiological relevance to explore systematically how the BAX-permeabilizing function is influenced by interactions of BIM/BID-derived proteins and BH3 motifs with multidomain BCL-2 family members and with membrane lipids. We found that nanomolar dosing of BIM proteins sufficed to reverse completely the inhibition of BAX permeabilizing activity exerted by all antiapoptotic proteins tested (BCL-2, BCL-XL, BCL-W, MCL-1, and A1). This effect was reproducible by a peptide representing the BH3 motif of BIM, whereas an equivalent BID BH3 peptide was less potent and more selective, reversing antiapoptotic inhibition. On the other hand, in the absence of BCL-2-type proteins, BIM proteins and the BIM BH3 peptide were inefficient, directly triggering the BAX-permeabilizing function. In contrast, tBID alone potently assisted BAX to permeabilize membranes at least in part by producing a structural distortion in the lipid bilayer via BH3-independent interaction of tBID with cardiolipin. Together, these results support the notion that BIM and tBID follow different strategies to trigger BAX-driven mitochondrial outer membrane permeabilization with strong potency.	[Terrones, Oihana; Etxebarria, Aitor; Landajuela, Ane; Landeta, Olatz; Basanez, Gorka] Univ Pais Vasco Euskal Herriko Unibertistatea, Unidad Biofis CSIC UPV EHU, Leioa 48940, Spain; [Antonsson, Bruno] Merck Serono Int SA, CH-1202 Geneva, Switzerland	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; Merck & Company; Serono International S.A.; Merck KGaA; EMD Serono Inc.	Basanez, G (corresponding author), Univ Pais Vasco Euskal Herriko Unibertistatea, Unidad Biofis CSIC UPV EHU, POB 644,Barrio Sarriena S-N, Leioa 48940, Spain.	gbzbaasg@lg.ehu.es	Terrones, Oihana/AAA-8903-2019; Basanez, Gorka/L-9509-2014; Terrones, Oihana/I-4023-2015	Basanez, Gorka/0000-0002-7475-7861; Terrones, Oihana/0000-0001-7421-6486; Landeta, Olatz/0000-0002-5494-0271				Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Basanez G, 2002, J BIOL CHEM, V277, P49360, DOI 10.1074/jbc.M206069200; Basanez G, 2002, FEBS LETT, V532, P115, DOI 10.1016/S0014-5793(02)03651-7; Basanez G, 2002, CELL MOL LIFE SCI, V59, P1478, DOI 10.1007/s00018-002-8523-6; Basanez G, 2001, J BIOL CHEM, V276, P31083, DOI 10.1074/jbc.M103879200; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chanturiya AN, 2004, J VIROL, V78, P6304, DOI 10.1128/JVI.78.12.6304-6312.2004; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Day CL, 1999, CELL DEATH DIFFER, V6, P1125, DOI 10.1038/sj.cdd.4400584; Day CL, 2005, J BIOL CHEM, V280, P4738, DOI 10.1074/jbc.M411434200; Denisov AY, 2006, BIOCHEMISTRY-US, V45, P2250, DOI 10.1021/bi052332s; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Epand RF, 2002, J BIOL CHEM, V277, P32632, DOI 10.1074/jbc.M202396200; Galonek HL, 2006, NAT CELL BIOL, V8, P1317, DOI 10.1038/ncb1206-1317; Garcia-Saez AJ, 2005, BIOPHYS J, V88, P3976, DOI 10.1529/biophysj.104.058008; Garcia-Saez AJ, 2007, BIOPHYS J, V93, P103, DOI 10.1529/biophysj.106.100370; Germain M, 2008, J BIOL CHEM, V283, P6384, DOI 10.1074/jbc.M707762200; Giordano A, 2005, CELL DEATH DIFFER, V12, P603, DOI 10.1038/sj.cdd.4401636; Gong XM, 2004, J BIOL CHEM, V279, P28954, DOI 10.1074/jbc.M403490200; Gonzalvez F, 2005, CELL DEATH DIFFER, V12, P659, DOI 10.1038/sj.cdd.4401585; Gonzalvez F, 2005, CELL DEATH DIFFER, V12, P614, DOI 10.1038/sj.cdd.4401571; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Guscetti F, 2005, FASEB J, V19, P464, DOI 10.1096/fj.04-2316fje; Hadders MA, 2007, SCIENCE, V317, P1552, DOI 10.1126/science.1147103; Hetz C, 2005, J BIOL CHEM, V280, P42960, DOI 10.1074/jbc.M505843200; Hinds MG, 2007, CELL DEATH DIFFER, V14, P128, DOI 10.1038/sj.cdd.4401934; Huang HW, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.198304; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Kim TH, 2004, MOL BIOL CELL, V15, P3061, DOI 10.1091/mbc.E03-12-0864; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Leber B, 2007, APOPTOSIS, V12, P897, DOI 10.1007/s10495-007-0746-4; Leontiadou H, 2006, J AM CHEM SOC, V128, P12156, DOI 10.1021/ja062927q; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Liu J, 2004, APOPTOSIS, V9, P533, DOI 10.1023/B:APPT.0000038034.16230.ea; Liu XQ, 2003, IMMUNITY, V19, P341, DOI 10.1016/S1074-7613(03)00234-6; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Mizuta T, 2007, J BIOL CHEM, V282, P16623, DOI 10.1074/jbc.M611060200; Munoz-Pinedo C, 2006, P NATL ACAD SCI USA, V103, P11573, DOI 10.1073/pnas.0603007103; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Oh KJ, 2006, J BIOL CHEM, V281, P36999, DOI 10.1074/jbc.M602341200; Pagliari LJ, 2005, P NATL ACAD SCI USA, V102, P17975, DOI 10.1073/pnas.0506712102; Petros AM, 2004, BBA-MOL CELL RES, V1644, P83, DOI 10.1016/j.bbamcr.2003.08.012; Polster BM, 2003, J NEUROSCI, V23, P2735; Rostovtseva TK, 2004, J BIOL CHEM, V279, P13575, DOI 10.1074/jbc.M310593200; Roucou X, 2002, BIOCHEM J, V368, P915, DOI 10.1042/BJ20020972; SCHMITT L, 1994, J AM CHEM SOC, V116, P8485, DOI 10.1021/ja00098a008; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tan CB, 2006, J BIOL CHEM, V281, P14764, DOI 10.1074/jbc.M602374200; Terradillos O, 2002, FEBS LETT, V522, P29, DOI 10.1016/S0014-5793(02)02871-5; Terrones O, 2004, J BIOL CHEM, V279, P30081, DOI 10.1074/jbc.M313420200; Thuduppathy GR, 2006, BIOCHEMISTRY-US, V45, P14533, DOI 10.1021/bi0616652; Tyurin VA, 2007, CELL DEATH DIFFER, V14, P872, DOI 10.1038/sj.cdd.4402068; Walensky LD, 2006, MOL CELL, V24, P199, DOI 10.1016/j.molcel.2006.08.020; Weber A, 2007, J CELL BIOL, V177, P625, DOI 10.1083/jcb.200610148; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Yamaguchi H, 2002, J BIOL CHEM, V277, P41604, DOI 10.1074/jbc.M207516200; Yethon JA, 2003, J BIOL CHEM, V278, P48935, DOI 10.1074/jbc.M306289200; YIN XM, 2006, GENE, V15, P369; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Youle RJ, 2007, SCIENCE, V315, P776, DOI 10.1126/science.1138870; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zhai DY, 2008, J BIOL CHEM, V283, P9580, DOI 10.1074/jbc.M708426200; [No title captured]	63	31	32	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7790	7803		10.1074/jbc.M708814200	http://dx.doi.org/10.1074/jbc.M708814200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18195012	hybrid			2022-12-25	WOS:000253997900055
J	Zhang, XM; Tan, FL; Zhang, YK; Skidgel, RA				Zhang, Xianming; Tan, Fulong; Zhang, Yongkang; Skidgel, Randal A.			Carboxypeptidase M and kinin B1 receptors interact to facilitate efficient b1 signaling from B2 agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-CONVERTING ENZYME; NITRIC-OXIDE PRODUCTION; MEMBRANE-BOUND CARBOXYPEPTIDASE; KINASE-C-EPSILON; CRYSTAL-STRUCTURE; B-1 RECEPTORS; LIPID RAFTS; BRADYKININ RECEPTORS; ENDOTHELIAL-CELLS; MOLECULAR-CLONING	Kinin B1 receptor (B1R) expression is induced by injury or inflammatory mediators, and its signaling produces both beneficial and deleterious effects. Kinins cleaved from kininogen are agonists of the B2R and must be processed by a carboxypeptidase to generate B1R agonists des-Arg(9)-bradykinin or desArg(10)-kallidin. Carboxypeptidase M(CPM) is a membrane protein potentially well suited for this function. Here we show that CPM expression is required to generate a B1R-dependent increase in [Ca2+](i) in cells stimulated with B2R agonists kallidin or bradykinin. CPM and the B1R interact on the cell membrane, as shown by co-immunoprecipitation, cross-linking, and fluorescence resonance energy transfer analysis. CPM and B1R are also co-localized in lipid raft/caveolin-enriched membrane fractions, as determined by gradient centrifugation. Treatment of cells co-expressing CPM and B1R with methyl-beta-cyclodextrin to disrupt lipid rafts reduced the B1R-dependent increase in [Ca2+](i) in response to B2R agonists, whereas cholesterol treatment enhanced the response. A monoclonal antibody to the C-terminal beta-sheet domain of CPM reduced the B1R response to B2R agonists without inhibiting CPM. Cells expressing a novel fusion protein containing CPM at the N terminus of the B1R also increased [Ca2+] i when stimulated with B2R agonists, but the response was not reduced by methyl-beta-cyclodextrin or CPM antibody. A B1R- and CPM-dependent calcium signal in response to B2R agonist bradykinin was also found in endothelial cells that express both proteins. Thus, a close relationship of B1Rs and CPM on themembraneis required for efficiently generating B1R signals, which play important roles in inflammation.	[Zhang, Xianming; Tan, Fulong; Zhang, Yongkang; Skidgel, Randal A.] Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; [Tan, Fulong; Skidgel, Randal A.] Univ Illinois, Coll Med, Dept Anesthesiol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Skidgel, RA (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, M-C 868,835 S Wolcott, Chicago, IL 60612 USA.	rskidgel@uic.edu	zhang, xian/GYA-0290-2022		NHLBI NIH HHS [P01 HL060678] Funding Source: Medline; NIDDK NIH HHS [DK 41431] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL060678] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK041431, R01DK041431, R56DK041431] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alberts B, 1998, CELL, V92, P291, DOI 10.1016/S0092-8674(00)80922-8; Aloy P, 2001, J BIOL CHEM, V276, P16177, DOI 10.1074/jbc.M011457200; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Boldt J, 1998, CRIT CARE MED, V26, P1663, DOI 10.1097/00003246-199810000-00018; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Campos MM, 2006, TRENDS PHARMACOL SCI, V27, P646, DOI 10.1016/j.tips.2006.10.007; Chen ZL, 2006, FASEB J, V20, P2261, DOI 10.1096/fj.06-6113com; de la Vega MR, 2007, FASEB J, V21, P851, DOI 10.1096/fj.06-7330com; DEDDISH PA, 1990, J BIOL CHEM, V265, P15083; DEDDISH PA, 1989, BIOCHEM J, V261, P289, DOI 10.1042/bj2610289; Donnini S, 2006, J PHARMACOL EXP THER, V319, P515, DOI 10.1124/jpet.106.108803; EATON DL, 1991, J BIOL CHEM, V266, P21833; Emanueli C, 2002, CIRCULATION, V105, P360, DOI 10.1161/hc0302.102142; Erdos EG, 1999, TRENDS ENDOCRIN MET, V10, P223, DOI 10.1016/S1043-2760(99)00156-3; Erdos EG, 2002, INT IMMUNOPHARMACOL, V2, P1741, DOI 10.1016/S1567-5769(02)00166-2; Erdos EG, 2002, CARDIOVASC RES, V54, P485, DOI 10.1016/S0008-6363(02)00284-5; ERDOS EG, 1962, BIOCHEM PHARMACOL, V11, P585, DOI 10.1016/0006-2952(62)90119-3; Fricker LD, 1999, TRENDS BIOCHEM SCI, V24, P390, DOI 10.1016/S0968-0004(99)01448-6; FRICKER LD, 2004, HDB PROTEOLYTIC ENZY, P844; Fricker LD, 2004, HDB PROTEOLYTIC ENZY, V8, P840; Goldspink PH, 2004, CIRC RES, V95, P424, DOI 10.1161/01.RES.0000138299.85648.92; Hadkar V, 2001, MOL PHARMACOL, V59, P1324, DOI 10.1124/mol.59.5.1324; Hagiwara M, 2004, HYPERTENS RES, V27, P399, DOI 10.1291/hypres.27.399; Ignjatovic T, 2004, MOL PHARMACOL, V66, P1310, DOI 10.1124/mol.104.001990; Ignjatovic T, 2002, J BIOL CHEM, V277, P16847, DOI 10.1074/jbc.M200355200; JASPARD E, 1993, J BIOL CHEM, V268, P9496; Kalinina E, 2007, FASEB J, V21, P836, DOI 10.1096/fj.06-7329com; Kang DS, 2005, MOL PHARMACOL, V67, P309, DOI 10.1124/mol.104.002840; Keil C, 2007, J MOL BIOL, V366, P504, DOI 10.1016/j.jmb.2006.11.025; Kenworthy A, 2002, TRENDS BIOCHEM SCI, V27, P435, DOI 10.1016/S0968-0004(02)02178-3; KUROKI K, 1994, J VIROL, V68, P2091, DOI 10.1128/JVI.68.4.2091-2096.1994; Lamb ME, 2001, BIOCHEM J, V355, P741, DOI 10.1042/bj3550741; Leeb-Lundberg LMF, 2005, PHARMACOL REV, V57, P27, DOI 10.1124/pr.57.1.2; Li JQ, 2002, GENE, V284, P189, DOI 10.1016/S0378-1119(01)00898-8; Liu J, 2004, J BIOL CHEM, V279, P55924, DOI 10.1074/jbc.M410024200; Macdonald JL, 2005, J LIPID RES, V46, P1061, DOI 10.1194/jlr.D400041-JLR200; Marcic B, 2000, J BIOL CHEM, V275, P16110, DOI 10.1074/jbc.M909490199; MCGWIRE GB, 1995, J BIOL CHEM, V270, P17154, DOI 10.1074/jbc.270.29.17154; Michel B, 1996, CIRC RES, V78, P635; Moniwa N, 2006, BIOL CHEM, V387, P203, DOI 10.1515/BC.2006.027; Oh P, 2001, MOL BIOL CELL, V12, P685, DOI 10.1091/mbc.12.3.685; Parenti A, 2001, FASEB J, V15, P1487, DOI 10.1096/fj.00-0503fje; Parkin ET, 2003, J CELL SCI, V116, P3079, DOI 10.1242/jcs.00626; Pesquero JB, 2006, BIOL CHEM, V387, P119, DOI 10.1515/BC.2006.017; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; REGOLI D, 1980, PHARMACOL REV, V32, P1; Reverter D, 2004, J MOL BIOL, V338, P257, DOI 10.1016/j.jmb.2004.02.058; Reznik SE, 2001, CELL MOL LIFE SCI, V58, P1790, DOI 10.1007/PL00000819; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; Sabourin T, 2002, MOL PHARMACOL, V61, P546, DOI 10.1124/mol.61.3.546; Sangsree S, 2003, AM J PHYSIOL-HEART C, V284, pH1959, DOI 10.1152/ajpheart.00036.2003; Schremmer-Danninger E, 1998, BIOCHEM BIOPH RES CO, V243, P246, DOI 10.1006/bbrc.1997.7999; SHINOHARA T, 1994, INT ARCH ALLERGY IMM, V103, P400, DOI 10.1159/000236661; Siebeck M, 1996, IMMUNOPHARMACOLOGY, V33, P81, DOI 10.1016/0162-3109(96)00060-4; Skidgel R. A., 1996, ZINC METALLOPROTEASE, P241; Skidgel RA, 2006, BIOL CHEM, V387, P159, DOI 10.1515/BC.2006.021; Skidgel RA, 1998, IMMUNOL REV, V161, P129, DOI 10.1111/j.1600-065X.1998.tb01577.x; SKIDGEL RA, 1989, J BIOL CHEM, V264, P2236; SKIDGEL RA, 1988, TRENDS PHARMACOL SCI, V9, P299, DOI 10.1016/0165-6147(88)90015-6; SKIDGEL RA, 1984, BIOCHEM PHARMACOL, V33, P3471, DOI 10.1016/0006-2952(84)90122-9; SKIDGEL RA, 2004, HDB PROTEOLYTIC ENZY, P851; SKIDGEL RA, 2004, HDB PROTEOLYTIC ENZY, P837; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Stanisavljevic S, 2006, J PHARMACOL EXP THER, V316, P1153, DOI 10.1124/jpet.105.093849; TAN FL, 1995, METHOD ENZYMOL, V248, P663; TAN FL, 1989, J BIOL CHEM, V264, P13165; Tan FL, 2003, BIOCHEM J, V370, P567, DOI 10.1042/BJ20021495; Varlamov O, 1998, J CELL SCI, V111, P877; Vendrell J, 2000, BBA-PROTEIN STRUCT M, V1477, P284, DOI 10.1016/S0167-4838(99)00280-0; Wiel E, 2004, INTENS CARE MED, V30, P1652, DOI 10.1007/s00134-004-2198-4; Zhang YK, 2007, J BIOL CHEM, V282, P32453, DOI 10.1074/jbc.M706242200	72	45	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7994	8004		10.1074/jbc.M709837200	http://dx.doi.org/10.1074/jbc.M709837200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18187413	hybrid			2022-12-25	WOS:000253997900074
J	Anderson, SB; Goldberg, AL; Whitman, M				Anderson, Sarah B.; Goldberg, Alfred L.; Whitman, Malcolm			Identification of a novel pool of extracellular pro-myostatin in skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; LATENT TGF-BETA; MOLECULAR-WEIGHT COMPLEX; BINDING-PROTEIN; SUPERFAMILY MEMBER; GDF-8 PROPEPTIDE; HUMAN-PLATELETS; IN-VIVO; MICE; ACTIVATION	Myostatin, a transforming growth factor-beta superfamily ligand, negatively regulates skeletal muscle growth. Generation of the mature signaling peptide requires cleavage of pro-myostatin by a proprotein convertase, which is thought to occur constitutively in the Golgi apparatus. In serum, mature myostatin is found in an inactive, non-covalent complex with its prodomain. We find that in skeletal muscle, unlike serum, myostatin is present extracellularly as uncleaved pro-myostatin. In cultured cells, co-expression of pro-myostatin and latent transforming growth factor-beta-binding protein-3 (LTBP-3) sequesters pro-myostatin in the extracellular matrix, and secreted pro-myostatin can be cleaved extracellularly by the proprotein convertase furin. Co-expression of LTBP-3 with myostatin reduces phosphorylation of Smad2, and ectopic expression of LTBP-3 in mature mouse skeletal muscle increases fiber area, consistent with reduction of myostatin activity. We propose that extracellular pro-myostatin constitutes the major pool of latent myostatin in muscle. Post-secretion activation of this pool by furin family proprotein convertases may therefore represent a major control point for activation of myostatin in skeletal muscle.	[Anderson, Sarah B.; Goldberg, Alfred L.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; [Anderson, Sarah B.; Whitman, Malcolm] Harvard Univ, Sch Dent Med, Dept Dev Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard School of Dental Medicine	Whitman, M (corresponding author), 188 Longwood Ave, Boston, MA 02115 USA.	mwhitman@hms.harvard.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029468] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-29468] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Altmann CR, 2002, DEV BIOL, V248, P118, DOI 10.1006/dbio.2002.0716; Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Baqui M, 2003, J BIOL CHEM, V278, P1206, DOI 10.1074/jbc.M210266200; Beck S, 2002, NAT CELL BIOL, V4, P981, DOI 10.1038/ncb890; Bogdanovich S, 2002, NATURE, V420, P418, DOI 10.1038/nature01154; Chen Y, 2003, J CELL PHYSIOL, V196, P319, DOI 10.1002/jcp.10296; Dabovic B, 2005, BONE, V37, P25, DOI 10.1016/j.bone.2005.02.021; Dabovic B, 2002, J CELL BIOL, V156, P227, DOI 10.1083/jcb.200111080; Durocher Y, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e9; Faure S, 2000, DEVELOPMENT, V127, P2917; FLAUMENHAFT R, 1993, J CELL BIOL, V120, P995, DOI 10.1083/jcb.120.4.995; Gleizes PE, 1996, J BIOL CHEM, V271, P29891, DOI 10.1074/jbc.271.47.29891; Gonzalez-Cadavid NF, 1998, P NATL ACAD SCI USA, V95, P14938, DOI 10.1073/pnas.95.25.14938; Hill JJ, 2002, J BIOL CHEM, V277, P40735, DOI 10.1074/jbc.M206379200; Hill JJ, 2003, MOL ENDOCRINOL, V17, P1144, DOI 10.1210/me.2002-0366; Ho DM, 2006, DEV BIOL, V295, P730, DOI 10.1016/j.ydbio.2006.03.050; Hosoyama T, 2005, ZOOL SCI, V22, P229, DOI 10.2108/zsj.22.229; Jiang MS, 2004, BIOCHEM BIOPH RES CO, V315, P525, DOI 10.1016/j.bbrc.2004.01.085; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; Koli K, 2001, MICROSC RES TECHNIQ, V52, P354, DOI 10.1002/1097-0029(20010215)52:4<354::AID-JEMT1020>3.0.CO;2-G; Langley B, 2002, J BIOL CHEM, V277, P49831, DOI 10.1074/jbc.M204291200; Lee MA, 2001, DEVELOPMENT, V128, P2939; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; Lee SJ, 2004, ANNU REV CELL DEV BI, V20, P61, DOI 10.1146/annurev.cellbio.20.012103.135836; Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098; Leitlein J, 2001, J IMMUNOL, V166, P7238, DOI 10.4049/jimmunol.166.12.7238; Liaw PCY, 2001, J BIOL CHEM, V276, P8364, DOI 10.1074/jbc.M010572200; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; MOREN A, 1994, J BIOL CHEM, V269, P32469; Noguera I, 2003, GENE, V308, P31, DOI 10.1016/S0378-1119(03)00463-3; Nunes I, 1997, J CELL BIOL, V136, P1151, DOI 10.1083/jcb.136.5.1151; Patel K, 2005, NEUROMUSCULAR DISORD, V15, P117, DOI 10.1016/j.nmd.2004.10.018; Penttinen C, 2002, J CELL SCI, V115, P3457; Rebbapragada A, 2003, MOL CELL BIOL, V23, P7230, DOI 10.1128/MCB.23.20.7230-7242.2003; Rifkin DB, 2005, J BIOL CHEM, V280, P7409, DOI 10.1074/jbc.R400029200; Saharinen J, 1996, EMBO J, V15, P245, DOI 10.1002/j.1460-2075.1996.tb00355.x; Saharinen J, 1998, J BIOL CHEM, V273, P18459, DOI 10.1074/jbc.273.29.18459; Sakuma K, 2000, BBA-MOL CELL RES, V1497, P77, DOI 10.1016/S0167-4889(00)00044-6; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Scamuffa N, 2006, FASEB J, V20, P1954, DOI 10.1096/fj.05-5491rev; Sharma M, 1999, J CELL PHYSIOL, V180, P1; Shipley JM, 2000, MOL CELL BIOL, V20, P4879, DOI 10.1128/MCB.20.13.4879-4887.2000; Siriett V, 2006, J CELL PHYSIOL, V209, P866, DOI 10.1002/jcp.20778; Thies RS, 2001, GROWTH FACTORS, V18, P251; Wagner KR, 2002, ANN NEUROL, V52, P832, DOI 10.1002/ana.10385; WAKEFIELD LM, 1988, J BIOL CHEM, V263, P7646; Wehling M, 2000, FASEB J, V14, P103, DOI 10.1096/fasebj.14.1.103; Whitman M, 2001, DEV CELL, V1, P605, DOI 10.1016/S1534-5807(01)00076-4; Whittemore LA, 2003, BIOCHEM BIOPH RES CO, V300, P965, DOI 10.1016/S0006-291X(02)02953-4; Wojcik S, 2005, ACTA NEUROPATHOL, V110, P173, DOI 10.1007/s00401-005-1035-3; Wolfman NM, 2003, P NATL ACAD SCI USA, V100, P15842, DOI 10.1073/pnas.2534946100; YIN WS, 1995, J BIOL CHEM, V270, P10147, DOI 10.1074/jbc.270.17.10147; Yin WS, 1998, BBA-PROTEIN STRUCT M, V1383, P340, DOI 10.1016/S0167-4838(98)00003-X; Zimmers TA, 2002, SCIENCE, V296, P1486, DOI 10.1126/science.1069525	56	108	123	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					7027	7035		10.1074/jbc.M706678200	http://dx.doi.org/10.1074/jbc.M706678200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18175804	hybrid			2022-12-25	WOS:000253779600047
J	Shi, D; Sagar, V; Jin, ZM; Yu, XL; Caldovic, L; Morizono, H; Allewell, NM; Tuchman, M				Shi, Dashuang; Sagar, Vatsala; Jin, Zhongmin; Yu, Xiaolin; Caldovic, Ljubica; Morizono, Hiroki; Allewell, Norma M.; Tuchman, Mendel			The crystal structure of N-acetyl-L-glutamate synthase from Neisseria gonorrhoeae provides insights into mechanisms of catalysis and regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININE-BIOSYNTHESIS; ACETYLGLUTAMATE SYNTHASE; ESCHERICHIA-COLI; HISTONE ACETYLTRANSFERASE; CARBAMOYL-PHOSPHATE; PYROCOCCUS-FURIOSUS; PROTEIN-STRUCTURE; KINASE; EXPRESSION; ENZYME	The crystal structures of N-acetylglutamate synthase ( NAGS) in the arginine biosynthetic pathway of Neisseria gonorrhoeae complexed with acetyl-CoA and with CoA plus N-acetylglutamate have been determined at 2.5- and 2.6-angstrom resolution, respectively. The monomer consists of two separately folded domains, an amino acid kinase ( AAK) domain and an N-acetyltransferase ( NAT) domain connected through a 10-angstrom linker. The monomers assemble into a hexameric ring that consists of a trimer of dimers with 32-point symmetry, inner and outer ring diameters of 20 and 100 A, respectively, and a height of 110 A. Each AAK domain interacts with the cognate domains of two adjacent monomers across two 2-fold symmetry axes and with the NAT domain from a second monomer of the adjacent dimer in the ring. The catalytic sites are located within the NAT domains. Three active site residues, Arg(316), Arg(425), and Ser(427), anchor N-acetylglutamate in a position at the active site to form hydrogen bond interactions to the main chain nitrogen atoms of Cys(356) and Leu(314), and hydrophobic interactions to the side chains of Leu(313) and Leu(314). The mode of binding of acetyl-CoA and CoA is similar to other NAT family proteins. The AAK domain, although catalytically inactive, appears to bind arginine. This is the first reported crystal structure of any NAGS, and it provides insights into the catalytic function and arginine regulation of NAGS enzymes.	[Shi, Dashuang; Yu, Xiaolin; Caldovic, Ljubica; Morizono, Hiroki; Tuchman, Mendel] George Washington Univ, Childrens Natl Med Ctr, Childrens Res Inst, Washington, DC 20010 USA; [Sagar, Vatsala; Allewell, Norma M.] Univ Maryland, Dept Chem & Biochem, Coll Chem & Life Sci, College Pk, MD 20742 USA; [Jin, Zhongmin] Argonne Natl Lab, SE Reg Collaborat Access Team Adv Photon Source, Argonne, IL 60439 USA	Children's National Health System; George Washington University; University System of Maryland; University of Maryland College Park; United States Department of Energy (DOE); Argonne National Laboratory	Shi, D (corresponding author), George Washington Univ, Childrens Natl Med Ctr, Childrens Res Inst, 11 Michigan Ave,NW, Washington, DC 20010 USA.	dshi@cnmcresearch.org	Morizono, Hiroki/E-9737-2013	Morizono, Hiroki/0000-0002-9678-5564; Sagar, Vatsala/0000-0003-4980-6462; Shi, Dashuang/0000-0002-5491-1104; Caldovic, Ljubica/0000-0002-9140-5585	NICHD NIH HHS [HD 32652, P01 HD032652] Funding Source: Medline; NIDDK NIH HHS [K01 DK067935, DK064913, DK067935, R01 DK064913] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD032652] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064913, K01DK067935] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACHMANN C, 1982, ADV EXP MED BIOL, V153, P39; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Briozzo P, 2005, J BIOL CHEM, V280, P25533, DOI 10.1074/jbc.M501849200; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Caldovic L, 2003, BIOCHEM J, V372, P279, DOI 10.1042/BJ20030002; Caldovic L, 2002, BIOCHEM BIOPH RES CO, V299, P581, DOI 10.1016/S0006-291X(02)02696-7; Caldovic L, 2002, BIOCHEM J, V364, P825, DOI 10.1042/BJ20020161; Chacon P, 2002, J MOL BIOL, V317, P375, DOI 10.1006/jmbi.2002.5438; CUNIN R, 1986, MICROBIOL REV, V50, P314, DOI 10.1128/MMBR.50.3.314-352.1986; Delano W.L, 2002, PYMOL USERS MANUAL; Dyda F, 2000, ANNU REV BIOPH BIOM, V29, P81, DOI 10.1146/annurev.biophys.29.1.81; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Errey JC, 2005, J BACTERIOL, V187, P3039, DOI 10.1128/JB.187.9.3039-3044.2005; GRISOLIA S, 1953, J BIOL CHEM, V204, P753; HAAS D, 1975, EUR J BIOCHEM, V52, P377; He HZ, 2003, J MOL BIOL, V325, P1019, DOI 10.1016/S0022-2836(02)01284-6; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kotaka M, 2006, J BIOL CHEM, V281, P31544, DOI 10.1074/jbc.M605886200; Labedan B, 2004, MOL BIOL EVOL, V21, P364, DOI 10.1093/molbev/msh024; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Marco-Marin C, 2005, J MOL BIOL, V352, P438, DOI 10.1016/j.jmb.2005.07.045; Marina A, 1999, PROTEIN SCI, V8, P934; Marmorstein R, 2001, CURR OPIN GENET DEV, V11, P155, DOI 10.1016/S0959-437X(00)00173-8; MAROMARIN C, 2007, J MOL BIOL, V367, P1431; MARTIN PR, 1992, J BACTERIOL, V174, P2694, DOI 10.1128/jb.174.8.2694-2701.1992; MARVIL DK, 1977, J BIOL CHEM, V252, P3295; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Painter J, 2006, ACTA CRYSTALLOGR D, V62, P439, DOI 10.1107/S0907444906005270; Qu Qiuhao, 2007, BMC Biochemistry, V8, DOI 10.1186/1471-2091-8-4; Ramon-Maiques S, 2000, J MOL BIOL, V299, P463, DOI 10.1006/jmbi.2000.3779; Ramon-Maiques S, 2006, J MOL BIOL, V356, P695, DOI 10.1016/j.jmb.2005.11.079; Ramon-Maiques S, 2002, STRUCTURE, V10, P329, DOI 10.1016/S0969-2126(02)00721-9; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Shi DS, 2006, ACTA CRYSTALLOGR F, V62, P1218, DOI 10.1107/S1744309106044101; Shi DS, 2005, ACTA CRYSTALLOGR F, V61, P676, DOI 10.1107/S1744309105018051; Sinclair JC, 2000, NAT STRUCT BIOL, V7, P560; Slocum RD, 2005, PLANT PHYSIOL BIOCH, V43, P729, DOI 10.1016/j.plaphy.2005.06.007; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Uson I, 1999, CURR OPIN STRUC BIOL, V9, P643, DOI 10.1016/S0959-440X(99)00020-2; Vetting MW, 2003, PROTEIN SCI, V12, P1954, DOI 10.1110/ps.03153703; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; WONG LJC, 1983, BIOCHEMISTRY-US, V22, P4637, DOI 10.1021/bi00289a004; Xu Y, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-4; Xu Y, 2007, MICROBIOL MOL BIOL R, V71, P36, DOI 10.1128/MMBR.00032-06; Yan Y, 2002, NAT STRUCT BIOL, V9, P862, DOI 10.1038/nsb849	51	26	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					7176	7184		10.1074/jbc.M707678200	http://dx.doi.org/10.1074/jbc.M707678200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18184660	Green Accepted, hybrid			2022-12-25	WOS:000253779600063
J	Wu, L; Yong, SL; Fan, C; Ni, Y; Yoo, S; Zhang, T; Zhang, X; Obejero-Paz, CA; Rho, HJ; Ke, T; Szafranski, P; Jones, SW; Chen, Q; Wang, QK				Wu, Ling; Yong, Sandro L.; Fan, Chun; Ni, Ying; Yoo, Shin; Zhang, Teng; Zhang, Xianqin; Obejero-Paz, Carlos A.; Rho, Hyun-Jin; Ke, Tie; Szafranski, Przemyslaw; Jones, Stephen W.; Chen, Qiuyun; Wang, Qing Kenneth			Identification of a new co-factor, MOG1, required for the full function of cardiac sodium channel Na(v)1.5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-MECHANISM; SCN5A MUTATION; PROTEIN; EXPRESSION; RAN; PHOSPHORYLATION; SUSCEPTIBILITY; ARRHYTHMIA; INTERACTS; SUBUNITS	The cardiac sodium channel Na(v)1.5 is essential for the physiological function of the heart and contributes to lethal cardiac arrhythmias and sudden death when mutated. Here, we report that MOG1, a small protein that is highly conserved from yeast to humans, is a central component of the channel complex and modulates the physiological function of Na(v)1.5. The yeast two-hybrid screen identified MOG1 as a new protein that interacts with the cytoplasmic loop II ( between transmembrane domains DII and DIII) of Na(v)1.5. The interaction was further demonstrated by both in vitro glutathione S-transferase pull-down and in vivo co-immunoprecipitation assays in both HEK293 cells with co-expression of MOG1 and Nav1.5 and native cardiac cells. Co-expression of MOG1 with Na(v)1.5 in HEK293 cells increased sodium current densities. In neonatal myocytes, overexpression of MOG1 increased current densities nearly 2-fold. Western blot analysis revealed that MOG1 increased cell surface expression of Na(v)1.5, which may be the underlying mechanism by which MOG1 increased sodium current densities. Immunostaining revealed that in the heart, MOG1 was expressed in both atrial and ventricular tissues with predominant localization at the intercalated discs. In cardiomyocytes, MOG1 is mostly localized in the cell membrane and co-localized with Na(v)1.5. These results indicate that MOG1 is a critical regulator of sodium channel function in the heart and reveal a new cellular function for MOG1. This study further demonstrates the functional diversity of Na(v)1.5-binding proteins, which serve important functions for Na(v)1.5 under different cellular conditions.	[Wang, Qing Kenneth] Huazhong Univ Sci & Technol, Minist Educ, Key Lab Mol Biophys, Wuhan 430074, Peoples R China; [Wang, Qing Kenneth] Huazhong Univ Sci & Technol, Ctr Human Genome Res, Wuhan 430074, Peoples R China; [Wang, Qing Kenneth] Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA; [Szafranski, Przemyslaw] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; [Obejero-Paz, Carlos A.; Jones, Stephen W.] Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; [Wu, Ling; Wang, Qing Kenneth] Cleveland State Univ, Dept Biol Geol & Environm Sci, Cleveland, OH 44115 USA; [Wu, Ling; Yong, Sandro L.; Fan, Chun; Ni, Ying; Yoo, Shin; Zhang, Teng; Zhang, Xianqin; Rho, Hyun-Jin; Ke, Tie; Chen, Qiuyun; Wang, Qing Kenneth] Cleveland Clin, Ctr Cardiovasc Genet NE40,Tausig Canc Ctr, Dept Cardiovasc Med, Lerner Res Inst,Dept Mol Cardiol, Cleveland, OH 44195 USA	Huazhong University of Science & Technology; Huazhong University of Science & Technology; University System of Ohio; Cleveland State University; Baylor College of Medicine; Case Western Reserve University; University System of Ohio; Cleveland State University; Cleveland Clinic Foundation	Wang, QK (corresponding author), Cleveland Clin, Ctr Cardiovasc Genet NE40,Tausig Canc Ctr, Dept Cardiovasc Med, Lerner Res Inst,Dept Mol Cardiol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	wangq2@ccf.org	Ke, Tie/AIC-5771-2022; Jones, Stephen/AAJ-4465-2020	Ke, Tie/0000-0002-8888-8424; 	NHLBI NIH HHS [R01 HL66251] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066251] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abriel H, 2005, TRENDS CARDIOVAS MED, V15, P35, DOI 10.1016/j.tcm.2005.01.001; Allouis M, 2006, CIRC RES, V98, P1538, DOI 10.1161/01.RES.0000229244.97497.2c; Chen QY, 1998, NATURE, V392, P293, DOI 10.1038/32675; Fahmi AI, 2001, J PHYSIOL-LONDON, V537, P693; Gavillet B, 2006, CIRC RES, V99, P407, DOI 10.1161/01.RES.0000237466.13252.5e; GELLENS ME, 1992, P NATL ACAD SCI USA, V89, P554, DOI 10.1073/pnas.89.2.554; Herfst LJ, 2004, J MOL CELL CARDIOL, V36, P185, DOI 10.1016/j.yjmcc.2003.11.014; Jespersen T, 2006, BIOCHEM BIOPH RES CO, V348, P1455, DOI 10.1016/j.bbrc.2006.08.014; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Lu JMY, 2004, EUKARYOT CELL, V3, P1544, DOI 10.1128/EC.3.6.1544-1556.2004; Lu JMY, 2003, EUKARYOT CELL, V2, P1304, DOI 10.1128/EC.2.6.1304-1314.2003; Malhotra JD, 2001, CIRCULATION, V103, P1303; Marfatia KA, 2001, GENE, V266, P45, DOI 10.1016/S0378-1119(01)00364-X; Meadows LS, 2005, CARDIOVASC RES, V67, P448, DOI 10.1016/j.cardiores.2005.04.003; Nuss HB, 1995, J GEN PHYSIOL, V106, P1171, DOI 10.1085/jgp.106.6.1171; Oki M, 1998, P NATL ACAD SCI USA, V95, P15388, DOI 10.1073/pnas.95.26.15388; Oki M, 2007, GENE, V400, P114, DOI 10.1016/j.gene.2007.06.012; Olson TM, 2005, JAMA-J AM MED ASSOC, V293, P447, DOI 10.1001/jama.293.4.447; QU YS, 1995, J BIOL CHEM, V270, P25696, DOI 10.1074/jbc.270.43.25696; Quimby BB, 2003, CURR OPIN CELL BIOL, V15, P338, DOI 10.1016/S0955-0674(03)00046-2; Rougier JS, 2005, AM J PHYSIOL-CELL PH, V288, pC692, DOI 10.1152/ajpcell.00460.2004; Steggerda SM, 2000, J BIOL CHEM, V275, P23175, DOI 10.1074/jbc.C000252200; Tan HL, 2001, NATURE, V409, P1043, DOI 10.1038/35059090; Tian XL, 2004, CARDIOVASC RES, V61, P256, DOI 10.1016/j.cardiores.2003.11.007; Tian XL, 2004, NATURE, V427, P640, DOI 10.1038/nature02320; van Bemmelen MX, 2004, CIRC RES, V95, P284, DOI 10.1161/01.RES.0000136816.05109.89; Wan XP, 2000, J MOL CELL CARDIOL, V32, P1873, DOI 10.1006/jmcc.2000.1223; Wan XP, 2001, AM J PHYSIOL-HEART C, V280, pH354, DOI 10.1152/ajpheart.2001.280.1.H354; Wang LJ, 2003, SCIENCE, V302, P1578, DOI 10.1126/science.1088477; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; WANG Q, 1995, HUM MOL GENET, V4, P1603, DOI 10.1093/hmg/4.9.1603; Wang Q, 1996, GENOMICS, V34, P9, DOI 10.1006/geno.1996.0236; Wu L, 2002, NEUROREPORT, V13, P2547, DOI 10.1097/00001756-200212200-00033; Yagi T, 2002, CARDIOVASC RES, V54, P405, DOI 10.1016/S0008-6363(02)00279-1; Yong Sandro L., 2006, V129, P127; Yong SRL, 2007, BIOCHEM BIOPH RES CO, V352, P378, DOI 10.1016/j.bbrc.2006.11.019; Yu FH, 2003, J NEUROSCI, V23, P7577; Zhang T, 2007, BIOCHEM BIOPH RES CO, V355, P444, DOI 10.1016/j.bbrc.2007.01.170; Zhou JS, 2002, CIRC RES, V91, P540, DOI 10.1161/01.RES.0000033598.00903.27; Zicha S, 2004, J MOL CELL CARDIOL, V37, P91, DOI 10.1016/j.yjmcc.2004.04.003	40	61	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					6968	6978		10.1074/jbc.M709721200	http://dx.doi.org/10.1074/jbc.M709721200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18184654	hybrid			2022-12-25	WOS:000253779600041
J	Yang, SH; Qiao, X; Farber, E; Chang, SY; Fong, LG; Young, SG				Yang, Shao H.; Qiao, Xin; Farber, Emily; Chang, Sandy Y.; Fong, Loren G.; Young, Stephen G.			Eliminating the synthesis of mature lamin A reduces disease phenotypes in mice carrying a Hutchinson-Gilford progeria syndrome allele	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRELAMIN-A; SYNDROME MUTATION; NUCLEAR-ENVELOPE; MOUSE MODEL; ZMPSTE24; FARNESYLATION; DEFICIENCY; INTEGRITY; B1	Hutchinson-Gilford progeria syndrome is caused by the synthesis of a mutant form of prelamin A, which is generally called progerin. Progerin is targeted to the nuclear rim, where it interferes with the integrity of the nuclear lamina, causes misshapen cell nuclei, and leads to multiple aging-like disease phenotypes. We created a gene-targeted allele yielding exclusively progerin (Lmna(HG)) and found that heterozygous mice (Lmna(HG/+)) exhibit many phenotypes of progeria. In this study, we tested the hypothesis that the phenotypes elicited by the LmnaHG allele might be modulated by compositional changes in the nuclear lamina. To explore this hypothesis, we bred mice harboring one Lmna(HG) allele and one Lmna(LCO) allele ( a mutant allele that produces lamin C but no lamin A). We then compared the phenotypes of Lmna(HG/LCO) mice ( which produce progerin and lamin C) with littermate Lmna(HG/+) mice ( which produce lamin A, lamin C, and progerin). Lmna(HG/LCO) mice exhibited improved body weight curves ( p< 0.0001), reduced numbers of spontaneous rib fractures ( p < 0.0001), and improved survival ( p < 0.0001). In addition, Lmna(HG/LCO) fibroblasts had fewer misshapen nuclei than Lmna(HG/+) fibroblasts ( p < 0.0001). A likely explanation for these differences was uncovered; the amount of progerin in Lmna(HG/LCO) fibroblasts and tissues was lower than in Lmna(HG/+) fibroblasts and tissues. These studies suggest that compositional changes in the nuclear lamina can influence both the steady-state levels of progerin and the severity of progeria-like disease phenotypes.	[Yang, Shao H.; Qiao, Xin; Farber, Emily; Chang, Sandy Y.; Fong, Loren G.; Young, Stephen G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA; [Young, Stephen G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Fong, LG (corresponding author), 695 Charles E Young Dr S, Los Angeles, CA 90095 USA.	lfong@mednet.ucla.edu	lewchavaroj, runglawan/B-5191-2009	Young, Stephen/0000-0001-7270-3176	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL086683, R01HL076839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050200] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL76839, HL86683] Funding Source: Medline; NIAMS NIH HHS [AR050200] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BECK LA, 1990, J CELL BIOL, V110, P1489, DOI 10.1083/jcb.110.5.1489; Bergo MO, 2002, P NATL ACAD SCI USA, V99, P13049, DOI 10.1073/pnas.192460799; Corrigan DP, 2005, BIOCHEM J, V387, P129, DOI 10.1042/BJ20041359; DALTON M, 1995, METHOD ENZYMOL, V250, P134; De Sandre-Giovannoli A, 2003, SCIENCE, V300, P2055, DOI 10.1126/science.1084125; DEBUSK FL, 1972, J PEDIATR-US, V80, P697, DOI 10.1016/S0022-3476(72)80229-4; Dechat T, 2007, P NATL ACAD SCI USA, V104, P4955, DOI 10.1073/pnas.0700854104; Delbarre E, 2006, HUM MOL GENET, V15, P1113, DOI 10.1093/hmg/ddl026; Eriksson M, 2003, NATURE, V423, P293, DOI 10.1038/nature01629; Fong LG, 2006, SCIENCE, V311, P1621, DOI 10.1126/science.1124875; Fong LG, 2004, P NATL ACAD SCI USA, V101, P18111, DOI 10.1073/pnas.0408558102; Fong LG, 2006, J CLIN INVEST, V116, P743, DOI 10.1172/JCI27125; Glynn MW, 2005, HUM MOL GENET, V14, P2959, DOI 10.1093/hmg/ddi326; Goldman RD, 2004, P NATL ACAD SCI USA, V101, P8963, DOI 10.1073/pnas.0402943101; Lammerding J, 2006, J BIOL CHEM, V281, P25768, DOI 10.1074/jbc.M513511200; LIN F, 1993, J BIOL CHEM, V268, P16321; Meta M, 2006, TRENDS MOL MED, V12, P480, DOI 10.1016/j.molmed.2006.08.006; Moulson CL, 2007, HUM MUTAT, V28, P882, DOI 10.1002/humu.20536; Muchir A, 2004, PHYSIOLOGY, V19, P309, DOI 10.1152/physiol.00022.2004; Scaffidi P, 2005, NAT MED, V11, P440, DOI 10.1038/nm1204; Sullivan T, 1999, J CELL BIOL, V147, P913, DOI 10.1083/jcb.147.5.913; Varga R, 2006, P NATL ACAD SCI USA, V103, P3250, DOI 10.1073/pnas.0600012103; Vergnes L, 2004, P NATL ACAD SCI USA, V101, P10428, DOI 10.1073/pnas.0401424101; Worman HJ, 2007, EXP CELL RES, V313, P2121, DOI 10.1016/j.yexcr.2007.03.028; Yang SH, 2005, P NATL ACAD SCI USA, V102, P10291, DOI 10.1073/pnas.0504641102; Yang SH, 2006, J CLIN INVEST, V116, P2115, DOI 10.1172/JCI28968; Young SG, 2005, J LIPID RES, V46, P2531, DOI 10.1194/jlr.R500011-JLR200	27	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					7094	7099		10.1074/jbc.M708138200	http://dx.doi.org/10.1074/jbc.M708138200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18178963	hybrid			2022-12-25	WOS:000253779600054
J	Dixon, RDS; Arneman, DK; Rachlin, AS; Sundaresan, NR; Costello, MJ; Campbell, SL; Otey, CA				Dixon, Richard D. S.; Arneman, Daniel K.; Rachlin, Andrew S.; Sundaresan, Naresh R.; Costello, M. Joseph; Campbell, Sharon L.; Otey, Carol A.			Palladin is an actin cross-linking protein that uses immunoglobulin-like domains to bind filamentous actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C C-PROTEIN; H MYBP-C; SARCOMERIC PROTEIN; CELL-ADHESION; F-ACTIN; Z-DISC; MYOSIN; IDENTIFICATION; TITIN; FAMILY	Palladin is a recently described phosphoprotein that plays an important role in cell adhesion and motility. Previous studies have shown that palladin overexpression results in profound changes in actin organization in cultured cells. Palladin binds to the actin-associated proteins alpha-actinin, vasodilator-stimulated phosphoprotein, profilin, Eps8, and ezrin, suggesting that it may affect actin organization indirectly. To determine its molecular function in generating actin arrays, we purified palladin and asked if it is also capable of binding to F-actin directly. In co-sedimentation and differential sedimentation assays, palladin was found to both bind and cross-link actin filaments. This bundling activity was confirmed by fluorescence and electron microscopy. Palladin fragments were then purified and used to determine the sequences necessary to bind and bundle F-actin. The Ig3 domain of palladin bound to F-actin, and a palladin fragment containing Ig3, Ig4, and the region linking these domains was identified as a fragment that was able to bundle F-actin. Because palladin has multiple Ig domains, and only one of them binds to F-actin, this suggests that different Ig domains may be specialized for distinct biological functions. In addition, our results suggest a potential role for palladin in generating specialized, actin-based cell morphologies via both direct actin cross-linking activity and indirect scaffolding activity.	[Arneman, Daniel K.; Rachlin, Andrew S.; Otey, Carol A.] Univ N Carolina, Sch Med, Dept Cel & Mol Physiol, Chapel Hill, NC 27599 USA; [Dixon, Richard D. S.; Sundaresan, Naresh R.; Campbell, Sharon L.] Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; [Costello, M. Joseph] Univ N Carolina, Sch Med, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Otey, CA (corresponding author), Univ N Carolina, Sch Med, Dept Cel & Mol Physiol, Chapel Hill, NC 27599 USA.	Carol_Otey@med.unc.edu		campbell, sharon/0000-0003-0311-409X; Arneman, Daniel/0000-0002-4031-8094	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061743, R01GM080568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043253] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM080568, GM 61743, R01 GM080568-01A1] Funding Source: Medline; NINDS NIH HHS [NS 43253] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams JC, 2004, CURR OPIN CELL BIOL, V16, P590, DOI 10.1016/j.ceb.2004.07.009; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Amann KJ, 1998, J BIOL CHEM, V273, P28419, DOI 10.1074/jbc.273.43.28419; Bang ML, 2001, J CELL BIOL, V153, P413, DOI 10.1083/jcb.153.2.413; Barclay AN, 2003, SEMIN IMMUNOL, V15, P215, DOI 10.1016/S1044-5323(03)00047-2; Bartles JR, 2000, CURR OPIN CELL BIOL, V12, P72, DOI 10.1016/S0955-0674(99)00059-9; Bassell G, 1997, CURR OPIN CELL BIOL, V9, P109, DOI 10.1016/S0955-0674(97)80159-7; Bennett PM, 1999, REV PHYSIOL BIOCH P, V138, P203, DOI 10.1007/BF02346664; BLANCHARD A, 1989, J MUSCLE RES CELL M, V10, P280, DOI 10.1007/BF01758424; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; Boukhelifa M, 2006, FEBS J, V273, P26, DOI 10.1111/j.1742-4658.2005.05036.x; Boukhelifa M, 2004, CELL MOTIL CYTOSKEL, V58, P17, DOI 10.1002/cm.10173; Boukhelifa M, 2003, MOL CELL NEUROSCI, V23, P661, DOI 10.1016/S1044-7431(03)00127-1; Boukhelifa M, 2001, MOL BIOL CELL, V12, P2721, DOI 10.1091/mbc.12.9.2721; Bryson K, 2005, NUCLEIC ACIDS RES, V33, pW36, DOI 10.1093/nar/gki410; Bullard B, 2006, P NATL ACAD SCI USA, V103, P4451, DOI 10.1073/pnas.0509016103; Bullard B, 2005, J MUSCLE RES CELL M, V26, P479, DOI 10.1007/s10974-005-9032-7; DEARRUDA MV, 1992, J BIOL CHEM, V267, P13079; Disanza A, 2006, NAT CELL BIOL, V8, P1337, DOI 10.1038/ncb1502; Dos Remedios CG, 2003, PHYSIOL REV, V83, P433, DOI 10.1152/physrev.00026.2002; EDWARDS RA, 1995, CELL MOTIL CYTOSKEL, V32, P1, DOI 10.1002/cm.970320102; Fischer D, 2003, PROTEINS, V51, P434, DOI 10.1002/prot.10357; Fucini P, 1997, NAT STRUCT BIOL, V4, P223, DOI 10.1038/nsb0397-223; Gerull B, 2006, J MOL MED-JMM, V84, P478, DOI 10.1007/s00109-006-0060-6; Gerull B, 2002, NAT GENET, V30, P201, DOI 10.1038/ng815; Gilbert R, 1999, J CELL SCI, V112, P69; Goicoechea S, 2006, J CELL SCI, V119, P3316, DOI 10.1242/jcs.03076; Gultice AD, 2006, BIOL REPROD, V74, P1041, DOI 10.1095/biolreprod.105.047845; Hakeda S, 2000, J CELL BIOL, V148, P101, DOI 10.1083/jcb.148.1.101; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; Heidemann SR, 2004, TRENDS CELL BIOL, V14, P160, DOI 10.1016/j.tcb.2004.02.003; Heidemann SR, 1999, J CELL BIOL, V145, P109, DOI 10.1083/jcb.145.1.109; HOLDEN HM, 1992, J MOL BIOL, V227, P840, DOI 10.1016/0022-2836(92)90226-A; Huttelmaier S, 1999, FEBS LETT, V451, P68, DOI 10.1016/S0014-5793(99)00546-3; Improta S, 1996, STRUCTURE, V4, P323, DOI 10.1016/S0969-2126(96)00036-6; Janssen MEW, 2006, MOL CELL, V21, P271, DOI 10.1016/j.molcel.2005.11.020; Jarvenpaa J, 2007, GYNECOL ENDOCRINOL, V23, P351, DOI 10.1080/09513590701350291; Jin L, 2007, CIRC RES, V100, P817, DOI 10.1161/01.RES.0000261351.54147.de; Johnson RP, 2000, J BIOL CHEM, V275, P95, DOI 10.1074/jbc.275.1.95; Kenny PA, 1999, GENE, V232, P11, DOI 10.1016/S0378-1119(99)00122-5; Kreis T., 1999, GUIDEBOOK CYTOSKELET, V2nd; LANGFORD GM, 1995, CURR OPIN CELL BIOL, V7, P82, DOI 10.1016/0955-0674(95)80048-4; Lee HS, 2004, J MOL BIOL, V343, P771, DOI 10.1016/j.jmb.2004.08.069; Li XL, 1998, J BIOL CHEM, V273, P19329, DOI 10.1074/jbc.273.30.19329; Linke WA, 2000, HISTOL HISTOPATHOL, V15, P799, DOI 10.14670/HH-15.799; Liu XS, 2007, J CELL BIOCHEM, V100, P1288, DOI 10.1002/jcb.21126; Luo HJ, 2005, MOL CELL NEUROSCI, V29, P507, DOI 10.1016/j.mcn.2004.12.002; Mahoney NM, 1997, NAT STRUCT BIOL, V4, P953, DOI 10.1038/nsb1197-953; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Moolman-Smook J, 2002, CIRC RES, V91, P704, DOI 10.1161/01.RES.0000036750.81083.83; Mykkanen OM, 2001, MOL BIOL CELL, V12, P3060, DOI 10.1091/mbc.12.10.3060; Oakley CE, 2004, CELL RES, V14, P95, DOI 10.1038/sj.cr.7290208; OKAGAKI T, 1993, J CELL BIOL, V123, P619, DOI 10.1083/jcb.123.3.619; Ono K, 2006, MOL BIOL CELL, V17, P2722, DOI 10.1091/mbc.E06-02-0114; Otey CA, 2005, INT REV CYTOL, V246, P31, DOI 10.1016/S0074-7696(05)46002-7; Parast MM, 2000, J CELL BIOL, V150, P643, DOI 10.1083/jcb.150.3.643; Pogue-Geile KL, 2006, PLOS MED, V3, P2216, DOI 10.1371/journal.pmed.0030516; Politou AS, 1996, J MOL BIOL, V255, P604, DOI 10.1006/jmbi.1996.0050; Popowicz GM, 2006, TRENDS BIOCHEM SCI, V31, P411, DOI 10.1016/j.tibs.2006.05.006; Puius YA, 1998, CURR OPIN CELL BIOL, V10, P23, DOI 10.1016/S0955-0674(98)80083-5; Rachlin AS, 2006, J CELL SCI, V119, P995, DOI 10.1242/jcs.02825; Ronty M, 2005, EXP CELL RES, V310, P88, DOI 10.1016/j.yexcr.2005.06.026; Ronty M, 2004, FEBS LETT, V566, P30, DOI 10.1061/j.febslet.2004.04.006; Ronty M, 2007, EXP CELL RES, V313, P2575, DOI 10.1016/j.yexcr.2007.04.030; Salmikangas P, 1999, HUM MOL GENET, V8, P1329, DOI 10.1093/hmg/8.7.1329; Salmikangas P, 2003, HUM MOL GENET, V12, P189, DOI 10.1093/hmg/ddg020; Shiffman D, 2005, AM J HUM GENET, V77, P596, DOI 10.1086/491674; Tang JX, 1997, EUR J BIOCHEM, V247, P432, DOI 10.1111/j.1432-1033.1997.00432.x; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tilney LG, 1998, J CELL BIOL, V143, P121, DOI 10.1083/jcb.143.1.121; Tseng Y, 2005, BIOCHEM BIOPH RES CO, V334, P183, DOI 10.1016/j.bbrc.2005.05.205; van der Flier A, 2001, BBA-MOL CELL RES, V1538, P99, DOI 10.1016/S0167-4889(01)00072-6; VAUGHAN KT, 1993, J BIOL CHEM, V268, P3670; von Nandelstadh P, 2005, EXP CELL RES, V310, P131, DOI 10.1016/j.yexcr.2005.06.027; Wang WG, 2004, CANCER RES, V64, P8585, DOI 10.1158/0008-5472.CAN-04-1136; WATKINS H, 1995, NAT GENET, V11, P434, DOI 10.1038/ng1295-434; Welch MD, 1997, CURR OPIN CELL BIOL, V9, P54, DOI 10.1016/S0955-0674(97)80152-4; Welikson RE, 2002, J CELL SCI, V115, P3517; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; Yarmola EG, 2001, J BIOL CHEM, V276, P22351, DOI 10.1074/jbc.M101457200; Zieseniss A, 2008, CELL MOTIL CYTOSKEL, V65, P59, DOI 10.1002/cm.20244	81	75	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2008	283	10					6222	6231		10.1074/jbc.M707694200	http://dx.doi.org/10.1074/jbc.M707694200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HM	18180288	hybrid			2022-12-25	WOS:000253779500029
J	Lee, IH; Lim, HJ; Yoon, S; Seong, JK; Bae, DS; Rhee, SG; Bae, YS				Lee, In Hye; Lim, Hee Jung; Yoon, Suhyeon; Seong, Je Kyung; Bae, Duk Soo; Rhee, Sue Goo; Bae, Yun Soo			Ahnak protein activates protein kinase C (PKC) through dissociation of the PKC-protein phosphatase 2A complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC REGULATION; SMALL T-ANTIGEN; CALCIUM-CHANNEL; CA2+ CHANNELS; MEMBRANE; ALPHA; PHOSPHORYLATION; MECHANISMS; CELLS; CYTOSKELETON	We have previously reported that central repeated units (CRUs) of Ahnak act as a scaffolding protein networking phospholipase C gamma and protein kinase C (PKC). Here, we demonstrate that an Ahnak derivative consisting of four central repeated units binds and activates PKC-alpha in a phosphatidylserine/1,2-dioleoyl-sn-glycerol-independent manner. Moreover, NIH3T3 cells expressing the 4 CRUs of Ahnak showed enhanced c-Raf, MEK, and Erk phosphorylation in response to phorbol 12-myristate 13-acetate (PMA) compared with parental cells. To evaluate the effect of loss-of-function of Ahnak in cell signaling, we investigated PKC activation and Raf phosphorylation in embryonic fibroblast cells (MEFs) of the Ahnak knock-out (Ahnak(-/-)) mouse. Membrane translocation of PKC-alpha and phosphorylation of Raf in response to PMA or platelet-derived growth factor were decreased in Ahnak null MEF cells compared with wild type MEFs. Several lines of evidence suggest that PKC-alpha activity is regulated through association with protein phosphatase 2A (PP2A). A co-immunoprecipitation assay indicated that the association of PKC-alpha with PP2A was disrupted in NIH3T3 cells expressing 4 CRUs of Ahnak in response to PMA. Consistently, Ahnak null MEF cells stimulated by PMA showed enhanced PKC-PP2A complex formation, and add-back expression of Ahnak into Ahnak null MEF cells abolished the PKC-PP2A complex formation in response to PMA. These data indicate that Ahnak potentiates PKC activation through inhibiting the interaction of PKC with PP2A.	[Lee, In Hye; Lim, Hee Jung; Yoon, Suhyeon; Rhee, Sue Goo; Bae, Yun Soo] Ewha Womans Univ, Dept Life Sci, Seoul 120750, South Korea; [Bae, Duk Soo] Sungkyunkwan Univ, Samsung Med Ctr, Dept Obstet & Gynecol, Seoul 135710, South Korea; [Seong, Je Kyung] Seoul Natl Univ, Coll Vet Med, Seoul 151742, South Korea	Ewha Womans University; Sungkyunkwan University (SKKU); Samsung Medical Center; Seoul National University (SNU)	Lee, IH (corresponding author), Ewha Womans Univ, Dept Life Sci, 11-1 Daehyun Dong, Seoul 120750, South Korea.	baeys@ewha.ac.kr	LEE, IN HYE/T-2714-2019	LEE, IN HYE/0000-0003-2334-3594				Alvarez J, 2004, J BIOL CHEM, V279, P12456, DOI 10.1074/jbc.M312177200; Arroyo JD, 2005, ONCOGENE, V24, P7746, DOI 10.1038/sj.onc.1209038; Benaud C, 2004, J CELL BIOL, V164, P133, DOI 10.1083/jcb.200307098; Boudreau RTM, 2002, J BIOL CHEM, V277, P5322, DOI 10.1074/jbc.M108623200; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; Chen Y, 2007, NAT STRUCT MOL BIOL, V14, P527, DOI 10.1038/nsmb1254; Cho US, 2007, PLOS BIOL, V5, P1810, DOI 10.1371/journal.pbio.0050202; Deval E, 2004, J BIOL CHEM, V279, P19531, DOI 10.1074/jbc.M313078200; Haase H, 2005, FASEB J, V19, P1969, DOI 10.1096/fj.05-3997com; Haase H, 1999, FASEB J, V13, P2161, DOI 10.1096/fasebj.13.15.2161; Haase H, 2007, CARDIOVASC RES, V73, P19, DOI 10.1016/j.cardiores.2006.09.001; HASHIMOTO T, 1995, EXP CELL RES, V217, P258, DOI 10.1006/excr.1995.1085; Hohaus A, 2002, FASEB J, V16, DOI 10.1096/fj.01-0855com; Huang YC, 2007, FASEB J, V21, P732, DOI 10.1096/fj.06-6628com; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Jiffar T, 2004, LEUKEMIA, V18, P505, DOI 10.1038/sj.leu.2403275; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Komuro A, 2004, P NATL ACAD SCI USA, V101, P4053, DOI 10.1073/pnas.0308619101; Larsson C, 2006, CELL SIGNAL, V18, P276, DOI 10.1016/j.cellsig.2005.07.010; Lee IH, 2004, J BIOL CHEM, V279, P26645, DOI 10.1074/jbc.M311525200; Li DJ, 2005, J NEUROSCI, V25, P1914, DOI 10.1523/JNEUROSCI.4790-04.2005; Lorusso A, 2006, EMBO J, V25, P5443, DOI 10.1038/sj.emboj.7601419; Medkova M, 1998, BIOCHEMISTRY-US, V37, P4892, DOI 10.1021/bi972495j; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Nakashima S, 2002, J BIOCHEM, V132, P669, DOI 10.1093/oxfordjournals.jbchem.a003272; Navedo MF, 2006, J GEN PHYSIOL, V127, P611, DOI 10.1085/jgp.200609519; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; Oh ES, 1997, J BIOL CHEM, V272, P11805, DOI 10.1074/jbc.272.18.11805; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Sekiya F, 1999, J BIOL CHEM, V274, P13900, DOI 10.1074/jbc.274.20.13900; Shirai Y, 2002, J BIOCHEM, V132, P663, DOI 10.1093/oxfordjournals.jbchem.a003271; SHTIVELMAN E, 1992, P NATL ACAD SCI USA, V89, P5472, DOI 10.1073/pnas.89.12.5472; SLEIGH MJ, 1978, CELL, V14, P79, DOI 10.1016/0092-8674(78)90303-3; Sontag E, 2001, CELL SIGNAL, V13, P7, DOI 10.1016/S0898-6568(00)00123-6; Stahelin RV, 2005, J BIOL CHEM, V280, P19784, DOI 10.1074/jbc.M411285200; Stahelin RV, 2004, J BIOL CHEM, V279, P29501, DOI 10.1074/jbc.M403191200; Sussman J, 2001, J CELL BIOL, V154, P1019, DOI 10.1083/jcb.200105121; Ugi S, 2004, MOL CELL BIOL, V24, P8778, DOI 10.1128/MCB.24.19.8778-8789.2004; Ugi S, 2002, MOL CELL BIOL, V22, P2375, DOI 10.1128/MCB.22.7.2375-2387.2002; Yang L, 2005, J BIOL CHEM, V280, P207, DOI 10.1074/jbc.M410509200; Yang SH, 2003, MOL CELL, V12, P63, DOI 10.1016/S1097-2765(03)00265-X	43	52	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2008	283	10					6312	6320		10.1074/jbc.M706878200	http://dx.doi.org/10.1074/jbc.M706878200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HM	18174170	hybrid			2022-12-25	WOS:000253779500038
J	Parikh, BA; Tortora, A; Li, XP; Tumer, NE				Parikh, Bijal A.; Tortora, Andrew; Li, Xiao-Ping; Tumer, Nilgun E.			Ricin inhibits activation of the unfolded protein response by preventing splicing of the HAC1 mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POKEWEED ANTIVIRAL PROTEIN; ENDOPLASMIC-RETICULUM STRESS; RIBOSOME-INACTIVATING PROTEINS; SACCHAROMYCES-CEREVISIAE; A-CHAIN; TRANSMEMBRANE PROTEIN; RETROGRADE TRANSPORT; TRANSCRIPTION FACTOR; GLYCOSIDASE ACTIVITY; CYTOSOL	Ricin A chain (RTA) inhibits protein synthesis by removing a specific adenine from the highly conserved alpha-sarcin/ricin loop in the large rRNA. Expression of RTA with its own signal sequence in yeast resulted in its translocation into the endoplasmic reticulum (ER) and subsequent glycosylation. Because RTA must unfold within the ER, it may be vulnerable to host defenses, such as the unfolded protein response (UPR). UPR was induced in cells expressing an active site mutant but not the wild type RTA, indicating that the active site of RTA played a role in perturbing the ER stress response. The inactive RTA without the signal sequence did not induce UPR, indicating that translocation into the ER was critical for induction of UPR. The wild type RTA inhibited activation of UPR not only due to ER stress induced by the protein itself but also by global effectors such as tunicamycin and dithiothreitol. Mature RTA without the signal sequence also inhibited UPR, providing evidence that inhibition of UPR occurred on the cytosolic face of the ER. RTA could not inhibit UPR when the spliced form of HAC1 mRNA was provided in trans, indicating that it had a direct effect on UPR upstream of HAC1-dependent transcriptional activation. Only the precursor form of HAC1 mRNA was detected in cells expressing RTA after exposure to ER stress, demonstrating that ricin inhibits activation of UPR by preventing HAC1 mRNA splicing. The RTA mutants that depurinated ribosomes but did not kill cells were not able to inhibit activation of UPR by tunicamycin, providing evidence that the inability to activate UPR in response to ER stress contributes to the cytotoxicity of ricin.	Rutgers State Univ, Sch Biol & Environm Sci, Dept Plant Biol & Pathol, New Brunswick, NJ 08901 USA; Rutgers State Univ, Sch Biol & Environm Sci, Biotechnol Ctr Agr & Environm, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick	Tumer, NE (corresponding author), Ctr Biotechnol, Foran Hall,SEBS,59 Dudley Rd, New Brunswick, NJ 08901 USA.	tumer@aesop.rutgers.edu	Parikh, Bijal/AAA-5839-2019	Parikh, Bijal/0000-0003-2490-8294	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072425] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI072425-01A1, R01 AI072425-02, AI 072425, R01 AI072425] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barbieri L, 1997, NUCLEIC ACIDS RES, V25, P518, DOI 10.1093/nar/25.3.518; Bernales S, 2006, ANNU REV CELL DEV BI, V22, P487, DOI 10.1146/annurev.cellbio.21.122303.120200; Chapman RE, 1997, CURR BIOL, V7, P850, DOI 10.1016/S0960-9822(06)00373-3; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; Deeks ED, 2002, BIOCHEMISTRY-US, V41, P3405, DOI 10.1021/bi011580v; Di R, 2005, MOL PLANT MICROBE IN, V18, P762, DOI 10.1094/MPMI-18-0762; ENDO Y, 1987, J BIOL CHEM, V262, P8128; Hartley MR, 2004, BBA-PROTEINS PROTEOM, V1701, P1, DOI 10.1016/j.bbapap.2004.06.004; Hetz C, 2006, SCIENCE, V312, P572, DOI 10.1126/science.1123480; Hudak KA, 2002, RNA, V8, P1148, DOI 10.1017/S1355838202026638; Isler JA, 2005, J VIROL, V79, P15388, DOI 10.1128/JVI.79.24.15388-15397.2005; Isler JA, 2005, J VIROL, V79, P6890, DOI 10.1128/JVI.79.11.6890-6899.2005; Jordan R, 2002, J VIROL, V76, P9588, DOI 10.1128/JVI.76.19.9588-9599.2002; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kawahara T, 1997, MOL BIOL CELL, V8, P1845, DOI 10.1091/mbc.8.10.1845; Lee AS, 2006, CANCER BIOL THER, V5, P721, DOI 10.4161/cbt.5.7.3120; Li XP, 2007, INFECT IMMUN, V75, P417, DOI 10.1128/IAI.01295-06; Lin JH, 2007, SCIENCE, V318, P944, DOI 10.1126/science.1146361; LORD JM, 1994, FASEB J, V8, P201, DOI 10.1096/fasebj.8.2.8119491; McCracken AA, 2005, CURR TOP MICROBIOL, V300, P17; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; MORI K, 1993, CELL, V74, P743; Ng DTW, 2000, J CELL BIOL, V150, P77, DOI 10.1083/jcb.150.1.77; Niwa M, 2005, GENOME BIOL, V6; Parikh BA, 2005, BIOCHEMISTRY-US, V44, P2478, DOI 10.1021/bi048188c; Parikh BA, 2002, J BIOL CHEM, V277, P41428, DOI 10.1074/jbc.M205463200; Picard D, 2005, J BIOL CHEM, V280, P20069, DOI 10.1074/jbc.M413452200; Rapak A, 1997, P NATL ACAD SCI USA, V94, P3783, DOI 10.1073/pnas.94.8.3783; Romisch K, 2005, ANNU REV CELL DEV BI, V21, P435, DOI 10.1146/annurev.cellbio.21.012704.133250; Ruegsegger U, 2001, CELL, V107, P103, DOI 10.1016/S0092-8674(01)00505-0; Sidrauski C, 1997, CELL, V90, P1031, DOI 10.1016/S0092-8674(00)80369-4; Sidrauski C, 1996, CELL, V87, P405, DOI 10.1016/S0092-8674(00)81361-6; Simpson JC, 1999, FEBS LETT, V459, P80, DOI 10.1016/S0014-5793(99)01222-3; Slominska-Wojewodzka M, 2006, MOL BIOL CELL, V17, P1664, DOI 10.1091/mbc.E05-10-0961; Stirpe F, 2006, CELL MOL LIFE SCI, V63, P1850, DOI 10.1007/s00018-006-6078-7; Su HL, 2002, J VIROL, V76, P4162, DOI 10.1128/JVI.76.9.4162-4171.2002; Tumer NE, 1998, J VIROL, V72, P1036, DOI 10.1128/JVI.72.2.1036-1042.1998; Welihinda AA, 1996, J BIOL CHEM, V271, P18181, DOI 10.1074/jbc.271.30.18181; Wesche J, 1999, J BIOL CHEM, V274, P34443, DOI 10.1074/jbc.274.48.34443; Wesche J, 2002, INT J MED MICROBIOL, V291, P517; Zhang KZ, 2005, J CLIN INVEST, V115, P268, DOI 10.1172/JCI200521848; Zhao LH, 2006, CURR OPIN CELL BIOL, V18, P444, DOI 10.1016/j.ceb.2006.06.005	43	31	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2008	283	10					6145	6153		10.1074/jbc.M707981200	http://dx.doi.org/10.1074/jbc.M707981200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HM	18180297	hybrid, Green Accepted			2022-12-25	WOS:000253779500021
J	Rizzolio, F; Bione, S; Sala, C; Tribioli, C; Ciccone, R; Zuffardi, O; di Iorgi, N; Maghnie, M; Toniolo, D				Rizzolio, Flavio; Bione, Silvia; Sala, Cinzia; Tribioli, Carla; Ciccone, Roberto; Zuffardi, Orsetta; di Iorgi, Natascia; Maghnie, Mohamad; Toniolo, Daniela			Highly Conserved Non-Coding Sequences and the 18q Critical Region for Short Stature: A Common Mechanism of Disease?	PLOS ONE			English	Article							PREMATURE OVARIAN FAILURE; PITUITARY-HORMONE DEFICIENCY; KEY DEVELOPMENTAL GENES; GALANIN; CHROMOSOME; EXPRESSION; CHILDREN; PATIENT; FAMILY; MEMBER	Background. Isolated growth hormone deficiency (IGHD) and multiple pituitary hormone deficiency (MPHD) are heterogeneous disorders with several different etiologies and they are responsible for most cases of short stature. Mutations in different genes have been identified but still many patients did not present mutations in any of the known genes. Chromosomal rearrangements may also be involved in short stature and, among others, deletions of 18q23 defined a critical region for the disorder. No gene was yet identified. Methodology/Principal Findings. We now report a balanced translocation X; 18 in a patient presenting a breakpoint in 18q23 that was surprisingly mapped about 500 Kb distal from the short stature critical region. It separated from the flanking SALL3 gene a region enriched in highly conserved non-coding elements (HCNE) that appeared to be regulatory sequences, active as enhancers or silencers during embryonic development. Conclusion. We propose that, during pituitary development, the 18q rearrangement may alter expression of 18q genes or of X chromosome genes that are translocated next to the HCNEs. Alteration of expression of developmentally regulated genes by translocation of HCNEs may represent a common mechanism for disorders associated to isolated chromosomal rearrangements.	[Rizzolio, Flavio; Bione, Silvia; Sala, Cinzia; Toniolo, Daniela] Ist Sci San Raffaele, Dept Biotechnol Res DIBIT, I-20132 Milan, Italy; [Bione, Silvia; Tribioli, Carla; Ciccone, Roberto; Zuffardi, Orsetta; Toniolo, Daniela] CNR, Inst Mol Genet, Pavia, Italy; Univ Pavia, Med Genet, Pavia, Italy; [di Iorgi, Natascia; Maghnie, Mohamad] Univ Genoa, IRCCS, Dept Pediat, Genoa, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); University of Pavia; University of Genoa	Toniolo, D (corresponding author), Ist Sci San Raffaele, Dept Biotechnol Res DIBIT, I-20132 Milan, Italy.	daniela.toniolo@hsr.it	Di Iorgi, Natascia/AAB-8486-2021; Sala, Cinzia Felicita/AAN-1900-2020; Rizzolio, Flavio/K-2690-2018; Toniolo, Daniela/AAE-2969-2019	Di Iorgi, Natascia/0000-0002-4492-4585; Rizzolio, Flavio/0000-0002-3400-4363; Toniolo, Daniela/0000-0001-9545-6032; zuffardi, orsetta/0000-0002-1466-4559; Venkatasubramanian, Siddharth/0000-0002-5860-0768; TRIBIOLI, CARLA/0000-0003-2544-476X; Bione, Silvia/0000-0002-3924-4606; s, hema/0000-0002-3440-9475	Telethon Italy [MIUR-FIRB RBNE0189HM_005]; MIUR-Genomica Funzional [CNR02.00157.ST97]; Fondazione Cariplo; Ministero dell'Universita e della Ricerca [cofin05-MIUR]; Mariani Foundation [R-06-55]	Telethon Italy(Fondazione Telethon); MIUR-Genomica Funzional; Fondazione Cariplo(Fondazione Cariplo); Ministero dell'Universita e della Ricerca(Ministry of Education, Universities and Research (MIUR)); Mariani Foundation	This work was supported by Telethon Italy, by MIUR-FIRB RBNE0189HM_005, and MIUR-Genomica Funzional CNR02.00157.ST97, by the Fondazione Cariplo (to DT and OZ), by the Ministero dell'Universita e della Ricerca (MIUR) (cofin05-MIUR to OZ) and by the Mariani Foundation (R-06-55) (to OZ).	Baroukh N, 2005, MAMM GENOME, V16, P91, DOI 10.1007/s00335-004-2442-9; Bejerano G, 2004, SCIENCE, V304, P1321, DOI 10.1126/science.1098119; Bekiesinska-Figatowska M, 2001, NEURORADIOLOGY, V43, P875, DOI 10.1007/s002340100578; Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Cody JD, 1997, AM J MED GENET, V71, P420, DOI 10.1002/(SICI)1096-8628(19970905)71:4<420::AID-AJMG9>3.3.CO;2-A; Coffinier C, 2001, MECH DEVELOP, V100, P119, DOI 10.1016/S0925-4773(00)00507-4; Dattani MT, 2005, CLIN ENDOCRINOL, V63, P121, DOI 10.1111/j.1365-2265.2005.02289.x; Feenstra I, 2007, AM J MED GENET A, V143A, P1858, DOI 10.1002/ajmg.a.31850; Hale DE, 2000, J CLIN ENDOCR METAB, V85, P4450, DOI 10.1210/jc.85.12.4450; Kelberman D, 2006, ANN MED, V38, P560, DOI 10.1080/07853890600994963; Kleinjan DA, 2005, AM J HUM GENET, V76, P8, DOI 10.1086/426833; Kohlhase J, 1999, GENOMICS, V62, P216, DOI 10.1006/geno.1999.6005; LARIZZA D, 1993, EUR J PEDIATR, V152, P424, DOI 10.1007/BF01955903; Lin JM, 2006, MOL CELL BIOL, V26, P4577, DOI 10.1128/MCB.02127-05; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Lundstrom L, 2005, NEUROMOL MED, V7, P157, DOI 10.1385/NMM:7:1-2:157; Mazarati A, 2004, NEUROSCIENCE, V128, P431, DOI 10.1016/j.neuroscience.2004.06.052; Mullis PE, 2007, ENDOCRIN METAB CLIN, V36, P17, DOI 10.1016/j.ecl.2006.11.010; Ott T, 2001, MECH DEVELOP, V101, P203, DOI 10.1016/S0925-4773(00)00552-9; Pennacchio LA, 2006, NATURE, V444, P499, DOI 10.1038/nature05295; Rainbow LA, 2005, CLIN ENDOCRINOL, V62, P163, DOI 10.1111/j.1365-2265.2004.02189.x; Rizzolio F, 2007, HUM GENET, V121, P441, DOI 10.1007/s00439-007-0329-z; Rizzolio F, 2007, GENE EXPR PATTERNS, V7, P529, DOI 10.1016/j.modgep.2006.10.005; Rizzolio F, 2006, HUM REPROD, V21, P1477, DOI 10.1093/humrep/dei495; Rosen KG, 2000, PRENAT NEONAT MED, V5, P155; Rosenfeld MG, 2000, RECENT PROG HORM RES, V55, P1; Rossetti F, 2004, EUR J HUM GENET, V12, P829, DOI 10.1038/sj.ejhg.5201186; ROSSI E, 1994, GENOMICS, V24, P34, DOI 10.1006/geno.1994.1579; Sandelin A, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-99; Sweetman D, 2006, DEV BIOL, V293, P285, DOI 10.1016/j.ydbio.2006.02.009; Walton KM, 2006, CURR OPIN DRUG DISC, V9, P560; Woolfe A, 2005, PLOS BIOL, V3, P116, DOI 10.1371/journal.pbio.0030007	33	7	8	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2008	3	1							e1460	10.1371/journal.pone.0001460	http://dx.doi.org/10.1371/journal.pone.0001460			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SO	18213369	Green Submitted, Green Published, gold			2022-12-25	WOS:000260503900006
J	Beringue, V; Le Dur, A; Tixador, P; Reine, F; Lepourry, L; Perret-Liaudet, A; Haik, S; Vilotte, JL; Fontes, M; Laude, H				Beringue, Vincent; Le Dur, Annick; Tixador, Philippe; Reine, Fabienne; Lepourry, Laurence; Perret-Liaudet, Armand; Haik, Stephane; Vilotte, Jean-Luc; Fontes, Michel; Laude, Hubert			Prominent and Persistent Extraneural Infection in Human PrP Transgenic Mice Infected with Variant CJD	PLOS ONE			English	Article							CREUTZFELDT-JAKOB-DISEASE; HUMAN PRION PROTEIN; BLOOD-TRANSFUSION; INCUBATION-TIME; TISSUE SAMPLES; SCRAPIE AGENT; VCJD; UK; CELLS; SUSCEPTIBILITY	Background. The evolution of the variant Creutzfeldt-Jakob disease (vCJD) epidemic is hazardous to predict due to uncertainty in ascertaining the prevalence of infection and because the disease might remain asymptomatic or produce an alternate, sporadic-like phenotype. Methodology/Principal Findings. Transgenic mice were produced that overexpress human prion protein with methionine at codon 129, the only allele found so far in vCJD-affected patients. These mice were infected with prions derived from variant and sporadic CJD (sCJD) cases by intracerebral or intraperitoneal route, and transmission efficiency and strain phenotype were analyzed in brain and spleen. We showed that i) the main features of vCJD infection in humans, including a prominent involvement of the lymphoid tissues compared to that in sCJD infection were faithfully reproduced in such mice; ii) transmission of vCJD agent by intracerebral route could lead to the propagation of either vCJD or sCJD-like prion in the brain, whereas vCJD prion was invariably propagated in the spleen, iii) after peripheral exposure, inefficient neuroinvasion was observed, resulting in an asymptomatic infection with life-long persistence of vCJD prion in the spleen at stable and elevated levels. Conclusion/Significance. Our findings emphasize the possibility that human-to-human transmission of vCJD might produce alternative neuropathogical phenotypes and that lymphoid tissue examination of CJD cases classified as sporadic might reveal an infection by vCJD-type prions. They also provide evidence for the strong propensity of this agent to establish long-lasting, subclinical vCJD infection of lymphoreticular tissues, thus amplifying the risk for iatrogenic transmission.	[Beringue, Vincent; Le Dur, Annick; Tixador, Philippe; Reine, Fabienne; Laude, Hubert] Inst Sci Rech Agron INRA, UR892, Jouy En Josas, France; [Lepourry, Laurence; Vilotte, Jean-Luc] Genet Biochim Cytogenet, Inst Sci Rech Agronom INRA, UR339, Jouy En Josas, France; [Perret-Liaudet, Armand] Grp Hosp Est Hopitaux Lyon, Ctr Biol Pathol CBPE, Serv Neurobiol, Bron, France; [Haik, Stephane] INSERM, Equipe Avenir, Maladies Prions lHomme, Paris, France; [Haik, Stephane] Assist Publ Hopit Paris AP HP, Lab Neuropathol R Escour, Grp Hosp Pitie Salpetriere, Paris, France; [Fontes, Michel] INSERM UMR 491 IPHM, Fac Med Timone, Marseille, France	INRAE; INRAE; CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Beringue, V (corresponding author), Inst Sci Rech Agron INRA, UR892, Jouy En Josas, France.	vincent.beringue@jouy.inra.fr; hubert.laude@jouy.inra.fr	Vilotte, Jean-Luc/AAF-4688-2019; Haik, Stephane/M-7247-2018		INRA; Institut de Veille Sanitaire (InVS); Ministry of Research, France	INRA; Institut de Veille Sanitaire (InVS); Ministry of Research, France(Ministry of Research, France)	This work was supported by INRA, Institut de Veille Sanitaire (InVS) and the Ministry of Research, France. The sponsors of this study had no role in study conduct, collection analysis, interpretation of the data, writing of the report or approval of the manuscript.	Aguzzi A, 2006, NAT CLIN PRACT NEURO, V2, P321, DOI 10.1038/ncpneuro0214; Asano M, 2006, BIOCHEM BIOPH RES CO, V342, P293, DOI 10.1016/j.bbrc.2006.01.149; Asante EA, 2002, EMBO J, V21, P6358, DOI 10.1093/emboj/cdf653; Beringue V, 2000, J VIROL, V74, P5432, DOI 10.1128/JVI.74.12.5432-5440.2000; Beringue V, 2003, BRAIN, V126, P2065, DOI 10.1093/brain/awg205; Beringue V, 2006, PLOS PATHOG, V2, P956, DOI 10.1371/journal.ppat.0020112; Bishop MT, 2006, LANCET NEUROL, V5, P393, DOI 10.1016/S1474-4422(06)70413-6; Bruce ME, 2001, LANCET, V358, P208, DOI 10.1016/S0140-6736(01)05411-3; Clarke P, 2005, J R SOC INTERFACE, V2, P19, DOI 10.1098/rsif.2004.0017; COLLIS SC, 1985, FEMS MICROBIOL LETT, V29, P111; Feraudet C, 2005, J BIOL CHEM, V280, P11247, DOI 10.1074/jbc.M407006200; Frosh A, 2004, LANCET, V364, P1260, DOI 10.1016/S0140-6736(04)17143-2; Glatzel M, 2003, LANCET NEUROL, V2, P757, DOI 10.1016/S1474-4422(03)00588-X; Hauw JJ, 2000, NEUROLOGY, V54, P1641, DOI 10.1212/WNL.54.8.1641; Hill AF, 1999, LANCET, V353, P183, DOI 10.1016/S0140-6736(98)12075-5; Hilton DA, 1998, LANCET, V352, P703, DOI 10.1016/S0140-6736(98)24035-9; Hilton DA, 2004, J PATHOL, V203, P733, DOI 10.1002/path.1580; Ironside JW, 2006, BRIT MED J, V332, P1186, DOI 10.1136/bmj.38804.511644.55; Kitamoto T, 2002, BIOCHEM BIOPH RES CO, V294, P280, DOI 10.1016/S0006-291X(02)00476-X; Korth C, 2003, P NATL ACAD SCI USA, V100, P4784, DOI 10.1073/pnas.2627989100; Lasmezas CI, 2001, P NATL ACAD SCI USA, V98, P4142, DOI 10.1073/pnas.041490898; Le Dur A, 2005, P NATL ACAD SCI USA, V102, P16031, DOI 10.1073/pnas.0502296102; Llewelyn CA, 2004, LANCET, V363, P417, DOI 10.1016/S0140-6736(04)15486-X; Mabbott NA, 2006, NAT REV MICROBIOL, V4, P201, DOI 10.1038/nrmicro1346; Minor P, 2004, J GEN VIROL, V85, P1777, DOI 10.1099/vir.0.79959-0; Peden AH, 2004, LANCET, V364, P527, DOI 10.1016/S0140-6736(04)16811-6; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; SCHMIDT ML, 1995, AM J PATHOL, V147, P503; Sun AY, 2002, J HISTOCHEM CYTOCHEM, V50, P463, DOI 10.1177/002215540205000403; Szakal AK, 2002, SEMIN IMMUNOL, V14, P267, DOI 10.1016/S1044-5323(02)00059-3; TARABOULOS A, 1990, J CELL BIOL, V110, P2117, DOI 10.1083/jcb.110.6.2117; Valleron AJ, 2001, SCIENCE, V294, P1726, DOI 10.1126/science.1066838; Wadsworth JDF, 2007, GUT, V56, P90, DOI 10.1136/gut.2006.091637; Wadsworth JDF, 2004, SCIENCE, V306, P1793, DOI 10.1126/science.1103932; Wadsworth JDF, 2001, LANCET, V358, P171, DOI 10.1016/S0140-6736(01)05403-4; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; Yull HM, 2006, AM J PATHOL, V168, P151, DOI 10.2353/ajpath.2006.050766; EURO SURVEILL, V12	38	83	84	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2008	3	1							e1419	10.1371/journal.pone.0001419	http://dx.doi.org/10.1371/journal.pone.0001419			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366GT	18183299	Green Published, gold, Green Submitted			2022-12-25	WOS:000260469400015
J	Kim, MS; Chang, X; Yamashita, K; Nagpal, JK; Baek, JH; Wu, G; Trink, B; Ratovitski, EA; Mori, M; Sidransky, D				Kim, M. S.; Chang, X.; Yamashita, K.; Nagpal, J. K.; Baek, J. H.; Wu, G.; Trink, B.; Ratovitski, E. A.; Mori, M.; Sidransky, D.			Aberrant promoter methylation and tumor suppressive activity of the DFNA5 gene in colorectal carcinoma	ONCOGENE			English	Article						promoter methylation; DFNA5; colon cancer	CELLULAR RETINOL-BINDING-PROTEIN-1; DNA METHYLATION; HYPERMETHYLATION; EXPRESSION; IDENTIFICATION; INACTIVATION; CANCERS; ICERE-1; PROFILE	To identify novel methylated gene promoters, we compared differential RNA expression profiles of colorectal cancer (CRC) cell lines with or without treatment of 5-aza-2'-deoxycytidine (5-aza-dC). Out of 1776 genes that were initially 'absent (that is, silenced)' by gene expression array analysis, we selected 163 genes that were increased after 5-aza-dC treatment in at least two of three CRC cell lines. The microarray results were confirmed by Reverse Transcription-PCR, and CpG island of the gene promoters were amplified and sequenced for examination of cancer-specific methylation. Among the genes identified, the deafness, autosomal dominant 5 gene, DFNA5, promoter was found to be methylated in primary tumor tissues with high frequency (65%, 65/100). Quantitative methylation-specific PCR of DFNA5 clearly discriminated primary CRC tissues from normal colon tissues (3%, 3/100). The mRNA expression of DFNA5 in four of five colon cancer tissues was significantly downregulated as compared to normal tissues. Moreover, forced expression of full-length DFNA5 in CRC cell lines markedly decreased the cell growth and colony-forming ability whereas knockdown of DFNA5 increased cell growth in culture. Our data implicate DFNA5 as a novel tumor suppressor gene in CRC and a valuable molecular marker for human cancer.	[Kim, M. S.; Chang, X.; Yamashita, K.; Nagpal, J. K.; Trink, B.; Ratovitski, E. A.; Sidransky, D.] Johns Hopkins Univ, Head & Neck Canc Res Div, Dept Otolaryngol, Baltimore, MD 21231 USA; [Baek, J. H.] Johns Hopkins Univ, Inst Cell Engn, Dept Med Genet, Baltimore, MD 21231 USA; [Wu, G.] Wayne State Univ, Karmanos Canc Inst, Dept Pathol, Detroit, MI USA; [Mori, M.] Kyushu Univ, Dept Surg Oncol, Med Inst Bioregulat, Beppu, Oita, Japan	Johns Hopkins University; Johns Hopkins University; Barbara Ann Karmanos Cancer Institute; Wayne State University; Kyushu University	Sidransky, D (corresponding author), Johns Hopkins Univ, Sch Med, Dept Oncol & Otolaryngol, Div Head & Neck Canc Res Inst, Johns Hopkins Canc Res Bldg 2,1150 Orleans St, Baltimore, MD 21231 USA.	dsidran1@jhmi.edu						Akino K, 2007, CANCER SCI, V98, P88, DOI 10.1111/j.1349-7006.2006.00351.x; Brakenhoff RH, 1997, J IMMUNOL, V159, P4879; Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001; Esteller M, 2002, CANCER RES, V62, P5902; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; Herman JG, 1999, SEMIN CANCER BIOL, V9, P359, DOI 10.1006/scbi.1999.0138; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jeronimo C, 2004, J CLIN PATHOL, V57, P872, DOI 10.1136/jcp.2003.014555; Kim JM, 2005, CLIN CANCER RES, V11, P473; Kim MS, 2006, CANCER RES, V66, P3409, DOI 10.1158/0008-5472.CAN-05-1608; Lage H, 2001, FEBS LETT, V494, P54, DOI 10.1016/S0014-5793(01)02304-3; Lind GE, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-28; Luo LP, 2005, INT J CANCER, V115, P747, DOI 10.1002/ijc.20936; Masuda Yoshiko, 2006, J Hum Genet, V51, P652, DOI 10.1007/s10038-006-0004-6; Rochester MA, 2005, CANCER GENE THER, V12, P90, DOI 10.1038/sj.cgt.7700775; Scanlan Matthew J, 2004, Cancer Immun, V4, P1; Shutoh M, 2005, CANCER-AM CANCER SOC, V104, P1609, DOI 10.1002/cncr.21392; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Thompson DA, 1998, EUR J BIOCHEM, V252, P169, DOI 10.1046/j.1432-1327.1998.2520169.x; Toyota M, 2000, P NATL ACAD SCI USA, V97, P710, DOI 10.1073/pnas.97.2.710; Van Laer L, 1998, NAT GENET, V20, P194; VANCAMP G, 1995, HUM MOL GENET, V4, P2159; Xu XL, 2004, WORLD J GASTROENTERO, V10, P3441; Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5	24	131	141	4	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2008	27	25					3624	3634		10.1038/sj.onc.1211021	http://dx.doi.org/10.1038/sj.onc.1211021			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18223688				2022-12-25	WOS:000256468500014
J	Varady, KA; Roohk, DJ; McEvoy-Hein, BK; Gaylinn, BD; Thorner, MO; Hellerstein, MK				Varady, K. A.; Roohk, D. J.; McEvoy-Hein, B. K.; Gaylinn, B. D.; Thorner, M. O.; Hellerstein, M. K.			Modified alternate-day fasting regimens reduce cell proliferation rates to a similar extent as daily calorie restriction in mice	FASEB JOURNAL			English	Article						cancer; insulin-like growth factor-1; insulin-like growth factor binding protein-3	GROWTH-FACTOR-I; SPONTANEOUS TUMORIGENESIS; MAMMARY CARCINOGENESIS; DIETARY RESTRICTION; ENERGY RESTRICTION; BINDING PROTEIN-3; DNA-SYNTHESIS; CANCER; GHRELIN; INSULIN	Calorie restriction (CR) and alternate-day fasting (ADF) reduce cancer risk and reduce cell proliferation rates. Whether modified ADF regimens (i.e., allowing a portion of energy needs to be consumed on the fast day) work, as well as true ADF or CR to reduce global cell proliferation rates, remains unresolved. Here, we measured the effects of true ADF, modified ADF, and daily CR on cell proliferation rates in mice. Thirty female C57BL/6J mice were randomized to one of five interventions for 4 wk: 1) CR-25% (25% reduction in daily energy intake), 2) ADF-75% (75% reduction on fast day), 3) ADF-85% (85% reduction on fast day), 4) ADF-100% (100% reduction on fast day), and 5) control (ad libitum intake). Body weights of the ADF groups did not differ from controls, whereas the CR-25% group weighed less than all other groups posttreatment. Epidermal cell proliferation decreased (P < 0.01) by 29, 20, and 31% in the CR-25%, ADF-85% and ADF-100% groups, respectively, relative to controls. Proliferation rates of splenic T cells were reduced (P < 0.01) by 37, 32, and 31% in the CR- 25%, ADF-85%, and ADF-100% groups, respectively, and mammary epithelial cell proliferation was 70, 65, and 62% lower (P < 0.01), compared with controls. Insulin-like growth factor-1 levels were reduced (P < 0.05) in the CR- 25% and ADF-100% groups only. In summary, modified ADF, allowing the consumption of 15% of energy needs on the restricted intake day, decreases global cell proliferation similarly as true ADF and daily CR without reducing body weight.	[Varady, K. A.; Roohk, D. J.; McEvoy-Hein, B. K.; Hellerstein, M. K.] Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA; [Gaylinn, B. D.; Thorner, M. O.] Univ Virginia, Div Endocrinol & Metab, Dept Internal Med, Charlottesville, VA USA	University of California System; University of California Berkeley; University of Virginia	Varady, KA (corresponding author), Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Morgan Hall,Rm 308, Berkeley, CA 94720 USA.	kvarady@nature.berkeley.edu; march@nture.berkeley.edu	Gaylinn, Bruce/AAD-4663-2020	Gaylinn, Bruce/0000-0003-1195-0864	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK076037] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK076037, R01 DK076037-04] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berrigan D, 2002, CARCINOGENESIS, V23, P817, DOI 10.1093/carcin/23.5.817; Collins ML, 2003, J APPL PHYSIOL, V94, P2203, DOI 10.1152/japplphysiol.00691.2002; Fontana L, 2007, JAMA-J AM MED ASSOC, V297, P986, DOI 10.1001/jama.297.9.986; Giovannucci E, 1999, HORM RES, V51, P34, DOI 10.1159/000053160; Gualillo O, 2002, OBES RES, V10, P682, DOI 10.1038/oby.2002.92; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Heilbronn LK, 2005, OBES RES, V13, P574, DOI 10.1038/oby.2005.61; Heilbronn LK, 2005, AM J CLIN NUTR, V81, P69; Higgins SC, 2007, ANN MED, V39, P116, DOI 10.1080/07853890601149179; Hsieh EA, 2005, AM J PHYSIOL-ENDOC M, V288, pE965, DOI 10.1152/ajpendo.00368.2004; Hsieh EA, 2004, J INVEST DERMATOL, V123, P530, DOI 10.1111/j.0022-202X.2004.23303.x; HURSTING SD, 1994, P NATL ACAD SCI USA, V91, P7036, DOI 10.1073/pnas.91.15.7036; Hursting SD, 2003, ANNU REV MED, V54, P131, DOI 10.1146/annurev.med.54.101601.152156; Ikeyama S, 2003, EXP GERONTOL, V38, P431, DOI 10.1016/S0531-5565(02)00239-5; Jenkins PJ, 2004, EUR J ENDOCRINOL, V151, pS17, DOI 10.1530/eje.0.151S017; Jolly CA, 2005, CURR OPIN CLIN NUTR, V8, P382, DOI 10.1097/01.mco.0000172577.56396.7a; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Lawrence CB, 2002, ENDOCRINOLOGY, V143, P155, DOI 10.1210/en.143.1.155; Lev-Ran A, 1998, MECH AGEING DEV, V102, P95, DOI 10.1016/S0047-6374(98)00027-X; Liu Jianhua, 2004, Growth Hormone & IGF Research, V14, P131; LOK E, 1988, CANCER LETT, V38, P249, DOI 10.1016/0304-3835(88)90016-X; Ma J, 1999, J NATL CANCER I, V91, P620, DOI 10.1093/jnci/91.7.620; Macallan DC, 1998, P NATL ACAD SCI USA, V95, P708, DOI 10.1073/pnas.95.2.708; Mai V, 2003, CANCER RES, V63, P1752; MERRY B, 1994, EFFECTS DIET AGING; Nakazato M, 2001, NATURE, V409, P194, DOI 10.1038/35051587; NANDI S, 1995, P NATL ACAD SCI USA, V92, P3650, DOI 10.1073/pnas.92.9.3650; Neese RA, 2002, P NATL ACAD SCI USA, V99, P15345, DOI 10.1073/pnas.232551499; Neese RA, 2001, ANAL BIOCHEM, V298, P189, DOI 10.1006/abio.2001.5375; NELSON JF, 1982, BIOL REPROD, V27, P327, DOI 10.1095/biolreprod27.2.327; Patel AC, 2004, J NUTR, V134, p3394S, DOI 10.1093/jn/134.12.3394S; Rocha NS, 2002, TERATOGEN CARCIN MUT, V22, P129, DOI 10.1002/tcm.10005; SIEGEL I, 1988, CANCER INVEST, V6, P677, DOI 10.3109/07357908809078034; Stewart JW, 2005, CARCINOGENESIS, V26, P1077, DOI 10.1093/carcin/bgi051; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; Varady KA, 2007, J LIPID RES, V48, P2212, DOI 10.1194/jlr.M700223-JLR200; Varady KA, 2007, J APPL PHYSIOL, V103, P547, DOI 10.1152/japplphysiol.00209.2007; Yakar S, 2005, CYTOKINE GROWTH F R, V16, P407, DOI 10.1016/j.cytogfr.2005.01.010; Zhu ZJ, 1999, CARCINOGENESIS, V20, P1721, DOI 10.1093/carcin/20.9.1721	39	28	28	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					2090	2096		10.1096/fj.07-098178	http://dx.doi.org/10.1096/fj.07-098178			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18184721	Green Accepted			2022-12-25	WOS:000256352700048
J	Glenn, KA; Nelson, RF; Wen, HM; Mallinger, AJ; Paulson, HL				Glenn, Kevin A.; Nelson, Rick F.; Wen, Hsiang M.; Mallinger, Adam J.; Paulson, Henry L.			Diversity in tissue expression, substrate binding, and SCF complex formation for a lectin family of ubiquitin ligases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-BOX PROTEIN; ER-ASSOCIATED DEGRADATION; RECOGNIZES SUGAR CHAINS; N-LINKED GLYCANS; ENDOPLASMIC-RETICULUM; QUALITY-CONTROL; MESSENGER-RNA; CATHEPSIN-B; MURINE BETA-1,4-GALACTOSYLTRANSFERASE; STRUCTURAL BASIS	Post-translational modification of proteins regulates many cellular processes. Some modifications, including N-linked glycosylation, serve multiple functions. For example, the attachment of N-linked glycans to nascent proteins in the endoplasmic reticulum facilitates proper folding, whereas retention of high mannose glycans on misfolded glycoproteins serves as a signal for retrotranslocation and ubiquitin-mediated proteasomal degradation. Here we examine the substrate specificity of the only family of ubiquitin ligase subunits thought to target glycoproteins through their attached glycans. The five proteins comprising this FBA family (FBXO2, FBXO6, FBXO17, FBXO27, and FBXO44) contain a conserved G domain that mediates substrate binding. Using a variety of complementary approaches, including glycan arrays, we show that each family member has differing specificity for glycosylated substrates. Collectively, the F-box proteins in the FBA family bind high mannose and sulfated glycoproteins, with one FBA protein, FBX044, failing to bind any glycans on the tested arrays. Site-directed mutagenesis of two aromatic amino acids in the G domain demonstrated that the hydrophobic pocket created by these amino acids is necessary for high affinity glycan binding. All FBA proteins co-precipitated components of the canonical SCF complex (Skp1, Cullin1, and Rbx1), yet FBXO2 bound very little Cullin1, suggesting that FBXO2 may exist primarily as a heterodimer with Skp1. Using subunit-specific antibodies, we further demonstrate marked divergence in tissue distribution and developmental expression. These differences in substrate recognition, SCF complex formation, and tissue distribution suggest that FBA proteins play diverse roles in glycoprotein quality control.	[Glenn, Kevin A.] Dept Vet Affairs Med Ctr, Iowa City, IA 52242 USA; [Nelson, Rick F.] Univ Iowa Hosp & Clin, Dept Otolaryngol, Iowa City, IA 52242 USA; [Paulson, Henry L.] Univ Michigan Hlth Syst, Dept Neurol, Ann Arbor, MI 48109 USA; [Mallinger, Adam J.] Kansas City Univ Med & Biosci, Kansas City, MO 64106 USA; [Glenn, Kevin A.; Wen, Hsiang M.] Univ Iowa Hosp & Clin, Dept Internal Med, Iowa City, IA 52242 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Iowa; University of Michigan System; University of Michigan; Kansas City University of Medicine & Biosciences; University of Iowa	Glenn, KA (corresponding author), Dept Vet Affairs Med Ctr, Iowa City, IA 52242 USA.	kevin-glenn@uiowa.edu		Glenn, Kevin/0000-0002-6941-9649; Nelson, Rick/0000-0001-5749-6383	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F30NS047872, R01NS047535] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM007337] Funding Source: Medline; NINDS NIH HHS [NS047872, R01 NS47535-01] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arias EB, 2004, DIABETES, V53, P921, DOI 10.2337/diabetes.53.4.921; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Baici A, 2006, BIOL CHEM, V387, P1017, DOI 10.1515/BC.2006.125; Bays NW, 2001, NAT CELL BIOL, V3, P24, DOI 10.1038/35050524; BEINTEMA JJ, 1976, EUR J BIOCHEM, V63, P441, DOI 10.1111/j.1432-1033.1976.tb10246.x; Blixt O, 2004, P NATL ACAD SCI USA, V101, P17033, DOI 10.1073/pnas.0407902101; Cabral CM, 2002, MOL BIOL CELL, V13, P2639, DOI 10.1091/mbc.E02-02-0068; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Contino G, 2004, GENE, V328, P69, DOI 10.1016/j.gene.2003.11.017; Croft L, 2000, NAT GENET, V24, P340, DOI 10.1038/74153; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; ENDO M, 1982, J BIOL CHEM, V257, P8755; Erhardt JA, 1998, J BIOL CHEM, V273, P35222, DOI 10.1074/jbc.273.52.35222; Galan JM, 1999, P NATL ACAD SCI USA, V96, P9124, DOI 10.1073/pnas.96.16.9124; Gardner RG, 2000, J CELL BIOL, V151, P69, DOI 10.1083/jcb.151.1.69; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Groisman B, 2006, ISRAEL J CHEM, V46, P189, DOI 10.1560/2QPD-9WP9-NCYK-58X3; Hagihara S, 2005, J MED CHEM, V48, P3126, DOI 10.1021/jm0489511; HARDUINLEPERS A, 1993, J BIOL CHEM, V268, P14348; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Henzl MT, 2004, HEARING RES, V191, P101, DOI 10.1016/j.heares.2004.01.005; Henzl MT, 1998, HEARING RES, V126, P37, DOI 10.1016/S0378-5955(98)00148-8; Henzl MT, 2001, HEARING RES, V157, P100, DOI 10.1016/S0378-5955(01)00285-4; Hong HY, 2000, ELECTROPHORESIS, V21, P841, DOI 10.1002/(SICI)1522-2683(20000301)21:5<841::AID-ELPS841>3.3.CO;2-W; Ilyin GP, 2002, GENE, V296, P11, DOI 10.1016/S0378-1119(02)00867-3; Jin JP, 2004, GENE DEV, V18, P2573, DOI 10.1101/gad.1255304; Kaneko C, 2003, BIOCHEM BIOPH RES CO, V300, P297, DOI 10.1016/S0006-291X(02)02834-6; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; KIJIMOTOOCHIAI S, 1985, ANAL BIOCHEM, V147, P222, DOI 10.1016/0003-2697(85)90031-4; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Kuhn K, 2004, DEV BRAIN RES, V149, P131, DOI 10.1016/j.devbrainres.2004.02.001; Lederkremer GZ, 2005, TRENDS BIOCHEM SCI, V30, P297, DOI 10.1016/j.tibs.2005.04.010; Manzella SM, 1996, J BIOL CHEM, V271, P12117, DOI 10.1074/jbc.271.21.12117; Mehtani S, 1998, J BIOL CHEM, V273, P13236, DOI 10.1074/jbc.273.21.13236; Misaghi S, 2004, CHEM BIOL, V11, P1677, DOI 10.1016/j.chembiol.2004.11.010; Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200; Mizushima T, 2004, NAT STRUCT MOL BIOL, V11, P365, DOI 10.1038/nsmb732; Mizushima T, 2007, P NATL ACAD SCI USA, V104, P5777, DOI 10.1073/pnas.0610312104; Moremen KW, 2006, CURR OPIN STRUC BIOL, V16, P592, DOI 10.1016/j.sbi.2006.08.005; Nelson RF, 2007, J NEUROSCI, V27, P5163, DOI 10.1523/JNEUROSCI.0206-07.2007; Nelson RF, 2006, J BIOL CHEM, V281, P20242, DOI 10.1074/jbc.M602423200; Pruitt KD, 2007, NUCLEIC ACIDS RES, V35, pD61, DOI 10.1093/nar/gkl842; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Semple CAM, 2003, GENOME RES, V13, P1389, DOI 10.1101/gr.980303; SHAPER NL, 1990, P NATL ACAD SCI USA, V87, P791, DOI 10.1073/pnas.87.2.791; Shiyan SD, 1997, GLYCOCONJUGATE J, V14, P631, DOI 10.1023/A:1018544711767; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; SPIK G, 1975, FEBS LETT, V50, P296, DOI 10.1016/0014-5793(75)90053-8; Ten Hagen KG, 2003, GLYCOBIOLOGY, V13, p1R, DOI 10.1093/glycob/cwg007; Thalmann R, 2003, ACTA OTO-LARYNGOL, V123, P203, DOI 10.1080/0036554021000028100; TOWNSEND RR, 1982, J BIOL CHEM, V257, P9704; Trowbridge JM, 2002, GLYCOBIOLOGY, V12, p117R, DOI 10.1093/glycob/cwf066; Turner GC, 2000, SCIENCE, V289, P2117, DOI 10.1126/science.289.5487.2117; Wei Z, 2001, J DAIRY SCI, V84, P2584, DOI 10.3168/jds.S0022-0302(01)74712-1; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; West CM, 2004, BBA-GEN SUBJECTS, V1673, P29, DOI 10.1016/j.bbagen.2004.04.007; West CM, 2003, CELL MOL LIFE SCI, V60, P229, DOI 10.1007/s000180300018; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Yamaguchi Y, 2007, BIOCHEM BIOPH RES CO, V362, P712, DOI 10.1016/j.bbrc.2007.08.056; YAMASHITA K, 1981, J BIOL CHEM, V256, P1283; Yang K, 2004, BIOCHEM BIOPH RES CO, V324, P432, DOI 10.1016/j.bbrc.2004.09.070; Yoshida Y, 2002, NATURE, V418, P438, DOI 10.1038/nature00890; Yoshida Y, 2003, J BIOL CHEM, V278, P43877, DOI 10.1074/jbc.M304157200; Yoshida Y, 2005, EMBO REP, V6, P239, DOI 10.1038/sj.embor.7400351; Yoshida Y, 2007, J BIOL CHEM, V282, P7137, DOI 10.1074/jbc.M611168200; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zhou XK, 2006, P NATL ACAD SCI USA, V103, P17214, DOI 10.1073/pnas.0602954103; Zwicky R, 2003, BIOL CHEM, V384, P1007, DOI 10.1515/BC.2003.113	71	58	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2008	283	19					12717	12729		10.1074/jbc.M709508200	http://dx.doi.org/10.1074/jbc.M709508200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295UQ	18203720	hybrid, Green Published			2022-12-25	WOS:000255499800007
J	Tschan, MP; Reddy, VA; Ress, A; Arvidsson, G; Fey, MF; Torbett, BE				Tschan, M. P.; Reddy, V. A.; Ress, A.; Arvidsson, G.; Fey, M. F.; Torbett, B. E.			PU.1 binding to the p53 family of tumor suppressors impairs their transcriptional activity	ONCOGENE			English	Article						PU.1; p53; p73; transcriptional repression	HEMATOPOIETIC STEM-CELLS; SELF-RENEWAL; FRIEND; GENE; EXPRESSION; ROLES; P73; PROGRESSION	The transcription factor PU.1 is essential for terminal myeloid differentiation, B- and T-cell development, erythropoiesis and hematopoietic stem cell maintenance. PU.1 functions as oncogene in Friend virus-induced erythroleukemia and as tumor suppressor in acute myeloid leukemias. Moreover, Friend virus-induced erythroleukemia requires maintenance of PU.1 expression and the disruption of p53 function greatly accelerates disease progression. It has been hypothesized that p53-mediated expression of the p21(Cip1) cell cycle inhibitor during differentiation of pre-erythroleukemia cells promotes selection against p53 function. In addition to the blockage of erythroblast differentiation provided by increased levels of PU.1, we propose that PU.1 alters p53 function. We demonstrate that PU.1 reduces the transcriptional activity of the p53 tumor suppressor family and thus inhibits activation of genes important for cell cycle regulation and apoptosis. Inhibition is mediated through binding of PU.1 to the DNA-binding and/or oligomerization domains of p53/p73 proteins. Lastly, knocking down endogenous PU.1 in p53 wild-type REH B-cell precursor leukemia cells leads to increased expression of the p53 target p21Cip1.	[Reddy, V. A.; Torbett, B. E.] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; [Tschan, M. P.; Ress, A.; Arvidsson, G.; Fey, M. F.] Univ Bern, Dept Clin Res, Bern, Switzerland; [Fey, M. F.] Univ Hosp Bern, Dept Med Oncol, CH-3010 Bern, Switzerland	Scripps Research Institute; University of Bern; University of Bern; University Hospital of Bern	Torbett, BE (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	betorbet@scripps.edu		Arvidsson, Gustav/0000-0001-7396-1820; Tschan, Mario P./0000-0001-5897-3647	NIAID NIH HHS [AI49165] Funding Source: Medline; NIDDK NIH HHS [DK49886] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049886] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Back J, 2004, BLOOD, V103, P3615, DOI 10.1182/blood-2003-11-4089; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; Benard J, 2003, HUM MUTAT, V21, P182, DOI 10.1002/humu.10172; Britschgi C, 2006, ONCOGENE, V25, P2030, DOI 10.1038/sj.onc.1209240; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Goldschneider D, 2005, J CELL SCI, V118, P1245, DOI 10.1242/jcs.01704; Houston IB, 2007, EXP HEMATOL, V35, P374, DOI 10.1016/j.exphem.2006.11.003; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Iwasaki H, 2005, BLOOD, V106, P1590, DOI 10.1182/blood-2005-03-0860; Jundt F, 2002, BLOOD, V99, P3060, DOI 10.1182/blood.V99.8.3060; Kelley LL, 1998, ONCOGENE, V17, P1119, DOI 10.1038/sj.onc.1202037; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Miyake N, 2006, STEM CELLS, V24, P653, DOI 10.1634/stemcells.2005-0328; Moll UM, 2004, MOL CANCER RES, V2, P371; Moreau-Gachelin F, 2006, HAEMATOLOGICA, V91, P1644; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; Nutt SL, 2005, J EXP MED, V201, P221, DOI 10.1084/jem.20041535; Pluta A, 2006, LEUKEMIA, V20, P757, DOI 10.1038/sj.leu.2404166; Prasher JM, 2001, ONCOGENE, V20, P2946, DOI 10.1038/sj.onc.1204395; Rimmele P, 2007, BLOOD, V109, P3007, DOI 10.1182/blood-2006-03-006718; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6	25	21	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	24					3489	3493		10.1038/sj.onc.1211004	http://dx.doi.org/10.1038/sj.onc.1211004			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18193090				2022-12-25	WOS:000256309900014
J	Mydel, P; Shipley, JM; Adair-Kirk, TL; Kelley, DG; Broekelmann, TJ; Mecham, RP; Senior, RM				Mydel, Piotr; Shipley, J. Michael; Adair-Kirk, Tracy L.; Kelley, Diane G.; Broekelmann, Thomas J.; Mecham, Robert P.; Senior, Robert M.			Neutrophil elastase cleaves laminin-332 (laminin-5) generating peptides that are chemotactic for neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL EPIDERMOLYSIS-BULLOSA; EPITHELIAL-CELL MIGRATION; HOMOZYGOUS NONSENSE MUTATION; ALPHA-3 CHAIN; GAMMA-2 CHAIN; INTEGRIN ALPHA(3)BETA(1); RESTRICTED DISTRIBUTION; PLASMINOGEN-ACTIVATOR; BASEMENT-MEMBRANES; PROCESSING ENZYME	Proteolytic processing of laminin-332 by matrix metalloproteinase (MMP)-2 and MMP-14 has been shown to yield fragments that are promigratory for epithelial cells. During acute and chronic inflammation, proteases are elaborated by neutrophils and macrophages that can degrade basement membranes. We investigated the susceptibility of laminin-332 to degradation by the following neutrophil and macrophage proteases: neutrophil elastase (NE), cathepsin G, proteinase-3, and MMPs-2, -8, -9, and -12. Protease-specific differences were seen in the capacity to cleave the individual chains of laminin-332. NE and MMP-12 showed the greatest activity toward the gamma 2 chain, generating a fragment similar in size to the gamma 2x fragment generated by MMP-2. The digestion pattern of laminin-332 by degranulated neutrophils was nearly identical to that generated with NE alone. Digestion by supernatants of degranulated neutrophils was blocked by an inhibitor of NE, and NE-deficient neutrophils were essentially unable to digest laminin-332, suggesting that NE is the major neutrophil-derived protease that degrades laminin-332. In vivo, laminin gamma 2 fragments were found in the bronchoalveolar lavage fluid of wild-type mice treated with lipopolysaccharide, whereas that obtained from NE-deficient mice showed a different cleavage pattern. In addition, NE cleaved a synthetic peptide derived from the region of human laminin gamma 2 containing the MMP-2 cleavage site, suggesting that NE may generate laminin-332 fragments that are also promigratory. Both laminin-332 fragments generated by NE digestion and NE-digested laminin gamma 2 peptide were found to be chemotactic for neutrophils. Collectively, these data suggest that degradation of laminin-332 by NE generates fragments with important biological activities.	[Broekelmann, Thomas J.; Mecham, Robert P.; Senior, Robert M.] Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; [Mydel, Piotr; Shipley, J. Michael; Adair-Kirk, Tracy L.; Kelley, Diane G.; Senior, Robert M.] Washington Univ, Dept Med, Div Pulm & Crit Care Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Senior, RM (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Campus Box 8052,660 S Euclid Ave, St Louis, MO 63110 USA.	rsenior@im.wustl.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 29594] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abrahamson DR, 2003, KIDNEY INT, V63, P826, DOI 10.1046/j.1523-1755.2003.00800.x; Adair-Kirk TL, 2005, J IMMUNOL, V174, P1621, DOI 10.4049/jimmunol.174.3.1621; Adair-Kirk TL, 2003, J IMMUNOL, V171, P398, DOI 10.4049/jimmunol.171.1.398; Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; Aumailley M, 2005, MATRIX BIOL, V24, P326, DOI 10.1016/j.matbio.2005.05.006; Belaaouaj A, 1998, NAT MED, V4, P615, DOI 10.1038/nm0598-615; Borradori L, 1999, J INVEST DERMATOL, V112, P411, DOI 10.1046/j.1523-1747.1999.00546.x; Bylund J, 2007, EUR J IMMUNOL, V37, P1087, DOI 10.1002/eji.200636651; Chua F, 2007, AM J PATHOL, V170, P65, DOI 10.2353/ajpath.2007.060352; CLARK RAF, 1988, J BIOL CHEM, V263, P12115; Falk M, 1999, MATRIX BIOL, V18, P557, DOI 10.1016/S0945-053X(99)00047-5; Franzke CW, 2002, EMBO J, V21, P5026, DOI 10.1093/emboj/cdf532; Franzke CW, 2004, J BIOL CHEM, V279, P24521, DOI 10.1074/jbc.M308835200; Ghosh S, 2000, J BIOL CHEM, V275, P23869, DOI 10.1074/jbc.M000935200; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; Gresham HD, 1996, J BIOL CHEM, V271, P30587, DOI 10.1074/jbc.271.48.30587; HARVATH L, 1994, J IMMUNOL, V152, P5447; HECK LW, 1990, AM J PATHOL, V136, P1267; HERSHKOVIZ R, 1995, IMMUNOLOGY, V85, P125; Hintermann E, 2005, J BIOL CHEM, V280, P8004, DOI 10.1074/jbc.M406301200; Hirche TO, 2004, AM J RESP CELL MOL, V30, P576, DOI 10.1165/rcmb.2003-0253OC; Hirosaki T, 2000, J BIOL CHEM, V275, P22495, DOI 10.1074/jbc.M001326200; HORTON MA, 1994, BONE, V15, P639, DOI 10.1016/8756-3282(94)90312-3; Houghton AM, 2006, J CLIN INVEST, V116, P753, DOI 10.1172/JCI25617; HUNNINGHAKE GW, 1981, SCIENCE, V212, P925, DOI 10.1126/science.7233186; Khan KMF, 2000, J BIOL CHEM, V275, P4492, DOI 10.1074/jbc.275.6.4492; KIVIRIKKO S, 1995, HUM MOL GENET, V4, P959, DOI 10.1093/hmg/4.5.959; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Koshikawa N, 2005, J BIOL CHEM, V280, P88, DOI 10.1074/jbc.M411824200; Liu Z, 2000, J CLIN INVEST, V105, P113, DOI 10.1172/JCI3693; Liu Z, 2000, CELL, V102, P647, DOI 10.1016/S0092-8674(00)00087-8; Meng XM, 2003, J INVEST DERMATOL, V121, P720, DOI 10.1046/j.1523-1747.2003.12515.x; Mizushima H, 1997, CELL GROWTH DIFFER, V8, P979; Parikka M, 2006, EXP CELL RES, V312, P1431, DOI 10.1016/j.yexcr.2006.01.015; PFAFF M, 1994, EUR J BIOCHEM, V225, P975, DOI 10.1111/j.1432-1033.1994.0975b.x; Pierce RA, 2000, AM J RESP CELL MOL, V23, P742, DOI 10.1165/ajrcmb.23.6.4202; Pirila E, 2003, BIOCHEM BIOPH RES CO, V303, P1012, DOI 10.1016/S0006-291X(03)00452-2; Plopper G, 1996, J CELL SCI, V109, P1965; PULKKINEN L, 1994, GENOMICS, V24, P357, DOI 10.1006/geno.1994.1627; Rajamaki MM, 2006, VET J, V171, P562, DOI 10.1016/j.tvjl.2004.11.018; Sadowski T, 2005, CELL MOL LIFE SCI, V62, P870, DOI 10.1007/s00018-005-4478-8; Schenk S, 2003, J CELL BIOL, V161, P197, DOI 10.1083/jcb.200208145; Seftor REB, 2001, CANCER RES, V61, P6322; SENIOR RM, 1989, AM J RESP CELL MOL, V1, P479, DOI 10.1165/ajrcmb/1.6.479; SENIOR RM, 1980, J CLIN INVEST, V66, P859, DOI 10.1172/JCI109926; Shang ML, 2001, J BIOL CHEM, V276, P33045, DOI 10.1074/jbc.M100798200; Shapiro SD, 2003, AM J PATHOL, V163, P2329, DOI 10.1016/S0002-9440(10)63589-4; Shimanovich I, 2004, J PATHOL, V204, P519, DOI 10.1002/path.1674; Spirito F, 2001, J BIOL CHEM, V276, P18828, DOI 10.1074/jbc.M100381200; STEADMAN R, 1993, J LEUKOCYTE BIOL, V53, P354, DOI 10.1002/jlb.53.4.354; SUNG U, 1993, J CELL BIOL, V123, P1255, DOI 10.1083/jcb.123.5.1255; Sung U, 1997, MOL CELLS, V7, P272; Udayakumar TS, 2003, CANCER RES, V63, P2292; Virtanen I, 2000, EXP CELL RES, V257, P298, DOI 10.1006/excr.2000.4883; Wang SJ, 2005, J CELL SCI, V118, P2067, DOI 10.1242/jcs.02340; Weathington NM, 2006, NAT MED, V12, P317, DOI 10.1038/nm1361; Young RE, 2004, J IMMUNOL, V172, P4493, DOI 10.4049/jimmunol.172.7.4493	58	78	83	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9513	9522		10.1074/jbc.M706239200	http://dx.doi.org/10.1074/jbc.M706239200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18178964	Green Published, hybrid			2022-12-25	WOS:000254671600004
J	Ura, H; Usuda, M; Kinoshita, K; Sun, C; Mori, K; Akagi, T; Matsuda, T; Koide, H; Yokota, T				Ura, Hiroki; Usuda, Masayuki; Kinoshita, Keita; Sun, Chuanhai; Mori, Keitaro; Akagi, Tadayuki; Matsuda, Takahiko; Koide, Hiroshi; Yokota, Takashi			STAT3 and Oct-3/4 control histone modification through induction of Eed in embryonic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTAL REGULATORS; MOUSE EMBRYOS; SELF-RENEWAL; ES CELLS; POLYCOMB; EXPRESSION; DIFFERENTIATION; TRANSCRIPTION; CHROMATIN; PLURIPOTENCY	Mouse embryonic stem (ES) cells can self-renew in the presence of leukemia inhibitory factor (LIF). Several essential transcription factors have been identified for the self-renewal of mouse ES cells, including STAT3, Oct-3/4, and Nanog. The molecular mechanism of ES cell self-renewal, however, is not fully understood. In the present study, we identified Eed, a core component of Polycomb repressive complex 2, as a downstream molecule of STAT3 and Oct-3/4. Artificial activation of STAT3 resulted in increased expression of Eed, whereas expression of a dominant negative mutant of STAT3 or suppression of Oct-3/4 expression led to down-regulation of Eed. Reporter, chromatin immunoprecipitation, and electrophoretic mobility shift assays revealed that STAT3 and Oct-3/4 directly bind to the promoter region of Eed, suggesting that Eed is a common target molecule of STAT3 and Oct-3/4. We also found that suppression of STAT3, Oct-3/4, or Eed causes induction of differentiation-associated genes as well as loss of Lys(27)-trimethylated histone H3 at the promoter regions of the differentiation-associated genes. Suppression of STAT3 and Oct-3/4 also resulted in the absence of Eed at the promoter regions. These results suggest that STAT3 and Oct-3/4 maintain silencing of differentiation-associated genes through up-regulation of Eed in self-renewing ES cells.	[Usuda, Masayuki; Koide, Hiroshi] Kanazawa Univ, Grad Sch Med Sci, Dept Stem Cell Biol, Kanazawa, Ishikawa 9208640, Japan	Kanazawa University	Koide, H (corresponding author), Kanazawa Univ, Grad Sch Med Sci, Dept Stem Cell Biol, 13-1 Takaramachi, Kanazawa, Ishikawa 9208640, Japan.	hkoide@med.kanasawa-u.ac.jp	Ura, Hiroki/ABD-8427-2020; Yokota, Takashi/J-8483-2015; Koide, Hiroshi/E-9000-2011; Yokota, Takashi/F-6021-2011; Akagi, Tadayuki/E-1078-2011	Ura, Hiroki/0000-0002-7600-3481; Akagi, Tadayuki/0000-0002-1733-9452; Koide, Hiroshi/0000-0001-5916-3179				Abate-Shen C, 2003, CANCER CELL, V4, P329, DOI 10.1016/S1535-6108(03)00277-0; Akagi T, 2005, BIOCHEM BIOPH RES CO, V331, P23, DOI 10.1016/j.bbrc.2005.03.118; Arguni E, 2006, INT IMMUNOL, V18, P1079, DOI 10.1093/intimm/dxl041; Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403; AZUMA S, 1991, Japanese Journal of Animal Reproduction, V37, P37; BENSHUSHAN E, 1995, MOL CELL BIOL, V15, P1034; Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Faust C, 1998, DEVELOPMENT, V125, P4495; Frank DA, 2007, CANCER LETT, V251, P199, DOI 10.1016/j.canlet.2006.10.017; Fuhrmann G, 2001, DEV CELL, V1, P377, DOI 10.1016/S1534-5807(01)00038-7; Kim SY, 2007, J BIOL CHEM, V282, P9962, DOI 10.1074/jbc.M608722200; Kuzmichev A, 2005, P NATL ACAD SCI USA, V102, P1859, DOI 10.1073/pnas.0409875102; Kuzmichev A, 2004, MOL CELL, V14, P183, DOI 10.1016/S1097-2765(04)00185-6; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Meshorer E, 2006, NAT REV MOL CELL BIO, V7, P540, DOI 10.1038/nrm1938; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Montgomery ND, 2005, CURR BIOL, V15, P942, DOI 10.1016/j.cub.2005.04.051; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Niwa H, 2007, DEVELOPMENT, V134, P635, DOI 10.1242/dev.02787; O'Carroll D, 2001, MOL CELL BIOL, V21, P4330, DOI 10.1128/MCB.21.13.4330-4336.2001; Pasini D, 2007, MOL CELL BIOL, V27, P3769, DOI 10.1128/MCB.01432-06; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; Yoshida-Koide U, 2004, BIOCHEM BIOPH RES CO, V313, P475, DOI 10.1016/j.bbrc.2003.11.138; Zhang L, 2006, MOL CELL BIOCHEM, V288, P179, DOI 10.1007/s11010-006-9137-3	35	48	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9713	9723		10.1074/jbc.M707275200	http://dx.doi.org/10.1074/jbc.M707275200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18201968	hybrid			2022-12-25	WOS:000254671600026
J	Bendjennat, M; Weil, PA				Bendjennat, Mourad; Weil, P. Anthony			The transcriptional repressor activator protein Rap1p is a direct regulator of TATA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-II TRANSCRIPTION; PROMOTERS IN-VIVO; SACCHAROMYCES-CEREVISIAE; RIBOSOMAL-PROTEIN; GENE-EXPRESSION; BOX-BINDING; DNA-BINDING; CRYSTAL-STRUCTURE; GENOME-WIDE; FUNCTIONAL-ANALYSIS	Essentially all nuclear eukaryotic gene transcription depends upon the function of the transcription factor TATA-binding protein (TBP). Here we show that the abundant, multifunctional DNA binding transcription factor repressor activator protein Rap1p interacts directly with TBP. TBP-Rap1p binding occurs efficiently in vivo at physiological expression levels, and in vitro analyses confirm that this is a direct interaction. The DNA binding domains of the two proteins mediate interaction between TBP and Rap1p. TBP-Rap1p complex formation inhibits TBP binding to TATA promoter DNA. Alterations in either Rap1p or TBP levels modulate mRNA gene transcription in vivo. We propose that Rap1p represents a heretofore unrecognized regulator of TBP.	[Bendjennat, Mourad; Weil, P. Anthony] Vanderbilt Univ, Dept Mol Physiol & Biophys, Sch Med, Nashville, TN 37232 USA	Vanderbilt University	Weil, PA (corresponding author), Vanderbilt Univ, Dept Mol Physiol & Biophys, Sch Med, Nashville, TN 37232 USA.	tony.weil@vanderbilt.edu			NIGMS NIH HHS [GM 52461, R01 GM052461, R01 GM052461-12] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM052461, R01GM052461] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexander DE, 2004, J BIOL CHEM, V279, P32401, DOI 10.1074/jbc.M405782200; Bai Y, 1997, MOL CELL BIOL, V17, P3081, DOI 10.1128/MCB.17.6.3081; Banik U, 2001, J BIOL CHEM, V276, P49100, DOI 10.1074/jbc.M109246200; Bernstein BE, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r62; Bi X, 1999, GENE DEV, V13, P1089, DOI 10.1101/gad.13.9.1089; Blair WS, 1997, MOL CELL BIOL, V17, P2888, DOI 10.1128/MCB.17.5.2888; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P5086, DOI 10.1128/MCB.8.12.5086; Buck MJ, 2006, NAT GENET, V38, P1446, DOI 10.1038/ng1917; Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; Chalkley GE, 1999, EMBO J, V18, P4835, DOI 10.1093/emboj/18.17.4835; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; COLEMAN RA, 1995, J BIOL CHEM, V270, P13850, DOI 10.1074/jbc.270.23.13850; Coleman RA, 1999, MOL CELL, V4, P451, DOI 10.1016/S1097-2765(00)80453-0; Collart MA, 2003, GENE, V313, P1, DOI 10.1016/S0378-1119(03)00672-3; CORMACK BP, 1993, SCIENCE, V262, P244, DOI 10.1126/science.8211143; De Sanctis V, 2002, J MOL BIOL, V318, P333, DOI 10.1016/S0022-2836(02)00110-9; Del Vescovo V, 2004, J MOL BIOL, V338, P877, DOI 10.1016/j.jmb.2004.03.047; Deminoff SJ, 2001, GENETICS, V158, P133; Drazinic CM, 1996, MOL CELL BIOL, V16, P3187; DURRIN LK, 1992, MOL CELL BIOL, V12, P1621, DOI 10.1128/MCB.12.4.1621; Fourel G, 2002, J BIOL CHEM, V277, P41736, DOI 10.1074/jbc.M202578200; FREEMAN K, 1995, GENETICS, V141, P1253; Garbett KA, 2007, MOL CELL BIOL, V27, P297, DOI 10.1128/MCB.01558-06; Geisberg JV, 2000, MOL CELL BIOL, V20, P1478, DOI 10.1128/MCB.20.5.1478-1488.2000; Graham IR, 1999, MOL CELL BIOL, V19, P7481; Gumbs OH, 2003, EMBO J, V22, P3131, DOI 10.1093/emboj/cdg304; Hall DB, 2006, MOL CELL BIOL, V26, P3672, DOI 10.1128/MCB.26.9.3672-3679.2006; HAN M, 1988, EMBO J, V7, P2221, DOI 10.1002/j.1460-2075.1988.tb03061.x; HARDY CFJ, 1992, MOL CELL BIOL, V12, P1209, DOI 10.1128/MCB.12.3.1209; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; Hinkley CS, 2003, J BIOL CHEM, V278, P18649, DOI 10.1074/jbc.M204247200; Huisinga KL, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-4-r46; Idrissi FZ, 2001, J BIOL CHEM, V276, P26090, DOI 10.1074/jbc.M101746200; Ioshikhes IP, 2006, NAT GENET, V38, P1210, DOI 10.1038/ng1878; Jackson-Fisher AJ, 1999, MOL CELL, V3, P717, DOI 10.1016/S1097-2765(01)80004-6; Jorgensen P, 2004, GENE DEV, V18, P2491, DOI 10.1101/gad.1228804; Kamada K, 2001, CELL, V106, P71, DOI 10.1016/S0092-8674(01)00417-2; Kasahara K, 2007, MOL CELL BIOL, V27, P6686, DOI 10.1128/MCB.00876-07; Kim S, 2000, MOL CELL BIOL, V20, P2455, DOI 10.1128/MCB.20.7.2455-2465.2000; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; Kotani T, 2000, P NATL ACAD SCI USA, V97, P7178, DOI 10.1073/pnas.120074297; Kou HP, 2004, J BIOL CHEM, V279, P20966, DOI 10.1074/jbc.M401535200; Kou HP, 2003, MOL CELL BIOL, V23, P3186, DOI 10.1128/MCB.23.9.3186-3201.2003; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; KYRION G, 1993, GENE DEV, V7, P1146, DOI 10.1101/gad.7.7a.1146; Lariviere L, 2006, NAT STRUCT MOL BIOL, V13, P895, DOI 10.1038/nsmb1143; Lee CK, 2004, NAT GENET, V36, P900, DOI 10.1038/ng1400; Lee DH, 2005, MOL CELL BIOL, V25, P9674, DOI 10.1128/MCB.25.21.9674-9686.2005; Li XY, 2000, SCIENCE, V288, P1242, DOI 10.1126/science.288.5469.1242; Lieb JD, 2001, NAT GENET, V28, P327, DOI 10.1038/ng569; Luo KH, 2002, GENE DEV, V16, P1528, DOI 10.1101/gad.988802; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; Marion RM, 2004, P NATL ACAD SCI USA, V101, P14315, DOI 10.1073/pnas.0405353101; Martin DE, 2004, CELL, V119, P969, DOI 10.1016/j.cell.2004.11.047; Mencia M, 2002, MOL CELL, V9, P823, DOI 10.1016/S1097-2765(02)00490-2; Metcalf CE, 2006, J BIOL CHEM, V281, P30015, DOI 10.1074/jbc.M606289200; Mnaimneh S, 2004, CELL, V118, P31, DOI 10.1016/j.cell.2004.06.013; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; Moretti P, 2001, MOL CELL BIOL, V21, P8082, DOI 10.1128/MCB.21.23.8082-8094.2001; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; Morse RH, 2000, TRENDS GENET, V16, P51, DOI 10.1016/S0168-9525(99)01936-8; Muller F, 2007, J BIOL CHEM, V282, P14685, DOI 10.1074/jbc.R700012200; MULLER T, 1994, J STRUCT BIOL, V113, P1, DOI 10.1006/jsbi.1994.1027; Nishikawa J, 1997, P NATL ACAD SCI USA, V94, P85, DOI 10.1073/pnas.94.1.85; Pardo B, 2005, EMBO J, V24, P3117, DOI 10.1038/sj.emboj.7600778; Pereira LA, 2003, GENE, V315, P1, DOI 10.1016/S0378-1119(03)00714-5; Pereira LA, 2001, MOL CELL BIOL, V21, P7523, DOI 10.1128/MCB.21.21.7523-7534.2001; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; Pina B, 2003, MOL GENET GENOMICS, V268, P791, DOI 10.1007/s00438-002-0801-3; Pugh BF, 2000, GENE, V255, P1, DOI 10.1016/S0378-1119(00)00288-2; Reid JL, 2000, MOL CELL, V6, P1297, DOI 10.1016/S1097-2765(00)00128-3; Rossetti L, 2001, J MOL BIOL, V306, P903, DOI 10.1006/jmbi.2001.4458; Rudra D, 2005, EMBO J, V24, P533, DOI 10.1038/sj.emboj.7600553; Rudra D, 2004, GENE DEV, V18, P2431, DOI 10.1101/gad.1256704; Sanders SL, 2002, MOL CELL BIOL, V22, P6000, DOI 10.1128/MCB.22.16.6000-6013.2002; Sanders SL, 2002, MOL CELL BIOL, V22, P4723, DOI 10.1128/MCB.22.13.4723-4738.2002; SCHROEDER SC, 1994, J BIOL CHEM, V269, P28335; Segal E, 2006, NATURE, V442, P772, DOI 10.1038/nature04979; Sekinger EA, 2005, MOL CELL, V18, P735, DOI 10.1016/j.molcel.2005.05.003; Sermwittayawong D, 2006, EMBO J, V25, P3791, DOI 10.1038/sj.emboj.7601265; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; Stavenhagen JB, 1998, GENE DEV, V12, P3044, DOI 10.1101/gad.12.19.3044; Szutorisz H, 2005, TRENDS BIOCHEM SCI, V30, P593, DOI 10.1016/j.tibs.2005.08.006; Takemaru K, 1997, P NATL ACAD SCI USA, V94, P7251, DOI 10.1073/pnas.94.14.7251; Tan S, 1996, NATURE, V381, P127, DOI 10.1038/381127a0; Thomas MC, 2006, CRIT REV BIOCHEM MOL, V41, P105, DOI 10.1080/10409230600648736; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; Wade JT, 2004, NATURE, V432, P1054, DOI 10.1038/nature03175; Warfield L, 2004, GENE DEV, V18, P1022, DOI 10.1101/gad.1192204; Wotton D, 1997, GENE DEV, V11, P748, DOI 10.1101/gad.11.6.748; Wu WH, 1999, P NATL ACAD SCI USA, V96, P2764, DOI 10.1073/pnas.96.6.2764; Wyrick JJ, 1999, NATURE, V402, P418, DOI 10.1038/46567; Xu SP, 2004, GENE, V338, P177, DOI 10.1016/j.gene.2004.04.034; Yu LN, 1999, MOL CELL BIOL, V19, P5279; Zanton SJ, 2006, GENE DEV, V20, P2250, DOI 10.1101/gad.1437506; Zhao Y, 2006, MOL CELL BIOL, V26, P4853, DOI 10.1128/MCB.02367-05	96	9	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8699	8710		10.1074/jbc.M709436200	http://dx.doi.org/10.1074/jbc.M709436200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18195009	hybrid, Green Accepted, Green Published			2022-12-25	WOS:000254288000068
J	Nguyen, N; Bonzo, JA; Chen, S; Chouinard, S; Kelner, MJ; Hardiman, G; Belanger, A; Tukey, RH				Nguyen, Nghia; Bonzo, Jessica A.; Chen, Shujuan; Chouinard, Sarah; Kelner, Michael J.; Hardiman, Gary; Belanger, Alain; Tukey, Robert H.			Disruption of the Ugt1 locus in mice resembles human Crigler-Najjar type I disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILIRUBIN-UDP-GLUCURONOSYLTRANSFERASE; URIDINE DIPHOSPHO-GLUCURONOSYLTRANSFERASES; MYCOPHENOLIC-ACID; GUNN-RATS; HUMAN LIVER; BILE-ACID; DIFFERENTIAL EXPRESSION; UNCONJUGATED BILIRUBIN; GILBERTS-SYNDROME; NUCLEAR RECEPTOR	The 9 UDP-glucuronosyltranferases (UGTs) encoded by the UGT1 locus in humans are key enzymes in the metabolism of most drugs as well as endogenous substances such as bile acids, fatty acids, steroids, hormones, neurotransmitters, and bilirubin. Severe unconjugated hyperbilirubinemia in humans that suffer from Crigler-Najjar type I disease results from lesions in the UGT1A1 gene and is often fatal. To examine the physiological importance of the Ugt1 locus in mice, this locus was rendered non-functional by interrupting exon 4 to create Ugt1(-/-) mice. Because UGT1A1 in humans is responsible for 100% of the conjugated bilirubin, it followed that newborn Ugt1(-/-) mice developed serum levels of unconjugated bilirubin that were 40 - 60 times higher than Ugt1(+/-) or wild-type mice. The result of extreme unconjugated bilirubin in Ugt1(-/-) mice, comparable to the induced levels noted in patients with Crigler-Najjar type 1 disease, is fatal in neonatal Ugt1(-/-) mice within 2 weeks following birth. The extreme jaundice is present as a phenotype in skin color after 8 h. Neonatal Ugt1(-/-) mice exhibit no detectable UGT1A-specific RNA, which corresponds to a complete absence of UGT1A proteins in liver microsomes. Conserved glucuronidation activity attributed to the Ugt1 locus can be defined in Ugt1(-/-) mice, because UGT2-dependent glucuronidation activity is unaffected. Remarkably, the loss of UGT1A functionality in liver results in significant alterations in cellular metabolism as investigated through changes in gene expression. Thus, the loss of UGT1A function in Ugt1(-/-) mice leads to a metabolic syndrome that can serve as a model to further investigate the toxicities associated with unconjugated bilirubin and the impact of this disease in humans.	[Nguyen, Nghia; Bonzo, Jessica A.; Chen, Shujuan; Tukey, Robert H.] Univ Calif San Diego, Dept Chem & Biochem, Lab Environm Toxicol, La Jolla, CA 92093 USA; [Nguyen, Nghia; Bonzo, Jessica A.; Chen, Shujuan; Tukey, Robert H.] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Kelner, Michael J.] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; [Hardiman, Gary] Univ Calif San Diego, Sch Med, Dept Med, Biomed Genom Microarray Facil, La Jolla, CA 92093 USA; [Chouinard, Sarah; Belanger, Alain] Ctr Hosp Univ Quebec, Oncol & Mol Endocrinol Res Ctr, Quebec City, PQ G1V 4G2, Canada	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Laval University	Tukey, RH (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, Lab Environm Toxicol, 9500 Gilman Dr,Leichtag Biomed Res Bldg, La Jolla, CA 92093 USA.	rtukey@ucsd.edu		Chen, Shujuan/0000-0002-1068-195X; Hardiman, Gary/0000-0003-4558-0400	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES010337] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES10337] Funding Source: Medline; PHS HHS [15RT-0251] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Albert C, 1999, ENDOCRINOLOGY, V140, P3292, DOI 10.1210/en.140.7.3292; Barbier O, 1999, BIOCHEM J, V337, P567, DOI 10.1042/0264-6021:3370567; Belanger G, 1999, EUR J BIOCHEM, V260, P701, DOI 10.1046/j.1432-1327.1999.00197.x; Bernard O, 2004, DRUG METAB DISPOS, V32, P775, DOI 10.1124/dmd.32.8.775; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Bosma PJ, 2003, J HEPATOL, V38, P107, DOI 10.1016/S0168-8278(02)00359-8; BOSMA PJ, 1994, J BIOL CHEM, V269, P17960; BOSMA PJ, 1995, NEW ENGL J MED, V333, P1171, DOI 10.1056/NEJM199511023331802; Buckley DB, 2007, DRUG METAB DISPOS, V35, P121, DOI 10.1124/dmd.106.012070; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; Chen SJ, 2005, J BIOL CHEM, V280, P37547, DOI 10.1074/jbc.M506683200; CHOWDHURY JR, 1993, ADV VET SCI COMP MED, V37, P149; Clarke DJ, 1997, CLIN CHIM ACTA, V266, P63, DOI 10.1016/S0009-8981(97)00167-8; Cole SW, 2003, BIOINFORMATICS, V19, P1808, DOI 10.1093/bioinformatics/btg242; CRIGLER JF, 1952, PEDIATRICS, V10, P169; CRIGLER JF, 1969, J CLIN INVEST, V48, P42, DOI 10.1172/JCI105973; ELAWADY M, 1990, J BIOL CHEM, V265, P10752; Fernandes A, 2006, J NEUROCHEM, V96, P1667, DOI 10.1111/j.1471-4159.2006.03680.x; Fernandes A, 2007, EUR J NEUROSCI, V25, P1058, DOI 10.1111/j.1460-9568.2007.05340.x; Gong QH, 2001, PHARMACOGENETICS, V11, P357, DOI 10.1097/00008571-200106000-00011; Graber ALY, 2007, PHARMACOGENET GENOM, V17, P619, DOI 10.1097/FPC.0b013e3280121fe9; Guillemette C, 1997, ENDOCRINOLOGY, V138, P2998, DOI 10.1210/en.138.7.2998; Huang WD, 2003, P NATL ACAD SCI USA, V100, P4156, DOI 10.1073/pnas.0630614100; Ishibashi S, 1996, J BIOL CHEM, V271, P18017, DOI 10.1074/jbc.271.30.18017; IYANAGI T, 1991, J BIOL CHEM, V266, P24048; KAPITULNIK J, 1993, MOL PHARMACOL, V43, P722; Kato Y, 2004, TOXICOL SCI, V81, P309, DOI 10.1093/toxsci/kfh225; KOMAKI T, 1991, J ENDOCRINOL INVEST, V14, P409, DOI 10.1007/BF03349091; Krishnaswamy S, 2005, J PHARMACOL EXP THER, V313, P1340, DOI 10.1124/jpet.104.081968; Krishnaswamy S, 2003, DRUG METAB DISPOS, V31, P133, DOI 10.1124/dmd.31.1.133; Kurkela M, 2007, PHARMACOGENET GENOM, V17, P115, DOI 10.1097/FPC.0b013e328011b598; LAMB JG, 1994, BIOCHEMISTRY-US, V33, P10513, DOI 10.1021/bi00200a037; Lankisch TO, 2006, HEPATOLOGY, V44, P1324, DOI 10.1002/hep.21361; Lepine J, 2004, J CLIN ENDOCR METAB, V89, P5222, DOI 10.1210/jc.2004-0331; Lin SZ, 2003, NEUROSCI LETT, V353, P209, DOI 10.1016/j.neulet.2003.09.053; Mackenzie PI, 2005, PHARMACOGENET GENOM, V15, P677, DOI 10.1097/01.fpc.0000173483.13689.56; Mackenzie PI, 2000, THER DRUG MONIT, V22, P10, DOI 10.1097/00007691-200002000-00002; Mojarrabi B, 1997, BIOCHEM BIOPH RES CO, V238, P775, DOI 10.1006/bbrc.1997.7388; Monaghan G, 1996, LANCET, V347, P578, DOI 10.1016/S0140-6736(96)91273-8; NATH KA, 1992, J CLIN INVEST, V90, P267, DOI 10.1172/JCI115847; Operana TN, 2007, J BIOL CHEM, V282, P4821, DOI 10.1074/jbc.M609417200; Ostrow JD, 2003, PEDIATR RES, V54, P926, DOI 10.1203/01.PDR.0000103388.01854.91; Phelan D, 1998, ARCH BIOCHEM BIOPHYS, V357, P155, DOI 10.1006/abbi.1998.0814; Picard N, 2005, DRUG METAB DISPOS, V33, P139, DOI 10.1124/dmd.104.001651; RITTER JK, 1992, J CLIN INVEST, V90, P150, DOI 10.1172/JCI115829; RITTER JK, 1992, J BIOL CHEM, V267, P3257; RIZZARDINI M, 1993, BIOCHEM J, V290, P343, DOI 10.1042/bj2900343; Rodrigues CMP, 2002, HEPATOLOGY, V35, P1186, DOI 10.1053/jhep.2002.32967; Rodrigues CMP, 2000, MOL MED, V6, P936, DOI 10.1007/BF03401828; Roger C, 1995, EARLY HUM DEV, V43, P133, DOI 10.1016/0378-3782(95)01668-6; Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712; Sasik R, 2004, J MOL ENDOCRINOL, V33, P1, DOI 10.1677/jme.0.0330001; Schauer R, 2003, J PEDIATR SURG, V38, P1227, DOI 10.1016/S0022-3468(03)00273-2; Senekeo-Effenberger K, 2007, DRUG METAB DISPOS, V35, P419, DOI 10.1124/dmd.106.013243d; Servedio V, 2005, HUM MUTAT, V25, DOI 10.1002/humu.9322; Shapiro SM, 2003, PEDIATR NEUROL, V29, P410, DOI 10.1016/j.pediatrneurol.2003.09.011; Shipkova M, 2001, BRIT J PHARMACOL, V132, P1027, DOI 10.1038/sj.bjp.0703898; SOKAL EM, 1995, TRANSPLANTATION, V60, P1095, DOI 10.1097/00007890-199511270-00006; Strassburg CP, 1997, MOL PHARMACOL, V52, P212, DOI 10.1124/mol.52.2.212; Strassburg CP, 1998, MOL PHARMACOL, V54, P647; Strassburg CP, 1999, GASTROENTEROLOGY, V116, P149, DOI 10.1016/S0016-5085(99)70239-8; Strauss KA, 2006, EUR J PEDIATR, V165, P306, DOI 10.1007/s00431-005-0055-2; Takahashi M, 1996, J BIOL CHEM, V271, P26536, DOI 10.1074/jbc.271.43.26536; Tukey RH, 2000, ANNU REV PHARMACOL, V40, P581, DOI 10.1146/annurev.pharmtox.40.1.581; Tukey RH, 2002, MOL PHARMACOL, V62, P446, DOI 10.1124/mol.62.3.446; Turgeon D, 2001, ENDOCRINOLOGY, V142, P778, DOI 10.1210/en.142.2.778; Verreault M, 2006, HEPATOLOGY, V44, P368, DOI 10.1002/hep.21259; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112; Wennberg RP, 2000, CELL MOL NEUROBIOL, V20, P97, DOI 10.1023/A:1006900111744; Yamamura H, 1993, Nagoya J Med Sci, V55, P11; Yueh MF, 2007, J BIOL CHEM, V282, P8749, DOI 10.1074/jbc.M610790200	71	63	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7901	7911		10.1074/jbc.M709244200	http://dx.doi.org/10.1074/jbc.M709244200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18180294	hybrid			2022-12-25	WOS:000253997900066
J	Yang, YW; Zhang, W; Bayrer, JR; Weiss, MA				Yang, Yanwu; Zhang, Wei; Bayrer, James R.; Weiss, Michael A.			Doublesex and the regulation of sexual dimorphism in Drosophila melanogaster - Structure, function, and mutagenesis of a female-specific domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL SOLUTION STRUCTURE; DNA-BINDING; MAGNETIC-RESONANCE; DISTANCE GEOMETRY; PROTEIN; DIFFERENTIATION; NMR; INTERSEX; BEHAVIOR; COMPLEX	The DSX ( Doublesex) transcription factor regulates somatic sexual differentiation in Drosophila. Female and male isoforms ( DSXF and DSXM) are formed due to sex-specific RNA splicing. DNA recognition, mediated by a shared N-terminal zinc module ( the DM domain), is enhanced by a C-terminal dimerization element. Sex-specific extension of this element in DSXF and DSXM leads to assembly of distinct transcriptional preinitiation complexes. Here, we describe the structure of the extended C-terminal dimerization domain of DSXF as determined by multidimensional NMR spectroscopy. The core dimerization element is well ordered, giving rise to a dense network of interresidue nuclear Overhauser enhancements. The structure contains dimer-related UBA folds similar to those defined by x-ray crystallographic studies of a truncated domain. Whereas the proximal portion of the female tail extends helix 3 of the UBA fold, the distal tail is disordered. Ala substitutions in the proximal tail disrupt the sex-specific binding of IX ( Intersex), an obligatory partner protein and putative transcriptional coactivator; IX-DSXF interaction is, by contrast, not disrupted by truncation of the distal tail. Mutagenesis of the UBA-like dimer of DSXF highlights the importance of steric and electrostatic complementarity across the interface. Two temperature-sensitive mutations at this interface have been characterized in yeast model systems. One weakens a network of solvated salt bridges, whereas the other perturbs the underlying nonpolar interface. These mutations confer graded gene-regulatory activity in yeast within a physiological temperature range and so may provide novel probes for genetic analysis of a sex-specific transcriptional program in Drosophila development.	[Yang, Yanwu; Zhang, Wei; Bayrer, James R.; Weiss, Michael A.] Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA	Case Western Reserve University	Weiss, MA (corresponding author), Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA.	michael.weiss@case.edu	zhang, wei/A-7015-2011		NIGMS NIH HHS [T32 GM07250, GM037731] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037731, T32GM007250, R01GM037731] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad SM, 2002, CELL, V109, P651, DOI 10.1016/S0092-8674(02)00744-4; AN WQ, 1995, EMBO J, V14, P1221, DOI 10.1002/j.1460-2075.1995.tb07105.x; An WQ, 1996, MOL CELL BIOL, V16, P3106; ARROWSMITH C, 1991, EUR J BIOCHEM, V202, P53, DOI 10.1111/j.1432-1033.1991.tb16344.x; Arthur BI, 1998, CURR BIOL, V8, P1187, DOI 10.1016/S0960-9822(07)00491-5; BAKER BS, 1980, GENETICS, V94, P383; Baker BS, 2001, CELL, V105, P13, DOI 10.1016/S0092-8674(01)00293-8; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BAX A, 1994, CURR OPIN STRUC BIOL, V4, P738, DOI 10.1016/S0959-440X(94)90173-2; Bayrer J, 2004, ACTA CRYSTALLOGR D, V60, P1328, DOI 10.1107/S0907444904012223; Bayrer JR, 2005, J BIOL CHEM, V280, P32989, DOI 10.1074/jbc.M507990200; BELOTE JM, 1987, P NATL ACAD SCI USA, V84, P8026, DOI 10.1073/pnas.84.22.8026; BOWNES M, 1981, MOL GEN GENET, V182, P222, DOI 10.1007/BF00269661; BRUNGER AT, 1993, XPLOR VERSION 3 1 MA; BURTIS KC, 1991, EMBO J, V10, P2577, DOI 10.1002/j.1460-2075.1991.tb07798.x; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; Burtis KC, 1993, CURR OPIN CELL BIOL, V5, P1006, DOI 10.1016/0955-0674(93)90085-5; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; Cai ML, 2001, EMBO J, V20, P4399, DOI 10.1093/emboj/20.16.4399; CHASE BA, 1995, GENETICS, V139, P1649; Cho S, 1997, J BIOL CHEM, V272, P3185, DOI 10.1074/jbc.272.6.3185; Cho S, 1998, BIOCHEMISTRY-US, V37, P11301, DOI 10.1021/bi972916x; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; CLINE TW, 1989, CELL, V59, P231, DOI 10.1016/0092-8674(89)90280-8; CLORE GM, 1986, EMBO J, V5, P2729, DOI 10.1002/j.1460-2075.1986.tb04557.x; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; COSCHIGANO KT, 1993, GENE DEV, V7, P42, DOI 10.1101/gad.7.1.42; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Demir E, 2005, CELL, V121, P785, DOI 10.1016/j.cell.2005.04.027; Erdman SE, 1996, GENETICS, V144, P1639; ERDMAN SE, 1993, EMBO J, V12, P527, DOI 10.1002/j.1460-2075.1993.tb05684.x; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Garrett-Engele CM, 2002, DEVELOPMENT, V129, P4661; GRZESIEK S, 1992, J MAGN RESON, V99, P201, DOI 10.1016/0022-2364(92)90169-8; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; IKURA M, 1992, J AM CHEM SOC, V114, P2433, DOI 10.1021/ja00033a019; JIN L, 1994, PROTEIN SCI, V3, P2351, DOI 10.1002/pro.5560031219; Keisman EL, 2001, DEVELOPMENT, V128, P1643; Keisman EL, 2001, DEV CELL, V1, P215, DOI 10.1016/S1534-5807(01)00027-2; Koradi R, 1996, J MOL GRAPHICS, V14, P29; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE W, 1994, FEBS LETT, V350, P87, DOI 10.1016/0014-5793(94)00740-3; Legault P, 1998, CELL, V93, P289, DOI 10.1016/S0092-8674(00)81579-2; Manoli DS, 2005, NATURE, V436, P395, DOI 10.1038/nature03859; MORGAN T, 1943, CARNEGIE I WASH YB, V42, P171; Mueller TD, 2002, J MOL BIOL, V319, P1243, DOI 10.1016/S0022-2836(02)00302-9; Muroya K, 2000, J CLIN ENDOCR METAB, V85, P3094, DOI 10.1210/jc.85.9.3094; Narendra U, 2002, J BIOL CHEM, V277, P43463, DOI 10.1074/jbc.M204616200; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; NOTHIGER R, 1987, GENET RES, V50, P113, DOI 10.1017/S001667230002351X; Oh DB, 2002, P NATL ACAD SCI USA, V99, P16666, DOI 10.1073/pnas.262672699; Omichinski JG, 1997, NAT STRUCT BIOL, V4, P122, DOI 10.1038/nsb0297-122; POWERS R, 1993, BIOCHEMISTRY-US, V32, P6744, DOI 10.1021/bi00077a030; Raymond CS, 1999, DEV BIOL, V215, P208, DOI 10.1006/dbio.1999.9461; Raymond CS, 1999, HUM MOL GENET, V8, P989, DOI 10.1093/hmg/8.6.989; Raymond CS, 1998, NATURE, V391, P691, DOI 10.1038/35618; Rong YS, 2000, SCIENCE, V288, P2013, DOI 10.1126/science.288.5473.2013; Sanchez L, 2001, BIOESSAYS, V23, P698, DOI 10.1002/bies.1099; Sanchez L, 2001, DEVELOPMENT, V128, P1033; Sato S, 2003, J BIOL CHEM, V278, P49671, DOI 10.1074/jbc.C300444200; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Siegal ML, 2005, DEV GENES EVOL, V215, P1, DOI 10.1007/s00427-004-0445-x; Stockinger P, 2005, CELL, V121, P795, DOI 10.1016/j.cell.2005.04.026; Su LL, 1997, BIOCHEMISTRY-US, V36, P12722, DOI 10.1021/bi971408k; Villella A, 1996, GENETICS, V143, P331; Vincent S, 2001, CELL, V106, P399, DOI 10.1016/S0092-8674(01)00468-8; Waterbury JA, 1999, GENETICS, V152, P1653; WEISS MA, 1990, J MAGN RESON, V86, P626, DOI 10.1016/0022-2364(90)90041-7; WILLIAMSON MP, 1985, J MOL BIOL, V182, P295, DOI 10.1016/0022-2836(85)90347-X; Withers-Ward ES, 2000, BIOCHEMISTRY-US, V39, P14103, DOI 10.1021/bi0017071; Wuthrich K, 1986, NMR PROTEINS NUCL AC, P117; Yamamoto D, 1996, NEUROSCI RES, V26, P95, DOI 10.1016/S0168-0102(96)01087-5; Zhang W, 2006, MOL CELL BIOL, V26, P535, DOI 10.1128/MCB.26.2.535-547.2006; Zhu LY, 2000, GENE DEV, V14, P1750; Zwahlen C, 1997, J AM CHEM SOC, V119, P6711, DOI 10.1021/ja970224q	75	17	17	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					7280	7292		10.1074/jbc.M708742200	http://dx.doi.org/10.1074/jbc.M708742200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18184648	hybrid			2022-12-25	WOS:000253779600073
J	Billington, RA; Travelli, C; Ercolano, E; Galli, U; Roman, CB; Grolla, AA; Canonico, PL; Condorelli, F; Genazzani, AA				Billington, Richard A.; Travelli, Cristina; Ercolano, Emanuela; Galli, Ubaldina; Roman, Cintia Blasi; Grolla, Ambra A.; Canonico, Pier Luigi; Condorelli, Fabrizio; Genazzani, Armando A.			Characterization of NAD uptake in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE ADENINE-DINUCLEOTIDE; CYCLIC ADP-RIBOSE; INTRACELLULAR CALCIUM; CD38; APOPTOSIS; BIOSYNTHESIS; METABOLISM; ASTROCYTES; INFLUX; DEATH	Recent evidence has shown that NAD(P) plays a variety of roles in cell-signaling processes. Surprisingly, the presence of NAD(P) utilizing ectoenzymes suggests that NAD(P) is present extracellularly. Indeed, nanomolar concentrations of NAD have been found in plasma and other body fluids. Although very high concentrations of NAD have been shown to enter cells, it is not known whether lower, more physiological concentrations are able to be taken up. Here we show that two mammalian cell types are able to transport low NAD concentrations effectively. Furthermore, extracellular application of NAD was able to counteract FK866-induced cell death and restore intracellular NAD(P) levels. We propose that NAD uptake may play a role in physiological NAD homeostasis.	Univ Piemonte Orientale, Dipartimento Sci Chim Alimentari Farmaceut & Farm, I-28100 Novara, Italy; Univ Piemonte Orientale, Drug & Food Biotechnol Ctr, I-28100 Novara, Italy	University of Eastern Piedmont Amedeo Avogadro; University of Eastern Piedmont Amedeo Avogadro	Billington, RA (corresponding author), Univ Piemonte Orientale, Dipartimento Sci Chim Alimentari Farmaceut & Farm, I-28100 Novara, Italy.	billington@pharm.unipmn.it	Travelli, Cristina/AAA-9450-2022; Billington, Richard/HGB-1970-2022; Condorelli, Fabrizio/AAT-1953-2020; Genazzani, Armando/AAI-8280-2020	Condorelli, Fabrizio/0000-0002-9943-0857; grolla, ambra/0000-0003-0233-0700; Galli, Ubaldina/0000-0003-1126-0142; Billington, Richard/0000-0001-7288-8916; Genazzani, Armando/0000-0003-1923-7430				Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Barbosa MTP, 2007, FASEB J, V21, P3629, DOI 10.1096/fj.07-8290com; Belenky P, 2007, TRENDS BIOCHEM SCI, V32, P12, DOI 10.1016/j.tibs.2006.11.006; Berger F, 2004, TRENDS BIOCHEM SCI, V29, P111, DOI 10.1016/j.tibs.2004.01.007; BIEDERMANN E, 2005, US PATENT, V903, P118; Bieganowski P, 2004, CELL, V117, P495, DOI 10.1016/S0092-8674(04)00416-7; Billington RA, 2000, BIOCHEM BIOPH RES CO, V276, P112, DOI 10.1006/bbrc.2000.3444; Billington RA, 2006, FASEB J, V20, P521, DOI 10.1096/fj.05-5058fje; Billington RA, 2006, MOL MED, V12, P324, DOI 10.2119/2006-00075.Billington; Bruzzone S, 2001, J BIOL CHEM, V276, P48300, DOI 10.1074/jbc.M107308200; Bruzzone S, 2001, FASEB J, V15, P10; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Franco L, 1998, FASEB J, V12, P1507; GASSER A, 2006, J BIOL CHEM, V281, P2008; Guida L, 2004, J BIOL CHEM, V279, P22066, DOI 10.1074/jbc.M314137200; Guida L, 2002, J BIOL CHEM, V277, P47097, DOI 10.1074/jbc.M207793200; Hasmann M, 2003, CANCER RES, V63, P7436; Heidemann AC, 2005, J BIOL CHEM, V280, P35630, DOI 10.1074/jbc.M507338200; Holen K, 2008, INVEST NEW DRUG, V26, P45, DOI 10.1007/s10637-007-9083-2; Khan JA, 2007, EXPERT OPIN THER TAR, V11, P695, DOI 10.1517/14728222.11.5.695; Khan JA, 2006, NAT STRUCT MOL BIOL, V13, P582, DOI 10.1038/nsmb1105; Lee HC, 2006, MOL MED, V12, P317, DOI 10.2119/2006-00086.Lee; Magni G, 2004, CELL MOL LIFE SCI, V61, P19, DOI 10.1007/s00018-003-3161-1; Moreschi I, 2006, J BIOL CHEM, V281, P31419, DOI 10.1074/jbc.M606625200; Morgan A.J., 2005, METHODS CALCIUM SIGN, P265; O'Reilly T, 2003, CAN J VET RES, V67, P229; Pillai JB, 2005, J BIOL CHEM, V280, P43121, DOI 10.1074/jbc.M506162200; Podesta M, 2005, J BIOL CHEM, V280, P5343, DOI 10.1074/jbc.M408085200; Revollo JR, 2007, CURR OPIN GASTROEN, V23, P164, DOI 10.1097/MOG.0b013e32801b3c8f; Smyth LM, 2004, J BIOL CHEM, V279, P48893, DOI 10.1074/jbc.M407266200; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697; Ying WH, 2003, BIOCHEM BIOPH RES CO, V308, P809, DOI 10.1016/S0006-291X(03)01483-9; Zhu KQ, 2005, NEUROREPORT, V16, P1209, DOI 10.1097/00001756-200508010-00015; Ziegler M, 2000, EUR J BIOCHEM, V267, P1550, DOI 10.1046/j.1432-1327.2000.01187.x; Zocchi E, 1999, FASEB J, V13, P273, DOI 10.1096/fasebj.13.2.273; Zocchi E, 1998, J BIOL CHEM, V273, P8017, DOI 10.1074/jbc.273.14.8017	38	66	69	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2008	283	10					6367	6374		10.1074/jbc.M706204200	http://dx.doi.org/10.1074/jbc.M706204200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HM	18180302	hybrid			2022-12-25	WOS:000253779500044
J	Williamson, SJ; Rusch, DB; Yooseph, S; Halpern, AL; Heidelberg, KB; Glass, JI; Andrews-Pfannkoch, C; Fadrosh, D; Miller, CS; Sutton, G; Frazier, M; Venter, JC				Williamson, Shannon J.; Rusch, Douglas B.; Yooseph, Shibu; Halpern, Aaron L.; Heidelberg, Karla B.; Glass, John I.; Andrews-Pfannkoch, Cynthia; Fadrosh, Douglas; Miller, Christopher S.; Sutton, Granger; Frazier, Marvin; Venter, J. Craig			The Sorcerer II Global Ocean Sampling Expedition: Metagenomic Characterization of Viruses within Aquatic Microbial Samples	PLOS ONE			English	Article							TROPHIC STATE INDEX; PHOTOSYNTHESIS GENES; MARINE-BACTERIA; SYNECHOCOCCUS; DIVERSITY; PROCHLOROCOCCUS; COMMUNITY; PROTEIN; VIRIOPLANKTON; CYANOPHAGES	Viruses are the most abundant biological entities on our planet. Interactions between viruses and their hosts impact several important biological processes in the world's oceans such as horizontal gene transfer, microbial diversity and biogeochemical cycling. Interrogation of microbial metagenomic sequence data collected as part of the Sorcerer II Global Ocean Expedition (GOS) revealed a high abundance of viral sequences, representing approximately 3% of the total predicted proteins. Cluster analyses of the viral sequences revealed hundreds to thousands of viral genes encoding various metabolic and cellular functions. Quantitative analyses of viral genes of host origin performed on the viral fraction of aquatic samples confirmed the viral nature of these sequences and suggested that significant portions of aquatic viral communities behave as reservoirs of such genetic material. Distributional and phylogenetic analyses of these host-derived viral sequences also suggested that viral acquisition of environmentally relevant genes of host origin is a more abundant and widespread phenomenon than previously appreciated. The predominant viral sequences identified within microbial fractions originated from tailed bacteriophages and exhibited varying global distributions according to viral family. Recruitment of GOS viral sequence fragments against 27 complete aquatic viral genomes revealed that only one reference bacteriophage genome was highly abundant and was closely related, but not identical, to the cyanomyovirus P-SSM4. The co-distribution across all sampling sites of P-SSM4-like sequences with the dominant ecotype of its host, Prochlorococcus supports the classification of the viral sequences as P-SSM4-like and suggests that this virus may influence the abundance, distribution and diversity of one of the most dominant components of picophytoplankton in oligotrophic oceans. In summary, the abundance and broad geographical distribution of viral sequences within microbial fractions, the prevalence of genes among viral sequences that encode microbial physiological function and their distinct phylogenetic distribution lend strong support to the notion that viral-mediated gene acquisition is a common and ongoing mechanism for generating microbial diversity in the marine environment.	[Williamson, Shannon J.; Rusch, Douglas B.; Yooseph, Shibu; Halpern, Aaron L.; Heidelberg, Karla B.; Glass, John I.; Andrews-Pfannkoch, Cynthia; Fadrosh, Douglas; Sutton, Granger; Frazier, Marvin; Venter, J. Craig] J Craig Venter Inst, Rockville, MD USA; [Heidelberg, Karla B.] USC, Los Angeles, CA USA; [Miller, Christopher S.] Univ Calif Los Angeles, Mol Biol Inst, Los Angeles, CA USA	J. Craig Venter Institute; University of Southern California; University of California System; University of California Los Angeles	Williamson, SJ (corresponding author), J Craig Venter Inst, Rockville, MD USA.	swilliamson@jcvi.org	Heidelberg, Karla B./L-2096-2017; Glass, John/A-6572-2015	Heidelberg, Karla B./0000-0002-2645-8269; Glass, John/0000-0002-3784-5301; Yooseph, Shibu/0000-0001-5581-5002; Miller, Christopher/0000-0002-9448-8144	The Department of Energy (DOE) Office of Science, and Office of Biological and Environmental Research [DE-FG02-02ER63453]; Gordon and Betty Moore Foundation; Discovery Channel; J. Craig Venter Science Foundation	The Department of Energy (DOE) Office of Science, and Office of Biological and Environmental Research(United States Department of Energy (DOE)); Gordon and Betty Moore Foundation(Gordon and Betty Moore Foundation); Discovery Channel; J. Craig Venter Science Foundation	This study was funded by The Department of Energy (DOE) Office of Science, and Office of Biological and Environmental Research (DE-FG02-02ER63453), the Gordon and Betty Moore Foundation, the Discovery Channel and the J. Craig Venter Science Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ackermann H., 1987, VIRUSES PROKARYOTES, V1; Angly FE, 2006, PLOS BIOL, V4, P2121, DOI 10.1371/journal.pbio.0040368; Auguet JC, 2006, MICROB ECOL, V51, P197, DOI 10.1007/s00248-005-0043-0; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; BERGH O, 1989, NATURE, V340, P467, DOI 10.1038/340467a0; BORSHEIM KY, 1990, APPL ENVIRON MICROB, V56, P352; Breitbart M, 2004, P ROY SOC B-BIOL SCI, V271, P565, DOI 10.1098/rspb.2003.2628; Breitbart M, 2003, J BACTERIOL, V185, P6220, DOI 10.1128/JB.185.20.6220-6223.2003; Breitbart M, 2002, P NATL ACAD SCI USA, V99, P14250, DOI 10.1073/pnas.202488399; BRUSSOW H, 2004, MICROBIOLOGY MOL BIO, V68; Canchaya C, 2003, MICROBIOL MOL BIOL R, V67, P238, DOI 10.1128/MMBR.67.2.238-276.2003; CARLSON RE, 1983, WATER RESOUR BULL, V19, P307; CARLSON RE, 1977, LIMNOL OCEANOGR, V22, P361, DOI 10.4319/lo.1977.22.2.0361; Claverie JM, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-52; DeLong EF, 2006, SCIENCE, V311, P496, DOI 10.1126/science.1120250; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Fuhrman JA, 1999, NATURE, V399, P541, DOI 10.1038/21119; FUHRMAN JA, 1993, BARCELONA SPAIN TREN, P295; Gobler CJ, 1997, LIMNOL OCEANOGR, V42, P1492, DOI 10.4319/lo.1997.42.7.1492; HELDAL M, 1991, MAR ECOL PROG SER, V72, P205, DOI 10.3354/meps072205; Hwang DM, 1996, J MOL EVOL, V43, P536, DOI 10.1007/PL00006114; Jiang SC, 1998, APPL ENVIRON MICROB, V64, P2780; Johnson ZI, 2006, SCIENCE, V311, P1737, DOI 10.1126/science.1118052; Li KB, 2003, BIOINFORMATICS, V19, P1585, DOI 10.1093/bioinformatics/btg192; LI WKW, 1983, SCIENCE, V219, P292, DOI 10.1126/science.219.4582.292; Lindell D, 2005, NATURE, V438, P86, DOI 10.1038/nature04111; Lindell D, 2004, P NATL ACAD SCI USA, V101, P11013, DOI 10.1073/pnas.0401526101; Mann NH, 2005, J BACTERIOL, V187, P3188, DOI 10.1128/JB.187.9.3188-3200.2005; Mann NH, 2003, NATURE, V424, P741, DOI 10.1038/424741a; Marston MF, 2003, APPL ENVIRON MICROB, V69, P4639, DOI 10.1128/AEM.69.8.4639-4647.2003; McDaniel L, 2005, APPL ENVIRON MICROB, V71, P842, DOI 10.1128/AEM.71.2.842-850.2005; McDaniel L, 2002, NATURE, V415, P496, DOI 10.1038/415496a; Millard A, 2004, P NATL ACAD SCI USA, V101, P11007, DOI 10.1073/pnas.0401478101; Montanie H, 2002, AQUAT MICROB ECOL, V28, P105, DOI 10.3354/ame028105; Partensky F, 1999, MICROBIOL MOL BIOL R, V63, P106, DOI 10.1128/MMBR.63.1.106-127.1999; PROCTOR LM, 1990, NATURE, V343, P60, DOI 10.1038/343060a0; Rohwer F, 2000, LIMNOL OCEANOGR, V45, P408, DOI 10.4319/lo.2000.45.2.0408; RUSCH DB, 2007, PLOS BIOL IN PRESS; Rusch DB, 2007, PLOS BIOL, V5, P398, DOI 10.1371/journal.pbio.0050077; Sambrook J., 2001, MOL CLONING LAB MANU; Sharon I, 2007, ISME J, V1, P492, DOI 10.1038/ismej.2007.67; SHERMAN LA, 1976, VIROLOGY, V71, P17, DOI 10.1016/0042-6822(76)90090-8; Shibata A, 1997, MAR ECOL PROG SER, V155, P303, DOI 10.3354/meps155303; STEWART FM, 1984, THEOR POPUL BIOL, V26, P93, DOI 10.1016/0040-5809(84)90026-1; Sullivan MB, 2006, PLOS BIOL, V4, P1344, DOI 10.1371/journal.pbio.0040234; Sullivan MB, 2005, PLOS BIOL, V3, P790, DOI 10.1371/journal.pbio.0030144; Sullivan MB, 2003, NATURE, V426, P584, DOI 10.1038/nature02147; Suttle C, 2005, ENVIRON MICROBIOL, V7, P481, DOI 10.1111/j.1462-2920.2005.803_11.x; SUTTLE CA, 1994, APPL ENVIRON MICROB, V60, P3167, DOI 10.1128/AEM.60.9.3167-3174.1994; Tyson GW, 2004, NATURE, V428, P37, DOI 10.1038/nature02340; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857; Wang K, 2004, AQUAT MICROB ECOL, V34, P105, DOI 10.3354/ame034105; WATERBURY JB, 1993, APPL ENVIRON MICROB, V59, P3393, DOI 10.1128/AEM.59.10.3393-3399.1993; WATERBURY JB, 1986, PHOTOSYNTHETIC PICOP, P71; Weinbauer MG, 2004, ENVIRON MICROBIOL, V6, P1, DOI 10.1046/j.1462-2920.2003.00539.x; Weitz JS, 2005, P NATL ACAD SCI USA, V102, P9535, DOI 10.1073/pnas.0504062102; Wichels A, 1998, APPL ENVIRON MICROB, V64, P4128; Williamson SJ, 2004, AQUAT MICROB ECOL, V36, P9, DOI 10.3354/ame036009; WOMMACK KE, 1992, APPL ENVIRON MICROB, V58, P2965, DOI 10.1128/AEM.58.9.2965-2970.1992; Wommack KE, 2000, MICROBIOL MOL BIOL R, V64, P69, DOI 10.1128/MMBR.64.1.69-114.2000; Yooseph S, 2007, PLOS BIOL, V5, P432, DOI 10.1371/journal.pbio.0050016; Zeidner G, 2005, ENVIRON MICROBIOL, V7, P1505, DOI 10.1111/j.1462-2920.2005.00833.x	62	236	248	2	50	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2008	3	1							e1456	10.1371/journal.pone.0001456	http://dx.doi.org/10.1371/journal.pone.0001456			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SO	18213365	Green Submitted, gold, Green Published			2022-12-25	WOS:000260503900002
J	Marella, M; Seo, BB; Nakamaru-Ogiso, E; Greenamyre, JT; Matsuno-Yagi, A; Yagi, T				Marella, Mathieu; Seo, Byoung Boo; Nakamaru-Ogiso, Eiko; Greenamyre, J. Timothy; Matsuno-Yagi, Akemi; Yagi, Takao			Protection by the NDI1 Gene against Neurodegeneration in a Rotenone Rat Model of Parkinson's Disease	PLOS ONE			English	Article								It is widely recognized that mitochondrial dysfunction, most notably defects in the NADH-quinone oxidoreductase (complex I), is closely related to the etiology of sporadic Parkinson's disease (PD). In fact, rotenone, a complex I inhibitor, has been used for establishing PD models both in vitro and in vivo. A rat model with chronic rotenone exposure seems to reproduce pathophysiological conditions of PD more closely than acute mouse models as manifested by neuronal cell death in the substantia nigra and Lewy body-like cytosolic aggregations. Using the rotenone rat model, we investigated the protective effects of alternative NADH dehydrogenase (Ndi1) which we previously demonstrated to act as a replacement for complex I both in vitro and in vivo. A single, unilateral injection of recombinant adeno-associated virus carrying the NDI1 gene into the vicinity of the substantia nigra resulted in expression of the Ndi1 protein in the entire substantia nigra of that side. It was clear that the introduction of the Ndi1 protein in the substantia nigra rendered resistance to the deleterious effects caused by rotenone exposure as assessed by the levels of tyrosine hydroxylase and dopamine. The presence of the Ndi1 protein also prevented cell death and oxidative damage to DNA in dopaminergic neurons observed in rotenone-treated rats. Unilateral protection also led to uni-directional rotation of the rotenone-exposed rats in the behavioral test. The present study shows, for the first time, the powerful neuroprotective effect offered by the Ndi1 enzyme in a rotenone rat model of PD.	[Marella, Mathieu; Seo, Byoung Boo; Nakamaru-Ogiso, Eiko; Yagi, Takao] Scripps Res Inst, Dept Mol & Expt Med, Div Biochem, La Jolla, CA USA; [Greenamyre, J. Timothy] Univ Pittsburgh, Pittsburgh Inst Neurodegen Dis, Dept Neurol, Pittsburgh, PA USA	Scripps Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Matsuno-Yagi, A (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, Div Biochem, La Jolla, CA USA.	ayagi@scripps.edu; yagi@scripps.edu	Greenamyre, J. Timothy/B-4049-2011; Waldvogel, Henry/D-6691-2012	Greenamyre, J. Timothy/0000-0003-3468-7878; Waldvogel, Henry/0000-0003-2165-8568	US Public Health Service [R01NS048441, R01DK053244, US4ES012068]; The Picower Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053244] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U54ES012068] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048441] Funding Source: NIH RePORTER	US Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); The Picower Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by US Public Health Service Grants R01NS048441 and R01DK053244 (to TY and AM-Y) and by The Picower Foundation and US Public Health Service Grant US4ES012068 (to JTG).	Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Alam M, 2002, BEHAV BRAIN RES, V136, P317, DOI 10.1016/S0166-4328(02)00180-8; Bashkatova V, 2004, EXP NEUROL, V186, P235, DOI 10.1016/j.expneurol.2003.12.005; Betarbet R, 2006, NEUROBIOL DIS, V22, P404, DOI 10.1016/j.nbd.2005.12.003; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Bolton JL, 2000, CHEM RES TOXICOL, V13, P135, DOI 10.1021/tx9902082; Burger C, 2005, HUM GENE THER, V16, P781, DOI 10.1089/hum.2005.16.781; Champy P, 2004, J NEUROCHEM, V88, P63, DOI 10.1046/j.1471-4159.2003.02138.x; Escobar-Khondiker M, 2007, J NEUROSCI, V27, P7827, DOI 10.1523/JNEUROSCI.1644-07.2007; GERLACH M, 1991, EUR J PHARM-MOLEC PH, V208, P273, DOI 10.1016/0922-4106(91)90073-Q; Huang J, 2006, BIOMATERIALS, V27, P937, DOI 10.1016/j.biomaterials.2005.07.005; Jankovic J, 2006, MT SINAI J MED, V73, P682; Kussmaul L, 2006, P NATL ACAD SCI USA, V103, P7607, DOI 10.1073/pnas.0510977103; LANGER R, 1990, SCIENCE, V249, P1527, DOI 10.1126/science.2218494; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; Lau YS, 2003, METH MOLEC MED, V79, P103; Marella M, 2007, J BIOL CHEM, V282, P24146, DOI 10.1074/jbc.M701819200; Melo AMP, 2004, MICROBIOL MOL BIOL R, V68, P603, DOI 10.1128/MMBR.68.4.603-616.2004; Moore DJ, 2005, ANNU REV NEUROSCI, V28, P57, DOI 10.1146/annurev.neuro.28.061604.135718; Park JS, 2007, BBA-MOL BASIS DIS, V1772, P533, DOI 10.1016/j.bbadis.2007.01.009; Petroske E, 2001, NEUROSCIENCE, V106, P589, DOI 10.1016/S0306-4522(01)00295-0; Przedborski S, 1998, MOVEMENT DISORD, V13, P35; PYCOCK CJ, 1980, NEUROSCIENCE, V5, P461, DOI 10.1016/0306-4522(80)90048-2; Richardson JR, 2007, TOXICOL SCI, V95, P196, DOI 10.1093/toxsci/kfl133; Savitt JM, 2006, J CLIN INVEST, V116, P1744, DOI 10.1172/JCI29178; Seo BB, 1998, P NATL ACAD SCI USA, V95, P9167, DOI 10.1073/pnas.95.16.9167; Seo BB, 2000, J BIOL CHEM, V275, P37774, DOI 10.1074/jbc.M007033200; Seo BB, 1999, BBA-BIOENERGETICS, V1412, P56, DOI 10.1016/S0005-2728(99)00051-1; Seo BB, 2004, HUM GENE THER, V15, P887, DOI 10.1089/1043034041839217; Seo BB, 2002, MOL THER, V6, P336, DOI 10.1006/mthe.2002.0674; Seo BB, 2006, FEBS LETT, V580, P6105, DOI 10.1016/j.febslet.2006.10.008; Seo BB, 2006, J BIOL CHEM, V281, P14250, DOI 10.1074/jbc.M600922200; Sherer TB, 2003, EXP NEUROL, V179, P9, DOI 10.1006/exnr.2002.8072; Sherer TB, 2006, MOVEMENT DISORD, V21, P136, DOI 10.1002/mds.20861; Sherer TB, 2003, J NEUROSCI, V23, P10756, DOI 10.1523/jneurosci.23-34-10756.2003; Stokes AH, 1999, J NEUROSCI RES, V55, P659, DOI 10.1002/(SICI)1097-4547(19990315)55:6<659::AID-JNR1>3.0.CO;2-C; Van Den Eeden SK, 2003, AM J EPIDEMIOL, V157, P1015, DOI 10.1093/aje/kwg068; Waldmeier P, 2006, BIOCHEM PHARMACOL, V72, P1197, DOI 10.1016/j.bcp.2006.06.031; YAGI T, 2004, ADV PHOTOSYNTHESIS R, P15	39	82	83	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2008	3	1							e1433	10.1371/journal.pone.0001433	http://dx.doi.org/10.1371/journal.pone.0001433			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SN	18197244	Green Accepted, gold, Green Published, Green Submitted			2022-12-25	WOS:000260503800005
J	Xu, ZF; Zhou, Y; Li, LJ; Zhou, R; Xiao, SB; Wan, Y; Zhang, SH; Wang, K; Li, W; Li, L; Jin, H; Kang, MS; Dalai, BL; Li, TT; Liu, L; Cheng, YY; Zhang, L; Xu, T; Zheng, HJ; Pu, SY; Wang, BF; Gu, WY; Zhang, XL; Zhu, GF; Wang, SY; Zhao, GP; Chen, HC				Xu, Zhuofei; Zhou, Yan; Li, Liangjun; Zhou, Rui; Xiao, Shaobo; Wan, Yun; Zhang, Sihua; Wang, Kai; Li, Wei; Li, Lu; Jin, Hui; Kang, Mingsong; Dalai, Baolige; Li, Tingting; Liu, Lei; Cheng, Yangyi; Zhang, Lei; Xu, Tao; Zheng, Huajun; Pu, Shiying; Wang, Bofei; Gu, Wenyi; Zhang, Xiang-Lin; Zhu, Geng-Feng; Wang, Shengyue; Zhao, Guo-Ping; Chen, Huanchun			Genome Biology of Actinobacillus pleuropneumoniae JL03, an Isolate of Serotype 3 Prevalent in China	PLOS ONE			English	Article							ESCHERICHIA-COLI; HAEMOPHILUS-INFLUENZAE; GENE-CLUSTER; ANAEROBIC RESPIRATION; MOLECULAR-CLONING; APX TOXINS; SEQUENCE; VIRULENCE; POLYSACCHARIDE; EXPRESSION	Actinobacillus pleuropneumoniae is the etiologic agent of porcine contagious pleuropneumonia, a cause of considerable world wide economic losses in the swine industry. We sequenced the complete genome of A. pleuropneumoniae, JL03, an isolate of serotype 3 prevalent in China. Its genome is a single chromosome of 2,242,062 base pairs containing 2,097 predicted protein-coding sequences, six ribosomal rRNA operons, and 63 tRNA genes. Preliminary analysis of the genomic sequence and the functions of the encoded proteins not only confirmed the present physiological and pathological knowledge but also offered new insights into the metabolic and virulence characteristics of this important pathogen. We identified a full spectrum of genes related to its characteristic chemoheterotrophic catabolism of fermentation and respiration with an incomplete TCA system for anabolism. In addition to confirming the lack of ApxI toxin, identification of a nonsense mutation in apxIVA and a 5' -proximal truncation of the flp operon deleting both its promoter and the flp1flp2tadV genes have provided convincing scenarios for the low virulence property of JL03. Comparative genomic analysis using the available sequences of other serotypes, probable strain ( serotype)specific genomic islands related to capsular polysaccharides and lipopolysaccharide O-antigen biosyntheses were identified in JL03, which provides a foundation for future research into the mechanisms of serotypic diversity of A. pleuropneumoniae.	[Zhou, Yan; Wang, Kai; Cheng, Yangyi; Zhang, Lei; Xu, Tao; Zheng, Huajun; Pu, Shiying; Wang, Bofei; Gu, Wenyi; Zhang, Xiang-Lin; Zhu, Geng-Feng; Wang, Shengyue; Zhao, Guo-Ping] Chinese Natl Human Genome Ctr Shanghai, Shanghai MOST Key Lab Hlth & Dis Genomics, Shanghai, Peoples R China; [Zhou, Yan; Wang, Shengyue; Zhao, Guo-Ping] Fudan Univ, Sch Life Sci, Dept Microbiol, State Key Lab Genet Engn, Shanghai, Peoples R China; [Zhao, Guo-Ping] Natl Engn Ctr Biochip Res Shanghai, Shanghai, Peoples R China; [Zhao, Guo-Ping] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Plant Physiol & Ecol, Lab Mol Microbiol, Shanghai, Peoples R China; [Xu, Zhuofei; Li, Liangjun; Xiao, Shaobo; Wan, Yun; Zhang, Sihua; Li, Wei; Li, Lu; Jin, Hui; Kang, Mingsong; Dalai, Baolige; Li, Tingting; Liu, Lei; Chen, Huanchun] Huazhong Agr Univ, Coll Vet Med, State Key Lab Agr Microbiol, Div Anim Infect Dis, Wuhan, Peoples R China	Fudan University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Huazhong Agricultural University	Zhou, R (corresponding author), Huazhong Agr Univ, Coll Vet Med, State Key Lab Agr Microbiol, Div Anim Infect Dis, Wuhan, Peoples R China.	rzhou@mail.hzau.edu; gpzhao@sibs.ac.cn; chenhch@mail.hzau.edu.cn	KANG, MINGSONG/A-9211-2017; zhu, gengfeng/HGC-7575-2022	KANG, MINGSONG/0000-0002-8795-2973; Xiao, Shaobo/0000-0003-0023-9188; WANG, kai/0000-0002-6194-0480; Zhao, Guo-Ping/0000-0002-7621-6620	National Natural Science Foundation of China [30530590, 30771599]; 973 Program [2006CB504402]; 863 Program [2007AA02Z193, 2006AA02Z335]; National Scientific and Technical Supporting Programs [2006BAD06A01, 2006BAD06A04]; Cultivation Fund of the Key Scientific and Technical Innovation Project, Ministry of Education of China [706042]; Shanghai Commission for Science and Technology [05DZ22201]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 973 Program(National Basic Research Program of China); 863 Program(National High Technology Research and Development Program of China); National Scientific and Technical Supporting Programs; Cultivation Fund of the Key Scientific and Technical Innovation Project, Ministry of Education of China(Ministry of Education, China); Shanghai Commission for Science and Technology	This work was supported by the National Natural Science Foundation of China (30530590; 30771599), 973 Program (2006CB504402), 863 Program (2007AA02Z193; 2006AA02Z335), National Scientific and Technical Supporting Programs (2006BAD06A01; 2006BAD06A04), Cultivation Fund of the Key Scientific and Technical Innovation Project, Ministry of Education of China (706042) and Shanghai Commission for Science and Technology (05DZ22201).	Allen JWA, 2005, BIOCHEM J, V389, P587, DOI 10.1042/BJ20041894; Bandara AB, 2003, INFECT IMMUN, V71, P3320, DOI 10.1128/IAI.71.6.3320-3328.2003; Barrangou R, 2007, SCIENCE, V315, P1709, DOI 10.1126/science.1138140; BEDDEK AJ, 2004, INFECT IMMUN, V74, P4124; Blackall PJ, 2002, VET MICROBIOL, V84, P47, DOI 10.1016/S0378-1135(01)00428-X; Bolotin A, 2005, MICROBIOL-SGM, V151, P2551, DOI 10.1099/mic.0.28048-0; Bosse JT, 1997, INFECT IMMUN, V65, P4389; Bosse JT, 2002, MICROBES INFECT, V4, P225, DOI 10.1016/S1286-4579(01)01534-9; Bosse JT, 2001, J BACTERIOL, V183, P1242, DOI 10.1128/JB.183.4.1242-1247.2001; Brondijk THC, 2002, MOL MICROBIOL, V44, P245, DOI 10.1046/j.1365-2958.2002.02875.x; Challacombe JF, 2007, J BACTERIOL, V189, P1890, DOI 10.1128/JB.01422-06; DEWHIRST FE, 1992, J BACTERIOL, V174, P2002, DOI 10.1128/jb.174.6.2002-2013.1992; Dippel R, 2005, J BACTERIOL, V187, P8322, DOI 10.1128/JB.187.24.8322-8331.2005; Dubreuil J. Daniel, 2000, Animal Health Research Reviews, V1, P73, DOI 10.1017/S1466252300000074; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FREY J, 1995, TRENDS MICROBIOL, V3, P257, DOI 10.1016/S0966-842X(00)88939-8; FREY J, 1993, J GEN MICROBIOL, V139, P1723, DOI 10.1099/00221287-139-8-1723; Gioia J, 2006, J BACTERIOL, V188, P7257, DOI 10.1128/JB.00675-06; Gonzalez OG, 2004, FEMS MICROBIOL LETT, V234, P81, DOI 10.1111/j.1574-6968.2004.tb09516.x; Harrison A, 2005, J BACTERIOL, V187, P4627, DOI 10.1128/JB.187.13.4627-4636.2005; [何启盖 He Qigai], 2003, [中国预防兽医学报, Chinase Journal of Preventive Veterinary Medicine], V25, P360; Hong SH, 2004, NAT BIOTECHNOL, V22, P1275, DOI 10.1038/nbt1010; Jacobsen I, 2005, INFECT IMMUN, V73, P3740, DOI 10.1128/IAI.73.6.3740-3744.2005; Jacobsen I, 2005, INFECT IMMUN, V73, P226, DOI 10.1128/IAI.73.1.226-234.2005; Jacobsen MJ, 1996, VET MICROBIOL, V49, P159, DOI 10.1016/0378-1135(95)00184-0; Jacques M, 2004, CAN J VET RES, V68, P81; Jansen R, 2002, MOL MICROBIOL, V43, P1565, DOI 10.1046/j.1365-2958.2002.02839.x; JANSEN R, 1994, INFECT IMMUN, V62, P4411, DOI 10.1128/IAI.62.10.4411-4418.1994; Kamp EM, 1997, INFECT IMMUN, V65, P4350, DOI 10.1128/IAI.65.10.4350-4354.1997; Kaplan JB, 2004, J BACTERIOL, V186, P8213, DOI 10.1128/JB.186.24.8213-8220.2004; LU Z, 2002, CHIN J VET SCI TECH, V37, P33; MACKIEWICZ P, 2004, NUCLEIC ACIDS RES, V25, P955; May BJ, 2001, P NATL ACAD SCI USA, V98, P3460, DOI 10.1073/pnas.051634598; Mikael LG, 2002, MICROBIOL-SGM, V148, P2869, DOI 10.1099/00221287-148-9-2869; Nakano Y, 2000, BBA-GENE STRUCT EXPR, V1493, P259, DOI 10.1016/S0167-4781(00)00179-2; Nika JR, 2002, INFECT IMMUN, V70, P2965, DOI 10.1128/IAI.70.6.2965-2975.2002; [陈凡 Chen Fan], 2004, [微生物学报, Acta Microbiologica Sinica], V44, P679; Provost M, 2003, FEMS MICROBIOL LETT, V223, P7, DOI 10.1016/S0378-1097(03)00247-7; Ravcheev DA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-54; Ruckert C, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-121; Samuel G, 2003, CARBOHYD RES, V338, P2503, DOI 10.1016/j.carres.2003.07.009; Satran P, 2002, VET MED-CZECH, V47, P92, DOI 10.17221/5810-VETMED; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; Sekowska A, 2000, J MOL MICROB BIOTECH, V2, P145; Sheehan BJ, 2003, INFECT IMMUN, V71, P3960, DOI 10.1128/IAI.71.7.3960-3970.2003; SIDIBE M, 1993, CAN J VET RES, V57, P204; Srikumar R, 2004, MICROBIOL-SGM, V150, P1723, DOI 10.1099/mic.0.27046-0; Staden R, 1996, MOL BIOTECHNOL, V5, P233, DOI 10.1007/BF02900361; Tian YQ, 2005, BIOCHEM BIOPH RES CO, V333, P14, DOI 10.1016/j.bbrc.2005.05.070; Tomich M, 2007, NAT REV MICROBIOL, V5, P363, DOI 10.1038/nrmicro1636; Tseng CP, 1996, J BACTERIOL, V178, P1094, DOI 10.1128/jb.178.4.1094-1098.1996; VANHELLEMOND JJ, 1994, BIOCHEM J, V304, P321, DOI 10.1042/bj3040321; Wilson JW, 2002, POSTGRAD MED J, V78, P216, DOI 10.1136/pmj.78.918.216; Zhao QX, 2000, FEMS MICROBIOL LETT, V184, P127, DOI 10.1111/j.1574-6968.2000.tb09002.x; ZHOU L, 2007, VET RECORD IN PRESS, V161	56	60	441	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2008	3	1							e1450	10.1371/journal.pone.0001450	http://dx.doi.org/10.1371/journal.pone.0001450			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SN	18197260	Green Published, gold			2022-12-25	WOS:000260503800021
J	Nadai, Y; Eyzaguirre, LM; Constantine, NT; Sill, AM; Cleghorn, F; Blattner, WA; Carr, JK				Nadai, Yuka; Eyzaguirre, Lindsay M.; Constantine, Niel T.; Sill, Anne M.; Cleghorn, Farley; Blattner, William A.; Carr, Jean K.			Protocol for Nearly Full-Length Sequencing of HIV-1 RNA from Plasma	PLOS ONE			English	Article							REVERSE-TRANSCRIPTASE; IN-VIVO; RT-PCR; VIRUS; DNA; AMPLIFICATION; RECOMBINATION; POLYMERASE; HYPERMUTATION; HYDROLYSIS	Nearly full-length genome sequencing of HIV-1 using peripheral blood mononuclear cells (PBMC) DNA as a template for PCR is now a relatively routine laboratory procedure. However, this has not been the case when using virion RNA as the template and this has made full genome analysis of circulating viruses difficult. Therefore, a well-developed procedure for sequencing of full-length HIV-1 RNA directly from plasma was needed. Plasma from U. S. donors representing a range of viral loads (VL) was used to develop the assay. RNA was extracted from plasma and reverse-transcribed. Two or three overlapping regions were PCR amplified to cover the entire viral genome and sequenced for verification. The success of the procedure was sensitive to VL but was routinely successful for VL greater than 10 5 and the rate declined in proportion to the VL. While the two-amplicon strategy had an advantage of increasing the possibility of amplifying a single species of HIV-1, the three-amplicon strategy was more successful in amplifying samples with low viral loads. This protocol provides a useful tool for molecular analysis to understand the HIV epidemic and pathogenesis, as well as diagnosis, therapy and future vaccine strategies.	[Nadai, Yuka; Eyzaguirre, Lindsay M.; Constantine, Niel T.; Sill, Anne M.; Blattner, William A.; Carr, Jean K.] Univ Maryland, Inst Human Virol, Dept Epidemiol, Baltimore, MD 21201 USA; [Cleghorn, Farley] Futures Grp Inc, Washington, DC USA	University System of Maryland; University of Maryland Baltimore	Carr, JK (corresponding author), Univ Maryland, Inst Human Virol, Dept Epidemiol, Baltimore, MD 21201 USA.	jecarr@ihv.umaryland.edu			NIH [R21-A1057084-02]; Henry M. Jackson Foundation for the Advancement of Military Medicine; U.S. Department of Defense	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Henry M. Jackson Foundation for the Advancement of Military Medicine; U.S. Department of Defense(United States Department of Defense)	The present work was supported by an NIH grant R21-A1057084-02 and a cooperative agreement between the Henry M. Jackson Foundation for the Advancement of Military Medicine and the U.S. Department of Defense.	AbouHaidar MG, 1999, Z NATURFORSCH C, V54, P542; Arens M, 1999, CLIN MICROBIOL REV, V12, P612, DOI 10.1128/CMR.12.4.612; Arroyo MA, 2004, AIDS RES HUM RETROV, V20, P895, DOI 10.1089/0889222041725235; Carninci P, 1998, P NATL ACAD SCI USA, V95, P520, DOI 10.1073/pnas.95.2.520; Carr JK, 1999, AIDS, V13, P1819, DOI 10.1097/00002030-199910010-00003; CHESTER N, 1993, ANAL BIOCHEM, V209, P284, DOI 10.1006/abio.1993.1121; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Das M, 2001, PHYSIOL GENOMICS, V6, P57, DOI 10.1152/physiolgenomics.2001.6.2.57; EIGEN M, 1993, SCI AM, V269, P42, DOI 10.1038/scientificamerican0793-42; Fang GW, 1998, J VIROL METHODS, V76, P139, DOI 10.1016/S0166-0934(98)00133-5; Gerard GF, 2002, BIOTECHNIQUES, V33, P984, DOI 10.2144/02335bm03; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Harrison GP, 1998, NUCLEIC ACIDS RES, V26, P3433, DOI 10.1093/nar/26.14.3433; Hawkins PR, 2003, BIOTECHNIQUES, V34, P768, DOI 10.2144/03344st06; JI JP, 1992, BIOCHEMISTRY-US, V31, P954, DOI 10.1021/bi00119a002; Judo MSB, 1998, NUCLEIC ACIDS RES, V26, P1819, DOI 10.1093/nar/26.7.1819; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; *LOS AL NAT LAB TH, 2006, HIV SEQ DAT; *LOS AL NAT LAB TH, 2006, PRIM HIV SEQ DAT TOO; Malboeuf CM, 2001, BIOTECHNIQUES, V30, P1074, DOI 10.2144/01305rr06; Malet I, 2003, J VIROL METHODS, V109, P161, DOI 10.1016/S0166-0934(03)00067-3; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; McCutchan FE, 2006, J MED VIROL, V78, pS7, DOI 10.1002/jmv.20599; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; Piche Caroline, 2005, J Biomol Tech, V16, P239; Preston BD, 1996, TRENDS MICROBIOL, V4, P16, DOI 10.1016/0966-842X(96)81500-9; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; ROBERTSON DL, 1995, NATURE, V374, P124, DOI 10.1038/374124b0; Rousseau CM, 2006, J VIROL METHODS, V136, P118, DOI 10.1016/j.jviromet.2006.04.009; Rozak DA, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni081; SALMINEN MO, 1995, VIROLOGY, V213, P80, DOI 10.1006/viro.1995.1548; SIMMONDS P, 1991, J VIROL, V65, P6266, DOI 10.1128/JVI.65.11.6266-6276.1991; Swift GH, 2000, BIOTECHNIQUES, V28, P524, DOI 10.2144/00283rr01; Van Laethem K, 2006, J VIROL METHODS, V132, P181, DOI 10.1016/j.jviromet.2005.10.008; Villahermosa ML, 2000, J HUMAN VIROL, V3, P27; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Yu W, 2006, BIOTECHNIQUES, V40, P499, DOI 10.2144/000112124; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707	42	48	69	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2008	3	1							e1420	10.1371/journal.pone.0001420	http://dx.doi.org/10.1371/journal.pone.0001420			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366GT	18183300	Green Published, Green Submitted, gold			2022-12-25	WOS:000260469400016
J	Cooley, M; Carychao, D; Crawford-Miksza, L; Jay, MT; Myers, C; Rose, C; Keys, C; Farrar, J; Mandrell, RE				Cooley, Michael; Carychao, Diana; Crawford-Miksza, Leta; Jay, Michele T.; Myers, Carol; Rose, Christopher; Keys, Christine; Farrar, Jeff; Mandrell, Robert E.			Incidence and Tracking of Escherichia coli O157:H7 in a Major Produce Production Region in California	PLOS ONE			English	Article								Fresh vegetables have become associated with outbreaks caused by Escherichia coli O157:H7 (EcO157). Between 1995-2006, 22 produce outbreaks were documented in the United States, with nearly half traced to lettuce or spinach grown in California. Outbreaks between 2002 and 2006 induced investigations of possible sources of pre-harvest contamination on implicated farms in the Salinas and San Juan valleys of California, and a survey of the Salinas watershed. EcO157 was isolated at least once from 15 of 22 different watershed sites over a 19 month period. The incidence of EcO157 increased significantly when heavy rain caused an increased flow rate in the rivers. Approximately 1000 EcO157 isolates obtained from cultures of >100 individual samples were typed using Multi-Locus Variable-number-tandem-repeat Analysis (MLVA) to assist in identifying potential fate and transport of EcO157 in this region. A subset of these environmental isolates were typed by Pulse Field Gel Electrophoresis (PFGE) in order to make comparisons with human clinical isolates associated with outbreak and sporadic illness. Recurrence of identical and closely related EcO157 strains from specific locations in the Salinas and San Juan valleys suggests that transport of the pathogen is usually restricted. In a preliminary study, EcO157 was detected in water at multiple locations in a low-flow creek only within 135 meters of a point source. However, possible transport up to 32 km was detected during periods of higher water flow associated with flooding. During the 2006 baby spinach outbreak investigation, transport was also detected where water was unlikely to be involved. These results indicate that contamination of the environment is a dynamic process involving multiple sources and methods of transport. Intensive studies of the sources, incidence, fate and transport of EcO157 near produce production are required to determine the mechanisms of pre-harvest contamination and potential risks for human illness.	[Cooley, Michael; Carychao, Diana; Mandrell, Robert E.] ARS, Produce Safety & Microbiol Res Unit, USDA, Western Reg Res Ctr, Albany, CA USA; [Crawford-Miksza, Leta; Jay, Michele T.] Calif Dept Hlth Serv, Food & Drug Lab Branch, Richmond, CA USA; [Rose, Christopher] Calif Environm Protect Agcy, Cent Coast Reg Water Qual Control Board, San Luis Obispo, CA USA; [Keys, Christine] US FDA, CFSAN, OPDF DMS, College Pk, MD USA	United States Department of Agriculture (USDA); California Department of Health Care Services; California Environmental Protection Agency; US Food & Drug Administration (FDA)	Cooley, M (corresponding author), ARS, Produce Safety & Microbiol Res Unit, USDA, Western Reg Res Ctr, Albany, CA USA.	mcooley@pw.usda.gov; mandrell@pw.usda.gov	Mandrell, Robert E/O-9814-2018; Bond, Ronald F./C-9201-2009	Bond, Ronald F./0000-0003-1823-2478	CRIS [5325-42000-045-00D, 5325-42000-044-00D]; FDA [5325-42000-045-01R]; CAL-EPA State Water Resources Control Board [05-221-130-0]; USDA-CSREES Section 32.1 [2006-01240]	CRIS; FDA(United States Department of Health & Human Services); CAL-EPA State Water Resources Control Board; USDA-CSREES Section 32.1(United States Department of Agriculture (USDA)National Institute of Food and Agriculture)	A portion of this work was funded by CRIS projects 5325-42000-045-00D and 5325-42000-044-00D, an interagency transfer of funds provided by FDA (5325-42000-045-01R), a contract with the CAL-EPA State Water Resources Control Board (05-221-130-0), and a grant from USDA-CSREES Section 32.1 (project no. 2006-01240).	Arthur TM, 2004, J FOOD PROTECT, V67, P658, DOI 10.4315/0362-028X-67.4.658; Barkocy-Gallagher GA, 2004, J FOOD PROTECT, V67, P993, DOI 10.4315/0362-028X-67.5.993; Barkocy-Gallagher GA, 2002, J FOOD PROTECT, V65, P1527, DOI 10.4315/0362-028X-65.10.1527; Barkocy-Gallagher GA, 2001, APPL ENVIRON MICROB, V67, P3810, DOI 10.1128/AEM.67.9.3810-3818.2001; BARRETT TJ, 1980, J CLIN MICROBIOL, V11, P385, DOI 10.1128/JCM.11.4.385-388.1980; Benham BL, 2006, T ASABE, V49, P987, DOI 10.13031/2013.21739; *CA EPA, 2002, 2002 CWA SECT 303 D; *CDHS, 2004, INV E COL O157 H7 OU; *CDHS, 2005, ADD REP INV PREW MIX; [CDHS-FDA] California Department of Human Services and the Food and Drug Administration, 2007, INV ESCH COL O157 H7; Chapman PA, 1997, EPIDEMIOL INFECT, V119, P245, DOI 10.1017/S0950268897007826; Cooley MB, 2003, APPL ENVIRON MICROB, V69, P4915, DOI 10.1128/AEM.69.8.4915-4926.2003; Cooley MB, 2006, J FOOD PROTECT, V69, P2329, DOI 10.4315/0362-028X-69.10.2329; Crabill C, 1999, WATER RES, V33, P2163, DOI 10.1016/S0043-1354(98)00437-0; Czajkowska D, 2005, POL J ENVIRON STUD, V14, P423; Davis MA, 2005, APPL ENVIRON MICROB, V71, P6816, DOI 10.1128/AEM.71.11.6816-6822.2005; Davis MA, 2003, EPIDEMIOL INFECT, V131, P923, DOI 10.1017/S0950268803008884; Desmarchelier PM, 1998, J CLIN MICROBIOL, V36, P1801, DOI 10.1128/JCM.36.6.1801-1804.1998; Dewell GA, 2005, FOODBORNE PATHOG DIS, V2, P70, DOI 10.1089/fpd.2005.2.70; Dorner SM, 2006, ENVIRON SCI TECHNOL, V40, P4746, DOI 10.1021/es060426z; Elder RO, 2000, P NATL ACAD SCI USA, V97, P2999, DOI 10.1073/pnas.060024897; *FDA CFSAN, 2006, TAC BELL E COL O157; *FDA CFSAN, 2007, FDA STAT CLOS ID SOU; Ferguson C, 2003, CRIT REV ENV SCI TEC, V33, P299, DOI 10.1080/10643380390814497; Foster G, 2006, APPL ENVIRON MICROB, V72, P2265, DOI 10.1128/AEM.72.3.2265-2267.2006; Fratamico PM, 2000, J FOOD PROTECT, V63, P1032, DOI 10.4315/0362-028X-63.8.1032; Gagliardi JV, 2000, APPL ENVIRON MICROB, V66, P877, DOI 10.1128/AEM.66.3.877-883.2000; Gannon VPJ, 2005, SCI TOTAL ENVIRON, V348, P19, DOI 10.1016/j.scitotenv.2004.12.076; Hyytia-Trees E, 2006, FOODBORNE PATHOG DIS, V3, P118, DOI 10.1089/fpd.2006.3.118; Ibekwe AM, 2004, CAN J MICROBIOL, V50, P1007, DOI 10.1139/W04-097; Ingham SC, 2005, J FOOD PROTECT, V68, P1134, DOI 10.4315/0362-028X-68.6.1134; Islam M, 2005, FOOD MICROBIOL, V22, P63, DOI 10.1016/j.fm.2004.04.007; Islam M, 2004, J FOOD PROTECT, V67, P1365, DOI 10.4315/0362-028X-67.7.1365; JACKSON SA, 2006, FORENSIC SCI INT; Johannessen GS, 2005, APPL ENVIRON MICROB, V71, P2221, DOI 10.1128/AEM.71.5.2221-2225.2005; Kaufmann M, 2006, J FOOD PROTECT, V69, P260, DOI 10.4315/0362-028X-69.2.260; Keen JE, 2006, EMERG INFECT DIS, V12, P780; Keen JE, 2002, J AM VET MED ASSOC, V220, P756, DOI 10.2460/javma.2002.220.756; Keys C, 2005, J APPL MICROBIOL, V98, P928, DOI 10.1111/j.1365-2672.2004.02532.x; LeJeune JT, 2001, APPL ENVIRON MICROB, V67, P3053, DOI 10.1128/AEM.67.7.3053-3057.2001; LeJeune JT, 2004, APPL ENVIRON MICROB, V70, P377, DOI 10.1128/AEM.70.1.377-384.2004; Lindstedt BA, 2004, J MICROBIOL METH, V58, P213, DOI 10.1016/j.mimet.2004.03.016; *MDPH, 2005, HLTH OFF INV E COLI; *MMWR, 2006, MORBITY MORTALITY WE, V55, P1045; Moriya K, 1999, MED VET ENTOMOL, V13, P214, DOI 10.1046/j.1365-2915.1999.00161.x; Muirhead RW, 2006, APPL ENVIRON MICROB, V72, P3406, DOI 10.1128/AEM.72.5.3406-3411.2006; Mukherjee A, 2006, J APPL MICROBIOL, V101, P429, DOI 10.1111/j.1365-2672.2006.02913.x; NEI M, 1973, P NATL ACAD SCI USA, V70, P3321, DOI 10.1073/pnas.70.12.3321; Nicholson FA, 2005, BIORESOURCE TECHNOL, V96, P135, DOI 10.1016/j.biortech.2004.02.030; Noller AC, 2003, J CLIN MICROBIOL, V41, P5389, DOI 10.1128/JCM.41.12.5389-5397.2003; Ogden ID, 2005, J APPL MICROBIOL, V98, P646, DOI 10.1111/j.1365-2672.2004.02493.x; OKREND AJG, 1992, J FOOD PROTECT, V55, P214, DOI 10.4315/0362-028X-55.3.214; Paiba GA, 2002, VET REC, V150, P593, DOI 10.1136/vr.150.19.593; Paton AW, 1998, INFECT IMMUN, V66, P5580, DOI 10.1128/IAI.66.11.5580-5586.1998; Rangel JM, 2005, EMERG INFECT DIS, V11, P603, DOI 10.3201/eid1104.040739; Rasmussen MA, 2001, CRIT REV MICROBIOL, V27, P57, DOI 10.1080/20014091096701; Ren JH, 2002, J ENVIRON ENG-ASCE, V128, P624, DOI 10.1061/(ASCE)0733-9372(2002)128:7(624); Ribot EM, 2006, FOODBORNE PATHOG DIS, V3, P59, DOI 10.1089/fpd.2006.3.59; Rivera-Betancourt M, 2004, J FOOD PROTECT, V67, P295, DOI 10.4315/0362-028X-67.2.295; ROSE C, 2006, PHASE 4 PROJECT ANAL; Sargeant JM, 1999, J AM VET MED ASSOC, V215, P792; Scott L, 2006, VET MICROBIOL, V114, P331, DOI 10.1016/j.vetmic.2005.11.066; Scott L, 2006, J FOOD PROTECT, V69, P6, DOI 10.4315/0362-028X-69.1.6; SEARS SD, 1984, J INFECT DIS, V149, P640, DOI 10.1093/infdis/149.4.640; Seo KH, 1999, J FOOD PROTECT, V62, P3, DOI 10.4315/0362-028X-62.1.3; SMALL I, 2005, ADDENDUM REPORT INVE; Solomon EB, 2002, APPL ENVIRON MICROB, V68, P397, DOI 10.1128/AEM.68.1.397-400.2002; Sproston EL, 2006, APPL ENVIRON MICROB, V72, P144, DOI 10.1128/AEM.72.1.144-149.2006; Takeuchi K, 2000, J FOOD PROTECT, V63, P434, DOI 10.4315/0362-028X-63.4.434; Tanaka Y, 2000, J APPL MICROBIOL, V88, P228, DOI 10.1046/j.1365-2672.2000.00960.x; Tutenel AV, 2003, INT J FOOD MICROBIOL, V84, P63, DOI 10.1016/S0168-1605(02)00395-1; *USDA, 2001, LETT OUT BAG; *USGS, 2007, NAT WAT INF SYST WEB; Wachtel MR, 2002, J FOOD PROTECT, V65, P18, DOI 10.4315/0362-028X-65.1.18; Wang GD, 1998, J FOOD PROTECT, V61, P662, DOI 10.4315/0362-028X-61.6.662; Watterworth L, 2006, WATER AIR SOIL POLL, V177, P367, DOI 10.1007/s11270-006-9179-x; Westerman RB, 1997, J CLIN MICROBIOL, V35, P679, DOI 10.1128/JCM.35.3.679-684.1997; Wetzel AN, 2006, APPL ENVIRON MICROB, V72, P2621, DOI 10.1128/AEM.72.4.2621-2626.2006; Yaron S, 2002, J APPL MICROBIOL, V92, P633, DOI 10.1046/j.1365-2672.2002.01563.x; Zhang W, 2006, GENOME RES, V16, P757, DOI 10.1101/gr.4759706	80	257	260	0	46	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 14	2007	2	11							e1159	10.1371/journal.pone.0001159	http://dx.doi.org/10.1371/journal.pone.0001159			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10JA	18174909	Green Published, gold, Green Submitted			2022-12-25	WOS:000207459100002
J	Wagner, N; Michiels, JF; Schedl, A; Wagner, KD				Wagner, N.; Michiels, J. F.; Schedl, A.; Wagner, K-D			The Wilms' tumour suppressor WT1 is involved in endothelial cell proliferation and migration: expression in tumour vessels in vivo	ONCOGENE			English	Article						cancer; endothelial cells; RNAi	TRANSCRIPTION FACTOR ETS-1; INDUCIBLE FACTOR-I; NESTIN EXPRESSION; ANGIOGENESIS; GENE; ACTIVATION; INTRON; KIDNEY; MOUSE	Vascularization is an important step in tumour growth. Although a variety of molecules, for example, VEGF, ETS-1 or nestin have been implicated in tumour angiogenesis, the molecular mechanisms of vessel formation are not fully characterized. We showed that the Wilms' tumour suppressor WT1 activates nestin during development. Here we tested whether WT1 might also be involved in tumour angiogenesis. Endothelial WT1 expression was detected in 95% of 113 tumours of different origin. To analyse the function of WT1 in endothelial cells, we used an RNAi approach in vitro and showed that inhibition of WT1 reduces cell proliferation, migration and endothelial tube formation. On a molecular level, WT1 silencing diminished expression of the ETS-1 transcription factor. WT1 and ETS-1 shared an overlapping expression in tumour endothelia. The ETS-1 promoter was stimulated approximately 10-fold by transient co-transfection of a WT1 expression construct and WT1 bound to the ETS-1 promoter in chromatin immunoprecipitation and electrophoretic mobility shift assays. Deletion of the identified WT1-binding site abolished stimulation of the ETS-1 promoter by WT1. These findings suggest that transcriptional activation of ETS-1 by the Wilms' tumour suppressor WT1 is a crucial step in tumour vascularization via regulation of endothelial cell proliferation and migration.	[Wagner, N.; Wagner, K-D] INSERM, U907, Fac Med, PACA, F-06107 Nice, France; [Wagner, N.; Michiels, J. F.; Schedl, A.; Wagner, K-D] Univ Nice Sophia Antipolis, Nice, France; [Michiels, J. F.] Univ Nice Sophia Antipolis, Dept Pathol, Nice, France; [Schedl, A.] INSERM, U636, Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Wagner, KD (corresponding author), INSERM, U907, Fac Med, PACA, 28 Ave Valombrose, F-06107 Nice, France.	kwagner@unice.fr	Wagner, Kay-Dietrich/E-6119-2016; Schedl, Andreas/GOP-3427-2022; Schedl, Andreas/F-8823-2015	Wagner, Kay-Dietrich/0000-0001-5483-7760; Schedl, Andreas/0000-0001-9380-7396; Wagner, Nicole/0000-0002-2746-0707				Aihara M, 2004, LAB INVEST, V84, P1581, DOI 10.1038/labinvest.3700186; Amoh Y, 2005, CANCER RES, V65, P5352, DOI 10.1158/0008-5472.CAN-05-0821; Brown C, 2004, J BIOL CHEM, V279, P12794, DOI 10.1074/jbc.M308593200; Cheville JC, 2003, AM J SURG PATHOL, V27, P612, DOI 10.1097/00000478-200305000-00005; Cohen MM, 2006, AM J MED GENET A, V140A, P2013, DOI 10.1002/ajmg.a.31333; Elvert G, 2003, J BIOL CHEM, V278, P7520, DOI 10.1074/jbc.M211298200; Gao XB, 2005, DEVELOPMENT, V132, P5437, DOI 10.1242/dev.02095; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; Hasegawa Y, 2004, BIOCHEM BIOPH RES CO, V316, P52, DOI 10.1016/j.bbrc.2004.02.019; Hashiya N, 2004, CIRCULATION, V109, P3035, DOI 10.1161/01.CIR.0000130643.41587.DB; Hohenstein P, 2006, HUM MOL GENET, V15, pR196, DOI 10.1093/hmg/ddl196; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Jorcyk CL, 1997, CELL MOL BIOL, V43, P211; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; Labrecque L, 2003, MOL BIOL CELL, V14, P334, DOI 10.1091/mbc.E02-07-0379; Mikami S, 2006, CANCER SCI, V97, P875, DOI 10.1111/j.1349-7006.2006.00268.x; Mokry J, 2004, STEM CELLS DEV, V13, P658, DOI 10.1089/scd.2004.13.658; Oikawa M, 2001, BIOCHEM BIOPH RES CO, V289, P39, DOI 10.1006/bbrc.2001.5927; Semenza GL, 2003, ANNU REV MED, V54, P17, DOI 10.1146/annurev.med.54.101601.152418; Seth A, 2005, EUR J CANCER, V41, P2462, DOI 10.1016/j.ejca.2005.08.013; Timar J, 2005, HISTOPATHOLOGY, V47, P67, DOI 10.1111/j.1365-2559.2005.02169.x; Wagner KD, 2003, FASEB J, V17, P1364, DOI 10.1096/fj.02-1065fje; Wagner KD, 2002, FASEB J, V16, P1117, DOI 10.1096/fj.01-0986fje; Wagner N, 2005, GENE DEV, V19, P2631, DOI 10.1101/gad.346405; Wagner N, 2004, J AM SOC NEPHROL, V15, P3044, DOI 10.1097/01.ASN.0000146687.99058.25; Wagner N, 2006, AM J PHYSIOL-REG I, V291, pR779, DOI 10.1152/ajpregu.00219.2006; WERNERT N, 1992, AM J PATHOL, V140, P119	27	76	78	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2008	27	26					3662	3672		10.1038/sj.onc.1211044	http://dx.doi.org/10.1038/sj.onc.1211044			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18212735				2022-12-25	WOS:000256659300003
J	Zuo, XS; Shen, L; Issa, JP; Moy, O; Morris, JS; Lippman, SM; Shureiqi, I				Zuo, Xiangsheng; Shen, Lanlan; Issa, Jean-Pierre; Moy, Ofir; Morris, Jeffrey S.; Lippman, Scott M.; Shureiqi, Imad			15-Lipoxygenase-1 transcriptional silencing by DNA methyltransferase-1 independently of DNA methylation	FASEB JOURNAL			English	Article						colon cancer; transcriptional regulation; histone deacetylase inhibitor; DNMT-1 hypomorph protein	COLORECTAL-CANCER CELLS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; HISTONE METHYLTRANSFERASE; PROMOTER METHYLATION; INDUCED APOPTOSIS; INDUCE APOPTOSIS; GENE PROMOTER; EXPRESSION; INFLAMMATION; DNMT1	Methylation of promoter DNA contributes to transcriptional silencing of various tumor-suppressor genes in cancer. Transcriptional silencing of 15-lipoxygenase-1 (15-LOX-1) promotes tumorigenesis. Methylation of 15-LOX-1 promoter DNA occurs in some cancers, but its mechanistic role in 15-LOX-1 transcriptional silencing is unclear. We examined the mechanistic role of 15-LOX-1 promoter DNA methylation in 15-LOX-1 transcriptional regulation in human colorectal cancers. 15-LOX-1 promoter methylation occurred in colorectal cancer cells in vitro, in 36% of tumor tissue samples of colorectal cancer patients, and in virtually no normal colonic mucosa samples of 50 human subjects with no history of colorectal cancer or polyps. 15-LOX-1 promoter DNA methylation levels, however, did not correlate with 15-LOX-1 expression levels (Spearman's r=0.21; P=0.38). We employed siRNA knockdown and genetic disruption models of DNA methyltransferases (DNMTs) to study the effects of this methylation on 15-LOX-1 expression in colon cancer cells. 15-LOX-1 promoter demethylation was insufficient to reestablish 15-LOX-1 expression. 15-LOX-1 transcription was activated by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) only after DNMT-1 dissociation from the 15-LOX- 1 promoter and without altering 15-LOX-1 promoter DNA methylation. DNMT-1 protein hypomorphism impaired DNMT-1 recruitment to the 15-LOX-1 promoter, which allowed 15-LOX-1 transcription activation by SAHA. DNMT-1 has a direct suppressive role in 15-LOX-1 transcriptional silencing that is independent of 15-LOX-1 promoter DNA methylation.	[Zuo, Xiangsheng; Moy, Ofir; Lippman, Scott M.; Shureiqi, Imad] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Unit 1360, Houston, TX 77030 USA; [Shen, Lanlan; Issa, Jean-Pierre] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; [Morris, Jeffrey S.] Univ Texas MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA; [Lippman, Scott M.] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; [Shureiqi, Imad] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Shureiqi, I (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Unit 1360, 1515 Holcombe Blvd, Houston, TX 77030 USA.	ishureiqi@mdanderson.org	Shureiqi, imad/T-6214-2019	Zuo, Xiangsheng/0000-0002-8593-1132; Shureiqi, Imad/0000-0003-2019-938X; Issa, Jean-Pierre/0000-0003-2258-5030	NCI NIH HHS [R01 CA106577-01A1, K07 CA086970-05, K07 CA086970-03, K07 CA086970-02, R01 CA106577, K07 CA086970, N02-CB-07008, K07 CA086970-06, R01 CA106577-03, K07 CA086970-04, K07 CA086970-01, R01 CA106577-02, K07 CA86970] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K07CA086970, R01CA106577] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ariel A, 2005, J BIOL CHEM, V280, P43079, DOI 10.1074/jbc.M509796200; Ariel A, 2007, TRENDS IMMUNOL, V28, P176, DOI 10.1016/j.it.2007.02.007; BAER AN, 1991, BIOCHEM BIOPH RES CO, V180, P98, DOI 10.1016/S0006-291X(05)81260-4; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; Damelin M, 2007, MOL CELL BIOL, V27, P3891, DOI 10.1128/MCB.00036-07; Deguchi A, 2005, CANCER RES, V65, P8442, DOI 10.1158/0008-5472.CAN-05-1109; Egger G, 2006, P NATL ACAD SCI USA, V103, P14080, DOI 10.1073/pnas.0604602103; EKBOM A, 1990, NEW ENGL J MED, V323, P1228, DOI 10.1056/NEJM199011013231802; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Hennig R, 2007, NEOPLASIA, V9, P917, DOI 10.1593/neo.07565; Heslin MJ, 2005, ANN SURG, V241, P941, DOI 10.1097/01.sla.0000164177.95620.c1; Hodge DR, 2005, CANCER RES, V65, P4673, DOI 10.1158/0008-5472.CAN-04-3589; Hodge DR, 2001, J BIOL CHEM, V276, P39508, DOI 10.1074/jbc.C100343200; Hsi LC, 2005, MOL CANCER THER, V4, P1740, DOI 10.1158/1535-7163.MCT-05-0218; Hsi LC, 2004, CANCER RES, V64, P8778, DOI 10.1158/0008-5472.CAN-04-1867; Jiang WG, 2006, PROSTAG LEUKOTR ESS, V74, P235, DOI 10.1016/j.plefa.2006.01.009; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kamitani H, 2001, CARCINOGENESIS, V22, P187, DOI 10.1093/carcin/22.1.187; Kelavkar U, 1998, MOL BIOL REP, V25, P173, DOI 10.1023/A:1006813009006; Kelavkar UP, 2007, PROSTAG OTH LIPID M, V82, P185, DOI 10.1016/j.prostaglandins.2006.05.015; Kuhn H, 2006, PROG LIPID RES, V45, P334, DOI 10.1016/j.plipres.2006.02.003; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Liu C, 2004, EXP CELL RES, V297, P61, DOI 10.1016/j.yexcr.2004.02.014; Makar KW, 2003, NAT IMMUNOL, V4, P1183, DOI 10.1038/ni1004; Martinez ME, 1997, GASTROENTEROLOGY, V113, P423, DOI 10.1053/gast.1997.v113.pm9247459; MARTINEZ ME, 1995, CANCER EPIDEM BIOMAR, V4, P703; Massaro M, 2006, P NATL ACAD SCI USA, V103, P15184, DOI 10.1073/pnas.0510086103; Munger KA, 1999, P NATL ACAD SCI USA, V96, P13375, DOI 10.1073/pnas.96.23.13375; Nixon JB, 2004, PROSTAG LEUKOTR ESS, V70, P7, DOI 10.1016/j.plefa.2003.06.001; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Serhan CN, 2003, J IMMUNOL, V171, P6856, DOI 10.4049/jimmunol.171.12.6856; Shu JM, 2006, CANCER RES, V66, P5077, DOI 10.1158/0008-5472.CAN-05-2629; Shureiqi I, 2000, J NATL CANCER I, V92, P1136, DOI 10.1093/jnci/92.14.1136; Shureiqi I, 1999, CARCINOGENESIS, V20, P1985, DOI 10.1093/carcin/20.10.1985; Shureiqi I, 2005, CANCER RES, V65, P11486, DOI 10.1158/0008-5472.CAN-05-2180; Shureiqi I, 2003, P NATL ACAD SCI USA, V100, P9968, DOI 10.1073/pnas.1631086100; Shureiqi I, 2001, CANCER RES, V61, P6307; Shureiqi I, 2001, CANCER RES, V61, P4879; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Wozniak RJ, 2007, ONCOGENE, V26, P77, DOI 10.1038/sj.onc.1209763; Wu J, 2003, CARCINOGENESIS, V24, P243, DOI 10.1093/carcin/24.2.243; Zhou Q, 2007, CANCER BIOL THER, V6, P64, DOI 10.4161/cbt.6.1.3549; Zuo X, 2006, ONCOGENE, V25, P1225, DOI 10.1038/sj.onc.1209160	50	20	21	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					1981	1992		10.1096/fj.07-098301	http://dx.doi.org/10.1096/fj.07-098301			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18198215	Green Accepted			2022-12-25	WOS:000256352700037
J	Keszler, A; Piknova, B; Schechter, AN; Hogg, N				Keszler, Agnes; Piknova, Barbora; Schechter, Alan N.; Hogg, Neil			The reaction between nitrite and oxyhemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; MEDIATED OXIDATION; INDUCED METHEMOGLOBINEMIA; AUTOCATALYTIC OXIDATION; NITROGEN-DIOXIDE; HUMAN-HEMOGLOBIN; OXIDE; MYOGLOBIN; MECHANISM; DEOXYHEMOGLOBIN	The nitrite anion (NO2-) has recently received much attention as an endogenous nitric oxide source that has the potential to be supplemented for therapeutic benefit. One major mechanism of nitrite reduction is the direct reaction between this anion and the ferrous heme group of deoxygenated hemoglobin. However, the reaction of nitrite with oxyhemoglobin (oxyHb) is well established and generates nitrate and methemoglobin (metHb). Several mechanisms have been proposed that involve the intermediacy of protein-free radicals, ferryl heme, nitrogen dioxide (NO2), and hydrogen peroxide (H2O2) in an autocatalytic free radical chain reaction, which could potentially limit the usefulness of nitrite therapy. In this study we show that none of the previously published mechanisms is sufficient to fully explain the kinetics of the reaction of nitrite with oxyHb. Based on experimental data and kinetic simulation, we have modified previous models for this reaction mechanism and show that the new model proposed here is consistent with experimental data. The important feature of this model is that, whereas previously both H2O2 and NO2 were thought to be integral to both the initiation and propagation steps, H2O2 now only plays a role as an initiator species, and NO2 only plays a role as an autocatalytic propagatory species. The consequences of uncoupling the roles of H2O2 and NO2 in the reaction mechanism for the in vivo reactivity of nitrite are discussed.	[Keszler, Agnes; Hogg, Neil] Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA; [Keszler, Agnes; Hogg, Neil] Med Coll Wisconsin, Free Radical Res Ctr, Milwaukee, WI 53226 USA; [Piknova, Barbora; Schechter, Alan N.] NIDDK, Mol Med Branch, NIH, Bethesda, MD 20892 USA	Medical College of Wisconsin; Medical College of Wisconsin; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Hogg, N (corresponding author), 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	nhogg@mcw.edu		Schechter, Alan N/0000-0002-5235-9408	NIBIB NIH HHS [EB 001980] Funding Source: Medline; NIGMS NIH HHS [GM 55792] Funding Source: Medline; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB001980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK025093, Z01DK025093] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM055792, R01GM055792] Funding Source: NIH RePORTER	NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 2002, MMWR MORB MORTAL WKL, V51, P639; Cosby K, 2003, NAT MED, V9, P1498, DOI 10.1038/nm954; De Jesus-Bonilla W, 2001, ARCH BIOCHEM BIOPHYS, V390, P304, DOI 10.1006/abbi.2001.2392; DEE G, 1991, FEBS LETT, V294, P38, DOI 10.1016/0014-5793(91)81338-9; Dejam A, 2005, BLOOD, V106, P734, DOI 10.1182/blood-2005-02-0567; DOYLE MP, 1981, J BIOL CHEM, V256, P2393; DOYLE MP, 1982, BIOCHEM BIOPH RES CO, V105, P127, DOI 10.1016/S0006-291X(82)80020-X; Gamgee A, 1868, PHILOS T ROY SOC LON, V158, P589, DOI DOI 10.1098/RSTL.1868.0025; Goldstein S, 2004, J AM CHEM SOC, V126, P15694, DOI 10.1021/ja046186+; Goldstein S, 2003, J BIOL CHEM, V278, P50949, DOI 10.1074/jbc.M308317200; Grubina R, 2007, J BIOL CHEM, V282, P12916, DOI 10.1074/jbc.M700546200; Grzelak A, 2001, BBA-GEN SUBJECTS, V1528, P97, DOI 10.1016/S0304-4165(01)00176-3; Herold S, 2003, FREE RADICAL BIO MED, V34, P531, DOI 10.1016/S0891-5849(02)01355-2; Herold S, 2001, BIOCHEMISTRY-US, V40, P3385, DOI 10.1021/bi002407m; Huang KT, 2005, J BIOL CHEM, V280, P31126, DOI 10.1074/jbc.M501496200; Hunter CJ, 2004, NAT MED, V10, P1122, DOI 10.1038/nm1109; Jourd'heuil D, 2003, J BIOL CHEM, V278, P15720, DOI 10.1074/jbc.M300203200; Keszler A, 2005, FREE RADICAL BIO MED, V39, pS19; Keszler A, 2006, FREE RADICAL BIO MED, V40, P507, DOI 10.1016/j.freeradbiomed.2005.09.005; Kim-Shapiro DB, 2005, J INORG BIOCHEM, V99, P237, DOI 10.1016/j.jinorgbio.2004.10.034; Kirsch M, 2002, BIOL CHEM, V383, P389, DOI 10.1515/BC.2002.043; Kleinbongard P, 2003, FREE RADICAL BIO MED, V35, P790, DOI 10.1016/S0891-5849(03)00406-4; Kohn MC, 2002, DRUG METAB DISPOS, V30, P676, DOI 10.1124/dmd.30.6.676; KOSAKA H, 1982, BIOCHIM BIOPHYS ACTA, V702, P237; KOSAKA H, 1979, BIOCHIM BIOPHYS ACTA, V581, P184, DOI 10.1016/0005-2795(79)90235-6; Lissi E, 1998, FREE RADICAL BIO MED, V24, P1535, DOI 10.1016/S0891-5849(98)00004-5; Matsui T, 1999, J BIOL CHEM, V274, P2838, DOI 10.1074/jbc.274.5.2838; Nakai K, 2005, FREE RADICAL BIO MED, V39, P1050, DOI 10.1016/j.freeradbiomed.2005.05.019; Nicolis S, 2004, CHEM-EUR J, V10, P2281, DOI 10.1002/chem.200304989; O'Donnell VB, 1999, METHOD ENZYMOL, V301, P454; Pietraforte D, 2004, FREE RADICAL BIO MED, V37, P1244, DOI 10.1016/j.freeradbiomed.2004.06.027; Reeder BJ, 2005, CURR MED CHEM, V12, P2741, DOI 10.2174/092986705774463021; ROSSIFANELLI A, 1961, J BIOL CHEM, V236, P391; SPAGNUOLO C, 1987, BIOCHIM BIOPHYS ACTA, V911, P59, DOI 10.1016/0167-4838(87)90270-6; SPEIJERS GJA, 2003, JEFCA WHO FOOD ADDIT, V50; Titov VY, 2005, BIOCHEMISTRY-MOSCOW+, V70, P473, DOI 10.1007/s10541-005-0139-7; Titov VY, 2003, BIOCHEMISTRY-MOSCOW+, V68, P627, DOI 10.1023/A:1024609624652; Tsikas D, 2001, J CHROMATOGR A, V915, P107, DOI 10.1016/S0021-9673(01)00634-3; Wade RS, 1996, CHEM RES TOXICOL, V9, P1382, DOI 10.1021/tx9600457; WATANABE S, 1981, ACTA MED OKAYAMA, V35, P173	40	81	82	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9615	9622		10.1074/jbc.M705630200	http://dx.doi.org/10.1074/jbc.M705630200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18203719	hybrid, Green Published			2022-12-25	WOS:000254671600015
J	Braun, NA; Theg, SM				Braun, Nikolai A.; Theg, Steven M.			The chloroplast tat pathway transports substrates in the dark	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-TRANSPORT; COUPLING FACTOR-I; ATP SYNTHESIS; THYLAKOID MEMBRANES; PROTON GRADIENT; PRECURSOR PROTEINS; ESCHERICHIA-COLI; PHOTOPHOSPHORYLATION; SYSTEM; TRANSLOCATION	Photosynthetic electron transport pumps protons into the thylakoid lumen, creating an electrochemical potential called the protonmotive force (PMF). The energy of the thylakoid PMF is utilized by such machinery as the chloroplast F0F1-ATPase as well as the chloroplast Tat (cpTat) pathway ( a protein transporter) to do work. The bulk phase thylakoid PMF decays rapidly after the termination of actinic illumination, and it has been well established via potentiometric measurements that there is no detectable electrical or chemical potential in the thylakoid after a brief time in the dark. Yet, we report herein that cpTat transport can occur for long periods in the dark. We show that the thylakoid PMF is actually present long after actinic illumination of the thylakoids ceases and that this energy is present in physiologically useful quantities. Consistent with previous studies, the dark-persisting thylakoid potential is not detectable by established indicators. We propose that cpTat transport in the dark is dependent on a pool of protons in the thylakoid held out of equilibrium with those in the bulk aqueous phase.	[Braun, Nikolai A.; Theg, Steven M.] Univ Calif Davis, Dept Plant Biol, Davis, CA 95616 USA	University of California System; University of California Davis	Theg, SM (corresponding author), Univ Calif Davis, Dept Plant Biol, 1 Shields Ave, Davis, CA 95616 USA.	smtheg@ucdavis.edu						Alder NN, 2003, CELL, V112, P231, DOI 10.1016/S0092-8674(03)00032-1; ARANA JL, 1982, J BIOL CHEM, V257, P1125; ARNON DI, 1949, PLANT PHYSIOL, V24, P15; AUSLANDER W, 1975, FEBS LETT, V59, P310, DOI 10.1016/0014-5793(75)80399-1; Bageshwar UK, 2007, J CELL BIOL, V179, P87, DOI 10.1083/jcb.200702082; Berry S, 1999, BBA-BIOENERGETICS, V1410, P248, DOI 10.1016/S0005-2728(99)00003-1; Bolhuis A, 2001, J BIOL CHEM, V276, P20213, DOI 10.1074/jbc.M100682200; Braun NA, 2007, BIOPHYS J, V93, P1993, DOI 10.1529/biophysj.106.098731; Bruser T, 2003, MICROBIOL RES, V158, P7, DOI 10.1078/0944-5013-00176; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; Cline K, 2001, J CELL BIOL, V154, P719, DOI 10.1083/jcb.200105149; CROFTS AR, 1966, BIOCHEM BIOPH RES CO, V24, P725, DOI 10.1016/0006-291X(66)90385-8; DAVENPORT JW, 1986, BIOCHIM BIOPHYS ACTA, V851, P136, DOI 10.1016/0005-2728(86)90256-2; Di Cola A, 2005, J BIOL CHEM, V280, P41165, DOI 10.1074/jbc.M509215200; Dilley RA, 2004, PHOTOSYNTH RES, V80, P245, DOI 10.1023/B:PRES.0000030436.32486.aa; Finazzi G, 2003, EMBO J, V22, P807, DOI 10.1093/emboj/cdg081; Gerard F, 2006, J BIOL CHEM, V281, P6130, DOI 10.1074/jbc.M512733200; Gohlke U, 2005, P NATL ACAD SCI USA, V102, P10482, DOI 10.1073/pnas.0503558102; HANGARTER RP, 1982, BIOCHIM BIOPHYS ACTA, V681, P397, DOI 10.1016/0005-2728(82)90181-5; HIND G, 1963, P NATL ACAD SCI USA, V49, P715, DOI 10.1073/pnas.49.5.715; HOCH G, 1963, BIOCHEM BIOPH RES CO, V12, P223, DOI 10.1016/0006-291X(63)90194-3; JAGENDORF AT, 1966, P NATL ACAD SCI USA, V55, P170, DOI 10.1073/pnas.55.1.170; JUNESCH U, 1987, BIOCHIM BIOPHYS ACTA, V893, P275, DOI 10.1016/0005-2728(87)90049-1; JUNGE W, 1968, Z NATURFORSCH PT B, VB 23, P244, DOI 10.1515/znb-1968-0222; KLOSGEN RB, 1992, PLANT MOL BIOL, V18, P1031, DOI 10.1007/BF00019226; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASZLO JA, 1984, J BIOENERG BIOMEMBR, V16, P37, DOI 10.1007/BF00744144; LYNN WS, 1968, J BIOL CHEM, V243, P1060; McDevitt CA, 2005, BIOCHEM BIOPH RES CO, V329, P693, DOI 10.1016/j.bbrc.2005.02.038; Mori H, 1999, J CELL BIOL, V146, P45, DOI 10.1083/jcb.146.1.45; Mori H, 2001, FEBS LETT, V501, P65, DOI 10.1016/S0014-5793(01)02626-6; MOULD RM, 1991, J BIOL CHEM, V266, P17286; MOULD RM, 1991, J BIOL CHEM, V266, P12189; NALIN CM, 1984, J BIOL CHEM, V259, P7275; OLSEN LJ, 1989, J BIOL CHEM, V264, P6724; ORT DR, 1976, BIOCHIM BIOPHYS ACTA, V449, P95, DOI 10.1016/0005-2728(76)90010-4; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PICK U, 1973, FEBS LETT, V32, P91, DOI 10.1016/0014-5793(73)80745-8; PORTIS AR, 1974, J BIOL CHEM, V249, P6250; Robinson C, 2004, BBA-MOL CELL RES, V1694, P135, DOI 10.1016/j.bbamcr.2004.03.010; ROTTENBERG H, 1972, EUR J BIOCHEM, V25, P54, DOI 10.1111/j.1432-1033.1972.tb01666.x; Sacksteder CA, 2001, PHOTOSYNTH RES, V70, P231, DOI 10.1023/A:1017906626288; SCHULDINER S, 1972, EUR J BIOCHEM, V25, P64, DOI 10.1111/j.1432-1033.1972.tb01667.x; SETTLES AM, 1997, SCIENCE, V278, P147; Teter SA, 1998, P NATL ACAD SCI USA, V95, P1590, DOI 10.1073/pnas.95.4.1590; THEG SM, 1988, J BIOL CHEM, V263, P673; THEG SM, 1982, FEBS LETT, V145, P25, DOI 10.1016/0014-5793(82)81199-X; THEG SM, 1987, BIOENGERG BIOMEMBR, V19, P53; Walker MB, 1999, J CELL BIOL, V147, P267, DOI 10.1083/jcb.147.2.267; WITT H T, 1971, Quarterly Reviews of Biophysics, V4, P365	51	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					8822	8828		10.1074/jbc.M708948200	http://dx.doi.org/10.1074/jbc.M708948200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18187420	hybrid, Green Submitted			2022-12-25	WOS:000254465800008
J	Fisher, AL; Page, KE; Lithgow, GJ; Nash, L				Fisher, Alfred L.; Page, Kathryn E.; Lithgow, Gordon J.; Nash, Lindsey			The Caenorhabditis elegans K10C2.4 gene encodes a member of the fumarylacetoacetate hydrolase family - A caenorhabditis elegans model of type i tyrosinemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY TYROSINEMIA; C-ELEGANS; LIFE-SPAN; CRYSTAL-STRUCTURE; MUTATIONS; INTERFERENCE; APOPTOSIS; STRESS; DAF-16; RESCUE	In eukaryotes and many bacteria, tyrosine is degraded to produce energy via a five-step tyrosine degradation pathway. Mutations affecting the tyrosine degradation pathway are also of medical importance as mutations affecting enzymes in the pathway are responsible for type I, type II, and type III tyrosinemia. The most severe of these is type I tyrosinemia, which is caused by mutations affecting the last enzyme in the pathway, fumarylacetoacetate hydrolase ( FAH). So far, tyrosine degradation in the nematode Caenorhabditis elegans has not been studied; however, genes predicted to encode enzymes in this pathway have been identified in several microarray, proteomic, and RNA interference ( RNAi) screens as perhaps being involved in aging and the control of protein folding. We sought to identify and characterize the genes in the worm tyrosine degradation pathway as an initial step in understanding these findings. Here we describe the characterization of the K10C2.4, which encodes a homolog of FAH. RNAi directed against K10C2.4 produces a lethal phenotype consisting of death in young adulthood, extensive damage to the intestine, impaired fertility, and activation of oxidative stress and endoplasmic stress response pathways. This phenotype is due to alterations in tyrosine metabolism as increases in dietary tyrosine enhance it, and inhibition of upstream enzymes in tyrosine degradation with RNAi or genetic mutations reduces the phenotype. We also use our model to identify genes that suppress the damage produced by K10C2.4 RNAi in a pilot genetic screen. Our results establish worms as a model for the study of type I tyrosinemia.	[Fisher, Alfred L.; Nash, Lindsey] Carnegie Mellon Univ, Div Geriatr Med, Dept Med, Pittsburgh, PA 15213 USA; [Page, Kathryn E.; Lithgow, Gordon J.] Buck Inst, Novato, CA 94945 USA	Carnegie Mellon University; Buck Institute for Research on Aging	Fisher, AL (corresponding author), 3471 5th Ave,Suite 500, Pittsburgh, PA 15260 USA.	fishera@dom.pitt.edu	Fisher, Alfred/H-3031-2012	Fisher, Alfred/0000-0001-6451-2644	NATIONAL INSTITUTE ON AGING [K08AG024414, R01AG022868, K08AG028977, R01AG021069] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG022868, R01 AG 21069, K08 AG028977, K08 AG024414, R01 AG021069, R01 AG 22868, K08 AG 028977] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		An JH, 2003, GENE DEV, V17, P1882, DOI 10.1101/gad.1107803; Aponte JL, 2001, P NATL ACAD SCI USA, V98, P641, DOI 10.1073/pnas.98.2.641; Bennett-Lovsey RM, 2008, PROTEINS, V70, P611, DOI 10.1002/prot.21688; Bergeron A, 2001, J BIOL CHEM, V276, P15225, DOI 10.1074/jbc.M009341200; BERGERON A, 2005, J BIOL CHEM; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; CITRON BA, 1992, P NATL ACAD SCI USA, V89, P11891, DOI 10.1073/pnas.89.24.11891; Davis MW, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-118; Dieter MZ, 2003, FREE RADICAL BIO MED, V35, P351, DOI 10.1016/S0891-5849(03)00273-9; Dong MQ, 2007, SCIENCE, V317, P660, DOI 10.1126/science.1139952; ENDO F, 1983, PEDIATR RES, V17, P92, DOI 10.1203/00006450-198302000-00002; Endo F, 1997, J BIOL CHEM, V272, P24426, DOI 10.1074/jbc.272.39.24426; Fernandez-Canon JM, 2002, MOL CELL BIOL, V22, P4943, DOI 10.1128/MCB.22.13.4943-4951.2002; FERNANDEZCANON JM, 1995, P NATL ACAD SCI USA, V92, P9132, DOI 10.1073/pnas.92.20.9132; Fisher AL, 2006, AGING CELL, V5, P127, DOI 10.1111/j.1474-9726.2006.00203.x; GOLDSMITH LA, 1973, J PEDIATR-US, V83, P798, DOI 10.1016/S0022-3476(73)80372-5; GROMPE M, 1993, GENE DEV, V7, P2298, DOI 10.1101/gad.7.12a.2298; Henderson ST, 2001, CURR BIOL, V11, P1975, DOI 10.1016/S0960-9822(01)00594-2; Hodgkin J, 1999, PRACT APPROACH SER, V213, P245; Jorquera R, 1999, FASEB J, V13, P2284, DOI 10.1096/fasebj.13.15.2284; Jorquera R, 1997, BIOCHEM BIOPH RES CO, V232, P42, DOI 10.1006/bbrc.1997.6220; Jorquera R, 2001, HUM MOL GENET, V10, P1741, DOI 10.1093/hmg/10.17.1741; Kamath RS, 2003, METHODS, V30, P313, DOI 10.1016/S1046-2023(03)00050-1; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; KELSEY G, 1993, GENE DEV, V7, P2285, DOI 10.1101/gad.7.12a.2285; KNOX WE, 1955, METHOD ENZYMOL, V2, P287, DOI 10.1016/S0076-6879(55)02202-7; Kubo S, 1998, P NATL ACAD SCI USA, V95, P9552, DOI 10.1073/pnas.95.16.9552; Laberge C, 1986, Adv Exp Med Biol, V206, P209; LADU BN, 1958, J BIOL CHEM, V230, P251; Lee SS, 2003, SCIENCE, V300, P644, DOI 10.1126/science.1083614; LINDBLAD B, 1977, P NATL ACAD SCI USA, V74, P4641, DOI 10.1073/pnas.74.10.4641; Link CD, 1999, CELL STRESS CHAPERON, V4, P235, DOI 10.1379/1466-1268(1999)004<0235:DOOSRI>2.3.CO;2; Link CD, 2002, METHOD ENZYMOL, V353, P497; MADURO M, 1995, GENETICS, V141, P977; Manning K, 1999, P NATL ACAD SCI USA, V96, P11928, DOI 10.1073/pnas.96.21.11928; McElwee J, 2003, AGING CELL, V2, P111, DOI 10.1046/j.1474-9728.2003.00043.x; McElwee JJ, 2004, J BIOL CHEM, V279, P44533, DOI 10.1074/jbc.M406207200; McKay SJ, 2003, COLD SPRING HARB SYM, V68, P159, DOI 10.1101/sqb.2003.68.159; MITCHELL GA, 2001, METABOLIC MOL BASES, P1777; Moran GR, 2005, ARCH BIOCHEM BIOPHYS, V433, P117, DOI 10.1016/j.abb.2004.08.015; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; NATT E, 1987, HUM GENET, V77, P352, DOI 10.1007/BF00291426; Nollen EAA, 2004, P NATL ACAD SCI USA, V101, P6403, DOI 10.1073/pnas.0307697101; PHANEUF D, 1991, AM J HUM GENET, V48, P525; Pitkanen ST, 2000, ANN MED, V32, P530, DOI 10.3109/07853890008998832; Praitis V, 2001, GENETICS, V157, P1217; Rual JF, 2004, GENOME RES, V14, P2162, DOI 10.1101/gr.2505604; RUSSO P, 1990, AM J HUM GENET, V47, P317; Simmer F, 2002, CURR BIOL, V12, P1317, DOI 10.1016/S0960-9822(02)01041-2; StLouis M, 1997, HUM MUTAT, V9, P291, DOI 10.1002/(SICI)1098-1004(1997)9:4<291::AID-HUMU1>3.0.CO;2-9; Sulston J., 1988, NEMATODE CAENORHABDI, P587; Sun MS, 2000, J AM SOC NEPHROL, V11, P291, DOI 10.1681/ASN.V112291; Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Timm DE, 1999, STRUCTURE, V7, P1023, DOI 10.1016/S0969-2126(99)80170-1; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; Titus GP, 2000, NAT STRUCT BIOL, V7, P542	58	32	40	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9127	9135		10.1074/jbc.M708341200	http://dx.doi.org/10.1074/jbc.M708341200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18227072	Green Published, hybrid			2022-12-25	WOS:000254465800042
J	Gauntlett, JC; Gebhard, S; Keis, S; Manson, JM; Pos, KM; Cook, GM				Gauntlett, Jonathan C.; Gebhard, Susanne; Keis, Stefanie; Manson, Janet M.; Pos, Klaas M.; Cook, Gregory M.			Molecular analysis of BcrR, a membrane-bound bacitracin sensor and DNA-binding protein from Enterococcus faecalis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY PROTEIN; VIBRIO-CHOLERAE; BACILLUS-SUBTILIS; ABC-TRANSPORTER; ACTIVATOR TOXR; RESISTANCE; EXPRESSION; REPRESSOR; PROMOTER; SYSTEM	BcrR has been identified as a novel regulatory protein of high level bacitracin resistance encoded by the bcrABD operon in Enterococcus faecalis. The N-terminal domain of BcrR has similarity to the helix-turn-helix motif of DNA-binding proteins, and topological modeling predicts that the C-terminal domain contains four transmembrane alpha-helices. These data have led to the hypothesis that BcrR functions as both a membrane- bound sensor and transducer of bacitracin availability to regulate bcrABD expression. To characterize the bcrABD promoter and identify the promoter elements to which BcrR binds, a series of bcrA-lacZ fusions were constructed. A 69-bp region was identified that was essential for bacitracin-dependent bcrA-lacZ expression. Mutations that targeted this region were used to identify two inverted repeat sequences, each with the sequence 5'-GACA(N)(7)TGTC-3', on the bcrABD promoter that were required for bcrA-lacZ expression. To study BcrR binding to this region, we overproduced BcrR with a C-terminal hexa-histidine tag in Escherichia coli membranes, extracted the protein with n-dodecyl-beta-D-maltoside, and subsequently purified it via Ni2+-nitrilotriacetic acid and gel filtration chromatography to apparent homogeneity. Purified BcrR was reconstituted into liposomes, and BcrR binding to bcrABD promoter DNA was analyzed using electrophoretic mobility shift assays. Both inverted repeat sequences were required for BcrR binding, both in the presence and absence of bacitracin. These data demonstrate that membrane- bound BcrR binds specifically to the bcrABD promoter, irrespective of bacitracin concentration. We therefore propose that bacitracin-dependent induction of bcrABD expression by BcrR occurs after DNA binding.	[Gauntlett, Jonathan C.; Gebhard, Susanne; Keis, Stefanie; Manson, Janet M.; Cook, Gregory M.] Univ Otago, Dept Microbiol & Immunol, Otago Sch Med Sci, Dunedin 9016, New Zealand; [Pos, Klaas M.] Univ Zurich, Inst Physiol, Zurich, Switzerland; [Pos, Klaas M.] Univ Zurich, Zurich Ctr Integrat Human Physiol, Zurich, Switzerland	University of Otago; University of Zurich; University of Zurich; Zurich Center Integrative Human Physiology (ZIHP)	Cook, GM (corresponding author), Univ Otago, Dept Microbiol & Immunol, Otago Sch Med Sci, POB 56, Dunedin 9016, New Zealand.	greg.cook@stonebow.otago.ac.nz	Cook, Gregory/E-5665-2011; Gebhard, Susanne/F-4154-2012	Gebhard, Susanne/0000-0003-4783-6115				AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; ANDERSON JS, 1965, P NATL ACAD SCI USA, V53, P881, DOI 10.1073/pnas.53.4.881; Bernard R, 2007, J BACTERIOL, V189, P8636, DOI 10.1128/JB.01132-07; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; Cho JH, 1998, MOL CELL BIOL, V18, P5712, DOI 10.1128/MCB.18.10.5712; Gebhard S, 2006, MICROBIOL-SGM, V152, P3453, DOI 10.1099/mic.0.29201-0; Haas W, 2002, NATURE, V415, P84, DOI 10.1038/415084a; HANAHAN D, 1991, METHOD ENZYMOL, V204, P63; Higgins DE, 1996, J BACTERIOL, V178, P1080, DOI 10.1128/jb.178.4.1080-1087.1996; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hung DT, 2005, P NATL ACAD SCI USA, V102, P3028, DOI 10.1073/pnas.0409559102; JACOB AE, 1974, J BACTERIOL, V117, P360, DOI 10.1128/JB.117.2.360-372.1974; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; Knol J, 1998, BIOCHEMISTRY-US, V37, P16410, DOI 10.1021/bi981596u; Kristich CJ, 2007, P NATL ACAD SCI USA, V104, P3508, DOI 10.1073/pnas.0608742104; Kuper C, 2005, J MOL MICROB BIOTECH, V10, P26, DOI 10.1159/000090346; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Letunic I, 2006, NUCLEIC ACIDS RES, V34, pD257, DOI 10.1093/nar/gkj079; Manson JM, 2004, ANTIMICROB AGENTS CH, V48, P3743, DOI 10.1128/AAC.48.10.3743-3748.2004; Manson JM, 2003, ANTIMICROB AGENTS CH, V47, P204, DOI 10.1128/AAC.47.1.204-210.2003; Marchler-Bauer A, 2007, NUCLEIC ACIDS RES, V35, pD237, DOI 10.1093/nar/gkl951; Meijer WJJ, 2001, MOL MICROBIOL, V39, P731, DOI 10.1046/j.1365-2958.2001.02260.x; MILLER VL, 1987, CELL, V48, P271, DOI 10.1016/0092-8674(87)90430-2; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Neumuller AM, 2001, EUR J BIOCHEM, V268, P3180, DOI 10.1046/j.1432-1327.2001.02203.x; Ohki R, 2003, MOL MICROBIOL, V49, P1135, DOI 10.1046/j.1365-2958.2003.03653.x; Osorio CR, 2000, J BACTERIOL, V182, P526, DOI 10.1128/JB.182.2.526-528.2000; Poyart C, 1997, FEMS MICROBIOL LETT, V156, P193, DOI 10.1016/S0378-1097(97)00423-0; Provenzano D, 2000, INFECT IMMUN, V68, P1491, DOI 10.1128/IAI.68.3.1491-1497.2000; Rumpel S, 2004, EMBO J, V23, P3632, DOI 10.1038/sj.emboj.7600367; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shepard B D, 1995, Methods Mol Biol, V47, P217; Shi K, 2005, P NATL ACAD SCI USA, V102, P18596, DOI 10.1073/pnas.0506163102; SMITH H, 1983, J BACTERIOL, V156, P101, DOI 10.1128/JB.156.1.101-108.1983; STONE KJ, 1971, P NATL ACAD SCI USA, V68, P3223, DOI 10.1073/pnas.68.12.3223; Tsuda H, 2002, ANTIMICROB AGENTS CH, V46, P3756, DOI 10.1128/AAC.46.12.3756-3764.2002; Ulrich LE, 2005, TRENDS MICROBIOL, V13, P52, DOI 10.1016/j.tim.2004.12.006; WOOD HE, 1990, GENE, V96, P83, DOI 10.1016/0378-1119(90)90344-Q	40	22	25	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8591	8600		10.1074/jbc.M709503200	http://dx.doi.org/10.1074/jbc.M709503200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18227063	Green Accepted, hybrid			2022-12-25	WOS:000254288000058
J	Lavery, GG; Walker, EA; Turan, N; Rogoff, D; Ryder, JW; Shelton, JM; Richardson, JA; Falciani, F; White, PC; Stewart, PM; Parker, KL; McMillan, DR				Lavery, Gareth G.; Walker, Elizabeth A.; Turan, Nil; Rogoff, Daniela; Ryder, Jeffery W.; Shelton, John M.; Richardson, James A.; Falciani, Francesco; White, Perrin C.; Stewart, Paul M.; Parker, Keith L.; McMillan, Daniel R.			Deletion of hexose-6-phosphate dehydrogenase activates the unfolded protein response pathway and induces skeletal myopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIALLY EXPRESSED GENES; ER-ASSOCIATED DEGRADATION; MUSCLE FIBER-TYPE; ENDOPLASMIC-RETICULUM; TRANSCRIPTIONAL COACTIVATOR; BODY MYOPATHY; MICE; CALCINEURIN; STRESS; TYPE-1	Hexose-6-phosphate dehydrogenase (H6PD) is the initial component of a pentose phosphate pathway inside the endoplasmic reticulum (ER) that generates NADPH for ER enzymes. In liver H6PD is required for the 11-oxoreductase activity of 11 beta-hydroxysteroid dehydrogenase type 1, which converts inactive 11-oxo-glucocorticoids to their active 11-hydroxyl counterparts; consequently, H6PD null mice are relatively insensitive to glucocorticoids, exhibiting fasting hypoglycemia, increased insulin sensitivity despite elevated circulating levels of corticosterone, and increased basal and insulin-stimulated glucose uptake in muscles normally enriched in type II (fast) fibers, which have increased glycogen content. Here, we show that H6PD null mice develop a severe skeletal myopathy characterized by switching of type II to type I (slow) fibers. Running wheel activity and electrically stimulated force generation in isolated skeletal muscle are both markedly reduced. Affected muscles have normal sarcomeric structure at the electron microscopy level but contain large intrafibrillar membranous vacuoles and abnormal triads indicative of defects in structure and function of the sarcoplasmic reticulum (SR). SR proteins involved in calcium metabolism, including the sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA), calreticulin, and calsequestrin, show dysregulated expression. Microarray analysis and real-time PCR demonstrate overexpression of genes encoding proteins in the unfolded protein response pathway. We propose that the absence of H6PD induces a progressive myopathy by altering the SR redox state, thereby impairing protein folding and activating the unfolded protein response pathway. These studies thus define a novel metabolic pathway that links ER stress to skeletal muscle integrity and function.	[Lavery, Gareth G.; Walker, Elizabeth A.; Stewart, Paul M.] Univ Birmingham, Div Med Sci, Birmingham B15 2TH, W Midlands, England; [Turan, Nil; Falciani, Francesco] Univ Birmingham, Sch Biosci, Birmingham B15 2TH, W Midlands, England; [Lavery, Gareth G.; Shelton, John M.; Parker, Keith L.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA; [Rogoff, Daniela; White, Perrin C.; McMillan, Daniel R.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA; [Ryder, Jeffery W.] Univ Texas SW Med Ctr Dallas, Dept Physiol, Dallas, TX 75390 USA; [Richardson, James A.] Univ Texas SW Med Ctr Dallas, Dept Pathol & Mol Biol, Dallas, TX 75390 USA	University of Birmingham; University of Birmingham; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	McMillan, DR (corresponding author), 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	daniel.mcmillan@UTSouthwestern.edu	Falciani, Francesco/F-3490-2010; Lavery, Gareth/F-9346-2010		NHLBI NIH HHS [T32 HL 007360] Funding Source: Medline; NIDDK NIH HHS [DK 068101, DK 54480] Funding Source: Medline; Wellcome Trust [066357, 074088/Z/04/Z] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054480, R01DK068101] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acosta-Alvear D, 2007, MOL CELL, V27, P53, DOI 10.1016/j.molcel.2007.06.011; Banhegyi G, 1997, J BIOL CHEM, V272, P13584, DOI 10.1074/jbc.272.21.13584; Bassel-Duby R, 2006, ANNU REV BIOCHEM, V75, P19, DOI 10.1146/annurev.biochem.75.103004.142622; Bernales S, 2006, ANNU REV CELL DEV BI, V22, P487, DOI 10.1146/annurev.cellbio.21.122303.120200; Bujalska IJ, 2005, J MOL ENDOCRINOL, V34, P675, DOI 10.1677/jme.1.01718; Bush E, 2004, P NATL ACAD SCI USA, V101, P2870, DOI 10.1073/pnas.0308723101; Calvano SE, 2005, NATURE, V437, P1032, DOI 10.1038/nature03985; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Coll AP, 2005, DIABETES, V54, P2269, DOI 10.2337/diabetes.54.8.2269; Corton JC, 2005, J GERONTOL A-BIOL, V60, P1494, DOI 10.1093/gerona/60.12.1494; Dulhunty AF, 2006, CLIN EXP PHARMACOL P, V33, P763, DOI 10.1111/j.1440-1681.2006.04441.x; FRANZINIARMSTRONG C, 1987, J CELL BIOL, V105, P49, DOI 10.1083/jcb.105.1.49; FUENTES JJ, 1995, HUM MOL GENET, V4, P1935, DOI 10.1093/hmg/4.10.1935; Harris CD, 2005, CELL MOL LIFE SCI, V62, P2477, DOI 10.1007/s00018-005-5085-4; Hori H, 1999, J BIOCHEM-TOKYO, V126, P722, DOI 10.1093/oxfordjournals.jbchem.a022509; Jain N, 2003, BIOINFORMATICS, V19, P1945, DOI 10.1093/bioinformatics/btg264; Kotelevtsev Y, 1997, P NATL ACAD SCI USA, V94, P14924, DOI 10.1073/pnas.94.26.14924; Lavery GG, 2007, ENDOCRINOLOGY, V148, P6100, DOI 10.1210/en.2007-0963; Lavery GG, 2006, J BIOL CHEM, V281, P6546, DOI 10.1074/jbc.M512635200; Leahy KP, 1999, ARCH BIOCHEM BIOPHYS, V368, P67, DOI 10.1006/abbi.1998.1059; LEFAUCHEUR JP, 1995, ANAT REC, V242, P70, DOI 10.1002/ar.1092420109; Liewluck T, 2007, MUSCLE NERVE, V35, P322, DOI 10.1002/mus.20691; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Manchester J, 1996, P NATL ACAD SCI USA, V93, P10707, DOI 10.1073/pnas.93.20.10707; Mason PJ, 1999, BLOOD CELL MOL DIS, V25, P30, DOI 10.1006/bcmd.1999.0224; MASON R M, 1984, Journal of Orthopaedic Research, V2, P333, DOI 10.1002/jor.1100020405; MORISAKI T, 1992, P NATL ACAD SCI USA, V89, P6457, DOI 10.1073/pnas.89.14.6457; O'Brien KM, 2003, J EXP BIOL, V206, P411, DOI 10.1242/jeb.00088; Oda Y, 2006, J CELL BIOL, V172, P383, DOI 10.1083/jcb.200507057; OGILVIE RW, 1990, STAIN TECHNOL, V65, P231, DOI 10.3109/10520299009105613; Olson EN, 2000, BIOESSAYS, V22, P510, DOI 10.1002/(SICI)1521-1878(200006)22:6<510::AID-BIES4>3.3.CO;2-T; Piccirella S, 2006, J BIOL CHEM, V281, P4671, DOI 10.1074/jbc.M509406200; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877; Rogoff D, 2007, ENDOCRINOLOGY, V148, P5072, DOI 10.1210/en.2007-0593; Rothermel BA, 2003, TRENDS CARDIOVAS MED, V13, P15, DOI 10.1016/S1050-1738(02)00188-3; Ryder JW, 2003, J BIOL CHEM, V278, P44298, DOI 10.1074/jbc.M304510200; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; Schroder M, 2006, MOL BIOTECHNOL, V34, P279, DOI 10.1385/MB:34:2:279; SHEHAN DC, 1980, THEORY PRACTICE HIST; Sriburi R, 2004, J CELL BIOL, V167, P35, DOI 10.1083/jcb.200406136; Tomlinson JW, 2004, ENDOCR REV, V25, P831, DOI 10.1210/er.2003-0031; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Vattemi G, 2004, AM J PATHOL, V164, P1, DOI 10.1016/S0002-9440(10)63089-1; Watts GDJ, 2004, NAT GENET, V36, P377, DOI 10.1038/ng1332; Woods A.E., 1996, LAB HISTOPATHOLOGY C; Wu J, 2006, CELL DEATH DIFFER, V13, P374, DOI 10.1038/sj.cdd.4401840; Yoshida H, 2007, FEBS J, V274, P630, DOI 10.1111/j.1742-4658.2007.05639.x	48	66	67	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8453	8461		10.1074/jbc.M710067200	http://dx.doi.org/10.1074/jbc.M710067200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18222920	Green Published, hybrid			2022-12-25	WOS:000254288000043
J	Taniguchi, N; Tokuda, H				Taniguchi, Naohiro; Tokuda, Hajime			Molecular events involved in a single cycle of ligand transfer from an ATP binding cassette transporter, LolCDE, to a molecular chaperone, LolA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI LIPOPROTEINS; ABC TRANSPORTER; OUTER-MEMBRANE; MALTOSE TRANSPORT; CYTOPLASMIC MEMBRANE; CRYSTAL-STRUCTURE; SORTING SIGNALS; INNER MEMBRANE; ACTIVE-SITE; LOCALIZATION	An ATP binding cassette transporter LolCDE complex releases lipoproteins from the inner membrane of Escherichia coli in an ATP-dependent manner, leading to the formation of a complex between a lipoprotein and a periplasmic chaperone, LolA. LolA is proposed to undergo a conformational change upon the lipoprotein binding. The lipoprotein is then transferred from the LolA-lipoprotein complex to the outer membrane via LolB. Unlike most ATP binding cassette transporters mediating the transmembrane flux of substrates, the LolCDE complex catalyzes the extrusion of lipoproteins anchored to the outer leaflet of the inner membrane. Moreover, the LolCDE complex is unique in that it can be purified as a liganded form, which is an intermediate of the lipoprotein release reaction. Taking advantage of these unique properties, we established an assay system that enabled the analysis of a single cycle of lipoprotein transfer reaction from liganded LolCDE to LolA in a detergent solution. The LolA-lipoprotein complex thus formed was physiologically functional and delivered lipoproteins to the outer membrane in a LolB-dependent manner. Vanadate, a potent inhibitor of the lipoprotein release from proteoliposomes, was found to inhibit the release of ADP from LolCDE. However, a single cycle of lipoprotein transfer occurred from vanadate-treated LolCDE to LolA, indicating that vanadate traps LolCDE at the energized state.	[Taniguchi, Naohiro; Tokuda, Hajime] Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	University of Tokyo	Tokuda, H (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	htokuda@iam.u-tokyo.ac.jp	Taniguchi, Naoyuki/A-7086-2016					Chen J, 2001, P NATL ACAD SCI USA, V98, P1525, DOI 10.1073/pnas.041542498; Davidson AL, 2004, ANNU REV BIOCHEM, V73, P241, DOI 10.1146/annurev.biochem.73.011303.073626; DAVIDSON AL, 1991, J BIOL CHEM, V266, P8946; Dawson RJP, 2006, NATURE, V443, P180, DOI 10.1038/nature05155; GOODNO CC, 1982, METHOD ENZYMOL, V85, P116; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; Higgins CF, 2004, NAT STRUCT MOL BIOL, V11, P918, DOI 10.1038/nsmb836; HIROTA Y, 1977, P NATL ACAD SCI USA, V74, P1417, DOI 10.1073/pnas.74.4.1417; HUSSAIN M, 1980, J BIOL CHEM, V255, P3707; Ito Y, 2006, MOL MICROBIOL, V62, P1064, DOI 10.1111/j.1365-2958.2006.05378.x; Kanamaru K, 2007, FEBS J, V274, P3034, DOI 10.1111/j.1742-4658.2007.05832.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Masuda K, 2002, P NATL ACAD SCI USA, V99, P7390, DOI 10.1073/pnas.112085599; MATSUYAMA S, 1995, EMBO J, V14, P3365, DOI 10.1002/j.1460-2075.1995.tb07342.x; MATSUYAMA S, 1997, EMBO J, V16, P6847; Miyamoto A, 2001, BIOCHEM BIOPH RES CO, V287, P1125, DOI 10.1006/bbrc.2001.5705; Miyamoto S, 2007, BBA-BIOMEMBRANES, V1768, P1848, DOI 10.1016/j.bbamem.2007.04.005; Narita S, 2002, J BACTERIOL, V184, P1417, DOI 10.1128/JB.184.5.1417-1422.2002; Oldham ML, 2007, NATURE, V450, P515, DOI 10.1038/nature06264; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; SANKARAN K, 1994, J BIOL CHEM, V269, P19701; Seydel A, 1999, MOL MICROBIOL, V34, P810, DOI 10.1046/j.1365-2958.1999.01647.x; Sharma S, 2000, J BACTERIOL, V182, P6570, DOI 10.1128/JB.182.23.6570-6576.2000; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Tajima T, 1998, FEBS LETT, V439, P51, DOI 10.1016/S0014-5793(98)01334-9; Takeda K, 2003, EMBO J, V22, P3199, DOI 10.1093/emboj/cdg324; Terada M, 2001, J BIOL CHEM, V276, P47690, DOI 10.1074/jbc.M109307200; Tokuda H, 2004, BBA-MOL CELL RES, V1693, P5, DOI 10.1016/j.bbamcr.2004.02.005; Tokuda H, 2007, PERIPLASM, P67; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; Watanabe S, 2006, J BIOL CHEM, V281, P3335, DOI 10.1074/jbc.M509596200; Yakushi T, 1998, J BIOL CHEM, V273, P32576, DOI 10.1074/jbc.273.49.32576; Yakushi T, 2000, NAT CELL BIOL, V2, P212, DOI 10.1038/35008635; YAMAGUCHI K, 1988, CELL, V53, P423, DOI 10.1016/0092-8674(88)90162-6; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yokota N, 1999, J BIOL CHEM, V274, P30995, DOI 10.1074/jbc.274.43.30995; Yuan YR, 2001, J BIOL CHEM, V276, P32313, DOI 10.1074/jbc.M100758200	37	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8538	8544		10.1074/jbc.M800026200	http://dx.doi.org/10.1074/jbc.M800026200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18218629	hybrid, Green Published			2022-12-25	WOS:000254288000052
J	Muik, M; Frischauf, I; Derler, I; Fahrner, M; Bergsmann, J; Eder, P; Schindl, R; Hesch, C; Polzinger, B; Fritsch, R; Kahr, H; Madl, J; Gruber, H; Groschner, K; Romanin, C				Muik, Martin; Frischauf, Irene; Derler, Isabella; Fahrner, Marc; Bergsmann, Judith; Eder, Petra; Schindl, Rainer; Hesch, Clemens; Polzinger, Bernhard; Fritsch, Reinhard; Kahr, Heike; Madl, Josef; Gruber, Hermann; Groschner, Klaus; Romanin, Christoph			Dynamic coupling of the putative coiled-coil domain of ORAI1 with STIM1 mediates ORAI1 channel activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPERATED CA2+ ENTRY; PLASMA-MEMBRANE; CRAC CHANNEL; CALCIUM-ENTRY; ENDOPLASMIC-RETICULUM; STORE DEPLETION; PROTEINS; INFLUX; RELEASE; CALMODULIN	STIM1 and ORAI1 (also termed CRACM1) are essential components of the classical calcium release-activated calcium current; however, the mechanism of the transmission of information of STIM1 to the calcium release-activated calcium/ORAI1 channel is as yet unknown. Here we demonstrate by Forster resonance energy transfer microscopy a dynamic coupling of STIM1 and ORAI1 that culminates in the activation of Ca2+ entry. Forster resonance energy transfer imaging of living cells provided insight into the time dependence of crucial events of this signaling pathway comprising Ca2+ store depletion, STIM1 multimerization, and STIM1-ORAI1 interaction. Accelerated store depletion allowed resolving a significant time lag between STIM1-STIM1 and STIM1-ORAI1 interactions. Store refilling reversed both STIM1 multimerization and STIM1-ORAI1 interaction. The cytosolic STIM1 C terminus itself was able, in vitro as well as in vivo, to associate with ORAI1 and to stimulate channel function, yet without ORAI1-STIM1 cluster formation. The dynamic interaction occurred via the C terminus of ORAI1 that includes a putative coiled-coil domain structure. An ORAI1 C terminus deletion mutant as well as a mutant (L273S) with impeded coiled-coil domain formation lacked both interaction as well as functional communication with STIM1 and failed to generate Ca2+ inward currents. An N-terminal deletion mutant of ORAI1 as well as the ORAI1 R91W mutant linked to severe combined immune deficiency syndrome was similarly impaired in terms of current activation despite being able to interact with STIM1. Hence, the C-terminal coiled-coil motif of ORAI1 represents a key domain for dynamic coupling to STIM1.	[Muik, Martin; Frischauf, Irene; Derler, Isabella; Fahrner, Marc; Bergsmann, Judith; Schindl, Rainer; Hesch, Clemens; Polzinger, Bernhard; Fritsch, Reinhard; Kahr, Heike; Madl, Josef; Gruber, Hermann; Romanin, Christoph] Univ Linz, Inst Biophys, A-4040 Linz, Austria; [Eder, Petra; Groschner, Klaus] Graz Univ, Dept Pharm, A-8010 Graz, Austria	Johannes Kepler University Linz; University of Graz	Romanin, C (corresponding author), Univ Linz, Inst Biophys, A-4040 Linz, Austria.	christoph.romanin@jku.at	Fahrner, Marc/AAI-7927-2021; Derler, Isabella/B-7871-2019; Romanin, Christoph/D-5399-2009; Schindl, Rainer/V-4205-2019; Schindl, Rainer/E-3959-2013; Groschner, Klaus/A-2550-2010; Frischauf, Irene/AAG-2007-2019	Derler, Isabella/0000-0002-4768-146X; Romanin, Christoph/0000-0003-3756-4136; Schindl, Rainer/0000-0003-0896-8887; Groschner, Klaus/0000-0002-8659-377X; Frischauf, Irene/0000-0003-0661-2932; Fahrner, Marc/0000-0002-2689-0158				Baba Y, 2006, P NATL ACAD SCI USA, V103, P16704, DOI 10.1073/pnas.0608358103; Berney C, 2003, BIOPHYS J, V84, P3992, DOI 10.1016/S0006-3495(03)75126-1; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Cahalan MD, 2007, CELL CALCIUM, V42, P133, DOI 10.1016/j.ceca.2007.03.002; Chakrabarti R, 2006, J CELL BIOCHEM, V99, P1503, DOI 10.1002/jcb.21102; Derler I, 2006, J PHYSIOL-LONDON, V577, P31, DOI 10.1113/jphysiol.2006.118661; Dutta D, 2000, J BIOSCIENCE, V25, P397, DOI 10.1007/BF02703793; Dziadek MA, 2007, CELL CALCIUM, V42, P123, DOI 10.1016/j.ceca.2007.02.006; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Gross SA, 2007, J BIOL CHEM, V282, P19375, DOI 10.1074/jbc.M701962200; Gwack Y, 2007, J BIOL CHEM, V282, P16232, DOI 10.1074/jbc.M609630200; Huang GN, 2006, NAT CELL BIOL, V8, P1003, DOI 10.1038/ncb1454; JODY M, 2004, CHEM BIO CHEM, V5, P170; Liao Y, 2007, P NATL ACAD SCI USA, V104, P4682, DOI 10.1073/pnas.0611692104; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; LIOU J, 2007, T P NATL ACAD SCI US, V104, P9301; Luik RM, 2006, J CELL BIOL, V174, P815, DOI 10.1083/jcb.200604015; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Parekh AB, 2006, NATURE, V441, P163, DOI 10.1038/441163a; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Parekh AB, 2006, NAT CELL BIOL, V8, P655, DOI 10.1038/ncb0706-655; Peinelt C, 2006, NAT CELL BIOL, V8, P771, DOI 10.1038/ncb1435; Prakriya M, 2002, J GEN PHYSIOL, V119, P487, DOI 10.1085/jgp.20028551; Prakriya M, 2006, NATURE, V443, P230, DOI 10.1038/nature05122; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Singh A, 2006, NAT NEUROSCI, V9, P1108, DOI 10.1038/nn1751; Smani T, 2004, NAT CELL BIOL, V6, P113, DOI 10.1038/ncb1089; Smyth JT, 2006, BBA-MOL CELL RES, V1763, P1147, DOI 10.1016/j.bbamcr.2006.08.050; Soboloff J, 2006, J BIOL CHEM, V281, P20661, DOI 10.1074/jbc.C600126200; Spassova MA, 2004, BBA-MOL CELL RES, V1742, P9, DOI 10.1016/j.bbamcr.2004.09.001; Takahashi Y, 2007, BIOCHEM BIOPH RES CO, V356, P45, DOI 10.1016/j.bbrc.2007.02.107; Varnai P, 2007, J BIOL CHEM, V282, P29678, DOI 10.1074/jbc.M704339200; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Vig M, 2006, CURR BIOL, V16, P2073, DOI 10.1016/j.cub.2006.08.085; Woolfson DN, 2005, ADV PROTEIN CHEM, V70, P79, DOI 10.1016/S0065-3233(04)70004-2; Wu MM, 2006, J CELL BIOL, V174, P803, DOI 10.1083/jcb.200604014; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Xu PY, 2006, BIOCHEM BIOPH RES CO, V350, P969, DOI 10.1016/j.bbrc.2006.09.134; Yeromin AV, 2006, NATURE, V443, P226, DOI 10.1038/nature05108; Zhang SL, 2006, P NATL ACAD SCI USA, V103, P9357, DOI 10.1073/pnas.0603161103	40	317	327	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					8014	8022		10.1074/jbc.M708898200	http://dx.doi.org/10.1074/jbc.M708898200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18187424	hybrid			2022-12-25	WOS:000253997900076
J	Dammer, EB; Sewer, MB				Dammer, Eric B.; Sewer, Marion B.			Phosphorylation of CtBP1 by cAMP-dependent protein kinase modulates induction of CYP17 by stimulating partnering of CtBP1 and 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE-ADENINE-DINUCLEOTIDE; TERMINAL BINDING-PROTEIN; TRANSCRIPTIONAL COREPRESSOR; BENZO(A)PYRENE METABOLISM; NUCLEAR-LOCALIZATION; ADENOVIRUS E1A; CO-REPRESSOR; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; RIP140; ACETYLATION	In the human adrenal cortex, the peptide hormone adrenocorticotropin (ACTH) directs cortisol and adrenal androgen biosynthesis by activating a cAMP/cAMP-dependent protein kinase (PKA) pathway. Carboxyl-terminal binding protein 1 (CtBP1) is a corepressor that regulates transcription of the CYP17 gene by periodically interacting with steroidogenic factor-1 in response to ACTH signaling. Given that CtBP1 function is regulated by NADH binding, we hypothesized that ACTH-stimulated changes in cellular pyridine nucleotide concentrations modulate the ability of CtBP1 to repress CYP17 transcription. Further, we postulated that PKA evokes changes in the phosphorylation status of CtBP1 that control the ability of the protein to bind to steroidogenic factor-1 and the coactivator GCN5 (general control nonderepressed 5) and repress CYP17 gene expression. We show that ACTH alters pyridine nucleotide redox state and identify amino acid residues in CtBP1 that are targeted by PKA and PAK6. Both ACTH/cAMP signaling and NADH/NAD(+) ratio stimulate nuclear-cytoplasmic oscillation of both CtBP proteins. We provide evidence that PKA 1) induces metabolic changes in the adrenal cortex and 2) phosphorylates CtBP proteins, particularly CtBP1 at T144, resulting in CtBP protein partnering and ACTH-dependent CYP17 transcription.	Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA; Georgia Inst Technol, Parker H Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA	University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology	Sewer, MB (corresponding author), Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA.	marion.sewer@biology.gatech.edu	Dammer, Eric B/V-8652-2019	Dammer, Eric B/0000-0003-2947-7606	NIGMS NIH HHS [GM073241, R01 GM073241, R56 GM073241, R01 GM073241-05] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM073241, R56GM073241] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Achouri Y, 2007, BIOCHEM BIOPH RES CO, V352, P903, DOI 10.1016/j.bbrc.2006.11.111; Alpatov R, 2004, MOL CELL BIOL, V24, P10223, DOI 10.1128/MCB.24.23.10223-10235.2004; Balasubramanian P, 2003, FEBS LETT, V537, P157, DOI 10.1016/S0014-5793(03)00119-4; Barnes CJ, 2003, NAT STRUCT BIOL, V10, P622, DOI 10.1038/nsb957; Bartholin L, 2006, MOL CELL BIOL, V26, P990, DOI 10.1128/MCB.26.3.990-1001.2006; Castet A, 2004, NUCLEIC ACIDS RES, V32, P1957, DOI 10.1093/nar/gkh524; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; Christian M, 2004, J BIOL CHEM, V279, P15645, DOI 10.1074/jbc.M313906200; Dammer EB, 2007, MOL ENDOCRINOL, V21, P415, DOI 10.1210/me.2006-0361; FEO F, 1987, INT J CANCER, V39, P560, DOI 10.1002/ijc.2910390504; Fjeld CC, 2003, P NATL ACAD SCI USA, V100, P9202, DOI 10.1073/pnas.1633591100; Frederiks WM, 2007, J HISTOCHEM CYTOCHEM, V55, P975, DOI 10.1369/jhc.7A7222.2007; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Kim JH, 2005, NAT STRUCT MOL BIOL, V12, P423, DOI 10.1038/nsmb924; Kumar V, 2002, MOL CELL, V10, P857, DOI 10.1016/S1097-2765(02)00650-0; Lopez-Garcia J, 2006, NUCLEIC ACIDS RES, V34, P6126, DOI 10.1093/nar/gkl875; Mellgren G, 2003, MOL CELL ENDOCRINOL, V203, P91, DOI 10.1016/S0303-7207(03)00097-2; MOUNTJOY KG, 1994, MOL CELL ENDOCRINOL, V99, pR17, DOI 10.1016/0303-7207(94)90160-0; PASCALE R, 1990, RES COMMUN CHEM PATH, V69, P361; Quinlan KGR, 2007, BBA-REV CANCER, V1775, P333, DOI 10.1016/j.bbcan.2007.05.001; Quinlan KGR, 2006, MOL CELL BIOL, V26, P8202, DOI 10.1128/MCB.00445-06; RATT H, 2003, AM J PHYSIOL, V284, pR78; ROSA LFBPC, 1995, BIOCHEM J, V310, P709, DOI 10.1042/bj3100709; SAAD MJA, 1991, HORM RES, V35, P1, DOI 10.1159/000181866; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Shorin Iu P, 1976, Biull Eksp Biol Med, V81, P173; STAELS B, 1993, MOL ENDOCRINOL, V7, P423, DOI 10.1210/me.7.3.423; Tazawa H, 2003, MOL CELL BIOL, V23, P4187, DOI 10.1128/MCB.23.12.4187-4198.2003; Thio SSC, 2004, NUCLEIC ACIDS RES, V32, P1836, DOI 10.1093/nar/gkh344; Verger A, 2006, MOL CELL BIOL, V26, P4882, DOI 10.1128/MCB.02402-05; Vo N, 2001, MOL CELL BIOL, V21, P6181, DOI 10.1128/MCB.21.18.6181-6188.2001; Wang JX, 2007, NATURE, V446, P882, DOI 10.1038/nature05671; Wei LN, 2001, J BIOL CHEM, V276, P16107, DOI 10.1074/jbc.M010185200; WILLIAMSON DH, 1967, BIOCHEM J, V103, P514, DOI 10.1042/bj1030514; Yang MJ, 2006, MOL CELL, V23, P377, DOI 10.1016/j.molcel.2006.07.012; Zhang QH, 2002, SCIENCE, V295, P1895; Zhang QH, 2007, P NATL ACAD SCI USA, V104, P829, DOI 10.1073/pnas.0610590104; Zhang QH, 2006, P NATL ACAD SCI USA, V103, P9029, DOI 10.1073/pnas.0603269103; Zhao LJ, 2006, J BIOL CHEM, V281, P4183, DOI 10.1074/jbc.M509051200	40	21	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					6925	6934		10.1074/jbc.M708432200	http://dx.doi.org/10.1074/jbc.M708432200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18184656	Green Accepted, hybrid			2022-12-25	WOS:000253779600036
J	Grossmann, C; Freudinger, R; Mildenberger, S; Husse, B; Gekle, M				Grossmann, Claudia; Freudinger, Ruth; Mildenberger, Sigrid; Husse, Britta; Gekle, Michael			EF domains are sufficient for nongenomic mineralocorticoid receptor actions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; NITRIC-OXIDE SYNTHASE; SMOOTH-MUSCLE-CELLS; ESTROGEN-RECEPTOR; HYPERTENSIVE-RATS; ANGIOTENSIN-II; PLASMA-MEMBRANE; GLUCOCORTICOID RECEPTOR; ENDOTHELIAL-CELLS; OXIDATIVE STRESS	The mineralocorticoid receptor ( MR) is important for salt homeostasis and reno-cardiovascular pathophysiology. Signaling mechanisms include, besides classical genomic pathways, nongenomic pathways with putative pathophysiological relevance involving the mitogen-activated protein kinases ERK1/2. We determined the MR domains required for nongenomic signaling and their potential to elicit pathophysiological effects in cultured cells under defined conditions. The expression of full-length human MR or truncated MR consisting of the domains CDEF (MRCDEF), DEF (MRDEF), or EF (MREF) renders cells responsive for the MR ligand aldosterone with respect to nongenomic ERK1/ 2 phosphorylation, whereas only full-length MR and MRCDEF conferred genomic responsiveness. ERK1/ 2 phosphorylation depends on the EGF receptor and cSRC kinase. MREF expression is sufficient to evoke the aldosterone-induced increase of collagen III levels, similar to full-length MR expression. Our data suggest that nongenomic MR signaling is mediated by the EF domains and present the first proof of principle showing that nongenomic signaling can be sufficient for some pathophysiological effects. The minimum amino acid motif required for nongenomic MR signaling and its importance in various effects have yet to be determined.	[Grossmann, Claudia; Freudinger, Ruth; Mildenberger, Sigrid; Husse, Britta; Gekle, Michael] Univ Halle Wittenberg, Julius Bernstein Inst Physiol, D-06097 Halle, Germany	Martin Luther University Halle Wittenberg	Gekle, M (corresponding author), Univ Halle Wittenberg, Julius Bernstein Inst Physiol, Magdeburger Str 6, D-06097 Halle, Germany.	michael.gekle@medizin.uni-halle.de						Alzamora R, 2000, HYPERTENSION, V35, P1099, DOI 10.1161/01.HYP.35.5.1099; Arima S, 2004, HYPERTENSION, V43, P352, DOI 10.1161/01.HYP.0000111138.78714.1a; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; Barletta F, 2004, MOL ENDOCRINOL, V18, P1096, DOI 10.1210/me.2003-0335; Bauersachs J, 2002, J AM COLL CARDIOL, V39, P351, DOI 10.1016/S0735-1097(01)01729-6; Blasi ER, 2003, KIDNEY INT, V63, P1791, DOI 10.1046/j.1523-1755.2003.00929.x; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; Callera GE, 2005, HYPERTENSION, V46, P1032, DOI 10.1161/01.HYP.0000176588.51027.35; CATO ACB, 2002, SCI STKE, V138, P1; Chambliss KL, 2005, MOL ENDOCRINOL, V19, P277, DOI 10.1210/me.2004-0008; Doolan CM, 1996, J BIOL CHEM, V271, P8763, DOI 10.1074/jbc.271.15.8763; Feng WJ, 2001, MOL ENDOCRINOL, V15, P32, DOI 10.1210/me.15.1.32; Fiebeler A, 2001, HYPERTENSION, V37, P787, DOI 10.1161/01.HYP.37.2.787; Filardo EJ, 2002, MOL ENDOCRINOL, V16, P70, DOI 10.1210/me.16.1.70; Flamant M, 2002, FASEB J, V16, P327, DOI 10.1096/fj.02-0115fje; Funder JW, 2005, ENDOCR REV, V26, P313, DOI 10.1210/er.2005-0004; Gekle M, 2002, AM J PHYSIOL-RENAL, V282, pF669, DOI 10.1152/ajprenal.00159.2001; Gekle M, 1996, P NATL ACAD SCI USA, V93, P10500, DOI 10.1073/pnas.93.19.10500; Gekle M, 2007, PFLUG ARCH EUR J PHY, V454, P403, DOI 10.1007/s00424-007-0211-9; Greger JG, 2007, MOL CELL BIOL, V27, P1904, DOI 10.1128/MCB.01732-06; Grossmann C, 2005, MOL ENDOCRINOL, V19, P1697, DOI 10.1210/me.2004-0469; Grossmann C, 2004, AM J PHYSIOL-RENAL, V286, pF1226, DOI 10.1152/ajprenal.00378.2003; Hafezi-Moghadam A, 2002, NAT MED, V8, P473, DOI 10.1038/nm0502-473; Haynes MP, 2000, CIRC RES, V87, P677, DOI 10.1161/01.RES.87.8.677; Hitomi H, 2007, HYPERTENSION, V50, P750, DOI 10.1161/HYPERTENSIONAHA.107.093955; Ishizawa K, 2005, HYPERTENSION, V46, P1046, DOI 10.1161/01.HYP.0000172622.51973.f5; Jaffe IZ, 2005, CIRC RES, V96, P643, DOI 10.1161/01.RES.0000159937.05502.d1; Kagiyama S, 2003, HYPERTENSION, V41, P824, DOI 10.1161/01.HYP.0000047104.42047.9B; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Krietsch T, 2006, MOL ENDOCRINOL, V20, P3146, DOI 10.1210/me.2006-0129; Krug AW, 2003, J BIOL CHEM, V278, P43060, DOI 10.1074/jbc.M308134200; Krug AW, 2002, J BIOL CHEM, V277, P45892, DOI 10.1074/jbc.M208851200; Kumar P, 2007, MOL ENDOCRINOL, V21, P1370, DOI 10.1210/me.2006-0360; Le Moellic C, 2004, J AM SOC NEPHROL, V15, P1145; Levin ER, 2003, MOL ENDOCRINOL, V17, P309, DOI 10.1210/me.2002-0368; Liu SL, 2003, CIRCULATION, V108, P2400, DOI 10.1161/01.CIR.0000093188.53554.44; Losel R, 2003, NAT REV MOL CELL BIO, V4, P46, DOI 10.1038/nrm1009; Mazak I, 2004, CIRCULATION, V109, P2792, DOI 10.1161/01.CIR.0000131860.80444.AB; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Min LJ, 2005, CIRC RES, V97, P434, DOI 10.1161/01.RES.0000180753.63183.95; Nagai Y, 2005, HYPERTENSION, V46, P1039, DOI 10.1161/01.HYP.0000174593.88899.68; Nakano S, 2005, HYPERTENS RES, V28, P925, DOI 10.1291/hypres.28.925; Ouvrard-Pascaud A, 2004, AM J PHYSIOL-RENAL, V286, pF180, DOI 10.1152/ajprenal.00301.2002; Pfau A, 2007, MOL CELL ENDOCRINOL, V264, P35, DOI 10.1016/j.mce.2006.10.002; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Rahman M, 2006, J PHARMACOL EXP THER, V318, P1323, DOI 10.1124/jpet.106.105106; Razandi M, 2003, MOL CELL BIOL, V23, P1633, DOI 10.1128/MCB.23.5.1633-1646.2003; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; RUPPRECHT R, 1993, MOL ENDOCRINOL, V7, P597, DOI 10.1210/me.7.4.597; Russell KS, 2000, P NATL ACAD SCI USA, V97, P5930, DOI 10.1073/pnas.97.11.5930; Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116; Stockand JD, 2002, AM J PHYSIOL-RENAL, V282, pF559, DOI 10.1152/ajprenal.00320.2001; Sun Y, 2002, AM J PATHOL, V161, P1773, DOI 10.1016/S0002-9440(10)64454-9; Tsybouleva N, 2004, CIRCULATION, V109, P1284, DOI 10.1161/01.CIR.0000121426.43044.2B; Uhrenholt TR, 2003, CIRC RES, V93, P1258, DOI 10.1161/01.RES.0000106135.02935.E1; Vasudevan N, 2001, P NATL ACAD SCI USA, V98, P12267, DOI 10.1073/pnas.221449798; Versteeg HH, 2000, BIOCHEM J, V350, P717, DOI 10.1042/0264-6021:3500717; Wyckoff MH, 2001, J BIOL CHEM, V276, P27071, DOI 10.1074/jbc.M100312200; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2231, DOI 10.1073/pnas.0336132100	59	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					7109	7116		10.1074/jbc.M708751200	http://dx.doi.org/10.1074/jbc.M708751200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18184651	hybrid			2022-12-25	WOS:000253779600056
J	Wyatt, K; Gao, C; Tsai, JY; Fariss, RN; Ray, S; Wistow, G				Wyatt, Keith; Gao, Chun; Tsai, Jen-Yue; Fariss, Robert N.; Ray, Sugata; Wistow, Graeme			A role for lengsin, a recruited enzyme, in terminal differentiation in the vertebrate lens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBER CELL-DIFFERENTIATION; FIBRILLARY ACIDIC PROTEIN; EYE LENS; GENE-EXPRESSION; NEIBANK PROJECT; VIMENTIN; FILENSIN; MOUSE; CYTOSKELETON; TRANSITION	Lengsin is an eye lens-specific member of the glutamine synthetase (GS) superfamily. Lengsin has no GS activity, suggesting that it has a structural rather than catalytic role in lens. In situ hybridization and immunofluorescence showed that lengsin is expressed in terminally differentiating secondary lens fiber cells. Yeast two-hybrid (Y2H) and recombinant protein experiments showed that full-length lengsin can bind the 2B filament region of vimentin. In affinity chromatography, lengsin also bound the equivalent region of CP49 (BFSP2; phakinin), a related intermediate filament protein specific to the lens. Both the vimentin and CP49 2B fragments bound lengsin in surface plasmon resonance spectroscopy with fast association and slow dissociation kinetics. Lengsin expression correlates with a transition zone in maturing lens fiber cells in which cytoskeleton is reorganized. Lengsin and lens intermediate filament proteins co-localize at the plasma membrane in maturing fiber cells. This suggests that lengsin may act as a component of the cytoskeleton itself or as a chaperone for the reorganization of intermediate filament proteins during terminal differentiation in the lens.	[Wyatt, Keith; Gao, Chun; Tsai, Jen-Yue; Fariss, Robert N.; Ray, Sugata; Wistow, Graeme] NEI, Sect Mol Struct & Funct Genom, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Wistow, G (corresponding author), NEI, Sect Mol Struct & Funct Genom, NIH, Bldg 7,Rm 201, Bethesda, MD 20892 USA.	graeme@helix.nih.gov	Fariss, Robert/ABI-1771-2020	Fariss, Robert/0000-0003-3227-7170	Intramural NIH HHS [Z01 EY000433-04] Funding Source: Medline; NATIONAL EYE INSTITUTE [Z01EY000459, Z01EY000433] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		[Anonymous], 1981, MOL CELLULAR BIOL EY; BASSNETT S, 1992, DEV DYNAM, V194, P85, DOI 10.1002/aja.1001940202; Beebe DC, 2001, INVEST OPHTH VIS SCI, V42, P727; BOYER S, 1990, J NEUROSCI RES, V27, P55, DOI 10.1002/jnr.490270109; CLARKE FM, 1985, CELL MOTILITY MECHAN, P235; GEORGATOS SD, 1994, BIOESSAYS, V16, P413, DOI 10.1002/bies.950160609; Grassi F, 2006, BIOCHEM BIOPH RES CO, V350, P424, DOI 10.1016/j.bbrc.2006.09.062; Harding JJ, 1984, EYE B, V1b, P207; HATFIELD JS, 1984, J CELL BIOL, V98, P1895, DOI 10.1083/jcb.98.5.1895; Hoover SB, 2000, PATHOLOGY OF GENETICALLY ENGINEERED MICE, P13; KNULL HR, 1992, CURR TOP CELL REGUL, V33, P15; Kuszak JR, 2004, EXP EYE RES, V78, P673, DOI 10.1016/j.exer.2003.09.016; MASTERS C, 1992, INT J BIOCHEM, V24, P405, DOI 10.1016/0020-711X(92)90031-U; McAvoy JW, 1999, EYE, V13, P425, DOI 10.1038/eye.1999.117; Medvedovic M, 2006, MOL VIS, V12, P422; Nishimoto S, 2003, NATURE, V424, P1071, DOI 10.1038/nature01895; PIATIGORSKY J, 1988, P NATL ACAD SCI USA, V85, P3479, DOI 10.1073/pnas.85.10.3479; PIATIGORSKY J, 1981, DIFFERENTIATION, V19, P134, DOI 10.1111/j.1432-0436.1981.tb01141.x; Prescott AR, 1996, OPHTHALMIC RES, V28, P58, DOI 10.1159/000267946; Quinlan RA, 1999, EYE, V13, P409, DOI 10.1038/eye.1999.115; Rose KML, 2006, INVEST OPHTH VIS SCI, V47, P1562, DOI 10.1167/iovs.05-1313; SANDILANDS A, 1995, EUR J CELL BIOL, V67, P238; SANDILANDS A, 1995, J CELL SCI, V108, P1397; Strelkov SV, 2002, EMBO J, V21, P1255, DOI 10.1093/emboj/21.6.1255; WISTOW G, 1987, SCIENCE, V236, P1554, DOI 10.1126/science.3589669; Wistow G, 2006, PROG RETIN EYE RES, V25, P43, DOI 10.1016/j.preteyeres.2005.05.003; Wistow G, 2005, FEBS J, V272, P2276, DOI 10.1111/j.1742-4658.2005.04655.x; Wistow G, 2002, MOL VIS, V8, P161; Wistow G, 2002, MOL VIS, V8, P171; WISTOW G, 1993, TRENDS BIOCHEM SCI, V18, P301, DOI 10.1016/0968-0004(93)90041-K; Wistow G, 1995, MOL BIOL EVOLUTION C; WISTOW GJ, 1987, NATURE, V326, P622, DOI 10.1038/326622a0; Wride MA, 2000, APOPTOSIS, V5, P203, DOI 10.1023/A:1009653326511; Wyatt K, 2006, STRUCTURE, V14, P1823, DOI 10.1016/j.str.2006.10.008; Yabe JT, 2003, CELL MOTIL CYTOSKEL, V56, P193, DOI 10.1002/cm.10137; Zelenka PS, 2004, INT J DEV BIOL, V48, P857, DOI 10.1387/ijdb.041871pz	36	24	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2008	283	10					6607	6615		10.1074/jbc.M709144200	http://dx.doi.org/10.1074/jbc.M709144200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HM	18178558	Green Accepted, hybrid			2022-12-25	WOS:000253779500066
J	Overduin, SA; Servos, P				Overduin, Simon A.; Servos, Philip			Symmetric Sensorimotor Somatotopy	PLOS ONE			English	Article							SOMATOSENSORY CORTEX; CEREBRAL-CORTEX; ORGANIZATION; MOTOR; FMRI; REPRESENTATION; AREA-3B	Background. Functional imaging has recently been used to investigate detailed somatosensory organization in human cortex. Such studies frequently assume that human cortical areas are only identifiable insofar as they resemble those measured invasively in monkeys. This is true despite the electrophysiological basis of the latter recordings, which are typically extracellular recordings of action potentials from a restricted sample of cells. Methodology/Principal Findings. Using high-resolution functional magnetic resonance imaging in human subjects, we found a widely distributed cortical response in both primary somatosensory and motor cortex upon pneumatic stimulation of the hairless surface of the thumb, index and ring fingers. Though not organized in a discrete somatotopic fashion, the population activity in response to thumb and index finger stimulation indicated a disproportionate response to fingertip stimulation, and one that was modulated by stimulation direction. Furthermore, the activation was structured with a line of symmetry through the central sulcus reflecting inputs both to primary somatosensory cortex and, precentrally, to primary motor cortex. Conclusions/Significance. In considering functional activation that is not somatotopically or anatomically restricted as in monkey electrophysiology studies, our methodology reveals finger-related activation that is not organized in a simple somatotopic manner but is nevertheless as structured as it is widespread. Our findings suggest a striking functional mirroring in cortical areas conventionally ascribed either an input or an output somatotopic function.	[Servos, Philip] Wilfrid Laurier Univ, Dept Psychol, Waterloo, ON N2L 3C5, Canada; [Overduin, Simon A.] MIT, McGovern Inst Brain Res, Dept Brain & Cogn Sci, Cambridge, MA USA	Wilfrid Laurier University; Massachusetts Institute of Technology (MIT)	Servos, P (corresponding author), Wilfrid Laurier Univ, Dept Psychol, Waterloo, ON N2L 3C5, Canada.	pservos@wlu.ca			Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Canada Research Chairs program; Ontario Premier's Research Excellence Award program	Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canada Research Chairs program(Canada Research Chairs); Ontario Premier's Research Excellence Award program	Part of this work was supported by grants from the Natural Sciences and Engineering Research Council of Canada (S.A.O. and P.S.), and from the Canadian Institutes of Health Research, the Canada Research Chairs program, and the Ontario Premier's Research Excellence Award program (P.S.).	Balasubramanian M, 2002, SCIENCE, V295; Blankenburg F, 2003, CEREB CORTEX, V13, P987, DOI 10.1093/cercor/13.9.987; BOLANOWSKI SJ, 1988, J ACOUST SOC AM, V84, P1680, DOI 10.1121/1.397184; Cox TF, 1994, MONOGRAPHS STAT APPL; Dechent P, 2003, HUM BRAIN MAPP, V18, P272, DOI 10.1002/hbm.10084; ENGEL SA, 1994, NATURE, V369, P525, DOI 10.1038/369525a0; Fisher NI, 1995, STAT ANAL CIRCULAR D; Formisano E, 2003, NEURON, V40, P859, DOI 10.1016/S0896-6273(03)00669-X; GELDARD FA, 1972, SCIENCE, V178, P178, DOI 10.1126/science.178.4057.178; Gelnar PA, 1998, NEUROIMAGE, V7, P261, DOI 10.1006/nimg.1998.0341; Hasson U, 2003, NEURON, V37, P1027, DOI 10.1016/S0896-6273(03)00144-2; Huffman KJ, 2001, CEREB CORTEX, V11, P849, DOI 10.1093/cercor/11.9.849; JANE JA, 1967, J NEUROSURG, V26, P244, DOI 10.3171/jns.1967.26.2.0244; JONES EG, 1982, J NEUROPHYSIOL, V48, P521, DOI 10.1152/jn.1982.48.2.521; Kurth R, 1998, NEUROREPORT, V9, P207, DOI 10.1097/00001756-199801260-00006; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; Malonek D, 1996, SCIENCE, V272, P551, DOI 10.1126/science.272.5261.551; McGlone F, 2002, BEHAV BRAIN RES, V135, P147, DOI 10.1016/S0166-4328(02)00144-4; Moore CI, 2000, J NEUROPHYSIOL, V84, P558, DOI 10.1152/jn.2000.84.1.558; Mountcastle V.B., 1998, PERCEPTUAL NEUROSCIE; Overduin SA, 2004, NEUROIMAGE, V23, P462, DOI 10.1016/j.neuroimage.2004.06.024; Penfield W, 1937, BRAIN, V60, P389, DOI 10.1093/brain/60.4.389; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1057, DOI 10.1152/jn.1992.67.5.1057; RUSSELL JR, 1961, NEUROLOGY, V11, P96, DOI 10.1212/WNL.11.2.96; SCHWARTZ EL, 1989, IEEE T PATTERN ANAL, V11, P1005, DOI 10.1109/34.35506; Servos P, 1998, NEUROREPORT, V9, P605, DOI 10.1097/00001756-199803090-00008; STRICK PL, 1982, J NEUROPHYSIOL, V48, P150, DOI 10.1152/jn.1982.48.1.150; Tenenbaum JB, 2000, SCIENCE, V290, P2319, DOI 10.1126/science.290.5500.2319; WOOLSEY CN, 1979, J NEUROSURG, V51, P476, DOI 10.3171/jns.1979.51.4.0476; Young JP, 2003, HUM BRAIN MAPP, V19, P183, DOI 10.1002/hbm.10114	30	18	18	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2008	3	1							e1505	10.1371/journal.pone.0001505	http://dx.doi.org/10.1371/journal.pone.0001505			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SR	18231592	Green Published, gold, Green Submitted			2022-12-25	WOS:000260504200018
J	Bhasin, JM; Chakrabarti, E; Peng, DQ; Kulkarni, A; Chen, X; Smith, JD				Bhasin, Jeffrey M.; Chakrabarti, Enakshi; Peng, Dao-Quan; Kulkarni, Aneesh; Chen, Xi; Smith, Jonathan D.			Sex Specific Gene Regulation and Expression QTLs in Mouse Macrophages from a Strain Intercross	PLOS ONE			English	Article								Background. A powerful way to identify genes for complex traits it to combine genetic and genomic methods. Many trait quantitative trait loci (QTLs) for complex traits are sex specific, but the reason for this is not well understood. Methodology/Principal Findings. RNA was prepared from bone marrow derived macrophages of 93 female and 114 male F-2 mice derived from a strain intercross between apoE-deficient mice on the AKR and DBA/2 genetic backgrounds, and was subjected to transcriptome profiling using microarrays. A high density genome scan was performed using a mouse SNP chip, and expression QTLs (eQTLs) were located for expressed transcripts. Using suggestive and significant LOD score cutoffs of 3.0 and 4.3, respectively, thousands of eQTLs in the female and male cohorts were identified. At the suggestive LOD threshold the majority of the eQTLs were trans eQTLs, mapping unlinked to the position of the gene. Cis eQTLs, which mapped to the location of the gene, had much higher LOD scores than trans eQTLs, indicating their more direct effect on gene expression. The majority of cis eQTLs were common to both males and females, but only similar to 1% of the trans eQTLs were shared by both sexes. At the significant LOD threshold, the majority of eQTLs were cis eQTLs, which were mostly sex-shared, while the trans eQTLs were overwhelmingly sex-specific. Pooling the male and female data, 31% of expressed transcripts were expressed at different levels in males vs. females after correction for multiple testing. Conclusions/Significance. These studies demonstrate a large sex effect on gene expression and trans regulation, under conditions where male and female derived cells were cultured ex vivo and thus without the influence of endogenous sex steroids. These data suggest that eQTL data from male and female mice should be analyzed separately, as many effects, such as trans regulation are sex specific.	[Bhasin, Jeffrey M.; Chakrabarti, Enakshi; Peng, Dao-Quan; Kulkarni, Aneesh; Smith, Jonathan D.] Cleveland Clin, Dept Cell Biol, Cleveland, OH 44106 USA; [Chen, Xi] Cleveland Clinic, Dept Quant Health Sci, Cleveland, OH USA; [Smith, Jonathan D.] Case Western Reserve Univ, Cleveland Clinic, Lerner Coll Med, Dept Molec Med, Cleveland, OH USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Case Western Reserve University; Cleveland Clinic Foundation	Smith, JD (corresponding author), Cleveland Clin, Dept Cell Biol, Cleveland, OH 44106 USA.	smithj4@ccf.org	; Smith, Jonathan D./H-9723-2013	Bhasin, Jeffrey/0000-0001-6134-1982; Smith, Jonathan D./0000-0002-0415-386X	National Heart Lung and Blood Institute of the National Institutes of Health [P50HL077107]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL077107] Funding Source: NIH RePORTER	National Heart Lung and Blood Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by SCCOR grant P50HL077107 from the National Heart Lung and Blood Institute of the National Institutes of Health.	Akiyama H, 2003, J BIOL CHEM, V278, P10752, DOI 10.1074/jbc.M209856200; Beissbarth T, 2004, BIOINFORMATICS, V20, P1464, DOI 10.1093/bioinformatics/bth088; Brem RB, 2002, SCIENCE, V296, P752, DOI 10.1126/science.1069516; Broman KW, 2003, BIOINFORMATICS, V19, P889, DOI 10.1093/bioinformatics/btg112; Bystrykh L, 2005, NAT GENET, V37, P225, DOI 10.1038/ng1497; Charng MJ, 1998, J BIOL CHEM, V273, P9365, DOI 10.1074/jbc.273.16.9365; Chesler EJ, 2005, NAT GENET, V37, P233, DOI 10.1038/ng1518; Chesler EJ, 2006, NAT GENET, V38, P856, DOI 10.1038/ng0806-856; Cheung VG, 2003, NAT GENET, V33, P422, DOI 10.1038/ng1094; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; Dansky HM, 2002, GENETICS, V160, P1599; Drake Thomas A, 2005, Am J Ther, V12, P503, DOI 10.1097/01.mjt.0000178775.39149.64; Drake TA, 2006, MAMM GENOME, V17, P466, DOI 10.1007/s00335-005-0175-z; Fitzgerald J, 2000, BRAIN RES, V877, P110, DOI 10.1016/S0006-8993(00)02692-5; Ghazalpour A, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-7-r59; Ghazalpour A, 2006, PLOS GENET, V2, P1182, DOI 10.1371/journal.pgen.0020130; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Grove M, 2004, MOL CELL BIOL, V24, P10905, DOI 10.1128/MCB.24.24.10905-10922.2004; Kobayashi S, 2006, CURR BIOL, V16, P166, DOI 10.1016/j.cub.2005.11.071; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Li AC, 2000, J CLIN INVEST, V106, P523, DOI 10.1172/JCI10370; Meng HJ, 2007, P NATL ACAD SCI USA, V104, P4530, DOI 10.1073/pnas.0607620104; Merla G, 2004, HUM MOL GENET, V13, P1505, DOI 10.1093/hmg/ddh163; Morley M, 2004, NATURE, V430, P743, DOI 10.1038/nature02797; Ng K, 2007, EMBO REP, V8, P34, DOI 10.1038/sj.embor.7400871; Peirce JL, 2006, MAMM GENOME, V17, P643, DOI 10.1007/s00335-005-0187-8; Petretto E, 2006, NAT GENET, V38, P858, DOI 10.1038/ng0806-858; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Schadt EE, 2003, NATURE, V422, P297, DOI 10.1038/nature01434; Smith JD, 2006, MAMM GENOME, V17, P220, DOI 10.1007/s00335-005-0099-7; Smith JD, 2006, ARTERIOSCL THROM VAS, V26, P597, DOI 10.1161/01.ATV.0000201044.33220.5c; Wang S, 2006, PLOS GENET, V2, P148, DOI 10.1371/journal.pgen.0020015; Wang YM, 2007, NAT GENET, V39, P380, DOI 10.1038/ng1969; Wurthner JU, 2001, J BIOL CHEM, V276, P19495, DOI 10.1074/jbc.M006473200; Yang X, 2006, GENOME RES, V16, P995, DOI 10.1101/gr.5217506; Yeom KH, 2006, NUCLEIC ACIDS RES, V34, P4622, DOI 10.1093/nar/gkl458; Yvert G, 2003, NAT GENET, V35, P57, DOI 10.1038/ng1222	37	39	40	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2008	3	1							e1435	10.1371/journal.pone.0001435	http://dx.doi.org/10.1371/journal.pone.0001435			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SN	18197246	Green Published, Green Submitted, gold			2022-12-25	WOS:000260503800007
J	McLear, JA; Lebrecht, D; Messer, A; Wolfgang, WJ				McLear, J. A.; Lebrecht, D.; Messer, A.; Wolfgang, W. J.			Combinational approach of intrabody with enhanced Hsp70 expression addresses multiple pathologies in a fly model of Huntington's disease	FASEB JOURNAL			English	Article						scFv; polyglutamine; Drosophila; neurodegenerative; disorder; chaperone protein	NEURONAL INTRANUCLEAR INCLUSIONS; MUTANT HUNTINGTIN; POLYGLUTAMINE TOXICITY; HSP90 INHIBITOR; HEAT-SHOCK; CHAPERONE SUPPRESSION; TRINUCLEOTIDE REPEAT; MOLECULAR CHAPERONES; TERMINAL HUNTINGTIN; PARKINSONS-DISEASE	Intracellular antibodies (intrabodies) and the chaperone, heat shock protein 70 (Hsp70), have each shown potential as therapeutics for neurodegenerative diseases in vitro and in vivo. Investigating combinational therapy in an established Drosophila model of Huntington's disease (HD), we show that Hsp70 and intrabody actually affect different aspects of the disease. Overexpression of human Hsp70 resulted in improved survival of HD flies to eclosion and prolonged adult life compared with intrabody treatment alone. An additive effect on adult survival was observed when the two therapies were combined. Intrabody was more successful at suppressing neurodegeneration in photoreceptors than was Hsp70. Furthermore, Hsp70 treatment alone did not block aggregation of mutant huntingtin, a process slowed by intrabody. Expression of each is restricted to the nervous system, which implies different neuronal populations respond distinctly to these treatments. Importantly, a role for endogenous Hsp70 in suppression of mutant huntingtin pathology was confirmed by a separate set of genetic studies in which HD flies deficient for Hsp70 showed significantly increased pathology. We conclude that a combinational approach of intrabody with enhanced Hsp70 expression is beneficial in addressing multiple pathologies associated with HD and has potential application for other neurodegenerative disorders.	[McLear, J. A.; Lebrecht, D.; Messer, A.; Wolfgang, W. J.] New York State Dept Hlth, Div Genet Disorders, Wadsworth Ctr, Albany, NY 12237 USA; [Lebrecht, D.; Messer, A.; Wolfgang, W. J.] SUNY Albany, Dept Biomed Sci, Albany, NY USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Messer, A (corresponding author), New York State Dept Hlth, Div Genet Disorders, Wadsworth Ctr, 120 New Scotland Ave, Albany, NY 12237 USA.	messer@wadsworth.org		Wolfgang, William/0000-0003-1769-0215	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS053912] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS053912] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adachi H, 2003, J NEUROSCI, V23, P2203; Agashe VR, 2000, SEMIN CELL DEV BIOL, V11, P15, DOI 10.1006/scdb.1999.0347; Agrawal N, 2005, P NATL ACAD SCI USA, V102, P3777, DOI 10.1073/pnas.0500055102; Alvarez RD, 2000, CLIN CANCER RES, V6, P3081; Andresen JM, 2007, ANN HUM GENET, V71, P295, DOI 10.1111/j.1469-1809.2006.00335.x; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Beliakoff J, 2004, ANTI-CANCER DRUG, V15, P651, DOI 10.1097/01.cad.0000136876.11928.be; Bodner RA, 2006, P NATL ACAD SCI USA, V103, P4246, DOI 10.1073/pnas.0511256103; Bolivar VJ, 2004, BRAIN RES, V1005, P29, DOI 10.1016/j.brainres.2004.01.021; Bossy-Wetzel E, 2004, NAT MED, V10, pS2, DOI 10.1038/nm1067; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Carter RJ, 1999, J NEUROSCI, V19, P3248; Chan HYE, 2000, HUM MOL GENET, V9, P2811, DOI 10.1093/hmg/9.19.2811; Chan HYE, 2002, HUM MOL GENET, V11, P2895, DOI 10.1093/hmg/11.23.2895; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Cummings CJ, 2001, HUM MOL GENET, V10, P1511, DOI 10.1093/hmg/10.14.1511; da Silva FA, 2004, J MOL BIOL, V340, P525, DOI 10.1016/j.jmb.2004.04.062; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Dehay B, 2006, J BIOL CHEM, V281, P35608, DOI 10.1074/jbc.M605558200; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; FRANCESCHINI N, 1971, KYBERNETIK, V9, P159, DOI 10.1007/BF02215177; FRANCESCHINI N, 1971, KYBERNETIK, V8, P1, DOI 10.1007/BF00270828; Garrido C, 2001, BIOCHEM BIOPH RES CO, V286, P433, DOI 10.1006/bbrc.2001.5427; Gong WJ, 2006, GENETICS, V172, P275, DOI 10.1534/genetics.105.048793; Gong WJ, 2004, GENETICS, V168, P1467, DOI 10.1534/genetics.104.030874; Gunawardena S, 2003, NEURON, V40, P25, DOI 10.1016/S0896-6273(03)00594-4; Hackam AS, 1998, J CELL BIOL, V141, P1097, DOI 10.1083/jcb.141.5.1097; Hansson O, 2003, BRAIN RES, V970, P47, DOI 10.1016/S0006-8993(02)04275-0; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; Jackson GR, 1998, NEURON, V21, P633, DOI 10.1016/S0896-6273(00)80573-5; Jana NR, 2005, J BIOL CHEM, V280, P11635, DOI 10.1074/jbc.M412042200; Kalchman MA, 1996, J BIOL CHEM, V271, P19385, DOI 10.1074/jbc.271.32.19385; Kazantsev A, 1999, P NATL ACAD SCI USA, V96, P11404, DOI 10.1073/pnas.96.20.11404; Kazemi-Esfarjani P, 2000, SCIENCE, V287, P1837, DOI 10.1126/science.287.5459.1837; Klucken J, 2006, FASEB J, V20, P2050, DOI 10.1096/fj.05-5422com; Kuhn A, 2007, HUM MOL GENET, V16, P1845, DOI 10.1093/hmg/ddm133; Lecerf JM, 2001, P NATL ACAD SCI USA, V98, P4764, DOI 10.1073/pnas.071058398; Lee WCM, 2004, P NATL ACAD SCI USA, V101, P3224, DOI 10.1073/pnas.0400243101; Li SH, 1998, HUM MOL GENET, V7, P777, DOI 10.1093/hmg/7.5.777; Lynch SM, 2008, J MOL BIOL, V377, P136, DOI 10.1016/j.jmb.2007.11.096; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Martindale D, 1998, NAT GENET, V18, P150, DOI 10.1038/ng0298-150; Messer A, 2006, BIODRUGS, V20, P327, DOI 10.2165/00063030-200620060-00002; Miller TW, 2005, NEUROBIOL DIS, V19, P47, DOI 10.1016/j.nbd.2004.11.003; Miyata Y, 2005, CURR PHARM DESIGN, V11, P1131, DOI 10.2174/1381612053507585; Murphy RC, 2004, MOL BRAIN RES, V121, P141, DOI 10.1016/j.molbrainres.2003.11.011; Naver B, 2003, NEUROSCIENCE, V122, P1049, DOI 10.1016/j.neuroscience.2003.08.053; Novoselova TV, 2005, J NEUROCHEM, V94, P597, DOI 10.1111/j.1471-4159.2005.03119.x; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Rezaval C, 2007, EUR J NEUROSCI, V25, P683, DOI 10.1111/j.1460-9568.2007.05317.x; Sittler A, 2001, HUM MOL GENET, V10, P1307, DOI 10.1093/hmg/10.12.1307; Smith DL, 2001, NEUROBIOL DIS, V8, P1017, DOI 10.1006/nbdi.2001.0438; SNELL RG, 1993, NAT GENET, V4, P393, DOI 10.1038/ng0893-393; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; Tagawa K, 2004, J NEUROCHEM, V89, P974, DOI 10.1111/j.1471-4159.2004.02372.x; Tagawa K, 2007, J NEUROSCI, V27, P868, DOI 10.1523/JNEUROSCI.4522-06.2007; Tsai YC, 2003, J BIOL CHEM, V278, P22044, DOI 10.1074/jbc.M212235200; Wacker JL, 2004, NAT STRUCT MOL BIOL, V11, P1215, DOI 10.1038/nsmb860; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Waza M, 2005, NAT MED, V11, P1088, DOI 10.1038/nm1298; Waza M, 2006, ANN NY ACAD SCI, V1086, P21, DOI 10.1196/annals.1377.012; Waza M, 2006, J MOL MED, V84, P635, DOI 10.1007/s00109-006-0066-0; Wheeler YRY, 2003, MOL THER, V8, P355, DOI 10.1016/S1525-0016(03)00183-7; Wolfgang WJ, 2005, P NATL ACAD SCI USA, V102, P11563, DOI 10.1073/pnas.0505321102; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6; Zhou Y, 2004, NEUROSCIENCE, V128, P281, DOI 10.1016/j.neuroscience.2004.06.048	69	34	35	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					2003	2011		10.1096/fj.07-099689	http://dx.doi.org/10.1096/fj.07-099689			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18199697				2022-12-25	WOS:000256352700039
J	Miyahara, S; Almulki, L; Noda, K; Nakazawa, T; Hisatomi, T; Nakao, S; Thomas, KL; Schering, A; Zandi, S; Frimmel, S; Tayyari, F; Garland, RC; Miller, JW; Gragoudas, ES; Masli, S; Hafezi-Moghadam, A				Miyahara, Shinsuke; Almulki, Lama; Noda, Kousuke; Nakazawa, Toru; Hisatomi, Toshio; Nakao, Shintaro; Thomas, Kennard L.; Schering, Alexander; Zandi, Souska; Frimmel, Sonja; Tayyari, Faryan; Garland, Rebecca C.; Miller, Joan W.; Gragoudas, Evangelos S.; Masli, Sharmila; Hafezi-Moghadam, Ali			In vivo imaging of endothelial injury in choriocapillaris during endotoxin-induced uveitis	FASEB JOURNAL			English	Article						inflammation; adhesion molecules; subclinical diagnosis; noninvasive molecular imaging; vascular diseases	OCULAR BLOOD-FLOW; P-SELECTIN; GLYCOPROTEIN LIGAND-1; CHOROIDAL CIRCULATION; LEUKOCYTE; NEUTROPHILS; RETINA; CELLS	Early detection of ocular inflammation may prevent the occurrence of structural damage or vision loss. Here, we introduce a novel noninvasive technique for molecular imaging and quantitative evaluation of endothelial injury in the choriocapillaris of live animals, which detects disease earlier than currently possible. Using an established model of ocular inflammation, endotoxin-induced uveitis (EIU), we visualized the rolling and adhesive interaction of fluorescent microspheres conjugated to recombinant P-selectin glycoprotein ligand-Ig (rPSGL-Ig) in choriocapillaris using a scanning laser ophthalmoscope (SLO). The number of rolling microspheres in the choriocapillaris peaked 4-10 h after LPS injection. The number of the accumulated microspheres peaked 4 h after LPS injection in the temporal choriocapillaris and 4 and 36 h after LPS injection in the central areas around the optic disk. Furthermore, we semiquantified the levels of P-selectin mRNA expression in the choroidal vessels by reverse transcription-PCR and found its pattern to match the functional microsphere interactions, with a peak at 4 h after LPS injection. These results indicate that PSGL-1-conjugated fluorescent microspheres allow specific detection of endothelial P-selectin expression in vivo and noninvasive assessment of endothelial injury. This technique may help to diagnose subclinical signs of ocular inflammatory diseases.	[Miyahara, Shinsuke; Almulki, Lama; Noda, Kousuke; Nakazawa, Toru; Hisatomi, Toshio; Nakao, Shintaro; Thomas, Kennard L.; Schering, Alexander; Zandi, Souska; Frimmel, Sonja; Tayyari, Faryan; Garland, Rebecca C.; Miller, Joan W.; Gragoudas, Evangelos S.; Hafezi-Moghadam, Ali] Massachusetts Eye & Ear Infirm, Angiogenesis Lab, Boston, MA 02114 USA; [Miyahara, Shinsuke; Almulki, Lama; Noda, Kousuke; Nakazawa, Toru; Hisatomi, Toshio; Nakao, Shintaro; Thomas, Kennard L.; Schering, Alexander; Zandi, Souska; Frimmel, Sonja; Tayyari, Faryan; Garland, Rebecca C.; Miller, Joan W.; Gragoudas, Evangelos S.; Masli, Sharmila; Hafezi-Moghadam, Ali] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA; [Masli, Sharmila] Schepens Eye Res Inst, Boston, MA USA	Harvard University; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical School; Harvard University; Schepens Eye Research Institute	Hafezi-Moghadam, A (corresponding author), Massachusetts Eye & Ear Infirm, Angiogenesis Lab, Boston, MA 02114 USA.	ahm@meei.harvard.edu		Miller, Joan/0000-0003-2046-3996; Hafezi-Moghadam, Ali/0000-0002-5336-0697; Hisatomi, Toshio/0000-0003-2552-9595; Zandi, Souska/0000-0001-9351-4278	NEI NIH HHS [EY14104] Funding Source: Medline; NIAID NIH HHS [AI050775] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY014104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI050775] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abiko T, 2003, DIABETES, V52, P829, DOI 10.2337/diabetes.52.3.829; Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0; BAATZ H, 1995, INVEST OPHTH VIS SCI, V36, P1960; BISCHOFF PM, 1995, RETINA-J RET VIT DIS, V15, P91, DOI 10.1097/00006982-199515020-00002; DORE M, 1993, BLOOD, V82, P1308; FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8; GABER AO, 2007, AM TRANSPL C; GHEZZI P, 1991, CYTOKINE, V3, P189, DOI 10.1016/1043-4666(91)90015-6; Hafezi-Moghadam A, 2007, FASEB J, V21, P464, DOI 10.1096/fj.06-6390com; Hafezi-Moghadam A, 2004, AM J PHYSIOL-CELL PH, V286, pC876, DOI 10.1152/ajpcell.00500.2003; Hafezi-Moghadam A, 2001, J EXP MED, V193, P863, DOI 10.1084/jem.193.7.863; Hafezi-Moghadam A, 1999, J EXP MED, V189, P939, DOI 10.1084/jem.189.6.939; Hirata Y, 2006, PROG RETIN EYE RES, V25, P129, DOI 10.1016/j.preteyeres.2005.08.001; Hirata Y, 2004, INVEST OPHTH VIS SCI, V45, P1954, DOI 10.1167/iovs.03-0759; Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807; Khoobehi B, 1997, OPHTHALMIC SURG LAS, V28, P937; Khor SP, 2000, J PHARMACOL EXP THER, V293, P618; Kuroki AM, 2002, OPHTHALMIC RES, V34, P200, DOI 10.1159/000063886; MATSUO Y, 1995, J CEREBR BLOOD F MET, V15, P941, DOI 10.1038/jcbfm.1995.119; Mertens P, 2006, AM HEART J, V152, DOI 10.1016/j.ahj.2006.04.020; Miyahara S, 2004, AM J PATHOL, V164, P1697, DOI 10.1016/S0002-9440(10)63728-5; Miyahara S, 2003, STROKE, V34, P2043, DOI 10.1161/01.STR.0000083052.01361.3D; Miyamoto K, 1996, INVEST OPHTH VIS SCI, V37, P2708; Miyamoto K, 1998, INVEST OPHTH VIS SCI, V39, P2190; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; Nagaoka T, 2004, BRIT J OPHTHALMOL, V88, P1060, DOI 10.1136/bjo.2003.035345; Nakazawa T, 2007, P NATL ACAD SCI USA, V104, P2425, DOI 10.1073/pnas.0608167104; Pournaras CJ, 2006, INVEST OPHTH VIS SCI, V47, P1581, DOI 10.1167/iovs.05-0434; Savage HI, 2004, INVEST OPHTH VIS SCI, V45, P4504, DOI 10.1167/iovs.04-0077; Schocket Lisa S., 2004, International Ophthalmology, V25, P89, DOI 10.1023/B:INTE.0000031744.93778.60; SUGAMA Y, 1992, J CELL BIOL, V119, P935, DOI 10.1083/jcb.119.4.935; Suzuma K, 1997, INVEST OPHTH VIS SCI, V38, P1610; VACHINO G, 1995, J BIOL CHEM, V270, P21966, DOI 10.1074/jbc.270.37.21966; Yang PZ, 1997, BRIT J OPHTHALMOL, V81, P396, DOI 10.1136/bjo.81.5.396	34	13	14	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1973	1980		10.1096/fj.07-096891	http://dx.doi.org/10.1096/fj.07-096891			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18216288				2022-12-25	WOS:000256352700036
J	Mukherjee, S; Negi, VS; Keitany, G; Tanaka, Y; Orth, K				Mukherjee, Sohini; Negi, Veera S.; Keitany, Gladys; Tanaka, Yuetsu; Orth, Kim			In vitro activation of the I kappa B kinase complex by human T-cell leukemia virus type-1 tax	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED ACTIVATION; LYMPHOTROPIC-VIRUS; YERSINIA EFFECTOR; PHOSPHATASE 2A; IKK-GAMMA; PROTEIN; YOPJ; ACETYLATION; RESIDUES	Human T-cell leukemia virus type-I expresses Tax, a 40-kDa oncoprotein that activates licB kinase (IKK), resulting in constitutive activation of NF kappa B. Herein, we have developed an in vitro signaling assay to analyze IKK complex activation by recombinant Tax. Using this assay in combination with reporter assays, we demonstrate that Tax-mediated activation of IKK is independent of phosphatases. We show that sustained activation of the Tax-mediated activation of the NF kappa B pathway is dependent on an intact Hsp90-IKK complex. By acetylating and thereby preventing activation of the IKK complex by the Yersinia effector YopJ, we demonstrate that Tax-mediated activation of the IKK complex requires a phosphorylation step. Our characterization of an in vitro signaling assay system for the mechanism of Tax-mediated activation of the IKK complex with a variety of mutants and inhibitors results in a working model for the biochemical mechanism of Tax-induced activation.	[Mukherjee, Sohini; Negi, Veera S.; Orth, Kim] Univ Texas SW Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA; [Keitany, Gladys] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA; [Tanaka, Yuetsu] Univ Ryukyus, Dept Immunol, Nishihara, Okinawa 9030215, Japan	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Washington; University of Washington Seattle; University of the Ryukyus	Orth, K (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Mol Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Kim.Orth@utsouthwestern.edu	Orth, Kim/AAV-4421-2021	Orth, Kim/0000-0002-0678-7620	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK072134] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 056404] Funding Source: Medline; NIDDK NIH HHS [R21 DK 072134] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Broemer M, 2004, ONCOGENE, V23, P5378, DOI 10.1038/sj.onc.1207705; Carter RS, 2003, J BIOL CHEM, V278, P48903, DOI 10.1074/jbc.M310686200; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Fu DX, 2003, J BIOL CHEM, V278, P1487, DOI 10.1074/jbc.M210631200; Harhaj EW, 2005, IUBMB LIFE, V57, P83, DOI 10.1080/15216540500078715; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Kray AE, 2005, J BIOL CHEM, V280, P35974, DOI 10.1074/jbc.M506093200; LEE B, 1989, TOHOKU J EXP MED, V157, P1, DOI 10.1620/tjem.157.1; Mittal R, 2006, P NATL ACAD SCI USA, V103, P18574, DOI 10.1073/pnas.0608995103; Mukherjee S, 2007, TRENDS BIOCHEM SCI, V32, P210, DOI 10.1016/j.tibs.2007.03.007; Mukherjee S, 2006, SCIENCE, V312, P1211, DOI 10.1126/science.1126867; Nejmeddine M, 2005, J BIOL CHEM, V280, P29653, DOI 10.1074/jbc.M502639200; Orth K, 2000, SCIENCE, V290, P1594, DOI 10.1126/science.290.5496.1594; Orth K, 1999, SCIENCE, V285, P1920, DOI 10.1126/science.285.5435.1920; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Viboud GI, 2005, ANNU REV MICROBIOL, V59, P69, DOI 10.1146/annurev.micro.59.030804.121320; Xiao GT, 2000, J BIOL CHEM, V275, P34060, DOI 10.1074/jbc.M002970200; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475	21	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15127	15133		10.1074/jbc.M704831200	http://dx.doi.org/10.1074/jbc.M704831200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18223255	Green Published, hybrid			2022-12-25	WOS:000256232000028
J	Zhai, DY; Jin, CF; Huang, ZW; Satterthwait, AC; Reed, JC				Zhai, Dayong; Jin, Chaofang; Huang, Ziwei; Satterthwait, Arnold C.; Reed, John C.			Differential regulation of Bax and Bak by anti-apoptotic Bcl-2 family proteins Bcl-B and Mcl-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BH3-ONLY PROTEINS; CELL-DEATH; BH3 DOMAINS; MITOCHONDRIA; ACTIVATION; MECHANISMS	The pro-apoptotic members of the Bcl-2 family include initiator proteins that contain only BH3 domains and downstream effector multi-BH domain-containing proteins, including Bax and Bak. In this report, we compared the ability of the six human anti-apoptotic Bcl-2 family members to suppress apoptosis induced by overexpression of Bax or Bak, correlating findings with protein interactions measured by three different methods: co-immunoprecipitation, glutathione S-transferase pulldown, and fluorescence polarization assays employing synthetic BH3 peptides from Bax and Bak. Bcl-B and Mcl-1 showed strong preferences for binding to and suppression of Bax and Bak, respectively. In contrast, the other anti-apoptotic Bcl-2 family proteins (Bcl-2, Bcl-X-L, Bcl-W, and Bfl-1) suppressed apoptosis induced by overexpression of either Bax or Bak, and they displayed an ability to bind both Bax and Bak by at least one of the three protein interaction methods. Interestingly, however, full-length Bax and Bak proteins and synthetic Bax and Bak BH3 peptides exhibited discernible differences in their interactions with some anti-apoptotic members of the Bcl-2 family, cautioning against reliance on a single method for detecting protein interactions of functional significance. Altogether, the findings reveal striking distinctions in the behaviors of Bcl-B and Mcl-1 relative to the other anti-apoptotic Bcl-2 family members, where Bcl-B and Mcl-1 display reciprocal abilities to bind and neutralize Bax and Bak.	[Zhai, Dayong; Jin, Chaofang; Huang, Ziwei; Satterthwait, Arnold C.; Reed, John C.] Burnham Inst Med Res, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Reed, JC (corresponding author), Burnham Inst Med Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	reedoffice@burnham.org			NATIONAL CANCER INSTITUTE [U19CA113318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060554] Funding Source: NIH RePORTER; NCI NIH HHS [CA 113318] Funding Source: Medline; NIGMS NIH HHS [GM 60554] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bruey JM, 2007, CELL, V129, P45, DOI 10.1016/j.cell.2007.01.045; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Labi V, 2006, CELL DEATH DIFFER, V13, P1325, DOI 10.1038/sj.cdd.4401940; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Luciano F, 2007, BLOOD, V109, P3849, DOI 10.1182/blood-2006-11-056879; Reed JC, 2006, CELL DEATH DIFFER, V13, P1378, DOI 10.1038/sj.cdd.4401975; Reed J. C., 2004, SCI STKE, V2004, pre9, DOI DOI 10.1126/STKE.2392004RE9; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Zhai D, 2006, CELL DEATH DIFFER, V13, P1419, DOI 10.1038/sj.cdd.4401937; Zhai DY, 2005, J BIOL CHEM, V280, P15815, DOI 10.1074/jbc.M411902200; Zhai DY, 2003, BIOCHEM J, V376, P229, DOI 10.1042/BJ20030374	25	104	110	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9580	9586		10.1074/jbc.M708426200	http://dx.doi.org/10.1074/jbc.M708426200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18178565	Green Published, hybrid			2022-12-25	WOS:000254671600011
J	Kawai, Y; Nishikawa, T; Shiba, Y; Saito, S; Murota, K; Shibata, N; Kobayashi, M; Kanayama, M; Uchida, K; Terao, J				Kawai, Yoshichika; Nishikawa, Tomomi; Shiba, Yuko; Saito, Satomi; Murota, Kaeko; Shibata, Noriyuki; Kobayashi, Makio; Kanayama, Masaya; Uchida, Koji; Terao, Junji			Macrophage as a target of quercetin glucuronides in human atherosclerotic arteries - Implication in the anti-atherosclerotic mechanism of dietary flavonoids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTENTIALLY ANTICARCINOGENIC FLAVONOIDS; LOW-DENSITY-LIPOPROTEIN; CORONARY-HEART-DISEASE; NITRIC-OXIDE SYNTHASE; LIPID-PEROXIDATION; ENDOTHELIAL-CELLS; DEFICIENT MICE; RAT PLASMA; IN-VITRO; RECEPTOR	Epidemiological studies suggest that the consumption of flavonoid-rich diets decreases the risk of cardiovascular diseases. However, the target sites of flavonoids underlying the protective mechanism in vivo are not known. Quercetin represents antioxidative/anti-inflammatory flavonoids widely distributed in the human diet. In this study, we raised a novel monoclonal antibody 14A2 targeting the quercetin-3-glucuronide (Q3GA), a major antioxidative quercetin metabolite in human plasma, and found that the activated macrophage might be a potential target of dietary flavonoids in the aorta. Immunohistochemical studies with monoclonal antibody 14A2 demonstrated that the positive staining specifically accumulates in human atherosclerotic lesions, but not in the normal aorta, and that the intense staining was primarily associated with the macrophage-derived foam cells. In vitro experiments with murine macrophage cell lines showed that the Q3GA was significantly taken up and deconjugated into the much more active aglycone, a part of which was further converted to the methylated form, in the activated macrophages. In addition, the mRNA expression of the class A scavenger receptor and CD36, which play an important role for the formation of foam cells, was suppressed by the treatment of Q3GA. These results suggest that injured/inflamed arteries with activated macrophages are the potential targets of the metabolites of dietary quercetin. Our data provide a new insight into the bioavailability of dietary flavonoids and the mechanism for the prevention of cardiovascular diseases.	[Kawai, Yoshichika; Nishikawa, Tomomi; Shiba, Yuko; Saito, Satomi; Murota, Kaeko; Terao, Junji] Univ Tokushima, Grad Sch Nutr & Biosci, Dept Food Sci, Tokushima 7708503, Japan; [Shibata, Noriyuki; Kobayashi, Makio] Tokyo Womens Med Univ, Dept Pathol, Tokyo 1628666, Japan; [Kawai, Yoshichika; Nishikawa, Tomomi; Shiba, Yuko; Saito, Satomi; Murota, Kaeko; Kanayama, Masaya; Uchida, Koji; Terao, Junji] Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan	Tokushima University; Tokyo Women's Medical University; Nagoya University	Kawai, Y (corresponding author), Univ Tokushima, Grad Sch Nutr & Biosci, Dept Food Sci, Tokushima 7708503, Japan.	y-kawai@nutr.med.tokushima-u.ac.jp	Kawai, Yoshichika/G-3231-2011; Murota, Kaeko/GRO-6464-2022	Uchida, Koji/0000-0003-3894-5299				Babaev VR, 2000, ARTERIOSCL THROM VAS, V20, P2593, DOI 10.1161/01.ATV.20.12.2593; Bentsath A, 1936, NATURE, V138, P798, DOI 10.1038/138798a0; Burleigh ME, 2002, CIRCULATION, V105, P1816, DOI 10.1161/01.CIR.0000014927.74465.7F; Cao GH, 1997, FREE RADICAL BIO MED, V22, P749, DOI 10.1016/S0891-5849(96)00351-6; da Silva EL, 1998, FEBS LETT, V430, P405, DOI 10.1016/S0014-5793(98)00709-1; Day AJ, 2001, FREE RADICAL RES, V35, P941, DOI 10.1080/10715760100301441; Detmers PA, 2000, J IMMUNOL, V165, P3430, DOI 10.4049/jimmunol.165.6.3430; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259; Gillotte-Taylor K, 2001, J LIPID RES, V42, P1474; HERTOG MGL, 1994, NUTR CANCER, V22, P175, DOI 10.1080/01635589409514342; HERTOG MGL, 1993, NUTR CANCER, V20, P21, DOI 10.1080/01635589309514267; HERTOG MGL, 1995, ARCH INTERN MED, V155, P381, DOI 10.1001/archinte.155.4.381; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; Hertog MGL, 1996, EUR J CLIN NUTR, V50, P63; HERTOG MGL, 1992, J AGR FOOD CHEM, V40, P2379, DOI 10.1021/jf00024a011; Isshiki M, 2002, J BIOL CHEM, V277, P43389, DOI 10.1074/jbc.M205411200; Kamada C, 2005, FREE RADICAL RES, V39, P185, DOI 10.1080/10715760400019638; Kato Y, 2003, BIOSCI BIOTECH BIOCH, V67, P1136, DOI 10.1271/bbb.67.1136; Keli SO, 1996, ARCH INTERN MED, V156, P637, DOI 10.1001/archinte.156.6.637; Le Marchand L, 2000, JNCI-J NATL CANCER I, V92, P154, DOI 10.1093/jnci/92.2.154; Lotito SB, 2006, J BIOL CHEM, V281, P37102, DOI 10.1074/jbc.M606804200; McMillen TS, 2005, CIRCULATION, V111, P2798, DOI 10.1161/CIRCULATIONAHA.104.516278; Mochizuki M, 2004, BIOFACTORS, V22, P201, DOI 10.1002/biof.5520220142; Moon JH, 2000, AM J PHYSIOL-REG I, V279, pR461, DOI 10.1152/ajpregu.2000.279.2.R461; Moon JH, 2001, FREE RADICAL BIO MED, V30, P1274, DOI 10.1016/S0891-5849(01)00522-6; Murota K, 2003, ARCH BIOCHEM BIOPHYS, V417, P12, DOI 10.1016/S0003-9861(03)00284-4; O'Leary KA, 2001, FEBS LETT, V503, P103, DOI 10.1016/S0014-5793(01)02684-9; Raso GM, 2001, LIFE SCI, V68, P921, DOI 10.1016/S0024-3205(00)00999-1; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Shimoi K, 2001, DRUG METAB DISPOS, V29, P1521; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Tachibana H, 2004, NAT STRUCT MOL BIOL, V11, P380, DOI 10.1038/nsmb743; Williams RJ, 2004, FREE RADICAL BIO MED, V36, P838, DOI 10.1016/j.freeradbiomed.2004.01.001; Williamson G, 2005, FREE RADICAL RES, V39, P457, DOI 10.1080/10715760500053610; Yan SY, 2005, SURGERY, V138, P464, DOI 10.1016/j.surg.2005.06.027	37	237	247	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9424	9434		10.1074/jbc.M706571200	http://dx.doi.org/10.1074/jbc.M706571200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18199750	hybrid			2022-12-25	WOS:000254465800072
J	Friedman, MJ; Wang, CE; Li, XJ; Li, SH				Friedman, Meyer J.; Wang, Chuan-En; Li, Xiao-Jiang; Li, Shihua			Polyglutamine expansion reduces the association of TATA-binding protein with DNA and induces DNA binding-independent neurotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; DOMINANT CEREBELLAR-ATAXIA; DISEASE-LIKE PHENOTYPE; REPEAT EXPANSION; EXPANDED POLYGLUTAMINE; NUCLEAR-LOCALIZATION; GENE-EXPRESSION; TERMINAL DOMAIN; TRANSCRIPTION; TBP	TATA-binding protein (TBP) is essential for eukaryotic gene transcription. Human TBP contains a polymorphic polyglutamine (polyQ) domain in its N terminus and a DNA-binding domain in its highly conserved C terminus. Expansion of the polyQ domain to > 42 glutamines typically results in spinocerebellar ataxia type 17 (SCA17), a neurodegenerative disorder that resembles Huntington disease. Our recent studies have demonstrated that polyQ expansion causes abnormal interaction of TBP with the general transcription factor TFIIB and induces neurodegeneration in transgenic SCA17 mice (Friedman, M. J., Shah, A. G., Fang, Z. H., Ward, E. G., Warren, S. T., Li, S., and Li, X. J. (2007) Nat. Neurosci. 10, 1519 - 1528). However, it remains unknown how polyQ expansion influences DNA binding by TBP. Here we report that polyQ expansion reduces in vitro binding of TBP to DNA and that mutant TBP fragments lacking an intact C-terminal DNA-binding domain are present in transgenic SCA17 mouse brains. polyQ-expanded TBP with a deletion spanning part of the DNA-binding domain does not bind DNA in vitro but forms nuclear aggregates and inhibits TATA-dependent transcription activity in cultured cells. When this TBP double mutant is expressed in transgenic mice, it forms nuclear inclusions in neurons and causes early death. These findings suggest that the polyQ tract affects the binding of TBP to promoter DNA and that polyQ-expanded TBP can induce neuronal toxicity independent of its interaction with DNA.	[Friedman, Meyer J.; Wang, Chuan-En; Li, Xiao-Jiang; Li, Shihua] Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA	Emory University	Li, XJ (corresponding author), Emory Univ, Sch Med, Dept Human Genet, 615 Michael St, Atlanta, GA 30322 USA.	xiaoli@genetics.emory.edu; shihual@genetics.emory.edu			NIA NIH HHS [R01 AG031153, AG 019206] Funding Source: Medline; NINDS NIH HHS [R01 NS041669, NS 045106, NS 041669, R01 NS045016] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045106, R01NS045016, R01NS041669] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019206, R01AG031153] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Baek HJ, 2006, J BIOL CHEM, V281, P15172, DOI 10.1074/jbc.M601983200; Bauer P, 2004, J MED GENET, V41, P230, DOI 10.1136/jmg.2003.015602; Bondareva AA, 2003, MOL BIOL EVOL, V20, P1932, DOI 10.1093/molbev/msg205; Bruni AC, 2004, ARCH NEUROL-CHICAGO, V61, P1314, DOI 10.1001/archneur.61.8.1314; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; Friedman MJ, 2007, NAT NEUROSCI, V10, P1519, DOI 10.1038/nn2011; Fujigasaki H, 2001, BRAIN, V124, P1939, DOI 10.1093/brain/124.10.1939; GOSTOUT B, 1993, AM J HUM GENET, V52, P1182; Hazeki N, 2000, BIOCHEM BIOPH RES CO, V277, P386, DOI 10.1006/bbrc.2000.3682; Hochheimer A, 2003, GENE DEV, V17, P1309, DOI 10.1101/gad.1099903; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; Jackson-Fisher AJ, 1999, MOL CELL, V3, P717, DOI 10.1016/S1097-2765(01)80004-6; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; Lam YC, 2006, CELL, V127, P1335, DOI 10.1016/j.cell.2006.11.038; Lasek K, 2006, BRAIN, V129, P2341, DOI 10.1093/brain/awl148; Lee TI, 2000, ANNU REV GENET, V34, P77, DOI 10.1146/annurev.genet.34.1.77; LESCURE A, 1994, EMBO J, V13, P1166, DOI 10.1002/j.1460-2075.1994.tb06366.x; Li SH, 2002, MOL CELL BIOL, V22, P1277, DOI 10.1128/MCB.22.5.1277-1287.2002; Malik S, 2005, TRENDS BIOCHEM SCI, V30, P256, DOI 10.1016/j.tibs.2005.03.009; Maltecca F, 2003, NEUROLOGY, V61, P1441, DOI 10.1212/01.WNL.0000094123.09098.A0; Mittal V, 1997, SCIENCE, V275, P1136, DOI 10.1126/science.275.5303.1136; Muller F, 2004, EMBO J, V23, P2, DOI 10.1038/sj.emboj.7600027; Nakamura K, 2001, HUM MOL GENET, V10, P1441, DOI 10.1093/hmg/10.14.1441; Orr HT, 2007, ANNU REV NEUROSCI, V30, P575, DOI 10.1146/annurev.neuro.29.051605.113042; Reid SJ, 2003, NEUROBIOL DIS, V13, P37, DOI 10.1016/S0969-9961(03)00014-7; Riley BE, 2006, GENE DEV, V20, P2183, DOI 10.1101/gad.1436506; Rolfs A, 2003, ANN NEUROL, V54, P367, DOI 10.1002/ana.10676; SEIPEL K, 1993, NUCLEIC ACIDS RES, V21, P5609, DOI 10.1093/nar/21.24.5609; Silveira I, 2002, ARCH NEUROL-CHICAGO, V59, P623, DOI 10.1001/archneur.59.4.623; STEVANIN G, 2007, CEREBELLUM, P1; Toyoshima Y, 2004, ANN NEUROL, V55, P281, DOI 10.1002/ana.10824; Walsh R, 2005, NEUROTOX RES, V7, P43, DOI 10.1007/BF03033775; YAMAMOTO T, 1992, P NATL ACAD SCI USA, V89, P2844, DOI 10.1073/pnas.89.7.2844; Zhao XM, 2002, CELL, V108, P615, DOI 10.1016/S0092-8674(02)00648-7; Zhou H, 2003, J CELL BIOL, V163, P109, DOI 10.1083/jcb.200306038; Zuhlke C, 2001, EUR J HUM GENET, V9, P160, DOI 10.1038/sj.ejhg.5200617	38	52	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8283	8290		10.1074/jbc.M709674200	http://dx.doi.org/10.1074/jbc.M709674200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18218637	Green Published, hybrid			2022-12-25	WOS:000254288000026
J	Jokela, TA; Jauhiainen, M; Auriola, S; Kauhanen, M; Tiihonen, R; Tammi, MI; Tammi, RH				Jokela, Tiina A.; Jauhiainen, Marjo; Auriola, Seppo; Kauhanen, Miia; Tiihonen, Riikka; Tammi, Markku I.; Tammi, Raija H.			Mannose inhibits hyaluronan synthesis by down-regulation of the cellular pool of UDP-N-acetylhexosamines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; ACTIVATES HYALURONAN; EPITHELIAL-CELLS; KERATINOCYTES; MIGRATION; SYNTHASES; CANCER; ACID; 4-METHYLUMBELLIFERONE; PROLIFERATION	We found that D-mannose dose-dependently decreases hyaluronan synthesis in cultured epidermal keratinocytes to similar to 50%, whereas glucose, galactose, and fructose up to 20 mM concentration had no effect. The full inhibition occurred within 3 h following introduction of mannose and did not involve down-regulation of hyaluronan synthase (Has1 - 3) mRNA. Following introduction of mannose, there was an similar to 50% reduction in the cellular concentration of UDP-N-acetylhexosamines (UDP-HexNAc, i. e. UDP-N-acetylglucosamine and UDP-N-acetylgalactosamine). On the other hand, 2 mM glucosamine in the culture medium increased UDP-HexNAc content, stimulated hyaluronan secretion, and negated the effect of mannose, supporting the notion that the inhibition by mannose on hyaluronan synthesis was because of down-regulated UDP-HexNAc content. The content of UDP-glucuronic acid, the other building block for hyaluronan synthesis, was not reduced by mannose but declined from 39 to 14% of controls by 0.2-1.0 mM 4-methylumbelliferone, another compound that inhibits hyaluronan synthesis. Applying 4-methylumbelliferone and mannose together produced the expected reductions in both UDP sugars but no additive reduction in hyaluronan production, indicating that the concentration of each substrate alone can limit hyaluronan synthesis. Mannose is a potentially useful tool in studies on hyaluronan-dependent cell functions, as demonstrated by reduced rates of keratinocyte proliferation and migration, functions known to depend on hyaluronan synthesis.	[Jokela, Tiina A.; Kauhanen, Miia; Tiihonen, Riikka; Tammi, Markku I.; Tammi, Raija H.] Univ Kuopio, Inst Biomed Anat, FIN-70211 Kuopio, Finland; [Jauhiainen, Marjo; Auriola, Seppo] Univ Kuopio, Dept Pharmaceut Chem, FIN-70211 Kuopio, Finland	University of Eastern Finland; University of Eastern Finland	Tammi, RH (corresponding author), Univ Kuopio, Inst Biomed Anat, POB 1627, FIN-70211 Kuopio, Finland.	raija.tammi@uku.fi	Jokela, Tiina/O-9206-2015; Tammi, Markku/AAQ-7878-2021	Jokela, Tiina/0000-0002-7521-3866; 				Anttila MA, 2000, CANCER RES, V60, P150; Aoki K, 2004, J BIOL CHEM, V279, P39798, DOI 10.1074/jbc.M402677200; Arreola R, 2003, FEBS LETT, V551, P63, DOI 10.1016/S0014-5793(03)00896-2; Auvinen P, 2000, AM J PATHOL, V156, P529, DOI 10.1016/S0002-9440(10)64757-8; Auvinen PK, 1997, INT J CANCER, V74, P477, DOI 10.1002/(SICI)1097-0215(19971021)74:5<477::AID-IJC1>3.3.CO;2-X; BADEN HP, 1983, J INVEST DERMATOL, V81, P558, DOI 10.1111/1523-1747.ep12523220; Bonder CS, 2006, BLOOD, V107, P4798, DOI 10.1182/blood-2005-09-3581; Bourguignon LYW, 2007, J BIOL CHEM, V282, P19426, DOI 10.1074/jbc.M610054200; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; Cayli A, 1999, BIOTECHNOL BIOENG, V65, P192, DOI 10.1002/(SICI)1097-0290(19991020)65:2<192::AID-BIT9>3.0.CO;2-9; Danese S, 2006, GASTROENTEROLOGY, V130, P2060, DOI 10.1053/j.gastro.2006.03.054; de la Motte CA, 2003, AM J PATHOL, V163, P121, DOI 10.1016/S0002-9440(10)63636-X; Fraser JRE, 1997, J INTERN MED, V242, P27, DOI 10.1046/j.1365-2796.1997.00170.x; Goentzel BJ, 2006, BIOCHEM J, V396, P347, DOI 10.1042/BJ20051782; Grigorian A, 2007, J BIOL CHEM, V282, P20027, DOI 10.1074/jbc.M701890200; Haylock DN, 2006, REGEN MED, V1, P437, DOI 10.2217/17460751.1.4.437; HELDIN P, 1989, BIOCHEM J, V258, P919, DOI 10.1042/bj2580919; Hiltunen ELJ, 2002, CANCER RES, V62, P6410; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Itano N, 2002, P NATL ACAD SCI USA, V99, P3609, DOI 10.1073/pnas.052026799; Kakizaki I, 2004, J BIOL CHEM, V279, P33281, DOI 10.1074/jbc.M405918200; Karvinen S, 2003, J BIOL CHEM, V278, P49495, DOI 10.1074/jbc.M310445200; Kawakita M, 1998, J BIOCHEM, V123, P777; KIM JJ, 1974, J BIOL CHEM, V249, P3091; Laurent Torvard C., 1996, Immunology and Cell Biology, V74, pA1, DOI 10.1038/icb.1996.32; Majors AK, 2003, J BIOL CHEM, V278, P47223, DOI 10.1074/jbc.M304871200; Misra S, 2003, J BIOL CHEM, V278, P25285, DOI 10.1074/jbc.C300173200; Niehues R, 1998, J CLIN INVEST, V101, P1414, DOI 10.1172/JCI2350; Pasonen-Seppanen S, 2003, J INVEST DERMATOL, V120, P1038, DOI 10.1046/j.1523-1747.2003.12249.x; Pienimaki JP, 2001, J BIOL CHEM, V276, P20428, DOI 10.1074/jbc.M007601200; PILLER F, 1983, J BIOL CHEM, V258, P774; PITSILLIDES AA, 1993, INT J EXP PATHOL, V74, P27; Pummill PE, 1998, J BIOL CHEM, V273, P4976, DOI 10.1074/jbc.273.9.4976; Pure E, 2001, TRENDS MOL MED, V7, P213, DOI 10.1016/S1471-4914(01)01963-3; Rilla K, 2004, J INVEST DERMATOL, V123, P708, DOI 10.1111/j.0022-202X.2004.23409.x; Rilla K, 2002, J CELL SCI, V115, P3633, DOI 10.1242/jcs.00042; Saavalainen K, 2005, J BIOL CHEM, V280, P14636, DOI 10.1074/jbc.M500206200; Sayo T, 2002, J INVEST DERMATOL, V118, P43, DOI 10.1046/j.0022-202x.2001.01613.x; Schleicher ED, 2000, KIDNEY INT, V58, pS13, DOI 10.1046/j.1523-1755.2000.07703.x; Selbi W, 2006, KIDNEY INT, V70, P1287, DOI 10.1038/sj.ki.5001760; Simpson MA, 2002, AM J PATHOL, V161, P849, DOI 10.1016/S0002-9440(10)64245-9; Slevin M, 1998, LAB INVEST, V78, P987; SWEENEY C, 1993, BIOCHEM J, V290, P563, DOI 10.1042/bj2900563; Takahashi Y, 2005, J BIOL CHEM, V280, P24195, DOI 10.1074/jbc.M411913200; Tammi R, 1998, J BIOL CHEM, V273, P28878, DOI 10.1074/jbc.273.44.28878; Tammi R, 2005, J INVEST DERMATOL, V124, P898, DOI 10.1111/j.0022-202X.2005.23697.x; TAMMI R, 1994, PROG HISTOCHEM CYTOC, V29, P1; Tammi RH, 2000, HISTOCHEM CELL BIOL, V113, P265, DOI 10.1007/s004180000128; Tellbach M, 2002, GLYCOCONJUGATE J, V19, P385, DOI 10.1023/B:GLYC.0000004010.24877.2f; Toole BP, 2002, AM J PATHOL, V161, P745, DOI 10.1016/S0002-9440(10)64232-0; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Vigetti D, 2006, J BIOL CHEM, V281, P8254, DOI 10.1074/jbc.M508516200; WALDMAN BC, 1990, BIOCHEMISTRY-US, V29, P44, DOI 10.1021/bi00453a006; WEST DC, 1989, EXP CELL RES, V183, P179, DOI 10.1016/0014-4827(89)90428-X; Yamada Y, 2004, J INVEST DERMATOL, V122, P631, DOI 10.1111/j.0022-202X.2004.22332.x; Yoshihara S, 2005, FEBS LETT, V579, P2722, DOI 10.1016/j.febslet.2005.03.079	56	59	62	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7666	7673		10.1074/jbc.M706001200	http://dx.doi.org/10.1074/jbc.M706001200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18201970	hybrid			2022-12-25	WOS:000253997900042
J	Ratti, A; Fallini, C; Colombrita, C; Pascale, A; Laforenza, U; Quattrone, A; Silani, V				Ratti, Antonia; Fallini, Claudia; Colombrita, Claudia; Pascale, Alessia; Laforenza, Umberto; Quattrone, Alessandro; Silani, Vincenzo			Post-transcriptional regulation of neuro-oncological ventral antigen 1 by the neuronal RNA-binding proteins ELAV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; UNTRANSLATED REGION; GENE-EXPRESSION; UP-REGULATION; HUD; CELLS; PLASTICITY; LETHAL; BRAIN; DIFFERENTIATION	Alternative splicing of pre-mRNAs plays an important role in generating biological and functional diversity. Neuro-oncological ventral antigen 1 (Nova1) is a neuron-specific splicing factor that controls the alternative processing of a wide array of mRNAs important for synaptic activity. It is essential for the proper development of the mammalian motor system and for the survival of motoneurons. Because Nova1 gene contains putative regulatory AU-rich elements (ARE) in its highly conserved 3'-untranslated region, we investigated whether its expression is regulated by post-transcriptional mechanisms mediated by ARE-binding proteins. Among these, the neuronal ELAV (nELAV) factors are interesting candidates, because their RNA binding activity is necessary for neuronal differentiation and maintenance. By analysis of ribonucleoprotein complexes in vivo and in vitro we demonstrated that the Nova1 mRNA is a novel target of the nELAV proteins. We defined the nELAV binding site by functional experiments with luciferase reporter gene and Nova1 3'-untranslated region deletion sequences. Gene silencing and overexpression of the nELAV member HuD in motoneuronal NSC34 cells indicate that Nova1 mRNA stability and translation are positively and strongly controlled by the nELAV proteins. In addition, nELAV phosphorylation by a PKC-dependent pathway induces the recruitment of Nova1 mRNA to polysomes. Noteworthy, we found that nELAV proteins are also able to modulate Nova1 splicing activity on its target genes. Our data indicate nELAV proteins as the first factors affecting the expression and activity of the neuronal splicing regulator Nova1 and, consequently, as major candidates for the physiological modulation of Nova1-dependent processing of pre-mRNAs in neurons.	[Ratti, Antonia; Fallini, Claudia; Colombrita, Claudia; Silani, Vincenzo] Univ Milan, Sch Med, IRCCS, Ist Auxol Italiano,Dept Neurol Sci,Dino Ferrari C, I-20095 Milan, Italy; [Pascale, Alessia] Univ Pavia, Dept Expt & Appl Pharmacol, I-27100 Pavia, Italy; [Laforenza, Umberto] Univ Pavia, Dept Expt Med, I-27100 Pavia, Italy; [Quattrone, Alessandro] Univ Trent, Ctr Integrat Biol, Lab Translat Genom, I-38100 Trento, Italy	IRCCS Istituto Auxologico Italiano; University of Milan; University of Pavia; University of Pavia; University of Trento	Ratti, A (corresponding author), Univ Milan, Sch Med, IRCCS, Ist Auxol Italiano,Dept Neurol Sci,Dino Ferrari C, Via Zucchi 18, I-20095 Milan, Italy.	antonia.ratti@unimi.it	Silani, Vincenzo/P-4421-2017; Fallini, Claudia/AAZ-1244-2020; colombrita, claudia/A-3295-2009	Silani, Vincenzo/0000-0002-7698-3854; Fallini, Claudia/0000-0001-8329-3467; colombrita, claudia/0000-0001-6567-8910; Quattrone, Alessandro/0000-0003-3333-7630; Laforenza, Umberto/0000-0003-2951-5983				Abe R, 1996, NUCLEIC ACIDS RES, V24, P2011, DOI 10.1093/nar/24.11.2011; Akamatsu W, 2005, P NATL ACAD SCI USA, V102, P4625, DOI 10.1073/pnas.0407523102; Antic D, 1999, GENE DEV, V13, P449, DOI 10.1101/gad.13.4.449; Antic D, 1997, AM J HUM GENET, V61, P273, DOI 10.1086/514866; Antic D, 1998, J CELL SCI, V111, P183; Aranda-Abreu GE, 1999, J NEUROSCI, V19, P6907, DOI 10.1523/JNEUROSCI.19-16-06907.1999; Aronov S, 2002, J CELL SCI, V115, P3817, DOI 10.1242/jcs.00058; Bakheet T, 2006, NUCLEIC ACIDS RES, V34, pD111, DOI 10.1093/nar/gkj052; Barreau C, 2005, NUCLEIC ACIDS RES, V33, P7138, DOI 10.1093/nar/gki1012; Black D L, 2003, Prog Mol Subcell Biol, V31, P187; Bolognani F, 2004, NEUROSCI LETT, V371, P152, DOI 10.1016/j.neulet.2004.08.074; Borgeson CD, 2005, NUCLEIC ACIDS RES, V33, P6372, DOI 10.1093/nar/gki942; Buckanovich RJ, 1996, J NEUROSCI, V16, P1114; Chung SM, 1997, J BIOL CHEM, V272, P6593, DOI 10.1074/jbc.272.10.6593; Deschenes-Furry J, 2006, BIOESSAYS, V28, P822, DOI 10.1002/bies.20449; DESCHENESFURRY J, 2005, CHEM-BIOL INTERACT, V43, P157; Ding Y, 2004, NUCLEIC ACIDS RES, V32, pW135, DOI 10.1093/nar/gkh449; Dredge BK, 2005, EMBO J, V24, P1608, DOI 10.1038/sj.emboj.7600630; Gerber AP, 2004, PLOS BIOL, V2, P342, DOI 10.1371/journal.pbio.0020079; GRAUS F, 1993, NEUROSCI LETT, V150, P212, DOI 10.1016/0304-3940(93)90538-V; Jensen KB, 2000, NEURON, V25, P359, DOI 10.1016/S0896-6273(00)80900-9; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; Keene JD, 2007, NAT REV GENET, V8, P533, DOI 10.1038/nrg2111; Keene JD, 2002, MOL CELL, V9, P1161, DOI 10.1016/S1097-2765(02)00559-2; Kosik KS, 2005, NEURON, V47, P779, DOI 10.1016/j.neuron.2005.08.019; Lipscombe D, 2005, CURR OPIN NEUROBIOL, V15, P358, DOI 10.1016/j.conb.2005.04.002; MECHLER BM, 1987, METHOD ENZYMOL, V152, P241; Moore MJ, 2005, SCIENCE, V309, P1514, DOI 10.1126/science.1111443; Okano HJ, 1997, J NEUROSCI, V17, P3024; Park HC, 2000, NEUROSCI LETT, V279, P81, DOI 10.1016/S0304-3940(99)00940-4; Pascale A, 2008, CELL MOL LIFE SCI, V65, P128, DOI 10.1007/s00018-007-7017-y; Pascale A, 1996, J NEUROCHEM, V67, P2471; Pascale A, 2005, P NATL ACAD SCI USA, V102, P12065, DOI 10.1073/pnas.0504702102; Pascale A, 2004, P NATL ACAD SCI USA, V101, P1217, DOI 10.1073/pnas.0307674100; Perrone-Bizzozero N, 2002, J NEUROSCI RES, V68, P121, DOI 10.1002/jnr.10175; Pullmann R, 2007, MOL CELL BIOL, V27, P6265, DOI 10.1128/MCB.00500-07; Quattrone A, 2001, P NATL ACAD SCI USA, V98, P11668, DOI 10.1073/pnas.191388398; Ratti A, 2006, J CELL SCI, V119, P1442, DOI 10.1242/jcs.02852; Rossoll W, 2003, J CELL BIOL, V163, P801, DOI 10.1083/jcb.200304128; Samson ML, 1998, GENETICS, V150, P723; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; Tenenbaum SA, 2002, METHODS, V26, P191, DOI 10.1016/S1046-2023(02)00022-1; Ule J, 2005, NAT GENET, V37, P844, DOI 10.1038/ng1610; Ule J, 2003, SCIENCE, V302, P1212, DOI 10.1126/science.1090095; Ule J, 2006, CURR OPIN NEUROBIOL, V16, P102, DOI 10.1016/j.conb.2006.01.003; Wakamatsu Y, 1997, DEVELOPMENT, V124, P3449; Yang YYL, 1998, P NATL ACAD SCI USA, V95, P13254, DOI 10.1073/pnas.95.22.13254; Zhu H, 2006, MOL BIOL CELL, V17, P5105, DOI 10.1091/mbc.E06-02-0099	48	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7531	7541		10.1074/jbc.M706082200	http://dx.doi.org/10.1074/jbc.M706082200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18218628	hybrid			2022-12-25	WOS:000253997900028
J	Reynolds, JM; Takebe, S; Choi, JY; El Bissati, K; Witola, WH; Bobenchik, AM; Hoch, JC; Voelker, DR; Ben Mamoun, C				Reynolds, Jennifer M.; Takebe, Sachiko; Choi, Jae-Yeon; El Bissati, Kamal; Witola, William H.; Bobenchik, April M.; Hoch, Jeffrey C.; Voelker, Dennis R.; Ben Mamoun, Choukri			Biochemical and genetic analysis of the phosphoethanolamine methyltransferase of the human malaria parasite Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-METHYLTRANSFERASE; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; PHOSPHOCHOLINE BIOSYNTHESIS; CAENORHABDITIS-ELEGANS; PATHWAY	The PfPMT enzyme of Plasmodium falciparum, the agent of severe human malaria, is a member of a large family of known and predicted phosphoethanolamine methyltransferases (PMTs) recently identified in plants, worms, and protozoa. Functional studies in P. falciparum revealed that PfPMT plays a critical role in the synthesis of phosphatidylcholine via a plant-like pathway involving serine decarboxylation and phosphoethanolamine methylation. Despite their important biological functions, PMT structures have not yet been solved, and nothing is known about which amino acids in these enzymes are critical for catalysis and binding to S-adenosyl-methionine and phosphoethanolamine substrates. Here we have performed a mutational analysis of PfPMT focused on 24 residues within and outside the predicted catalytic motif. The ability of PfPMT to complement the choline auxotrophy of a yeast mutant defective in phospholipid methylation enabled us to characterize the activity of the PfPMT mutants. Mutations in residues Asp-61, Gly-83 and Asp-128 dramatically altered PfPMT activity and its complementation of the yeast mutant. Our analyses identify the importance of these residues in PfPMT activity and set the stage for advanced structural understanding of this class of enzymes.	[Reynolds, Jennifer M.; Takebe, Sachiko; El Bissati, Kamal; Witola, William H.; Bobenchik, April M.; Ben Mamoun, Choukri] Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA; [Hoch, Jeffrey C.] Univ Connecticut, Ctr Hlth, Dept Mol Microbial & Struct Biol, Farmington, CT 06030 USA; [Choi, Jae-Yeon; Voelker, Dennis R.] Natl Jewish Ctr Immunol & Resp Med, Dept Med, Cell Biol Program, Denver, CO 80206 USA	University of Connecticut; University of Connecticut; National Jewish Health	Ben Mamoun, C (corresponding author), Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, 263 Farmington Ave, Farmington, CT 06030 USA.	Choukri@up.uchc.edu	Witola, WIlliam Harold/AAD-6647-2020	EL BISSATI, KAMAL/0000-0001-9341-4162; Hoch, Jeffrey/0000-0002-9230-2019	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI058962, R01AI051507] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032453] Funding Source: NIH RePORTER; NIAID NIH HHS [AI58962, AI51507] Funding Source: Medline; NIGMS NIH HHS [5R37GM32453] Funding Source: Medline; OCPHP CDC HHS [PR033005] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OCPHP CDC HHS		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bolognese CP, 2000, PLANT PHYSIOL, V124, P1800, DOI 10.1104/pp.124.4.1800; Brendza KM, 2007, BIOCHEM J, V404, P439, DOI 10.1042/BJ20061815; Charron JBF, 2002, PLANT PHYSIOL, V129, P363, DOI 10.1104/pp.001776; Guthrie C, 1991, GUIDE YEAST GENETICS; Nikulina K, 2004, CELL MOTIL CYTOSKEL, V57, P233, DOI 10.1002/cm.10172; Nuccio ML, 2000, J BIOL CHEM, V275, P14095, DOI 10.1074/jbc.275.19.14095; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Palavalli LH, 2006, BIOCHEMISTRY-US, V45, P6056, DOI 10.1021/bi060199d; Pessi G, 2005, J BIOL CHEM, V280, P12461, DOI 10.1074/jbc.M414626200; Pessi G, 2004, P NATL ACAD SCI USA, V101, P6206, DOI 10.1073/pnas.0307742101; Pessi G, 2006, FUTURE LIPIDOL, V1, P173, DOI 10.2217/17460875.1.2.173; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; Vial H., 1998, MALARIA PARASITE BIO, P159; Vial HJ, 2005, MOLECULAR APPROACHES TO MALARIA, P327; White NJ, 2004, J CLIN INVEST, V113, P1084, DOI [10.1172/JCI21682, 10.1172/JCI200421682]; *WHO EXP COMM MAL, 2000, WORLD HLTH ORG, V892; Witola WH, 2006, J BIOL CHEM, V281, P21305, DOI 10.1074/jbc.M603260200; Witola WH, 2007, EUKARYOT CELL, V6, P1618, DOI 10.1128/EC.00229-07	19	19	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7894	7900		10.1074/jbc.M709869200	http://dx.doi.org/10.1074/jbc.M709869200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18178564	hybrid			2022-12-25	WOS:000253997900065
J	Yan, L; Lavin, VA; Moser, LR; Cui, QH; Kanies, C; Yang, E				Yan, Ling; Lavin, Viviana A.; Moser, Leta R.; Cui, Qinghua; Kanies, Cindy; Yang, Elizabeth			PP2A regulates the pro-apoptotic activity of FOXO1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTOR; PROTEIN PHOSPHATASE 2A; PROTEASOMAL DEGRADATION; PHOSPHORYLATION SITES; TUMOR SUPPRESSION; GENE-EXPRESSION; CELL-SURVIVAL; AKT; BIM; FKHR	FOXO1, a member of the evolutionarily conserved forkhead family of transcription factors, regulates expression of a number of genes that play critical roles in cell cycle and apoptosis. A pivotal regulatory mechanism of FOXO is reversible phosphorylation, catalyzed by kinases and phosphatases. Phosphorylation of FOXO1 is associated with 14-3-3 binding and cytosolic localization, whereas dephosphorylated FOXO1 translocates to the nucleus and is transcriptionally active. Experiments were performed to identify the serine/ threonine phosphatase that dephosphorylates FOXO1. PP2A inhibitors, okadaic acid and fostriecin, increased FOXO1 phosphorylation in vitro and in cells. Microcystin-agarose pull-downs suggested that a phosphatase binds to FOXO1, and PP2A catalytic subunit was identified in endogenous FOXO1 immunocomplexes, indicating that PP2A is a FOXO1 phosphatase. Purified PP2A interacted directly with FOXO1 and dephosphorylated FOXO1 in vitro. Silencing of PP2A protected FOXO1 from dephosphorylation and delayed FOXO1 nuclear translocation, confirming the physiologic role of PP2A in the regulation of FOXO1 function. Furthermore, inhibition of PP2A phosphatases rescued FOXO1-mediated cell death by regulating the level of the proapoptotic protein BIM. We conclude that PP2A is a physiologic phosphatase of FOXO1.	Vanderbilt Univ, Ctr Med, Dept Pediat, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Yang, E (corresponding author), Vanderbilt Univ, Ctr Med, Dept Pediat, Nashville, TN 37232 USA.	elizabeth.yang@vanderbilt.edu			NCI NIH HHS [T32 CA009592, R01CA92498] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092498, T32CA009592] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Aoki M, 2004, P NATL ACAD SCI USA, V101, P13613, DOI 10.1073/pnas.0405454101; Arden KC, 2007, CELL, V128, P235, DOI 10.1016/j.cell.2007.01.009; Arden KC, 2006, EXP GERONTOL, V41, P709, DOI 10.1016/j.exger.2006.05.015; Barreyro FJ, 2007, J BIOL CHEM, V282, P27141, DOI 10.1074/jbc.M704391200; Birkenkamp KU, 2003, BIOCHEM SOC T, V31, P292, DOI 10.1042/bst0310292; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Chen J, 1998, BIOCHEM BIOPH RES CO, V247, P827, DOI 10.1006/bbrc.1998.8792; Chiang CW, 2003, MOL CELL BIOL, V23, P6350, DOI 10.1128/MCB.23.18.6350-6362.2003; Coffer PJ, 2007, NAT CELL BIOL, V9, P251, DOI 10.1038/ncb0307-251; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Gallego M, 2005, CURR OPIN CELL BIOL, V17, P197, DOI 10.1016/j.ceb.2005.01.002; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Hosaka T, 2004, P NATL ACAD SCI USA, V101, P2975, DOI 10.1073/pnas.0400093101; Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004; Klumpp S, 2002, CURR OPIN PHARMACOL, V2, P458, DOI 10.1016/S1471-4892(02)00176-5; Kong M, 2004, SCIENCE, V306, P695, DOI 10.1126/science.1100537; Lam EWF, 2006, BIOCHEM SOC T, V34, P722, DOI 10.1042/BST0340722; Margolis SS, 2006, CELL, V127, P759, DOI 10.1016/j.cell.2006.10.035; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Moorhead GBG, 2007, NAT REV MOL CELL BIO, V8, P234, DOI 10.1038/nrm2126; Mumby M, 2007, ACS CHEM BIOL, V2, P99, DOI 10.1021/cb700021z; Murata K, 1997, P NATL ACAD SCI USA, V94, P10624, DOI 10.1073/pnas.94.20.10624; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Ni YG, 2007, P NATL ACAD SCI USA, V104, P20517, DOI 10.1073/pnas.0610290104; Ostman A, 2006, NAT REV CANCER, V6, P307, DOI 10.1038/nrc1837; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Rena G, 2002, EMBO J, V21, P2263, DOI 10.1093/emboj/21.9.2263; Rena G, 2001, BIOCHEM J, V354, P605, DOI 10.1042/0264-6021:3540605; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tothova Z, 2007, CELL, V128, P325, DOI 10.1016/j.cell.2007.01.003; TRAN H, 2003, SCI STKE, pRE5, DOI DOI 10.1126/STKE.2003.172.RE5; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Urbich C, 2005, FASEB J, V19, P974, DOI 10.1096/fj.04-2727fje; van der Heide LP, 2004, BIOCHEM J, V380, P297, DOI 10.1042/BJ20040167; Vogt PK, 2005, CELL CYCLE, V4, P908, DOI 10.4161/cc.4.7.1796; Walsh AH, 1997, FEBS LETT, V416, P230, DOI 10.1016/S0014-5793(97)01210-6; Wang BC, 1999, BIOCHEMISTRY-US, V38, P12499, DOI 10.1021/bi991353h; Xing Y, 2006, CELL, V127, P341, DOI 10.1016/j.cell.2006.09.025; Xu YH, 2006, CELL, V127, P1239, DOI 10.1016/j.cell.2006.11.033; Zhang WW, 2006, J BIOL CHEM, V281, P10105, DOI 10.1074/jbc.M600272200; Zhao XS, 2004, BIOCHEM J, V378, P839, DOI 10.1042/BJ20031450	50	102	105	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7411	7420		10.1074/jbc.M708083200	http://dx.doi.org/10.1074/jbc.M708083200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18211894	Green Published, hybrid			2022-12-25	WOS:000253997900015
J	Lipson, C; Alalouf, G; Bajorek, M; Rabinovich, E; Atir-Lande, A; Glickman, M; Bar-Nun, S				Lipson, Carni; Alalouf, Guy; Bajorek, Monika; Rabinovich, Efrat; Atir-Lande, Avigail; Glickman, Michael; Bar-Nun, Shoshana			A proteasomal ATPase contributes to dislocation of endoplasmic reticulum-associated degradation (ERAD) substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; AAA-ATPASE; REGULATORY PARTICLE; TRANSLOCATION CHANNEL; RETRO-TRANSLOCATION; UBIQUITIN LIGASES; MEMBRANE-PROTEIN; QUALITY-CONTROL; 26S PROTEASOME; CORE PARTICLE	Endoplasmic reticulum ( ER)-associated degradation ( ERAD) eliminates aberrant proteins from the ER by dislocating them to the cytoplasm where they are tagged by ubiquitin and degraded by the proteasome. Six distinct AAA-ATPases ( Rpt1-6) at the base of the 19S regulatory particle of the 26S proteasome recognize, unfold, and translocate substrates into the 20S catalytic chamber. Here we show unique contributions of individual Rpts to ERAD by employing equivalent conservative substitutions of the invariant lysine in the ATP-binding motif of each Rpt subunit. ERAD of two substrates, luminal CPY*-HA and membrane 6myc-Hmg2, is inhibited only in rpt4R and rpt2RF mutants. Conversely, in vivo degradation of a cytosolic substrate, Delta ssCPY*-GFP, as well as in vitro cleavage of Suc-LLVY-AMC are hardly affected in rpt4R mutant yet are inhibited in rpt2RF mutant. Together, we find that equivalent mutations in RPT4 and RPT2 result in different phenotypes. The Rpt4 mutation is manifested in ERAD defects, whereas the Rpt2 mutation is manifested downstream, in global proteasomal activity. Accordingly, rpt4R strain is particularly sensitive to ER stress and exhibits an activated unfolded protein response, whereas rpt2RF strain is sensitive to general stress. Further characterization of Rpt4 involvement in ERAD reveals that it participates in CPY*-HA dislocation, a function previously attributed to p97/ Cdc48, another AAA-ATPase essential for ERAD of CPY*-HA but dispensable for proteasomal degradation of Delta ssCPY*-GFP. Pointing to Cdc48 and Rpt4 overlapping functions, excess Cdc48 partially restores impaired ERAD in rpt4R, but not in rpt2RF. We discuss models for Cdc48 and Rpt4 cooperation in ERAD.	[Lipson, Carni; Alalouf, Guy; Rabinovich, Efrat; Bar-Nun, Shoshana] Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel; [Bajorek, Monika; Atir-Lande, Avigail; Glickman, Michael] Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel	Tel Aviv University; Technion Israel Institute of Technology	Bar-Nun, S (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel.	shoshbn@tauex.tau.ac.il		Bajorek, Monika/0000-0002-0160-4709; Glickman, Michael/0000-0002-1222-8104				Bajorek M, 2003, CURR BIOL, V13, P1140, DOI 10.1016/S0960-9822(03)00417-2; Bar-Nun S, 2005, CURR TOP MICROBIOL, V300, P95; Bays NW, 2001, MOL BIOL CELL, V12, P4114, DOI 10.1091/mbc.12.12.4114; Benaroudj N, 2003, MOL CELL, V11, P69, DOI 10.1016/S1097-2765(02)00775-X; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; Dai RM, 2001, NAT CELL BIOL, V3, P740, DOI 10.1038/35087056; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; Elkabetz Y, 2004, J BIOL CHEM, V279, P3980, DOI 10.1074/jbc.M309938200; Elkabetz Y, 2003, J BIOL CHEM, V278, P18922, DOI 10.1074/jbc.M208730200; Elsasser S, 2005, NAT CELL BIOL, V7, P742, DOI 10.1038/ncb0805-742; Fu HY, 2001, EMBO J, V20, P7096, DOI 10.1093/emboj/20.24.7096; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992; Guttmann-Raviv N, 2002, MOL CELL BIOL, V22, P2047, DOI 10.1128/MCB.22.7.2047-2056.2002; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; Hill K, 2000, EMBO J, V19, P550, DOI 10.1093/emboj/19.4.550; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hirsch C, 2000, TRENDS CELL BIOL, V10, P268, DOI 10.1016/S0962-8924(00)01768-2; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; Kalies KU, 2005, EMBO J, V24, P2284, DOI 10.1038/sj.emboj.7600731; Kaplun L, 2000, P NATL ACAD SCI USA, V97, P10077, DOI 10.1073/pnas.97.18.10077; Kawahara T, 1997, MOL BIOL CELL, V8, P1845, DOI 10.1091/mbc.8.10.1845; Kohler A, 2001, MOL CELL, V7, P1143, DOI 10.1016/S1097-2765(01)00274-X; Kohler A, 2001, BIOCHIMIE, V83, P325, DOI 10.1016/S0300-9084(01)01242-1; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Lederkremer GZ, 2005, TRENDS BIOCHEM SCI, V30, P297, DOI 10.1016/j.tibs.2005.04.010; Lee RJ, 2004, EMBO J, V23, P2206, DOI 10.1038/sj.emboj.7600232; Leggett David S., 2005, V301, P57; Lilley BN, 2005, P NATL ACAD SCI USA, V102, P14296, DOI 10.1073/pnas.0505014102; Lupas AN, 2002, CURR OPIN STRUC BIOL, V12, P746, DOI 10.1016/S0959-440X(02)00388-3; Mayer TU, 1998, EMBO J, V17, P3251, DOI 10.1093/emboj/17.12.3251; Medicherla B, 2004, EMBO REP, V5, P692, DOI 10.1038/sj.embor.7400164; Navon A, 2001, MOL CELL, V8, P1339, DOI 10.1016/S1097-2765(01)00407-5; Neuber O, 2005, NAT CELL BIOL, V7, P993, DOI 10.1038/ncb1298; Ortega J, 2000, MOL CELL, V6, P1515, DOI 10.1016/S1097-2765(00)00148-9; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; Rabinovich E, 2006, ISR MED ASSOC J, V8, P238; Rabinovich E, 2006, ISRAEL J CHEM, V46, P219, DOI 10.1560/DA1X-C4K6-K8F7-RG5F; Rivett AJ, 1998, CURR OPIN IMMUNOL, V10, P110, DOI 10.1016/S0952-7915(98)80040-X; Rouiller I, 2002, NAT STRUCT BIOL, V9, P950, DOI 10.1038/nsb872; Rubin DM, 1998, EMBO J, V17, P4909, DOI 10.1093/emboj/17.17.4909; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Schuberth C, 2005, NAT CELL BIOL, V7, P999, DOI 10.1038/ncb1299; Sears C, 1998, J BIOL CHEM, V273, P1409, DOI 10.1074/jbc.273.3.1409; Smith DM, 2005, MOL CELL, V20, P687, DOI 10.1016/j.molcel.2005.10.019; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; Urano F, 2002, J CELL BIOL, V158, P639, DOI 10.1083/jcb.200203086; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Wang QQ, 2003, EMBO J, V22, P3792, DOI 10.1093/emboj/cdg378; Ye YH, 2003, J CELL BIOL, V162, P71, DOI 10.1083/jcb.200302169; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Ye YH, 2005, P NATL ACAD SCI USA, V102, P14132, DOI 10.1073/pnas.0505006102; Ye YH, 2004, NATURE, V429, P841, DOI 10.1038/nature02656; Zhong XY, 2004, J BIOL CHEM, V279, P45676, DOI 10.1074/jbc.M409034200; Zhou MY, 1999, MOL CELL, V4, P925, DOI 10.1016/S1097-2765(00)80222-1	60	53	55	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					7166	7175		10.1074/jbc.M705893200	http://dx.doi.org/10.1074/jbc.M705893200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18174173	Green Published, hybrid			2022-12-25	WOS:000253779600062
J	Yarwood, SJ; Borland, G; Sands, WA; Palmer, TM				Yarwood, Stephen J.; Borland, Gillian; Sands, William A.; Palmer, Timothy M.			Identification of CCAAT/enhancer-binding proteins as exchange protein activated by cAMP-activated transcription factors that mediate the induction of the SOCS-3 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP; HORMONAL-REGULATION; C/EBP-ALPHA; FACTOR CREB; RAP1; EXPRESSION; PROMOTER; CELLS; PHOSPHODIESTERASES; PHOSPHORYLATION	The prototypical second messenger cAMP is a key regulator of immune and inflammatory responses. Its ability to inhibit interleukin (IL)-6 responses is due to induction of suppressor of cytokine signaling-3 (SOCS-3), a negative regulator of IL-6 receptor signaling. We have determined previously that SOCS-3 induction by cAMP occurs independently of cAMP-dependent protein kinase, instead requiring the recently identified cAMP sensor exchange protein activated by cAMP1 (EPAC1). Here we present evidence to suggest that the C/EBP family of transcription factors link EPAC1 activation to SOCS-3 induction. Firstly, selective activation of EPAC in human umbilical vein endothelial cells increased C/EBP DNA binding activity and recruitment of C/EBP beta to the SOCS-3 promoter. Secondly, knockdown of C/EBP beta and -delta isoforms abolished both SOCS-3 induction and inhibition of IL-6 signaling in response to cAMP. Thirdly, overexpression of C/EBP alpha, -beta, or -delta potentiated EPAC-mediated accumulation of SOCS-3. Finally, these effects were not restricted to human umbilical vein endothelial cells, because similar phenomena were observed in murine embryonic fibroblasts in which C/EBP beta or delta had been deleted. In summary, our findings constitute the first description of an EPAC-C/EBP pathway that can control cAMP-mediated changes in gene expression independently of protein kinase A.	[Yarwood, Stephen J.; Borland, Gillian; Sands, William A.; Palmer, Timothy M.] Univ Glasgow, Fac Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	Yarwood, SJ (corresponding author), Univ Glasgow, Fac Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	Yarwood@bio.gla.ac.uk; T.Palmer@bio.gla.ac.uk	Palmer, Timothy/C-4975-2009; Palmer, Timothy/E-7290-2013	Palmer, Timothy/0000-0002-9803-7164; Yarwood, Stephen/0000-0001-9489-9253	BBSRC [BB/D015324/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/D015324/1] Funding Source: researchfish; Biotechnology and Biological Sciences Research Council [bb/d015324/1] Funding Source: Medline; British Heart Foundation [pg/05/026] Funding Source: Medline	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); British Heart Foundation(British Heart Foundation)		Beavo JA, 2002, NAT REV MOL CELL BIO, V3, P710, DOI 10.1038/nrm911; Brenner S, 2003, J BIOL CHEM, V278, P5597, DOI 10.1074/jbc.M207448200; Conkright MD, 2005, TRENDS CELL BIOL, V15, P457, DOI 10.1016/j.tcb.2005.07.007; Conti M, 2003, J BIOL CHEM, V278, P5493, DOI 10.1074/jbc.R200029200; Crosson SM, 2000, J BIOL CHEM, V275, P5804, DOI 10.1074/jbc.275.8.5804; Daniel PB, 1998, ANNU REV NUTR, V18, P353, DOI 10.1146/annurev.nutr.18.1.353; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Edelstein LC, 2003, MOL CELL BIOL, V23, P2749, DOI 10.1128/MCB.23.8.2749-2761.2003; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Gronning LM, 1999, ENDOCRINOLOGY, V140, P835, DOI 10.1210/en.140.2.835; He B, 2003, BIOCHEM BIOPH RES CO, V301, P386, DOI 10.1016/S0006-291X(02)03071-1; Houslay MD, 1998, SEMIN CELL DEV BIOL, V9, P161, DOI 10.1006/scdb.1997.0221; Huang AM, 2004, ONCOGENE, V23, P1549, DOI 10.1038/sj.onc.1207285; Insel PA, 2003, CELL MOL NEUROBIOL, V23, P305, DOI 10.1023/A:1023684503883; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kel-Margoulis OV, 2002, NUCLEIC ACIDS RES, V30, P332, DOI 10.1093/nar/30.1.332; Kooistra MRH, 2005, FEBS LETT, V579, P4966, DOI 10.1016/j.febslet.2005.07.080; Kubo M, 2003, NAT IMMUNOL, V4, P1169, DOI 10.1038/ni1012; Lee YH, 1997, MOL CELL BIOL, V17, P6014, DOI 10.1128/MCB.17.10.6014; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Pelletier N, 1998, FEBS LETT, V439, P275, DOI 10.1016/S0014-5793(98)01388-X; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Roesler WJ, 2001, ANNU REV NUTR, V21, P141, DOI 10.1146/annurev.nutr.21.1.141; Sands WA, 2006, MOL CELL BIOL, V26, P6333, DOI 10.1128/MCB.00207-06; SPIEGEL AM, 1987, MOL CELL ENDOCRINOL, V49, P1, DOI 10.1016/0303-7207(87)90058-X; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; Wilson HL, 2002, MOL CELL ENDOCRINOL, V188, P15, DOI 10.1016/S0303-7207(01)00754-7; Wilson HL, 2001, MOL CELL ENDOCRINOL, V181, P27, DOI 10.1016/S0303-7207(01)00540-8; Yarwood SJ, 1998, MOL CELL ENDOCRINOL, V138, P41	33	69	69	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					6843	6853		10.1074/jbc.M710342200	http://dx.doi.org/10.1074/jbc.M710342200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18195020	hybrid			2022-12-25	WOS:000253779600027
J	Bright, RA; Carter, DM; Crevar, CJ; Toapanta, FR; Steckbeck, JD; Cole, KS; Kumar, NM; Pushko, P; Smith, G; Tumpey, TM; Ross, TM				Bright, Rick A.; Carter, Donald M.; Crevar, Corey J.; Toapanta, Franklin R.; Steckbeck, Jonathan D.; Cole, Kelly S.; Kumar, Niranjan M.; Pushko, Peter; Smith, Gale; Tumpey, Terrence M.; Ross, Ted M.			Cross-Clade Protective Immune Responses to Influenza Viruses with H5N1 HA and NA Elicited by an Influenza Virus-Like Particle	PLOS ONE			English	Article							CYTOTOXIC T-LYMPHOCYTE; A H5N1; REVERSE-GENETICS; HETEROSUBTYPIC IMMUNITY; NEUTRALIZING ANTIBODIES; ADAMANTANE RESISTANCE; HUMAN-DISEASE; PLAQUE ASSAY; VACCINE; MICE	Background. Vaccination is a cost-effective counter-measure to the threat of seasonal or pandemic outbreaks of influenza. To address the need for improved influenza vaccines and alternatives to egg-based manufacturing, we have engineered an influenza virus-like particle (VLP) as a new generation of non-egg or non-mammalian cell culture-based candidate vaccine. Methodology/Principal Findings. We generated from a baculovirus expression system using insect cells, a non-infectious recombinant VLP vaccine from both influenza A H5N1 clade 1 and clade 2 isolates with pandemic potential. VLPs were administered to mice in either a one-dose or two-dose regimen and the immune responses were compared to those induced by recombinant hemagglutinin (rHA). Both humoral and cellular responses were analyzed. Mice vaccinated with VLPs were protected against challenge with lethal reassortant viruses expressing the H5N1 HA and NA, regardless if the H5N1 clade was homologous or heterologous to the vaccine. However, rHA-vaccinated mice showed considerable weight loss and death following challenge with the heterovariant clade virus. Protection against death induced by VLPs was independent of the prechallenge HAI titer or cell-mediated responses to HA or M1 since vaccinated mice, with low to undetectable cross-clade HAI antibodies or cellular responses to influenza antigens, were still protected from a lethal viral challenge. However, an apparent association rate of antibody binding to HA correlated with protection and was enhanced using VLPs, particularly when delivered intranasally, compared to rHA vaccines. Conclusion/Significance. This is the first report describing the use of an H5N1 VLP vaccine created from a clade 2 isolate. The results show that a non-replicating virus-like particle is effective at eliciting a broadened, cross-clade protective immune response to proteins from emerging H5N1 influenza isolates giving rise to a potential pandemic influenza vaccine candidate for humans that can be stockpiled for use in the event of an outbreak of H5N1 influenza.	[Bright, Rick A.; Kumar, Niranjan M.; Pushko, Peter; Smith, Gale] Novavax Inc, Rockville, MD USA; [Carter, Donald M.; Crevar, Corey J.; Toapanta, Franklin R.; Steckbeck, Jonathan D.; Cole, Kelly S.; Ross, Ted M.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA; [Tumpey, Terrence M.] Ctr Dis Control & Prev, Influenza Div, Atlanta, GA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Centers for Disease Control & Prevention - USA	Bright, RA (corresponding author), Novavax Inc, Rockville, MD USA.	rbright@novavax.com; tmr15@pitt.edu	Toapanta, Franklin/Y-1774-2019		Center for Vaccine Research, Novavax	Center for Vaccine Research, Novavax	The Center for Vaccine Research, Novavax supported this work.	Asahi-Ozaki Y, 2004, J MED VIROL, V74, P328, DOI 10.1002/jmv.20173; Askonas BA, 1982, BASIC APPLIED INFLUE, P159; Booy R, 2006, MED J AUSTRALIA, V185, pS62; Bower JF, 2005, CURR HIV RES, V3, P191, DOI 10.2174/1570162053506937; Bower JF, 2004, VIROLOGY, V328, P292, DOI 10.1016/j.virol.2004.07.031; BRACIALE TJ, 1978, J EXP MED, V147, P1236, DOI 10.1084/jem.147.4.1236; Bresson JL, 2006, LANCET, V367, P1657, DOI 10.1016/S0140-6736(06)68656-X; Bright RA, 2006, JAMA-J AM MED ASSOC, V295, P891, DOI 10.1001/jama.295.8.joc60020; Bright RA, 2005, LANCET, V366, P1175, DOI 10.1016/S0140-6736(05)67338-2; Bright RA, 2003, VIROLOGY, V308, P270, DOI 10.1016/S0042-6822(03)00008-4; Bright RA, 2007, VACCINE, V25, P3871, DOI 10.1016/j.vaccine.2007.01.106; Cheung CL, 2006, J INFECT DIS, V193, P1626, DOI 10.1086/504723; Cheung CY, 2002, LANCET, V360, P1831, DOI 10.1016/S0140-6736(02)11772-7; Chotpitayasunondh T, 2005, EMERG INFECT DIS, V11, P201, DOI 10.3201/eid1102.041061; de Jong MD, 2005, NEW ENGL J MED, V353, P2667, DOI 10.1056/NEJMoa054512; de Jong MD, 2006, NAT MED, V12, P1203, DOI 10.1038/nm1477; Despres P, 2005, J INFECT DIS, V191, P207, DOI 10.1086/426824; Epstein SL, 1998, J IMMUNOL, V160, P322; Evans TG, 2001, J INFECT DIS, V183, P1485, DOI 10.1086/320190; Flynn KJ, 1998, IMMUNITY, V8, P683, DOI 10.1016/S1074-7613(00)80573-7; Flynn KJ, 1999, P NATL ACAD SCI USA, V96, P8597, DOI 10.1073/pnas.96.15.8597; Focosi D, 2006, NEW ENGL J MED, V354, P2724; Gao WT, 2006, J VIROL, V80, P1959, DOI 10.1128/JVI.80.4.1959-1964.2006; Gillim-Ross L, 2006, CLIN MICROBIOL REV, V19, P614, DOI 10.1128/CMR.00005-06; Govorkova EA, 2006, J INFECT DIS, V194, P159, DOI 10.1086/505225; HAFFAR OK, 1991, VIROLOGY, V183, P487, DOI 10.1016/0042-6822(91)90978-K; Hien TT, 2004, NEW ENGL J MED, V350, P1179, DOI 10.1056/NEJMoa040419; Hoelscher MA, 2006, LANCET, V367, P475, DOI 10.1016/S0140-6736(06)68076-8; HURT AC, 2006, SUSCEPTIBILITY HIGHL; Koutsky LA, 2002, NEW ENGL J MED, V347, P1645, DOI 10.1056/NEJMoa020586; Kozak W, 1997, AM J PHYSIOL-REG I, V272, pR621, DOI 10.1152/ajpregu.1997.272.2.R621; Lalvani A, 1997, J IMMUNOL METHODS, V210, P65, DOI 10.1016/S0022-1759(97)00177-4; Le QM, 2005, NATURE, V437, P1108, DOI 10.1038/4371108a; Leroux-Roels I, 2007, LANCET, V370, P580, DOI 10.1016/S0140-6736(07)61297-5; LIEW FY, 1984, EUR J IMMUNOL, V14, P350, DOI 10.1002/eji.1830140414; Lin JT, 2006, LANCET, V368, P991, DOI 10.1016/S0140-6736(06)69294-5; Lorin C, 2004, J VIROL, V78, P146, DOI 10.1128/JVI.78.1.146-157.2004; Luke CJ, 2006, EMERG INFECT DIS, V12, P66, DOI 10.3201/eid1201.051147; McBurney SP, 2006, CURR HIV RES, V4, P475, DOI 10.2174/157016206778560018; MCBURNEY SP, 2006, VIROLOGY; Mitchell JA, 2003, VACCINE, V21, P902, DOI 10.1016/S0264-410X(02)00539-X; Nicolson C, 2005, VACCINE, V23, P2943, DOI 10.1016/j.vaccine.2004.08.054; ORGANIZATION WH, 2005, EMERG INFECT DIS, V11, P1515; ORGANIZATION WH, 2006, RECOMMENDATION PANDE; ORGANIZATION WH, 2006, AVIAN INFLUENZA SITU; Pushko P, 2005, VACCINE, V23, P5751, DOI 10.1016/j.vaccine.2005.07.098; Qiao C, 2006, DEV BIOLOGICALS, V124, P127; REED L. J., 1938, AMER JOUR HYG, V27, P493; Riberdy JM, 1999, J VIROL, V73, P1453, DOI 10.1128/JVI.73.2.1453-1459.1999; Ross TM, 2000, NAT IMMUNOL, V1, P127, DOI 10.1038/77802; Sambhara S, 2001, CELL IMMUNOL, V210, P1, DOI 10.1006/cimm.2001.1799; Sambhara S, 2001, CELL IMMUNOL, V211, P143, DOI 10.1006/cimm.2001.1835; Sandbulte MR, 2007, PLOS MED, V4, P265, DOI 10.1371/journal.pmed.0040059; SMINIA T, 1999, MUCOSAL IMMUNOLOGY, V2, P357; Steckbeck JD, 2006, J MED PRIMATOL, V35, P248, DOI 10.1111/j.1600-0684.2006.00173.x; Steckbeck JD, 2005, J VIROL, V79, P12311, DOI 10.1128/JVI.79.19.12311-12320.2005; Stephenson I, 2005, J INFECT DIS, V191, P1210, DOI 10.1086/428948; STOHR K, 2005, NEW ENGL J MED, V352, P333; Subbarao K, 2006, IMMUNITY, V24, P5, DOI 10.1016/j.immuni.2005.12.005; Subbarao K, 1998, SCIENCE, V279, P393, DOI 10.1126/science.279.5349.393; Subbarao K, 2003, VIROLOGY, V305, P192, DOI 10.1006/viro.2002.1742; Suguitan AL, 2006, PLOS MED, V3, P1541, DOI 10.1371/journal.pmed.0030360; Szucs TD, 2001, INFECT CONT HOSP EP, V22, P472, DOI 10.1086/503405; TILNEY NL, 1971, J ANAT, V109, P369; To KF, 2001, J MED VIROL, V63, P242, DOI 10.1002/1096-9071(200103)63:3&lt;242::AID-JMV1007&gt;3.0.CO;2-N; Toapanta FR, 2004, VACCINE, V22, P1773, DOI 10.1016/j.vaccine.2003.10.050; TOBITA K, 1975, MED MICROBIOL IMMUN, V162, P9, DOI 10.1007/BF02123572; TOBITA K, 1975, MED MICROBIOL IMMUN, V162, P23, DOI 10.1007/BF02123574; Tochikubo K, 1998, VACCINE, V16, P150, DOI 10.1016/S0264-410X(97)00194-1; Treanor JJ, 2006, NEW ENGL J MED, V354, P1343, DOI 10.1056/NEJMoa055778; Webster RG, 2006, VIROLOGY, V351, P303, DOI 10.1016/j.virol.2006.01.044; Wiley JA, 2001, AM J PATHOL, V158, P119, DOI 10.1016/S0002-9440(10)63950-8; Wiley JA, 2001, J IMMUNOL, V167, P3293, DOI 10.4049/jimmunol.167.6.3293; WOOD J, 1997, DEV BIOL STAND, V39, P193; Wu HY, 1997, SCAND J IMMUNOL, V46, P506, DOI 10.1046/j.1365-3083.1997.d01-159.x; YAP KL, 1978, NATURE, V273, P238, DOI 10.1038/273238a0; Yoshikawa T, 2004, J GEN VIROL, V85, P2339, DOI 10.1099/vir.0.79892-0; Young KR, 2006, AIDS RES HUM RETROV, V22, P99, DOI 10.1089/aid.2006.22.99; Yuen KY, 1998, LANCET, V351, P467, DOI 10.1016/S0140-6736(98)01182-9	79	208	235	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2008	3	1							e1501	10.1371/journal.pone.0001501	http://dx.doi.org/10.1371/journal.pone.0001501			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SR	18231588	Green Accepted, Green Published, Green Submitted, gold			2022-12-25	WOS:000260504200014
J	Kerneis, S; Grais, RF; Boelle, PY; Flahault, A; Vergu, E				Kerneis, Solen; Grais, Rebecca F.; Boelle, Pierre-Yves; Flahault, Antoine; Vergu, Elisabeta			Does the Effectiveness of Control Measures Depend on the Influenza Pandemic Profile?	PLOS ONE			English	Article								Background. Although strategies to contain influenza pandemics are well studied, the characterization and the implications of different geographical and temporal diffusion patterns of the pandemic have been given less attention. Methodology/Main Findings. Using a well-documented metapopulation model incorporating air travel between 52 major world cities, we identified potential influenza pandemic diffusion profiles and examined how the impact of interventions might be affected by this heterogeneity. Clustering methods applied to a set of pandemic simulations, characterized by seven parameters related to the conditions of emergence that were varied following Latin hypercube sampling, were used to identify six pandemic profiles exhibiting different characteristics notably in terms of global burden ( from 415 to.160 million of cases) and duration ( from 26 to 360 days). A multivariate sensitivity analysis showed that the transmission rate and proportion of susceptibles have a strong impact on the pandemic diffusion. The correlation between interventions and pandemic outcomes were analyzed for two specific profiles: a fast, massive pandemic and a slow building, long-lasting one. In both cases, the date of introduction for five control measures ( masks, isolation, prophylactic or therapeutic use of antivirals, vaccination) correlated strongly with pandemic outcomes. Conversely, the coverage and efficacy of these interventions only moderately correlated with pandemic outcomes in the case of a massive pandemic. Pre-pandemic vaccination influenced pandemic outcomes in both profiles, while travel restriction was the only measure without any measurable effect in either. Conclusions. Our study highlights: (i) the great heterogeneity in possible profiles of a future influenza pandemic; (ii) the value of being well prepared in every country since a pandemic may have heavy consequences wherever and whenever it starts; (iii) the need to quickly implement control measures and even to anticipate pandemic emergence through pre-pandemic vaccination; and (iv) the value of combining all available control measures except perhaps travel restrictions.	[Vergu, Elisabeta] INRA, Math & Informat Appl UR341, Jouy En Josas, France; [Kerneis, Solen; Grais, Rebecca F.; Boelle, Pierre-Yves; Flahault, Antoine] Univ Pierre Marie Curie Paris 6, UMR S 707, Paris, France; [Kerneis, Solen; Grais, Rebecca F.; Boelle, Pierre-Yves; Flahault, Antoine] INSERM, UMR S 707, Paris, France	INRAE; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Vergu, E (corresponding author), INRA, Math & Informat Appl UR341, Jouy En Josas, France.	elisabeta.vergu@jouy.inra.fr		Boelle, Pierre-Yves/0000-0002-5367-8232; Freeman Grais, Rebecca/0000-0002-5037-8218	Fondation Recherche Medicale	Fondation Recherche Medicale	Solen Kerneis received a research grant from the Fondation Recherche Medicale. The views expressed in this article are those of the authors.	Arino J, 2006, J R SOC INTERFACE, V3, P453, DOI 10.1098/rsif.2006.0112; BLOWER SM, 1994, INT STAT REV, V62, P229, DOI 10.2307/1403510; Bush R., 2007, ENCY INFECT DIS MODE, P199; Caley P, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000143; CARRAT F, AM J EPIDEM IN PRESS; Carrat F, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-26; Chowell G, 2006, J THEOR BIOL, V241, P193, DOI 10.1016/j.jtbi.2005.11.026; Colizza V, 2006, P NATL ACAD SCI USA, V103, P2015, DOI 10.1073/pnas.0510525103; Colizza V, 2007, PLOS MED, V4, P95, DOI 10.1371/journal.pmed.0040013; Cooper BS, 2006, PLOS MED, V3, P845, DOI 10.1371/journal.pmed.0030212; Epstein JM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000401; Ferguson NM, 2006, NATURE, V442, P448, DOI 10.1038/nature04795; Ferguson NM, 2005, NATURE, V437, P209, DOI 10.1038/nature04017; Flahault A, 2006, VACCINE, V24, P6751, DOI 10.1016/j.vaccine.2006.05.079; Fraser C, 2004, P NATL ACAD SCI USA, V101, P6146, DOI 10.1073/pnas.0307506101; Germann TC, 2006, P NATL ACAD SCI USA, V103, P5935, DOI 10.1073/pnas.0601266103; Grais R F, 2004, Health Care Manag Sci, V7, P127, DOI 10.1023/B:HCMS.0000020652.38181.da; Grais RF, 2003, EUR J EPIDEMIOL, V18, P1065, DOI 10.1023/A:1026140019146; Hollingsworth TD, 2006, NAT MED, V12, P497, DOI 10.1038/nm0506-497; Kendall MG, 1942, BIOMETRIKA, V32, P277, DOI 10.1093/biomet/32.3-4.277; Kilbourne ED, 2006, EMERG INFECT DIS, V12, P9, DOI 10.3201/eid1201.051254; Lipsitch M, 2007, PLOS MED, V4, P111, DOI 10.1371/journal.pmed.0040015; Lofgren E, 2007, J VIROL, V81, P5429, DOI 10.1128/JVI.01680-06; Longini IM, 2004, AM J EPIDEMIOL, V159, P623, DOI 10.1093/aje/kwh092; Longini IM, 2005, SCIENCE, V309, P1083, DOI 10.1126/science.1115717; MCKAY MD, 1979, TECHNOMETRICS, V21; Mills CE, 2004, NATURE, V432, P904, DOI 10.1038/nature03063; Nuno M, 2007, J R SOC INTERFACE, V4, P505, DOI 10.1098/rsif.2006.0186; Riley S, 2007, PLOS MED, V4, P1032, DOI 10.1371/journal.pmed.0040218; Roberts MG, 2007, J MATH BIOL, V55, P803, DOI 10.1007/s00285-007-0112-8; RVACHEV LA, 1985, MATH BIOSCI, V75, P3, DOI 10.1016/0025-5564(85)90064-1; Viboud C, 2006, SCIENCE, V312, P447, DOI 10.1126/science.1125237; WARD JH, 1963, J AM STAT ASSOC, V58, P236, DOI 10.2307/2282967; *WHO, 2006, EMERG INFECT DIS; Wu JT, 2006, PLOS MED, V3, P1532, DOI 10.1371/journal.pmed.0030361	35	20	20	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2008	3	1							e1478	10.1371/journal.pone.0001478	http://dx.doi.org/10.1371/journal.pone.0001478			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SO	18213386	Green Published, gold, Green Submitted			2022-12-25	WOS:000260503900023
J	Trenner, MU; Heekeren, HR; Bauer, M; Rossner, K; Wenzel, R; Villringer, A; Fahle, M				Trenner, Maja U.; Heekeren, Hauke R.; Bauer, Markus; Rossner, Konstanze; Wenzel, Ruediger; Villringer, Arno; Fahle, Manfred			What Happens in Between? Human Oscillatory Brain Activity Related to Crossmodal Spatial Cueing	PLOS ONE			English	Article							PERCEPTUAL DECISION-MAKING; SCALE NEURAL-NETWORK; PREFRONTAL CORTEX; ATTENTIONAL SHIFTS; VISUAL-ATTENTION; VISUOSPATIAL ATTENTION; POLYSENSORY MECHANISMS; SELECTIVE ATTENTION; EXOGENOUS ATTENTION; AUDIOVISUAL LINKS	Previous studies investigated the effects of crossmodal spatial attention by comparing the responses to validly versus invalidly cued target stimuli. Dynamics of cortical rhythms in the time interval between cue and target might contribute to cue effects on performance. Here, we studied the influence of spatial attention on ongoing oscillatory brain activity in the interval between cue and target onset. In a first experiment, subjects underwent periods of tactile stimulation (cue) followed by visual stimulation (target) in a spatial cueing task as well as tactile stimulation as a control. In a second experiment, cue validity was modified to be 50%, 75%, or else 25%, to separate effects of exogenous shifts of attention caused by tactile stimuli from that of endogenous shifts. Tactile stimuli produced: 1) a stronger lateralization of the sensorimotor beta-rhythm rebound (15-22 Hz) after tactile stimuli serving as cues versus not serving as cues; 2) a suppression of the occipital alpha-rhythm (7-13 Hz) appearing only in the cueing task (this suppression was stronger contralateral to the endogenously attended side and was predictive of behavioral success); 3) an increase of prefrontal gamma-activity (25-35 Hz) specifically in the cueing task. We measured cue-related modulations of cortical rhythms which may accompany crossmodal spatial attention, expectation or decision, and therefore contribute to cue validity effects. The clearly lateralized alpha suppression after tactile cues in our data indicates its dependence on endogenous rather than exogenous shifts of visuo-spatial attention following a cue independent of its modality.	[Trenner, Maja U.; Rossner, Konstanze; Wenzel, Ruediger; Villringer, Arno] Charite, Berlin NeuroImaging Ctr, Neurol Klin & Poliklin, D-13353 Berlin, Germany; [Heekeren, Hauke R.; Bauer, Markus] Max Planck Inst Human Dev, Berlin, Germany; [Fahle, Manfred] Univ Bremen, Ctr Cognitive Sci Human Neurobiol, Bremen, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Hamburg; University Medical Center Hamburg-Eppendorf; Max Planck Society; University of Bremen	Trenner, MU (corresponding author), Charite, Berlin NeuroImaging Ctr, Neurol Klin & Poliklin, D-13353 Berlin, Germany.	maja.trenner@charite.de	Bauer, Markus/G-3808-2012; Heekeren, Hauke/B-7739-2008; Bauer, Markus/AAR-2596-2020	Bauer, Markus/0000-0001-6906-1678; Heekeren, Hauke/0000-0001-7912-6826; Villringer, Arno/0000-0003-2604-2404	BMBF; Kommission fur wissenschaftlichen Nachwuchs of Charite Universitatsmedizin Berlin	BMBF(Federal Ministry of Education & Research (BMBF)); Kommission fur wissenschaftlichen Nachwuchs of Charite Universitatsmedizin Berlin	This work was supported by grants of the BMBF (Berlin NeuroImaging Center, BNIC, BMBF-DLR, FKZ 01 GO 020), Center for Advanced Imaging (CAI), and by the Kommission fur wissenschaftlichen Nachwuchs of Charite Universitatsmedizin Berlin.	Bauer M, 2006, J NEUROSCI, V26, P490, DOI 10.1523/JNEUROSCI.5228-04.2006; BROVELLI A, 2005, NEUROIMAGE; BUCHTEL HA, 1988, NEUROPSYCHOLOGIA, V26, P499, DOI 10.1016/0028-3932(88)90107-8; Buschman TJ, 2007, SCIENCE, V315, P1860, DOI 10.1126/science.1138071; BUTTER CM, 1989, NEUROPSYCHOLOGIA, V27, P1231, DOI 10.1016/0028-3932(89)90035-3; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; D'Esposito M, 2000, NEUROIMAGE, V11, P400, DOI 10.1006/nimg.2000.0571; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Eimer M, 2002, J COGNITIVE NEUROSCI, V14, P254, DOI 10.1162/089892902317236885; Fell J, 2003, BRAIN RES REV, V42, P265, DOI 10.1016/S0165-0173(03)00178-4; Foxe JJ, 1998, NEUROREPORT, V9, P3929, DOI 10.1097/00001756-199812010-00030; Fries P, 2001, SCIENCE, V291, P1560, DOI 10.1126/science.1055465; Fu KMG, 2001, COGNITIVE BRAIN RES, V12, P145, DOI 10.1016/S0926-6410(01)00034-9; Fuster JM, 2001, NEURON, V30, P319, DOI 10.1016/S0896-6273(01)00285-9; Gaetz W, 2006, NEUROIMAGE, V30, P899, DOI 10.1016/j.neuroimage.2005.10.009; Gobbele R, 2002, NEUROSCI LETT, V327, P57, DOI 10.1016/S0304-3940(02)00384-1; GRATTON G, 1983, ELECTROEN CLIN NEURO, V55, P468, DOI 10.1016/0013-4694(83)90135-9; Green JJ, 2006, PSYCHOPHYSIOLOGY, V43, P161, DOI 10.1111/j.1469-8986.2006.00394.x; Gruber T, 1999, CLIN NEUROPHYSIOL, V110, P2074, DOI 10.1016/S1388-2457(99)00176-5; Heekeren HR, 2006, P NATL ACAD SCI USA, V103, P10023, DOI 10.1073/pnas.0603949103; Heekeren HR, 2004, NATURE, V431, P859, DOI 10.1038/nature02966; Hopfinger JB, 2006, NEUROIMAGE, V31, P774, DOI 10.1016/j.neuroimage.2005.12.049; Huettel SA, 2002, NAT NEUROSCI, V5, P485, DOI 10.1038/nn841; Hummel F, 2002, BRAIN, V125, P404, DOI 10.1093/brain/awf030; Ivry R, 2002, NAT NEUROSCI, V5, P394, DOI 10.1038/nn0502-394; Jensen O, 2005, NEUROIMAGE, V26, P347, DOI 10.1016/j.neuroimage.2005.02.008; Jensen O, 2002, CEREB CORTEX, V12, P877, DOI 10.1093/cercor/12.8.877; JENSEN O, 2007, TRENDS NEUROSCI; Jokisch D, 2007, J NEUROSCI, V27, P3244, DOI 10.1523/JNEUROSCI.5399-06.2007; Jongen EMM, 2006, PSYCHOPHYSIOLOGY, V43, P113, DOI 10.1111/j.1469-8986.2006.00375.x; Kelly SP, 2006, J NEUROPHYSIOL, V95, P3844, DOI 10.1152/jn.01234.2005; Kennett S, 2001, J COGNITIVE NEUROSCI, V13, P462, DOI 10.1162/08989290152001899; Kim YH, 1999, NEUROIMAGE, V9, P269, DOI 10.1006/nimg.1999.0408; KLIMESCH W, 2006, BRAIN RES BRAIN RES; MAKEIG S, 1993, ELECTROEN CLIN NEURO, V86, P283, DOI 10.1016/0013-4694(93)90110-H; Marrufo MV, 2001, COGNITIVE BRAIN RES, V12, P315; Mayer AR, 2004, NEUROIMAGE, V23, P534, DOI 10.1016/j.neuroimage.2004.06.027; McDonald JJ, 1999, PERCEPT PSYCHOPHYS, V61, P1411, DOI 10.3758/BF03206190; McDonald JJ, 2001, CAN J EXP PSYCHOL, V55, P141, DOI 10.1037/h0087361; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Moosmann M, 2003, NEUROIMAGE, V20, P145, DOI 10.1016/S1053-8119(03)00344-6; MULLER HJ, 1989, J EXP PSYCHOL HUMAN, V15, P315, DOI 10.1037/0096-1523.15.2.315; Neuper C, 2006, PROG BRAIN RES, V159, P211, DOI 10.1016/S0079-6123(06)59014-4; Nobre AC, 1997, BRAIN, V120, P515, DOI 10.1093/brain/120.3.515; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Peelen MV, 2004, NEUROIMAGE, V22, P822, DOI 10.1016/j.neuroimage.2004.01.044; Pfurtscheller G, 2002, NEUROSCI LETT, V323, P113, DOI 10.1016/S0304-3940(02)00119-2; Pfurtscheller G, 2001, VISION RES, V41, P1257, DOI 10.1016/S0042-6989(00)00235-2; Posner M.I., 1978, CHRONOMETRIC EXPLORA; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; POSNER MI, 1985, COGNITIVE NEUROPSYCH, V2, P211, DOI 10.1080/02643298508252866; POSNER MI, 1984, ATTENTION PERFORM, V10, P531; RAFAL RD, 1989, J EXP PSYCHOL HUMAN, V15, P673, DOI 10.1037/0096-1523.15.4.673; Rihs TA, 2007, EUR J NEUROSCI, V25, P603, DOI 10.1111/j.1460-9568.2007.05278.x; Rosen AC, 1999, J COGNITIVE NEUROSCI, V11, P135, DOI 10.1162/089892999563283; Salenius S, 1997, NEUROIMAGE, V5, P221, DOI 10.1006/nimg.1997.0261; Sauseng P, 2005, EUR J NEUROSCI, V22, P2917, DOI 10.1111/j.1460-9568.2005.04482.x; Schnitzler A, 1997, NEUROIMAGE, V6, P201, DOI 10.1006/nimg.1997.0286; Senkowski D, 2005, EXP BRAIN RES, V166, P411, DOI 10.1007/s00221-005-2381-z; Spence C, 1998, PERCEPT PSYCHOPHYS, V60, P544, DOI 10.3758/BF03206045; Spence C, 1996, J EXP PSYCHOL HUMAN, V22, P1005, DOI 10.1037/0096-1523.22.4.1005; Spence C, 1997, PERCEPT PSYCHOPHYS, V59, P1, DOI 10.3758/BF03206843; Spence C, 2000, J EXP PSYCHOL HUMAN, V26, P1298, DOI 10.1037//0096-1523.26.4.1298; TASSINARI G, 1989, ACTA PSYCHOL, V70, P267, DOI 10.1016/0001-6918(89)90026-7; Taylor TL, 1998, PSYCHON B REV, V5, P625, DOI 10.3758/BF03208839; Thut G, 2003, NEUROIMAGE, V18, P334, DOI 10.1016/S1053-8119(02)00048-4; Thut G, 2006, J NEUROSCI, V26, P9494, DOI 10.1523/JNEUROSCI.0875-06.2006; Van Velzen J, 2002, PSYCHOPHYSIOLOGY, V39, P874, DOI 10.1017/S0048577202020140; WARD LM, 1994, CAN J EXP PSYCHOL, V48, P242, DOI 10.1037/1196-1961.48.2.242; Worden MS, 2000, J NEUROSCI, V20; Yamagishi N, 2005, COGNITIVE BRAIN RES, V25, P799, DOI 10.1016/j.cogbrainres.2005.09.006	71	29	29	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2008	3	1							e1467	10.1371/journal.pone.0001467	http://dx.doi.org/10.1371/journal.pone.0001467			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	366SO	18213376	Green Published, Green Submitted, gold			2022-12-25	WOS:000260503900013
J	Christ-Crain, M; Kola, B; Lolli, F; Fekete, C; Seboek, D; Wittmann, G; Feltrin, D; Igreja, SC; Ajodha, S; Harvey-White, J; Kunos, G; Mueller, B; Pralong, F; Aubert, G; Arnaldi, G; Giacchetti, G; Boscaro, M; Grossman, AB; Korbonits, M				Christ-Crain, Mirjam; Kola, Blerina; Lolli, Francesca; Fekete, Csaba; Seboek, Dalma; Wittmann, Gabor; Feltrin, Daniel; Igreja, Susana C.; Ajodha, Sharon; Harvey-White, Judith; Kunos, George; Mueller, Beat; Pralong, Francois; Aubert, Gregory; Arnaldi, Giorgio; Giacchetti, Gilberta; Boscaro, Marco; Grossman, Ashley B.; Korbonits, Marta			AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome	FASEB JOURNAL			English	Article						obesity; insulin resistance; lipid metabolism	HUMAN ADIPOSE-TISSUE; FATTY-ACID OXIDATION; CARDIOVASCULAR RISK; FOOD-INTAKE; ENDOCANNABINOID RELEASE; HYPOTHALAMIC NEURONS; ORAL CORTICOSTEROIDS; HUMAN ADIPOCYTES; GLUCOSE-UPTAKE; INSULIN	Chronic exposure to glucocorticoid hormones, resulting from either drug treatment or Cushing's syndrome, results in insulin resistance, central obesity, and symptoms similar to the metabolic syndrome. We hypothesized that the major metabolic effects of corticosteroids are mediated by changes in the key metabolic enzyme adenosine monophosphate-activated protein kinase (AMPK) activity. Activation of AMPK is known to stimulate appetite in the hypothalamus and stimulate catabolic processes in the periphery. We assessed AMPK activity and the expression of several metabolic enzymes in the hypothalamus, liver, adipose tissue, and heart of a rat glucocorticoid- excess model as well as in in vitro studies using primary human adipose and primary rat hypothalamic cell cultures, and a human hepatoma cell line treated with dexamethasone and metformin. Glucocorticoid treatment inhibited AMPK activity in rat adipose tissue and heart, while stimulating it in the liver and hypothalamus. Similar data were observed in vitro in the primary adipose and hypothalamic cells and in the liver cell line. Metformin, a known AMPK regulator, prevented the corticosteroid-induced effects on AMPK in human adipocytes and rat hypothalamic neurons. Our data suggest that glucocorticoid-induced changes in AMPK constitute a novel mechanism that could explain the increase in appetite, the deposition of lipids in visceral adipose and hepatic tissue, as well as the cardiac changes that are all characteristic of glucocorticoid excess. Our data suggest that metformin treatment could be effective in preventing the metabolic complications of chronic glucocorticoid excess.	[Christ-Crain, Mirjam; Kola, Blerina; Lolli, Francesca; Feltrin, Daniel; Igreja, Susana C.; Ajodha, Sharon; Grossman, Ashley B.; Korbonits, Marta] Univ London, Queen Marys Sch Med, William Harvey Res Inst, John Vane Sci Ctr,Dept Endocrinol, London EC1M 6BQ, England; [Fekete, Csaba; Wittmann, Gabor] Hungarian Acad Sci, Inst Expt Med, Dept Endocrine Neurobiol, Budapest, Hungary; [Fekete, Csaba; Wittmann, Gabor] Tufts Univ New England Med Ctr, Div Endocrinol Diabet Metab & Mol Med, Tupper Res Inst, Boston, MA USA; [Fekete, Csaba; Wittmann, Gabor] Tufts Univ New England Med Ctr, Div Endocrinol Diabet Metab & Mol Med, Dept Med, Boston, MA USA; [Seboek, Dalma] Univ Basel Hosp, Div Endocrinol Diabet & Clin Nutr, CH-4031 Basel, Switzerland; [Harvey-White, Judith; Kunos, George] NIAAA, Lab Physiol Studies, US Natl Inst Hlth, Bethesda, MD USA; [Pralong, Francois; Aubert, Gregory] CHU Vaudois, Dept Internal Med, Serv Endocrinol Diabetol & Metab, CH-1011 Lausanne, Switzerland; [Arnaldi, Giorgio; Giacchetti, Gilberta; Boscaro, Marco] Univ Ancona, Dept Internal Med, Ancona, Italy	University of London; Queen Mary University London; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Institute of Experimental Medicine; Tufts Medical Center; Tufts Medical Center; University of Basel; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Marche Polytechnic University	Korbonits, M (corresponding author), Univ London, Queen Marys Sch Med, William Harvey Res Inst, John Vane Sci Ctr,Dept Endocrinol, London EC1M 6BQ, England.	m.korbonits@qmul.ac.uk	igreja, susana/M-3223-2015; Arnaldi, Giorgio/AAC-1674-2019; Aubert, Gregory/S-7075-2019; Mueller, Beat/G-2662-2012; GIACCHETTI, Gilberta/AAF-1074-2020; GIACCHETTI, Gilberta/AAF-4316-2020	igreja, susana/0000-0003-2811-4766; BOSCARO, MARCO/0000-0003-2596-1652; Korbonits, Marta/0000-0002-4101-9432; Christ-Crain, Mirjam/0000-0002-6336-0965; Arnaldi, Giorgio/0000-0002-6204-3423; Aubert, Gregory/0000-0002-5539-0224; Fekete, Csaba/0000-0002-8206-562X; Giacchetti, Gilberta/0000-0002-3942-1748	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [ZIAAA000350, Z01AA000350] Funding Source: NIH RePORTER; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); Wellcome Trust(Wellcome TrustEuropean Commission)		Altarejos JY, 2005, J BIOL CHEM, V280, P183, DOI 10.1074/jbc.M411810200; Andersson U, 2004, J BIOL CHEM, V279, P12005, DOI 10.1074/jbc.C300557200; Arnaldi G, 2003, J CLIN ENDOCR METAB, V88, P5593, DOI 10.1210/jc.2003-030871; Bell ME, 2000, J NEUROENDOCRINOL, V12, P461; Boffa MB, 2003, J BIOL CHEM, V278, P9250, DOI 10.1074/jbc.M209588200; Brown PD, 2007, MOL CELL BIOCHEM, V297, P171, DOI 10.1007/s11010-006-9344-y; Bujalska IJ, 1997, LANCET, V349, P1210, DOI 10.1016/S0140-6736(96)11222-8; Burcelin R, 2003, ENDOCRINOLOGY, V144, P4484, DOI 10.1210/en.2003-0457; Chandola T, 2006, BMJ-BRIT MED J, V332, P521, DOI 10.1136/bmj.38693.435301.80; Chau-Van C, 2007, ENDOCRINOLOGY, V148, P507, DOI 10.1210/en.2006-1237; Colao A, 1999, J CLIN ENDOCR METAB, V84, P2664, DOI 10.1210/jc.84.8.2664; Dallman MF, 1995, ANN NY ACAD SCI, V771, P730, DOI 10.1111/j.1749-6632.1995.tb44724.x; Dallman MF, 2003, P NATL ACAD SCI USA, V100, P11696, DOI 10.1073/pnas.1934666100; DANESE RD, 1994, ENDOCRIN METAB CLIN, V23, P299, DOI 10.1016/S0889-8529(18)30099-9; Di S, 2005, ENDOCRINOLOGY, V146, P4292, DOI 10.1210/en.2005-0610; Di S, 2003, J NEUROSCI, V23, P4850; DIVERTIE GD, 1991, DIABETES, V40, P1228, DOI 10.2337/diabetes.40.10.1228; Djurhuus CB, 2002, AM J PHYSIOL-ENDOC M, V283, pE172, DOI 10.1152/ajpendo.00544.2001; Foretz M, 2005, DIABETES, V54, P1331, DOI 10.2337/diabetes.54.5.1331; GREEN PK, 1992, ENDOCRINOLOGY, V130, P269, DOI 10.1210/en.130.1.269; Gudbjornsson B, 2002, ANN RHEUM DIS, V61, P32, DOI 10.1136/ard.61.1.32; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hill MN, 2005, EUR J PHARMACOL, V528, P99, DOI 10.1016/j.ejphar.2005.10.058; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kola B, 2005, J BIOL CHEM, V280, P25196, DOI 10.1074/jbc.C500175200; Koricanac G, 2006, GEN PHYSIOL BIOPHYS, V25, P11; Kraegen EW, 2006, AM J PHYSIOL-ENDOC M, V290, pE471, DOI 10.1152/ajpendo.00316.2005; Kudo N, 1996, BBA-LIPID LIPID MET, V1301, P67, DOI 10.1016/0005-2760(96)00013-6; LANGLEY SC, 1990, BRAIN RES, V533, P268, DOI 10.1016/0006-8993(90)91349-L; Lindsay JR, 2006, J CLIN ENDOCR METAB, V91, P447, DOI 10.1210/jc.2005-1058; Linscheid P, 2005, ENDOCRINOLOGY, V146, P2699, DOI 10.1210/en.2004-1424; Linscheid P, 2006, AM J PHYSIOL-ENDOC M, V290, pE1068, DOI 10.1152/ajpendo.00374.2005; Lundgren M, 2004, J CLIN ENDOCR METAB, V89, P2989, DOI 10.1210/jc.2003-031157; Makimura Hideo, 2003, BMC Physiol, V3, P5, DOI 10.1186/1472-6793-3-5; Mancini T, 2004, CLIN ENDOCRINOL, V61, P768, DOI 10.1111/j.1365-2265.2004.02168.x; MAYOSMITH W, 1989, RADIOLOGY, V170, P515, DOI 10.1148/radiology.170.2.2911678; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Muiesan ML, 2003, J AM COLL CARDIOL, V41, P2275, DOI 10.1016/S0735-1097(03)00493-5; Phillips DIW, 1998, J CLIN ENDOCR METAB, V83, P757, DOI 10.1210/jc.83.3.757; Pivonello R, 2005, ENDOCRIN METAB CLIN, V34, P327, DOI 10.1016/j.ecl.2005.01.010; Rockall AG, 2003, EUR J ENDOCRINOL, V149, P543, DOI 10.1530/eje.0.1490543; Russell RR, 2004, J CLIN INVEST, V114, P495, DOI 10.1172/JCI200419297; Seboek D, 2004, J CLIN ENDOCR METAB, V89, P4833, DOI 10.1210/jc.2004-0271; Seckl JR, 2004, TRENDS ENDOCRIN MET, V15, P418, DOI 10.1016/j.tem.2004.09.007; Shaw RJ, 2005, SCIENCE, V310, P1642, DOI 10.1126/science.1120781; SULLIVAN JE, 1994, FEBS LETT, V353, P33, DOI 10.1016/0014-5793(94)01006-4; Tataranni PA, 1996, AM J PHYSIOL-ENDOC M, V271, pE317, DOI 10.1152/ajpendo.1996.271.2.E317; van Staa TP, 2000, QJM-MON J ASSOC PHYS, V93, P105, DOI 10.1093/qjmed/93.2.105; Vander Kooi BT, 2005, MOL ENDOCRINOL, V19, P3001, DOI 10.1210/me.2004-0497; Viana AYI, 2006, DIABETES RES CLIN PR, V73, P135, DOI 10.1016/j.diabres.2005.12.011; Viollet B, 2006, J PHYSIOL-LONDON, V574, P41, DOI 10.1113/jphysiol.2006.108506; Walsh LJ, 1996, BRIT MED J, V313, P344, DOI 10.1136/bmj.313.7053.344; Wang L, 2003, P NATL ACAD SCI USA, V100, P1393, DOI 10.1073/pnas.0336351100; Wang YX, 2004, J NUTR, V134, P1032; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Zakrzewska KE, 1999, DIABETES, V48, P365, DOI 10.2337/diabetes.48.2.365; Zelena D, 2006, BRAIN RES BULL, V69, P48, DOI 10.1016/j.brainresbull.2005.10.009; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505	59	129	131	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					1672	1683		10.1096/fj.07-094144	http://dx.doi.org/10.1096/fj.07-094144			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18198220	Green Submitted			2022-12-25	WOS:000256352700008
J	Kawaguchi, M; Toyama, T; Kaneko, R; Hirayama, T; Kawamura, Y; Yagi, T				Kawaguchi, Masahumi; Toyama, Tomoko; Kaneko, Ryosuke; Hirayama, Teruyoshi; Kawamura, Yoshimi; Yagi, Takeshi			Relationship between DNA methylation states and transcription of individual isoforms encoded by the protocadherin-alpha gene cluster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA DSCAM; PURKINJE-CELLS; CPG ISLAND; BDNF-GENE; EXPRESSION; FAMILY; DIVERSITY; PROMOTER; TISSUE; MOUSE	The protocadherin-alpha (Pcdh-alpha) gene encodes diverse transmembrane proteins that are differentially expressed in individual neurons in the vertebrate central nervous system. The Pcdh-alpha genomic structure contains variable first exons, each regulated by its own promoter. Here, we investigated the effect of DNA methylation on gene regulation in the Pcdh-alpha gene cluster. We studied two mouse cell lines, C1300 and M3, that expressed different combinations of Pcdh-alpha isoforms and found that 1) the transcription of specific Pcdh-alpha isoforms correlated significantly with the methylation state of the promoter and the 5' (but not the 3') region of the first exon and 2) mosaic or mixed methylation states of the promoters were associated with both active and inactive transcription. Demethylation of C1300 cells up-regulated all of the Pcdh-alpha isoforms, and, in a promoter assay, hypermethylation of the promoters repressed their transcriptional activity. Cell lines subcloned from the demethylated C1300 cells transcribed different combinations of Pcdh-alpha isoforms than the parental, nondemethylated cells, and the promoters showed differential mosaic or mixed methylation patterns. In vivo, the promoter and 5'-regions of the Pcdh-alpha C1 and alpha C2 exons, which are transcribed in all neurons, were extensively hypomethylated. In contrast, the promoters of the Pcdh-alpha 1 to -alpha 12 isoforms, which are transcribed differentially by individual Purkinje cells, exhibited mosaic methylation patterns. Overall, our results demonstrated that mosaic or mixed DNA methylation states in the promoter and 5'-region of the first exon may help regulate differential Pcdh-alpha transcription and that hypermethylation is sufficient to repress transcription.	[Kawaguchi, Masahumi; Kaneko, Ryosuke; Hirayama, Teruyoshi; Kawamura, Yoshimi; Yagi, Takeshi] Osaka Univ, Grad Sch Frontier Biosci, KOKORO Biol Grp, Labs Integrated Biol, Suita, Osaka 5650871, Japan; [Toyama, Tomoko] Osaka Univ, Microbial Dis Res Inst, Lab Malariol, Suita, Osaka 5650871, Japan	Osaka University; Osaka University	Yagi, T (corresponding author), Osaka Univ, Grad Sch Frontier Biosci, KOKORO Biol Grp, Labs Integrated Biol, 1-3 Yamadaoka, Suita, Osaka 5650871, Japan.	yagi@fbs.osaka-u.ac.jp	Kawamura, Yoshimi/L-1289-2013	Kawamura, Yoshimi/0000-0002-9864-7974				Bornman DM, 2001, AM J PATHOL, V159, P831, DOI 10.1016/S0002-9440(10)61758-0; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Chen WG, 2003, SCIENCE, V302, P885, DOI 10.1126/science.1086446; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; Esumi S, 2005, NAT GENET, V37, P171, DOI 10.1038/ng1500; Esumi S, 2006, NAT PROTOC, V1, P2143, DOI 10.1038/nprot.2006.343; Fuss SH, 2007, CELL, V130, P373, DOI 10.1016/j.cell.2007.06.023; Hattori D, 2007, NATURE, V449, P223, DOI 10.1038/nature06099; Imamura T, 2001, GENOMICS, V76, P117, DOI 10.1006/geno.2001.6607; Kaneko R, 2006, J BIOL CHEM, V281, P30551, DOI 10.1074/jbc.M605677200; Kim TH, 2007, CELL, V128, P1231, DOI 10.1016/j.cell.2006.12.048; Kohmura N, 1998, NEURON, V20, P1137, DOI 10.1016/S0896-6273(00)80495-X; Lomvardas S, 2006, CELL, V126, P403, DOI 10.1016/j.cell.2006.06.035; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; Martinowich K, 2003, SCIENCE, V302, P890, DOI 10.1126/science.1090842; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Newell-Price J, 2001, MOL ENDOCRINOL, V15, P338, DOI 10.1210/me.15.2.338; Pao MM, 2001, HUM MOL GENET, V10, P903, DOI 10.1093/hmg/10.9.903; Paulin R, 1998, NUCLEIC ACIDS RES, V26, P5009, DOI 10.1093/nar/26.21.5009; Recillas-Targa F, 2006, J CELL MOL MED, V10, P554, DOI 10.1111/j.1582-4934.2006.tb00420.x; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; Ribich S, 2006, P NATL ACAD SCI USA, V103, P19719, DOI 10.1073/pnas.0609445104; Schmucker D, 2000, CELL, V101, P671, DOI 10.1016/S0092-8674(00)80878-8; Serizawa S, 2003, SCIENCE, V302, P2088, DOI 10.1126/science.1089122; Sugino H, 2004, GENE, V337, P91, DOI 10.1016/j.gene.2004.04.011; Tasic B, 2002, MOL CELL, V10, P21, DOI 10.1016/S1097-2765(02)00578-6; TIMMUSK T, 1993, NEURON, V10, P475, DOI 10.1016/0896-6273(93)90335-O; Tomikawa J, 2006, J BIOL CHEM, V281, P12163, DOI 10.1074/jbc.M513782200; Waha A, 2005, NEOPLASIA, V7, P193, DOI 10.1593/neo.04490; Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276; Wojtowicz WM, 2004, CELL, V118, P619, DOI 10.1016/j.cell.2004.08.021; Wu Q, 2001, GENOME RES, V11, P389, DOI 10.1101/gr.167301; Wu Q, 1999, CELL, V97, P779, DOI 10.1016/S0092-8674(00)80789-8	33	47	48	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2008	283	18					12064	12075		10.1074/jbc.M709648200	http://dx.doi.org/10.1074/jbc.M709648200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	293MS	18204046	hybrid			2022-12-25	WOS:000255340000022
J	Ogasawara, Y; Kaya, H; Hiraoka, G; Yumoto, F; Kimura, S; Kadota, Y; Hishinuma, H; Senzaki, E; Yamagoe, S; Nagata, K; Nara, M; Suzuki, K; Tanokura, M; Kuchitsu, K				Ogasawara, Yoko; Kaya, Hidetaka; Hiraoka, Goro; Yumoto, Fumiaki; Kimura, Sachie; Kadota, Yasuhiro; Hishinuma, Haruka; Senzaki, Eriko; Yamagoe, Satoshi; Nagata, Koji; Nara, Masayuki; Suzuki, Kazuo; Tanokura, Masaru; Kuchitsu, Kazuyuki			Synergistic activation of the Arabidopsis NADPH oxidase AtrbohD by Ca2+ and phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; PROTEIN PHOSPHATASE INHIBITOR; CULTURED SOYBEAN CELLS; GTP-BINDING PROTEIN; REACTIVE OXYGEN; OXIDATIVE BURST; REGULATORY MECHANISMS; ARACHIDONIC-ACID; CALCIUM-BINDING; TOBACCO CELLS	Plant respiratory burst oxidase homolog ( rboh) proteins, which are homologous to the mammalian 91-kDa glycoprotein subunit of the phagocyte oxidase ( gp91(phox)) or NADPH oxidase 2 ( NOX2), have been implicated in the production of reactive oxygen species ( ROS) both in stress responses and during development. Unlike mammalian gp91(phox)/NOX2 protein, plant rboh proteins have hydrophilic N-terminal regions containing two EF-hand motifs, suggesting that their activation is dependent on Ca2+. However, the significance of Ca2+ binding to the EF-hand motifs on ROS production has been unclear. By employing a heterologous expression system, we showed that ROS production by Arabidopsis thaliana rbohD ( AtrbohD) was induced by ionomycin, which is a Ca2+ ionophore that induces Ca2+ influx into the cell. This activation required a conformational change in the EF-hand region, as a result of Ca2+ binding to the EF-hand motifs. We also showed that AtrbohD was directly phosphorylated in vivo, and that this was enhanced by the protein phosphatase inhibitor calyculin A ( CA). Moreover, CA itself induced ROS production and dramatically enhanced the ionomycin-induced ROS production of AtrbohD. Our results suggest that Ca2+ binding and phosphorylation synergistically activate the ROS-producing enzyme activity of AtrbohD.	[Ogasawara, Yoko; Kaya, Hidetaka; Hiraoka, Goro; Kimura, Sachie; Kadota, Yasuhiro; Hishinuma, Haruka; Senzaki, Eriko; Kuchitsu, Kazuyuki] Tokyo Univ Sci, Dept Appl Biol Sci, Chiba 2788510, Japan; [Kuchitsu, Kazuyuki] Tokyo Univ Sci, Genome & Drug Res Ctr, Chiba 2788510, Japan; [Yumoto, Fumiaki; Nagata, Koji; Tanokura, Masaru] Univ Tokyo, Dept Appl Biol Chem, Grad Sch Agr & Life Sci, Bunkyo Ku, Tokyo 1138657, Japan; [Yumoto, Fumiaki] Jikei Univ, Sch Med, Dept Physiol 2, Minato Ku, Tokyo 1058461, Japan; [Yamagoe, Satoshi; Suzuki, Kazuo] Natl Inst Infect Dis, Dept Bioact Mol, Shinjuku Ku, Tokyo 1628640, Japan; [Nara, Masayuki] Tokyo Med & Dent Univ, Chem Lab, Coll Liberal Arts & Sci, Chiba 2720827, Japan	Tokyo University of Science; Tokyo University of Science; University of Tokyo; Jikei University; National Institute of Infectious Diseases (NIID); Tokyo Medical & Dental University (TMDU)	Kuchitsu, K (corresponding author), Tokyo Univ Sci, Dept Appl Biol Sci, Chiba 2788510, Japan.	kuchitsu@rs.noda.tus.ac.jp	Kadota, Yasuhiro/AAC-4545-2019; Kimura, Sachie/AAZ-4468-2020; Nara, Masayuki/L-3712-2019; Kadota, Yasuhiro/AGJ-3017-2022; Kuchitsu, Kazuyuki/G-3024-2013; Kadota, Yasuhiro/A-9406-2011	Kadota, Yasuhiro/0000-0002-4782-1418; Kimura, Sachie/0000-0001-5736-2123; Kadota, Yasuhiro/0000-0002-4782-1418; Kuchitsu, Kazuyuki/0000-0001-8854-0375; Kadota, Yasuhiro/0000-0002-4782-1418; Kaya, Hidetaka/0000-0003-4711-8236; Nagata, Koji/0000-0002-4704-0603; Tanokura, Masaru/0000-0001-5072-2480				Amicucci E, 1999, PLANT BIOLOGY, V1, P524, DOI 10.1111/j.1438-8677.1999.tb00778.x; AUH CK, 1995, PLANT PHYSIOL, V107, P1241, DOI 10.1104/pp.107.4.1241; Banfi B, 2004, J BIOL CHEM, V279, P18583, DOI 10.1074/jbc.M310268200; Banfi B, 2001, J BIOL CHEM, V276, P37594, DOI 10.1074/jbc.M103034200; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Benschop JJ, 2007, MOL CELL PROTEOMICS, V6, P1198, DOI 10.1074/mcp.M600429-MCP200; Blume B, 2000, PLANT CELL, V12, P1425, DOI 10.1105/tpc.12.8.1425; Carol RJ, 2006, J EXP BOT, V57, P1829, DOI 10.1093/jxb/erj201; Carol RJ, 2005, NATURE, V438, P1013, DOI 10.1038/nature04198; CHANDRA S, 1995, P NATL ACAD SCI USA, V92, P4120, DOI 10.1073/pnas.92.10.4120; FELIX G, 1994, P NATL ACAD SCI USA, V91, P952, DOI 10.1073/pnas.91.3.952; Foreman J, 2003, NATURE, V422, P442, DOI 10.1038/nature01485; Gapper C, 2006, PLANT PHYSIOL, V141, P341, DOI 10.1104/pp.106.079079; GRABAREK Z, 1981, J BIOL CHEM, V256, P3121; Groom QJ, 1996, PLANT J, V10, P515, DOI 10.1046/j.1365-313X.1996.10030515.x; Gutierrez-Ford C, 2003, BIOCHEMISTRY-US, V42, P14553, DOI 10.1021/bi034870f; Jones MA, 2007, J EXP BOT, V58, P1261, DOI 10.1093/jxb/erl279; Kadota Y, 2004, PLANT CELL PHYSIOL, V45, P160, DOI 10.1093/pcp/pch020; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Kawasaki T, 1999, P NATL ACAD SCI USA, V96, P10922, DOI 10.1073/pnas.96.19.10922; Keller T, 1998, PLANT CELL, V10, P255, DOI 10.1105/tpc.10.2.255; Kobayashi M, 2007, PLANT CELL, V19, P1065, DOI 10.1105/tpc.106.048884; Kojo K, 2006, PLANT CELL PHYSIOL, V47, P1035, DOI 10.1093/pcp/pcj074; KUCHITSU K, 1995, PROTOPLASMA, V188, P138, DOI 10.1007/BF01276805; Kurusu T, 2005, PLANT J, V42, P798, DOI 10.1111/j.1365-313X.2005.02415.x; Kwak JM, 2003, EMBO J, V22, P2623, DOI 10.1093/emboj/cdg277; Lamb C, 1997, ANNU REV PLANT PHYS, V48, P251, DOI 10.1146/annurev.arplant.48.1.251; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Morel J, 2004, PLANT J, V37, P282, DOI 10.1046/j.1365-313X.2003.01957.x; Murphy TM, 1996, PLANT PHYSIOL, V110, P621, DOI 10.1104/pp.110.2.621; Nakamura A, 2000, BIOCHEMISTRY-US, V39, P3827, DOI 10.1021/bi991855v; Nara M, 2004, BIOPOLYMERS, V74, P77, DOI 10.1002/bip.20048; Nuhse TS, 2007, PLANT J, V51, P931, DOI 10.1111/j.1365-313X.2007.03192.x; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; Park J, 2000, PLANT PHYSIOL, V124, P725, DOI 10.1104/pp.124.2.725; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Rajasekhar VK, 1999, PLANT PHYSIOL, V120, P1137, DOI 10.1104/pp.120.4.1137; Sagi M, 2001, PLANT PHYSIOL, V126, P1281, DOI 10.1104/pp.126.3.1281; Shiose A, 2000, J BIOL CHEM, V275, P13793, DOI 10.1074/jbc.275.18.13793; Simon-Plas F, 2002, PLANT J, V31, P137, DOI 10.1046/j.1365-313X.2002.01342.x; Takahashi A, 1999, PLANT J, V17, P535, DOI 10.1046/j.1365-313X.1999.00405.x; TANOKURA M, 1984, J BIOCHEM-TOKYO, V95, P643, DOI 10.1093/oxfordjournals.jbchem.a134653; TAVERNIER E, 1995, PLANT PHYSIOL, V109, P1025, DOI 10.1104/pp.109.3.1025; Torres MA, 1998, PLANT J, V14, P365, DOI 10.1046/j.1365-313X.1998.00136.x; Torres MA, 2005, NAT GENET, V37, P1130, DOI 10.1038/ng1639; Torres MA, 2005, CURR OPIN PLANT BIOL, V8, P397, DOI 10.1016/j.pbi.2005.05.014; Torres MA, 2002, P NATL ACAD SCI USA, V99, P517, DOI 10.1073/pnas.012452499; Torres MA, 2006, PLANT PHYSIOL, V141, P373, DOI 10.1104/pp.106.079467; Van Breusegem F, 2006, PLANT PHYSIOL, V141, P384, DOI 10.1104/pp.106.078295; VanGestelen P, 1997, PLANT PHYSIOL, V115, P543, DOI 10.1104/pp.115.2.543; WYMANN MP, 1987, ANAL BIOCHEM, V165, P371, DOI 10.1016/0003-2697(87)90284-3; Xing T, 2001, MOL PLANT MICROBE IN, V14, P1261, DOI 10.1094/MPMI.2001.14.10.1261; Ying G, 2004, CURR OPIN PLANT BIOL, V7, P527, DOI 10.1016/j.pbi.2004.07.006; Yoshioka H, 2001, MOL PLANT MICROBE IN, V14, P725, DOI 10.1094/MPMI.2001.14.6.725; Zhao J, 2005, BIOTECHNOL ADV, V23, P283, DOI 10.1016/j.biotechadv.2005.01.003	55	321	341	5	73	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					8885	8892		10.1074/jbc.M708106200	http://dx.doi.org/10.1074/jbc.M708106200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18218618	hybrid			2022-12-25	WOS:000254465800016
J	Zaffagnini, M; Michelet, L; Massot, V; Trost, P; Lemaire, SD				Zaffagnini, Mirko; Michelet, Laure; Massot, Vincent; Trost, Paolo; Lemaire, Stephane D.			Biochemical characterization of glutaredoxins from Chlamydomonas reinhardtii reveals the unique properties of a chloroplastic CGFS-type glutaredoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEHYDROASCORBATE REDUCTASE-ACTIVITY; PROTEIN DISULFIDE-ISOMERASE; THIOREDOXIN REDUCTASE; ESCHERICHIA-COLI; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; ARABIDOPSIS-THALIANA; POPLAR GLUTAREDOXIN; S-GLUTATHIONYLATION; REDOX-REGULATION; THIOLTRANSFERASE GLUTAREDOXIN	Glutaredoxins (GRXs) are small ubiquitous disulfide oxidoreductases known to use GSH as electron donor. In photosynthetic organisms, little is known about the biochemical properties of GRXs despite the existence of similar to 30 different isoforms in higher plants. We report here the biochemical characterization of Chlamydomonas GRX1 and GRX3, the major cytosolic and chloroplastic isoforms, respectively. Glutaredoxins are classified on the basis of the amino acid sequence of the active site. GRX1 is a typical CPYC-type GRX, which is reduced by GSH and exhibits disulfide reductase, dehydroascorbate reductase, and deglutathionylation activities. In contrast, GRX3 exhibits unique properties. This chloroplastic CGFS-type GRX is not reduced by GSH and has an atypically low redox potential ( - 323 +/- 4 mV at pH 7.9). Remarkably, GRX3 can be reduced in the light by photoreduced ferredoxin and ferredoxin-thioredoxin reductase. Both GRXs proved to be very efficient catalysts of A(4)-glyceraldehyde-3-phosphate dehydrogenase deglutathionylation, whereas cytosolic and chloroplastic thioredoxins were inefficient. Glutathionylated A(4)-glyceraldehyde-3-phosphate dehydrogenase is the first physiological substrate identified for a CGFS-type GRX.	[Zaffagnini, Mirko; Michelet, Laure; Massot, Vincent; Lemaire, Stephane D.] Univ Paris 11, CNRS, Inst Biotechnol Plantes, UMR 8618, F-91405 Orsay, France; [Zaffagnini, Mirko; Trost, Paolo] Univ Bologna, Dept Expt Evol Biol, Lab Mol Plant Physiol, I-40126 Bologna, Italy	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Bologna	Lemaire, SD (corresponding author), Univ Paris 11, CNRS, Inst Biotechnol Plantes, UMR 8618, Batiment 630, F-91405 Orsay, France.	stephane.lemaire@u-psud.fr	Trost, Paolo/F-2425-2011; Lemaire, Stéphane D/A-3530-2008	Lemaire, Stéphane D/0000-0001-6442-0547; Zaffagnini, Mirko/0000-0001-5115-0859; Trost, Paolo/0000-0002-6347-8701; Massot, Vincent/0000-0002-7858-8145				Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; Cheng NH, 2006, J BIOL CHEM, V281, P26280, DOI 10.1074/jbc.M601354200; Collin V, 2004, PLANT PHYSIOL, V136, P4088, DOI 10.1104/pp.104.052233; Collin V, 2003, J BIOL CHEM, V278, P23747, DOI 10.1074/jbc.M302077200; Cotgreave IA, 2002, METHOD ENZYMOL, V348, P175, DOI 10.1016/S0076-6879(02)48636-3; Dixon DP, 2002, J BIOL CHEM, V277, P30859, DOI 10.1074/jbc.M202919200; Dixon DP, 2005, BIOCHEMISTRY-US, V44, P7696, DOI 10.1021/bi047324a; Dixon DP, 2005, PLANT PHYSIOL, V138, P2233, DOI 10.1104/pp.104.058917; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Feng YG, 2006, BIOCHEMISTRY-US, V45, P7998, DOI 10.1021/bi060444t; Fernandes AP, 2005, J BIOL CHEM, V280, P24544, DOI 10.1074/jbc.M500678200; Fernandes AP, 2004, ANTIOXID REDOX SIGN, V6, P63, DOI 10.1089/152308604771978354; Gelhaye E, 2004, P NATL ACAD SCI USA, V101, P14545, DOI 10.1073/pnas.0405282101; Ghezzi P, 2005, ANTIOXID REDOX SIGN, V7, P964, DOI 10.1089/ars.2005.7.964; Hirasawa M, 1999, BIOCHEMISTRY-US, V38, P5200, DOI 10.1021/bi982783v; HOLMGREN A, 1979, J BIOL CHEM, V254, P3664; HUTCHISON RS, 1995, METHOD ENZYMOL, V252, P220; Ito H, 2003, PLANT CELL PHYSIOL, V44, P655, DOI 10.1093/pcp/pcg098; Jacquot JP, 1997, FEBS LETT, V400, P293, DOI 10.1016/S0014-5793(96)01407-X; JACQUOT JP, 1994, J MOL BIOL, V235, P1357, DOI 10.1006/jmbi.1994.1091; Johansson C, 2004, J BIOL CHEM, V279, P7537, DOI 10.1074/jbc.M312719200; Jung CH, 1996, ARCH BIOCHEM BIOPHYS, V335, P61, DOI 10.1006/abbi.1996.0482; Lemaire SD, 2004, PHOTOSYNTH RES, V79, P305, DOI 10.1023/B:PRES.0000017174.60951.74; Lemaire SD, 2007, CURR GENET, V51, P343, DOI 10.1007/s00294-007-0128-z; Meyer AJ, 2005, PHOTOSYNTH RES, V86, P435, DOI 10.1007/s11120-005-8425-1; Meyer Y, 2006, PHOTOSYNTH RES, V89, P179, DOI 10.1007/s11120-006-9095-3; Michelet L, 2005, P NATL ACAD SCI USA, V102, P16478, DOI 10.1073/pnas.0507498102; Michelet L, 2006, PHOTOSYNTH RES, V89, P225, DOI 10.1007/s11120-006-9096-2; Mohr S, 1999, J BIOL CHEM, V274, P9427, DOI 10.1074/jbc.274.14.9427; Molina MM, 2004, J BIOL CHEM, V279, P51923, DOI 10.1074/jbc.M410219200; Noguera-Mazon V, 2006, J BIOL CHEM, V281, P31736, DOI 10.1074/jbc.M602188200; Nulton-Persson AC, 2003, BIOCHEMISTRY-US, V42, P4235, DOI 10.1021/bi027370f; Pujol-Carrion N, 2006, J CELL SCI, V119, P4554, DOI 10.1242/jcs.03229; RAVICHANDRAN V, 1994, J BIOL CHEM, V269, P25010; Rodriguez-Manzaneque MT, 2002, MOL BIOL CELL, V13, P1109, DOI 10.1091/mbc.01-10-0517; Rouhier N, 2004, CELL MOL LIFE SCI, V61, P1266, DOI 10.1007/s00018-004-3410-y; Rouhier N, 2003, ANTIOXID REDOX SIGN, V5, P15, DOI 10.1089/152308603321223504; Rouhier N, 2002, FEBS LETT, V511, P145, DOI 10.1016/S0014-5793(01)03302-6; Rouhier N, 2002, J BIOL CHEM, V277, P13609, DOI 10.1074/jbc.M111489200; Rouhier N, 2007, P NATL ACAD SCI USA, V104, P7379, DOI 10.1073/pnas.0702268104; Schurmann P, 2002, METHOD ENZYMOL, V347, P403; Serrato AJ, 2004, J BIOL CHEM, V279, P43821, DOI 10.1074/jbc.M404696200; Sparla F, 2005, PLANT PHYSIOL, V138, P2210, DOI 10.1104/pp.105.062117; STEIN M, 1995, PLANT MOL BIOL, V28, P487, DOI 10.1007/BF00020396; Tamarit J, 2003, J BIOL CHEM, V278, P25745, DOI 10.1074/jbc.M303477200; VlamisGardikas A, 1997, J BIOL CHEM, V272, P11236; Washburn MP, 1999, BIOCHEMISTRY-US, V38, P268, DOI 10.1021/bi980480v; WELLS WW, 1990, J BIOL CHEM, V265, P15361; Zaffagnini M, 2007, FEBS J, V274, P212, DOI 10.1111/j.1742-4658.2006.05577.x	50	107	107	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					8868	8876		10.1074/jbc.M709567200	http://dx.doi.org/10.1074/jbc.M709567200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18216016	hybrid			2022-12-25	WOS:000254465800014
J	Gurel, Z; Ronni, T; Ho, S; Kuchar, J; Payne, KJ; Turk, CW; Dovat, S				Gurel, Zafer; Ronni, Tapani; Ho, Sam; Kuchar, Jason; Payne, Kimberly J.; Turk, Christoph W.; Dovat, Sinisa			Recruitment of Ikaros to pericentromeric heterochromatin is regulated by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; DNA-BINDING PROTEINS; TERMINAL TRANSFERASE GENE; TRANSCRIPTION FACTOR; CENTROMERIC HETEROCHROMATIN; SILENT CHROMATIN; CELLS; LYMPHOCYTES; EXPRESSION; COMPLEXES	Ikaros encodes a zinc finger protein that is involved in heritable gene silencing. In hematopoietic cells, Ikaros localizes to pericentromeric heterochromatin (PC-HC) where it recruits its target genes, resulting in their activation or repression via chromatin remodeling. The function of Ikaros is controlled by post-translational modifications. CK2 kinase has been shown to phosphorylate Ikaros at its C terminus, affecting cell cycle progression. Using in vivo labeling of murine thymocytes followed by phosphopeptide mapping, we identified four novel Ikaros phosphorylation sites. Functional analysis of phosphomimetic mutants showed that the phosphorylation of individual amino acids determines the affinity of Ikaros toward probes derived from PC-HC. In vivo experiments demonstrated that targeting of Ikaros to PC-HC is regulated by phosphorylation. The ability of Ikaros to bind the upstream regulatory elements of its known target gene terminal deoxynucleotidyltransferase (TdT) was decreased by phosphorylation of two amino acids. In thymocytes, Ikaros acts as a repressor of the TdT gene. Induction of differentiation of thymocytes with phorbol 12-myristate 13-acetate plus ionomycin results in transcriptional repression of TdT expression. This process has been associated with increased binding of Ikaros to the upstream regulatory element of TdT. Phosphopeptide analysis of in vivo-labeled thymocytes revealed that Ikaros undergoes dephosphorylation during induction of thymocyte differentiation and that dephosphorylation is responsible for increased DNA binding affinity of Ikaros toward the TdT promoter. We propose a model whereby reversible phosphorylation of Ikaros at specific amino acids controls the subcellular localization of Ikaros as well as its ability to regulate TdT expression during thymocyte differentiation.	[Gurel, Zafer; Ronni, Tapani; Ho, Sam; Dovat, Sinisa] Univ Wisconsin, Dept Pediat, Div Pediat Hematol Oncol, Madison, WI 53792 USA; [Kuchar, Jason] Michigan State Univ, E Lansing, MI 48824 USA; [Turk, Christoph W.] Proteom & Biomarkers Max Planck Inst Psychiat, D-80804 Munich, Germany; [Payne, Kimberly J.] Loma Linda Univ, Sch Med, Ctr Hlth Dispar & Mol Med, Loma Linda, CA 92350 USA; [Payne, Kimberly J.] Loma Linda Univ, Sch Med, Dept Pathol & Human Anat, Loma Linda, CA 92350 USA	University of Wisconsin System; University of Wisconsin Madison; Michigan State University; Max Planck Society; Loma Linda University; Loma Linda University	Dovat, S (corresponding author), Univ Wisconsin, Dept Pediat, Div Pediat Hematol Oncol, 600 Highland Ave,H4-431 CSC, Madison, WI 53792 USA.	dovat@pediatrics.wisc.edu	Gurel, Zafer/AAF-3072-2021; Payne, Kimberly/AAS-6814-2020	Payne, Kimberly/0000-0002-7025-5821; Dovat, Sinisa/0000-0003-3906-6165	NATIONAL CANCER INSTITUTE [K22CA111392] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK066163] Funding Source: NIH RePORTER; NCI NIH HHS [K22 CA 111392] Funding Source: Medline; NIDDK NIH HHS [5 K01 DK 066163] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arco PGD, 2005, MOL CELL BIOL, V25, P2688, DOI 10.1128/MCB.25.7.2688-2697.2005; Avitahl N, 1999, IMMUNITY, V10, P333, DOI 10.1016/S1074-7613(00)80033-3; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brown KE, 1999, MOL CELL, V3, P207, DOI 10.1016/S1097-2765(00)80311-1; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; CARROLL D, 1988, COLD SPRING HARB SYM, V53, P91, DOI 10.1101/SQB.1988.053.01.014; Channavajhala P, 2002, ONCOGENE, V21, P5280, DOI 10.1038/sj.onc.1205640; Cobb BS, 2000, GENE DEV, V14, P2146, DOI 10.1101/gad.816400; Dovat S, 2002, GENE DEV, V16, P2985, DOI 10.1101/gad.1040502; Dovat S, 2005, J IMMUNOL, V175, P3508, DOI 10.4049/jimmunol.175.6.3508; Dumortier A, 2003, BLOOD, V101, P2219, DOI 10.1182/blood-2002-05-1336; Ernst P, 1996, MOL CELL BIOL, V16, P6121; ERNST P, 1993, MOL CELL BIOL, V13, P2982, DOI 10.1128/MCB.13.5.2982; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; Gomez-del Arco P, 2004, MOL CELL BIOL, V24, P2797, DOI 10.1128/MCB.24.7.2797-2807.2004; GROVES T, 1995, J IMMUNOL, V154, P5011; Hahm K, 1998, GENE DEV, V12, P782, DOI 10.1101/gad.12.6.782; HAHM KM, 1994, MOL CELL BIOL, V14, P7111, DOI 10.1128/MCB.14.11.7111; Harker N, 2002, MOL CELL, V10, P1403, DOI 10.1016/S1097-2765(02)00711-6; HILL BL, 1988, J BIOL CHEM, V263, P5499; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; Klug CA, 1998, P NATL ACAD SCI USA, V95, P657, DOI 10.1073/pnas.95.2.657; Koipally J, 2000, J BIOL CHEM, V275, P19594, DOI 10.1074/jbc.M000254200; Koipally J, 1999, EMBO J, V18, P3090, DOI 10.1093/emboj/18.11.3090; Liberg D, 2003, TRENDS IMMUNOL, V24, P567, DOI 10.1016/j.it.2003.09.008; MARIN O, 1992, FEBS LETT, V301, P111, DOI 10.1016/0014-5793(92)80221-2; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; O'Neill DW, 2000, MOL CELL BIOL, V20, P7572, DOI 10.1128/MCB.20.20.7572-7582.2000; Rifkin IR, 1998, J IMMUNOL, V161, P5164; Ronni T, 2007, J BIOL CHEM, V282, P2538, DOI 10.1074/jbc.M605627200; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; Sridharan R, 2007, J BIOL CHEM, V282, P30227, DOI 10.1074/jbc.M702541200; Su RC, 2005, SEMIN IMMUNOL, V17, P129, DOI 10.1016/j.smim.2005.01.003; Su RC, 2004, NAT GENET, V36, P502, DOI 10.1038/ng1351; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; Thompson EC, 2007, IMMUNITY, V26, P335, DOI 10.1016/j.immuni.2007.02.010; Trinh LA, 2001, GENE DEV, V15, P1817, DOI 10.1101/gad.905601; WALTON GM, 1985, J BIOL CHEM, V260, P4745; WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1; Winandy S, 1999, J EXP MED, V190, P1039, DOI 10.1084/jem.190.8.1039; Wojcik H, 2007, EUR J IMMUNOL, V37, P1022, DOI 10.1002/eji.200637026; Wu L, 1997, IMMUNITY, V7, P483, DOI 10.1016/S1074-7613(00)80370-2; Yoshida T, 2006, NAT IMMUNOL, V7, P382, DOI 10.1038/ni1314; Yu SJ, 2002, MOL ENDOCRINOL, V16, P1069, DOI 10.1210/me.16.5.1069	47	45	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8291	8300		10.1074/jbc.M707906200	http://dx.doi.org/10.1074/jbc.M707906200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18223295	Green Published, hybrid			2022-12-25	WOS:000254288000027
J	Aherrahrou, Z; Doehring, LC; Ehlers, EM; Liptau, H; Depping, R; Linsel-Nitschke, P; Kaczmarek, PM; Erdmann, J; Schunkert, H				Aherrahrou, Zouhair; Doehring, Lars C.; Ehlers, Eva-Maria; Liptau, Henrike; Depping, Reinhard; Linsel-Nitschke, Patrick; Kaczmarek, Piotr M.; Erdmann, Jeanette; Schunkert, Heribert			An alternative splice variant in Abcc6, the gene causing dystrophic calcification, leads to protein deficiency in C3H/He mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOCARDIAL-CELL NECROSIS; PSEUDOXANTHOMA ELASTICUM; CARDIAC CALCINOSIS; CHROMOSOME 16P13.1; DBA/2 MICE; LOCUS; HYDROCORTISONE; TRANSPORTER; MUTATIONS; TISSUES	Dystrophic cardiac calcification (DCC) is an autosomal recessive trait characterized by calcium phosphate deposits in myocardial tissue. The Abcc6 gene locus was recently found to mediate DCC; however, at the molecular level the causative variants remain to be determined. Examining the sequences of Abcc6 cDNA in DCC-resistant C57BL/6 and DCC-susceptible C3H/He mice, we identified a missense mutation (Cys to Thr at codon 619, rs32756904) at the 3'-border of exon 14 that creates an additional donor splice site (GT). Accordingly, an alternative transcript variant was detected, lacking the last 5 bp of exon 14 (-AGG(C/T) GCTgtga-) in DCC-susceptible C3H/He mice that carry the Thr allele. The 5-bp deletion was found to result in premature termination at codon 684, in turn leading to protein deficiency in DCC-susceptible mouse tissue as well as in cells transfected with Abcc6c DNA lacking the last 5 bp of exon 14. All mouse strains that were found to carry the Thr allele, including C3H/He, DBA/2J, and 129S1/SvJ, were also found to be positive for DCC. In summary, we identified a splice variant leading to a 5-bp deletion in the Abcc6 transcript that gives rise to protein deficiency both in vivo and in vitro. The fact that all mouse strains that carry the deletion also develop dystrophic calcifications further suggests that the underlying splice variant affects the biological function of MRP6 protein and is a cause of DCC in mice.	[Aherrahrou, Zouhair; Doehring, Lars C.; Ehlers, Eva-Maria; Liptau, Henrike; Linsel-Nitschke, Patrick; Kaczmarek, Piotr M.; Erdmann, Jeanette; Schunkert, Heribert] Med Univ Lubeck, Med Klin 2, Dept Med 2, D-23538 Lubeck, Germany; [Depping, Reinhard] Med Univ Lubeck, Inst Physiol, D-23538 Lubeck, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Lubeck; University of Lubeck	Aherrahrou, Z (corresponding author), Med Univ Lubeck, Med Klin 2, Dept Med 2, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	Zouhair.Aherrahrou@uk-sh.de	Depping, Reinhard RD/B-6880-2018; Depping, Reinhard/AAT-3612-2020; Erdmann, Jeanette/A-4417-2009; Erdmann, Jeanette/P-7513-2014	Depping, Reinhard/0000-0002-4860-6058; Erdmann, Jeanette/0000-0002-4486-6231; Aherrahrou, Zouhair/0000-0002-1241-8733				Aherrahrou Z, 2004, AM J PATHOL, V164, P1379, DOI 10.1016/S0002-9440(10)63224-5; Aherrahrou Z, 2007, PHYSIOL GENOMICS, V28, P203, DOI 10.1152/physiolgenomics.00133.2006; Beck K, 2003, J HISTOCHEM CYTOCHEM, V51, P887, DOI 10.1177/002215540305100704; Bergen AAB, 2000, NAT GENET, V25, P228, DOI 10.1038/76109; Brunnert SR, 1999, GENOMICS, V59, P105, DOI 10.1006/geno.1999.5862; Cai L, 2000, J MOL MED-JMM, V78, P36, DOI 10.1007/s001090000079; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; Doehring LC, 2006, ANN ANAT, V188, P235, DOI 10.1016/j.aanat.2006.01.013; EATON GJ, 1978, AM J PATHOL, V90, P173; EVERITT JI, 1988, LAB ANIM SCI, V38, P426; GANG DL, 1986, AM J PATHOL, V124, P207; Gorgels TGMF, 2005, HUM MOL GENET, V14, P1763, DOI 10.1093/hmg/ddi183; Hendig D, 2005, J MOL MED, V83, P140, DOI 10.1007/s00109-004-0588-2; HIGHMAN B, 1965, ARCH PATHOL, V52, P221; Ilias A, 2002, J BIOL CHEM, V277, P16860, DOI 10.1074/jbc.M110918200; Ivandic BT, 2001, PHYSIOL GENOMICS, V6, P137, DOI 10.1152/physiolgenomics.2001.6.3.137; Ivandic BT, 1996, P NATL ACAD SCI USA, V93, P5483, DOI 10.1073/pnas.93.11.5483; Klement JF, 2005, MOL CELL BIOL, V25, P8299, DOI 10.1128/MCB.25.18.8299-8310.2005; LOSTROH A, 1955, NATURE, V176, P504, DOI 10.1038/176504a0; Matsuzaki Y, 2005, J INVEST DERMATOL, V125, P900, DOI 10.1111/j.0022-202X.2005.23897.x; Meng HJ, 2007, P NATL ACAD SCI USA, V104, P4530, DOI 10.1073/pnas.0607620104; PRICE P, 1991, AM J PATHOL, V138, P59; SPARKS LL, 1955, NATURE, V176, P503, DOI 10.1038/176503a0; Stamm S, 2005, GENE, V344, P1, DOI 10.1016/j.gene.2004.10.022; vanSoest S, 1997, GENOME RES, V7, P830, DOI 10.1101/gr.7.8.830; VANVLEET JF, 1987, AM J VET RES, V48, P255	26	51	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7608	7615		10.1074/jbc.M708290200	http://dx.doi.org/10.1074/jbc.M708290200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18201967	hybrid			2022-12-25	WOS:000253997900036
J	Hess, D; Keusch, JJ; Oberstein, SAL; Hennekam, RCM; Hofsteenge, J				Hess, Daniel; Keusch, Jeremy J.; Oberstein, Saskia A. Lesnik; Hennekam, Raoul C. M.; Hofsteenge, Jan			Peters plus syndrome is a new congenital disorder of glycosylation and involves defective O-glycosylation of thrombospondin type 1 repeats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS-SPECTROMETRY; C-MANNOSYLATION; FUCOSYLATION; PROTEIN; GLYCOSYLTRANSFERASE; PROPERDIN; FRINGE; IDENTIFICATION; MODULATION; SECRETION	Peters Plus syndrome is an autosomal recessive disorder characterized by anterior eye chamber defects, disproportionate short stature, developmental delay, and cleft lip and/ or palate. It is caused by splice site mutations in what was thought to be a beta 1,3-galactosyltransferase-like gene ( B3GALTL). Recently, we and others found this gene to encode a beta 1,3-glucosyltransferase involved in the synthesis of the disaccharide Glc-beta 1,3-Fuc-O-that occurs on thrombospondin type 1 repeats of many biologically important proteins. No functional tests have been performed to date on the presumed glycosylation defect in Peters Plus syndrome. We have established a sensitive immunopurification-mass spectrometry method, using multiple reaction monitoring, to analyze O-fucosyl glycans. It was used to compare the reporter protein properdin from Peters Plus patients with that from control heterozygous relatives. In properdin from patients, we could not detect the Glc-beta 1,3-Fuc-O-disaccharide, and we only found Fuc-O- at all four O-fucosylation sites. In contrast, properdin from heterozygous relatives and a healthy volunteer carried the Glc-beta 1,3-Fuc-O-disaccharide. These data firmly establish Peters Plus syndrome as a new congenital disorder of glycosylation.	[Hess, Daniel; Keusch, Jeremy J.; Hofsteenge, Jan] Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland; [Oberstein, Saskia A. Lesnik] Leiden Univ, Med Ctr, Dept Clin Genet, Ctr Human Clin Genet, NL-2300 RC Leiden, Netherlands; [Hennekam, Raoul C. M.] Inst Child Hlth, Clin & Mol Genet Unit, London WC1N 3JH, England	Friedrich Miescher Institute for Biomedical Research; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of London; University College London	Hofsteenge, J (corresponding author), Friedrich Miescher Inst Biomed Res, Maulbeer Str 66, CH-4058 Basel, Switzerland.	jan.hofsteenge@fmi.ch	Oberstein, Saskia A.J. Lesnik/C-3643-2016	Oberstein, Saskia A.J. Lesnik/0000-0002-1268-8995				CANEVASCINI S, 2006, EUROPEAN WORM MEETIN, P71; Chen JH, 2001, P NATL ACAD SCI USA, V98, P13716, DOI 10.1073/pnas.241398098; de Peredo AG, 2002, MOL CELL PROTEOMICS, V1, P11, DOI 10.1074/mcp.M100011-MCP200; DEBUY WPL, 2002, ANN GENET, V45, P97; Fijen CAP, 1999, MOL IMMUNOL, V36, P863, DOI 10.1016/S0161-5890(99)00107-8; Freeze HH, 2006, NAT REV GENET, V7, P537, DOI 10.1038/nrg1894; Haltiwanger RS, 2002, BBA-GEN SUBJECTS, V1573, P328, DOI 10.1016/S0304-4165(02)00400-2; Hartmann S, 2000, J BIOL CHEM, V275, P28569, DOI 10.1074/jbc.M001732200; Heinonen TYK, 2003, BIOCHEM BIOPH RES CO, V309, P166, DOI 10.1016/S0006-291X(03)01540-7; Hofsteenge J, 2001, J BIOL CHEM, V276, P6485, DOI 10.1074/jbc.M008073200; HOFSTEENGE J, 1994, BIOCHEMISTRY-US, V33, P13524, DOI 10.1021/bi00250a003; Hulsmeier AJ, 2007, MOL CELL PROTEOMICS, V6, P2132, DOI 10.1074/mcp.M700361-MCP200; Jaeken J, 2001, ANNU REV GENOM HUM G, V2, P129, DOI 10.1146/annurev.genom.2.1.129; Jaeken J, 2007, ANNU REV GENOM HUM G, V8, P261, DOI 10.1146/annurev.genom.8.080706.092327; Kozma K, 2006, J BIOL CHEM, V281, P36742, DOI 10.1074/jbc.M605912200; Krieg J, 1998, MOL BIOL CELL, V9, P301, DOI 10.1091/mbc.9.2.301; Luo Y, 2006, J BIOL CHEM, V281, P9385, DOI 10.1074/jbc.M511974200; Luo Y, 2006, J BIOL CHEM, V281, P9393, DOI 10.1074/jbc.M511975200; Macek B, 2001, RAPID COMMUN MASS SP, V15, P771, DOI 10.1002/rcm.298; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; NOLAN KF, 1993, METHOD ENZYMOL, V223, P35; Oberstein SAJL, 2006, AM J HUM GENET, V79, P562, DOI 10.1086/507567; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Ricketts LM, 2007, J BIOL CHEM, V282, P17014, DOI 10.1074/jbc.M700317200; Sato T, 2006, GLYCOBIOLOGY, V16, P1194, DOI 10.1093/glycob/cwl035; Tucker RP, 2004, INT J BIOCHEM CELL B, V36, P969, DOI 10.1016/j.biocel.2003.12.011; Unwin RD, 2006, TRENDS BIOCHEM SCI, V31, P473, DOI 10.1016/j.tibs.2006.06.003; Wada Y, 2006, J CHROMATOGR B, V838, P3, DOI 10.1016/j.jchromb.2006.02.028; Wang LW, 2007, J BIOL CHEM, V282, P17024, DOI 10.1074/jbc.M701065200; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	30	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7354	7360		10.1074/jbc.M710251200	http://dx.doi.org/10.1074/jbc.M710251200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18199743	hybrid			2022-12-25	WOS:000253997900009
J	Husain, M; Bourret, TJ; McCollister, BD; Jones-Carson, J; Laughlin, J; Vazquez-Torres, A				Husain, Maroof; Bourret, Travis J.; McCollister, Bruce D.; Jones-Carson, Jessica; Laughlin, James; Vazquez-Torres, Andres			Nitric oxide evokes an adaptive response to oxidative stress by arresting respiration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D TERMINAL OXIDASE; ESCHERICHIA-COLI; HYDROGEN-PEROXIDE; SALMONELLA-TYPHIMURIUM; ACTIVATED MACROPHAGES; TRANSCRIPTION FACTOR; REACTIVE OXYGEN; FENTON-REACTION; DNA-DAMAGE; PEROXYNITRITE	Aerobic metabolism generates biologically challenging reactive oxygen species (ROS) by the endogenous autooxidation of components of the electron transport chain (ETC). Basal levels of oxidative stress can dramatically rise upon activation of the NADPH oxidase-dependent respiratory burst. To minimize ROS toxicity, prokaryotic and eukaryotic organisms express a battery of low-molecular-weight thiol scavengers, a legion of detoxifying catalases, peroxidases, and superoxide dismutases, as well as a variety of repair systems. We present herein blockage of bacterial respiration as a novel strategy that helps the intracellular pathogen Salmonella survive extreme oxidative stress conditions. A Salmonella strain bearing mutations in complex I NADH dehydrogenases is refractory to the early NADPH oxidase-dependent antimicrobial activity of IFN gamma-activated macrophages. The ability of NADH-rich, complex I-deficient Salmonella to survive oxidative stress is associated with resistance to peroxynitrite (ONOO-) and hydrogen peroxide (H2O2). Inhibition of respiration with nitric oxide (NO) also triggered a protective adaptive response against oxidative stress. Expression of the NDH-II dehydrogenase decreases NADH levels, thereby abrogating resistance of NO-adapted Salmonella to H2O2. NADH antagonizes the hydroxyl radical (OH center dot) generated in classical Fenton chemistry or spontaneous decomposition of peroxynitrous acid (ONOOH), while fueling AhpCF alkylhydroperoxidase. Together, these findings identify the accumulation of NADH following the NO-mediated inhibition of Salmonella's ETC as a novel antioxidant strategy. NO-dependent respiratory arrest may help mitochondria and a plethora of organisms cope with oxidative stress engendered in situations as diverse as aerobic respiration, ischemia reperfusion, and inflammation.	[Husain, Maroof; Bourret, Travis J.; McCollister, Bruce D.; Jones-Carson, Jessica; Laughlin, James; Vazquez-Torres, Andres] UCHSC Sch Med Fitzsimons, Dept Microbiol, Aurora, CO 80045 USA; [McCollister, Bruce D.; Jones-Carson, Jessica; Vazquez-Torres, Andres] UCHSC Fitzsimons, Dept Med, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Vazquez-Torres, A (corresponding author), UCHSC Sch Med Fitzsimons, Dept Microbiol, Mail Box 8333,POB 6511,Rm P18-9120, Aurora, CO 80045 USA.	andres.vazquez-torres@uchsc.edu	Bourret, Travis/J-4673-2019	Bourret, Travis/0000-0002-4154-929X	NIAID NIH HHS [AI54959] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI054959, R01AI054959] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Almeida A, 2001, J NEUROCHEM, V77, P676, DOI 10.1046/j.1471-4159.2001.00276.x; Aslund F, 1999, P NATL ACAD SCI USA, V96, P6161, DOI 10.1073/pnas.96.11.6161; Bang IS, 2006, J BIOL CHEM, V281, P28039, DOI 10.1074/jbc.M605174200; Barreto Jose C., 1995, Life Sciences, V56, pPL89; Beltran B, 2000, P NATL ACAD SCI USA, V97, P14602, DOI 10.1073/pnas.97.26.14602; Brunelli L, 2001, FREE RADICAL BIO MED, V30, P709, DOI 10.1016/S0891-5849(00)00512-8; Bryk R, 2000, NATURE, V407, P211, DOI 10.1038/35025109; Butler CS, 1997, BIOCHEMISTRY-US, V36, P16259, DOI 10.1021/bi971481a; Cassina A, 1996, ARCH BIOCHEM BIOPHYS, V328, P309, DOI 10.1006/abbi.1996.0178; CASTRO L, 1994, J BIOL CHEM, V269, P29409; Chakravortty D, 2002, J EXP MED, V195, P1155, DOI 10.1084/jem.20011547; CHEREPANOV PP, 1995, GENE, V158, P9, DOI 10.1016/0378-1119(95)00193-A; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DEGROOTE MA, 1995, P NATL ACAD SCI USA, V92, P6399, DOI 10.1073/pnas.92.14.6399; Fang FC, 2004, NAT REV MICROBIOL, V2, P820, DOI 10.1038/nrmicro1004; Freeman JA, 2002, J BACTERIOL, V184, P4971, DOI 10.1128/JB.184.18.4971-4980.2002; GEORGIOU CD, 1988, J BACTERIOL, V170, P961, DOI 10.1128/jb.170.2.961-966.1988; Goldstein S, 2000, CHEM RES TOXICOL, V13, P736, DOI 10.1021/tx000099n; Gorbunov NV, 1997, J BIOL CHEM, V272, P12328, DOI 10.1074/jbc.272.19.12328; Gusarov I, 2005, P NATL ACAD SCI USA, V102, P13855, DOI 10.1073/pnas.0504307102; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; Hori H, 1996, J BIOL CHEM, V271, P9254, DOI 10.1074/jbc.271.16.9254; IMLAY JA, 1988, SCIENCE, V240, P640, DOI 10.1126/science.2834821; JOHNSON G, 1991, CRIT CARE MED, V19, P244, DOI 10.1097/00003246-199102000-00021; Jonsson TJ, 2007, BIOCHEMISTRY-US, V46, P5709, DOI 10.1021/bi7001218; Joshi MS, 1999, FREE RADICAL BIO MED, V27, P1357, DOI 10.1016/S0891-5849(99)00179-3; Jung IL, 2003, BIOCHEM BIOPH RES CO, V301, P915, DOI 10.1016/S0006-291X(03)00064-0; Keyer K, 1997, J BIOL CHEM, V272, P27652, DOI 10.1074/jbc.272.44.27652; Kim SO, 2002, CELL, V109, P383, DOI 10.1016/S0092-8674(02)00723-7; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; Lu CY, 2005, J BIOL INORG CHEM, V10, P732, DOI 10.1007/s00775-005-0019-z; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; McCollister BD, 2005, J EXP MED, V202, P625, DOI 10.1084/jem.20050246; MILLER MJ, 1986, METHOD ENZYMOL, V126, P87; NUNOSHIBA T, 1993, P NATL ACAD SCI USA, V90, P9993, DOI 10.1073/pnas.90.21.9993; PACELLI R, 1995, J EXP MED, V182, P1469, DOI 10.1084/jem.182.5.1469; POLLOCK JD, 1995, NAT GENET, V9, P202, DOI 10.1038/ng0295-202; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; RADI R, 1993, BIOCHEM J, V290, P51, DOI 10.1042/bj2900051; San KY, 2002, METAB ENG, V4, P182, DOI 10.1006/mben.2001.0220; SCHWEIZER M, 1994, BIOCHEM BIOPH RES CO, V204, P169, DOI 10.1006/bbrc.1994.2441; STORZ G, 1989, J BACTERIOL, V171, P2049, DOI 10.1128/jb.171.4.2049-2055.1989; Thomas DD, 2001, P NATL ACAD SCI USA, V98, P355, DOI 10.1073/pnas.98.1.355; Trimmer BA, 2001, SCIENCE, V292, P2486, DOI 10.1126/science.1059833; Uchiya K, 1999, EMBO J, V18, P3924, DOI 10.1093/emboj/18.14.3924; Vazquez-Torres A, 2000, SCIENCE, V287, P1655, DOI 10.1126/science.287.5458.1655; Vazquez-Torres A, 2000, J EXP MED, V192, P227, DOI 10.1084/jem.192.2.227; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; WINK DA, 1993, P NATL ACAD SCI USA, V90, P9813, DOI 10.1073/pnas.90.21.9813; Woodmansee AN, 2002, J BIOL CHEM, V277, P34055, DOI 10.1074/jbc.M203977200; Yu XJ, 2002, CELL MICROBIOL, V4, P531, DOI 10.1046/j.1462-5822.2002.00211.x	54	69	73	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7682	7689		10.1074/jbc.M708845200	http://dx.doi.org/10.1074/jbc.M708845200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18198179	hybrid			2022-12-25	WOS:000253997900044
J	Paris, S; Burlacu, A; Durocher, Y				Paris, Sebastien; Burlacu, Alina; Durocher, Yves			Opposing roles of syndecan-1 and syndecan-2 in polyethyleneimine-mediated gene delivery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; TRANSIENT TRANSFECTION; CYTOPLASMIC DOMAIN; MAMMALIAN-CELLS; CORE PROTEIN; PDZ PROTEIN; PROTEOGLYCANS; MEMBRANE; EXPRESSION; BINDS	Polyethyleneimines (PEIs) are efficient non-viral vectors for gene transfer. Heparan sulfate proteoglycans have been proposed to be the cell-surface receptors for PEI.DNA complexes (polyplexes). Here, we investigated if syndecan-1 (SDC1) and syndecan-2 (SDC2) are involved in PEI-mediated transfection. Following addition of polyplexes to HEK293 cells, green fluorescent protein-tagged SDCs rapidly formed clusters with PEI that were dependent of lipid raft integrity. However, although SDC1 overexpression slightly enhanced PEI-mediated gene expression, SDC2 dramatically inhibited it. Confocal microscopy analysis showed that SDC1.polyplex endocytosis occurred within minutes after addition of polyplexes, whereas SDC2.polyplex endocytosis took hours. Expression of SDC1 cytoplasmic deletion mutants revealed that the SDC1 cytoplasmic tail is required for gene expression, but not for clustering or endocytosis, whereas overexpression of SDC1/SDC2 chimeras showed that the SDC2 ectodomain is responsible for the inhibitory effect on gene transfer. This study provides evidence that SDCs may have opposing effects on PEI-mediated transfection.	[Paris, Sebastien; Burlacu, Alina; Durocher, Yves] Natl Res Council Canada, Biotechnol Res Inst, Bioproc Sector, Biotechnol Res Inst,Anim Cell Technol Grp, Montreal, PQ H4P 2R2, Canada	National Research Council Canada	Durocher, Y (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, Bioproc Sector, Biotechnol Res Inst,Anim Cell Technol Grp, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.	yves.durocher@cnrc-nrc.gc.ca	Durocher, Yves/K-8709-2019					Almeida PFF, 2005, BBA-BIOMEMBRANES, V1720, P1, DOI 10.1016/j.bbamem.2005.12.004; Belting M, 1999, BIOCHEM J, V342, P281, DOI 10.1042/0264-6021:3420281; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Boussif O, 1996, GENE THER, V3, P1074; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; Carey DJ, 1996, J BIOL CHEM, V271, P15253, DOI 10.1074/jbc.271.25.15253; CAREY DJ, 1994, EXP CELL RES, V214, P12, DOI 10.1006/excr.1994.1228; Carey DJ, 1997, BIOCHEM J, V327, P1; Carpentier E, 2007, J BIOTECHNOL, V128, P268, DOI 10.1016/j.jbiotec.2006.10.014; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Couchman JR, 2003, NAT REV MOL CELL BIO, V4, P926, DOI 10.1038/nrm1257; Demeneix B, 2005, ADV GENET, V53, P217, DOI 10.1016/S0065-2660(05)53008-6; Derouazi M, 2004, BIOTECHNOL BIOENG, V87, P537, DOI 10.1002/bit.20161; Dull RO, 2003, AM J PHYSIOL-LUNG C, V285, pL986, DOI 10.1152/ajplung.00022.2003; Durocher Y, 2001, RECOMBINANT PROTEIN PRODUCTION WITH PROKARYOTIC AND EUKARYOTIC CELLS: A COMPARATIVE VIEW ON HOST PHYSIOLOGY, P331; Durocher Y, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e9; Endo K, 2003, J BIOL CHEM, V278, P40764, DOI 10.1074/jbc.M306736200; Ethell IM, 2001, NEURON, V31, P1001, DOI 10.1016/S0896-6273(01)00440-8; Ethell IM, 2000, J CELL BIOL, V151, P53, DOI 10.1083/jcb.151.1.53; Fuki IV, 2000, BIOCHEM J, V351, P607, DOI 10.1042/0264-6021:3510607; Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685; Gao YH, 2000, J CELL PHYSIOL, V184, P373, DOI 10.1002/1097-4652(200009)184:3<373::AID-JCP12>3.0.CO;2-I; Gautam A, 2001, MOL THER, V3, P551, DOI 10.1006/mthe.2001.0300; Goula D, 1998, GENE THER, V5, P1291, DOI 10.1038/sj.gt.3300717; Goula D, 1998, GENE THER, V5, P712, DOI 10.1038/sj.gt.3300635; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; Grosse S, 2006, J GENE MED, V8, P845, DOI 10.1002/jgm.915; Grzelinski M, 2006, HUM GENE THER, V17, P751, DOI 10.1089/hum.2006.17.751; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Kircheis R, 1999, J GENE MED, V1, P111; Lander AD, 2000, J CELL BIOL, V148, P227, DOI 10.1083/jcb.148.2.227; Mislick KA, 1996, P NATL ACAD SCI USA, V93, P12349, DOI 10.1073/pnas.93.22.12349; Mounkes LC, 1998, J BIOL CHEM, V273, P26164, DOI 10.1074/jbc.273.40.26164; NUMA F, 1995, CANCER RES, V55, P4676; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Pham PL, 2006, MOL BIOTECHNOL, V34, P225, DOI 10.1385/MB:34:2:225; Piguet V, 1998, EMBO J, V17, P2472, DOI 10.1093/emboj/17.9.2472; Rapraeger AC, 1998, CURR OPIN CELL BIOL, V10, P620, DOI 10.1016/S0955-0674(98)80038-0; Shi CH, 2005, BIOCHEMISTRY-US, V44, P15705, DOI 10.1021/bi051292p; Tang GP, 2006, J GENE MED, V8, P736, DOI 10.1002/jgm.874; Thomas M, 2005, PHARM RES-DORDR, V22, P373, DOI 10.1007/s11095-004-1874-y; Tkachenko E, 2005, CIRC RES, V96, P488, DOI 10.1161/01.RES.0000159708.71142.c8; Tkachenko E, 2004, J CELL SCI, V117, P3189, DOI 10.1242/jcs.01190; Tkachenko E, 2002, J BIOL CHEM, V277, P19946, DOI 10.1074/jbc.M200841200; Utani A, 2001, J BIOL CHEM, V276, P28779, DOI 10.1074/jbc.M101420200; Woods A, 1998, MATRIX BIOL, V17, P477, DOI 10.1016/S0945-053X(98)90095-6; Woods A, 1998, TRENDS CELL BIOL, V8, P189, DOI 10.1016/S0962-8924(98)01244-6; Yoneda A, 2003, MATRIX BIOL, V22, P25, DOI 10.1016/S0945-053X(03)00010-6; ZHANG LJ, 1994, J BIOL CHEM, V269, P19295; Zimmermann P, 2005, DEV CELL, V9, P377, DOI 10.1016/j.devcel.2005.07.011	51	54	61	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7697	7704		10.1074/jbc.M705424200	http://dx.doi.org/10.1074/jbc.M705424200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18216019	hybrid			2022-12-25	WOS:000253997900046
J	Thakur, M; Chaba, R; Mondal, AK; Chakraborti, PK				Thakur, Meghna; Chaba, Rachna; Mondal, Alok K.; Chakraborti, Pradip K.			Interdomain interaction reconstitutes the functionality of PknA, a eukaryotic type Ser/Thr kinase from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE/THREONINE PROTEIN-KINASE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; HISTIDINE KINASE; TYROSINE KINASE; ACTIVATION; PHOSPHORYLATION; AUTOPHOSPHORYLATION; DOMAIN; MECHANISM	Eukaryotic type Ser/Thr protein kinases have recently been shown to regulate a variety of cellular functions in bacteria. PknA, a transmembrane Ser/Thr protein kinase from Mycobacterium tuberculosis, when constitutively expressed in Escherichia coli resulted in cell elongation and therefore has been thought to be regulating morphological changes associated with cell division. Bioinformatic analysis revealed that PknA has N-terminal catalytic, juxtamembrane, transmembrane, and C-terminal extracellular domains, like known eukaryotic type Ser/Thr protein kinases from other bacteria. To identify the minimum region capable of exhibiting phosphorylation activity of PknA, we created several deletion mutants. Surprisingly, we found that the catalytic domain itself was not sufficient for exhibiting phosphorylation ability of PknA. However, the juxtamembrane region together with the kinase domain was necessary for the enzymatic activity and thus constitutes the catalytic core of PknA. Utilizing this core, we deduce that the autophosphorylation of PknA is an intermolecular event. Interestingly, the core itself was unable to restore the cell elongation phenotype as manifested by the full-length protein in E. coli; however, its co-expression along with the C-terminal region of PknA can associate them in trans to reconstitute a functional protein in vivo. Therefore, these findings argue that the transmembrane and extracellular domains of PknA, although dispensable for phosphorylation activities, are crucial in responding to signals. Thus, our results for the first time establish the significance of different domains in a bacterial eukaryotic type Ser/Thr kinase for reconstitution of its functionality.	[Thakur, Meghna; Chaba, Rachna; Mondal, Alok K.; Chakraborti, Pradip K.] Inst Microbiol Technol, Chandigarh 160036, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Microbial Technology (IMTECH)	Chakraborti, PK (corresponding author), Inst Microbiol Technol, Sector 39A, Chandigarh 160036, India.	pradip@imtech.res.in	Thakur, Meghna/J-4011-2019	Thakur, Meghna/0000-0001-7952-6029				Ascano M, 2004, MOL CELL BIOL, V24, P10397, DOI 10.1128/MCB.24.23.10397-10405.2004; Av-Gay Y, 2000, TRENDS MICROBIOL, V8, P238, DOI 10.1016/S0966-842X(00)01734-0; Boitel B, 2003, MOL MICROBIOL, V49, P1493, DOI 10.1046/j.1365-2958.2003.03657.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cai SJ, 2003, J MOL BIOL, V329, P495, DOI 10.1016/S0022-2836(03)00446-7; Canova MJ, 2008, PROTEOMICS, V8, P521, DOI 10.1002/pmic.200700442; Chaba R, 2002, EUR J BIOCHEM, V269, P1078, DOI 10.1046/j.1432-1033.2002.02778.x; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; DeLano WL, 1998, PYMOL MOL GRAPHICS S; Duran R, 2005, BIOCHEM BIOPH RES CO, V333, P858, DOI 10.1016/j.bbrc.2005.05.173; Ginsberg AM, 2007, NAT MED, V13, P290, DOI 10.1038/nm0307-290; Gopalaswamy R, 2004, PROTEIN EXPRES PURIF, V36, P82, DOI 10.1016/j.pep.2004.03.011; Greenstein AE, 2005, J MOL MICROB BIOTECH, V9, P167, DOI 10.1159/000089645; Greenstein AE, 2007, J BIOL CHEM, V282, P11427, DOI 10.1074/jbc.M610193200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Huse M, 1999, CELL, V96, P425, DOI 10.1016/S0092-8674(00)80555-3; IUCHI S, 1993, J BIOL CHEM, V268, P23972; JOHNSON LN, 1996, CELL, V85, P49; Kang CM, 2005, GENE DEV, V19, P1692, DOI 10.1101/gad.1311105; Koul A, 2001, MICROBIOL-SGM, V147, P2307, DOI 10.1099/00221287-147-8-2307; LAMMERS R, 1990, J BIOL CHEM, V265, P16886; McCarty DR, 2000, CELL, V103, P201, DOI 10.1016/S0092-8674(00)00113-6; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Molle V, 2003, BIOCHEMISTRY-US, V42, P15300, DOI 10.1021/bi035150b; Molle V, 2003, BIOCHEM BIOPH RES CO, V308, P820, DOI 10.1016/S0006-291X(03)01476-1; Nolen B, 2004, MOL CELL, V15, P661, DOI 10.1016/j.molcel.2004.08.024; Oliver AW, 2007, TRENDS BIOCHEM SCI, V32, P351, DOI 10.1016/j.tibs.2007.06.004; Ortiz-Lombardia M, 2003, J BIOL CHEM, V278, P13094, DOI 10.1074/jbc.M300660200; Park SY, 2004, J BIOL CHEM, V279, P33315, DOI 10.1074/jbc.M313527200; Rogers JA, 1996, J BIOL CHEM, V271, P17519, DOI 10.1074/jbc.271.29.17519; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Sharma K, 2004, FEMS MICROBIOL LETT, V233, P107, DOI 10.1016/j.femsle.2004.01.045; Sierk ML, 2004, STRUCTURE, V12, P2103, DOI 10.1016/j.str.2004.09.016; Thakur M, 2006, J BIOL CHEM, V281, P40107, DOI 10.1074/jbc.M607216200; Thiel KW, 2007, P NATL ACAD SCI USA, V104, P19238, DOI 10.1073/pnas.0703854104; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; UDO H, 1995, GENE DEV, V9, P972, DOI 10.1101/gad.9.8.972; Villarino A, 2005, J MOL BIOL, V350, P953, DOI 10.1016/j.jmb.2005.05.049; Walburger A, 2004, SCIENCE, V304, P1800, DOI 10.1126/science.1099384; West AH, 2001, TRENDS BIOCHEM SCI, V26, P369, DOI 10.1016/S0968-0004(01)01852-7; Yang W, 2001, PROTEIN EXPRES PURIF, V22, P472, DOI 10.1006/prep.2001.1453; Young TA, 2003, NAT STRUCT BIOL, V10, P168, DOI 10.1038/nsb897	44	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					8023	8033		10.1074/jbc.M707535200	http://dx.doi.org/10.1074/jbc.M707535200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18199749	hybrid			2022-12-25	WOS:000253997900077
J	Cenci, C; Barzotti, R; Galeano, F; Corbelli, S; Rota, R; Massimi, L; Di Rocco, C; O'Connell, MA; Gallo, A				Cenci, Caterina; Barzotti, Rita; Galeano, Federica; Corbelli, Sandro; Rota, Rossella; Massimi, Luca; Di Rocco, Concezio; O'Connell, Mary A.; Gallo, Angela			Down-regulation of RNA editing in pediatric astrocytomas - ADAR2 editing activity inhibits cell migration and proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; ADENOSINE-DEAMINASE; GLUTAMATE RECEPTORS; BINDING DOMAINS; GLIAL-CELLS; IN-VIVO; GLUR-B; GENE; DIMERIZATION; ENZYME	Since alterations in post-transcriptional events can contribute to the appearance and/ or progression of cancer, we investigated whether RNA editing, catalyzed by the ADAR ( adenosine deaminases that act on RNA) enzymes, is altered in pediatric astrocytomas. We find a decrease in ADAR2 editing activity that seems to correlate with the grade of malignancy in children. Despite the loss of ADAR2 editing activity in tumor tissues, the high grade astrocytomas do not exhibit alterations in ADAR2 expression when compared with their specific control tissues. However, high expression levels of ADAR1 and ADAR3 were found in tumors when compared with normal tissues dissected in the same area of the brain. We reintroduced either ADAR2 or the inactive version of ADAR2 in three astrocytoma cell lines ( U118, A172, U87). The "reverted" editing status is necessary and sufficient for a significant decrease in cell malignant behavior as measured by proliferation, cell cycle, and migration assays. We show that elevated levels of ADAR1, as found in astrocytomas, do indeed interfere with ADAR2 specific editing activity. Furthermore, we show that the endogenous ADAR1 can form heterodimers with ADAR2 in astrocytes.	[Rota, Rossella] Osped Pediat Bambino Gesu Res Inst, Angiogenesis, I-00165 Rome, Italy; [Cenci, Caterina; Barzotti, Rita; Galeano, Federica; Corbelli, Sandro; Gallo, Angela] Osped Pediat Bambino Gesu Res Inst, RNA Editing Lab, I-00165 Rome, Italy; [Massimi, Luca; Di Rocco, Concezio] Pediat Neurosurg Policlin Gemelli, I-00168 Rome, Italy; [O'Connell, Mary A.] Western Gen Hosp, MRC Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland	IRCCS Bambino Gesu; IRCCS Bambino Gesu; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Edinburgh	Gallo, A (corresponding author), Osped Pediat Bambino Gesu Res Inst, Angiogenesis, Piazza S Onofrio 4, I-00165 Rome, Italy.	gallo@opbg.net	Rota, Rossella/AAB-2497-2019; Gallo, Angela/AAA-5003-2020; O'Connell, Mary Anne/U-7693-2019; OConnell, Mary Anne/G-4740-2015; Corbelli, Sandro/AAA-6621-2020; Gallo, Angela/E-7837-2011	Rota, Rossella/0000-0002-9408-7711; Gallo, Angela/0000-0003-0297-1807; O'Connell, Mary Anne/0000-0003-3844-6174; OConnell, Mary Anne/0000-0003-3844-6174; Corbelli, Sandro/0000-0001-9112-2852; Gallo, Angela/0000-0003-0297-1807	Medical Research Council [MC_U127584490] Funding Source: Medline; Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom; MRC [MC_U127584490] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BASILIO C, 1962, P NATL ACAD SCI USA, V48, P613, DOI 10.1073/pnas.48.4.613; Bernard A, 1999, EUR J NEUROSCI, V11, P604, DOI 10.1046/j.1460-9568.1999.00479.x; Chen CX, 2000, RNA, V6, P755, DOI 10.1017/S1355838200000170; Chilibeck KA, 2006, J BIOL CHEM, V281, P16530, DOI 10.1074/jbc.M511831200; Cho DSC, 2003, J BIOL CHEM, V278, P17093, DOI 10.1074/jbc.M213127200; Desterro JMP, 2003, J CELL SCI, V116, P1805, DOI 10.1242/jcs.00371; Gallo A, 2003, EMBO J, V22, P3421, DOI 10.1093/emboj/cdg327; Gerber A, 1997, RNA, V3, P453; Higuchi M, 2000, NATURE, V406, P78, DOI 10.1038/35017558; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; Ichimura K, 2004, J NEURO-ONCOL, V70, P137, DOI 10.1007/s11060-004-2747-2; Ishiuchi S, 2002, NAT MED, V8, P971, DOI 10.1038/nm746; Kawahara Y, 2004, NATURE, V427, P801, DOI 10.1038/427801a; Keegan LP, 2001, NAT REV GENET, V2, P869, DOI 10.1038/35098584; Koeller KK, 2004, RADIOGRAPHICS, V24, P1693, DOI 10.1148/rg.246045146; Kwak S, 2005, J MOL MED, V83, P110, DOI 10.1007/s00109-004-0599-z; LAI F, 1995, J BIOL CHEM, V270, P17098, DOI 10.1074/jbc.270.29.17098; LARDER BA, 1993, NATURE, V365, P671, DOI 10.1038/365671a0; Liu Y, 1997, J BIOL CHEM, V272, P4419, DOI 10.1074/jbc.272.7.4419; Maas S, 2001, P NATL ACAD SCI USA, V98, P14687, DOI 10.1073/pnas.251531398; Maas Stefan, 2006, RNA Biol, V3, P1; Melcher T, 1996, J BIOL CHEM, V271, P31795, DOI 10.1074/jbc.271.50.31795; Nie YZ, 2005, MOL CELL BIOL, V25, P6956, DOI 10.1128/MCB.25.16.6956-6963.2005; Nishikura K, 2006, NAT REV MOL CELL BIO, V7, P919, DOI 10.1038/nrm2061; PATNEAU DK, 1994, NEURON, V12, P357, DOI 10.1016/0896-6273(94)90277-1; Paupard MC, 2000, NEUROSCIENCE, V95, P869; Paz N, 2007, GENOME RES, V17, P1586, DOI 10.1101/gr.6493107; *PE APPL BIOS, 1997, ABI PRISM 7700 SEQ D, V2; Peng PL, 2006, NEURON, V49, P719, DOI 10.1016/j.neuron.2006.01.025; Poulsen H, 2006, RNA, V12, P1350, DOI 10.1261/rna.2314406; Steinhauser C, 1996, TRENDS NEUROSCI, V19, P339, DOI 10.1016/0166-2236(96)10043-6; Tamber Mandeep S, 2003, Neurosurg Focus, V14, pe1; Toschi E, 2000, J INVEST DERMATOL, V114, P1188, DOI 10.1046/j.1523-1747.2000.00000.x; WAGNER RW, 1990, MOL CELL BIOL, V10, P5586, DOI 10.1128/MCB.10.10.5586; Wang Q, 2000, SCIENCE, V290, P1765, DOI 10.1126/science.290.5497.1765	35	149	165	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					7251	7260		10.1074/jbc.M708316200	http://dx.doi.org/10.1074/jbc.M708316200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18178553	hybrid			2022-12-25	WOS:000253779600070
J	Lea-Smith, DJ; Martin, KL; Pyke, JS; Tull, D; McConville, MJ; Coppel, RL; Crellin, PK				Lea-Smith, David J.; Martin, Kirstee L.; Pyke, James S.; Tull, Dedreia; McConville, Malcolm J.; Coppel, Ross L.; Crellin, Paul K.			Analysis of a new mannosyltransferase required for the synthesis of phosphatidylinositol mannosides and lipoarbinomannan reveals two lipomannan pools in corynebacterineae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOLIC ACID BIOSYNTHESIS; CELL-WALL; MONOPHOSPHOMANNOSE SYNTHASE; MYCOBACTERIUM-TUBERCULOSIS; CLONING VECTORS; LIPOARABINOMANNAN; IDENTIFICATION; GLUTAMICUM; GROWTH; DEFINITION	The cell walls of the Corynebacterineae, which includes the important human pathogen Mycobacterium tuberculosis, contain two major lipopolysaccharides, lipoarabinomannan ( LAM) and lipomannan (LM). LAM is assembled on a subpool of phosphatidylinositol mannosides (PIMs), whereas the identity of the LM lipid anchor is less well characterized. In this study we have identified a new gene (Rv2188c in M. tuberculosis and NCgl2106 in Corynebacterium glutamicum) that encodes a mannosyltransferase involved in the synthesis of the early dimannosylated PIM species, acyl-PIM2, and LAM. Disruption of the C. glutamicum NCgl2106 gene resulted in loss of synthesis of AcPIM2 and accumulation of the monomannosylated precursor, AcPIM1. The synthesis of a structurally unrelated mannolipid, Gl-X, was unaffected. The synthesis of AcPIM2 in C. glutamicum Delta NCgl2106 was restored by complementation with M. tuberculosis Rv2188c. In vivo labeling of the mutant with [H-3] Man and in vitro labeling of membranes with GDP-[H-3] Man confirmed that NCgl2106/Rv2188c catalyzed the second mannose addition in PIM biosynthesis, a function previously ascribed to PimB/Rv0557. The C. glutamicum Delta NCgl2106 mutant lacked mature LAM but unexpectedly still synthesized the major pool of LM. Biochemical analyses of the LM core indicated that this lipopolysaccharide was assembled on Gl-X. These data suggest that NCgl2106/Rv2188c and the previously studied PimB/Rv0557 transfer mannose residues to distinct mannoglycolipids that act as precursors for LAM and LM, respectively.	[Lea-Smith, David J.; Coppel, Ross L.; Crellin, Paul K.] Monash Univ, Dept Microbiol, Australian Res Council Ctr Excellence Struct & Fu, Clayton, Vic 3800, Australia; [Lea-Smith, David J.; Coppel, Ross L.; Crellin, Paul K.] Monash Univ, Dept Microbiol, Victorian Bioinformat Consortium, Clayton, Vic 3800, Australia; [Martin, Kirstee L.; Pyke, James S.; Tull, Dedreia; McConville, Malcolm J.] Univ Melbourne, Inst Mol Sci & Biotechnol Bio21, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia	Monash University; Monash University; University of Melbourne	Crellin, PK (corresponding author), Monash Univ, Dept Microbiol, Australian Res Council Ctr Excellence Struct & Fu, Clayton, Vic 3800, Australia.	paul.crellin@med.monash.edu.au	Lea-Smith, David/U-9151-2019; Coppel, Ross L/A-6626-2008	Lea-Smith, David/0000-0003-2463-406X; Coppel, Ross L/0000-0002-4476-9124; Crellin, Paul K/0000-0002-2017-4935; Tull, Dedreia/0000-0003-2546-6707	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		Alderwick LJ, 2005, J BIOL CHEM, V280, P32362, DOI 10.1074/jbc.M506339200; Alderwick LJ, 2006, J BIOL CHEM, V281, P15653, DOI 10.1074/jbc.M600045200; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Berg S, 2007, GLYCOBIOLOGY, V17, p35R, DOI 10.1093/glycob/cwm010; Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; Billman-Jacobe H, 1999, MOL MICROBIOL, V33, P1244, DOI 10.1046/j.1365-2958.1999.01572.x; Brennan PJ, 2003, TUBERCULOSIS, V83, P91, DOI 10.1016/S1472-9792(02)00089-6; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Gande R, 2004, J BIOL CHEM, V279, P44847, DOI 10.1074/jbc.M408648200; Gibson KJC, 2003, J BIOL CHEM, V278, P40842, DOI 10.1074/jbc.M307988200; Gurcha SS, 2002, BIOCHEM J, V365, P441, DOI 10.1042/BJ20020107; Kacem R, 2004, MICROBIOL-SGM, V150, P73, DOI 10.1099/mic.0.26583-0; Kalinowski J, 2003, J BIOTECHNOL, V104, P5, DOI 10.1016/S0168-1656(03)00154-8; Kaur D, 2007, J BIOL CHEM, V282, P27133, DOI 10.1074/jbc.M703389200; Kaur D, 2006, P NATL ACAD SCI USA, V103, P13664, DOI 10.1073/pnas.0603049103; KHOO KH, 1995, GLYCOBIOLOGY, V5, P117, DOI 10.1093/glycob/5.1.117; Kordulakova J, 2002, J BIOL CHEM, V277, P31335, DOI 10.1074/jbc.M204060200; Koul A, 2004, NAT REV MICROBIOL, V2, P189, DOI 10.1038/nrmicro840; Kovacevic S, 2006, J BIOL CHEM, V281, P9011, DOI 10.1074/jbc.M511709200; Kremer L, 2002, BIOCHEM J, V363, P437, DOI 10.1042/0264-6021:3630437; Lea-Smith DJ, 2007, J BIOL CHEM, V282, P11000, DOI 10.1074/jbc.M608686200; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; McKean S, 2005, MICROBES INFECT, V7, P1352, DOI 10.1016/j.micinf.2005.05.002; Morita YS, 2006, J BIOL CHEM, V281, P25143, DOI 10.1074/jbc.M604214200; Morita YS, 2005, J BIOL CHEM, V280, P21645, DOI 10.1074/jbc.m414181200; Morita YS, 2004, BIOCHEM J, V378, P589, DOI 10.1042/BJ20031372; Portevin D, 2005, J BIOL CHEM, V280, P8862, DOI 10.1074/jbc.M408578200; Portevin D, 2004, P NATL ACAD SCI USA, V101, P314, DOI 10.1073/pnas.0305439101; Puech V, 2000, MOL MICROBIOL, V35, P1026, DOI 10.1046/j.1365-2958.2000.01738.x; Raviglione MC, 2003, TUBERCULOSIS, V83, P4, DOI 10.1016/S1472-9792(02)00071-9; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Schaeffer ML, 1999, J BIOL CHEM, V274, P31625, DOI 10.1074/jbc.274.44.31625; SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7; Tatituri RVV, 2007, J BIOL CHEM, V282, P4561, DOI 10.1074/jbc.M608695200; Tatituri RVV, 2007, MICROBIOL-SGM, V153, P2621, DOI 10.1099/mic.0.2007/008078-0; Torrelles JB, 2004, J BIOL CHEM, V279, P41227, DOI 10.1074/jbc.M405180200; Tropis M, 2005, J BIOL CHEM, V280, P26573, DOI 10.1074/jbc.M502104200; van der Rest ME, 1999, APPL MICROBIOL BIOT, V52, P541, DOI 10.1007/s002530051557; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	39	57	59	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					6773	6782		10.1074/jbc.M707139200	http://dx.doi.org/10.1074/jbc.M707139200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18178556	hybrid			2022-12-25	WOS:000253779600019
J	Sadaie, M; Shinmyozu, K; Nakayama, JI				Sadaie, Mahito; Shinmyozu, Kaori; Nakayama, Jun-ichi			A conserved SET domain methyltransferase, Set11, modifies ribosomal protein Rpl12 in fission yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS-SPECTROMETRIC ANALYSIS; SCHIZOSACCHAROMYCES-POMBE; ESCHERICHIA-COLI; L11 METHYLTRANSFERASE; LYSINE METHYLATION; P53 ACTIVITY; HETEROCHROMATIN; SUBUNIT; PRMA; TRIMETHYLATION	SET domain-containing methyltransferases post-translationally modify a variety of cellular proteins, such as histones, cytochrome c, ribulose-bisphosphate carboxylase/ oxygenase, and ribosomal proteins. In the fission yeast Schizosaccharomyces pombe, at least 13 SET domain-containing proteins have been identified in the genome, four of which are involved in transcriptional regulation through their modification of histone tails. However, the roles played by the other SET domain proteins in cellular processes and their physiological substrates remain unresolved. We show here that S. pombe Set11, a SET domain-containing protein encoded by SPCC1223.04c, specifically modifies Rpl12 ( ribosomal protein L12). Recombinant Set11 prepared from Escherichia coli had catalytic activity and methylated a 17-kDa polypeptide in cellular extracts of set11 mutant cells. The methylated protein was isolated by two-dimensional gel electrophoresis or by reverse-phase chromatography and was identified as Rpl12 by mass spectrometry. In vitro methylation experiments using wild-type and mutant Rpl12 proteins verified that Set11 modified recombinant Rpl12 and suggested that its potential target site was lysine 3. The methylation site modified by Set11 was also confirmed by mass spectrometric analysis, which also revealed other unique methylation sites of Rpl12. Finally, we found that Set11 predominantly localized to the nucleolus and that the overproduction of Set11 caused a severe growth defect. These results suggest that Rpl12 methylation occurs during the ribosomal assembly processes and that control of the Set11 expression level is important for its cellular function.	[Sadaie, Mahito; Nakayama, Jun-ichi] RIKEN, Chuo Ku, Lab Chromatin Dynam, Kobe, Hyogo 6500047, Japan; [Shinmyozu, Kaori] RIKEN, Prote Support Unit, Ctr Dev Biol, Kobe, Hyogo 6500047, Japan	RIKEN; RIKEN	Nakayama, JI (corresponding author), RIKEN, Chuo Ku, Lab Chromatin Dynam, 2-2-3 Minatojimaminamimachi, Kobe, Hyogo 6500047, Japan.	jnakayam@cdb.riken.jp	Nakayama, Jun-ichi/C-6003-2011	Nakayama, Jun-ichi/0000-0002-5597-8239				Bachand F, 2006, MOL CELL BIOL, V26, P1731, DOI 10.1128/MCB.26.5.1731-1742.2006; Bachand F, 2004, EMBO J, V23, P2641, DOI 10.1038/sj.emboj.7600265; Cameron DM, 2004, J BACTERIOL, V186, P5819, DOI 10.1128/JB.186.17.5819-5825.2004; Chen T, 2007, NAT CELL BIOL, V9, P596, DOI 10.1038/ncb1572; Chern MK, 2002, J BIOL CHEM, V277, P15345, DOI 10.1074/jbc.M111379200; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; COLSON C, 1979, MOL GEN GENET, V169, P245, DOI 10.1007/BF00382270; Cuccurese M, 2005, NUCLEIC ACIDS RES, V33, P5965, DOI 10.1093/nar/gki905; DOGNIN MJ, 1977, FEBS LETT, V84, P342, DOI 10.1016/0014-5793(77)80721-7; Ekwall K, 1997, CELL, V91, P1021, DOI 10.1016/S0092-8674(00)80492-4; Houtz RL, 2003, ARCH BIOCHEM BIOPHYS, V414, P150, DOI 10.1016/S0003-9861(03)00122-X; Huang J, 2006, NATURE, V444, P629, DOI 10.1038/nature05287; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; Krawchuk MD, 1999, YEAST, V15, P1419, DOI 10.1002/(SICI)1097-0061(19990930)15:13<1419::AID-YEA466>3.0.CO;2-Q; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lee SW, 2002, P NATL ACAD SCI USA, V99, P5942, DOI 10.1073/pnas.082119899; Louie DF, 1996, J BIOL CHEM, V271, P28189, DOI 10.1074/jbc.271.45.28189; Marmorstein R, 2003, TRENDS BIOCHEM SCI, V28, P59, DOI 10.1016/S0968-0004(03)00007-0; Mata J, 2002, NAT GENET, V32, P143, DOI 10.1038/ng951; Matsuyama A, 2006, NAT BIOTECHNOL, V24, P841, DOI 10.1038/nbt1222; Meng FY, 2004, ANAL CHEM, V76, P2852, DOI 10.1021/ac0354903; Mitrovich QM, 2000, GENE DEV, V14, P2173, DOI 10.1101/gad.819900; Morris SA, 2005, EUKARYOT CELL, V4, P1446, DOI 10.1128/EC.4.8.1446-1454.2005; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Noma K, 2002, P NATL ACAD SCI USA, V99, P16438, DOI 10.1073/pnas.182436399; Odintsova TI, 2003, J PROTEIN CHEM, V22, P249, DOI 10.1023/A:1025068419698; Olsson I, 2007, EXP CELL RES, V313, P1778, DOI 10.1016/j.yexcr.2007.03.007; Peng X, 2005, MOL BIOL CELL, V16, P1026, DOI 10.1091/mbc.E04-04-0299; Pilch DR, 2004, METHOD ENZYMOL, V375, P76; Polevoda B, 2000, J BIOL CHEM, V275, P20508, DOI 10.1074/jbc.M001891200; Polevoda B, 2007, MOL MICROBIOL, V65, P590, DOI 10.1111/j.1365-2958.2007.05831.x; Porras-Yakushi TR, 2007, J BIOL CHEM, V282, P12368, DOI 10.1074/jbc.M611896200; Porras-Yakushi TR, 2006, J BIOL CHEM, V281, P35835, DOI 10.1074/jbc.M606578200; Porras-Yakushi TR, 2005, J BIOL CHEM, V280, P34590, DOI 10.1074/jbc.M507672200; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Sanders SL, 2004, CELL, V119, P603, DOI 10.1016/j.cell.2004.11.009; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; STOCK A, 1987, FEBS LETT, V220, P8, DOI 10.1016/0014-5793(87)80866-9; Swiercz R, 2005, BIOCHEM J, V386, P85, DOI 10.1042/BJ20041466; VANET A, 1994, MOL MICROBIOL, V14, P947, DOI 10.1111/j.1365-2958.1994.tb01330.x; Williamson NA, 1997, EUR J BIOCHEM, V246, P786, DOI 10.1111/j.1432-1033.1997.00786.x; Wimberly BT, 1999, CELL, V97, P491, DOI 10.1016/S0092-8674(00)80759-X; Yu YH, 2005, PROTEIN SCI, V14, P1438, DOI 10.1110/ps.041293005	44	32	33	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					7185	7195		10.1074/jbc.M709429200	http://dx.doi.org/10.1074/jbc.M709429200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18195021	hybrid			2022-12-25	WOS:000253779600064
J	Stewart, L; Overath, T; Warren, JD; Foxton, JM; Griffiths, TD				Stewart, Lauren; Overath, Tobias; Warren, Jason D.; Foxton, Jessica M.; Griffiths, Timothy D.			fMRI Evidence for a Cortical Hierarchy of Pitch Pattern Processing	PLOS ONE			English	Article								Pitch patterns, such as melodies, consist of two levels of structure: a global level, comprising the pattern of ups and downs, or contour; and a local level, comprising the precise intervals that make up this contour. An influential neuropsychological model suggests that these two levels of processing are hierarchically linked, with processing of the global structure occurring within the right hemisphere in advance of local processing within the left. However, the predictions of this model and its anatomical basis have not been tested in neurologically normal individuals. The present study used fMRI and required participants to listen to consecutive pitch sequences while performing a same/different one-back task. Sequences, when different, either preserved (local) or violated (global) the contour of the sequence preceding them. When the activations for the local and global conditions were contrasted directly, additional activation was seen for local processing in right planum temporale and posterior superior temporal sulcus (pSTS). The presence of additional activation for local over global processing supports the hierarchical view that the global structure of a pitch sequence acts as a "framework'' on which the local detail is subsequently hung. However, the lateralisation of activation seen in the present study, with global processing occurring in left pSTS and local processing occurring bilaterally, differed from that predicted by the neuroanatomical model. A re-examination of the individual lesion data on which the neuroanatomical model is based revealed that the lesion data equally well support the laterality scheme suggested by our data. While the present study supports the hierarchical view of local and global processing, there is an evident need for further research, both in patients and neurologically normal individuals, before an understanding of the functional lateralisation of local and global processing can be considered established.	[Stewart, Lauren] Univ London, Dept Psychol, London, England; [Overath, Tobias; Griffiths, Timothy D.] Inst Neurol, Wellcome Trust Ctr Neuroimaging, London, England; [Overath, Tobias; Griffiths, Timothy D.] Newcastle Univ, Med Sch, Auditory Grp, Newcastle Upon Tyne, Tyne & Wear, England; [Warren, Jason D.] Inst Neurol, Dementia Res Ctr, London, England; [Foxton, Jessica M.] Ctr Hosp Le Vinatier, INSERM, Unit 280, Lyon, France	University of London; University of London; University College London; Newcastle University - UK; University of London; University College London; Institut National de la Sante et de la Recherche Medicale (Inserm)	Stewart, L (corresponding author), Univ London, Dept Psychol, London, England.	l.stewart@gold.ac.uk; t.overath@fil.ion.ucl.ac.uk	Stewart, Lauren/HHC-2911-2022	stewart, lauren/0000-0002-6221-6064; Warren, Jason/0000-0002-5405-0826; Griffiths, Timothy/0000-0001-8066-4381	Wellcome Trust (UK) [Intermediate Clinical Fellowship]; Research Councils UK (RCUK) [academic fellowship]; German Academic Exchange Service; Engineering and Physical Sciences Research Council [EP/E500161/1] Funding Source: researchfish	Wellcome Trust (UK)(Wellcome Trust); Research Councils UK (RCUK)(UK Research & Innovation (UKRI)); German Academic Exchange Service(Deutscher Akademischer Austausch Dienst (DAAD)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	This work is supported by the Wellcome Trust (UK). LS is supported by an academic fellowship awarded by Research Councils UK (RCUK). TO is supported by the German Academic Exchange Service. JDW is supported by a Wellcome Trust Intermediate Clinical Fellowship.	BARTLETT JC, 1980, J EXP PSYCHOL HUMAN, V6, P501, DOI 10.1037/0096-1523.6.3.501; CUDDY LL, 1976, Q J EXP PSYCHOL, V28, P255, DOI 10.1080/14640747608400555; DOWLING WJ, 1987, PERCEPT PSYCHOPHYS, V41, P642, DOI 10.3758/BF03210496; DOWLING WJ, 1978, PSYCHOL REV, V85, P341, DOI 10.1037/0033-295X.85.4.341; Edmister WB, 1999, HUM BRAIN MAPP, V7, P89, DOI 10.1002/(SICI)1097-0193(1999)7:2<89::AID-HBM2>3.3.CO;2-E; Foxton JM, 2003, NAT NEUROSCI, V6, P343, DOI 10.1038/nn1035; Friston K. J., 1995, HUMAN BRAIN MAPPING, V2, P189, DOI DOI 10.1002/HBM.460020402; Friston KJ, 1995, HUM BRAIN MAPP, V3, P165, DOI 10.1002/hbm.460030303; Fujioka T, 2004, J COGNITIVE NEUROSCI, V16, P1010, DOI 10.1162/0898929041502706; Hall DA, 1999, HUM BRAIN MAPP, V7, P213, DOI 10.1002/(SICI)1097-0193(1999)7:3<213::AID-HBM5>3.0.CO;2-N; Justus T, 2005, COGNITION, V98, P31, DOI 10.1016/j.cognition.2004.11.001; Ligeois-Chauvel C, 1998, BRAIN, V121, P1853, DOI 10.1093/brain/121.10.1853; List A, 2007, BRAIN RES, V1153, P122, DOI 10.1016/j.brainres.2007.03.040; PATEL AD, TRENDS COGN IN PRESS; PERETZ I, 1990, BRAIN, V113, P1185, DOI 10.1093/brain/113.4.1185; Sanders LD, 2007, NEUROPSYCHOLOGIA, V45, P1172, DOI 10.1016/j.neuropsychologia.2006.10.010; Schiavetto A, 1999, NEUROREPORT, V10, P2467, DOI 10.1097/00001756-199908200-00006; Schuppert M, 2000, BRAIN, V123, P546, DOI 10.1093/brain/123.3.546; Trainor LJ, 2002, J COGNITIVE NEUROSCI, V14, P430, DOI 10.1162/089892902317361949; Trainor LJ, 1999, AUST J PSYCHOL, V51, P147, DOI 10.1080/00049539908255352; TREHUB SE, 1993, INFANT BEHAV DEV, V16, P193, DOI 10.1016/0163-6383(93)80017-3	21	44	44	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2008	3	1							e1470	10.1371/journal.pone.0001470	http://dx.doi.org/10.1371/journal.pone.0001470			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SR	18231575	Green Submitted, Green Accepted, gold, Green Published			2022-12-25	WOS:000260504200001
J	Allen, DJ; Gray, JJ; Gallimore, CI; Xerry, J; Iturriza-Gomara, M				Allen, David J.; Gray, Jim J.; Gallimore, Chris I.; Xerry, Jacqueline; Iturriza-Gomara, Miren			Analysis of Amino Acid Variation in the P2 Domain of the GII-4 Norovirus VP1 Protein Reveals Putative Variant-Specific Epitopes	PLOS ONE			English	Article							EPOCHAL EVOLUTION; HUMAN CALICIVIRUS; CAPSID PROTEIN; GASTROENTERITIS; OUTBREAKS; ENGLAND; RECOMBINATION; SURVEILLANCE; MUTATIONS; DIVERSITY	Background. Human noroviruses are a highly diverse group of viruses classified into three of the five currently recognised Norovirus genogroups, and contain numerous genotypes or genetic clusters. Noroviruses are the major aetiological agent of endemic gastroenteritis in all age groups, as well as the cause of periodic epidemic gastroenteritis. The noroviruses most commonly associated with outbreaks of gastroenteritis are genogroup II genotype 4 (GII-4) strains. The relationship between genotypes of noroviruses with their phenotypes and antigenic profile remains poorly understood through an inability to culture these viruses and the lack of a suitable animal model. Methodology/ Principal Findings. Here we describe a study of the diversity of amino acid sequences of the highly variable P2 region in the major capsid protein, VP1, of the GII-4 human noroviruses strains using sequence analysis and homology modelling techniques. Conclusions/Significance. Our data identifies two sites in this region, which show significant amino acid substitutions associated with the appearance of variant strains responsible for epidemics with major public health impact. Homology modelling studies revealed the exposed nature of these sites on the capsid surface, providing supportive structural data that these two sites are likely to be associated with putative variant-specific epitopes. Furthermore, the patterns in the evolution of these viruses at these sites suggests that noroviruses follow a neutral network pattern of evolution.	[Allen, David J.; Gray, Jim J.; Gallimore, Chris I.; Xerry, Jacqueline; Iturriza-Gomara, Miren] Hlth Protect Agcy, Ctr Infect, Virus Reference Dept, Enter Virus Unit, London, England; [Allen, David J.] London Sch Hyg & Tropical Med, Dept Infect & Tropical Dis, London, England	Health Protection Agency; University of London; London School of Hygiene & Tropical Medicine	Allen, DJ (corresponding author), Hlth Protect Agcy, Ctr Infect, Virus Reference Dept, Enter Virus Unit, London, England.	david.james.allen@hpa.org.uk	Gomara, Miren Iturriza/B-4351-2013	Gomara, Miren Iturriza/0000-0001-5816-6423; Allen, David/0000-0002-1194-0415	European Commission, DG Research Quality of Life Program [SP22-CT-2004-502571]	European Commission, DG Research Quality of Life Program(European CommissionEuropean Commission Joint Research Centre)	This work was supported by the European Commission, DG Research Quality of Life Program, under the 6th Framework (EVENT; SP22-CT-2004-502571).	Ambert-Balay K, 2005, J CLIN MICROBIOL, V43, P5179, DOI 10.1128/JCM.43.10.5179-5186.2005; Bertolotti-Ciarlet A, 2003, J VIROL, V77, P11603, DOI 10.1128/JVI.77.21.11603-11615.2003; BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; Bull RA, 2005, EMERG INFECT DIS, V11, P1079; Cao S, 2007, J VIROL, V81, P5949, DOI 10.1128/JVI.00219-07; Domingo E, 1997, ANNU REV MICROBIOL, V51, P151, DOI 10.1146/annurev.micro.51.1.151; Gallimore CI, 2007, ARCH VIROL, V152, P1295, DOI 10.1007/s00705-007-0954-9; Green K, 2007, FIELDS VIROLOGY, P949; GUNSON RN, 2007, J CLIN MICROBIOL; Hall T.A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [DOI 10.1021/BK-1999-0734.CH008, citeulike-article-id:691774, 10.12691/ajmr-6-4-3]; Hardy ME, 1997, ARCH VIROL, V142, P1469, DOI 10.1007/s007050050173; Jiang X, 1999, ARCH VIROL, V144, P2377, DOI 10.1007/s007050050651; Katayama K, 2002, VIROLOGY, V299, P225, DOI 10.1006/viro.2002.1568; KIMURA M, 1968, NATURE, V217, P624, DOI 10.1038/217624a0; Koelle K, 2006, SCIENCE, V314, P1898, DOI 10.1126/science.1132745; LAU KF, 1990, P NATL ACAD SCI USA, V87, P638, DOI 10.1073/pnas.87.2.638; Lochridge VP, 2005, J GEN VIROL, V86, P2799, DOI 10.1099/vir.0.81134-0; Lopman B, 2004, LANCET, V363, P682, DOI 10.1016/S0140-6736(04)15641-9; Lopman BA, 2004, EMERG INFECT DIS, V10, P1827, DOI 10.3201/eid1010.030941; Lopman BA, 2003, EMERG INFECT DIS, V9, P71; Lopman BA, 2003, BMC PUBLIC HEALTH, V3, DOI 10.1186/1471-2458-3-13; Mounts AW, 2000, J INFECT DIS, V181, pS284, DOI 10.1086/315586; Noel JS, 1997, J MED VIROL, V53, P372, DOI 10.1002/(SICI)1096-9071(199712)53:4&lt;372::AID-JMV10&gt;3.0.CO;2-H; Prasad BVV, 1999, SCIENCE, V286, P287, DOI 10.1126/science.286.5438.287; Rohayem J, 2005, J VIROL, V79, P4977, DOI 10.1128/JVI.79.8.4977-4990.2005; Siebenga JJ, 2007, J VIROL, V81, P9932, DOI 10.1128/JVI.00674-07; Tan M, 2005, J VIROL, V79, P14017, DOI 10.1128/JVI.79.22.14017-14030.2005; Tan M, 2003, J VIROL, V77, P12562, DOI 10.1128/JVI.77.23.12562-12571.2003; Vinje J, 2000, ARCH VIROL, V145, P223, DOI 10.1007/s007050050020	29	108	114	0	44	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2008	3	1							e1485	10.1371/journal.pone.0001485	http://dx.doi.org/10.1371/journal.pone.0001485			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SO	18213393	Green Accepted, Green Submitted, gold, Green Published			2022-12-25	WOS:000260503900030
J	Jovanic, T; Roche, B; Attal-Bonnefoy, G; Leclercq, O; Rougeon, F				Jovanic, Tihana; Roche, Benjamin; Attal-Bonnefoy, Geraldine; Leclercq, Olivier; Rougeon, Francois			Ectopic Expression of AID in a Non-B Cell Line Triggers A:T and G:C Point Mutations in Non-Replicating Episomal Vectors	PLOS ONE			English	Article								Somatic hypermutation (SHM) of immunoglobulin genes is currently viewed as a two step process initiated by the deamination of deoxycytidine (C) to deoxyuridine (U), catalysed by the activation induced deaminase (AID). Phase 1 mutations arise from DNA replication across the uracil residue or the abasic site, generated by the uracil-DNA glycosylase, yielding transitions or transversions at G:C pairs. Phase 2 mutations result from the recognition of the U:G mismatch by the Msh2/Msh6 complex (MutS Homologue), followed by the excision of the mismatched nucleotide and the repair, by the low fidelity DNA polymerase g, of the gap generated by the exonuclease I. These mutations are mainly focused at A:T pairs. Whereas in activated B cells both G:C and A:T pairs are equally targeted, ectopic expression of AID was shown to trigger only G:C mutations on a stably integrated reporter gene. Here we show that when using non-replicative episomal vectors containing a GFP gene, inactivated by the introduction of stop codons at various positions, a high level of EGFP positive cells was obtained after transient expression in Jurkat cells constitutively expressing AID. We show that mutations at G:C and A:T pairs are produced. EGFP positive cells are obtained in the absence of vector replication demonstrating that the mutations are dependent only on the mismatch repair (MMR) pathway. This implies that the generation of phase 1 mutations is not a prerequisite for the expression of phase 2 mutations.	[Jovanic, Tihana; Roche, Benjamin; Attal-Bonnefoy, Geraldine; Leclercq, Olivier; Rougeon, Francois] Inst Pasteur, CNRS, Dept Immunol, Unite Genet & Biochim Dev,URA 2581, Paris, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Rougeon, F (corresponding author), Inst Pasteur, CNRS, Dept Immunol, Unite Genet & Biochim Dev,URA 2581, Paris, France.	frougeon@pasteur.fr		Roche, Benjamin/0000-0003-3912-6340; Leclercq, Olivier/0000-0003-1333-0044	Fondation de France; ARC (Association pour la Recherche sur le Cancer)	Fondation de France(Fondation de France); ARC (Association pour la Recherche sur le Cancer)(Fondation ARC pour la Recherche sur le Cancer)	This work was supported by grants from Fondation de France and ARC (Association pour la Recherche sur le Cancer).	Bachl J, 2001, J IMMUNOL, V166, P5051, DOI 10.4049/jimmunol.166.8.5051; Bachl J, 1999, EUR J IMMUNOL, V29, P1383, DOI 10.1002/(SICI)1521-4141(199904)29:04<1383::AID-IMMU1383>3.3.CO;2-O; Bransteitter R, 2003, P NATL ACAD SCI USA, V100, P4102, DOI 10.1073/pnas.0730835100; Casali P, 2006, TRENDS IMMUNOL, V27, P313, DOI 10.1016/j.it.2006.05.001; Chaudhuri J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574; Di Nola JM, 2007, ANNU REV BIOCHEM, V76, P1, DOI 10.1146/annurev.biochem.76.061705.090740; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Fukita Y, 1998, IMMUNITY, V9, P105, DOI 10.1016/S1074-7613(00)80592-0; Kunkel TA, 2005, ANNU REV BIOCHEM, V74, P681, DOI 10.1146/annurev.biochem.74.082803.133243; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; MacPhee DG, 1996, GENETICA, V97, P183, DOI 10.1007/BF00054625; Maizels N, 2005, ANNU REV GENET, V39, P23, DOI 10.1146/annurev.genet.39.073003.110544; Martomo SA, 2006, CURR OPIN IMMUNOL, V18, P243, DOI 10.1016/j.coi.2006.03.007; Modrich P, 2006, J BIOL CHEM, V281, P30305, DOI 10.1074/jbc.R600022200; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Neuberger MS, 2007, J EXP MED, V204, P7, DOI 10.1084/jem.20062409; Rada C, 2002, CURR BIOL, V12, P1748, DOI 10.1016/S0960-9822(02)01215-0; Ramiro AR, 2003, NAT IMMUNOL, V4, P452, DOI 10.1038/ni920; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Seki M, 2005, EMBO REP, V6, P1143, DOI 10.1038/sj.embor.7400582; Wright BE, 2004, GENES IMMUN, V5, P176, DOI 10.1038/sj.gene.6364053; Wright BE, 2003, MOL MICROBIOL, V48, P429, DOI 10.1046/j.1365-2958.2003.t01-1-03436.x; Wright BE, 2002, CANCER RES, V62, P5641; Yoshikawa K, 2002, SCIENCE, V296, P2033, DOI 10.1126/science.1071556	24	2	2	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2008	3	1							e1480	10.1371/journal.pone.0001480	http://dx.doi.org/10.1371/journal.pone.0001480			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SO	18213388	gold, Green Submitted, Green Published			2022-12-25	WOS:000260503900025
J	Yang, J; Wang, ZL; Zhao, XQ; Wang, DP; Qi, DL; Xu, BH; Ren, YH; Tian, HF				Yang, Jie; Wang, Zhen Long; Zhao, Xin Quan; Wang, De Peng; Qi, De Lin; Xu, Bao Hong; Ren, Yong Hong; Tian, Hui Fang			Natural Selection and Adaptive Evolution of Leptin in the Ochotona Family Driven by the Cold Environmental Stress	PLOS ONE			English	Article							CODON-SUBSTITUTION MODELS; AMINO-ACID SITES; TISSUE IN-VITRO; BODY-WEIGHT; GENE-EXPRESSION; PLASMA LEPTIN; FOOD-INTAKE; GLUCOSE-METABOLISM; OBESE GENE; OB/OB MICE	Background. Environmental stress can accelerate the evolutionary rate of specific stress-response proteins and create new functions specialized for different environments, enhancing an organism's fitness to stressful environments. Pikas (order Lagomorpha), endemic, non-hibernating mammals in the modern Holarctic Region, live in cold regions at either high altitudes or high latitudes and have a maximum distribution of species diversification confined to the Qinghai-Tibet Plateau. Variations in energy metabolism are remarkable for them living in cold environments. Leptin, an adipocyte-derived hormone, plays important roles in energy homeostasis. Methodology/Principal Findings. To examine the extent of leptin variations within the Ochotona family, we cloned the entire coding sequence of pika leptin from 6 species in two regions (Qinghai-Tibet Plateau and Inner Mongolia steppe in China) and the leptin sequences of plateau pikas (O. curzonia) from different altitudes on Qinghai-Tibet Plateau. We carried out both DNA and amino acid sequence analyses in molecular evolution and compared modeled spatial structures. Our results show that positive selection (PS) acts on pika leptin, while nine PS sites located within the functionally significant segment 85-119 of leptin and one unique motif appeared only in pika lineages-the ATP synthase a and b subunit signature site. To reveal the environmental factors affecting sequence evolution of pika leptin, relative rate test was performed in pikas from different altitudes. Stepwise multiple regression shows that temperature is significantly and negatively correlated with the rates of non-synonymous substitution (Ka) and amino acid substitution (Aa), whereas altitude does not significantly affect synonymous substitution (Ks), Ka and Aa. Conclusions/Significance. Our findings support the viewpoint that adaptive evolution may occur in pika leptin, which may play important roles in pikas' ecological adaptation to extreme environmental stress. We speculate that cold, and probably not hypoxia, may be the primary environmental factor for driving adaptive evolution of pika leptin.	[Yang, Jie; Wang, Zhen Long; Zhao, Xin Quan; Wang, De Peng; Qi, De Lin] Chinese Acad Sci, Northwest Inst Plateau Biol, Key Lab Qinghai Tibetan Plateau Biol Evolut & Ada, Xining, Qinghai, Peoples R China; [Yang, Jie; Wang, Zhen Long; Wang, De Peng; Qi, De Lin] Chinese Acad Sci, Grad Sch, Beijing, Peoples R China; Qufu Normal Univ, Coll Life Sci, Shandong, Peoples R China; [Xu, Bao Hong; Ren, Yong Hong; Tian, Hui Fang] Shijiazhuang Ctr Dis Control & Prevent, Shijiazhuang, Hebei, Peoples R China	Chinese Academy of Sciences; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Qufu Normal University	Zhao, XQ (corresponding author), Chinese Acad Sci, Northwest Inst Plateau Biol, Key Lab Qinghai Tibetan Plateau Biol Evolut & Ada, Xining, Qinghai, Peoples R China.	xqzhao@nwipb.ac.cn			National Natural Science Foundation of China [30700073]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (30700073).	Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Baldi P, 2004, J MACH LEARN RES, V4, P575, DOI 10.1162/153244304773936054; BRADFORD BL, 2000, NATURE, V404, P652; Caro JF, 1996, DIABETES, V45, P1455, DOI 10.2337/diab.45.11.1455; Casabiell X, 1998, J CLIN ENDOCR METAB, V83, P2149, DOI 10.1210/jc.83.6.2149; Cohen P, 2002, SCIENCE, V297, P240, DOI 10.1126/science.1071527; CORBET GB, 1978, MAMMALS PALAEARCTIC, P67; Cusin I, 1998, DIABETES, V47, P1014, DOI 10.2337/diabetes.47.7.1014; Dawson M.R., 1967, ESSAYS PALEONTOLOGY, V2, P287; DEVOS P, 1995, J BIOL CHEM, V270, P15958, DOI 10.1074/jbc.270.27.15958; DONG G, 1995, CHINA SOC QINGHAI TI, P13; DU J, 1984, Acta Zoologica Fennica, V171, P201; Du J., 1982, Acta Theriologica Sinica, V2, P35; FANG X, 1995, CHINA SOC QINGHAI TI, P41; FELSENSTEIN J, 2006, PHYLIP PHYLOGENY INF; FENG ZJ, 1985, ACTA THERIO SINICA, V20, P269; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GOLDMAN N, 1994, MOL BIOL EVOL, V11, P725; Grasso P, 1997, ENDOCRINOLOGY, V138, P1413, DOI 10.1210/en.138.4.1413; Grasso P, 1999, REGUL PEPTIDES, V85, P93, DOI 10.1016/S0167-0115(99)00082-8; Grasso P, 1999, DIABETES, V48, P2204, DOI 10.2337/diabetes.48.11.2204; Grayson DK, 2005, J BIOGEOGR, V32, P2103, DOI 10.1111/j.1365-2699.2005.01341.x; Grosfeld A, 2002, J BIOL CHEM, V277, P42953, DOI 10.1074/jbc.M206775200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hall E. R., 1981, MAMMALS N AM; Havel PJ, 1996, J CLIN ENDOCR METAB, V81, P4406, DOI 10.1210/jc.81.12.4406; Hoffman Robert S., 1993, P807; HUNTLEY B, 1989, J BIOGEOGR, V16, P5, DOI 10.2307/2845307; Imagawa K, 1998, J BIOL CHEM, V273, P35245, DOI 10.1074/jbc.273.52.35245; Iserentant H, 2005, J CELL SCI, V118, P2519, DOI 10.1242/jcs.02386; Kamohara S, 1997, NATURE, V389, P374, DOI 10.1038/38717; Kimura M., 1983, NEUTRAL THEORY MOL E, P367, DOI [10.1017/CBO9780511623486, DOI 10.1139/cjz-2013-0127]; Li QF, 2001, COMP BIOCHEM PHYS A, V129, P949, DOI 10.1016/S1095-6433(01)00357-9; Li XS, 2005, HORM BEHAV, V48, P321, DOI 10.1016/j.yhbeh.2005.04.004; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Mantzoros CS, 1996, DIABETES, V45, P909, DOI 10.2337/diabetes.45.7.909; Masuzaki H, 1997, J CLIN ENDOCR METAB, V82, P2542, DOI 10.1210/jc.82.8.2542; MEAD JI, 1987, BOREAS, V16, P165; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Muoio DM, 1997, DIABETES, V46, P1360, DOI 10.2337/diabetes.46.8.1360; Nei M, 2005, MOL BIOL EVOL, V22, P2318, DOI 10.1093/molbev/msi242; Nevo E, 2001, P NATL ACAD SCI USA, V98, P6233, DOI 10.1073/pnas.101109298; Nielsen R, 1998, GENETICS, V148, P929; Nielsen R, 2005, ANNU REV GENET, V39, P197, DOI 10.1146/annurev.genet.39.073003.112420; OHTA T, 1992, ANNU REV ECOL SYST, V23, P263, DOI 10.1146/annurev.es.23.110192.001403; Peacock AJ, 1998, BRIT MED J, V317, P1063; Peelman F, 2004, J BIOL CHEM, V279, P41038, DOI 10.1074/jbc.M404962200; Peelman F, 2006, J BIOL CHEM, V281, P15496, DOI 10.1074/jbc.M512622200; Peino R, 2000, EUR J ENDOCRINOL, V142, P195, DOI 10.1530/eje.0.1420195; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Pineiro V, 1999, J ENDOCRINOL, V160, P425, DOI 10.1677/joe.0.1600425; Pineiro V, 1998, BIOCHEM BIOPH RES CO, V252, P345, DOI 10.1006/bbrc.1998.9649; POLLASTRI G, 2002, BIOINFORMATICS S1, V18, P62; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; PUGH LGCE, 1957, J PHYSIOL-LONDON, V135, P590, DOI 10.1113/jphysiol.1957.sp005733; Robinson-Rechavi M, 2000, BIOINFORMATICS, V16, P296, DOI 10.1093/bioinformatics/16.3.296; Rossetti L, 1997, J BIOL CHEM, V272, P27758, DOI 10.1074/jbc.272.44.27758; Scarpace PJ, 1998, AM J PHYSIOL-ENDOC M, V275, pE259, DOI 10.1152/ajpendo.1998.275.2.E259; Scarpace PJ, 1997, AM J PHYSIOL-ENDOC M, V273, pE226, DOI 10.1152/ajpendo.1997.273.1.E226; Seufert J, 2004, DIABETES, V53, pS152, DOI 10.2337/diabetes.53.2007.S152; SMITH A E, 1990, P14; Smith AT, 1999, ANIM CONSERV, V2, P235, DOI 10.1111/j.1469-1795.1999.tb00069.x; STOREY KB, 1999, ENV STRESS GENE REGU, P1; Swofford D. L., 2011, PAUP PHYLOGENETIC AN; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Toyoshima Y, 2005, ENDOCRINOLOGY, V146, P4024, DOI 10.1210/en.2005-0087; TRAYHUM P, 1986, BROWN ADIPOSE TISSUE, P214; TRAYHURN P, 1995, BIOCHEM J, V311, P729, DOI 10.1042/bj3110729; Wang JM, 2006, OECOLOGIA, V149, P373, DOI 10.1007/s00442-006-0469-1; Wong WSW, 2004, GENETICS, V168, P1041, DOI 10.1534/genetics.104.031153; Wright BE, 2004, MOL MICROBIOL, V52, P643, DOI 10.1111/j.1365-2958.2004.04012.x; Wright BE, 1997, FEBS LETT, V402, P4, DOI 10.1016/S0014-5793(96)01479-2; Yang J, 2006, BIOCHEM BIOPH RES CO, V345, P1405, DOI 10.1016/j.bbrc.2006.05.052; Yang ZH, 2002, MOL BIOL EVOL, V19, P908, DOI 10.1093/oxfordjournals.molbev.a004148; Yang ZH, 2000, GENETICS, V155, P431; Yang ZH, 2005, MOL BIOL EVOL, V22, P1107, DOI 10.1093/molbev/msi097; YANG ZH, 1995, GENETICS, V141, P1641; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555; Yu N, 2000, MOL PHYLOGENET EVOL, V16, P85, DOI 10.1006/mpev.2000.0776; Zabeau L, 2004, MOL ENDOCRINOL, V18, P150, DOI 10.1210/me.2003-0078; Zhang FM, 1997, NATURE, V387, P206, DOI 10.1038/387206a0; Zhang JZ, 2005, MOL BIOL EVOL, V22, P2472, DOI 10.1093/molbev/msi237; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	83	54	67	1	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2008	3	1							e1472	10.1371/journal.pone.0001472	http://dx.doi.org/10.1371/journal.pone.0001472			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SO	18213380	gold, Green Published, Green Submitted			2022-12-25	WOS:000260503900017
J	Banda, AC; Makombe, SD; Jahn, A; Tweya, H; Chuka, S; Yu, JKL; Hedt, B; Weigel, R; Nkhata, A; Schouten, EJ; Kamoto, K; Harries, AD				Banda, Alfred C.; Makombe, Simon D.; Jahn, Andreas; Tweya, Hannock; Chuka, Stuart; Yu, Joseph Kwong-Leung; Hedt, Bethany; Weigel, Ralf; Nkhata, Amon; Schouten, Erik J.; Kamoto, Kelita; Harries, Anthony D.			Antiretroviral Therapy in the Malawi Defence Force: Access, Treatment Outcomes and Impact on Mortality	PLOS ONE			English	Article								Background. HIV/AIDS affects all sectors of the population and the defence forces are not exempt. A national survey was conducted in all public and private sectors in Malawi that provide antiretroviral therapy (ART) to determine the uptake of ART by army personnel, their outcomes while on treatment, and the impact of ART on mortality in the Malawi Defence Force. Methodology/Principal Findings. A retrospective cohort analysis was carried out, collecting data on access and retention on treatment from all 103 public and 38 private sector ART clinics in Malawi, using standardised patient master cards and clinic registers. Observations were censored on December 31(st) 2006. Independent data on mortality trends in army personnel from all causes between 2002 and 2006 were available from army records. By December 31st 2006, there were 85,168 patients ever started on ART in both public and private sectors, of whom 547 (0.7%) were army personnel. Of these, 22% started ART in WHO clinical stage 1 or 2 with a CD4-lymphocyte count of <= 250/mm(3) and 78% started in stage 3 or 4. Treatment outcomes of army personnel by December 31st 2006 were: 2365 (67%) alive and on ART at their registration facility, 98 (18%) transferred out to another facility, 71 (13%) dead, 9 (2%) lost to follow-up, and 4 (< 1%) stopped treatment. The probability of being alive on ART at 6-, 12- and 18-months was 89.8%, 83.4% and 78.8% respectively. All-cause mortality in army personnel declined dramatically over the five year period from 2002-2006. Conclusion/Significance. There has been a good access of army personnel to ART during the last five years with excellent outcomes, and this should serve as an example for other defence forces and large companies in the region.	[Banda, Alfred C.] Malawi Def Force, Med Dept, Lilongwe, Malawi; [Jahn, Andreas; Tweya, Hannock; Weigel, Ralf] Lighthouse Trust, Lilongwe, Malawi; [Jahn, Andreas] Int Train & Educ Ctr HIV, Seattle, WA USA; [Chuka, Stuart] Malawi Bus Coal Against AIDS, Blantyre, Malawi; [Yu, Joseph Kwong-Leung] Mzuzu Ctr Hosp, Taiwan Med Mission, Mzuzu, Malawi; [Hedt, Bethany] Harvard Sch Pub Hlth, Boston, MA USA; [Schouten, Erik J.] Manage Sci Hlth, Lilongwe, Malawi; Fam Hlth Int, Malawi Country Off, Lilongwe, Malawi; London Sch Hyg & Trop Med, London, England; [Makombe, Simon D.; Nkhata, Amon; Schouten, Erik J.; Kamoto, Kelita] Minist Hlth, HIV Unit, Lilongwe, Malawi	Harvard University; Harvard T.H. Chan School of Public Health; University of London; London School of Hygiene & Tropical Medicine	Harries, AD (corresponding author), Minist Hlth, HIV Unit, Lilongwe, Malawi.	adharries@malawi.net	Jahn, Andreas/ABB-7796-2020; Weigel, Ralf/ABD-2310-2020	Jahn, Andreas/0000-0003-4645-1600; Weigel, Ralf/0000-0001-9034-2634				Harries AD, 2006, LANCET, V367, P1870, DOI 10.1016/S0140-6736(06)68809-0; Libamba E, 2006, B WORLD HEALTH ORGAN, V84, P320; Libamba E, 2005, INT J TUBERC LUNG D, V9, P1062; Makombe SD, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000620; *MIN HLTH MAL, 2006, TREATM AIDS GUID US; van Oosterhout JJG, 2005, JAIDS-J ACQ IMM DEF, V39, P626; World Health Organization, 2006, ANT THER HIV INF AD	7	11	11	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2008	3	1							e1445	10.1371/journal.pone.0001445	http://dx.doi.org/10.1371/journal.pone.0001445			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SN	18197255	gold, Green Published, Green Submitted			2022-12-25	WOS:000260503800016
J	Bennett, CB; Westmoreland, TJ; Verrier, CS; Blanchette, CAB; Sabin, TL; Phatnani, HP; Mishina, YV; Huper, G; Selim, AL; Madison, ER; Bailey, DD; Falae, AI; Galli, A; Olson, JA; Greenleaf, AL; Marks, JR				Bennett, Craig B.; Westmoreland, Tammy J.; Verrier, Carmel S.; Blanchette, Carrie A. B.; Sabin, Tiffany L.; Phatnani, Hemali P.; Mishina, Yuliya V.; Huper, Gudrun; Selim, Alice L.; Madison, Ernest R.; Bailey, Dominique D.; Falae, Adebola I.; Galli, Alvaro; Olson, John A., Jr.; Greenleaf, Arno L.; Marks, Jeffrey R.			Yeast Screens Identify the RNA Polymerase II CTD and SPT5 as Relevant Targets of BRCA1 Interaction	PLOS ONE			English	Article								BRCA1 has been implicated in numerous DNA repair pathways that maintain genome integrity, however the function responsible for its tumor suppressor activity in breast cancer remains obscure. To identify the most highly conserved of the many BRCA1 functions, we screened the evolutionarily distant eukaryote Saccharomyces cerevisiae for mutants that suppressed the G1 checkpoint arrest and lethality induced following heterologous BRCA1 expression. A genome-wide screen in the diploid deletion collection combined with a screen of ionizing radiation sensitive gene deletions identified mutants that permit growth in the presence of BRCA1. These genes delineate a metabolic mRNA pathway that temporally links transcription elongation (SPT4, SPT5, CTK1, DEF1) to nucleopore-mediated mRNA export (ASM4, MLP1, MLP2, NUP2, NUP53, NUP120, NUP133, NUP170, NUP188, POM34) and cytoplasmic mRNA decay at P-bodies (CCR4, DHH1). Strikingly, BRCA1 interacted with the p hosphorylated RNA polymerase II (RNAPII) c arboxy terminal domain (P-CTD), phosphorylated in the pattern specified by the CTDK-I kinase, to induce DEF1-dependent cleavage and accumulation of a RNAPII fragment containing the P-CTD. Significantly, breast cancer associated BRCT domain defects in BRCA1 that suppressed P-CTD cleavage and lethality in yeast also suppressed the physical interaction of BRCA1 with human SPT5 in breast epithelial cells, thus confirming SPT5 as a relevant target of BRCA1 interaction. Furthermore, enhanced P-CTD cleavage was observed in both yeast and human breast cells following UV-irradiation indicating a conserved eukaryotic damage response. Moreover, P-CTD cleavage in breast epithelial cells was BRCA1-dependent since damage-induced P-CTD cleavage was only observed in the mutant BRCA1 cell line HCC1937 following ectopic expression of wild type BRCA1. Finally, BRCA1, SPT5 and hyperphosphorylated RPB1 form a complex that was rapidly degraded following MMS treatment in wild type but not BRCA1 mutant breast cells. These results extend the mechanistic links between BRCA1 and transcriptional consequences in response to DNA damage and suggest an important role for RNAPII P-CTD cleavage in BRCA1-mediated cancer suppression.	[Verrier, Carmel S.] Duke Univ, Med Ctr, Dept Med, Durham, NC USA; [Sabin, Tiffany L.; Phatnani, Hemali P.; Mishina, Yuliya V.; Greenleaf, Arno L.] Duke Univ, Med Ctr, Dept Biochem, Durham, NC USA; [Galli, Alvaro] CNR, Inst Clin Physiol, Gene & Mol Therapy Lab, CNR Res Area Moruzzi, Pisa, Italy; [Westmoreland, Tammy J.; Blanchette, Carrie A. B.; Huper, Gudrun; Selim, Alice L.; Madison, Ernest R.; Bailey, Dominique D.; Falae, Adebola I.; Olson, John A., Jr.; Marks, Jeffrey R.] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA	Duke University; Duke University; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); Duke University	Bennett, CB (corresponding author), Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA.	benne048@mc.duke.edu	Galli, Alvaro/AAL-7247-2020; Galli, Alvaro/K-3146-2018	Galli, Alvaro/0000-0002-9091-5639	CDMRP DOD Breast Cancer Initiative [DAMD17-03-1-0232]; Italian Association for Research on Cancer; NIH [CA84955]; NATIONAL CANCER INSTITUTE [U01CA084955] Funding Source: NIH RePORTER	CDMRP DOD Breast Cancer Initiative; Italian Association for Research on Cancer(Fondazione AIRC per la ricerca sul cancro); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by a CDMRP DOD Breast Cancer Initiative grant DAMD17-03-1-0232 to CBB, a regional grant of the Italian Association for Research on Cancer to AG and a NIH grant CA84955 to JRM.	Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Aiyar S, 2005, J CELL BIOCHEM, V94, P1103, DOI 10.1002/jcb.20386; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Basrai MA, 1996, MOL CELL BIOL, V16, P2838; Bau DT, 2006, CANCER LETT, V240, P1, DOI 10.1016/j.canlet.2005.08.003; Bennett CB, 2001, NAT GENET, V29, P426, DOI 10.1038/ng778; Bennett CB, 1996, MOL CELL BIOL, V16, P4414; Bergkessel M, 2004, GENETICS, V167, P21, DOI 10.1534/genetics.167.1.21; Chiba N, 2001, J BIOL CHEM, V276, P38549, DOI 10.1074/jbc.M105227200; Choudhury AD, 2004, J BIOL CHEM, V279, P33909, DOI 10.1074/jbc.M403646200; Cougot N, 2004, J CELL BIOL, V165, P31, DOI 10.1083/jcb.200309008; Coyne RS, 2004, CANCER BIOL THER, V3, P453, DOI 10.4161/cbt.3.5.809; Deng CX, 2000, BIOESSAYS, V22, P728; Elstrodt F, 2006, CANCER RES, V66, P41, DOI 10.1158/0008-5472.CAN-05-2853; Fabbro M, 2004, J BIOL CHEM, V279, P31251, DOI 10.1074/jbc.M405372200; Gillette TG, 2004, P NATL ACAD SCI USA, V101, P5904, DOI 10.1073/pnas.0305411101; Giorgini F, 2005, NAT GENET, V37, P526, DOI 10.1038/ng1542; Greenberg RA, 2006, GENE DEV, V20, P34, DOI 10.1101/gad.1381306; Guo SC, 2005, CANCER RES, V65, P3011, DOI 10.1158/0008-5472.CAN-04-3624; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; Jansen LET, 2000, EMBO J, V19, P6498, DOI 10.1093/emboj/19.23.6498; Jeong SJ, 2005, J MICROBIOL, V43, P516; Jona G, 2001, GENE, V267, P31, DOI 10.1016/S0378-1119(01)00389-4; Jones JC, 2004, J BIOL CHEM, V279, P24957, DOI 10.1074/jbc.M402218200; Kleiman FE, 2005, GENE DEV, V19, P1227, DOI 10.1101/gad.1309505; Krum SA, 2003, J BIOL CHEM, V278, P52012, DOI 10.1074/jbc.M308418200; Le Page F, 2000, CANCER RES, V60, P5548; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; LEE JM, 1991, GENE EXPRESSION, V1, P149; Lindsey-Boltz LA, 2007, P NATL ACAD SCI USA, V104, P13213, DOI 10.1073/pnas.0706316104; Ljungman M, 2004, NAT REV CANCER, V4, P727, DOI 10.1038/nrc1435; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; Moisan A, 2004, MOL CELL BIOL, V24, P6947, DOI 10.1128/MCB.24.16.6947-6956.2004; Mulder KW, 2005, NUCLEIC ACIDS RES, V33, P6384, DOI 10.1093/nar/gki938; Phatnani HP, 2006, GENE DEV, V20, P2922, DOI 10.1101/gad.1477006; Phatnani HP, 2004, BIOCHEMISTRY-US, V43, P15702, DOI 10.1021/bi048364h; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; Reid J, 2004, J BIOL CHEM, V279, P29875, DOI 10.1074/jbc.C400185200; Resnick MA, 2000, MUTAT RES-FUND MOL M, V451, P1, DOI 10.1016/S0027-5107(00)00036-1; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sheth U, 2003, SCIENCE, V300, P805, DOI 10.1126/science.1082320; Somesh BP, 2005, CELL, V121, P913, DOI 10.1016/j.cell.2005.04.010; Starita LM, 2005, J BIOL CHEM, V280, P24498, DOI 10.1074/jbc.M414020200; Traven A, 2005, GENETICS, V169, P65, DOI 10.1534/genetics.104.030940; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Wang Y, 2000, GENE DEV, V14, P927; Westmoreland TJ, 2004, EUKARYOT CELL, V3, P430, DOI 10.1128/EC.3.2.430-446.2004; Westmoreland TJ, 2003, J SURG RES, V113, P62, DOI 10.1016/S0022-4804(03)00155-0; Willingham S, 2003, SCIENCE, V302, P1769, DOI 10.1126/science.1090389; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Woolstencroft RN, 2006, J CELL SCI, V119, P5178, DOI 10.1242/jcs.03221; Woudstra EC, 2002, NATURE, V415, P929, DOI 10.1038/415929a; Yamaguchi Y, 2002, MOL CELL BIOL, V22, P2918, DOI 10.1128/MCB.22.9.2918-2927.2002; Ye QN, 2001, J CELL BIOL, V155, P911, DOI 10.1083/jcb.200108049; Zhong Q, 2002, J BIOL CHEM, V277, P28641, DOI 10.1074/jbc.M200748200	57	25	28	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2008	3	1							e1448	10.1371/journal.pone.0001448	http://dx.doi.org/10.1371/journal.pone.0001448			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SN	18197258	gold, Green Published			2022-12-25	WOS:000260503800019
J	Fleming, JN; Nash, RA; McLeod, DO; Fiorentino, DF; Shulman, HM; Connolly, MK; Molitor, JA; Henstorf, G; Lafyatis, R; Pritchard, DK; Adams, LD; Furst, DE; Schwartz, SM				Fleming, Jo N.; Nash, Richard A.; McLeod, D. O.; Fiorentino, David F.; Shulman, Howard M.; Connolly, M. Kari; Molitor, Jerry A.; Henstorf, Gretchen; Lafyatis, Robert; Pritchard, David K.; Adams, Lawrence D.; Furst, Daniel E.; Schwartz, Stephen M.			Capillary Regeneration in Scleroderma: Stem Cell Therapy Reverses Phenotype?	PLOS ONE			English	Article								Background. Scleroderma is an autoimmune disease with a characteristic vascular pathology. The vasculopathy associated with scleroderma is one of the major contributors to the clinical manifestations of the disease. Methodology/Principal Findings. We used immunohistochemical and mRNA in situ hybridization techniques to characterize this vasculopathy and showed with morphometry that scleroderma has true capillary rarefaction. We compared skin biopsies from 23 scleroderma patients and 24 normal controls and 7 scleroderma patients who had undergone high dose immunosuppressive therapy followed by autologous hematopoietic cell transplant. Along with the loss of capillaries there was a dramatic change in endothelial phenotype in the residual vessels. The molecules defining this phenotype are: vascular endothelial cadherin, a supposedly universal endothelial marker required for tube formation (lost in the scleroderma tissue), antiangiogenic interferon a (overexpressed in the scleroderma dermis) and RGS5, a signaling molecule whose expression coincides with the end of branching morphogenesis during development and tumor angiogenesis (also overexpressed in scleroderma skin. Following high dose immunosuppressive therapy, patients experienced clinical improvement and 5 of the 7 patients with scleroderma had increased capillary counts. It was also observed in the same 5 patients, that the interferon a and vascular endothelial cadherin had returned to normal as other clinical signs in the skin regressed, and in all 7 patients, RGS5 had returned to normal. Conclusion/Significance. These data provide the first objective evidence for loss of vessels in scleroderma and show that this phenomenon is reversible. Coordinate changes in expression of three molecules already implicated in angiogenesis or anti-angiogenesis suggest that control of expression of these three molecules may be the underlying mechanism for at least the vascular component of this disease. Since rarefaction has been little studied, these data may have implications for other diseases characterized by loss of capillaries including hypertension, congestive heart failure and scar formation.	[Nash, Richard A.] Fred Hutchinson Canc Res Ctr, Clin Res Div, Seattle, WA USA; [Fiorentino, David F.] Stanford Univ, Sch Med, Dept Dermatol, Stanford, CA USA; [Shulman, Howard M.] Fred Hutchinson Canc Ctr, Seattle Canc Alliance, Clin Res Div, Seattle, WA USA; [Connolly, M. Kari] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Molitor, Jerry A.] Virginia Mason Med Ctr, Dept Rheumatol, Seattle, WA USA; [Henstorf, Gretchen] Fred Hutchinson Canc Res Ctr, Clin Res Div, Progr Transplant Biol, Seattle, WA USA; [Lafyatis, Robert] Boston Univ, Sch Med, Rheumatol Sect, Boston, MA USA; [Furst, Daniel E.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Rheumatol, Los Angeles, CA USA; [McLeod, D. O.; Pritchard, David K.; Adams, Lawrence D.; Schwartz, Stephen M.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; Stanford University; Fred Hutchinson Cancer Center; University of California System; University of California San Francisco; Virginia Mason Medical Center; Fred Hutchinson Cancer Center; Boston University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Washington; University of Washington Seattle	Fleming, JN (corresponding author), Univ Washington, Dept Pathol, Seattle, WA 98195 USA.	flemij@u.washington.edu		Lafyatis, Robert/0000-0002-9398-5034	Scleroderma Research Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI005419] Funding Source: NIH RePORTER	Scleroderma Research Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was funded by the Scleroderma Research Foundation that had no role in the design and conduct of the study, in the collection, analysis, and interpretation of data, or in the preparation, review and approval of the manuscript.	Adams LD, 2000, CIRC RES, V87, P623, DOI 10.1161/01.RES.87.7.623; Akers IA, 2000, AM J PHYSIOL-LUNG C, V278, pL193, DOI 10.1152/ajplung.2000.278.1.L193; ANGIOLILLO AL, 1995, J EXP MED, V182, P155, DOI 10.1084/jem.182.1.155; Antonios TFT, 1999, HYPERTENSION, V34, P655, DOI 10.1161/01.HYP.34.4.655; Antonios TFT, 2003, HEART, V89, P175, DOI 10.1136/heart.89.2.175; Asahara T, 2002, J HEMATOTH STEM CELL, V11, P171, DOI 10.1089/152581602753658385; Bachmeyer C, 1996, BRIT J DERMATOL, V135, P481, DOI 10.1046/j.1365-2133.1996.d01-1028.x; Beretta L, 2002, BRIT J DERMATOL, V147, P385, DOI 10.1046/j.1365-2133.2002.48901.x; Bielenberg DR, 1999, J INVEST DERMATOL, V112, P802, DOI 10.1046/j.1523-1747.1999.00566.x; Black CM, 1999, ARTHRITIS RHEUM, V42, P299, DOI 10.1002/1529-0131(199902)42:2<299::AID-ANR12>3.0.CO;2-R; BLANN AD, 1993, J RHEUMATOL, V20, P1325; Braverman IM, 2000, J INVEST DERM SYMP P, V5, P3, DOI 10.1046/j.1087-0024.2000.00010.x; CARPENTIER PH, 1990, RHEUM DIS CLIN N AM, V16, P75; Cederqvist K, 2005, PEDIATR RES, V57, P831, DOI 10.1203/01.PDR.0000161416.63314.70; Cho H, 2003, FASEB J, V17, P440, DOI 10.1096/fj.02-0340fje; Choi JJ, 2003, J RHEUMATOL, V30, P1529; Clements PJ, 2003, SYSTEMIC SCLEROSIS, P129; CLOUGH G, 2005, MICROVASCULAR RES BI, P565; D'Andrea MR, 2000, BIOTECH HISTOCHEM, V75, P85, DOI 10.3109/10520290009064152; de Kleer I, 2006, BLOOD, V107, P1696, DOI 10.1182/blood-2005-07-2800; DENTON CP, 2003, SYSTEMIC SCLEROSIS, P184; Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x; Distler O, 2004, CIRC RES, V95, P109, DOI 10.1161/01.RES.0000134644.89917.96; DUIJVESTIJN AM, 1988, AM J PATHOL, V130, P147; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Facchetti F, 2003, VIRCHOWS ARCH, V443, P703, DOI 10.1007/s00428-003-0918-8; Garlanda C, 1997, ARTERIOSCL THROM VAS, V17, P1193, DOI 10.1161/01.ATV.17.7.1193; GERRITSEN M, 2005, MICROVASCULAR RES BI, P51; GIRARD JP, 1995, IMMUNOL TODAY, V16, P449, DOI 10.1016/0167-5699(95)80023-9; Goodbourn S, 2000, J GEN VIROL, V81, P2341, DOI 10.1099/0022-1317-81-10-2341; Gown AM, 2002, J HISTOCHEM CYTOCHEM, V50, P449, DOI 10.1177/002215540205000401; GRUSCHWITZ M, 1992, J AM ACAD DERMATOL, V27, P169, DOI 10.1016/0190-9622(92)70165-C; HANDA R, 2002, J INDIAN ACAD CLIN M, V3, P35; HERRICK AL, 2003, SYSTEMIC SCLEROSIS, P309; HIGGINS JC, 1981, BRIT J DERMATOL, V104, P521, DOI 10.1111/j.1365-2133.1981.tb08166.x; Houben AJH, 2003, MICROCIRCULATION, V10, P471, DOI 10.1038/sj.mn.7800211; Isner JM, 2001, ANN NY ACAD SCI, V953, P75, DOI 10.1111/j.1749-6632.2001.tb02075.x; Isner JM, 2000, J CLIN INVEST, V106, P615, DOI 10.1172/JCI10961; Jimenez SA, 1996, RHEUM DIS CLIN N AM, V22, P647, DOI 10.1016/S0889-857X(05)70294-5; Jimenez SA, 2004, ANN INTERN MED, V140, P37, DOI 10.7326/0003-4819-140-1-200401060-00010; JONES NF, 2003, SYSTEMIC SCLEROSIS, P269; Kahaleh MB, 2004, CLIN EXP RHEUMATOL, V22, pS19; Komminoth P., 1996, NONRADIOACTIVE IN SI, P126; Kuwana M, 2004, LANCET, V364, P603, DOI 10.1016/S0140-6736(04)16853-0; Larcher F, 1998, ONCOGENE, V17, P303, DOI 10.1038/sj.onc.1201928; LeRoy EC, 1996, RHEUM DIS CLIN N AM, V22, P675, DOI 10.1016/S0889-857X(05)70295-7; Liu XL, 2005, PLOS MED, V2, P1334, DOI 10.1371/journal.pmed.0020354; McSweeney PA, 2002, BLOOD, V100, P1602, DOI 10.1182/blood.V100.5.1602.h81702001602_1602_1610; MEDSGER TA, 2003, SYSTEMIC SCLEROSIS, P17; MINASIAN LM, 1993, J CLIN ONCOL, V11, P1368, DOI 10.1200/JCO.1993.11.7.1368; Muraro PA, 2005, J EXP MED, V201, P805, DOI 10.1084/jem.20041679; Murayama T, 2002, CURR OPIN MOL THER, V4, P395; Nash RA, 2007, BLOOD, V110, P1388, DOI 10.1182/blood-2007-02-072389; Nash RA, 2006, ARTHRITIS RHEUM-US, V54, P1982, DOI 10.1002/art.21908; NEWMAN PJ, 1992, J CELL BIOL, V119, P239, DOI 10.1083/jcb.119.1.239; Nystedt S, 1996, J BIOL CHEM, V271, P14910, DOI 10.1074/jbc.271.25.14910; Renaudineau Y, 2001, AUTOIMMUNITY, V33, P171, DOI 10.3109/08916930109008045; Rivera-Nieves J, 2006, J EXP MED, V203, P907, DOI 10.1084/jem.20052530; Romero LI, 1997, J CELL PHYSIOL, V173, P84, DOI 10.1002/(SICI)1097-4652(199710)173:1<84::AID-JCP10>3.0.CO;2-N; SALOMON RN, 1991, AM J PATHOL, V138, P791; Sapadin AN, 2001, MT SINAI J MED, V68, P233; SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960; Shore AC, 2000, BRIT J CLIN PHARMACO, V50, P501, DOI 10.1046/j.1365-2125.2000.00278.x; Siegal FP, 1999, SCIENCE, V284, P1835, DOI 10.1126/science.284.5421.1835; SINGH RK, 1995, P NATL ACAD SCI USA, V92, P4562, DOI 10.1073/pnas.92.10.4562; Sperandio M, 2003, J EXP MED, V197, P1355, DOI 10.1084/jem.20021854; Steinberg SF, 2005, MOL PHARMACOL, V67, P2, DOI 10.1124/mol.104.003103; Steinhoff M, 1999, EXP DERMATOL, V8, P282; Storek J, 2004, CLIN IMMUNOL, V113, P285, DOI 10.1016/j.clim.2004.07.006; Theofilopoulos AN, 2005, ANNU REV IMMUNOL, V23, P307, DOI 10.1146/annurev.immunol.23.021704.115843; TROTTA F, 1984, CLIN EXP RHEUMATOL, V2, P209; Wallez Y, 2006, TRENDS CARDIOVAS MED, V16, P55, DOI 10.1016/j.tcm.2005.11.008; WHITE B, 2003, SYSTEMIC SCLEROSIS, P163; Wieland T, 2003, PHARMACOL THERAPEUT, V97, P95, DOI 10.1016/S0163-7258(02)00326-1; Wollenberg A, 2002, J INVEST DERMATOL, V119, P1096, DOI 10.1046/j.1523-1747.2002.19515.x; York MR, 2007, ARTHRITIS RHEUM-US, V56, P1010, DOI 10.1002/art.22382	76	152	152	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2008	3	1							e1452	10.1371/journal.pone.0001452	http://dx.doi.org/10.1371/journal.pone.0001452			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SN	18197262	Green Published, gold			2022-12-25	WOS:000260503800022
J	Ueno, A; Hirata, S; Fuwa, K; Sugama, K; Kusunoki, K; Matsuda, G; Fukushima, H; Hiraki, K; Tomonaga, M; Hasegawa, T				Ueno, Ari; Hirata, Satoshi; Fuwa, Kohki; Sugama, Keiko; Kusunoki, Kiyo; Matsuda, Goh; Fukushima, Hirokata; Hiraki, Kazuo; Tomonaga, Masaki; Hasegawa, Toshikazu			Auditory ERPs to Stimulus Deviance in an Awake Chimpanzee (Pan troglodytes): Towards Hominid Cognitive Neurosciences	PLOS ONE			English	Article							EVENT-RELATED POTENTIALS; MISMATCH NEGATIVITY MMN; STAGE-2 SLEEP; RECOGNITION; PERCEPTION; TOOL	Background. For decades, the chimpanzee, phylogenetically closest to humans, has been analyzed intensively in comparative cognitive studies. Other than the accumulation of behavioral data, the neural basis for cognitive processing in the chimpanzee remains to be clarified. To increase our knowledge on the evolutionary and neural basis of human cognition, comparative neurophysiological studies exploring endogenous neural activities in the awake state are needed. However, to date, such studies have rarely been reported in non-human hominid species, due to the practical difficulties in conducting non-invasive measurements on awake individuals. Methodology/Principal Findings. We measured auditory event-related potentials (ERPs) of a fully awake chimpanzee, with reference to a well-documented component of human studies, namely mismatch negativity (MMN). In response to infrequent, deviant tones that were delivered in a uniform sound stream, a comparable ERP component could be detected as negative deflections in early latencies. Conclusions/Significance. The present study reports the MMN-like component in a chimpanzee for the first time. In human studies, various ERP components, including MMN, are well-documented indicators of cognitive and neural processing. The results of the present study validate the use of noninvasive ERP measurements for studies on cognitive and neural processing in chimpanzees, and open the way for future studies comparing endogenous neural activities between humans and chimpanzees. This signifies an essential step in hominid cognitive neurosciences.	[Hirata, Satoshi; Fuwa, Kohki; Sugama, Keiko; Kusunoki, Kiyo] Great Ape Res Inst, Hayashibara Biochem Lab, Okayama, Japan; [Tomonaga, Masaki] Kyoto Univ, Primate Res Inst, Aichi, Japan; [Matsuda, Goh; Fukushima, Hirokata; Hiraki, Kazuo; Hasegawa, Toshikazu] Univ Tokyo, Tokyo, Japan	Hayashibara Biochemical Laboratories, Inc.; Kyoto University; University of Tokyo	Ueno, A (corresponding author), Univ Tokyo, Tokyo, Japan.	aueno@ecs.c.u-tokyo.ac.jp			21st century COE program, University of Tokyo), Japan	21st century COE program, University of Tokyo), Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This research was funded by the 21st century COE program (the center for evolutionary cognitive sciences at the University of Tokyo), Japan.	ALHO K, 1995, EAR HEARING, V16, P38, DOI 10.1097/00003446-199502000-00004; BERNTSON GG, 1993, DEV PSYCHOBIOL, V26, P305, DOI 10.1002/dev.420260602; BERNTSON GG, 1989, BEHAV NEUROSCI, V103, P235, DOI 10.1037/0735-7044.103.2.235; BERNTSON GG, 1989, DEV PSYCHOBIOL, V22, P771, DOI 10.1002/dev.420220803; BERNTSON GG, 1990, ADV INFANCY RES, V6, P187; BOYSEN ST, 1986, J COMP PSYCHOL, V100, P321, DOI 10.1037/0735-7036.100.3.321; BOYSEN ST, 1985, ELECTROEN CLIN NEURO, V62, P150, DOI 10.1016/0168-5597(85)90027-9; BOYSEN ST, 1989, J COMP PSYCHOL, V103, P215, DOI 10.1037/0735-7036.103.3.215; Burrows AM, 2006, J ANAT, V208, P153, DOI 10.1111/j.1469-7580.2006.00523.x; Cheour M, 2000, CLIN NEUROPHYSIOL, V111, P4, DOI 10.1016/S1388-2457(99)00191-1; Friedman D, 2001, NEUROSCI BIOBEHAV R, V25, P355, DOI 10.1016/S0149-7634(01)00019-7; Hirata S, 2007, PRIMATES, V48, P13, DOI 10.1007/s10329-006-0022-1; Idani G., 2006, PRIMATE PERSPECTIVES, P29; JAVITT DC, 1992, ELECTROEN CLIN NEURO, V83, P87, DOI 10.1016/0013-4694(92)90137-7; KOJIMA S, 1990, FOLIA PRIMATOL, V55, P62, DOI 10.1159/000156501; NAATANEN R, 1995, EAR HEARING, V16, P6; NAATANEN R, 1993, PSYCHOPHYSIOLOGY, V30, P436, DOI 10.1111/j.1469-8986.1993.tb02067.x; Paavilainen P, 1987, Electroencephalogr Clin Neurophysiol Suppl, V40, P246; Parr L A, 2001, Anim Cogn, V4, P223, DOI 10.1007/s100710100085; Parr LA, 2000, PHYSIOL BEHAV, V71, P363, DOI 10.1016/S0031-9384(00)00349-8; SALLINEN M, 1994, ELECTROEN CLIN NEURO, V91, P140, DOI 10.1016/0013-4694(94)90035-3; Umbricht D, 2000, ARCH GEN PSYCHIAT, V57, P1139, DOI 10.1001/archpsyc.57.12.1139; WINTER O, 1995, EVOKED POTENTIAL, V96, P398, DOI 10.1016/0168-5597(95)00030-V	23	28	30	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2008	3	1							e1442	10.1371/journal.pone.0001442	http://dx.doi.org/10.1371/journal.pone.0001442			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	366SN	18197252	Green Published, Green Submitted, gold			2022-12-25	WOS:000260503800013
J	Wu, LJ; Ren, M; Wang, HS; Kim, SS; Cao, XY; Zhuo, M				Wu, Long-Jun; Ren, Ming; Wang, Hansen; Kim, Susan S.; Cao, Xiaoyan; Zhuo, Min			Neurabin Contributes to Hippocampal Long-Term Potentiation and Contextual Fear Memory	PLOS ONE			English	Article							AMPA RECEPTOR TRAFFICKING; PRIMATE PREFRONTAL CORTEX; FILAMENT-BINDING PROTEIN; SYNAPTIC PLASTICITY; DENDRITIC SPINES; SUBCELLULAR-DISTRIBUTION; SILENT SYNAPSES; SPINOPHILIN; PHOSPHATASE-1; LTP	Neurabin is a scaffolding protein that interacts with actin and protein phosphatase-1. Highly enriched in the dendritic spine, neurabin is important for spine morphogenesis and synaptic formation. However, less is known about the role of neurabin in hippocampal plasticity and its possible effect on behavioral functions. Using neurabin knockout (KO) mice, here we studied the function of neurabin in hippocampal synaptic transmission, plasticity and behavioral memory. We demonstrated that neurabin KO mice showed a deficit in contextual fear memory but not auditory fear memory. Whole-cell patch clamp recordings in the hippocampal CA1 neurons showed that long-term potentiation (LTP) was significantly reduced, whereas long-term depression (LTD) was unaltered in neurabin KO mice. Moreover, increased AMPA receptor but not NMDA receptor-mediated synaptic transmission was found in neurabin KO mice, and is accompanied by decreased phosphorylation of GluR1 at the PKA site (Ser845) but no change at the CaMKII/PKC site (Ser831). Pre-conditioning with LTD induction rescued the following LTP in neurabin KO mice, suggesting the loss of LTP may be due to the saturated synaptic transmission. Our results indicate that neurabin regulates contextual fear memory and LTP in hippocampal CA1 pyramidal neurons.	[Wu, Long-Jun; Ren, Ming; Wang, Hansen; Kim, Susan S.; Cao, Xiaoyan] Univ Toronto, Dept Physiol, Toronto, ON, Canada	University of Toronto	Zhuo, M (corresponding author), Univ Toronto, Dept Physiol, Toronto, ON, Canada.	min.zhuo@utoronto.ca	Wu, Long-Jun/E-2684-2012; Wu, Long-Jun/AAK-7113-2020; wang, hansen/I-2510-2019; Zhuo, Min/A-2072-2008	Wu, Long-Jun/0000-0001-8019-3380; wang, hansen/0000-0003-4414-3372; Zhuo, Min/0000-0001-9062-3241	EJLB-CIHR Michael Smith Chair in Neurosciences and Mental Health; Canada Research Chair; CIHR [postdoctoral fellowships]; Fragile X Research Foundation of Canada [postdoctoral fellowships]	EJLB-CIHR Michael Smith Chair in Neurosciences and Mental Health(Canadian Institutes of Health Research (CIHR)); Canada Research Chair(Natural Resources CanadaCanadian Forest ServiceCanada Research Chairs); CIHR(Canadian Institutes of Health Research (CIHR)); Fragile X Research Foundation of Canada	Supported by the EJLB-CIHR Michael Smith Chair in Neurosciences and Mental Health, and the Canada Research Chair to MZ. L-JW is supported by postdoctoral fellowships from the CIHR and Fragile X Research Foundation of Canada.	Allen PB, 2006, NEUROSCIENCE, V140, P897, DOI 10.1016/j.neuroscience.2006.02.067; Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Blitzer RD, 1998, SCIENCE, V280, P1940, DOI 10.1126/science.280.5371.1940; BOLSHAKOV VY, 1995, SCIENCE, V269, P1730, DOI 10.1126/science.7569903; Bredt DS, 2003, NEURON, V40, P361, DOI 10.1016/S0896-6273(03)00640-8; Derkach VA, 2007, NAT REV NEUROSCI, V8, P101, DOI 10.1038/nrn2055; Esteban JA, 2003, NAT NEUROSCI, V6, P136, DOI 10.1038/nn997; Feng J, 2000, P NATL ACAD SCI USA, V97, P9287, DOI 10.1073/pnas.97.16.9287; Hu XD, 2006, J NEUROCHEM, V98, P1841, DOI 10.1111/j.1471-4159.2006.04070.x; Hu XD, 2007, J NEUROSCI, V27, P4674, DOI 10.1523/JNEUROSCI.5365-06.2007; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; Janz R, 1999, NEURON, V24, P687, DOI 10.1016/S0896-6273(00)81122-8; Kameyama K, 1998, NEURON, V21, P1163, DOI 10.1016/S0896-6273(00)80633-9; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Kavalali ET, 2006, NEUROSCIENTIST, V12, P57, DOI 10.1177/1073858405281852; LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155; Lee HK, 2000, NATURE, V405, P955, DOI 10.1038/35016089; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Malinow R, 2003, PHILOS T ROY SOC B, V358, P707, DOI 10.1098/rstb.2002.1233; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; Morishita W, 2001, NEURON, V32, P1133, DOI 10.1016/S0896-6273(01)00554-2; MULKEY RM, 1993, SCIENCE, V261, P1051, DOI 10.1126/science.8394601; Muly EC, 2004, J COMP NEUROL, V469, P185, DOI 10.1002/cne.11001; Muly EC, 2004, CEREB CORTEX, V14, P1398, DOI 10.1093/cercor/bhh101; Nakanishi H, 1997, J CELL BIOL, V139, P951, DOI 10.1083/jcb.139.4.951; Radley JJ, 2006, EUR J NEUROSCI, V24, P876, DOI 10.1111/j.1460-9568.2006.04962.x; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; Sarrouilhe D, 2006, BIOCHIMIE, V88, P1099, DOI 10.1016/j.biochi.2006.04.010; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; Silva AJ, 2003, J NEUROBIOL, V54, P224, DOI 10.1002/neu.10169; Strack S, 1997, J NEUROCHEM, V68, P2119; Terry-Lorenzo RT, 2005, MOL BIOL CELL, V16, P2349, DOI 10.1091/mbc.E04-12-1054; Wei F, 2002, NAT NEUROSCI, V5, P573, DOI 10.1038/nn0602-855; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93; Wu LJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000167; Yan Z, 1999, NAT NEUROSCI, V2, P13, DOI 10.1038/4516; Zhao MG, 2005, NEURON, V47, P859, DOI 10.1016/j.neuron.2005.08.014; Zhuo M, 1999, P NATL ACAD SCI USA, V96, P4650, DOI 10.1073/pnas.96.8.4650; Zito K, 2004, NEURON, V44, P321, DOI 10.1016/j.neuron.2004.09.022	42	28	30	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2008	3	1							e1407	10.1371/journal.pone.0001407	http://dx.doi.org/10.1371/journal.pone.0001407			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366GT	18183288	Green Published, Green Submitted, gold			2022-12-25	WOS:000260469400004
J	Didier, C; Cavelier, C; Quaranta, M; Galcera, MO; Demur, C; Laurent, G; Manenti, S; Ducommun, B				Didier, C.; Cavelier, C.; Quaranta, M.; Galcera, M-O; Demur, C.; Laurent, G.; Manenti, S.; Ducommun, B.			G2/M checkpoint stringency is a key parameter in the sensitivity of AML cells to genotoxic stress	ONCOGENE			English	Article						AML; G2/M checkpoint; chemoresistance; CDC25 phosphatase; CHK1 kinase	ACUTE MYELOID-LEUKEMIA; DNA-DAMAGE; IONIZING-RADIATION; CDC25 PHOSPHATASES; MAMMALIAN-CELLS; PROTEIN-KINASE; HUMAN CLASPIN; IN-VITRO; CHK1; RECOVERY	Acute myeloid leukemia ( AML) cells exposed to genotoxic agents arrest their cell cycle at the G2/M checkpoint and are inherently chemoresistant. To understand the mechanism of this chemoresistance, we compared the ability of immature CD34+ versus mature CD34- AML cell lines ( KG1a and U937, respectively) to recover from a DNA damage-induced cell cycle checkpoint in G2. Here, we report that KG1a cells have a more stringent G2/M checkpoint response than U937 cells. We show that in both cell types, the CDC25B phosphatase participates in the G2/M checkpoint recovery and that its expression is upregulated. Furthermore, we show that CHK1 inhibition by UCN-01 in immature KG1a cells allows checkpoint exit and induces sensitivity to genotoxic agents. Similarly, UCN-01 treatment potentializes genotoxic-induced inhibition of colony formation efficiency of primary leukemic cells from AML patients. Altogether, our results demonstrate that checkpoint stringency varies during the maturation process and indicate that targeting checkpoint mechanisms might represent an attractive therapeutic opportunity for chemoresistant immature AML cells.	[Didier, C.; Cavelier, C.; Quaranta, M.; Ducommun, B.] Univ Toulouse 3, CNRS, LBCMCP, UMR5088,IFR109,Inst Explorat Fonct Genomes, F-31062 Toulouse, France; [Galcera, M-O] Inst Henri Beaufour, IPSEN, F-91952 Les Ulis, France; [Demur, C.; Laurent, G.; Manenti, S.] CHU Purpan, Ctr Physiopathol Toulouse, INSERM, U563, Toulouse, France; [Demur, C.; Laurent, G.; Ducommun, B.] TSA, CHU Purpan, Serv Hematol, Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse	Ducommun, B (corresponding author), Univ Toulouse 3, CNRS, LBCMCP, UMR5088,IFR109,Inst Explorat Fonct Genomes, 118 Route Narbonne, F-31062 Toulouse, France.	ducommun@cict.fr	DUCOMMUN, Bernard/B-3208-2008; manenti, stephane/P-1518-2014; DIDIER, Christine O/P-2785-2014	manenti, stephane/0000-0002-4793-3196; DIDIER, Christine O/0000-0003-3979-0743; DUCOMMUN, Bernard/0000-0002-7126-8368				Amico D, 2003, BLOOD, V101, P4589, DOI 10.1182/blood-2002-07-2311; Bansal P, 2007, CANCER RES, V67, P3356, DOI 10.1158/0008-5472.CAN-06-3685; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartek J, 2007, CURR OPIN CELL BIOL, V19, P238, DOI 10.1016/j.ceb.2007.02.009; Blagosklonny MV, 2006, LEUKEMIA, V20, P385, DOI 10.1038/sj.leu.2404075; Bouquet F, 2006, CELL CYCLE, V5, P1116, DOI 10.4161/cc.5.10.2799; Boutros R, 2006, CURR OPIN CELL BIOL, V18, P185, DOI 10.1016/j.ceb.2006.02.003; Brezak MC, 2005, MOL CANCER THER, V4, P1378, DOI 10.1158/1535-7163.MCT-05-0168; Bruno AP, 1998, CELL DEATH DIFFER, V5, P172, DOI 10.1038/sj.cdd.4400330; Bugler B, 2006, MOL CANCER THER, V5, P1446, DOI 10.1158/1535-7163.MCT-06-0099; Chini C, 2006, ONCOGENE, V25, P4165, DOI 10.1038/sj.onc.1209447; Chini CCS, 2006, J BIOL CHEM, V281, P33276, DOI 10.1074/jbc.M604373200; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Clarke CAL, 2005, BIOCHEM J, V388, P705, DOI 10.1042/BJ20041966; Clave E, 1997, LEUKEMIA, V11, P114, DOI 10.1038/sj.leu.2400528; Dutertre S, 2004, J CELL SCI, V117, P2523, DOI 10.1242/jcs.01108; Fernandez-Vidal A, 2006, CANCER RES, V66, P7128, DOI 10.1158/0008-5472.CAN-05-2552; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Humbert O, 2002, J BIOL CHEM, V277, P18061, DOI 10.1074/jbc.M103451200; Kramer A, 2004, NAT CELL BIOL, V6, P884, DOI 10.1038/ncb1165; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Kumagai A, 2004, J BIOL CHEM, V279, P49599, DOI 10.1074/jbc.M408353200; Lindqvist A, 2004, J CELL SCI, V117, P4979, DOI 10.1242/jcs.01395; Mailand N, 2006, MOL CELL, V23, P307, DOI 10.1016/j.molcel.2006.06.016; Mamely I, 2006, CURR BIOL, V16, P1950, DOI 10.1016/j.cub.2006.08.026; McManus KJ, 2005, MOL BIOL CELL, V16, P5013, DOI 10.1091/mbc.E05-01-0065; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Peschiaroli A, 2006, MOL CELL, V23, P319, DOI 10.1016/j.molcel.2006.06.013; Roberge M, 1998, CANCER RES, V58, P5701; Sampath D, 2006, BLOOD, V107, P2517, DOI 10.1182/blood-2005-08-3351; Schmitt E, 2006, J CELL SCI, V119, P4269, DOI 10.1242/jcs.03200; Shiloh Y, 2003, CELL CYCLE, V2, P116, DOI 10.4161/cc.2.2.342; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; Syljuasen RG, 2006, CANCER RES, V66, P10253, DOI 10.1158/0008-5472.CAN-06-2144; van Vugt MATM, 2004, CELL CYCLE, V3, P1383, DOI 10.4161/cc.3.11.1248; van Vugt MATM, 2004, MOL CELL, V15, P799, DOI 10.1016/j.molcel.2004.07.015; WARTERS RL, 1995, MUTAT RES-DNA REPAIR, V336, P1, DOI 10.1016/0921-8777(94)00036-6; Watanabe N, 2005, P NATL ACAD SCI USA, V102, P11663, DOI 10.1073/pnas.0500410102; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002	40	30	32	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2008	27	27					3811	3820		10.1038/sj.onc.1211041	http://dx.doi.org/10.1038/sj.onc.1211041			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18212737				2022-12-25	WOS:000256904700005
J	Caspi, M; Zilberberg, A; Eldar-Finkelman, H; Rosin-Arbesfeld, R				Caspi, M.; Zilberberg, A.; Eldar-Finkelman, H.; Rosin-Arbesfeld, R.			Nuclear GSK-3 beta inhibits the canonical Wnt signalling pathway in a beta-catenin phosphorylation-independent manner	ONCOGENE			English	Article						Wnt signalling; beta-catenin; GSK-3 beta; colorectal cancer; nucleus	GLYCOGEN-SYNTHASE KINASE-3; SUBCELLULAR-LOCALIZATION; NEGATIVE REGULATOR; EXPORT; INSULIN; AXIN; TRANSCRIPTION; PROTEOLYSIS; ACTIVATION; CELLS	beta-Catenin is the central signalling molecule of the canonical Wnt pathway, where it activates target genes in a complex with lymphoid enhancer factor/T-cell factor transcription factors in the nucleus. The regulation of beta-catenin activity is thought to occur via a cytoplasmatic multiprotein complex that includes the serine/threonine kinase glycogen synthase kinase-3 beta (GSK-3 beta) that phosphorylates beta-catenin, marking it for degradation by the proteasome. Here, we provide evidence showing that GSK-3 beta has a nuclear function in downregulating the activity of beta-catenin. Using colorectal cell lines that express a mutant form of beta-catenin, which cannot be phosphorylated by GSK-3 beta and ectopically expressed mutant beta-catenin protein, we show that nuclear GSK-3 beta functions in a mechanism that does not involve beta-catenin phosphorylation to reduce the levels of Wnt signalling. We show that GSK-3 beta enters the nucleus, forms a complex with beta-catenin and lowers the levels of beta-catenin/TCFdependent transcription in a mechanism that involves GSK-3 beta-Axin binding.	[Caspi, M.; Zilberberg, A.; Rosin-Arbesfeld, R.] Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Eldar-Finkelman, H.] Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, IL-69978 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine	Rosin-Arbesfeld, R (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel.	arina@tau.ac.il	Eldar-Finkelman, Hagit/AAF-8329-2019	Eldar-Finkelman, Hagit/0000-0002-8460-9686				Bachelder RE, 2005, J CELL BIOL, V168, P29, DOI 10.1083/jcb.200409067; Beaulieu JM, 2004, P NATL ACAD SCI USA, V101, P5099, DOI 10.1073/pnas.0307921101; Bijur GN, 2001, J BIOL CHEM, V276, P37436, DOI 10.1074/jbc.M105725200; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Cole A, 2004, BIOCHEM J, V377, P249, DOI 10.1042/BJ20031259; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; Cong F, 2004, P NATL ACAD SCI USA, V101, P2882, DOI 10.1073/pnas.0307344101; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Doble BW, 2007, DEV CELL, V12, P957, DOI 10.1016/j.devcel.2007.04.001; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Franca-Koh J, 2002, J BIOL CHEM, V277, P43844, DOI 10.1074/jbc.M207265200; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Ginger RS, 2000, EMBO J, V19, P5483, DOI 10.1093/emboj/19.20.5483; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; Itoh Keiji, 2005, J Biol, V4, P3, DOI 10.1186/jbiol20; Kikuchi A, 2006, EXP MOL MED, V38, P1, DOI 10.1038/emm.2006.1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Langford KJ, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-3; Liberman Z, 2005, J BIOL CHEM, V280, P4422, DOI 10.1074/jbc.M410610200; Linseman DA, 2004, J NEUROSCI, V24, P9993, DOI 10.1523/JNEUROSCI.2057-04.2004; Meijer L, 2004, TRENDS PHARMACOL SCI, V25, P471, DOI 10.1016/j.tips.2004.07.006; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Morisco C, 2001, J BIOL CHEM, V276, P28586, DOI 10.1074/jbc.M103166200; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Patel S, 2004, BIOCHEM SOC T, V32, P803, DOI 10.1042/BST0320803; Plotkin B, 2003, J PHARMACOL EXP THER, V305, P974, DOI 10.1124/jpet.102.047381; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Salazar M, 2006, J BIOL CHEM, V281, P14841, DOI 10.1074/jbc.M513737200; Staal FJT, 2002, EMBO REP, V3, P63, DOI 10.1093/embo-reports/kvf002; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299; Wiechens N, 2004, J BIOL CHEM, V279, P5263, DOI 10.1074/jbc.M307253200; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Yang M, 2005, P NATL ACAD SCI USA, V102, P6027, DOI 10.1073/pnas.0501535102; Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; Zilberberg A, 2004, J BIOL CHEM, V279, P17535, DOI 10.1074/jbc.M311292200	43	74	77	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2008	27	25					3546	3555		10.1038/sj.onc.1211026	http://dx.doi.org/10.1038/sj.onc.1211026			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18223684				2022-12-25	WOS:000256468500006
J	Hassan, HH; Bailey, D; Lee, DYD; Iatan, I; Hafiane, A; Ruel, I; Krimbou, L; Genest, J				Hassan, Houssein Hajj; Bailey, Dana; Lee, Dong-Young Donna; Iatan, Iulia; Hafiane, Anouar; Ruel, Isabelle; Krimbou, Larbi; Genest, Jacques			Quantitative analysis of ABCA1-dependent compartmentalization and trafficking of apolipoprotein A-I - Implications for determining cellular kinetics of nascent high density lipoprotein biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASSETTE TRANSPORTER A1; ABCA1-MEDIATED LIPID EFFLUX; APOA-I; CHOLESTEROL EFFLUX; ABCA1 TRANSPORTER; PLASMA-MEMBRANE; CARDIOVASCULAR-DISEASE; ENDOTHELIAL-CELLS; TANGIER-DISEASE; BINDING	The molecular mechanisms underlying the apoA-I/ABCA1 endocytic trafficking pathway in relation to high density lipoprotein (HDL) formation remain poorly understood. We have developed a quantitative cell surface biotinylation assay to determine the compartmentalization and trafficking of apoA-I between the plasma membrane (PM) and intracellular compartments (ICCs). Here we report that I-125-apoA-I exhibited saturable association with the PM and ICCs in baby hamster kidney cells stably overexpressing ABCA1 and in fibroblasts. The PM was found to have a 2-fold higher capacity to accommodate apoA-I as compared with ICCs. Overexpressing various levels of ABCA1 in baby hamster kidney cells promoted the association of apoA-I with PM and ICCs compartments. The C-terminal deletion of apoA-I Delta(187-243) and reconstituted HDL particles exhibited reduced association of apoA-I with both the PM and ICCs. Interestingly, cell surface biotinylation with a cleavable biotin revealed that apoA-I induces ABCA1 endocytosis. Such endocytosis was impaired by naturally occurring mutations of ABCA1 (Q597R and C1477R). To better understand the role of the endocytotic pathway in the dynamics of the lipidation of apoA-I, a pulse-chase experiment was performed, and the dissociation (re-secretion) of I-125-apoA-I from both PM and ICCs was monitored over a 6-h period. Unexpectedly, we found that the time required for 50% dissociation of I-125-apoA-I from the PM was 4-fold slower than that from ICCs at 37 degrees C. Finally, treatment of the cells with phosphatidylcholine-specific phospholipase C, increased the dissociation of apoA-I from the PM. This study provides evidence that the lipidation of apoA-I occurs in two kinetically distinguishable compartments. The finding that apoA-I specifically mediates the continuous endocytic recycling of ABCA1, together with the kinetic data showing that apoA-I associated with ICCs is rapidly re-secreted, suggests that the endocytotic pathway plays a central role in the genesis of nascent HDL.	[Hassan, Houssein Hajj; Bailey, Dana; Lee, Dong-Young Donna; Iatan, Iulia; Hafiane, Anouar; Ruel, Isabelle; Krimbou, Larbi; Genest, Jacques] McGill Univ, Div Cardiol, Hlth Ctr Royal Vic Hosp, Cardiovasc Genet Lab, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital	Genest, J (corresponding author), McGill Univ, Div Cardiol, Hlth Ctr Royal Vic Hosp, Cardiovasc Genet Lab, 687 Pine Ave, Montreal, PQ H3A 1A1, Canada.	jacques.genest@muhc.mcgill.ca	Hafiane, Anouar/AAE-3481-2020	Hafiane, Anouar/0000-0001-7494-722X				Basso F, 2003, J LIPID RES, V44, P296, DOI 10.1194/jlr.M200414-JLR200; Brewer HB, 2004, ARTERIOSCL THROM VAS, V24, P1755, DOI 10.1161/01.ATV.0000142804.27420.5b; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Cavelier C, 2006, CIRC RES, V99, P1060, DOI 10.1161/01.RES.0000250567.17569.b3; Chen W, 2001, J BIOL CHEM, V276, P43564, DOI 10.1074/jbc.M107938200; Chen WG, 2005, J BIOL CHEM, V280, P29277, DOI 10.1074/jbc.M505566200; Chroni A, 2004, BIOCHEMISTRY-US, V43, P2126, DOI 10.1021/bi035813p; Denis M, 2004, J BIOL CHEM, V279, P41529, DOI 10.1074/jbc.M406881200; Denis M, 2004, J BIOL CHEM, V279, P7384, DOI 10.1074/jbc.M306963200; Denis M, 2007, CIRCULATION, V116, P284; Favari E, 2004, ARTERIOSCL THROM VAS, V24, P2345, DOI 10.1161/01.ATV.0000148706.15947.8a; Feng B, 2003, NAT CELL BIOL, V5, P781, DOI 10.1038/ncb1035; Fitzgerald ML, 2004, J LIPID RES, V45, P287, DOI 10.1194/jlr.M300355-JLR200; Fitzgerald ML, 2002, J BIOL CHEM, V277, P33178, DOI 10.1074/jbc.M204996200; Frank PG, 1997, BIOCHEMISTRY-US, V36, P1798, DOI 10.1021/bi962118r; Haidar B, 2004, J BIOL CHEM, V279, P9963, DOI 10.1074/jbc.M313487200; Hassan HH, 2005, J LIPID RES, V46, P1457, DOI 10.1194/jlr.M400477-JLR200; Hassan HH, 2007, J LIPID RES, V48, P2428, DOI 10.1194/jlr.M700206-JLR200; JONAS A, 1993, J BIOL CHEM, V268, P1596; Krimbou L, 2005, J LIPID RES, V46, P1668, DOI 10.1194/jlr.M500038-JLR200; Krimbou L, 2004, J LIPID RES, V45, P839, DOI 10.1194/jlr.M300418-JLR200; Krimbou L, 2006, CURR OPIN LIPIDOL, V17, P258, DOI 10.1097/01.mol.0000226117.43178.7c; Le Goff W, 2004, ARTERIOSCL THROM VAS, V24, P2155, DOI 10.1161/01.ATV.0000144811.94581.52; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; Leventhal AR, 2001, J BIOL CHEM, V276, P44976, DOI 10.1074/jbc.M106455200; Linsel-Nitschke P, 2005, NAT REV DRUG DISCOV, V4, P193, DOI 10.1038/nrd1658; Maric J, 2005, J BIOL CHEM, V280, P39942, DOI 10.1074/jbc.M507733200; Martinez LO, 2003, J BIOL CHEM, V278, P37368, DOI 10.1074/jbc.M307161200; Neufeld EB, 2004, J BIOL CHEM, V279, P15571, DOI 10.1074/jbc.M314160200; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; Oram JF, 2005, PHYSIOL REV, V85, P1343, DOI 10.1152/physrev.00005.2005; Oram JF, 2001, J BIOL CHEM, V276, P39898, DOI 10.1074/jbc.M106984200; RAUB TJ, 1991, J CELL PHYSIOL, V149, P141, DOI 10.1002/jcp.1041490118; SCHMITZ G, 1985, EMBO J, V4, P613, DOI 10.1002/j.1460-2075.1985.tb03674.x; Smith JD, 2002, J BIOL CHEM, V277, P17797, DOI 10.1074/jbc.M201594200; Tabas I, 2002, J CLIN INVEST, V110, P905, DOI 10.1172/JCI200216452; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; Timmins JM, 2005, J CLIN INVEST, V115, P1333, DOI 10.1172/JCI200523915; Vaughan AM, 2003, J LIPID RES, V44, P1373, DOI 10.1194/jlr.M300078-JLR200; Vedhachalam C, 2004, J BIOL CHEM, V279, P49931, DOI 10.1074/jbc.M406924200; Vedhachalam C, 2007, J BIOL CHEM, V282, P25123, DOI 10.1074/jbc.M704590200; Vedhachalam C, 2007, ARTERIOSCL THROM VAS, V27, P1603, DOI 10.1161/ATVBAHA.107.145789; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; Wu CA, 2004, J BIOL CHEM, V279, P30168, DOI 10.1074/jbc.M403765200	44	46	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2008	283	17					11164	11175		10.1074/jbc.M707720200	http://dx.doi.org/10.1074/jbc.M707720200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	289PW	18218626	hybrid			2022-12-25	WOS:000255067400012
J	Patel, VN; Likar, KM; Zisman-Rozen, S; Cowherd, SN; Lassiter, KS; Sher, I; Yates, EA; Turnbull, JE; Ron, D; Hoffman, MP				Patel, Vaishali N.; Likar, Karen M.; Zisman-Rozen, Simona; Cowherd, Samuel N.; Lassiter, Keyonica S.; Sher, Ifat; Yates, Edwin A.; Turnbull, Jeremy E.; Ron, Dina; Hoffman, Matthew P.			Specific heparan sulfate structures modulate FGF10-mediated submandibular gland epithelial morphogenesis and differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; BRANCHING MORPHOGENESIS; SALIVARY-GLAND; RECEPTOR SPECIFICITY; CRYSTAL-STRUCTURE; FACTOR FAMILY; FGF; BINDING; MOUSE; EXPRESSION	FGF10, a heparan sulfate ( HS)-binding growth factor, is required for branching morphogenesis of mouse submandibular glands ( SMGs). HS increases the affinity of FGF10 for FGFR2b, which forms an FGF10 center dot FGFR2b center dot HS ternary signaling complex, and results in diverse biological outcomes, including proliferation and epithelial morphogenesis. Defining the HS structures involved in specific FGF10-mediated events is critical to understand how HS modulates growth factor signaling in specific developmental contexts. We used HS-deficient BaF3/FGFR2b cells, which require exogenous HS to proliferate, to investigate the HS requirements for FGF10-mediated proliferation and primary SMG epithelia to investigate the structural requirements of HS for FGF10-mediated epithelial morphogenesis. In BaF3/FGFR2b cells, heparin with at least 10 saccharides and 6-O-, 2-O-, and N-sulfates were required for maximal proliferation. During FGF10-mediated SMG epithelial morphogenesis, HS increased proliferation and end bud expansion. Defined heparin decasaccharide libraries showed that 2-O-sulfation with either an N- or 6-O-sulfate induced end bud expansion, whereas decasaccharides with 6-O-sulfation alone induced duct elongation. End bud expansion resulted from increased FGFR1b signaling, with increased FGFR1b, Fgf1, and Spry1 as well as increased Aqp5 expression, a marker of end bud differentiation. Duct elongation was associated with expression of Cp2L1, a marker of developing ducts. Collectively, these findings show that the size and sulfate patterns of HS modulate specific FGF10-mediated events, such as proliferation, duct elongation, end bud expansion, and differentiation, and provide mechanistic insight as to how the developmental localization of specific HS structures in tissues influences FGF10-mediated morphogenesis and differentiation.	[Patel, Vaishali N.; Likar, Karen M.; Cowherd, Samuel N.; Lassiter, Keyonica S.; Hoffman, Matthew P.] NIH, DHHS, NIDCR, LCDB,Matrix & Morphogenesis Unit, Bethesda, MD 20892 USA; [Likar, Karen M.] Howard Hughes Med Inst, Natl Inst Hlth Res Scholars Program, Bethesda, MD 20817 USA; [Zisman-Rozen, Simona; Sher, Ifat; Ron, Dina] Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel; [Yates, Edwin A.; Turnbull, Jeremy E.] Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; Technion Israel Institute of Technology; University of Liverpool	Hoffman, MP (corresponding author), NIH, DHHS, NIDCR, LCDB,Matrix & Morphogenesis Unit, Bldg 30-Rm 430,30 Convent Dr,MSC 4370, Bethesda, MD 20892 USA.	mhoffman@mail.nih.gov	Yates, Edwin A/I-4808-2013	Yates, Edwin/0000-0001-9365-5433	MRC [G117/423] Funding Source: UKRI; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000707] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; Medical Research Council [G117/423] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ashikari-Hada S, 2004, J BIOL CHEM, V279, P12346, DOI 10.1074/jbc.M313523200; AVIVI A, 1993, FEBS LETT, V330, P249, DOI 10.1016/0014-5793(93)80882-U; Berman B, 1999, J BIOL CHEM, V274, P36132, DOI 10.1074/jbc.274.51.36132; de Vega S, 2007, J BIOL CHEM, V282, P30878, DOI 10.1074/jbc.M705847200; Entesarian M, 2005, NAT GENET, V37, P125, DOI 10.1038/ng1507; Ford-Perriss M, 2002, GLYCOBIOLOGY, V12, P721, DOI 10.1093/glycob/cwf072; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; Guimond SE, 1999, CURR BIOL, V9, P1343, DOI 10.1016/S0960-9822(00)80060-3; Hoffman MP, 2002, DEVELOPMENT, V129, P5767, DOI 10.1242/dev.00172; Hoffman MP, 2001, J BIOL CHEM, V276, P22077, DOI 10.1074/jbc.M100774200; Igarashi M, 1998, J BIOL CHEM, V273, P13230, DOI 10.1074/jbc.273.21.13230; Izvolsky KI, 2003, DEV BIOL, V258, P185, DOI 10.1016/S0012-1606(03)00114-3; Jaskoll T, 2005, BMC DEV BIOL, V5, DOI 10.1186/1471-213X-5-11; Jastrebova N, 2006, J BIOL CHEM, V281, P26884, DOI 10.1074/jbc.M600806200; Kreuger J, 2006, J CELL BIOL, V174, P323, DOI 10.1083/jcb.200604035; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; Merry CLR, 1999, J BIOL CHEM, V274, P18455, DOI 10.1074/jbc.274.26.18455; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; Min HS, 1998, GENE DEV, V12, P3156, DOI 10.1101/gad.12.20.3156; Mohammadi M, 2005, CURR OPIN STRUC BIOL, V15, P506, DOI 10.1016/j.sbi.2005.09.002; Nugent MA, 2000, INT J BIOCHEM CELL B, V32, P115, DOI 10.1016/S1357-2725(99)00123-5; Ohuchi H, 2000, BIOCHEM BIOPH RES CO, V277, P643, DOI 10.1006/bbrc.2000.3721; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Ostrovsky O, 2002, J BIOL CHEM, V277, P2444, DOI 10.1074/jbc.M108540200; Patel VN, 2007, DEVELOPMENT, V134, P4177, DOI 10.1242/dev.011171; Patel VN, 2006, DIFFERENTIATION, V74, P349, DOI 10.1111/j.1432-0436.2006.00088.x; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; RAPRAEGER AC, 1994, METHOD ENZYMOL, V245, P219; Rebustini IT, 2007, DEV BIOL, V308, P15, DOI 10.1016/j.ydbio.2007.04.031; REICHSLOTKY R, 1995, J BIOL CHEM, V270, P29813; RON D, 1993, J BIOL CHEM, V268, P2984; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Sekine K, 1999, NAT GENET, V21, P138, DOI 10.1038/5096; Sperinde GV, 1998, BIOCHEMISTRY-US, V37, P13153, DOI 10.1021/bi980600z; Steinberg Z, 2005, DEVELOPMENT, V132, P1223, DOI 10.1242/dev.01690; Vlodavsky I, 1996, CANCER METAST REV, V15, P177, DOI 10.1007/BF00437470; Wei C, 2007, TISSUE ENG, V13, P721, DOI 10.1089/ten.2006.0123; Yamaguchi Y, 2005, DEV DYNAM, V233, P484, DOI 10.1002/dvdy.20348; Yamaguchi Y, 2006, DEVELOPMENT, V133, P4737, DOI 10.1242/dev.02658; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; Yates EA, 2004, J MED CHEM, V47, P277, DOI 10.1021/jm0309755; Yeh BK, 2003, P NATL ACAD SCI USA, V100, P2266, DOI 10.1073/pnas.0436500100; Zhang XQ, 2006, J BIOL CHEM, V281, P15694, DOI 10.1074/jbc.M601252200	46	80	81	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9308	9317		10.1074/jbc.M709995200	http://dx.doi.org/10.1074/jbc.M709995200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18230614	hybrid, Green Published			2022-12-25	WOS:000254465800061
J	Wen, KK; Mckane, M; Houtman, JCD; Rubenstein, PA				Wen, Kuo-Kuang; Mckane, Melissa; Houtman, Jon C. D.; Rubenstein, Peter A.			Control of the ability of profilin to bind and facilitate nucleotide exchange from G-actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST ACTIN; ANGSTROM RESOLUTION; ATP HYDROLYSIS; BETA-ACTIN; F-ACTIN; FILAMENT; DYNAMICS; FORMIN; SUBSTITUTION; ELONGATION	A major factor in profilin regulation of actin cytoskeletal dynamics is its facilitation of G-actin nucleotide exchange. However, the mechanism of this facilitation is unknown. We studied the interaction of yeast (YPF) and human profilin 1 (HPF1) with yeast and mammalian skeletal muscle actins. Homologous pairs ( YPF and yeast actin, HPF1 and muscle actin) bound more tightly to one another than heterologous pairs. However, with saturating profilin, HPF1 caused a faster etheno-ATP exchange with both yeast and muscle actins than did YPF. Based on the -fold change in ATP exchange rate/K-d, however, the homologous pairs are more efficient than the heterologous pairs. Thus, strength of binding of profilin to actin and nucleotide exchange rate are not tightly coupled. Actin/HPF interactions were entropically driven, whereas YPF interactions were enthalpically driven. Hybrid yeast actins containing subdomain 1 (sub1) or subdomain 1 and 2 (sub12) muscle actin residues bound more weakly to YPF than did yeast actin (K-d = 2 mu M versus 0.6 mu M). These hybrids bound even more weakly to HPF than did yeast actin (K-d = 5 mu M versus 3.2 mu M). sub1/YPF interactions were entropically driven, whereas the sub12/YPF binding was enthalpically driven. Compared with WT yeast actin, YPF binding to sub1 occurred with a 5 times faster k(off) and a 2 times faster k(on). sub12 bound with a 3 times faster koff and a 1.5 times slower kon. Profilin controls the energetics of its interaction with nonhybrid actin, but interactions between actin sub-domains 1 and 2 affect the topography of the profilin binding site.	[Wen, Kuo-Kuang; Mckane, Melissa; Rubenstein, Peter A.] Univ Iowa, Carver Coll Med, Dept Biochem, Iowa City, IA 52242 USA; [Houtman, Jon C. D.] Univ Iowa, Carver Coll Med, Dept Microbiol, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Rubenstein, PA (corresponding author), Univ Iowa, Carver Coll Med, Dept Biochem, Iowa City, IA 52242 USA.	peter-rubenstein@uiowa.edu		Rubenstein, Peter/0000-0003-1225-4414; Houtman, Jon/0000-0002-5307-9854	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033689] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 33689] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arasada R, 2007, BBA-MOL CELL RES, V1773, P631, DOI 10.1016/j.bbamcr.2007.03.009; BABCOCK G, 1993, CELL MOTIL CYTOSKEL, V24, P179, DOI 10.1002/cm.970240305; Belmont LD, 1999, P NATL ACAD SCI USA, V96, P29, DOI 10.1073/pnas.96.1.29; Carlier M F, 1990, Adv Biophys, V26, P51, DOI 10.1016/0065-227X(90)90007-G; CARLIER MF, 1991, J BIOL CHEM, V266, P1; CEDERGRENZEPPEZAUER ES, 1994, J MOL BIOL, V240, P459, DOI 10.1006/jmbi.1994.1461; Chik JK, 1996, J MOL BIOL, V263, P607, DOI 10.1006/jmbi.1996.0602; COOK RK, 1991, J BIOL CHEM, V266, P16825; CROSBIE RH, 1994, BIOPHYS J, V67, P1957, DOI 10.1016/S0006-3495(94)80678-2; Eads JC, 1998, BIOCHEMISTRY-US, V37, P11171, DOI 10.1021/bi9720033; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; KHAITLINA SY, 1993, EUR J BIOCHEM, V218, P911, DOI 10.1111/j.1432-1033.1993.tb18447.x; Kinosian HJ, 2002, BIOCHEMISTRY-US, V41, P6734, DOI 10.1021/bi016083t; Kovar DR, 2006, CELL, V124, P423, DOI 10.1016/j.cell.2005.11.038; Lu J, 2001, MOL BIOL CELL, V12, P1161, DOI 10.1091/mbc.12.4.1161; MAGDOLEN V, 1993, FEBS LETT, V316, P41, DOI 10.1016/0014-5793(93)81733-G; McKane M, 2005, J BIOL CHEM, V280, P36494, DOI 10.1074/jbc.M506970200; McKane M, 2006, J BIOL CHEM, V281, P29916, DOI 10.1074/jbc.M602251200; Minehardt TJ, 2006, BIOPHYS J, V90, P2445, DOI 10.1529/biophysj.105.072900; Page R, 1998, J MOL BIOL, V280, P463, DOI 10.1006/jmbi.1998.1879; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; Perelroizen I, 1996, J BIOL CHEM, V271, P12302, DOI 10.1074/jbc.271.21.12302; Romero S, 2004, CELL, V119, P419, DOI 10.1016/j.cell.2004.09.039; Romero S, 2007, J BIOL CHEM, V282, P8435, DOI 10.1074/jbc.M609886200; RUBENSTEIN PA, 1990, BIOESSAYS, V12, P309, DOI 10.1002/bies.950120702; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; Selden LA, 1999, BIOCHEMISTRY-US, V38, P2769, DOI 10.1021/bi981543c; SOUTHWICK FS, 1990, J CELL BIOL, V110, P1965, DOI 10.1083/jcb.110.6.1965; Vavylonis D, 2006, MOL CELL, V21, P455, DOI 10.1016/j.molcel.2006.01.016; Vinson VK, 1998, BIOCHEMISTRY-US, V37, P10871, DOI 10.1021/bi980093l; Wen KK, 2002, J BIOL CHEM, V277, P41101, DOI 10.1074/jbc.M204025200; Yao XY, 2001, J BIOL CHEM, V276, P25598, DOI 10.1074/jbc.M011797200; Zheng XG, 2007, BIOPHYS J, V93, P1277, DOI 10.1529/biophysj.107.109215	33	18	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9444	9453		10.1074/jbc.M709806200	http://dx.doi.org/10.1074/jbc.M709806200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18223293	hybrid, Green Published			2022-12-25	WOS:000254465800074
J	Santhoshkumar, P; Udupa, P; Murugesan, R; Sharma, KK				Santhoshkumar, Puttur; Udupa, Padmanabha; Murugesan, Raju; Sharma, K. Krishna			Significance of interactions of low molecular weight crystallin fragments in lens aging and cataract formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-B-CRYSTALLIN; OXIDIZED BETA-B3-CRYSTALLIN PEPTIDE; UBIQUITIN-PROTEASOME PATHWAY; AGE-RELATED-CHANGES; HEAT-SHOCK-PROTEIN; BOVINE LENS; EPITHELIAL-CELLS; A-CRYSTALLIN; POSTTRANSLATIONAL MODIFICATIONS; LIGHT-SCATTERING	Analysis of aged and cataract lenses shows the presence of increased amounts of crystallin fragments in the high molecular weight aggregates of water-soluble and water-insoluble fractions. However, the significance of accumulation and interaction of low molecular weight crystallin fragments in aging and cataract development is not clearly understood. In this study, 23 low molecular mass (< 3.5-kDa) peptides in the urea-soluble fractions of young, aged, and aged cataract human lenses were identified by mass spectroscopy. Two peptides, alpha B-(1-18) (MDIAIHHPWIRRPFFPFH) and beta A3/A1-(59-74) (SD(N) AYHIERLMSFRPIC), present in aged and cataract lens but not young lens, and a third peptide, gamma S-(167-178) (SPAVQSFRRIVE) present in all three lens groups were synthesized to study the effects of interaction of these peptides with intact alpha-, beta-, and gamma-crystallins and alcohol dehydrogenase, a protein used in aggregation studies. Interaction of alpha B-(1-18) and beta A3/A1-(59-74) peptides increased the scattering of light by beta- and gamma-crystallin and alcohol dehydrogenase. The ability of alpha-crystallin subunits to function as molecular chaperones was significantly reduced by interaction with alpha B-(1-18) and beta A3/A1-(59-74) peptides, whereas gamma S peptide had no effect on chaperone-like activity of alpha-crystallin. The beta A3/A1-(59-74) peptide caused a 5.64-fold increase in alpha B-crystallin oligomeric mass and partial precipitation. Replacing hydrophobic residues in alpha B-(118) and beta A3/A1-(59-74) peptides abolished their ability to induce crystallin aggregation and light scattering. Our study suggests that interaction of crystallin-derived peptides with intact crystallins could be a key event in age-related protein aggregation in lens and cataractogenesis.	[Santhoshkumar, Puttur; Udupa, Padmanabha; Murugesan, Raju; Sharma, K. Krishna] Univ Missouri, Dept Ophthalmol, Columbia Sch Med, Columbia, MO 65212 USA; [Sharma, K. Krishna] Univ Missouri, Dept Biochem, Columbia Sch Med, Columbia, MO 65212 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Sharma, KK (corresponding author), Univ Missouri, Dept Ophthalmol, Columbia Sch Med, EC213,1 Hosp Dr, Columbia, MO 65212 USA.	Sharmak@health.missouri.edu	Santhoshkumar, Puttur/G-1798-2010	Santhoshkumar, Puttur/0000-0002-6897-7278	NATIONAL EYE INSTITUTE [R24EY014795, R01EY009855, R29EY009855, R01EY011981] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY011981, R24 EY014795, EY 11981, EY009855, EY 14795] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		DAS KP, 1995, BIOCHEM J, V311, P367, DOI 10.1042/bj3110367; David L L, 1989, Lens Eye Toxic Res, V6, P725; DAVID LL, 1994, INVEST OPHTH VIS SCI, V35, P785; Friguet Bertrand, 2002, TheScientificWorldJOURNAL, V2, P248; GARBER AT, 1984, J BIOL CHEM, V259, P376; Ghosh JG, 2005, PROTEIN SCI, V14, P684, DOI 10.1110/ps.041152805; Ghosh JG, 2005, BIOCHEMISTRY-US, V44, P14854, DOI 10.1021/bi0503910; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; Han J, 2006, INVEST OPHTH VIS SCI, V47, P2990, DOI 10.1167/iovs.05-1529; Hanson SRA, 2000, EXP EYE RES, V71, P195, DOI 10.1006/exer.2000.0868; Harding JJ, 2002, AGEING RES REV, V1, P465, DOI 10.1016/S1568-1637(02)00012-0; Harrington V, 2004, MOL VIS, V10, P476; Hoehenwarter W, 2006, AMINO ACIDS, V30, P369, DOI 10.1007/s00726-005-0283-9; HORWITZ J, 1983, BIOCHEM BIOPH RES CO, V113, P65, DOI 10.1016/0006-291X(83)90432-1; Hosler MR, 2003, INT J BIOCHEM CELL B, V35, P685, DOI 10.1016/S1357-2725(02)00397-7; HUANG LL, 1995, EXP EYE RES, V61, P45, DOI 10.1016/S0014-4835(95)80057-3; Kumar RS, 2000, J PEPT RES, V56, P157, DOI 10.1034/j.1399-3011.2000.00785.x; Lampi KJ, 1998, EXP EYE RES, V67, P31, DOI 10.1006/exer.1998.0481; Mathur P, 2000, CURR EYE RES, V21, P926, DOI 10.1076/ceyr.21.6.926.6990; MIESBAUER LR, 1994, J BIOL CHEM, V269, P12494; ROY D, 1978, EXP EYE RES, V26, P429, DOI 10.1016/0014-4835(78)90130-6; Ruotolo R, 2003, MOL VIS, V9, P538; Santhoshkumar P, 2006, PROTEIN SCI, V15, P2488, DOI 10.1110/ps.062338206; Senthilkumar R, 2002, J BIOL CHEM, V277, P39136, DOI 10.1074/jbc.M204684200; Shang F, 2001, EXP EYE RES, V73, P229, DOI 10.1006/exer.2001.1029; Sharma KK, 1996, CURR EYE RES, V15, P363, DOI 10.3109/02713689608995826; Sharma KK, 2000, J BIOL CHEM, V275, P3767, DOI 10.1074/jbc.275.6.3767; Shih M, 1998, Mol Vis, V4, P4; Shih M, 2001, CURR EYE RES, V22, P458, DOI 10.1076/ceyr.22.6.458.5483; Sreelakshmi Y, 2004, BIOCHEMISTRY-US, V43, P15785, DOI 10.1021/bi048151s; Srivastava OP, 2004, J BIOL CHEM, V279, P10901, DOI 10.1074/jbc.M308884200; SRIVASTAVA OP, 1988, EXP EYE RES, V47, P525, DOI 10.1016/0014-4835(88)90092-9; Srivastava OP, 1996, CURR EYE RES, V15, P511, DOI 10.3109/02713689609000762; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; SWAMINATHAN S, 1986, BIOCHEM MED METAB B, V35, P184, DOI 10.1016/0885-4505(86)90073-3; SWANSON AA, 1985, CURR EYE RES, V4, P43, DOI 10.3109/02713688508999965; Thampi P, 2002, INVEST OPHTH VIS SCI, V43, P3265; Udupa EGP, 2005, INVEST OPHTH VIS SCI, V46, P2514, DOI 10.1167/iovs.05-0031; Udupa PEG, 2005, EXP EYE RES, V80, P185, DOI 10.1016/j.exer.2004.08.028; Ueda Y, 2002, INVEST OPHTH VIS SCI, V43, P205; Viteri G, 2004, ARCH BIOCHEM BIOPHYS, V427, P197, DOI 10.1016/j.abb.2004.05.006; VOORTER CEM, 1988, J BIOL CHEM, V263, P19020; Werten PJL, 1999, EXP EYE RES, V68, P99, DOI 10.1006/exer.1998.0584; Wilmarth PA, 2006, J PROTEOME RES, V5, P2554, DOI 10.1021/pr050473a; Wride Michael A., 2006, Birth Defects Research, V78, P90, DOI 10.1002/bdrc.20063; Zeng JM, 2006, BIOCHEM J, V398, P197, DOI 10.1042/BJ20060019; Zhang H, 2001, HISTOCHEM J, V33, P511, DOI 10.1023/A:1014943522613	47	67	68	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8477	8485		10.1074/jbc.M705876200	http://dx.doi.org/10.1074/jbc.M705876200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18227073	Green Published, hybrid			2022-12-25	WOS:000254288000046
J	Zhu, H; Shuman, S				Zhu, Hui; Shuman, Stewart			Bacterial nonhomologous end joining ligases preferentially seal breaks with a 3 '-OH monoribonucleotide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T4 RNA LIGASE-2; GUIDED MUTATIONAL ANALYSIS; DNA-LIGASE; POLYMERASE COMPONENT; BACILLUS-SUBTILIS; CRYSTAL-STRUCTURE; NICK RECOGNITION; REPAIR SYSTEM; KU; MYCOBACTERIA	Many bacterial species have a nonhomologous end joining system of DNA repair driven by dedicated DNA ligases (LigD and LigC). LigD is a multifunctional enzyme composed of a ligase domain fused to two other catalytic modules: a polymerase that preferentially adds ribonucleotides to double-strand break ends and a phosphoesterase that trims 3'-oligoribonucleotide tracts until only a single 3'-ribonucleotide remains. LigD and LigC have a feeble capacity to seal 3'-OH/ 5'-PO4 DNA nicks. Here, we report that nick sealing by LigD and LigC enzymes is stimulated by the presence of a single ribonucleotide at the broken 3'-OH end. The ribonucleotide effect on LigD and LigC is specific for the 3'-terminal nucleotide and is either diminished or abolished when additional vicinal ribonucleotides are present. No such 3'-ribonucleotide effect is observed for bacterial LigA or Chlorella virus ligase. We found that in vitro repair of a double-strand break by Pseudomonas LigD requires the polymerase module and results in incorporation of an alkalilabile ribonucleotide at the repair junction. These results illuminate an underlying logic for the domain organization of LigD, whereby the polymerase and phosphoesterase domains can heal the broken 3'-end to generate the monoribonucleotide terminus favored by the nonhomologous end joining ligases.	[Zhu, Hui; Shuman, Stewart] Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.	s-shuman@ski.mskcc.org			NIGMS NIH HHS [GM 63611] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063611] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akey D, 2006, J BIOL CHEM, V281, P13412, DOI 10.1074/jbc.M513550200; Aniukwu J, 2008, GENE DEV, V22, P512, DOI 10.1101/gad.1631908; Aravind L, 2001, GENOME RES, V11, P1365, DOI 10.1101/gr.181001; Brissett NC, 2007, SCIENCE, V318, P456, DOI 10.1126/science.1145112; Bullard DR, 2006, BIOCHEM J, V398, P135, DOI 10.1042/BJ20060313; Della M, 2004, SCIENCE, V306, P683, DOI 10.1126/science.1099824; Doherty AJ, 2001, FEBS LETT, V500, P186, DOI 10.1016/S0014-5793(01)02589-3; Gong CL, 2005, NAT STRUCT MOL BIOL, V12, P304, DOI 10.1038/nsmb915; Gong CL, 2004, J BIOL CHEM, V279, P20594, DOI 10.1074/jbc.M401841200; Ho CK, 2002, P NATL ACAD SCI USA, V99, P12709, DOI 10.1073/pnas.192184699; Korycka-Machala M, 2006, FEMS MICROBIOL LETT, V258, P83, DOI 10.1111/j.1574-6968.2006.00199.x; LEHMAN IR, 1974, SCIENCE, V186, P790; Lubini P, 1994, CHEM BIOL, V1, P39, DOI 10.1016/1074-5521(94)90039-6; Moeller R, 2007, J BACTERIOL, V189, P3306, DOI 10.1128/JB.00018-07; Nair PA, 2007, NAT STRUCT MOL BIOL, V14, P770, DOI 10.1038/nsmb1266; Nandakumar J, 2004, MOL CELL, V16, P211, DOI 10.1016/j.molcel.2004.09.022; Nandakumar J, 2004, J BIOL CHEM, V279, P31337, DOI 10.1074/jbc.M402394200; Nandakumar J, 2007, MOL CELL, V26, P257, DOI 10.1016/j.molcel.2007.02.026; Nandakumar J, 2006, CELL, V127, P71, DOI 10.1016/j.cell.2006.08.038; Odell M, 2000, MOL CELL, V6, P1183, DOI 10.1016/S1097-2765(00)00115-5; Pascal JM, 2004, NATURE, V432, P473, DOI 10.1038/nature03082; Pitcher RS, 2007, DNA REPAIR, V6, P1271, DOI 10.1016/j.dnarep.2007.02.009; Pitcher RS, 2007, J MOL BIOL, V366, P391, DOI 10.1016/j.jmb.2006.10.046; Pitcher RS, 2005, J MOL BIOL, V351, P531, DOI 10.1016/j.jmb.2005.06.038; Sekiguchi J, 1997, BIOCHEMISTRY-US, V36, P9073, DOI 10.1021/bi970705m; Sriskanda V, 1998, NUCLEIC ACIDS RES, V26, P525, DOI 10.1093/nar/26.2.525; Stephanou NC, 2007, J BACTERIOL, V189, P5237, DOI 10.1128/JB.00332-07; Wang ST, 2006, J MOL BIOL, V358, P16, DOI 10.1016/j.jmb.2006.01.059; Weller GR, 2002, SCIENCE, V297, P1686, DOI 10.1126/science.1074584; Yakovleva L, 2006, J BIOL CHEM, V281, P25026, DOI 10.1074/jbc.M603302200; Zhu H, 2006, P NATL ACAD SCI USA, V103, P1711, DOI 10.1073/pnas.0509083103; Zhu H, 2005, J BIOL CHEM, V280, P33707, DOI 10.1074/jbc.M506838200; Zhu H, 2005, J BIOL CHEM, V280, P25973, DOI 10.1074/jbc.M504002200; Zhu H, 2005, J BIOL CHEM, V280, P12137, DOI 10.1074/jbc.M413685200; Zhu H, 2005, J BIOL CHEM, V280, P418, DOI 10.1074/jbc.M410110200; Zhu H, 2007, NUCLEIC ACIDS RES, V35, P3631, DOI 10.1093/nar/gkm145	36	44	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8331	8339		10.1074/jbc.M705476200	http://dx.doi.org/10.1074/jbc.M705476200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18203718	hybrid, Green Published			2022-12-25	WOS:000254288000031
J	Hook, VYH; Kindy, M; Hook, G				Hook, Vivian Y. H.; Kindy, Mark; Hook, Gregory			Inhibitors of cathepsin B improve memory and reduce beta-amyloid in transgenic Alzheimer disease mice expressing the wild-type, but not the Swedish mutant, beta-secretase site of the amyloid precursor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; SELECTIVE INHIBITOR; CHROMAFFIN CELLS; GUINEA-PIGS; HUMAN BRAIN; PEPTIDE; PROTEASES; BACE1; THERAPEUTICS; ACCUMULATION	Elucidation of A beta-lowering agents that inhibit processing of the wild-type (WT) beta-secretase amyloid precursor protein (APP) site, present in most Alzheimer disease (AD) patients, is a logical approach for improving memory deficit in AD. The cysteine protease inhibitors CA074Me and E64d were selected by inhibition of beta-secretase activity in regulated secretory vesicles that produce beta-amyloid (A beta). The regulated secretory vesicle activity, represented by cathepsin B, selectively cleaves the WT beta-secretase site but not the rare Swedish mutant beta-secretase site. In vivo treatment of London APP mice, expressing the WT beta-secretase site, with these inhibitors resulted in substantial improvement in memory deficit assessed by the Morris water maze test. After inhibitor treatment, the improved memory function was accompanied by reduced amyloid plaque load, decreasedA beta 40 and A beta 42, and reduced C-terminal beta-secretase fragment derived from APP by beta-secretase. However, the inhibitors had no effects on any of these parameters in mice expressing the Swedish mutant beta-secretase site of APP. The notable efficacy of these inhibitors to improve memory and reduce A beta in an AD animal model expressing the WT beta-secretase APP site present in the majority of AD patients provides support for CA074Me and E64d inhibitors as potential AD therapeutic agents.	[Hook, Vivian Y. H.] Univ Calif San Diego, Skaggs Sch Phar & Pharmaceut Sci, Dept Neurosci, La Jolla, CA 92093 USA; [Kindy, Mark] Appl Neurotechnol Inc, Charleston, SC 29425 USA; [Hook, Gregory] Amer Life Sci Pharmaceut Inc, San Diego, CA 92109 USA	University of California System; University of California San Diego	Hook, VYH (corresponding author), Univ Calif San Diego, Skaggs Sch Phar & Pharmaceut Sci, Dept Neurosci, 9500 Gilman Dr MC 0744, La Jolla, CA 92093 USA.	vhook@ucsd.edu			NIA NIH HHS [AG18044] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R44AG018044, R43AG018044] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Barrett AJ, 2004, HDB PROTEOLYTIC ENZY, P1051; Beck M, 1997, BBA-GENE STRUCT EXPR, V1351, P17, DOI 10.1016/S0167-4781(96)00232-1; Beck M, 2003, NEUROCHEM RES, V28, P637, DOI 10.1023/A:1022850113083; BERNSTEIN HG, 1990, BRAIN RES BULL, V24, P543, DOI 10.1016/0361-9230(90)90157-U; BEYNON R, 2001, PROTEOLYTIC ENZYMES, P293; BUTTLE DJ, 1992, ARCH BIOCHEM BIOPHYS, V299, P377, DOI 10.1016/0003-9861(92)90290-D; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Caroni P, 1997, J NEUROSCI METH, V71, P3, DOI 10.1016/S0165-0270(96)00121-5; CATALDO AM, 1991, P NATL ACAD SCI USA, V88, P10998, DOI 10.1073/pnas.88.24.10998; CATALDO AM, 1990, P NATL ACAD SCI USA, V87, P3861, DOI 10.1073/pnas.87.10.3861; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Deane R, 2003, NAT MED, V9, P907, DOI 10.1038/nm890; Dewachter I, 2000, EXP GERONTOL, V35, P831, DOI 10.1016/S0531-5565(00)00149-2; Dodart JC, 2002, GENES BRAIN BEHAV, V1, P142, DOI 10.1034/j.1601-183X.2002.10302.x; Gandy S, 2003, ALZ DIS ASSOC DIS, V17, P259, DOI 10.1097/00002093-200310000-00011; Hook G, 2007, BIOL CHEM, V388, P979, DOI 10.1515/BC.2007.117; Hook V, 2005, BIOL CHEM, V386, P931, DOI 10.1515/BC.2005.108; Hook V, 2007, BIOL CHEM, V388, P247, DOI 10.1515/BC.2007.027; Hook VYH, 2002, J NEUROCHEM, V81, P237; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; IVERSEN LL, 1995, BIOCHEM J, V311, P1; IVY GO, 1984, SCIENCE, V226, P985, DOI 10.1126/science.6505679; KRIEGER TJ, 1991, J BIOL CHEM, V266, P8376; Liang K C, 1994, Chin J Physiol, V37, P201; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Marr RA, 2004, J MOL NEUROSCI, V22, P5, DOI 10.1385/JMN:22:1-2:5; McGowan E, 2006, TRENDS GENET, V22, P281, DOI 10.1016/j.tig.2006.03.007; Moechars D, 1999, J BIOL CHEM, V274, P6483, DOI 10.1074/jbc.274.10.6483; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Mueller-Steiner S, 2006, NEURON, V51, P703, DOI 10.1016/j.neuron.2006.07.027; NAKAMURA Y, 1991, NEUROSCI LETT, V130, P195, DOI 10.1016/0304-3940(91)90395-A; NAKANISHI H, 1994, EXP NEUROL, V126, P119, DOI 10.1006/exnr.1994.1048; Rice GI, 2004, BIOCHEM J, V383, P45, DOI 10.1042/BJ20040634; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; SARATH G, 2001, PROTEOLYTIC ENZYMES, P59; SATOYOSHI E, 1992, INTERNAL MED, V31, P841, DOI 10.2169/internalmedicine.31.841; SCHECHTE.I, 1970, EUR J BIOCHEM, V14, P516, DOI 10.1111/j.1432-1033.1970.tb00318.x; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shi XP, 2001, J BIOL CHEM, V276, P10366, DOI 10.1074/jbc.M009200200; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Sinha S, 1999, P NATL ACAD SCI USA, V96, P11049, DOI 10.1073/pnas.96.20.11049; Sisodia SS, 1999, J CLIN INVEST, V104, P1169, DOI 10.1172/JCI8508; Strasser JF, 1995, J PHARMACOL EXP THER, V275, P1647; TOWATARI T, 1991, FEBS LETT, V280, P311, DOI 10.1016/0014-5793(91)80319-X; van Leuven F, 2000, PROG NEUROBIOL, V61, P305, DOI 10.1016/S0301-0082(99)00055-6; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vassar R, 2004, J MOL NEUROSCI, V23, P105, DOI 10.1385/JMN:23:1-2:105; YAMAMOTO A, 1992, J MOL BIOL, V227, P942, DOI 10.1016/0022-2836(92)90234-B; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Zhang J, 2005, J ALZHEIMERS DIS, V7, P125	52	160	170	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7745	7753		10.1074/jbc.M708362200	http://dx.doi.org/10.1074/jbc.M708362200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18184658	hybrid			2022-12-25	WOS:000253997900051
J	Hurst, DR; Xie, Y; Vaidya, KS; Mehta, A; Moore, BP; Accavitti-Loper, MA; Samant, RS; Saxena, R; Silveira, AC; Welch, DR				Hurst, Douglas R.; Xie, Yi; Vaidya, Kedar S.; Mehta, Alka; Moore, Blake P.; Accavitti-Loper, Mary Ann; Samant, Rajeev S.; Saxena, Ritu; Silveira, Alexandra C.; Welch, Danny R.			Alterations of BRMS1-ARID4A interaction modify gene expression but still suppress metastasis in human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOMA METASTASIS; DEACETYLASE COMPLEX; MDA-MB-435 CELLS; IN-VIVO; BRMS1; PROTEINS; RBP1; IDENTIFICATION; MECHANISMS; LINES	The BRMS1 metastasis suppressor interacts with the protein AT-rich interactive domain 4A ( ARID4A, RBBP1) as part of SIN3.histone deacetylase chromatin remodeling complexes. These transcriptional co-repressors regulate diverse cell phenotypes depending upon complex composition. To define BRMS1 complexes and their roles in metastasis suppression, we generated BRMS1 mutants ( BRMS1(mut)) and mapped ARID4A interactions. BRMS1(L174D) disrupted direct interaction with ARID4A in yeast two-hybrid genetic screens but retained an indirect association with ARID4A in MDA-MB-231 and - 435 human breast cancer cell lines by co-immunoprecipitation. Deletion of the first coiled-coil domain ( BRMS1(Delta CC1)) did not disrupt direct interaction in yeast two-hybrid screens but did prevent association by co-immunoprecipitation. These results suggest altered complex composition with BRMS1mut. Although basal transcription repression was impaired and the pro-metastatic protein osteopontin was differentially down-regulated by BRMS1(L174D) and BRMS1(Delta CC1), both down-regulated the epidermal growth factor receptor and suppressed metastasis in MDA-MB-231 and - 435 breast cancer xenograft models. We conclude that BRMS1mut, which modifies the composition of a SIN3.histone deacetylase chromatin remodeling complex, leads to altered gene expression profiles. Because metastasis requires the coordinate expression of multiple genes, down-regulation of at least one important gene, such as the epidermal growth factor receptor, had the ability to suppress metastasis. Understanding which interactions are necessary for particular biochemical/ cellular functions may prove important for future strategies targeting metastasis.	[Hurst, Douglas R.; Xie, Yi; Vaidya, Kedar S.; Mehta, Alka; Moore, Blake P.; Silveira, Alexandra C.; Welch, Danny R.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; [Welch, Danny R.] Univ Alabama Birmingham, Dept Pharmacol Toxicol, Birmingham, AL 35294 USA; [Saxena, Ritu; Welch, Danny R.] Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; [Accavitti-Loper, Mary Ann; Welch, Danny R.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA; [Accavitti-Loper, Mary Ann] Univ Alabama Birmingham, Epitope Recognit & Immunoreagent Core Facil, Birmingham, AL 35294 USA; [Samant, Rajeev S.] Univ S Alabama, Mitchell Canc Inst, Mobile, AL 36688 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of South Alabama	Welch, DR (corresponding author), Univ Alabama Birmingham, Dept Pathol, Univ Blvd,Rm VH-G019, Birmingham, AL 35294 USA.	DanWelch@uab.edu	vaidya, kedar/B-7339-2009; Welch, Danny R/B-7310-2009; Hurst, Douglas R/B-7341-2009	Welch, Danny R/0000-0002-1951-4947; Samant, Rajeev/0000-0001-5681-4976; Vaidya, Kedar/0000-0001-6600-2648; Hurst, Douglas/0000-0002-1296-2210	NATIONAL CANCER INSTITUTE [R01CA087728, F32CA113037] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA087728-08, F32CA113037, R01 CA087728-07, R01 CA087728-05A1, F32 CA113037-01A1, CA87728, F32 CA113037-02, F32 CA113037, R01 CA087728, F32 CA113037-03, R01 CA087728-06] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Binda O, 2006, MOL CELL BIOL, V26, P1917, DOI 10.1128/MCB.26.5.1917-1931.2006; CAILLEAU R, 1978, IN VITRO CELL DEV B, V14, P911; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; Champine PJ, 2007, CLIN EXP METASTAS, V24, P551, DOI 10.1007/s10585-007-9092-8; Cicek M, 2005, CANCER RES, V65, P3586, DOI 10.1158/0008-5472.CAN-04-3139; Cicek M, 2004, CLIN EXP METASTAS, V21, P149, DOI 10.1023/B:CLIN.0000024729.19084.f0; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Eccles SA, 2007, LANCET, V369, P1742, DOI 10.1016/S0140-6736(07)60781-8; FATTAEY AR, 1993, ONCOGENE, V8, P3149; Hicks DG, 2006, CLIN CANCER RES, V12, P6702, DOI 10.1158/1078-0432.CCR-06-0635; Hurst DR, 2006, BIOCHEM BIOPH RES CO, V348, P1429, DOI 10.1016/j.bbrc.2006.08.005; Lai A, 1999, ONCOGENE, V18, P2091, DOI 10.1038/sj.onc.1202520; Laj A, 1999, MOL CELL BIOL, V19, P6632; Langley RR, 2007, ENDOCR REV, V28, P297, DOI 10.1210/er.2006-0027; Le Guezennec X, 2006, NUCLEIC ACIDS RES, V34, P3929, DOI 10.1093/nar/gkl537; Liu Y, 2006, MOL CELL BIOL, V26, P8683, DOI 10.1128/MCB.00940-06; Meehan WJ, 2004, J BIOL CHEM, V279, P1562, DOI 10.1074/jbc.M307969200; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Nash KT, 2007, JNCI-J NATL CANCER I, V99, P309, DOI 10.1093/jnci/djk053; Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101; Nikolaev AY, 2004, BIOCHEM BIOPH RES CO, V323, P1216, DOI 10.1016/j.bbrc.2004.08.227; Phadke PA, 2006, CLIN CANCER RES, V12, P1431, DOI 10.1158/1078-0432.CCR-05-1806; PHADKE PA, 2008, IN PRESS AM J PATHOL; Rae JM, 2007, BREAST CANCER RES TR, V104, P13, DOI 10.1007/s10549-006-9392-8; Rivera J, 2007, J PROTEOME RES, V6, P4006, DOI 10.1021/pr0703167; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Samant RS, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-6; Samant RS, 2001, CLIN EXP METASTAS, V18, P683, DOI 10.1023/A:1013124725690; Saunders MM, 2001, CANCER RES, V61, P1765; Sellappan S, 2004, CANCER RES, V64, P3479, DOI 10.1158/0008-5472.CAN-3299-2; Seraj MJ, 2000, CANCER RES, V60, P2764; Shevde LA, 2002, EXP CELL RES, V273, P229, DOI 10.1006/excr.2001.5452; Silverstein RA, 2005, CURR GENET, V47, P1, DOI 10.1007/s00294-004-0541-5; Vidal M, 1999, NUCLEIC ACIDS RES, V27, P919, DOI 10.1093/nar/27.4.919; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10321, DOI 10.1073/pnas.93.19.10321; Welch DR, 1997, CLIN EXP METASTAS, V15, P272, DOI 10.1023/A:1018477516367; Zhang S, 2006, INT J GYNECOL CANCER, V16, P522, DOI 10.1111/j.1525-1438.2006.00547.x	37	62	64	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7438	7444		10.1074/jbc.M709446200	http://dx.doi.org/10.1074/jbc.M709446200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18211900	Green Accepted, hybrid			2022-12-25	WOS:000253997900018
J	Akashiba, H; Ikegaya, Y; Nishiyama, N; Matsuki, N				Akashiba, Hiroki; Ikegaya, Yuji; Nishiyama, Nobuyoshi; Matsuki, Norio			Differential involvement of cell cycle reactivation between striatal and cortical neurons in cell death induced by 3-nitropropionic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALPAIN-I ACTIVATION; MITOCHONDRIAL TOXIN; HUNTINGTONS-DISEASE; HIPPOCAMPAL-NEURONS; PROMOTE SURVIVAL; PC12 CELLS; APOPTOSIS; DEGENERATION; INDUCTION; KINASES	Recent evidence suggests that unscheduled cell cycle activity leads to neuronal cell death. 3-Nitropropionic acid (3-NP) is an irreversible inhibitor of succinate dehydrogenase and induces cell death in both striatum and cerebral cortex. Here we analyzed the involvement of aberrant cell cycle progression in 3-NP-induced cell death in these brain regions. 3-NP reduced the level of cyclin-dependent kinase inhibitor p27 in striatum but not in cerebral cortex. 3-NP also induced phosphorylation of retinoblastoma protein, a marker of cell cycle progression at late G(1) phase, only in striatum. Pharmacological experiments revealed that cyclin-dependent kinase activity and N-methyl-D-aspartate (NMDA) receptor were cooperatively involved in cell death by 3-NP in striatal neurons, whereas only NMDA receptor was involved in 3-NP-induced neurotoxicity in cortical neurons. Death of striatal neurons was preceded by elevation of somatic Ca2+ and activation of calpain, a Ca2+-dependent protease. Both striatal p27 down-regulation and cell death provoked by 3-NP were dependent on calpain activity. Moreover, transfection of p27 small interfering RNA reduced striatal cell viability. In cortical neurons, however, there was no change in somatic Ca2+ and calpain activity by 3-NP, and calpain inhibitors were not protective. These results suggest that 3-NP induces aberrant cell cycle progression and neuronal cell death via p27 down-regulation by calpain in striatum but not in the cerebral cortex. This is the first report for differential involvement of cell cycle reactivation in different brain regions and lightens the mechanism for region-selective vulnerability in human disease, including Huntington disease.	[Akashiba, Hiroki; Ikegaya, Yuji; Nishiyama, Nobuyoshi; Matsuki, Norio] Univ Tokyo, Grad Sch Pharmaceut Sci, Chem Pharmacol Lab, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Nishiyama, N (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Chem Pharmacol Lab, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	nisiyama@mol.f.u-tokyo.ac.jp		Ikegaya, Yuji/0000-0003-2260-8191				Abe K, 2000, NEUROSCI RES, V38, P325, DOI 10.1016/S0168-0102(00)00188-7; Adamec E, 1998, MOL BRAIN RES, V54, P35, DOI 10.1016/S0169-328X(97)00304-5; Akashiba H, 2006, CELL MOL LIFE SCI, V63, P2397, DOI 10.1007/s00018-006-6194-4; Akashiba H, 2006, J NEUROCHEM, V99, P733, DOI 10.1111/j.1471-4159.2006.04100.x; BEAL MF, 1992, ANN NEUROL, V31, P119, DOI 10.1002/ana.410310202; BEAL MF, 1993, J NEUROSCI, V13, P4181; Becker EBE, 2004, PROG NEUROBIOL, V72, P1, DOI 10.1016/j.pneurobio.2003.12.005; BEHRENS MI, 1995, NEUROREPORT, V6, P545, DOI 10.1097/00001756-199502000-00034; Benchoua A, 2006, MOL BIOL CELL, V17, P1652, DOI 10.1091/mbc.E05-07-0607; Bizat N, 2005, NEUROPHARMACOLOGY, V49, P695, DOI 10.1016/j.neuropharm.2005.04.030; Bizat N, 2003, J NEUROSCI, V23, P5020; Bogush A, 2007, J BIOL CHEM, V282, P7352, DOI 10.1074/jbc.M606508200; BORLONGAN CV, 1995, BRAIN RES BULL, V36, P549, DOI 10.1016/0361-9230(94)00242-S; Brecht S, 2001, MOL BRAIN RES, V94, P25, DOI 10.1016/S0006-8993(01)02767-6; Brouillet E, 2005, J NEUROCHEM, V95, P1521, DOI 10.1111/j.1471-4159.2005.03515.x; Brouillet E, 1998, J NEUROCHEM, V70, P794; BROUILLET E, 1993, J NEUROCHEM, V60, P356, DOI 10.1111/j.1471-4159.1993.tb05859.x; BROUILLET E, 1995, P NATL ACAD SCI USA, V92, P7105, DOI 10.1073/pnas.92.15.7105; Browne SE, 1997, ANN NEUROL, V41, P646, DOI 10.1002/ana.410410514; Brustovetsky N, 2003, J NEUROSCI, V23, P4858; Cepeda C, 2001, J NEUROSCI RES, V66, P525, DOI 10.1002/jnr.1244; Copani A, 2001, TRENDS NEUROSCI, V24, P25, DOI 10.1016/S0166-2236(00)01663-5; Farinelli SE, 1996, J NEUROSCI, V16, P1150, DOI 10.1523/jneurosci.16-03-01150.1996; Fink SL, 1996, EXP NEUROL, V138, P298, DOI 10.1006/exnr.1996.0068; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; Gafni J, 2002, J NEUROSCI, V22, P4842, DOI 10.1523/JNEUROSCI.22-12-04842.2002; Galas MC, 2004, NEUROBIOL DIS, V15, P152, DOI 10.1016/j.nbd.2003.09.013; Garcia M, 2002, J NEUROSCI, V22, P2174, DOI 10.1523/JNEUROSCI.22-06-02174.2002; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; GOULD DH, 1985, TOXICOL LETT, V27, P83, DOI 10.1016/0378-4274(85)90123-7; GOULD DH, 1982, NEUROPATH APPL NEURO, V8, P377, DOI 10.1111/j.1365-2990.1982.tb00306.x; Gu M, 1996, ANN NEUROL, V39, P385, DOI 10.1002/ana.410390317; Guyot MC, 1997, NEUROSCIENCE, V79, P45, DOI 10.1016/S0306-4522(96)00602-1; HAMAKUBO T, 1986, J NEUROSCI, V6, P3103, DOI 10.1523/jneurosci.06-11-03103.1986; Ino H, 2001, J NEUROSCI, V21, P6086, DOI 10.1523/JNEUROSCI.21-16-06086.2001; Jacquard C, 2006, FASEB J, V20, P1021, DOI 10.1096/fj.05-5085fje; Kim GW, 2000, J CEREBR BLOOD F MET, V20, P119, DOI 10.1097/00004647-200001000-00016; Liu DX, 2001, CELL TISSUE RES, V305, P217, DOI 10.1007/s004410100396; Nasr P, 2003, NEUROCHEM INT, V43, P89, DOI 10.1016/S0197-0186(02)00229-2; Okuda S, 1996, P NATL ACAD SCI USA, V93, P12553, DOI 10.1073/pnas.93.22.12553; Ouimet CC, 1998, BRAIN RES, V808, P8, DOI 10.1016/S0006-8993(98)00724-0; Padmanabhan J, 1999, J NEUROSCI, V19, P8747, DOI 10.1523/JNEUROSCI.19-20-08747.1999; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pang Z, 1997, J NEUROSCI, V17, P3064; Pang Z, 2003, J NEUROPATH EXP NEUR, V62, P633, DOI 10.1093/jnen/62.6.633; Park DS, 2000, NEUROBIOL AGING, V21, P771, DOI 10.1016/S0197-4580(00)00220-7; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Park DS, 1997, J NEUROSCI, V17, P8975; Park DS, 1996, J BIOL CHEM, V271, P8161, DOI 10.1074/jbc.271.14.8161; Rashidian J, 2005, P NATL ACAD SCI USA, V102, P14080, DOI 10.1073/pnas.0500099102; Rideout HJ, 2003, J NEUROSCI, V23, P1237, DOI 10.1523/JNEUROSCI.23-04-01237.2003; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; Sasaki T, 2007, J NEUROSCI, V27, P517, DOI 10.1523/JNEUROSCI.4514-06.2007; Sato K, 2001, BIOL CHEM, V382, P743, DOI 10.1515/BC.2001.090; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SIMAN R, 1989, J NEUROSCI, V9, P1579; Stefanis L, 1997, CURR OPIN NEUROL, V10, P299, DOI 10.1097/00019052-199708000-00004; Sugino T, 2000, NEUROSCI LETT, V278, P101, DOI 10.1016/S0304-3940(99)00906-4; Tenneti L, 2000, J NEUROCHEM, V74, P134, DOI 10.1046/j.1471-4159.2000.0740134.x; Timsit S, 1999, EUR J NEUROSCI, V11, P263, DOI 10.1046/j.1460-9568.1999.00434.x; Verdaguer E, 2004, NEUROCHEM INT, V44, P251, DOI 10.1016/S0197-0186(03)00147-5; Wen Y, 2005, FEBS LETT, V579, P4591, DOI 10.1016/j.febslet.2005.07.028; WULLNER U, 1994, J NEUROCHEM, V63, P1772	63	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2008	283	10					6594	6606		10.1074/jbc.M707730200	http://dx.doi.org/10.1074/jbc.M707730200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HM	18182390	hybrid			2022-12-25	WOS:000253779500065
J	Brascamp, JW; Knapen, THJ; Kanai, R; Noest, AJ; van Ee, R; van den Berg, AV				Brascamp, Jan W.; Knapen, Tomas H. J.; Kanai, Ryota; Noest, Andre J.; van Ee, Raymond; van den Berg, Albert V.			Multi-Timescale Perceptual History Resolves Visual Ambiguity	PLOS ONE			English	Article							NEURAL PLASTICITY; BINOCULAR-RIVALRY; CONTRAST GAIN; ADAPTATION; ATTENTION; DYNAMICS; DOMINANCE; CORTEX	When visual input is inconclusive, does previous experience aid the visual system in attaining an accurate perceptual interpretation? Prolonged viewing of a visually ambiguous stimulus causes perception to alternate between conflicting interpretations. When viewed intermittently, however, ambiguous stimuli tend to evoke the same percept on many consecutive presentations. This perceptual stabilization has been suggested to reflect persistence of the most recent percept throughout the blank that separates two presentations. Here we show that the memory trace that causes stabilization reflects not just the latest percept, but perception during a much longer period. That is, the choice between competing percepts at stimulus reappearance is determined by an elaborate history of prior perception. Specifically, we demonstrate a seconds-long influence of the latest percept, as well as a more persistent influence based on the relative proportion of dominance during a preceding period of at least one minute. In case short-term perceptual history and long-term perceptual history are opposed (because perception has recently switched after prolonged stabilization), the long-term influence recovers after the effect of the latest percept has worn off, indicating independence between time scales. We accommodate these results by adding two positive adaptation terms, one with a short time constant and one with a long time constant, to a standard model of perceptual switching.	[Brascamp, Jan W.; Noest, Andre J.; van den Berg, Albert V.] Univ Utrecht, Helmholtz Inst, Funct Neurobiol, Utrecht, Netherlands; [Knapen, Tomas H. J.; van Ee, Raymond] Univ Utrecht, Helmholtz Inst, Dept Phys, Utrecht, Netherlands; [Kanai, Ryota] CALTECH, Biol Div, Pasadena, CA USA	Utrecht University; Utrecht University; California Institute of Technology	Brascamp, JW (corresponding author), Univ Utrecht, Helmholtz Inst, Funct Neurobiol, Utrecht, Netherlands.	j.w.brascamp@uu.nl; r.vanee@phys.uu.nl	Kanai, Ryota/A-1191-2007; Knapen, Tomas/H-4431-2019; van den Berg, Albert/G-3108-2012; van Ee, Raymond/C-4881-2013; Brascamp, Jan/W-5294-2018	Knapen, Tomas/0000-0001-5863-8689; Kanai, Ryota/0000-0002-0186-2687; van den Berg, Albert Victor/0000-0002-1543-5408; van Ee, Raymond/0000-0002-1134-8665				ALBRECHT DG, 1984, J PHYSIOL-LONDON, V347, P713, DOI 10.1113/jphysiol.1984.sp015092; BONDS AB, 1991, VISUAL NEUROSCI, V6, P239, DOI 10.1017/S0952523800006258; Brascamp JW, 2007, J VISION, V7, DOI 10.1167/7.12.12; Carter O, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000343; Chen XC, 2004, CURR BIOL, V14, P1013, DOI 10.1016/j.cub.2004.05.042; Dorris MC, 2000, J NEUROSCI, V20; Drew PJ, 2006, J NEUROPHYSIOL, V96, P826, DOI 10.1152/jn.00134.2006; Ernst MO, 2004, TRENDS COGN SCI, V8, P162, DOI 10.1016/j.tics.2004.02.002; Ernst MO, 2000, NAT NEUROSCI, V3, P69, DOI 10.1038/71140; Gilboa G, 2005, J NEUROSCI, V25, P6479, DOI 10.1523/JNEUROSCI.0763-05.2005; Jiang Y, 1998, PERCEPT PSYCHOPHYS, V60, P275, DOI 10.3758/BF03206036; Kanai R, 2005, VISION RES, V45, P3109, DOI 10.1016/j.visres.2005.05.014; Kristjansson A, 2006, VIS COGN, V13, P324, DOI 10.1080/13506280544000039; Leopold DA, 1999, TRENDS COGN SCI, V3, P254, DOI 10.1016/S1364-6613(99)01332-7; Leopold DA, 2002, NAT NEUROSCI, V5, P605, DOI 10.1038/nn0602-851; Maier A, 2003, CURR BIOL, V13, P1076, DOI 10.1016/S0960-9822(03)00414-7; Maljkovic V, 2000, VIS COGN, V7, P571, DOI 10.1080/135062800407202; Maloney LT, 2005, P NATL ACAD SCI USA, V102, P3164, DOI 10.1073/pnas.0407157102; McPeek RM, 1999, VISION RES, V39, P1555, DOI 10.1016/S0042-6989(98)00228-4; Mitchell JF, 2004, NATURE, V429, P410, DOI 10.1038/nature02584; Muller JR, 1999, SCIENCE, V285, P1405, DOI 10.1126/science.285.5432.1405; Noest AJ, 2007, J VISION, V7, DOI 10.1167/7.8.10; OHZAWA I, 1985, J NEUROPHYSIOL, V54, P651, DOI 10.1152/jn.1985.54.3.651; ORBACH J, 1963, Percept Mot Skills, V17, P439; PASTUKHOV A, 2007, J VIS, V7, P367, DOI DOI 10.1167/7.9.367; Pearson J, 2005, VISION RES, V45, P707, DOI 10.1016/j.visres.2004.09.040; ROSE D, 1982, PERCEPTION, V11, P505, DOI 10.1068/p110505; Ulanovsky N, 2004, J NEUROSCI, V24, P10440, DOI 10.1523/JNEUROSCI.1905-04.2004; Wilson HR, 2007, VISION RES, V47, P2741, DOI 10.1016/j.visres.2007.07.007; WOLFE JM, 1984, VISION RES, V24, P471, DOI 10.1016/0042-6989(84)90044-0	30	78	79	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2008	3	1							e1497	10.1371/journal.pone.0001497	http://dx.doi.org/10.1371/journal.pone.0001497			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	366SR	18231584	Green Published, gold, Green Submitted, Green Accepted			2022-12-25	WOS:000260504200010
J	Khalil, AM; Faghihi, MA; Modarresi, F; Brothers, SP; Wahlestedt, C				Khalil, Ahmad M.; Faghihi, Mohammad Ali; Modarresi, Farzaneh; Brothers, Shaun P.; Wahlestedt, Claes			A Novel RNA Transcript with Antiapoptotic Function Is Silenced in Fragile X Syndrome	PLOS ONE			English	Article								Several genome-wide transcriptomics efforts have shown that a large percentage of the mammalian genome is transcribed into RNAs, however, only a small percentage (1-2%) of these RNAs is translated into proteins. Currently there is an intense interest in characterizing the function of the different classes of noncoding RNAs and their relevance to human disease. Using genomic approaches we discovered FMR4, a primate-specific noncoding RNA transcript (2.4 kb) that resides upstream and likely shares a bidirectional promoter with FMR1. FMR4 is a product of RNA polymerase II and has a similar half-life to FMR1. The CGG expansion in the 5' UTR of FMR1 appears to affect transcription in both directions as we found FMR4, similar to FMR1, to be silenced in fragile X patients and up-regulated in premutation carriers. Knockdown of FMR4 by several siRNAs did not affect FMR1 expression, nor vice versa, suggesting that FMR4 is not a direct regulatory transcript for FMR1. However, FMR4 markedly affected human cell proliferation in vitro; siRNAs knockdown of FMR4 resulted in alterations in the cell cycle and increased apoptosis, while the overexpression of FMR4 caused an increase in cell proliferation. Collectively, our results demonstrate an antiapoptotic function of FMR4 and provide evidence that a well-studied genomic locus can show unexpected functional complexity. It cannot be excluded that altered FMR4 expression might contribute to aspects of the clinical presentation of fragile X syndrome and/or related disorders.	[Khalil, Ahmad M.; Faghihi, Mohammad Ali; Modarresi, Farzaneh; Brothers, Shaun P.; Wahlestedt, Claes] Scripps Res Inst, MIND, Jupiter, FL USA	Scripps Research Institute	Wahlestedt, C (corresponding author), Scripps Res Inst, MIND, Jupiter, FL USA.	clawah@scripps.edu	Faghihi, Mohammad Ali/AAD-7159-2020; Faghihi, Mohammad Ali/AAH-3139-2019; Brothers, Shaun/G-8690-2012	Faghihi, Mohammad Ali/0000-0002-8330-9067; Brothers, Shaun/0000-0003-2184-4037	Conquer Fragile X Foundation; Scripps Research Institute	Conquer Fragile X Foundation; Scripps Research Institute	Conquer Fragile X Foundation and the Scripps Research Institute have provided funding.	Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874; Carmell MA, 2007, DEV CELL, V12, P503, DOI 10.1016/j.devcel.2007.03.001; Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014; Cheng J, 2005, SCIENCE, V308, P1149, DOI 10.1126/science.1108625; Chureau C, 2002, GENOME RES, V12, P894, DOI 10.1101/gr.152902; Davidow LS, 2007, CHROMOSOME RES, V15, P137, DOI 10.1007/s10577-007-1121-6; Engstrom PG, 2006, PLOS GENET, V2, P564, DOI 10.1371/journal.pgen.0020047; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Garber K, 2006, CURR OPIN GENET DEV, V16, P270, DOI 10.1016/j.gde.2006.04.010; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; HINDS HL, 1993, NAT GENET, V3, P36, DOI 10.1038/ng0193-36; Hore TA, 2007, CHROMOSOME RES, V15, P147, DOI 10.1007/s10577-007-1119-0; Houwing S, 2007, CELL, V129, P69, DOI 10.1016/j.cell.2007.03.026; IKEDA S, 2007, PHYSL GENOMICS; Katayama S, 2005, SCIENCE, V309, P1564, DOI 10.1126/science.1112009; LADD PD, 2007, HUM MOL GENET; Mehler MF, 2007, PHYSIOL REV, V87, P799, DOI 10.1152/physrev.00036.2006; Migeon BR, 2002, CYTOGENET GENOME RES, V99, P8, DOI 10.1159/000071568; Nesterova TB, 2001, GENOME RES, V11, P833, DOI 10.1101/gr.174901; Okamoto I, 2004, SCIENCE, V303, P644, DOI 10.1126/science.1092727; Oostra BA, 2003, HUM MOL GENET, V12, pR249, DOI 10.1093/hmg/ddg298; Oostra BA, 2001, CLIN GENET, V60, P399, DOI 10.1034/j.1399-0004.2001.600601.x; Pang KC, 2006, TRENDS GENET, V22, P1, DOI 10.1016/j.tig.2005.10.003; Ponjavic J, 2007, GENOME RES, V17, P556, DOI 10.1101/gr.6036807; Prasanth KV, 2005, CELL, V123, P249, DOI 10.1016/j.cell.2005.08.033; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; Scacheri PC, 2004, P NATL ACAD SCI USA, V101, P1892, DOI 10.1073/pnas.0308698100; SREERAM N, 1989, BRIT HEART J, V61, P289; Tassone F, 2000, AM J HUM GENET, V66, P6, DOI 10.1086/302720; Tassone F, 2001, J MED GENET, V38, P453, DOI 10.1136/jmg.38.7.453; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; Wahlestedt C, 2006, DRUG DISCOV TODAY, V11, P503, DOI 10.1016/j.drudis.2006.04.013; WALDSTEIN G, 1988, AM J MED GENET, V30, P83, DOI 10.1002/ajmg.1320300107	34	144	150	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2008	3	1							e1486	10.1371/journal.pone.0001486	http://dx.doi.org/10.1371/journal.pone.0001486			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SO	18213394	gold, Green Published, Green Submitted			2022-12-25	WOS:000260503900031
J	Pezeron, G; Lambert, G; Dickmeis, T; Strahle, U; Rosa, FM; Mourrain, P				Pezeron, Guillaume; Lambert, Guillaume; Dickmeis, Thomas; Straehle, Uwe; Rosa, Frederic M.; Mourrain, Philippe			Rasl11b Knock Down in Zebrafish Suppresses One-Eyed-Pinhead Mutant Phenotype	PLOS ONE			English	Article							ENDODERM FORMATION; ACTIVIN RECEPTOR; AXIS FORMATION; NODAL SIGNALS; RAS PROTEINS; TARAM-A; GENE; PATHWAY; CRIPTO; IDENTIFICATION	The EGF-CFC factor Oep/Cripto1/Frl1 has been implicated in embryogenesis and several human cancers. During vertebrate development, Oep/Cripto1/Frl1 has been shown to act as an essential coreceptor in the TGF beta/Nodal pathway, which is crucial for germ layer formation. Although studies in cell cultures suggest that Oep/Cripto1/Frl1 is also implicated in other pathways, in vivo it is solely regarded as a Nodal coreceptor. We have found that Rasl11b, a small GTPase belonging to a Ras subfamily of putative tumor suppressor genes, modulates Oep function in zebrafish independently of the Nodal pathway. rasl11b down regulation partially rescues endodermal and prechordal plate defects of zygotic oep(-/-) mutants (Zoep). Rasl11b inhibitory action was only observed in oep-deficient backgrounds, suggesting that normal oep expression prevents Rasl11b function. Surprisingly, rasl11b down regulation does not rescue mesendodermal defects in other Nodal pathway mutants, nor does it influence the phosphorylation state of the downstream effector Smad2. Thus, Rasl11b modifies the effect of Oep on mesendoderm development independently of the main known Oep output: the Nodal signaling pathway. This data suggests a new branch of Oep signaling that has implications for germ layer development, as well as for studies of Oep/Frl1/Cripto1 dysfunction, such as that found in tumors.	[Pezeron, Guillaume; Lambert, Guillaume; Rosa, Frederic M.] INSERM, U784, Paris, France; [Pezeron, Guillaume; Lambert, Guillaume; Rosa, Frederic M.; Mourrain, Philippe] Ecole Normale Superieure, Paris, France; [Dickmeis, Thomas] Max Planck Inst Dev Biol, Tubingen, Germany; [Straehle, Uwe] Inst Toxicol & Genetics, Forschungszentrum Karlsruhe, Karlsruhe, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Max Planck Society; Helmholtz Association; Karlsruhe Institute of Technology	Mourrain, P (corresponding author), INSERM, U784, Paris, France.	mourrain@wotan.ens.fr	Straehle, Uwe/K-7054-2013; Mourrain, Philippe/N-4671-2017; Rosa, Frederic/L-5990-2017; PEZERON, Guillaume/A-6291-2009; Dickmeis, Thomas/H-1355-2013; PEZERON, Guillaume/ABB-8395-2021	Pezeron, Guillaume/0000-0003-1395-6397	Ministere de l'Enseignement Superieur et de la Recherche fellowship; La ligue Nationale Contre le Cancer; EU FP6 program [ZF-MODELS]; Association pour le Recherche contre le Cancer	Ministere de l'Enseignement Superieur et de la Recherche fellowship; La ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); EU FP6 program(European Commission); Association pour le Recherche contre le Cancer	GP was supported by a fellowship from the Ministere de l'Enseignement Superieur et de la Recherche and La ligue Nationale Contre le Cancer. FR was supported by grants ZF-MODELS (EU FP6 program) and Association pour le Recherche contre le Cancer.	Alexander J, 1999, CURR BIOL, V9, P1147, DOI 10.1016/S0960-9822(00)80016-0; Aoki TO, 2002, DEV BIOL, V241, P273, DOI 10.1006/dbio.2001.0510; Aoki TO, 2002, DEVELOPMENT, V129, P275; Barradas M, 2002, EXP CELL RES, V273, P127, DOI 10.1006/excr.2001.5434; Bianco C, 2003, CANCER RES, V63, P1192; Bianco C, 2002, MOL CELL BIOL, V22, P2586, DOI 10.1128/MCB.22.8.2586-2597.2002; BRANDT R, 1994, J BIOL CHEM, V269, P17320; Cheng AMS, 2000, DEVELOPMENT, V127, P1049; Colicelli John, 2004, Sci STKE, V2004, pRE13, DOI 10.1126/stke.2502004re13; CONLON FL, 1994, DEVELOPMENT, V120, P1919; David NB, 2001, DEVELOPMENT, V128, P3937; De Santis ML, 1997, CELL GROWTH DIFFER, V8, P1257; Dickmeis T, 2001, DEV DYNAM, V222, P571, DOI 10.1002/dvdy.1220; Dickmeis T, 2001, GENE DEV, V15, P1487, DOI 10.1101/gad.196901; Ding JX, 1998, NATURE, V395, P702, DOI 10.1038/27215; Draper BW, 2001, GENESIS, V30, P154, DOI 10.1002/gene.1053; Etard C, 2005, DEV DYNAM, V234, P1016, DOI 10.1002/dvdy.20592; Feldman B, 1998, NATURE, V395, P181, DOI 10.1038/26013; Finlin BS, 2001, J BIOL CHEM, V276, P42259, DOI 10.1074/jbc.M105888200; Gray PC, 2000, J BIOL CHEM, V275, P3206, DOI 10.1074/jbc.275.5.3206; Gritsman K, 2000, DEVELOPMENT, V127, P921; Gritsman K, 1999, CELL, V97, P121, DOI 10.1016/S0092-8674(00)80720-5; Halpern ME, 1997, DEV BIOL, V187, P154, DOI 10.1006/dbio.1997.8605; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; HAUPTMANN G, 1994, TRENDS GENET, V10, P266, DOI 10.1016/0168-9525(90)90008-T; Kannan S, 1997, J BIOL CHEM, V272, P3330, DOI 10.1074/jbc.272.6.3330; Key MD, 2006, METHOD ENZYMOL, V407, P513, DOI 10.1016/S0076-6879(05)07041-2; Kiecker C, 2000, MECH DEVELOP, V94, P37, DOI 10.1016/S0925-4773(00)00329-4; Kikuchi Y, 2000, GENE DEV, V14, P1279; KINOSHITA N, 1995, CELL, V83, P621, DOI 10.1016/0092-8674(95)90102-7; Louro R, 2004, BIOCHEM BIOPH RES CO, V316, P618, DOI 10.1016/j.bbrc.2004.02.091; Maroon H, 2002, DEVELOPMENT, V129, P2099; Melby AE, 1996, DEVELOPMENT, V122, P2225; Meno C, 1999, MOL CELL, V4, P287, DOI 10.1016/S1097-2765(00)80331-7; Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092-8674(00)81472-5; Minchiotti G, 2000, MECH DEVELOP, V90, P133, DOI 10.1016/S0925-4773(99)00235-X; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Nieto M, 2007, ONCOGENE, V26, P1673, DOI 10.1038/sj.onc.1209978; Normanno N, 2004, J CELL PHYSIOL, V198, P31, DOI 10.1002/jcp.10375; Norton WH, 2005, DEVELOPMENT, V132, P645, DOI 10.1242/dev.01611; Osada SI, 1999, DEVELOPMENT, V126, P3229; Peyrieras N, 1998, CURR BIOL, V8, P783, DOI 10.1016/S0960-9822(98)70303-3; Poulain M, 2002, DEVELOPMENT, V129, P4901; Prior IA, 2003, J CELL BIOL, V160, P165, DOI 10.1083/jcb.200209091; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Rebagliati MR, 1998, P NATL ACAD SCI USA, V95, P9932, DOI 10.1073/pnas.95.17.9932; Rebagliati MR, 1998, DEV BIOL, V199, P261, DOI 10.1006/dbio.1998.8935; Reissmann E, 2001, GENE DEV, V15, P2010, DOI 10.1101/gad.201801; Reiter JF, 1999, GENE DEV, V13, P2983, DOI 10.1101/gad.13.22.2983; Renucci A, 1996, DEVELOPMENT, V122, P3735; ROSA FM, 2002, SCI STKE, pPE47; Sampath K, 1998, NATURE, V395, P185, DOI 10.1038/26020; Schier AF, 2005, ANNU REV GENET, V39, P561, DOI 10.1146/annurev.genet.37.110801.143752; Schier AF, 1997, DEVELOPMENT, V124, P327; SEKIYA T, 1984, P NATL ACAD SCI-BIOL, V81, P4771, DOI 10.1073/pnas.81.15.4771; Shen MM, 1997, DEVELOPMENT, V124, P429; Silva J, 2006, MUTAT RES-FUND MOL M, V594, P78, DOI 10.1016/j.mrfmmm.2005.07.017; Strahle U, 1997, Genes Funct, V1, P131; Strizzi L, 2005, ONCOGENE, V24, P5731, DOI 10.1038/sj.onc.1208918; Tao QH, 2005, CELL, V120, P857, DOI 10.1016/j.cell.2005.01.013; Thisse C, 1999, DEVELOPMENT, V126, P229; Tian T, 2006, CELL MOL LIFE SCI, V63, P672, DOI 10.1007/s00018-005-5503-7; Warga RA, 2003, DEV BIOL, V261, P391, DOI 10.1016/S0012-1606(03)00328-2; Warga RM, 1999, DEVELOPMENT, V126, P827; Willis SA, 1996, MOL ENDOCRINOL, V10, P367, DOI 10.1210/me.10.4.367; Xu CH, 1999, DEVELOPMENT, V126, P483; Yan YT, 2002, MOL CELL BIOL, V22, P4439, DOI 10.1128/MCB.22.13.4439-4449.2002; Yeo CY, 2001, MOL CELL, V7, P949, DOI 10.1016/S1097-2765(01)00249-0; Zhang JJ, 1998, CELL, V92, P241, DOI 10.1016/S0092-8674(00)80918-6; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	70	15	15	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2008	3	1							e1434	10.1371/journal.pone.0001434	http://dx.doi.org/10.1371/journal.pone.0001434			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SN	18197245	gold, Green Submitted, Green Published			2022-12-25	WOS:000260503800006
J	Watt, S; Mata, J; Lopez-Maury, L; Marguerat, S; Burns, G; Bahler, J				Watt, Stephen; Mata, Juan; Lopez-Maury, Luis; Marguerat, Samuel; Burns, Gavin; Bahler, Jurg			urg1: A Uracil-Regulatable Promoter System for Fission Yeast with Short Induction and Repression Times	PLOS ONE			English	Article								Background. The fission yeast Schizosaccharomyces pombe is a popular genetic model organism with powerful experimental tools. The thiamine-regulatable nmt1 promoter and derivatives, which take > 15 hours for full induction, are most commonly used for controlled expression of ectopic genes. Given the short cell cycle of fission yeast, however, a promoter system that can be rapidly regulated, similar to the GAL system for budding yeast, would provide a key advantage for many experiments. Methodology/Principal Findings. We used S. pombe microarrays to identify three neighbouring genes (urg1, urg2, and urg3) whose transcript levels rapidly and strongly increased in response to uracil, a condition which otherwise had little effect on global gene expression. We cloned the promoter of urg1(uracil-regulatable gene) to create several PCR-based gene targeting modules for replacing native promoters with the urg1 promoter (P urg1) in the normal chromosomal locations of genes of interest. The kanMX6 and natMX6 markers allow selection under urg1 induced and repressed conditions, respectively. Some modules also allow N-terminal tagging of gene products placed under urg1 control. Using pom1 as a proof-of-principle, we observed a maximal increase of P urg1-pom1 transcripts after uracil addition within less than 30 minutes, and a similarly rapid decrease after uracil removal. The induced and repressed transcriptional states remained stable over 24-hour periods. RT-PCR comparisons showed that both induced and repressed P urg1- pom1 transcript levels were lower than corresponding P3 nmt1-pom1 levels (wild-type nmt1 promoter) but higher than P81 nmt1-pom1 levels (weak nmt1 derivative). Conclusions/Significance. We exploited the urg1 promoter system to rapidly induce pom1 expression at defined cell-cycle stages, showing that ectopic pom1 expression leads to cell branching in G2-phase but much less so in G1-phase. The high temporal resolution provided by the urg1 promoter should facilitate experimental design and improve the genetic toolbox for the fission yeast community.	[Watt, Stephen; Mata, Juan; Lopez-Maury, Luis; Marguerat, Samuel; Burns, Gavin] Wellcome Trust Sanger Inst, Canc Res United Kingdom Fiss Yeast Funct Genom Gr, Cambridge, England	Wellcome Trust Sanger Institute	Bahler, J (corresponding author), Wellcome Trust Sanger Inst, Canc Res United Kingdom Fiss Yeast Funct Genom Gr, Cambridge, England.	jurg@sanger.ac.uk	Marguerat, Samuel/AAY-3792-2020; Bahler, Jurg/B-4572-2009; Lopez-Maury, Luis/B-3715-2015	Marguerat, Samuel/0000-0002-2402-3165; Bahler, Jurg/0000-0003-4036-1532; Lopez-Maury, Luis/0000-0002-3510-0621; Mata, Juan/0000-0002-5514-3653	Cancer Research UK [C9546/A6517]	Cancer Research UK(Cancer Research UK)	This work was funded by Cancer Research UK [CUK] Grant No. C9546/A6517. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bahler J, 1998, GENE DEV, V12, P1356, DOI 10.1101/gad.12.9.1356; Bahler J, 2001, EMBO J, V20, P1064, DOI 10.1093/emboj/20.5.1064; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Bakheet T, 2006, NUCLEIC ACIDS RES, V34, pD111, DOI 10.1093/nar/gkj052; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; Bellemare DR, 2001, GENE, V273, P191, DOI 10.1016/S0378-1119(01)00591-1; CHEN D, 2008, MOL BIOL CE IN PRESS; Chen DR, 2003, MOL BIOL CELL, V14, P214, DOI 10.1091/mbc.E02-08-0499; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Erler A, 2006, YEAST, V23, P813, DOI 10.1002/yea.1396; FARYAR K, 1992, CURR GENET, V21, P345, DOI 10.1007/BF00351693; FORSBURG SL, 1993, NUCLEIC ACIDS RES, V21, P2955, DOI 10.1093/nar/21.12.2955; Fujita Y, 2006, FEMS YEAST RES, V6, P883, DOI 10.1111/j.1567-1364.2006.00093.x; Garneau NL, 2007, NAT REV MOL CELL BIO, V8, P113, DOI 10.1038/nrm2104; Hansen KR, 2005, MOL CELL BIOL, V25, P590, DOI 10.1128/MCB.25.2.590-601.2005; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; Hentges P, 2005, YEAST, V22, P1013, DOI 10.1002/yea.1291; HOFFMAN CS, 1989, GENE, V84, P473, DOI 10.1016/0378-1119(89)90523-4; Iacovoni JS, 1999, GENE, V232, P53, DOI 10.1016/S0378-1119(99)00116-X; Jenkins CCL, 2005, EUKARYOT CELL, V4, P1840, DOI 10.1128/EC.4.11.1840-1850.2005; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KERN L, 1990, GENE, V88, P149, DOI 10.1016/0378-1119(90)90026-N; Kumar R, 2006, YEAST, V23, P55, DOI 10.1002/yea.1343; Lackner DH, 2007, MOL CELL, V26, P145, DOI 10.1016/j.molcel.2007.03.002; Lyne R, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-27; Marguerat S, 2006, YEAST, V23, P261, DOI 10.1002/yea.1351; Mata J, 2005, TRENDS BIOCHEM SCI, V30, P506, DOI 10.1016/j.tibs.2005.07.005; Mata J, 2003, GENOME RES, V13, P2686, DOI 10.1101/gr.1420903; Mata J, 2002, NAT GENET, V32, P143, DOI 10.1038/ng951; Mata J, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r217; Mata J, 2006, P NATL ACAD SCI USA, V103, P15517, DOI 10.1073/pnas.0603403103; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Penkett CJ, 2006, YEAST, V23, P921, DOI 10.1002/yea.1422; Ren J, 2005, J BIOL CHEM, V280, P36912, DOI 10.1074/jbc.M507725200; Rozen S, 2000, Methods Mol Biol, V132, P365; Rustici G, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r73; Siam R, 2004, METHODS, V33, P189, DOI 10.1016/j.ymeth.2003.11.013	39	45	53	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2008	3	1							e1428	10.1371/journal.pone.0001428	http://dx.doi.org/10.1371/journal.pone.0001428			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SN	18197241	gold, Green Published, Green Submitted			2022-12-25	WOS:000260503800002
J	Dietemann, V; Zheng, HQ; Hepburn, C; Hepburn, HR; Jin, SH; Crewe, RM; Radloff, SE; Hu, FL; Pirk, CWW				Dietemann, Vincent; Zheng, Huo-Qing; Hepburn, Colleen; Hepburn, H. Randall; Jin, Shui-Hua; Crewe, Robin M.; Radloff, Sarah E.; Hu, Fu-Liang; Pirk, Christian W. W.			Self Assessment in Insects: Honeybee Queens Know Their Own Strength	PLOS ONE			English	Article							APIS-MELLIFERA; SHELL WARS; EVOLUTION; BEHAVIOR; EXPERIENCE; DECISIONS; DISPLAYS; COMMUNICATION; ELIMINATION; CONFLICT	Contests mediate access to reproductive opportunities in almost all species of animals. An important aspect of the evolution of contests is the reduction of the costs incurred during intra-specific encounters to a minimum. However, escalated fights are commonly lethal in some species like the honeybee, Apis mellifera. By experimentally reducing honeybee queens' fighting abilities, we demonstrate that they refrain from engaging in lethal contests that typically characterize their reproductive dominance behavior and coexist peacefully within a colony. This suggests that weak queens exploit an alternative reproductive strategy and provides an explanation for rare occurrences of queen cohabitation in nature. Our results further indicate that self-assessment, but not mutual assessment of fighting ability occurs prior to and during the agonistic encounters.	[Zheng, Huo-Qing; Hu, Fu-Liang] Zhejiang Univ, Coll Anim Sci, Hangzhou 310003, Zhejiang, Peoples R China; [Dietemann, Vincent; Crewe, Robin M.; Pirk, Christian W. W.] Univ Pretoria, Dept Zool & Entomol, Pretoria, South Africa; [Hepburn, Colleen; Hepburn, H. Randall] Rhodes Univ, Dept Zool & Entomol, Grahamstown, South Africa; [Jin, Shui-Hua] Pinghu Breeding Apiary, Zhejiang, Peoples R China; [Radloff, Sarah E.] Rhodes Univ, Dept Stat, Grahamstown, South Africa	Zhejiang University; University of Pretoria; Rhodes University; Rhodes University	Hu, FL (corresponding author), Zhejiang Univ, Coll Anim Sci, Hangzhou 310003, Zhejiang, Peoples R China.	flhu@zju.edu.cn	Zheng, Huoqing/AAQ-3307-2021; Crewe, Robin M/B-3069-2009; Crewe, Robin/N-1973-2019; Pirk, Christian/E-4180-2010	Crewe, Robin M/0000-0003-4398-8250; Crewe, Robin/0000-0003-4398-8250; Pirk, Christian/0000-0001-6821-7044	University of Pretoria [postdoctoral fellowship]; South African National Research Foundation; National Natural Science Foundation of China [30371089]	University of Pretoria; South African National Research Foundation(National Research Foundation - South Africa); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	CWWP and VD were funded by a postdoctoral fellowship of the University of Pretoria, and the work was supported by a grant from the South African National Research Foundation, FH was funded by the National Natural Science Foundation of China (NSFC, No. 30371089). Funders had no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript.	ADAMS ES, 1990, ANIM BEHAV, V39, P706, DOI 10.1016/S0003-3472(05)80382-3; Archer J., 1988, BEHAV BIOL AGGRESSIO, DOI DOI 10.1046/J.1420-9101.1991.4030515.X; Burmeister SS, 2002, ANIM BEHAV, V64, P715, DOI 10.1006/anbe.2002.4012; BUTZ VM, 1994, J APICULT RES, V33, P87, DOI 10.1080/00218839.1994.11100855; Crowley PH, 2000, J THEOR BIOL, V204, P543, DOI 10.1006/jtbi.2000.2037; Dodson GN, 2001, J INSECT BEHAV, V14, P841, DOI 10.1023/A:1013045602493; DOWDS BM, 1983, BEHAVIOUR, V85, P1, DOI 10.1163/156853983X00011; DOWDS BM, 1985, ANIM BEHAV, V33, P649, DOI 10.1016/S0003-3472(85)80088-9; Eggert AK, 2000, ECOL ENTOMOL, V25, P262, DOI 10.1046/j.1365-2311.2000.00262.x; Elwood RW, 2006, ANIM BEHAV, V72, P853, DOI 10.1016/j.anbehav.2006.01.025; ENQUIST M, 1983, J THEOR BIOL, V102, P387, DOI 10.1016/0022-5193(83)90376-4; ENQUIST M, 1990, ANIM BEHAV, V39, P1, DOI 10.1016/S0003-3472(05)80721-3; Gilley DC, 2001, ETHOLOGY, V107, P601, DOI 10.1046/j.1439-0310.2001.00692.x; Gilley DC, 2005, APIDOLOGIE, V36, P461, DOI 10.1051/apido:2005033; Hughes M, 2000, BEHAV ECOL, V11, P614, DOI 10.1093/beheco/11.6.614; Huntingford F.A., 1987, ANIMAL CONFLICT; Jennings DJ, 2004, ANIM BEHAV, V68, P213, DOI 10.1016/j.anbehav.2003.11.005; Labra A, 2006, ETHOLOGY, V112, P993, DOI 10.1111/j.1439-0310.2006.01256.x; LINCOLN GA, 1972, J EXP ZOOL, V182, P233, DOI 10.1002/jez.1401820208; Maan ME, 2001, ANIM BEHAV, V62, P623, DOI 10.1006/anbe.2001.1819; Maynard Smith J., 1982, pi; MAYNARDSMITH J, 1976, ANIM BEHAV, V24, P159, DOI DOI 10.1016/S0003-3472(76)80110-8); MestertonGibbons M, 1996, J THEOR BIOL, V181, P65, DOI 10.1006/jtbi.1996.0115; Neat FC, 1998, ANIM BEHAV, V55, P875, DOI 10.1006/anbe.1997.0668; PARKER GA, 1974, J THEOR BIOL, V47, P223, DOI 10.1016/0022-5193(74)90111-8; Payne RJH, 1996, J THEOR BIOL, V183, P185, DOI 10.1006/jtbi.1996.0212; Payne RJH, 1998, ANIM BEHAV, V56, P651, DOI 10.1006/anbe.1998.0835; Pflugfelder J, 2003, APIDOLOGIE, V34, P249, DOI 10.1051/apido:2003016; Prenter J, 2006, ANIM BEHAV, V72, P861, DOI 10.1016/j.anbehav.2006.01.023; RIECHERT SE, 1978, BEHAV ECOL SOCIOBIOL, V3, P135, DOI 10.1007/BF00294986; Rutte C, 2006, TRENDS ECOL EVOL, V21, P16, DOI 10.1016/j.tree.2005.10.014; Schneider SS, 2001, ANIM BEHAV, V61, P1173, DOI 10.1006/anbe.2000.1689; Setchell JM, 2005, ETHOLOGY, V111, P25, DOI 10.1111/j.1439-0310.2004.01054.x; Slessor KN, 2005, J CHEM ECOL, V31, P2731, DOI 10.1007/s10886-005-7623-9; SMITH JM, 1974, J THEOR BIOL, V47, P209, DOI 10.1016/0022-5193(74)90110-6; Taylor PW, 2003, ANIM BEHAV, V65, P1195, DOI 10.1006/anbe.2003.2169; Tibbetts EA, 2004, NATURE, V432, P218, DOI 10.1038/nature02949; VISSCHER PK, 1993, J THEOR BIOL, V165, P191, DOI 10.1006/jtbi.1993.1185; Whitehouse MEA, 1997, ANIM BEHAV, V53, P913, DOI 10.1006/anbe.1996.0313; Winston, 1987, BIOL HONEYBEE; Wise SE, 1998, ANIM BEHAV, V55, P1707, DOI 10.1006/anbe.1997.0720	41	23	26	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2008	3	1							e1412	10.1371/journal.pone.0001412	http://dx.doi.org/10.1371/journal.pone.0001412			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366GT	18183293	Green Submitted, gold, Green Published			2022-12-25	WOS:000260469400009
J	Palermo, C; Hope, JC; Freyer, GA; Rao, H; Walworth, NC				Palermo, Carmela; Hope, Justin C.; Freyer, Greg A.; Rao, Hui; Walworth, Nancy C.			Importance of a C-Terminal Conserved Region of Chk1 for Checkpoint Function	PLOS ONE			English	Article							DNA-DAMAGE CHECKPOINT; XENOPUS EGG EXTRACTS; CELL-CYCLE ARREST; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; REPLICATION CHECKPOINT; KINASE CHK1; TOPOISOMERASE-I; PROTEIN-KINASE; S-PHASE	Background. The protein kinase Chk1 is an essential component of the DNA damage checkpoint pathway. Chk1 is phosphorylated and activated in the fission yeast Schizosaccharomyces pombe when cells are exposed to agents that damage DNA. Phosphorylation, kinase activation, and nuclear accumulation are events critical to the ability of Chk1 to induce a transient delay in cell cycle progression. The catalytic domain of Chk1 is well-conserved amongst all species, while there are only a few regions of homology within the C-terminus. A potential pseudosubstrate domain exists in the C-terminus of S. pombe Chk1, raising the possibility that the C-terminus acts to inhibit the catalytic domain through interaction of this domain with the substrate binding site. Methodology/Principal Findings. To evaluate this hypothesis, we characterized mutations in the pseudosubstrate region. Mutation of a conserved aspartic acid at position 469 to alanine or glycine compromises Chk1 function when the mutants are integrated as single copies, demonstrating that this domain of Chk1 is critical for function. Our data does not support, however, the hypothesis that the domain acts to inhibit Chk1 function as other mutations in the amino acids predicted to comprise the pseudosubstrate do not result in constitutive activation of the protein. When expressed in multi-copy, Chk1D469A remains non-functional. In contrast, multi-copy Chk1D469G confers cell survival and imposes a checkpoint delay in response to some, though not all forms of DNA damage. Conclusions/Significance. Thus, we conclude that this C-terminal region of Chk1 is important for checkpoint function and predict that a limiting factor capable of associating with Chk1D469G, but not Chk1D469A, interacts with Chk1 to elicit checkpoint activation in response to a subset of DNA lesions.	[Palermo, Carmela; Walworth, Nancy C.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA; [Palermo, Carmela; Rao, Hui; Walworth, Nancy C.] State Univ NJ, Rutgers, Grad Sch Biomed, UMDNJ, Joint Grad Prog Cell & Mol Pharmacol, Piscataway, NJ USA; [Hope, Justin C.; Freyer, Greg A.] Columbia Univ, Grad Prog Env Hlth Sci & Anat & Cell Biol, New York, NY USA; [Walworth, Nancy C.] Canc Inst NJ, New Brunswick, NJ USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Columbia University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Walworth, NC (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA.	walworna@umdnj.edu		Walworth, Nancy/0000-0001-5940-8236	NIH [GM53194]; National Institute of General Medical Science; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053194] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of General Medical Science(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Public Health Service Grant NIH GM53194 from the National Institute of General Medical Science.	Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Ahmed S, 2004, MOL CELL BIOL, V24, P3660, DOI 10.1128/MCB.24.9.3660-3669.2004; ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; Capasso H, 2002, J CELL SCI, V115, P4555, DOI 10.1242/jcs.00133; Chen L, 1999, GENE DEV, V13, P675, DOI 10.1101/gad.13.6.675; Chen P, 2000, CELL, V100, P681, DOI 10.1016/S0092-8674(00)80704-7; Chen ZH, 2006, INT J CANCER, V119, P2784, DOI 10.1002/ijc.22198; COTTAREL G, 1993, CURR GENET, V23, P547, DOI 10.1007/BF00312650; Dunaway S, 2004, METHODS, V33, P260, DOI 10.1016/j.ymeth.2003.11.022; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; Francesconi S, 2002, GENES CELLS, V7, P663, DOI 10.1046/j.1365-2443.2002.00552.x; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; HSIANG YH, 1989, CANCER RES, V49, P5077; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; Hutchins JRA, 2000, FEBS LETT, V466, P91, DOI 10.1016/S0014-5793(99)01763-9; Jackson JR, 2000, CANCER RES, V60, P566; Katsuragi Y, 2004, MOL BIOL CELL, V15, P1680, DOI 10.1091/mbc.E03-12-0874; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Latif C, 2004, J CELL SCI, V117, P3489, DOI 10.1242/jcs.01204; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Liu QH, 2000, GENE DEV, V14, P1448; Lopez-Girona A, 2001, P NATL ACAD SCI USA, V98, P11289, DOI 10.1073/pnas.191557598; MacDougall CA, 2007, GENE DEV, V21, P898, DOI 10.1101/gad.1522607; Martinho RG, 1998, EMBO J, V17, P7239, DOI 10.1093/emboj/17.24.7239; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; NASMYTH KA, 1977, CELL, V12, P1109, DOI 10.1016/0092-8674(77)90173-8; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; O'Neill T, 2002, J BIOL CHEM, V277, P16102, DOI 10.1074/jbc.M111705200; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; Oe T, 2001, DEV BIOL, V229, P250, DOI 10.1006/dbio.2000.9968; Onishi H, 1997, BIOCHEMISTRY-US, V36, P3767, DOI 10.1021/bi9630772; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Shann YJ, 2001, J BIOL CHEM, V276, P48863, DOI 10.1074/jbc.M108253200; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Wan S, 2001, CURR GENET, V38, P299, DOI 10.1007/s002940000172; Wan SH, 1999, YEAST, V15, P821, DOI 10.1002/(SICI)1097-0061(199907)15:10A<821::AID-YEA422>3.3.CO;2-R; Willson J, 1997, NUCLEIC ACIDS RES, V25, P2138, DOI 10.1093/nar/25.11.2138; Yoo HY, 2006, GENE DEV, V20, P772, DOI 10.1101/gad.1398806; Zachos G, 2007, DEV CELL, V12, P247, DOI 10.1016/j.devcel.2007.01.003; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	49	13	13	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2008	3	1							e1427	10.1371/journal.pone.0001427	http://dx.doi.org/10.1371/journal.pone.0001427			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366GT	18183307	Green Published, gold, Green Submitted			2022-12-25	WOS:000260469400023
J	Rolland, M; Heckerman, D; Deng, WJ; Rousseau, CM; Coovadia, H; Bishop, K; Goulder, PJR; Walker, BD; Brander, C; Mullins, JI				Rolland, Morgane; Heckerman, David; Deng, Wenjie; Rousseau, Christine M.; Coovadia, Hoosen; Bishop, Karen; Goulder, Philip J. R.; Walker, Bruce D.; Brander, Christian; Mullins, James I.			Broad and Gag-Biased HIV-1 Epitope Repertoires Are Associated with Lower Viral Loads	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL RESPONSES; LONG-TERM NONPROGRESSORS; DISEASE PROGRESSION; TYPE-1 INFECTION; HLA SUPERTYPE; CD8(+); AIDS; LYMPHOCYTES; PROTEINS	Background. HLA class-I alleles differ in their ability to control HIV replication through cell-mediated immune responses. No consistent associations have been found between the breadth of Cytotoxic T Lymphocytes (CTL) responses and the control of HIV-1, and it is unknown whether the size or distribution of the viral proteome-wide epitope repertoire, i.e., the intrinsic ability to present fewer, more or specific viral epitopes, could affect clinical markers of disease progression. Methodology/Principal Findings. We used an epitope prediction model to identify all epitope motifs in a set of 302 HIV-1 full-length proteomes according to each individual's HLA (Human Leukocyte Antigen) genotype. The epitope repertoire, i.e., the number of predicted epitopes per HIV-1 proteome, varied considerably between HLA alleles and thus among individual proteomes. In a subgroup of 270 chronically infected individuals, we found that lower viral loads and higher CD4 counts were associated with a larger predicted epitope repertoire. Additionally, in Gag and Rev only, more epitopes were restricted by alleles associated with low viral loads than by alleles associated with higher viral loads. Conclusions/Significance. This comprehensive analysis puts forth the epitope repertoire as a mechanistic component of the multi-faceted HIV-specific CTL response. The favorable impact on markers of disease status of the propensity to present more HLA binding peptides and specific proteins gives impetus to vaccine design strategies that seek to elicit responses to a broad array of HIV-1 epitopes, and suggest a particular focus on Gag.	[Rolland, Morgane; Deng, Wenjie; Rousseau, Christine M.; Mullins, James I.] Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA; [Heckerman, David] Microsoft Res, Machine Learn & Appl Stat Grp, Washington, DC USA; [Coovadia, Hoosen; Bishop, Karen; Goulder, Philip J. R.; Walker, Bruce D.] Univ KwaZulu Natal, Doris Duke Med Res Inst, HIV Path Prog, Durban, South Africa; [Goulder, Philip J. R.] Univ Oxford, Nuffield Dept Med, Oxford, England; [Goulder, Philip J. R.; Walker, Bruce D.; Brander, Christian] Harvard Med Sch, Mass Gen Hosp, Partners AIDS Res Ctr, Charlestown, MA USA	University of Washington; University of Washington Seattle; Microsoft; University of Kwazulu Natal; University of Oxford	Mullins, JI (corresponding author), Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA.	jmullins@u.washington.edu	Bishop, Karen/G-7073-2015	Bishop, Karen/0000-0003-4935-7708; Brander, Christian/0000-0002-0548-5778	Boeing Corporation; US Public Health Service [AI57005, AI058894]; University of Washington Center for AIDS Research [AI27757]; Microsoft Research; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI057005, P30AI027757, R01AI058894] Funding Source: NIH RePORTER	Boeing Corporation; US Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); University of Washington Center for AIDS Research; Microsoft Research(Microsoft); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by an unrestricted gift from the Boeing Corporation and US Public Health Service grants to JIM (AI57005, AI058894) and the University of Washington Center for AIDS Research (AI27757), and by Microsoft Research. These sponsors had no role in any aspect of the design preparation or submission of this work.	Addo MM, 2003, J VIROL, V77, P2081, DOI 10.1128/JVI.77.3.2081-2092.2003; Allen TM, 2005, J VIROL, V79, P13239, DOI 10.1128/JVI.79.21.13239-13249.2005; Altfeld M, 2006, TRENDS IMMUNOL, V27, P504, DOI 10.1016/j.it.2006.09.007; Betts MR, 2001, J VIROL, V75, P11983, DOI 10.1128/JVI.75.24.11983-11991.2001; Borghans JAM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000920; Carrington M, 2003, ANNU REV MED, V54, P535, DOI 10.1146/annurev.med.54.101601.152346; Carrington M, 1999, SCIENCE, V283, P1748, DOI 10.1126/science.283.5408.1748; CRAWFORD H, 2007, J VIROL; Edwards BH, 2002, J VIROL, V76, P2298, DOI 10.1128/JVI.76.5.2298-2305.2002; Frahm N, 2006, NAT IMMUNOL, V7, P173, DOI 10.1038/ni1281; Frahm N, 2005, J VIROL, V79, P10218, DOI 10.1128/JVI.79.16.10218-10225.2005; Frahm N, 2004, J VIROL, V78, P2187, DOI 10.1128/JVI.78.5.2187-2200.2004; Frahm N, 2007, EUR J IMMUNOL, V37, P2419, DOI 10.1002/eji.200737365; Gao XJ, 2001, NEW ENGL J MED, V344, P1668, DOI 10.1056/NEJM200105313442203; Gea-Banacloche JC, 2000, J IMMUNOL, V165, P1082, DOI 10.4049/jimmunol.165.2.1082; Geldmacher C, 2007, J VIROL, V81, P2440, DOI 10.1128/JVI.01847-06; HECKERMAN D, 2006, 10 ANN INT C RES COM; Honeyborne I, 2007, J VIROL, V81, P3667, DOI 10.1128/JVI.02689-06; Jones NA, 2004, J EXP MED, V200, P1243, DOI 10.1084/jem.20040511; Kiepiela P, 2004, NATURE, V432, P769, DOI 10.1038/nature03113; Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520; Korber BTM, 2005, 060036 LAUR LOS AL N; Larsen MV, 2005, EUR J IMMUNOL, V35, P2295, DOI 10.1002/eji.200425811; Learn GH, 2002, J VIROL, V76, P11953, DOI 10.1128/JVI.76.23.11953-11959.2002; Leslie A, 2006, J IMMUNOL, V177, P4699, DOI 10.4049/jimmunol.177.7.4699; Liu SL, 1997, J VIROL, V71, P4284, DOI 10.1128/JVI.71.6.4284-4295.1997; LIU Y, 2007, EVOLUTION HIV 1 CTL; Liu Y, 2006, J VIROL, V80, P9519, DOI 10.1128/JVI.00575-06; Louzoun Y, 2006, MOL IMMUNOL, V43, P559, DOI 10.1016/j.molimm.2005.04.017; Lundegaard C, 2006, TRENDS BIOTECHNOL, V24, P537, DOI 10.1016/j.tibtech.2006.10.001; MacDonald KS, 2001, J INFECT DIS, V183, P503, DOI 10.1086/318092; MacDonald KS, 2000, J INFECT DIS, V181, P1581, DOI 10.1086/315472; Masemola A, 2004, J VIROL, V78, P3233, DOI 10.1128/JVI.78.7.3233-3243.2004; Migueles SA, 2000, P NATL ACAD SCI USA, V97, P2709, DOI 10.1073/pnas.050567397; Musey L, 1997, NEW ENGL J MED, V337, P1267, DOI 10.1056/NEJM199710303371803; Novitsky V, 2003, J VIROL, V77, P882, DOI 10.1128/JVI.77.2.882-890.2003; O'Brien SJ, 2001, TRENDS MOL MED, V7, P379, DOI 10.1016/S1471-4914(01)02131-1; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; Ramduth D, 2005, J INFECT DIS, V192, P1588, DOI 10.1086/496894; RIVIERE Y, 1995, AIDS RES HUM RETROV, V11, P903, DOI 10.1089/aid.1995.11.903; ROLLAND M, 2007, PLOS PATHOG IN PRESS; Rousseau CM, 2007, J VIROL, V81, P4492, DOI 10.1128/JVI.02050-06; Rousseau CM, 2006, J VIROL METHODS, V136, P118, DOI 10.1016/j.jviromet.2006.04.009; Sacha JB, 2007, J IMMUNOL, V178, P2746, DOI 10.4049/jimmunol.178.5.2746; Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001; Streeck H, 2007, AIDS, V21, P889, DOI 10.1097/QAD.0b013e3280f77439; SUHRBIER A, 1993, IMMUNOLOGY, V79, P171; Trachtenberg E, 2003, NAT MED, V9, P928, DOI 10.1038/nm893; Truong HHM, 2002, J ACQ IMMUN DEF SYND, V29, P232, DOI 10.1097/00042560-200203010-00003; Wu CH, 2006, NUCLEIC ACIDS RES, V34, pD187, DOI 10.1093/nar/gkj161; Zuniga R, 2006, J VIROL, V80, P3122, DOI 10.1128/JVI.80.6.3122-3125.2006	51	127	133	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2008	3	1							e1424	10.1371/journal.pone.0001424	http://dx.doi.org/10.1371/journal.pone.0001424			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366GT	18183304	gold, Green Published, Green Submitted			2022-12-25	WOS:000260469400020
J	Clybouw, C; El Mchichi, B; Hadji, A; Portier, A; Auffredou, MT; Arnoult, D; Leca, G; Vazquez, A				Clybouw, C.; El Mchichi, B.; Hadji, A.; Portier, A.; Auffredou, M. T.; Arnoult, D.; Leca, G.; Vazquez, A.			TGF beta-mediated apoptosis of Burkitt's lymphoma BL41 cells is associated with the relocation of mitochondrial BimEL	ONCOGENE			English	Article						Bim; TGF beta; mitochondrial delocalization; apoptosis; lymphoma	BCL-2 FAMILY-MEMBER; HUMAN B-CELLS; BH3-ONLY PROTEINS; P38 MAPK; CASPASE-8 ACTIVATION; DEPENDENT APOPTOSIS; BH3 DOMAINS; T-CELLS; MCL-1; PHOSPHORYLATION	In this study, we showed that the transforming growth factor beta ( TGF beta)-mediated apoptosis of Burkitt's lymphoma BL41 cells is dependent on the BH3-only protein Bim. In contrast to what has been observed with other cell types, TGFb activation did not promote Bim upregulation in BL41 cells, but instead resulted in Bim release from the mitochondria. Indeed, Bim levels were high in healthy BL41 cells, in which they dimerized with the Bcl-2-like protein Mcl-1 at the mitochondrial surface. In healthy and TGF beta-activated BL41 cells, unlike in epithelial cells or hepatocytes, Bim did not associate with Bcl-2 or Bcl-xL. TGFb activation of BL41 cells triggered the p38-dependent activation of caspase-8, causing the cleavage of Mcl-1 and the transfer of Bim from the mitochondria to the cytoskeleton. In addition to mitochondrial activation, this relocation of Bim may facilitate the complete demise of a cell death that is beyond the commitment point to apoptosis and may represent a hallmark of the TGF beta-mediated apoptosis of human lymphoma B cells.	[Clybouw, C.; El Mchichi, B.; Hadji, A.; Portier, A.; Auffredou, M. T.; Arnoult, D.; Leca, G.; Vazquez, A.] Univ Paris Sud, Hop Paul Brousse, INSERM, U542, F-94807 Villejuif, Val De Marne, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Vazquez, A (corresponding author), Univ Paris Sud, Hop Paul Brousse, INSERM, U542, Batiment,Lavoisier,14 Ave Paul Vaillant Couturier, F-94807 Villejuif, Val De Marne, France.	vazquez@vjf.inserm.fr	Arnoult, Damien/R-2032-2018					Alvarado-Kristensson M, 2004, J EXP MED, V199, P449, DOI 10.1084/jem.20031771; Bingle CD, 2000, J BIOL CHEM, V275, P22136, DOI 10.1074/jbc.M909572199; Bouillet P, 2001, DEV CELL, V1, P645, DOI 10.1016/S1534-5807(01)00083-1; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Cai BB, 2006, J BIOL CHEM, V281, P25215, DOI 10.1074/jbc.M512627200; CHAOUCHI N, 1995, ONCOGENE, V11, P1615; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Choi WS, 2004, J BIOL CHEM, V279, P20451, DOI 10.1074/jbc.M311164200; Clybouw C, 2005, J IMMUNOL, V175, P2968, DOI 10.4049/jimmunol.175.5.2968; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Domina AM, 2004, ONCOGENE, V23, P5301, DOI 10.1038/sj.onc.1207692; El Mchichi B, 2007, CELL DEATH DIFFER, V14, P1826, DOI 10.1038/sj.cdd.4402187; Ewings KE, 2007, EMBO J, V26, P2856, DOI 10.1038/sj.emboj.7601723; Gomez-Bougie P, 2004, EUR J IMMUNOL, V34, P3156, DOI 10.1002/eji.200424981; Gomez-Bougie P, 2005, EUR J IMMUNOL, V35, P971, DOI 10.1002/eji.200425878; Han J, 2006, J BIOL CHEM, V281, P10153, DOI 10.1074/jbc.M510349200; Han J, 2004, J BIOL CHEM, V279, P22020, DOI 10.1074/jbc.M313234200; Herrant M, 2004, ONCOGENE, V23, P7863, DOI 10.1038/sj.onc.1208069; Herrant M, 2002, ONCOGENE, V21, P4957, DOI 10.1038/sj.onc.1205689; Hildeman DA, 2002, IMMUNITY, V16, P759, DOI 10.1016/S1074-7613(02)00322-9; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Kobayashi S, 2007, J BIOL CHEM, V282, P18407, DOI 10.1074/jbc.M610010200; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Ley R, 2004, J BIOL CHEM, V279, P8837, DOI 10.1074/jbc.M311578200; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; MAURER F, 1906, HDB VERGLEICHENDEN 1, V3, P1; Michels J, 2004, ONCOGENE, V23, P4818, DOI 10.1038/sj.onc.1207648; Miyashita MUT, 2001, FEBS LETT, V509, P135, DOI 10.1016/S0014-5793(01)03145-3; Mouhamad S, 2004, J IMMUNOL, V172, P2084, DOI 10.4049/jimmunol.172.4.2084; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Ohgushi M, 2005, MOL CELL BIOL, V25, P10017, DOI 10.1128/MCB.25.22.10017-10028.2005; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Park HJ, 2002, HEPATOLOGY, V35, P1360, DOI 10.1053/jhep.2002.33205; Park MT, 2003, J BIOL CHEM, V278, P50624, DOI 10.1074/jbc.M309011200; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Ramjaun AR, 2007, ONCOGENE, V26, P970, DOI 10.1038/sj.onc.1209852; Schrantz N, 2001, MOL BIOL CELL, V12, P3139, DOI 10.1091/mbc.12.10.3139; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Wildey GM, 2003, J BIOL CHEM, V278, P18069, DOI 10.1074/jbc.M211958200; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Yoo JY, 2003, J BIOL CHEM, V278, P43001, DOI 10.1074/jbc.M307869200; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Zhu YN, 2004, P NATL ACAD SCI USA, V101, P7681, DOI 10.1073/pnas.0402293101	55	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	24					3446	3456		10.1038/sj.onc.1211009	http://dx.doi.org/10.1038/sj.onc.1211009			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18193085				2022-12-25	WOS:000256309900009
J	Taketa, K; Matsumura, T; Yano, M; Ishii, N; Senokuchi, T; Motoshima, H; Murata, Y; Kim-Mitsuyama, S; Kawada, T; Itabe, H; Takeya, M; Nishikawa, T; Tsuruzoe, K; Araki, E				Taketa, Kayo; Matsumura, Takeshi; Yano, Miyuki; Ishii, Norio; Senokuchi, Takafumi; Motoshima, Hiroyuki; Murata, Yusuke; Kim-Mitsuyama, Shokei; Kawada, Teruo; Itabe, Hiroyuki; Takeya, Motohiro; Nishikawa, Takeshi; Tsuruzoe, Kaku; Araki, Eiichi			Oxidized low density lipoprotein activates peroxisome proliferator-activated receptor-alpha(PPAR alpha) and PPAR gamma through MAPK-dependent COX-2 expression in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; FOAM CELLS; DIFFERENTIAL EXPRESSION; SIGNALING PATHWAYS; GENE-EXPRESSION; RECEPTOR-GAMMA; KAPPA-B; ALPHA; CHOLESTEROL; CYCLOOXYGENASE-2	It has been reported that oxidized low density lipoprotein ( OxLDL) can activate both peroxisome proliferator-activated receptor-alpha(PPAR alpha) and PPAR gamma. However, the detailed mechanisms of Ox-LDL-induced PPAR alpha and PPAR gamma activation are not fully understood. In the present study, we investigated the effect of Ox-LDL on PPAR alpha and PPAR gamma activation in macrophages. Ox-LDL, but not LDL, induced PPAR alpha and PPAR gamma activation in a dose-dependent manner. Ox-LDL transiently induced cyclooxygenase-2 (COX-2) mRNA and protein expression, and COX-2 specific inhibition by NS-398 or meloxicam or small interference RNA of COX-2 suppressed Ox-LDL-induced PPAR alpha and PPAR gamma activation. Ox-LDL induced phosphorylation of ERK1/2 and p38 MAPK, and ERK1/2 specific inhibition abrogated Ox-LDL-induced COX-2 expression and PPAR alpha and PPAR gamma activation, whereas p38 MAPK-specific inhibition had no effect. Ox-LDL decreased the amounts of intracellular long chain fatty acids, such as arachidonic, linoleic, oleic, and docosahexaenoic acids. On the other hand, Ox-LDL increased intracellular 15-deoxy-Delta(12,14)-prostaglandin J(2)(15d- PGJ(2)) level through ERK1/2- dependent overexpression of COX-2. Moreover, 15d- PGJ(2) induced both PPAR alpha and PPAR gamma activation. Furthermore, COX-2 and 15d- PGJ(2) expression and PPAR activity were increased in atherosclerotic lesions of apoE-deficient mice. Finally, we investigated the involvement of PPAR alpha and PPAR gamma on Ox-LDL-induced mRNA expression of ATP-binding cassette transporter A1 and monocyte chemoattractant protein-1. Interestingly, specific inhibition of PPAR alpha and PPAR gamma suppressed Ox-LDL-induced ATP-binding cassette transporter A1 mRNA expression and enhanced Ox-LDL-induced monocyte chemoattractant protein-1 mRNA expression. In conclusion, Ox-LDL-induced increase in 15d- PGJ(2) level through ERK1/2- dependent COX-2 expression is one of the mechanisms of PPAR alpha and PPAR gamma activation in macrophages. These effects of Ox-LDL may control excess atherosclerotic progression.	[Taketa, Kayo; Matsumura, Takeshi; Yano, Miyuki; Ishii, Norio; Senokuchi, Takafumi; Motoshima, Hiroyuki; Murata, Yusuke; Nishikawa, Takeshi; Tsuruzoe, Kaku; Araki, Eiichi] Kumamoto Univ, Grad Sch Med Sci, Dept Metab Med, Kumamoto 8618556, Japan; [Kim-Mitsuyama, Shokei] Kumamoto Univ, Grad Sch Med Sci, Dept Pharmacol & Mol Therapeut, Kumamoto 8618556, Japan; [Araki, Eiichi] Kumamoto Univ, Grad Sch Med Sci, Dept Cell Pathol, Kumamoto 8618556, Japan; [Kawada, Teruo] Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Nutr Chem Lab, Kyoto 6110011, Japan; [Itabe, Hiroyuki] Showa Univ, Sch Pharmaceut Sci, Dept Biol Chem, Tokyo 148555, Japan	Kumamoto University; Kumamoto University; Kumamoto University; Kyoto University; Showa University	Nishikawa, T (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Metab Med, 1-1-1 Honjo, Kumamoto 8618556, Japan.	takeshim@gpo.kumamoto-u.ac.jp	板部板部, 洋之/ABC-7746-2020					Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Burleigh ME, 2002, CIRCULATION, V105, P1816, DOI 10.1161/01.CIR.0000014927.74465.7F; CAMPBELL WB, 1996, GOODMAN GILMANS PHAR, P601; Charo IF, 2004, CIRC RES, V95, P858, DOI 10.1161/01.RES.0000146672.10582.17; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; CHODAKEWITZ JA, 1988, J IMMUNOL, V140, P832; Claus R, 1996, BIOCHEMISTRY-US, V35, P4911, DOI 10.1021/bi952036n; Delerive P, 2000, FEBS LETT, V471, P34, DOI 10.1016/S0014-5793(00)01364-8; FitzGerald GA, 2004, NEW ENGL J MED, V351, P1709, DOI 10.1056/NEJMp048288; FOLCH J, 1957, J BIOL CHEM, V226, P497; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Fujiwara Y, 2007, ARTERIOSCL THROM VAS, V27, P2400, DOI 10.1161/ATVBAHA.107.147405; Furberg CD, 2005, CIRCULATION, V111, P249, DOI 10.1161/01.CIR.0000155081.76164.17; HAKAMATA H, 1994, ARTERIOSCLER THROMB, V14, P1860, DOI 10.1161/01.ATV.14.11.1860; HAMILTON TA, 1995, J CLIN INVEST, V95, P2020, DOI 10.1172/JCI117887; Hernandez-Presa MA, 2002, ATHEROSCLEROSIS, V160, P49, DOI 10.1016/S0021-9150(01)00547-0; Hu JB, 2001, J BIOL CHEM, V276, P287, DOI 10.1074/jbc.M004885200; ITABE H, 1994, J BIOL CHEM, V269, P15274; JONES PS, 1995, EUR J BIOCHEM, V233, P219, DOI 10.1111/j.1432-1033.1995.219_1.x; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Lee H, 2000, CIRC RES, V87, P516; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; Li AC, 2000, J CLIN INVEST, V106, P523, DOI 10.1172/JCI10370; Li AC, 2004, J CLIN INVEST, V114, P1564, DOI 10.1172/JCI200418730; LINDSTEDT KA, 1993, J BIOL CHEM, V268, P7741; Matsumura T, 1997, ARTERIOSCL THROM VAS, V17, P3013, DOI 10.1161/01.ATV.17.11.3013; Matsumura T, 1999, J BIOL CHEM, V274, P37665, DOI 10.1074/jbc.274.53.37665; Matsuo T, 2004, BIOCHEM BIOPH RES CO, V314, P817, DOI 10.1016/j.bbrc.2003.12.161; Miyamoto T, 1997, J BIOL CHEM, V272, P7752, DOI 10.1074/jbc.272.12.7752; MUNKER R, 1986, NATURE, V323, P79, DOI 10.1038/323079a0; NAGANO Y, 1991, P NATL ACAD SCI USA, V88, P6457, DOI 10.1073/pnas.88.15.6457; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NOBLE RP, 1968, J LIPID RES, V9, P693; Ohlsson BG, 1996, J CLIN INVEST, V98, P78, DOI 10.1172/JCI118780; Oram JF, 2000, CURR OPIN LIPIDOL, V11, P253, DOI 10.1097/00041433-200006000-00005; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; Pontsler AV, 2002, J BIOL CHEM, V277, P13029, DOI 10.1074/jbc.M109546200; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SAKAI M, 1992, FEBS LETT, V314, P199, DOI 10.1016/0014-5793(92)80974-L; Senokuchi T, 2005, J BIOL CHEM, V280, P6627, DOI 10.1074/jbc.M412531200; Senokuchi T, 2004, ATHEROSCLEROSIS, V176, P233, DOI 10.1016/j.atherosclerosis.2004.05.019; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Takahashi N, 2002, FEBS LETT, V514, P315, DOI 10.1016/S0014-5793(02)02390-6; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Ueda A, 1997, J BIOL CHEM, V272, P31092, DOI 10.1074/jbc.272.49.31092; Wong DR, 2005, CURR OPIN PHARMACOL, V5, P204, DOI 10.1016/j.coph.2005.02.001; Wu KK, 2005, ARTERIOSCL THROM VAS, V25, P679, DOI 10.1161/01.ATV.0000157899.35660.61; Yano M, 2007, CIRC RES, V100, P1442, DOI 10.1161/01.RES.0000268411.49545.9c; Zhan YM, 2003, ARTERIOSCL THROM VAS, V23, P795, DOI 10.1161/01.ATV.0000066132.32063.F2	54	52	57	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9852	9862		10.1074/jbc.M703318200	http://dx.doi.org/10.1074/jbc.M703318200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18208815	hybrid			2022-12-25	WOS:000254671600041
J	Watanabe, M; Fiji, HDG; Guo, L; Chan, L; Kinderman, SS; Slamon, DJ; Kwon, O; Tamanoi, F				Watanabe, Masaru; Fiji, Hannah D. G.; Guo, Lea; Chan, Lai; Kinderman, Sape S.; Slamon, Dennis J.; Kwon, Ohyun; Tamanoi, Fuyuhiko			Inhibitors of protein geranylgeranyltransferase I and Rab geranylgeranyltransferase identified from a library of allenoate-derived compounds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHINE-CATALYZED SYNTHESIS; PRENYLATION; GTPASES; CELLS; CANCER; P21(WAF1/CIP1); EXPRESSION; COMPLEX; FARNESYLTRANSFERASE; TRANSFERASE	Protein geranylgeranylation is critical for the function of a number of proteins such as RhoA, Rac, and Rab. Protein geranylgeranyltransferase I (GGTase-I) and Rab geranylgeranyltransferase (RabGGTase) catalyze these modifications. In this work, we first describe the identification and characterization of small molecule inhibitors of GGTase-I (GGTI) with two novel scaffolds from a library consisting of allenoate-derived compounds. These compounds exhibit specific inhibition of GGTase-I and act by competing with a substrate protein. Derivatization of a carboxylic acid emanating from the core ring of one of the GGTI compounds dramatically improves their cellular activity. The improved GGTI compounds inhibit proliferation of a variety of human cancer cell lines and cause G(1) cell cycle arrest and induction of p21(CIP1/WAF1). We also report the identification of novel small molecule inhibitors of RabGGTase. These compounds were identified first by screening our GGTI compounds for those that also exhibited RabGGTase inhibition. This led to the discovery of a common structural feature for RabGGTase inhibitors: the presence of a characteristic six-atom aliphatic tail attached to the penta-substituted pyrrolidine core. Further screening led to the identification of compounds with preferential inhibition of RabGGTase. These compounds inhibit RabGGTase activity by competing with the substrate protein. These novel compounds may provide valuable reagents to study protein geranylgeranylation.	[Watanabe, Masaru; Guo, Lea; Tamanoi, Fuyuhiko] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; [Fiji, Hannah D. G.; Kinderman, Sape S.; Kwon, Ohyun] Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; [Chan, Lai] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; [Slamon, Dennis J.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Tamanoi, F (corresponding author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, 1602 Mol Sci Bldg,609 Charles E Young Dr, Los Angeles, CA 90095 USA.	fuyut@microbio.ucla.edu			NATIONAL CANCER INSTITUTE [P01CA032737, P30CA016042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028697] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071779, P41GM081282] Funding Source: NIH RePORTER; NCI NIH HHS [CA 32737, CA 16042] Funding Source: Medline; NIAID NIH HHS [AI 28697] Funding Source: Medline; NIGMS NIH HHS [R01 GM071779, P41 GM081282, GM 071779] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; Castellano S, 2007, J AM CHEM SOC, V129, P5843, DOI 10.1021/ja070274n; Cheng KW, 2005, CANCER RES, V65, P2516, DOI 10.1158/0008-5472.CAN-05-0573; Cheng KW, 2004, NAT MED, V10, P1251, DOI 10.1038/nm1125; Chien YC, 2003, EMBO REP, V4, P800, DOI 10.1038/sj.embor.embor899; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; Coxon FP, 2001, J BIOL CHEM, V276, P48213, DOI 10.1074/jbc.M106473200; Croizet-Berger K, 2002, P NATL ACAD SCI USA, V99, P8277, DOI 10.1073/pnas.122187699; El Oualid F, 2006, CURR MED CHEM, V13, P2385, DOI 10.2174/092986706777935078; Gelb MH, 2006, NAT CHEM BIOL, V2, P518, DOI 10.1038/nchembio818; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; Gomes AQ, 2003, MOL BIOL CELL, V14, P1882, DOI 10.1091/mbc.E02-10-0639; Guo WT, 1997, ONCOGENE, V15, P1143, DOI 10.1038/sj.onc.1201287; Hakem A, 2005, GENE DEV, V19, P1974, DOI 10.1101/gad.1310805; He H, 2002, GENE EXPRESSION, V10, P231, DOI 10.3727/000000002783992406; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; Kato-Stankiewicz J, 2002, P NATL ACAD SCI USA, V99, P14398, DOI 10.1073/pnas.222222699; Lackner MR, 2005, CANCER CELL, V7, P325, DOI 10.1016/j.ccr.2005.03.024; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; Leung KF, 2006, J LIPID RES, V47, P467, DOI 10.1194/jlr.R500017-JLR200; Lim KH, 2005, CANCER CELL, V7, P533, DOI 10.1016/j.ccr.2005.04.030; Lu J, 2007, SMALL, V3, P1341, DOI 10.1002/smll.200700005; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Peterson YK, 2006, J BIOL CHEM, V281, P12445, DOI 10.1074/jbc.M600168200; Pylypenko O, 2003, MOL CELL, V11, P483, DOI 10.1016/S1097-2765(03)00044-3; Pylypenko O, 2006, EMBO J, V25, P13, DOI 10.1038/sj.emboj.7600921; Rak A, 2004, CELL, V117, P749, DOI 10.1016/j.cell.2004.05.017; SANFORD JC, 1995, ANAL BIOCHEM, V224, P547, DOI 10.1006/abio.1995.1086; Sebti SM, 2004, SEMIN ONCOL, V31, P28, DOI 10.1053/j.seminoncol.2003.12.012; Sjogren AKM, 2007, J CLIN INVEST, V117, P1294, DOI 10.1172/JCI30868; Sun JZ, 2003, CANCER RES, V63, P8922; Sun JZ, 1998, ONCOGENE, V16, P1467, DOI 10.1038/sj.onc.1201656; Tamanoi F., 2001, ENZYMES, V21; Taylor JS, 2003, EMBO J, V22, P5963, DOI 10.1093/emboj/cdg571; Vasudevan A, 1999, J MED CHEM, V42, P1333, DOI 10.1021/jm9900873; Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zhang H, 2000, STRUCTURE, V8, P241, DOI 10.1016/S0969-2126(00)00102-7; Zhu XF, 2005, TETRAHEDRON, V61, P6276, DOI 10.1016/j.tet.2005.03.104; Zhu XF, 2005, ORG LETT, V7, P2977, DOI 10.1021/ol050946j; Zhu XF, 2005, ORG LETT, V7, P1387, DOI 10.1021/ol050203y; Zhu XF, 2003, J AM CHEM SOC, V125, P4716, DOI 10.1021/ja0344009	43	74	78	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9571	9579		10.1074/jbc.M706229200	http://dx.doi.org/10.1074/jbc.M706229200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18230616	hybrid, Green Published			2022-12-25	WOS:000254671600010
J	Gao, JM; Huo, LH; Sun, XO; Liu, M; Li, DW; Dong, JT; Zhou, J				Gao, Jinmin; Huo, Lihong; Sun, Xiaoou; Liu, Min; Li, Dengwen; Dong, Jin-Tang; Zhou, Jun			The tumor suppressor CYLD regulates microtubule dynamics and plays a role in cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; CAP-GLY DOMAIN; STRUCTURAL BASIS; CRYSTAL-STRUCTURE; TUBULIN; PROTEIN; BINDING; P150(GLUED); DRUGS; RICH	The familial cylindromatosis tumor suppressor CYLD is known to contain three cytoskeleton-associated protein glycine-rich (CAP-Gly) domains, which exist in a number of microtubule-binding proteins and are responsible for their association with microtubules. However, it remains elusive whether CYLD interacts with microtubules and, if so, whether the interaction is mediated by the CAP-Gly domains. In this study, our data demonstrate that CYLD associates with microtubules both in cells and in vitro, and the first CAP-Gly domain of CYLD is mainly responsible for the interaction. Knockdown of cellular CYLD expression dramatically delays microtubule regrowth after nocodazole washout, indicating an activity for CYLD in promoting microtubule assembly. Our data further demonstrate that CYLD enhances tubulin polymerization into microtubules by lowering the critical concentration for microtubule assembly. In addition, we have identified by wound healing assay a critical role for CYLD in mediating cell migration and found that its first CAP-Gly domain is required for this activity. Thus CYLD joins a growing list of CAP-Gly domain-containing proteins that regulate microtubule dynamics and function.	[Gao, Jinmin; Huo, Lihong; Sun, Xiaoou; Liu, Min; Li, Dengwen; Dong, Jin-Tang; Zhou, Jun] Nankai Univ, Dept Genet & Cell Biol, Coll Life Sci, Tianjin 300071, Peoples R China	Nankai University	Zhou, J (corresponding author), Nankai Univ, Dept Genet & Cell Biol, Coll Life Sci, 94 Weijin Rd, Tianjin 300071, Peoples R China.	junzhou@nankai.edu.cn	Huo, Lihong/ABI-4909-2020; Zhou, Jun/D-4654-2017; Gao, Jinmin/J-8967-2015	Zhou, Jun/0000-0001-7858-8260; Huo, Lihong/0000-0001-7901-6758; Dong, Jin-Tang/0000-0003-2349-5782; Gao, Jinmin/0000-0002-5894-6515				Amos LA, 2005, ADV PROTEIN CHEM, V71, P257, DOI 10.1016/S0065-3233(04)71007-4; BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; Bignell GR, 2000, NAT GENET, V25, P160, DOI 10.1038/76006; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Downing KH, 2000, ANNU REV CELL DEV BI, V16, P89, DOI 10.1146/annurev.cellbio.16.1.89; Ezratty EJ, 2005, NAT CELL BIOL, V7, P581, DOI 10.1038/ncb1262; Feierbach B, 1999, J CELL BIOL, V144, P113, DOI 10.1083/jcb.144.1.113; Guasch A, 2002, J MOL BIOL, V318, P1139, DOI 10.1016/S0022-2836(02)00185-7; Hayashi I, 2005, MOL CELL, V19, P449, DOI 10.1016/j.molcel.2005.06.034; Hayashi I, 2003, J BIOL CHEM, V278, P36430, DOI 10.1074/jbc.M305773200; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Joshi HC, 1998, CURR OPIN CELL BIOL, V10, P35, DOI 10.1016/S0955-0674(98)80084-7; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Li HP, 1997, P NATL ACAD SCI USA, V94, P1086, DOI 10.1073/pnas.94.4.1086; Li SL, 2002, J BIOL CHEM, V277, P48596, DOI 10.1074/jbc.M208512200; Liu M, 2006, J BIOL CHEM, V281, P18090, DOI 10.1074/jbc.M601324200; Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.03.041; Mishima M, 2007, P NATL ACAD SCI USA, V104, P10346, DOI 10.1073/pnas.0703876104; Mollinedo F, 2003, APOPTOSIS, V8, P413, DOI 10.1023/A:1025513106330; PIERRE P, 1994, J CELL SCI, V107, P1909; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; Regamey A, 2003, J EXP MED, V198, P1959, DOI 10.1084/jem.20031187; Saito K, 2004, STRUCTURE, V12, P1719, DOI 10.1016/j.str.2004.07.012; Stegmeier F, 2007, P NATL ACAD SCI USA, V104, P8869, DOI 10.1073/pnas.0703268104; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Vaughan PS, 2002, J CELL BIOL, V158, P305, DOI 10.1083/jcb.200201029; Watanabe T, 2005, TRENDS CELL BIOL, V15, P76, DOI 10.1016/j.tcb.2004.12.006; Xuan CH, 2007, J BIOL CHEM, V282, P28800, DOI 10.1074/jbc.M702823200	28	104	112	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					8802	8809		10.1074/jbc.M708470200	http://dx.doi.org/10.1074/jbc.M708470200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18222923	hybrid			2022-12-25	WOS:000254465800006
J	Geisinger, E; George, EA; Muir, TW; Novick, RP				Geisinger, Edward; George, Elizabeth A.; Muir, Tom W.; Novick, Richard P.			Identification of ligand specificity determinants in AgrC, the Staphylococcus aureus quorum-sensing receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE TOPOLOGY; GENETIC-VARIABILITY; VIRULENCE; LOCUS; PEPTIDE; CHEMORECEPTOR; ACTIVATION; EXPRESSION; CLONING; SYSTEM	Activation of the agr system, a major regulator of staphylococcal virulence, is initiated by the binding of a specific autoinducing peptide ( AIP) to the extracellular domain of AgrC, a classical receptor histidine protein kinase. There are four known agr specificity groups in Staphylococcus aureus, and we have previously localized the determinant of AIP receptor specificity to the C-terminal half of the AgrC sensor domain. We have now identified the specific amino acid residues that determine ligand activation specificity for agr groups I and IV, the two most closely related. Comparison of the AgrC-I and AgrC-IV sequences revealed a set of five divergent residues in the region of the second extracellular loop of the receptor that could be responsible. Accordingly, we exchanged these residues between AgrC-I and AgrC-IV and tested the resulting constructs for activation by the respective AIPs, measuring activation kinetics with a transcriptional fusion of blaZ to the principal agr promoter, P3. Exchange of all five residues caused a complete switch in receptor specificity. Replacement of two of the AgrC-IV residues by the corresponding residues in AgrC-I caused the receptor to be activated by AIP-I nearly as well as the wild type AgrC-I receptor. Replacement of two different AgrC-I residues by the corresponding AgrC-IV residues broadened receptor recognition specificity to include both AIPs. Various types of intermediate activity were observed with other replacement mutations. Preliminary characterization of the AgrC-I-AIP-I interaction suggests that ligand specificity may be sterically determined.	[Geisinger, Edward; Novick, Richard P.] NYU, Sch Med, Mol Pathogenesis Program, Kimmel Ctr Biol & Med,Skirball Inst, New York, NY 10016 USA; [Geisinger, Edward; Novick, Richard P.] NYU, Sch Med, Dept Microbiol, Kimmel Ctr Biol & Med,Skirball Inst, New York, NY 10016 USA; [Geisinger, Edward; Novick, Richard P.] NYU, Sch Med, Dept Med, Kimmel Ctr Biol & Med,Skirball Inst, New York, NY 10016 USA; [George, Elizabeth A.; Muir, Tom W.] Rockefeller Univ, Lab Synthet Prot Chem, New York, NY 10021 USA	New York University; New York University; New York University; Rockefeller University	Novick, RP (corresponding author), 540 1st Ave, New York, NY 10016 USA.	novick@saturn.med.nyu.edu	Muir, Tom/AHD-0860-2022	Muir, Tom/0000-0001-9635-0344; Novick, richard/0000-0003-4418-7893	NIAID NIH HHS [R01 AI 42783] Funding Source: Medline; NIGMS NIH HHS [5T32 GM 07308] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042783] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007308] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Autret N, 2003, INFECT IMMUN, V71, P4463, DOI 10.1128/IAI.71.8.4463-4471.2003; AZAVEDO JC, 1985, INFECT IMMUN, V50, P304; Bonner G, 2000, EUR J PHARMACOL, V403, P37, DOI 10.1016/S0014-2999(00)00578-1; Charpentier E, 2004, APPL ENVIRON MICROB, V70, P6076, DOI 10.1128/AEM.70.10.6076-6085.2004; Derr P, 2006, J MOL BIOL, V355, P923, DOI 10.1016/j.jmb.2005.11.025; Dufour P, 2002, J BACTERIOL, V184, P1180, DOI 10.1128/jb.184.4.1180-1186.2002; Dunman PM, 2001, J BACTERIOL, V183, P7341, DOI 10.1128/JB.183.24.7341-7353.2001; GETHER U, 1993, J BIOL CHEM, V268, P7893; Gilot P, 2004, J CLIN MICROBIOL, V42, P1265, DOI 10.1128/JCM.42.3.1265-1269.2004; Hao B, 2002, BIOCHEMISTRY-US, V41, P12952, DOI 10.1021/bi020144l; Jarraud S, 2000, J BACTERIOL, V182, P6517, DOI 10.1128/JB.182.22.6517-6522.2000; Ji GY, 1995, P NATL ACAD SCI USA, V92, P12055, DOI 10.1073/pnas.92.26.12055; Ji GY, 1997, SCIENCE, V276, P2027, DOI 10.1126/science.276.5321.2027; Lina G, 1998, MOL MICROBIOL, V28, P655, DOI 10.1046/j.1365-2958.1998.00830.x; Lyon GJ, 2002, BIOCHEMISTRY-US, V41, P10095, DOI 10.1021/bi026049u; Lyon GJ, 2002, J BIOL CHEM, V277, P6247, DOI 10.1074/jbc.M109989200; Mayville P, 1999, P NATL ACAD SCI USA, V96, P1218, DOI 10.1073/pnas.96.4.1218; MORFELDT E, 1988, MOL GEN GENET, V211, P435, DOI 10.1007/BF00425697; NOVICK RP, 1993, EMBO J, V12, P3967, DOI 10.1002/j.1460-2075.1993.tb06074.x; NOVICK RP, 1991, METHOD ENZYMOL, V204, P587; PENG HL, 1988, J BACTERIOL, V170, P4365, DOI 10.1128/jb.170.9.4365-4372.1988; RECSEI P, 1986, MOL GEN GENET, V202, P58, DOI 10.1007/BF00330517; Rodgers KR, 2005, J INORG BIOCHEM, V99, P963, DOI 10.1016/j.jinorgbio.2005.02.016; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; Sturme MHJ, 2005, J BACTERIOL, V187, P5224, DOI 10.1128/JB.187.15.5224-5235.2005; Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849; van Leeuwen W, 2000, J BACTERIOL, V182, P5721, DOI 10.1128/JB.182.20.5721-5729.2000; Vojtov N, 2002, P NATL ACAD SCI USA, V99, P10102, DOI 10.1073/pnas.152152499; WOLFF C, 1988, J BACTERIOL, V170, P4509, DOI 10.1128/jb.170.10.4509-4515.1988; Wright JS, 2005, J BACTERIOL, V187, P5585, DOI 10.1128/JB.187.16.5585-5594.2005; Wright JS, 2004, P NATL ACAD SCI USA, V101, P16168, DOI 10.1073/pnas.0404039101	32	64	65	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					8930	8938		10.1074/jbc.M710227200	http://dx.doi.org/10.1074/jbc.M710227200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18222919	Green Published, hybrid			2022-12-25	WOS:000254465800021
J	Szegedi, SS; Castro, CC; Koutmos, M; Garrow, TA				Szegedi, Sandra S.; Castro, Carmen C.; Koutmos, Markos; Garrow, Timothy A.			Betaine-homocysteine S-methyltransferase-2 is an S-methylmethionine-homocysteine methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHIONINE METABOLISM; CDNA CLONING; VITAMIN-U; ADENOSYLMETHIONINE; EXPRESSION; LIVER; CHOLINE; ZINC; RAT; OLIGOMERIZATION	We demonstrate that purified recombinant human betaine-homocysteine methyltransferase-2 ( BHMT-2) is a zinc metalloenzyme that uses S-methylmethionine ( SMM) as a methyl donor for the methylation of homocysteine. Unlike the highly homologous betaine-homocysteine methyltransferase ( BHMT), BHMT-2 cannot use betaine. The Km of BHMT-2 for SMM was determined to be 0.94 mM, and it has a turnover number similar to BHMT. Several compounds were tested as inhibitors of recombinant human BHMT and BHMT-2. The SMM-specific methyltransferase activity of BHMT-2 is not inhibited by dimethylglycine and betaine, whereas the former is a potent inhibitor of BHMT. Methionine is a stronger inhibitor of BHMT-2 than BHMT, and S-adenosylmethionine does not inhibit BHMT but is a weak inhibitor of BHMT-2. BHMT can use SMM as a methyl donor with a k(cat)/K-m that is 5-fold lower than the k(cat)/K-m for betaine. However, SMM does not inhibit BHMT activity when it is presented to the enzyme at concentrations that are 10-fold greater than the subsaturating amounts of betaine used in the assay. Based on these data, it is our current hypothesis that in vivo most if not all of the SMM-dependent methylation of homocysteine occurs via BHMT-2.	[Szegedi, Sandra S.] Univ Illinois, Dept Anim Sci, Urbana, IL 61801 USA; [Garrow, Timothy A.] Univ Illinois, Dept Food Sci & Human Nutr, Urbana, IL 61801 USA; [Castro, Carmen C.] Univ Cadiz, Fac Med, Area Fisiol, Cadiz 11003, Spain; [Koutmos, Markos] Univ Michigan, Div Biophys Res, Ann Arbor, MI 48109 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Universidad de Cadiz; University of Michigan System; University of Michigan	Garrow, TA (corresponding author), 1201 W Gregory Dr,359 ERML, Urbana, IL 61801 USA.	tagarrow@uiuc.edu	Carmen, Castro/C-7813-2009	Carmen, Castro/0000-0002-6802-0572; Koutmos, Markos/0000-0003-0933-6312	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052501, R29DK052501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048533] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 52501] Funding Source: Medline; NIGMS NIH HHS [GM 48533] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Augspurger NR, 2005, J NUTR, V135, P1712, DOI 10.1093/jn/135.7.1712; AWAD WM, 1983, J BIOL CHEM, V258, P2790; Bose N, 2002, PROTEIN EXPRES PURIF, V25, P73, DOI 10.1006/prep.2001.1611; Breksa AP, 1999, BIOCHEMISTRY-US, V38, P13991, DOI 10.1021/bi991003v; Castro C, 2004, BIOCHEMISTRY-US, V43, P5341, DOI 10.1021/bi049821x; Chadwick LH, 2000, GENOMICS, V70, P66, DOI 10.1006/geno.2000.6319; Collinsova M, 2003, CHEM BIOL, V10, P113, DOI 10.1016/S1074-5521(03)00008-5; DUBNOFF JW, 1948, J BIOL CHEM, V176, P789; Evans JC, 2002, STRUCTURE, V10, P1159, DOI 10.1016/S0969-2126(02)00796-7; FINKELSTEIN JD, 1972, ARCH BIOCHEM BIOPHYS, V153, P320, DOI 10.1016/0003-9861(72)90451-1; FINKELSTEIN JD, 1984, J BIOL CHEM, V259, P9508; Garrow TA, 1996, J BIOL CHEM, V271, P22831, DOI 10.1074/jbc.271.37.22831; Gonzalez B, 2004, J MOL BIOL, V338, P771, DOI 10.1016/j.jmb.2004.03.005; Gonzalez B, 2003, BIOCHEM J, V370, P945, DOI 10.1042/BJ20021510; GRUNAU JA, 1991, COMMUN SOIL SCI PLAN, V22, P1873, DOI 10.1080/00103629109368542; HANSON AD, 1994, PLANT PHYSIOL, V105, P103, DOI 10.1104/pp.105.1.103; HEGEDUS M, 1992, ACTA VET HUNG, V40, P145; HOLCOMB ER, 1975, J BACTERIOL, V121, P267, DOI 10.1128/JB.121.1.267-271.1975; Kim GH, 2003, FOOD SCI TECHNOL RES, V9, P316, DOI 10.3136/fstr.9.316; Koc H, 2002, ANAL CHEM, V74, P4734, DOI 10.1021/ac025624x; LAVINE TF, 1954, J BIOL CHEM, V207, P107; Martin JL, 2002, CURR OPIN STRUC BIOL, V12, P783, DOI 10.1016/S0959-440X(02)00391-3; MATSUO T, 1980, ARZNEIMITTEL-FORSCH, V30-1, P68; Miller CM, 2005, BIOCHEM J, V392, P443, DOI 10.1042/BJ20050356; Millian NS, 1998, ARCH BIOCHEM BIOPHYS, V356, P93, DOI 10.1006/abbi.1998.0757; Nakajima K, 2006, J NUTR SCI VITAMINOL, V52, P61, DOI 10.3177/jnsv.52.61; Neuhierl B, 1999, J BIOL CHEM, V274, P5407, DOI 10.1074/jbc.274.9.5407; Ranocha P, 2000, J BIOL CHEM, V275, P15962, DOI 10.1074/jbc.M001116200; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SHAPIRO SK, 1959, BIOCHIM BIOPHYS ACTA, V36, P241, DOI 10.1016/0006-3002(59)90089-7; Steele W, 2005, REPROD BIOMED ONLINE, V10, P755, DOI 10.1016/S1472-6483(10)61120-0; Szegedi SS, 2004, ARCH BIOCHEM BIOPHYS, V426, P32, DOI 10.1016/j.abb.2004.03.040; Thomas D, 2000, J BIOL CHEM, V275, P40718, DOI 10.1074/jbc.M005967200; Ulrey CL, 2005, HUM MOL GENET, V14, pR139, DOI 10.1093/hmg/ddi100	34	63	71	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					8939	8945		10.1074/jbc.M710449200	http://dx.doi.org/10.1074/jbc.M710449200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18230605	Green Published, hybrid			2022-12-25	WOS:000254465800022
J	Carayol, N; Katsoulidis, E; Sassano, A; Altman, JK; Druker, BJ; Platanias, LC				Carayol, Nathalie; Katsoulidis, Efstratios; Sassano, Antonella; Altman, Jessica K.; Druker, Brian J.; Platanias, Leonidas C.			Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; IMATINIB-RESISTANT; TUMOR-SUPPRESSOR; TYROSINE KINASE; LYMPHOBLASTIC-LEUKEMIA; TRANSFORMATION POTENCY; CYTOGENETIC RESPONSES; SELECTIVE INHIBITOR; AMN107 NILOTINIB	There is accumulating evidence that mammalian target of rapamycin (mTOR)-activated pathways play important roles in cell growth and survival of BCR-ABL-transformed cells. We have previously shown that the mTOR/p70 S6 kinase (p70 S6K) pathway is constitutively activated in BCR-ABLtransformed cells and that inhibition of BCR-ABL kinase activity by imatinib mesylate abrogates such activation. We now provide evidence for the existence of a novel regulatory mechanism by which BCR-ABL promotes cell proliferation, involving p70 S6K-mediated suppression of expression of programmed cell death 4 (PDCD4), a tumor suppressor protein that acts as an inhibitor of cap-dependent translation by blocking the translation initiation factor eIF4A. Our data also establish that second generation BCR-ABL kinase inhibitors block activation of p70 S6K and downstream engagement of the S6 ribosomal protein in BCR-ABL-transformed cells. Moreover, PDCD4 protein expression is up-regulated by inhibition of the BCR-ABL kinase in K562 cells and BaF3/BCR-ABL transfectants, suggesting a mechanism for the generation of the proapoptotic effects of such inhibitors. Knockdown of PDCD4 expression results in reversal of the suppressive effects of nilotinib and imatinib mesylate on leukemic progenitor colony formation, suggesting an important role for this protein in the generation of antileukemic responses. Altogether, our studies identify a novel mechanism by which BCR-ABL may promote leukemic cell growth, involving sequential engagement of the mTOR/p70 S6K pathway and downstream suppression of PDCD4 expression.	[Carayol, Nathalie; Katsoulidis, Efstratios; Sassano, Antonella; Altman, Jessica K.; Platanias, Leonidas C.] Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; [Carayol, Nathalie; Katsoulidis, Efstratios; Sassano, Antonella; Altman, Jessica K.; Platanias, Leonidas C.] Northwestern Univ, Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA; [Carayol, Nathalie; Katsoulidis, Efstratios; Sassano, Antonella; Altman, Jessica K.; Platanias, Leonidas C.] Jess Brown Vet Affairs Med Ctr, Chicago, IL 60611 USA; [Druker, Brian J.] Oregon Hlth & Sci Univ, Dept Hematol & Med Oncol, Portland, OR 97239 USA; [Druker, Brian J.] Oregon Hlth & Sci Univ, Howard Hughes Med Inst, Portland, OR 97239 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center; Oregon Health & Science University; Howard Hughes Medical Institute; Oregon Health & Science University	Platanias, LC (corresponding author), Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, 303 E Super St,Lurie 3-107, Chicago, IL 60611 USA.	l-platanias@northwestern.edu		Druker, Brian/0000-0001-8331-8206	NATIONAL CANCER INSTITUTE [R01CA121192, R01CA077816, R01CA094079, R01CA100579] Funding Source: NIH RePORTER; NCI NIH HHS [CA 100579, CA 94079, CA 121192, CA 77816] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Afonja O, 2004, ONCOGENE, V23, P8135, DOI 10.1038/sj.onc.1207983; Ahmad S, 1997, J BIOL CHEM, V272, P29991, DOI 10.1074/jbc.272.48.29991; Alsayed Y, 2001, J BIOL CHEM, V276, P4012, DOI 10.1074/jbc.M007431200; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; Bhaskar PT, 2007, DEV CELL, V12, P487, DOI 10.1016/j.devcel.2007.03.020; Burgess MR, 2006, THESCIENTIFICWORLDJO, V6, P918, DOI 10.1100/tsw.2006.184; Chen Y, 2003, J PATHOL, V200, P640, DOI 10.1002/path.1378; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; Dai Y, 2004, J BIOL CHEM, V279, P34227, DOI 10.1074/jbc.M402290200; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DanhauserRiedl S, 1996, CANCER RES, V56, P3589; Deininger M, 2005, BLOOD, V105, P2640, DOI 10.1182/blood-2004-08-3097; Deininger MWN, 2003, PHARMACOL REV, V55, P401, DOI 10.1124/pr.55.3.4; Doggrell S, 2005, EXPERT OPIN INV DRUG, V14, P1063, DOI 10.1517/13543784.14.8.1063; Donato NJ, 2003, BLOOD, V101, P690, DOI 10.1182/blood.V101.2.690; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 2004, ADV CANCER RES, V91, P1, DOI 10.1016/S0065-230X(04)91001-9; Druker BJ, 2003, SEMIN HEMATOL, V40, P50, DOI 10.1053/shem.2003.50000; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Druker BJ, 2006, NEW ENGL J MED, V354, P2594, DOI 10.1056/NEJMe068073; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Gao F, 2007, ONCOL REP, V17, P123; Gingras AC, 2001, GENE DEV, V15, P2852; Goke R, 2004, ANN NY ACAD SCI, V1014, P220, DOI 10.1196/annals.1294.024; Golemovic M, 2005, CLIN CANCER RES, V11, P4941, DOI 10.1158/1078-0432.CCR-04-2601; Griswold IJ, 2006, MOL CELL BIOL, V26, P6082, DOI 10.1128/MCB.02202-05; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Guilhot F, 2007, BLOOD, V109, P4143, DOI 10.1182/blood-2006-09-046839; Hay N, 2005, CANCER CELL, V8, P179, DOI 10.1016/j.ccr.2005.08.008; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; Hilliard A, 2006, J IMMUNOL, V177, P8095, DOI 10.4049/jimmunol.177.11.8095; Hochhaus A, 2007, BLOOD, V109, P2303, DOI 10.1182/blood-2006-09-047266; Hu YG, 2004, NAT GENET, V36, P453, DOI 10.1038/ng1343; Jacinto E, 2003, NAT REV MOL CELL BIO, V4, P117, DOI 10.1038/nrm1018; Jansen AP, 2005, CANCER RES, V65, P6034, DOI 10.1158/0008-5472.CAN-04-2119; Kannan-Thulasiraman P, 2006, J BIOL CHEM, V281, P22446, DOI 10.1074/jbc.M603111200; Kantarjian H, 2006, NAT REV DRUG DISCOV, V5, P717, DOI 10.1038/nrd2135; Kantarjian H, 2006, NEW ENGL J MED, V354, P2542, DOI 10.1056/NEJMoa055104; Kantarjian HM, 2006, ANN INTERN MED, V145, P913, DOI 10.7326/0003-4819-145-12-200612190-00008; Katsoulidis E, 2005, CANCER RES, V65, P9029, DOI 10.1158/0008-5472.CAN-04-4555; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; Kurzrock R, 2003, ANN INTERN MED, V138, P819, DOI 10.7326/0003-4819-138-10-200305200-00010; Lankat-Buttgereit B, 2003, BIOL CELL, V95, P515, DOI 10.1016/j.biolcel.2003.09.003; LaRonde-LeBlanc N, 2007, MOL CELL BIOL, V27, P147, DOI 10.1128/MCB.00867-06; Lionberger JM, 2000, J BIOL CHEM, V275, P18581, DOI 10.1074/jbc.C000126200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Ly C, 2003, CANCER RES, V63, P5716; Lydon NB, 2004, LEUKEMIA RES, V28, pS29, DOI 10.1016/j.leukres.2003.10.002; Mauro MJ, 2002, J CLIN ONCOL, V20, P325, DOI 10.1200/JCO.20.1.325; Melo JV, 2007, CANCER LETT, V249, P121, DOI 10.1016/j.canlet.2006.07.010; Mohi MG, 2004, P NATL ACAD SCI USA, V101, P3130, DOI 10.1073/pnas.0400063101; Nimmanapalli R, 2002, CURR OPIN ONCOL, V14, P616, DOI 10.1097/00001622-200211000-00005; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; O'Hare T, 2005, CANCER RES, V65, P4500, DOI 10.1158/0008-5472.CAN-05-0259; O'Hare T, 2005, CANCER CELL, V7, P117, DOI 10.1016/j.ccr.2005.01.020; Ozpolat B, 2007, MOL CANCER RES, V5, P95, DOI 10.1158/1541-7786.MCR-06-0125; Palamarchuk A, 2005, CANCER RES, V65, P11282, DOI 10.1158/0008-5472.CAN-05-3469; Parmar S, 2005, BLOOD, V106, P2436, DOI 10.1182/blood-2004-10-4003; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Prabhu S, 2007, ONCOGENE, V26, P1188, DOI 10.1038/sj.onc.1209901; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; Ray A, 2007, BLOOD, V109, P5011, DOI 10.1182/blood-2006-01-015347; Shah NP, 2003, ONCOGENE, V22, P7389, DOI 10.1038/sj.onc.1206942; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; Talpaz M, 2006, NEW ENGL J MED, V354, P2531, DOI 10.1056/NEJMoa055229; Tauchi T, 2006, INT J HEMATOL, V83, P294, DOI 10.1532/IJH97.06025; Verma A, 2002, LEUKEMIA LYMPHOMA, V43, P703, DOI 10.1080/10428190290016782; von Bubnoff N, 2006, BLOOD, V108, P1328, DOI 10.1182/blood-2005-12-010132; Weisberg E, 2006, BRIT J CANCER, V94, P1765, DOI 10.1038/sj.bjc.6603170; Weisberg E, 2005, CANCER CELL, V7, P129, DOI 10.1016/j.ccr.2005.01.007; Weisberg E, 2007, BLOOD, V109, P2112, DOI 10.1182/BLOOD-2006-06-026377; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2006, MOL CELL BIOL, V26, P1297, DOI 10.1128/MCB.26.4.1297-1306.2006; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Zhang H, 2006, ONCOGENE, V25, P6101, DOI 10.1038/sj.onc.1209634	78	58	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8601	8610		10.1074/jbc.M707934200	http://dx.doi.org/10.1074/jbc.M707934200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18223253	Green Published, hybrid			2022-12-25	WOS:000254288000059
J	Mbonye, UR; Yuan, C; Harris, CE; Sidhu, RS; Song, I; Arakawa, T; Smith, WL				Mbonye, Uri R.; Yuan, Chong; Harris, Clair E.; Sidhu, Ranjinder S.; Song, Inseok; Arakawa, Toshiya; Smith, William L.			Two distinct pathways for cyclooxygenase-2 protein degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETICULUM-ASSOCIATED DEGRADATION; CYTOSOLIC PHOSPHOLIPASE A(2); PROSTAGLANDIN-H SYNTHASE-1; ER-ASSOCIATED DEGRADATION; EPIDERMAL-GROWTH-FACTOR; GLYCOPROTEIN QUALITY-CONTROL; ARACHIDONIC-ACID RELEASE; ENDOPLASMIC-RETICULUM; MANNOSIDASE-I; MISFOLDED GLYCOPROTEINS	Cyclooxygenases (COX-1 and COX-2) are N-glycosylated, endoplasmic reticulum-resident, integral membrane proteins that catalyze the committed step in prostanoid synthesis. COX-1 is constitutively expressed in many types of cells, whereas COX-2 is usually expressed inducibly and transiently. The control of COX-2 protein expression occurs at several levels, and overexpression of COX-2 is associated with pathologies such as colon cancer. Here we have investigated COX-2 protein degradation and demonstrate that it can occur through two independent pathways. One pathway is initiated by post-translational N-glycosylation at Asn-594. The N-glycosyl group is then processed, and the protein is translocated to the cytoplasm, where it undergoes proteasomal degradation. We provide evidence from site-directed mutagenesis that a 27-amino acid instability motif (27-IM) regulates post-translational N-glycosylation of Asn-594. This motif begins with Glu-586 8 residues upstream of the N-glycosylation site and ends with Lys-612 near the C terminus at Leu-618. Key elements of the 27-IM include a helix involving residues Glu-586 to Ser-596 with Asn-594 near the end of this helix and residues Leu-610 and Leu-611, which are located in an apparently unstructured downstream region of the 27-IM. The last 16 residues of the 27-IM, including Leu-610 and Leu-611, appear to promote N-glycosylation of Asn-594 perhaps by causing this residue to become exposed to appropriate glycosyl transferases. A second pathway for COX-2 protein degradation is initiated by substrate-dependent suicide inactivation. Suicide-inactivated protein is then degraded. The biochemical steps have not been resolved, but substrate-dependent degradation is not inhibited by proteasome inhibitors or inhibitors of lysosomal proteases. The pathway involving the 27-IM occurs at a constant rate, whereas degradation through the substrate-dependent process is coupled to the rate of substrate turnover.	[Mbonye, Uri R.; Yuan, Chong; Harris, Clair E.; Sidhu, Ranjinder S.; Song, Inseok; Arakawa, Toshiya; Smith, William L.] Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Smith, WL (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, 1150 W Med Ctr Dr,5301 Med Sci Res Bldg 3, Ann Arbor, MI 48109 USA.	smithww@umich.edu	Mbonye, Uri/AAG-8861-2020	Mbonye, Uri/0000-0002-7694-0803				Avezov E, 2008, MOL BIOL CELL, V19, P216, DOI 10.1091/mbc.E07-05-0505; Bolt G, 2005, GLYCOBIOLOGY, V15, P541, DOI 10.1093/glycob/cwi032; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; Cabral CM, 2001, TRENDS BIOCHEM SCI, V26, P619, DOI 10.1016/S0968-0004(01)01942-9; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; Denic V, 2006, CELL, V126, P349, DOI 10.1016/j.cell.2006.05.045; DEWITT DL, 1993, ARCH BIOCHEM BIOPHYS, V306, P94, DOI 10.1006/abbi.1993.1485; Donoso G, 2005, BIOCHEM J, V387, P897, DOI 10.1042/BJ20041312; Duquette M, 2002, J BIOL CHEM, V277, P44631, DOI 10.1074/jbc.M207007200; Fagioli C, 2001, J BIOL CHEM, V276, P12885, DOI 10.1074/jbc.M009603200; Gnann A, 2004, MOL BIOL CELL, V15, P4125, DOI 10.1091/mbc.e04-01-0024; Heinemann FS, 1998, MOL BIOL CELL, V9, P3445, DOI 10.1091/mbc.9.12.3445; Heinemann FS, 2003, BIOCHEMISTRY-US, V42, P6929, DOI 10.1021/bi034071x; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; Hosokawa N, 2003, J BIOL CHEM, V278, P26287, DOI 10.1074/jbc.M303395200; Hosokawa N, 2001, EMBO REP, V2, P415, DOI 10.1093/embo-reports/kve084; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; Kabani M, 2003, MOL BIOL CELL, V14, P3437, DOI 10.1091/mbc.E02-12-0847; Kang YJ, 2006, J IMMUNOL, V177, P8111, DOI 10.4049/jimmunol.177.11.8111; Kim W, 2005, MOL CELL, V19, P753, DOI 10.1016/j.molcel.2005.08.010; Kitzmuller C, 2003, BIOCHEM J, V376, P687, DOI 10.1042/BJ20030887; Leslie CC, 2004, BIOCHEM CELL BIOL, V82, P1, DOI 10.1139/o03-080; LIN LL, 1992, J BIOL CHEM, V267, P23451; MAXWELL AP, 1993, BIOCHEM J, V295, P763, DOI 10.1042/bj2950763; Mbonye UR, 2006, J BIOL CHEM, V281, P35770, DOI 10.1074/jbc.M608281200; Mevkh A T, 1993, Biokhimiia, V58, P1573; MEVKH AT, 1993, FEBS LETT, V321, P205, DOI 10.1016/0014-5793(93)80109-8; MirAfzali Z, 2006, J BIOL CHEM, V281, P28354, DOI 10.1074/jbc.M605206200; Miyakawa T, 1998, BIOCHEM J, V329, P107, DOI 10.1042/bj3290107; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; Molinari M, 2007, NAT CHEM BIOL, V3, P313, DOI 10.1038/nchembio880; Mounier CM, 2004, J BIOL CHEM, V279, P25024, DOI 10.1074/jbc.M313019200; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181; OTTO JC, 1993, J BIOL CHEM, V268, P18234; OTTO JC, 1994, J BIOL CHEM, V269, P19868; Perkins DJ, 1997, BIOCHEM J, V321, P677, DOI 10.1042/bj3210677; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; REDDY ST, 1994, J BIOL CHEM, V269, P15473; Rich G, 1998, J CELL PHYSIOL, V176, P495, DOI 10.1002/(SICI)1097-4652(199809)176:3<495::AID-JCP6>3.0.CO;2-J; RIESE J, 1994, J LEUKOCYTE BIOL, V55, P476, DOI 10.1002/jlb.55.4.476; Rockwell P, 2000, ARCH BIOCHEM BIOPHYS, V374, P325, DOI 10.1006/abbi.1999.1646; Rouzer CA, 2003, CHEM REV, V103, P2239, DOI 10.1021/cr000068x; Rowlinson SW, 1999, J BIOL CHEM, V274, P23305, DOI 10.1074/jbc.274.33.23305; Saric T, 2002, NAT IMMUNOL, V3, P1169, DOI 10.1038/ni859; Saveanu L, 2005, NAT IMMUNOL, V6, P689, DOI 10.1038/ni1208; Serwold T, 2002, NATURE, V419, P480, DOI 10.1038/nature01074; Sevigny MB, 2006, FEBS LETT, V580, P6533, DOI 10.1016/j.febslet.2006.10.073; Smith WL, 2002, PROSTAG OTH LIPID M, V68-9, P115, DOI 10.1016/S0090-6980(02)00025-4; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Solda T, 2007, MOL CELL, V27, P238, DOI 10.1016/j.molcel.2007.05.032; Spencer AG, 1999, J BIOL CHEM, V274, P32936, DOI 10.1074/jbc.274.46.32936; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; Spiro RG, 2004, CELL MOL LIFE SCI, V61, P1025, DOI 10.1007/s00018-004-4037-8; Tanabe T, 2002, PROSTAG OTH LIPID M, V68-9, P95, DOI 10.1016/S0090-6980(02)00024-2; Tanaka N, 2004, ARTERIOSCL THROM VAS, V24, P607, DOI 10.1161/01.ATV.0000117181.68309.10; Tokunaga F, 2000, J BIOL CHEM, V275, P40757, DOI 10.1074/jbc.M001073200; Tsuda H, 2006, THROMB RES, V117, P323, DOI 10.1016/j.thromres.2005.02.017; van der Donk WA, 2002, BIOCHEMISTRY-US, V41, P15451, DOI 10.1021/bi026938h; Wada M, 2007, J BIOL CHEM, V282, P22254, DOI 10.1074/jbc.M703169200; WU T, 1994, J CLIN INVEST, V93, P571, DOI 10.1172/JCI117009; Wu Y, 2003, P NATL ACAD SCI USA, V100, P8229, DOI 10.1073/pnas.1430537100; Wu Y, 2007, J BIOL CHEM, V282, P4841, DOI 10.1074/jbc.M607156200; Xiao GS, 1998, J BIOL CHEM, V273, P6801, DOI 10.1074/jbc.273.12.6801; Xu XM, 1997, J BIOL CHEM, V272, P6943, DOI 10.1074/jbc.272.11.6943; Xu XM, 1996, AM J PHYSIOL-CELL PH, V270, pC259, DOI 10.1152/ajpcell.1996.270.1.C259; York IA, 2002, NAT IMMUNOL, V3, P1177, DOI 10.1038/ni860; Yuan C, 2006, P NATL ACAD SCI USA, V103, P6142, DOI 10.1073/pnas.0601805103; Zaric J, 2005, J BIOL CHEM, V280, P1077, DOI 10.1074/jbc.M410006200	70	83	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8611	8623		10.1074/jbc.M710137200	http://dx.doi.org/10.1074/jbc.M710137200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18203712	hybrid			2022-12-25	WOS:000254288000060
J	Kirkbride, KC; Townsend, TA; Bruinsma, MW; Barnett, JV; Blobe, GC				Kirkbride, Kellye C.; Townsend, Todd A.; Bruinsma, Monique W.; Barnett, Joey V.; Blobe, Gerard C.			Bone morphogenetic proteins signal through the transforming growth factor-beta type III receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING SITE; PROSTATE-CANCER; PROTEOGLYCAN BETAGLYCAN; MESENCHYMAL TRANSITION; MEMBRANE PROTEOGLYCAN; CELL-PROLIFERATION; OVARIAN-CANCER; HUMAN-DISEASE; I RECEPTORS; EXPRESSION	The bone morphogenetic protein (BMP) family, the largest subfamily of the structurally conserved transforming growth factor-beta(TGF-beta) superfamily of growth factors, are multifunctional regulators of development, proliferation, and differentiation. The TGF-beta type III receptor (T beta RIII or betaglycan) is an abundant cell surface proteoglycan that has been well characterized as a TGF-beta and inhibin receptor. Here we demonstrate that T beta RIII functions as a BMP cell surface receptor. T beta RIII directly and specifically binds to multiple members of the BMP subfamily, including BMP-2, BMP-4, BMP-7, and GDF-5, with similar kinetics and ligand binding domains as previously identified for TGF-beta. T beta RIII also enhances ligand binding to the BMP type I receptors, whereas short hairpin RNA-mediated silencing of endogenous T beta RIII attenuates BMP-mediated Smad1 phosphorylation. Using a biologically relevant model for T beta RIII function, we demonstrate that BMP-2 specifically stimulates T beta RIII-mediated epithelial to mesenchymal cell transformation. The ability of T beta RIII to serve as a cell surface receptor and mediate BMP, inhibin, and TGF-beta signaling suggests a broader role for T beta RIII in orchestrating TGF-beta superfamily signaling.	[Kirkbride, Kellye C.; Blobe, Gerard C.] Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27708 USA; [Bruinsma, Monique W.; Blobe, Gerard C.] Duke Univ, Dept Med, Durham, NC 27708 USA; [Townsend, Todd A.; Barnett, Joey V.] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA	Duke University; Duke University; Vanderbilt University	Blobe, GC (corresponding author), 354 LSRC Res Dr,Box 91004 DUMC, Durham, NC 27708 USA.	blobe001@mc.duke.edu	Blobe, Gerard/AAJ-5945-2020	Blobe, Gerard/0000-0002-4274-8901; Bruinsma, Monique/0000-0001-8213-1060	NCI NIH HHS [CA106307] Funding Source: Medline; NHLBI NIH HHS [R01 HL052922-10, HL52922, R01 HL052922] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA106307] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052922] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRES JL, 1991, J BIOL CHEM, V266, P23282; ANDRES JL, 1992, J BIOL CHEM, V267, P5927; Babitt JL, 2006, NAT GENET, V38, P531, DOI 10.1038/ng1777; Babitt JL, 2005, J BIOL CHEM, V280, P29820, DOI 10.1074/jbc.M503511200; Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; Barnett Joey V., 2003, Birth Defects Research, V69, P58, DOI 10.1002/bdrc.10006; Beck SE, 2006, AM J PHYSIOL-GASTR L, V291, pG135, DOI 10.1152/ajpgi.00482.2005; Blobe GC, 2001, J BIOL CHEM, V276, P24627, DOI 10.1074/jbc.M100188200; Blobe GC, 2001, J BIOL CHEM, V276, P39608, DOI 10.1074/jbc.M106831200; Brown CB, 1999, SCIENCE, V283, P2080, DOI 10.1126/science.283.5410.2080; Brown MA, 2005, J BIOL CHEM, V280, P25111, DOI 10.1074/jbc.M503328200; Brubaker KD, 2004, J CELL BIOCHEM, V91, P151, DOI 10.1002/jcb.10679; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; Chen W, 2003, SCIENCE, V301, P1394, DOI 10.1126/science.1083195; Clement JH, 2005, INT J ONCOL, V27, P401; Compton LA, 2007, CIRC RES, V101, P784, DOI 10.1161/CIRCRESAHA.107.152082; De Crescenzo G, 2001, J BIOL CHEM, V276, P29632, DOI 10.1074/jbc.M009765200; Desgrosellier JS, 2005, DEV BIOL, V280, P201, DOI 10.1016/j.ydbio.2004.12.037; DEWULF N, 1995, ENDOCRINOLOGY, V136, P2652, DOI 10.1210/en.136.6.2652; Dong M, 2007, J CLIN INVEST, V117, P206, DOI 10.1172/JCI29293; Esparza-Lopez J, 2001, J BIOL CHEM, V276, P14588, DOI 10.1074/jbc.M008866200; Farnworth PG, 2006, ENDOCRINOLOGY, V147, P3462, DOI 10.1210/en.2006-0023; Fivash M, 1998, CURR OPIN BIOTECH, V9, P97, DOI 10.1016/S0958-1669(98)80091-8; GORDON KJ, 2008, IN PRESS CARCINOGENE; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; Goumans MJ, 2003, MOL CELL, V12, P817, DOI 10.1016/S1097-2765(03)00386-1; Griffith DL, 1996, P NATL ACAD SCI USA, V93, P878, DOI 10.1073/pnas.93.2.878; Harradine KA, 2006, ANN MED, V38, P403, DOI 10.1080/07853890600919911; Hatta T, 2000, BIOPOLYMERS, V55, P399, DOI 10.1002/1097-0282(2000)55:5<399::AID-BIP1014>3.0.CO;2-9; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hempel N, 2007, CANCER RES, V67, P5231, DOI 10.1158/0008-5472.CAN-07-0035; Ide H, 1997, CANCER RES, V57, P5022; Irie A, 2003, BIOCHEM BIOPH RES CO, V308, P858, DOI 10.1016/S0006-291X(03)01500-6; Jiao K, 2003, GENE DEV, V17, P2362, DOI 10.1101/gad.1124803; Karlsson R, 2004, J MOL RECOGNIT, V17, P151, DOI 10.1002/jmr.660; Kirkbride KC, 2005, TRENDS BIOCHEM SCI, V30, P611, DOI 10.1016/j.tibs.2005.09.003; Kleeff J, 1999, GASTROENTEROLOGY, V116, P1202, DOI 10.1016/S0016-5085(99)70024-7; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; Lebrin F, 2004, EMBO J, V23, P4018, DOI 10.1038/sj.emboj.7600386; Lewis KA, 2000, NATURE, V404, P411, DOI 10.1038/35006129; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Ma LJ, 2005, DEVELOPMENT, V132, P5601, DOI 10.1242/dev.02156; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Miyazono K, 2005, CYTOKINE GROWTH F R, V16, P251, DOI 10.1016/j.cytogfr.2005.01.009; Miyazono K, 2001, J CELL PHYSIOL, V187, P265, DOI 10.1002/jcp.1080; Natsume T, 1997, J BIOL CHEM, V272, P11535; Pepin MC, 1995, FEBS LETT, V377, P368, DOI 10.1016/0014-5793(95)01378-4; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Raida M, 2005, INT J ONCOL, V26, P1465; Rivera-Feliciano J, 2006, DEV BIOL, V295, P580, DOI 10.1016/j.ydbio.2006.03.043; Samad TA, 2005, J BIOL CHEM, V280, P14122, DOI 10.1074/jbc.M410034200; SEGARINI PR, 1988, J BIOL CHEM, V263, P8366; Sharifi N, 2007, PROSTATE, V67, P301, DOI 10.1002/pros.20526; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Song LY, 2007, DEV BIOL, V301, P276, DOI 10.1016/j.ydbio.2006.08.004; Stenvers KL, 2003, MOL CELL BIOL, V23, P4371, DOI 10.1128/MCB.23.12.4371-4385.2003; Takada T, 2003, J BIOL CHEM, V278, P43229, DOI 10.1074/jbc.M300937200; ten Dijke P, 2003, MOL CELL ENDOCRINOL, V211, P105, DOI 10.1016/j.mce.2003.09.016; Theriault BL, 2007, CARCINOGENESIS, V28, P1153, DOI 10.1093/carcin/bgm015; Turley RS, 2007, CANCER RES, V67, P1090, DOI 10.1158/0008-5472.CAN-06-3117; Velasco-Loyden G, 2004, J BIOL CHEM, V279, P7721, DOI 10.1074/jbc.M306499200; Waite KA, 2003, NAT REV GENET, V4, P763, DOI 10.1038/nrg1178; Wang SN, 2004, J BIOL CHEM, V279, P23200, DOI 10.1074/jbc.M311998200; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; Wiater E, 2006, J BIOL CHEM, V281, P17011, DOI 10.1074/jbc.M601459200; You HJ, 2007, CARCINOGENESIS, V28, P2491, DOI 10.1093/carcin/bgm195; Zeisberg EM, 2007, NAT MED, V13, P952, DOI 10.1038/nm1613; Zhao GQ, 2003, GENESIS, V35, P43, DOI 10.1002/gene.10167	73	144	151	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7628	7637		10.1074/jbc.M704883200	http://dx.doi.org/10.1074/jbc.M704883200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18184661	hybrid			2022-12-25	WOS:000253997900038
J	Dittmer, S; Sahin, M; Pantlen, A; Saxena, A; Toutzaris, D; Pina, AL; Geerts, A; Golz, S; Methner, A				Dittmer, Sonja; Sahin, Mert; Pantlen, Anna; Saxena, Ambrish; Toutzaris, Diamandis; Pina, Ana-Luisa; Geerts, Andreas; Golz, Stefan; Methner, Axel			The constitutively active orphan G-protein-coupled receptor GPR39 protects from cell death by increasing secretion of pigment epithelium-derived growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE GLUTAMATE TOXICITY; HORMONE SECRETAGOGUE; SIGNALING PATHWAYS; GENE; IDENTIFICATION; ACTIVATION; EXPRESSION; SURVIVAL; KINASE; FAMILY	GPR39 is a constitutively active orphan G-protein-coupled receptor capable of increasing serum response element-mediated transcription. We found GPR39 to be up-regulated in a hippocampal cell line resistant against diverse stimulators of cell death and show that its overexpression protects against oxidative and endoplasmic reticulum stress, as well as against direct activation of the caspase cascade by Bax overexpression. In contrast, silencing GPR39 rendered cells more susceptible to cell death. An array analysis of transcripts induced by GPR39 revealed up-regulation of RGS16 ( inhibitor of G-protein signaling 16), which suggested coupling to G alpha(13) and induction of serum response element-mediated transcription by the small GTPase RhoA. In line with this, co-expression of GPR39 with RGS16, dominant-negative RhoA, or serum response factor abolished cell protection, whereas overexpression of the serum response factor protected from cell death. Further downstream the signaling cascade, GPR39 overexpression leads to increased secretion of the cytoprotective pigment epithelium-derived growth factor ( PEDF). Medium conditioned by cells overexpressing GPR39 contained 4-fold more PEDF, and when stripped off it lost most but not all of its protective properties. We conclude that GPR39 is a novel inhibitor of cell death, which might represent a therapeutic target with implications for processes involving apoptosis and endoplasmic reticulum stress like cancer, ischemia/ reperfusion injury, and neurodegenerative disease.	[Dittmer, Sonja; Saxena, Ambrish; Toutzaris, Diamandis; Methner, Axel] Univ Dusseldorf, Dept Neurol, Res Grp Protect Signaling, D-40225 Dusseldorf, Germany; [Sahin, Mert; Pantlen, Anna] Zentrum Mol Neurobiol Hamburg, D-20251 Hamburg, Germany; [Pina, Ana-Luisa] Univ Clin Regensburg, Dept Neurosurg, Neurobiol Res Grp, D-93053 Regensburg, Germany; [Geerts, Andreas; Golz, Stefan] Bayer HealthCare, Inst Target Res, D-42096 Wuppertal, Germany	Heinrich Heine University Dusseldorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Regensburg; Bayer AG; Bayer Healthcare Pharmaceuticals	Methner, A (corresponding author), Univ Dusseldorf, Dept Neurol, Res Grp Protect Signaling, Moorenstr 5, D-40225 Dusseldorf, Germany.		Saxena, Ambrish/AAQ-5984-2020	Methner, Axel/0000-0002-8774-0057				Chan CB, 2004, MOL CELL ENDOCRINOL, V214, P81, DOI 10.1016/j.mce.2003.11.020; Donovan FM, 1998, J BIOL CHEM, V273, P12746, DOI 10.1074/jbc.273.21.12746; Drews J, 2000, DRUG DISCOV TODAY, V5, P2, DOI 10.1016/S1359-6446(99)01428-2; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Egerod KL, 2007, MOL ENDOCRINOL, V21, P1685, DOI 10.1210/me.2007-0055; Flynn AN, 2004, APOPTOSIS, V9, P729, DOI 10.1023/B:APPT.0000045784.49886.96; Frederickson CJ, 2005, NAT REV NEUROSCI, V6, P449, DOI 10.1038/nrn1671; Heiber M, 1996, GENOMICS, V32, P462, DOI 10.1006/geno.1996.0143; Holst B, 2004, J BIOL CHEM, V279, P53806, DOI 10.1074/jbc.M407676200; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; Johnson EN, 2003, NAT CELL BIOL, V5, P1095, DOI 10.1038/ncb1065; JOOST P, GENOME BIOL, V3; Lefkowitz RJ, 2000, NAT CELL BIOL, V2, pE133, DOI 10.1038/35017152; Lewerenz J, 2006, J NEUROCHEM, V98, P916, DOI 10.1111/j.1471-4159.2006.03921.x; McKee KK, 1997, GENOMICS, V46, P426, DOI 10.1006/geno.1997.5069; Radeff-Huang J, 2004, J CELL BIOCHEM, V92, P949, DOI 10.1002/jcb.20094; Sahin M, 2006, FREE RADICAL RES, V40, P1113, DOI 10.1080/10715760600838191; Schratt G, 2004, EMBO J, V23, P1834, DOI 10.1038/sj.emboj.7600188; Tan Shirlee, 2001, Current Topics in Medicinal Chemistry, V1, P497, DOI 10.2174/1568026013394741; Tombran-Tink J, 2003, NAT REV NEUROSCI, V4, P628, DOI 10.1038/nrn1176; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; XU C, 1995, J CLIN INVEST, V115, P2656; Zhang JV, 2005, SCIENCE, V310, P996, DOI 10.1126/science.1117255	23	51	54	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					7074	7081		10.1074/jbc.M704323200	http://dx.doi.org/10.1074/jbc.M704323200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18180304	hybrid			2022-12-25	WOS:000253779600052
J	Ha, CH; Bennett, AM; Jin, ZG				Ha, Chang Hoon; Bennett, Anton M.; Jin, Zheng-Gen			A novel role of vascular endothelial cadherin in modulating c-Src activation and downstream signaling of vascular endothelial growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; SHP-2 TYROSINE PHOSPHATASE; VE-CADHERIN; INDUCED ANGIOGENESIS; CELL-PROLIFERATION; DNA-SYNTHESIS; KINASE; PERMEABILITY; PHOSPHORYLATION; PATHWAY	Vascular endothelial growth factor ( VEGF) is a potent mediator of angiogenesis and vascular permeability, in which c-Src tyrosine kinase plays an essential role. However, the mechanisms by which VEGF stimulates c-Src activation have remained unclear. Here, we demonstrate that vascular endothelial cadherin ( VE-cadherin) plays a critical role in regulating c-Src activation in response to VEGF. In vascular endothelial cells, VE-cadherin was basally associated with c-Src and Csk ( C-terminal Src kinase), a negative regulator of Src activation. VEGF stimulated Csk release from VE-cadherin by recruiting the protein tyrosine phosphatase SHP2 to VE-cadherin signaling complex, leading to an increase in c-Src activation. Silencing VE-cadherin with small interference RNA significantly reduced VEGF-stimulated c-Src activation. Disrupting the association of VE-cadherin and Csk through the reconstitution of Csk binding-defective mutant of VE-cadherin also diminished Src activation. Moreover, inhibiting SHP2 by small interference RNA and adenovirus-mediated expression of a catalytically inactive mutant of SHP2 attenuated c-Src activation by blocking the disassociation of Csk from VE-cadherin. Furthermore, VE-cadherin and SHP2 differentially regulates VEGF downstream signaling. The inhibition of c-Src, VE-cadherin, and SHP2 diminished VEGF-mediated activation of Akt and endothelial nitric-oxide synthase. In contrast, inhibiting VE-cadherin and SHP2 enhanced ERK1/2 activation in response to VEGF. These findings reveal a novel role for VE-cadherin in modulating c-Src activation in VEGF signaling, thus providing new insights into the importance of VE-cadherin in VEGF signaling and vascular function.	[Ha, Chang Hoon; Jin, Zheng-Gen] Univ Rochester, Sch Med & Dent, Aab Cardiovasc Res Inst, Rochester, NY 14586 USA; [Bennett, Anton M.] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	University of Rochester; Yale University	Jin, ZG (corresponding author), Univ Rochester, Sch Med & Dent, Aab Cardiovasc Res Inst, 211 Bailey Rd, Rochester, NY 14586 USA.	zheng-gen_jin@urmc.rochester.edu	Ha, C/GZL-9046-2022	Ha, Chang Hoon/0000-0001-7606-4340; Bennett, Anton/0000-0001-5187-7599	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080611] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046524] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL080611, R01 HL080611-05] Funding Source: Medline; NIAMS NIH HHS [R01 AR046524, R01 AR046524-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Baumeister U, 2005, EMBO J, V24, P1686, DOI 10.1038/sj.emboj.7600647; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Chan RJ, 2007, BLOOD, V109, P862, DOI 10.1182/blood-2006-07-028829; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; Dejana E, 2001, THROMB HAEMOSTASIS, V86, P308; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079; Esser S, 1998, J CELL SCI, V111, P1853; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fukumura D, 2001, P NATL ACAD SCI USA, V98, P2604, DOI 10.1073/pnas.041359198; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Jin ZG, 2005, J BIOL CHEM, V280, P12305, DOI 10.1074/jbc.M500294200; Jin ZG, 2003, CIRC RES, V93, P354, DOI 10.1161/01.RES.0000089257.94002.96; Kontaridis MI, 2002, MOL CELL BIOL, V22, P3875, DOI 10.1128/MCB.22.11.3875-3891.2002; Lampugnani MG, 2003, J CELL BIOL, V161, P793, DOI 10.1083/jcb.200209019; LIEBL EC, 1992, ONCOGENE, V7, P2417; Lungu AO, 2004, J BIOL CHEM, V279, P48794, DOI 10.1074/jbc.M313897200; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Okuda M, 1999, J BIOL CHEM, V274, P26803, DOI 10.1074/jbc.274.38.26803; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Radisavljevic Z, 2000, J BIOL CHEM, V275, P20770, DOI 10.1074/jbc.M002448200; Ren Y, 2004, J BIOL CHEM, V279, P8497, DOI 10.1074/jbc.M312575200; Sakurai Y, 2005, P NATL ACAD SCI USA, V102, P1076, DOI 10.1073/pnas.0404984102; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; Sessa WC, 2005, MEM I OSWALDO CRUZ, V100, P15, DOI 10.1590/S0074-02762005000900004; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shay-Salit A, 2002, P NATL ACAD SCI USA, V99, P9462, DOI 10.1073/pnas.142224299; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Ukropec JA, 2000, J BIOL CHEM, V275, P5983, DOI 10.1074/jbc.275.8.5983; Weis SM, 2005, NATURE, V437, P497, DOI 10.1038/nature03987; Wong C, 2005, J BIOL CHEM, V280, P33262, DOI 10.1074/jbc.M503198200; Yamaoka-Tojo M, 2006, ARTERIOSCL THROM VAS, V26, P1991, DOI 10.1161/01.ATV.0000231524.14873.e7; Zachary I, 2003, BIOCHEM SOC T, V31, P1171; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4	42	53	58	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					7261	7270		10.1074/jbc.M702881200	http://dx.doi.org/10.1074/jbc.M702881200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18180305	Green Accepted, hybrid			2022-12-25	WOS:000253779600071
J	Li, W; Bengtson, MH; Ulbrich, A; Matsuda, A; Reddy, VA; Orth, A; Chanda, SK; Batalov, S; Joazeiro, CAP				Li, Wei; Bengtson, Mario H.; Ulbrich, Axel; Matsuda, Akio; Reddy, Venkateshwar A.; Orth, Anthony; Chanda, Sumit K.; Batalov, Serge; Joazeiro, Claudio A. P.			Genome-Wide and Functional Annotation of Human E3 Ubiquitin Ligases Identifies MULAN, a Mitochondrial E3 that Regulates the Organelle's Dynamics and Signaling	PLOS ONE			English	Article								Specificity of protein ubiquitylation is conferred by E3 ubiquitin (Ub) ligases. We have annotated similar to 617 putative E3s and substrate-recognition subunits of E3 complexes encoded in the human genome. The limited knowledge of the function of members of the large E3 superfamily prompted us to generate genome-wide E3 cDNA and RNAi expression libraries designed for functional screening. An imaging-based screen using these libraries to identify E3s that regulate mitochondrial dynamics uncovered MULAN/FLJ12875, a RING finger protein whose ectopic expression and knockdown both interfered with mitochondrial trafficking and morphology. We found that MULAN is a mitochondrial protein - two transmembrane domains mediate its localization to the organelle's outer membrane. MULAN is oriented such that its E3-active, C-terminal RING finger is exposed to the cytosol, where it has access to other components of the Ub system. Both an intact RING finger and the correct subcellular localization were required for regulation of mitochondrial dynamics, suggesting that MULAN's downstream effectors are proteins that are either integral to, or associated with, mitochondria and that become modified with Ub. Interestingly, MULAN had previously been identified as an activator of NF-kappa B, thus providing a link between mitochondrial dynamics and mitochondria-to-nucleus signaling. These findings suggest the existence of a new, Ub-mediated mechanism responsible for integration of mitochondria into the cellular environment.	[Li, Wei; Bengtson, Mario H.; Ulbrich, Axel; Joazeiro, Claudio A. P.] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; [Matsuda, Akio] ASAHI KASEI Corp, Inst Life Sci Res, Shizuoka, Japan; [Reddy, Venkateshwar A.; Orth, Anthony; Chanda, Sumit K.; Batalov, Serge] Novartis Res Fdn, Gen Inst, San Diego, CA USA	Scripps Research Institute; Asahi Kasei Corporation; Novartis	Joazeiro, CAP (corresponding author), Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA.	joazeiro@scripps.edu		Batalov, Sergey/0000-0002-0925-0554	The Genomics Institute of the Novartis Research Foundation (GNF)	The Genomics Institute of the Novartis Research Foundation (GNF)	TSRI start-up funds and funds from The Genomics Institute of the Novartis Research Foundation (GNF)	Beckmann JS, 2005, HUM MUTAT, V25, P507, DOI 10.1002/humu.20175; Chan DC, 2006, CELL, V125, P1241, DOI 10.1016/j.cell.2006.06.010; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Eisenhaber B, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-3-209; Fisk HA, 1999, J CELL BIOL, V145, P1199, DOI 10.1083/jcb.145.6.1199; Fritz S, 2003, MOL BIOL CELL, V14, P2303, DOI 10.1091/mbc.E02-12-0831; Harder Z, 2004, CURR BIOL, V14, P340, DOI 10.1016/j.cub.2004.02.004; Hollenbeck PJ, 2005, J CELL SCI, V118, P5411, DOI 10.1242/jcs.053850; Jin JP, 2004, GENE DEV, V18, P2573, DOI 10.1101/gad.1255304; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Karbowski M, 2007, J CELL BIOL, V178, P71, DOI 10.1083/jcb.200611064; Karbowski M, 2006, NATURE, V443, P658, DOI 10.1038/nature05111; Koppen M, 2007, CRIT REV BIOCHEM MOL, V42, P221, DOI 10.1080/10409230701380452; Li W, 2005, METHOD ENZYMOL, V398, P280, DOI 10.1016/S0076-6879(05)98023-3; Marin I, 2004, PHYSIOL GENOMICS, V17, P253, DOI 10.1152/physiolgenomics.00226.2003; Marin I, 2002, MOL BIOL EVOL, V19, P2039, DOI 10.1093/oxfordjournals.molbev.a004029; Matsuda A, 2003, ONCOGENE, V22, P3307, DOI 10.1038/sj.onc.1206406; Meroni G, 2005, BIOESSAYS, V27, P1147, DOI 10.1002/bies.20304; Nakamura N, 2006, EMBO REP, V7, P1019, DOI 10.1038/sj.embor.7400790; Neutzner A, 2005, J BIOL CHEM, V280, P18598, DOI 10.1074/jbc.M500807200; Okamoto K, 2005, ANNU REV GENET, V39, P503, DOI 10.1146/annurev.genet.38.072902.093019; Perez-Torrado R, 2006, BIOESSAYS, V28, P1194, DOI 10.1002/bies.20500; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Rezaul K, 2005, MOL CELL PROTEOMICS, V4, P169, DOI 10.1074/mcp.M400115-MCP200; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Short KM, 2006, J BIOL CHEM, V281, P8970, DOI 10.1074/jbc.M512755200; Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245; Stogios PJ, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-10-r82; Waizenegger T, 2003, J BIOL CHEM, V278, P42064, DOI 10.1074/jbc.M305736200; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200; Yaffe MP, 1999, SCIENCE, V283, P1493, DOI 10.1126/science.283.5407.1493; Yonashiro R, 2006, EMBO J, V25, P3618, DOI 10.1038/sj.emboj.7601249; Zhao Q, 2002, EMBO J, V21, P4411, DOI 10.1093/emboj/cdf445; Zhou HL, 2005, CANCER CELL, V7, P425, DOI 10.1016/j.ccr.2005.04.012; Zhu CJ, 2005, MOL BIOL CELL, V16, P3187, DOI 10.1091/mbc.E05-02-0167	39	499	519	6	44	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2008	3	1							e1487	10.1371/journal.pone.0001487	http://dx.doi.org/10.1371/journal.pone.0001487			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SO	18213395	Green Submitted, gold, Green Published			2022-12-25	WOS:000260503900032
J	Poderoso, C; Converso, DP; Maloberti, P; Duarte, A; Neuman, I; Galli, S; Maciel, FC; Paz, C; Carreras, MC; Poderoso, JJ; Podesta, EJ				Poderoso, Cecilia; Converso, Daniela P.; Maloberti, Paula; Duarte, Alejandra; Neuman, Isabel; Galli, Soledad; Maciel, Fabiana Cornejo; Paz, Cristina; Carreras, Maria C.; Poderoso, Juan J.; Podesta, Ernesto J.			A Mitochondrial Kinase Complex Is Essential to Mediate an ERK1/2-Dependent Phosphorylation of a Key Regulatory Protein in Steroid Biosynthesis	PLOS ONE			English	Article								ERK1/2 is known to be involved in hormone-stimulated steroid synthesis, but its exact roles and the underlying mechanisms remain elusive. Both ERK1/2 phosphorylation and steroidogenesis may be triggered by cAMP/cAMP-dependent protein kinase (PKA)-dependent and-independent mechanisms; however, ERK1/2 activation by cAMP results in a maximal steroidogenic rate, whereas canonical activation by epidermal growth factor (EGF) does not. We demonstrate herein by Western blot analysis and confocal studies that temporal mitochondrial ERK1/2 activation is obligatory for PKA-mediated steroidogenesis in the Leydig-transformed MA-10 cell line. PKA activity leads to the phosphorylation of a constitutive mitochondrial MEK1/2 pool with a lower effect in cytosolic MEKs, while EGF allows predominant cytosolic MEK activation and nuclear pERK1/2 localization. These results would explain why PKA favors a more durable ERK1/2 activation in mitochondria than does EGF. By means of ex vivo experiments, we showed that mitochondrial maximal steroidogenesis occurred as a result of the mutual action of steroidogenic acute regulatory (StAR) protein -a key regulatory component in steroid biosynthesis-, active ERK1/2 and PKA. Our results indicate that there is an interaction between mitochondrial StAR and ERK1/2, involving a D domain with sequential basic-hydrophobic motifs similar to ERK substrates. As a result of this binding and only in the presence of cholesterol, ERK1/2 phosphorylates StAR at Ser(232). Directed mutagenesis of Ser(232) to a non-phosphorylable amino acid such as Ala ( StAR S232A) inhibited in vitro StAR phosphorylation by active ERK1/2. Transient transfection of MA-10 cells with StAR S232A markedly reduced the yield of progesterone production. In summary, here we show that StAR is a novel substrate of ERK1/2, and that mitochondrial ERK1/2 is part of a multimeric protein kinase complex that regulates cholesterol transport. The role of MAPKs in mitochondrial function is underlined.	[Converso, Daniela P.; Galli, Soledad; Carreras, Maria C.; Poderoso, Juan J.] Univ Buenos Aires, Univ Hosp, Lab Oxygen Metab, Buenos Aires, DF, Argentina; [Carreras, Maria C.] Univ Buenos Aires, Univ Hosp, Dept Clin Biochem, Buenos Aires, DF, Argentina; [Poderoso, Cecilia; Maloberti, Paula; Duarte, Alejandra; Neuman, Isabel; Maciel, Fabiana Cornejo; Paz, Cristina; Podesta, Ernesto J.] Univ Buenos Aires, Sch Med, Dept Human Biochem, IIMHNO, Buenos Aires, DF, Argentina	University of Buenos Aires; University of Buenos Aires; University of Buenos Aires	Podesta, EJ (corresponding author), Univ Buenos Aires, Sch Med, Dept Human Biochem, IIMHNO, Buenos Aires, DF, Argentina.	biohrdc@fmed.uba.ar	Maloberti, Paula/AAU-5216-2020	CORNEJO MACIEL, MARIA FABIANA/0000-0003-0685-9038	National Research Council (CONICET); University of Buenos Aires (UBA); National Agency for Promotion of Science and Technology (ANPCyT); Sigma Xi; Scientific Research Society	National Research Council (CONICET)(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); University of Buenos Aires (UBA)(University of Buenos Aires); National Agency for Promotion of Science and Technology (ANPCyT)(ANPCyT); Sigma Xi; Scientific Research Society	National Research Council (CONICET) University of Buenos Aires (UBA) National Agency for Promotion of Science and Technology (ANPCyT) Sigma Xi, the Scientific Research Society.	Allen JA, 2006, ENDOCRINOLOGY, V147, P3924, DOI 10.1210/en.2005-1204; Alonso M, 2004, J NEUROCHEM, V89, P248, DOI 10.1111/j.1471-4159.2004.02323.x; Arakane F, 1997, J BIOL CHEM, V272, P32656, DOI 10.1074/jbc.272.51.32656; Arakane F, 1996, P NATL ACAD SCI USA, V93, P13731, DOI 10.1073/pnas.93.24.13731; Artemenko IP, 2001, J BIOL CHEM, V276, P46583, DOI 10.1074/jbc.M107815200; ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; ASCOLI M, 1987, J BIOL CHEM, V262, P9196; Baines CP, 2002, CIRC RES, V90, P390, DOI 10.1161/01.RES.0000012702.90501.8D; Bardwell AJ, 2003, BIOCHEM J, V370, P1077, DOI 10.1042/BJ20021806; Bose HS, 2002, NATURE, V417, P87, DOI 10.1038/417087a; Castillo AF, 2006, FEBS J, V273, P5011, DOI 10.1111/j.1742-4658.2006.05496.x; CHAREST DL, 1993, MOL CELL BIOL, V13, P4679, DOI 10.1128/MCB.13.8.4679; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; Colonna C, 2005, EXP CELL RES, V304, P432, DOI 10.1016/j.yexcr.2004.11.019; COOKE BA, 1976, BIOCHEM J, V160, P439, DOI 10.1042/bj1600439; CRIVELLO JF, 1980, J BIOL CHEM, V255, P8144; Duarte A, 2007, FEBS LETT, V581, P4023, DOI 10.1016/j.febslet.2007.07.040; EPSTEIN LF, 1991, J BIOL CHEM, V266, P19739; Fantz DA, 2001, J BIOL CHEM, V276, P27256, DOI 10.1074/jbc.M102512200; Fleury A, 2004, J STEROID BIOCHEM, V91, P259, DOI 10.1016/j.jsbmb.2004.04.010; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; Granot Z, 2007, MOL CELL ENDOCRINOL, V265, P51, DOI 10.1016/j.mce.2006.12.003; Gyles SL, 2001, J BIOL CHEM, V276, P34888, DOI 10.1074/jbc.M102063200; Gyles SL, 2000, ENDOCR RES, V26, P579, DOI 10.3109/07435800009048574; Hengen PN, 1996, TRENDS BIOCHEM SCI, V21, P400, DOI 10.1016/S0968-0004(96)30035-2; Hirakawa T, 2003, MOL ENDOCRINOL, V17, P2189, DOI 10.1210/me.2003-0205; KRUEGER RJ, 1983, J BIOL CHEM, V258, P159; Liu J, 2006, J BIOL CHEM, V281, P38879, DOI 10.1074/jbc.M608820200; Maciel FC, 2001, J ENDOCRINOL, V170, P403, DOI 10.1677/joe.0.1700403; Maloberti P, 2005, FEBS J, V272, P1804, DOI 10.1111/j.1742-4658.2005.04616.x; Maloberti P, 2002, EUR J BIOCHEM, V269, P5599, DOI 10.1046/j.1432-1033.2002.03267.x; Manna PR, 2007, J ENDOCRINOL, V193, P53, DOI 10.1677/JOE-06-0201; Martinelle N, 2004, ENDOCRINOLOGY, V145, P4629, DOI 10.1210/en.2004-0496; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; Miller WL, 2007, MOL CELL ENDOCRINOL, V265, P46, DOI 10.1016/j.mce.2006.12.002; Miller WL, 2007, MOL ENDOCRINOL, V21, P589, DOI 10.1210/me.2006-0303; NEHER R, 1982, P NATL ACAD SCI-BIOL, V79, P1727, DOI 10.1073/pnas.79.6.1727; Otis M, 2007, MOL CELL ENDOCRINOL, V265, P126, DOI 10.1016/j.mce.2006.12.008; Papadopoulos V, 2006, TRENDS PHARMACOL SCI, V27, P402, DOI 10.1016/j.tips.2006.06.005; Paz C, 2002, J ENDOCRINOL, V175, P793, DOI 10.1677/joe.0.1750793; Petrescu AD, 2001, J BIOL CHEM, V276, P36970, DOI 10.1074/jbc.M101939200; PODESTA EJ, 1979, P NATL ACAD SCI USA, V76, P5187, DOI 10.1073/pnas.76.10.5187; PODESTA EJ, 1976, FEBS LETT, V70, P212, DOI 10.1016/0014-5793(76)80760-0; PRIVALLE CT, 1983, P NATL ACAD SCI-BIOL, V80, P702, DOI 10.1073/pnas.80.3.702; RAE PA, 1979, P NATL ACAD SCI USA, V76, P1896, DOI 10.1073/pnas.76.4.1896; Renlund N, 2006, J MOL ENDOCRINOL, V36, P327, DOI 10.1677/jme.1.01963; Robinson FL, 2002, J BIOL CHEM, V277, P14844, DOI 10.1074/jbc.M107776200; SALA GB, 1979, J BIOL CHEM, V254, P3861; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Seger R, 2001, J BIOL CHEM, V276, P13957, DOI 10.1074/jbc.M006852200; Shiraishi K, 2006, ENDOCRINOLOGY, V147, P3419, DOI 10.1210/en.2005-1478; Soltys BJ, 1999, TRENDS BIOCHEM SCI, V24, P174, DOI 10.1016/S0968-0004(99)01390-0; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; Stocco DM, 2005, MOL ENDOCRINOL, V19, P2647, DOI 10.1210/me.2004-0532; STOCCO DM, 1991, J BIOL CHEM, V266, P19731; STOCCO DM, 1983, ANAL BIOCHEM, V131, P453, DOI 10.1016/0003-2697(83)90198-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wang XJ, 1998, ENDOCRINOLOGY, V139, P3903, DOI 10.1210/en.139.9.3903; Xu BE, 2001, J BIOL CHEM, V276, P26509, DOI 10.1074/jbc.M102769200; Yamazaki T, 2006, BBA-PROTEINS PROTEOM, V1764, P1561, DOI 10.1016/j.bbapap.2006.08.016; Zhou TJ, 2006, STRUCTURE, V14, P1011, DOI 10.1016/j.str.2006.04.006	62	89	91	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2008	3	1							e1443	10.1371/journal.pone.0001443	http://dx.doi.org/10.1371/journal.pone.0001443			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SN	18197253	gold, Green Published, Green Submitted			2022-12-25	WOS:000260503800014
J	Bassichetto, KC; Bergamaschi, DP; Oliveira, SM; Deienno, MCV; Bortolato, R; de Rezende, HV; Arthur, T; Tomiyama, H; Watkins, C; Mesquita, F; Abbate, MC; Kallas, EG				Bassichetto, Katia Cristina; Bergamaschi, Denise Pimentel; Oliveira, Solange Maria; Verri Deienno, Marylei Casteldelli; Bortolato, Reginaldo; de Rezende, Heloiza Vilma; Arthur, Thais; Tomiyama, Helena; Watkins, Colyn; Mesquita, Fabio; Abbate, Maria Cristina; Kallas, Esper Georges			Elevated Risk for HIV-1 Infection in Adolescents and Young Adults in Sao Paulo, Brazil	PLOS ONE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; SENSITIVE ENZYME-IMMUNOASSAY; TESTING STRATEGY; MEN; PREVENTION; BEHAVIORS; HIV/AIDS; SANTOS; SEX	Background. Recent studies have sought to describe HIV infection and transmission characteristics around the world. Identification of early HIV-1 infection is essential to proper surveillance and description of regional transmission trends. In this study we compare people recently infected (RI) with HIV-1, as defined by Serologic Testing Algorithm for Recent HIV Seroconversion (STARHS), to those with chronic infection. Methodology/Principal Findings. Subjects were identified from 2002-2004 at four testing sites in Sao Paulo. Of 485 HIV-1-positive subjects, 57 (12%) were defined as RI. Of the participants, 165 (34.0%) were aware of their serostatus at the time of HIV-1 testing. This proportion was statistically larger (p<0.001) among the individuals without recent infection (n = 158, 95.8%) compared to 7 individuals (4.2%) with recently acquired HIV-1 infection. In the univariate analysis, RI was more frequent in,25 and >59 years-old age strata (p < 0.001). The majority of study participants were male (78.4%), 25 to 45 years-old (65.8%), white (63.2%), single (61.7%), with family income of four or more times the minimum wage (41.0%), but with an equally distributed educational level. Of those individuals infected with HIV-1, the predominant route of infection was sexual contact (89.4%), with both hetero (47.5%) and homosexual (34.5%) exposure. Regarding sexual activity in these individuals, 43.9% reported possible HIV-1 exposure through a seropositive partner, and 49.4% reported multiple partners, with 47% having 2 to 10 partners and 37.4% 11 or more; 53.4% of infected individuals reported condom use sometimes; 34.2% reported non-injecting, recreational drug use and 23.6% were reactive for syphilis by VDRL. Subjects younger than 25 years of age were most vulnerable according to the multivariate analysis. Conclusions/Significance. In this study, we evaluated RI individuals and discovered that HIV-1 has been spreading among younger individuals in Sao Paulo and preventive approaches should, therefore, target this age stratum.	[Bassichetto, Katia Cristina; Mesquita, Fabio; Abbate, Maria Cristina] Publ Hlth Dept Sao Paulo, Sao Paulo, Brazil; [Bergamaschi, Denise Pimentel; Arthur, Thais; Kallas, Esper Georges] Univ Sao Paulo, Dept Allergy & Immunol, Sao Paulo, Brazil; [Oliveira, Solange Maria] Henfil Counseling & Testing Ctr, Sao Paulo, Brazil; [Verri Deienno, Marylei Casteldelli] Spec Attend Serv STD Aids Camp Eliseos, Sao Paulo, Brazil; [Bortolato, Reginaldo] Spec Attend Serv STD Aids Lapa, Sao Paulo, Brazil; [de Rezende, Heloiza Vilma] Pirituba Counsel & Test Ctr, Sao Paulo, Brazil; [Tomiyama, Helena; Watkins, Colyn; Kallas, Esper Georges] Univ Fed Sao Paulo, Div Infect Dis, Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP)	Bassichetto, KC (corresponding author), Publ Hlth Dept Sao Paulo, Sao Paulo, Brazil.	kbassichetto@prefeitura.sp.gov.br	Kallas, Esper G/C-9539-2012; Bergamaschi, Denise Pimentel/I-7383-2017; Mesquita, Fabio/AAZ-7021-2020	Bergamaschi, Denise Pimentel/0000-0002-6889-8588; Kallas, Esper/0000-0003-2026-6925; Mesquita, Fabio/0000-0002-8297-0224	Brazilian Program for STD and AIDS; Ministry of Health [TC282/05, 914/BRA/3014]; Sao Paulo City Health Department [2004-0.168.922-7]; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [04/15856-9]	Brazilian Program for STD and AIDS; Ministry of Health; Sao Paulo City Health Department; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	This study was supported with funding from the Brazilian Program for STD and AIDS, Ministry of Health (TC282/05, UNESCO/Bassichetto and 914/BRA/3014, UNESCO/Kallas), the Sao Paulo City Health Department (2004-0.168.922-7/Kallas), and Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (04/15856-9/Kallas).	Alves K, 2003, JAIDS-J ACQ IMM DEF, V32, P551, DOI 10.1097/00126334-200304150-00014; Sucupira MCA, 2007, AIDS PATIENT CARE ST, V21, P116, DOI 10.1089/apc.2006.0079; *BRAS MIN SAUD, 2002, B EP AIDS, V15; *BRAS MIN SAUD SEC, 2002, VIG HIV BRAS NOV DIR; *BRAS MIN SAUD SEC, 2002, SIST INF CENTR TEST; *CDCP, 2001, MMWR, V50; Chawla A, 2007, J CLIN MICROBIOL, V45, P415, DOI 10.1128/JCM.01879-06; Cochran W.G., 1967, STAT METHODS; Cooperman NA, 2007, AIDS EDUC PREV, V19, P321, DOI 10.1521/aeap.2007.19.4.321; da Silva CGM, 2005, AIDS, V19, pS31, DOI 10.1097/01.aids.0000191488.77038.bb; DEAN AG, 2002, EPI INFO DATABASE ST; Diaz RS, 1999, AIDS, V13, P1417, DOI 10.1097/00002030-199907300-00024; Hosmer DW, 2001, APPL LOGISTIC REGRES; Janssen RS, 1998, JAMA-J AM MED ASSOC, V280, P42, DOI 10.1001/jama.280.1.42; Jarlais DC, 2005, AM J PUBLIC HEALTH, V95, P1439, DOI 10.2105/AJPH.2003.036517; Kallas Esper Georges, 2004, Braz J Infect Dis, V8, P399, DOI 10.1590/S1413-86702004000600003; Kellerman SE, 2002, JAIDS-J ACQ IMM DEF, V31, P202, DOI 10.1097/00126334-200210010-00011; Oliveira CAD, 2005, J CLIN MICROBIOL, V43, P1439, DOI 10.1128/JCM.43.3.1439-1442.2005; Ostrow DE, 2002, AIDS, V16, P775, DOI 10.1097/00002030-200203290-00013; Puchhammer-Stokl E, 2005, J CLIN MICROBIOL, V43, P497, DOI 10.1128/JCM.43.1.497-498.2005; Rawal BD, 2003, JAIDS-J ACQ IMM DEF, V33, P349, DOI 10.1097/00126334-200307010-00009; Rosa H, 2006, REV SAUDE PUBL, V40, P220, DOI 10.1590/S0034-89102006000200006; Schwarcz SK, 2002, J INFECT DIS, V186, P1019, DOI 10.1086/342954; *SECR MUN SAUD SAO, 2007, B EP AIDS DST HEP B; STALL R, 1994, ARCH INTERN MED, V154, P57, DOI 10.1001/archinte.154.1.57; STATA, 2001, STAT STAT SOFTW REL; Stolte IG, 2004, AIDS, V18, P303, DOI 10.1097/00002030-200401230-00021; Szwarcwald CL, 2005, AIDS, V19, pS51, DOI 10.1097/01.aids.0000191491.66736.16	28	9	9	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2008	3	1							e1423	10.1371/journal.pone.0001423	http://dx.doi.org/10.1371/journal.pone.0001423			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	366GT	18183303	Green Published, gold, Green Submitted			2022-12-25	WOS:000260469400019
J	Zhou, G; Xie, TX; Zhao, M; Jasser, SA; Younes, MN; Sano, D; Lin, J; Kupferman, ME; Santillan, AA; Patel, V; Gutkind, JS; Ei-Naggar, AK; Emberley, ED; Watson, PH; Matsuzawa, SI; Reed, JC; Myers, JN				Zhou, G.; Xie, T-X; Zhao, M.; Jasser, S. A.; Younes, M. N.; Sano, D.; Lin, J.; Kupferman, M. E.; Santillan, A. A.; Patel, V.; Gutkind, J. S.; Ei-Naggar, A. K.; Emberley, E. D.; Watson, P. H.; Matsuzawa, S-I; Reed, J. C.; Myers, J. N.			Reciprocal negative regulation between S100A7/psoriasin and beta-catenin signaling plays an important role in tumor progression of squamous cell carcinoma of oral cavity	ONCOGENE			English	Article						S100A7; psoriasin; beta-catenin; oral squamous cell carcinoma; head and neck squamous cell carcinoma	F-BOX PROTEIN; DEGRADATION PATHWAY; COLORECTAL-CANCER; PSORIASIN S100A7; C-MYC; EXPRESSION; COMPLEX; ACTIVATION; CALCIUM; SIAH-1	Overexpression of S100A7 (psoriasin), a small calcium-binding protein, has been associated with the development of psoriasis and carcinomas in different types of epithelia, but its precise functions are still unknown. Using human tissue specimens, cultured cell lines, and a mouse model, we found that S100A7 is highly expressed in preinvasive, well-differentiated and early staged human squamous cell carcinoma of the oral cavity (SCCOC), but little or no expression was found in poorly differentiated, later-staged invasive tumors. Interestingly, our results showed that S100A7 inhibits both SCCOC cell proliferation in vitro and tumor growth/invasion in vivo. Furthermore, we demonstrated that S100A7 is associated with the beta-catenin complex, and inhibits beta-catenin signaling by targeting beta-catenin degradation via a noncanonical mechanism that is independent of GSK3 beta-mediated phosphorylation. More importantly, our results also indicated that beta-catenin signaling negatively regulates S100A7 expression. Thus, this reciprocal negative regulation between S100A7 and beta-catenin signaling implies their important roles in tumor development and progression. Despite its high levels of expression in early stage SCCOC tumorigenesis, S100A7 actually inhibits SCCOC tumor growth/invasion as well as tumor progression. Downregulation of S100A7 in later stages of tumorigenesis increases beta-catenin signaling, leading to promotion of tumor growth and tumor progression.	[Zhou, G.; Xie, T-X; Zhao, M.; Jasser, S. A.; Younes, M. N.; Sano, D.; Lin, J.; Kupferman, M. E.; Santillan, A. A.; Myers, J. N.] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA; [Patel, V.; Gutkind, J. S.] Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD USA; [Ei-Naggar, A. K.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Emberley, E. D.; Watson, P. H.] BC Canc Agcy, Deeley Res Ctr, Victoria, BC, Canada; [Matsuzawa, S-I; Reed, J. C.] Burnham Inst Med Res, La Jolla, CA USA; [Myers, J. N.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Texas System; UTMD Anderson Cancer Center; British Columbia Cancer Agency; Sanford Burnham Prebys Medical Discovery Institute; University of Texas System; UTMD Anderson Cancer Center	Myers, JN (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, 1515 Holcombe Blvd,Unit 441, Houston, TX 77030 USA.	jmyers@mdanderson.org	Gutkind, J. Silvio/A-1053-2009; Lin, Jing/I-3889-2013; Sano, Daisuke/R-6591-2018; Gutkind, J. Silvio/J-1201-2016	Lin, Jing/0000-0002-2563-5083; Sano, Daisuke/0000-0002-7686-4724; Gutkind, J. Silvio/0000-0002-5150-4482; Watson, Peter/0000-0002-1642-0638	NATIONAL CANCER INSTITUTE [P30CA016672, P01CA069381] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA016672, CA16672, CA69381] Funding Source: Medline; NIDCR NIH HHS [R01DE01461301] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Alowami Salem, 2003, BMC Dermatol, V3, P1, DOI 10.1186/1471-5945-3-1; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Blanpain C, 2007, CELL, V128, P445, DOI 10.1016/j.cell.2007.01.014; Broome AM, 2003, J HISTOCHEM CYTOCHEM, V51, P675, DOI 10.1177/002215540305100513; Di Nuzzo S, 2000, PHOTOCHEM PHOTOBIOL, V72, P374; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; Emberley ED, 2005, CANCER RES, V65, P5696, DOI 10.1158/0008-5472.CAN-04-3927; Emberley ED, 2003, CLIN CANCER RES, V9, P2627; Emberley ED, 2003, CANCER RES, V63, P1954; Enerback C, 2002, CANCER RES, V62, P43; Filipek A, 2002, J BIOL CHEM, V277, P28848, DOI 10.1074/jbc.M203602200; Fukushima T, 2006, IMMUNITY, V24, P29, DOI 10.1016/j.immuni.2005.12.002; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; HOFFMANN HJ, 1994, J INVEST DERMATOL, V103, P370, DOI 10.1111/1523-1747.ep12395202; Kennedy RD, 2005, CANCER RES, V65, P10265, DOI 10.1158/0008-5472.CAN-05-1841; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Krop I, 2005, CANCER RES, V65, P11326, DOI 10.1158/0008-5472.CAN-05-1523; Leygue E, 1996, CANCER RES, V56, P4606; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Martinsson H, 2005, EXP DERMATOL, V14, P161, DOI 10.1111/j.0906-6705.2005.00239.x; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; MOOGLUTZ C, 1995, INT J CANCER, V63, P297, DOI 10.1002/ijc.2910630225; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Morin Patrice J, 2003, Cancer Treat Res, V115, P169; Patel JH, 2004, NAT REV CANCER, V4, P562, DOI 10.1038/nrc1393; Reischl J, 2007, J INVEST DERMATOL, V127, P163, DOI 10.1038/sj.jid.5700488; Taketo MM, 2004, NAT GENET, V36, P320, DOI 10.1038/ng0404-320; TAVAKKOL A, 1994, MOL BIOL REP, V20, P75, DOI 10.1007/BF00996356; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Watson PH, 1998, INT J BIOCHEM CELL B, V30, P567, DOI 10.1016/S1357-2725(97)00066-6; Willert K, 2006, GENE DEV, V20, P1394, DOI 10.1101/gad.1424006; Yigitbasi OG, 2004, CANCER RES, V64, P7977, DOI 10.1158/0008-5472.CAN-04-1477	37	44	45	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2008	27	25					3527	3538		10.1038/sj.onc.1211015	http://dx.doi.org/10.1038/sj.onc.1211015			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18223693				2022-12-25	WOS:000256468500004
J	Lingbeck, JM; Trausch-Azar, JS; Ciechanover, A; Schwartz, AL				Lingbeck, Jody M.; Trausch-Azar, Julie S.; Ciechanover, Aaron; Schwartz, Alan L.			In vivo interactions of MyoD, Id1, and E2A proteins determined by acceptor photobleaching fluorescence resonance energy transfer	FASEB JOURNAL			English	Article						ubiquitin-proteasome degradation	PROTEASOME-MEDIATED DEGRADATION; LOOP-HELIX PROTEINS; DNA-BINDING; INVIVO; DIFFERENTIATION; HETERODIMERS; HOMODIMERS; NUCLEAR; CELLS; E12	MyoD, a skeletal muscle transcription factor, is rapidly degraded by the ubiquitin-proteasome system. MyoD interacts with ubiquitously expressed E2A or inhibitor of DNA binding (Id) proteins to activate or inhibit transcription, respectively. Furthermore, MyoD has been shown to modulate the ubiquitinmediated degradation of Id1 and E2A proteins, E12 and E47. The molecular mechanisms governing these events are not clear but are hypothesized to occur via heterodimer formation. Fluorescence resonance energy transfer (FRET) is a technique for evaluation of protein-protein interactions in vivo. Using acceptor photobleaching FRET and chimeric proteins composed of MyoD, Id1, E12, E47, E12(NLS), or MyoD(NLS) and either cyan fluorescent protein or yellow fluorescent protein, we show that each of the wild-type proteins is capable of homodimerization. In addition, heterodimers form between Id1 and E2A proteins, as well as between MyoD and E2A proteins. The Id1: E2A interaction is stronger than the MyoD: E2A interaction, which is consistent with the notion that inhibition of MyoD action occurs by the sequestration of E2A proteins by Id. The stronger interaction of Id1 with E2A may also explain the decrease in the rate of ubiquitin-proteasome degradation of Id1 that is significantly greater than that of MyoD when E2A proteins are abundant. Thus, these studies extend our understanding of the molecular mechanisms of MyoD action.	[Lingbeck, Jody M.; Trausch-Azar, Julie S.; Schwartz, Alan L.] Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat & Mol Biol & Pha, St Louis, MO 63110 USA; [Lingbeck, Jody M.; Trausch-Azar, Julie S.; Schwartz, Alan L.] St Louis Childrens Hosp, St Louis, MO 63178 USA; [Ciechanover, Aaron] Technion Israel Inst Technol, Fac Med, Dept Biochem, Haifa, Israel; [Ciechanover, Aaron] Technion Israel Inst Technol, Fac Med, Rappaport Inst Res Med Sci, Haifa, Israel	Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Schwartz, AL (corresponding author), Washington Univ, Sch Med, Dept Pediat, 660 S Euclid Ave,CB 8116, St Louis, MO 63110 USA.	schwartz@kids.wustl.edu	Ciechanover, Aaron J/C-9166-2017					BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENEZRA R, 1994, CELL, V79, P1057, DOI 10.1016/0092-8674(94)90036-1; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; FINKEL T, 1993, J BIOL CHEM, V268, P5; Floyd ZE, 2001, J BIOL CHEM, V276, P22468, DOI 10.1074/jbc.M009388200; Gu Y, 2004, J MICROSC-OXFORD, V215, P162, DOI 10.1111/j.0022-2720.2004.01365.x; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Karpova TS, 2003, J MICROSC-OXFORD, V209, P56, DOI 10.1046/j.1365-2818.2003.01100.x; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Lingbeck JM, 2005, ONCOGENE, V24, P6376, DOI 10.1038/sj.onc.1208789; Lingbeck JM, 2003, J BIOL CHEM, V278, P1817, DOI 10.1074/jbc.M208815200; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Paulmurugan R, 2002, P NATL ACAD SCI USA, V99, P15608, DOI 10.1073/pnas.242594299; PESCE S, 1993, MOL CELL BIOL, V13, P7874, DOI 10.1128/MCB.13.12.7874; Russo S, 1998, J CELL SCI, V111, P691; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Trausch-Azar JS, 2004, J BIOL CHEM, V279, P32614, DOI 10.1074/jbc.M403794200; Wendt H, 1998, J BIOL CHEM, V273, P5735, DOI 10.1074/jbc.273.10.5735; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	22	7	7	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					1694	1701		10.1096/fj.07-095000	http://dx.doi.org/10.1096/fj.07-095000			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18198216				2022-12-25	WOS:000256352700010
J	Mizuno, T; Zhang, GQ; Takeuchi, H; Kawanokuchi, J; Wang, JY; Sonobe, Y; Jin, SJ; Takada, N; Komatsu, Y; Suzumura, A				Mizuno, Tetsuya; Zhang, Guiqin; Takeuchi, Hideyuki; Kawanokuchi, Jun; Wang, Jinyan; Sonobe, Yoshifumi; Jin, Shijie; Takada, Naoki; Komatsu, Yukio; Suzumura, Akio			Interferon-gamma directly induces neurotoxicity through a neuron specific, calcium-permeable complex of IFN gamma receptor and AMPA GluR1 receptor	FASEB JOURNAL			English	Article						proinflammatory cytokine; neuronal dysfunction	NECROSIS-FACTOR-ALPHA; NITRIC-OXIDE; UP-REGULATION; CELL-DEATH; HIPPOCAMPAL; INTERLEUKIN-6; ACTIVATION; MICROGLIA; CONNECTIONS; CYTOKINE	Interferon-gamma (IFN-gamma) is a proinflammatory cytokine that plays a pivotal role in pathology of diseases in the central nervous system (CNS), such as multiple sclerosis. However, the direct effect of IFN-gamma on neuronal cells has yet to be elucidated. We show here that IFN-gamma directly induces neuronal dysfunction, which appears as dendritic bead formation in mouse cortical neurons and enhances glutamate neurotoxicity mediated via alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic (AMPA) receptors but not N-methyl-D-aspartate receptors. In the CNS, IFN-gamma receptor forms a unique, neuron-specific, calcium-permeable receptor complex with AMPA receptor subunit GluR1. Through this receptor complex, IFN-gamma phosphorylates GluR1 at serine 845 position by JAK1 center dot 2/ STAT1 pathway, increases Ca2+ influx and following nitric oxide production, and subsequently decreases ATP production, leading to the dendritic bead formation. These findings provide novel mechanisms of neuronal excitotoxicity, which may occur in both inflammatory and neurodegenerative diseases in the CNS.	[Mizuno, Tetsuya; Zhang, Guiqin; Takeuchi, Hideyuki; Kawanokuchi, Jun; Wang, Jinyan; Sonobe, Yoshifumi; Jin, Shijie; Suzumura, Akio] Nagoya Univ, Environm Med Res Inst, Dept Neuroimmunol, Chikusa Ku, Nagoya, Aichi 4648601, Japan; [Takada, Naoki; Komatsu, Yukio] Nagoya Univ, Environm Med Res Inst, Dept Visual Neurosci, Nagoya, Aichi 4648601, Japan	Nagoya University; Nagoya University	Mizuno, T (corresponding author), Nagoya Univ, Environm Med Res Inst, Dept Neuroimmunol, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648601, Japan.	tmizuno@riem.nagoya-u.ac.jp		Takeuchi, Hideyuki/0000-0001-5912-7581				Aarts M, 2003, CELL, V115, P863, DOI 10.1016/S0092-8674(03)01017-1; Ali C, 2000, J CEREBR BLOOD F MET, V20, P956, DOI 10.1097/00004647-200006000-00008; Banno M, 2005, NEUROPHARMACOLOGY, V48, P283, DOI 10.1016/j.neuropharm.2004.10.002; BARISH ME, 1991, DEV BIOL, V144, P412, DOI 10.1016/0012-1606(91)90433-4; Bernardino L, 2005, J NEUROSCI, V25, P6734, DOI 10.1523/JNEUROSCI.1510-05.2005; BINDOKAS VP, 1995, J NEUROSCI, V15, P6999; Brask J, 2004, EUR J NEUROSCI, V19, P3193, DOI 10.1111/j.0953-816X.2004.03445.x; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; CHAO CC, 1995, J LEUKOCYTE BIOL, V58, P65, DOI 10.1002/jlb.58.1.65; Gomes AR, 2003, NEUROCHEM RES, V28, P1459, DOI 10.1023/A:1025610122776; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hasbani MJ, 1998, EXP NEUROL, V154, P241, DOI 10.1006/exnr.1998.6929; Hemmer B, 2002, NAT REV NEUROSCI, V3, P291, DOI 10.1038/nrn784; Jensen MB, 2000, J NEUROSCI, V20, P3612, DOI 10.1523/JNEUROSCI.20-10-03612.2000; Kawahara Y, 2004, NATURE, V427, P801, DOI 10.1038/427801a; Kawanokuchi J, 2006, MULT SCLER J, V12, P558, DOI 10.1177/1352458506070763; Kim IJ, 2002, J NEUROSCI, V22, P4530, DOI 10.1523/JNEUROSCI.22-11-04530.2002; Koike M, 1997, NEUROSCI RES, V29, P27, DOI 10.1016/S0168-0102(97)00067-9; Lafortune L, 1996, J NEUROPATH EXP NEUR, V55, P515, DOI 10.1097/00005072-199605000-00003; LEE AP, 1993, P 7 INT C SOL STAT S, V1, P46; Marx CE, 2001, BIOL PSYCHIAT, V50, P743, DOI 10.1016/S0006-3223(01)01209-4; Mizuno T, 2004, NEUROPHARMACOLOGY, V46, P404, DOI 10.1016/j.neuropharm.2003.09.009; Oliva AA, 2002, J NEUROSCI, V22, P8052; Park JS, 1996, NEUROBIOL DIS, V3, P215, DOI 10.1006/nbdi.1996.0022; Pitt D, 2000, NAT MED, V6, P67, DOI 10.1038/71555; Possel H, 2000, GLIA, V32, P51, DOI 10.1002/1098-1136(200010)32:1<51::AID-GLIA50>3.0.CO;2-4; Qiu ZH, 1998, J NEUROSCI, V18, P10445; Roychowdhury S, 2006, NITRIC OXIDE-BIOL CH, V14, P290, DOI 10.1016/j.niox.2005.12.001; Song JH, 2005, J BIOL CHEM, V280, P12896, DOI 10.1074/jbc.M412139200; Sonkusare SK, 2005, PHARMACOL RES, V51, P1, DOI 10.1016/j.phrs.2004.05.005; Steinman L, 2002, ANNU REV NEUROSCI, V25, P491, DOI 10.1146/annurev.neuro.25.112701.142913; Tabata T, 2004, P NATL ACAD SCI USA, V101, P16952, DOI 10.1073/pnas.0405387101; Takada N, 2005, EUR J NEUROSCI, V21, P422, DOI 10.1111/j.1460-9568.2005.03881.x; Takeuchi H, 2002, J BIOL CHEM, V277, P50966, DOI 10.1074/jbc.M209356200; Takeuchi H, 2005, J BIOL CHEM, V280, P10444, DOI 10.1074/jbc.M413863200; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; TSUBOKAWA H, 1995, J NEUROPHYSIOL, V74, P218, DOI 10.1152/jn.1995.74.1.218; Van Den Bosch L, 2000, J NEUROL SCI, V180, P29, DOI 10.1016/S0022-510X(00)00414-7; Vikman KS, 2001, BRAIN RES, V896, P18, DOI 10.1016/S0006-8993(00)03238-8; Viviani B, 2003, J NEUROSCI, V23, P8692; YAMAMOTO N, 1992, NEURON, V9, P217, DOI 10.1016/0896-6273(92)90161-6; YAMAMOTO N, 1989, SCIENCE, V245, P192, DOI 10.1126/science.2749258; Yu ZF, 2002, NEUROBIOL DIS, V11, P199, DOI 10.1006/nbdi.2002.0530; Zhou YP, 2006, NEUROPHARMACOLOGY, V51, P67, DOI 10.1016/j.neuropharm.2006.03.002; Zhu B, 2003, AM J PATHOL, V162, P1639, DOI 10.1016/S0002-9440(10)64298-8	45	126	133	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1797	1806		10.1096/fj.07-099499	http://dx.doi.org/10.1096/fj.07-099499			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18198214				2022-12-25	WOS:000256352700020
J	Shahrzad, S; Shirasawa, S; Sasazuki, T; Rak, JW; Coomber, BL				Shahrzad, S.; Shirasawa, S.; Sasazuki, T.; Rak, J. W.; Coomber, B. L.			Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts	ONCOGENE			English	Article						hypoxia; antiangiogenic therapy; K-ras mutation; tumor microenvironment; metronomic cyclophosphamide	METASTATIC BREAST-CANCER; GROWTH-FACTOR RECEPTOR-2; HUMAN LIVER-MICROSOMES; MISMATCH-REPAIR GENES; TUMOR-CELL LINES; MICROSATELLITE INSTABILITY; ANTIANGIOGENIC THERAPY; ANGIOGENESIS; HYPOXIA; BEVACIZUMAB	Antiangiogenic therapies are promising approaches to cancer control, but the details of their effects on subsequent tumor progression are not fully understood. Such therapies have the potential to eventually generate extensive amounts of tumor ischemia, and we previously demonstrated that ischemic conditions induce K-ras mutations in cells with deficient mismatch repair (MMR) mechanisms. This suggested that similar effects on oncogene mutagenesis may accompany antiangiogenic therapy. To test this, MMR-deficient colorectal cancer cells (Dks-8) were xenografted into immune-deficient mice and treated with the antiangiogenic regimen of low-dose/metronomic cyclophosphamide for 2 weeks followed by a 2-week recovery period without therapy. This treatment resulted in transient tumor growth inhibition, increased hypoxia, and decreased microvessel density, and cancer cells from treated tumors acquired activating mutations of the K-ras oncogene (K-ras(G13D)). In vitro exposure of Dks-8 cells to the active metabolite of cyclophosphamide (4-hydroxycyclophosphamide) had no effect on the K-ras status, indicating that there was no direct action of this alkylating agent on K-ras mutagenesis. In addition, cells sorted from hypoxic regions of Dks-8 tumors were enriched in K-ras(G13D) mutants. Collectively, our studies suggest that increases in tumor hypoxia induced by antiangiogenic treatment may lead to K-ras mutation and consequently tumor progression, especially in susceptible individuals.	[Shahrzad, S.; Coomber, B. L.] Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, Guelph, ON N1G 2W1, Canada; [Shirasawa, S.] Fukuoka Univ, Sch Med, Dept Cell Biol, Fukuoka 81401, Japan; [Sasazuki, T.] Int Med Ctr Japan, Res Inst, Tokyo, Japan; [Rak, J. W.] McGill Univ, Montreal Childrens Hosp, Dept Pediat, Montreal, PQ H3H 1P3, Canada	University of Guelph; Fukuoka University; National Center for Global Health & Medicine - Japan; McGill University	Coomber, BL (corresponding author), Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, Guelph, ON N1G 2W1, Canada.	bcoomber@uoguelph.ca						Aarnio M, 1999, INT J CANCER, V81, P214, DOI 10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.3.CO;2-C; Bernhard EJ, 2000, CANCER RES, V60, P6597; BOS JL, 1989, CANCER RES, V49, P4682; BOYER JC, 1995, CANCER RES, V55, P6063; Browder T, 2000, CANCER RES, V60, P1878; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Brown JM, 2000, DRUG RESIST UPDATE, V3, P7, DOI 10.1054/drup.2000.0120; CHANG TKH, 1993, CANCER RES, V53, P5629; CHEN JZ, 1994, CURR OPIN IMMUNOL, V6, P313, DOI 10.1016/0952-7915(94)90107-4; DeLisser HM, 1997, AM J PATHOL, V151, P671; DEXTER DL, 1981, AM J MED, V71, P949, DOI 10.1016/0002-9343(81)90312-0; Emmenegger U, 2006, CANCER RES, V66, P1664, DOI 10.1158/0008-5472.CAN-05-2598; Esteller M, 1998, ONCOGENE, V17, P2413, DOI 10.1038/sj.onc.1202178; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Franco M, 2006, CANCER RES, V66, P3639, DOI 10.1158/0008-5472.CAN-05-3295; Galmarini Carlos Maria, 2003, Curr Opin Investig Drugs, V4, P1416; Gasparini G, 2005, NAT CLIN PRACT ONCOL, V2, P562, DOI 10.1038/ncponc0342; Halvarsson B, 2004, VIRCHOWS ARCH, V444, P135, DOI 10.1007/s00428-003-0922-z; HERMAN TS, 1989, CANCER RES, V49, P3338; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Janssen HL, 2005, HEAD NECK-J SCI SPEC, V27, P622, DOI 10.1002/hed.20223; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; Jubb AM, 2006, NAT REV CANCER, V6, P626, DOI 10.1038/nrc1946; Kane MF, 1997, CANCER RES, V57, P808; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Kerbel RS, 2006, SCIENCE, V312, P1171, DOI 10.1126/science.1125950; Kerbel RS, 2001, CANCER METAST REV, V20, P79, DOI 10.1023/A:1013172910858; Klement G, 2000, J CLIN INVEST, V105, pR15, DOI 10.1172/JCI8829; Koukourakis MI, 2000, INT J RADIAT ONCOL, V48, P545, DOI 10.1016/S0360-3016(00)00677-5; LIOTTA LA, 1974, CANCER RES, V34, P997; Miller KD, 2005, CLIN CANCER RES, V11, P3369, DOI 10.1158/1078-0432.CCR-04-1923; Miller KD, 2005, J CLIN ONCOL, V23, P792, DOI 10.1200/JCO.2005.05.098; Minamoto Toshinari, 2002, Expert Rev Mol Diagn, V2, P565, DOI 10.1586/14737159.2.6.565; Mitchell RJ, 2002, AM J EPIDEMIOL, V156, P885, DOI 10.1093/aje/kwf139; Motzer RJ, 2006, J CLIN ONCOL, V24, P5601, DOI 10.1200/JCO.2006.08.5415; Peltomaki P, 2004, DIS MARKERS, V20, P269, DOI 10.1155/2004/305058; Perona R, 2004, BRIT J CANCER, V90, P573, DOI 10.1038/sj.bjc.6601552; Rak J, 1996, EUR J CANCER, V32A, P2438, DOI 10.1016/S0959-8049(96)00396-6; RAK J, 1995, CANCER RES, V55, P4575; Rak JW, 2006, CANC DRUG DISC DEV, P67, DOI 10.1007/978-1-59745-035-5_4; Ren S, 1997, CANCER RES, V57, P4229; Rofstad EK, 2007, CLIN CANCER RES, V13, P1971, DOI 10.1158/1078-0432.CCR-06-1967; Shahrzad S, 2005, CANCER RES, V65, P8134, DOI 10.1158/0008-5472.CAN-05-0713; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; SRIVASTAVA A, 1988, AM J PATHOL, V133, P419; TAKAMIZAWA A, 1975, J MED CHEM, V18, P376, DOI 10.1021/jm00238a011; Toyooka S, 2003, ONCOL REP, V10, P1455; Varker KA, 2007, ANN SURG ONCOL, V14, P2367, DOI 10.1245/s10434-007-9389-5; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491; Yu JL, 2002, SCIENCE, V295, P1526, DOI 10.1126/science.1068327; Yu JL, 2001, AM J PATHOL, V158, P1325, DOI 10.1016/S0002-9440(10)64083-7; Yu L, 1996, DRUG METAB DISPOS, V24, P1254; Yuan JL, 1998, MUTAT RES-FUND MOL M, V400, P439, DOI 10.1016/S0027-5107(98)00042-6; ZON G, 1984, J MED CHEM, V27, P466, DOI 10.1021/jm00370a008	56	15	15	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	26					3729	3738		10.1038/sj.onc.1211031	http://dx.doi.org/10.1038/sj.onc.1211031			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18223682				2022-12-25	WOS:000256659300010
J	Aliprandi, P; Sizun, C; Perez, J; Mareuil, F; Caputo, S; Leroy, JL; Odaert, B; Laalami, S; Uzan, M; Bontems, F				Aliprandi, Pascale; Sizun, Christina; Perez, Javier; Mareuil, Fabien; Caputo, Sandrine; Leroy, Jean-Louis; Odaert, Benoit; Laalami, Soumaya; Uzan, Marc; Bontems, Francois			S1 ribosomal protein functions in translation initiation and ribonuclease RegB activation are mediated by similar RNA-protein interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MESSENGER-RNA; BINDING DOMAIN; REPLICASE; SUBUNIT; ENDORIBONUCLEASE; SCATTERING; RECOGNITION; EFFICIENCY; EVOLUTION	The ribosomal protein S1, in Escherichia coli, is necessary for the recognition by the ribosome of the translation initiation codon of most messenger RNAs. It also participates in other functions. In particular, it stimulates the T4 endoribonuclease RegB, which inactivates some of the phage mRNAs, when their translation is no longer required, by cleaving them in the middle of their Shine-Dalgarno sequence. In each function, S1 seems to target very different RNAs, which led to the hypothesis that it possesses different RNA-binding sites. We previously demonstrated that the ability of S1 to activate RegB is carried by a fragment of the protein formed of three consecutive domains (domains D3, D4, and D5). The same fragment plays a central role in all other functions. We analyzed its structural organization and its interactions with three RNAs: two RegB substrates and a translation initiation region. We show that these three RNAs bind the same area of the protein through a set of systematic (common to the three RNAs) and specific (RNA-dependent) interactions. We also show that, in the absence of RNA, the D4 and D5 domains are associated, whereas the D3 and D4 domains are in equilibrium between open (noninteracting) and closed (weakly interacting) forms and that RNA binding induces a structural reorganization of the fragment. All of these results suggest that the ability of S1 to recognize different RNAs results from a high adaptability of both its structure and its binding surface.	[Aliprandi, Pascale; Sizun, Christina; Mareuil, Fabien; Caputo, Sandrine; Odaert, Benoit; Bontems, Francois] Ecole Polytech, UPR2301, Antenne ICSN, CNRS, F-91198 Gif Sur Yvette, France; [Perez, Javier] Synchrotron SOLEIL, LOrmedes Merisiers, SWING, F-91192 Gif Sur Yvette, France; [Leroy, Jean-Louis] ICSN, Lab Chim & Biol Struct, CNRS, UPR2301, F-91190 Gif Sur Yvette, France; [Laalami, Soumaya; Uzan, Marc] Univ Paris 06, Inst Jacques Monod, F-75251 Paris 05, France; [Laalami, Soumaya; Uzan, Marc] Univ Paris 07, Inst Jacques Monod, F-75251 Paris 05, France; [Laalami, Soumaya; Uzan, Marc] Inst Jacques Monod, UMR7592, CNRS, F-75251 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universite Paris Saclay; SOLEIL Synchrotron; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite	Bontems, F (corresponding author), Ecole Polytech, UPR2301, Antenne ICSN, CNRS, 1 Ave Terrase, F-91198 Gif Sur Yvette, France.	Francois.Bontems@icsn.cnrs-gif.fr	Caputo, Sandrine M./C-3860-2018; Mareuil, Fabien/AAO-2844-2020; Caputo, Sandrine M/I-7460-2019	Caputo, Sandrine M./0000-0001-5338-9388; Mareuil, Fabien/0000-0002-3832-9157; Sizun, Christina/0000-0002-5760-2614				Agalarov SC, 2006, FEBS LETT, V580, P6797, DOI 10.1016/j.febslet.2006.11.036; Bernstein JR, 2007, J BIOL CHEM, V282, P18929, DOI 10.1074/jbc.M701395200; Bisaglia M, 2003, J BIOL CHEM, V278, P15261, DOI 10.1074/jbc.M212731200; Boni IV, 2000, J BACTERIOL, V182, P5872, DOI 10.1128/JB.182.20.5872-5879.2000; BONI IV, 1991, NUCLEIC ACIDS RES, V19, P155, DOI 10.1093/nar/19.1.155; Bycroft M, 1997, CELL, V88, P235, DOI 10.1016/S0092-8674(00)81844-9; CALOGERO RA, 1988, P NATL ACAD SCI USA, V85, P6427, DOI 10.1073/pnas.85.17.6427; CANONACO MA, 1989, EUR J BIOCHEM, V182, P501, DOI 10.1111/j.1432-1033.1989.tb14856.x; COMMANS S, 1995, J MOL BIOL, V253, P100, DOI 10.1006/jmbi.1995.0539; Dar AC, 2002, MOL CELL, V10, P295, DOI 10.1016/S1097-2765(02)00590-7; Draper DE, 1999, NUCLEIC ACIDS RES, V27, P381, DOI 10.1093/nar/27.2.381; Durand S, 2006, NUCLEIC ACIDS RES, V34, P6549, DOI 10.1093/nar/gkl911; Eiler S, 1999, EMBO J, V18, P6532, DOI 10.1093/emboj/18.22.6532; FARWELL MA, 1992, MOL MICROBIOL, V6, P3375, DOI 10.1111/j.1365-2958.1992.tb02205.x; FRANZETTI B, 1992, J BIOL CHEM, V267, P19075; Glatter O., 1982, SMALL ANGLE X RAY SC; GUERRIERTAKADA C, 1983, J BIOL CHEM, V258, P3649; Hubbard TJP, 1997, NUCLEIC ACIDS RES, V25, P236, DOI 10.1093/nar/25.1.236; Kalapos MP, 1997, BIOCHIMIE, V79, P493, DOI 10.1016/S0300-9084(97)82741-1; Konarev PV, 2003, J APPL CRYSTALLOGR, V36, P1277, DOI 10.1107/S0021889803012779; Kozak M, 2005, GENE, V361, P13, DOI 10.1016/j.gene.2005.06.037; Lebars I, 2001, J BIOL CHEM, V276, P13264, DOI 10.1074/jbc.M010680200; Mareuil F, 2007, EUR BIOPHYS J BIOPHY, V37, P95, DOI 10.1007/s00249-007-0170-2; MCCARTHY JEG, 1990, TRENDS GENET, V6, P78, DOI 10.1016/0168-9525(90)90098-Q; McGinness KE, 2004, P NATL ACAD SCI USA, V101, P13454, DOI 10.1073/pnas.0405521101; Miranda G, 1997, J MOL BIOL, V267, P1089, DOI 10.1006/jmbi.1997.0939; MUNIYAPPA K, 1993, BIOCHEM MOL BIOL INT, V31, P1; MURALIKRISHNA P, 1985, BIOCHEM INT, V11, P691; Pioletti M, 2001, EMBO J, V20, P1829, DOI 10.1093/emboj/20.8.1829; Rajkowitsch L, 2007, RNA, V13, P2053, DOI 10.1261/rna.671807; RINGQUIST S, 1995, BIOCHEMISTRY-US, V34, P3640, DOI 10.1021/bi00011a019; RUCKMAN J, 1994, J BIOL CHEM, V269, P26655; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schluenzen F, 2000, CELL, V102, P615, DOI 10.1016/S0092-8674(00)00084-2; Schuppli D, 1998, J MOL BIOL, V283, P585, DOI 10.1006/jmbi.1998.2123; Schuwirth BS, 2005, SCIENCE, V310, P827, DOI 10.1126/science.1117230; Selivanova OM, 2003, J BIOL CHEM, V278, P36311, DOI 10.1074/jbc.M304713200; Sengupta J, 2001, P NATL ACAD SCI USA, V98, P11991, DOI 10.1073/pnas.211266898; Snoussi K, 2001, J MOL BIOL, V309, P139, DOI 10.1006/jmbi.2001.4618; Sorensen MA, 1998, J MOL BIOL, V280, P561, DOI 10.1006/jmbi.1998.1909; SUBRAMANIAN AR, 1983, PROG NUCLEIC ACID RE, V28, P101, DOI 10.1016/S0079-6603(08)60085-9; Sugiura M, 1998, ANNU REV GENET, V32, P437, DOI 10.1146/annurev.genet.32.1.437; Sukhodolets MV, 2006, RNA, V12, P1505, DOI 10.1261/rna.2321606; Todone F, 2001, MOL CELL, V8, P1137, DOI 10.1016/S1097-2765(01)00379-3; Vachette P, 2003, METHOD ENZYMOL, V374, P584, DOI 10.1016/S0076-6879(03)74024-5; WAHBA AJ, 1974, J BIOL CHEM, V249, P3314; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; Wishart DS, 2001, METHOD ENZYMOL, V338, P3; Wower IK, 2000, EMBO J, V19, P6612, DOI 10.1093/emboj/19.23.6612	50	38	39	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2008	283	19					13289	13301		10.1074/jbc.M707111200	http://dx.doi.org/10.1074/jbc.M707111200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295UQ	18211890	hybrid			2022-12-25	WOS:000255499800069
J	Cai, CQ; Peng, Y; Buckley, MT; Wei, J; Chen, F; Liebes, L; Gerald, WI; Pincus, MR; Osman, I; Lee, P				Cai, C. Q.; Peng, Y.; Buckley, M. T.; Wei, J.; Chen, F.; Liebes, L.; Gerald, W. I.; Pincus, M. R.; Osman, I.; Lee, P.			Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations	ONCOGENE			English	Article						EGFR; mutation; prostate cancer	CELL LUNG-CANCER; ONCOGENIC TRANSFORMATION; SOMATIC MUTATIONS; SIGNAL TRANSDUCER; EGFR MUTATIONS; KINASE DOMAIN; GEFITINIB; STAT3; INHIBITION; GENE	While epidermal growth factor receptor (EGFR) dysregulation is known to play a critical role in prostate carcinogenesis, there has been no direct evidence indicating EGFR mutations induce tumorigenesis in prostate cancer. We previously identified four novel EGFR somatic mutations in the EGFR tyrosine kinase domain of prostate cancer patients: G735S, G796S, E804G and R841K. In this study, we investigated the oncogenic potential of these somatic mutations by establishing stable clonal NIH3T3 cells expressing these four mutations and WT EGFR to determine their ability to increase cell proliferation and invasion. In the absence of the EGF ligand, cell proliferation was readily increased in G735S, G796S and E804G mutants compared to WT EGFR. The addition of EGF ligand greatly increased cell growth and transforming ability of these same EGFR mutants. Matrigel invasion assays showed enhanced invasion with G735S, G796S and E804G mutants. Western blot analysis showed that these EGFR mutations enhanced cell growth and invasion via constitutive and hyperactive tyrosine phosphorylation and led to the activation of mitogen-activated protein kinase (MAPK), signal transducer and activator of transcription 3 (STAT3) and Akt pathways. Our findings demonstrate the oncogenic activation of three novel EGFR somatic missense mutations in prostate cancer. Molecules that regulate the mechanisms of their oncogenic activation represent novel targets for limiting tumor cell progression, and further elucidation of these mutations will have utility in prostate cancer treatment.	[Cai, C. Q.; Peng, Y.; Wei, J.; Chen, F.; Lee, P.] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; [Buckley, M. T.; Liebes, L.; Osman, I.] NYU, Sch Med, Dept Med, New York, NY 10016 USA; [Gerald, W. I.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; [Pincus, M. R.; Lee, P.] New York Harbor Healthcare Syst, New York, NY USA; [Pincus, M. R.] SUNY, Dept Pathol, New York, NY USA; [Osman, I.] NYU, Sch Med, Dept Urol, New York, NY 10003 USA	New York University; New York University; Memorial Sloan Kettering Cancer Center; State University of New York (SUNY) System; SUNY Community College; SUNY Maritime College; SUNY Optometry; New York University	Osman, I (corresponding author), NYU, Sch Med, Dept Urol & Med, 522 1st Ave,SML 405, New York, NY 10016 USA.	iman.osman@med.nyu.edu						Arteaga CL, 2006, CANCER CELL, V9, P421, DOI 10.1016/j.ccr.2006.05.014; Barton BE, 2004, MOL CANCER THER, V3, P11; Bell DW, 2005, J CLIN ONCOL, V23, P8081, DOI 10.1200/JCO.2005.02.7078; Bellezza I, 2006, AM J PATHOL, V169, P2199, DOI 10.2353/ajpath.2006.060171; Choi SH, 2007, ONCOGENE, V26, P1567, DOI 10.1038/sj.onc.1209957; CHU YW, 1993, P NATL ACAD SCI USA, V90, P4261, DOI 10.1073/pnas.90.9.4261; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Danielsen AJ, 2002, EXP CELL RES, V275, P9, DOI 10.1006/excr.2002.5494; DeMiguel F, 2002, PROSTATE, V52, P123, DOI 10.1002/pros.10110; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; Douglas DA, 2006, FRONT BIOSCI-LANDMRK, V11, P2518, DOI 10.2741/1986; Giri D, 2001, AM J PATHOL, V159, P2159, DOI 10.1016/S0002-9440(10)63067-2; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Huang HF, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-2; Hubbard SR, 2005, CANCER CELL, V7, P287, DOI 10.1016/j.ccr.2005.04.004; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Lee JC, 2006, PLOS MED, V3, P2264, DOI 10.1371/journal.pmed.0030485; Lee JW, 2005, CLIN CANCER RES, V11, P2879, DOI 10.1158/1078-0432.CCR-04-2029; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Nagahara H, 2005, CLIN CANCER RES, V11, P1368, DOI 10.1158/1078-0432.CCR-04-1894; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Ratan HL, 2003, BJU INT, V92, P890, DOI 10.1111/j.1464-410X.2003.04503.x; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCHREIBER AB, 1983, J BIOL CHEM, V258, P846; Shao H, 2003, CANCER RES, V63, P3923; Sherwood ER, 1998, BRIT J CANCER, V77, P855, DOI 10.1038/bjc.1998.142; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Spiotto MT, 2000, PROSTATE, V42, P88, DOI 10.1002/(SICI)1097-0045(20000201)42:2<88::AID-PROS2>3.0.CO;2-P; Torring N, 2003, PROSTATE, V56, P142, DOI 10.1002/pros.10245; USHIRO H, 1980, J BIOL CHEM, V255, P8363; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013	34	25	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	22					3201	3210		10.1038/sj.onc.1210983	http://dx.doi.org/10.1038/sj.onc.1210983			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301LL	18193092				2022-12-25	WOS:000255897600013
J	Hu, CP; Dandapat, A; Sun, LQ; Khan, JA; Liu, Y; Hermonat, PL; Mehta, JL				Hu, Changping; Dandapat, Abhijit; Sun, Liuqin; Khan, Junaid A.; Liu, Yong; Hermonat, Paul L.; Mehta, Jawahar L.			Regulation of TGF beta(1)-mediated collagen formation by LOX-1 - Studies based on forced overexpression of TGF beta(1) in wild-type and LOX-1 knock-out mouse cardiac fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; INDUCED APOPTOSIS; LECTIN-LIKE; EXPRESSION; ACTIVATION; OXIDASE; BETA; ATHEROGENESIS; ANGIOGENESIS; BLOCKADE	Transforming growth factor beta(1) (TGF beta(1)) activation leads to tissue fibrosis. Here, we report on the role of LOX-1, a lectin-like 52-kDa receptor for oxidized low density lipoprotein, inTGF beta(1)-mediated collagen expression and underlying signaling in mouse cardiac fibroblasts. TGF beta(1) was overexpressed in wildtype (WT) and LOX-1 knock-out mouse cardiac fibroblasts by transfection with adeno-associated virus type 2 vector carrying the active TGF beta(1) moiety (AAV/TGF beta(ACT)(1)). Transfection of WT mouse cardiac fibroblasts with AAV/TGF beta(ACT)(1) markedly enhanced the expression of NADPH oxidases (p22(phox), p47(phox), and gp91(phox) subunits) and LOX-1, formation of reactive oxygen species, and collagen synthesis, concomitant with an increase in the activation of p38 and p44/42 mitogen-activated protein kinases (MAPK). The TGF beta(1)-mediated increase in collagen synthesis was markedly attenuated in the LOX-1 knock-out mouse cardiac fibroblasts as well as in WT mouse cardiac fibroblasts treated with a specific anti-LOX-1 antibody. Treatment with anti-LOX-1 antibody also reduced NADPH oxidase expression and MAPK activation. The NADPH oxidase inhibitors and gp91phox small interfering RNA reduced LOX-1 expression, MAPK activation, and collagen formation. The p38 MAPK inhibitors as well as the p44/42 MAPK inhibitors reduced collagen formation without affecting LOX-1 expression in cardiac fibroblasts. These observations suggest that collagen synthesis in cardiac fibroblasts involves a facilitative interaction between TGF beta(1)-NADPH oxidase and LOX-1. Further, the activation of MAPK pathway appears to be downstream of TGF beta(1)-reactive oxygen species-LOX-1 cascade.	[Hu, Changping; Dandapat, Abhijit; Sun, Liuqin; Khan, Junaid A.; Liu, Yong; Hermonat, Paul L.; Mehta, Jawahar L.] Univ Arkansas Med Sci, Cardiovasc Med, Little Rock, AR 72205 USA; [Hu, Changping; Dandapat, Abhijit; Sun, Liuqin; Khan, Junaid A.; Liu, Yong; Hermonat, Paul L.; Mehta, Jawahar L.] Cent Arkansas Vet Healthcare Syst, Little Rock, AR 72205 USA; [Hu, Changping] Cent S Univ, Sch Pharmaceut Sci, Dept Pharmacol, Changsha 410078, Peoples R China; [Sun, Liuqin] Heping Hosp, Changzhi Med Coll, Dept Ophthalmol, Changzhi 046000, Peoples R China	University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System; Central South University; Changzhi Medical College	Mehta, JL (corresponding author), Univ Arkansas Med Sci, Cardiovasc Med, Little Rock, AR 72205 USA.	mehtaJL@uams.edu	Mehta, JL/AAG-7572-2020; Mehta, jl/AAB-8832-2019	Mehta, jl/0000-0003-0384-2097				Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Chen HJ, 2001, CIRC RES, V89, P1155, DOI 10.1161/hh2401.100598; Chen JX, 2007, AM J PHYSIOL-HEART C, V292, pH1664, DOI 10.1152/ajpheart.01138.2006; Chen J, 2006, AM J PHYSIOL-HEART C, V291, pH1738, DOI 10.1152/ajpheart.00341.2006; Chen K, 2005, HYPERTENSION, V46, P622, DOI 10.1161/01.HYP.0000179045.95915.b0; Chen XP, 2007, VASC PHARMACOL, V47, P1, DOI 10.1016/j.vph.2007.01.004; Cominacini L, 2001, J BIOL CHEM, V276, P13750, DOI 10.1074/jbc.M010612200; Dandapat A, 2007, ARTERIOSCL THROM VAS, V27, P2435, DOI 10.1161/ATVBAHA.107.152272; Draude G, 2000, AM J PHYSIOL-HEART C, V278, pH1042, DOI 10.1152/ajpheart.2000.278.4.H1042; Heeneman S, 2003, J PATHOL, V200, P516, DOI 10.1002/path.1395; Hu CP, 2007, AM J PHYSIOL-HEART C, V293, pH1833, DOI 10.1152/ajpheart.00488.2007; Hu CP, 2007, CARDIOVASC RES, V76, P292, DOI 10.1016/j.cardiores.2007.07.003; Huang M, 2002, J CLIN INVEST, V109, P931, DOI 10.1172/JCI200214685; Joseph Jacob, 2003, Journal of Cardiovascular Pharmacology and Therapeutics, V8, P161, DOI 10.1177/107424840300800209; Lee OH, 1999, BIOCHEM BIOPH RES CO, V264, P743, DOI 10.1006/bbrc.1999.1586; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Li DY, 2006, BIOCHEM BIOPH RES CO, V344, P701, DOI 10.1016/j.bbrc.2006.04.010; Mehta JL, 2007, CIRC RES, V100, P1634, DOI 10.1161/CIRCRESAHA.107.149724; Mehta JL, 2007, CARDIOVASC RES, V74, P181, DOI 10.1016/j.cardiores.2007.03.011; Mehta JL, 2006, CARDIOVASC RES, V69, P36, DOI 10.1016/j.cardiores.2005.09.006; Minami M, 2000, BIOCHEM BIOPH RES CO, V272, P357, DOI 10.1006/bbrc.2000.2778; Nykanen AI, 2006, CIRC RES, V98, P1373, DOI 10.1161/01.RES.0000225987.52765.13; Rhyu DY, 2005, J AM SOC NEPHROL, V16, P667, DOI 10.1681/ASN.2004050425; Sturrock A, 2006, AM J PHYSIOL-LUNG C, V290, pL661, DOI 10.1152/ajplung.00269.2005; Usatyuk PV, 2007, J BIOL CHEM, V282, P23284, DOI 10.1074/jbc.M700535200; Yang BC, 1999, J PHARMACOL EXP THER, V291, P733; Zhao WH, 2006, VIROLOGY, V353, P283, DOI 10.1016/j.virol.2006.04.042	27	61	68	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10226	10231		10.1074/jbc.M708820200	http://dx.doi.org/10.1074/jbc.M708820200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18182394	hybrid			2022-12-25	WOS:000254894700003
J	Zhang, DH; Harry, GJ; Blackshear, PJ; Zeldin, DC				Zhang, Donghui; Harry, G. Jean; Blackshear, Perry J.; Zeldin, Darryl C.			G-protein pathway suppressor 2 (GPS2) interacts with the regulatory factor X4 variant 3 (RFX4_v3) and functions as a transcriptional co-activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDENTIFICATION; FRACTALKINE; EXPRESSION; BINDS; DIFFERENTIATION; NUCLEUS; SIGNALS; COMPLEX; ROLES; CELLS	RFX4_v3 (regulatory factor X4 variant 3) is a brain-specific isoform of the transcription factor RFX4. Insertional mutagenesis in mice demonstrates that Rfx4_v3 is crucial for normal brain development. Many genes involved in critical processes during brain morphogenesis are dysregulated in Rfx4_v3 mutant brains. For example, Cx3cl1 is a CX3C-type chemokine that is abundant in brain and is a direct transcriptional target of RFX4_v3 through a specific promoter X-box (X-box 1), the responsive element for RFX proteins. To identify potential interacting partners for RFX4_v3, we performed yeast two-hybrid analysis. Nine candidate interactors were identified, including GPS2 (G-protein pathway suppressor 2). Indirect immunofluorescence demonstrated that GPS2 and RFX4_v3 co-localized to the nucleus. Both GPS2 and RFX4_v3 mRNAs were also present in most portions of the adult mouse brain as well as in brains at different ages, suggesting that the two proteins could bind to each other. Co-immunoprecipitation assays indicated that physical interactions between GPS2 and RFX4_v3 did indeed occur. Furthermore, GPS2 was recruited to the Cx3cl1 promoter by RFX4_v3 and potentiated RFX4_v3 transactivation on this promoter through X-box 1, suggesting that the protein-protein interaction was functionally relevant. GPS2 bound to both the carboxyl-terminal region (amino acids 575-735) and the middle region (amino acids 250-574) of the RFX4_v3 protein. RFX4_v3 amino acids 1-574 stimulated the Cx3cl1 promoter to a similar extent as the full-length RFX4_v3 protein; however, deletion of the carboxyl-terminal region of RFX4_v3 impaired the co-activating abilities of GPS2. Based on these data, we conclude that GPS2 interacts with RFX4_v3 to modulate transactivation of genes involved in brain morphogenesis, including Cx3Cl1.	[Zhang, Donghui; Zeldin, Darryl C.] NIEHS, Natl Inst Hlth, Lab Resp Biol, Res Triangle Pk, NC 27709 USA; [Zhang, Donghui; Harry, G. Jean; Blackshear, Perry J.] NIEHS, Natl Inst Hlth, Neurobiol Lab, Res Triangle Pk, NC 27709 USA; [Blackshear, Perry J.; Zeldin, Darryl C.] NIEHS, Natl Inst Hlth, Off Clin Res, Res Triangle Pk, NC 27709 USA; [Blackshear, Perry J.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; [Blackshear, Perry J.] Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Duke University; Duke University	Zeldin, DC (corresponding author), NIEHS, Natl Inst Hlth, Lab Resp Biol, 111 TW Alexander Dr,Bldg 101,Rm D236, Res Triangle Pk, NC 27709 USA.	zeldin@niehs.nih.gov	Harry, Gaylia Jean/AAC-1171-2022; Zeldin, Darryl C/Y-7091-2018; Blackshear, Perry J./C-6206-2019	Harry, Gaylia Jean/0000-0002-0829-7318; Zeldin, Darryl C/0000-0002-2087-7307; Blackshear, Perry J./0000-0002-9561-8529	Intramural NIH HHS [Z01 ES101583-05] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090092, Z01ES021164, ZIAES101583] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alvania RS, 2006, NEURON, V50, P813, DOI 10.1016/j.neuron.2006.06.001; Araki R, 2004, J BIOL CHEM, V279, P10237, DOI 10.1074/jbc.M312761200; Bibel M, 2004, NAT NEUROSCI, V7, P1003, DOI 10.1038/nn1301; Blackshear PJ, 2003, DEVELOPMENT, V130, P4539, DOI 10.1242/dev.00661; Bonnafe E, 2004, MOL CELL BIOL, V24, P4417, DOI 10.1128/MCB.24.10.4417-4427.2004; Breiding DE, 1997, MOL CELL BIOL, V17, P7208, DOI 10.1128/MCB.17.12.7208; Colbran RJ, 2004, CURR OPIN NEUROBIOL, V14, P318, DOI 10.1016/j.conb.2004.05.008; Dateki M, 2005, J BIOL CHEM, V280, P20503, DOI 10.1074/jbc.M414033200; Degenhardt YY, 2001, J VIROL, V75, P151, DOI 10.1128/JVI.75.1.151-160.2001; Gajiwala KS, 2000, NATURE, V403, P916, DOI 10.1038/35002634; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Glaser B, 2005, MOL PSYCHIATR, V10, P920, DOI 10.1038/sj.mp.4001689; Hol EM, 2006, EXPERT REV NEUROTHER, V6, P1337, DOI 10.1586/14737175.6.9.1337; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; Katayama S, 2005, SCIENCE, V309, P1564, DOI 10.1126/science.1112009; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lee TH, 2006, DNA REPAIR, V5, P32, DOI 10.1016/j.dnarep.2005.07.004; Liour SS, 2003, GLIA, V42, P109, DOI 10.1002/glia.10202; Matsushita H, 2005, CANCER SCI, V96, P801, DOI 10.1111/j.1349-7006.2005.00112.x; Melnick A, 2002, MOL CELL BIOL, V22, P1804, DOI 10.1128/MCB.22.6.1804-1818.2002; Moon SY, 2003, J BIOL CHEM, V278, P4151, DOI 10.1074/jbc.M207789200; Morotami-Yano K, 2002, J BIOL CHEM, V277, P836, DOI 10.1074/jbc.M108638200; Peng YC, 2000, J VIROL, V74, P5872, DOI 10.1128/JVI.74.13.5872-5879.2000; Peng YC, 2001, MOL CELL BIOL, V21, P5913, DOI 10.1128/MCB.21.17.5913-5924.2001; PETERS JM, 1994, J BIOL CHEM, V269, P7709; Reith W, 2001, ANNU REV IMMUNOL, V19, P331, DOI 10.1146/annurev.immunol.19.1.331; Schmidt T, 2000, BBA-GENE STRUCT EXPR, V1493, P249, DOI 10.1016/S0167-4781(00)00163-9; Seubert J, 2004, CIRC RES, V95, P506, DOI 10.1161/01.RES.0000139436.89654.c8; Soriano SG, 2002, J NEUROIMMUNOL, V125, P59, DOI 10.1016/S0165-5728(02)00033-4; Spain BH, 1996, MOL CELL BIOL, V16, P6698; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Tarozzo G, 2003, J NEUROSCI RES, V73, P81, DOI 10.1002/jnr.10645; Teruel MN, 2000, CURR BIOL, V10, P86, DOI 10.1016/S0960-9822(00)00295-5; Tong N, 2000, J IMMUNOL, V164, P1333, DOI 10.4049/jimmunol.164.3.1333; Yoon HG, 2003, EMBO J, V22, P1336, DOI 10.1093/emboj/cdg120; Zhang DH, 2006, J NEUROCHEM, V98, P860, DOI 10.1111/j.1471-4159.2006.03930.x; Zhang JS, 2002, MOL CELL, V9, P611, DOI 10.1016/S1097-2765(02)00468-9	37	23	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8580	8590		10.1074/jbc.M708209200	http://dx.doi.org/10.1074/jbc.M708209200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18218630	Green Accepted, Green Published, hybrid			2022-12-25	WOS:000254288000057
J	Mitrousis, G; Olia, AS; Walker-Kopp, N; Cingolani, G				Mitrousis, Gregory; Olia, Adam S.; Walker-Kopp, Nancy; Cingolani, Gino			Molecular basis for the recognition of snurportin 1 by importin beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-LOCALIZATION SIGNALS; STRUCTURAL BASIS; NUCLEOCYTOPLASMIC TRANSPORT; RECEPTOR; DOMAIN; RAN; DISSOCIATION; PATHWAYS; ALPHA	The nuclear import of uridine-rich ribonucleoproteins is mediated by the transport adaptor snurportin 1 (SNP1). Similar to importin alpha, SNP1 uses an N-terminal importin beta binding (sIBB) domain to recruit the receptor importin beta and gain access to the nucleus. In this study, we demonstrate that the sIBB domain has a bipartite nature, which contains two distinct binding determinants for importin beta. The first determinant spans residues 25 - 65 and includes the previously identified importin alpha IBB (alpha IBB) region of homology. The second binding determinant encompasses residues 1 - 24 and resembles region 1011 1035 of the nucleoporin 153 (Nup153). The two binding determinants synergize within the sIBB domain to confer a low nanomolar binding affinity for importin beta (K-d similar to 2 nM) in an interaction that, in vitro, is displaced by RanGTP. We propose that in vivo the synergy of Nup153 and nuclear RanGTP promotes translocation of uridine-rich ribonucleoproteins into the nucleus.	[Mitrousis, Gregory; Olia, Adam S.; Walker-Kopp, Nancy; Cingolani, Gino] SUNY Upsate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Cingolani, G (corresponding author), SUNY Upsate Med Univ, Dept Biochem & Mol Biol, 750 E,Adams St, Syracuse, NY 13210 USA.	cingolag@upstate.edu			NIGMS NIH HHS [R01 GM074846-02, R01 GM074846, GM074846] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM074846] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bayliss R, 2000, CELL, V102, P99, DOI 10.1016/S0092-8674(00)00014-3; Bednenko J, 2003, J CELL BIOL, V162, P391, DOI 10.1083/jcb.200303085; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Catimel B, 2001, J BIOL CHEM, V276, P34189, DOI 10.1074/jbc.M103531200; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; Conti E, 2006, CURR OPIN STRUC BIOL, V16, P237, DOI 10.1016/j.sbi.2006.03.010; Cook A, 2007, ANNU REV BIOCHEM, V76, P647, DOI 10.1146/annurev.biochem.76.052705.161529; DELANO WL, 2002, PYMOL DELANO SCIENTI; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fried H, 2003, CELL MOL LIFE SCI, V60, P1659, DOI 10.1007/s00018-003-3070-3; Gilchrist D, 2003, J BIOL CHEM, V278, P51937, DOI 10.1074/jbc.M307371200; Huber J, 1998, EMBO J, V17, P4114, DOI 10.1093/emboj/17.14.4114; Huber J, 2002, J CELL BIOL, V156, P467, DOI 10.1083/jcb.200108114; Kalab P, 2006, NATURE, V440, P697, DOI 10.1038/nature04589; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; Lange A, 2007, J BIOL CHEM, V282, P5101, DOI 10.1074/jbc.R600026200; Lee BJ, 2006, CELL, V126, P543, DOI 10.1016/j.cell.2006.05.049; Lee SJ, 2005, NATURE, V435, P693, DOI 10.1038/nature03578; Lee SJ, 2003, SCIENCE, V302, P1571, DOI 10.1126/science.1088372; Lyman SK, 2002, J CELL BIOL, V159, P55, DOI 10.1083/jcb.200204163; Madrid AS, 2006, CHROMOSOMA, V115, P98, DOI 10.1007/s00412-005-0043-3; Matsuura Y, 2003, EMBO J, V22, P5358, DOI 10.1093/emboj/cdg538; Mosammaparast N, 2004, TRENDS CELL BIOL, V14, P547, DOI 10.1016/j.tcb.2004.09.004; Olia AS, 2006, J MOL BIOL, V363, P558, DOI 10.1016/j.jmb.2006.08.014; Ospina JK, 2005, MOL BIOL CELL, V16, P4660, DOI 10.1091/mbc.E05-04-0316; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Palacios I, 1997, EMBO J, V16, P6783, DOI 10.1093/emboj/16.22.6783; Paraskeva E, 1999, J CELL BIOL, V145, P255, DOI 10.1083/jcb.145.2.255; Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x; Rollenhagen C, 2003, MOL BIOL CELL, V14, P2104, DOI 10.1091/mbc.e02-06-0372; Rollenhagen C, 2006, CAN J PHYSIOL PHARM, V84, P367, DOI 10.1139/Y05-101; Stewart M, 2007, NAT REV MOL CELL BIO, V8, P195, DOI 10.1038/nrm2114; Strasser A, 2005, EMBO J, V24, P2235, DOI 10.1038/sj.emboj.7600701; Strom AC, 2001, GENOME BIOL, V2; Suel KE, 2006, METHODS, V39, P342, DOI 10.1016/j.ymeth.2006.06.015; Tran EJ, 2006, CELL, V125, P1041, DOI 10.1016/j.cell.2006.05.027; Vetter IR, 1999, CELL, V97, P635, DOI 10.1016/S0092-8674(00)80774-6; Weis K, 2002, CURR OPIN CELL BIOL, V14, P328, DOI 10.1016/S0955-0674(02)00337-X; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385	41	56	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7877	7884		10.1074/jbc.M709093200	http://dx.doi.org/10.1074/jbc.M709093200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18187419	hybrid			2022-12-25	WOS:000253997900063
J	Spitzner, M; Martins, JR; Soria, RB; Ousingsawat, J; Scheidt, K; Schreiber, R; Kunzelmann, K				Spitzner, Melanie; Martins, Joana Raquel; Soria, Rene Barro; Ousingsawat, Jiraporn; Scheidt, Kerstin; Schreiber, Rainer; Kunzelmann, Karl			Eag1 and bestrophin 1 are up-regulated in fast-growing colonic cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED POTASSIUM CHANNELS; CHLORIDE CHANNELS; ION CHANNELS; K+ CHANNELS; ELECTROLYTE TRANSPORT; EPITHELIAL-CELLS; PROLIFERATION; CALCIUM; FAMILY; IDENTIFICATION	Ion channels like voltage-gated ether-a-go-go ( Eag1) K+ channels or Ca2+-activated Cl- channels have been shown to support cell proliferation. Bestrophin 1 ( Best1) has been proposed to form Ca2+-activated Cl- channels in epithelial cells. Here we show that original T-84 colonic carcinoma cells grow slowly ( T-84-slow) and express low amounts of Eag1 and Best1, whereas spontaneously transformed T-84 cells grow fast ( T-84-fast) and express high levels of both proteins. Both Eag1 and Best1 currents are up-regulated in T-84-fast cells. Eag1 currents were cell cycle-dependent with up-regulation during G1/ S transition. T-84-slow, but not T-84-fast, cells formed tight monolayers when grown on permeable supports. RNA interference inhibition of Eag1 and Best1 reduced proliferation of T-84-fast cells, whereas overexpression of Best1 turned T-84-slow into fast-growing cells. Eag1 and Best1 improve intracellular Ca2+ signaling and cell volume regulation. These results establish a novel role for bestrophins in cell proliferation.	[Spitzner, Melanie; Martins, Joana Raquel; Soria, Rene Barro; Ousingsawat, Jiraporn; Scheidt, Kerstin; Schreiber, Rainer; Kunzelmann, Karl] Univ Regensburg, Inst Physiol, D-93053 Regensburg, Germany	University of Regensburg	Kunzelmann, K (corresponding author), Univ Regensburg, Inst Physiol, Univ Str 31, D-93053 Regensburg, Germany.	uqkkunze@mailbox.uq.edu	Martins, Joana/L-2965-2016	Martins, Joana/0000-0002-3784-9775; Kunzelmann, Karl/0000-0002-4583-7037; Spitzner, Melanie/0000-0002-3673-0625				Alessandro R, 2005, J CELL PHYSIOL, V203, P261, DOI 10.1002/jcp.20236; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; Boyd DD, 2004, CLIN CANCER RES, V10, P1545, DOI 10.1158/1078-0432.CCR-1565-02; Chien LT, 2007, J GEN PHYSIOL, V130, P513, DOI 10.1085/jgp.200709795; DHARMSATHAPHORN K, 1984, AM J PHYSIOL, V246, pG204, DOI 10.1152/ajpgi.1984.246.2.G204; Fischmeister R, 2005, J PHYSIOL-LONDON, V562, P477, DOI 10.1113/jphysiol.2004.075622; Fraser GM, 1997, PFLUG ARCH EUR J PHY, V434, P801, DOI 10.1007/s004240050468; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Kunzelmann K, 2005, J MEMBRANE BIOL, V205, P159, DOI 10.1007/s00232-005-0781-4; Kunzelmann K, 2002, PHYSIOL REV, V82, P245, DOI 10.1152/physrev.00026.2001; Kunzelmann K, 2007, PFLUG ARCH EUR J PHY, V454, P879, DOI 10.1007/s00424-007-0245-z; MORRIS AP, 1993, AM J PHYSIOL, V264, pC968, DOI 10.1152/ajpcell.1993.264.4.C968; Ousingsawat J, 2007, CLIN CANCER RES, V13, P824, DOI 10.1158/1078-0432.CCR-06-1940; Pardo LA, 2005, J MEMBRANE BIOL, V205, P115, DOI 10.1007/s00232-005-0776-1; Pardo LA, 2004, PHYSIOLOGY, V19, P285, DOI 10.1152/physiol.00011.2004; Pauli BU, 2000, CLIN EXP PHARMACOL P, V27, P901, DOI 10.1046/j.1440-1681.2000.03358.x; Puntheeranurak S, 2007, CELL PHYSIOL BIOCHEM, V19, P77, DOI 10.1159/000099194; Qu ZQ, 2004, J GEN PHYSIOL, V123, P327, DOI 10.1085/jgp.200409031; Rao JN, 2002, AM J PHYSIOL-CELL PH, V282, pC885, DOI 10.1152/ajpcell.00361.2001; Rosenthal R, 2005, FASEB J, V19, P178, DOI 10.1096/fj.05-4495fje; Schonherr R, 2005, J MEMBRANE BIOL, V205, P175, DOI 10.1007/s00232-005-0782-3; SCHWAB A, 1994, J CLIN INVEST, V93, P1631, DOI 10.1172/JCI117144; Schwab A, 2001, NEWS PHYSIOL SCI, V16, P29, DOI 10.1152/physiologyonline.2001.16.1.29; SORIA RB, 2006, J BIOL CHEM, V281, P17460; Spitzner M, 2007, FASEB J, V21, P35, DOI 10.1096/fj.06-6200com; Stansfeld CE, 1996, P NATL ACAD SCI USA, V93, P9910, DOI 10.1073/pnas.93.18.9910; Stuhmer W, 2006, FEBS LETT, V580, P2850, DOI 10.1016/j.febslet.2006.03.062; Sun H, 2002, P NATL ACAD SCI USA, V99, P4008, DOI 10.1073/pnas.052692999; Szabo I, 1996, J BIOL CHEM, V271, P20465, DOI 10.1074/jbc.271.34.20465; Tsunenari T, 2003, J BIOL CHEM, V278, P41114, DOI 10.1074/jbc.M306150200; Wang ZG, 2004, PFLUG ARCH EUR J PHY, V448, P274, DOI 10.1007/s00424-004-1258-5; Wonderlin WF, 1996, J MEMBRANE BIOL, V154, P91, DOI 10.1007/s002329900135	32	52	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7421	7428		10.1074/jbc.M703758200	http://dx.doi.org/10.1074/jbc.M703758200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18222922	hybrid			2022-12-25	WOS:000253997900016
J	Zhang, H; Li, ZH; Zhang, MQ; Katz, MS; Zhang, BX				Zhang, Hua; Li, Zhen-Hua; Zhang, Michael Q.; Katz, Michael S.; Zhang, Bin-Xian			Heat shock protein 90 beta 1 is essential for polyunsaturated fatty acid-induced mitochondrial Ca2+ efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-2 DIABETIC-PATIENTS; ENDOPLASMIC-RETICULUM; SUBSTRATE OXIDATION; INTRACELLULAR CA2+; CALCIUM-TRANSPORT; SKELETAL-MUSCLE; CELLS; HSP90; DYSFUNCTION; GLUCOSE	Nonesterified fatty acids may influence mitochondrial function by alterations in gene expression, metabolism, and/or mitochondrial Ca2+ ([Ca2+](m)) homeostasis. We have previously reported that polyunsaturated fatty acids induce Ca2+ efflux from mitochondria, an action that may deplete [Ca2+](m) and thus contribute to nonesterified fatty acid-responsive mitochondrial dysfunction. Here we show that the chaperone protein heat shock protein 90 beta 1 (hsp90 beta 1) is required for polyunsaturated fatty acid-induced mitochondrial Ca2+ efflux (PIMCE). Retinoic acid induced differentiation of human teratocarcinoma NT2 cells in association with attenuation of PIMCE. Proteomic analysis of mitochondrial proteins revealed that hsp90 beta 1, among other proteins, was reduced in retinoic acid-differentiated cells. Blockade of PIMCE in NT2 cells by 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin, a known inhibitor of the chaperone activity of hsp90, and hsp90 beta 1 RNA interference demonstrated that hsp90 beta 1 is essential for PIMCE. We also show localization of hsp90 beta 1 in mitochondria by Western blot and immunofluorescence. Distinctive effects of inhibitors binding to the N or C terminus of hsp90 on PIMCE in isolated mitochondria suggested that the C terminus of hsp90 beta 1 plays a critical role in PIMCE.	[Zhang, Hua; Li, Zhen-Hua; Zhang, Michael Q.; Katz, Michael S.; Zhang, Bin-Xian] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Audie L Murphy Div, S Texas Vet Hlth Care Syst,Geriatr Res Educ & Cli, San Antonio, TX 78229 USA	Geriatric Research Education & Clinical Center; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Zhang, BX (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Audie L Murphy Div, S Texas Vet Hlth Care Syst,Geriatr Res Educ & Cli, GRECC 182,7400 Merton Minter Blvd, San Antonio, TX 78229 USA.				NHLBI NIH HHS [HL075011] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075011] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allan RK, 2006, J BIOL CHEM, V281, P7161, DOI 10.1074/jbc.M512406200; Asquith KL, 2005, BIOL REPROD, V72, P328, DOI 10.1095/biolreprod.104.034470; Befroy DE, 2007, DIABETES, V56, P1376, DOI 10.2337/db06-0783; Biden TJ, 2004, DIABETES, V53, pS159, DOI 10.2337/diabetes.53.2007.S159; Deryabina YI, 2004, BIOCHEMISTRY-MOSCOW+, V69, P91, DOI 10.1023/B:BIRY.0000016357.17251.7b; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; Egorin MJ, 2002, CANCER CHEMOTH PHARM, V49, P7, DOI 10.1007/s00280-001-0380-8; Fan ACY, 2006, J BIOL CHEM, V281, P33313, DOI 10.1074/jbc.M605250200; Hansford RG, 1998, MOL CELL BIOCHEM, V184, P359, DOI 10.1023/A:1006893903113; Hawkins TE, 2000, CELL BIOCHEM BIOPHYS, V33, P275, DOI 10.1385/CBB:33:3:275; Hoyt KR, 1998, J PHYSIOL-LONDON, V509, P103, DOI 10.1111/j.1469-7793.1998.103bo.x; Joseph JW, 2004, J BIOL CHEM, V279, P51049, DOI 10.1074/jbc.M409189200; Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944; Lambert AJ, 2004, EXP GERONTOL, V39, P289, DOI 10.1016/j.exger.2003.12.009; Liu XB, 2000, CELL DEATH DIFFER, V7, P1119, DOI 10.1038/sj.cdd.4400745; Lowell BB, 2005, SCIENCE, V307, P384, DOI 10.1126/science.1104343; Marchler-Bauer A, 2004, NUCLEIC ACIDS RES, V32, pW327, DOI 10.1093/nar/gkh454; Mayers RM, 2003, BIOCHEM SOC T, V31, P1165; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; Mogensen M, 2007, DIABETES, V56, P1592, DOI 10.2337/db06-0981; PAOLISSO G, 1995, DIABETOLOGIA, V38, P1213, DOI 10.1007/BF00422371; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; REAVEN GM, 1988, DIABETES, V37, P1020, DOI 10.2337/diabetes.37.8.1020; REITSCHNEIDER NH, 2006, J PROTEOME RES, V5, P1117; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Rodriguez-Sinovas A, 2006, CIRC RES, V99, P93, DOI 10.1161/01.RES.0000230315.56904.de; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPARAGNA GC, 1995, J BIOL CHEM, V270, P27510, DOI 10.1074/jbc.270.46.27510; Sreedhar AS, 2004, FEBS LETT, V562, P11; Stanley WC, 1997, CARDIOVASC RES, V34, P25, DOI 10.1016/S0008-6363(97)00047-3; Szabadkai G, 2006, J CELL BIOL, V175, P901, DOI 10.1083/jcb.200608073; Yi L, 2007, CHEM PHYS LIPIDS, V150, P204, DOI 10.1016/j.chemphyslip.2007.08.002; Yu HY, 2001, DIABETOLOGIA, V44, P614, DOI 10.1007/s001250051668; Zhang BX, 2006, CELL BIOCHEM BIOPHYS, V44, P187, DOI 10.1385/CBB:44:2:187; Zhang BX, 2006, AM J PHYSIOL-CELL PH, V290, pC1321, DOI 10.1152/ajpcell.00335.2005; Zhang BX, 2002, J BIOL CHEM, V277, P48165, DOI 10.1074/jbc.M208077200; Zhang WK, 2007, AM J PHYSIOL-RENAL, V292, pF1054, DOI 10.1152/ajprenal.00286.2006; Zhou YP, 1996, DIABETES, V45, P580, DOI 10.2337/diabetes.45.5.580	40	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7580	7589		10.1074/jbc.M707192200	http://dx.doi.org/10.1074/jbc.M707192200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18178560	hybrid			2022-12-25	WOS:000253997900033
J	Cuddihy, SL; Ali, SS; Musiek, ES; Lucero, J; Kopp, SJ; Morrow, JD; Dugan, LL				Cuddihy, Sarah L.; Ali, Sameh S.; Musiek, Erik S.; Lucero, Jacinta; Kopp, Sarah J.; Morrow, Jason D.; Dugan, Laura L.			Prolonged alpha-tocopherol deficiency decreases oxidative stress and unmasks alpha-tocopherol-dependent regulation of mitochondrial function in the brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-E-DEFICIENCY; CYTOCHROME BC(1) COMPLEX; REACTIVE OXYGEN; LIPID-PEROXIDATION; COENZYME Q(10); AGED MICE; IN-VIVO; DOCOSAHEXAENOIC ACID; MOLECULAR-MECHANISM; SUPEROXIDE ANION	Vitamin E is the major lipid-soluble chain-breaking antioxidant in mammals and plays an important role in normal development and physiology. Deficiency (whether dietary or genetic) results in primarily nervous system pathology, including cerebellar neurodegeneration and progressive ataxia (abnormal gait). However, despite the widely acknowledged antioxidant properties of vitamin E, only a few studies have directly correlated levels of reactive oxygen species with vitamin E availability in animal models. We explored the relationship between vitamin E and reactive oxygen species in two mouse models of vitamin E deficiency: dietary deficiency and a genetic model (tocopherol transfer protein, Ttp(-/-) mice). Both groups of mice developed nearly complete depletion of alpha-tocopherol (the major tocopherol in vitamin E) in most organs, but not in the brain, which was relatively resistant to loss of alpha-tocopherol. F4-neuroprostanes, an index of lipid peroxidation, were unexpectedly lower in brains of deficient mice compared with controls. In vivo oxidation of dihydroethidium by superoxide radical was also significantly lower in brains of deficient animals. Superoxide production by brain mitochondria isolated from vitamin E-deficient and Ttp(-/-) mice, measured by electron paramagnetic resonance spectroscopy, demonstrated a biphasic dependence on exogenously added alpha-tocopherol. At low concentrations, alpha-tocopherol enhanced superoxide flux from mitochondria, a response that was reversed at higher concentrations. Here we propose a mechanism, supported by molecular modeling, to explain decreased superoxide production during alpha-tocopherol deficiency and speculate that this could be a beneficial response under conditions of alpha-tocopherol deficiency.	[Ali, Sameh S.; Lucero, Jacinta; Dugan, Laura L.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Ali, Sameh S.; Lucero, Jacinta; Dugan, Laura L.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; [Cuddihy, Sarah L.; Ali, Sameh S.; Kopp, Sarah J.; Dugan, Laura L.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Musiek, Erik S.; Morrow, Jason D.] Vanderbilt Univ, Sch Med, Dept Med & Pharmacol, Nashville, TN 37232 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Washington University (WUSTL); Vanderbilt University	Dugan, LL (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr MC0746, La Jolla, CA 92093 USA.	ladugan@ucsd.edu		Musiek, Erik/0000-0002-8873-0360; Ali, Sameh Saad/0000-0002-0339-6106	NCI NIH HHS [CA77839] Funding Source: Medline; NIGMS NIH HHS [GM15431] Funding Source: Medline; NINDS NIH HHS [NS41796] Funding Source: Medline; PHS HHS [DDK48831] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA077839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM015431, P01GM015431] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041796] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alex G, 2000, J PAEDIATR CHILD H, V36, P515, DOI 10.1046/j.1440-1754.2000.00534.x; Ali SS, 2006, AGING CELL, V5, P565, DOI 10.1111/j.1474-9726.2006.00252.x; Azzi A, 2004, BIOL CHEM, V385, P585, DOI 10.1515/BC.2004.072; Azzi A, 2002, FEBS LETT, V519, P8, DOI 10.1016/S0014-5793(02)02706-0; Azzi A, 2007, FREE RADICAL BIO MED, V43, P16, DOI 10.1016/j.freeradbiomed.2007.03.013; Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; Brigelius-Flohe R, 2002, AM J CLIN NUTR, V76, P703, DOI 10.1093/ajcn/76.4.703; Brigelius-Flohe R, 2007, FREE RADICAL BIO MED, V43, P2, DOI 10.1016/j.freeradbiomed.2007.05.016; Burczynski JM, 2001, FREE RADICAL BIO MED, V30, P1029, DOI 10.1016/S0891-5849(01)00497-X; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; CADENAS E, 1989, FEBS LETT, V253, P235, DOI 10.1016/0014-5793(89)80966-4; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; ELMADFA I, 1986, Z GERONTOL, V19, P206; Evans HM, 1922, SCIENCE, V56, P650, DOI 10.1126/science.56.1458.650; Gabsi S, 2001, EUR J NEUROL, V8, P477, DOI 10.1046/j.1468-1331.2001.00273.x; Gregor W, 2006, BIOCHEM PHARMACOL, V71, P1589, DOI 10.1016/j.bcp.2006.02.012; Han D, 2001, BIOCHEM J, V353, P411, DOI 10.1042/0264-6021:3530411; Hsieh CC, 2006, NUTRITION, V22, P433, DOI 10.1016/j.nut.2005.10.001; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Jezek P, 2005, INT J BIOCHEM CELL B, V37, P2478, DOI 10.1016/j.biocel.2005.05.013; Jishage K, 2001, J BIOL CHEM, V276, P1669, DOI 10.1074/jbc.C000676200; Kadiiska MB, 2005, FREE RADICAL BIO MED, V38, P698, DOI 10.1016/j.freeradbiomed.2004.09.017; Kamzalov S, 2003, J NUTR, V133, P3175, DOI 10.1093/jn/133.10.3175; Lange C, 2001, EMBO J, V20, P6591, DOI 10.1093/emboj/20.23.6591; Lass A, 1998, ARCH BIOCHEM BIOPHYS, V352, P229, DOI 10.1006/abbi.1997.0606; Lass A, 1999, FREE RADICAL BIO MED, V26, P1375, DOI 10.1016/S0891-5849(98)00330-X; MacEvilly CJ, 1996, FREE RADICAL BIO MED, V20, P639, DOI 10.1016/0891-5849(95)02147-7; Maggi-Capeyron MF, 2002, J NUTR BIOCHEM, V13, P296, DOI 10.1016/S0955-2863(01)00222-4; Mcdonald SR, 2005, FREE RADICAL BIO MED, V38, P729, DOI 10.1016/j.freeradbiomed.2004.11.014; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; Muegge I, 1999, J MED CHEM, V42, P791, DOI 10.1021/jm980536j; Muller FL, 2004, J BIOL CHEM, V279, P49064, DOI 10.1074/jbc.M407715200; Musiek ES, 2004, J CHROMATOGR B, V799, P95, DOI 10.1016/j.jchromb.2003.10.036; Nicholls D.G, 2004, BIOCHEMISTRY-MOSCOW+, V69, P818; Nohl H, 2004, ACTA BIOCHIM POL, V51, P223; Papa S, 1997, MOL CELL BIOCHEM, V174, P305, DOI 10.1023/A:1006873518427; PARAIDATHATHU T, 1994, TOXICOLOGY, V90, P103, DOI 10.1016/0300-483X(94)90209-7; Quick KL, 2008, NEUROBIOL AGING, V29, P117, DOI 10.1016/j.neurobiolaging.2006.09.014; Quick KL, 2001, ANN NEUROL, V49, P627, DOI 10.1002/ana.1005; Quiles JL, 2005, BIOFACTORS, V25, P73, DOI 10.1002/biof.5520250109; QUINTANILHA AT, 1982, ANN NY ACAD SCI, V393, P32, DOI 10.1111/j.1749-6632.1982.tb31230.x; Rafique R, 2004, FREE RADICAL RES, V38, P157, DOI 10.1080/10715760310001643311; Rafique R, 2001, BIOCHEM J, V357, P887, DOI 10.1042/0264-6021:3570887; Raymond LJ, 2004, EXP BIOL MED, V229, P885, DOI 10.1177/153537020422900904; Reich EE, 2001, J NEUROSCI, V21, P5993, DOI 10.1523/JNEUROSCI.21-16-05993.2001; Ricciarelli R, 2001, FASEB J, V15, P2314, DOI 10.1096/fj.01-0258rev; Roberts LJ, 1998, J BIOL CHEM, V273, P13605, DOI 10.1074/jbc.273.22.13605; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; SOKOL RJ, 1989, AM J CLIN NUTR, V50, P1064, DOI 10.1093/ajcn/50.5.1064; Sumien N, 2004, FREE RADICAL BIO MED, V36, P1424, DOI 10.1016/j.freeradbiomed.2004.02.081; Tarpey MM, 2004, AM J PHYSIOL-REG I, V286, pR431, DOI 10.1152/ajpregu.00361.2003; Terasawa Y, 2000, P NATL ACAD SCI USA, V97, P13830, DOI 10.1073/pnas.240462697; THOMAS PK, 1993, J ANAT, V183, P451; Traber MG, 2007, FREE RADICAL BIO MED, V43, P4, DOI 10.1016/j.freeradbiomed.2007.03.024; Traber MG, 2005, FREE RADICAL BIO MED, V38, P773, DOI 10.1016/j.freeradbiomed.2004.11.027; VATASSERY GT, 1984, J NEUROCHEM, V42, P554, DOI 10.1111/j.1471-4159.1984.tb02713.x; VATASSERY GT, 1984, BIOCHIM BIOPHYS ACTA, V792, P118, DOI 10.1016/0005-2760(84)90211-X; Vatassery GT, 2004, BBA-MOL BASIS DIS, V1688, P265, DOI 10.1016/j.bbadis.2003.12.013; Wang XY, 2000, MOL MEMBR BIOL, V17, P143, DOI 10.1080/09687680010000311	61	41	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					6915	6924		10.1074/jbc.M702572200	http://dx.doi.org/10.1074/jbc.M702572200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18180306	hybrid			2022-12-25	WOS:000253779600035
J	Teer, JK; Dutta, A				Teer, Jamie K.; Dutta, Anindya			Human Cdt1 lacking the evolutionarily conserved region that interacts with MCM2-7 is capable of inducing re-replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINICHROMOSOME MAINTENANCE PROTEINS; EUKARYOTIC DNA-REPLICATION; LICENSING FACTOR CDT1; PREREPLICATION COMPLEXES; TRANSCRIPTIONAL CONTROL; G(2)/M CHECKPOINT; HELICASE ACTIVITY; MAMMALIAN-CELLS; GEMININ BINDING; S-PHASE	Replication initiation must be a carefully regulated process to avoid genomic instability caused by aberrant replication. In eukaryotic cells, distinct steps of protein loading ( origin licensing) and replication activation are choreographed such that a cell can replicate only once per cell cycle. The first proteins recruited to the origins form the pre-replication complex. Of these proteins, Cdt1 is of interest, as it is the focus of several pathways to control replication initiation. It is degraded by two different pathways, mediated by the interaction of Cdt1 with proliferating cell nuclear antigen ( PCNA) or with cyclin-Cdk2 and inhibited by geminin once cells are in S-phase, presumably to prevent reloading of pre-replication complexes once S-phase has begun. Although the requirement of Cdt1 in loading MCM2-7 is known, the mechanism by which overexpressed Cdt1 stimulates re-replication is unclear. In this study we have designed various mutations in Cdt1 to determine which portion of Cdt1 is important for re-replication, providing insight into possible mechanisms. Surprisingly, we found that mutants of Cdt1 that do not interact with MCM2-7 are able to induce rereplication when overexpressed. The re-replication is not due to titration of geminin from endogenous Cdt1 and is not accompanied by stabilization of endogenous Cdt1. Additionally, the N-terminal one-third of Cdt1 is sufficient to induce re-replication. The N terminus contains the PCNA-and cyclin-interacting motifs, and deletion of both motifs simultaneously in the overexpressed Cdt1 prevents re-replication. These findings suggest that exogenous Cdt1 induces re-replication by de-repressing endogenous Cdt1 through the titration of PCNA and cyclin.	[Teer, Jamie K.; Dutta, Anindya] Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; [Teer, Jamie K.; Dutta, Anindya] Harvard Univ, Sch Med, Biol & Biomed Sci Program, Boston, MA 02115 USA	University of Virginia; Harvard University; Harvard Medical School	Dutta, A (corresponding author), Univ Virginia, Sch Med, Dept Biochem & Mol Genet, 1340 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	ad8q@virginia.edu	Dutta, Anindya/P-3203-2016	Dutta, Anindya/0000-0002-4319-0073	NCI NIH HHS [R01CA60499, R01 CA060499-15, R01 CA060499] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060499] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arentson E, 2002, ONCOGENE, V21, P1150, DOI 10.1038/sj.onc.1205175; Arias EE, 2005, GENE DEV, V19, P114, DOI 10.1101/gad.1255805; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Cook JG, 2004, J BIOL CHEM, V279, P9625, DOI 10.1074/jbc.M311933200; Cook JG, 2002, P NATL ACAD SCI USA, V99, P1347, DOI 10.1073/pnas.032677499; Devault A, 2002, CURR BIOL, V12, P689, DOI 10.1016/S0960-9822(02)00768-6; Dominguez-Sola D, 2007, NATURE, V448, P445, DOI 10.1038/nature05953; Ferenbach A, 2005, NUCLEIC ACIDS RES, V33, P316, DOI 10.1093/nar/gki176; Fujita M, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-22; Garnier J, 1996, METHOD ENZYMOL, V266, P540; Geng Y, 2007, MOL CELL, V25, P127, DOI 10.1016/j.molcel.2006.11.029; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Karakaidos P, 2004, AM J PATHOL, V165, P1351, DOI 10.1016/S0002-9440(10)63393-7; Lee JK, 2000, J BIOL CHEM, V275, P18871, DOI 10.1074/jbc.M001118200; Li A, 2005, EMBO J, V24, P395, DOI 10.1038/sj.emboj.7600520; Machida YJ, 2007, GENE DEV, V21, P184, DOI 10.1101/gad.1495007; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Moyer SE, 2006, P NATL ACAD SCI USA, V103, P10236, DOI 10.1073/pnas.0602400103; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Randell JCW, 2006, MOL CELL, V21, P29, DOI 10.1016/j.molcel.2005.11.023; Senga T, 2006, J BIOL CHEM, V281, P6246, DOI 10.1074/jbc.M512705200; Sugimoto N, 2004, J BIOL CHEM, V279, P19691, DOI 10.1074/jbc.M313175200; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Takeda DY, 2005, J BIOL CHEM, V280, P23416, DOI 10.1074/jbc.M501208200; Tanaka S, 2002, NAT CELL BIOL, V4, P198, DOI 10.1038/ncb757; Teer Jamie K., 2006, V42, P31, DOI 10.1007/b137221; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Yanagi K, 2002, J BIOL CHEM, V277, P40871, DOI 10.1074/jbc.M206202200; You ZY, 1999, MOL CELL BIOL, V19, P8003; Zhong WW, 2003, NATURE, V423, P885, DOI 10.1038/nature01747; Zhu WG, 2006, MOL CELL BIOL, V26, P4601, DOI 10.1128/MCB.02141-05; Zhu WG, 2004, MOL CELL BIOL, V24, P7140, DOI 10.1128/MCB.24.16.7140-7150.2004	36	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					6817	6825		10.1074/jbc.M708767200	http://dx.doi.org/10.1074/jbc.M708767200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18184650	hybrid			2022-12-25	WOS:000253779600024
J	Caunt, CJ; Rivers, CA; Conway-Campbell, BL; Norman, MR; McArdle, CA				Caunt, Christopher J.; Rivers, Caroline A.; Conway-Campbell, Becky L.; Norman, Michael R.; McArdle, Craig A.			Epidermal growth factor receptor and protein kinase C signaling to ERK2 - Spatiotemporal regulation of ERK2 by dual specificity phosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OF-FUNCTION MUTATION; P42 MAP KINASE; NUCLEAR TRANSLOCATION; HORMONE RECEPTORS; RECOMBINANT ADENOVIRUS; DOCKING SITES; IN-VIVO; ACTIVATION; COMPARTMENTALIZATION; RECOGNITION	Spatiotemporal aspects of ERK activation are stimulus-specific and dictate cellular consequences. They are dependent upon dual specificity phosphatases (DUSPs) that bind ERK via docking domains and can both inactivate and anchor ERK in cellular compartments. Using high throughput fluorescence microscopy in combination with a system where endogenous ERKs are removed and replaced with wild-type or mutated ERK2-green fluorescent protein (GFP), we show that ERK2 activation responses to epidermal growth factor (EGF) and protein kinase C (PKC) are transient and sustained, respectively. PKC-mediated ERK2 activation is associated with prolonged nuclear localization in the dephosphorylated form, whereas EGF-stimulated ERK2 activation mediates only transient nuclear accumulation. By using short inhibitory RNAs to nuclear inducible DUSP1, -2, or -4 (alone or in combination), we demonstrate that all three of these enzymes contribute to the dephosphorylation of PKC (but not EGF)-activated ERK2 in the nucleus but that they have opposing effects on localization. DUSP2 and -4 inactivate and anchor ERK2, whereas DUSP1 dephosphorylates ERK in the nucleus but allows its traffic back to the cytoplasm. Overexpression of DUSP1, -2, or -4 prevented ERK2 activation, but only DUSP2 and -4 caused ERK2-GFP nuclear accumulation or could be immunoprecipitated with ERK2. Furthermore, protein synthesis inhibition or replacement of wild-type ERK2-GFP with docking domain mutants selectively increased PKC effects on ERK activity and altered ERK2-GFP localization. These mutations also impaired the ability of ERK2-GFP to bind DUSP2 and -4. Together, our data reveal a novel, stimulus-specific, and phosphatase-specific mechanism of ERK2 regulation in the nucleus by DUSP1, -2, and -4.	[Caunt, Christopher J.; Rivers, Caroline A.; Conway-Campbell, Becky L.; Norman, Michael R.; McArdle, Craig A.] Univ Bristol, Dept Clin Sci, Labs Integrated Neurosci & Endocrinol, Bristol BS1 3NY, Avon, England	University of Bristol	McArdle, CA (corresponding author), Univ Bristol, Dept Clin Sci, Labs Integrated Neurosci & Endocrinol, Whitson St, Bristol BS1 3NY, Avon, England.	craig.mcardle@bris.ac.uk	Conway-Campbell, Becky/B-8571-2009; McArdle, Craig/AAQ-5660-2021	McArdle, Craig/0000-0003-4836-5351	Wellcome Trust [076557, 078407, 062918] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Anderson RD, 2000, GENE THER, V7, P1034, DOI 10.1038/sj.gt.3301197; BOTT CM, 1994, FEBS LETT, V352, P201, DOI 10.1016/0014-5793(94)00958-9; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Casar B, 2007, EMBO J, V26, P635, DOI 10.1038/sj.emboj.7601523; Caunt CJ, 2006, TRENDS ENDOCRIN MET, V17, P276, DOI 10.1016/j.tem.2006.07.008; Caunt CJ, 2006, J BIOL CHEM, V281, P2701, DOI 10.1074/jbc.M507242200; Chen PL, 2001, J BIOL CHEM, V276, P29440, DOI 10.1074/jbc.M103463200; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Dimitri CA, 2005, CURR BIOL, V15, P1319, DOI 10.1016/j.cub.2005.06.037; Ebisuya M, 2005, J CELL SCI, V118, P2997, DOI 10.1242/jcs.02505; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Hislop JN, 2001, J BIOL CHEM, V276, P39685, DOI 10.1074/jbc.M104542200; Hislop JN, 2000, ENDOCRINOLOGY, V141, P4564, DOI 10.1210/en.141.12.4564; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Jeffrey KL, 2007, NAT REV DRUG DISCOV, V6, P391, DOI 10.1038/nrd2289; Lee T, 2004, MOL CELL, V14, P43, DOI 10.1016/S1097-2765(04)00161-3; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; Mandl M, 2005, MOL CELL BIOL, V25, P1830, DOI 10.1128/MCB.25.5.1830-1845.2005; Murphy LO, 2006, TRENDS BIOCHEM SCI, V31, P268, DOI 10.1016/j.tibs.2006.03.009; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Owens DM, 2007, ONCOGENE, V26, P3203, DOI 10.1038/sj.onc.1210412; Slack DN, 2001, J BIOL CHEM, V276, P16491, DOI 10.1074/jbc.M010966200; Tanoue T, 2002, J BIOL CHEM, V277, P22942, DOI 10.1074/jbc.M202096200; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Volmat V, 2001, J CELL SCI, V114, P3433; Whitehurst A, 2004, MOL CELL BIOL, V24, P10145, DOI 10.1128/MCB.24.23.10145-10150.2004; Yamamoto T, 2006, CURR BIOL, V16, P1171, DOI 10.1016/j.cub.2006.04.044; Yazicioglu MN, 2007, J BIOL CHEM, V282, P28759, DOI 10.1074/jbc.M703460200; Zhang JL, 2003, J BIOL CHEM, V278, P29901, DOI 10.1074/jbc.M303909200; Zhou B, 2001, J BIOL CHEM, V276, P6506, DOI 10.1074/jbc.M009753200	33	59	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2008	283	10					6241	6252		10.1074/jbc.M706624200	http://dx.doi.org/10.1074/jbc.M706624200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HM	18178562	hybrid, Green Accepted			2022-12-25	WOS:000253779500031
J	Minahk, C; Kim, KW; Nelson, R; Trigatti, B; Lehner, R; Vance, DE				Minahk, Carlos; Kim, Kyung-Wook; Nelson, Randy; Trigatti, Bernardo; Lehner, Richard; Vance, Dennis E.			Conversion of low density lipoprotein-associated phosphatidylcholine to triacylglycerol by primary hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR CLASS-B; PHOSPHOLIPID TRANSFER PROTEIN; HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; MEDIATED SELECTIVE UPTAKE; CHOLESTERYL ESTERS; HUMAN-FIBROBLASTS; SR-BI; LDL RECEPTOR; SULFATE PROTEOGLYCANS; INSULIN-RESISTANCE	We have studied the uptake and metabolism of phosphatidylcholine (PC), the major phospholipid of low density lipoproteins (LDL), by cultures of primary hepatocytes. Strikingly, in the absence of the LDL receptor, PC incorporation into hepatocytes was inhibited by only 30%, whereas cholesteryl ether uptake was inhibited by 60-70%. On the other hand, scavenger receptor class B, type I, the other important receptor for LDL in the liver, was found to be responsible for the uptake of the remaining 30-40% of LDL-cholesteryl ether. PC uptake was, however, only partially inhibited (30%) in scavenger receptor class B, type I, knock-out hepatocytes. Once LDL-PC was taken up by hepatocytes, similar to 50% of LDL-[H-3]oleate-PC was converted to triacylglycerol rather than degraded in lysosomes as occurs for LDL-derived cholesteryl esters. The remainder of the LDL- derived PC was not significantly metabolized to other products. Triacylglycerol synthesis from LDL- PC requires a PC-phospholipase C activity as demonstrated by inhibition with the phospholipase C inhibitor D609 or activation with rattlesnake venom. Small interfering RNA-mediated suppression of acyl-CoA:diacylglycerol acyltransferase 2(DGAT2), but not DGAT1, decreased the acylation of the LDL- derived diacylglycerol. These findings show that PC in LDL particles is taken up not only by the classical receptors but also by additional mechanism(s) followed by metabolism that is completely different from the cholesteryl esters or apoB100, the other main components of LDL.	[Minahk, Carlos; Nelson, Randy; Vance, Dennis E.] Univ Alberta, HMRC 328, Dept Biochem, Edmonton, AB T6G 2S2, Canada; [Minahk, Carlos; Nelson, Randy; Lehner, Richard; Vance, Dennis E.] Univ Alberta, Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada; [Kim, Kyung-Wook; Trigatti, Bernardo] McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON L8N 3Z5, Canada; [Lehner, Richard] Univ Alberta, Dept Pediat, Dept Cell Biol, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta; McMaster University; University of Alberta	Vance, DE (corresponding author), Univ Alberta, HMRC 328, Dept Biochem, Edmonton, AB T6G 2S2, Canada.	dennis.vance@ualberta.ca		Trigatti, Bernardo (Dino) L./0000-0002-4556-119X; Lehner, Richard/0000-0002-6008-1805; Minahk, Carlos/0000-0001-8765-8398				Albers JJ, 1996, CURR OPIN LIPIDOL, V7, P88, DOI 10.1097/00041433-199604000-00007; Amtmann E, 1996, DRUG EXP CLIN RES, V22, P287; ANDERSON RGW, 1977, CELL, V10, P351, DOI 10.1016/0092-8674(77)90022-8; Auger A, 2001, EUR J BIOCHEM, V268, P2322, DOI 10.1046/j.1432-1327.2001.02115.x; AVIRAM M, 1988, J BIOL CHEM, V263, P15416; AZHAR S, 1988, J LIPID RES, V29, P869; BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; Benitez S, 2004, BIOCHEMISTRY-US, V43, P15863, DOI 10.1021/bi048825z; BROWN MS, 1974, P NATL ACAD SCI USA, V71, P788, DOI 10.1073/pnas.71.3.788; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1975, P NATL ACAD SCI USA, V72, P2925, DOI 10.1073/pnas.72.8.2925; Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200; Chen HC, 2002, J CLIN INVEST, V109, P1049, DOI [10.1172/JCI200214672, 10.1172/JCI0214672]; Choi CS, 2007, J BIOL CHEM, V282, P22678, DOI 10.1074/jbc.M704213200; Dobner P, 1998, AM J PHYSIOL-ENDOC M, V275, pE777, DOI 10.1152/ajpendo.1998.275.5.E777; Dobner P, 1999, FEBS LETT, V444, P270, DOI 10.1016/S0014-5793(98)01687-1; Engelmann B, 1998, J BIOL CHEM, V273, P27800, DOI 10.1074/jbc.273.43.27800; Engelmann B, 1996, BIOCHEM J, V315, P781, DOI 10.1042/bj3150781; Foger B, 1997, J BIOL CHEM, V272, P27393, DOI 10.1074/jbc.272.43.27393; FOLCH J, 1957, J BIOL CHEM, V226, P497; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; GOLDSTEIN JL, 1975, J BIOL CHEM, V250, P7854; GOLDSTEIN JL, 1974, P NATL ACAD SCI USA, V71, P4288, DOI 10.1073/pnas.71.11.4288; GOTTARDI CJ, 1995, AM J PHYSIOL-RENAL, V268, pF285, DOI 10.1152/ajprenal.1995.268.2.F285; GREEN SR, 1991, J LIPID RES, V32, P667; Gu XJ, 2000, J BIOL CHEM, V275, P9120, DOI 10.1074/jbc.275.13.9120; Hagishita S, 1996, J MED CHEM, V39, P3636, DOI 10.1021/jm960395q; Hassan HH, 2007, J LIPID RES, V48, P2428, DOI 10.1194/jlr.M700206-JLR200; Hornberger TA, 2006, P NATL ACAD SCI USA, V103, P4741, DOI 10.1073/pnas.0600678103; HUANG CF, 1990, J BIOL CHEM, V265, P14858; Igal RA, 2001, J LIPID RES, V42, P88; ISHIKAWA Y, 1989, ATHEROSCLEROSIS, V80, P1, DOI 10.1016/0021-9150(89)90061-0; Jansen SM, 1999, BBA-MOL CELL BIOL L, V1436, P363, DOI 10.1016/S0005-2760(98)00129-5; Li J, 2007, BIOCHEM J, V406, P203, DOI 10.1042/BJ20070664; Lie J, 2004, J LIPID RES, V45, P805, DOI 10.1194/jlr.M300487-JLR200; Liu B, 2007, J LIPID RES, V48, P1710, DOI 10.1194/jlr.M700125-JLR200; LOOKENE A, 1994, EUR J BIOCHEM, V222, P395, DOI 10.1111/j.1432-1033.1994.tb18878.x; Luberto C, 1998, J BIOL CHEM, V273, P14550, DOI 10.1074/jbc.273.23.14550; MA PTS, 1986, P NATL ACAD SCI USA, V83, P792, DOI 10.1073/pnas.83.3.792; MacArthur JM, 2007, J CLIN INVEST, V117, P153, DOI 10.1172/JCI29154; Macphee CH, 2006, CURR OPIN PHARMACOL, V6, P154, DOI 10.1016/j.coph.2005.11.008; Maxwell KN, 2004, P NATL ACAD SCI USA, V101, P7100, DOI 10.1073/pnas.0402133101; McNutt MC, 2007, J BIOL CHEM, V282, P20799, DOI 10.1074/jbc.C700095200; Millar JS, 2006, J LIPID RES, V47, P2297, DOI 10.1194/jlr.M600213-JLR200; Monetti M, 2007, CELL METAB, V6, P69, DOI 10.1016/j.cmet.2007.05.005; Nieland TJF, 2005, BBA-MOL CELL BIOL L, V1734, P44, DOI 10.1016/j.bbalip.2005.02.007; Noga AA, 2002, J BIOL CHEM, V277, P42358, DOI 10.1074/jbc.M204542200; Pagler TA, 2006, J BIOL CHEM, V281, P11193, DOI 10.1074/jbc.M510261200; PARTHASARATHY S, 1990, P NATL ACAD SCI USA, V87, P9741, DOI 10.1073/pnas.87.24.9741; Ramoni C, 2004, EXP CELL RES, V299, P370, DOI 10.1016/j.yexcr.2004.05.037; Rashid S, 2005, P NATL ACAD SCI USA, V102, P5374, DOI 10.1073/pnas.0501652102; Rhainds D, 1999, EUR J BIOCHEM, V261, P227, DOI 10.1046/j.1432-1327.1999.00264.x; Rhainds D, 2003, BIOCHEMISTRY-US, V42, P7527, DOI 10.1021/bi026949a; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; Rosenson RS, 2004, ATHEROSCLEROSIS, V173, P1, DOI 10.1016/S0021-9150(03)00239-9; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; Santamarina-Fojo S, 1998, CURR OPIN LIPIDOL, V9, P211, DOI 10.1097/00041433-199806000-00005; SCAGNELLI GP, 1991, J BIOL CHEM, V266, P18002; Scott J, 2004, CURR OPIN GENET DEV, V14, P271, DOI 10.1016/j.gde.2004.04.012; Seo T, 2000, J BIOL CHEM, V275, P30355, DOI 10.1074/jbc.M910327199; Silver DL, 2001, J BIOL CHEM, V276, P25287, DOI 10.1074/jbc.M101726200; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; Sovic A, 2004, NEUROSCI LETT, V368, P11, DOI 10.1016/j.neulet.2004.04.097; SPARROW CP, 1990, BIOCHIM BIOPHYS ACTA, V1043, P203, DOI 10.1016/0005-2760(90)90297-B; STEIN Y, 1984, BIOCHIM BIOPHYS ACTA, V793, P354, DOI 10.1016/0005-2760(84)90249-2; Stone SJ, 2004, J BIOL CHEM, V279, P11767, DOI 10.1074/jbc.M311000200; Swarnakar S, 1999, J BIOL CHEM, V274, P29733, DOI 10.1074/jbc.274.42.29733; Swarnakar S, 2001, J BIOL CHEM, V276, P21121, DOI 10.1074/jbc.M101691200; TALL AR, 1983, J BIOL CHEM, V258, P2174; Trigatti BL, 2003, ARTERIOSCL THROM VAS, V23, P1732, DOI 10.1161/01.ATV.0000091363.28501.84; Truong TQ, 2000, BBA-MOL CELL BIOL L, V1484, P307, DOI 10.1016/S1388-1981(00)00023-8; Urban S, 2000, J BIOL CHEM, V275, P33409, DOI 10.1074/jbc.M004031200; Walter M, 1996, J CLIN INVEST, V98, P2315, DOI 10.1172/JCI119043; Wiggins D, 1996, BIOCHEM J, V320, P673, DOI 10.1042/bj3200673; Williams SD, 2000, J LIPID RES, V41, P1585; Yen CLE, 2005, J LIPID RES, V46, P1502, DOI 10.1194/jlr.M500036-JLR200; Zhang DW, 2007, J BIOL CHEM, V282, P18602, DOI 10.1074/jbc.M702027200; Zhang Y, 2007, J LIPID RES, V48, P405, DOI 10.1194/jlr.M600326-JLR200; Zhao QT, 2004, TOXICON, V44, P161, DOI 10.1016/j.toxicon.2004.05.015	80	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2008	283	10					6449	6458		10.1074/jbc.M706995200	http://dx.doi.org/10.1074/jbc.M706995200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HM	18175806	hybrid			2022-12-25	WOS:000253779500052
J	Childress, AR; Ehrman, RN; Wang, Z; Li, Y; Sciortino, N; Hakun, J; Jens, W; Suh, J; Listerud, J; Marquez, K; Franklin, T; Langleben, D; Detre, J; O'Brien, CP				Childress, Anna Rose; Ehrman, Ronald N.; Wang, Ze; Li, Yin; Sciortino, Nathan; Hakun, Jonathan; Jens, William; Suh, Jesse; Listerud, John; Marquez, Kathleen; Franklin, Teresa; Langleben, Daniel; Detre, John; O'Brien, Charles P.			Prelude to Passion: Limbic Activation by "Unseen" Drug and Sexual Cues	PLOS ONE			English	Article							AMYGDALA RESPONSE; PERCEPTION; SENSITIVITY; AWARENESS; STIMULI; FACES; FEAR	Background. The human brain responds to recognizable signals for sex and for rewarding drugs of abuse by activation of limbic reward circuitry. Does the brain respond in similar way to such reward signals even when they are "unseen'', i.e., presented in a way that prevents their conscious recognition? Can the brain response to "unseen'' reward cues predict the future affective response to recognizable versions of such cues, revealing a link between affective/motivational processes inside and outside awareness? Methodology/Principal Findings. We exploited the fast temporal resolution of event-related functional magnetic resonance imaging (fMRI) to test the brain response to "unseen'' (backward-masked) cocaine, sexual, aversive and neutral cues of 33 milliseconds duration in male cocaine patients (n = 22). Two days after scanning, the affective valence for visible versions of each cue type was determined using an affective bias (priming) task. We demonstrate, for the first time, limbic brain activation by "unseen'' drug and sexual cues of only 33 msec duration. Importantly, increased activity in an large interconnected ventral pallidum/amygdala cluster to the "unseen'' cocaine cues strongly predicted future positive affect to visible versions of the same cues in subsequent off-magnet testing, pointing both to the functional significance of the rapid brain response, and to shared brain substrates for appetitive motivation within and outside awareness. Conclusions/Significance. These findings represent the first evidence that brain reward circuitry responds to drug and sexual cues presented outside awareness. The results underscore the sensitivity of the brain to "unseen'' reward signals and may represent the brain's primordial signature for desire. The limbic brain response to reward cues outside awareness may represent a potential vulnerability in disorders (e. g., the addictions) for whom poorly-controlled appetitive motivation is a central feature.	[Childress, Anna Rose; Ehrman, Ronald N.; Wang, Ze; Li, Yin; Sciortino, Nathan; Hakun, Jonathan; Jens, William; Suh, Jesse; Listerud, John; Marquez, Kathleen; Franklin, Teresa; Langleben, Daniel; O'Brien, Charles P.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA; [Wang, Ze; Detre, John] Univ Penn, Med Sch, Dept Neurol, Philadelphia, PA USA; [Childress, Anna Rose; Ehrman, Ronald N.; Wang, Ze; Li, Yin; Suh, Jesse; Listerud, John; Marquez, Kathleen; Langleben, Daniel; O'Brien, Charles P.] Phila Dept VA Med Ctr, MIRECC, VISN 4, Philadelphia, PA USA	University of Pennsylvania; University of Pennsylvania	Childress, AR (corresponding author), Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA.	childress_a@mail.trc.upenn.edu	Wang, Ze/A-1043-2007; Langleben, Daniel D/K-7407-2014	Jens, William/0000-0001-5201-1412	NIH/NIDA [RO1-10241, RO1-15149, P-60-DA-05186, P-50-DA-12756]; VA VISN 4 MIRECC; Alexander Foundation; DANA Foundation; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA012756, R01DA015149, R01DA010241, P60DA005186] Funding Source: NIH RePORTER	NIH/NIDA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); VA VISN 4 MIRECC; Alexander Foundation; DANA Foundation; NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by NIH/NIDA (RO1-10241, RO1-15149, P-60-DA-05186, P-50-DA-12756) VA VISN 4 MIRECC, the Alexander Foundation and the DANA Foundation. The sponsors had no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript.	Adams RB, 2003, SCIENCE, V300, P1536, DOI 10.1126/science.1082244; Childress AR, 1999, AM J PSYCHIAT, V156, P11, DOI 10.1176/ajp.156.1.11; CHILDRESS AR, 2002, NEUROPSYCHOPHARMACOL, P1575; Dale AM, 1999, HUM BRAIN MAPP, V8, P109, DOI 10.1002/(SICI)1097-0193(1999)8:2/3<109::AID-HBM7>3.0.CO;2-W; Darwin C., 1876, NATURE, V15, P18, DOI [10.1038/015018a0, DOI 10.1038/015018A0]; EHRMAN RN, 1992, PSYCHOPHARMACOLOGY, V107, P523, DOI 10.1007/BF02245266; Everitt BJ, 2003, ANN NY ACAD SCI, V985, P233; FAZIO RH, 1995, J PERS SOC PSYCHOL, V69, P1013, DOI 10.1037/0022-3514.69.6.1013; FREUD, 1900, INTERPRETATION DREAM; Garavan H, 2000, AM J PSYCHIAT, V157, P1789, DOI 10.1176/appi.ajp.157.11.1789; Garavan H, 2001, NEUROREPORT, V12, P2779, DOI 10.1097/00001756-200108280-00036; Greenwald AG, 1996, SCIENCE, V273, P1699, DOI 10.1126/science.273.5282.1699; GREVE D, 2002, OPTSEQ; Hamann S, 2004, NAT NEUROSCI, V7, P411, DOI 10.1038/nn1208; Hamann SB, 2002, PSYCHOL SCI, V13, P135, DOI 10.1111/1467-9280.00425; Hendler T, 2003, NEUROIMAGE, V19, P587, DOI 10.1016/S1053-8119(03)00141-1; Holender D, 2004, PERCEPT PSYCHOPHYS, V66, P872, DOI 10.3758/BF03194980; Karama S, 2002, HUM BRAIN MAPP, V16, P1, DOI 10.1002/hbm.10014; Killgore WDS, 2004, NEUROIMAGE, V21, P1215, DOI 10.1016/j.neuroimage.2003.12.033; Killgore WDS, 2001, NEUROREPORT, V12, P427, DOI 10.1097/00001756-200102120-00047; Lang P.J., 1988, INT AFFECTIVE PICTUR; Mcclure SM, 2004, NEUROSCIENTIST, V10, P260, DOI 10.1177/1073858404263526; Merikle PM, 2001, COGNITION, V79, P115, DOI 10.1016/S0010-0277(00)00126-8; Morris JS, 1999, P NATL ACAD SCI USA, V96, P1680, DOI 10.1073/pnas.96.4.1680; Morris JS, 1998, NATURE, V393, P467, DOI 10.1038/30976; MURPHY ST, 1993, J PERS SOC PSYCHOL, V64, P723, DOI 10.1037/0022-3514.64.5.723; Ohman A, 2005, PSYCHONEUROENDOCRINO, V30, P953, DOI 10.1016/j.psyneuen.2005.03.019; Overgaard M, 2006, CONSCIOUS COGN, V15, P700, DOI 10.1016/j.concog.2006.04.002; Pavlov I.P., 1927, CONDITIONED REFLEXES; Pessiglione M, 2007, SCIENCE, V316, P904, DOI 10.1126/science.1140459; Rauch SL, 2000, BIOL PSYCHIAT, V47, P769, DOI 10.1016/S0006-3223(00)00828-3; Sheline YI, 2001, BIOL PSYCHIAT, V50, P651, DOI 10.1016/S0006-3223(01)01263-X; *WELLC DEP IM NEUR, 2002, SPM 2; Whalen PJ, 2004, SCIENCE, V306, P2061, DOI 10.1126/science.1103617; Whalen PJ, 1998, J NEUROSCI, V18, P411; Wright P, 2006, NEUROIMAGE, V29, P628, DOI 10.1016/j.neuroimage.2005.07.047	36	195	198	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2008	3	1							e1506	10.1371/journal.pone.0001506	http://dx.doi.org/10.1371/journal.pone.0001506			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	366SR	18231593	Green Published, Green Submitted, gold			2022-12-25	WOS:000260504200019
J	Li, L; Johnson, LA; Dai-Ju, JQ; Sandri-Goldin, RM				Li, Ling; Johnson, Lisa A.; Dai-Ju, Jenny Q.; Sandri-Goldin, Rozanne M.			Hsc70 Focus Formation at the Periphery of HSV-1 Transcription Sites Requires ICP27	PLOS ONE			English	Article							RNA-POLYMERASE-II; CARBOXYL-TERMINAL DOMAIN; REGULATORY PROTEIN ICP27; REPLICATION COMPARTMENTS; MESSENGER-RNAS; PHOSPHORYLATION; LOCALIZATION; EXPRESSION; INTERACTS; CHAPERONE	Background. The cellular chaperone protein Hsc70, along with components of the 26S proteasome and ubiquitin-conjugated proteins have been shown to be sequestered in discrete foci in the nuclei of herpes simplex virus 1 (HSV-1) infected cells. We recently reported that cellular RNA polymerase II (RNAP II) undergoes proteasomal degradation during robust HSV-1 transcription, and that the immediate early protein ICP27 interacts with the C-terminal domain and is involved in the recruitment of RNAP II to viral transcription/replication compartments. Methodology/Principle Findings. Here we show that ICP27 also interacts with Hsc70, and is required for the formation of Hsc70 nuclear foci. During infection with ICP27 mutants that are unable to recruit RNAP II to viral replication sites, viral transcript levels were greatly reduced, viral replication compartments were poorly formed and Hsc70 focus formation was curtailed. Further, a dominant negative Hsc70 mutant that cannot hydrolyze ATP, interfered with RNAP II degradation during HSV-1 infection, and an increase in ubiquitinated forms of RNAP II was observed. There was also a decrease in virus yields, indicating that proteasomal degradation of stalled RNAP II complexes during robust HSV-1 transcription and replication benefits viral gene expression. Conclusions/Significance. We propose that one function of the Hsc70 nuclear foci may be to serve to facilitate the process of clearing stalled RNAP II complexes from viral genomes during times of highly active transcription.	[Li, Ling; Johnson, Lisa A.; Dai-Ju, Jenny Q.; Sandri-Goldin, Rozanne M.] Univ Calif Irvine, Sch Med, Dept Microbiol & Mol Genet, Irvine, CA 92717 USA	University of California System; University of California Irvine	Sandri-Goldin, RM (corresponding author), Univ Calif Irvine, Sch Med, Dept Microbiol & Mol Genet, Irvine, CA 92717 USA.	rmsandri@uci.edu			National Institute of Allergy and Infectious Diseases (NIAID) [RO1 61397, R37 21215]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI021515] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by the National Institute of Allergy and Infectious Diseases (NIAID grants RO1 61397 and R37 21215).	Ahn SH, 2004, MOL CELL, V13, P67, DOI 10.1016/S1097-2765(03)00492-1; Bentley D, 1999, CURR OPIN CELL BIOL, V11, P347, DOI 10.1016/S0955-0674(99)80048-9; Burch AD, 2005, J VIROL, V79, P10740, DOI 10.1128/JVI.79.16.10740-10749.2005; Burch AD, 2004, J VIROL, V78, P7175, DOI 10.1128/JVI.78.13.7175-7185.2004; Chen IHB, 2005, J VIROL, V79, P3949, DOI 10.1128/JVI.79.7.3949-3961.2005; Chen IHB, 2002, J VIROL, V76, P12877, DOI 10.1128/JVI.76.24.12877-12889.2002; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Dai-Ju JQ, 2006, J VIROL, V80, P3567, DOI 10.1128/JVI.80.7.3567-3581.2006; Doyle O, 2002, J STRUCT BIOL, V140, P154, DOI 10.1016/S1047-8477(02)00547-6; Elefant F, 1999, MOL BIOL CELL, V10, P2101, DOI 10.1091/mbc.10.7.2101; Everett RD, 2000, J VIROL, V74, P9994, DOI 10.1128/JVI.74.21.9994-10005.2000; Fraser KA, 2005, J VIROL, V79, P11323, DOI 10.1128/JVI.79.17.11323-11334.2005; Fraser KA, 2007, J VIROL, V81, P5091, DOI 10.1128/JVI.00184-07; Gillette TG, 2004, P NATL ACAD SCI USA, V101, P5904, DOI 10.1073/pnas.0305411101; HARDWICKE MA, 1989, J VIROL, V63, P4590, DOI 10.1128/JVI.63.11.4590-4602.1989; HIBBARD MK, 1995, J VIROL, V69, P4656, DOI 10.1128/JVI.69.8.4656-4667.1995; Inukai N, 2004, J BIOL CHEM, V279, P8190, DOI 10.1074/jbc.M311412200; Jean S, 2001, VIROLOGY, V283, P273, DOI 10.1006/viro.2001.0902; Jiang JW, 2005, MOL CELL, V20, P513, DOI 10.1016/j.molcel.2005.09.028; Kauppinen KP, 2005, J BIOL CHEM, V280, P21638, DOI 10.1074/jbc.M413984200; Kleiman FE, 2005, GENE DEV, V19, P1227, DOI 10.1101/gad.1309505; Koffa MD, 2001, EMBO J, V20, P5769, DOI 10.1093/emboj/20.20.5769; KOPS AD, 1988, CELL, V55, P857, DOI 10.1016/0092-8674(88)90141-9; Lee KB, 2004, BIOCHEMISTRY-US, V43, P15223, DOI 10.1021/bi048719x; Lengyel J, 2002, J VIROL, V76, P11866, DOI 10.1128/JVI.76.23.11866-11879.2002; Long MC, 1999, J VIROL, V73, P5593, DOI 10.1128/JVI.73.7.5593-5604.1999; Lukonis CJ, 1997, J VIROL, V71, P2390, DOI 10.1128/JVI.71.3.2390-2399.1997; MCCARTHY AM, 1989, J VIROL, V63, P18, DOI 10.1128/JVI.63.1.18-27.1989; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Newmyer SL, 2001, J CELL BIOL, V152, P607, DOI 10.1083/jcb.152.3.607; OBrien MC, 1996, J BIOL CHEM, V271, P15874, DOI 10.1074/jbc.271.27.15874; Pearson A, 2004, J VIROL, V78, P23, DOI 10.1128/JVI.78.1.23-32.2004; RICE SA, 1994, J VIROL, V68, P988, DOI 10.1128/JVI.68.2.988-1001.1994; RICE SA, 1990, J VIROL, V64, P1704, DOI 10.1128/JVI.64.4.1704-1715.1990; RICE SA, 1994, J VIROL, V68, P823, DOI 10.1128/JVI.68.2.823-833.1994; RICE SA, 1993, J VIROL, V67, P1778, DOI 10.1128/JVI.67.4.1778-1787.1993; SandriGoldin RM, 1996, J VIROL, V70, P108, DOI 10.1128/JVI.70.1.108-118.1996; Sciabica KS, 2003, EMBO J, V22, P1608, DOI 10.1093/emboj/cdg166; SMITH IL, 1992, VIROLOGY, V186, P74, DOI 10.1016/0042-6822(92)90062-T; Somesh BP, 2005, CELL, V121, P913, DOI 10.1016/j.cell.2005.04.010; Stingley SW, 2000, J VIROL, V74, P9916, DOI 10.1128/JVI.74.21.9916-9927.2000; Sun AX, 2004, J VIROL, V78, P10470, DOI 10.1128/JVI.78.19.10470-10478.2004; Ungewickell E, 1997, J BIOL CHEM, V272, P19594, DOI 10.1074/jbc.272.31.19594; ZHANG J, 1991, J BIOL CHEM, V266, P2290; ZHANG J, 1991, J BIOL CHEM, V266, P2297; Zhi Y, 1999, VIROLOGY, V257, P341, DOI 10.1006/viro.1999.9698; Zhou CH, 2002, J VIROL, V76, P5893, DOI 10.1128/JVI.76.12.5893-5904.2002	48	45	47	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2008	3	1							e1491	10.1371/journal.pone.0001491	http://dx.doi.org/10.1371/journal.pone.0001491			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SR	18231578	Green Published, gold			2022-12-25	WOS:000260504200004
J	Wang, ZP; Zhang, SC; Wang, GF; An, Y				Wang, Zhiping; Zhang, Shicui; Wang, Guangfeng; An, Yan			Complement Activity in the Egg Cytosol of Zebrafish Danio rerio: Evidence for the Defense Role of Maternal Complement Components	PLOS ONE			English	Article								Most fish embryos that develop externally are exposed to an environment full of microbes. How they survive microbial attacks are not understood to date. Here we demonstrated that the egg cytosol prepared from the newly fertilized eggs of zebrafish Danio rerio is capable of killing the Gram-negative bacterium Escherichia coli, via in vitro assay system of the complement activity established. All findings indicate that it is the complement system operating via the alternative pathway that is attributable to the bacteriolytic activity. This is the first report providing the evidence for the functional role of the maternal complement components in fish eggs, paving the way for study of maternal immunity in other organisms whose eggs are fertilized in vitro.	[Wang, Zhiping; Zhang, Shicui; Wang, Guangfeng; An, Yan] Ocean Univ China, Dept Marine Biol, Qingdao, Peoples R China	Ocean University of China	Zhang, SC (corresponding author), Ocean Univ China, Dept Marine Biol, Qingdao, Peoples R China.	sczhang@ouc.edu.cn			Ministry of Science and Technology (MOST) [2006CB101805, 30730072]; Natural Science Foundation of China (NSFC) [2006CB101805, 30730072]	Ministry of Science and Technology (MOST)(Ministry of Science and Technology, China); Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC))	This work was supported by grants (2006CB101805; 30730072) of Ministry of Science and Technology (MOST) and Natural Science Foundation of China (NSFC).	BLY JE, 1986, COMP BIOCHEM PHYS A, V84, P309, DOI 10.1016/0300-9629(86)90620-1; Boshra H, 2006, FISH SHELLFISH IMMUN, V20, P239, DOI 10.1016/j.fsi.2005.04.004; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breuil G, 1997, FISH SHELLFISH IMMUN, V7, P29, DOI 10.1006/fsim.1996.0061; CASTILLO A, 1993, DEV COMP IMMUNOL, V17, P419, DOI 10.1016/0145-305X(93)90033-M; Ellingsen T, 2005, FISH SHELLFISH IMMUN, V18, P351, DOI 10.1016/j.fsi.2004.09.002; Ellis A. E., 1988, Fish vaccination., P20; Herbomel P, 1999, DEVELOPMENT, V126, P3735; Huttenhuis HBT, 2006, FISH SHELLFISH IMMUN, V20, P586, DOI 10.1016/j.fsi.2005.07.008; KANLIS G, 1995, FISHERIES SCI, V61, P787, DOI 10.2331/fishsci.61.787; Kishore U, 2000, IMMUNOPHARMACOLOGY, V49, P159, DOI 10.1016/S0162-3109(00)80301-X; Koppenheffer TL, 1998, DEV COMP IMMUNOL, V22, P231, DOI 10.1016/S0145-305X(98)00015-9; Kuo MM, 2000, J PARASITOL, V86, P1223, DOI 10.1645/0022-3395(2000)086[1223:ACSOMA]2.0.CO;2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lieschke GJ, 2001, BLOOD, V98, P3087, DOI 10.1182/blood.V98.10.3087; Lovoll M, 2007, FISH SHELLFISH IMMUN, V23, P542, DOI 10.1016/j.fsi.2007.01.002; Lvoll M, 2006, IMMUNOGENETICS, V58, P168, DOI 10.1007/s00251-006-0096-3; Magnadottir B, 2004, COMP BIOCHEM PHYS B, V139, P217, DOI 10.1016/j.cbpc.2004.07.009; MOR A, 1990, J FISH BIOL, V37, P249, DOI 10.1111/j.1095-8649.1990.tb05856.x; MORGAN BP, 1995, CRIT REV CL LAB SCI, V32, P265, DOI 10.3109/10408369509084686; Nonaka M, 1999, J IMMUNOL, V162, P387; Olsen YA, 1997, FISH SHELLFISH IMMUN, V7, P81, DOI 10.1006/fsim.1996.0064; Picchietti S, 2004, CELL TISSUE RES, V315, P259, DOI 10.1007/s00441-003-0819-9; Picchietti S, 2001, J FISH BIOL, V59, P1503, DOI 10.1111/j.1095-8649.2001.tb00215.x; Robertson M, 1998, CURR BIOL, V8, pR595, DOI 10.1016/S0960-9822(98)70384-7; Rubio-Godoy M, 2004, FISH SHELLFISH IMMUN, V17, P95, DOI 10.1016/j.fsi.2003.11.005; RUDDY S, 1974, TRANSPLANT P, V6, P1; SUNYER JO, 1995, VET IMMUNOL IMMUNOP, V45, P333, DOI 10.1016/0165-2427(94)05430-Z; Swain P, 2006, FISH SHELLFISH IMMUN, V20, P519, DOI 10.1016/j.fsi.2005.06.011; Takemura A, 1997, FISH SHELLFISH IMMUN, V7, P355, DOI 10.1006/fsim.1997.0090; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; van Loon J. J. A, 1981, ASPECTS DEV COMP IMM, P469; VANDIJK H, 1985, J IMMUNOL METHODS, V85, P233, DOI 10.1016/0022-1759(85)90134-6; Yano Tomoki, 1996, Fish Physiology, V15, P105; Zapata A, 2006, FISH SHELLFISH IMMUN, V20, P126, DOI 10.1016/j.fsi.2004.09.005; Zarkadis IK, 2001, DEV COMP IMMUNOL, V25, P745, DOI 10.1016/S0145-305X(01)00034-9; Zhang SC, 2003, ZOOL SCI, V20, P1207, DOI 10.2108/zsj.20.1207	39	56	60	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2008	3	1							e1463	10.1371/journal.pone.0001463	http://dx.doi.org/10.1371/journal.pone.0001463			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SO	18213372	Green Published, gold, Green Submitted			2022-12-25	WOS:000260503900009
J	Ilyinskii, PO; Gambaryan, AS; Meriin, AB; Gabai, V; Kartashov, A; Thoidis, G; Shneider, AM				Ilyinskii, Petr O.; Gambaryan, Alexandra S.; Meriin, Anatoli B.; Gabai, Vladimir; Kartashov, Alex; Thoidis, Galini; Shneider, Alexander M.			Inhibition of Influenza M2-Induced Cell Death Alleviates Its Negative Contribution to Vaccination Efficiency	PLOS ONE			English	Article								The effectiveness of recombinant vaccines encoding full-length M2 protein of influenza virus or its ectodomain (M2e) have previously been tested in a number of models with varying degrees of success. Recently, we reported a strong cytotoxic effect exhibited by M2 on mammalian cells in vitro. Here we demonstrated a decrease in protection when M2 was added to a DNA vaccination regimen that included influenza NP. Furthermore, we have constructed several fusion proteins of conserved genes of influenza virus and tested their expression in vitro and protective potential in vivo. The four-partite NP-M1-M2-NS1 fusion antigen that has M2 sequence engineered in the middle part of the composite protein was shown to not be cytotoxic in vitro. A three-partite fusion protein (consisting of NP, M1 and NS1) was expressed much more efficiently than the four-partite protein. Both of these constructs provided statistically significant protection upon DNA vaccination, with construct NP-M1-M2-NS1 being the most effective. We conclude that incorporation of M2 into a vaccination regimen may be beneficial only when its apparent cytotoxicity-linked negative effects are neutralized. The possible significance of this data for influenza vaccination regimens and preparations is discussed.	[Ilyinskii, Petr O.; Thoidis, Galini; Shneider, Alexander M.] Cure Lab, Canton, MA USA; [Gambaryan, Alexandra S.] Chumakov Inst Poliomyelitis & Viral Encephalitis, Moscow, Russia; [Meriin, Anatoli B.; Gabai, Vladimir] Boston Univ, Sch Med, Boston, MA USA; [Kartashov, Alex] Policy Anal, Brookline, MA USA	Chumakov Federal Scientific Center for Research & Development of Immune & Biological Products of Russian Academy of Sciences; Boston University; Policy Analysis Inc	Shneider, AM (corresponding author), Cure Lab, Canton, MA USA.	ashneider@curelab.com	Gabai, Vladimir L/I-1650-2013; Gambaryan, Alexandra S/E-2667-2014	Gabai, Vladimir L/0000-0003-4505-4718; Meriin, Anatoli/0000-0003-0087-814X	Cure Lab, Inc	Cure Lab, Inc	This work was entirely funded by Cure Lab, Inc	Altstein AD, 2006, ARCH VIROL, V151, P921, DOI 10.1007/s00705-005-0676-9; De Filette M, 2005, VIROLOGY, V337, P149, DOI 10.1016/j.virol.2005.04.004; De Filette M, 2006, VACCINE, V24, P6597, DOI 10.1016/j.vaccine.2006.05.082; Fiers W, 2004, VIRUS RES, V103, P173, DOI 10.1016/j.virusres.2004.02.030; GITELMAN AK, 1984, VIROLOGY, V134, P230, DOI 10.1016/0042-6822(84)90288-5; Heinen PP, 2002, J GEN VIROL, V83, P1851, DOI 10.1099/0022-1317-83-8-1851; ILYINSKII P, 2007, CELL CYCLE IN PRESS, V6; Jimenez GS, 2007, HUM VACCINES, V3, P157, DOI 10.4161/hv.3.5.4175; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Pinto LH, 2007, MOL BIOSYST, V3, P18, DOI 10.1039/b611613m; Schroeder C, 2005, EUR BIOPHYS J BIOPHY, V34, P52, DOI 10.1007/s00249-004-0424-1; SLEPUSHKIN VA, 1995, VACCINE, V13, P1399, DOI 10.1016/0264-410X(95)92777-Y; Tompkins SM, 2007, EMERG INFECT DIS, V13, P426, DOI 10.3201/eid1303.061125; ZEBEDEE SL, 1988, J VIROL, V62, P2762, DOI 10.1128/JVI.62.8.2762-2772.1988; Zhirnov OP, 2007, INFLUENZA OTHER RESP, V1, P71, DOI 10.1111/j.1750-2659.2007.00010.x	15	8	11	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2008	3	1							e1417	10.1371/journal.pone.0001417	http://dx.doi.org/10.1371/journal.pone.0001417			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SN	18197240	Green Published, gold			2022-12-25	WOS:000260503800001
J	Rashid, ST; Fuller, B; Hamilton, G; Seifalian, AM				Rashid, S. T.; Fuller, B.; Hamilton, G.; Seifalian, A. M.			Tissue engineering of a hybrid bypass graft for coronary and lower limb bypass surgery	FASEB JOURNAL			English	Article						compliance; polyurethanes; shear stress; smooth muscle cell; endothelial	ENDOTHELIAL-CELL RETENTION; PULSATILE SHEAR-STRESS; VASCULAR GRAFTS; IN-VITRO; BLOOD-VESSEL; POLYTETRAFLUOROETHYLENE GRAFTS; SAPHENOUS-VEIN; PROSTHESES; COLLAGEN; VIVO	Tissue-engineered blood vessels have largely relied on inelastic scaffolds or biological solutions with uncertain long-term in vivo durability. In this report we present for the first time a hybrid tissue-engineered bypass graft consisting of an elastic scaffold of compliant poly(carbonate-urea) urethane (CPU), incorporated with human smooth muscle cells (SMCs) and endothelial cells (ECs) from the same human source. Human vascular SMCs and ECs were extracted from umbilical cord vessels. The effect of shear stress preconditioning on cell retention on the hybrid bypass graft was investigated under pulsatile arterial flow conditions. Retention of ECs seeded onto CPU precoated with SMCs was significantly improved by a period of shear stress preconditioning, especially when the stress incrementally increased. This is probably because the mechanical stimuli orient cells and increase the release of matrix proteins and attachment factors. The stage is now set for developing a hybrid graft for in vivo studies.	[Rashid, S. T.; Fuller, B.; Seifalian, A. M.] UCL, Royal Free & Univ Coll Med Sch, Div Surg & Intervent Sci, Biomat & Tissue Engn Ctr, London NW3 2PF, England; [Hamilton, G.] Royal Free Hampstead Natl Hlth Serv, Vasc Unit, London, England	University of London; University College London	Seifalian, AM (corresponding author), UCL, Royal Free & Univ Coll Med Sch, Div Surg & Intervent Sci, Biomat & Tissue Engn Ctr, Rowland Hill St, London NW3 2PF, England.	a.seifalian@ucl.ac.uk	Seifalian, Alexander M/I-6028-2013; hamilton, george/K-4764-2013; Rashid, T/B-9474-2008	Seifalian, Alexander M/0000-0002-1180-3322; seifalian, Alexander/0000-0002-8334-9376; RASHID, TAWQEER/0000-0002-5377-8671				ABBOTT WM, 1993, J VASC SURG, V17, P746, DOI 10.1016/0741-5214(93)90120-B; BENNION RS, 1985, SURG GYNECOL OBSTET, V160, P239; BUTTON M, 2002, CARDIOVASC PATHOL, V11, P39; Dardik A, 1999, J VASC SURG, V29, P157, DOI 10.1016/S0741-5214(99)70357-5; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; Edwards A, 1995, J BIOMATER APPL, V10, P171, DOI 10.1177/088532829501000207; Fisher AB, 2001, AM J PHYSIOL-LUNG C, V281, pL529, DOI 10.1152/ajplung.2001.281.3.L529; Giudiceandrea A, 1998, EUR J VASC ENDOVASC, V15, P147, DOI 10.1016/S1078-5884(98)80136-6; Giudiceandrea A, 2000, J ARTIF ORGANS, V3, P16; Greenwald SE, 2000, J PATHOL, V190, P292, DOI 10.1002/(SICI)1096-9896(200002)190:3<292::AID-PATH528>3.0.CO;2-S; Hirai J, 1996, CELL TRANSPLANT, V5, P93, DOI 10.1016/0963-6897(95)02002-0; Hoerstrup SP, 2001, EUR J CARDIO-THORAC, V20, P164, DOI 10.1016/S1010-7940(01)00706-0; Ishibashi K, 1994, ASAIO J, V40, pM284, DOI 10.1097/00002480-199407000-00009; KANDA K, 1994, CELL TRANSPLANT, V3, P481, DOI 10.1177/096368979400300605; Kannan RY, 2005, J BIOMED MATER RES B, V74B, P570, DOI 10.1002/jbm.b.30247; Kaushal S, 2001, NAT MED, V7, P1035, DOI 10.1038/nm0901-1035; Kobashi T, 1999, TISSUE ENG, V5, P515, DOI 10.1089/ten.1999.5.515; Kobashi T, 1999, CELL TRANSPLANT, V8, P477, DOI 10.1177/096368979900800503; L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; Lebaron RG, 2000, TISSUE ENG, V6, P85, DOI 10.1089/107632700320720; MILLS I, 1999, TISSUE ENG PROSTHETI, P425; Nerem RM, 2000, YONSEI MED J, V41, P735, DOI 10.3349/ymj.2000.41.6.735; Niklason LE, 1999, SCIENCE, V284, P489, DOI 10.1126/science.284.5413.489; Niklason LE, 2001, J VASC SURG, V33, P628, DOI 10.1067/mva.2001.111747; Parikh SA, 2000, ADV DRUG DELIVER REV, V42, P139, DOI 10.1016/S0169-409X(00)00058-2; Rashid ST, 2004, EUR J VASC ENDOVASC, V27, P608, DOI 10.1016/j.ejvs.2004.01.020; Salacinski HJ, 2001, ARTIF ORGANS, V25, P974, DOI 10.1046/j.1525-1594.2001.06716.x; Salacinski HJ, 2002, J BIOMED MATER RES, V59, P207; Salacinski HJ, 2001, J BIOMATER APPL, V15, P241, DOI 10.1106/NA5T-J57A-JTDD-FD04; Seifalian AM, 2003, BIOMATERIALS, V24, P2549, DOI 10.1016/S0142-9612(02)00608-7; Seliktar D, 2000, ANN BIOMED ENG, V28, P351, DOI 10.1114/1.275; Shigematsu K, 2000, INT ANGIOL, V19, P39; Solan A, 2003, TISSUE ENG, V9, P579, DOI 10.1089/107632703768247287; STANSBY G, 1994, BRIT J SURG, V81, P1286, DOI 10.1002/bjs.1800810908; Stock UA, 2001, TISSUE ENG, V7, P1, DOI 10.1089/107632701300003241; Tai NR, 2000, BRIT J SURG, V87, P1516, DOI 10.1046/j.1365-2168.2000.01566.x; Thakrar RR, 2006, FASEB J, V20, P874, DOI 10.1096/fj.05-5304com; Tiwari A, 2002, FASEB J, V16, DOI 10.1096/fj.01-0826com; Tiwari A, 2002, CARDIOVASC SURG, V10, P191, DOI 10.1016/S0967-2109(02)00004-2; WATKINS MT, 1984, J SURG RES, V36, P588, DOI 10.1016/0022-4804(84)90145-8; World Health Organization, 1999, WHO WORLD HLTH REP 1; WU MHD, 1995, J VASC SURG, V22, P382, DOI 10.1016/S0741-5214(95)70005-6; Yu H, 2003, J VASC SURG, V38, P557, DOI 10.1016/S0741-5214(03)00334-3; Yu H, 2001, J VASC SURG, V34, P337, DOI 10.1067/mva.2001.114817	44	45	49	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					2084	2089		10.1096/fj.07-096586	http://dx.doi.org/10.1096/fj.07-096586			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18203957				2022-12-25	WOS:000256352700047
J	Yang, S; Liu, X; Yin, YQ; Fukuda, MN; Zhou, JW				Yang, Shuo; Liu, Xuan; Yin, Yanqing; Fukuda, Michiko N.; Zhou, Jiawei			Tastin is required for bipolar spindle assembly and centrosome integrity during mitosis	FASEB JOURNAL			English	Article						microtubules; mitotic block	ENDOMETRIAL EPITHELIAL-CELLS; MITOTIC SPINDLE; CYTOPLASMIC DYNEIN; LIGHT-CHAIN; PROTEIN; COMPLEX; ORGANIZATION; MECHANISMS; TROPHININ; INTERACTS	Tastin was previously characterized as an accessory protein for cell adhesion that participates in early embryo implantation. Here, we report that tastin is also required for spindle assembly during mitosis. Tastin protein levels peaked in the G(2)/M phase and abruptly declined after cell division. Microscopy showed that tastin is primarily localized on the microtubules, centrosomes, and the mitotic spindle during the cell cycle. Tastin interacted with the dynein intermediate chain, p150(Glued), and gamma-tubulin in addition to Tctex-1 ( the light chain of dynein). Overexpression of tastin led to monopolar spindle formation, whereas loss of tastin expression caused profound mitotic block and preferentially induced multipolar spindles. These multipolar spindles were generated through a loss of cohesion in mitotic centrosomes; specifically, tastin depletion caused the fragmentation of pericentrosomal material and the splitting of the centrioles at the spindle poles. Tastin depletion induced centrosome abnormalities exclusively during mitosis and required both microtubule integrity and Eg5 activity. However, tastin depletion did not disrupt the organization of spindle poles, as revealed by localization of nuclear mitotic apparatus protein (NuMA) and the p150(Glued) component of dynactin. These data indicate that the major function of tastin during mitosis is to maintain the structural and dynamic features of centrosomes, thereby contributing to spindle bipolarity.	[Yang, Shuo; Liu, Xuan; Yin, Yanqing; Zhou, Jiawei] Chinese Acad Sci, Inst Neurosci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol,Lab Mol Cell Biol, Shanghai 200031, Peoples R China; [Fukuda, Michiko N.] Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Sanford Burnham Prebys Medical Discovery Institute	Zhou, JW (corresponding author), Chinese Acad Sci, Inst Neurosci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol,Lab Mol Cell Biol, 320 Yueyang Rd, Shanghai 200031, Peoples R China.	jwzhou@ion.ac.cn		Zhou, Jiawei/0000-0002-1844-9178				Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; Cassimeris L, 2004, MOL BIOL CELL, V15, P1580, DOI 10.1091/mbc.E03-07-0544; COMPTON DA, 1995, J CELL SCI, V108, P621; COMPTON DA, 1993, J CELL BIOL, V120, P947, DOI 10.1083/jcb.120.4.947; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Di Fiore B, 2003, J CELL SCI, V116, P3399, DOI 10.1242/jcs.00624; Dohmen RJ, 2004, BBA-MOL CELL RES, V1695, P113, DOI 10.1016/j.bbamcr.2004.09.021; DOXSEY SJ, 1994, CELL, V76, P639, DOI 10.1016/0092-8674(94)90504-5; Doxsey SJ, 2001, NAT CELL BIOL, V3, pE105, DOI 10.1038/35074618; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Fukuda MN, 1999, SEMIN REPROD ENDOCR, V17, P229, DOI 10.1055/s-2007-1016230; Gadde S, 2004, CURR BIOL, V14, pR797, DOI 10.1016/j.cub.2004.09.021; Garrett S, 2002, CURR BIOL, V12, P2055, DOI 10.1016/S0960-9822(02)01277-0; Huang SC, 2005, MOL BIOL CELL, V16, P117, DOI 10.1091/mbc.E04-05-0426; Hyman AA, 1996, CELL, V84, P401, DOI 10.1016/S0092-8674(00)81285-4; Kapoor TM, 2000, J CELL BIOL, V150, P975, DOI 10.1083/jcb.150.5.975; King SM, 1996, J BIOL CHEM, V271, P32281, DOI 10.1074/jbc.271.50.32281; Lingle WL, 2000, CURR TOP DEV BIOL, V49, P313; Maxwell CA, 2005, CANCER RES, V65, P850; Maxwell CA, 2003, MOL BIOL CELL, V14, P2262, DOI 10.1091/mbc.e02-07-0377; Mayor T, 2000, J CELL BIOL, V151, P837, DOI 10.1083/jcb.151.4.837; Mayor T, 1999, FEBS LETT, V452, P92, DOI 10.1016/S0014-5793(99)00534-7; Merdes A, 2000, J CELL BIOL, V149, P851, DOI 10.1083/jcb.149.4.851; Merdes A, 1997, J CELL BIOL, V138, P953, DOI 10.1083/jcb.138.5.953; Mills JC, 1999, J CELL BIOL, V146, P703, DOI 10.1083/jcb.146.4.703; Mitchison TJ, 1989, CURR OPIN CELL BIOL, V1, P67, DOI 10.1016/S0955-0674(89)80039-0; Nadano D, 2002, BIOCHEM J, V364, P669, DOI 10.1042/BJ20011836; Pihan GA, 1999, SEMIN CANCER BIOL, V9, P289, DOI 10.1006/scbi.1999.0131; Pihan GA, 2001, CANCER RES, V61, P2212; Rieder CL, 1991, CURR OPIN CELL BIOL, V3, P59, DOI 10.1016/0955-0674(91)90166-V; Suzuki N, 1998, P NATL ACAD SCI USA, V95, P5027, DOI 10.1073/pnas.95.9.5027; Suzuki N, 1999, BIOL REPROD, V60, P621, DOI 10.1095/biolreprod60.3.621; Tai AW, 1998, J BIOL CHEM, V273, P19639, DOI 10.1074/jbc.273.31.19639; Uto K, 2000, EMBO J, V19, P1816, DOI 10.1093/emboj/19.8.1816; Walczak CE, 1998, CURR BIOL, V8, P903, DOI 10.1016/S0960-9822(07)00370-3; Yan XM, 2003, MOL CELL BIOL, V23, P1239, DOI 10.1128/MCB.23.4.1239-1250.2003; Yang J, 2006, MOL BIOL CELL, V17, P1033, DOI 10.1091/mbc.E05-10-0943; Zimmerman W, 2000, TRAFFIC, V1, P927, DOI 10.1034/j.1600-0854.2000.011202.x	38	31	31	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					1960	1972		10.1096/fj.07-081463	http://dx.doi.org/10.1096/fj.07-081463			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18218922				2022-12-25	WOS:000256352700035
J	Mizuno, T; Yamasaki, N; Miyazaki, K; Tazaki, T; Koller, R; Oda, H; Honda, Z; Ochi, M; Wolff, L; Honda, H				Mizuno, T.; Yamasaki, N.; Miyazaki, K.; Tazaki, T.; Koller, R.; Oda, H.; Honda, Z-i; Ochi, M.; Wolff, L.; Honda, H.			Overexpression/enhanced kinase activity of BCR/ABL and altered expression of Notch1 induced acute leukemia in p210BCR/ABL transgenic mice	ONCOGENE			English	Article						chronic myelogenous leukemia; blast crisis; transgenic mice; p210BCR/ABL; Notch1	CHRONIC MYELOGENOUS LEUKEMIA; RETROVIRAL INSERTIONAL MUTAGENESIS; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; BCR-ABL; MYELOPROLIFERATIVE DISEASE; CELL LEUKEMIA; BLAST CRISIS; GENE; CML	Chronic myelogenous leukemia (CML) is a hematopoietic disorder, which begins as indolent chronic phase but inevitably progresses to fatal blast crisis. p210BCR/ABL, a constitutively active tyrosine kinase, is responsible for disease initiation but molecular mechanism(s) underlying disease evolution remains largely unknown. To explore this process, we employed retroviral insertional mutagenesis to CML-exhibiting p210BCR/ABL transgenic mice (Tg). Virus infection induced acute lymphoblastic leukemia (ALL) in p210BCR/ABL Tg with a higher frequency and in a shorter latency than wild-type littermates, and inverse PCR detected two retrovirus common integration sites (CISs) in p210BCR/ABL Tg tumors. Interestingly, one CIS was the transgene itself, where retrovirus integrations induced upregulation of p210BCR/ABL and production of truncated BCR/ABL with an enhanced kinase activity. Another CIS was Notch1 gene, where retrovirus integrations resulted in overexpression of Notch1 and generation of Notch1 lacking the C-terminal region (Notch1DC) associated with stable expression of its activated product, C-terminal-truncated Notch intracellular domain (NICDDC). In addition, generation of Tg for both p210BCR/ABL and Notch1DC developed ALL in a shortened period with Stat5 activation, demonstrating the cooperative oncogenicity of Notch1DC/NICDDC with p210BCR/ABL involving Stat5-mediated pathway. These results demonstrated that overexpression/enhanced kinase activity of BCR/ABL and altered expression of Notch1 induces acute leukemia in a transgenic model for CML.	[Mizuno, T.; Yamasaki, N.; Miyazaki, K.; Tazaki, T.; Honda, H.] Hiroshima Univ, Dept Dev Biol, Res Inst Radiat Biol & Med, Minami Ku, Hiroshima 7348553, Japan; [Mizuno, T.; Ochi, M.] Hiroshima Univ, Sch Med, Dept Orthoped Surg, Hiroshima, Japan; [Koller, R.; Wolff, L.] NCI, Cellular Oncol Lab, Leukemogenesis Sect, Bethesda, MD 20892 USA; [Oda, H.] Tokyo Womens Med Univ, Dept Pathol, Tokyo, Japan; [Honda, Z-i] Univ Tokyo, Grad Sch Sci, Dept Allergy & Rheumatol, Fac Med, Tokyo 113, Japan	Hiroshima University; Hiroshima University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Tokyo Women's Medical University; University of Tokyo	Honda, H (corresponding author), Hiroshima Univ, Dept Dev Biol, Res Inst Radiat Biol & Med, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.	hhonda@hiroshima-u.ac.jp	Tazaki, Tatsuya/AAT-4215-2021	Tazaki, Tatsuya/0000-0001-9327-9749	NATIONAL CANCER INSTITUTE [ZIABC011027, Z01BC011027] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; Akagi K, 2004, NUCLEIC ACIDS RES, V32, pD523, DOI 10.1093/nar/gkh013; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Calabretta B, 2004, BLOOD, V103, P4010, DOI 10.1182/blood-2003-12-4111; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Grabher C, 2006, NAT REV CANCER, V6, P347, DOI 10.1038/nrc1880; Honda H, 2000, BLOOD, V95, P1144, DOI 10.1182/blood.V95.4.1144.004k04_1144_1150; HONDA H, 1995, BLOOD, V85, P2853, DOI 10.1182/blood.V85.10.2853.bloodjournal85102853; Honda H, 1998, BLOOD, V91, P2067, DOI 10.1182/blood.V91.6.2067.2067_2067_2075; Honda H, 1997, BIOCHEM BIOPH RES CO, V234, P376, DOI 10.1006/bbrc.1997.6650; Huettner CS, 2003, BLOOD, V102, P3363, DOI 10.1182/blood-2003-03-0768; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Ilagan Maria Xenia G, 2007, Cell, V128, P1246; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; Kamakura S, 2004, NAT CELL BIOL, V6, P547, DOI 10.1038/ncb1138; Koschmieder S, 2005, BLOOD, V105, P324, DOI 10.1182/blood-2003-12-4369; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Lin YW, 2006, BLOOD, V107, P2540, DOI 10.1182/blood-2005-07-3013; Mikkers H, 2003, ADV CANCER RES, V88, P53, DOI 10.1016/S0065-230X(03)88304-5; Monsalve E, 2006, J IMMUNOL, V176, P5362, DOI 10.4049/jimmunol.176.9.5362; Nakamura T, 2005, CANCER SCI, V96, P7, DOI 10.1111/j.1349-7006.2005.00011.x; Niki M, 2004, J EXP MED, V200, P1689, DOI 10.1084/jem.20041306; O'Neil J, 2006, BLOOD, V107, P781, DOI 10.1182/blood-2005-06-2553; Pane F, 2002, ONCOGENE, V21, P8652, DOI 10.1038/sj.onc.1206094; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Scherr M, 2006, BLOOD, V107, P3279, DOI 10.1182/blood-2005-08-3087; SHORE SK, 1994, J BIOL CHEM, V269, P5413; Shuai K, 1996, ONCOGENE, V13, P247; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wolff L, 2003, ONCOGENE, V22, P9265, DOI 10.1038/sj.onc.1207092; Wolff L, 2003, J VIROL, V77, P4965, DOI 10.1128/JVI.77.8.4965-4971.2003; Yamashita N, 2005, BRIT J HAEMATOL, V131, P495, DOI 10.1111/j.1365-2141.2005.05793.x; Ye D, 2006, BLOOD, V107, P4917, DOI 10.1182/blood-2005-10-4110; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829	38	20	21	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	24					3465	3474		10.1038/sj.onc.1211007	http://dx.doi.org/10.1038/sj.onc.1211007			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18193087	Green Submitted, Bronze			2022-12-25	WOS:000256309900011
J	Hu, YH; Lund, IV; Gravielle, MC; Farb, DH; Brooks-Kayal, AR; Russek, SJ				Hu, Yinghui; Lund, Ingrid V.; Gravielle, Maria C.; Farb, David H.; Brooks-Kayal, Amy R.; Russek, Shelley J.			Surface expression of GABA(A) receptors is transcriptionally controlled by the interplay of cAMP-response element-binding protein and its binding partner inducible cAMP early repressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT MESSENGER-RNAS; CEREBELLAR GRANULE NEURONS; AMINOBUTYRIC ACID(A) RECEPTORS; TEMPORAL-LOBE EPILEPSY; RAT-BRAIN; DENTATE GRANULE; DOWN-REGULATION; BENZODIAZEPINE RECEPTORS; DEVELOPMENTAL EXPRESSION; MOLECULAR-BIOLOGY	The regulated expression of type A gamma-aminobutyric acid ( GABA) receptor ( GABA(A)R) subunit genes plays a critical role in neuronal maturation and synaptogenesis. It is also associated with a variety of neurological diseases. Changes in GABA(A) receptor alpha 1 subunit gene ( GABRA1) expression have been reported in animal models of epilepsy, alcohol abuse, withdrawal, and stress. Understanding the genetic mechanism behind such changes in alpha subunit expression will lead to a better understanding of the role that signal transduction plays in control over GABAAR function and brings with it the promise of providing new therapeutic tools for the prevention or cure of a variety of neurological disorders. Here we show that activation of protein kinase C increases alpha 1 subunit levels via phosphorylation of CREB ( pCREB) that is bound to the GABRA1 promoter ( GABRA1p). In contrast, activation of protein kinase A decreases levels of alpha 1 even in the presence of pCREB. Decrease of alpha 1 is dependent upon the inducible cAMP early repressor ( ICER) as directly demonstrated by ICER-induced down-regulation of endogenous alpha 1-containing GABA(A)Rs at the cell surface of cortical neurons. Taken together with the fact that there are less alpha 1 gamma 2-containing GABAARs in neurons after protein kinase A stimulation and that activation of endogenous dopamine receptors down-regulates alpha 1 subunit mRNA levels subsequent to induction of ICER, our studies identify a transcriptional mechanism for regulating the cell surface expression of alpha 1-containing GABAARs that is dependent upon the formation of CREB heterodimers.	[Hu, Yinghui; Russek, Shelley J.] Boston Univ, Sch Med, Lab Translat Epilepsy, Boston, MA 02118 USA; [Hu, Yinghui; Gravielle, Maria C.; Farb, David H.; Russek, Shelley J.] Boston Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02118 USA; [Hu, Yinghui] Univ Penn, Childrens Hosp, Div Neurol, Program BioMed Neurosci, Philadelphia, PA 19104 USA; [Lund, Ingrid V.] Univ Penn, Childrens Hosp, Div Neurol, Neurosci Grad Grp, Philadelphia, PA 19104 USA; [Gravielle, Maria C.; Farb, David H.] Univ Penn, Childrens Hosp, Div Neurol, Mol Neurobiol Lab, Philadelphia, PA 19104 USA; [Brooks-Kayal, Amy R.] Univ Penn, Childrens Hosp, Div Neurol, Dept Neurol, Philadelphia, PA 19104 USA; [Brooks-Kayal, Amy R.] Univ Penn, Childrens Hosp, Div Neurol, Dept Pediat, Philadelphia, PA 19104 USA	Boston University; Boston University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Russek, SJ (corresponding author), Boston Univ, Sch Med, Lab Translat Epilepsy, Boston, MA 02118 USA.	srussek@bu.edu	Farb, david H/C-7089-2014	Farb, david H/0000-0002-9050-6480; Gravielle, Maria/0000-0003-4353-5526; Russek, Shelley/0000-0001-7547-3089	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS050393, R01NS051710, F31NS051943] Funding Source: NIH RePORTER; NINDS NIH HHS [F31 NS 51943, R01 NS 051710, R01 NS 050393] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barnard EA, 1998, PHARMACOL REV, V50, P291; BAUMGARTNER BJ, 1994, MOL BRAIN RES, V26, P9, DOI 10.1016/0169-328X(94)90068-X; BEATTIE CE, 1993, J NEUROSCI, V13, P1784; Blednov YA, 2003, J PHARMACOL EXP THER, V304, P30, DOI 10.1124/jpet.102.042960; Brooks-Kayal AR, 1998, NAT MED, V4, P1166, DOI 10.1038/2661; Brooks-Kayal AR, 1999, J NEUROSCI, V19, P8312; BRUSSAARD AB, 1995, NEUROSCI LETT, V191, P111, DOI 10.1016/0304-3940(95)11539-6; Buhl EH, 1996, SCIENCE, V271, P369, DOI 10.1126/science.271.5247.369; Bullock BP, 1998, BIOCHEMISTRY-US, V37, P3795, DOI 10.1021/bi970982t; Burkart AD, 2006, MOL ENDOCRINOL, V20, P584, DOI 10.1210/me.2005-0204; BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; Cardenas C, 2004, J BIOL CHEM, V279, P39122, DOI 10.1074/jbc.M401044200; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Devaud LL, 1997, J NEUROCHEM, V69, P126; Drewett V, 2001, NUCLEIC ACIDS RES, V29, P479, DOI 10.1093/nar/29.2.479; DUGGAN MJ, 1990, J BIOL CHEM, V265, P3831; ENDO S, 1993, J NEUROCHEM, V60, P1388, DOI 10.1111/j.1471-4159.1993.tb03300.x; Gellersen B, 1997, MOL ENDOCRINOL, V11, P97, DOI 10.1210/me.11.1.97; Gibbs JW, 1997, J NEUROPHYSIOL, V77, P1924, DOI 10.1152/jn.1997.77.4.1924; Grobin AC, 1998, PSYCHOPHARMACOLOGY, V139, P2, DOI 10.1007/s002130050685; HARRIS BT, 1994, MOL PHARMACOL, V45, P637; Hsu FC, 2003, P NATL ACAD SCI USA, V100, P12213, DOI 10.1073/pnas.2131679100; HUNTSMAN MM, 1994, J NEUROSCI, V14, P2236; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; Kim TK, 1998, P NATL ACAD SCI USA, V95, P12191, DOI 10.1073/pnas.95.21.12191; Kralic JE, 2002, J PHARMACOL EXP THER, V302, P1037, DOI 10.1124/jpet.102.036665; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAURIE DJ, 1992, J NEUROSCI, V12, P4151; LEVITAN ES, 1988, NATURE, V335, P76, DOI 10.1038/335076a0; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Lyons HR, 2000, J NEUROCHEM, V74, P1041, DOI 10.1046/j.1471-4159.2000.0741041.x; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; Malatynska E, 2000, NEUROCHEM INT, V36, P45, DOI 10.1016/S0197-0186(99)00100-X; Mao DL, 1998, MOL ENDOCRINOL, V12, P492, DOI 10.1210/me.12.4.492; Mayr BM, 2001, P NATL ACAD SCI USA, V98, P10936, DOI 10.1073/pnas.191152098; MCKERNAN RM, 1991, NEURON, V7, P667, DOI 10.1016/0896-6273(91)90379-E; MCKERNAN RM, 1991, FEBS LETT, V286, P44, DOI 10.1016/0014-5793(91)80936-W; McLean PJ, 2000, J NEUROCHEM, V74, P1858, DOI 10.1046/j.1471-4159.2000.0741858.x; MEINECKE DL, 1990, DEV BRAIN RES, V55, P73, DOI 10.1016/0165-3806(90)90107-A; Mioduszewska B, 2003, J NEUROCHEM, V87, P1313, DOI 10.1046/j.1471-4159.2003.02116.x; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MONTPIED P, 1991, J BIOL CHEM, V266, P6011; MONTPIED P, 1993, MOL BRAIN RES, V18, P267, DOI 10.1016/0169-328X(93)90199-Y; Mtchedlishvili Z, 2001, J PHYSIOL-LONDON, V537, P453, DOI 10.1111/j.1469-7793.2001.00453.x; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; PRITCHETT DB, 1989, SCIENCE, V245, P1389, DOI 10.1126/science.2551039; PUIA G, 1991, MOL PHARMACOL, V39, P691; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Reynolds DS, 2003, NEUROPHARMACOLOGY, V44, P190, DOI 10.1016/S0028-3908(02)00370-2; Roberson ED, 1999, J NEUROSCI, V19, P4337; Russek SJ, 2000, P NATL ACAD SCI USA, V97, P8600, DOI 10.1073/pnas.97.15.8600; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SEEBURG PH, 1990, COLD SH Q B, V55, P29; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shumate MD, 1998, EPILEPSY RES, V32, P114, DOI 10.1016/S0920-1211(98)00045-X; Sieghart W, 2000, TRENDS PHARMACOL SCI, V21, P411, DOI 10.1016/S0165-6147(00)01564-9; SIEGHART W, 1989, TRENDS PHARMACOL SCI, V10, P407, DOI 10.1016/0165-6147(89)90189-2; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; SUN PQ, 1995, J BIOL CHEM, V270, P7041, DOI 10.1074/jbc.270.13.7041; Sur C, 2001, J NEUROSCI, V21, P3409, DOI 10.1523/JNEUROSCI.21-10-03409.2001; TIETZ EI, 1993, J MOL NEUROSCI, V4, P277, DOI 10.1007/BF02821559; Vicini S, 2001, J NEUROSCI, V21, P3009, DOI 10.1523/JNEUROSCI.21-09-03009.2001; WISDEN W, 1992, J NEUROSCI, V12, P1040; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; ZHENG T, 1993, DEV BRAIN RES, V75, P91, DOI 10.1016/0165-3806(93)90068-L; ZHU WJ, 1995, J NEUROSCI, V15, P7692	71	44	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9328	9340		10.1074/jbc.M705110200	http://dx.doi.org/10.1074/jbc.M705110200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18180303	Green Published, hybrid			2022-12-25	WOS:000254465800063
J	Ikezawa, N; Iwasa, K; Sato, F				Ikezawa, Nobuhiro; Iwasa, Kinuko; Sato, Fumihiko			Molecular cloning and characterization of CYP80G2, a cytochrome p450 that catalyzes an intramolecular C - C phenol coupling of (S)-reticuline in magnoflorine biosynthesis, from cultured Coptis japonica cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKALOID BIOSYNTHESIS; BENZOPHENANTHRIDINE ALKALOIDS; SACCHAROMYCES-CEREVISIAE; HETEROLOGOUS EXPRESSION; BERBERIS-STOLONIFERA; N-METHYLTRANSFERASE; CRYSTAL-STRUCTURE; ENZYME; BINDING; YEAST	Cytochrome P450s (P450) play a key role in oxidative reactions in plant secondary metabolism. Some of them, which catalyze unique reactions other than the standard hydroxylation, increase the structural diversity of plant secondary metabolites. In isoquinoline alkaloid biosyntheses, several unique P450 reactions have been reported, such as methylenedioxy bridge formation, intramolecular C-C phenol-coupling and intermolecular C-O phenol-coupling reactions. We report here the isolation and characterization of a C-C phenol-coupling P450 cDNA (CYP80G2) from an expressed sequence tag library of cultured Coptis japonica cells. Structural analysis showed that CYP80G2 had high amino acid sequence similarity to Berberis stolonifera CYP80A1, an intermolecular C-O phenol-coupling P450 involved in berbamunine biosynthesis. Heterologous expression in yeast indicated that CYP80G2 had intramolecular C-C phenol-coupling activity to produce ( S)-corytuberine ( aporphinetype) from (S)-reticuline (benzylisoquinoline type). Despite this intriguing reaction, recombinant CYP80G2 showed typical P450 properties: its C-C phenol-coupling reaction required NADPH and oxygen and was inhibited by a typical P450 inhibitor. Based on a detailed substrate-specificity analysis, this unique reaction mechanism and substrate recognition were discussed. CYP80G2 may be involved in magnoflorine biosynthesis in C. japonica, based on the fact that recombinant C. japonica S-adenosyl-L-methionine: coclaurine N-methyltransferase could convert (S)-corytuberine to magnoflorine.	[Ikezawa, Nobuhiro; Sato, Fumihiko] Kyoto Univ, Grad Sch Biostudies, Div Integrated Life Sci, Sakyo Ku, Kyoto 6068502, Japan; [Iwasa, Kinuko] Kobe Pharmaceut Univ, Kobe, Hyogo 6588558, Japan	Kyoto University; Kobe Pharmaceutical University	Sato, F (corresponding author), Kyoto Univ, Grad Sch Biostudies, Div Integrated Life Sci, Sakyo Ku, Kyoto 6068502, Japan.	fsato@lif.kyoto-u.ac.jp	Sato, Fumihiko/C-1078-2011	Sato, Fumihiko/0000-0001-9497-4452				BAUER W, 1991, PHYTOCHEMISTRY, V30, P2953, DOI 10.1016/S0031-9422(00)98230-X; BHAKUNI DS, 1980, TETRAHEDRON, V36, P2525, DOI 10.1016/0040-4020(80)80233-X; Bischoff D, 2001, ANGEW CHEM INT EDIT, V40, P4688, DOI 10.1002/1521-3773(20011217)40:24<4688::AID-ANIE4688>3.0.CO;2-M; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chapple C, 1998, ANNU REV PLANT PHYS, V49, P311, DOI 10.1146/annurev.arplant.49.1.311; Choi KB, 2002, J BIOL CHEM, V277, P830, DOI 10.1074/jbc.M106405200; Croteau R., 2000, BIOCH MOL BIOL PLANT, P1250, DOI DOI 10.1201/B11003-3; Cui WH, 2006, PHYTOCHEMISTRY, V67, P70, DOI 10.1016/j.phytochem.2005.10.007; DITTRICH H, 1991, P NATL ACAD SCI USA, V88, P9969, DOI 10.1073/pnas.88.22.9969; Durst Francis, 1995, Drug Metabolism and Drug Interactions, V12, P189; Funa N, 2005, J BACTERIOL, V187, P8149, DOI 10.1128/JB.187.23.8149-8155.2005; GERARDY R, 1993, PHYTOCHEMISTRY, V32, P79, DOI 10.1016/0031-9422(92)80111-Q; Graening T, 2004, ANGEW CHEM INT EDIT, V43, P3230, DOI 10.1002/anie.200300615; Herbert RB, 2001, NAT PROD REP, V18, P50, DOI 10.1039/a809393h; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Howard-Jones AR, 2006, J AM CHEM SOC, V128, P12289, DOI 10.1021/ja063898m; Ikezawa N, 2003, J BIOL CHEM, V278, P38557, DOI 10.1074/jbc.M302470200; Ikezawa N, 2007, FEBS J, V274, P1019, DOI 10.1111/j.1742-4658.2007.05652.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Iwasa K, 2005, J NAT PROD, V68, P992, DOI 10.1021/np0402219; Iwasa K, 2004, PHARMAZIE, V59, P480; KRAUS PFX, 1995, P NATL ACAD SCI USA, V92, P2071, DOI 10.1073/pnas.92.6.2071; KUTCHAN TM, 1998, ALKALOIDS, V50, P257; Liscombe DK, 2007, J BIOL CHEM, V282, P14741, DOI 10.1074/jbc.M611908200; Milanowski DJ, 2002, J NAT PROD, V65, P814, DOI 10.1021/np000270v; Miller GP, 2001, BIOCHEMISTRY-US, V40, P7262, DOI 10.1021/bi010402z; Minami H, 2007, J BIOL CHEM, V282, P6274, DOI 10.1074/jbc.M608933200; Morishige T, 2000, J BIOL CHEM, V275, P23398, DOI 10.1074/jbc.M002439200; Morishige T, 2002, EUR J BIOCHEM, V269, P5659, DOI 10.1046/j.1432-1033.2002.03275.x; MUTO N, 1987, BIOCHEM BIOPH RES CO, V146, P487, DOI 10.1016/0006-291X(87)90555-9; Nasreen A, 1996, TETRAHEDRON LETT, V37, P8161, DOI 10.1016/0040-4039(96)01852-7; Nelson DR, 2004, PHARMACOGENETICS, V14, P1, DOI 10.1097/00008571-200401000-00001; Nelson DR, 2004, PLANT PHYSIOL, V135, P756, DOI 10.1104/pp.104.039826; OEDA K, 1985, DNA-J MOLEC CELL BIO, V4, P203, DOI 10.1089/dna.1985.4.203; OMURA T, 1964, J BIOL CHEM, V239, P2379; Ono E, 2006, P NATL ACAD SCI USA, V103, P10116, DOI 10.1073/pnas.0603865103; Pauli HH, 1998, PLANT J, V13, P793, DOI 10.1046/j.1365-313X.1998.00085.x; POULOS TL, 1985, J BIOL CHEM, V260, P6122; PREININGER V, 1986, ALKALOIDS, V29, P1; SAKAKI T, 1990, DNA CELL BIOL, V9, P603, DOI 10.1089/dna.1990.9.603; SAKAKI T, 1992, J BIOL CHEM, V267, P16497; SATO F, 1984, PHYTOCHEMISTRY, V23, P281, DOI 10.1016/S0031-9422(00)80318-0; STADLER R, 1993, J BIOL CHEM, V268, P823; TAKESHITA N, 1995, PLANT CELL PHYSIOL, V36, P29; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Werck-Reichhart D., 2002, ARABIDOPSIS BOOK; ZENK MH, 1994, PURE APPL CHEM, V66, P2023, DOI 10.1351/pac199466102023; Zhao B, 2005, J BIOL CHEM, V280, P11599, DOI 10.1074/jbc.M410933200	48	104	116	5	51	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					8810	8821		10.1074/jbc.M705082200	http://dx.doi.org/10.1074/jbc.M705082200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18230623	hybrid			2022-12-25	WOS:000254465800007
J	Pautsch, A; Stadler, N; Wissdorf, O; Langkopf, E; Moreth, W; Streicher, R				Pautsch, Alexander; Stadler, Nadja; Wissdorf, Oliver; Langkopf, Elke; Moreth, Werner; Streicher, Ruediger			Molecular recognition of the protein phosphatase 1 glycogen targeting subunit by glycogen phosphorylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 1; AMINO-ACID-SEQUENCE; HEPATIC EXPRESSION; LIVER; MUSCLE; INHIBITORS; INSULIN; TISSUE; SITE; PTG	Disrupting the interaction between glycogen phosphorylase and the glycogen targeting subunit ( G(L)) of protein phosphatase 1 is emerging as a novel target for the treatment of type 2 diabetes. To elucidate the molecular basis of binding, we have determined the crystal structure of liver phosphorylase bound to a G(L)-derived peptide. The structure reveals the C terminus of G(L) binding in a hydrophobically collapsed conformation to the allosteric regulator-binding site at the phosphorylase dimer interface. G(L) mimics interactions that are otherwise employed by the activator AMP. Functional studies show that G(L) binds tighter than AMP and confirm that the C-terminal Tyr-Tyr motif is the major determinant for GL binding potency. Our study validates the G(L)-phosphorylase interface as a novel target for small molecule interaction.	[Pautsch, Alexander; Stadler, Nadja; Wissdorf, Oliver] Boehringer Ingelheim Pharma GmbH & Co KG, Dept Lead Discovery, D-88397 Biberach, Germany; [Langkopf, Elke] Boehringer Ingelheim Pharma GmbH & Co KG, Dept Med Chem, D-88397 Biberach, Germany; [Moreth, Werner; Streicher, Ruediger] Boehringer Ingelheim Pharma GmbH & Co KG, Dept Metab Dis Res, D-88397 Biberach, Germany	Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim	Pautsch, A (corresponding author), Boehringer Ingelheim Pharma GmbH & Co KG, Dept Lead Discovery, Birkendorferstr 65, D-88397 Biberach, Germany.	alexander.pautsch@boehringer-ingelheim.com						ALEMANY S, 1986, FEBS LETT, V198, P194, DOI 10.1016/0014-5793(86)80404-5; Armstrong CG, 1997, FEBS LETT, V418, P210, DOI 10.1016/S0014-5793(97)01385-9; Armstrong CG, 1998, BIOCHEM J, V336, P699, DOI 10.1042/bj3360699; BARFORD D, 1991, J MOL BIOL, V218, P233, DOI 10.1016/0022-2836(91)90887-C; Ceulemans H, 2002, BIOESSAYS, V24, P371, DOI 10.1002/bies.10069; CHEN YH, 1994, DIABETES, V43, P1234, DOI 10.2337/diabetes.43.10.1234; Cohen P, 2006, NAT REV MOL CELL BIO, V7, P867, DOI 10.1038/nrm2043; DeFronzo RA, 1999, ANN INTERN MED, V131, P281, DOI 10.7326/0003-4819-131-4-199908170-00008; DOHERTY MJ, 1995, FEBS LETT, V375, P294, DOI 10.1016/0014-5793(95)01184-G; Doherty MJ, 1996, FEBS LETT, V399, P339, DOI 10.1016/S0014-5793(96)01357-9; Ekstrom JL, 2002, CHEM BIOL, V9, P915, DOI 10.1016/S1074-5521(02)00186-2; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; GAN D, 2007, DIABETES ATLAS; Gasa R, 2000, J BIOL CHEM, V275, P26396, DOI 10.1074/jbc.M002427200; Gasa R, 2002, J BIOL CHEM, V277, P1524, DOI 10.1074/jbc.M107744200; Henke BR, 2006, MINI-REV MED CHEM, V6, P845, DOI 10.2174/138955706777934991; JOHNSON LN, 1992, FASEB J, V6, P2274, DOI 10.1096/fasebj.6.6.1544539; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kelsall IR, 2007, FEBS LETT, V581, P4749, DOI 10.1016/j.febslet.2007.08.073; Klabunde T, 2005, J MED CHEM, V48, P6178, DOI 10.1021/jm049034y; KOBAYASHI M, 1982, J BIOL CHEM, V257, P4041; Montori-Grau M, 2007, BIOCHEM J, V405, P107, DOI 10.1042/BJ20061572; MOORHEAD G, 1995, FEBS LETT, V362, P101, DOI 10.1016/0014-5793(95)00197-H; Munro S, 2005, FEBS J, V272, P1478, DOI 10.1111/j.1742-4658.2005.04585.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; Rath VL, 2000, CHEM BIOL, V7, P677, DOI 10.1016/S1074-5521(00)00004-1; Rath VL, 2000, MOL CELL, V6, P139, DOI 10.1016/S1097-2765(00)00015-0; SERRANO FSJ, 1995, INT J BIOCHEM CELL B, V27, P911, DOI 10.1016/1357-2725(95)00058-W; Yang RJ, 2003, J BIOL CHEM, V278, P23418, DOI 10.1074/jbc.M213112200	30	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					8913	8918		10.1074/jbc.M706612200	http://dx.doi.org/10.1074/jbc.M706612200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18198182	hybrid, Green Published			2022-12-25	WOS:000254465800019
J	Smith, SB; Verhamme, IM; Sun, MF; Bock, PE; Gailani, D				Smith, Stephen B.; Verhamme, Ingrid M.; Sun, Mao-Fu; Bock, Paul E.; Gailani, David			Characterization of novel forms of coagulation factor XIa - Independence of factor XIa subunits in factor IX activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT KININOGEN; PLASMA THROMBOPLASTIN ANTECEDENT; GLYCOPROTEIN IB-ALPHA; 4 TANDEM REPEATS; HUMAN GRANZYME-A; BLOOD-COAGULATION; CHRISTMAS-FACTOR; TISSUE FACTOR; BINDING-SITE; HEAVY-CHAIN	Factor XI is the zymogen of a dimeric plasma protease, factor XIa, with two active sites. In solution, and during contact activation in plasma, conversion of factor XI to factor XIa proceeds through an intermediate with one active site (1/2-FXIa). Factor XIa and 1/2-FXIa activate the substrate factor IX, with similar kinetic parameters in purified and plasma systems. During hemostasis, factor IX is activated by factors XIa or VIIa, by cleavage of the peptide bonds after Arg(145) and Arg(180). Factor VIIa cleaves these bonds sequentially, with accumulation of factor IX alpha, an intermediate cleaved after Arg(145). Factor XIa also cleaves factor IX preferentially after Arg(145), but little intermediate is detected. It has been postulated that the two factor XIa active sites cleave both factor IX peptide bonds prior to releasing factor IXa beta. To test this, we examined cleavage of factor IX by four single active site factor XIa proteases. Little intermediate formation was detected with 1/2-FXIa, factor XIa with one inhibited active site, or a recombinant factor XIa monomer. However, factor IX alpha accumulated during activation by the factor XIa catalytic domain, demonstrating the importance of the factor XIa heavy chain. Fluorescence titration of active site-labeled factor XIa revealed a binding stoichiometry of 1.9 +/- 0.4 mol of factor IX/mol of factor XIa (K-d = 70 +/- 40 nM). The results indicate that two forms of activated factor XI are generated during coagulation, and that each half of a factor XIa dimer behaves as an independent enzyme with respect to factor IX.	[Smith, Stephen B.; Verhamme, Ingrid M.; Sun, Mao-Fu; Bock, Paul E.; Gailani, David] Vanderbilt Univ, Dept Pathol, Nashville, TN 37232 USA; [Bock, Paul E.; Gailani, David] Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Gailani, D (corresponding author), Vanderbilt Univ, Div Hematol Oncol, 538 Preston Res Bldg,2220 Pierce Ave, Nashville, TN 37232 USA.	dave.gailani@vanderbilt.edu			NHLBI NIH HHS [R01 HL038779, HL080018, HL58837, R01 HL058837, HL07751, R01 HL058837-12, R01 HL080018-03, R01 HL080018, HL38779, R01 HL038779-21] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007751, R01HL038779, R29HL038779, R01HL058837, R01HL080018] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aktimur A, 2003, J BIOL CHEM, V278, P7981, DOI 10.1074/jbc.M212748200; ASAKAI R, 1991, NEW ENGL J MED, V325, P153, DOI 10.1056/NEJM199107183250303; Baglia FA, 2004, J BIOL CHEM, V279, P49323, DOI 10.1074/jbc.M407889200; Baglia FA, 2004, J BIOL CHEM, V279, P45470, DOI 10.1074/jbc.M406727200; BAGLIA FA, 1991, J BIOL CHEM, V266, P24190; BAJAJ SP, 1983, BIOCHEMISTRY-US, V22, P4047, DOI 10.1021/bi00286a009; Bell JK, 2003, NAT STRUCT BIOL, V10, P527, DOI 10.1038/nsb944; Bianchini EP, 2005, P NATL ACAD SCI USA, V102, P10099, DOI 10.1073/pnas.0504704102; BOCK PE, 1992, J BIOL CHEM, V267, P14974; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; Cheng Q, 2003, J THROMB HAEMOST, V1, P2340, DOI 10.1046/j.1538-7836.2003.00418.x; CHUNG DW, 1986, BIOCHEMISTRY-US, V25, P2410, DOI 10.1021/bi00357a017; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Dharmawardana KR, 1998, BIOCHEMISTRY-US, V37, P13143, DOI 10.1021/bi9812165; DISCIPIO RG, 1978, J CLIN INVEST, V61, P1528, DOI 10.1172/JCI109073; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P4508, DOI 10.1021/bi00719a006; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; Gailani D, 2001, BLOOD, V97, P3117, DOI 10.1182/blood.V97.10.3117; Hink-Schauer C, 2003, NAT STRUCT BIOL, V10, P535, DOI 10.1038/nsb945; Ho DH, 2000, J BIOL CHEM, V275, P25139, DOI 10.1074/jbc.M001890200; Keularts IMLW, 2001, THROMB HAEMOSTASIS, V85, P1060, DOI 10.1055/s-0037-1615964; Krishnaswamy S, 2005, J THROMB HAEMOST, V3, P54, DOI 10.1111/j.1538-7836.2004.01021.x; LAWSON JH, 1991, J BIOL CHEM, V266, P11317; LINDQUIST PA, 1978, J BIOL CHEM, V253, P1902; MANN KG, 1992, SEMIN HEMATOL, V29, P213; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2056, DOI 10.1021/bi00222a008; MEIJERS JCM, 1992, BIOCHEMISTRY-US, V31, P4680, DOI 10.1021/bi00134a021; NAITO K, 1991, J BIOL CHEM, V266, P7353; Ogawa T, 2005, J BIOL CHEM, V280, P23523, DOI 10.1074/jbc.M500894200; Orcutt SJ, 2004, J BIOL CHEM, V279, P54927, DOI 10.1074/jbc.M410866200; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; OSTERUD B, 1978, J BIOL CHEM, V253, P5946; Papagrigoriou E, 2006, NAT STRUCT MOL BIOL, V13, P557, DOI 10.1038/nsmb1095; Samuel D, 2007, P NATL ACAD SCI USA, V104, P15693, DOI 10.1073/pnas.0703080104; Sinha D, 2002, BIOCHEM J, V367, P49, DOI 10.1042/BJ20020232; SINHA D, 1987, BIOCHEMISTRY-US, V26, P3768, DOI 10.1021/bi00387a005; Sinha D, 2007, BIOCHEMISTRY-US, V46, P9830, DOI 10.1021/bi062296c; Sun MF, 1999, J BIOL CHEM, V274, P36373, DOI 10.1074/jbc.274.51.36373; Sun YH, 1996, J BIOL CHEM, V271, P29023, DOI 10.1074/jbc.271.46.29023; THOMPSON RE, 1977, J CLIN INVEST, V60, P1376, DOI 10.1172/JCI108898; VANDERGRAAF F, 1983, J BIOL CHEM, V258, P9669; VONDEMBORNE PAK, 1995, BLOOD, V86, P3035; WARNCRAMER BJ, 1985, BIOCHEM BIOPH RES CO, V133, P417, DOI 10.1016/0006-291X(85)90922-2; Wielders SJH, 2004, ARTERIOSCL THROM VAS, V24, P1138, DOI 10.1161/01.ATV.0000128125.80559.9c; Wolberg AS, 1997, BIOCHEMISTRY-US, V36, P4074, DOI 10.1021/bi962274y	48	26	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					6696	6705		10.1074/jbc.M707234200	http://dx.doi.org/10.1074/jbc.M707234200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18192270	Green Accepted, hybrid			2022-12-25	WOS:000253779600011
J	Letcher, BH; Nislow, KH; Coombs, JA; O'Donnell, MJ; Dubreuil, TL				Letcher, Benjamin H.; Nislow, Keith H.; Coombs, Jason A.; O'Donnell, Matthew J.; Dubreuil, Todd L.			Population Response to Habitat Fragmentation in a Stream-Dwelling Brook Trout Population	PLOS ONE			English	Article							CUTTHROAT TROUT; RECAPTURE; EVOLUTION; DYNAMICS; GROWTH; SIZE; DISPERSAL; SURVIVAL; TRENDS; FISH	Fragmentation can strongly influence population persistence and expression of life-history strategies in spatially-structured populations. In this study, we directly estimated size-specific dispersal, growth, and survival of stream-dwelling brook trout in a stream network with connected and naturally-isolated tributaries. We used multiple-generation, individual-based data to develop and parameterize a size-class and location-based population projection model, allowing us to test effects of fragmentation on population dynamics at local (i.e., subpopulation) and system-wide (i.e., metapopulation) scales, and to identify demographic rates which influence the persistence of isolated and fragmented populations. In the naturally-isolated tributary, persistence was associated with higher early juvenile survival (similar to 45% greater), shorter generation time (one-half) and strong selection against large body size compared to the open system, resulting in a stage-distribution skewed towards younger, smaller fish. Simulating barriers to upstream migration into two currently-connected tributary populations caused rapid (2-6 generations) local extinction. These local extinctions in turn increased the likelihood of system-wide extinction, as tributaries could no longer function as population sources. Extinction could be prevented in the open system if sufficient immigrants from downstream areas were available, but the influx of individuals necessary to counteract fragmentation effects was high (7-46% of the total population annually). In the absence of sufficient immigration, a demographic change (higher early survival characteristic of the isolated tributary) was also sufficient to rescue the population from fragmentation, suggesting that the observed differences in size distributions between the naturally-isolated and open system may reflect an evolutionary response to isolation. Combined with strong genetic divergence between the isolated tributary and open system, these results suggest that local adaptation can 'rescue' isolated populations, particularly in one-dimensional stream networks where both natural and anthropogenically-mediated isolation is common. However, whether rescue will occur before extinction depends critically on the race between adaptation and reduced survival in response to fragmentation.	[Letcher, Benjamin H.; Coombs, Jason A.; O'Donnell, Matthew J.; Dubreuil, Todd L.] US Geol Survey, Leetown Sci Ctr, SO Conte Anadromous Fish Res Ctr, Turners Falls, MA USA; [Coombs, Jason A.] Univ Massachusetts, Program Organism & Evolutionary Biol, Amherst, MA 01003 USA; [Nislow, Keith H.] Univ Massachusetts, No Res Stn, USDA, US Forest Serv, Amherst, MA 01003 USA	United States Department of the Interior; United States Geological Survey; University of Massachusetts System; University of Massachusetts Amherst; United States Department of Agriculture (USDA); United States Forest Service; University of Massachusetts System; University of Massachusetts Amherst	Letcher, BH (corresponding author), US Geol Survey, Leetown Sci Ctr, SO Conte Anadromous Fish Res Ctr, Turners Falls, MA USA.	ben_letcher@usgs.gov	O'Donnell, Matt/O-5850-2019	O'Donnell, Matt/0000-0002-9089-2377; Coombs, Jason/0000-0001-6099-3954	USGS Conte Anadromous Fish Research Center; US Forest Service; Northeastern Research Station; USGS Eastern Region; Nature Conservancy, Connecticut River Program	USGS Conte Anadromous Fish Research Center(United States Geological Survey); US Forest Service(United States Department of Agriculture (USDA)United States Forest Service); Northeastern Research Station; USGS Eastern Region(United States Geological Survey); Nature Conservancy, Connecticut River Program	This work was funded by USGS Conte Anadromous Fish Research Center, the US Forest Service, Northeastern Research Station, USGS Eastern Region, and The Nature Conservancy, Connecticut River Program. Funders were not involved in any details of the study. The manuscript was approved by USGS.	BROWNIE C, 1993, BIOMETRICS, V49, P1173, DOI 10.2307/2532259; Burnham K. P., 1998, MODEL SELECTION INFE, P353; CASE TJ, 1978, ECOLOGY, V59, P1, DOI 10.2307/1936628; CASWELL H, 2001, MATRIX POPULATION MO, P723; Choquet R., 2004, Animal Biodiversity and Conservation, V27, P207; Choquet R., 2005, U CARE 2 2 USERS MAN; Conover DO, 2002, SCIENCE, V297, P94, DOI 10.1126/science.1074085; DRISCOLL CT, 2001, BIOSCIENCE WASHINGTO, P180; Dunham Jason B., 1997, North American Journal of Fisheries Management, V17, P1126, DOI 10.1577/1548-8675(1997)017<1126:HFAERO>2.3.CO;2; Einum S, 2006, OIKOS, V113, P489, DOI 10.1111/j.2006.0030-1299.14806.x; Fahrig L, 2003, ANNU REV ECOL EVOL S, V34, P487, DOI 10.1146/annurev.ecolsys.34.011802.132419; FAUSCH KD, 2006, RMRSGTR174 U GEN; Felsenstein J, PHYLIP PHYLOGENY INF; Fishback AG, 2002, AQUACULTURE, V206, P137, DOI 10.1016/S0044-8486(01)00707-4; Fujiwara M, 2002, ECOLOGY, V83, P3257, DOI 10.2307/3072076; Grant EHC, 2007, ECOL LETT, V10, P165, DOI 10.1111/j.1461-0248.2006.01007.x; Gries G, 2002, N AM J FISH MANAGE, V22, P219, DOI 10.1577/1548-8675(2002)022<0219:TRASOA>2.0.CO;2; Hanski I, 1998, NATURE, V396, P41, DOI 10.1038/23876; Hanski I, 2006, PLOS BIOL, V4, P719, DOI 10.1371/journal.pbio.0040129; Harig AL, 2002, ECOL APPL, V12, P535, DOI 10.1890/1051-0761(2002)012[0535:MHRFET]2.0.CO;2; Hilderbrand RH, 2000, T AM FISH SOC, V129, P1160, DOI 10.1577/1548-8659(2000)129<1160:MPOSRC>2.0.CO;2; King TL, 2005, MOL ECOL NOTES, V5, P130, DOI 10.1111/j.1471-8286.2005.00860.x; Kinnison MT, 2007, FUNCT ECOL, V21, P444, DOI 10.1111/j.1365-2435.2007.01278.x; Kinnison MT, 2003, EVOLUTION ILLUMINATED: SALMON AND THEIR RELATIVES, P208; Koskinen MT, 2002, NATURE, V419, P826, DOI 10.1038/nature01029; Lebreton JD, 2002, J APPL STAT, V29, P353, DOI 10.1080/02664760120108638; Lowe WH, 2002, CONSERV BIOL, V16, P183, DOI 10.1046/j.1523-1739.2002.00360.x; Lowe WH, 2003, ECOLOGY, V84, P2145, DOI 10.1890/0012-9658(2003)084[2145:LDTLPD]2.0.CO;2; MAC ARTHUR ROBERT H., 1967; Morita K, 2002, ECOL MODEL, V155, P85, DOI 10.1016/S0304-3800(02)00128-X; Morita K, 2002, CONSERV BIOL, V16, P1318, DOI 10.1046/j.1523-1739.2002.01476.x; NEI M, 1972, AM NAT, V106, P283, DOI 10.1086/282771; NILSSON J, 1994, T AM FISH SOC, V123, P430, DOI 10.1577/1548-8659(1994)123&lt;0430:GOGOJA&gt;2.3.CO;2; Olsen EM, 2004, NATURE, V428, P932, DOI 10.1038/nature02430; Price TD, 2003, P ROY SOC B-BIOL SCI, V270, P1433, DOI 10.1098/rspb.2003.2372; RIEMAN BE, 1995, T AM FISH SOC, V124, P285, DOI 10.1577/1548-8659(1995)124<0285:OOBTIN>2.3.CO;2; Saccheri I, 2006, TRENDS ECOL EVOL, V21, P341, DOI 10.1016/j.tree.2006.03.018; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Wang JL, 2001, GENET RES, V78, P243, DOI 10.1017/S0016672301005286; Wang JL, 2003, GENETICS, V163, P429; Wang SZ, 2002, REV FISH BIOL FISHER, V11, P301; Warren ML, 1998, T AM FISH SOC, V127, P637, DOI 10.1577/1548-8659(1998)127<0637:RCABTS>2.0.CO;2; Wilson IJ, 2003, J R STAT SOC A STAT, V166, P155, DOI 10.1111/1467-985X.00264; Winemiller KO, 2005, CAN J FISH AQUAT SCI, V62, P872, DOI 10.1139/F05-040; Zydlewski GB, 2006, FISHERIES, V31, P492, DOI 10.1577/1548-8446(2006)31[492:RMOFIS]2.0.CO;2	45	138	141	2	50	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 7	2007	2	11							e1139	10.1371/journal.pone.0001139	http://dx.doi.org/10.1371/journal.pone.0001139			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10IZ	18188404	Green Published, gold, Green Submitted			2022-12-25	WOS:000207459000023
J	Hara, T; Schwieger, M; Kazama, R; Okamoto, S; Minehata, K; Ziegler, M; Lohler, J; Stocking, C				Hara, T.; Schwieger, M.; Kazama, R.; Okamoto, S.; Minehata, K.; Ziegler, M.; Loehler, J.; Stocking, C.			Acceleration of chronic myeloproliferation by enforced expression of Meis1 or Meis3 in Icsbp-deficient bone marrow cells	ONCOGENE			English	Article						Meis1; Meis3; Icsbp; AML	SEQUENCE-BINDING-PROTEIN; HUMAN MYELOID LEUKEMIAS; TRANSCRIPTION FACTOR; HEMATOPOIETIC STEM; HOMEOBOX GENES; BXH-2 MICE; TRANSFORMATION; NUP98-HOXD13; COEXPRESSION; MUTATION	Identifying genetic pathways that cooperate in leukemo-genesis facilitates our understanding of the molecular mechanisms at play. Interferon consensus sequence-binding protein ( ICSBP) is a tumor suppressor, whose downregulation cooperates with BCR-ABL and NUP98-TOP1 gene products to accelerate leukemia induction in mouse models. Similarly, Meis1 synergizes with HoxA9 or NUP98-HOX ( but not NUP98-TOP1) fusion genes to promote the early onset of leukemia. To investigate whether Icsbp deficiency interacts with Meis1 or its family member Meis3, we transplanted Icsbp -/- bone marrow ( BM) cells after transduction with Meis1 or Meis3 retroviral vectors. Here, we show that enforced expression of Meis1 or Meis3 in Icsbp -/- BM cells induces a fatal, invasive myeloproliferative disease. Secondary mutations, such as activation of Mn1, led to the progression to acute myeloid leukemia in a few mice. Interestingly, expression of endogenous Meis1 and Meis3 mRNAs was repressed in the granulocytic progenitor population of Icsbp -/- mice. These results reveal a novel collaboration between Icsbp deficiency and Meis1/Meis3 in the acceleration of chronic myeloid leukemia-like disease.	[Hara, T.] Tokyo Metropolitan Org Med Res, Tokyo Metropolitan Inst Med Sci, Stem Cell Project Grp, Bunkyo Ku, Tokyo 1138613, Japan; [Schwieger, M.; Ziegler, M.; Loehler, J.; Stocking, C.] Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Mol Pathol Grp, D-2000 Hamburg, Germany	Tokyo Metropolitan Institute of Medical Science; Heinrich Pette Institute; University of Hamburg	Hara, T (corresponding author), Tokyo Metropolitan Org Med Res, Tokyo Metropolitan Inst Med Sci, Stem Cell Project Grp, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.	thara@rinshoken.or.jp	Okamoto, Shiki/X-7274-2018	Okamoto, Shiki/0000-0002-2802-0527				Burchert A, 2004, BLOOD, V103, P3480, DOI 10.1182/blood-2003-08-2970; Diaz-Blanco E, 2007, LEUKEMIA, V21, P494, DOI 10.1038/sj.leu.2404549; Gabriele L, 1999, J EXP MED, V190, P411, DOI 10.1084/jem.190.3.411; Gurevich RM, 2006, EXP HEMATOL, V34, P1192, DOI 10.1016/j.exphem.2006.04.020; Hao SX, 2000, MOL CELL BIOL, V20, P1149, DOI 10.1128/MCB.20.4.1149-1161.2000; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Kelly LM, 2002, ANNU REV GENOM HUM G, V3, P179, DOI 10.1146/annurev.genom.3.032802.115046; Kroon E, 2001, EMBO J, V20, P350, DOI 10.1093/emboj/20.3.350; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Lawrence HJ, 1999, LEUKEMIA, V13, P1993, DOI 10.1038/sj.leu.2401578; MOSKOW JJ, 1995, MOL CELL BIOL, V15, P5434; Nakamura T, 1996, ONCOGENE, V13, P2235; Pineault N, 2004, MOL CELL BIOL, V24, P1907, DOI 10.1128/MCB.24.5.1907-1917.2004; Pineault N, 2003, BLOOD, V101, P4529, DOI 10.1182/blood-2002-08-2484; Scheller M, 1999, BLOOD, V94, P3764, DOI 10.1182/blood.V94.11.3764.423k03_3764_3771; Schmidt M, 2004, BLOOD, V103, P4142, DOI 10.1182/blood-2003-01-0285; Schmidt M, 1998, BLOOD, V91, P22, DOI 10.1182/blood.V91.1.22.22_22_29; Schmidt M, 2001, BLOOD, V97, P3648, DOI 10.1182/blood.V97.11.3648; Schmidt M, 2001, HUM GENE THER, V12, P743, DOI 10.1089/104303401750148649; Schwieger M, 2002, J EXP MED, V196, P1227, DOI 10.1084/jem.20020824; Serrano E, 2006, ACTA HAEMATOL-BASEL, V116, P77, DOI 10.1159/000093636; Slape C, 2007, CANCER RES, V67, P5148, DOI 10.1158/0008-5472.CAN-07-0075; Turcotte K, 2005, J EXP MED, V201, P881, DOI 10.1084/jem.20042170; Wang GG, 2006, MOL CELL BIOL, V26, P3902, DOI 10.1128/MCB.26.10.3902-3916.2006; Zhu CL, 2004, J BIOL CHEM, V279, P50874, DOI 10.1074/jbc.M405736200	25	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2008	27	27					3865	3869		10.1038/sj.onc.1211043	http://dx.doi.org/10.1038/sj.onc.1211043			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18223676				2022-12-25	WOS:000256904700010
J	Yan, HHN; Mruk, DD; Lee, WM; Cheng, CY				Yan, Helen H. N.; Mruk, Dolores D.; Lee, Will M.; Cheng, C. Yan			Blood-testis barrier dynamics are regulated by testosterone and cytokines via their differential effects on the kinetics of protein endocytosis and recycling in Sertoli cells	FASEB JOURNAL			English	Article						preleptotene spermatocyte migration; seminiferous epithelial cycle; spermatogenesis; tight junction; basal ectoplasmic specialization	NECROSIS-FACTOR-ALPHA; TIGHT JUNCTION PROTEINS; ADULT-RAT TESTES; ANDROGEN RECEPTOR; SEMINIFEROUS EPITHELIUM; MICE LACKING; IN-VITRO; ECTOPLASMIC SPECIALIZATION; ADHERENS JUNCTIONS; SELECTIVE KNOCKOUT	During spermatogenesis in the mammalian testis, preleptotene/leptotene spermatocytes differentiate from type B spermatogonia and traverse the blood-testis barrier (BTB) at stage VIII of the seminiferous epithelial cycle for further development. This timely movement of germ cells involves extensive junction restructuring at the BTB. Previous studies have shown that these events are regulated by testosterone (T) and cytokines [e.g., the transforming growth factor (TGF) -beta s], which promote and disrupt the BTB assembly, respectively. However, the mechanisms underlying the "opening" of the BTB above a migrating preleptotene/leptotene spermatocyte and the "resealing" of the barrier underneath this cell remain obscure. We now report findings on a novel mechanism utilized by the testes to regulate these events. Using cell surface protein biotinylation coupled with immunoblotting and immunofluorescent microscopy, we assessed the kinetics of endocytosis and recycling of BTB-associated integral membrane proteins: occludin, JAM-A, and N-cadherin. It was shown that these proteins were continuously endocytosed and recycled back to the Sertoli cell surface via the clathrin-mediated but not the caveolin-mediated pathway. When T or TGF-beta 2 was added to Sertoli cell cultures with established functional BTB, both factors accelerated the kinetics of internalization of BTB proteins from the cell surface, perhaps above the migrating preleptotene spermatocyte, thereby opening the BTB. Likewise, T also enhanced the kinetics of recycling of internalized biotinylated proteins back to the cell surface, plausibly relocating these proteins beneath the migrating spermatocyte to reassemble the BTB. In contrast, TGF-beta 2 targeted internalized biotinylated proteins to late endosomes for degradation, destabilizing the BTB. In summary, the transient opening of the BTB that facilitates germ cell movement is mediated via the differential effects of T and cytokines on the kinetics of endocytosis and recycling of integral membrane proteins at the BTB. The net result of these interactions, in turn, determines the steady-state protein levels at the Sertoli-Sertoli cell interface at the BTB.	[Yan, Helen H. N.; Mruk, Dolores D.; Cheng, C. Yan] Populat Council, Mary M Wohlford Lab Male Contracept Res, Ctr Biomed Res, New York, NY 10065 USA; [Lee, Will M.] Univ Hong Kong, Sch Biol Sci, Pokfulam, Hong Kong, Peoples R China	Population Council; University of Hong Kong	Cheng, CY (corresponding author), Populat Council, Mary M Wohlford Lab Male Contracept Res, Ctr Biomed Res, 1230 York Ave, New York, NY 10065 USA.	y-cheng@popcbr.rockefeller.edu	Lee, Will M/D-2357-2009	Yan, Hoi Ning Helen/0000-0001-5693-8231; Cheng, C Yan/0000-0003-3117-3791	NICHD NIH HHS [U54 HD029990-110007, U01 HD045908-04, U01 HD045908-01, U01 HD045908-03, R03 HD051512-01A2, U01 HD045908, R03 HD051512, U01 HD045908-05, U01 HD045908-02, U54 HD029990] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD029990] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD045908, R03HD051512] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Barbero P, 2002, J CELL BIOL, V156, P511, DOI 10.1083/jcb.200109030; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREMNER WJ, 1994, ENDOCRINOLOGY, V135, P1227, DOI 10.1210/en.135.3.1227; BRETSCHER MS, 1992, EMBO J, V11, P405, DOI 10.1002/j.1460-2075.1992.tb05068.x; Bruewer M, 2005, FASEB J, V19, P923, DOI 10.1096/fj.04-3260com; BYERS SW, 1986, J ANDROL, V7, P59; CAVICCHIA JC, 1988, TISSUE CELL, V20, P577, DOI 10.1016/0040-8166(88)90059-6; Chang CS, 2004, P NATL ACAD SCI USA, V101, P6876, DOI 10.1073/pnas.0307306101; Chung NPY, 2001, ENDOCRINOLOGY, V142, P1878, DOI 10.1210/en.142.5.1878; CLERMONT Y, 1987, ANN NY ACAD SCI, V513, P1, DOI 10.1111/j.1749-6632.1987.tb24994.x; CYR DG, 1992, ENDOCRINOLOGY, V131, P139, DOI 10.1210/en.131.1.139; De Gendt K, 2004, P NATL ACAD SCI USA, V101, P1327, DOI 10.1073/pnas.0308114100; DEKRETSER DM, 1988, CYTOLOGY TESTIS, V1; Denolet E, 2006, MOL ENDOCRINOL, V20, P321, DOI 10.1210/me.2005-0113; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; DYM M, 1994, ENDOCR REV, V15, P102, DOI 10.1210/er.15.1.102; Florin A, 2005, ENDOCRINOLOGY, V146, P1532, DOI 10.1210/en.2004-0834; GALDIERI M, 1981, J ANDROL, V2, P249; Guttman JA, 2004, BIOL REPROD, V71, P548, DOI 10.1095/biolreprod.104.028803; Gye MC, 2003, INT J ANDROL, V26, P271, DOI 10.1046/j.1365-2605.2003.00423.x; Ivanov AI, 2005, BIOESSAYS, V27, P356, DOI 10.1002/bies.20203; Ivanov AI, 2004, MOL BIOL CELL, V15, P176, DOI 10.1091/mbc.E03-05-0319; JANECKI A, 1986, J ANDROL, V7, P69; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; Li DX, 2000, J CELL BIOL, V148, P791, DOI 10.1083/jcb.148.4.791; Li MWM, 2006, J ENDOCRINOL, V190, P313, DOI 10.1677/joe.1.06781; Lui WY, 2003, ENDOCRINOLOGY, V144, P1139, DOI 10.1210/en.2002-0211; Lui WY, 2001, ENDOCRINOLOGY, V142, P1865, DOI 10.1210/en.142.5.1865; Lui WY, 2003, BIOL REPROD, V68, P1597, DOI 10.1095/biolreprod.102.011387; Matsuda M, 2004, J CELL SCI, V117, P1247, DOI 10.1242/jcs.00972; Meng J, 2005, P NATL ACAD SCI USA, V102, P16696, DOI 10.1073/pnas.0506084102; Morimoto S, 2005, J BIOL CHEM, V280, P2220, DOI 10.1074/jbc.M406906200; Mruk DD, 2004, ENDOCR REV, V25, P747, DOI 10.1210/er.2003-0022; Mruk DD, 2006, NAT MED, V12, P1323, DOI 10.1038/nm1420; ODonnell L, 1996, BIOL REPROD, V55, P895, DOI 10.1095/biolreprod55.4.895; Payne CK, 2007, TRAFFIC, V8, P389, DOI 10.1111/j.1600-0854.2007.00540.x; PETERSON GL, 1979, ANAL BIOCHEM, V100, P201, DOI 10.1016/0003-2697(79)90222-7; Pierini LM, 2000, BLOOD, V95, P2471; Qian ZM, 2002, PHARMACOL REV, V54, P561, DOI 10.1124/pr.54.4.561; RUSSELL L, 1977, AM J ANAT, V148, P313, DOI 10.1002/aja.1001480303; Russell L. D., 1993, SERTOLI CELL, P1; RUSSELL LD, 1985, INT REV CYTOL, V94, P177, DOI 10.1016/S0074-7696(08)60397-6; Saitou M, 2000, MOL BIOL CELL, V11, P4131, DOI 10.1091/mbc.11.12.4131; Sasaki N, 2007, GENES CELLS, V12, P89, DOI 10.1111/j.1365-2443.2007.01037.x; Schmitz H, 1999, J CELL SCI, V112, P137; Shan LX, 1997, ENDOCRINOLOGY, V138, P1259, DOI 10.1210/en.138.3.1259; Siu MKY, 2005, J BIOL CHEM, V280, P25029, DOI 10.1074/jbc.M501049200; Siu MKY, 2003, ENDOCRINOLOGY, V144, P371, DOI 10.1210/en.2002-220786; Sluka P, 2006, J ENDOCRINOL, V189, P381, DOI 10.1677/joe.1.06634; Smith MW, 2006, J DRUG TARGET, V14, P191, DOI 10.1080/10611860600650086; Spencer BJ, 2007, P NATL ACAD SCI USA, V104, P7594, DOI 10.1073/pnas.0702170104; TCHOLAKIAN RK, 1979, STEROIDS, V33, P495, DOI 10.1016/0039-128X(79)90032-1; Tsai MY, 2006, P NATL ACAD SCI USA, V103, P18975, DOI 10.1073/pnas.0608565103; Ueno M, 2007, CURR MED CHEM, V14, P1199, DOI 10.2174/092986707780597943; Utech M, 2005, MOL BIOL CELL, V16, P5040, DOI 10.1091/mbc.E05-03-0193; Vaid KS, 2007, J CELL PHYSIOL, V210, P644, DOI 10.1002/jcp.20855; Wang RS, 2006, ENDOCRINOLOGY, V147, P5624, DOI 10.1210/en.2006-0138; WELSH MJ, 1978, ENDOCRINOLOGY, V103, P838, DOI 10.1210/endo-103-3-838; Wong CH, 2005, CURR TOP DEV BIOL, V71, P263, DOI 10.1016/S0070-2153(05)71008-5; Wong CH, 2007, FASEB J, V21, P438, DOI 10.1096/fj.05-4144com; Xia WL, 2006, J BIOL CHEM, V281, P16799, DOI 10.1074/jbc.M601618200; Yan HHN, 2007, BIOESSAYS, V29, P36, DOI 10.1002/bies.20513; Yan HHN, 2006, J BIOL CHEM, V281, P17286, DOI 10.1074/jbc.M513218200; Yan HHN, 2005, P NATL ACAD SCI USA, V102, P11722, DOI 10.1073/pnas.0503855102; Yeh SY, 2002, P NATL ACAD SCI USA, V99, P13498, DOI 10.1073/pnas.212474399	66	182	194	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1945	1959		10.1096/fj.06-070342	http://dx.doi.org/10.1096/fj.06-070342			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18192323	Green Accepted			2022-12-25	WOS:000256352700034
J	Otsuguro, KI; Tang, JS; Tang, YF; Xiao, R; Freichel, M; Tsvilovskyy, V; Ito, S; Flockerzi, V; Zhu, MX; Zholos, AV				Otsuguro, Ken-ichi; Tang, Jisen; Tang, Yufang; Xiao, Rui; Freichel, Marc; Tsvilovskyy, Volodymyr; Ito, Shigeo; Flockerzi, Veit; Zhu, Michael X.; Zholos, Alexander V.			Isoform-specific Inhibition of TRPC4 Channel by Phosphatidylinositol 4,5-Bisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSELECTIVE CATION CHANNELS; PLECKSTRIN HOMOLOGY DOMAINS; PHOSPHOLIPASE-C; SMOOTH-MUSCLE; MEDIATED REGULATION; CAPSAICIN RECEPTOR; ION CHANNELS; CA2+ CURRENT; PROTEIN; ACTIVATION	Full-length transient receptor potential (TRP) cation channel TRPC4 alpha and shorter TRPC4 beta lacking 84 amino acids in the cytosolic C terminus are expressed in smooth muscle and endothelial cells where they regulate membrane potential and Ca2+ influx. In common with other "classical" TRPCs, TRPC4 is activated by G(q)/phospholipase C-coupled receptors, but the underlying mechanism remains elusive. Little is also known about any isoform-specific channel regulation. Here we show that TRPC4 alpha but not TRPC4 beta was strongly inhibited by intracellularly applied phosphatidylinositol 4,5-bisphosphate (PIP2). In contrast, several other phosphoinositides (PI), including PI(3,4)P-2, PI(3,5)P-2, and PI(3,4,5)P-3, had no effect or even potentiated TRPC4 alpha indicating that PIP2 inhibits TRPC4 alpha in a highly selective manner. We show that PIP2 binds to the C terminus of TRPC4 & but not that of TRPC4 beta in vitro. Its inhibitory action was dependent on the association of TRPC4 alpha with actin cytoskeleton as it was prevented by cytochalasin D treatment or by the deletion of the C-terminal PDZ-binding motif (Thr-Thr-Arg-Leu) that links TRPC4 to F-actin through the sodium-hydrogen exchanger regulatory factor and ezrin. PIP2 breakdown appears to be a required step in TRPC4 alpha channel activation as PIP2 depletion alone was insufficient for channel opening, which additionally required Ca2+ and pertussis toxin-sensitive G(i/o) proteins. Thus, TRPC4 channels integrate a variety of G-protein-dependent stimuli, including a PIP2/cytoskeleton dependence reminiscent of the TRPC4-like muscarinic agonist activated cation channels in ileal myocytes.	[Otsuguro, Ken-ichi; Zholos, Alexander V.] Queens Univ Belfast, Sch Med & Dent, Cardiovasc Biomed Res Ctr, Belfast BT9 7BL, Antrim, North Ireland; [Tang, Jisen; Tang, Yufang; Xiao, Rui; Zhu, Michael X.] Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; [Tang, Jisen; Tang, Yufang; Xiao, Rui; Zhu, Michael X.] Ohio State Univ, Ctr Mol Neurobiol, Columbus, OH 43210 USA; [Freichel, Marc; Tsvilovskyy, Volodymyr; Flockerzi, Veit] Univ Saarland, Dept Pharmacol & Toxicol, D-66421 Homburg, Germany; [Ito, Shigeo] Hokkaido Univ, Grad Sch Vet Med, Dept Biomed Sci, Pharmacol Lab, Sapporo, Hokkaido 0600818, Japan	Queens University Belfast; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Saarland University; Hokkaido University	Zhu, MX (corresponding author), Ohio State Univ, Ctr Mol Neurobiol, Columbus, OH 43210 USA.	zhu.55@osu.edu; a.zholos@qub.ac.uk	Zholos, Alexander/A-7017-2011; Otsuguro, Ken-ichi/A-4840-2012; Xiao, Rui/G-1193-2011	Zholos, Alexander/0000-0002-4320-149X; Otsuguro, Ken-ichi/0000-0002-2481-5592; Xiao, Rui/0000-0001-5541-6685	NINDS NIH HHS [R01 NS042183-04, P30 NS045758-049003, P30 NS045758, P30 NS045758-01A29003, R01 NS042183-02, R21 NS056942, R21 NS056942-01, P30 NS045758-039003, R01 NS042183-03, R01 NS042183] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS045758, R21NS056942, R01NS042183] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; Chuang HH, 2001, NATURE, V411, P957, DOI 10.1038/35082088; Estacion M, 2001, J PHYSIOL-LONDON, V530, P1, DOI 10.1111/j.1469-7793.2001.0001m.x; Feisst C, 2005, MOL PHARMACOL, V67, P1751, DOI 10.1124/mol.105.011007; Flockerzi V, 2005, PFLUG ARCH EUR J PHY, V451, P81, DOI 10.1007/s00424-005-1443-1; Freichel M, 2005, J PHYSIOL-LONDON, V567, P59, DOI 10.1113/jphysiol.2005.092999; Freichel M, 2001, NAT CELL BIOL, V3, P121, DOI 10.1038/35055019; Gwanyanya A, 2006, AM J PHYSIOL-CELL PH, V291, pC627, DOI 10.1152/ajpcell.00074.2006; Hardie RC, 2007, J PHYSIOL-LONDON, V578, P9, DOI 10.1113/jphysiol.2006.118372; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Hu HZ, 2004, J BIOL CHEM, V279, P35741, DOI 10.1074/jbc.M404164200; INOUE R, 1990, J PHYSIOL-LONDON, V424, P73, DOI 10.1113/jphysiol.1990.sp018056; INOUE R, 1990, AM J PHYSIOL, V258, pC1173, DOI 10.1152/ajpcell.1990.258.6.C1173; Kim YC, 1998, PFLUG ARCH EUR J PHY, V436, P494, DOI 10.1007/s004240050663; KOMORI S, 1992, J PHYSIOL-LONDON, V450, P105, DOI 10.1113/jphysiol.1992.sp019118; Kwon Y, 2007, MOL CELL, V25, P491, DOI 10.1016/j.molcel.2007.01.021; Lee J, 2005, J GEN PHYSIOL, V126, P439, DOI 10.1085/jgp.200509314; Lee KP, 2005, MOL CELLS, V20, P435; Liu BY, 2005, J NEUROSCI, V25, P1674, DOI 10.1523/JNEUROSCI.3632-04.2005; Liu D, 2003, P NATL ACAD SCI USA, V100, P15160, DOI 10.1073/pnas.2334159100; Lukacs V, 2007, J NEUROSCI, V27, P7070, DOI 10.1523/JNEUROSCI.1866-07.2007; McLaughlin S, 2002, ANNU REV BIOPH BIOM, V31, P151, DOI 10.1146/annurev.biophys.31.082901.134259; Mery L, 2002, J CELL SCI, V115, P3497; Nilius B, 2007, BIOCHEM SOC T, V35, P105, DOI 10.1042/BST0350105; Nilius B, 2006, EMBO J, V25, P467, DOI 10.1038/sj.emboj.7600963; Obukhov AG, 2004, J CELL PHYSIOL, V201, P227, DOI 10.1002/jcp.20057; Okamoto H, 2004, J PHARMACOL SCI, V95, P203, DOI 10.1254/jphs.FP0030635; Plant TD, 2005, N-S ARCH PHARMACOL, V371, P266, DOI 10.1007/s00210-005-1055-5; Prescott ED, 2003, SCIENCE, V300, P1284, DOI 10.1126/science.1083646; Ramsey IS, 2006, ANNU REV PHYSIOL, V68, P619, DOI 10.1146/annurev.physiol.68.040204.100431; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Rohacs T, 2005, NAT NEUROSCI, V8, P626, DOI 10.1038/nn1451; Rohacs T, 2007, PFLUG ARCH EUR J PHY, V455, P157, DOI 10.1007/s00424-007-0275-6; Rohacs T, 2007, PFLUG ARCH EUR J PHY, V453, P753, DOI 10.1007/s00424-006-0153-7; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; Schaefer M, 2002, J BIOL CHEM, V277, P3752, DOI 10.1074/jbc.M109850200; Stein AT, 2006, J GEN PHYSIOL, V128, P509, DOI 10.1085/jgp.200609576; Suh BC, 2005, CURR OPIN NEUROBIOL, V15, P370, DOI 10.1016/j.conb.2005.05.005; Tang J, 2001, J BIOL CHEM, V276, P21303, DOI 10.1074/jbc.M102316200; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; Tiruppathi C, 2002, CIRC RES, V91, P70, DOI 10.1161/01.RES.0000023391.40106.A8; Tseng PH, 2004, BIOCHEMISTRY-US, V43, P11701, DOI 10.1021/bi049349f; Voets T, 2003, J GEN PHYSIOL, V121, P245, DOI 10.1085/jgp.20028752; Voets T, 2007, J PHYSIOL-LONDON, V582, P939, DOI 10.1113/jphysiol.2007.132522; Walker RL, 2001, AM J PHYSIOL-CELL PH, V280, pC1184, DOI 10.1152/ajpcell.2001.280.5.C1184; Weissgerber P, 2006, CIRC RES, V99, P749, DOI 10.1161/01.RES.0000243978.15182.c1; Xu SZ, 2008, NATURE, V451, P69, DOI 10.1038/nature06414; Yan HD, 2003, BRIT J PHARMACOL, V139, P605, DOI 10.1038/sj.bjp.0705289; Zhang Z, 2005, J BIOL CHEM, V280, P39185, DOI 10.1074/jbc.M506965200; Zholos AV, 2006, ACTA PHARMACOL SIN, V27, P833, DOI 10.1111/j.1745-7254.2006.00392.x; Zholos AV, 1996, BRIT J PHARMACOL, V119, P997, DOI 10.1111/j.1476-5381.1996.tb15770.x; Zholos AV, 2004, BRIT J PHARMACOL, V141, P23, DOI 10.1038/sj.bjp.0705584; Zholos AV, 1997, BRIT J PHARMACOL, V122, P885, DOI 10.1038/sj.bjp.0701438; Zhu MX, 2005, PFLUG ARCH EUR J PHY, V451, P105, DOI 10.1007/s00424-005-1427-1	55	133	135	3	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					10026	10036		10.1074/jbc.M707306200	http://dx.doi.org/10.1074/jbc.M707306200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	18230622	Green Accepted, hybrid, Green Published			2022-12-25	WOS:000254671600074
J	Cironi, P; Swinburne, IA; Silver, PA				Cironi, Pablo; Swinburne, Ian A.; Silver, Pamela A.			Enhancement of cell type specificity by quantitative modulation of a chimeric ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; PSEUDOMONAS EXOTOXIN; FACTOR RECEPTOR; FACTOR-ALPHA; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; COMPLEX; MODEL; MICE	Evolution modulates the quantitative characteristics of protein interactions and often uses combinations of weak interactions to achieve a particular specificity. We addressed how quantitative optimization might be used in the design of multidomain proteins, using a chimera containing epidermal growth factor (EGF) as a cell targeting element and interferon alpha-2 alpha (IFN alpha-2 alpha) to initiate signal transduction. We first connected EGF and IFN alpha-2 alpha via a linker that allows both ligands to bind to their receptors on a cell surface and then incorporated a series of mutations into the IFN alpha-2 alpha portion that progressively decrease both the on rate and the dissociation constant of the IFN alpha-2 alpha-IFN alpha receptor 2 (IFNAR2) interaction. Using this strategy, we designed chimeric proteins in which the activation of the IFN alpha receptor in HeLa, A431, and engineered Daudi cells depends on the presence of EGF receptor on the same cell. The mutant chimeric proteins also inhibited proliferation of IFN alpha-sensitive cells in an EGF receptor-dependent manner. These results provide insights into the quantitative requirements for specific binding to multisubunit receptors and illustrate the value of a quantitative approach in the design of synthetic-biological constructs.	[Cironi, Pablo; Swinburne, Ian A.; Silver, Pamela A.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Silver, PA (corresponding author), Harvard Univ, Sch Med, Dept Syst Biol, 200 Longwood Ave, Boston, MA 02115 USA.	pamela_silver@hms.harvard.edu						Adam G., 1968, STRUCTURAL CHEM MOL, P198; Caraglia M, 1999, CELL DEATH DIFFER, V6, P773, DOI 10.1038/sj.cdd.4400550; Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; CLARE JJ, 1991, GENE, V105, P205, DOI 10.1016/0378-1119(91)90152-2; Evinger M, 1981, Methods Enzymol, V79, P362; Franklin MC, 2004, CANCER CELL, V5, P317, DOI 10.1016/S1535-6108(04)00083-2; FRENCH AR, 1995, J BIOL CHEM, V270, P4334, DOI 10.1074/jbc.270.9.4334; Garcia Julia N., 1995, Biotecnologia Aplicada, V12, P152; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; HEIMBROOK DC, 1990, P NATL ACAD SCI USA, V87, P4697, DOI 10.1073/pnas.87.12.4697; Huston J S, 1993, Cell Biophys, V22, P189; Kreitman R. J., 1999, V137, P89; Liu TF, 2003, MOL CANCER THER, V2, P783; LORBERBOUMGALSKI H, 1988, P NATL ACAD SCI USA, V85, P1922, DOI 10.1073/pnas.85.6.1922; MASUI H, 1984, CANCER RES, V44, P1002; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; PAI LH, 1991, CANCER RES, V51, P2808; Piehler J, 1999, J MOL BIOL, V289, P57, DOI 10.1006/jmbi.1999.2726; Piehler J, 2000, J BIOL CHEM, V275, P40425, DOI 10.1074/jbc.M006854200; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Quadt-Akabayov SR, 2006, PROTEIN SCI, V15, P2656, DOI 10.1110/ps.062283006; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Roisman LC, 2001, P NATL ACAD SCI USA, V98, P13231, DOI 10.1073/pnas.221290398; SIEGALL CB, 1989, FASEB J, V3, P2647, DOI 10.1096/fasebj.3.14.2556314; Todhunter DA, 2004, PROTEIN ENG DES SEL, V17, P157, DOI 10.1093/protein/gzh023	25	23	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8469	8476		10.1074/jbc.M708502200	http://dx.doi.org/10.1074/jbc.M708502200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18230610	Green Published, hybrid			2022-12-25	WOS:000254288000045
J	Cottevieille, M; Larquet, E; Jonic, S; Petoukhov, MV; Caprini, G; Paravisi, S; Svergun, DI; Vanoni, MA; Boisset, N				Cottevieille, Magali; Larquet, Eric; Jonic, Slavica; Petoukhov, Maxim V.; Caprini, Gianluca; Paravisi, Stefano; Svergun, Dmitri I.; Vanoni, Maria A.; Boisset, Nicolas			The subnanometer resolution structure of the glutamate synthase 1.2-MDa hexamer by cryoelectron microscopy and its oligomerization behavior in solution - Functional implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR FLAVOPROTEIN; HYDROPHOBIC CLUSTER-ANALYSIS; SCATTERING DATA-ANALYSIS; 3D ELECTRON-MICROSCOPY; X-RAY-SCATTERING; AZOSPIRILLUM-BRASILENSE; DIHYDROPYRIMIDINE DEHYDROGENASE; 3-DIMENSIONAL RECONSTRUCTION; CATALYTIC-PROPERTIES; ANGSTROM RESOLUTION	The three-dimensional structure of the hexameric (alpha beta)(6) 1.2-MDa complex formed by glutamate synthase has been determined at subnanometric resolution by combining cryoelectron microscopy, small angle x-ray scattering, and molecular modeling, providing for the first time a molecular model of this complex iron-sulfur flavoprotein. In the hexameric species, interprotomeric alpha-alpha and alpha-beta contacts are mediated by the C-terminal domain of the alpha subunit, which is based on a beta helical fold so far unique to glutamate synthases. The alpha beta protomer extracted from the hexameric model is fully consistent with it being the minimal catalytically active form of the enzyme. The structure clarifies the electron transfer pathway from the FAD cofactor on the beta subunit, to the FMN on the alpha subunit, through the low potential [4Fe-4S](1+/2+) centers on the beta subunit and the [3Fe-4S](0/1+) cluster on the alpha subunit. The(alpha beta)(6) hexamer exhibits a concentration-dependent equilibrium with alpha beta monomers and (alpha beta)(2) dimers, in solution, the hexamer being destabilized by high ionic strength and, to a lower extent, by the reaction product NADP(+). Hexamerization seems to decrease the catalytic efficiency of the alpha beta protomer only 3-fold by increasing the K-m values measured for L-Gln and 2-OG. However, it cannot be ruled out that the (alpha beta)(6) hexamer acts as a scaffold for the assembly of multienzymatic complexes of nitrogen metabolism or that it provides a means to regulate the activity of the enzyme through an as yet unknown ligand.	[Caprini, Gianluca; Paravisi, Stefano; Vanoni, Maria A.] Univ Milan, Dipartimento Sci Biomol & Biotecnol, I-20133 Milan, Italy; [Cottevieille, Magali; Larquet, Eric; Jonic, Slavica; Boisset, Nicolas] Univ Paris 06, Dept Biol Struct, CNRS, IMPMC UMR 7590, F-75252 Paris, France; [Cottevieille, Magali; Larquet, Eric; Jonic, Slavica; Boisset, Nicolas] Univ Paris 07, IPGP, F-75252 Paris, France; [Petoukhov, Maxim V.; Svergun, Dmitri I.] DESY, European Mol Biol Lab, Hamburg Outstn, D-22603 Hamburg, Germany; [Petoukhov, Maxim V.; Svergun, Dmitri I.] Russian Acad Sci, Inst Crystallog, Moscow 117333, Russia	University of Milan; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Sorbonne Universite; Institut de Recherche pour le Developpement (IRD); UDICE-French Research Universities; Universite Paris Cite; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Russian Academy of Sciences; FSRC Crystallography & Photonics RAS	Vanoni, MA (corresponding author), Univ Milan, Dipartimento Sci Biomol & Biotecnol, Via Celoria 26, I-20133 Milan, Italy.	maria.vanoni@unimi.it	Vanoni, Maria/AAP-2089-2021; larquet, eric/ABB-3063-2021; Petoukhov, Maxim V/R-7371-2016	Vanoni, Maria/0000-0001-7213-732X; larquet, eric/0000-0002-9994-6845; Petoukhov, Maxim V/0000-0001-6760-4595; Jonic, Slavica/0000-0001-5112-2743; Svergun, Dmitri/0000-0003-0830-5696				ADRIAN M, 1984, NATURE, V308, P32, DOI 10.1038/308032a0; Agnelli P, 2005, ARCH BIOCHEM BIOPHYS, V436, P355, DOI 10.1016/j.abb.2005.02.009; Binda C, 2000, STRUCTURE, V8, P1299, DOI 10.1016/S0969-2126(00)00540-2; Callebaut I, 1997, CELL MOL LIFE SCI, V53, P621, DOI 10.1007/s000180050082; Chacon P, 2002, J MOL BIOL, V317, P375, DOI 10.1006/jmbi.2002.5438; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Connell SR, 2007, MOL CELL, V25, P751, DOI 10.1016/j.molcel.2007.01.027; Coschigano KT, 1998, PLANT CELL, V10, P741, DOI 10.1105/tpc.10.5.741; Dobritzsch D, 2001, EMBO J, V20, P650, DOI 10.1093/emboj/20.4.650; Fotin A, 2006, J STRUCT BIOL, V156, P453, DOI 10.1016/j.jsb.2006.07.001; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Gabashvili IS, 2000, CELL, V100, P537, DOI 10.1016/S0092-8674(00)80690-X; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; Goddard TD, 2007, J STRUCT BIOL, V157, P281, DOI 10.1016/j.jsb.2006.06.010; Guinier A., 1939, ANN PHYS-LEIPZIG, DOI DOI 10.1051/ANPHYS/193911120161; Hagen WR, 2000, EUR J BIOCHEM, V267, P3640, DOI 10.1046/j.1432-1327.2000.01393.x; Hagen WR, 2000, J BIOL INORG CHEM, V5, P527, DOI 10.1007/s007750050013; HARAUZ G, 1986, OPTIK, V73, P146; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Hudson JM, 2005, J AM CHEM SOC, V127, P6977, DOI 10.1021/ja043404q; Jiang W, 2001, J MOL BIOL, V308, P1033, DOI 10.1006/jmbi.2001.4633; Jonic S, 2007, J STRUCT BIOL, V157, P156, DOI 10.1016/j.jsb.2006.06.014; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Konarev PV, 2003, J APPL CRYSTALLOGR, V36, P1277, DOI 10.1107/S0021889803012779; Kong QX, 2007, APPL MICROBIOL BIOT, V73, P1382, DOI 10.1007/s00253-006-0610-4; Lamichhane G, 2003, P NATL ACAD SCI USA, V100, P7213, DOI 10.1073/pnas.1231432100; Lancien M, 2002, PLANT J, V29, P347, DOI 10.1046/j.1365-313X.2002.01218.x; Ludtke SJ, 2004, STRUCTURE, V12, P1129, DOI 10.1016/j.str.2004.05.006; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Martin AG, 2007, J MOL BIOL, V366, P1332, DOI 10.1016/j.jmb.2006.11.075; Mindell JA, 2003, J STRUCT BIOL, V142, P334, DOI 10.1016/S1047-8477(03)00069-8; Natera V, 2006, CURR MICROBIOL, V53, P479, DOI 10.1007/s00284-006-0146-y; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; PENCZEK PA, 1997, SCANNING MICROSCOPY, V11, P147, DOI DOI 10.1016/0304-3991(92)90011-8; Petoukhov MV, 2007, J APPL CRYSTALLOGR, V40, pS223, DOI 10.1107/S0021889807002853; Petoukhov MV, 2003, J BIOL CHEM, V278, P29933, DOI 10.1074/jbc.M304147200; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; RADERMACHER M, 1988, J ELECTRON MICR TECH, V9, P359, DOI 10.1002/jemt.1060090405; RADERMACHER M, 1987, J MICROSC-OXFORD, V146, P113, DOI 10.1111/j.1365-2818.1987.tb01333.x; Ravasio S, 2002, BIOCHEMISTRY-US, V41, P8120, DOI 10.1021/bi020083r; Ravasio S, 2001, BIOCHEMISTRY-US, V40, P5533, DOI 10.1021/bi0100889; Roessle MW, 2007, J APPL CRYSTALLOGR, V40, pS190, DOI 10.1107/S0021889806055506; Roseman AM, 2004, J STRUCT BIOL, V145, P91, DOI 10.1016/j.jsb.2003.11.007; Rosenbaum K, 1998, BIOCHEMISTRY-US, V37, P17598, DOI 10.1021/bi9815997; Saban SD, 2006, J VIROL, V80, P12049, DOI 10.1128/JVI.01652-06; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sorzano COS, 2007, EUR BIOPHYS J BIOPHY, V36, P995, DOI 10.1007/s00249-007-0203-x; Stabile H, 2000, EUR J BIOCHEM, V267, P2720, DOI 10.1046/j.1432-1327.2000.01289.x; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; van den Heuvel RHH, 2004, CELL MOL LIFE SCI, V61, P669, DOI 10.1007/s00018-003-3316-0; Vanoni MA, 2005, ARCH BIOCHEM BIOPHYS, V433, P193, DOI 10.1016/j.abb.2004.08.033; VANONI MA, 1992, BIOCHEMISTRY-US, V31, P4613, DOI 10.1021/bi00134a011; Vanoni MA, 1998, BIOCHEMISTRY-US, V37, P1828, DOI 10.1021/bi972342w; VANONI MA, 1994, EUR J BIOCHEM, V226, P505, DOI 10.1111/j.1432-1033.1994.tb20075.x; VANONI MA, 1991, EUR J BIOCHEM, V202, P181, DOI 10.1111/j.1432-1033.1991.tb16361.x; Vanoni MA, 1999, CELL MOL LIFE SCI, V55, P617, DOI 10.1007/s000180050319; VANONI MA, 1991, BIOCHEMISTRY-US, V30, P11478, DOI 10.1021/bi00112a016; Wriggers W, 1999, J STRUCT BIOL, V125, P185, DOI 10.1006/jsbi.1998.4080	59	21	21	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8237	8249		10.1074/jbc.M708529200	http://dx.doi.org/10.1074/jbc.M708529200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18199747	hybrid, Green Published			2022-12-25	WOS:000254288000021
J	Gyimesi, M; Kintses, B; Bodor, A; Perczel, A; Fischer, S; Bagshaw, CR; Malnasi-Csizmadia, A				Gyimesi, Mate; Kintses, Balint; Bodor, Andrea; Perczel, Andras; Fischer, Stefan; Bagshaw, Clive R.; Malnasi-Csizmadia, Andras			The mechanism of the reverse recovery step, phosphate release, and actin activation of Dictyostelium myosin II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT PSOAS MUSCLE; RATE-LIMITING STEP; DISCOIDEUM MYOSIN; MOTOR DOMAIN; ADENOSINE-TRIPHOSPHATASE; KINETIC CHARACTERIZATION; INORGANIC-PHOSPHATE; NUCLEOTIDE COMPLEXES; MOLECULAR-MECHANISM; TRYPTOPHAN RESIDUE	The rate-limiting step of the myosin basal ATPase (i.e. in absence of actin) is assumed to be a post-hydrolysis swinging of the lever arm ( reverse recovery step), that limits the subsequent rapid product release steps. However, direct experimental evidence for this assignment is lacking. To investigate the binding and the release of ADP and phosphate independently from the lever arm motion, two single tryptophan-containing motor domains of Dictyostelium myosin II were used. The single tryptophans of the W129+ and W501+ constructs are located at the entrance of the nucleotide binding pocket and near the lever arm, respectively. Kinetic experiments show that the rate-limiting step in the basal ATPase cycle is indeed the reverse recovery step, which is a slow equilibrium step (k(forward) = 0.05 s(-1), k(reverse) = 0.15 s(-1)) that precedes the phosphate release step. Actin directly activates the reverse recovery step, which becomes practically irreversible in the actin-bound form, triggering the power stroke. Even at low actin concentrations the power stroke occurs in the actin-attached states despite the low actin affinity of myosin in the pre-power stroke conformation.	[Gyimesi, Mate; Kintses, Balint; Malnasi-Csizmadia, Andras] Eotvos Lorand Univ, Inst Biol, Dept Biochem, H-1117 Budapest, Hungary; [Bodor, Andrea] Eotvos Lorand Univ, Inst Chem, Lab Struct Chem & Biol, H-1117 Budapest, Hungary; [Perczel, Andras] Eotvos Lorand Univ, Inst Chem, Prot Modelling Grp, MTA ELTE, H-1117 Budapest, Hungary; [Fischer, Stefan] Univ Heidelberg, Interdisciplinary Ctr Sci Comp, D-69120 Heidelberg, Germany; [Bagshaw, Clive R.] Univ Leicester, Dept Biochem, Leicester LE1 9HN, Leics, England	Eotvos Lorand University; Eotvos Lorand University; Hungarian Academy of Sciences; Eotvos Lorand University; Hungarian Academy of Sciences; Ruprecht Karls University Heidelberg; University of Leicester	Malnasi-Csizmadia, A (corresponding author), Eotvos Lorand Univ, Inst Biol, Dept Biochem, Pazmany Peter Setany 1-A, H-1117 Budapest, Hungary.	malna@elte.hu	Csizmadia, András Málnási/K-7632-2018; Bodor, Andrea/G-1797-2018; Bagshaw, Clive R./L-5484-2019; Bodor, Andrea/AAL-7854-2020; Gyimesi, Mate/I-2639-2017	Csizmadia, András Málnási/0000-0002-2430-8398; Bodor, Andrea/0000-0002-7422-298X; Bagshaw, Clive R./0000-0002-5396-153X; Bodor, Andrea/0000-0002-7422-298X; Kintses, Balint/0000-0003-0844-0310; Gyimesi, Mate/0000-0002-7195-1925	Biotechnology and Biological Sciences Research Council Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		BAGSHAW CR, 1974, BIOCHEM J, V141, P331, DOI 10.1042/bj1410331; Bauer CB, 1997, J MOL BIOL, V274, P394, DOI 10.1006/jmbi.1997.1325; BEYNON RJ, 1996, BUFFERS PH CONTROL B; Conibear PB, 2004, BIOCHEMISTRY-US, V43, P15404, DOI 10.1021/bi048338j; Conibear PB, 2003, NAT STRUCT BIOL, V10, P831, DOI 10.1038/nsb986; Coureux PD, 2003, NATURE, V425, P419, DOI 10.1038/nature01927; DANTZIG JA, 1992, J PHYSIOL-LONDON, V451, P247, DOI 10.1113/jphysiol.1992.sp019163; DANTZIG JA, 1985, J GEN PHYSIOL, V86, P305, DOI 10.1085/jgp.86.3.305; Geeves MA, 2005, ADV PROTEIN CHEM, V71, P161, DOI 10.1016/S0065-3233(04)71005-0; GOLDMAN YE, 1987, ANNU REV PHYSIOL, V49, P629; GOODNO CC, 1982, METHOD ENZYMOL, V85, P116; GOODY RS, 1977, EUR J BIOCHEM, V78, P317, DOI 10.1111/j.1432-1033.1977.tb11742.x; Gyimesi M, 2008, BIOCHEMISTRY-US, V47, P283, DOI 10.1021/bi701554a; Jahn W, 2007, BIOCHEMISTRY-US, V46, P9654, DOI 10.1021/bi700318t; KAWAI M, 1993, BIOPHYS J, V65, P638, DOI 10.1016/S0006-3495(93)81109-3; KAWAI M, 1991, BIOPHYS J, V59, P329, DOI 10.1016/S0006-3495(91)82227-5; Kintses B, 2007, EMBO J, V26, P265, DOI 10.1038/sj.emboj.7601482; Kintses B, 2006, BIOPHYS J, V91, P4605, DOI 10.1529/biophysj.106.092833; Koppole S, 2007, STRUCTURE, V15, P825, DOI 10.1016/j.str.2007.06.008; Koppole S, 2006, J MOL BIOL, V361, P604, DOI 10.1016/j.jmb.2006.06.022; Kovacs M, 2002, J BIOL CHEM, V277, P28459, DOI 10.1074/jbc.M202180200; Kuhlman PA, 1998, J MUSCLE RES CELL M, V19, P491, DOI 10.1023/A:1005304408812; Kurzawa SE, 1997, BIOCHEMISTRY-US, V36, P317, DOI 10.1021/bi962166b; Lionne C, 2002, BIOCHEMISTRY-US, V41, P13297, DOI 10.1021/bi0260278; LIONNE C, 1995, FEBS LETT, V364, P59, DOI 10.1016/0014-5793(95)00356-E; Malnasi-Csizmadia A, 2005, J MUSCLE RES CELL M, V26, P31, DOI 10.1007/s10974-005-9004-y; Malnasi-Csizmadia A, 2001, BIOCHEMISTRY-US, V40, P12727, DOI 10.1021/bi010963q; Malnasi-Csizmadia A, 2001, J BIOL CHEM, V276, P19483, DOI 10.1074/jbc.M010886200; Malnasi-Csizmadia A, 2000, BIOCHEMISTRY-US, V39, P16135, DOI 10.1021/bi001125j; MANNHERZ HG, 1974, EUR J BIOCHEM, V48, P287, DOI 10.1111/j.1432-1033.1974.tb03767.x; MANSTEIN DJ, 1995, GENE, V162, P129, DOI 10.1016/0378-1119(95)00351-6; Mesentean S, 2007, J MOL BIOL, V367, P591, DOI 10.1016/j.jmb.2006.12.058; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Reubold TF, 2003, NAT STRUCT BIOL, V10, P826, DOI 10.1038/nsb987; RITCHIE MD, 1993, P NATL ACAD SCI USA, V90, P8619, DOI 10.1073/pnas.90.18.8619; SCHRODER RR, 1993, NATURE, V364, P171, DOI 10.1038/364171a0; Schwarzl SM, 2006, BIOCHEMISTRY-US, V45, P5830, DOI 10.1021/bi052433q; Siththanandan VB, 2006, BIOPHYS J, V90, P3653, DOI 10.1529/biophysj.105.072413; Smith DA, 2004, BIOPHYS J, V87, P442, DOI 10.1529/biophysj.103.037788; Takagi Y, 2004, PHILOS T R SOC B, V359, P1913, DOI 10.1098/rstb.2004.1561; Tesi C, 2002, J PHYSIOL-LONDON, V541, P187, DOI 10.1113/jphysiol.2001.013418; TRENTHAM DR, 1976, Q REV BIOPHYS, V9, P217, DOI 10.1017/S0033583500002419; TRENTHAM DR, 1972, BIOCHEM J, V126, P635, DOI 10.1042/bj1260635; Wakelin S, 2002, J MUSCLE RES CELL M, V23, P673, DOI 10.1023/A:1024411208497; WELLS C, 1984, J MUSCLE RES CELL M, V5, P97, DOI 10.1007/BF00713154; WERBER MM, 1992, BIOCHEMISTRY-US, V31, P7190, DOI 10.1021/bi00146a023; WHITE HD, 1976, BIOCHEMISTRY-US, V15, P5818, DOI 10.1021/bi00671a020; White HD, 1997, BIOCHEMISTRY-US, V36, P11828, DOI 10.1021/bi970540h; Woodward SKA, 1995, BIOCHEMISTRY-US, V34, P16056, DOI 10.1021/bi00049a020; Yang YT, 2007, STRUCTURE, V15, P553, DOI 10.1016/j.str.2007.03.010; Zeng W, 2004, PHILOS T R SOC B, V359, P1843, DOI 10.1098/rstb.2004.1527	53	40	40	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8153	8163		10.1074/jbc.M708863200	http://dx.doi.org/10.1074/jbc.M708863200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18211892	hybrid			2022-12-25	WOS:000254288000012
J	Gong, RJ; Rifai, A; Ge, Y; Chen, S; Dworkin, LD				Gong, Rujun; Rifai, Abdalla; Ge, Yan; Chen, Shan; Dworkin, Lance D.			Hepatocyte growth factor suppresses proinflammatory NF kappa B activation through GSK3 beta inactivation in renal tubular epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; INFLAMMATORY-BOWEL-DISEASE; SIGNAL-TRANSDUCTION; LIVER-REGENERATION; TYROSINE KINASE; GENE-EXPRESSION; SCATTER FACTOR; MET RECEPTOR; RAT MODEL; PATHWAY	Activation of NF kappa B is a fundamental cellular event central to all inflammatory diseases. Hepatocyte growth factor ( HGF) ameliorates both acute and chronic inflammation in a multitude of organ systems through modulating NF kappa B activity; nevertheless, the exact molecular mechanism remains uncertain. Here we report that HGF through inactivation of GSK3 beta suppresses NF kappa B p65 phosphorylation specifically at position Ser-468. The Ser-468 of RelA/p65 situates in a GSK3 beta consensus motif and could be directly phosphorylated by GSK3 beta both in vivo and in vitro, signifying Ser-468 of RelA/ p65 as a putative substrate for GSK3 beta. In addition, the C terminus of RelA/ p65 harbors a highly conserved domain homologue of the consensus docking sequence for GSK3 beta. Moreover, this domain was required for efficient phosphorylation of Ser- 468 and was indispensable for the physical interaction between RelA/ p65 and GSK3 beta. HGF substantially intercepted this interaction by inactivating GSK3 beta. Functionally, phosphorylation of Ser-468 of RelA/p65 was required for the induced expression of a particular subset of proinflammatory NF kappa B-dependent genes. Diminished phosphorylation at Ser- 468 by HGF resulted in a gene-specific inhibition of these genes' expression. The action of HGF on proinflammatory NF kappa B activation was consistently mimicked by a selective GSK3 beta inhibitor or GSK3 beta knockdown by RNA interference but largely abrogated in cells expressing the mutant uninhibitable GSK3 beta. Collectively, our findings suggest that HGF has a potent suppressive effect on NF kappa B activation, which is mediated by GSK3 beta, an important signaling transducer controlling RelA/ p65 phosphorylation specificity and directing the transcription of selective proinflammatory cytokines implicated in inflammatory kidney disease.	[Gong, Rujun; Ge, Yan; Chen, Shan; Dworkin, Lance D.] Brown Univ, Dept Med, Sch Med, Div Kidney Dis & Hypertens, Providence, RI 02903 USA; [Rifai, Abdalla] Brown Univ, Dept Med, Sch Med, Dept Pathol, Providence, RI 02903 USA; [Chen, Shan] Third Mil Med Univ, Dept Biochem & Mol Biol, Chongqing 400038, Peoples R China	Brown University; Brown University; Army Medical University	Gong, RJ (corresponding author), Brown Univ, Dept Med, Sch Med, Div Kidney Dis & Hypertens, 593 Eddy St, Providence, RI 02903 USA.	Rujun_Gong@Brown.edu			NCCIH NIH HHS [AT001465-01A2] Funding Source: Medline; NIDDK NIH HHS [R01-DK52314] Funding Source: Medline; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R21AT001465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052314] Funding Source: NIH RePORTER	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arthur LG, 2004, J PEDIATR SURG, V39, P139, DOI 10.1016/j.jpedsurg.2003.10.001; Arthur LG, 2003, J GASTROINTEST SURG, V7, P1062, DOI 10.1016/j.gassur.2003.09.014; Baeuerle PA, 1998, CELL, V95, P729, DOI 10.1016/S0092-8674(00)81694-3; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; BOROS P, 1995, LANCET, V345, P293, DOI 10.1016/S0140-6736(95)90279-1; Buss H, 2004, J BIOL CHEM, V279, P49571, DOI 10.1074/jbc.C400442200; Chen H, 2007, J CELL BIOCHEM, V102, P1281, DOI 10.1002/jcb.21358; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Cho JH, 2004, J NEUROCHEM, V88, P349, DOI 10.1046/j.1471-4159.2003.02155.x; Cohen P, 2004, NAT REV DRUG DISCOV, V3, P479, DOI 10.1038/nrd1415; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Deng J, 2004, MOL CARCINOGEN, V39, P139, DOI 10.1002/mc.10169; Dignass AU, 2001, EUR J GASTROEN HEPAT, V13, P763, DOI 10.1097/00042737-200107000-00002; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Dugo L, 2007, SHOCK, V27, P113, DOI 10.1097/01.shk.0000238059.23837.68; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; Ghosh S, 1999, IMMUNOL RES, V19, P183, DOI 10.1007/BF02786486; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; Gong R, 2006, KIDNEY INT, V69, P1166, DOI 10.1038/sj.ki.5000246; Gong R, 2003, J AM SOC NEPHROL, V14, P3047, DOI 10.1097/01.ASN.0000098686.72971.DB; Gong RJ, 2005, BIOCHEM BIOPH RES CO, V330, P27, DOI 10.1016/j.bbrc.2005.02.122; Gong RJ, 2004, J AM SOC NEPHROL, V15, P2868, DOI 10.1097/01.ASN.0000141962.44300.3A; Gong RJ, 2006, J AM SOC NEPHROL, V17, P2464, DOI 10.1681/ASN.2006020185; Haefner B, 2003, DRUG DISCOV TODAY, V8, P1062, DOI 10.1016/S1359-6446(03)02898-8; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Herrero-Fresneda I, 2006, KIDNEY INT, V70, P265, DOI 10.1038/sj.ki.5001510; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Ito W, 2005, AM J RESP CELL MOL, V32, P268, DOI 10.1165/rcmb.2004-0058OC; Jope RS, 2007, NEUROCHEM RES, V32, P577, DOI 10.1007/s11064-006-9128-5; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Kim AJ, 2005, J CELL SCI, V118, P89, DOI 10.1242/jcs.01562; Liu YH, 2004, AM J PHYSIOL-RENAL, V287, pF7, DOI 10.1152/ajprenal.00451.2003; Matsumoto K, 2001, KIDNEY INT, V59, P2023, DOI 10.1046/j.1523-1755.2001.00717.x; MATSUMOTO K, 1991, J GASTROEN HEPATOL, V6, P509, DOI 10.1111/j.1440-1746.1991.tb00897.x; Mattioli I, 2004, BLOOD, V104, P3302, DOI 10.1182/blood-2004-04-1536; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Min JK, 2005, CIRC RES, V96, P300, DOI 10.1161/01.RES.0000155330.07887.EE; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; Oh K, 2005, AM J PHYSIOL-GASTR L, V288, pG729, DOI 10.1152/ajpgi.00438.2004; Okazaki T, 2003, BIOCHEM BIOPH RES CO, V300, P807, DOI 10.1016/S0006-291X(02)02932-7; OUGOLKOV AV, 2007, BLOOD, V100, P375; Perkins ND, 2006, ONCOGENE, V25, P6717, DOI 10.1038/sj.onc.1209937; Pomerantz JL, 2000, NATURE, V406, P26, DOI 10.1038/35017673; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; Schwabe RF, 2002, AM J PHYSIOL-GASTR L, V283, pG204, DOI 10.1152/ajpgi.00016.2002; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Sreenivasan Y, 2003, ONCOGENE, V22, P4356, DOI 10.1038/sj.onc.1206486; Steinbrecher KA, 2005, MOL CELL BIOL, V25, P8444, DOI 10.1128/MCB.25.19.8444-8455.2005; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Stuart KA, 2000, INT J EXP PATHOL, V81, P17, DOI 10.1046/j.1365-2613.2000.00138.x; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Ware LB, 2002, AM J PHYSIOL-LUNG C, V282, pL924, DOI 10.1152/ajplung.00439.2001; Xavier IJ, 2000, J BIOL CHEM, V275, P29147, DOI 10.1074/jbc.M002169200; Xiao CC, 2005, ADV EXP MED BIOL, V560, P41	55	85	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7401	7410		10.1074/jbc.M710396200	http://dx.doi.org/10.1074/jbc.M710396200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18201972	Green Published, hybrid			2022-12-25	WOS:000253997900014
J	Moncada, CA; Clarkson, A; Perez-Leal, O; Merali, S				Moncada, Camilo A.; Clarkson, Allen; Perez-leal, Oscar; Merali, Salim			Mechanism and tissue specificity of nicotine-mediated lung S-adenosylmethionine reduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PNEUMOCYSTIS-CARINII-PNEUMONIA; DL-ALPHA-DIFLUOROMETHYLORNITHINE; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; ORNITHINE DECARBOXYLASE ACTIVITY; RAT MODEL; CONTINUOUS-INFUSION; AIDS PATIENTS; EFLORNITHINE; INHIBITOR; DIAGNOSIS	We previously reported that chronic nicotine infusion blocks development of Pneumocystis pneumonia. This discovery developed from our work demonstrating the inability of this fungal pathogen to synthesize the critical metabolic intermediate S-adenosylmethionine and work by others showing nicotine to cause lung-specific reduction of S-adenosylmethionine in guinea pigs. We had found nicotine infusion to cause increased lung ornithine decarboxylase activity (rate-controlling enzyme of polyamine synthesis) and hypothesized that S-adenosylmethionine reduction is driven by up-regulated polyamine biosynthesis. Here we report a critical test of our hypothesis; inhibition of ornithine decarboxylase blocks the effect of nicotine on lung S-adenosylmethionine. Further support is provided by metabolite analyses showing nicotine to cause a strong diversion of S-adenosylmethionine toward polyamine synthesis and away from methylation reactions; these shifts are reversed by inhibition of ornithine decarboxylase. Because the nicotine effect on Pneumocystis is so striking, we considered the possibility of tissue specificity. Using laser capture microdissection, we collected samples of lung alveolar regions (site of infection) and respiratory epithelium for controls. We found nicotine to cause increased ornithine decarboxylase protein in alveolar regions but not airway epithelium; we conclude that tissue specificity likely contributes to the effect of nicotine on Pneumocystis pneumonia. Earlier we reported that the full effect of nicotine requires 3 weeks of treatment, and here we show recovery is symmetrical, also requiring 3 weeks after treatment cessation. Because this time frame is similar to pneumocyte turnover time, the shift in polyamine metabolism may occur as new pneumocytes are produced.	[Moncada, Camilo A.; Perez-leal, Oscar; Merali, Salim] Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; [Clarkson, Allen] NYU, Sch Med, Dept Med Parasitol, New York, NY 10016 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; New York University	Merali, S (corresponding author), Temple Univ, Sch Med, Dept Biochem, 3307 N Broad St, Philadelphia, PA 19140 USA.	smerali@temple.edu	Moncada-Benavides, Camilo/B-9407-2009; Moncada, Camilo/L-7468-2018	Moncada, Camilo/0000-0001-9458-5684; Perez-Leal, Oscar/0000-0002-5641-0311	NIAID NIH HHS [R01 AI064017] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI064017] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Babbar N, 2006, J BIOL CHEM, V281, P24182, DOI 10.1074/jbc.M601871200; Bergeron C, 2007, J ALLERGY CLIN IMMUN, V119, P391, DOI 10.1016/j.jaci.2006.10.030; Chin K, 1996, ANTIMICROB AGENTS CH, V40, P2318, DOI 10.1128/AAC.40.10.2318; CLARKSON AB, 1988, ANTIMICROB AGENTS CH, V32, P1158, DOI 10.1128/AAC.32.8.1158; FILLET G, 1989, BLOOD, V74, P844; Fojtova M, 1998, EUR J BIOCHEM, V252, P347, DOI 10.1046/j.1432-1327.1998.2520347.x; GODIN CS, 1986, TOXICOL LETT, V31, P23, DOI 10.1016/0378-4274(86)90190-6; GOLDEN JA, 1984, WESTERN J MED, V141, P613; HALLINE AG, 1989, BIOCHEM J, V259, P513, DOI 10.1042/bj2590513; HORN Y, 1987, EUR J CANCER CLIN ON, V23, P1103, DOI 10.1016/0277-5379(87)90141-6; Kee K, 2004, J BIOL CHEM, V279, P40076, DOI 10.1074/jbc.M406002200; Kim K, 2005, BIOCHEM BIOPH RES CO, V331, P78, DOI 10.1016/j.bbrc.2005.03.121; Merali S, 2000, J BIOL CHEM, V275, P14958, DOI 10.1074/jbc.275.20.14958; Merali S, 1996, J CHROMATOGR B, V675, P321, DOI 10.1016/0378-4347(95)00363-0; Merali S, 1996, ANTIMICROB AGENTS CH, V40, P973, DOI 10.1128/AAC.40.4.973; Merali S, 2000, ANTIMICROB AGENTS CH, V44, P337, DOI 10.1128/AAC.44.2.337-343.2000; MERALI S, 1995, ANTIMICROB AGENTS CH, V39, P1442, DOI 10.1128/AAC.39.7.1442; Movsas B, 1997, CHEST, V111, P1061, DOI 10.1378/chest.111.4.1061; OLSON JW, 1985, LIFE SCI, V37, P2165, DOI 10.1016/0024-3205(85)90567-3; OLSON JW, 1985, CARCINOGENESIS, V6, P1517, DOI 10.1093/carcin/6.10.1517; PAULSON YJ, 1992, CHEST, V101, P67, DOI 10.1378/chest.101.1.67; PEGG AE, 1984, BIOCHEM J, V224, P29, DOI 10.1042/bj2240029; SARIC M, 1994, ANTIMICROB AGENTS CH, V38, P2545, DOI 10.1128/AAC.38.11.2545; Shivji M, 2005, J BIOL CHEM, V280, P15219, DOI 10.1074/jbc.M413946200; Skelly M, 2003, LANCET, V361, P1267, DOI 10.1016/S0140-6736(03)12984-4; Skelly MJ, 2008, CLIN INFECT DIS, V46, P467, DOI 10.1086/525854; SMITH D, 1990, AIDS, V4, P1019, DOI 10.1097/00002030-199010000-00012; SMITH DE, 1992, AIDS, V6, P1489, DOI 10.1097/00002030-199212000-00011	28	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2008	283	12					7690	7696		10.1074/jbc.M709399200	http://dx.doi.org/10.1074/jbc.M709399200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	274JP	18180293	hybrid			2022-12-25	WOS:000253997900045
J	Hu, XQ; Peoples, RW				Hu, Xiang-Qun; Peoples, Robert W.			The 5-HT3B subunit confers spontaneous channel opening and altered ligand properties of the 5-HT3 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEROTONIN-RECEPTOR; GABA(A) RECEPTORS; AGONISM; BINDING; COEXPRESSION; SENSITIVITY; MODULATION; ACTIVATION; MICROSCOPY; INVERSE	Current receptor theory suggests that there is an equilibrium between the inactive ( R) and active (R*) conformations of ligand-gated ion channels and G protein-coupled receptors. The actions of ligands in both receptor types could be appropriately explained by this two-state model. Ligands such as agonists and antagonists affect receptor function by stabilizing one or both conformations. The 5-HT3 receptor is a member of the Cys-loop ligand-gated ion channel superfamily participating in synaptic transmission. Here we show that co-expression of the 5-HT3A and 5-HT3B receptor subunits in the human embryonic kidney (HEK) 293 cells results in a receptor that displays a low level of constitutive ( or agonist- independent) activity. Furthermore, we also demonstrate that the properties of ligands can be modified by receptor composition. Whereas the 5-hydroxytryptamine (5-HT) analog 5-methoxyindole is a partial agonist at the 5-HT3A receptor, it becomes a "protean agonist" ( functioning as an agonist and an inverse agonist at the same receptor) at the 5-HT3AB receptor ( after the Greek god Proteus, who was able to change his shape and appearance at will). In addition, the 5-HT analog 5-hydroxyindole is a positive allosteric modulator for the liganded active (AR*) conformation of the 5-HT3A and 5-HT3AB receptors and a negative allosteric modulator for the spontaneously active ( R*) conformation of the 5-HT3AB receptor, suggesting that the spontaneously active (R*) and liganded active ( AR*) conformations are differentially modulated by 5-hydroxyindole. Thus, the incorporation of the 5-HT3B subunit leads to spontaneous channel opening and altered ligand properties.	[Hu, Xiang-Qun; Peoples, Robert W.] Marquette Univ, Coll Hlth Sci, Dept Biomed Sci, Milwaukee, WI 53201 USA	Marquette University	Hu, XQ (corresponding author), Marquette Univ, Coll Hlth Sci, Dept Biomed Sci, POB 1881, Milwaukee, WI 53201 USA.	xiangqun.hu@marquette.edu			NIAAA NIH HHS [AA015203] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA015203] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Barrera NP, 2005, P NATL ACAD SCI USA, V102, P12595, DOI 10.1073/pnas.0503253102; Beckstead MJ, 2002, J NEUROCHEM, V82, P1343, DOI 10.1046/j.1471-4159.2002.01086.x; Bhattacharya A, 2004, J NEUROSCI, V24, P5537, DOI 10.1523/JNEUROSCI.5658-03.2004; Bianchi MT, 2001, J NEUROSCI, V21, P9083, DOI 10.1523/JNEUROSCI.21-23-09083.2001; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; COSTA T, 1989, P NATL ACAD SCI USA, V86, P7321, DOI 10.1073/pnas.86.19.7321; Davies PA, 1999, NATURE, V397, P359, DOI 10.1038/16941; de Ligt RAF, 2000, BRIT J PHARMACOL, V130, P1, DOI 10.1038/sj.bjp.0703311; DELCASTILLO J, 1957, PROC R SOC SER B-BIO, V146, P369; Dubin AE, 1999, J BIOL CHEM, V274, P30799, DOI 10.1074/jbc.274.43.30799; Farrant M, 2005, NAT REV NEUROSCI, V6, P215, DOI 10.1038/nrn1625; Gbahou F, 2003, P NATL ACAD SCI USA, V100, P11086, DOI 10.1073/pnas.1932276100; Grosman C, 2000, J GEN PHYSIOL, V115, P621, DOI 10.1085/jgp.115.5.621; Gunthorpe MJ, 1999, J PHYSIOL-LONDON, V519, P713, DOI 10.1111/j.1469-7793.1999.0713n.x; Hapfelmeier G, 2003, BIOPHYS J, V84, P1720, DOI 10.1016/S0006-3495(03)74980-7; Hayrapetyan V, 2005, MOL BRAIN RES, V142, P146, DOI 10.1016/j.molbraines.2005.09.011; Hu XQ, 2005, J PHYSIOL-LONDON, V568, P381, DOI 10.1113/jphysiol.2005.092866; Hu XQ, 2003, J BIOL CHEM, V278, P46583, DOI 10.1074/jbc.M308974200; Jones BL, 2006, J PHYSIOL-LONDON, V573, P571, DOI 10.1113/jphysiol.2006.106534; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P256, DOI 10.1016/S0165-6147(00)89037-9; Kenakin T, 2001, FASEB J, V15, P598, DOI 10.1096/fj.00-0438rev; KOOYMAN AR, 1993, BRIT J PHARMACOL, V108, P287, DOI 10.1111/j.1476-5381.1993.tb12795.x; LEFF P, 1995, TRENDS PHARMACOL SCI, V16, P89, DOI 10.1016/S0165-6147(00)88989-0; Lummis SCR, 2005, NATURE, V438, P248, DOI 10.1038/nature04130; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Neelands TR, 1999, MOL PHARMACOL, V55, P168, DOI 10.1124/mol.55.1.168; Solt K, 2005, J PHARMACOL EXP THER, V315, P771, DOI 10.1124/jpet.105.090621; Stevens R, 2005, J PHARMACOL EXP THER, V314, P338, DOI 10.1124/jpet.105.085076; Unwin N, 2003, FEBS LETT, V555, P91, DOI 10.1016/S0014-5793(03)01084-6; Urban JD, 2007, J PHARMACOL EXP THER, V320, P1, DOI 10.1124/jpet.106.104463; Zhang L, 2002, J BIOL CHEM, V277, P46256, DOI 10.1074/jbc.M207683200	32	35	37	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2008	283	11					6826	6831		10.1074/jbc.M707571200	http://dx.doi.org/10.1074/jbc.M707571200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HN	18187416	hybrid			2022-12-25	WOS:000253779600025
J	Huntley, B; Collingham, YC; Willis, SG; Green, RE				Huntley, Brian; Collingham, Yvonne C.; Willis, Stephen G.; Green, Rhys E.			Potential Impacts of Climatic Change on European Breeding Birds	PLOS ONE			English	Article								Background. Climatic change is expected to lead to changes in species' geographical ranges. Adaptation strategies for biodiversity conservation require quantitative estimates of the magnitude, direction and rates of these potential changes. Such estimates are of greatest value when they are made for large ensembles of species and for extensive (sub-continental or continental) regions. Methodology/Principal Findings. For six climate scenarios for 2070-99 changes have been estimated for 431 European breeding bird species using models relating species' distributions in Europe to climate. Mean range centroid potentially shifted 258-882 km in a direction between 341 degrees (NNW) and 45 degrees (NE), depending upon the climate scenario considered. Potential future range extent averaged 72-89% of the present range, and overlapped the present range by an average of 31-53% of the extent of the present range. Even if potential range changes were realised, the average number of species breeding per 50x50 km grid square would decrease by 6.8-23.2%. Many species endemic or near-endemic to Europe have little or no overlap between their present and potential future ranges; such species face an enhanced extinction risk as a consequence of climatic change. Conclusions/Significance. Although many human activities exert pressures upon wildlife, the magnitude of the potential impacts estimated for European breeding birds emphasises the importance of climatic change. The development of adaptation strategies for biodiversity conservation in the face of climatic change is an urgent need; such strategies must take into account quantitative evidence of potential climatic change impacts such as is presented here.	[Collingham, Yvonne C.; Willis, Stephen G.] Univ Durham, Sch Biol & Biomed Sci, Inst Ecosyst Sci, Durham, England; [Green, Rhys E.] Roy Soc Protect Birds, Conserv Sci Dept, Sandy, Beds, England; [Green, Rhys E.] Univ Cambridge, Dept Zool, Conservation Sci Grp, Cambridge, England	Durham University; Royal Society for Protection of Birds; University of Cambridge	Huntley, B (corresponding author), Univ Durham, Sch Biol & Biomed Sci, Inst Ecosyst Sci, Durham, England.	brian.huntley@durham.ac.uk; reg29@hermes.cam.ac.uk	Willis, Stephen G/F-8503-2015	Willis, Stephen G/0000-0002-8656-5808	UK Natural Environment Research Council; Royal Society for the Protection of Birds (RSPB); Royal Society - Wolfson Foundation Research Merit Award	UK Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Royal Society for the Protection of Birds (RSPB); Royal Society - Wolfson Foundation Research Merit Award	The research work reported was supported in part by a grant from the UK Natural Environment Research Council and in part by a contract from the Royal Society for the Protection of Birds (RSPB). During the preparation of the manuscript Prof. Brian Huntley was in receipt of financial support from a Royal Society - Wolfson Foundation Research Merit Award. The post of Prof. Rhys E. Green at Cambridge University also is funded by the RSPB. Nonetheless, the sponsors have played no direct role in the design or conduct of the study, nor in the interpretation of the data or the preparation, review or approval of the manuscript. Data relating to the European breeding distributions of birds were collected by the European Bird Census Council (EBCC), who made those data available to us to use in our work. The EBCC played no role in the research work nor in the preparation of this paper.	[Anonymous], 2000, SPECIAL REPORT EMISS; Araujo MB, 2006, J BIOGEOGR, V33, P1712, DOI 10.1111/j.1365-2699.2006.01482.x; Araujo MB, 2004, GLOBAL CHANGE BIOL, V10, P1618, DOI 10.1111/j.1365-2486.2004.00828.x; Araujo MB, 2007, TRENDS ECOL EVOL, V22, P42, DOI 10.1016/j.tree.2006.09.010; CLEVELAND WS, 1988, J AM STAT ASSOC, V83, P596, DOI 10.2307/2289282; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Cramer W., 1988, NORSK GEOGR TIDSSKR, V42, P149, DOI DOI 10.1080/00291958808552193; Cubasch U., 2001, PROJECTIONS FUTURE C, P525; Davis M., 1976, GEOSCIENCE MAN, V13, P13; Davis MB, 2005, ECOLOGY, V86, P1704, DOI 10.1890/03-0788; Gordon C, 2000, CLIM DYNAM, V16, P147, DOI 10.1007/s003820050010; Hagemeijer E.J.M., 1997, EBCC ATLAS EUROPEAN; Hannah L, 2007, FRONT ECOL ENVIRON, V5, P131, DOI 10.1890/1540-9295(2007)5[131:PANIAC]2.0.CO;2; Hickling R, 2006, GLOBAL CHANGE BIOL, V12, P450, DOI 10.1111/j.1365-2486.2006.01116.x; Hill JK, 2001, ECOL LETT, V4, P313, DOI 10.1046/j.1461-0248.2001.00222.x; HUNTLEY B, 1991, ANN BOT-LONDON, V67, P15, DOI 10.1093/oxfordjournals.aob.a088205; Huntley B, 2004, ECOL LETT, V7, P417, DOI 10.1111/j.1461-0248.2004.00598.x; Huntley B, 1995, J BIOGEOGR, V22, P967, DOI 10.2307/2845830; HUNTLEY B, 1989, J BIOGEOGR, V16, P5, DOI 10.2307/2845307; Huntley B, 2006, IBIS, V148, P8, DOI 10.1111/j.1474-919X.2006.00523.x; Huppop O, 2006, J ORNITHOL, V147, P344, DOI 10.1007/s10336-005-0049-x; JACOBSON GL, 1987, N AM ADJACENT OCEANS, P277; Knutson TR, 1999, J GEOPHYS RES-ATMOS, V104, P30981, DOI 10.1029/1999JD900965; Liu CR, 2005, ECOGRAPHY, V28, P385, DOI 10.1111/j.0906-7590.2005.03957.x; McLachlan JS, 2005, ECOLOGY, V86, P2088, DOI 10.1890/04-1036; METZ CE, 1978, SEMIN NUCL MED, V8, P283, DOI 10.1016/S0001-2998(78)80014-2; Midgley GF, 2002, GLOBAL ECOL BIOGEOGR, V11, P445, DOI 10.1046/j.1466-822X.2002.00307.x; Mila B, 2006, EVOLUTION, V60, P2403; New M, 1999, J CLIMATE, V12, P829, DOI 10.1175/1520-0442(1999)012<0829:RTCSTC>2.0.CO;2; Parmesan C, 2003, NATURE, V421, P37, DOI 10.1038/nature01286; Parmesan C, 2006, ANNU REV ECOL EVOL S, V37, P637, DOI 10.1146/annurev.ecolsys.37.091305.110100; Pearson RG, 2006, J BIOGEOGR, V33, P1704, DOI 10.1111/j.1365-2699.2006.01460.x; PIGOTT CD, 1981, ANN BOT FENN, V18, P255; PIGOTT CD, 1993, J ECOL, V81, P557, DOI 10.2307/2261534; PIGOTT CD, 1981, NEW PHYTOL, V87, P817, DOI 10.1111/j.1469-8137.1981.tb01716.x; PIGOTT CD, 1975, WEATHER, V30, P82; Roeckner E, 1996, CLIM DYNAM, V12, P737, DOI 10.1007/s003820050140; Ruegg KC, 2002, P ROY SOC B-BIOL SCI, V269, P1375, DOI 10.1098/rspb.2002.2032; SHIPLEY JW, 2000, CAUSE CORRELATION BI; SODANO EM, 1963, DIRECT INVERSE SOLUT; SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615; Thomas CD, 2004, NATURE, V427, P145, DOI 10.1038/nature02121; Thuiller W, 2003, GLOBAL CHANGE BIOL, V9, P1353, DOI 10.1046/j.1365-2486.2003.00666.x; Thuiller W, 2006, GLOBAL CHANGE BIOL, V12, P424, DOI 10.1111/j.1365-2486.2006.01115.x; VANDENBOSCH F, 1992, J BIOGEOGR, V19, P135, DOI 10.2307/2845500; Warren MS, 2001, NATURE, V414, P65, DOI 10.1038/35102054; Williams P, 2005, CONSERV BIOL, V19, P1063, DOI 10.1111/j.1523-1739.2005.00080.x	47	192	200	0	87	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2008	3	1							e1439	10.1371/journal.pone.0001439	http://dx.doi.org/10.1371/journal.pone.0001439			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SN	18197250	Green Published, Green Submitted, Green Accepted, gold			2022-12-25	WOS:000260503800011
J	Eliseev, RA; Dong, YF; Sampson, E; Zuscik, MJ; Schwarz, EM; O'Keefe, RJ; Rosier, RN; Drissi, MH				Eliseev, R. A.; Dong, Y-F; Sampson, E.; Zuscik, M. J.; Schwarz, E. M.; O'Keefe, R. J.; Rosier, R. N.; Drissi, M. H.			Runx2-mediated activation of the Bax gene increases osteosarcoma cell sensitivity to apoptosis	ONCOGENE			English	Article						Runx2; Bax; osteosarcoma; apoptosis	TUMOR-SUPPRESSOR; OSTEOBLAST DIFFERENTIATION; GASTRIC-CANCER; TRANSCRIPTIONAL ACTIVATOR; INDUCE APOPTOSIS; RUNX3; GROWTH; DEATH; EXPRESSION; PROTEINS	The Runx family of transcription factors regulate cell growth and differentiation, and control the expression of target genes involved in cell fate decisions. We examined the role of the bone-related member of this family, Runx2, in regulating apoptosis via modulation of the Bcl2 family of genes in the osteosarcoma cell line Saos2. Our data demonstrate that Runx2 directly binds to two Runx-specific regulatory elements on the human bax promoter thereby inducing Bax expression. Furthermore, bone morphogenetic protein-induced or vector-mediated expression of Runx2 resulted in upregulation of Bax expression, and subsequent increased sensitivity of Saos2 cells to apoptosis. Finally, the observed upregulation of Bax expression and increased apoptosis were Runx2 dependent as Runx2 loss of function abrogated these effects. Our study provides the first evidence for Bax as a direct target of Runx2, suggesting that Runx2 may act as a proapoptotic factor in osteosarcoma cells.	[Drissi, M. H.] Univ Connecticut, Ctr Hlth, Dept Orthopaed, New England Musculoskeletal Inst,MARB, Farmington, CT 06034 USA; [Eliseev, R. A.; Dong, Y-F; Sampson, E.; Zuscik, M. J.; Schwarz, E. M.; O'Keefe, R. J.; Rosier, R. N.] Univ Rochester, Med Ctr, Ctr Musculoskeletal Res, Dept Orthopaed, Rochester, NY 14642 USA	University of Connecticut; University of Rochester	Drissi, MH (corresponding author), Univ Connecticut, Ctr Hlth, Dept Orthopaed, New England Musculoskeletal Inst,MARB, Suite 4048,263 Farmington Ave, Farmington, CT 06034 USA.	Drissi@UCHC.edu		drissi, hicham/0000-0002-3322-281X; Zuscik, Michael/0000-0003-0461-8708	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR052674] Funding Source: NIH RePORTER; NIAMS NIH HHS [R0-1 AR-052674-01, R01 AR052674] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Antignani A, 2006, CURR OPIN CELL BIOL, V18, P685, DOI 10.1016/j.ceb.2006.10.004; Bae SC, 2006, GENE, V366, P58, DOI 10.1016/j.gene.2005.10.017; Bae SC, 2004, ONCOGENE, V23, P4336, DOI 10.1038/sj.onc.1207286; Barnes GL, 2003, CANCER RES, V63, P2631; Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607; Brubaker KD, 2003, PROSTATE, V56, P13, DOI 10.1002/pros.10233; Cande C, 2002, BIOCHIMIE, V84, P215, DOI 10.1016/S0300-9084(02)01374-3; Coffman JA, 2003, CELL BIOL INT, V27, P315, DOI 10.1016/S1065-6995(03)00018-0; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Drissi H, 2002, J CELL BIOCHEM, V86, P403, DOI 10.1002/jcb.10238; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Fukuda N, 2006, ONCOGENE, V25, P3509, DOI 10.1038/sj.onc.1209393; Galindo M, 2005, J BIOL CHEM, V280, P20274, DOI 10.1074/jbc.M413665200; Guo WH, 2002, ONCOGENE, V21, P8351, DOI 10.1038/sj.onc.1206037; Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; Komori T, 2003, J BONE MINER METAB, V21, P193, DOI 10.1007/s00774-002-0408-0; Lee JS, 2006, J BONE MINER RES, V21, P921, DOI 10.1359/JBMR.060303; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; MIYASHITA T, 1995, CELL, V80, P293; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Noda M, 2006, J PHARMACOL SCI, V100, P211, DOI 10.1254/jphs.FMJ05004X6; NUNEZ G, 1989, P NATL ACAD SCI USA, V86, P4589, DOI 10.1073/pnas.86.12.4589; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Pratap J, 2003, CANCER RES, V63, P5357; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Reed JC, 2006, CELL DEATH DIFFER, V13, P1378, DOI 10.1038/sj.cdd.4401975; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Thomas DM, 2004, J CELL BIOL, V167, P925, DOI 10.1083/jcb.200409187; Torquati A, 2004, SURGERY, V136, P310, DOI 10.1016/j.surg.2004.05.005; van Gurp M, 2003, BIOCHEM BIOPH RES CO, V304, P487, DOI 10.1016/S0006-291X(03)00621-1; van Wijnen AJ, 2004, ONCOGENE, V23, P4209, DOI 10.1038/sj.onc.1207758; Vogiatzi P, 2006, CANCER BIOL THER, V5, P371, DOI 10.4161/cbt.5.4.2748; Wang LL, 2005, CANCER J, V11, P294, DOI 10.1097/00130404-200507000-00005; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Yano T, 2006, MOL CELL BIOL, V26, P4474, DOI 10.1128/MCB.01926-05	43	55	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2008	27	25					3605	3614		10.1038/sj.onc.1211020	http://dx.doi.org/10.1038/sj.onc.1211020			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18223689	Green Accepted			2022-12-25	WOS:000256468500012
J	Tarry-Adkins, JL; Martin-Gronert, MS; Chen, JH; Cripps, RL; Ozanne, SE				Tarry-Adkins, J. L.; Martin-Gronert, M. S.; Chen, J. -H.; Cripps, R. L.; Ozanne, S. E.			Maternal diet influences DNA damage, aortic telomere length, oxidative stress, and antioxidant defense capacity in rats	FASEB JOURNAL			English	Article						developmental programming; aging; aorta	SINGLE-STRAND BREAKS; FOR-GESTATIONAL-AGE; LOW-PROTEIN-DIET; SUPEROXIDE-DISMUTASE; CARDIOVASCULAR-DISEASE; ENDOTHELIAL FUNCTION; ADHESION MOLECULE-1; ADULT LIFE; RESTRICTION; GROWTH	Low birth weight is associated with increased cardiovascular disease (CVD) in humans. Detrimental effects of low birth weight are amplified by rapid catch-up growth. Conversely, slow growth during lactation reduces CVD risk. Gestational protein restriction causes low birth weight, vascular dysfunction, and accelerated aging in rats. Atherosclerotic aortic tissue has shortened telomeres, and oxidative stress accelerates telomere shortening through generation of DNA single-strand breaks (ssbs). This study tested the hypothesis that maternal diet influences aortic telomere length through changes in DNA ssbs, antioxidant capacity, and oxidative stress. We used our models of gestational protein restriction followed by rapid catch-up growth (the recuperated group) and protein restriction during lactation (the postnatal low-protein [PLP] group). Southern blotting revealed fewer aortic DNA ssbs and subsequently fewer short telomeres (P < 0.05) in the PLP group. This result was associated with reduced ( P < 0.01) 8-hydroxy-2-deoxyguanosine, a marker of oxidative stress. PLP animals expressed increased (P < 0.01) manganese superoxide-dismutase, copper-zinc superoxide-dismutase, catalase, and glutathione-reductase. Age-dependent changes in antioxidant defense enzymes indicated more protection to oxidative stress in the PLP animals; conversely, recuperated animals demonstrated age-associated impairment of antioxidant defenses. We conclude that maternal diet has a major influence on aortic telomere length. This finding may provide a mechanistic link between early growth patterns and CVD.	[Tarry-Adkins, J. L.; Martin-Gronert, M. S.; Chen, J. -H.; Cripps, R. L.; Ozanne, S. E.] Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Cambridge CB2 2QR, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Tarry-Adkins, JL (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Box 232,Hills Rd, Cambridge CB2 2QR, England.	janeadkins@googlemail.com		Ozanne, Susan/0000-0001-8753-5144	Biotechnology and Biological Sciences Research Council [BB/E002161/1, BB/D007909/1, BB/E00797X/1] Funding Source: Medline; British Heart Foundation Funding Source: Medline; BBSRC [BB/D007909/1, BB/E002161/1, BB/E00797X/1] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); British Heart Foundation(British Heart Foundation); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Aviv H, 2001, ATHEROSCLEROSIS, V159, P281, DOI 10.1016/S0021-9150(01)00506-8; Baird DM, 2004, ANN NY ACAD SCI, V1019, P265, DOI 10.1196/annals.1297.044; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; Bennett MR, 2002, ARTERIOSCL THROM VAS, V22, P713, DOI 10.1161/01.ATV.0000019008.18226.C3; Brawley L., 2003, Archives of Physiology and Biochemistry, V111, P23, DOI 10.1076/apab.111.1.23.15138; Cambonie G, 2007, AM J PHYSIOL-REG I, V292, pR1236, DOI 10.1152/ajpregu.00227.2006; Castello L, 2005, FASEB J, V19, P1863, DOI 10.1096/fj.04-2864fje; Celli GB, 2006, NAT CELL BIOL, V8, P885, DOI 10.1038/ncb1444; CHANG E, 1995, P NATL ACAD SCI USA, V92, P11190, DOI 10.1073/pnas.92.24.11190; Chen JH, 2007, NUCLEIC ACIDS RES, V35, P7417, DOI 10.1093/nar/gkm681; Cooke CLM, 2003, CARDIOVASC RES, V60, P635, DOI 10.1016/j.cardiores.2003.08.011; Corstius HB, 2005, PEDIATR RES, V57, P796, DOI 10.1203/01.PDR.0000157726.65492.CD; Cutler RG, 2005, REJUV RES, V8, P138, DOI 10.1089/rej.2005.8.138; di Fagagna FD, 2001, CURR BIOL, V11, P1192, DOI 10.1016/S0960-9822(01)00328-1; Didion SP, 2006, HYPERTENSION, V48, P1072, DOI 10.1161/01.HYP.0000247302.20559.3a; Dwivedi VK, 2006, J ENZYM INHIB MED CH, V21, P43, DOI 10.1080/14756360500286070; Eriksson JG, 2002, ANN MED, V34, P157, DOI 10.1080/713782141; Forgione MA, 2002, CIRCULATION, V106, P1154, DOI 10.1161/01.CIR.0000026820.87824.6A; Franco MDP, 2003, CARDIOVASC RES, V59, P767, DOI 10.1016/S0008-6363(03)00461-9; Halliwell B, 1999, FREE RADICAL RES, V31, P261, DOI 10.1080/10715769900300841; Harder T, 2005, AM J EPIDEMIOL, V162, P397, DOI 10.1093/aje/kwi222; Honda S, 2001, INVEST OPHTH VIS SCI, V42, P2139; Jennings BJ, 1999, FEBS LETT, V448, P4, DOI 10.1016/S0014-5793(99)00336-1; Ju YJ, 2006, EXP MOL MED, V38, P686, DOI 10.1038/emm.2006.81; Kajstura J, 2000, AM J PATHOL, V156, P813, DOI 10.1016/S0002-9440(10)64949-8; Lee HC, 2007, EXP BIOL MED, V232, P592; Leeson CPM, 2001, CIRCULATION, V103, P1264; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Lim KJ, 2006, PEDIATR RES, V60, P83, DOI 10.1203/01.pdr.0000220361.08181.c3; Lin SJ, 2005, ARTERIOSCL THROM VAS, V25, P334, DOI 10.1161/01.ATV.0000152114.00114.d8; Mohn A, 2007, J CLIN ENDOCR METAB, V92, P1372, DOI 10.1210/jc.2006-1344; Okuda K, 2000, ATHEROSCLEROSIS, V152, P391, DOI 10.1016/S0021-9150(99)00482-7; Rich-Edwards JW, 2004, EPIDEMIOLOGY, V15, P550, DOI 10.1097/01.ede.0000129513.69321.ba; Ridker PM, 1998, LANCET, V351, P88, DOI 10.1016/S0140-6736(97)09032-6; Sambrook J, 1989, MOL CLONING LAB MANU, pE3; Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653; Shen X, 2006, DIABETES, V55, P798, DOI 10.2337/diabetes.55.03.06.db05-1039; Singhal A, 2004, CIRCULATION, V109, P1108, DOI 10.1161/01.CIR.0000118500.23649.DF; Singhal A, 2004, LANCET, V363, P1571, DOI 10.1016/S0140-6736(04)16198-9; Singhal A, 2007, CIRCULATION, V115, P213, DOI 10.1161/CIRCULATIONAHA.106.617811; Skilton MR, 2006, CLIN SCI, V111, P281, DOI 10.1042/CS20060036; SNOECK A, 1990, BIOL NEONATE, V57, P107, DOI 10.1159/000243170; STARR JM, EXP GERONTOL, V6, P571; Tarry-Adkins JL, 2007, AM J PHYSIOL-REG I, V293, pR1259, DOI 10.1152/ajpregu.00231.2007; Tarry-Adkins JL, 2006, AM J PHYSIOL-RENAL, V290, pF509, DOI 10.1152/ajprenal.00215.2005; Tsukahara H, 2007, CURR MED CHEM, V14, P339, DOI 10.2174/092986707779941177; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Van Remmen H, 2003, PHYSIOL GENOMICS, V16, P29, DOI 10.1152/physiolgenomics.00122.2003; Von Zglinicki T, 2000, FREE RADICAL BIO MED, V28, P64, DOI 10.1016/S0891-5849(99)00207-5; von Zglinicki T, 2002, TRENDS BIOCHEM SCI, V27, P339, DOI 10.1016/S0968-0004(02)02110-2; Zou Y, 2003, FASEB J, V17, P320, DOI 10.1096/fj.03-0849fje	51	114	116	1	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					2037	2044		10.1096/fj.07-099523	http://dx.doi.org/10.1096/fj.07-099523			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18230683				2022-12-25	WOS:000256352700042
J	Ceradini, DJ; Yao, DC; Grogan, RH; Callaghan, MJ; Edelstein, D; Brownlee, M; Gurtner, GC				Ceradini, Daniel J.; Yao, Dachun; Grogan, Raymon H.; Callaghan, Matthew J.; Edelstein, Diane; Brownlee, Michael; Gurtner, Geoffrey C.			Decreasing intracellular superoxide corrects defective ischemia-induced new vessel formation in diabetic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; ENDOTHELIAL PROGENITOR CELLS; ADVANCED GLYCATION; ANGIOGENESIS; RECRUITMENT; PROTEINS; HYPOXIA; PROLIFERATION; MOBILIZATION; PROMOTER	Tissue ischemia promotes vasculogenesis through chemokine-induced recruitment of bone marrow-derived endothelial progenitor cells (EPCs). Diabetes significantly impairs this process. Because hyperglycemia increases reactive oxygen species in a number of cell types, and because many of the defects responsible for impaired vasculogenesis involve HIF1-regulated genes, we hypothesized that HIF1 function is impaired in diabetes because of reactive oxygen species-induced modification of HIF1 alpha by the glyoxalase 1 (GLO1) substrate methylglyoxal. Decreasing superoxide in diabetic mice by either transgenic expression of manganese superoxide dismutase or by administration of an superoxide dismutase mimetic corrected post-ischemic defects in neovascularization, oxygen delivery, and chemokine expression, and normalized tissue survival. In hypoxic fibroblasts cultured in high glucose, overexpression of GLO1 prevented reduced expression of both the EPC mobilizing chemokine stromal cell-derived factor-1 (SDF-1) and of vascular epidermal growth factor, which modulates growth and differentiation of recruited EPCs. In hypoxic EPCs cultured in high glucose, overexpression of GLO1 prevented reduced expression of both the SDF-1 receptor CXCR4, and endothelial nitric-oxide synthase, an enzyme essential for EPC mobilization. HIF1 alpha modification by methylglyoxal reduced heterodimer formation and HIF1 alpha binding to all relevant promoters. These results provide a basis for the rational design of new therapeutics to normalize impaired ischemia-induced vasculogenesis in patients with diabetes.	[Ceradini, Daniel J.; Grogan, Raymon H.; Callaghan, Matthew J.; Gurtner, Geoffrey C.] Stanford Univ, Sch Med, Dept Surg, Stanford, CA 94305 USA; [Yao, Dachun; Edelstein, Diane; Brownlee, Michael] Albert Einstein Coll Med, Int Ctr Diabet Complicat Res, JDRF, Bronx, NY 10461 USA	Stanford University; Yeshiva University; Albert Einstein College of Medicine	Brownlee, M (corresponding author), 1300 Morris Pk Ave, Bronx, NY 10461 USA.	brownlee@aecom.yu.edu	/ABE-5226-2021		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK074153, R01DK074095] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK74153-01, R01 DK74095-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abaci A, 1999, CIRCULATION, V99, P2239, DOI 10.1161/01.CIR.99.17.2239; Ahmed N, 2005, J BIOL CHEM, V280, P5724, DOI 10.1074/jbc.M410973200; Ahmed N, 2002, BIOCHEM J, V364, P1; Ahmed N, 2003, BIOCHEM SOC T, V31, P1417; Aicher A, 2003, NAT MED, V9, P1370, DOI 10.1038/nm948; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; Awad O, 2005, STEM CELLS, V23, P575, DOI 10.1634/stemcells.2004-0185; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Ceradini DJ, 2005, TRENDS CARDIOVAS MED, V15, P57, DOI 10.1016/j.tcm.2005.02.002; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Chakraborty S, 2001, J CELL BIOCHEM, V82, P310, DOI 10.1002/jcb.1165; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; Coulet F, 2003, J BIOL CHEM, V278, P46230, DOI 10.1074/jbc.M305420200; Dimmeler S, 2001, J CLIN INVEST, V108, P391, DOI 10.1172/JCI200113152; Du XL, 2001, J CLIN INVEST, V108, P1341, DOI 10.1172/JCI11235; Fingerman IM, 2004, CELL, V117, P690, DOI 10.1016/j.cell.2004.05.021; Galasso G, 2006, CIRC RES, V98, P254, DOI 10.1161/01.RES.0000200740.57764.52; Gallagher KA, 2007, J CLIN INVEST, V117, P1249, DOI 10.1172/JCI29710; Hart GW, 2007, NATURE, V446, P1017, DOI 10.1038/nature05815; Kaelin WG, 2005, ANNU REV BIOCHEM, V74, P115, DOI 10.1146/annurev.biochem.74.082803.133142; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Michel G, 2002, BBA-GENE STRUCT EXPR, V1578, P73, DOI 10.1016/S0167-4781(02)00484-0; Rivard A, 1999, AM J PATHOL, V154, P355, DOI 10.1016/S0002-9440(10)65282-0; Schatteman GC, 2000, J CLIN INVEST, V106, P571, DOI 10.1172/JCI9087; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Tepper OM, 2005, BLOOD, V105, P1068, DOI 10.1182/blood-2004-03-1051; Tepper OM, 2002, CIRCULATION, V106, P2781, DOI 10.1161/01.CIR.0000039526.42991.93; Yao D, 2007, J BIOL CHEM, V282, P31038, DOI 10.1074/jbc.M704703200; YAROM R, 1992, J PATHOL, V166, P265, DOI 10.1002/path.1711660308	30	180	194	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10930	10938		10.1074/jbc.M707451200	http://dx.doi.org/10.1074/jbc.M707451200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18227068	Green Published, hybrid			2022-12-25	WOS:000254894700074
J	Schar, CR; Blouse, GE; Minor, KH; Peterson, CB				Schar, Christine R.; Blouse, Grant E.; Minor, Kenneth H.; Peterson, Cynthia B.			A deletion mutant of vitronectin lacking the somatomedin B domain exhibits residual plasminogen activator inhibitor-1-binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIZE-DISTRIBUTION ANALYSIS; UROKINASE RECEPTOR; INHIBITOR TYPE-1; SELF-ASSOCIATION; BINDING-SITES; STRUCTURAL REQUIREMENTS; 3-DIMENSIONAL STRUCTURE; MULTIMERIC VITRONECTIN; HEPARIN-BINDING; CELL-MIGRATION	Vitronectin and plasminogen activator inhibitor-1 (PAI-1) are important physiological binding partners that work in concert to regulate cellular adhesion, migration, and fibrinolysis. The high affinity binding site for PAI-1 is located within the N-terminal somatomedin B domain of vitronectin; however, several studies have suggested a second PAI-1-binding site within vitronectin. To investigate this secondary site, a vitronectin mutant lacking the somatomedin B domain (r Delta sBVN) was engineered. The short deletion had no effect on heparin-binding, integrin-binding, or cellular adhesion. Binding to the urokinase receptor was completely abolished while PAI-1 binding was still observed, albeit with a lower affinity. Analytical ultracentrifugation on the PAI-1-vitronectin complex demonstrated that increasing NaCl concentration favors 1:1 versus 2:1 PAI-1-vitronectin complexes and hampers formation of higher order complexes, pointing to the contribution of charge-charge interactions for PAI-1 binding to the second site. Furthermore, fluorescence resonance energy transfer between differentially labeled PAI-1 molecules confirmed that two independent molecules of PAI-1 are capable of binding to vitronectin. These results support a model for the assembly of higher order PAI-1-vitronectin complexes via two distinct binding sites in both proteins.	[Schar, Christine R.; Minor, Kenneth H.; Peterson, Cynthia B.] Univ Tennessee, Dept Biochem Cellular & Mol Biol, Knoxville, TN 37996 USA; [Blouse, Grant E.] Univ Aarhus, Dept Mol & Struct Biol, Lab Cellular Protein Sci, DK-8000 Aarhus, Denmark	University of Tennessee System; University of Tennessee Knoxville; Aarhus University	Peterson, CB (corresponding author), Univ Tennessee, Dept Biochem Cellular & Mol Biol, M407 Walters Life Sci Bldg, Knoxville, TN 37996 USA.	cynthia_peterson@utk.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL050676, R01HL050676] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50676] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREASEN PA, 1986, FEBS LETT, V209, P213, DOI 10.1016/0014-5793(86)81113-9; BAKER D, 1994, BIOCHEMISTRY-US, V33, P7505, DOI 10.1021/bi00190a002; BERKENPAS MB, 1995, EMBO J, V14, P2969, DOI 10.1002/j.1460-2075.1995.tb07299.x; BITTORF SV, 1993, J BIOL CHEM, V268, P24838; CHAIN D, 1991, FEBS LETT, V285, P251, DOI 10.1016/0014-5793(91)80810-P; Czekay RP, 2003, J CELL BIOL, V160, P781, DOI 10.1083/jcb.200208117; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; Deng G, 1996, J BIOL CHEM, V271, P12716, DOI 10.1074/jbc.271.22.12716; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Devy L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0552com; GECHTMAN Z, 1993, FEBS LETT, V315, P293, DOI 10.1016/0014-5793(93)81181-X; Gibson A, 1997, J BIOL CHEM, V272, P5112, DOI 10.1074/jbc.272.8.5112; Gibson AD, 2001, BBA-PROTEIN STRUCT M, V1545, P289, DOI 10.1016/S0167-4838(00)00290-9; Hagglof P, 2004, J MOL BIOL, V335, P823, DOI 10.1016/j.jmb.2003.11.005; HOLMES R, 1967, J CELL BIOL, V32, P297, DOI 10.1083/jcb.32.2.297; Horn NA, 2004, J BIOL CHEM, V279, P35867, DOI 10.1074/jbc.M405716200; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; IZUMI M, 1988, CELL STRUCT FUNCT, V13, P217, DOI 10.1247/csf.13.217; Jensen JK, 2004, FEBS LETT, V556, P175, DOI 10.1016/S0014-5793(03)01405-4; Jensen JK, 2002, FEBS LETT, V521, P91, DOI 10.1016/S0014-5793(02)02830-2; Kamikubo Y, 2006, BIOCHEMISTRY-US, V45, P3297, DOI 10.1021/bi052278f; Kamikubo Y, 2004, BIOCHEMISTRY-US, V43, P6519, DOI 10.1021/bi049647c; Kamikubo Y, 2002, J BIOL CHEM, V277, P27109, DOI 10.1074/jbc.M200354200; Kanse SM, 1996, EXP CELL RES, V224, P344, DOI 10.1006/excr.1996.0144; Kjaergaard M, 2007, PROTEIN SCI, V16, P1934, DOI 10.1110/ps.072949607; KOST C, 1992, J BIOL CHEM, V267, P12098; Lakowicz J.R, 1999, PRINCIPLES FLUORESCE, P368; Lambert V, 2003, INVEST OPHTH VIS SCI, V44, P2791, DOI 10.1167/iovs.02-1179; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; Lawrence DA, 1997, J BIOL CHEM, V272, P7676, DOI 10.1074/jbc.272.12.7676; Li XQ, 2007, J BIOL CHEM, V282, P5318, DOI 10.1074/jbc.M611396200; Lynn GW, 2005, BIOCHEMISTRY-US, V44, P565, DOI 10.1021/bi048347s; Mayasundari A, 2004, J BIOL CHEM, V279, P29359, DOI 10.1074/jbc.M401279200; MIMURO J, 1993, BIOCHEMISTRY-US, V32, P2314, DOI 10.1021/bi00060a024; Minor KH, 2005, J BIOL CHEM, V280, P28711, DOI 10.1074/jbc.M500478200; Minor KH, 2002, J BIOL CHEM, V277, P10337, DOI 10.1074/jbc.M109564200; Mondino Anna, 1999, Thrombosis and Haemostasis, V82, P19; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; Okumura Y, 2002, J BIOL CHEM, V277, P9395, DOI 10.1074/jbc.M111225200; Olson ST, 2001, BIOCHEMISTRY-US, V40, P11742, DOI 10.1021/bi0107290; Peterson CB, 1998, TRENDS CARDIOVAS MED, V8, P124, DOI 10.1016/S1050-1738(97)00136-9; PETERSON CB, 1987, J BIOL CHEM, V262, P7567; PHILLIPS DR, 1988, BLOOD, V71, P831; Podor TJ, 2002, J BIOL CHEM, V277, P7520, DOI 10.1074/jbc.M109677200; Podor TJ, 2000, J BIOL CHEM, V275, P25402, DOI 10.1074/jbc.M000362200; PREISSNER KT, 1990, J BIOL CHEM, V265, P18490; PREISSNER KT, 1986, EUR J BIOCHEM, V156, P645, DOI 10.1111/j.1432-1033.1986.tb09626.x; Rich RL, 2001, J MOL RECOGNIT, V14, P223, DOI 10.1002/jmr.535; Royle G, 2001, ANAL BIOCHEM, V296, P245, DOI 10.1006/abio.2001.5316; Schuck P, 2002, BIOPHYS J, V82, P1096, DOI 10.1016/S0006-3495(02)75469-6; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Schvartz I, 2002, BIOCHEM BIOPH RES CO, V290, P682, DOI 10.1006/bbrc.2001.6273; Seger D, 1998, J BIOL CHEM, V273, P24805, DOI 10.1074/jbc.273.38.24805; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SEIFFERT D, 1994, J BIOL CHEM, V269, P2659; Seiffert D, 1996, J BIOL CHEM, V271, P29644, DOI 10.1074/jbc.271.47.29644; SEIFFERT D, 1991, BIOCHIM BIOPHYS ACTA, V1078, P23, DOI 10.1016/0167-4838(91)90087-G; SHARP AM, 1999, STRUCT FOLD DES, V7; Sidenius N, 2002, J BIOL CHEM, V277, P27982, DOI 10.1074/jbc.M111736200; Sivasothy P, 2000, J BIOL CHEM, V275, P33663, DOI 10.1074/jbc.M004054200; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; STOCKMANN A, 1993, J BIOL CHEM, V268, P22874; Stoop AA, 2001, J MOL BIOL, V305, P773, DOI 10.1006/jmbi.2000.4356; Stout TJ, 2000, BIOCHEMISTRY-US, V39, P8460, DOI 10.1021/bi000290w; STRATIKOS E, 1997, P NATL ACAD SCI US, V94; THIAGARAJAN P, 1988, J BIOL CHEM, V263, P3035; Waltz DA, 1997, J CLIN INVEST, V100, P58, DOI 10.1172/JCI119521; WALTZ DA, 1994, J BIOL CHEM, V269, P14746; Wilkins-Port CE, 2003, CELL COMMUN ADHES, V10, P85, DOI 10.1080/714040415; Xu D, 2001, PROTEINS, V44, P312, DOI 10.1002/prot.1096; Yoneda A, 1998, BIOCHEMISTRY-US, V37, P6351, DOI 10.1021/bi972247n; ZHAO Y, 1993, ARCH BIOCHEM BIOPHYS, V304, P434, DOI 10.1006/abbi.1993.1372; Zhou AW, 2007, PROTEIN SCI, V16, P1502, DOI 10.1110/ps.072819107; Zhou AW, 2003, NAT STRUCT BIOL, V10, P541, DOI 10.1038/nsb943; Zhuang P, 1997, J BIOL CHEM, V272, P6858, DOI 10.1074/jbc.272.11.6858	75	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2008	283	16					10297	10309		10.1074/jbc.M708017200	http://dx.doi.org/10.1074/jbc.M708017200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	287CQ	18174166	Green Published, hybrid			2022-12-25	WOS:000254894700010
J	Simon, GM; Cravatt, BF				Simon, Gabriel M.; Cravatt, Benjamin F.			Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho-n-acyl ethanolamine precursors in mouse brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID AMIDES; MOLECULAR CHARACTERIZATION; CANNABINOID RECEPTOR; PATHWAY; PHOSPHATIDYLETHANOLAMINE; PHOSPHOLIPIDS; METABOLISM; CONGENERS	Anandamide (AEA) is an endogenous ligand of cannabinoid receptors and a well characterized mediator of many physiological processes including inflammation, pain, and appetite. The biosynthetic pathway(s) for anandamide and its N-acyl ethanolamine (NAE) congeners remain enigmatic. Previously, we proposed an enzymatic route for producing NAEs that involves the double-O-deacylation of N-acyl phosphatidylethanolamines (NAPEs) by alpha/beta-hydrolase 4 (ABDH4 or Abh4) to form glycerophospho (GP)-NAEs, followed by conversion of these intermediates to NAEs by an unidentified phosphodiesterase. Here, we report the detection and measurement of GP-NAEs, including the anandamide precursor glycerophospho-N-arachidonoylethanolamine (GP-NArE), as endogenous constituents of mouse brain tissue. Inhibition of the phosphodiesterase-mediated degradation of GP-NAEs ex vivo resulted in a striking accumulation of these lipids in brain extracts, suggesting a rapid endogenous flux through this pathway. Furthermore, we identify the glycerophosphodiesterase GDE1, also known as MIR16, as a broadly expressed membrane enzyme with robust GP-NAE phosphodiesterase activity. Together, these data provide evidence for a multistep pathway for the production of anandamide in the nervous system by the sequential actions of Abh4 and GDE1.	[Simon, Gabriel M.; Cravatt, Benjamin F.] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; [Simon, Gabriel M.; Cravatt, Benjamin F.] Scripps Res Inst, Dept Physiol Chem, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Cravatt, BF (corresponding author), 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	cravatt@scripps.edu			NIDA NIH HHS [R01 DA015197-06, R01 DA015197, DA 015197, P01 DA017259-05, DA 017259, P01 DA017259] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA015197, P01DA017259] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Almaguer C, 2006, CURR GENET, V50, P367, DOI 10.1007/s00294-006-0096-8; BACHUR NR, 1965, J BIOL CHEM, V240, P1019; Bifulco M, 2007, MOL PHARMACOL, V71, P1445, DOI 10.1124/mol.106.033118; Cadas H, 1997, J NEUROSCI, V17, P1226; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Hansen HH, 2000, J NEUROCHEM, V75, P861, DOI 10.1046/j.1471-4159.2000.0750861.x; Jin XH, 2007, J BIOL CHEM, V282, P3614, DOI 10.1074/jbc.M606369200; Kathuria S, 2003, NAT MED, V9, P76, DOI 10.1038/nm803; KUEHL FA, 1957, J AM CHEM SOC, V79, P5577, DOI 10.1021/ja01577a066; Leung D, 2006, BIOCHEMISTRY-US, V45, P4720, DOI 10.1021/bi060163l; Liu J, 2008, NEUROPHARMACOLOGY, V54, P1, DOI 10.1016/j.neuropharm.2007.05.020; Liu J, 2006, P NATL ACAD SCI USA, V103, P13345, DOI 10.1073/pnas.0601832103; NATARAJAN V, 1982, BIOCHIM BIOPHYS ACTA, V712, P342, DOI 10.1016/0005-2760(82)90352-6; Nogusa Y, 2004, GENE, V337, P173, DOI 10.1016/j.gene.2004.04.026; Okamoto Y, 2004, J BIOL CHEM, V279, P5298, DOI 10.1074/jbc.M306642200; Okamoto Y, 2007, CHEM BIODIVERS, V4, P1842, DOI 10.1002/cbdv.200790155; Patton-Vogt J, 2007, BBA-MOL CELL BIOL L, V1771, P337, DOI 10.1016/j.bbalip.2006.04.013; Rao M, 2005, SCIENCE, V309, P2212, DOI 10.1126/science.1117156; Simon GM, 2006, J BIOL CHEM, V281, P26465, DOI 10.1074/jbc.M604660200; Sugiura T, 1996, BIOCHEM BIOPH RES CO, V218, P113, DOI 10.1006/bbrc.1996.0020; Sun YX, 2004, BIOCHEM J, V380, P749, DOI 10.1042/BJ20040031; TOMMASSEN J, 1991, MOL GEN GENET, V226, P321, DOI 10.1007/BF00273621; van der Rest B, 2002, PLANT PHYSIOL, V130, P244, DOI 10.1104/pp.003392; Yanaka N, 2007, BIOSCI BIOTECH BIOCH, V71, P1811, DOI 10.1271/bbb.70062; Zheng B, 2003, P NATL ACAD SCI USA, V100, P1745, DOI 10.1073/pnas.0337605100; Zheng B, 2000, P NATL ACAD SCI USA, V97, P3999, DOI 10.1073/pnas.97.8.3999	28	165	171	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9341	9349		10.1074/jbc.M707807200	http://dx.doi.org/10.1074/jbc.M707807200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18227059	Green Published, hybrid			2022-12-25	WOS:000254465800064
J	Bunce, MW; Boronenkov, IV; Anderson, RA				Bunce, Matthew W.; Boronenkov, Igor V.; Anderson, Richard A.			Coordinated activation of the nuclear ubiquitin ligase Cul3-SPOP by the generation of phosphatidylinositol 5-phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE KINASE; DEPENDENT DEGRADATION; TRANSCRIPTION FACTOR; BTB PROTEINS; E3 LIGASE; IN-VIVO; DOMAIN; IDENTIFICATION; 4-KINASE; ADAPTERS	Phosphoinositide signaling pathways regulate numerous processes in eukaryotic cells, including migration, proliferation, and survival. The regulatory lipid phosphatidylinositol 4,5-bisphosphate is synthesized by two distinct classes of phosphatidylinositol phosphate kinases (PIPKs), the type I and II PIPKs. Although numerous physiological functions have been identified for type I PIPKs, little is known about the functions and regulation of type II PIPK. Using a yeast two-hybrid screen, we identified an interaction between the type II beta PIPK isoform (PIPKII beta) and SPOP (speckle-type POZ domain protein), a nuclear speckle-associated protein that recruits substrates to Cul3-based ubiquitin ligases. PIPKII beta and SPOP interact and co-localize at nuclear speckles in mammalian cells, and SPOP mediates the ubiquitylation of PIPKII beta by Cul3-based ubiquitin ligases. Additionally, stimulation of the p38 MAPK pathway enhances the ubiquitin ligase activity of Cul3-SPOP toward multiple substrate proteins. Finally, a kinase-dead PIPKII beta mutant enhanced ubiquitylation of Cul3-SPOP substrates. The kinase- dead PIPKII beta mutant increases the cellular content of its substrate lipid phosphatidylinositol 5-phosphate (PI5P), suggesting that PI5P may stimulate Cul3-SPOP activity through a p38-dependent signaling pathway. Expression of phosphatidylinositol-4,5-bisphosphate 4-phosphatases that generate PI5P dramatically stimulated Cul3-SPOP activity and was blocked by the p38 inhibitor SB203580. Taken together, these data define a novel mechanism whereby the phosphoinositide PI5P leads to stimulation of Cul3-SPOP ubiquitin ligase activity and also implicate PIPKII beta as a key regulator of this signaling pathway through its association with the Cul3-SPOP complex.	[Anderson, Richard A.] Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA; [Bunce, Matthew W.; Boronenkov, Igor V.] Univ Wisconsin, Biomol Chem Grad Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Anderson, RA (corresponding author), 1300 Univ Ave,Rm 3750 MSC, Madison, WI 53706 USA.	raanders@wisc.edu		Anderson, Richard/0000-0001-6265-8359	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051968] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM051968] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RA, 1999, J BIOL CHEM, V274, P9907, DOI 10.1074/jbc.274.15.9907; Bairstow SF, 2006, J BIOL CHEM, V281, P20632, DOI 10.1074/jbc.M601465200; Boronenkov IV, 1998, MOL BIOL CELL, V9, P3547, DOI 10.1091/mbc.9.12.3547; Bunce MW, 2006, BBA-MOL CELL BIOL L, V1761, P560, DOI 10.1016/j.bbalip.2006.03.002; Carricaburu V, 2003, P NATL ACAD SCI USA, V100, P9867, DOI 10.1073/pnas.1734038100; Ciruela A, 2000, BIOCHEM J, V346, P587, DOI 10.1042/0264-6021:3460587; Deffenbaugh AE, 2003, CELL, V114, P611, DOI 10.1016/S0092-8674(03)00641-X; DeRenzo C, 2003, NATURE, V424, P685, DOI 10.1038/nature01887; Furukawa M, 2003, NAT CELL BIOL, V5, P1001, DOI 10.1038/ncb1056; Galan JM, 1999, P NATL ACAD SCI USA, V96, P9124, DOI 10.1073/pnas.96.16.9124; Geyer R, 2003, MOL CELL, V12, P783, DOI 10.1016/S1097-2765(03)00341-1; Gong LM, 1999, J BIOL CHEM, V274, P12036, DOI 10.1074/jbc.274.17.12036; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; Hernadez-Munoz I, 2005, P NATL ACAD SCI USA, V102, P7635, DOI 10.1073/pnas.0408918102; Ishihara H, 1998, J BIOL CHEM, V273, P8741, DOI 10.1074/jbc.273.15.8741; Jaffray EG, 2006, METHODS, V38, P35, DOI 10.1016/j.ymeth.2005.07.020; Jones DR, 2006, MOL CELL, V23, P685, DOI 10.1016/j.molcel.2006.07.014; Khurana A, 2006, J BIOL CHEM, V281, P35316, DOI 10.1074/jbc.M606568200; Krek W, 2003, NAT CELL BIOL, V5, P950, DOI 10.1038/ncb1103-950; Kunz J, 2000, MOL CELL, V5, P1, DOI 10.1016/S1097-2765(00)80398-6; Kwon JE, 2006, J BIOL CHEM, V281, P12664, DOI 10.1074/jbc.M600204200; La M, 2004, BIOCHEM BIOPH RES CO, V320, P760, DOI 10.1016/j.bbrc.2004.06.022; Lamia KA, 2004, MOL CELL BIOL, V24, P5080, DOI 10.1128/MCB.24.11.5080-5087.2004; Ling K, 2003, J CELL BIOL, V163, P1339, DOI 10.1083/jcb.200310067; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; Ling K, 2007, J CELL BIOL, V176, P343, DOI 10.1083/jcb.200606023; Liu AH, 2004, MOL CELL BIOL, V24, P4372, DOI 10.1128/MCB.24.10.4372-4383.2004; Liu AH, 2006, FEBS LETT, V580, P6701, DOI 10.1016/j.febslet.2006.11.021; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Pintard L, 2003, NATURE, V425, P311, DOI 10.1038/nature01959; Richardson JP, 2007, CELL SIGNAL, V19, P1309, DOI 10.1016/j.cellsig.2007.01.010; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; Ungewickell A, 2005, P NATL ACAD SCI USA, V102, P18854, DOI 10.1073/pnas.0509740102; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; Zhang Q, 2006, DEV CELL, V10, P719, DOI 10.1016/j.devcel.2006.05.004; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2	37	55	58	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8678	8686		10.1074/jbc.M710222200	http://dx.doi.org/10.1074/jbc.M710222200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18218622	hybrid			2022-12-25	WOS:000254288000066
J	Luo, WJ; Liu, JY; Li, JX; Zhang, DY; Liu, MC; Addo, JK; Patil, S; Zhang, L; Yu, J; Buolamwini, JK; Chen, JY; Huang, CS				Luo, Wenjing; Liu, Jinyi; Li, Jingxia; Zhang, Dongyun; Liu, Mingchao; Addo, James K.; Patil, Shivaputra; Zhang, Lin; Yu, Jian; Buolamwini, John K.; Chen, Jingyuan; Huang, Chuanshu			Anti-cancer effects of JKA97 are associated with its induction of cell apoptosis via a Bax-dependent and p53-independent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION PORE; MITOCHONDRIAL-MEMBRANE; P53 PATHWAY; CANCER; ACTIVATION; TRANSLOCATION; DEATH; OLIGOMERIZATION; PROLIFERATION	p53, one of the most commonly mutated genes in human cancers, is thought to be associated with cancer development. Hence, screening and identifying natural or synthetic compounds with anti-cancer activity via p53-independent pathway is one of the most challenging tasks for scientists in this field. Compound JKA97 (methoxy-1-styryl-9H-pyrid-[3,4-b]-indole) is a small molecule synthetic anti-cancer agent, with unknown mechanism(s). In this study we have demonstrated that the anticancer activity of JKA97 is associated with apoptotic induction via p53-independent mechanisms. We found that co-incubation of human colon cancer HCT116 cells with JKA97 inhibited HCT116 cell anchorage-independent growth in vitro and tumorigenicity in nude mice and also induced a cell apoptotic response, both in the cell culture model and in a tumorigenesis nude mouse model. Further studies showed that JKA97-induced apoptosis was dramatically impaired in Bax knock-out (Bax(-/-)) HCT116 cells, whereas the knock-out of p53 or PUMA did not show any inhibitory effects. The p53-independent apoptotic induction by JKA97 was confirmed in other colon cancer and hepatocarcinoma cell lines. In addition, our results showed an induction of Bax translocation and cytochrome c release from the mitochondria to the cytosol in HCT116 cells, demonstrating that the compound induces apoptosis through a Bax-initiated mitochondria-dependent pathway. These studies provide a molecular basis for the therapeutic application of JKA97 against human cancers with p53 mutations.	[Addo, James K.; Patil, Shivaputra; Buolamwini, John K.] Univ Tennessee, Ctr Hlth Sci, Dept Pharmaceut Sci, Coll Pharm, Memphis, TN 38163 USA; [Luo, Wenjing; Liu, Jinyi; Li, Jingxia; Zhang, Dongyun; Huang, Chuanshu] NYU, Sch Med, Nelson Inst Environm Med, Tuxedo Pk, NY 10987 USA; [Luo, Wenjing; Liu, Mingchao; Chen, Jingyuan] Fourth Mil Med Univ, Dept Occupat & Environm Hlth Sci, Xian 710032, Peoples R China; [Zhang, Lin; Yu, Jian] Univ Pittsburgh, Pittsburgh Canc Inst, Dept Pharmacol, Pittsburgh, PA 15213 USA; [Zhang, Lin; Yu, Jian] Univ Pittsburgh, Pittsburgh Canc Inst, Dept Pathol, Pittsburgh, PA 15213 USA	University of Tennessee System; University of Tennessee Health Science Center; New York University; Air Force Military Medical University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute	Buolamwini, JK (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Pharmaceut Sci, Coll Pharm, Memphis, TN 38163 USA.	jbuolamw@utmem.edu; jy_chen@fmmu.edu.cn; chuanshu@env.med.nyu.edu	Yu, Jian/A-8301-2009; Zhang, Lin/A-7389-2009	Yu, Jian/0000-0002-4021-1000; Zhang, Lin/0000-0003-0018-3903; Huang, Chuanshu/0000-0003-4133-5096	NCI NIH HHS [CA 1002102, CA 103180, R15 CA100102, CA 094964, CA 112557] Funding Source: Medline; NIEHS NIH HHS [ES 000260, ES 012451] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA112557, R15CA100102, R01CA103180, R01CA094964] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012451, P30ES000260] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; Cho HJ, 2006, CANCER LETT, V237, P56, DOI 10.1016/j.canlet.2005.05.039; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cragg GM, 1997, J NAT PROD, V60, P52, DOI 10.1021/np9604893; Debatin KM, 2000, TOXICOL LETT, V112, P41, DOI 10.1016/S0378-4274(99)00252-0; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Gogvadze V, 2001, J BIOL CHEM, V276, P19066, DOI 10.1074/jbc.M100614200; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Hajra KM, 2004, APOPTOSIS, V9, P691, DOI 10.1023/B:APPT.0000045786.98031.1d; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Jalota A, 2005, J BIOL CHEM, V280, P16019, DOI 10.1074/jbc.M413200200; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Kim BJ, 2006, J BIOL CHEM, V281, P21256, DOI 10.1074/jbc.M510644200; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; LANE DP, 1993, NATURE, V362, P786, DOI 10.1038/362786a0; Li JX, 2006, J CELL BIOCHEM, V99, P1010, DOI 10.1002/jcb.20834; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Lin CH, 2005, NEUROSCI LETT, V387, P22, DOI 10.1016/j.neulet.2005.06.070; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Marsoni S, 2004, ANN ONCOL, V15, P229, DOI 10.1093/annonc/mdh931; Mullen SF, 2004, METH MOL B, V254, P393; Nagle DG, 2004, CURR MED CHEM, V11, P1725, DOI 10.2174/0929867043364991; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Ouyang WM, 2005, CANCER RES, V65, P9287, DOI 10.1158/0008-5472.CAN-05-0469; Peyruchaud O, 2003, J BIOL CHEM, V278, P45826, DOI 10.1074/jbc.M309024200; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Sarkar FH, 2003, J NUTR, V133, p2434S, DOI 10.1093/jn/133.7.2434S; Song YC, 2004, BIOCHEM BIOPH RES CO, V317, P128, DOI 10.1016/j.bbrc.2004.03.019; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Svec J, 2005, Bratisl Lek Listy, V106, P238; Tachibana M, 2004, INT J ONCOL, V25, P913; Tikhomirov O, 2005, J CELL SCI, V118, P5681, DOI 10.1242/jcs.02676; Tweddle DA, 2003, CANCER LETT, V197, P93, DOI 10.1016/S0304-3835(03)00088-0; Wang J, 2005, CANCER RES, V65, P6601, DOI 10.1158/0008-5472.CAN-04-4184; Yu J, 2003, CANCER CELL, V4, P248, DOI 10.1016/S1535-6108(03)00249-6; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	43	38	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8624	8633		10.1074/jbc.M707860200	http://dx.doi.org/10.1074/jbc.M707860200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18218619	Green Published, hybrid			2022-12-25	WOS:000254288000061
J	Takagi, Y; Yang, Y; Fujiwara, I; Jacobs, D; Cheney, RE; Sellers, JR; Kovacs, M				Takagi, Yasuharu; Yang, Yi; Fujiwara, Ikuko; Jacobs, Damon; Cheney, Richard E.; Sellers, James R.; Kovacs, Mihaly			Human myosin Vc is a low duty ratio, nonprocessive molecular motor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BASED MOTOR; HAND-OVER-HAND; KINETIC CHARACTERIZATION; UNCONVENTIONAL MYOSIN; MUSCLE-CONTRACTION; REAL-TIME; VESICLE TRANSPORT; FLUORESCENT-PROBE; NECK LENGTH; MECHANISM	Myosin Vc is the product of one of the three genes of the class V myosin found in vertebrates. It is widely found in secretory and glandular tissues, with a possible involvement in transferrin trafficking. Transient and steady-state kinetic studies of human myosin Vc were performed using a truncated, single-headed construct. Steady-state actin-activated ATPase measurements revealed a V-max of 1.8 +/- 0.3 s(-1) and a K-ATPase of 43 +/- 11 mu M. Unlike previously studied vertebrate myosin Vs, the rate-limiting step in the actomyosin Vc ATPase pathway is the release of inorganic phosphate (similar to 1.5 s(-1)), rather than the ADP release step (similar to 12.0-16.0 s(-1)). Nevertheless, the ADP affinity of actomyosin Vc (K-d = 0.25 +/- 0.02 mu M) reflects a higher ADP affinity than seen in other myosin V isoforms. Using the measured kinetic rates, the calculated duty ratio of myosin Vc was similar to 10%, indicating that myosin Vc spends the majority of the actomyosin ATPase cycle in weak actin-binding states, unlike the other vertebrate myosin V isoforms. Consistent with this, a fluorescently labeled double-headed heavy meromyosin form showed no processive movements along actin filaments in a single molecule assay, but it did move actin filaments at a velocity of similar to 24 nm/s in ensemble assays. Kinetic simulations reveal that the high ADP affinity of actomyosin Vc may lead to elevations of the duty ratio of myosin Vc to as high as 64% under possible physiological ADP concentrations. This, in turn, may possibly imply a regulatory mechanism that may be sensitive to moderate changes in ADP concentration.	[Takagi, Yasuharu; Yang, Yi; Sellers, James R.] NHLBI, Lab Mol Physiol, Natl Inst Hlth, Bethesda, MD 20892 USA; [Fujiwara, Ikuko] NHLBI, Cell Biol Lab, Natl Inst Hlth, Bethesda, MD 20892 USA; [Jacobs, Damon; Cheney, Richard E.] Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA; [Kovacs, Mihaly] Eotvos Lorand Univ, Dept Biochem, H-1117 Budapest, Hungary	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Eotvos Lorand University	Sellers, JR (corresponding author), NHLBI, Lab Mol Physiol, Natl Inst Hlth, Bldg 50,Rm 3523, Bethesda, MD 20892 USA.	sellersj@mail.nih.gov; stoci1@gmail.com	Kovacs, Mihaly/A-6841-2011; Fujiwara, Ikuko/H-5717-2016	Fujiwara, Ikuko/0000-0002-9361-636X; Cheney, Richard/0000-0001-6565-7888; Kovacs, Mihaly/0000-0002-1200-4741	FIC NIH HHS [1 R01 TW 007241-01, D43 TW 006230] Funding Source: Medline; Howard Hughes Medical Institute Funding Source: Medline; NIDCD NIH HHS [R01 DC003299] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R01TW007241, R01TW006230] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL004229] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC003299] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; Brown SS, 1999, ANNU REV CELL DEV BI, V15, P63, DOI 10.1146/annurev.cellbio.15.1.63; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; Brune M, 2001, BIOCHEMISTRY-US, V40, P5087, DOI 10.1021/bi002484h; Burgess S, 2002, J CELL BIOL, V159, P983, DOI 10.1083/jcb.200208172; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; Coluccio LR, 1999, J BIOL CHEM, V274, P21575, DOI 10.1074/jbc.274.31.21575; Coureux PD, 2004, EMBO J, V23, P4527, DOI 10.1038/sj.emboj.7600458; DAWSON MJ, 1978, NATURE, V274, P861, DOI 10.1038/274861a0; De la Cruz EM, 2000, BIOPHYS J, V79, P1524, DOI 10.1016/S0006-3495(00)76403-4; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; De La Cruz EM, 2004, CURR OPIN CELL BIOL, V16, P61, DOI 10.1016/j.ceb.2003.11.011; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; DePina AS, 1999, MICROSC RES TECHNIQ, V47, P93, DOI 10.1002/(SICI)1097-0029(19991015)47:2<93::AID-JEMT2>3.0.CO;2-P; El Mezgueldi M, 2002, J BIOL CHEM, V277, P21514, DOI 10.1074/jbc.M200713200; ESPINDOLA FS, 1992, J CELL BIOL, V118, P359, DOI 10.1083/jcb.118.2.359; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; Forkey JN, 2003, NATURE, V422, P399, DOI 10.1038/nature01529; GEEVES MA, 1991, BIOCHEM J, V274, P1; Homma K, 2000, J BIOL CHEM, V275, P34766, DOI 10.1074/jbc.M003132200; HOUK TW, 1974, ANAL BIOCHEM, V62, P66, DOI 10.1016/0003-2697(74)90367-4; Ishijima A, 1998, CELL, V92, P161, DOI 10.1016/S0092-8674(00)80911-3; Kovacs M, 2003, J BIOL CHEM, V278, P38132, DOI 10.1074/jbc.M305453200; Kovacs M, 2005, J BIOL CHEM, V280, P15071, DOI 10.1074/jbc.M500616200; Krendel M, 2005, PHYSIOLOGY, V20, P239, DOI 10.1152/physiol.00014.2005; Kuhn JR, 2005, BIOPHYS J, V88, P1387, DOI 10.1529/biophysj.104.047399; KUSHMERICK MJ, 1992, P NATL ACAD SCI USA, V89, P7521, DOI 10.1073/pnas.89.16.7521; Lapierre LA, 2001, MOL BIOL CELL, V12, P1843, DOI 10.1091/mbc.12.6.1843; Libby RT, 2004, J CELL SCI, V117, P4509, DOI 10.1242/jcs.01316; Matesic LE, 2001, P NATL ACAD SCI USA, V98, P10238, DOI 10.1073/pnas.181336698; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; Nascimento AAC, 1996, J BIOL CHEM, V271, P17561, DOI 10.1074/jbc.271.29.17561; Ostap EM, 1996, J CELL BIOL, V132, P1053, DOI 10.1083/jcb.132.6.1053; POLLARD TD, 1984, J CELL BIOL, V99, P769, DOI 10.1083/jcb.99.3.769; Provance DW, 1996, P NATL ACAD SCI USA, V93, P14554, DOI 10.1073/pnas.93.25.14554; RADDA GK, 1986, SCIENCE, V233, P640, DOI 10.1126/science.3726553; Reck-Peterson SL, 2000, BBA-MOL CELL RES, V1496, P36, DOI 10.1016/S0167-4889(00)00007-0; Richards TA, 2005, NATURE, V436, P1113, DOI 10.1038/nature03949; Rodriguez OC, 2002, J CELL SCI, V115, P991; Sakamoto T, 2005, BIOCHEMISTRY-US, V44, P16203, DOI 10.1021/bi0512086; Sakamoto T, 2000, BIOCHEM BIOPH RES CO, V272, P586, DOI 10.1006/bbrc.2000.2819; Sakamoto T, 2003, J BIOL CHEM, V278, P29201, DOI 10.1074/jbc.M303662200; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; Sellers JR, 2006, CURR OPIN CELL BIOL, V18, P68, DOI 10.1016/j.ceb.2005.12.014; SELLERS JR, 1999, MYOSINS, P289; Snyder GE, 2004, BIOPHYS J, V87, P1776, DOI 10.1529/biophysj.103.036897; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Sweeney HL, 2004, PHILOS T R SOC B, V359, P1829, DOI 10.1098/rstb.2004.1576; SWIATECKA U, 2007, J BIOL CHEM, V282, P23725; Takagi Y, 2006, BIOPHYS J, V90, P1295, DOI 10.1529/biophysj.105.068429; Toth J, 2005, J BIOL CHEM, V280, P30594, DOI 10.1074/jbc.M505209200; TRENTHAM DR, 1972, BIOCHEM J, V126, P635, DOI 10.1042/bj1260635; Trybus KM, 1999, J BIOL CHEM, V274, P27448, DOI 10.1074/jbc.274.39.27448; Tuxworth RI, 2000, TRAFFIC, V1, P11, DOI 10.1034/j.1600-0854.2000.010103.x; Volpicelli LA, 2002, J NEUROSCI, V22, P9776, DOI 10.1523/jneurosci.22-22-09776.2002; Walker ML, 2000, NATURE, V405, P804, DOI 10.1038/35015592; Wang F, 2003, J BIOL CHEM, V278, P27439, DOI 10.1074/jbc.M302510200; Wang F, 2000, J BIOL CHEM, V275, P4329, DOI 10.1074/jbc.275.6.4329; Watanabe S, 2006, BIOCHEMISTRY-US, V45, P2729, DOI 10.1021/bi051682b; Watanabe S, 2008, J BIOL CHEM, V283, P10581, DOI 10.1074/jbc.M707657200; Westbroek W, 2003, J INVEST DERMATOL, V120, P465, DOI 10.1046/j.1523-1747.2003.12068.x; White HD, 1997, BIOCHEMISTRY-US, V36, P11828, DOI 10.1021/bi970540h; Wilson SM, 2000, P NATL ACAD SCI USA, V97, P7933, DOI 10.1073/pnas.140212797; Wu X, 1998, J CELL BIOL, V143, P241, DOI 10.1083/jcb.143.1.241; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760; Yang Y, 2005, J BIOL CHEM, V280, P32061, DOI 10.1074/jbc.M506765200; Yengo CM, 2004, BIOCHEMISTRY-US, V43, P2605, DOI 10.1021/bi035510v; Yengo CM, 2002, BIOCHEMISTRY-US, V41, P8508, DOI 10.1021/bi015969u; Yildiz A, 2003, SCIENCE, V300, P2061, DOI 10.1126/science.1084398; Zhao LP, 1996, P NATL ACAD SCI USA, V93, P10826, DOI 10.1073/pnas.93.20.10826	71	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2008	283	13					8527	8537		10.1074/jbc.M709150200	http://dx.doi.org/10.1074/jbc.M709150200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	278LT	18201966	hybrid, Green Published			2022-12-25	WOS:000254288000051
J	Liang, J; Wang, J; Azfer, A; Song, W; Tromp, G; Kolattukudy, PE; Fu, M				Liang, Jian; Wang, Jing; Azfer, Asim; Song, Wenjun; Tromp, Gail; Kolattukudy, Pappachan E.; Fu, Mingui			A novel CCCH-zinc finger protein family regulates proinflammatory activation of macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRISTETRAPROLIN; ALPHA; UBIQUITINATION; INHIBITION; DOMAINS; TTP	Activated macrophages play an important role in many inflammatory diseases. However, the molecular mechanisms controlling macrophage activation are not completely understood. Here we report that a novel CCCH-zinc finger protein family, MCPIP1, 2, 3, and 4, encoded by four genes, Zc3h12a, Zc3h12b, Zc3h12c, and Zc3h12d, respectively, regulates macrophage activation. Northern blot analysis revealed that the expression of MCPIP1 and MCPIP3 was highly induced in macrophages in response to treatment with lipopolysaccharide (LPS). Although not affecting cell surface marker expression and phagocytotic function, overexpression of MCPIP1 significantly blunted LPS-induced inflammatory cytokine and NO(2)radical anion. production as well as their gene expression. Conversely, short interfering RNA-mediated reduction in MCPIP1 augmented LPS-induced inflammatory gene expression. Further studies demonstrated that MCPIP1 did not directly affect the mRNA stability of tumor necrosis factor alpha and monocyte chemoattractant protein 1 (MCP-1) but strongly inhibited LPS-induced tumor necrosis factor alpha and inducible nitric-oxide synthase promoter activation. Moreover, we found that forced expression of MCPIP1 significantly inhibited LPS-induced nuclear factor-kappa B activation. These results identify MCP-induced proteins, a novel CCCH-zinc finger protein family, as negative regulators in macrophage activation and may implicate them in host immunity and inflammatory diseases.	[Liang, Jian; Wang, Jing; Azfer, Asim; Song, Wenjun; Tromp, Gail; Kolattukudy, Pappachan E.; Fu, Mingui] Univ Cent Florida, Coll Med, Biomol Sci Ctr, Orlando, FL 32816 USA	State University System of Florida; University of Central Florida	Fu, M (corresponding author), Univ Cent Florida, Coll Med, Biomol Sci Ctr, 4000 Cent Florida Blvd, Orlando, FL 32816 USA.	mfu@mail.ucf.edu	Song, Wenjun/HGB-4891-2022; kolattukudy, pappachan e/A-1350-2012	Song, Wenjun/0000-0002-6355-2983	NHLBI NIH HHS [HL 69458] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL069458, R01HL069458] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beutler B, 2003, NAT REV IMMUNOL, V3, P169, DOI 10.1038/nri1004; Brown RS, 2005, CURR OPIN STRUC BIOL, V15, P94, DOI 10.1016/j.sbi.2005.01.006; BURKE B, 2002, MACROPHAGE, P1; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Carmody RJ, 2007, SCIENCE, V317, P675, DOI 10.1126/science.1142953; Carrick DM, 2004, ARTHRITIS RES THER, V6, P248, DOI 10.1186/ar1441; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; Gao GX, 2002, SCIENCE, V297, P1703, DOI 10.1126/science.1074276; Hall TMT, 2005, CURR OPIN STRUC BIOL, V15, P367, DOI 10.1016/j.sbi.2005.04.004; Kim JH, 2005, GENE DEV, V19, P776, DOI 10.1101/gad.1289405; Kuprash DV, 1999, J IMMUNOL, V162, P4045; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lim W, 2002, J IMMUNOL, V168, P1759, DOI 10.4049/jimmunol.168.4.1759; Lykke-Andersen J, 2005, GENE DEV, V19, P351, DOI 10.1101/gad.1282305; Ma J, 2003, CELL MOL LIFE SCI, V60, P2334, DOI 10.1007/s00018-003-3020-0; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; MASHIMA R, 2005, NAT IMMUNOL, V280, P41289; Matthews JM, 2002, IUBMB LIFE, V54, P351, DOI 10.1080/15216540216035; McAdam AJ, 1998, IMMUNOL REV, V165, P231; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Tanaka T, 2007, NAT IMMUNOL, V8, P584, DOI 10.1038/ni1464; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Vinuesa CG, 2005, NATURE, V435, P452, DOI 10.1038/nature03555; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Woo CH, 2004, J IMMUNOL, V173, P6973, DOI 10.4049/jimmunol.173.11.6973; Yoshimura A, 2007, NAT REV IMMUNOL, V7, P454, DOI 10.1038/nri2093; Zhao JL, 1996, J EXP MED, V183, P777, DOI 10.1084/jem.183.3.777; Zhou L, 2006, CIRC RES, V98, P1, DOI DOI 10.1161/01	29	193	210	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2008	283	10					6337	6346		10.1074/jbc.M707861200	http://dx.doi.org/10.1074/jbc.M707861200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HM	18178554	hybrid, Green Published			2022-12-25	WOS:000253779500041
J	Shetty, PK; Huang, FL; Huang, KP				Shetty, Pavan K.; Huang, Freesia L.; Huang, Kuo-Ping			Ischemia-elicited oxidative modulation of Ca2+/calmodulin-dependent protein kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; RAT-BRAIN NEUROGRANIN/RC3; DISULFIDE S-OXIDE; POSTSYNAPTIC DENSITIES; HIPPOCAMPAL-NEURONS; SELF-ASSOCIATION; CEREBRAL-ISCHEMIA; DENDRITIC SPINES; NITRIC-OXIDE; CAMKII	Ca2+/calmodulin (CaM)-dependent protein kinase II (CaMKII) plays a critical role in neuronal signal transduction and synaptic plasticity. Here, we showed that this kinase was very susceptible to oxidative modulation. Treatment of mouse brain synaptosomes with H2O2, diamide, and sodium nitroprusside caused aggregation of CaMKII through formation of disulfide and non-disulfide linkages, and partial inhibition of the kinase activity. These CaMKII aggregates were found to associate with the post synaptic density. However, treatment of purified CaMKII with these oxidants did not replicate those effects observed in the synaptosomes. Using two previously identified potential mediators of oxidants in the brain, glutathione disulfide S-monoxide (GS-DSMO) and glutathione disulfide S-dioxide (GS-DSDO), we showed that they oxidized and inhibited CaMKII in a manner partly related to those of the oxidant-treated synaptosomes as well as the ischemia-elicited oxidative stress in the acutely prepared hippocampal slices. Interestingly, the autophosphorylated and activated CaMKII was relatively refractory to GS-DSMO- and GS-DSDO-mediated aggregation. Short term ischemia (10 min) caused a depression of basal synaptic response of the hippocampal slices, and re-oxygenation (after 10 min) reversed the depression. However, oxidation of CaMKII remained at above the pre-ischemic level throughout the treatment. Oxidation of CaMKII also prevented full recovery of CaMKII autophosphorylation after re-oxygenation. Subsequently, the high frequency stimulation-mediated synaptic potentiation in the hippocampal CA1 region was significantly reduced compared with the control without ischemia. Thus, ischemia-evoked oxidation of CaMKII, probably via the action of glutathione disulfide S-oxides or their analogues, may be involved in the suppression of synaptic plasticity.	[Shetty, Pavan K.; Huang, Freesia L.; Huang, Kuo-Ping] NICHD, Natl Inst Hlth, Dev Neurobiol Program, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Huang, KP (corresponding author), NIH, Bldg 49,Rm6A10,49 Convent Dr MSC 4510, Bethesda, MD 20892 USA.	huangk@mail.nih.gov	SHETTY, PAVAN/B-9804-2012	Shetty, Pavan/0000-0002-6484-7417	Intramural NIH HHS Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000187] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000187] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aronowski J, 1996, BRAIN RES, V709, P103, DOI 10.1016/0006-8993(95)01311-3; ARONOWSKI J, 1992, J NEUROCHEM, V58, P1743, DOI 10.1111/j.1471-4159.1992.tb10049.x; Bayer KM, 2001, BIOCHEM BIOPH RES CO, V289, P917, DOI 10.1006/bbrc.2001.6063; Bindokas VP, 1996, J NEUROSCI, V16, P1324; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; CHETKOVICH DM, 1993, NEUROREPORT, V4, P919, DOI 10.1097/00001756-199307000-00020; Dosemeci A, 2000, J NEUROSCI, V20, P3076, DOI 10.1523/JNEUROSCI.20-09-03076.2000; DUNKLEY PR, 1986, BRAIN RES, V372, P115, DOI 10.1016/0006-8993(86)91464-2; ERONDU NE, 1985, J NEUROSCI, V5, P3270; Fink CC, 2003, NEURON, V39, P283, DOI 10.1016/S0896-6273(03)00428-8; Frey U, 1998, TRENDS NEUROSCI, V21, P181, DOI 10.1016/S0166-2236(97)01189-2; Halestrap AP, 2006, BIOCHEM SOC T, V34, P232, DOI 10.1042/BST0340232; Halliwell B, 2006, J NEUROCHEM, V97, P1634, DOI 10.1111/j.1471-4159.2006.03907.x; HARTLEY Z, 1993, J NEUROSCI, V13, P4690; Ho YS, 1997, J BIOL CHEM, V272, P16644, DOI 10.1074/jbc.272.26.16644; Hu BR, 1998, J NEUROSCI, V18, P625; Huang FL, 2006, J NEUROSCI, V26, P6230, DOI 10.1523/JNEUROSCI.1182-06.2006; Huang KP, 2002, BIOCHEM PHARMACOL, V64, P1049, DOI 10.1016/S0006-2952(02)01175-9; Huang KP, 2000, BIOCHEMISTRY-US, V39, P7291, DOI 10.1021/bi000336l; Huang KP, 2007, BIOCHEMISTRY-US, V46, P1961, DOI 10.1021/bi061955i; Hudmon A, 2002, ANNU REV BIOCHEM, V71, P473, DOI 10.1146/annurev.biochem.71.110601.135410; Hudmon A, 2005, J CELL BIOL, V171, P537, DOI 10.1083/jcb.200505155; Hudmon A, 2005, J NEUROSCI, V25, P6971, DOI 10.1523/JNEUROSCI.4698-04.2005; Hudmon A, 1996, J BIOL CHEM, V271, P8800, DOI 10.1074/jbc.271.15.8800; Hudmon A, 2001, J NEUROCHEM, V76, P1364, DOI 10.1046/j.1471-4159.2001.00119.x; IRWIN RP, 1994, J NEUROSCI, V14, P1352, DOI 10.1523/JNEUROSCI.14-03-01352.1994; Leonard AS, 2002, J BIOL CHEM, V277, P48441, DOI 10.1074/jbc.M205164200; Li JF, 2001, J BIOL CHEM, V276, P3098, DOI 10.1074/jbc.M008260200; Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; Merrill MA, 2005, TRENDS PHARMACOL SCI, V26, P645, DOI 10.1016/j.tips.2005.10.003; Moncada S, 2006, J NEUROCHEM, V97, P1676, DOI 10.1111/j.1471-4159.2006.03988.x; Otmakhov N, 2004, J NEUROSCI, V24, P9324, DOI 10.1523/JNEUROSCI.2350-04.2004; Rich RC, 1998, J BIOL CHEM, V273, P28424, DOI 10.1074/jbc.273.43.28424; Robison AJ, 2007, BIOCHEM BIOPH RES CO, V356, P97, DOI 10.1016/j.bbrc.2007.02.087; Robison AJ, 2005, J BIOL CHEM, V280, P35329, DOI 10.1074/jbc.M502191200; Rosenberg OS, 2005, CELL, V123, P849, DOI 10.1016/j.cell.2005.10.029; Shen K, 1998, NEURON, V21, P593, DOI 10.1016/S0896-6273(00)80569-3; Shen K, 1999, SCIENCE, V284, P162, DOI 10.1126/science.284.5411.162; Shen K, 2000, NAT NEUROSCI, V3, P881, DOI 10.1038/78783; SILVER IA, 1992, J CEREBR BLOOD F MET, V12, P759, DOI 10.1038/jcbfm.1992.107; Soderling TR, 2001, J BIOL CHEM, V276, P3719, DOI 10.1074/jbc.R000013200; Strack S, 1997, J BIOL CHEM, V272, P13467, DOI 10.1074/jbc.272.21.13467; SUCHER NJ, 1991, J NEUROSCI RES, V30, P582, DOI 10.1002/jnr.490300316; SUZUKI T, 1994, J NEUROCHEM, V63, P1529, DOI 10.1046/j.1471-4159.1994.63041529.x; Takahashi H, 2007, NEURON, V53, P53, DOI 10.1016/j.neuron.2006.11.023; Tao-Cheng JH, 2005, NEUROSCIENCE, V130, P651, DOI 10.1016/j.neuroscience.2004.10.008; Tao-Cheng JH, 2002, NEUROSCIENCE, V115, P435, DOI 10.1016/S0306-4522(02)00451-7; Tao-Cheng JH, 2001, NEUROSCIENCE, V106, P69, DOI 10.1016/S0306-4522(01)00262-7; Villasana LE, 2006, J NEUROSCI METH, V158, P30, DOI 10.1016/j.jneumeth.2006.05.008; WESTGATE SA, 1994, J NEUROCHEM, V63, P2217; Wu JF, 2003, J NEUROCHEM, V86, P1524, DOI 10.1046/j.1471-4159.2003.01963.x; Yamagata Y, 2004, J NEUROCHEM, V91, P745, DOI 10.1111/j.1471-4159.2004.02753.x	53	20	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 29	2008	283	9					5389	5401		10.1074/jbc.M708479200	http://dx.doi.org/10.1074/jbc.M708479200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266IC	18174165	hybrid			2022-12-25	WOS:000253426700019
J	Manderson, EN; Malleshaiah, M; Michnick, SW				Manderson, Emily N.; Malleshaiah, Mohan; Michnick, Stephen W.			A Novel Genetic Screen Implicates Elm1 in the Inactivation of the Yeast Transcription Factor SBF	PLOS ONE			English	Article								Background. Despite extensive large scale analyses of expression and protein-protein interactions (PPI) in the model organism Saccharomyces cerevisiae, over a thousand yeast genes remain uncharacterized. We have developed a novel strategy in yeast that directly combines genetics with proteomics in the same screen to assign function to proteins based on the observation of genetic perturbations of sentinel protein interactions (GePPI). As proof of principle of the GePPI screen, we applied it to identify proteins involved in the regulation of an important yeast cell cycle transcription factor, SBF that activates gene expression during G1 and S phase. Methodology/Principle Findings. The principle of GePPI is that if a protein is involved in a pathway of interest, deletion of the corresponding gene will result in perturbation of sentinel PPIs that report on the activity of the pathway. We created a fluorescent protein-fragment complementation assay (PCA) to detect the interaction between Cdc28 and Swi4, which leads to the inactivation of SBF. The PCA signal was quantified by microscopy and image analysis in deletion strains corresponding to 25 candidate genes that are periodically expressed during the cell cycle and are substrates of Cdc28. We showed that the serine-threonine kinase Elm1 plays a role in the inactivation of SBF and that phosphorylation of Elm1 by Cdc28 may be a mechanism to inactivate Elm1 upon completion of mitosis. Conclusions/Significance. Our findings demonstrate that GePPI is an effective strategy to directly link proteins of known or unknown function to a specific biological pathway of interest. The ease in generating PCA assays for any protein interaction and the availability of the yeast deletion strain collection allows GePPI to be applied to any cellular network. In addition, the high degree of conservation between yeast and mammalian proteins and pathways suggest GePPI could be used to generate insight into human disease.	[Manderson, Emily N.; Malleshaiah, Mohan; Michnick, Stephen W.] Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Michnick, SW (corresponding author), Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada.	stephen.michnick@umontreal.ca		Malleshaiah, Mohan/0000-0003-2896-8585	Genome Canada; Genome Quebec; Canadian Institutes of Health Research (CIHR) [MOP -152556]; Fonds de la recherche en sante Quebec [post-doctoral fellowship]	Genome Canada(Genome Canada); Genome Quebec; Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Fonds de la recherche en sante Quebec(Fonds de la Recherche en Sante du Quebec)	This research was supported by grants from Genome Canada, Genome Quebec and the Canadian Institutes of Health Research (CIHR) (MOP -152556) to S.W. Michnick. E.N. Manderson is the recipient of a post-doctoral fellowship from the Fonds de la recherche en sante Quebec.	AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; Bailly E, 2003, J CELL SCI, V116, P4119, DOI 10.1242/jcs.00706; Bean JM, 2005, GENETICS, V171, P49, DOI 10.1534/genetics.105.044560; BLACKETER MJ, 1995, GENETICS, V140, P1259; BLACKETER MJ, 1993, MOL CELL BIOL, V13, P5567, DOI 10.1128/MCB.13.9.5567; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; Bouquin N, 2000, J CELL SCI, V113, P1435; Collins SR, 2007, NATURE, V446, P806, DOI 10.1038/nature05649; Costanzo M, 2004, CELL, V117, P899, DOI 10.1016/j.cell.2004.05.024; de Lichtenberg U, 2005, SCIENCE, V307, P724, DOI 10.1126/science.1105103; Edgington NP, 1999, MOL CELL BIOL, V19, P1369; Geymonat M, 2004, MOL CELL BIOL, V24, P2277, DOI 10.1128/MCB.24.6.2277-2285.2004; Hong SP, 2005, J BIOL CHEM, V280, P21804, DOI 10.1074/jbc.M501887200; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; Koehler CM, 1997, FEBS LETT, V408, P109, DOI 10.1016/S0014-5793(97)00401-8; MacDonald ML, 2006, NAT CHEM BIOL, V2, P329, DOI 10.1038/nchembio790; Magliery TJ, 2005, J AM CHEM SOC, V127, P146, DOI 10.1021/ja046699g; Michnick SW, 2007, NAT REV DRUG DISCOV, V6, P569, DOI 10.1038/nrd2311; Michnick SW, 2006, METHODS, V40, P287, DOI 10.1016/j.ymeth.2006.07.016; Mnaimneh S, 2004, CELL, V118, P31, DOI 10.1016/j.cell.2004.06.013; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Murray DB, 2007, P NATL ACAD SCI USA, V104, P2241, DOI 10.1073/pnas.0606677104; Pan XW, 2004, MOL CELL, V16, P487, DOI 10.1016/j.molcel.2004.09.035; Pena-Castillo L, 2007, GENETICS, V176, P7, DOI 10.1534/genetics.107.074468; Remy I, 2004, NAT CELL BIOL, V6, P358, DOI 10.1038/ncb1113; Remy I, 2004, MOL CELL BIOL, V24, P1493, DOI 10.1128/MCB.24.4.1493-1504.2004; Remy I, 2001, P NATL ACAD SCI USA, V98, P7678, DOI 10.1073/pnas.131216098; Remy I, 2006, NAT METHODS, V3, P977, DOI 10.1038/nmeth979; Schuldiner M, 2005, CELL, V123, P507, DOI 10.1016/j.cell.2005.08.031; Sheff MA, 2004, YEAST, V21, P661, DOI 10.1002/yea.1130; Sherman F., 1974, METHODS YEAST GENETI; Siegmund RF, 1996, MOL CELL BIOL, V16, P2647; SIKORSKI RS, 1989, GENETICS, V122, P19; Sreenivasan A, 1999, MOL CELL BIOL, V19, P7983; Stefan E, 2007, P NATL ACAD SCI USA, V104, P16916, DOI 10.1073/pnas.0704257104; Sutherland CM, 2003, CURR BIOL, V13, P1299, DOI 10.1016/S0960-9822(03)00459-7; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	40	14	15	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2008	3	1							e1500	10.1371/journal.pone.0001500	http://dx.doi.org/10.1371/journal.pone.0001500			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SR	18231587	Green Published, Green Submitted, gold			2022-12-25	WOS:000260504200013
J	Nomura, T; Takahashi, M; Hara, Y; Osumi, N				Nomura, Tadashi; Takahashi, Masanori; Hara, Yoshinobu; Osumi, Noriko			Patterns of Neurogenesis and Amplitude of Reelin Expression Are Essential for Making a Mammalian-Type Cortex	PLOS ONE			English	Article								The mammalian neocortex is characterized as a six-layered laminar structure, in which distinct types of pyramidal neurons are distributed coordinately during embryogenesis. In contrast, no other vertebrate class possesses a brain region that is strictly analogous to the neocortical structure. Although it is widely accepted that the pallium, a dorsal forebrain region, is specified in all vertebrate species, little is known of the differential mechanisms underlying laminated or non-laminated structures in the pallium. Here we show that differences in patterns of neuronal specification and migration provide the pallial architectonic diversity. We compared the neurogenesis in mammalian and avian pallium, focusing on subtype-specific gene expression, and found that the avian pallium generates distinct types of neurons in a spatially restricted manner. Furthermore, expression of Reelin gene is hardly detected in the developing avian pallium, and an experimental increase in Reelin-positive cells in the avian pallium modified radial fiber organization, which resulted in dramatic changes in the morphology of migrating neurons. Our results demonstrate that distinct mechanisms govern the patterns of neuronal specification in mammalian and avian pallial development, and that Reelin-dependent neuronal migration plays a critical role in mammalian type corticogenesis. These lines of evidence shed light on the developmental programs underlying the evolution of the mammalian specific laminated cortex.	[Nomura, Tadashi; Takahashi, Masanori; Hara, Yoshinobu] Tohoku Univ, Sch Med, CTTAR, Div Dev Neurosci, Sendai, Miyagi 980, Japan; [Hara, Yoshinobu; Osumi, Noriko] Japan Sci & Technol Agency, Core Res Evol Sci & Technol, Kawaguchi, Japan	Tohoku University; Japan Science & Technology Agency (JST)	Osumi, N (corresponding author), Tohoku Univ, Sch Med, CTTAR, Div Dev Neurosci, Sendai, Miyagi 980, Japan.	osumi@mail.tains.tohoku.ac.jp	Osumi, Noriko/T-2823-2019	Osumi, Noriko/0000-0003-0548-6452; hara, Yoshinobu/0000-0001-6339-5116	Japanese Ministry of Education, Culture, Sports and Technology [18053003]; Uehara Memorial Foundation; Core Research for Evolutional Science and Technology from Japanese Science and Technology Agency	Japanese Ministry of Education, Culture, Sports and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Uehara Memorial Foundation(Uehara Memorial Foundation); Core Research for Evolutional Science and Technology from Japanese Science and Technology Agency	This work was supported by Grants-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports and Technology (18053003 to TN), Uehara Memorial Foundation (to TN), and by the Core Research for Evolutional Science and Technology from Japanese Science and Technology Agency (to NO).	Aboitiz F, 2002, BRAZ J MED BIOL RES, V35, P1455, DOI 10.1590/S0100-879X2002001200006; Arimura N, 2007, NAT REV NEUROSCI, V8, P194, DOI 10.1038/nrn2056; Bernier B, 2000, J COMP NEUROL, V422, P448; Bielle F, 2005, NAT NEUROSCI, V8, P1002, DOI 10.1038/nn1511; BRUCE LL, 1995, BRAIN BEHAV EVOLUT, V46, P224, DOI 10.1159/000113276; Cabrera-Socorro A, 2007, BRAIN RES, V1132, P59, DOI 10.1016/j.brainres.2006.11.015; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; Fernandez AS, 1998, DEVELOPMENT, V125, P2099; GOFFINET AM, 1986, J COMP NEUROL, V243, P106, DOI 10.1002/cne.902430109; GRAY GE, 1992, DEVELOPMENT, V114, P271; Guillemot F, 2006, EUR J NEUROSCI, V23, P857, DOI 10.1111/j.1460-9568.2006.04626.x; Haesler S, 2004, J NEUROSCI, V24, P3164, DOI 10.1523/JNEUROSCI.4369-03.2004; Hanashima C, 2004, SCIENCE, V303, P56, DOI 10.1126/science.1090674; Hand R, 2005, NEURON, V48, P45, DOI 10.1016/j.neuron.2005.08.032; Hartfuss E, 2003, DEVELOPMENT, V130, P4597, DOI 10.1242/dev.00654; Henion PD, 2000, DEV DYNAM, V218, P150, DOI 10.1002/(SICI)1097-0177(200005)218:1<150::AID-DVDY13>3.0.CO;2-6; Hevner RF, 2003, DEV NEUROSCI-BASEL, V25, P139, DOI 10.1159/000072263; Hevner RF, 2001, NEURON, V29, P353, DOI 10.1016/S0896-6273(01)00211-2; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Inoue T, 2000, DEV BIOL, V219, P373, DOI 10.1006/dbio.2000.9616; Jarvis ED, 2005, NAT REV NEUROSCI, V6, P151, DOI 10.1038/nrn1606; Jossin Y, 2003, CEREB CORTEX, V13, P627, DOI 10.1093/cercor/13.6.627; KARTEN HJ, 1991, BRAIN BEHAV EVOLUT, V38, P264, DOI 10.1159/000114393; Kriegstein AR, 2004, TRENDS NEUROSCI, V27, P392, DOI 10.1016/j.tins.2004.05.001; LAVAIL JH, 1971, BRAIN RES, V28, P421; Marin O, 2003, ANNU REV NEUROSCI, V26, P441, DOI 10.1146/annurev.neuro.26.041002.131058; Marin-Padilla M, 1998, TRENDS NEUROSCI, V21, P64, DOI 10.1016/S0166-2236(97)01164-8; MARINPADILLA M, 1992, J COMP NEUROL, V321, P223, DOI 10.1002/cne.903210205; Medina L, 2000, TRENDS NEUROSCI, V23, P1, DOI 10.1016/S0166-2236(99)01486-1; Meyer G, 1999, EUR J NEUROSCI, V11, P3937, DOI 10.1046/j.1460-9568.1999.00818.x; Meyer G, 1999, CEREB CORTEX, V9, P765, DOI 10.1093/cercor/9.8.765; Molnar Z, 2006, EUR J NEUROSCI, V23, P921, DOI 10.1111/j.1460-9568.2006.04611.x; Molyneaux BJ, 2007, NAT REV NEUROSCI, V8, P427, DOI 10.1038/nrn2151; Nakamura H, 2001, METHODS, V24, P43, DOI 10.1006/meth.2001.1155; NIEUWENHUYS R, 1994, ANAT EMBRYOL, V190, P307; Nomura T, 2006, DEVELOPMENT, V133, P1335, DOI 10.1242/dev.02290; Nomura T, 2000, DEVELOPMENT, V127, P1899; NORTHCUTT RG, 1995, TRENDS NEUROSCI, V18, P373; OGAWA M, 1995, NEURON, V14, P899, DOI 10.1016/0896-6273(95)90329-1; Puelles L, 2000, J COMP NEUROL, V424, P409, DOI 10.1002/1096-9861(20000828)424:3<409::AID-CNE3>3.0.CO;2-7; Puelles L, 2003, TRENDS NEUROSCI, V26, P469, DOI 10.1016/S0166-2236(03)00234-0; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; Rakic P, 2003, CEREB CORTEX, V13, P541, DOI 10.1093/cercor/13.6.541; Rakic P, 2007, BRAIN RES REV, V55, P204, DOI 10.1016/j.brainresrev.2007.02.010; Rakic P, 2006, CEREB CORTEX, V16, pI3, DOI 10.1093/cercor/bhk036; Rice DS, 2001, ANNU REV NEUROSCI, V24, P1005, DOI 10.1146/annurev.neuro.24.1.1005; Rubenstein JLR, 1998, ANNU REV NEUROSCI, V21, P445, DOI 10.1146/annurev.neuro.21.1.445; Striedter GF, 2000, J NEUROSCI, V20, P8021; Striedter GF, 1997, BRAIN BEHAV EVOLUT, V49, P179, DOI 10.1159/000112991; STRIEDTER GF, 2005, PRINCIPLES BRAIN EVO, P255; Sugitani Y, 2002, GENE DEV, V16, P1760, DOI 10.1101/gad.978002; Sugiyama S, 2003, DEVELOPMENT, V130, P451, DOI 10.1242/dev.00232; Tabata H, 2003, J NEUROSCI, V23, P9996; Takahashi M, 2002, DEVELOPMENT, V129, P1327; Takiguchi-Hayashi K, 2004, J NEUROSCI, V24, P2286, DOI 10.1523/JNEUROSCI.4671-03.2004; Tissir F, 2003, NAT REV NEUROSCI, V4, P496, DOI 10.1038/nrn1113; Tissir F, 2002, BRAZ J MED BIOL RES, V35, P1473, DOI 10.1590/S0100-879X2002001200007; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; TSAI HM, 1981, J COMP NEUROL, V198, P293, DOI 10.1002/cne.901980208; TSAI HM, 1981, J COMP NEUROL, V198, P275, DOI 10.1002/cne.901980207; Weiss KH, 2003, J COMP NEUROL, V460, P56, DOI 10.1002/cne.10644; WILD JM, 1993, J COMP NEUROL, V338, P225, DOI 10.1002/cne.903380207; Yoneshima H, 2006, NEUROSCIENCE, V137, P401, DOI 10.1016/j.neuroscience.2005.08.075; Yoshida M, 2006, DEVELOPMENT, V133, P537, DOI 10.1242/dev.02209; Yun K, 2001, DEVELOPMENT, V128, P193; Zhao ST, 2004, DEVELOPMENT, V131, P5117, DOI 10.1242/dev.01387	66	68	68	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2008	3	1							e1454	10.1371/journal.pone.0001454	http://dx.doi.org/10.1371/journal.pone.0001454			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366SN	18197264	Green Published, gold, Green Submitted			2022-12-25	WOS:000260503800025
